@prefix ns0: <https://schema.org/> .
@prefix ns1: <http://ld.iospress.nl/rdf/artifact/> .
@prefix ns101: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:6.ID:> .
@prefix ns102: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:6.ID:> .
@prefix ns106: <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:7.ID:> .
@prefix ns112: <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:2.ID:> .
@prefix ns114: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:11.ID:> .
@prefix ns116: <http://ld.iospress.nl/rdf/contributor/Editor:0.ID:> .
@prefix ns117: <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:3.ID:> .
@prefix ns118: <http://ld.iospress.nl/rdf/contributor/Author:30.ID:> .
@prefix ns119: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:30.ID:> .
@prefix ns12: <http://ld.iospress.nl/rdf/contributor/Author:2.ID:> .
@prefix ns120: <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:4.ID:> .
@prefix ns121: <http://ld.iospress.nl/rdf/organization/Affiliation:affd.Author:4.ID:> .
@prefix ns122: <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:4.ID:> .
@prefix ns123: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:4.ID:> .
@prefix ns124: <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:4.ID:> .
@prefix ns125: <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:5.ID:> .
@prefix ns13: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:2.ID:> .
@prefix ns130: <http://ld.iospress.nl/rdf/contributor/Author:16.ID:> .
@prefix ns131: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:16.ID:> .
@prefix ns132: <http://ld.iospress.nl/rdf/contributor/Author:18.ID:> .
@prefix ns133: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:18.ID:> .
@prefix ns134: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:19.ID:> .
@prefix ns138: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:2.ID:> .
@prefix ns139: <http://ld.iospress.nl/rdf/contributor/Author:21.ID:> .
@prefix ns14: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:2.ID:> .
@prefix ns140: <http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:21.ID:> .
@prefix ns141: <http://ld.iospress.nl/rdf/contributor/Author:25.ID:> .
@prefix ns143: <http://ld.iospress.nl/rdf/contributor/Author:27.ID:> .
@prefix ns149: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:17.ID:> .
@prefix ns15: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:2.ID:> .
@prefix ns150: <http://ld.iospress.nl/rdf/contributor/List.Role:authors.ID:> .
@prefix ns153: <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:4.ID:> .
@prefix ns16: <http://ld.iospress.nl/rdf/contributor/Author:5.ID:> .
@prefix ns163: <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:7.ID:> .
@prefix ns168: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:8.ID:> .
@prefix ns169: <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:8.ID:> .
@prefix ns174: <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:9.ID:> .
@prefix ns176: <http://ld.iospress.nl/rdf/contributor/Author:20.ID:> .
@prefix ns177: <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:20.ID:> .
@prefix ns179: <http://ld.iospress.nl/rdf/organization/Affiliation:aff21.Author:21.ID:> .
@prefix ns180: <http://ld.iospress.nl/rdf/contributor/Author:24.ID:> .
@prefix ns181: <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:24.ID:> .
@prefix ns182: <http://ld.iospress.nl/rdf/organization/Affiliation:aff19.Author:25.ID:> .
@prefix ns183: <http://ld.iospress.nl/rdf/contributor/Author:28.ID:> .
@prefix ns184: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:28.ID:> .
@prefix ns185: <http://ld.iospress.nl/rdf/organization/Affiliation:aff19.Author:28.ID:> .
@prefix ns186: <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:3.ID:> .
@prefix ns192: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:5.ID:> .
@prefix ns193: <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:5.ID:> .
@prefix ns194: <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:5.ID:> .
@prefix ns195: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:5.ID:> .
@prefix ns199: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:6.ID:> .
@prefix ns2: <http://ld.iospress.nl/rdf/contributor/Author:0.ID:> .
@prefix ns200: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:6.ID:> .
@prefix ns201: <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:6.ID:> .
@prefix ns203: <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:6.ID:> .
@prefix ns204: <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:6.ID:> .
@prefix ns208: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:7.ID:> .
@prefix ns209: <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:7.ID:> .
@prefix ns21: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:5.ID:> .
@prefix ns210: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:7.ID:> .
@prefix ns215: <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:8.ID:> .
@prefix ns216: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:8.ID:> .
@prefix ns217: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:8.ID:> .
@prefix ns218: <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:8.ID:> .
@prefix ns219: <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:8.ID:> .
@prefix ns22: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:5.ID:> .
@prefix ns227: <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:9.ID:> .
@prefix ns228: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:9.ID:> .
@prefix ns229: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:9.ID:> .
@prefix ns230: <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:9.ID:> .
@prefix ns231: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:9.ID:> .
@prefix ns235: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:21.ID:> .
@prefix ns24: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:1.ID:> .
@prefix ns242: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:0.ID:> .
@prefix ns243: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:0.ID:> .
@prefix ns244: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:0.ID:> .
@prefix ns246: <http://ld.iospress.nl/rdf/organization/Affiliation:aff18.Author:20.ID:> .
@prefix ns25: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:1.ID:> .
@prefix ns251: <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:6.ID:> .
@prefix ns252: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:3.ID:> .
@prefix ns258: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:1.ID:> .
@prefix ns259: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:1.ID:> .
@prefix ns26: <http://ld.iospress.nl/rdf/contributor/Author:10.ID:> .
@prefix ns264: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:16.ID:> .
@prefix ns265: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:16.ID:> .
@prefix ns270: <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:9.ID:> .
@prefix ns28: <http://ld.iospress.nl/rdf/contributor/Author:13.ID:> .
@prefix ns30: <http://ld.iospress.nl/rdf/contributor/Author:3.ID:> .
@prefix ns31: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:3.ID:> .
@prefix ns33: <http://ld.iospress.nl/rdf/contributor/Author:9.ID:> .
@prefix ns37: <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:9.ID:> .
@prefix ns39: <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:10.ID:> .
@prefix ns40: <http://ld.iospress.nl/rdf/contributor/Author:11.ID:> .
@prefix ns43: <http://ld.iospress.nl/rdf/contributor/Author:15.ID:> .
@prefix ns44: <http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:15.ID:> .
@prefix ns46: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:16.ID:> .
@prefix ns5: <http://ld.iospress.nl/rdf/contributor/Author:4.ID:> .
@prefix ns50: <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:4.ID:> .
@prefix ns52: <http://ld.iospress.nl/rdf/contributor/Author:6.ID:> .
@prefix ns55: <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:6.ID:> .
@prefix ns57: <http://ld.iospress.nl/rdf/contributor/Author:7.ID:> .
@prefix ns6: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:4.ID:> .
@prefix ns60: <http://ld.iospress.nl/rdf/contributor/Author:8.ID:> .
@prefix ns63: <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:3.ID:> .
@prefix ns64: <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:3.ID:> .
@prefix ns71: <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:4.ID:> .
@prefix ns73: <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:2.ID:> .
@prefix ns75: <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:5.ID:> .
@prefix ns77: <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:8.ID:> .
@prefix ns79: <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:7.ID:> .
@prefix ns8: <http://ld.iospress.nl/rdf/contributor/Author:1.ID:> .
@prefix ns81: <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:8.ID:> .
@prefix ns83: <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:2.ID:> .
@prefix ns84: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:3.ID:> .
@prefix ns87: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:4.ID:> .
@prefix ns88: <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:7.ID:> .
@prefix ns90: <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:1.ID:> .
@prefix ns91: <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:1.ID:> .
@prefix owl: <http://www.w3.org/2002/07/owl#> .

ns2:AAC192101 owl:sameAs ns8:AAC180425 ;
    ns0:fullName "Jean-Guy Mailly" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AAC192101> ;
    ns0:hasArticle ns1:aac-v10-i2-AAC192101 ;
    ns0:inAuthorList ns150:AAC192101 .

ns2:AIC190617 owl:sameAs ns8:AIC725 ;
    ns0:fullName "Nicoletta Fornara" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AIC190617> ;
    ns0:hasArticle ns1:aic-v32-i4-AIC190617 ;
    ns0:inAuthorList ns150:AIC190617 .

ns2:AIC190622 owl:sameAs ns8:AAC004,
        ns8:FI1583 ;
    ns0:fullName "Juan Carlos Nieves" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AIC190622> ;
    ns0:hasArticle ns1:aic-v32-i4-AIC190622 ;
    ns0:inAuthorList ns150:AIC190622 .

ns2:AIS190539 owl:sameAs ns8:AIS190524 ;
    ns0:fullName "Dennis Sprute" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AIS190539>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:0.ID:AIS190539> ;
    ns0:hasArticle ns1:ais-v11-i6-AIS190539 ;
    ns0:inAuthorList ns150:AIS190539 .

ns2:AO190214 owl:sameAs ns8:AO193 ;
    ns0:fullName "Alessander Botti Benevides" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AO190214> ;
    ns0:hasArticle ns1:ao-v14-i3-AO190214 ;
    ns0:inAuthorList ns150:AO190214 .

ns2:ASY181516 owl:sameAs ns2:ASY1361,
        ns2:ASY1420 ;
    ns0:fullName "Ryo Ikehata" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY181516> ;
    ns0:hasArticle ns1:asy-v114-i1-2-ASY181516 ;
    ns0:inAuthorList ns150:ASY181516 .

ns2:ASY191518 owl:sameAs ns8:ASY1348 ;
    ns0:fullName "Eduard Feireisl" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY191518>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:0.ID:ASY191518> ;
    ns0:hasArticle ns1:asy-v114-i1-2-ASY191518 ;
    ns0:inAuthorList ns150:ASY191518 .

ns2:ASY191521 owl:sameAs ns2:ASY1387,
        ns2:ASY191520 ;
    ns0:fullName "Habib Ammari" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY191521> ;
    ns0:hasArticle ns1:asy-v114-i3-4-ASY191521 ;
    ns0:inAuthorList ns150:ASY191521 .

ns2:ASY191524 owl:sameAs ns2:ASY1380 ;
    ns0:fullName "Pierluigi Colli" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY191524>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:0.ID:ASY191524> ;
    ns0:hasArticle ns1:asy-v114-i1-2-ASY191524 ;
    ns0:inAuthorList ns150:ASY191524 .

ns2:BD160230 owl:sameAs ns2:bd000362 ;
    ns0:fullName "Megha Tandon" ;
    ns0:hasAffiliation ns242:BD160230 ;
    ns0:hasArticle ns1:bd-v38-i3-4-BD160230 ;
    ns0:inAuthorList ns150:BD160230 .

ns2:BD180365 owl:sameAs ns2:BD402,
        ns2:bd000365 ;
    ns0:fullName "Marco Mele" ;
    ns0:hasAffiliation ns242:BD180365 ;
    ns0:hasArticle ns1:bd-v38-i2-BD180365 ;
    ns0:inAuthorList ns150:BD180365 .

ns2:BLC190211 owl:sameAs ns30:BLC150039 ;
    ns0:fullName "Michael A. O’Donnell" ;
    ns0:hasAffiliation ns242:BLC190211 ;
    ns0:hasArticle ns1:blc-v5-i2-BLC190211 ;
    ns0:inAuthorList ns150:BLC190211 .

ns2:BLC190228 owl:sameAs ns2:BLC170120 ;
    ns0:fullName "Madhuri Koti" ;
    ns0:hasAffiliation ns242:BLC190228,
        ns243:BLC190228,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:BLC190228>,
        ns244:BLC190228 ;
    ns0:hasArticle ns1:blc-v5-i3-BLC190228 ;
    ns0:inAuthorList ns150:BLC190228 .

ns2:BME191064 owl:sameAs ns2:BME1732 ;
    ns0:fullName "Mahsa Jahed" ;
    ns0:hasAffiliation ns242:BME191064 ;
    ns0:hasArticle ns1:bme-v30-i4-BME191064 ;
    ns0:inAuthorList ns150:BME191064 .

ns2:BMR171041 owl:sameAs ns12:BMR169775 ;
    ns0:fullName "Taher Babaee" ;
    ns0:hasAffiliation ns242:BMR171041 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR171041 ;
    ns0:inAuthorList ns150:BMR171041 .

ns2:BMR181131 owl:sameAs ns2:BMR160585 ;
    ns0:fullName "Erika Zemková" ;
    ns0:hasAffiliation ns242:BMR181131,
        ns243:BMR181131,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:BMR181131> ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181131 ;
    ns0:inAuthorList ns150:BMR181131 .

ns2:BMR181171 owl:sameAs ns2:BMR171036 ;
    ns0:fullName "Sevgi Özdinç" ;
    ns0:hasAffiliation ns242:BMR181171 ;
    ns0:hasArticle ns1:bmr-v32-i6-BMR181171 ;
    ns0:inAuthorList ns150:BMR181171 .

ns2:BMR181185 owl:sameAs ns57:BMR160543 ;
    ns0:fullName "Sibel Demir-Deviren" ;
    ns0:hasAffiliation ns242:BMR181185 ;
    ns0:hasArticle ns1:bmr-v32-i5-BMR181185 ;
    ns0:inAuthorList ns150:BMR181185 .

ns2:BMR181236 owl:sameAs ns2:bmr00184,
        ns8:bmr00447,
        ns12:bmr00321,
        ns52:BMR171067 ;
    ns0:fullName "Mahmood Akbari" ;
    ns0:hasAffiliation ns242:BMR181236 ;
    ns0:hasArticle ns1:bmr-v32-i6-BMR181236 ;
    ns0:inAuthorList ns150:BMR181236 .

ns2:BRS190143 owl:sameAs ns2:BRS190144 ;
    ns0:fullName "Yahya M. Mohammed" ;
    ns0:hasAffiliation ns242:BRS190143 ;
    ns0:hasArticle ns1:brs-v14-i4-BRS190143 ;
    ns0:inAuthorList ns150:BRS190143 .

ns2:BSI190185 owl:sameAs ns2:BSI183 ;
    ns0:fullName "Michael J. Knight" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:BSI190185> ;
    ns0:hasArticle ns1:bsi-v8-i1-2-BSI190185 ;
    ns0:inAuthorList ns150:BSI190185 .

ns2:CBM182231 owl:sameAs ns5:CBM477 ;
    ns0:fullName "Murat Serilmez" ;
    ns0:hasAffiliation ns242:CBM182231 ;
    ns0:hasArticle ns1:cbm-v25-i2-CBM182231 ;
    ns0:inAuthorList ns150:CBM182231 .

ns2:CBM190273 owl:sameAs ns8:CBM160533 ;
    ns0:fullName "Xuelong Jiao" ;
    ns0:hasAffiliation ns242:CBM190273 ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM190273 ;
    ns0:inAuthorList ns150:CBM190273 .

ns2:CBM192435 owl:sameAs ns2:CBM170472 ;
    ns0:fullName "Runhua Feng" ;
    ns0:hasAffiliation ns242:CBM192435,
        ns243:CBM192435,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:CBM192435> ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM192435 ;
    ns0:inAuthorList ns150:CBM192435 .

ns2:CH180402 owl:sameAs ns8:BIR180175 ;
    ns0:fullName "Fatma Unver" ;
    ns0:hasAffiliation ns242:CH180402 ;
    ns0:hasArticle ns1:ch-v71-i4-CH180402 ;
    ns0:inAuthorList ns150:CH180402 .

ns2:CH180457 owl:sameAs ns2:CH180545 ;
    ns0:fullName "Huaqun Zhao" ;
    ns0:hasAffiliation ns242:CH180457 ;
    ns0:hasArticle ns1:ch-v72-i1-CH180457 ;
    ns0:inAuthorList ns150:CH180457 .

ns2:CH180470 owl:sameAs ns2:CH160241 ;
    ns0:fullName "Katarzyna Filar-Mierzwa" ;
    ns0:hasAffiliation ns242:CH180470 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180470 ;
    ns0:inAuthorList ns150:CH180470 .

ns2:CH180476 owl:sameAs ns8:CH189126 ;
    ns0:fullName "Chang Youn Lee" ;
    ns0:hasAffiliation ns242:CH180476 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180476 ;
    ns0:inAuthorList ns150:CH180476 .

ns2:CH189907 owl:sameAs ns2:CH180428 ;
    ns0:fullName "David Astapenko" ;
    ns0:hasAffiliation ns242:CH189907 ;
    ns0:hasArticle ns1:ch-v72-i1-CH189907 ;
    ns0:inAuthorList ns150:CH189907 .

ns2:CH199005 owl:sameAs ns16:CH179210,
        ns52:CH168121,
        ns52:CH179208 ;
    ns0:fullName "Zijun Deng" ;
    ns0:hasAffiliation ns242:CH199005,
        ns243:CH199005 ;
    ns0:hasArticle ns1:ch-v71-i4-CH199005 ;
    ns0:inAuthorList ns150:CH199005 .

ns2:CH199202 owl:sameAs ns2:CH189116,
        ns2:CH189405,
        ns8:CH189115,
        ns12:CH189310,
        ns30:CH199204 ;
    ns0:fullName "G. Negrão de Figueiredo" ;
    ns0:hasAffiliation ns242:CH199202 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199202 ;
    ns0:inAuthorList ns150:CH199202 .

ns2:CH199205 owl:sameAs ns2:CH179210,
        ns8:CH199005,
        ns5:CH199206 ;
    ns0:fullName "Jie Zou" ;
    ns0:hasAffiliation ns242:CH199205,
        ns243:CH199205 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199205 ;
    ns0:inAuthorList ns150:CH199205 .

ns2:CH199220 owl:sameAs ns12:CH179227,
        ns30:CH189411,
        ns57:CH189309 ;
    ns0:fullName "V. Brebant" ;
    ns0:hasAffiliation ns242:CH199220 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199220 ;
    ns0:inAuthorList ns150:CH199220 .

ns2:CH199223 owl:sameAs ns8:CH199222,
        ns30:CH189407 ;
    ns0:fullName "M. Chaloupka" ;
    ns0:hasAffiliation ns242:CH199223 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199223 ;
    ns0:inAuthorList ns150:CH199223 .

ns2:CH199225 owl:sameAs ns60:CH179216 ;
    ns0:fullName "Daniel Schiltz" ;
    ns0:hasAffiliation ns242:CH199225 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199225 ;
    ns0:inAuthorList ns150:CH199225 .

ns2:CH199226 owl:sameAs ns8:CH189904 ;
    ns0:fullName "Christian Schulz" ;
    ns0:hasAffiliation ns242:CH199226 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199226 ;
    ns0:inAuthorList ns150:CH199226 .

ns2:COM099 owl:sameAs ns2:COM101 ;
    ns0:fullName "Matthew Harrison-Trainor" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:COM099> ;
    ns0:hasArticle ns1:com-v8-i3-4-COM099 ;
    ns0:inAuthorList ns150:COM099 .

ns2:COM180231 owl:sameAs ns2:COM040 ;
    ns0:fullName "Eric P. Astor" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:COM180231> ;
    ns0:hasArticle ns1:com-v8-i2-COM180231 ;
    ns0:inAuthorList ns150:COM180231 .

ns2:FI1814 owl:sameAs ns2:FI1703,
        ns12:FI1455 ;
    ns0:fullName "Marcin Michalak" ;
    ns0:hasAffiliation ns242:FI1814 ;
    ns0:hasArticle ns1:fi-v167-i3-FI1814 ;
    ns0:inAuthorList ns150:FI1814 .

ns2:FI1816 owl:sameAs ns8:FI1711,
        ns12:FI1633 ;
    ns0:fullName "Piotr Wasilewski" ;
    ns0:hasAffiliation ns242:FI1816 ;
    ns0:hasArticle ns1:fi-v167-i3-FI1816 ;
    ns0:inAuthorList ns150:FI1816 .

ns2:FI1819 owl:sameAs ns2:FI1627 ;
    ns0:fullName "Gösta Grahne" ;
    ns0:hasAffiliation ns242:FI1819 ;
    ns0:hasArticle ns1:fi-v167-i4-FI1819 ;
    ns0:inAuthorList ns150:FI1819 .

ns2:FI1830 owl:sameAs ns5:JAE160081 ;
    ns0:fullName "Jin Hong" ;
    ns0:hasAffiliation ns242:FI1830 ;
    ns0:hasArticle ns1:fi-v168-i2-4-FI1830 ;
    ns0:inAuthorList ns150:FI1830 .

ns2:FI1837 owl:sameAs ns8:FI1708 ;
    ns0:fullName "Raymond Devillers" ;
    ns0:hasAffiliation ns242:FI1837 ;
    ns0:hasArticle ns1:fi-v169-i1-2-FI1837 ;
    ns0:inAuthorList ns150:FI1837 .

ns2:FI1838 owl:sameAs ns2:FI1562,
        ns2:FI1574 ;
    ns0:fullName "Ryszard Janicki" ;
    ns0:hasAffiliation ns242:FI1838 ;
    ns0:hasArticle ns1:fi-v169-i1-2-FI1838 ;
    ns0:inAuthorList ns150:FI1838 .

ns2:FI1870 owl:sameAs ns2:mgs00071,
        ns8:kes00172,
        ns30:WEB190403,
        ns5:IA102,
        ns5:IA110 ;
    ns0:fullName "Stefania Bandini" ;
    ns0:hasAffiliation ns242:FI1870 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1870 ;
    ns0:inAuthorList ns150:FI1870 .

ns2:FI1882 owl:sameAs ns8:FI1528,
        ns8:FI1562,
        ns8:FI1574 ;
    ns0:fullName "Jetty Kleijn" ;
    ns0:hasAffiliation ns242:FI1882 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1882 ;
    ns0:inAuthorList ns150:FI1882 .

ns2:FI1885 owl:sameAs ns8:FI1324 ;
    ns0:fullName "Linqiang Pan" ;
    ns0:hasAffiliation ns242:FI1885 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1885 ;
    ns0:inAuthorList ns150:FI1885 .

ns2:HAB190364 owl:sameAs ns12:HAB190371 ;
    ns0:fullName "Ali Ardalan" ;
    ns0:hasAffiliation ns242:HAB190364 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190364 ;
    ns0:inAuthorList ns150:HAB190364 .

ns2:HAB190367 owl:sameAs ns2:HAB190363,
        ns2:HAB190383,
        ns8:HAB190368,
        ns8:HAB190369,
        ns8:HAB304 ;
    ns0:fullName "Addis Adera Gebru" ;
    ns0:hasAffiliation ns243:HAB190367,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:HAB190367> ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190367 ;
    ns0:inAuthorList ns150:HAB190367 .

ns2:HAB190371 owl:sameAs ns30:HAB190364 ;
    ns0:fullName "Mohammad Javad Hosseinzadeh-Attar" ;
    ns0:hasAffiliation ns242:HAB190371 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190371 ;
    ns0:inAuthorList ns150:HAB190371 .

ns2:HAB190373 owl:sameAs ns2:HAB180345 ;
    ns0:fullName "Adi E. Zarei" ;
    ns0:hasAffiliation ns242:HAB190373,
        ns243:HAB190373 ;
    ns0:hasArticle ns1:hab-v27-i3-HAB190373 ;
    ns0:inAuthorList ns150:HAB190373 .

ns2:HAB190374 owl:sameAs ns2:HAB180356 ;
    ns0:fullName "Zahra Azizi" ;
    ns0:hasAffiliation ns242:HAB190374 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190374 ;
    ns0:inAuthorList ns150:HAB190374 .

ns2:HAB190375 owl:sameAs ns2:HAB180360,
        ns8:HAB190379,
        ns8:HAB190386,
        ns52:HAB282 ;
    ns0:fullName "O. Erhabor" ;
    ns0:hasAffiliation ns242:HAB190375 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190375 ;
    ns0:inAuthorList ns150:HAB190375 .

ns2:HAB190385 owl:sameAs ns30:BMR579 ;
    ns0:fullName "Fatemeh Ghaed Amini" ;
    ns0:hasAffiliation ns242:HAB190385 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190385 ;
    ns0:inAuthorList ns150:HAB190385 .

ns2:HIS190271 owl:sameAs ns8:HIS252 ;
    ns0:fullName "M.A. Tawhid" ;
    ns0:hasAffiliation ns242:HIS190271 ;
    ns0:hasArticle ns1:his-v15-i4-HIS190271 ;
    ns0:inAuthorList ns150:HIS190271 .

ns2:HSM180413 owl:sameAs ns2:HSM1641,
        ns2:HSM1785 ;
    ns0:fullName "Kais Mtar" ;
    ns0:hasAffiliation ns242:HSM180413 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180413 ;
    ns0:inAuthorList ns150:HSM180413 .

ns2:HSM180425 owl:sameAs ns2:HSM180472,
        ns8:mgs00081,
        ns30:HSM17166 ;
    ns0:fullName "Kashif Iqbal" ;
    ns0:hasAffiliation ns242:HSM180425 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180425 ;
    ns0:inAuthorList ns150:HSM180425 .

ns2:HSM190516 owl:sameAs ns8:HSM190486 ;
    ns0:fullName "Lila Rajabion" ;
    ns0:hasAffiliation ns242:HSM190516 ;
    ns0:hasArticle ns1:hsm-v38-i4-HSM190516 ;
    ns0:inAuthorList ns150:HSM190516 .

ns2:IA180016 owl:sameAs ns2:IA111,
        ns5:SW156 ;
    ns0:fullName "Antonio Lieto" ;
    ns0:hasAffiliation ns242:IA180016 ;
    ns0:hasArticle ns1:ia-v13-i1-IA180016 ;
    ns0:inAuthorList ns150:IA180016 .

ns2:IA190018 owl:sameAs ns2:IA109 ;
    ns0:fullName "Danilo Croce" ;
    ns0:hasAffiliation ns242:IA190018 ;
    ns0:hasArticle ns1:ia-v13-i1-IA190018 ;
    ns0:inAuthorList ns150:IA190018 .

ns2:IDA183930 owl:sameAs ns30:THC1109 ;
    ns0:fullName "Chung-Chian Hsu" ;
    ns0:hasAffiliation ns242:IDA183930 ;
    ns0:hasArticle ns1:ida-v23-i4-IDA183930 ;
    ns0:inAuthorList ns150:IDA183930 .

ns2:IDA184238 owl:sameAs ns8:IDA814 ;
    ns0:fullName "Bijan Ranjbar-Sahraei" ;
    ns0:hasAffiliation ns242:IDA184238 ;
    ns0:hasArticle ns1:ida-v23-i5-IDA184238 ;
    ns0:inAuthorList ns150:IDA184238 .

ns2:IDA184339 owl:sameAs ns2:IDA818,
        ns2:ida00582,
        ns8:IA106,
        ns8:SW154,
        ns30:FI1658 ;
    ns0:fullName "Elena Bellodi" ;
    ns0:hasAffiliation ns242:IDA184339 ;
    ns0:hasArticle ns1:ida-v23-i6-IDA184339 ;
    ns0:inAuthorList ns150:IDA184339 .

ns2:IDA192765 owl:sameAs ns2:IFS169160,
        ns2:IFS169577 ;
    ns0:fullName "Chun Yan" ;
    ns0:hasAffiliation ns242:IDA192765 ;
    ns0:hasArticle ns1:ida-v23-iS1-IDA192765 ;
    ns0:inAuthorList ns150:IDA192765 .

ns2:IDA192786 owl:sameAs ns2:IDA192829 ;
    ns0:fullName "Ye Li" ;
    ns0:hasAffiliation ns242:IDA192786 ;
    ns0:hasArticle ns1:ida-v23-iS1-IDA192786 ;
    ns0:inAuthorList ns150:IDA192786 .

ns2:IDT180003 owl:sameAs ns12:IFS190078 ;
    ns0:fullName "Nikita Jain" ;
    ns0:hasAffiliation ns243:IDT180003 ;
    ns0:hasArticle ns1:idt-v13-i3-IDT180003 ;
    ns0:inAuthorList ns150:IDT180003 .

ns2:IDT180064 owl:sameAs ns2:KES180385 ;
    ns0:fullName "Wael Farag" ;
    ns0:hasAffiliation ns242:IDT180064,
        ns243:IDT180064 ;
    ns0:hasArticle ns1:idt-v13-i3-IDT180064 ;
    ns0:inAuthorList ns150:IDT180064 .

ns2:IES183201 owl:sameAs ns8:IES211162 ;
    ns0:fullName "Yong-Seok Jee" ;
    ns0:hasAffiliation ns242:IES183201,
        ns243:IES183201 ;
    ns0:hasArticle ns1:ies-v27-i3-IES183201 ;
    ns0:inAuthorList ns150:IES183201 .

ns2:IES193141 owl:sameAs ns8:IES182156 ;
    ns0:fullName "Armağan Kafkas" ;
    ns0:hasAffiliation ns242:IES193141 ;
    ns0:hasArticle ns1:ies-v27-i4-IES193141 ;
    ns0:inAuthorList ns150:IES193141 .

ns2:IFS162405 owl:sameAs ns2:IFS18579,
        ns30:HIS241 ;
    ns0:fullName "Atta Rahman" ;
    ns0:hasAffiliation ns242:IFS162405 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS162405 ;
    ns0:inAuthorList ns150:IFS162405 .

ns2:IFS17193 owl:sameAs ns30:IFS18904 ;
    ns0:fullName "Yimin Zhou" ;
    ns0:hasAffiliation ns242:IFS17193 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS17193 ;
    ns0:inAuthorList ns150:IFS17193 .

ns2:IFS171953 owl:sameAs ns2:IFS18106 ;
    ns0:fullName "Aliasghar Samadi" ;
    ns0:hasAffiliation ns242:IFS171953 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS171953 ;
    ns0:inAuthorList ns150:IFS171953 .

ns2:IFS172129 owl:sameAs ns2:IFS17845 ;
    ns0:fullName "Yi Shi" ;
    ns0:hasAffiliation ns242:IFS172129,
        ns243:IFS172129 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS172129 ;
    ns0:inAuthorList ns150:IFS172129 .

ns2:IFS179060 owl:sameAs ns8:IFS169390,
        ns12:IFS169590,
        ns52:IFS169328 ;
    ns0:fullName "Shuicheng Tian" ;
    ns0:hasAffiliation ns242:IFS179060 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS179060 ;
    ns0:inAuthorList ns150:IFS179060 .

ns2:IFS179090 owl:sameAs ns30:IFS169403 ;
    ns0:fullName "Qiang Yin" ;
    ns0:hasAffiliation ns242:IFS179090 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS179090 ;
    ns0:inAuthorList ns150:IFS179090 .

ns2:IFS179101 owl:sameAs ns2:IFS179199 ;
    ns0:fullName "Wang Yu" ;
    ns0:hasAffiliation ns242:IFS179101 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS179101 ;
    ns0:inAuthorList ns150:IFS179101 .

ns2:IFS179120 owl:sameAs ns2:IFS169173 ;
    ns0:fullName "Q. Yue" ;
    ns0:hasAffiliation ns242:IFS179120 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS179120 ;
    ns0:inAuthorList ns150:IFS179120 .

ns2:IFS179123 owl:sameAs ns30:IFS179094 ;
    ns0:fullName "Yan Zhao" ;
    ns0:hasAffiliation ns242:IFS179123 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS179123 ;
    ns0:inAuthorList ns150:IFS179123 .

ns2:IFS179196 owl:sameAs ns8:IFS179069 ;
    ns0:fullName "Jiangbo Li" ;
    ns0:hasAffiliation ns242:IFS179196 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS179196 ;
    ns0:inAuthorList ns150:IFS179196 .

ns2:IFS179200 owl:sameAs ns2:IFS179069 ;
    ns0:fullName "Fei Kong" ;
    ns0:hasAffiliation ns242:IFS179200 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS179200 ;
    ns0:inAuthorList ns150:IFS179200 .

ns2:IFS179201 owl:sameAs ns5:IFS152168 ;
    ns0:fullName "Wang Bo" ;
    ns0:hasAffiliation ns242:IFS179201,
        ns243:IFS179201 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS179201 ;
    ns0:inAuthorList ns150:IFS179201 .

ns2:IFS179210 owl:sameAs ns12:IFS179083 ;
    ns0:fullName "Wu Yue" ;
    ns0:hasAffiliation ns242:IFS179210 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS179210 ;
    ns0:inAuthorList ns150:IFS179210 .

ns2:IFS179236 owl:sameAs ns2:IFS16554,
        ns2:IFS16946,
        ns8:IFS179241,
        ns8:IFS18266 ;
    ns0:fullName "Jianping Lu" ;
    ns0:hasAffiliation ns242:IFS179236 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179236 ;
    ns0:inAuthorList ns150:IFS179236 .

ns2:IFS179246 owl:sameAs ns2:WEB190407 ;
    ns0:fullName "Bin Dai" ;
    ns0:hasAffiliation ns242:IFS179246 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179246 ;
    ns0:inAuthorList ns150:IFS179246 .

ns2:IFS179251 owl:sameAs ns12:IFS169583 ;
    ns0:fullName "Sin-Jin Lin" ;
    ns0:hasAffiliation ns242:IFS179251 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179251 ;
    ns0:inAuthorList ns150:IFS179251 .

ns2:IFS179252 owl:sameAs ns2:IFS169572,
        ns5:IFS169572 ;
    ns0:fullName "Yit Yin Wee" ;
    ns0:hasAffiliation ns242:IFS179252 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179252 ;
    ns0:inAuthorList ns150:IFS179252 .

ns2:IFS179266 owl:sameAs ns2:IFS16216,
        ns2:KES190394 ;
    ns0:fullName "Xiqing Zhao" ;
    ns0:hasAffiliation ns242:IFS179266,
        ns243:IFS179266 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179266 ;
    ns0:inAuthorList ns150:IFS179266 .

ns2:IFS179280 owl:sameAs ns2:IFS1705 ;
    ns0:fullName "Quan Gu" ;
    ns0:hasAffiliation ns242:IFS179280 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179280 ;
    ns0:inAuthorList ns150:IFS179280 .

ns2:IFS179291 owl:sameAs ns2:IFS179289 ;
    ns0:fullName "Haibo Yi" ;
    ns0:hasAffiliation ns242:IFS179291 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179291 ;
    ns0:inAuthorList ns150:IFS179291 .

ns2:IFS179316 owl:sameAs ns30:BME1542 ;
    ns0:fullName "Hui Pang" ;
    ns0:hasAffiliation ns242:IFS179316 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179316 ;
    ns0:inAuthorList ns150:IFS179316 .

ns2:IFS181127 owl:sameAs ns30:IFS18760 ;
    ns0:fullName "Muhammad Adnan Khan" ;
    ns0:hasAffiliation ns242:IFS181127 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181127 ;
    ns0:inAuthorList ns150:IFS181127 .

ns2:IFS181191 owl:sameAs ns12:IFS171448 ;
    ns0:fullName "Feng Zhao" ;
    ns0:hasAffiliation ns243:IFS181191 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181191 ;
    ns0:inAuthorList ns150:IFS181191 .

ns2:IFS181220 owl:sameAs ns8:IFS17104,
        ns8:IFS190988 ;
    ns0:fullName "Hee Sik Kim" ;
    ns0:hasAffiliation ns242:IFS181220 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181220 ;
    ns0:inAuthorList ns150:IFS181220 .

ns2:IFS181339 owl:sameAs ns2:IFS16232 ;
    ns0:fullName "Lukui Shi" ;
    ns0:hasAffiliation ns242:IFS181339 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS181339 ;
    ns0:inAuthorList ns150:IFS181339 .

ns2:IFS181362 owl:sameAs ns2:IFS18577 ;
    ns0:fullName "Hao Guan" ;
    ns0:hasAffiliation ns242:IFS181362 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181362 ;
    ns0:inAuthorList ns150:IFS181362 .

ns2:IFS181501 owl:sameAs ns12:IFS162245,
        ns12:IFS18702 ;
    ns0:fullName "Shibo Jing" ;
    ns0:hasAffiliation ns242:IFS181501 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181501 ;
    ns0:inAuthorList ns150:IFS181501 .

ns2:IFS181502 owl:sameAs ns2:IFS171172,
        ns2:IFS190447,
        ns2:JAE150030,
        ns8:IFS191197 ;
    ns0:fullName "Abbas Ali" ;
    ns0:hasAffiliation ns242:IFS181502 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181502 ;
    ns0:inAuthorList ns150:IFS181502 .

ns2:IFS181516 owl:sameAs ns8:IFS18943 ;
    ns0:fullName "Faisal Khan" ;
    ns0:hasAffiliation ns242:IFS181516 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181516 ;
    ns0:inAuthorList ns150:IFS181516 .

ns2:IFS181527 owl:sameAs ns8:IFS190810 ;
    ns0:fullName "Arshdeep Kaur" ;
    ns0:hasAffiliation ns242:IFS181527 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181527 ;
    ns0:inAuthorList ns150:IFS181527 .

ns2:IFS181538 owl:sameAs ns30:IFS141877,
        ns30:IFS16727 ;
    ns0:fullName "Basar Oztaysi" ;
    ns0:hasAffiliation ns242:IFS181538 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181538 ;
    ns0:inAuthorList ns150:IFS181538 .

ns2:IFS181547 owl:sameAs ns2:IFS162234 ;
    ns0:fullName "Akansha Mishra" ;
    ns0:hasAffiliation ns242:IFS181547 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181547 ;
    ns0:inAuthorList ns150:IFS181547 .

ns2:IFS181663 owl:sameAs ns2:IFS16661,
        ns12:IFS182569 ;
    ns0:fullName "Zhen-Yu Xiu" ;
    ns0:hasAffiliation ns242:IFS181663,
        ns243:IFS181663 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS181663 ;
    ns0:inAuthorList ns150:IFS181663 .

ns2:IFS181762 owl:sameAs ns2:IFS17756 ;
    ns0:fullName "Yuan Zhi" ;
    ns0:hasAffiliation ns242:IFS181762,
        ns243:IFS181762 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181762 ;
    ns0:inAuthorList ns150:IFS181762 .

ns2:IFS181769 owl:sameAs ns2:IFS172094 ;
    ns0:fullName "Ahmed Mostafa Khalil" ;
    ns0:hasAffiliation ns242:IFS181769,
        ns243:IFS181769 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181769 ;
    ns0:inAuthorList ns150:IFS181769 .

ns2:IFS181790 owl:sameAs ns8:IFS169951 ;
    ns0:fullName "Hussain Ahmed Choudhury" ;
    ns0:hasAffiliation ns242:IFS181790 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181790 ;
    ns0:inAuthorList ns150:IFS181790 .

ns2:IFS181799 owl:sameAs ns12:IFS169608 ;
    ns0:fullName "Yajun Liang" ;
    ns0:hasAffiliation ns242:IFS181799 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181799 ;
    ns0:inAuthorList ns150:IFS181799 .

ns2:IFS181810 owl:sameAs ns2:IFS18963 ;
    ns0:fullName "Quanyu Ding" ;
    ns0:hasAffiliation ns242:IFS181810 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181810 ;
    ns0:inAuthorList ns150:IFS181810 .

ns2:IFS181813 owl:sameAs ns5:HSM17111 ;
    ns0:fullName "Muhammad Imran" ;
    ns0:hasAffiliation ns242:IFS181813,
        ns243:IFS181813 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS181813 ;
    ns0:inAuthorList ns150:IFS181813 .

ns2:IFS181829 owl:sameAs ns2:IFS171744,
        ns2:IFS181296,
        ns8:IFS17850,
        ns8:IFS182595 ;
    ns0:fullName "Muhammad Gulistan" ;
    ns0:hasAffiliation ns242:IFS181829 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181829 ;
    ns0:inAuthorList ns150:IFS181829 .

ns2:IFS181970 owl:sameAs ns2:IFS171090,
        ns2:IFS182634,
        ns2:IFS18667 ;
    ns0:fullName "Guohua Qu" ;
    ns0:hasAffiliation ns242:IFS181970 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS181970 ;
    ns0:inAuthorList ns150:IFS181970 .

ns2:IFS181990 owl:sameAs ns2:IFS17698 ;
    ns0:fullName "M.H. Nazari" ;
    ns0:hasAffiliation ns242:IFS181990 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181990 ;
    ns0:inAuthorList ns150:IFS181990 .

ns2:IFS182512 owl:sameAs ns2:IFS17682 ;
    ns0:fullName "Zhongying Zhao" ;
    ns0:hasAffiliation ns242:IFS182512,
        ns243:IFS182512 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182512 ;
    ns0:inAuthorList ns150:IFS182512 .

ns2:IFS182518 owl:sameAs ns2:IFS17227 ;
    ns0:fullName "Zongwen Fan" ;
    ns0:hasAffiliation ns242:IFS182518 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182518 ;
    ns0:inAuthorList ns150:IFS182518 .

ns2:IFS182540 owl:sameAs ns2:IFS181084 ;
    ns0:fullName "Nguyen Xuan Thao" ;
    ns0:hasAffiliation ns242:IFS182540 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182540 ;
    ns0:inAuthorList ns150:IFS182540 .

ns2:IFS182554 owl:sameAs ns2:IFS18890 ;
    ns0:fullName "Peide Liu" ;
    ns0:hasAffiliation ns242:IFS182554 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182554 ;
    ns0:inAuthorList ns150:IFS182554 .

ns2:IFS182558 owl:sameAs ns8:IFS141907,
        ns8:IFS2062 ;
    ns0:fullName "Wenyi Zeng" ;
    ns0:hasAffiliation ns242:IFS182558 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182558 ;
    ns0:inAuthorList ns150:IFS182558 .

ns2:IFS182579 owl:sameAs ns8:IFS181123 ;
    ns0:fullName "Naeem Jan" ;
    ns0:hasAffiliation ns242:IFS182579 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182579 ;
    ns0:inAuthorList ns150:IFS182579 .

ns2:IFS182581 owl:sameAs ns2:IFS161922,
        ns16:IFS172130 ;
    ns0:fullName "Yuping Xing" ;
    ns0:hasAffiliation ns242:IFS182581 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182581 ;
    ns0:inAuthorList ns150:IFS182581 .

ns2:IFS182590 owl:sameAs ns2:IFS18675 ;
    ns0:fullName "Nguyen Thi Kim Son" ;
    ns0:hasAffiliation ns242:IFS182590,
        ns243:IFS182590 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182590 ;
    ns0:inAuthorList ns150:IFS182590 .

ns2:IFS182595 owl:sameAs ns2:IFS152261,
        ns2:IFS181611 ;
    ns0:fullName "Sheikh Rashid" ;
    ns0:hasAffiliation ns242:IFS182595 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182595 ;
    ns0:inAuthorList ns150:IFS182595 .

ns2:IFS182616 owl:sameAs ns2:IFS162207,
        ns2:IFS162347,
        ns2:IFS171443,
        ns2:IFS181697,
        ns2:IFS181972,
        ns2:IFS18244,
        ns2:IFS2107,
        ns8:IFS171395,
        ns8:IFS17758,
        ns8:IFS190054 ;
    ns0:fullName "Muhammad Akram" ;
    ns0:hasAffiliation ns242:IFS182616 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182616 ;
    ns0:inAuthorList ns150:IFS182616 .

ns2:IFS182618 owl:sameAs ns2:IFS151517,
        ns2:IFS1667,
        ns2:IFS190036,
        ns12:IFS190148 ;
    ns0:fullName "Mohammad Hamidi" ;
    ns0:hasAffiliation ns242:IFS182618 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182618 ;
    ns0:inAuthorList ns150:IFS182618 .

ns2:IFS182651 owl:sameAs ns2:IFS181172 ;
    ns0:fullName "Fatma Kutlu Gündoğdu" ;
    ns0:hasAffiliation ns242:IFS182651,
        ns243:IFS182651 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182651 ;
    ns0:inAuthorList ns150:IFS182651 .

ns2:IFS182766 owl:sameAs ns2:IFS181097 ;
    ns0:fullName "Jiasheng Zeng" ;
    ns0:hasAffiliation ns242:IFS182766 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182766 ;
    ns0:inAuthorList ns150:IFS182766 .

ns2:IFS182774 owl:sameAs ns2:IFS171278,
        ns8:IFS161695,
        ns8:IFS162175,
        ns8:IFS162403,
        ns8:IFS16920,
        ns8:IFS1699,
        ns8:IFS17488,
        ns8:IFS1889,
        ns12:IFS17636 ;
    ns0:fullName "Peide Liu" ;
    ns0:hasAffiliation ns242:IFS182774 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182774 ;
    ns0:inAuthorList ns150:IFS182774 .

ns2:IFS182778 owl:sameAs ns2:INF1160 ;
    ns0:fullName "Jan Sher Khan" ;
    ns0:hasAffiliation ns242:IFS182778 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182778 ;
    ns0:inAuthorList ns150:IFS182778 .

ns2:IFS182821 owl:sameAs ns2:IFS17851 ;
    ns0:fullName "Jinshan Ma" ;
    ns0:hasAffiliation ns242:IFS182821 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182821 ;
    ns0:inAuthorList ns150:IFS182821 .

ns2:IFS182864 owl:sameAs ns2:IFS18268 ;
    ns0:fullName "Lifen Jia" ;
    ns0:hasAffiliation ns242:IFS182864 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182864 ;
    ns0:inAuthorList ns150:IFS182864 .

ns2:IFS182876 owl:sameAs ns2:IFS161467,
        ns2:IFS161919,
        ns2:IFS171070,
        ns2:IFS182863,
        ns2:IFS190952,
        ns8:IFS181657,
        ns8:IFS181698 ;
    ns0:fullName "Ho Vu" ;
    ns0:hasAffiliation ns242:IFS182876 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182876 ;
    ns0:inAuthorList ns150:IFS182876 .

ns2:IFS182893 owl:sameAs ns8:IFS1848 ;
    ns0:fullName "Zhikai Xing" ;
    ns0:hasAffiliation ns242:IFS182893 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182893 ;
    ns0:inAuthorList ns150:IFS182893 .

ns2:IFS182907 owl:sameAs ns2:IFS182810 ;
    ns0:fullName "Davoud Mougouei" ;
    ns0:hasAffiliation ns242:IFS182907 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182907 ;
    ns0:inAuthorList ns150:IFS182907 .

ns2:IFS182924 owl:sameAs ns8:IFS1793 ;
    ns0:fullName "Emin Aygün" ;
    ns0:hasAffiliation ns242:IFS182924 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182924 ;
    ns0:inAuthorList ns150:IFS182924 .

ns2:IFS182928 owl:sameAs ns2:IFS161821,
        ns2:IFS162058,
        ns2:IFS171587,
        ns2:IFS17728,
        ns2:IFS179250,
        ns2:IFS182572,
        ns8:IFS181188,
        ns12:IFS181460 ;
    ns0:fullName "Asghar Khan" ;
    ns0:hasAffiliation ns242:IFS182928 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182928 ;
    ns0:inAuthorList ns150:IFS182928 .

ns2:IFS182961 owl:sameAs ns8:IFS182746,
        ns8:IFS2075,
        ns8:IFS2082,
        ns8:IFS2110,
        ns8:IFS2114,
        ns8:IFS2121,
        ns12:IFS171060,
        ns12:IFS2113 ;
    ns0:fullName "Hossein Rashmanlou" ;
    ns0:hasAffiliation ns242:IFS182961 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182961 ;
    ns0:inAuthorList ns150:IFS182961 .

ns2:IFS18473 owl:sameAs ns2:IFS169468 ;
    ns0:fullName "Ruchika Malhotra" ;
    ns0:hasAffiliation ns242:IFS18473 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18473 ;
    ns0:inAuthorList ns150:IFS18473 .

ns2:IFS18586 owl:sameAs ns2:IFS172114,
        ns8:IFS181649 ;
    ns0:fullName "Haidong Zhang" ;
    ns0:hasAffiliation ns242:IFS18586 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS18586 ;
    ns0:inAuthorList ns150:IFS18586 .

ns2:IFS18659 owl:sameAs ns2:IFS161927,
        ns2:IFS162136,
        ns2:IFS182568,
        ns8:IFS17465,
        ns8:IFS17912,
        ns30:JAD190113 ;
    ns0:fullName "Yu Zhong" ;
    ns0:hasAffiliation ns242:IFS18659 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18659 ;
    ns0:inAuthorList ns150:IFS18659 .

ns2:IFS18725 owl:sameAs ns2:IFS2060 ;
    ns0:fullName "Yu-Hsien Liao" ;
    ns0:hasAffiliation ns242:IFS18725 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18725 ;
    ns0:inAuthorList ns150:IFS18725 .

ns2:IFS18755 owl:sameAs ns12:IFS17530 ;
    ns0:fullName "Lanzhen Yang" ;
    ns0:hasAffiliation ns242:IFS18755 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18755 ;
    ns0:inAuthorList ns150:IFS18755 .

ns2:IFS18998 owl:sameAs ns2:IFS16236,
        ns2:IFS190554 ;
    ns0:fullName "R.J. Kuo" ;
    ns0:hasAffiliation ns242:IFS18998 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18998 ;
    ns0:inAuthorList ns150:IFS18998 .

ns2:IFS190042 owl:sameAs ns12:IFS2125 ;
    ns0:fullName "Libang Lai" ;
    ns0:hasAffiliation ns242:IFS190042 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS190042 ;
    ns0:inAuthorList ns150:IFS190042 .

ns2:IFS190111 owl:sameAs ns12:IFS17158,
        ns12:IFS1827 ;
    ns0:fullName "Yanhong She" ;
    ns0:hasAffiliation ns242:IFS190111 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS190111 ;
    ns0:inAuthorList ns150:IFS190111 .

ns2:IFS190149 owl:sameAs ns2:IFS161413 ;
    ns0:fullName "Shokrollah Ziari" ;
    ns0:hasAffiliation ns242:IFS190149 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190149 ;
    ns0:inAuthorList ns150:IFS190149 .

ns2:IFS190215 owl:sameAs ns8:IFS18746 ;
    ns0:fullName "C.J. Mantas" ;
    ns0:hasAffiliation ns242:IFS190215 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190215 ;
    ns0:inAuthorList ns150:IFS190215 .

ns2:IFS190344 owl:sameAs ns2:IFS16381 ;
    ns0:fullName "Zhifu Tao" ;
    ns0:hasAffiliation ns242:IFS190344 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190344 ;
    ns0:inAuthorList ns150:IFS190344 .

ns2:IFS190349 owl:sameAs ns8:IFS190707 ;
    ns0:fullName "V. Vanitha" ;
    ns0:hasAffiliation ns242:IFS190349 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190349 ;
    ns0:inAuthorList ns150:IFS190349 .

ns2:IFS190450 owl:sameAs ns2:IFS182747 ;
    ns0:fullName "Jianping Fan" ;
    ns0:hasAffiliation ns242:IFS190450 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190450 ;
    ns0:inAuthorList ns150:IFS190450 .

ns2:IFS190550 owl:sameAs ns2:IFS181648,
        ns2:IFS182751,
        ns2:IFS182809,
        ns2:IFS182919,
        ns8:IFS190668,
        ns8:IFS190905 ;
    ns0:fullName "Muhammad Riaz" ;
    ns0:hasAffiliation ns242:IFS190550 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190550 ;
    ns0:inAuthorList ns150:IFS190550 .

ns2:IFS190580 owl:sameAs ns2:IFS171515 ;
    ns0:fullName "Jamshaid Ahmad" ;
    ns0:hasAffiliation ns242:IFS190580 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190580 ;
    ns0:inAuthorList ns150:IFS190580 .

ns2:IFS190668 owl:sameAs ns8:IFS182751 ;
    ns0:fullName "Syeda Tayyba Tehrim" ;
    ns0:hasAffiliation ns242:IFS190668 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190668 ;
    ns0:inAuthorList ns150:IFS190668 .

ns2:IFS190782 owl:sameAs ns8:IFS182893 ;
    ns0:fullName "Heming Jia" ;
    ns0:hasAffiliation ns242:IFS190782 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190782 ;
    ns0:inAuthorList ns150:IFS190782 .

ns2:ISP180248 owl:sameAs ns2:ISP180256 ;
    ns0:fullName "Francesco Mauro" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ISP180248>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:0.ID:ISP180248> ;
    ns0:hasArticle ns1:isp-v66-i2-ISP180248 ;
    ns0:inAuthorList ns150:ISP180248 .

ns2:ISU180039 owl:sameAs ns12:ISU830 ;
    ns0:fullName "Emily B. Peterson" ;
    ns0:hasAffiliation ns242:ISU180039 ;
    ns0:hasArticle ns1:isu-v39-i1-2-ISU180039 ;
    ns0:inAuthorList ns150:ISU180039 .

ns2:JAD180492 owl:sameAs ns2:JAD190541,
        ns30:JAD161208,
        ns5:JAD170731 ;
    ns0:fullName "Kay Deckers" ;
    ns0:hasAffiliation ns242:JAD180492 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180492 ;
    ns0:inAuthorList ns150:JAD180492 .

ns2:JAD180501 owl:sameAs ns5:NRE172353 ;
    ns0:fullName "Isobel E.M. Evans" ;
    ns0:hasAffiliation ns242:JAD180501 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180501 ;
    ns0:inAuthorList ns150:JAD180501 .

ns2:JAD180521 owl:sameAs ns43:JAD180572 ;
    ns0:fullName "Kay L. Cox" ;
    ns0:hasAffiliation ns242:JAD180521 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180521 ;
    ns0:inAuthorList ns150:JAD180521 .

ns2:JAD180525 owl:sameAs ns2:JAD111697,
        ns2:JAD130086,
        ns2:JAD170587,
        ns26:JAD132147,
        ns30:JAD102103,
        ns30:JAD160163,
        ns30:JAD190230,
        ns52:JAD140276,
        ns57:JAD170555 ;
    ns0:fullName "Daniel A. Nation" ;
    ns0:hasAffiliation ns242:JAD180525,
        ns243:JAD180525 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180525 ;
    ns0:inAuthorList ns150:JAD180525 .

ns2:JAD180562 owl:sameAs ns30:JAD170055 ;
    ns0:fullName "Nicolas Cherbuin" ;
    ns0:hasAffiliation ns242:JAD180562 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180562 ;
    ns0:inAuthorList ns150:JAD180562 .

ns2:JAD180571 owl:sameAs ns8:JAD170130,
        ns8:JAD190342 ;
    ns0:fullName "G. Peggy McFall" ;
    ns0:hasAffiliation ns242:JAD180571,
        ns243:JAD180571 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180571 ;
    ns0:inAuthorList ns150:JAD180571 .

ns2:JAD180572 owl:sameAs ns8:JAD120169 ;
    ns0:fullName "Megan Heffernan" ;
    ns0:hasAffiliation ns242:JAD180572 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180572 ;
    ns0:inAuthorList ns150:JAD180572 .

ns2:JAD180630 owl:sameAs ns2:JAD160970 ;
    ns0:fullName "Hana Markova" ;
    ns0:hasAffiliation ns242:JAD180630,
        ns243:JAD180630 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD180630 ;
    ns0:inAuthorList ns150:JAD180630 .

ns2:JAD180847 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190019> ;
    ns0:fullName "Lisa T. Eyler" ;
    ns0:hasAffiliation ns242:JAD180847,
        ns243:JAD180847 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD180847 ;
    ns0:inAuthorList ns150:JAD180847 .

ns2:JAD180899 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD141338> ;
    ns0:fullName "Kenichi Meguro" ;
    ns0:hasAffiliation ns242:JAD180899,
        ns243:JAD180899 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180899 ;
    ns0:inAuthorList ns150:JAD180899 .

ns2:JAD180900 owl:sameAs ns30:JAD170002 ;
    ns0:fullName "Rachel H. Tan" ;
    ns0:hasAffiliation ns242:JAD180900,
        ns243:JAD180900 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180900 ;
    ns0:inAuthorList ns150:JAD180900 .

ns2:JAD180938 owl:sameAs ns2:JAD161285 ;
    ns0:fullName "Julie M. Robillard" ;
    ns0:hasAffiliation ns242:JAD180938,
        ns243:JAD180938 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180938 ;
    ns0:inAuthorList ns150:JAD180938 .

ns2:JAD180991 owl:sameAs ns60:JAD170574,
        ns33:JAD180087 ;
    ns0:fullName "Marc Teichmann" ;
    ns0:hasAffiliation ns243:JAD180991 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180991 ;
    ns0:inAuthorList ns150:JAD180991 .

ns2:JAD181030 owl:sameAs ns8:JAD161162 ;
    ns0:fullName "Chinedu T. Udeh-Momoh" ;
    ns0:hasAffiliation ns242:JAD181030,
        ns243:JAD181030 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181030 ;
    ns0:inAuthorList ns150:JAD181030 .

ns2:JAD181033 owl:sameAs ns5:JAD160268 ;
    ns0:fullName "Alexandra König" ;
    ns0:hasAffiliation ns242:JAD181033 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181033 ;
    ns0:inAuthorList ns150:JAD181033 .

ns2:JAD181141 owl:sameAs ns12:JAD180335 ;
    ns0:fullName "Carol A. Derby" ;
    ns0:hasAffiliation ns242:JAD181141,
        ns243:JAD181141 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD181141 ;
    ns0:inAuthorList ns150:JAD181141 .

ns2:JAD181169 owl:sameAs ns2:JAD181170 ;
    ns0:fullName "Susan W. Hunter" ;
    ns0:hasAffiliation ns242:JAD181169 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181169 ;
    ns0:inAuthorList ns150:JAD181169 .

ns2:JAD181171 owl:sameAs ns30:JAD160685 ;
    ns0:fullName "Hamizah Shahirah Hamezah" ;
    ns0:hasAffiliation ns242:JAD181171 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD181171 ;
    ns0:inAuthorList ns150:JAD181171 .

ns2:JAD181178 owl:sameAs ns30:JAD160244,
        ns30:JAD170195 ;
    ns0:fullName "Kota Tsutsumimoto" ;
    ns0:hasAffiliation ns242:JAD181178,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD181178> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181178 ;
    ns0:inAuthorList ns150:JAD181178 .

ns2:JAD181230 owl:sameAs ns12:JAD170275 ;
    ns0:fullName "Caleb Vegh" ;
    ns0:hasAffiliation ns242:JAD181230 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181230 ;
    ns0:inAuthorList ns150:JAD181230 .

ns2:JAD181261 owl:sameAs ns30:JAD190159 ;
    ns0:fullName "Benjamin Yi Xin Wong" ;
    ns0:hasAffiliation ns242:JAD181261 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181261 ;
    ns0:inAuthorList ns150:JAD181261 .

ns2:JAD181282 owl:sameAs ns30:JAD132489 ;
    ns0:fullName "Jon B. Toledo" ;
    ns0:hasAffiliation ns242:JAD181282,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD181282> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181282 ;
    ns0:inAuthorList ns150:JAD181282 .

ns2:JAD181296 owl:sameAs ns2:jad01207,
        ns5:JPD171264,
        ns5:JPD191612,
        ns16:jad00870 ;
    ns0:fullName "Hailun Cui" ;
    ns0:hasAffiliation ns242:JAD181296 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181296 ;
    ns0:inAuthorList ns150:JAD181296 .

ns2:JAD190011 owl:sameAs ns2:JAD110341,
        ns2:JAD120763,
        ns2:JAD130245,
        ns2:JAD161198,
        ns30:JAD150778 ;
    ns0:fullName "Whitney Wharton" ;
    ns0:hasAffiliation ns242:JAD190011,
        ns243:JAD190011 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190011 ;
    ns0:inAuthorList ns150:JAD190011 .

ns2:JAD190019 owl:sameAs ns12:JAD170555,
        ns30:JAD170017,
        ns52:JAD170444,
        ns60:JAD132147 ;
    ns0:fullName "Melissa Lamar" ;
    ns0:hasAffiliation ns242:JAD190019,
        ns243:JAD190019,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190019>,
        ns244:JAD190019 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190019 ;
    ns0:inAuthorList ns150:JAD190019 .

ns2:JAD190074 owl:sameAs ns2:JAD151101 ;
    ns0:fullName "Shira Simonovitch" ;
    ns0:hasAffiliation ns242:JAD190074 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190074 ;
    ns0:inAuthorList ns150:JAD190074 .

ns2:JAD190087 owl:sameAs ns40:JAD151139 ;
    ns0:fullName "Nobuya Kitaguchi" ;
    ns0:hasAffiliation ns242:JAD190087 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190087 ;
    ns0:inAuthorList ns150:JAD190087 .

ns2:JAD190091 owl:sameAs ns2:JAD190725,
        ns52:JAD150985 ;
    ns0:fullName "Meghan K. Mattos" ;
    ns0:hasAffiliation ns242:JAD190091 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190091 ;
    ns0:inAuthorList ns150:JAD190091 .

ns2:JAD190094 owl:sameAs ns57:JAD180219 ;
    ns0:fullName "Jenni Ilomäki" ;
    ns0:hasAffiliation ns242:JAD190094,
        ns243:JAD190094 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190094 ;
    ns0:inAuthorList ns150:JAD190094 .

ns2:JAD190107 owl:sameAs ns16:JAD190660 ;
    ns0:fullName "Sara López-García" ;
    ns0:hasAffiliation ns242:JAD190107,
        ns243:JAD190107,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190107> ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190107 ;
    ns0:inAuthorList ns150:JAD190107 .

ns2:JAD190113 owl:sameAs ns5:JAD160008,
        ns16:JAD150727,
        ns16:JAD181108 ;
    ns0:fullName "Yue Cui" ;
    ns0:hasAffiliation ns242:JAD190113 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190113 ;
    ns0:inAuthorList ns150:JAD190113 .

ns2:JAD190119 owl:sameAs ns2:JAD120523,
        ns2:JAD170712,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD102124>,
        ns30:JAD180723,
        ns16:JAD150863,
        ns16:JAD160073,
        ns16:JAD170861,
        ns52:JAD140756 ;
    ns0:fullName "Andrea Arighi" ;
    ns0:hasAffiliation ns243:JAD190119 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

ns2:JAD190142 owl:sameAs ns12:JAD130287,
        ns5:JAD140636 ;
    ns0:fullName "Raymond R. Romano" ;
    ns0:hasAffiliation ns242:JAD190142 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190142 ;
    ns0:inAuthorList ns150:JAD190142 .

ns2:JAD190158 owl:sameAs ns30:JAD131595 ;
    ns0:fullName "Beibei Wu" ;
    ns0:hasAffiliation ns242:JAD190158 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190158 ;
    ns0:inAuthorList ns150:JAD190158 .

ns2:JAD190180 owl:sameAs ns2:JAD160025 ;
    ns0:fullName "Seokjo Kang" ;
    ns0:hasAffiliation ns242:JAD190180 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190180 ;
    ns0:inAuthorList ns150:JAD190180 .

ns2:JAD190183 owl:sameAs ns2:JAD161023,
        ns2:JAD170990,
        ns2:JAD190459,
        ns28:JAD170410,
        ns52:JAD142337 ;
    ns0:fullName "Isabelle Rouch" ;
    ns0:hasAffiliation ns242:JAD190183,
        ns243:JAD190183 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190183 ;
    ns0:inAuthorList ns150:JAD190183 .

ns2:JAD190196 owl:sameAs ns52:JAE2212 ;
    ns0:fullName "Koji Yoshida" ;
    ns0:hasAffiliation ns242:JAD190196,
        ns243:JAD190196 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190196 ;
    ns0:inAuthorList ns150:JAD190196 .

ns2:JAD190197 owl:sameAs ns26:jad091054,
        ns28:JAD132345,
        ns33:jad091549,
        ns33:jad100234 ;
    ns0:fullName "Harald Hampel" ;
    ns0:hasAffiliation ns242:JAD190197 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190197 ;
    ns0:inAuthorList ns150:JAD190197 .

ns2:JAD190262 owl:sameAs ns5:JAD180737 ;
    ns0:fullName "Ali Ezzati" ;
    ns0:hasAffiliation ns242:JAD190262,
        ns243:JAD190262 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190262 ;
    ns0:inAuthorList ns150:JAD190262 .

ns2:JAD190265 owl:sameAs ns2:jad01094 ;
    ns0:fullName "Janardan P. Pandey" ;
    ns0:hasAffiliation ns242:JAD190265 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190265 ;
    ns0:inAuthorList ns150:JAD190265 .

ns2:JAD190266 owl:sameAs ns2:JAD120424,
        ns2:JAD131733,
        ns2:JAD150261,
        ns2:JAD171053,
        ns8:JAD150254 ;
    ns0:fullName "Donald R. Royall" ;
    ns0:hasAffiliation ns242:JAD190266,
        ns243:JAD190266,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190266> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190266 ;
    ns0:inAuthorList ns150:JAD190266 .

ns2:JAD190278 owl:sameAs ns12:JAD150250 ;
    ns0:fullName "Teruyuki Matsuoka" ;
    ns0:hasAffiliation ns242:JAD190278 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190278 ;
    ns0:inAuthorList ns150:JAD190278 .

ns2:JAD190293 owl:sameAs ns2:JAD121168,
        ns2:JAD142085,
        ns8:JAD160158,
        ns8:JAD160582,
        ns8:JAD180092 ;
    ns0:fullName "Amber Watts" ;
    ns0:hasAffiliation ns242:JAD190293,
        ns243:JAD190293 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190293 ;
    ns0:inAuthorList ns150:JAD190293 .

ns2:JAD190316 owl:sameAs ns2:JAD160289,
        ns12:JAD180755 ;
    ns0:fullName "Richard McClure" ;
    ns0:hasAffiliation ns242:JAD190316 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190316 ;
    ns0:inAuthorList ns150:JAD190316 .

ns2:JAD190322 owl:sameAs ns2:JAD160965,
        ns2:JAD170390 ;
    ns0:fullName "Michael S. Rafii" ;
    ns0:hasAffiliation ns242:JAD190322 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190322 ;
    ns0:inAuthorList ns150:JAD190322 .

ns2:JAD190340 owl:sameAs ns2:JAD160651,
        ns2:JAD170971,
        ns8:JAD171177,
        ns5:jad100075 ;
    ns0:fullName "Moeko Noguchi-Shinohara" ;
    ns0:hasAffiliation ns242:JAD190340,
        ns243:JAD190340 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190340 ;
    ns0:inAuthorList ns150:JAD190340 .

ns2:JAD190346 owl:sameAs ns12:JAD160927 ;
    ns0:fullName "Li Xiong" ;
    ns0:hasAffiliation ns242:JAD190346 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190346 ;
    ns0:inAuthorList ns150:JAD190346 .

ns2:JAD190368 owl:sameAs ns2:JAD171047,
        ns8:JAD170715 ;
    ns0:fullName "Jianlan Gu" ;
    ns0:hasAffiliation ns242:JAD190368,
        ns243:JAD190368,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190368> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190368 ;
    ns0:inAuthorList ns150:JAD190368 .

ns2:JAD190369 owl:sameAs ns52:JAD181218 ;
    ns0:fullName "Tian Feng" ;
    ns0:hasAffiliation ns242:JAD190369 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190369 ;
    ns0:inAuthorList ns150:JAD190369 .

ns2:JAD190385 owl:sameAs ns8:JAD160525,
        <http://ld.iospress.nl/rdf/contributor/Author:26.ID:JAD160883>,
        ns57:JAD180890 ;
    ns0:fullName "Fabrizia D’Antonio" ;
    ns0:hasAffiliation ns242:JAD190385,
        ns243:JAD190385 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190385 ;
    ns0:inAuthorList ns150:JAD190385 .

ns2:JAD190394 owl:sameAs ns2:JAD170625 ;
    ns0:fullName "Anna Pedrinolla" ;
    ns0:hasAffiliation ns242:JAD190394 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190394 ;
    ns0:inAuthorList ns150:JAD190394 .

ns2:JAD190397 owl:sameAs ns2:JAD180024,
        ns2:JAD190124,
        ns12:JAD170319,
        ns5:JAD190708,
        ns5:NRE182452,
        ns52:JAD150864,
        ns57:JAD130032,
        ns57:JAD131481 ;
    ns0:fullName "Mario F. Mendez" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190397> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190397 ;
    ns0:inAuthorList ns150:JAD190397 .

ns2:JAD190399 owl:sameAs ns2:JAD160108,
        ns52:VES560 ;
    ns0:fullName "Seung Wan Suh" ;
    ns0:hasAffiliation ns242:JAD190399 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns2:JAD190405 owl:sameAs ns2:JAD110722,
        ns2:JAD141365,
        ns2:JAD142685,
        ns2:JAD160472,
        ns2:JAD160510,
        ns2:JAD180853,
        ns2:JAD190331,
        ns30:JAD181186,
        ns5:JAD170012 ;
    ns0:fullName "Lilian Calderón-Garcidueñas" ;
    ns0:hasAffiliation ns242:JAD190405 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190405 ;
    ns0:inAuthorList ns150:JAD190405 .

ns2:JAD190413 owl:sameAs ns8:JAD150481,
        ns8:JAD160124,
        ns8:JAD160485,
        ns8:JAD160828,
        ns8:JAD190030,
        ns12:JAD170905,
        ns12:JAD180427 ;
    ns0:fullName "Christina Jensen-Dahm" ;
    ns0:hasAffiliation ns242:JAD190413 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190413 ;
    ns0:inAuthorList ns150:JAD190413 .

ns2:JAD190423 owl:sameAs ns2:JAD160348,
        ns2:JAD180223,
        ns12:JAD160304 ;
    ns0:fullName "Ioulietta Lazarou" ;
    ns0:hasAffiliation ns242:JAD190423,
        ns243:JAD190423 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190423 ;
    ns0:inAuthorList ns150:JAD190423 .

ns2:JAD190446 owl:sameAs ns2:JAD131829,
        ns12:JAD110329,
        ns16:JAD160273,
        ns16:JAD161197,
        ns52:JAD091153,
        ns52:JAD141554,
        ns52:JAD160773 ;
    ns0:fullName "Stefan J. Teipel" ;
    ns0:hasAffiliation ns242:JAD190446,
        ns243:JAD190446 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns2:JAD190461 owl:sameAs ns26:JAD170410,
        ns40:JAD161023,
        ns28:JAD110515,
        ns28:JAD120361,
        ns28:JAD131916,
        ns30:JAD171131,
        ns5:JAD130170,
        ns16:JAD111490,
        ns16:JAD180403,
        ns52:JAD190459,
        ns57:JAD112003,
        ns57:JAD142337,
        ns57:JAD170990,
        ns60:JAD190183 ;
    ns0:fullName "Pierre Krolak-Salmon" ;
    ns0:hasAffiliation ns242:JAD190461,
        ns243:JAD190461,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190461> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190461 ;
    ns0:inAuthorList ns150:JAD190461 .

ns2:JAD190484 owl:sameAs ns2:JAD170045,
        ns2:JAD170218 ;
    ns0:fullName "Gisela Esquerda-Canals" ;
    ns0:hasAffiliation ns242:JAD190484,
        ns243:JAD190484 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190484 ;
    ns0:inAuthorList ns150:JAD190484 .

ns2:JAD190494 owl:sameAs ns2:JAD110884,
        ns8:JAD170298,
        ns8:JAD170581,
        ns5:jad100729 ;
    ns0:fullName "Michela Guglielmotto" ;
    ns0:hasAffiliation ns242:JAD190494,
        ns243:JAD190494 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190494 ;
    ns0:inAuthorList ns150:JAD190494 .

ns2:JAD190546 owl:sameAs ns2:JAD190256,
        ns8:JAD180888,
        ns5:JAD190087 ;
    ns0:fullName "Shinji Matsunaga" ;
    ns0:hasAffiliation ns242:JAD190546 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190546 ;
    ns0:inAuthorList ns150:JAD190546 .

ns2:JAD190549 owl:sameAs ns12:JAD180082 ;
    ns0:fullName "Brice Laurens" ;
    ns0:hasAffiliation ns242:JAD190549,
        ns243:JAD190549 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190549 ;
    ns0:inAuthorList ns150:JAD190549 .

ns2:JAD190555 owl:sameAs ns2:JAD180119 ;
    ns0:fullName "Angelina R. Sutin" ;
    ns0:hasAffiliation ns242:JAD190555 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190555 ;
    ns0:inAuthorList ns150:JAD190555 .

ns2:JAD190562 owl:sameAs ns8:JAD151005,
        ns8:JAD181062 ;
    ns0:fullName "Yu Wan" ;
    ns0:hasAffiliation ns242:JAD190562,
        ns243:JAD190562 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190562 ;
    ns0:inAuthorList ns150:JAD190562 .

ns2:JAD190577 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD150948> ;
    ns0:fullName "Stuart G. Snowden" ;
    ns0:hasAffiliation ns242:JAD190577 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190577 ;
    ns0:inAuthorList ns150:JAD190577 .

ns2:JAD190581 owl:sameAs ns2:JAD180569,
        ns2:JAD190508,
        ns8:JAD181180,
        ns12:JAD180808,
        ns12:JAD181194,
        ns30:VES190668 ;
    ns0:fullName "Karel Kostev" ;
    ns0:hasAffiliation ns242:JAD190581 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190581 ;
    ns0:inAuthorList ns150:JAD190581 .

ns2:JAD190590 owl:sameAs ns2:JAD150898,
        ns2:JAD160935,
        ns2:JAD171077 ;
    ns0:fullName "Miharu Nakanishi" ;
    ns0:hasAffiliation ns242:JAD190590 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190590 ;
    ns0:inAuthorList ns150:JAD190590 .

ns2:JAD190596 owl:sameAs ns2:CBM181628 ;
    ns0:fullName "Yuan Tian" ;
    ns0:hasAffiliation ns242:JAD190596 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190596 ;
    ns0:inAuthorList ns150:JAD190596 .

ns2:JAD190609 owl:sameAs ns2:JAD130956,
        ns2:JAD140516,
        ns2:JAD150747,
        ns2:JAD170938,
        ns2:JAD181298,
        ns16:JAD180524 ;
    ns0:fullName "Maurizio Gallucci" ;
    ns0:hasAffiliation ns242:JAD190609,
        ns243:JAD190609 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190609 ;
    ns0:inAuthorList ns150:JAD190609 .

ns2:JAD190620 owl:sameAs ns52:JAD180701 ;
    ns0:fullName "Naoto Takenoshita" ;
    ns0:hasAffiliation ns242:JAD190620 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190620 ;
    ns0:inAuthorList ns150:JAD190620 .

ns2:JAD190622 owl:sameAs ns2:JAD160923 ;
    ns0:fullName "Taiki Sugimoto" ;
    ns0:hasAffiliation ns242:JAD190622,
        ns243:JAD190622,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190622> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190622 ;
    ns0:inAuthorList ns150:JAD190622 .

ns2:JAD190644 owl:sameAs ns33:JAD190369 ;
    ns0:fullName "Koh Tadokoro" ;
    ns0:hasAffiliation ns242:JAD190644 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns2:JAD190656 owl:sameAs ns8:JAD180776 ;
    ns0:fullName "Brent Aulston" ;
    ns0:hasAffiliation ns242:JAD190656 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190656 ;
    ns0:inAuthorList ns150:JAD190656 .

ns2:JAD190660 owl:sameAs ns5:JAD110794,
        ns5:jad100432 ;
    ns0:fullName "Ana Pozueta" ;
    ns0:hasAffiliation ns242:JAD190660 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190660 ;
    ns0:inAuthorList ns150:JAD190660 .

ns2:JAD190670 owl:sameAs ns52:JAD132087,
        ns33:JAD111997 ;
    ns0:fullName "Paolo Maria Rossini" ;
    ns0:hasAffiliation ns242:JAD190670,
        ns243:JAD190670 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190670 ;
    ns0:inAuthorList ns150:JAD190670 .

ns2:JAD190685 owl:sameAs ns2:JAD190032 ;
    ns0:fullName "Jung-Min Pyun" ;
    ns0:hasAffiliation ns242:JAD190685 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190685 ;
    ns0:inAuthorList ns150:JAD190685 .

ns2:JAD190707 owl:sameAs ns2:JAD161095 ;
    ns0:fullName "Elizabeth M. Rhea" ;
    ns0:hasAffiliation ns243:JAD190707 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190707 ;
    ns0:inAuthorList ns150:JAD190707 .

ns2:JAD190708 owl:sameAs ns12:JAD180598,
        ns30:JAD170281,
        ns16:JAD160833 ;
    ns0:fullName "Somayeh Meysami" ;
    ns0:hasAffiliation ns242:JAD190708 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190708 ;
    ns0:inAuthorList ns150:JAD190708 .

ns2:JAD190721 owl:sameAs ns2:JAD111376,
        ns2:JAD121090,
        ns2:JAD170101,
        ns2:JAD171119,
        ns8:JAD121336,
        ns8:JAD141284,
        ns26:JAD122182,
        ns43:JAD150862,
        ns12:JAD190146,
        ns139:JAD101914,
        ns30:jad101368,
        <http://ld.iospress.nl/rdf/contributor/Author:38.ID:JAD110824>,
        ns5:JAD110473,
        ns5:JAD131430,
        ns16:JAD140684,
        ns16:JAD141869,
        ns52:JAD131694,
        ns57:JAD140321,
        ns57:JAD142970,
        ns60:JAD131496 ;
    ns0:fullName "Patrick G. Kehoe" ;
    ns0:hasAffiliation ns242:JAD190721 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190721 ;
    ns0:inAuthorList ns150:JAD190721 .

ns2:JAD190772 owl:sameAs ns60:JAD170560 ;
    ns0:fullName "Bjoern O. Schelter" ;
    ns0:hasAffiliation ns243:JAD190772 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190772 ;
    ns0:inAuthorList ns150:JAD190772 .

ns2:JAD190782 owl:sameAs ns2:JAD110808,
        ns2:JAD170669,
        ns2:JAD180721,
        ns2:jad00768,
        ns2:jad00869,
        ns2:jad01151,
        ns8:JAD00003,
        ns30:JAD170654,
        ns57:JAD181039 ;
    ns0:fullName "Rudy J. Castellani" ;
    ns0:hasAffiliation ns242:JAD190782,
        ns243:JAD190782 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190782 ;
    ns0:inAuthorList ns150:JAD190782 .

ns2:JAD190823 owl:sameAs ns2:JAD190889 ;
    ns0:fullName "Emma Richards" ;
    ns0:hasAffiliation ns242:JAD190823,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190823> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190823 ;
    ns0:inAuthorList ns150:JAD190823 .

ns2:JAD190870 owl:sameAs ns8:cbm00437 ;
    ns0:fullName "Yangfei Ji" ;
    ns0:hasAffiliation ns242:JAD190870 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190870 ;
    ns0:inAuthorList ns150:JAD190870 .

ns2:JAE180058 owl:sameAs ns2:JAE189064 ;
    ns0:fullName "Li Zheng" ;
    ns0:hasAffiliation ns242:JAE180058 ;
    ns0:hasArticle ns1:jae-v58-i2-JAE180058 ;
    ns0:inAuthorList ns150:JAE180058 .

ns2:JAE190021 owl:sameAs ns8:JAE180086 ;
    ns0:fullName "Songling Huang" ;
    ns0:hasAffiliation ns242:JAE190021 ;
    ns0:hasArticle ns1:jae-v61-i3-JAE190021 ;
    ns0:inAuthorList ns150:JAE190021 .

ns2:JAE191149 owl:sameAs ns8:JAE190821 ;
    ns0:fullName "Yuya Ako" ;
    ns0:hasAffiliation ns242:JAE191149 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191149 ;
    ns0:inAuthorList ns150:JAE191149 .

ns2:JAE198976 owl:sameAs ns2:JAE198972,
        ns8:JAE198972,
        ns30:JAE2259 ;
    ns0:fullName "Gheorghe Paltanea" ;
    ns0:hasAffiliation ns242:JAE198976 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE198976 ;
    ns0:inAuthorList ns150:JAE198976 .

ns2:JBR180349 owl:sameAs ns2:JBR180361 ;
    ns0:fullName "Mohamed M. El-Mogy" ;
    ns0:hasAffiliation ns242:JBR180349 ;
    ns0:hasArticle ns1:jbr-v9-i2-JBR180349 ;
    ns0:inAuthorList ns150:JBR180349 .

ns2:JBR190390 owl:sameAs ns2:JBR104 ;
    ns0:fullName "R. Nestby" ;
    ns0:hasAffiliation ns242:JBR190390 ;
    ns0:hasArticle ns1:jbr-v9-i3-JBR190390 ;
    ns0:inAuthorList ns150:JBR190390 .

ns2:JCS191289 owl:sameAs ns2:JCS171017 ;
    ns0:fullName "Kiran Balagani" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:JCS191289> ;
    ns0:hasArticle ns1:jcs-v27-i4-JCS191289 ;
    ns0:inAuthorList ns150:JCS191289 .

ns2:JHD180337 owl:sameAs ns12:JHD170284,
        ns5:JHD180325,
        ns16:JHD180285 ;
    ns0:fullName "Tamara Matheis" ;
    ns0:hasAffiliation ns242:JHD180337,
        ns243:JHD180337 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD180337 ;
    ns0:inAuthorList ns150:JHD180337 .

ns2:JHD190353 owl:sameAs ns2:JND190397 ;
    ns0:fullName "Ellen van der Plas" ;
    ns0:hasAffiliation ns242:JHD190353 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD190353 ;
    ns0:inAuthorList ns150:JHD190353 .

ns2:JHD190355 owl:sameAs ns2:JHD180328 ;
    ns0:fullName "Tanya M. Bardakjian" ;
    ns0:hasAffiliation ns242:JHD190355 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190355 ;
    ns0:inAuthorList ns150:JHD190355 .

ns2:JHD190364 owl:sameAs ns60:JHD170238 ;
    ns0:fullName "Noelle E. Carlozzi" ;
    ns0:hasAffiliation ns242:JHD190364 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190364 ;
    ns0:inAuthorList ns150:JHD190364 .

ns2:JHD190365 owl:sameAs ns30:JHD160206 ;
    ns0:fullName "Elise Kayson" ;
    ns0:hasAffiliation ns242:JHD190365,
        ns243:JHD190365 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190365 ;
    ns0:inAuthorList ns150:JHD190365 .

ns2:JHD190380 owl:sameAs ns2:JHD160206,
        ns2:JHD180293,
        ns12:JHD190365 ;
    ns0:fullName "Karen E. Anderson" ;
    ns0:hasAffiliation ns242:JHD190380 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190380 ;
    ns0:inAuthorList ns150:JHD190380 .

ns2:JHD199003 owl:sameAs ns8:JHD170245 ;
    ns0:fullName "Filipe B. Rodrigues" ;
    ns0:hasAffiliation ns242:JHD199003,
        ns243:JHD199003 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD199003 ;
    ns0:inAuthorList ns150:JHD199003 .

ns2:JHS190616 owl:sameAs ns2:IDT309 ;
    ns0:fullName "Kadri Sylejmani" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:JHS190616> ;
    ns0:hasArticle ns1:jhs-v25-i3-JHS190616 ;
    ns0:inAuthorList ns150:JHS190616 .

ns2:JHS190622 owl:sameAs ns2:JHS520 ;
    ns0:fullName "Heejung Byun" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:JHS190622> ;
    ns0:hasArticle ns1:jhs-v25-i4-JHS190622 ;
    ns0:inAuthorList ns150:JHS190622 .

ns2:JHS190623 owl:sameAs ns30:JHS550 ;
    ns0:fullName "Yohaan Yoon" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:JHS190623> ;
    ns0:hasArticle ns1:jhs-v25-i4-JHS190623 ;
    ns0:inAuthorList ns150:JHS190623 .

ns2:JND190416 owl:sameAs ns43:JND170231 ;
    ns0:fullName "Maggie C. Walter" ;
    ns0:hasAffiliation ns242:JND190416 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190416 ;
    ns0:inAuthorList ns150:JND190416 .

ns2:JPD181518 owl:sameAs ns57:JPD171081 ;
    ns0:fullName "Lana M. Chahine" ;
    ns0:hasAffiliation ns242:JPD181518 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181518 ;
    ns0:inAuthorList ns150:JPD181518 .

ns2:JPD191577 owl:sameAs ns2:JPD181309 ;
    ns0:fullName "Stephen Polgar" ;
    ns0:hasAffiliation ns242:JPD191577 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191577 ;
    ns0:inAuthorList ns150:JPD191577 .

ns2:JPD191593 owl:sameAs ns8:JPD191635,
        ns30:JPD181460,
        ns57:JAD132156 ;
    ns0:fullName "Andrew Lees" ;
    ns0:hasAffiliation ns242:JPD191593 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191593 ;
    ns0:inAuthorList ns150:JPD191593 .

ns2:JPD191600 owl:sameAs ns16:RNN160703 ;
    ns0:fullName "Laura J. de Schipper" ;
    ns0:hasAffiliation ns242:JPD191600 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191600 ;
    ns0:inAuthorList ns150:JPD191600 .

ns2:JPD191605 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JPD181568>,
        ns12:JPD150685,
        ns5:JPD191593,
        ns52:JPD160847 ;
    ns0:fullName "Werner Poewe" ;
    ns0:hasAffiliation ns242:JPD191605 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191605 ;
    ns0:inAuthorList ns150:JPD191605 .

ns2:JPD191610 owl:sameAs ns57:JPD150680 ;
    ns0:fullName "Erika D. Driver-Dunckley" ;
    ns0:hasAffiliation ns242:JPD191610 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191610 ;
    ns0:inAuthorList ns150:JPD191610 .

ns2:JPD191648 owl:sameAs ns16:JAD130575 ;
    ns0:fullName "Diane Stephenson" ;
    ns0:hasAffiliation ns242:JPD191648 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191648 ;
    ns0:inAuthorList ns150:JPD191648 .

ns2:JPD191802 owl:sameAs ns57:JPD171228 ;
    ns0:fullName "T. Van Laar" ;
    ns0:hasAffiliation ns242:JPD191802 ;
    ns0:hasArticle ns1:jpd-v9-is2-JPD191802 ;
    ns0:inAuthorList ns150:JPD191802 .

ns2:JSA190242 owl:sameAs ns5:JAD180663 ;
    ns0:fullName "Justin M. Barber" ;
    ns0:hasAffiliation ns242:JSA190242 ;
    ns0:hasArticle ns1:jsa-v5-i3-JSA190242 ;
    ns0:inAuthorList ns150:JSA190242 .

ns2:JVR191020 owl:sameAs ns2:JVR191022,
        ns8:JVR191021 ;
    ns0:fullName "Phillip D. Rumrill," ;
    ns0:hasAffiliation ns242:JVR191020 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191020 ;
    ns0:inAuthorList ns150:JVR191020 .

ns2:JVR191031 owl:sameAs ns8:JVR191030 ;
    ns0:fullName "Thomas P. Golden" ;
    ns0:hasAffiliation ns242:JVR191031 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191031 ;
    ns0:inAuthorList ns150:JVR191031 .

ns2:JVR191034 owl:sameAs ns2:JVR191040 ;
    ns0:fullName "Mark S. Tucker" ;
    ns0:hasAffiliation ns242:JVR191034 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191034 ;
    ns0:inAuthorList ns150:JVR191034 .

ns2:JVR191038 owl:sameAs ns5:JVR191039 ;
    ns0:fullName "Catherine E. Chambless" ;
    ns0:hasAffiliation ns242:JVR191038 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191038 ;
    ns0:inAuthorList ns150:JVR191038 .

ns2:JVR191045 owl:sameAs ns12:JVR191014 ;
    ns0:fullName "Kelly Nye-Lengerman" ;
    ns0:hasAffiliation ns242:JVR191045 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191045 ;
    ns0:inAuthorList ns150:JVR191045 .

ns2:JVR191046 owl:sameAs ns5:JVR922 ;
    ns0:fullName "Anne M. Roux" ;
    ns0:hasAffiliation ns242:JVR191046 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191046 ;
    ns0:inAuthorList ns150:JVR191046 .

ns2:JVR191049 owl:sameAs ns2:WOR2737 ;
    ns0:fullName "Susann Porter" ;
    ns0:hasAffiliation ns242:JVR191049 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191049 ;
    ns0:inAuthorList ns150:JVR191049 .

ns2:KCA190056 owl:sameAs ns8:KCA170006,
        ns12:KCA170007,
        ns5:KCA180047 ;
    ns0:fullName "Nazli Dizman" ;
    ns0:hasAffiliation ns242:KCA190056 ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190056 ;
    ns0:inAuthorList ns150:KCA190056 .

ns2:KCA190063 owl:sameAs ns2:KCA189003,
        ns8:KCA180034 ;
    ns0:fullName "Mamta Parikh" ;
    ns0:hasAffiliation ns242:KCA190063 ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190063 ;
    ns0:inAuthorList ns150:KCA190063 .

ns2:MAS190464 owl:sameAs ns30:MAS180455 ;
    ns0:fullName "Edwin M.M. Ortega" ;
    ns0:hasAffiliation ns242:MAS190464 ;
    ns0:hasArticle ns1:mas-v14-i3-MAS190464 ;
    ns0:inAuthorList ns150:MAS190464 .

ns2:MGC180689 owl:sameAs ns2:MGC218 ;
    ns0:fullName "Nagy Morsy" ;
    ns0:hasAffiliation ns242:MGC180689,
        ns243:MGC180689 ;
    ns0:hasArticle ns1:mgc-v18-i3-MGC180689 ;
    ns0:inAuthorList ns150:MGC180689 .

ns2:MGC180717 owl:sameAs ns2:MGC180682 ;
    ns0:fullName "Hao Han" ;
    ns0:hasAffiliation ns242:MGC180717 ;
    ns0:hasArticle ns1:mgc-v18-i3-MGC180717 ;
    ns0:inAuthorList ns150:MGC180717 .

ns2:MGC180750 owl:sameAs ns2:MGC180760 ;
    ns0:fullName "Chunqiang Hu" ;
    ns0:hasAffiliation ns242:MGC180750 ;
    ns0:hasArticle ns1:mgc-v18-i3-MGC180750 ;
    ns0:inAuthorList ns150:MGC180750 .

ns2:MGC190783 owl:sameAs ns12:ida00653 ;
    ns0:fullName "Bo Xiao" ;
    ns0:hasAffiliation ns242:MGC190783 ;
    ns0:hasArticle ns1:mgc-v18-i4-MGC190783 ;
    ns0:inAuthorList ns150:MGC190783 .

ns2:MGC190794 owl:sameAs ns2:MGC180761,
        ns2:MGC231,
        ns2:MGC246,
        ns2:MGC255 ;
    ns0:fullName "Panayiotis V. Ioannou" ;
    ns0:hasAffiliation ns242:MGC190794 ;
    ns0:hasArticle ns1:mgc-v18-i4-MGC190794 ;
    ns0:inAuthorList ns150:MGC190794 .

ns2:MGC194 owl:sameAs ns8:MGC193,
        ns8:hab00178 ;
    ns0:fullName "Hanan H. Omar" ;
    ns0:hasAffiliation ns242:MGC194,
        ns243:MGC194 ;
    ns0:hasArticle ns1:mgc-v15-i2-MGC194 ;
    ns0:inAuthorList ns150:MGC194 .

ns2:MGC196 owl:sameAs ns8:MGC181 ;
    ns0:fullName "Amit Kumar" ;
    ns0:hasAffiliation ns242:MGC196,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:MGC196> ;
    ns0:hasArticle ns1:mgc-v15-i2-MGC196 ;
    ns0:inAuthorList ns150:MGC196 .

ns2:MGS190313 owl:sameAs ns2:MGS284 ;
    ns0:fullName "Asif Ali Laghari" ;
    ns0:hasAffiliation ns242:MGS190313 ;
    ns0:hasArticle ns1:mgs-v15-i3-MGS190313 ;
    ns0:inAuthorList ns150:MGS190313 .

ns2:MNM180275 owl:sameAs ns2:MNM180249 ;
    ns0:fullName "Maria Michou" ;
    ns0:hasAffiliation ns242:MNM180275 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180275 ;
    ns0:inAuthorList ns150:MNM180275 .

ns2:MNM180278 owl:sameAs ns5:MNM180224,
        ns16:MNM180242,
        ns57:MNM180261 ;
    ns0:fullName "Roya Kelishadi" ;
    ns0:hasAffiliation ns242:MNM180278 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180278 ;
    ns0:inAuthorList ns150:MNM180278 .

ns2:NHA170034 owl:sameAs ns2:NHA180042 ;
    ns0:fullName "Iftikhar Alam" ;
    ns0:hasAffiliation ns242:NHA170034,
        ns243:NHA170034,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:NHA170034> ;
    ns0:hasArticle ns1:nha-v5-i2-NHA170034 ;
    ns0:inAuthorList ns150:NHA170034 .

ns2:NHA180059 owl:sameAs ns2:NHA170035 ;
    ns0:fullName "Devin Wahl" ;
    ns0:hasAffiliation ns242:NHA180059,
        ns243:NHA180059 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA180059 ;
    ns0:inAuthorList ns150:NHA180059 .

ns2:NHA190068 owl:sameAs ns2:NHA170023 ;
    ns0:fullName "Sumit Bhattacharyya" ;
    ns0:hasAffiliation ns242:NHA190068,
        ns243:NHA190068 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA190068 ;
    ns0:inAuthorList ns150:NHA190068 .

ns2:NPM180140 owl:sameAs ns2:NPM1610,
        ns2:NPM17145,
        ns2:NPM1786 ;
    ns0:fullName "L. Cordero" ;
    ns0:hasAffiliation ns242:NPM180140 ;
    ns0:hasArticle ns1:npm-v12-i3-NPM180140 ;
    ns0:inAuthorList ns150:NPM180140 .

ns2:NPM18119 owl:sameAs ns2:NPM1686,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:NPM18117> ;
    ns0:fullName "T. Sawyer" ;
    ns0:hasAffiliation ns242:NPM18119 ;
    ns0:hasArticle ns1:npm-v12-i3-NPM18119 ;
    ns0:inAuthorList ns150:NPM18119 .

ns2:NPM1814 owl:sameAs ns2:NPM17125,
        ns8:NPM17133 ;
    ns0:fullName "R.A. Brown" ;
    ns0:hasAffiliation ns242:NPM1814 ;
    ns0:hasArticle ns1:npm-v12-i2-NPM1814 ;
    ns0:inAuthorList ns150:NPM1814 .

ns2:NRE182635 owl:sameAs ns8:JAD160808,
        ns12:JAD132735 ;
    ns0:fullName "Alberto Castagna" ;
    ns0:hasAffiliation ns242:NRE182635 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182635 ;
    ns0:inAuthorList ns150:NRE182635 .

ns2:NRE182636 owl:sameAs ns2:BMR181259 ;
    ns0:fullName "Marwa Shafiek Mustafa Saleh" ;
    ns0:hasAffiliation ns242:NRE182636 ;
    ns0:hasArticle ns1:nre-v44-i4-NRE182636 ;
    ns0:inAuthorList ns150:NRE182636 .

ns2:NRE182641 owl:sameAs ns30:NRE182424 ;
    ns0:fullName "Stephanie A. Combs-Miller" ;
    ns0:hasAffiliation ns242:NRE182641 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182641 ;
    ns0:inAuthorList ns150:NRE182641 .

ns2:NRE182665 owl:sameAs ns8:IES182177,
        ns8:NRE1259,
        ns30:NRE192754 ;
    ns0:fullName "Débora Carvalho de Oliveira" ;
    ns0:hasAffiliation ns242:NRE182665 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182665 ;
    ns0:inAuthorList ns150:NRE182665 .

ns2:NRE182671 owl:sameAs ns2:WOR2508 ;
    ns0:fullName "Ardalan Shariat" ;
    ns0:hasAffiliation ns242:NRE182671 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182671 ;
    ns0:inAuthorList ns150:NRE182671 .

ns2:NRE192700 owl:sameAs ns2:NRE192771 ;
    ns0:fullName "Pietro Santos" ;
    ns0:hasAffiliation ns242:NRE192700 ;
    ns0:hasArticle ns1:nre-v44-i4-NRE192700 ;
    ns0:inAuthorList ns150:NRE192700 .

ns2:NRE192722 owl:sameAs ns2:NRE189009 ;
    ns0:fullName "B. Amatya" ;
    ns0:hasAffiliation ns242:NRE192722,
        ns243:NRE192722,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:NRE192722> ;
    ns0:hasArticle ns1:nre-v45-i1-NRE192722 ;
    ns0:inAuthorList ns150:NRE192722 .

ns2:NRE192748 owl:sameAs ns30:NRE172212 ;
    ns0:fullName "Alham Al-Sharman" ;
    ns0:hasAffiliation ns242:NRE192748 ;
    ns0:hasArticle ns1:nre-v45-i1-NRE192748 ;
    ns0:inAuthorList ns150:NRE192748 .

ns2:NRE192752 owl:sameAs ns2:NRE182565 ;
    ns0:fullName "Anders West" ;
    ns0:hasAffiliation ns242:NRE192752 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192752 ;
    ns0:inAuthorList ns150:NRE192752 .

ns2:NRE192788 owl:sameAs ns2:JPD181516 ;
    ns0:fullName "H.H.N. Kalyani" ;
    ns0:hasAffiliation ns242:NRE192788,
        ns243:NRE192788,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:NRE192788> ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192788 ;
    ns0:inAuthorList ns150:NRE192788 .

ns2:NRE192801 owl:sameAs ns2:NRE1475,
        ns12:NRE172238 ;
    ns0:fullName "John Brincks" ;
    ns0:hasAffiliation ns242:NRE192801 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192801 ;
    ns0:inAuthorList ns150:NRE192801 .

ns2:PPR190132 owl:sameAs ns8:JSA154 ;
    ns0:fullName "John O’Brien" ;
    ns0:hasAffiliation ns242:PPR190132,
        ns243:PPR190132 ;
    ns0:hasArticle ns1:ppr-v40-i2-PPR190132 ;
    ns0:inAuthorList ns150:PPR190132 .

ns2:RNN190910 owl:sameAs ns2:RNN160661 ;
    ns0:fullName "T.L. Moore" ;
    ns0:hasAffiliation ns242:RNN190910 ;
    ns0:hasArticle ns1:rnn-v37-i4-RNN190910 ;
    ns0:inAuthorList ns150:RNN190910 .

ns2:SW190359 owl:sameAs ns2:AIC746 ;
    ns0:fullName "Muhammad Rizwan Saeed" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:SW190359> ;
    ns0:hasArticle ns1:sw-v10-i6-SW190359 ;
    ns0:inAuthorList ns150:SW190359 .

ns2:SW190362 owl:sameAs ns2:SW303 ;
    ns0:fullName "Marjan Alirezaie" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:SW190362> ;
    ns0:hasArticle ns1:sw-v10-i5-SW190362 ;
    ns0:inAuthorList ns150:SW190362 .

ns2:SW190364 owl:sameAs ns116:SW180338,
        ns116:SW190361,
        ns116:SW190362,
        ns116:SW190363,
        ns116:SW318 ;
    ns0:fullName "Dagmar Gromann" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:SW190364> ;
    ns0:hasArticle ns1:sw-v10-i5-SW190364 ;
    ns0:inAuthorList ns150:SW190364 .

ns2:SW318 owl:sameAs ns8:SW204 ;
    ns0:fullName "Dai Quoc Nguyen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:SW318> ;
    ns0:hasArticle ns1:sw-v10-i5-SW318 ;
    ns0:inAuthorList ns150:SW318 .

ns2:THC191715 owl:sameAs ns60:THC170967 ;
    ns0:fullName "Jong Kun Kim" ;
    ns0:hasAffiliation ns242:THC191715 ;
    ns0:hasArticle ns1:thc-v27-i6-THC191715 ;
    ns0:inAuthorList ns150:THC191715 .

ns2:THC191731 owl:sameAs ns30:THC191730 ;
    ns0:fullName "Kyungyong Chung" ;
    ns0:hasAffiliation ns242:THC191731 ;
    ns0:hasArticle ns1:thc-v27-i5-THC191731 ;
    ns0:inAuthorList ns150:THC191731 .

ns2:THC199002 owl:sameAs ns8:THC174615 ;
    ns0:fullName "Qun Wei" ;
    ns0:hasAffiliation ns242:THC199002 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199002 ;
    ns0:inAuthorList ns150:THC199002 .

ns2:THC199007 owl:sameAs ns12:THC199006 ;
    ns0:fullName "Hayriye Korkmaz" ;
    ns0:hasAffiliation ns242:THC199007 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199007 ;
    ns0:inAuthorList ns150:THC199007 .

ns2:THC199034 owl:sameAs ns2:IDA757,
        ns2:IDA789,
        ns12:IFS169204 ;
    ns0:fullName "Chong Su" ;
    ns0:hasAffiliation ns242:THC199034 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199034 ;
    ns0:inAuthorList ns150:THC199034 .

ns2:THC199039 owl:sameAs ns12:BME1447 ;
    ns0:fullName "Dong Ho Shin" ;
    ns0:hasAffiliation ns242:THC199039 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199039 ;
    ns0:inAuthorList ns150:THC199039 .

ns2:WOR192918 owl:sameAs ns2:WOR192932,
        ns2:WOR2301,
        ns8:WOR192917 ;
    ns0:fullName "Valerie Rice" ;
    ns0:hasAffiliation ns242:WOR192918 ;
    ns0:hasArticle ns1:wor-v63-i2-WOR192918 ;
    ns0:inAuthorList ns150:WOR192918 .

ns2:WOR192925 owl:sameAs ns30:bmr00531 ;
    ns0:fullName "Shirley Telles" ;
    ns0:hasAffiliation ns242:WOR192925 ;
    ns0:hasArticle ns1:wor-v63-i2-WOR192925 ;
    ns0:inAuthorList ns150:WOR192925 .

ns2:WOR192937 owl:sameAs ns2:WOR192936 ;
    ns0:fullName "Jennifer Long" ;
    ns0:hasAffiliation ns243:WOR192937 ;
    ns0:hasArticle ns1:wor-v63-i3-WOR192937 ;
    ns0:inAuthorList ns150:WOR192937 .

ns2:WOR192938 owl:sameAs ns2:WOR192968,
        ns2:WOR2661 ;
    ns0:fullName "Deokhoon Jun" ;
    ns0:hasAffiliation ns242:WOR192938,
        ns244:WOR192938 ;
    ns0:hasArticle ns1:wor-v63-i3-WOR192938 ;
    ns0:inAuthorList ns150:WOR192938 .

ns2:WOR192950 owl:sameAs ns2:WOR2643 ;
    ns0:fullName "Damian Mellifont" ;
    ns0:hasAffiliation ns242:WOR192950 ;
    ns0:hasArticle ns1:wor-v63-i3-WOR192950 ;
    ns0:inAuthorList ns150:WOR192950 .

ns2:WOR192955 owl:sameAs ns2:WOR192953 ;
    ns0:fullName "Daniel P. Armstrong" ;
    ns0:hasAffiliation ns242:WOR192955 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192955 ;
    ns0:inAuthorList ns150:WOR192955 .

ns2:WOR192961 owl:sameAs ns12:WOR192962 ;
    ns0:fullName "Gemma S. Milligan" ;
    ns0:hasAffiliation ns242:WOR192961 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192961 ;
    ns0:inAuthorList ns150:WOR192961 .

ns2:WOR192971 owl:sameAs ns2:WOR192942 ;
    ns0:fullName "Pattariya Intolo" ;
    ns0:hasAffiliation ns242:WOR192971 ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192971 ;
    ns0:inAuthorList ns150:WOR192971 .

ns2:WOR192976 owl:sameAs ns2:thc00776,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:ADR170051> ;
    ns0:fullName "Jan Johansson" ;
    ns0:hasAffiliation ns242:WOR192976 ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192976 ;
    ns0:inAuthorList ns150:WOR192976 .

ns2:WOR192987 owl:sameAs ns2:WOR192992 ;
    ns0:fullName "Ana Slišković" ;
    ns0:hasAffiliation ns242:WOR192987 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192987 ;
    ns0:inAuthorList ns150:WOR192987 .

ns2:WOR193009 owl:sameAs ns2:WOR192857,
        ns2:WOR192997,
        ns2:WOR2590,
        ns2:WOR2603,
        ns2:WOR2674 ;
    ns0:fullName "Mogammad Shaheed Soeker" ;
    ns0:hasAffiliation ns242:WOR193009 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193009 ;
    ns0:inAuthorList ns150:WOR193009 .

ns2:WOR193013 owl:sameAs ns2:WOR2522 ;
    ns0:fullName "Eva Charlotta Nylén" ;
    ns0:hasAffiliation ns242:WOR193013 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193013 ;
    ns0:inAuthorList ns150:WOR193013 .

ns2:WOR193015 owl:sameAs ns8:NRE162128 ;
    ns0:fullName "Mariam A. Ameer" ;
    ns0:hasAffiliation ns242:WOR193015,
        ns243:WOR193015 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193015 ;
    ns0:inAuthorList ns150:WOR193015 .

ns2:XST180460 owl:sameAs ns16:XST18369 ;
    ns0:fullName "Nan Yin" ;
    ns0:hasAffiliation ns242:XST180460 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180460 ;
    ns0:inAuthorList ns150:XST180460 .

ns2:XST180465 owl:sameAs ns2:XST17282,
        ns8:XST180488,
        ns8:XST18377 ;
    ns0:fullName "Zong-Qiong Sun" ;
    ns0:hasAffiliation ns242:XST180465 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180465 ;
    ns0:inAuthorList ns150:XST180465 .

ns2:XST180466 owl:sameAs ns12:XST180430 ;
    ns0:fullName "Yang Liu" ;
    ns0:hasAffiliation ns242:XST180466 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180466 ;
    ns0:inAuthorList ns150:XST180466 .

ns2:XST190503 owl:sameAs ns2:XST598 ;
    ns0:fullName "Chia-Chun Kuo" ;
    ns0:hasAffiliation ns243:XST190503,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:0.ID:XST190503> ;
    ns0:hasArticle ns1:xst-v27-i4-XST190503 ;
    ns0:inAuthorList ns150:XST190503 .

ns2:XST190507 owl:sameAs ns52:CBM170572 ;
    ns0:fullName "Wei Tao" ;
    ns0:hasAffiliation ns242:XST190507 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190507 ;
    ns0:inAuthorList ns150:XST190507 .

ns2:XST190523 owl:sameAs ns8:XST17289 ;
    ns0:fullName "Dmitri Matenine" ;
    ns0:hasAffiliation ns242:XST190523 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190523 ;
    ns0:inAuthorList ns150:XST190523 .

ns2:XST190541 owl:sameAs ns2:XST180443 ;
    ns0:fullName "Yongxia Zhao" ;
    ns0:hasAffiliation ns242:XST190541 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190541 ;
    ns0:inAuthorList ns150:XST190541 .

ns2:ajw190043 owl:sameAs ns57:ajw190019 ;
    ns0:fullName "Larisa R. Zagitova" ;
    ns0:hasAffiliation ns242:ajw190043 ;
    ns0:hasArticle ns1:ajw-v16-i4-ajw190043 ;
    ns0:inAuthorList ns150:ajw190043 .

ns2:ajw190048 owl:sameAs ns2:ajw190007 ;
    ns0:fullName "Prabal Barua" ;
    ns0:hasAffiliation ns242:ajw190048 ;
    ns0:hasArticle ns1:ajw-v16-i4-ajw190048 ;
    ns0:inAuthorList ns150:ajw190048 .

ns2:ajw190054 owl:sameAs ns2:ajw190052 ;
    ns0:fullName "Mohammad Pooteh Rigi" ;
    ns0:hasAffiliation ns242:ajw190054 ;
    ns0:hasArticle ns1:ajw-v16-i4-ajw190054 ;
    ns0:inAuthorList ns150:ajw190054 .

ns2:red160101 owl:sameAs ns2:RED131204 ;
    ns0:fullName "Partho Pratim Chatterjee" ;
    ns0:hasAffiliation ns242:red160101 ;
    ns0:hasArticle ns1:red-v16-i1-red160101 ;
    ns0:inAuthorList ns150:red160101 .

ns2:wdl12104 owl:sameAs ns2:wdl11105 ;
    ns0:fullName "A. Gawadekar" ;
    ns0:hasAffiliation ns242:wdl12104 ;
    ns0:hasArticle ns1:wdl-v12-i1-wdl12104 ;
    ns0:inAuthorList ns150:wdl12104 .

ns8:AAC192101 owl:sameAs ns2:FI1655,
        ns2:FI1807,
        ns2:IA103,
        ns8:AIC701,
        ns8:FI1395,
        ns12:IA096,
        ns12:IA170030,
        ns12:IA190020 ;
    ns0:fullName "Marco Maratea" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:AAC192101> ;
    ns0:hasArticle ns1:aac-v10-i2-AAC192101 ;
    ns0:inAuthorList ns150:AAC192101 .

ns8:ADR190124 owl:sameAs ns2:JAD142499 ;
    ns0:fullName "Ruth Remington" ;
    ns0:hasAffiliation ns25:ADR190124 ;
    ns0:hasArticle ns1:adr-v3-i1-ADR190124 ;
    ns0:inAuthorList ns150:ADR190124 .

ns8:AIS190536 owl:sameAs ns8:AIS180509 ;
    ns0:fullName "Stefano Chessa" ;
    ns0:hasAffiliation ns91:AIS190536,
        <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:AIS190536> ;
    ns0:hasArticle ns1:ais-v11-i5-AIS190536 ;
    ns0:inAuthorList ns150:AIS190536 .

ns8:ASY191521 owl:sameAs ns8:ASY191520 ;
    ns0:fullName "Kthim Imeri" ;
    ns0:hasAffiliation ns91:ASY191521 ;
    ns0:hasArticle ns1:asy-v114-i3-4-ASY191521 ;
    ns0:inAuthorList ns150:ASY191521 .

ns8:BD180341 owl:sameAs ns8:bd000349 ;
    ns0:fullName "Ivana Mrklić" ;
    ns0:hasAffiliation ns24:BD180341 ;
    ns0:hasArticle ns1:bd-v38-i2-BD180341 ;
    ns0:inAuthorList ns150:BD180341 .

ns8:BD190393 owl:sameAs ns8:bd000366,
        ns12:bd000355 ;
    ns0:fullName "Mukta Pujani" ;
    ns0:hasAffiliation ns24:BD190393 ;
    ns0:hasArticle ns1:bd-v38-i3-4-BD190393 ;
    ns0:inAuthorList ns150:BD190393 .

ns8:BLC190221 owl:sameAs ns2:KCA180044 ;
    ns0:fullName "Yuval Freifeld" ;
    ns0:hasAffiliation ns24:BLC190221 ;
    ns0:hasArticle ns1:blc-v5-i2-BLC190221 ;
    ns0:inAuthorList ns150:BLC190221 .

ns8:BLC190236 owl:sameAs ns60:BLC170111 ;
    ns0:fullName "John A. Taylor" ;
    ns0:hasAffiliation ns25:BLC190236 ;
    ns0:hasArticle ns1:blc-v5-i3-BLC190236 ;
    ns0:inAuthorList ns150:BLC190236 .

ns8:BME191060 owl:sameAs ns12:BME1709 ;
    ns0:fullName "Naohiro Horiuchi" ;
    ns0:hasAffiliation ns25:BME191060 ;
    ns0:hasArticle ns1:bme-v30-i4-BME191060 ;
    ns0:inAuthorList ns150:BME191060 .

ns8:BME191064 owl:sameAs ns8:BME1732,
        ns12:BME1715 ;
    ns0:fullName "Farzan Ghalichi" ;
    ns0:hasAffiliation ns24:BME191064 ;
    ns0:hasArticle ns1:bme-v30-i4-BME191064 ;
    ns0:inAuthorList ns150:BME191064 .

ns8:BMR171041 owl:sameAs ns8:BMR181128 ;
    ns0:fullName "Mojtaba Kamyab" ;
    ns0:hasAffiliation ns24:BMR171041 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR171041 ;
    ns0:inAuthorList ns150:BMR171041 .

ns8:BMR181228 owl:sameAs ns8:THC181467 ;
    ns0:fullName "Eunsang Lee" ;
    ns0:hasAffiliation ns24:BMR181228 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181228 ;
    ns0:inAuthorList ns150:BMR181228 .

ns8:BMR181260 owl:sameAs ns16:BMR160756 ;
    ns0:fullName "Andoni Carrasco-Uribarren" ;
    ns0:hasAffiliation ns25:BMR181260 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181260 ;
    ns0:inAuthorList ns150:BMR181260 .

ns8:BMR181326 owl:sameAs ns8:BMR181448,
        ns16:bmr00519 ;
    ns0:fullName "Levent Özçakar" ;
    ns0:hasAffiliation ns25:BMR181326 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181326 ;
    ns0:inAuthorList ns150:BMR181326 .

ns8:BMR181332 owl:sameAs ns8:bmr00302 ;
    ns0:fullName "Ipek Yeldan" ;
    ns0:hasAffiliation ns25:BMR181332 ;
    ns0:hasArticle ns1:bmr-v32-i6-BMR181332 ;
    ns0:inAuthorList ns150:BMR181332 .

ns8:BRS190143 owl:sameAs ns8:BRS190144 ;
    ns0:fullName "Nasim Uddin" ;
    ns0:hasAffiliation ns24:BRS190143 ;
    ns0:hasArticle ns1:brs-v14-i4-BRS190143 ;
    ns0:inAuthorList ns150:BRS190143 .

ns8:BRS190154 owl:sameAs ns2:BRS113 ;
    ns0:fullName "A. Taghavi" ;
    ns0:hasAffiliation ns24:BRS190154 ;
    ns0:hasArticle ns1:brs-v15-i1-2-BRS190154 ;
    ns0:inAuthorList ns150:BRS190154 .

ns8:BSI190185 owl:sameAs ns8:BSI183 ;
    ns0:fullName "Robin A. Damion" ;
    ns0:hasAffiliation ns91:BSI190185 ;
    ns0:hasArticle ns1:bsi-v8-i1-2-BSI190185 ;
    ns0:inAuthorList ns150:BSI190185 .

ns8:CBM182075 owl:sameAs ns8:JAD181152 ;
    ns0:fullName "Tomoki Nakamura" ;
    ns0:hasAffiliation ns24:CBM182075 ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM182075 ;
    ns0:inAuthorList ns150:CBM182075 .

ns8:CBM182143 owl:sameAs ns8:XST190507 ;
    ns0:fullName "Yongping Xue" ;
    ns0:hasAffiliation ns24:CBM182143 ;
    ns0:hasArticle ns1:cbm-v26-i3-CBM182143 ;
    ns0:inAuthorList ns150:CBM182143 .

ns8:CBM182212 owl:sameAs ns30:CBM181368 ;
    ns0:fullName "Amal Rayan" ;
    ns0:hasAffiliation ns25:CBM182212 ;
    ns0:hasArticle ns1:cbm-v25-i4-CBM182212 ;
    ns0:inAuthorList ns150:CBM182212 .

ns8:CH180402 owl:sameAs ns2:BIR180175,
        ns8:BIR14030 ;
    ns0:fullName "Emine Kilic-Toprak" ;
    ns0:hasAffiliation ns25:CH180402 ;
    ns0:hasArticle ns1:ch-v71-i4-CH180402 ;
    ns0:inAuthorList ns150:CH180402 .

ns8:CH180470 owl:sameAs ns8:CH160241 ;
    ns0:fullName "Anna Marchewka" ;
    ns0:hasAffiliation ns25:CH180470 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180470 ;
    ns0:inAuthorList ns150:CH180470 .

ns8:CH180528 owl:sameAs ns2:CH189106,
        ns2:CH189301,
        ns30:CH189403 ;
    ns0:fullName "Eun-Seok Shin" ;
    ns0:hasAffiliation ns25:CH180528 ;
    ns0:hasArticle ns1:ch-v72-i4-CH180528 ;
    ns0:inAuthorList ns150:CH180528 .

ns8:CH180531 owl:sameAs ns2:CH1967,
        ns8:BME1336,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181135> ;
    ns0:fullName "Yi Dong" ;
    ns0:hasAffiliation ns24:CH180531 ;
    ns0:hasArticle ns1:ch-v72-i3-CH180531 ;
    ns0:inAuthorList ns150:CH180531 .

ns8:CH180545 owl:sameAs ns8:CH180457 ;
    ns0:fullName "Xueling Liu" ;
    ns0:hasAffiliation ns24:CH180545 ;
    ns0:hasArticle ns1:ch-v72-i3-CH180545 ;
    ns0:inAuthorList ns150:CH180545 .

ns8:CH199009 owl:sameAs ns2:CH189409 ;
    ns0:fullName "A. Krüger-Genge" ;
    ns0:hasAffiliation ns25:CH199009 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199009 ;
    ns0:inAuthorList ns150:CH199009 .

ns8:CH199202 owl:sameAs ns2:CH179221,
        ns2:CH189114,
        ns2:CH189115,
        ns2:CH189406,
        ns8:CH189116,
        ns8:CH189310,
        ns8:CH189405 ;
    ns0:fullName "K. Mueller-Peltzer" ;
    ns0:hasAffiliation ns24:CH199202 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199202 ;
    ns0:inAuthorList ns150:CH199202 .

ns8:CH199210 owl:sameAs ns2:CH1999,
        ns2:JCB15025 ;
    ns0:fullName "S. George" ;
    ns0:hasAffiliation ns24:CH199210 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199210 ;
    ns0:inAuthorList ns150:CH199210 .

ns8:CH199214 owl:sameAs ns2:CH168005 ;
    ns0:fullName "Tommaso Gori" ;
    ns0:hasAffiliation ns24:CH199214 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199214 ;
    ns0:inAuthorList ns150:CH199214 .

ns8:CH199218 owl:sameAs ns30:CH1982 ;
    ns0:fullName "Fabian Pohl" ;
    ns0:hasAffiliation ns90:CH199218 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199218 ;
    ns0:inAuthorList ns150:CH199218 .

ns8:CH199224 owl:sameAs ns2:CH168044,
        ns2:CH189131,
        ns2:CH1962,
        ns12:CH179103,
        ns12:CH179218,
        ns5:CH179217,
        ns16:CH168029 ;
    ns0:fullName "Isabel Wiesinger" ;
    ns0:hasAffiliation ns24:CH199224 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199224 ;
    ns0:inAuthorList ns150:CH199224 .

ns8:CH199226 owl:sameAs ns2:JCB179012 ;
    ns0:fullName "Sarah Kammerer" ;
    ns0:hasAffiliation ns25:CH199226 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199226 ;
    ns0:inAuthorList ns150:CH199226 .

ns8:COM093 owl:sameAs ns8:COM180103 ;
    ns0:fullName "Rod G. Downey" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:COM093> ;
    ns0:hasArticle ns1:com-v8-i3-4-COM093 ;
    ns0:inAuthorList ns150:COM093 .

ns8:COM180231 owl:sameAs ns2:COM035,
        ns12:COM094 ;
    ns0:fullName "Denis R. Hirschfeldt" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:COM180231> ;
    ns0:hasArticle ns1:com-v8-i2-COM180231 ;
    ns0:inAuthorList ns150:COM180231 .

ns8:DEV190266 owl:sameAs ns2:DEV180256 ;
    ns0:fullName "Sylvie Mrug" ;
    ns0:hasAffiliation ns25:DEV190266 ;
    ns0:hasArticle ns1:dev-v13-i1-2-DEV190266 ;
    ns0:inAuthorList ns150:DEV190266 .

ns8:DS190015 owl:sameAs ns2:DS190019,
        ns8:DS190023 ;
    ns0:fullName "Francesco Osborne" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:DS190015> ;
    ns0:hasArticle ns1:ds-v2-i1-2-DS190015 ;
    ns0:inAuthorList ns150:DS190015 .

ns8:DS190016A owl:sameAs ns8:SW177,
        ns12:DS190023,
        ns12:SW224,
        ns30:SW222 ;
    ns0:fullName "Silvio Peroni" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:DS190016A> ;
    ns0:hasArticle ns1:ds-v2-i1-2-DS190016A ;
    ns0:inAuthorList ns150:DS190016A .

ns8:EFI190268 owl:sameAs ns2:isu448,
        ns2:isu465 ;
    ns0:fullName "Thomas Mandl" ;
    ns0:hasAffiliation ns25:EFI190268 ;
    ns0:hasArticle ns1:efi-v35-i2-EFI190268 ;
    ns0:inAuthorList ns150:EFI190268 .

ns8:EFI190289 owl:sameAs ns8:EFI190290 ;
    ns0:fullName "Francisco Carlos Paletta" ;
    ns0:hasAffiliation ns90:EFI190289 ;
    ns0:hasArticle ns1:efi-v35-i3-EFI190289 ;
    ns0:inAuthorList ns150:EFI190289 .

ns8:FI1814 owl:sameAs ns8:FI1419,
        ns8:FI1703,
        ns8:his00034 ;
    ns0:fullName "Dominik Ślęzak" ;
    ns0:hasAffiliation ns25:FI1814 ;
    ns0:hasArticle ns1:fi-v167-i3-FI1814 ;
    ns0:inAuthorList ns150:FI1814 .

ns8:FI1837 owl:sameAs ns2:FI1376,
        ns2:FI1708 ;
    ns0:fullName "Thomas Hujsa" ;
    ns0:hasAffiliation ns25:FI1837 ;
    ns0:hasArticle ns1:fi-v169-i1-2-FI1837 ;
    ns0:inAuthorList ns150:FI1837 .

ns8:FI1870 owl:sameAs ns8:IA110 ;
    ns0:fullName "Luca Crociani" ;
    ns0:hasAffiliation ns24:FI1870 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1870 ;
    ns0:inAuthorList ns150:FI1870 .

ns8:FI1874 owl:sameAs ns2:FI1566 ;
    ns0:fullName "Sabrina Mantaci" ;
    ns0:hasAffiliation ns24:FI1874 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1874 ;
    ns0:inAuthorList ns150:FI1874 .

ns8:FI1878 owl:sameAs ns2:FI1565 ;
    ns0:fullName "Alberto Leporati" ;
    ns0:hasAffiliation ns24:FI1878 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1878 ;
    ns0:inAuthorList ns150:FI1878 .

ns8:FI1881 owl:sameAs ns8:FI1573 ;
    ns0:fullName "Jarkko Kari" ;
    ns0:hasAffiliation ns24:FI1881 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1881 ;
    ns0:inAuthorList ns150:FI1881 .

ns8:FI1882 owl:sameAs ns8:FI1567,
        ns8:FI1820,
        ns8:FI1838,
        ns12:FI1528,
        ns12:FI1574,
        ns12:FI1631 ;
    ns0:fullName "Maciej Koutny" ;
    ns0:hasAffiliation ns25:FI1882 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1882 ;
    ns0:inAuthorList ns150:FI1882 .

ns8:HAB190362 owl:sameAs ns8:NIB180141,
        ns12:BD248,
        ns5:HAB299 ;
    ns0:fullName "Rezvan Noroozi" ;
    ns0:hasAffiliation ns25:HAB190362,
        ns90:HAB190362 ;
    ns0:hasArticle ns1:hab-v27-i3-HAB190362 ;
    ns0:inAuthorList ns150:HAB190362 .

ns8:HAB190363 owl:sameAs ns2:HAB190368,
        ns2:HAB190369,
        ns8:HAB190367,
        ns8:HAB190383 ;
    ns0:fullName "Ali Mohammad Mosadeghrad" ;
    ns0:hasAffiliation ns258:HAB190363 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190363 ;
    ns0:inAuthorList ns150:HAB190363 .

ns8:HAB190371 owl:sameAs ns8:HAB190364,
        ns30:HAB304 ;
    ns0:fullName "Gosaye Degu Belay" ;
    ns0:hasAffiliation ns25:HAB190371,
        ns90:HAB190371 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190371 ;
    ns0:inAuthorList ns150:HAB190371 .

ns8:HAB190384 owl:sameAs ns30:BD248,
        ns30:HAB180358,
        ns5:BD180351,
        ns5:HAB180344,
        ns5:HAB190362,
        ns5:HAB341,
        ns52:NIB180141,
        ns60:BD264 ;
    ns0:fullName "Soudeh Ghafouri-Fard" ;
    ns0:hasAffiliation ns24:HAB190384,
        ns25:HAB190384 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190384 ;
    ns0:inAuthorList ns150:HAB190384 .

ns8:HSM180397 owl:sameAs ns8:HSM17101,
        ns8:HSM180405,
        ns5:HSM17118 ;
    ns0:fullName "Jianqiu Zeng" ;
    ns0:hasAffiliation ns24:HSM180397 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180397 ;
    ns0:inAuthorList ns150:HSM180397 .

ns8:HSM180410 owl:sameAs ns8:HSM17229 ;
    ns0:fullName "Enjun Xia" ;
    ns0:hasAffiliation ns24:HSM180410 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180410 ;
    ns0:inAuthorList ns150:HSM180410 .

ns8:HSM180472 owl:sameAs ns8:HSM180425 ;
    ns0:fullName "Hui Peng" ;
    ns0:hasAffiliation ns24:HSM180472 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180472 ;
    ns0:inAuthorList ns150:HSM180472 .

ns8:HSM190517 owl:sameAs ns8:HSM1768 ;
    ns0:fullName "Peng Hui" ;
    ns0:hasAffiliation ns24:HSM190517 ;
    ns0:hasArticle ns1:hsm-v38-i4-HSM190517 ;
    ns0:inAuthorList ns150:HSM190517 .

ns8:HSM190548 owl:sameAs ns8:HSM180385 ;
    ns0:fullName "Weiwei Wu" ;
    ns0:hasAffiliation ns24:HSM190548 ;
    ns0:hasArticle ns1:hsm-v38-i4-HSM190548 ;
    ns0:inAuthorList ns150:HSM190548 .

ns8:IA180016 owl:sameAs ns8:FI1699,
        ns8:IA082,
        ns30:FI1457 ;
    ns0:fullName "Gian Luca Pozzato" ;
    ns0:hasAffiliation ns24:IA180016 ;
    ns0:hasArticle ns1:ia-v13-i1-IA180016 ;
    ns0:inAuthorList ns150:IA180016 .

ns8:IA190023 owl:sameAs ns12:SW180336 ;
    ns0:fullName "Diego Calvanese" ;
    ns0:hasAffiliation ns25:IA190023 ;
    ns0:hasArticle ns1:ia-v13-i1-IA190023 ;
    ns0:inAuthorList ns150:IA190023 .

ns8:IDA184195 owl:sameAs ns12:IDT269,
        ns12:ida00587 ;
    ns0:fullName "Bernardete Ribeiro" ;
    ns0:hasAffiliation ns25:IDA184195 ;
    ns0:hasArticle ns1:ida-v23-i4-IDA184195 ;
    ns0:inAuthorList ns150:IDA184195 .

ns8:IDA184238 owl:sameAs ns2:IDA750,
        ns2:IDA800,
        ns2:IDA814 ;
    ns0:fullName "Hossein Rahmani" ;
    ns0:hasAffiliation ns24:IDA184238,
        ns25:IDA184238 ;
    ns0:hasArticle ns1:ida-v23-i5-IDA184238 ;
    ns0:inAuthorList ns150:IDA184238 .

ns8:IDA184390 owl:sameAs ns2:WEB333 ;
    ns0:fullName "Masoud Makrehchi" ;
    ns0:hasAffiliation ns25:IDA184390 ;
    ns0:hasArticle ns1:ida-v23-i6-IDA184390 ;
    ns0:inAuthorList ns150:IDA184390 .

ns8:IDA192786 owl:sameAs ns8:IDA192829 ;
    ns0:fullName "Yiyan Chen" ;
    ns0:hasAffiliation ns24:IDA192786 ;
    ns0:hasArticle ns1:ida-v23-iS1-IDA192786 ;
    ns0:inAuthorList ns150:IDA192786 .

ns8:IDT180003 owl:sameAs ns8:IFS169811 ;
    ns0:fullName "Deepali Virmani" ;
    ns0:hasAffiliation ns90:IDT180003 ;
    ns0:hasArticle ns1:idt-v13-i3-IDT180003 ;
    ns0:inAuthorList ns150:IDT180003 .

ns8:IDT180136 owl:sameAs ns30:IFS169571 ;
    ns0:fullName "V. Tampakas" ;
    ns0:hasAffiliation ns25:IDT180136 ;
    ns0:hasArticle ns1:idt-v13-i3-IDT180136 ;
    ns0:inAuthorList ns150:IDT180136 .

ns8:IES183210 owl:sameAs ns2:IES173142,
        ns2:IES182207,
        ns16:IES182177 ;
    ns0:fullName "Leonardo Sousa Fortes" ;
    ns0:hasAffiliation ns25:IES183210 ;
    ns0:hasArticle ns1:ies-v27-i3-IES183210 ;
    ns0:inAuthorList ns150:IES183210 .

ns8:IES192152 owl:sameAs ns2:BMR171004,
        ns30:NRE172306 ;
    ns0:fullName "Jung-Hoon Lee" ;
    ns0:hasAffiliation ns90:IES192152 ;
    ns0:hasArticle ns1:ies-v27-i3-IES192152 ;
    ns0:inAuthorList ns150:IES192152 .

ns8:IES192167 owl:sameAs ns8:IES192150 ;
    ns0:fullName "Yukio Urabe" ;
    ns0:hasAffiliation ns24:IES192167 ;
    ns0:hasArticle ns1:ies-v27-i4-IES192167 ;
    ns0:inAuthorList ns150:IES192167 .

ns8:IFS172129 owl:sameAs ns8:IFS161759,
        ns8:IFS162150,
        ns8:IFS17267,
        ns8:IFS17482,
        ns8:IFS18659,
        ns8:IFS18891,
        ns12:IFS162136,
        ns12:IFS171142,
        ns12:IFS17912,
        ns12:IFS182910 ;
    ns0:fullName "Fu-Gui Shi" ;
    ns0:hasAffiliation ns24:IFS172129,
        ns25:IFS172129 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS172129 ;
    ns0:inAuthorList ns150:IFS172129 .

ns8:IFS172286 owl:sameAs ns8:IFS181762 ;
    ns0:fullName "Xiangnan Zhou" ;
    ns0:hasAffiliation ns24:IFS172286 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS172286 ;
    ns0:inAuthorList ns150:IFS172286 .

ns8:IFS17283 owl:sameAs ns12:jid150006 ;
    ns0:fullName "W. F. Xie" ;
    ns0:hasAffiliation ns25:IFS17283 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS17283 ;
    ns0:inAuthorList ns150:IFS17283 .

ns8:IFS17707 owl:sameAs ns8:IFS171685 ;
    ns0:fullName "R. Sujatha" ;
    ns0:hasAffiliation ns90:IFS17707 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS17707 ;
    ns0:inAuthorList ns150:IFS17707 .

ns8:IFS179062 owl:sameAs ns12:IFS179081 ;
    ns0:fullName "Lijiao Chen" ;
    ns0:hasAffiliation ns24:IFS179062 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS179062 ;
    ns0:inAuthorList ns150:IFS179062 .

ns8:IFS179085 owl:sameAs ns12:IFS179061 ;
    ns0:fullName "Noura Metawa" ;
    ns0:hasAffiliation ns25:IFS179085,
        ns90:IFS179085 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS179085 ;
    ns0:inAuthorList ns150:IFS179085 .

ns8:IFS179101 owl:sameAs ns8:IFS179199 ;
    ns0:fullName "Wang Huafeng" ;
    ns0:hasAffiliation ns25:IFS179101 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS179101 ;
    ns0:inAuthorList ns150:IFS179101 .

ns8:IFS179118 owl:sameAs ns16:IFS179116 ;
    ns0:fullName "Hongmin Zhou" ;
    ns0:hasAffiliation ns24:IFS179118,
        ns25:IFS179118 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS179118 ;
    ns0:inAuthorList ns150:IFS179118 .

ns8:IFS179141 owl:sameAs ns8:IFS179145,
        ns12:his00158 ;
    ns0:fullName "Durbadal Mandal" ;
    ns0:hasAffiliation ns25:IFS179141 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS179141 ;
    ns0:inAuthorList ns150:IFS179141 .

ns8:IFS179233 owl:sameAs ns2:IFS171055,
        ns30:CBM190091 ;
    ns0:fullName "Tian Tian" ;
    ns0:hasAffiliation ns24:IFS179233 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179233 ;
    ns0:inAuthorList ns150:IFS179233 .

ns8:IFS179252 owl:sameAs ns8:IFS169572 ;
    ns0:fullName "Wooi Ping Cheah" ;
    ns0:hasAffiliation ns24:IFS179252 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179252 ;
    ns0:inAuthorList ns150:IFS179252 .

ns8:IFS179262 owl:sameAs ns2:FI1669,
        ns2:IFS18266,
        ns8:IFS179240 ;
    ns0:fullName "Hui Gao" ;
    ns0:hasAffiliation ns24:IFS179262 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179262 ;
    ns0:inAuthorList ns150:IFS179262 .

ns8:IFS179295 owl:sameAs ns12:AIC763 ;
    ns0:fullName "Geguang Pu" ;
    ns0:hasAffiliation ns24:IFS179295 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179295 ;
    ns0:inAuthorList ns150:IFS179295 .

ns8:IFS179323 owl:sameAs ns12:IFS181051 ;
    ns0:fullName "R. Tavakkoli-Moghaddam" ;
    ns0:hasAffiliation ns25:IFS179323,
        ns258:IFS179323 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS179323 ;
    ns0:inAuthorList ns150:IFS179323 .

ns8:IFS179373 owl:sameAs ns2:IFS16550,
        ns2:IFS1665,
        ns2:IFS169170,
        ns2:IFS2196,
        ns8:IFS17366,
        ns8:IFS182860,
        ns8:IFS2161,
        ns12:IFS190565 ;
    ns0:fullName "Xiaolong Xin" ;
    ns0:hasAffiliation ns25:IFS179373 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179373 ;
    ns0:inAuthorList ns150:IFS179373 .

ns8:IFS18034 owl:sameAs ns12:IFS161320 ;
    ns0:fullName "Naser Shabakhty" ;
    ns0:hasAffiliation ns25:IFS18034 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS18034 ;
    ns0:inAuthorList ns150:IFS18034 .

ns8:IFS18071 owl:sameAs ns30:IFS169495 ;
    ns0:fullName "Pranab K. Muhuri" ;
    ns0:hasAffiliation ns24:IFS18071 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18071 ;
    ns0:inAuthorList ns150:IFS18071 .

ns8:IFS18106 owl:sameAs ns8:IFS171953 ;
    ns0:fullName "Mostafa Jazaeri" ;
    ns0:hasAffiliation ns24:IFS18106 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18106 ;
    ns0:inAuthorList ns150:IFS18106 .

ns8:IFS181097 owl:sameAs ns8:IFS181098 ;
    ns0:fullName "Jiali He" ;
    ns0:hasAffiliation ns25:IFS181097 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181097 ;
    ns0:inAuthorList ns150:IFS181097 .

ns8:IFS181133 owl:sameAs ns12:THC946 ;
    ns0:fullName "Yun Xiong" ;
    ns0:hasAffiliation ns24:IFS181133 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181133 ;
    ns0:inAuthorList ns150:IFS181133 .

ns8:IFS181220 owl:sameAs ns12:IFS17104 ;
    ns0:fullName "Joseph Neggers" ;
    ns0:hasAffiliation ns25:IFS181220 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181220 ;
    ns0:inAuthorList ns150:IFS181220 .

ns8:IFS181293 owl:sameAs ns2:IFS151050,
        ns8:IFS162013,
        ns8:IFS172252,
        ns12:IFS17467,
        ns12:IFS181482,
        ns30:IFS152520 ;
    ns0:fullName "S. Meysam Mousavi" ;
    ns0:hasAffiliation ns25:IFS181293 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181293 ;
    ns0:inAuthorList ns150:IFS181293 .

ns8:IFS181322 owl:sameAs ns2:IFS18979 ;
    ns0:fullName "Eda Bolturk" ;
    ns0:hasAffiliation ns24:IFS181322 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181322 ;
    ns0:inAuthorList ns150:IFS181322 .

ns8:IFS181339 owl:sameAs ns8:IFS179088 ;
    ns0:fullName "Weifang Du" ;
    ns0:hasAffiliation ns24:IFS181339 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS181339 ;
    ns0:inAuthorList ns150:IFS181339 .

ns8:IFS181347 owl:sameAs ns12:IFS162053 ;
    ns0:fullName "Xiao-Yu Huang" ;
    ns0:hasAffiliation ns25:IFS181347 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181347 ;
    ns0:inAuthorList ns150:IFS181347 .

ns8:IFS181362 owl:sameAs ns8:IFS18577 ;
    ns0:fullName "Zhiyong An" ;
    ns0:hasAffiliation ns25:IFS181362 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181362 ;
    ns0:inAuthorList ns150:IFS181362 .

ns8:IFS181408 owl:sameAs ns8:IFS181467 ;
    ns0:fullName "Qingwei Hao" ;
    ns0:hasAffiliation ns24:IFS181408 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS181408 ;
    ns0:inAuthorList ns150:IFS181408 .

ns8:IFS181415 owl:sameAs ns2:IFS161654,
        ns2:IFS17940 ;
    ns0:fullName "Hifsi Altinok" ;
    ns0:hasAffiliation ns24:IFS181415 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181415 ;
    ns0:inAuthorList ns150:IFS181415 .

ns8:IFS181425 owl:sameAs ns8:IFS171907,
        ns8:IFS1798,
        ns8:IFS18607,
        ns30:IFS172130,
        ns30:IFS181171 ;
    ns0:fullName "Runtong Zhang" ;
    ns0:hasAffiliation ns24:IFS181425 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181425 ;
    ns0:inAuthorList ns150:IFS181425 .

ns8:IFS181452 owl:sameAs ns12:IFS2082 ;
    ns0:fullName "Sovan Samanta" ;
    ns0:hasAffiliation ns25:IFS181452 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS181452 ;
    ns0:inAuthorList ns150:IFS181452 .

ns8:IFS181478 owl:sameAs ns8:IFS171060 ;
    ns0:fullName "Imran Ahmed" ;
    ns0:hasAffiliation ns24:IFS181478 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181478 ;
    ns0:inAuthorList ns150:IFS181478 .

ns8:IFS181502 owl:sameAs ns2:IFS191197,
        ns8:IFS190447,
        ns12:IFS171172,
        ns12:IFS18757,
        ns12:IFS18993 ;
    ns0:fullName "Noor Rehman" ;
    ns0:hasAffiliation ns25:IFS181502 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181502 ;
    ns0:inAuthorList ns150:IFS181502 .

ns8:IFS181527 owl:sameAs ns8:IFS181040,
        ns8:IFS181541,
        ns8:IFS181547 ;
    ns0:fullName "Amit Kumar" ;
    ns0:hasAffiliation ns24:IFS181527 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181527 ;
    ns0:inAuthorList ns150:IFS181527 .

ns8:IFS181586 owl:sameAs ns16:THC1286 ;
    ns0:fullName "Muhammad Hussain" ;
    ns0:hasAffiliation ns24:IFS181586 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181586 ;
    ns0:inAuthorList ns150:IFS181586 .

ns8:IFS181602 owl:sameAs ns8:IFS182671,
        ns30:IFS181291 ;
    ns0:fullName "Radko Mesiar" ;
    ns0:hasAffiliation ns25:IFS181602,
        ns90:IFS181602 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181602 ;
    ns0:inAuthorList ns150:IFS181602 .

ns8:IFS181604 owl:sameAs ns30:IFS161152 ;
    ns0:fullName "Brígida Ramati Pereira da Rocha" ;
    ns0:hasAffiliation ns25:IFS181604 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181604 ;
    ns0:inAuthorList ns150:IFS181604 .

ns8:IFS181663 owl:sameAs ns8:IFS181504 ;
    ns0:fullName "Qing-Guo Li" ;
    ns0:hasAffiliation ns24:IFS181663 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS181663 ;
    ns0:inAuthorList ns150:IFS181663 .

ns8:IFS181799 owl:sameAs ns8:IFS169608,
        ns8:IFS18169 ;
    ns0:fullName "Mingqing Xiao" ;
    ns0:hasAffiliation ns24:IFS181799 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181799 ;
    ns0:inAuthorList ns150:IFS181799 .

ns8:IFS181813 owl:sameAs ns8:IFS169366,
        ns12:IFS169768 ;
    ns0:fullName "Muhammad Kamran Siddiqui" ;
    ns0:hasAffiliation ns90:IFS181813 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS181813 ;
    ns0:inAuthorList ns150:IFS181813 .

ns8:IFS181922 owl:sameAs ns2:IFS172009,
        ns2:IFS181941 ;
    ns0:fullName "Shahzaib Ashraf" ;
    ns0:hasAffiliation ns25:IFS181922 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181922 ;
    ns0:inAuthorList ns150:IFS181922 .

ns8:IFS181934 owl:sameAs ns12:ida00324 ;
    ns0:fullName "Ofelia Cervantes" ;
    ns0:hasAffiliation ns24:IFS181934 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181934 ;
    ns0:inAuthorList ns150:IFS181934 .

ns8:IFS181941 owl:sameAs ns8:IFS151652,
        ns8:IFS162007,
        ns8:IFS16797,
        ns8:IFS172009,
        ns8:IFS17811,
        ns8:IFS18125,
        ns8:IFS181329,
        ns8:IFS181516,
        ns8:IFS181703,
        ns8:IFS182951,
        ns8:JIN092,
        ns12:IFS171049,
        ns12:IFS171567,
        ns12:IFS181922 ;
    ns0:fullName "Saleem Abdullah" ;
    ns0:hasAffiliation ns24:IFS181941 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181941 ;
    ns0:inAuthorList ns150:IFS181941 .

ns8:IFS181966 owl:sameAs ns8:IFS171118 ;
    ns0:fullName "Rodrigo B. Santos" ;
    ns0:hasAffiliation ns24:IFS181966 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181966 ;
    ns0:inAuthorList ns150:IFS181966 .

ns8:IFS181970 owl:sameAs ns5:IFS18667 ;
    ns0:fullName "Qianying An" ;
    ns0:hasAffiliation ns24:IFS181970 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS181970 ;
    ns0:inAuthorList ns150:IFS181970 .

ns8:IFS181990 owl:sameAs ns30:IFS17698 ;
    ns0:fullName "S.H. Hosseinian" ;
    ns0:hasAffiliation ns24:IFS181990 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181990 ;
    ns0:inAuthorList ns150:IFS181990 .

ns8:IFS181997 owl:sameAs ns2:IFS169324,
        ns8:IFS190863 ;
    ns0:fullName "Shaojian Qu" ;
    ns0:hasAffiliation ns24:IFS181997 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181997 ;
    ns0:inAuthorList ns150:IFS181997 .

ns8:IFS182540 owl:sameAs ns8:IFS190036,
        ns12:IFS181084,
        ns12:IFS182618,
        ns12:IFS1906,
        ns12:INF1131,
        ns30:IFS181742,
        ns30:INF1215 ;
    ns0:fullName "Florentin Smarandache" ;
    ns0:hasAffiliation ns25:IFS182540 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182540 ;
    ns0:inAuthorList ns150:IFS182540 .

ns8:IFS182568 owl:sameAs ns2:IFS17465 ;
    ns0:fullName "Fan-Hong Chen" ;
    ns0:hasAffiliation ns25:IFS182568,
        ns90:IFS182568 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182568 ;
    ns0:inAuthorList ns150:IFS182568 .

ns8:IFS182572 owl:sameAs ns2:IFS181188,
        ns8:IFS162058,
        ns8:IFS182928,
        ns30:IFS181460 ;
    ns0:fullName "Muhammad Izhar" ;
    ns0:hasAffiliation ns24:IFS182572 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182572 ;
    ns0:inAuthorList ns150:IFS182572 .

ns8:IFS182590 owl:sameAs ns8:IFS171145 ;
    ns0:fullName "Hoang Thi Phuong Thao" ;
    ns0:hasAffiliation ns90:IFS182590 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182590 ;
    ns0:inAuthorList ns150:IFS182590 .

ns8:IFS182616 owl:sameAs ns8:IFS172282 ;
    ns0:fullName "Ghous Ali" ;
    ns0:hasAffiliation ns24:IFS182616 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182616 ;
    ns0:inAuthorList ns150:IFS182616 .

ns8:IFS182618 owl:sameAs ns2:IFS1688,
        ns8:IFS151517,
        ns8:IFS171838,
        ns8:IFS1773,
        ns8:IFS181039,
        ns8:IFS181218,
        ns8:IFS2148,
        ns12:IFS152553,
        ns12:IFS1667,
        ns12:IFS17597,
        ns12:IFS179373,
        ns12:IFS181697,
        ns30:IFS161299 ;
    ns0:fullName "Arsham Borumand Saeid" ;
    ns0:hasAffiliation ns25:IFS182618 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182618 ;
    ns0:inAuthorList ns150:IFS182618 .

ns8:IFS182643 owl:sameAs ns2:IFS18568 ;
    ns0:fullName "Lvqing Bi" ;
    ns0:hasAffiliation ns25:IFS182643 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182643 ;
    ns0:inAuthorList ns150:IFS182643 .

ns8:IFS182654 owl:sameAs ns2:FI1290,
        ns12:IFS16845,
        ns30:IFS181739 ;
    ns0:fullName "Keyun Qin" ;
    ns0:hasAffiliation ns24:IFS182654 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182654 ;
    ns0:inAuthorList ns150:IFS182654 .

ns8:IFS182673 owl:sameAs ns12:IFS181617 ;
    ns0:fullName "Bibin Mathew" ;
    ns0:hasAffiliation ns25:IFS182673 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182673 ;
    ns0:inAuthorList ns150:IFS182673 .

ns8:IFS182681 owl:sameAs ns2:IFS16468 ;
    ns0:fullName "Zengtai Gong" ;
    ns0:hasAffiliation ns24:IFS182681 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182681 ;
    ns0:inAuthorList ns150:IFS182681 .

ns8:IFS182709 owl:sameAs ns2:IFS17876,
        ns2:IFS18339,
        ns8:IFS182924 ;
    ns0:fullName "Hüseyin Kamacı" ;
    ns0:hasAffiliation ns24:IFS182709,
        ns25:IFS182709 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182709 ;
    ns0:inAuthorList ns150:IFS182709 .

ns8:IFS182725 owl:sameAs ns8:IFS161988,
        ns8:IFS1650,
        ns8:IFS1788,
        ns12:IFS17465,
        ns12:IFS182568 ;
    ns0:fullName "Fu-Gui Shi" ;
    ns0:hasAffiliation ns24:IFS182725 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182725 ;
    ns0:inAuthorList ns150:IFS182725 .

ns8:IFS182774 owl:sameAs ns8:INF1217 ;
    ns0:fullName "Qaisar Khan" ;
    ns0:hasAffiliation ns25:IFS182774 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182774 ;
    ns0:inAuthorList ns150:IFS182774 .

ns8:IFS182775 owl:sameAs ns2:IFS1737,
        ns2:IFS1805,
        ns8:IFS181296 ;
    ns0:fullName "Ismat Beg" ;
    ns0:hasAffiliation ns24:IFS182775 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182775 ;
    ns0:inAuthorList ns150:IFS182775 .

ns8:IFS182778 owl:sameAs ns12:INF1160,
        ns30:IFS17656 ;
    ns0:fullName "Jawad Ahmad" ;
    ns0:hasAffiliation ns25:IFS182778 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182778 ;
    ns0:inAuthorList ns150:IFS182778 .

ns8:IFS182780 owl:sameAs ns2:IFS2057 ;
    ns0:fullName "Tabasam Rashid" ;
    ns0:hasAffiliation ns24:IFS182780 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182780 ;
    ns0:inAuthorList ns150:IFS182780 .

ns8:IFS182809 owl:sameAs ns8:IFS190550 ;
    ns0:fullName "Masooma Raza Hashmi" ;
    ns0:hasAffiliation ns24:IFS182809 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182809 ;
    ns0:inAuthorList ns150:IFS182809 .

ns8:IFS182828 owl:sameAs ns2:IFS190280 ;
    ns0:fullName "Chao-Zan Fan" ;
    ns0:hasAffiliation ns24:IFS182828 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182828 ;
    ns0:inAuthorList ns150:IFS182828 .

ns8:IFS182832 owl:sameAs ns8:IFS17077,
        ns12:IFS17741 ;
    ns0:fullName "Ayhan Esi" ;
    ns0:hasAffiliation ns25:IFS182832 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182832 ;
    ns0:inAuthorList ns150:IFS182832 .

ns8:IFS182836 owl:sameAs ns2:IFS171946 ;
    ns0:fullName "Yumin Chen" ;
    ns0:hasAffiliation ns25:IFS182836 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182836 ;
    ns0:inAuthorList ns150:IFS182836 .

ns8:IFS182868 owl:sameAs ns2:IDA173473 ;
    ns0:fullName "Ebrahim Ansari" ;
    ns0:hasAffiliation ns25:IFS182868,
        ns90:IFS182868 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182868 ;
    ns0:inAuthorList ns150:IFS182868 .

ns8:IFS182873 owl:sameAs ns2:IFS171033,
        ns12:IFS190543 ;
    ns0:fullName "Mohammad Imdad" ;
    ns0:hasAffiliation ns24:IFS182873 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182873 ;
    ns0:inAuthorList ns150:IFS182873 .

ns8:IFS182876 owl:sameAs ns2:IFS152405,
        ns2:IFS181657,
        ns2:IFS181698,
        ns8:IFS182863,
        ns8:IFS18604,
        ns12:IFS190952 ;
    ns0:fullName "Truong Vinh An" ;
    ns0:hasAffiliation ns25:IFS182876 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182876 ;
    ns0:inAuthorList ns150:IFS182876 .

ns8:IFS182877 owl:sameAs ns2:IFS17277,
        ns12:IFS17378 ;
    ns0:fullName "Yuhong Sheng" ;
    ns0:hasAffiliation ns24:IFS182877 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS182877 ;
    ns0:inAuthorList ns150:IFS182877 .

ns8:IFS182887 owl:sameAs ns2:IFS182569,
        ns2:IFS182808 ;
    ns0:fullName "Qing-Hua Li" ;
    ns0:hasAffiliation ns25:IFS182887 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182887 ;
    ns0:inAuthorList ns150:IFS182887 .

ns8:IFS182907 owl:sameAs ns8:IFS182810 ;
    ns0:fullName "David M.W. Powers" ;
    ns0:hasAffiliation ns25:IFS182907 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182907 ;
    ns0:inAuthorList ns150:IFS182907 .

ns8:IFS182919 owl:sameAs ns8:IFS1992,
        ns8:IFS2058 ;
    ns0:fullName "Naim Çağman" ;
    ns0:hasAffiliation ns25:IFS182919 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182919 ;
    ns0:inAuthorList ns150:IFS182919 .

ns8:IFS182926 owl:sameAs ns2:kes00297 ;
    ns0:fullName "Zied Kechaou" ;
    ns0:hasAffiliation ns24:IFS182926 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182926 ;
    ns0:inAuthorList ns150:IFS182926 .

ns8:IFS182934 owl:sameAs ns8:IFS162299,
        ns8:IFS16557,
        ns8:IFS17595,
        ns8:IFS17821,
        ns8:IFS181980,
        ns8:IFS2125 ;
    ns0:fullName "Deng-Feng Li" ;
    ns0:hasAffiliation ns24:IFS182934 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182934 ;
    ns0:inAuthorList ns150:IFS182934 .

ns8:IFS182947 owl:sameAs ns2:IFS1856,
        ns2:IFS190988,
        ns2:IFS2074,
        ns2:IFS2075,
        ns2:IFS2082,
        ns2:IFS2110,
        ns2:IFS2114,
        ns2:IFS2121,
        ns2:IFS2128,
        ns8:IFS152553,
        ns8:IFS161586,
        ns8:IFS17088,
        ns8:IFS190148,
        ns8:IFS2041,
        ns8:IFS2077,
        ns12:IFS171443,
        ns12:IFS181488,
        ns30:IFS17848,
        ns30:IFS181755,
        ns30:IFS2113,
        ns5:IFS190565 ;
    ns0:fullName "R.A. Borzooei" ;
    ns0:hasAffiliation ns25:IFS182947 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS182947 ;
    ns0:inAuthorList ns150:IFS182947 .

ns8:IFS182953 owl:sameAs ns2:IFS181364,
        ns5:IFS190067 ;
    ns0:fullName "Ghasem Tohidi" ;
    ns0:hasAffiliation ns24:IFS182953 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182953 ;
    ns0:inAuthorList ns150:IFS182953 .

ns8:IFS182963 owl:sameAs ns2:IFS2019,
        ns2:IFS2021 ;
    ns0:fullName "Bin Pang" ;
    ns0:hasAffiliation ns25:IFS182963,
        ns90:IFS182963 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182963 ;
    ns0:inAuthorList ns150:IFS182963 .

ns8:IFS18678 owl:sameAs ns2:IFS179161,
        ns40:JAD160587 ;
    ns0:fullName "Ying Peng" ;
    ns0:hasAffiliation ns25:IFS18678 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS18678 ;
    ns0:inAuthorList ns150:IFS18678 .

ns8:IFS18755 owl:sameAs ns2:IFS17530,
        ns2:IFS18104,
        ns2:IFS181642 ;
    ns0:fullName "Hua Mao" ;
    ns0:hasAffiliation ns24:IFS18755 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18755 ;
    ns0:inAuthorList ns150:IFS18755 .

ns8:IFS18760 owl:sameAs ns5:IFS181127 ;
    ns0:fullName "Sagheer Abbas" ;
    ns0:hasAffiliation ns24:IFS18760 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS18760 ;
    ns0:inAuthorList ns150:IFS18760 .

ns8:IFS18824 owl:sameAs ns8:IFS171176,
        ns8:IFS171187,
        ns8:IFS17848,
        ns8:IFS181262,
        ns8:IFS181488,
        ns8:IFS182961,
        ns8:IFS2113,
        ns12:IFS172195,
        ns12:IFS181452,
        ns12:IFS2175,
        ns30:IFS171442,
        ns30:IFS18877,
        ns30:IFS2082,
        ns30:IFS2114,
        ns30:IFS2121,
        ns5:IFS171685,
        ns5:IFS18347 ;
    ns0:fullName "Madhumangal Pal" ;
    ns0:hasAffiliation ns24:IFS18824 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS18824 ;
    ns0:inAuthorList ns150:IFS18824 .

ns8:IFS190016 owl:sameAs ns2:IFS2047 ;
    ns0:fullName "R. Ameri" ;
    ns0:hasAffiliation ns25:IFS190016 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190016 ;
    ns0:inAuthorList ns150:IFS190016 .

ns8:IFS190126 owl:sameAs ns2:IFS18411,
        ns8:IFS181754,
        ns12:IFS152261,
        ns5:IFS181153 ;
    ns0:fullName "Akbar Azam" ;
    ns0:hasAffiliation ns24:IFS190126 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190126 ;
    ns0:inAuthorList ns150:IFS190126 .

ns8:IFS190128 owl:sameAs ns30:THC1136 ;
    ns0:fullName "Syed Hammad Mian" ;
    ns0:hasAffiliation ns24:IFS190128 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190128 ;
    ns0:inAuthorList ns150:IFS190128 .

ns8:IFS190137 owl:sameAs ns8:IFS16357 ;
    ns0:fullName "Tariq Shah" ;
    ns0:hasAffiliation ns24:IFS190137 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190137 ;
    ns0:inAuthorList ns150:IFS190137 .

ns8:IFS190205 owl:sameAs ns2:THC1290 ;
    ns0:fullName "Sujit Das" ;
    ns0:hasAffiliation ns25:IFS190205 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190205 ;
    ns0:inAuthorList ns150:IFS190205 .

ns8:IFS190213 owl:sameAs ns5:IFS182671 ;
    ns0:fullName "Jiejie Qin" ;
    ns0:hasAffiliation ns24:IFS190213 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190213 ;
    ns0:inAuthorList ns150:IFS190213 .

ns8:IFS190217 owl:sameAs ns12:IFS182673 ;
    ns0:fullName "Sunil Jacob John" ;
    ns0:hasAffiliation ns24:IFS190217 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190217 ;
    ns0:inAuthorList ns150:IFS190217 .

ns8:IFS190264 owl:sameAs ns8:IFS161836,
        ns8:IFS17319 ;
    ns0:fullName "Yufu Ning" ;
    ns0:hasAffiliation ns90:IFS190264 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190264 ;
    ns0:inAuthorList ns150:IFS190264 .

ns8:IFS190280 owl:sameAs ns2:IFS182828,
        ns8:IFS180001 ;
    ns0:fullName "Fu-Gui Shi" ;
    ns0:hasAffiliation ns24:IFS190280 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190280 ;
    ns0:inAuthorList ns150:IFS190280 .

ns8:IFS190325 owl:sameAs ns8:IFS152261 ;
    ns0:fullName "Aqeel Shahzad" ;
    ns0:hasAffiliation ns24:IFS190325 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190325 ;
    ns0:inAuthorList ns150:IFS190325 .

ns8:IFS190408 owl:sameAs ns8:IFS151940,
        ns8:IFS1781,
        ns12:IFS171104,
        ns12:IFS171707,
        ns12:IFS181055 ;
    ns0:fullName "T. Allahviranloo" ;
    ns0:hasAffiliation ns24:IFS190408,
        ns25:IFS190408 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190408 ;
    ns0:inAuthorList ns150:IFS190408 .

ns8:IFS190683 owl:sameAs ns5:IFS182515 ;
    ns0:fullName "Songyi Dian" ;
    ns0:hasAffiliation ns24:IFS190683 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190683 ;
    ns0:inAuthorList ns150:IFS190683 .

ns8:IFS190711 owl:sameAs ns12:IFS181330 ;
    ns0:fullName "A. Ebrahimnejad" ;
    ns0:hasAffiliation ns25:IFS190711 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190711 ;
    ns0:inAuthorList ns150:IFS190711 .

ns8:IFS190952 owl:sameAs ns8:IFS2096,
        ns12:IFS171070,
        ns12:IFS181657,
        ns12:IFS181698,
        ns12:IFS182863,
        ns12:IFS182876 ;
    ns0:fullName "Ngo Van Hoa" ;
    ns0:hasAffiliation ns25:IFS190952,
        ns90:IFS190952 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190952 ;
    ns0:inAuthorList ns150:IFS190952 .

ns8:ISP180249 owl:sameAs ns30:thc00473 ;
    ns0:fullName "Mohamad Alizadeh" ;
    ns0:hasAffiliation ns91:ISP180249 ;
    ns0:hasArticle ns1:isp-v66-i3-ISP180249 ;
    ns0:inAuthorList ns150:ISP180249 .

ns8:JAD170300 owl:sameAs ns8:JAD151114,
        ns26:JAD110860,
        ns12:JAD112009,
        ns5:JAD130551,
        ns57:JAD129041 ;
    ns0:fullName "Nicole Schupf" ;
    ns0:hasAffiliation ns24:JAD170300,
        ns25:JAD170300,
        ns90:JAD170300,
        ns258:JAD170300 ;
    ns0:hasArticle ns1:jad-v60-i3-JAD170300 ;
    ns0:inAuthorList ns150:JAD170300 .

ns8:JAD180381 owl:sameAs ns52:JAD170267 ;
    ns0:fullName "Maturin Tabue-Teguo" ;
    ns0:hasAffiliation ns25:JAD180381 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD180381 ;
    ns0:inAuthorList ns150:JAD180381 .

ns8:JAD180511 owl:sameAs ns5:JAD160685,
        ns16:JAD180496,
        ns57:JAD170880,
        ns57:JAD181171 ;
    ns0:fullName "Hanafi Ahmad Damanhuri" ;
    ns0:hasAffiliation ns24:JAD180511 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180511 ;
    ns0:inAuthorList ns150:JAD180511 .

ns8:JAD180630 owl:sameAs ns8:JAD132642,
        ns5:JAD160970 ;
    ns0:fullName "Tomas Nikolai" ;
    ns0:hasAffiliation ns24:JAD180630,
        ns25:JAD180630,
        ns90:JAD180630,
        ns258:JAD180630 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD180630 ;
    ns0:inAuthorList ns150:JAD180630 .

ns8:JAD180730 owl:sameAs ns52:JAD140183 ;
    ns0:fullName "Jesus Landeira-Fernandez" ;
    ns0:hasAffiliation ns24:JAD180730 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180730 ;
    ns0:inAuthorList ns150:JAD180730 .

ns8:JAD180780 owl:sameAs ns12:jad01041 ;
    ns0:fullName "Sarah Aldred" ;
    ns0:hasAffiliation ns24:JAD180780 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180780 ;
    ns0:inAuthorList ns150:JAD180780 .

ns8:JAD180857 owl:sameAs ns8:JAD160766,
        ns8:JAD170564,
        ns130:JAD160126,
        ns12:JAD170522,
        ns12:JAD190041,
        ns5:JAD151120,
        ns52:JAD111628 ;
    ns0:fullName "Inez H.G.B. Ramakers" ;
    ns0:hasAffiliation ns24:JAD180857 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD180857 ;
    ns0:inAuthorList ns150:JAD180857 .

ns8:JAD180949 owl:sameAs ns5:JAD180981 ;
    ns0:fullName "Susanne Roehr" ;
    ns0:hasAffiliation ns24:JAD180949,
        ns25:JAD180949 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

ns8:JAD180962 owl:sameAs ns2:JAD150585,
        ns8:JAD161028,
        ns12:JAD170238,
        ns16:JAD161227 ;
    ns0:fullName "Brandy L. Callahan" ;
    ns0:hasAffiliation ns24:JAD180962,
        ns25:JAD180962,
        ns90:JAD180962 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD180962 ;
    ns0:inAuthorList ns150:JAD180962 .

ns8:JAD181102 owl:sameAs ns5:JAD180982,
        ns16:JAD150785 ;
    ns0:fullName "Peter Dal-Bianco" ;
    ns0:hasAffiliation ns25:JAD181102 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD181102 ;
    ns0:inAuthorList ns150:JAD181102 .

ns8:JAD181141 owl:sameAs ns2:JAD180335,
        ns12:JAD111631,
        ns12:JAD160291,
        ns12:JAD170714,
        ns12:JAD180604,
        ns12:JAD180737 ;
    ns0:fullName "Mindy J. Katz" ;
    ns0:hasAffiliation ns24:JAD181141 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD181141 ;
    ns0:inAuthorList ns150:JAD181141 .

ns8:JAD181170 owl:sameAs ns8:JAD181169 ;
    ns0:fullName "Alison Divine" ;
    ns0:hasAffiliation ns25:JAD181170 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181170 ;
    ns0:inAuthorList ns150:JAD181170 .

ns8:JAD181173 owl:sameAs ns2:JAD181174 ;
    ns0:fullName "Morag E. Taylor" ;
    ns0:hasAffiliation ns25:JAD181173,
        ns90:JAD181173,
        ns258:JAD181173 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181173 ;
    ns0:inAuthorList ns150:JAD181173 .

ns8:JAD181178 owl:sameAs ns2:JAD170195,
        ns12:JAD160244 ;
    ns0:fullName "Takehiko Doi" ;
    ns0:hasAffiliation ns24:JAD181178 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181178 ;
    ns0:inAuthorList ns150:JAD181178 .

ns8:JAD181196 owl:sameAs ns16:JAD140759 ;
    ns0:fullName "Michael Borrie" ;
    ns0:hasAffiliation ns24:JAD181196,
        ns90:JAD181196,
        ns258:JAD181196 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181196 ;
    ns0:inAuthorList ns150:JAD181196 .

ns8:JAD181203 owl:sameAs ns2:JAD161292,
        ns30:JAD161248 ;
    ns0:fullName "Mahwesh Saleem" ;
    ns0:hasAffiliation ns25:JAD181203 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181203 ;
    ns0:inAuthorList ns150:JAD181203 .

ns8:JAD181212 owl:sameAs ns12:JAD181087 ;
    ns0:fullName "Laura E. Gibbons" ;
    ns0:hasAffiliation ns25:JAD181212 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181212 ;
    ns0:inAuthorList ns150:JAD181212 .

ns8:JAD181220 owl:sameAs ns2:JAD190056 ;
    ns0:fullName "Wei-Wei Li" ;
    ns0:hasAffiliation ns24:JAD181220 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181220 ;
    ns0:inAuthorList ns150:JAD181220 .

ns8:JAD181256 owl:sameAs ns8:JAD111109,
        ns8:JAD140777,
        ns8:jad100597,
        ns12:JAD00041,
        ns12:JAD130104,
        ns30:JAD101911,
        ns30:JAD120946,
        ns5:JAD170534,
        ns16:JAD190334,
        ns52:JAD170854,
        ns57:JAD190132,
        ns60:JAD161142 ;
    ns0:fullName "Seppo Helisalmi" ;
    ns0:hasAffiliation ns90:JAD181256 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181256 ;
    ns0:inAuthorList ns150:JAD181256 .

ns8:JAD181259 owl:sameAs ns8:JAD180250 ;
    ns0:fullName "Marina Saresella" ;
    ns0:hasAffiliation ns24:JAD181259,
        ns258:JAD181259 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD181259 ;
    ns0:inAuthorList ns150:JAD181259 .

ns8:JAD181261 owl:sameAs ns5:JAD180280 ;
    ns0:fullName "Ting Ting Yong" ;
    ns0:hasAffiliation ns24:JAD181261 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181261 ;
    ns0:inAuthorList ns150:JAD181261 .

ns8:JAD181265 owl:sameAs ns5:JAD180855,
        ns5:jad091594,
        ns5:jad101023 ;
    ns0:fullName "Vilmantas Giedraitis" ;
    ns0:hasAffiliation ns24:JAD181265 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181265 ;
    ns0:inAuthorList ns150:JAD181265 .

ns8:JAD181277 owl:sameAs ns12:JAD180224,
        ns16:JAD171140 ;
    ns0:fullName "Jean-Christophe Bier" ;
    ns0:hasAffiliation ns25:JAD181277 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181277 ;
    ns0:inAuthorList ns150:JAD181277 .

ns8:JAD181295 owl:sameAs ns2:JAD140282,
        ns2:JAD180912,
        ns8:JAD180594 ;
    ns0:fullName "Heidi Taipale" ;
    ns0:hasAffiliation ns24:JAD181295,
        ns25:JAD181295,
        ns90:JAD181295,
        ns258:JAD181295 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181295 ;
    ns0:inAuthorList ns150:JAD181295 .

ns8:JAD181296 owl:sameAs ns5:JAD170692 ;
    ns0:fullName "Rujing Ren" ;
    ns0:hasAffiliation ns24:JAD181296 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181296 ;
    ns0:inAuthorList ns150:JAD181296 .

ns8:JAD181298 owl:sameAs ns8:JAD180524 ;
    ns0:fullName "Carola Dell’Acqua" ;
    ns0:hasAffiliation ns24:JAD181298 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181298 ;
    ns0:inAuthorList ns150:JAD181298 .

ns8:JAD190025 owl:sameAs ns2:JAD110713 ;
    ns0:fullName "Maria Soto" ;
    ns0:hasAffiliation ns24:JAD190025 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190025 ;
    ns0:inAuthorList ns150:JAD190025 .

ns8:JAD190038 owl:sameAs ns12:JAD160382 ;
    ns0:fullName "Maxime Montembeault" ;
    ns0:hasAffiliation ns90:JAD190038 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD190038 ;
    ns0:inAuthorList ns150:JAD190038 .

ns8:JAD190074 owl:sameAs ns8:JAD151101 ;
    ns0:fullName "Eran Schmukler" ;
    ns0:hasAffiliation ns24:JAD190074 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190074 ;
    ns0:inAuthorList ns150:JAD190074 .

ns8:JAD190153 owl:sameAs ns2:CBM638 ;
    ns0:fullName "Rui Yin" ;
    ns0:hasAffiliation ns25:JAD190153 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190153 ;
    ns0:inAuthorList ns150:JAD190153 .

ns8:JAD190155 owl:sameAs ns130:JAD190772,
        ns5:JAD170727,
        ns57:JAD142874 ;
    ns0:fullName "Charles R. Harrington" ;
    ns0:hasAffiliation ns90:JAD190155 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190155 ;
    ns0:inAuthorList ns150:JAD190155 .

ns8:JAD190159 owl:sameAs ns8:JAD179924,
        ns30:JAD150736,
        ns5:JAD181261,
        ns16:JAD150471,
        ns16:JAD170409,
        ns57:JAD181261 ;
    ns0:fullName "Kok Pin Ng" ;
    ns0:hasAffiliation ns24:JAD190159 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190159 ;
    ns0:inAuthorList ns150:JAD190159 .

ns8:JAD190162 owl:sameAs ns2:JAD170982 ;
    ns0:fullName "Julia Gilmartin-Thomas" ;
    ns0:hasAffiliation ns90:JAD190162 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190162 ;
    ns0:inAuthorList ns150:JAD190162 .

ns8:JAD190181 owl:sameAs ns8:JAD180631 ;
    ns0:fullName "Nicole Ee" ;
    ns0:hasAffiliation ns24:JAD190181,
        ns25:JAD190181 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD190181 ;
    ns0:inAuthorList ns150:JAD190181 .

ns8:JAD190183 owl:sameAs ns8:JAD170419,
        ns28:JAD161023,
        ns16:JAD190459 ;
    ns0:fullName "Jean-Michel Dorey" ;
    ns0:hasAffiliation ns25:JAD190183,
        ns90:JAD190183,
        ns258:JAD190183 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190183 ;
    ns0:inAuthorList ns150:JAD190183 .

ns8:JAD190187 owl:sameAs ns2:JAD120508,
        ns2:JAD120994,
        ns2:jad100573,
        ns8:JAD120019,
        ns8:JAD121471,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD170875>,
        ns5:jad00918 ;
    ns0:fullName "Erik Portelius" ;
    ns0:hasAffiliation ns24:JAD190187,
        ns25:JAD190187 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190187 ;
    ns0:inAuthorList ns150:JAD190187 .

ns8:JAD190230 owl:sameAs ns12:JAD170587,
        ns12:JAD180525 ;
    ns0:fullName "Shubir Dutt" ;
    ns0:hasAffiliation ns24:JAD190230 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190230 ;
    ns0:inAuthorList ns150:JAD190230 .

ns8:JAD190241 owl:sameAs ns8:BPL180071 ;
    ns0:fullName "Andrea Santi" ;
    ns0:hasAffiliation ns24:JAD190241 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190241 ;
    ns0:inAuthorList ns150:JAD190241 .

ns8:JAD190262 owl:sameAs ns2:JAD180604 ;
    ns0:fullName "Andrea R. Zammit" ;
    ns0:hasAffiliation ns24:JAD190262 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190262 ;
    ns0:inAuthorList ns150:JAD190262 .

ns8:JAD190266 owl:sameAs ns2:JAD150254,
        ns8:JAD120424,
        ns8:JAD120430,
        ns8:JAD121639,
        ns8:JAD130353,
        ns8:JAD131733,
        ns8:JAD140042,
        ns8:JAD140264,
        ns8:JAD150250,
        ns8:JAD150261,
        ns8:JAD171053 ;
    ns0:fullName "Raymond F. Palmer" ;
    ns0:hasAffiliation ns90:JAD190266 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190266 ;
    ns0:inAuthorList ns150:JAD190266 .

ns8:JAD190283 owl:sameAs ns8:JAD160873 ;
    ns0:fullName "Andrew J. Holbrook" ;
    ns0:hasAffiliation ns90:JAD190283 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190283 ;
    ns0:inAuthorList ns150:JAD190283 .

ns8:JAD190293 owl:sameAs ns2:JAD142334,
        ns2:JAD170077,
        ns30:JAD111172,
        ns30:JAD170148,
        ns60:JAD180820 ;
    ns0:fullName "Heather M. Wilkins" ;
    ns0:hasAffiliation ns24:JAD190293 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190293 ;
    ns0:inAuthorList ns150:JAD190293 .

ns8:JAD190302 owl:sameAs ns8:JAD179901 ;
    ns0:fullName "Aaron Ritter" ;
    ns0:hasAffiliation ns24:JAD190302 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190302 ;
    ns0:inAuthorList ns150:JAD190302 .

ns8:JAD190319 owl:sameAs ns2:JAD161166,
        ns2:JAD180943 ;
    ns0:fullName "Chris Moran" ;
    ns0:hasAffiliation ns24:JAD190319,
        ns25:JAD190319 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190319 ;
    ns0:inAuthorList ns150:JAD190319 .

ns8:JAD190322 owl:sameAs ns52:JAD142844 ;
    ns0:fullName "Michael C. Donohue" ;
    ns0:hasAffiliation ns24:JAD190322 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190322 ;
    ns0:inAuthorList ns150:JAD190322 .

ns8:JAD190344 owl:sameAs ns5:JAD132561,
        ns16:JAD151068 ;
    ns0:fullName "Charlotte E. Teunissen" ;
    ns0:hasAffiliation ns25:JAD190344 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190344 ;
    ns0:inAuthorList ns150:JAD190344 .

ns8:JAD190345 owl:sameAs ns12:JAD180050 ;
    ns0:fullName "Albert Gjedde" ;
    ns0:hasAffiliation ns25:JAD190345,
        ns90:JAD190345 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190345 ;
    ns0:inAuthorList ns150:JAD190345 .

ns8:JAD190362 owl:sameAs ns2:JAD161234,
        ns2:JAD181194,
        ns8:JAD170091,
        ns8:JAD180808,
        ns12:JAD180569,
        ns12:JAD190239,
        ns12:JAD190581,
        ns30:JAD190508 ;
    ns0:fullName "Louis Jacob" ;
    ns0:hasAffiliation ns25:JAD190362 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190362 ;
    ns0:inAuthorList ns150:JAD190362 .

ns8:JAD190368 owl:sameAs ns12:JAD180882,
        ns30:JAD171047 ;
    ns0:fullName "Dandan Chu" ;
    ns0:hasAffiliation ns24:JAD190368 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190368 ;
    ns0:inAuthorList ns150:JAD190368 .

ns8:JAD190371 owl:sameAs ns2:JAD151122,
        ns2:JAD161283,
        ns2:JAD170807,
        ns2:JAD190440,
        ns2:JIN030,
        ns8:JAD180182,
        ns57:JIN073 ;
    ns0:fullName "Mohamad El Haj" ;
    ns0:hasAffiliation ns90:JAD190371 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190371 ;
    ns0:inAuthorList ns150:JAD190371 .

ns8:JAD190394 owl:sameAs ns8:JAD141794,
        ns8:RNN180897,
        ns52:JAD170625 ;
    ns0:fullName "Stefano Tamburin" ;
    ns0:hasAffiliation ns24:JAD190394 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190394 ;
    ns0:inAuthorList ns150:JAD190394 .

ns8:JAD190399 owl:sameAs ns2:JAD160619,
        ns8:JAD160108,
        ns8:JAD160538,
        ns12:JAD122458,
        ns30:JAD141632 ;
    ns0:fullName "Ji Won Han" ;
    ns0:hasAffiliation ns24:JAD190399 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns8:JAD190413 owl:sameAs ns2:JAD160485,
        ns2:JAD190030 ;
    ns0:fullName "Johanne Købstrup Zakarias" ;
    ns0:hasAffiliation ns24:JAD190413 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190413 ;
    ns0:inAuthorList ns150:JAD190413 .

ns8:JAD190414 owl:sameAs ns5:JAD122098 ;
    ns0:fullName "Sandra Cardoso" ;
    ns0:hasAffiliation ns24:JAD190414 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190414 ;
    ns0:inAuthorList ns150:JAD190414 .

ns8:JAD190423 owl:sameAs ns8:AIS412,
        ns12:JAD160348 ;
    ns0:fullName "Thanos G. Stavropoulos" ;
    ns0:hasAffiliation ns24:JAD190423 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190423 ;
    ns0:inAuthorList ns150:JAD190423 .

ns8:JAD190427 owl:sameAs ns2:JAD141629,
        ns8:JAD101614,
        ns8:jad100378,
        ns33:jad01389 ;
    ns0:fullName "Carole Dufouil" ;
    ns0:hasAffiliation ns24:JAD190427 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190427 ;
    ns0:inAuthorList ns150:JAD190427 .

ns8:JAD190430 owl:sameAs ns130:JAD180788,
        ns5:JAD132768,
        ns52:JAD131796,
        ns60:JAD170001 ;
    ns0:fullName "Dorene M. Rentz" ;
    ns0:hasAffiliation ns25:JAD190430,
        ns90:JAD190430 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190430 ;
    ns0:inAuthorList ns150:JAD190430 .

ns8:JAD190459 owl:sameAs ns12:JAD111490,
        ns12:JAD190183 ;
    ns0:fullName "Catherine Padovan" ;
    ns0:hasAffiliation ns90:JAD190459 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190459 ;
    ns0:inAuthorList ns150:JAD190459 .

ns8:JAD190480 owl:sameAs ns2:JAD161127 ;
    ns0:fullName "Lucia Paolacci" ;
    ns0:hasAffiliation ns24:JAD190480 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190480 ;
    ns0:inAuthorList ns150:JAD190480 .

ns8:JAD190485 owl:sameAs ns16:JAD180644 ;
    ns0:fullName "Mattias Haglund" ;
    ns0:hasAffiliation ns24:JAD190485 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190485 ;
    ns0:inAuthorList ns150:JAD190485 .

ns8:JAD190487 owl:sameAs ns30:JAD180183 ;
    ns0:fullName "Wenjie Li" ;
    ns0:hasAffiliation ns24:JAD190487 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190487 ;
    ns0:inAuthorList ns150:JAD190487 .

ns8:JAD190507 owl:sameAs ns30:jad00543,
        ns16:JAD130080,
        ns57:JAD148009,
        ns33:JAD150729 ;
    ns0:fullName "Martin R. Farlow" ;
    ns0:hasAffiliation ns90:JAD190507 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190507 ;
    ns0:inAuthorList ns150:JAD190507 .

ns8:JAD190517 owl:sameAs ns2:JAD181227,
        ns8:JAD160230 ;
    ns0:fullName "Emmeline Ayers" ;
    ns0:hasAffiliation ns24:JAD190517 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD190517 ;
    ns0:inAuthorList ns150:JAD190517 .

ns8:JAD190540 owl:sameAs ns8:JAD180911,
        ns12:JAD150390 ;
    ns0:fullName "Muhammad Amin Shaik" ;
    ns0:hasAffiliation ns25:JAD190540 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190540 ;
    ns0:inAuthorList ns150:JAD190540 .

ns8:JAD190546 owl:sameAs ns8:JAD190256,
        ns16:JAD120022 ;
    ns0:fullName "Hiroshige Fujishiro" ;
    ns0:hasAffiliation ns25:JAD190546 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190546 ;
    ns0:inAuthorList ns150:JAD190546 .

ns8:JAD190555 owl:sameAs ns8:JAD180119 ;
    ns0:fullName "Yannick Stephan" ;
    ns0:hasAffiliation ns25:JAD190555 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190555 ;
    ns0:inAuthorList ns150:JAD190555 .

ns8:JAD190572 owl:sameAs ns5:RNN180882 ;
    ns0:fullName "Fredrik Clausen" ;
    ns0:hasAffiliation ns25:JAD190572 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190572 ;
    ns0:inAuthorList ns150:JAD190572 .

ns8:JAD190589 owl:sameAs ns16:JAD132219 ;
    ns0:fullName "Alex D. Leow" ;
    ns0:hasAffiliation ns258:JAD190589 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190589 ;
    ns0:inAuthorList ns150:JAD190589 .

ns8:JAD190622 owl:sameAs ns12:JAD160923 ;
    ns0:fullName "Rei Ono" ;
    ns0:hasAffiliation ns90:JAD190622 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190622 ;
    ns0:inAuthorList ns150:JAD190622 .

ns8:JAD190635 owl:sameAs ns8:JPD160867 ;
    ns0:fullName "Michaeline L. Hebron" ;
    ns0:hasAffiliation ns24:JAD190635 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190635 ;
    ns0:inAuthorList ns150:JAD190635 .

ns8:JAD190660 owl:sameAs ns30:JAD161267 ;
    ns0:fullName "Carmen Lage" ;
    ns0:hasAffiliation ns24:JAD190660 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190660 ;
    ns0:inAuthorList ns150:JAD190660 .

ns8:JAD190661 owl:sameAs ns2:mas00255,
        ns8:JAD161201,
        ns5:jad01051,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:mas00255>,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:mas00256> ;
    ns0:fullName "Wenyaw Chan" ;
    ns0:hasAffiliation ns25:JAD190661 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190661 ;
    ns0:inAuthorList ns150:JAD190661 .

ns8:JAD190666 owl:sameAs ns2:JAD111577,
        ns40:JAD160587 ;
    ns0:fullName "Xing Peng" ;
    ns0:hasAffiliation ns25:JAD190666,
        ns258:JAD190666 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190666 ;
    ns0:inAuthorList ns150:JAD190666 .

ns8:JAD190670 owl:sameAs ns16:JAD110788,
        ns57:JAD150605 ;
    ns0:fullName "Stefano F. Cappa" ;
    ns0:hasAffiliation ns90:JAD190670 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190670 ;
    ns0:inAuthorList ns150:JAD190670 .

ns8:JAD190691 owl:sameAs ns2:JAD170972 ;
    ns0:fullName "Laura L. Ekblad" ;
    ns0:hasAffiliation ns24:JAD190691 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190691 ;
    ns0:inAuthorList ns150:JAD190691 .

ns8:JAD190725 owl:sameAs ns2:JAD150985,
        ns40:JAD190091 ;
    ns0:fullName "Jennifer H. Lingler" ;
    ns0:hasAffiliation ns25:JAD190725 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190725 ;
    ns0:inAuthorList ns150:JAD190725 .

ns8:JAD190756 owl:sameAs ns2:JAD160593,
        ns30:JAD180455 ;
    ns0:fullName "Krister Håkansson" ;
    ns0:hasAffiliation ns25:JAD190756,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:1.ID:JAD190756> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190756 ;
    ns0:inAuthorList ns150:JAD190756 .

ns8:JAD190771 owl:sameAs ns2:jad00741,
        ns12:JAD111961 ;
    ns0:fullName "Cristina Lanni" ;
    ns0:hasAffiliation ns24:JAD190771 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190771 ;
    ns0:inAuthorList ns150:JAD190771 .

ns8:JAD190775 owl:sameAs ns12:JAD142622 ;
    ns0:fullName "Kengo Uemura" ;
    ns0:hasAffiliation ns24:JAD190775,
        ns90:JAD190775 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190775 ;
    ns0:inAuthorList ns150:JAD190775 .

ns8:JAD190889 owl:sameAs ns8:JAD101818,
        ns8:JAD190823,
        ns30:JAD132414,
        ns30:JAD141294 ;
    ns0:fullName "Antony Bayer" ;
    ns0:hasAffiliation ns25:JAD190889 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190889 ;
    ns0:inAuthorList ns150:JAD190889 .

ns8:JAE180067 owl:sameAs ns12:JAE191491,
        ns12:JAE1988 ;
    ns0:fullName "Stéphane Clénet" ;
    ns0:hasAffiliation ns24:JAE180067 ;
    ns0:hasArticle ns1:jae-v60-i4-JAE180067 ;
    ns0:inAuthorList ns150:JAE180067 .

ns8:JAE180089 owl:sameAs ns2:JAE180035 ;
    ns0:fullName "Gaorong Qian" ;
    ns0:hasAffiliation ns24:JAE180089 ;
    ns0:hasArticle ns1:jae-v61-i1-JAE180089 ;
    ns0:inAuthorList ns150:JAE180089 .

ns8:JAE180100 owl:sameAs ns8:JAE180034 ;
    ns0:fullName "Xiaoqi Ma" ;
    ns0:hasAffiliation ns24:JAE180100 ;
    ns0:hasArticle ns1:jae-v61-i2-JAE180100 ;
    ns0:inAuthorList ns150:JAE180100 .

ns8:JAE180107 owl:sameAs ns8:JAE150132,
        ns8:JAE170034 ;
    ns0:fullName "Enrique E. Mombello" ;
    ns0:hasAffiliation ns25:JAE180107 ;
    ns0:hasArticle ns1:jae-v61-i2-JAE180107 ;
    ns0:inAuthorList ns150:JAE180107 .

ns8:JAE180133 owl:sameAs ns2:JAE160099 ;
    ns0:fullName "Xiaohua Bao" ;
    ns0:hasAffiliation ns24:JAE180133 ;
    ns0:hasArticle ns1:jae-v61-i3-JAE180133 ;
    ns0:inAuthorList ns150:JAE180133 .

ns8:JAE191283 owl:sameAs ns8:JAE171008,
        ns8:JAE171252,
        ns8:JAE190924,
        ns8:JAE191148,
        ns8:JAE191149,
        ns8:JAE2122,
        ns8:JAE2271,
        ns12:JAE190821,
        ns12:JAE1979 ;
    ns0:fullName "Yasuhito Takahashi" ;
    ns0:hasAffiliation ns24:JAE191283 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191283 ;
    ns0:inAuthorList ns150:JAE191283 .

ns8:JAE191291 owl:sameAs ns8:JAE191491,
        ns8:JAE1988 ;
    ns0:fullName "AbdelKader Benabou" ;
    ns0:hasAffiliation ns25:JAE191291 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191291 ;
    ns0:inAuthorList ns150:JAE191291 .

ns8:JBR180345 owl:sameAs ns8:AF180258 ;
    ns0:fullName "Luca Capriotti" ;
    ns0:hasAffiliation ns24:JBR180345 ;
    ns0:hasArticle ns1:jbr-v9-i2-JBR180345 ;
    ns0:inAuthorList ns150:JBR180345 .

ns8:JBR180368 owl:sameAs ns8:JAD161298 ;
    ns0:fullName "Carla Vidal-San Martín" ;
    ns0:hasAffiliation ns24:JBR180368 ;
    ns0:hasArticle ns1:jbr-v9-i3-JBR180368 ;
    ns0:inAuthorList ns150:JBR180368 .

ns8:JCS181244 owl:sameAs ns8:jcs351,
        ns12:JCS15756 ;
    ns0:fullName "Luca Viganò" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:JCS181244> ;
    ns0:hasArticle ns1:jcs-v27-i3-JCS181244 ;
    ns0:inAuthorList ns150:JCS181244 .

ns8:JCS191315 owl:sameAs ns12:jcs484,
        ns5:JCS17947 ;
    ns0:fullName "Vijayalakshmi Atluri" ;
    ns0:hasAffiliation ns91:JCS191315 ;
    ns0:hasArticle ns1:jcs-v27-i4-JCS191315 ;
    ns0:inAuthorList ns150:JCS191315 .

ns8:JHD190364 owl:sameAs ns8:bmr00284 ;
    ns0:fullName "Siera Goodnight" ;
    ns0:hasAffiliation ns24:JHD190364 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190364 ;
    ns0:inAuthorList ns150:JHD190364 .

ns8:JHD190366 owl:sameAs ns2:JPD171285 ;
    ns0:fullName "Annekatrin König" ;
    ns0:hasAffiliation ns24:JHD190366 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD190366 ;
    ns0:inAuthorList ns150:JHD190366 .

ns8:JHS190624 owl:sameAs ns2:JHS541,
        ns8:JHS592,
        ns12:JHS583 ;
    ns0:fullName "Mahmood Ahmadi" ;
    ns0:hasAffiliation ns91:JHS190624 ;
    ns0:hasArticle ns1:jhs-v25-i4-JHS190624 ;
    ns0:inAuthorList ns150:JHS190624 .

ns8:JND180314 owl:sameAs ns26:JND170238,
        ns57:JND150125 ;
    ns0:fullName "Jocelyn Laporte" ;
    ns0:hasAffiliation ns258:JND180314 ;
    ns0:hasArticle ns1:jnd-v6-i3-JND180314 ;
    ns0:inAuthorList ns150:JND180314 .

ns8:JND190403 owl:sameAs ns143:JND180327 ;
    ns0:fullName "Stephen J. Kolb" ;
    ns0:hasAffiliation ns90:JND190403,
        ns258:JND190403 ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190403 ;
    ns0:inAuthorList ns150:JND190403 .

ns8:JND190416 owl:sameAs ns52:JND180331 ;
    ns0:fullName "Stephan Wenninger" ;
    ns0:hasAffiliation ns24:JND190416 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190416 ;
    ns0:inAuthorList ns150:JND190416 .

ns8:JND190428 owl:sameAs ns52:JND180315 ;
    ns0:fullName "Heike Kölbel" ;
    ns0:hasAffiliation ns25:JND190428 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190428 ;
    ns0:inAuthorList ns150:JND190428 .

ns8:JPD181568 owl:sameAs ns8:JPD150685,
        ns8:jad00189,
        ns57:JHD170283 ;
    ns0:fullName "Klaus Seppi" ;
    ns0:hasAffiliation ns24:JPD181568,
        ns25:JPD181568 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181568 ;
    ns0:inAuthorList ns150:JPD181568 .

ns8:JPD191604 owl:sameAs ns2:JPD171081,
        ns40:JAD132147 ;
    ns0:fullName "Laura Brennan" ;
    ns0:hasAffiliation ns25:JPD191604 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191604 ;
    ns0:inAuthorList ns150:JPD191604 .

ns8:JPD191630 owl:sameAs ns33:JAD101932 ;
    ns0:fullName "Jan O. Aasly" ;
    ns0:hasAffiliation ns25:JPD191630 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191630 ;
    ns0:inAuthorList ns150:JPD191630 .

ns8:JPD191707 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JPD160888>,
        ns28:JAD141512,
        ns16:JPD150670,
        ns60:JAD110761,
        ns60:jad01116 ;
    ns0:fullName "Pascal Derkinderen" ;
    ns0:hasAffiliation ns90:JPD191707 ;
    ns0:hasArticle ns1:jpd-v9-is2-JPD191707 ;
    ns0:inAuthorList ns150:JPD191707 .

ns8:JPD191802 owl:sameAs ns2:JPD191711 ;
    ns0:fullName "J.M. Boertien" ;
    ns0:hasAffiliation ns24:JPD191802 ;
    ns0:hasArticle ns1:jpd-v9-is2-JPD191802 ;
    ns0:inAuthorList ns150:JPD191802 .

ns8:JVR191022 owl:sameAs ns2:JVR191021,
        ns2:JVR191055,
        ns12:JVR191047,
        ns5:JVR191024,
        ns5:JVR813 ;
    ns0:fullName "David R. Strauser" ;
    ns0:hasAffiliation ns25:JVR191022 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191022 ;
    ns0:inAuthorList ns150:JVR191022 .

ns8:JVR191023 owl:sameAs ns2:JVR930,
        ns2:JVR972,
        ns30:JVR180999,
        ns30:JVR914,
        ns16:JVR812 ;
    ns0:fullName "Kanako Iwanaga" ;
    ns0:hasAffiliation ns25:JVR191023 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191023 ;
    ns0:inAuthorList ns150:JVR191023 .

ns8:JVR191033 owl:sameAs ns2:JVR191042 ;
    ns0:fullName "Paul B. Gold" ;
    ns0:hasAffiliation ns24:JVR191033 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191033 ;
    ns0:inAuthorList ns150:JVR191033 .

ns8:JVR191034 owl:sameAs ns8:JVR191040 ;
    ns0:fullName "Mari S. Guillermo" ;
    ns0:hasAffiliation ns25:JVR191034 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191034 ;
    ns0:inAuthorList ns150:JVR191034 .

ns8:JVR191035 owl:sameAs ns8:JVR944 ;
    ns0:fullName "Wen-Juo Lo" ;
    ns0:hasAffiliation ns24:JVR191035 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191035 ;
    ns0:inAuthorList ns150:JVR191035 .

ns8:JVR191036 owl:sameAs ns2:JVR191032,
        ns8:JVR191043 ;
    ns0:fullName "Amanda Schlegelmilch" ;
    ns0:hasAffiliation ns24:JVR191036 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191036 ;
    ns0:inAuthorList ns150:JVR191036 .

ns8:JVR191042 owl:sameAs ns2:JVR191033,
        ns8:JVR191041 ;
    ns0:fullName "Kelli Thuli Crane" ;
    ns0:hasAffiliation ns24:JVR191042 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191042 ;
    ns0:inAuthorList ns150:JVR191042 .

ns8:JVR191044 owl:sameAs ns8:JVR191037 ;
    ns0:fullName "Leslie A. Shaw" ;
    ns0:hasAffiliation ns24:JVR191044 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191044 ;
    ns0:inAuthorList ns150:JVR191044 .

ns8:JVR191049 owl:sameAs ns2:JVR786,
        ns2:WOR193011,
        ns2:WOR2318,
        ns8:JVR180997,
        ns8:WOR2737 ;
    ns0:fullName "Annika Lexén" ;
    ns0:hasAffiliation ns24:JVR191049,
        ns25:JVR191049 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191049 ;
    ns0:inAuthorList ns150:JVR191049 .

ns8:JVR191050 owl:sameAs ns12:JEM417,
        ns12:JVR918 ;
    ns0:fullName "Andrew J. Houtenville" ;
    ns0:hasAffiliation ns24:JVR191050 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191050 ;
    ns0:inAuthorList ns150:JVR191050 .

ns8:KCA180049 owl:sameAs ns30:KCA170018 ;
    ns0:fullName "Melissa Plets" ;
    ns0:hasAffiliation ns25:KCA180049 ;
    ns0:hasArticle ns1:kca-v3-i2-KCA180049 ;
    ns0:inAuthorList ns150:KCA180049 .

ns8:KCA190056 owl:sameAs ns12:KCA170019 ;
    ns0:fullName "Paulo G. Bergerot" ;
    ns0:hasAffiliation ns24:KCA190056 ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190056 ;
    ns0:inAuthorList ns150:KCA190056 .

ns8:KES190402 owl:sameAs ns2:IFS179078 ;
    ns0:fullName "Sachi Nandan Mohanty" ;
    ns0:hasAffiliation ns25:KES190402 ;
    ns0:hasArticle ns1:kes-v23-i2-KES190402 ;
    ns0:inAuthorList ns150:KES190402 .

ns8:KES190403 owl:sameAs ns8:KES190407 ;
    ns0:fullName "R. Rajender" ;
    ns0:hasAffiliation ns25:KES190403 ;
    ns0:hasArticle ns1:kes-v23-i2-KES190403 ;
    ns0:inAuthorList ns150:KES190403 .

ns8:KES190406 owl:sameAs ns8:ida00577 ;
    ns0:fullName "Mohammad Reza Keyvanpour" ;
    ns0:hasAffiliation ns25:KES190406 ;
    ns0:hasArticle ns1:kes-v23-i3-KES190406 ;
    ns0:inAuthorList ns150:KES190406 .

ns8:MGC180760 owl:sameAs ns8:MGC180750 ;
    ns0:fullName "Mengmeng Xi" ;
    ns0:hasAffiliation ns24:MGC180760 ;
    ns0:hasArticle ns1:mgc-v18-i3-MGC180760 ;
    ns0:inAuthorList ns150:MGC180760 .

ns8:MGC180761 owl:sameAs ns8:MGC190794 ;
    ns0:fullName "Dimitris G. Vachliotis" ;
    ns0:hasAffiliation ns24:MGC180761 ;
    ns0:hasArticle ns1:mgc-v18-i4-MGC180761 ;
    ns0:inAuthorList ns150:MGC180761 .

ns8:MGC190801 owl:sameAs ns30:MGC239,
        ns57:MGC210 ;
    ns0:fullName "Emek Moroydor Derun" ;
    ns0:hasAffiliation ns24:MGC190801 ;
    ns0:hasArticle ns1:mgc-v18-i4-MGC190801 ;
    ns0:inAuthorList ns150:MGC190801 .

ns8:MGC196 owl:sameAs ns5:MGC247 ;
    ns0:fullName "Pratibha Chaudhary" ;
    ns0:hasAffiliation ns25:MGC196 ;
    ns0:hasArticle ns1:mgc-v15-i2-MGC196 ;
    ns0:inAuthorList ns150:MGC196 .

ns8:MGS190307 owl:sameAs ns8:MGS267,
        ns8:MGS277 ;
    ns0:fullName "Farid Mokhati" ;
    ns0:hasAffiliation ns24:MGS190307 ;
    ns0:hasArticle ns1:mgs-v15-i2-MGS190307 ;
    ns0:inAuthorList ns150:MGS190307 .

ns8:MGS190313 owl:sameAs ns8:MGS284 ;
    ns0:fullName "Hui He" ;
    ns0:hasAffiliation ns24:MGS190313 ;
    ns0:hasArticle ns1:mgs-v15-i3-MGS190313 ;
    ns0:inAuthorList ns150:MGS190313 .

ns8:MGS190314 owl:sameAs ns2:mgs00009,
        ns8:mgs00018,
        ns8:mgs00201,
        ns8:mgs00215,
        ns30:mgs00038,
        ns30:mgs00217 ;
    ns0:fullName "Huaglory Tianfield" ;
    ns0:hasAffiliation ns25:MGS190314 ;
    ns0:hasArticle ns1:mgs-v15-i3-MGS190314 ;
    ns0:inAuthorList ns150:MGS190314 .

ns8:MNM180250 owl:sameAs ns8:MNM180249,
        ns8:MNM180275 ;
    ns0:fullName "Demosthenes B. Panagiotakos" ;
    ns0:hasAffiliation ns24:MNM180250 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180250 ;
    ns0:inAuthorList ns150:MNM180250 .

ns8:MNM180265 owl:sameAs ns8:MNM180233 ;
    ns0:fullName "Hassan Mozaffari-Khosravi" ;
    ns0:hasAffiliation ns24:MNM180265 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180265 ;
    ns0:inAuthorList ns150:MNM180265 .

ns8:NHA180056 owl:sameAs ns5:NHA1615,
        ns5:NHA170038 ;
    ns0:fullName "Claire M. Williams" ;
    ns0:hasAffiliation ns25:NHA180056 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA180056 ;
    ns0:inAuthorList ns150:NHA180056 .

ns8:NHA190068 owl:sameAs ns12:NHA170023 ;
    ns0:fullName "Hui Xie" ;
    ns0:hasAffiliation ns258:NHA190068,
        ns259:NHA190068 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA190068 ;
    ns0:inAuthorList ns150:NHA190068 .

ns8:NPM180140 owl:sameAs ns12:NPM1786 ;
    ns0:fullName "M.R. Stenger" ;
    ns0:hasAffiliation ns24:NPM180140 ;
    ns0:hasArticle ns1:npm-v12-i3-NPM180140 ;
    ns0:inAuthorList ns150:NPM180140 .

ns8:NPM1814 owl:sameAs ns2:NPM17133 ;
    ns0:fullName "H. Dakkak" ;
    ns0:hasAffiliation ns24:NPM1814 ;
    ns0:hasArticle ns1:npm-v12-i2-NPM1814 ;
    ns0:inAuthorList ns150:NPM1814 .

ns8:NRE182634 owl:sameAs ns8:BMR181362 ;
    ns0:fullName "Gozde Iyigun" ;
    ns0:hasAffiliation ns24:NRE182634 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182634 ;
    ns0:inAuthorList ns150:NRE182634 .

ns8:NRE182637 owl:sameAs ns8:NRE182505,
        ns12:NRE172274 ;
    ns0:fullName "Tommaso Schirinzi" ;
    ns0:hasAffiliation ns24:NRE182637,
        ns90:NRE182637 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182637 ;
    ns0:inAuthorList ns150:NRE182637 .

ns8:NRE182641 owl:sameAs ns12:NRE182424 ;
    ns0:fullName "Elizabeth S. Moore" ;
    ns0:hasAffiliation ns24:NRE182641 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182641 ;
    ns0:inAuthorList ns150:NRE182641 .

ns8:NRE192701 owl:sameAs ns8:RNN150623,
        ns12:RNN170785,
        ns5:RNN170773,
        ns5:RNN190916 ;
    ns0:fullName "Michael Borich" ;
    ns0:hasAffiliation ns24:NRE192701 ;
    ns0:hasArticle ns1:nre-v44-i4-NRE192701 ;
    ns0:inAuthorList ns150:NRE192701 .

ns8:NRE192721 owl:sameAs ns2:NRE172351 ;
    ns0:fullName "Hyun Im Moon" ;
    ns0:hasAffiliation ns25:NRE192721 ;
    ns0:hasArticle ns1:nre-v45-i1-NRE192721 ;
    ns0:inAuthorList ns150:NRE192721 .

ns8:NRE192723 owl:sameAs ns2:bmr00062 ;
    ns0:fullName "Mati Pääsuke" ;
    ns0:hasAffiliation ns24:NRE192723 ;
    ns0:hasArticle ns1:nre-v44-i4-NRE192723 ;
    ns0:inAuthorList ns150:NRE192723 .

ns8:NRE192725 owl:sameAs ns8:NRE1428 ;
    ns0:fullName "Elena V. Donoso Brown" ;
    ns0:hasAffiliation ns25:NRE192725 ;
    ns0:hasArticle ns1:nre-v45-i1-NRE192725 ;
    ns0:inAuthorList ns150:NRE192725 .

ns8:PPR190136 owl:sameAs ns8:PPR180120 ;
    ns0:fullName "Keith Smart" ;
    ns0:hasAffiliation ns25:PPR190136 ;
    ns0:hasArticle ns1:ppr-v40-i2-PPR190136 ;
    ns0:inAuthorList ns150:PPR190136 .

ns8:RFT180106 owl:sameAs ns30:RFT1512 ;
    ns0:fullName "A. Volpi" ;
    ns0:hasAffiliation ns25:RFT180106 ;
    ns0:hasArticle ns1:rft-v10-i1-2-RFT180106 ;
    ns0:inAuthorList ns150:RFT180106 .

ns8:RNN190916 owl:sameAs ns2:RNN170790 ;
    ns0:fullName "K.E. Brown" ;
    ns0:hasAffiliation ns25:RNN190916 ;
    ns0:hasArticle ns1:rnn-v37-i3-RNN190916 ;
    ns0:inAuthorList ns150:RNN190916 .

ns8:RNN190927 owl:sameAs ns57:JAD170024 ;
    ns0:fullName "Kenneth N.K. Fong" ;
    ns0:hasAffiliation ns24:RNN190927 ;
    ns0:hasArticle ns1:rnn-v37-i5-RNN190927 ;
    ns0:inAuthorList ns150:RNN190927 .

ns8:SW190355 owl:sameAs ns30:SW294 ;
    ns0:fullName "Elena Demidova" ;
    ns0:hasAffiliation ns91:SW190355 ;
    ns0:hasArticle ns1:sw-v10-i6-SW190355 ;
    ns0:inAuthorList ns150:SW190355 .

ns8:SW190359 owl:sameAs ns8:AIC746 ;
    ns0:fullName "Charalampos Chelmis" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:SW190359> ;
    ns0:hasArticle ns1:sw-v10-i6-SW190359 ;
    ns0:inAuthorList ns150:SW190359 .

ns8:SW190365 owl:sameAs ns2:SW190348 ;
    ns0:fullName "Giuseppe Pirrò" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:SW190365> ;
    ns0:hasArticle ns1:sw-v10-i6-SW190365 ;
    ns0:inAuthorList ns150:SW190365 .

ns8:TAD190225 owl:sameAs ns8:tad00412,
        ns12:JAD160223 ;
    ns0:fullName "Yuki Yamamoto" ;
    ns0:hasAffiliation ns24:TAD190225 ;
    ns0:hasArticle ns1:tad-v31-i3-TAD190225 ;
    ns0:inAuthorList ns150:TAD190225 .

ns8:THC181480 owl:sameAs ns12:THC1072 ;
    ns0:fullName "Ali Motie Nasrabadi" ;
    ns0:hasAffiliation ns25:THC181480 ;
    ns0:hasArticle ns1:thc-v27-i4-THC181480 ;
    ns0:inAuthorList ns150:THC181480 .

ns8:THC199029 owl:sameAs ns8:THC199031 ;
    ns0:fullName "Maojun Liu" ;
    ns0:hasAffiliation ns24:THC199029 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199029 ;
    ns0:inAuthorList ns150:THC199029 .

ns8:VES190655 owl:sameAs ns8:VES190658,
        ns52:VES589 ;
    ns0:fullName "Alexandre Bisdorff" ;
    ns0:hasAffiliation ns25:VES190655 ;
    ns0:hasArticle ns1:ves-v29-i2-3-VES190655 ;
    ns0:inAuthorList ns150:VES190655 .

ns8:WOR192923 owl:sameAs ns8:WOR2010 ;
    ns0:fullName "Pedro Arezes" ;
    ns0:hasAffiliation ns24:WOR192923 ;
    ns0:hasArticle ns1:wor-v63-i2-WOR192923 ;
    ns0:inAuthorList ns150:WOR192923 .

ns8:WOR192947 owl:sameAs ns8:WOR182840 ;
    ns0:fullName "Nidhi Patel" ;
    ns0:hasAffiliation ns24:WOR192947,
        ns25:WOR192947 ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192947 ;
    ns0:inAuthorList ns150:WOR192947 .

ns8:WOR192958 owl:sameAs ns30:WOR192956 ;
    ns0:fullName "Maria C. Canino" ;
    ns0:hasAffiliation ns24:WOR192958 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192958 ;
    ns0:inAuthorList ns150:WOR192958 .

ns8:WOR192962 owl:sameAs ns12:WOR192961 ;
    ns0:fullName "Mike J. Tipton" ;
    ns0:hasAffiliation ns24:WOR192962 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192962 ;
    ns0:inAuthorList ns150:WOR192962 .

ns8:WOR192966 owl:sameAs ns2:WOR2425 ;
    ns0:fullName "Arto Reiman" ;
    ns0:hasAffiliation ns24:WOR192966 ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192966 ;
    ns0:inAuthorList ns150:WOR192966 .

ns8:WOR192975 owl:sameAs ns12:WOR2617 ;
    ns0:fullName "Urban Schwegler" ;
    ns0:hasAffiliation ns24:WOR192975,
        ns25:WOR192975 ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192975 ;
    ns0:inAuthorList ns150:WOR192975 .

ns8:WOR192984 owl:sameAs ns8:WOR2180,
        ns8:WOR2685,
        ns30:WOR2401 ;
    ns0:fullName "Alireza Choobineh" ;
    ns0:hasAffiliation ns25:WOR192984 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192984 ;
    ns0:inAuthorList ns150:WOR192984 .

ns8:WOR193005 owl:sameAs ns12:WOR2334,
        ns12:WOR2559 ;
    ns0:fullName "Myung Hwan Yun" ;
    ns0:hasAffiliation ns24:WOR193005 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193005 ;
    ns0:inAuthorList ns150:WOR193005 .

ns8:WOR193013 owl:sameAs ns8:WOR2522,
        ns12:WOR1840 ;
    ns0:fullName "Petra Lindfors" ;
    ns0:hasAffiliation ns24:WOR193013 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193013 ;
    ns0:inAuthorList ns150:WOR193013 .

ns8:WOR193015 owl:sameAs ns2:BMR598 ;
    ns0:fullName "Mohamed I. Kamel" ;
    ns0:hasAffiliation ns90:WOR193015 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193015 ;
    ns0:inAuthorList ns150:WOR193015 .

ns8:WOR193018 owl:sameAs ns8:WOR2761 ;
    ns0:fullName "Lynda R. Matthews" ;
    ns0:hasAffiliation ns24:WOR193018 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193018 ;
    ns0:inAuthorList ns150:WOR193018 .

ns8:XST180466 owl:sameAs ns2:XST180430 ;
    ns0:fullName "Ketong Wu" ;
    ns0:hasAffiliation ns24:XST180466 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180466 ;
    ns0:inAuthorList ns150:XST180466 .

ns8:XST180473 owl:sameAs ns2:THC160474,
        ns2:THC171064,
        ns8:IDT314,
        ns8:THC1081,
        ns8:THC1130 ;
    ns0:fullName "Chung-Dann Kan" ;
    ns0:hasAffiliation ns25:XST180473 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180473 ;
    ns0:inAuthorList ns150:XST180473 .

ns8:XST180486 owl:sameAs ns8:THC1315,
        ns8:THC174800,
        ns8:XST180429 ;
    ns0:fullName "Yongliang Dai" ;
    ns0:hasAffiliation ns25:XST180486 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180486 ;
    ns0:inAuthorList ns150:XST180486 .

ns8:XST180487 owl:sameAs ns2:XST180427 ;
    ns0:fullName "Fengqi Lu" ;
    ns0:hasAffiliation ns24:XST180487 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180487 ;
    ns0:inAuthorList ns150:XST180487 .

ns8:XST190503 owl:sameAs ns8:XST598 ;
    ns0:fullName "Ho-Chiao Chuang" ;
    ns0:hasAffiliation ns24:XST190503 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190503 ;
    ns0:inAuthorList ns150:XST190503 .

ns8:XST190514 owl:sameAs ns2:XST502,
        ns8:XST495 ;
    ns0:fullName "Jong-Hyun Ryu" ;
    ns0:hasAffiliation ns24:XST190514 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190514 ;
    ns0:inAuthorList ns150:XST190514 .

ns8:XST190526 owl:sameAs ns12:THC199033 ;
    ns0:fullName "Jing Gong" ;
    ns0:hasAffiliation ns24:XST190526 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190526 ;
    ns0:inAuthorList ns150:XST190526 .

ns8:XST190533 owl:sameAs ns8:XST190548 ;
    ns0:fullName "Ke Chen" ;
    ns0:hasAffiliation ns24:XST190533 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190533 ;
    ns0:inAuthorList ns150:XST190533 .

ns8:XST190538 owl:sameAs ns2:BME1441,
        ns12:XST180395 ;
    ns0:fullName "Jo-Chi Jao" ;
    ns0:hasAffiliation ns90:XST190538 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190538 ;
    ns0:inAuthorList ns150:XST190538 .

ns8:ajw190035 owl:sameAs ns2:MGC180688 ;
    ns0:fullName "Zahra Akbari" ;
    ns0:hasAffiliation ns25:ajw190035 ;
    ns0:hasArticle ns1:ajw-v16-i3-ajw190035 ;
    ns0:inAuthorList ns150:ajw190035 .

ns8:jid190002 owl:sameAs ns12:JAD111313 ;
    ns0:fullName "Dapeng Liang" ;
    ns0:hasAffiliation ns24:jid190002 ;
    ns0:hasArticle ns1:jid-v22-i4-jid190002 ;
    ns0:inAuthorList ns150:jid190002 .

ns26:CH199208 owl:sameAs ns12:JCB189010 ;
    ns0:fullName "Jens Pietzsch" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:CH199208>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:10.ID:CH199208> ;
    ns0:hasArticle ns1:ch-v73-i1-CH199208 ;
    ns0:inAuthorList ns150:CH199208 .

ns26:CH199219 owl:sameAs ns2:JCB179002,
        ns12:CH168123,
        ns16:CH189313,
        ns16:JCB15034 ;
    ns0:fullName "B. Hiebl" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:CH199219> ;
    ns0:hasArticle ns1:ch-v73-i1-CH199219 ;
    ns0:inAuthorList ns150:CH199219 .

ns26:JAD180511 owl:sameAs ns12:JAD180496 ;
    ns0:fullName "Musalmah Mazlan" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:10.ID:JAD180511> ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180511 ;
    ns0:inAuthorList ns150:JAD180511 .

ns26:JAD180634 owl:sameAs ns2:NRE182534,
        ns2:jad01168,
        ns8:JAD130281,
        ns8:JAD170414,
        ns8:JAD180746,
        ns8:jad01105,
        ns8:jad01180,
        ns26:JAD150749,
        ns28:JAD181212,
        ns12:JAD101821,
        ns5:JAD120202,
        ns16:JAD161224,
        ns16:JAD181080,
        ns60:JAD180942,
        ns33:JAD160374 ;
    ns0:fullName "Eric B. Larson" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JAD180634> ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180634 ;
    ns0:inAuthorList ns150:JAD180634 .

ns26:JAD181175 owl:sameAs ns52:JAD150895,
        ns57:JAD190128,
        ns60:JAD161006,
        ns60:JAD170415 ;
    ns0:fullName "Kyle B. Womack" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD181175>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:10.ID:JAD181175> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD181175 ;
    ns0:inAuthorList ns150:JAD181175 .

ns26:JAD181217 owl:sameAs ns30:JAD180425 ;
    ns0:fullName "Qiu-Jin Yu" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD181217> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181217 ;
    ns0:inAuthorList ns150:JAD181217 .

ns26:JAD181259 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD140057>,
        ns16:JAD170966,
        ns60:JAD150464,
        ns60:JAD160152,
        ns60:JAD170520,
        ns60:JAD180250 ;
    ns0:fullName "Mario Clerici" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD181259>,
        ns39:JAD181259 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD181259 ;
    ns0:inAuthorList ns150:JAD181259 .

ns26:JAD181277 owl:sameAs ns43:JAD171140,
        ns12:JAD142253,
        ns12:jad100042,
        ns33:jad01393 ;
    ns0:fullName "Eric Salmon" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:10.ID:JAD181277>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:10.ID:JAD181277> ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181277 ;
    ns0:inAuthorList ns150:JAD181277 .

ns26:JAD190010 owl:sameAs ns8:JAD181009,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150832>,
        ns43:JAD130461,
        ns30:JAD160413,
        ns30:JAD170798,
        ns5:JAD0006,
        ns16:JAD141287,
        ns16:JAD181282,
        ns60:JAD121156,
        ns33:JAD161114 ;
    ns0:fullName "Michael W. Weiner" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:JAD190010> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190010 ;
    ns0:inAuthorList ns150:JAD190010 .

ns26:JAD190098 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190023> ;
    ns0:fullName "Fuyuki Kametani" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:10.ID:JAD190098> ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190098 ;
    ns0:inAuthorList ns150:JAD190098 .

ns26:JAD190132 owl:sameAs ns2:JAD112060,
        ns12:JAD101911,
        ns5:JAD170854 ;
    ns0:fullName "Päivi Hartikainen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD190132> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

ns26:JAD190133 owl:sameAs ns26:JAD120946,
        ns26:JAD122260,
        ns26:JAD130380,
        ns26:jad100114,
        ns40:JAD140942,
        ns40:JAD170534,
        ns40:JAD170583,
        ns28:JAD190132,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD0004>,
        ns43:JAD170123,
        ns130:jad100201,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD122182>,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD170092>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD190334>,
        ns12:JAD120802,
        ns12:JAD129021,
        ns12:JAD130899,
        ns12:JAD170039,
        ns12:jad00817,
        <http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD161097>,
        ns30:ADR170035,
        ns30:JAD00041,
        ns30:JAD101908,
        ns30:JAD132102,
        ns30:JAD180512,
        ns30:jad00920,
        <http://ld.iospress.nl/rdf/contributor/Author:39.ID:JAD160668>,
        ns5:JAD101911,
        ns5:JAD111736,
        ns5:JAD130359,
        ns5:JAD140336,
        ns5:JAD140669,
        ns5:JAD160645,
        ns16:JAD110200,
        ns16:JAD130698,
        ns16:JAD131088,
        ns16:JAD140924,
        ns16:JAD141137,
        ns16:JAD150440,
        ns52:JAD110365,
        <http://ld.iospress.nl/rdf/contributor/Author:69.ID:jad100933>,
        ns57:JAD132225,
        ns57:JAD160983,
        ns57:jad100597,
        ns60:JAD111370,
        ns60:JAD111592,
        ns60:JAD112060,
        ns60:JAD121408,
        ns60:JAD142214,
        ns60:JAD150909,
        ns60:JAD180897,
        ns33:JAD0044,
        ns33:JAD111109,
        ns33:JAD121363,
        ns33:JAD122110,
        ns33:JAD170362 ;
    ns0:fullName "Hilkka Soininen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:10.ID:JAD190133>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JAD190133> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190133 ;
    ns0:inAuthorList ns150:JAD190133 .

ns26:JAD190155 owl:sameAs ns2:JAD00003,
        ns2:JAD129909,
        ns2:JAD1439,
        ns2:jad00545,
        ns8:JAD129005,
        ns8:JAD141626,
        ns8:JAD150134,
        ns8:JAD190790,
        ns8:jad00407,
        ns8:jad01346,
        ns26:JAD151208,
        ns40:JAD180629,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad01239>,
        ns12:JAD00024,
        ns12:JAD110021,
        ns12:JAD122223,
        ns12:JAD132762,
        ns12:jad100669,
        ns30:JAD190782,
        ns30:jad00942,
        ns30:jad100666,
        ns5:JAD190197,
        ns5:JAD190281,
        ns5:jad00325,
        ns16:jad00838,
        ns52:JAD180023,
        ns52:JAD181039,
        ns52:jad00733,
        ns52:jad01155,
        ns57:JAD170999,
        ns57:jad00309,
        ns57:jad00418,
        ns57:jad01021,
        ns60:JAD170190 ;
    ns0:fullName "George Perry" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:10.ID:JAD190155> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190155 ;
    ns0:inAuthorList ns150:JAD190155 .

ns26:JAD190191 owl:sameAs ns5:JAD160742 ;
    ns0:fullName "Daniel Z. Press" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:10.ID:JAD190191> ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190191 ;
    ns0:inAuthorList ns150:JAD190191 .

ns26:JAD190274 owl:sameAs ns2:JAD110890,
        ns2:jad01033,
        ns8:JAD120973,
        ns8:jad00710,
        ns8:jad100501 ;
    ns0:fullName "Ana Lloret" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190274> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190274 ;
    ns0:inAuthorList ns150:JAD190274 .

ns26:JAD190334 owl:sameAs ns5:JAD190132,
        ns16:JAD170854 ;
    ns0:fullName "Ville Korhonen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns26:JAD190369 owl:sameAs ns52:JAD190644 ;
    ns0:fullName "Namiko Matsumoto" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190369> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190369 ;
    ns0:inAuthorList ns150:JAD190369 .

ns26:JAD190399 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160538>,
        <http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD160108>,
        ns60:JAD171182 ;
    ns0:fullName "Seok Woo Moon" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:10.ID:JAD190399> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns26:JAD190414 owl:sameAs ns12:JAD180274,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:jad01378>,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:jad01404>,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:jad01408>,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:jad01420> ;
    ns0:fullName "Alexandre de Mendonça" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190414> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190414 ;
    ns0:inAuthorList ns150:JAD190414 .

ns26:JAD190446 owl:sameAs ns57:JAD170360 ;
    ns0:fullName "Birgit Ertl-Wagner" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:10.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff24.Author:10.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns26:JAD190454 owl:sameAs ns8:ida00637 ;
    ns0:fullName "Jun Ni" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190454> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190454 ;
    ns0:inAuthorList ns150:JAD190454 .

ns26:JAD190469 owl:sameAs ns8:JAD121927,
        ns8:JAD130461,
        ns26:JAD150841,
        ns26:JAD170943,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180394>,
        ns28:JAD141623,
        ns28:JAD170556,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170507>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170537>,
        ns130:JAD141773 ;
    ns0:fullName "Sang Won Seo" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190469>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD190469>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JAD190469>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:JAD190469> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190469 ;
    ns0:inAuthorList ns150:JAD190469 .

ns26:JAD190480 owl:sameAs ns2:jad00307,
        ns26:jad01114,
        ns40:JAD121363,
        ns12:JAD120871,
        ns141:JAD161097,
        ns5:JAD150862,
        ns16:JAD121045,
        ns52:JAD100525,
        ns52:JAD140669,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:jad00737> ;
    ns0:fullName "Patrizia Mecocci" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190480> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190480 ;
    ns0:inAuthorList ns150:JAD190480 .

ns26:JAD190533 owl:sameAs ns12:JAD161050,
        ns5:JAD110584,
        ns60:JAD180025 ;
    ns0:fullName "Kevin Taddei" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD190533>,
        ns39:JAD190533 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190533 ;
    ns0:inAuthorList ns150:JAD190533 .

ns26:JAD190644 owl:sameAs ns33:JAD181218 ;
    ns0:fullName "Mami Takemoto" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190644> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns26:JAD190691 owl:sameAs ns5:JAD180554,
        ns16:JAD170092 ;
    ns0:fullName "Riitta Parkkola" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:JAD190691> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190691 ;
    ns0:inAuthorList ns150:JAD190691 .

ns26:JAD190772 owl:sameAs ns132:JAD170560,
        ns12:jad100879,
        ns5:JAD180336,
        ns52:jad00764 ;
    ns0:fullName "Gernot Riedel" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:10.ID:JAD190772> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190772 ;
    ns0:inAuthorList ns150:JAD190772 .

ns26:JAD190775 owl:sameAs ns26:JAD142622 ;
    ns0:fullName "Ayae Kinoshita" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD190775> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190775 ;
    ns0:inAuthorList ns150:JAD190775 .

ns26:JAD190817 owl:sameAs ns2:JAD110173,
        ns30:JAD180904,
        ns5:JAD141572,
        ns33:JAD180985 ;
    ns0:fullName "Jun Kawamata" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:10.ID:JAD190817> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190817 ;
    ns0:inAuthorList ns150:JAD190817 .

ns26:JHD190346 owl:sameAs ns16:JHD150175 ;
    ns0:fullName "Paul E. Gilbert" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JHD190346>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JHD190346> ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190346 ;
    ns0:inAuthorList ns150:JHD190346 .

ns26:JHD190355 owl:sameAs ns12:JHD180287,
        ns12:JHD180328 ;
    ns0:fullName "Pedro Gonzalez-Alegre" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JHD190355> ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190355 ;
    ns0:inAuthorList ns150:JHD190355 .

ns26:JND190379 owl:sameAs ns2:JND150122,
        ns2:PRM435,
        ns30:JND180320 ;
    ns0:fullName "L. van den Engel-Hoek" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:10.ID:JND190379> ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190379 ;
    ns0:inAuthorList ns150:JND190379 .

ns26:JND190397 owl:sameAs ns5:BPL160039 ;
    ns0:fullName "Vincent A. Magnotta" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:10.ID:JND190397> ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190397 ;
    ns0:inAuthorList ns150:JND190397 .

ns26:JND190416 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JND170231>,
        ns16:JND180331 ;
    ns0:fullName "Benedikt Schoser" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JND190416> ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190416 ;
    ns0:inAuthorList ns150:JND190416 .

ns26:KCA180049 owl:sameAs ns33:KCA170018 ;
    ns0:fullName "Ian Murchie Thompson" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:KCA180049> ;
    ns0:hasArticle ns1:kca-v3-i2-KCA180049 ;
    ns0:inAuthorList ns150:KCA180049 .

ns26:KCA190064 owl:sameAs ns8:KCA180045 ;
    ns0:fullName "J. Puente" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:KCA190064> ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190064 ;
    ns0:inAuthorList ns150:KCA190064 .

ns26:NRE192778 owl:sameAs ns26:NRE172156,
        ns12:NRE1435 ;
    ns0:fullName "Marco Franceschini" ;
    ns0:hasAffiliation ns39:NRE192778 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192778 ;
    ns0:inAuthorList ns150:NRE192778 .

ns40:JAD180847 owl:sameAs ns52:JAD161078 ;
    ns0:fullName "Michael J. Lyons" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:11.ID:JAD180847> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD180847 ;
    ns0:inAuthorList ns150:JAD180847 .

ns40:JAD190010 owl:sameAs ns8:JAD160077,
        ns26:JAD161114,
        ns26:JAD181212,
        ns28:JAD148009,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD150651>,
        ns16:PRM348,
        ns60:JAD130080,
        ns60:JAD150729 ;
    ns0:fullName "Andrew J. Saykin" ;
    ns0:hasAffiliation ns114:JAD190010,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:11.ID:JAD190010>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:11.ID:JAD190010> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190010 ;
    ns0:inAuthorList ns150:JAD190010 .

ns40:JAD190023 owl:sameAs ns26:JAD140225,
        ns60:JAD181152 ;
    ns0:fullName "Yasuo Harigaya" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:11.ID:JAD190023> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190023 ;
    ns0:inAuthorList ns150:JAD190023 .

ns40:JAD190046 owl:sameAs ns2:JAD150899,
        ns12:JAD112120,
        ns57:JAD140624,
        ns57:jad100678 ;
    ns0:fullName "Raquel Sánchez-Valle" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:11.ID:JAD190046> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190046 ;
    ns0:inAuthorList ns150:JAD190046 .

ns40:JAD190119 owl:sameAs ns52:JAD180723 ;
    ns0:fullName "Annalisa Colombi" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JAD190119> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

ns40:JAD190132 owl:sameAs ns2:jad01154,
        ns26:JAD111109,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120946>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170362>,
        ns28:JAD130104,
        ns28:JAD160554,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD140777>,
        ns12:JAD180216,
        ns12:jad091681,
        ns143:JAD180512,
        ns5:JAD101908,
        ns5:JAD190334,
        ns16:jad100933,
        ns52:JAD160633,
        ns52:JAD181256,
        ns60:JAD180645,
        ns60:jad100597,
        ns33:JAD161142,
        ns33:JAD180071 ;
    ns0:fullName "Mikko Hiltunen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:11.ID:JAD190132> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

ns40:JAD190155 owl:sameAs ns2:jad00490,
        ns8:JAD130490,
        ns8:jad00867,
        ns12:JAD130617 ;
    ns0:fullName "Alejandra D. Alonso" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:11.ID:JAD190155> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190155 ;
    ns0:inAuthorList ns150:JAD190155 .

ns40:JAD190274 owl:sameAs ns2:jad00710,
        ns16:jad01033,
        ns52:JAD120973,
        ns57:JAD110890 ;
    ns0:fullName "Jose Viña" ;
    ns0:hasAffiliation ns114:JAD190274 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190274 ;
    ns0:inAuthorList ns150:JAD190274 .

ns40:JAD190369 owl:sameAs ns8:JAD143084,
        ns26:JAD181218,
        ns30:JAD190644 ;
    ns0:fullName "Nozomi Hishikawa" ;
    ns0:hasAffiliation ns114:JAD190369 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190369 ;
    ns0:inAuthorList ns150:JAD190369 .

ns40:JAD190399 owl:sameAs ns8:JAD101221,
        ns52:JAD122458 ;
    ns0:fullName "Joon Hyuk Park" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:11.ID:JAD190399> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns40:JAD190469 owl:sameAs ns60:JAD121180 ;
    ns0:fullName "Jin Whan Cho" ;
    ns0:hasAffiliation ns114:JAD190469,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JAD190469> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190469 ;
    ns0:inAuthorList ns150:JAD190469 .

ns40:JAD190644 owl:sameAs ns8:JAD190369,
        ns40:JAD181218,
        ns30:JAD143084 ;
    ns0:fullName "Toru Yamashita" ;
    ns0:hasAffiliation ns114:JAD190644 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns40:JAD190660 owl:sameAs ns52:JAD170985 ;
    ns0:fullName "Julio Jimenez Bonilla" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:11.ID:JAD190660> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190660 ;
    ns0:inAuthorList ns150:JAD190660 .

ns40:JAD190666 owl:sameAs ns40:JAD121963,
        ns33:JAD140147 ;
    ns0:fullName "Hongxing Lei" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JAD190666>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:11.ID:JAD190666>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:11.ID:JAD190666> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190666 ;
    ns0:inAuthorList ns150:JAD190666 .

ns40:JAD190691 owl:sameAs ns57:JAD132783 ;
    ns0:fullName "Matti Viitanen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:11.ID:JAD190691>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JAD190691> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190691 ;
    ns0:inAuthorList ns150:JAD190691 .

ns40:JAD190772 owl:sameAs ns2:JAD179924,
        ns8:JAD170560,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD131574>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181108>,
        ns28:JAD190113,
        ns12:JAD150978,
        ns118:JAD180341,
        ns5:jad100078,
        ns52:JAD160979,
        ns33:jad00971 ;
    ns0:fullName "Serge Gauthier" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:11.ID:JAD190772> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190772 ;
    ns0:inAuthorList ns150:JAD190772 .

ns40:JCS191289 owl:sameAs ns8:jcs342 ;
    ns0:fullName "Gene Tsudik" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:11.ID:JCS191289> ;
    ns0:hasArticle ns1:jcs-v27-i4-JCS191289 ;
    ns0:inAuthorList ns150:JCS191289 .

ns40:JND190414 owl:sameAs ns40:JND160151 ;
    ns0:fullName "Carsten G. Bönnemann" ;
    ns0:hasAffiliation ns114:JND190414 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190414 ;
    ns0:inAuthorList ns150:JND190414 .

ns40:JPD181568 owl:sameAs ns12:jad00189,
        ns16:JAD170601 ;
    ns0:fullName "Gregor K. Wenning" ;
    ns0:hasAffiliation ns114:JPD181568 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181568 ;
    ns0:inAuthorList ns150:JPD181568 .

ns40:JPD191672 owl:sameAs ns30:JPD140451,
        ns52:JPD150764,
        ns52:JPD160996,
        ns33:JPD150656 ;
    ns0:fullName "Alexander Storch" ;
    ns0:hasAffiliation ns114:JPD191672,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JPD191672> ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191672 ;
    ns0:inAuthorList ns150:JPD191672 .

ns40:KCA180049 owl:sameAs ns12:KCA180034 ;
    ns0:fullName "Christopher W. Ryan" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:11.ID:KCA180049> ;
    ns0:hasArticle ns1:kca-v3-i2-KCA180049 ;
    ns0:inAuthorList ns150:KCA180049 .

ns40:XST190500 owl:sameAs ns57:XST180418 ;
    ns0:fullName "Peng Feng" ;
    ns0:hasAffiliation ns114:XST190500,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:XST190500>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:11.ID:XST190500> ;
    ns0:hasArticle ns1:xst-v27-i3-XST190500 ;
    ns0:inAuthorList ns150:XST190500 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:HAB190375> owl:sameAs ns12:HAB180360,
        ns30:HAB190386 ;
    ns0:fullName "T. Erhabor" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:12.ID:HAB190375> ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190375 ;
    ns0:inAuthorList ns150:HAB190375 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180573> owl:sameAs ns60:JAD171027 ;
    ns0:fullName "Gerald A. Broe" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:12.ID:JAD180573> ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180573 ;
    ns0:inAuthorList ns150:JAD180573 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181212> owl:sameAs ns2:JAD179939,
        ns12:jad00265,
        ns12:jad00664,
        ns30:JAD120952,
        ns30:JAD161132,
        ns5:JAD170903,
        ns5:jad00770,
        ns16:JAD110629,
        ns16:JAD180604,
        ns16:JAD180737,
        ns52:JAD160977,
        ns33:JAD101515 ;
    ns0:fullName "David A. Bennett" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:12.ID:JAD181212> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181212 ;
    ns0:inAuthorList ns150:JAD181212 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181277> owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD171140>,
        ns12:JAD170759,
        ns12:JAD180563,
        ns5:JAD160320 ;
    ns0:fullName "Anne Sieben" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:12.ID:JAD181277> ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181277 ;
    ns0:inAuthorList ns150:JAD181277 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190046> owl:sameAs ns40:JAD161173 ;
    ns0:fullName "Matti Laine" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:12.ID:JAD190046> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190046 ;
    ns0:inAuthorList ns150:JAD190046 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190087> owl:sameAs ns60:JAD151139 ;
    ns0:fullName "Shigeru Nakai" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190087> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190087 ;
    ns0:inAuthorList ns150:JAD190087 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190113> owl:sameAs ns28:JAD131574,
        ns5:JAD179924,
        ns33:JAD181108 ;
    ns0:fullName "Pedro Rosa-Neto" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:12.ID:JAD190113> ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190113 ;
    ns0:inAuthorList ns150:JAD190113 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190119> owl:sameAs ns5:JAD150863,
        ns16:JAD180723 ;
    ns0:fullName "Marta Scarioni" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:12.ID:JAD190119> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190133> owl:sameAs ns8:JAD170123,
        ns8:JAD179919,
        ns12:JAD170092,
        ns12:JAD180897,
        ns5:JAD140924,
        ns5:JAD170858,
        ns16:JAD160560,
        ns52:JAD132363 ;
    ns0:fullName "Tiia Ngandu" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190133>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:12.ID:JAD190133> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190133 ;
    ns0:inAuthorList ns150:JAD190133 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190272> owl:sameAs ns33:JAD170028 ;
    ns0:fullName "Manabu Ikeda" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:12.ID:JAD190272> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190272 ;
    ns0:inAuthorList ns150:JAD190272 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190346> owl:sameAs ns60:JAD140864 ;
    ns0:fullName "Anand Viswanathan" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190346> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190346 ;
    ns0:inAuthorList ns150:JAD190346 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190399> owl:sameAs ns33:JAD160108 ;
    ns0:fullName "Jiyeong Seo" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:12.ID:JAD190399> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190446> owl:sameAs ns176:JAD160380 ;
    ns0:fullName "John-Dylan Haynes" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:12.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190660> owl:sameAs ns60:jad100432 ;
    ns0:fullName "José Berciano" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190660> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190660 ;
    ns0:inAuthorList ns150:JAD190660 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190691> owl:sameAs ns2:JAD180645,
        ns26:JAD180645,
        ns12:JAD180554,
        ns30:JAD170092,
        ns30:JAD170569,
        ns5:JAD141959,
        ns5:JAD160377,
        ns5:jad00914,
        ns16:JAD170972,
        ns52:jad100870,
        ns60:JAD132783 ;
    ns0:fullName "Juha O. Rinne" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190691>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:12.ID:JAD190691> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190691 ;
    ns0:inAuthorList ns150:JAD190691 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190772> owl:sameAs ns2:jad00404,
        ns8:JAD160119,
        ns40:JAD101533,
        ns43:JAD142409,
        ns30:JAD170560,
        ns30:JAD171109,
        ns30:JAD190166,
        ns16:JAD161188,
        ns16:JAD171094,
        ns52:JAD151158,
        ns52:JAD160357,
        ns52:JAD161193,
        ns52:JAD170530,
        ns52:JAD181291,
        ns57:JAD140054,
        ns33:JAD150824 ;
    ns0:fullName "Jianping Jia" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:12.ID:JAD190772> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190772 ;
    ns0:inAuthorList ns150:JAD190772 .

ns28:BLC180206 owl:sameAs ns16:BLC170159 ;
    ns0:fullName "Núria Malats" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:13.ID:BLC180206> ;
    ns0:hasArticle ns1:blc-v5-i2-BLC180206 ;
    ns0:inAuthorList ns150:BLC180206 .

ns28:JAD180521 owl:sameAs ns5:JAD180344,
        ns16:JAD131820,
        ns52:jad01018,
        ns60:JAD140678,
        ns60:JAD180572 ;
    ns0:fullName "Nicola T. Lautenschlager" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:13.ID:JAD180521>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:13.ID:JAD180521> ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180521 ;
    ns0:inAuthorList ns150:JAD180521 .

ns28:JAD180949 owl:sameAs ns43:JAD160209 ;
    ns0:fullName "Hans-Helmut König" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:13.ID:JAD180949> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

ns28:JAD181095 owl:sameAs ns26:JAD170327,
        ns132:JAD180404,
        ns30:JAD131085,
        ns30:JAD181277,
        ns5:JAD101005,
        ns5:JAD180563,
        ns16:JAD110029,
        ns16:JAD130107,
        ns16:JAD142103,
        ns60:JAD171140 ;
    ns0:fullName "Peter Paul De Deyn" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:13.ID:JAD181095> ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181095 ;
    ns0:inAuthorList ns150:JAD181095 .

ns28:JAD181175 owl:sameAs ns8:JAD111385,
        ns12:JAD150895,
        ns5:JAD120709 ;
    ns0:fullName "Linda Hynan" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:13.ID:JAD181175>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:13.ID:JAD181175> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD181175 ;
    ns0:inAuthorList ns150:JAD181175 .

ns28:JAD190019 owl:sameAs ns26:JAD151125,
        ns12:JAD170017 ;
    ns0:fullName "Martha L. Daviglus" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190019>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:13.ID:JAD190019> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190019 ;
    ns0:inAuthorList ns150:JAD190019 .

ns28:JAD190046 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD161173> ;
    ns0:fullName "Antoni Rodríguez-Fornells" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:13.ID:JAD190046>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:13.ID:JAD190046>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:13.ID:JAD190046> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190046 ;
    ns0:inAuthorList ns150:JAD190046 .

ns28:JAD190334 owl:sameAs ns5:JAD160647 ;
    ns0:fullName "Jaana Rummukainen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:13.ID:JAD190334>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:13.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns28:JAD190369 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181218>,
        <http://ld.iospress.nl/rdf/contributor/Author:26.ID:JAD190644>,
        ns30:jad100723,
        ns52:JAD143084,
        ns60:JAD111070 ;
    ns0:fullName "Koji Abe" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190369> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190369 ;
    ns0:inAuthorList ns150:JAD190369 .

ns28:JAD190399 owl:sameAs ns43:JAD160108,
        ns5:JAD122458,
        ns57:JAD160619 ;
    ns0:fullName "Jong Chul Youn" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:13.ID:JAD190399> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns28:JAD190446 owl:sameAs ns26:JAD180106,
        ns30:JAD130203,
        ns57:JAD142322 ;
    ns0:fullName "Michael T. Heneka" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:13.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:13.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns28:JAD190568 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad00656>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad00804>,
        ns28:JAD160524,
        ns16:jad00584,
        ns16:jad01165,
        ns60:jad00809,
        ns33:jad00896 ;
    ns0:fullName "Gerard D. Schellenberg" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190568>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:13.ID:JAD190568>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:13.ID:JAD190568>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:13.ID:JAD190568> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190568 ;
    ns0:inAuthorList ns150:JAD190568 .

ns28:JAD190660 owl:sameAs ns26:jad101348,
        ns30:JAD110794 ;
    ns0:fullName "Eloy Rodríguez-Rodríguez" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190660> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190660 ;
    ns0:inAuthorList ns150:JAD190660 .

ns28:JAD190817 owl:sameAs ns8:JAD110173,
        ns40:JAD160887,
        ns52:jad00315,
        ns33:JAD141572 ;
    ns0:fullName "Shun Shimohama" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190817> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190817 ;
    ns0:inAuthorList ns150:JAD190817 .

ns28:JND190403 owl:sameAs ns57:JND170209 ;
    ns0:fullName "W. David Arnold" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:13.ID:JND190403> ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190403 ;
    ns0:inAuthorList ns150:JND190403 .

ns28:JPD181518 owl:sameAs ns8:JHD170241 ;
    ns0:fullName "Karl Kieburtz" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:13.ID:JPD181518> ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181518 ;
    ns0:inAuthorList ns150:JPD181518 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:BSI190185> owl:sameAs ns12:BSI183,
        ns52:BSI155 ;
    ns0:fullName "Risto A. Kauppinen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:14.ID:BSI190185> ;
    ns0:hasArticle ns1:bsi-v8-i1-2-BSI190185 ;
    ns0:inAuthorList ns150:BSI190185 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD180949> owl:sameAs ns26:JAD160209,
        ns26:JAD180981,
        ns28:JAD160407,
        ns5:JAD141521 ;
    ns0:fullName "Siegfried Weyerer" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:14.ID:JAD180949> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD181212> owl:sameAs ns8:JAD180942,
        ns26:JAD161224,
        ns12:JAD180746,
        ns183:JAD150749,
        ns5:JAD181080,
        ns57:JAD160374,
        ns60:JAD170414 ;
    ns0:fullName "Paul K. Crane" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD181212> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181212 ;
    ns0:inAuthorList ns150:JAD181212 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190019> owl:sameAs ns26:JAD170017 ;
    ns0:fullName "Hector M. González" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:14.ID:JAD190019> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190019 ;
    ns0:inAuthorList ns150:JAD190019 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190046> owl:sameAs ns2:JAD101422,
        ns26:JAD121906,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD130203>,
        ns12:JAD170698,
        ns16:JAD132195 ;
    ns0:fullName "Lorena Rami" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:14.ID:JAD190046> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190046 ;
    ns0:inAuthorList ns150:JAD190046 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190113> owl:sameAs ns2:JAD170561,
        ns26:JAD181108 ;
    ns0:fullName "Liyong Wu" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:14.ID:JAD190113>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:14.ID:JAD190113> ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190113 ;
    ns0:inAuthorList ns150:JAD190113 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190119> owl:sameAs ns2:JAD110074,
        ns2:JAD141167,
        ns2:JAD170861,
        ns26:JAD132075,
        ns26:JAD180723,
        ns40:JAD130053,
        ns130:JAD160949,
        ns12:JAD150863,
        ns12:JAD170702,
        ns30:JAD131151,
        ns30:JAD131172,
        ns30:jad01225,
        ns5:JAD141380,
        ns5:JAD180715,
        ns16:JAD102124,
        ns16:JAD122302,
        ns57:jad01170,
        ns60:JAD111046,
        ns60:JAD120379,
        ns60:JAD122263 ;
    ns0:fullName "Maria Serpente" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD190119> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190155> owl:sameAs ns2:JAD150134,
        ns2:jad00445,
        ns2:jad00773,
        ns26:JAD150837 ;
    ns0:fullName "José Luna-Muñoz" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD190155> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190155 ;
    ns0:inAuthorList ns150:JAD190155 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190334> owl:sameAs ns2:JAD00041,
        ns2:JAD129024,
        ns8:JAD130548,
        ns12:JAD150909,
        ns30:JAD170446,
        ns57:JAD120946,
        ns57:JAD160554,
        ns60:JAD130104 ;
    ns0:fullName "Irina Alafuzoff" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:14.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190399> owl:sameAs ns40:JAD160108,
        ns28:JAD101221 ;
    ns0:fullName "Dong Young Lee" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:14.ID:JAD190399>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:14.ID:JAD190399> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190446> owl:sameAs ns2:JAD132345,
        ns40:JAD180106,
        ns12:JAD142064,
        ns30:JAD160581,
        ns52:JAD160778,
        ns57:JAD150935 ;
    ns0:fullName "Ingo Kilimann" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:14.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190533> owl:sameAs ns2:JAD170309,
        ns8:jad00814,
        ns8:jad01145,
        ns8:jad100819,
        ns26:JAD170998,
        ns26:jad00868,
        ns40:JAD131802,
        ns40:jad00836,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD121474>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180025>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad100141>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:jad00802>,
        ns43:JAD161158,
        ns130:JAD150948,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD170742>,
        ns12:JAD101944,
        ns183:jad090249,
        ns30:JAD161050,
        ns16:JAD161200,
        ns16:jad00435,
        ns52:jad00639,
        ns57:JAD110584,
        ns57:JAD121516,
        ns60:JAD131820,
        ns60:JAD141497,
        ns60:JAD161259,
        ns60:JAD170072,
        ns60:jad00471,
        ns33:JAD140678,
        ns33:jad01018,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:jad00765>,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:jad00769>,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:jad00771>,
        <http://ld.iospress.nl/rdf/contributor/Guest-editor:0.ID:jad00815> ;
    ns0:fullName "Ralph N. Martins" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:14.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:14.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:14.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:14.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:14.ID:JAD190533> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190533 ;
    ns0:inAuthorList ns150:JAD190533 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD190660> owl:sameAs ns28:JAD170985,
        ns12:JAD110794,
        ns12:jad100432,
        <http://ld.iospress.nl/rdf/contributor/Author:37.ID:JAD150555>,
        ns52:jad101348,
        ns57:JAD190107,
        ns60:JAD161267,
        ns33:JAD181116 ;
    ns0:fullName "Pascual Sánchez-Juan" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:14.ID:JAD190660> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190660 ;
    ns0:inAuthorList ns150:JAD190660 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JND190403> owl:sameAs ns16:JND170292 ;
    ns0:fullName "John T. Kissel" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JND190403> ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190403 ;
    ns0:inAuthorList ns150:JND190403 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JPD181518> owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:23.ID:JPD191648> ;
    ns0:fullName "Kenneth Marek" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:14.ID:JPD181518> ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181518 ;
    ns0:inAuthorList ns150:JPD181518 .

ns43:JAD180847 owl:sameAs ns130:JAD0002,
        ns60:JAD161078 ;
    ns0:fullName "William S. Kremen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:15.ID:JAD180847>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:15.ID:JAD180847> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD180847 ;
    ns0:inAuthorList ns150:JAD180847 .

ns43:JAD180949 owl:sameAs ns26:JAD141521,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD180981>,
        ns30:JAD160407 ;
    ns0:fullName "Edelgard Mösch" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:15.ID:JAD180949> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

ns43:JAD180957 owl:sameAs ns40:JAD160300,
        ns16:JAD171088,
        ns52:JAD140312,
        ns52:JAD142109,
        ns52:JAD160300,
        ns52:JAD181145,
        ns57:JAD111916,
        ns57:JAD121156 ;
    ns0:fullName "Bruce L. Miller" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:15.ID:JAD180957> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD180957 ;
    ns0:inAuthorList ns150:JAD180957 .

ns43:JAD190023 owl:sameAs ns5:JAD150587,
        ns5:jad01360 ;
    ns0:fullName "Peter St. George-Hyslop" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:15.ID:JAD190023> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190023 ;
    ns0:inAuthorList ns150:JAD190023 .

ns43:JAD190098 owl:sameAs ns57:jad00091 ;
    ns0:fullName "Wataru Araki" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:15.ID:JAD190098> ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190098 ;
    ns0:inAuthorList ns150:JAD190098 .

ns43:JAD190334 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170583> ;
    ns0:fullName "Juha E. Jääskeläinen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:15.ID:JAD190334>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:15.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns43:JAD190399 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD171182>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD101221> ;
    ns0:fullName "Dong Woo Lee" ;
    ns0:hasAffiliation ns44:JAD190399 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns43:JAD190446 owl:sameAs ns52:jad01004,
        ns57:JAD131469 ;
    ns0:fullName "Christoph Laske" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:15.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:15.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns130:JAD180949 owl:sameAs ns130:JAD180981,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD141521>,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD160407>,
        ns5:JAD110857,
        ns60:jad01187 ;
    ns0:fullName "Wolfgang Maier" ;
    ns0:hasAffiliation ns264:JAD180949,
        ns131:JAD180949 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

ns130:JAD190023 owl:sameAs ns2:jad00110 ;
    ns0:fullName "Mikio Shoji" ;
    ns0:hasAffiliation ns46:JAD190023,
        ns265:JAD190023 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190023 ;
    ns0:inAuthorList ns150:JAD190023 .

ns130:JAD190087 owl:sameAs ns26:JAD151139 ;
    ns0:fullName "Yukio Yuzawa" ;
    ns0:hasAffiliation ns131:JAD190087 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190087 ;
    ns0:inAuthorList ns150:JAD190087 .

ns130:JAD190119 owl:sameAs ns2:JAD110134,
        ns8:JAD170702,
        ns40:JAD132075,
        ns28:jad01285,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD112123>,
        ns43:JAD170712,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD111046>,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:jad01170>,
        ns132:JAD102124,
        ns176:JAD101416,
        ns176:jad01225,
        ns176:jad091516,
        <http://ld.iospress.nl/rdf/contributor/Author:26.ID:JAD150863>,
        ns30:JAD181253,
        ns52:JAD122302,
        ns52:JAD160073,
        ns60:JAD112006,
        ns60:JAD170861,
        ns60:jad01129,
        ns60:jad01309 ;
    ns0:fullName "Elio Scarpini" ;
    ns0:hasAffiliation ns265:JAD190119 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

ns130:JAD190334 owl:sameAs ns26:JAD170583,
        ns40:JAD170362,
        ns28:JAD170534,
        ns43:JAD140777,
        ns130:JAD190132,
        ns57:JAD181256 ;
    ns0:fullName "Anne M. Remes" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:16.ID:JAD190334>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:16.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns130:JAD190399 owl:sameAs ns28:JAD171182 ;
    ns0:fullName "Seok Bum Lee" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:16.ID:JAD190399> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD180949> owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD160209>,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD180981>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD141521> ;
    ns0:fullName "Martin Scherer" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:17.ID:JAD180949> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD190087> owl:sameAs ns16:JAD132786 ;
    ns0:fullName "Takahiko Tokuda" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:17.ID:JAD190087> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190087 ;
    ns0:inAuthorList ns150:JAD190087 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD190334> owl:sameAs ns8:JAD111736,
        ns8:JAD120802,
        ns8:JAD130035,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD170123>,
        ns132:JAD170092,
        ns12:JAD110065,
        ns12:JAD160643,
        ns12:jad100663,
        ns12:jad100795,
        ns30:JAD180897,
        ns16:ADR170035,
        ns57:JAD140924,
        ns60:JAD160560 ;
    ns0:fullName "Alina Solomon" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:17.ID:JAD190334>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:17.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD190399> owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD171182>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD160108> ;
    ns0:fullName "Jung Jae Lee" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:17.ID:JAD190399> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns132:JAD190334 owl:sameAs ns8:JAD110065,
        ns8:JAD129021,
        ns8:JAD132363,
        ns8:jad01404,
        ns8:jad091450,
        ns40:JAD170858,
        ns40:JAD190133,
        ns130:JAD170123,
        ns30:JAD120802,
        ns30:JAD142052,
        ns5:ADR170035,
        ns5:JAD132225,
        ns5:JAD180199,
        ns5:jad00920,
        ns16:JAD111736,
        ns16:jad100795,
        ns52:JAD130698,
        ns52:JAD140924,
        ns52:JAD160593,
        ns52:jad100114,
        ns52:jad100663,
        ns60:JAD120946 ;
    ns0:fullName "Miia Kivipelto" ;
    ns0:hasAffiliation ns133:JAD190334,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:18.ID:JAD190334>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:18.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns132:JAD190399 owl:sameAs ns176:JAD101221 ;
    ns0:fullName "Jin Hyeong Jhoo" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff16.Author:18.ID:JAD190399> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns132:JAD190446 owl:sameAs ns8:JAD180106 ;
    ns0:fullName "Coraline D. Metzger" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:18.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff16.Author:18.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff17.Author:18.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD180949> owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD160407>,
        ns12:WOR2722,
        ns5:JAD110251,
        ns5:JAD160209,
        ns60:JAD141521 ;
    ns0:fullName "Steffi G. Riedel-Heller" ;
    ns0:hasAffiliation ns134:JAD180949 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD190446> owl:sameAs ns60:JHD180293 ;
    ns0:fullName "Josef Priller" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff19.Author:19.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns12:AAC190457 owl:sameAs ns8:FI1810,
        ns12:1036922 ;
    ns0:fullName "Stefan Woltran" ;
    ns0:hasAffiliation ns73:AAC190457 ;
    ns0:hasArticle ns1:aac-v10-i2-AAC190457 ;
    ns0:inAuthorList ns150:AAC190457 .

ns12:ADR190135 owl:sameAs ns8:ADR180091 ;
    ns0:fullName "Swarup Kumar Chakrabarti" ;
    ns0:hasAffiliation ns83:ADR190135 ;
    ns0:hasArticle ns1:adr-v3-i1-ADR190135 ;
    ns0:inAuthorList ns150:ADR190135 .

ns12:AIC190616 owl:sameAs ns16:mgs00024 ;
    ns0:fullName "Nir Oren" ;
    ns0:hasAffiliation ns73:AIC190616 ;
    ns0:hasArticle ns1:aic-v32-i4-AIC190616 ;
    ns0:inAuthorList ns150:AIC190616 .

ns12:AIC190618 owl:sameAs ns8:ica00341 ;
    ns0:fullName "Juan Pavón" ;
    ns0:hasAffiliation ns73:AIC190618 ;
    ns0:hasArticle ns1:aic-v32-i3-AIC190618 ;
    ns0:inAuthorList ns150:AIC190618 .

ns12:AIS190536 owl:sameAs ns12:AIS180507 ;
    ns0:fullName "Maurits Kaptein" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:AIS190536> ;
    ns0:hasArticle ns1:ais-v11-i5-AIS190536 ;
    ns0:inAuthorList ns150:AIS190536 .

ns12:AO190214 owl:sameAs ns2:AO157,
        ns30:AO197 ;
    ns0:fullName "Giancarlo Guizzardi" ;
    ns0:hasAffiliation ns73:AO190214,
        <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:2.ID:AO190214> ;
    ns0:hasArticle ns1:ao-v14-i3-AO190214 ;
    ns0:inAuthorList ns150:AO190214 .

ns12:ASY191519 owl:sameAs ns2:ASY1287 ;
    ns0:fullName "Makram Hamouda" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:2.ID:ASY191519> ;
    ns0:hasArticle ns1:asy-v114-i1-2-ASY191519 ;
    ns0:inAuthorList ns150:ASY191519 .

ns12:ASY191520 owl:sameAs ns12:ASY191521 ;
    ns0:fullName "Wei Wu" ;
    ns0:hasAffiliation ns73:ASY191520 ;
    ns0:hasArticle ns1:asy-v114-i3-4-ASY191520 ;
    ns0:inAuthorList ns150:ASY191520 .

ns12:BLC190218 owl:sameAs ns2:BLC180191,
        ns8:BLC180167 ;
    ns0:fullName "Florus C. De Jong" ;
    ns0:hasAffiliation ns83:BLC190218 ;
    ns0:hasArticle ns1:blc-v5-i2-BLC190218 ;
    ns0:inAuthorList ns150:BLC190218 .

ns12:BLC190236 owl:sameAs ns2:BLC9001,
        ns8:BLC170118,
        ns8:BLC179017,
        ns132:BLC180182,
        <http://ld.iospress.nl/rdf/contributor/Author:39.ID:BLC189037> ;
    ns0:fullName "Seth P. Lerner" ;
    ns0:hasAffiliation ns15:BLC190236 ;
    ns0:hasArticle ns1:blc-v5-i3-BLC190236 ;
    ns0:inAuthorList ns150:BLC190236 .

ns12:BLC190238 owl:sameAs ns12:BLC180175 ;
    ns0:fullName "Brant A. Inman" ;
    ns0:hasAffiliation ns15:BLC190238 ;
    ns0:hasArticle ns1:blc-v5-i3-BLC190238 ;
    ns0:inAuthorList ns150:BLC190238 .

ns12:BME191058 owl:sameAs ns12:WOR2379 ;
    ns0:fullName "Martin Lamontagne" ;
    ns0:hasAffiliation ns83:BME191058 ;
    ns0:hasArticle ns1:bme-v30-i4-BME191058 ;
    ns0:inAuthorList ns150:BME191058 .

ns12:BME191060 owl:sameAs ns8:BME1709,
        ns5:BME1571 ;
    ns0:fullName "Kosuke Nozaki" ;
    ns0:hasAffiliation ns83:BME191060 ;
    ns0:hasArticle ns1:bme-v30-i4-BME191060 ;
    ns0:inAuthorList ns150:BME191060 .

ns12:BME191064 owl:sameAs ns12:BME1732 ;
    ns0:fullName "Mehdi Farhoudi" ;
    ns0:hasAffiliation ns14:BME191064 ;
    ns0:hasArticle ns1:bme-v30-i4-BME191064 ;
    ns0:inAuthorList ns150:BME191064 .

ns12:BME191067 owl:sameAs ns8:BME1672,
        ns12:BME1734 ;
    ns0:fullName "Irfan Anjum Badruddin" ;
    ns0:hasAffiliation ns15:BME191067 ;
    ns0:hasArticle ns1:bme-v30-i4-BME191067 ;
    ns0:inAuthorList ns150:BME191067 .

ns12:BMR181128 owl:sameAs ns12:BMR171041,
        ns12:bmr00426 ;
    ns0:fullName "Amir Ahmadi" ;
    ns0:hasAffiliation ns14:BMR181128 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181128 ;
    ns0:inAuthorList ns150:BMR181128 .

ns12:BMR181131 owl:sameAs ns12:BMR160585 ;
    ns0:fullName "Michal Jeleň" ;
    ns0:hasAffiliation ns14:BMR181131 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181131 ;
    ns0:inAuthorList ns150:BMR181131 .

ns12:BMR181181 owl:sameAs ns30:VES534 ;
    ns0:fullName "Noha Daher" ;
    ns0:hasAffiliation ns83:BMR181181,
        ns13:BMR181181 ;
    ns0:hasArticle ns1:bmr-v32-i5-BMR181181 ;
    ns0:inAuthorList ns150:BMR181181 .

ns12:BMR181185 owl:sameAs ns2:BMR160543 ;
    ns0:fullName "Savas Sencan" ;
    ns0:hasAffiliation ns14:BMR181185 ;
    ns0:hasArticle ns1:bmr-v32-i5-BMR181185 ;
    ns0:inAuthorList ns150:BMR181185 .

ns12:BMR181228 owl:sameAs ns12:THC181467 ;
    ns0:fullName "Seungwon Lee" ;
    ns0:hasAffiliation ns83:BMR181228 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181228 ;
    ns0:inAuthorList ns150:BMR181228 .

ns12:BMR181286 owl:sameAs ns8:BMR181236 ;
    ns0:fullName "Javad Sarrafzadeh" ;
    ns0:hasAffiliation ns15:BMR181286 ;
    ns0:hasArticle ns1:bmr-v32-i5-BMR181286 ;
    ns0:inAuthorList ns150:BMR181286 .

ns12:BMR181296 owl:sameAs ns33:IES171187 ;
    ns0:fullName "F. Ayala" ;
    ns0:hasAffiliation ns14:BMR181296 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181296 ;
    ns0:inAuthorList ns150:BMR181296 .

ns12:BMR181341 owl:sameAs ns8:BMR169588 ;
    ns0:fullName "Tamer Mohamed Shousha" ;
    ns0:hasAffiliation ns13:BMR181341 ;
    ns0:hasArticle ns1:bmr-v32-i6-BMR181341 ;
    ns0:inAuthorList ns150:BMR181341 .

ns12:BMR181380 owl:sameAs ns2:BMR170898 ;
    ns0:fullName "Jelena Zvekic-Svorcan" ;
    ns0:hasAffiliation ns14:BMR181380 ;
    ns0:hasArticle ns1:bmr-v32-i5-BMR181380 ;
    ns0:inAuthorList ns150:BMR181380 .

ns12:BRS190144 owl:sameAs ns12:BRS106 ;
    ns0:fullName "Eugene J. Obrien" ;
    ns0:hasAffiliation ns14:BRS190144 ;
    ns0:hasArticle ns1:brs-v14-i4-BRS190144 ;
    ns0:inAuthorList ns150:BRS190144 .

ns12:BRS190154 owl:sameAs ns12:BRS113,
        ns30:jad091630 ;
    ns0:fullName "M. Davidson" ;
    ns0:hasAffiliation ns15:BRS190154 ;
    ns0:hasArticle ns1:brs-v15-i1-2-BRS190154 ;
    ns0:inAuthorList ns150:BRS190154 .

ns12:BSI190185 owl:sameAs ns30:BSI155 ;
    ns0:fullName "Bryony L. McGarry" ;
    ns0:hasAffiliation ns73:BSI190185 ;
    ns0:hasArticle ns1:bsi-v8-i1-2-BSI190185 ;
    ns0:inAuthorList ns150:BSI190185 .

ns12:CBM182111 owl:sameAs ns2:IFS169359,
        ns52:CBM660,
        ns57:CBM515,
        ns57:CBM655 ;
    ns0:fullName "Yuan Yuan" ;
    ns0:hasAffiliation ns15:CBM182111 ;
    ns0:hasArticle ns1:cbm-v26-i1-CBM182111 ;
    ns0:inAuthorList ns150:CBM182111 .

ns12:CBM182212 owl:sameAs ns12:CBM181368 ;
    ns0:fullName "Heba Abdel Razik Sayed" ;
    ns0:hasAffiliation ns83:CBM182212 ;
    ns0:hasArticle ns1:cbm-v25-i4-CBM182212 ;
    ns0:inAuthorList ns150:CBM182212 .

ns12:CBM192435 owl:sameAs ns8:CBM170472 ;
    ns0:fullName "Birendra K. Sah" ;
    ns0:hasAffiliation ns15:CBM192435 ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM192435 ;
    ns0:inAuthorList ns150:CBM192435 .

ns12:CH180402 owl:sameAs ns2:BIR14030,
        ns12:BIR180175,
        ns12:CH180417 ;
    ns0:fullName "Ozgen Kilic-Erkek" ;
    ns0:hasAffiliation ns14:CH180402 ;
    ns0:hasArticle ns1:ch-v71-i4-CH180402 ;
    ns0:inAuthorList ns150:CH180402 .

ns12:CH180404 owl:sameAs ns30:CH170252 ;
    ns0:fullName "Xiao-Long Li" ;
    ns0:hasAffiliation ns14:CH180404,
        ns83:CH180404 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180404 ;
    ns0:inAuthorList ns150:CH180404 .

ns12:CH180450 owl:sameAs ns12:CH170245,
        ns16:CH180544 ;
    ns0:fullName "Raymund E. Horch" ;
    ns0:hasAffiliation ns15:CH180450 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180450 ;
    ns0:inAuthorList ns150:CH180450 .

ns12:CH180452 owl:sameAs ns30:CH16142,
        ns57:CH16197 ;
    ns0:fullName "Bo-Ji Liu" ;
    ns0:hasAffiliation ns15:CH180452,
        ns14:CH180452,
        ns83:CH180452 ;
    ns0:hasArticle ns1:ch-v72-i1-CH180452 ;
    ns0:inAuthorList ns150:CH180452 .

ns12:CH180470 owl:sameAs ns5:CH160241,
        ns16:CH160230 ;
    ns0:fullName "Zbigniew Dąbrowski" ;
    ns0:hasAffiliation ns14:CH180470 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180470 ;
    ns0:inAuthorList ns150:CH180470 .

ns12:CH180476 owl:sameAs ns12:CH189126 ;
    ns0:fullName "Hyang-Hee Seo" ;
    ns0:hasAffiliation ns14:CH180476 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180476 ;
    ns0:inAuthorList ns150:CH180476 .

ns12:CH180545 owl:sameAs ns12:CH180457 ;
    ns0:fullName "Bei Lei" ;
    ns0:hasAffiliation ns15:CH180545 ;
    ns0:hasArticle ns1:ch-v72-i3-CH180545 ;
    ns0:inAuthorList ns150:CH180545 .

ns12:CH199002 owl:sameAs ns8:CH168016 ;
    ns0:fullName "Pierre Boulot" ;
    ns0:hasAffiliation ns13:CH199002 ;
    ns0:hasArticle ns1:ch-v71-i4-CH199002 ;
    ns0:inAuthorList ns150:CH199002 .

ns12:CH199007 owl:sameAs ns30:CH168047 ;
    ns0:fullName "Francesco Misiti" ;
    ns0:hasAffiliation ns15:CH199007 ;
    ns0:hasArticle ns1:ch-v71-i4-CH199007 ;
    ns0:inAuthorList ns150:CH199007 .

ns12:CH199009 owl:sameAs ns8:CH199217,
        ns5:JCB189014 ;
    ns0:fullName "R.P. Franke" ;
    ns0:hasAffiliation ns83:CH199009 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199009 ;
    ns0:inAuthorList ns150:CH199009 .

ns12:CH199202 owl:sameAs ns2:CH199204 ;
    ns0:fullName "V. Schwarze" ;
    ns0:hasAffiliation ns15:CH199202 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199202 ;
    ns0:inAuthorList ns150:CH199202 .

ns12:CH199205 owl:sameAs ns30:CH199005 ;
    ns0:fullName "Yan Nie" ;
    ns0:hasAffiliation ns15:CH199205 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199205 ;
    ns0:inAuthorList ns150:CH199205 .

ns12:CH199210 owl:sameAs ns2:JCB189013,
        ns8:CH189125 ;
    ns0:fullName "S. Steinbrecht" ;
    ns0:hasAffiliation ns15:CH199210 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199210 ;
    ns0:inAuthorList ns150:CH199210 .

ns12:CH199212 owl:sameAs ns30:CH16195 ;
    ns0:fullName "Oliver Felthaus" ;
    ns0:hasAffiliation ns83:CH199212 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199212 ;
    ns0:inAuthorList ns150:CH199212 .

ns12:CH199213 owl:sameAs ns2:CH2049,
        ns8:CH199225,
        ns12:CH170265,
        ns12:CH179224,
        ns30:CH170266,
        ns5:CH189309,
        ns5:CH189905 ;
    ns0:fullName "Christian D. Taeger" ;
    ns0:hasAffiliation ns14:CH199213 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199213 ;
    ns0:inAuthorList ns150:CH199213 .

ns12:CH199219 owl:sameAs ns52:CH189108 ;
    ns0:fullName "M.E. Nehring" ;
    ns0:hasAffiliation ns15:CH199219 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199219 ;
    ns0:inAuthorList ns150:CH199219 .

ns12:CH199220 owl:sameAs ns2:CH179201,
        ns2:CH199009,
        ns30:CH1964 ;
    ns0:fullName "P. Lamby" ;
    ns0:hasAffiliation ns15:CH199220 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199220 ;
    ns0:inAuthorList ns150:CH199220 .

ns12:CH199224 owl:sameAs ns2:CH179220,
        ns8:CH179112,
        ns8:CH179218,
        ns8:CH179225,
        ns8:CH180449,
        ns8:CH189131,
        ns12:CH1985,
        ns12:CH1990,
        ns12:CH199221,
        ns30:CH179217,
        ns5:CH168029 ;
    ns0:fullName "Lukas Philipp Beyer" ;
    ns0:hasAffiliation ns15:CH199224 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199224 ;
    ns0:inAuthorList ns150:CH199224 .

ns12:CH199226 owl:sameAs ns8:CH189321,
        ns12:CH189120,
        ns12:JCB189013,
        ns16:CH199210 ;
    ns0:fullName "Jan-Heiner Küpper" ;
    ns0:hasAffiliation ns14:CH199226 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199226 ;
    ns0:inAuthorList ns150:CH199226 .

ns12:COM101 owl:sameAs ns12:COM180219 ;
    ns0:fullName "Daniel Turetsky" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:COM101> ;
    ns0:hasArticle ns1:com-v8-i3-4-COM101 ;
    ns0:inAuthorList ns150:COM101 .

ns12:COM180207 owl:sameAs ns2:COM049 ;
    ns0:fullName "Arno Pauly" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:COM180207> ;
    ns0:hasArticle ns1:com-v8-i3-4-COM180207 ;
    ns0:inAuthorList ns150:COM180207 .

ns12:FI1821 owl:sameAs ns12:FI1604 ;
    ns0:fullName "Fei Xu" ;
    ns0:hasAffiliation ns14:FI1821 ;
    ns0:hasArticle ns1:fi-v168-i1-FI1821 ;
    ns0:inAuthorList ns150:FI1821 .

ns12:FI1831 owl:sameAs ns2:kes00048,
        ns8:idt00082,
        ns8:idt00132,
        ns8:idt00133 ;
    ns0:fullName "Bozena Kostek" ;
    ns0:hasAffiliation ns14:FI1831 ;
    ns0:hasArticle ns1:fi-v168-i2-4-FI1831 ;
    ns0:inAuthorList ns150:FI1831 .

ns12:FI1833 owl:sameAs ns2:FI1827 ;
    ns0:fullName "Władysław Skarbek" ;
    ns0:hasAffiliation ns15:FI1833 ;
    ns0:hasArticle ns1:fi-v168-i2-4-FI1833 ;
    ns0:inAuthorList ns150:FI1833 .

ns12:FI1843 owl:sameAs ns12:FI1799 ;
    ns0:fullName "Christos Rantsoudis" ;
    ns0:hasAffiliation ns83:FI1843 ;
    ns0:hasArticle ns1:fi-v169-i3-FI1843 ;
    ns0:inAuthorList ns150:FI1843 .

ns12:FI1848 owl:sameAs ns2:FI1546,
        <http://ld.iospress.nl/rdf/contributor/Author:3.ID:JCM2(3-4)10> ;
    ns0:fullName "Michał Wroński" ;
    ns0:hasAffiliation ns15:FI1848 ;
    ns0:hasArticle ns1:fi-v169-i4-FI1848 ;
    ns0:inAuthorList ns150:FI1848 .

ns12:FI1870 owl:sameAs ns12:IA110 ;
    ns0:fullName "Andrea Gorrini" ;
    ns0:hasAffiliation ns15:FI1870 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1870 ;
    ns0:inAuthorList ns150:FI1870 .

ns12:FI1874 owl:sameAs ns8:FI1566 ;
    ns0:fullName "Antonio Restivo" ;
    ns0:hasAffiliation ns15:FI1874 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1874 ;
    ns0:inAuthorList ns150:FI1874 .

ns12:FI1878 owl:sameAs ns8:FI1565,
        ns8:FI1872 ;
    ns0:fullName "Luca Manzoni" ;
    ns0:hasAffiliation ns15:FI1878 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1878 ;
    ns0:inAuthorList ns150:FI1878 .

ns12:FI1882 owl:sameAs ns30:FI1562,
        ns30:FI1574,
        ns30:FI1631 ;
    ns0:fullName "Łukasz Mikulski" ;
    ns0:hasAffiliation ns83:FI1882 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1882 ;
    ns0:inAuthorList ns150:FI1882 .

ns12:HAB190367 owl:sameAs ns8:JRS740,
        ns12:HAB190363,
        ns12:HAB190368,
        ns12:HAB190369,
        ns12:HAB190383 ;
    ns0:fullName "Ali Akbari Sari" ;
    ns0:hasAffiliation ns83:HAB190367 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190367 ;
    ns0:inAuthorList ns150:HAB190367 .

ns12:HAB190373 owl:sameAs ns2:hab00171,
        ns8:HAB342,
        ns30:HAB302,
        ns5:HAB324 ;
    ns0:fullName "Elrashdy M. Redwan" ;
    ns0:hasAffiliation ns15:HAB190373,
        ns14:HAB190373,
        ns13:HAB190373 ;
    ns0:hasArticle ns1:hab-v27-i3-HAB190373 ;
    ns0:inAuthorList ns150:HAB190373 .

ns12:HSM180472 owl:sameAs ns30:HSM180415,
        ns30:HSM180425,
        ns5:HSM1773 ;
    ns0:fullName "Muhammad Hafeez" ;
    ns0:hasAffiliation ns15:HSM180472 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180472 ;
    ns0:inAuthorList ns150:HSM180472 .

ns12:HSM190517 owl:sameAs ns2:HSM1768,
        ns12:HSM1794,
        ns12:HSM180465,
        ns30:HSM18288 ;
    ns0:fullName "Umair Akram" ;
    ns0:hasAffiliation ns14:HSM190517 ;
    ns0:hasArticle ns1:hsm-v38-i4-HSM190517 ;
    ns0:inAuthorList ns150:HSM190517 .

ns12:IA180015 owl:sameAs ns30:IA103 ;
    ns0:fullName "Marco Gori" ;
    ns0:hasAffiliation ns14:IA180015 ;
    ns0:hasArticle ns1:ia-v13-i1-IA180015 ;
    ns0:inAuthorList ns150:IA180015 .

ns12:IA190018 owl:sameAs ns12:IA109 ;
    ns0:fullName "Roberto Basili" ;
    ns0:hasAffiliation ns15:IA190018 ;
    ns0:hasArticle ns1:ia-v13-i1-IA190018 ;
    ns0:inAuthorList ns150:IA190018 .

ns12:IA190023 owl:sameAs ns8:SW217 ;
    ns0:fullName "Benjamin Cogrel" ;
    ns0:hasAffiliation ns14:IA190023 ;
    ns0:hasArticle ns1:ia-v13-i1-IA190023 ;
    ns0:inAuthorList ns150:IA190023 .

ns12:ICA190603 owl:sameAs ns30:ICA00047,
        ns30:ica00404,
        ns5:ica00441 ;
    ns0:fullName "Arturo de la Escalera" ;
    ns0:hasAffiliation ns15:ICA190603 ;
    ns0:hasArticle ns1:ica-v26-i4-ICA190603 ;
    ns0:inAuthorList ns150:ICA190603 .

ns12:IDA184238 owl:sameAs ns12:IDA814 ;
    ns0:fullName "Gerhard Weiss" ;
    ns0:hasAffiliation ns15:IDA184238 ;
    ns0:hasArticle ns1:ida-v23-i5-IDA184238 ;
    ns0:inAuthorList ns150:IDA184238 .

ns12:IDA184334 owl:sameAs ns8:IDA173589,
        ns8:IDA183918,
        ns8:IDA184183 ;
    ns0:fullName "Yonglong Luo" ;
    ns0:hasAffiliation ns15:IDA184334,
        ns14:IDA184334,
        ns83:IDA184334 ;
    ns0:hasArticle ns1:ida-v23-i6-IDA184334 ;
    ns0:inAuthorList ns150:IDA184334 .

ns12:IDT180003 owl:sameAs ns2:mgs00109,
        ns8:HIS180258,
        ns8:his00005,
        ns8:idt00117,
        ns30:IFS15372 ;
    ns0:fullName "Ajith Abraham" ;
    ns0:hasAffiliation ns13:IDT180003 ;
    ns0:hasArticle ns1:idt-v13-i3-IDT180003 ;
    ns0:inAuthorList ns150:IDT180003 .

ns12:IDT180136 owl:sameAs ns8:idt00190 ;
    ns0:fullName "N. Karacapilidis" ;
    ns0:hasAffiliation ns83:IDT180136 ;
    ns0:hasArticle ns1:idt-v13-i3-IDT180136 ;
    ns0:inAuthorList ns150:IDT180136 .

ns12:IES182206 owl:sameAs ns16:BMR181215 ;
    ns0:fullName "Frank Mayer" ;
    ns0:hasAffiliation ns15:IES182206 ;
    ns0:hasArticle ns1:ies-v27-i3-IES182206 ;
    ns0:inAuthorList ns150:IES182206 .

ns12:IES183210 owl:sameAs ns8:bmr00331 ;
    ns0:fullName "Telma Maria Araujo Moura Lemos" ;
    ns0:hasAffiliation ns83:IES183210 ;
    ns0:hasArticle ns1:ies-v27-i3-IES183210 ;
    ns0:inAuthorList ns150:IES183210 .

ns12:IES192105 owl:sameAs ns30:IES183223 ;
    ns0:fullName "Muhammet Hakan Mayda" ;
    ns0:hasAffiliation ns14:IES192105 ;
    ns0:hasArticle ns1:ies-v27-i4-IES192105 ;
    ns0:inAuthorList ns150:IES192105 .

ns12:IES192150 owl:sameAs ns12:IES192167 ;
    ns0:fullName "Junpei Sasadai" ;
    ns0:hasAffiliation ns15:IES192150 ;
    ns0:hasArticle ns1:ies-v27-i3-IES192150 ;
    ns0:inAuthorList ns150:IES192150 .

ns12:IES193141 owl:sameAs ns8:IES656 ;
    ns0:fullName "Cem Kurt" ;
    ns0:hasAffiliation ns14:IES193141 ;
    ns0:hasArticle ns1:ies-v27-i4-IES193141 ;
    ns0:inAuthorList ns150:IES193141 .

ns12:IFS16913 owl:sameAs ns12:IFS1913,
        ns12:IFS2013,
        ns30:IFS152503,
        ns30:IFS161499,
        ns30:IFS16875,
        ns30:IFS172127 ;
    ns0:fullName "Manoranjan Maiti" ;
    ns0:hasAffiliation ns15:IFS16913 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS16913 ;
    ns0:inAuthorList ns150:IFS16913 .

ns12:IFS171488 owl:sameAs ns8:IFS171980,
        ns8:IFS17763,
        ns8:IFS2170 ;
    ns0:fullName "Soodabeh Soleymani" ;
    ns0:hasAffiliation ns15:IFS171488 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS171488 ;
    ns0:inAuthorList ns150:IFS171488 .

ns12:IFS171587 owl:sameAs ns12:IFS181385 ;
    ns0:fullName "Muhammad Ibrar" ;
    ns0:hasAffiliation ns15:IFS171587 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS171587 ;
    ns0:inAuthorList ns150:IFS171587 .

ns12:IFS17707 owl:sameAs ns12:IFS18347 ;
    ns0:fullName "R. Sundareswaran" ;
    ns0:hasAffiliation ns83:IFS17707 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS17707 ;
    ns0:inAuthorList ns150:IFS17707 .

ns12:IFS179223 owl:sameAs ns2:FI1628,
        ns2:FI1794,
        ns2:IFS161798,
        ns2:IFS161811,
        ns2:IFS162030,
        ns2:KES337,
        ns8:IFS171636,
        ns12:FI1669,
        ns30:IFS190098 ;
    ns0:fullName "Guiwu Wei" ;
    ns0:hasAffiliation ns14:IFS179223 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179223 ;
    ns0:inAuthorList ns150:IFS179223 .

ns12:IFS179250 owl:sameAs ns8:IFS171587 ;
    ns0:fullName "Asmat Hadi" ;
    ns0:hasAffiliation ns15:IFS179250 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179250 ;
    ns0:inAuthorList ns150:IFS179250 .

ns12:IFS179262 owl:sameAs ns8:IFS179236 ;
    ns0:fullName "Cun Wei" ;
    ns0:hasAffiliation ns14:IFS179262 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179262 ;
    ns0:inAuthorList ns150:IFS179262 .

ns12:IFS179302 owl:sameAs ns12:ica00416 ;
    ns0:fullName "Qian Cai" ;
    ns0:hasAffiliation ns15:IFS179302 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179302 ;
    ns0:inAuthorList ns150:IFS179302 .

ns12:IFS179305 owl:sameAs ns30:CH180531 ;
    ns0:fullName "Feng Mao" ;
    ns0:hasAffiliation ns15:IFS179305 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179305 ;
    ns0:inAuthorList ns150:IFS179305 .

ns12:IFS179315 owl:sameAs ns8:IFS16232,
        ns8:JAE180097 ;
    ns0:fullName "Huihui Hao" ;
    ns0:hasAffiliation ns15:IFS179315 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179315 ;
    ns0:inAuthorList ns150:IFS179315 .

ns12:IFS179322 owl:sameAs ns12:IDA857 ;
    ns0:fullName "Xin Jin" ;
    ns0:hasAffiliation ns15:IFS179322,
        ns14:IFS179322 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179322 ;
    ns0:inAuthorList ns150:IFS179322 .

ns12:IFS181408 owl:sameAs ns12:IFS181467 ;
    ns0:fullName "Jie Shen" ;
    ns0:hasAffiliation ns15:IFS181408 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS181408 ;
    ns0:inAuthorList ns150:IFS181408 .

ns12:IFS181415 owl:sameAs ns12:IFS17940 ;
    ns0:fullName "Yavuz Altin" ;
    ns0:hasAffiliation ns15:IFS181415 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181415 ;
    ns0:inAuthorList ns150:IFS181415 .

ns12:IFS181502 owl:sameAs ns8:IFS171172,
        ns8:IFS172121,
        ns8:IFS181832,
        ns8:IFS18757,
        ns12:IFS161681,
        ns30:IFS191197,
        ns5:IFS18993 ;
    ns0:fullName "Muhammad Irfan Ali" ;
    ns0:hasAffiliation ns83:IFS181502 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181502 ;
    ns0:inAuthorList ns150:IFS181502 .

ns12:IFS181516 owl:sameAs ns8:IFS181460,
        ns8:THC1227,
        ns5:IFS181329 ;
    ns0:fullName "Tariq Mahmood" ;
    ns0:hasAffiliation ns83:IFS181516 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181516 ;
    ns0:inAuthorList ns150:IFS181516 .

ns12:IFS181524 owl:sameAs ns12:IFS2170 ;
    ns0:fullName "Babak Mozafari" ;
    ns0:hasAffiliation ns15:IFS181524 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS181524 ;
    ns0:inAuthorList ns150:IFS181524 .

ns12:IFS181541 owl:sameAs ns12:IFS181040,
        ns12:IFS181527,
        ns12:IFS2134 ;
    ns0:fullName "S.S. Appadoo" ;
    ns0:hasAffiliation ns14:IFS181541 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181541 ;
    ns0:inAuthorList ns150:IFS181541 .

ns12:IFS181545 owl:sameAs ns2:IFS172262,
        ns8:IFS179235,
        ns8:INF1165 ;
    ns0:fullName "Hui Gao" ;
    ns0:hasAffiliation ns15:IFS181545 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181545 ;
    ns0:inAuthorList ns150:IFS181545 .

ns12:IFS181547 owl:sameAs ns12:IFS162234 ;
    ns0:fullName "Meraj Ali Khan" ;
    ns0:hasAffiliation ns14:IFS181547 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181547 ;
    ns0:inAuthorList ns150:IFS181547 .

ns12:IFS181777 owl:sameAs ns2:IFS17506,
        ns12:IFS172139 ;
    ns0:fullName "Ya Qin" ;
    ns0:hasAffiliation ns83:IFS181777 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181777 ;
    ns0:inAuthorList ns150:IFS181777 .

ns12:IFS181799 owl:sameAs ns12:IFS18169 ;
    ns0:fullName "Xilang Tang" ;
    ns0:hasAffiliation ns15:IFS181799 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181799 ;
    ns0:inAuthorList ns150:IFS181799 .

ns12:IFS181813 owl:sameAs ns12:IFS169770 ;
    ns0:fullName "Abdul Qudair Baig" ;
    ns0:hasAffiliation ns13:IFS181813 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS181813 ;
    ns0:inAuthorList ns150:IFS181813 .

ns12:IFS181829 owl:sameAs ns8:IFS172303 ;
    ns0:fullName "Shah Nawaz" ;
    ns0:hasAffiliation ns15:IFS181829 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181829 ;
    ns0:inAuthorList ns150:IFS181829 .

ns12:IFS181832 owl:sameAs ns8:IFS181153,
        ns12:IFS172009,
        ns12:IFS181123,
        ns12:IFS181253,
        ns12:IFS182579,
        ns12:IFS182774,
        ns12:INF1217,
        ns30:IFS181922 ;
    ns0:fullName "Tahir Mahmood" ;
    ns0:hasAffiliation ns15:IFS181832 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181832 ;
    ns0:inAuthorList ns150:IFS181832 .

ns12:IFS181874 owl:sameAs ns12:IFS171297 ;
    ns0:fullName "Mohammad Sadegh Helfroush" ;
    ns0:hasAffiliation ns15:IFS181874 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS181874 ;
    ns0:inAuthorList ns150:IFS181874 .

ns12:IFS181917 owl:sameAs ns8:KES190397 ;
    ns0:fullName "Prasant Kumar Pattnaik" ;
    ns0:hasAffiliation ns83:IFS181917 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181917 ;
    ns0:inAuthorList ns150:IFS181917 .

ns12:IFS181966 owl:sameAs ns5:IFS171118 ;
    ns0:fullName "Lester A. Faria" ;
    ns0:hasAffiliation ns15:IFS181966 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181966 ;
    ns0:inAuthorList ns150:IFS181966 .

ns12:IFS181970 owl:sameAs ns8:IFS162131,
        ns12:IFS17649,
        ns12:IFS182634,
        ns30:IFS18667 ;
    ns0:fullName "Weihua Qu" ;
    ns0:hasAffiliation ns14:IFS181970,
        ns83:IFS181970 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS181970 ;
    ns0:inAuthorList ns150:IFS181970 .

ns12:IFS182555 owl:sameAs ns2:IFS171413,
        ns2:IFS171941,
        ns2:INF1089,
        ns2:INF1108,
        ns8:IFS152381,
        ns8:IFS169620,
        ns8:IFS171652,
        ns8:IFS17270,
        ns8:IFS18331,
        ns8:JCM819,
        ns12:IFS190116 ;
    ns0:fullName "Jun Ye" ;
    ns0:hasAffiliation ns15:IFS182555 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182555 ;
    ns0:inAuthorList ns150:IFS182555 .

ns12:IFS182572 owl:sameAs ns8:IFS171365,
        ns30:IFS17497,
        ns30:IFS17850,
        ns30:IFS181502 ;
    ns0:fullName "Kostaq Hila" ;
    ns0:hasAffiliation ns14:IFS182572 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182572 ;
    ns0:inAuthorList ns150:IFS182572 .

ns12:IFS182581 owl:sameAs ns30:IFS181425 ;
    ns0:fullName "Xiaomin Zhu" ;
    ns0:hasAffiliation ns14:IFS182581 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182581 ;
    ns0:inAuthorList ns150:IFS182581 .

ns12:IFS182595 owl:sameAs ns2:IFS172270,
        ns2:IFS1869,
        ns2:IFS2190,
        ns8:IFS1734,
        ns8:IFS18518,
        ns8:IFS190565,
        ns12:IFS161601,
        ns12:IFS181755,
        ns12:IFS2074,
        ns30:IFS151031,
        ns30:IFS171587 ;
    ns0:fullName "Young Bae Jun" ;
    ns0:hasAffiliation ns14:IFS182595 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182595 ;
    ns0:inAuthorList ns150:IFS182595 .

ns12:IFS182616 owl:sameAs ns12:IFS181972 ;
    ns0:fullName "José Carlos R. Alcantud" ;
    ns0:hasAffiliation ns14:IFS182616 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182616 ;
    ns0:inAuthorList ns150:IFS182616 .

ns12:IFS182643 owl:sameAs ns2:IFS169457,
        ns8:IFS18568,
        ns12:IFS172264,
        ns12:IFS181131 ;
    ns0:fullName "Songsong Dai" ;
    ns0:hasAffiliation ns83:IFS182643 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182643 ;
    ns0:inAuthorList ns150:IFS182643 .

ns12:IFS18266 owl:sameAs ns8:IFS171741,
        ns30:FI1669 ;
    ns0:fullName "Yu Wei" ;
    ns0:hasAffiliation ns14:IFS18266 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS18266 ;
    ns0:inAuthorList ns150:IFS18266 .

ns12:IFS182671 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:1.ID:IDA1(1)04>,
        ns8:INF1216,
        ns12:IFS181291 ;
    ns0:fullName "Ronald R. Yager" ;
    ns0:hasAffiliation ns83:IFS182671 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182671 ;
    ns0:inAuthorList ns150:IFS182671 .

ns12:IFS182745 owl:sameAs ns30:IDT180353 ;
    ns0:fullName "Lan Su" ;
    ns0:hasAffiliation ns14:IFS182745 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182745 ;
    ns0:inAuthorList ns150:IFS182745 .

ns12:IFS182746 owl:sameAs ns30:IFS182961 ;
    ns0:fullName "F. Mofidnakhaei" ;
    ns0:hasAffiliation ns13:IFS182746 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182746 ;
    ns0:inAuthorList ns150:IFS182746 .

ns12:IFS182747 owl:sameAs ns5:IFS181477 ;
    ns0:fullName "Meiqin Wu" ;
    ns0:hasAffiliation ns15:IFS182747 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182747 ;
    ns0:inAuthorList ns150:IFS182747 .

ns12:IFS182798 owl:sameAs ns2:IFS17108 ;
    ns0:fullName "Huiming Duan" ;
    ns0:hasAffiliation ns15:IFS182798 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182798 ;
    ns0:inAuthorList ns150:IFS182798 .

ns12:IFS182815 owl:sameAs ns2:IFS171399 ;
    ns0:fullName "Wei Chen" ;
    ns0:hasAffiliation ns15:IFS182815 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182815 ;
    ns0:inAuthorList ns150:IFS182815 .

ns12:IFS182823 owl:sameAs ns12:IFS17267 ;
    ns0:fullName "Jen-Chih Yao" ;
    ns0:hasAffiliation ns83:IFS182823 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS182823 ;
    ns0:inAuthorList ns150:IFS182823 .

ns12:IFS182832 owl:sameAs ns12:IFS17077,
        ns12:IFS171017,
        ns12:IFS181189 ;
    ns0:fullName "Nagarajan Subramanian" ;
    ns0:hasAffiliation ns83:IFS182832 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182832 ;
    ns0:inAuthorList ns150:IFS182832 .

ns12:IFS182893 owl:sameAs ns12:IFS179275,
        ns30:IFS169340 ;
    ns0:fullName "Wenlong Song" ;
    ns0:hasAffiliation ns15:IFS182893 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182893 ;
    ns0:inAuthorList ns150:IFS182893 .

ns12:IFS182951 owl:sameAs ns30:IFS172009,
        ns16:IFS171567 ;
    ns0:fullName "Fazal Ghani" ;
    ns0:hasAffiliation ns14:IFS182951 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182951 ;
    ns0:inAuthorList ns150:IFS182951 .

ns12:IFS18877 owl:sameAs ns12:IFS18518 ;
    ns0:fullName "K.P. Shum" ;
    ns0:hasAffiliation ns83:IFS18877 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS18877 ;
    ns0:inAuthorList ns150:IFS18877 .

ns12:IFS18950 owl:sameAs ns2:ica00369 ;
    ns0:fullName "Timothy J. Ross" ;
    ns0:hasAffiliation ns14:IFS18950 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18950 ;
    ns0:inAuthorList ns150:IFS18950 .

ns12:IFS190001 owl:sameAs ns8:IFS181122 ;
    ns0:fullName "Jiafu Su" ;
    ns0:hasAffiliation ns14:IFS190001,
        ns83:IFS190001 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190001 ;
    ns0:inAuthorList ns150:IFS190001 .

ns12:IFS190054 owl:sameAs ns2:IFS162414,
        ns2:IFS181123,
        ns2:IFS181295,
        ns2:IFS181892,
        ns8:IFS161589,
        ns8:IFS16244,
        ns8:IFS16339,
        ns8:IFS16419,
        ns8:IFS1665,
        ns8:IFS17301,
        ns8:IFS17334,
        ns8:IFS181094,
        ns8:IFS181648,
        ns8:IFS18833,
        ns8:IFS2117,
        ns12:IFS161702,
        ns12:IFS161740,
        ns12:IFS161747,
        ns12:IFS1673,
        ns12:IFS169940,
        ns12:IFS171265,
        ns12:IFS17728,
        ns12:IFS18663,
        ns12:IFS18824,
        ns30:IFS172282,
        ns5:IFS181460 ;
    ns0:fullName "Bijan Davvaz" ;
    ns0:hasAffiliation ns14:IFS190054 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190054 ;
    ns0:inAuthorList ns150:IFS190054 .

ns12:IFS190293 owl:sameAs ns2:IFS16339 ;
    ns0:fullName "Noor Mohammad Khan" ;
    ns0:hasAffiliation ns14:IFS190293 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190293 ;
    ns0:inAuthorList ns150:IFS190293 .

ns12:IFS190344 owl:sameAs ns30:INF1183,
        ns5:IFS16252 ;
    ns0:fullName "Ligang Zhou" ;
    ns0:hasAffiliation ns83:IFS190344,
        ns13:IFS190344 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190344 ;
    ns0:inAuthorList ns150:IFS190344 .

ns12:IFS190444 owl:sameAs ns8:IFS2101 ;
    ns0:fullName "Kwai-Sang Chin" ;
    ns0:hasAffiliation ns83:IFS190444 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190444 ;
    ns0:inAuthorList ns150:IFS190444 .

ns12:IFS190459 owl:sameAs ns30:THC891 ;
    ns0:fullName "Jun Yao" ;
    ns0:hasAffiliation ns83:IFS190459 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190459 ;
    ns0:inAuthorList ns150:IFS190459 .

ns12:IFS190706 owl:sameAs ns8:his00113 ;
    ns0:fullName "A. Atwan" ;
    ns0:hasAffiliation ns83:IFS190706,
        ns13:IFS190706 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190706 ;
    ns0:inAuthorList ns150:IFS190706 .

ns12:IFS190711 owl:sameAs ns8:IFS1657,
        ns8:IFS171927,
        ns8:IFS181330 ;
    ns0:fullName "H. Motameni" ;
    ns0:hasAffiliation ns83:IFS190711 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190711 ;
    ns0:inAuthorList ns150:IFS190711 .

ns12:IFS190810 owl:sameAs ns2:IFS182945 ;
    ns0:fullName "Vishal Gupta" ;
    ns0:hasAffiliation ns83:IFS190810 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190810 ;
    ns0:inAuthorList ns150:IFS190810 .

ns12:IFS190905 owl:sameAs ns2:IFS161548,
        ns2:IFS17124,
        ns2:IFS182594,
        ns2:IFS182768,
        ns8:FI1522 ;
    ns0:fullName "Xindong Peng" ;
    ns0:hasAffiliation ns83:IFS190905 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190905 ;
    ns0:inAuthorList ns150:IFS190905 .

ns12:IFS191092 owl:sameAs ns8:IFS1824 ;
    ns0:fullName "Yinghua Shen" ;
    ns0:hasAffiliation ns83:IFS191092 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS191092 ;
    ns0:inAuthorList ns150:IFS191092 .

ns12:JAD170300 owl:sameAs ns28:JAD170555,
        ns30:JAD129041,
        ns52:JAD151114,
        ns57:JAD150493,
        ns57:JAD190415 ;
    ns0:fullName "Jennifer J. Manly" ;
    ns0:hasAffiliation ns15:JAD170300,
        ns14:JAD170300,
        ns83:JAD170300 ;
    ns0:hasArticle ns1:jad-v60-i3-JAD170300 ;
    ns0:inAuthorList ns150:JAD170300 .

ns12:JAD180464 owl:sameAs ns33:JAD180511 ;
    ns0:fullName "Rosdinom Razali" ;
    ns0:hasAffiliation ns83:JAD180464 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180464 ;
    ns0:inAuthorList ns150:JAD180464 .

ns12:JAD180492 owl:sameAs ns8:JAD102043,
        ns8:JAD161208,
        ns12:JAD190541 ;
    ns0:fullName "Martin van Boxtel" ;
    ns0:hasAffiliation ns15:JAD180492 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180492 ;
    ns0:inAuthorList ns150:JAD180492 .

ns12:JAD180501 owl:sameAs ns2:JAD180608 ;
    ns0:fullName "Rachel Collins" ;
    ns0:hasAffiliation ns15:JAD180501 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180501 ;
    ns0:inAuthorList ns150:JAD180501 .

ns12:JAD180521 owl:sameAs ns2:JAD122170,
        ns8:JAD110752,
        ns8:JAD121771,
        ns40:JAD121474,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD131820>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150446>,
        ns43:JAD170128,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD171145>,
        ns57:JAD131265,
        ns33:jad090249 ;
    ns0:fullName "Kathryn A. Ellis" ;
    ns0:hasAffiliation ns83:JAD180521 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180521 ;
    ns0:inAuthorList ns150:JAD180521 .

ns12:JAD180562 owl:sameAs ns12:JAD141926 ;
    ns0:fullName "A. Matthew Prina" ;
    ns0:hasAffiliation ns14:JAD180562 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180562 ;
    ns0:inAuthorList ns150:JAD180562 .

ns12:JAD180571 owl:sameAs ns8:JAD170909,
        ns12:JAD141248,
        ns30:JAD170130,
        ns30:JAD190342,
        ns52:JAD180711 ;
    ns0:fullName "Roger A. Dixon" ;
    ns0:hasAffiliation ns15:JAD180571,
        ns14:JAD180571 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180571 ;
    ns0:inAuthorList ns150:JAD180571 .

ns12:JAD180573 owl:sameAs ns30:JAD181174 ;
    ns0:fullName "Kim Delbaere" ;
    ns0:hasAffiliation ns14:JAD180573 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180573 ;
    ns0:inAuthorList ns150:JAD180573 .

ns12:JAD180608 owl:sameAs ns2:JAD150794,
        ns8:JAD160611,
        ns30:JAD170404,
        ns5:JAD180501,
        ns52:JAD150378 ;
    ns0:fullName "Linda Clare" ;
    ns0:hasAffiliation ns15:JAD180608,
        ns83:JAD180608 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180608 ;
    ns0:inAuthorList ns150:JAD180608 .

ns12:JAD180949 owl:sameAs ns40:JAD160407 ;
    ns0:fullName "Tobias Luck" ;
    ns0:hasAffiliation ns83:JAD180949 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

ns12:JAD181030 owl:sameAs ns12:JAD180101 ;
    ns0:fullName "Stephanie Evans" ;
    ns0:hasAffiliation ns13:JAD181030 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181030 ;
    ns0:inAuthorList ns150:JAD181030 .

ns12:JAD181102 owl:sameAs ns40:JAD180982,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD122383>,
        ns43:JAD170657,
        ns12:JAD132750,
        ns30:JAD122383 ;
    ns0:fullName "Reinhold Schmidt" ;
    ns0:hasAffiliation ns83:JAD181102 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD181102 ;
    ns0:inAuthorList ns150:JAD181102 .

ns12:JAD181132 owl:sameAs ns8:JAD121432 ;
    ns0:fullName "David J. Llewellyn" ;
    ns0:hasAffiliation ns14:JAD181132,
        ns83:JAD181132 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD181132 ;
    ns0:inAuthorList ns150:JAD181132 .

ns12:JAD181157 owl:sameAs ns52:JAD161152,
        ns52:JAD161166,
        ns57:JAD160230,
        ns57:JAD180943 ;
    ns0:fullName "Velandai K. Srikanth" ;
    ns0:hasAffiliation ns14:JAD181157,
        ns83:JAD181157 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181157 ;
    ns0:inAuthorList ns150:JAD181157 .

ns12:JAD181169 owl:sameAs ns12:JAD181170 ;
    ns0:fullName "Humberto Omana" ;
    ns0:hasAffiliation ns83:JAD181169 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181169 ;
    ns0:inAuthorList ns150:JAD181169 .

ns12:JAD181171 owl:sameAs ns2:JAD102100,
        ns2:JAD131025,
        ns8:JAD140798,
        ns8:JAD160685,
        ns5:JAD160574,
        ns16:JAD142595 ;
    ns0:fullName "Daijiro Yanagisawa" ;
    ns0:hasAffiliation ns15:JAD181171 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD181171 ;
    ns0:inAuthorList ns150:JAD181171 .

ns12:JAD181173 owl:sameAs ns26:JAD181174 ;
    ns0:fullName "Stephen R. Lord" ;
    ns0:hasAffiliation ns14:JAD181173,
        ns138:JAD181173 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181173 ;
    ns0:inAuthorList ns150:JAD181173 .

ns12:JAD181178 owl:sameAs ns16:JAD160244 ;
    ns0:fullName "Sho Nakakubo" ;
    ns0:hasAffiliation ns15:JAD181178 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181178 ;
    ns0:inAuthorList ns150:JAD181178 .

ns12:JAD181203 owl:sameAs ns8:JAD160641,
        ns8:JAD161292,
        ns8:JAD190202,
        ns12:JAD151026,
        ns12:JAD151113,
        ns12:JAD180030,
        ns52:JAD180485,
        ns33:JAD181195 ;
    ns0:fullName "Nathan Herrmann" ;
    ns0:hasAffiliation ns14:JAD181203,
        ns83:JAD181203 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181203 ;
    ns0:inAuthorList ns150:JAD181203 .

ns12:JAD181261 owl:sameAs ns2:JAD170409,
        ns8:JAD170313,
        ns12:JAD170409 ;
    ns0:fullName "Levinia Lim" ;
    ns0:hasAffiliation ns15:JAD181261 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181261 ;
    ns0:inAuthorList ns150:JAD181261 .

ns12:JAD181285 owl:sameAs ns2:JAD160745,
        ns8:jad00728 ;
    ns0:fullName "Jeffrey L. Cummings" ;
    ns0:hasAffiliation ns15:JAD181285,
        ns83:JAD181285 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181285 ;
    ns0:inAuthorList ns150:JAD181285 .

ns12:JAD190010 owl:sameAs ns2:jad00269,
        ns30:JAD150729 ;
    ns0:fullName "Kathleen A. Lane" ;
    ns0:hasAffiliation ns138:JAD190010 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190010 ;
    ns0:inAuthorList ns150:JAD190010 .

ns12:JAD190011 owl:sameAs ns2:JAD170769 ;
    ns0:fullName "Kyle Steenland" ;
    ns0:hasAffiliation ns13:JAD190011 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190011 ;
    ns0:inAuthorList ns150:JAD190011 .

ns12:JAD190091 owl:sameAs ns8:tad00279 ;
    ns0:fullName "Scott R. Beach" ;
    ns0:hasAffiliation ns83:JAD190091 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190091 ;
    ns0:inAuthorList ns150:JAD190091 .

ns12:JAD190092 owl:sameAs ns5:JAD160881 ;
    ns0:fullName "Noam Alperin" ;
    ns0:hasAffiliation ns14:JAD190092,
        ns13:JAD190092 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190092 ;
    ns0:inAuthorList ns150:JAD190092 .

ns12:JAD190123 owl:sameAs ns30:JAD171150 ;
    ns0:fullName "Rebecca E.K. MacPherson" ;
    ns0:hasAffiliation ns15:JAD190123 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190123 ;
    ns0:inAuthorList ns150:JAD190123 .

ns12:JAD190132 owl:sameAs ns2:JAD140942,
        ns8:JAD190334,
        ns12:JAD122260,
        ns16:JAD160983,
        ns52:JAD170039 ;
    ns0:fullName "Anette Hall" ;
    ns0:hasAffiliation ns15:JAD190132 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

ns12:JAD190155 owl:sameAs ns2:JAD142874,
        ns2:JAD170727,
        ns2:jad00693,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD190772>,
        ns139:JAD170560 ;
    ns0:fullName "Claude M. Wischik" ;
    ns0:hasAffiliation ns83:JAD190155 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190155 ;
    ns0:inAuthorList ns150:JAD190155 .

ns12:JAD190159 owl:sameAs ns2:JAD170313,
        ns8:JAD150736,
        ns30:JAD180280 ;
    ns0:fullName "Russell Jude Chander" ;
    ns0:hasAffiliation ns15:JAD190159,
        ns83:JAD190159 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190159 ;
    ns0:inAuthorList ns150:JAD190159 .

ns12:JAD190180 owl:sameAs ns30:JAD111778 ;
    ns0:fullName "Sung Hoon Baik" ;
    ns0:hasAffiliation ns15:JAD190180 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190180 ;
    ns0:inAuthorList ns150:JAD190180 .

ns12:JAD190187 owl:sameAs ns8:JAD160286 ;
    ns0:fullName "Shorena Janelidze" ;
    ns0:hasAffiliation ns83:JAD190187 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190187 ;
    ns0:inAuthorList ns150:JAD190187 .

ns12:JAD190216 owl:sameAs ns12:WOR192889,
        ns5:BMR160633 ;
    ns0:fullName "David A. Groneberg" ;
    ns0:hasAffiliation ns15:JAD190216 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190216 ;
    ns0:inAuthorList ns150:JAD190216 .

ns12:JAD190217 owl:sameAs ns30:jad101011,
        ns16:JAD170753 ;
    ns0:fullName "Alvaro Alonso" ;
    ns0:hasAffiliation ns83:JAD190217 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190217 ;
    ns0:inAuthorList ns150:JAD190217 .

ns12:JAD190222 owl:sameAs ns8:jad01390,
        ns26:JAD170813,
        ns52:JAD180432 ;
    ns0:fullName "Craig W. Ritchie" ;
    ns0:hasAffiliation ns15:JAD190222,
        ns14:JAD190222 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190222 ;
    ns0:inAuthorList ns150:JAD190222 .

ns12:JAD190261 owl:sameAs ns8:JAD140210,
        ns40:JAD170444,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD132147>,
        ns43:JAD170555,
        ns30:JAD129040,
        ns5:JAD170917,
        ns16:JAD170948,
        ns52:JAD150543,
        ns57:JAD180017,
        ns60:JAD161047,
        ns33:JAD160163 ;
    ns0:fullName "Rhoda Au" ;
    ns0:hasAffiliation ns13:JAD190261,
        ns138:JAD190261 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190261 ;
    ns0:inAuthorList ns150:JAD190261 .

ns12:JAD190262 owl:sameAs ns30:JAD180965 ;
    ns0:fullName "Danielle J. Harvey" ;
    ns0:hasAffiliation ns83:JAD190262 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190262 ;
    ns0:inAuthorList ns150:JAD190262 .

ns12:JAD190269 owl:sameAs ns2:JAD170162,
        ns8:JAD181126,
        ns5:JAD160053,
        ns5:JAD171038 ;
    ns0:fullName "Sai Tian" ;
    ns0:hasAffiliation ns14:JAD190269 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190269 ;
    ns0:inAuthorList ns150:JAD190269 .

ns12:JAD190278 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150250>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150261>,
        ns60:JAD171169 ;
    ns0:fullName "Jin Narumoto" ;
    ns0:hasAffiliation ns15:JAD190278 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190278 ;
    ns0:inAuthorList ns150:JAD190278 .

ns12:JAD190281 owl:sameAs ns5:JAD170190 ;
    ns0:fullName "Ju Gao" ;
    ns0:hasAffiliation ns14:JAD190281 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190281 ;
    ns0:inAuthorList ns150:JAD190281 .

ns12:JAD190331 owl:sameAs ns8:JAD190405,
        ns12:JAD181208,
        ns5:JAD181186 ;
    ns0:fullName "Randy J. Kulesza" ;
    ns0:hasAffiliation ns13:JAD190331 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190331 ;
    ns0:inAuthorList ns150:JAD190331 .

ns12:JAD190342 owl:sameAs ns30:JAD180631 ;
    ns0:fullName "Andrew Booth" ;
    ns0:hasAffiliation ns13:JAD190342 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190342 ;
    ns0:inAuthorList ns150:JAD190342 .

ns12:JAD190365 owl:sameAs ns8:JAD180131,
        ns8:JAD190278,
        ns12:JPD191619 ;
    ns0:fullName "Zahinoor Ismail" ;
    ns0:hasAffiliation ns112:JAD190365 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190365 ;
    ns0:inAuthorList ns150:JAD190365 .

ns12:JAD190369 owl:sameAs ns30:JAD181218 ;
    ns0:fullName "Jingwei Shang" ;
    ns0:hasAffiliation ns15:JAD190369 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190369 ;
    ns0:inAuthorList ns150:JAD190369 .

ns12:JAD190403 owl:sameAs ns2:JAD142079 ;
    ns0:fullName "Kara M. Hawkins" ;
    ns0:hasAffiliation ns15:JAD190403 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190403 ;
    ns0:inAuthorList ns150:JAD190403 .

ns12:JAD190405 owl:sameAs ns2:JAD181186 ;
    ns0:fullName "Yusra Mansour" ;
    ns0:hasAffiliation ns83:JAD190405 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190405 ;
    ns0:inAuthorList ns150:JAD190405 .

ns12:JAD190413 owl:sameAs ns12:JAD150481,
        ns12:JAD160828,
        ns30:JAD160124,
        ns30:JAD170905,
        ns30:JAD180427,
        ns5:JAD160485,
        ns5:JAD190030 ;
    ns0:fullName "Christiane Gasse" ;
    ns0:hasAffiliation ns14:JAD190413,
        ns83:JAD190413 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190413 ;
    ns0:inAuthorList ns150:JAD190413 .

ns12:JAD190414 owl:sameAs ns8:JAD122098 ;
    ns0:fullName "Manuela Guerreiro" ;
    ns0:hasAffiliation ns15:JAD190414 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190414 ;
    ns0:inAuthorList ns150:JAD190414 .

ns12:JAD190419 owl:sameAs ns12:JAD180497 ;
    ns0:fullName "Weijian Hang" ;
    ns0:hasAffiliation ns15:JAD190419 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190419 ;
    ns0:inAuthorList ns150:JAD190419 .

ns12:JAD190427 owl:sameAs ns8:JAD110428,
        ns5:JAD121648,
        ns5:JAD160820,
        ns5:JAD190295,
        ns57:JAD150574 ;
    ns0:fullName "Catherine Helmer" ;
    ns0:hasAffiliation ns14:JAD190427 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190427 ;
    ns0:inAuthorList ns150:JAD190427 .

ns12:JAD190440 owl:sameAs ns5:JAD170807 ;
    ns0:fullName "Pascal Antoine" ;
    ns0:hasAffiliation ns13:JAD190440 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190440 ;
    ns0:inAuthorList ns150:JAD190440 .

ns12:JAD190454 owl:sameAs ns8:CBM182165 ;
    ns0:fullName "Ming Yao" ;
    ns0:hasAffiliation ns15:JAD190454 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190454 ;
    ns0:inAuthorList ns150:JAD190454 .

ns12:JAD190460 owl:sameAs ns2:JAD181281 ;
    ns0:fullName "Blanka Klimova" ;
    ns0:hasAffiliation ns83:JAD190460,
        ns13:JAD190460 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190460 ;
    ns0:inAuthorList ns150:JAD190460 .

ns12:JAD190469 owl:sameAs ns30:JAD190007,
        ns60:JAD161139 ;
    ns0:fullName "Seongbeom Park" ;
    ns0:hasAffiliation ns15:JAD190469,
        ns14:JAD190469 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190469 ;
    ns0:inAuthorList ns150:JAD190469 .

ns12:JAD190474 owl:sameAs ns12:JAD190524 ;
    ns0:fullName "John D. Crawford" ;
    ns0:hasAffiliation ns15:JAD190474,
        ns14:JAD190474 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190474 ;
    ns0:inAuthorList ns150:JAD190474 .

ns12:JAD190484 owl:sameAs ns8:JAD170218 ;
    ns0:fullName "Joaquim Martí-Clúa" ;
    ns0:hasAffiliation ns15:JAD190484,
        ns14:JAD190484 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190484 ;
    ns0:inAuthorList ns150:JAD190484 .

ns12:JAD190501 owl:sameAs ns43:JAD170347,
        ns30:JAD181049 ;
    ns0:fullName "Wenying Du" ;
    ns0:hasAffiliation ns15:JAD190501,
        ns13:JAD190501 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190501 ;
    ns0:inAuthorList ns150:JAD190501 .

ns12:JAD190518 owl:sameAs ns2:JAD171071,
        ns57:JAD170388,
        ns33:JAD131589 ;
    ns0:fullName "Cassia Overk" ;
    ns0:hasAffiliation ns83:JAD190518 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190518 ;
    ns0:inAuthorList ns150:JAD190518 .

ns12:JAD190519 owl:sameAs ns2:jad00804 ;
    ns0:fullName "Lynn M. Bekris" ;
    ns0:hasAffiliation ns83:JAD190519 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190519 ;
    ns0:inAuthorList ns150:JAD190519 .

ns12:JAD190533 owl:sameAs ns8:JAD180025 ;
    ns0:fullName "Kathryn Goozee" ;
    ns0:hasAffiliation ns15:JAD190533,
        ns14:JAD190533,
        ns83:JAD190533,
        ns138:JAD190533,
        ns112:JAD190533 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190533 ;
    ns0:inAuthorList ns150:JAD190533 .

ns12:JAD190538 owl:sameAs ns8:JAD161132,
        ns5:JAD160977,
        ns5:JAD179939 ;
    ns0:fullName "Robert S. Wilson" ;
    ns0:hasAffiliation ns83:JAD190538,
        ns13:JAD190538,
        ns138:JAD190538 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190538 ;
    ns0:inAuthorList ns150:JAD190538 .

ns12:JAD190546 owl:sameAs ns40:JAD190087,
        ns12:JAD190256 ;
    ns0:fullName "Hajime Takechi" ;
    ns0:hasAffiliation ns15:JAD190546 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190546 ;
    ns0:inAuthorList ns150:JAD190546 .

ns12:JAD190563 owl:sameAs ns30:jad00408 ;
    ns0:fullName "Elaine R. Peskind" ;
    ns0:hasAffiliation ns83:JAD190563,
        ns13:JAD190563 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190563 ;
    ns0:inAuthorList ns150:JAD190563 .

ns12:JAD190564 owl:sameAs ns5:JAD190074,
        ns5:jad101008 ;
    ns0:fullName "Daniel M. Michaelson" ;
    ns0:hasAffiliation ns15:JAD190564,
        ns14:JAD190564 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190564 ;
    ns0:inAuthorList ns150:JAD190564 .

ns12:JAD190567 owl:sameAs ns8:JAD120481 ;
    ns0:fullName "Zeinab Abdel-All" ;
    ns0:hasAffiliation ns14:JAD190567 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190567 ;
    ns0:inAuthorList ns150:JAD190567 .

ns12:JAD190577 owl:sameAs ns30:jad101350 ;
    ns0:fullName "Abdul Hye" ;
    ns0:hasAffiliation ns14:JAD190577 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190577 ;
    ns0:inAuthorList ns150:JAD190577 .

ns12:JAD190590 owl:sameAs ns40:JAD171077,
        ns5:JAD150898 ;
    ns0:fullName "Atsushi Nishida" ;
    ns0:hasAffiliation ns14:JAD190590 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190590 ;
    ns0:inAuthorList ns150:JAD190590 .

ns12:JAD190610 owl:sameAs ns12:JAD190540 ;
    ns0:fullName "Narayanaswamy Venketasubramanian" ;
    ns0:hasAffiliation ns83:JAD190610 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190610 ;
    ns0:inAuthorList ns150:JAD190610 .

ns12:JAD190644 owl:sameAs ns8:JAD181218,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190369>,
        ns12:JAD143084,
        ns12:jad100723,
        ns52:JAD111070 ;
    ns0:fullName "Yasuyuki Ohta" ;
    ns0:hasAffiliation ns15:JAD190644 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns12:JAD190645 owl:sameAs ns2:ADR170004,
        ns2:JAD170402,
        ns12:JAD160528 ;
    ns0:fullName "Sara E. Berman" ;
    ns0:hasAffiliation ns138:JAD190645 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190645 ;
    ns0:inAuthorList ns150:JAD190645 .

ns12:JAD190656 owl:sameAs ns33:JAD110914 ;
    ns0:fullName "Michael Mante" ;
    ns0:hasAffiliation ns15:JAD190656 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190656 ;
    ns0:inAuthorList ns150:JAD190656 .

ns12:JAD190661 owl:sameAs ns5:JAD110405 ;
    ns0:fullName "Eveleen Darby" ;
    ns0:hasAffiliation ns15:JAD190661 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190661 ;
    ns0:inAuthorList ns150:JAD190661 .

ns12:JAD190685 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160143>,
        ns16:JAD142088 ;
    ns0:fullName "Young Chul Youn" ;
    ns0:hasAffiliation ns83:JAD190685 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190685 ;
    ns0:inAuthorList ns150:JAD190685 .

ns12:JAD190704 owl:sameAs ns5:JAD160850,
        ns16:JAD161080 ;
    ns0:fullName "Gholamreza Anbarjafari" ;
    ns0:hasAffiliation ns15:JAD190704,
        ns14:JAD190704 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190704 ;
    ns0:inAuthorList ns150:JAD190704 .

ns12:JAD190708 owl:sameAs ns12:JAD171152 ;
    ns0:fullName "David A. Merrill" ;
    ns0:hasAffiliation ns83:JAD190708,
        ns13:JAD190708 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190708 ;
    ns0:inAuthorList ns150:JAD190708 .

ns12:JAD190721 owl:sameAs ns8:JAD110566,
        ns40:JAD121930,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD171116>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad091651>,
        <http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD170875>,
        ns5:JAD190187,
        ns16:JAD142025,
        ns57:JAD150897,
        ns60:JAD190077,
        ns33:JAD121471 ;
    ns0:fullName "Henrik Zetterberg" ;
    ns0:hasAffiliation ns14:JAD190721,
        ns83:JAD190721,
        ns13:JAD190721,
        ns138:JAD190721 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190721 ;
    ns0:inAuthorList ns150:JAD190721 .

ns12:JAD190756 owl:sameAs ns16:JAD160593 ;
    ns0:fullName "Roger Carlsson" ;
    ns0:hasAffiliation ns83:JAD190756 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190756 ;
    ns0:inAuthorList ns150:JAD190756 .

ns12:JAD190771 owl:sameAs ns8:jad01347,
        ns12:jad00202,
        ns12:jad00741,
        ns57:jad00967,
        ns33:JAD120358 ;
    ns0:fullName "Marco Racchi" ;
    ns0:hasAffiliation ns15:JAD190771 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190771 ;
    ns0:inAuthorList ns150:JAD190771 .

ns12:JAD190782 owl:sameAs ns30:JAD181039 ;
    ns0:fullName "Kristi Bailey" ;
    ns0:hasAffiliation ns14:JAD190782 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190782 ;
    ns0:inAuthorList ns150:JAD190782 .

ns12:JAD190798 owl:sameAs ns8:JAD190638,
        ns28:JAD190311 ;
    ns0:fullName "Despina Moraitou" ;
    ns0:hasAffiliation ns15:JAD190798 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190798 ;
    ns0:inAuthorList ns150:JAD190798 .

ns12:JAD190817 owl:sameAs ns8:JAD160887,
        ns12:JAD180904,
        ns30:JAD141572,
        ns60:JAD180985 ;
    ns0:fullName "Shin Hisahara" ;
    ns0:hasAffiliation ns15:JAD190817 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190817 ;
    ns0:inAuthorList ns150:JAD190817 .

ns12:JAD190823 owl:sameAs ns30:JAD190889 ;
    ns0:fullName "Claire Hanley" ;
    ns0:hasAffiliation ns83:JAD190823 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190823 ;
    ns0:inAuthorList ns150:JAD190823 .

ns12:JAE180028 owl:sameAs ns8:JAE180021,
        ns12:XST17364,
        ns30:XST180422,
        ns60:XST180467 ;
    ns0:fullName "Yu Lei" ;
    ns0:hasAffiliation ns15:JAE180028 ;
    ns0:hasArticle ns1:jae-v58-i2-JAE180028 ;
    ns0:inAuthorList ns150:JAE180028 .

ns12:JAE190924 owl:sameAs ns12:JAE171008,
        ns12:JAE171252,
        ns12:JAE191148,
        ns12:JAE191149,
        ns12:JAE191283,
        ns12:JAE2122,
        ns12:JAE2271,
        ns30:JAE190821,
        ns30:JAE1979 ;
    ns0:fullName "Koji Fujiwara" ;
    ns0:hasAffiliation ns15:JAE190924 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE190924 ;
    ns0:inAuthorList ns150:JAE190924 .

ns12:JAE198972 owl:sameAs ns5:JAE198976 ;
    ns0:fullName "Paul Cristian Andrei" ;
    ns0:hasAffiliation ns15:JAE198972 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE198972 ;
    ns0:inAuthorList ns150:JAE198972 .

ns12:JBR180345 owl:sameAs ns30:JBR124 ;
    ns0:fullName "Luca Mazzoni" ;
    ns0:hasAffiliation ns15:JBR180345 ;
    ns0:hasArticle ns1:jbr-v9-i2-JBR180345 ;
    ns0:inAuthorList ns150:JBR180345 .

ns12:JBR180350 owl:sameAs ns33:cbm00414 ;
    ns0:fullName "Lijia An" ;
    ns0:hasAffiliation ns15:JBR180350 ;
    ns0:hasArticle ns1:jbr-v9-i2-JBR180350 ;
    ns0:inAuthorList ns150:JBR180350 .

ns12:JCM190017 owl:sameAs ns30:JCM190015 ;
    ns0:fullName "Jing Qiu" ;
    ns0:hasAffiliation ns15:JCM190017 ;
    ns0:hasArticle ns1:jcm-v19-i3-JCM190017 ;
    ns0:inAuthorList ns150:JCM190017 .

ns12:JCS171070 owl:sameAs ns2:jcs340,
        ns8:jcs244 ;
    ns0:fullName "Stéphanie Delaune" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:JCS171070> ;
    ns0:hasArticle ns1:jcs-v27-i3-JCS171070 ;
    ns0:inAuthorList ns150:JCS171070 .

ns12:JCS191287 owl:sameAs ns30:jcs410,
        ns30:jcs494 ;
    ns0:fullName "Thorsten Holz" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:2.ID:JCS191287> ;
    ns0:hasArticle ns1:jcs-v27-i4-JCS191287 ;
    ns0:inAuthorList ns150:JCS191287 .

ns12:JCS191289 owl:sameAs ns30:IFS181231 ;
    ns0:fullName "Mauro Conti" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:2.ID:JCS191289> ;
    ns0:hasArticle ns1:jcs-v27-i4-JCS191289 ;
    ns0:inAuthorList ns150:JCS191289 .

ns12:JCS191306 owl:sameAs ns2:JCS555,
        ns8:JCS171094,
        <http://ld.iospress.nl/rdf/contributor/Author:1.ID:JCS2(4)04>,
        ns12:JCS108,
        ns12:JCS171106,
        <http://ld.iospress.nl/rdf/contributor/Author:2.ID:JCS3(2-3)02>,
        ns12:JCS513,
        ns12:JCS545,
        ns12:jcs289,
        ns30:JCS548,
        ns30:jcs151,
        ns30:jcs265 ;
    ns0:fullName "Sushil Jajodia" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:JCS191306> ;
    ns0:hasArticle ns1:jcs-v27-i4-JCS191306 ;
    ns0:inAuthorList ns150:JCS191306 .

ns12:JCS191315 owl:sameAs ns12:JCS17947 ;
    ns0:fullName "Jaideep Vaidya" ;
    ns0:hasAffiliation ns73:JCS191315 ;
    ns0:hasArticle ns1:jcs-v27-i4-JCS191315 ;
    ns0:inAuthorList ns150:JCS191315 .

ns12:JHD180337 owl:sameAs ns8:JHD190353,
        ns12:JHD180325,
        ns16:JHD190354 ;
    ns0:fullName "Robin Schubert" ;
    ns0:hasAffiliation ns15:JHD180337 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD180337 ;
    ns0:inAuthorList ns150:JHD180337 .

ns12:JHD190349 owl:sameAs ns2:JPD150668,
        ns12:JPD171173,
        ns30:JHD180326,
        ns30:JHD190361,
        ns5:JHD170256 ;
    ns0:fullName "Danny Bega" ;
    ns0:hasAffiliation ns83:JHD190349 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD190349 ;
    ns0:inAuthorList ns150:JHD190349 .

ns12:JHD190353 owl:sameAs ns26:JHD180285,
        ns52:JHD180337,
        ns57:JHD160197,
        ns57:JHD180325,
        ns57:JHD190354,
        ns33:JHD170284 ;
    ns0:fullName "Ralf Reilmann" ;
    ns0:hasAffiliation ns14:JHD190353,
        ns83:JHD190353,
        ns13:JHD190353 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD190353 ;
    ns0:inAuthorList ns150:JHD190353 .

ns12:JHD199003 owl:sameAs ns8:JHD170262,
        ns8:JHD189001,
        ns8:JHD189003,
        ns12:JHD190001,
        ns57:JHD170269 ;
    ns0:fullName "Edward J. Wild" ;
    ns0:hasAffiliation ns15:JHD199003 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD199003 ;
    ns0:inAuthorList ns150:JHD199003 .

ns12:JND180314 owl:sameAs ns8:JND150125 ;
    ns0:fullName "Johann Böhm" ;
    ns0:hasAffiliation ns13:JND180314 ;
    ns0:hasArticle ns1:jnd-v6-i3-JND180314 ;
    ns0:inAuthorList ns150:JND180314 .

ns12:JND190403 owl:sameAs ns2:PRM362 ;
    ns0:fullName "Linda Lowes" ;
    ns0:hasAffiliation ns15:JND190403,
        ns14:JND190403 ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190403 ;
    ns0:inAuthorList ns150:JND190403 .

ns12:JND190414 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JND160151> ;
    ns0:fullName "Sandra Donkervoort" ;
    ns0:hasAffiliation ns15:JND190414 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190414 ;
    ns0:inAuthorList ns150:JND190414 .

ns12:JND190428 owl:sameAs ns57:JND180315 ;
    ns0:fullName "Oliver Schwartz" ;
    ns0:hasAffiliation ns83:JND190428 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190428 ;
    ns0:inAuthorList ns150:JND190428 .

ns12:JPD181565 owl:sameAs ns12:JPD150622 ;
    ns0:fullName "Lawrence W. Elmer" ;
    ns0:hasAffiliation ns83:JPD181565 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD181565 ;
    ns0:inAuthorList ns150:JPD181565 .

ns12:JPD191579 owl:sameAs ns8:JPD171271,
        ns52:JAD111223 ;
    ns0:fullName "Roger L. Albin" ;
    ns0:hasAffiliation ns15:JPD191579,
        ns14:JPD191579,
        ns83:JPD191579 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191579 ;
    ns0:inAuthorList ns150:JPD191579 .

ns12:JPD191600 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170893>,
        ns12:JAD101026 ;
    ns0:fullName "Jeroen van der Grond" ;
    ns0:hasAffiliation ns14:JPD191600 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191600 ;
    ns0:inAuthorList ns150:JPD191600 .

ns12:JPD191610 owl:sameAs ns8:JPD150680,
        ns52:JPD181386 ;
    ns0:fullName "Charles H. Adler" ;
    ns0:hasAffiliation ns15:JPD191610 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191610 ;
    ns0:inAuthorList ns150:JPD191610 .

ns12:JPD191616 owl:sameAs ns2:JPD181314 ;
    ns0:fullName "Sara Riggare" ;
    ns0:hasAffiliation ns83:JPD191616 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191616 ;
    ns0:inAuthorList ns150:JPD191616 .

ns12:JPD191675 owl:sameAs ns2:JAD180986,
        ns8:JAD151015,
        ns12:JPD181365,
        ns30:JAD170894,
        ns5:JAD151116 ;
    ns0:fullName "Yoshiki Takamatsu" ;
    ns0:hasAffiliation ns15:JPD191675 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191675 ;
    ns0:inAuthorList ns150:JPD191675 .

ns12:JPD191688 owl:sameAs ns12:JAD180248,
        ns5:JAD150992 ;
    ns0:fullName "Jodie R. Gawryluk" ;
    ns0:hasAffiliation ns15:JPD191688,
        ns83:JPD191688 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191688 ;
    ns0:inAuthorList ns150:JPD191688 .

ns12:JPD191699 owl:sameAs ns12:JPD181486,
        ns30:JPD171127 ;
    ns0:fullName "Per Svenningsson" ;
    ns0:hasAffiliation ns15:JPD191699,
        ns14:JPD191699 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191699 ;
    ns0:inAuthorList ns150:JPD191699 .

ns12:JRS180021 owl:sameAs ns57:bd000357 ;
    ns0:fullName "Anurag Jain" ;
    ns0:hasAffiliation ns14:JRS180021 ;
    ns0:hasArticle ns1:jrs-v30-i2-JRS180021 ;
    ns0:inAuthorList ns150:JRS180021 .

ns12:JVR191021 owl:sameAs ns16:JVR191055 ;
    ns0:fullName "Chelsea Greco" ;
    ns0:hasAffiliation ns15:JVR191021 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191021 ;
    ns0:inAuthorList ns150:JVR191021 .

ns12:JVR191022 owl:sameAs ns2:JVR836,
        ns2:WOR2206,
        ns12:JVR808,
        ns12:JVR817,
        ns12:WOR2201 ;
    ns0:fullName "Jian Li" ;
    ns0:hasAffiliation ns83:JVR191022 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191022 ;
    ns0:inAuthorList ns150:JVR191022 .

ns12:JVR191024 owl:sameAs ns2:JVR830,
        ns2:JVR856,
        ns8:JVR803,
        ns8:JVR830,
        ns30:JVR808,
        ns33:JVR810 ;
    ns0:fullName "Brian T. McMahon" ;
    ns0:hasAffiliation ns83:JVR191024 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191024 ;
    ns0:inAuthorList ns150:JVR191024 .

ns12:JVR191025 owl:sameAs ns2:JVR191024,
        ns2:JVR810,
        ns2:JVR889,
        ns2:WOR2201,
        ns8:JVR180983,
        ns8:JVR808,
        ns8:JVR817,
        ns8:JVR888,
        ns8:JVR931,
        ns12:JVR811,
        ns12:JVR812,
        ns12:JVR836,
        ns12:JVR894,
        ns12:JVR899,
        ns12:JVR940,
        ns12:JVR941,
        ns30:JVR191026,
        ns30:JVR891,
        ns30:JVR893,
        ns30:JVR896,
        ns30:NRE1271,
        ns30:WOR2206,
        ns52:WOR2596,
        ns60:NRE1274 ;
    ns0:fullName "Phillip Rumrill" ;
    ns0:hasAffiliation ns14:JVR191025 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191025 ;
    ns0:inAuthorList ns150:JVR191025 .

ns12:JVR191031 owl:sameAs ns30:JVR191037 ;
    ns0:fullName "Michelle Podolec" ;
    ns0:hasAffiliation ns15:JVR191031 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191031 ;
    ns0:inAuthorList ns150:JVR191031 .

ns12:JVR191034 owl:sameAs ns12:JVR191040 ;
    ns0:fullName "Vanessa C. Corona" ;
    ns0:hasAffiliation ns14:JVR191034 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191034 ;
    ns0:inAuthorList ns150:JVR191034 .

ns12:JVR191035 owl:sameAs ns2:JVR895,
        ns2:JVR941 ;
    ns0:fullName "Julie Hill" ;
    ns0:hasAffiliation ns15:JVR191035 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191035 ;
    ns0:inAuthorList ns150:JVR191035 .

ns12:JVR191036 owl:sameAs ns8:JVR191032 ;
    ns0:fullName "Matthew Roskowski" ;
    ns0:hasAffiliation ns15:JVR191036 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191036 ;
    ns0:inAuthorList ns150:JVR191036 .

ns12:JVR191038 owl:sameAs ns2:JVR180991,
        ns2:JVR191039,
        ns2:JVR191048 ;
    ns0:fullName "Catherine Ipsen" ;
    ns0:hasAffiliation ns14:JVR191038 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191038 ;
    ns0:inAuthorList ns150:JVR191038 .

ns12:JVR191039 owl:sameAs ns8:JVR191038,
        ns12:JVR180991 ;
    ns0:fullName "Sara McCormick" ;
    ns0:hasAffiliation ns83:JVR191039 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191039 ;
    ns0:inAuthorList ns150:JVR191039 .

ns12:JVR191043 owl:sameAs ns2:JVR191036,
        ns30:JVR191032,
        ns5:JVR889 ;
    ns0:fullName "Ellie Hartman" ;
    ns0:hasAffiliation ns14:JVR191043 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191043 ;
    ns0:inAuthorList ns150:JVR191043 .

ns12:JVR191046 owl:sameAs ns5:JVR180976,
        ns16:JVR922 ;
    ns0:fullName "Paul T. Shattuck" ;
    ns0:hasAffiliation ns15:JVR191046 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191046 ;
    ns0:inAuthorList ns150:JVR191046 .

ns12:JVR191049 owl:sameAs ns30:WOR193011,
        ns30:WOR2318,
        ns30:WOR2737 ;
    ns0:fullName "Ulrika Bejerholm" ;
    ns0:hasAffiliation ns15:JVR191049 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191049 ;
    ns0:inAuthorList ns150:JVR191049 .

ns12:JVR191055 owl:sameAs ns2:JVR805,
        ns2:JVR806,
        ns8:JVR812,
        ns8:WOR2202,
        ns12:JVR180999,
        ns12:JVR838,
        ns12:JVR898,
        ns30:JVR809,
        ns30:JVR814,
        ns30:JVR816,
        ns30:JVR889,
        ns5:JVR191022,
        ns5:JVR811,
        ns5:JVR972,
        ns16:JVR813,
        ns52:JVR914,
        ns57:JVR930,
        ns60:JVR191023 ;
    ns0:fullName "Fong Chan" ;
    ns0:hasAffiliation ns83:JVR191055 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191055 ;
    ns0:inAuthorList ns150:JVR191055 .

ns12:KCA180049 owl:sameAs ns118:BLC160053 ;
    ns0:fullName "Catherine M. Tangen" ;
    ns0:hasAffiliation ns14:KCA180049 ;
    ns0:hasArticle ns1:kca-v3-i2-KCA180049 ;
    ns0:inAuthorList ns150:KCA180049 .

ns12:KCA190056 owl:sameAs ns12:KCA170019 ;
    ns0:fullName "Cristiane D. Bergerot" ;
    ns0:hasAffiliation ns15:KCA190056 ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190056 ;
    ns0:inAuthorList ns150:KCA190056 .

ns12:KCA190059 owl:sameAs ns130:KCA170010 ;
    ns0:fullName "Daniel J. George" ;
    ns0:hasAffiliation ns15:KCA190059 ;
    ns0:hasArticle ns1:kca-v3-i2-KCA190059 ;
    ns0:inAuthorList ns150:KCA190059 .

ns12:KES190402 owl:sameAs ns8:IDT180346 ;
    ns0:fullName "Alok Kumar Jagadev" ;
    ns0:hasAffiliation ns14:KES190402 ;
    ns0:hasArticle ns1:kes-v23-i2-KES190402 ;
    ns0:inAuthorList ns150:KES190402 .

ns12:KES190403 owl:sameAs ns12:KES190407 ;
    ns0:fullName "Nilambar Sethi" ;
    ns0:hasAffiliation ns83:KES190403 ;
    ns0:hasArticle ns1:kes-v23-i2-KES190403 ;
    ns0:inAuthorList ns150:KES190403 .

ns12:KES190409 owl:sameAs ns8:IFS169934 ;
    ns0:fullName "M.M. Sufyan Beg" ;
    ns0:hasAffiliation ns14:KES190409 ;
    ns0:hasArticle ns1:kes-v23-i3-KES190409 ;
    ns0:inAuthorList ns150:KES190409 .

ns12:MAS190464 owl:sameAs ns2:MAS180455 ;
    ns0:fullName "Gauss M. Cordeiro" ;
    ns0:hasAffiliation ns83:MAS190464 ;
    ns0:hasArticle ns1:mas-v14-i3-MAS190464 ;
    ns0:inAuthorList ns150:MAS190464 .

ns12:MGC180751 owl:sameAs ns2:MGC180 ;
    ns0:fullName "Ayman Gouda" ;
    ns0:hasAffiliation ns15:MGC180751,
        ns83:MGC180751 ;
    ns0:hasArticle ns1:mgc-v18-i4-MGC180751 ;
    ns0:inAuthorList ns150:MGC180751 .

ns12:MGS190307 owl:sameAs ns12:MGS267 ;
    ns0:fullName "Mourad Badri" ;
    ns0:hasAffiliation ns14:MGS190307 ;
    ns0:hasArticle ns1:mgs-v15-i2-MGS190307 ;
    ns0:inAuthorList ns150:MGS190307 .

ns12:NHA180056 owl:sameAs ns16:NHA1615 ;
    ns0:fullName "Laurie T. Butler" ;
    ns0:hasAffiliation ns14:NHA180056 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA180056 ;
    ns0:inAuthorList ns150:NHA180056 .

ns12:NHA190068 owl:sameAs ns30:NHA170023 ;
    ns0:fullName "Amar Dodda" ;
    ns0:hasAffiliation ns15:NHA190068 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA190068 ;
    ns0:inAuthorList ns150:NHA190068 .

ns12:NPM180140 owl:sameAs ns30:NPM1786 ;
    ns0:fullName "M.B. Landon" ;
    ns0:hasAffiliation ns15:NPM180140 ;
    ns0:hasArticle ns1:npm-v12-i3-NPM180140 ;
    ns0:inAuthorList ns150:NPM180140 .

ns12:NPM1813 owl:sameAs ns2:NPM1792 ;
    ns0:fullName "S.M. Donn" ;
    ns0:hasAffiliation ns15:NPM1813 ;
    ns0:hasArticle ns1:npm-v12-i2-NPM1813 ;
    ns0:inAuthorList ns150:NPM1813 .

ns12:NPM1814 owl:sameAs ns8:NPM16112,
        ns16:NPM1741 ;
    ns0:fullName "J. Gilliland" ;
    ns0:hasAffiliation ns14:NPM1814,
        ns83:NPM1814,
        ns13:NPM1814,
        ns138:NPM1814,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:2.ID:NPM1814>,
        ns112:NPM1814,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:2.ID:NPM1814> ;
    ns0:hasArticle ns1:npm-v12-i2-NPM1814 ;
    ns0:inAuthorList ns150:NPM1814 .

ns12:NRE182671 owl:sameAs ns8:NRE1420,
        ns12:WOR182813,
        ns12:bmr00447,
        ns52:WOR2762 ;
    ns0:fullName "Noureddin Nakhostin Ansari" ;
    ns0:hasAffiliation ns15:NRE182671,
        ns83:NRE182671 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182671 ;
    ns0:inAuthorList ns150:NRE182671 .

ns12:NRE192687 owl:sameAs ns5:NRE182446 ;
    ns0:fullName "Liselot Thijs" ;
    ns0:hasAffiliation ns15:NRE192687 ;
    ns0:hasArticle ns1:nre-v44-i4-NRE192687 ;
    ns0:inAuthorList ns150:NRE192687 .

ns12:NRE192698 owl:sameAs ns57:JAD170964,
        ns60:JAD160273 ;
    ns0:fullName "Bernhard Heimbach" ;
    ns0:hasAffiliation ns15:NRE192698 ;
    ns0:hasArticle ns1:nre-v44-i4-NRE192698 ;
    ns0:inAuthorList ns150:NRE192698 .

ns12:NRE192725 owl:sameAs ns52:NRE1428 ;
    ns0:fullName "James B. Schreiber" ;
    ns0:hasAffiliation ns83:NRE192725 ;
    ns0:hasArticle ns1:nre-v45-i1-NRE192725 ;
    ns0:inAuthorList ns150:NRE192725 .

ns12:NRE192748 owl:sameAs ns12:NRE182471 ;
    ns0:fullName "Khalid El-Salem" ;
    ns0:hasAffiliation ns14:NRE192748 ;
    ns0:hasArticle ns1:nre-v45-i1-NRE192748 ;
    ns0:inAuthorList ns150:NRE192748 .

ns12:NRE192762 owl:sameAs ns30:VES586 ;
    ns0:fullName "Lorenzo Priano" ;
    ns0:hasAffiliation ns83:NRE192762,
        ns13:NRE192762 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192762 ;
    ns0:inAuthorList ns150:NRE192762 .

ns12:NRE192771 owl:sameAs ns12:NRE192700 ;
    ns0:fullName "Luan Santos" ;
    ns0:hasAffiliation ns14:NRE192771 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192771 ;
    ns0:inAuthorList ns150:NRE192771 .

ns12:NRE192788 owl:sameAs ns12:JPD181516 ;
    ns0:fullName "G. Moyle" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:2.ID:NRE192788> ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192788 ;
    ns0:inAuthorList ns150:NRE192788 .

ns12:PRM190611 owl:sameAs ns8:PRM160428 ;
    ns0:fullName "Jessica Keim-Malpass" ;
    ns0:hasAffiliation ns83:PRM190611 ;
    ns0:hasArticle ns1:prm-v12-i3-PRM190611 ;
    ns0:inAuthorList ns150:PRM190611 .

ns12:RNN190908 owl:sameAs ns5:RNN150563 ;
    ns0:fullName "Catherine Mercier" ;
    ns0:hasAffiliation ns14:RNN190908 ;
    ns0:hasArticle ns1:rnn-v37-i4-RNN190908 ;
    ns0:inAuthorList ns150:RNN190908 .

ns12:RNN190910 owl:sameAs ns8:RNN160661 ;
    ns0:fullName "M.A. Pessina" ;
    ns0:hasAffiliation ns15:RNN190910 ;
    ns0:hasArticle ns1:rnn-v37-i4-RNN190910 ;
    ns0:inAuthorList ns150:RNN190910 .

ns12:RNN190919 owl:sameAs ns8:RNN170767,
        ns30:RNN180812 ;
    ns0:fullName "Jane B. Allendorfer" ;
    ns0:hasAffiliation ns15:RNN190919 ;
    ns0:hasArticle ns1:rnn-v37-i5-RNN190919 ;
    ns0:inAuthorList ns150:RNN190919 .

ns12:RNN190924 owl:sameAs ns12:NRE182683 ;
    ns0:fullName "Tanvi Bhatt" ;
    ns0:hasAffiliation ns15:RNN190924 ;
    ns0:hasArticle ns1:rnn-v37-i5-RNN190924 ;
    ns0:inAuthorList ns150:RNN190924 .

ns12:SW190359 owl:sameAs ns12:AIC746 ;
    ns0:fullName "Viktor K. Prasanna" ;
    ns0:hasAffiliation ns73:SW190359 ;
    ns0:hasArticle ns1:sw-v10-i6-SW190359 ;
    ns0:inAuthorList ns150:SW190359 .

ns12:SW190369 owl:sameAs ns8:ida00647 ;
    ns0:fullName "Behrouz Minaei-Bidgoli" ;
    ns0:hasAffiliation ns73:SW190369 ;
    ns0:hasArticle ns1:sw-v10-i6-SW190369 ;
    ns0:inAuthorList ns150:SW190369 .

ns12:TAD180217 owl:sameAs ns2:tad00068,
        ns16:AIS385 ;
    ns0:fullName "Alex Mihailidis" ;
    ns0:hasAffiliation ns83:TAD180217 ;
    ns0:hasArticle ns1:tad-v31-i1-2-TAD180217 ;
    ns0:inAuthorList ns150:TAD180217 .

ns12:THC199009 owl:sameAs ns30:BME1486 ;
    ns0:fullName "Hua Chai" ;
    ns0:hasAffiliation ns15:THC199009 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199009 ;
    ns0:inAuthorList ns150:THC199009 .

ns12:VES190651 owl:sameAs ns52:VES619 ;
    ns0:fullName "C.C. Della Santina" ;
    ns0:hasAffiliation ns15:VES190651 ;
    ns0:hasArticle ns1:ves-v29-i2-3-VES190651 ;
    ns0:inAuthorList ns150:VES190651 .

ns12:WOR192938 owl:sameAs ns8:WOR192968,
        ns30:WOR2661 ;
    ns0:fullName "Shaun O’Leary" ;
    ns0:hasAffiliation ns15:WOR192938,
        ns14:WOR192938 ;
    ns0:hasArticle ns1:wor-v63-i3-WOR192938 ;
    ns0:inAuthorList ns150:WOR192938 .

ns12:WOR192952 owl:sameAs ns12:WOR192957 ;
    ns0:fullName "Norman Gledhill" ;
    ns0:hasAffiliation ns15:WOR192952 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192952 ;
    ns0:inAuthorList ns150:WOR192952 .

ns12:WOR192975 owl:sameAs ns30:WOR2617 ;
    ns0:fullName "Stefan Staubli" ;
    ns0:hasAffiliation ns83:WOR192975 ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192975 ;
    ns0:inAuthorList ns150:WOR192975 .

ns12:WOR192976 owl:sameAs ns2:thc00776 ;
    ns0:fullName "Maria Johansson" ;
    ns0:hasAffiliation ns15:WOR192976 ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192976 ;
    ns0:inAuthorList ns150:WOR192976 .

ns12:WOR192984 owl:sameAs ns8:PPR072,
        ns12:WOR2685 ;
    ns0:fullName "Mohsen Razeghi" ;
    ns0:hasAffiliation ns83:WOR192984 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192984 ;
    ns0:inAuthorList ns150:WOR192984 .

ns12:WOR192988 owl:sameAs ns2:WOR2010 ;
    ns0:fullName "Matilde A. Rodrigues" ;
    ns0:hasAffiliation ns15:WOR192988,
        ns83:WOR192988 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192988 ;
    ns0:inAuthorList ns150:WOR192988 .

ns12:WOR192989 owl:sameAs ns57:BMR640 ;
    ns0:fullName "Joy MacDermid" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:2.ID:WOR192989> ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192989 ;
    ns0:inAuthorList ns150:WOR192989 .

ns12:WOR192998 owl:sameAs ns30:WOR2589 ;
    ns0:fullName "Lars Peter Andersen" ;
    ns0:hasAffiliation ns15:WOR192998 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192998 ;
    ns0:inAuthorList ns150:WOR192998 .

ns12:WOR193008 owl:sameAs ns33:WOR1973 ;
    ns0:fullName "Abraham Rudnick" ;
    ns0:hasAffiliation ns83:WOR193008 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193008 ;
    ns0:inAuthorList ns150:WOR193008 .

ns12:WOR193022 owl:sameAs ns8:WOR2184 ;
    ns0:fullName "Wen-Ko Chiou" ;
    ns0:hasAffiliation ns83:WOR193022 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193022 ;
    ns0:inAuthorList ns150:WOR193022 .

ns12:XST180477 owl:sameAs ns16:XST190506 ;
    ns0:fullName "Qiyang Zhang" ;
    ns0:hasAffiliation ns15:XST180477 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180477 ;
    ns0:inAuthorList ns150:XST180477 .

ns12:XST180486 owl:sameAs ns8:XST180391 ;
    ns0:fullName "Xiaoyi Duan" ;
    ns0:hasAffiliation ns15:XST180486 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180486 ;
    ns0:inAuthorList ns150:XST180486 .

ns12:XST180488 owl:sameAs ns2:XST18377 ;
    ns0:fullName "You-Gen Cheng" ;
    ns0:hasAffiliation ns15:XST180488 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180488 ;
    ns0:inAuthorList ns150:XST180488 .

ns12:XST190491 owl:sameAs ns30:XST17366 ;
    ns0:fullName "S.M. Dom" ;
    ns0:hasAffiliation ns83:XST190491 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190491 ;
    ns0:inAuthorList ns150:XST190491 .

ns12:XST190527 owl:sameAs ns8:XST579 ;
    ns0:fullName "Qiegen Liu" ;
    ns0:hasAffiliation ns83:XST190527 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190527 ;
    ns0:inAuthorList ns150:XST190527 .

ns12:XST190533 owl:sameAs ns12:XST190548 ;
    ns0:fullName "Lin Han" ;
    ns0:hasAffiliation ns15:XST190533 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190533 ;
    ns0:inAuthorList ns150:XST190533 .

ns12:ajw190048 owl:sameAs ns12:MNM180263 ;
    ns0:fullName "Syed Hafizur Rahman" ;
    ns0:hasAffiliation ns15:ajw190048 ;
    ns0:hasArticle ns1:ajw-v16-i4-ajw190048 ;
    ns0:inAuthorList ns150:ajw190048 .

ns12:ajw190055 owl:sameAs ns8:IDT180349 ;
    ns0:fullName "Deepti Mehrotra" ;
    ns0:hasAffiliation ns15:ajw190055 ;
    ns0:hasArticle ns1:ajw-v16-i4-ajw190055 ;
    ns0:inAuthorList ns150:ajw190055 .

ns176:JAD190334 owl:sameAs ns52:JAD180645,
        ns60:JAD170583 ;
    ns0:fullName "Tuomas Rauramaa" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:20.ID:JAD190334>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:20.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns176:JAD190399 owl:sameAs ns180:JAD160108,
        ns5:JAD160762 ;
    ns0:fullName "Ki Woong Kim" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:20.ID:JAD190399>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:20.ID:JAD190399>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff17.Author:20.ID:JAD190399>,
        ns246:JAD190399 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns176:JAD190644 owl:sameAs ns5:JAD143084 ;
    ns0:fullName "Kentaro Deguchi" ;
    ns0:hasAffiliation ns177:JAD190644 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns139:JAD180572 owl:sameAs ns5:JAD120169,
        ns5:JAD150537 ;
    ns0:fullName "Nicole A. Kochan" ;
    ns0:hasAffiliation ns235:JAD180572 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180572 ;
    ns0:inAuthorList ns150:JAD180572 .

ns139:JAD190334 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160554>,
        ns33:JAD150909 ;
    ns0:fullName "Ville Leinonen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:21.ID:JAD190334>,
        ns140:JAD190334,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:21.ID:JAD190334>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:21.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns139:JAD190446 owl:sameAs ns2:JAD141521 ;
    ns0:fullName "Alfredo Ramirez" ;
    ns0:hasAffiliation ns179:JAD190446 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns180:JAD190644 owl:sameAs ns12:JBR152 ;
    ns0:fullName "Toshikazu Yoshikawa" ;
    ns0:hasAffiliation ns181:JAD190644 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns141:JAD190446 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD180106> ;
    ns0:fullName "Eike J. Spruth" ;
    ns0:hasAffiliation ns182:JAD190446 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

<http://ld.iospress.nl/rdf/contributor/Author:26.ID:JAD190446> owl:sameAs ns132:JAD160209,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD180981>,
        ns12:JAD160407,
        <http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD180106>,
        ns30:JAD180949,
        ns16:JAD160637,
        ns60:JAD171088 ;
    ns0:fullName "Michael Wagner" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:26.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:26.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns143:JAD190446 owl:sameAs ns12:JAD170639,
        ns176:JAD150257,
        ns180:JAD180321,
        ns5:JAD110329,
        ns5:JAD111796,
        <http://ld.iospress.nl/rdf/contributor/Author:52.ID:JAD110824>,
        ns52:JAD101551,
        ns52:JAD150394,
        ns60:JAD160398,
        ns60:JAD161252 ;
    ns0:fullName "Jens Wiltfang" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:27.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:27.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns183:JAD180572 owl:sameAs ns30:JPD150581,
        ns30:JPD160823 ;
    ns0:fullName "Courtney C. Walton" ;
    ns0:hasAffiliation ns185:JAD180572,
        ns184:JAD180572 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180572 ;
    ns0:inAuthorList ns150:JAD180572 .

ns183:JAD190446 owl:sameAs ns2:JAD160407,
        ns2:JAD161252,
        ns8:JAD141521,
        ns12:JAD142322,
        ns30:JAD160637 ;
    ns0:fullName "Steffen Wolfsgruber" ;
    ns0:hasAffiliation ns184:JAD190446 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns30:ADR190132 owl:sameAs ns26:JAD160408,
        ns5:JAD121945,
        ns57:JAD150394,
        ns60:JAD131373 ;
    ns0:fullName "Thomas A. Bayer" ;
    ns0:hasAffiliation ns252:ADR190132 ;
    ns0:hasArticle ns1:adr-v3-i1-ADR190132 ;
    ns0:inAuthorList ns150:ADR190132 .

ns30:ADR190135 owl:sameAs ns30:ADR180091 ;
    ns0:fullName "Mas R.W. Abdul Hamid" ;
    ns0:hasAffiliation ns252:ADR190135 ;
    ns0:hasArticle ns1:adr-v3-i1-ADR190135 ;
    ns0:inAuthorList ns150:ADR190135 .

ns30:AIC190615 owl:sameAs ns8:mgs00202,
        ns12:AAC013,
        ns30:913075,
        ns30:AAC181002 ;
    ns0:fullName "Peter McBurney" ;
    ns0:hasAffiliation ns117:AIC190615 ;
    ns0:hasArticle ns1:aic-v32-i4-AIC190615 ;
    ns0:inAuthorList ns150:AIC190615 .

ns30:AOP051 owl:sameAs ns8:AOP047 ;
    ns0:fullName "Josip Stjepandić" ;
    ns0:hasAffiliation ns252:AOP051 ;
    ns0:hasArticle <http://ld.iospress.nl/rdf/artifact/aop-v3-i3,4-AOP051> ;
    ns0:inAuthorList ns150:AOP051 .

ns30:BD180365 owl:sameAs ns30:BD402 ;
    ns0:fullName "Jonas Amstrup Funder" ;
    ns0:hasAffiliation ns31:BD180365 ;
    ns0:hasArticle ns1:bd-v38-i2-BD180365 ;
    ns0:inAuthorList ns150:BD180365 .

ns30:BLC190218 owl:sameAs ns2:BLC180167 ;
    ns0:fullName "Tahlita C.M. Zuiverloon" ;
    ns0:hasAffiliation ns252:BLC190218,
        ns64:BLC190218 ;
    ns0:hasArticle ns1:blc-v5-i2-BLC190218 ;
    ns0:inAuthorList ns150:BLC190218 .

ns30:BME191060 owl:sameAs ns16:BME1571,
        ns16:BME1651,
        ns16:BME1709 ;
    ns0:fullName "Akiko Nagai" ;
    ns0:hasAffiliation ns63:BME191060 ;
    ns0:hasArticle ns1:bme-v30-i4-BME191060 ;
    ns0:inAuthorList ns150:BME191060 .

ns30:BMR171043 owl:sameAs ns2:CH170269,
        ns2:CH180382 ;
    ns0:fullName "René Schiffner" ;
    ns0:hasAffiliation ns252:BMR171043 ;
    ns0:hasArticle ns1:bmr-v32-i6-BMR171043 ;
    ns0:inAuthorList ns150:BMR171043 .

ns30:BMR181128 owl:sameAs ns5:BMR171041 ;
    ns0:fullName "Mohammad Saleh Ganjavian" ;
    ns0:hasAffiliation ns64:BMR181128 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181128 ;
    ns0:inAuthorList ns150:BMR181128 .

ns30:BMR181185 owl:sameAs ns12:BMR160543 ;
    ns0:fullName "Hemra Cil" ;
    ns0:hasAffiliation ns252:BMR181185 ;
    ns0:hasArticle ns1:bmr-v32-i5-BMR181185 ;
    ns0:inAuthorList ns150:BMR181185 .

ns30:BMR181289 owl:sameAs ns2:BMR735 ;
    ns0:fullName "Fariba Ghaderi" ;
    ns0:hasAffiliation ns252:BMR181289 ;
    ns0:hasArticle ns1:bmr-v32-i5-BMR181289 ;
    ns0:inAuthorList ns150:BMR181289 .

ns30:CBM182009 owl:sameAs ns8:CBM160512 ;
    ns0:fullName "Jiankai Xu" ;
    ns0:hasAffiliation ns63:CBM182009 ;
    ns0:hasArticle ns1:cbm-v26-i1-CBM182009 ;
    ns0:inAuthorList ns150:CBM182009 .

ns30:CBM182333 owl:sameAs ns12:cbm00432 ;
    ns0:fullName "Ying Xiang" ;
    ns0:hasAffiliation ns63:CBM182333 ;
    ns0:hasArticle ns1:cbm-v25-i4-CBM182333 ;
    ns0:inAuthorList ns150:CBM182333 .

ns30:CBM182383 owl:sameAs ns8:CBM181772 ;
    ns0:fullName "Foivos Lazaris" ;
    ns0:hasAffiliation ns31:CBM182383 ;
    ns0:hasArticle ns1:cbm-v25-i2-CBM182383 ;
    ns0:inAuthorList ns150:CBM182383 .

ns30:CBM190161 owl:sameAs ns30:cbm00178 ;
    ns0:fullName "Sanford A. Stass" ;
    ns0:hasAffiliation ns252:CBM190161 ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM190161 ;
    ns0:inAuthorList ns150:CBM190161 .

ns30:CBM192435 owl:sameAs ns5:CBM171099 ;
    ns0:fullName "Fei Yuan" ;
    ns0:hasAffiliation ns63:CBM192435 ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM192435 ;
    ns0:inAuthorList ns150:CBM192435 .

ns30:CH180402 owl:sameAs ns30:BIR180175 ;
    ns0:fullName "Halil Korkmaz" ;
    ns0:hasAffiliation ns64:CH180402 ;
    ns0:hasArticle ns1:ch-v71-i4-CH180402 ;
    ns0:inAuthorList ns150:CH180402 .

ns30:CH180404 owl:sameAs ns52:CH170252,
        ns57:CH170253 ;
    ns0:fullName "Bo-Ji Liu" ;
    ns0:hasAffiliation ns31:CH180404,
        ns64:CH180404 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180404 ;
    ns0:inAuthorList ns150:CH180404 .

ns30:CH180450 owl:sameAs ns2:CH180544 ;
    ns0:fullName "Ingo Ludolph" ;
    ns0:hasAffiliation ns252:CH180450 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180450 ;
    ns0:inAuthorList ns150:CH180450 .

ns30:CH180470 owl:sameAs ns12:CH160241 ;
    ns0:fullName "Aneta Bac" ;
    ns0:hasAffiliation ns252:CH180470 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180470 ;
    ns0:inAuthorList ns150:CH180470 .

ns30:CH180545 owl:sameAs ns30:CH180457 ;
    ns0:fullName "Ping Cheng" ;
    ns0:hasAffiliation ns252:CH180545 ;
    ns0:hasArticle ns1:ch-v72-i3-CH180545 ;
    ns0:inAuthorList ns150:CH180545 .

ns30:CH199009 owl:sameAs ns60:CH199219 ;
    ns0:fullName "C. Mrowietz" ;
    ns0:hasAffiliation ns63:CH199009 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199009 ;
    ns0:inAuthorList ns150:CH199009 .

ns30:CH199206 owl:sameAs ns30:CH199205 ;
    ns0:fullName "Xun Xu" ;
    ns0:hasAffiliation ns252:CH199206 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199206 ;
    ns0:inAuthorList ns150:CH199206 .

ns30:CH199209 owl:sameAs ns12:CH179203,
        ns5:JCB179006,
        ns52:JCB179013 ;
    ns0:fullName "Folker Wenzel" ;
    ns0:hasAffiliation ns252:CH199209 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199209 ;
    ns0:inAuthorList ns150:CH199209 .

ns30:CH199212 owl:sameAs ns12:CH189319,
        ns5:CH179202 ;
    ns0:fullName "Vanessa Brébant" ;
    ns0:hasAffiliation ns64:CH199212 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199212 ;
    ns0:inAuthorList ns150:CH199212 .

ns30:CH199219 owl:sameAs ns12:JCB179010 ;
    ns0:fullName "C. Gruber" ;
    ns0:hasAffiliation ns252:CH199219 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199219 ;
    ns0:inAuthorList ns150:CH199219 .

ns30:CH199221 owl:sameAs ns16:CH179225,
        ns52:CH179220 ;
    ns0:fullName "E.M. Jung" ;
    ns0:hasAffiliation ns252:CH199221 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199221 ;
    ns0:inAuthorList ns150:CH199221 .

ns30:CH199222 owl:sameAs ns30:CH168039,
        ns30:CH168052,
        ns30:CH189123,
        ns5:CH168115,
        ns5:CH189407,
        ns57:CH199223 ;
    ns0:fullName "C.G. Stief" ;
    ns0:hasAffiliation ns252:CH199222 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199222 ;
    ns0:inAuthorList ns150:CH199222 .

ns30:CH199224 owl:sameAs ns30:CH180449 ;
    ns0:fullName "Andreas Schicho" ;
    ns0:hasAffiliation ns252:CH199224 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199224 ;
    ns0:inAuthorList ns150:CH199224 .

ns30:CH199225 owl:sameAs ns2:CH179216 ;
    ns0:fullName "Marco Ranieri" ;
    ns0:hasAffiliation ns252:CH199225 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199225 ;
    ns0:inAuthorList ns150:CH199225 .

ns30:DEV180249 owl:sameAs ns2:DEV189002,
        ns8:DEV189003 ;
    ns0:fullName "Panayiotis Stavrinides" ;
    ns0:hasAffiliation ns252:DEV180249 ;
    ns0:hasArticle ns1:dev-v13-i1-2-DEV180249 ;
    ns0:inAuthorList ns150:DEV180249 .

ns30:DS190019 owl:sameAs ns12:DS190015,
        ns12:SW151,
        ns12:SW266 ;
    ns0:fullName "Enrico Motta" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affd.Author:3.ID:DS190019> ;
    ns0:hasArticle ns1:ds-v2-i1-2-DS190019 ;
    ns0:inAuthorList ns150:DS190019 .

ns30:FI1831 owl:sameAs ns12:idt00132,
        ns5:idt00105 ;
    ns0:fullName "Andrzej Czyzewski" ;
    ns0:hasAffiliation ns252:FI1831 ;
    ns0:hasArticle ns1:fi-v168-i2-4-FI1831 ;
    ns0:inAuthorList ns150:FI1831 .

ns30:FI1870 owl:sameAs ns30:IA102,
        ns16:IA110 ;
    ns0:fullName "Katsuhiro Nishinari" ;
    ns0:hasAffiliation ns31:FI1870 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1870 ;
    ns0:inAuthorList ns150:FI1870 .

ns30:FI1878 owl:sameAs ns30:FI1565 ;
    ns0:fullName "Antonio E. Porreca" ;
    ns0:hasAffiliation ns31:FI1878 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1878 ;
    ns0:inAuthorList ns150:FI1878 .

ns30:HAB190367 owl:sameAs ns2:HAB304,
        ns30:HAB190363,
        ns30:HAB190369 ;
    ns0:fullName "Tadesse Bekele Tafesse" ;
    ns0:hasAffiliation ns84:HAB190367 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190367 ;
    ns0:inAuthorList ns150:HAB190367 .

ns30:HAB190371 owl:sameAs ns12:HAB190364 ;
    ns0:fullName "Mohammed Assen" ;
    ns0:hasAffiliation ns63:HAB190371 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190371 ;
    ns0:inAuthorList ns150:HAB190371 .

ns30:HAB190374 owl:sameAs ns12:BD248,
        ns5:HAB299 ;
    ns0:fullName "Zahra Noroozi" ;
    ns0:hasAffiliation ns252:HAB190374 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190374 ;
    ns0:inAuthorList ns150:HAB190374 .

ns30:HAB190375 owl:sameAs ns2:HAB190386,
        ns40:HAB282 ;
    ns0:fullName "T.C. Adias" ;
    ns0:hasAffiliation ns252:HAB190375 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190375 ;
    ns0:inAuthorList ns150:HAB190375 .

ns30:HSM180397 owl:sameAs ns2:HSM17118,
        ns12:HSM17251,
        ns30:HSM180405,
        ns16:HSM17166 ;
    ns0:fullName "Shafaq Salam" ;
    ns0:hasAffiliation ns252:HSM180397 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180397 ;
    ns0:inAuthorList ns150:HSM180397 .

ns30:HSM190490 owl:sameAs ns2:HSM1768,
        ns12:HSM17133,
        ns12:HSM1794,
        ns5:HSM17100 ;
    ns0:fullName "Zubair Akram" ;
    ns0:hasAffiliation ns31:HSM190490 ;
    ns0:hasArticle ns1:hsm-v38-i4-HSM190490 ;
    ns0:inAuthorList ns150:HSM190490 .

ns30:ICA190603 owl:sameAs ns8:ICA00047,
        ns12:ica00404,
        ns30:ica00441 ;
    ns0:fullName "José María Armingol" ;
    ns0:hasAffiliation ns252:ICA190603 ;
    ns0:hasArticle ns1:ica-v26-i4-ICA190603 ;
    ns0:inAuthorList ns150:ICA190603 .

ns30:ICA190605 owl:sameAs ns16:FI1507 ;
    ns0:fullName "Bin Liu" ;
    ns0:hasAffiliation ns84:ICA190605 ;
    ns0:hasArticle ns1:ica-v26-i4-ICA190605 ;
    ns0:inAuthorList ns150:ICA190605 .

ns30:IDA184239 owl:sameAs ns2:ida00034,
        ns2:ida00234,
        ns2:ida00270,
        ns2:ida00326,
        ns2:ida00372,
        <http://ld.iospress.nl/rdf/contributor/Author:1.ID:IDA1(4)05>,
        ns8:ida00166,
        ns8:ida00355,
        ns8:ida00377 ;
    ns0:fullName "João Gama" ;
    ns0:hasAffiliation ns31:IDA184239 ;
    ns0:hasArticle ns1:ida-v23-i6-IDA184239 ;
    ns0:inAuthorList ns150:IDA184239 .

ns30:IDA192847 owl:sameAs ns12:JHS580 ;
    ns0:fullName "He Xu" ;
    ns0:hasAffiliation ns252:IDA192847 ;
    ns0:hasArticle ns1:ida-v23-iS1-IDA192847 ;
    ns0:inAuthorList ns150:IDA192847 .

ns30:IES182206 owl:sameAs ns2:BMR181215,
        ns2:CH16194 ;
    ns0:fullName "Steffen Mueller" ;
    ns0:hasAffiliation ns31:IES182206 ;
    ns0:hasArticle ns1:ies-v27-i3-IES182206 ;
    ns0:inAuthorList ns150:IES182206 .

ns30:IES183210 owl:sameAs ns12:IES173142 ;
    ns0:fullName "Arnaldo Luis Mortatti" ;
    ns0:hasAffiliation ns252:IES183210 ;
    ns0:hasArticle ns1:ies-v27-i3-IES183210 ;
    ns0:inAuthorList ns150:IES183210 .

ns30:IES192167 owl:sameAs ns5:IES192150 ;
    ns0:fullName "Hironori Fujishita" ;
    ns0:hasAffiliation ns31:IES192167 ;
    ns0:hasArticle ns1:ies-v27-i4-IES192167 ;
    ns0:inAuthorList ns150:IES192167 .

ns30:IFS171049 owl:sameAs ns12:IFS181941,
        ns30:IFS182919 ;
    ns0:fullName "M. Aslam" ;
    ns0:hasAffiliation ns64:IFS171049 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS171049 ;
    ns0:inAuthorList ns150:IFS171049 .

ns30:IFS179078 owl:sameAs ns2:IFS169982 ;
    ns0:fullName "K.C. Ramya" ;
    ns0:hasAffiliation ns63:IFS179078 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS179078 ;
    ns0:inAuthorList ns150:IFS179078 .

ns30:IFS179155 owl:sameAs ns2:IFS17348,
        ns8:IFS179057,
        ns8:IFS179121,
        ns5:IFS179095 ;
    ns0:fullName "Mohamed Elhoseny" ;
    ns0:hasAffiliation ns63:IFS179155 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS179155 ;
    ns0:inAuthorList ns150:IFS179155 .

ns30:IFS179211 owl:sameAs ns12:INF1100 ;
    ns0:fullName "Shuai Ding" ;
    ns0:hasAffiliation ns252:IFS179211 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS179211 ;
    ns0:inAuthorList ns150:IFS179211 .

ns30:IFS179252 owl:sameAs ns2:IFS169572,
        ns5:IFS169572 ;
    ns0:fullName "KuokKwee Wee" ;
    ns0:hasAffiliation ns252:IFS179252 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179252 ;
    ns0:inAuthorList ns150:IFS179252 .

ns30:IFS179300 owl:sameAs ns8:IFS169415 ;
    ns0:fullName "Zhanfang Chen" ;
    ns0:hasAffiliation ns31:IFS179300 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179300 ;
    ns0:inAuthorList ns150:IFS179300 .

ns30:IFS181246 owl:sameAs ns2:IFS17938 ;
    ns0:fullName "Lixiang Duan" ;
    ns0:hasAffiliation ns31:IFS181246 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181246 ;
    ns0:inAuthorList ns150:IFS181246 .

ns30:IFS181293 owl:sameAs ns8:IFS151050,
        ns8:IFS1682 ;
    ns0:fullName "B. Vahdani" ;
    ns0:hasAffiliation ns64:IFS181293 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181293 ;
    ns0:inAuthorList ns150:IFS181293 .

ns30:IFS181516 owl:sameAs ns2:IFS181329,
        ns2:JIN092 ;
    ns0:fullName "Muhammad Shakeel" ;
    ns0:hasAffiliation ns252:IFS181516 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181516 ;
    ns0:inAuthorList ns150:IFS181516 .

ns30:IFS181538 owl:sameAs ns2:IFS141877,
        ns8:IFS17169,
        ns8:IFS181172,
        ns8:IFS181401,
        ns8:IFS182651,
        ns8:IFS182700,
        ns8:IFS18730,
        ns8:IFS18979,
        ns8:INF1223,
        ns12:IFS181255,
        ns12:IFS181322,
        ns16:IFS16727 ;
    ns0:fullName "Cengiz Kahraman" ;
    ns0:hasAffiliation ns252:IFS181538 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181538 ;
    ns0:inAuthorList ns150:IFS181538 .

ns30:IFS181604 owl:sameAs ns5:IFS161152 ;
    ns0:fullName "José Alberto Silva de Sá" ;
    ns0:hasAffiliation ns64:IFS181604 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181604 ;
    ns0:inAuthorList ns150:IFS181604 .

ns30:IFS181633 owl:sameAs ns8:IFS169963 ;
    ns0:fullName "K.S. Ravichandran" ;
    ns0:hasAffiliation ns252:IFS181633 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181633 ;
    ns0:inAuthorList ns150:IFS181633 .

ns30:IFS181769 owl:sameAs ns30:IFS18647,
        ns5:IFS172203 ;
    ns0:fullName "Sheng-Quan Ma" ;
    ns0:hasAffiliation ns63:IFS181769 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181769 ;
    ns0:inAuthorList ns150:IFS181769 .

ns30:IFS181799 owl:sameAs ns30:IFS18169 ;
    ns0:fullName "Yawei Ge" ;
    ns0:hasAffiliation ns252:IFS181799 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181799 ;
    ns0:inAuthorList ns150:IFS181799 .

ns30:IFS181982 owl:sameAs ns12:IFS16117 ;
    ns0:fullName "Dongshuang Hou" ;
    ns0:hasAffiliation ns252:IFS181982 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181982 ;
    ns0:inAuthorList ns150:IFS181982 .

ns30:IFS182581 owl:sameAs ns8:IFS181171 ;
    ns0:fullName "Kaiyuan Bai" ;
    ns0:hasAffiliation ns31:IFS182581 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182581 ;
    ns0:inAuthorList ns150:IFS182581 .

ns30:IFS182615 owl:sameAs ns12:IFS161916,
        ns12:IFS2149 ;
    ns0:fullName "Mohammad Mohammadi" ;
    ns0:hasAffiliation ns252:IFS182615 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182615 ;
    ns0:inAuthorList ns150:IFS182615 .

ns30:IFS182673 owl:sameAs ns2:FI1755,
        ns8:IFS18040,
        ns12:IFS190217,
        ns30:IFS190711 ;
    ns0:fullName "Harish Garg" ;
    ns0:hasAffiliation ns64:IFS182673 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182673 ;
    ns0:inAuthorList ns150:IFS182673 .

ns30:IFS182746 owl:sameAs ns30:IFS169212,
        ns30:IFS171717,
        ns16:IFS18347 ;
    ns0:fullName "Anita Pal" ;
    ns0:hasAffiliation ns252:IFS182746 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182746 ;
    ns0:inAuthorList ns150:IFS182746 .

ns30:IFS182798 owl:sameAs ns2:IFS17063,
        ns2:IFS2115 ;
    ns0:fullName "Dong Qiu" ;
    ns0:hasAffiliation ns252:IFS182798 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182798 ;
    ns0:inAuthorList ns150:IFS182798 .

ns30:IFS190067 owl:sameAs ns30:IFS172005,
        ns30:IFS181519 ;
    ns0:fullName "Farhad Hoseinzadeh Lotfi" ;
    ns0:hasAffiliation ns252:IFS190067 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS190067 ;
    ns0:inAuthorList ns150:IFS190067 .

ns30:IFS190447 owl:sameAs ns5:IFS191197 ;
    ns0:fullName "Choonkil Park" ;
    ns0:hasAffiliation ns63:IFS190447 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190447 ;
    ns0:inAuthorList ns150:IFS190447 .

ns30:JAD180492 owl:sameAs ns8:JAD131892,
        ns8:JAD141305,
        ns40:JAD170564,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181095>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160474>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160766>,
        ns43:JAD160126,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD151120>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD161208>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD170039>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:jad00971>,
        ns12:JAD110797,
        ns12:JAD170859,
        ns12:JAD180676,
        ns12:JAD180857,
        ns176:JAD180275,
        ns139:JAD180531,
        ns30:JAD190541,
        ns5:JAD111400,
        ns5:JAD131232,
        ns5:JAD180513,
        ns5:jad01091,
        ns16:JAD140138,
        ns52:JAD102043,
        ns52:JAD130296,
        ns52:JAD170324,
        ns57:JAD121003,
        ns57:JAD141767 ;
    ns0:fullName "Frans Verhey" ;
    ns0:hasAffiliation ns252:JAD180492 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180492 ;
    ns0:inAuthorList ns150:JAD180492 .

ns30:JAD180496 owl:sameAs ns26:JAD170880,
        ns16:JAD102100,
        ns57:JAD160574,
        ns60:JAD142595,
        ns60:JAD181171,
        ns33:JAD131025,
        ns33:JAD140798,
        ns33:JAD160685,
        ns33:JAD170962 ;
    ns0:fullName "Ikuo Tooyama" ;
    ns0:hasAffiliation ns64:JAD180496 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180496 ;
    ns0:inAuthorList ns150:JAD180496 .

ns30:JAD180501 owl:sameAs ns2:JAD129006,
        ns2:JAD190448,
        ns2:jad01182,
        ns8:JAD091402,
        ns8:JAD141413,
        ns8:JAD190688,
        ns40:JAD170813,
        <http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD110824>,
        ns30:JAD110377,
        ns30:JAD140213,
        ns5:JAD171125,
        ns16:JAD111268,
        ns57:JAD170858,
        ns60:JAD132351,
        ns33:JAD110518 ;
    ns0:fullName "Carol Brayne" ;
    ns0:hasAffiliation ns31:JAD180501 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180501 ;
    ns0:inAuthorList ns150:JAD180501 .

ns30:JAD180521 owl:sameAs ns8:JAD160148,
        ns28:JAD161158,
        ns132:JAD171145,
        ns30:JAD131820,
        ns30:JAD180344,
        ns5:JAD131850,
        ns60:JAD161019,
        ns33:JAD141497 ;
    ns0:fullName "David Ames" ;
    ns0:hasAffiliation ns64:JAD180521 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180521 ;
    ns0:inAuthorList ns150:JAD180521 .

ns30:JAD180572 owl:sameAs ns12:JAD101977 ;
    ns0:fullName "Michael Valenzuela" ;
    ns0:hasAffiliation ns64:JAD180572,
        ns84:JAD180572 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180572 ;
    ns0:inAuthorList ns150:JAD180572 .

ns30:JAD180573 owl:sameAs ns12:JAD120169,
        ns52:JAD150537 ;
    ns0:fullName "Brian Draper" ;
    ns0:hasAffiliation ns31:JAD180573,
        ns64:JAD180573 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180573 ;
    ns0:inAuthorList ns150:JAD180573 .

ns30:JAD180634 owl:sameAs ns2:JAD160374,
        ns57:JAD170414 ;
    ns0:fullName "Sascha Dublin" ;
    ns0:hasAffiliation ns64:JAD180634 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180634 ;
    ns0:inAuthorList ns150:JAD180634 .

ns30:JAD180900 owl:sameAs ns5:JAD140393 ;
    ns0:fullName "Claire Shepherd" ;
    ns0:hasAffiliation ns31:JAD180900 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180900 ;
    ns0:inAuthorList ns150:JAD180900 .

ns30:JAD180932 owl:sameAs ns12:JPD150632 ;
    ns0:fullName "Jared Tanner" ;
    ns0:hasAffiliation ns252:JAD180932 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180932 ;
    ns0:inAuthorList ns150:JAD180932 .

ns30:JAD181037 owl:sameAs ns8:JAD181189,
        ns12:JAD181189,
        ns16:JAD171162 ;
    ns0:fullName "Annelie Nordin Adolfsson" ;
    ns0:hasAffiliation ns63:JAD181037 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD181037 ;
    ns0:inAuthorList ns150:JAD181037 .

ns30:JAD181132 owl:sameAs ns60:JAD180013 ;
    ns0:fullName "Elina Hyppönen" ;
    ns0:hasAffiliation ns252:JAD181132,
        ns63:JAD181132,
        ns84:JAD181132 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD181132 ;
    ns0:inAuthorList ns150:JAD181132 .

ns30:JAD181168 owl:sameAs ns30:JAD150827 ;
    ns0:fullName "Zhen Fan" ;
    ns0:hasAffiliation ns252:JAD181168 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181168 ;
    ns0:inAuthorList ns150:JAD181168 .

ns30:JAD181171 owl:sameAs ns2:JAD160685,
        ns12:JAD131025,
        ns12:JAD170880 ;
    ns0:fullName "Nor Faeizah Ibrahim" ;
    ns0:hasAffiliation ns31:JAD181171 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD181171 ;
    ns0:inAuthorList ns150:JAD181171 .

ns30:JAD181175 owl:sameAs ns5:JAD112111 ;
    ns0:fullName "Thomas Harris" ;
    ns0:hasAffiliation ns31:JAD181175 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD181175 ;
    ns0:inAuthorList ns150:JAD181175 .

ns30:JAD181268 owl:sameAs ns2:JAD160158,
        ns2:jad01245,
        ns8:JAD120676,
        ns8:jad01163,
        ns12:JAD120424,
        ns12:JAD121639,
        ns12:JAD170148,
        ns12:jad01185,
        ns16:JAD142085,
        ns57:JAD180092 ;
    ns0:fullName "Eric D. Vidoni" ;
    ns0:hasAffiliation ns31:JAD181268 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181268 ;
    ns0:inAuthorList ns150:JAD181268 .

ns30:JAD181282 owl:sameAs ns2:JAD110566,
        ns40:JAD151097,
        ns12:JAD121960,
        ns12:JAD122440,
        ns16:JAD141053 ;
    ns0:fullName "Maria Bjerke" ;
    ns0:hasAffiliation ns252:JAD181282,
        ns31:JAD181282 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181282 ;
    ns0:inAuthorList ns150:JAD181282 .

ns30:JAD181295 owl:sameAs ns12:JAD151181 ;
    ns0:fullName "Antti Tanskanen" ;
    ns0:hasAffiliation ns64:JAD181295,
        ns63:JAD181295,
        ns84:JAD181295 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181295 ;
    ns0:inAuthorList ns150:JAD181295 .

ns30:JAD181298 owl:sameAs ns2:jad01170,
        ns8:JAD110074,
        ns8:jad01225,
        ns40:JAD170712,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160668>,
        ns12:JAD101416,
        ns12:JAD111544,
        ns12:JAD122263,
        ns12:JAD131151,
        ns12:JAD131172,
        ns12:JAD140756,
        ns12:JAD190119,
        ns30:JAD101704,
        ns30:JAD102124,
        ns30:JAD120523,
        ns30:JAD180524,
        ns30:jad01019,
        ns5:JAD122302,
        ns16:JAD130053,
        ns16:jad01309,
        ns52:JAD160599,
        ns60:JAD160074,
        ns33:JAD132075,
        ns33:JAD180723 ;
    ns0:fullName "Chiara Fenoglio" ;
    ns0:hasAffiliation ns64:JAD181298 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181298 ;
    ns0:inAuthorList ns150:JAD181298 .

ns30:JAD190011 owl:sameAs ns2:JAD190468,
        ns8:JAD150778,
        ns8:JAD161198,
        ns12:JAD131343 ;
    ns0:fullName "Felicia C. Goldstein" ;
    ns0:hasAffiliation ns252:JAD190011 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190011 ;
    ns0:inAuthorList ns150:JAD190011 .

ns30:JAD190049 owl:sameAs ns30:JAD131058 ;
    ns0:fullName "Antony Payton" ;
    ns0:hasAffiliation ns64:JAD190049 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190049 ;
    ns0:inAuthorList ns150:JAD190049 .

ns30:JAD190060 owl:sameAs ns40:JAD161181,
        ns28:JAD160341 ;
    ns0:fullName "Sungkwon Chung" ;
    ns0:hasAffiliation ns252:JAD190060 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190060 ;
    ns0:inAuthorList ns150:JAD190060 .

ns30:JAD190075 owl:sameAs ns30:JAD150482 ;
    ns0:fullName "Eloise Ferreira" ;
    ns0:hasAffiliation ns252:JAD190075 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190075 ;
    ns0:inAuthorList ns150:JAD190075 .

ns30:JAD190077 owl:sameAs ns28:JAD150914 ;
    ns0:fullName "Kimberly R. Pechman" ;
    ns0:hasAffiliation ns252:JAD190077 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190077 ;
    ns0:inAuthorList ns150:JAD190077 .

ns30:JAD190087 owl:sameAs ns57:JAD151139 ;
    ns0:fullName "Kazunori Kawaguchi" ;
    ns0:hasAffiliation ns252:JAD190087 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190087 ;
    ns0:inAuthorList ns150:JAD190087 .

ns30:JAD190132 owl:sameAs ns2:JAD170854 ;
    ns0:fullName "Kasper Katisko" ;
    ns0:hasAffiliation ns252:JAD190132 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

ns30:JAD190133 owl:sameAs ns5:JAD170123 ;
    ns0:fullName "Riitta Antikainen" ;
    ns0:hasAffiliation ns63:JAD190133,
        ns84:JAD190133 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190133 ;
    ns0:inAuthorList ns150:JAD190133 .

ns30:JAD190142 owl:sameAs ns30:JAD170532 ;
    ns0:fullName "Mary S. Dietrich" ;
    ns0:hasAffiliation ns252:JAD190142,
        ns31:JAD190142,
        ns64:JAD190142 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190142 ;
    ns0:inAuthorList ns150:JAD190142 .

ns30:JAD190152 owl:sameAs ns12:JAD179908 ;
    ns0:fullName "Beatriz Santiago" ;
    ns0:hasAffiliation ns64:JAD190152 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190152 ;
    ns0:inAuthorList ns150:JAD190152 .

ns30:JAD190175 owl:sameAs ns12:JAD150234,
        ns176:JAD170231 ;
    ns0:fullName "Sigrid Botne Sando" ;
    ns0:hasAffiliation ns31:JAD190175,
        ns64:JAD190175 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190175 ;
    ns0:inAuthorList ns150:JAD190175 .

ns30:JAD190181 owl:sameAs ns12:JAD132279 ;
    ns0:fullName "Carol Jagger" ;
    ns0:hasAffiliation ns64:JAD190181 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD190181 ;
    ns0:inAuthorList ns150:JAD190181 .

ns30:JAD190183 owl:sameAs ns60:JAD170419 ;
    ns0:fullName "Béatrice Trombert-Paviot" ;
    ns0:hasAffiliation ns84:JAD190183 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190183 ;
    ns0:inAuthorList ns150:JAD190183 .

ns30:JAD190190 owl:sameAs ns30:JPD181353 ;
    ns0:fullName "Jian Feng" ;
    ns0:hasAffiliation ns252:JAD190190 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190190 ;
    ns0:inAuthorList ns150:JAD190190 .

ns30:JAD190197 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170368>,
        ns132:JAD101839,
        ns12:JAD130278 ;
    ns0:fullName "Robert Nisticò" ;
    ns0:hasAffiliation ns63:JAD190197,
        ns84:JAD190197 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190197 ;
    ns0:inAuthorList ns150:JAD190197 .

ns30:JAD190198 owl:sameAs ns16:JAD131604 ;
    ns0:fullName "Eva Carro" ;
    ns0:hasAffiliation ns31:JAD190198 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190198 ;
    ns0:inAuthorList ns150:JAD190198 .

ns30:JAD190202 owl:sameAs ns12:JAD190160 ;
    ns0:fullName "Nicolaas Paul L.G. Verhoeff" ;
    ns0:hasAffiliation ns63:JAD190202 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190202 ;
    ns0:inAuthorList ns150:JAD190202 .

ns30:JAD190222 owl:sameAs ns8:JAD180737,
        ns30:JAD180604 ;
    ns0:fullName "Graciela Muniz-Terrera" ;
    ns0:hasAffiliation ns252:JAD190222,
        ns31:JAD190222 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190222 ;
    ns0:inAuthorList ns150:JAD190222 .

ns30:JAD190237 owl:sameAs ns57:JAD171134 ;
    ns0:fullName "Marco Onofrj" ;
    ns0:hasAffiliation ns252:JAD190237,
        ns31:JAD190237 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190237 ;
    ns0:inAuthorList ns150:JAD190237 .

ns30:JAD190244 owl:sameAs ns12:JAD101668,
        ns5:JAD120769,
        ns5:JAD180432,
        ns16:JAD151016,
        ns60:JAD170771 ;
    ns0:fullName "Michael Hornberger" ;
    ns0:hasAffiliation ns252:JAD190244 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190244 ;
    ns0:inAuthorList ns150:JAD190244 .

ns30:JAD190264 owl:sameAs ns5:JAD122071 ;
    ns0:fullName "Michael D. Devous" ;
    ns0:hasAffiliation ns84:JAD190264 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190264 ;
    ns0:inAuthorList ns150:JAD190264 .

ns30:JAD190293 owl:sameAs ns57:JAD110866 ;
    ns0:fullName "Russell H. Swerdlow" ;
    ns0:hasAffiliation ns252:JAD190293,
        ns63:JAD190293,
        ns84:JAD190293,
        ns186:JAD190293 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190293 ;
    ns0:inAuthorList ns150:JAD190293 .

ns30:JAD190298 owl:sameAs ns2:JAD141371,
        ns12:JAD121963,
        ns12:JAD170370,
        ns5:JAD180176,
        ns5:JAD190056 ;
    ns0:fullName "Fan Zeng" ;
    ns0:hasAffiliation ns31:JAD190298 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190298 ;
    ns0:inAuthorList ns150:JAD190298 .

ns30:JAD190316 owl:sameAs ns40:JAD140798,
        ns40:JAD160289,
        ns52:JAD180755 ;
    ns0:fullName "Wellington Pham" ;
    ns0:hasAffiliation ns252:JAD190316,
        ns31:JAD190316,
        ns64:JAD190316,
        ns186:JAD190316,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:3.ID:JAD190316>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:3.ID:JAD190316>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:3.ID:JAD190316> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190316 ;
    ns0:inAuthorList ns150:JAD190316 .

ns30:JAD190319 owl:sameAs ns5:JAD180943 ;
    ns0:fullName "Richard Beare" ;
    ns0:hasAffiliation ns252:JAD190319,
        ns31:JAD190319 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190319 ;
    ns0:inAuthorList ns150:JAD190319 .

ns30:JAD190329 owl:sameAs ns2:JAD150847 ;
    ns0:fullName "Richard E. Kennedy" ;
    ns0:hasAffiliation ns31:JAD190329,
        ns64:JAD190329 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190329 ;
    ns0:inAuthorList ns150:JAD190329 .

ns30:JAD190339 owl:sameAs ns8:JAD160939,
        ns60:JAD180486 ;
    ns0:fullName "Efrat Kliper" ;
    ns0:hasAffiliation ns252:JAD190339 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190339 ;
    ns0:inAuthorList ns150:JAD190339 .

ns30:JAD190344 owl:sameAs ns5:jad01265,
        ns60:JAD180316 ;
    ns0:fullName "Annemieke J.M. Rozemuller" ;
    ns0:hasAffiliation ns64:JAD190344 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190344 ;
    ns0:inAuthorList ns150:JAD190344 .

ns30:JAD190346 owl:sameAs ns30:JAD160927 ;
    ns0:fullName "Gregoire Boulouis" ;
    ns0:hasAffiliation ns31:JAD190346 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190346 ;
    ns0:inAuthorList ns150:JAD190346 .

ns30:JAD190365 owl:sameAs ns57:JAD181099 ;
    ns0:fullName "Joseph J. Barfett" ;
    ns0:hasAffiliation ns252:JAD190365,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:3.ID:JAD190365> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190365 ;
    ns0:inAuthorList ns150:JAD190365 .

ns30:JAD190368 owl:sameAs ns8:JAD180882 ;
    ns0:fullName "Feng Chen" ;
    ns0:hasAffiliation ns252:JAD190368,
        ns64:JAD190368 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190368 ;
    ns0:inAuthorList ns150:JAD190368 .

ns30:JAD190385 owl:sameAs ns2:JAD160525 ;
    ns0:fullName "Alessandro Trebbastoni" ;
    ns0:hasAffiliation ns252:JAD190385 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190385 ;
    ns0:inAuthorList ns150:JAD190385 .

ns30:JAD190403 owl:sameAs ns8:JAD140051 ;
    ns0:fullName "Lauren E. Sergio" ;
    ns0:hasAffiliation ns252:JAD190403,
        ns31:JAD190403 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190403 ;
    ns0:inAuthorList ns150:JAD190403 .

ns30:JAD190413 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD150817>,
        ns30:JAD151085,
        ns30:JAD190341,
        ns5:JAD150481,
        ns5:JAD160124,
        ns5:JAD160828,
        ns16:JAD110365,
        ns16:JAD120934,
        ns60:JAD160766,
        ns33:JAD160485,
        ns33:JAD170502,
        ns33:JAD180300 ;
    ns0:fullName "Gunhild Waldemar" ;
    ns0:hasAffiliation ns252:JAD190413 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190413 ;
    ns0:inAuthorList ns150:JAD190413 .

ns30:JAD190415 owl:sameAs ns57:JAD141989,
        ns60:JAD100714,
        ns33:JAD160524 ;
    ns0:fullName "Margaret A. Pericak-Vance" ;
    ns0:hasAffiliation ns64:JAD190415 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190415 ;
    ns0:inAuthorList ns150:JAD190415 .

ns30:JAD190427 owl:sameAs ns26:jad100933,
        ns40:jad100630,
        ns28:jad100126,
        ns139:JAD150749,
        ns30:JAD150825,
        ns16:JAD150436,
        ns52:JAD120064,
        ns52:JAD180919 ;
    ns0:fullName "Claudine Berr" ;
    ns0:hasAffiliation ns64:JAD190427 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190427 ;
    ns0:inAuthorList ns150:JAD190427 .

ns30:JAD190440 owl:sameAs ns52:JIN073 ;
    ns0:fullName "Ahmed A. Moustafa" ;
    ns0:hasAffiliation ns84:JAD190440 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190440 ;
    ns0:inAuthorList ns150:JAD190440 .

ns30:JAD190459 owl:sameAs ns57:JAD190183 ;
    ns0:fullName "Nawéle Boublay" ;
    ns0:hasAffiliation ns31:JAD190459 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190459 ;
    ns0:inAuthorList ns150:JAD190459 .

ns30:JAD190484 owl:sameAs ns8:JAD170045,
        ns8:JAD180740 ;
    ns0:fullName "Laia Montoliu-Gaya" ;
    ns0:hasAffiliation ns252:JAD190484,
        ns64:JAD190484 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190484 ;
    ns0:inAuthorList ns150:JAD190484 .

ns30:JAD190491 owl:sameAs ns8:JAD161295 ;
    ns0:fullName "Donna Kritz-Silverstein" ;
    ns0:hasAffiliation ns31:JAD190491 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190491 ;
    ns0:inAuthorList ns150:JAD190491 .

ns30:JAD190494 owl:sameAs ns30:JAD170298,
        ns5:JAD170581 ;
    ns0:fullName "Valeria Vasciaveo" ;
    ns0:hasAffiliation ns252:JAD190494,
        ns31:JAD190494 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190494 ;
    ns0:inAuthorList ns150:JAD190494 .

ns30:JAD190501 owl:sameAs ns16:JAD170347 ;
    ns0:fullName "Xiaochen Hu" ;
    ns0:hasAffiliation ns186:JAD190501 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190501 ;
    ns0:inAuthorList ns150:JAD190501 .

ns30:JAD190517 owl:sameAs ns5:NHA170028 ;
    ns0:fullName "Sofiya Milman" ;
    ns0:hasAffiliation ns31:JAD190517 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD190517 ;
    ns0:inAuthorList ns150:JAD190517 .

ns30:JAD190518 owl:sameAs ns2:jad00084,
        ns2:jad00519,
        ns8:JAD171071,
        ns26:JAD131589,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad00130>,
        ns12:JAD190074,
        ns52:JAD151101,
        ns52:JAD151116,
        ns52:JHD180309,
        ns57:JAD170894,
        ns57:JPD181365,
        ns57:JPD191675 ;
    ns0:fullName "Eliezer Masliah" ;
    ns0:hasAffiliation ns63:JAD190518,
        ns84:JAD190518 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190518 ;
    ns0:inAuthorList ns150:JAD190518 .

ns30:JAD190533 owl:sameAs ns5:JAD171145,
        ns5:JAD180025,
        ns52:JAD151084 ;
    ns0:fullName "Tejal Shah" ;
    ns0:hasAffiliation ns252:JAD190533,
        ns31:JAD190533,
        ns186:JAD190533 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190533 ;
    ns0:inAuthorList ns150:JAD190533 .

ns30:JAD190540 owl:sameAs ns5:JAD180911,
        ns16:JAD160067 ;
    ns0:fullName "Christopher Chen" ;
    ns0:hasAffiliation ns252:JAD190540,
        ns64:JAD190540 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190540 ;
    ns0:inAuthorList ns150:JAD190540 .

ns30:JAD190609 owl:sameAs ns12:JAD180381,
        ns52:JAD170229 ;
    ns0:fullName "Bertrand Fougère" ;
    ns0:hasAffiliation ns64:JAD190609,
        ns63:JAD190609 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190609 ;
    ns0:inAuthorList ns150:JAD190609 .

ns30:JAD190620 owl:sameAs ns26:JAD180701 ;
    ns0:fullName "Hirofumi Sakurai" ;
    ns0:hasAffiliation ns252:JAD190620 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190620 ;
    ns0:inAuthorList ns150:JAD190620 .

ns30:JAD190622 owl:sameAs ns5:JAD160923 ;
    ns0:fullName "Naoki Saji" ;
    ns0:hasAffiliation ns252:JAD190622 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190622 ;
    ns0:inAuthorList ns150:JAD190622 .

ns30:JAD190645 owl:sameAs ns8:JAD170602,
        ns40:JAD120763,
        ns40:JAD160110,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180291>,
        ns28:JAD170402,
        ns43:JAD160195,
        ns16:JAD170448,
        ns16:JAD180592,
        ns60:JAD160252 ;
    ns0:fullName "Sterling C. Johnson" ;
    ns0:hasAffiliation ns252:JAD190645,
        ns31:JAD190645,
        ns64:JAD190645 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190645 ;
    ns0:inAuthorList ns150:JAD190645 .

ns30:JAD190660 owl:sameAs ns5:JAD170985 ;
    ns0:fullName "Martha Kazimierczak" ;
    ns0:hasAffiliation ns252:JAD190660 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190660 ;
    ns0:inAuthorList ns150:JAD190660 .

ns30:JAD190670 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD111748>,
        ns16:JAD151000,
        ns33:JAD141275,
        ns33:JAD160682,
        ns33:JAD170158 ;
    ns0:fullName "Daniela Perani" ;
    ns0:hasAffiliation ns186:JAD190670 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190670 ;
    ns0:inAuthorList ns150:JAD190670 .

ns30:JAD190685 owl:sameAs ns40:JAD160143,
        ns30:JAD190032 ;
    ns0:fullName "Young Ho Park" ;
    ns0:hasAffiliation ns252:JAD190685 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190685 ;
    ns0:inAuthorList ns150:JAD190685 .

ns30:JAD190691 owl:sameAs ns43:JAD180071 ;
    ns0:fullName "Semi Helin" ;
    ns0:hasAffiliation ns252:JAD190691 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190691 ;
    ns0:inAuthorList ns150:JAD190691 .

ns30:JAD190700 owl:sameAs ns30:JAD101359 ;
    ns0:fullName "Toru Kimura" ;
    ns0:hasAffiliation ns252:JAD190700 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190700 ;
    ns0:inAuthorList ns150:JAD190700 .

ns30:JAD190708 owl:sameAs ns16:JAD131844 ;
    ns0:fullName "Verna R. Porter" ;
    ns0:hasAffiliation ns252:JAD190708,
        ns63:JAD190708 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190708 ;
    ns0:inAuthorList ns150:JAD190708 .

ns30:JAD190721 owl:sameAs ns2:JAD170773,
        ns2:jad01177,
        ns8:JAD129035,
        ns40:JAD120787,
        ns40:JAD131334,
        ns40:JAD180025,
        ns40:JAD180071,
        ns40:jad091651,
        ns28:JAD120508,
        ns28:JAD190533,
        ns43:jad00759,
        ns130:JAD150167,
        ns12:JAD101959,
        ns12:JAD150525,
        ns12:JAD170502,
        ns141:JAD160310,
        ns30:JAD150883,
        ns30:JAD161275,
        ns5:JAD122425,
        ns5:JAD130035,
        ns5:JAD160110,
        ns5:JAD160573,
        ns5:JAD170368,
        ns5:jad091012,
        ns5:jad100207,
        ns16:JAD111361,
        ns16:JAD160730,
        ns16:JAD161114,
        ns16:JAD161257,
        ns16:JAD180099,
        ns16:JAD190187,
        ns16:jad00125,
        ns52:JAD142025,
        ns52:JAD170226,
        ns52:JAD170250,
        ns52:JAD170784,
        ns52:JAD170950,
        ns57:JAD101878,
        ns57:JAD120019,
        ns57:JAD140339,
        ns57:JAD160195,
        ns57:JAD160528,
        ns57:JAD161146,
        ns57:JAD170402,
        ns57:JAD170602,
        ns57:JAD190077,
        ns57:jad00966,
        ns60:JAD120931,
        ns60:JAD120976,
        ns60:JAD150897,
        ns60:JAD161126,
        ns33:JAD160461,
        ns33:jad101023 ;
    ns0:fullName "Kaj Blennow" ;
    ns0:hasAffiliation ns31:JAD190721,
        ns64:JAD190721 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190721 ;
    ns0:inAuthorList ns150:JAD190721 .

ns30:JAD190779 owl:sameAs ns2:JAD160702,
        ns8:JAD160822 ;
    ns0:fullName "Lan Guo" ;
    ns0:hasAffiliation ns252:JAD190779 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190779 ;
    ns0:inAuthorList ns150:JAD190779 .

ns30:JAD190838 owl:sameAs ns30:JAD190545 ;
    ns0:fullName "Vanesa Pytel" ;
    ns0:hasAffiliation ns252:JAD190838 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190838 ;
    ns0:inAuthorList ns150:JAD190838 .

ns30:JAE180057 owl:sameAs ns2:JAE2135 ;
    ns0:fullName "Qinghua Liang" ;
    ns0:hasAffiliation ns252:JAE180057 ;
    ns0:hasArticle ns1:jae-v61-i1-JAE180057 ;
    ns0:inAuthorList ns150:JAE180057 .

ns30:JAE180058 owl:sameAs ns16:JAE180064,
        ns16:JAE189064 ;
    ns0:fullName "Wang Qunjing" ;
    ns0:hasAffiliation ns31:JAE180058 ;
    ns0:hasArticle ns1:jae-v58-i2-JAE180058 ;
    ns0:inAuthorList ns150:JAE180058 .

ns30:JAE180100 owl:sameAs ns30:JAE180085 ;
    ns0:fullName "Zhicheng Wan" ;
    ns0:hasAffiliation ns252:JAE180100 ;
    ns0:hasArticle ns1:jae-v61-i2-JAE180100 ;
    ns0:inAuthorList ns150:JAE180100 .

ns30:JAE190086 owl:sameAs ns2:JAE2203,
        ns8:JAE150168,
        ns8:JAE171155,
        ns8:JAE171220,
        ns8:JAE2229,
        ns12:JAE170136,
        ns12:JAE171060 ;
    ns0:fullName "Jinhao Qiu" ;
    ns0:hasAffiliation ns31:JAE190086 ;
    ns0:hasArticle ns1:jae-v61-i3-JAE190086 ;
    ns0:inAuthorList ns150:JAE190086 .

ns30:JBR180349 owl:sameAs ns5:JBR180361 ;
    ns0:fullName "Hilary J. Rogers" ;
    ns0:hasAffiliation ns64:JBR180349 ;
    ns0:hasArticle ns1:jbr-v9-i2-JBR180349 ;
    ns0:inAuthorList ns150:JBR180349 .

ns30:JBR190387 owl:sameAs ns8:JBR155 ;
    ns0:fullName "Anita Sønsteby" ;
    ns0:hasAffiliation ns64:JBR190387 ;
    ns0:hasArticle ns1:jbr-v9-i3-JBR190387 ;
    ns0:inAuthorList ns150:JBR190387 .

ns30:JCS191274 owl:sameAs ns2:jcs440,
        ns12:JCS16866 ;
    ns0:fullName "Robert Huijie Deng" ;
    ns0:hasAffiliation ns117:JCS191274 ;
    ns0:hasArticle ns1:jcs-v27-i3-JCS191274 ;
    ns0:inAuthorList ns150:JCS191274 .

ns30:JCS191289 owl:sameAs ns8:JCS171017 ;
    ns0:fullName "Paolo Gasti" ;
    ns0:hasAffiliation ns117:JCS191289 ;
    ns0:hasArticle ns1:jcs-v27-i4-JCS191289 ;
    ns0:inAuthorList ns150:JCS191289 .

ns30:JCS191315 owl:sameAs ns8:JCS17975,
        ns8:JCS512,
        ns30:jcs510 ;
    ns0:fullName "Shamik Sural" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:3.ID:JCS191315> ;
    ns0:hasArticle ns1:jcs-v27-i4-JCS191315 ;
    ns0:inAuthorList ns150:JCS191315 .

ns30:JHD190351 owl:sameAs ns8:JHD170283 ;
    ns0:fullName "Sarah von Hein" ;
    ns0:hasAffiliation ns252:JHD190351 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190351 ;
    ns0:inAuthorList ns150:JHD190351 .

ns30:JHD190353 owl:sameAs ns8:JHD180287,
        ns8:JHD180306,
        ns28:JND190397 ;
    ns0:fullName "Peggy C. Nopoulos" ;
    ns0:hasAffiliation ns252:JHD190353 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD190353 ;
    ns0:inAuthorList ns150:JHD190353 .

ns30:JHD190364 owl:sameAs ns16:JHD170250 ;
    ns0:fullName "Julie C. Stout" ;
    ns0:hasAffiliation ns31:JHD190364 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190364 ;
    ns0:inAuthorList ns150:JHD190364 .

ns30:JHD190365 owl:sameAs ns5:JAD129041,
        ns5:JHD180297 ;
    ns0:fullName "Karen Marder" ;
    ns0:hasAffiliation ns84:JHD190365 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190365 ;
    ns0:inAuthorList ns150:JHD190365 .

ns30:JHD190370 owl:sameAs ns2:JHD160192,
        ns12:JHD160210,
        ns12:JHD170270,
        ns52:JHD180294 ;
    ns0:fullName "Jan C. Frich" ;
    ns0:hasAffiliation ns252:JHD190370 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190370 ;
    ns0:inAuthorList ns150:JHD190370 .

ns30:JHS190615 owl:sameAs ns12:JCM181004 ;
    ns0:fullName "Radhika M. Pai" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:3.ID:JHS190615> ;
    ns0:hasArticle ns1:jhs-v25-i3-JHS190615 ;
    ns0:inAuthorList ns150:JHS190615 .

ns30:JPD181518 owl:sameAs ns12:JPD181434 ;
    ns0:fullName "Nicholas Seedorff" ;
    ns0:hasAffiliation ns64:JPD181518 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181518 ;
    ns0:inAuthorList ns150:JPD181518 .

ns30:JPD191579 owl:sameAs ns2:JPD191627,
        ns8:JPD160985,
        ns8:JPD181472 ;
    ns0:fullName "Nicolaas I. Bohnen" ;
    ns0:hasAffiliation ns252:JPD191579,
        ns31:JPD191579,
        ns64:JPD191579,
        ns63:JPD191579 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191579 ;
    ns0:inAuthorList ns150:JPD191579 .

ns30:JPD191610 owl:sameAs ns2:JAD140162,
        ns12:JPD150680,
        ns5:JAD170762,
        ns57:JPD181434 ;
    ns0:fullName "Geidy E. Serrano" ;
    ns0:hasAffiliation ns64:JPD191610 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191610 ;
    ns0:inAuthorList ns150:JPD191610 .

ns30:JPD191616 owl:sameAs ns16:JPD160848,
        ns60:JPD171135 ;
    ns0:fullName "Catarina Godinho" ;
    ns0:hasAffiliation ns63:JPD191616 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191616 ;
    ns0:inAuthorList ns150:JPD191616 .

ns30:JVR191025 owl:sameAs ns2:WOR2601,
        ns8:JVR191024,
        ns8:WOR2201,
        ns30:JVR191022 ;
    ns0:fullName "Richard T. Roessler" ;
    ns0:hasAffiliation ns64:JVR191025 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191025 ;
    ns0:inAuthorList ns150:JVR191025 .

ns30:JVR191033 owl:sameAs ns12:JVR191042 ;
    ns0:fullName "Ellen S. Fabian" ;
    ns0:hasAffiliation ns252:JVR191033 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191033 ;
    ns0:inAuthorList ns150:JVR191033 .

ns30:JVR191036 owl:sameAs ns2:JVR191043 ;
    ns0:fullName "Catherine A. Anderson" ;
    ns0:hasAffiliation ns31:JVR191036 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191036 ;
    ns0:inAuthorList ns150:JVR191036 .

ns30:JVR191038 owl:sameAs ns8:JVR180991,
        ns8:JVR191039 ;
    ns0:fullName "Noelle Kurth" ;
    ns0:hasAffiliation ns64:JVR191038 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191038 ;
    ns0:inAuthorList ns150:JVR191038 .

ns30:JVR191039 owl:sameAs ns30:JVR180991,
        ns5:JVR191038 ;
    ns0:fullName "Jean P. Hall" ;
    ns0:hasAffiliation ns31:JVR191039 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191039 ;
    ns0:inAuthorList ns150:JVR191039 .

ns30:JVR191040 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:0.ID:TAD5(3-4)14>,
        ns30:tad00403 ;
    ns0:fullName "Caren L. Sax" ;
    ns0:hasAffiliation ns64:JVR191040 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191040 ;
    ns0:inAuthorList ns150:JVR191040 .

ns30:KCA190056 owl:sameAs ns30:KCA170007,
        ns16:KCA180047 ;
    ns0:fullName "JoAnn Hsu" ;
    ns0:hasAffiliation ns252:KCA190056 ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190056 ;
    ns0:inAuthorList ns150:KCA190056 .

ns30:MGC180771 owl:sameAs ns30:MGC190793,
        ns5:MGC180262,
        ns5:MGC249,
        ns16:MGC256 ;
    ns0:fullName "Yun-Yin Niu" ;
    ns0:hasAffiliation ns252:MGC180771 ;
    ns0:hasArticle ns1:mgc-v18-i3-MGC180771 ;
    ns0:inAuthorList ns150:MGC180771 .

ns30:NHA190065 owl:sameAs ns12:JAD131682 ;
    ns0:fullName "Jeffrey Welge" ;
    ns0:hasAffiliation ns252:NHA190065 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA190065 ;
    ns0:inAuthorList ns150:NHA190065 .

ns30:NHA190068 owl:sameAs ns30:NHA1611,
        ns5:NHA170023,
        ns57:NHA170036 ;
    ns0:fullName "Krista A. Varady" ;
    ns0:hasAffiliation ns186:NHA190068 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA190068 ;
    ns0:inAuthorList ns150:NHA190068 .

ns30:NPM180140 owl:sameAs ns30:NPM17145,
        ns5:NPM1610,
        ns5:NPM1786 ;
    ns0:fullName "C.A. Nankervis" ;
    ns0:hasAffiliation ns252:NPM180140 ;
    ns0:hasArticle ns1:npm-v12-i3-NPM180140 ;
    ns0:inAuthorList ns150:NPM180140 .

ns30:NPM18117 owl:sameAs ns16:NPM915112 ;
    ns0:fullName "B. Vergales" ;
    ns0:hasAffiliation ns63:NPM18117 ;
    ns0:hasArticle ns1:npm-v12-i2-NPM18117 ;
    ns0:inAuthorList ns150:NPM18117 .

ns30:NPM1814 owl:sameAs ns2:NPM1741,
        ns12:NPM17125 ;
    ns0:fullName "J.A. Seabrook" ;
    ns0:hasAffiliation ns252:NPM1814,
        ns31:NPM1814,
        ns64:NPM1814,
        ns63:NPM1814,
        ns84:NPM1814,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:3.ID:NPM1814> ;
    ns0:hasArticle ns1:npm-v12-i2-NPM1814 ;
    ns0:inAuthorList ns150:NPM1814 .

ns30:NPM1818 owl:sameAs ns12:WOR192876 ;
    ns0:fullName "H.R. Khalkhali" ;
    ns0:hasAffiliation ns63:NPM1818 ;
    ns0:hasArticle ns1:npm-v12-i2-NPM1818 ;
    ns0:inAuthorList ns150:NPM1818 .

ns30:NRE182671 owl:sameAs ns12:BMR140162,
        ns12:WOR2738 ;
    ns0:fullName "Joshua A. Cleland" ;
    ns0:hasAffiliation ns63:NRE182671 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182671 ;
    ns0:inAuthorList ns150:NRE182671 .

ns30:NRE192687 owl:sameAs ns30:NRE182446 ;
    ns0:fullName "Geert Verheyden" ;
    ns0:hasAffiliation ns252:NRE192687 ;
    ns0:hasArticle ns1:nre-v44-i4-NRE192687 ;
    ns0:inAuthorList ns150:NRE192687 .

ns30:NRE192700 owl:sameAs ns30:NRE192771 ;
    ns0:fullName "Nildo Ribeiro" ;
    ns0:hasAffiliation ns252:NRE192700,
        ns31:NRE192700 ;
    ns0:hasArticle ns1:nre-v44-i4-NRE192700 ;
    ns0:inAuthorList ns150:NRE192700 .

ns30:NRE192745 owl:sameAs ns12:NRE182525 ;
    ns0:fullName "Martin Gareth Edwards" ;
    ns0:hasAffiliation ns31:NRE192745,
        ns84:NRE192745 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192745 ;
    ns0:inAuthorList ns150:NRE192745 .

ns30:NRE192788 owl:sameAs ns30:JPD181516 ;
    ns0:fullName "S. Brauer" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:3.ID:NRE192788> ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192788 ;
    ns0:inAuthorList ns150:NRE192788 .

ns30:RNN190909 owl:sameAs ns12:JAD170276,
        ns5:JAD142442 ;
    ns0:fullName "Steven T. Dekosky" ;
    ns0:hasAffiliation ns186:RNN190909 ;
    ns0:hasArticle ns1:rnn-v37-i3-RNN190909 ;
    ns0:inAuthorList ns150:RNN190909 .

ns30:RNN190919 owl:sameAs ns60:RNN180812 ;
    ns0:fullName "Roy C. Martin" ;
    ns0:hasAffiliation ns252:RNN190919 ;
    ns0:hasArticle ns1:rnn-v37-i5-RNN190919 ;
    ns0:inAuthorList ns150:RNN190919 .

ns30:RNN190926 owl:sameAs ns8:RNN150515,
        ns12:RNN170725 ;
    ns0:fullName "Huiling Qu" ;
    ns0:hasAffiliation ns31:RNN190926 ;
    ns0:hasArticle ns1:rnn-v37-i4-RNN190926 ;
    ns0:inAuthorList ns150:RNN190926 .

ns30:SW190358 owl:sameAs ns116:SW286 ;
    ns0:fullName "Ruben Verborgh" ;
    ns0:hasAffiliation ns117:SW190358 ;
    ns0:hasArticle ns1:sw-v10-i6-SW190358 ;
    ns0:inAuthorList ns150:SW190358 .

ns30:SW190362 owl:sameAs ns8:AIS323 ;
    ns0:fullName "Amy Loutfi" ;
    ns0:hasAffiliation ns117:SW190362 ;
    ns0:hasArticle ns1:sw-v10-i5-SW190362 ;
    ns0:inAuthorList ns150:SW190362 .

ns30:THC191715 owl:sameAs ns5:THC170967 ;
    ns0:fullName "Dong Eun Lee" ;
    ns0:hasAffiliation ns252:THC191715 ;
    ns0:hasArticle ns1:thc-v27-i6-THC191715 ;
    ns0:inAuthorList ns150:THC191715 .

ns30:THC199007 owl:sameAs ns2:THC199006 ;
    ns0:fullName "Zehra Aysun Altikardes" ;
    ns0:hasAffiliation ns63:THC199007 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199007 ;
    ns0:inAuthorList ns150:THC199007 .

ns30:THC199009 owl:sameAs ns12:BME1486 ;
    ns0:fullName "Yong Liang" ;
    ns0:hasAffiliation ns252:THC199009,
        ns31:THC199009 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199009 ;
    ns0:inAuthorList ns150:THC199009 .

ns30:THC199010 owl:sameAs ns2:BME1464,
        ns30:BME1377,
        ns30:BME1464,
        ns30:THC199011,
        ns5:THC199011 ;
    ns0:fullName "Lung-Fa Pan" ;
    ns0:hasAffiliation ns252:THC199010 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199010 ;
    ns0:inAuthorList ns150:THC199010 .

ns30:THC199029 owl:sameAs ns2:THC199031 ;
    ns0:fullName "Feng Tang" ;
    ns0:hasAffiliation ns252:THC199029 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199029 ;
    ns0:inAuthorList ns150:THC199029 .

ns30:THC199031 owl:sameAs ns5:THC199029 ;
    ns0:fullName "Wenting Tan" ;
    ns0:hasAffiliation ns252:THC199031 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199031 ;
    ns0:inAuthorList ns150:THC199031 .

ns30:THC199039 owl:sameAs ns12:THC1309 ;
    ns0:fullName "Jin-Ho Cho" ;
    ns0:hasAffiliation ns252:THC199039 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199039 ;
    ns0:inAuthorList ns150:THC199039 .

ns30:VES190666 owl:sameAs ns2:JPD160874,
        ns16:RNN170745 ;
    ns0:fullName "Jeong-Hoon Oh" ;
    ns0:hasAffiliation ns252:VES190666 ;
    ns0:hasArticle ns1:ves-v29-i4-VES190666 ;
    ns0:inAuthorList ns150:VES190666 .

ns30:WOR192958 owl:sameAs ns2:WOR192964 ;
    ns0:fullName "Deborah L. Gebhardt" ;
    ns0:hasAffiliation ns31:WOR192958 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192958 ;
    ns0:inAuthorList ns150:WOR192958 .

ns30:WOR192968 owl:sameAs ns8:WOR2661,
        ns12:WOR2578,
        ns12:WOR2692,
        ns30:WOR192938 ;
    ns0:fullName "Venerina Johnston" ;
    ns0:hasAffiliation ns252:WOR192968,
        ns84:WOR192968 ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192968 ;
    ns0:inAuthorList ns150:WOR192968 .

ns30:WOR192984 owl:sameAs ns2:WOR2328,
        ns12:WOR192986 ;
    ns0:fullName "Reza Kazemi" ;
    ns0:hasAffiliation ns63:WOR192984 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192984 ;
    ns0:inAuthorList ns150:WOR192984 .

ns30:WOR192990 owl:sameAs ns8:WOR192973 ;
    ns0:fullName "Gregor Wolbring" ;
    ns0:hasAffiliation ns252:WOR192990 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192990 ;
    ns0:inAuthorList ns150:WOR192990 .

ns30:WOR193013 owl:sameAs ns52:WOR2522 ;
    ns0:fullName "Magnus Sverke" ;
    ns0:hasAffiliation ns252:WOR193013,
        ns64:WOR193013 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193013 ;
    ns0:inAuthorList ns150:WOR193013 .

ns30:XST180465 owl:sameAs ns5:XST17271 ;
    ns0:fullName "Lin-Fang Jin" ;
    ns0:hasAffiliation ns31:XST180465 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180465 ;
    ns0:inAuthorList ns150:XST180465 .

ns30:XST180477 owl:sameAs ns52:XST190506 ;
    ns0:fullName "Yongshuai Ge" ;
    ns0:hasAffiliation ns252:XST180477 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180477 ;
    ns0:inAuthorList ns150:XST180477 .

ns30:XST180487 owl:sameAs ns30:XST180427 ;
    ns0:fullName "Peng Qiao" ;
    ns0:hasAffiliation ns252:XST180487 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180487 ;
    ns0:inAuthorList ns150:XST180487 .

ns30:XST190506 owl:sameAs ns5:XST190527 ;
    ns0:fullName "Mengxi Zhang" ;
    ns0:hasAffiliation ns64:XST190506 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190506 ;
    ns0:inAuthorList ns150:XST190506 .

ns30:XST190527 owl:sameAs ns12:XST190506 ;
    ns0:fullName "Xuezhu Zhang" ;
    ns0:hasAffiliation ns63:XST190527 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190527 ;
    ns0:inAuthorList ns150:XST190527 .

ns30:XST190528 owl:sameAs ns12:XST17285,
        ns12:XST180393 ;
    ns0:fullName "Kuidong Huang" ;
    ns0:hasAffiliation ns252:XST190528 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190528 ;
    ns0:inAuthorList ns150:XST190528 .

ns30:XST190533 owl:sameAs ns8:CBM542,
        ns30:XST190548 ;
    ns0:fullName "Yulan Peng" ;
    ns0:hasAffiliation ns31:XST190533 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190533 ;
    ns0:inAuthorList ns150:XST190533 .

ns30:ajw190027 owl:sameAs ns8:ajw170014 ;
    ns0:fullName "Sharifah Mastura Syed Abdullah" ;
    ns0:hasAffiliation ns252:ajw190027 ;
    ns0:hasArticle ns1:ajw-v16-i3-ajw190027 ;
    ns0:inAuthorList ns150:ajw190027 .

ns30:ajw190043 owl:sameAs ns60:ajw190019,
        ns33:ajw190019 ;
    ns0:fullName "Damir N. Kutliyarov" ;
    ns0:hasAffiliation ns252:ajw190043 ;
    ns0:hasArticle ns1:ajw-v16-i4-ajw190043 ;
    ns0:inAuthorList ns150:ajw190043 .

ns118:JAD180572 owl:sameAs ns2:JAD120169,
        ns2:JAD131850,
        ns12:JAD160979,
        ns12:JAD180468,
        ns30:JAD180439,
        ns5:JAD131265,
        ns5:JAD141266,
        ns5:JAD170265,
        ns16:JAD111766,
        ns16:JAD130143,
        ns16:JAD150619,
        ns16:JAD171027,
        ns57:JAD190306,
        ns57:JAD190524,
        ns60:JAD141314,
        ns60:JAD150946,
        ns60:JAD160148,
        ns33:JAD150537 ;
    ns0:fullName "Henry Brodaty" ;
    ns0:hasAffiliation ns119:JAD180572 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180572 ;
    ns0:inAuthorList ns150:JAD180572 .

ns118:JAD190446 owl:sameAs ns52:jad100561,
        ns33:jad01187 ;
    ns0:fullName "Frank Jessen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff21.Author:30.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:30.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns5:ADR190118 owl:sameAs ns8:JAD170900 ;
    ns0:fullName "Subashchandrabose Chinnathambi" ;
    ns0:hasAffiliation ns6:ADR190118,
        ns120:ADR190118 ;
    ns0:hasArticle ns1:adr-v3-i1-ADR190118 ;
    ns0:inAuthorList ns150:ADR190118 .

ns5:ADR190132 owl:sameAs ns8:JAD142868 ;
    ns0:fullName "Yvonne Bouter" ;
    ns0:hasAffiliation ns6:ADR190132 ;
    ns0:hasArticle ns1:adr-v3-i1-ADR190132 ;
    ns0:inAuthorList ns150:ADR190132 .

ns5:AO190211 owl:sameAs ns16:AO179 ;
    ns0:fullName "Yehoshua Perl" ;
    ns0:hasAffiliation ns121:AO190211 ;
    ns0:hasArticle ns1:ao-v14-i3-AO190211 ;
    ns0:inAuthorList ns150:AO190211 .

ns5:BLC190209 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:BLC180172>,
        ns30:BLC170152 ;
    ns0:fullName "Maurice P. Zeegers" ;
    ns0:hasAffiliation ns120:BLC190209 ;
    ns0:hasArticle ns1:blc-v5-i2-BLC190209 ;
    ns0:inAuthorList ns150:BLC190209 .

ns5:BME191060 owl:sameAs ns5:BME1651 ;
    ns0:fullName "Kimihiro Yamashita" ;
    ns0:hasAffiliation ns50:BME191060 ;
    ns0:hasArticle ns1:bme-v30-i4-BME191060 ;
    ns0:inAuthorList ns150:BME191060 .

ns5:BSI190186 owl:sameAs ns8:XST519 ;
    ns0:fullName "Aimin Yan" ;
    ns0:hasAffiliation ns122:BSI190186 ;
    ns0:hasArticle ns1:bsi-v8-i1-2-BSI190186 ;
    ns0:inAuthorList ns150:BSI190186 .

ns5:CBM182020 owl:sameAs ns52:JAD150735 ;
    ns0:fullName "Yong Fang" ;
    ns0:hasAffiliation ns6:CBM182020 ;
    ns0:hasArticle ns1:cbm-v25-i2-CBM182020 ;
    ns0:inAuthorList ns150:CBM182020 .

ns5:CBM182143 owl:sameAs ns26:CBM170711 ;
    ns0:fullName "Qiao Xiong" ;
    ns0:hasAffiliation ns6:CBM182143 ;
    ns0:hasArticle ns1:cbm-v26-i3-CBM182143 ;
    ns0:inAuthorList ns150:CBM182143 .

ns5:CBM190013 owl:sameAs ns12:IFS169965 ;
    ns0:fullName "Bipin Nair" ;
    ns0:hasAffiliation ns50:CBM190013 ;
    ns0:hasArticle ns1:cbm-v25-i2-CBM190013 ;
    ns0:inAuthorList ns150:CBM190013 .

ns5:CBM192435 owl:sameAs ns16:CBM170472,
        ns16:CBM181526 ;
    ns0:fullName "Xiaolong Jin" ;
    ns0:hasAffiliation ns123:CBM192435 ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM192435 ;
    ns0:inAuthorList ns150:CBM192435 .

ns5:CH180428 owl:sameAs ns2:CH168021,
        ns2:CH179231,
        ns8:CH189408,
        ns28:CH179232,
        ns12:CH179000,
        ns12:CH180427,
        ns12:CH189901,
        ns12:CH199008,
        ns30:CH179233,
        ns30:JCB179014,
        ns5:CH170244,
        ns16:CH1958,
        ns52:CH160207,
        ns52:CH179235,
        ns60:CH179205,
        ns60:CH189907,
        ns60:CH2064 ;
    ns0:fullName "Christian Lehmann" ;
    ns0:hasAffiliation ns87:CH180428,
        ns71:CH180428,
        ns124:CH180428,
        ns153:CH180428,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:4.ID:CH180428> ;
    ns0:hasArticle ns1:ch-v72-i1-CH180428 ;
    ns0:inAuthorList ns150:CH180428 .

ns5:CH180454 owl:sameAs ns2:JAD190382 ;
    ns0:fullName "Hong Ding" ;
    ns0:hasAffiliation ns6:CH180454 ;
    ns0:hasArticle ns1:ch-v72-i1-CH180454 ;
    ns0:inAuthorList ns150:CH180454 .

ns5:CH180457 owl:sameAs ns5:CH180545 ;
    ns0:fullName "Jian Li" ;
    ns0:hasAffiliation ns6:CH180457 ;
    ns0:hasArticle ns1:ch-v72-i1-CH180457 ;
    ns0:inAuthorList ns150:CH180457 .

ns5:CH180470 owl:sameAs ns8:CH160241 ;
    ns0:fullName "Jakub Marchewka" ;
    ns0:hasAffiliation ns120:CH180470 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180470 ;
    ns0:inAuthorList ns150:CH180470 .

ns5:CH199005 owl:sameAs ns2:CH199201,
        ns8:CH199206 ;
    ns0:fullName "Wing-Tai Tung" ;
    ns0:hasAffiliation ns6:CH199005,
        ns120:CH199005 ;
    ns0:hasArticle ns1:ch-v71-i4-CH199005 ;
    ns0:inAuthorList ns150:CH199005 .

ns5:CH199009 owl:sameAs ns12:CH168110 ;
    ns0:fullName "J. Falter" ;
    ns0:hasAffiliation ns6:CH199009 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199009 ;
    ns0:inAuthorList ns150:CH199009 .

ns5:CH199201 owl:sameAs ns8:CH168033,
        ns8:CH2004,
        ns12:CH168114,
        ns30:CH168107,
        ns5:CH189130,
        ns52:CH199206 ;
    ns0:fullName "Karl Kratz" ;
    ns0:hasAffiliation ns6:CH199201 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199201 ;
    ns0:inAuthorList ns150:CH199201 .

ns5:CH199202 owl:sameAs ns2:CH168034,
        ns2:CH179102,
        ns2:CH179104,
        ns2:CH179105,
        ns2:CH2010,
        ns8:CH168039,
        ns8:CH2009,
        ns12:CH168052,
        ns12:CH168115,
        ns30:CH189404,
        ns30:CH189406,
        ns5:CH189114,
        ns5:CH189115,
        ns5:CH189116,
        ns5:CH189310,
        ns5:CH189405,
        ns5:CH199204 ;
    ns0:fullName "J. Rübenthaler" ;
    ns0:hasAffiliation ns6:CH199202 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199202 ;
    ns0:inAuthorList ns150:CH199202 .

ns5:CH199205 owl:sameAs ns26:CH179209,
        ns16:CH199201,
        ns57:CH199206 ;
    ns0:fullName "Nan Ma" ;
    ns0:hasAffiliation ns6:CH199205,
        ns50:CH199205 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199205 ;
    ns0:inAuthorList ns150:CH199205 .

ns5:CH199218 owl:sameAs ns2:CH170365,
        ns2:CH1963 ;
    ns0:fullName "Britta Kuehlmann" ;
    ns0:hasAffiliation ns87:CH199218 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199218 ;
    ns0:inAuthorList ns150:CH199218 .

ns5:CH199219 owl:sameAs ns30:JCB179010 ;
    ns0:fullName "H. Sievers" ;
    ns0:hasAffiliation ns6:CH199219 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199219 ;
    ns0:inAuthorList ns150:CH199219 .

ns5:CH199224 owl:sameAs ns8:CH199221,
        ns30:CH1962,
        ns5:CH189323,
        ns5:CH189415,
        ns16:CH168044,
        ns16:CH179112,
        ns16:CH179217,
        ns16:CH179220,
        ns16:CH189131,
        ns16:CH189324,
        ns57:CH1990 ;
    ns0:fullName "Christian Stroszczynski" ;
    ns0:hasAffiliation ns6:CH199224 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199224 ;
    ns0:inAuthorList ns150:CH199224 .

ns5:CH199225 owl:sameAs ns2:CH16195,
        ns8:CH170266,
        ns52:CH179216,
        ns57:CH189107,
        ns33:CH189129 ;
    ns0:fullName "Silvan Klein" ;
    ns0:hasAffiliation ns6:CH199225 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199225 ;
    ns0:inAuthorList ns150:CH199225 .

ns5:FI1834 owl:sameAs ns8:FI1832 ;
    ns0:fullName "Tomasz Trzciński" ;
    ns0:hasAffiliation ns6:FI1834 ;
    ns0:hasArticle ns1:fi-v168-i2-4-FI1834 ;
    ns0:inAuthorList ns150:FI1834 .

ns5:FI1870 owl:sameAs ns8:IA102,
        ns12:WEB190403,
        ns12:mgs00071,
        ns30:IA110 ;
    ns0:fullName "Giuseppe Vizzari" ;
    ns0:hasAffiliation ns120:FI1870 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1870 ;
    ns0:inAuthorList ns150:FI1870 .

ns5:HAB190367 owl:sameAs ns5:HAB190363 ;
    ns0:fullName "Woldegebriel Gebreegziabher Kahsay" ;
    ns0:hasAffiliation ns71:HAB190367 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190367 ;
    ns0:inAuthorList ns150:HAB190367 .

ns5:HAB190370 owl:sameAs ns2:cbm00108 ;
    ns0:fullName "Mostafa K. El Awady" ;
    ns0:hasAffiliation ns50:HAB190370 ;
    ns0:hasArticle ns1:hab-v27-i3-HAB190370 ;
    ns0:inAuthorList ns150:HAB190370 .

ns5:HAB190371 owl:sameAs ns5:HAB190364 ;
    ns0:fullName "Effat Merghati Khoei" ;
    ns0:hasAffiliation ns87:HAB190371 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190371 ;
    ns0:inAuthorList ns150:HAB190371 .

ns5:HAB190374 owl:sameAs ns5:CBM170831 ;
    ns0:fullName "Elahe Motevaseli" ;
    ns0:hasAffiliation ns6:HAB190374 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190374 ;
    ns0:inAuthorList ns150:HAB190374 .

ns5:HSM180397 owl:sameAs ns2:HSM180415,
        ns12:HSM180405,
        ns5:HSM190490 ;
    ns0:fullName "Khuram Shahzad" ;
    ns0:hasAffiliation ns6:HSM180397 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180397 ;
    ns0:inAuthorList ns150:HSM180397 .

ns5:HSM180425 owl:sameAs ns5:HSM180472 ;
    ns0:fullName "Khurshaid Ahmad" ;
    ns0:hasAffiliation ns120:HSM180425 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180425 ;
    ns0:inAuthorList ns150:HSM180425 .

ns5:IA190023 owl:sameAs ns8:SW180336,
        ns57:SW217 ;
    ns0:fullName "Guohui Xiao" ;
    ns0:hasAffiliation ns50:IA190023 ;
    ns0:hasArticle ns1:ia-v13-i1-IA190023 ;
    ns0:inAuthorList ns150:IA190023 .

ns5:ICA190605 owl:sameAs ns12:JAD180654 ;
    ns0:fullName "Javier Ramirez" ;
    ns0:hasAffiliation ns6:ICA190605,
        ns71:ICA190605 ;
    ns0:hasArticle ns1:ica-v26-i4-ICA190605 ;
    ns0:inAuthorList ns150:ICA190605 .

ns5:IES192167 owl:sameAs ns8:HIS220 ;
    ns0:fullName "Shogo Sakai" ;
    ns0:hasAffiliation ns6:IES192167 ;
    ns0:hasArticle ns1:ies-v27-i4-IES192167 ;
    ns0:inAuthorList ns150:IES192167 .

ns5:IES193178 owl:sameAs ns5:thc00362,
        ns52:thc00307 ;
    ns0:fullName "Feza Korkusuz" ;
    ns0:hasAffiliation ns123:IES193178 ;
    ns0:hasArticle ns1:ies-v27-i4-IES193178 ;
    ns0:inAuthorList ns150:IES193178 .

ns5:IFS179086 owl:sameAs ns5:IFS179084 ;
    ns0:fullName "K. Shankar" ;
    ns0:hasAffiliation ns50:IFS179086 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS179086 ;
    ns0:inAuthorList ns150:IFS179086 .

ns5:IFS179151 owl:sameAs ns12:IFS179122 ;
    ns0:fullName "Amit Kumar Singh" ;
    ns0:hasAffiliation ns50:IFS179151 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS179151 ;
    ns0:inAuthorList ns150:IFS179151 .

ns5:IFS179302 owl:sameAs ns8:JAE160054,
        ns12:ica00416 ;
    ns0:fullName "Chengfeng Cai" ;
    ns0:hasAffiliation ns6:IFS179302 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179302 ;
    ns0:inAuthorList ns150:IFS179302 .

ns5:IFS179319 owl:sameAs ns2:CBM544 ;
    ns0:fullName "Yang Lv" ;
    ns0:hasAffiliation ns50:IFS179319 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS179319 ;
    ns0:inAuthorList ns150:IFS179319 .

ns5:IFS181425 owl:sameAs ns8:IFS172130,
        ns30:RFT18109,
        ns5:IFS18607 ;
    ns0:fullName "Xiaopu Shang" ;
    ns0:hasAffiliation ns6:IFS181425 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181425 ;
    ns0:inAuthorList ns150:IFS181425 .

ns5:IFS181633 owl:sameAs ns2:ADR180082,
        ns8:IFS171203,
        ns8:IFS17175,
        ns12:IFS152503,
        ns12:IFS169212,
        ns12:IFS171717,
        ns12:IFS190205 ;
    ns0:fullName "Samarjit Kar" ;
    ns0:hasAffiliation ns50:IFS181633 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181633 ;
    ns0:inAuthorList ns150:IFS181633 .

ns5:IFS181742 owl:sameAs ns30:IFS18144 ;
    ns0:fullName "Choonkil Park" ;
    ns0:hasAffiliation ns87:IFS181742 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS181742 ;
    ns0:inAuthorList ns150:IFS181742 .

ns5:IFS182512 owl:sameAs ns12:IFS17682 ;
    ns0:fullName "Chao Li" ;
    ns0:hasAffiliation ns6:IFS182512 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182512 ;
    ns0:inAuthorList ns150:IFS182512 .

ns5:IFS182843 owl:sameAs ns2:IFS17493,
        ns2:IFS18961,
        ns8:IFS18567,
        ns8:IFS190595,
        ns12:IFS171058 ;
    ns0:fullName "Hua Ke" ;
    ns0:hasAffiliation ns124:IFS182843 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182843 ;
    ns0:inAuthorList ns150:IFS182843 .

ns5:JAD180521 owl:sameAs ns5:JAD160544,
        ns5:JAD180865,
        ns5:JAD190033 ;
    ns0:fullName "Patricia Desmond" ;
    ns0:hasAffiliation ns123:JAD180521 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180521 ;
    ns0:inAuthorList ns150:JAD180521 .

ns5:JAD180636 owl:sameAs ns33:JAD180531 ;
    ns0:fullName "Manuel Gonçalves-Pereira" ;
    ns0:hasAffiliation ns123:JAD180636 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180636 ;
    ns0:inAuthorList ns150:JAD180636 .

ns5:JAD180857 owl:sameAs ns8:JAD140138,
        ns8:NRE1298,
        ns33:JAD150573 ;
    ns0:fullName "Roy P.C. Kessels" ;
    ns0:hasAffiliation ns50:JAD180857,
        ns120:JAD180857 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD180857 ;
    ns0:inAuthorList ns150:JAD180857 .

ns5:JAD180900 owl:sameAs ns12:JAD131241,
        ns12:JAD170743,
        ns30:JAD141320,
        ns30:JAD150368 ;
    ns0:fullName "Glenda M. Halliday" ;
    ns0:hasAffiliation ns6:JAD180900,
        ns50:JAD180900 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180900 ;
    ns0:inAuthorList ns150:JAD180900 .

ns5:JAD180949 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180981>,
        ns130:JAD160407 ;
    ns0:fullName "Angela Fuchs" ;
    ns0:hasAffiliation ns71:JAD180949 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

ns5:JAD181030 owl:sameAs ns2:ADR170035,
        ns2:JAD170123 ;
    ns0:fullName "Shireen Sindi" ;
    ns0:hasAffiliation ns6:JAD181030,
        ns87:JAD181030 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181030 ;
    ns0:inAuthorList ns150:JAD181030 .

ns5:JAD181110 owl:sameAs ns2:jad00926,
        ns2:jad091603,
        ns8:JAD181119,
        ns30:JAD122350,
        ns30:JAD160077,
        ns57:JAD180514,
        ns60:JAD102133,
        ns60:JAD180663,
        ns33:JAD101980 ;
    ns0:fullName "Peter T. Nelson" ;
    ns0:hasAffiliation ns87:JAD181110 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181110 ;
    ns0:inAuthorList ns150:JAD181110 .

ns5:JAD181140 owl:sameAs ns2:JAD180634,
        ns8:JAD141563,
        ns8:JAD190104,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120466>,
        ns5:JAD181145,
        ns57:JAD161228 ;
    ns0:fullName "Kristine Yaffe" ;
    ns0:hasAffiliation ns120:JAD181140 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181140 ;
    ns0:inAuthorList ns150:JAD181140 .

ns5:JAD181141 owl:sameAs ns8:JAD111631,
        ns8:JAD180604,
        ns5:JAD190262 ;
    ns0:fullName "Charles B. Hall" ;
    ns0:hasAffiliation ns6:JAD181141,
        ns50:JAD181141 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD181141 ;
    ns0:inAuthorList ns150:JAD181141 .

ns5:JAD181169 owl:sameAs ns5:JAD181170 ;
    ns0:fullName "Keith D. Hill" ;
    ns0:hasAffiliation ns87:JAD181169 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181169 ;
    ns0:inAuthorList ns150:JAD181169 .

ns5:JAD181174 owl:sameAs ns30:JAD181173 ;
    ns0:fullName "Jacqueline C.T. Close" ;
    ns0:hasAffiliation ns6:JAD181174,
        ns120:JAD181174 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181174 ;
    ns0:inAuthorList ns150:JAD181174 .

ns5:JAD181196 owl:sameAs ns8:JAD170149 ;
    ns0:fullName "Frederico Pieruccini-Faria" ;
    ns0:hasAffiliation ns6:JAD181196,
        ns120:JAD181196 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181196 ;
    ns0:inAuthorList ns150:JAD181196 .

ns5:JAD181203 owl:sameAs ns2:JAD110086,
        ns8:JAD0007,
        ns8:JAD170735,
        ns8:jad100456,
        ns26:JAD160697,
        ns30:JAD161292,
        ns16:JAD170041,
        ns16:JAD180446,
        ns52:JAD121270,
        ns52:JAD160326,
        ns33:JAD160258 ;
    ns0:fullName "Michelle M. Mielke" ;
    ns0:hasAffiliation ns87:JAD181203 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181203 ;
    ns0:inAuthorList ns150:JAD181203 .

ns5:JAD181212 owl:sameAs ns52:JAD180746,
        ns57:JAD120202 ;
    ns0:fullName "Susan M. McCurry" ;
    ns0:hasAffiliation ns120:JAD181212 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181212 ;
    ns0:inAuthorList ns150:JAD181212 .

ns5:JAD181217 owl:sameAs ns8:JAD180425 ;
    ns0:fullName "Peng Guo" ;
    ns0:hasAffiliation ns6:JAD181217 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181217 ;
    ns0:inAuthorList ns150:JAD181217 .

ns5:JAD181246 owl:sameAs ns5:JAD130779,
        ns52:jad091474,
        ns57:JAD170398,
        ns57:JAD180987 ;
    ns0:fullName "Alexander Samokhin" ;
    ns0:hasAffiliation ns6:JAD181246 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181246 ;
    ns0:inAuthorList ns150:JAD181246 .

ns5:JAD181256 owl:sameAs ns8:JAD190132,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170534> ;
    ns0:fullName "Eino Solje" ;
    ns0:hasAffiliation ns120:JAD181256,
        ns87:JAD181256 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181256 ;
    ns0:inAuthorList ns150:JAD181256 .

ns5:JAD181272 owl:sameAs ns26:JAD161163,
        ns26:JAD180202,
        ns30:JAD160517,
        ns52:JAD150652,
        ns60:JAD170124 ;
    ns0:fullName "Tamàs Fülöp" ;
    ns0:hasAffiliation ns120:JAD181272 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181272 ;
    ns0:inAuthorList ns150:JAD181272 .

ns5:JAD181288 owl:sameAs ns30:JAD170288 ;
    ns0:fullName "Edward R. Marcantonio" ;
    ns0:hasAffiliation ns50:JAD181288 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181288 ;
    ns0:inAuthorList ns150:JAD181288 .

ns5:JAD181295 owl:sameAs ns30:JAD151181,
        ns30:JAD160956,
        ns30:JAD180594,
        ns5:JAD140282,
        ns5:JAD180125,
        ns5:JAD180912,
        ns16:JAD150630 ;
    ns0:fullName "Jari Tiihonen" ;
    ns0:hasAffiliation ns120:JAD181295,
        ns123:JAD181295,
        ns71:JAD181295 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181295 ;
    ns0:inAuthorList ns150:JAD181295 .

ns5:JAD181297 owl:sameAs ns16:JAD132558,
        ns16:JAD160116 ;
    ns0:fullName "Aad van der Lugt" ;
    ns0:hasAffiliation ns6:JAD181297 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD181297 ;
    ns0:inAuthorList ns150:JAD181297 .

ns5:JAD181298 owl:sameAs ns2:JAD131172,
        ns2:JAD140756,
        ns2:JAD160073,
        ns2:jad01225,
        ns8:JAD131151,
        ns8:JAD160185,
        ns26:JAD150849,
        ns40:JAD111544,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120523>,
        ns28:JAD130128,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160949>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170712>,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD122263>,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD190119>,
        ns132:JAD111046,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD102124>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:jad01328>,
        ns12:JAD110788,
        ns12:JAD121606,
        ns12:JAD122302,
        ns12:JAD130053,
        ns12:JAD132075,
        ns12:JAD180242,
        ns176:JAD110074,
        ns143:JAD150863,
        ns30:JAD170702,
        ns30:JAD190147,
        ns5:jad01129,
        ns5:jad01309,
        ns16:JAD180715,
        ns52:JAD150786,
        ns52:jad01285,
        <http://ld.iospress.nl/rdf/contributor/Author:61.ID:jad100933>,
        ns57:JAD112006,
        ns57:JAD112084,
        ns60:JAD101764,
        ns33:JAD140057,
        ns33:JAD170861 ;
    ns0:fullName "Daniela Galimberti" ;
    ns0:hasAffiliation ns120:JAD181298 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181298 ;
    ns0:inAuthorList ns150:JAD181298 .

ns5:JAD190011 owl:sameAs ns2:jad01227,
        ns8:JAD110629,
        ns8:JAD120952,
        ns8:jad00610,
        ns12:JAD161132,
        ns5:JAD140162,
        ns16:JAD101995,
        ns16:JAD129007,
        ns16:JAD179939 ;
    ns0:fullName "Julie A. Schneider" ;
    ns0:hasAffiliation ns87:JAD190011,
        ns71:JAD190011 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190011 ;
    ns0:inAuthorList ns150:JAD190011 .

ns5:JAD190023 owl:sameAs ns5:JAD181152 ;
    ns0:fullName "Sakiko Narita" ;
    ns0:hasAffiliation ns50:JAD190023 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190023 ;
    ns0:inAuthorList ns150:JAD190023 .

ns5:JAD190041 owl:sameAs ns12:JAD160897,
        ns12:JAD170481,
        ns30:JAD120364,
        ns30:JAD131040,
        ns30:JAD160952,
        ns16:JAD170522 ;
    ns0:fullName "Huiberdina L. Koek" ;
    ns0:hasAffiliation ns120:JAD190041 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190041 ;
    ns0:inAuthorList ns150:JAD190041 .

ns5:JAD190091 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD170720>,
        ns16:JAD150985 ;
    ns0:fullName "William E. Klunk" ;
    ns0:hasAffiliation ns87:JAD190091 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190091 ;
    ns0:inAuthorList ns150:JAD190091 .

ns5:JAD190106 owl:sameAs ns5:JAD131343,
        ns52:jad00907 ;
    ns0:fullName "James J. Lah" ;
    ns0:hasAffiliation ns6:JAD190106 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD190106 ;
    ns0:inAuthorList ns150:JAD190106 .

ns5:JAD190113 owl:sameAs ns16:JAD170561 ;
    ns0:fullName "Yang Liu" ;
    ns0:hasAffiliation ns6:JAD190113 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190113 ;
    ns0:inAuthorList ns150:JAD190113 .

ns5:JAD190119 owl:sameAs ns40:JAD180723 ;
    ns0:fullName "Marianna D’Anca" ;
    ns0:hasAffiliation ns50:JAD190119 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

ns5:JAD190124 owl:sameAs ns30:JAD131481,
        ns30:JAD150864,
        ns5:JAD132219 ;
    ns0:fullName "Elvira E. Jimenez" ;
    ns0:hasAffiliation ns6:JAD190124 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190124 ;
    ns0:inAuthorList ns150:JAD190124 .

ns5:JAD190128 owl:sameAs ns8:jad01079,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD181175>,
        ns52:JAD161006,
        ns60:jad01051 ;
    ns0:fullName "Ramon Diaz-Arrastia" ;
    ns0:hasAffiliation ns71:JAD190128 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190128 ;
    ns0:inAuthorList ns150:JAD190128 .

ns5:JAD190142 owl:sameAs ns12:JAD170532 ;
    ns0:fullName "Sebastian Atalla" ;
    ns0:hasAffiliation ns6:JAD190142 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190142 ;
    ns0:inAuthorList ns150:JAD190142 .

ns5:JAD190153 owl:sameAs ns16:JAD181038,
        ns16:JAD190562,
        ns52:JAD180971 ;
    ns0:fullName "Jin-Tai Yu" ;
    ns0:hasAffiliation ns123:JAD190153 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190153 ;
    ns0:inAuthorList ns150:JAD190153 .

ns5:JAD190165 owl:sameAs ns2:ida00193,
        ns2:ida00212,
        ns2:ida00215,
        ns2:ida00229,
        ns2:ida00285,
        ns2:ida00409,
        ns8:ica00314,
        ns8:jcm00395 ;
    ns0:fullName "Taghi M. Khoshgoftaar" ;
    ns0:hasAffiliation ns50:JAD190165 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190165 ;
    ns0:inAuthorList ns150:JAD190165 .

ns5:JAD190180 owl:sameAs ns8:JAD00022,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD130311>,
        ns28:JAD102145,
        ns28:JAD160025,
        ns12:JAD132417,
        ns30:JAD111793,
        ns16:jad100261,
        ns52:JAD101263,
        ns52:JAD151200,
        ns57:JAD141356,
        ns60:JAD111778 ;
    ns0:fullName "Inhee Mook-Jung" ;
    ns0:hasAffiliation ns6:JAD190180 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190180 ;
    ns0:inAuthorList ns150:JAD190180 .

ns5:JAD190181 owl:sameAs ns2:JAD180631,
        ns8:JAD190506,
        ns12:JAD160826 ;
    ns0:fullName "Ruth Peters" ;
    ns0:hasAffiliation ns6:JAD190181,
        ns50:JAD190181 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD190181 ;
    ns0:inAuthorList ns150:JAD190181 .

ns5:JAD190183 owl:sameAs ns52:JAD150181 ;
    ns0:fullName "Michel Benoit" ;
    ns0:hasAffiliation ns71:JAD190183 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190183 ;
    ns0:inAuthorList ns150:JAD190183 .

ns5:JAD190202 owl:sameAs ns5:JAD181099,
        ns5:JAD190160 ;
    ns0:fullName "Damien Gallagher" ;
    ns0:hasAffiliation ns6:JAD190202 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190202 ;
    ns0:inAuthorList ns150:JAD190202 .

ns5:JAD190240 owl:sameAs ns12:CH180515 ;
    ns0:fullName "Cheng Gu" ;
    ns0:hasAffiliation ns6:JAD190240 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190240 ;
    ns0:inAuthorList ns150:JAD190240 .

ns5:JAD190241 owl:sameAs ns12:BPL180071,
        ns60:JAD160149 ;
    ns0:fullName "Ignacio Torres Aleman" ;
    ns0:hasAffiliation ns6:JAD190241 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190241 ;
    ns0:inAuthorList ns150:JAD190241 .

ns5:JAD190272 owl:sameAs ns30:JAD170028 ;
    ns0:fullName "Ryuji Fukuhara" ;
    ns0:hasAffiliation ns123:JAD190272 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190272 ;
    ns0:inAuthorList ns150:JAD190272 .

ns5:JAD190302 owl:sameAs ns5:JAD180028 ;
    ns0:fullName "Sarah J. Banks" ;
    ns0:hasAffiliation ns6:JAD190302,
        ns120:JAD190302 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190302 ;
    ns0:inAuthorList ns150:JAD190302 .

ns5:JAD190327 owl:sameAs ns8:JAD180300,
        ns57:JAD180819 ;
    ns0:fullName "Knut Engedal" ;
    ns0:hasAffiliation ns123:JAD190327,
        ns87:JAD190327 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190327 ;
    ns0:inAuthorList ns150:JAD190327 .

ns5:JAD190329 owl:sameAs ns176:JAD161223,
        ns5:JAD160716 ;
    ns0:fullName "Susan Landau" ;
    ns0:hasAffiliation ns123:JAD190329 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190329 ;
    ns0:inAuthorList ns150:JAD190329 .

ns5:JAD190333 owl:sameAs ns40:jad100702 ;
    ns0:fullName "Albert A. Rizvanov" ;
    ns0:hasAffiliation ns6:JAD190333 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190333 ;
    ns0:inAuthorList ns150:JAD190333 .

ns5:JAD190339 owl:sameAs ns33:JAD180486 ;
    ns0:fullName "Eitan Auriel" ;
    ns0:hasAffiliation ns50:JAD190339,
        ns120:JAD190339 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190339 ;
    ns0:inAuthorList ns150:JAD190339 .

ns5:JAD190344 owl:sameAs ns2:JAD121189,
        ns8:JAD160745,
        ns8:JAD170850,
        ns8:jad00194,
        ns26:JAD150695,
        ns26:JAD150796,
        ns26:JAD160285,
        ns26:JAD180914,
        ns40:JAD131892,
        ns40:JAD132306,
        ns40:JAD160091,
        ns40:JAD170608,
        ns40:JAD171088,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD141305>,
        ns28:JAD160126,
        ns43:JAD150446,
        ns130:JAD122182,
        ns12:JAD0058,
        ns12:JAD141503,
        ns12:JAD150692,
        ns30:jad100888,
        <http://ld.iospress.nl/rdf/contributor/Author:38.ID:JAD160668>,
        ns5:JAD122227,
        ns5:JAD142136,
        ns5:JAD170784,
        ns5:jad00999,
        ns5:jad01337,
        ns5:jad01367,
        ns5:jad091198,
        ns16:JAD141230,
        ns16:JAD170502,
        ns52:JAD122233,
        ns52:JAD131496,
        ns52:JAD150548,
        ns52:JAD151068,
        ns52:JAD151120,
        ns52:JAD151198,
        ns52:JAD171111,
        ns52:JAD180316,
        ns52:JPD181351,
        ns57:JAD111694,
        ns57:JAD111934,
        ns57:JAD121291,
        ns57:JAD132561,
        ns57:JAD150429,
        ns57:jad100186,
        ns33:JAD110494,
        ns33:JAD150812,
        ns33:JAD170893,
        ns33:JAD181095 ;
    ns0:fullName "Philip Scheltens" ;
    ns0:hasAffiliation ns123:JAD190344 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190344 ;
    ns0:inAuthorList ns150:JAD190344 .

ns5:JAD190369 owl:sameAs ns16:JAD143084,
        ns16:JAD181218,
        ns60:JAD190644 ;
    ns0:fullName "Yumiko Nakano" ;
    ns0:hasAffiliation ns6:JAD190369 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190369 ;
    ns0:inAuthorList ns150:JAD190369 .

ns5:JAD190382 owl:sameAs ns5:CBM609,
        ns5:cbm00245 ;
    ns0:fullName "Yi-Ting Mao" ;
    ns0:hasAffiliation ns6:JAD190382 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190382 ;
    ns0:inAuthorList ns150:JAD190382 .

ns5:JAD190402 owl:sameAs ns8:JAD131496,
        ns26:JAD190041,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160091>,
        ns12:JAD160061,
        ns30:JAD160566,
        ns30:jad01337,
        ns30:jad01410 ;
    ns0:fullName "Wiesje M. van der Flier" ;
    ns0:hasAffiliation ns120:JAD190402 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190402 ;
    ns0:inAuthorList ns150:JAD190402 .

ns5:JAD190414 owl:sameAs ns16:JAD171034 ;
    ns0:fullName "Dina Silva" ;
    ns0:hasAffiliation ns6:JAD190414,
        ns123:JAD190414 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190414 ;
    ns0:inAuthorList ns150:JAD190414 .

ns5:JAD190423 owl:sameAs ns16:JAD180223 ;
    ns0:fullName "Ioannis (Yiannis) Kompatsiaris" ;
    ns0:hasAffiliation ns6:JAD190423 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190423 ;
    ns0:inAuthorList ns150:JAD190423 .

ns5:JAD190426 owl:sameAs ns12:JAD180595 ;
    ns0:fullName "Clive Ballard" ;
    ns0:hasAffiliation ns120:JAD190426 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190426 ;
    ns0:inAuthorList ns150:JAD190426 .

ns5:JAD190427 owl:sameAs ns8:JAD131862,
        ns180:JAD190193,
        ns30:JAD120064,
        ns5:JAD101632,
        ns5:JAD120877,
        ns5:JAD121228,
        ns52:JAD110428 ;
    ns0:fullName "Sophie Auriacombe" ;
    ns0:hasAffiliation ns123:JAD190427 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190427 ;
    ns0:inAuthorList ns150:JAD190427 .

ns5:JAD190459 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD161023>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170410>,
        ns16:JAD190183,
        ns33:JAD170990 ;
    ns0:fullName "Bernard Laurent" ;
    ns0:hasAffiliation ns6:JAD190459,
        ns123:JAD190459 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190459 ;
    ns0:inAuthorList ns150:JAD190459 .

ns5:JAD190468 owl:sameAs ns5:JAD180036 ;
    ns0:fullName "Ihab Hajjar" ;
    ns0:hasAffiliation ns6:JAD190468,
        ns50:JAD190468 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190468 ;
    ns0:inAuthorList ns150:JAD190468 .

ns5:JAD190469 owl:sameAs ns43:JAD180048,
        ns30:JAD180394,
        ns60:JAD190007 ;
    ns0:fullName "Soo Hyun Cho" ;
    ns0:hasAffiliation ns6:JAD190469,
        ns50:JAD190469,
        ns120:JAD190469,
        ns71:JAD190469 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190469 ;
    ns0:inAuthorList ns150:JAD190469 .

ns5:JAD190491 owl:sameAs ns16:JAD161153,
        ns52:JAD161295 ;
    ns0:fullName "Linda K. McEvoy" ;
    ns0:hasAffiliation ns50:JAD190491,
        ns120:JAD190491 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190491 ;
    ns0:inAuthorList ns150:JAD190491 .

ns5:JAD190524 owl:sameAs ns12:JAD141266 ;
    ns0:fullName "Fei Song" ;
    ns0:hasAffiliation ns6:JAD190524 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190524 ;
    ns0:inAuthorList ns150:JAD190524 .

ns5:JAD190533 owl:sameAs ns12:JAD161158,
        ns12:JAD171145 ;
    ns0:fullName "Hamid R. Sohrabi" ;
    ns0:hasAffiliation ns6:JAD190533,
        ns50:JAD190533,
        ns87:JAD190533,
        ns71:JAD190533 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190533 ;
    ns0:inAuthorList ns150:JAD190533 .

ns5:JAD190538 owl:sameAs ns8:JAD101995,
        ns12:jad01227,
        ns30:JAD179939,
        ns16:JAD190011 ;
    ns0:fullName "Lisa L. Barnes" ;
    ns0:hasAffiliation ns120:JAD190538,
        ns123:JAD190538,
        ns87:JAD190538 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190538 ;
    ns0:inAuthorList ns150:JAD190538 .

ns5:JAD190541 owl:sameAs ns5:JAD161160 ;
    ns0:fullName "Andrew Steptoe" ;
    ns0:hasAffiliation ns50:JAD190541,
        ns120:JAD190541 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190541 ;
    ns0:inAuthorList ns150:JAD190541 .

ns5:JAD190545 owl:sameAs ns2:JAD190838,
        ns52:JAD160874,
        ns57:JAD190838,
        ns60:JAD170604,
        ns33:JAD160866 ;
    ns0:fullName "Jorge Matías-Guiu" ;
    ns0:hasAffiliation ns120:JAD190545 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190545 ;
    ns0:inAuthorList ns150:JAD190545 .

ns5:JAD190549 owl:sameAs ns52:JAD180082 ;
    ns0:fullName "Sandrine Dupouy" ;
    ns0:hasAffiliation ns6:JAD190549,
        ns50:JAD190549 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190549 ;
    ns0:inAuthorList ns150:JAD190549 .

ns5:JAD190609 owl:sameAs ns5:JAD131403,
        ns60:jad01300 ;
    ns0:fullName "Enzo Grossi" ;
    ns0:hasAffiliation ns87:JAD190609 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190609 ;
    ns0:inAuthorList ns150:JAD190609 .

ns5:JAD190610 owl:sameAs ns8:JAD101560,
        ns8:JAD190527,
        ns8:jad01137,
        ns143:JAD150749,
        ns30:JAD132225,
        ns30:JAD170831,
        ns30:JAD180055,
        ns5:JAD179938,
        ns16:JAD141542,
        ns16:JAD170407,
        ns16:JAD170796,
        ns16:JAD180055,
        ns52:JAD140186,
        ns52:JAD160952,
        ns52:JAD180375,
        ns57:JAD181297,
        ns60:JAD132558,
        ns33:JAD160116 ;
    ns0:fullName "M.K. Ikram" ;
    ns0:hasAffiliation ns87:JAD190610 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190610 ;
    ns0:inAuthorList ns150:JAD190610 .

ns5:JAD190622 owl:sameAs ns16:JAD160923 ;
    ns0:fullName "Shumpei Niida" ;
    ns0:hasAffiliation ns50:JAD190622 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190622 ;
    ns0:inAuthorList ns150:JAD190622 .

ns5:JAD190645 owl:sameAs ns26:JAD170602,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD180291>,
        ns30:JAD0040,
        ns52:JAD170402,
        ns33:JAD160195 ;
    ns0:fullName "Barbara B. Bendlin" ;
    ns0:hasAffiliation ns6:JAD190645,
        ns50:JAD190645 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190645 ;
    ns0:inAuthorList ns150:JAD190645 .

ns5:JAD190685 owl:sameAs ns2:JAD100660,
        ns28:JAD160143 ;
    ns0:fullName "SangYun Kim" ;
    ns0:hasAffiliation ns6:JAD190685 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190685 ;
    ns0:inAuthorList ns150:JAD190685 .

ns5:JAD190700 owl:sameAs ns2:jad101311,
        ns8:JAD160122,
        ns8:jad00087,
        ns8:jad01113,
        ns40:JAD101518,
        ns40:JAD160046,
        ns40:JAD161109,
        ns12:jad01361,
        ns12:jad100327,
        ns30:JAD101068,
        ns30:JAD120724,
        ns30:jad100174,
        <http://ld.iospress.nl/rdf/contributor/Author:38.ID:JAD150883>,
        ns5:JAD101359,
        ns5:JAD101512,
        ns5:JAD121369,
        ns5:JAD190898,
        ns5:jad00147,
        ns5:jad00866,
        ns5:jad100795,
        ns16:JAD122122,
        ns16:JAD130296,
        ns16:JAD131901,
        ns16:JAD160758,
        ns16:JAD180653,
        ns16:jad00079,
        ns16:jad091450,
        ns16:jad100663,
        ns52:JAD160254,
        ns57:ADR170051,
        ns57:JAD160593,
        ns57:JAD170324,
        ns60:JAD170502,
        ns60:JAD190756,
        ns33:JAD160022,
        ns33:JAD170575 ;
    ns0:fullName "Bengt Winblad" ;
    ns0:hasAffiliation ns50:JAD190700,
        ns120:JAD190700 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190700 ;
    ns0:inAuthorList ns150:JAD190700 .

ns5:JAD190771 owl:sameAs ns30:JAD160299,
        ns30:jad00741,
        ns57:JAD120358 ;
    ns0:fullName "Stefano Govoni" ;
    ns0:hasAffiliation ns6:JAD190771 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190771 ;
    ns0:inAuthorList ns150:JAD190771 .

ns5:JAD190779 owl:sameAs ns12:JAD160702,
        ns16:JAD170721 ;
    ns0:fullName "Heng Du" ;
    ns0:hasAffiliation ns6:JAD190779 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190779 ;
    ns0:inAuthorList ns150:JAD190779 .

ns5:JAD190798 owl:sameAs ns2:JAD160304,
        ns26:JAD0044,
        ns26:jad100201,
        ns40:JAD111592,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190311>,
        ns28:JAD170027,
        ns130:JAD170039,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD122182>,
        ns12:JAD190638,
        ns176:JAD180152,
        ns139:JAD180321,
        <http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD180512>,
        <http://ld.iospress.nl/rdf/contributor/Author:23.ID:JAD181016>,
        ns180:JAD161097,
        ns30:JAD161020,
        ns118:JAD180158,
        ns5:JAD131640,
        ns5:JAD140942,
        <http://ld.iospress.nl/rdf/contributor/Author:42.ID:JAD160668>,
        ns16:JAD131121,
        ns16:JAD170564,
        ns16:JAD190423,
        ns16:jad100459,
        ns52:JAD121408,
        ns52:JAD122110,
        ns52:JAD142214,
        ns52:JAD160348,
        ns52:JAD160766,
        ns52:JAD180223,
        ns57:JAD140669,
        ns57:JAD160645,
        <http://ld.iospress.nl/rdf/contributor/Author:76.ID:JAD110824>,
        ns60:JAD141260,
        ns60:JAD150440,
        ns60:JAD160518 ;
    ns0:fullName "Magda Tsolaki" ;
    ns0:hasAffiliation ns123:JAD190798 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190798 ;
    ns0:inAuthorList ns150:JAD190798 .

ns5:JAD190817 owl:sameAs ns57:jad00340 ;
    ns0:fullName "Taro Saito" ;
    ns0:hasAffiliation ns6:JAD190817 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190817 ;
    ns0:inAuthorList ns150:JAD190817 .

ns5:JAD190823 owl:sameAs ns12:JAD190889 ;
    ns0:fullName "Jeremy J. Tree" ;
    ns0:hasAffiliation ns120:JAD190823 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190823 ;
    ns0:inAuthorList ns150:JAD190823 .

ns5:JAD190889 owl:sameAs ns30:JAD190823 ;
    ns0:fullName "Jade E. Norris" ;
    ns0:hasAffiliation ns123:JAD190889 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190889 ;
    ns0:inAuthorList ns150:JAD190889 .

ns5:JAE170051 owl:sameAs ns12:JAE170162 ;
    ns0:fullName "Sai Ji" ;
    ns0:hasAffiliation ns120:JAE170051 ;
    ns0:hasArticle ns1:jae-v60-i4-JAE170051 ;
    ns0:inAuthorList ns150:JAE170051 .

ns5:JAE180100 owl:sameAs ns8:JAE180085,
        ns12:JAE190015,
        ns5:JAE180092 ;
    ns0:fullName "Lujin Cai" ;
    ns0:hasAffiliation ns6:JAE180100 ;
    ns0:hasArticle ns1:jae-v61-i2-JAE180100 ;
    ns0:inAuthorList ns150:JAE180100 .

ns5:JAE190009 owl:sameAs ns2:JAE170038,
        ns2:JAE170163,
        ns12:JAE170092,
        ns30:IFS182699,
        ns5:JAE180001 ;
    ns0:fullName "Li Qiu" ;
    ns0:hasAffiliation ns50:JAE190009 ;
    ns0:hasArticle ns1:jae-v61-i3-JAE190009 ;
    ns0:inAuthorList ns150:JAE190009 .

ns5:JAE190021 owl:sameAs ns5:JAE180086 ;
    ns0:fullName "Wei Zhao" ;
    ns0:hasAffiliation ns6:JAE190021 ;
    ns0:hasArticle ns1:jae-v61-i3-JAE190021 ;
    ns0:inAuthorList ns150:JAE190021 .

ns5:JBR180332 owl:sameAs ns2:IFS181460,
        ns8:IFS17728,
        ns5:IFS171164 ;
    ns0:fullName "Muhammad Farooq" ;
    ns0:hasAffiliation ns50:JBR180332,
        ns120:JBR180332 ;
    ns0:hasArticle ns1:jbr-v9-i2-JBR180332 ;
    ns0:inAuthorList ns150:JBR180332 .

ns5:JCS191286 owl:sameAs ns8:jcs153,
        ns8:jcs167,
        ns8:jcs370 ;
    ns0:fullName "Dimitris Gritzalis" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:4.ID:JCS191286> ;
    ns0:hasArticle ns1:jcs-v27-i5-JCS191286 ;
    ns0:inAuthorList ns150:JCS191286 .

ns5:JHD190365 owl:sameAs ns12:JHD180297,
        ns52:JHD160206 ;
    ns0:fullName "Ira Shoulson" ;
    ns0:hasAffiliation ns50:JHD190365 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190365 ;
    ns0:inAuthorList ns150:JHD190365 .

ns5:JND190397 owl:sameAs ns30:JHD160185 ;
    ns0:fullName "Jeffrey D. Long" ;
    ns0:hasAffiliation ns6:JND190397,
        ns123:JND190397 ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190397 ;
    ns0:inAuthorList ns150:JND190397 .

ns5:JND190407 owl:sameAs ns8:JND180313,
        <http://ld.iospress.nl/rdf/contributor/Author:62.ID:JND170280>,
        ns57:JND160201 ;
    ns0:fullName "Jan J.G.M. Verschuuren" ;
    ns0:hasAffiliation ns6:JND190407 ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190407 ;
    ns0:inAuthorList ns150:JND190407 .

ns5:JND190415 owl:sameAs ns8:JND170232 ;
    ns0:fullName "Karim Wahbi" ;
    ns0:hasAffiliation ns123:JND190415 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190415 ;
    ns0:inAuthorList ns150:JND190415 .

ns5:JPD181460 owl:sameAs ns52:JHD150172 ;
    ns0:fullName "Thomas T. Warner" ;
    ns0:hasAffiliation ns6:JPD181460,
        ns50:JPD181460 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD181460 ;
    ns0:inAuthorList ns150:JPD181460 .

ns5:JPD191610 owl:sameAs ns12:JAD140162,
        ns30:JAD101815,
        ns33:JPD160888 ;
    ns0:fullName "Lucia I. Sue" ;
    ns0:hasAffiliation ns120:JPD191610 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191610 ;
    ns0:inAuthorList ns150:JPD191610 .

ns5:JPD191675 owl:sameAs ns12:JAD170894,
        ns5:JPD181365,
        ns16:JAD151015 ;
    ns0:fullName "Shuei Sugama" ;
    ns0:hasAffiliation ns120:JPD191675 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191675 ;
    ns0:inAuthorList ns150:JPD191675 .

ns5:JVR191023 owl:sameAs ns2:JVR814,
        ns16:JAD170498 ;
    ns0:fullName "Emre Umucu" ;
    ns0:hasAffiliation ns123:JVR191023 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191023 ;
    ns0:inAuthorList ns150:JVR191023 .

ns5:JVR191033 owl:sameAs ns30:JVR191041,
        ns30:JVR191042 ;
    ns0:fullName "Taylor R. Morris" ;
    ns0:hasAffiliation ns6:JVR191033 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191033 ;
    ns0:inAuthorList ns150:JVR191033 .

ns5:JVR191036 owl:sameAs ns2:JVR816,
        ns30:JVR191055,
        ns16:JVR889 ;
    ns0:fullName "Timothy N. Tansey" ;
    ns0:hasAffiliation ns50:JVR191036 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191036 ;
    ns0:inAuthorList ns150:JVR191036 .

ns5:KCA180049 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:40.ID:BLC189037> ;
    ns0:fullName "Ganesh S. Palapattu" ;
    ns0:hasAffiliation ns123:KCA180049 ;
    ns0:hasArticle ns1:kca-v3-i2-KCA180049 ;
    ns0:inAuthorList ns150:KCA180049 .

ns5:KCA190054 owl:sameAs ns8:KCA170024 ;
    ns0:fullName "G. De Velasco" ;
    ns0:hasAffiliation ns6:KCA190054 ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190054 ;
    ns0:inAuthorList ns150:KCA190054 .

ns5:KCA190056 owl:sameAs ns8:BLC170149,
        ns30:KCA170019 ;
    ns0:fullName "Sumanta K. Pal" ;
    ns0:hasAffiliation ns6:KCA190056 ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190056 ;
    ns0:inAuthorList ns150:KCA190056 .

ns5:MGC180753 owl:sameAs ns2:BME1423,
        ns30:BME1348 ;
    ns0:fullName "Peng Xia" ;
    ns0:hasAffiliation ns6:MGC180753 ;
    ns0:hasArticle ns1:mgc-v18-i4-MGC180753 ;
    ns0:inAuthorList ns150:MGC180753 .

ns5:MNM180261 owl:sameAs ns12:MNM180224,
        ns12:MNM180242 ;
    ns0:fullName "Mohammad Esmail Motlagh" ;
    ns0:hasAffiliation ns123:MNM180261 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180261 ;
    ns0:inAuthorList ns150:MNM180261 .

ns5:MNM180275 owl:sameAs ns5:MNM16133 ;
    ns0:fullName "Vassiliki Costarelli" ;
    ns0:hasAffiliation ns6:MNM180275 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180275 ;
    ns0:inAuthorList ns150:MNM180275 .

ns5:NHA190065 owl:sameAs ns30:JAD131682 ;
    ns0:fullName "Robert Krikorian" ;
    ns0:hasAffiliation ns6:NHA190065 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA190065 ;
    ns0:inAuthorList ns150:NHA190065 .

ns5:NHA190068 owl:sameAs ns2:CBM170680,
        ns16:NHA170023 ;
    ns0:fullName "Leo Feferman" ;
    ns0:hasAffiliation ns6:NHA190068,
        ns50:NHA190068 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA190068 ;
    ns0:inAuthorList ns150:NHA190068 .

ns5:NRE192722 owl:sameAs ns2:NRE1413 ;
    ns0:fullName "M.P. Galea" ;
    ns0:hasAffiliation ns6:NRE192722,
        ns50:NRE192722,
        ns120:NRE192722 ;
    ns0:hasArticle ns1:nre-v45-i1-NRE192722 ;
    ns0:inAuthorList ns150:NRE192722 .

ns5:NRE192745 owl:sameAs ns30:bmr00396,
        ns5:BMR170963 ;
    ns0:fullName "Christine Detrembleur" ;
    ns0:hasAffiliation ns6:NRE192745,
        ns87:NRE192745 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192745 ;
    ns0:inAuthorList ns150:NRE192745 .

ns5:NRE192771 owl:sameAs ns16:NRE192700 ;
    ns0:fullName "Ailton Melo" ;
    ns0:hasAffiliation ns6:NRE192771 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192771 ;
    ns0:inAuthorList ns150:NRE192771 .

ns5:NRE192801 owl:sameAs ns2:NRE172238 ;
    ns0:fullName "Jacob Callesen" ;
    ns0:hasAffiliation ns6:NRE192801,
        ns50:NRE192801 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192801 ;
    ns0:inAuthorList ns150:NRE192801 .

ns5:PPR190137 owl:sameAs ns2:WOR2379 ;
    ns0:fullName "François Desmeules" ;
    ns0:hasAffiliation ns87:PPR190137 ;
    ns0:hasArticle ns1:ppr-v40-i2-PPR190137 ;
    ns0:inAuthorList ns150:PPR190137 .

ns5:RNN180883 owl:sameAs ns8:WOR2278 ;
    ns0:fullName "Sung-Bom Pyun" ;
    ns0:hasAffiliation ns6:RNN180883,
        ns50:RNN180883 ;
    ns0:hasArticle ns1:rnn-v37-i3-RNN180883 ;
    ns0:inAuthorList ns150:RNN180883 .

ns5:RNN190909 owl:sameAs ns2:jad00225,
        ns12:JAD180316,
        ns5:JAD122353,
        ns5:JAD131166,
        ns16:JAD141518 ;
    ns0:fullName "Milos D. Ikonomovic" ;
    ns0:hasAffiliation ns6:RNN190909,
        ns50:RNN190909,
        ns120:RNN190909 ;
    ns0:hasArticle ns1:rnn-v37-i3-RNN190909 ;
    ns0:inAuthorList ns150:RNN190909 .

ns5:THC181184 owl:sameAs ns12:CBM567 ;
    ns0:fullName "Chunxiang Jin" ;
    ns0:hasAffiliation ns6:THC181184 ;
    ns0:hasArticle ns1:thc-v27-i4-THC181184 ;
    ns0:inAuthorList ns150:THC181184 .

ns5:THC181510 owl:sameAs ns2:jad01133 ;
    ns0:fullName "Yan Hou" ;
    ns0:hasAffiliation ns50:THC181510 ;
    ns0:hasArticle ns1:thc-v27-i6-THC181510 ;
    ns0:inAuthorList ns150:THC181510 .

ns5:THC191659 owl:sameAs ns16:THC171055 ;
    ns0:fullName "Sönke P. Frey" ;
    ns0:hasAffiliation ns50:THC191659 ;
    ns0:hasArticle ns1:thc-v27-i4-THC191659 ;
    ns0:inAuthorList ns150:THC191659 .

ns5:THC199004 owl:sameAs ns16:CBM170278 ;
    ns0:fullName "Renhua Lv" ;
    ns0:hasAffiliation ns6:THC199004 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199004 ;
    ns0:inAuthorList ns150:THC199004 .

ns5:THC199010 owl:sameAs ns2:BME1377,
        ns2:BME1464,
        ns8:BME1467,
        ns30:BME1377,
        ns30:BME1464,
        ns30:THC199011,
        ns5:THC199011 ;
    ns0:fullName "Lung-Kwang Pan" ;
    ns0:hasAffiliation ns6:THC199010 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199010 ;
    ns0:inAuthorList ns150:THC199010 .

ns5:THC199015 owl:sameAs ns30:BME1299 ;
    ns0:fullName "Hsia-Wei Liu" ;
    ns0:hasAffiliation ns87:THC199015 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199015 ;
    ns0:inAuthorList ns150:THC199015 .

ns5:WOR192952 owl:sameAs ns30:WOR192957 ;
    ns0:fullName "Veronica Jamnik" ;
    ns0:hasAffiliation ns6:WOR192952 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192952 ;
    ns0:inAuthorList ns150:WOR192952 .

ns5:WOR192953 owl:sameAs ns30:WOR192955,
        ns16:WOR2733 ;
    ns0:fullName "Steven L. Fischer" ;
    ns0:hasAffiliation ns6:WOR192953 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192953 ;
    ns0:inAuthorList ns150:WOR192953 .

ns5:WOR192989 owl:sameAs ns2:WOR182824 ;
    ns0:fullName "Rebecca E. Gewurtz" ;
    ns0:hasAffiliation ns6:WOR192989 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192989 ;
    ns0:inAuthorList ns150:WOR192989 .

ns5:WOR193010 owl:sameAs ns8:WOR2426 ;
    ns0:fullName "Bhibha Das" ;
    ns0:hasAffiliation ns6:WOR193010 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193010 ;
    ns0:inAuthorList ns150:WOR193010 .

ns5:XST180457 owl:sameAs ns30:BME1468 ;
    ns0:fullName "Peng Feng" ;
    ns0:hasAffiliation ns6:XST180457 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180457 ;
    ns0:inAuthorList ns150:XST180457 .

ns5:XST180486 owl:sameAs ns40:XST180391,
        ns12:THC174800,
        ns5:THC1315,
        ns5:XST17264,
        ns5:XST180460,
        ns16:XST16216,
        ns16:XST180429,
        ns60:XST18369 ;
    ns0:fullName "Youmin Guo" ;
    ns0:hasAffiliation ns6:XST180486 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180486 ;
    ns0:inAuthorList ns150:XST180486 .

ns5:XST180487 owl:sameAs ns5:XST180427 ;
    ns0:fullName "Min Shao" ;
    ns0:hasAffiliation ns6:XST180487 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180487 ;
    ns0:inAuthorList ns150:XST180487 .

ns5:XST180490 owl:sameAs ns2:JAD100987,
        ns2:JAD130824,
        ns2:jad01317,
        ns5:XST16212,
        ns16:JAD170418,
        ns52:XST180461,
        ns57:XST180464,
        ns60:XST18374,
        ns60:XST18388 ;
    ns0:fullName "Wei Qian" ;
    ns0:hasAffiliation ns6:XST180490,
        ns123:XST180490 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180490 ;
    ns0:inAuthorList ns150:XST180490 .

ns5:XST190491 owl:sameAs ns2:XST180397 ;
    ns0:fullName "M.K.A Karim" ;
    ns0:hasAffiliation ns123:XST190491,
        ns87:XST190491 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190491 ;
    ns0:inAuthorList ns150:XST190491 .

ns5:XST190494 owl:sameAs ns12:VES634 ;
    ns0:fullName "Jing Zou" ;
    ns0:hasAffiliation ns50:XST190494 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190494 ;
    ns0:inAuthorList ns150:XST190494 .

ns5:XST190500 owl:sameAs ns30:XST180418 ;
    ns0:fullName "Mianyi Chen" ;
    ns0:hasAffiliation ns6:XST190500 ;
    ns0:hasArticle ns1:xst-v27-i3-XST190500 ;
    ns0:inAuthorList ns150:XST190500 .

ns5:XST190502 owl:sameAs ns30:JAD150727 ;
    ns0:fullName "Qinghong Duan" ;
    ns0:hasAffiliation ns6:XST190502 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190502 ;
    ns0:inAuthorList ns150:XST190502 .

ns5:XST190503 owl:sameAs ns5:XST598 ;
    ns0:fullName "Der-Chi Tien" ;
    ns0:hasAffiliation ns6:XST190503 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190503 ;
    ns0:inAuthorList ns150:XST190503 .

ns5:XST190506 owl:sameAs ns8:XST180477 ;
    ns0:fullName "Changhui Jiang" ;
    ns0:hasAffiliation ns6:XST190506 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190506 ;
    ns0:inAuthorList ns150:XST190506 .

ns5:XST190514 owl:sameAs ns2:XST495,
        ns12:XST502 ;
    ns0:fullName "Chang-Won Jeong" ;
    ns0:hasAffiliation ns6:XST190514 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190514 ;
    ns0:inAuthorList ns150:XST190514 .

ns16:BLC190218 owl:sameAs ns8:BLC179021 ;
    ns0:fullName "Dan Theodorescu" ;
    ns0:hasAffiliation ns192:BLC190218 ;
    ns0:hasArticle ns1:blc-v5-i2-BLC190218 ;
    ns0:inAuthorList ns150:BLC190218 .

ns16:BSI190185 owl:sameAs ns16:BSI155 ;
    ns0:fullName "Olli H.J. Gröhn" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:5.ID:BSI190185> ;
    ns0:hasArticle ns1:bsi-v8-i1-2-BSI190185 ;
    ns0:inAuthorList ns150:BSI190185 .

ns16:CBM192435 owl:sameAs ns52:CBM181526 ;
    ns0:fullName "Min Yan" ;
    ns0:hasAffiliation ns21:CBM192435 ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM192435 ;
    ns0:inAuthorList ns150:CBM192435 .

ns16:CH180402 owl:sameAs ns16:BIR180175 ;
    ns0:fullName "Burak Oymak" ;
    ns0:hasAffiliation ns22:CH180402 ;
    ns0:hasArticle ns1:ch-v71-i4-CH180402 ;
    ns0:inAuthorList ns150:CH180402 .

ns16:CH180476 owl:sameAs ns57:CH189126 ;
    ns0:fullName "Seahyoung Lee" ;
    ns0:hasAffiliation ns193:CH180476 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180476 ;
    ns0:inAuthorList ns150:CH180476 .

ns16:CH180515 owl:sameAs ns12:JAD190240 ;
    ns0:fullName "Peixi Zang" ;
    ns0:hasAffiliation ns21:CH180515 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180515 ;
    ns0:inAuthorList ns150:CH180515 .

ns16:CH180528 owl:sameAs ns12:CH189301 ;
    ns0:fullName "Ahmed Saleh" ;
    ns0:hasAffiliation ns193:CH180528 ;
    ns0:hasArticle ns1:ch-v72-i4-CH180528 ;
    ns0:inAuthorList ns150:CH180528 .

ns16:CH180540 owl:sameAs ns5:thc00503 ;
    ns0:fullName "A. Anayiotos" ;
    ns0:hasAffiliation ns21:CH180540 ;
    ns0:hasArticle ns1:ch-v72-i4-CH180540 ;
    ns0:inAuthorList ns150:CH180540 .

ns16:CH180545 owl:sameAs ns16:CH180457 ;
    ns0:fullName "Yedong Wu" ;
    ns0:hasAffiliation ns21:CH180545 ;
    ns0:hasArticle ns1:ch-v72-i3-CH180545 ;
    ns0:inAuthorList ns150:CH180545 .

ns16:CH199005 owl:sameAs ns26:CH2001,
        ns12:CH168033,
        ns52:CH189318,
        ns57:CH179210 ;
    ns0:fullName "Nan Ma" ;
    ns0:hasAffiliation ns21:CH199005,
        ns22:CH199005,
        ns192:CH199005 ;
    ns0:hasArticle ns1:ch-v71-i4-CH199005 ;
    ns0:inAuthorList ns150:CH199005 .

ns16:CH199009 owl:sameAs ns5:CH168110 ;
    ns0:fullName "S. Graf" ;
    ns0:hasAffiliation ns21:CH199009 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199009 ;
    ns0:inAuthorList ns150:CH199009 .

ns16:CH199206 owl:sameAs ns30:CH199201 ;
    ns0:fullName "Oliver E. C. Gould" ;
    ns0:hasAffiliation ns21:CH199206 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199206 ;
    ns0:inAuthorList ns150:CH199206 .

ns16:CH199215 owl:sameAs ns5:CH170259 ;
    ns0:fullName "Ernst Klar" ;
    ns0:hasAffiliation ns21:CH199215 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199215 ;
    ns0:inAuthorList ns150:CH199215 .

ns16:CH199219 owl:sameAs ns12:JCB15016,
        ns30:CH2002 ;
    ns0:fullName "H. Hünigen" ;
    ns0:hasAffiliation ns22:CH199219 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199219 ;
    ns0:inAuthorList ns150:CH199219 .

ns16:CH199225 owl:sameAs ns2:CH2005,
        ns8:CH16195,
        ns8:CH168124,
        ns8:CH179201,
        ns8:CH189129,
        ns8:CH189415,
        ns8:CH1963,
        ns8:CH1964,
        ns26:CH179226,
        ns28:CH1920,
        ns12:CH189411,
        ns30:CH168105,
        ns30:CH170365,
        ns30:CH179202,
        ns30:CH179212,
        ns30:CH179216,
        ns30:CH199004,
        ns30:CH199213,
        ns30:CH199218,
        ns5:CH179106,
        ns5:CH179224,
        ns16:CH16194,
        ns16:CH168100,
        ns16:CH170266,
        ns16:CH179227,
        ns16:CH189319,
        ns16:CH1982,
        ns16:CH199212,
        ns16:CH199220,
        ns52:CH170265,
        ns57:CH168110,
        ns57:CH168120,
        ns57:CH170246,
        ns60:CH189107,
        ns60:CH189905,
        ns60:CH199009,
        ns33:CH189309,
        ns33:CH189315 ;
    ns0:fullName "Lukas Prantl" ;
    ns0:hasAffiliation ns21:CH199225 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199225 ;
    ns0:inAuthorList ns150:CH199225 .

ns16:HAB190371 owl:sameAs ns16:HAB190364 ;
    ns0:fullName "Abbas Ostadtaghizadeh" ;
    ns0:hasAffiliation ns22:HAB190371 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190371 ;
    ns0:inAuthorList ns150:HAB190371 .

ns16:ICA190605 owl:sameAs ns33:JAD170069 ;
    ns0:fullName "Juan Manuel Gorriz" ;
    ns0:hasAffiliation ns21:ICA190605,
        ns194:ICA190605 ;
    ns0:hasArticle ns1:ica-v26-i4-ICA190605 ;
    ns0:inAuthorList ns150:ICA190605 .

ns16:IES192167 owl:sameAs ns2:IES192150 ;
    ns0:fullName "Noriaki Maeda" ;
    ns0:hasAffiliation ns21:IES192167 ;
    ns0:hasArticle ns1:ies-v27-i4-IES192167 ;
    ns0:inAuthorList ns150:IES192167 .

ns16:IFS172242 owl:sameAs ns2:IDA183874 ;
    ns0:fullName "Yue Zhao" ;
    ns0:hasAffiliation ns21:IFS172242 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS172242 ;
    ns0:inAuthorList ns150:IFS172242 .

ns16:IFS181516 owl:sameAs ns5:IFS171049,
        ns16:IFS181329 ;
    ns0:fullName "Noor ul Amin" ;
    ns0:hasAffiliation ns192:IFS181516 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181516 ;
    ns0:inAuthorList ns150:IFS181516 .

ns16:IFS181717 owl:sameAs ns12:IFS16381 ;
    ns0:fullName "Huayou Chen" ;
    ns0:hasAffiliation ns193:IFS181717 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181717 ;
    ns0:inAuthorList ns150:IFS181717 .

ns16:ISP180253 owl:sameAs ns57:ISP180254 ;
    ns0:fullName "Vittorio Bucci" ;
    ns0:hasAffiliation ns125:ISP180253 ;
    ns0:hasArticle ns1:isp-v66-i2-ISP180253 ;
    ns0:inAuthorList ns150:ISP180253 .

ns16:JAD170300 owl:sameAs ns8:jad01255,
        ns30:JAD101977,
        ns5:JAD130320,
        ns5:JAD150244,
        ns16:JAD129041 ;
    ns0:fullName "Richard Mayeux" ;
    ns0:hasAffiliation ns21:JAD170300,
        ns22:JAD170300,
        ns193:JAD170300 ;
    ns0:hasArticle ns1:jad-v60-i3-JAD170300 ;
    ns0:inAuthorList ns150:JAD170300 .

ns16:JAD180492 owl:sameAs ns8:JAD180513,
        ns12:JAD160766,
        ns139:JAD161208,
        ns30:JAD170731,
        ns30:JAD180857,
        ns16:JAD190541 ;
    ns0:fullName "Sebastian Köhler" ;
    ns0:hasAffiliation ns21:JAD180492 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180492 ;
    ns0:inAuthorList ns150:JAD180492 .

ns16:JAD180498 owl:sameAs ns2:JAD141248,
        ns2:JAD160826,
        ns2:JAD161209,
        ns2:JAD190181,
        ns2:JAD190506,
        ns8:JAD112126,
        ns26:JAD180763,
        ns12:JAD140630,
        ns12:JAD160774,
        ns12:JAD170055,
        ns5:JAD170050,
        ns5:JAD180572,
        ns5:JAD190342,
        ns16:JAD180631 ;
    ns0:fullName "Kaarin J. Anstey" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:5.ID:JAD180498> ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180498 ;
    ns0:inAuthorList ns150:JAD180498 .

ns16:JAD180857 owl:sameAs ns130:JAD180275,
        ns5:JAD161208 ;
    ns0:fullName "Marjolein E. de Vugt" ;
    ns0:hasAffiliation ns21:JAD180857 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD180857 ;
    ns0:inAuthorList ns150:JAD180857 .

ns16:JAD180932 owl:sameAs ns30:JAD170496,
        ns57:JPD150632 ;
    ns0:fullName "Mark Rice" ;
    ns0:hasAffiliation ns193:JAD180932 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180932 ;
    ns0:inAuthorList ns150:JAD180932 .

ns16:JAD180949 owl:sameAs ns8:JAD110251,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD141521>,
        ns12:JAD160209,
        ns12:JAD180981,
        ns57:JAD160407 ;
    ns0:fullName "Birgitt Wiese" ;
    ns0:hasAffiliation ns194:JAD180949 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

ns16:JAD181033 owl:sameAs ns30:AIS370 ;
    ns0:fullName "Jan Alexandersson" ;
    ns0:hasAffiliation ns193:JAD181033 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181033 ;
    ns0:inAuthorList ns150:JAD181033 .

ns16:JAD181047 owl:sameAs ns132:JAD170624,
        ns30:JAD120073 ;
    ns0:fullName "Zuzana Walker" ;
    ns0:hasAffiliation ns21:JAD181047 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181047 ;
    ns0:inAuthorList ns150:JAD181047 .

ns16:JAD181113 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JND190421> ;
    ns0:fullName "Antonio M. Persico" ;
    ns0:hasAffiliation ns193:JAD181113,
        ns192:JAD181113 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD181113 ;
    ns0:inAuthorList ns150:JAD181113 .

ns16:JAD181140 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:26.ID:JAD150749> ;
    ns0:fullName "Lenore Launer" ;
    ns0:hasAffiliation ns192:JAD181140 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181140 ;
    ns0:inAuthorList ns150:JAD181140 .

ns16:JAD181170 owl:sameAs ns16:JAD181169 ;
    ns0:fullName "Andrew M. Johnson" ;
    ns0:hasAffiliation ns75:JAD181170 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181170 ;
    ns0:inAuthorList ns150:JAD181170 .

ns16:JAD181171 owl:sameAs ns8:JAD180496,
        ns12:JAD180511,
        ns60:JAD170880 ;
    ns0:fullName "Suzana Makpol" ;
    ns0:hasAffiliation ns22:JAD181171 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD181171 ;
    ns0:inAuthorList ns150:JAD181171 .

ns16:JAD181203 owl:sameAs ns5:JAD161292,
        ns5:JAD170238,
        ns16:JAD161248,
        ns16:JAD180030 ;
    ns0:fullName "Paul I. Oh" ;
    ns0:hasAffiliation ns75:JAD181203 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181203 ;
    ns0:inAuthorList ns150:JAD181203 .

ns16:JAD181217 owl:sameAs ns2:JAD180425 ;
    ns0:fullName "Li-Jun Zuo" ;
    ns0:hasAffiliation ns21:JAD181217 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181217 ;
    ns0:inAuthorList ns150:JAD181217 .

ns16:JAD181224 owl:sameAs ns52:JAD180531 ;
    ns0:fullName "Martin Orrell" ;
    ns0:hasAffiliation ns21:JAD181224 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181224 ;
    ns0:inAuthorList ns150:JAD181224 .

ns16:JAD181246 owl:sameAs ns30:JAD161182 ;
    ns0:fullName "Alexander Deev" ;
    ns0:hasAffiliation ns22:JAD181246 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181246 ;
    ns0:inAuthorList ns150:JAD181246 .

ns16:JAD181256 owl:sameAs ns26:JAD160554,
        ns28:JAD170583,
        ns43:JAD190132,
        ns60:JAD111109 ;
    ns0:fullName "Annakaisa Haapasalo" ;
    ns0:hasAffiliation ns75:JAD181256 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181256 ;
    ns0:inAuthorList ns150:JAD181256 .

ns16:JAD181259 owl:sameAs ns30:JAD151078 ;
    ns0:fullName "Nasser Al-Daghri" ;
    ns0:hasAffiliation ns22:JAD181259 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD181259 ;
    ns0:inAuthorList ns150:JAD181259 .

ns16:JAD181261 owl:sameAs ns2:JAD131844,
        ns57:JAD161277,
        ns57:JAD180280 ;
    ns0:fullName "Simon Kang Seng Ting" ;
    ns0:hasAffiliation ns21:JAD181261 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181261 ;
    ns0:inAuthorList ns150:JAD181261 .

ns16:JAD181272 owl:sameAs ns8:JAD150770,
        ns12:JAD102094,
        ns12:jad091729,
        ns30:jad100405,
        ns5:JAD112141,
        ns5:jad100417 ;
    ns0:fullName "Charles Ramassamy" ;
    ns0:hasAffiliation ns22:JAD181272 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181272 ;
    ns0:inAuthorList ns150:JAD181272 .

ns16:JAD181277 owl:sameAs ns28:JAD160188,
        ns139:JAD170327,
        ns30:jad100198,
        ns5:JAD131085,
        ns5:jad01310,
        ns16:JAD121246,
        ns33:JAD140405,
        ns33:JAD141986 ;
    ns0:fullName "Sebastiaan Engelborghs" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff17.Author:5.ID:JAD181277>,
        ns192:JAD181277 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181277 ;
    ns0:inAuthorList ns150:JAD181277 .

ns16:JAD181288 owl:sameAs ns52:JAD150438 ;
    ns0:fullName "Zhongcong Xie" ;
    ns0:hasAffiliation ns193:JAD181288 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181288 ;
    ns0:inAuthorList ns150:JAD181288 .

ns16:JAD181295 owl:sameAs ns2:JAD120802,
        ns2:JAD130698,
        ns8:JAD160643,
        ns8:JAD160956,
        ns30:JAD140282,
        ns5:JAD150630,
        ns16:JAD160671,
        ns16:JAD180125,
        ns52:JAD140336,
        ns52:JAD180594,
        ns52:JAD180912 ;
    ns0:fullName "Anna-Maija Tolppanen" ;
    ns0:hasAffiliation ns22:JAD181295,
        ns194:JAD181295 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181295 ;
    ns0:inAuthorList ns150:JAD181295 .

ns16:JAD181298 owl:sameAs ns2:JAD180524,
        ns12:JAD170938,
        ns12:JAD190609 ;
    ns0:fullName "Maria Elena Di Battista" ;
    ns0:hasAffiliation ns21:JAD181298 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181298 ;
    ns0:inAuthorList ns150:JAD181298 .

ns16:JAD190019 owl:sameAs ns8:JAD160291,
        <http://ld.iospress.nl/rdf/contributor/Author:2.ID:BMR11(1)02>,
        ns30:JAD111631,
        ns30:JAD150776,
        ns30:JAD180335,
        ns30:JAD181141,
        ns16:JAD160230,
        ns16:JAD170289,
        ns16:JAD190262,
        ns52:JAD180604 ;
    ns0:fullName "Richard B. Lipton" ;
    ns0:hasAffiliation ns194:JAD190019 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190019 ;
    ns0:inAuthorList ns150:JAD190019 .

ns16:JAD190038 owl:sameAs ns12:RNN150581,
        ns16:JAD181176 ;
    ns0:fullName "Louis Bherer" ;
    ns0:hasAffiliation ns193:JAD190038,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190038> ;
    ns0:hasArticle ns1:jad-v71-is1-JAD190038 ;
    ns0:inAuthorList ns150:JAD190038 .

ns16:JAD190041 owl:sameAs ns2:JAD141305,
        ns26:JAD140138,
        ns26:JAD160126,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160474>,
        ns30:JAD141137,
        ns30:jad100288,
        ns16:JAD151120,
        ns16:JAD171083 ;
    ns0:fullName "Marcel G.M. Olde Rikkert" ;
    ns0:hasAffiliation ns192:JAD190041 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190041 ;
    ns0:inAuthorList ns150:JAD190041 .

ns16:JAD190052 owl:sameAs ns26:JAD160110,
        ns26:JAD170402,
        ns28:JAD120763,
        ns28:JAD160642,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160195>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:jad00799>,
        ns5:JAD180592,
        ns52:jad01165,
        ns60:JAD110341,
        ns60:JAD190645,
        ns33:JAD161067,
        ns33:JAD180291 ;
    ns0:fullName "Sanjay Asthana" ;
    ns0:hasAffiliation ns192:JAD190052,
        ns195:JAD190052,
        ns75:JAD190052 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190052 ;
    ns0:inAuthorList ns150:JAD190052 .

ns16:JAD190075 owl:sameAs ns26:JAD150482 ;
    ns0:fullName "Stefan F.T. Weiss" ;
    ns0:hasAffiliation ns21:JAD190075 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190075 ;
    ns0:inAuthorList ns150:JAD190075 .

ns16:JAD190077 owl:sameAs ns8:JAD150914 ;
    ns0:fullName "Katherine A. Gifford" ;
    ns0:hasAffiliation ns21:JAD190077 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190077 ;
    ns0:inAuthorList ns150:JAD190077 .

ns16:JAD190090 owl:sameAs ns2:jad01196 ;
    ns0:fullName "Scott E. Counts" ;
    ns0:hasAffiliation ns21:JAD190090,
        ns22:JAD190090,
        ns193:JAD190090,
        ns195:JAD190090,
        ns75:JAD190090,
        ns194:JAD190090 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190090 ;
    ns0:inAuthorList ns150:JAD190090 .

ns16:JAD190092 owl:sameAs ns16:JAD180070 ;
    ns0:fullName "Clinton B. Wright" ;
    ns0:hasAffiliation ns75:JAD190092 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190092 ;
    ns0:inAuthorList ns150:JAD190092 .

ns16:JAD190106 owl:sameAs ns5:JAD140177 ;
    ns0:fullName "Allan I. Levey" ;
    ns0:hasAffiliation ns21:JAD190106 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD190106 ;
    ns0:inAuthorList ns150:JAD190106 .

ns16:JAD190119 owl:sameAs ns2:JAD180723,
        ns16:JAD170712,
        ns52:JAD170861 ;
    ns0:fullName "Giorgio Giulio Fumagalli" ;
    ns0:hasAffiliation ns22:JAD190119,
        ns75:JAD190119 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

ns16:JAD190128 owl:sameAs ns5:JAD122071,
        ns52:JAD121420 ;
    ns0:fullName "Michael Devous" ;
    ns0:hasAffiliation ns21:JAD190128,
        ns22:JAD190128 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190128 ;
    ns0:inAuthorList ns150:JAD190128 .

ns16:JAD190133 owl:sameAs ns30:JAD132363,
        ns52:JAD170092,
        ns57:JAD170123 ;
    ns0:fullName "Tiina Laatikainen" ;
    ns0:hasAffiliation ns21:JAD190133,
        ns194:JAD190133,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190133> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190133 ;
    ns0:inAuthorList ns150:JAD190133 .

ns16:JAD190146 owl:sameAs ns16:JAD170101 ;
    ns0:fullName "Jeremy Horwood" ;
    ns0:hasAffiliation ns21:JAD190146,
        ns22:JAD190146 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190146 ;
    ns0:inAuthorList ns150:JAD190146 .

ns16:JAD190153 owl:sameAs ns8:JAD150826,
        ns30:JAD180971,
        ns30:JAD181062,
        ns5:JAD170061,
        ns5:JAD180205,
        ns5:JAD181038,
        ns16:JAD180971 ;
    ns0:fullName "Lan Tan" ;
    ns0:hasAffiliation ns21:JAD190153 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190153 ;
    ns0:inAuthorList ns150:JAD190153 .

ns16:JAD190154 owl:sameAs ns2:jad00419,
        ns8:JAD00018,
        ns26:JAD180564,
        ns40:JAD140174,
        ns28:jad00971,
        ns43:JAD150948,
        ns43:JAD170834,
        ns12:JAD00050,
        ns12:JAD150855,
        ns12:jad00272,
        ns12:jad00527,
        ns30:JAD121594,
        ns5:JAD122026,
        ns16:JAD141743,
        ns52:JAD150478,
        ns57:JAD160722,
        ns60:JAD170521 ;
    ns0:fullName "John C. Morris" ;
    ns0:hasAffiliation ns192:JAD190154,
        ns195:JAD190154 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190154 ;
    ns0:inAuthorList ns150:JAD190154 .

ns16:JAD190165 owl:sameAs ns2:jad00175,
        ns2:jad00418,
        ns8:JAD181089 ;
    ns0:fullName "J. Wesson Ashford" ;
    ns0:hasAffiliation ns195:JAD190165 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190165 ;
    ns0:inAuthorList ns150:JAD190165 .

ns16:JAD190175 owl:sameAs ns30:JAD150750 ;
    ns0:fullName "Guro Berge" ;
    ns0:hasAffiliation ns193:JAD190175 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190175 ;
    ns0:inAuthorList ns150:JAD190175 .

ns16:JAD190197 owl:sameAs ns12:JAD129025,
        ns30:JAD122223,
        ns30:jad00795,
        ns16:jad100285 ;
    ns0:fullName "Jesus Avila" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190197> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190197 ;
    ns0:inAuthorList ns150:JAD190197 .

ns16:JAD190202 owl:sameAs ns26:jad101413,
        ns40:JAD170238,
        ns30:jad01275,
        ns16:JAD132528,
        ns52:JAD0058,
        ns57:JAD140588 ;
    ns0:fullName "Sandra E. Black" ;
    ns0:hasAffiliation ns21:JAD190202,
        ns195:JAD190202 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190202 ;
    ns0:inAuthorList ns150:JAD190202 .

ns16:JAD190237 owl:sameAs ns2:jad01199 ;
    ns0:fullName "Annamaria Cimini" ;
    ns0:hasAffiliation ns193:JAD190237,
        ns195:JAD190237,
        ns75:JAD190237 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190237 ;
    ns0:inAuthorList ns150:JAD190237 .

ns16:JAD190280 owl:sameAs ns2:ida00641,
        ns2:jad00890,
        ns8:JAD170839,
        ns8:jad00490,
        ns12:JAD160845,
        ns12:JAD179921,
        ns30:jad01003,
        ns5:JAD180882,
        ns5:jad00079,
        ns5:jad100069,
        ns16:jad00418,
        ns52:JAD100987,
        ns52:JAD150497,
        ns57:JAD130824 ;
    ns0:fullName "Khalid Iqbal" ;
    ns0:hasAffiliation ns21:JAD190280 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190280 ;
    ns0:inAuthorList ns150:JAD190280 .

ns16:JAD190323 owl:sameAs ns130:jad100933 ;
    ns0:fullName "Gloria Tognoni" ;
    ns0:hasAffiliation ns21:JAD190323 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190323 ;
    ns0:inAuthorList ns150:JAD190323 .

ns16:JAD190331 owl:sameAs ns8:JAD180853,
        ns8:JAD181208,
        ns30:JAD170012,
        ns5:JAD190405 ;
    ns0:fullName "Partha S. Mukherjee" ;
    ns0:hasAffiliation ns195:JAD190331 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190331 ;
    ns0:inAuthorList ns150:JAD190331 .

ns16:JAD190339 owl:sameAs ns60:JAD160939 ;
    ns0:fullName "Natan M. Bornstein" ;
    ns0:hasAffiliation ns22:JAD190339,
        ns192:JAD190339 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190339 ;
    ns0:inAuthorList ns150:JAD190339 .

ns16:JAD190340 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170971>,
        ns43:JAD170971,
        ns60:JAD160651,
        ns33:JAD130398,
        ns33:JAD171177 ;
    ns0:fullName "Hiroyuki Nakamura" ;
    ns0:hasAffiliation ns75:JAD190340 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190340 ;
    ns0:inAuthorList ns150:JAD190340 .

ns16:JAD190344 owl:sameAs ns8:JAD111934,
        ns8:JAD132306,
        ns8:JAD151063,
        ns40:JAD150812,
        ns40:JAD160386,
        ns40:JAD180839,
        ns28:JAD160285,
        ns30:JAD160061,
        ns5:JAD141230,
        ns5:JAD170859,
        ns16:JAD181004,
        ns16:jad01337,
        ns60:JAD140138,
        ns60:JAD150695,
        ns60:JAD151198,
        ns60:JAD170893,
        ns60:jad01392 ;
    ns0:fullName "Yolande A.L. Pijnenburg" ;
    ns0:hasAffiliation ns192:JAD190344 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190344 ;
    ns0:inAuthorList ns150:JAD190344 .

ns16:JAD190365 owl:sameAs ns30:JAD160506,
        ns30:JAD160780,
        ns16:JPD160888,
        ns52:JAD181099,
        ns60:JAD150606 ;
    ns0:fullName "David G. Munoz" ;
    ns0:hasAffiliation ns21:JAD190365,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190365>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:5.ID:JAD190365> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190365 ;
    ns0:inAuthorList ns150:JAD190365 .

ns16:JAD190369 owl:sameAs ns8:JAD190644 ;
    ns0:fullName "Ryuta Morihara" ;
    ns0:hasAffiliation ns21:JAD190369 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190369 ;
    ns0:inAuthorList ns150:JAD190369 .

ns16:JAD190414 owl:sameAs ns2:JAD171034 ;
    ns0:fullName "Luísa Alves" ;
    ns0:hasAffiliation ns195:JAD190414 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190414 ;
    ns0:inAuthorList ns150:JAD190414 .

ns16:JAD190427 owl:sameAs ns12:JAD141629 ;
    ns0:fullName "Geneviève Chêne" ;
    ns0:hasAffiliation ns21:JAD190427 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190427 ;
    ns0:inAuthorList ns150:JAD190427 .

ns16:JAD190446 owl:sameAs ns40:jad091549,
        ns30:JAD180106,
        ns60:JAD0025 ;
    ns0:fullName "Katharina Buerger" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:5.ID:JAD190446>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:5.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns16:JAD190458 owl:sameAs ns30:JAD151121 ;
    ns0:fullName "Qi Xiang" ;
    ns0:hasAffiliation ns21:JAD190458,
        ns22:JAD190458 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190458 ;
    ns0:inAuthorList ns150:JAD190458 .

ns16:JAD190484 owl:sameAs ns30:JAD170045 ;
    ns0:fullName "Sandra Villegas" ;
    ns0:hasAffiliation ns21:JAD190484 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190484 ;
    ns0:inAuthorList ns150:JAD190484 .

ns16:JAD190495 owl:sameAs ns26:JAD122224,
        ns12:JAD111886,
        ns12:JAD130347,
        ns30:JAD110047,
        ns30:JAD122140,
        ns30:JAD131337,
        ns5:JAD120532,
        ns5:JAD170995,
        ns5:NRE1421,
        ns5:RNN180850,
        ns16:JAD121144,
        ns16:JAD142895,
        ns16:JAD170086,
        ns16:JAD170317,
        ns16:JAD180503,
        ns16:JAD180609,
        ns16:JAD180690,
        ns16:jad01223,
        ns16:jad01300,
        ns16:jad01352,
        ns16:jad100780,
        ns52:JAD110116,
        ns52:JAD131766,
        ns52:JAD150612,
        ns52:JAD160892,
        ns52:jad01191,
        ns57:jad01257,
        ns57:jad01384,
        ns57:jad100048,
        ns60:jad01031,
        ns33:JAD121663,
        ns33:JAD130656,
        ns33:JAD141824,
        ns33:JAD160975,
        ns33:jad01144 ;
    ns0:fullName "Carlo Caltagirone" ;
    ns0:hasAffiliation ns22:JAD190495 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190495 ;
    ns0:inAuthorList ns150:JAD190495 .

ns16:JAD190507 owl:sameAs ns2:JAD129044,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad01390>,
        ns57:jad100816,
        ns60:JAD190562 ;
    ns0:fullName "Rudolph E. Tanzi" ;
    ns0:hasAffiliation ns75:JAD190507 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190507 ;
    ns0:inAuthorList ns150:JAD190507 .

ns16:JAD190517 owl:sameAs ns30:mas00306 ;
    ns0:fullName "Kenneth Rockwood" ;
    ns0:hasAffiliation ns193:JAD190517 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD190517 ;
    ns0:inAuthorList ns150:JAD190517 .

ns16:JAD190519 owl:sameAs ns5:jad00595,
        ns16:jad00896,
        ns52:JAD111076,
        ns33:jad00584 ;
    ns0:fullName "James B. Leverenz" ;
    ns0:hasAffiliation ns21:JAD190519,
        ns22:JAD190519 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190519 ;
    ns0:inAuthorList ns150:JAD190519 .

ns16:JAD190524 owl:sameAs ns8:JAD141314,
        ns8:JAD150537,
        ns16:JAD140846,
        ns57:JAD150619 ;
    ns0:fullName "Karen A. Mather" ;
    ns0:hasAffiliation ns21:JAD190524,
        ns193:JAD190524 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190524 ;
    ns0:inAuthorList ns150:JAD190524 .

ns16:JAD190538 owl:sameAs ns8:jad00609 ;
    ns0:fullName "Denis A. Evans" ;
    ns0:hasAffiliation ns22:JAD190538 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190538 ;
    ns0:inAuthorList ns150:JAD190538 .

ns16:JAD190567 owl:sameAs ns8:JAD00045,
        ns16:JAD120481,
        ns60:JAD180976 ;
    ns0:fullName "Rajesh N. Kalaria" ;
    ns0:hasAffiliation ns21:JAD190567 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190567 ;
    ns0:inAuthorList ns150:JAD190567 .

ns16:JAD190569 owl:sameAs ns60:jad01212 ;
    ns0:fullName "Kathleen A. Welsh-Bohmer" ;
    ns0:hasAffiliation ns21:JAD190569 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190569 ;
    ns0:inAuthorList ns150:JAD190569 .

ns16:JAD190571 owl:sameAs ns30:JAD122116,
        ns30:JAD190590 ;
    ns0:fullName "Marcus Richards" ;
    ns0:hasAffiliation ns22:JAD190571 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190571 ;
    ns0:inAuthorList ns150:JAD190571 .

ns16:JAD190572 owl:sameAs ns16:JAD170278,
        ns52:JAD160271 ;
    ns0:fullName "Anna Erlandsson" ;
    ns0:hasAffiliation ns21:JAD190572 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190572 ;
    ns0:inAuthorList ns150:JAD190572 .

ns16:JAD190604 owl:sameAs ns12:jad00468 ;
    ns0:fullName "Stefani N. Thomas" ;
    ns0:hasAffiliation ns192:JAD190604 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190604 ;
    ns0:inAuthorList ns150:JAD190604 .

ns16:JAD190610 owl:sameAs ns30:JAD170796,
        ns57:JAD160139 ;
    ns0:fullName "Ching-Yu Cheng" ;
    ns0:hasAffiliation ns75:JAD190610,
        ns194:JAD190610,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190610> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190610 ;
    ns0:inAuthorList ns150:JAD190610 .

ns16:JAD190644 owl:sameAs ns60:JAD190369 ;
    ns0:fullName "Ryo Sasaki" ;
    ns0:hasAffiliation ns21:JAD190644 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns16:JAD190688 owl:sameAs ns12:JAD160254 ;
    ns0:fullName "Pavla Cermakova" ;
    ns0:hasAffiliation ns195:JAD190688,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190688> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190688 ;
    ns0:inAuthorList ns150:JAD190688 .

ns16:JAD190756 owl:sameAs ns30:JAD160593 ;
    ns0:fullName "Yvonne Terjestam" ;
    ns0:hasAffiliation ns193:JAD190756 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190756 ;
    ns0:inAuthorList ns150:JAD190756 .

ns16:JAD190775 owl:sameAs ns2:JAD170755 ;
    ns0:fullName "Masatsune Ishikawa" ;
    ns0:hasAffiliation ns192:JAD190775 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190775 ;
    ns0:inAuthorList ns150:JAD190775 .

ns16:JAD190817 owl:sameAs ns26:JAD180985,
        ns33:JAD180904 ;
    ns0:fullName "Hiromi Suzuki" ;
    ns0:hasAffiliation ns21:JAD190817 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190817 ;
    ns0:inAuthorList ns150:JAD190817 .

ns16:JAD190838 owl:sameAs ns2:JAD121975,
        ns12:JAD190545,
        ns30:JAD160874,
        ns16:JAD170604,
        ns57:JAD160866 ;
    ns0:fullName "Teresa Moreno-Ramos" ;
    ns0:hasAffiliation ns21:JAD190838 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190838 ;
    ns0:inAuthorList ns150:JAD190838 .

ns16:JAD190888 owl:sameAs ns16:JPD171172 ;
    ns0:fullName "Lisa Cipolotti" ;
    ns0:hasAffiliation ns195:JAD190888 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190888 ;
    ns0:inAuthorList ns150:JAD190888 .

ns16:JAD190889 owl:sameAs ns2:JAD101818,
        ns2:JAD120505,
        ns2:JAD132414,
        ns30:JAD170599,
        ns30:JAD180810,
        ns5:JAD140930,
        ns5:JAD160545,
        ns16:JAD131934,
        ns16:JAD150791,
        ns16:JAD190823 ;
    ns0:fullName "Andrea Tales" ;
    ns0:hasAffiliation ns21:JAD190889 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190889 ;
    ns0:inAuthorList ns150:JAD190889 .

ns16:JAE191291 owl:sameAs ns5:JAE1988 ;
    ns0:fullName "Pierre Faverolle" ;
    ns0:hasAffiliation ns193:JAE191291 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191291 ;
    ns0:inAuthorList ns150:JAE191291 .

ns16:JHD180337 owl:sameAs ns52:JHD180325,
        ns57:JHD170284,
        ns60:JHD180285 ;
    ns0:fullName "Nicole Kemper" ;
    ns0:hasAffiliation ns22:JHD180337 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD180337 ;
    ns0:inAuthorList ns150:JHD180337 .

ns16:JHD190364 owl:sameAs ns12:JHD170236 ;
    ns0:fullName "Jane S. Paulsen" ;
    ns0:hasAffiliation ns195:JHD190364 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190364 ;
    ns0:inAuthorList ns150:JHD190364 .

ns16:JND180345 owl:sameAs ns132:JND170280,
        ns30:JND170277 ;
    ns0:fullName "Craig Campbell" ;
    ns0:hasAffiliation ns193:JND180345 ;
    ns0:hasArticle ns1:jnd-v6-i3-JND180345 ;
    ns0:inAuthorList ns150:JND180345 .

ns16:JPD181518 owl:sameAs ns52:JPD171199 ;
    ns0:fullName "Tanya Simuni" ;
    ns0:hasAffiliation ns192:JPD181518 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181518 ;
    ns0:inAuthorList ns150:JPD181518 .

ns16:JPD191610 owl:sameAs ns8:JPD160860,
        ns52:JPD150680 ;
    ns0:fullName "Holly A. Shill" ;
    ns0:hasAffiliation ns192:JPD191610 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191610 ;
    ns0:inAuthorList ns150:JPD191610 .

ns16:JPD191648 owl:sameAs ns43:JAD160573,
        ns12:JAD130575 ;
    ns0:fullName "Klaus Romero" ;
    ns0:hasAffiliation ns21:JPD191648 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191648 ;
    ns0:inAuthorList ns150:JPD191648 .

ns16:JPD191675 owl:sameAs ns16:JHD180309,
        ns16:JPD181365 ;
    ns0:fullName "Takato Takenouchi" ;
    ns0:hasAffiliation ns192:JPD191675 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191675 ;
    ns0:inAuthorList ns150:JPD191675 .

ns16:JVR191022 owl:sameAs ns2:JVR191026,
        ns8:JVR191020 ;
    ns0:fullName "Malachy L. Bishop" ;
    ns0:hasAffiliation ns195:JVR191022 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191022 ;
    ns0:inAuthorList ns150:JVR191022 .

ns16:JVR191023 owl:sameAs ns2:JAD170477 ;
    ns0:fullName "Jing Tao" ;
    ns0:hasAffiliation ns195:JVR191023 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191023 ;
    ns0:inAuthorList ns150:JVR191023 .

ns16:MGC180763 owl:sameAs ns52:MGC242 ;
    ns0:fullName "Bao-Xian Ye" ;
    ns0:hasAffiliation ns21:MGC180763 ;
    ns0:hasArticle ns1:mgc-v18-i4-MGC180763 ;
    ns0:inAuthorList ns150:MGC180763 .

ns16:MGS190313 owl:sameAs ns30:MGS284 ;
    ns0:fullName "Asiya Khan" ;
    ns0:hasAffiliation ns195:MGS190313 ;
    ns0:hasArticle ns1:mgs-v15-i3-MGS190313 ;
    ns0:inAuthorList ns150:MGS190313 .

ns16:NPM1854 owl:sameAs ns12:NPM16101 ;
    ns0:fullName "E.I. Rubio" ;
    ns0:hasAffiliation ns22:NPM1854 ;
    ns0:hasArticle ns1:npm-v12-i3-NPM1854 ;
    ns0:inAuthorList ns150:NPM1854 .

ns16:NRE182565 owl:sameAs ns12:NRE192752 ;
    ns0:fullName "Poul Jennum" ;
    ns0:hasAffiliation ns22:NRE182565,
        ns193:NRE182565 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182565 ;
    ns0:inAuthorList ns150:NRE182565 .

ns16:NRE182637 owl:sameAs ns8:JAD180769,
        ns5:NRE172274,
        ns52:JAD171166,
        ns52:NRE182505 ;
    ns0:fullName "Nicola Biagio Mercuri" ;
    ns0:hasAffiliation ns21:NRE182637,
        ns22:NRE182637 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182637 ;
    ns0:inAuthorList ns150:NRE182637 .

ns16:NRE192722 owl:sameAs ns12:NRE189009 ;
    ns0:fullName "F. Khan" ;
    ns0:hasAffiliation ns21:NRE192722,
        ns22:NRE192722,
        ns193:NRE192722 ;
    ns0:hasArticle ns1:nre-v45-i1-NRE192722 ;
    ns0:inAuthorList ns150:NRE192722 .

ns16:NRE192745 owl:sameAs ns5:NRE182525 ;
    ns0:fullName "Gaëtan Stoquart" ;
    ns0:hasAffiliation ns21:NRE192745,
        ns193:NRE192745,
        ns195:NRE192745 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192745 ;
    ns0:inAuthorList ns150:NRE192745 .

ns16:NRE192788 owl:sameAs ns57:JPD181516 ;
    ns0:fullName "G.K. Kerr" ;
    ns0:hasAffiliation ns21:NRE192788,
        ns22:NRE192788 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192788 ;
    ns0:inAuthorList ns150:NRE192788 .

ns16:PPR190133 owl:sameAs ns2:PPR180122 ;
    ns0:fullName "Jessie Janssen" ;
    ns0:hasAffiliation ns193:PPR190133 ;
    ns0:hasArticle ns1:ppr-v40-i2-PPR190133 ;
    ns0:inAuthorList ns150:PPR190133 .

ns16:RNN190919 owl:sameAs ns2:RNN180812,
        ns60:RNN170767 ;
    ns0:fullName "Jerzy P. Szaflarski" ;
    ns0:hasAffiliation ns21:RNN190919,
        ns193:RNN190919 ;
    ns0:hasArticle ns1:rnn-v37-i5-RNN190919 ;
    ns0:inAuthorList ns150:RNN190919 .

ns16:THC191639 owl:sameAs ns30:thc00680 ;
    ns0:fullName "Makoto Ohta" ;
    ns0:hasAffiliation ns21:THC191639 ;
    ns0:hasArticle ns1:thc-v27-i6-THC191639 ;
    ns0:inAuthorList ns150:THC191639 .

ns16:THC199029 owl:sameAs ns2:BME1508,
        ns30:RNN150515,
        ns5:RNN170725,
        ns52:RNN190926 ;
    ns0:fullName "Ting Xiao" ;
    ns0:hasAffiliation ns21:THC199029 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199029 ;
    ns0:inAuthorList ns150:THC199029 .

ns16:THC199031 owl:sameAs ns12:THC199029 ;
    ns0:fullName "Shengquan Liu" ;
    ns0:hasAffiliation ns21:THC199031 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199031 ;
    ns0:inAuthorList ns150:THC199031 .

ns16:WOR192942 owl:sameAs ns16:WOR192971 ;
    ns0:fullName "David G. Baxter" ;
    ns0:hasAffiliation ns193:WOR192942 ;
    ns0:hasArticle ns1:wor-v63-i3-WOR192942 ;
    ns0:inAuthorList ns150:WOR192942 .

ns16:WOR192958 owl:sameAs ns8:WOR192956 ;
    ns0:fullName "Marilyn A. Sharp" ;
    ns0:hasAffiliation ns21:WOR192958 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192958 ;
    ns0:inAuthorList ns150:WOR192958 .

ns16:XST180453 owl:sameAs ns16:CH16242,
        ns16:CH170316 ;
    ns0:fullName "Weijun Peng" ;
    ns0:hasAffiliation ns193:XST180453 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180453 ;
    ns0:inAuthorList ns150:XST180453 .

ns16:XST180460 owl:sameAs ns30:jcm00516,
        ns52:XST18369 ;
    ns0:fullName "Lu Bai" ;
    ns0:hasAffiliation ns21:XST180460 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180460 ;
    ns0:inAuthorList ns150:XST180460 .

ns16:XST180477 owl:sameAs ns57:XST190527,
        ns33:XST190506 ;
    ns0:fullName "Xin Liu" ;
    ns0:hasAffiliation ns21:XST180477 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180477 ;
    ns0:inAuthorList ns150:XST180477 .

ns16:XST180487 owl:sameAs ns16:XST180427 ;
    ns0:fullName "Min Xie" ;
    ns0:hasAffiliation ns21:XST180487 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180487 ;
    ns0:inAuthorList ns150:XST180487 .

ns16:XST190494 owl:sameAs ns2:XST515,
        ns8:XST16208,
        ns8:XST16211,
        ns12:XST180413,
        ns12:XST18383,
        ns12:XST547,
        ns12:XST574,
        ns12:XST602,
        ns30:XST16173,
        ns30:XST17324 ;
    ns0:fullName "Hengyong Yu" ;
    ns0:hasAffiliation ns193:XST190494 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190494 ;
    ns0:inAuthorList ns150:XST190494 .

ns16:XST190514 owl:sameAs ns57:XST502 ;
    ns0:fullName "Kwon-Ha Yoon" ;
    ns0:hasAffiliation ns21:XST190514,
        ns22:XST190514 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190514 ;
    ns0:inAuthorList ns150:XST190514 .

ns16:XST190526 owl:sameAs ns8:XST16214,
        ns5:XST180476 ;
    ns0:fullName "Sheng-Dong Nie" ;
    ns0:hasAffiliation ns21:XST190526 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190526 ;
    ns0:inAuthorList ns150:XST190526 .

ns52:BLC190209 owl:sameAs ns16:BLC170152,
        ns60:BLC180172 ;
    ns0:fullName "Nicholas D. James" ;
    ns0:hasAffiliation ns199:BLC190209 ;
    ns0:hasArticle ns1:blc-v5-i2-BLC190209 ;
    ns0:inAuthorList ns150:BLC190209 .

ns52:BMR170948 owl:sameAs ns8:BMR540 ;
    ns0:fullName "Tomasz Kotwicki" ;
    ns0:hasAffiliation ns102:BMR170948 ;
    ns0:hasArticle ns1:bmr-v32-i5-BMR170948 ;
    ns0:inAuthorList ns150:BMR170948 .

ns52:CBM182257 owl:sameAs ns57:CBM170175 ;
    ns0:fullName "Qing Mao" ;
    ns0:hasAffiliation ns101:CBM182257 ;
    ns0:hasArticle ns1:cbm-v26-i1-CBM182257 ;
    ns0:inAuthorList ns150:CBM182257 .

ns52:CBM192435 owl:sameAs ns57:CBM181526 ;
    ns0:fullName "Bingya Liu" ;
    ns0:hasAffiliation ns101:CBM192435,
        ns55:CBM192435 ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM192435 ;
    ns0:inAuthorList ns150:CBM192435 .

ns52:CBM192437 owl:sameAs ns30:XST16245 ;
    ns0:fullName "Zhi-Gang Peng" ;
    ns0:hasAffiliation ns101:CBM192437 ;
    ns0:hasArticle ns1:cbm-v25-i3-CBM192437 ;
    ns0:inAuthorList ns150:CBM192437 .

ns52:CH180402 owl:sameAs ns52:BIR180175 ;
    ns0:fullName "Alten Oskay" ;
    ns0:hasAffiliation ns199:CH180402 ;
    ns0:hasArticle ns1:ch-v71-i4-CH180402 ;
    ns0:inAuthorList ns150:CH180402 .

ns52:CH180404 owl:sameAs ns2:CH180452,
        ns8:CH16212,
        ns8:CH170252,
        ns26:CH170275,
        ns26:CH180388,
        ns16:CH16196,
        ns57:CH16142,
        ns33:CH170253 ;
    ns0:fullName "Hui-Xiong Xu" ;
    ns0:hasAffiliation ns200:CH180404,
        ns101:CH180404,
        ns55:CH180404 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180404 ;
    ns0:inAuthorList ns150:CH180404 .

ns52:CH180457 owl:sameAs ns52:CH180545 ;
    ns0:fullName "Zhen Ma" ;
    ns0:hasAffiliation ns200:CH180457 ;
    ns0:hasArticle ns1:ch-v72-i1-CH180457 ;
    ns0:inAuthorList ns150:CH180457 .

ns52:CH180476 owl:sameAs ns60:CH189126 ;
    ns0:fullName "Soyeon Lim" ;
    ns0:hasAffiliation ns55:CH180476 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180476 ;
    ns0:inAuthorList ns150:CH180476 .

ns52:CH180477 owl:sameAs ns16:CH170364 ;
    ns0:fullName "Xian-Li Zhou" ;
    ns0:hasAffiliation ns200:CH180477 ;
    ns0:hasArticle ns1:ch-v72-i3-CH180477 ;
    ns0:inAuthorList ns150:CH180477 .

ns52:CH189907 owl:sameAs ns5:CH179235 ;
    ns0:fullName "Alena Ticha" ;
    ns0:hasAffiliation ns55:CH189907 ;
    ns0:hasArticle ns1:ch-v72-i1-CH189907 ;
    ns0:inAuthorList ns150:CH189907 .

ns52:CH199220 owl:sameAs ns60:CH199212 ;
    ns0:fullName "T. Aung" ;
    ns0:hasAffiliation ns200:CH199220 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199220 ;
    ns0:inAuthorList ns150:CH199220 .

ns52:CH199223 owl:sameAs ns12:CH199222 ;
    ns0:fullName "B. Schlenker" ;
    ns0:hasAffiliation ns200:CH199223 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199223 ;
    ns0:inAuthorList ns150:CH199223 .

ns52:CH199224 owl:sameAs ns16:CH179218,
        ns52:CH180449,
        ns52:CH189131 ;
    ns0:fullName "Ernst Michael Jung" ;
    ns0:hasAffiliation ns200:CH199224 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199224 ;
    ns0:inAuthorList ns150:CH199224 .

ns52:CH199225 owl:sameAs ns8:CH2005,
        ns12:CH189309,
        ns30:CH189905,
        ns16:CH179216,
        ns52:CH170266,
        ns52:CH189129 ;
    ns0:fullName "Sebastian Geis" ;
    ns0:hasAffiliation ns200:CH199225 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199225 ;
    ns0:inAuthorList ns150:CH199225 .

ns52:HAB190372 owl:sameAs ns2:hab00271,
        ns12:HAB330 ;
    ns0:fullName "Ashraf A. Tabll" ;
    ns0:hasAffiliation ns102:HAB190372 ;
    ns0:hasArticle ns1:hab-v27-i3-HAB190372 ;
    ns0:inAuthorList ns150:HAB190372 .

ns52:HAB190384 owl:sameAs ns12:BD180351 ;
    ns0:fullName "Vahid Kholghi Oskooei" ;
    ns0:hasAffiliation ns101:HAB190384 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190384 ;
    ns0:inAuthorList ns150:HAB190384 .

ns52:IFS179239 owl:sameAs ns12:IFS17168 ;
    ns0:fullName "Dongxiao Niu" ;
    ns0:hasAffiliation ns200:IFS179239 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179239 ;
    ns0:inAuthorList ns150:IFS179239 .

ns52:JAD180630 owl:sameAs ns12:JAD170595,
        ns30:JAD160970,
        ns5:JAD190688 ;
    ns0:fullName "Miloslav Kopecek" ;
    ns0:hasAffiliation ns199:JAD180630 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD180630 ;
    ns0:inAuthorList ns150:JAD180630 .

ns52:JAD180932 owl:sameAs ns12:JAD170496 ;
    ns0:fullName "Hari Parvataneni" ;
    ns0:hasAffiliation ns199:JAD180932 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180932 ;
    ns0:inAuthorList ns150:JAD180932 .

ns52:JAD180966 owl:sameAs ns2:JAD111370,
        ns2:JAD150692,
        ns2:JAD170536,
        ns8:JAD180843,
        ns26:jad091150,
        ns40:JAD160522,
        ns40:JAD170368,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD179932>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad100837>,
        ns12:JAD130203,
        ns12:JAD141959,
        ns30:JAD170914,
        <http://ld.iospress.nl/rdf/contributor/Author:31.ID:JAD150883>,
        <http://ld.iospress.nl/rdf/contributor/Author:36.ID:JAD121456>,
        ns5:JAD122293,
        ns16:JAD150686,
        ns16:JAD170367,
        ns52:JAD150804,
        ns57:JAD180991,
        ns60:JAD180087,
        ns33:JAD170399 ;
    ns0:fullName "Bruno Dubois" ;
    ns0:hasAffiliation ns199:JAD180966 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD180966 ;
    ns0:inAuthorList ns150:JAD180966 .

ns52:JAD180991 owl:sameAs ns2:JAD121456,
        ns26:JAD120172 ;
    ns0:fullName "Isabelle Le Ber" ;
    ns0:hasAffiliation ns101:JAD180991 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180991 ;
    ns0:inAuthorList ns150:JAD180991 .

ns52:JAD181030 owl:sameAs ns2:jad01117,
        ns8:JAD102139,
        ns26:JAD110983,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD181088>,
        ns16:JAD161162,
        ns60:JAD122329,
        ns60:JAD142229,
        ns60:JAD181022 ;
    ns0:fullName "Robert Perneczky" ;
    ns0:hasAffiliation ns200:JAD181030,
        ns201:JAD181030,
        ns203:JAD181030 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181030 ;
    ns0:inAuthorList ns150:JAD181030 .

ns52:JAD181033 owl:sameAs ns26:JAD141599,
        ns28:JAD112003,
        ns43:JAD160536,
        ns130:jad00971,
        ns30:JAD150194,
        ns5:JAD111370,
        ns5:JAD132672,
        ns5:JAD160238,
        ns52:JAD150280,
        ns33:JAD141767,
        ns33:JAD160268 ;
    ns0:fullName "Philippe Robert" ;
    ns0:hasAffiliation ns200:JAD181033 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181033 ;
    ns0:inAuthorList ns150:JAD181033 .

ns52:JAD181169 owl:sameAs ns52:JAD181170,
        ns57:JAD161240 ;
    ns0:fullName "Jeffrey D. Holmes" ;
    ns0:hasAffiliation ns203:JAD181169 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181169 ;
    ns0:inAuthorList ns150:JAD181169 .

ns52:JAD181171 owl:sameAs ns28:JAD180511,
        ns5:JAD180496,
        ns16:JAD160685,
        ns33:JAD170880 ;
    ns0:fullName "Wan Zurinah Wan Ngah" ;
    ns0:hasAffiliation ns101:JAD181171 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD181171 ;
    ns0:inAuthorList ns150:JAD181171 .

ns52:JAD181196 owl:sameAs ns2:JAD140759,
        ns2:JAD170149,
        ns2:JAD190790 ;
    ns0:fullName "Manuel Montero-Odasso" ;
    ns0:hasAffiliation ns200:JAD181196,
        ns101:JAD181196,
        ns55:JAD181196,
        ns199:JAD181196 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181196 ;
    ns0:inAuthorList ns150:JAD181196 .

ns52:JAD181217 owl:sameAs ns52:JAD180425 ;
    ns0:fullName "Yang Hu" ;
    ns0:hasAffiliation ns200:JAD181217 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181217 ;
    ns0:inAuthorList ns150:JAD181217 .

ns52:JAD181261 owl:sameAs ns52:JAD150471,
        ns52:JAD180280,
        ns60:JAD161277 ;
    ns0:fullName "Shahul Hameed" ;
    ns0:hasAffiliation ns200:JAD181261 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181261 ;
    ns0:inAuthorList ns150:JAD181261 .

ns52:JAD181265 owl:sameAs ns8:jad01125,
        ns8:jad01126,
        ns26:jad091594,
        ns26:jad101023,
        ns12:JAD140867,
        ns52:JAD170102,
        ns57:JAD180855 ;
    ns0:fullName "Lena Kilander" ;
    ns0:hasAffiliation ns200:JAD181265 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181265 ;
    ns0:inAuthorList ns150:JAD181265 .

ns52:JAD181268 owl:sameAs ns2:JAD180092,
        ns8:JAD150788,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad100123>,
        ns12:JAD121168,
        ns12:JAD160158,
        ns12:jad01245,
        ns30:JAD120676,
        ns30:jad01163,
        ns30:jad01364,
        ns5:JAD120424,
        ns52:JAD121822,
        ns57:JAD170148 ;
    ns0:fullName "Jeffrey M. Burns" ;
    ns0:hasAffiliation ns101:JAD181268 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181268 ;
    ns0:inAuthorList ns150:JAD181268 .

ns52:JAD181277 owl:sameAs ns5:JAD180788,
        ns52:JAD140651,
        ns57:JAD170578 ;
    ns0:fullName "Bernard Hanseeuw" ;
    ns0:hasAffiliation ns251:JAD181277 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181277 ;
    ns0:inAuthorList ns150:JAD181277 .

ns52:JAD181295 owl:sameAs ns52:JAD180125 ;
    ns0:fullName "Sirpa Hartikainen" ;
    ns0:hasAffiliation ns200:JAD181295,
        ns101:JAD181295 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181295 ;
    ns0:inAuthorList ns150:JAD181295 .

ns52:JAD181297 owl:sameAs ns57:JAD132558,
        ns60:JAD170458 ;
    ns0:fullName "Meike W. Vernooij" ;
    ns0:hasAffiliation ns200:JAD181297,
        ns101:JAD181297 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD181297 ;
    ns0:inAuthorList ns150:JAD181297 .

ns52:JAD190010 owl:sameAs ns8:JAD150729,
        ns8:JAD161114,
        ns16:JAD148009 ;
    ns0:fullName "Shannon L. Risacher" ;
    ns0:hasAffiliation ns55:JAD190010,
        ns201:JAD190010 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190010 ;
    ns0:inAuthorList ns150:JAD190010 .

ns52:JAD190011 owl:sameAs ns8:JAD141704,
        ns12:JAD170954 ;
    ns0:fullName "Marla Gearing" ;
    ns0:hasAffiliation ns200:JAD190011 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190011 ;
    ns0:inAuthorList ns150:JAD190011 .

ns52:JAD190023 owl:sameAs ns8:JAD181152 ;
    ns0:fullName "Takumi Nakamura" ;
    ns0:hasAffiliation ns101:JAD190023,
        ns102:JAD190023 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190023 ;
    ns0:inAuthorList ns150:JAD190023 .

ns52:JAD190028 owl:sameAs ns130:JAD181175,
        ns12:JAD120709,
        ns16:JAD180586,
        ns57:JAD132018,
        ns60:JAD150895 ;
    ns0:fullName "C. Munro Cullum" ;
    ns0:hasAffiliation ns200:JAD190028,
        ns101:JAD190028,
        ns199:JAD190028 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190028 ;
    ns0:inAuthorList ns150:JAD190028 .

ns52:JAD190077 owl:sameAs ns8:JAD130989,
        ns8:JAD141812,
        ns52:JAD170555,
        ns60:JAD150914 ;
    ns0:fullName "Timothy J. Hohman" ;
    ns0:hasAffiliation ns200:JAD190077,
        ns55:JAD190077 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190077 ;
    ns0:inAuthorList ns150:JAD190077 .

ns52:JAD190091 owl:sameAs ns57:JAD181140 ;
    ns0:fullName "Neelesh K. Nadkarni" ;
    ns0:hasAffiliation ns201:JAD190091 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190091 ;
    ns0:inAuthorList ns150:JAD190091 .

ns52:JAD190094 owl:sameAs ns30:JAD180219 ;
    ns0:fullName "Atte Meretoja" ;
    ns0:hasAffiliation ns203:JAD190094,
        ns251:JAD190094 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190094 ;
    ns0:inAuthorList ns150:JAD190094 .

ns52:JAD190099 owl:sameAs ns52:JAD160191 ;
    ns0:fullName "Yafang Hu" ;
    ns0:hasAffiliation ns200:JAD190099 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190099 ;
    ns0:inAuthorList ns150:JAD190099 .

ns52:JAD190107 owl:sameAs ns60:JAD161179 ;
    ns0:fullName "Eloy Rodríguez Rodríguez" ;
    ns0:hasAffiliation ns200:JAD190107 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190107 ;
    ns0:inAuthorList ns150:JAD190107 .

ns52:JAD190113 owl:sameAs ns12:JAD181108 ;
    ns0:fullName "Donglai Jing" ;
    ns0:hasAffiliation ns200:JAD190113 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190113 ;
    ns0:inAuthorList ns150:JAD190113 .

ns52:JAD190128 owl:sameAs ns60:JAD150586 ;
    ns0:fullName "John Hart" ;
    ns0:hasAffiliation ns200:JAD190128,
        ns101:JAD190128,
        ns55:JAD190128 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190128 ;
    ns0:inAuthorList ns150:JAD190128 .

ns52:JAD190133 owl:sameAs ns2:JAD122110,
        ns2:jad100459,
        ns8:jad100201,
        ns16:JAD180897,
        ns57:JAD170092,
        ns57:JAD170534,
        ns33:JAD170123 ;
    ns0:fullName "Teemu Paajanen" ;
    ns0:hasAffiliation ns204:JAD190133 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190133 ;
    ns0:inAuthorList ns150:JAD190133 .

ns52:JAD190152 owl:sameAs ns16:JAD170239 ;
    ns0:fullName "António Francisco Ambrósio" ;
    ns0:hasAffiliation ns199:JAD190152,
        ns102:JAD190152,
        ns201:JAD190152 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190152 ;
    ns0:inAuthorList ns150:JAD190152 .

ns52:JAD190154 owl:sameAs ns8:jad091711 ;
    ns0:fullName "Carlos Cruchaga" ;
    ns0:hasAffiliation ns199:JAD190154,
        ns201:JAD190154 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190154 ;
    ns0:inAuthorList ns150:JAD190154 .

ns52:JAD190161 owl:sameAs ns5:MGC180763 ;
    ns0:fullName "Hua Tian" ;
    ns0:hasAffiliation ns200:JAD190161,
        ns102:JAD190161 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190161 ;
    ns0:inAuthorList ns150:JAD190161 .

ns52:JAD190175 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170231> ;
    ns0:fullName "Gøril Rolfseng Grøntvedt" ;
    ns0:hasAffiliation ns101:JAD190175 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190175 ;
    ns0:inAuthorList ns150:JAD190175 .

ns52:JAD190187 owl:sameAs ns12:jad100573,
        ns12:jad101293,
        ns16:JAD101878,
        ns16:JAD110566,
        ns16:JAD120994,
        ns16:JAD150883,
        ns16:JAD170226,
        ns52:JAD120508 ;
    ns0:fullName "Ulf Andreasson" ;
    ns0:hasAffiliation ns200:JAD190187,
        ns101:JAD190187 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190187 ;
    ns0:inAuthorList ns150:JAD190187 .

ns52:JAD190197 owl:sameAs ns8:jad100912,
        ns12:JAD132255,
        ns5:JAD161053 ;
    ns0:fullName "Felix Hernandez" ;
    ns0:hasAffiliation ns251:JAD190197 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190197 ;
    ns0:inAuthorList ns150:JAD190197 .

ns52:JAD190202 owl:sameAs ns5:JAD0058,
        ns16:JAD140588,
        ns16:JAD160641 ;
    ns0:fullName "Alex Kiss" ;
    ns0:hasAffiliation ns200:JAD190202,
        ns201:JAD190202 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190202 ;
    ns0:inAuthorList ns150:JAD190202 .

ns52:JAD190220 owl:sameAs ns40:JAD130485,
        ns5:JAD180050 ;
    ns0:fullName "Abass Alavi" ;
    ns0:hasAffiliation ns101:JAD190220 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190220 ;
    ns0:inAuthorList ns150:JAD190220 .

ns52:JAD190237 owl:sameAs ns2:jad00454,
        ns5:jad00463 ;
    ns0:fullName "Stefano L. Sensi" ;
    ns0:hasAffiliation ns200:JAD190237,
        ns101:JAD190237,
        ns203:JAD190237 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190237 ;
    ns0:inAuthorList ns150:JAD190237 .

ns52:JAD190280 owl:sameAs ns5:JAD190368,
        ns52:JAD180882 ;
    ns0:fullName "Fei Liu" ;
    ns0:hasAffiliation ns200:JAD190280 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190280 ;
    ns0:inAuthorList ns150:JAD190280 .

ns52:JAD190322 owl:sameAs ns2:jad01153,
        ns8:JAD141890,
        ns26:JAD180789,
        ns5:JAD190656,
        ns16:JAD141722,
        ns16:JAD160562,
        ns57:JAD141281,
        ns57:JAD180776,
        ns60:JAD180619,
        ns33:JAD170388 ;
    ns0:fullName "Robert A. Rissman" ;
    ns0:hasAffiliation ns102:JAD190322 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190322 ;
    ns0:inAuthorList ns150:JAD190322 .

ns52:JAD190323 owl:sameAs ns5:RNN170738,
        ns60:jad100333 ;
    ns0:fullName "Ubaldo Bonuccelli" ;
    ns0:hasAffiliation ns200:JAD190323 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190323 ;
    ns0:inAuthorList ns150:JAD190323 .

ns52:JAD190334 owl:sameAs ns26:JAD180071,
        ns40:JAD120946,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD190132>,
        <http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD160668>,
        ns30:jad100114,
        ns16:jad100597,
        ns52:JAD111109,
        ns33:JAD170039 ;
    ns0:fullName "Sanna-Kaisa Herukka" ;
    ns0:hasAffiliation ns200:JAD190334,
        ns199:JAD190334 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns52:JAD190335 owl:sameAs ns57:JAD160018 ;
    ns0:fullName "Christopher R. Butler" ;
    ns0:hasAffiliation ns101:JAD190335 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190335 ;
    ns0:inAuthorList ns150:JAD190335 .

ns52:JAD190339 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180486> ;
    ns0:fullName "Einor Ben Assayag" ;
    ns0:hasAffiliation ns200:JAD190339,
        ns101:JAD190339 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190339 ;
    ns0:inAuthorList ns150:JAD190339 .

ns52:JAD190340 owl:sameAs ns8:jad00185,
        ns26:JAD130398,
        ns26:JAD171177,
        ns130:JAD170971,
        ns139:JAD140225,
        ns30:JAD132231,
        ns57:JAD110455,
        ns57:jad100075,
        ns33:JAD160651 ;
    ns0:fullName "Masahito Yamada" ;
    ns0:hasAffiliation ns200:JAD190340 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190340 ;
    ns0:inAuthorList ns150:JAD190340 .

ns52:JAD190385 owl:sameAs ns33:JAD180890 ;
    ns0:fullName "Carlo de Lena" ;
    ns0:hasAffiliation ns200:JAD190385 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190385 ;
    ns0:inAuthorList ns150:JAD190385 .

ns52:JAD190394 owl:sameAs ns52:JAD160625 ;
    ns0:fullName "Nicola Smania" ;
    ns0:hasAffiliation ns200:JAD190394 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190394 ;
    ns0:inAuthorList ns150:JAD190394 .

ns52:JAD190399 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160108> ;
    ns0:fullName "Shin Gyeom Kim" ;
    ns0:hasAffiliation ns199:JAD190399 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns52:JAD190414 owl:sameAs ns2:JAD131484,
        ns8:JAD112216 ;
    ns0:fullName "Ben Schmand" ;
    ns0:hasAffiliation ns201:JAD190414 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190414 ;
    ns0:inAuthorList ns150:JAD190414 .

ns52:JAD190415 owl:sameAs ns12:JAD151114 ;
    ns0:fullName "Adam M. Brickman" ;
    ns0:hasAffiliation ns200:JAD190415 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190415 ;
    ns0:inAuthorList ns150:JAD190415 .

ns52:JAD190446 owl:sameAs ns16:JAD180106,
        ns33:JAD170360 ;
    ns0:fullName "Cihan Catak" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:6.ID:JAD190446> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190446 ;
    ns0:inAuthorList ns150:JAD190446 .

ns52:JAD190458 owl:sameAs ns5:JAD151121 ;
    ns0:fullName "Zhijian Su" ;
    ns0:hasAffiliation ns200:JAD190458,
        ns101:JAD190458 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190458 ;
    ns0:inAuthorList ns150:JAD190458 .

ns52:JAD190469 owl:sameAs ns2:JAD170507,
        ns8:JAD170943,
        ns8:JAD180394,
        ns132:JAD180048,
        ns52:JAD170556,
        ns52:JAD190007,
        ns60:JAD170537 ;
    ns0:fullName "Hyemin Jang" ;
    ns0:hasAffiliation ns200:JAD190469,
        ns101:JAD190469,
        ns55:JAD190469 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190469 ;
    ns0:inAuthorList ns150:JAD190469 .

ns52:JAD190480 owl:sameAs ns12:JAD142052,
        ns57:JAD100525 ;
    ns0:fullName "Roberta Cecchetti" ;
    ns0:hasAffiliation ns200:JAD190480 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190480 ;
    ns0:inAuthorList ns150:JAD190480 .

ns52:JAD190487 owl:sameAs ns12:JAD180183 ;
    ns0:fullName "Haiyan Mu" ;
    ns0:hasAffiliation ns200:JAD190487 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190487 ;
    ns0:inAuthorList ns150:JAD190487 .

ns52:JAD190495 owl:sameAs ns2:JAD122140,
        ns30:JAD160975 ;
    ns0:fullName "Simona Gabriella Di Santo" ;
    ns0:hasAffiliation ns101:JAD190495 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190495 ;
    ns0:inAuthorList ns150:JAD190495 .

ns52:JAD190517 owl:sameAs ns8:JAD181227,
        ns30:NHA170028,
        ns5:JAD170195,
        ns52:JAD150523,
        ns60:JAD160230 ;
    ns0:fullName "Joe Verghese" ;
    ns0:hasAffiliation ns200:JAD190517,
        ns101:JAD190517 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD190517 ;
    ns0:inAuthorList ns150:JAD190517 .

ns52:JAD190524 owl:sameAs ns8:bmr00185,
        ns57:JAD141266,
        ns60:JAD140846 ;
    ns0:fullName "John Attia" ;
    ns0:hasAffiliation ns199:JAD190524 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190524 ;
    ns0:inAuthorList ns150:JAD190524 .

ns52:JAD190533 owl:sameAs ns40:JAD171145 ;
    ns0:fullName "Steve Pedrini" ;
    ns0:hasAffiliation ns101:JAD190533 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190533 ;
    ns0:inAuthorList ns150:JAD190533 .

ns52:JAD190549 owl:sameAs ns12:JAD180292,
        ns5:JAD110989,
        ns60:JAD180082 ;
    ns0:fullName "Lejla Koric" ;
    ns0:hasAffiliation ns199:JAD190549 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190549 ;
    ns0:inAuthorList ns150:JAD190549 .

ns52:JAD190567 owl:sameAs ns2:JAD131640 ;
    ns0:fullName "Elizabeta B. Mukaetova-Ladinska" ;
    ns0:hasAffiliation ns101:JAD190567,
        ns102:JAD190567 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190567 ;
    ns0:inAuthorList ns150:JAD190567 .

ns52:JAD190574 owl:sameAs ns8:jad01011,
        ns8:jad091489,
        ns139:JAD150883,
        ns5:JAD150257,
        ns16:JAD170964,
        ns52:JAD110329 ;
    ns0:fullName "Lutz Frölich" ;
    ns0:hasAffiliation ns201:JAD190574 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190574 ;
    ns0:inAuthorList ns150:JAD190574 .

ns52:JAD190610 owl:sameAs ns2:JAD170458,
        ns12:JAD160067,
        ns12:JAD190527,
        ns5:JAD190540,
        ns16:JAD122026,
        ns57:JAD170796 ;
    ns0:fullName "Saima Hilal" ;
    ns0:hasAffiliation ns200:JAD190610,
        ns199:JAD190610 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190610 ;
    ns0:inAuthorList ns150:JAD190610 .

ns52:JAD190622 owl:sameAs ns57:JAD160923 ;
    ns0:fullName "Takashi Sakurai" ;
    ns0:hasAffiliation ns200:JAD190622,
        ns199:JAD190622 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190622 ;
    ns0:inAuthorList ns150:JAD190622 .

ns52:JAD190628 owl:sameAs ns141:JAD170347,
        ns5:JAD190501,
        ns60:JAD181049,
        ns33:JAD190401 ;
    ns0:fullName "Ying Han" ;
    ns0:hasAffiliation ns199:JAD190628,
        ns102:JAD190628,
        ns201:JAD190628,
        ns203:JAD190628 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190628 ;
    ns0:inAuthorList ns150:JAD190628 .

ns52:JAD190631 owl:sameAs ns2:WOR182792 ;
    ns0:fullName "Sandra Moreira" ;
    ns0:hasAffiliation ns201:JAD190631 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190631 ;
    ns0:inAuthorList ns150:JAD190631 .

ns52:JAD190634 owl:sameAs ns2:JAD180619,
        ns16:JAD190322 ;
    ns0:fullName "Sid O’Bryant" ;
    ns0:hasAffiliation ns55:JAD190634,
        ns199:JAD190634 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190634 ;
    ns0:inAuthorList ns150:JAD190634 .

ns52:JAD190660 owl:sameAs ns2:JAD161179,
        ns2:JAD161267,
        ns30:JAD170985 ;
    ns0:fullName "Javier Riancho" ;
    ns0:hasAffiliation ns101:JAD190660 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190660 ;
    ns0:inAuthorList ns150:JAD190660 .

ns52:JAD190670 owl:sameAs ns8:JAD131808,
        ns8:JAD160235,
        ns26:JAD150786,
        ns12:JAD190461,
        ns16:JAD121606,
        ns57:JAD180416 ;
    ns0:fullName "Nicola Vanacore" ;
    ns0:hasAffiliation ns204:JAD190670 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190670 ;
    ns0:inAuthorList ns150:JAD190670 .

ns52:JAD190696 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:64.ID:JAD110824> ;
    ns0:fullName "Gill Livingston" ;
    ns0:hasAffiliation ns200:JAD190696 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190696 ;
    ns0:inAuthorList ns150:JAD190696 .

ns52:JAD190707 owl:sameAs ns12:JAD160416,
        ns12:JAD181240,
        ns16:JAD110662,
        ns60:jad01074 ;
    ns0:fullName "Michael L. Niehoff" ;
    ns0:hasAffiliation ns199:JAD190707 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190707 ;
    ns0:inAuthorList ns150:JAD190707 .

ns52:JAD190772 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170560> ;
    ns0:fullName "Vesna Vuksanovic" ;
    ns0:hasAffiliation ns102:JAD190772 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190772 ;
    ns0:inAuthorList ns150:JAD190772 .

ns52:JAD190817 owl:sameAs ns2:JAD180985 ;
    ns0:fullName "Tatsuo Manabe" ;
    ns0:hasAffiliation ns200:JAD190817 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190817 ;
    ns0:inAuthorList ns150:JAD190817 .

ns52:JAD190838 owl:sameAs ns8:JAD170604,
        ns52:JAD190545 ;
    ns0:fullName "María Nieves Cabrera-Martín" ;
    ns0:hasAffiliation ns102:JAD190838 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190838 ;
    ns0:inAuthorList ns150:JAD190838 .

ns52:JBR180345 owl:sameAs ns8:JBR180314,
        ns52:JBR180316 ;
    ns0:fullName "Francesca Giampieri" ;
    ns0:hasAffiliation ns55:JBR180345 ;
    ns0:hasArticle ns1:jbr-v9-i2-JBR180345 ;
    ns0:inAuthorList ns150:JBR180345 .

ns52:JHD190346 owl:sameAs ns2:JPD150652 ;
    ns0:fullName "Eva Pirogovsky-Turk" ;
    ns0:hasAffiliation ns55:JHD190346,
        ns199:JHD190346 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190346 ;
    ns0:inAuthorList ns150:JHD190346 .

ns52:JND190416 owl:sameAs ns12:JND180331 ;
    ns0:fullName "Kristina Stahl" ;
    ns0:hasAffiliation ns200:JND190416 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190416 ;
    ns0:inAuthorList ns150:JND190416 .

ns52:JPD181518 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:23.ID:JND180327>,
        ns5:JPD181434 ;
    ns0:fullName "Christopher S. Coffey" ;
    ns0:hasAffiliation ns55:JPD181518 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181518 ;
    ns0:inAuthorList ns150:JPD181518 .

ns52:JPD191616 owl:sameAs ns12:JPD181523,
        ns52:JPD171277 ;
    ns0:fullName "Nienke M. de Vries" ;
    ns0:hasAffiliation ns200:JPD191616 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191616 ;
    ns0:inAuthorList ns150:JPD191616 .

ns52:JPD191675 owl:sameAs ns2:JAD120253,
        ns2:JAD132786,
        ns2:JAD170450,
        ns12:JAD180986,
        ns30:JAD151015,
        ns5:JAD131610,
        ns52:JAD170894,
        ns52:JPD181365,
        ns57:JHD180309 ;
    ns0:fullName "Masaaki Waragai" ;
    ns0:hasAffiliation ns200:JPD191675 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191675 ;
    ns0:inAuthorList ns150:JPD191675 .

ns52:JPD191713 owl:sameAs ns5:JPD160828,
        ns16:JPD140498 ;
    ns0:fullName "Luc Defebvre" ;
    ns0:hasAffiliation ns200:JPD191713 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191713 ;
    ns0:inAuthorList ns150:JPD191713 .

ns52:JVR191022 owl:sameAs ns2:NRE1271,
        ns8:JVR894,
        ns30:JVR191024,
        ns5:WOR2201 ;
    ns0:fullName "Mykal Leslie" ;
    ns0:hasAffiliation ns200:JVR191022 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191022 ;
    ns0:inAuthorList ns150:JVR191022 .

ns52:JVR191023 owl:sameAs ns52:JVR972 ;
    ns0:fullName "Teresa A. Grenawalt" ;
    ns0:hasAffiliation ns201:JVR191023 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191023 ;
    ns0:inAuthorList ns150:JVR191023 .

ns52:MNM180261 owl:sameAs ns8:MNM180224,
        ns30:MNM180242,
        ns16:MNM180278 ;
    ns0:fullName "Mostafa Qorbani" ;
    ns0:hasAffiliation ns201:MNM180261 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180261 ;
    ns0:inAuthorList ns150:MNM180261 .

ns52:NHA180059 owl:sameAs ns12:NHA180055,
        ns5:NHA170035 ;
    ns0:fullName "David G. Le Couteur" ;
    ns0:hasAffiliation ns200:NHA180059,
        ns101:NHA180059 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA180059 ;
    ns0:inAuthorList ns150:NHA180059 .

ns52:NPM17149 owl:sameAs ns5:NPM1637 ;
    ns0:fullName "C. Michael Cotten" ;
    ns0:hasAffiliation ns200:NPM17149 ;
    ns0:hasArticle ns1:npm-v12-i2-NPM17149 ;
    ns0:inAuthorList ns150:NPM17149 .

ns52:NRE182637 owl:sameAs ns16:NRE172274 ;
    ns0:fullName "Antonio Pisani" ;
    ns0:hasAffiliation ns200:NRE182637,
        ns101:NRE182637 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182637 ;
    ns0:inAuthorList ns150:NRE182637 .

ns52:NRE182665 owl:sameAs ns12:WOR2131 ;
    ns0:fullName "Edgar Ramos Vieira" ;
    ns0:hasAffiliation ns55:NRE182665 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182665 ;
    ns0:inAuthorList ns150:NRE182665 .

ns52:NRE192714 owl:sameAs ns16:JAD120358 ;
    ns0:fullName "Elena Sinforiani" ;
    ns0:hasAffiliation ns200:NRE192714 ;
    ns0:hasArticle ns1:nre-v44-i4-NRE192714 ;
    ns0:inAuthorList ns150:NRE192714 .

ns52:NRE192752 owl:sameAs ns52:NRE182565 ;
    ns0:fullName "Birgit Sander" ;
    ns0:hasAffiliation ns55:NRE192752 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192752 ;
    ns0:inAuthorList ns150:NRE192752 .

ns52:NRE192754 owl:sameAs ns12:NRE182665 ;
    ns0:fullName "Aline Braga Galvão Silveira Fernandes" ;
    ns0:hasAffiliation ns55:NRE192754 ;
    ns0:hasArticle ns1:nre-v45-i1-NRE192754 ;
    ns0:inAuthorList ns150:NRE192754 .

ns52:RNN190916 owl:sameAs ns5:RNN150623,
        ns5:RNN170790 ;
    ns0:fullName "L.A. Boyd" ;
    ns0:hasAffiliation ns200:RNN190916,
        ns201:RNN190916 ;
    ns0:hasArticle ns1:rnn-v37-i3-RNN190916 ;
    ns0:inAuthorList ns150:RNN190916 .

ns52:THC191715 owl:sameAs ns57:THC170967 ;
    ns0:fullName "Kang Suk Seo" ;
    ns0:hasAffiliation ns200:THC191715 ;
    ns0:hasArticle ns1:thc-v27-i6-THC191715 ;
    ns0:inAuthorList ns150:THC191715 .

ns52:THC199029 owl:sameAs ns57:THC199031 ;
    ns0:fullName "Chun Chu" ;
    ns0:hasAffiliation ns101:THC199029 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199029 ;
    ns0:inAuthorList ns150:THC199029 .

ns52:VES190655 owl:sameAs ns2:VES589,
        ns5:VES622 ;
    ns0:fullName "Michael Strupp" ;
    ns0:hasAffiliation ns203:VES190655 ;
    ns0:hasArticle ns1:ves-v29-i2-3-VES190655 ;
    ns0:inAuthorList ns150:VES190655 .

ns52:WOR192920 owl:sameAs ns2:WOR192919 ;
    ns0:fullName "Arlene A. Schmid" ;
    ns0:hasAffiliation ns200:WOR192920 ;
    ns0:hasArticle ns1:wor-v63-i2-WOR192920 ;
    ns0:inAuthorList ns150:WOR192920 .

ns52:WOR192947 owl:sameAs ns8:thc00632,
        ns5:WOR182840 ;
    ns0:fullName "Geoff Fernie" ;
    ns0:hasAffiliation ns200:WOR192947,
        ns199:WOR192947,
        ns102:WOR192947,
        ns201:WOR192947 ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192947 ;
    ns0:inAuthorList ns150:WOR192947 .

ns52:WOR192960 owl:sameAs ns8:WOR192951 ;
    ns0:fullName "Sam D. Blacker" ;
    ns0:hasAffiliation ns200:WOR192960 ;
    ns0:hasArticle ns1:wor-v63-i4-WOR192960 ;
    ns0:inAuthorList ns150:WOR192960 .

ns52:XST180465 owl:sameAs ns8:XST17271 ;
    ns0:fullName "Gen Yan" ;
    ns0:hasAffiliation ns200:XST180465 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180465 ;
    ns0:inAuthorList ns150:XST180465 .

ns52:XST180477 owl:sameAs ns16:XST190527,
        ns60:XST190506 ;
    ns0:fullName "Yongfeng Yang" ;
    ns0:hasAffiliation ns200:XST180477 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180477 ;
    ns0:inAuthorList ns150:XST180477 .

ns52:XST190503 owl:sameAs ns57:XST598 ;
    ns0:fullName "Jeng-Fong Chiou" ;
    ns0:hasAffiliation ns101:XST190503,
        ns199:XST190503,
        ns102:XST190503 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190503 ;
    ns0:inAuthorList ns150:XST190503 .

ns52:XST190527 owl:sameAs ns8:JCM607,
        ns5:XST180477,
        ns57:XST190506,
        ns57:XST579 ;
    ns0:fullName "Dong Liang" ;
    ns0:hasAffiliation ns200:XST190527 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190527 ;
    ns0:inAuthorList ns150:XST190527 .

ns52:XST190548 owl:sameAs ns16:XST190533 ;
    ns0:fullName "Jiangli Lin" ;
    ns0:hasAffiliation ns200:XST190548 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190548 ;
    ns0:inAuthorList ns150:XST190548 .

ns57:ADR190139 owl:sameAs ns5:JAD170554,
        ns16:JAD160803,
        ns60:JAD160056 ;
    ns0:fullName "Francisco Lopera" ;
    ns0:hasAffiliation ns79:ADR190139 ;
    ns0:hasArticle ns1:adr-v3-i1-ADR190139 ;
    ns0:inAuthorList ns150:ADR190139 .

ns57:BLC190209 owl:sameAs ns26:BLC180172 ;
    ns0:fullName "Richard T. Bryan" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:BLC190209> ;
    ns0:hasArticle ns1:blc-v5-i2-BLC190209 ;
    ns0:inAuthorList ns150:BLC190209 .

ns57:CH180434 owl:sameAs ns8:CH16163,
        ns12:CH1953,
        ns30:CH15081,
        ns5:JAD101611,
        ns16:CH170331,
        ns57:CH1961 ;
    ns0:fullName "Sehyun Shin" ;
    ns0:hasAffiliation ns79:CH180434 ;
    ns0:hasArticle ns1:ch-v72-i1-CH180434 ;
    ns0:inAuthorList ns150:CH180434 .

ns57:CH180476 owl:sameAs ns52:CH189126,
        ns52:CH1915,
        ns57:CH1981 ;
    ns0:fullName "Ki-Chul Hwang" ;
    ns0:hasAffiliation ns79:CH180476 ;
    ns0:hasArticle ns1:ch-v72-i2-CH180476 ;
    ns0:inAuthorList ns150:CH180476 .

ns57:CH189907 owl:sameAs ns30:CH179235 ;
    ns0:fullName "Radomir Hyspler" ;
    ns0:hasAffiliation ns79:CH189907 ;
    ns0:hasArticle ns1:ch-v72-i1-CH189907 ;
    ns0:inAuthorList ns150:CH189907 .

ns57:CH199009 owl:sameAs ns8:CH168110,
        ns8:CH179100,
        ns8:CH189303,
        ns8:CH189902,
        ns12:CH168051,
        ns12:CH189307,
        ns30:CH189409,
        ns5:CH179211,
        ns5:CH189125,
        ns5:CH189402,
        ns5:CH1983,
        ns16:CH168101,
        ns16:CH179201,
        ns16:CH189107,
        ns16:CH189410,
        ns52:CH189906,
        ns57:CH179209,
        ns57:JCB15014,
        ns33:CH189108 ;
    ns0:fullName "F. Jung" ;
    ns0:hasAffiliation ns106:CH199009 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199009 ;
    ns0:inAuthorList ns150:CH199009 .

ns57:CH199219 owl:sameAs ns5:JCB15027 ;
    ns0:fullName "O. Gemeinhardt" ;
    ns0:hasAffiliation ns79:CH199219 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199219 ;
    ns0:inAuthorList ns150:CH199219 .

ns57:HAB190375 owl:sameAs ns12:HAB282 ;
    ns0:fullName "K. Ibrahim" ;
    ns0:hasAffiliation ns210:HAB190375 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190375 ;
    ns0:inAuthorList ns150:HAB190375 .

ns57:HAB190384 owl:sameAs ns2:BD248,
        ns2:HAB291,
        ns2:HAB303,
        ns2:HAB320,
        ns8:HAB292,
        ns8:HAB296,
        ns8:HAB297,
        ns8:HAB334,
        ns40:HAB299,
        ns12:HAB289,
        ns12:HAB317,
        ns12:HAB325,
        ns12:HAB335,
        ns30:BD180351,
        ns30:HAB180344,
        ns30:HAB190362,
        ns30:HAB316,
        ns5:cbm00364,
        ns16:HAB180352,
        ns16:HAB328,
        ns16:NIB180141,
        ns57:HAB341,
        ns60:CBM160058 ;
    ns0:fullName "Mohammad Taheri" ;
    ns0:hasAffiliation ns88:HAB190384 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190384 ;
    ns0:inAuthorList ns150:HAB190384 .

ns57:JAD180521 owl:sameAs ns2:JAD180815,
        ns26:JAD110752,
        ns26:JAD122170,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD121771>,
        ns28:JAD131265,
        ns28:JAD131820,
        <http://ld.iospress.nl/rdf/contributor/Author:23.ID:jad090249> ;
    ns0:fullName "Cassandra Szoeke" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JAD180521>,
        ns209:JAD180521 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180521 ;
    ns0:inAuthorList ns150:JAD180521 .

ns57:JAD180630 owl:sameAs ns30:JAD180693,
        ns5:JAD120148,
        ns52:JAD132642,
        ns57:JAD160667 ;
    ns0:fullName "Jan Laczó" ;
    ns0:hasAffiliation ns210:JAD180630,
        ns208:JAD180630 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD180630 ;
    ns0:inAuthorList ns150:JAD180630 .

ns57:JAD180848 owl:sameAs ns8:BPL180067,
        ns33:JAD170221 ;
    ns0:fullName "Teresa Liu-Ambrose" ;
    ns0:hasAffiliation ns210:JAD180848,
        ns208:JAD180848,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JAD180848> ;
    ns0:hasArticle ns1:jad-v71-is1-JAD180848 ;
    ns0:inAuthorList ns150:JAD180848 .

ns57:JAD180932 owl:sameAs ns16:JAD170496 ;
    ns0:fullName "Mingzhou Ding" ;
    ns0:hasAffiliation ns208:JAD180932 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180932 ;
    ns0:inAuthorList ns150:JAD180932 .

ns57:JAD180949 owl:sameAs ns43:JAD141521 ;
    ns0:fullName "Christian Brettschneider" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:7.ID:JAD180949> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

ns57:JAD181030 owl:sameAs ns30:JPD150693 ;
    ns0:fullName "Lefkos T. Middleton" ;
    ns0:hasAffiliation ns210:JAD181030 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181030 ;
    ns0:inAuthorList ns150:JAD181030 .

ns57:JAD181113 owl:sameAs ns2:JAD111340,
        ns2:JAD129020,
        ns2:JAD150732,
        ns2:JAD170762,
        ns2:JPD160888,
        ns8:JPD181434,
        ns26:JPD191610,
        ns30:JAD190014,
        ns5:jad100129,
        ns52:JAD101809,
        ns52:JAD121864,
        ns33:JAD110608 ;
    ns0:fullName "Thomas G. Beach" ;
    ns0:hasAffiliation ns88:JAD181113 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD181113 ;
    ns0:inAuthorList ns150:JAD181113 .

ns57:JAD181168 owl:sameAs ns8:JAD179929 ;
    ns0:fullName "David James Brooks" ;
    ns0:hasAffiliation ns210:JAD181168,
        ns88:JAD181168,
        ns106:JAD181168 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181168 ;
    ns0:inAuthorList ns150:JAD181168 .

ns57:JAD181212 owl:sameAs ns33:JAD180746 ;
    ns0:fullName "Emily Trittschuh" ;
    ns0:hasAffiliation ns88:JAD181212,
        ns106:JAD181212 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181212 ;
    ns0:inAuthorList ns150:JAD181212 .

ns57:JAD181217 owl:sameAs ns30:JAD180425 ;
    ns0:fullName "Shu-Yang Yu" ;
    ns0:hasAffiliation ns210:JAD181217 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181217 ;
    ns0:inAuthorList ns150:JAD181217 .

ns57:JAD181220 owl:sameAs ns12:JAD111946 ;
    ns0:fullName "Xiu-Qing Yao" ;
    ns0:hasAffiliation ns210:JAD181220 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181220 ;
    ns0:inAuthorList ns150:JAD181220 .

ns57:JAD181265 owl:sameAs ns33:JAD170014 ;
    ns0:fullName "Erik Rosendahl" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD181265> ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181265 ;
    ns0:inAuthorList ns150:JAD181265 .

ns57:JAD181282 owl:sameAs ns60:JAD170557 ;
    ns0:fullName "Christos Davatzikos" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD181282> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181282 ;
    ns0:inAuthorList ns150:JAD181282 .

ns57:JAD190010 owl:sameAs ns26:JPD181434,
        ns5:JAD101515,
        ns60:JAD148009 ;
    ns0:fullName "Tatiana M. Foroud" ;
    ns0:hasAffiliation ns210:JAD190010,
        ns208:JAD190010,
        ns79:JAD190010 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190010 ;
    ns0:inAuthorList ns150:JAD190010 .

ns57:JAD190019 owl:sameAs ns16:JAD170017 ;
    ns0:fullName "Linda C. Gallo" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:7.ID:JAD190019> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190019 ;
    ns0:inAuthorList ns150:JAD190019 .

ns57:JAD190025 owl:sameAs ns8:JAD112202,
        ns40:jad100201,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD121189>,
        ns28:JAD120637,
        ns139:jad00971,
        ns30:JAD141179,
        ns16:JAD121408,
        ns16:JAD142214,
        ns16:JAD161012,
        ns52:jad00987,
        ns52:jad090940,
        ns52:jad091489,
        ns57:JAD122110,
        ns57:JAD140942,
        ns57:JAD150280,
        ns57:JAD170229,
        ns57:JAD180209,
        ns60:JAD160449,
        ns33:JAD150440 ;
    ns0:fullName "Bruno Vellas" ;
    ns0:hasAffiliation ns210:JAD190025 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190025 ;
    ns0:inAuthorList ns150:JAD190025 .

ns57:JAD190041 owl:sameAs ns33:JAD180700 ;
    ns0:fullName "Janne M. Papma" ;
    ns0:hasAffiliation ns106:JAD190041 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190041 ;
    ns0:inAuthorList ns150:JAD190041 .

ns57:JAD190046 owl:sameAs ns16:JAD180554 ;
    ns0:fullName "Petra Grönholm-Nyman" ;
    ns0:hasAffiliation ns79:JAD190046 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190046 ;
    ns0:inAuthorList ns150:JAD190046 .

ns57:JAD190154 owl:sameAs ns8:JAD131844,
        ns26:JAD150948,
        ns12:JAD141743,
        ns30:JAD150478,
        ns52:JAD181242,
        ns60:JAD180564,
        ns33:JAD170521 ;
    ns0:fullName "Tammie L.S. Benzinger" ;
    ns0:hasAffiliation ns208:JAD190154,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD190154> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190154 ;
    ns0:inAuthorList ns150:JAD190154 .

ns57:JAD190161 owl:sameAs ns8:JAD111472,
        ns8:JAD150428,
        ns8:JAD160677,
        ns8:JAD160800,
        ns8:JAD170948,
        ns12:JAD140210,
        ns30:JAD130716 ;
    ns0:fullName "Haihao Zhu" ;
    ns0:hasAffiliation ns210:JAD190161 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190161 ;
    ns0:inAuthorList ns150:JAD190161 .

ns57:JAD190175 owl:sameAs ns8:JAD181223,
        ns5:JAD170231 ;
    ns0:fullName "Geir Bråthen" ;
    ns0:hasAffiliation ns208:JAD190175,
        ns79:JAD190175 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190175 ;
    ns0:inAuthorList ns150:JAD190175 .

ns57:JAD190220 owl:sameAs ns2:jad01391,
        ns30:JAD160207,
        ns30:JAD161232 ;
    ns0:fullName "Andrew B. Newberg" ;
    ns0:hasAffiliation ns210:JAD190220,
        ns79:JAD190220 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190220 ;
    ns0:inAuthorList ns150:JAD190220 .

ns57:JAD190264 owl:sameAs ns33:JAD120832 ;
    ns0:fullName "Adam J. Schwarz" ;
    ns0:hasAffiliation ns210:JAD190264,
        ns208:JAD190264,
        ns79:JAD190264 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190264 ;
    ns0:inAuthorList ns150:JAD190264 .

ns57:JAD190280 owl:sameAs ns16:JAD130527,
        ns57:JAD100987,
        ns57:JAD121294 ;
    ns0:fullName "Cheng-Xin Gong" ;
    ns0:hasAffiliation ns210:JAD190280 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190280 ;
    ns0:inAuthorList ns150:JAD190280 .

ns57:JAD190338 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD132075>,
        ns28:JAD130053,
        ns28:JAD140057,
        ns180:JAD150863,
        ns5:JAD130506,
        ns60:JAD131172,
        ns60:JAD160324,
        ns33:JAD131652,
        ns33:JAD141167 ;
    ns0:fullName "Daniela Mari" ;
    ns0:hasAffiliation ns79:JAD190338 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190338 ;
    ns0:inAuthorList ns150:JAD190338 .

ns57:JAD190365 owl:sameAs ns2:JAD150606,
        ns2:JAD181099,
        ns40:JAD190160,
        ns12:JAD160995,
        ns52:JAD181195 ;
    ns0:fullName "Corinne E. Fischer" ;
    ns0:hasAffiliation ns210:JAD190365,
        ns163:JAD190365,
        ns79:JAD190365 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190365 ;
    ns0:inAuthorList ns150:JAD190365 .

ns57:JAD190426 owl:sameAs ns26:JAD180152,
        ns26:JAD190046,
        ns40:JAD181016,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD180321>,
        ns130:JAD180158,
        ns12:JAD132216,
        ns30:JAD121525,
        ns5:JAD180595,
        ns16:JAD170324,
        ns16:JAD180299,
        ns52:JAD160750,
        ns52:JAD170627,
        ns52:jad100678,
        ns57:JAD132195,
        ns57:JAD170553,
        ns60:JAD140624,
        ns60:JAD150776,
        ns60:JAD151175,
        ns33:JAD112120,
        ns33:JAD130062,
        ns33:JAD150899,
        ns33:JAD160448,
        ns33:JAD180378 ;
    ns0:fullName "José Luis Molinuevo" ;
    ns0:hasAffiliation ns88:JAD190426 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190426 ;
    ns0:inAuthorList ns150:JAD190426 .

ns57:JAD190494 owl:sameAs ns2:JAD170581,
        ns16:jad100729 ;
    ns0:fullName "Elena Tamagno" ;
    ns0:hasAffiliation ns210:JAD190494,
        ns208:JAD190494 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190494 ;
    ns0:inAuthorList ns150:JAD190494 .

ns57:JAD190533 owl:sameAs ns30:JAD180025 ;
    ns0:fullName "Kaikai Shen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:7.ID:JAD190533> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190533 ;
    ns0:inAuthorList ns150:JAD190533 .

ns57:JAD190545 owl:sameAs ns8:JAD190838 ;
    ns0:fullName "Ulises Gómez-Pinedo" ;
    ns0:hasAffiliation ns79:JAD190545 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190545 ;
    ns0:inAuthorList ns150:JAD190545 .

ns57:JAD190569 owl:sameAs ns52:jad01212 ;
    ns0:fullName "James Burke" ;
    ns0:hasAffiliation ns79:JAD190569 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190569 ;
    ns0:inAuthorList ns150:JAD190569 .

ns57:JAD190577 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD160645> ;
    ns0:fullName "Cristina Legido-Quigley" ;
    ns0:hasAffiliation ns210:JAD190577 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190577 ;
    ns0:inAuthorList ns150:JAD190577 .

ns57:JAD190620 owl:sameAs ns5:JAD140639,
        ns52:JAD181115,
        ns57:JAD141338 ;
    ns0:fullName "Kenji Ishii" ;
    ns0:hasAffiliation ns79:JAD190620 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190620 ;
    ns0:inAuthorList ns150:JAD190620 .

ns57:JAD190644 owl:sameAs ns57:JAD190369 ;
    ns0:fullName "Emi Nomura" ;
    ns0:hasAffiliation ns210:JAD190644 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns57:JAD190645 owl:sameAs ns2:jad00799,
        ns2:jad00906,
        ns2:jad100012,
        ns40:JAD160528,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160642>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD120763>,
        ns30:JAD130245,
        ns16:JAD0010,
        ns16:JAD160195,
        ns52:JAD110341,
        ns52:JAD150897,
        ns52:JAD180291,
        ns57:JAD161067,
        ns60:JAD170602,
        ns33:JAD160110,
        ns33:JAD170402,
        ns33:JAD170498 ;
    ns0:fullName "Cynthia Carlsson" ;
    ns0:hasAffiliation ns210:JAD190645,
        ns208:JAD190645,
        ns79:JAD190645 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190645 ;
    ns0:inAuthorList ns150:JAD190645 .

ns57:JAD190691 owl:sameAs ns8:JAD180554 ;
    ns0:fullName "Mira Karrasch" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JAD190691> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190691 ;
    ns0:inAuthorList ns150:JAD190691 .

ns57:JAD190716 owl:sameAs ns8:JAD140570,
        ns12:JAD132087,
        ns12:jad00950,
        ns141:JAD180158,
        ns30:JAD130881,
        ns30:JAD170995,
        ns5:JAD130656,
        ns5:JAD170086,
        ns16:JAD131766,
        ns16:JAD141824,
        ns16:jad100048,
        ns52:JAD170638,
        ns57:JAD160735,
        ns60:JAD121663,
        ns60:JAD150961 ;
    ns0:fullName "Camillo Marra" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD190716> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190716 ;
    ns0:inAuthorList ns150:JAD190716 .

ns57:JAD190817 owl:sameAs ns2:JAD141572,
        ns8:JAD180985,
        ns5:JAD180904 ;
    ns0:fullName "Akihiro Matsumura" ;
    ns0:hasAffiliation ns210:JAD190817 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190817 ;
    ns0:inAuthorList ns150:JAD190817 .

ns57:JAD190898 owl:sameAs ns16:JAD190700 ;
    ns0:fullName "Lars O. Tjernberg" ;
    ns0:hasAffiliation ns210:JAD190898 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190898 ;
    ns0:inAuthorList ns150:JAD190898 .

ns57:JHD180337 owl:sameAs ns12:JHD180285 ;
    ns0:fullName "Lisa Muratori" ;
    ns0:hasAffiliation ns210:JHD180337,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JHD180337> ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD180337 ;
    ns0:inAuthorList ns150:JHD180337 .

ns57:JHD190355 owl:sameAs ns5:JPD171081 ;
    ns0:fullName "Baochan Tran" ;
    ns0:hasAffiliation ns210:JHD190355 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190355 ;
    ns0:inAuthorList ns150:JHD190355 .

ns57:JHD190364 owl:sameAs ns30:JHD170238 ;
    ns0:fullName "David Cella" ;
    ns0:hasAffiliation ns106:JHD190364 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190364 ;
    ns0:inAuthorList ns150:JHD190364 .

ns57:JHD190365 owl:sameAs ns26:JHD160197 ;
    ns0:fullName "Kevin Biglan" ;
    ns0:hasAffiliation ns208:JHD190365 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190365 ;
    ns0:inAuthorList ns150:JHD190365 .

ns57:JND190397 owl:sameAs ns2:JND170299 ;
    ns0:fullName "Maria Elena Farrugia" ;
    ns0:hasAffiliation ns88:JND190397 ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190397 ;
    ns0:inAuthorList ns150:JND190397 .

ns57:JND190416 owl:sameAs ns2:JND180315 ;
    ns0:fullName "Astrid Pechmann" ;
    ns0:hasAffiliation ns208:JND190416 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190416 ;
    ns0:inAuthorList ns150:JND190416 .

ns57:JPD181518 owl:sameAs ns2:jad00530,
        ns8:JAD00028,
        ns40:jad00656,
        ns12:JAD143099,
        ns30:JAD131403,
        ns5:JAD141287,
        ns16:JAD170865,
        ns16:JAD180351,
        ns52:JAD111208,
        ns52:JAD111697,
        ns52:jad00804,
        ns57:JAD180789,
        ns60:jad00896,
        ns33:JAD140276,
        ns33:JAD171013 ;
    ns0:fullName "Douglas Galasko" ;
    ns0:hasAffiliation ns88:JPD181518 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181518 ;
    ns0:inAuthorList ns150:JPD181518 .

ns57:JPD191610 owl:sameAs ns8:jad00932 ;
    ns0:fullName "Christine M. Belden" ;
    ns0:hasAffiliation ns79:JPD191610 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191610 ;
    ns0:inAuthorList ns150:JPD191610 .

ns57:JPD191616 owl:sameAs ns8:JHD199003,
        ns8:JPD191593,
        ns28:JPD171135,
        ns30:JHD170245,
        ns5:JPD181383 ;
    ns0:fullName "Joaquim Ferreira" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JPD191616> ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191616 ;
    ns0:inAuthorList ns150:JPD191616 .

ns57:JVR191022 owl:sameAs ns52:JVR191026 ;
    ns0:fullName "Michael Frain" ;
    ns0:hasAffiliation ns106:JVR191022 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191022 ;
    ns0:inAuthorList ns150:JVR191022 .

ns57:JVR191023 owl:sameAs ns12:JVR851 ;
    ns0:fullName "Joseph Pfaller" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JVR191023> ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191023 ;
    ns0:inAuthorList ns150:JVR191023 .

ns57:JVR191026 owl:sameAs ns2:JVR939 ;
    ns0:fullName "Bradley McDaniels" ;
    ns0:hasAffiliation ns106:JVR191026 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191026 ;
    ns0:inAuthorList ns150:JVR191026 .

ns57:KCA190064 owl:sameAs ns2:KCA180045 ;
    ns0:fullName "A. Martín" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:KCA190064> ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190064 ;
    ns0:inAuthorList ns150:KCA190064 .

ns57:NRE182665 owl:sameAs ns2:NRE192754 ;
    ns0:fullName "Tania Fernandes Campos" ;
    ns0:hasAffiliation ns210:NRE182665 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182665 ;
    ns0:inAuthorList ns150:NRE182665 .

ns57:NRE192752 owl:sameAs ns57:NRE182565 ;
    ns0:fullName "Helle K. Iversen" ;
    ns0:hasAffiliation ns210:NRE192752 ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192752 ;
    ns0:inAuthorList ns150:NRE192752 .

ns57:NRE192778 owl:sameAs ns12:NRE172156 ;
    ns0:fullName "Luca Padua" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:NRE192778> ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192778 ;
    ns0:inAuthorList ns150:NRE192778 .

ns57:RNN190926 owl:sameAs ns16:RNN170725,
        ns60:RNN150515 ;
    ns0:fullName "Chuansheng Zhao" ;
    ns0:hasAffiliation ns210:RNN190926 ;
    ns0:hasArticle ns1:rnn-v37-i4-RNN190926 ;
    ns0:inAuthorList ns150:RNN190926 .

ns57:THC199029 owl:sameAs ns52:THC199031 ;
    ns0:fullName "Jun Yang" ;
    ns0:hasAffiliation ns210:THC199029 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199029 ;
    ns0:inAuthorList ns150:THC199029 .

ns57:XST190500 owl:sameAs ns2:XST180457 ;
    ns0:fullName "Luzhen Deng" ;
    ns0:hasAffiliation ns210:XST190500 ;
    ns0:hasArticle ns1:xst-v27-i3-XST190500 ;
    ns0:inAuthorList ns150:XST190500 .

ns60:BD180350 owl:sameAs ns5:CBM181308,
        ns16:CBM181836 ;
    ns0:fullName "Ryoji Kushima" ;
    ns0:hasAffiliation ns216:BD180350 ;
    ns0:hasArticle ns1:bd-v38-i2-BD180350 ;
    ns0:inAuthorList ns150:BD180350 .

ns60:BLC180206 owl:sameAs ns16:CBM170230 ;
    ns0:fullName "Adonina Tardón" ;
    ns0:hasAffiliation ns169:BLC180206,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:8.ID:BLC180206> ;
    ns0:hasArticle ns1:blc-v5-i2-BLC180206 ;
    ns0:inAuthorList ns150:BLC180206 .

ns60:CBM192435 owl:sameAs ns60:CBM171099 ;
    ns0:fullName "Zhenggang Zhu" ;
    ns0:hasAffiliation ns77:CBM192435,
        ns168:CBM192435,
        ns215:CBM192435 ;
    ns0:hasArticle ns1:cbm-v26-i2-CBM192435 ;
    ns0:inAuthorList ns150:CBM192435 .

ns60:CH180528 owl:sameAs ns12:JCB15018,
        ns16:CH189415,
        ns16:JCB189014 ;
    ns0:fullName "Friedrich Jung" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:CH180528> ;
    ns0:hasArticle ns1:ch-v72-i4-CH180528 ;
    ns0:inAuthorList ns150:CH180528 .

ns60:CH199206 owl:sameAs ns26:CH179208,
        ns12:CH2028,
        ns30:CH168033,
        ns30:CH189125,
        ns30:CH189904,
        ns30:CH2004,
        ns16:CH168107,
        ns16:CH168114,
        ns16:CH189418,
        ns16:CH199006,
        ns16:CH199205,
        ns52:CH168040,
        ns52:CH199005,
        ns52:CH199201,
        ns57:CH189906,
        ns60:CH179210,
        ns33:CH2001 ;
    ns0:fullName "Andreas Lendlein" ;
    ns0:hasAffiliation ns77:CH199206,
        ns168:CH199206,
        ns215:CH199206 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199206 ;
    ns0:inAuthorList ns150:CH199206 .

ns60:CH199223 owl:sameAs ns8:CH189123,
        ns12:CH189312,
        ns5:CH168002,
        ns5:CH168116,
        ns5:CH179102,
        ns5:CH189308,
        ns5:CH189404,
        ns5:CH199222,
        ns16:CH179221,
        ns16:CH189114,
        ns16:CH189115,
        ns16:CH189116,
        ns16:CH189405,
        ns16:CH189407,
        ns16:CH199202,
        ns16:CH2009,
        ns16:CH2010,
        ns52:CH168115,
        ns57:CH168034,
        ns57:CH1986,
        ns57:CH2046 ;
    ns0:fullName "D.-A. Clevert" ;
    ns0:hasAffiliation ns168:CH199223 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199223 ;
    ns0:inAuthorList ns150:CH199223 .

ns60:FI1872 owl:sameAs ns2:FI1887 ;
    ns0:fullName "Leonardo Rundo" ;
    ns0:hasAffiliation ns216:FI1872 ;
    ns0:hasArticle ns1:fi-v171-i1-4-FI1872 ;
    ns0:inAuthorList ns150:FI1872 .

ns60:JAD180521 owl:sameAs ns8:JAD129034,
        ns8:JAD141110,
        ns26:JAD121516,
        ns26:JAD180713,
        ns28:JAD121474,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD161019>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD180507>,
        ns132:JAD170742,
        ns12:JAD132729,
        <http://ld.iospress.nl/rdf/contributor/Author:34.ID:JAD171145>,
        ns5:JAD101722,
        ns5:JAD101974,
        ns5:JAD131820,
        ns5:JAD150752,
        ns57:JAD121315,
        ns60:JAD122170,
        ns60:JAD131802,
        ns33:JAD170072,
        ns33:JAD180344,
        ns33:JAD180640 ;
    ns0:fullName "Christopher C. Rowe" ;
    ns0:hasAffiliation ns218:JAD180521 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180521 ;
    ns0:inAuthorList ns150:JAD180521 .

ns60:JAD180630 owl:sameAs ns40:JAD120148,
        ns12:JAD141803,
        ns30:JAD181281,
        ns16:JAD150622,
        ns16:JAD160970,
        ns52:JAD122431,
        ns52:JAD160667,
        ns52:JAD180693,
        ns57:JAD170815,
        ns33:JAD132642 ;
    ns0:fullName "Jakub Hort" ;
    ns0:hasAffiliation ns77:JAD180630,
        ns168:JAD180630 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD180630 ;
    ns0:inAuthorList ns150:JAD180630 .

ns60:JAD180932 owl:sameAs ns2:JPD150632,
        ns12:JPD150672,
        ns30:JAD132147 ;
    ns0:fullName "Catherine C. Price" ;
    ns0:hasAffiliation ns168:JAD180932,
        ns216:JAD180932 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD180932 ;
    ns0:inAuthorList ns150:JAD180932 .

ns60:JAD180949 owl:sameAs ns40:JAD160209 ;
    ns0:fullName "Jochen Werle" ;
    ns0:hasAffiliation ns218:JAD180949 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180949 ;
    ns0:inAuthorList ns150:JAD180949 .

ns60:JAD181095 owl:sameAs ns8:jad100186,
        ns40:JAD160322,
        ns30:JAD132306,
        ns30:JAD190402,
        ns16:JAD150548,
        ns52:JAD161109,
        ns33:JAD190041 ;
    ns0:fullName "Afina W. Lemstra" ;
    ns0:hasAffiliation ns217:JAD181095 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181095 ;
    ns0:inAuthorList ns150:JAD181095 .

ns60:JAD181113 owl:sameAs ns57:jad100129 ;
    ns0:fullName "Matthew J. Huentelman" ;
    ns0:hasAffiliation ns77:JAD181113 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD181113 ;
    ns0:inAuthorList ns150:JAD181113 .

ns60:JAD181140 owl:sameAs ns8:JAD121585,
        ns60:JAD161228 ;
    ns0:fullName "Caterina Rosano" ;
    ns0:hasAffiliation ns77:JAD181140 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181140 ;
    ns0:inAuthorList ns150:JAD181140 .

ns60:JAD181168 owl:sameAs ns2:JAD179929,
        ns30:JAD180365 ;
    ns0:fullName "Paul Edison" ;
    ns0:hasAffiliation ns77:JAD181168 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181168 ;
    ns0:inAuthorList ns150:JAD181168 .

ns60:JAD181175 owl:sameAs ns12:jad01079 ;
    ns0:fullName "Kristin Martin-Cook" ;
    ns0:hasAffiliation ns217:JAD181175 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD181175 ;
    ns0:inAuthorList ns150:JAD181175 .

ns60:JAD181203 owl:sameAs ns8:JAD151113,
        ns26:JAD160979,
        ns52:JAD160641,
        ns52:JAD161248,
        ns57:JAD180030,
        ns57:JAD180485,
        ns57:JAD190202,
        ns33:JAD161292 ;
    ns0:fullName "Krista L. Lanctôt" ;
    ns0:hasAffiliation ns77:JAD181203,
        ns168:JAD181203,
        ns216:JAD181203,
        ns81:JAD181203 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181203 ;
    ns0:inAuthorList ns150:JAD181203 .

ns60:JAD181256 owl:sameAs ns30:JAD170854,
        ns5:JAD160983,
        ns52:JAD161142 ;
    ns0:fullName "Johanna Krüger" ;
    ns0:hasAffiliation ns77:JAD181256,
        ns168:JAD181256 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181256 ;
    ns0:inAuthorList ns150:JAD181256 .

ns60:JAD181265 owl:sameAs ns40:JAD180855,
        ns30:JAD170278,
        ns30:jad100933,
        ns5:jad100609,
        ns57:jad091594,
        ns57:jad101023,
        ns60:JAD160271 ;
    ns0:fullName "Martin Ingelsson" ;
    ns0:hasAffiliation ns77:JAD181265 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181265 ;
    ns0:inAuthorList ns150:JAD181265 .

ns60:JAD181282 owl:sameAs ns2:JAD00025,
        ns8:jad00498,
        ns26:JAD121570,
        ns26:JAD190069,
        ns28:JPD171081,
        ns12:JAD160413,
        ns30:JAD0006,
        ns52:JAD132489,
        ns60:JAD161114,
        ns60:JAD171013,
        ns60:JPD171113 ;
    ns0:fullName "John Q. Trojanowski" ;
    ns0:hasAffiliation ns77:JAD181282 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181282 ;
    ns0:inAuthorList ns150:JAD181282 .

ns60:JAD190010 owl:sameAs ns8:jad00269,
        ns12:JAD161250 ;
    ns0:fullName "Sujuan Gao" ;
    ns0:hasAffiliation ns216:JAD190010 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190010 ;
    ns0:inAuthorList ns150:JAD190010 .

ns60:JAD190041 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD161109> ;
    ns0:fullName "Frank Jan de Jong" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190041> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190041 ;
    ns0:inAuthorList ns150:JAD190041 .

ns60:JAD190091 owl:sameAs ns60:JAD150985 ;
    ns0:fullName "J. Scott Roberts" ;
    ns0:hasAffiliation ns169:JAD190091 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190091 ;
    ns0:inAuthorList ns150:JAD190091 .

ns60:JAD190094 owl:sameAs ns8:JAD160470,
        ns26:JAD170982,
        ns12:JAD120808,
        ns12:JAD180219 ;
    ns0:fullName "J. Simon Bell" ;
    ns0:hasAffiliation ns77:JAD190094,
        ns168:JAD190094,
        ns217:JAD190094 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190094 ;
    ns0:inAuthorList ns150:JAD190094 .

ns60:JAD190119 owl:sameAs ns5:JAD170712 ;
    ns0:fullName "Anna Margherita Pietroboni" ;
    ns0:hasAffiliation ns168:JAD190119 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

ns60:JAD190132 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:31.ID:JAD160668>,
        ns16:JAD170039,
        ns52:JAD160983,
        ns33:JAD170534 ;
    ns0:fullName "Maria Pikkarainen" ;
    ns0:hasAffiliation ns77:JAD190132 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

ns60:JAD190133 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:29.ID:JAD160152> ;
    ns0:fullName "Timo Strandberg" ;
    ns0:hasAffiliation ns219:JAD190133,
        ns217:JAD190133 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190133 ;
    ns0:inAuthorList ns150:JAD190133 .

ns60:JAD190152 owl:sameAs ns26:JAD180274,
        ns5:JAD110719 ;
    ns0:fullName "Miguel Castelo-Branco" ;
    ns0:hasAffiliation ns77:JAD190152,
        ns168:JAD190152,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190152> ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190152 ;
    ns0:inAuthorList ns150:JAD190152 .

ns60:JAD190154 owl:sameAs ns2:JAD130011 ;
    ns0:fullName "Brian A. Gordon" ;
    ns0:hasAffiliation ns168:JAD190154,
        ns217:JAD190154 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190154 ;
    ns0:inAuthorList ns150:JAD190154 .

ns60:JAD190161 owl:sameAs ns2:jad00098,
        ns8:jad00434,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170123>,
        ns30:jad100843,
        ns16:JAD111472 ;
    ns0:fullName "Benjamin Wolozin" ;
    ns0:hasAffiliation ns77:JAD190161,
        ns168:JAD190161 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190161 ;
    ns0:inAuthorList ns150:JAD190161 .

ns60:JAD190175 owl:sameAs ns12:JAD181223,
        ns60:JAD150234 ;
    ns0:fullName "Linda R. White" ;
    ns0:hasAffiliation ns168:JAD190175,
        ns215:JAD190175 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190175 ;
    ns0:inAuthorList ns150:JAD190175 .

ns60:JAD190283 owl:sameAs ns12:JAD180069 ;
    ns0:fullName "Daniel L. Gillen" ;
    ns0:hasAffiliation ns215:JAD190283 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190283 ;
    ns0:inAuthorList ns150:JAD190283 .

ns60:JAD190323 owl:sameAs ns30:jad00634 ;
    ns0:fullName "Roberto Ceravolo" ;
    ns0:hasAffiliation ns77:JAD190323 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190323 ;
    ns0:inAuthorList ns150:JAD190323 .

ns60:JAD190334 owl:sameAs ns30:JAD150909,
        ns16:JAD170583 ;
    ns0:fullName "Anna Sutela" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns60:JAD190338 owl:sameAs ns8:JAD130506,
        ns139:jad100933 ;
    ns0:fullName "Beatrice Arosio" ;
    ns0:hasAffiliation ns215:JAD190338 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190338 ;
    ns0:inAuthorList ns150:JAD190338 .

ns60:JAD190346 owl:sameAs ns8:JAD151130,
        ns26:JAD160927 ;
    ns0:fullName "Edip M. Gurol" ;
    ns0:hasAffiliation ns77:JAD190346 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190346 ;
    ns0:inAuthorList ns150:JAD190346 .

ns60:JAD190399 owl:sameAs ns52:JAD171182 ;
    ns0:fullName "Tae Hui Kim" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190399> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns60:JAD190480 owl:sameAs ns8:JAD150931,
        ns5:JAD142052,
        ns16:JAD170494,
        ns52:JAD160904 ;
    ns0:fullName "Carmelinda Ruggiero" ;
    ns0:hasAffiliation ns77:JAD190480 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190480 ;
    ns0:inAuthorList ns150:JAD190480 .

ns60:JAD190577 owl:sameAs ns2:jad101350,
        ns130:JAD151155,
        ns16:JAD170531,
        ns52:JAD170287,
        ns33:JAD160645,
        ns33:JAD170557 ;
    ns0:fullName "Madhav Thambisetty" ;
    ns0:hasAffiliation ns216:JAD190577 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190577 ;
    ns0:inAuthorList ns150:JAD190577 .

ns60:JAD190620 owl:sameAs ns12:JAD170749 ;
    ns0:fullName "Hitoshi Shimada" ;
    ns0:hasAffiliation ns217:JAD190620 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190620 ;
    ns0:inAuthorList ns150:JAD190620 .

ns60:JAD190634 owl:sameAs ns5:JAD121420,
        ns5:JAD131724,
        ns57:JAD122074 ;
    ns0:fullName "Robert C. Barber" ;
    ns0:hasAffiliation ns217:JAD190634 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190634 ;
    ns0:inAuthorList ns150:JAD190634 .

ns60:JAD190660 owl:sameAs ns2:JAD110794,
        ns8:JAD161179,
        ns8:jad100432,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD150555> ;
    ns0:fullName "José Luis Vázquez-Higuera" ;
    ns0:hasAffiliation ns77:JAD190660 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190660 ;
    ns0:inAuthorList ns150:JAD190660 .

ns60:JAD190707 owl:sameAs ns2:JAD110662,
        ns2:JAD120130,
        ns2:JAD131883,
        ns2:JAD160416,
        ns2:JAD181240,
        ns8:JAD111928,
        ns8:jad01230,
        ns12:JAD100021,
        ns12:JAD111517,
        ns30:JAD161095,
        ns30:jad01074 ;
    ns0:fullName "Susan A. Farr" ;
    ns0:hasAffiliation ns217:JAD190707 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190707 ;
    ns0:inAuthorList ns150:JAD190707 .

ns60:JAD190716 owl:sameAs ns2:JAD141824,
        ns26:JAD121663,
        ns57:jad01223,
        ns60:JAD131766 ;
    ns0:fullName "Marco Bozzali" ;
    ns0:hasAffiliation ns216:JAD190716 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190716 ;
    ns0:inAuthorList ns150:JAD190716 .

ns60:JAD190817 owl:sameAs ns52:JAD180985,
        ns60:JAD180904,
        ns33:JAD160887 ;
    ns0:fullName "Takashi Matsushita" ;
    ns0:hasAffiliation ns77:JAD190817 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190817 ;
    ns0:inAuthorList ns150:JAD190817 .

ns60:JHD190346 owl:sameAs ns8:JPD150652 ;
    ns0:fullName "J. Vincent Filoteo" ;
    ns0:hasAffiliation ns215:JHD190346,
        ns217:JHD190346 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190346 ;
    ns0:inAuthorList ns150:JHD190346 .

ns60:JHD190364 owl:sameAs ns2:JHD180341 ;
    ns0:fullName "Rebecca E. Ready" ;
    ns0:hasAffiliation ns81:JHD190364 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190364 ;
    ns0:inAuthorList ns150:JHD190364 .

ns60:JND190379 owl:sameAs ns30:JND160182 ;
    ns0:fullName "L.H. van den Berg" ;
    ns0:hasAffiliation ns77:JND190379 ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190379 ;
    ns0:inAuthorList ns150:JND190379 .

ns60:JND190416 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:63.ID:JND170280> ;
    ns0:fullName "Hanns Lochmüller" ;
    ns0:hasAffiliation ns215:JND190416 ;
    ns0:hasArticle ns1:jnd-v6-i4-JND190416 ;
    ns0:inAuthorList ns150:JND190416 .

ns60:JPD181518 owl:sameAs ns8:JPD150639 ;
    ns0:fullName "Brit Mollenhauer" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JPD181518> ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181518 ;
    ns0:inAuthorList ns150:JPD181518 .

ns60:JPD191616 owl:sameAs ns2:JPD171277,
        ns2:JPD181541,
        ns8:JPD150673,
        ns8:JPD161055,
        ns8:JPD189002,
        ns12:JPD150733,
        ns12:JPD160816,
        ns30:JPD150568,
        ns30:JPD150638,
        ns30:JPD160927,
        ns30:JPD179000,
        ns30:JPD181332,
        ns30:JPD181519,
        ns30:JPD181523,
        ns5:JAD110482,
        ns5:JPD150532,
        ns5:JPD160853,
        ns5:JPD181431,
        ns5:JPD181500,
        ns16:JPD181383,
        ns52:JPD140515,
        ns52:JPD150755,
        ns52:JPD181374,
        ns60:JPD171195 ;
    ns0:fullName "Bastiaan R. Bloem" ;
    ns0:hasAffiliation ns77:JPD191616 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191616 ;
    ns0:inAuthorList ns150:JPD191616 .

ns60:JVR191026 owl:sameAs ns8:JVR814,
        ns30:JVR191023,
        ns30:JVR930 ;
    ns0:fullName "Beatrice Lee" ;
    ns0:hasAffiliation ns77:JVR191026 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191026 ;
    ns0:inAuthorList ns150:JVR191026 .

ns60:KCA180049 owl:sameAs ns2:KCA179001,
        ns8:KCA170005,
        ns26:KCA170018,
        ns5:KCA190063,
        ns33:KCA180041 ;
    ns0:fullName "Primo Lara" ;
    ns0:hasAffiliation ns216:KCA180049 ;
    ns0:hasArticle ns1:kca-v3-i2-KCA180049 ;
    ns0:inAuthorList ns150:KCA180049 .

ns60:KCA190064 owl:sameAs ns33:KCA180045 ;
    ns0:fullName "I. Gallegos" ;
    ns0:hasAffiliation ns169:KCA190064 ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190064 ;
    ns0:inAuthorList ns150:KCA190064 .

ns60:XST180477 owl:sameAs ns40:XST190506,
        ns33:XST190527 ;
    ns0:fullName "Zhanli Hu" ;
    ns0:hasAffiliation ns77:XST180477 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180477 ;
    ns0:inAuthorList ns150:XST180477 .

ns60:XST190527 owl:sameAs ns26:XST190506,
        ns57:XST180477 ;
    ns0:fullName "Hairong Zheng" ;
    ns0:hasAffiliation ns77:XST190527 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190527 ;
    ns0:inAuthorList ns150:XST190527 .

ns33:CBM182020 owl:sameAs ns12:XST16245 ;
    ns0:fullName "Chengqiang Mo" ;
    ns0:hasAffiliation ns229:CBM182020 ;
    ns0:hasArticle ns1:cbm-v25-i2-CBM182020 ;
    ns0:inAuthorList ns150:CBM182020 .

ns33:CH180528 owl:sameAs ns57:CH189301 ;
    ns0:fullName "Johannes Brachmann" ;
    ns0:hasAffiliation ns227:CH180528 ;
    ns0:hasArticle ns1:ch-v72-i4-CH180528 ;
    ns0:inAuthorList ns150:CH180528 .

ns33:CH189907 owl:sameAs ns2:CH179235,
        ns52:CH180428 ;
    ns0:fullName "Vladimir Cerny" ;
    ns0:hasAffiliation ns229:CH189907,
        ns231:CH189907,
        ns230:CH189907,
        ns270:CH189907 ;
    ns0:hasArticle ns1:ch-v72-i1-CH189907 ;
    ns0:inAuthorList ns150:CH189907 .

ns33:CH199223 owl:sameAs ns2:CH189123,
        ns2:CH199222,
        ns8:CH189308,
        ns8:CH189407 ;
    ns0:fullName "M. Apfelbeck" ;
    ns0:hasAffiliation ns229:CH199223 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199223 ;
    ns0:inAuthorList ns150:CH199223 .

ns33:JAD180521 owl:sameAs ns2:jad00072,
        ns26:JAD170072,
        ns40:JAD150948,
        ns43:JAD161019,
        ns130:JAD121474,
        ns130:JAD150446,
        ns130:jad090249,
        ns12:jad00106,
        ns176:JAD170128,
        ns30:JAD132024,
        <http://ld.iospress.nl/rdf/contributor/Author:36.ID:JAD171145>,
        ns5:JAD161050,
        ns5:jad00209,
        ns57:JAD00021,
        ns57:jad00195,
        ns60:JAD160821,
        ns60:JAD170998 ;
    ns0:fullName "Colin L. Masters" ;
    ns0:hasAffiliation ns174:JAD180521 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180521 ;
    ns0:inAuthorList ns150:JAD180521 .

ns33:JAD180572 owl:sameAs ns8:JAD141302,
        ns40:JAD141314,
        ns30:JAD190474,
        ns5:JAD130971,
        ns16:JAD101977,
        ns52:JAD140846,
        ns52:JAD190306,
        ns57:JAD120169,
        ns60:JAD150537,
        ns60:JAD190524,
        ns33:JAD141266 ;
    ns0:fullName "Perminder S. Sachdev" ;
    ns0:hasAffiliation ns229:JAD180572 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180572 ;
    ns0:inAuthorList ns150:JAD180572 .

ns33:JAD180630 owl:sameAs ns2:JAD132642,
        ns30:JAD132393,
        ns5:JAD170595,
        ns16:JAD170815,
        ns57:JAD160970 ;
    ns0:fullName "Martin Vyhnalek" ;
    ns0:hasAffiliation ns229:JAD180630,
        ns228:JAD180630 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD180630 ;
    ns0:inAuthorList ns150:JAD180630 .

ns33:JAD181203 owl:sameAs ns57:JAD170238 ;
    ns0:fullName "Walter Swardfager" ;
    ns0:hasAffiliation ns230:JAD181203,
        ns37:JAD181203,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:9.ID:JAD181203> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181203 ;
    ns0:inAuthorList ns150:JAD181203 .

ns33:JAD181217 owl:sameAs ns30:JAD190401,
        ns5:CBM533,
        ns52:BME1403,
        ns57:JAD180425 ;
    ns0:fullName "Zhao Jin" ;
    ns0:hasAffiliation ns229:JAD181217 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181217 ;
    ns0:inAuthorList ns150:JAD181217 .

ns33:JAD181232 owl:sameAs ns132:JAD120172 ;
    ns0:fullName "François Sellal" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:9.ID:JAD181232> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD181232 ;
    ns0:inAuthorList ns150:JAD181232 .

ns33:JAD181246 owl:sameAs ns2:JAD130779,
        ns2:JAD160146,
        ns8:JAD180987,
        ns26:JAD170398,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170483>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad091474> ;
    ns0:fullName "Natalia Bobkova" ;
    ns0:hasAffiliation ns229:JAD181246 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181246 ;
    ns0:inAuthorList ns150:JAD181246 .

ns33:JAD181259 owl:sameAs ns43:JAD170260,
        ns12:jad00305 ;
    ns0:fullName "Carlo Ferrarese" ;
    ns0:hasAffiliation ns227:JAD181259,
        ns231:JAD181259,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:9.ID:JAD181259> ;
    ns0:hasArticle ns1:jad-v72-i2-JAD181259 ;
    ns0:inAuthorList ns150:JAD181259 .

ns33:JAD181261 owl:sameAs ns2:JAD150736,
        ns5:JAD190159 ;
    ns0:fullName "Nagaendran Kandiah" ;
    ns0:hasAffiliation ns229:JAD181261,
        ns227:JAD181261 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181261 ;
    ns0:inAuthorList ns150:JAD181261 .

ns33:JAD190046 owl:sameAs ns8:JAD101422,
        ns26:JAD161113,
        ns40:JAD180167,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD150167>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD150746>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170073>,
        ns12:JAD160639,
        ns180:JAD170920,
        ns30:JAD120223,
        ns52:JAD131334,
        ns60:JAD140240,
        ns60:JAD161173,
        ns33:JAD130914 ;
    ns0:fullName "Juan Fortea" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:9.ID:JAD190046> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190046 ;
    ns0:inAuthorList ns150:JAD190046 .

ns33:JAD190077 owl:sameAs ns2:JAD101536,
        ns2:JAD150914,
        ns5:JAD170555 ;
    ns0:fullName "Angela L. Jefferson" ;
    ns0:hasAffiliation ns229:JAD190077 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190077 ;
    ns0:inAuthorList ns150:JAD190077 .

ns33:JAD190091 owl:sameAs ns33:JAD150985 ;
    ns0:fullName "Richard Schulz" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:9.ID:JAD190091> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190091 ;
    ns0:inAuthorList ns150:JAD190091 .

ns33:JAD190119 owl:sameAs ns8:JAD102124,
        ns12:JAD101704,
        ns30:JAD122263,
        ns5:JAD140756,
        ns57:JAD170861,
        ns60:JAD180723 ;
    ns0:fullName "Laura Ghezzi" ;
    ns0:hasAffiliation ns228:JAD190119 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

ns33:JAD190132 owl:sameAs ns2:JAD150909,
        ns8:JAD101911,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD140777>,
        ns12:JAD110200,
        ns12:JAD170854,
        ns30:JAD190334,
        ns16:JAD170697,
        ns16:JAD180645,
        ns57:JAD180071,
        ns33:JAD170583 ;
    ns0:fullName "Anne Koivisto" ;
    ns0:hasAffiliation ns229:JAD190132,
        ns228:JAD190132 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

ns33:JAD190161 owl:sameAs ns2:JAD140210,
        ns12:JAD180366,
        ns5:JAD160800,
        ns52:JAD150428,
        ns57:JAD170948,
        ns33:JAD111472 ;
    ns0:fullName "Wei Qiao Qiu" ;
    ns0:hasAffiliation ns229:JAD190161,
        ns227:JAD190161,
        ns231:JAD190161 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190161 ;
    ns0:inAuthorList ns150:JAD190161 .

ns33:JAD190175 owl:sameAs ns2:JAD132246 ;
    ns0:fullName "Henrietta M. Nielsen" ;
    ns0:hasAffiliation ns229:JAD190175 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190175 ;
    ns0:inAuthorList ns150:JAD190175 .

ns33:JAD190283 owl:sameAs ns2:JAD0005 ;
    ns0:fullName "Michael A. Yassa" ;
    ns0:hasAffiliation ns228:JAD190283 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190283 ;
    ns0:inAuthorList ns150:JAD190283 .

ns33:JAD190319 owl:sameAs ns57:JAD160230,
        ns57:JAD180943 ;
    ns0:fullName "Velandai Srikanth" ;
    ns0:hasAffiliation ns229:JAD190319,
        ns228:JAD190319,
        ns231:JAD190319 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190319 ;
    ns0:inAuthorList ns150:JAD190319 .

ns33:JAD190335 owl:sameAs ns33:JAD160359 ;
    ns0:fullName "Sebastian J. Crutch" ;
    ns0:hasAffiliation ns229:JAD190335 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190335 ;
    ns0:inAuthorList ns150:JAD190335 .

ns33:JAD190399 owl:sameAs ns2:JAD160463,
        ns26:JAD101221,
        ns57:JAD171182,
        ns60:JAD160619 ;
    ns0:fullName "Seung-Ho Ryu" ;
    ns0:hasAffiliation ns270:JAD190399 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190399 ;
    ns0:inAuthorList ns150:JAD190399 .

ns33:JAD190414 owl:sameAs ns8:jad00878,
        ns26:JAD180669,
        ns12:JAD122098,
        <http://ld.iospress.nl/rdf/contributor/Author:36.ID:JAD160668>,
        ns5:JAD190152 ;
    ns0:fullName "Isabel Santana" ;
    ns0:hasAffiliation ns270:JAD190414,
        ns37:JAD190414 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190414 ;
    ns0:inAuthorList ns150:JAD190414 .

ns33:JAD190426 owl:sameAs ns8:JAD180595 ;
    ns0:fullName "Alireza Atri" ;
    ns0:hasAffiliation ns270:JAD190426,
        ns37:JAD190426 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190426 ;
    ns0:inAuthorList ns150:JAD190426 .

ns33:JAD190469 owl:sameAs ns26:JAD160257,
        ns40:JAD121180,
        ns40:JAD141044,
        ns40:JAD150637,
        ns40:JAD160025,
        ns40:JAD180049,
        ns40:JAD180394,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD141623>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170556>,
        ns28:JAD161139,
        ns28:JAD170507,
        ns28:JAD170537,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD121927>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD141773>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150556>,
        ns43:JAD111832,
        ns43:JAD132072,
        ns43:JAD141011,
        ns43:JAD150832,
        ns130:JAD180048,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD140318>,
        ns132:JAD190007,
        ns176:JAD130461,
        ns16:JAD132333,
        ns52:JAD102145,
        ns57:JAD100660,
        ns57:JAD161181,
        ns33:JAD160341,
        ns33:JAD170943 ;
    ns0:fullName "Duk L. Na" ;
    ns0:hasAffiliation ns229:JAD190469,
        ns228:JAD190469,
        ns227:JAD190469,
        ns37:JAD190469 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190469 ;
    ns0:inAuthorList ns150:JAD190469 .

ns33:JAD190487 owl:sameAs ns2:JAD180183 ;
    ns0:fullName "Jihui Lyu" ;
    ns0:hasAffiliation ns229:JAD190487,
        ns228:JAD190487 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190487 ;
    ns0:inAuthorList ns150:JAD190487 .

ns33:JAD190524 owl:sameAs ns8:JAD101977,
        ns8:JAD141266,
        ns5:JAD141314 ;
    ns0:fullName "Anne Poljak" ;
    ns0:hasAffiliation ns229:JAD190524,
        ns228:JAD190524,
        ns230:JAD190524 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190524 ;
    ns0:inAuthorList ns150:JAD190524 .

ns33:JAD190549 owl:sameAs ns40:JAD110515,
        ns40:JAD131382,
        ns40:JAD180082,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD131916> ;
    ns0:fullName "Alain Vighetto" ;
    ns0:hasAffiliation ns227:JAD190549 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190549 ;
    ns0:inAuthorList ns150:JAD190549 .

ns33:JAD190620 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170509>,
        ns16:JAD132429 ;
    ns0:fullName "Makoto Higuchi" ;
    ns0:hasAffiliation ns231:JAD190620 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190620 ;
    ns0:inAuthorList ns150:JAD190620 .

ns33:JAD190645 owl:sameAs ns12:JAD110341,
        ns52:JAD160110 ;
    ns0:fullName "Carey E. Gleason" ;
    ns0:hasAffiliation ns229:JAD190645,
        ns227:JAD190645 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190645 ;
    ns0:inAuthorList ns150:JAD190645 .

ns33:JAD190707 owl:sameAs ns40:jad01074,
        ns12:JAD120130,
        ns12:jad01230 ;
    ns0:fullName "William A. Banks" ;
    ns0:hasAffiliation ns228:JAD190707 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190707 ;
    ns0:inAuthorList ns150:JAD190707 .

ns33:JAD190756 owl:sameAs ns2:jad01306,
        ns12:JAD160593,
        ns16:JAD180455,
        ns52:JAD121861 ;
    ns0:fullName "Kirk Daffner" ;
    ns0:hasAffiliation ns230:JAD190756 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190756 ;
    ns0:inAuthorList ns150:JAD190756 .

ns33:JHD190346 owl:sameAs ns57:JAD102103 ;
    ns0:fullName "Dean C. Delis" ;
    ns0:hasAffiliation ns228:JHD190346,
        ns227:JHD190346 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190346 ;
    ns0:inAuthorList ns150:JHD190346 .

ns33:JPD191610 owl:sameAs ns57:jad101185 ;
    ns0:fullName "Kathryn Davis" ;
    ns0:hasAffiliation ns227:JPD191610 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191610 ;
    ns0:inAuthorList ns150:JPD191610 .

ns33:JPD191612 owl:sameAs ns33:JPD171264 ;
    ns0:fullName "Qin Xiao" ;
    ns0:hasAffiliation ns228:JPD191612 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191612 ;
    ns0:inAuthorList ns150:JPD191612 .

ns33:KCA190064 owl:sameAs ns130:KCA180045 ;
    ns0:fullName "J.A. Arranz" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:9.ID:KCA190064> ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190064 ;
    ns0:inAuthorList ns150:KCA190064 .

ns33:NRE182671 owl:sameAs ns8:WOR182813,
        ns12:NRE1420,
        ns12:bmr00380 ;
    ns0:fullName "Soofia Naghdi" ;
    ns0:hasAffiliation ns229:NRE182671,
        ns227:NRE182671 ;
    ns0:hasArticle ns1:nre-v44-i3-NRE182671 ;
    ns0:inAuthorList ns150:NRE182671 .

ns33:NRE192745 owl:sameAs ns60:NRE182525 ;
    ns0:fullName "Thierry Lejeune" ;
    ns0:hasAffiliation ns229:NRE192745,
        ns227:NRE192745,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:9.ID:NRE192745> ;
    ns0:hasArticle ns1:nre-v45-i2-NRE192745 ;
    ns0:inAuthorList ns150:NRE192745 .

ns33:THC199026 owl:sameAs ns2:THC174526 ;
    ns0:fullName "Jian Sun" ;
    ns0:hasAffiliation ns229:THC199026,
        ns227:THC199026 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199026 ;
    ns0:inAuthorList ns150:THC199026 .

ns1:aac-v10-i2-AAC190457 ns0:hasKeywords "Abstract argumentation"@en,
        "SETAF"@en,
        "collective attacks"@en,
        "expressiveness"@en ;
    ns0:hasPubAbstract "In this paper, we consider argumentation frameworks with sets of attacking arguments (SETAFs) due to Nielsen and Parsons, an extension of Dung’s abstract argumentation frameworks that allow for collective attacks. We first provide a comprehensive analysis of the expressiveness of SETAFs under conflict-free, naive, stable, complete, admissible, preferred, semi-stable, and stage semantics. Our analysis shows that SETAFs are strictly more expressive than Dung AFs. Towards a uniform characterization of SETAFs and Dung AFs we provide general results on expressiveness which take the maximum degree of the collective attacks into account. Our results show that, for each  k > 0, SETAFs that allow for collective attacks of  k + 1 arguments are more expressive than SETAFs that only allow for collective attacks of at most k arguments."@en ;
    ns0:hasPubTitle "On the expressive power of collective attacks"@en .

ns1:adr-v3-i1-ADR190118 ns0:hasKeywords "Aggregation"@en,
        "Alzheimer’s disease"@en,
        "limonoids"@en,
        "natural products"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Tau is a phosphoprotein with natively unfolded conformation that functions to stabilize microtubules in axons. Alzheimer’s disease pathology triggers several modifications in tau, which causes it to lose its affinity towards microtubule, thus, leading to microtubule disassembly and loss of axonal integrity. This elicit accumulation of tau as paired helical filaments is followed by stable neurofibrillary tangles formation. A large number of small molecules have been isolated from Azadirachta indica with varied medicinal applications. The intermediate and final limonoids, nimbin and salannin respectively, isolated from Azadirachta indica, were screened against tau aggregation. ThS and ANS fluorescence assay showed the role of intermediate and final limonoids in preventing heparin induced cross-β sheet formation and also decreased hydrophobicity, which are characteristic nature of tau aggregation. Transmission electron microscopy studies revealed that limonoids restricted the aggregation of tau to fibrils; in turn, limonoids led to the formation of short and fragile aggregates. Both the limonoids were non-toxic to HEK293T cells thus, substantiating limonoids as a potential lead in overcoming Alzheimer’s disease."@en ;
    ns0:hasPubTitle "Neem Derivatives Inhibits Tau Aggregation"@en .

ns1:adr-v3-i1-ADR190124 ns0:hasKeywords "Cognitive impairment"@en,
        "dementia"@en,
        "lifestyle modification"@en,
        "nutritional supplements"@en ;
    ns0:hasPubAbstract "A nutritional supplement has maintained or improved cognitive performance for healthy adults and individuals with mild cognitive impairment (MCI). Performance varied between 93 healthy adults aged 18–73 years versus 43 aged 75–85 years and among individuals with MCI. Healthy adult performance was stratified by age and for MCI as “intact” or “impaired” (Dementia Rating Scale guidelines). Some older individuals performed as well as younger individuals. All intact individuals with MCI maintained baseline performance; only impaired individuals receiving the supplement maintained baseline performance. Variation among elderly individuals can preclude observation of efficacy. Supplementation may maintain rather than improve performance for some individuals."@en ;
    ns0:hasPubTitle "Relative Efficacy of a Nutritional Intervention on Cognitive Performance Across the Adult Lifespan and During Early Cognitive Decline"@en .

ns1:adr-v3-i1-ADR190139 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Presenilin-1"@en,
        "behavioral symptoms"@en,
        "mental disorders"@en ;
    ns0:hasPubAbstract "Background: There are forms of Alzheimer’s disease (AD) that have an autosomal dominant inheritance pattern; one of them is caused by the E280A mutation in the gene that codes for Presenilin-1 (PSEN1). Studying families of people with this mutation allows the evaluation of characteristics of the subjects before cognitive decline begins.   Objective: To determine whether having the mutation E280A in PSEN1 increases the risk of presenting mental disorders in adults under 30 years old who are in the preclinical stage of AD and may be eligible for primary prevention studies of AD.   Methods: A psychiatric evaluation was made to 120 people belonging to families with a history of early onset AD. Of these, 62 carried the E280A mutation in PSEN1. The occurrence of mental disorders between carriers and non-carriers of the mutation was compared.   Results: No statistically significant differences were found in the frequency of any mental disorder between the group of carriers and non-carriers of the mutation (Hazard Ratio: 0.80, 95% CI 0.49 to 1.31); nor were differences observed when evaluating specific disorders.   Conclusion: The E280A mutation does not increase the risk of mental disorders before the age of 30 in the relatives of people affected by familial AD. Studies with larger sample sizes are required to assess the risk of low incidence mental disorders."@en ;
    ns0:hasPubTitle "Mental Disorders in Young Adults from Families with the Presenilin-1 Gene Mutation E280A in the Preclinical Stage of Alzheimer’s Disease"@en .

ns1:aic-v32-i3-AIC190618 ns0:hasKeywords "INGENIAS"@en,
        "JADE"@en,
        "Multi-agent systems (MAS)"@en,
        "agent-based modeling"@en,
        "computational creativity"@en,
        "symbolic Brainstorming"@en ;
    ns0:hasPubAbstract "Many creative methods, such as different types of brainstorming, are based on the collaboration among a set of persons. The collaboration follows some well established workflows, which could be formalized. This would allow the generation of computational models that can be implemented to make some tools that facilitate the enactment of creative processes, or the simulation for the analysis of their characteristics. This work shows how to model this kind of collaborative creative processes as multi-agent systems, by representing the participants as interacting agents in well-defined workflows. This is done with the INGENIAS modeling language and tools, which also support rapid prototyping using the JADE agent platform. A concrete creative method, Symbolic Brainstorming, is used to illustrate and validate the feasibility of the approach."@en ;
    ns0:hasPubTitle "Agent-based modeling of collaborative creative processes with INGENIAS"@en .

ns1:aic-v32-i4-AIC190615 ns0:hasKeywords "Deception"@en,
        "agent-oriented programming languages"@en,
        "machine deception"@en,
        "theory of mind"@en ;
    ns0:hasPubAbstract "Agreement, cooperation and trust would be straightforward if deception did not ever occur in communicative interactions. Humans have deceived one another since the species began. Do machines deceive one another or indeed humans? If they do, how may we detect this? To detect machine deception, arguably requires a model of how machines may deceive, and how such deception may be identified. Theory of Mind (ToM) provides the opportunity to create intelligent machines that are able to model the minds of other agents. The future implications of a machine that has the capability to understand other minds (human or artificial) and that also has the reasons and intentions to deceive others are dark from an ethical perspective. Being able to understand the dishonest and unethical behaviour of such machines is crucial to current research in AI. In this paper, we present a high-level approach for modelling machine deception using ToM under factors of uncertainty and we propose an implementation of this model in an Agent-Oriented Programming Language (AOPL). We show that the Multi-Agent Systems (MAS) paradigm can be used to integrate concepts from two major theories of deception, namely Information Manipulation Theory 2 (IMT2) and Interpersonal Deception Theory (IDT), and how to apply these concepts in order to build a model of computational deception that takes into account ToM. To show how agents use ToM in order to deceive, we define an epistemic agent mechanism using BDI-like architectures to analyse deceptive interactions between deceivers and their potential targets and we also explain the steps in which the model can be implemented in an AOPL. To the best of our knowledge, this work is one of the first attempts in AI that (i) uses ToM along with components of IMT2 and IDT in order to analyse deceptive interactions and (ii) implements such a model."@en ;
    ns0:hasPubTitle "Modelling deception using theory of mind in multi-agent systems"@en .

ns1:aic-v32-i4-AIC190616 ns0:hasKeywords "Trust"@en,
        "delegation"@en ;
    ns0:hasPubAbstract "Task delegation is essential to many applications, ranging from outsourcing of work to the design of routing protocols. Much research in computational trust has been devoted to the generation of policies to determine which agent should the task be delegated to, given the agent’s past behaviour. Such work, however, does not consider the possibility of the agent delegating the task onwards, inducing a chain of delegation events before the task is finally executed. In this paper, we consider the process of delegation chain formation, introducing a new algorithm based on quitting games to cater for recursive scenarios. We evaluate our proposal under various network topologies, consistently demonstrating its superiority with respect to recursive adaptations of existing multi-armed bandit algorithms."@en ;
    ns0:hasPubTitle "Algorithms for recursive delegation"@en .

ns1:aic-v32-i4-AIC190617 ns0:hasKeywords "Norms"@en,
        "Semantic Web technologies"@en,
        "multiagent systems"@en,
        "obligations"@en,
        "permissions"@en,
        "policies"@en,
        "production rules"@en,
        "prohibitions"@en ;
    ns0:hasPubAbstract "Nowadays the studies on the formalization, enforcement, and monitoring of policies and norms is crucial in different fields of research and in numerous applications. ODRL 2.2 (Open Digital Right Language) is a W3C standard policy expression language formalized using Semantic Web technologies. It is used to represent permitted and prohibited actions over a certain asset, and obligations required to be met by parties involved in the exchange of a digital asset. In this paper, we propose to extend the model of obligation, permission, and prohibition proposed by ODRL 2.2 in two directions. Firstly, by inserting in the model the notion of activation event (or action) and by expressing event and action as complex constructs having types and application-independent properties. Secondly, by considering the temporal aspects of obligations, permissions, and prohibitions (e.g. expiration dates and deadlines) as part of their application independent model. These extensions are necessary in order to be able to propose an application-independent operational semantics of the extended model, which is formalized using State Machines and is computed by a specific production rule system. The proposed approach has been tested by developing a framework in Java able to get as input a set of policies formalized using Semantic Web languages, and to compute their evolution in time based on the events and actions that happen in the interaction among the parties involved in the specified policies."@en ;
    ns0:hasPubTitle "Using Semantic Web technologies and production rules for reasoning on obligations, permissions, and prohibitions1"@en .

ns1:aic-v32-i4-AIC190622 ns0:hasKeywords "Formal dialogues"@en,
        "goal reasoning"@en,
        "logic programming"@en,
        "non-monotonic reasoning"@en,
        "strategic argumentation"@en ;
    ns0:hasPubAbstract "In many real applications, to reach an agreement between the participants of a dialogue, which can be for instance a negotiation, is not easy. Indeed, there are application domains such as the medical domain where to reach a consensus among medical professionals is not feasible and might be even regarded as counterproductive. In this paper, we introduce an approach for expressing qualitative preferences between the goals of a dialogue considering ordered disjunction rules. By applying argumentation semantics and degrees of satisfaction of goals, we introduce the so-called dialogue agreement degree. Moreover, by considering sets of dialogue agreement degrees, we define a lattice of agreement degrees. We argue that a lattice of agreement degrees suggests different approximations between the current state of a dialogue and its aimed goals; hence, a lattice of agreement degrees can help to define different heuristics in the settings of strategic argumentation."@en ;
    ns0:hasPubTitle "Approximating agreements in formal argumentation dialogues1"@en .

ns1:ais-v11-i6-AIS190539 ns0:hasKeywords "Robot workspace restriction"@en,
        "network robot system"@en,
        "smart home environment"@en,
        "virtual borders"@en ;
    ns0:hasPubAbstract "Virtual borders are employed to allow humans the interactive and flexible restriction of their mobile robots’ workspaces in human-centered environments, e.g. to exclude privacy zones from the workspace or to indicate certain areas for working. They have been successfully specified in interaction processes using methods from human-robot interaction. However, these methods often lack an expressive feedback system, are restricted to robot’s on-board interaction capabilities and require a direct line of sight between human and robot. This negatively affects the user experience and interaction time. Therefore, we investigate the effect of a smart environment on the teaching of virtual borders with the objective to enhance the perceptual and interaction capabilities of a robot. For this purpose, we propose a novel interaction method based on a laser pointer, that leverages a smart home environment in the interaction process. This interaction method comprises an architecture for a smart home environment designed to support the interaction process, the cooperation of human, robot and smart environment in the interaction process, a cooperative perception including stationary and mobile cameras to perceive laser spots and an algorithm to extract virtual borders from multiple camera observations. The results of an experimental evaluation support our hypotheses that our novel interaction method features a significantly shorter interaction time and a better user experience compared to an approach without support of a smart environment. Moreover, the interaction method does not negatively affect other user requirements concerning completeness and accuracy."@en ;
    ns0:hasPubTitle "Interactive restriction of a mobile robot’s workspace in a smart home environment"@en .

ns1:ajw-v16-i3-ajw190027 ns0:hasKeywords "Carbon sequestration"@en,
        "carbon price"@en,
        "emission reduction"@en,
        "mitigation"@en ;
    ns0:hasPubAbstract "Rising atmospheric concentration of greenhouse gases has been increasing with its negative effects on climatic system. Forests absorb and store a huge amount of atmospheric carbon dioxide (one of the major greenhouse gases) as tree biomass. Because of such capacity of forests which is called carbon sequestration, it has received much attention due to the concerns of global climate change. The research question is whether forest carbon sequestration could potentially reduce emissions in a cost effective way or not. Therefore, this article reviews and summarises emission reduction potential and cost savings through forest carbon sequestration. However, tropical forests have the highest aboveground carbon density and carbon sequestration potential compared to the subtropical, temperate and boreal forests. Instead, carbon sequestration potential found to be higher in Africa followed by North America, Asia, South America, Europe and Australia. The cost for one tonne of forest carbon sink enhancement ranges between 0 to US$ 443 in 2011 prices. Forest carbon sink enhancement cost in tropical region is found cheaper than any other region in the world. Carbon forestry options i.e. forest management, afforestation and reforestation can decrease the equilibrium carbon price up to 80% and reduce the emission reduction costs up to 40% whereas afforestation found to be the most low-cost carbon sequestration option. Hence, forest carbon sequestration plays an important role in reducing emissions which offers an opportunity for cost-effective climate change mitigation."@en ;
    ns0:hasPubTitle "A Review of Emission Reduction Potential and Cost Savings through Forest Carbon Sequestration"@en .

ns1:ajw-v16-i3-ajw190035 ns0:hasKeywords "Fe(III)-reduction"@en,
        "Tabrizicola aquatica RCRI19T"@en,
        "bioabsorption of heavy metals"@en ;
    ns0:hasPubAbstract "Environmental bacteria have an important role in the removal and improvement of metals from polluted area. Metal–microbe interactions as a form of detoxification of metal have been developed. In this study, we investigated the ability of Tabrizicola aquatica RCRI19T, a novel environmental bacterium isolated from deepwater from Qurugöl Lake nearby Tabriz city, Iran, to Fe(III)-reduction as an electron acceptor in minimal essential elements condition. Subsequently, bioabsorption behaviour of heavy metals (Ni2+, Co2+, pb2+) by strain RCRI19T has been demonstrated. Our results showed that strain RCRI19T can reduce 20mM ferric-citrate particularly in anaerobic condition, and a positive correlation was observed between bacterial growth and iron (II) production. Owing to its iron reduction rate, T. aquatica RCRI19T may contribute to iron mineral transformation and element cycling in deepwater of the lake. We further observed that the dead biomass of strain RCRI19T absorbs of heavy metals (Ni2+, Co2+ and Pb2+) from aqueous solution. The optimum conditions of biosorption are in pH = 4 for Ni2+, Pb2+ and pH = 5 for Co2+. The equilibrium experimental data fitted both of Freundlich and Langmuir isotherms and displayed monolayer adsorption. Two kinetic models, namely pseudo-first-order and pseudo-second-order were used to describe the kinetics of heavy metal ion biosorption on T. aquatica. Pseudo second order was the best of the other kinetic."@en ;
    ns0:hasPubTitle "Bioreduction of Iron and Biosorption of Heavy Metals (Ni2+, Co2+, Pb2+) by a Novel Environmental Bacterium, Tabrizicola aquatica RCRI19T"@en .

ns1:ajw-v16-i4-ajw190054 ns0:hasKeywords "Mann-Kendall test"@en,
        "Piper"@en,
        "Schuler"@en,
        "Water quality"@en,
        "Wilcox"@en ;
    ns0:hasPubAbstract "River water quality evaluation is one of the first and perhaps most important steps in river water quality management, because it makes the analyst’s vision clear about trends and how pollution changes relative to time, place, and circumstances. The purpose of this research is to evaluate the water quality and the process of changes in the water quality parameters of this river by graphic methods such as Wilcox, Schuler and Piper diagrams. These charts were used to monitor water quality and evaluate the data obtained from Berthaen Station from 1976 to 2007. In this study, Piper introduced water qualitative type of chlorine and water façade from saddle type. Based on the Schuler diagram, all water samples of the river Rudan are in a moderate and acceptable category for drinking and there is no barrier to drinking. The Wilcox chart also shows that most of the specimens are highly salty and suitable for farming (C3S1, C3S2) and in some water are poor, highly unsuitable water areas (C4S2). The results of water quality parameters analysis using non-parametric Mann-Kendall test showed that the parameters of acidity, carbonate, soluble salts, total cations, sodium, magnesium and chloride adsorption percentages, and other parameters were not trendy at the surface The confidence is 95%. The upward trend in water soluble solute changes indicates a decrease in water quality and an increase in soluble salts of this river."@en ;
    ns0:hasPubTitle "Trend Analyzing of Chemical Water Quality Parameters (Case Study: Rudan River, Bernetin Station—Code 27013)"@en .

ns1:ajw-v16-i4-ajw190055 ns0:hasKeywords "PM2.5"@en,
        "air pollution"@en,
        "break point analysis"@en ;
    ns0:hasPubAbstract "Fine particles like PM2.5 are known to trigger or exacerbate unending ailment, for example, asthma, heart assault, bronchitis and other respiratory issues. The factors affecting the density of PM2.5 in atmosphere are temperature, humidity and pressure. Other factors like burning fire crackers, thrashes, etc. compliments them which leads to adverse effect of PM2.5 on mankind. We cannot control the natural activities of temperature, humidity and pressure but we can at least prevent complimenting them by knowing at what duration of a year there is sudden change in density of PM2.5 in environment due to these factors. In this research, prediction of breakpoint of PM2.5 density in a year with respect to these factors using segment analysis is being tried."@en ;
    ns0:hasPubTitle "Break Point Analysis of Particulate Matter"@en .

ns1:ao-v14-i3-AO190211 ns0:hasKeywords "ChEBI"@en,
        "biological interest"@en,
        "chemical ontology"@en,
        "ontology quality assurance"@en,
        "relationship type"@en ;
    ns0:hasPubAbstract "The Chemical Entities of Biological Interest (ChEBI) ontology is an important reference for applications dealing with chemical annotations and data mining. Modeling errors and inconsistencies in the large and complex ChEBI ontology are unavoidable. The errors can adversely affect applications dependent on it. We present a quality assurance (QA) methodology based on the correspondence between a concept’s number of errors and its number of distinct relationship types – an intuitive measure of complexity. Specifically, we hypothesize that concepts with more relationship types tend to concentrate more errors. A study is carried out to assess the hypothesis. Two domain experts reviewed the correctness of a random sample of ChEBI concepts and formed a QA consensus report, which was then reviewed by a ChEBI curator. A two-tailed Fisher’s exact test is performed on the consensus report and the curator’s report to test the hypothesis. Various kinds of errors, including errors of both a relationship and non-relationship nature, were discovered and reported to the ChEBI’s curator, who confirmed and corrected 65.8% of them. Our hypothesis was confirmed with statistical significance for both the domain experts’ and the curator’s reviews. Thus, ChEBI curators should employ a QA methodology concentrating on concepts with many relationship types."@en ;
    ns0:hasPubTitle "Quality assurance of complex ChEBI concepts based on number of relationship types"@en .

<http://ld.iospress.nl/rdf/artifact/aop-v3-i3,4-AOP051> ns0:hasKeywords "Mechatronics"@en,
        "collaboration"@en,
        "electrical CAD"@en,
        "integration"@en,
        "mechanical CAD"@en ;
    ns0:hasPubAbstract "Adopting the mechatronics as contemporary most emerging engineering discipline the integration of mechanical and electrical CAD (MCAD/ECAD) systems remains a big challenge in concurrent engineering because their data models and functionality have been developed continuously further apart. Market research confirms that an integrated tool chain for ECAD and MCAD design is prerequisite for a better mechatronic development process. This paper presents the overview of various integration approaches with different degree of maturity and describes the concept of deep integration for mechatronic products conducted by ProSTEP iViP Association which combines existing standards in engineering collaboration context. Version 3 of the current ProSTEP iViP Recommendation PSI 5 entitled “ECAD/MCAD-Collaboration” provides a comprehensive specification for collaboration between the ECAD and MCAD worlds. A considerable number of vendors have now implemented the underlying data schema and integrated it in the corresponding products. As a result, users can now choose the solutions that best meet their particular needs from an increasingly wide range of efficient systems for collaborative product development within the ECAD and MCAD fields."@en ;
    ns0:hasPubTitle "Advances in standardized approach to ECAD/MCAD collaboration"@en .

ns1:asy-v114-i1-2-ASY181516 ns0:hasKeywords "Wave equation"@en,
        "asymptotic expansion"@en,
        "diffusion phenomena"@en,
        "double damping terms"@en,
        "lower bounds estimates"@en,
        "moment condition"@en ;
    ns0:hasPubAbstract "In this report we obtain higher order asymptotic expansions of solutions to wave equations with frictional and viscoelastic damping terms. Although the diffusion phenomena are dominant, differences between the solutions we deal with and those of heat equations can be seen by comparing the second order expansions of them. In order to analyze such effects we consider the weighted    L   1   initial data. We also give some lower bounds which show the optimality of obtained expansions."@en ;
    ns0:hasPubTitle "Moment conditions and lower bounds in expanding solutions of wave equations with double damping terms"@en .

ns1:asy-v114-i1-2-ASY191518 ns0:hasKeywords "Compressible Euler equations"@en,
        "dissipative measure-valued solutions"@en,
        "low Froude number"@en,
        "low Mach number"@en,
        "singular limit"@en ;
    ns0:hasPubAbstract "We consider a singular limit for the compressible Euler system in the low Mach number regime driven by a large external force. We show that any dissipative measure-valued solution approaches a solution of the lake equation in the asymptotic regime of low Mach and Froude numbers. The result holds for the ill-prepared initial data creating rapidly oscillating acoustic waves. We use dispersive estimates of Strichartz type to eliminate the effect of the acoustic waves in the asymptotic limit."@en ;
    ns0:hasPubTitle "On a singular limit for the stratified compressible Euler system"@en .

ns1:asy-v114-i1-2-ASY191519 ns0:hasKeywords "Lower bounds"@en,
        "Timoshenko system"@en,
        "optimality"@en,
        "strong asymptotic stability"@en,
        "thermoelasticity"@en ;
    ns0:hasPubAbstract "In this paper, we consider a vibrating nonlinear Timoshenko system with thermoelasticity with second sound. We first investigate the stability of this system, then we devote our efforts to obtain the strong lower energy estimates using Alabau-Boussouira’s energy comparison principle introduced in (J. Differ. Equations 248 (2010), 1473–1517) (see also NoDEA Nonlinear Differential Equations Appl. 18(5) (2011), 571–597). We extend to our model the results achieved in (NoDEA Nonlinear Differential Equations Appl. 18(5) (2011), 571–597) for the case of nonlinearly damped Timoshenko system with thermoelasticity. The proof of our results relies on the approach in (NoDEA Nonlinear Differential Equations Appl. 14(5–6) (2007), 643–669 and Appl. Math. Optim. 51(1) (2005), 61–105)."@en ;
    ns0:hasPubTitle "Lower bound and optimality for a nonlinearly damped Timoshenko system with thermoelasticity"@en .

ns1:asy-v114-i1-2-ASY191524 ns0:hasKeywords "Allen–Cahn equations"@en,
        "Fractional operators"@en,
        "asymptotics"@en,
        "phase field system"@en,
        "regularity"@en,
        "well-posedness"@en ;
    ns0:hasPubAbstract "This paper is concerned with a non-conserved phase field system of Caginalp type in which the main operators are fractional versions of two fixed linear operators A and B. The operators A and B are supposed to be densely defined, unbounded, self-adjoint, monotone in the Hilbert space    L   2   ( Ω ), for some bounded and smooth domain Ω, and have compact resolvents. Our definition of the fractional powers of operators uses the approach via spectral theory. A nonlinearity of double-well type occurs in the phase equation and either a regular or logarithmic potential, as well as a non-differentiable potential involving an indicator function, is admitted in our approach. We show general well-posedness and regularity results, extending the corresponding results that are known for the non-fractional elliptic operators with zero Neumann conditions or other boundary conditions like Dirichlet or Robin ones. Then, we investigate the longtime behavior of the system, by fully characterizing every element of the ω-limit as a stationary solution. In the final part of the paper we study the asymptotic behavior of the system as the parameter σ appearing in the operator    B   2 σ   that plays in the phase equation decreasingly tends to zero. We can prove convergence to a phase relaxation problem at the limit, in which an additional term containing the projection of the phase variable on the kernel of B appears."@en ;
    ns0:hasPubTitle "Well-posedness, regularity and asymptotic analyses for a fractional phase field system"@en .

ns1:bd-v38-i2-BD180341 ns0:hasKeywords "Breast cancer"@en,
        "Ki-67"@en,
        "immunohistochemistry"@en,
        "proliferation index"@en ;
    ns0:hasPubAbstract "BACKGROUND: Proliferation rate is a major determinant of the biologic behavior of the tumor and provides information that can be used to guide treatment decisions.   METHODS: This ring study included 27 pathologists from 14 Institutions, in order to assess inter-observer concordance between pathologists in Croatia. We analyzed Ki-67 proliferative index on ten randomly selected breast cancer samples comparing consistency between visual assessment using light microscopy compared to digital image analyses results from one central laboratory as a referral value.   RESULTS: When we analyzed Ki-67 as numeric value high concordance rate was found between Ki-67 score visually assessed in all participating Institutions compared to referral value assessed by digital image analysis (ICC 0.76, 95% CI 0.58–0.91), and Krippendorff’s alpha was 0.79 (95% CI 0.58–1.00). Concordance was better in slides with higher Ki-67 values. When we categorized Ki-67 values according to generally accepted 20% cut-off value we noticed the lower concordance rate among participants in our study.   CONCLUSION: Proliferation remains one of the most important parameters for tumor characterization helpful in making clinical decisions, but it should be used with great caution. Standardization of the Ki-67 assessment is essential and proliferating index should be expressed as exact numeric value. For patients with proliferative index near the cut-off value, other factors must be considered in making clinical decisions."@en ;
    ns0:hasPubTitle "Inter-laboratory comparison of Ki-67 proliferating index detected by visual assessment and automated digital image analysis"@en .

ns1:bd-v38-i2-BD180350 ns0:hasKeywords "Breast carcinoma"@en,
        "HER2"@en,
        "immunohistochemistry"@en,
        "trastuzumab"@en,
        "tumor-infiltrating lymphocyte"@en ;
    ns0:hasPubAbstract "BACKGROUND: Trastuzumab (Tz) is assumed to prime antibody-dependent cellular cytotoxicity (ADCC); however, it remains unclear whether Tz therapy can clinically induce adaptive cellular immunity.   OBJECTIVE: Adaptive Cellular Immune Effect of Tz Therapy.   METHODS: This study included 29 surgical invasive breast carcinomas administered neoadjuvant chemotherapy with Tz (15 cases) or without Tz (14 cases). The numbers of immunoreactive cells (CD4, CD8, CD56, and Fox-P3) in three different compartments (intratumoral, adjacent stromal, and distant stromal) were determined.   RESULTS: The average number of adjacent stromal CD4-positive, CD8-positive, and Fox-P3-positive cells in the Tz+ group was significantly greater than that in the Tz− group (p = 0.036, 0.0049, and 0.043, respectively). However, the number of Fox-P3-positive cells was much less than that of CD4-positive cells. Moreover, distant stromal CD4-positive and CD8-positive cells in the Tz+ group was also significantly greater than that of the Tz− group (p = 0.029 and 0.032, respectively). Only a small number of CD56-positive natural killer cells, playing a main role in ADCC, accumulated at the tumor site after Tz therapy.   CONCLUSIONS: The results suggest that Tz therapy induces adaptive cellular immunity, including infiltration of both CD4-positive helper T cells and CD8-positive cytotoxic T cells into the breast carcinoma lesion."@en ;
    ns0:hasPubTitle "Infiltration of CD4, CD8, CD56, and Fox-P3-positive lymphocytes in breast carcinoma tissue after neoadjuvant chemotherapy with or without trastuzumab"@en .

ns1:bd-v38-i3-4-BD160230 ns0:hasKeywords "ANC (Axillary Nodal Clearance)"@en,
        "AUS (Axillary ultrasound)"@en,
        "OSNA (One Step Nucleic Acid amplification)"@en,
        "SLNB (Sentinel Lymph Node Biopsy)"@en ;
    ns0:hasPubAbstract "BACKGROUND: Axillary Ultrasound (AUS) is now performed as a protocol in every newly diagnosed breast cancer in most European countries. It is an inexpensive and sensitive tool in hands of a trained operator. All AUS negative patients undergo Sentinel Lymph Node Biopsy (SLNB), while AUS positive patients bypass SLNB and undergo axillary nodal clearance (ANC) as a standard protocol. We wish to analyse these two groups to see if ANC can be foregone in these patients.   AIMS AND OBJECTIVES: To compare and analyse the axillary disease burden in early breast cancer patients, with positive axilla, detected by AUS+ Biopsy versus those patients with normal axillary ultrasound or negative axillary biopsy that underwent ANC due to positive SLNB.   MATERIAL AND METHODS: A retrospective review of all patients who underwent axillary lymph node clearance following histologically confirmed positive ultrasound (US) axilla (year 2009–2014) was performed and was compared with data collected for patients with USG negative but SLNB (OSNA- One Step Nucleic Acid Amplification) positive axilla.   RESULTS: Axillary clearances performed for positive US axilla yielded significantly more positive lymph nodes than SLNB/OSNA positive axilla (p = 0.00496). These patients also had larger primary tumours (median 33 mm versus 21 mm, p = 0.01242) of a higher grade. Almost half of the patients in AUS positive group (49%) had high axillary nodal burden (>4 LNs). This is in great contrast with AUS negative, SLNB/OSNA positive group where 82.7% of patients had <4 positive nodes with more than half patients (51.7%) having no further positive nodes in their final histopathology specimen.   CONCLUSIONS: ANC should be a standard protocol in AUS positive patients as they invariably have high axillary disease burden while ANC can be omitted in case of select AUS negative and SLNB patients. However, further studies with more subjects may be require to substantiate the findings."@en ;
    ns0:hasPubTitle "A comparative analysis of axillary nodal burden in ultrasound/biopsy positive axilla vs ultrasound negative sentinel lymph node biopsy positive axilla"@en .

ns1:bd-v38-i3-4-BD190393 ns0:hasKeywords "FNAC"@en,
        "IAC"@en,
        "breast lesions"@en,
        "cyto-histopathological correlation"@en,
        "triple approach"@en ;
    ns0:hasPubAbstract "BACKGROUND: Breast cytology is a significant component of the “Triple approach” for pre-operative diagnosis of breast lumps, the other two being clinical assessment and radiological imaging. The role of Fine needle aspiration cytology (FNAC) as a first line investigation in diagnosing breast lesions is well documented, however histopathology is the gold standard. Cyto-histopathological correlation is of great relevance and also increases precision.   AIMS \\& OBJECTIVES: The present study was conducted with the aim to categorize breast lesions according to the latest standardized reporting system proposed by International academy of cytologists (IAC) in 2016. Evaluation of diagnostic accuracy, sensitivity and specificity of FNAC in diagnosing breast lesions and cyto-histopathological correlation was planned.   MATERIALS AND METHODS: All FNAs of breast lesions over a period of 2 years were included in the study. The cases were grouped into five standardized categories proposed by the International academy of cytology: Category I (Insufficient material), Category II (Benign), Category III (Atypical, probably benign), Category IV (Suspicious, probably in situ or invasive) & Category V (Malignant) respectively. Specificity, sensitivity, diagnostic accuracy, negative and positive predictive value of FNAC were calculated and cyto-histopathological correlation assessed wherever possible.   RESULTS: Out of 468 breast lesions reported on FNAC, the category wise distribution was – Category I, II, III, IV & V accounting for 23(4.9%), 342(73.07%), 7(1.5%), 11(2.35%) and 85(18.16%) respectively. Histopathology was performed in 331/468 cases with cyto histological concordance of 98.4% and a type agreement rate of 90.9%. The sensitivity, specificity, positive and negative predictive value and diagnostic accuracy was 98.90%, 99.16%, 97.82%, 99.58% and 99.09% respectively.   CONCLUSION: FNAC is a simple, reliable, cost effective, first line diagnostic procedure for all breast lumps. In collaboration with physical examination and imaging studies (triple approach), FNAC is a highly sensitive diagnostic tool. Adopting a universally acceptable standardized reporting system for breast cytology can enhance the diagnostic accuracy of FNAC."@en ;
    ns0:hasPubTitle "IAC standardized reporting of breast fine-needle aspiration cytology, Yokohama 2016: A critical appraisal over a 2 year period"@en .

ns1:blc-v5-i2-BLC190211 ns0:hasKeywords "BCG recurrent NMIBC"@en,
        "BCG refractory NMIBC"@en,
        "BCG relapsing NMIBC"@en,
        "BCG unresponsive NMIBC"@en,
        "CADI-05"@en,
        "TLR2 agonist"@en,
        "desmocollin-3"@en,
        "intradermal immunotherapy"@en,
        "non-muscle invasive bladder cancer"@en ;
    ns0:hasPubAbstract "Background: CADI-05, a TLR-2 agonist, induces Th1 immune response following intradermal administration and has been found useful in management of lung cancer and melanoma.   Objective: To evaluate CADI-05 in patients with BCG recurrent and unresponsive Non-muscle invasive bladder cancer (NMIBC) for 15-months recurrence free survival (RFS) rate.   Methods: In BCG unresponsive (BU) or recurrent (BR) NMIBC, CADI-05 was administered intradermally every two weeks for 3 months followed by every month for 3 months and subsequently every 2 months for 6 months following transurethral resection (TUR) in a single arm study (ClinicalTrials.gov: NCT00694798). Cystoscopy, cytology, and sonography were performed for the presence/recurrence of NMIBC at 3, 6, 9, 12, 15 months and beyond and confirmed by biopsy. Evaluation of preoperative biopsy for Desmocollin-3 (DSC3) expression and tumor infiltrating lymphocytes (TIL) was optional.   Results: Twenty patients with NMIBC received intradermal CADI-05. RFS at 15 and 30 months was 35% (7/20) patients. The median RFS was also better for BU compared to BR group (HR, 0.329; 95% CI, 0.071 to 1.532). DSC3 expression was present in 68.8% (11/16) patients. TIL and RFS beyond 30 months were seen 2.3 times and 2.8 times more often in DSC3 expressing NMIBC respectively. No grade IV or V adverse events occurred. Local site reactions were the most common adverse event.   Conclusion: Intradermal CADI-05 following TUR is associated with 35% RFS at 30 months."@en ;
    ns0:hasPubTitle "A Clinical Trial of the Intradermal TLR2 Agonist CADI-05 for BCG Recurrent and Unresponsive Non-Muscle Invasive Bladder Cancer"@en .

ns1:blc-v5-i2-BLC190221 ns0:hasKeywords "Hematuria"@en,
        "evaluation"@en,
        "public health care system"@en,
        "referral"@en,
        "socioeconomic status"@en ;
    ns0:hasPubAbstract "Background: Hematuria is the most common presenting symptom in bladder cancer, but many patients are not adequately evaluated.   Objectives: To evaluate the type and frequency of hematuria evaluation in a large public health care system.   Patients and Methods: Electronic medical records of adult patients with urinalysis positive for hematuria (≥3 RBCs/HPF) from January 2015 to April 2018 in an outpatient setting were reviewed. Logistic regression was performed to determine factors associated with urology referral and complete evaluation.   Results: 11,422 patients met the inclusion criteria; the majority were females (72%) and white race (60%). There were an additional 3,221 patient’s with initial diagnosis of UTI. Median age was 49.0 years. Testing included repeat urinalysis (50%), imaging (26%), urology referral (11.4%), cystoscopy (4.4%) and complete evaluation defined as cystoscopy and US/CT/MRI (4%). In the multivariable analysis, factors independently associated with higher referral to urology were age >35, male gender, hypertension, RBCs ≥20. African American race was associated with less referral to urology. Smoking was a significant variable on univariable analysis only. 37 patients (0.25%) were diagnosed with urological malignancies, with bladder cancer in 33, 12 of whom are missed by excluding UTI patients.   Conclusions: In the outpatient setting of a public health care system, the vast majority of patients with hematuria are not referred and evaluated properly across all age categories and regardless of smoking status. This might result in missed cancer diagnoses and requires quality improvement measures."@en ;
    ns0:hasPubTitle "Evaluation of Hematuria in a Large Public Health Care System"@en .

ns1:blc-v5-i3-BLC190228 ns0:hasKeywords "BCG"@en,
        "CD8+ TIL"@en,
        "CXCL10"@en,
        "NMIBC"@en,
        "STING agonist"@en,
        "immunotherapy"@en,
        "interferon"@en ;
    ns0:hasPubAbstract "Background: Intravesical Bacillus Calmette Guerin (BCG) has been the gold standard immunotherapy to treat high risk non-muscle invasive bladder cancer (NMIBC) for over 40 years. Attenuation of Mycobacterium bovis for clinical use as BCG results in loss of its ability to activate the “Stimulator of Interferon Genes” (STING) pathway and potentially limits local anti-tumor immune activity and subsequent BCG responsiveness due to reduced induction of the immune cell recruiting chemokines primarily, CXCL10. We conducted the current study to determine the potential of STING pathway agonist in synergizing with BCG to enhance chemokine induction.   Methods: The TICE strain of BCG (OncoTICE) was used in combination with STING agonist to determine STING pathway activation and CXCL10 production in THP-1 monocytic cell line, THP-1 defNLRP3, THP-1 dual STING knock out cells, RT112 bladder cancer cells and primary bladder epithelial cells. NanoString platform-based gene expression profiling and multiplex cytokine analysis were performed to determine induction of interferon associated genes and secreted cytokines.   Results: Activation of cytosolic pattern recognition receptor and downstream IFN1 pathways demonstrated synergistic activation of STING pathway enhanced BCG induced inflammasome and STING pathway gene expression in monocytes and bladder cancer cells. The significant differences in CXCL10, CCL5, IL-8 and MIP-1a/1b amongst the knock-out cell lines confirm the convergence of these pathways following combination treatment with BCG and STING agonist.   Conclusions: Findings from our study are the first evidence indicating that STING pathway activators are promising new innate immune modulators with a potential to synergize with BCG therapy in the treatment of NMIBC."@en ;
    ns0:hasPubTitle "Investigating the STING Pathway to Explain Mechanisms of BCG Failures in Non-Muscle Invasive Bladder Cancer: Prognostic and Therapeutic Implications"@en .

ns1:blc-v5-i3-BLC190238 ns0:hasKeywords "B7-H1"@en,
        "B7H1 biomarker"@en,
        "PD-1"@en,
        "PD-L1"@en,
        "meta-analysis"@en,
        "systematic review"@en ;
    ns0:hasPubAbstract "Background: Immune checkpoint inhibitors (ICI) are extremely expensive and most patients with metastatic urothelial carcinoma (mUC) do not benefit significantly from their use.   Objective: We performed a systematic review and meta-analysis to determine response rates and survival outcomes on patients with mUC progressing despite prior platinum-based chemotherapy receiving ICI stratified by biomarker status.   Methods: We performed a comprehensive literature search for all articles in PubMed and Embase up to 06/15/2019 to identify all studies pertaining to programmed death-ligand 1 (PD-L1) and programmed death 1 (PD-1) receptor targeted therapies for mUC that reported biomarkers. Given that biomarkers are reported on different scales and with different metrics, we defined each biomarker as either positive or negative using the definitions implemented in each individual trial. We meta-analyzed the data, reconstructed overall (OS) and progression-free survival (PFS) curves, and analyzed response rates by biomarker status. OS and PFS were analyzed in a pooled Kaplan-Meier analysis and pseudo-individualized patient data (IPD) extracted.   Results: We identified 1429 manuscripts of which 8 met inclusion criteria, with a total of 1837 treated patients with outcomes data. On proportional hazards survival analysis, patients in the biomarker negative group were associated with a lower PFS (HR 1.48, 95% CI: 1.18 - 1.85, p < 0.001) and lower OS (HR 1.54, 95% CI: 1.32 - 1.80, p < 0.001) when compared to the biomarker positive group. Response data was available for 1641 patients and random effects proportion show complete response in 8% and 3% in biomarker positive and negative patients, respectively.   Conclusions: ICI therapy for metastatic UC post platinum therapy has a higher overall response rate, OS and PFS in patients who are biomarker positive compared to those who are negative. However, some patients who are biomarker negative do achieve complete responses. A better biomarker for patient selection is essential before biomarkers can be used to stratify candidates for ICI therapy."@en ;
    ns0:hasPubTitle "PD-L1/PD-1 Biomarker for Metastatic Urothelial Cancer that Progress Post-platinum Therapy: A Systematic Review and Meta-analysis"@en .

ns1:bme-v30-i4-BME191058 ns0:hasKeywords "Chitosan"@en,
        "injectable implants"@en,
        "platelet-rich plasma"@en ;
    ns0:hasPubAbstract "BACKGROUND: Platelet-rich plasma (PRP) has been used to solubilize freeze-dried chitosan (CS) formulations to form injectable implants for tissue repair.   OBJECTIVE: To determine whether the in vitro performance of the formulations depends on the type of PRP preparation used to solubilize CS.   METHODS: Formulations containing 1% (w/v) CS with varying degrees of deacetylation (DDA 80.5–84.8%) and number average molar mass (Mn 32–55 kDa), 1% (w/v) trehalose and 42.2 mM calcium chloride were freeze-dried. Seven different PRP preparations were used to solubilize the formulations. Controls were recalcified PRP.   RESULTS: CS solubilization was achieved with all PRP preparations. CS-PRP formulations were less runny than their corresponding PRP controls. All CS-PRP formulations had a clotting time below 9 minutes, assessed by thromboelastography, while the leukocyte-rich PRP controls took longer to coagulate (>32 min), and the leukocyte-reduced PRP controls did not coagulate in this dynamic assay. In glass culture tubes, all PRP controls clotted, expressed serum and retracted (43–82% clot mass lost) significantly more than CS-PRP clots (no mass lost). CS dispersion was homogenous within CS-PRP clots.   CONCLUSIONS: In vitro performance of the CS-PRP formulations was comparable for all types of PRPs assessed."@en ;
    ns0:hasPubTitle "Multiple platelet-rich plasma preparations can solubilize freeze-dried chitosan formulations to form injectable implants for orthopedic indications"@en .

ns1:bme-v30-i4-BME191067 ns0:hasKeywords "CFD"@en,
        "Coronary artery"@en,
        "computer tomography"@en,
        "non-Newtonian flow"@en,
        "stenosis"@en ;
    ns0:hasPubAbstract "BACKGROUND: The most common cause of coronary artery disease (CAD) is vascular damage with the cholesterol built-up and other materials on the inner arterial wall, known as atherosclerosis.   OBJECTIVE: This paper aims to investigate the effect of stenosis on the hemodynamics in the four suspected coronary artery disease patients. Computer tomography (CT) data was acquired from patients of suspected coronary artery disease to reconstruct left coronary artery.   METHODS: The 3D computational simulation was carried out with four patient-specific models with area stenosis >50% located at the left anterior descending (LAD) and left circumflex (LCX) branches.   RESULTS: The pressure, velocity and wall shear stress were calculated during the cardiac cycle. A significant pressure drop across the stenosis and increase in the velocity at the stenosis were observed at LAD and LCX branches. An increase in the wall shear stress in the region of stenosis also observed with the prevalence of the recirculation zone at the post stenosis region which results in the formation of stenosis.   CONCLUSIONS: Our analysis provides an insight into the progression of stenosis and wall rupture, thus improving our understanding the flow behavior patient-specific realistic artery models."@en ;
    ns0:hasPubTitle "Effect of stenosis on hemodynamics in left coronary artery based on patient-specific CT scan"@en .

ns1:bmr-v32-i4-BMR181260 ns0:hasKeywords "CROM"@en,
        "Range of motion"@en,
        "cervical spine"@en,
        "inclinometer"@en,
        "reliability"@en,
        "validity"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Cervical pain is the biggest musculoskeletal health problem in industrialised countries. There is an important association between this and decrease in range of motion.   OBJECTIVE:  Estimate the validity and reliability intra and inter examiner of two Smartphone apps regarding the measurement of lower and upper cervical spine range of motion in subjects with chronic cervical pain.   METHODS:  A cross-sectional study was conducted. The sample consisted of 25 subjects with chronic cervical pain. An examiner made a measurement of the range of motion using the CROM device as a gold standard, afterwards, another examiner did the same using a Smartphone, in order to establish validity. After this, the Smartphone examiner and a new examiner simultaneously conducted the intra and inter examiner reliability.   RESULTS:  Measurement of the lower and upper cervical spine range show an excellent validity (> 0.75), with an excellent intra and inter reliability (> 0.75) in all movements except flexion of upper cervical spine (0.75–0.65).   CONCLUSION:  The two Smartphone applications used in this study showed an excellent validity compared to the CROM. The intra and inter reliability is excellent for all movements, except for the upper cervical spine flexion."@en ;
    ns0:hasPubTitle "Validity and reliability of two Smartphone applications to measure the lower and upper cervical spine range of motion in subjects with chronic cervical pain"@en .

ns1:bmr-v32-i4-BMR181296 ns0:hasKeywords "Injury prevention"@en,
        "flexibility training"@en,
        "muscle flexibility"@en,
        "rotation-related sports"@en,
        "tennis"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Although low back pain (LBP) is known to be multi-factorial, certain studies have suggested that a deficit in hip extension and rotation range of motion (ROM) may be associated with LBP in athletes.   OBJETIVE: The purpose of this study was to compare hip extension and rotation ROMs in elite tennis players with and without a history of LBP.   METHODS:  Forty-two male and 22 female young elite tennis players completed this study. Participants were divided into two groups: (1) 32 with history of LBP and (2) 32 without history of LBP. Descriptive measures of passive hip extension and rotation ROMs of the dominant and non-dominant limbs were taken. Active hip rotation ROMs were also assessed. Magnitude-based inferences on differences between groups and legs were made by standardizing differences.   RESULTS:  The inter-group statistical analysis reported no significant differences (p> 0.05; trivial effect with a probability higher than 95%; d⩽ 0.4) in any ROM measure analyzed. Further, neither LBP group nor control group reported significant bilateral or side-to-side differences (p> 0.05; trivial effect with a probability higher than 99%; d< 0.3) between legs regarding hip extension and rotation ROM measures.   CONCLUSION:  No relationship between hip extension and rotation ROM and history of LBP was found."@en ;
    ns0:hasPubTitle "Comparison of hip extension and rotation ranges of motion in young elite tennis players with and without history of low back pain"@en .

ns1:bmr-v32-i4-BMR181326 ns0:hasKeywords "Osteoarthritis"@en,
        "cartilage"@en,
        "endothelin-1"@en,
        "hand"@en,
        "knee"@en,
        "ultrasound"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Endothelin-1 (ET-1) is one of the probable inflammatory factors stimulating cartilage degradation in osteoarthritis (OA) pathogenesis.   OBJECTIVE:  To assess ET-1 level in OA and its correlation with radiographic findings, cartilage morphology and clinical parameters.   METHODS:  One hundred and thirty-nine subjects (89 OA, 50 controls) were included in this cross-sectional study. Both knee and hand joints of the participants were examined using plain radiography and ultrasound imaging by which distal femoral cartilage thickness/grading and second metacarpophalangeal cartilage thickness were assessed. Subjects were evaluated for pain and functional status using visual analogue scale, Western Ontario and McMaster Universities Arthritis Index and Duruöz Hand Index.   RESULTS:  Serum ET-1 levels were higher in the OA group than the control group. Serum ET-1 levels were not correlated with cartilage thickness in patients with OA. Serum ET-1 levels were not correlated with either pain or other clinical parameters in the knee OA group and in the hand OA group.   CONCLUSION:  This is the first study evaluating the relationship between serum ET-1 levels and cartilage morphology and clinical parameters, which did not show any conclusive result. Future studies, overcoming the limitations of this study, might provide a better understanding of the role of ET-1 in the pathogenesis of OA."@en ;
    ns0:hasPubTitle "Serum endothelin-1 levels, radiographic and ultrasonographic evaluations, and clinical parameters in patients with knee and/or hand osteoarthritis"@en .

ns1:bmr-v32-i4-BMR181448 ns0:hasKeywords "Glenohumeral joint"@en,
        "adhesive capsulitis"@en,
        "dynamic ultrasonography"@en ;
    ns0:hasPubAbstract "Frozen shoulder is a common disorder characterized by pain and limitation of the glenohumeral joint motions. While it is usually clinically diagnosed, as it can also mimic several other painful shoulder pathologies, imaging techniques can contribute to the differential diagnosis. In the literature, static and dynamic ultrasonographic findings have been reported to better characterize this condition and plan for treatment. We studied a 50-year-old male patient with capsular stiffness of the shoulder on whom Ultrasound (US) examination was performed. Our study exemplifies another interesting ultrasonographic finding: during dynamic evaluation the “frozen” movements of the glenohumeral joint can simply be visualized."@en ;
    ns0:hasPubTitle "Looking into the joint when it is frozen: A report on dynamic shoulder ultrasound"@en .

ns1:bmr-v32-i5-BMR170948 ns0:hasKeywords "Idiopathic scoliosis"@en,
        "body height"@en,
        "diurnal variation"@en,
        "evaluation"@en,
        "progression"@en,
        "treatment"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Body height (BH) measurement is an important part of the clinical evaluation of children with idiopathic scoliosis (IS) as its progression is defined based on the observation of a growth spurt.   OBJECTIVE:  The aim of the study is to assess diurnal variation of BH in children with IS.   METHODS: BH was measured in 98 children with IS (Cobb angle: 10∘–52∘, mean 21.2∘± 9.9∘) both in standing and sitting position. The measurements were performed 4 times a day – between: (1) 7:00 and 8:00; (2) 11:00 and 12:00; (3) 15:00 and 16:00 and (4) 19:00 and 20:00.   RESULTS:  A significant decrease in BH during the day was observed in both standing and sitting positions (p< 0.001). The highest decrease in height was observed between the measurements performed between 7:00 and 8:00 and measurements carried out in the evening (19:00–20:00). For standing, the mean loss of height was 0.7 cm (± 0.7), i.e. 0.43% of initial standing height, for sitting the mean decrease in height was 0.7 cm (± 0.7), i.e. 0.79% of initial sitting height.   CONCLUSIONS: BH decreases in children with IS during daytime. Due to diurnal BH variation, the time of the day should be recorded when measuring patients with IS."@en ;
    ns0:hasPubTitle "Diurnal variation of body height in children with idiopathic scoliosis"@en .

ns1:bmr-v32-i5-BMR181181 ns0:hasKeywords "Brief International Classification of Functioning Core Set"@en,
        "Ulnar wrist pain"@en,
        "hand conditions"@en,
        "physical therapy"@en ;
    ns0:hasPubAbstract "OBJECTIVE:  The purpose of this study was to apply the Brief International Classification of Functioning (ICF) Core Set for Hand Conditions to the physical therapy outcome measures, and to evaluate the contribution of these measures to overall health in subjects with ulnar wrist pain.   METHODS:  Thirty-five subjects with ulnar wrist pain received a 4-week home-based treatment program including orthotics and strengthening exercises. Investigators measured pain, function, grip strength, and overall health four weeks post-intervention. Regression analysis was used to investigate the effect of these variables on overall health represented by the Short Form (SF-36) questionnaire.   RESULTS:  Fifty-three percent of the variability in SF-36 physical health summary scores was explained by the studied variables with grip strength predicting 31% of the variability.   CONCLUSIONS: The Brief ICF Core Set for Hand Conditions can be a useful abridged list of categories relevant to functioning and health in subjects with ulnar wrist pain."@en ;
    ns0:hasPubTitle "Linking physical therapy outcome measures to the Brief International Classification of Functioning Core Set for Hand Conditions in subjects with ulnar wrist pain"@en .

ns1:bmr-v32-i5-BMR181286 ns0:hasKeywords "Trigger point"@en,
        "dry needling"@en,
        "local twitch response"@en,
        "upper trapezius"@en,
        "“de qi”"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Pain from myofascial trigger points is often treated by dry needling (DN). Empirical evidence suggests eliciting a local twitch response (LTR) during needling is essential. Muscle damage after eliciting LTR can increase the risk of tissue fibrosis in some cases.   OBJECTIVE:  This study aimed to compare two methods of DN including with and without LTR on clinical parameters.   METHODS:  Twenty-six participants suffering from chronic non-specific neck pain with an active trigger point (TrP) in their upper trapezius muscles were recruited via the convenience sampling method. Participants were randomly assigned in DN with LTR (control group) and without eliciting LTR or “de qi” (experimental group). Then, they received 3 sessions of dry needling, 3 days apart. We evaluated pain, pain pressure threshold, active cervical lateral flexion range of motion, and Neck Disability Index before the intervention and 4 weeks after the treatment.   RESULTS:  After the treatment, significant higher changes were seen in the experimental group compared to the control group (p< 0.05) regarding pain, pain pressure threshold, and active cervical lateral flexion. However, there was no significant difference between groups according to the disability (p> 0.05).   CONCLUSION:  DN without eliciting LTR has superiority over the DN along with eliciting LTR while the treatment aimed to receive long-term effects."@en ;
    ns0:hasPubTitle "The effect of dry needling on the active trigger point of upper trapezius muscle: Eliciting local twitch response on long-term clinical outcomes"@en .

ns1:bmr-v32-i5-BMR181289 ns0:hasKeywords "Neck pain"@en,
        "dry needling"@en,
        "extracorporeal shock wave"@en,
        "myofascial trigger point"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Chronic neck pain is associated with various myofascial trigger points (MTrPs).   OBJECTIVE:  A single-blind randomized clinical trial was designed to compare the effects of extracorporeal shock wave therapy (ESWT) with dry needling (DN) techniques on the upper trapezius muscle trigger point in patients with non-specific neck pain (NSNP).   METHODS:  Seventy patients with NSNP and active MTrPs of the upper trapezius muscle were randomly divided into two groups: an ESWT group (n= 35) and a DN group (n= 35). Treatment sessions were performed for three weeks and all participants received related intervention once a week. The outcome measures were pain intensity, measured by a numeric pain rating scale (NPRS), pain pressure threshold (PPT), measured with a digital algometer, and functional disability, evaluated by using the neck disability index (NDI).   RESULTS:  NPRS and NDI were significantly decreased in the DN group and ESWT group (P< 0.05). Also, the PPT was significantly increased in the DN group and ESWT. However, there was no significant difference in pain intensity, NDI, and the PPT between the two groups (P⩾ 0.05).   CONCLUSION:  Both ESWT and DN can be employed to treat MTrPs of the upper trapezius muscle in patients with NSNP."@en ;
    ns0:hasPubTitle "The effects of shock wave and dry needling on active trigger points of upper trapezius muscle in patients with non-specific neck pain: A randomized clinical trial"@en .

ns1:bmr-v32-i5-BMR181380 ns0:hasKeywords "Low back pain"@en,
        "children"@en,
        "physical activity"@en ;
    ns0:hasPubAbstract "OBJECTIVES:  Back pain often develops in early childhood and becomes more frequent during adolescence. The aim of this study was to determine potential risk factors and the therapy effects on back pain in children.   METHODS:  This retrospective study included 96 boys and girls treated for back pain in outpatient and hospital setting in the 1.1.2016–31.12.2016 period at the Institute of Child and Youth Health Care of Vojvodina, Serbia. The influence of sex, age, physical activity and presence of concomitant locomotor system deformities, as well as applied therapies, on the back pain in children was analyzed using SPSS ver. 21.   RESULTS:  The studied sample comprised of 56.3% girls. The average age of the subjects was 14.64 years, 43 (44.8%) of the children were physically active. In children suffering from back pain, spinal column deformities were also noted, mostly scoliosis (27.1%) and kyphosis (20.8%). Chronic pain was diagnosed in 54 children (56.3%). The average pain intensity, as measured on the VAS, was 5.72 and 0.92 before and after therapy, respectively (p< 0.05).   CONCLUSION:  Among the analyzed parameters, only lumboishialgia was a significant factor in the onset of back pain, which declined following ergonomic education and physical therapy."@en ;
    ns0:hasPubTitle "Potential risk factors for back pain in children"@en .

ns1:bmr-v32-i6-BMR171004 ns0:hasKeywords "Balance taping"@en,
        "PFPS"@en,
        "complementary treatment"@en,
        "congruence angle"@en ;
    ns0:hasPubAbstract "BACKGROUND: Patellofemoral pain syndrome (PFPS) is one of the most common knee disorders affecting women.   OBJECTIVE: The purpose of this study was to investigate the effects of balance taping on PFPS.   METHODS: Balance taping using kinesiology tape was applied for 2.5 months (average of 16 h/day) to both knees in a 26-year-old female nurse with bilateral PFPS.   RESULTS:  The congruence angle decreased in the right and left knees from 30∘ to 5∘ and from 20∘ to 5∘, respectively. The Patient Specific Functional Scale score increased from 17/50 to 50/50, indicating improved functional state of the knees, while the Numeric Pain Rating Scale scores for from sitting to standing, from standing to sitting, and kneeling improved from 6/10 and 0/10, indicating no pain in the knee joints. Application of repeated balance taping for 2.5 months reduced PFPS.   CONCLUSION: Considering the outcome of the study, we recommend balance taping as a complementary treatment method for PFPS."@en ;
    ns0:hasPubTitle "Effects of balance taping using kinesiology tape in a female with patellofemoral pain syndrome: A case report"@en .

ns1:bmr-v32-i6-BMR171043 ns0:hasKeywords "Iloprost"@en,
        "bone marrow edema"@en,
        "in vitro"@en,
        "osteoblasts"@en ;
    ns0:hasPubAbstract "BACKGROUND AND OBJECTIVES:  Bone marrow oedema is a multifactorial conditioned illness. Alongside any strain relief of an affected joint, treatment with Iloprost also belongs to the choice of cures. In past studies, a modulatory effect on bone could be shown. The hypothesis of the present work is that Iloprost has a growth-stimulating effect on osteoblasts in vitro.   METHODS:  Human osteoblasts were isolated and cultivated. Subsequently, the cells were treated with Iloprost in bioavailable concentrations. Alterations of the cell structure were examined by means of light microscopy. A regulation of the number of vital cells was carried out by using a CASY cell counter. Possible cell impairment after Iloprost treatment was analysed by means of XTT Elisa as well as FDA and PI staining via fluorescence microscopy.   RESULTS:  Using light microscopy, no changes in cell structure could be observed. With the CASY cell counter, no increase in the numbers of osteoblasts appeared after Iloprost treatment. Also, XTT Elisas and fluorescence microscopy did not reveal any cell impairment due to Iloprost.   CONCLUSION:  Our results could not confirm a modulatory effect in mature osteoblasts. On the basis of the present work we could not verify any growth-stimulating effect by Iloprost in mature osteoblasts in vitro. Admittedly, effects had been shown previously during osteogenesis, but we do exclude an effect on mature osteoblasts which have already differentiated."@en ;
    ns0:hasPubTitle "Effects of iloprost on human mature osteoblasts in vitro"@en .

ns1:bmr-v32-i6-BMR181171 ns0:hasKeywords "Academic training"@en,
        "musculoskeletal pain"@en,
        "occupational health"@en,
        "pain"@en ;
    ns0:hasPubAbstract "BACKGROUND AND OBJECTIVE:  Musculoskeletal problems are a common health problem with professional and ergonomic features. This study’s purpose was to investigate the musculoskeletal problems distribution and related factors among academicians.   METHODS:  This study was performed by using a personal and professional information questionnaire, the Extended Nordic Musculoskeletal Questionnaire and International Physical Activity Questionnaire Short Form.   RESULTS:  The study was completed with 142 academicians (89 female, 53 male). Mean age was 39.91 ± 8.90 years, physical activity level was 1067.31 ± 1866.95 MET-minute/week, and work time was 13.73 ± 9.15 years. Neck and lower back pain were mostly seen in academicians and their incidence was equal (63.4%). The most experienced pain the previous year was neck pain (39.4%), and upper back pain is the most experienced pain today (19%). The body part that mostly caused the use of medication is neck pain (23%), and mostly caused limitation and sick-leave was low back in the past 12 months (respectively 19.7% and 9.2%). Gender, body mass index, weekly workload, physical activity level, and marital status have been determined to have an effect on musculoskeletal problems in academicians (p< 0.05).   CONCLUSION:  The most common musculoskeletal problems reported by academicians were in the upper back and neck regions, which have low level physical activity."@en ;
    ns0:hasPubTitle "Musculoskeletal problems in academicians and related factors in Turkey"@en .

ns1:bmr-v32-i6-BMR181332 ns0:hasKeywords "Q angle"@en,
        "lower extremity"@en,
        "single leg stance test"@en,
        "star excursion balance test"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Changes in postural stability may be a reason for injuries in individuals who have altered musculoskeletal alignment. Q angle (QA) has shown to be a predictor for lower extremity injuries. However, the relationship between balance and QA has not been investigated in young adults.   OBJECTIVE:  The aim of the study was to investigate the relationship between QA and balance in young adults.   METHODS:  Ninety participants performed the single leg stance test (SLST) and Star Excursion Balance Test (SEBT) to assess static and dynamic balance, respectively. QA was measured using a manual goniometer. Participants were divided into low, normal and high QA groups.   RESULTS:  The relationship between SLST and QA was not statistically significant in both eyes opened and closed condition (r=-0.030, p= 0.782; r= 0.031, p= 0.774; respectively). SLST scores did not differ among the three groups in both eyes opened and closed condition (p= 0.781, p= 0.790; respectively). QA significantly correlated with lateral, posterolateral directions and sum score of SEBT (r= 0.240, p= 0.023; r= 0.269, p= 0.010; r= 0.210, p= 0.047). The comparisons among the low, normal and high Q angle groups’ SEBT scores showed that balance performance in lateral direction was poorer in low QA group (p= 0.027).   CONCLUSIONS:  The results of the study showed that QA and dynamic balance have a significant relationship. To reduce musculoskeletal injury risk, the dynamic balance should be assessed in young adults who have lower QA."@en ;
    ns0:hasPubTitle "Influence of quadriceps angle on static and dynamic balance in young adults"@en .

ns1:bmr-v32-i6-BMR181341 ns0:hasKeywords "High intensity laser therapy"@en,
        "low back pain"@en,
        "neck pain"@en,
        "rehabilitation"@en,
        "spinal disorders"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Spinal disorders are common health problems which include wide categories of diseases that affect the spinal soft tissues, joints and bone.   OBJECTIVE:  The aim of this systematic review was to evaluate the effectiveness of high intensity laser therapy (HILT) on pain and function in patients with spinal disorders.   METHODS:  Six databases were searched up to the end of February 2018 including PubMed, MEDLINE, the Cochrane Central Register of Controlled Trials (CENTRAL), Physiotherapy Evidence Database (PEDro), Open Grey and Grey Literature Report. In addition, the reference lists of all included studies were searched for any relevant studies. PEDro scale and GRADE system were performed to assess the quality of the studies. A meta-analysis was conducted to calculate the overall effect size.   RESULTS:  A total of ten randomised controlled trials (RCTs) met the inclusion criteria, with four studies of the efficacy of HILT on neck pain (NP) and six on low back pain (LBP). According to the PEDro scale assessment, only two studies were rated as high quality, while the remainder were rated as fair or low quality. Forest plots showed that HILT with exercise was significantly more effective than placebo HILT with exercise in terms of pain reduction (SMD -1.11; 95% CI -1.42 to -0.80; P< 0.00001; I2 0%) and functional improvement (SMD -1.03; 95% CI -1.33 to -0.72; P< 0.00001; I2 0%). Meta-analyses also showed that HILT alone or HILT with conventional physiotherapy (CPT) significantly provided better outcomes than CPT alone.   CONCLUSIONS:  HILT is considered as a complementary modality for pain reduction and function improvement in patients with spinal disorders. However, the quality of the body of evidence was rated from ‘very low’ to ‘low’ quality. Further high quality trials are required for standardisation of irradiation parameters and the treatment protocol to establish the efficacy of HILT for spinal disorders."@en ;
    ns0:hasPubTitle "The effectiveness of high intensity laser therapy in the management of spinal disorders: A systematic review and meta-analysis"@en .

ns1:brs-v14-i4-BRS190144 ns0:hasKeywords "B-WIM"@en,
        "Bridge WIM"@en,
        "FEM, LS-Dyna"@en,
        "MFI"@en,
        "Real-time"@en,
        "eigenvalue"@en,
        "load control"@en,
        "moving force identification"@en,
        "strain"@en ;
    ns0:hasPubAbstract "Moving Force Identification (MFI) is one of the Bridge Weigh-In-Motion (B-WIM) techniques that utilize bridge responses to passing vehicles to infer the forces applied by those vehicles. A challenge with MFI is the computational time needed to obtain results, especially when using 2-D or 3-D finite element models (FEMs) with large numbers of degrees of freedom (DOFs). This technical note proposes a new technique to reduce the computational time, which allows for real-time load monitoring and the potential for control of overloaded trucks. The technique utilizes the most critical parts of the bridge eigenvectors instead of the full system eigenvectors. The selected parts include the DOFs for the elements where sensors are located, and DOFs of track elements, where vehicle axles interact with the bridge. The method is verified experimentally in this paper."@en ;
    ns0:hasPubTitle "Moving force identification for real-time bridge weigh-in-motion"@en .

ns1:bsi-v8-i1-2-BSI190186 ns0:hasKeywords "Phase retrieval"@en,
        "high-energy phase contrast imaging"@en,
        "spatial resolution"@en ;
    ns0:hasPubAbstract "A single-projection based phase retrieval method based on the phase attenuation duality principle (PAD) was used to compare the spatial resolution of the acquired phase sensitive and PAD processed phase retrieved images. An inline phase sensitive prototype was used to acquire the phase sensitive images. The prototype incorporates a micro-focus x-ray source and a flat panel detector with a 50 μm pixel pitch. A phantom composed of a 2 cm thick 50–50 adipose-glandular mimicking slab sandwiched with a 0.82 cm thick slanted PMMA sharp edge was used. Phase sensitive image of the phantom was acquired at 120 kV, 3.35 mAs with a 16 μm tube focal spot size under a geometric magnification (M) of 2.5. The PAD based method was applied to the acquired phase sensitive image for the retrieval of phase values. With necessary data processing, modulation transfer function (MTF) curves were determined for the estimation and comparison of the spatial resolution. The PAD processed phase retrieved values of the phantom were in good agreement with the theoretically calculated values. Phase sensitive images showed higher spatial resolution at all spatial frequencies compared to the phase retrieved images. It was noted that the high-frequency signal components in the retrieved image were suppressed that resulted in lower MTF values. When compared to the phase sensitive image, the cutoff resolution (10% MTF) for phase retrieved image dropped 32% from 15.6 lp/mm (32 μm) to 10.6 lp/mm (47 μm). The resolution offered by this phase sensitive prototype is radiographically enough to detect breast cancer."@en ;
    ns0:hasPubTitle "Impact of a single distance phase retrieval algorithm on spatial resolution in X-ray inline phase sensitive imaging"@en .

ns1:cbm-v25-i2-CBM182231 ns0:hasKeywords "Reseptor tyrosine kinases"@en,
        "growth factors"@en,
        "lung cancer"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Reseptor tyrosine kinases (cMET and EGFR) are important in lung cancer targeted therapy. We believe if we can use them as markers for clinicians to help decide the diagnosis of lung cancer. This parameter will be important in serum samples of patients with lung cancer diagnosis and treatment. The aim of this study is aimed to evaluate the clinical utility of serum protein and circulating mRNA of cMET and HGF in lung cancer patients. We also analyzed the correlation of mRNA expression with clinicopathologic parameters.   METHODS:  We performed enzyme-linked immunosorbent assay (ELISA) to measure and compare serum protein and circulating mRNA of cMET and HGF levels in peripheral blood from 60 lung cancer patients and 40 healthy control group.   RESULTS:  We found that both protein and gene expression levels of serum c-MET, HGF and EGFR were significantly higher in patients with lung cancer than control group. There was no association between HGF, cMET, EGF, EGFR (both protein and gene) expression levels with age, gender, smoking habit, COPD, pathological types or tumor size, stage, metastatic-non metastatic adenocarcinoma-squamous carcinoma, SCLC-NSCLC. As a result of ROC analysis, serum cMET (AUC: 0.892) and HGF protein (AUC: 0.784) were diagnosed in lung cancer patients (Fig. 1). The AUC values of serum EGF and EGFR proteins were calculated to be 0.631 and 0.692, respectively.   CONCLUSION:  To our knowledge this is the first study comparing the levels of protein and mRNA in the serum material of HGF, c-MET, EGF and EGFR parameters in lung cancer patients’ blood samples. Further prospective studies with more participants for better understanding of mechanism and effect for HGF and c-MET inhibitors in lung cancer will help us to identify of these biomarkers role for guiding us to sellect individualized itargeted therapies."@en ;
    ns0:hasPubTitle "Detection of serum protein and circulating mRNA of cMET, HGF EGF and EGFR levels in lung cancer patients to guide individualized therapy"@en .

ns1:cbm-v25-i2-CBM182383 ns0:hasKeywords "CRC"@en,
        "HOTAIR"@en,
        "MALAT1"@en,
        "drug resistance"@en,
        "lncRNA"@en,
        "rs3200401"@en,
        "rs4759314 irinotecan"@en,
        "toxicity"@en ;
    ns0:hasPubAbstract "BACKGROUND : Colorectal cancer is the fourth cause of cancer related death. Drug resistance and toxicity remain major clinical issues. HOTAIR and MALAT1 are long non-coding RNAS that affect cellular proliferation, apoptosis and drug resistance; their up-regulation has been linked with a poor prognosis.   OBJECTIVE:  Investigation of the association between rs4759314 HOTAIR and rs3200401 MALAT1 polymorphisms and irinotecan-based chemotherapy in terms of drug efficacy and toxicity.   METHODS:  Samples from 98 patients receiving different regimens of irinotecan-based therapy were included. Efficacy and toxicity were evaluated. KRAS mutation, rs3200401 HOTAIR and rs4759314 MALAT1 polymorphisms genotyping in the tumors and peripheral blood respectively were performed with PCR.   RESULTS:  Neither rs3200401 MALAT1 nor rs4759314 HOTAIR polymorphism are associated with response to treatment regimens. Rs4759314 was also not associated with increased toxicity in patients receiving irinotecan-based regimens. CT genotype of rs3200401 was associated with significantly reduced overall survival. An association between KRAS mutation and AG/GG genotypes in the rs4759314 was detected.   CONCLUSIONS:  CT genotype of rs3200401 MALAT1 polymorphism could serve as a toxicity biomarker. Carriers of the G allele of the rs4759314 HOTAIR are more likely to be carriers of KRAS mutations too. However, further studies in larger patient populations are required."@en ;
    ns0:hasPubTitle "Long non-coding RNA polymorphisms and prediction of response to chemotherapy based on irinotecan in patients with metastatic colorectal cancer"@en .

ns1:cbm-v25-i2-CBM190013 ns0:hasKeywords "EMT"@en,
        "ETS transcription factor"@en,
        "bladder cancer"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Transcription factors are commonly deregulated in various cancers. Here, we evaluated role of ELF3 in pathogenesis of bladder carcinoma (BCa).   MATERIALS AND METHODS:  We confirmed ELF3 expression pattern in BCa cell lines using western blot; and in different grades of tumors using Immunohistochemistry. Cell invasion assay was employed to demonstrate potential role of ELF3 in EMT.   RESULTS AND CONCLUSION:  ELF3 showed selective expression in low-grade cell lines and tumor tissues. Overexpression of ELF3 in mesenchymal cell line UMUC3 resulted in reduced invasion and decreased expression of mesenchymal markers. We observed association of low ELF3 expression with increased risk and overall poor survival using publicly available data. ELF3-modulated reversal of EMT might be a useful strategy in the treatment of bladder cancer."@en ;
    ns0:hasPubTitle "E74 like ETS transcription factor 3 (ELF3) is a negative regulator of epithelial- mesenchymal transition in bladder carcinoma"@en .

ns1:cbm-v25-i3-CBM192437 ns0:hasKeywords "Epstein-Barr virus"@en,
        "Neuropilin-1"@en,
        "clinical parameters"@en,
        "lymphoma"@en,
        "prognosis"@en ;
    ns0:hasPubAbstract "BACKGROUND:  The expression of neuropilin-1 (NRP-1) in Epstein-Barr virus (EBV)-associated lymphomas and its relationships with clinicopathological parameters was investigated.   METHODS:  The researchers compared 111 cases of patients with lymphoma to 20 cases of reactive lymphoid hyperplasia. In situ hybridization was applied to observe the expression of EBV-encoded RNA (EBER) in lymphomas, and immunohistochemistry was used to detect the NRP-1 expression in lymphoma tissues and lymph node tissues with reactive hyperplasia.   RESULTS:  In these 111 cases, the EBER of 62 cases (55.9%) appeared positive. NRP-1 was relatively highly expressed in lymphomas (P= 0.019). Further, NRP-1 showed higher expression in lymphomas with positive EBER than in negative ones. A comprehensive analysis revealed that NRP-1 was differently expressed in NK/T-cell lymphoma, Hodgkin’s lymphoma, diffuse large B-cell lymphoma, and anaplastic large cell lymphoma (P= 0.027). Moreover, highly expressed NRP-1 was found to be a useful independent prognostic factor in assessing overall survival and progression-free survival rates in cases of non-Hodgkin’s lymphoma (NHL).   CONCLUSIONS:  NRP-1 exhibited higher expression in lymphomas, and it was positively expressed in EBV-positive lymphomas. Moreover, highly expressed NRP-1 can be used as an undesirable independent prognostic factor in NHL."@en ;
    ns0:hasPubTitle "Expression and clinical significance of neuropilin-1 in Epstein-Barr virus-associated lymphomas"@en .

ns1:cbm-v25-i4-CBM182333 ns0:hasKeywords "Arsenic"@en,
        "TCGA"@en,
        "bioinformatics"@en,
        "differentially expressed genes"@en,
        "lung carcinoma"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Evidence indicates that inorganic arsenic (iAs) can directly damage cells and result in malignant transformation with unclear complicated mechanisms. In the present study, we aimed to explore the possible molecules, pathways and therapeutic agents by using bioinformatics methods.   METHODS:  Microarray-based data were retrieved and analyzed to screen the differentially expressed genes (DEGs) between iAs-treated lung cells and controls. Then, the functions of DEGs were annotated and the hub genes were filtrated. The key genes were selected from the hub genes through validation in The Cancer Genome Atlas (TCGA) cohorts. Possible drugs were predicted by using CMAP tool.   RESULTS:  Two datasets (GSE33520 and GSE36684) were retrieved, and 61 up-regulated and 228 down-regulated DEGs were screened out, which were enriched in various pathways, particularly metabolism-related pathways. Among the DEGs, four hub genes including MTIF2, ACOX1, CAV1, and MRPL17, which might affect lung cancer prognosis, were selected as the key genes. Interestingly, Quinostatin was predicted to be a potential agent reversing iAs-induced lung cell malignant transformation.   CONCLUSION:  The present study sheds novel insights into the mechanisms of iAs-induced lung cell malignant transformation and identified several potential small agents for iAs toxicity prevention and therapy."@en ;
    ns0:hasPubTitle "Screening of key genes and prediction of therapeutic agents in Arsenic-induced lung carcinoma"@en .

ns1:cbm-v26-i1-CBM182009 ns0:hasKeywords "PIWIL2"@en,
        "leukoplakia"@en,
        "oral cancer"@en,
        "prognosis"@en,
        "tumor microenvironment"@en ;
    ns0:hasPubAbstract "PIWIL2 is a human Argonaute protein, which is guided by small RNAs to its targets, plays a role in germ cell maintenance and has been proposed to be expressed in precancerous stem cells and tumor stem cells. However, the significance of PIWIL2 expression in oral cancer and precancerous lesions has not been investigated. In this study, we analyzed the expression of the stem cell protein PIWIL2 in oral squamous-cell carcinoma (OSCC) and in premalignant oral leukoplakia (OL) with predominant expression in malignant and premalignant tissues. In the evaluated patients, we found that PIWIL2 was associated significantly with OSCC prognosis and OL. Furthermore, PIWIL2 was found to be expressed in tumor epithelial cells and macrophages in the tumor microenvironment, which are not derived from enlarged lymph nodes. Cytological experiments confirmed that the human squamous cell carcinoma cell line SCC-25, can promote the PIWIL2 and Nanog level in THP-1 cells, which are extensively used to study the modulation of monocytes and macrophages. Our findings showed that PIWIL2 can predict effectively OSCC prognosis and OL with a high risk of OSCC development and substantiate the deduction that cancer stem(-like) cells in oral cancer have the ability to reconstitute the heterogeneity of the bulk tumor and contribute to poor outcome and immunosuppression."@en ;
    ns0:hasPubTitle "Expression of PIWIL2 in oral cancer and leukoplakia: Prognostic implications and insights from tumors"@en .

ns1:cbm-v26-i1-CBM182111 ns0:hasKeywords "Circ-ITCH"@en,
        "expression"@en,
        "pathological features"@en,
        "prognosis"@en,
        "prostate cancer"@en ;
    ns0:hasPubAbstract "OBJECTIVE:  This study aimed to explore the correlation of circular RNA itchy E3 ubiquitin protein ligase (circ-ITCH) with pathological features as well as its predictive value on prognosis in prostate cancer patients.   METHODS:  Three hundred and twenty-four patients with prostate cancer underwent radical prostatectomy were consecutively included in this retrospective study, and patients’ specimens of tumor as well as paired adjacent tissues were collected for detection of circ-ITCH expression. Patients’ baseline characteristics and survival data were obtained from follow-up records, and correlation of circ-ITCH with patients’ pathological features and survival was determined.   RESULTS:  Circ-ITCH expression was decreased in tumor tissue compared with paired adjacent tissues (P< 0.001), and it presented with good value in distinguishing tumor tissues from paired adjacent tissues with area under curve (AUC) of 0.812 (95%CI: 0.780–0.845). Circ-ITCH low expression was associated with advanced pathologic T stage (P= 0.002) and high risk of lymph node metastasis (P= 0.047) in prostate cancer patients. As for prognosis, patients with circ-ITCH high expression had longer disease-free survival (DFS) (P< 0.001) and overall survival (OS) (P< 0.001). Additionally, circ-ITCH (high vs. low) independently predicted better survival, while Gleason score (> 7 vs. ⩽ 7) and surgical margin status (positive vs. negative) independently predicted worse survival in prostate patients underwent radical prostatectomy.   CONCLUSIONS:  Circ-ITCH is downregulated in prostate cancer tissues, and its low expression correlates with advanced pathologic T stage, high lymph mode metastasis risk and poor survival in prostate cancer patients underwent radical prostatectomy."@en ;
    ns0:hasPubTitle "Downregulated circular RNA itchy E3 ubiquitin protein ligase correlates with advanced pathologic T stage, high lymph node metastasis risk and poor survivals in prostate cancer patients"@en .

ns1:cbm-v26-i1-CBM182257 ns0:hasKeywords "LHX3"@en,
        "hepatocellular carcinoma"@en,
        "metastasis"@en,
        "oncogene"@en,
        "prognostic biomarker"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Hepatocellular carcinoma (HCC) is a common cancer and exhibits high morbidity and mortality in the world. We recently identified LHX3 as a preferentially expressed gene with a possible involvement in HCC.   OBJECTIVE:  To determine the expression, clinical relevance, prognostic significance and functions of LHX3 in HCC.   MATERIALS AND METHODS:  LHX3 expression was assessed in 190 cancerous and 40 adjacent non-cancerous tissues by PCR, western blot and immunohistochemistry. Associations between LHX3 expression and clinicopathological characteristics of patients were investigated. Correlations between LHX3 expression and overall survival of patients were analyzed by Kaplan-Meier and Cox-regression methods. Functional roles of LHX3 were evaluated by transwell assays.   RESULTS:  LHX3 expression is significantly increased in carcinoma tissues, and associated with clinical stage and metastasis of patients. LHX3 expression is much higher in the advanced-stage patients than the early-stage patients, and is sharply increased in metastasic patients. High LHX3 expression is associated with unfavorable overall survival, and is an independent prognostic factor of patients. Moreover, LHX3 is an unfavorable and independent prognostic factor unique to advanced-stage patients. Knockdown expression of LHX3 obviously inhibits tumor cell migration and invasion.   CONCLUSION:  LHX3 is an advanced-stage prognostic biomarker, and acts as a new potential metastatic oncogene in HCC."@en ;
    ns0:hasPubTitle "LHX3 is an advanced-stage prognostic biomarker and metastatic oncogene in hepatocellular carcinoma"@en .

ns1:cbm-v26-i2-CBM182075 ns0:hasKeywords "Thrombomodulin"@en,
        "metastasis"@en,
        "prognosis"@en,
        "soft tissue sarcoma"@en,
        "soft tissue tumor"@en ;
    ns0:hasPubAbstract "BACKGROUND: Thrombomodulin (TM) has multiple biological functions and modulates not only anti-coagulation, but also cell proliferation, adhesion, and anti-inflammation activities. The main function of TM is to activate the anticoagulant pathway of protein C. Soluble TM is related to metastasis by its inactivation of thrombin.   OBJECTIVES:  To clarify the correlation between serum TM levels and clinicopathological parameters.   METHODS:  The plasma TM levels (FU/ml) of 135 primary soft tissue tumors (benign, 67; soft tissue sarcoma (STS), 68) were measured before biopsy or treatment. TM levels were analyzed and compared to various clinicopathological parameters. Log-rank test and Cox proportional analysis were used to evaluate recurrence-free survival, metastasis-free survival, and overall survival.   RESULTS:  STS tumors had significantly higher TM values (15.9) than benign tumors (13.7) (p= 0.0138). 5-year MFS was 81.1% in low TM and 40.0% in high TM (p= 0.00671), and 5-year OS was 85.5% in low and 52.5% in high TM in grades 1–3 (p= 0.0673). In multivariate COX proportional analysis, high-TM showed a significant difference (MFS: HR 4.37, p= 0.0147; OS: HR 3.60, p= 0.0557) in grades 1–3.   CONCLUSIONS:  We demonstrated that a high level of soluble TM has the potential to be a significant predictor of metastasis and poor prognosis in STS patients. TM is a candidate molecular marker for high metastatic potential and can be clinically useful for guiding therapeutic strategy."@en ;
    ns0:hasPubTitle "Serum thrombomodulin as a metastatic and prognostic marker in soft tissue sarcomas"@en .

ns1:cbm-v26-i2-CBM190161 ns0:hasKeywords "Diagnosis"@en,
        "biomarkers"@en,
        "lncRNA"@en,
        "lung cancer"@en,
        "sputum"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Analysis of molecular changes in sputum may help diagnose lung cancer. Long non-coding RNAs (lncRNAs) play vital roles in various biological processes, and their dysregulations contribute to the development and progression of lung tumorigenesis. Herein, we determine whether aberrant lncRNAs could be used as potential sputum biomarkers for lung cancer.   METHODS:  Using reverse transcription PCR, we measure expressions of lung cancer-associated lncRNAs in sputum of a discovery cohort of 67 lung cancer patients and 65 cancer-free smokers with benign diseases and a validation cohort of 59 lung cancer patients and 60 cancer-free smokers with benign diseases.   RESULTS:  In the discovery cohort, four of the lncRNAs displayed a significantly different level in sputum of lung cancer patients vs.cancer-free smokers with benign diseases (all P< 0.001). From the four lncRNAs, three lncRNAs (SNHG1, H19, and HOTAIR) are identified as a biomarker panel, producing 82.09% sensitivity and 89.23% specificity for diagnosis of lung cancer. Furthermore, the biomarker panel has a higher sensitivity (82.09% vs. 52.24%, P= 0.02) and a similar specificity compared with sputum cytology (89.23% vs. 90.77%, P= 0.45). In addition, the lncRNA biomarker panel had a higher sensitivity (87.50% vs. 70.07%, p= 0.03) for diagnosis of squamous cell carcinoma compared with adenocarcinoma of the lung, while maintaining the same specificity (89.23%). The potential of the sputum lncRNA biomarkers for lung cancer detection is confirmed in the validation cohort.   CONCLUSION:  We have for the first time shown that the analysis of lncRNAs in sputum might be a noninvasive approach for diagnosis of lung cancer."@en ;
    ns0:hasPubTitle "Sputum long non-coding RNA biomarkers for diagnosis of lung cancer"@en .

ns1:cbm-v26-i2-CBM190273 ns0:hasKeywords "Papillary thyroid carcinoma"@en,
        "diagnosis"@en,
        "long non-coding RNA H19"@en,
        "prognosis"@en ;
    ns0:hasPubAbstract "OBJECTIVE:  To investigate the diagnostic and prognostic values of long non-coding RNA H19 (H19) in patients with papillary thyroid carcinoma (PTC).   METHODS:  This retrospective, nonrandomised study included 410 patients with PTC and 89 patients with benign thyroid nodes (BTN)who underwent standard total thyroidectomy. Real-time quantitative polymerase chain reaction (RT-qPCR) was used to detect H19 expression in these tissues. The relationship between H19 expression and the patients’ clinicopathological factors, including histopathological characteristics of the tumour, diagnosis and prognosis was explored.   RESULTS:  Expression of H19 was lower in the PTC tissues (1.259 ± 1.15) compared to the BNT tissues (2.8347 ± 2.176) (p= 0.001). Low expression of H19 was associated with patient’s age, tumor size, extrathyroid extension, pathological lateral node metastasis (pN1b), histological aggressive type and poorer disease-free survival (p< 0.0001). The sensitivity for distinguishing PTC from benign was 81.3%. H19 was found to be an independent risk factor for extrathyroidal extension, lymph node metastasis.   CONCLUSIONS:  H19 may serve as a potential predictor of poor prognoses in patients with PTC."@en ;
    ns0:hasPubTitle "Long non-coding RNA H19 may be a marker for prediction of prognosis in the follow-up of patients with papillary thyroid cancer"@en .

ns1:ch-v71-i4-CH199002 ns0:hasKeywords "Blood fluidity"@en,
        "hemostasis"@en,
        "hypertensive disorders of pregnancy"@en,
        "obesity"@en,
        "preeclampsia"@en,
        "pregnancy"@en,
        "small for gestational age"@en ;
    ns0:hasPubAbstract "Physiological modifications of blood rheology during pregnancy and their alterations in pregnant hypertensive women have been extensively studied in the 1980’s. Since vascular resistance is higher in hypertensive pregnant women whose newborns are small-for gestational-age (SGA), we investigated in a personal database if growth retardation of newborns is related to the oxygen delivery index (ratio hematocrit/blood viscosity) and to the difference between hematocrit (Hct) and the prediction of its optimal valued based on Quemada’s equation. A sample of 38 hypertensive pregnant women (age 29 yr±1) was compared with 64 controls matched for age and gestational age, studied at 35±1 weeks gestation, extracted from a larger series of 162 pregnant women. On the whole the hypertensive group gave birth to smaller children (p = 0.014). Plasma viscosity correlated with blood pressure (BP) only in hypertensive women (r = 0.403 p < 0.05). The bell-shaped curve of predicted optimal Hct of non hypertensive pregnant women was similar to that of non-pregnant women, but in hypertensive women it was shifted toward higher values (p = 0.07), and the predicted optimal Hct (but not the actual one) was correlated with systolic blood pressure (SBP) (r = 0.349 p < 0.001) and diastolic blood pressure (DBP) (r = 0.218 p < 0.05). The predicted optimal Hct/viscosity (h/η) ratio was higher in hypertensive women whose newborns exhibited a low birth weight (p = 0.03), resulting in a higher discrepancy between actual and model-predicted «ideal» values of h/η ratio (p = 0.03) and Hct (p = 0.02) compared with the subgroup with no growth retardation. Therefore, in hypertensive women whose newborns exhibited a low birth weight, hemorheological parameters predicting oxygen supply are shifted to lower values than predicted by the model."@en ;
    ns0:hasPubTitle "Fetal growth retardation and hemorheological predictors of oxygen delivery in hypertensive vs normotensive pregnant women"@en .

ns1:ch-v71-i4-CH199004 ns0:hasKeywords "Degloving"@en,
        "avulsion"@en,
        "replantation"@en,
        "thumb"@en ;
    ns0:hasPubAbstract "BACKGROUND: Degloving injuries of the fingers and especially the thumb are highly demanding problems in hand surgery and replantation often is not successful because of severe soft tissue contusion. Only few cases of successfull replantation for hand degloving injuries in thumbs are reported in literature.   CASE PRESENTATION: We present the case of a young right hand dominant worker experiencing an occupational accident with a circumferential avulsion of his right thumbs‘ soft tissue at the level of the metacarpophalangeal (MCP) joint with complete skeletization of his thumb and a deep laceration of the nail bed as he got trapped in a machine. Bony structures and tendons remained intact corresponding Urbaniak class III/Kay class IV injury. Immediate defect coverage by replantation was performed. Additionally, a deep palmar soft tissue defect to his middle finger pulp and a laceration with disruption of his eighth finger nerve on his ring finger was adressed by revision, debridement, direct coaptation of the nerve and occlusive dressing to the middle finger. The patient regained full function and excellent cosmesis without nail deformity but only protective sensibility. He is back to his former sports and occupation.   CONCLUSIONS: Though sensitive outcome is poor we recommend primary attempt for defect coverage with replantation following degloving to achieve pliable skin coverage and good cosmesis. Especially in Urbaniak III cases with complete soft tissue degloving lacking fractures or tendon lacerations good functional outcome is possible but we recommend to consent the patient in advance for other reconstructive options and give them realistic exspectations in case of failure. Contrary to popular belief replantation of completely degloved fingers is more than saving nonfunctional parts as motivated patients are able to get back to previous sports and occupation after successful replantation."@en ;
    ns0:hasPubTitle "Replantation of a circumferentially degloved thumb in an occupational crush injury – A case report and review of the literature"@en .

ns1:ch-v71-i4-CH199007 ns0:hasKeywords "Amyloid beta peptide"@en,
        "PKC"@en,
        "RBC"@en,
        "atomic force microscopy"@en,
        "caspase 3"@en,
        "membrane roughness"@en,
        "nitric oxide synthase"@en ;
    ns0:hasPubAbstract "BACKGROUND: Circulating red blood cells (RBCs) undergo aging, a fundamental physiological phenomenon that regulates their turnover. Objective: Understanding the role of Aβ in the cross talk between cell signalling pathways and modulation of the cell structural and biomechanical properties occurring in RBCs during aging.   METHODS: The morphological pattern has been monitored using Atomic Force Microscopy (AFM) imaging and measuring the RBCs’ plasma membrane roughness employed as a morphological parameter capable to provide information on the structure and integrity of the membrane-skeleton.   RESULTS: We show that treatment with Aβ accelerates the occurrence of morphological and biochemical aging markers in human RBC and influences the cell metabolism. Biochemical data demonstrate that contemporaneously to morphological alterations, Aβ triggers: (i) metabolic alterations and (ii) a complex signaling pathway involving caspase 3, protein kinase C and nitric oxide derived metabolites.   CONCLUSIONS: our study provides a comprehensive picture in which Aβ treatment of RBC induces changes in specific cell signalling events and/or metabolic pathways, in turns affecting the membrane–cytoskeleton interaction and the membrane integrity."@en ;
    ns0:hasPubTitle "Amyloid β peptide affects erythrocyte morphology: Role of intracellular signaling pathways"@en .

ns1:ch-v72-i1-CH180434 ns0:hasKeywords "Diabetic nephropathy"@en,
        "RBC deformability"@en,
        "elongation index"@en,
        "hemorheology"@en ;
    ns0:hasPubAbstract "BACKGROUND AND OBJECTIVE: Hemorheologic alterations have been suggested to play a role in the pathogenesis of diabetic microvascular complications. We measured various hemorheologic parameters and assessed their possible role as a diagnostic tool for diabetic nephropathy (DN).   METHODS: 248 subjects with type 2 diabetes and 222 subjects with prediabetes were included in this study. Hemorheologic parameters, including erythrocyte sedimentation rate (ESR), elongation index at 3 Pa (EI) were measured using microfluidic hemorheometer. Various metabolic parameters were measured from fasting blood samples. The subjects were stratified into three groups according to classification of DN by urinary albumin to creatinine ratio (ACR) and four groups by estimated glomerular filtration rate (GFR), than analyzed.   RESULTS: Significant differences were observed in metabolic and hemorheologic parameters according to progression of DN. Among them, (Fibrinogen×ESR)/ EI differed in all three groups of urinary ACR. In multiple regression analysis, (Fibrinogen×ESR)/ EI was an independent predictor of urine ACR after adjusted with confounding factors (ß = 0.010, p < 0.001). (Fibrinogen×ESR)/ EI also showed significant difference no or minimal CKD stage, moderate CKD and severe CKD classified by GFR. This parameter showed area under curve (AUC) of the receiver operating characteristic (ROC) curve of 0.762, and moderate sensitivity and specificity to predict prevalence of microalbuminuria.   CONCLUSIONS: (Fibrinogen×ESR)/ EI is a sensitive parameter for screening diabetic nephropathy."@en ;
    ns0:hasPubTitle "Use of RBC deformability index as an early marker of diabetic nephropathy"@en .

ns1:ch-v72-i1-CH180454 ns0:hasKeywords "Contrast-enhanced ultrasound (CEUS)"@en,
        "cervical"@en,
        "cervical lymph node metastasis (CLNM)"@en,
        "fine needle aspiration (FNA)"@en,
        "papillary thyroid carcinoma (PTC)"@en ;
    ns0:hasPubAbstract "The objective of this research was to investigate the clinical value of contrast-enhanced ultrasound (CEUS) for prediction of cervical lymph node metastasis (CLNM) in papillary thyroid cancer (PTC). One hundred and eighty-six patients with PTC confirmed by fine needle aspiration (FNA) were preoperatively performed CEUS.A multivariate analysis was performed to predict CLNM by 15 independent variables. Receiver operating characteristic (ROC) curve analysis was used to evaluate the diagnostic performance. There were totally 37 patients with CLNM confirmed by pathology. Multivariate analysis demonstrated that intensity at peak time, capsule contact and size on CEUS were the three strongest independent predictors for CLNM. ROC analyses of these characteristics showed the areas under the curve (Az), sensitivity, and specificity were 0.650, 48.6 %, 79.8 %; 0.586, 67.6%, 49.7%; and 0.612, 56.8%, 64.4% for intensity at peak time, capsule contact, and size, respectively. The CEUS patterns of PTC are relative to not only the size of PTC but also the possibility of CLNM after thyroidectomy. CEUS seem to be a tool to predict CLNM in PTC patients."@en ;
    ns0:hasPubTitle "Predicting cervical lymph node metastasis in patients with papillary thyroid cancer (PTC) - Why contrast-enhanced ultrasound (CEUS) was performed before thyroidectomy"@en .

ns1:ch-v72-i2-CH180515 ns0:hasKeywords "CSVD"@en,
        "TLR4/NF-κB"@en,
        "cognitive impairment"@en ;
    ns0:hasPubAbstract "OBJECTIVE:  To investigate the role and potential mechanism of Toll-like receptor 4 (TLR4)/nuclear factor-kappa B (NF-κB) signaling pathway in cognitive impairment induced by cerebral small vascular disease (CSVD), so as to provide a reference for the clinical treatment of CSVD-induced cognitive impairment.  METHODS:  Mice with TLR4 gene knockout (n = 20) and those with wild-type TLR4 gene (n = 40) aged 8–10 weeks old were divided into blank control group (Control group, n = 20), wild-type + CSVD group (WT + CSVD group, n = 20) and TLR4 gene knockout + CSVD group (TLR4 KO + CSVD group, n = 20). Allogeneic thrombosis (particle diameter: 50–70 mm) was injected to the mouse’s external carotid artery to create a model of learning and memory dysfunction. Step-down test and Y-type maze test were utilized to examine the learning and memory abilities of the mice. Reverse transcription-polymerase chain reaction (RT-PCR) and immunoblotting techniques were adopted to measure the levels of apoptosis-related genes [B-cell lymphoma/leukemia-2 (Bcl-2), Bcl-2-associated X protein (Bax), C-caspase-3 and T-caspase-3] in the brain tissues of mice. Terminal dexynucleotidyl transferase (TdT)-mediated dUTP nick end labeling (TUNEL) method was applied to detect the apoptosis of neuronal cells in the brain tissues. Meanwhile, the levels of oxidative stress markers, including superoxide dismutase (SOD), gp91 and malondialdehyde (MDA), were measured. Finally, the expression level of TLR4/NF-κB pathway was detected.  RESULTS:  The latency in the step-down test in the WT + CSVD group was remarkably longer than that in the Control group, and the number of errors was evidently larger than that in the Control group (p < 0.05). At the same time, in the WT + CSVD group, the expression levels of pro-apoptotic genes Bax and C-caspase-3 were up-regulated markedly, while the expression level of anti-apoptotic gene Bcl-2 declined notably (p < 0.05). TUNEL results showed that the number of apoptotic cells in the brain tissues in the WT + CSVD group was about 12 times that in the Control group (p < 0.05). Meanwhile, the SOD expression level was lowered, and the MDA expression level was elevated in the brain tissues in the WT + CSVD group. In addition, the TLR4/NF-κB pathway was prominently activated in the mice in the WT + CSVD group (p < 0.05). After TLR4 gene knockout, the cognitive functions of the mice were improved markedly, and the apoptosis of neuronal cells and oxidative stress in the brain tissues were suppressed significantly in the meantime. Moreover, the activation of the TLR4/NF-κB signaling pathway was also inhibited.  CONCLUSION:  The TLR4/NF-κB pathway is involved in the occurrence and development of CSVD-induced cognitive impairment through regulating oxidative stress and cell apoptosis."@en ;
    ns0:hasPubTitle "A study on role and mechanism of TLR4/NF-κB pathway in cognitive impairment induced by cerebral small vascular disease"@en .

ns1:ch-v72-i3-CH180477 ns0:hasKeywords "Ultrasound"@en,
        "elastography"@en,
        "thyroid imaging reporting and data system"@en,
        "thyroid nodule"@en,
        "virtual touch tissue imaging and quantification"@en ;
    ns0:hasPubAbstract "OBJECTIVE: This study was conducted to investigate the diagnostic performance of Virtual Touch Tissue Imaging and Quantification (VTIQ), combined with the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) in differentiating malignant and benign thyroid nodules.   METHODS: A total of 130 thyroid nodules in 128 patients were included. The diagnostic performance of conventional ultrasound (US), VTIQ, and the combination of these two techniques was calculated and compared according to the area under the receiver operating characteristic curve (AUROC), for sensitivity, specificity, and accuracy.   RESULTS: The sensitivity and specificity for the ACR TI-RADS were 98.6% (72/73) and 24.6% (14/57), respectively. There was a strong agreement with ACR TI-RADS categories of thyroid nodules (all ICCs > 0.60). With an optimal cutoff value of 2.46 m/s, the sensitivity and specificity of the minimal shear wave velocity (SWVmin) were 87.7% (64/73) and 70.2% (40/57). By applying this value to downgrade or upgrade ACR TI-RADS, the specificity significantly increased from 24.6% (14/57) to 47.4% (27/57; P < 0.05) and the sensitivity remained at 98.6% (72/73).   CONCLUSIONS: VTIQ combined with ACR TI-RADS could improve the specificity of the differential diagnosis of thyroid nodules without a loss of sensitivity."@en ;
    ns0:hasPubTitle "Virtual Touch Tissue Imaging and Quantification (VTIQ) combined with the American College of Radiology Thyroid Imaging Reporting and Data System (ACR TI-RADS) for malignancy risk stratification of thyroid nodules"@en .

ns1:ch-v72-i3-CH180531 ns0:hasKeywords "Three-dimensional"@en,
        "contrast-enhanced ultrasound"@en,
        "focal liver lesion"@en,
        "two-dimensional"@en ;
    ns0:hasPubAbstract "BACKGROUND: Dynamic three-dimensional contrast-enhanced ultrasound (3D-CEUS) with quantitative analysis is updated in recent years.   OBJECTIVE: To explore the feasibility of dynamic 3D-CEUS in evaluation of dynamic vascular patterns of focal liver lesions (FLL), and to analyze the correlation of time-intensity curve (TIC) parameters between dynamic 3D-CEUS and two-dimensional CEUS (2D-CEUS).   METHODS: Dynamic 3D-CEUS and 2D-CEUS were both carried out in 106 FLL cases with SonoVue. Divided into arterial, portal and late phases, dynamic 3D-CEUS image quality of 106 FLLs were scored by 2 readers separately and graded according to the overall score. The 2D-CEUS and identical 3D-CEUS TIC parameters of the same FLL were compared and the correlation of these parameters were analyzed.   RESULTS: A satisfactory correlation (0.953) and a good inter-observer agreement (0.700) of 2 readers were achieved by using five-point score scale to image quality in 3 phases of dynamic 3D-CEUS. The boundaries of FLLs were clearest in arterial phase on dynamic 3D-CEUS. The depth and vascularization of FLLs only had influence on its image quality in only arterial phase (P = 0.002 and 0.000 respectively). The comparison of quantification between dynamic 3D-CEUS and 2D-CEUS of 56 FLLs were also underwent. Interclass correlation coefficient (ICC) of mean transit time (MTT) and time to peak (TP), were both 0.96, and Pearson correlation coefficients of all 5 TIC parameters were no less than 0.90 between dynamic 3D-CEUS and 2D-CEUS.   CONCLUSION: Dynamic 3D-CEUS is technically feasible and can be used for clinical evaluation of the perfusion of FLL avoiding adverse factors of sampling. Quantitative 3D-CEUS parameters are stable and reliable, and have good correlation with those of 2D-CEUS."@en ;
    ns0:hasPubTitle "Feasibility of dynamic three-dimensional contrast-enhanced ultrasound in focal liver lesions: Image quality evaluation and correlation of quantification with two-dimensional contrast-enhanced ultrasound"@en .

ns1:ch-v72-i4-CH180540 ns0:hasKeywords "Cardiovascular stent"@en,
        "blood viscosity"@en,
        "lysis"@en,
        "red blood cell aggregation"@en,
        "red blood cell deformability"@en ;
    ns0:hasPubAbstract "Despite their wide clinical usage, stent functionality may be compromised by complications at the site of implantation, including early/late stent thrombosis and occlusion. Although several studies have described the effect of fluid-structure interaction on local haemodynamics, there is yet limited information on the effect of the stent presence on specific hemorheological parameters. The current work investigates the red blood cell (RBC) mechanical behavior and physiological changes as a result of flow through stented vessels. Blood samples from healthy volunteers were prepared as RBC suspensions in plasma and in phosphate buffer saline at 45% haematocrit. Self-expanding nitinol stents were inserted in clear perfluoroalkoxy alkane tubing which was connected to a syringe, and integrated in a syringe pump. The samples were tested at flow rates of 17.5, 35 and 70 ml/min, and control tests were performed in non-stented vessels. For each flow rate, the sample viscosity, RBC aggregation and deformability, and RBC lysis were estimated. The results indicate that the presence of a stent in a vessel has an influence on the hemorheological characteristics of blood. The viscosity of all samples increases slightly with the increase of the flow rate and exposure. RBC aggregation and elongation index (EI) decrease as the flow rate and exposure increases. RBC lysis for the extreme cases is evident. The results indicate that the stresses developed in the stent area for the extreme conditions could be sufficiently high to influence the integrity of the RBC membrane."@en ;
    ns0:hasPubTitle "The effects of stenting on hemorheological parameters: An in vitro investigation under various blood flow conditions"@en .

ns1:ch-v72-i4-CH180544 ns0:hasKeywords "Vascular autonomization"@en,
        "free flaps"@en,
        "indocyanine green angiography"@en,
        "microcirculation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Free tissue transfer has become a routine procedure with low failure. In case of a compromised vascular pedicle, flap survival is time dependantly possible due to flap autonomization. However it remains unknown at what time and to which degree different factors influence flap autonomization.   METHODS: We investigated 16 patients after free flap reconstruction at different anatomic locations who eventually presented for other medical reasons. To assess the perfusion pattern we performed Indocyanine Green angiography.   RESULTS: The mean follow-up after free flap reconstruction was 58,1 month. A total of 16 flaps were examined at different anatomic locations. In 2 cases digital subtraction angiography demonstrated an occlusion of the anastomosis after arteriovenous loop despite vital flaps. Indocyanine Green angiography showed no signs of mal-perfusion or non-perfusion in the transplanted flaps and capillaries across the flap borders in 9 cases.   CONCLUSION: Flap autonomization is possible even in patients with problem wounds and poorly vascularized wound beds independent from the anatomic localization. Multiple factors exist, that influence the autonomization process over time. Indocyanine Green angiography seems to be a promising tool to visualize and study the skin perfusion pattern of free flaps over longer periods."@en ;
    ns0:hasPubTitle "Indocyanine green angiography and the old question of vascular autonomy – Long term changes of microcirculation in microsurgically transplanted free flaps"@en .

ns1:ch-v73-i1-CH199208 ns0:hasKeywords "Artificial extracellular matrices"@en,
        "[18F]fluoride"@en,
        "[18F]fluorodeoxyglucose"@en,
        "bone healing"@en,
        "glycosaminoglycans"@en,
        "inflammation"@en,
        "metabolism"@en,
        "molecular imaging"@en,
        "revascularization"@en ;
    ns0:hasPubAbstract "Biomaterials coated with artificial extracellular matrices (aECM) are intended to support the healing of critical size bone defects. This pilot study investigated (i) the feasibility of dual-tracer PET/CT imaging for functional characterization of biomaterial-assisted bone healing in a rat femoral defect model and (ii) the bone healing ability of polycaprolactone-co-lactide (PCL) scaffolds, coated with various aECM consisting of collagen type I (Col) and glycosaminoglycans (GAGs) such as chondroitin sulfate (CS) or polysulfated hyaluronan (sHA3). [18F]FDG and [18F]fluoride PET 4 and 8 weeks after implantation of aECM-coated PCL scaffolds, which provide an in vivo measure of cellular activation and bone mineralization, respectively, combined with CT imaging (in vivo/ex vivo) and histological/immunohistochemical investigations (ex vivo) showed that coating with CS in particular is beneficial for bone healing. The possible involvement of COX-2 and TGase 2, key enzymes of inflammation and ECM remodeling, in these processes offers starting points for targeted adjuvant therapy in the course of various bone healing phases. Our investigations show the feasibility of the selected dual-tracer approach for PET/CT imaging. In principle, this approach can be extended by further PET tracers for the functional characterization of physiological processes such as hypoxia/reperfusion or selected molecular players."@en ;
    ns0:hasPubTitle "Biomaterials in repairing rat femoral defects: In vivo insights from small animal positron emission tomography/computed tomography (PET/CT) studies"@en .

ns1:ch-v73-i1-CH199209 ns0:hasKeywords "Microplastic"@en,
        "extraction method"@en,
        "human tissue"@en,
        "microparticel"@en ;
    ns0:hasPubAbstract "INTRODUCTION: Since the beginning of industrial production in 1950, plastic production has continued to grow strongly worldwide and is now at 322 million tonnes in the year 2015. From these very high production volumes ever larger quantities are found in the environment. There the plastics degradate to microplasticity and spread ubiquitously in the world. The present work deals with the possible uptake of microplastic particles in human organisms. For the detection of these plastic particles, an extraction method was developed and validated.   MATERIALS AND METHODS: Biological materials consist of human blood (healthy volunteers, n = 4) and different tissues of pigs and cattles. Various lysis solutions were tested for degradation efficiency of biological material and for effects on the plastics. The mass loss, surfaces and structure variations as well as the physicochemical spectrum of the material were observed after treatment by atomic force (AFM) and electron microscopy (EM) and Fourier transform infrared spectrometry (FTIR).   RESULTS: The different plastic types as polyamide (PA), polycarbonate (PC), polyethylene (PE), polypropylene (PP), polystyrene (PS) and polyvinyl chloride (PVC) could be clearly differentiated and identified by FTIR. Regarding the surface control, especially PVC showed detectable alterations: After extraction an irregular surface structure caused by protuberances or bubbles could be observed. However, instead of these alterations an equivalent count of plastic particles was found in correlation to the applied plastic amount (recovery rate overall was 99,12±0,67%).   CONCLUSION: The applied method can be used for plastic extractions from human or animal tissues without remarkable effects on the plastics."@en ;
    ns0:hasPubTitle "Validation of an extraction method for microplastics from human materials"@en .

ns1:ch-v73-i1-CH199214 ns0:hasKeywords "Endothelium"@en,
        "acute coronary syndromes"@en,
        "stent"@en,
        "thrombosis"@en ;
    ns0:hasPubAbstract "Percutaneous coronary intervention is the most often used method for coronary revascularization. Stenting restores blood perfusion to ischemic areas, but it also causes mechanical disruption of the atheromatous plaque and the nearby endothelium, stimulating the activation of platelets. In a similar way, platelets are activated by thrombin exposure in the setting of plaque rupture. The interaction between platelets, oxidative stress and inflammation is an important factor determining the extent and severity of vascular dysfunction observed in these settings. Platelets activated by the vessel trauma release inflammatory and mitogenic mediators into the vascular microenvironment, activating leukocyte chemotaxis and switching the endothelial phenotypefrom a quiescent to an activate one. The increased bioavailability of reactive oxygen species from the vessel wall, from leukocytes and from platelets, and the subsequent decreased bioavailability of nitric oxide, further stimulates platelets, which are otherwise inhibited by this endothelial mediator. Thus, inflammation, oxidative stress and platelet activation cooperate in a feed-forward mechanism leading to vascular dysfunction and possibly compromising the effect of stenting. Inhibitors of platelet function have thus important ancillary effects beyond their antithrombotic ones, which will be discussed in the present short review."@en ;
    ns0:hasPubTitle "The pleiotropic effects of antiplatelet therapies"@en .

ns1:ch-v73-i1-CH199215 ns0:hasKeywords "Hyperspectral imaging"@en,
        "perfusion imaging"@en,
        "screening"@en,
        "skin microcirculation"@en,
        "vascular surgery"@en ;
    ns0:hasPubAbstract "BACKGROUND: Objective, reliable and easy screening for peripheral artery disease (PAD) is essential to confirm the diagnosis and initiate the respective treatment. Therefore, a new non-invasive hyperspectral camera (TIVITA® Tissue) was tested in patients with and without PAD.   OBJECTIVE: It was hypothesized that the oxygenation parameters of the TIVITA® Tissue correlate to established modalities for detection of PAD and allow differentiation between individuals with and without PAD.   METHODS: Evaluation of tissue oxygenation was performed in the angiosome of the medial plantar artery in 25 healthy young people and in 24 patients with and 25 patients without PAD in comparable age. Thereby, superficial oxygenation (StO2) and near-infrared (NIR) perfusion index were measured with the TIVITA® Tissue. Additionally, the ankle-brachial-index (ABI), the complaint free walking distance and the vascular quality of life were assessed and demographic data were obtained from all participants.   RESULTS: TIVITA® Tissue analysis revealed significantly reduced StO2 and NIR perfusion index in PAD compared to healthy young participants and patients without PAD. StO2 and NIR perfusion index positively correlated with ABI, the complaint free walking distance and the vascular quality of life score.   CONCLUSIONS: In summary, this new hyperspectral imaging camera bears great potential for PAD screening as well as for follow up."@en ;
    ns0:hasPubTitle "Evaluation of peripheral artery disease with the TIVITA® Tissue hyperspectral imaging camera system"@en .

ns1:com-v8-i3-4-COM093 ns0:hasKeywords "Splitting"@en,
        "computably enumerable set"@en,
        "domination"@en,
        "low"@en,
        "non-uniformity"@en ;
    ns0:hasPubAbstract "We prove that if A is a non-low c.e. set, then there exists noncomputable sets    A   1   ⊔   A   2   = A splitting A with    A   1   non-low."@en ;
    ns0:hasPubTitle "Splitting theorems and low degrees"@en .

ns1:com-v8-i3-4-COM094 ns0:hasKeywords "Hindman’s Theorem"@en,
        "Lovász Local Lemma"@en,
        "Reverse mathematics"@en ;
    ns0:hasPubAbstract "Hindman’s Theorem (HT) states that for every coloring of  N with finitely many colors, there is an infinite set  H ⊆ N such that all nonempty sums of distinct elements of H have the same color. The investigation of restricted versions of HT from the computability-theoretic and reverse-mathematical perspectives has been a productive line of research recently. In particular,    HT   k   ⩽ n   is the restriction of HT to sums of at most n many elements, with at most k colors allowed, and    HT   k   = n   is the restriction of HT to sums of exactly n many elements and k colors. Even    HT   2   ⩽ 2   appears to be a strong principle, and may even imply HT itself over RCA0. In contrast,    HT   2   = 2   is known to be strictly weaker than HT over RCA0, since    HT   2   = 2   follows immediately from Ramsey’s Theorem for 2-colorings of pairs. In fact, it was open for several years whether    HT   2   = 2   is computably true. We show that    HT   2   = 2   and similar results with addition replaced by subtraction and other operations are not provable in RCA0, or even WKL0. In fact, we show that there is a computable instance of    HT   2   = 2   such that all solutions can compute a function that is diagonally noncomputable relative to    ∅   ′  . It follows that there is a computable instance of    HT   2   = 2   with no    Σ   2   0   solution, which is the best possible result with respect to the arithmetical hierarchy. Furthermore, a careful analysis of the proof of the result above about solutions DNC relative to    ∅   ′   shows that    HT   2   = 2   implies    RRT   2   2  , the Rainbow Ramsey Theorem for colorings of pairs for which there are most two pairs with each color, over RCA0. The most interesting aspect of our construction of computable colorings as above is the use of an effective version of the Lovász Local Lemma due to Rumyantsev and Shen."@en ;
    ns0:hasPubTitle "The reverse mathematics of Hindman’s Theorem for sums of exactly two elements"@en .

ns1:com-v8-i3-4-COM099 ns0:hasKeywords "Borel reducibility"@en,
        "computable structure theory"@en,
        "p-groups"@en ;
    ns0:hasPubAbstract "The class of Abelian p-groups are an example of some very interesting phenomena in computable structure theory. We will give an elementary first-order theory    T   p   whose models are each bi-interpretable with the disjoint union of an Abelian p-group and a pure set (and so that every Abelian p-group is bi-interpretable with a model of    T   p  ) using computable infinitary formulas. This answers a question of Knight by giving an example of an elementary first-order theory of “Ulm type”: Any two models, low for    ω   1   C K  , and with the same computable infinitary theory, are isomorphic. It also gives a new example of an elementary first-order theory whose isomorphism problem is    Σ   1   1  -complete but not Borel complete."@en ;
    ns0:hasPubTitle "A first-order theory of Ulm type"@en .

ns1:com-v8-i3-4-COM101 ns0:hasKeywords "Random structures"@en,
        "degree of a structure"@en,
        "random groups"@en,
        "word problem"@en ;
    ns0:hasPubAbstract "In this paper we study various properties of algorithmically random infinite structures. Our results address the following questions. How would one define algorithmic randomness for infinite structures? Could algorithmically random structures be computable? What are the similarities and differences between algorithmically random structures and algorithmically random infinite strings? What are the possible Turing degrees of algorithmically random structures? Are there algorithmically random infinite groups? For instance, we prove the following in this paper: (1) there are classes which contain algorithmically random yet computable structures, (2) there exist algorithmically random universal algebras with co-computably enumerable as well as computably enumerable word problems, (3) there are natural classes of structures in which the Turing degrees of algorithmically random structures can only be either computable or equivalent to the halting set, and (4) there are examples of algorithmically random groups. The first result shows a dramatic difference between algorithmically random strings and algorithmically random structures. The second result significantly improves the known theorem that algorithmically random structures computable in the halting set exist; these examples of algebras are sharp in terms of arithmetical hierarchy of the word problem for random algebras. The third result is a dichotomy theorem that characterises all possible Turing degrees of algorithmically random structures. Finally, the fourth result answers a nontrivial open question about the existence of algorithmically random groups."@en ;
    ns0:hasPubTitle "Effective aspects of algorithmically random structures"@en .

ns1:com-v8-i3-4-COM180207 ns0:hasKeywords "Projection operators"@en,
        "Weihrauch degrees"@en,
        "computable analysis"@en ;
    ns0:hasPubAbstract "In this paper we study, for  n ⩾ 1, the projection operators over    R   n  , that is the multi-valued functions that associate to  x ∈   R   n   and  A ⊆   R   n   closed, the points of A which are closest to x. We also deal with approximate projections, where we content ourselves with points of A which are almost the closest to x. We use the tools of Weihrauch reducibility to classify these operators depending on the representation of A and the dimension n. It turns out that, depending on the representation of the closed sets and the dimension of the space, the projection and approximate projection operators characterize some of the most fundamental computational classes in the Weihrauch lattice."@en ;
    ns0:hasPubTitle "Projection operators in the Weihrauch lattice"@en .

ns1:dev-v13-i1-2-DEV180249 ns0:hasKeywords "Multiple attachment relationships"@en,
        "adolescence"@en,
        "bullying"@en,
        "teacher-student-interaction"@en ;
    ns0:hasPubAbstract "The present study sought to examine the independent, hierarchical, and integrative models of multiple attachment relationships in a sample of Greek-Cypriots in middle adolescence and to test the distinct and interactive effects of these relationships on bullying involvement. A sample of Greek-Cypriot adolescents (N = 406, 55.4% females, Mage = 16.01, SD = 0.82) completed the Greek forms of the Revised Olweus Bully-Victim Questionnaire (BVQ-R), the Inventory of Parental and Peer Attachment (IPPA), and the Questionnaire on Teacher Interaction (QTI). Path models were used to test for the effect of multiple attachment relationships on bullying and victimization, using AMOS 24.0.The integrative model of multiple attachment relationships was supported and found to have significant effects on bullying involvement. The effect of the quality of the mother-adolescent relationship on bullying involvement was fully mediated by the quality of the attachment relationships with peers and the interpersonal relationship with teachers. The quality of adolescents’ relationship with teachers affected their interactions with peers, and not the opposite, though both continued to have distinct effects on bullying involvement."@en ;
    ns0:hasPubTitle "The Integrative Model of Multiple Attachment Relationships in Adolescence: Linkages to Bullying and Victimization"@en .

ns1:dev-v13-i1-2-DEV190266 ns0:hasKeywords "Emotion socialization"@en,
        "coping"@en,
        "emerging adulthood"@en,
        "internalizing problems"@en,
        "late adolescence"@en ;
    ns0:hasPubAbstract "This study examined coping strategies as mediators of the relationship between parental emotion socialization and internalizing problems in late adolescence and emerging adulthood, and whether these relationships varied by gender or ethnicity. Participants were 1,087 individuals (Mage = 19.35 years; 50% male; 61% African American, 36% European American). Results from structural equation modeling indicated that parental supportive responses to sadness and fear were associated with less emotional distress, and this relationship was partly mediated by greater use of task-oriented coping and lower use of emotion-oriented coping. Parental unsupportive responses were related to greater emotional distress, and this relationship was fully mediated by greater use of emotion-oriented coping. Gender and ethnic differences emerged in the links between parental responses and several coping strategies. The findings suggest that parental emotion socialization may contribute to emotional functioning by fostering specific coping strategies, with some differences across gender and ethnicity."@en ;
    ns0:hasPubTitle "Emotion Socialization and Internalizing Problems in Late Adolescence and Emerging Adulthood: Coping Styles as Mediators"@en .

ns1:ds-v2-i1-2-DS190016A ns0:hasKeywords "COCI"@en,
        "OCC"@en,
        "OSCAR"@en,
        "OpenCitations"@en,
        "SPARQL"@en,
        "advanced search"@en,
        "free-text search"@en,
        "scholarly data"@en ;
    ns0:hasPubAbstract "In this paper we introduce the latest version (Version 2.0) of OSCAR, the OpenCitations RDF Search Application, which has several improved features and extends the query workflow comparing with the previous version (Version 1.0) that we presented at the workshop entitled Semantics, Analytics, Visualisation: Enhancing Scholarly Dissemination (SAVE-SD 2018), held in conjunction with The Web Conference 2018. OSCAR is a user-friendly search platform that can be used to search any RDF triplestore providing a SPARQL endpoint, while hiding the complexities of SPARQL, thus making the search operations accessible to those who are not experts in Semantic Web technologies. We present here the basic features and the main extensions of this latest version of OSCAR. In addition, we demonstrate how it can be adapted to work with different SPARQL endpoints containing scholarly data, using as examples the OpenCitations Corpus (OCC) and the OpenCitations Index of Crossref open DOI-to-DOI citations (COCI), both provided by OpenCitations, and also the Wikidata dataset provided by the Wikimedia Foundation. We conclude by reporting the usage statistics of OSCAR, retrieved from the OpenCitations website logs, so as to demonstrate its uptake."@en ;
    ns0:hasPubTitle "Enabling text search on SPARQL endpoints through OSCAR"@en .

ns1:ds-v2-i1-2-DS190019 ns0:hasKeywords "Systematic reviews"@en,
        "digital libraries"@en,
        "ontology learning"@en,
        "semantic web"@en,
        "software architecture"@en,
        "software engineering"@en ;
    ns0:hasPubAbstract "Context: Systematic Reviews (SRs) are means for collecting and synthesizing evidence from the identification and analysis of relevant studies from multiple sources. To this aim, they use a well-defined methodology meant to mitigate the risks of biases and ensure repeatability for later updates. SRs, however, involve significant effort.   Goal: The goal of this paper is to introduce a novel methodology that reduces the amount of manual tedious tasks involved in SRs while taking advantage of the value provided by human expertise.   Method: Starting from current methodologies for SRs, we replaced the steps of keywording and data extraction with an automatic methodology for generating a domain ontology and classifying the primary studies. This methodology has been applied in the Software Engineering sub-area of Software Architecture and evaluated by human annotators.   Results: The result is a novel Expert-Driven Automatic Methodology, EDAM, for assisting researchers in performing SRs. EDAM combines ontology-learning techniques and semantic technologies with the human-in-the-loop. The first (thanks to automation) fosters scalability, objectivity, reproducibility and granularity of the studies; the second allows tailoring to the specific focus of the study at hand and knowledge reuse from domain experts. We evaluated EDAM on the field of Software Architecture against six senior researchers. As a result, we found that the performance of the senior researchers in classifying papers was not statistically significantly different from EDAM.   Conclusions: Thanks to automation of the less-creative steps in SRs, our methodology allows researchers to skip the tedious tasks of keywording and manually classifying primary studies, thus freeing effort for the analysis and the discussion."@en ;
    ns0:hasPubTitle "Reducing the effort for systematic reviews in software engineering"@en .

ns1:efi-v35-i2-EFI190268 ns0:hasKeywords "Library and information science education"@en,
        "higher education"@en,
        "learning"@en,
        "pedagogical innovation"@en,
        "study programme"@en,
        "teaching"@en ;
    ns0:hasPubAbstract "The information disciplines are rapidly developing and that development brings twofold challenge for library and information science (LIS) education; in terms of delivering the content, and in terms of the content itself. The former means that, as with any other discipline, it needs to implement new technologies and didactic approaches to provide its students with better learning experiences, greater retention of knowledge, and skills for rapidly changing and challenging labour market. The latter means that LIS education needs to train its students to understand how technical and social changes affect diverse information ecologies and successfully work in such environments. To address these ideas this paper aims to investigate how trends in LIS education are identified, implemented and evaluated in the LIS study programmes, both in terms of technology used for teaching, and in terms of teaching methods. The methodology used to address the research questions and objectives consisted of a literature review of the topic, a content analysis of LIS curricula from a sample of eight European universities that offer education in the LIS field, and an interview study with programme directors from the respective universities. The results have shown that there is a strong and positive culture of innovation in the LIS field that derives from the identity of the discipline and its natural inclination towards responding promptly to social and technical changes. Diverse didactic methods are applied in the analysed study programmes with an aim to offer a more flexible, authentic and individually tailored learning experience. There are obstacles in implementing innovations, and they usually arise from a mismatch between efforts to innovate and how university policies and procedure support those efforts. Another significant obstacle is the general learning culture of a country."@en ;
    ns0:hasPubTitle "Didactic trends in LIS education and their reflection in curricula design"@en .

ns1:efi-v35-i3-EFI190289 ns0:hasKeywords "MOOC"@en,
        "MetroTeach"@en,
        "Visual learning"@en,
        "instructional design method"@en,
        "metro map metaphor"@en ;
    ns0:hasPubAbstract "Currently, modelling of knowledge and skills in a MOOC and the associated instructional and pedagogical engineering process is a major challenge in order to support designers and facilitate learning. This article explains how visuo-cognitive metaphors of the “metro map” and “travel” make possible the design of connections between the representation of knowledge and learning. The researcher can measure this approach in a double movement: topography to topology (from visual-spatial experience to cognitive change) and topology to topography (from metaphor to artifact design). Our reflections focus first on the application of Lakoff and Johnson’s conceptual metaphor theory in learning, as well as on the contributions of the Loci method on cognition. These theories and the results of previous work have shown the interest of the metro map metaphor in the Computer Environment for Human Learning (EIAH in French), which we have implemented in our ©Metroteach model with the Design-Based Research method. Recent studies have revealed a heterogeneity of MOOC devices and a lack of application of instructional engineering principles. We therefore pose these questions again by proposing a model of the MetroTeach system. This will allow us to rethink the ontological dimensions of MOOCs and their legitimate status as a research object."@en ;
    ns0:hasPubTitle "MetroTeach: Modelling of knowledge and skills in a MOOC with the visuo-cognitive metaphor of the metro map"@en .

ns1:fi-v167-i3-FI1816 ns0:hasKeywords "Formal Concept"@en,
        "Formal Concept Analysis"@en,
        "Granular Set"@en,
        "Lattice"@en,
        "Rough Set"@en,
        "Rough Set Theory"@en ;
    ns0:hasPubAbstract "The paper is aimed at comparing Rough Set Theory (RST) and Formal Concept Analysis (FCA) with respect to algebraic structures of concepts appearing in both theories, namely algebras of definable sets and concept lattices. The paper presents also basic ideas and concepts of RST and FCA together with some set theoretical concepts connected with set spaces which can serve as a convenient platform for a comparison of RST and FCA. In the last section there are shown necessary and sufficient conditions for the fact, that families of definable sets and concept extents determined by the same formal contexts are equal . This in finite cases is equivalent to an isomorphism of respective structures and generally reflects a very specific situation when both theories give the same conceptual hierarchies."@en ;
    ns0:hasPubTitle "Algebras of Definable Sets vs. Concept Lattices"@en .

ns1:fi-v167-i4-FI1819 ns0:hasKeywords "Cylindric Set Algebra"@en,
        "Incomplete Information"@en,
        "Query Languages"@en,
        "Relational Algebra"@en ;
    ns0:hasPubAbstract "Incomplete Information research is quite mature when it comes to so called existential nulls, where an existential null is a value stored in the database, representing an unknown object. For some reason universal nulls, that is, values representing all possible objects, have received almost no attention. We remedy the situation in this paper, by showing that a suitable finite representation mechanism, called Star Cylinders, handling universal nulls can be developed based on the Cylindric Set Algebra of Henkin, Monk and Tarski. We provide a finitary version of the cylindric set algebra, called Cylindric Star Algebra, and show that our star-cylinders are closed under this algebra. Moreover, we show that any First Order Relational Calculus query over databases containing universal nulls can be translated into an equivalent expression in our cylindric star-algebra, and vice versa. All cylindric star-algebra expressions can be evaluated in time polynomial in the size of the database. The representation mechanism is then extended to Naive Star Cylinders, which are star-cylinders allowing existential nulls in addition to universal nulls. For positive queries (with universal quantification), the well known naive evaluation technique can still be applied on the existential nulls, thereby allowing polynomial time evaluation of certain answers on databases containing both universal and existential nulls. If precise answers are required, certain answer evaluation with universal and existential nulls remains in coNP. Note that the problem is coNP-hard, already for positive existential queries and databases with only existential nulls. If inequalities ¬(xi ≈ xj) are allowed, reasoning over existential databases is known to be    ∏ 2 p    -complete, and it remains in    ∏ 2 p     when universal nulls and full first order queries are allowed."@en ;
    ns0:hasPubTitle "Universal (and Existential) Nulls"@en .

ns1:fi-v167-i4-FI1820 ns0:hasKeywords "Interval Temporal Logic"@en,
        "Petri nets"@en,
        "box algebra"@en,
        "composition"@en,
        "equivalence"@en,
        "general synchronisation"@en,
        "semantics"@en,
        "step sequence"@en ;
    ns0:hasPubAbstract "In this paper, we further develop a recently introduced semantic link between temporal logics and Petri nets. We focus on two specific formalisms, Interval Temporal Logic (ITL) and Box Algebra (BA), which are closely related by their compositional approach to constructing system descriptions. The overall goal of our investigation is to translate Petri nets into behaviourally equivalent logical formulas. As a result, the analysis of system properties can be carried out using either of the two formalisms, exploiting their respective strengths and powerful tool support. The contribution of this paper is twofold. First, we extend the existing translation from BA to ITL, by removing restrictions concerning the way control flow of concurrent system is modelled, and by allowing a fully general synchronisation operator. Second, we strengthen the notion of equivalence between a Petri net and the corresponding logical formula by proving such an equivalence at the level of transition-based executions of Petri nets rather than just by looking at their labels. We also show that the complexity of the proposed translation compares favourably with the complexity of the translation from BA expressions to Petri nets."@en ;
    ns0:hasPubTitle "From Box Algebra to Interval Temporal Logic"@en .

ns1:fi-v168-i1-FI1821 ns0:hasKeywords "Bio-inspired computing"@en,
        "Cell-like P system"@en,
        "Channel state"@en,
        "Flat maximal parallelism"@en,
        "Membrane computing"@en,
        "Symport/antiport rule"@en ;
    ns0:hasPubAbstract "Communication P systems with channel states (CC P systems, for short) are a class of distributed parallel computing models, where communication (symport/antiport) rules associated with channel states are executed in a sequential manner on membrane channels. In this work, communication P systems with channel states working in flat maximally parallel manner are considered and the computational power is investigated. Specifically, it is proved that communication P systems with channel states using symport rules of length two are Turing universal when having one membrane and any number of channel states, or two membranes and three channel states. Furthermore, membrane division is introduced into communication P systems with channel states, communication P systems with channel states and membrane division (CCD P systems, for short) are proposed. We provide a uniform solution to the Hamiltonian path problem (HPP) by CCD P systems working in a flat maximally parallel manner."@en ;
    ns0:hasPubTitle "Communication P Systems with Channel States Working in Flat Maximally Parallel Manner"@en .

ns1:fi-v168-i2-4-FI1830 ns0:hasKeywords "center loss"@en,
        "cerebral microbleeds"@en,
        "convolution neural network"@en,
        "discriminative feature learning"@en ;
    ns0:hasPubAbstract "The existence and distribution pattern of cerebral microbleeds (CMBs) are associated with some underlying aetiologies caused by intra-cerebral hemorrhage (ICH). CMBs as a kind of subclinical sign can be recognized via magnetic resonance (MR) imaging technique in a few years before the onset of the disease. Hence, detecting CMBs accurately is important for treating and preventing related cerebral disease. In this study, we employed convolution neural network (CNN) for CMBs detection because of its powerful ability in image recognition. In view of too many efforts on optimizing the structure of CNN for achieving a better performance, we introduced center loss, which can greatly enhance the discriminative power of the deeply learned features, to CMBs detection for the first time. It is found that the performances of convolution neural network (CNN) trained under the joint supervision of softmax loss and center loss were significantly better than that under the supervision of softmax loss, even if there are few mislabelled samples in training data. With this trick, we achieved a high performance with a sensitivity of 98.869 ± 1.026%, a specificity of 96.491 ± 0.367%, and an accuracy of 97.681 ± 0.497%, which is better than four state-of-the-art methods."@en ;
    ns0:hasPubTitle "Improvement of Cerebral Microbleeds Detection Based on Discriminative Feature Learning"@en .

ns1:fi-v168-i2-4-FI1833 ns0:hasKeywords "CNN classifier"@en,
        "SVM classifier"@en,
        "face expression recognition"@en,
        "face landmarks"@en,
        "facial action units"@en ;
    ns0:hasPubAbstract "Several computer algorithms for recognition of visible human emotions are compared at the web camera scenario using CNN/MMOD face detector. The recognition refers to four face expressions: smile, surprise, anger, and neutral. At the feature extraction stage, the following three concepts of face description are confronted: (a) static 2D face geometry represented by its 68 characteristic landmarks (FP68); (b) dynamic 3D geometry defined by motion parameters for eight distinguished face parts (denoted as AU8) of personalized Candide-3 model; (c) static 2D visual description as 2D array of gray scale pixels (known as facial raw image). At the classification stage, the performance of two major models are analyzed: (a) support vector machine (SVM) with kernel options; (b) convolutional neural network (CNN) with variety of relevant tensor processing layers and blocks of them. The models are trained for frontal views of human faces while they are tested for arbitrary head poses. For geometric features, the success rate (accuracy) indicate nearly triple increase of performance of CNN with respect to SVM classifiers. For raw images, CNN outperforms in accuracy its best geometric counterpart (AU/CNN) by about 30 percent while the best SVM solutions are inferior. For F-score the high advantage of raw/CNN over geometric/CNN and geometric/SVM is observed, as well. We conclude that contrary to CNN based emotion classifiers, the generalization capability wrt human head pose for SVM based emotion classifiers, is worse too."@en ;
    ns0:hasPubTitle "Human Face Expressions from Images"@en .

ns1:fi-v168-i2-4-FI1834 ns0:hasKeywords "Comics"@en,
        "Comics Style"@en,
        "Computer Vision"@en,
        "Neural Network"@en,
        "Neural Style Transfer"@en,
        "Style Transfer"@en ;
    ns0:hasPubAbstract "In this paper, we propose a solution to transform a video into a comics. We approach this task using a neural style algorithm based on Generative Adversarial Networks (GANs). Several recent works in the field of Neural Style Transfer showed that producing an image in the style of another image is feasible. In this paper, we build up on these works and extend the existing set of style transfer use cases with a working application of video comixification. To that end, we train an end-to-end solution that transforms input video into a comics in two stages. In the first stage, we propose a state-of-the-art keyframes extraction algorithm that selects a subset of frames from the video to provide the most comprehensive video context and we filter those frames using image aesthetic estimation engine. In the second stage, the style of selected keyframes is transferred into a comics. To provide the most aesthetically compelling results, we selected the most state-of-the art style transfer solution and based on that implement our own ComixGAN framework. The final contribution of our work is a Web-based working application of video comixification available at http://comixify.ii.pw.edu.pl."@en ;
    ns0:hasPubTitle "Comixify: Transform Video Into Comics"@en .

ns1:fi-v169-i3-FI1843 ns0:hasKeywords "active integrity constraints"@en,
        "dynamic logic"@en,
        "propositional assignments"@en ;
    ns0:hasPubAbstract "Active integrity constraints have been introduced in the database community as a way to restore integrity based on a set of preferred update actions. We view active integrity constraints as dynamic logic programs and show how several semantics of database repair that were proposed in the literature can be characterised in Dynamic Logic of Propositional Assignments DL-PA. We moreover propose a new definition of repair which makes use of the programs of Dynamic Logic to provide repair solutions based on an iterating procedure. After an analysis of their properties and a comparison to the previous approaches, we provide complexity results for the problem of existence of these new repairs. Furthermore, an extension on databases with history is explored and the behavior of the various repairs is adjusted to work in this setting. For all these definitions we provide DL-PA counterparts of reasoning and decision problems, such as the existence of a repair or the existence of a unique repair."@en ;
    ns0:hasPubTitle "A Dynamic Logic Account of Active Integrity Constraints"@en .

ns1:fi-v169-i4-FI1848 ns0:hasKeywords "Gröbner bases"@en,
        "Montgomery ladder"@en,
        "alternative models of elliptic curves"@en,
        "point compression"@en,
        "scalar multiplication"@en ;
    ns0:hasPubAbstract "Let E be an elliptic curve given by any model over a field K. A rational function f : E → K of degree 2 such that f(P) = f(Q) ⇔ Q = ±P can be used as a point compression on E. Then there exists induced from E multiplication of values of f by integers given by [n]f(P) := f([n]P), which can be computed using the Montgomery ladder algorithm. For this algorithm one needs the generalized Montgomery formulas for differential addition and doubling that is rational functions A(X1, X2, X3) ∈ K(X1, X2, X3) and [2] ∈ K(X) such that f(P + Q) = A(f(P), f(Q), f(Q − P)) and [2]f(P) = f([2]P) for generic P,Q ∈ E. For most standard models of elliptic curves generalized Montgomery formulas are known. To use compression for scalar multiplication [n]P for P ∈ E, one can compute after compression [n]f(P), which is followed by [n + 1]f(P) in the Montgomery ladder algorithm, then one can recover [n]P on E, since there exists a rational map B such that [n]P = B(P, [n]f(P), [n + 1]f(P)) for generic P ∈ E and n ∈ Z. Such a map B is known for Weierstrass and Edwards curves, but to our knowledge it seems that it was not given for other models of elliptic curves. In this paper for an elliptic curve E and the above compression function f we give an algorithm to search for generalized Montgomery formulas, functions on K induced after compression by endomorphisms of E, and the above map B for point recovering. All these tasks require searching for solutions of similar type problems for which we describe an algorithm based on Gröbner bases. As applications we give formulas for differential addition, doubling and the above map B for Jacobi quartic, Huff curves, and twisted Hessian curves."@en ;
    ns0:hasPubTitle "Determining Formulas Related to Point Compression on Alternative Models of Elliptic Curves"@en .

ns1:fi-v171-i1-4-FI1872 ns0:hasKeywords "Computational Intelligence"@en,
        "Evolutionary Computation"@en,
        "Genetic Algorithm"@en,
        "Genetic Programming"@en,
        "Haplotype Assembly"@en,
        "Parameter Estimation"@en,
        "Particle Swarm Optimization"@en,
        "Protein Folding"@en,
        "Swarm Intelligence"@en ;
    ns0:hasPubAbstract "Computational Intelligence (CI) is a computer science discipline encompassing the theory, design, development and application of biologically and linguistically derived computational paradigms. Traditionally, the main elements of CI are Evolutionary Computation, Swarm Intelligence, Fuzzy Logic, and Neural Networks. CI aims at proposing new algorithms able to solve complex computational problems by taking inspiration from natural phenomena. In an intriguing turn of events, these nature-inspired methods have been widely adopted to investigate a plethora of problems related to nature itself. In this paper we present a variety of CI methods applied to three problems in life sciences, highlighting their effectiveness: we describe how protein folding can be faced by exploiting Genetic Programming, the inference of haplotypes can be tackled using Genetic Algorithms, and the estimation of biochemical kinetic parameters can be performed by means of Swarm Intelligence. We show that CI methods can generate very high quality solutions, providing a sound methodology to solve complex optimization problems in life sciences."@en ;
    ns0:hasPubTitle "Computational Intelligence for Life Sciences"@en .

ns1:fi-v171-i1-4-FI1881 ns0:hasKeywords "cellular automata"@en,
        "expansivity"@en,
        "pseudo-orbit tracing property"@en ;
    ns0:hasPubAbstract "Ultimate expansivity extends concepts of expansivity and positive expansivity. We consider one-sided variants of ultimate expansivity and pseudo-orbit tracing property (also known as the shadowing property) for surjective one-dimensional cellular automata. We show that ultimately right (or left) expansive surjective cellular automata are chain-transitive; this improves a result by Boyle that expansive reversible cellular automata are chain-transitive. We then use this to show that left-sided pseudo-orbit tracing property and right-sided ultimate expansivity together imply pseudo-orbit tracing property for surjective cellular automata. This reproves some known results, most notably some of Nasu’s. Our result improves Nasu’s result by dropping an assumption of chain-recurrence, however, we remark that this improvement can also be achieved using the Poincaré recurrence theorem. The pseudo-orbit tracing property implies that the trace subshifts of the cellular automaton are sofic shifts. We end by mentioning that among reversible cellular automata over full shifts we have examples of right expansive cellular automata with non-sofic traces, as well as examples of cellular automata with left pseudo-orbit tracing property but non-sofic traces, illustrating that neither assumption can be dropped from the theorem mentioned above. This paper is a generalized and improved version of a conference paper presented in AUTOMATA 2018."@en ;
    ns0:hasPubTitle "On Expansivity and Pseudo-Orbit Tracing Property for Cellular Automata*"@en .

ns1:fi-v171-i1-4-FI1885 ns0:hasKeywords "Bio-inspired Computing"@en,
        "Catalytic P System"@en,
        "Membrane Computing"@en,
        "SAT Problem"@en,
        "Universality"@en ;
    ns0:hasPubAbstract "P systems are a class of parallel computational models inspired by the structure and functioning of living cells, where all the evolution rules used in a system are initially set up and keep unchanged during a computation. In this work, inspired by the fact that chemical reactions in a cell can be affected by both the contents of the cell and the environmental conditions, we introduce a variant of P systems, called P systems with rule production and removal (abbreviated as RPR P systems), where rules in a system are dynamically changed during a computation, that is, at any computation step new rules can be produced and some existing rules can be removed. The computational power of RPR P systems and catalytic RPR P systems is investigated. Specifically, it is proved that catalytic RPR P systems with one catalyst and one membrane are Turing universal; for purely catalytic RPR P systems, one membrane and two catalysts are enough for reaching Turing universality. Moreover, a uniform solution to the SAT problem is provided by using RPR P systems with membrane division. It is known that standard catalytic P systems with one catalyst and one membrane are not Turing universal. These results imply that rule production and removal is a powerful feature for the computational power of P systems."@en ;
    ns0:hasPubTitle "P Systems with Rule Production and Removal"@en .

ns1:hab-v27-i3-HAB180360 ns0:hasKeywords "Haematological parameters"@en,
        "children"@en,
        "copper"@en,
        "nigeria"@en,
        "selenium"@en,
        "sickle cell disease in specialist hospital sokoto"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Sickle cell disease is a genetic disorder of haemoglobin causing myriad of pathology including anaemia.   OBJECTIVES:  The aim of this study was to evaluate some haematological parameters and trace elements of total of forty-five (45) children with Sickle cell disease attending Specialist Hospital Sokoto.   METHOD:  Twenty-five (25) apparently healthy children which were assessed as controls. The haematological parameters were determined using automated method and trace elements (copper and selenium) were determined using colorimetric and atomic absorption spectrophotometry method respectively.   RESULTS:  The Mean WBC and PLT was significantly higher among sickle cell disease subjects when compared to controls individuals (p< 0.05). The Mean RBC, HCT, HGB, MCV, MCH and MCHC was significantly lower among Sickle cell disease patients when compared to controls (p< 0.05). The Mean Copper and Selenium value was significantly lower (40.4 ± 1.44 μg/dl and 54.6 ± 1.60 ng/ml) among Sickle cell disease subjects compared to controls (75.6 ± 1.30 μg/dl and 86.3 ± 2.30 ng/ml) (p< 0.05). The WBC, HGB, HGT and Copper values of Sickle cell disease subjects shows a weak positive put non-statistically significant correlation with age (p> 0.05). The RBC, MCV, MCH, MCHC, PLT, and Selenium values of sickle cell disease patients shows a negative non-statistically significant correlation indicating that the selenium level decreases as the age increases (p< 0.05).   CONCLUSION:  This study shows that the WBC and platelet count was significantly higher among sickle cell disease subjects compared to controls. The RBC, HCT, HGB, MCV, MCH and MCHC were significantly lower among sickle cell disease patients compared to controls. The serum copper and selenium levels were significantly lower among sickle cell subjects compared to controls. We recommend that trace elements (copper and selenium) and haematological parameters be monitored routinely among sickle cell disease children to optimize the care offered to these individuals."@en ;
    ns0:hasPubTitle "Some haematological parameters, copper and selenium level among children of African descent with sickle cell disease in Specialist Hospital Sokoto, Nigeria"@en .

ns1:hab-v27-i3-HAB190370 ns0:hasKeywords "Coculture"@en,
        "HCV infectivity"@en,
        "viral replication"@en ;
    ns0:hasPubAbstract "BACKGROUND AND AIMS:  Although HCV is one of the major health problems worldwide with the highest prevalence of genotype 4a in Egypt, it is poorly understood because of the limitations of having a robust in vitro model that allows the investigation and understanding of viral pathogenesis and life cycle. Genomic replicons for HCV are widely used and proved to have strong replication efficiency in cell culture, however, they are not able to produce infectious particles to enable the investigation of the whole viral life cycle and they mostly represent few sub-genomic classes for HCV. Hence, Genotype specific replication system is necessary to address specific sub-genomic phenotypes related to Hepatitis C pathogenicity.   METHODS:  In this study we attempt to develop a sustainable co-culture model, which potentially provides essential route of infection for HCV by using HCV-positive sera from infected patients. In this novel in vitro model, we tested the viral replication in co-cultured Huh 7.5 and HepG2 cells in order to sustain full viral replication cycle. We used high viral load serum of HCV-infected patients (10 × 106 to 20 × 106 IU/ml) as a source for HCV particles to infect co-cultured cells for 7 days.   RESULTS AND CONCLUSIONS : Viral replication capacity was increased 3–5 folds in the coculture condition compared to the individual cell lines, which indicates an improvement to viral infectivity in vitro.   SIGNIFICANCE STATEMENT : This novel coculture system represents a new in vitro model that will help study the underlying mechanisms of HCV pathogenicity."@en ;
    ns0:hasPubTitle "Establishment of serum derived infectivity coculture model for enhancement of hepatitis C virus replication in vitro"@en .

ns1:hab-v27-i3-HAB190372 ns0:hasKeywords "Helicobacter pylori"@en,
        "Lewis b expression BabA2"@en,
        "genotype"@en,
        "immunohistochemistry"@en,
        "polymerase chain reaction"@en ;
    ns0:hasPubAbstract "BACKGROUND:  The Lewis (b) blood group antigen-Binding Adhesion2 (BabA2) has been reported to mediate the attachment of H. pylori to human.   AIM:  assessment the diagnostic potential of detection of (BabA2) gene compared with immunostaining of Lewis (b) by specific mouse monoclonal antibodies in gastric biopsies from Egyptian Patients as a diagnostic maker for Helicobacter pylori infection.   MATERIALS AND METHODS:  Fifty untreated patients suffering from dyspeptic complaints were enrolled in this study and underwent for upper gastro-duodenal endoscopy. Biopsies were taken for histological examination by (H&E) and immunohistochemical analysis for Lewis b by specific mouse monoclonal antibodies, and scoring of Lewis b expression in gastric tissue biopsy as well as molecular detection of BabA2 gene of H. pylori by PCR. Biochemical analysis was performed to detect the presence of H. pylori urease activity using Rapid Urease Test (RUT).   RESULTS : Out of 50 gastric biopsies, 41 biopsies were positive for histological, Immunostaining for Lewis b expression and urease activity test (RUT) for H pylori. RUT showed a sensitivity of 87.8%, specificity 88.9%, positive predictive value (PPV) 97.2%, and negative predictive value (NPV) 61.5%. BabA2 gene results revealed that, out of 41 positive biopsied cases, 39 (95.1%) were positive by the PCR test for BabA2 gene. And all 9 negative biopsies (100%) for H pylori negative for BabA2gene so the sensitivity and specificity of BabA2 gene detection in gastric biopsies by PCR were 95.1% and 100%; respectively.   CONCLUSION : BabA2 gene detection in gastric tissue biopsies could be suggested as a diagnostic biomarker to be included among the other biomarkers routinely performed for clinical diagnosis of H. pylori infection."@en ;
    ns0:hasPubTitle "Blood group antigen-Binding Adhesion2 (BabA2) gene in gastric tissue biopsies as a diagnostic biomarker for Helicobacter pylori infection"@en .

ns1:hab-v27-i4-HAB190379 ns0:hasKeywords "African descent"@en,
        "Haematological parameters"@en,
        "Nigeria"@en,
        "Sokoto"@en,
        "antenatal clinic"@en,
        "pregnancy"@en ;
    ns0:hasPubAbstract "Pregnancy is the fertilization and development of one or more offspring, known as an embryo or foetus in a woman’s uterus. Pregnancy is a critical stage of development during which maternal nutrition can strongly influence obstetric and neonatal outcomes. The aim of this study was to determine the effect of pregnancy on the full blood count parameters of pregnant women of African descent residing in Sokoto, North Western Nigeria. This case-control study investigated 74 pregnant subjects and 22 non-pregnant controls. The mean age and income of the subjects were 28.00 ± 8.295 and 2760.42 ± 7975.178 respectively. Haematological parameters were determined using a fully automated 5-part differential haematology analyzer (Model Mythic 22-CT, Orpheee, Switzerland). Results obtained of pregnant subjects were compared with that of non-pregnant controls. The prevalence of anaemia (Hb < 11 g/dl) and thrombocytopenia (Platelet count < 140 × 109/L) was 58.11% and 6.75% respectively among the pregnant subjects. The mean haemoglobin, PCV, platelet and red cell count were significantly lower among the pregnant subjects (10.7 ± 0.13 g/dl and 31.4 ± 0.38%, 252.7 ± 14.35 × 109/L and 3.7 ± 0.04) compared to the non-pregnant controls (12.2 ± 0.44 g/dl, 36.2 ± 1.17 %, 362.7 ± 36.51 × 109/L and 4.3 ± 0.11) (p= 0.004, 0.001, 0.009 and 0.000) respectively. There were no significant differences in the total white blood cell count between the pregnant subjects (5.3 ± 0.22) and non-pregnant controls (4.6 ± 0.59) (p= 0.267). The Neutrophils count was significantly higher among the pregnant subjects (42.6 ± 3.06) compared to the non-pregnant controls (20.0 ± 2.33) (p= 0.000). This study has shown that pregnancy has a significant effect on some haematological parameters of women of African descent. The results of this research work indicates the need to routinely monitor the full blood count, anaemia and thrombocytopenia among pregnant women of African descent."@en ;
    ns0:hasPubTitle "Some haematological parameters among pregnant women of African descent attending antenatal clinic in Sokoto North Western Nigeria"@en .

ns1:hab-v27-i4-HAB190385 ns0:hasKeywords "GDM"@en,
        "insulin NPH"@en,
        "insulin levemir"@en,
        "insulin novo-rapid"@en,
        "insulin regular"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Gestational diabetes mellitus (GDM) is one of the prevalent adverse conditions among pregnant women which needs delicate monitoring and control. GDM is a state in which the pregnant women’s blood glucose level exceeds the normal range. Our goal was to determine the best therapeutic method to control the blood glucose level among GDM patients by comparing of the efficacy between two Insulin consisting, Novo-rapid + Levemir Insulin and Regular + NPH Insulin.   METHOD:  In this double-blind, randomized clinical trial study, we enrolled 100 women with GDM as an inpatient. In group A, patients underwent treating with Regular + NPH Insulin, and in group B, patients underwent treating with Novo-rapid + Levemir Insulin. Patient’s demographic and clinical information gathered by specified several times during the study and analysis performed by SPSS21.   RESULTS:  Despite significant changes in the two groups patient’s blood glucose levels; we could not find any remarkable differences between the two groups. In the case of patient and health care system satisfaction and the length of the hospitalization group, B was better than group A.   CONCLUSION:  Altogether, The Novo-rapid and Levemir Insulin in comparing with the Regular and NPH Insulin were practically advantageous due to the simple using method and short hospitalization period of the patient. Thus, we prefer and suggest this beneficial method (using Novo-rapid and Levemir Insulin) to reach therapeutic goals."@en ;
    ns0:hasPubTitle "Comparison between the effect of regular human insulin and NPH with novo-rapid and levemir insulin in glycemic control in gestational diabetes"@en .

ns1:hab-v27-iS1-HAB190368 ns0:hasKeywords "Emergency medical services"@en,
        "Ethiopia"@en,
        "challenges"@en,
        "opportunities"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Ethiopia has a well established health care system but lacks significant improvements on emergency medical services and suffers a shortage of equally initiative among all regional states and city administration of Ethiopia. This study aimed to examine the drivers, challenges, and opportunities of Emergency Medical Services (EMS) and to identify new evidence for future policy making in Ethiopia.   METHOD:  A narrative review of the literature related to EMS was undertaken to describe the drivers, challenges, and opportunities for EMS in Ethiopia from July, 2000 to September, 2018. The search was done from four relevant electronic databases: MEDLINE, Science Directs, Scopus and PubMed by using Google Scholar and Google with key search words used mainly as “Emergency Medical services in Ethiopia”. The inclusion criteria were an original study or review studies involving Emergency Medical Services in Ethiopia. Among the available papers, the relevant articles were selected while the irrelevant ones were excluded.   RESULTS:  There was lack of trained emergency medical providers and misdistribution of trained professionals, immaturity of the program, lack of partnership and stakeholders and lack of motivation towards Emergency medical services. Emergency medical services hamper significant problems similar to other African countries that required being addressed in Ethiopia context for achieving the program and in order to obtain intended outcomes for the country.   CONCLUSION:  A long-term discussion is needed to further improve the services system in various health care facilities. An Emergency Medical services policy making and analysis framework is needed to make quality emergency medical care at Emergency department in hospitals and outside the hospitals."@en ;
    ns0:hasPubTitle "Emergency medical services in Ethiopia: Drivers, challenges and opportunities"@en .

ns1:his-v15-i4-HIS190271 ns0:hasKeywords "Particle swarm optimization"@en,
        "binary algorithms"@en,
        "feature selection problem"@en,
        "genetic algorithm"@en,
        "hybridization"@en,
        "meta-heuristics"@en ;
    ns0:hasPubAbstract "In this paper, a new hybrid binary version of Genetic algorithm (GA) and enhanced particle swarm optimization (PSO) algorithm is presented in order to solve feature selection (FS) problem. The proposed algorithm is called Hybrid Binary Genetic Enhanced PSO Algorithm (HBGEPSO). In the proposed HBGEPSO algorithm, the GA is combined with its capacity for exploration of the data through crossover and mutation and enhanced version of the PSO with its ability to converge to the best global solution in the search space. In order to investigate the general performance of the proposed HBGEPSO algorithm, the proposed algorithm is compared with the original optimizers and other optimizers that have been used for FS in the past. A set of assessment indicators are used to evaluate and compare the different optimizers over 20 standard data sets obtained from the UCI repository. Results prove the ability of the proposed HBGEPSO algorithm to search the feature space for optimal feature combinations."@en ;
    ns0:hasPubTitle "Solving feature selection problem by hybrid binary genetic enhanced particle swarm optimization algorithm"@en .

ns1:hsm-v38-i3-HSM180410 ns0:hasKeywords "Remittances"@en,
        "growth"@en,
        "low-income region"@en,
        "panel co-integration"@en,
        "self-development"@en ;
    ns0:hasPubAbstract "This empirical study’s intent was to assess the role that remittances play in the economic growth and self-development of low-income country regions. The diverse results in previous studies necessitate using a proper methodological approach. Namely panel co-integration analysis allows gauging the long-run interactions among growth, remittances, and self-development. Having confirmed, via the augmented Dickey-Fuller (ADF) test, the dynamic equilibrium of the data, gleaned from 31 low-income countries over the 1991–2015 time period, the cointegration between economic growth and remittances was established through the Johansen panel test. Pertinent to heterogeneous cointegrated panels, the fully modified ordinary least squares (FMOLS) results show that remittances have a significant, positive effect on long-term economic growth. Besides, the study’s empirical results also unconceal the significant, long-term effects of economic growth and remittances, facilitating self-development in low-income regions, in terms of finance, savings, trade, and labor-force participation, except that of household consumption. And an endogeneity test strongly suggests the need for policymaking towards obtaining maximum benefits from the increased inflows of remittances. Despite its limitations, the study offers pragmatic policymaking recommendations, along with future research directions."@en ;
    ns0:hasPubTitle "Growth, remittances and self-development in low-income regions"@en .

ns1:hsm-v38-i3-HSM180413 ns0:hasKeywords "Just-in-time"@en,
        "manufacturing management"@en,
        "matching estimator"@en,
        "matching method"@en,
        "performance"@en ;
    ns0:hasPubAbstract "Relying on the matching method that D.B. Rubin developed in 1974, this study empirically evaluates the impact of the just-in-time (JIT) inventory-control technique on the performance of small and medium enterprises (SMEs), engaged in manufacturing. Data were gleaned from two merged databases: ‘Diane’, and the ‘Organizational Change and Computerization’ survey, the latter carried out in 2006 by The French National Institute for Statistics and Economic Studies (INSEE). Ergo, the study sample consists of 1109 manufacturing SMEs, operating in France. One of a few works of its kind, the empirical study’s contribution highlights the positive effect of JIT implementation on SME turnover, SME value added and SME labor productivity. Despite its limitations, the study offers pragmatic policymaking recommendations for manufacturing SMEs, as well as pertinent future-research directions."@en ;
    ns0:hasPubTitle "JIT inventory control and manufacturing SME performance"@en .

ns1:hsm-v38-i3-HSM180465 ns0:hasKeywords "Female tourist"@en,
        "behavior of crowds"@en,
        "tipping point"@en,
        "tourism app"@en ;
    ns0:hasPubAbstract "As a singularly important tourism group, women have unique perceptions and preferences, regarding the travel-information platforms that influence their tourism decisions. Based on the societal-development capital, technology acceptance and societal psychology constructs, this article proposes and empirically assesses an innovative research framework, in the tipping-points context. The empirical study discloses important effects by the pivotal virtual community, informational and environmental factors in China. The results show that collegial group centrality has a positive effect on participative behavior, while the latter, along with perceived usefulness and imitation of others, have positive effects on usage behavior. Besides, gender plays a moderating role in the relation between collegial group centrality and imitation of others-usage behavior. Despite the study’s limitations, these empirical results enable future researches to conduct comprehensive, dynamic studies of women tourists in the virtual tourism communities. And accurate perceptions of personalized needs of specific groups of tourists can substantially benefit travel application or ‘app’ operators."@en ;
    ns0:hasPubTitle "Tourism apps women prefer and their tipping point"@en .

ns1:hsm-v38-i4-HSM190490 ns0:hasKeywords "Information communication technology (ICT)"@en,
        "Pakistan"@en,
        "entrepreneurship"@en,
        "networking"@en,
        "women empowerment"@en ;
    ns0:hasPubAbstract "The information communication technology (ICT) and networking are playing a significant role in supporting and empowering women entrepreneurs in Pakistan. We focused on four core factors that greatly influence women entrepreneurs and studied them through structural equation modeling (SEM) in AMOS 22 software. Our results show that family support positively affects the success of women entrepreneurs. Besides, the education level and knowledge of ICT and networking are empowering women entrepreneurs. We also conclude that networking relations through ICT tools positively aid women entrepreneurs in case where face to face meetings are not possible. The educated women can effectively use ICT and networking tools to become a successful entrepreneur. This work provides important understanding about the role of ICT and networking tools in empowering women entrepreneurs of Pakistan."@en ;
    ns0:hasPubTitle "Revolution of ICT: Women entrepreneurs in Pakistan"@en .

ns1:hsm-v38-i4-HSM190516 ns0:hasKeywords "Knowledge management"@en,
        "human resources"@en,
        "knowledge sharing"@en,
        "virtual communities"@en ;
    ns0:hasPubAbstract "Knowledge has become a key factor to success in social environments and virtual communities. Also, human resources are a critical part of the creation and dissemination of the knowledge-based resources in virtual communities. Comprehensive understanding of virtual community dynamics can aid us to address critical organizational and information systems issues. Furthermore, virtual communities have gained high acceptance for people to learn and share knowledge. However, the detailed review and deep discussion in this filed are very rare. Therefore, this paper reviews and discusses the recently introduced mechanisms in this field as well as providing a deep analysis of their applied domains. This survey will help to a conceptual understanding of nature and the position of KS in virtual communities. Moreover, the drawbacks and benefits of the reviewed mechanisms in three categories such as social factors, motivation factors, and medical factors have been discussed and the main challenges of these mechanisms are highlighted for developing more efficient KS in virtual communities in the future. The obtained results indicated that helps the creativity and the success of the organizations, saving time and cost, reducing medical errors and also optimizing the learning effect. Trust is also the greatest prerequisite for KS."@en ;
    ns0:hasPubTitle "Knowledge sharing mechanisms in virtual communities: A review of the current literature and recommendations for future research"@en .

ns1:hsm-v38-i4-HSM190548 ns0:hasKeywords "Leader humility"@en,
        "individual differences"@en,
        "innovative behavior"@en,
        "intrapreneurial personality"@en,
        "signaling theory"@en ;
    ns0:hasPubAbstract "This quantitative study empirically analyzes the relation between leader humility and innovative behavior by assessing the moderating role of intrapreneurial personality. Cross-sectional data were collected from 498 respondents in Karachi, Pakistan. The study has two purposes. First, on the basis of signaling theory, it investigates the relation between leader behavior (humility) and innovative behavior (at the individual level). Second, on the basis of personality and individual differences it considers follower effects to investigate whether the intrapreneurial personalities of subordinates moderates this relationship, using a PROCESS macro to test two-way interactions. Empirical assessments of the hypotheses show that intrapreneurial personality plays a distinct moderating role between leader humility and innovative behavior. The results of the study have significant implications and open up several avenues for future research."@en ;
    ns0:hasPubTitle "The moderating role of intrapreneurial personality in relation between leader humility and innovative behavior"@en .

ns1:ia-v13-i1-IA180015 ns0:hasKeywords "Coherence Constraints"@en,
        "Convolutional Neural Networks"@en,
        "Facial Expression Recognition"@en,
        "Learning from Constraints"@en ;
    ns0:hasPubAbstract "This paper investigates the role of coherence constraints in recognizing facial expressions from images and video sequences. A set of constraints are introduced to bridge a pool of Convolutional Neural Networks (CNNs) during their training stage. Constraints are inspired by practical considerations on the regularity of the temporal evolution of the predictions, and by the idea of connecting the information extracted from multiple representations. We study CNNs with the aim of building a versatile recognizer of expressions in static images that can be further applied to video sequences. First, the importance of different face parts in the recognition task is studied, considering appearance and shape-related features. Then we focus on the Semi-Supervised learning setting, exploiting video data, where only a few frames are supervised. The unsupervised portion of the training data is used to enforce three types of coherence, namely temporal coherence, coherence among the predictions on the face parts and coherence between appearance and shape-based representation. Our experimental analysis shows that coherence constraints improve the quality of the expression recognizer, thus offering a suitable basis to profitably exploit unsupervised video sequences, also in cases in which some portions of the input face are not visible."@en ;
    ns0:hasPubTitle "Coherence constraints in facial expression recognition"@en .

ns1:ida-v23-i4-IDA183930 ns0:hasKeywords "Self-organizing map"@en,
        "categorical attribute"@en,
        "mixed-type data"@en,
        "unsupervised learning"@en,
        "visualization"@en ;
    ns0:hasPubAbstract "The original self-organizing map (SOM) was proposed in the context of processing numeric data. In previous studies, an extended SOM incorporating data structure distance hierarchies has been proposed to facilitate handling of categorical values. The model could take into account the semantics embedded in categorical values via distance hierarchies. In addition to manual construction by domain experts, an approach to learning distance hierarchies from datasets has been devised. However, the proposed approach in the previous study was based on supervised learning which demands presence of a class attribute in the dataset. In real-world applications, class attribute may not be available. Thus, the supervised approach can be inapplicable. In this article, we present several methods of unsupervised learning of distance hierarchies so that neither are class attribute nor domain experts required in measuring similarity degree between categorical values. We then integrate the learned distance hierarchies with the extended SOM to facilitate the application to datasets without a class attribute. We conduct experiments to verify feasibility and compare performance of the proposed unsupervised-learning methods."@en ;
    ns0:hasPubTitle "Unsupervised distance learning for extended self-organizing map and visualization of mixed-type data"@en .

ns1:ida-v23-i4-IDA184195 ns0:hasKeywords "Semi-supervised classification"@en,
        "entropy"@en,
        "multi-label learning vector quantization"@en,
        "self-training"@en,
        "soft label"@en ;
    ns0:hasPubAbstract "In the context of expensive and time-consuming acquisition of reliably labeled data, how to utilize the unlabeled instances that can potentially improve the classification accuracy becomes an attractive problem with significant importance in practice. Semi-supervised classification that fills the gap between supervised learning and unsupervised learning is designed to take advantage of the unlabeled data in regular supervised learning procedure for classification tasks. In this paper we proposed a self-learning framework, that firstly pre-learns a classification model using the labeled data, then makes the prediction of unlabeled instances in the form of soft class labels, and re-learned a model based on the enlarged training data. Two multi-label Learning Vector Quantization Neural Networks (LVQ-NNs) are proposed, namely multi-label online LVQ-NN (mLVQo) and multi-label batch LVQ-NN (mLVQb), to work with the soft labels of training instances. The experiments demonstrate that the semi-supervised models using multi-label LVQ-NN as the base classifier can produce better generalization accuracy than the supervised counterpart."@en ;
    ns0:hasPubTitle "Multi-label learning vector quantization for semi-supervised classification"@en .

ns1:ida-v23-i5-IDA184183 ns0:hasKeywords "Location-privacy preservation"@en,
        "bottom-up grid search"@en,
        "k-anonymity"@en,
        "locality-sensitive hashing"@en,
        "subspace"@en ;
    ns0:hasPubAbstract "Existing location-privacy-preserving methods primarily focus on solving the problem of location-privacy preservation in the global space. This not only increases the response time of the location service, it also degrades the data quality. In this paper, a k-anonymity algorithm based on locality-sensitive hashing is proposed to solve the problem of location-privacy preservation in the subspace. In the proposed algorithm, higher efficiency and higher quality of service are achieved by applying a bottom-up grid-search method. Further, reasonable division is obtained based on locality-sensitive hashing by retaining position characteristics. The results of experiments conducted to evaluate the proposed algorithm indicate that the proposed algorithm provides a smaller anonymous spatial region, higher data quality, and lower time cost than methods with no subspace."@en ;
    ns0:hasPubTitle "Subspace k-anonymity algorithm for location-privacy preservation based on locality-sensitive hashing"@en .

ns1:ida-v23-i6-IDA184239 ns0:hasKeywords "Credit scoring"@en,
        "emerging markets"@en,
        "logistic regression"@en,
        "microfinance"@en,
        "support vector machine"@en ;
    ns0:hasPubAbstract "Emerging markets contain the vast majority of the world’s population. Despite the enormous number of inhabitants, these markets still lack a proper finance infrastructure. One of the main difficulties felt by customers is the access to loans. This limitation arises from the fact that most customers usually lack a verifiable credit history. As such, traditional banks are unable to provide loans. This paper proposes credit scoring modeling based on non-traditional-data, acquired from smartphones, for loan classification processes. We use Logistic Regression (LR) and Support Vector Machine (SVM) models which are the top linear models in traditional banking. Then we compared the transformation of the training datasets creating boolean indicators against the categorization using Weight of Evidence (WoE). Our models surpassed the performance of the manual loan application selection process, improving the approval rate and decreasing the overdue rate. Compared to the baseline, the loans approved by meeting the criteria of the SVM model presented a decreased overdue rate. At the same time, using the score generated by a SVM model we were able to grant more loans. This paper shows that credit scoring can be useful in emerging markets. The non-traditional data can be used to build robust algorithms that can identify good borrowers as in traditional banking."@en ;
    ns0:hasPubTitle "Credit scoring for microfinance using behavioral data in emerging markets"@en .

ns1:ida-v23-i6-IDA184334 ns0:hasKeywords "Hausdorff distance"@en,
        "anonymity"@en,
        "hierarchical granularity"@en,
        "interpolation points"@en,
        "trajectory privacy protection"@en ;
    ns0:hasPubAbstract "The traditional trajectory privacy protection algorithm approaches the task as a single-layer problem. Taking a perspective in harmony with an approach more characteristic of human thinking, in which complex problems are solved hierarchically, we propose a two-level hierarchical granularity model for this problem. The first level of the proposed model is a coarse-grained layer, in which the original dataset is divided into groups. The second level is a fine-grained layer, where problems are solved in each group instead of on the original dataset, which reduces complexity and computation while improving efficiency. On the basis of this hierarchical model, we propose the interpolation trajectory-anonymous privacy protection algorithm with temporal and spatial granularity constraints. In addition, we propose interpolation-based modified Hausdorff distance on adjacent segment (IMHD_AS), which provides a smaller clustering area and better data utility than the traditional Euclidean distance, as the trajectory similarity criterion for clustering within each group. Further, we theoretically prove that the proposed algorithm outperforms the traditional algorithm in terms of data distortion and anonymity cost and verify its efficacy experimentally. Compared with the classic anonymity algorithm, the maximum information loss and the anonymity cost are reduced by up to 21.04% and 28.32%, respectively."@en ;
    ns0:hasPubTitle "Hierarchical interpolation point anonymity for trajectory privacy protection"@en .

ns1:ida-v23-i6-IDA184339 ns0:hasKeywords "Subgraph summarization"@en,
        "logic programs with annotated disjunctions"@en,
        "probabilistic logic programming"@en,
        "significant subgraph mining"@en,
        "statistical significance"@en ;
    ns0:hasPubAbstract "Although recent advances of significant subgraph mining enable us to find subgraphs that are statistically significantly associated with the class variable from graph databases, it is challenging to interpret the resulting subgraphs due to their massive number and their propositional representation. Here we represent graphs by probabilistic logic programming and solve the problem of summarizing significant subgraphs by structure learning of probabilistic logic programs. Learning probabilistic logical models leads to a much more interpretable, expressive and succinct representation of significant subgraphs. We empirically demonstrate that our approach can effectively summarize significant subgraphs with keeping high accuracy."@en ;
    ns0:hasPubTitle "Summarizing significant subgraphs by probabilistic logic programming"@en .

ns1:ida-v23-i6-IDA184390 ns0:hasKeywords "Link prediction"@en,
        "classification problem"@en,
        "self-training"@en,
        "semi-supervised learning"@en ;
    ns0:hasPubAbstract "In this paper, learning social networks from incomplete relationship data is proposed. Link prediction is addressed as a semi-supervised learning problem where the task is to predict a larger part of networks using available knowledge of smaller parts. By this assumption, social network extraction is translated into a classification problem. While in real case scenarios majority of links are unknown, we hypothesis self-training as the most common semi-supervised learning method can provide an effective approach for learning from unlabelled data. We proposed an interpolative self-training technique that leverages node information to generate a set of examples in learning phase along with their connections as their associated labels. The approach generates data by interpolation of documents assigned to a pair of nodes. Documents as the implicit content shared between the individual nodes provide a scope for the estimation of their similarities. Then generated training data are employed in a link prediction model with two different scenarios. The first scenario interprets the link prediction as a conventional classification problem in which we have examples from both positive (link) and negative (no-link) classes. However, the second scenario addresses more realistic case where only some positive examples (links or connections) are known. Social networks are usually very sparse structures. The sparsity of social networks implies that in the classification framework of link prediction, we deal with an imbalance class distribution in which among all possible links there are a few connections (positive class) vs. many disconnections (negative class). In order to deal with class skew and enhance the performance of the classifier, a data selection method based on node similarity was proposed. To evaluate the merit of the proposed methods, a set of experiments were conducted on co-authorship networks of 18 different domains. The result implies the feasibility of achieving significantly high performance for most of the networks using the proposed self training approach."@en ;
    ns0:hasPubTitle "Interpolative self-training approach for link prediction"@en .

ns1:ida-v23-iS1-IDA192765 ns0:hasKeywords "Vehicle insurance fraud"@en,
        "artificial fish swarm algorithm"@en,
        "extreme learning machine"@en ;
    ns0:hasPubAbstract "With the rapid development of China’s insurance industry, insurance fraud incidents are also increasing, especially in the field of auto insurance. Therefore, the vehicle insurance fraud identification model based on extreme learning machine is studied. Because the initial connection weight and hidden layer neuron threshold of the ELM are generated randomly, the recognition results are unstable and the accuracy is affected. Therefore, artificial fish swarm algorithm is used to optimize the model parameters. This paper adaptively improves the step size, visual field and crowding degree of artificial fish swarm. First of all, the principal component analysis method is used to generate the input vector of the ELM model for vehicle insurance fraud. Then the weights and thresholds of the ELM model are optimized by improved artificial fish swarm algorithm. Finally, the model is applied to vehicle insurance fraud identification. The empirical analysis shows that the optimized model has less recognition error and higher recognition stability compared with the traditional ELM classification model."@en ;
    ns0:hasPubTitle "Improved ELM optimization model for automobile insurance fraud identification based on AFSA"@en .

ns1:ida-v23-iS1-IDA192847 ns0:hasKeywords "Fuzzy description logic"@en,
        "Semantic Web"@en,
        "fuzzy spatio-temporal knowledge"@en,
        "reasoning"@en,
        "representation"@en ;
    ns0:hasPubAbstract "Description logic, as a logical foundation of knowledge representation and reasoning, plays an important role in the Semantic Web. In practical applications, many fields contain a large number of fuzzy spatio-temporal knowledge. With a large amount of fuzzy spatio-temporal knowledge and many corresponding applications being incorporated into the Semantic Web, description logic becomes an effective method to solve the problem of fuzzy spatio-temporal knowledge representation and reasoning. Currently, many efforts have been done on fuzzy spatio-temporal extensions of description logics, and the literature on fuzzy spatio-temporal description logic has been booming. To address these issues and more importantly, in this paper, we provide a comprehensive survey of the research literature that applies description logics techniques in fuzzy spatio-temporal representation and reasoning. The paper serves as helping readers grasp the main results and highlighting the direction of fuzzy spatio-temporal representation and reasoning based on description logics."@en ;
    ns0:hasPubTitle "Representing and reasoning fuzzy spatio- temporal knowledge with description logics: A survey"@en .

ns1:idt-v13-i3-IDT180064 ns0:hasKeywords "Deep learning"@en,
        "adam optimization"@en,
        "convolutional neural network"@en,
        "self-driving car"@en,
        "traffic sign recognition"@en ;
    ns0:hasPubAbstract "In this paper, we have proposed and developed a comprehensive Convolutional Neural Network (CNN) classifier “WAF-LeNet” to be used in traffic signs recognition and identification as an empowerment of autonomous driving technologies. The implemented architecture is a deep fifteen-layer network that has been selected after extensive trials to be fast enough to suit the designated application. The CNN got trained using Adam’s optimization algorithm as a variant of the Stochastic Gradient Descent (SGD) technique. The learning process is carried out using the well-known “German Traffic Sign Dataset – GTSRB”. The data has been partitioned into training, validation and testing data sets. Additionally, more random traffic signs images are collected from the web and further used to test the robustness of the proposed CNN classifier. The paper goes through the development process in details and shows the image processing pipeline harnessed in the development. The proposed approach proved successful in identifying correctly 96.5% of the testing data set and 100% of the robustness dataset with the much smaller and faster network than other counterparts."@en ;
    ns0:hasPubTitle "Traffic signs classification by deep learning for advanced driving assistance systems"@en .

ns1:ies-v27-i3-IES183201 ns0:hasKeywords "Whole body-electromyostimulation"@en,
        "adipokines"@en,
        "isokinetic strength"@en,
        "thigh circumference"@en ;
    ns0:hasPubAbstract "BACKGROUND : Although whole body electromyostimulation (WB-EMS) has been shown to improve body composition and muscle strength in several research studies, it has not been confirmed whether a dose-response effect using various impulse-intensities exists and how they affect adipose tissue-derived adipokines (APK), body composition, and strength.   OBJECTIVE:  To investigate the dose-response effect of wearing a WB-EMS suit in conjunction with isometric exercise on adipokines (APK), body composition including thigh circumference, and thigh muscle strength in normal healthy men for 6 weeks.   METHOD:  Fifty-two male subjects were randomly assigned to one of four groups: control group (CON, n= 13), low impulse-intensity (LII) group (n= 12), mid impulse-intensity (MII) group (n= 14), and high impulse-intensity (HII) group (n= 13). Low-, mid- and high-impulse intensities were set at 50%, 60% and 80% of maximum tolerance (1MT). Subjects in CON group wore WB-EMS suits, but did not receive any impulses. The WB-EMS suits used in this study enabled the simultaneous activation of eight muscle groups with selectable intensities. Stimulation frequency was selected at 85 Hz, impulse-width at 350 microsecond, and impulse-rise as a rectangular application. Impulse duration was 6 s with a 4 s break between impulses. The 20-minute WB-EMS sessions were combined with isometric exercises 3 times a week for 6 weeks. APK, body composition including thigh circumference, and isokinetic peak moment (PT) and work per repetition (WR) of the knee extensors and flexors were measured on Week 0, Week 2, Week 4, and Week 6.   RESULTS:  Compared with the CON group, 1) there was a significant group by time interaction difference in Resistin (P= 0.016). That is, Resistin increased in the CON and LII groups, but decreased in the MII and HII groups. These changes in Resistin for both groups began to appear at Week 4. 2) Body weight (P= 0.024) and muscle mass (P= 0.037) were significantly different in group by time interaction. The decrease of body weight in the HII group began to appear at Week 4. In particular, the level of muscle mass increased only in the HII group at Week 6. 3) There were significant group by time interaction differences in the circumferences of thigh subcutaneous fat (TSF) and thigh total fat (TTF) on right and left sides. The right TSF (P= 0.045) and TTF (P=0.019) decreased from baseline to Week 6 in the HII group. These changes were similar to the left TSF (P= 0.038) and TTF (P= 0.011). The changes in the HII group showed a marked decrease at Week 6. 4) There were significant group by time interaction effects in the PT of the left knee extensor (P= 0.037) and PT of the right knee flexor (P= 0.012). These results were similar with the WR of the right knee flexor (P= 0.002) and the WR of the left knee flexor (P= 0.019) in the HII group, which were significantly higher than those of the other three groups at Week 4 and 6.   CONCLUSIONS:  WB-EMS administered at high impulse intensity can improve Resistin, body composition including thigh circumference, and isokinetic strength in healthy men after approximately 4 to 6 weeks."@en ;
    ns0:hasPubTitle "The effect of high-impulse- electromyostimulation on adipokine profiles, body composition and strength: A pilot study"@en .

ns1:ies-v27-i3-IES192150 ns0:hasKeywords "Ankle brace"@en,
        "forward and lateral landing"@en,
        "kinematic and kinetic change"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Ankle braces are commonly used to protect ankle joints from a sprain by restricting inversion. However, the difference between a soft brace (SB) and a semi-rigid brace (SRB) regarding kinematic and kinetic changes of the lower limb joints after forward and lateral drop landing is unknown.   OBJECTIVE:  The aim of this study was to evaluate the effect of SB and SRB, on kinematic and kinetic changes after each drop landing in healthy young women.   METHODS:  Ten female adults were assessed for one leg while wearing SB, SRB or non-brace (NB). For assessing kinematic and kinetic changes after drop landing, the participant jumped and landed forward and laterally with one leg on a force platform. Knee and ankle joint angle and moment, peak ground reaction force (pGRF), time to peak GRF (TpGRF), the rate of force development (RFD) and GRF impulse (impulse) were measured.   RESULTS:  The results indicated that knee flexion angle, TpGRF, RFD, and impulse were significantly different between SRB and NB after forward drop landing. SRB demonstrated significant increases in RFD and decreases in impulse.   CONCLUSIONS:  Semi rigid brace may be beneficial in providing more restriction to the ankle joint for preventing ankle sprains during landing."@en ;
    ns0:hasPubTitle "Effect of soft and semi-rigid ankle braces on kinematic and kinetic changes of the knee and ankle joints after forward and lateral drop landing in healthy young women"@en .

ns1:ies-v27-i3-IES192152 ns0:hasKeywords "Isokinetic"@en,
        "KT"@en,
        "delayed onset"@en,
        "fatigue"@en,
        "peak moment"@en ;
    ns0:hasPubAbstract "BACKGROUND:  A number of studies have assessed the effect of kinesiology tape (KT) application with respect to the delayed onset of muscle fatigue.   OBJECTIVE:  To determine the effects of direction of KT application on the delayed onset of quadriceps fatigue.   METHODS:  An isokinetic dynamometer was used to induce concentric quadriceps fatigue in 15 healthy participants prior to applying KT. The KT was randomly applied on the muscles in two possible orientations: from origin to insertion or from insertion to origin. After the application the number of repetitions of knee extension required to induce fatigue was recorded.   RESULTS:  Regardless of the direction of application, the number of repetitions needed to generate muscle fatigue increased after the KT was applied. On the other hand, there was no significant difference between taping directions.   CONCLUSIONS:  KT application on the quadriceps delays the onset of its isokinetically-induced fatigue, irrespective of the direction of application. Therefore, using KT may be considered as a possible technique in those tasks where fatigue may seriously hamper performance."@en ;
    ns0:hasPubTitle "Effects of the direction of kinesiology tape application on the delayed onset of quadriceps muscle fatigue in athletes"@en .

ns1:ies-v27-i4-IES192105 ns0:hasKeywords "Pulmonary functions"@en,
        "boys"@en,
        "exercise"@en,
        "respiratory muscle strength"@en ;
    ns0:hasPubAbstract "BACKGROUND:  An enthusiasm for physical exercise is often developed in the paediatric age group through collective game-based sporting activities. Regular exercise via sports can create positive effects on the respiratory systems of boys as well as on their overall growth and development. To help identify deviations from positive trends in these areas, respiratory function tests have become an essential part of the diagnosis and assessment of pulmonary disease.   OBJECTIVE:  To investigate the effect of different types of sports on pulmonary functions and respiratory muscle strength and to help establish baseline reference values in healthy Turkish boys aged 8–12 years.   METHODS:  A total of 624 healthy boys, who train at least twice a week for football (128), basketball (105), archery (60), swimming (111) and wrestling (74), as well as 146 boys who do not perform regular physical activities voluntarily, participated in the study. To evaluate and potentially differentiate amongst the merits of these several sports, we obtained a variety of baseline measurements from our subjects, including forced vital capacity (FVC), forced expiratory volume in one second (FEV1), FEV1/FVC, maximal peak expiratory flow (PEF max), maximal voluntary ventilation (MVV), maximal inspiratory pressure (MIP) and maximal expiratory pressure (MEP).   RESULTS:  There were statistically significant differences amongst the types of sports regarding the various metrics we examined: FVC, FEV1, FEV1/FVC, PEF max, MVV, MIP and MEP (p< 0.05). The active boys showed higher mean values for pulmonary functions and respiratory muscle strength than the passive ones. Also, the wrestlers generally had better respiratory parameters than those of athletes in the other four sports we investigated.   CONCLUSIONS:  It was clear that exercise, especially regarding pulmonary function and respiratory muscle strength, produced better outcomes in the active boys compared with our control group of relatively passive boys. The mechanisms responsible for this difference are likely due to the resistance effect of exercise."@en ;
    ns0:hasPubTitle "The differential impact of several types of sports on pulmonary functions and respiratory muscle strength in boys aged 8–12"@en .

ns1:ies-v27-i4-IES193178 ns0:hasKeywords "30–15IFT"@en,
        "Handball"@en,
        "ball speed"@en,
        "fatigue"@en,
        "shooting accuracy"@en,
        "wrist acceleration"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Shooting accuracy and ball speed are important factors relating to scoring in handball that could be affected by skeletal muscle fatigue.   OBJECTIVE:  To explore the effects of muscle fatigue on male handball players’ shooting accuracy and ball speed.   METHODS:  Sixteen elite handball players (Mage= 17.1 ± 1.7 years) participated in the laboratory and the field-testing sessions. Running speeds equal to 75% of participants’ maximal oxygen uptake (VO2max) values from laboratory tests were used as the initial velocity for the 30–15 intermittent fitness test (30–15IFT) in the fatigue protocol. Participants shot to the target at random visual signals placed behind the target before and after fatigue. In order to measure wrist acceleration and ball speed, an accelerometer and a radar gun are used respectively and numbers of accurate and inaccurate shots also recorded.   RESULTS:  There were no significant differences between pre-fatigue and post-fatigue protocols in terms of accurate and inaccurate shots, and ball speed. Only wrist acceleration in the Y axis (Mpre - fatigue= 33.12, SD = 1.17msec; Mpost - fatigue= 34.50, SD = 1.21msec) was affected by the fatigue protocol in inaccurate shots (p= 0.042).   CONCLUSIONS:  Muscular fatigue does not affect shooting accuracy and ball speed in male handball players."@en ;
    ns0:hasPubTitle "Skeletal muscle fatigue does not affect shooting accuracy of handball players"@en .

ns1:ifs-v36-i6-IFS171927 ns0:hasKeywords "Green computing"@en,
        "cloud data centers"@en,
        "dynamic voltage and frequency scaling (DVFS)"@en,
        "energy consumption"@en,
        "slack time"@en,
        "task duplication"@en,
        "throughput"@en ;
    ns0:hasPubAbstract "Energy consumption and performance metrics have become critical issues for scheduling parallel task-based applications in high-performance computing systems such as cloud datacenters. The duplication and clustering strategy, as well as Dynamic Voltage Frequency Scaling (DVFS) technique, have separately been concentrated on reducing energy consumption and optimizing performance parameters such as throughput and makespan. In this paper, a dual-phase algorithm called EATSDCD which is an energy efficient time aware has been proposed. The algorithm uses the combination of duplication and clustering strategies to schedule the precedence-constrained task graph on datacenter processors through DVFS. The first phase focuses on a smart combination of duplication and clustering strategy to reduce makespan and energy consumed by processors in an effort to execute Directed Acyclic Graph (DAG) while satisfying the throughput constraint. The main idea behind EATSDCD intended to minimize energy consumption in the second phase. After determining the critical path and specifying a set of dependent tasks in non-critical paths, the slack time for each task in non-critical paths was distributed among all dependent tasks in that path. Then, the frequency of DVFS-enabled processors is scaled down to execute non-critical tasks as well as idle and communication phases, without extending the execution time of tasks. Finally, a testbed is developed and different parameters are tested on the randomly generated DAG to evaluate and illustrate the effectiveness of EATSDCD. It was also compared against duplication and clustering-based algorithms and DVFS-based algorithms. In terms of energy consumption and makespan, the results show that our proposed algorithm can save up to 8.3% and 20% energy compared against Power Aware List-based Scheduling (PALS) and Power Aware Task Clustering (PATC) algorithms, respectively. Furthermore, there is 16% improvement over Parallel Pipeline Latency Optimization (PaPilo) algorithm with Encur = 1.2Enmin (G). In comparison with Reliability Aware Scheduling with Duplication (RASD) algorithm, the execution time has been reduced in heterogeneous environments."@en ;
    ns0:hasPubTitle "EATSDCD: A green energy-aware scheduling algorithm for parallel task-based application using clustering, duplication and DVFS technique in cloud datacenters"@en .

ns1:ifs-v36-i6-IFS172242 ns0:hasKeywords "Ego-net"@en,
        "complex network"@en,
        "friend intimacy"@en,
        "overlapping community"@en ;
    ns0:hasPubAbstract "Methods for detecting overlapping communities are essential for understanding complex network structures and extracting implied information. Traditional community detection algorithms have been proven to be unsatisfactory when the network community structure is relatively fuzzy. In this paper, we proposed a novel overlapping community discovery algorithm (ENFI) to address this problem on the micro level using ego-nets. The ENFI approach exploits the micro-characteristics of ego-nets, extracts the ego-net’s local community by calculating the friend intimacy, and then forms the overlapping communities of the network. We conducted experiments on both synthetic and real-world social networks using normalized mutual information (NMI) and overlapping community modularity as evaluation criteria. The results demonstrated that the proposed ENFI algorithm can detect community structures in complex networks more efficiently and accurately than existing state-of-the-art algorithms."@en ;
    ns0:hasPubTitle "Discovering overlapping communities in ego-nets using friend intimacy"@en .

ns1:ifs-v36-i6-IFS172286 ns0:hasKeywords "Contravariant functor"@en,
        "L-fuzzy ideal"@en,
        "Minimal prime L-fuzzy ideal"@en,
        "Ordered semigroup"@en,
        "Spectrum"@en ;
    ns0:hasPubAbstract "In this paper, we redefine the concept of prime L-fuzzy ideals of an ordered semigroup so that the prime L-fuzzy ideals are not necessarily 2-valued. Then a topological space, called the spectrum of prime L-fuzzy ideals of an ordered semigroup, has been obtained and some topological properties like separation axioms, compactness, connectedness are researched. Further, a contravariant functor from the category of commutative ordered semigroups into the category of compact and connected topological spaces is gotten. Finally, we focus on the subspace which is defined in the set of all minimal prime ideals in an ordered semigroup S and show that if S is commutative, then this subspace is Hausdorff, totally disconnected and completely regular."@en ;
    ns0:hasPubTitle "Spectrum of prime L-fuzzy ideals of an ordered semigroup"@en .

ns1:ifs-v36-i6-IFS179323 ns0:hasKeywords "Fuel consumption"@en,
        "Green periodic VRP"@en,
        "Particle swarm optimization algorithm"@en,
        "robust optimization"@en ;
    ns0:hasPubAbstract "The purpose of this paper is to examine and evaluate a new mathematical model of vehicle routing problem in order to optimize fuel consumption and maximize commercial profitability under the conditions of uncertainty of distributor service to customers using robust approach under scenario. According to the real world, distribution companies are interested in minimizing consumption of fuel in the distribution of goods for two reasons: the first reason is that reducing the consumption of fuel will reduce the current costs of distribution companies and ultimately increase their profits. The second reason is that reducing fuel consumption will reduce the harmful effects of greenhouse gases and air pollution. Other words, distribution companies operate in a competitive environment that has more than one distributor in the distribution network, and start time for serving customers has a significant impact on the profitability of the distributors. To calculate the efficiency of the proposed model, we used differential evolution (DE) algorithm and Particle swarm optimization (PSO), and the results were compared in small and medium scales with the results of the exact solution method. To verify proceeds of proposed algorithms in large scales, a number of sample problems were created in large scales and the figures were evaluated. The computational results indicate that DE algorithm has a better computational function, but the PSO algorithm has better computational time."@en ;
    ns0:hasPubTitle "A robust approach for a green periodic competitive VRP under uncertainty: DE and PSO algorithms"@en .

ns1:ifs-v36-i6-IFS18071 ns0:hasKeywords "Bibliographic analysis"@en,
        "Centroid defuzzification"@en,
        "Decision making"@en,
        "General type-2 fuzzy sets"@en,
        "Real-time traffic dataset"@en ;
    ns0:hasPubAbstract "The Decision making has been a major research topic in the computing literature for so long due to its vast significance in many real-world applications. Traditional fuzzy decision making (FDM) approaches have limitations due to the inability of the type-1 fuzzy sets (T1 FSs) in modeling higher order uncertainties. Since, the membership function (MF) of an interval type-2 fuzzy set (IT2 FS) is also fuzzy, as superior to T1 FSs, researchers considered IT2 FSs to model higher level of uncertainties in FDM and proposed a number of IT2 FDM methods. However, unlike IT2 FSs, general type-2 fuzzy sets (GT2 FSs) do not consider equal secondary membership values for all its primary membership functions. Hence, GT2 FSs offer more suitability in modelling uncertainties that exist in real-world scenarios. Thus, this paper proposes a more efficient decision making method called the “GT2 Fuzzy Decision Making (GT2 FDM)”, which considers GT2 FSs to model the fuzzy goals and fuzzy constraints in a problem. The working of the proposed approach is demonstrated using an example of room temperature selection. Then we have applied it to the problem of convenient travel time selection using a real-time traffic data set. It is observed that the proposed GT2 FDM approach offers more flexibility to the decision makers in choosing an optimal solution from a much wider solution space and hence is found to be more efficient than the IT2 FDM and classical FDM approaches."@en ;
    ns0:hasPubTitle "General Type-2 fuzzy decision making and its application to travel time selection"@en .

ns1:ifs-v36-i6-IFS18106 ns0:hasKeywords "Auto Tuning Fuzzy PI(ATFPI) controller"@en,
        "DFIG"@en,
        "coordinator unit"@en,
        "isolated system"@en,
        "transient condition"@en ;
    ns0:hasPubAbstract "An isolated network with Wind Turbine implemented by Double Fed Induction Generator (WTDFIG) that maintaining different electrical variables in safe ranges following a severe transient condition is always a serious challenge. This paper proposes a control scheme based on Auto-Tuning Fuzzy PI (ATFPI) concept for the Rotor Side Converter (RSC) of the DFIG by online tuning of the output scaling factor of the ATFPI for enhancement the transient behavior of the system under various condition of operation. The scheme includes a coordinator unit which is elaborated to effectively regulate the frequency and active power of the system. The performance of the proposed ATFPI controller is evaluated in a typical network in Matlab Simulink environment. Obtained results show that the control can successfully meet all functions drawn in the scope and easily put behind the conventional competitors like conventional PI and/or fuzzy PI controllers."@en ;
    ns0:hasPubTitle "Performance analysis of an isolated WTDFIG under transient condition using a fuzzy control strategy"@en .

ns1:ifs-v36-i6-IFS181097 ns0:hasKeywords "Dependence; Inclusion degree"@en,
        "Gaussian kernel"@en,
        "Granular computing"@en,
        "Incomplete real-valued information system"@en,
        "Information granule"@en,
        "Information structure"@en,
        "Information structures"@en ;
    ns0:hasPubAbstract "An information system as a database that shows relationships between objects and attributes is a crucial mathematical model in the field of artificial intelligence. A real-valued information system is an information system where information function values of each attribute are real numbers. This paper explores information structures in an incomplete real-valued information system. Distances between two objects in a given subsystem of an incomplete real-valued information system is first constructed. Then, the fuzzy Tcos-equivalence relation, induced by this subsystem by using Gaussian kernel method, is obtained, where Gaussian kernel is based on this distance. Next, information structure of this subsystem is proposed. Moreover, relationships between two information structures are studied from the two aspects of dependence and separation. Finally, the dependence between two information structures is studied by using inclusion degree. These results will be helpful for establishing a framework of granular computing."@en ;
    ns0:hasPubTitle "Information structures in an incomplete real-valued information system1"@en .

ns1:ifs-v36-i6-IFS181191 ns0:hasKeywords "Image segmentation"@en,
        "interval valued fuzzy clustering"@en,
        "multi-objective optimization"@en,
        "non-local spatial information"@en ;
    ns0:hasPubAbstract "Interval valued fuzzy c-means (IVFCM) clustering algorithm is one of effective clustering algorithms. When applied to image segmentation, IVFCM includes three problems as follows: (1) It is sensitive to the initial values of algorithm and may easily fall into the local optimal. (2) The algorithm is sensitive to the image noise and cannot obtain the satisfying performance on images corrupted by noise. (3) It always performs image segmentation under one objective function, therefore it cannot meet multiple practical needs. In order to address these problems, a multi-objective interval valued fuzzy clustering algorithm is proposed in this paper. This method constructs two novel interval valued fuzzy fitness functions which utilize the non-local spatial information of the image. Then a new mutation operator combining the interval valued fuzzy information of image is designed. Furthermore, an effective interval valued fuzzy cluster validity index using the non-local spatial information of image is presented to select a single solution from the non-dominated solution set. Experimental results show that the proposed method behaves well in noisy image segmentation."@en ;
    ns0:hasPubTitle "A multi-objective interval valued fuzzy clustering algorithm with spatial information for noisy image segmentation"@en .

ns1:ifs-v36-i6-IFS181246 ns0:hasKeywords "Symbolic aggregate approximation (SAX)"@en,
        "bearing defect diagnosis"@en,
        "enhanced SAX"@en,
        "fault pattern"@en ;
    ns0:hasPubAbstract "This paper proposes a novel symbolic representation method of feature extraction for fault diagnosis and condition monitoring. The Symbolic Aggregate approXimation (SAX) technique basically transforming real-valued time series into symbol sequences, has been proven as a newly developed tool of feature extraction for fault diagnosis. However, the original SAX is based on the Piecewise Aggregate Approximation (PAA) representation, which is primarily transformed by the calculation of mean value of the equal sized data subsection for dimensionality reduction. Such mean value-based method has a high possibility of missing important information patterns in vibration signals. To overcome this limitation, an enhanced SAX (ESAX) is proposed to extract fault features well from vibration signals. The ESAX utilizes mean value together with two additional important points (the max and min points) to conduct the symbol representation in PAA process. Next, the Shannon entropy technique is conducted on the symbol sequences generated by ESAX to extract features for classification tasks. Compared with SAX, the ESAX can extract more comprehensive signal characteristics considering important information points and local fault patterns. The effectiveness and superiority of the ESAX were validated by experimental studies using the fault signals of rolling bearings."@en ;
    ns0:hasPubTitle "A novel feature extraction algorithm for bearing fault diagnosis based on enhanced symbolic aggregate approximation"@en .

ns1:ifs-v36-i6-IFS181347 ns0:hasKeywords "discriminant analysis"@en,
        "face recognition"@en,
        "graph embedding"@en,
        "kernel method"@en,
        "support vector domain description (SVDD)"@en ;
    ns0:hasPubAbstract "This paper addresses the problem of Face Recognition based on Image Set (FRIS) by kernel learning and proposed an extended kernel discriminant analysis framework for FRIS. By support vector machine learning, an image set from the original input space is mapped into the model space and described with Support Vector Domain Description (SVDD) to handle the underlying non-linearity in data space. In model space, a hyper-sphere encloses most of the mapped data, and the outliers lie outside the hyper-sphere. By exploring an efficient metric for the data domains in model space, we derive a kernel function maps the data from the model space to a high-dimensional feature space, to which many Euclidean algorithms can be generalized. The proposed method is evaluated on face recognition tasks. Comparisons with several state-of-the-art FRIS methods are performed on ChokePoint and CMU MoBo video database. The proposed methods have demonstrated promising performance."@en ;
    ns0:hasPubTitle "Kernel Analysis based on SVDD for Face Recognition from Image Set"@en .

ns1:ifs-v36-i6-IFS181478 ns0:hasKeywords "Betti number"@en,
        "Gallai simplicial complex"@en,
        "f-graph"@en,
        "f-vector"@en ;
    ns0:hasPubAbstract "Let ΔΓ (G) be Gallai simplicial complex defined as a generalization of Gallai graph Γ (G) such that G is a finite simple graph. The Betti numbers are topological objects which were proved to be invariants by Poincaré. In this note, we give formula for Betti numbers of Gallai simplicial complex associated to prism graph by coding in MATLAB. We prove that a simple graph G having n vertices of the form n = 3l + 2 or 3l + 3 is f-Gallai graph for   G =    𝕊    4 l     (respectively   G =    𝕊    4 l + 1    ) a graph consisting of star graphs S2l and    S  2 l  ′    (respectively S2l and S2l+1) with l common vertices such that l ≥ 2."@en ;
    ns0:hasPubTitle "Gallai simplicial complexes"@en .

ns1:ifs-v36-i6-IFS181545 ns0:hasKeywords "IVIFWDHM operator"@en,
        "IVIFWHM operator"@en,
        "Multiple attribute decision making (MADM)"@en,
        "competiveness evaluation"@en,
        "interval-valued intuitionistic fuzzy numbers (IVIFNs)"@en,
        "tourist destination"@en ;
    ns0:hasPubAbstract "In this paper, we expand the Hamy mean (HM) operator and dual Hamy mean (DHM) operator with IVIFNs to propose the interval -valued intuitionistic fuzzy Hamy mean (IVIFHM) operator, interval-valued intuitionistic fuzzy weighted Hamy mean (IVIFWHM) operator, interval-valued intuitionistic fuzzy dual Hamy mean (IVIFDHM) operator and interval-valued intuitionistic fuzzy weighted dual Hamy mean (IVIFWDHM) operator. Then the MADM models are designed with IVIFWHM and IVIFWDHM operators. Finally, we gave an example for competiveness evaluation of tourist destination to show the proposed models."@en ;
    ns0:hasPubTitle "Models for competiveness evaluation of tourist destination with some interval-valued intuitionistic fuzzy Hamy mean operators"@en .

ns1:ifs-v36-i6-IFS181602 ns0:hasKeywords "Nullnorm"@en,
        "bounded lattice"@en,
        "direct product"@en ;
    ns0:hasPubAbstract "Nullnorms are aggregation functions on the unit interval [0, 1] related to ordinal sums of t-conorms defined on [0, a] and t-norms defined on [a, 1], where a is the annihilator of the considered aggregation function. In this paper some basic algebraic properties like idempotent and nilpotent elements of nullnorms on the unit interval are introduced and discussed. Then, the direct product of nullnorms on bounded lattices is defined and properties of introduced nullnorms are deeply investigated. Thus by defining such algebraic properties and direct product of nullnorms, triangular norms and triangular conorms are extended to a more general form. Finally, we study some properties concerning orders induced by nullnorms acting on lattices."@en ;
    ns0:hasPubTitle "Direct product of nullnorms on bounded lattices"@en .

ns1:ifs-v36-i6-IFS181642 ns0:hasKeywords "Fuzzy formal concept"@en,
        "crisp-fuzzy concept"@en,
        "graph theory"@en ;
    ns0:hasPubAbstract "In order to find a more efficient method for constructing a fuzzy concept lattice, This paper applies graph theory to a fuzzy formal context. A fuzzy formal context is represented by a weighted graph. A method for generating all crisp-fuzzy concepts by a weighted graph is proposed and the corresponding algorithm–Algorithm 1 is given in a fuzzy formal context. Through algorithm analysis, it is illustrated that Algorithm 1 is better than some of existed algorithms to obtain crisp-fuzzy concepts in a fuzzy formal context."@en ;
    ns0:hasPubTitle "The construction of fuzzy concept lattice based on weighted complete graph"@en .

ns1:ifs-v36-i6-IFS181717 ns0:hasKeywords "Power load forecasting"@en,
        "particle swarm optimization"@en,
        "support vector regression"@en,
        "triangular fuzzy discrete difference equation"@en ;
    ns0:hasPubAbstract "In this paper, we develop a new triangular fuzzy series combination forecasting method based on triangular fuzzy discrete difference equation forecasting model and PSO-SVR, and use the developed forecasting method to power load forecasting. First, we propose a triangular fuzzy discrete difference equation (TFDDE) forecasting model to predict the triangular fuzzy series, which can accurately predict the fluctuating trend and is suitable for small sample data. Then, the support vector regression optimized by particle swarm optimization (PSO-SVR) is adopted to further improve the forecast result of TFDDE forecasting model, in which the parameters of support vector regression are optimally obtained by particle swarm optimization algorithm so as to avoid the blindness of artificial selection. Finally, the practical example of load forecasting of US PJM power market is employed to illustrate the proposed forecasting method. The experimental results show that the proposed forecasting method produces much better forecasting performance than some existing triangular fuzzy series models. The proposed combination forecasting method, which fully capitalizes on the time series forecasting model and intelligent algorithm, makes the triangular fuzzy series prediction more accurate than before and has good applicability. This is the first attempt of employing discrete difference equation theory for the triangular fuzzy series forecasting."@en ;
    ns0:hasPubTitle "Power load combination forecasting based on triangular fuzzy discrete difference equation forecasting model and PSO-SVR"@en .

ns1:ifs-v36-i6-IFS181762 ns0:hasKeywords "Homomorphisms"@en,
        "Ideals"@en,
        "Rough ideals"@en,
        "Rough s-ideals"@en,
        "Rough sets"@en,
        "S-ideals"@en,
        "Skew lattices"@en ;
    ns0:hasPubAbstract "Skew lattice theory and rough set theory are relatively independent. In this paper, we focus on the relationship between rough sets and skew lattices, a non-commutative generalization of lattices. Motivated by the study on rough ideals in algebraic structures such as lattices, groups and gamma semigroups, we investigate rough substructures of skew lattices, including rough sub-skew lattices and rough sublattices, rough ideals and rough filters, as well as rough s-ideals and rough s-filters."@en ;
    ns0:hasPubTitle "Roughness in Substructures of Skew Lattices"@en .

ns1:ifs-v36-i6-IFS181777 ns0:hasKeywords "DIF-MADM"@en,
        "Evidential reasoning algorithm"@en,
        "MDIFWG operator"@en ;
    ns0:hasPubAbstract "The present work is focused on dynamic intuitionistic fuzzy multi-attribute decision making (DIF-MADM) problem, while \"dynamic\" means the decision-related information may be collected at different periods, a situation commonly happened in many of real world MADM problems. After the review and analysis of some drawbacks on the existing DIF-MADM methods, on the one hand, we propose a new DIF-MADM method based on the evidential reasoning (ER) algorithm in order to address some of those limits; on the other hand, and a new dynamic intuitionistic fuzzy weighted geometric (DIFWG) operator is introduced, named modified dynamic intuitionistic fuzzy weighted geometric (MDIFWG) operator, then a MDIFWG-based DIF-MADM method is also proposed to address some other limits of the existing methods. Some numerical examples are provided to illustrate the practicality and feasibility of the proposed two methods through, the comparative analysis with the existing DIF-MADM methods, along with some sensitivity analyses also carried out to analyse the distinct features of the proposed methods."@en ;
    ns0:hasPubTitle "Dynamic intuitionistic fuzzy multiattribute decision making based on evidential reasoning and MDIFWG operator"@en .

ns1:ifs-v36-i6-IFS181790 ns0:hasKeywords "4SS"@en,
        "Block matching algorithms"@en,
        "ME"@en,
        "MV"@en,
        "TSS"@en ;
    ns0:hasPubAbstract "To exploit the temporal and spatial redundancy and to expedite the process of video encoding it is required to find the motion Vector (MV) by a process called Motion Estimation (ME). In this paper, optimal motion estimation algorithms based on correlation that exists between consecutive macro blocks in a frame of a video with stopping criteria are proposed. The different neighborhood macro blocks (MB) form the Locality of Reference (LOR) of the candidate macro blocks in the reference frame and these LOR defines the types of algorithms which are named as Correlation Based Rood Pattern Search (CBRPS) in four variations which effectively reduce the search time, computational complexity without compromising the PSNR values i.e. quality of the compensated image. The results obtained are compared with the results with relevant existing techniques to highlight the superior performance of the proposed algorithms. All the proposed algorithms outperform the existing techniques both in terms of computational complexity and PSNR values. Amongst the four proposed algorithms the fourth type of CBRPS i.e. CBRPS_T4 is found to be the best for linear and transverse motion of objects in the videos in terms of computational complexity."@en ;
    ns0:hasPubTitle "Correlation Based Rood Pattern Search (CBRPS) for Motion Estimation in Video Processing"@en .

ns1:ifs-v36-i6-IFS181934 ns0:hasKeywords "Authorship verification"@en,
        "centrality measures"@en,
        "social network analysis"@en,
        "supervised learning"@en,
        "syntactic flow graph"@en ;
    ns0:hasPubAbstract "This paper presents an approach to solve authorship verification, a forensic text problem which consists in determining whether or not an unknown document was written by a particular author, from some samples of the author’s writing style. The core of the approach is the use of a graph representation to extract relevant linguistic features based on network analysis techniques. The use of graphs provides rich data structures for representing lexical and syntactic aspects of texts, allowing the reinterpretation of centrality measures to extract linguistic features that do not depend entirely of stylistic elements of text documents. The proposed method is applied on the English language partitions of the clef PAN 2014 and 2015 author verification datasets, producing competitive results that outperform the state of the art baselines and are near (or surpass in one of the cases) to the best results reported so far, given the same training and test corpora. These experimental results showed that our interpretation of the four centrality measures: closeness, betweenness, degree and eigenvector allow to detect relevant patterns of an author’s writing style. In particular, words with high closeness which are part of some chunk phrases and words with high betweenness that are included in bigrams and trigrams, contribute in a more effective way to verify document authorship."@en ;
    ns0:hasPubTitle "Authorship Verification using a Graph Knowledge Discovery Approach"@en .

ns1:ifs-v36-i6-IFS181972 ns0:hasKeywords "N-soft sets"@en,
        "TOPSIS"@en,
        "decision-making"@en,
        "hesitant fuzzy N-soft set"@en,
        "hesitant fuzzy sets"@en ;
    ns0:hasPubAbstract "Hesitant fuzzy set theory is a renowned approach to the formal modeling of uncertain data. An evidence of its success is that it has been extensively used in multi-attribute decision-making problems. Hesitant fuzzy computations make the decision-makers’ assessments more flexible and rich, thus improving reliability of the decisions that depend on them. In this research article we introduce a novel hybrid model called hesitant fuzzy N-soft sets, which further enhances the virtues of hesitant fuzzy set theory with the benefits of N-soft sets. This theoretical model is capable of incorporating information about the occurrence of ratings or grades in a hesitant environment. We investigate some useful properties of hesitant fuzzy N-soft sets and construct fundamental operations on them. By doing so we lay the groundwork for subsequent analyses and applications. We then develop novel approaches to decision-making including TOPSIS (Technique for Order Preference by Similarity to an Ideal Solution), choice value and L-choice value based on hesitant fuzzy N-soft sets. Finally, we describe potential applications of our model and present the proposed methods as algorithms."@en ;
    ns0:hasPubTitle "Hesitant fuzzy N-soft sets: A new model with applications in decision-making"@en .

ns1:ifs-v36-i6-IFS181982 ns0:hasKeywords "Cooperative games"@en,
        "bargaining sets"@en,
        "core"@en,
        "fuzzy payoffs"@en,
        "nucleolus"@en ;
    ns0:hasPubAbstract "Depended on the expected values of fuzzy numbers, a total order relation of fuzzy numbers is proposed. We show that three concepts of the indifference fuzzy core, nucleolus and bargaining sets of cooperative games with fuzzy payoffs are well-defined following from this total order relation, whereas it is impossible to define by any partial order relation of fuzzy numbers for these concepts. Moreover, we raise a necessary and sufficient condition for non-emptiness of the indifference fuzzy core. It is further shown that there is at least one fuzzy payoff vector in the indifference fuzzy nucleolus. For convex or superadditive cooperative games with fuzzy payoffs, the indifference fuzzy bargaining sets coincide with the indifference fuzzy core."@en ;
    ns0:hasPubTitle "On the core, nucleolus and bargaining sets of cooperative games with fuzzy payoffs"@en .

ns1:ifs-v36-i6-IFS181997 ns0:hasKeywords "Distribution supply chain"@en,
        "algorithm"@en,
        "fuzzy demand"@en,
        "uncertainty theory"@en ;
    ns0:hasPubAbstract "This paper applies the credibility distribution of fuzzy variables in uncertainty theory to formulate a fuzzy optimization model, so as to study the coordination mechanism of a distribution supply chain system with fuzzy demand. This practical system, focusing on the demand side of the supply chain, comprises multi-period, multi-manufacturer, multi-retailer, and multi-consumer. Next, using a novel modified sequence quadratic programming algorithm, the optimal order quantity, sales volume of the retailers, and the maximum expected return of the distribution supply chain are obtained. The effects of the wholesale price, retail price, and inventory cost on the expected return are also analyzed. Finally, the usfulness of the proposed modified sequence quadratic programming algorithm is compared against the conventional MATLAB optimal toolbox and genetic algorithm. Our computational results validate in favour of the proposed algorithm in terms of the computational time, number of iterations, and convergence rate."@en ;
    ns0:hasPubTitle "Optimization of fuzzy demand distribution supply chain using modified sequence quadratic programming approach"@en .

ns1:ifs-v36-i6-IFS182518 ns0:hasKeywords "Two-layer Wang-Mendel model"@en,
        "bottom-up prediction"@en,
        "prediction of residuaryresistance"@en,
        "top-down construction"@en ;
    ns0:hasPubAbstract "Residuary resistance prediction is an important initial step in the process of designing a sailing yacht. Being able to predict the residuary resistance accurately is crucial for calculating the required propulsive power and ensuring good performance of the sailing yacht. This paper presents a two-layer Wang-Mendel (WM) fuzzy approach to improve the approximation ability of the WM model for this prediction task. Unlike the traditional WM method, in which the consequent of its fuzzy rules is a fuzzy set, the consequent of our proposed approach corresponds to a fuzzy rule base. We apply a top-down method and fuzzy-rule clustering to construct the two-layer WM model, while a bottom-up method is employed to predict the residuary resistance. Experimental results based on two benchmark functions and a yacht hydrodynamics application show that the proposed approach is able to obtain improved robustness and accuracy in predicting residuary resistance compared to other WM model variants and well-known machine learning algorithms."@en ;
    ns0:hasPubTitle "A two-layer Wang-Mendel fuzzy approach for predicting the residuary resistance of sailing yachts"@en .

ns1:ifs-v36-i6-IFS182594 ns0:hasKeywords "CODAS"@en,
        "Hesitant fuzzy soft set"@en,
        "WDBA"@en,
        "decision-making approach"@en,
        "revised aggregation operators"@en ;
    ns0:hasPubAbstract "Realistically, it isn’t invariably the case that decision makers (DMs) or experts are capable of evaluating alternatives by means of exact values. With the uncertain information achieved, the DMs tend to offer their evaluations by giving various values in corresponding parameters. Hesitant fuzzy soft sets (HFSSs) permit each element to possess diverse number of parameter values of those parameters are denoted by multiple conceivable membership values. This paper develops three novel decision making methods in hesitant fuzzy soft text. First, the revised hesitant fuzzy aggregation operators are proposed for avoiding the counterintuitive phenomena. Later, the objective weights of diverse parameters are counted by deviation-based method. Then, we introduce the combination weights, which can reveal both the subjective decision information and the objective decision information. Afterwards, we present three methods for dealing hesitant fuzzy soft decision making issue via revised aggregation operators, WDBA (Weighted Distance Based Approximation) and CODAS (COmbinative Distance-based ASsessment). Finally, the feasibility and effectiveness of algorithms are stated by some numerical examples. The notable traits of the developed algorithms, compared to the existing hesitant fuzzy soft decision making algorithms, are (1) they can achieve the best alternative out of counterintuitive phenomena; (2) they have a stronger ability in differentiating the best alternative; (3) they can forbear the parameter selection issues."@en ;
    ns0:hasPubTitle "Algorithms for hesitant fuzzy soft decision making based on revised aggregation operators, WDBA and CODAS"@en .

ns1:ifs-v36-i6-IFS182654 ns0:hasKeywords "Soft fuzzy rough set"@en,
        "decision making"@en,
        "fuzzy soft set"@en,
        "modal-style operator"@en ;
    ns0:hasPubAbstract "The hybrid soft sets such as, fuzzy soft sets and soft fuzzy rough sets, have been regarded as mathematical tools for handling uncertainties. The aim of this paper is to develop a novel decision making approach for fuzzy soft sets. The modal-style operators of formal context are introduced to fuzzy soft sets and some basic properties of these operators are discussed in detail. A novel fuzzy soft set based decision making approach is presented by using modal-style operators. Further, some shortcomings of an existing decision making method have been highlighted and overcome by the proposed decision making approach. Some numerical examples are employed to show the effectiveness of the approach presented in this study."@en ;
    ns0:hasPubTitle "Modal-style operators on fuzzy soft sets and their application to decision making"@en .

ns1:ifs-v36-i6-IFS182709 ns0:hasKeywords "Soft set"@en,
        "inverse soft matrix, products of inverse soft matrices"@en,
        "inverse soft set"@en,
        "multicriteria decision making"@en ;
    ns0:hasPubAbstract "In this paper, we first describe the inverse soft matrices corresponding to the inverse soft sets over both the universal set and the parameter set. For these matrices, we derive some row-products such as And, Or and some column-products such as If, Iff. As an endeavor to find the authentic-life applications of these products in multicriteria decision making (MCDM) through inverse soft matrices, we propose two decision making methods called inverse soft distributive sum-max decision making method (ISDSMDM) and inverse soft distributive If-sum decision making method (ISDISDM). The ISDSMDM aims to obtain a solution for the MCDM problem based on the inverse soft structures consisting of multi-disjoint parameter sets and the common universal set. The ISDISDM focuses on the optimal choice for MCDM problem based on the inverse soft structures consisting of multi-disjoint parameter sets and two discrete universal sets. Also, we present the outstanding applications of these methods. In integration, we give Scilab codes of our algorithms to perform the decision making process expeditiously."@en ;
    ns0:hasPubTitle "The row-products of inverse soft matrices in multicriteria decision making"@en .

ns1:ifs-v36-i6-IFS182815 ns0:hasKeywords "Uncertain variable"@en,
        "convergence in measure"@en,
        "numerical series"@en,
        "positive numerical series"@en ;
    ns0:hasPubAbstract "This paper presents some continuous dependence theorems on solutions of uncertain differential equations based on uncertain measure. We first introduce some properties on solution of uncertain differential equation. And then, we provide a continuous dependence theorem, and a continuity theorem to the initial value. In the proposed continuity theorem, the solution is regarded as a ternary function of initial values. Furthermore, we discuss how the solution continuously depends on initial value and parameter, and propose two theorems, namely, continuous dependence theorem on parameter, and continuity theorem on parameter to the initial value."@en ;
    ns0:hasPubTitle "Continuous dependence on solutions of uncertain differential equations via uncertain measure"@en .

ns1:ifs-v36-i6-IFS182873 ns0:hasKeywords "MA-simulation function"@en,
        "fixed point"@en,
        "fuzzy metric space"@en,
        "t-norm"@en,
        "α-admissible ΞMA-contraction mapping"@en ;
    ns0:hasPubAbstract "In this paper, the idea of MA-simulation function is introduced which has further been utilized to establish new fixed point results in fuzzy metric spaces. Moreover, it is shown that the proven result is quite a unified one to generalize several existing result. Furthermore, some new results are established to show the utility of our results. Some illustrative examples are also given which exhibit the usability of our results. Finally, we provide an application of our main results."@en ;
    ns0:hasPubTitle "Proving new fixed point results in fuzzy metric spaces employing simulation function"@en .

ns1:ifs-v36-i6-IFS182924 ns0:hasKeywords "Soft sets"@en,
        "decision making"@en,
        "similarity measure"@en,
        "soft operations"@en ;
    ns0:hasPubAbstract "The primary objective of this study is to introduce some generalized operations on the soft sets and to investigate their related characteristic properties. It also aims to propose new similarity measure and decision making method using these generalized operations. Furthermore, the emerging similarity measure and decision making method are compared with some of the existing similarity measure and decision making method based on soft sets, thus the credibility of the proposed ones is shown. Additionally, the congruous examples which help to better understand the similarity measure and decision making method are presented."@en ;
    ns0:hasPubTitle "Some generalized operations in soft set theory and their role in similarity and decision making"@en .

ns1:ifs-v36-i6-IFS18473 ns0:hasKeywords "Feature selection"@en,
        "feature ranking"@en,
        "machine learning"@en,
        "web application quality"@en ;
    ns0:hasPubAbstract "In order to minimize the over-fitting and related factors that are caused by the high dimensionality of the input data in software defect prediction, the attributes are often optimized using various feature selection techniques. However, the comparative performance of these selection techniques in combination with machine learning algorithms remains largely unexplored using web applications. In this work, we investigate the best possible combination of feature selection technique with machine learning algorithms, with the sample space chosen from open source Apache Click and Rave data sets. Our results are based on 945 defect prediction models derived from parametric, non-parametric and ensemble-based machine learning algorithms, for which the metrics are derived from the various filter and threshold-based ranking techniques. Friedman and Nemenyi post-hoc statistical tests are adopted to identify the performance difference of these models. We find that filter-based feature selection in combination with ensemble-based machine learning algorithms not only poise as the best strategy but also yields a maximum feature set redundancy by 94%, with little or no comprise on the performance index."@en ;
    ns0:hasPubTitle "Empirical assessment of feature selection techniques in defect prediction models using web applications"@en .

ns1:ifs-v36-i6-IFS18725 ns0:hasKeywords "Multicriteria fuzzy TU games"@en,
        "dynamic process"@en,
        "excess function"@en,
        "reduced game"@en,
        "supreme-utility"@en ;
    ns0:hasPubAbstract "By considering supreme-utilities among fuzzy level (decision) vectors, we introduce an index and its efficient extension to investigate power mensuration mechanism in the framework of multicriteria fuzzy transferable-utility (TU) games. We also adopt reduced games and related consistency to analyze the rationality for these two indexes. Further, alternative formulation for the efficient index is also proposed by applying excess function. Based on reduced game and excess function, we introduce different dynamic processes for the efficient index."@en ;
    ns0:hasPubTitle "Power mensuration mechanism under fuzzy behavior and multicriteria situation"@en .

ns1:ifs-v36-i6-IFS18950 ns0:hasKeywords "Construction site factors"@en,
        "concrete strength"@en ;
    ns0:hasPubAbstract "Concrete is influenced by affecting conditions during its production and construction processes. The literature reveals that there is limited understanding about the effect of unstructured factors (i.e., construction site factors) on concrete product. Crew experience, compaction method, mixing time, curing humidity, and curing temperature were selected to quantify their impact on concrete compressive strength, fabrication cost, and production rates. Each response was measured and utilized for fuzzy modeling. A Sugeno-type fuzzy inference system (FIS) was obtained for quantifying each response. Model validation was accomplished by plotting predicted versus experimental data while sensitivity analysis used Monte Carlo simulation and Spearman’s correlation coefficients. Curing temperature was identified as the most influential factor for concrete compressive strength while mixing time was identified to have the largest impact on concrete cost and production rates. All FISs can be used as supporting tools to discern desired concrete operating conditions."@en ;
    ns0:hasPubTitle "Impact of unstructured factors on concrete through fuzzy models"@en .

ns1:ifs-v36-i6-IFS18998 ns0:hasKeywords "Fuzzy neural network"@en,
        "fuzzy systems"@en,
        "intuitionistic fuzzy sets"@en ;
    ns0:hasPubAbstract "In this study, an intuitionistic fuzzy neural network (IFNN) with Gaussian membership function and Yager-generating function is proposed. Since intuitionistic fuzzy logic (IFL) considers membership, non-membership and hesitation values simultaneously, the incorporation of the concept of IFL into a fuzzy neural network (FNN) can enhance the performance of an FNN. A back-propagation learning algorithm is developed to optimize the IFNN parameters and weights. The proposed IFNN is applied to ten problems, including nonlinear control and prediction problems. The computational results indicate that the proposed IFNN is more efficient than conventional algorithms, such as artificial neural networks (ANN), fuzzy neural networks (FNN), and a support vector regression (SVR)."@en ;
    ns0:hasPubTitle "An intuitionistic fuzzy neural network with gaussian membership function"@en .

ns1:ifs-v37-i1-IFS162405 ns0:hasKeywords "Digital image watermarking"@en,
        "IWT"@en,
        "PSNR"@en,
        "block-based"@en,
        "optimum embedding"@en ;
    ns0:hasPubAbstract "In this research, a novel block-based, integer wavelet transform (IWT) domain digital image watermarking scheme for optimum information embedding using a Fuzzy Rule Based System (FRBS) is proposed. There are three famous conflicting parameters in digital image watermarking, namely, robustness, imperceptibility and payload are linked with each other and a change in one parameter affects others and vice versa. That’s why it is hard to optimize them, jointly because of the inherent non-linearity and in the literature, any pair of parameters is optimized while third is assumed as fixed. In this proposal, this non-linear problem is solved using FRBS by using the logical relationship among three parameters and it consequently suggests the image from the image-bank that may convey the desired payload (capacity) with maximum imperceptibility and robustness. The proposed FRBS is two-fold. Firstly, selection of candidate image blocks from the given image and secondly selection of the candidate coefficients from the already chosen blocks for embedding the desired payload. Images having coefficients greater than a certain threshold are chosen and the payload is embedded. Consequently, the watermarked images are passed through various attacks and the image with maximum robustness is selected. The effectiveness of the proposed scheme is demonstrated through MATLAB simulations and comparison with state-of-the-art techniques."@en ;
    ns0:hasPubTitle "Optimum information embedding in digital watermarking"@en .

ns1:ifs-v37-i1-IFS16913 ns0:hasKeywords "Credibility/Trust measure"@en,
        "Deterioration"@en,
        "Particle Swarm Optimization"@en,
        "Promotional Cost"@en,
        "Two-warehouse model"@en ;
    ns0:hasPubAbstract "Here two-level supply chain model is considered for a deteriorating item where the retailer’s warehouse in the market place has a limited capacity. Therefore the retailer can rent a warehouse (RW) if needed with a higher cost compared to own warehouse (OW). This model includes one wholesaler and one retailer and our aim is to maximize the total profit. The demand rate in retailer is stock-dependent and in case of any shortages, the demand is partially backlogged. Retailer also introduces some promotional cost to boost the base demand of the item. It is established that if the wholesaler shares a part of promotional cost then channel profit as well as individual profit increase. The supply chain model is also considered for imprecise environment when different inventory parameters are fuzzy/rough in nature. In this case individual profits as well as channel profit become fuzzy/rough in nature. As optimization of fuzzy/rough objective is not well defined, following credibility/trust measure of fuzzy/rough event, an approach is proposed for comparison of fuzzy/rough objectives and a Particle Swarm Optimization (PSO) algorithm is used to find marketing decisions. Models are illustrated with numerical examples."@en ;
    ns0:hasPubTitle "A supply chain of deteriorating items with variable demand"@en .

ns1:ifs-v37-i1-IFS171488 ns0:hasKeywords "Generalized unified power flow controller (GUPFC)"@en,
        "critical cleaning time (CCT)"@en,
        "lyapunov energy function"@en,
        "neuro-fuzzy control"@en,
        "transient stability"@en ;
    ns0:hasPubAbstract "In recent years, because of the regeneration and development of power systems many of their technical and economical characteristics have been changed in different sections of generation, transmission, distribution and consumption. This issue has great impact on transmission systems because of the increased demand and limitation in creation of new lines. System stability against disturbances of big signal is one of the important issues that have been under threat as a result of this issue. In such circumstances, FACTS devices have great impact on increase of control ability and power system stability. One of the most effective FACTS devices is generalized unified power flow controller (GUPFC). It can combine the capabilities of SSSC, STATCOM and TCPAR by control of different parameters of network and can be used as a multipurpose tool. In this essay, designing a neuro-fuzzy controller for GUPFC to improve transient stability has been investigated. For this purposed, a controllable compensator has been designed to increase transient stability margin and damp transient oscillation in such systems by use of lyapunov stability criterion. Since transient energy function of system is a suitable tool for investigating of stability issue, optimization of GUPFC energy function has been noticed in order to reach the highest margin of transient stability. This idea is the basis of producing required teaching information in ANFIS network and can be used as a GUPFC controller. In this essay, the impact of GUPFC on single machine system, infinite bus (SMIB) and 9-bus system (Anderson and Fouad, 1977) by use of supposed method has been studied. Moreover by simulation of other FACTS devices such as UPFC and IPFC, the priority of GUPFC has been shown and the comparison of its result has been proved."@en ;
    ns0:hasPubTitle "Transient stability improvement with neuro-fuzzy control of GUPFC in multi machine system"@en .

ns1:ifs-v37-i1-IFS17283 ns0:hasKeywords "Hyperspectral face recognition"@en,
        "histogram of oriented gradients (HOG)"@en,
        "minimum noise fraction (MNF)"@en ;
    ns0:hasPubAbstract "Hyperspectral imaging provides new opportunities for improving face recognition accuracy. However, it poses such challenges as difficulty in data acquisition, low signal to noise ratio (SNR), and high dimensionality. In this paper, we propose a novel method for hyperspectral face recognition with good recognition rates. We first reduce noise adaptively from each spectral band and then crop each face. We perform minimum noise fraction (MNF) transform to the cropped face data cube in order to extract a number of MNF bands. We extract histogram of oriented gradients (HOG) features from each MNF band. We conducted some experiments to test this new method for hyperspectral face recognition with very promising results. For Hong Kong Polytechnic University Hyperspectral Face Database (PolyU-HSFD), we achieved an average correct recognition rate of 95.4% with standard deviation of 2.6 (95.4% ±2.6). For CMU Hyperspectral Face Database (CMU-HSFD), we achieved an average correct recognition rate of 98.1% with standard deviation of 0.8 (98.1% ±0.8). The reasons why we choose MNF for hyperspectral face recognition are because it can separate noise from fine features in the face data cube and at the same time reduce the dimensionality of the face data cube. In this way, our proposed face recognition method will be faster than those methods without dimensionality reduction."@en ;
    ns0:hasPubTitle "Hyperspectral face recognition with minimum noise fraction, histogram of oriented gradient features and collaborative representation-based classifier"@en .

ns1:ifs-v37-i1-IFS179060 ns0:hasKeywords "Cloud computing"@en,
        "optimization decision"@en,
        "safety behavior coefficient"@en,
        "safety management"@en ;
    ns0:hasPubAbstract "To build a safety behavior evaluation system in network management, the cloud computing model is introduced in this study for parametric study. First, the development model of cloud computing management is expounded, a parametric model of safety behavior coefficient is constructed by using a cloud computing platform. Then, an optimization and update scheme is put forward from the algorithm flow and evaluation model, and an adequate evaluation model is established by effectively evaluating the state of security management. Finally, the parameter data is refined through USES data mining algorithm to ensure the reasonable calculation of the data. In the test of the parameter model, the simulation is carried out by adopting the cloud computing platform. The test results prove that the application of the parameter model can guarantee the reasonable management of safety behavior, the error in the process of safety behavior management can be reduced, and the accuracy of control can be enhanced. The parameter model is worthy of further application and extension."@en ;
    ns0:hasPubTitle "Secure cloud computing model for communication network management"@en .

ns1:ifs-v37-i1-IFS179062 ns0:hasKeywords "Artificial intelligence"@en,
        "English teaching"@en,
        "network platform"@en ;
    ns0:hasPubAbstract "At present, artificial intelligence has developed rapidly and has been increasingly used in teaching, which has brought about earth-shaking changes in the education of various subjects. To further promote the intelligent development of college online courses, this paper studies the mathematical models and algorithms in the learning management system based on the knowledge forgetting curve. Through the analysis of the current situation of mathematical modeling and application of “knowledge forgetting curve,” the method of fuzzy mathematical knowledge and differential modeling is used, the mathematical model and algorithm design of a new “knowledge forgetting curve” is proposed. And the English word review program test is designed. The results show that the use of the program can overcome the oblivion of the words. It can be seen that the “integrated intelligent teaching network platform” has great application prospects and potential benefits."@en ;
    ns0:hasPubTitle "Artificial intelligence-based platform for online teaching management systems"@en .

ns1:ifs-v37-i1-IFS179078 ns0:hasKeywords "Recommendation"@en,
        "clustering"@en,
        "ontology"@en,
        "optimization"@en,
        "products"@en,
        "rough fuzzy"@en,
        "web page"@en ;
    ns0:hasPubAbstract "Personalized information recommendation in view of social labeling is a hot issue in the scholarly community and this web page data collected from the Internet of Things (IoT). To accomplish personalized web pages, the current investigation proposes a recommendation framework with two methodologies on user access behavior using Rough-Fuzzy Clustering (RFC) technique. In this paper, Fuzzy-based Web Page Recommendation (WPR) framework is provided with the user profile and ontology design. At first, the weblog documents were gathered from IoT to clean the data and undergo learning process. In the profile ontology module, the learner profile was spared as the ontology with an obvious structure and data. For identification of the similar data, innovative similarity measure was considered and for effective WPR process, the generated rules in RFC were optimized with the help of Chicken Swarm Optimization (CSO) technique. Finally, these optimal rules-based output recommends e-commence shopping websites with better performances. A group of randomly-selected users was isolated and on the basis of the obtained data, their clustering was performed by cluster analysis. Based on the current proposed model, the results were analyzed with performance measures and a number of top recommended pages were provided to users compared to existing clustering tech-niques."@en ;
    ns0:hasPubTitle "Optimal rough fuzzy clustering for user profile ontology based web page recommendation analysis"@en .

ns1:ifs-v37-i1-IFS179085 ns0:hasKeywords "optimal investment"@en,
        "reinsurance"@en,
        "stochastic interest rate"@en,
        "stochastic volatility"@en ;
    ns0:hasPubAbstract "Financial mathematics, an interdisciplinary subject between mathematics and finance, is the application of mathematics in the financial field, which carries mainly out the quantitative analysis and research of financial issues by mathematical theories and methods. The idea of financial mathematics is adopted to study investment. First of all, an investment risk prediction model is designed based on cluster analysis-hybrid genetic algorithm and integrated improved support vector machine, and AdaBoost-support vector machine and clustering-AdaBoost support vector machine, the model is fully analyzed and verified. Combining the ways of more than half random sampling, the imbalance state is adjusted and reduced. Then the idea of integrated learning is used to cope further the data imbalance state and improve the classifier’s attention to a few classes. Finally, the algorithm is tested. The results show that this algorithm effectively reduces the cost of accidentalinjury."@en ;
    ns0:hasPubTitle "Intelligent algorithm of optimal investment model under stochastic interest rate and stochastic volatility"@en .

ns1:ifs-v37-i1-IFS179086 ns0:hasKeywords "NDN"@en,
        "Network"@en,
        "PIT"@en,
        "bat optimization"@en,
        "fuzzy logic"@en ;
    ns0:hasPubAbstract "Named Data Networking (NDN) is a recent Internet model, takes the advantages and resolves the drawbacks of traditional TCP/IP architecture to satisfy the increasing demands on communication. Every NDN router has a pending interest table (PI) to store all the interest packets (I-pkts) waiting for the arrival of data packets (D-pkts). In case of the arrival of enormous I-pkts, it might be hard for an NDN router to store all I-pkts in the limited PIT space. So, a novel PIT management scheme becomes essential for effective PIT utilization. This paper presents a new PIT sharing algorithm based on the hybridization of bat optimization (BO) algorithm and fuzzy logic (BFPIT), to accommodate number of I-pkts in a sharing NDN (SN) node. The BFPIT algorithm intends to identify the optimal SN node sharing node to store I-pkts of a requestor NDN (RN) node. The proposed BFPIT algorithm operates in two stages: BO algorithm for preliminary SN (PSN) node selection and fuzzy logic for final SN (FSN) node selection. For validation, the proposed method is implemented, and the simulation results are compared with the k-nearest neighbor (k-NN) algorithm. The experimental results revealed that the BFPIT algorithm significantly increases the CHR and minimizes the average content delivery time."@en ;
    ns0:hasPubTitle "Bat optimization algorithm with fuzzy based PIT sharing (BF-PIT) algorithm for Named Data Networking (NDN)"@en .

ns1:ifs-v37-i1-IFS179090 ns0:hasKeywords "Green manufacturing"@en,
        "PID"@en,
        "coal blending"@en,
        "fuzzy self-tuning"@en,
        "intelligent control"@en ;
    ns0:hasPubAbstract "Due to the continuous improvement of industrial production requirements and green manufacturing demand, manufacturing enterprises and factories need to constantly optimize and improve the system structure. Based on the actual problems in the actual coal blending process, this paper analyzes the reason of the coal blending error in coal blending process and the optimization scheme of intelligent control of coal blending process. We optimized the overall structure of the coal blending system, improved the coal blending system which use the fuzzy control system. At the same time, we used MATLAB to simulate and analyse the simulation results. This paper gives an illustration to the optimal structure and system of the coal blending system, effectively improves the accuracy and stability of the coal blending process control system, reduces the coal blending error and improves the quality of coal blending in general."@en ;
    ns0:hasPubTitle "Optimization of coal blending process control based on fuzzy self-tuning"@en .

ns1:ifs-v37-i1-IFS179095 ns0:hasKeywords "Intelligent electric vehicle"@en,
        "quintic bézier curve"@en,
        "rolling window"@en,
        "s-shaped curve"@en,
        "trajectory planning"@en ;
    ns0:hasPubAbstract "Specific to the trajectory planning of intelligent electric vehicles with multi-constraints in some unknown environment, using rolling optimization principle of predictive model control for reference, an online trajectory planning algorithm based on a rolling window is proposed. Making full use of the local environmental information measured in real-time by intelligent electric vehicle, the path of continuous curvature is generated in the planning window by the Quintic Bézier curve and is optimized by the sequential quadratic planning algorithm. Furthermore, the optimal speed sequence for a given path is planed using the S-shaped curve velocity algorithm. Combining with the actual application scenario of an intelligent electric vehicle, the algorithm is simulated, and the trajectory planning experiment is carried out based on the actual environmental data. The results show that a safe trajectory with continuous curvature and optimal speed can be produced by using this algorithm in some unknown environment scenarios."@en ;
    ns0:hasPubTitle "Intelligent trajectory planning model for electric vehicle in unknown environment"@en .

ns1:ifs-v37-i1-IFS18034 ns0:hasKeywords "Space domes"@en,
        "particle swarm method"@en,
        "probabilistic constraints"@en,
        "reliability index"@en,
        "reliability-based optimization"@en ;
    ns0:hasPubAbstract "Reliability-based dome optimization (RBDO) is one of the most robust methods nowadays, which has made it possible to achieve a high degree of safety and optimum structural design at the same time. The purpose of optimization, based on the reliability of space domes, is to find the best set of sections of the structural members, which leads to the minimum structural weight, incorporating the probabilistic constrains. In the contest of reliability or probabilistic constrain, the applied loads, the module of elasticity, and the cross-sections of the members are considered as random variables with the specified probability distributions. The particle swarm method (PSO) is used as optimization algorithm because it is a simple and robust method in the case of nonlinear objective functions. In order to investigate the effect of probabilistic constraints selections based on three displacement, stress, and combination of displacement and stress, three space domes with different height to span ratios are considered in this research. The results indicate the optimal structural weight of space domes vary with changes the height-to-span ratio and type of the constraint model selections. Therefore, in order to obtain the optimum space domes in regards to the structural weight, incorporation of both probabilistic constraints of combined stress and displacement is essential in design step."@en ;
    ns0:hasPubTitle "Effect of different probabilistic constraints on optimization of space structure domes"@en .

ns1:ifs-v37-i1-IFS181127 ns0:hasKeywords "BER"@en,
        "MIMO"@en,
        "MMCE"@en,
        "MMSE"@en,
        "TOMPSO"@en ;
    ns0:hasPubAbstract "In modern communication, MIMO technology appeared to be one of the important technologies. System capacity and service quality are enhanced by using this technology. The mission of both channel and data estimation based on the principle of maximum likelihood is achieved by means of continuous and discrete TOMPSO algorithm over Rayleigh Fading Channel. The algorithm has three levels. At the first stage, channel and data populations are prepared. The continuous TOMPSO is using to estimate channel parameters at the second stage. Once the channel is estimated, it is used at stage 3 along with discrete TOMPSO to estimate transmitted symbols. It is observed that due to included total opposite based learning of swarmand velocity factor the TOMPSO gives a fast convergence rate and attractive results in terms of MMSE and MMCE."@en ;
    ns0:hasPubTitle "CDE using improved opposite based swarm optimization for MIMO systems"@en .

ns1:ifs-v37-i1-IFS181133 ns0:hasKeywords "Failure mode and effect analysis (FMEA)"@en,
        "fuzzy petri net (FPN)"@en,
        "fuzzy reasoning"@en,
        "interval type-2 fuzzy set (IT2FS)"@en ;
    ns0:hasPubAbstract "Failure mode and effect analysis (FMEA) is a powerful reliability management tool for identifying and eliminating known and potential failures in systems, designs, processes, or services to improve their safety and reliability. At present, FMEA has been widely used in various industries. However, the traditional risk priority number (RPN) method has been criticized for many defects. For example, it ignores the relative importance of the risk factors severity (S), occurrence (O), and detection (D), and it is difficult for experts to evaluate the risk of failure modes using precise values from 1 to 10. In this study, we develop a new FMEA model that combines interval type-2 fuzzy sets (IT2FSs) and fuzzy Petri nets (FPNs) to overcome the drawbacks and improve the effectiveness of the traditional FMEA. The rationality and accuracy of the proposed FMEA are illustrated by an example of aerospace electronics manufacturing project. The results show that the new risk assessment model can produce more reliable and reasonable risk ranking results of failure modes in the practical application."@en ;
    ns0:hasPubTitle "Failure mode and effect analysis using interval type-2 fuzzy sets and fuzzy Petri nets"@en .

ns1:ifs-v37-i1-IFS181501 ns0:hasKeywords "DC programming"@en,
        "Extreme learning machine"@en,
        "arbitrary norm"@en,
        "mixed integer programming"@en,
        "semi-supervised classification"@en ;
    ns0:hasPubAbstract "Applying semi-supervised learning to extreme learning machine (ELM), we propose a semi-supervised extreme learning machine classification framework (SSELM) with arbitrary norm (q-norm, q=0,1 and 2). However, the SSELM involves nonconvex and nonsmooth problem. In this work, two types of optimization methods are developed to solve the proposed SSELM. The first one is an exact solution approach that reformulates SSELM as mixed integer programming. The second is an approximation approach that approximates the SSELM framework by DC (difference of convex functions) programming. Several formulations for SSELM are presented with different norm. Furthermore, the proposed methods are applied in a practical medical dataset using near-infrared spectral technology. Experimental results in different spectral regions show that incorporating unlabeled samples in training improves the generalization compared with the supervised ELM when insufficient training information is available. Moreover, the proposed methods achieve equivalent performance in benchmark data sets compared to the supervised ELM algorithms and other semi-supervised methods. These results show the feasibility and effectiveness of the proposed algorithms."@en ;
    ns0:hasPubTitle "Arbitrary norm semi-supervised extreme learning machine"@en .

ns1:ifs-v37-i1-IFS181541 ns0:hasKeywords "Trapezoidal neutrosophic number (TrNNs)"@en,
        "linear programming"@en,
        "neutrosophic set"@en,
        "ranking function"@en ;
    ns0:hasPubAbstract "Abdel-Basset et al. (Neural Computing and Applications, 2018, https://doi.org/10.1007/s00521-018-3404-6) proposed methods for solving different types of neutrosophic linear programming problems (NLPPs) (NLPPs in which some/all the parameters are represented as trapezoidal neutrosophic numbers (TrNNs)). Abdel-Basset et al. also pointed out that as a trapezoidal fuzzy number is a special case of trapezoidal neutrosophic number. Therefore, the fuzzy linear programming problems which can be solved by the existing methods (Ganesan and Veermani, Ann Oper Res, 2006, 143 : 305-315; Ebrahimnejad and Tavana, Appl Math Model, 2014, 38 : 4388-4395; Kumar et al., 2011, Appl Math Model, 35 : 817-823; Satti et al., Int J Decis Sci, 7 : 312-33) can also be solved by thier proposed method. In addition to that, to show the advantages of their proposed method over the existing methods (Ganesan and Veermani, Ann Oper Res, 2006, 143 : 305-315; Ebrahimnejad and Tavana, Appl Math Model, 2014, 38 : 4388-4395; Kumar et al., 2011, Appl Math Model, 35 : 817-823; Satti et al., Int J Decis Sci, 7 : 312-33), Abdel-Basset et al. solved the same fuzzy linear programming problems by their proposed method as well as the existing methods (Ganesan and Veermani, Ann Oper Res, 2006, 143 : 305-315; Ebrahimnejad and Tavana, Appl Math Model, 2014, 38 : 4388-4395; Kumar et al., 2011, Appl Math Model, 35 : 817-823; Satti et al., Int J Decis Sci, 7 : 312-33) and shown that the results, obtained on applying by their proposed method are better than the results, obtained on applying the existing methods (Ganesan and Veermani, Ann Oper Res, 2006, 143 : 305-315; Ebrahimnejad and Tavana, Appl Math Model, 2014, 38 : 4388-4395; Kumar et al., 2011, Appl Math Model, 35 : 817-823; Satti et al., Int J Decis Sci, 7 : 312-33). After a deep study of Abdel-Basset et al. ’s method, it is observed that Abdel-Basset et al. have considered several mathematical incorrect assumptions in their proposed method and hence, it is scientifically incorrect to use Abdel-Basset et al. ’s method in its present form. The aim of this paper is to make the researchers aware about the mathematical incorrect assumptions, considered by Abdel-Basset et al. in their proposed method, as well as to suggest the required modifications in Abdel-Basset et al. ’s method."@en ;
    ns0:hasPubTitle "A novel method for solving the fully neutrosophic linear programming problems: Suggested modifications"@en .

ns1:ifs-v37-i1-IFS181586 ns0:hasKeywords "Electroencephalography (EEG)"@en,
        "class means based minimum distance classifier (CMMDC)"@en,
        "fluid intelligence"@en,
        "nuclear features"@en,
        "singular value decomposition (SVD)"@en ;
    ns0:hasPubAbstract "Representation and classification of Electroencephalography (EEG) brain signals are critical processes for their analysis in cognitive tasks. Particularly, extraction of discriminative features from raw EEG signals, without any pre-processing, is a challenging task. Motivated by nuclear norm, we observed that there is a significant difference between the variances of EEG signals captured from the same brain region when a subject performs different tasks. This observation lead us to use singular value decomposition for computing dominant variances of EEG signals captured from a certain brain region while performing a certain task and use them as features (nuclear features). A simple and efficient class means based minimum distance classifier (CMMDC) is enough to predict brain states. This approach results in the feature space of significantly small dimension and gives equally good classification results on clean as well as raw data. We validated the effectiveness and robustness of the technique using four datasets of different tasks: fluid intelligence clean data (FICD), fluid intelligence raw data (FIRD), memory recall task (MRT), and eyes open / eyes closed task (EOEC). For each task, we analyzed EEG signals over six (06) different brain regions with 8, 16, 20, 18, 18 and 100 electrodes. The nuclear features from frontal brain region gave the 100% prediction accuracy. The discriminant analysis of the nuclear features has been conducted using intra-class and inter-class variations. Comparisons with the state-of-the-art techniques showed the superiority of the proposed system."@en ;
    ns0:hasPubTitle "An efficient intelligent system for the classification of electroencephalography (EEG) brain signals using nuclear features for human cognitive tasks"@en .

ns1:ifs-v37-i1-IFS181810 ns0:hasKeywords "IVTrIFHGA operator"@en,
        "IVTrIFOWGA operator"@en,
        "IVTrIFWGA operator"@en,
        "Multiple attribute group decision making"@en,
        "fuzzy cross-entropy"@en,
        "grey relation analysis"@en ;
    ns0:hasPubAbstract "This paper investigates a method to deal with multiple attribute group decision making (MAGDM) problems in which the decision makers’ weights are expressed as crisp numbers, the weights of attributes are unknown, and attribute values are expressed as interval-valued trapezoidal intuitionistic fuzzy numbers (IVTrIFNs). Firstly, some new aggregation operators are proposed, including the interval-valued trapezoidal intuitionistic fuzzy weighted geometric averaging (IVTrIFWGA) operator, the interval-valued trapezoidal intuitionistic fuzzy ordered weighted geometric averaging(IVTrIFOWGA) operator, and the interval-valued trapezoidal intuitionistic fuzzy hybrid geometric averaging (IVTrIFHGA) operator. Some desirable properties of these operators are studied. The results of using these operators for aggregation are also interval-valued trapezoidal intuitionistic fuzzy numbers. Secondly, a fuzzy cross-entropy of interval-valued trapezoidal intuitionistic fuzzy sets(IVTrIFSs) is defined, based on which a new mathematical model is established to determine the weights of attributes. Finally, the fuzzy grey relation analysis (GRA) is utilized to rank decision alternatives. Numerical examples are provided to demonstrate the effectiveness of the proposed multiple attribute group decision making method and its advantages in overcoming the defects of the existing methods."@en ;
    ns0:hasPubTitle "An Improved Aggregation Operators-based Method for Multiple Attribute Group Decision Making Using Interval-valued Trapezoidal Intuitionistic Fuzzy Sets"@en .

ns1:ifs-v37-i1-IFS181917 ns0:hasKeywords "Bezier curve"@en,
        "Obstacle awareness"@en,
        "link duration"@en,
        "mobility awareness"@en,
        "obstacle"@en ;
    ns0:hasPubAbstract "In Mobile Adhoc Network (MANET), obstacles in terrain and nodes mobility are main constrains due which performance degrades. To mitigate these effects, the routing protocol should be mobility and obstacles aware. In this work, we proposed a novel Obstacle and Mobility Aware Routing (OMAR) protocol. In OMAR, for obstacles avoidance, DeCasteljau Algorithm based on Bezier curve is been used. And to reduce effects of mobility and energy shortage of a node, an Energy based Mobility Index (EMI) routing scheme is been developed. The path possesses high EMI is selected as route. The performance of proposed Mobility and Obstacle Aware Routing protocol is evaluated using NS2 simulator. Simulation results show that the proposed algorithm reduces energy consumption, overhead, delay and increases data delivery in the network."@en ;
    ns0:hasPubTitle "Obstacle and mobility aware optimal routing for manet"@en .

ns1:ifs-v37-i1-IFS182555 ns0:hasKeywords "Cubic hesitant fuzzy set"@en,
        "Jaccard measure"@en,
        "multiple attribute decision-making"@en,
        "similarity measure"@en ;
    ns0:hasPubAbstract "A cubic hesitant fuzzy set is a hybrid set which can express uncertain and hesitancy fuzzy information simultaneously. For multiple attribute decision-making problems in engineering practice, the complicated decision information is generally incomplete and indeterminate. Cubic hesitant fuzzy set can be a valuable tool for describing uncertain and hesitancy fuzzy information in uncertain decision environment. Nevertheless, no similarity measure has been used to solve decision-making problems under cubic hesitant environment in previous studies. This paper presents a Jaccard similarity measure between cubic hesitant fuzzy sets and investigates their properties. Then a multiple attribute decision-making method is developed based on the weighted Jaccard similarity measure under cubic hesitant environment. Using this method, the similarity measure values between the ideal alternative and each evaluated alternative are determined to obtain the ranking order of similarity measure values and the best alternative. An illustrative example of the selection problem of project alternatives is utilized to illustrate the application of the developed decision-making method. Finally, the validity of the proposed decision-making method was demonstrated based on the comparison of the decision-making results of the illustrative example with two distance-based similarity measures."@en ;
    ns0:hasPubTitle "Multiple attribute decision method using similarity measure of cubic hesitant fuzzy sets"@en .

ns1:ifs-v37-i1-IFS182558 ns0:hasKeywords "Aggregation operator"@en,
        "Group decision making"@en,
        "Hesitant fuzzy linguistic term sets"@en,
        "Hesitant fuzzy sets"@en,
        "Weighted hesitant fuzzy linguistic term sets"@en ;
    ns0:hasPubAbstract "Hesitant fuzzy linguistic term set(HFLTS), which permits decision makers to use several linguistic terms to assess a variable, is a useful tool to deal with situations in which people are hesitant in providing their assessment. In this paper, we introduce the concept of weighted hesitant fuzzy linguistic term set(WHFLTS), in which different weights are designed to these possible linguistic terms, and the weights indicate that the decision maker has different confidence in giving every possible assessment. After that, we introduce some operations such as union, intersection, complement, multiplication of weighted hesitant fuzzy linguistic elements, discuss their operation properties, and propose the score function of the weighted hesitant fuzzy linguistic element(WHFLE) to compare weighted hesitant fuzzy linguistic elements(WHFLEs). Furthermore, we introduce the concept of hesitance degree of weighted hesitant fuzzy linguistic element, present four aggregation operators such as the weighted hesitant fuzzy linguistic weighted averaging(WHFLWA) operator, the weighted hesitant fuzzy linguistic weighted geometric(WHFLWG) operator, the generalized weighted hesitant fuzzy linguistic weighted averaging(GWHFLWA) operator and the generalized weighted hesitant fuzzy linguistic weighted geometric(GWHFLWG) operator to aggregate weighted hesitant fuzzy linguistic information, and build the mathematical model of multi-criteria group decision making based on weighted hesitant fuzzy linguistic environment. Finally, two numerical examples are used to illustrate the effectiveness and applicability of our proposed method."@en ;
    ns0:hasPubTitle "Weighted hesitant fuzzy linguistic term sets and its application in group decision making"@en .

ns1:ifs-v37-i1-IFS182615 ns0:hasKeywords "Convolutional neural network (CNN)"@en,
        "Differential protection"@en,
        "Inrush current"@en,
        "Power transformer protection"@en ;
    ns0:hasPubAbstract "Differential protection of power transformers, as the fundamental protection, plays an important role in power system reliability and security. The main challenge in differential protection is discrimination between internal faults of power transformers and inrush current. Development of differential protection, especially discrimination between internal faults from other disturbances, have been a favorite subject in power system protection field over decades. Traditional methods proposed so far have several shortcomings: i) high computational burden, ii) sensitivity to noise, iii) being influenced by predefined threshold value/additional parameters/different models at varying ambient conditions, and iv) dependence on handcrafted or spectral analysis to extract features. Deep neural networks (DNN) is selected as the potential solution in this paper, which is able to capture the hierarchical features of a half-cycle of raw data. This paper proposes convolutional neural networks (CNN), in which batch normalization and scaled exponential linear unit (SELU) are merged to enhance differential protection performance. In order to generalize the CNN-based differential protection, several external factors, i.e. the compensation error of current transformer (CT) saturation, series compensated line, and superconducting fault current limiter (SFCL) are conducted to verify the reliability of the proposed method through different reliability metrics. The simulation and experimental results are assessed to show high reliability and the speed of the proposed method."@en ;
    ns0:hasPubTitle "Power transformers internal fault diagnosis based on deep convolutional neural networks"@en .

ns1:ifs-v37-i1-IFS182681 ns0:hasKeywords "Intuitionistic fuzzy set"@en,
        "intuitionistic fuzzy partition"@en,
        "intuitionistic fuzzy transform"@en,
        "inverse intuitionistic fuzzy transform"@en ;
    ns0:hasPubAbstract "Intuitionistic fuzzy transform is an approximate method based on the intuitionistic fuzzy partition. To begin with, a novel definition of intuitionistic fuzzy partition is given, and the properties of triangular intuitionistic fuzzy partition are also given. Secondly, the method of intuitionistic fuzzy transform is introduced, which transforms a continuous function into two gravity vectors according to the membership and non-membership functions that based on intuitionistic fuzzy partition. Some fundamental properties of intuitionistic fuzzy partition are surveyed. Thirdly, the method of inverse intuitionistic fuzzy transform is established by using the previous gravity vectors corresponding to the intuitionistic fuzzy partition. The results show that the approximate function of the original one can be rebuilt by the membership and non-membership functions respectively. even a hybrid approximate function can be rebuilt by both the membership and non-membership functions. Finally, some elementary properties of the inverse intuitionistic fuzzy transform are studied and the method is illustrated by a specific example."@en ;
    ns0:hasPubTitle "Intuitionistic fuzzy transform and its application1"@en .

ns1:ifs-v37-i1-IFS182699 ns0:hasKeywords "Choquet integral"@en,
        "Classification"@en,
        "discriminant analysis"@en,
        "fuzzy measure"@en,
        "genetic algorithm"@en ;
    ns0:hasPubAbstract "The Choquet integral, established with respect to signed fuzzy measure, is an effective aggregation tool in information fusion and classification. Critical coefficients in Classifiers based on Choquet Integral (CCI) are the values of signed fuzzy measure. Currently, determination of these coefficients is either preset subjectively by experience, or retrieved by global optimization methods which are time-consuming, especially when the number of predictive attributes is large. In this paper, an analytic derivation to retrieve the values of signed fuzzy measure in CCI is proposed via discriminant analysis for the first time. On this basis, a generalized Hierarchical Classifiers based on Choquet Integral (HCCI) is established, where a set of scaling parameters is added to CCI to balance the scales of different dimensions. Retrieving of the scaling parameters and the signed fuzzy measure is achieved by a hierarchical structure of program in which a genetic algorithm is embedded with the analytic derivation being proposed in this paper. Performance validation on synthetic and benchmark data sets are conducted to reveal the feasibility and effectiveness of the proposed methods."@en ;
    ns0:hasPubTitle "Data-driven hierarchical classifiers based on Choquet integral"@en .

ns1:ifs-v37-i1-IFS182745 ns0:hasKeywords "Chinese train control(CTC) systems"@en,
        "Risk"@en,
        "cloud model"@en,
        "fuzzy analytical hierarchy process (FAHP)"@en,
        "t-examination"@en,
        "validation"@en ;
    ns0:hasPubAbstract "In view of defects that traditional Fuzzy Analytical Hierarchy Process (FAHP) cannot accurately describe the ambiguity and randomness of the assessment, and as well as inconsistency existed in judgment process, in this paper a novel risk evaluation method is proposed using Fuzzy Failure Modes Effects and Criticality Analysis (FMECA) based on could model. The method firstly applies FMECA to identify the risk, and then uses FAHP to determine the subjection degree function with cloud model based. In the end, the group decision can be conducted with the synthetically aggregated cloud model, which can be directly observed through the distribution of the cloud pictures. Compared with traditional FAHP, the relevant practical examples in Chinese train control (CTC) systems show that the results of the two possess difference due to their original data coming from different 20-expert questionnaires, the reason is found that there exists inconsistence in 20-expert questionnaires on FAHP via t-examination method. Hence, though another 20-expert questionnaires and after inconsistence test, we obtain consistent result in both methods, but the Fuzzy-FMECA with cloud model based could implement the transformation between exact value and quantized one by incorporating the ambiguity and randomness, and provide more abundant information than subjection degree function of the conventional FAHP method, and possesses better consistency, and is a feasible and more effective decision method. In addition, the correlation coefficient method and center-of-gravity method are also applied to verify the correctness and effectiveness of the proposed method, and such that it can be widely applied to solve real-world practical issues."@en ;
    ns0:hasPubTitle "Fuzzy FMECA risk evaluation and its applications in Chinese train control systems based on cloud model"@en .

ns1:ifs-v37-i1-IFS182843 ns0:hasKeywords "NSGA-II"@en,
        "Supplier selection"@en,
        "genetic algorithm"@en,
        "incremental discount"@en,
        "order allocation"@en,
        "zimmermann fuzzy approach"@en ;
    ns0:hasPubAbstract "It is generally believed that the process of supplier selection plays a critical role in the purchasing management. To improve the performance of a supply chain network, it is essential to build a strategic and a strong relationships. As such, all firms should select the best suppliers by applying appropriate methods through different selection criteria. An appropriate supplier reduces all purchasing costs as well as increases customer satisfaction to improve the final product and strengthen corporate competitiveness. Due to the natural uncertainty of this dilemma, most of recent works show a great deal of interest in applying uncertainty approaches. The main innovation of this paper is to develop a new multi-objective model for both supplier selection and order allocation operations considering incremental discount in a fuzzy environment. The proposed model considers the material cost with incremental discount and the transportation cost, holding costs along with its control and interest as well as the possibility of payment, brought back, and replacement costs, simultaneously, for the first time in this research area. Based on the proposed fuzzy model, the Zimmermann fuzzy approach is used in order to covert the model in a single objective form. Accordingly, a Genetic Algorithm (GA) is applied to solve the proposed problem. Based on the multi-objective optimization proposed, a Non-dominated Sorting GA (NSGA-II) is also employed to solve the developed model through the multi-objective assessment methodologies. Finally, a comprehensive evaluation and discussion based on the results are provided to reveal the performance of developed methodology."@en ;
    ns0:hasPubTitle "A multi-objective supplier selection and order allocation through incremental discount in a fuzzy environment"@en .

ns1:ifs-v37-i1-IFS182860 ns0:hasKeywords "Equality algebra"@en,
        "hertz algebra"@en,
        "nodal filter"@en,
        "node"@en,
        "seminode"@en ;
    ns0:hasPubAbstract "In this paper, we introduce the notions of node, nodal filter and seminode in equality algebras and study some properties of them. First, we study the relation between nodes and other specific elements. Furthermore, by defining some operations on   N F ( E )  , which is the set of all nodal filters in an equality algebra E, we prove that   ( N F ( E ) , ∧ , ↔ , E )   is an equality algebra. In fact, we show that   N F ( E )   is a Hertz algebra, BCK-algebra, Hilbert algebra, Kleene algebra and semi-De Morgan algebra. Then we investigate the relation among nodal filters and (positive) implicative, fantastic, prime, and boolean filters in any equality algebras. Finally, we study the relation between nodes and seminodes. And we prove the set of all seminodes SN (E) is a lattice, Heyting algebra and Hertz algebra under the conditions."@en ;
    ns0:hasPubTitle "Nodal filters and seminodes in equality algebras"@en .

ns1:ifs-v37-i1-IFS182868 ns0:hasKeywords "Supervised learning"@en,
        "Support vector machine"@en,
        "Word embedding"@en,
        "Word sense disambiguation"@en ;
    ns0:hasPubAbstract "Supervised Word Sense Disambiguation (WSD) systems use features of the target word and its context to learn about all possible samples in an annotated dataset. Recently, word embeddings have emerged as a powerful feature in many NLP tasks. In supervised WSD, word embeddings can be used as a high-quality feature representing the context of an ambiguous word. In this paper, four improvements to existing state-of-the-art WSD methods are proposed. First, we propose a new model for assigning vector coefficients for a more precise context representation. Second, we apply a PCA dimensionality reduction process to find a better transformation of feature matrices and train a more informative model. Third, a new weighting scheme is suggested to tackle the problem of unbalanced data in standard WSD datasets and finally, a novel idea is presented to combine word embedding features extracted from different independent corpora, which uses a voting aggregator among available trained models. All of these proposals individually improve disambiguation performance on Standard English lexical sample tasks, and using the combination of all proposed ideas makes a significant improvement in the accuracy score."@en ;
    ns0:hasPubTitle "Supervised word sense disambiguation using new features based on word embeddings"@en .

ns1:ifs-v37-i1-IFS182934 ns0:hasKeywords "Large group decision-making"@en,
        "generalized multi-attribute and multi-scale method"@en,
        "large-scale heterogeneous data processing"@en,
        "linear programming technique for multidimensional analysis of preference"@en,
        "property perceived service quality"@en ;
    ns0:hasPubAbstract "With the development of modern property service industry, the property perceived service quality (PPSQ) evaluation data is characterized by multiple evaluation subjects, complicated data structure and large scale data. Since the traditional decision-making methods are difficult to solve the above similar problems, this paper proposes a large group decision-making (LGDM) method of generalized multi-attribute and multi-scale (MAMS) based on the linear programming technique for multidimensional analysis of preference (LINMAP). In this method, the large-scale heterogeneous data of expert preference and user evaluation is fused. The decision matrix of generalized MAMS is used to process user evaluation information. The positive ideal solution (PIS) and the attribute weights are determined by the LINMAP model. The comprehensive evaluation values are calculated and hereby the alternatives are ranked order. According to the relation between attribute weights and preset values, a mechanism for identifying invalid data is designed. This paper analyzes a set of survey data of PPSQ for the four public construction projects in the same city. The analysis results show the validity and rationality of the proposed method, and develop the property service evaluation theory."@en ;
    ns0:hasPubTitle "A large group decision-making method and its application to the evaluation of property perceived service quality"@en .

ns1:ifs-v37-i1-IFS18579 ns0:hasKeywords "Troesch problem"@en,
        "boundary value problem"@en,
        "differential evolution"@en,
        "gaussian radial basis function"@en,
        "interior point algorithm (IPA)"@en,
        "memetic computing (MC)"@en,
        "pattern search (PS)"@en ;
    ns0:hasPubAbstract "In this paper, a numerical solution to the Troesch problem using a memetic computing technique is proposed. In this regard, a linear combination of Gaussian radial basis functions (GRBF) as approximate mathematical framework is suggested. A set of unknown yet adaptable parameters are modeled in a cost function, representing the trial solution. Differential Evolution (DE) algorithm crossed with Interior Point algorithm (IPA) and Pattern Search (PS) are utilized to find the unknowns. Numerical results based on three special cases of proposed scheme are compared with the exact solution as well as many other numerical and classical approximation methods. Analysis reveals that the proposed scheme is promising in terms of accuracy and conformation to the exact solution."@en ;
    ns0:hasPubTitle "Memetic computing based numerical solution to Troesch problem"@en .

ns1:ifs-v37-i1-IFS18586 ns0:hasKeywords "Approximation reduction"@en,
        "Hesitant fuzzy granulations"@en,
        "Multi-granulation hesitant fuzzy rough set"@en,
        "Single-granulation hesitant fuzzy rough set"@en ;
    ns0:hasPubAbstract "Through a combination of hesitant fuzzy sets with rough sets, this study develops a single-granulation hesitant fuzzy rough set model from the perspective of granular computing. In the multi-granulation framework, we propose two types of multi-granulation rough set model, called the optimistic multi-granulation hesitant fuzzy rough sets and pessimistic multi-granulation hesitant fuzzy rough sets. In the models, the multi-granulation hesitant fuzzy lower and upper approximations are defined based on multiple hesitant fuzzy tolerance relations. The relationships among the single-granulation hesitant fuzzy rough sets, optimistic multi-granulation hesitant fuzzy rough sets and pessimistic multi-granulation hesitant fuzzy rough sets are also investigated. Finally, we develop an approximation reduction approach of multi-granulation hesitant fuzzy rough sets to eliminate redundant hesitant fuzzy granulations with a detailed example."@en ;
    ns0:hasPubTitle "An approximation reduction approach in multi-granulation hesitant fuzzy decision information system"@en .

ns1:ifs-v37-i2-IFS179223 ns0:hasKeywords "2-tuple linguistic neutrosophic number Hamacher weighted average (2TLNNHWA) operators"@en,
        "2-tuple linguistic neutrosophic number Hamacher weighted geometric (2TLNNHWG) operators"@en,
        "2-tuple linguistic neutrosophic sets (2TLNSs)"@en,
        "2TLNNs EDAS model"@en,
        "EDAS model"@en,
        "MADM problems"@en,
        "construction project"@en ;
    ns0:hasPubAbstract "In this paper, we present 2-tuple linguistic neutrosophic EDAS model based on traditional EDAS (Evaluation based on Distance from Average Solution) model and some fundamental theories of 2-tuple linguistic neutrosophic information. Firstly, we briefly review the definition of 2-tuple linguistic neutrosophic sets (2TLNNSs) and introduce the score function, accuracy function and operational laws of 2TLNNs. Next, to fuse overall 2-tuple linguistic neutrosophic evaluation information, we define some new aggregation operators of 2TLNNs based on Hamacher product and sum to propose 2TLNNHWA and 2TLNNHWG operators. Furthermore, combine traditional EDAS model with 2TLNNs information, the 2-tuple linguistic neutrosophic EDAS model is established and all computing steps are simply depicted. In our presented model; it’s more accuracy and effective for considering the conflicting attributes. Finally, a numerical example for safety assessment of construction project has been given to illustrate this new model and some comparisons between 2TLNNs EDAS model and 2TLNNWA, 2TLNNWG, 2TLNNHWA, 2TLNNHWG aggregation operators are also conducted to further illustrate advantages of the new method."@en ;
    ns0:hasPubTitle "EDAS method for multiple criteria group decision making under 2-tuple linguistic neutrosophic environment"@en .

ns1:ifs-v37-i2-IFS179233 ns0:hasKeywords "Multiple attribute decision making"@en,
        "hesitant triangular fuzzy geometric Bonferroni Mean (HTFGBM) operator"@en,
        "hesitant triangular fuzzy weighted geometric Bonferroni Mean (HTFWGBM) operator"@en,
        "manufacturing corporations"@en,
        "supply chain cooperation"@en ;
    ns0:hasPubAbstract "Currently, with the rapid development of the globalization and the increasing competition of the market, competitions among enterprises gradually give way to competitions between supply chains, and the relationship between enterprises within the supply chain gradually shift from competition to cooperation. In China, although the development trend of cooperation is inevitable, but the supply chain management is immature, especially for the large number of manufacturing corporations, most of which lack professional experiences. All of these have important theoretical and practical meaning for the supply chain collaboration and supply chain performance evaluation of manufacturing corporations. In this paper, we investigate the multiple attribute decision making(MADM) problems using the hesitant triangular fuzzy information. Then, we have developed the hesitant triangular fuzzy geometric Bonferroni Mean (HTFGBM) operator and hesitant triangular fuzzy weighted geometric Bonferroni Mean (HTFWGBM) operator. We have utilized the HTFWGBM operator to MADM for evaluating the performance of supply chain cooperation for manufacturing corporations with hesitant triangular fuzzy information. Finally, an illustrative example is proposed to demonstrate the effectiveness of our proposed method."@en ;
    ns0:hasPubTitle "Performance evaluation of supply chain cooperation for manufacturing corporations with hesitant triangular fuzzy information"@en .

ns1:ifs-v37-i2-IFS179236 ns0:hasKeywords "IVIF-TODIM method"@en,
        "Multiple attribute decision making (MADM)"@en,
        "Prospect theory"@en,
        "TODIM method"@en,
        "interval-valued intuitionistic fuzzy numbers (IVIFNs)"@en,
        "performance appraisal"@en,
        "social-integration-based rural reconstruction"@en ;
    ns0:hasPubAbstract "Recently, the TODIM has been used to solve multiple attribute decision making (MADM) problems. The interval-valued intuitionistic fuzzy sets (IVIFSs) are useful tools to depict uncertainty of the MADM. In this paper, we will extend TODIM method to the MADM with the interval-valued intuitionistic fuzzy numbers (IVIFNs). Firstly, the definition, comparison and distance of IVIFNs are introduced, and the steps of the classical TODIM method for MADM problems are presented. Then, the extended classical TODIM method is proposed to deal with MADM problems with the IVIFNs, and its significant characteristic is that it can fully consider the decision makers’ bounded rationality which is a real action in decision making. Finally, a numerical example for performance appraisal on social-integration-based rural reconstruction is proposed and a comparative analysis is also given."@en ;
    ns0:hasPubTitle "TODIM method for performance appraisal on social-integration-based rural reconstruction with interval-valued intuitionistic fuzzy information"@en .

ns1:ifs-v37-i2-IFS179239 ns0:hasKeywords "economic evaluation of power system dispatch"@en,
        "hesitant fuzzy uncertain linguistic values"@en,
        "induced hesitant fuzzy uncertain linguistic ordered weighted averaging (IHFULOWA) operator"@en,
        "multiple attribute decision making (MADM)"@en ;
    ns0:hasPubAbstract "With the rapid development of economy, the growth of energy demand and the improvement of environmental awareness prompted the development of wind, which is clean and do not consume fossil fuel. As wind power technology has been basically mature, wing power becomes the power generation model in renewable energy with good development prospects. The intermittent and volatility of wind farm’s output has brought great influence on power system operation. In order to use of wind power fully and effectively, reduce pollution emissions, cut scheduling costs, reduce the influence of the wind power uncertainty on power system, the reasonable scheduling model and solving method is of great significance. In this paper, we investigate the multiple attribute decision making (MADM) problem with hesitant fuzzy uncertain linguistic information. Then, motivated by the ideal of induced OWA (IOWA) operator, we have developed the induced hesitant fuzzy uncertain linguistic ordered weighted averaging (IHFULOWA) operator. The prominent characteristic of this proposed operator are studied. Then, we have utilized induced hesitant fuzzy uncertain linguistic ordered weighted averaging (IHFULOWA) operator to develop some approaches to solve the hesitant fuzzy uncertain linguistic multiple attribute decision making problems. Finally, a practical example for economic evaluation of power system dispatch is given to verify the developed approach and to demonstrate its practicality and effectiveness."@en ;
    ns0:hasPubTitle "Economic evaluation of power system dispatch with hesitant fuzzy uncertain linguistic information"@en .

ns1:ifs-v37-i2-IFS179240 ns0:hasKeywords "2-tuple linguistic Pythagorean fuzzy numbers set (2TLPFNs)"@en,
        "Multiple attribute decision making (MADM)"@en,
        "TODIM model"@en,
        "construction project"@en ;
    ns0:hasPubAbstract "In this article, we expand the original TODIM(Portuguese acronym for Interactive Multi-Criteria Decision Making) method to the 2-tuple linguistic Pythagorean fuzzy environment to propose the 2TLPFs TODIM method. In the extended method, we use 2-tuple linguistic Pythagorean fuzzy numbers (2TLPFNs) to present the criteria values in multiple attribute decision making (MADM) problems. Firstly, we briefly introduce the definition, operational laws, some aggregation operators and the distance calculating method of 2TLPFNs. Then, the calculation steps of the original TODIM model are presented in simplified form. Thereafter, we extend the original TODIM model to the 2TLPFNs environment to build the 2TLPFNs TODIM model, our proposed method, which is more reasonable and scientific in considering the subjectivity of DM’s behaviors and the dominance of each alternative over others. Finally, a numerical example for the safety assessment of a construction project is proposed to illustrate the new method, and some comparisons are also conducted to further illustrate the advantages of the new method."@en ;
    ns0:hasPubTitle "TODIM method for multiple attribute decision making with 2-tuple linguistic pythagorean fuzzy information"@en .

ns1:ifs-v37-i2-IFS179241 ns0:hasKeywords "Hamming distance"@en,
        "Hausdorff distance"@en,
        "Pythagorean fuzzy sets"@en,
        "hybrid Pythagorean fuzzy normalized distance"@en,
        "the continuous functions"@en,
        "the matching function"@en,
        "the notion of complement"@en,
        "the set-theoretic approach"@en ;
    ns0:hasPubAbstract "In this paper, we extend the Hamming distance, the Hausdorff distance with Pythagorean fuzzy sets (PFSs) to define the generalized Pythagorean fuzzy normalized Hamming distance, the generalized Pythagorean fuzzy normalized Hausdorff distance and the generalized hybrid Pythagorean fuzzy normalized distance. According to the relation between distance and similarity measure, we can obtain similarity measure. Furthermore, we study the Pythagorean fuzzy weighted distance and similarity measures. On the basis of the set-theoretic approach, the matching function, the notion of complement and the continuous functions, we extend other similarity measures. In the end, we utilize an applicable example to prove the proposed methods."@en ;
    ns0:hasPubTitle "Some novel similarity and distance measures of pythagorean fuzzy sets and their applications"@en .

ns1:ifs-v37-i2-IFS179246 ns0:hasKeywords "Multiple attribute decision making"@en,
        "finance achievements"@en,
        "hesitant triangular fuzzy generalized Bonferroni Mean (HTFGBM) operator"@en,
        "hesitant triangular fuzzy generalized weighted Bonferroni Mean (HTFGWBM) operator"@en,
        "transnational corporation"@en ;
    ns0:hasPubAbstract "We study on the multiple attribute decision making problems using the hesitant triangular fuzzy information. Afterwards, we have designed the hesitant triangular fuzzy generalized Bonferroni Mean (HTFGBM) operator and hesitant triangular fuzzy generalized weighted Bonferroni Mean (HTFGWBM) operator. We have utilized the HTFGBM and HTFGWBM operators to multiple attribute decision making for evaluating the finance achievements of the transnational corporation with hesitant triangular fuzzy information. In the end, an illustrative example for evaluating the finance achievements of the transnational corporation is proposed to demonstrate the effectiveness of our proposed method."@en ;
    ns0:hasPubTitle "Novel model for evaluating the finance achievements of transnational corporation with hesitant triangular fuzzy information"@en .

ns1:ifs-v37-i2-IFS179251 ns0:hasKeywords "Decision making"@en,
        "artificial intelligence"@en,
        "data envelopment analysis"@en,
        "fuzzy c means"@en,
        "knowledge management"@en ;
    ns0:hasPubAbstract "It is widely acknowledged that a corporate’s profitability that decreases dramatically not only threatens both potential and current investors, but also can freeze stock market transactions as well as deteriorate the flow of economic resources. However, far too little attention has been paid to this issue, which also has been deemed as a main trigger for a financial crisis. To confront this problem, a decision support system can be built up to evaluate a corporate’s operating performance. Thus, this study introduces a novel architecture for forecasting the online operating performance of a firm when entering data at different time intervals. The introduced architecture is grounded on multiple data envelopment analysis specifications, dynamic fuzzy c-means (DFCM), and extreme support vector machine (ESVM). Because obtaining a comprehensible architecture is essential for achieving high accuracy in today’s knowledge-based economy, this study advances the opaque nature of the introduced architecture and extracts the inherent knowledge to represent it in a transparent, human-readable format. The decision logics can be judged or examined by users, which will increase the acceptance rate of the architecture as well as enhance its practical application. Our built-up architecture, tested by real cases, is a promising alternative for financial performance forecasting."@en ;
    ns0:hasPubTitle "An emerging online business decision making architecture in a dynamic economic environment"@en .

ns1:ifs-v37-i2-IFS179266 ns0:hasKeywords "Multiple attribute decision making"@en,
        "micro defects"@en,
        "picture fuzzy set"@en,
        "picture fuzzy weighted average (PFWA) operator"@en,
        "textile composites"@en ;
    ns0:hasPubAbstract "Human body damage accidents occur frequently caused by falling objects and traffic accidents, so scholars pay great attention to the design of the protective materials of human. At present most scholars have done a lot of researches on damage failure and energy absorption under low impact of textile composites, which reveals the shock mode and mechanism of the textile composites. But scholars pay little attention to the human body damages caused by the protection materials due to less design for the transmission of shock energy. In this paper, we investigate the multiple attribute decision making problems for evaluating the micro defects of textile composites with picture fuzzy information. Then, we utilize the picture fuzzy weighted average (PFWA) operator to develop an approach to solve the picture fuzzy multiple attribute decision making problems for evaluating the micro defects of textile composites. Finally, a practical example for evaluating the micro defects of textile composites is given to verify the developed approach and to demonstrate its practicality and effectiveness."@en ;
    ns0:hasPubTitle "Model for evaluating the microdefects of textile composites with picture fuzzy information"@en .

ns1:ifs-v37-i2-IFS182569 ns0:hasKeywords "L-CC mapping"@en,
        "L-CP mapping"@en,
        "L-IP mapping"@en,
        "L-convex space"@en,
        "L-interval space"@en ;
    ns0:hasPubAbstract "By using the residual implication on a frame L, a degree approach to special mappings in L-convex spaces and L-interval spaces is introduced. In the framework of L-convex spaces, degrees of L-CP mappings and L-CC mappings between L-convex spaces are defined. Also, in the situation of L-interval spaces, degrees of L-IP mappings and L-AIP mappings are proposed. Moreover, many conclusions with respect to theses mappings are discussed in a degree sense."@en ;
    ns0:hasPubTitle "Degrees of special mappings in the theory of L-convex spaces"@en .

ns1:ifs-v37-i2-IFS182725 ns0:hasKeywords "M-fuzzifying convexity space"@en,
        "M-fuzzy poset"@en,
        "M-hazy lattice"@en,
        "M-hazy semilattice"@en ;
    ns0:hasPubAbstract "In this paper we propose a new approach to the fuzzification of lattices, which is defined from the view of algebraic structure. It is also called an M-hazy lattice. Some properties of M-hazy semilattices and M-hazy lattices are discussed. Besides, we also discuss its relations with M-fuzzifying interval spaces and M-fuzzifying convex spaces."@en ;
    ns0:hasPubTitle "M-hazy lattices and its induced fuzzifying convexities"@en .

ns1:ifs-v37-i2-IFS182747 ns0:hasKeywords "DEA"@en,
        "Pythagorean fuzzy set"@en,
        "green supplier selection"@en,
        "undesirable outputs"@en ;
    ns0:hasPubAbstract "With the enhancement of the global environmental awareness, green supplier selection is playing an increasingly important role in the development of enterprises. Green supplier evaluation criteria include quantitative and qualitative criteria. Due to the complexity and ambiguity of actual decision making problems, and the subjectivity of decision makers (DMs), it is difficult to describe qualitative criteria with precise data. In this paper, Pythagorean fuzzy numbers (PFNs) are used to describe the qualitative criteria, then a data envelopment analysis (DEA) model with undesirable outputs under Pythagorean fuzzy environment is developed. Finally, a numerical example ahout green supplier selection is provided to demonstrate the usefulness of the proposed method."@en ;
    ns0:hasPubTitle "Green supplier selection with undesirable outputs DEA under Pythagorean fuzzy environment"@en .

ns1:ifs-v37-i2-IFS182751 ns0:hasKeywords "Averaging aggregation operators for CBFSs"@en,
        "Cubic bipolar fuzzy set"@en,
        "MAGDM"@en ;
    ns0:hasPubAbstract "A huge range of human decisions is involved bipolar subjective thoughts. For illustration, effects and side effects are two different aspects of decision analysis. The equilibrium and mutual coexistence of these two aspects are treated as a key for balanced social environment. A verity of bipolar fuzzy decision making with different technique is available for bipolar fuzzy characterizations of the universe of options that depend on a limited number of grades. So, the concept of simple bipolar fuzzy set is insufficient to provide the information about the occurrence of ranking with accuracy because information is limited. In this regard, we use cubic bipolar fuzzy sets (CBFSs) as the generalization of bipolar fuzzy sets. In human decisions, the second important part is ranking of alternatives obtained after evaluation. The motivation behind this research is to develop an appropriate aggregation method which is simple reliable and efficient enough to handle cubic bipolar fuzzy data. We propose aggregation operators, including, cubic bipolar fuzzy weighted averaging operator, cubic bipolar fuzzy ordered weighted averaging operator and cubic bipolar fuzzy hybrid weighted averaging operator for   P  -order and   R  -order. We demonstrate simplicity and efficiency of proposed aggregation operators and algorithm by discussing multi-attribute group decision making (MAGDM) problem under cubic bipolar fuzzy information. We also discuss the comparison analysis of the proposed method of aggregation."@en ;
    ns0:hasPubTitle "Multi-attribute group decision making based on cubic bipolar fuzzy information using averaging aggregation operators"@en .

ns1:ifs-v37-i2-IFS182775 ns0:hasKeywords "Truthfulness"@en,
        "additive reciprocity"@en,
        "group decision making"@en,
        "social influence networks"@en ;
    ns0:hasPubAbstract "The aim of this paper is to introduce the notion of truthfulness in an influence based decision making model. An expert may submit his opinions truthfully or he may dismantle the original situation by undermining the actual opinion, such a decision maker is called an evasive decision maker or an almost truthful decision maker in this paper. It is assumed that experts in the panel are dignified members hence even though they are not habitual liars, they are either “almost truthful” or evasive. To measure their degree of truthfulness, we use the information provided by them in the form of preference relations. We use this information to state the foundation of influence model of evasive decision makers. Finally, a ranking method is proposed to find best possible solutions."@en ;
    ns0:hasPubTitle "Influence model of evasive decision makers"@en .

ns1:ifs-v37-i2-IFS182780 ns0:hasKeywords "Fuzzy preference relations"@en,
        "Fuzzy rankings"@en,
        "Group decision making"@en,
        "Hesitant fuzzy preference relation"@en,
        "Hesitant fuzzy sets"@en ;
    ns0:hasPubAbstract "Hesitant fuzzy sets (HFSs) play a dominant role in the decision making process. Different tools are developed to attract the decision makers (DMs) in making the effective decision, the hesitant fuzzy preference relation (HFPR) is one of the important implementation of them. Preference of an alternative over another alternative is a useful way to express the opinion of decision maker. In this paper, a hesitant fuzzy ranking (HFR) technique is established, constructed the hesitant fuzzy ranking from the HFPR in the group decision making situations. Secondly, a correlation between the alternatives is developed by using Spearman ranked correlation coefficient formula, which helps the DMs to identify the better alternative. The novelty of the proposed strategy is that it evades the need to compute the cooperative preference relations and approvals are generated for the individuals in their original domains."@en ;
    ns0:hasPubTitle "Group decision making based on hesitant fuzzy ranking of hesitant fuzzy preference relations"@en .

ns1:ifs-v37-i2-IFS182808 ns0:hasKeywords "(Stratified) L-ordered Cauchy space"@en,
        "(Stratified) L-ordered limit space"@en,
        "(Stratified) L-ordered uniform convergence space"@en,
        "Bireflective subcategory"@en,
        "Cartesian closed category"@en ;
    ns0:hasPubAbstract "Based on fuzzy inclusion order between L-subsets, stratified L-ordered uniform convergence spaces and stratified L-ordered limit spaces are introduced. It is shown that the resulting categories are all Cartesian closed topological categories. Also, the relationship among stratified L-ordered limit spaces, stratified L-ordered Cauchy spaces and stratified L-ordered uniform convergence spaces are investigated."@en ;
    ns0:hasPubTitle "Applications of fuzzy inclusion orders between L-subsets in fuzzy topological structures"@en .

ns1:ifs-v37-i2-IFS182821 ns0:hasKeywords "Gini-Simpson index"@en,
        "binary connection number"@en,
        "generalised grey target decision method"@en,
        "mixed attributes"@en ;
    ns0:hasPubAbstract "A novel Gini-Simpson (G-S) index based generalised grey target decision method for mixed attributes is put forward. The proposed method improves the G-S index and adopts it as the mixed attribute-based target centre distance from the viewpoint of measuring the difference of alternative index and target centre index. The core of this algorithm is to obtain the ratio of each alternative index to the target centre index. And the ratio is regarded as the pseudo probability, as makes a bridge between the alternative index and the target centre index. This method first transforms all indices into binary connection numbers and divides them into the deterministic terms and uncertain terms to constitute the two-tuple (determinacy, uncertainty) numbers. Then the target centre indices of two-tuple (determinacy, uncertainty) number are determined. Following this, the ratios of deterministic terms and uncertain terms of alternative indices to those of the target centre indices are calculated. Finally, the comprehensive weighted Gini-Simpson indices (CWGSIs) of all alternatives are obtained for decision-making with which the smaller value being the better. A case study illustrates the proposed approach."@en ;
    ns0:hasPubTitle "Gini-Simpson index based generalised grey target decision method for mixed attributes"@en .

ns1:ifs-v37-i2-IFS182910 ns0:hasKeywords "M-fuzzifying convex structure"@en,
        "M-fuzzifying convexly derived operator"@en,
        "M-fuzzifying derived operator"@en,
        "M-fuzzifying restricted convexly derived operator"@en,
        "M-fuzzifying restricted hull operator"@en ;
    ns0:hasPubAbstract "The main objective of this paper is to provide some characterizations of M-fuzzifying convex structures in terms of derived operators. We first introduce the notion of M-fuzzifying convexly derived operators, and then establish the one-to-one correspondence between M-fuzzifying convexly derived operators and M-fuzzifying convex structures. Additionally, it is proved that M-fuzzifying CP mappings can be expressed as formulas of derived sets. Finally, we introduce the notion of M-fuzzifying restricted convexly derived operators and prove that it is isomorphic to M-fuzzifying convex structures."@en ;
    ns0:hasPubTitle "Derived operators on M-fuzzifying convex spaces"@en .

ns1:ifs-v37-i2-IFS182926 ns0:hasKeywords "Medical diagnostic decision"@en,
        "accuracy"@en,
        "intensive care unit"@en,
        "intuitionistic fuzzy logic decision support system"@en,
        "mobile cloud computing"@en,
        "multi agent system"@en,
        "smart healthcare"@en ;
    ns0:hasPubAbstract "The present study is intended to provide a practical Decision Support System framework, based on Multi Agent System (MAS) and Intuitionistic Fuzzy Logic (IFL), useful for implementation in the healthcare area. The major objective consists in enabling the implementing of the conceived incremental project design, dubbed “smart healthcare”, in public or private healthcare centers (hospitals, polyclinics, etc.) through mobile cloud computing technology. In this regard, the present work is conceived to involve a thorough investigation and discussion of the IFL efficiency scope, as integrated into MAS architecture, for the purpose of detecting the patient’s health status in Intensive Care Units (ICUs). To this end, an implementation of the Intuitionistic Fuzzy Logic Decision Support System (IFLDSS), based on the Modified Early Warning Score (MEWS) standard, is carried out in the Tunisian Sfax city based ESSALEMA polyclinic. The proposed solution’s achieved results appears to reveal that the IFLDSS proves to display a commanding capacity in detecting uncertainty related to the ICU patients’ deteriorating cases. On comparing the IFL provided performance to that exhibited by the IFLDSS application, the findings appears to reveal well that the IFL MEWS appears to achieve remarkably higher accuracy scores than those provided by the MEWS standard."@en ;
    ns0:hasPubTitle "Multi-agent based intuitionistic fuzzy logic healthcare decision support system"@en .

ns1:ifs-v37-i2-IFS182953 ns0:hasKeywords "Data envelopment analysis"@en,
        "bi-level optimization"@en,
        "centralized resource allocation"@en,
        "neural network"@en,
        "revenueefficiency"@en ;
    ns0:hasPubAbstract "This paper presents a new bi-level centralized resource allocation (CRA) model based on revenue efficiency which extends the classical revenue efficiency models to a more general case. In real world, there are large organizations like restaurant chains in which all the decision making units (DMUs) operate under the supervision of a central decision maker. In such intraorganizational scenario, the proposed bi-level model attempts to maximize the total revenue produced by all the DMUs and to minimize the reallocation cost in a hierarchical order under a centralized decision-making environment. Using the Karush-Kuhn-Tucker (KKT) conditions, the bi-level CRA model is reduced to a one-level mathematical program with complementarity constraints (MPCC). According to optimization theory and some concepts of ordinary differential equations, a capable neural network is then developed to solve this one-level mathematical programming problem. Under proper assumptions and utilizing a suitable Lyapunov function, the proposed neural network is analyzed to be Lyapunov stable and convergent to an exact optimal solution of the original problem. Finally, some illustrative examples are elaborated to substantiate the applicability and effectiveness of the proposed approach."@en ;
    ns0:hasPubTitle "A neurodynamic scheme to bi-level revenue-based centralized resource allocation models"@en .

ns1:ifs-v37-i2-IFS18760 ns0:hasKeywords "Trust"@en,
        "cognitive agent"@en,
        "dempster-shafer theory"@en,
        "multi-agent models"@en,
        "socio-FIS"@en,
        "trustworthiness"@en ;
    ns0:hasPubAbstract "Social network analysis for multi agent based models can support deeper and empirically grounded understanding of the activities as well as agent’s roles in the system. An agent may store and share information of its environment with other agents of the system. Implementing a secure communication setup, in accordance with requested information is significant to select appropriate recipient. In such state of affairs cognitive phenomena like trust plays a vital role. Agents when converse based on trust establish emotional ties of varying strength in their social network. This paper presents a trust based fuzzy inference model in multi agent system by incorporating social relationships and contributes to analyze for cognitive agents for their roles as being influential, trustworthy and perilous. The model has also been implemented using Dempster Shafer Theory (DST) and the results are compared."@en ;
    ns0:hasPubTitle "Estimating virtual trust of cognitive agents using multi layered socio-fuzzy inference system"@en .

ns1:ifs-v37-i2-IFS190042 ns0:hasKeywords "Fuzzy game theory"@en,
        "average tree solution"@en,
        "interval computing"@en,
        "interval-valued graph cooperative game"@en,
        "restricted coalition"@en ;
    ns0:hasPubAbstract "This paper proposes the concept of interval-valued average tree solution (“AT solution” for short) of graph cooperative games with interval-valued payoffs, and develop an effective and a direct simplified method for solving a subclass of interval-valued graph cooperative games. In this method, the interval-valued AT solution is proved to be a monotonic and non-decreasing function of coalitions’ values under specific condition. Hence, the lower and upper bounds of interval-valued AT solutions of graph cooperative games can be obtained directly by using the lower and upper bounds of the interval-valued coalitions’ payoffs, respectively. The proposed method gives better results than general interval subtraction and the partial subtraction operator methods. In addition, some important properties of the interval-valued AT solutions of interval-valued graph cooperative games are discussed. At last, the applicability and superiority of the proposed approach is demonstrated by comparing with other methods."@en ;
    ns0:hasPubTitle "A graph cooperative game with interval-valued payoffs and its simplified solving method"@en .

ns1:ifs-v37-i2-IFS190067 ns0:hasKeywords "Data envelopment analysis"@en,
        "Iranian Bank"@en,
        "New product"@en,
        "RUSSELL model"@en,
        "Uncertainty theory"@en ;
    ns0:hasPubAbstract "Data Envelopment Analysis (DEA) is recognized as a robust analytical tool extensively utilized in measuring the relative efficiency of a group of decision-making units (DMUs) with multiple inputs and outputs. The DEA models require inputs and outputs equipped with precise information. However, in real-world situations, inputs and outputs may be unstable and complicated, thus unable to be accurately measured. This problem resulted in the investigation of uncertain DEA models. The RUSSELL model was studied in this paper in an uncertain environment where uncertain inputs and outputs were belief degree-based uncertainty, useful for the cases for which no historical information of an uncertain event is available. As the solution method, the uncertain RUSSELL model was converted to a crisp form using two approaches of expected value model and expected value and dependent chance-constrained model separately. Finally, an applied example regarding the Iranian banking system was presented to document the proposed models."@en ;
    ns0:hasPubTitle "Uncertain RUSSEL data envelopment analysis model: A case study in iranian banks"@en .

ns1:ifs-v37-i2-IFS190078 ns0:hasKeywords "WEKA"@en,
        "XGBoost"@en,
        "artificial neural network"@en,
        "bagging ensembles"@en,
        "cfsSubsetEval"@en ;
    ns0:hasPubAbstract "Risk assessment is an important aspect of decision making while granting policy to an applicant. In the vast economy with enormous feature criteria for everyone, it is an ongoing challenge for the insurance companies to assess each applicant based on various factors to provide right policies on the basis of a risk score. We propose a method of ensemble learning as a solution to this problem where the predictions from pre-existing supervised learning algorithms can be used to enhance the accuracy of prediction. A real-world dataset having 128 attributes has been used to study the risk value associated with a policy applicant. Machine learning algorithms were applied to the dataset to predict the risk associated with the applicant. Two ensembles have been used for classification of risk level assigned to a person which further leveraged our approach to an optimized and efficient class of predictors namely ANN and gradient boosting algorithm XGBoost. As a result, we discovered that the XGBoost algorithm with optimized hyperparameters gave us the best results in terms of Quadratic Weighted Kappa Score. The proposed methodology outperforms other existing methodologies as discussed in the later sections of the paper."@en ;
    ns0:hasPubTitle "Assessing risk in life insurance using ensemble learning"@en .

ns1:ifs-v37-i2-IFS190111 ns0:hasKeywords "Formal context"@en,
        "attribute implication"@en,
        "partially-known concept"@en,
        "three-valued logic"@en ;
    ns0:hasPubAbstract "Formal concept analysis, originally proposed by Wille, is a mathematical tool to analyse and represent data in the form of complete formal context. However, in situations with incomplete information, one only has partial knowledge about a concept, recently, a common conceptual framework of the notions of interval sets and incomplete formal contexts for representing partially-known concepts were presented. In this study, we examine and reinterpret the existing studies on partially known concepts by means of three-valued logics. By treating an incomplete formal context as a three-valued formal context and considering the one-to-one correspondence between interval sets and three-valued mappings, we investigate the condition under which the four types of partially known concepts can be generated by using three-valued implication operators. Moreover, we also evaluate the role of three-valued logic in characterizing attribute implications. A sufficient and necessary condition for computing the true value of an implication correctly in the sense of Kriple semantics is provided."@en ;
    ns0:hasPubTitle "A three-valued logic approach to partially known formal concepts1"@en .

ns1:ifs-v37-i3-IFS179118 ns0:hasKeywords "Passive building"@en,
        "demand incentive"@en,
        "evolutionary game"@en,
        "numerical simulation"@en ;
    ns0:hasPubAbstract "The promotion and use of passive building can effectively promote the modernization of the construction industry and alleviate the increasingly severe environmental and energy crisis. Based on this, the evolutionary game theory is used to establish an evolutionary game model between government and consumers, and the game strategies of both sides are analyzed, the influence of system equilibrium stability and parameters on the stability of evolutionary game is discussed. The dynamic evolution game law of government and consumers based on passive building demand incentive is studied under the premise of limited rationality and fuzzy trust. Then the game trajectory between stakeholders is simulated by MATLAB software, the effects of parameters and initial intention on the evolution process and results are analyzed. It clearly clarifies the dynamic mechanism of the impact of government incentives on behavioral strategies for consumers to buy passive building. It shows that the passive building demand incentive work is focused on government, and the initial intention of government and consumers will directly affect the behavior strategies of both parties. Aiming at the demand incentives of passive building, the corresponding countermeasures and suggestions are proposed at the three levels of awareness, cost control and income."@en ;
    ns0:hasPubTitle "Simulation study on passive buildings’ demand incentive based on evolutionary game"@en .

ns1:ifs-v37-i3-IFS179120 ns0:hasKeywords "Stable bipartite matching"@en,
        "bipartite matching model"@en,
        "linguistic scoring"@en,
        "satisfaction degree"@en ;
    ns0:hasPubAbstract "The paper proposes a new approach to solving bipartite matching problems with linguistic scorings. The bipartite matching problem based on strict linguistic scorings is firstly described. Some basic concepts are also introduced, including bipartite matching, stable matching, and satisfaction degree. In the proposed approach, linguistic scoring preferences are changed to satisfaction degree preferences. For maximizing satisfaction degrees of agents, a bipartite matching model under the conditions of matching constraints and stability constraints is developed. Considering the important degrees of agents in each side, the bipartite matching model can be changed to a single target model by using the linear weighting approach twice. The stable bipartite matching result is determined through model solution. A numerical case is used to state the practicability of the presented approach."@en ;
    ns0:hasPubTitle "Linguistic scoring bipartite matching considering stability and satisfaction degrees"@en .

ns1:ifs-v37-i3-IFS179121 ns0:hasKeywords "Neural network"@en,
        "computer"@en,
        "network security"@en ;
    ns0:hasPubAbstract "The computer network security evaluation simulation model is analyzed based on neural network. Firstly, based on the system security experimental platform, the system security detection algorithm is constructed, and the selection strategy of calculation scale is analyzed. The Prefix Span algorithm is introduced, improving its algorithm. Data mining based on Prefix is carried out, with the relationship between intrusions and their relationships analyzed. Secondly, the implementation steps of the algorithm are explained. Finally, the algorithm is tested, and the results are analyzed from three aspects: entropy value feature, active entropy algorithm and cloud platform performance. The conclusion is that the algorithm designed in this paper has good accuracy and adaptability, and it can play a good supporting role in system safety practice training, and the encryption protocol in the network security protocol is further improved, which has laid a solid foundation for the security development of the network."@en ;
    ns0:hasPubTitle "Computer network security evaluation simulation model based on neural network"@en .

ns1:ifs-v37-i3-IFS179123 ns0:hasKeywords "Big data"@en,
        "data mining"@en,
        "drug factors"@en,
        "hypertension"@en ;
    ns0:hasPubAbstract "Hypertension is a common disease. The treatment of hypertension is one of the major public health problems in the world. Currently, in the clinical treatment of hypertension, most of which are with oral medicine in order to control the blood pressure. However, because every patient differs in pathogeny and symptom of hypertension, and the combination of various medicines is also complex. All these factors make it difficult for clinicians to give the best drug treatment for each patient. Thus, this paper takes advantage of the data mining technology to analyze the medication treatment schemes of hypertension and find out the key factors that affect the success of each treatment scheme. These key factors will be regarded as criteria to guide clinicians to prescribe medications for patients so as to reduce the pain of patient, improve medical quality and save limited health resources."@en ;
    ns0:hasPubTitle "Study on the effect of hypertensive treatment based on drug factor analysis model under the background of big data"@en .

ns1:ifs-v37-i3-IFS179141 ns0:hasKeywords "artificial intelligence"@en,
        "system construction"@en,
        "teaching English"@en ;
    ns0:hasPubAbstract "The automatic scoring of English composition is an inevitable trend of the rapid development of computer technology and artificial intelligence technology. This makes the research on the automatic scoring system of the composition more theoretical and feasible. The integration of information technology and English curriculum has deepened the application of artificial intelligence in the field of teaching, creating a new opportunity for the optimization of English teaching process, and opening up a new space for the creation of intelligent and personalized English teaching environment. Based on the integration of information technology and curriculum, aiming at improving the quality and effect of English teaching in middle schools, this paper explores the application of artificial intelligence in English teaching in middle schools by using relevant theories of curriculum theory, literature analysis and field investigation. An implementation plan of College English assisted instruction system based on AI technology is proposed. Combined with English teaching, some functions of the English teaching system are improved and humanized. The application of artificial intelligence technology in English teaching is explored in order to improve the quality and effect of English teaching."@en ;
    ns0:hasPubTitle "English teaching practice based on artificial intelligence technology"@en .

ns1:ifs-v37-i3-IFS179145 ns0:hasKeywords "IOT"@en,
        "drama"@en,
        "film and literature major"@en,
        "teaching practice"@en ;
    ns0:hasPubAbstract "The Internet of things is known as the third wave of the world information industry after computer and Internet. With its connectivity and intelligence, the Internet of Things has unique advantages in breaking the time and space constraints, expanding learning resources and improving the depth of exploration. Its integration with the teaching practice curriculum of drama, film and television literature specialty is conducive to the improvement of the above problems. Based on this, through the intelligent optimization algorithm and the theoretical framework of experiential learning, this paper constructs a teaching model of drama, film and Television Literature Specialty Based on experiential learning theory under the Internet of Things environment, thus creating a professional teaching practice platform, and makes a thorough study on the optimization algorithm of drama, film and television literature specialty. Now the teaching and learning optimization algorithm based on the Internet of Things can be well used in the teaching practice platform of drama, film and television literature specialty."@en ;
    ns0:hasPubTitle "Research on the construction of teaching platform of drama film and television literature based on IoT"@en .

ns1:ifs-v37-i3-IFS179151 ns0:hasKeywords "Salar language"@en,
        "parameters database"@en,
        "voice acoustic"@en ;
    ns0:hasPubAbstract "“The preservation of endangered ethnic minority languages” and “application of ethnic minority languages” have become an important research direction and topic for the ethnic minority language researchers. Based on the previous studies, the combined quantitative and qualitative analysis was made to carry out a systematic study on vowels and consonants in the Salar language, especially the strong vowels, weak vowels, voiceless consonants, and voiced consonants, in order to create the “Salar Acoustical Phonetics Parameter Database”. According to the relevant norms, the segmentation, labeling, parameters extraction and database creation were conducted against the collected signals, and the experimental research on the Salar phonetics was implemented by making a comprehensive statistical analysis of the database. Through the study of Salar phonetics based on the Salar Acoustical Phonetics Parameter Database, it not only provides basic parameters of acoustic physiology for preservation and research of Salar language, but also provides the basic data for the future Salar acoustical corpus construction, speech recognition and speech synthesis, and provides a practical theoretical basis for the acoustical research of the national language project under construction."@en ;
    ns0:hasPubTitle "Design and creation of salar acoustical phonetics parameter database"@en .

ns1:ifs-v37-i3-IFS179155 ns0:hasKeywords "Plant diseases"@en,
        "deep neural networks"@en,
        "detection"@en,
        "false positives"@en,
        "filter banks"@en ;
    ns0:hasPubAbstract "A fundamental problem facing deep neural networks is that they require a large amount of data to keep the system efficient in complex applications. Promising results of this problem are made possible by using techniques such as data enhancement or transfer learning in large data sets. However, when the application provides limited or unbalanced data, the problem persists. In addition, the number of false positives generated by deep model training has a significant negative impact on system performance. This study aims to solve the problem of false positives and class imbalances by implementing an improved filter library framework for Cole pest identification. The system consists of three main units: First, the primary diagnostic unit (boundary box generator) generates a bounding box containing the location of the infected area and class. Then, the promising box belonging to each category is used as an input to the secondary diagnostic unit (CNN filter bank) for verification. In the second unit, the misclassified samples are filtered by training for each category of independent CNN classifiers. The result of the CNN filter bank is to determine if a target belongs to the category because it is detected (true) or no (false), otherwise. Finally, an integrated unit combines the information of the autonomous unit and the secondary unit in the future while maintaining a true positive sample and eliminating false positives of misclassification in the first unit. By this implementation, the recognition rate of this method is about 96%, which is 13% higher than our previous work in the complex task of Cole disease and pest identification. In addition, our system is able to handle false positives generated by bounding box generators and class imbalances that occur on data sets with limited data."@en ;
    ns0:hasPubTitle "Real-time detection of cole diseases and insect pests in wireless sensor networks"@en .

ns1:ifs-v37-i3-IFS182554 ns0:hasKeywords "Linguistic intuitionistic fuzzy numbers"@en,
        "TODIM method"@en,
        "fuzzy measures"@en,
        "multiple attribute decision making"@en ;
    ns0:hasPubAbstract "As the extension of intuitionistic fuzzy numbers (IFNs), linguistic intuitionistic fuzzy numbers (LIFNs) are proposed. LIFNs are expressed by linguistic variables and take the membership degree (MD) and non-membership degree (NMD) into consideration. The MD and NMD of LIFNs can easier describe complex and fuzzy information in multiple attribute decision-making (MADM) problems. The TODIM method based on prospect theory can reflect the psychological factors of the decision makers (DMs). However, existing TODIM methods neither handle the decision-making problems under linguistic intuitionistic environment nor consider interrelations among multiple attributes. Based on these problems, in this paper, combining the fuzzy measure with the TODIM method, an extended Choquet-TODIM method is proposed to process the MADM problems. The extended Choquet-TODIM method considers the interrelationship of multiple attributes and the bounded rationality of DMs. Firstly, the relative theories of LIFNs, the classical TODIM method and λ-fuzzy measures are briefly reviewed. Secondly, the TODIM method is extended to linguistic intuitionistic fuzzy environment and C-TODIM method of LIFNs is proposed. Then λ-fuzzy measure is extended to the classical TODIM method and a model of determining fuzzy measures is proposed. The proposed method gives the new solution to calculate the fuzzy measures and address the MADM problems with interrelationship among different attributes. Lastly, two numerical examples are used to compare with two existing methods and explain the effectiveness and superiority of this method."@en ;
    ns0:hasPubTitle "An extended C-TODIM method with linguistic intuitionistic fuzzy numbers"@en .

ns1:ifs-v37-i3-IFS182634 ns0:hasKeywords "Interval-valued dual hesitant fuzzy set"@en,
        "group satisfaction degree"@en,
        "regret theory"@en,
        "stochastic multiple attribute decision making"@en ;
    ns0:hasPubAbstract "Interval-value dual hesitant fuzzy set, first proposed by Ju et al. (Interval-valued dual hesitant fuzzy aggregation operators and their applications to multiple attribute decision making, 1203–1218, 2014). Multiple attribute decision making with dual hesitant fuzzy information is a new research topic since dual hesitant fuzzy set was firstly proposed, it has been widely studied in the fuzzy decision making literature. As a new generalization of fuzzy sets, interval-value dual hesitant fuzzy set (IVDHF) This article develops a multi-attribute decision making method considering the regret value theory and group satisfaction for the interval-value dual hesitant fuzzy element and incomplete weight information. Considering that decision makers have different level of the degree of evaluation, firstly, based on the score function and the accuracy function of the interval-valued hesitant fuzzy element, the deviation function of the interval-valued hesitant fuzzy set is defined. On this basis, a new group satisfaction is proposed. And then, for the situation where the information of attribute weight is incompletely known and completely unknown, some optimization models of attribute weight are established by using the new group satisfaction degree, and then the attribute weight can be determined. Finally, a real example of investment alternative evaluation is carried out to validate the implementation of the proposed approach."@en ;
    ns0:hasPubTitle "Algorithms for regret theory and group satisfaction degree under interval-valued dual hesitant fuzzy sets in stochastic multiple attribute decision making method"@en .

ns1:ifs-v37-i3-IFS182836 ns0:hasKeywords "Image steganalysis"@en,
        "blind steganalysis"@en,
        "feature selection"@en,
        "neighborhood rough sets"@en,
        "rough sets"@en ;
    ns0:hasPubAbstract "Feature extraction for blind image steganalysis produces much features or high dimensional data, which bring about time consuming and even a low detection percentage. As being one of the most important phases of preprocessing, feature selection can reduce these extracted features, and improve the performance of steganalysis. Firstly, we introduce the Neighborhood Rough Sets (NRS) to the field of blind image steganalysis. Then, some concepts of feature significance and feature reduct are presented based on NRS. Furthermore, we propose a Feature Selection approach by NRS for blind image steganalysis (FSNRS). The FSNRS has the ability to delete redundant features, meanwhile maintaining the classification accuracy of a steganalysis system. The FSNRS is a filter feature selection technique for blind image steganalysis, which filtrates extracted features depending on a positive region preserving in NRS. The compact feature subset with a shortest feature dimension for blind image steganalysis is selected. Moreover, some experiments for blind steganalysis using SVM and KNN classifiers on selected feature subset are carried out. The experimental results show that our proposed approach can obtain compact features for blind image steganalysis and the performances of classifiers on those selected features are improved. Since the FSNRS is used with an adjustable neighborhood parameter, as a result, the classification performance of selected features is better than that of original whole features in most cases."@en ;
    ns0:hasPubTitle "Feature selection for blind image steganalysis using neighborhood rough sets"@en .

ns1:ifs-v37-i3-IFS182963 ns0:hasKeywords "(L, M)-fuzzy closure system, (L, M)-fuzzy convex structure, (L, M)-fuzzy cotopology, coreflective subcategory"@en ;
    ns0:hasPubAbstract "In this paper, we mainly focus on the relationship between (L, M)-fuzzy closure systems and (L, M)-fuzzy convex structures as well as the relationship between (L, M)-fuzzy closure systems and (L, M)-fuzzy cotopologies. Firstly, we show that there is an adjunction between the category LMFC of (L, M)-fuzzy convex spaces and the category LMFS of (L, M)-fuzzy closure spaces, and there is also an adjunction between the category LMFT of (L, M)-fuzzy cotopological spaces and LMFS. In particular, the categories LMFC and LMFT are both coreflective subcategories of LMFS. Secondly, we prove that there is an adjunction between the category ELFC of extensional L-fuzzy convex spaces and the category LFC of L-fuzzy convex spaces, and there is also an adjunction between the category ELFT of extensional L-fuzzy cotopological spaces and the category LFT of (L, M)-fuzzy cotopological spaces. Specially, ELFC is a coreflective subcategory of LFC and ELFT is a coreflective subcategory of LFT."@en ;
    ns0:hasPubTitle "Coreflectivities of (L, M)-fuzzy convex structures and (L, M)-fuzzy cotopologies in (L, M)-fuzzy closure systems"@en .

ns1:ifs-v37-i3-IFS190098 ns0:hasKeywords "Archimedean t-conorm and t-norm"@en,
        "Dual hesitant fuzzy linguistic set"@en,
        "group decision making"@en,
        "power-geometric operator"@en ;
    ns0:hasPubAbstract "Dual hesitant fuzzy linguistic set consists of linguistic terms, membership hesitancy degrees and non-membership hesitancy degrees, which is widely applied to describe the quantitative and qualitative information in the decision-making problem. In this article, some new power aggregation operators of dual hesitant fuzzy linguistic set on the Archimedean t-conorms and t-norms functions are introduced. Then, the properties of those new operators are studied and the relationships between novel operators and existing ones are discussed. Furthermore, an approach to resolve group decision making problem is described. Finally, an example is used to illustrate the developed approach."@en ;
    ns0:hasPubTitle "Dual hesitant fuzzy linguistic power-geometric operators based on Archimedean t-conorms and t-norms and their application to group decision making"@en .

ns1:ifs-v37-i3-IFS190116 ns0:hasKeywords "Q-neutrosophic cubic element weighted geometric averaging (Q-NCEWAA) operator"@en,
        "Q-neutrosophic cubic element weighted geometric averaging (Q-NCEWGA) operator"@en,
        "Q-neutrosophic cubic set"@en,
        "decision making"@en,
        "two-dimensional universal sets"@en ;
    ns0:hasPubAbstract "A neutrosophic cubic set (NCS) can depict single-valued and interval neutrosophic information simultaneously in real life. Then, the NCS concept cannot describe neutrosophic cubic information regarding the assessment problems of two-dimensional universal sets (TDUSs), while a Q-neutrosophic set (Q-NS) can depict neutrosophic information in TDUSs but not describe neutrosophic cubic information in TDUSs. Motivated by the Q-NS and NCS concepts, we need to extend the Q-NS concept to Q-NCS for indicating neutrosophic cubic information in TDUSs. Therefore, this study first proposes a Q-NCS concept, which indicates its truth, falsity, and indeterminacy values independently in TDUSs, and then the basic operations of Q-neutrosophic cubic elements (Q-NCEs) and some weighted aggregation operators of Q-NCEs, such as a Q-NCE weighted arithmetic averaging (Q-NCEWAA) operator and a Q-NCE weighted geometric averaging (Q-NCEWGA) operator. Next, Q-neutrosophic cubic multi-attribute decision-making (MADM) methods regarding the proposed Q-NCEWAA and Q-NCEWGA operators are proposed under TDUSs and Q-NCS setting. Eventually, an illustrative example shows the applicability of the proposed MADM methods in TDUSs and Q-NCS setting."@en ;
    ns0:hasPubTitle "Some aggregation operators of Q-neutrosophic cubic sets for multi-attribute decision making"@en .

ns1:ifs-v37-i3-IFS190126 ns0:hasKeywords "E-soft fixed point"@en,
        "delay differential equation 2010 Mathematics Subject Classification: 46S40, 47H10, 54H25."@en,
        "soft set"@en,
        "soft set-valued mapping"@en ;
    ns0:hasPubAbstract "In this paper, the notion of soft set-valued mappings and E-soft fixed points are introduced. These ideas are used to establish some analogues of classical fixed point theorems in the literature. Some Examples are given to support the hypotheses of the theorems. A few graphical and tabular illustrations are also provided so as to visualize the novel concepts pictorially. Moreover, as an application of one of the presented results, an existence condition for a solution of nonlinear discrete-type delay differential equation is provided."@en ;
    ns0:hasPubTitle "Fixed points of soft-set valued and fuzzy set-valued maps with applications"@en .

ns1:ifs-v37-i3-IFS190128 ns0:hasKeywords "Rapid prototyping"@en,
        "additive manufacturing"@en,
        "fuzzy analytical hierarchy process"@en,
        "grey relational analysis"@en,
        "sustainability"@en,
        "trapezoidal fuzzy number"@en ;
    ns0:hasPubAbstract "A multitude of rapid prototyping (RP) systems and technologies have come up since the introduction of additive process. Owing to the enlarging number of these systems with distinctive efficacy, the problem of selecting an appropriate system for a particular requirement is a cumbersome task. Henceforth, this work comes up with a strategy based on multi-attribute decision making to select a most suitable RP system. The presence of subjectivity in decision making as well as the existence of imprecision from various sources emphasize the methods which must consider uncertainty and vagueness. A decision advisor based on uncertainty theories, including fuzzy analytical hierarchy process (FAHP) and grey relational analysis (GRA) has been introduced. It provides a comprehensive database comprising thirty nine commercially available RP systems. The evaluation attributes consisting of machine cost, accuracy, layer thickness, machine speed, material cost, net build size volume, machine weight, surface roughness, and material strength were utilized to characterize the different machines. The FAHP based on trapezoidal fuzzy number was implemented to determine the priority weights of various attributes, while the GRA was employed to realize the best RP system and technology. The authors believe that this system has the potential to transform into a fully developed RP selection system."@en ;
    ns0:hasPubTitle "Decision advisor based on uncertainty theories for the selection of rapid prototyping system"@en .

ns1:ifs-v37-i3-IFS190137 ns0:hasKeywords "AES algorithm"@en,
        "Galois field"@en,
        "Galois ring"@en,
        "Primitive BCH-code"@en,
        "generator polynomial"@en ;
    ns0:hasPubAbstract "Accelerated adventures in computer Science and technology has made digital technology, a need of the day. Academicians, researchers, and technologists are anxious to share their secret data through the communication channel along with its security. The security of data, transmission rate, and error correction capability are the fundamental questions against the data transmission through any algebraic code dependent communication channel. Though, data security is always questioned due to the synchronized encoding and decoding algorithms. In this paper, a novel approach is developed to ensure the data security issues occurred due to synchronized encoding-decoding of a BCH code and for data transmission, a computational technique is designed by which data can be encoded and transmitted by using Field-Linear BCH code or a Ring-Linear BCH code of the same dimension, designed distance and code length. Although the Ring-Linear BCH code is preferable for encoding, on the other hand decoding of data is adept by Field-Linear BCH code. Accordingly, a computational technique of Barlekamp Massey Algorithm is utilized for the purpose. This scheme provides a quick code selection of the desired level of transmission rate and error correction capability during the communication. Thus, it also addresses the dimension issue of primitive BCH code. In addition, for the data security perspective we utilize a BCH code in round key addition and mixed column matrix steps in AES algorithm and then put on this modified AES algorithm to image encryption. The image encryption quality permits to incorporate this alteration in AES."@en ;
    ns0:hasPubTitle "BCH Codes with computational approach and its applications in image encryption"@en .

ns1:ifs-v37-i3-IFS190148 ns0:hasKeywords "Cyclic graph"@en,
        "connected graph"@en,
        "fuzzy graph"@en,
        "hesitancy fuzzy magic labeling graph"@en,
        "star graph"@en ;
    ns0:hasPubAbstract "In this paper, by considering the concept of hesitancy fuzzy magic labeling of a graph, we show that whether any simple graph is hesitancy fuzzy magic labelizing. For this we prove that, any finite path graph, cyclic graph, star graph and by using them, any complete graph and so any connected graph has hesitancy fuzzy magic labelizing. Finally, we give some applications for hesitancy fuzzy magic labeling graphs in plumbing system and traffic flow."@en ;
    ns0:hasPubTitle "Hesitancy fuzzy magic labeling of simple graphs"@en .

ns1:ifs-v37-i3-IFS190213 ns0:hasKeywords "Hybrid renewable energy system"@en,
        "off-grid"@en,
        "optimization"@en,
        "photovoltaic"@en,
        "whale optimization algorithm"@en,
        "wind"@en ;
    ns0:hasPubAbstract "In this paper, a new optimization methodology to assess the designs of the various renewable generation systems of electrical energy is used. This methodology utilizes Whale Optimization Algorithm (WOA) to minimize the cost of the electrical energy generated. The methodology permits to examine and to combine different sources of energy as to touch base at an optimal configuration of the hybrid system. This system is capable of providing energy to the predefined site in an achievable way as indicated by certain specialized and financial criteria. The system incorporates wind generation, photovoltaic generation and batteries for energy storage. The recreation results have been acquired with the help of MATLAB programming. Moreover, the outcomes of the proposed methodology have been compared with Particle Swarm Optimization (PSO) Algorithm for validation. The recreation results demonstrated the predominance of the proposed methodology."@en ;
    ns0:hasPubTitle "A new sizing and optimization framework for stand-alone hybrid renewable energy systems"@en .

ns1:ifs-v37-i3-IFS190215 ns0:hasKeywords "First-order recurrent neural networks"@en,
        "finite state automata"@en,
        "fuzzy rules"@en,
        "regular grammars"@en ;
    ns0:hasPubAbstract "First-order recurrent neural networks can be trained to recognize strings of a regular language. Finite state automata can be extracted from these neural networks. Normally, a search process in the output domain of the neurons is necessary for carrying out this extraction procedure. On the other hand, studies about fuzzy rules extraction from feedforward multilayered neural networks can be considered to define new techniques that transform first-order recurrent neural networks into finite state automata. With these new techniques, a fuzzy description of the action of each neuron can be obtained. From these descriptions, the transition function of the automaton can be directly found and, in this way, the search process is not necessary. A technique with this approach is presented in this paper. Besides, the used method to extract fuzzy rules from a neuron has the advantage that the inputs of the fuzzy system coincide with the inputs of the neuron. Thus, the fuzzy system is more intuitive. Once the transition function is obtained, the automaton structure can be found with the analysis of the transitions for every state and input from the initial state. Finally, several examples are presented to illustrate the method."@en ;
    ns0:hasPubTitle "Interpretation of first-order recurrent neural networks by means of fuzzy rules"@en .

ns1:ifs-v37-i3-IFS190264 ns0:hasKeywords "Uncertain delay differential equation"@en,
        "existence and uniqueness"@en,
        "infinite domain"@en,
        "linear growth condition"@en,
        "one-sided local Lipschitz condition"@en ;
    ns0:hasPubAbstract "Uncertain delay differential equations are a type of differential equations driven by a Liu process. So far, it has been proved that uncertain delay differential equation has a unique solution in the finite domain, in which its coefficients satisfy the global Lipschitz continuity. This paper continues to focus on the existence and uniqueness of the solutions of uncertain delay differential equations on the infinite domain. Meanwhile, a new existence and uniqueness theorem for uncertain delay differential equations under one-sided local Lipschitz condition and linear growth condition is deduced."@en ;
    ns0:hasPubTitle "A new existence and uniqueness theorem for uncertain delay differential equations"@en .

ns1:ifs-v37-i3-IFS190280 ns0:hasKeywords "M-fuzzifying matroids"@en,
        "M-fuzzifying rank function"@en,
        "M-fuzzifying span mapping"@en,
        "fuzzifying dual matroids"@en ;
    ns0:hasPubAbstract "In this paper, we give a new characterization of M-fuzzifying span mappings defined by M-fuzzifying rank functions. Then we research the relations between M-fuzzifying span mappings and other M-fuzzifying mappings on M-fuzzifying matroid, and characterize the M-fuzzifying coindependent, nonspan and hyperplane mappings. Based on these characterizations, we put forward one class of special fuzzifying matroids."@en ;
    ns0:hasPubTitle "M-Fuzzifying span mappings in M-Fuzzifying matroids1"@en .

ns1:ifs-v37-i3-IFS190293 ns0:hasKeywords "(∈ , ∈ ∨ (k*, qk))-fuzzy semiprime subsets"@en,
        "Ordered semigroups"@en,
        "fuzzy subsets"@en ;
    ns0:hasPubAbstract "The concept of an (∈ , ∈ ∨ (k*, qk))-fuzzy semiprime subset in an ordered semigroup is introduced, and investigate the properties of (∈ , ∈ ∨ (k*, qk))-fuzzy generalized bi-ideals by concerning the (∈ , ∈ ∨ (k*, qk))-fuzzy semiprime subsets. Moreover, some properties of (∈ , ∈ ∨ (k*, qk))-fuzzy semiprime subsets are defined in terms of its (k*, k)-lower part. Finally, completely regular ordered semigroups are characterized in terms of its (∈ , ∈ ∨ (k*, qk))-fuzzy semiprime generalized bi-ideals and their (k*, k)-lower parts."@en ;
    ns0:hasPubTitle "A new type of fuzzy semiprime subsets in ordered semigroups"@en .

ns1:ifs-v37-i3-IFS190325 ns0:hasKeywords "46S40"@en,
        "47H10"@en,
        "54H25"@en,
        "Fixed point"@en,
        "fuzzy mapping"@en,
        "generalized contraction"@en,
        "left (right) K-sequentially complete dislocated quasi metric space"@en,
        "open ball"@en ;
    ns0:hasPubAbstract "In this paper, we have achieved fixed point results for pair of fuzzy mappings satisfying Ciric type contraction on a sequence contained in an open ball in ordered left (right) K-sequentially complete dislocated quasi metric space. An example and an application are presented to demonstrate the novelty of the results. Our results generalize and extend some recent results in literature."@en ;
    ns0:hasPubTitle "Fixed point results for fuzzy mappings on an intersection of an open ball and a sequence"@en .

ns1:ifs-v37-i3-IFS190444 ns0:hasKeywords "Quality function deployment (QFD)"@en,
        "customer requirement (CR)"@en,
        "group decision-making (GDM)"@en,
        "ordinal scale"@en,
        "preference ordering"@en ;
    ns0:hasPubAbstract "Quality function deployment (QFD) is an effective tool for the design and improvement of products/services. The prioritization of customer requirements (CRs), as an essential component of the house of quality, is fundamental and strategic in the whole process of QFD product planning. This study proposes a novel ordinal scale values based group decision-making (GDM) approach first and it is subsequently used to prioritize CRs in QFD product planning. The proposed approach is composed of three stages, that is, constructing the integrated preference vector, defining the extraction sequence and constructing the comprehensive preference vector. The proposed GDM approach is good for utilizing the ordinal scale values provided by respondents due to limited experience and knowledge. An illustrative example is presented to verify the applicability and efficiency of the proposed approach. Further, to demonstrate the superiority of the proposed approach, comparisons are made between the proposed approach and two other similar methods. Practical results demonstrated that the proposed approach can be effective when the importance of customers and the preference evaluations of CRs are given by an ordinal scale."@en ;
    ns0:hasPubTitle "An ordinal scale-based GDM approach to prioritize customer requirements in QFD product planning"@en .

ns1:ifs-v37-i3-IFS190450 ns0:hasKeywords "Data envelopment analysis"@en,
        "cross-efficiency"@en,
        "dempster-shafer theory"@en,
        "interval number"@en,
        "prospect theory"@en ;
    ns0:hasPubAbstract "Cross-efficiency assessment method is a useful tool for assessing the relative performance of decision-making units (DMUs). It is generally assumed that decision makers (DMs) are completely rational in the cross-efficiency model, and DMs’ risk attitude has not been considered important in the evaluation process. When the self-evaluation score of the DMU is optimal, the input and output weights are non-unique, resulting in non-unique cross-efficiency score, which affects the ranking result. The relative importance of DMUs is ignored when aggregating cross-efficiency scores. in view of the above problems, a cross-efficiency method based on prospect theory is proposed to capture the bounded rational psychological behavior of risk DMs. This method considers all multiple optimal solutions and constructs interval cross-efficiency. The credibility of each cross-efficiency score is obtained based on the D-S evidence theory, and the weight of each DMU is obtained by using the Dempster rule. DMUs are ranked by calculating the prospect value. The validity and feasibility of the proposed method and how does the risk preference of DMs characterized by parameters α, β, λ affect the evaluation results are verified by an illustrative example."@en ;
    ns0:hasPubTitle "Improvement of cross-efficiency based on prospect theory"@en .

ns1:ifs-v37-i4-IFS17193 ns0:hasKeywords "Frontal face"@en,
        "Gender recognition"@en,
        "Genetic feature selection"@en,
        "Neural network"@en,
        "Principal component analysis"@en ;
    ns0:hasPubAbstract "This paper proposes a novel image processing method to extract the gender feature from frontal face combining Principal Component Analysis (PCA) and an improved Genetic Algorithm (GA) to reduce the interference of facial expression, lighting or wear. The collected facial images are first cropped and aligned automatically, then the gray-level information can be converted to feature vectors via PCA. After eigen-features are extracted with high classification performance by the aid of an improved GA, the neural network classifier can be trained accordingly. Compared to the classification methods based on global gray-level information, the obtained classifier has better identification rate but less used feature dimension, so the calculation load can substantially be reduced during training and classification procedures, which benefits to the development of a real-time identification system. Furthermore, FERET dataset and FEI dataset are used to validate the generality of the proposed method, where 94% and 96% accuracy rates of the gender recognition can be achieved respectively."@en ;
    ns0:hasPubTitle "Facial Eigen-Feature based gender recognition with an improved genetic algorithm"@en .

ns1:ifs-v37-i4-IFS171953 ns0:hasKeywords "DFIG"@en,
        "PI controller"@en,
        "fuzzy PI controller"@en,
        "modal analysis"@en,
        "rotor side convertor"@en,
        "transient condition"@en ;
    ns0:hasPubAbstract "An isolated network with Wind Turbine implemented by Double Fed Induction Generator (WTDFIG) that maintaining different electrical variables in safe ranges following a severe transient condition is always a serious challenge. This paper proposes a control scheme based on Auto-Tuning Fuzzy PI (ATFPI) concept for the Rotor Side Converter (RSC) of the DFIG by online tuning of the output scaling factor of the ATFPI for enhancement the transient behavior of the system under various condition of operation. The scheme includes a coordinator unit which is elaborated to effectively regulate the frequency and active power of the system. The performance of the proposed ATFPI controller is evaluated in a typical network in Matlab Simulink environment. Obtained results show that the control can successfully meet all functions drawn in the scope and easily put behind the conventional competitors like conventional PI and/or fuzzy PI controllers."@en ;
    ns0:hasPubTitle "Fuzzy modal control implemented in grid connected WTDFIG for transient behaviour enhancement"@en .

ns1:ifs-v37-i4-IFS179280 ns0:hasKeywords "Deep learning"@en,
        "algorithmic trading"@en,
        "commodity futures introduction"@en,
        "trend trading"@en ;
    ns0:hasPubAbstract "This paper attempts to apply recurrent neural networks (RNN) to price forecasts and financial trading. Compared with previous neural networks models, the recurrent neural network can better use the previous information to infer subsequent events, which is more suitable for price time series analysis. Long Short-Term Memory (LSTM) has made structural changes to the RNN to avoid long-term dependency problems. The empirical research uses the 2010–2017 price panel data of four kinds of soybean futures in China’s futures market, and confirms the model’s improved predictive ability through statistical tests. The empirical analysis of futures trading verifies the practice of these model strategies in terms of risked return. This paper improves and expands the application of recurrent neural networks model, and provides a new idea for applying artificial neural network algorithm to futures trading."@en ;
    ns0:hasPubTitle "A novel recurrent neural network algorithm with long short-term memory model for futures trading"@en .

ns1:ifs-v37-i4-IFS179291 ns0:hasKeywords "Multiplication"@en,
        "finite field"@en,
        "multivariate signature"@en,
        "wireless sensor networks (WSNs)"@en ;
    ns0:hasPubAbstract "There has been a continuous and increasing interest in research and application of Wireless Sensor Networks (WSNs). Although the future of WSNs is very prospective, the security issues become more and more important because they are used for very critical applications in engineering areas. Furthermore, they are very vulnerable and thus attractive to attacks because of human-unattended deployment and their limited prices. Generally, they are protected by public key cryptosystems. Such systems depends on the difficulty of the elliptic curve discrete logarithms or integer factorizations. However, they can be attacked by Shor’s algorithm on quantum computers. Multivariate Public Key Cryptography (MPKC) schemes are secure to attacks by quantum computers. Among such schemes, multivariate signatures use various multiplications in a finite field, which are time-consuming operations during signature generations. Thus, we focus on improving multiplications in finite fields for multivariate signatures. We propose a variant of Mastrovito multiplications based on trinomial, Special Trinomial (ST), pentanomial, Special Pentanomial (SP), Equally-spaced-polynomial (ESP), All-One-polynomial (AOP), and successive-one-polynomial (SOP). Our design is implemented on hardware and can be used to improve the implementations of multivariate signatures including UOV, enTTS and Rainbow for protecting data security in WSNs."@en ;
    ns0:hasPubTitle "Efficient multiplications in finite fields for multivariate signatures"@en .

ns1:ifs-v37-i4-IFS179295 ns0:hasKeywords "Deep neural network"@en,
        "big data"@en,
        "coverage"@en,
        "robustness"@en ;
    ns0:hasPubAbstract "Deep Neural Network is an application of Big Data, and the robustness of Big Data is one of the most important issues. This paper proposes a new approach named PCD for computing adversarial examples for Deep Neural Network (DNN) and increase the robustness of Big Data. In safety-critical applications, adversarial examples are big threats to the reliability of DNNs. PCD generates adversarial examples by generating different coverage of pooling functions using gradient ascent. Among the 2707 input images, PCD generates 672 adversarial examples with L∞ distances less than 0.3. Comparing to PGD (state-of-art tool for generating adversarial examples with distances less than 0.3), PCD finds 1.5 times more adversarial examples than PGD (449) does."@en ;
    ns0:hasPubTitle "Generating adversarial examples for DNN using pooling layers"@en .

ns1:ifs-v37-i4-IFS179300 ns0:hasKeywords "Regression analysis"@en,
        "data deletion model"@en,
        "mean shift model"@en,
        "outlier"@en,
        "residual sum of squares"@en,
        "sample quantile"@en ;
    ns0:hasPubAbstract "Outlier detection has always been a more active research topic in statistical diagnosis. Outliers are ubiquitous at data analysis areas in current and may produce erroneous results. In multivariate linear regression model, the existence of outliers will directly affect the modeling, parameter estimation and prediction. A set of data contains abnormal values, which will have a great impact on the estimation of the mean and standard deviation of the data, and also affect the estimation results of the least squares method. In the paper, on the basis of the linear regression model and deleting model and mean shift model, from the perspective of residual sum of squares and by introducing sample quantile to estimate the overall parameters robustly, a special statistic which is combined with the sample quantile method is used to detected the outliers. Finally, an example is analyzed and compared with the traditional method. The results show that the method is more effective."@en ;
    ns0:hasPubTitle "Robust estimation and outlier detection based on linear regression model"@en .

ns1:ifs-v37-i4-IFS179305 ns0:hasKeywords "E-commerce product quality"@en,
        "Naive Bayesian algorithm"@en,
        "cost sensitive leaning"@en,
        "fuzzy c-means clustering algorithm"@en,
        "risk assessment"@en ;
    ns0:hasPubAbstract "In order to pre-warning the product quality risk of the e-commerce platform, this paper studies the machine learning algorithm for the products quality risk assessment, which propose the Fuzzy C-Means clustering algorithm for the feature extraction and the Cost Sensitive Leaning (CSL)-Naive Bayesian algorithm to construct the assessment model for E-commerce product quality risk form the massive and unbalanced data. The experimental results show that the Machine Learning algorithm based on Spark has better scalability and superiority in the large-scale data environment, which can accurately identify e-commerce product quality risk."@en ;
    ns0:hasPubTitle "The product quality risk assessment of e-commerce by machine learning algorithm on spark in big data environment"@en .

ns1:ifs-v37-i4-IFS179315 ns0:hasKeywords "Intelligent"@en,
        "graph-based ranking"@en,
        "similarity calculation"@en,
        "text summarization"@en ;
    ns0:hasPubAbstract "With the rapid development of clinical and laboratory medicine, the field of bioinformatics boasts of extensive clinical records and research literature. Retrieving effective information from this huge data has become a challenging task. Hence, Intelligent text summarization, which enables users to find and understand relevant source texts more quickly and effortlessly, becomes a very significant and valuable field of research. In this study, we propose an improved TextRank algorithm with weight calculation based on sentence graph to solve this problem. For the experimental dataset obtained from Pubmed, we represent terms as vectors by using Skip-gram model. We design three methods which utilize word embeddings to calculate weights between sentences. Then we build an undirected graph with sentences as nodes. At last, we use the improved TextRank algorithm to calculate the importance of sentences and further generated summarizations base on its ranking. The experimental results and analysis on the datasets demonstrate the effectiveness of the proposed model."@en ;
    ns0:hasPubTitle "Intelligent multi-document summarization for biomedical literature by word embeddings and graph-based ranking"@en .

ns1:ifs-v37-i4-IFS179316 ns0:hasKeywords "Inventory coordination"@en,
        "economic order quantity"@en,
        "inventory strategy"@en,
        "multi-objective genetic algorithm"@en,
        "revenue sharing"@en ;
    ns0:hasPubAbstract "In this paper, under the circumstance of uncertain customer demand, the enterprises on the same node in multiple supply chains conduct horizontal inventory coordination according to their own inventory and demand. Based on the combination of horizontal inventory replenishment and vertical normal replenishment, the related mathematical model has been established. By studying the inventory strategy in the decentralized and centralized decision-making, the dual marginalization effects are found in the network system composed of multiple supply chain. So the revenue sharing contract is introduced to solve this problem. It has been found in the study that after adopting the horizontal inventory coordination mechanism of the supply chain, the profit of the members in the supply chain system and the overall profit of the system are both higher than those which didn’t adopt the mechanism. The improved multi-objective genetic algorithm is used to calculate and verify the problem. In particular, after the revenue sharing contract is adopted, the profits are further enhanced."@en ;
    ns0:hasPubTitle "Horizontal inventory coordination in supply chain based on multi-objective genetic algorithm"@en .

ns1:ifs-v37-i4-IFS179319 ns0:hasKeywords "ANFIS"@en,
        "closing performance"@en,
        "controlled switching"@en,
        "risk of failure"@en,
        "ultra-high-voltage"@en ;
    ns0:hasPubAbstract "Controlled switching strategy can reduce overvoltages due to UHV transmission line closing. However, the traditional method is difficult to determine the quantitative relationship between the closing performance of circuit breakers and the risk of failure of transmission lines. Based on the risk of failure data calculated by the statistical method, an adaptive network-based fuzzy inference system (ANFIS) model for forecasting risk of failure that occurs during the closing of transmission lines is presented. An ANFIS model is employed to map the closing performance of circuit breakers and the risk of failure of the UHV transmission line. The model is based on a system of fuzzy-rules written on the basis of previous results, the knowledge and experience. The fuzzication of input variables is carried out using fuzzy sets with the Gauss membership functions. “Grid partition” was used to generate the fuzzy inference system, and a hybrid learning rule was used to optimize the fuzzy system parameters. After the appropriate model is established through training and checking, it can forecast the risk of failure in different closing performance of circuit breakers. Then, it is easy to analyze the closing performance of circuit breakers in different risk of failure requirements."@en ;
    ns0:hasPubTitle "Forecasting failure risk of transmission line in ultra-high-voltage networks using ANFIS"@en .

ns1:ifs-v37-i4-IFS179322 ns0:hasKeywords "PLC control"@en,
        "Vegetable pot seedling"@en,
        "design"@en,
        "intelligent transplanting system"@en ;
    ns0:hasPubAbstract "Pot seedling transplanting is the main way of vegetable planting, there were some problems of labor intensity and low level of automation in the process of mechanized transplanting of vegetable pot seedling. Aiming at this problem, this paper designed an intelligent transplanting system for vegetable pot seedling, which included the function of the seeding storage mechanism, the seedling feeding mechanism, the ejecting seedling mechanism, the pinch mechanism and the planting mechanism, the system monitors the whole movement process of planting through pressure sensing, stroke detection and limit switch, obtains each planting stage of the seedlings during planting, and uses the CCD camera to identify the key steps of planting and seedlings to determine whether it is missing. Three broccoli seedlings with different moisture content and the age of 42d were used as the experimental object of seedlings planting experiment. Results indicated that: Under the conditions of meeting the agronomic requirements of vegetable pot seedlings, when the speed of picking-up seedlings was 75 seedlings per minute, which resulted in a 95% success rate of picking-up seedlings and 5% leaked seedlings rate, the planting effect of vegetable pot seedlings was the best. The research can provide useful reference for the development of intelligent transplanting technology of vegetable pot seedling."@en ;
    ns0:hasPubTitle "Design of intelligent transplanting system for vegetable pot seedling based on PLC control"@en .

ns1:ifs-v37-i4-IFS181519 ns0:hasKeywords "Two-stage data envelopment analysis"@en,
        "credibility measure"@en,
        "fuzzy input- intermediate -output data"@en,
        "sensitivity and stability analysis"@en ;
    ns0:hasPubAbstract "In this paper, crisp two-stage data envelopment analysis (TSDEA) models are expanded for decision-making problems where inputs, intermediate data, and outputs are expressed with fuzzy numbers. Considering the merits of credibility theory, we propose the use of this theory in the efficiency measurement of fuzzy serially-connected two-stage systems. For determined credibility levels, we transform the fuzzy model into a linear programming problem and then obtain the credibility function and membership function for fuzzy efficiency of two-stage decision-making units (DMUs). We also explore the sensitivity and stability analysis of two-stage DMUs based on the proposed methodology. As a result, the projection of inefficient fuzzy two-stage DMUs and the stability radius of efficient fuzzy two-stage DMUs, i.e. the region in which efficiency status is preserved, are also determined. We also provide an illustrative example to better explain the method and demonstrate its performance in comparison with other developed methods for fuzzy TSDEA."@en ;
    ns0:hasPubTitle "Using credibility theory to evaluate the fuzzy two-stage DEA: Sensitivity and stability analysis"@en .

ns1:ifs-v37-i4-IFS181524 ns0:hasKeywords "Fuzzy logic"@en,
        "damping controller"@en,
        "doubly-fed induction generator"@en,
        "power system oscillations"@en ;
    ns0:hasPubAbstract "Doubly-fed induction generator (DFIG) is the most commonly used technology for wind power generation due to the variable speed performance, decoupled control of active and reactive powers, and high efficiency. However, the DFIG originally cannot participate in damping of power system oscillations since it is not synchronously connected to the power system. This paper proposes an optimal and robust additional damping controller for the DFIG wind turbine to contribute it to damp power system oscillations. It is a fuzzy logic controller that its parameters are optimally tuned using the genetic algorithm (GA). The proposed controller modifies the DFIG active power output by using feedback from grid oscillations. Here, a comparative study is carried out for different feedback signals to determine the best of them. Comparing the results reveal that the rotor speed difference of synchronous generators is the best feedback signal to damp power system oscillations. Time domain simulations also confirm the effectiveness and robustness of the proposed controller under both the small and large disturbances."@en ;
    ns0:hasPubTitle "A comparative study on fuzzy damping controller for DFIG wind farms to improve power system oscillations"@en .

ns1:ifs-v37-i4-IFS181980 ns0:hasKeywords "Hesitant fuzzy set"@en,
        "aggregation operators"@en,
        "entropy"@en,
        "priority level"@en ;
    ns0:hasPubAbstract "In this paper, we investigate the hesitant fuzzy multi-attribute decision-making method based on entropy and prioritization relationship. Considering the double impact of priority levels of attributes and the dispersion degree of hesitant fuzzy elements, we propose a prioritized level weighted method based on entropy. The weighted method can guarantee a constant priority level of the attributes and distinguish the unity degree of expert opinions effectively. Then, we put forward the hesitant fuzzy prioritized level average (HFPLA) and hesitant fuzzy prioritized level geometric (HFPLG) operators based on the prioritized level weighted method. Furthermore, we discuss some desirable properties of the proposed operators. Finally, the practicability and effectiveness of the proposed methods are verified by numerical examples."@en ;
    ns0:hasPubTitle "A multi-attribute decision-making method with prioritization relationship and hesitant fuzzy decision information"@en .

ns1:ifs-v37-i4-IFS182766 ns0:hasKeywords "(C1) and (C2) axioms"@en,
        "LF-approximating space"@en,
        "LF-approximation space"@en,
        "LF-rough set"@en,
        "LF-set"@en,
        "LF-topology"@en ;
    ns0:hasPubAbstract "Rough set theory (for short, RST) are widely applied to artificial intelligence. Fuzzy rough sets (for short, FRSs) are the results of approximation of fuzzy sets on a fuzzy approximation space. In this paper, L-fuzzy is briefly denoted by LF. We study a topological problem of FRSs based on residuated lattices, i.e., suppose that L is a complete residuated lattice, then when may the given LF-topology be consistent with the LF-topology induced by some preorder LF-relation? In order to answer this problem, the notion of LF-approximating spaces is introduced. Moreover, determinant conditions for LF-topological spaces to be LF-approximating spaces are given."@en ;
    ns0:hasPubTitle "L-fuzzy approximating spaces"@en .

ns1:ifs-v37-i4-IFS182864 ns0:hasKeywords "Spring vibration equation"@en,
        "stability"@en,
        "uncertain differential equation"@en,
        "uncertain process"@en,
        "uncertainty theory"@en ;
    ns0:hasPubAbstract "Uncertain Differential equations are a type of differential equations driven by the Liu processes rather than the Wiener processes. Depending on the order of differentials it contains, an uncertain differential equation could be classified into first-order uncertain differential equation, second-order uncertain differential equation, third-order uncertain differential equation, and so on. The concepts of stability in various senses for the uncertain differential equations could be specified and applied to the uncertain spring vibration differential equations. However, to the best knowledge of mine, many types of stability have been proposed for first-order uncertain differential equations, for example, stability in mean, stability in p-th moment, stability in distribution, almost sure stability and exponential stability. However, stability in measure and stability in mean of high-order uncertain differential equations have been proposed. But only the concept of stability in mean and the concept of stability in measure have been proposed for high-order uncertain differential equations. In this paper, following the concept of stability in p-th moment for first-order uncertain differential equations, we present the concept of stability in p-th moment for general uncertain spring vibration differential equations which are a type of second-order uncertain differential equations."@en ;
    ns0:hasPubTitle "Stability in p-th moment for uncertain spring vibration equation"@en .

ns1:ifs-v37-i4-IFS182887 ns0:hasKeywords "(Stratified) Soft L-topology"@en,
        "Coreflective"@en,
        "Galois correspondence"@en,
        "Reflective"@en,
        "Soft topology"@en ;
    ns0:hasPubAbstract "The aim of this paper is to study the relations among soft topological spaces, soft L-topological spaces and stratified soft L-topological spaces. Firstly, we construct a Galois correspondence between the category SoTop of soft topological spaces and the category SoL-Top of soft L-topological spaces, and obtain that SoTop is a coreflective subcategory of SoL-Top. Secondly, we show that there is a Galois correspondence between the category SSoL-Top of stratified soft L-topological spaces and SoTop and obtain that SoTop is a reflective subcategory of SSoL-Top. Finally, we study the stratification of soft L-topological spaces. We also construct a Galois correspondence between SSoL-Top and SoL-Top, and obtain that SSoL-Top is a coreflective subcategory of SoL-Top."@en ;
    ns0:hasPubTitle "Galois correspondences in soft L-topological spaces"@en .

ns1:ifs-v37-i4-IFS18678 ns0:hasKeywords "IT2FS fuzzy factor"@en,
        "IT2FS interval factor"@en,
        "comprehensive relative cross-entropy"@en,
        "cross-entropy"@en,
        "utility function"@en ;
    ns0:hasPubAbstract "In recent years, interval type-2 fuzzy set has played an increasingly important role in decision-making. The purpose of this paper is firstly to propose fuzzy factor and interval factor of interval type-2 fuzzy sets (IT2FSs) based on α-cuts. Then, entropy and cross-entropy formulas of IT2FSs are put forward to measure the fuzzy information and mutual information between IT2FSs based on the two factors. Furthermore, IT2FS comprehensive cross-entropy formula is brought forward to measure the relative uncertain relationships among IT2FSs based on IT2FS cross-entropy formula and total probability formula. In the next moment, a utility function of IT2FS is proposed to compare the ordering relationship among IT2FSs. On the other hands, an optimal linear programming model is constructed based on IT2FS entropy, comprehensive cross-entropy and utility function to solve the optimal alternative. Finally, a simple example is utilized to testify the practicability and effectiveness of the proposed approach."@en ;
    ns0:hasPubTitle "Comprehensive cross-entropy and entropy measures and their applications under interval type-2 fuzzy environment"@en .

ns1:ifs-v37-i4-IFS190016 ns0:hasKeywords "Soft set"@en,
        "fuzzy soft hyperalgebra"@en,
        "homomorphism"@en,
        "soft hyperalgebra"@en ;
    ns0:hasPubAbstract "We introduce the notion of fuzzy soft hypealgebras as an extension of the notion of soft hyperalgebras as well as soft algebras. Also, some basic properties of fuzzy soft sets and homomorphisms between fuzzy soft hypealgebras are presented and discussed. Finally, we study the image and inverse image of a fuzzy soft hypealgebra under a fuzzy soft hyperalgebra homomorphism."@en ;
    ns0:hasPubTitle "Fuzzy soft hyperalgebras"@en .

ns1:ifs-v37-i4-IFS190408 ns0:hasKeywords "Fuzzy number, fuzzy poisson’s equation, fuzzy finite difference method, convergence, fuzzy divergence theorem"@en ;
    ns0:hasPubAbstract "In this paper, first, the fuzzy Poisson’s equation and the fuzzy finite difference method are introduced. Then, the fuzzy Poisson’s equation is discretized by fuzzy finite difference method and it is solved as a linear system of equations. In addition, we discuss fuzzy Laplace equation as a special case of fuzzy Poisson’s equation. Finally, the convergence of method is taken into account and for more illustration a numerrical example is solved."@en ;
    ns0:hasPubTitle "Fuzzy finite difference method for solving fuzzy Poisson’s equation"@en .

ns1:ifs-v37-i4-IFS190459 ns0:hasKeywords "Cloud computing"@en,
        "average response time"@en,
        "task schedule"@en,
        "task sets"@en,
        "three-way clustering"@en,
        "three-way decisions"@en ;
    ns0:hasPubAbstract "Task clustering is an effective approach of improving cloud computing resource utilization, which includes other benefits such as better QoS, load balance and low energy consumption. Different existing clustering methods have sharp boundaries, three-way clustering as an application of three-way decision, uses core region and fringe region to represent a cluster. In this paper, we propose a novel idea of clustering weight algorithm called TWCW algorithm(Three-way clustering weight) based on three-way decision to overcome the low utilization aiming at improving energy-efficient. The algorithm encompasses two steps, the identified tasks are assigned into the core region and the uncertain tasks are assigned into the fringe region based on diversity of cloud tasks and the dynamic nature of resources using the three-way K-means clustering firstly. The cluster center of CSi, centroidi = {mips, ram, bw} is obtained from the result of three-way clustering. In the second step is to score clusters and schedule tasks. We define a scoring matrix to record scores of the weight between clusters and the preference of attributes within clusters according to the cluster center, and then schedule tasks based on scoring matrix. We validate the high utilization of resources of the proposed algorithm by using simulation of CloudSim. The experiment shows the proposed algorithms significantly reduce energy consumption while significant improving response time of tasks comparing with K-means algorithm and FCM algorithm."@en ;
    ns0:hasPubTitle "Resource-utilization-aware task scheduling in cloud platform using three-way clustering"@en .

ns1:ifs-v37-i4-IFS190550 ns0:hasKeywords "Linear Diophantine fuzzy set (LDFS)"@en,
        "MADM"@en,
        "geometrical interpretation of LDFS"@en,
        "linear Diophantine fuzzy topological space (LDFTS)"@en,
        "linear Diophantine fuzzy weighted geometric aggregation (LDFWGA) operator"@en ;
    ns0:hasPubAbstract "The prevailing concepts of intuitionistic fuzzy sets (IFSs), Pythagorean fuzzy sets (PFSs) and q-rung orthopair fuzzy sets (q-ROFSs) have numerous applications in various fields from real life. Unfortunately, these theories have their own limitations related to the membership and non-membership grades. To eradicate these restrictions, we introduce the novel concept of linear Diophantine fuzzy set (LDFS) with the addition of reference parameters. This idea removes the restrictions of existing methodologies and the decision maker (DM) can freely choose the grades without any limitations. This structure also categorizes the problem by changing the physical sense of reference parameters. We present some fundamental operations on linear Diophantine fuzzy sets (LDFSs). We present geometrical interpretation for different operations of LDFSs. We also introduce the novel concepts of linear Diophantine fuzzy topological space (LDFTS) and linear Diophantine fuzzy weighted geometric aggregation (LDFWGA) operator. We discuss several properties of LDFTS with the help of examples. We introduce score functions and accuracy functions with different orders for the comparison of linear Diophantine fuzzy numbers (LDFNs). We propose two algorithms for solving multi-attribute decision-making (MADM) problem accompanied by an interesting application employing LDFTSs and LDFWGA operator."@en ;
    ns0:hasPubTitle "Linear Diophantine fuzzy set and its applications towards multi-attribute decision-making problems"@en .

ns1:ifs-v37-i4-IFS190554 ns0:hasKeywords "Fuzzy neural network"@en,
        "continuous genetic algorithm"@en,
        "intuitionistic fuzzy logic"@en,
        "intuitionistic fuzzy neural network"@en,
        "medical cost forecasting"@en ;
    ns0:hasPubAbstract "Taiwan is an endemic area for chronic hepatitis disease. Since the early 1980’s, liver cancer has become the first cancer mortality causes among other cancers in Taiwan. Besides, liver cirrhosis and chronic liver diseases are the sixth rank and seventh rank in the causes of death, respectively. This is a serious disease affecting people’s health and it brings a lot of medical cost as well. This study develops a medical cost forecasting model for the acute hepatitis patients in the emergency room. In order to consider the uncertainty and hesitation in the human being’s thinking, this study employs the intuitionistic fuzzy logic (IFL) since it considers membership, non-membership, and hesitation values simultaneously. The proposed model combines the intuitionistic fuzzy neural network (IFNN) with Gaussian membership function and Yager-Generating function to enhance the performance of FNN. Furthermore, a back-propagation learning algorithm and genetic algorithm (GA) are applied in order to optimize the parameters and weights of the proposed IFNN. The proposed IFNN is applied to solve ten benchmark datasets including the nonlinear control and prediction problems. The computational results showed that the GA-IFNN is more efficient than conventional algorithms, such as an artificial neural network (ANN), a fuzzy neural network (FNN), and a support vector regression (SVR). In the real-world problem, the proposed method can really support physicians in planning medical resources and make a good decision to make the most efficient use of limited resources."@en ;
    ns0:hasPubTitle "Application of genetic algorithm-based intuitionistic fuzzy neural network to medical cost forecasting for acute hepatitis patients in emergency room"@en .

ns1:ifs-v37-i4-IFS190580 ns0:hasKeywords "46S40"@en,
        "47H10"@en,
        "54H25"@en,
        "F-contraction"@en,
        "complete metric space"@en,
        "fixed point"@en,
        "fuzzy mapping"@en ;
    ns0:hasPubAbstract "In this manuscript, we study the existence of common α- fuzzy fixed points for fuzzy mappings via F-contractions on a metric space. We obtain some common fixed points of fuzzy (multivalued) mappings satisfying an F-contraction associated with the σ∞ (Hausdorff) metric. In closing, we provide an application of our results."@en ;
    ns0:hasPubTitle "Fuzzy fixed points of fuzzy mappings via F-contractions and an application"@en .

ns1:ifs-v37-i4-IFS190595 ns0:hasKeywords "Social media retailing"@en,
        "dual channel"@en,
        "pricing decision"@en,
        "social relationship"@en,
        "uncertainty theory"@en ;
    ns0:hasPubAbstract "With the rapid-developing social media, firms increasingly employ social media for different organizational purposes, including operations, marketing and innovation management. Meanwhile, a social media retailing channel as the outcome of integrating social media with online retailing has received increasing attention in a variety of industries and academic fields. Moreover, products update is getting faster and faster with rapid-developing technologies, which usually leads to more indeterminate information on demands and costs, thus the indeterminacy should be taken into account in pricing decisions. Based on this, we explore the impact of introducing this new channel on a traditional distribution channel under uncertain environment. Specifically, we construct two uncertain bilevel programming models under different channel structures, in which the demand of the social media channel is characterized as sensitive to the intensity of the social relationship. We find introducing the social media channel may either increase or decrease wholesale price and the traditional retailer’s retail price, depending on the expected value of the intensity of the social relationship. When the social media channel is introduced, equilibrium prices will increase with the intensity of social relationship, namely, a stronger social relationship leads to a higher retail price not only in the social media channel but also in the tradition channel. A series of numerical experiments show that a rise in the uncertain degree of the intensity of the social relationship will raise the manufacturer’s expected profit, but has no impact on equilibrium prices and the retailer’s expected profit."@en ;
    ns0:hasPubTitle "Impact of social media retailing on pricing decisions under uncertain environment"@en .

ns1:ifs-v37-i4-IFS190706 ns0:hasKeywords "Complex activities recognition"@en,
        "emerging pattern"@en,
        "fuzzy sets"@en,
        "multi-label classification"@en,
        "nonlinear separation"@en ;
    ns0:hasPubAbstract "Sensor-based human activity recognition gained a lot of research interest within the field of pervasive computing due to its wide range of application domains. Recognition of complex human activities is a challenging task due to the tendency of humans to perform activities in an interleaved and concurrent scenario. In this paper, we address the problem of complex activities recognition using a combination of the discriminative features called Strong Jumping Emerging Patterns (SJEPs) and the fuzzy sets theory. The proposed approach is designed to fit the challenges of multi-label classification, nonlinear separation, and recognition of multiple overlaps of interleaved and concurrent activities. Besides the need for a training dataset of complex activities that is difficult to obtain. The proposed approach uses a training dataset of simple activities to extract two sets of SJEPs for linear and nonlinear activities. Then, a novel SJEP-based recognition approach is presented to recognize simple and complex activities. We evaluate our approach using two datasets collected from two different labs. Experimental results show the efficiency of our approach in recognizing simple and complex human activities, besides the superiority of our approach against other competing approaches with regard to recognition accuracy."@en ;
    ns0:hasPubTitle "Data driven recognition of interleaved and concurrent human activities with nonlinear characteristics"@en .

ns1:ifs-v37-i4-IFS190810 ns0:hasKeywords "47H10"@en,
        "54H25"@en,
        "Fixed function"@en,
        "complete metric space"@en,
        "expansive mappings"@en ;
    ns0:hasPubAbstract "In the present article, the concept of expansion is extended in a refined manner by introducing   P  -expansion defined on a family   F   of bounded functions. Some fixed function theorems using expansive mappings in complete metric spaces are investigated. These results improve and generalize various results existing in literature. The authenticity of obtained results is verified with the help of some comparative examples. In addition, an application has also been presented which is based on the best approximation of dose distribution for a number of patients (at a same time) getting Tomotherapy."@en ;
    ns0:hasPubTitle "Some new results on expansion mapping and their application"@en .

ns1:ifs-v37-i4-IFS190863 ns0:hasKeywords "Group decision making"@en,
        "consensus"@en,
        "marketing plan"@en,
        "robust optimization"@en,
        "uncertain set"@en ;
    ns0:hasPubAbstract "In the process of group decision making, perturbation of input data always reduces the quality of the optimal solution or even makes it unfeasible. Hence, the value of the optimal solution is often limited. In this paper, a robust optimization method is proposed to overcome the inherent uncertainty of input data in group decision making (such as experts’ unit adjustment cost). Firstly, the minimum cost consensus model based on norm definition is established. Then, four different forms of uncertainty sets are proposed, and the corresponding robust models of four minimum consensus cost models are established. Finally, in order to evaluate the robustness of the solutions obtained by the robust consensus model, the results with different parameters are compared. The robust consensus model is also compared with the minimum cost consensus model. A numerical example proves that the result of the minimum cost consensus model is too optimistic, and the robust consensus model is more robust."@en ;
    ns0:hasPubTitle "Robust consensus models based on minimum cost with an application to marketing plan"@en .

ns1:ifs-v37-i5-IFS179161 ns0:hasKeywords "Kalman filter"@en,
        "dynamic monitoring"@en,
        "early-warning"@en,
        "operational risks"@en ;
    ns0:hasPubAbstract "With the rapid development of China’s economy, early-warning of operational risk has attracted significant attention of financial risk researchers in recent years. To analysis dynamic early-warning of operational risks, Chinese manufacturing industry publicly listed companies were selected as research object. A measure model of early-warning index of operational risks in Chinese manufacturing industry listed companies based on grey Kalman Filter was constructed. With the early-warning results of sample listed companies in manufacturing industry through calculating process noise covariance, measurement noise covariance and Kalman gain matrix; thirdly, a model of investors’ reactions was designed to test correctness of early-warning index of operational risks. Results demonstrate that, for the case study, it can get precise result of early-warning results by using Kalman filter, and investors react negatively towards the operational risks. The conclusions contribute to prior literatures on the dynamic evaluation of early-warning of operational risks by providing operational processes."@en ;
    ns0:hasPubTitle "Intelligent early-warning analysis of operational risks based on grey Kalman filter"@en .

ns1:ifs-v37-i5-IFS179196 ns0:hasKeywords "Fuzzy model"@en,
        "complex network"@en,
        "industrial cluster"@en,
        "technological innovation"@en ;
    ns0:hasPubAbstract "Industrial cluster is a common phenomenon in the process of industrialization. It is an external scale formed by agglomeration effect. Cluster enterprises based on their comparative advantages, innovation will be in the system innovation, management innovation, technological innovation, corporate culture innovation and other all-round development. The empirical results show that the development of industrial clusters attracts and promotes a large number of intermediary service-oriented organizations, as well as institutions providing research and development and technical support, providing innovative incubation platform. The diffusion behavior of technological innovation of enterprises in clusters plays an important role in upgrading industrial clusters, but uncontrolled imitation behavior will reduce the expected profits of enterprises taking the lead in innovation and increase innovation risks. At the same time, the supporting innovation service system integrates and improves the factors gathering and optimization needed for innovation, and provides a technological support platform for enterprises in clusters to innovate.Therefore, the government’s policy should be biased towards establishing an effective mechanism for the interaction between scientific and technological innovation and industrial clusters, so as to achieve a good situation of the interaction between economy and science and technology."@en ;
    ns0:hasPubTitle "Coupling effect of regional industrial cluster and innovation based on complex system metric and fuzzy mathematics"@en .

ns1:ifs-v37-i5-IFS179200 ns0:hasKeywords "Support vector"@en,
        "computer interactive system"@en,
        "improved model"@en,
        "recognition algorithm"@en ;
    ns0:hasPubAbstract "At present, there is less software related to sport technical behavior recognition, and there are few studies on the classification and identification of detailed actions. By introducing computer technology to analyze the efficiency and regularity of sports, not only the characteristics of athletes can be excavated, but also the visibility and dynamic tracking of sport training can be provided. The process of sports education is a fast and complex systematic process. Through the interactive system of physical education, we can use different methods to collect sports data and make a comparative analysis of athletes’ movements. Through the data mining of the relationship between athletes’ physiological indexes and sports load, the unreasonable link in sports training can be avoided. Also, in sports training, we can use computer vision and modern biomechanics to construct a virtual sports education situation. With the classification accuracy as the fitness function, this paper collects the data through the network database, and returns the corresponding sport training parameters on this basis. The results showed that the accuracy of the model was nearly 98%, which met the actual demand. Therefore, the development of sports education assistant system can provide strong support for the process control of sports training and education."@en ;
    ns0:hasPubTitle "Design of computer interactive system for sports training based on artificial intelligence and improved support vector"@en .

ns1:ifs-v37-i5-IFS179201 ns0:hasKeywords "BP neural network"@en,
        "economic growth"@en,
        "financial innovation"@en,
        "synergy"@en ;
    ns0:hasPubAbstract "There is little research on the relationship between financial innovation and economic growth, and the research on the synergy between the two is basically blank. Based on this, from a general perspective, through constructing the corresponding subsystems in combination with financial innovation and economic growth, establishing the corresponding synergy model, and discovering the synergy development relationship by studying the degree of synergy in the past period, this study builds a BP neural network simulation model to predict the degree of synergy between financial innovation and economic growth in 2018 on the basis of practice. At the same time, this study compares it with the actual situation to verify its effectiveness. Through analysis, the research model has certain effectiveness, which is basically consistent with the actual development trend. The research proposes that the main trend of financial innovation from the perspective of generalized virtual economy is Internet finance. This is the first time to study this issue from a new perspective, theory and method, which expands the existing research results."@en ;
    ns0:hasPubTitle "Research and analysis on the coordination mechanism of financial innovation and economic growth based on BP neural network"@en .

ns1:ifs-v37-i5-IFS179210 ns0:hasKeywords "SOM neural network"@en,
        "chain enterprises"@en,
        "fuzzy model"@en,
        "performance analysis"@en ;
    ns0:hasPubAbstract "With the rapid expansion of chain network, enterprises meet the consumption demand scattered around in a large range. In this paper, SOM neural network algorithm is introduced for empirical test. Design includes the structure of the fuzzy neural network identification and parameter identification, structural identification include input space division and the number of fuzzy rules to determine. Through summarizing and analyzing the characteristics of chain retail enterprises, this paper proposes to build a hierarchical and differentiated incentive mechanism by cultivating retail culture. The result shows that the knowledge staff is been higher the education level, the work creativity is stronger, cooperates the demand to the team members. In the era of the knowledge economy, knowledge has replaced capital as the core source of the enterprise core competence. The performance evaluation of knowledge workers is complex and the performance of the general staff is often easier to get a more objective evaluation. In conclusion, performance characteristics of knowledge workers should include general knowledge staff quality, knowledge staff performance behavior and performance results three aspects of characteristics."@en ;
    ns0:hasPubTitle "Statistical analysis of chain company employee performance based on SOM neural network and fuzzy model"@en .

ns1:ifs-v37-i5-IFS179211 ns0:hasKeywords "Particle algorithm"@en,
        "cell detection"@en,
        "model"@en,
        "neural network"@en ;
    ns0:hasPubAbstract "Due to the lack of uniform standards for pathological cell detection, it is difficult to identify. In order to improve the accuracy of pathological cell identification, this study combines the actual situation of cell detection based on traditional particle algorithm to construct a C-V model based on level set algorithm and curve evolution theory, which realizes the effective separation of different substances inside the cell. At the same time, in order to effectively extract the characteristics of cell images, this paper uses the global research method to extract the features of the research object and adopts the improved gray level co-occurrence matrix to extract the texture features, thus effectively improving the feature extraction quality. In addition, in order to study the accuracy of the algorithm model identification in this study, this paper designs a comparative experiment for performance analysis. The research shows that the proposed algorithm model has good performance, can achieve accurate recognition and feature extraction of pathological cells, has certain practical effects, and can provide theoretical reference for subsequent related research."@en ;
    ns0:hasPubTitle "Improvement effect of improved particle algorithm on BP neural network cell detection model"@en .

ns1:ifs-v37-i5-IFS181739 ns0:hasKeywords "Dissimilarity functions"@en,
        "Fuzzy equivalencies"@en,
        "Intuitionistic fuzzy equivalencies"@en,
        "Intuitionistic fuzzy sets"@en,
        "Similarity measures"@en ;
    ns0:hasPubAbstract "The measure of the similarity between intuitionistic fuzzy sets (IFSs) is an important topic in IFSs theory. In this paper, we propose two computational formulae for similarity measures on IFSs based on a quaternary function called intuitionistic fuzzy equivalence. We first propose the concept of intuitionistic fuzzy equivalence. Then we give a computational formula for intuitionistic fuzzy equivalencies (i.e., Eq. (1)), which is obtained from combining dissimilarity functions and fuzzy equivalencies. Based on Eq. (1), we obtain two computational formulae for similarity measures on IFSs. The first one is obtained by aggregating Eq. (1). The second one is obtained by respectively aggregating the numerator and the denominator of Eq. (1). We also examine some properties of the proposed similarity measures on IFSs. Finally, we make a comparison between the proposed similarity measures on IFSs and those existing ones in the literature through several counter-intuitive cases."@en ;
    ns0:hasPubTitle "Two computational formulae for similarity measures on intuitionistic fuzzy sets based on intuitionistic fuzzy equivalencies"@en .

ns1:ifs-v37-i5-IFS181874 ns0:hasKeywords "Multi-rate reference data"@en,
        "fuzzy-based rate allocation"@en,
        "highly-scalable self-recovery"@en,
        "source-channel coding scheme"@en,
        "tamper tolerability"@en ;
    ns0:hasPubAbstract "This paper proposes a self-recovery method of fragile watermarking. Generally, self-recovery methods embed two types of data into the original image: check-bits for tamper detection and reference data for image recovery. Generating reference data is the primary challenge of every self-recovery method for more tamper resiliency and higher reconstruction quality. The proposed Multi-Rate Reference Embedding (MRRE) method makes unique reference data with several redundancy rates, instead of generating multiple reference data. According to the proposed methodology, the image is compressed by a source coding algorithm and the compressed data is separated into ten parts. Each part is protected by a channel coding algorithm based on pre-assigned redundancy rates. A fuzzy-based rate allocation system is used to assign the redundancy rates based on the importance of data. The generated data is packetized and randomly embedded into an image block. For tamper detection purpose, check-bits are generated by an MD5 hash function for every block. Both reference data and check-bits are embedded into three least significant bits (LSB) of the image pixels. To increase restoration efficiency, the proposed MRRE method provides ten scales of image recovery named highly-scalable self-recovery. The simulation results show an improvement in both tamper tolerability and reconstruction quality in comparison with the most recent methods."@en ;
    ns0:hasPubTitle "Multi-rate reference embedding for highly-scalable self-recovery using fuzzy mamdani"@en .

ns1:ifs-v37-i5-IFS182823 ns0:hasKeywords "Fuzzy data envelopment analysis"@en,
        "Fuzzy inequality"@en,
        "Minimal element"@en,
        "The positive output-axes"@en,
        "The production possibility set"@en ;
    ns0:hasPubAbstract "Evaluating the performances of a set of entities called decision making units (DMUs) which convert multiple inputs into multiple outputs has long been considered as a difficult task because one is dealing with complex economics. This work proposes an inequality approach to evaluate the performances of DMUs. Inequalities consist of expressions of the production possibility set and the line segments joining the evaluated DMU to the positive output-axes. However, in real-world application involving performance measurement, inputs and outputs are often imprecise and fluctuated. In this case, a fuzzy inequality approach is proposed to evaluate the performances. What is more, fuzzy relative efficiency is dependent upon the number of solutions. Furthermore, the minimal element is used to distinguish the fuzzy relative efficient DMUs. Finally, two numerical examples are used to illustrate the fuzzy approach and compare the results with those obtained with alternative fuzzy approaches."@en ;
    ns0:hasPubTitle "A fuzzy inequality evaluation approach for measuring the relative efficiency"@en .

ns1:ifs-v37-i5-IFS182877 ns0:hasKeywords "Uncertain distribution"@en,
        "backward uncertain differential equation"@en,
        "stability in distribution"@en,
        "uncertain process"@en ;
    ns0:hasPubAbstract "Backward uncertain differential equation is a specical type of differential equation driven by a Liu process. There are some concepts of stability such as stability in measure, stability in mean, stability in p-th moment, stability moment exponential and almost sure stability of backward uncertain differential equations have been proposed. As a supplement, this paper gives a concept of stability in uncertain distribution of backward uncertain differential equation. Some sufficient conditions for a backward uncertain differential equation being stable in uncertain distribution are provided. In addition, this paper further discusses their relationships among stability in uncertain distribution, stability in uncertain measure, stability in mean and stability in p-th moment. Last, this paper discusses some examples to illustrate the theoretical considerations."@en ;
    ns0:hasPubTitle "Stability in uncertain distribution for backward uncertain differential equation"@en .

ns1:ifs-v37-i5-IFS182947 ns0:hasKeywords "03G12"@en,
        "03G25"@en,
        "54A05"@en,
        "54A10"@en,
        "Basic algebra"@en,
        "continuous"@en,
        "separation axioms"@en,
        "topological basic algebra"@en,
        "topological quotient basic algebras"@en ;
    ns0:hasPubAbstract "In this paper, the notions of (semi) topological basic algebra and (semi) topological implication basic algebra are introduced, along with evaluating their properties. Then, different operations are defined based on basic algebras and the relationship between semicontinuity and continuity of operations is considered. In addition, the separation axioms on (semi) topological basic algebras are investigated by considering some conditions implying that a (semi) topological basic algebra becomes a Ti- space, for i ∈ {0, 1, 2}. In the sequel, some relations between (weak) ideals and (weak) filters of basic algebras are obtained and (left) topological (implication) basic algebra is constructed by using the concepts of (weak) filters, which is a zero dimensional, normal, disconnected, locally compact and completely regular (left) topological space. Further, the notion of quotient basic algebras are presented along with evaluating the interaction of topological basic algebras and topological quotient basic algebras. Finally, it is proved that there is an implication basic algebra    IB *    with cardinality n + 1 and filter F* = F ∪ {z*}, which    z *  ∉ IB   for any implication basic algebra   IB   of cardinality n and filter F. Accordingly, it is proved that there is at least one nontrivial regular and normal topological implication basic algebra of cardinality n."@en ;
    ns0:hasPubTitle "On topological basic algebras"@en .

ns1:ifs-v37-i5-IFS190001 ns0:hasKeywords "SIR method"@en,
        "interval-valued intuitionistic fuzzy Set"@en,
        "multiple criteria group decision making"@en ;
    ns0:hasPubAbstract "In the field of engineering economy, engineering investment selection is a common problem, where the preference information is usually intuitionistic and fuzzy. To deal with the consistency and integrity of the information in the selection process, the aim of this article is to extend the superiority and inferiority ranking method and use the interval-valued intuitionistic fuzzy theory, where the individual evaluation values and the weights information of criteria and decision-makers are all described by interval-valued intuitionistic fuzzy numbers. First, some concepts of interval-valued intuitionistic fuzzy set are introduced. Then, the interval-valued intuitionistic fuzzy superiority and inferiority ranking (IVIF-SIR) method is developed. Moreover, an engineering investment selection model based on IVIF-SIR method is investigated. Finally, an illustration of choosing investment alternatives is used to prove the developed approach and a comparative study is also use to demonstrate the effectiveness."@en ;
    ns0:hasPubTitle "A novel superiority and inferiority ranking method for engineering investment selection under interval-valued intuitionistic fuzzy environment"@en .

ns1:ifs-v37-i5-IFS190149 ns0:hasKeywords "Iterative numerical method"@en,
        "L-Lipschitz fuzzy functions"@en,
        "Nonlinear fuzzy Volterra-Hammerstein integral equations"@en ;
    ns0:hasPubAbstract "In this paper, an iterative numerical method has been developed to solve nonlinear fuzzy Volterra integral equations based on three-point quadrature formula. The error estimation of the method is obtained based on Lipschitz condition and in order to confirm the yielded theoretical results, we perform the iterative method on some numerical examples."@en ;
    ns0:hasPubTitle "An iterative numerical method to solve nonlinear fuzzy Volterra-Hammerstein integral equations"@en .

ns1:ifs-v37-i5-IFS190349 ns0:hasKeywords "Learning path"@en,
        "ant colony optimisation"@en,
        "curriculum sequencing"@en,
        "learning content sequence"@en,
        "personalised E-learning"@en ;
    ns0:hasPubAbstract "An e-learning system offering a personalised learning path will be vastly appealing to the learners. Adaptive techniques when employed in e-learning can sustain the interest and motivation of the learners and help them to complete the enrolled courses successfully. In addition, it would improve their performance and thus, enhance the overall learning experience. Personalisation takes into consideration the characteristics of the individual learner and the diversity in his/her needs. The main challenge is finding a match between these individual characteristics and the sequence of the learning content. It is a complex task to implement as it involves selection of the appropriate material from a vast amount of the available learning materials. It is a challenge to perform this process manually as it requires both technical savvy and pedagogical skills. In this paper, a stigmergy model is proposed, which was applied to build a customised learning path. The aim was to provide personalisation that satisfied the needs of an individual in a widely heterogeneous e-learning environment. Compared with the traditional teaching method, this tailored learning path, generated using the proposed approach, shows promise and was found to enhance the performance of the learners."@en ;
    ns0:hasPubTitle "A modified ant colony algorithm for personalized learning path construction"@en .

ns1:ifs-v37-i5-IFS190683 ns0:hasKeywords "Mobile two-wheeled self-balancing robot"@en,
        "firing strength"@en,
        "non-singleton general type-2 fuzzy logic controllers"@en,
        "similarity measure"@en ;
    ns0:hasPubAbstract "Since the non-singleton fuzzy logic controllers (NFLCs) can effectively reflect the uncertainty brought by the inputs, they are used for balance control and position control of the mobile two-wheeled self-balancing robot (MTWSBR) in this paper. The similarity between the inputs and the antecedent fuzzy sets as the firing strength, that is, the similarity-based non-singleton fuzzy logic controller (Sim-NFLC), is proposed to deal with the problem of information loss caused by the standard non-singleton fuzzy logic controller (Sta-NFLC) in terms of the interaction of the inputs and antecedents. A comparative study among singleton fuzzy logic controllers (SFLCs), Sta-NFLCs and Sim-NFLCs, and interval type-2 fuzzy logic controllers (IT2FLCs) and general type-2 fuzzy logic controllers (GT2FLCs) are also shown. The simulation results show that the performance of Sim-NFLCs is better than that of SFLCs and Sta-NFLCs. The similarity-based general type-2 fuzzy logic controller (Sim-NGT2FLC) gets the best performance in handling the input uncertainty."@en ;
    ns0:hasPubTitle "Similarity-based non-singleton general type-2 fuzzy logic controller with applications to mobile two-wheeled robots"@en .

ns1:ifs-v37-i5-IFS190782 ns0:hasKeywords "Grasshopper optimization algorithm"@en,
        "differential evolution"@en,
        "functions optimization"@en,
        "hybrid optimization"@en,
        "self-adapting based algorithm"@en ;
    ns0:hasPubAbstract "Grasshopper optimization algorithm (GOA) is proposed for imitating grasshopper’s behavior in nature, which has the disadvantages of slow convergence speed and unbalanced exploration and exploitation, etc. Therefore, an algorithm called GOA_jDE, which combines GOA and jDE is proposed to improve the optimization performance. Firstly, the adaptive strategy is introduced into DE to improve the global search ability in the proposed algorithm. Secondly, the combination of jDE and GOA greatly improves the convergence efficiency while maintaining the population diversity. Finally, it can be observed in the work that the proposed algorithm improves the convergence speed and calculation precision. In the subsequent experiments, 14 well-known test benchmark functions are used to compare the advantages of GOA_jDE. The experimental results illustrate that the performance of proposed algorithm has significant improvement, which also proves the feasibility and effectiveness. Considering the complexity of engineering problems, three classical engineering design problems (tension/compression spring, welded beam, and pressure vessel designs) are used to evaluate the performance of the proposed algorithm. In addition, the classical engineering design results proves the merits of this algorithm in solving real problems with unknown search spaces."@en ;
    ns0:hasPubTitle "Hybrid grasshopper optimization algorithm and differential evolution for global optimization"@en .

ns1:ifs-v37-i5-IFS190905 ns0:hasKeywords "MCGDM"@en,
        "Pythagorean fuzzy soft sets"@en,
        "TOPSIS"@en,
        "VIKOR"@en,
        "aggregation operator"@en,
        "linguistic variable"@en ;
    ns0:hasPubAbstract "We study, in this paper, some notions related to Pythagorean fuzzy soft sets (PFSSs) along with their algebraic structures. We present operations on PFSSs and their peculiar characteristics and elaborate them with real life examples and tabular representation to develop the affluence of linguistic variables based on Pythagorean fuzzy soft (PFS) information. We present an application of PFSSs to the multi-criteria group decision-making (MCGDM) related to site selection, accompanied by Algorithm and flow chart. We develop PFS TOPSIS method and PFS VIKOR method as extensions of the TOPSIS (Technique for Order of Preference by Similarity to Ideal Solution) and VIKOR (Vlse Kriterijumska Optimizacija Kompromisno Resenje) respectively. Finally, we rendered an application in stock exchange investment problem and tackled it by both PFS TOPSIS and PFS VIKOR methods."@en ;
    ns0:hasPubTitle "Pythagorean fuzzy soft MCGDM methods based on TOPSIS, VIKOR and aggregation operators"@en .

ns1:ifs-v37-i5-IFS190988 ns0:hasKeywords "(Semi)topological BL-algebra"@en,
        "metric space"@en,
        "norm"@en,
        "premetric"@en,
        "prenorm"@en ;
    ns0:hasPubAbstract "In this paper we define the notions of a norm and a prenorm on BL-algebras and we give some methods for constructing them. We introduce (pre)metrics on BL-algebras and find some connections between them and (pre)norms. Using prenorms, we find some conditions that a BL-algebra become a metric space. Finally, we show that if there exists a prenorm on a BL-algebra A, then for any filter F in A, there are topologies   U   and   V   on A and on A/F respectively such that   ( A , U )   and   ( A / F , V )   are (semi)topological BL-algebras."@en ;
    ns0:hasPubTitle "Constructing (pre)norms in BL-algebras and its action on topological BL-algebras"@en .

ns1:ifs-v37-i5-IFS191092 ns0:hasKeywords "Large-group decision-making (LGDM)"@en,
        "expert clustering"@en,
        "interval-valued 2-tuple linguistic (IV2TL) representation model"@en,
        "outside knowledge"@en ;
    ns0:hasPubAbstract "Investigating clusters of experts is an interesting topic in the large-group decision-making (LGDM) problem, since being familiar with patterns (groups) of experts is beneficial to some other actions needed for decision-making (e.g., reconciliation of opinions derived from different expert groups). However, not too much attention has been paid to expert clustering in the LGDM problem under a linguistic environment. Besides, it seems that only the decision information is utilized to group experts while the auxiliary (outside) knowledge (e.g., expertise and occupation) about these experts has not been fully considered during the clustering process. To address this issue, this study proposes a hybrid method integrating outside knowledge about experts with practical preference information under the interval-valued linguistic environment to cluster experts. The method consists of four elements: pre-clustering of experts according to the given knowledge, the optimization model to transform the interval-valued 2-tuple linguistic (IV2TL) decision information, the data envelopment analysis-discriminant analysis (DEA-DA) model to deal with a two-cluster issue, and iterative clustering based on the DEA-DA model to cluster experts into multiple clusters. The feasibility and validity of the proposed method are illustrated with a real-world example. A comparison with the maximal tree clustering method in the linguistic environment is provided."@en ;
    ns0:hasPubTitle "Clustering experts in linguistic environment: A hybrid method"@en .

ns1:isp-v66-i2-ISP180248 ns0:hasKeywords "Dynamic positioning"@en,
        "offshore vessels"@en,
        "optimisation"@en,
        "thrusters positions"@en ;
    ns0:hasPubAbstract "During the design process of an offshore vessel, the DP system is not representing one of the primary constraints for the general arrangement of the vessel. Usually the location of the thruster devices is driven by the internal spaces available, i.e. the thrusters position is not optimised to reach the maximum capability. This is also true for a conversion of an existing vessel. Nowadays almost all offshore vessels require the installation of a DP system on board, means that it could be worthy to study more in detail the arrangement of the thrusters in such a way to maximise the capability of the vessel to keep position with a determined amount of power installed on board. In the present work a procedure aimed to find an optimal thruster location on the hull during early design stage will be presented. Using a quasi-static approach for DP capability evaluation, an optimisation procedure based on genetic algorithm has been developed, considering the constraints given by the vessel geometry. The discussion is supported by a test case on a reference vessel, were the original layout is compared with two possible optimised configurations."@en ;
    ns0:hasPubTitle "Optimal thruster location on offshore DP vessels"@en .

ns1:isp-v66-i2-ISP180253 ns0:hasKeywords "Marine engines"@en,
        "composites"@en,
        "material design"@en,
        "plastic components"@en,
        "reinforced polymers"@en ;
    ns0:hasPubAbstract "Metallic alloys play the leading role in marine engine construction. Yet, under the compelling goal of reducing cost and weights, this industrial sector is in constant need of new, high-performance materials for the production of marine engine non-structural components. In this respect, nano-engineered thermoplastic polymers are ideal alternatives, allowing for additional benefits (e.g., simplified maintenance and inspection operations). The use of these materials in marine engine design requires computer multiscale simulations to tailor-fit their molecular structure in order to achieve the expected performances required by specific, advanced functions. Importantly, replacing metal alloys with plastic-based materials also contributes to environmental sustainability, in terms of both component production process and recyclability. The introduction of non-structural plastic components in marine engines constitutes a major innovation in the field; thus, a specific rule framework must be still defined. Under this perspective, starting from the analysis of the rule framework currently used for metallic alloys, in this paper a certification procedure is proposed and applied to a case study: a four-stroke marine engine plastic cylinder head cover for which the mechanical properties of the new material have been predicted and verified trough multiscale simulations carried out on the relevant model."@en ;
    ns0:hasPubTitle "Design of non-structural components for marine engines based on nano-engineered thermoplastic polymers"@en .

ns1:isp-v66-i3-ISP180249 ns0:hasKeywords "Riser"@en,
        "fatigue"@en,
        "random waves"@en,
        "seabed"@en,
        "soil stiffness"@en ;
    ns0:hasPubAbstract "Today’s oil and gas industry is facing deeper waters and harsher environmental conditions. Offshore platforms and marine risers, as the main parts of this industry, have many challenges and design issues. Steel Catenary Riser (SCR) connected to Floating, Production, Storage, and Offloading unit (FPSO), is a preferred and commonly used solution to the challenges. It is needed to have more understandings of SCR behavior. So in this study, the significance of SCR-seabed interaction is investigated. Also, the effect of seabed stiffness on the structural behavior of the SCR is studied. Results show that the seabed stiffness makes considerable differences in dynamic and fatigue responses of SCRs in the touch down zone (TDZ) and reveal the importance of proper seabed stiffness modeling. Model (I), which represents weak soils with very low stiffness, could resist on continuously applied harsh environmental condition for 139.6 days. Model (IV) which represents a very stiff seabed, had a minimum fatigue life of about 6.5 percent of the model (I). The results indicated that the SCR responses were highly separated in terms of fatigue performance especially for weak to normal soils."@en ;
    ns0:hasPubTitle "Effect of seabed stiffness on fatigue life of steel catenary risers due to random waves"@en .

ns1:isu-v39-i1-2-ISU180039 ns0:hasKeywords "Health literacy"@en,
        "patient support groups"@en,
        "peer-to-peer health communication"@en,
        "social media"@en ;
    ns0:hasPubAbstract "This chapter explores the impact and role of health literacy in peer-to-peer health communication contexts, such as social media platforms and online patient support groups. The chapter contends that health literacy efforts of researchers, health care providers, and public health practitioners will need to include innovative strategies to help consumers critically evaluate and appropriately utilize the health information found in online communities. The chapter first discusses the rise of peer-to-peer sharing of health information and accompanying health literacy concerns. Next, a series of case studies are presented that illustrate the potential role of health literacy in three different online settings: clinical trial patient support networks, social media channels, and personal blogs. The chapter then explores common themes highlighted in these examples and discusses the range of health literacy benefits and pitfalls that accompany the use of these channels for health information. Finally, the chapter explores existing individual-level and system-level health literacy initiatives for peer-to-peer health communication and suggests opportunities for future work in this area. Such efforts to address and improve health literacy can help individuals and communities successfully navigate online platforms where peer-to-peer health information is exchanged."@en ;
    ns0:hasPubTitle "The role and impact of health literacy on peer-to-peer health communication"@en .

ns1:jad-v69-i3-JAD180780 ns0:hasKeywords "Aging"@en,
        "Alzheimer’s disease"@en,
        "amyloidosis"@en,
        "depression"@en,
        "second generation antidepressive agents"@en ;
    ns0:hasPubAbstract "Depression is a common co-morbidity seen in people with Alzheimer’s disease (AD). However, the successful treatment of depressive symptoms in people with AD is rarely seen. In fact, multiple randomized controlled trials have shown selective serotonin reuptake inhibitors (SSRIs), the current best recommended treatment for depression, to be ineffective in treating depressive symptoms in people with AD. One explanation for this lack of treatment effect may be that depressive symptoms can reflect the progression of AD, rather than clinical depression and are a consequence of more severe neurodegeneration. This raises several questions regarding not only the efficacy of SSRIs in the treatment of depression in people with AD but also regarding the accuracy of diagnosis of depression in AD. However, there may be a rationale for the prescription of SSRIs in early AD. Even in the absence of depression, SSRIs have been shown to slow the conversion from mild cognitive impairment to AD. This may be attributed to the effect of SSRIs on the processing of amyloid-β precursor protein, which may cause a reduction in the accumulation of amyloid-β. Thus, although SSRIs may lack efficacy in treating depression in people with AD, they may hold therapeutic potential for treating and delaying the progression of AD especially if treatment begins in the early stages of AD. This article reviews the current consensus for SSRI treatment of depression in people with AD and highlights the possibility of SSRIs being a treatment option for delaying the progression of AD."@en ;
    ns0:hasPubTitle "Depression in Alzheimer’s Disease: An Alternative Role for Selective Serotonin Reuptake Inhibitors?"@en .

ns1:jad-v69-i3-JAD181189 ns0:hasKeywords "Alzheimer’s disease"@en,
        "NMR"@en,
        "biomarker"@en,
        "dementia"@en,
        "metabolomics/metabonomics"@en,
        "serum"@en,
        "vascular dementia"@en ;
    ns0:hasPubAbstract "There is a great need for diagnostic biomarkers of impending dementia. Metabolite markers in blood have been investigated in several studies, but inconclusive findings encourage further investigation, particularly in the pre-diagnostic phase. In the present study, the serum metabolomes of 110 dementia or pre-diagnostic dementia individuals and 201 healthy individuals matched for age, gender, and education were analyzed by nuclear magnetic resonance spectroscopy in combination with multivariate data analysis. 58 metabolites were quantified in each of the 311 samples. Individuals with dementia were discriminated from controls using a panel of seven metabolites, while the pre-diagnostic dementia subjects were distinguished from controls using a separate set of seven metabolites, where threonine was a common significant metabolite in both panels. Metabolite and pathway alterations specific for dementia and pre-diagnostic dementia were identified, in particular a disturbed threonine catabolism at the pre-diagnostic stage that extends to several threonine-linked pathways at the dementia stage."@en ;
    ns0:hasPubTitle "Serum Metabolite Markers of Dementia Through Quantitative NMR Analysis: The Importance of Threonine-Linked Metabolic Pathways"@en .

ns1:jad-v69-i3-JAD181224 ns0:hasKeywords "Alcohol"@en,
        "dementia"@en,
        "disease prevention"@en,
        "older people"@en,
        "risk reduction"@en ;
    ns0:hasPubAbstract "Background: People over 50 are increasing their alcohol intake, potentially increasing their risk of dementia.   Objective: This study investigates whether people would be willing to adhere to current United Kingdom (UK, “low-risk”) alcohol guidelines to reduce dementia risk.   Methods: A national cross-sectional online survey recruited a non-probabilistic sample of 3,948 individuals aged 50 and over without dementia in the UK. Self-reported willingness to comply with low-risk guidelines was predicted using logistic regression. Other relevant self-reported variables included physical health, lifestyle, and current alcohol intake.   Results: Majority of the sample (90%, n = 3,527) reported drinking alcohol at least once a month with 23% (n = 795) exceeding the low-risk guidelines (> 14 units per week). A larger proportion of men, those who were overweight, and people without a partner reported drinking above the recommended level. Most people who consumed alcohol (n = 2,934; 74.3%) appeared willing to adhere to low-risk guidelines if they were told that their risk of having dementia could be reduced. Increased willingness was found in women (OR 1.81; CI 1.47–2.23), in people who had at least one child (OR 1.36; CI 1.09–1.70), and those who slept well (OR 1.45; CI 1.06–2.00). People who were obese (OR 0.72; CI 0.54–0.95), those who drank alcohol above limits (OR 0.13; CI 0.11–0.16), and those who were smokers (OR 0.56; CI 0.36–0.88) were less willing to adhere to current guidelines.   Conclusion: Men and people with more lifestyle risk factors for common chronic diseases (e.g., smoking, obesity, and excess alcohol consumption) are less willing to adhere to current alcohol low-risk guidelines to reduce dementia risk."@en ;
    ns0:hasPubTitle "Willingness to Adhere to Current UK Low-Risk Alcohol Guidelines to Potentially Reduce Dementia Risk: A National Survey of People Aged 50 and Over"@en .

ns1:jad-v69-i3-JAD181230 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β plaques"@en,
        "ashwagandha"@en,
        "autophagy"@en,
        "mitochondrial dysfunction"@en,
        "oxidative stress"@en,
        "presenilin-1"@en,
        "water-soluble coenzyme-Q10"@en ;
    ns0:hasPubAbstract "Neurons consume the highest amount of oxygen, depend on oxidative metabolism for energy, and survive for the lifetime of an individual. Therefore, neurons are vulnerable to death caused by oxidative-stress, accumulation of damaged and dysfunctional proteins and organelles. There is an exponential increase in the number of patients diagnosed with neurodegenerative diseases such as Alzheimer’s (AD) as the number of elderly increases exponentially. Development of AD pathology is a complex phenomenon characterized by neuronal death, accumulation of extracellular amyloid-β plaques and neurofibrillary tangles, and most importantly loss of memory and cognition. These pathologies are most likely caused by mechanisms including oxidative stress, mitochondrial dysfunction/stress, accumulation of misfolded proteins, and defective organelles due to impaired proteasome and autophagy mechanisms. Currently, there are no effective treatments to halt the progression of this disease. In order to treat this complex disease with multiple biochemical pathways involved, a complex treatment regimen targeting different mechanisms should be investigated. Furthermore, as AD is a progressive disease-causing morbidity over many years, any chemo-modulator for treatment must be used over long period of time. Therefore, treatments must be safe and non-interfering with other processes. Ideally, a treatment like medicinal food or a supplement that can be taken regularly without any side effect capable of reducing oxidative stress, stabilizing mitochondria, activating autophagy or proteasome, and increasing energy levels of neurons would be the best solution. This review summarizes progress in research on different mechanisms of AD development and some of the potential therapeutic development strategies targeting the aforementioned pathologies."@en ;
    ns0:hasPubTitle "A Bird’s-Eye View of the Multiple Biochemical Mechanisms that Propel Pathology of Alzheimer’s Disease: Recent Advances and Mechanistic Perspectives on How to Halt the Disease Progression Targeting Multiple Pathways"@en .

ns1:jad-v69-i4-JAD180525 ns0:hasKeywords "Alzheimer’s disease"@en,
        "biomarkers"@en,
        "cognitive decline"@en,
        "dementia"@en ;
    ns0:hasPubAbstract "Background: A clinical diagnosis of cognitive impairment is traditionally based on a single cognitive exam, but serial cognitive testing can be sensitive to subtle cognitive changes in asymptomatic individuals and inform cognitive trajectory.   Objective: We evaluated the prognostic utility of identifying longitudinal neuropsychological decline along with single cognitive exam and Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers in predicting dementia. We also examined brain volumetric differences based on decline trajectories.   Method: Regression models quantified 12-month neuropsychological decline relative to normative expectations among non-demented older adults (N = 1,074). Progression to dementia over follow-up (18-120 months) was diagnosed using independent modes of assessment.   Results: In Cox regression models controlling for age, sex, education, apolipoprotein E4, and baseline cognitive diagnosis, neuropsychological decline predicted increased dementia risk, χ2 = 69.861, p < 0.001, odds ratio = 2.841, even after correction for CSF biomarkers (amyloid-β, phosphorylated tau, total tau), χ2 = 26.365, p < 0.001, odds ratio = 2.283. Voxel-based morphometry analysis indicated smaller hippocampal and medial temporal volume in participants with neuropsychological decline.   Conclusions: Longitudinal diagnosis of neuropsychological decline improved prognostic accuracy beyond single cognitive exam diagnoses and AD CSF biomarkers, even in asymptomatic older adults. Older adults with a trajectory of neuropsychological decline exhibit smaller medial temporal and hippocampal brain volume. Longitudinal diagnostic approaches may benefit selection and randomization procedures for AD clinical trials in asymptomatic individuals."@en ;
    ns0:hasPubTitle "Neuropsychological Decline Improves Prediction of Dementia Beyond Alzheimer’s Disease Biomarker and Mild Cognitive Impairment Diagnoses"@en .

ns1:jad-v69-i4-JAD180730 ns0:hasKeywords "Affective sharing"@en,
        "awareness"@en,
        "dementia"@en,
        "emotion regulation"@en,
        "mental flexibility"@en ;
    ns0:hasPubAbstract "Empathy is essential for social interaction and a crucial trait to understand the intentions and behaviors of others and to react accordingly. Alzheimer’s disease (AD) affects both cognitive and emotional processes and can lead to social dysfunction. Empathy results from the interaction of four components: shared neural representation, self-awareness, mental flexibility, and emotion regulation. This review discusses the abilities and deficits of patients with AD from the perspective of subcomponents of empathy and integrates these facets into a model of human empathy. The aim was to investigate the components that are affected by AD and the ways in which patients are still able to empathize with others in their social environment. It concludes that AD patients show a pattern of relatively preserved affective aspects and impairments in cognitive components of empathy and points out specific areas with the need for further research."@en ;
    ns0:hasPubTitle "Empathy in Alzheimer’s Disease: Review of Findings and Proposed Model"@en .

ns1:jad-v69-i4-JAD180938 ns0:hasKeywords "Dementia"@en,
        "ethics"@en,
        "healthcare"@en,
        "technology"@en ;
    ns0:hasPubAbstract "Background: As the global prevalence of dementia rises, care costs impose a large burden on healthcare systems. Technology solutions in dementia care have the potential to ease this burden. While policies exist to guide and govern the use of dementia care technologies, little is known about how ethical considerations are incorporated into these documents.   Objective: The goal of this study was to examine ethics-related content in dementia care technology policies.   Methods: We used a two-step data mining approach to collect a sample of dementia technology policies. Policy documents were analyzed using emergent content analysis. Following the coding of the sample, thematic categories were organized using the principles of biomedical ethics as a framework.   Results: A total of 23 policy documents from four Alzheimer associations in four countries were included in our analysis. General ethics considerations and themes related to beneficence were mentioned in 96% of the documents. Thematic categories related to justice were present in 74% of the sample, themes related to non-maleficence appeared in 52% of documents, and themes related to autonomy appeared in 43% of the sample.   Conclusion: While ethical considerations are present in existing policies for dementia care technology, these considerations revolve primarily around the benefit of the technologies. Further efforts are needed to provide formal guidance that incorporates both benefits and potential harms."@en ;
    ns0:hasPubTitle "Prioritizing Benefits: A Content Analysis of the Ethics in Dementia Technology Policies"@en .

ns1:jad-v69-i4-JAD181047 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cognitive decline"@en,
        "dementia"@en,
        "rate of decline"@en,
        "young-onset"@en ;
    ns0:hasPubAbstract "Background: There is only limited information available about the effect of age on course of cognitive decline in patients with onset of Alzheimer’s disease (AD) over the age of 64 years.   Objective: We compared the rate of, and factors affecting, cognitive decline in patients with AD aged < 65 years (young-onset AD), 65–74 years (middle-onset AD), and ≥75 years (late-onset AD).   Method: The study used longitudinal data from the Essex Memory Clinic which included a total of 305 participants; 56 had YOAD, 73 had MOAD, and 176 had LOAD. The rate of cognitive decline was measured using scores from the Mini-Mental State Examination (MMSE), and the data were examined using multilevel models analysis.   Results: There was evidence of a difference in cognitive decline across the age groups with the YOAD group declining 2.8 MMSE points per year, those with MOAD declined 2.0 MMSE points per year, and the LOAD group declined 1.4 MMSE points per year.   Conclusions: Patients with LOAD have a better prognosis than YOAD and MOAD. However, even between the MOAD and LOAD groups, age is a significant predictor of cognitive decline, with older patients having a more benign course."@en ;
    ns0:hasPubTitle "Rate of Cognitive Decline in Alzheimer’s Disease Stratified by Age"@en .

ns1:jad-v69-i4-JAD181285 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Lewy body"@en,
        "TDP-43"@en,
        "neuropsychiatric symptoms"@en ;
    ns0:hasPubAbstract "More than half of the patients with Alzheimer’s disease (AD) have comorbidities including TDP-43 and Lewy bodies, which are also associated with frontotemporal lobar degeneration and dementia with Lewy bodies, respectively. These comorbidities may help explain the overlapping neuropsychiatric symptoms between AD and other dementias. Data on 221 AD patients with Neuropsychiatric Inventory-Questionnaire were obtained from the National Alzheimer’s Coordinating Center. TDP-43 was associated with aberrant motor activity, whereas Lewy bodies were associated with anxiety, irritability, sleep behavior, and appetite problems. The associations between these comorbidities and neuropsychiatric symptoms were more significant for patients with sparse diffuse plaques."@en ;
    ns0:hasPubTitle "Associations between Comorbid TDP-43, Lewy Body Pathology, and Neuropsychiatric Symptoms in Alzheimer’s Disease"@en .

ns1:jad-v69-i4-JAD190049 ns0:hasKeywords "Alzheimer’s disease"@en,
        "BDNF"@en,
        "DNA methylation"@en,
        "prefrontal cortex"@en ;
    ns0:hasPubAbstract "Background: Brain-derived neurotrophic factor (BDNF) is essential for neurogenesis and has been implicated in Alzheimer’s disease (AD). However, few studies have investigated together the epigenetic, transcriptional, and translational regulation of this peptide in the brain in relation to AD.   Objective: To investigate mechanisms underlying how BDNF is possibly dysregulated in the brain in relation to aging and AD neuropathology.   Methods: Prefrontal cortex tissues were acquired from the Manchester Brain Bank (N = 67). BDNF exon I, and exon IV-containing transcripts and total long 3’ transcript gene expression were determined by quantitative PCR and bisulfite pyrosequencing was used to quantify DNA methylation within promoters I and IV. Protein concentrations were quantified via ELISA.   Results: BDNF exon IV and total long 3’ isoform gene expression levels negatively associated with donor’s age at death (IV: r = –0.291, p = 0.020; total: r = –0.354, p = 0.004). Expression of BDNF exon I- containing isoform was significantly higher in Met-carriers of the rs6265 variant, compared to Val-homozygotes, when accounting for donor ages (F = 6.455, p = 0.014). BDNF total long 3’ transcript expression was significantly lower in those with early AD neuropathology, compared to those without any neuropathology (p = 0.021). There were no associations between BDNF promoter I and IV methylation or protein levels with ages, rs6265 genotype or AD neuropathology status.   Conclusion: Prefrontal cortex BDNF gene expression is associated with aging, rs6265 carrier status, and AD neuropathology in a variant-specific manner that seems to be independent of DNA methylation influences."@en ;
    ns0:hasPubTitle "Dysregulation of BDNF in Prefrontal Cortex in Alzheimer’s Disease"@en .

ns1:jad-v69-i4-JAD190060 ns0:hasKeywords "Alzheimer’s disease"@en,
        "O-GlcNAcylation"@en,
        "amyloid-β"@en,
        "amyloid-β protein precursor"@en,
        "insulin"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is caused by the accumulation of neurotoxic amyloid-β (Aβ) peptides. Aβ is derived from amyloid-β protein precursor (AβPP). In the non-amyloidogenic pathway, AβPP is cleaved by α-secretase and γ-secretase at the plasma membrane, excluding Aβ production. Alternatively, AβPP in the plasma membrane is internalized via endocytosis, and delivered to early endosomes and lysosomes, where it is cleaved by β-secretase and γ-secretase. Recent studies have shown that insulin in the periphery crosses the blood-brain barrier, and plays important roles in the brain. Furthermore, impaired insulin signaling has been linked to the progression of AD, and intranasal insulin administration improves memory impairments and cognition. However, the underlying molecular mechanisms of insulin treatment remain largely unknown. To investigate the effects of insulin on AβPP processing, we tested the effects of insulin on neuroblastoma SH-SY5Y cells overexpressing AβPP, and cultured rat cortical neurons. We found that insulin increased the level of cell surface AβPP, decreasing the endocytosis rate of AβPP. Insulin reduced Aβ generation through upregulation of AβPP O-GlcNAcylation via Akt insulin signaling. Our present data suggest that insulin affects Aβ production by regulating AβPP processing through AβPP O-GlcNAcylation. These results provide mechanistic insight into the beneficial effects of insulin, and a possible link between insulin deficient diabetes and cerebral amyloidosis in the pathogenesis of AD."@en ;
    ns0:hasPubTitle "O-GlcNAcylation of Amyloid-β Protein Precursor by Insulin Signaling Reduces Amyloid-β Production"@en .

ns1:jad-v69-i4-JAD190256 ns0:hasKeywords "Alzheimer’s disease"@en,
        "glycogen synthase kinase 3"@en,
        "lithium"@en,
        "meta-analysis"@en,
        "tideglusib"@en ;
    ns0:hasPubAbstract "Background: The efficacy and safety of glycogen synthase kinase 3 (GSK-3) inhibitors in patients with Alzheimer’s disease (AD) is unknown.   Objective: A systematic review and meta-analysis of randomized controlled trials (RCTs) to test GSK-3 inhibitors on AD patients.   Methods: We included RCTs of GSK-3 inhibitors in AD patients and subjects with mild cognitive impairment (MCI), using cognitive function scores as a primary measure.   Results: Five RCTs (three RCTs using lithium and two RCTs using tideglusib) with 568 patients were included. There was no significant difference in cognitive function scores between the GSK-3 inhibitors and placebo groups [standardized mean difference (SMD) = –0.25, p = 0.11, I2 = 55% ]. However, significant heterogeneity remained. A sensitivity analysis revealed that the lithium subgroup was more effective on cognitive function scores than placebo for AD and MCI (lithium subgroup: SMD = –0.41, p = 0.04; tideglusib subgroup: SMD = –0.02, p = 0.89). Moreover, a meta-regression analysis showed that the effect size of GSK-3 inhibitors on cognitive function scores was associated with study duration (coefficient, –0.0116). For safety outcomes, tideglusib was associated with a higher incidence of increased aspartate aminotransferase than placebo. There were no significant differences in other secondary outcomes between treatments.   Conclusion: Our results suggested that GSK-3 inhibitors were ineffective in treating AD and MCI; however, several studies included in the present meta-analysis were small, and future studies using a larger sample size are needed."@en ;
    ns0:hasPubTitle "Efficacy and Safety of Glycogen Synthase Kinase 3 Inhibitors for Alzheimer’s Disease: A Systematic Review and Meta-Analysis"@en .

ns1:jad-v70-i1-JAD181110 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid plaques"@en,
        "centenarians"@en,
        "cognition"@en,
        "neurofibrillary tangles"@en,
        "neuropathology"@en ;
    ns0:hasPubAbstract "Background: Centenarian studies are important sources for understanding of factors that contribute to longevity and healthy aging. Clinico-neuropathological finding is a key in identifying pathology and factors contributing to age-related cognitive decline and dementia in the oldest old.   Objective: To characterize the cross-sectional relationship between neuropathologies and measures of premortem cognitive performance in centenarians.   Methods: Data were acquired from 49 centenarians (≥98 years) from the Georgia Centenarian Study. Cognitive assessment from the time point closest to mortality was used (<1 year for all subjects) and scores for cognitive domains were established. Neuropathologies [cerebral atrophy, ventricular dilation, atherosclerosis, cerebral amyloid angiopathy (CAA), Lewy bodies, hippocampal sclerosis (HS), hippocampal TDP-43 proteinopathy, neuritic plaque (NP) and neurofibrillary tangle (NFT) counts, Braak staging, and National Institute on Aging-Reagan Institute (NIARI) criteria for the neuropathological diagnosis of Alzheimer’s disease (AD)] were compared among subjects with different ratings of dementia. Linear regression was applied to evaluate the association between cognitive domain scores and neuropathologies.   Results: Wide ranges of AD-type neuropathological changes were observed in both non-demented and demented subjects. Neocortical NFT and Braak staging were related to clinical dementia rating. Neocortical NFT and NP, Braak and NIARI staging, cerebral and ventricular atrophy, HS, CAA, and TDP-43 proteinopathy were differentially associated with poor performance in multiple cognitive domains and activities of daily living.   Conclusion: AD-type pathology was associated with severe dementia and poor cognition but was not the only variable that explained cognitive impairment, indicating the complexity and heterogeneity of pathophysiology of dementia in the oldest old."@en ;
    ns0:hasPubTitle "Clinico-Neuropathological Findings in the Oldest Old from the Georgia Centenarian Study"@en .

ns1:jad-v70-i1-JAD190269 ns0:hasKeywords "Adipocytokine"@en,
        "Alzheimer’s disease"@en,
        "hypomnesia"@en,
        "mild cognition impairment"@en,
        "nicotinamide phosphoribosyltransferase"@en,
        "type 2 diabetes"@en ;
    ns0:hasPubAbstract "Background: In addition to glucose metabolism, adipocytokine Nicotinamide phosphoribosyltransferase (Nampt) has been proposed as a multifunctional protein involved in insulin resistance. Insulin resistance always occurs before the onset of type 2 diabetes mellitus (T2DM) and damages the cognition of T2DM patients very early.   Objective: We aimed to investigate the role and potential clinical value of Nampt in early cognitive decline of T2DM.   Methods: A total of 195 Chinese T2DM patients were enrolled and divided into a mild cognition impairment (MCI) group and a healthy cognition group according to Montreal Cognitive Assessment (MoCA) score. Their cognitive function was extensively assessed. The plasma level of Nampt was measured via enzyme-linked immunosorbent assay.   Results: In the MCI group (n = 78, MoCA < 26), the plasma level of Nampt was significantly higher than the controls (p < 0.01). After adjusting for age, sex, and level of education, Nampt levels were negatively associated with most of the cognitive domains forecasting hypomnesia (all p < 0.007). Nevertheless, hierarchical regression analysis further revealed that Nampt was an independent risk factor of MCI in Chinese T2DM patients (all p < 0.05), including Logic Memory Test (β= –0.31, p < 0.01), Auditory Verbal Learning Test delayed recall (β= –0.26, p < 0.01), and so on, which represent memory function. Correlation analysis showed that Nampt related to insulin resistance (HOMA-IR), glycosylated hemoglobin (HbA1c), and lipid levels (all p < 0.05).   Conclusions: We found that higher plasma level of Nampt presages memory dysfunction in MCI in Chinese T2DM patients. Further studies are necessary to confirm its scanning and prognosis prediction value of the disease clinically."@en ;
    ns0:hasPubTitle "Higher Plasma Level of Nampt Presaging Memory Dysfunction in Chinese Type 2 Diabetes Patients with Mild Cognitive Impairment"@en .

ns1:jad-v70-i1-JAD190333 ns0:hasKeywords "Alternative energy source"@en,
        "Alzheimer’s disease"@en,
        "Physcomitrella"@en,
        "co-cultivation"@en,
        "famine"@en,
        "fibroblast"@en,
        "glucose"@en,
        "hypometabolism"@en,
        "moss"@en,
        "natural scaffold"@en,
        "regenerative medicine"@en,
        "space flight"@en,
        "tissue engineering"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is a devastating slowly progressive neurodegenerative disorder with no cure. While there are many hypotheses, the exact mechanism causing this pathology is still unknown. Among many other features, AD is characterized by brain hypometabolism and decreased sugar availability, to which neurons eventually succumb. In light of this aspect of the disease, we hypothesized that boosting fuel supply to neurons may help them survive or at least alleviate some of the symptoms. Here we demonstrate that live moss Physcomitrella patens cells can be safely co-cultured with human fibroblasts in vitro and thus have a potential for providing human cells with energy and other vital biomolecules. These data may form the foundation for the development of novel approaches to metabolic bioengineering and treatment of diseased cells based on live plants. In addition, by providing alternative energy sources to human tissues, the biotechnological potential of this interkingdom setup could also serve as a springboard to foster innovative dietary processes addressing current challenges of mankind such as famine or supporting long-haul space flight."@en ;
    ns0:hasPubTitle "Stable Co-Cultivation of the Moss Physcomitrella patens with Human Cells in vitro as a New Approach to Support Metabolism of Diseased Alzheimer Cells"@en .

ns1:jad-v70-i1-JAD190362 ns0:hasKeywords "Antihypertensive drugs"@en,
        "Germany"@en,
        "dementia"@en,
        "elderly persons"@en,
        "general practices"@en ;
    ns0:hasPubAbstract "Background: In recent years, there has been a growing interest in the association between the use of antihypertensive drugs and the incidence of dementia.   Objective: The goal of this retrospective study was to investigate the relationship between antihypertensive drug use and dementia in elderly persons followed in general practices in Germany.   Methods: This study included patients ≥60 years with documented blood pressure values who were diagnosed with dementia in general practices in Germany for the first time between 2013 and 2017 (index date). Dementia cases were matched to non-dementia controls using propensity scores based on age, sex, index year, and co-diagnoses. The main outcome of the study was the incidence of dementia as a function of the use of antihypertensive drugs.   Results: The present study included 12,405 patients with dementia and 12,405 patients without dementia. The use of angiotensin II receptor blockers (odds ratios [ORs] ranging from 0.74 to 0.79), angiotensin-converting enzyme inhibitors (ORs ranging from 0.85 to 0.88), calcium channel blockers (ORs ranging from 0.82 to 0.89), and beta blockers (OR = 0.88) was associated with a decrease in dementia incidence.   Conclusion: Antihypertensive drug use is negatively associated with dementia in elderly persons followed in general practices in Germany."@en ;
    ns0:hasPubTitle "The Relationship Between the Use of Antihypertensive Drugs and the Incidence of Dementia in General Practices in Germany"@en .

ns1:jad-v70-i2-JAD180381 ns0:hasKeywords "Daily clinical practice"@en,
        "detection"@en,
        "neurocognitive disorders"@en,
        "older people"@en,
        "prevention"@en,
        "tools"@en ;
    ns0:hasPubAbstract "Neurocognitive disorders create important challenges for patients, their families, and clinicians who provide their health care. Early/timely detection in daily clinical practice allows for diagnosis and adequate treatment, psychosocial support, education, and engagement in shared decision-making related to health care, life planning, involvement in research, and financial matters. However, neurocognitive disorders, when present, are not detected or not diagnosed and not documented, in more than half of patients seen by primary care physicians. The aim of this paper is to highlight the strategies and the perspectives to improve the early/timely detection of neurocognitive disorders in daily clinical practice."@en ;
    ns0:hasPubTitle "Neurocognitive Disorders: Importance of Early/Timely Detection in Daily Clinical Practice"@en .

ns1:jad-v70-i2-JAD190052 ns0:hasKeywords "Alzheimer’s disease"@en,
        "computer-assisted decision making"@en,
        "dementia"@en,
        "family caregivers"@en,
        "health information technology"@en,
        "psychological stress"@en,
        "social support"@en,
        "technological innovations"@en,
        "technology"@en,
        "telemedicine"@en ;
    ns0:hasPubAbstract "Background: Family members absorb much of the care of dementia patients. The burden of care substantially impacts caregivers’ health, further straining our healthcare system. By 2050, the incidence of Alzheimer’s disease will more than double, increasing the numbers of family caregivers proportionally. Interventions that reduce their burden are needed to preserve their health as well as the viability of the healthcare system.   Objective: This paper reports on the development and feasibility testing of a computer-based system intended to improve the lives of caregivers. D-CHESS (Dementia–Comprehensive Health Enhancement Support System) allows users to obtain information, communicate with other caregivers, get help with care decisions, and share information with experts.   Method: Thirty-one caregivers were randomly assigned to an intervention group receiving D-CHESS for 6 months or to a control group receiving a caregiving book. Surveys at 0, 2, 4, and 6 months evaluated caregiver burden, family conflict, satisfaction with decisions, social support, loneliness, anxiety, depression, and coping competence.   Results: Survey findings suggest D-CHESS participants may perform better on measures of social support, anxiety, loneliness, and coping competence; the groups were equivalent on caregiver burden, decision satisfaction, and depression, and the control group reported less family conflict than the intervention. D-CHESS use data suggested enhancements to system design and content to increase awareness and use of various features.   Conclusion: This study suggests that D-CHESS has potential to positively impact family caregivers and that the system merits further development and investigation with a full-scale clinical trial."@en ;
    ns0:hasPubTitle "Pilot Test of a Computer-Based System to Help Family Caregivers of Dementia Patients"@en .

ns1:jad-v70-i2-JAD190090 ns0:hasKeywords "Alzheimer’s disease"@en,
        "blood-brain barrier"@en,
        "cerebral amyloid angiopathy"@en,
        "locus coeruleus"@en,
        "vascular remodeling"@en ;
    ns0:hasPubAbstract "Noradrenergic locus coeruleus (LC) neuron loss is a significant feature of mild cognitive impairment and Alzheimer’s disease (AD). The LC is the primary source of norepinephrine in the forebrain, where it modulates attention and memory in vulnerable cognitive regions such as prefrontal cortex (PFC) and hippocampus. Furthermore, LC-mediated norepinephrine signaling is thought to play a role in blood-brain barrier (BBB) maintenance and neurovascular coupling, suggesting that LC degeneration may impact the high comorbidity of cerebrovascular disease and AD. However, the extent to which LC projection system degeneration influences vascular pathology is not fully understood. To address this question in vivo, we stereotactically lesioned LC projection neurons innervating the PFC of six-month-old Tg344-19 AD rats using the noradrenergic immunotoxin, dopamine-β-hydroxylase IgG-saporin (DBH-sap), or an untargeted control IgG-saporin (IgG-sap). DBH-sap-lesioned animals performed significantly worse than IgG-sap animals on the Barnes maze task in measures of both spatial and working memory. DBH-sap-lesioned rats also displayed increased amyloid and inflammation pathology compared to IgG-sap controls. However, we also discovered prominent parenchymal albumin extravasation with DBH-sap lesions indicative of BBB breakdown. Moreover, microvessel wall-to-lumen ratios were increased in the PFC of DBH-sap compared to IgG-sap rats, suggesting that LC deafferentation results in vascular remodeling. Finally, we noted an early emergence of amyloid angiopathy in the DBH-sap-lesioned Tg344-19 AD rats. Taken together, these data indicate that LC projection system degeneration is a nexus lesion that compromises both vascular and neuronal function in cognitive brain areas during the prodromal stages of AD."@en ;
    ns0:hasPubTitle "Locus Coeruleus Degeneration Induces Forebrain Vascular Pathology in a Transgenic Rat Model of Alzheimer’s Disease"@en .

ns1:jad-v70-i2-JAD190099 ns0:hasKeywords "Adeno-associated virus"@en,
        "Cdk5 inhibitory peptide"@en,
        "hyperphosphorylation of tau"@en,
        "neurodegeneration"@en,
        "p25"@en ;
    ns0:hasPubAbstract "Background: Under stress stimulation, p25 is generated by cleavage of p35 and acts as an activator of cyclin-dependent kinase 5 (Cdk5) like p35. Unlike Cdk5/p35, which is important for brain development, aberrant activity of Cdk5/p25 plays a pathological role in neurodegenerative diseases, such as Alzheimer’s disease, by inducing hyperphosphorylation of downstream substrates related to pathological progression. A truncated fragment of the c-terminus of p35, the Cdk5 inhibitory peptide (CIP), selectively inhibits Cdk5/ p25 activity in cultured neurons and in CIP/p25 tetra-transgenic mice.   Objective: First, we aimed to establish a p25 overexpression adult mouse model, then to evaluate whether CIP delivered by adeno-associated virus serotype 9 (AAV9) can ameliorate neuronal toxicity induced by p25.   Methods: The p25 overexpression mouse model was established by intracerebroventricular (i.c.v.) injection of AAV8-GFP-p25 in 8-week-old mice. One month later, these mice were i.c.v. injected with AAV9-CIP-T2A-mCherry or AAV9 vector as control. Pathological and behavioral changes were assessed 3-months post-injection in all mice.   Results: The p25 overexpression mice displayed hyperphosphorylation of tau at multiple sites, activation of astrocytes, and elevated inflammatory factors, including IL-1 and TNF-α, which were significantly decreased by the administration of CIP. However, Aβ deposition and microgliosis were not obvious in p25 overexpression mice. In addition, a significant learning decline and anxiety-like behavior were induced by p25 toxicity, and CIP treatment improved learning ability in p25 mice.   Conclusion: AAV-mediated p25 overexpression mouse model is easy to construct to study p25-induced neuronal toxicity. Application of CIP after p25 insult reverses the pathological changes and behavioral abnormalities."@en ;
    ns0:hasPubTitle "AAV9-Mediated Cdk5 Inhibitory Peptide Reduces Hyperphosphorylated Tau and Inflammation and Ameliorates Behavioral Changes Caused by Overexpression of p25 in the Brain"@en .

ns1:jad-v70-i2-JAD190240 ns0:hasKeywords "Cerebral small vessel disease"@en,
        "glial cell"@en,
        "neuroinflammation"@en,
        "spontaneous hypertension rats"@en,
        "toll-like receptor 4"@en,
        "vascular cognitive impairment"@en ;
    ns0:hasPubAbstract "Background: Cerebral small vessel disease (CSVD) can lead to leukodystrophy and cognitive impairment. The inflammatory response mediated by Toll-like receptor 4 (TLR4) is involved in the pathological process of CSVD, but the roles of TLR4 in vascular cognitive impairment (VCI) following CSVD are not clear.   Objective: To explore the roles and mechanisms of TLR4 in the development of VCI.   Methods: Male spontaneous hypertension rats (SHR) and Wistar Kyoto rats (WKY) were monitored for blood pressure (BP). The spatial learning and memory were assessed every 6 weeks using Morris water maze (MWM). Blood samples from femoral artery were collected and serum was isolated. Cerebral white matter damage was evaluated using a 3.0T magnetic resonance imaging (MRI) every 12 weeks. After 35 weeks, all rats were decapitated, and the expression of TLR4 in the hippocampus was determined using western blot. The number of positive cells of TLR4, active astrocyte and microglia in hippocampus were measured using immunohistochemistry and immunofluorescence.   Results: Compared with WKY, the BP of SHR was maintained at a high level. Spatial learning and memory declined. IL-1β and TNF-α levels were elevated. Cranial coronal scanning with T2-weighted MRI showed high signal intensity in corpus callosum and external capsule of SHR. Furthermore, in SHR, the expression of TLR4, GFAP, and Iba1 in the hippocampus were increased.   Conclusion: Hypertension can cause small vascular damage and partial white matter degeneration in the brain. SHR showed cognitive impairment with increasing age. High expression of TLR4 and glial cell response in hippocampus is one of the key mechanisms of this disease."@en ;
    ns0:hasPubTitle "Vascular Cognitive Impairment Caused by Cerebral Small Vessel Disease Is Associated with the TLR4 in the Hippocampus"@en .

ns1:jad-v70-i3-JAD180962 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Lewy body disease"@en,
        "biomarkers"@en,
        "cognitive assessment"@en,
        "memory"@en,
        "neuropathology"@en ;
    ns0:hasPubAbstract "Background: The percentage of verbal forgetting (VF%) measure of the Rey Auditory Verbal Learning Test (RAVLT) has been proposed to differentiate patients diagnosed clinically with Alzheimer’s disease (AD) and dementia with Lewy bodies (DLB).   Objective: To determine if VF% aligns with gold-standard biomarker and autopsy evidence of AD and DLB neuropathology.   Methods: Clinical, cognitive, sociodemographic, and biomarker data were collected from 315 patients with baseline cognitive impairment and 485 normal controls from the Alzheimer’s Disease Neuroimaging Initiative (ADNI). AD markers included reduced cerebrospinal fluid (CSF) amyloid-β, elevated total-tau and phosphorylated-tau, hippocampal atrophy, and the presence of amyloid plaques and neurofibrillary tangles at autopsy. DLB markers included reduced CSF α-synuclein, preserved hippocampus, atrophied putamen, occipital glucose metabolism, and the presence of Lewy bodies at autopsy. Cognitively impaired participants were classified as ADVF% (n = 190) or DLBVF% (n = 125) based on their RAVLT VF% scores using a 75% cut-off (≥75% = ADVF%, <75% = DLBVF%). Postmortem data were available for 13 ADVF% participants, 13 DLBVF% patients, and six healthy controls.   Results: ADVF% and DLBVF% participants did not differ on CSF or neuroimaging biomarkers, with the exception of total tau levels which were higher in ADVF%. In the subset of participants with autopsy data, comorbid AD and DLB pathology was most frequent in ADVF% participants, and pure DLB pathology was most frequent in DLBVF% participants, however, these differences were not statistically significant.   Conclusion: The RAVLT VF% measure does not reliably align with AD and DLB neuropathology in ADNI participants."@en ;
    ns0:hasPubTitle "Investigating the Association Between Verbal Forgetting and Pathological Markers of Alzheimer’s and Lewy Body Diseases"@en .

ns1:jad-v70-i3-JAD180966 ns0:hasKeywords "Alzheimer’s disease"@en,
        "biomarkers"@en,
        "cognition"@en,
        "episodic memory"@en,
        "preclinical"@en ;
    ns0:hasPubAbstract "Background: Alzheimer’s disease (AD) pathology is found in the brain years before symptoms are usually detected. An episodic memory (EM) decline is considered to be the specific cognitive sign indicating a transition from the preclinical to the prodromal stage of AD. However, there is still no consensus on the most sensitive tool to detect it.   Objective: The goal of our study was to determine which EM measures, among three clinically used EM tests and one research EM test, would be optimal to use for detection of early decline in elderly cognitive complainers.   Methods: 318 healthy elderly participants with subjective cognitive complaint were followed for two years. We applied generalized linear mixed models to investigate the effect of baseline brain amyloid and metabolism on the longitudinal evolution of four EM tests.   Results: Our findings show that participants performed significantly worse in two out of four EM tests (i.e., the Memory Binding Test and the Delayed Matched Sample test 48 items) as their level of brain amyloid load increased. However, we did not find an association between EM measures and brain metabolism. An interaction of the two biomarkers was associated with the number of intrusions in the Memory Binding Test over two years.   Conclusion: As most clinical trials in AD are now including patients at its early clinical stage, the precise delineation of the transition phase between the preclinical and prodromal stages of the disease is of crucial importance. Our study indicates that challenging EM tests and intrusions are valuable tools to identify this critical transition."@en ;
    ns0:hasPubTitle "Which Episodic Memory Performance is Associated with Alzheimer’s Disease Biomarkers in Elderly Cognitive Complainers? Evidence from a Longitudinal Observational Study with Four Episodic Memory Tests (Insight-PreAD)"@en .

ns1:jad-v70-i3-JAD190028 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Lewy body dementia"@en,
        "Parkinson’s disease"@en,
        "brain imaging"@en,
        "chronic traumatic encephalopathy"@en,
        "cognition"@en,
        "concussion"@en,
        "dementia"@en,
        "frontotemporal dementia"@en,
        "traumatic brain injury"@en ;
    ns0:hasPubAbstract "Traumatic brain injuries (TBI) have received widespread media attention in recent years as being a risk factor for the development of dementia and chronic traumatic encephalopathy (CTE). This has sparked fears about the potential long-term effects of TBI of any severity on cognitive aging, leading to a public health concern. This article reviews the evidence surrounding TBI as a risk factor for the later development of changes in brain structure and function, and an increased risk of neurodegenerative disorders. A number of studies have shown evidence of long-term brain changes and accumulation of pathological biomarkers (e.g., amyloid and tau proteins) related to a history of moderate-to-severe TBI, and research has also demonstrated that individuals with moderate-to-severe injuries have an increased risk of dementia. While milder injuries have been found to be associated with an increased risk for dementia in some recent studies, reports on long-term brain changes have been mixed and often are complicated by factors related to injury exposure (i.e., number of injuries) and severity/complications, psychiatric conditions, and opioid use disorder. CTE, although often described as a neurodegenerative disorder, remains a neuropathological condition that is poorly understood. Future research is needed to clarify the significance of CTE pathology and determine whether that can explain any clinical symptoms. Overall, it is clear that most individuals who sustain a TBI (particularly milder injuries) do not experience worse outcomes with aging, as the incidence for dementia is found to be less than 7% across the literature."@en ;
    ns0:hasPubTitle "Traumatic Brain Injury and Risk of Long-Term Brain Changes, Accumulation of Pathological Markers, and Developing Dementia: A Review"@en .

ns1:jad-v70-i3-JAD190191 ns0:hasKeywords "Alzheimer’s disease"@en,
        "meditation"@en,
        "mild cognitive impairment"@en,
        "mindfulness"@en,
        "randomized clinical trial"@en,
        "yoga"@en ;
    ns0:hasPubAbstract "Background/Objective: High levels of chronic stress negatively impact the hippocampus and are associated with increased incidence of mild cognitive impairment (MCI) and Alzheimer’s disease. While mindfulness meditation may mitigate the effects of chronic stress, it is uncertain if adults with MCI have the capacity to learn mindfulness meditation.   Methods: 14 adults with MCI were randomized 2:1 to Mindfulness Based Stress Reduction (MBSR) or a wait-list control group. We conducted qualitative interviews with those who completed MBSR. Transcribed interviews were: a) coded using an emergent themes inductive approach informed by grounded theory; b) rated 0–10, with higher scores reflecting greater perceived benefit from, and understanding of, mindfulness meditation. Ratings were correlated with daily home practice times and baseline level of cognitive function.   Results: Seven themes emerged from the interviews: positive perceptions of class; development of mindfulness skills, including meta-cognition; importance of the group experience; enhanced well-being; shift in MCI perspective; decreased stress reactivity and increased relaxation; improvement in interpersonal skills. Ratings of perceived benefit and understanding ranged from 2–10 (mean = 7) and of 0–9.5 (mean = 6), respectively. Many participants experienced substantial benefit/understanding, some had moderate, and a few had minimal benefit/understanding. Understanding the key concepts of mindfulness was highly positively correlated with ≥20 minutes/day of home practice (r = 0.90) but not with baseline cognitive function (r = 0.13).   Conclusions: Most adults with MCI were able to learn mindfulness meditation and had improved MCI acceptance, self-efficacy, and social engagement. Cognitive reserve may be enhanced through a mindfulness meditation program even in patients with MCI."@en ;
    ns0:hasPubTitle "Can Adults with Mild Cognitive Impairment Build Cognitive Reserve and Learn Mindfulness Meditation? Qualitative Theme Analyses from a Small Pilot Study"@en .

ns1:jad-v70-i3-JAD190265 ns0:hasKeywords "APOE4"@en,
        "Antibody dependent cellular cytotoxicity"@en,
        "Fcγ receptor"@en,
        "HSV1"@en,
        "immunoevasion"@en,
        "γ marker (GM) allotypes"@en ;
    ns0:hasPubAbstract "Although genome-wide association studies (GWAS) of late-onset Alzheimer’s disease (AD) have identified numerous genes that influence the risk for disease, the majority of the genetic variance of AD remains uncharacterized. Furthermore, current GWAS, despite their name, do not evaluate all genes in the human genome. One such gene complex is immunoglobulin GM (γ marker) genes on chromosome 14. GM genes are excellent candidate genes for AD because they influence immunity to herpes simplex virus type 1 (HSV1), which has been implicated in AD pathology by an increasing number of reports. The aim of this investigation was to determine if particular GM genotypes were associated with AD and mild cognitive impairment (MCI), and whether they contributed to the interindividual differences in the level of anti-HSV1 IgG antibodies. A total of 141 HSV1 seropositive individuals—56 AD patients, 48 MCI individuals, and 37 sex- and age-matched healthy controls—were characterized for GM alleles 3, 17, and 23. The homozygosity for the GM 3 allele was significantly associated with MCI (p = 0.025). GM 3/17 heterozygous AD patients had significantly higher levels of anti-HSV1 antibodies than the healthy controls expressing the same genotype (p = 0.0004). Among MCI subjects, the GM 3/17 genotype was associated with significantly higher level of anti-HSV1 antibodies as compared to the GM 17/17 homozygous genotype (pc = 0.040). Among AD patients, the GM 23+/–genotype was significantly associated with anti-HSV1 antibody responses (pc = 0.025). These results suggest that GM genes could act as potential unifiers of the genetic and viral etiology of AD."@en ;
    ns0:hasPubTitle "Immunoglobulin Genes and Immunity to HSV1 in Alzheimer’s Disease"@en .

ns1:jad-v70-i4-JAD190190 ns0:hasKeywords "AMPA receptor"@en,
        "Alzheimer’s disease"@en,
        "EHMT1"@en,
        "amyloid-β"@en,
        "epigenetics"@en,
        "histone methylation"@en,
        "histone methyltransferase"@en,
        "human stem cell-derived neurons"@en ;
    ns0:hasPubAbstract "Emerging evidence suggests that epigenetic dysregulation of gene expression is one of the key molecular mechanisms of neurodegeneration and Alzheimer’s disease (AD). However, little is known about the role of epigenetic dysregulation on synaptic dysfunction in humans, because of the difficulties of obtaining live human neurons. Here we generated mature human cortical neurons differentiated from human embryonic stem cells, and exposed them to amyloid-β (Aβ). We found that the histone methyltransferase, EHMT1, which catalyzes histone lysine 9 dimethylation (H3K9me2, a mark for gene repression), was significantly elevated in Aβ-treated human stem cell-derived neurons. Aβ treatment led to a significant reduction of AMPAR-mediated whole-cell current and excitatory postsynaptic current. Application of BIX01294, a selective inhibitor of EHMT1/2, restored AMPAR currents and glutamatergic synaptic transmission in Aβ-treated human cortical neurons. These results suggest that inhibition of the aberrant histone methylation is a novel approach to reverse Aβ-induced synaptic deficits in human neurons."@en ;
    ns0:hasPubTitle "Inhibition of Histone Methyltransferases EHMT1/2 Reverses Amyloid-β-Induced Loss of AMPAR Currents in Human Stem Cell-Derived Cortical Neurons"@en .

ns1:jad-v70-i4-JAD190216 ns0:hasKeywords "Citation"@en,
        "Prestige Index"@en,
        "gender gap"@en,
        "odds ratio"@en,
        "productivity"@en ;
    ns0:hasPubAbstract "Background: Alzheimer’s disease and dementia are an increasing burden affecting more than 50 million patients worldwide. Hence, research has increased significantly in recent decades. It is recognized that female authors are systematically underrepresented in research in general.   Objective: In this article, we examine gender disparities in academic research on dementia and Alzheimer’s disease in the last decade.   Methods: 104,858 male and female authorships from 37,961 original research articles were analyzed. The global and country-specific distribution of women across first, co, and last authorships was determined with the inclusion of a citation and productivity analysis.   Results: 42.1% of all authorships and 50.2% of the first, 42.2% of the co, and 32.8% of the last authorships were held by women. Women were less commonly cited, published fewer articles and were also less likely to secure prestigious authorships in articles with multiple authors compared with men. Distinct differences were observed among the countries.   Conclusion: Substantial growth in the number of prestigious female authorships has been observed to date and is predicted to continue in the future, with an emphasis on the progressive representation of women and a diminishing gender gap."@en ;
    ns0:hasPubTitle "Gender Disparities in Authorships of Alzheimer’s Disease and Dementia Research Articles"@en .

ns1:jad-v70-i4-JAD190327 ns0:hasKeywords "Atherosclerosis"@en,
        "Montreal Cognitive Assessment"@en,
        "NCT01555411"@en,
        "cardiovascular risk factors"@en,
        "carotid plaque"@en,
        "cognition"@en,
        "cognitive function"@en,
        "http://www.clinicaltrials.gov"@en ;
    ns0:hasPubAbstract "Background: Studies on the relationship between carotid atherosclerosis and cognitive function in subjects from the general population are few and results have been inconsistent.   Objective: We aimed to investigate the association between carotid atherosclerotic burden and cognitive function in a cross-sectional analysis of a population-based cohort aged 63–65 years.   Methods: All habitants born in 1950 from Akershus County, Norway were invited to participate. A linear regression model was used to assess the association between carotid atherosclerosis and cognitive function. We used carotid plaque score as a measure of carotid atherosclerotic burden and the Montreal Cognitive Assessment (MoCA) for global cognitive function.   Results: We analyzed 3,413 individuals aged 63–65 with mean MoCA score 25.3±2.9 and 87% visible carotid plaques. We found a negative correlation between carotid plaque score and MoCA score (r = –0.14, p < 0.001), but this association was lost in multivariable analysis. In contrast, diameter or area of the thickest plaque was independently associated with MoCA score. Lower educational level, male sex, current smoking, and diabetes were also associated with lower MoCA score in multivariable analysis.   Conclusion: Carotid atherosclerotic burden was, unlike other measures of advanced carotid atherosclerosis, not independently associated with global cognitive function."@en ;
    ns0:hasPubTitle "Carotid Atherosclerosis and Cognitive Function in a General Population Aged 63-65 Years: Data from the Akershus Cardiac Examination (ACE) 1950 Study"@en .

ns1:jad-v70-is1-JAD180464 ns0:hasKeywords "Cognitive"@en,
        "WESIHAT 2.0©"@en,
        "cost"@en,
        "disability"@en,
        "informational support"@en,
        "older adults"@en,
        "randomized controlled trial"@en,
        "web-based health education"@en ;
    ns0:hasPubAbstract "Background: Intervention strategies, especially online based approaches, are considered to be beneficial in improving the health of the senior. The effectiveness of such approaches is yet to be determined.   Objective: This study aims to determine the effectiveness of the web-based application, WESIHAT 2.0©, for improving cognitive function, physical fitness, biochemical indices, and psychosocial variables among older adults in Klang Valley, Malaysia. The cost analysis of WESIHAT 2.0© was also determined.   Method: The study utilized a two-arm randomized controlled trial with 25 subjects in each of the intervention and control groups. The participants chosen for the study included those who were 60 years and above with at least secondary education and had internet access using a computer at home. The intervention group was exposed to the website (30 minutes per day, 4 days per week) for six months, while the control group was given health education pamphlets. Activity-Based Costing method was used to determine the cost saved using WESIHAT 2.0© as compared to using the pamphlet.   Results: Significant intervention effects were observed for self-perception of disability and informational support scores. WESIHAT 2.0© was able to save costs in improving the self-perception of disability score and the informational support score at MYR 6.92 and MYR 13.52, respectively, compared to the conventional method.   Conclusion: WESIHAT 2.0© was able to save costs in improving the self-perceived disability and informational support scores for the intervention group."@en ;
    ns0:hasPubTitle "The Effectiveness of a Web-Based Health Education Tool, WESIHAT 2.0, among Older Adults: A Randomized Controlled Trial"@en .

ns1:jad-v70-is1-JAD180498 ns0:hasKeywords "Cardiovascular diseases"@en,
        "cognition disorders"@en,
        "cognitive decline"@en,
        "cognitive impairment"@en,
        "cohort studies"@en,
        "kidney diseases"@en ;
    ns0:hasPubAbstract "Background: The role of chronic kidney disease (CKD) as a risk factor for cognitive impairment independent of their shared antecedents remains controversial.   Objective: To determine whether kidney damage (indicated by albuminuria) or kidney dysfunction (estimated glomerular filtration rate [eGFR] <60 ml/min/1.73 m2) predict future (12-year) cognitive function independently of their shared risk factors.   Methods: We studied 4,128 individuals from the 1999/00 population-based Australian Diabetes, Obesity, and Lifestyle (AusDiab) Study who returned in 2011/12 for follow-up cognitive function testing. Albuminuria was defined by urinary albumin:creatinine≥3.5 (women) or≥2.5 mg/mmol (men). Kidney dysfunction was indicated by eGFR <60 ml/min/1.73 m2. Cognitive function domains assessed included memory (California Verbal Learning Test [CVLT]) and processing speed (Symbol Digit Modalities Test [SDMT]).   Results: Baseline albuminuria and kidney dysfunction were identified in 142 (3.4%) and 39 (0.9%) individuals, respectively, with minimal overlap (n = 7). Those with albuminuria demonstrated concurrently reduced 12-year SDMT (p = 0.084) and CVLT scores (p = 0.005) following adjustment for age, sex, and education. However, only CVLT performance remained worse (p = 0.027) following additional adjustment for myocardial infarction, stroke, and related risk factors (hypertension, diabetes, dyslipidemia, smoking, BMI, physical activity, and alcohol intake). Indeed, these collective covariates were responsible for 47% of the effect of albuminuria on SDMT, but only 21% of its effect on CVLT. Kidney dysfunction was not associated with either SDMT or CVLT performance (p > 0.10).   Conclusions: Albuminuria predicted worse memory function at 12 years follow-up, whereas its effect on processing speed was driven largely by differences in cardiovascular risk. Kidney dysfunction based on eGFR predicted neither cognitive domain."@en ;
    ns0:hasPubTitle "Associations of Chronic Kidney Disease Markers with Cognitive Function: A 12-Year Follow-Up Study"@en .

ns1:jad-v70-is1-JAD180608 ns0:hasKeywords "Commissioner"@en,
        "government"@en,
        "modifiable risk"@en,
        "policymaker"@en,
        "primary healthcare"@en ;
    ns0:hasPubAbstract "Background: Understanding the policy context and how policy is implemented at the local and clinical level is an important precursor to developing preventive strategies focusing on dementia risk reduction in primary healthcare settings.   Objective: Using England as a case study, we review policies and strategies relevant to dementia prevention from the national to local level and how these are translated into primary healthcare services.   Methods: We conducted a scoping review covering: 1) identification of national, regional, and local policies and strategies that include dementia prevention; 2) identification of national guidelines for implementing dementia prevention at the clinical level; and 3) evaluation of the implementation of these at the clinical level.   Results: Dementia prevention is addressed in national policy, and this filters through to regional and local levels. Focus on dementia prevention is limited and variable. Reference to modifiable risk factors is associated with other non-communicable diseases, placing less emphasis on factors more dementia specific. Evidence of implementation of dementia prevention policies at the clinical level is limited and inconsistent. Available evidence suggests messages about dementia prevention may best be delivered through primary healthcare services such as the National Health Service (NHS) Health Check.   Conclusion: The limitations identified in this review could be addressed through development of a national policy focused specifically on dementia prevention. This could provide a platform for increasing knowledge and understanding among the general population and healthcare professionals. It would be important for such a policy to cover the full range of modifiable risk factors relevant to dementia."@en ;
    ns0:hasPubTitle "Dementia Primary Prevention Policies and Strategies and Their Local Implementation: A Scoping Review Using England as a Case Study"@en .

ns1:jad-v70-is1-JAD180631 ns0:hasKeywords "Air pollutants"@en,
        "cognitive decline"@en,
        "dementia"@en,
        "particulate matter"@en ;
    ns0:hasPubAbstract "Background: Both air pollution and dementia are current and growing global issues. There are plausible links between exposure to specific air pollutants and dementia.   Objective: To systematically review the evidence base with respect to the relationship between air pollution and later cognitive decline and dementia.   Methods: Medline, Embase, and PsychINFO® were searched from their inception to September 2018, for publications reporting on longitudinal studies of exposure to air pollution and incident dementia or cognitive decline in adults. Studies reporting on exposure to tobacco smoke including passive smoking or on occupational exposure to pollutants were excluded. Using standard Cochrane methodology, two readers identified relevant abstracts, read full text publications, and extracted data into structured tables from relevant papers, as defined by inclusion and exclusion criteria. Papers were also assessed for validity. CRD42018094299   Results: From 3,720 records, 13 papers were found to be relevant, with studies from the USA, Canada, Taiwan, Sweden, and the UK. Study follow-up ranged from one to 15 years. Pollutants examined included particulate matter ≤2.5 μ (PM2.5), nitrogen dioxide (NO2), nitrous oxides (NOx), carbon monoxide (CO), and ozone. Studies varied in their methodology, population selection, assessment of exposure to pollution, and method of cognitive testing. Greater exposure to PM2.5, NO2/NOx, and CO were all associated with increased risk of dementia. The evidence for air pollutant exposure and cognitive decline was more equivocal.   Conclusion: Evidence is emerging that greater exposure to airborne pollutants is associated with increased risk of dementia."@en ;
    ns0:hasPubTitle "Air Pollution and Dementia: A Systematic Review"@en .

ns1:jad-v70-is1-JAD180636 ns0:hasKeywords "Alzheimer’s disease"@en,
        "dementia"@en,
        "low- and middle-income countries"@en,
        "prevention"@en,
        "risk reduction"@en ;
    ns0:hasPubAbstract "Background:  Most people with dementia live in low- and middle-income countries and little is known about the potential for reducing these numbers by reducing key risk factors.  Objective:  To investigate the potential for dementia incidence reduction in Brazil, Mozambique, and Portugal (a culturally related, high-income country).  Methods:  We replicated previously published methods and based on the relative risks from previous studies, we estimated the population-attributable risk (PAR) of dementia in Mozambique, Brazil, and Portugal for seven modifiable risk factors associated with dementia (low educational attainment, physical inactivity, midlife hypertension, midlife obesity, depression, smoking, and diabetes mellitus). The combined PAR was calculated and adjusted for associations between risk factors. The potential for risk factor reduction was assessed by examining the effect of relative reductions of 10% and 20% per decade for each of the risk factors on projections for dementia cases for each decade until 2050.  Results:  After adjusting for non-independence of risk factors, 24.4%, 32.3%, and 40.1% of dementia cases could be related to seven potentially modifiable risk factors in Mozambique, Brazil, and Portugal, respectively. Reducing the prevalence of each risk factor by 20% per decade could, by 2050, potentially reduce the prevalence of dementia in Mozambique, Brazil, and Portugal by 12.9%, 16.2%, and 19.5%, respectively.  Conclusion:  There is a substantial difference between the countries in the percentage of dementia cases that could be attributable to the seven potentially modifiable risk factors. The proportion of cases that could be prevented by 2050 if measures were taken to address these main risk factors was higher in Portugal than in Brazil and Mozambique. Each country or region should consider their unique risk factor profile when developing dementia risk reduction programs."@en ;
    ns0:hasPubTitle "Reducing the Number of People with Dementia Through Primary Prevention in Mozambique, Brazil, and Portugal: An Analysis of Population-Based Data"@en .

ns1:jad-v70-is1-JAD180763 ns0:hasKeywords "Body weight"@en,
        "dementia"@en,
        "meta-analysis"@en,
        "older people"@en ;
    ns0:hasPubAbstract "Background: It is unclear whether overweight and obesity in older age reduces or increases the risk of incident dementia.   Objective: To assess the impacts of overweight and obesity in older age on incident dementia.   Methods: We searched cohort studies reporting body weight measured in older age and dementia through PubMed, Embase, Medline, PyschInfo, and Cochrane library until July 2016. Sixteen articles were identified for the review. We pooled data from them and a new unpublished study from China, to calculate relative risk (RR) of incident dementia in relation to body mass index (BMI) and waist circumference (WC).   Results: All 16 cohort studies were undertaken in high income countries, with follow-up periods ranging between 3 to 18 years. Thirteen studies showed an inverse association between BMI and dementia, and three studies demonstrated a positive association. Pooled RR of dementia in relation to continuous BMI from 14 studied populations, including the new Chinese data, was 0.97 (95% CI 0.95–1.00); in those followed up <9 years it was 0.95 (0.93–0.96) while in ≥9 years follow-up it was 1.03 (0.96–1.11). In five studied populations examining categorical BMI, RR of dementia in older people classified as overweight and obese was 0.98 (0.54–1.77) and 1.17 (0.65–2.10) respectively, in comparison with other weights. The pooled WC data showed no association between increased WC and reduced risk of dementia.   Conclusion: The current evidence did not support a paradox on beneficial impacts of overweight and obesity in older age on incident dementia. More studies with long term follow up are needed to clarify the association of body weight in older age with dementia risk."@en ;
    ns0:hasPubTitle "Impacts of Overweight and Obesity in Older Age on the Risk of Dementia: A Systematic Literature Review and a Meta-Analysis"@en .

ns1:jad-v70-is1-JAD180899 ns0:hasKeywords "Community"@en,
        "kurihara project"@en,
        "mild cognitive impairment"@en,
        "tajiri project"@en,
        "vascular MCI"@en,
        "vascular dementia"@en ;
    ns0:hasPubAbstract "Vascular mild cognitive impairment (MCI) is a critical disease. Its prognosis includes not only onset of vascular dementia, but also death by cardiovascular disease. The vascular risk factors for vascular MCI are treatable, and appropriate treatment can prevent or delay the progression to dementia. Therefore, this group is an excellent candidate for secondary prevention. However, community-dwelling older adults with vascular MCI are often undetected and are not clinically identified until they develop frank dementia. Furthermore, older adults with undetected vascular MCI often have decreased ability to follow their medication regimens and this poor medication adherence worsens their vascular comorbidities. This vicious cycle needs to be prevented through community-based interventions. There is evidence that treatment of hypertension or diabetes mellitus could lead to a reduced incidence of vascular MCI and dementia. In this review article, we first explain the background and etiology of vascular MCI. We then summarize phenotype of subcortical vascular dementia which is often unrecognized or “hidden” in the community. Then we introduce the Osaki-Tajiri and Kurihara Projects which have been conducted in Northern Japan, as an example of prevention projects aimed to identify early-stage vascular MCI in the community, reduce the risk factors and facilitate their treatment. Early identification of vascular MCI in the community could lead to a large reduction in the dementia burden worldwide. The outreach efforts presented here could be useful in developing secondary prevention strategies targeted to vascular MCI."@en ;
    ns0:hasPubTitle "Vascular Mild Cognitive Impairment: Identifying Disease in Community-Dwelling Older Adults, Reducing Risk Factors, and Providing Support. The Osaki-Tajiri and Kurihara Projects"@en .

ns1:jad-v71-i1-JAD180957 ns0:hasKeywords "Care navigation"@en,
        "caregivers"@en,
        "dementia"@en,
        "health care workforce"@en ;
    ns0:hasPubAbstract "Background: Care navigation is an approach to personalized care management and care coordination that can help overcome barriers to care. Care navigation has not been extensively studied in dementia, where health care workforce innovations are needed as a result of increasing disease prevalence and resulting costs to the health care system.   Objective: To identify facilitators and barriers to care navigation in dementia and to assess dementia caregiver satisfaction with care navigation.   Methods: Methods include qualitative research (interviews, focus groups, observations) with “Care Team Navigators” (CTNs) who were part of a dementia care navigation program, the Care Ecosystem, and a quantitative survey with caregivers about their experiences with CTNs. Transcripts were analyzed to identify themes within the data.   Results: CTNs identified the following facilitators to care navigation in dementia: working closely with caregivers; providing emotional support; tailoring education and resources; and coordinating with a clinical team around issues ranging from clinical questions to financial and legal decision-making. The barriers CTNS identified included burn-out, the progressive nature of the disease; coordinating with primary care providers; and identifying resources for dyads who are low-income, do not speak English, or live in rural areas. Caregivers across both sites highly rated CTNs, though satisfaction was higher among those in Nebraska and Iowa.   Conclusions: Innovative approaches to care delivery in dementia are crucial. Care navigation offers a feasible model to train unlicensed people to deliver care as a way to deliver larger-scale support for the growing population of adults living with dementia and their caregivers."@en ;
    ns0:hasPubTitle "The Role of Care Navigators Working with People with Dementia and Their Caregivers"@en .

ns1:jad-v71-i1-JAD190158 ns0:hasKeywords "Advanced glycation end products"@en,
        "GSK-3β oxidative stress"@en,
        "brain-derived neurotrophic factor"@en,
        "ribosylation"@en,
        "tau hyperphosphorylation"@en ;
    ns0:hasPubAbstract "Advanced glycation end products (AGEs) have been implicated in the disease process of diabetes mellitus. They have also been found in senile plaques and neurofibrillary tangles in the brains of Alzheimer’s disease patients. Furthermore, abnormally high levels of D-ribose and D-glucose were found in the urine of patients with type 2 diabetes mellitus, suggesting that diabetic patients suffer from dysmetabolism of not only D-glucose but also D-ribose. In the present study, intravenous tail injections of ribosylated rat serum albumin (RRSA) were found to impair memory in rats, but they did not markedly impair learning, as measured by the Morris water maze test. Injections of RRSA were found to trigger tau hyperphosphorylation in the rat hippocampus via GSK-3β activation. Tau hyperphosphorylation and GSK-3β activation were also observed in N2a cells in the presence of ribosylation-derived AGEs. Furthermore, the administration of ribosylation-derived AGEs induced the suppression of brain-derived neurotrophic factor (BDNF) and tropomyosin-related kinase B (TrkB). Both GSK-3β inhibition and BDNF treatment decreased the levels of phosphorylated tau in N2a cells. In particular, the administration of BDNF could rescue memory failure in ribosylated AGE-injected rats. Ribosylation-derived AGEs downregulated the BDNF-TrkB pathway in rat brains and N2a cells, leading to GSK-3β activation-mediated tau hyperphosphorylation, which was involved in the observed rat memory loss. Targeting ribosylation may be a promising therapeutic strategy to prevent Alzheimer’s disease and diabetic encephalopathies."@en ;
    ns0:hasPubTitle "Ribosylation-Derived Advanced Glycation End Products Induce Tau Hyperphosphorylation Through Brain-Derived Neurotrophic Factor Reduction"@en .

ns1:jad-v71-i1-JAD190162 ns0:hasKeywords "Cognitive impairment"@en,
        "dementia"@en,
        "health outcome"@en,
        "impact"@en,
        "intervention"@en,
        "pharmacist"@en,
        "quality of life"@en,
        "role"@en,
        "systematic review"@en ;
    ns0:hasPubAbstract "Background: Medication use in people with dementia and/or cognitive impairment (PWD/CI) is challenging. As medication experts, pharmacists have an important role in improving care of this vulnerable population.   Objective: Systematically review evidence for the effectiveness of pharmacist-led interventions on quality use of medicines, quality of life, and health outcomes of PWD/CI.   Methods: A systematic review was conducted using MEDLINE, EMBASE, PsycINFO, Allied and Complementary Medicine (AMED) and Cumulative index to Nursing and Allied Health Literature (CINAHL) databases from conception to 20 March 2017. Full articles published in English were included. Data were synthesized using a narrative approach.   Results: Nine studies were eligible for inclusion. All studies were from high-income countries and assessed pharmacist-led medication management services. There was great variability in the content and focus of services described and outcomes reported. Pharmacists were found to provide a number of cognitive services including medication reconciliation, medication review, and medication adherence services. These services were generally effective with regards to improving quality use of medicines and health outcomes for PWD/CI and their caregivers, and for saving costs to the healthcare system. Pharmacist-led medication and dementia consultation services may also improve caregiver understanding of dementia and the different aspects of pharmacotherapy, thus improving medication adherence.   Conclusion: Emerging evidence suggests that pharmacist-led medication management services for PWD/CI may improve outcomes. Future research should confirm these findings using more robust study designs and explore additional roles that pharmacists could undertake in the pursuit of supporting PWD/CI."@en ;
    ns0:hasPubTitle "The Impact of Pharmacist Interventions on Quality Use of Medicines, Quality of Life, and Health Outcomes in People with Dementia and/or Cognitive Impairment: A Systematic Review"@en .

ns1:jad-v71-i1-JAD190198 ns0:hasKeywords "Antioxidants"@en,
        "cognitive dysfunction"@en,
        "neurodegenerative diseases"@en,
        "oxidants"@en,
        "oxidative stress"@en,
        "preclinical markers"@en ;
    ns0:hasPubAbstract "Oxidative stress plays an essential and early role in the pathophysiology of Alzheimer’s disease (AD). Alterations in the redox state in AD and in mild cognitive impairment (MCI) patients appear in the brain and at peripheral level. Given that it is easier to study the latter, most of the research has been focused on plasma. However, the analysis of redox parameters in whole blood cells (including erythrocytes and leukocytes) has not really been investigated. Moreover, the association of these parameters with Mini-Mental State Examination (MMSE) clinical scores, has scarcely been studied. Therefore, the aim of the present work was to analyze several redox markers in whole blood cells from male and female MCI and AD patients. Antioxidant (superoxide dismutase, catalase (CAT), glutathione peroxidase (GPx), and reductase (GR) activities, and reduced glutathione (GSH) concentration) together with oxidant parameters (oxidized glutathione (GSSG) and thiobarbituric acid-reactive substances (TBARS)) were investigated using MCI and AD (10 women and 10 men in each group) and their age-matched control groups (15 women and 15 men). The results show an altered redox state in whole blood cells from AD patients (higher CAT, GSSG/GSH, TBARS and lower GPx, GR, GSH). Some of these redox parameters are already affected in MCI patients (higher TBARS and lower GPx and GR activities) in both sexes and, consequently, they could be used as markers of prodromal AD. Since GR, GSH, GSSG, and GSSG/GSH were found to be associated with MMSE scores, they seem to be useful clinically to monitor cognitive decline in AD progression."@en ;
    ns0:hasPubTitle "Altered Redox State in Whole Blood Cells from Patients with Mild Cognitive Impairment and Alzheimer’s Disease"@en .

ns1:jad-v71-i2-JAD181232 ns0:hasKeywords "Arabic version"@en,
        "Lebanon"@en,
        "dementia"@en,
        "mini-mental state examination"@en,
        "normative data"@en,
        "reliability"@en,
        "validity"@en ;
    ns0:hasPubAbstract "Background: The Mini-Mental State Examination (MMSE) has not been validated in the Lebanese population and no normative data exist at the national level.   Objective: To evaluate the reliability and validity of an Arabic version of MMSE developed by the “Groupe de Travail sur les Démences de l’Université Saint Joseph” (A-MMSE(GTD-USJ)) and to provide normative data by gender, age, and education in adults over 55.   Methods: Study design: national cross-sectional survey. Study population: 1,010 literate community-dwelling Lebanese residents aged 55 and above. Outcomes: reproducibility, internal consistency, sensitivity, specificity, predictive values, and area under the curve of the A-MMSE(GTD-USJ) for the detection of cognitive impairment using the Clinical Dementia Rating (CDR) as the gold standard. Normative data were established from 720 healthy adults. A-MMSE(GTD-USJ) scores corresponding to the 5th, 10th, 15th, and 50th percentiles were identified according to gender, age, and education.   Results: Intra-rater and inter-rater test-retest score correlations were 0.89 and 0.72, respectively. Cronbach alpha coefficient for internal consistency of the A-MMSE(GTD-USJ) was 0.71. A threshold value of 23 provided a sensitivity of 80% and a specificity of 89.4%. The area under the curve was 0.92. A-MMSE(GTD-USJ) scores increased with education and decreased with age. Women had significantly lower scores than men. Normative data for A-MMSE(GTD-USJ) stratified by gender, age, and education were generated.   Conclusion: In reference to the CDR, the A-MMSE(GTD-USJ) is a valid tool to assess cognitive status among Lebanese subjects aged 55 and above. Normative data will help clinicians in detecting cognitive impairment in this population."@en ;
    ns0:hasPubTitle "An Arabic Version of the Mini-Mental State Examination for the Lebanese Population: Reliability, Validity, and Normative Data"@en .

ns1:jad-v71-i2-JAD190397 ns0:hasKeywords "Alzheimer’s disease"@en,
        "bilingualism"@en,
        "dementia"@en,
        "language"@en ;
    ns0:hasPubAbstract "Despite the large number of elderly bilinguals at risk for Alzheimer’s disease (AD) and dementia worldwide, significant questions remain about the relationship between speaking more than one language and later cognitive decline. Bilingualism may impact on cognitive and neural reserve, time of onset of dementia symptoms and neuropathology, and linguistic competency in dementia. This review indicates increased cognitive reserve from executive (monitoring, selecting, inhibiting) control of two languages and increased neural reserve involving left frontal and related areas for language control. Many, but not all, studies indicate a delay in dementia symptom onset but worse hippocampal and mesiotemporal atrophy among bilinguals versus monolinguals with AD. In contrast, bilinguals do worse on language measures, and bilinguals with AD or dementia have difficulty maintaining and monitoring their second language. Together, these studies suggest that early-acquired and proficient bilingualism increases reserve through frontal-predominant executive control, and these executive abilities compensate for early dementia symptoms, delaying their onset but not the neuropathology of their disease. Finally, as executive control decreases further with advancing dementia, there is increasing difficulty inhibiting the dominant first language and staying in the second language. These conclusions must be interpreted with caution, given the problems inherent in this type of research; however, they do recommend more work on the pre-dementia neuroprotective effects and the dementia-related language impairments of bilingualism."@en ;
    ns0:hasPubTitle "Bilingualism and Dementia: Cognitive Reserve to Linguistic Competency"@en .

ns1:jad-v71-i2-JAD190419 ns0:hasKeywords "Alzheimer’s disease"@en,
        "apolipoprotein E4 (1–272)"@en,
        "axonopathy"@en,
        "endoplasmic reticulum stress"@en,
        "tau phosphorylation"@en ;
    ns0:hasPubAbstract "Apolipoprotein (apo) E4 is the major genetic risk factor for Alzheimer’s disease (AD). It is shown that apoE4 preferentially undergoes aberrant cleavage in neurons, yielding neurotoxic C-terminal-truncated apoE4 fragment. Endoplasmic reticulum (ER) stress has also been known to be involved in the pathogenesis of AD. However, little is known about the contribution of ER stress to the neurotoxicity of apoE4 fragment. In the present study, we established the neuron-specific expression human C-terminal-truncated apoE4(1–272) fragment transgenic mice and also transfected apoE4(1–272) fragment in neuroblastoma N2a cells. We found that human apoE4(1–272) fragment could trigger ER stress as evidenced by increasing the expression of ER stress markers both in vivo and in vitro. Meanwhile, the apoE4(1–272) transgenic mice presented obviously AD-like neuropathological changes, including the impairment of spatial learning and memory, prominent axonal morphological changes, and hyperphosphorylation of tau. At the same time, we also found that glycogen synthase kinase-3 activities were significantly increased. Furthermore, these neuropathological changes, especially tau hyperphosphorylation and axonal transport impairment, were significantly rescued by the ER stress protector 4-phenylbutyric acid (4-PBA) in apoE4(1–272)-transfected N2a cells. Pretreatment with 4-PBA not only decreased the protein expression of immunoglobulin binding protein (BiP) and C/EBP-homologous protein (CHOP), but also significantly reversed these defects in axonal transport. These results suggested that the neurotoxic effects of apoE4(1–272) fragment found in AD subjects, at least in part, through triggering ER stress and inducing tau hyperphosphorylation, led to the enduring impairment of axonal transport."@en ;
    ns0:hasPubTitle "Neuron-Specific Apolipoprotein E4 (1-272) Fragment Induces Tau Hyperphosphorylation and Axonopathy via Triggering Endoplasmic Reticulum Stress"@en .

ns1:jad-v71-i2-JAD190631 ns0:hasKeywords "Cognition disorders"@en,
        "cognitive screening"@en,
        "computer-assisted decision making"@en,
        "dementia"@en,
        "mild cognitive impairment"@en ;
    ns0:hasPubAbstract "Repeated measurements could be helpful to identify patients with early cognitive decline. We compare the variation of cognitive performance over one year in patients with mild cognitive impairment (MCI) and healthy individuals using the Brain on Track self-applied computerized test (BoT). The study was initiated 30 patients with probable MCI and 377 controls from a population-based cohort, who performed the BoT test from home every three months for one year. The scores were compared using a linear mixed-effects model. All participants increased their scores in the first tests, after 120 days MCI patients started to decline, with a statistically significant higher rate. The area under the curve to detect MCI was 0.94. We identified a significant decline in cognitive performance over one year in patients with MCI using BoT and the test presented a high discriminative ability."@en ;
    ns0:hasPubTitle "Tracking Cognitive Performance in the General Population and in Patients with Mild Cognitive Impairment with a Self-Applied Computerized Test (Brain on Track)"@en .

ns1:jad-v71-i3-JAD190123 ns0:hasKeywords "Autophagy"@en,
        "BDNF"@en,
        "metformin"@en,
        "resveratrol"@en,
        "synaptophysin"@en ;
    ns0:hasPubAbstract "Background: Obesity, insulin resistance, and type 2 diabetes are established risk factors for the development of Alzheimer’s disease (AD). Given this connection, two drugs, metformin (MET) and resveratrol (RESV), are considered for the clearance of amyloid-β peptides through AMPK-mediated activation of autophagy. However, overactivation of AMPK observed in late-stage AD brains and relationships between AMPK and neurogenesis (through mTORC1 inhibition), questions treatment with these drugs.   Objective: To examine if MET and/or RESV supplementation activates brain AMPK, regulates markers of autophagy, and affects markers of neuronal health/neurogenesis.   Methods: 8-week-old male C57BL/6J mice were fed a low (N = 12; 10% kcal fat; LFD) or high fat diet (N = 40; 60% kcal fat; HFD) for 9 weeks to induce insulin resistance and obesity. HFD mice were then treated with/without MET (250 mg/kg/day), RESV (100 mg/kg/day), or COMBO (MET: 250 mg/kg/day, RESV: 100 mg/kg/day) for 5 weeks. Hippocampus and prefrontal cortex were extracted for western blotting analysis.   Results: Cortex AMPK (T172) and raptor (S792, the regulatory subunit of mTORC1) phosphorylation were upregulated following RESV, COMBO treatments. mTOR (S2448) and ULK1 (S555) activation was seen following MET, COMBO and RESV, COMBO treatments, respectively, in the cortex and hippocampus. p62 content was decreased following RESV, COMBO, with LC3 content being increased following RESV treatment in the cortex. Brain derived neurotropic factor (BDNF) was significantly decreased following RESV, COMBO, and synaptophysin following all treatment in the cortex.   Conclusion: These results demonstrate that while treatments upregulated markers of autophagy in the prefrontal cortex, reductions in neuronal health markers question the efficacy of AMPK as a therapy for AD."@en ;
    ns0:hasPubTitle "Resveratrol and Metformin Recover Prefrontal Cortex AMPK Activation in Diet-Induced Obese Mice but Reduce BDNF and Synaptophysin Protein Content"@en .

ns1:jad-v71-i3-JAD190217 ns0:hasKeywords "Epidemiology"@en,
        "prevention"@en,
        "risk factors"@en ;
    ns0:hasPubAbstract "Background/Objective: The 2020 Strategic Impact Goal introduced by the American Heart Association (AHA) aims at improving cardiovascular health (CVH) of all Americans by 20%. AHA defined ideal CVH across seven established modifiable risk factors for cardiovascular diseases. Prior studies have indicated that ideal CVH also benefits brain health and cognitive aging, but it is possible that this association is explained by familial factors.   Methods: We examined 272 male monozygotic and dizygotic twin pairs (total 544 subjects) free of overt cardiovascular disease and dementia from the Vietnam Era Twin Registry. Memory and learning were measured by Trail Making tests and Wechsler Memory Scale (Immediate and Delayed Memory tests and Visual Reproductive Test). Each of the seven CVH components (smoking, body mass index, physical activity, diet, total cholesterol, blood pressure, and blood glucose) was scored per established criterion.   Results: The mean age of the twins was 55 years, 96% were whites, and 61% monozygotic. When considering twins as individuals, for every unit increase in CVH score (indicating better cardiovascular health), twins demonstrated faster cognitive processing speed (Trail B: – 5.6 s, 95% CI – 10.3, – 0.9; p = 0.03) and better story recall, both immediate (0.35, 95% CI 0.06, 0.62; p = 0.02) and delayed (0.39, 95% CI 0.08, 0.70; p = 0.01).   Conclusions: Better CVH is associated with better cognitive health in several domains. As suggested by within-pair analysis, this association is largely explained by familial factors, implying that early life exposures are shared determinants of both brain health and cardiovascular health."@en ;
    ns0:hasPubTitle "Association Between Cardiovascular Health and Cognitive Performance: A Twins Study"@en .

ns1:jad-v71-i3-JAD190244 ns0:hasKeywords "Dementia"@en,
        "risk factors"@en,
        "spatial analysis"@en,
        "spatial navigation"@en ;
    ns0:hasPubAbstract "Background: Dementia-related missing incidents are highly prevalent but still poorly understood. This is particularly true for environmental/geospatial risk factors, which might contribute to these missing incidents.   Objective: The study aimed to conduct a retrospective, observational analysis on a large sample of missing dementia patient case records provided by the police (n = 210), covering dates from January 2014 to December 2017. In particular, we wanted to explore 1) whether there were any hotspot regions of missing incidents and 2) the relationship between outdoor landmark density and missing incidents.   Methods: Global spatial autocorrelation (Moran’s I) was used to identify the potential hotspot regions for missing incidents. Meanwhile, spatial buffer and regression modelling were used to determine the relationship between outdoor landmark density and missing incidents.   Results: Our demographics measures replicated and extended previous studies of dementia-related missing incidents. Meanwhile, no hotspot regions for missing incidents were identified, while higher outdoor landmark density led to increased missing incidents.   Conclusion: Our results highlight that missing incidents do not occur in isolated hotspots of regions but instead are endemic in patients regardless of location. Higher outdoor landmark density emerges as a significant geospatial factor for missing incidents in dementia, which crucially informs future safeguarding/intervention studies."@en ;
    ns0:hasPubTitle "Geospatial Analysis of Environmental Risk Factors for Missing Dementia Patients"@en .

ns1:jad-v71-i3-JAD190261 ns0:hasKeywords "Aging"@en,
        "Alzheimer’s disease"@en,
        "apolipoprotein E"@en,
        "cognition"@en,
        "diabetes"@en,
        "metabolic syndrome"@en,
        "neuropsychology"@en,
        "vascular risk"@en ;
    ns0:hasPubAbstract "Metabolic syndrome (MetS) has been linked to increased risk of developing cognitive impairment and dementia including Alzheimer’s disease. It remains unclear whether and at what stage in the adult lifespan MetS and its components begin to alter the trajectory of cognitive performance. In the present study, 2,892 Framingham Offspring participants completed health assessments every four years since 1971 and underwent repeat neuropsychological testing from 1999 to 2014. We estimated the associations of levels and changes in cognitive trajectories with hazard of MetS using a joint growth/survival model. All models were adjusted for baseline age, sex, education, and smoking status. Findings showed that both mid-life and late-life MetS were associated with lower level of cognitive functioning but not cognitive trajectories. Associations were strongest among those who were nondemented and apolipoprotein (APOE) ɛ4 noncarriers. In addition, individuals with the most rapid cognitive decline were more likely to have MetS. The pattern of results showed that associations between MetS and cognition varied, depending upon whether the sample was stratified by genetic and cognitive status and whether we considered cognitive performance as a continuous variable or examined categorical groupings. Given that mid-life MetS was associated with poorer cognition at age 55, cognitive changes may occur early during the MetS process. Our findings suggest that those with MetS are at greater risk of dementia given their lower level of cognitive functioning and also suggest that MetS may be a risk factor for decline in the absence of known risk factors including the APOE ɛ4 allele."@en ;
    ns0:hasPubTitle "Metabolic Syndrome and Cognitive Trajectories in the Framingham Offspring Study"@en .

ns1:jad-v71-i3-JAD190295 ns0:hasKeywords "Alzheimer’s disease"@en,
        "dementia"@en,
        "endotoxins"@en,
        "inflammation"@en,
        "interleukin-6"@en,
        "lipopolysaccharide"@en,
        "lipopolysaccharide-binding protein"@en,
        "soluble cluster of differentiation-14"@en ;
    ns0:hasPubAbstract "Background: Identifying the mechanisms involved in the pathogenesis of Alzheimer’s disease (AD) remains crucially important. Chronic age-related low-grade inflammation is considered to be one such mechanism, although its causes are unclear. Lipopolysaccharide (LPS)-type endotoxins, a major component of the outer membrane of Gram-negative bacteria, are known as potent pro-inflammatory molecules. Therefore, we hypothesized that greater exposure to circulating LPS, potentially mediated by the inflammatory pathway, would be a key step of the onset of AD.   Objective: The aim of this study was to investigate the link between plasma endotoxin-exposure, inflammation, and AD.   Methods: Applying a nested case-control design, we evaluated the associations among baseline plasma endotoxin-exposure (assessed by measuring LPS-binding protein (LBP) and soluble cluster of differentiation-14 (sCD14) levels), inflammation (assessed by measuring interleukin-6 (IL6) levels), and the odds of developing AD over 12 years. Selected from a population-based cohort, 212 incident cases of AD were matched with 424 controls without dementia with regard to age, gender, and education level.   Results: After adjusting for a large set of confounders, including the use of anti-inflammatory drugs, only higher LBP levels were significantly associated with a 30% higher odds of developing AD over 12 years (OR 1.30, 95% CIs [1.07–1.59]), regardless of IL6 levels.   Conclusion: This large case-control study provides preliminary results concerning plasma endotoxin-exposure among the elderly and suggests that higher LBP levels, an acute-phase reactant involved in the pro-inflammatory response to LPS, are associated with higher odds of developing AD."@en ;
    ns0:hasPubTitle "Lipopolysaccharide-Binding Protein, Soluble CD14, and the Long-Term Risk of Alzheimer’s Disease: A Nested Case-Control Pilot Study of Older Community Dwellers from the Three-City Cohort"@en .

ns1:jad-v71-i3-JAD190341 ns0:hasKeywords "Dementia"@en,
        "Faroe Islands"@en,
        "incidence study"@en,
        "nationwide study"@en,
        "prevalence study"@en,
        "trend in incidence and prevalence"@en ;
    ns0:hasPubAbstract "Background: Dementia has become an important public health, economic, and social issue. Knowledge about prevalence, incidence, and trends of dementia in a country is of crucial importance. However, no studies of incidence or prevalence of dementia have been undertaken in the Faroe Islands.   Objectives: The aim was to estimate the overall and trend in incidence and prevalence of dementia among individuals ≥60 years in the Faroe Islands from 2010-2017.   Methods: Population-based register study where all individuals ≥60 years with a dementia diagnosis from January 2010 to December 2017 were identified. The overall crude and age-and-sex-specific incidence and prevalence was assessed.   Results: The overall crude incidence among individuals ≥60 years from 2010 to 2017 was 5.1 per 1000 individuals and the prevalence 22.5 per 1000 individuals. The age-and sex-standardized annual incidence of dementia fluctuated between 4.8 and 6.7 per 1000, with no clear secular trend while the age-and sex-standardized prevalence increased steadily from 14.5 in 2010 to 30.8 per 1000 individuals in 2017.   Conclusion: The age-standardized incidence or prevalence estimates in the Faroes seem to be lower than in other countries. The incidence was relatively stable in the period while the prevalence of dementia simultaneously increased."@en ;
    ns0:hasPubTitle "Trend in the Incidence and Prevalence of Dementia in the Faroe Islands"@en .

ns1:jad-v71-i3-JAD190371 ns0:hasKeywords "Alzheimer’s disease"@en,
        "anosognosia"@en,
        "awareness"@en,
        "self"@en,
        "self-assessment"@en ;
    ns0:hasPubAbstract "Background: People with Alzheimer’s disease (PwAD) remain able to speak coherently about their daily life for a long time, and their level of awareness could be determined through their discourse. In a grounded-theory approach, awareness of self and awareness of disease are intertwined and can be observed through three domains: mechanisms, objects and modes of expression.   Objective: Based on preliminary results, in this article, we present the ASDA (Awareness of Self and Disease Assessment), a new subjective measurement tool for awareness in PwAD. To consider its use in research and practice, we initially performed validation analyses, including internal consistency, test-retest reliability and interrater reliability analyses.   Methods: The new assessment tool consists of a semi-structured interview and ratings of 22 items divided into three categories. As part of our observational study, we assessed a sample of 28 PwAD who participated in four interviews (one every two weeks).   Results: The ASDA shows good homogeneity within the domains of awareness and a certain degree of stability between two measurement times and between investigators. Missing values in the results provided information regarding awareness levels within and across the subjects.   Conclusion: The results suggest that awareness could be assessed through subjective experience without reference to a comparison."@en ;
    ns0:hasPubTitle "Awareness of Self and Disease Assessment: Development and Validation of a Subjective Measure in People with Alzheimer’s Disease"@en .

ns1:jad-v71-i3-JAD190460 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cognitive disorders"@en,
        "dementia"@en,
        "exercise"@en,
        "microbiome"@en,
        "physical activity"@en,
        "probiotics"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is one of the most common forms of dementia, which cannot be cured at the moment. Therefore, researchers also look for the alternative approaches to its treatment. It is suggested that changes in human gut microbiome mediated by exercise could influence the development and progression of AD and a new term “muscle-gut-brain axis” is introduced. There is much evidence to support this assumption. The gut microbiology is closely related to a wide range of diseases of the nervous system and therefore any negative qualitative and quantitative changes in the composition of the gut microbiota can potentially contribute to the pathophysiology of AD. Research shows that the treatment of intestinal dysbiosis with probiotics/synbiotics/eubiotics can prevent or alleviate the symptoms of these chronic neurological diseases. Studies also point to the positive effects of movement on the health of seniors. A positive correlation can be found between cognitive functions and physical stress, both in the elderly and in AD patients. Even short-term interventions with a relatively low frequency seem to produce positive results, while physical activities can be performed by using relatively simple and cost-effective means. In addition, physical activity can significantly modulate gut microbiome. Thus, it can be concluded that physical activity in humans seems to correlate with gut microbiome, which can prevent the incidence and development of AD."@en ;
    ns0:hasPubTitle "“Muscle-Gut-Brain Axis”: Can Physical Activity Help Patients with Alzheimer’s Disease Due to Microbiome Modulation?"@en .

ns1:jad-v71-i3-JAD190485 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Lewy body disease"@en,
        "autopsy"@en,
        "cardiovascular disease"@en,
        "dementia"@en,
        "diabetes mellitus"@en,
        "hypertension"@en,
        "risk factors"@en,
        "vascular"@en ;
    ns0:hasPubAbstract "Background: Research concerning the potential roles of cardiovascular disease (CaVD) and diabetes mellitus (DM) as risk factors for Lewy body disease (LBD) is limited. These disorders are, however, established risk factors for vascular dementia (VaD) and have been proposed as risk factors for Alzheimer’s disease (AD).   Objective: The aim of this study was to investigate the prevalence of CaVD and DM in LBD and compare the results with previous findings in cases with AD, VaD, and mixed AD-VaD (MD).   Methods: Autopsy reports at the Clinical Department of Pathology in Lund from 2001–2018 were analyzed. All cases with a complete neuropathological diagnosis of LBD were selected, not distinguishing between subjects with clinical Parkinson disease dementia and dementia with Lewy bodies, on the condition of a clinical diagnosis of dementia. Clinical data were retrieved through the patients’ medical records and the Swedish National Diabetes Register (NDR) and compared with those of the AD, VaD, and MD cases.   Results: In LBD, there was less CaVD, significantly less DM (p = 0.002) and likewise significantly less hypertension (p < 0.001) than in VaD. The results of the LBD group were consistent with the results of the AD group.   Conclusion: Our findings of a low prevalence of CaVD and CaVD risk factors in LBD and in AD argue against the association between these risk factors and their contribution to the development of neurodegenerative diseases."@en ;
    ns0:hasPubTitle "Cardiovascular Disease, Diabetes Mellitus, and Hypertension in Lewy Body Disease: A Comparison with Other Dementia Disorders"@en .

ns1:jad-v71-i3-JAD190563 ns0:hasKeywords "Alzheimer’s disease"@en,
        "biomarkers"@en,
        "cellular adhesion molecules"@en,
        "cerebrospinal fluid"@en,
        "cerebrovascular disorders"@en,
        "dementia"@en,
        "particulate matter"@en ;
    ns0:hasPubAbstract "Background: Cerebrovascular diseases play an important role in dementia. Air pollution is associated with cardiovascular disease, with growing links to neurodegeneration. Prior studies demonstrate associations between fine particulate matter (PM2.5) and biomarkers of endothelial injury in the blood; however, no studies have evaluated these biomarkers in cerebrospinal fluid (CSF). Objective: We evaluate associations between short-term and long-term PM2.5 exposure with CSF vascular cell adhesion molecule-1 (VCAM-1) and e-selectin in cognitively normal and mild cognitive impairment (MCI)/Alzheimer’s disease (AD) individuals. Methods: We collected CSF from 133 community volunteers at VA Puget Sound between 2001–2012. We assigned short-term PM2.5 from central monitors and long-term PM2.5 based on annual average exposure predictions linked to participant addresses. We performed analyses stratified by cognitive status and adjusted for key covariates with tiered models. Our primary exposure windows for the short-term and long-term analyses were 7-day and 1-year averages, respectively. Results: Among cognitively normal individuals, a 5 μg/m3 increase in 7-day and 1-year average PM2.5 was associated with elevated VCAM-1 (7-day: 35.4 (9.7, 61.1) ng/ml; 1-year: 51.8 (6.5, 97.1) ng/ml). A 5 μg/m3 increase in 1-year average PM2.5, but not 7-day average, was associated with elevated e-selectin (53.3 (11.0, 95.5) pg/ml). We found no consistent associations among MCI/AD individuals. Conclusions: We report associations between short-term and long term PM2.5 and CSF biomarkers of vascular damage in cognitively normal adults. These results are aligned with prior research linking PM2.5 to vascular damage in other biofluids as well as emerging evidence of the role of PM2.5 in neurodegeneration."@en ;
    ns0:hasPubTitle "Fine Particulate Matter Exposure and Cerebrospinal Fluid Markers of Vascular Injury"@en .

ns1:jad-v71-i3-JAD190574 ns0:hasKeywords "Aggregometry"@en,
        "Alzheimer’s disease"@en,
        "blood-based biomarker"@en,
        "platelet morphology"@en ;
    ns0:hasPubAbstract "Background: Early diagnosis of Alzheimer’s disease (AD) is challenging, and easily accessible biomarkers are an unmet need. Blood platelets frequently serve as peripheral model for studying AD pathogenesis and might represent a reasonable biomarker source.   Objective: In the present study, we investigated the potential to differentiate AD patients from healthy controls (HC) based on blood count, platelet morphology, and function as well as molecular markers at the time of first clinical diagnosis.   Methods: Blood samples from 40 AD patients and 29 age-matched HC were included for determination of 78 parameter by blood counting, platelet morphometry, aggregometry, flow cytometry (CD62P, CD63, activated fibrinogen receptor), protein quantification of nicotinic acetylcholine receptor α7 (nAChRα7) and caveolin-1 (CAV-1), and miRNA quantification (miR-26b, miR-199a, miR-335). Group comparison between patients and controls was performed in univariate and multivariate statistical analyses.   Results: AD patients showed significantly lower aggregation response to ADP and arachidonic acid and significantly decreased CD62P and CD63 surface expression induced by ADP and U46619 compared to HC. Relative nAChRα7 and CAV-1 expression was significantly higher AD platelets than in HC. Multivariate analysis of 63 parameter revealed significant differences between AD patients and healthy controls. The best performing feature model revealed a sensitivity of 96.6%, a specificity of 80.0%, and a positive predictive value of 89.3%. No grouping could be achieved by using single parameter groups.   Conclusion: Significant differences between platelet characteristics from AD patients and HC at the time of first clinical diagnosis were observed. The best performing parameter can be used as a blood-based biomarker for AD diagnosis in a multivariate model in addition to the standardized mental tests."@en ;
    ns0:hasPubTitle "Multivariate Platelet Analysis Differentiates Between Patients with Alzheimer’s Disease and Healthy Controls at First Clinical Diagnosis"@en .

ns1:jad-v71-i3-JAD190596 ns0:hasKeywords "Alzheimer’s disease"@en,
        "IGF1R"@en,
        "miR-223-3p"@en,
        "sevoflurane"@en ;
    ns0:hasPubAbstract "Administration of sevoflurane (SEVO) may induce learning and memory deficits, which increases the chances of developing Alzheimer’s disease. Here, we studied the effects of SEVO exposure on rats with a focus on the role of insulin-like growth factor (IGF) signaling. SEVO exposure significantly increased neuron cell apoptosis, and caused poor performance of the rats in behavior tests, by suppressing IGF-1 receptor (IGF1R). Bioinformatic analysis predicted microRNA(miR)-223-3p as an IGF1R-binding miRNA, the level of which increased in neurons after exposure to SEVO. In vitro, miR-223-3p suppressed the translation of IGF1R in neural cells. Moreover, transfection with antisense of miR-223-3p significantly attenuated SEVO exposure-induced neuron cell apoptosis. Taken together, these data suggest that SEVO-induced miR-223-3p upregulation suppresses IGF1R to impair IGF signaling, which subsequently leads to learning and memory impairments."@en ;
    ns0:hasPubTitle "Sevoflurane Affects Memory Through Impairing Insulin-Like Growth Factor Receptor Signaling"@en .

ns1:jad-v71-i3-JAD190604 ns0:hasKeywords "Aging"@en,
        "Alzheimer’s disease"@en,
        "mass spectrometry"@en,
        "methylation"@en,
        "phosphorylation"@en,
        "post-translational modification"@en,
        "tau protein"@en ;
    ns0:hasPubAbstract "Tau is a microtubule-associated protein that normally interacts in monomeric form with the neuronal cytoskeleton. In Alzheimer’s disease, however, it aggregates to form the structural component of neurofibrillary lesions. The transformation is controlled in part by age- and disease-associated post-translational modifications. Recently we reported that tau isolated from cognitively normal human brain was methylated on lysine residues, and that high-stoichiometry methylation depressed tau aggregation propensity in vitro. However, whether methylation stoichiometry reached levels needed to influence aggregation propensity in human brain was unknown. Here we address this problem using liquid chromatography–tandem mass spectrometry approaches and human-derived tau samples. Results revealed that lysine methylation was present in soluble tau isolated from cognitively normal elderly cases at multiple sites that only partially overlapped with the distributions reported for cognitively normal middle aged and AD cohorts, and that the quality of methylation shifted from predominantly dimethyl-lysine to monomethyl-lysine with aging and disease. However, bulk mol methylation/mol tau stoichiometries never exceeded 1 mol methyl group/mol tau protein. We conclude that lysine methylation is a physiological post-translational modification of tau protein that changes qualitatively with aging and disease, and that pharmacological elevation of tau methylation may provide a means for protecting against pathological tau aggregation."@en ;
    ns0:hasPubTitle "Quantification of Tau Protein Lysine Methylation in Aging and Alzheimer’s Disease"@en .

ns1:jad-v71-i4-JAD190311 ns0:hasKeywords "Emotional destination memory"@en,
        "Mu suppression"@en,
        "fronto-temporal"@en,
        "mild cognitive impairment"@en,
        "mirror neurons"@en ;
    ns0:hasPubAbstract "Leading theories of affect development and empirical studies suggest that emotion can enhance memory in older adults. Destination memory which is defined as the ability to remember to whom we told a piece of information is being found to be compromised in aging. In the present study, we sought to assess destination memory using emotional stimuli (Emotional Destination Memory, EDM) in 16 older adults with mild cognitive impairment (MCI) and 16 healthy controls and shed light onto its potential neurophysiological aspects. We measured Mu suppression in frontal and temporal regions via EEG in real time while participants performed the task of EDM. Results showed no group differences in task performance but significant differences in fronto-temporal activations, specifically in electrodes F7 and F8. Differential Mu rhythm pattern was observed between healthy controls and MCI with the first exhibiting Mu suppression and the last Mu enhancement. Furthermore, Mu enhancement in temporal electrodes within the MCI group was associated with lower scores on EDM. The absence of group differences in the task can be explained by the fact that even if there are underlying structural or functional deficits in the MCI group, these deficits are manifested only at neurophysiological level and not at a behavioral level, which is a common pattern in the process of cognitive decline in its initial phases. The overall findings reveal that, even if there are not any behavioral decrements in MCI patients, they show reduced activations in fronto-temporal regions and this can be attributed to general impairment in emotional destination memory due to possible mirror neuron deficiency."@en ;
    ns0:hasPubTitle "The Pattern of Mu Rhythm Modulation During Emotional Destination Memory: Comparison Between Mild Cognitive Impairment Patients and Healthy Controls"@en .

ns1:jad-v71-i4-JAD190345 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Avicenna"@en,
        "Persian medicine"@en,
        "dementia"@en,
        "history of medicine"@en ;
    ns0:hasPubAbstract "According to the World Health Organization (WHO), dementia is a disorder that occurs as result of a neurodegenerative process in brain, and usually is chronic or progressive by nature. Most descriptions of senile dementia date back to Alois Alzheimer. In 1906, Alzheimer described the first patient, Auguste Deter, who suffered from the disorder that later became known as Alzheimer’s disease. Although, the history of the disease before 1906 is quite rich, little has been said about the contributions of ancient and medieval physicians to the understanding of dementia. Over the centuries, the concept of senile dementia changed from an inevitable mental decline with aging, to different sets of clinical features with narrow limits of diagnosis of a disease in its own right. Documentation of the historical origins of prevention, diagnosis, and therapies of dementia would make an important contribution to a more complete understanding of this pathological degeneration of dementia. The present review focuses on the contributions of Avicenna (AD 980–1037) to the development of diagnosis and the discovery of etiology of different forms of dementia, with the goal of revealing the extent to which dementia was understood in the golden age of Islam in Persia."@en ;
    ns0:hasPubTitle "Avicenna (980–1037 CE) and his Early Description and Classification of Dementia"@en .

ns1:jad-v71-i4-JAD190589 ns0:hasKeywords "Cognitive dysfunction"@en,
        "digital medicine"@en,
        "disclosure"@en,
        "information dissemination"@en,
        "informed consent"@en,
        "mobile health"@en,
        "patient rights"@en,
        "privacy"@en,
        "research ethics"@en,
        "return of results"@en ;
    ns0:hasPubAbstract "The implementation of digital health technologies into research studies for Alzheimer’s disease and other clinical populations is on the rise. Digital tools and strategies create opportunities to further expand the framework for conducting research beyond the traditional medical research model. The combination of participatory and community-based research methods, electronic health records, and the creation of multi-dimensional, large-scale research platforms to support precision medicine, along with the Internet of Things era, have led to more engaged and informed research participants. Research participants increasingly possess an expectation they will play a critical role as partners in the design and conduct of research. Moreover, there is growing interest among research participants to have access to individual-level research data in real-time and/or at study completion. The traditional medical research model is largely one-directional where participants contribute data that is analyzed by researchers to yield generalizable knowledge. In this Ethics Review, we discuss a framework for a more nuanced intermediate research model, which is largely bidirectional and individually customized. Based on the seven ethical guidelines adopted by the National Institutes of Health, we speak to the ethical challenges of this intermediate type research. We also introduce a concept we are calling “MyTerms,” in which prospective participants tailor the terms and conditions of informed consent to their personalized preferences for receiving information, including research results. Digital health technologies offer a convenient and flexible approach for researchers to develop protocols that make it possible for participants to obtain access to their study data in a personalized and meaningful way."@en ;
    ns0:hasPubTitle "From Return of Information to Return of Value: Ethical Considerations when Sharing Individual-Level Research Data"@en .

ns1:jad-v71-is1-JAD180848 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "mild cognitive impairment"@en,
        "mobility"@en,
        "physical function"@en ;
    ns0:hasPubAbstract "Background: Impaired physical function (i.e., slowing of gait, muscle weakness, and poor mobility) is common in older adults with cognitive impairment and dementia. Evidence suggests that cerebral small vessel disease, specifically white matter lesions (WMLs), is associated with impaired physical function, but little research has been conducted to understand the specific role of Alzheimer’s disease pathology in physical outcomes.   Objective: The objective of this study was to examine the association between cerebral amyloid-β (Aβ) deposition and physical function in people with cognitive impairment.   Methods: Thirty participants completed an 11C Pittsburgh compound B (PIB) position emission tomography (PET) scan to quantify global Aβ deposition using standardized uptake value ratio (SUVR). We assessed usual gait speed, muscle strength of the lower extremities, balance, and functional mobility using the Short Physical Performance Battery (SPPB) and the Timed Up and Go Test (TUGT). Multiple linear regression analyses examined the association between Aβ and each measure of physical function, adjusting for age, body mass index, and WML load.   Results: Global PIB SUVR was significantly associated with usual gait speed (β= –0.52, p = 0.01) and SPPB performance (β= –0.47, p = 0.02), such that increased Aβ deposition was associated with reduced performance on both measures. Global PIB SUVR was not significantly associated with TUGT performance (β= 0.32, p = 0.08).   Conclusions: Cerebral Aβ deposition is associated with reduced gait speed, muscle strength, and balance in older adults with cognitive impairment independent of WML load. However, Aβ deposition was not associated with functional mobility."@en ;
    ns0:hasPubTitle "Cerebral Amyloid-β Deposition Is Associated with Impaired Gait Speed and Lower Extremity Function"@en .

ns1:jad-v71-is1-JAD181157 ns0:hasKeywords "Apolipoprotein E4"@en,
        "cognitive dysfunction"@en,
        "gait variability"@en,
        "specific cognitive domains"@en,
        "walking speed"@en,
        "walking speed reserve"@en ;
    ns0:hasPubAbstract "Background: Gait impairments are emerging predictors of dementia. However, few studies have examined whether gait predicts decline in specific cognitive domains.   Objective: This study aimed to determine whether gait speed or other gait characteristics were associated with decline in specific cognitive domains and the role of the ApoE4 genotype in modifying these associations.   Methods: Participants (n = 410; mean age 72.0±7.0 years) were randomly selected from the electoral roll. At baseline, gait speed was assessed using the GAITRite walkway. Gait variability in step time, step length, step width, and double support time (DST) was calculated as the standard deviation of each measure across all steps. In a subsample (n = 177), speed was measured under fast pace. The difference between usual and fast pace was calculated. At baseline, 2.6 and 4.6 years processing speed, memory, executive and visuospatial function were measured using neuropsychological tests. Multivariable mixed models were used to examine 1) associations between gait and the different cognitive domains over time and 2) whether the presence of ApoE4 genotype modified these associations.   Results: Higher DST variability was associated with greater decline in memory (p for interaction 0.03). Slow gait speed predicted decline in processing speed (p = 0.02) and visuospatial function (p = 0.03). In ApoE4 carriers, gait speed also predicted decline in memory (p = 0.02). Other gait characteristics did not predict decline in any of the cognitive domains (p > 0.05).   Conclusions: These findings add to the evidence that gait is an early indicator of cognitive decline, but that specific gait measures may provide diagnostic insights into specific cognitive domains."@en ;
    ns0:hasPubTitle "Gait Characteristics and Cognitive Decline: A Longitudinal Population-Based Study"@en .

ns1:jad-v71-is1-JAD181174 ns0:hasKeywords "Accidental falls"@en,
        "daily-life gait"@en,
        "dementia"@en,
        "executive function"@en,
        "neurocognitive disorders"@en,
        "physical activity"@en,
        "walking speed"@en ;
    ns0:hasPubAbstract "Understanding the characteristics of physical activity and daily-life gait in older people with dementia may help identify those at risk of negative health outcomes and inform targeted interventions. Questionnaires are often used to assess physical activity but may be more affected by recall bias in people with dementia and provide little information about daily-life gait characteristics. The aim of the study was to assess differences in daily-life activity levels and gait characteristics between community-dwelling older people with mild to moderate dementia (n = 45; mean age 81±6 years, 42% female) and age-sex matched (1:2) cognitively-healthy controls (n = 90). Participants wore a tri-axial accelerometer (DynaPort MoveMonitor, McRoberts) on their lower back for 7 days and were assessed on neuropsychological and physical performance. Compared to age-sex matched controls, participants with dementia demonstrated reduced daily-life activity (fewer steps per day, fewer and shorter walking bouts, and lower daily walk time) and walking intensity (reduced speed, stride length and cadence). Participants with dementia also had significantly increased within-walk variability (stride time) and less regular gait (higher sample entropy). Within the group of participants with dementia, higher daily-life activity levels were associated with greater self-reported physical activity and better executive function. Fallers (1+ falls past year) with dementia had significantly reduced daily-life activity and walking speed when compared to non-fallers with dementia. In conclusion, people with dementia are less active in daily-life and present with significant impairments across multiple gait domains when compared to age-sex matched controls. These findings highlight opportunities for targeted interventions and support further research to examine interventions aimed at addressing these deficits."@en ;
    ns0:hasPubTitle "Older People with Dementia Have Reduced Daily-Life Activity and Impaired Daily-Life Gait When Compared to Age-Sex Matched Controls"@en .

ns1:jad-v72-i1-JAD190430 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid"@en,
        "burden of illness"@en,
        "florbetapir F18"@en,
        "mild Alzheimer’s dementia"@en,
        "mild cognitive impairment"@en ;
    ns0:hasPubAbstract "Background: Alzheimer’s disease (AD) is one of the costliest diseases in the United States.   Objective: To describe aspects of real-world patient and caregiver burden in patients with clinician-diagnosed early AD, including mild cognitive impairment (MCI) and mild dementia (MILD) due to AD.   Methods: Cross-sectional assessment of GERAS-US, a 36-month cohort study of patients seeking care for early AD. Eligible patients were categorized based on study-defined categories of MCI and MILD and by amyloid positivity [+] or negativity [–] within each severity cohort. Demographic characteristics, health-related outcomes, medical history, and caregiver burden by amyloid status are described.   Results: Of 1,198 patients with clinician-diagnosed early AD, 52% were amyloid[+]. For patients in both cohorts, amyloid[–] was more likely to occur in those with: delayed time to an AD-related diagnosis, higher rates of depression, poorer Bath Assessment of Subjective Quality of Life in Dementia scores, and Hispanic/Latino ethnicity (all p < 0.05). MILD[–] patients (versus MILD[+]) were more medically complex with greater rates of depression (55.7% versus 40.4%), sleep disorders (34.3% versus 26.5%), and obstructive pulmonary disease (11.8% versus 6.6%); and higher caregiver burden (Zarit Burden Interview) (all p < 0.05). MILD[+] patients had lower function according to the Functional Activities Questionnaire (p < 0.001), yet self-assessment of cognitive complaints across multiple measures did not differ by amyloid status in either severity cohort.   Conclusions: Considerable patient and caregiver burden was observed in patients seeking care for memory concerns. Different patterns emerged when both disease severity and amyloid status were evaluated underscoring the need for further diagnostic assessment and care for patients.   Study Registry: H8A-US-B004; ClinicalTrials.gov: NCT02951598."@en ;
    ns0:hasPubTitle "Observation of Patient and Caregiver Burden Associated with Early Alzheimer’s Disease in the United States: Design and Baseline Findings of the GERAS-US Cohort Study1"@en .

ns1:jad-v72-i1-JAD190564 ns0:hasKeywords "Apolipoprotein E"@en,
        "basolateral amygdala"@en,
        "conditioned taste aversion"@en,
        "extinction"@en,
        "gustatory cortex"@en,
        "hippocampus"@en,
        "learning"@en,
        "medial prefrontal cortex"@en,
        "synaptic plasticity"@en,
        "synaptophysin"@en,
        "taste"@en,
        "vesicular GABA transporter"@en,
        "vesicular glutamate transporter"@en,
        "young age"@en ;
    ns0:hasPubAbstract "The E4 allele of apolipoprotein (apoE4) is the primary genetic risk factor for late onset Alzheimer’s disease (AD), yet the exact manner in which apoE4 leads to the development of AD is undetermined. Human and animal studies report that apoE4-related memory deficits appear earlier than the AD clinical manifestation, thus suggesting the existence of early, pre-pathological, apoE4 impairments that may later lead to AD onset. While current research regards the hippocampus as the initial and primary effected locus by apoE4, we presently investigate the possibility that apoE4 innately impairs any brain area that requires synaptic plasticity. To test this hypothesis, we trained young (3-4-month-old) target-replacement apoE3 and apoE4 mice in conditioned taste aversion (CTA) acquisition and extinction learnings— hippocampus-independent learnings that are easily performed at a young age. Synaptic vesicular markers analysis was conducted in the gustatory cortex (GC), basolateral amygdala (BLA), medial prefrontal cortex (mPFC), and hippocampal CA3 to reveal underlying apoE4-related impairments. We have found that young apoE4 mice are severely impaired in CTA acquisition and extinction learning. CTA acquisition impairments were correlated with reduced vGat and vGlut levels in the BLA and GC, but not in the CA3. CTA extinction was correlated with lower synaptophysin and vGlut levels in the mPFC, a central region in CTA extinction. Our results support apoE4-related early-life plasticity impairments that precede the AD clinical manifestations and affect any brain area that depends on extensive plasticity; early impairments that may promote the development of AD pathologies later in life."@en ;
    ns0:hasPubTitle "Extra-Hippocampal Learning Deficits in Young Apolipoprotein E4 Mice and Their Synaptic Underpinning"@en .

ns1:jad-v72-i1-JAD190568 ns0:hasKeywords "Alzheimer’s disease"@en,
        "bioinformatics"@en,
        "genetics"@en,
        "genomics"@en,
        "long noncoding RNA"@en ;
    ns0:hasPubAbstract "Most of the loci identified by genome-wide association studies (GWAS) for late-onset Alzheimer’s disease (LOAD) are in strong linkage disequilibrium (LD) with nearby variants all of which could be the actual functional variants, often in non-protein-coding regions and implicating underlying gene regulatory mechanisms. We set out to characterize the causal variants, regulatory mechanisms, tissue contexts, and target genes underlying these associations. We applied our INFERNO algorithm to the top 19 non-APOE loci from the IGAP GWAS study. INFERNO annotated all LD-expanded variants at each locus with tissue-specific regulatory activity. Bayesian co-localization analysis of summary statistics and eQTL data was performed to identify tissue-specific target genes. INFERNO identified enhancer dysregulation in all 19 tag regions analyzed, significant enrichments of enhancer overlaps in the immune-related blood category, and co-localized eQTL signals overlapping enhancers from the matching tissue class in ten regions (ABCA7, BIN1, CASS4, CD2AP, CD33, CELF1, CLU, EPHA1, FERMT2, ZCWPW1). In several cases, we identified dysregulation of long noncoding RNA (lncRNA) transcripts and applied the lncRNA target identification algorithm from INFERNO to characterize their downstream biological effects. We also validated the allele-specific effects of several variants on enhancer function using luciferase expression assays. By integrating functional genomics with GWAS signals, our analysis yielded insights into the regulatory mechanisms, tissue contexts, genes, and biological processes affected by noncoding genetic variation associated with LOAD risk."@en ;
    ns0:hasPubTitle "Inferring the Molecular Mechanisms of Noncoding Alzheimer’s Disease-Associated Genetic Variants"@en .

ns1:jad-v72-i2-JAD190196 ns0:hasKeywords "APOE"@en,
        "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "neuropathology"@en,
        "suicide"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Background: Aggregation of abnormal phosphorylated tau in brain stem areas may be a possible early pathological manifestation of Alzheimer’s disease (AD).   Objective: This study aimed to explore the prevalence of cases with AD-related pathology in subjects <40 years of age and to explore the association of such pathology, neuropsychiatric symptoms, and APOE genotype.   Method: We conducted brain immunohistochemistry for 189 cases <40 years of age (mean±standard deviation age 25.3±13.1 years). Tau positive cases were then assessed for the distribution of tau pathology in the locus ceruleus (LC), raphe nucleus (RN), and entorhinal cortex (ErC), and the distinction between neuronal threads and cellular inclusions. Apolipoprotein E (APOE) genotype was also examined.   Results: Tau pathology was detected in 135 cases (71.4%; 13–39 years; only LC, 23 cases; only RN, 4 cases; only ErC, 35 cases; LC+RN, 3 cases; LC+ErC, 57 cases; all three regions, 10 cases). The prevalence of thread pathology was higher than that of cellular inclusions. Significantly higher prevalence of the APOE ɛ2 allele were found in 10–39 years of age natural death cases (p < 0.05). Amyloid-β deposition was found in only 7 cases, along with a significantly high frequency of the ɛ4 allele (p < 0.05). While a past history of psychiatric disease was a significant risk factor for suicide, AD-related pathology was not associated with suicide.   Conclusions: Both the brain stem and entorhinal cortex was the initial site of tau pathology in many younger subjects. AD-related pathology may not be a significant accelerating factor for suicide in younger subjects."@en ;
    ns0:hasPubTitle "Tau and Amyloid-β Pathology in Japanese Forensic Autopsy Series Under 40 Years of Age: Prevalence and Association with APOE Genotype and Suicide Risk"@en .

ns1:jad-v72-i2-JAD190298 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Cathepsin B"@en,
        "Porphyromonas gingivalis infection"@en,
        "interleukin 1β"@en,
        "monocytes/macrophages"@en,
        "nuclear factor-kappa B"@en,
        "peripheral amyloid-β"@en,
        "systemic inflammation"@en ;
    ns0:hasPubAbstract "Abnormal accumulation of amyloid-β (Aβ) in the brain is the most significant pathological hallmark of Alzheimer’s disease (AD). We have found that chronic systemic exposure to lipopolysaccharide of Porphyromonas gingivalis (P. gingivalis) induces the accumulation of Aβ in the brain of middle-aged mice. On the other hand, recent research has shown that circulating Aβ is transferred into the brain; however, the involvement of chronic systemic P. gingivalis infection in the peripheral Aβ metabolism is unknown. We hypothesized that chronic P. gingivalis infection expands Aβ pools in peripheral inflammatory tissues and thereby contributes to the accumulation of Aβ in the brain of patients with periodontitis. We showed that the increased expression of IL-1β, AβPP770, CatB, Aβ1-42, and Aβ3-42 was mainly co-localized with macrophages in the liver of P. gingivalis infected mice. Blocking CatB and NF-κB significantly inhibited the P. gingivalis-induced expression of IL-1β, AβPP770, Aβ1-42, and Aβ3-42 in RAW264.7 cells. Aβ3-42, but not Aβ1-42, induced the significant death of macrophages, and the reduction of phagocytic abilities induced by Aβ3-42 tended to be higher than that induced by Aβ1-42. Additionally, the expression of AβPP770, CatB, Aβ1-42, and Aβ3-42 was determined in the macrophages of gingival tissues from periodontitis patients. These findings indicate that chronic systemic P. gingivalis infection induces the Aβ accumulation in inflammatory monocytes/macrophages via the activation of CatB/NF-κB signaling, thus suggesting monocytes/macrophages serve as a circulating pool of Aβ in patients with periodontitis. Taken together, CatB may be a novel therapeutic target for preventing the periodontitis-related AD initiation and pathological progression."@en ;
    ns0:hasPubTitle "Porphyromonas gingivalis Infection Induces Amyloid-β Accumulation in Monocytes/Macrophages"@en .

ns1:jad-v72-i2-JAD190571 ns0:hasKeywords "Bereavement"@en,
        "Clinical Practice Research Datalink"@en,
        "dementia"@en,
        "diagnosis"@en,
        "epidemiology"@en ;
    ns0:hasPubAbstract "Background: In the UK, an estimated one third of people with dementia have not received a diagnosis. Good evidence suggests that dementia risk is increased among widowed individuals; however, it is not clear if they are being diagnosed in routine primary care.   Objective: This study aimed to investigate if bereavement influenced the probability of having received a dementia diagnosis.   Methods: A population-based cohort study using UK electronic health records, between 1997 and 2017, among 247,586 opposite-sex partners. Those experiencing partner bereavement were matched (age, sex, and date of bereavement) to a non-bereaved person living in a partnership. Multivariate cox regression was performed.   Results: Partner bereavement was associated with an increased risk of receiving a diagnosis of dementia in the first three months (hazard ratio (HR) 1.43, 95% CI 1.20–1.71) and first six months (HR 1.24, 95% CI 1.09–1.41), while there was a small reduced risk of getting a dementia diagnosis over all follow-up (HR 0.94, 95% CI 0.89–0.98).   Conclusions: Partner bereavement appears to lead to a short-term increased risk of the surviving partner receiving a diagnosis of dementia, suggesting that bereavement unmasks existing undiagnosed dementia. Over the longer term, however, bereaved individuals are less likely to have a diagnosis of dementia in their health records than non-bereaved individuals."@en ;
    ns0:hasPubTitle "Partner Bereavement and Detection of Dementia: A UK-Based Cohort Study Using Routine Health Data"@en .

ns1:jad-v72-i2-JAD190628 ns0:hasKeywords "2017LCSY345"@en,
        "Attention"@en,
        "electroencephalography"@en,
        "eye movement"@en,
        "mild cognitive impairment"@en,
        "multimodal detection"@en ;
    ns0:hasPubAbstract "Background: Detecting subtle changes in visual attention from electroencephalography (EEG) and the perspective of eye movement in mild cognitive impairment (MCI) patients can be of great significance in screening early Alzheimer’s disease (AD) in a large population at primary care.   Objective: We proposed an automatic, non-invasive, and quick MCI detection approach based on multimodal physiological signals for clinical decision-marking.   Methods: The proposed model recruited 152 patients with MCI and 184 healthy elderly controls (HC) who underwent EEG and eye movement signal recording under a visual stimuli task, as well as other neuropsychological assessments. Forty features were extracted from EEG and eye movement signals by linear and nonlinear analysis. The features related to MCI were selected by logistic regression analysis. To evaluate the efficacy of this MCI detection approach, we applied the same procedures to achieve the Clinical model, EEG model, Eye movement model, EEG+ Clinical model, Eye movement+ Clinical model, and Combined model, and compared the classification accuracy between the MCI and HC groups with the above six models.   Results: After the penalization of logistic regression analysis, five features from EEG and eye movement features exhibited significant differences (p < 0.05). In the classification experiment, the combined model resulted in the best accuracy. The average accuracy for the Clinical/EEG/Eye movement/EEG+ Clinical/Eye movement+ Clinical/Combined model was 68.69%, 61.79%, 73.13%, 69.46%, 75.61%, and 81.51%, respectively.   Conclusion: These results suggest that the proposed MCI detection tool has the potential to screen MCI patients from HCs and may be a powerful tool for personalized precision MCI screening in the large-scale population under primary care condition."@en ;
    ns0:hasPubTitle "A Novel Detection Tool for Mild Cognitive Impairment Patients Based on Eye Movement and Electroencephalogram"@en .

ns1:jad-v72-i2-JAD190635 ns0:hasKeywords "Alzheimer’s disease"@en,
        "USP13"@en,
        "amyloid"@en,
        "tau"@en,
        "ubiquitin"@en ;
    ns0:hasPubAbstract "Ubiquitin Specific Protease-13 (USP13) is a de-ubiquinating enzyme that regulates protein ubiquitination and clearance. The role of USP13 is largely unknown in neurodegeneration. In this study we aim to demonstrate whether tau accumulation and/or clearance depends on ubiquitination/de-ubiquitination via USP-13. We used transgenic animal models of human amyloid precursor protein (APP) or P301L tau mutations and genetically knocked-down USP13 expression via shRNA to determine USP13 effects on tau ubiquitination and levels. We found a two-fold increase of USP13 levels in postmortem Alzheimer’s disease (AD) brains. USP13 knockdown significantly increased the activity of the 20S proteasome and reduced the levels of hyper-phosphorylated tau (p-tau) in primary cortical neurons. USP13 knockdown also reduced the levels of amyloid and increased p-tau ubiquitination and clearance in transgenic animal models that overexpress murine tau as a result of the expression of familial APP mutations (TgAPP) and the human mutant P301L tau (rTg4510), respectively. Clearance of p-tau appears to be mediated by autophagy in these animal models. Taken together, these data suggest that USP13 knockdown reduces p-tau accumulation via regulation of ubiquitination/de-ubiquitination and mediates its clearance via autophagy and/or the proteasome. These results suggest that USP13 inhibition may be a therapeutic strategy to reduce accumulation of plaques and toxic p-tau in AD and human tauopathies."@en ;
    ns0:hasPubTitle "Ubiquitin Specific Protease 13 Regulates Tau Accumulation and Clearance in Models of Alzheimer’s Disease"@en .

ns1:jad-v72-i2-JAD190696 ns0:hasKeywords "Acceptability"@en,
        "activity scheduling"@en,
        "behavioral activation"@en,
        "behavioral therapy"@en,
        "dementia"@en,
        "feasibility"@en,
        "low mood"@en,
        "pleasant events"@en,
        "randomized controlled trial"@en ;
    ns0:hasPubAbstract "Engaging in meaningful and enjoyable activities is an important contributor to well-being and maintaining good quality of life. There is a paucity of randomized controlled trials of interventions supporting people with mild dementia to engage in meaningful and purposeful activity. The aim of this study was to assess whether Behavioral Activation (BA) is an acceptable psychological intervention for people with mild dementia and whether a large-scale trial is feasible. Participants were randomly assigned to BA (n = 42) or treatment as usual (TAU) (n = 21). BA aimed at increasing engagement in enjoyable and meaningful activity, and preventing low mood. Follow-up was at 3 and 6 months. Assessors were blind to treatment allocation (trial registration number: ISRCTN75503960). Retention rate was above 80% at both assessment time points. Treatment acceptability and credibility were high. Depressive symptoms remained unchanged in both groups. There was evidence of improvement associated with BA for every day function (–3.92, 95% Confidence Interval (CI) –6.87 to –0.97), and engagement in meaningful and enjoyable activity (5.08, 95% CI 0.99 to 9.16) post-treatment (3 months) in comparison to TAU. Both carer-rated patient health-related quality of life (0.16, 95% CI 0.04 to 0.28) and physical health (11.31, 95% CI 2.03 to 20.59) showed evidence of improvement at 3 months. Improvements in meaningful and enjoyable activity were maintained at 6 months. BA for people with mild dementia is feasible and acceptable and may be associated with clinically significant changes in function and quality of life. A full scale randomized controlled trial of clinical effectiveness is now needed."@en ;
    ns0:hasPubTitle "Behavioral Activation for Promoting Well-Being in Mild Dementia: Feasibility and Outcomes of a Pilot Randomized Controlled Trial"@en .

ns1:jad-v72-i2-JAD190704 ns0:hasKeywords "Alzheimer’s disease"@en,
        "computer vision"@en,
        "feature extraction"@en,
        "individual grey matter"@en,
        "machine learning"@en,
        "magnetic resonance imaging"@en ;
    ns0:hasPubAbstract "In this research work, machine learning techniques are used to classify magnetic resonance imaging brain scans of people with Alzheimer’s disease. This work deals with binary classification between Alzheimer’s disease and cognitively normal. Supervised learning algorithms were used to train classifiers in which the accuracies are being compared. The database used is from The Alzheimer’s Disease Neuroimaging Initiative (ADNI). Histogram is used for all slices of all images. Based on the highest performance, specific slices were selected for further examination. Majority voting and weighted voting is applied in which the accuracy is calculated and the best result is 69.5% for majority voting."@en ;
    ns0:hasPubTitle "Volumetric Histogram-Based Alzheimer’s Disease Detection Using Support Vector Machine"@en .

ns1:jad-v72-i2-JAD190888 ns0:hasKeywords "Alzheimer’s disease"@en,
        "prefrontal cortex"@en,
        "recognition memory"@en,
        "repetitive transcranial magnetic stimulation"@en ;
    ns0:hasPubAbstract "Background: The lack of effective pharmacological or behavioral interventions for memory impairments associated with Alzheimer’s disease (AD) emphasizes the need for the investigation of approaches based on neuromodulation.   Objective: This study examined the effects of inhibitory repetitive transcranial magnetic stimulation (rTMS) of prefrontal cortex on recognition memory in AD patients.   Methods: In a first experiment, 24 mild AD patients received sham and real 1Hz rTMS over the left and right dorsolateral prefrontal cortex (DLPFC), in different sessions, between encoding and retrieval phases of a non-verbal recognition memory task. In a second experiment, another group of 14 AD patients underwent sham controlled repeated sessions of 1Hz rTMS of the right DLPFC across a two week treatment. Non-verbal recognition memory task was performed at baseline, at the end of the two weeks period and at a follow up of 1 month.   Results: Right real rTMS significantly improved memory performance compared to right sham rTMS (p = 0.001). Left real rTMS left the memory performance unchanged as compared with left sham rTMS (p = 0.46). The two sham conditions did not differ between each other (p = 0.24). In the second experiment, AD patients treated with real rTMS showed an improvement of memory performance at the end of the two weeks treatment (p = 0.0009), that persisted at 1-month follow-up (p = 0.002).   Conclusion: These findings provide evidence that inhibitory rTMS over the right DLPFC can improve recognition memory function in AD patients. They also suggest the importance of a new approach of non-invasive brain stimulation as a promising treatment in AD."@en ;
    ns0:hasPubTitle "Low-Frequency Repetitive Transcranial Magnetic Stimulation of the Right Dorsolateral Prefrontal Cortex Enhances Recognition Memory in Alzheimer’s Disease"@en .

ns1:jad-v72-i3-JAD190870 ns0:hasKeywords "1-methyl-4-phenyl-1, 2, 3, 6-tetrahydropyridine (MPTP)"@en,
        "Alzheimer’s disease"@en,
        "PI3K/Akt signaling pathway"@en,
        "Parkinson’s disease"@en,
        "bergenin"@en ;
    ns0:hasPubAbstract "Background: Parkinson’s disease (PD) is the second most prevalent progressive neurodegenerative disease, second only to Alzheimer’s disease, with motor disorders and cognitive impairment. Bergenin (Berg), extracted from the herb of Saxifrage stolonifera Curt. (Hu-Er-Cao), has anti-tumor, anti-inflammation, anti-oxidative stress, and neuroprotective properties.   Objective: In this study, we wanted to investigate the effects of Berg on PD and the underlying mechanisms.   Methods: 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) was used to introduce PD symptoms in mice. The expression levels of tyrosine hydroxylase, dopamine, and Iba-1 were examined. The levels of a series of inflammatory mediators were measured by qPCR. In addition, the PI3K/Akt signaling pathway was investigated to illustrate the underlying mechanism. In vitro, PC12 cells subjected to lipopolysaccharide (LPS) were treated with Berg.   Results: We found that MPTP injection introduced motor deficits, apoptosis of neurons and inflammation, as well as inhibited the PI3K/Akt signaling pathway. However, Berg treatment suppressed the MPTP-induced alterations. In vitro, Berg attenuated the cytotoxic effects on PC12 cells induced by the culture supernatants derived from LPS-induced microglial cells.   Conclusion: Berg attenuated the PD symptoms via activating the PI3K/Akt signaling pathway in vivo and in vitro."@en ;
    ns0:hasPubTitle "Bergenin Ameliorates MPTP-Induced Parkinson’s Disease by Activating PI3K/Akt Signaling Pathway"@en .

ns1:jae-v58-i2-JAE170034 ns0:hasKeywords "Circulating currents"@en,
        "integral methods"@en,
        "power transformers"@en,
        "skin depth"@en ;
    ns0:hasPubAbstract "Power transformer design normally includes an optimization process which involves the assessment of a great number of design alternatives. This calculation process normally requires a high computation time and its reduction is always a desirable goal. Circulating currents in parallel connected conductors in transformer windings are a critical design aspect to be analyzed. This article presents a new methodology for the fast calculation of circulating currents for parallel connected conductors in power transformers. The formulation for solid conductor modeling has been developed using the same calculation strategy as in Semianalytic Integral Method (SAIM) [1], which allows a significant reduction of computational effort. A realistic case study of a 25 MVA transformer was used to validate the proposed methodology. As for the accuracy of the calculations, the comparison of the results obtained by the proposed methodology and those calculated using the Finite Element Method (FEM) shows an excellent agreement between both approaches. However, the computational performance of the new approach was found to be much higher than that of FEM. This makes the proposed method much more efficient for transformer design purposes."@en ;
    ns0:hasPubTitle "Semianalytic integral method for the fast solution of circulating currents in power transformers"@en .

ns1:jae-v58-i2-JAE180028 ns0:hasKeywords "AZ31 magnesium alloy"@en,
        "electromagnetic forming"@en,
        "forming limit diagrams"@en,
        "high strain rates"@en,
        "warm forming"@en ;
    ns0:hasPubAbstract "Weight reduction is a primary concern in the automotive and electrical industries because of the intensive requirements of energy conservation and emission reduction. As the lightest structural metal, magnesium (Mg) alloys are widely used in the automotive and aerospace industries. However, the current industrial application of this material is mainly limited to pressure casting parts due to its poor formability at room temperature. Therefore, identifying the factors that affect the formability of Mg alloy is highly important. In this study, forming limits of Mg alloy sheet under electromagnetic forming (EMF) condition were analyzed at different temperatures based on the Johnson–Cook constitutive model and the failure model. The complete forming limit diagrams of AZ31 Mg alloy at different temperatures and high strain rates were established. The effects of voltage, capacitance, and temperature on the forming limit of AZ31 Mg alloy under EMF were systematically investigated. Results showed that increased discharge voltage and temperature can effectively improve the EMF limit of Mg alloy. The effect of increasing capacitance on the formability of Mg alloy was not obvious."@en ;
    ns0:hasPubTitle "Forming limit diagrams of AZ31 Mg sheet at elevated temperatures and high strain rates by electromagnetic hybrid forming"@en .

ns1:jae-v60-i4-JAE170051 ns0:hasKeywords "Wireless sensor network (WSN)"@en,
        "high-speed sampling"@en,
        "structural health monitoring (SHM)"@en ;
    ns0:hasPubAbstract "At present, the sampling rate in a wireless sensor network is generally low, which does not meet the requirements for high-speed sensor signal acquisition and detection. To address the shortcomings of wireless sensor networks in terms of the design methods and effects assessment, a high-speed wireless sensor network node was designed based on structural health monitoring. Based on the general framework of a wireless sensor node, combined with the requirement of active health monitoring, a test of screws loosening in a reinforced aluminum plate were conducted. The theory of compressed sensing was used to test the effects of compressed sampling for the high-speed acquisition nodes. The results demonstrated that high-speed wireless sensor nodes could complete active excitation, sampling, and processing of the response signal for the application of active structure monitoring with integrated software and hardware and that the system could distinguish the looseness of the screws in the aviation specimens accurately. The nodes also met the requirements of small size, low cost, and low power consumption. The results of the experiment verified that the hardware and software modules for the high-speed wireless sensor nodes functioned and monitored the structural damage effectively. The system solves many key problems of node design in wireless sensor networks in the industrial field."@en ;
    ns0:hasPubTitle "Design of a high-speed low-power wireless sensor node and verification for structural health monitoring"@en .

ns1:jae-v60-i4-JAE180067 ns0:hasKeywords "Finite-element analyses"@en,
        "Schur complement"@en,
        "buried permanent magnet machines"@en,
        "discrete Fourier transform"@en,
        "electromagnetic fields"@en,
        "geometrical periodicity"@en,
        "model reduction"@en,
        "rotating electrical machines"@en ;
    ns0:hasPubAbstract "In this paper we present a-priori model reduction technique that enables to take full advantage of the periodicity existing in the stator and rotor geometrical structures of electrical machines in order to reduce the computational time. Firstly, a change of basis is performed by applying two distinct discrete Fourier transformations on the stator and rotor periodic structures independently. Secondly, the Schur complement is introduced in the new spectral basis, to allow a parallel solving of the resulting block-diagonal matrix systems. Moreover, the using of a matrix-free Krylov method based on the conjugate gradient solver has verified an efficient solving of the equation system associated to the stator-rotor interface. Furthermore, in the peculiar case of balanced supply conditions, a model order reduction can be carried out by considering only the dominant discrete Fourier transform components. This model reduction approach is applied on a buried permanent magnet machine and has successfully shown its efficiency under balanced and unbalanced conditions."@en ;
    ns0:hasPubTitle "Exploitation of independent stator and rotor geometrical periodicities in electrical machines using the Schur complement"@en .

ns1:jae-v61-i1-JAE180057 ns0:hasKeywords "Hot-line robot"@en,
        "air breakdown"@en,
        "electric field distortion"@en,
        "substation insulation"@en ;
    ns0:hasPubAbstract "With the popularization of intelligent substations, hot-line working robots that can replace the manual operation without shutting down the power of the corresponding equipments are increasingly widely applied in the maintenance and monitoring of substations. Robotic operation can ensure the safety of the operators and reliability of operation while improving the economic benefits of substation. However, because of the compact structure of the intelligent substations, the operating space is small. Further, as the main material of hot-line working robots is metal, which greatly changes the strength and distribution of the electric field around its working position when entering the working position and in the process of operation. In serious cases, interphases or phase to ground air breakdown occurs. Hence the working space of hot-line working robots is limited not only by the narrow space between devices in the substation but also by the electrical safety clearance of phase to phase and phase to ground. Therefore, it is necessary to find a safe working space (“SWS”) for the robot which should not be too small for the robot to accomplish the task effectively. The purpose of this paper is to provide: (i) a design reference for hot-line working robots which can not only guarantee the electrical safety distance but also minimize the effect to the electric field and (ii) a method to find the SWS of the robot in which the robot can accomplish the task effectively with the example of the hot-line working robot for isolated circuit breaker (“ICBot”). We analyze the influence of different installation positions and postures of the manipulators on the electric field in this paper and present a calculation method of the SWS of the manipulator in a very non-uniform electric field caused by the intervention of manipulators, which is significant to the research on hot-line working robots. The SWS has been tested in simulated and energized experimental system, and the experiment results show that the robot can work safely and efficiently."@en ;
    ns0:hasPubTitle "Planning of safe working space for the hot-line working robot ICBot"@en .

ns1:jae-v61-i1-JAE180089 ns0:hasKeywords "L-type impedance matching circuit"@en,
        "power transfer efficiency"@en,
        "sensitivity"@en ;
    ns0:hasPubAbstract "L-type impedance matching circuits (IMCs) can maximize the power transfer efficiency (PTE) by converting the load to the optimum one in the wireless power transfer system. However, their effectiveness is inadequately studied. In this work, the applicability of the L-type IMCs is carefully examined under the restriction of capacitance realization. The sensitivities with respect to the deviation of the capacitance in mass production as well as the variations of the load and the mutual inductance are analyzed in detail and validated by experiments. By comparison with the basic-type IMCs, the L-type IMCs have higher, nearly equal and lower sensitivities with respect to the deviation of the capacitance, the variation of the load, and the variation of the mutual inductance, respectively."@en ;
    ns0:hasPubTitle "Sensitivity analysis of L-type impedance matching circuits for inductively coupled wireless power transfer"@en .

ns1:jae-v61-i2-JAE180107 ns0:hasKeywords "Magnetic field"@en,
        "analytical methods"@en,
        "numerical methods"@en,
        "surface current"@en ;
    ns0:hasPubAbstract "There are currently two main trends in solving magnetic field problems, numerical methods, of which the Finite Element Method (FEM) is undoubtedly the most popular, and analytical methods, of which there is a great diversity of approaches. The main advantage of numerical methods is their flexibility in modeling complicated geometries; however, its calculation times are generally considerable. Analytical methods attain very short calculation times by sacrificing flexibility. This paper presents the mathematical formulation of a new linear surface element for the semi-analytical solution of axisymmetric magnetic field problems. The importance of this formulation is that it is capable of dealing with arbitrary geometries while retaining the flexibility of numerical methods with considerably shorter calculation times. The results of the application of the proposed formulation to a case study are presented in the validation section. The results obtained are compared with those calculated with FEM showing an excellent agreement between them."@en ;
    ns0:hasPubTitle "Mathematical formulation of a new linear surface element for the modeling of axisymmetric magnetic field problems"@en .

ns1:jae-v61-i3-JAE180133 ns0:hasKeywords "EAST tokamak"@en,
        "free-boundary equilibrium calculation"@en,
        "orthogonal test method"@en,
        "plasma shape response"@en ;
    ns0:hasPubAbstract "This paper studies the impact of Poloidal Field (PF) coil current disturbance on plasma shape in Experimental Advanced Superconductive Tokamak (EAST). First, the concept of the free-boundary equilibrium problem is studied. Based on the non-rigid plasma model, a free-boundary equilibrium solver developed in MATLAB software is presented to calculate the flux distribution and plasma profile of EAST plasma equilibrium, and the results are validated against the experiments. Second, given a typical double-null plasma equilibrium, the responses of plasma shape to the lower PF coil currents are computed using the orthogonal test method. The dependences of the elongation and triangularity of plasma shape on PF coil currents are obtained, showing that the currents in PF6 and PF8 have the greatest impact on triangularity and elongation for lower single-null (LSN) divertor configuration, respectively. And for double-null (DN) divertor plasma configuration, PF5 and PF7 play equally important roles due to the up-down symmetry. The conclusions will be useful for the design of EAST plasma shape feedback control."@en ;
    ns0:hasPubTitle "Impact of poloidal field coil current disturbance on tokamak plasma shape"@en .

ns1:jae-v61-i3-JAE190009 ns0:hasKeywords "Electromagnetic forming"@en,
        "coil design"@en,
        "the maximum forming depth"@en ;
    ns0:hasPubAbstract "Electromagnetic forming (EMF) technology uses pulsed current to generate a pulsed electromagnetic force on metal workpiece to accomplish plastic deformation. It is a promising solution for the room temperature processing of lightweight alloy. Coil design is important to energy efficiency and forming performance of EMF. In order to clarify the effect of the equivalent radius of the drive coil on the forming performance, a simulation study is conducted. The preliminary experiment results show good agreement with results of the simulation, and prove the reliability of the simulation model. Then the process of the electromagnetic sheet free bulging is simulated and analyzed. It is found that the combined action of the boundary constraint and the inertia effect will influence the maximum forming depth. And the maximum values can be obtained at different systems when the ratio of the equivalent coil radius to the active workpiece radius is about 0.68."@en ;
    ns0:hasPubTitle "Effect of equivalent radius of drive coil on forming depth in electromagnetic sheet free bulging"@en .

ns1:jae-v61-i3-JAE190086 ns0:hasKeywords "Piezoelectric stack actuators"@en,
        "Preisach model"@en,
        "hysteresis nonlinearity"@en,
        "neural network"@en ;
    ns0:hasPubAbstract "Classic Preisach model can precisely describe the hysteresis of piezoelectric stack actuators, but its model identification is relatively complicated. Neural network is easy to be identified with available training algorithm, but it cannot directly describe the multi-valued mapping of hysteresis. A neural-Preisach model was proposed for modeling and control of piezoelectric stack actuators. The neural-Preisach model inherits the advantages of Preisach model and neural network, which can describe the hysteresis and update parameters by training algorithm. A feedforward controller was designed with the inverse neural-Preisach model, and then experiments of tracking control were performed to validate the effectiveness of the neural-Preisach model. The maximal error, in case of feedforward and PID controller, is reduced by 83.97%, comparing with the case without control. This indicates that control accuracy with hysteresis compensation is greatly improved compared to that without hysteresis compensation."@en ;
    ns0:hasPubTitle "Hysteresis modeling and tracking control for piezoelectric stack actuators using neural-Preisach model"@en .

ns1:jae-v61-iS1-JAE190821 ns0:hasKeywords "AC magnetic loss"@en,
        "Nd–Fe–B sintered magnet"@en,
        "anisotropy"@en,
        "conductivity"@en,
        "motor"@en ;
    ns0:hasPubAbstract "This paper investigates the influences of the grade, the alignment direction and magnetization ratio of Nd–Fe–B sintered magnet on its conductivity and AC loss to achieve further high-efficiency of permanent magnet synchronous motors. As a result, it is confirmed that the difference in grade had little effect on the conductivity and AC loss. The difference in conductivity is not caused by the magnetization ratio. Furthermore, the influence of hysteresis loss and skin effect varies depending on the magnetization ratio."@en ;
    ns0:hasPubTitle "Conductivity and AC magnetic loss of Nd–Fe–B sintered magnet"@en .

ns1:jae-v61-iS1-JAE190924 ns0:hasKeywords "Distortion factor"@en,
        "electrical steel sheet"@en,
        "magnetic properties"@en,
        "single sheet tester"@en ;
    ns0:hasPubAbstract "It is desirable that the waveform of induced voltage 𝜐b in the B-coil is substantially sinusoidal when magnetic properties of electrical steel sheets are measured. To realize a sinusoidal 𝜐b, the IEC standards specify that its form factor FF should be controlled within 1.11 ± 0.01. However, the condition is not sufficient because a non-sinusoidal waveform can also give FF = 1.11. Ideally, the distortion factor DF𝜐b of 𝜐b should be equal to 0. Therefore, this paper discusses the influence of the DF𝜐b on magnetic properties of electrical steel sheets measured with a single sheet tester. As a result, it is confirmed that the iron loss is directly proportional to the distortion factor of induced voltage in the B-coil. Therefore, the distortion factor should be specified relating accuracy of the iron loss measurements."@en ;
    ns0:hasPubTitle "Influence of distortion factor of induced voltage in B-coil on magnetic property measured with a single sheet tester"@en .

ns1:jae-v61-iS1-JAE191491 ns0:hasKeywords "Claw pole rotor"@en,
        "FE simulation"@en,
        "correction factor"@en,
        "electromagnetic properties"@en,
        "four point measurement"@en,
        "mini SST"@en ;
    ns0:hasPubAbstract "Claw pole machine performances are strongly related to the electromagnetic properties of ferromagnetic materials. These properties are impacted by the manufacturing processes, in a heterogeneous way, as well as by the thermal behavior of the machine and the mechanical stress distribution. Due to the complexity of CP geometry, extracted samples cannot respect the dimensions prescribed in international standards of electric and magnetic measurements. This paper proposes a specific methodology to characterize the electrical conductivity and the magnetic behavior of massive parallelepiped specimens extracted from different locations of a CP rotor."@en ;
    ns0:hasPubTitle "Development and validation of an electrical and magnetic characterization device for massive parallelepiped specimens"@en .

ns1:jbr-v9-i2-JBR180332 ns0:hasKeywords "Phalsa"@en,
        "anthocyanins"@en,
        "bioactive compounds"@en,
        "health benefits"@en,
        "processing challenges"@en ;
    ns0:hasPubAbstract "Fruit berries are one of the most effective source of bioactive food ingredients with multiple health benefits when consumed regularly. Phalsa fruit (Grewia asiatica L.) a native to the Himalayan region grows equally well in tropical areas of the world yet unexplored with regards to its immense nutritional benefits. The phalsa seed, fruit, and pulp contain numerous functional phytochemicals that can be used to treat various diseases, and have be found to be highly effective in improving respiratory and cardiac functioning. Its cultivation has been limited to subsistence cultivation and it is sold in the form of raw fruit mostly. There are certain challenges as regards to its perishable nature of the berry fruit, and the optimization of the crop yield. Therefore, this comprehensive review is designed to highlight its economic and nutritional potential for the food and beverage industry as an effective source of bioactive functional food/beverage ingredients. Further potential area of research and developments have been identified for the subsequent authentication of health effects of phalsa berry fruit. Moreover, issues related to value addition in food product development have been explained along with proposed solutions."@en ;
    ns0:hasPubTitle "Phalsa (Grewia asiatica L) fruit berry a promising functional food ingredient: A comprehensive review"@en .

ns1:jbr-v9-i2-JBR180350 ns0:hasKeywords "Fatigue"@en,
        "anthocyanin"@en,
        "blueberry juice"@en,
        "dopamine transporter"@en,
        "forced swimming test"@en,
        "tyrosine hydroxylase"@en ;
    ns0:hasPubAbstract "BACKGROUND: Blueberry juice is a common drink for relieving fatigue, but its mechanisms of action are unclear.   OBJECTIVE: This study aimed to validate changes in the dopaminergic system, especially changes in dopamine transporter (DAT) levels, in a fatigued state and assess whether such fatigue-related changes can be ameliorated by blueberry juice.   METHODS: We investigated the expression of striatal DAT and tyrosine hydroxylase (TH) in mice subjected to a forced swimming fatigue task and subsequently administered blueberry juice (anthocyanin), caffeine, or Red Bull (caffeine + taurine) to assess DAT and TH changes in the nigrostriatal pathway related with fatigue as well as their relief.   RESULTS: Striatal DAT and TH expression was downregulated by fatigue and upregulated by treatment with blueberry juice, caffeine, and Red Bull. In addition, DAT and TH expression exhibited positive correlations with fatigue-related motor performance.   CONCLUSIONS: We provided evidence of compensatory responses of striatal DAT and TH in the fatigued state, and treatments to relieve fatigue might upregulate the expression of both striatal DAT and TH. Moreover, small amounts of blueberry juice exerted similar effects as large amounts, suggesting that anthocyanin has relatively strong anti-fatigue effects."@en ;
    ns0:hasPubTitle "Changes in striatal dopamine transporter and tyrosine hydroxylase expression associated with fatigue and their reversal by blueberry juice"@en .

ns1:jbr-v9-i3-JBR180368 ns0:hasKeywords "Aristotelia chilensis"@en,
        "color"@en,
        "cryoconcentration"@en,
        "maqui-berry"@en,
        "total 39 anthocyanins"@en,
        "total polyphenols"@en ;
    ns0:hasPubAbstract "BACKGROUND: At the present time, the food industry is increasingly interested in the development of formulations with maqui-berry extracts as a rich source of bioactive compounds. Maqui, native to Chile, is a relatively new food raw material that is often called a “superfruit”, The berries of this plant are rich in anthocyanins, phenolic acids, and tannins; compounds that play an important role as sources of bioactive compounds in the health of consumers. Cryoconcentration, a technology that preserves thermolabile bioactive compounds by combining techniques of freezing-centrifugation, makes it possible to obtain concentrates with a greater content of bioactive compounds than traditional methods of concentration. In this study, maqui fruits were pulped to obtain juice (J) and chaff. The chaff was subjected to aqueous extraction with distilled water in a ratio of 1 : 1 p/v to obtain maqui extract (E). Combined J and E were homogenized, and vacuum filtered to obtain the final extract (A), which was cryoconcentrated at – 30°C and then subjected to 3 continuous cycles of freezing-centrifugation and filtration.   MATERIAL AND METHODS: Three continuous centrifugation-filtration cycles were used. The polyphenol content was determined by the Folin-Ciocalteu method with gallic acid as a standard. Anthocyanins were identified by high-performance liquid chromatography (HPLC) and total anthocyanin content was determined by the pH differential method the anthocyaninds present were identified by high performance liquid chromatography (HPLC).   RESULTS: After application of the cryoconcentration cycles assisted by centrifugation-filtration, the separation efficiency of solute was found to be maintained over 90%. The content of soluble solids significantly increased in the concentrated fractions and reached 54.2 °Brix at the end of the third cycle. Finally, the ratio of the concentration of total polyphenol and anthocyanin increased 2.8 and 6.7 times, with respect to the initial content in the maqui-berry extract.   CONCLUSIONS: The maqui cryoconcentrate is a product with a large content of antioxidants and bioactive compounds commonly considered as functional characteristics. This concentration method also conserved the profile of anthocyanins present in maqui fruit extract. The efficient separation solutes and bioactive compounds achieved will permit scaling these process conditions to the industrial level.   OBJECTIVE: To assess the process parameters and polyphenol-anthocyanin content of cryoconcentrates obtained from maqui-berry (Aristotelia chilensis (Mol.) Stuntz)."@en ;
    ns0:hasPubTitle "Cryoconcentration procedure for aqueous extracts of maqui fruits prepared by centrifugation and filtration from fruits harvested in different years from the same localities"@en .

ns1:jbr-v9-i3-JBR190387 ns0:hasKeywords "Raspberry"@en,
        "correlation"@en,
        "instrumental analysis"@en,
        "sensory profiling"@en,
        "volatile compounds"@en ;
    ns0:hasPubAbstract "BACKGROUND: There is a search for raspberry cultivars with high sensory quality. The best way to determine sensory quality is by descriptive analysis. To perform sensory analysis by a trained panel is, however, not always feasible. Therefore, there is a need for instrumental measurements that correlate with sensory attributes.   OBJECTIVE: To characterize eight genotypes of raspberry (Rubus idaeus L.) and to correlate sensory attributes with instrumentally determined quality.   METHODS: Raspberry fruits were analysed by descriptive sensory analysis and by instrumental measurements, i.e. colour, total monomeric anthocyanins, soluble solids (SS), pH, titratable acidity (TA) and volatile compounds. The relationships between sensory attributes and instrumentally measured quality were determined by partial least square regression and by univariate correlation analysis.   RESULTS: Sour and green odours/flavours versus chemical and cloying odours/flavours described most of the sensory variation of the raspberry genotypes. TA correlated with acidic taste, astringency and flavour intensity. SS/TA was positively correlated with sour flavour and sweet taste and negatively correlated with acidic taste and astringency. C6-aldehydes and (Z)-3-hexen-1-ol correlated positively with green flavour. β-ionone and α-ionone correlated with flower odour and flavour, respectively.   CONCLUSIONS: Eight raspberry genotypes were characterized. Important sensory attributes could be predicted by instrumental measurements."@en ;
    ns0:hasPubTitle "Sensory and instrumental analysis of eight genotypes of red raspberry (Rubus idaeus L.) fruits"@en .

ns1:jbr-v9-i3-JBR190390 ns0:hasKeywords "E. nigrum"@en,
        "UV-B"@en,
        "V. myrtillus"@en,
        "V. oxycoccos"@en,
        "V. uliginosum"@en,
        "V. vitis-idaea"@en,
        "breeding"@en,
        "disturbance"@en,
        "drought"@en,
        "freezing"@en ;
    ns0:hasPubAbstract "BACKGROUND: Interest in the wild berries of dwarf shrubs (wild berries) is increasing. Therefore, an update is important regarding how these species react to and interact with different climatic factors, and on how the predicted climatic changes will affect their distribution, growth and content of compounds affecting health.   OBJECTIVE: To systemize knowledge of the Ericaceae and Empetraceae wild berry species.   METHODS: A review of literature covering the above topics.   CONCLUSION: This review includes five wild berry species and their subspecies: Vaccinium myrtillus, Vaccinium vitis-idaea, Vaccinium uliginosum, Vaccinium oxycoccos with ssp. microcarpon, and Empetrum nigrum with ssp. nigrum, hermaphroditum and japonicum. They have been and still are collected in the wild, by local households and industry. The berries have high content of biological compounds of interest for human health. Despite the increasing interest in and demand for these wild berries, domestication attempts have been rare. The species often grow together and are competitors. Which species dominate depends on soil conditions and is determined by small differences. The changing climate and various disturbances will also influence the distribution patterns of wild berries and competing plant species. Semi-cultivation in the natural habitat is probably the best solution for viable and sustainable commercial exploitation of these resources, at least if they are sold with the label “wild berries”. However, these species are easily propagated by fresh cuttings, and they can grow on arable land, adapting soil conditions to fit their growing preferences. Such cultivation, to our knowledge has not yet been performed on a large economic scale."@en ;
    ns0:hasPubTitle "Review of botanical characterization, growth preferences, climatic adaptation and human health effects of Ericaceae and Empetraceae wild dwarf shrub berries in boreal, alpine and arctic areas"@en .

ns1:jcm-v19-i3-JCM190017 ns0:hasKeywords "BP neural network"@en,
        "Foundation pit monitoring"@en,
        "genetic algorithm"@en,
        "time series and spatial features"@en ;
    ns0:hasPubAbstract "Predicting the deformation of the foundation pit is one of the key issues for the construction safety of the foundation pit. In the traditional construction process often neglects the deformation prediction. It will cause the best time of repairing the pit is often missed. BP neural network has the characteristic of markova chain which is exactly match temporal-series data collected from displacement monitoring. So the BP neural network can understand the data better than SVM and RF. Further, the GA-BP neural network improved the training process based on BP neural network. We proposed a GA-BP neural network to predict the deformation of the foundation pit. To enforce the validation of the performance, we collected the real data from the Zhoushan foundation pit project. Compared with support vector regression and random forest regression, the results showed that GA-BP method has the error basically within -0.05–0.05 mm, the maximum relative error 0.36% and the predicted fitting value IA above 0.9, which are obviously better than other two methods."@en ;
    ns0:hasPubTitle "The prediction of foundation pit based on genetic back propagation neural network"@en .

ns1:jcs-v27-i3-JCS171070 ns0:hasKeywords "Formal verification"@en,
        "equivalence-based properties"@en,
        "security protocols"@en,
        "symbolic model"@en ;
    ns0:hasPubAbstract "In this paper, we consider the problem of verifying anonymity and unlinkability in the symbolic model, where protocols are represented as processes in a variant of the applied pi calculus, notably used in the  ProVerif tool. Existing tools and techniques do not allow to verify directly these properties, expressed as behavioral equivalences. We propose a different approach: we design two conditions on protocols which are sufficient to ensure anonymity and unlinkability, and which can then be effectively checked automatically using  ProVerif. Our two conditions correspond to two broad classes of attacks on unlinkability, i.e. data and control-flow leaks. This theoretical result is general enough that it applies to a wide class of protocols based on a variety of cryptographic primitives. In particular, using our tool,  UKano, we provide the first formal security proofs of protocols such as BAC and PACE (e-passport), Hash-Lock (RFID authentication), etc. Our work has also lead to the discovery of new attacks, including one on the LAK protocol (RFID authentication) which was previously claimed to be unlinkable (in a weak sense)."@en ;
    ns0:hasPubTitle "A method for unbounded verification of privacy-type properties"@en .

ns1:jcs-v27-i3-JCS181244 ns0:hasKeywords "AI-based security"@en,
        "Workflow satisfiability and resiliency"@en,
        "dynamic controllability"@en,
        "extended game automata"@en,
        "formal methods"@en,
        "high availability"@en,
        "resource allocation under uncertainty"@en,
        "unbreakable security"@en ;
    ns0:hasPubAbstract "The workflow satisfiability problem is the problem of finding an assignment of users to tasks (i.e., a plan) so that all authorization constraints are satisfied. The workflow resiliency problem is a dynamic workflow satisfiability problem coping with the absence of users. If a workflow is resilient, it is of course satisfiable, but the vice versa does not hold. There are three levels of resiliency: in static resiliency, up to k users might be absent before the execution starts and never become available for that execution; in decremental resiliency, up to k users might be absent before or during execution and, again, they never become available for that execution; in dynamic resiliency, up to k users might be absent before executing any task and they may in general turn absent and available continuously, before or during the execution. Much work has been carried out to address static resiliency, little for decremental resiliency and, to the best of our knowledge, for dynamic resiliency no exact approach that returns a dynamic execution plan if and only if a workflow is resilient has been provided so far. In this paper, we tackle workflow resiliency via extended game automata. We provide three encodings (having polynomial-time complexity) from workflows to extended game automata to model each kind of resiliency as an instantaneous game and we use Uppaal-TIGA to synthesize a winning strategy (i.e., a controller) for such a game. If a controller exists, then the workflow is resilient (as the controller’s strategy corresponds to a dynamic plan). If it doesn’t, then the workflow is breakable. The approach that we propose is correct because it corresponds to a reachability problem for extended game automata (TCTL model checking). Moreover, we have developed Erre, the first tool for workflow resiliency that relies on a controller synthesis approach for the three kinds of resiliency. Thanks to Erre, our approach is thus also fully-automated from analysis to simulation."@en ;
    ns0:hasPubTitle "Last man standing: Static, decremental and dynamic resiliency via controller synthesis"@en .

ns1:jcs-v27-i3-JCS191274 ns0:hasKeywords "Bitcoin"@en,
        "collusion attacks"@en,
        "double-spending"@en,
        "fair deposit"@en,
        "time-locked"@en ;
    ns0:hasPubAbstract "In Bitcoin network, the distributed storage of multiple copies of the block chain opens up possibilities for double-spending, i.e., a payer issues two separate transactions to two different payees transferring the same coins. While Bitcoin has inherent security mechanism to prevent double-spending attacks, it requires a certain amount of time to detect the double-spending attacks after the transaction has been initiated. Therefore, it is impractical to protect the payees from suffering in double-spending attacks in fast payment scenarios where the time between the exchange of currency and goods or services is shorten to few seconds. Although we cannot prevent double-spending attacks immediately for fast payments, decentralized non-equivocation contracts have been proposed to penalize the malicious payer after the attacks have been detected. The basic idea of these contracts is that the payer locks some coins in a deposit when he initiates a transaction with the payee. If the payer double-spends, a cryptographic primitive called accountable assertions can be used to reveal his Bitcoin credentials for the deposit. Thus, the malicious payer could be penalized by the loss of deposit coins. However, such decentralized non-equivocation contracts are subjected to collusion attacks where the payer colludes with the beneficiary of the depoist and transfers the Bitcoin deposit back to himself when he double-spends, resulting in no penalties. On the other hand, even if the beneficiary behaves honestly, the victim payee cannot get any compensation directly from the deposit in the original design. To prevent such collusion attacks, we design fair time-locked deposits for Bitcoin transactions to defend against double-spending. The fair deposits ensure that the payer will be penalized by the loss of his deposit coins if he double-spends and the victim payee’s loss will be compensated within a locked time period. We start with the protocols of making a deposit for one transaction. In particular, for the transaction with single input and output and the transaction with multiple inputs and outputs, we provide different designs of the deposits. We analyze the performance of deposits made for one transaction and show how the fair deposits work efficiently in Bitcoin. We also provide protocols of making a deposit for multiple transactions, which can reduce the burdens of a honest payer. In the end, we extend the fair deposits to non-equivocation contracts for other distributed systems."@en ;
    ns0:hasPubTitle "Collusion attacks and fair time-locked deposits for fast-payment transactions in Bitcoin1"@en .

ns1:jcs-v27-i4-JCS191287 ns0:hasKeywords "Adware"@en,
        "data leakage"@en,
        "online tracking"@en,
        "potentially unwanted programs"@en,
        "privacy"@en ;
    ns0:hasPubAbstract "Advertisements are the fuel that runs many online services such as websites or mobile apps, but also adversaries started to abuse ads for financial gains. Nowadays, online advertising companies track users all over the web in order to create successful online ads campaigns specifically tailored for a target audience. A popular phenomenon on the Internet, so-called adware, abuses online advertisements by maliciously injecting or replacing ads on websites. As many consider ads to be quite privacy intrusive, much work has gone into studying the effects of online advertisements on users’ privacy. However, only little work has been done so far into analyzing the privacy implications of adware. In this work, we shed light on the capabilities, mainly concerning tracking and personal data exfiltrating, of adware and potentially unwanted programs (PUPs), at scale. To this end, we capture the communication of adware/PUPs in the Firefox browser on the application level to circumvent lower-level encryption (e.g., TLS). Using this framework for capturing the network traffic, we dynamically analyze the communication of over 16,000 adware or potentially unwanted program samples. We find that around 37% of requests issued by the analyzed samples contain some kind of personal information. Furthermore, we identify the services used by adversaries and provide insights on the used tracking techniques."@en ;
    ns0:hasPubTitle "Analyzing leakage of personal information by malware"@en .

ns1:jcs-v27-i4-JCS191306 ns0:hasKeywords "Security metric"@en,
        "attack graph"@en,
        "cloud security"@en,
        "insider attack"@en,
        "service dependency graph"@en ;
    ns0:hasPubAbstract "Today’s cloud providers strive to attract customers with better services and less downtime in a highly competitive market. The need for minimizing the operational cost unavoidably leads cloud providers to rely on third party remote administrators for fulfilling regular maintenance tasks. In such a scenario, the lack of trust in those third party remote administrators paired with the extra privileges granted to them to complete the maintenance tasks usually implies undesirable security threats. A dishonest remote administrator, or an attacker armed with the stolen credential of a remote administrator, can pose severe insider threats to both the cloud provider and its tenants. In this paper, we take the first step towards understanding and mitigating such insider threats of remote administrators in clouds. Specifically, we first model the maintenance task assignments and their corresponding security impact due to privilege escalation. We then mitigate such impact through optimizing the task assignments with respect to given constraints. Finally, the simulation results demonstrate the effectiveness of our solution in various scenarios."@en ;
    ns0:hasPubTitle "Mitigating the insider threat of remote administrators in clouds through maintenance task assignments"@en .

ns1:jcs-v27-i5-JCS191286 ns0:hasKeywords "CART"@en,
        "Malware traffic"@en,
        "botnet"@en,
        "defacement"@en,
        "machine learning"@en,
        "malware detection"@en,
        "reverse shells"@en,
        "trojan"@en ;
    ns0:hasPubAbstract "During the past years, deep packet inspection has been prevalent in network intrusion detection systems. Most solutions employ complex algorithms to analyze the intended behaviour and underlying characteristics of packets and their payloads, in an effort to detect and prevent malicious users and software from communicating over business intranets and wider networks. Still, there are multiple issues that inhibit their success rate. Most signature-based security software is plagued by false positives and/or false negatives. On the other hand, behavioral-based solutions achieve better detection rates but need to analyze large amounts of traffic. In this article, we present a real-time network traffic monitoring system that implements machine learning over side channel characteristics of TCP network packets to distinguish normal from malicious TCP sessions, even when encryption is in place. We test in university networks and test multiple different types of traffic. We show that, our approach (i) requires notably less information to achieve similar (if not better) detection rates, (ii) works over encrypted traffic as well, and (iii) has notably low false positives and false negatives in everyday case study scenarios."@en ;
    ns0:hasPubTitle "Using side channel TCP features for real-time detection of malware connections"@en .

ns1:jhd-v8-i3-JHD190349 ns0:hasKeywords "Ancillary services"@en,
        "Huntington’s disease"@en,
        "counseling"@en,
        "enroll-hd"@en,
        "occupational"@en,
        "physical"@en,
        "psychotherapy"@en,
        "speech"@en,
        "swallow"@en,
        "therapy"@en ;
    ns0:hasPubAbstract "Background: Prior Huntington’s disease (HD) studies suggest ancillary services improve motor symptoms, cognition, mood, and quality of life but frequency of use and clinicalcharacteristics are unclear.   Objective: Describe ancillary service utilization in a cohort of individuals with HD and determine which participant characteristics are associated with ancillary service utilization.   Methods: Retrospective cross-sectional analysis of Enroll-HD database. Participants were grouped by therapy: physical and/or occupational (PT/OT), psychotherapy and/or counseling (PC), speech and/or swallowing (ST). We performed bivariate comparisons analysis of demographic and disease characteristics between those with/without each therapy and to analyze one-year mean change in assessment scores.   Results: Of 4751 participants, 1537 (32.35%) utilized therapies (11.82% PT/OT, 5.33% PC, 3.01% ST, 1.98% all three, 10.21% two therapies). PT/OT participants had worse motor and functional scores: mean UHDRS motor score (41.17 vs. 38.05, p = 0.002), median total functional capacity score (TFC) (8.00 vs. 9.00, p < 0.001). PC participants had worse mood but better cognitive and functional scores: median depression score (7.00 vs. 2.00, p < 0.001), median MMSE (28.00 vs. 26.00, p < 0.001), median TFC (10.00 vs. 8.00, p < 0.001). ST participants had more dysarthria, and worse cognitive and functional scores: dysarthria (32.2% vs. 20.1% p < 0.001), mean correct Symbol Digit Modality Test (16.79 vs. 23.27, p < 0.001), median TFC (6.00 vs. 9.00, p < 0.001). Over one year, PC participants’ depression scores improved compared to untreated (– 1.24 vs. – 0.11, p = 0.040). ST participants’ depression scores worsened (1.14 vs. – 0.23, p = 0.044). Mean change in TFC was not significant for any therapies.   Conclusions: Only 32% of Enroll-HD site participants received ancillary services. Use correlated with expected clinical characteristics, though impact of use remains unclear."@en ;
    ns0:hasPubTitle "Ancillary Service Utilization and Impact in Huntington’s Disease"@en .

ns1:jhd-v8-i3-JHD190361 ns0:hasKeywords "Electroconvulsive therapy"@en,
        "Huntington’s disease"@en,
        "depression"@en,
        "mood disorders"@en,
        "psychotic disorders"@en ;
    ns0:hasPubAbstract "Background: Huntington’s disease (HD) is a progressive neurodegenerative disease characterized by involuntary movements and neuropsychiatric decline. With suicide rates five times higher in patients with HD compared to the general population, there is a need for further research into the management of affective symptoms in these patients. Electroconvulsive therapy (ECT) has been long used as a treatment for severe or medication-refractory mood disorders and catatonia. There are some case studies demonstrating ECT’s positive effect on depression and agitation in HD, but the data is limited.   Objective: In this single site case series, we review ECT use for four HD patients with medication-refractory depression and/or psychosis to better assess the utility of ECT in this population. We also compile and review the existing literature on the topic.   Methods: A single-center retrospective case series was conducted reviewing the indications, outcomes, and regimen of ECT treatments. Literature review was conducted via PubMed.   Results: Four patients received ECT treatment during an inpatient hospitalization with three continuing maintenance therapy as an outpatient. All four had improvements in depression, agitation, and suicidal ideation leading to successful hospital discharge. One of the four patients also demonstrated subjective improvement in cognitive and motor symptoms after ECT initiation. Nineteen reported cases were identified through the literature review and are summarized.   Conclusions: This case series adds to the existing literature demonstrating the successful use of ECT for psychiatric symptoms in HD. Larger scale studies are warranted to further investigate the specific role and protocol for the use of ECT in the management of refractory depression and psychosis in this population."@en ;
    ns0:hasPubTitle "Electroconvulsive Therapy (ECT) for Refractory Psychiatric Symptoms in Huntington’s Disease: A Case Series and Review of the Literature"@en .

ns1:jhd-v8-i3-JHD190366 ns0:hasKeywords "Huntington’s disease"@en,
        "advanced glycation end products"@en,
        "diabetes mellitus"@en,
        "glycation"@en,
        "huntingtin"@en ;
    ns0:hasPubAbstract "Glycation is the non-enzymatic reaction between reactive dicarbonyls and amino groups, and gives rise to a variety of different reaction products known as advanced glycation end products (AGEs). Accumulation of AGEs on proteins is inevitable, and is associated with the aging process. Importantly, glycation is highly relevant in diabetic patients that experience periods of hyperglycemia. AGEs also play an important role in neurodegenerative diseases including Alzheimer’s (AD) and Parkinson’s disease (PD). Huntington’s disease (HD) is a hereditary neurodegenerative disease caused by an expansion of a CAG repeat in the huntingtin gene. The resulting expanded polyglutamine stretch in the huntingtin (HTT) protein induces its misfolding and aggregation, leading to neuronal dysfunction and death. HD patients exhibit chorea and psychiatric disturbances, along with abnormalities in glucose and energy homeostasis. Interestingly, an increased prevalence of diabetes mellitus has been reported in HD and in other CAG triplet repeat disorders. However, the mechanisms underlying the connection between glycation and HD progression remain unclear. In this review, we explore the possible connection between glycation and proteostasis imbalances in HD, and posit that it may contribute to disease progression, possibly by accelerating protein aggregation and deposition. Finally, we review therapeutic interventions that might be able to alleviate the negative impact of glycation in HD."@en ;
    ns0:hasPubTitle "Glycation in Huntington’s Disease: A Possible Modifier and Target for Intervention"@en .

ns1:jhd-v8-i4-JHD190351 ns0:hasKeywords "Huntington’s disease"@en,
        "neuropsychological tests"@en,
        "obsessive behaviour"@en,
        "obsessive-compulsive disorder"@en,
        "psychological tests"@en ;
    ns0:hasPubAbstract "Background: Previous research using the Symptom-Checklist-90-Revised (SCL-90-R) has shown that compulsive symptoms in Huntington’s disease (HD) occur in 10% to 52% of all cases. The “Hamburger-Zwangsinventar” (HZI), a self-rating questionnaire comprising 188 items, taps into the domain of compulsiveness in greater detail, but has not been used in HD so far. In addition, little is known about the association of obsessive-compulsive symptoms with pre-clinical stages of HD.   Objective: Comparison of OC symptoms measured by the SCL-90-R and the HZI in pre-HD and HD.   Methods: 29 premanifest mutation carriers (pre-HD) and 40 manifest HD patients completed both questionnaires. Clinical characteristics of HD were rated by using the UHDRS.   Results: Compared to data from general population prevalence of OC symptoms were not higher as expected in preHD and only slightly elevated in manifest HD if using HZI. Both instruments detected more OC symptoms in HD patients compared to pre-HD. The SCL-90-R more often detects compulsivity than the HZI. Results of both questionnaires showed correlations to cognition, depression, and disease duration. Compared to findings from OCD patients, there was a subordinate role in the HZI subscale for “washing and cleaning” in HD.   Conclusions: OC symptoms in pre-HD occur not more often than in general population. The HZI appears to be useful for examining OC symptoms in detail in pre-HD and HD. HZI-subscale ratings for washing and cleaning compulsions were less pronounced in HD compared to OCD patients, possibly due to loss of disgust. The SCL-90-R might overestimate OC symptoms in both groups."@en ;
    ns0:hasPubTitle "Obsessive-Compulsive Symptoms are Less Common in Huntington’s Disease than Reported Earlier"@en .

ns1:jhd-v8-i4-JHD190354 ns0:hasKeywords "Huntington’s disease"@en,
        "Motor"@en,
        "endpoint"@en,
        "foot"@en,
        "function"@en,
        "hand"@en ;
    ns0:hasPubAbstract "Background: Assessment of motor symptoms in Huntington’s disease (HD) is based on the Unified-HD-Rating-Scale-Total-Motor-Score (UHDRS-TMS). Its categorical and rater-dependent nature reduces the ability to detect subtle changes and often placebo effects have been observed in trials. We have previously shown that impairments in isometric force matching can be detected by quantitative motor (Q-Motor) assessments of tongue protrusion forces (glossomotography) in HD.   Objective: We aimed to investigate whether similar impairments in isometric force matching can be detected in tasks assessing hand and foot force coordination and whether correlations with clinical measures and the disease burden score can be found.   Methods: Using a pre-calibrated force transducer, the ability of subjects to generate and maintain isometric forces at different target levels displayed on a monitor was assessed. Target forces applied in the hand were 1.5 and 5 Newton [N] and in feet 1, 5, and 10 N. Subjects with HD (n = 31) and age-matched controls (n = 22) were recruited from the HD out-patient clinic.   Results: All paradigms distinguished controls from HD. The static coefficient of variability (%) was the most robust measure across all matching tasks. Correlations with clinical measures, such as the UHDRS-TMS, TFC, and the DBS were found.   Conclusions: Assessment of hand and foot force matching tasks was feasible and provided quantitative objective measures for severity of motor phenotype in HD. Since both upper and lower extremity motor function are relevant for everyday activities, these measures should be further assessed as candidates for developing functionally meaningful quantitative motor tasks."@en ;
    ns0:hasPubTitle "Impaired Isometric Force Matching in Upper and Lower Limbs Revealed by Quantitative Motor Assessments in Huntington’s Disease"@en .

ns1:jhd-v8-i4-JHD190370 ns0:hasKeywords "Huntington’s disease"@en,
        "Music therapy"@en,
        "art therapy"@en,
        "dance therapy"@en ;
    ns0:hasPubAbstract "Background: Studies have assessed the therapeutic effect of music, dance, and rhythmic auditory cueing for patients with Huntington’s disease (HD). However, the synthesis of evidence in support of their positive impact on symptoms is lacking.   Objective: We conducted a systematic literature review to evaluate the potential benefits of music, dance, and rhythm on the cognitive, psychiatric and motor function in patients with HD.   Methods: Two- and three-keyword searches and a manual search identified medical literature published from 1999 through 2019. We considered literature that assessed outcomes of art-based rehabilitation programs or individual modalities for persons with early, middle, or advanced HD. Structured analysis was conducted using data entry tables with categories for patient health status, art methods, and outcomes.   Results: Seven articles and six abstracts met eligibility criteria, of which nine evaluated art-based rehabilitation programs. Studies mainly assessed cognitive, psychiatric, and motor functions through music, dance, or rhythm modalities. Although results were conflicting, in summary improvements to motor function were dependent on disease severity and more responsive to art therapy programs than rhythm-motor synchronization. Benefits to global cognition that resulted from rhythmic training correlated with microstructural changes. Qualitative data verified a positive impact on language production, chorea, behavior, and quality of life.   Conclusions: Our review has shown a potential benefit of music, dance, and rhythm for patients with HD, which is particularly important for a disease that has no cure. Art forms seemed to affect cognitive, psychiatric, motor, psychosocial, and neuroanatomical domains. However, evidence is preliminary, warranting further investigation to establish the foundation for this field."@en ;
    ns0:hasPubTitle "Therapeutic Use of Music, Dance, and Rhythmic Auditory Cueing for Patients with Huntington’s Disease: A Systematic Review"@en .

ns1:jhd-v8-i4-JHD190380 ns0:hasKeywords "Huntington’s disease"@en,
        "caregiver"@en,
        "specialty care"@en,
        "survey"@en ;
    ns0:hasPubAbstract "Background: Little is known about the quality of care for people living with Huntington’s disease (HD) in the United States.   Objective: To document the current HD care experience and identify gaps in care provision in the United States.   Methods: Web-based surveys for persons self-identifying as being affected by HD (PAHD, which included individuals with, or at risk for HD) or as caregivers/family members, were developed and refined with targeted input from focus groups comprised of caregivers and family members. The surveys were disseminated via social media and patient advocacy partners from April-May 2017.   Results: Total valid responses numbered 797, including 585 caregiver/family respondents and 212 PAHD responses. Respondents reported care provision from HD specialty centers, primary care, movement disorder clinics, and other settings. One in five respondents reported that the person with HD was not currently receiving medical or community care. Respondents generally reported a good level of care, with HD specialists providing the highest rated healthcare experience. Caregiver/family respondents reported helping with a range of activities including budget/finances (60.5%), housekeeping (57.1%) and daily help (53.2%). Most respondents (97.9%) reported searching online, including general information about HD (86.4%), using HD social media channels (61.3%) and looking up clinical trials (59.8%). Respondents emphasized a need for support in financial planning and accessing care, and also for more HD education in the medical community.   Conclusions: There is need for more support for HD patients and families. People desire more credible, accessible information. Improving resources available to patients and families should be a goal for HD organizations, along with measurement of patient outcomes."@en ;
    ns0:hasPubTitle "Quality of Care for Huntington’s Disease in the United States: Findings from a National Survey of Patients and Caregivers"@en .

ns1:jhs-v25-i3-JHS190615 ns0:hasKeywords "Intelligent transportation systems"@en,
        "network simulators"@en,
        "simulation tools"@en,
        "traffic control interface"@en,
        "traffic simulators"@en,
        "vehicular ad-hoc networks"@en ;
    ns0:hasPubAbstract "Vehicular Ad-hoc Network (VANET) is one of the future technologies that envisions the real-time vehicular communication. This technology uses the support of IEEE wireless communication protocols to successfully exchange messages between vehicles. The implementation and testing of VANET scenarios in real-time is challenging since it requires an expensive infrastructure. Hence, the simulation of VANET scenarios play an important role in evaluating the performance of these large-scale networks. However, the proper simulation of VANET scenarios should satisfy two main requirements: realistic mobility of vehicles on the roads and wireless network communication. A comparison of the various simulation tools that can be used for VANET scenarios has been undertaken in this work. The work also proposes an architecture for online and offline communication between Network Simulator 3 (NS3) and Simulation of Urban Mobility (SUMO) with public cloud support. The performance of the proposed architecture has been evaluated using various VANET simulation scenarios with varied number of vehicles along with real-time road traffic scenarios. The discussed and illustrated results show that the proposed architecture can be used for simulating various realistic VANET scenarios efficiently with a large number of vehicles in real-time."@en ;
    ns0:hasPubTitle "Online and offline communication architecture for vehicular ad-hoc networks using NS3 and SUMO simulators"@en .

ns1:jhs-v25-i3-JHS190616 ns0:hasKeywords "Router placement"@en,
        "genetic algorithms"@en,
        "greedy randomized adaptive search procedure"@en,
        "wireless networks"@en ;
    ns0:hasPubAbstract "Wireless networks are present in all the large buildings or sites, and they are expected to provide high speed Internet for the connected users. This can be achieved by connecting wireless routers to the Internet backbone through fast connection cables (e.g. fiber optics), as well finding optimal distribution of the routers along the building, so that the targeted area is covered with Internet access as much as possible, provided that the cost constraints of routers and the cost of their mutual interconnection are satisfied. Therefore, in this paper, we present two approaches for solving the problem of router placement in a two-dimensional area, where the goal is to provide optimal Internet coverage by meeting the cost constraints. Our first approach is based on Genetic Algorithms, and the second one employs the Greedy-Randomized Adaptive Search Procedure. Both approaches utilize a neighborhood exploration mechanism that consists of operators which are dealing with adding, removing, jumping and shifting routers in the target area. Furthermore, an advanced operator for intelligent shifting of routers inside a predefined neighborhood is implemented. The computational experiments, performed over a data set of four large instances, indicate that both proposed approaches can obtain competitive results to the ones that are presently available in the literature. Consequently, the results indicate that both approaches can be easily adapted for application in practice for designing the topography of wireless networks, in terms of router placement and distribution."@en ;
    ns0:hasPubTitle "Genetic algorithms and greedy-randomized adaptive search procedure for router placement problem in wireless networks"@en .

ns1:jhs-v25-i4-JHS190622 ns0:hasKeywords "Wireless sensor networks"@en,
        "dissemination"@en,
        "monitoring of sensor state"@en ;
    ns0:hasPubAbstract "Wireless sensor network (WSN) is a group of spatially dispersed sensors for monitoring the physical conditions of the environment and organizing the collected data at a central location. Since WSNs typically have no infrastructure, one of the challenges in WSNs is the lack of appropriate method for an operator to interact with the WSN. Practical tasks for WSNs require sensor node adaptive to changes in WSN configuration, user input, and commands hence, monitoring and interaction with the WSN is needed. In this paper, a new scheme for configuration dissemination with monitoring of sensor state is proposed to control dynamically sensor node operation in real time. Moreover, a method is provided for the operator to observe the state of the sensor node, which helps the operator provide an appropriate control input to the WSN. We prove the stability properties of the proposed algorithm and show the simulation results."@en ;
    ns0:hasPubTitle "A study on user-input dissemination for wireless sensor networking systems"@en .

ns1:jhs-v25-i4-JHS190623 ns0:hasKeywords "3D video quality assessment"@en,
        "3D video streaming"@en,
        "IEEE 802.11 wireless networks"@en,
        "Temporal synchronization in 3D video"@en ;
    ns0:hasPubAbstract "Although 3D video has become popular, successful 3D video streaming over wireless networks involves a number of challenges. Due to the frequent frame damages and losses in wireless networks, temporal asynchrony occurs and results in serious visual fatigue for viewers. In order to provide higher quality 3D video, this paper proposes a new scheme termed the Temporal Synchronization Scheme (TSS) for live 3D video streaming. TSS delivers video frames for the left and right views in the same frame sequence with the same transmission priority, and it compensates for frame damage and losses during the decoding phase. In addition, a new metric called the Stereoscopic Temporal Variation Index (STVI) is proposed; it measures the degree of temporal asynchrony in 3D video. Subjective assessments demonstrate that STVI is an objective metric for measuring subjective quality given that it exhibits a strong positive correlation with the subjective MOS rating. This paper demonstrates that TSS significantly improves the visual quality of 3D videos given the use of STVI and the Mean Opinion Score (MOS) even when frame damage and losses occur. The contributions of the paper are as follows: i) The proposed TSS is the first scheme to address the temporal asynchrony issue in live 3D video streaming over wireless networks. ii) TSS only requires slight modifications to decoders. iii) A new metric (i.e., STVI) is proposed to measure the degree of temporal asynchrony in 3D videos. Therefore, 3D video streaming over wireless networks can be performed with temporal synchronization, and it is expected using TSS will reduce visual fatigue."@en ;
    ns0:hasPubTitle "A Temporal Synchronization Scheme to reduce and compensate for temporal asynchrony in wireless 3D video streaming"@en .

ns1:jhs-v25-i4-JHS190624 ns0:hasKeywords "Bloom filter"@en,
        "Single hash-lookup Cuckoo filter"@en,
        "approximate membership query"@en ;
    ns0:hasPubAbstract "Approximate Membership Query (AMG) data structures are widely used in the networking area recently. The most popular AMQ data structures are Bloom, Quotient and Cuckoo Filter (CF). The CF is more efficient than the Quotient and Bloom filters in term of the lookup time and false positive rate. An issue in CF is utilization of two hash functions in the query phase that increases the lookup time. Another issue is the relocation loop problem in the programming phase that attempts to find an empty bucket for the collied items. In this paper, a new approach called Single-hash Lookup Cuckoo Filter (SLCF) using one hash function to lookup an item is proposed. In the programming phase, SLCF utilizes a sequence of hash functions without any relocation to find an empty bucket and storing the overflowed items. It finds a bucket with an empty place and sets an index in the original bucket to the address of found bucket. To accelerate the query phase, a handle as a tiny part of the fingerprint is placed in conjunction with the index value in the bucket. In the query phase, only one hash function is used and if the queried item cannot be found in the bucket, the handle is investigated to membership checking. Otherwise, the second bucket pointed by the index is accessed. The simulation results for name search in the named data networking demonstrate that the lookup time is improved 27% for 16 million names in comparison to CF."@en ;
    ns0:hasPubTitle "SLCF: Single-hash lookup cuckoo filter"@en .

ns1:jid-v22-i4-jid190002 ns0:hasKeywords "China"@en,
        "Cooperative behaviors"@en,
        "innovation capability"@en,
        "knowledge sharing"@en,
        "oswaldojim@gmail.com"@en ;
    ns0:hasPubAbstract "This paper explores individual’s role in the innovation process of firms by determining staff members’ openness to engage in cooperative behaviors with their peers in the Chinese context, and subsequently, the impact of those interactions on the perceptions of trust among colleagues, and how those links influence the innovation capability of firms. Also, we size the extent to which employees’ years of experience can moderate those relations. Questionnaire responses derived from employees in Chinese technology-driven firms were used to perform the statistical analysis and test the hypotheses drawn in this study. The individual’s engagement in cooperative behaviors was proven to be rather unbiased among colleagues. Likewise, those dynamics led to positive perceptions of trust among them and added to the innovation capability of firms while an individual’s years of experience didn’t influence those dynamics. The present article examined two knowledge-sharing approaches used to ease cooperative behaviors among staff members. However, it is also necessary to examine the influence of other approaches in order to generate more precise comparisons of the frameworks that can yield better results. It is suggested that Chinese firms adopt a more reflexive learning approach that would facilitate individual’s engagement in cooperative behavior that lead to innovation. These results can be useful for managers in industries such as software-engineering and product-design which depend heavily on the effective transmission of knowledge among staff."@en ;
    ns0:hasPubTitle "Impact of Individual’s Cooperative Behaviors on Innovation: Evidence from China"@en .

ns1:jnd-v6-i3-JND180345 ns0:hasKeywords "Human Phenotype Ontology"@en,
        "Myotonic dystrophy"@en,
        "PhenoStacks"@en,
        "congenital"@en ;
    ns0:hasPubAbstract "Background: Congenital Myotonic Dystrophy (CDM1) is a rare neuromuscular condition caused by a triplet repeat expansion in the DMPK gene. Despite there being a well-recognized clinical syndrome, there has not been an effort to use a standardized ontology system to describe the disease characteristics in existing literature. Thus, comparing or contrasting different cohorts from the literature can be challenging, and coding disease features for clinical research or for registry data items is not uniform. PhenoStacks is a visualization analytics tool which helps graphically illustrate phenotypes of patients with genetic disorders using Human Phenotype Ontology (HPO) terms and can sort phenotypes by different disease characteristics.   Objective: To demonstrate the efficacy of PhenoStacks and the HPO system as clinical research tools when describing CDM1 cohorts.   Methods: Health Endpoints and Longitudinal progression in congenital myotonic dystrophy (HELP-CDM) is an ongoing study which longitudinally follows patients with CDM1. Items from the HELP-CDM data sheet were matched to corresponding HPO terms and analyzed using PhenoStacks.   Results: In total 40 subjects’ phenotypes were visualized through PhenoStacks and 73 HPO terms were used for the analysis. Frequent phenotypic features included “high narrow palate”, “facial palsy”, “ptosis”, “hyporeflexia”, and “weak voice”. Contractures were associated with higher repeat sizes. Hypoplastic muscles and infantile axial hypotonia were more frequently observed in infants.   Conclusions: PhenoStacks is a valuable clinical and scientific tool as it identifies variability within cohorts and highlights significant phenotypic features."@en ;
    ns0:hasPubTitle "A Phenotypic Description of Congenital Myotonic Dystrophy using PhenoStacks"@en .

ns1:jnd-v6-i3-JND190407 ns0:hasKeywords "Myasthenia gravis"@en,
        "diplopia"@en,
        "fluctuations"@en,
        "ocular weakness"@en,
        "ptosis"@en ;
    ns0:hasPubAbstract "Introduction: In this study we quantitatively describe ocular weakness patterns in myasthenia gravis (MG) to help neurologists in making the clinical diagnosis and to investigate how the current outcome measures reflect ocular weakness in MG.   Methods: We investigated ptosis and diplopia patterns in a retro- and prospective cohort of 306 MG patients. Diplopia was systematically examined by testing extra-ocular muscle (EOM) fatigability in two horizontal and four oblique directions for 60 seconds.   Results: Of patients with initial symmetric ptosis, 40% developed asymmetric ptosis at the second visit. Changes in form of ptosis occurred less often in seronegative MG patients (50%) than in patients with acetylcholine receptor (AChR) antibodies (70%) or muscle-specific kinase (MuSK) antibodies (69%) (p = 0.038). Of patients with diplopia on the first visit, double vision contained both a vertical and horizontal component in 95%. At the second visit, 83% manifested diplopia in other gaze directions. The mean time (in seconds) to diplopia was 11.6±14.0 and the mean time to ptosis was 27.6±19.8. Diplopia or ptosis manifested within 30 seconds in 87% and 58%, respectively. Patients who manifested diplopia after 30 seconds, reported no limitations due to diplopia.   Discussion: Changes in the gaze directions in which diplopia occurs or ptosis side occur frequently in MG. In diagnostically challenging cases, we recommend testing ptosis and diplopia in multiple gaze directions for 30–60 seconds during at least two follow-up visits to maximize the chance of observing changes in ocular weakness patterns."@en ;
    ns0:hasPubTitle "Ocular Weakness in Myasthenia Gravis: Changes in Affected Muscles are a Distinct Clinical Feature"@en .

ns1:jnd-v6-i4-JND190415 ns0:hasKeywords "Muscular dystrophies"@en,
        "cardiac magnetic resonance"@en,
        "cardiomyopathy"@en,
        "myocardial involvement"@en,
        "sudden death"@en ;
    ns0:hasPubAbstract "Muscular dystrophies (MD) represent a heterogeneous group of rare genetic diseases that often lead to significant weakness due to progressive muscle degeneration. In many forms of MD, cardiac manifestations including heart failure, atrial and ventricular arrhythmias and conduction abnormalities can occur and may be a predominant feature of the disease. Cardiac magnetic resonance (CMR) can assess cardiac anatomy, global and regional ventricular function, volumes and mass as well as presence of myocardial inflammation, infiltration or fibrosis. The role for cardiac MRI has been well-established in a wide range of muscular dystrophies related cardiomyopathies. CMR is a more sensitive technique than echocardiography for early diagnosis of cardiac involvement. It has also great potential to improve the prediction of long-term outcome, particularly the development of heart failure and arrhythmic events; however it still has to be validated by longitudinal studies including large populations. This review will outline the utility of CMR in patients with muscular dystrophies for assessment of myocardial involvement, risk stratification, and in guiding therapeutic management."@en ;
    ns0:hasPubTitle "The Added Value of Cardiac Magnetic Resonance in Muscular Dystrophies"@en .

ns1:jpd-v9-i3-JPD181565 ns0:hasKeywords "Amantadine"@en,
        "OFF"@en,
        "Parkinson disease"@en,
        "delayed-action preparations"@en,
        "double-blind method"@en,
        "dyskinesias"@en,
        "episodes"@en,
        "humans"@en,
        "levodopa"@en,
        "transitions"@en,
        "treatment"@en ;
    ns0:hasPubAbstract "Background: Parkinson’s disease (PD) patients using levodopa commonly develop dyskinesia and OFF episodes that reduce quality of life.   Objective: Evaluate prevalence of troublesome dyskinesia and OFF through the day, assessed by 30-minute intervals, as well as the mean number and duration of troublesome dyskinesia and OFF episodes, transitions between PD states, and effects of Gocovri® (amantadine) extended release capsules on these episodes.   Methods: Evaluate diary data from pooled Gocovri phase 3, placebo-controlled trials—analyzed for 17 hours following wake-up—at baseline and week 12.   Results: Diaries were evaluable for 162 patients. At baseline, 67% of patients woke up OFF, with prevalence decreasing to 13% at 2 hours and then remaining relatively steady at ∼12% (range, 6–17%) across half-hour intervals thereafter. Troublesome dyskinesia prevalence rose steadily from 5% to 24% over the first 2 hours, then fluctuated between 20% and 44% through the rest of the waking day. At baseline, patients experienced a mean of 3.0 daily episodes of troublesome dyskinesia (average duration 2.0 hours each), and 2.2 daily episodes of OFF (average duration 1.1 hour each). At week 12, Gocovri-treated patients showed greater reductions than placebo in troublesome dyskinesia and OFF episodes per day (treatment difference: –1.0 episodes and –0.4 episodes, respectively) and average episode duration (treatment difference: –0.6 hours and –0.3 hours, respectively). Mean duration of individual episodes of ON without troublesome dyskinesia (Good ON) increased by 5.0 hours for Gocovri, compared with 2.0 hours for placebo. Patients taking Gocovri experienced 2.2 fewer transitions between states than patients taking placebo.   Conclusions: Troublesome dyskinesia and OFF occurred in the morning and throughout the waking day. Gocovri-treated patients experienced fewer, shorter episodes of both troublesome dyskinesia and OFF, thereby increasing the duration of continuous Good ON episodes and reducing the frequency of transitions between motor states."@en ;
    ns0:hasPubTitle "Prevalence of Dyskinesia and OFF by 30-Minute Intervals Through the Day and Assessment of Daily Episodes of Dyskinesia and OFF: Novel Analyses of Diary Data from Gocovri Pivotal Trials"@en .

ns1:jpd-v9-i3-JPD191577 ns0:hasKeywords "Ethics of sham surgery"@en,
        "Parkinson’s disease"@en,
        "evidence-based ethics"@en,
        "patient-centered methods"@en,
        "stem cells"@en,
        "surgical placebo-controlled trials"@en ;
    ns0:hasPubAbstract "The stated purpose of sham or placebo surgery is to enable the implementation of surgical placebo-controlled trials (SPTs) for evaluating the safety and efficacy of surgical interventions. Exposing the participants to the burdens and harms of sham surgery has been justified on the grounds of the absolute necessity for controlling large placebo effects and observer bias, assumed to be associated with surgical procedures. In the present review, we argue that evidence obtained from SPTs of cellular therapies for the treatment of Parkinson’s disease (PD) has failed to demonstrate either large and consistent placebo effects or decisive methodological advantages for relying on sham surgical controls. We outline several alternative assessment strategies and designs available to establish the efficacy of cellular therapies. It is concluded that the evidence evaluated in the present analysis indicated that use of sham surgery in the context of developing novel surgical procedures for PD is not necessary, and therefore, unethical under a utilitarian model."@en ;
    ns0:hasPubTitle "Evidence-Based Evaluation of the Ethics of Sham Surgery for Parkinson’s Disease"@en .

ns1:jpd-v9-i3-JPD191604 ns0:hasKeywords "Frailty"@en,
        "Parkinson’s disease"@en,
        "systematic review"@en ;
    ns0:hasPubAbstract "Background: Parkinson’s disease (PD) and frailty are two conditions that are increasingly common with advancing age, yet little is known about their relationship.   Objective: The aim of this study was to examine the co-occurrence of frailty in people with PD; to describe the measures used to assess frailty in PD, and assess the prevalence of frailty in subjects with PD.   Methods: We conducted a systematic review of Pubmed and Embase in April 2018. Studies that assessed frailty in subjects with PD were included in the review and data was extracted on the prevalence of frailty in subjects with PD. Due to heterogeneity of studies a meta-analysis was not performed.   Results: Eight studies were included in the review, of which 7 were cross-sectional and 1 a prospective cohort study. Mean age of participants with PD in the studies ranged from 66 to 85 years. The majority (6/8) used the 5-item, Fried criteria to measure frailty, with the remainder using index-based measures. 5 studies provided data on the prevalence of frailty in PD, which ranged from 29% to 67%.   Conclusions: Few studies have quantified the prevalence of frailty in PD, but those that have suggest a high concurrence of these two conditions."@en ;
    ns0:hasPubTitle "Frailty in Parkinson’s Disease: A Systematic Review"@en .

ns1:jpd-v9-i3-JPD191605 ns0:hasKeywords "GLORIA"@en,
        "Parkinson’s disease"@en,
        "levodopa-carbidopa intestinal gel"@en,
        "monotherapy"@en,
        "multinational registry"@en ;
    ns0:hasPubAbstract "Background: Continuous delivery of levodopa-carbidopa intestinal gel (LCIG) provides stable plasma levodopa concentrations and reduces motor fluctuations in advanced Parkinson’s disease (PD) patients.   Objective: To compare the effectiveness and safety of LCIG monotherapy vs polytherapy in patients in the GLORIA registry.   Methods: This was a post hoc analysis of a 24-month, multinational observational registry where advanced PD patients with persistent motor complications received LCIG (with adjunctive PD treatment, as necessary). Patients were categorized retrospectively into three stable treatment groups: LCIG monotherapy, LCIG in combination with oral levodopa only (“levodopa monotherapy” [including nighttime oral levodopa]), or LCIG in combination with any other antiparkinsonian medication (“LCIG polytherapy”).   Results: Of 356 patients, 208 were on stable regimens (LCIG monotherapy n = 80; levodopa monotherapy n = 47; LCIG polytherapy n = 81). Baseline characteristics were similar across groups. LCIG monotherapy showed significant improvements until month 18 in activities of daily living and quality of life, and until month 24 for Unified Parkinson’s Disease Rating Scale (UPDRS) motor examination (p < 0.05), “Off” time (p < 0.001), “On” time with dyskinesia (p < 0.01), and non-motor symptoms (p < 0.01). More patients in the levodopa monotherapy and LCIG polytherapy groups experienced treatment-related adverse drug reactions (ADRs) including dyskinesias and serious ADRs than did patients in the LCIG monotherapy group. There were few polyneuropathy-related ADRs, of which one case of polyneuropathy led to discontinuation from the Levodopa monotherapy group.   Conclusions: These data demonstrate that LCIG monotherapy is an effective treatment option in appropriate advanced PD patients; however, definitive baseline clinical predictors identifying patients who can discontinue concomitant oral therapy have not yet been defined."@en ;
    ns0:hasPubTitle "Levodopa-Carbidopa Intestinal Gel Monotherapy: GLORIA Registry Demographics, Efficacy, and Safety"@en .

ns1:jpd-v9-i3-JPD191627 ns0:hasKeywords "Acetylcholine"@en,
        "GABA"@en,
        "amyloid-β"@en,
        "glymphatic clearance"@en,
        "inflammation"@en,
        "neural circuits"@en,
        "sleep"@en,
        "tau"@en,
        "α-synuclein"@en ;
    ns0:hasPubAbstract "Sleep disturbances are common and a major source of disability in Parkinson’s disease (PD). Primary and secondary insomnia, rapid eye movement sleep behavior disorder (RDB), central sleep apnea, restless legs, and nocturnal akinesia are common sleep disturbances in PD. Prodromal presence of RBD is associated with a more severe motor and non-motor PD subtype implying a significant disease-modifying effect of this parasomnia. Other disease-modifying mechanisms of sleep disturbances in PD include impaired glymphatic clearance, endoplasmic reticulum stress, nocturnal brain deoxygenation and inflammatory processes among others. Impairments of neural circuit switching and imbalance between inhibitory and excitatory neuronal populations are likely responsible for episodic sleep disturbances, in particular RBD. As neural circuits may predict patterns of α-synuclein propagation in the nervous system, impairments of such circuits are of high relevance for PD pathophysiology. Future research is needed to determine whether appropriate treatment for disturbed sleep might slow progression of PD."@en ;
    ns0:hasPubTitle "Sleep Disturbance as Potential Risk and Progression Factor for Parkinson’s Disease"@en .

ns1:jpd-v9-i3-JPD191630 ns0:hasKeywords "Biomarkers"@en,
        "Parkinson’s disease"@en,
        "cerebrospinal fluid"@en,
        "mutation"@en ;
    ns0:hasPubAbstract "Mutations in the leucine-rich repeat kinase 2 (LRRK2) gene are the most common known cause of autosomal dominant Parkinson’s disease (PD) and sporadic PD (sPD). The clinical presentation of LRRK2 PD is similar to sPD, and except for genetic testing, no biochemical or imaging markers can differentiate LRRK2 PD from sPD. Discovery of such biomarkers could indicate neuropathological mechanisms that are unique to or increased in LRRK2 PD. This review discusses findings in 17 LRRK2 - related CSF studies found on PubMed. Most of these studies compared analyte concentrations between four diagnostic groups: LRRK2 PD patients, sPD patients, asymptomatic control subjects carrying PD-associated LRRK2 mutations (LRRK2 CTL), and healthy control subjects lacking LRRK2 mutations (CTL). Analytes examined in these studies included Aβ1-42, tau, α-synuclein, oxidative stress markers, autophagy-related proteins, pteridines, neurotransmitter metabolites, exosomal LRRK2 protein, RNA species, inflammatory cytokines, mitochondrial DNA (mtDNA), and intermediary metabolites. FINDINGS: Pteridines, α-synuclein, mtDNA, 5-hydroxyindolacetic acid, β-D-glucose, lamp2, interleukin-8, and vascular endothelial growth factor were suggested to differentiate LRRK2 PD from sPD patients; 8-hydroxy-2’-deoxyguanosine (8-OHdG), 8-isoprostane (8-ISO), 2-hydroxybutyrate, mtDNA, lamp2, and neopterin may differentiate between LRRK2 CTL and LRRK2 PD subjects; and soluble oligomeric α-synuclein, 8-OHdG, and 8-ISO might differentiate LRRK2 CTL from CTL subjects. CONCLUSIONS: The low numbers of investigations of each analyte, small sample sizes, and methodological differences limit conclusions that can be drawn from these studies. Further investigations are indicated to determine the validity of the analytes identified in these studies as possible biomarkers for LRRK2 PD patients and/or LRRK2 CTL subjects."@en ;
    ns0:hasPubTitle "What Have We Learned from Cerebrospinal Fluid Studies about Biomarkers for Detecting LRRK2 Parkinson’s Disease Patients and Healthy Subjects with Parkinson’s-Associated LRRK2 Mutations?"@en .

ns1:jpd-v9-i3-JPD191635 ns0:hasKeywords "Parkinson’s disease"@en,
        "hallucination state"@en,
        "stroboscopic light"@en,
        "visual hallucinations"@en ;
    ns0:hasPubAbstract "Visual hallucinations are a common and often distressing feature of Parkinson’s disease; they are ephemeral and capricious, making them difficult to study but tend to be more prominent in dim illumination. Flickering stimuli can induce simple hallucinations even in healthy individuals. We tested a stroboscope and an equivalent full-screen flickering stimulus in 16 participants: 7 patients with Parkinson’s and habitual visual hallucinations, 6 Parkinson’s patients without hallucinations and 3 controls. Both flicker sources induced varied geometrical hallucinations in 4 participants (25%) and complex hallucinations in 1 but neither induced typical Parkinson’s-associated hallucinations."@en ;
    ns0:hasPubTitle "Flickering Stimuli Do Not Reliably Induce Visual Hallucinations in Parkinson’s Disease"@en .

ns1:jpd-v9-i4-JPD191672 ns0:hasKeywords "Non-motor fluctuations"@en,
        "dopamine turnover"@en,
        "long-term major health outcomes"@en,
        "motor complication"@en,
        "prediction"@en ;
    ns0:hasPubAbstract "Background and Objective: To investigate the predictive value of striatal dopamine turnover in patients with de novo Parkinson’s disease (PD) for later occurrence of major non-motor health outcomes.   Methods: This retrospective, observer-blinded cohort study followed up 29 patients with de novo PD for a median of 10.7 years, who completed 18Fluorodopa PET imaging to measure striatal effective distribution volume ratio (EDVR, inverse of dopamine turnover) prior to antiparkinsonian treatment. Outcomes were assessed with a battery of non-motor, health-related quality-of-life and non-motor fluctuation (WOQ-19) measures and survival.   Results: During follow-up, 52% of patients developed wearing-off, 43% neuropsychiatric fluctuations, 35% sensory fluctuations, 32% dementia, 46% depression, 30% psychosis, and PD-related mortality was 26%. Patients with wearing-off and neuropsychiatric fluctuations showed significantly lower baseline EDVR (higher dopamine turnover) in the putamen but not in the caudate nucleus than those without these fluctuations. Consistently, baseline EDVR in the putamen predicted development of wearing-off and neuropsychiatric fluctuations with a lower risk with higher EDVR (lower dopamine turnover), whereas EDVR in caudate nucleus did not correlate with these fluctuations. No relationships were observed between baseline PET measures and the presence of other major health outcomes including survival.   Conclusions: Lower putaminal dopamine turnover in de novo PD is associated with reduced risk for later neuropsychiatric fluctuations comprising a disease-intrinsic predisposing factor for their development, similar as reported for levodopa-induced motor complications. Striatal (putaminal/caudate) dopamine turnover is not predictive for other long-term major health outcomes. These results should be treated as hypothesis generating and require confirmation."@en ;
    ns0:hasPubTitle "Putaminal Dopamine Turnover in de novo Parkinson’s Disease Predicts Later Neuropsychiatric Fluctuations but Not Other Major Health Outcomes"@en .

ns1:jpd-v9-i4-JPD191688 ns0:hasKeywords "Parkinson’s disease"@en,
        "diffusion tensor imaging"@en,
        "rapid eye movement sleep behavior disorder"@en,
        "white matter"@en ;
    ns0:hasPubAbstract "Background: Parkinson’s disease (PD) is characterized by distinct motor symptoms which do not manifest until significant neurodegeneration has already occurred. Therefore, preventative treatments depend on PD being detected in a prodromal phase. To date, prodromal PD (pPD) has been conceptualized based on conditions such as REM Sleep Behavior Disorder (RBD), which has a high conversion rate to clinical PD (cPD). However, few studies have examined microstructural differences between healthy controls (HC), pPD, and cPD.   Objective: The current study examined white matter microstructure in different phases of PD progression.   Methods: Participants included 21 HC, 20 pPD (14 with RBD and 6 with hyposmia), and 17 cPD from the Parkinson’s Progression Markers Initiative database. Tract-based spatial statistics were used to determine between group differences in fractional anisotropy (FA) and mean diffusivity (MD).   Results: Mean diffusivity was significantly increased in pPD relative to cPD in widespread, but mostly right lateralized regions. Post-hoc analyses indicated that this pattern was particular to individuals with RBD. There were no microstructural differences between HC and pPD or cPD. The pPD group had significantly higher RBD symptoms and the cPD group had significantly higher motor symptoms.   Conclusions: Observed microstructural deterioration in individuals with RBD relative to cPD may indicate an altered pattern of neurodegeneration associated with RBD as a prodromal symptom of PD. Future studies should aim to further characterize possible differential patterns of progression from various non-motor symptoms (e.g., RBD, hyposmia) to cPD using longitudinal designs."@en ;
    ns0:hasPubTitle "Tract-Based Spatial Statistics Reveal Lower White Matter Integrity Specific to Idiopathic Rapid Eye Movement Sleep Behavior Disorder as a Proxy for Prodromal Parkinson’s Disease"@en .

ns1:jpd-v9-i4-JPD191699 ns0:hasKeywords "Parkinson’s disease"@en,
        "biomarker"@en,
        "inflammation"@en,
        "plasma"@en ;
    ns0:hasPubAbstract "The nature of the inflammatory response in Parkinson’s disease (PD) remains to be better understood. Here, we used highly sensitive Single Molecule Array (SIMOA) technology to measure the levels of the inflammatory mediators Interleukin 6 (IL-6), Interleukin 17A (IL-17A), Tumour Necrosis Factor α (TNFα) and Transforming Growth Factor β (TGFβ) in plasma from PD patients and age- and gender-matched healthy controls. We report that IL-17A correlates with non-motor symptoms (NMS) scores, while IL-6 positively correlates with motor scores. We found no correlations between cytokines and disease duration suggesting that IL-6 and IL-17A are associated with disease severity rather than disease duration in this cohort, furthermore IL-17A may be involved in the underlying pathophysiology of NMS in PD."@en ;
    ns0:hasPubTitle "Plasma IL-6 and IL-17A Correlate with Severity of Motor and Non-Motor Symptoms in Parkinson’s Disease"@en .

ns1:jpd-v9-i4-JPD191713 ns0:hasKeywords "Parkinson’s disease"@en,
        "anxiety"@en,
        "dyspnea"@en,
        "non-motor symptom"@en,
        "ventilatory dysfunction"@en ;
    ns0:hasPubAbstract "Background: Dyspnea is a multidimensional sensation that is reported in Parkinson’s disease (PD). The multidimensional dyspnea profile (MDP) questionnaire can help to distinguish the perceptive dimension and the emotion response.   Objective: The aim was to assess the clinical features associated with dyspnea using the MDP questionnaire in order to determine which aspects of the symptom was linked with anxiety, depression or motor severity of the disease.   Methods: Non-demented patients were asked whether they experienced shortness of breath in the last month. In case of positive answer, dyspnea was assessed by the MDP. MDS-UPDRS, global cognitive performance, non-motor symptoms and quality of life were assessed.   Results: 60/163 patients were dyspneic since 4.6±2.4 years. The most frequent best sensory quality (SQ) described were: hyperpnoea (35%), physical breathing effort (25%) and air hunger (20%). Hyperpnoea and air hunger had the highest SQ intensity. Anxiety had the highest intensity in the emotional domain.   Conclusion: Dyspnea is a frequent symptom in PD, with specific presentations and two main aspects: one related with anxiety and another with ventilation control impairment."@en ;
    ns0:hasPubTitle "Dyspnea Is a Specific Symptom in Parkinson’s Disease"@en .

ns1:jpd-v9-is2-JPD191707 ns0:hasKeywords "Intestinal barrier"@en,
        "Parkinson’s disease"@en,
        "enteric nervous system"@en,
        "tight junctions"@en ;
    ns0:hasPubAbstract "The intestinal barrier, which primarily consists of epithelial cells stitched together with connecting proteins called tight junctions, plays a critical role in health and disease. It is in close contact with the gut microbiota on its luminal side and with the enteric neurons on the tissue side. Both microbiota and the enteric nervous system are regulatory housekeepers of the intestinal barrier. Therefore, the recently observed enteric neuropathology along with gut dysbiosis in Parkinson’s disease have prompted research on intestinal permeability in this neurodegenerative disorder. In this mini-review we attempt to concisely summarize the current knowledge on intestinal barrier in Parkinson’s disease. We envision future direction research that should be pursued in order to demonstrate its possible role in disease development and progression."@en ;
    ns0:hasPubTitle "The Intestinal Barrier in Parkinson’s Disease: Current State of Knowledge"@en .

ns1:jrs-v30-i2-JRS180021 ns0:hasKeywords "Prescription"@en,
        "dental junior residents"@en,
        "dental prescription"@en,
        "doctors"@en,
        "drugs"@en,
        "knowledge"@en ;
    ns0:hasPubAbstract "BACKGROUND: There has been an increasing need to examine undergraduate dental education in prescribing to confirm whether it is establishing the goal of producing safe and rational prescribers. Prescribing by dental doctors after graduation is influenced by a variety of factors: the different teaching approaches of the professors at the clinics and in the pharmacology course, fellow colleagues and even the information provided by the pharmaceutical industry.   OBJECTIVE: The aim of this study was to assess the prescription knowledge, attitude, preference and common errors made by junior resident dental doctors in the dental department of two medical colleges and hospitals in India.   METHODS: Dental graduates (n = 70) who served as junior resident doctors at dental departments and graduated from various dental colleges in India, participated in the study. A survey was conducted among 70 junior resident dental doctors in the dental department, applying a previously validated questionnaire consisting of open-ended questions. The knowledge, attitude and practice preference of resident doctors regarding drug prescription and common errors made by them were analyzed and reviewed.   RESULTS: The most frequent response to each question was considered the most significant. The most common reason for prescribing medication was infection (n = 33, 47.14%) and the most widely prescribed antibiotic was amoxicillin (n = 29, 41.42%). The most frequent error reported by resident doctors was lack of knowledge about drug posology (n = 31, 44.28%). Maximum number of junior doctors acquired the information for prescribing drugs from their faculty (n = 33, 47.14%). Around 45.71% dental doctors had no knowledge about the WHO Guide to Good Prescribing. About 50– 60% doctors had knowledge about the dose, frequency, duration and route of administration of the drug prescribed. While prescribing drugs to the patient, 25.71% doctors explain the disease and treatment properly to the patient; 24.28% doctors do not criticize other doctors, and 10% doctors address the patient by name.   CONCLUSION: The results of this study indicate that resident dental doctors’ knowledge, attitudes and behavior about the drug prescription need to be improved. More studies are needed to determine whether this issue affects the quality of patient care and the effectiveness and safety of treatments."@en ;
    ns0:hasPubTitle "Knowledge, attitudes and practice preference regarding drug prescriptions of resident dental doctors: A quantitative study"@en .

ns1:jsa-v5-i3-JSA190242 ns0:hasKeywords "Aesthetic sports"@en,
        "basketball"@en,
        "dunk"@en,
        "judging"@en,
        "linear mixed-model"@en,
        "nonparametric regression"@en,
        "slam"@en ;
    ns0:hasPubAbstract "Scores of 464 dunks (of 682) in the 1984-2016 NBA Slam Dunk Contests (SDCs) were analyzed. Nonparametric regression was used to analyze the elements of dunks themselves (R2 = 0.44). Residuals were the dependent variable in a linear mixed-model with contest formatting and superlative variables as fixed effects; contestant and year were random effects. SDC scores were significantly influenced by the elements of a given dunk such as whether a pass was thrown, if the contestant rotated his body while airborne, or spun his arm while possessing the ball. Dunking later in the scheduled sequence increased scores in the initial round. Higher contestant popularity (measured by proportional newspaper mentions) and competing in home arenas increased scores. Replacing missed dunks reduced scores. Histrionic displays that were exhibited prior to dunking but were uninvolved in the execution of the dunk itself increased scores. Greater dunk novelty and judge experience reduced scores. The results are interpreted to show that athleticism influences scoring, that excitement factors prominently in scoring, and that SDC scoring is subject to similar superlative pressures found in other aesthetic sports. The findings are discussed and related to the NBA, SDC, and dunk contests in general."@en ;
    ns0:hasPubTitle "Factors influencing scoring in the NBA Slam Dunk Contest"@en .

ns1:jvr-v51-i2-JVR191037 ns0:hasKeywords "PROMISE"@en,
        "Supplemental Security Income"@en,
        "Transition to adulthood"@en,
        "interagency collaboration"@en,
        "service coordination"@en,
        "transition planning"@en,
        "youth with disabilities"@en ;
    ns0:hasPubAbstract "BACKGROUND: Interagency collaboration is one of the most highly recommended practices in transition to adulthood for youth with disabilities, but it is also one of the least empirically understood. Recent literature cites the need to clarify collaboration as a construct, and focus on collaborative practices and processes to supplement research on antecedents and outcomes.   OBJECTIVES: This exploratory, mixed methods research looks to highlight collaborative practices and processes in NYS PROMISE, a statewide project aiming to improve outcomes for youth with disabilities who receive Supplemental Security Income. The project used interagency agreements to specify required service coordination processes, communications, information sharing, professional development, and cross-training.   METHODS: The mixed methods approach combines three studies. In Study 1, the Levels of Collaboration Survey (LCS, Frey et al., 2006) provided data on regional network changes over time. In Study 2, an organizational attitudes and experiences (OAE) survey measured satisfaction of partner communications. In Study 3, qualitative analysis of biannual on-site interviews helped contextualize the characteristics of partnerships that project staff found effective.   RESULTS: In a descriptive sense, the LCS showed increases in regional cohesion, peaking in the project’s penultimate year. Changes were statistically significant in at least one region. OAE responses showed regional increases in satisfaction with partner communications. Qualitative analysis indicated that characteristics of partnerships described as effective included: (a) joint objectives and clearly defined roles; (b) extensive sharing of information and resources; and (c) frequent communication (formal and informal). Staff turnover, inadequate organizational capacity, and partners not executing key functions were described as barriers to productive collaboration.   CONCLUSIONS: Feedback from project staff provides clarification of the experiences of agency staff coordinating services, and helps refine certain constructs and assumptions common in collaboration research about transition. The authors discuss implications for future research and the development of sustainable systems of interagency collaboration in the field of transition."@en ;
    ns0:hasPubTitle "Interagency collaboration in transition to adulthood: A mixed methods approach to identifying promising practices and processes in the NYS PROMISE project"@en .

ns1:jvr-v51-i2-JVR191040 ns0:hasKeywords "Parents"@en,
        "SSI"@en,
        "guardians"@en,
        "transition-age youth"@en ;
    ns0:hasPubAbstract "BACKGROUND: Parents and guardians play significant roles helping young individuals with disabilities to develop expectations about adult endeavors, including postsecondary education and work. These expectations are partially shaped by access to information and training related to disability, education, employment, community resources, and disability-related services and supports.   OBJECTIVE: The purpose of this research is to illustrate the findings of a longitudinal examination of provision of information and training interventions to parents of young recipients of Supplemental Security Income (SSI).   METHODS: The inquiry examined case service data of 1,646 young SSI recipients and their parents or guardians. Analyses examined trends in parent/guardian information and training interventions based upon the youth’s age, gender, disability type, the parent’s employment status, parent’s education level, and youth and parent expectations about work and college.   RESULTS: There were no differences in interventions received associated with gender, age, parent education level, or parent expectation that the youth would work after completing high school. However, there were differences in interventions received associated with type of disability and parent/guardian employment status. Additionally, youth who expected to seek employment or attend college after high school and parents who expected their youth to attend college received significantly fewer interventions, while those who did not hold those expectations received significantly more interventions."@en ;
    ns0:hasPubTitle "CaPromise: Training interventions for parents and guardians of young recipients of Supplemental Security Income"@en .

ns1:jvr-v51-i2-JVR191041 ns0:hasKeywords "Supplemental Security Income"@en,
        "implementation"@en,
        "transition-age youth"@en ;
    ns0:hasPubAbstract "BACKGROUND: Maryland Promoting Readiness of Minors in Supplemental Security Income (PROMISE) model demonstration project has implemented and is evaluating a collaborative, integrated community-based intervention. PROMISE is designed to increase the likelihood that youth who receive Supplemental Security Income (SSI) in Maryland, and their families, will experience better employment outcomes, increased earnings, and decreased public income support. The intervention was conceptualized from extant research identifying factors, which promote competitive integrated employment outcomes for youth with disabilities.   OBJECTIVE: In order to effectively assess the impact of the intervention on the participating youth and families it is necessary to ensure that the large-scale statewide project upholds a strong measure of fidelity across implementation sites. That is, does the project deliver the intervention as intended and is it implemented the same way no matter the individual characteristics of the participants and no matter where they live?   RESULTS: The authors present a descriptive report on the implementation of Maryland PROMISE, illustrate measures of fidelity achieved in serving 997 transition age youth receiving SSI across the state, show preliminary data on early impact, and offer implications for ongoing PROMISE evaluation and its potential influence on policy and practice."@en ;
    ns0:hasPubTitle "Intervention fidelity in a large scale model demonstration project: Lessons from Maryland PROMISE"@en .

ns1:jvr-v51-i2-JVR191043 ns0:hasKeywords "Supplemental Security Income"@en,
        "Transition-age youth"@en,
        "employment"@en ;
    ns0:hasPubAbstract "BACKGROUND: Promoting the Readiness of Minors in Supplemental Security Income (PROMISE) is a federal demonstration grant funded by the U.S. Department of Education in collaboration with Health and Human Services, Labor, and the Social Security Administration. Wisconsin PROMISE is one of six model demonstration sites.   OBJECTIVE: This analysis was conducted to help illustrate the estimated costs and potential savings associated with supporting transition-age youth receiving Supplemental Security Income (SSI) achieve competitive, integrated employment.   RESULTS: While not all youth achieve earnings at substantial levels, the research clearly indicates that providing opportunities for employment during the transition age years increases the likelihood of employment in adulthood. Additionally, youth with access to coordinated services and supports are more likely to be employed at higher rates, preparing them for improved employment and earnings trajectories into adulthood.   CONCLUSION: Two options are presented, and the integration of employment-focused targeted outreach and case management and/or family navigator advocates is recommended for all transition-age youth receiving SSI and their families."@en ;
    ns0:hasPubTitle "Wisconsin PROMISE cost-benefit analysis and sustainability framework"@en .

ns1:jvr-v51-i2-JVR191044 ns0:hasKeywords "Supplemental Security Income"@en,
        "return on investment"@en,
        "transition-age youth"@en ;
    ns0:hasPubAbstract "BACKGROUND: Promoting Readiness of Minors in SSI (PROMISE) is a uniquely large initiative, with over $229 million awarded to sites across the country, by the U.S. Departments of Education, Labor, and Health and Human services to improve the education and employment outcomes for youth who receive Supplemental Security Income (SSI) and their families.   OBJECTIVE: Policy makers need a clear understanding of the impact of the PROMISE intervention and the cost to roll out policy changes to the broader population; however, a comprehensive return on investment (ROI) analysis of PROMISE will not be available for many years, as it will require long-run information on the employment patterns of the participants. Although a full ROI analysis will be an essential tool to evaluate the policy implications of PROMISE, there is also a current need to understand the range of the ROI. To that end, this study aims to frame the bounds of the ROI for PROMISE and highlight the costs of expanding the availability of select services.   CONCLUSION: The bounds of the ROI are determined by estimating the range of lifetime cost savings over levels of employment for SSI youth, accounting for benefit receipt and tax revenue. Using administrative data from the PROMISE sites, the study additionally estimates the cost to expanding select PROMISE services or activities within each state or site."@en ;
    ns0:hasPubTitle "Bounding the return on investment and projecting the costs of expanding PROMISE services and activities: Initial insights from PROMISE for policymakers"@en .

ns1:jvr-v51-i2-JVR191045 ns0:hasKeywords "PROMISE"@en,
        "Transition-age youth"@en,
        "employment"@en,
        "supplemental security income"@en ;
    ns0:hasPubAbstract "BACKGROUND: PROMISE Model Demonstration Projects (MDPs) are on the front line of innovative, comprehensive supports for transition-aged youth and their families. Investments made through PROMISE can inform future policy and practice in youth transition, family engagement, and systems collaboration. This paper gives an overview of emerging lessons learned throughout the implementation of PROMISE MDPs.   DOCUMENTS REVIEWED: This paper provides a comprehensive overview of documents from key stages of project implementation, including technical assistance plans, briefing books, mid-course and annual progress reports, and comprehensive process reports. These documents were reviewed regarding five core areas around which PROMISE was developed: collaboration models, professional development, leadership, service delivery, and family engagement.   FINDINGS: The most salient emerging themes concern service delivery, leadership, interagency collaboration, professional development, and family engagement.   FUTURE DIRECTIONS: This document review provides the foundation and directions for a further evaluation of lessons learned in PROMISE MDPs. These lessons can inform recommendations for sustainability, the use of best practices, and the integration of policies that support employment and post-secondary education for youth with disabilities and their families. It is essential that future research continues to develop a deeper and more comprehensive understanding of these emerging themes."@en ;
    ns0:hasPubTitle "What matters: Lessons learned from the implementation of PROMISE model demonstration projects"@en .

ns1:jvr-v51-i3-JVR191047 ns0:hasKeywords "Trauma"@en,
        "disability"@en,
        "rehabilitation counseling"@en,
        "trauma-informed care"@en ;
    ns0:hasPubAbstract "BACKGROUND: Individuals with disabilities are more likely to have experienced trauma over the course of the lifespan, however, these experiences and their impact on individual functioning have yet to be fully recognized within rehabilitation counseling practice, research, and education.   OBJECTIVE: The following manuscript outlines trauma-informed principles related to rehabilitation service provision.   METHODS: An overview of relevant theories that may be unfamiliar to rehabilitation professionals is included, as well as recommended assessment tools for use in practice and research.   CONCLUSIONS: By employing specific tenants of trauma-informed care, infused with traditional rehabilitation practice, rehabilitation counselors are in a unique position to comprehensively address consumers’ needs and ultimately foster more constructive outcomes."@en ;
    ns0:hasPubTitle "Trauma-sensitive rehabilitation counseling: Paradigms and principles"@en .

ns1:jvr-v51-i3-JVR191050 ns0:hasKeywords "Disability"@en,
        "effective practices"@en,
        "employer practices"@en,
        "supervisor"@en ;
    ns0:hasPubAbstract "BACKGROUND: Employers are increasingly interested in overcoming barriers to hire and retain workers with disabilities. While much is known about barriers that employers report, little is known about employer practices that successfully overcome these barriers. Research about the effectiveness of employer practices is also lacking, making it difficult to translate research findings in actionable ways for employers.   OBJECTIVE: This study describes initial findings from the 2017 Kessler Foundation National Employment and Disability Survey-Supervisor Perspectives (KFNEDS-SP), which represents a new approach to investigating employer practices related to disability.   METHODS: The KFNEDS-SP, a web-based survey, was designed using standard, replicable survey methods and fielded via a Qualtrics business-to-business panel to supervisors at U.S. organizations. Respondents included 6,530 supervisors ages 18 and older from private, nonprofit, and governmental organizations across industries.   RESULTS: The study identifies several employer practices that are underused but that supervisors perceive to be highly effective for employees, generally, and employees with disabilities. It also highlights the importance of upper management commitment to accommodating employees with disabilities.   CONCLUSION: Information about the utilization and effectiveness of workplace practices will support new policies and programs to educate and assist employers as they strive to increase employment of people with disabilities."@en ;
    ns0:hasPubTitle "The effectiveness of employer practices to recruit, hire, and retain employees with disabilities: Supervisor perspectives"@en .

ns1:kca-v3-i2-KCA190059 ns0:hasKeywords "Kidney neoplasms"@en,
        "healthcare disparities"@en,
        "outcome assessment"@en,
        "renal cell carcinoma"@en ;
    ns0:hasPubAbstract "Background: No studies have looked at comparative outcomes in the treatment of metastatic renal cell carcinoma (mRCC) between academic and community practice settings.   Methods: We created a joint academic (ACAD) and community (COMM) retrospective registry of patients treated for mRCC. This registry represents a collaboration of an academic research network (Duke Oncology Network; Durham, NC) and a community-based oncology network (ACORN Research; Memphis, TN) of multiple member practices. We compared progression free survival and overall survival between these centers. We included patients diagnosed with mRCC after January 1, 2007 and before February 7, 2011.   Results: Four hundred and fifty-five patients were captured in the registry including N = 255 COMM patients and N = 200 ACAD patients. Initial analysis of COMM patients showed a median PFS of 6.24 months [95% CI, 5.4, 7.5], 3.88 months [95% CI, 3.0, 4.8], and 3.35 months [95% CI 2.9, 4.4] with first, second, and third line systemic therapy. ACAD patients had longer median PFS estimates of 11.3 months [95% CI, 7.5, 13.6], 4.4 months [95% CI, 2.7, 8.9], and 5.22 months [95% CI, 2.7, 6.3] respectively. Median OS was 12.06 months [95% CI 8.7, 15.4] among COMM patients and 36.73 months [95% CI 26.2 42.2) among ACAD patients. Differences persisted with inclusion of well-established prognostic models and predictive factors such as treatment exposures.   Conclusions: There may be differences between outcomes for mRCC patients in community versus academic settings; however rselection most likely plays a role and we need further studies to determine reasons for these potential disparities. A prospective metastatic renal cell carcinoma (MaRCC) registry has been accrued encompassing sixty academic and community treatment sites across the United States rwith the goal of examining real-world treatment patterns and outcomes; MaRCC may shed further light on any potential outcomes differences."@en ;
    ns0:hasPubTitle "Real-World Data from a Metastatic Renal Cell Carcinoma Community-Academic Registry: Comparative Outcomes of Progression Free Survival and Overall Survival"@en .

ns1:kca-v3-i3-KCA190054 ns0:hasKeywords "Immune checkpoint inhibitors"@en,
        "clinical trials"@en,
        "double immune checkpoint blockade"@en,
        "immunotherapy"@en,
        "renal cell carcinoma"@en ;
    ns0:hasPubAbstract "Long considered an immunogenic tumour, immunotherapy has been the cornerstone of systemic treatment in renal cell carcinoma (RCC) for decades, since the introduction of interleukin 2 and interferon-alfa in the 1980s to the more recently approved immune checkpoint inhibitors. Moreover, on the basis that anti-CTLA-4 and anti-PD-1/PD-L1 intrinsic mechanisms are different, double checkpoint inhibition was proposed to further improve anti-tumor immune response. The first trial to assess double checkpoint inhibition was Checkmate 016 (nivolumab and ipilimumab). It showed acceptable safety and promising antitumor activity that led to the first phase III trial with combination immunotherapy in RCC, Checkmate 214. This trial showed superior overall survival and response rate of the combination immunotherapy (nivolumab and ipilimumab) versus sunitinib in intermediate- and poor-risk advanced RCC, leading to its approval in this setting. Despite these advances, there is still room for improvement. In this context, cytokines and T-cell costimulatory molecules are currently under investigation. This review summarizes the principles of immunotherapy and its role in RCC, provides an update on double checkpoint blockade and discusses the major challenges with double checkpoint blockade."@en ;
    ns0:hasPubTitle "Double Immune Checkpoint Blockade in Renal Cell Carcinoma"@en .

ns1:kes-v23-i3-KES190406 ns0:hasKeywords "Event prediction"@en,
        "TsEP-TC"@en,
        "fuzzy logic"@en,
        "healthcare"@en,
        "metaheuristics"@en,
        "weighting"@en ;
    ns0:hasPubAbstract "Nowadays, there is a large volume of time series data, which generates by different parts of the healthcare domain such as hospitals, medical organizations, and health centers. Time series event-based prediction (TsEP) has recently become an active research trend in the healthcare domain, which is widely served outcome of it by the healthcare decision-makers. Actually, a valid and reliable prediction can play an important and key role in the society for forewarning crisis and supporting health management. Hence, the main motivation of this paper is to offer an enhanced hybrid model to the TsEP in healthcare, which is named TsEP-TC. TsEP-TC contains three components (TC) that combines relevant concepts to weighting, fuzzy logic, and metaheuristics in the TsEP problem. Experimental results indicate that TsEP-TC can provide the superior performance in comparison to the previous prediction models in the healthcare and biomedical domains. Additionally, TsEP-TC model can be introduced as a useful way for handling the complex and uncertain behaviors of time series and fuzzy events predicting in healthcare."@en ;
    ns0:hasPubTitle "An enhanced hybrid model for event prediction in healthcare time series"@en .

ns1:kes-v23-i3-KES190409 ns0:hasKeywords "Language identification"@en,
        "Natural Language Processing"@en,
        "cBoW"@en,
        "character embedding"@en,
        "skip-gram"@en,
        "transliteration"@en,
        "word embedding"@en ;
    ns0:hasPubAbstract "The language used by the users in social media nowadays is Code-mixed text, i.e., mixing of two or more languages. This paper describes the application of the code mixed index in Indian social media texts and comparing the complexity to identify language at word level using Bi-directional Long Short Term Memory model. Social media platforms are now widely used by people to express their opinion and interest. The major contribution of the work is to propose a technique for identifying the language of Hindi-English code-mixed data used in three social media platforms namely, Facebook, Twitter, and WhatsApp. We recommend a deep learning framework based on cBoW and Skip gram model that predicts the origin of the word from language perspective in the sequence based on the specific words that have come before it in the sequence. The context capture module of the system gives better accuracy for word embedding model as compared to character embedding."@en ;
    ns0:hasPubTitle "An effective cybernated word embedding system for analysis and language identification in code-mixed social media text"@en .

ns1:mgc-v15-i2-MGC193 ns0:hasKeywords "1H-NMR"@en,
        "GC-MS"@en,
        "MIC"@en,
        "Macroalgae"@en,
        "antibacterial activity"@en ;
    ns0:hasPubAbstract "The present investigation aimed to evaluate the antibacterial activity of marine macroalgae collected during winter and spring 2011 from the Red Sea of Jeddah, Saudi Arabia. The activity of petroleum ether, diethyl ether, ethyl acetate and methanol extract of algae belonging to Chlorophyta, Phaeophyta and Rhodophyta were examined against pathogenic bacteria. The crude extract of algae evoked several patterns of antibacterial activities. The petroleum ether extract of Gracilaria multipartita, Ulva reticulata and Sargassum marginatum collected in spring recorded the maximum inhibitory activity against Bacillus subtilis (14–25 mm), MRSA (24–35 mm) and Staphylococcus aureus (14–18 mm), respectively. However, Escherichia coli, Klebsiella pneumoniae were highly inhibited by petroleum ether extract of G. multipartita collected in spring (17–24 mm and 15–19 mm, respectively). Pseudomonas aeruginosa recorded the greatest zone of inhibition (18–22 mm) by the petroleum ether extract of S. marginatum gathered during winter. The MICs values for bacteria were ranged between 1.00–2.75 μg/ml. The chemical composition of the most effective algae extract against pathogenic bacteria was performed by GC-MS and 1H-NMR analysis. The major components of extract were hydrocarbons, carotene derivatives, fatty acids and sterols. The present finding revealed that the tested algae can be used as possible natural source of antibacterial compounds."@en ;
    ns0:hasPubTitle "Marine macroalgae as a potential source of bioactive natural products with antibacterial activity"@en .

ns1:mgc-v15-i2-MGC194 ns0:hasKeywords "Cyanobacteria"@en,
        "IR"@en,
        "PHB"@en,
        "TEM"@en,
        "pH"@en,
        "starvation"@en ;
    ns0:hasPubAbstract "The accumulation and factors affecting Poly 3-hydroxybutyric acid (PHB) production in cyanobacteria have not been clearly documented. In the present study, three PHB producers belonging to cyanobacteria were identified as Oscillatoria salina, Anabaena cylindrica and Nostoc linckia, based on their morphological features and microscopic observations. Their growth and PHB production after 7, 14 and 21 days in BG11 medium were determined. The highest dry weight for the isolates was observed at stationary phase (14 days) and PHB accumulation (%, w/w of dry cells) increased with increasing dry weight up to 14 days, then a decline was observed after 21 days. At the stationary phase, cells of O. salina, A. cylindrica and N. linckia accumulated PHB up to 13.62, 11.88 and 10.03% (w/w of dry cells), respectively. The pH values between 8 and 9 were preferred for PHB accumulation. O. salina, A. cylindrica and N. linckia accumulated the highest PHB 17.31, 15.22 and 14.95%, respectively at pH 8. Nitrogen and phosphorus starvation were found stimulatory for PHB accumulation and he highest PHB production was recorded for O. salina, 20.41 and 26.32%, respectively after 14 days of incubation. Electron microscopic analyses of O. salina cells showed the bioplastic accumulation in granule-like structures which was extracted and studied using IRFT analysis. In conclusion, cyanobacteria are capable of synthesizing high poly-β-hydroxybutyrate (PHB) under stress."@en ;
    ns0:hasPubTitle "Production and enhancement of poly-β-hydroxybutyrate in cyanobacteria"@en .

ns1:mgc-v18-i3-MGC180689 ns0:hasKeywords "Phytochemical studies"@en,
        "anticancer agents"@en,
        "clinical developments"@en,
        "drug discovery"@en,
        "natural products"@en ;
    ns0:hasPubAbstract "Natural products remain an important source of new drugs. Many natural materials are used for treatment of diseases. The diversity in natural compounds make it a rich source for discovering and studying the biological activities for overcoming of several diseases. Cancer is a leading reason of death all over the world. Many anticancer agents originate from plant sources occupies an important position in anticancer studies. The advances happened in chemical and clinical tools encourage many of researcher to rediscover many natural compounds and plants could not be studied in past. This chapter reviews the natural products from plant sources with anticancer activity. It represents the most effective natural products with anticancer activity. Their structures and chemical classifications with the plant sources are presented. The article focuses on the promising natural products and the ongoing trails to evaluate the plant wealth as anticancer phytochemicals. The natural compounds in the advanced stages of clinical development is discussed."@en ;
    ns0:hasPubTitle "Anticancer agents from plants"@en .

ns1:mgc-v18-i3-MGC180717 ns0:hasKeywords "4-Hydroxycoumarin"@en,
        "X-ray"@en,
        "cancer cell"@en,
        "molecular docking"@en ;
    ns0:hasPubAbstract "The synthesis and characterization of new 4-hydroxycoumarin derivatives (1–6) were realized by means of infrared spectroscopy (IR), 1H nuclearmagnetic resonance spectroscopy (1H NMR), high resolution mass spectrum (HRMS) and single crystal X-ray crystallography. The anticancer activity of these compounds was investigated against four human liver cancer cells (SMMC-7721, Bel-7402, MHCC97 and Hep3B) by 3-(4,5)-dimethylthiahiazo(-z-y1)-3,5-di-phenytetrazoliumromide (MTT) assay. Furthermore, molecular docking studies supported the biological assay data and suggested that compounds 1 and 2 may be potential anticancer agents."@en ;
    ns0:hasPubTitle "Synthesis, biological evaluation and docking studies of 4-hydroxycoumarin derivatives as anti-liver cancer agents"@en .

ns1:mgc-v18-i3-MGC180750 ns0:hasKeywords "Iodocuprate"@en,
        "photocatalytic activity"@en,
        "synthesis"@en,
        "thermostability"@en ;
    ns0:hasPubAbstract "A novel cation-stabilized iodocuprate, named {CuI3](1,3-bip)} (1), [1,3-bip = 1,3-bis(isoquinoline)propane] have been constructed from mixtures of bis(isoquinoline) and silver iodide in acetonitrile solution. Compound 1 was characterized by elemental analysis, IR spectra and X-ray crystallography. The dianions of 1 have planar triangular geometry with each halide atom being bound to the central trigonally coordinated copper atom. The optical band gap of 1 was estimated to be 2.5 eV. Interestingly, nearly 52% of contaminant (methylene blue aqueous solution (MB), 50 mL, 1.0×10–5 M) could be decolorized after exposure to visible light within 100 min, illustrating an impressive photocatalytic activity of compound 1. The thermal properties of 1 along with 1,3-bip have also been investigated."@en ;
    ns0:hasPubTitle "Structure, optical and thermal properties of a new iodocuprate(I) complex stabilized by bis(isoquinoline)alkane cation"@en .

ns1:mgc-v18-i3-MGC180760 ns0:hasKeywords "Iodocuprate"@en,
        "crystal structure"@en,
        "synthesis"@en,
        "thermostability"@en ;
    ns0:hasPubAbstract "A novel cation-stabilized iodocuprate, named {CuI3](1,6-bpx)}1), [1,6-bpx = 1,6-bis(pyridinium)xylol] have been constructed from mixtures of bis(pyridinium) xylol and cuprous iodide in acetonitrile solution. Compound 1 was characterized by elemental analysis, IR spectra and X-ray crystallography. The dianions of 1 have planar triangular geometry with each halide atom being bound to the central trigonally coordinated copper atom. The chemical and thermal properties of 1 along with 1,6-bpx have also been investigated."@en ;
    ns0:hasPubTitle "Iodocuprate(I)-doped long-chain bis(pyridinium)xylol system: Syntheses, structure, chemical and thermal stability"@en .

ns1:mgc-v18-i3-MGC180771 ns0:hasKeywords "Template effect"@en,
        "adsorption"@en,
        "fluorescent probe"@en,
        "octamolybdate"@en ;
    ns0:hasPubAbstract "A new supermolecular compound, [C7H10N4][Mo8O26]0.5·H2O has been synthesized from 1,1-bis(imidazole) methane and (NH4)6Mo7O24·4H2O by hydrothermal method. Structural analysis reveals that every asymmetric structure unit of the compound is composed of one [C7H10N4]2+ and half [Mo8O26]4– and one water molecule. Crystal pack of the compound suggests that polyacid anions represent the one-dimensional chain-shaped structure and organic cations parallel the one-dimensional chains. The compound has the characteristics of detection Fe3+, adsorption and catalysis activities."@en ;
    ns0:hasPubTitle "A new polyoxometalate supermolecular compound as fluorescent probe for detecting of Fe (III): Synthesis, structures, and properties"@en .

ns1:mgc-v18-i4-MGC180751 ns0:hasKeywords "Cloud point extraction"@en,
        "alizarin red s"@en,
        "aluminium(iii)"@en,
        "certified reference materials"@en,
        "food samples"@en,
        "spectrophotometry"@en ;
    ns0:hasPubAbstract "A new, green, and simple cloud point extraction process of aluminum (III) from aqueous solution was investigated. The method is based on the complexation reaction of aluminum (III) with alizarin red S (ARS) at pH 5.0 and micelle-mediated extraction of the complex with nonionic surfactant Triton X-114. The enriched analyte in the surfactant-rich phase was determined spectrophotometrically at 515 nm. The optimal conditions including pH, reagent volume, surfactant concentration, temperature and centrifugation time were optimized. The proposed CPE method showed linear calibration within the range 5.0–300 ng mL–1 of aluminum (III) and the limit of detection was 1.0 ng mL–1 with a preconcentration factor of ∼100. The relative standard deviation (RSD%) and relative error (RE%) were found to be 1.70% and 1.78%, respectively. The accuracy of method was evaluated by the analysis of certified reference materials. The interference effect of some cations and anions was also studied. In the presence of foreign ions, no significant interference was observed. The method was applied to the determination of aluminum (III) in real food samples with a recovery for the spiked samples in the range of 95.0–102%."@en ;
    ns0:hasPubTitle "Application of cloud point extraction for preconcentration, separation and determination of Aluminum in food samples"@en .

ns1:mgc-v18-i4-MGC180753 ns0:hasKeywords "Heterocycles"@en,
        "X-ray crystallography"@en,
        "anticancer activity"@en ;
    ns0:hasPubAbstract "In this study, a new heterocyclic compound 2-(5-bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene (1), designed using 5-bromo-2-methylbenzoic acid (2) as the starting material, was successfully obtained via a three-step synthesis route and finally characterized by IR, 1H NMR, and single crystal X-ray crystallography (SCXRD). The X-ray single-crystal diffraction study reveals that compound 1 belongs to the monoclinic space group of P21/c with the presence of the inter-molecular H-bond interactions. Furthermore, the in vitro anticancer activities of the newly synthesized compound 1 have been studied against three human gastric cancer cells MGC-803, BGC-823 and SGC-7901 along with the human mammary epithelial cell MCF-10A using the doxorubicinis as the positive control via the MTT assay, which reveals its promising anticancer activity and low cytotoxicity against the human normal cell lines. In addition, molecular docking of complex 1 was studied to understand the drug-DNA interactions and calculate the potential binding mode and energy. The present results enrich the F-atom decorated organic molecules for the anticancer activity evaluation."@en ;
    ns0:hasPubTitle "Synthesis, crystal structure, anti-gastric cancer activity of 2-(5-bromo-2-methylbenzyl)-5-(4-fluorophenyl)thiophene"@en .

ns1:mgc-v18-i4-MGC180763 ns0:hasKeywords "Stannic oxide"@en,
        "controlled synthesis"@en,
        "hydro-thermal method"@en,
        "nanoflowers"@en,
        "photocatalysis"@en ;
    ns0:hasPubAbstract "The controllable stannic oxide nanoflowers had been synthesized by hydro-thermal method through changing synthesized reagent and temperature, in this paper. Then the structure and micromorphology were characterized by X-ray diffraction (XRD) and scanning electron microscopy (SEM). Finally, the photocatalytic degradation ability of prepared products was studied by ultraviolet absorption method. The results showed that the prepared products were pure stannic oxide crystals with rutile structure, micromorphology of flower, good dispersibility, uniform size and strong photocatalytic degradation ability."@en ;
    ns0:hasPubTitle "Controlled synthesis and high photocatalytic properties of stannic oxide nanoflowers"@en .

ns1:mgc-v18-i4-MGC190783 ns0:hasKeywords "Sb(V) complex"@en,
        "anticancer activity"@en,
        "nano-crystals"@en,
        "singe crystal X-ray diffraction"@en ;
    ns0:hasPubAbstract "Reaction of triphenylantimony dichloride, MeONa and 2,3-difluorobenzoic acid (2,3-H2dfa) in methylbenzene gave a new organoantimony (V) complex Sb(phenyl)3(2,3-dfa)2 (1) in 68% yield. The structure of this complex was characterized by infrared (IR) spectrum, elemental analysis (EA), powder X-ray diffraction (PXRD) and single-crystal X-ray diffraction (SCXRD). Furthermore, the morphology of complex 1 could be downsized into nanosized region via a sonochemical treatment. In addition, the anticancer activity of 1 in nano-region has been studied via Cell Counting Kit-8 (CCK-8) assay on MG63 human osteosarcoma cells."@en ;
    ns0:hasPubTitle "Synthesis, characterization and anticancer activity on human osteosarcoma cells of a pentavalent antimony complex"@en .

ns1:mgc-v18-i4-MGC190794 ns0:hasKeywords "Arsonolipids"@en,
        "L-cysteine"@en,
        "L-cysteine hydrochloride"@en,
        "arsenoso compounds"@en,
        "glutathione"@en ;
    ns0:hasPubAbstract "From the arsonolipids (2,3-diacyloxypropylarsonic acids, 1) the stearoyl and palmitoyl are not reduced by ascorbic acid/iodine in methanol while the myristoyl and lauroyl arsonolipids are reduced to the arsenoso compounds 3. The reaction of arsenoso compounds 3 and of arsonolipids 1 with L-cysteine (cysSH), L-cysteine hydrochloride (cysSH·HCl) and glutathione (GSH) under various conditions was studied. Lipo-dithioarsonites [R-As(SR′)2] 4 have been isolated with GSH with both lipids 1 and 3. The product 4 was obtained only from 3 and cysSH. The salt cysSH·HCl reacted with 3 in methanol but gave it back on attempts at isolation of 4, while in DMSO unknown products were obtained. The arsonolipids 1 can be components of biological membranes and all lipo-dithioarsonites 4 prepared were insoluble in water and once formed must remain anchored in a membrane, thus altering its properties."@en ;
    ns0:hasPubTitle "The reaction of L-cysteine, L-cysteine hydrochloride and glutathione with arsonolipids (2,3-diacyloxypropylarsonic acids) and their arsenoso derivatives"@en .

ns1:mgc-v18-i4-MGC190801 ns0:hasKeywords "Geopolymer"@en,
        "adsorption"@en,
        "gold mine tailings"@en,
        "heavy metals"@en ;
    ns0:hasPubAbstract "In today’s world, heavy metal pollution is one of the major problems. Various methods have been developed for the removal of pollution caused by heavy metals. However, adsorption is the most advantageous process among these methods. Mining waste is another source of pollution. The evaluation of these wastes will both solve the storage problems and prevent environmental pollution. In this study, Bergama gold mine wastes were evaluated and used in geopolymer production. Alkaline fusion method was used for geopolymer synthesis in the experimental process. The obtained geopolymer sample was suitable for adsorption in terms of porosity and surface area and was used in the adsorption of Cu2+. According to the results of the studies, the surface area of the gold mine waste increased from 3.845 m2/g to 74.916 m2/g. Adsorption studies were carried out at different parameters such as geopolymer dosage, contact time, temperature and initial concentration. Also, isotherm and kinetic studies were applied. Cu2+ adsorption is suitable for the Langmuir isotherm model (R2 = 1) and the Pseudo-second order kinetic model (R2 = 0.997)."@en ;
    ns0:hasPubTitle "Usage of gold mine tailings based geopolymer on Cu2+ adsorption from water"@en .

ns1:mgs-v15-i3-MGS190314 ns0:hasKeywords "Glowworm swarm optimisation (GSO)"@en,
        "hybrid metaheuristic algorithm"@en,
        "metaheuristic"@en,
        "moth-flame optimisation (MFO)"@en ;
    ns0:hasPubAbstract "One of the drawbacks of glowworm swarm optimisation (GSO) is its premature convergence, which leaves it often ineffective for solving complex practical problems. This paper proposes a new hybrid metaheuristic algorithm, that is, moth-flame glowworm swarm optimisation (MFGSO). The main idea of the hybrid algorithm is to combine the exploration ability in moth-flame optimisation (MFO) with the exploitation ability in GSO. Performance evaluations are conducted on benchmarking test functions in comparison with the basic GSO and other metaheuristic algorithms. The results show that MFGSO outperforms the basic GSO and other metaheuristic algorithms on most test functions in terms of local optima avoidance and convergence speed."@en ;
    ns0:hasPubTitle "Moth-flame glowworm swarm optimisation"@en .

ns1:mnm-v12-i2-MNM180250 ns0:hasKeywords "Sweet consumption"@en,
        "adolescents"@en,
        "children"@en,
        "dietary habits"@en,
        "lifestyle factors"@en ;
    ns0:hasPubAbstract "BACKGROUND: Frequent sweet consumption constitutes a significant health issue among children which leads to a predisposition towards overweight and cardiovascular disease risk factors.   OBJECTIVE: To examine the prevalence of sweet consumption and to identify associated lifestyle factors.   METHODS: Cross-sectional, observational study. Population data derived from a health survey carried out in 2015 on a representative sample of 177091 children aged 8 to 17 years. Sweet consumption and dietary habits were evaluated using questionnaires (KIDMED index). Frequency of sweets consumption constitutes a question of KIDMED and it was classified as rare or frequent. Physical activity status, screen time and sleeping habits were assessed through self-completed questionnaires.   RESULTS: More boys than girls (19.6% vs. 17.5%, p < 0.001) consumed sweet frequently (more than twice daily). Sweet consumption was strongly associated with unhealthy dietary habits such as skipping breakfast and fast food consumption. Adjusting for several covariates, insufficient dietary habits, insufficient sleep and increased screen time were increased on participant’s odds of being frequent sweet consumers by 80% (95% CI 0.17–0.23), 18% (95% CI1.05–1.29) and 218% (95% CI 1.96–2.41) in boys and by 80% (95% CI 0.17–0.24), 31% (95% CI1.17–1.47) and 241% (95% CI 2.15–2.72) in girls.   CONCLUSIONS: Frequent sweet consumption was associated with an unhealthy lifestyle profile."@en ;
    ns0:hasPubTitle "Frequent sweet consumption associated with poor dietary habits and increased screen time in children and adolescents: Results from the National Action for Children’s Health program"@en .

ns1:mnm-v12-i2-MNM180265 ns0:hasKeywords "HbA1c"@en,
        "Non-alcoholic fatty liver disease"@en,
        "Omega 3 fatty acids"@en,
        "Type 2 diabetes"@en ;
    ns0:hasPubAbstract "INTRODUCTION: Serum phospholipid omega-3 fatty acid levels in patients suffering from both type 2 diabetes (T2DM) and non-alcoholic fatty liver (NAFLD) are lower than in their healthy counterparts. Omega-3 supplementation can be effective in controlling glycemic indices in T2DM, and in improving lipid profiles in T2DM and NAFLD as well. The aim of this study was to evaluate the effects of omega-3 fatty acid supplementation on glycemic control and lipid profile in patients with T2DM and NAFLD.   METHODS: In this randomized double-blind placebo-controlled clinical trial, 60 patients with T2DM and NAFLD were enrolled. The participants were randomly divided into two groups. The omega-3 group (OG) received capsules containing omega-3 fatty acids (2g/d), and the placebo group (PG) received placebo capsules (2g/d) during a12 week period. Dietary intake was assessed with 24-hour dietary recalls. Fasting blood samples and anthropometric measurements were collected at the baseline and after 12 weeks. Serum levels of glycemic indices (fasting blood glucose (FBG) levels, glycosylated hemoglobin (HbA1c)) and lipid profile (levels of triglyceride (TG), total cholesterol (TC), low density lipoprotein cholesterol (LDL-c) and high density lipoprotein cholesterol (HDL-c)) were measured.   RESULTS: Fifty-six patients completed the study. Paired t-test revealed no significant differences in the baseline measurements between the two groups. At the end of the study compared with the PG, the OG had a significant reduction in serum TG levels. However, there was no significant effect of omega-3 supplementation on the other parameters: the mean FBG or HbA1c concentration, neither on TC, LDL-c and HDL-c levels.   CONCLUSION: Two grams per day of omega-3 supplementation after 12 weeks led to a significant reduction in serum TG levels in patients with T2DM and NAFLD. However, no significant effects were observed on FBG, HbA1c, TC, LDL-c, and HDL-c levels."@en ;
    ns0:hasPubTitle "The effect of omega-3 supplementation on glycemic indices and lipid profile in type 2 diabetic patients with non-alcoholic fatty liver disease: A double-blind, randomized, clinical trial"@en .

ns1:nha-v5-i2-NHA170034 ns0:hasKeywords "Nutrition"@en,
        "T cells"@en,
        "aging"@en,
        "aging nutrimmunity"@en,
        "immunity"@en,
        "immunocompetence"@en ;
    ns0:hasPubAbstract "Nutrition influences immunity in multiple ways, with different nutrients affecting many immune parameters. Aging also affects immunity, making the outcome of the interplay between nutrition, age and immunity complex. Moreover, a particular nutrient may alter the whole immune constellation as deficiency of one nutrient may affect the proper metabolism of another nutrient and elicit a chain reaction of secondary malnutrition. In this article, we review these interactions and the possible mechanisms mediating such relationships."@en ;
    ns0:hasPubTitle "The immune-nutrition interplay in aging – facts and controversies"@en .

ns1:npm-v12-i2-NPM17149 ns0:hasKeywords "Intranasal drug delivery"@en,
        "drug safety"@en,
        "infant pharmacology"@en,
        "procedural pain"@en ;
    ns0:hasPubAbstract "BACKGROUND:  The intranasal route is a minimally invasive method for rapidly delivering midazolam and fentanyl to provide short-term analgesia and sedation in infants. However, intranasal use of midazolam and fentanyl is not labeled for infants and safety data are sparse. The objective of this study is to evaluate the safety of intranasal midazolam and intranasal fentanyl in infants admitted to the Neonatal Intensive Care Unit (NICU).  METHODS:  We retrospectively identified all infants receiving intranasal midazolam or fentanyl in the NICU from 2009 to 2015. We recorded indication for use and vital signs and determined the proportion of infants experiencing the following adverse events: death within 24 hours, hypotension, bradycardia, worsening respiratory status, and chest wall rigidity. Vital signs 4 hours before and after each dose were compared using the Wilcoxon signed-rank test.  RESULTS:  We identified 17 infants (gestational ages 23– 41 weeks) receiving 25 intranasal doses. None of the infants died or developed hypotension, bradycardia, or chest wall rigidity. Intranasal delivery was most commonly used for sedation during magnetic resonance imaging studies. Other indications include analgesia or sedation for retinopathy of prematurity surgery, intubation, and peripherally inserted central catheter placement. One infant receiving intranasal midazolam experienced worsening respiratory status. Vital signs before and after dosing were not significantly different.  CONCLUSIONS:  Intranasal midazolam and fentanyl use in term and preterm infants appeared safe and well-tolerated in this small cohort of infants. Larger, prospective studies evaluating the safety and efficacy of intranasal midazolam and fentanyl use in infants are warranted."@en ;
    ns0:hasPubTitle "Intranasal midazolam and fentanyl for procedural sedation and analgesia in infants in the neonatal intensive care unit"@en .

ns1:npm-v12-i2-NPM18117 ns0:hasKeywords "Boot camp"@en,
        "Neonatal-perinatal medicine"@en,
        "neonatal fellowship"@en,
        "simulation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Simulation is widely used in graduate medical education. A prior survey showed that 80% of Neonatal-Perinatal Medicine (NPM) fellowship programs in the U.S. use simulation. There are multiple ways to provide simulation-based education. One such method is through intensive simulation-based education sessions held at the beginning of a training program, common called ‘boot camps’. The aim of this study was to describe the use of simulation-based boot camps in NPM fellowship programs.   METHODS: Survey study of Accreditation Council for Graduate Medical Education (ACGME) accredited NPM fellowships in the U.S.   RESULTS: Fifty-nine of 98 programs (60%) responded. Thirty six (61%) participated in 1st year fellow boot camps, which focused on procedural skills and newborn resuscitation. Nearly half of programs participated in regional boot camps. Most boot camps were one or two days long. Eleven programs (19%) held 2nd or 3rd year fellow boot camps, which focused on advanced resuscitation and communication. Barriers included lack of faculty protected time (57%), funding (39%), and lack of faculty experience (31%).   CONCLUSIONS: A majority of ACGME accredited NPM fellowships participate in 1st year fellows’ boot camps. Many participate in regional boot camps. A few programs have 2nd or 3rd year fellow boot camps. Lack of time, funding, and faculty experience were common barriers."@en ;
    ns0:hasPubTitle "Boot camps in neonatal-perinatal medicine fellowship programs: A national survey"@en .

ns1:npm-v12-i2-NPM1813 ns0:hasKeywords "Hemodynamic"@en,
        "neonates"@en,
        "rescue"@en,
        "respiratory failure"@en,
        "surgery"@en ;
    ns0:hasPubAbstract "INTRODUCTION: High frequency jet (HFJV) and oscillatory (HFOV) ventilation were used to rescue newborns with congenital diaphragmatic hernia (CDH), who failed conventional mechanical ventilation (CV). Changes in ventilator settings and pulmonary gas exchange were evaluated following transition to high frequency ventilation (HFV).   METHODS: Records of patients with CDH rescued with HFV prior to surgical intervention between 2006 and 2015 were reviewed. Mean airway pressure (Pāw) and arterial blood gases during CV and those obtained within the first hour of HFV were compared. A composite repeated measure analysis was performed to evaluate longitudinal and intergroup variances.   RESULTS: Twenty-seven patients were rescued from CV, 16 by HFJV and 11 by HFOV. The two groups had similar gestational ages and birth weights. Prior to HFV, both groups had similar Pāw, PaCO2, FiO2 and PaO2. HFV was associated with a significant improvement in ventilation, and the rate of decrease of PaCO2 was no different between groups. There was a significantly higher increase in Pāw increase with HFOV compared to HFJV.   CONCLUSIONS: In newborns with CDH rescued with HFV, ventilation improved but Pāw was significantly lower in patients supported with HFJV compared to HFOV."@en ;
    ns0:hasPubTitle "Rescue high frequency ventilation for congenital diaphragmatic hernia"@en .

ns1:npm-v12-i2-NPM1818 ns0:hasKeywords "Perceived stress"@en,
        "cortisol"@en,
        "fetal growth"@en,
        "leptin"@en,
        "pregnancy"@en,
        "umbilical cord"@en ;
    ns0:hasPubAbstract "BACKGROUND: The present study aimed to determine the effect of perceived stress during pregnancy on neonatal outcomes and cortisol and leptin levels in mothers and their newborns.   METHODS: This longitudinal study was carried out on 110 pregnant women in Miandoab city, Iran. Mothers, who had singleton pregnancies and gestational age of 24 to 28 weeks, were included in the study. The participants were asked to fill out Cohen’s Perceived Stress Scale (PSS). The mothers were then tracked in gestational ages of 28–32 weeks, 32–36 weeks, and the time of delivery. The maternal and umbilical cord blood samples were obtained during labor in order to measure leptin and cortisol levels.   RESULTS: Umbilical cortisol level was significantly higher in newborns who had meconium stained amniotic fluid than those who did not. Maternal blood leptin levels at delivery were significantly higher in the mothers whose neonates had respiratory distress, low birth weight, low head circumference, low Apgar score, and were premature than those whose neonates did not have such problems. The level of leptin in umbilical cord blood was significantly higher in neonates who had respiratory distress than those who did not. The results also showed a significant correlation between maternal cortisol levels and PSS during weeks 24–28 and the entire pregnancy. A significant relationship was observed between umbilical leptin and maternal leptin levels.   CONCLUSIONS: It can be concluded that stress during pregnancy is accompanied by fetal distress. The probable reason for newborns distress may be related to increased maternal leptin levels."@en ;
    ns0:hasPubTitle "Stress during pregnancy affected neonatal outcomes and changed cortisol and leptin levels both in mothers and newborns"@en .

ns1:npm-v12-i3-NPM18119 ns0:hasKeywords "Positive pressure ventilation coaching"@en,
        "bag-mask ventilation"@en,
        "mask ventilation"@en,
        "neonatal resuscitation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Positive pressure ventilation (PPV) is the most important procedure during neonatal resuscitation. Providing effective PPV seems easy. However, performing the procedure correctly is extremely challenging. Airway obstruction and face mask large leaks are common. It is estimated that two-thirds of continued neonatal respiratory depression after the time of birth is caused by ineffective or improperly provided PPV. Finding methods to improve PPV performance are critically needed. Performance coaching is a simple and easy method of improving performing in procedural skills, and has been used previously to optimize compression technique. We performed the simulation-based pilot study to evaluate the impact of PPV coaching during neonatal bag-mask ventilation.   METHODS: Randomized cross-over study of nurses performing PPV on a SMART Newborn Resuscitation Training System with, and without, coaching. The PPV coach provided real-time feedback on chest rise, mask hold, and ventilation rate. The SMART system captured data on peak inspiratory pressure (PIP), tidal volume (Vt), mask leak, and ventilation rate. Data were analyzed by a blinded reviewer.   RESULTS: PPV coaching resulted in more appropriate PIPs (34 cmH2O, IQR 32-38 vs. 36 cmH2O, IQR 28–37; P < 0.001), lower Vt (4.7 ml/kg, IQR 4–8 vs. 5.5 ml/kg, IQR 4–13; P < 0.001), and less mask leak (39% leak, IQR 21–70 vs. 45%, IQR 22–98; P = 0.005). There was no difference in respiratory rate (P = 0.93).   CONCLUSIONS: Coaching improved PPV performance in this simulation-based pilot study. Further research on PPV coaching during neonatal resuscitation is warranted."@en ;
    ns0:hasPubTitle "Positive pressure ventilation coaching during neonatal bag-mask ventilation: A simulation-based pilot study"@en .

ns1:npm-v12-i3-NPM1854 ns0:hasKeywords "Peters-plus syndrome"@en,
        "fetal MRI"@en,
        "low PAPP-A"@en,
        "prenatal diagnosis"@en,
        "ultrasound anomalies"@en,
        "whole-exome sequencing"@en ;
    ns0:hasPubAbstract "We report a case of two consecutive pregnancies in the same couple presenting with very low pregnancy-associated plasma protein A (PAPP-A), with both pregnancies affected by multiple anomalies of a similar phenotype identified during mid-trimester ultrasound, and eventual diagnosis of Peters-plus syndrome. This case is important in expanding the differential for very low PAPP-A. It also demonstrates the diagnostic value of whole-exome sequencing (WES) after prenatal diagnosis of recurrent fetal ultrasonographic findings. The importance and complexity of providing patient education to enable informed consent for next generation sequencing technologies is discussed."@en ;
    ns0:hasPubTitle "Whole-exome sequencing for diagnosis of Peters-plus syndrome after prenatal diagnosis of recurrent low PAPP-A and multiple fetal anomalies in two consecutive pregnancies"@en .

ns1:nre-v44-i3-NRE182565 ns0:hasKeywords "Circadian rhythm"@en,
        "anxiety"@en,
        "clinical trial"@en,
        "cognitive"@en,
        "depression"@en,
        "light"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "BACKGROUND: Patients admitted for rehabilitation often lack sufficient natural light to entrain their circadian rhythm.   OBJECTIVE: Installed diurnal naturalistic light may positively influence the outcome of depressive mood, anxiety, and cognition in such patients.   METHODS: A quasi-randomized controlled trial. Ninety stroke patients in need of rehabilitation were randomized between May 1, 2014, and June 1, 2015 to either a rehabilitation unit equipped entirely with always on naturalistic lighting (IU), or to a rehabilitation unit with standard indoor lighting (CU). Examinations were performed at inclusion and discharge. The following changes were investigated: depressive mood based on the Hamilton Depression scale (HAM-D6) and Major Depression Inventory scale (MDI), anxiety based on the Hospital Anxiety and Depression Scale (HADS), cognition based on the Montreal Cognitive Assessment (MoCA) and well-being based on the Well-being Index (WHO-5).   RESULTS: Depressive mood (MDI p = 0.0005, HAM-D6 p = 0.011) and anxiety (HADS anxiety p = 0.045) was reduced, and well-being (WHO-5 p = 0.046) was increased, in the IU at discharge compared to the CU. No difference was found in cognition (MoCA p = 0.969).   CONCLUSIONS: This study is the first to demonstrate that exposure to naturalistic light during admission may significantly improve mental health in rehabilitation patients. Further studies are needed to confirm these findings."@en ;
    ns0:hasPubTitle "An exploratory investigation of the effect of naturalistic light on depression, anxiety, and cognitive outcomes in stroke patients during admission for rehabilitation: A randomized controlled trial"@en .

ns1:nre-v44-i3-NRE182634 ns0:hasKeywords "Stroke"@en,
        "force platform"@en,
        "function in sitting"@en,
        "sitting balance"@en ;
    ns0:hasPubAbstract "BACKGROUND: Balance problems are common after stroke.   OBJECTIVE: The aims of this study was to compare the results of computerized and clinical sitting balance measurements in stroke patients and healthy individuals and to identify the agreement and relationship between the two measurement methods in stroke patients.   METHODS: This study included 30 chronic stroke patients and 30 age-matched healthy individuals. A force platform chair was used for the computerized and the Function in Sitting Test (FIST) was used for the clinical sitting balance measurement.   RESULTS: The sitting balance of the stroke patients, measured with computerized and clinical measurements, were still affected in the chronic phase. The CoP deviation (eyes-open and eyes-closed) was higher whereas the FIST score was lower in the stroke group than the healthy group (p < 0.05). The computerized sitting balance measurements [eyes-open (r = –0.177, p = 0.349) and eyes-closed (r = –0.294, p = 0.114)] CoP deviation was not correlated with the FIST scores (p < 0.05). However, there was an excellent agreement (96.6%) between the methods.   CONCLUSION: The results of this study implies that both the computerized and clinical sitting balance measurements can be used objectively for the assessment of sitting balance but the computerized methods might be preferable due to requiring shorter time with less intra-tester variability."@en ;
    ns0:hasPubTitle "The comparison of clinical and computerized measurement of sitting balance in stroke patients and healthy individuals"@en .

ns1:nre-v44-i3-NRE182635 ns0:hasKeywords "Dysphagia outcome"@en,
        "cognitive impairment"@en,
        "functional conditions"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "BACKGROUND: Dysphagia prevalence increases with age and a significant contribution is given by stroke survivors; its treatment is mainly based on rehabilitation, but outcome cannot be easily predicted.   OBJECTIVE: The aim of this study is to detect possible predictors of the outcome of dysphagia in patients beginning rehabilitation after a major Central Nervous System injury.   METHODS: Dysphagia severity was measured in 95 consecutive patients (71 with ischemic or hemorrhagic stroke) upon admission to our neurorehabilitation unit and at discharge, during the year 2017. The initial evaluation included also demographic data, functional and geriatric multidimensional assessment, laboratory test results and comorbidities. Their possible predictive value on the degree of recovery of the swallowing process at discharge has been analyzed.   RESULTS: Poor functional conditions and the presence of cognitive impairment on admission appear to be associated with a worse outcome of dysphagia at discharge. A significant correlation exists between scores at functional scales at the beginning of rehabilitation and dysphagia score at discharge. Patients with cognitive impairment at the beginning (n = 60) showed a significantly lower degree of recovery of dysphagia at discharge.   CONCLUSION: Other factors, beside the degree of dysphagia itself, are important to predict its outcome. Their knowledge not only allows an initial prognostic assessment; it can also be useful to decide which aspects should receive greater attention when treating patients with dysphagia."@en ;
    ns0:hasPubTitle "Functional limitations and cognitive impairment predict the outcome of dysphagia in older patients after an acute neurologic event"@en .

ns1:nre-v44-i4-NRE182636 ns0:hasKeywords "Aquatic exercise"@en,
        "balance"@en,
        "chronic stroke"@en,
        "gait"@en,
        "motor dual task training"@en ;
    ns0:hasPubAbstract "BACKGROUND: Patients with stroke are more likely to be at risk of falling, which lead to limitation in their abilities to perform daily living activities and participation in society. Falling is due to an increase in postural sway and a decline in gait ability. Exercise in water helps them to safely and comfortably improve their motor ability by providing low-risk exercise environments.   OBJECTIVE: This study was conducted to compare the effect of aquatic versus land motor dual task training on balance and gait of patients with chronic stroke.   METHODS: Fifty patients with chronic stroke of both sexes aging from 45 to 55 years were randomly assigned to aquatic or land group. Both groups received the same motor dual task training either in water or on land for 45 minutes, 3 days a week for six weeks. Measurement of the dynamic balance indices assessed using Biodex Balance System as well as kinematic gait parameters using Biodex Gait Trainer was performed before and after the intervention.   RESULTS: There was a significant improvement in all outcome variables post treatment compared with that pre-treatment in both groups (P < 0.05). There was a significant improvement in patients who received the motor dual task training in water compared with patients treated on the land in overall stability index (P = 0.02), anteroposterior stability index (P = 0.03), mediolateral stability index (P = 0.002), walking speed (P = 0.01), step length of affected limb (P = 0.03), step length of non-affected limb (P = 0.01), and time of support on the affected limb (P = 0.002).   CONCLUSION: Aquatic motor dual task training is more effective in improving balance and gait abilities of patients with chronic stroke than land motor dual task training."@en ;
    ns0:hasPubTitle "Effect of aquatic versus land motor dual task training on balance and gait of patients with chronic stroke: A randomized controlled trial"@en .

ns1:nre-v44-i4-NRE192698 ns0:hasKeywords "Amyotrophic Lateral Sclerosis"@en,
        "balance"@en,
        "postural control"@en,
        "sensory weighting"@en,
        "trunk control"@en ;
    ns0:hasPubAbstract "BACKGROUND: Postural instability in Amyotrophic Lateral Sclerosis (ALS) occurs at an early stage of the disease and often results in falls. As ALS is considered a multisystem neurodegenerative disorder, postural instability may result from motor, sensory and central processing deficits.   OBJECTIVE AND METHODS: We analysed postural control of 12 ALS patients and 12 healthy age-matched control subjects. Postural control was characterised by spontaneous sway measures and measures of postural reactions to pseudorandom anterior-posterior platform tilts, which were then correlated with clinical test scores.   RESULTS: Spontaneous sway amplitudes and velocities were significantly larger and sway frequencies higher in ALS patients than in control subjects. ALS patients’ body excursions following platform tilts were smaller, with relatively higher upper body excursions. We found high correlations between abnormal postural reactions and clinical tests representing motor or balance deficits.   CONCLUSIONS: We conclude that ALS patients’ postural abnormalities are mainly determined by an abnormal axial control and abnormally small body excursions as a function of support surface tilts, seemingly indicating better postural stabilization than control subjects. The latter contradicts the hypothesis that muscle weakness is the main source for this deficit. Instead, we suggest an altered central control strategy."@en ;
    ns0:hasPubTitle "Abnormal trunk control determines postural abnormalities in Amyotrophic Lateral Sclerosis"@en .

ns1:nre-v44-i4-NRE192701 ns0:hasKeywords "Treadmill training"@en,
        "neuroplasticity"@en,
        "spasticity"@en,
        "spinal excitability"@en ;
    ns0:hasPubAbstract "BACKGROUND: Downslope walking (DSW) is an eccentric-based exercise intervention that promotes neuroplasticity of spinal reflex circuitry by inducing depression of Soleus Hoffman (H)-reflexes in young, neurologically unimpaired adults.   OBJECTIVE: The objective of the study was to evaluate the effects of DSW on spinal excitability (SE) and walking function (WF) in people with multiple sclerosis (PwMS).   METHODS: Our study comprised two experiments on 12 PwMS (11 women; 45.3±11.8 years). Experiment 1 evaluated acute effects of a single 20-minute session of treadmill walking at three different walking grades on SE, 0% or level walking (LW), – 7.5% DSW, and – 15% DSW. Experiment 2 evaluated the effects of 6 sessions of DSW, at – 7.5% DSW (with second session being – 15% DSW) on SE and WF.   RESULTS: Experiment 1 showed significantly greater acute % H-reflex depression following – 15% DSW compared to LW (p = 0.02) and – 7.5% DSW (p = 0.05). Experiment 2 demonstrated significant improvements in WF. PwMS who showed greater acute H-reflex depression during the – 15% DSW session also demonstrated greater physical activity, long-distance WF, and the ability to have greater H-reflex depression after DSW training. Significant changes were not observed in regards to SE.   CONCLUSIONS: Though significant changes were not observed in SE after DSW training, we observed an improvement in WF which merits further investigation of DSW in PwMS."@en ;
    ns0:hasPubTitle "Effects of downslope walking on Soleus H-reflexes and walking function in individuals with multiple sclerosis: A preliminary study"@en .

ns1:nre-v44-i4-NRE192714 ns0:hasKeywords "Cognitive training"@en,
        "Parkinson’s Disease"@en,
        "executive dysfunctions"@en,
        "randomized controlled trial"@en ;
    ns0:hasPubAbstract "BACKGROUND: There is no successful pharmacological treatment for cognitive impairment in Parkinson’s Disease, therefore treatments capable of slowing down the progression of cognitive dysfunction are needed.   OBJECTIVE: To evaluate the effectiveness of a cognitive training, supported by the CoRe computerized tool, in patients with Parkinson’s Disease Mild Cognitive Impairment.   METHODS: This is a prospective, open-unblinded, randomized, controlled study. After baseline cognitive assessment (T0), enrolled patients were randomized to receive motor rehabilitation plus cognitive intervention (G1) or motor rehabilitation only (G2). Follow-up assessments were scheduled 4 weeks (T1) and 6 months after (T2). Global cognitive functioning scores (MOCA and MMSE) were considered as primary outcome. Outcome measures at T0, T1 and T2 were compared within- and between-groups. A percentage change score between T0 and next assessments was calculated to identify patients who improved, remain stable or worsened.   RESULTS: Differently from G2, G1 showed a medium/large effect size improvement in primary (MoCA) and secondary outcome, both between T0 and T1 and T0 and T2. Moreover, within G1, most patients improved their cognitive state compared to the baseline.   CONCLUSIONS: Patients trained with CoRe showed a better evolution of cognitive decline, while untreated patients tended to get worse over time."@en ;
    ns0:hasPubTitle "A computer-based cognitive training in Mild Cognitive Impairment in Parkinson’s Disease"@en .

ns1:nre-v44-i4-NRE192723 ns0:hasKeywords "Parkinson’s disease"@en,
        "gait speed"@en,
        "physiotherapy"@en ;
    ns0:hasPubAbstract "BACKGROUND: Gait function is known to be impaired by Parkinson’s disease (PD). The effect of exercise to improve gait has been widely examined, often with special intervention. However, in clinical settings, physiotherapy rarely consists only of gait training.   OBJECTIVE: To examine whether versatile physiotherapy intervention conducted in accordance with European Physiotherapy Guideline for Parkinson’s Disease (EPGPD) is sufficient to increase gait speed (GS).   METHODS: Participants (24) with idiopathic PD were randomly enrolled into intervention (IG) and control groups (CG) (n = 12, 7 females and 5 males in each group). Sixteen one-hour therapy sessions (twice per week) were conducted for IG. Each session focused on core areas recommended in EPGPD. Participants were assessed twice with 10 weeks between assessments. GS was calculated based on a gait test of Short Physical Performance Battery. Dominant side hip flexion and abduction range of motion (HFLEX & HABD) were measured and Freezing of Gait questionnaire (FOG) was administered.   RESULTS: Versatile intervention in groups resulted in increase of GS (ES –0.9 [CI{0.1}–{0.4}] m/s) and HFLEX (ES–0.6 [CI{5.9}–{16.6°}]. FOG was reduced (ES –0.41 [CI {–2.8}{–5.5}]). Re-evaluation HABD differed between groups and indicated large ES (r = –0.5).   CONCLUSIONS: Versatile physiotherapy is sufficient to improve GS, range of motion and reduce FOG."@en ;
    ns0:hasPubTitle "Versatile guideline-based physiotherapy intervention in groups to improve gait speed in Parkinson’s disease patients"@en .

ns1:nre-v45-i1-NRE192721 ns0:hasKeywords "constraining time"@en,
        "hemiplegia"@en,
        "mCIMT"@en,
        "outcome"@en,
        "rehabilitation time"@en ;
    ns0:hasPubAbstract "BACKGROUND: Impairment of upper extremity function is a common sequelae of stroke. It has been reported that modified constraint-induced movement therapy (mCIMT) could prove to be effective.   OBJECTIVE: To investigate the relationship between the intensity of rehabilitation such as treatment and constraining time, and the functional outcome for the paretic upper extremity in stroke patients through mCIMT.   METHODS: We conducted an observational prospective study of 31 patients with hemiplegia and subacute or chronic stroke. The mCIMT was performed for two weeks. Rehabilitation time and constraining time were variable among patients. The rehabilitation time included an individualized task-oriented program and conventional occupation treatment with an individualized therapist. The constraining time, with mit or splint, was also asked to self-record individually. The outcome was evaluated on the more affected side by the Wolf Motor Function Test, Fugl-Meyer Assessment, Motor Activity Log 14, and Functional Independence Measure for self-care tasks after the therapy.   RESULTS: All participants after the modified constraint-induced movement therapy program for two weeks improved on the evaluated outcome measures (P < 0.05). No significant correlation was found between the dose-dependent treatment or constraining time and outcomes. Comparisons improvement with subgroups based on the duration from onset, constraining component, dominant hand consistent with lesion side of stroke, and initial medical research council score for muscle strength, also showed no significant differences.   CONCLUSIONS: This is the first study on the effects of intensity of mCIMT with respect to time-dosage. Although all patients in this study showed improved functional status, no significant correlation between dose-dependent rehabilitation or constraining time and outcomes was seen."@en ;
    ns0:hasPubTitle "Is there a dose-dependent effect of modified constraint-induced movement therapy in patients with hemiplegia?"@en .

ns1:nre-v45-i1-NRE192754 ns0:hasKeywords "Cerebrovascular disorder"@en,
        "activities of daily living"@en,
        "disability and health"@en,
        "disability evaluation"@en,
        "international classification of functioning"@en,
        "social participation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Functional autonomy and social inclusion are of key importance for stroke patient‘s rehabilitation.   OBJECTIVE: To evaluate activity and participation of chronic stroke patients by means of basic (BADL), instrumental (IADL) and social (SADL) activities of daily living.   METHODS: Forty individuals, 24 patients and 16 healthy individuals fill in a functional activities habits questionnaire.   RESULTS: Regarding BADL, 25% of the patients did not get out of bed and 70.8% did not use toilet by themselves. Considering IADL, 29.2% of the patients did not dial the telephone, 70.8% did not wash dishes and clothes, 58.3% did not cook, 100% did not sew, 87.5% did not carry out repairs, 41.7% did not go to the bank, 54.2% did not shop and 45.8% did not write (all p < 0.05). Regarding SADL, 87.5% of the patients were not working professionally, 41.7% did not visit friends or relatives, 75% did not travel and go to the beach and 95.8% did not dance (all p < 0.05).   CONCLUSIONS: Chronic stroke patients have limitations in activity and restrictions to participation, even after few years of stroke onset, particularly regarding applying knowledge, use of communication devices, domestic life, major life areas and community, social and civic life."@en ;
    ns0:hasPubTitle "Functional activities habits in chronic stroke patients: A perspective based on ICF framework"@en .

ns1:nre-v45-i2-NRE192762 ns0:hasKeywords "Multiple sclerosis"@en,
        "constraint-induced movement therapy"@en,
        "kinematics"@en,
        "muscle strength"@en,
        "physical therapy modalities"@en,
        "rehabilitation"@en,
        "upper extremity"@en ;
    ns0:hasPubAbstract "BACKGROUND: There are few evidences on safety of Constraint-Induced Movement Therapy (CIMT), as well as its effects in neurological conditions, including multiple sclerosis (MS).   OBJECTIVE: To evaluate safety and effectiveness of a 2-week CIMT protocol on upper limb activity of progressive MS patients through a three-dimensional (3D) kinematic analysis.   METHODS: In this randomized single-blind pilot study, we randomly allocated patients affected by progressive MS reporting a reduced use of one upper limb into two different groups: CIMT group (less affected limb blocked by a splint) and control group (undergoing bi-manual treatment). Primary outcome was CIMT safety. Furthermore, we assessed CIMT effects through clinical outcomes (hand grip strength, HGS, and 9 Hole Peg Test, 9HPT) and 3D kinematic analysis (normalized jerk, number of movement units, going phase duration, mean velocity, endpoint error). All evaluations were performed at baseline (T0) and after 2 weeks of treatment (T1) for both arms in both groups.   RESULTS: Ten MS patients, mean aged 51.0±7.7 years, were randomly allocated in the 2 groups. After treatment, no differences were found in the blocked arm. Furthermore, CIMT group showed significant improvements in clinical and kinematic parameters.   CONCLUSIONS: CIMT might be considered a safe and effective technique in MS patients."@en ;
    ns0:hasPubTitle "Constraint-Induced Movement Therapy in multiple sclerosis: Safety and three-dimensional kinematic analysis of upper limb activity. A randomized single-blind pilot study"@en .

ns1:ppr-v40-i2-PPR190132 ns0:hasKeywords "Rehabilitation"@en,
        "virtual reality"@en ;
    ns0:hasPubAbstract "In Ireland, stroke is the leading cause of disability with 5000–6000 new stroke survivors each year requiring rehabilitation. While clinical rehabilitation programmes have been proven effective in motor re-learning, barriers exist in the sustainability of regular and repetitive behavioural activities. A common barrier to effective rehabilitation is patient motivation with repetitive training in itself often described by patients as boring and time consuming. Virtual reality is the use of “interactive simulations created with computer hardware and software to present users with opportunities to engage in environments that appear and feel similar to real world objects and events”. With recent advancements in digital technology; gaming and virtual reality are attracting much attention as innovative solutions to the resourcing and motivational challenges facing conventional clinical stroke therapy. In this commentary, we highlight the potential of immersive and non-immersive virtual reality in the rehabilitation after stroke. The value of virtual reality may not lie in replacing conventional therapy but in providing an alternative method of therapy that increases rehabilitation activity time and motivates users into repetitive practice. Such a therapy would be even more advantageous in the sub-acute and chronic phases of recovery when patients have limited access to further rehabilitation."@en ;
    ns0:hasPubTitle "Virtual reality to improve motor function after stroke: Past, present, and future"@en .

ns1:ppr-v40-i2-PPR190133 ns0:hasKeywords "Stroke"@en,
        "cycling"@en,
        "leisure"@en,
        "participation"@en,
        "rehabilitation"@en ;
    ns0:hasPubAbstract "BACKGROUND: New and innovative approaches are needed to overcome the barriers to engaging people in physical and leisure activity after stroke. Outdoor cycling, including the use of adapted or electric bicycles, may be one approach. However, perceptions of stroke survivors on this topic have not yet been explored.   PURPOSE: To explore a sample of stroke survivors’ perspectives, who expressed an interest in cycling, about cycling and the use of electric bicycles.   METHODS: A convenience sample of stroke survivors were identified through focus groups at a ‘Cycling after Stroke’ event, local stroke support groups, and structured interviews at a national conference for stroke survivors. Quantitative data were analysed descriptively, and qualitative data analysed thematically.   RESULTS: Data were collected from 21 stroke survivors, seven of whom were current cyclists. All participants were independently mobile with, or without, the use of a walking aid. Themes oriented around the value of cycling (e.g. getting out of the house, doing something for yourself, and feeling part of a community); concerns and challenges (safety and negotiating adaptations); and how they could be overcome (starting slowly and identifying sources of assistance).   CONCLUSION: Outdoor cycling may be a worthwhile approach to increasing physical and leisure activity after stroke. However, barriers still exist and need to be addressed to provide inclusive opportunities for adapted and electric cycling for stroke survivors. Due to the small sample size and bias population, further research is needed to explore stroke survivors’ perspectives on cycling to provide solutions to overcome the barriers identified."@en ;
    ns0:hasPubTitle "An exploration of stroke survivors’ perspectives on cycling and the use of electric bikes"@en .

ns1:ppr-v40-i2-PPR190136 ns0:hasKeywords "Thoracic spine pain"@en,
        "physiotherapy"@en,
        "physiotherapy triage"@en,
        "service evaluation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Thoracic spine pain and dysfunction (TSPD) has received less attention in the literature compared to the lumbar and cervical spine, which has created challenges for differential diagnosis in the region.   AIMS: The study purpose was to describe the clinical activity and outcomes of TSPD patients attending a clinical specialist physiotherapist (CSP)-led orthopaedic and rheumatology triage service, known as the ‘Musculoskeletal Assessment Clinic’ (MAC).   METHODS: The Clinical Audit department of St Vincent’s University Hospital, Dublin, approved this study. A retrospective service evaluation was carried out of patients who attended the MAC with TSPD between August 2012 and October 2015. Data were analysed using descriptive statistics with SPSS version 20.   RESULTS: Of the n = 5,143 new patients referred to the MAC over a period of 37 months, 88 of these (2%) (mean age 36.66, years sd = 16.61), were referred primarily for TSPD. Sixty nine percent (n = 61) of patients were categorized as non-specific thoracic spine pain (NSTSP) and 18% (n = 16) structural. Seventy-six investigations were requested for 59% (n = 52) of patients and plain radiograph was the most frequently requested (40.8%, n = 31). Eighty percent (n = 70) of patients were independently managed by CSPs, with 16% (n = 14) of patients being referred for a surgical or medical consultant opinion.   CONCLUSION: The majority (80%) of the patients were independently managed by the CSPs. Presentations of TSPD to a physiotherapy-led triage service in a secondary care setting attributable to underlying serious pathologies appears to be rare. Replication of this study in other healthcare institutions would be useful for corroborating our findings."@en ;
    ns0:hasPubTitle "Physiotherapist-led triage of patients with thoracic spine pain in a musculoskeletal assessment clinic: A service evaluation of activity and outcomes"@en .

ns1:ppr-v40-i2-PPR190137 ns0:hasKeywords "Advanced practice physiotherapy"@en,
        "cost minimisation"@en,
        "economic evaluation"@en,
        "paediatric orthopaedics"@en ;
    ns0:hasPubAbstract "PURPOSE: Advanced Practice Physiotherapy (APP) in paediatric orthopaedics is an effective adjunct to traditional consultant-led clinics, improving patient access to outpatient services, and reducing both waiting lists and times. However there has been no published economic evaluation of a paediatric orthopaedic APP service. This study performs a cost analysis, utilising a cost minimisation approach, comparing an APP Clinic in Paediatric Orthopaedics with usual care, from a health care perspective.   METHODS: Data on all patients managed by the APP clinic for one calendar year were collected and outcomes and associated costs were calculated, including follow-up care. These costs were compared to the estimated costs of the usual care pathway, an Orthopaedic Consultant Elective Clinic (OCEC) and incremental savings per patient was calculated.   RESULTS: A total of 534 patients attended the APP clinic for initial assessment during the calendar year 2017. The unit cost of a new appintment with the APP clinic is € 32.46 in comparison with € 56.98 for a new appointment in the OCEC. Our results demonstrate an incremental per patient saving of € 24.51 in favour of the APP clinic. Sensitivity analysis demonstrates that the cost savings obtained hold consistent in all cases, varying from € 23.13 to € 29.67 per patient in favour of the APP clinic pathway. This represents a cost saving of 43% for the APP Pathway over that of usual care.   CONCLUSION(S): This is the first study to perform an economic analysis of the APP role in paediatric orthopaedics and demonstrates that an APP clinic for non-complex paediatric orthopaedic patients is substantially less costly than usual care."@en ;
    ns0:hasPubTitle "An advanced practice physiotherapy clinic in paediatric orthopaedics: A cost minimisation analysis"@en .

ns1:prm-v12-i3-PRM190611 ns0:hasKeywords "Children with medical complexity"@en,
        "compassionate care"@en,
        "coordination of care"@en ;
    ns0:hasPubAbstract "Employing a cross-sectional qualitative descriptive design, using individual, semi-structured interviews collected from primary care and specialty clinicians who routinely care for children with medical complexity (CMC) in a largely rural area in central Virginia, this study aimed to better understand the current state of care, the motivations, and barriers for expansion of care for CMC in a semi-rural academic hospital center. Five themes emerged describing the current practice of the participants: (1) complexities of care, (2) compassion and empathy for families, (3) limited resources, (4) essential nature of coordination and teamwork, and (5) proximity to care. Each of the five themes that emerged from our interviews present both challenges and rewards. The theme of compassion for families of CMC is seen as a key potential motivational driver for expansion and reorganization of clinical care for CMC."@en ;
    ns0:hasPubTitle "Compassion and connectedness as motivational drivers in the care of children with medical complexity"@en .

ns1:red-v16-i1-red160101 ns0:hasKeywords "Mechanical stress"@en,
        "Piezoelectricity"@en,
        "Polypropylene–quartz combination"@en,
        "Spring stiffness"@en,
        "Thermal stress"@en,
        "Voltage sensitivity"@en,
        "Wind speed"@en,
        "Young’s modulus"@en ;
    ns0:hasPubAbstract "The dire need of the present era is generation of power at high voltage levels in a cost-effective and an eco-friendly manner. Against this backdrop, this paper discusses the concept of piezoelectric potential difference generation using a combination of solar energy and wind energy simultaneously in an integrated manner. Due to solar energy, the thermal stress created in one member develops mechanical stress in another member and the mechanical stress, thus developed, is responsible for the generation of potential difference. In the case of wind energy, elastic deformation in the spring attached to the rotor mill develops mechanical stress in the quartz bar which leads to piezoelectric potential difference generation. Further, the device has an advantage over conventional solar cells or windmills owing to reduced wear and tear, no hazard from dust, operational flexibility in both odd and even weather conditions, among others."@en ;
    ns0:hasPubTitle "Integration of Solar and Wind Energy to Generate Piezoelectric Potential Difference"@en .

ns1:rft-v10-i1-2-RFT180106 ns0:hasKeywords "EPC"@en,
        "HF"@en,
        "Inlay"@en,
        "NFC"@en,
        "RFID"@en,
        "UHF"@en,
        "apparel"@en,
        "dual frequency"@en,
        "performance benchmarking"@en ;
    ns0:hasPubAbstract "The paper aims to benchmark the performances of dual-frequency inlays, operating in the UHF and HF bands, when deployed in the apparel logistics and end user retail processes. The developed testing protocol makes it possible to evaluate the performances of RFID devices in simulated supply chain and end user-oriented processes. It has been designed considering the need for identification of the supply chain and the end users, who can take advantage of the adoption of NFC technology. We applied the testing procedure to RFID inlays equipped with an innovative integrated circuit (IC) and two antennas, capable of managing both EPC communication in the UHF band and NFC communication in the HF band with smart devices. The performances of the inlays were compared to those of standard tags commonly used in the EPC and NFC fields. We measured and compared the read rate, accuracy and read time when testing EPC capabilities and the read/write throughput, time and distance when measuring NFC functionalities. By simulating a real-world environment, the test results provide a direct insight into the performances that can be expected from different dual-frequency RFID inlays. This information is useful for IT and logistics managers, who can better understand how these innovative tags perform and which would be the best choice for new RFID applications."@en ;
    ns0:hasPubTitle "Assessing the performances of RFID UHF and HF dual-frequency apparel tags"@en .

ns1:rnn-v37-i3-RNN180883 ns0:hasKeywords "Transcranial magnetic stimulation"@en,
        "hemiplegia"@en,
        "recovery of function"@en,
        "stroke"@en,
        "stroke rehabilitation"@en ;
    ns0:hasPubAbstract "Background: Repetitive transcranial magnetic stimulation (rTMS) modulates cortical excitability and facilitates motor learning to improve motor recovery after stroke. Action observation (AO) therapy effectively facilitates physical training for motor memory formation.  Objective: To compare the effectiveness of rTMS alone with that of combined rTMS and AO for the functional recovery of upper extremity function in subacute stroke patients and to verify the safety of the interventions.  Methods: The present study was a prospective, randomized controlled trial involving subacute unilateral stroke patients. In total, 22 patients were randomly assigned to 2 groups: the trial group (rTMS with AO) and the control group (rTMS alone). Both groups received 1 Hz rTMS (intensity: 120% of resting motor threshold; rMT) over the contralesional primary motor cortex for 20 minutes on 10 consecutive days. Trial group received rTMS while watching a video of 5 different complex hand movements. The functional parameters were the Brunnstrom stage, Fugl-Meyer assessment (FMA) score of the upper extremity, Manual Function Test (MFT) score, and grip power. The following motor evoked potential (MEP) parameters were recorded from the abductor pollicis brevis muscle: rMT, latency, and amplitude. Both parameters were measured before and after the 2 week intervention.  Results: After the 2 week trial, the total FMA and MFT scores were significantly improved in both groups, but the MFT subscores of hand motor function and grip power were significantly improved in the combination therapy group only. In contrast, the changes (Δ) of FMA, MFT, grip power test, and MEP outcomes were not significantly different between the 2 groups. No adverse events or complications were reported.  Conclusions: Distal upper extremity function, as measured by MFT and grip power, was improved after rTMS and AO in combination. The combination of rTMS with AO may be applied safely to improve upper extremity function after stroke."@en ;
    ns0:hasPubTitle "Effects and safety of combined rTMS and action observation for recovery of function in the upper extremities in stroke patients: A randomized controlled trial"@en .

ns1:rnn-v37-i3-RNN180897 ns0:hasKeywords "Robotic gait training"@en,
        "cerebral palsy"@en,
        "endurance"@en,
        "neurorehabilitation"@en,
        "outcome"@en ;
    ns0:hasPubAbstract "Background: Robot-assisted gait training (RAGT) is widely used in children with cerebral palsy (CP), but information about optimal intervention frequency and duration is still lacking and the current evidence about effect of RAGT on motor endurance and fitness is very preliminary.  Objective: To investigate the effect of RAGT on motor performance and endurance in children affected by CP.  Methods: Data from 14 consecutive children (6 females, age range: 4.6–15.8 years) affected by CP, who underwent a multidisciplinary rehabilitation program during a 18–24 month period, were retrospectively collected. Rehabilitation program included conventional physical therapy and RAGT (60/60 minutes, 20 daily sessions, 5 days/week). CP severity was stratified according to the Gross Motor Function Classification System. Clinical evaluation was performed by means of the six-minute walking test, the modified Ashworth scale, and RAGT measures (total distance, mean distance for session and speed).  Results: Clinical outcomes and speed did not improve after treatment, while total distance (p = 0.006) and mean distance for session (p = 0.007) significantly improved.  Conclusions: Our preliminary study suggests that RAGT combined with conventional treatment may improve motor performance and endurance in children with CP. Future randomized controlled trials comparing RAGT to conventional treatment are needed."@en ;
    ns0:hasPubTitle "Improvement of motor performance in children with cerebral palsy treated with exoskeleton robotic training: A retrospective explorative analysis"@en .

ns1:rnn-v37-i4-RNN190908 ns0:hasKeywords "Transcranial direct current stimulation"@en,
        "resistance training"@en,
        "stroke rehabilitation"@en,
        "treatment outcome"@en ;
    ns0:hasPubAbstract "Background: Transcranial direct current stimulation (tDCS) is a promising tool for stroke rehabilitation. Yet, so far, results from the available clinical trials are inconclusive.   Objectives: The primary objective of the present work was to test the efficacy of multiple sessions of tDCS combined with a highly standardized and progressive resistance training program of the affected upper limb in individuals in the chronic phase of recovery after a stroke. Secondary objectives were to test the safety and tolerability of these combined interventions.   Methods: This two-arm parallel pilot trial recruited participants that were ≥18 years old, community-dwelling, and had sustained a supratentorial stroke ≥6 months prior to the study. They were allocated using a stratified randomization into two groups: 1) real tDCS + resistance training and 2) sham tDCS + resistance training. The resistance training program targeted the affected upper limb and consisted in 60 minutes of exercises, 3 times/week over 4 weeks. During each session, participants received either real- or sham-tDCS, using a bi-hemispheric montage for the first 20 minutes, and were blinded to the tDCS intervention. Outcome measures of clinical efficacy (Fugl-Meyer Assessment, Box and Block Test, Wolf Motor Function Test, grip strength, modified Ashworth scale and Motor Activity Log) were assessed by a blinded evaluator before and after the 4-week training program. Safety and tolerability were evaluated, respectively, by the number and characteristics of tDCS adverse events and dropout rates with their reasons.   Results: From the 147 individuals screened for eligibility, 14 participants (68.9±10.0 years old; 70.9±57.6 months post-stroke) met the selection criteria and were allocated to real-tDCS (n = 7) or sham-tDCS (n = 7) groups. Both groups improved on the clinical outcome measures, but these changes were not significantly different between groups (p > 0.17). No dropout occurred throughout the study. Participants frequently reported mild skin tingling during the administration of both real- and sham-tDCS, and no group difference was noted for its frequency and intensity (p > 0.38). One participant having received real-tDCS complained about a mild skin burning sensation after two sessions. The a priori sample size analysis performed on the Fugl-Meyer Assessment scores revealed that 56 participants would be required in a future clinical trial to reach 80% power at a significance level of 0.05.   Conclusions: In this pilot study, repeated sessions of bi-hemispheric tDCS coupled with resistance training were found safe and tolerable for individuals at the chronic phase post-stroke. However, the use of tDCS did not result in additional sensorimotor improvements when compared to sham-tDCS. Further research is needed to better assess the clinical benefits of combining non-invasive transcranial stimulation with rehabilitation after a stroke."@en ;
    ns0:hasPubTitle "Efficacy, safety, and tolerability of bilateral transcranial direct current stimulation combined to a resistance training program in chronic stroke survivors: A double-blind, randomized, placebo-controlled pilot study"@en .

ns1:rnn-v37-i5-RNN190924 ns0:hasKeywords "Perturbation training"@en,
        "adaptation"@en,
        "generalization"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "Background: Chronic stroke survivors demonstrate the potential to acquire reactive adaptations to external perturbations. However, such adaptations in postural stability and compensatory stepping responses are perturbation-type specific and the ability to generalize such adaptation to an opposing perturbation has not been studied.   Objective: The study aimed to examine whether improved reactive balance control acquired through prior slip-perturbation training would positively transfer to, or interfere with, the reactive response to an unexpected novel trip.   Methods: Twenty-six chronic stroke survivors were assigned to either the training group (TR) who received treadmill-induced slips (12 m/s2) while standing followed by a novel trip (16.8 m/s2) or the control group (TC) who experienced a single unannounced trip. The primary outcome measure was postural stability (examined by relative center of mass position (RCoMP) and velocity (RCoMV)) with step length and trunk angle being secondary measures. Perturbation outcome (fall vs recovery) and number of compensatory steps were also recorded.   Results: The TR group showed an anterior shift in RCoMP via longer compensatory backward step and reduced number of steps from first to last slip-perturbation (p < 0.05). Post-slip adaptation, the TR group exhibited a more posterior RCoMP on the novel trip along with a longer forward step and decreased trunk flexion compared to the TC group (p < 0.05).   Conclusions: Chronic stroke survivors demonstrated improved direction-specific compensatory stepping response on a novel trip-perturbation following reactive adaptation to large-magnitude, stance-slip perturbation training. The present study investigates the ability of chronic stroke survivors to generalize motor adaptation from stance-slip perturbation training to a novel, diametrically opposing trip-perturbation. We report that people with chronic hemi-paretic stroke could execute the acquired adaptation in reactive postural stability to improve reactive stepping responses to a novel stance-trip perturbation via generation of a direction-specific effective compensatory stepping response, such that the training group demonstrated a longer forward compensatory step and better control of postural stability than the control group."@en ;
    ns0:hasPubTitle "Transfer of reactive balance adaptation from stance-slip perturbation to stance-trip perturbation in chronic stroke survivors"@en .

ns1:rnn-v37-i5-RNN190927 ns0:hasKeywords "Theta burst stimulation"@en,
        "event-related desynchronization"@en,
        "mirror neuron system"@en,
        "mirror visual feedback"@en ;
    ns0:hasPubAbstract "Background: Excitatory brain stimulation, in the form of intermittent theta burst stimulation (iTBS), combined with mirror visual feedback (MVF), is hypothesized to promote neuroplasticity and motor performance.   Objective: This study aimed to investigate the combined effects of iTBS with mirror training (MT) on the MVF-induced sensorimotor event-related desynchronization (ERD) and the non-dominant hand motor performance in healthy adults.   Methods: Eighteen healthy right-handed subjects were randomly assigned to one of three groups (Group 1: iTBS plus MT, Group 2: iTBS plus sham MT, or Group 3: sham iTBS plus MT). For participants in Groups 1 and 3, motor training was performed for 15 minutes for the right hand over four consecutive days, with MVF superimposing on their inactive left hand behind a mirror. Participants in Group 2 received the same right-hand motor training, but the mirror was covered without MVF. iTBS or sham iTBS was applied daily over the right primary motor cortex prior to the training. Electroencephalography at pre/post-training was recorded while participants performed right-hand movement under mirror and direct view. Motor performance was assessed at baseline and post-training.   Results: Baseline comparisons demonstrated that a shift in sensorimotor ERD towards the right hemisphere was induced by MVF, in mu-1 (8–10 Hz) (p = 0.002), mu-2 (10–12 Hz) (p = 0.004) and beta-1 (12–16 Hz) (p = 0.049) bands. After the training, participants in Group 1 showed a stronger MVF-induced sensorimotor ERD in mu-1 (p = 0.017) and mu-2 (p = 0.009) bands than those in Group 3. No significant between-group difference in motor outcomes was observed.   Conclusions: iTBS appears to prime subjects’ brain to be more receptive to MVF."@en ;
    ns0:hasPubTitle "Enhancing mirror visual feedback with intermittent theta burst stimulation in healthy adults"@en .

ns1:sw-v10-i5-SW190364 ns0:hasKeywords "Deep learning"@en,
        "Semantic Web"@en,
        "knowledge injection"@en ;
    ns0:hasPubAbstract "Numerous success use cases involving deep learning have recently started to be propagated to the Semantic Web. Approaches range from utilizing structured knowledge in the training process of neural networks to enriching such architectures with ontological reasoning mechanisms. Bridging the neural-symbolic gap by joining deep learning and Semantic Web not only holds the potential of improving performance but also of opening up new avenues of research. This editorial introduces the Semantic Web Journal special issue on Semantic Deep Learning, which brings together Semantic Web and deep learning research. After a general introduction to the topic and a brief overview of recent contributions, we continue to introduce the submissions published in this special issue."@en ;
    ns0:hasPubTitle "Special issue on Semantic Deep Learning"@en .

ns1:sw-v10-i5-SW318 ns0:hasKeywords "ConvKB"@en,
        "Knowledge base completion"@en,
        "convolutional neural network"@en,
        "link prediction"@en,
        "search personalization"@en,
        "triple classification"@en ;
    ns0:hasPubAbstract "In this paper, we propose a novel embedding model, named ConvKB, for knowledge base completion. Our model ConvKB advances state-of-the-art models by employing a convolutional neural network, so that it can capture global relationships and transitional characteristics between entities and relations in knowledge bases. In ConvKB, each triple (head entity, relation, tail entity) is represented as a 3-column matrix where each column vector represents a triple element. This 3-column matrix is then fed to a convolution layer where multiple filters are operated on the matrix to generate different feature maps. These feature maps are then concatenated into a single feature vector representing the input triple. The feature vector is multiplied with a weight vector via a dot product to return a score. This score is then used to predict whether the triple is valid or not. Experiments show that ConvKB obtains better link prediction and triple classification results than previous state-of-the-art models on benchmark datasets WN18RR, FB15k-237, WN11 and FB13. We further apply our ConvKB to a search personalization problem which aims to tailor the search results to each specific user based on the user’s personal interests and preferences. In particular, we model the potential relationship between the submitted query, the user and the search result (i.e., document) as a triple (query, user, document) on which the ConvKB is able to work. Experimental results on query logs from a commercial web search engine show that ConvKB achieves better performances than the standard ranker as well as strong search personalization baselines."@en ;
    ns0:hasPubTitle "A convolutional neural network-based model for knowledge base completion and its application to search personalization"@en .

ns1:sw-v10-i6-SW190355 ns0:hasKeywords "Events"@en,
        "biographical timelines"@en,
        "knowledge graph"@en ;
    ns0:hasPubAbstract "One of the key requirements to facilitate the semantic analytics of information regarding contemporary and historical events on the Web, in the news and in social media is the availability of reference knowledge repositories containing comprehensive representations of events, entities and temporal relations. Existing knowledge graphs, with popular examples including DBpedia, YAGO and Wikidata, focus mostly on entity-centric information and are insufficient in terms of their coverage and completeness with respect to events and temporal relations. In this article we address this limitation, formalise the concept of a temporal knowledge graph and present its instantiation – EventKG. EventKG is a multilingual event-centric temporal knowledge graph that incorporates over 690 thousand events and over 2.3 million temporal relations obtained from several large-scale knowledge graphs and semi-structured sources and makes them available through a canonical RDF representation. Whereas popular entities often possess hundreds of relations within a temporal knowledge graph such as EventKG, generating a concise overview of the most important temporal relations for a given entity is a challenging task. In this article we demonstrate an application of EventKG to biographical timeline generation, where we adopt a distant supervision method to identify relations most relevant for an entity biography. Our evaluation results provide insights on the characteristics of EventKG and demonstrate the effectiveness of the proposed biographical timeline generation method."@en ;
    ns0:hasPubTitle "EventKG – the hub of event knowledge on the web – and biographical timeline generation"@en .

ns1:sw-v10-i6-SW190358 ns0:hasKeywords "Inconsistency"@en,
        "knowledge graph"@en,
        "methodology"@en,
        "resolution"@en,
        "rule-driven"@en ;
    ns0:hasPubAbstract "Knowledge graphs, which contain annotated descriptions of entities and their interrelations, are often generated using rules that apply semantic annotations to certain data sources. (Re)using ontology terms without adhering to the axioms defined by their ontologies results in inconsistencies in these graphs, affecting their quality. Methods and tools were proposed to detect and resolve inconsistencies, the root causes of which include rules and ontologies. However, these either require access to the complete knowledge graph, which is not always available in a time-constrained situation, or assume that only generation rules can be refined but not ontologies. In the past, we proposed a rule-driven method for detecting and resolving inconsistencies without complete knowledge graph access, but it requires a predefined set of refinements to the rules and does not guide users with respect to the order the rules should be inspected. We extend our previous work with a rule-driven method, called Resglass, that considers refinements for generation rules as well as ontologies. In this article, we describe Resglass, which includes a ranking to determine the order with which rules and ontology elements should be inspected, and its implementation. The ranking is evaluated by comparing the manual ranking of experts to our automatic ranking. The evaluation shows that our automatic ranking achieves an overlap of 80% with experts ranking, reducing this way the effort required during the resolution of inconsistencies in both rules and ontologies."@en ;
    ns0:hasPubTitle "Rule-driven inconsistency resolution for knowledge graph generation rules"@en .

ns1:sw-v10-i6-SW190365 ns0:hasKeywords "Property Paths"@en,
        "SPARQL"@en,
        "expressive power"@en,
        "navigational languages"@en,
        "query-based reasoning"@en,
        "translation"@en ;
    ns0:hasPubAbstract "The increasing number of Knowledge Graphs (KGs) available today calls for powerful query languages that can strike a balance between expressiveness and complexity of query evaluation, and that can be easily integrated into existing query processing infrastructures. We present Extended Property Paths (EPPs), a significant enhancement of Property Paths (PPs), the navigational core included in the SPARQL query language. We introduce the EPPs syntax, which allows to capture in a succinct way a larger class of navigational queries than PPs and other navigational extensions of SPARQL, and provide formal semantics. We describe a translation from non-recursive EPPs (nEPPs) into SPARQL queries and provide novel expressiveness results about the capability of SPARQL sub-languages to express navigational queries. We prove that the language of EPPs is more expressive than that of PPs; using EPPs within SPARQL allows to express things that cannot be expressed when only using PPs. We also study the expressiveness of SPARQL with EPPs in terms of reasoning capabilities. We show that SPARQL with EPPs is expressive enough to capture the main RDFS reasoning functionalities and describe how a query can be rewritten into another query enhanced with reasoning capabilities. We complement our contributions with an implementation of EPPs as the SPARQL-independent iEPPs language and an implementation of the translation of nEPPs into SPARQL queries. What sets our approach apart from previous research on querying KGs is the possibility to evaluate both nEPPs and SPARQL with nEPPs queries under the RDFS entailment regime on existing query processors. We report on an experimental evaluation on a variety of real KGs."@en ;
    ns0:hasPubTitle "Querying knowledge graphs with extended property paths"@en .

ns1:sw-v10-i6-SW190369 ns0:hasKeywords "Linked Date"@en,
        "Persian"@en,
        "Semantic Web"@en,
        "knowledge graph"@en ;
    ns0:hasPubAbstract "Over the last decade, extensive research has been done on automatic construction of knowledge graphs from Web resources, resulting in a number of large-scale knowledge graphs such as YAGO, DBpedia, BabelNet, and Wikidata. Despite that some of these knowledge graphs are multilingual, they contain few or no linked data in Persian, and do not support tools for extracting knowledge from Persian information sources. FarsBase (available at http://farsbase.net/about) is the first Persian multi-source knowledge graph, which is specifically designed for semantic search engines to support Persian knowledge. FarsBase uses a diverse set of hybrid and flexible techniques to extract and integrate knowledge from various sources, such as Wikipedia, Web tables and unstructured texts. It also supports entity linking, which allows integration with other knowledge graphs. To maintain high accuracy for triples, we adopt a low-cost mechanism for verifying candidate knowledge by human experts, where the candidates for human verification are prioritized using different heuristics. FarsBase is being used as the semantic-search system of a Persian search engine and efficiently answers hundreds of semantic queries per second."@en ;
    ns0:hasPubTitle "FarsBase: The Persian knowledge graph"@en .

ns1:tad-v31-i1-2-TAD180217 ns0:hasKeywords "Assistive technology"@en,
        "caregiver"@en,
        "dementia"@en,
        "financial strain"@en,
        "financial wealth"@en,
        "independence"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Older adults with dementia have been targeted toward the development of assistive technologies intended to facilitate aging in place. Researchers have documented financial and occupation strain for the caregiver and the financial limitations experienced by persons with dementia. These factors constitute a potential hindrance to the use and applicability of assistive technologies; technologies that may reduce caregiver burden, allow more time for paid work, and, in consequence, reduce occupational strain.   OBJECTIVE:  To unpack how financial burden, operationalized as direct (e.g., income) and indirect (e.g., caregiver education, employment status) measures of wealth and assets, affect the perceived independence of people with dementia.   METHODS:  We draw on data collected through a cross-Canada survey of caregivers to develop a set of predictive models of care-recipient task independence.   RESULTS:  Our findings suggest that said measures of wealth can predict task independence, and more complicated or instrumental daily tasks (e.g., shopping, driving) are perceived as being those with which care recipients need most assistance.   CONCLUSIONS:  Considering the economical and emotional obstacles that affect both the caregiver and the care recipient, the development of assistive technologies that would be both financially realistic and assistive for this population in these instrumental daily tasks is warranted."@en ;
    ns0:hasPubTitle "Informing the development of assistive technologies for persons with dementia by connecting financial measures of wealth to perceptions of task dependence"@en .

ns1:tad-v31-i3-TAD190225 ns0:hasKeywords "Duchenne Muscular Dystrophy"@en,
        "Electric wheelchair"@en,
        "cooperative operation"@en,
        "hand function"@en,
        "one-dimensional input device"@en ;
    ns0:hasPubAbstract "Persons with Duchenne Muscular Dystrophy (DMD) usually have difficult in operating electric wheelchairs (EWs) using standard input device due to the lack of muscular power and the deformation of their hands. To solve this problem, various kinds of input devices are developed considering their physical limits. However, as the disease progresses, persons with severe DMD will gradually lose the ability to operate the developed input devices. In this study, we first made an investigation of physical functions for persons with severe DMD and found that functions of upper limb, especially functions of the fingers, tended to remain better in at least one-dimensional direction. A novel one-dimensional input device (1DID) was developed for persons with severe DMD based on a quantitative evaluation of the hand functions. Thus, this device can be operated using slight force and one-dimensional movement of a finger. Therefore, persons with severe DMD can adjust the straight and turning motion of an EW using two 1DIDs with the cooperative operation by two fingers. The validity of this device was demonstrated by evaluation experiments of 10 persons with severe DMD including those who do not have a proper input device. The evaluation results also show that the developed 1DID has the possibility to be widely used as a generic input device with computers for persons with severe disabilities."@en ;
    ns0:hasPubTitle "One-dimensional input device of electric wheelchair for persons with severe Duchenne Muscular Dystrophy"@en .

ns1:thc-v27-i4-THC181184 ns0:hasKeywords "Lumen diameter"@en,
        "color Doppler"@en,
        "inflation pressure"@en,
        "neointimal hyperplasia"@en ;
    ns0:hasPubAbstract "BACKGROUND:  The mechanical stretch injury imposed by the intravascular intervention contributes to neointimal hyperplasia. Lessening of this damage without the compromise of luminal dilation could be an alternative way to alleviate restenosis.   OBJECTIVE:  We aimed to assess the relationship of lumen diameter and neointimal hyperplasia with inflation pressure using color Doppler ultrasound-guided balloon dilation.   METHODS:  The anteroposterior diameter of the given aortic segment in rabbits was measured by ultrasonography to ensure the similar original diameter. Then they were assigned into three groups with the inflation force at 1, 5, 10 atmosphere pressure (atm), respectively. Balloon dilation and injury of the given aortic segment were performed. Two weeks later, all rabbits were euthanized for histologic evaluation.   RESULTS:  After operation, the lumen diameter of each group enlarged significantly (P< 0.05) with a similar rate of change. However, neointimal area, circumference and hepatocyte growth factor (HGF) positive cells in group with 1 atm were significantly less than those of the other two (P< 0.05). Maximal neointima thickness increased significantly with the elevation of the inflation pressure (P< 0.05).   CONCLUSIONS:  Based on sufficient dilation of the balloon, the balloon inflated with the less pressure caused the similar increase in lumen diameter as the higher pressure but the less neointimal hyperplasia and HGF positive cells."@en ;
    ns0:hasPubTitle "The relationship of lumen diameter and neointimal hyperplasia with inflation pressure"@en .

ns1:thc-v27-i4-THC181480 ns0:hasKeywords "Dynamic causal modeling"@en,
        "active cortical regions"@en,
        "effective connectivity"@en,
        "mental fatigue"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Recognition of sources in the brain and their interaction with mental fatigue states are interesting subjects for researchers.   OBJECTIVE:  The aim of this study was to investigate the mental fatigue effects on brain areas by dynamic causal modeling (DCM) parameters that are extracted from event-related potential (ERP) signals which were then estimated based on mental fatigue data with visual stimulation.   METHODS:  ERP were recorded based on a Continuous Performance Task in four consecutive trials. Active regions and brain sources were extracted by a Multiple Sparse Priors algorithm.   RESULTS:  Four models are proposed for DCM. The parameters and the structure of the best model were obtained by SPM software for ERP in each of the four trials.   CONCLUSION:  The results illustrate that an increase of mental fatigue through trials leads to increased likelihood of choosing forward models."@en ;
    ns0:hasPubTitle "Effective connectivity of mental fatigue: Dynamic causal modeling of EEG data"@en .

ns1:thc-v27-i4-THC191659 ns0:hasKeywords "Distal intra-articular humerus fracture"@en,
        "angle-stable implants"@en,
        "loss of muscle force"@en,
        "reduction of elbow agility"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Treatment of distal intra-articular humerus fractures is still a technical challenge. Until now, little is known about the regain of strength and elbow agility after surgical treatment of these fractures. Due to small collectives there is only limited data.   OBJECTIVE:  Investigation of regained strength and elbow agility in patients with intra-articular distal humerus fractures.   METHODS:  A total of 28 patients were treated with distal intra-articular humerus fractures followed up for an average period of 62.3 months. The following parameters were examined: Arthrosis, heterotopic ossification, functional outcome (MEPS, DASH score, LES) and isometric strength of the elbow in extension and flexion was tested in 30∘, 60∘ and 90∘ in a custom-made positioning device.   RESULTS : There was a high complication rate with 32%. At the 60th month post injury, range of motion (ROM) of the elbow was 114∘ with a reduction of 32∘ compared to the contralateral uninjured side (p< 0.001). The highest reduction was seen in extension with an average loss of 16∘ (p< 0.001). Loss of motion correlated with the fracture severity regarding the AO-classification (r= 0.54, p< 0.01). The average regained muscle force was 81.5% in flexion and 92% in extension in comparison to the contralateral healthy side. Patients over 60 years had less range of motion and inferior results in the DASH score compared to younger patients.   CONCLUSIONS:  Functional impairment in terms of reduced ROM and muscle force is a common complication after distal intra-articular humerus fracture. Patients over 60 years have a higher deficit of motion in the injured elbow joint and an inferior clinical outcome. Superiority of modern angle-stable implants could yet not be shown."@en ;
    ns0:hasPubTitle "Posttraumatic elbow agility and reduction of muscle force after intra-articular distal fractures of the humerus in adults"@en .

ns1:thc-v27-i5-THC191731 ns0:hasKeywords "Big data"@en,
        "ICT"@en,
        "algorithm"@en,
        "healthcare service"@en,
        "nutrition management"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Due to environmental factors such as nutrient intake imbalance, lack of exercise, and increased stress, it is necessary to control nutrition in order to prevent diseases and provide treatment in terms of healthcare.   OBJECTIVE:  This study proposes the activity-based nutrition management model with the use of the cluster analysis of similar group for healthcare.   METHODS:  The proposed method is to conduct the cluster analysis of similar group for nutrition management and to develop the real-time activity information based nutrition management algorithm with the use of big data in order to improve the quality of healthcare management service. It is to re-process an existing nutrition database and add voice recognition function in line with the service so as to improve convenience of intake-food inputs. In addition, the Bluetooth Low Energy (BLE) communication based standard collection of bio signals occurring in real-time is developed. This study also proposes the method of improving an existing algorithm of drawing a daily recommended allowance with the use of real-time activity information, and the proposed service provides the essential information of nutrition management with the use of public big data.   RESULTS:  To verify the developed technology and service model and its effectiveness, the nutrition management service system is designed and developed with human interface.   CONCLUSIONS:  The developed health model helps to solve the obesity problem, save medical costs, and address the issue of national health."@en ;
    ns0:hasPubTitle "Activity-based nutrition management model for healthcare using similar group analysis"@en .

ns1:thc-v27-i6-THC181510 ns0:hasKeywords "Granulosa cells"@en,
        "hsa-miR-3135b"@en,
        "hsa-miR-3188"@en,
        "polycystic ovary syndrome"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Polycystic Ovary Syndrome (PCOS) is a major cause of anovulatory infertility. Some studies showed that miRNAs were used as diagnostic/prognostic biomarkers for various diseases.   OBJECTIVE:  To identify candidate miRNAs in Granulosa Cells (GCs) of PCOS and evaluate their potential values for PCOS diagnosis.   METHODS:  We screened differentially expressed miRNAs in GCs between PCOS and controls by the microarray data from the GEO database. GCs were collected from 21 controls and 24 PCOS. The candidate miRNAs were verified by qRT-PCR. The correlation was investigated between candidate miRNAs and clinical characteristics in participants. Diagnostic value of candidate miRNAs was analyzed by receiver operating characteristic (ROC) curve.   RESULTS:  Seven miRNAs were differentially expressed in PCOS compared with controls. Furthermore, the validation results demonstrated that hsa-miR-3188 and hsa-miR-3135b showed higher levels in GCs with PCOS patients (p< 0.05). In addition, the expressions of hsa-miR-3188 and hsa-miR-3135b were negative correlated with FSH and hsa-miR-3188 was positive correlated with BMI (p< 0.05). ROC analysis indicated that hsa-miR-3188 and hsa-miR-3135b could differentiate PCOS from controls, and the hsa-miR-3188/3135b improved the predictive accuracy for PCOS.   CONCLUSIONS:  The expressions of hsa-miR-3188 and hsa-miR-3135b in human GCs were significantly associated with PCOS. Moreover, the hsa-miR-3188/3135b has certain diagnostic value for distinguishing PCOS."@en ;
    ns0:hasPubTitle "Identification and potential value of candidate microRNAs in granulosa cells of polycystic ovary syndrome"@en .

ns1:thc-v27-i6-THC191639 ns0:hasKeywords "Catheter ablation"@en,
        "PVA-H"@en,
        "contact force"@en,
        "electrode cooling"@en,
        "vibration"@en ;
    ns0:hasPubAbstract "BACKGROUND:  A new cooling method is proposed for preventing electrode-tissue overheating during cardiac catheter ablation using a vibrating catheter. Previous work has shown that vibration that results from increased flow velocity around the catheter can have a cooling effect on the electrode.   OBJECTIVE:  Contact force has been shown to be an important factor that affects cooling and lesion formation, because contact force determines the ratio of power delivery between blood and tissue. In this study, the effect of contact force on electrode cooling and tissue heating was investigated during the operation of an electrode cooled by vibration.   METHODS:  Using PVA-H or myocardium ablation tissue models under conditions of no flow, electrode and tissue temperatures and lesion sizes were measured at various vibrational frequencies and contact force conditions.   RESULTS:  The experiments showed that the catheter vibration still decreases the electrode temperature over a contact force range of 2–30 gf. The lesion size was increased with increasing contact force at each vibrational frequency.   CONCLUSIONS:  Increasing contact force can increase lesion size with cooling by vibration remaining effective."@en ;
    ns0:hasPubTitle "The effect of contact force during radiofrequency catheter ablation using a vibrating catheter: New cooling method for catheter ablation"@en .

ns1:thc-v27-iS1-THC199002 ns0:hasKeywords "Children"@en,
        "mood light"@en,
        "sleep aid"@en,
        "sleep environment"@en,
        "smartphone dongle"@en,
        "wireless multi-channel communication"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Children struggle to fall asleep by themselves because of their physiological characteristics. Therefore, research has been carried on various devices (such as a smartphone) to assist in improving the sleep quality of children. However, all such devices need to be controlled by parents and do not have functions for monitoring the sleep environment.   OBJECTIVE:  In this paper, a smart sleep-lighting system that includes a sleep-lighting device and a smartphone dongle is developed to improve the sleep environment of children.   METHODS: The temperature, humidity, and luminance of the sleep environment are monitored and analyzed by the sleep-lighting device to control multi-color light and audio components. The colored light emitted by the multi-color light can be adjusted to improve the sleep atmosphere. Also, the audio component can play white noise to induce sleep. In addition, parents can use a smartphone dongle with a multi-channel wireless communication method to monitor and control one or more lighting devices in different locations in real time.   RESULTS:  For environmental monitoring, average difference between proposed device and commercial sensor from chamber setting temperature 15∘C to 35∘C was 0.588∘C ± 0.10∘C, and average error value of the humidity measurement was 0.74% at 40% ∼ 60% RH. Also, the manufactured sleep-lighting device shows good performance in multi-color light emission, and playing of white noise. As result, the smartphone connected to the proposed smartphone dongle enables monitoring and control of the proposed lighting device in a wireless well.   CONCLUSIONS: The manufactured sleep-lighting device has a high-precision temperature and humidity sensor and a luminance sensor that can accurately monitor the sleeping environment. The lighting device can play white noise to induce sleep in children. Also, a multi-color LED light is operated via a smartphone application to improve the sleep atmosphere. The measured data will be sent to the lighting device and processed together with sleep environment data in order to improve the sleep quality. Additionally, the final system will be tested for real end-users with clinical experiments by sleep research center of a university hospital."@en ;
    ns0:hasPubTitle "Novel design of smart sleep-lighting system for improving the sleep environment of children"@en .

ns1:thc-v27-iS1-THC199004 ns0:hasKeywords "Youth stroke"@en,
        "obstructive sleep apnea"@en,
        "patent foramen ovale"@en,
        "sleep monitoring"@en,
        "transcranial doppler"@en,
        "wake-up stroke"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Patent foramen ovale (PFO) and obstructive sleep apnea (OSA) are independent risk factors for young conscious stroke which may also be concomitant symptoms with it. But there is no sufficient attention on these phenomena.   OBJECTIVE: To investigate the relationship between PFO, OSA and young stroke, and to look for proper treatment.   METHODS: Three patients with young conscious stroke were reported, each of them was combined with PFO and OSA. All patients were diagnosed as wake-up stroke (WUS). Contrast-enhanced transcranial doppler ultrasound (c-TCD) and polysomnography (PSG) test were used for auxiliary diagnosis.   RESULTS:  Right-to-left shunts and moderate to severe sleep apnea were observed. Increased body mass index (BMI), hemoglobin (HGB) and hematocrit (HCT) index were also observed. After continuous positive airway pressure (CPAP) therapy, the number of microbubbles was reduced in one patient.   CONCLUSIONS:  These suggest that coexistence of PFO and OSA may associate with a greater risk of youth stroke. Decrease risk of stroke might occur if treating with CPAP in patients with OSA."@en ;
    ns0:hasPubTitle "The coexistence of a patent foramen ovale and obstructive sleep apnea may increase the risk of wake-up stroke in young adults"@en .

ns1:thc-v27-iS1-THC199015 ns0:hasKeywords "Bevacizumab"@en,
        "angiogenesis"@en,
        "intraocular neovascular diseases"@en,
        "thermo-responsive hydrogel"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Wet age-related macular degeneration (Wet AMD) has been treated clinically by intravitreal injection of bevacizumab, which is a kind of the anti-VEGF antibody drug. Nevertheless, because of the short half-life and frequent injections, the use of this treatment is limited.   OBJECTIVE:  To confirm whether mPEG-PLGA-BOX can be considered as a VEGF drug delivery system to inhibit retinal angiogenesis.   METHODS:  A thermo-responsive hydrogel of methoxy-poly (ethylene glycol)-block-poly (lactic-co-glycolic acid) (mPEG-PLGA-BOX) was synthesized. The thermo-responsive hydrogel mPEG-PLGA-BOX was able to have sol-gel phase transition upon stimulation by the body temperature with improved biocompatibility and biodegradation. The bevacizumab released from mPEG-PLGA-BOX inhibited RF/6A cells according to a JC-1 assay, which indicated that the released bevacizumab was active to be able to suppress the growth of new blood vessels. In an animal study, retinal laser photocoagulation was performed to induce angiogenesis in the eyes of Rex rabbits using an 810-mm laser.   RESULTS:  The retina was penetrated when the laser power was more than 500 mW and the exposure time was more than 500 ms. New blood vessels were created at the 28th day after retinal laser photocoagulation. At this time, intravitreal 0.05-mL injections of mPEG-PLGA-BOX (bevacizumab) solution were administered. The bevacizumab released from mPEG-PLGA-BOX (bevacizumab) solution suppressed the angiogenesis. In an in vivo study, the histomorphology of the rabbit retina also indicated that mPEG-PLGA-BOX after intravitreal injection is not toxic to the rabbit retina.   CONCLUSIONS:  Bevacizumab released from mPEG-PLGA-BOX (bevacizumab) solution suppressed angiogenesis, and mPEG-PLGA-BOX can be considered as a novel thermo-responsive hydrogel with potential as a gelling carrier for extended bevacizumab drug release to treat intraocular neovascular diseases."@en ;
    ns0:hasPubTitle "Thermo-responsive hydrogel as an anti-VEGF drug delivery system to inhibit retinal angiogenesis in Rex rabbits"@en .

ns1:thc-v27-iS1-THC199026 ns0:hasKeywords "Magnetic induction phase shift"@en,
        "cerebral edema"@en,
        "healthy volunteer"@en,
        "intracranial pressure"@en ;
    ns0:hasPubAbstract "BACKGROUND: Cerebral edema is a common secondary disease after stroke. It is very important to realize real-time continuous monitoring of cerebral edema for stroke patients.   OBJECTIVE: A non-contact magnetic induction phase shift (MIPS) detection system is used to monitor the change of global brain electrical conductivity during cerebral edema.   METHODS: In order to verify the feasibility of this system monitoring, we carry out salt solution simulation experiments and healthy people breath holding experiments. As a comparison of later clinical experiments, 13 young healthy volunteers aged 22–35 are selected for this study to carry out a 10 minute/time monitoring experiment.   RESULTS: It is found that the MIPS values measured by the salt solution of edema and the salt solution of bleeding are significantly different. The results show that the MIPS value of healthy young people is in a stable state with an MIPS mean value of 1.106 (± 0.736)∘. Compare it with the monitoring results of a cerebral edema patient. The MIPS of patient fluctuates greatly, and the changes of MIPS and intracranial pressure show consistent trend at the peak of the edema period.   CONCLUSIONS:  We preliminarily verify that the system can be used for cerebral edema monitoring."@en ;
    ns0:hasPubTitle "Experimental study on healthy volunteers based on magnetic induction brain edema monitoring system"@en .

ns1:thc-v27-iS1-THC199033 ns0:hasKeywords "17β-HSDs"@en,
        "Dexamethasone"@en,
        "rat optic nerve"@en ;
    ns0:hasPubAbstract "Dexamethasone (DEX) is associated with many inflammation and metabolic diseases. We analyzed the effects of DEX on the expression of estrogen metabolism enzyme 17β-HSD1 at the optic nerve. Rats were treated with different concentrations of intraperitoneal DEX. Western Blot analysis showed that 17β-HSD protein was expressed in the optic nerve tissue. The enzyme was detected by immunohistochemistry on the terminal foot of Muller cells from the ganglion cell layer of rat retina. ELISA analysis showed that the 17β-HSD1 protein expression of DEX-treated group is 2.4 fold comparing to the control group. The results indicated that DMXS sodium phosphate might modulate the expression of 17β-HSD1 protein in optic tissue. This study sheds light on understanding of the relationship among DEX, 17β-HSD presence and distribution of visual neural systems. At the same time, DEX treatment affects the athletic ability and memory of the animals. Compared with the control group, the experimental group showed slow response to stimulation, inertia, depression, cowardice and lack of appetite. The results of ethology experiments showed that all the parameters decreased by 15–30%."@en ;
    ns0:hasPubTitle "The effects of dexamethasone on 17β-HSD1 levels at the rat optic nerve"@en .

ns1:thc-v27-iS1-THC199034 ns0:hasKeywords "Hybrid knowledge"@en,
        "Monte Carlo Tree Search (MCTS) algorithm"@en,
        "multiple acupoints"@en,
        "sequential decision-making"@en ;
    ns0:hasPubAbstract "Traditional Chinese Medicine (TCM) multiple-acupoints stimulation is widely used to improve dysphagia among post-stroke patients. However, prior research in evidence-based acupuncture mostly focused on the treatment effects of single acupoint’s on dysphagia, while the evidence of optimal sequence of multiple-acupoints stimulation remains limited. In this paper, we developed an evaluation method of hybrid knowledge (deterministic knowledge and the experiential group decision knowledge) sequences based on segmentation mechanism of sub-sequence fragments, and then, we proposed a Monte Carlo Tree Search (MCTS) sequential decision-making method under the hybrid knowledge. Thereafter, we applied this proposed sequential decision-making approach to optimizing sequential decision-making schema of multiple-acupoints stimulation, to treat dysphagia among post-stroke patients. Finally, we verified the validity and the feasibility of this method by comparing it to other sequential decision-making search methods."@en ;
    ns0:hasPubTitle "A TCM acupoints ranking approach towards post-stroke dysphagia based on an improved MCTS decision method"@en .

ns1:ves-v29-i2-3-VES190651 ns0:hasKeywords "Vestibular system"@en,
        "direct current"@en,
        "electrical stimulation"@en,
        "neural implant"@en,
        "vestibular prosthesis"@en,
        "vestibulo-ocular reflex"@en ;
    ns0:hasPubAbstract "BACKGROUND: Vestibular prostheses emulate normal vestibular function by electrically stimulating the semicircular canals using pulse frequency modulation (PFM). Spontaneous activity at the vestibular nerve may limit the dynamic range elicited by PFM. One proposed solution is the co-application of ionic direct current (iDC) to inhibit this spontaneous activity.   OBJECTIVE: We aimed to test the hypothesis that a tonic iDC baseline delivered in conjunction with PFM to the vestibular semicircular canals could improve the dynamic range of evoked eye responses.   METHODS: Gentamicin-treated chinchillas were implanted with microcatheter electrodes in the vestibular semicircular canals through which pulsatile and iDC current was delivered. PFM was used to modulate vestibulo-ocular reflex (VOR) once it was adapted to a preset iDC and pulse-frequency baseline. Responses to stimulation were assessed by recording the evoked VOR eye direction and velocity.   RESULTS: PFM produced VOR responses aligned to the stimulated canal. Introduction of an iDC baseline lead to a small but statistically significant increase in eye response velocity, without influencing the direction of eye rotation.   CONCLUSIONS: Tonic iDC baselines increase the dynamic range of encoding head velocity evoked by pulsatile stimulation, potentially via the inhibition of spontaneous activity in the vestibular nerve."@en ;
    ns0:hasPubTitle "Combined ionic direct current and pulse frequency modulation improves the dynamic range of vestibular canal stimulation"@en .

ns1:ves-v29-i4-VES190666 ns0:hasKeywords "Benign paroxysmal positional vertigo"@en,
        "Dix-Hallpike test"@en,
        "modified test"@en,
        "vertigo"@en ;
    ns0:hasPubAbstract "BACKGROUND: Dix-Hallpike (DH) test is sometimes done in a modified or reduced manner in a clinical setting. However, there has been no study that evaluated the reliability of this modified test.   OBJECTIVES: The purposes of this study were to determine whether the efficacy of a modified DH test, named the ‘pillow under shoulders’ test, was equivalent to the standard DH test and to assess the difference in patient discomfort between the two methods.   METHODS: Randomized controlled study at three academic referral hospitals, conducted in compliance with the CONSORT statement. Patients suspected for BPPV based on symptoms were randomly assigned to Group A or Group B. Patients in Group A received a standard DH test initially, followed by a modified DH test with a pillow under shoulders. Patients in Group B also received the two tests, but in the reverse order. The diagnostic results of both tests and patients’ subjective scoring for uneasiness (discomfort, pain, anxiety) were statistically analyzed.   RESULTS: McNemar’s test and Kappa statistics showed a statistically equivalent diagnostic value between standard and modified DH tests (Cohen’s kappa = 0.823 and McNemar P = 0.18). The modified DH test had high sensitivity (95.5%) and fairly good specificity (87.9%). There was no statistical significance in the patients’ subjective scoring for uneasiness between the two methods, although most patients reported less inconvenience after the modified DH test compared to the standard DH test.   CONCLUSIONS: The modified version of the standard DH test, the ‘pillow under shoulders’ method, may be a reliable, comfortable option to diagnose vertical canal BPPV. We suggest that this method can be used when head hanging is not feasible or sufficient for the standard DH test."@en ;
    ns0:hasPubTitle "The efficacy of a modified Dix-Hallpike test with a pillow under shoulders"@en .

ns1:ves-v29-i4-VES190668 ns0:hasKeywords "BPPV"@en,
        "ENT practices"@en,
        "Germany"@en,
        "Meniere’s disease"@en,
        "Vestibular disorders"@en,
        "benign paroxysmal positioning vertigo"@en,
        "demographic data"@en,
        "seasonal variation"@en,
        "vestibular neuritis"@en,
        "vestibular neuronitis"@en ;
    ns0:hasPubAbstract "AIM: The aim of this study was to analyze the demographic data pertaining to and seasonal variation in specific vestibular disorders in ear, nose, and throat (ENT) practices in Germany based on data from a representative nationwide practice database.   METHOD: The study sample included patients from 116 ENT practices in Germany who received an initial diagnosis (ICD-10 code) of Meniere’s disease (MD, H81.0), benign paroxysmal positioning vertigo (BPPV, H81.1), or vestibular neuronitis (VN, H81.2) between January 2014 and December 2016. Collected parameters included age, sex, and month of diagnosis. Seasonal variation was analyzed for younger vs. older patients (≤50 vs. >50 years of age). Two univariate Poisson regression models were fitted to estimate the association between the month of diagnosis and the number of diagnosed patients per practice.   RESULTS: A total of 20,720 patients were available for analysis. The average case numbers for MD, BPPV, and VN were 0.8 patients, 2.7 patients, and 1.5 patients per practice per month, respectively. The mean ages of female vs. male patients were 55 and 56 years (MD), 59 and 60 years (BPPV), and 58 and 57 years (VN), respectively. The proportions of female patients with these diagnoses were 62%, 70%, and 61%, respectively. All diagnoses were evenly distributed throughout the years in all age groups. No seasonal variation was observed.   CONCLUSIONS: The demographic data of MD and BPPV patients are comparable to those found by previous large-scale epidemiologic studies. However, no seasonal variation was demonstrated for any vestibular disorder in this large sample."@en ;
    ns0:hasPubTitle "Demographic data and seasonal variation in peripheral vestibular disorders in ENT practices in Germany"@en .

ns1:wdl-v12-i1-wdl12104 ns0:hasKeywords "Collaboration culture"@en,
        "Google Drive"@en,
        "Library Services"@en,
        "Web-based collaborative environment"@en ;
    ns0:hasPubAbstract "The technological revolution in information and communication has created new avenues for libraries to deliver library services and information resources to end users. This study elucidates how library and information science professionals (LISP) use information and communication technology (ICT) tools in communicating, storing, and managing library data and convert the information for enhancing the quality of library services and developing a web-based collaborative system culture in libraries. The study provides a practical approach to using Google Drive and has created a web-based collaborative working culture for libraries. Revolutionary technological tools and applications are helping to create/develop easy-to-use platforms that allow professionals and end users to collaborate in both synchronized and non-synchronized modes."@en ;
    ns0:hasPubTitle "Google Drive: A Boon for Developing a Web-based Collaborating Working Culture in Libraries"@en .

ns1:wor-v63-i2-WOR192918 ns0:hasKeywords "Automated neuropsychological assessment metrics"@en,
        "balance"@en,
        "brain acoustic monitor"@en,
        "voice analysis"@en ;
    ns0:hasPubAbstract "BACKGROUND: A standard, reliable, objective measure is needed for identifying individuals with mild to moderate traumatic brain injury (TBI).   OBJECTIVE: The purpose of this study was to examine balance using an AMTI OR6-7 force platform (FP), neurocognition and mood using the Automated Neuropsychological Assessment Metric4 (ANAM4), blood flow comparisons using a Brain Acoustic Monitor (BAM), and voice using Voice Analysis software (VA) for screening service members for a mild to moderate TBI.   METHODS: Active duty and retired service member volunteers (n = 88, 35 with a diagnosis of mild to moderate TBI and 53 who never had a TBI) completed an informed consent document, and evaluations using the four technologies.   RESULTS: Development of a clinical prediction rule yielded two FP variables and one ANAM4 Mood Scale variable (vigor) as helpful in predicting the presence of a TBI. Assuming a 15% pre-test probability, these predictors yield a post-test probability of 75.7% for a positive result with any two or more measures being positive, and a post-test probability of 2.3% for a negative result with zero measures being positive.   CONCLUSIONS: This study demonstrated the usefulness of a force platform and a self-reported mood scale for predicting presence of mild to moderate TBI."@en ;
    ns0:hasPubTitle "The investigation of four technologies to assist in detecting mild to moderate traumatic brain injury of U.S. Military service members"@en .

ns1:wor-v63-i2-WOR192920 ns0:hasKeywords "Occupational therapy"@en,
        "complementary and integrative health"@en,
        "holistic"@en,
        "mind-body"@en,
        "occupational performance"@en ;
    ns0:hasPubAbstract "Patients in the medical intensive care unit (MICU) face life-threatening conditions leading to physical and psychological stress, and decreased occupational engagement. Mind-body interventions include techniques based on connecting the mind, body, brain, and behavior to positively influence health. The purpose of this study was to explore the use of mind-body interventions as a tool for use by occupational therapists (OT) to improve health and occupational performance. This was an exploratory case study completed with the patient, “Ann” in a MICU. Ann was a 57-year-old female who was admitted to the MICU for abdominal pain and later diagnosed with septic shock. Two mind-body sessions were completed with Ann and her responses were assessed via multiple variables, including: respiratory rate; blood pressure; heart rate; oxygen saturation; and anxiety. Ann stayed within normal ranges for all variables. This study demonstrates it was feasible to elicit mind-body interventions in this setting, with this patient."@en ;
    ns0:hasPubTitle "Mind-body interventions utilized by an occupational therapist in a medical intensive care unit: An exploratory case study"@en .

ns1:wor-v63-i2-WOR192923 ns0:hasKeywords "Borg CR-10 scale"@en,
        "Lifting and lowering"@en,
        "obesity"@en,
        "psychophysical approach"@en ;
    ns0:hasPubAbstract "BACKGROUND: Obesity prevalence in the workforce is clearly increasing. Simultaneously, manual lifting/lowering loads, referred to as Vertical Handling Tasks (VHT) in this paper, are common in industries and services. Performing VHT exposes workers to physical overload, which can be measured using a psychophysical approach. Various risk factors can increase this overload, including individual factors such as workers’ Body Mass Index (BMI).   OBJECTIVE: To study the possible effects of workers’ BMI and some task conditions on physical overload during VHT.   METHODS: Psychophysical data were collected from 51 participants having different body constitutions (including non-obese, overweight and obese). The participants performed 6 VHT (3 different loads ×2 workstation configurations), during which they lifted and lowered a test-box between their knees and shoulders. For each task, they reported their perceived exertion using the Borg Category Ratio-10 (CR-10) scale.   RESULTS: The results showed that the CR-10 scale is sensitive to the variation of the task conditions tested. However, the psychophysical data pointed to a tendency to decrease the perception of physical overload as workers’ BMI increases.   CONCLUSIONS: This may compromise the validity of the application of psychophysical data as an ergonomic approach for Work-Related Musculoskeletal Disorders (WRMSD) prevention in obese workers."@en ;
    ns0:hasPubTitle "Effects of workers’ Body Mass Index and task conditions on exertion psychophysics during Vertical Handling Tasks"@en .

ns1:wor-v63-i2-WOR192925 ns0:hasKeywords "Alertness"@en,
        "armed forces"@en,
        "insomnia"@en,
        "unease"@en ;
    ns0:hasPubAbstract "BACKGROUND: Military occupations require heightened vigilance with resultant sleep disturbances, increased anxiety and reduced vigilance.   OBJECTIVE: To compare yoga with physical training to reduce insomnia, anxiety and increase vigilance in security personnel.   METHODS: One hundred and twelve Border Security Force personnel (BSF group, males; mean age±SD = 30.4±7.4 years) were compared with 112 personnel of a private security firm (SIS group). The BSF group received yoga for nine days and the SIS group received physical training for the same period. Assessments were at baseline and after 9 days, with the digit vigilance test (DVT), Spielberger’s STAI-S, and a sleep rating questionnaire.   RESULTS: (1) Between groups: (i) at baseline the BSF group had higher vigilance and more daytime naps compared to the SIS group and (ii) after nine days the SIS group had higher state anxiety compared to the BSF group (ANOVA, Bonferroni adjusted post-hoc comparisons; SPSS Version 24.0) (2) In post-pre intervention comparisons (i) the BSF group increased vigilance and decreased state anxiety after yoga, with improved sleep, while (ii) the SIS group showed increased vigilance after physical training.   CONCLUSION: Yoga may improve sleep, reduce anxiety while increasing vigilance in occupations requiring vigilance."@en ;
    ns0:hasPubTitle "Effect of yoga on vigilance, self rated sleep and state anxiety in Border Security Force personnel in India"@en .

ns1:wor-v63-i3-WOR192937 ns0:hasKeywords "Computer"@en,
        "design"@en,
        "lighting"@en,
        "smartphone"@en,
        "visual displays"@en ;
    ns0:hasPubAbstract "Mobile technology has revolutionised how we work. It is now relatively easy to work anywhere and anytime, but this has placed the onus is on mobile (or flexible) workers to set up their own work environment for comfort and ease of use. Vision is an important driver of posture, and hence visual ergonomics principles are integral for setting up digital devices. If mobile workers do not have visual ergonomics knowledge, or are unable to apply visual ergonomics knowledge to appropriately set up their work environment, then they are at risk of developing visual-related occupational health issues due to exposure to adverse physical work environments. To address this potential health care issue, we propose the introduction of Visual Ergonomics Health Literacy. This would provide mobile workers (including school children) with the knowledge and skills to set up their work environment for comfort and ease of use, wherever they work. It is important to address this issue now before we have a widespread epidemic of discomfort and injury from not applying sound visual ergonomics principles to work environments."@en ;
    ns0:hasPubTitle "The pitfalls of the traditional office ergonomics model in the current mobile work environment: Is visual ergonomics health literacy the remedy?"@en .

ns1:wor-v63-i3-WOR192942 ns0:hasKeywords "Notebook computer"@en,
        "discomfort"@en,
        "electromyography"@en,
        "non-desk location"@en,
        "position"@en ;
    ns0:hasPubAbstract "BACKGROUND: Laptop computers are used in various places and situations. The number of laptop users experiencing musculoskeletal disorders (MSDs) has increased drastically due to, in part, inappropriate workstations.   OBJECTIVE: To investigate the neck and shoulder postures, and muscle activity relative to perceived pain when using the laptop at a low-height table, sofa, and bed.   METHODS: Twenty male participants aged 18–25 years were randomly assigned to perform laptop computer operation at 3 workstations for 10 minutes during which neck and shoulder angles, muscle activity, and pain were recorded by using an Electrogoniometer, Electromyography (EMG), and visual analog scale (VAS), respectively.   RESULTS: Neck flexions when working at the sofa (18.6°±12.2°) and bed (17.2°±10.5°) were significantly (p < 0.05) greater than that at the low-height table (7.8°±6.5°). However, shoulder flexion when working at the low-height table (28.2°±13.0°) was significantly (p < 0.05) greater than that at the sofa (13.8°±8.6°) and bed (10.91°±7.8°). Working at the low-height table caused the shoulder flexor muscle activity to be significantly (p < 0.05) higher than working at the sofa and bed. Neck pain was reported during laptop computer use at the sofa and bed, and upper back pain when working at the low-height table.   CONCLUSIONS: High neck flexion and pain were found while working at sofa and bed, whereas high muscle activity at shoulder and upper back pain were found while working at the low-height table."@en ;
    ns0:hasPubTitle "Analysis of neck and shoulder postures, and muscle activities relative to perceived pain during laptop computer use at a low-height table, sofa and bed"@en .

ns1:wor-v63-i3-WOR192950 ns0:hasKeywords "Neurodiversity"@en,
        "anxiety disorders"@en,
        "high functioning anxiety"@en,
        "thematic analysis"@en ;
    ns0:hasPubAbstract "BACKGROUND: Progressive workplaces should be aware of emerging neurodiversity related issues. People are sharing their narratives of high functioning anxiety in a variety of forums. Despite news text reporting upon this phenomenon, the concept has managed to escape a research spotlight.   OBJECTIVE: To critically investigate the evidence base of news article reporting of anxiety-related work performance strengths, challenges and support measures.   METHODS: Thematic analysis was applied to news texts derived from CrossSearch database and internet enquiries and journal articles obtained from Scopus, Medline and Science Direct databases.   RESULTS: The analysis of eight news texts and 36 journal articles produced evidence-based themes including those of work performance strengths (quality, quantity, creativity) challenges (overreaching, perfectionism, overthinking, communication) and support measures (medical, cognitive, physical, flexibility).   CONCLUSION: This investigative review reveals that anxiety-related work performance strengths, challenges and support measures as identified within news text reporting of the high functioning anxiety concept have at least some basis in the literature. It might therefore be the case that organizations who invest in supporting employees who identify with high functioning dimensions of their anxiety disorders are the ones who are ultimately rewarded with work performance advantages."@en ;
    ns0:hasPubTitle "Neuro magnifico! An exploratory study critically reviewing news text reporting of anxiety-related work performance strengths, challenges and support measures"@en .

ns1:wor-v63-i4-WOR192953 ns0:hasKeywords "Physical employment standard"@en,
        "accommodation"@en,
        "bona fide occupational requirement"@en,
        "fitness for duty"@en ;
    ns0:hasPubAbstract "BACKGROUND: The Ottawa Paramedic Physical Ability Test (OPPAT™) is a physical employment standard for the paramedic sector. If a candidate is unsuccessful in meeting the OPPAT™ performance standard they should be provided with an appropriate accommodation, such as a strength and conditioning program, to improve performance.   OBJECTIVE: Develop, implement and evaluate the effectiveness of a 4-week strength and conditioning program on improving OPPAT™ performance and associated fitness measures in paramedic candidates.   METHODS: A 4-week strength and conditioning program was developed to focus on strength and power improvements. Based on initial OPPAT™ performance, participants were divided into high and low performing groups; only the low performing group received the training intervention. OPPAT™ completion times and relevant fitness measures were compared pre- to post- intervention and between groups.   RESULTS: Over the 4-weeks, peak lower body power and grip strength did not significantly improve in the intervention group, however OPPAT™ performance improved by 10%. The control group had significantly lower OPPAT™ completion times both pre- and post-intervention (19% and 11% lower respectively), as well as greater grip strength and peak lower body power.   CONCLUSIONS: Implementation of a targeted strength and conditioning program successfully improved OPPAT™ performance in low performing candidates."@en ;
    ns0:hasPubTitle "Evaluating the effect of a strength and conditioning program to improve paramedic candidates’ physical readiness for duty"@en .

ns1:wor-v63-i4-WOR192955 ns0:hasKeywords "Artificial intelligence"@en,
        "biomechanical exposure"@en,
        "demand-capacity-competency"@en,
        "ergonomics"@en,
        "machine learning"@en ;
    ns0:hasPubAbstract "BACKGROUND: Physical employment standards (PES) ensure that candidates can demonstrate the physical capacity required to perform duties of work. However, movement competency, or an individual’s movement strategy, can relate to injury risk and safety, and therefore should be considered in PES.   OBJECTIVE: Demonstrate the utility of using artificial intelligence (AI) to detect risk-potential of different movement strategies within PES.   METHODS: Biomechanical analysis was used to calculate peak flexion angles and peak extensor moment about the lumbar spine during participants’ performance of a backboard lifting task. Lifts performed with relatively lower and higher exposure to postural and moment loading on the spine were characterized as “low” or “high” exposure, respectively. An AI model including principal component and linear discriminant analyses was then trained to detect and classify backboard lifts as “low” or “high”.   RESULTS: The AI model accurately classified over 85% of lifts as “low” or “high” exposure using only motion data as an input.   CONCLUSIONS: This proof-of-principle demonstrates that movement competency can be assessed in PES using AI. Similar classification approaches could be used to improve the utility of PES as a musculoskeletal disorders (MSD) prevention tool by proactively identifying candidates at higher risk of MSD based on movement competency."@en ;
    ns0:hasPubTitle "Considering movement competency within physical employment standards"@en .

ns1:wor-v63-i4-WOR192960 ns0:hasKeywords "Emergency services"@en,
        "paramedics"@en,
        "physical employment standards"@en ;
    ns0:hasPubAbstract "BACKGROUND: The National Ambulance Resilience Unit (NARU) works on behalf of each National Health Service (NHS) Ambulance Trust in England to strengthen national resilience and improve patient outcome in challenging pre-hospital scenarios.   OBJECTIVE: To conduct a Job Task Analysis and describe the physical demands of NARU roles.   METHODS: A focus group was conducted to describe the physically demanding tasks performed by NARU personnel. Subsequently, the physical demands of the identified tasks were measured in 34 NARU personnel (29 male and 5 female).   RESULTS: Eleven criterion tasks were identified; Swift Water Rescue (SWR), Re-board Inflatable Boat (RBIB), Set up Decontamination Tent (SDT), Clinical Decontamination (CD), Movement in Gas Tight Suits (MGTS), Marauding Terrorist Fire Arms (MTFA), Over Ground Rescue (OGR), Unload Incidence Response Unit Vehicle (UIRUV), Above Ground Rescue (AGR), Over Rubble Rescue (ORR) and Subterranean Rescue (SR). The greatest cardiovascular strain was measured during SWR, MGTS, and MTFA. The most thermally challenging tasks were the MTFA, CD, SR and OGR. The greatest muscular strength requirements were during MTFA and OGR.   CONCLUSIONS: All five components of fitness (aerobic endurance, anaerobic endurance, muscular strength, muscular endurance and mobility) were required for successful completion of the physically demanding tasks performed by NARU personnel."@en ;
    ns0:hasPubTitle "A job task analysis to describe the physical demands of specialist paramedic roles in the National Ambulance Resilience Unit (NARU)"@en .

ns1:wor-v63-i4-WOR192961 ns0:hasKeywords "Subject matter experts"@en,
        "ladder climbing"@en,
        "physically demanding tasks"@en,
        "wind technicians"@en ;
    ns0:hasPubAbstract "BACKGROUND: To establish whether an organization has a valid Physical Employment Standard (PES), it is important to determine those aspects of the job that are critical to operational success.   OBJECTIVE: To determine the tasks of the Offshore Wind Industry (OWI) and whether the ability to undertake these tasks is adequately assessed.   METHODS: The task analysis was completed through: observations; the research team undertaking tasks; reviewing operational manuals; and focus groups. In addition, a review of existing PES for the OWI was completed to determine whether standards matched with the results of the task analysis.   RESULTS: Five critical tasks were identified: transfer from the vessel to the Transition Piece; ascent of the internal ladder; manoeuvre through hatches; torque and tensioning; and hauling a casualty up the tower. With the exception of aerobic capacity, the physical components required by Technicians are not assessed by the current medical standards, nor are these assessments standardized across companies.   CONCLUSIONS: The Job Task Analysis undertaken can be used to inform decisions regarding the physical fitness requirements (selection), assessments and training of Technicians, with a view to ensuring that they are physically capable of undertaking the critical tasks without undue risk of injury to themselves or others."@en ;
    ns0:hasPubTitle "A Job Task Analysis for Technicians in the Offshore Wind Industry"@en .

ns1:wor-v63-i4-WOR192962 ns0:hasKeywords "Aging worker"@en,
        "healthy worker effect"@en,
        "older worker"@en ;
    ns0:hasPubAbstract "BACKGROUND: If current population and health trends continue, workplace demographics will look significantly different by the turn of the century. Organizations will no longer have a steady pipeline of younger workers and will likely need to rely on older workers to remain competitive in the global marketplace. The future multi-generational workforce will bring with it the challenge of maximizing contributions from each generation whilst at the same time addressing the health, safety and wellbeing needs of all workers.   OBJECTIVE: This review provides an insight into aging and older workers, and presents recommendations to promote worker longevity.   METHODS: This narrative review draws on evidence from 108 published sources.   RESULTS: The relationship between age and work is not simple; factors including the physical nature of the job and worker’s health and fitness interact with age to either increase or decrease the potential effect of age. Evidence suggests that the issues arising from an aging workforce can be managed through polices that focus on active aging through: attitude management; flexible working and the provision of occupational health.   CONCLUSION: The integration of such interventions would require company and organizational commitment from the top down with educational programs at all levels to ensure understanding and participation."@en ;
    ns0:hasPubTitle "Considerations for physical employment standards in the aging workforce"@en .

ns1:wor-v64-i1-WOR192966 ns0:hasKeywords "Load factors"@en,
        "macroergonomics"@en,
        "participatory development"@en,
        "public sector"@en,
        "work system"@en ;
    ns0:hasPubAbstract "BACKGROUND: Service organizations and their employees encounter challenges today due to an increase in the average age of employees, a decrease in recruitment, and changes in work tasks, sites, and communities. These factors give rise to physical and psychosocial burdens that can lower the work ability and productivity of the employees.   OBJECTIVE: The goal of this study is to find practical solutions for challenges related to the work environment and practices at a public in-house enterprise providing meal and cleaning services. Also, the design of a model for the management of these load factors at municipal workplaces, where stakeholders from different subdivisions work together, is intended.   METHODS: The materials comprised of documents provided by the case organization, interviews, and work observations. Root cause analysis and participatory development sessions were carried out to find causes for the observed challenges and to discover practical solutions.   RESULTS: A number of microergonomic solutions were found. Also, broader subjects for development, common to several target workplaces, were discovered.   CONCLUSIONS: The concept of a shared workplace, proved useful in exploring ways to manage work ability and productivity. A generalizable macroergonomics model for the management of load factors at shared workplaces in the public sector was proposed."@en ;
    ns0:hasPubTitle "Schools and kindergartens as shared workplaces: An analysis of the work ability management challenges of the meal and cleaning service employees"@en .

ns1:wor-v64-i1-WOR192971 ns0:hasKeywords "EMG"@en,
        "discomfort"@en,
        "information technology"@en,
        "kids"@en,
        "mobile device"@en ;
    ns0:hasPubAbstract "BACKGROUND: Children regularly use tablets in a variety of postures. Previous studies have shown that prolonged use of such an IT device increases the risk of musculoskeletal pain.   OBJECTIVE: To investigate pain and muscle activity during tablet use by children in three different workstation positions–on the table with a case set, on a table, and on the lap.   METHODS: Twenty five healthy and right-handed participants aged 10–12 years were recruited and assigned to play computer games for 15 minutes in each workstation. Pain(VAS) was measured at the neck, shoulder, upper back, and forearm regions immediately after tablet use. Electromyography (EMG) was measured at the cervical erector spinae (CES), upper trapezius (UT), middle trapezius (MT), and wrist extensors (WE) muscles during the final two minutes.   RESULTS: Results showed that using a tablet on the table with a case set caused the least pain in the neck region (p < 0.05), compared with the use on the table and on the lap(which had pain scales of 0.37±0.86, 1.74±1.77, 1.72±1.90, respectively; mean±SD). EMG of cervical erector spinae during tablet use on the table with a case set was significantly lower (p < 0.05) than those on the table and on the lap (muscle activity of 22.38±9.54,35.37±16.82, 35.29±13.30 respectively).   CONCLUSIONS: Tablet use on the table with a case set demonstrated a significantly lower severity of pain at the neck region than tablet use on the table and on the lap. To prevent musculoskeletal disorders, tablet use on the table with a case set is recommended as the optimal workstation for children."@en ;
    ns0:hasPubTitle "Pain and muscle activity of neck, shoulder, upper back, and forearm during touch screen tablet use by children"@en .

ns1:wor-v64-i2-WOR192986 ns0:hasKeywords "Musculoskeletal diseases"@en,
        "ergonomics"@en,
        "farmers"@en,
        "participatory"@en,
        "postural"@en,
        "risk factors"@en ;
    ns0:hasPubAbstract "BACKGROUND: Workers engaged in dairy farming are exposed to awkward and poor postures that may result in work-related musculoskeletal disorders (WMSDs).   OBJECTIVE: This study carried out ergonomic interventions in order to eliminate and reduce awkward postures in dairy farming.   METHODS: This quasi-experimental study applied rapid entire body assessments (REBA) to evaluate the risks associated with each posture while performing the assigned tasks on a dairy farm in Iran to identify high and very high-risk tasks. A participatory ergonomics model was used that incorporated suggestions by dairy workers to design the used interventions.   RESULTS: In the first intervention, by using an automatic transmission system for pouring milk, one high and one very high-risk task— pouring milk into a bucket and pouring milk from a bucket into a tank, respectively— were eliminated. In the second intervention, two high-risk tasks— filling corn containers and pouring corn into the milling machine— were eliminated by using a material conveying vacuum pump to transfer corn from the ground to the opening of the milling machine. In the third intervention, a simple and cheap holding device for the bag was designed to reduce the posture risk score from very high to medium. The fourth intervention involved the use of a shovel with a handle appropriate to the anthropometric characteristics of the workers that reduced the posture risk from very high to medium.   CONCLUSIONS: The results indicated that applying participatory ergonomic principles along with low cost and simple designs with high performance resulted in significant reductions in postural risks pertaining to of musculoskeletal disorders on Iran dairy farms."@en ;
    ns0:hasPubTitle "Low cost ergonomic interventions to reduce risk factors for work related musculoskeletal disorders during dairy farming"@en .

ns1:wor-v64-i2-WOR192987 ns0:hasKeywords "Primary school"@en,
        "disengagement"@en,
        "exhaustion"@en,
        "well-being"@en,
        "work motivation"@en ;
    ns0:hasPubAbstract "BACKGROUND: One of the resources that may prevent burnout and foster the work engagement of teachers is Principal support. In this study we aimed to further explore the links between Principal support and work engagement and burnout, by testing the role of the teachers’ emotions and the educational levels of primary schools.   OBJECTIVES: Testing 1) the mediating role of teachers’ emotions in explaining the relationship between perceived Principal support and work engagement and burnout, 2) differences in tested constructs, and the structural equivalence of the proposed relationship among constructs, between teachers from two educational levels of primary schools.   METHODS: The study included subsamples of 868 class teachers (lower grades) and 1057 subject teachers (upper grades) employed at 104 primary schools in Croatia. Teachers filled out self-report scales measuring burnout, work engagement, perceived Principal support and the positive and negative emotions experienced in relation to students.   RESULTS: Emotions partially mediate the relationship between perceived Principal support and work engagement and burnout among teachers. Although class teachers experience higher levels of positive emotions and work engagement compared to subject teachers, the results confirmed the structural equivalence of the hypothesized model across two education levels of primary school.   CONSLUSION: The Principal support predicts work engagement and burnout in teachers both directly and indirectly via emotions."@en ;
    ns0:hasPubTitle "The relations between Principal support and work engagement and burnout: Testing the role of teachers’ emotions and educational level"@en .

ns1:wor-v64-i2-WOR192988 ns0:hasKeywords "Indicators"@en,
        "OSH conditions"@en,
        "OSH performance"@en,
        "SMEs"@en,
        "occupational safety & health"@en,
        "risk level"@en ;
    ns0:hasPubAbstract "BACKGROUND: Small and medium-sized enterprises (SMEs) face greatest difficulty in managing occupational risks compared to large enterprises. Limited resources, little knowledge about risk management process and deficiencies in organizational processes are often pointed in the literature as important obstacles to occupational safety and health (OSH) performance in SMEs. However, external factors can also be of paramount importance, such as the economic crisis. Because under specific scenarios OSH conditions may deteriorate in SMEs, is important to establish effective indicators.   OBJECTIVE: This study aims to identify OSH performance indicators within the context of SMEs.   METHODS: To identify the indicators, a literature review was carried out on different studies published in scientific journals in the OSH field between 2008 and October 2018 using the Scopus, ScienceDirect, Web of Science and PubMed databases.   RESULTS: As a result, 14 management and organization OSH indicators applied to SMEs were identified, along with 5 at individual OSH indicators.   CONCLUSION: The indicators were discussed in relation to its applicability to assess OSH performance, as well as their reliability. Future research should be done to assess the identified indicators in SMEs."@en ;
    ns0:hasPubTitle "Occupational safety and health performance indicators in SMEs: A literature review"@en .

ns1:wor-v64-i2-WOR192990 ns0:hasKeywords "Occupational therapy"@en,
        "autonomous cars"@en,
        "brain machine interface"@en,
        "governance"@en,
        "human enhancement"@en,
        "innovation"@en,
        "robotics"@en,
        "science"@en,
        "students"@en,
        "technology"@en ;
    ns0:hasPubAbstract "BACKGROUND: Science, technology and innovation (STI) governance concerns itself with the societal impact of STI. Occupation, whether used with the meaning of paid, unpaid work or any activity that is considered meaningful to the individual on an everyday basis, is one area of societal impact of STI. Fields such as occupational therapy, occupational science and occupational health and safety concern themselves with the relationship between occupation and the health and well-being of human beings albeit all with different foci.   OBJECTIVE: To ascertain the knowledge of students from two Occupational Therapy programs on STI governance, specific STI products and their views on the impact of STI governance and STI products on occupational therapy and its clients.   METHODS: Online survey employing Yes/No’ questions with comment boxes and open-ended textbox questions. Descriptive quantitative and thematic qualitative data was generated.   RESULTS: Students were unfamiliar with STI governance discourses but felt that they should be aware of them. Students stated that how one governs STI impacts occupational therapy on all levels and that the occupational therapy community has expertise that would enrich STI governance discourses around occupation.   CONCLUSION: Education actions seem to be warranted on the level of students and practitioners by the occupational therapy and STI governance communities."@en ;
    ns0:hasPubTitle "Utility of science, technology and innovation governance for occupational discourses from the perspective of occupational therapy students"@en .

ns1:wor-v64-i2-WOR192997 ns0:hasKeywords "ICF"@en,
        "Self-efficacy"@en,
        "caregiver perception"@en,
        "employer perception"@en,
        "employment"@en,
        "qualitative research"@en,
        "quality of life"@en,
        "vocational rehabilitation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Traumatic brain injury (TBI) has contributed significantly to the burden of health care in many countries. The scarcity of resources in the public sector available for rehabilitation has caused many families to take responsibility for the care and rehabilitation of their family members who sustain a TBI. The roles of employers and caregivers in facilitating the return to work (RTW) process of individuals who sustained a TBI, is now commonly acknowledged.   OBJECTIVE: The aim of this study was to explore the perceptions and experiences of employers and caregivers of individuals with mild to moderate traumatic brain injury who are returning to work after completing a vocational rehabilitation program (VR), using the Model of Occupational Self-Efficacy (MOOSE).   METHODS: A qualitative research design was used to explore the experiences and perceptions of caregivers and employers of ten individuals who sustained a mild to moderate brain injury. Semi-structured interviews were completed and data analyzed according to thematic analysis.   RESULTS: Five themes emerged: Themes one and two describe the employers’ and caregivers’ experiences and perceptions that hinder the RTW process. Theme three relates to the enabling aspects that the employers and caregivers, as well as the TBI individuals concerned, derive from engaging in the VR process. Themes four and five present the coping strategies that aid the employers and caregivers in playing an ongoing role in the RTW process. All ethical principles with regard to confidentiality, anonymity and informed consent were adhered to in the study.   CONCLUSIONS: Occupational therapists (OT) using the MOOSE should regard employers and caregivers as key role players during therapy. Employers should have a better understanding of TBI and allow for sick leave to be granted to individuals with TBI during the rehabilitation process. Caregivers would benefit from establishing a support network for themselves, and by connecting with employers of the individuals with TBI in order to understand the their work environment."@en ;
    ns0:hasPubTitle "The experiences and perceptions of employers and caregivers of individuals with mild-moderate traumatic brain injury in returning to work"@en .

ns1:wor-v64-i2-WOR192998 ns0:hasKeywords "Violence"@en,
        "aggression"@en,
        "bullying"@en,
        "conflicts"@en,
        "emotional exhaustion"@en,
        "escalation"@en,
        "threats"@en ;
    ns0:hasPubAbstract "BACKGROUND: Aggression theories and cross-sectional studies imply an escalatory pattern of aggressive behaviors; however, this has not been investigated in a follow-up study.   OBJECTIVE: To investigate whether bullying or conflicts are antecedents of threats and physical violence, and whether threats mediate the relationship between bullying or conflicts and violence. Lastly, it was explored whether associations could be explained through the effect of emotional exhaustion.   METHODS: Survey data was collected from a follow-up sample of 3,584 employees from four human service sectors, namely psychiatry, special schools, eldercare, and the prison and probation services. The main analysis uses hierarchical logistic regression.   RESULTS: The analyses showed that frequent /intense conflicts, not bullying, at baseline were significantly related to higher exposure rates of threats (OR = 4.98, CI = [3.19–7.76]) and violence (OR = 3.01, CI = [1.96–4.76]) at follow-up. Emotional exhaustion was not confirmed as a substantial mediator. However, the proportion mediated by threats was significant (70%) for the relationship between frequent /intense conflicts and violence.   CONCLUSION: This study finds that aggressive workplace behaviors may indeed escalate, particularly within a similar victim-perpetrator relationship, such as between employees and clients. The study highlights the need for de-escalation techniques that transcend specific encounters, recognizing that aggressive behavior may escalate over time."@en ;
    ns0:hasPubTitle "A longitudinal study of the possible escalation of aggressive behaviors – from bullying and conflicts to workplace violence. Is emotional exhaustion a mediator?"@en .

ns1:wor-v64-i3-WOR193005 ns0:hasKeywords "School furniture"@en,
        "anthropometry"@en,
        "desk height"@en,
        "guideline"@en,
        "primary school children"@en,
        "seat height"@en,
        "size recommendation"@en ;
    ns0:hasPubAbstract "BACKGROUND: The use of school furniture with a height that is anthropometrically mismatched can lead children into taking awkward postures while sitting. In Korea, desks and chairs for primary schools have seven different height levels, and these levels are regulated by the national standard KSG-2010. These levels serve to accommodate children of all heights, but the choice problem remains because of the many alternatives.   OBJECTIVE: This study evaluates the anthropometric feasibility of the currently used guidelines for the selection of height level for Korean primary school furniture. In addition, we examine children’s ability to select anthropometrically recommendable desk and seat heights.   METHODS: In study 1, anthropometric data from 2005 Korean children were acquired and a mismatch analysis was performed under the assumption that children were paired with the height level recommended by the guidelines. In study 2, we conducted a desk and seat height selection experiment that included 36 children.   RESULTS: The results of study 1 revealed that about three quarters of children could be matched by following the guidelines. The results of study 2 showed that a quarter of children selected matchable desk and seat heights by themselves. We developed new guidelines using classification algorithms based on the employed data in study 1, and it was confirmed that the new guidelines could significantly increase the degree of match.   CONCLUSION: This study confirmed that the currently used guidelines need to be revised and that children had difficulty in selecting the appropriate height of school furniture by themselves. The new guidelines suggested in this study are expected to contribute to the correct usage by Korean primary school children."@en ;
    ns0:hasPubTitle "Evaluation of the guidelines and children’s ability to select the anthropometrically recommendable height of school furniture: A case study of Korean primary school children"@en .

ns1:wor-v64-i3-WOR193008 ns0:hasKeywords "Accommodation"@en,
        "employment"@en,
        "mental disorder"@en,
        "psychiatric disability"@en,
        "work"@en ;
    ns0:hasPubAbstract "BACKGROUND: Work accommodations are adjustments made in the work place or to policies surrounding employment to accommodate an individual with a mental disorder to be successful in completing work related tasks.   OBJECTIVE: The purpose of this systematic review is to identify work accommodations that are available and that are provided to individuals with mental disorders. In addition, associated cost-effectiveness and cost-benefits of these accommodations are examined.   METHODS: Studies published between 1990–2016 from four databases were reviewed. From these databases, studies that specified accommodations that were available/provided and/or addressed cost-effectiveness or cost-benefit analysis of work accommodations were included.   RESULTS: Of the 1362 eligible studies, only 15 were included. Work accommodations that were provided to individuals assisted in mitigating limitations in the work place and improved length of job tenure, as well as reduced the severity of certain mental disorders. The costs associated with these accommodations were found to be minimal and had positive economic benefits for employers.   CONCLUSION: Work accommodations help individuals with mental disorders meet employment expectations with minimal cost."@en ;
    ns0:hasPubTitle "A systematic review of work accommodations for people with mental disorders"@en .

ns1:wor-v64-i3-WOR193009 ns0:hasKeywords "Return to work"@en,
        "self-efficacy"@en,
        "therapeutic use of self"@en ;
    ns0:hasPubAbstract "BACKGROUND: Traumatic Brain Injury (TBI) is a serious global public health problem. Globally and annually, at least 10 million individuals live with TBI that is serious enough to result in death or hospitalisation   OBJECTIVE: This study aimed to explore and describe the experiences of women with traumatic brain injury, in their work environments utilising the Model of Occupational Self-efficacy as a vocational rehabilitation approach   METHOD: Ten females with mild to moderate traumatic brain injury participated in the study. Semi-structured interviews were conducted and data were analysed utilising a qualitative approach to elucidate themes. Semi-structured interviews were also conducted with two occupational therapists who served as key informants.   RESULTS: Two themes emerged depicting the participants’ experiences and perceptions of barriers and facilitators which influenced their return to work: (1) Barriers to work participation for women with TBI, 2) Re-establishing a worker identity by means of vocational rehabilitation.   CONCLUSION: Both personal and environmental factors emerged as hindrances to returning to work for women with traumatic brain injury. Vocational rehabilitation proved successful in establishing a worker identity amongst participants; however, particular focus should be placed on the function-dysfunction continuum of the process of work place integration to further develop and enhance sustainable return to work programmes for women with traumatic brain injury."@en ;
    ns0:hasPubTitle "The experiences of women with traumatic brain injury about the barriers and facilitators experienced after vocational rehabilitation in the Western Cape Metropole, South Africa"@en .

ns1:wor-v64-i3-WOR193010 ns0:hasKeywords "Physical activity"@en,
        "canines"@en,
        "workplace"@en ;
    ns0:hasPubAbstract "BACKGROUND: Workplace walking interventions can lead to positive physical and psychological outcomes for employees. For optimal success, however, innovative approaches that appeal to employees are needed.   OBJECTIVE: The purpose of this study was to assess the physical activity levels and experiences of university staff members who walked shelter dogs during their lunch breaks.   METHOD: Participants walked with a dog and a partner for 30 minutes during their lunch break one day a week for four weeks. Accelerometer data was collected during participant walks and interviews conducted post-intervention.   RESULTS: Quantitative results indicated that participants averaged 24.9±7.4 minutes of moderate-to-vigorous physical activity (range 12– 37 min) during the walk. Qualitative findings suggested that the incorporation of shelter dogs into a walking intervention encouraged participants to take part in the study and continue each week.   CONCLUSIONS: Both the quantitative and qualitative data from this pilot study support the notion that including shelter dogs into a university-based walking program encouraged physical activity engagement and adherence."@en ;
    ns0:hasPubTitle "Shelter dogs, university employees, and lunchtime walks: A pilot study"@en .

ns1:wor-v64-i3-WOR193018 ns0:hasKeywords "Life insurance"@en,
        "forensic"@en,
        "lump sum benefit"@en,
        "vocational expert"@en,
        "vocational rehabilitation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Expert employment information helps life insurers to decide total and permanent disability claims. The employability assessment model was developed a decade ago by rehabilitation counselors and has not been critically examined.   OBJECTIVE: This exploratory descriptive study aims to elicit key issues of employability assessment within Australian life insurance.   METHODS: Ten rehabilitation advisors with knowledge of employability assessment in the total and permanent disability sector participated in a single focus group. They each nominated issues of concern about employability assessment. These issues were collated then discussed within the group. Qualitative thematic analysis was used to identify key issues.   RESULTS: The predominant theme was the forensic nature of employment evidence. There were three categories of key issues. First, assessment providers— their training, qualifications, experience, and role. Second, methodology— approaches that provide most realistic information about a claimant’s likelihood of work. Third, policy definitions that illustrate reliance on legal interpretation of employability.   CONCLUSIONS: To withstand legal scrutiny, the credentials of providers, assessment methodology, and quality of forensic reports are key issues which need to be addressed. This foundational study will contribute to broader research on this topic, with implications particularly for rehabilitation, life insurance, and claimants."@en ;
    ns0:hasPubTitle "Issues facing employability assessment in total and permanent disability insurance claims: A rehabilitation perspective"@en .

ns1:wor-v64-i3-WOR193022 ns0:hasKeywords "Cleaning job"@en,
        "NMQ"@en,
        "musculoskeletal symptoms"@en,
        "task analysis"@en,
        "working posture"@en ;
    ns0:hasPubAbstract "BACKGROUND: Cleaning workers experience severe musculoskeletal symptoms.   OBJECTIVE: The objective of this paper was to examine musculoskeletal symptoms in cleaners of different heights to evaluate the effects of height on working postures in the work environment (schools).   METHODS: We used a three-stage method including using the Nordic Musculoskeletal Questionnaire (NMQ) to evaluate musculoskeletal symptoms, a task analysis to confirm typical cleaning tasks, and the OVAKO Working Posture Assessment System (OWAS) for posture analysis. Multinomial logistic regression was performed to evaluate the adjusted effects of individual characteristics on painful body regions, using individuals without any pain as the reference category.   RESULTS: This study found that the prevalence of musculoskeletal symptoms is very high for cleaners, especially in the shoulders, elbows, and lower back. Odds ratios for the accumulation of two or more risk factors were higher among men and were inversely associated with national economic indicators. The relatively high prevalence of musculoskeletal symptoms may stem from the multiple operations involved in cleaning tasks, such as trash collecting, floor mopping, toilet cleaning, and mirror polishing. Workers of different heights had differential work loadings for different tasks.   CONCLUSIONS: This paper proposes recommendations for job adaptations and occupational safety training. Cleaners of different heights execute the typical tasks via different postures, and awkward postures often result in musculoskeletal symptoms. Cleaners should be provided with specific tools and training regarding working postures on the basis of height. These findings can be used as a reference for related operation designs and task improvements to ensure correct tool usage and safer working postures during cleaning."@en ;
    ns0:hasPubTitle "Using the OVAKO working posture analysis system in cleaning occupations"@en .

ns1:xst-v27-i3-XST180413 ns0:hasKeywords "Spectral computed tomography"@en,
        "noise estimation"@en,
        "non-local means"@en,
        "tensor decomposition"@en ;
    ns0:hasPubAbstract "BACKGROUND As one type of the state-of-the-art detectors, photon counting detectors are used in spectral computed tomography (CT) to classify the received photons into several energy channels and generate multichannel projections simultaneously. However, FBP reconstructed images contain severe noise due to the low photon counts in each energy channel.   OBJECTIVE A spectral CT image denoising method based on tensor-decomposition and non-local means (TDNLM) is proposed.   METHODS In a CT image, it is widely accepted that there exists self-similarity over the spatial domain. In addition, because a multichannel CT image is obtained from the same object at different energies, images among different channels are highly correlated. Motivated by these two characteristics of the spectral CT images, tensor decomposition and non-local means are employed to recover fine structures in spectral CT images. Moreover, images in all energy channels are added together to form a high signal-to-noise ratio image, which is applied to encourage the signal preservation of the TDNLM. The combination of TD, NLM and the guidance of a high-quality image enhances the low-dose spectral CT, and a parameter selection strategy is designed to achieve the optimal image quality.   RESULTS The effectiveness of the developed algorithm is validated on both numerical simulations and realistic preclinical applications. The root mean square error (RMSE) and the structural similarity (SSIM) are used to quantitatively assess the image quality. The proposed method successfully restored high-quality images (average RMSE=0.0217 cm-1 and SSIM=0.987) from noisy spectral CT images (average RMSE=0.225 cm-1 and SSIM=0.633). In addition, RMSE of each decomposed material component is also remarkably reduced. Compared to the state-of-the-art iterative spectral CT reconstruction algorithms, the proposed method achieves comparable performance with dramatically reduced computational cost, resulting in a speedup of >50.   CONCLUSIONS The outstanding denoising performance, the high computational efficiency and the adaptive parameter selection strategy make the proposed method practical for spectral CT applications."@en ;
    ns0:hasPubTitle "Tensor decomposition and non-local means based spectral CT image denoising"@en .

ns1:xst-v27-i3-XST180453 ns0:hasKeywords "Breast imaging"@en,
        "Hounsfield units"@en,
        "phase-contrast tomography"@en ;
    ns0:hasPubAbstract "BACKGROUND: Grating-based X-ray phase-contrast imaging (GPCI) has received growing interests in recent years due to its high capability of visualizing soft tissue. Breast imaging is one of the most promising candidates for the first clinical application of this imaging modality.   OBJECTIVE: In this work, quantitative breast tissue characterization based on GPCI computed tomography (CT) is investigated with a laboratory X-ray tube through a comparison between attenuation-based CT images and phase-contrast CT images.   METHODS: The Hounsfield units (HU) scale was introduced to phase-contrast images due to its wide application in clinical medicine. In this work, instead of water, plastic cylinders composed of polyethylene terephthalate (PET) was treated as the calibration material. An alternative test-retest reliability (TRR) was presented to evaluate the repeatability of GPCI. Comparison between attenuation-based CT imaging and GPCI CT imaging was operated with the use of statistical analysis methods like histograms and receiver operating characteristic (ROC) curves.   RESULTS: The determined mean TRR related to cylinders is slightly larger in phase-contrast imaging (0.93) than that in attenuation-based imaging (0.89). With respect to distinguishing breast tissues, the AUC (area under curve) values of ROC curves of phase-contrast images are higher than that of attenuation-based images.   CONCLUSIONS: An ex vivo study of GPCI shows that it is a stable imaging modality for visualizing the breast tissue with good repeatability, and that it could be of potential for the diagnosis of breast cancer as well."@en ;
    ns0:hasPubTitle "Quantitative characterization of ex vivo breast tissue via x-ray phase-contrast tomography"@en .

ns1:xst-v27-i3-XST180457 ns0:hasKeywords "Computed tomography"@en,
        "image resolution"@en,
        "x-ray dose"@en,
        "x-ray fluorescence computed tomography"@en ;
    ns0:hasPubAbstract "OBJECTIVE: To investigate the image quality and x-ray dose associated with a transmission computed tomography (CT) component implemented within the same platform of an experimental benchtop x-ray fluorescence CT (XFCT) system for multimodal preclinical imaging applications.   METHODS: Cone-beam CT scans were performed using an experimental benchtop CT + XFCT system and a cylindrically-shaped 3D-printed polymethyl methacrylate phantom (3 cm in diameter, 7 cm in height) loaded with various concentrations (0.05–1 wt. %) of gold nanoparticles (GNPs). Two commercial CT quality assurance phantoms containing 3D line-pair (LP) targets and contrast targets were also scanned. The x-ray beams of 40 and 62 kVp, both filtered by 0.08 mm Cu and 0.4 mm Al, were used with 17 ms of exposure time per projection at three current settings (2.5, 5, and 10 mA). The ordered-subset simultaneous algebraic reconstruction and total variation–minimization methods were used to reconstruct images. Sparse projection and short scan were considered to reduce the x-ray dose. The contrast-to-noise ratio (CNR) and modulation transfer function (MTF) were calculated.   RESULTS: The lowest detectable concentration of GNPs (CNR > 5) and the highest spatial resolution (per MTF50%) were 0.10 wt. % and 9.5 LP/CM, respectively, based on the images reconstructed from 360 projections of the 40 kVp beam (or x-ray dose of 3.44 cGy). The background noise for the image resulting in the lowest GNP detection limit was 25 Hounsfield units.   CONCLUSION: The transmission CT component within the current experimental benchtop CT + XFCT system produced images deemed acceptable for multimodal (CT + XFCT) imaging purposes, with less than 4 cGy of x-ray dose."@en ;
    ns0:hasPubTitle "Investigation of transmission computed tomography (CT) image quality and x-ray dose achievable from an experimental dual-mode benchtop x-ray fluorescence CT and transmission CT system"@en .

ns1:xst-v27-i3-XST180464 ns0:hasKeywords "CT image"@en,
        "Image-guided surgery"@en,
        "fiducial point localization"@en,
        "marker detection"@en,
        "point-based registration"@en ;
    ns0:hasPubAbstract "In the lung biopsy image-guided surgery systems, the fiducial markers are used for point-based registration of the patient space to the CT image space. Fiducial marker detection and fiducial point localization in CT images have great influence on the accuracy of registration and guidance. This study proposes a fiducial marker detection approach based on the features of marker image slice sequences and a fiducial point localization approach according to marker projection images, without depending on the priori-knowledge of the marker default parameters provided by the manufacturers. The accuracy of our method was validated based on a CT image dataset of 24 patients. The experimental results showed that all 144 markers of 24 patients were correctly detected, and the fiducial points were localized with the average error of 0.35 mm. In addition, the localization accuracy of the proposed method was improved by an average of 12.5% compared with the accuracy of the previous method using the marker default parameters provided by the manufacturers. Thus, the study demonstrated that the proposed detection and localization methods are accurate and robust, which is quite encouraging to meet the requirement of future clinical applications in the image guided lung biopsy and surgery systems."@en ;
    ns0:hasPubTitle "Automated fiducial marker detection and fiducial point localization in CT images for lung biopsy image-guided surgery systems"@en .

ns1:xst-v27-i3-XST180473 ns0:hasKeywords "Pleural effusion"@en,
        "computer aided diagnosis"@en,
        "fractional-order convolution"@en,
        "fractional-order parameter"@en ;
    ns0:hasPubAbstract "Pleural effusion is a pathologic symptom in which there is accumulation of body fluids around the lungs. A chest radiograph is a rapid examination technique and does not require complex setup for making a preliminary diagnosis of lung and heart diseases. In radiographic visualization, the symptom patterns appear as light or dark areas in the lung cavity. Computer-aided diagnosis is an automatic manner that can rapidly highlight the object region by preanalyzing medical images. It can improve the problems of manual inspection and allow diagnosis in remote medical facilities. Based on the ratios of lung anatomy, the automatic screening manner based on pattern recognition can be viewed as pixel value detection in the bilateral lung cavities. In this study, a fractional-order convolution (FOC) process is used to enhance the original image for an accurate extrapolation of the desired object in an image. The specific object image feature can be improved, and an accurate quantification of the pleural effusion region can be obtained using the suitable ranges of fractional-order parameters. Based on the boundaries of homogeneous regions, the pixel ratios of the lung anatomy between normal and abnormal conditions can be computed. The pleural effusion sizes and volumes can be rapidly estimated through the number of pixel changes. The experimental results reveal that the feature maps are similar and stable on image enhancement and segmentation with two fractional-order enhancement masks, as fractional-order v = 0.05 to 0.20 for mask 1# and v = 0.80 to 0.95 for mask 2#, respectively. The results also demonstrate the feasibility of the study on combining two-dimensional image FOC-process and bounding box pixel analysis to estimate the moderate and large effusion sizes from 500–2,000 mL."@en ;
    ns0:hasPubTitle "Application of two-dimensional fractional-order convolution and bounding box pixel analysis for rapid screening of pleural effusion"@en .

ns1:xst-v27-i4-XST180467 ns0:hasKeywords "Marking method"@en,
        "cone beam computed tomography"@en,
        "setup errors"@en,
        "tumors"@en,
        "vacuum cushion"@en ;
    ns0:hasPubAbstract "OBJECTIVE: The skin marking method (SMM) and bow-form-ruler marking method (BFRM) are two commonly used patient marking methods in mainland China. This study aims to evaluate SMM and BFRM by comparing the inter-fraction setup errors from using these two methods together with vacuum cushion immobilization in patients underwent radiotherapy for different treatment sites.   MATERIALS AND METHODS: Eighteen patients diagnosed with pelvic, abdominal and thoracic malignant tumors (with 6 patients per treatment site) were enrolled in this prospective study. All patients were immobilized with vacuum cushion. Each patient was marked by both SMM and BFRM before computed tomography (CT) simulation. Target location was verified by cone beam CT images with displacements assessed prior to each sampled treatment session. The localization errors in three translational and three rotational directions were recorded and analyzed.   RESULTS: Images from 108 fractions in 18 patients produced 324 translational and 324 rotational comparisons for SMM and BFRM. The setup errors of all treatment sites showed no difference in two marking methods in any directions (p > 0.05). In subgroups of treatment site analysis, SMM significantly lessened the lateral and yaw setup errors compared to BFRM in the pelvic sites (0.39±1.85 mm vs –1.28±1.13 mm, p < 0.01 and –0.19±0.59° vs –0.61±0.59°, p < 0.05). However, in the abdominal subgroup, BFRM was superior to SMM for reduced vertical errors (0.17±2.73 mm vs 2.28±3.16 mm, p < 0.05). For the underweight or obese patients (with Body Mass Index, BMI < 18.5 or BMI≥24), SMM resulted in less yaw errors compared to BFRM (–0.05±0.38° vs –0.43±0.48°, p < 0.05). No significant difference between SMM and BFRM in setup errors of normal weighted patients (18.5≤BMI < 24) was observed for all three studied treatment sites.   CONCLUSIONS: This study shows no significant difference in patient setup errors for various treatment sites between SMM and BFRM in general. SMM may be suitable for the pelvic tumor and patients with BMI < 18.5 or BMI≥24, while BFRM is recommended for the abdominal tumor sites."@en ;
    ns0:hasPubTitle "Comparison of geometrical uncertainties in the radiotherapy for various treatment sites with two different immobilization marking methods"@en .

ns1:xst-v27-i4-XST180490 ns0:hasKeywords "Convolutional neural networks"@en,
        "deep learning"@en,
        "lung cancer"@en,
        "nodule classification"@en,
        "transfer learning"@en ;
    ns0:hasPubAbstract "BACKGROUND: Deep learning has made spectacular achievements in analysing natural images, but it faces challenges for medical applications partly due to inadequate images.   OBJECTIVE: Aiming to classify malignant and benign pulmonary nodules using CT images, we explore different strategies to utilize the state-of-the-art deep convolutional neural networks (CNN).   METHODS: Experiments are conducted using the Lung Image Database Consortium image collection (LIDC-IDRI), which is a public database containing 1018 cases. Three strategies are implemented including to 1) modify some state-of-the-art CNN architectures, 2) integrate different CNNs and 3) adopt transfer learning. Totally, 11 deep CNN models are compared using the same dataset.   RESULTS: Study demonstrates that, for the model modification scheme, a concise CifarNet performs better than the other modified CNNs with more complex architectures, achieving an area under ROC curve of AUC = 0.90. Integrated CNN models do not significantly improve the classification performance, but the model complexity is reduced. Transfer learning outperforms the other two schemes and ResNet with fine-tuning leads to the best performance with an AUC = 0.94, as well as the sensitivity of 91% and an overall accuracy of 88%.   CONCLUSIONS: Model modification, model integration, and transfer learning can play important roles to identify and generate optimal deep CNN models in classifying pulmonary nodules based on CT images efficiently. Transfer learning is preferred when applying deep learning to medical imaging applications."@en ;
    ns0:hasPubTitle "Deep CNN models for pulmonary nodule classification: Model modification, model integration, and transfer learning"@en .

ns1:xst-v27-i4-XST190507 ns0:hasKeywords "Benign prostatic hyperplasia (BPH) treatment"@en,
        "laser surgery"@en,
        "vaporization outcomes"@en ;
    ns0:hasPubAbstract "OBJECTIVE: To evaluate safety, efficacy, and long-term outcomes of photoselective vaporization of prostate using 120-W HPS GreenLight KTP laser and compare the results with those obtained with 2-micrometer continuous-wave (2 um CW) laser for treatment of patients with benign prostatic hyperplasia (BPH).   MATERIALS AND METHODS: One group of 216 patients diagnosed with BPH underwent 120-W KTP laser vaporization of the prostate, while another group of 198 BPH patients underwent 2 um CW laser vaporization. The relevant pre-, peri-, and post-operative parameters were compared between the two therapy groups. Functional results in terms of improvement of International Prostate Symptom Score (IPSS), maximum flow rate (Qmax), and post-void residual (PVR) urine were assessed at 3, 6, 12, and 24 months.   RESULTS: BPH was successfully treated with 120-W HPS KTP laser and 2 um CW laser in all patients. There were no significant difference between two patient groups in the baseline characteristics (such as PSA, IPSS, QoL, and Qmax). No major complications occurred intraoperatively (capsule perforation and TUR syndrome) or postoperatively (electric unbalance), and no blood transfusions were required in both groups. Average catheterization time was 1.9±1.3 days for the 120-W PVP and 2.2±1.9 days for the 2 um CW laser treatment. In addition, the hospitalization times were 3.8±1.2days (120-W PVP) and 4.8±1.5 days (2 um CW laser), respectively. The incidence of dysuria and urge incontinence was higher in the 2 um CW laser group (35/198, 24/198) than in the 120 W PVP group (15/216, 10/216). Dramatic improvement was observed in Qmax, IPSS, Qol, and PVR as compared with the respective pre-operative values. The degree of improvement during the follow-up period was comparable in both groups. No significant differences were observed in terms of re-operation rates, bladder neck stricture, and urethral stricture.   CONCLUSIONS: Both 120-W HPS laser and 2 um CW laser vaporization present effective treatment options in patients with BPH, but 120-W PVP provides safer therapy with less post-operative complications within the 2-year follow-up period."@en ;
    ns0:hasPubTitle "Comparison of vaporization using 120-W GreenLight laser versus 2-micrometer continuous laser for treating benign prostatic hyperplasia: A 24-month follow-up study of a single center"@en .

ns1:xst-v27-i5-XST190502 ns0:hasKeywords "Shear wave elastography"@en,
        "diagnostic efficiency"@en,
        "multislice computed tomography"@en,
        "nonalcoholic fatty liver disease"@en,
        "nonalcoholic steatohepatitis"@en ;
    ns0:hasPubAbstract "OBJECTIVE: This study aims to assess the value of ultrasound real-time shear wave elastography (US-SWE) for evaluation of nonalcoholic fatty liver disease (NAFLD) in a rabbit model compared with multislice computed tomography (MSCT).   MATERIAL AND METHODS: Twenty-six rabbits were fed with high-fat, high-cholesterol diet and six rabbits were fed with a standard diet. All rabbits were performed with MSCT and US-SWE at various time points to measure changes in liver parenchyma. The diagnostic efficiency of US-SWE was analyzed using receiver operating characteristics (ROC) curves compared with MSCT based on the liver pathology.   RESULTS: The statistically significant differences in the areas under the ROC curves between using MSCT and US-SWE modalities were detected to discriminate between normal vs. NAFLD or higher severity pathology. Similarly, for normal or NAFLD vs. borderline or NASH livers, statistically significant differences between using US-SWE and MSCT modalities were also detected for nonalcoholic steatohepatitis (NASH) vs. lower severity pathology.   CONCLUSIONS: MSCT, but not US-SWE, had a better ability to differentiate normal or NAFLD livers from higher severity NAFLD livers. However, the diagnostic efficiency of US-SWE was superior to that of MSCT for differentiating NASH from normal or lower severity NAFLD."@en ;
    ns0:hasPubTitle "NAFLD evaluation: Which is more appropriate, multislice computed tomography or ultrasound real-time shear wave elastography?"@en .

ns1:xst-v27-i5-XST190523 ns0:hasKeywords "Cone beam CT"@en,
        "few-view CT"@en,
        "iterative reconstruction"@en,
        "low-dose CT"@en ;
    ns0:hasPubAbstract "BACKGROUND: Iterative reconstruction is well-established in diagnostic multidetector computed tomography (MDCT) for dose reduction and image quality enhancement. Its application to diagnostic cone beam computed tomography (CBCT) is only emerging and warrants a quantitative evaluation.   METHODS: Several phantoms and a canine head specimen were imaged using a commercially available small-field CBCT scanner. Raw projection data were reconstructed using the Feldkamp-Davis-Kress (FDK) method with different filters, including denoising via total variation (TV) minimization (FDK-TV). Iterative reconstruction was carried out using the TV-regularized ordered subsets convex technique (OSC-TV). Signal-to-noise ratio (SNR), noise power spectrum (NPS) and spatial resolution of images were estimated. Dose levels were measured via the weighted computed tomography dose index, while low-dose image quality degradation was estimated via structural similarity (SSIM).   RESULTS: OSC-TV and FDK-TV were shown to significantly improve image signal-to-noise ratio (SNR) compared to FDK with a standard filter, 5.8 and 4.0 times, respectively. Spatial resolution attained with different algorithms varied moderately across different experiments. For low-dose acquisitions, image quality decreased dramatically for FDK but not for FDK-TV nor OSC-TV. For low-dose canine head images acquired using about 1/5 of the dose compared to a reference image, SSIM dropped to about 0.3 for FDK, while remaining at 0.92 for FDK-TV and 0.96 for OSC-TV.   CONCLUSION: OSC-TV was shown to improve image quality compared to FDK and FDK-TV. Moreover, this iterative approach allowed for significant dose reduction while maintaining image quality."@en ;
    ns0:hasPubTitle "Iterative reconstruction for image enhancement and dose reduction in diagnostic cone beam CT imaging"@en .

ns1:xst-v27-i5-XST190528 ns0:hasKeywords "Scattering estimation"@en,
        "angular sequence"@en,
        "cone-beam computed tomography"@en,
        "corrected projection"@en,
        "structural tensor"@en ;
    ns0:hasPubAbstract "Based on the structural tensor of projection, this study aims to address and test a new improved algorithm applying to the distort projection data to generate a high qualified image by reducing the artifacts and noise from scattering in the cone-beam computed tomography (CBCT). Since the scattering information has a large relationship with the structure of the object, which is reflected by the projection, regional model knowledge for scattering is accomplished by finding the relationship between projection and scattering. As the tensor, the gradient of projection is first calculated in the process for estimating the direction and structural edge of the object. Then, the Determinant and Traces of the tensor map with different characteristics are computed to determine the different regions. By modeling and fitting the regions of scattering distribution, the knowledge of scattering parameters corresponding to a different region is obtained. Based on the similarity of scattering distribution in adjacent angles, the scatterings with angle sequence are completed by interpolating the prior knowledge obtained through the sparse sampling. By performing the studies on polychromatic X-ray to test the performance of the scattering estimation algorithm, the results show a significant improvement in the images that are reconstructed from the corrected projection. The root mean square error (RMSE) of the proposed method is reduced by 21.8% and 39.8%, respectively. Peak signal to noise ratio (PSNR), and universal quality index (UQI) also indicate better uniformity, where the PSNR is increased by 7.4% and 56.7%, UQI is increased by 70.8% and 262.3% for experimental #Wheel and #Cylinder, respectively."@en ;
    ns0:hasPubTitle "Scattering measurement and estimation in angular sequence for cone-beam CT based on projection structural tensor and modeling"@en .

ns1:xst-v27-i5-XST190538 ns0:hasKeywords "Sprague-Dawley rat"@en,
        "Time of flight magnetic resonance angiography"@en,
        "apparent diffusion coefficient"@en,
        "diffusion weighted magnetic resonance imaging"@en,
        "ischemic stroke"@en,
        "middle cerebral artery occlusion animal model"@en ;
    ns0:hasPubAbstract "BACKGROUND: Arterial embolism is a major cause of ischemic stroke. Currently, digital subtraction angiography (DSA) is the gold standard in clinical arterial embolization examinations. However, it is invasive and risky.   OBJECTIVE: This study aims to longitudinally assess the progression of carotid artery embolism in middle cerebral artery occlusion animal model (MCAO) using magnetic resonance imaging (MRI) techniques.   METHODS: Turbo spin echo (TSE), time of flight magnetic resonance angiography (TOF-MRA) and diffusion weighted magnetic resonance imaging (DWI) were used to evaluate the image characteristics of cerebral tissues at 1, 2, 3, 7, 14, 21 and 28 days after MCAO microsurgery on Sprague-Dawley (SD) rats. Quantitative analysis was performed and compared in MCAO hemisphere and contralateral normal hemisphere. Furthermore, pathologic section using triphenyl tetrazolium chloride (TTC) stain was performed as well.   RESULTS: TOF-MRA showed carotid signal void in the embolism side, which is evidence of artery occlusion. The used MRI techniques showed that edema gradually dissipated within one week, but there was no significant change afterwards. The time-varying signal intensity of MRI techniques in MCAO hemisphere changed significantly, but there were no significant changes in contralateral normal hemisphere. Cerebral injury was also confirmed by analysis of pathology images.   CONCLUSIONS: The MCAO animal model was successfully established on SD rats using the microsurgery to assess arterial embolization of intracranial tissue injury."@en ;
    ns0:hasPubTitle "Longitudinal investigation of ischemic stroke using magnetic resonance imaging: Animal model"@en .

ns1:xst-v27-i5-XST190541 ns0:hasKeywords "Gemstone spectral imaging"@en,
        "head-neck CT angiography"@en,
        "image quality"@en,
        "low iodine intake"@en,
        "radiation dose"@en ;
    ns0:hasPubAbstract "OBJECTIVE: To compare image quality, radiation dose, and iodine intake of head-neck CT angiography (CTA) acquired by wide-detector with the gemstone spectral imaging (GSI) combination with low iodine intake or routine scan protocol.   METHODS: Three hundred patients who had head-neck CTA were enrolled and divided into three groups according to their BMI values: group A (18.5 kg/m2 ≦ BMI <24.9 kg/m2), group B (24.9 kg/m2 ≦ BMI <29.9 kg/m2) and group C (29.9 kg/m2 ≦ BMI ≦ 34.9 kg/m2) with 100 patients in each group. Patients in each group were randomly divided into two subgroups (n = 50) namely, A1, A2, B1, B2, C1 and C2. The patients in subgroups A1, B1 and C1 underwent GSI with low iodine intake (270 mgI/ml, 50 ml) and combined with the ASiR-V algorithm. Other patients underwent three dimensional (3D) smart mA modulation with routine iodine intake (350 mgI/ml, 60 ml). Signal-to-noise ratio (SNR) and contrast-to-noise ratio (CNR) of all images were calculated after angiography. Images were then subjectively assessed using a 5-point scale. CT dose index of volume and dose-length product (DLP) was converted to the effective dose (ED) and then compared.   RESULTS: The mean CT values, SNR, CNR and subjective image quality in subgroups A2, B2 and C2 are significantly lower than in subgroups A1, B1, and C1 (P < 0.01), respectively. The ED values in subgroup A1, B1, and C1 are 55.18%, 61.89%, and 69.64% lower than those in A2, B2, and C2, respectively (P < 0.01). The total iodine intakes in subgroups A1, B1, and C1 are 35.72% lower than those in subgroups A2, B2, and C2.   CONCLUSIONS: The gemstone spectral imaging with monochromatic images at 53–57 keV combined with ASiR-V algorithm allows significant reduction in iodine load and radiation dose in head-neck CT angiography than those yielded in routine scan protocol. It also enhances signal intensity of head-neck CTA and maintains image quality."@en ;
    ns0:hasPubTitle "Assessment of radiation dose and iodine load reduction in head-neck CT angiography using two scan protocols with wide-detector"@en .

ns2:ADR170004 ns0:inAuthorList ns150:ADR170004 .

ns2:ADR170035 ns0:inAuthorList ns150:ADR170035 .

ns2:ADR180082 ns0:inAuthorList ns150:ADR180082 .

ns2:AIC746 ns0:inAuthorList ns150:AIC746 .

ns2:AO157 ns0:inAuthorList ns150:AO157 .

ns2:ASY1287 ns0:inAuthorList ns150:ASY1287 .

ns2:ASY1361 ns0:inAuthorList ns150:ASY1361 .

ns2:ASY1380 ns0:inAuthorList ns150:ASY1380 .

ns2:ASY1420 ns0:inAuthorList ns150:ASY1420 .

ns2:ASY191520 owl:sameAs ns2:ASY1387 ;
    ns0:fullName "Habib Ammari" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY191520> ;
    ns0:hasArticle ns1:asy-v114-i3-4-ASY191520 ;
    ns0:inAuthorList ns150:ASY191520 .

ns2:BD402 ns0:inAuthorList ns150:BD402 .

ns2:BIR14030 ns0:inAuthorList ns150:BIR14030 .

ns2:BIR180175 ns0:inAuthorList ns150:BIR180175 .

ns2:BLC170120 ns0:inAuthorList ns150:BLC170120 .

ns2:BLC180167 ns0:inAuthorList ns150:BLC180167 .

ns2:BLC180191 ns0:inAuthorList ns150:BLC180191 .

ns2:BLC9001 ns0:inAuthorList ns150:BLC9001 .

ns2:BME1377 ns0:inAuthorList ns150:BME1377 .

ns2:BME1423 ns0:inAuthorList ns150:BME1423 .

ns2:BME1441 ns0:inAuthorList ns150:BME1441 .

ns2:BME1508 ns0:inAuthorList ns150:BME1508 .

ns2:BME1732 ns0:inAuthorList ns150:BME1732 .

ns2:BMR160543 ns0:inAuthorList ns150:BMR160543 .

ns2:BMR160585 ns0:inAuthorList ns150:BMR160585 .

ns2:BMR170898 ns0:inAuthorList ns150:BMR170898 .

ns2:BMR171004 owl:sameAs ns30:NRE172306 ;
    ns0:fullName "Jung-Hoon Lee" ;
    ns0:hasAffiliation ns242:BMR171004 ;
    ns0:hasArticle ns1:bmr-v32-i6-BMR171004 ;
    ns0:inAuthorList ns150:BMR171004 .

ns2:BMR171036 ns0:inAuthorList ns150:BMR171036 .

ns2:BMR181215 ns0:inAuthorList ns150:BMR181215 .

ns2:BMR181259 ns0:inAuthorList ns150:BMR181259 .

ns2:BMR598 ns0:inAuthorList ns150:BMR598 .

ns2:BMR735 ns0:inAuthorList ns150:BMR735 .

ns2:BRS113 ns0:inAuthorList ns150:BRS113 .

ns2:BRS190144 ns0:inAuthorList ns150:BRS190144 .

ns2:BSI183 ns0:inAuthorList ns150:BSI183 .

ns2:CBM170472 ns0:inAuthorList ns150:CBM170472 .

ns2:CBM170680 ns0:inAuthorList ns150:CBM170680 .

ns2:CBM181628 ns0:inAuthorList ns150:CBM181628 .

ns2:CBM544 ns0:inAuthorList ns150:CBM544 .

ns2:CBM638 ns0:inAuthorList ns150:CBM638 .

ns2:CH160241 ns0:inAuthorList ns150:CH160241 .

ns2:CH16194 ns0:inAuthorList ns150:CH16194 .

ns2:CH16195 ns0:inAuthorList ns150:CH16195 .

ns2:CH168005 ns0:inAuthorList ns150:CH168005 .

ns2:CH168034 ns0:inAuthorList ns150:CH168034 .

ns2:CH168044 ns0:inAuthorList ns150:CH168044 .

ns2:CH170269 ns0:inAuthorList ns150:CH170269 .

ns2:CH170365 ns0:inAuthorList ns150:CH170365 .

ns2:CH179102 ns0:inAuthorList ns150:CH179102 .

ns2:CH179105 ns0:inAuthorList ns150:CH179105 .

ns2:CH179216 ns0:inAuthorList ns150:CH179216 .

ns2:CH179220 ns0:inAuthorList ns150:CH179220 .

ns2:CH179221 ns0:inAuthorList ns150:CH179221 .

ns2:CH179231 ns0:inAuthorList ns150:CH179231 .

ns2:CH180382 ns0:inAuthorList ns150:CH180382 .

ns2:CH180428 ns0:inAuthorList ns150:CH180428 .

ns2:CH180452 owl:sameAs ns8:CH16212,
        ns8:CH170252,
        ns26:CH170275,
        ns26:CH180388,
        ns16:CH16196,
        ns57:CH16142,
        ns33:CH170253 ;
    ns0:fullName "Hui-Xiong Xu" ;
    ns0:hasAffiliation ns242:CH180452,
        ns243:CH180452,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:CH180452> ;
    ns0:hasArticle ns1:ch-v72-i1-CH180452 ;
    ns0:inAuthorList ns150:CH180452 .

ns2:CH180544 ns0:inAuthorList ns150:CH180544 .

ns2:CH180545 ns0:inAuthorList ns150:CH180545 .

ns2:CH189106 ns0:inAuthorList ns150:CH189106 .

ns2:CH189114 ns0:inAuthorList ns150:CH189114 .

ns2:CH189115 ns0:inAuthorList ns150:CH189115 .

ns2:CH189116 ns0:inAuthorList ns150:CH189116 .

ns2:CH189123 ns0:inAuthorList ns150:CH189123 .

ns2:CH189131 ns0:inAuthorList ns150:CH189131 .

ns2:CH189301 ns0:inAuthorList ns150:CH189301 .

ns2:CH189406 ns0:inAuthorList ns150:CH189406 .

ns2:CH189409 ns0:inAuthorList ns150:CH189409 .

ns2:CH1962 ns0:inAuthorList ns150:CH1962 .

ns2:CH1963 ns0:inAuthorList ns150:CH1963 .

ns2:CH1967 ns0:inAuthorList ns150:CH1967 .

ns2:CH199009 owl:sameAs ns2:CH179201 ;
    ns0:fullName "P. Lamby" ;
    ns0:hasAffiliation ns242:CH199009 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199009 ;
    ns0:inAuthorList ns150:CH199009 .

ns2:CH199204 ns0:inAuthorList ns150:CH199204 .

ns2:CH199222 owl:sameAs ns8:CH189308 ;
    ns0:fullName "M. Apfelbeck" ;
    ns0:hasAffiliation ns242:CH199222 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199222 ;
    ns0:inAuthorList ns150:CH199222 .

ns2:CH1999 ns0:inAuthorList ns150:CH1999 .

ns2:COM040 ns0:inAuthorList ns150:COM040 .

ns2:COM049 ns0:inAuthorList ns150:COM049 .

ns2:COM101 ns0:inAuthorList ns150:COM101 .

ns2:DEV180256 ns0:inAuthorList ns150:DEV180256 .

ns2:DEV189002 ns0:inAuthorList ns150:DEV189002 .

ns2:FI1376 ns0:inAuthorList ns150:FI1376 .

ns2:FI1546 ns0:inAuthorList ns150:FI1546 .

ns2:FI1562 ns0:inAuthorList ns150:FI1562 .

ns2:FI1565 ns0:inAuthorList ns150:FI1565 .

ns2:FI1566 ns0:inAuthorList ns150:FI1566 .

ns2:FI1574 ns0:inAuthorList ns150:FI1574 .

ns2:FI1627 ns0:inAuthorList ns150:FI1627 .

ns2:FI1628 ns0:inAuthorList ns150:FI1628 .

ns2:FI1655 ns0:inAuthorList ns150:FI1655 .

ns2:FI1703 ns0:inAuthorList ns150:FI1703 .

ns2:FI1708 ns0:inAuthorList ns150:FI1708 .

ns2:FI1794 ns0:inAuthorList ns150:FI1794 .

ns2:FI1807 ns0:inAuthorList ns150:FI1807 .

ns2:FI1827 ns0:inAuthorList ns150:FI1827 .

ns2:FI1887 ns0:inAuthorList ns150:FI1887 .

ns2:HAB180345 ns0:inAuthorList ns150:HAB180345 .

ns2:HAB180356 ns0:inAuthorList ns150:HAB180356 .

ns2:HAB190369 owl:sameAs ns2:HAB190368,
        ns8:HAB190367,
        ns8:HAB190383 ;
    ns0:fullName "Ali Mohammad Mosadeghrad" ;
    ns0:hasAffiliation ns242:HAB190369 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190369 ;
    ns0:inAuthorList ns150:HAB190369 .

ns2:HAB190383 owl:sameAs ns2:HAB190363,
        ns8:HAB190368,
        ns8:HAB190369,
        ns8:HAB304 ;
    ns0:fullName "Addis Adera Gebru" ;
    ns0:hasAffiliation ns242:HAB190383,
        ns243:HAB190383 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190383 ;
    ns0:inAuthorList ns150:HAB190383 .

ns2:HAB190386 ns0:inAuthorList ns150:HAB190386 .

ns2:HAB291 ns0:inAuthorList ns150:HAB291 .

ns2:HAB320 ns0:inAuthorList ns150:HAB320 .

ns2:HSM1641 ns0:inAuthorList ns150:HSM1641 .

ns2:HSM17118 ns0:inAuthorList ns150:HSM17118 .

ns2:HSM1785 ns0:inAuthorList ns150:HSM1785 .

ns2:HSM180415 ns0:inAuthorList ns150:HSM180415 .

ns2:HSM180472 ns0:inAuthorList ns150:HSM180472 .

ns2:IA103 ns0:inAuthorList ns150:IA103 .

ns2:IA109 ns0:inAuthorList ns150:IA109 .

ns2:IA111 ns0:inAuthorList ns150:IA111 .

ns2:IDA173473 ns0:inAuthorList ns150:IDA173473 .

ns2:IDA183874 ns0:inAuthorList ns150:IDA183874 .

ns2:IDA192829 ns0:inAuthorList ns150:IDA192829 .

ns2:IDA750 ns0:inAuthorList ns150:IDA750 .

ns2:IDA757 ns0:inAuthorList ns150:IDA757 .

ns2:IDA789 ns0:inAuthorList ns150:IDA789 .

ns2:IDA800 ns0:inAuthorList ns150:IDA800 .

ns2:IDA814 ns0:inAuthorList ns150:IDA814 .

ns2:IDA818 ns0:inAuthorList ns150:IDA818 .

ns2:IDT309 ns0:inAuthorList ns150:IDT309 .

ns2:IES173142 ns0:inAuthorList ns150:IES173142 .

ns2:IES182207 ns0:inAuthorList ns150:IES182207 .

ns2:IES192150 ns0:inAuthorList ns150:IES192150 .

ns2:IFS151050 ns0:inAuthorList ns150:IFS151050 .

ns2:IFS152261 ns0:inAuthorList ns150:IFS152261 .

ns2:IFS161413 ns0:inAuthorList ns150:IFS161413 .

ns2:IFS161467 ns0:inAuthorList ns150:IFS161467 .

ns2:IFS161548 ns0:inAuthorList ns150:IFS161548 .

ns2:IFS161654 ns0:inAuthorList ns150:IFS161654 .

ns2:IFS161798 ns0:inAuthorList ns150:IFS161798 .

ns2:IFS161811 ns0:inAuthorList ns150:IFS161811 .

ns2:IFS161922 ns0:inAuthorList ns150:IFS161922 .

ns2:IFS162030 ns0:inAuthorList ns150:IFS162030 .

ns2:IFS162058 ns0:inAuthorList ns150:IFS162058 .

ns2:IFS162136 ns0:inAuthorList ns150:IFS162136 .

ns2:IFS16216 ns0:inAuthorList ns150:IFS16216 .

ns2:IFS162207 ns0:inAuthorList ns150:IFS162207 .

ns2:IFS162234 ns0:inAuthorList ns150:IFS162234 .

ns2:IFS16232 ns0:inAuthorList ns150:IFS16232 .

ns2:IFS162414 ns0:inAuthorList ns150:IFS162414 .

ns2:IFS16339 ns0:inAuthorList ns150:IFS16339 .

ns2:IFS16381 ns0:inAuthorList ns150:IFS16381 .

ns2:IFS16468 ns0:inAuthorList ns150:IFS16468 .

ns2:IFS169160 ns0:inAuthorList ns150:IFS169160 .

ns2:IFS169173 ns0:inAuthorList ns150:IFS169173 .

ns2:IFS169359 ns0:inAuthorList ns150:IFS169359 .

ns2:IFS169457 ns0:inAuthorList ns150:IFS169457 .

ns2:IFS169468 ns0:inAuthorList ns150:IFS169468 .

ns2:IFS169577 ns0:inAuthorList ns150:IFS169577 .

ns2:IFS169982 ns0:inAuthorList ns150:IFS169982 .

ns2:IFS1705 ns0:inAuthorList ns150:IFS1705 .

ns2:IFS17063 ns0:inAuthorList ns150:IFS17063 .

ns2:IFS171033 ns0:inAuthorList ns150:IFS171033 .

ns2:IFS171055 ns0:inAuthorList ns150:IFS171055 .

ns2:IFS17108 ns0:inAuthorList ns150:IFS17108 .

ns2:IFS171090 ns0:inAuthorList ns150:IFS171090 .

ns2:IFS171278 ns0:inAuthorList ns150:IFS171278 .

ns2:IFS171399 ns0:inAuthorList ns150:IFS171399 .

ns2:IFS171515 ns0:inAuthorList ns150:IFS171515 .

ns2:IFS171744 ns0:inAuthorList ns150:IFS171744 .

ns2:IFS171941 ns0:inAuthorList ns150:IFS171941 .

ns2:IFS171946 ns0:inAuthorList ns150:IFS171946 .

ns2:IFS172009 ns0:inAuthorList ns150:IFS172009 .

ns2:IFS172094 ns0:inAuthorList ns150:IFS172094 .

ns2:IFS172114 ns0:inAuthorList ns150:IFS172114 .

ns2:IFS17227 ns0:inAuthorList ns150:IFS17227 .

ns2:IFS17277 ns0:inAuthorList ns150:IFS17277 .

ns2:IFS17348 ns0:inAuthorList ns150:IFS17348 .

ns2:IFS1737 ns0:inAuthorList ns150:IFS1737 .

ns2:IFS17465 ns0:inAuthorList ns150:IFS17465 .

ns2:IFS17493 ns0:inAuthorList ns150:IFS17493 .

ns2:IFS17506 ns0:inAuthorList ns150:IFS17506 .

ns2:IFS17682 ns0:inAuthorList ns150:IFS17682 .

ns2:IFS17698 ns0:inAuthorList ns150:IFS17698 .

ns2:IFS17756 ns0:inAuthorList ns150:IFS17756 .

ns2:IFS17845 ns0:inAuthorList ns150:IFS17845 .

ns2:IFS17851 ns0:inAuthorList ns150:IFS17851 .

ns2:IFS17876 ns0:inAuthorList ns150:IFS17876 .

ns2:IFS179069 ns0:inAuthorList ns150:IFS179069 .

ns2:IFS179078 ns0:inAuthorList ns150:IFS179078 .

ns2:IFS179161 owl:sameAs ns40:JAD160587 ;
    ns0:fullName "Ying Peng" ;
    ns0:hasAffiliation ns242:IFS179161,
        ns243:IFS179161 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS179161 ;
    ns0:inAuthorList ns150:IFS179161 .

ns2:IFS179199 ns0:inAuthorList ns150:IFS179199 .

ns2:IFS179250 owl:sameAs ns2:IFS161821,
        ns2:IFS171587,
        ns2:IFS17728,
        ns2:IFS182572,
        ns8:IFS181188,
        ns12:IFS181460 ;
    ns0:fullName "Asghar Khan" ;
    ns0:hasAffiliation ns242:IFS179250 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179250 ;
    ns0:inAuthorList ns150:IFS179250 .

ns2:IFS179289 ns0:inAuthorList ns150:IFS179289 .

ns2:IFS17938 ns0:inAuthorList ns150:IFS17938 .

ns2:IFS17940 ns0:inAuthorList ns150:IFS17940 .

ns2:IFS1805 ns0:inAuthorList ns150:IFS1805 .

ns2:IFS18104 ns0:inAuthorList ns150:IFS18104 .

ns2:IFS18106 ns0:inAuthorList ns150:IFS18106 .

ns2:IFS181084 ns0:inAuthorList ns150:IFS181084 .

ns2:IFS181097 ns0:inAuthorList ns150:IFS181097 .

ns2:IFS181123 ns0:inAuthorList ns150:IFS181123 .

ns2:IFS181172 ns0:inAuthorList ns150:IFS181172 .

ns2:IFS181188 ns0:inAuthorList ns150:IFS181188 .

ns2:IFS181329 ns0:inAuthorList ns150:IFS181329 .

ns2:IFS181364 ns0:inAuthorList ns150:IFS181364 .

ns2:IFS181460 owl:sameAs ns8:IFS17728,
        ns5:IFS171164 ;
    ns0:fullName "Muhammad Farooq" ;
    ns0:hasAffiliation ns242:IFS181460 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181460 ;
    ns0:inAuthorList ns150:IFS181460 .

ns2:IFS181611 ns0:inAuthorList ns150:IFS181611 .

ns2:IFS181642 owl:sameAs ns2:IFS17530 ;
    ns0:fullName "Hua Mao" ;
    ns0:hasAffiliation ns242:IFS181642 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181642 ;
    ns0:inAuthorList ns150:IFS181642 .

ns2:IFS181697 owl:sameAs ns2:IFS162347,
        ns2:IFS171443,
        ns2:IFS181972,
        ns2:IFS2107,
        ns8:IFS190054 ;
    ns0:fullName "Muhammad Akram" ;
    ns0:hasAffiliation ns242:IFS181697 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181697 ;
    ns0:inAuthorList ns150:IFS181697 .

ns2:IFS181941 ns0:inAuthorList ns150:IFS181941 .

ns2:IFS18244 ns0:inAuthorList ns150:IFS18244 .

ns2:IFS182568 owl:sameAs ns2:IFS161927,
        ns8:IFS17465,
        ns8:IFS17912,
        ns30:JAD190113 ;
    ns0:fullName "Yu Zhong" ;
    ns0:hasAffiliation ns242:IFS182568 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182568 ;
    ns0:inAuthorList ns150:IFS182568 .

ns2:IFS182594 owl:sameAs ns2:IFS17124,
        ns2:IFS182768 ;
    ns0:fullName "Xindong Peng" ;
    ns0:hasAffiliation ns242:IFS182594,
        ns243:IFS182594 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182594 ;
    ns0:inAuthorList ns150:IFS182594 .

ns2:IFS182634 ns0:inAuthorList ns150:IFS182634 .

ns2:IFS18268 ns0:inAuthorList ns150:IFS18268 .

ns2:IFS182747 ns0:inAuthorList ns150:IFS182747 .

ns2:IFS182808 owl:sameAs ns2:IFS182569 ;
    ns0:fullName "Qing-Hua Li" ;
    ns0:hasAffiliation ns242:IFS182808 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182808 ;
    ns0:inAuthorList ns150:IFS182808 .

ns2:IFS182810 ns0:inAuthorList ns150:IFS182810 .

ns2:IFS182828 owl:sameAs ns8:IFS180001 ;
    ns0:fullName "Fu-Gui Shi" ;
    ns0:hasAffiliation ns242:IFS182828 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182828 ;
    ns0:inAuthorList ns150:IFS182828 .

ns2:IFS182945 ns0:inAuthorList ns150:IFS182945 .

ns2:IFS18339 ns0:inAuthorList ns150:IFS18339 .

ns2:IFS18411 ns0:inAuthorList ns150:IFS18411 .

ns2:IFS18568 ns0:inAuthorList ns150:IFS18568 .

ns2:IFS18577 ns0:inAuthorList ns150:IFS18577 .

ns2:IFS18579 owl:sameAs ns30:HIS241 ;
    ns0:fullName "Atta Rahman" ;
    ns0:hasAffiliation ns242:IFS18579 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS18579 ;
    ns0:inAuthorList ns150:IFS18579 .

ns2:IFS18667 ns0:inAuthorList ns150:IFS18667 .

ns2:IFS18675 ns0:inAuthorList ns150:IFS18675 .

ns2:IFS18890 ns0:inAuthorList ns150:IFS18890 .

ns2:IFS18963 ns0:inAuthorList ns150:IFS18963 .

ns2:IFS18979 ns0:inAuthorList ns150:IFS18979 .

ns2:IFS190036 owl:sameAs ns2:IFS151517,
        ns2:IFS1667,
        ns12:IFS190148 ;
    ns0:fullName "Mohammad Hamidi" ;
    ns0:hasAffiliation ns242:IFS190036 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS190036 ;
    ns0:inAuthorList ns150:IFS190036 .

ns2:IFS190280 ns0:inAuthorList ns150:IFS190280 .

ns2:IFS190447 owl:sameAs ns2:IFS171172,
        ns2:JAE150030,
        ns8:IFS191197 ;
    ns0:fullName "Abbas Ali" ;
    ns0:hasAffiliation ns242:IFS190447 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190447 ;
    ns0:inAuthorList ns150:IFS190447 .

ns2:IFS190554 owl:sameAs ns2:IFS16236 ;
    ns0:fullName "R.J. Kuo" ;
    ns0:hasAffiliation ns242:IFS190554 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190554 ;
    ns0:inAuthorList ns150:IFS190554 .

ns2:IFS190952 owl:sameAs ns2:IFS161919,
        ns2:IFS171070,
        ns2:IFS182863,
        ns8:IFS181657,
        ns8:IFS181698 ;
    ns0:fullName "Ho Vu" ;
    ns0:hasAffiliation ns242:IFS190952 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190952 ;
    ns0:inAuthorList ns150:IFS190952 .

ns2:IFS190988 owl:sameAs ns2:IFS1856,
        ns2:IFS2074,
        ns2:IFS2075,
        ns2:IFS2082,
        ns2:IFS2110,
        ns2:IFS2114,
        ns2:IFS2121,
        ns2:IFS2128,
        ns8:IFS152553,
        ns8:IFS161586,
        ns8:IFS17088,
        ns8:IFS190148,
        ns8:IFS2041,
        ns8:IFS2077,
        ns12:IFS171443,
        ns12:IFS181488,
        ns30:IFS17848,
        ns5:IFS190565 ;
    ns0:fullName "R.A. Borzooei" ;
    ns0:hasAffiliation ns242:IFS190988 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190988 ;
    ns0:inAuthorList ns150:IFS190988 .

ns2:IFS2019 ns0:inAuthorList ns150:IFS2019 .

ns2:IFS2021 ns0:inAuthorList ns150:IFS2021 .

ns2:IFS2047 ns0:inAuthorList ns150:IFS2047 .

ns2:IFS2057 ns0:inAuthorList ns150:IFS2057 .

ns2:IFS2060 ns0:inAuthorList ns150:IFS2060 .

ns2:IFS2115 ns0:inAuthorList ns150:IFS2115 .

ns2:IFS2196 ns0:inAuthorList ns150:IFS2196 .

ns2:INF1089 ns0:inAuthorList ns150:INF1089 .

ns2:INF1108 ns0:inAuthorList ns150:INF1108 .

ns2:INF1160 ns0:inAuthorList ns150:INF1160 .

ns2:ISP180256 ns0:inAuthorList ns150:ISP180256 .

ns2:JAD00025 ns0:inAuthorList ns150:JAD00025 .

ns2:JAD00041 ns0:inAuthorList ns150:JAD00041 .

ns2:JAD0005 ns0:inAuthorList ns150:JAD0005 .

ns2:JAD100660 ns0:inAuthorList ns150:JAD100660 .

ns2:JAD101422 ns0:inAuthorList ns150:JAD101422 .

ns2:JAD101536 ns0:inAuthorList ns150:JAD101536 .

ns2:JAD101818 ns0:inAuthorList ns150:JAD101818 .

ns2:JAD102100 ns0:inAuthorList ns150:JAD102100 .

ns2:JAD110074 ns0:inAuthorList ns150:JAD110074 .

ns2:JAD110086 ns0:inAuthorList ns150:JAD110086 .

ns2:JAD110134 ns0:inAuthorList ns150:JAD110134 .

ns2:JAD110173 ns0:inAuthorList ns150:JAD110173 .

ns2:JAD110341 ns0:inAuthorList ns150:JAD110341 .

ns2:JAD110566 ns0:inAuthorList ns150:JAD110566 .

ns2:JAD110662 ns0:inAuthorList ns150:JAD110662 .

ns2:JAD110713 ns0:inAuthorList ns150:JAD110713 .

ns2:JAD110722 ns0:inAuthorList ns150:JAD110722 .

ns2:JAD110794 ns0:inAuthorList ns150:JAD110794 .

ns2:JAD110808 ns0:inAuthorList ns150:JAD110808 .

ns2:JAD110884 ns0:inAuthorList ns150:JAD110884 .

ns2:JAD110890 ns0:inAuthorList ns150:JAD110890 .

ns2:JAD111376 ns0:inAuthorList ns150:JAD111376 .

ns2:JAD111577 ns0:inAuthorList ns150:JAD111577 .

ns2:JAD112060 ns0:inAuthorList ns150:JAD112060 .

ns2:JAD120130 ns0:inAuthorList ns150:JAD120130 .

ns2:JAD120169 ns0:inAuthorList ns150:JAD120169 .

ns2:JAD120253 ns0:inAuthorList ns150:JAD120253 .

ns2:JAD120424 ns0:inAuthorList ns150:JAD120424 .

ns2:JAD120508 ns0:inAuthorList ns150:JAD120508 .

ns2:JAD120523 ns0:inAuthorList ns150:JAD120523 .

ns2:JAD120763 ns0:inAuthorList ns150:JAD120763 .

ns2:JAD120802 ns0:inAuthorList ns150:JAD120802 .

ns2:JAD120994 ns0:inAuthorList ns150:JAD120994 .

ns2:JAD121168 ns0:inAuthorList ns150:JAD121168 .

ns2:JAD121189 ns0:inAuthorList ns150:JAD121189 .

ns2:JAD121456 ns0:inAuthorList ns150:JAD121456 .

ns2:JAD121975 ns0:inAuthorList ns150:JAD121975 .

ns2:JAD122110 ns0:inAuthorList ns150:JAD122110 .

ns2:JAD122140 ns0:inAuthorList ns150:JAD122140 .

ns2:JAD122170 ns0:inAuthorList ns150:JAD122170 .

ns2:JAD129006 ns0:inAuthorList ns150:JAD129006 .

ns2:JAD129020 ns0:inAuthorList ns150:JAD129020 .

ns2:JAD129024 ns0:inAuthorList ns150:JAD129024 .

ns2:JAD129044 ns0:inAuthorList ns150:JAD129044 .

ns2:JAD129909 ns0:inAuthorList ns150:JAD129909 .

ns2:JAD130011 ns0:inAuthorList ns150:JAD130011 .

ns2:JAD130203 ns0:inAuthorList ns150:JAD130203 .

ns2:JAD130245 ns0:inAuthorList ns150:JAD130245 .

ns2:JAD130698 ns0:inAuthorList ns150:JAD130698 .

ns2:JAD130779 ns0:inAuthorList ns150:JAD130779 .

ns2:JAD130956 ns0:inAuthorList ns150:JAD130956 .

ns2:JAD131025 ns0:inAuthorList ns150:JAD131025 .

ns2:JAD131433 ns0:inAuthorList ns150:JAD131433 .

ns2:JAD131484 ns0:inAuthorList ns150:JAD131484 .

ns2:JAD131640 ns0:inAuthorList ns150:JAD131640 .

ns2:JAD131733 ns0:inAuthorList ns150:JAD131733 .

ns2:JAD131829 ns0:inAuthorList ns150:JAD131829 .

ns2:JAD131844 ns0:inAuthorList ns150:JAD131844 .

ns2:JAD131883 ns0:inAuthorList ns150:JAD131883 .

ns2:JAD132246 ns0:inAuthorList ns150:JAD132246 .

ns2:JAD132345 ns0:inAuthorList ns150:JAD132345 .

ns2:JAD132414 ns0:inAuthorList ns150:JAD132414 .

ns2:JAD132642 ns0:inAuthorList ns150:JAD132642 .

ns2:JAD132786 ns0:inAuthorList ns150:JAD132786 .

ns2:JAD140162 ns0:inAuthorList ns150:JAD140162 .

ns2:JAD140210 ns0:inAuthorList ns150:JAD140210 .

ns2:JAD140282 ns0:inAuthorList ns150:JAD140282 .

ns2:JAD140516 ns0:inAuthorList ns150:JAD140516 .

ns2:JAD140756 ns0:inAuthorList ns150:JAD140756 .

ns2:JAD140759 ns0:inAuthorList ns150:JAD140759 .

ns2:JAD140942 ns0:inAuthorList ns150:JAD140942 .

ns2:JAD141167 ns0:inAuthorList ns150:JAD141167 .

ns2:JAD141305 ns0:inAuthorList ns150:JAD141305 .

ns2:JAD141365 ns0:inAuthorList ns150:JAD141365 .

ns2:JAD141371 ns0:inAuthorList ns150:JAD141371 .

ns2:JAD141521 ns0:inAuthorList ns150:JAD141521 .

ns2:JAD141572 ns0:inAuthorList ns150:JAD141572 .

ns2:JAD141629 ns0:inAuthorList ns150:JAD141629 .

ns2:JAD141824 ns0:inAuthorList ns150:JAD141824 .

ns2:JAD142079 ns0:inAuthorList ns150:JAD142079 .

ns2:JAD142085 ns0:inAuthorList ns150:JAD142085 .

ns2:JAD142334 ns0:inAuthorList ns150:JAD142334 .

ns2:JAD142499 ns0:inAuthorList ns150:JAD142499 .

ns2:JAD142874 ns0:inAuthorList ns150:JAD142874 .

ns2:JAD1439 ns0:inAuthorList ns150:JAD1439 .

ns2:JAD150134 ns0:inAuthorList ns150:JAD150134 .

ns2:JAD150254 ns0:inAuthorList ns150:JAD150254 .

ns2:JAD150261 ns0:inAuthorList ns150:JAD150261 .

ns2:JAD150585 ns0:inAuthorList ns150:JAD150585 .

ns2:JAD150606 ns0:inAuthorList ns150:JAD150606 .

ns2:JAD150692 ns0:inAuthorList ns150:JAD150692 .

ns2:JAD150732 ns0:inAuthorList ns150:JAD150732 .

ns2:JAD150794 ns0:inAuthorList ns150:JAD150794 .

ns2:JAD150847 ns0:inAuthorList ns150:JAD150847 .

ns2:JAD150898 ns0:inAuthorList ns150:JAD150898 .

ns2:JAD150899 ns0:inAuthorList ns150:JAD150899 .

ns2:JAD150909 ns0:inAuthorList ns150:JAD150909 .

ns2:JAD150914 ns0:inAuthorList ns150:JAD150914 .

ns2:JAD151101 ns0:inAuthorList ns150:JAD151101 .

ns2:JAD151122 ns0:inAuthorList ns150:JAD151122 .

ns2:JAD160025 ns0:inAuthorList ns150:JAD160025 .

ns2:JAD160073 ns0:inAuthorList ns150:JAD160073 .

ns2:JAD160108 ns0:inAuthorList ns150:JAD160108 .

ns2:JAD160146 ns0:inAuthorList ns150:JAD160146 .

ns2:JAD160158 ns0:inAuthorList ns150:JAD160158 .

ns2:JAD160289 ns0:inAuthorList ns150:JAD160289 .

ns2:JAD160348 ns0:inAuthorList ns150:JAD160348 .

ns2:JAD160374 ns0:inAuthorList ns150:JAD160374 .

ns2:JAD160407 ns0:inAuthorList ns150:JAD160407 .

ns2:JAD160416 ns0:inAuthorList ns150:JAD160416 .

ns2:JAD160463 ns0:inAuthorList ns150:JAD160463 .

ns2:JAD160472 ns0:inAuthorList ns150:JAD160472 .

ns2:JAD160485 ns0:inAuthorList ns150:JAD160485 .

ns2:JAD160510 ns0:inAuthorList ns150:JAD160510 .

ns2:JAD160525 ns0:inAuthorList ns150:JAD160525 .

ns2:JAD160593 ns0:inAuthorList ns150:JAD160593 .

ns2:JAD160619 ns0:inAuthorList ns150:JAD160619 .

ns2:JAD160651 ns0:inAuthorList ns150:JAD160651 .

ns2:JAD160685 ns0:inAuthorList ns150:JAD160685 .

ns2:JAD160702 ns0:inAuthorList ns150:JAD160702 .

ns2:JAD160745 ns0:inAuthorList ns150:JAD160745 .

ns2:JAD160923 ns0:inAuthorList ns150:JAD160923 .

ns2:JAD160935 ns0:inAuthorList ns150:JAD160935 .

ns2:JAD160965 ns0:inAuthorList ns150:JAD160965 .

ns2:JAD160970 ns0:inAuthorList ns150:JAD160970 .

ns2:JAD161095 ns0:inAuthorList ns150:JAD161095 .

ns2:JAD161127 ns0:inAuthorList ns150:JAD161127 .

ns2:JAD161166 ns0:inAuthorList ns150:JAD161166 .

ns2:JAD161179 ns0:inAuthorList ns150:JAD161179 .

ns2:JAD161198 ns0:inAuthorList ns150:JAD161198 .

ns2:JAD161252 ns0:inAuthorList ns150:JAD161252 .

ns2:JAD161267 ns0:inAuthorList ns150:JAD161267 .

ns2:JAD161283 ns0:inAuthorList ns150:JAD161283 .

ns2:JAD161285 ns0:inAuthorList ns150:JAD161285 .

ns2:JAD161292 ns0:inAuthorList ns150:JAD161292 .

ns2:JAD170045 ns0:inAuthorList ns150:JAD170045 .

ns2:JAD170077 ns0:inAuthorList ns150:JAD170077 .

ns2:JAD170101 ns0:inAuthorList ns150:JAD170101 .

ns2:JAD170123 ns0:inAuthorList ns150:JAD170123 .

ns2:JAD170149 ns0:inAuthorList ns150:JAD170149 .

ns2:JAD170162 ns0:inAuthorList ns150:JAD170162 .

ns2:JAD170195 ns0:inAuthorList ns150:JAD170195 .

ns2:JAD170218 ns0:inAuthorList ns150:JAD170218 .

ns2:JAD170309 ns0:inAuthorList ns150:JAD170309 .

ns2:JAD170313 ns0:inAuthorList ns150:JAD170313 .

ns2:JAD170390 ns0:inAuthorList ns150:JAD170390 .

ns2:JAD170402 ns0:inAuthorList ns150:JAD170402 .

ns2:JAD170409 ns0:inAuthorList ns150:JAD170409 .

ns2:JAD170450 ns0:inAuthorList ns150:JAD170450 .

ns2:JAD170458 ns0:inAuthorList ns150:JAD170458 .

ns2:JAD170477 ns0:inAuthorList ns150:JAD170477 .

ns2:JAD170507 ns0:inAuthorList ns150:JAD170507 .

ns2:JAD170536 ns0:inAuthorList ns150:JAD170536 .

ns2:JAD170561 ns0:inAuthorList ns150:JAD170561 .

ns2:JAD170581 ns0:inAuthorList ns150:JAD170581 .

ns2:JAD170625 ns0:inAuthorList ns150:JAD170625 .

ns2:JAD170669 ns0:inAuthorList ns150:JAD170669 .

ns2:JAD170712 ns0:inAuthorList ns150:JAD170712 .

ns2:JAD170727 ns0:inAuthorList ns150:JAD170727 .

ns2:JAD170755 ns0:inAuthorList ns150:JAD170755 .

ns2:JAD170762 ns0:inAuthorList ns150:JAD170762 .

ns2:JAD170769 ns0:inAuthorList ns150:JAD170769 .

ns2:JAD170854 ns0:inAuthorList ns150:JAD170854 .

ns2:JAD170861 ns0:inAuthorList ns150:JAD170861 .

ns2:JAD170938 ns0:inAuthorList ns150:JAD170938 .

ns2:JAD170971 ns0:inAuthorList ns150:JAD170971 .

ns2:JAD170972 ns0:inAuthorList ns150:JAD170972 .

ns2:JAD170982 ns0:inAuthorList ns150:JAD170982 .

ns2:JAD171034 ns0:inAuthorList ns150:JAD171034 .

ns2:JAD171047 ns0:inAuthorList ns150:JAD171047 .

ns2:JAD171053 ns0:inAuthorList ns150:JAD171053 .

ns2:JAD171071 ns0:inAuthorList ns150:JAD171071 .

ns2:JAD171077 ns0:inAuthorList ns150:JAD171077 .

ns2:JAD171119 ns0:inAuthorList ns150:JAD171119 .

ns2:JAD179929 ns0:inAuthorList ns150:JAD179929 .

ns2:JAD179939 ns0:inAuthorList ns150:JAD179939 .

ns2:JAD180092 ns0:inAuthorList ns150:JAD180092 .

ns2:JAD180119 ns0:inAuthorList ns150:JAD180119 .

ns2:JAD180183 ns0:inAuthorList ns150:JAD180183 .

ns2:JAD180223 ns0:inAuthorList ns150:JAD180223 .

ns2:JAD180335 ns0:inAuthorList ns150:JAD180335 .

ns2:JAD180425 ns0:inAuthorList ns150:JAD180425 .

ns2:JAD180441 ns0:inAuthorList ns150:JAD180441 .

ns2:JAD180569 ns0:inAuthorList ns150:JAD180569 .

ns2:JAD180604 ns0:inAuthorList ns150:JAD180604 .

ns2:JAD180608 ns0:inAuthorList ns150:JAD180608 .

ns2:JAD180631 ns0:inAuthorList ns150:JAD180631 .

ns2:JAD180634 owl:sameAs ns8:JAD141563,
        ns8:JAD190104,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120466>,
        ns5:JAD181145,
        ns57:JAD161228 ;
    ns0:fullName "Kristine Yaffe" ;
    ns0:hasAffiliation ns242:JAD180634 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180634 ;
    ns0:inAuthorList ns150:JAD180634 .

ns2:JAD180645 ns0:inAuthorList ns150:JAD180645 .

ns2:JAD180721 ns0:inAuthorList ns150:JAD180721 .

ns2:JAD180723 ns0:inAuthorList ns150:JAD180723 .

ns2:JAD180815 ns0:inAuthorList ns150:JAD180815 .

ns2:JAD180853 ns0:inAuthorList ns150:JAD180853 .

ns2:JAD180912 ns0:inAuthorList ns150:JAD180912 .

ns2:JAD180943 ns0:inAuthorList ns150:JAD180943 .

ns2:JAD180985 ns0:inAuthorList ns150:JAD180985 .

ns2:JAD180986 ns0:inAuthorList ns150:JAD180986 .

ns2:JAD181099 ns0:inAuthorList ns150:JAD181099 .

ns2:JAD181170 ns0:inAuthorList ns150:JAD181170 .

ns2:JAD181174 ns0:inAuthorList ns150:JAD181174 .

ns2:JAD181186 ns0:inAuthorList ns150:JAD181186 .

ns2:JAD181227 owl:sameAs ns8:JAD160230 ;
    ns0:fullName "Emmeline Ayers" ;
    ns0:hasAffiliation ns242:JAD181227 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181227 ;
    ns0:inAuthorList ns150:JAD181227 .

ns2:JAD181240 ns0:inAuthorList ns150:JAD181240 .

ns2:JAD181281 ns0:inAuthorList ns150:JAD181281 .

ns2:JAD181298 owl:sameAs ns2:JAD150747,
        ns16:JAD180524 ;
    ns0:fullName "Maurizio Gallucci" ;
    ns0:hasAffiliation ns242:JAD181298 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181298 ;
    ns0:inAuthorList ns150:JAD181298 .

ns2:JAD190030 ns0:inAuthorList ns150:JAD190030 .

ns2:JAD190032 ns0:inAuthorList ns150:JAD190032 .

ns2:JAD190056 ns0:inAuthorList ns150:JAD190056 .

ns2:JAD190124 owl:sameAs ns2:JAD180024,
        ns12:JAD170319,
        ns5:JAD190708,
        ns5:NRE182452,
        ns52:JAD150864,
        ns57:JAD130032,
        ns57:JAD131481 ;
    ns0:fullName "Mario F. Mendez" ;
    ns0:hasAffiliation ns242:JAD190124,
        ns243:JAD190124 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190124 ;
    ns0:inAuthorList ns150:JAD190124 .

ns2:JAD190331 owl:sameAs ns2:JAD142685,
        ns30:JAD181186 ;
    ns0:fullName "Lilian Calderón-Garcidueñas" ;
    ns0:hasAffiliation ns242:JAD190331 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190331 ;
    ns0:inAuthorList ns150:JAD190331 .

ns2:JAD190382 owl:sameAs ns30:jad100318 ;
    ns0:fullName "Meng-Yuan Ding" ;
    ns0:hasAffiliation ns242:JAD190382 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190382 ;
    ns0:inAuthorList ns150:JAD190382 .

ns2:JAD190440 owl:sameAs ns2:JAD170807,
        ns2:JIN030 ;
    ns0:fullName "Mohamad El Haj" ;
    ns0:hasAffiliation ns242:JAD190440,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190440> ;
    ns0:hasArticle ns1:jad-v70-i4-JAD190440 ;
    ns0:inAuthorList ns150:JAD190440 .

ns2:JAD190448 ns0:inAuthorList ns150:JAD190448 .

ns2:JAD190459 owl:sameAs ns2:JAD161023,
        ns2:JAD170990,
        ns28:JAD170410,
        ns52:JAD142337 ;
    ns0:fullName "Isabelle Rouch" ;
    ns0:hasAffiliation ns242:JAD190459,
        ns243:JAD190459 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190459 ;
    ns0:inAuthorList ns150:JAD190459 .

ns2:JAD190468 owl:sameAs ns12:JAD131343 ;
    ns0:fullName "Felicia C. Goldstein" ;
    ns0:hasAffiliation ns242:JAD190468 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190468 ;
    ns0:inAuthorList ns150:JAD190468 .

ns2:JAD190508 owl:sameAs ns8:JAD181180,
        ns12:JAD180808,
        ns12:JAD181194,
        ns30:VES190668 ;
    ns0:fullName "Karel Kostev" ;
    ns0:hasAffiliation ns242:JAD190508 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190508 ;
    ns0:inAuthorList ns150:JAD190508 .

ns2:JAD190541 owl:sameAs ns5:JAD170731 ;
    ns0:fullName "Kay Deckers" ;
    ns0:hasAffiliation ns242:JAD190541 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190541 ;
    ns0:inAuthorList ns150:JAD190541 .

ns2:JAD190725 owl:sameAs ns52:JAD150985 ;
    ns0:fullName "Meghan K. Mattos" ;
    ns0:hasAffiliation ns242:JAD190725 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190725 ;
    ns0:inAuthorList ns150:JAD190725 .

ns2:JAD190790 ns0:inAuthorList ns150:JAD190790 .

ns2:JAD190838 owl:sameAs ns2:JAD160866,
        ns52:JAD160874,
        ns60:JAD170604,
        ns33:JAD160866,
        ns33:JAD190545 ;
    ns0:fullName "Jordi A. Matías-Guiu" ;
    ns0:hasAffiliation ns242:JAD190838 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190838 ;
    ns0:inAuthorList ns150:JAD190838 .

ns2:JAD190889 ns0:inAuthorList ns150:JAD190889 .

ns2:JAE160099 ns0:inAuthorList ns150:JAE160099 .

ns2:JAE180035 ns0:inAuthorList ns150:JAE180035 .

ns2:JAE189064 ns0:inAuthorList ns150:JAE189064 .

ns2:JAE198972 owl:sameAs ns8:JAE198976 ;
    ns0:fullName "Veronica Manescu Paltanea" ;
    ns0:hasAffiliation ns242:JAE198972 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE198972 ;
    ns0:inAuthorList ns150:JAE198972 .

ns2:JAE2135 ns0:inAuthorList ns150:JAE2135 .

ns2:JAE2203 ns0:inAuthorList ns150:JAE2203 .

ns2:JBR104 ns0:inAuthorList ns150:JBR104 .

ns2:JBR180361 ns0:inAuthorList ns150:JBR180361 .

ns2:JCB15025 ns0:inAuthorList ns150:JCB15025 .

ns2:JCB179002 ns0:inAuthorList ns150:JCB179002 .

ns2:JCB179012 ns0:inAuthorList ns150:JCB179012 .

ns2:JCB189013 ns0:inAuthorList ns150:JCB189013 .

ns2:JCS171017 ns0:inAuthorList ns150:JCS171017 .

ns2:JCS555 ns0:inAuthorList ns150:JCS555 .

ns2:JHD160192 ns0:inAuthorList ns150:JHD160192 .

ns2:JHD160206 ns0:inAuthorList ns150:JHD160206 .

ns2:JHD180328 ns0:inAuthorList ns150:JHD180328 .

ns2:JHD180341 ns0:inAuthorList ns150:JHD180341 .

ns2:JHS190601 ns0:inAuthorList ns150:JHS190601 .

ns2:JHS520 ns0:inAuthorList ns150:JHS520 .

ns2:JHS541 ns0:inAuthorList ns150:JHS541 .

ns2:JIN092 ns0:inAuthorList ns150:JIN092 .

ns2:JND150122 ns0:inAuthorList ns150:JND150122 .

ns2:JND170299 ns0:inAuthorList ns150:JND170299 .

ns2:JND180315 ns0:inAuthorList ns150:JND180315 .

ns2:JND190397 ns0:inAuthorList ns150:JND190397 .

ns2:JPD140493 ns0:inAuthorList ns150:JPD140493 .

ns2:JPD150632 ns0:inAuthorList ns150:JPD150632 .

ns2:JPD150652 ns0:inAuthorList ns150:JPD150652 .

ns2:JPD160874 ns0:inAuthorList ns150:JPD160874 .

ns2:JPD160888 ns0:inAuthorList ns150:JPD160888 .

ns2:JPD171081 ns0:inAuthorList ns150:JPD171081 .

ns2:JPD171277 ns0:inAuthorList ns150:JPD171277 .

ns2:JPD171285 ns0:inAuthorList ns150:JPD171285 .

ns2:JPD181309 ns0:inAuthorList ns150:JPD181309 .

ns2:JPD181314 ns0:inAuthorList ns150:JPD181314 .

ns2:JPD181516 ns0:inAuthorList ns150:JPD181516 .

ns2:JPD181541 ns0:inAuthorList ns150:JPD181541 .

ns2:JPD191627 owl:sameAs ns8:JPD160985 ;
    ns0:fullName "Nicolaas I. Bohnen" ;
    ns0:hasAffiliation ns242:JPD191627,
        ns243:JPD191627,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JPD191627>,
        ns244:JPD191627 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191627 ;
    ns0:inAuthorList ns150:JPD191627 .

ns2:JPD191711 ns0:inAuthorList ns150:JPD191711 .

ns2:JVR191022 owl:sameAs ns8:JVR191021 ;
    ns0:fullName "Phillip D. Rumrill," ;
    ns0:hasAffiliation ns242:JVR191022 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191022 ;
    ns0:inAuthorList ns150:JVR191022 .

ns2:JVR191032 owl:sameAs ns8:JVR191043 ;
    ns0:fullName "Amanda Schlegelmilch" ;
    ns0:hasAffiliation ns242:JVR191032 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191032 ;
    ns0:inAuthorList ns150:JVR191032 .

ns2:JVR191039 owl:sameAs ns2:JVR180991,
        ns2:JVR191048 ;
    ns0:fullName "Catherine Ipsen" ;
    ns0:hasAffiliation ns242:JVR191039 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191039 ;
    ns0:inAuthorList ns150:JVR191039 .

ns2:JVR191040 ns0:inAuthorList ns150:JVR191040 .

ns2:JVR191042 ns0:inAuthorList ns150:JVR191042 .

ns2:JVR191043 ns0:inAuthorList ns150:JVR191043 .

ns2:JVR786 ns0:inAuthorList ns150:JVR786 .

ns2:JVR805 ns0:inAuthorList ns150:JVR805 .

ns2:JVR806 ns0:inAuthorList ns150:JVR806 .

ns2:JVR814 ns0:inAuthorList ns150:JVR814 .

ns2:JVR830 ns0:inAuthorList ns150:JVR830 .

ns2:JVR836 ns0:inAuthorList ns150:JVR836 .

ns2:JVR856 ns0:inAuthorList ns150:JVR856 .

ns2:JVR895 ns0:inAuthorList ns150:JVR895 .

ns2:JVR930 ns0:inAuthorList ns150:JVR930 .

ns2:JVR939 ns0:inAuthorList ns150:JVR939 .

ns2:JVR941 ns0:inAuthorList ns150:JVR941 .

ns2:JVR972 ns0:inAuthorList ns150:JVR972 .

ns2:KCA179001 ns0:inAuthorList ns150:KCA179001 .

ns2:KCA180044 ns0:inAuthorList ns150:KCA180044 .

ns2:KCA180045 ns0:inAuthorList ns150:KCA180045 .

ns2:KCA189003 ns0:inAuthorList ns150:KCA189003 .

ns2:KES180385 ns0:inAuthorList ns150:KES180385 .

ns2:KES190394 ns0:inAuthorList ns150:KES190394 .

ns2:KES337 ns0:inAuthorList ns150:KES337 .

ns2:MAS180455 ns0:inAuthorList ns150:MAS180455 .

ns2:MGC180 ns0:inAuthorList ns150:MGC180 .

ns2:MGC180682 ns0:inAuthorList ns150:MGC180682 .

ns2:MGC180688 ns0:inAuthorList ns150:MGC180688 .

ns2:MGC180760 ns0:inAuthorList ns150:MGC180760 .

ns2:MGC180761 owl:sameAs ns2:MGC246,
        ns2:MGC255 ;
    ns0:fullName "Panayiotis V. Ioannou" ;
    ns0:hasAffiliation ns242:MGC180761 ;
    ns0:hasArticle ns1:mgc-v18-i4-MGC180761 ;
    ns0:inAuthorList ns150:MGC180761 .

ns2:MGC218 ns0:inAuthorList ns150:MGC218 .

ns2:MGC231 ns0:inAuthorList ns150:MGC231 .

ns2:MGS284 ns0:inAuthorList ns150:MGS284 .

ns2:MNM180249 ns0:inAuthorList ns150:MNM180249 .

ns2:NHA170023 ns0:inAuthorList ns150:NHA170023 .

ns2:NHA170035 ns0:inAuthorList ns150:NHA170035 .

ns2:NHA180042 ns0:inAuthorList ns150:NHA180042 .

ns2:NPM1610 ns0:inAuthorList ns150:NPM1610 .

ns2:NPM1686 ns0:inAuthorList ns150:NPM1686 .

ns2:NPM17125 ns0:inAuthorList ns150:NPM17125 .

ns2:NPM17133 ns0:inAuthorList ns150:NPM17133 .

ns2:NPM17145 ns0:inAuthorList ns150:NPM17145 .

ns2:NPM1741 ns0:inAuthorList ns150:NPM1741 .

ns2:NPM1786 ns0:inAuthorList ns150:NPM1786 .

ns2:NPM1792 ns0:inAuthorList ns150:NPM1792 .

ns2:NRE1413 ns0:inAuthorList ns150:NRE1413 .

ns2:NRE1475 ns0:inAuthorList ns150:NRE1475 .

ns2:NRE172238 ns0:inAuthorList ns150:NRE172238 .

ns2:NRE172351 ns0:inAuthorList ns150:NRE172351 .

ns2:NRE182565 ns0:inAuthorList ns150:NRE182565 .

ns2:NRE189009 ns0:inAuthorList ns150:NRE189009 .

ns2:NRE192754 ns0:inAuthorList ns150:NRE192754 .

ns2:NRE192771 ns0:inAuthorList ns150:NRE192771 .

ns2:PPR180122 ns0:inAuthorList ns150:PPR180122 .

ns2:PRM362 ns0:inAuthorList ns150:PRM362 .

ns2:PRM435 ns0:inAuthorList ns150:PRM435 .

ns2:RED131204 ns0:inAuthorList ns150:RED131204 .

ns2:RNN160661 ns0:inAuthorList ns150:RNN160661 .

ns2:RNN170790 ns0:inAuthorList ns150:RNN170790 .

ns2:RNN180812 ns0:inAuthorList ns150:RNN180812 .

ns2:SW190348 ns0:inAuthorList ns150:SW190348 .

ns2:SW303 ns0:inAuthorList ns150:SW303 .

<http://ld.iospress.nl/rdf/contributor/Author:0.ID:TAD5(3-4)14> ns0:inAuthorList <http://ld.iospress.nl/rdf/contributor/List.Role:authors.ID:TAD5(3-4)14> .

ns2:THC1290 ns0:inAuthorList ns150:THC1290 .

ns2:THC160474 ns0:inAuthorList ns150:THC160474 .

ns2:THC171064 ns0:inAuthorList ns150:THC171064 .

ns2:THC174526 ns0:inAuthorList ns150:THC174526 .

ns2:THC199006 ns0:inAuthorList ns150:THC199006 .

ns2:THC199031 ns0:inAuthorList ns150:THC199031 .

ns2:VES589 ns0:inAuthorList ns150:VES589 .

ns2:WEB190407 ns0:inAuthorList ns150:WEB190407 .

ns2:WEB333 ns0:inAuthorList ns150:WEB333 .

ns2:WOR182792 ns0:inAuthorList ns150:WOR182792 .

ns2:WOR182824 ns0:inAuthorList ns150:WOR182824 .

ns2:WOR192919 ns0:inAuthorList ns150:WOR192919 .

ns2:WOR192932 ns0:inAuthorList ns150:WOR192932 .

ns2:WOR192936 ns0:inAuthorList ns150:WOR192936 .

ns2:WOR192942 ns0:inAuthorList ns150:WOR192942 .

ns2:WOR192953 ns0:inAuthorList ns150:WOR192953 .

ns2:WOR192964 ns0:inAuthorList ns150:WOR192964 .

ns2:WOR192968 owl:sameAs ns2:WOR2661 ;
    ns0:fullName "Deokhoon Jun" ;
    ns0:hasAffiliation ns242:WOR192968,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:0.ID:WOR192968> ;
    ns0:hasArticle ns1:wor-v64-i1-WOR192968 ;
    ns0:inAuthorList ns150:WOR192968 .

ns2:WOR192992 ns0:inAuthorList ns150:WOR192992 .

ns2:WOR192997 owl:sameAs ns2:WOR192857 ;
    ns0:fullName "Mogammad Shaheed Soeker" ;
    ns0:hasAffiliation ns242:WOR192997 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192997 ;
    ns0:inAuthorList ns150:WOR192997 .

ns2:WOR193011 owl:sameAs ns8:JVR180997 ;
    ns0:fullName "Annika Lexén" ;
    ns0:hasAffiliation ns242:WOR193011 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193011 ;
    ns0:inAuthorList ns150:WOR193011 .

ns2:WOR2010 ns0:inAuthorList ns150:WOR2010 .

ns2:WOR2203 ns0:inAuthorList ns150:WOR2203 .

ns2:WOR2206 ns0:inAuthorList ns150:WOR2206 .

ns2:WOR2301 ns0:inAuthorList ns150:WOR2301 .

ns2:WOR2318 ns0:inAuthorList ns150:WOR2318 .

ns2:WOR2379 ns0:inAuthorList ns150:WOR2379 .

ns2:WOR2425 ns0:inAuthorList ns150:WOR2425 .

ns2:WOR2508 ns0:inAuthorList ns150:WOR2508 .

ns2:WOR2522 ns0:inAuthorList ns150:WOR2522 .

ns2:WOR2590 ns0:inAuthorList ns150:WOR2590 .

ns2:WOR2603 ns0:inAuthorList ns150:WOR2603 .

ns2:WOR2643 ns0:inAuthorList ns150:WOR2643 .

ns2:WOR2674 ns0:inAuthorList ns150:WOR2674 .

ns2:WOR2737 ns0:inAuthorList ns150:WOR2737 .

ns2:XST180397 ns0:inAuthorList ns150:XST180397 .

ns2:XST180427 ns0:inAuthorList ns150:XST180427 .

ns2:XST180430 ns0:inAuthorList ns150:XST180430 .

ns2:XST180443 ns0:inAuthorList ns150:XST180443 .

ns2:XST180457 ns0:inAuthorList ns150:XST180457 .

ns2:XST18377 ns0:inAuthorList ns150:XST18377 .

ns2:XST495 ns0:inAuthorList ns150:XST495 .

ns2:XST502 ns0:inAuthorList ns150:XST502 .

ns2:XST598 ns0:inAuthorList ns150:XST598 .

ns2:ajw190007 ns0:inAuthorList ns150:ajw190007 .

ns2:ajw190052 ns0:inAuthorList ns150:ajw190052 .

ns2:bd000362 ns0:inAuthorList ns150:bd000362 .

ns2:bd000365 ns0:inAuthorList ns150:bd000365 .

ns2:bmr00062 ns0:inAuthorList ns150:bmr00062 .

ns2:bmr00184 ns0:inAuthorList ns150:bmr00184 .

ns2:cbm00108 ns0:inAuthorList ns150:cbm00108 .

ns2:hab00171 ns0:inAuthorList ns150:hab00171 .

ns2:hab00271 ns0:inAuthorList ns150:hab00271 .

ns2:ica00369 ns0:inAuthorList ns150:ica00369 .

ns2:ida00034 ns0:inAuthorList ns150:ida00034 .

ns2:ida00193 ns0:inAuthorList ns150:ida00193 .

ns2:ida00212 ns0:inAuthorList ns150:ida00212 .

ns2:ida00215 ns0:inAuthorList ns150:ida00215 .

ns2:ida00229 ns0:inAuthorList ns150:ida00229 .

ns2:ida00234 ns0:inAuthorList ns150:ida00234 .

ns2:ida00270 ns0:inAuthorList ns150:ida00270 .

ns2:ida00285 ns0:inAuthorList ns150:ida00285 .

ns2:ida00326 ns0:inAuthorList ns150:ida00326 .

ns2:ida00372 ns0:inAuthorList ns150:ida00372 .

ns2:ida00409 ns0:inAuthorList ns150:ida00409 .

ns2:ida00582 ns0:inAuthorList ns150:ida00582 .

ns2:ida00641 ns0:inAuthorList ns150:ida00641 .

ns2:isu448 ns0:inAuthorList ns150:isu448 .

ns2:isu465 ns0:inAuthorList ns150:isu465 .

ns2:jad00072 ns0:inAuthorList ns150:jad00072 .

ns2:jad00098 ns0:inAuthorList ns150:jad00098 .

ns2:jad00110 ns0:inAuthorList ns150:jad00110 .

ns2:jad00175 ns0:inAuthorList ns150:jad00175 .

ns2:jad00225 ns0:inAuthorList ns150:jad00225 .

ns2:jad00269 ns0:inAuthorList ns150:jad00269 .

ns2:jad00307 ns0:inAuthorList ns150:jad00307 .

ns2:jad00404 ns0:inAuthorList ns150:jad00404 .

ns2:jad00418 ns0:inAuthorList ns150:jad00418 .

ns2:jad00419 ns0:inAuthorList ns150:jad00419 .

ns2:jad00445 ns0:inAuthorList ns150:jad00445 .

ns2:jad00454 ns0:inAuthorList ns150:jad00454 .

ns2:jad00490 ns0:inAuthorList ns150:jad00490 .

ns2:jad00530 ns0:inAuthorList ns150:jad00530 .

ns2:jad00710 ns0:inAuthorList ns150:jad00710 .

ns2:jad00741 ns0:inAuthorList ns150:jad00741 .

ns2:jad00768 ns0:inAuthorList ns150:jad00768 .

ns2:jad00773 ns0:inAuthorList ns150:jad00773 .

ns2:jad00799 ns0:inAuthorList ns150:jad00799 .

ns2:jad00804 ns0:inAuthorList ns150:jad00804 .

ns2:jad00869 ns0:inAuthorList ns150:jad00869 .

ns2:jad00890 ns0:inAuthorList ns150:jad00890 .

ns2:jad00906 ns0:inAuthorList ns150:jad00906 .

ns2:jad00926 ns0:inAuthorList ns150:jad00926 .

ns2:jad01033 ns0:inAuthorList ns150:jad01033 .

ns2:jad01094 ns0:inAuthorList ns150:jad01094 .

ns2:jad01117 ns0:inAuthorList ns150:jad01117 .

ns2:jad01133 ns0:inAuthorList ns150:jad01133 .

ns2:jad01151 ns0:inAuthorList ns150:jad01151 .

ns2:jad01154 ns0:inAuthorList ns150:jad01154 .

ns2:jad01182 ns0:inAuthorList ns150:jad01182 .

ns2:jad01196 ns0:inAuthorList ns150:jad01196 .

ns2:jad01199 ns0:inAuthorList ns150:jad01199 .

ns2:jad01225 ns0:inAuthorList ns150:jad01225 .

ns2:jad01227 ns0:inAuthorList ns150:jad01227 .

ns2:jad01245 ns0:inAuthorList ns150:jad01245 .

ns2:jad01306 ns0:inAuthorList ns150:jad01306 .

ns2:jad01391 ns0:inAuthorList ns150:jad01391 .

ns2:jad091603 ns0:inAuthorList ns150:jad091603 .

ns2:jad100012 ns0:inAuthorList ns150:jad100012 .

ns2:jad100459 ns0:inAuthorList ns150:jad100459 .

ns2:jad100573 ns0:inAuthorList ns150:jad100573 .

ns2:jad101350 ns0:inAuthorList ns150:jad101350 .

ns2:jcs340 ns0:inAuthorList ns150:jcs340 .

ns2:jcs440 ns0:inAuthorList ns150:jcs440 .

ns2:kes00048 ns0:inAuthorList ns150:kes00048 .

ns2:kes00297 ns0:inAuthorList ns150:kes00297 .

ns2:mas00255 ns0:inAuthorList ns150:mas00255 .

ns2:mgs00009 ns0:inAuthorList ns150:mgs00009 .

ns2:mgs00071 ns0:inAuthorList ns150:mgs00071 .

ns2:mgs00109 ns0:inAuthorList ns150:mgs00109 .

ns2:tad00068 ns0:inAuthorList ns150:tad00068 .

ns2:wdl11105 ns0:inAuthorList ns150:wdl11105 .

ns8:AAC004 ns0:inAuthorList ns150:AAC004 .

ns8:AAC180425 ns0:inAuthorList ns150:AAC180425 .

ns8:ADR180091 ns0:inAuthorList ns150:ADR180091 .

ns8:AF180258 ns0:inAuthorList ns150:AF180258 .

ns8:AIC701 ns0:inAuthorList ns150:AIC701 .

ns8:AIC725 ns0:inAuthorList ns150:AIC725 .

ns8:AIC746 ns0:inAuthorList ns150:AIC746 .

ns8:AIS180509 ns0:inAuthorList ns150:AIS180509 .

ns8:AIS190524 ns0:inAuthorList ns150:AIS190524 .

ns8:AIS323 ns0:inAuthorList ns150:AIS323 .

ns8:AIS412 ns0:inAuthorList ns150:AIS412 .

ns8:AO193 ns0:inAuthorList ns150:AO193 .

ns8:AOP047 ns0:inAuthorList ns150:AOP047 .

ns8:ASY1348 ns0:inAuthorList ns150:ASY1348 .

ns8:ASY191520 ns0:inAuthorList ns150:ASY191520 .

ns8:BIR14030 ns0:inAuthorList ns150:BIR14030 .

ns8:BIR180175 ns0:inAuthorList ns150:BIR180175 .

ns8:BLC170118 ns0:inAuthorList ns150:BLC170118 .

ns8:BLC170149 ns0:inAuthorList ns150:BLC170149 .

ns8:BLC179017 ns0:inAuthorList ns150:BLC179017 .

ns8:BLC179021 ns0:inAuthorList ns150:BLC179021 .

ns8:BLC180167 ns0:inAuthorList ns150:BLC180167 .

ns8:BME1336 ns0:inAuthorList ns150:BME1336 .

ns8:BME1467 ns0:inAuthorList ns150:BME1467 .

ns8:BME1672 ns0:inAuthorList ns150:BME1672 .

ns8:BME1709 ns0:inAuthorList ns150:BME1709 .

ns8:BME1732 ns0:inAuthorList ns150:BME1732 .

ns8:BMR169588 ns0:inAuthorList ns150:BMR169588 .

ns8:BMR181128 ns0:inAuthorList ns150:BMR181128 .

ns8:BMR181236 owl:sameAs ns30:BD264 ;
    ns0:fullName "Javad Sarrafzadeh" ;
    ns0:hasAffiliation ns25:BMR181236 ;
    ns0:hasArticle ns1:bmr-v32-i6-BMR181236 ;
    ns0:inAuthorList ns150:BMR181236 .

ns8:BMR181362 ns0:inAuthorList ns150:BMR181362 .

ns8:BMR181448 owl:sameAs ns16:bmr00519 ;
    ns0:fullName "Levent Özçakar" ;
    ns0:hasAffiliation ns25:BMR181448 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR181448 ;
    ns0:inAuthorList ns150:BMR181448 .

ns8:BMR540 ns0:inAuthorList ns150:BMR540 .

ns8:BPL180067 ns0:inAuthorList ns150:BPL180067 .

ns8:BPL180071 ns0:inAuthorList ns150:BPL180071 .

ns8:BRS190144 ns0:inAuthorList ns150:BRS190144 .

ns8:BSI183 ns0:inAuthorList ns150:BSI183 .

ns8:CBM160512 ns0:inAuthorList ns150:CBM160512 .

ns8:CBM160533 ns0:inAuthorList ns150:CBM160533 .

ns8:CBM170472 ns0:inAuthorList ns150:CBM170472 .

ns8:CBM181772 ns0:inAuthorList ns150:CBM181772 .

ns8:CBM182165 ns0:inAuthorList ns150:CBM182165 .

ns8:CH16163 ns0:inAuthorList ns150:CH16163 .

ns8:CH168016 ns0:inAuthorList ns150:CH168016 .

ns8:CH168033 ns0:inAuthorList ns150:CH168033 .

ns8:CH168110 ns0:inAuthorList ns150:CH168110 .

ns8:CH170266 ns0:inAuthorList ns150:CH170266 .

ns8:CH179100 ns0:inAuthorList ns150:CH179100 .

ns8:CH180449 ns0:inAuthorList ns150:CH180449 .

ns8:CH180457 ns0:inAuthorList ns150:CH180457 .

ns8:CH189115 ns0:inAuthorList ns150:CH189115 .

ns8:CH189116 ns0:inAuthorList ns150:CH189116 .

ns8:CH189125 ns0:inAuthorList ns150:CH189125 .

ns8:CH189126 ns0:inAuthorList ns150:CH189126 .

ns8:CH189131 ns0:inAuthorList ns150:CH189131 .

ns8:CH189303 ns0:inAuthorList ns150:CH189303 .

ns8:CH189310 ns0:inAuthorList ns150:CH189310 .

ns8:CH189405 ns0:inAuthorList ns150:CH189405 .

ns8:CH189407 ns0:inAuthorList ns150:CH189407 .

ns8:CH189902 ns0:inAuthorList ns150:CH189902 .

ns8:CH189904 ns0:inAuthorList ns150:CH189904 .

ns8:CH199005 owl:sameAs ns2:CH179210,
        ns5:CH199206 ;
    ns0:fullName "Jie Zou" ;
    ns0:hasAffiliation ns24:CH199005,
        ns25:CH199005 ;
    ns0:hasArticle ns1:ch-v71-i4-CH199005 ;
    ns0:inAuthorList ns150:CH199005 .

ns8:CH199206 owl:sameAs ns2:CH199201 ;
    ns0:fullName "Wingtai Tung" ;
    ns0:hasAffiliation ns24:CH199206 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199206 ;
    ns0:inAuthorList ns150:CH199206 .

ns8:CH199217 ns0:inAuthorList ns150:CH199217 .

ns8:CH199221 owl:sameAs ns30:CH1962,
        ns5:CH189323,
        ns5:CH189415,
        ns16:CH168044,
        ns16:CH189324 ;
    ns0:fullName "C. Stroszczynski" ;
    ns0:hasAffiliation ns24:CH199221 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199221 ;
    ns0:inAuthorList ns150:CH199221 .

ns8:CH199222 owl:sameAs ns30:CH189407 ;
    ns0:fullName "M. Chaloupka" ;
    ns0:hasAffiliation ns24:CH199222 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199222 ;
    ns0:inAuthorList ns150:CH199222 .

ns8:CH199225 owl:sameAs ns2:CH2049,
        ns12:CH170265,
        ns12:CH179224,
        ns5:CH189309,
        ns5:CH189905 ;
    ns0:fullName "Christian D. Taeger" ;
    ns0:hasAffiliation ns24:CH199225 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199225 ;
    ns0:inAuthorList ns150:CH199225 .

ns8:CH2005 ns0:inAuthorList ns150:CH2005 .

ns8:COM180103 ns0:inAuthorList ns150:COM180103 .

ns8:DEV189003 ns0:inAuthorList ns150:DEV189003 .

ns8:DS190023 owl:sameAs ns2:DS190019 ;
    ns0:fullName "Francesco Osborne" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:DS190023> ;
    ns0:hasArticle ns1:ds-v2-i1-2-DS190023 ;
    ns0:inAuthorList ns150:DS190023 .

ns8:EFI190290 ns0:inAuthorList ns150:EFI190290 .

ns8:FI1324 ns0:inAuthorList ns150:FI1324 .

ns8:FI1395 ns0:inAuthorList ns150:FI1395 .

ns8:FI1419 ns0:inAuthorList ns150:FI1419 .

ns8:FI1522 ns0:inAuthorList ns150:FI1522 .

ns8:FI1528 ns0:inAuthorList ns150:FI1528 .

ns8:FI1562 ns0:inAuthorList ns150:FI1562 .

ns8:FI1565 ns0:inAuthorList ns150:FI1565 .

ns8:FI1566 ns0:inAuthorList ns150:FI1566 .

ns8:FI1573 ns0:inAuthorList ns150:FI1573 .

ns8:FI1574 ns0:inAuthorList ns150:FI1574 .

ns8:FI1583 ns0:inAuthorList ns150:FI1583 .

ns8:FI1699 ns0:inAuthorList ns150:FI1699 .

ns8:FI1703 ns0:inAuthorList ns150:FI1703 .

ns8:FI1708 ns0:inAuthorList ns150:FI1708 .

ns8:FI1711 ns0:inAuthorList ns150:FI1711 .

ns8:FI1810 ns0:inAuthorList ns150:FI1810 .

ns8:FI1832 ns0:inAuthorList ns150:FI1832 .

ns8:FI1838 owl:sameAs ns8:FI1567,
        ns8:FI1820,
        ns12:FI1574 ;
    ns0:fullName "Maciej Koutny" ;
    ns0:hasAffiliation ns25:FI1838 ;
    ns0:hasArticle ns1:fi-v169-i1-2-FI1838 ;
    ns0:inAuthorList ns150:FI1838 .

ns8:FI1872 ns0:inAuthorList ns150:FI1872 .

ns8:HAB190364 owl:sameAs ns30:HAB304 ;
    ns0:fullName "Gosaye Degu Belay" ;
    ns0:hasAffiliation ns24:HAB190364,
        ns25:HAB190364 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190364 ;
    ns0:inAuthorList ns150:HAB190364 .

ns8:HAB190379 owl:sameAs ns2:HAB180360,
        ns8:HAB190386,
        ns52:HAB282 ;
    ns0:fullName "Osaro Erhabor" ;
    ns0:hasAffiliation ns25:HAB190379 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190379 ;
    ns0:inAuthorList ns150:HAB190379 .

ns8:HAB292 ns0:inAuthorList ns150:HAB292 .

ns8:HAB296 ns0:inAuthorList ns150:HAB296 .

ns8:HAB297 ns0:inAuthorList ns150:HAB297 .

ns8:HAB334 ns0:inAuthorList ns150:HAB334 .

ns8:HAB342 ns0:inAuthorList ns150:HAB342 .

ns8:HIS180258 ns0:inAuthorList ns150:HIS180258 .

ns8:HIS220 ns0:inAuthorList ns150:HIS220 .

ns8:HIS252 ns0:inAuthorList ns150:HIS252 .

ns8:HSM17101 ns0:inAuthorList ns150:HSM17101 .

ns8:HSM17229 ns0:inAuthorList ns150:HSM17229 .

ns8:HSM1768 ns0:inAuthorList ns150:HSM1768 .

ns8:HSM180385 ns0:inAuthorList ns150:HSM180385 .

ns8:HSM180405 ns0:inAuthorList ns150:HSM180405 .

ns8:HSM180425 ns0:inAuthorList ns150:HSM180425 .

ns8:HSM190486 ns0:inAuthorList ns150:HSM190486 .

ns8:IA082 ns0:inAuthorList ns150:IA082 .

ns8:IA102 ns0:inAuthorList ns150:IA102 .

ns8:IA106 ns0:inAuthorList ns150:IA106 .

ns8:IA110 ns0:inAuthorList ns150:IA110 .

ns8:ICA00047 ns0:inAuthorList ns150:ICA00047 .

<http://ld.iospress.nl/rdf/contributor/Author:1.ID:IDA1(1)04> ns0:inAuthorList <http://ld.iospress.nl/rdf/contributor/List.Role:authors.ID:IDA1(1)04> .

<http://ld.iospress.nl/rdf/contributor/Author:1.ID:IDA1(4)05> ns0:inAuthorList <http://ld.iospress.nl/rdf/contributor/List.Role:authors.ID:IDA1(4)05> .

ns8:IDA184183 owl:sameAs ns8:IDA173589,
        ns8:IDA183918 ;
    ns0:fullName "Yonglong Luo" ;
    ns0:hasAffiliation ns24:IDA184183,
        ns25:IDA184183,
        ns90:IDA184183 ;
    ns0:hasArticle ns1:ida-v23-i5-IDA184183 ;
    ns0:inAuthorList ns150:IDA184183 .

ns8:IDA192829 ns0:inAuthorList ns150:IDA192829 .

ns8:IDA814 ns0:inAuthorList ns150:IDA814 .

ns8:IDT180346 ns0:inAuthorList ns150:IDT180346 .

ns8:IDT180349 ns0:inAuthorList ns150:IDT180349 .

ns8:IDT314 ns0:inAuthorList ns150:IDT314 .

ns8:IES182156 ns0:inAuthorList ns150:IES182156 .

ns8:IES182177 ns0:inAuthorList ns150:IES182177 .

ns8:IES192150 ns0:inAuthorList ns150:IES192150 .

ns8:IES211162 ns0:inAuthorList ns150:IES211162 .

ns8:IES656 ns0:inAuthorList ns150:IES656 .

ns8:IFS141907 ns0:inAuthorList ns150:IFS141907 .

ns8:IFS151050 ns0:inAuthorList ns150:IFS151050 .

ns8:IFS151940 ns0:inAuthorList ns150:IFS151940 .

ns8:IFS152261 ns0:inAuthorList ns150:IFS152261 .

ns8:IFS152381 ns0:inAuthorList ns150:IFS152381 .

ns8:IFS161695 ns0:inAuthorList ns150:IFS161695 .

ns8:IFS161836 ns0:inAuthorList ns150:IFS161836 .

ns8:IFS162013 ns0:inAuthorList ns150:IFS162013 .

ns8:IFS162150 ns0:inAuthorList ns150:IFS162150 .

ns8:IFS162175 ns0:inAuthorList ns150:IFS162175 .

ns8:IFS16232 ns0:inAuthorList ns150:IFS16232 .

ns8:IFS162403 ns0:inAuthorList ns150:IFS162403 .

ns8:IFS16357 ns0:inAuthorList ns150:IFS16357 .

ns8:IFS16419 ns0:inAuthorList ns150:IFS16419 .

ns8:IFS16557 ns0:inAuthorList ns150:IFS16557 .

ns8:IFS1665 ns0:inAuthorList ns150:IFS1665 .

ns8:IFS1682 ns0:inAuthorList ns150:IFS1682 .

ns8:IFS16920 ns0:inAuthorList ns150:IFS16920 .

ns8:IFS169366 ns0:inAuthorList ns150:IFS169366 .

ns8:IFS169390 ns0:inAuthorList ns150:IFS169390 .

ns8:IFS169415 ns0:inAuthorList ns150:IFS169415 .

ns8:IFS169572 ns0:inAuthorList ns150:IFS169572 .

ns8:IFS169608 ns0:inAuthorList ns150:IFS169608 .

ns8:IFS169811 ns0:inAuthorList ns150:IFS169811 .

ns8:IFS1699 ns0:inAuthorList ns150:IFS1699 .

ns8:IFS169934 ns0:inAuthorList ns150:IFS169934 .

ns8:IFS169951 ns0:inAuthorList ns150:IFS169951 .

ns8:IFS169963 ns0:inAuthorList ns150:IFS169963 .

ns8:IFS17077 ns0:inAuthorList ns150:IFS17077 .

ns8:IFS17104 ns0:inAuthorList ns150:IFS17104 .

ns8:IFS171060 ns0:inAuthorList ns150:IFS171060 .

ns8:IFS171118 ns0:inAuthorList ns150:IFS171118 .

ns8:IFS171145 ns0:inAuthorList ns150:IFS171145 .

ns8:IFS171172 ns0:inAuthorList ns150:IFS171172 .

ns8:IFS171203 ns0:inAuthorList ns150:IFS171203 .

ns8:IFS171365 ns0:inAuthorList ns150:IFS171365 .

ns8:IFS171395 ns0:inAuthorList ns150:IFS171395 .

ns8:IFS171587 ns0:inAuthorList ns150:IFS171587 .

ns8:IFS171652 ns0:inAuthorList ns150:IFS171652 .

ns8:IFS171685 ns0:inAuthorList ns150:IFS171685 .

ns8:IFS171741 ns0:inAuthorList ns150:IFS171741 .

ns8:IFS17175 ns0:inAuthorList ns150:IFS17175 .

ns8:IFS171907 ns0:inAuthorList ns150:IFS171907 .

ns8:IFS171927 owl:sameAs ns8:IFS1657,
        ns8:IFS181330 ;
    ns0:fullName "Homayun Motameni" ;
    ns0:hasAffiliation ns24:IFS171927 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS171927 ;
    ns0:inAuthorList ns150:IFS171927 .

ns8:IFS171953 ns0:inAuthorList ns150:IFS171953 .

ns8:IFS171980 ns0:inAuthorList ns150:IFS171980 .

ns8:IFS172121 ns0:inAuthorList ns150:IFS172121 .

ns8:IFS172130 ns0:inAuthorList ns150:IFS172130 .

ns8:IFS172252 ns0:inAuthorList ns150:IFS172252 .

ns8:IFS172282 ns0:inAuthorList ns150:IFS172282 .

ns8:IFS172303 ns0:inAuthorList ns150:IFS172303 .

ns8:IFS17301 ns0:inAuthorList ns150:IFS17301 .

ns8:IFS17319 ns0:inAuthorList ns150:IFS17319 .

ns8:IFS17488 ns0:inAuthorList ns150:IFS17488 .

ns8:IFS1773 ns0:inAuthorList ns150:IFS1773 .

ns8:IFS17758 ns0:inAuthorList ns150:IFS17758 .

ns8:IFS17763 ns0:inAuthorList ns150:IFS17763 .

ns8:IFS1781 ns0:inAuthorList ns150:IFS1781 .

ns8:IFS17821 ns0:inAuthorList ns150:IFS17821 .

ns8:IFS17848 ns0:inAuthorList ns150:IFS17848 .

ns8:IFS179069 ns0:inAuthorList ns150:IFS179069 .

ns8:IFS179088 ns0:inAuthorList ns150:IFS179088 .

ns8:IFS179121 owl:sameAs ns8:IFS179057,
        ns5:IFS179095 ;
    ns0:fullName "Mohamed Elhoseny" ;
    ns0:hasAffiliation ns25:IFS179121 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS179121 ;
    ns0:inAuthorList ns150:IFS179121 .

ns8:IFS179145 owl:sameAs ns12:his00158 ;
    ns0:fullName "Durbadal Mandal" ;
    ns0:hasAffiliation ns25:IFS179145 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS179145 ;
    ns0:inAuthorList ns150:IFS179145 .

ns8:IFS179199 ns0:inAuthorList ns150:IFS179199 .

ns8:IFS179236 ns0:inAuthorList ns150:IFS179236 .

ns8:IFS179240 owl:sameAs ns2:FI1669,
        ns2:IFS172262,
        ns2:IFS18266,
        ns8:IFS179235 ;
    ns0:fullName "Hui Gao" ;
    ns0:hasAffiliation ns25:IFS179240 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179240 ;
    ns0:inAuthorList ns150:IFS179240 .

ns8:IFS179241 owl:sameAs ns2:IFS16554,
        ns2:IFS16946,
        ns8:IFS18266,
        ns12:IFS179235 ;
    ns0:fullName "Mao Lu" ;
    ns0:hasAffiliation ns25:IFS179241 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179241 ;
    ns0:inAuthorList ns150:IFS179241 .

ns8:IFS1793 ns0:inAuthorList ns150:IFS1793 .

ns8:IFS1798 ns0:inAuthorList ns150:IFS1798 .

ns8:IFS181039 ns0:inAuthorList ns150:IFS181039 .

ns8:IFS181094 ns0:inAuthorList ns150:IFS181094 .

ns8:IFS181098 ns0:inAuthorList ns150:IFS181098 .

ns8:IFS181122 ns0:inAuthorList ns150:IFS181122 .

ns8:IFS181123 ns0:inAuthorList ns150:IFS181123 .

ns8:IFS181171 ns0:inAuthorList ns150:IFS181171 .

ns8:IFS181218 ns0:inAuthorList ns150:IFS181218 .

ns8:IFS18125 ns0:inAuthorList ns150:IFS18125 .

ns8:IFS181262 ns0:inAuthorList ns150:IFS181262 .

ns8:IFS181296 ns0:inAuthorList ns150:IFS181296 .

ns8:IFS181460 owl:sameAs ns8:THC1227 ;
    ns0:fullName "Tariq Mahmood" ;
    ns0:hasAffiliation ns25:IFS181460 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181460 ;
    ns0:inAuthorList ns150:IFS181460 .

ns8:IFS181467 ns0:inAuthorList ns150:IFS181467 .

ns8:IFS181504 ns0:inAuthorList ns150:IFS181504 .

ns8:IFS181547 owl:sameAs ns8:IFS181040,
        ns8:IFS181541 ;
    ns0:fullName "Amit Kumar" ;
    ns0:hasAffiliation ns24:IFS181547 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181547 ;
    ns0:inAuthorList ns150:IFS181547 .

ns8:IFS181648 ns0:inAuthorList ns150:IFS181648 .

ns8:IFS181649 ns0:inAuthorList ns150:IFS181649 .

ns8:IFS18169 ns0:inAuthorList ns150:IFS18169 .

ns8:IFS181703 ns0:inAuthorList ns150:IFS181703 .

ns8:IFS181754 ns0:inAuthorList ns150:IFS181754 .

ns8:IFS181762 ns0:inAuthorList ns150:IFS181762 .

ns8:IFS181980 owl:sameAs ns8:IFS162299,
        ns8:IFS17595,
        ns8:IFS2125 ;
    ns0:fullName "Deng-Feng Li" ;
    ns0:hasAffiliation ns25:IFS181980 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS181980 ;
    ns0:inAuthorList ns150:IFS181980 .

ns8:IFS1824 ns0:inAuthorList ns150:IFS1824 .

ns8:IFS182595 owl:sameAs ns2:IFS181296,
        ns8:IFS17850 ;
    ns0:fullName "Muhammad Gulistan" ;
    ns0:hasAffiliation ns24:IFS182595 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS182595 ;
    ns0:inAuthorList ns150:IFS182595 .

ns8:IFS182671 owl:sameAs ns30:IFS181291 ;
    ns0:fullName "Radko Mesiar" ;
    ns0:hasAffiliation ns25:IFS182671 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182671 ;
    ns0:inAuthorList ns150:IFS182671 .

ns8:IFS182746 owl:sameAs ns8:IFS2075,
        ns8:IFS2082,
        ns8:IFS2110,
        ns8:IFS2114,
        ns8:IFS2121,
        ns12:IFS171060 ;
    ns0:fullName "Hossein Rashmanlou" ;
    ns0:hasAffiliation ns25:IFS182746,
        ns90:IFS182746 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182746 ;
    ns0:inAuthorList ns150:IFS182746 .

ns8:IFS182751 ns0:inAuthorList ns150:IFS182751 .

ns8:IFS182810 ns0:inAuthorList ns150:IFS182810 .

ns8:IFS182863 owl:sameAs ns2:IFS152405,
        ns2:IFS181657,
        ns2:IFS181698,
        ns8:IFS18604,
        ns12:IFS190952 ;
    ns0:fullName "Truong Vinh An" ;
    ns0:hasAffiliation ns25:IFS182863 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182863 ;
    ns0:inAuthorList ns150:IFS182863 .

ns8:IFS182893 ns0:inAuthorList ns150:IFS182893 .

ns8:IFS182924 ns0:inAuthorList ns150:IFS182924 .

ns8:IFS182928 owl:sameAs ns8:IFS162058,
        ns30:IFS181460 ;
    ns0:fullName "Muhammad Izhar" ;
    ns0:hasAffiliation ns24:IFS182928 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182928 ;
    ns0:inAuthorList ns150:IFS182928 .

ns8:IFS182951 owl:sameAs ns8:IFS151652,
        ns8:IFS162007,
        ns8:IFS16797,
        ns8:IFS172009,
        ns8:IFS17811,
        ns8:IFS181329,
        ns8:IFS181516,
        ns8:JIN092,
        ns12:IFS171049,
        ns12:IFS171567,
        ns12:IFS181922 ;
    ns0:fullName "Saleem Abdullah" ;
    ns0:hasAffiliation ns25:IFS182951 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182951 ;
    ns0:inAuthorList ns150:IFS182951 .

ns8:IFS182961 owl:sameAs ns8:IFS171176,
        ns8:IFS171187,
        ns8:IFS181488,
        ns8:IFS2113,
        ns12:IFS172195,
        ns12:IFS181452,
        ns30:IFS18877,
        ns30:IFS2114,
        ns30:IFS2121,
        ns5:IFS171685,
        ns5:IFS18347 ;
    ns0:fullName "Madhumangal Pal" ;
    ns0:hasAffiliation ns25:IFS182961 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182961 ;
    ns0:inAuthorList ns150:IFS182961 .

ns8:IFS18331 ns0:inAuthorList ns150:IFS18331 .

ns8:IFS1848 ns0:inAuthorList ns150:IFS1848 .

ns8:IFS18567 ns0:inAuthorList ns150:IFS18567 .

ns8:IFS18568 ns0:inAuthorList ns150:IFS18568 .

ns8:IFS18577 ns0:inAuthorList ns150:IFS18577 .

ns8:IFS18607 ns0:inAuthorList ns150:IFS18607 .

ns8:IFS18730 ns0:inAuthorList ns150:IFS18730 .

ns8:IFS18746 ns0:inAuthorList ns150:IFS18746 .

ns8:IFS1884 ns0:inAuthorList ns150:IFS1884 .

ns8:IFS1889 ns0:inAuthorList ns150:IFS1889 .

ns8:IFS18891 ns0:inAuthorList ns150:IFS18891 .

ns8:IFS18943 ns0:inAuthorList ns150:IFS18943 .

ns8:IFS190447 owl:sameAs ns2:IFS191197,
        ns12:IFS18757 ;
    ns0:fullName "Noor Rehman" ;
    ns0:hasAffiliation ns25:IFS190447 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190447 ;
    ns0:inAuthorList ns150:IFS190447 .

ns8:IFS190550 ns0:inAuthorList ns150:IFS190550 .

ns8:IFS190595 owl:sameAs ns2:IFS18961 ;
    ns0:fullName "Hua Ke" ;
    ns0:hasAffiliation ns24:IFS190595 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190595 ;
    ns0:inAuthorList ns150:IFS190595 .

ns8:IFS190668 owl:sameAs ns2:IFS181648,
        ns2:IFS182751,
        ns2:IFS182809,
        ns2:IFS182919,
        ns8:IFS190905 ;
    ns0:fullName "Muhammad Riaz" ;
    ns0:hasAffiliation ns24:IFS190668 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190668 ;
    ns0:inAuthorList ns150:IFS190668 .

ns8:IFS190707 ns0:inAuthorList ns150:IFS190707 .

ns8:IFS190810 ns0:inAuthorList ns150:IFS190810 .

ns8:IFS190863 owl:sameAs ns2:IFS169324 ;
    ns0:fullName "Shaojian Qu" ;
    ns0:hasAffiliation ns24:IFS190863 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190863 ;
    ns0:inAuthorList ns150:IFS190863 .

ns8:IFS190988 ns0:inAuthorList ns150:IFS190988 .

ns8:IFS1992 ns0:inAuthorList ns150:IFS1992 .

ns8:IFS2058 ns0:inAuthorList ns150:IFS2058 .

ns8:IFS2062 ns0:inAuthorList ns150:IFS2062 .

ns8:IFS2096 ns0:inAuthorList ns150:IFS2096 .

ns8:IFS2101 ns0:inAuthorList ns150:IFS2101 .

ns8:IFS2117 ns0:inAuthorList ns150:IFS2117 .

ns8:IFS2148 ns0:inAuthorList ns150:IFS2148 .

ns8:IFS2170 ns0:inAuthorList ns150:IFS2170 .

ns8:INF1216 ns0:inAuthorList ns150:INF1216 .

ns8:INF1217 ns0:inAuthorList ns150:INF1217 .

ns8:JAD00003 ns0:inAuthorList ns150:JAD00003 .

ns8:JAD00018 ns0:inAuthorList ns150:JAD00018 .

ns8:JAD00022 ns0:inAuthorList ns150:JAD00022 .

ns8:JAD00028 ns0:inAuthorList ns150:JAD00028 .

ns8:JAD00045 ns0:inAuthorList ns150:JAD00045 .

ns8:JAD0007 ns0:inAuthorList ns150:JAD0007 .

ns8:JAD091402 ns0:inAuthorList ns150:JAD091402 .

ns8:JAD101221 ns0:inAuthorList ns150:JAD101221 .

ns8:JAD101422 ns0:inAuthorList ns150:JAD101422 .

ns8:JAD101614 ns0:inAuthorList ns150:JAD101614 .

ns8:JAD101911 ns0:inAuthorList ns150:JAD101911 .

ns8:JAD101977 ns0:inAuthorList ns150:JAD101977 .

ns8:JAD102124 ns0:inAuthorList ns150:JAD102124 .

ns8:JAD102139 ns0:inAuthorList ns150:JAD102139 .

ns8:JAD110074 ns0:inAuthorList ns150:JAD110074 .

ns8:JAD110173 ns0:inAuthorList ns150:JAD110173 .

ns8:JAD110251 ns0:inAuthorList ns150:JAD110251 .

ns8:JAD110566 ns0:inAuthorList ns150:JAD110566 .

ns8:JAD110629 ns0:inAuthorList ns150:JAD110629 .

ns8:JAD110752 ns0:inAuthorList ns150:JAD110752 .

ns8:JAD111385 ns0:inAuthorList ns150:JAD111385 .

ns8:JAD111472 ns0:inAuthorList ns150:JAD111472 .

ns8:JAD111736 ns0:inAuthorList ns150:JAD111736 .

ns8:JAD111928 ns0:inAuthorList ns150:JAD111928 .

ns8:JAD111934 ns0:inAuthorList ns150:JAD111934 .

ns8:JAD112202 ns0:inAuthorList ns150:JAD112202 .

ns8:JAD112216 ns0:inAuthorList ns150:JAD112216 .

ns8:JAD120019 ns0:inAuthorList ns150:JAD120019 .

ns8:JAD120169 ns0:inAuthorList ns150:JAD120169 .

ns8:JAD120424 ns0:inAuthorList ns150:JAD120424 .

ns8:JAD120430 ns0:inAuthorList ns150:JAD120430 .

ns8:JAD120481 ns0:inAuthorList ns150:JAD120481 .

ns8:JAD120676 ns0:inAuthorList ns150:JAD120676 .

ns8:JAD120802 ns0:inAuthorList ns150:JAD120802 .

ns8:JAD120952 ns0:inAuthorList ns150:JAD120952 .

ns8:JAD120973 ns0:inAuthorList ns150:JAD120973 .

ns8:JAD121336 ns0:inAuthorList ns150:JAD121336 .

ns8:JAD121432 ns0:inAuthorList ns150:JAD121432 .

ns8:JAD121471 ns0:inAuthorList ns150:JAD121471 .

ns8:JAD121585 ns0:inAuthorList ns150:JAD121585 .

ns8:JAD121639 ns0:inAuthorList ns150:JAD121639 .

ns8:JAD121771 ns0:inAuthorList ns150:JAD121771 .

ns8:JAD121927 ns0:inAuthorList ns150:JAD121927 .

ns8:JAD122098 ns0:inAuthorList ns150:JAD122098 .

ns8:JAD129005 ns0:inAuthorList ns150:JAD129005 .

ns8:JAD129034 ns0:inAuthorList ns150:JAD129034 .

ns8:JAD130035 ns0:inAuthorList ns150:JAD130035 .

ns8:JAD130353 ns0:inAuthorList ns150:JAD130353 .

ns8:JAD130461 ns0:inAuthorList ns150:JAD130461 .

ns8:JAD130490 ns0:inAuthorList ns150:JAD130490 .

ns8:JAD130506 ns0:inAuthorList ns150:JAD130506 .

ns8:JAD130548 ns0:inAuthorList ns150:JAD130548 .

ns8:JAD130989 ns0:inAuthorList ns150:JAD130989 .

ns8:JAD131085 ns0:inAuthorList ns150:JAD131085 .

ns8:JAD131151 ns0:inAuthorList ns150:JAD131151 .

ns8:JAD131496 ns0:inAuthorList ns150:JAD131496 .

ns8:JAD131733 ns0:inAuthorList ns150:JAD131733 .

ns8:JAD131808 ns0:inAuthorList ns150:JAD131808 .

ns8:JAD131844 ns0:inAuthorList ns150:JAD131844 .

ns8:JAD131862 ns0:inAuthorList ns150:JAD131862 .

ns8:JAD132306 ns0:inAuthorList ns150:JAD132306 .

ns8:JAD132642 ns0:inAuthorList ns150:JAD132642 .

ns8:JAD140042 ns0:inAuthorList ns150:JAD140042 .

ns8:JAD140051 ns0:inAuthorList ns150:JAD140051 .

ns8:JAD140138 ns0:inAuthorList ns150:JAD140138 .

ns8:JAD140210 ns0:inAuthorList ns150:JAD140210 .

ns8:JAD140264 ns0:inAuthorList ns150:JAD140264 .

ns8:JAD140570 ns0:inAuthorList ns150:JAD140570 .

ns8:JAD140798 ns0:inAuthorList ns150:JAD140798 .

ns8:JAD141110 ns0:inAuthorList ns150:JAD141110 .

ns8:JAD141266 ns0:inAuthorList ns150:JAD141266 .

ns8:JAD141302 ns0:inAuthorList ns150:JAD141302 .

ns8:JAD141314 ns0:inAuthorList ns150:JAD141314 .

ns8:JAD141521 ns0:inAuthorList ns150:JAD141521 .

ns8:JAD141704 ns0:inAuthorList ns150:JAD141704 .

ns8:JAD141812 ns0:inAuthorList ns150:JAD141812 .

ns8:JAD142868 ns0:inAuthorList ns150:JAD142868 .

ns8:JAD143084 ns0:inAuthorList ns150:JAD143084 .

ns8:JAD150250 ns0:inAuthorList ns150:JAD150250 .

ns8:JAD150254 ns0:inAuthorList ns150:JAD150254 .

ns8:JAD150261 ns0:inAuthorList ns150:JAD150261 .

ns8:JAD150428 ns0:inAuthorList ns150:JAD150428 .

ns8:JAD150481 ns0:inAuthorList ns150:JAD150481 .

ns8:JAD150537 ns0:inAuthorList ns150:JAD150537 .

ns8:JAD150729 ns0:inAuthorList ns150:JAD150729 .

ns8:JAD150736 ns0:inAuthorList ns150:JAD150736 .

ns8:JAD150770 ns0:inAuthorList ns150:JAD150770 .

ns8:JAD150778 ns0:inAuthorList ns150:JAD150778 .

ns8:JAD150788 ns0:inAuthorList ns150:JAD150788 .

ns8:JAD150826 ns0:inAuthorList ns150:JAD150826 .

ns8:JAD150914 ns0:inAuthorList ns150:JAD150914 .

ns8:JAD150931 ns0:inAuthorList ns150:JAD150931 .

ns8:JAD151005 ns0:inAuthorList ns150:JAD151005 .

ns8:JAD151015 ns0:inAuthorList ns150:JAD151015 .

ns8:JAD151063 ns0:inAuthorList ns150:JAD151063 .

ns8:JAD151101 ns0:inAuthorList ns150:JAD151101 .

ns8:JAD151114 ns0:inAuthorList ns150:JAD151114 .

ns8:JAD151130 ns0:inAuthorList ns150:JAD151130 .

ns8:JAD160077 ns0:inAuthorList ns150:JAD160077 .

ns8:JAD160108 ns0:inAuthorList ns150:JAD160108 .

ns8:JAD160119 ns0:inAuthorList ns150:JAD160119 .

ns8:JAD160124 ns0:inAuthorList ns150:JAD160124 .

ns8:JAD160148 ns0:inAuthorList ns150:JAD160148 .

ns8:JAD160158 ns0:inAuthorList ns150:JAD160158 .

ns8:JAD160185 ns0:inAuthorList ns150:JAD160185 .

ns8:JAD160286 ns0:inAuthorList ns150:JAD160286 .

ns8:JAD160470 ns0:inAuthorList ns150:JAD160470 .

ns8:JAD160485 ns0:inAuthorList ns150:JAD160485 .

ns8:JAD160525 ns0:inAuthorList ns150:JAD160525 .

ns8:JAD160538 ns0:inAuthorList ns150:JAD160538 .

ns8:JAD160582 ns0:inAuthorList ns150:JAD160582 .

ns8:JAD160611 ns0:inAuthorList ns150:JAD160611 .

ns8:JAD160643 ns0:inAuthorList ns150:JAD160643 .

ns8:JAD160677 ns0:inAuthorList ns150:JAD160677 .

ns8:JAD160685 ns0:inAuthorList ns150:JAD160685 .

ns8:JAD160745 ns0:inAuthorList ns150:JAD160745 .

ns8:JAD160766 ns0:inAuthorList ns150:JAD160766 .

ns8:JAD160800 ns0:inAuthorList ns150:JAD160800 .

ns8:JAD160808 ns0:inAuthorList ns150:JAD160808 .

ns8:JAD160822 ns0:inAuthorList ns150:JAD160822 .

ns8:JAD160828 ns0:inAuthorList ns150:JAD160828 .

ns8:JAD160873 ns0:inAuthorList ns150:JAD160873 .

ns8:JAD160887 ns0:inAuthorList ns150:JAD160887 .

ns8:JAD160939 ns0:inAuthorList ns150:JAD160939 .

ns8:JAD160956 ns0:inAuthorList ns150:JAD160956 .

ns8:JAD161028 ns0:inAuthorList ns150:JAD161028 .

ns8:JAD161114 ns0:inAuthorList ns150:JAD161114 .

ns8:JAD161132 ns0:inAuthorList ns150:JAD161132 .

ns8:JAD161162 ns0:inAuthorList ns150:JAD161162 .

ns8:JAD161179 ns0:inAuthorList ns150:JAD161179 .

ns8:JAD161198 ns0:inAuthorList ns150:JAD161198 .

ns8:JAD161201 ns0:inAuthorList ns150:JAD161201 .

ns8:JAD161277 ns0:inAuthorList ns150:JAD161277 .

ns8:JAD161292 ns0:inAuthorList ns150:JAD161292 .

ns8:JAD161295 ns0:inAuthorList ns150:JAD161295 .

ns8:JAD161298 ns0:inAuthorList ns150:JAD161298 .

ns8:JAD170045 ns0:inAuthorList ns150:JAD170045 .

ns8:JAD170091 ns0:inAuthorList ns150:JAD170091 .

ns8:JAD170123 ns0:inAuthorList ns150:JAD170123 .

ns8:JAD170149 ns0:inAuthorList ns150:JAD170149 .

ns8:JAD170218 ns0:inAuthorList ns150:JAD170218 .

ns8:JAD170298 ns0:inAuthorList ns150:JAD170298 .

ns8:JAD170313 ns0:inAuthorList ns150:JAD170313 .

ns8:JAD170419 ns0:inAuthorList ns150:JAD170419 .

ns8:JAD170560 ns0:inAuthorList ns150:JAD170560 .

ns8:JAD170581 ns0:inAuthorList ns150:JAD170581 .

ns8:JAD170602 ns0:inAuthorList ns150:JAD170602 .

ns8:JAD170604 ns0:inAuthorList ns150:JAD170604 .

ns8:JAD170702 ns0:inAuthorList ns150:JAD170702 .

ns8:JAD170715 ns0:inAuthorList ns150:JAD170715 .

ns8:JAD170735 ns0:inAuthorList ns150:JAD170735 .

ns8:JAD170839 ns0:inAuthorList ns150:JAD170839 .

ns8:JAD170900 ns0:inAuthorList ns150:JAD170900 .

ns8:JAD170909 ns0:inAuthorList ns150:JAD170909 .

ns8:JAD170943 ns0:inAuthorList ns150:JAD170943 .

ns8:JAD170948 ns0:inAuthorList ns150:JAD170948 .

ns8:JAD171053 ns0:inAuthorList ns150:JAD171053 .

ns8:JAD171177 ns0:inAuthorList ns150:JAD171177 .

ns8:JAD179901 ns0:inAuthorList ns150:JAD179901 .

ns8:JAD179919 ns0:inAuthorList ns150:JAD179919 .

ns8:JAD179929 ns0:inAuthorList ns150:JAD179929 .

ns8:JAD180025 ns0:inAuthorList ns150:JAD180025 .

ns8:JAD180092 ns0:inAuthorList ns150:JAD180092 .

ns8:JAD180106 ns0:inAuthorList ns150:JAD180106 .

ns8:JAD180119 ns0:inAuthorList ns150:JAD180119 .

ns8:JAD180182 ns0:inAuthorList ns150:JAD180182 .

ns8:JAD180250 ns0:inAuthorList ns150:JAD180250 .

ns8:JAD180300 ns0:inAuthorList ns150:JAD180300 .

ns8:JAD180394 ns0:inAuthorList ns150:JAD180394 .

ns8:JAD180425 ns0:inAuthorList ns150:JAD180425 .

ns8:JAD180496 owl:sameAs ns12:JAD180511,
        ns60:JAD170880 ;
    ns0:fullName "Suzana Makpol" ;
    ns0:hasAffiliation ns24:JAD180496 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180496 ;
    ns0:inAuthorList ns150:JAD180496 .

ns8:JAD180513 ns0:inAuthorList ns150:JAD180513 .

ns8:JAD180524 ns0:inAuthorList ns150:JAD180524 .

ns8:JAD180554 ns0:inAuthorList ns150:JAD180554 .

ns8:JAD180594 ns0:inAuthorList ns150:JAD180594 .

ns8:JAD180595 ns0:inAuthorList ns150:JAD180595 .

ns8:JAD180631 ns0:inAuthorList ns150:JAD180631 .

ns8:JAD180737 ns0:inAuthorList ns150:JAD180737 .

ns8:JAD180740 ns0:inAuthorList ns150:JAD180740 .

ns8:JAD180769 ns0:inAuthorList ns150:JAD180769 .

ns8:JAD180776 ns0:inAuthorList ns150:JAD180776 .

ns8:JAD180808 ns0:inAuthorList ns150:JAD180808 .

ns8:JAD180843 ns0:inAuthorList ns150:JAD180843 .

ns8:JAD180853 ns0:inAuthorList ns150:JAD180853 .

ns8:JAD180882 ns0:inAuthorList ns150:JAD180882 .

ns8:JAD180888 ns0:inAuthorList ns150:JAD180888 .

ns8:JAD180911 ns0:inAuthorList ns150:JAD180911 .

ns8:JAD180942 ns0:inAuthorList ns150:JAD180942 .

ns8:JAD180985 ns0:inAuthorList ns150:JAD180985 .

ns8:JAD180987 ns0:inAuthorList ns150:JAD180987 .

ns8:JAD181062 ns0:inAuthorList ns150:JAD181062 .

ns8:JAD181089 ns0:inAuthorList ns150:JAD181089 .

ns8:JAD181119 ns0:inAuthorList ns150:JAD181119 .

ns8:JAD181126 ns0:inAuthorList ns150:JAD181126 .

ns8:JAD181169 ns0:inAuthorList ns150:JAD181169 .

ns8:JAD181208 ns0:inAuthorList ns150:JAD181208 .

ns8:JAD181223 ns0:inAuthorList ns150:JAD181223 .

ns8:JAD181227 owl:sameAs ns5:JAD170195,
        ns60:JAD160230 ;
    ns0:fullName "Joe Verghese" ;
    ns0:hasAffiliation ns24:JAD181227,
        ns25:JAD181227 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181227 ;
    ns0:inAuthorList ns150:JAD181227 .

ns8:JAD190030 ns0:inAuthorList ns150:JAD190030 .

ns8:JAD190132 ns0:inAuthorList ns150:JAD190132 .

ns8:JAD190202 owl:sameAs ns8:JAD160641,
        ns12:JAD151026,
        ns12:JAD180030,
        ns52:JAD180485,
        ns33:JAD181195 ;
    ns0:fullName "Nathan Herrmann" ;
    ns0:hasAffiliation ns25:JAD190202,
        ns90:JAD190202 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190202 ;
    ns0:inAuthorList ns150:JAD190202 .

ns8:JAD190256 owl:sameAs ns16:JAD120022 ;
    ns0:fullName "Hiroshige Fujishiro" ;
    ns0:hasAffiliation ns25:JAD190256 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190256 ;
    ns0:inAuthorList ns150:JAD190256 .

ns8:JAD190278 owl:sameAs ns8:JAD180131,
        ns12:JPD191619 ;
    ns0:fullName "Zahinoor Ismail" ;
    ns0:hasAffiliation ns25:JAD190278 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190278 ;
    ns0:inAuthorList ns150:JAD190278 .

ns8:JAD190334 owl:sameAs ns52:JAD170039 ;
    ns0:fullName "Anette Hall" ;
    ns0:hasAffiliation ns24:JAD190334 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns8:JAD190342 owl:sameAs ns8:JAD170130 ;
    ns0:fullName "G. Peggy McFall" ;
    ns0:hasAffiliation ns25:JAD190342,
        ns90:JAD190342 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190342 ;
    ns0:inAuthorList ns150:JAD190342 .

ns8:JAD190369 owl:sameAs ns40:JAD181218,
        ns30:JAD143084 ;
    ns0:fullName "Toru Yamashita" ;
    ns0:hasAffiliation ns24:JAD190369 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190369 ;
    ns0:inAuthorList ns150:JAD190369 .

ns8:JAD190405 ns0:inAuthorList ns150:JAD190405 .

ns8:JAD190506 ns0:inAuthorList ns150:JAD190506 .

ns8:JAD190527 owl:sameAs ns8:JAD101560,
        ns8:jad01137,
        ns12:JAD141596,
        ns30:JAD132225,
        ns30:JAD141659,
        ns30:JAD180055,
        ns5:JAD179938,
        ns16:JAD141542,
        ns16:JAD151130,
        ns16:JAD170407,
        ns16:JAD180055,
        ns52:JAD140186,
        ns52:JAD160952,
        ns52:JAD180375,
        ns57:JAD170458,
        ns57:JAD181297,
        ns60:JAD132558,
        ns33:JAD160116 ;
    ns0:fullName "M. Kamran Ikram" ;
    ns0:hasAffiliation ns24:JAD190527,
        ns25:JAD190527 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190527 ;
    ns0:inAuthorList ns150:JAD190527 .

ns8:JAD190638 owl:sameAs ns28:JAD190311 ;
    ns0:fullName "Despina Moraitou" ;
    ns0:hasAffiliation ns24:JAD190638,
        ns258:JAD190638 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190638 ;
    ns0:inAuthorList ns150:JAD190638 .

ns8:JAD190644 ns0:inAuthorList ns150:JAD190644 .

ns8:JAD190688 owl:sameAs ns8:JAD141413,
        ns60:JAD132351 ;
    ns0:fullName "Carol Brayne" ;
    ns0:hasAffiliation ns258:JAD190688 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190688 ;
    ns0:inAuthorList ns150:JAD190688 .

ns8:JAD190823 owl:sameAs ns8:JAD101818,
        ns30:JAD132414,
        ns30:JAD141294 ;
    ns0:fullName "Antony Bayer" ;
    ns0:hasAffiliation ns25:JAD190823 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190823 ;
    ns0:inAuthorList ns150:JAD190823 .

ns8:JAD190838 ns0:inAuthorList ns150:JAD190838 .

ns8:JAE150168 ns0:inAuthorList ns150:JAE150168 .

ns8:JAE160054 ns0:inAuthorList ns150:JAE160054 .

ns8:JAE170034 owl:sameAs ns8:JAE150132 ;
    ns0:fullName "Enrique E. Mombello" ;
    ns0:hasAffiliation ns25:JAE170034 ;
    ns0:hasArticle ns1:jae-v58-i2-JAE170034 ;
    ns0:inAuthorList ns150:JAE170034 .

ns8:JAE171155 ns0:inAuthorList ns150:JAE171155 .

ns8:JAE171220 ns0:inAuthorList ns150:JAE171220 .

ns8:JAE180021 ns0:inAuthorList ns150:JAE180021 .

ns8:JAE180034 ns0:inAuthorList ns150:JAE180034 .

ns8:JAE180085 ns0:inAuthorList ns150:JAE180085 .

ns8:JAE180086 ns0:inAuthorList ns150:JAE180086 .

ns8:JAE180097 ns0:inAuthorList ns150:JAE180097 .

ns8:JAE190821 ns0:inAuthorList ns150:JAE190821 .

ns8:JAE191148 owl:sameAs ns8:JAE171008,
        ns8:JAE171252,
        ns8:JAE190924,
        ns8:JAE191149,
        ns8:JAE2122,
        ns8:JAE2271,
        ns12:JAE190821,
        ns12:JAE1979 ;
    ns0:fullName "Yasuhito Takahashi" ;
    ns0:hasAffiliation ns24:JAE191148 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191148 ;
    ns0:inAuthorList ns150:JAE191148 .

ns8:JAE191491 ns0:inAuthorList ns150:JAE191491 .

ns8:JAE1988 ns0:inAuthorList ns150:JAE1988 .

ns8:JAE198976 owl:sameAs ns8:JAE198972 ;
    ns0:fullName "Veronica Manescu Paltanea" ;
    ns0:hasAffiliation ns24:JAE198976 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE198976 ;
    ns0:inAuthorList ns150:JAE198976 .

ns8:JAE2229 ns0:inAuthorList ns150:JAE2229 .

ns8:JBR155 ns0:inAuthorList ns150:JBR155 .

ns8:JBR180314 ns0:inAuthorList ns150:JBR180314 .

ns8:JCS171017 ns0:inAuthorList ns150:JCS171017 .

ns8:JCS171094 ns0:inAuthorList ns150:JCS171094 .

ns8:JCS17975 ns0:inAuthorList ns150:JCS17975 .

<http://ld.iospress.nl/rdf/contributor/Author:1.ID:JCS2(4)04> ns0:inAuthorList <http://ld.iospress.nl/rdf/contributor/List.Role:authors.ID:JCS2(4)04> .

ns8:JCS512 ns0:inAuthorList ns150:JCS512 .

ns8:JHD170241 ns0:inAuthorList ns150:JHD170241 .

ns8:JHD170245 ns0:inAuthorList ns150:JHD170245 .

ns8:JHD170262 ns0:inAuthorList ns150:JHD170262 .

ns8:JHD170283 ns0:inAuthorList ns150:JHD170283 .

ns8:JHD180306 ns0:inAuthorList ns150:JHD180306 .

ns8:JHD189001 ns0:inAuthorList ns150:JHD189001 .

ns8:JHD189003 ns0:inAuthorList ns150:JHD189003 .

ns8:JHD190353 owl:sameAs ns12:JHD180325,
        ns16:JHD190354 ;
    ns0:fullName "Robin Schubert" ;
    ns0:hasAffiliation ns25:JHD190353 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD190353 ;
    ns0:inAuthorList ns150:JHD190353 .

ns8:JHS592 ns0:inAuthorList ns150:JHS592 .

ns8:JND150125 ns0:inAuthorList ns150:JND150125 .

ns8:JND170232 ns0:inAuthorList ns150:JND170232 .

ns8:JND180313 ns0:inAuthorList ns150:JND180313 .

ns8:JPD150639 ns0:inAuthorList ns150:JPD150639 .

ns8:JPD150652 ns0:inAuthorList ns150:JPD150652 .

ns8:JPD150673 ns0:inAuthorList ns150:JPD150673 .

ns8:JPD150680 ns0:inAuthorList ns150:JPD150680 .

ns8:JPD150685 ns0:inAuthorList ns150:JPD150685 .

ns8:JPD160860 ns0:inAuthorList ns150:JPD160860 .

ns8:JPD160867 ns0:inAuthorList ns150:JPD160867 .

ns8:JPD161055 ns0:inAuthorList ns150:JPD161055 .

ns8:JPD171271 ns0:inAuthorList ns150:JPD171271 .

ns8:JPD181434 ns0:inAuthorList ns150:JPD181434 .

ns8:JPD181472 ns0:inAuthorList ns150:JPD181472 .

ns8:JPD189002 ns0:inAuthorList ns150:JPD189002 .

ns8:JPD191593 owl:sameAs ns2:JPD140493,
        ns8:JHD199003 ;
    ns0:fullName "Joaquim J. Ferreira" ;
    ns0:hasAffiliation ns25:JPD191593 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191593 ;
    ns0:inAuthorList ns150:JPD191593 .

ns8:JSA154 ns0:inAuthorList ns150:JSA154 .

ns8:JVR191020 owl:sameAs ns2:JVR191026,
        ns2:WOR2200,
        ns2:WOR2203,
        ns30:WOR2204 ;
    ns0:fullName "Malachy Bishop" ;
    ns0:hasAffiliation ns25:JVR191020 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191020 ;
    ns0:inAuthorList ns150:JVR191020 .

ns8:JVR191024 owl:sameAs ns2:WOR2601,
        ns8:WOR2201,
        ns30:JVR191022 ;
    ns0:fullName "Richard T. Roessler" ;
    ns0:hasAffiliation ns25:JVR191024 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191024 ;
    ns0:inAuthorList ns150:JVR191024 .

ns8:JVR191030 ns0:inAuthorList ns150:JVR191030 .

ns8:JVR191032 ns0:inAuthorList ns150:JVR191032 .

ns8:JVR191037 owl:sameAs ns132:JAD160573 ;
    ns0:fullName "Leslie Shaw" ;
    ns0:hasAffiliation ns24:JVR191037 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191037 ;
    ns0:inAuthorList ns150:JVR191037 .

ns8:JVR191038 owl:sameAs ns12:JVR180991 ;
    ns0:fullName "Sara McCormick" ;
    ns0:hasAffiliation ns24:JVR191038 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191038 ;
    ns0:inAuthorList ns150:JVR191038 .

ns8:JVR191039 owl:sameAs ns8:JVR180991 ;
    ns0:fullName "Noelle Kurth" ;
    ns0:hasAffiliation ns25:JVR191039 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191039 ;
    ns0:inAuthorList ns150:JVR191039 .

ns8:JVR191040 ns0:inAuthorList ns150:JVR191040 .

ns8:JVR191041 owl:sameAs ns2:JVR191033 ;
    ns0:fullName "Kelli Thuli Crane" ;
    ns0:hasAffiliation ns24:JVR191041 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191041 ;
    ns0:inAuthorList ns150:JVR191041 .

ns8:JVR803 ns0:inAuthorList ns150:JVR803 .

ns8:JVR812 ns0:inAuthorList ns150:JVR812 .

ns8:JVR814 ns0:inAuthorList ns150:JVR814 .

ns8:JVR830 ns0:inAuthorList ns150:JVR830 .

ns8:JVR944 ns0:inAuthorList ns150:JVR944 .

ns8:KCA170006 ns0:inAuthorList ns150:KCA170006 .

ns8:KCA170024 ns0:inAuthorList ns150:KCA170024 .

ns8:KCA180034 ns0:inAuthorList ns150:KCA180034 .

ns8:KCA180045 ns0:inAuthorList ns150:KCA180045 .

ns8:KES190397 ns0:inAuthorList ns150:KES190397 .

ns8:KES190407 ns0:inAuthorList ns150:KES190407 .

ns8:MGC180750 ns0:inAuthorList ns150:MGC180750 .

ns8:MGC181 ns0:inAuthorList ns150:MGC181 .

ns8:MGC190794 ns0:inAuthorList ns150:MGC190794 .

ns8:MGC193 owl:sameAs ns8:hab00178 ;
    ns0:fullName "Hanan H. Omar" ;
    ns0:hasAffiliation ns24:MGC193,
        ns25:MGC193 ;
    ns0:hasArticle ns1:mgc-v15-i2-MGC193 ;
    ns0:inAuthorList ns150:MGC193 .

ns8:MGS267 ns0:inAuthorList ns150:MGS267 .

ns8:MGS277 ns0:inAuthorList ns150:MGS277 .

ns8:MGS284 ns0:inAuthorList ns150:MGS284 .

ns8:MNM180224 ns0:inAuthorList ns150:MNM180224 .

ns8:MNM180233 ns0:inAuthorList ns150:MNM180233 .

ns8:MNM180275 owl:sameAs ns8:MNM180249 ;
    ns0:fullName "Demosthenes B. Panagiotakos" ;
    ns0:hasAffiliation ns25:MNM180275 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180275 ;
    ns0:inAuthorList ns150:MNM180275 .

ns8:NIB180141 ns0:inAuthorList ns150:NIB180141 .

ns8:NPM16112 ns0:inAuthorList ns150:NPM16112 .

ns8:NPM17133 ns0:inAuthorList ns150:NPM17133 .

ns8:NRE1259 ns0:inAuthorList ns150:NRE1259 .

ns8:NRE1298 ns0:inAuthorList ns150:NRE1298 .

ns8:NRE1420 ns0:inAuthorList ns150:NRE1420 .

ns8:NRE1428 ns0:inAuthorList ns150:NRE1428 .

ns8:NRE162128 ns0:inAuthorList ns150:NRE162128 .

ns8:NRE182505 ns0:inAuthorList ns150:NRE182505 .

ns8:PPR072 ns0:inAuthorList ns150:PPR072 .

ns8:PPR180120 ns0:inAuthorList ns150:PPR180120 .

ns8:PRM160428 ns0:inAuthorList ns150:PRM160428 .

ns8:RNN150515 ns0:inAuthorList ns150:RNN150515 .

ns8:RNN160661 ns0:inAuthorList ns150:RNN160661 .

ns8:RNN170767 ns0:inAuthorList ns150:RNN170767 .

ns8:RNN180897 owl:sameAs ns8:JAD141794,
        ns52:JAD170625 ;
    ns0:fullName "Stefano Tamburin" ;
    ns0:hasAffiliation ns25:RNN180897 ;
    ns0:hasArticle ns1:rnn-v37-i3-RNN180897 ;
    ns0:inAuthorList ns150:RNN180897 .

ns8:SW154 ns0:inAuthorList ns150:SW154 .

ns8:SW177 ns0:inAuthorList ns150:SW177 .

ns8:SW180336 ns0:inAuthorList ns150:SW180336 .

ns8:SW204 ns0:inAuthorList ns150:SW204 .

ns8:SW217 ns0:inAuthorList ns150:SW217 .

ns8:THC1081 ns0:inAuthorList ns150:THC1081 .

ns8:THC1130 ns0:inAuthorList ns150:THC1130 .

ns8:THC1315 ns0:inAuthorList ns150:THC1315 .

ns8:THC174615 ns0:inAuthorList ns150:THC174615 .

ns8:THC174800 ns0:inAuthorList ns150:THC174800 .

ns8:THC181467 ns0:inAuthorList ns150:THC181467 .

ns8:THC199031 ns0:inAuthorList ns150:THC199031 .

ns8:VES190658 ns0:inAuthorList ns150:VES190658 .

ns8:WOR182813 ns0:inAuthorList ns150:WOR182813 .

ns8:WOR182840 ns0:inAuthorList ns150:WOR182840 .

ns8:WOR192917 ns0:inAuthorList ns150:WOR192917 .

ns8:WOR192951 ns0:inAuthorList ns150:WOR192951 .

ns8:WOR192956 ns0:inAuthorList ns150:WOR192956 .

ns8:WOR192968 ns0:inAuthorList ns150:WOR192968 .

ns8:WOR192973 ns0:inAuthorList ns150:WOR192973 .

ns8:WOR2010 ns0:inAuthorList ns150:WOR2010 .

ns8:WOR2180 ns0:inAuthorList ns150:WOR2180 .

ns8:WOR2184 ns0:inAuthorList ns150:WOR2184 .

ns8:WOR2202 ns0:inAuthorList ns150:WOR2202 .

ns8:WOR2278 ns0:inAuthorList ns150:WOR2278 .

ns8:WOR2426 ns0:inAuthorList ns150:WOR2426 .

ns8:WOR2522 ns0:inAuthorList ns150:WOR2522 .

ns8:WOR2685 ns0:inAuthorList ns150:WOR2685 .

ns8:WOR2737 ns0:inAuthorList ns150:WOR2737 .

ns8:WOR2761 ns0:inAuthorList ns150:WOR2761 .

ns8:XST16214 ns0:inAuthorList ns150:XST16214 .

ns8:XST17271 ns0:inAuthorList ns150:XST17271 .

ns8:XST17289 ns0:inAuthorList ns150:XST17289 .

ns8:XST180391 ns0:inAuthorList ns150:XST180391 .

ns8:XST180429 ns0:inAuthorList ns150:XST180429 .

ns8:XST180477 ns0:inAuthorList ns150:XST180477 .

ns8:XST180488 owl:sameAs ns2:XST17282,
        ns8:XST18377 ;
    ns0:fullName "Zong-Qiong Sun" ;
    ns0:hasAffiliation ns25:XST180488 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180488 ;
    ns0:inAuthorList ns150:XST180488 .

ns8:XST190507 ns0:inAuthorList ns150:XST190507 .

ns8:XST190548 ns0:inAuthorList ns150:XST190548 .

ns8:XST495 ns0:inAuthorList ns150:XST495 .

ns8:XST519 ns0:inAuthorList ns150:XST519 .

ns8:XST579 ns0:inAuthorList ns150:XST579 .

ns8:XST598 ns0:inAuthorList ns150:XST598 .

ns8:ajw170014 ns0:inAuthorList ns150:ajw170014 .

ns8:bd000349 ns0:inAuthorList ns150:bd000349 .

ns8:bd000366 ns0:inAuthorList ns150:bd000366 .

ns8:bmr00185 ns0:inAuthorList ns150:bmr00185 .

ns8:bmr00284 ns0:inAuthorList ns150:bmr00284 .

ns8:bmr00302 ns0:inAuthorList ns150:bmr00302 .

ns8:bmr00331 ns0:inAuthorList ns150:bmr00331 .

ns8:bmr00447 ns0:inAuthorList ns150:bmr00447 .

ns8:cbm00437 ns0:inAuthorList ns150:cbm00437 .

ns8:his00005 ns0:inAuthorList ns150:his00005 .

ns8:his00034 ns0:inAuthorList ns150:his00034 .

ns8:his00113 ns0:inAuthorList ns150:his00113 .

ns8:ica00314 ns0:inAuthorList ns150:ica00314 .

ns8:ica00341 ns0:inAuthorList ns150:ica00341 .

ns8:ida00166 ns0:inAuthorList ns150:ida00166 .

ns8:ida00355 ns0:inAuthorList ns150:ida00355 .

ns8:ida00377 ns0:inAuthorList ns150:ida00377 .

ns8:ida00577 ns0:inAuthorList ns150:ida00577 .

ns8:ida00637 ns0:inAuthorList ns150:ida00637 .

ns8:ida00647 ns0:inAuthorList ns150:ida00647 .

ns8:idt00082 ns0:inAuthorList ns150:idt00082 .

ns8:idt00117 ns0:inAuthorList ns150:idt00117 .

ns8:idt00132 ns0:inAuthorList ns150:idt00132 .

ns8:idt00133 ns0:inAuthorList ns150:idt00133 .

ns8:idt00190 ns0:inAuthorList ns150:idt00190 .

ns8:jad00185 ns0:inAuthorList ns150:jad00185 .

ns8:jad00189 ns0:inAuthorList ns150:jad00189 .

ns8:jad00194 ns0:inAuthorList ns150:jad00194 .

ns8:jad00269 ns0:inAuthorList ns150:jad00269 .

ns8:jad00434 ns0:inAuthorList ns150:jad00434 .

ns8:jad00490 ns0:inAuthorList ns150:jad00490 .

ns8:jad00498 ns0:inAuthorList ns150:jad00498 .

ns8:jad00609 ns0:inAuthorList ns150:jad00609 .

ns8:jad00610 ns0:inAuthorList ns150:jad00610 .

ns8:jad00710 ns0:inAuthorList ns150:jad00710 .

ns8:jad00728 ns0:inAuthorList ns150:jad00728 .

ns8:jad00814 ns0:inAuthorList ns150:jad00814 .

ns8:jad00867 ns0:inAuthorList ns150:jad00867 .

ns8:jad00932 ns0:inAuthorList ns150:jad00932 .

ns8:jad01011 ns0:inAuthorList ns150:jad01011 .

ns8:jad01079 ns0:inAuthorList ns150:jad01079 .

ns8:jad01105 ns0:inAuthorList ns150:jad01105 .

ns8:jad01125 ns0:inAuthorList ns150:jad01125 .

ns8:jad01126 ns0:inAuthorList ns150:jad01126 .

ns8:jad01145 ns0:inAuthorList ns150:jad01145 .

ns8:jad01163 ns0:inAuthorList ns150:jad01163 .

ns8:jad01225 ns0:inAuthorList ns150:jad01225 .

ns8:jad01230 ns0:inAuthorList ns150:jad01230 .

ns8:jad01255 ns0:inAuthorList ns150:jad01255 .

ns8:jad01346 ns0:inAuthorList ns150:jad01346 .

ns8:jad01347 ns0:inAuthorList ns150:jad01347 .

ns8:jad01390 ns0:inAuthorList ns150:jad01390 .

ns8:jad091489 ns0:inAuthorList ns150:jad091489 .

ns8:jad091711 ns0:inAuthorList ns150:jad091711 .

ns8:jad100201 ns0:inAuthorList ns150:jad100201 .

ns8:jad100378 ns0:inAuthorList ns150:jad100378 .

ns8:jad100432 ns0:inAuthorList ns150:jad100432 .

ns8:jad100456 ns0:inAuthorList ns150:jad100456 .

ns8:jad100501 ns0:inAuthorList ns150:jad100501 .

ns8:jad100819 ns0:inAuthorList ns150:jad100819 .

ns8:jad100912 ns0:inAuthorList ns150:jad100912 .

ns8:jcm00395 ns0:inAuthorList ns150:jcm00395 .

ns8:jcs153 ns0:inAuthorList ns150:jcs153 .

ns8:jcs167 ns0:inAuthorList ns150:jcs167 .

ns8:jcs244 ns0:inAuthorList ns150:jcs244 .

ns8:jcs342 ns0:inAuthorList ns150:jcs342 .

ns8:jcs351 ns0:inAuthorList ns150:jcs351 .

ns8:jcs370 ns0:inAuthorList ns150:jcs370 .

ns8:kes00172 ns0:inAuthorList ns150:kes00172 .

ns8:mgs00018 ns0:inAuthorList ns150:mgs00018 .

ns8:mgs00081 ns0:inAuthorList ns150:mgs00081 .

ns8:mgs00201 ns0:inAuthorList ns150:mgs00201 .

ns8:mgs00202 ns0:inAuthorList ns150:mgs00202 .

ns8:mgs00215 ns0:inAuthorList ns150:mgs00215 .

ns8:tad00279 ns0:inAuthorList ns150:tad00279 .

ns8:tad00412 ns0:inAuthorList ns150:tad00412 .

ns8:thc00632 ns0:inAuthorList ns150:thc00632 .

ns26:BLC180172 ns0:inAuthorList ns150:BLC180172 .

ns26:CBM170711 ns0:inAuthorList ns150:CBM170711 .

ns26:CH179208 ns0:inAuthorList ns150:CH179208 .

ns26:CH179209 ns0:inAuthorList ns150:CH179209 .

ns26:CH2001 ns0:inAuthorList ns150:CH2001 .

ns26:JAD101221 ns0:inAuthorList ns150:JAD101221 .

ns26:JAD110752 ns0:inAuthorList ns150:JAD110752 .

ns26:JAD110860 ns0:inAuthorList ns150:JAD110860 .

ns26:JAD110983 ns0:inAuthorList ns150:JAD110983 .

ns26:JAD120172 ns0:inAuthorList ns150:JAD120172 .

ns26:JAD120946 ns0:inAuthorList ns150:JAD120946 .

ns26:JAD121516 ns0:inAuthorList ns150:JAD121516 .

ns26:JAD121570 ns0:inAuthorList ns150:JAD121570 .

ns26:JAD121663 ns0:inAuthorList ns150:JAD121663 .

ns26:JAD121906 ns0:inAuthorList ns150:JAD121906 .

ns26:JAD122170 ns0:inAuthorList ns150:JAD122170 .

ns26:JAD122224 ns0:inAuthorList ns150:JAD122224 .

ns26:JAD122260 ns0:inAuthorList ns150:JAD122260 .

ns26:JAD130398 ns0:inAuthorList ns150:JAD130398 .

ns26:JAD132075 ns0:inAuthorList ns150:JAD132075 .

ns26:JAD140138 ns0:inAuthorList ns150:JAD140138 .

ns26:JAD140225 ns0:inAuthorList ns150:JAD140225 .

ns26:JAD141521 ns0:inAuthorList ns150:JAD141521 .

ns26:JAD141599 ns0:inAuthorList ns150:JAD141599 .

ns26:JAD142622 ns0:inAuthorList ns150:JAD142622 .

ns26:JAD150482 ns0:inAuthorList ns150:JAD150482 .

ns26:JAD150837 ns0:inAuthorList ns150:JAD150837 .

ns26:JAD150841 ns0:inAuthorList ns150:JAD150841 .

ns26:JAD150948 ns0:inAuthorList ns150:JAD150948 .

ns26:JAD151097 ns0:inAuthorList ns150:JAD151097 .

ns26:JAD151125 ns0:inAuthorList ns150:JAD151125 .

ns26:JAD151139 ns0:inAuthorList ns150:JAD151139 .

ns26:JAD151208 ns0:inAuthorList ns150:JAD151208 .

ns26:JAD160126 ns0:inAuthorList ns150:JAD160126 .

ns26:JAD160209 ns0:inAuthorList ns150:JAD160209 .

ns26:JAD160257 ns0:inAuthorList ns150:JAD160257 .

ns26:JAD160408 ns0:inAuthorList ns150:JAD160408 .

ns26:JAD160554 ns0:inAuthorList ns150:JAD160554 .

ns26:JAD160697 ns0:inAuthorList ns150:JAD160697 .

ns26:JAD160927 ns0:inAuthorList ns150:JAD160927 .

ns26:JAD161113 ns0:inAuthorList ns150:JAD161113 .

ns26:JAD161114 ns0:inAuthorList ns150:JAD161114 .

ns26:JAD161163 ns0:inAuthorList ns150:JAD161163 .

ns26:JAD161173 ns0:inAuthorList ns150:JAD161173 .

ns26:JAD161224 ns0:inAuthorList ns150:JAD161224 .

ns26:JAD170017 ns0:inAuthorList ns150:JAD170017 .

ns26:JAD170072 ns0:inAuthorList ns150:JAD170072 .

ns26:JAD170398 ns0:inAuthorList ns150:JAD170398 .

ns26:JAD170410 ns0:inAuthorList ns150:JAD170410 .

ns26:JAD170602 ns0:inAuthorList ns150:JAD170602 .

ns26:JAD170813 ns0:inAuthorList ns150:JAD170813 .

ns26:JAD170943 ns0:inAuthorList ns150:JAD170943 .

ns26:JAD170982 ns0:inAuthorList ns150:JAD170982 .

ns26:JAD170998 ns0:inAuthorList ns150:JAD170998 .

ns26:JAD171177 ns0:inAuthorList ns150:JAD171177 .

ns26:JAD180106 ns0:inAuthorList ns150:JAD180106 .

ns26:JAD180152 ns0:inAuthorList ns150:JAD180152 .

ns26:JAD180202 ns0:inAuthorList ns150:JAD180202 .

ns26:JAD180274 ns0:inAuthorList ns150:JAD180274 .

ns26:JAD180564 ns0:inAuthorList ns150:JAD180564 .

ns26:JAD180645 ns0:inAuthorList ns150:JAD180645 .

ns26:JAD180701 ns0:inAuthorList ns150:JAD180701 .

ns26:JAD180713 ns0:inAuthorList ns150:JAD180713 .

ns26:JAD180723 ns0:inAuthorList ns150:JAD180723 .

ns26:JAD180763 owl:sameAs ns2:JAD141248,
        ns2:JAD160826,
        ns2:JAD161209,
        ns2:JAD190181,
        ns2:JAD190506,
        ns8:JAD112126,
        ns12:JAD140630,
        ns12:JAD160774,
        ns12:JAD170055,
        ns5:JAD170050,
        ns5:JAD180572,
        ns5:JAD190342,
        ns16:JAD180631 ;
    ns0:fullName "Kaarin J. Anstey" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:10.ID:JAD180763> ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180763 ;
    ns0:inAuthorList ns150:JAD180763 .

ns26:JAD180789 ns0:inAuthorList ns150:JAD180789 .

ns26:JAD180914 ns0:inAuthorList ns150:JAD180914 .

ns26:JAD180981 ns0:inAuthorList ns150:JAD180981 .

ns26:JAD180985 ns0:inAuthorList ns150:JAD180985 .

ns26:JAD181108 ns0:inAuthorList ns150:JAD181108 .

ns26:JAD181174 ns0:inAuthorList ns150:JAD181174 .

ns26:JAD181212 owl:sameAs ns28:JAD148009,
        ns60:JAD130080,
        ns60:JAD150729 ;
    ns0:fullName "Andrew J. Saykin" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:JAD181212> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181212 ;
    ns0:inAuthorList ns150:JAD181212 .

ns26:JAD190041 owl:sameAs ns30:jad01337 ;
    ns0:fullName "Wiesje M. van der Flier" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190041> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190041 ;
    ns0:inAuthorList ns150:JAD190041 .

ns26:JAD190046 owl:sameAs ns2:JAD130203,
        ns2:JAD131433,
        ns8:JAD131085,
        ns26:JAD161173,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120223>,
        ns28:JAD131334,
        ns30:JAD121525,
        ns5:JAD110911,
        ns5:JAD132186,
        ns5:JAD160722,
        ns5:JAD180595,
        <http://ld.iospress.nl/rdf/contributor/Author:48.ID:JAD160668>,
        ns16:JAD170324,
        ns16:JAD180299,
        ns52:JAD160750,
        ns52:JAD170627,
        ns52:jad100678,
        ns57:JAD101422,
        ns57:JAD132195,
        ns57:JAD161113,
        ns60:JAD111949,
        ns60:JAD140624,
        ns60:JAD150776,
        ns60:JAD151175,
        ns33:JAD112120,
        ns33:JAD130062,
        ns33:JAD132027,
        ns33:JAD150899,
        ns33:JAD180378 ;
    ns0:fullName "José L. Molinuevo" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:10.ID:JAD190046> ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190046 ;
    ns0:inAuthorList ns150:JAD190046 .

ns26:JAD190069 ns0:inAuthorList ns150:JAD190069 .

ns26:JHD160197 ns0:inAuthorList ns150:JHD160197 .

ns26:JND170238 ns0:inAuthorList ns150:JND170238 .

ns26:JPD181434 ns0:inAuthorList ns150:JPD181434 .

ns26:JPD191610 owl:sameAs ns2:JAD111340,
        ns30:JAD190014,
        ns52:JAD101809,
        ns33:JAD110608 ;
    ns0:fullName "Thomas G. Beach" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JPD191610> ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191610 ;
    ns0:inAuthorList ns150:JPD191610 .

ns26:KCA170018 ns0:inAuthorList ns150:KCA170018 .

ns26:NRE172156 ns0:inAuthorList ns150:NRE172156 .

ns26:XST190506 owl:sameAs ns57:XST180477 ;
    ns0:fullName "Hairong Zheng" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:XST190506> ;
    ns0:hasArticle ns1:xst-v27-i4-XST190506 ;
    ns0:inAuthorList ns150:XST190506 .

ns26:jad00868 ns0:inAuthorList ns150:jad00868 .

ns26:jad01114 ns0:inAuthorList ns150:jad01114 .

ns26:jad091054 ns0:inAuthorList ns150:jad091054 .

ns26:jad091150 ns0:inAuthorList ns150:jad091150 .

ns26:jad091594 ns0:inAuthorList ns150:jad091594 .

ns26:jad100114 ns0:inAuthorList ns150:jad100114 .

ns26:jad100933 ns0:inAuthorList ns150:jad100933 .

ns26:jad101023 ns0:inAuthorList ns150:jad101023 .

ns26:jad101348 ns0:inAuthorList ns150:jad101348 .

ns26:jad101413 ns0:inAuthorList ns150:jad101413 .

ns40:HAB282 ns0:inAuthorList ns150:HAB282 .

ns40:HAB299 ns0:inAuthorList ns150:HAB299 .

ns40:JAD101533 ns0:inAuthorList ns150:JAD101533 .

ns40:JAD110515 ns0:inAuthorList ns150:JAD110515 .

ns40:JAD120148 ns0:inAuthorList ns150:JAD120148 .

ns40:JAD120763 ns0:inAuthorList ns150:JAD120763 .

ns40:JAD120946 ns0:inAuthorList ns150:JAD120946 .

ns40:JAD121180 ns0:inAuthorList ns150:JAD121180 .

ns40:JAD121363 ns0:inAuthorList ns150:JAD121363 .

ns40:JAD121474 ns0:inAuthorList ns150:JAD121474 .

ns40:JAD121963 ns0:inAuthorList ns150:JAD121963 .

ns40:JAD130053 ns0:inAuthorList ns150:JAD130053 .

ns40:JAD130485 ns0:inAuthorList ns150:JAD130485 .

ns40:JAD131334 ns0:inAuthorList ns150:JAD131334 .

ns40:JAD131382 ns0:inAuthorList ns150:JAD131382 .

ns40:JAD131802 ns0:inAuthorList ns150:JAD131802 .

ns40:JAD131892 ns0:inAuthorList ns150:JAD131892 .

ns40:JAD132075 ns0:inAuthorList ns150:JAD132075 .

ns40:JAD132147 ns0:inAuthorList ns150:JAD132147 .

ns40:JAD140174 ns0:inAuthorList ns150:JAD140174 .

ns40:JAD140798 ns0:inAuthorList ns150:JAD140798 .

ns40:JAD141044 ns0:inAuthorList ns150:JAD141044 .

ns40:JAD150637 ns0:inAuthorList ns150:JAD150637 .

ns40:JAD150812 ns0:inAuthorList ns150:JAD150812 .

ns40:JAD150948 ns0:inAuthorList ns150:JAD150948 .

ns40:JAD151097 ns0:inAuthorList ns150:JAD151097 .

ns40:JAD151139 ns0:inAuthorList ns150:JAD151139 .

ns40:JAD160025 ns0:inAuthorList ns150:JAD160025 .

ns40:JAD160108 ns0:inAuthorList ns150:JAD160108 .

ns40:JAD160110 ns0:inAuthorList ns150:JAD160110 .

ns40:JAD160143 ns0:inAuthorList ns150:JAD160143 .

ns40:JAD160209 ns0:inAuthorList ns150:JAD160209 .

ns40:JAD160289 ns0:inAuthorList ns150:JAD160289 .

ns40:JAD160300 ns0:inAuthorList ns150:JAD160300 .

ns40:JAD160386 ns0:inAuthorList ns150:JAD160386 .

ns40:JAD160407 ns0:inAuthorList ns150:JAD160407 .

ns40:JAD160522 ns0:inAuthorList ns150:JAD160522 .

ns40:JAD160528 ns0:inAuthorList ns150:JAD160528 .

ns40:JAD160887 ns0:inAuthorList ns150:JAD160887 .

ns40:JAD161173 ns0:inAuthorList ns150:JAD161173 .

ns40:JAD161181 ns0:inAuthorList ns150:JAD161181 .

ns40:JAD170238 ns0:inAuthorList ns150:JAD170238 .

ns40:JAD170368 ns0:inAuthorList ns150:JAD170368 .

ns40:JAD170444 ns0:inAuthorList ns150:JAD170444 .

ns40:JAD170534 ns0:inAuthorList ns150:JAD170534 .

ns40:JAD170712 ns0:inAuthorList ns150:JAD170712 .

ns40:JAD170813 ns0:inAuthorList ns150:JAD170813 .

ns40:JAD171077 ns0:inAuthorList ns150:JAD171077 .

ns40:JAD171145 ns0:inAuthorList ns150:JAD171145 .

ns40:JAD180049 ns0:inAuthorList ns150:JAD180049 .

ns40:JAD180071 ns0:inAuthorList ns150:JAD180071 .

ns40:JAD180082 ns0:inAuthorList ns150:JAD180082 .

ns40:JAD180106 ns0:inAuthorList ns150:JAD180106 .

ns40:JAD180167 ns0:inAuthorList ns150:JAD180167 .

ns40:JAD180394 ns0:inAuthorList ns150:JAD180394 .

ns40:JAD180629 ns0:inAuthorList ns150:JAD180629 .

ns40:JAD180723 ns0:inAuthorList ns150:JAD180723 .

ns40:JAD180839 ns0:inAuthorList ns150:JAD180839 .

ns40:JAD180855 ns0:inAuthorList ns150:JAD180855 .

ns40:JAD180982 ns0:inAuthorList ns150:JAD180982 .

ns40:JAD181016 ns0:inAuthorList ns150:JAD181016 .

ns40:JAD190087 owl:sameAs ns12:JAD190256 ;
    ns0:fullName "Hajime Takechi" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:11.ID:JAD190087> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190087 ;
    ns0:inAuthorList ns150:JAD190087 .

ns40:JAD190091 owl:sameAs ns2:JAD150985 ;
    ns0:fullName "Jennifer H. Lingler" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:11.ID:JAD190091> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190091 ;
    ns0:inAuthorList ns150:JAD190091 .

ns40:JAD190133 owl:sameAs ns8:JAD110065,
        ns8:JAD129021,
        ns8:JAD132363,
        ns8:jad01404,
        ns8:jad091450,
        ns40:JAD170858,
        ns130:JAD170123,
        ns30:JAD120802,
        ns30:JAD142052,
        ns5:ADR170035,
        ns5:JAD132225,
        ns5:JAD180199,
        ns5:jad00920,
        ns16:JAD111736,
        ns16:jad100795,
        ns52:JAD130698,
        ns52:JAD140924,
        ns52:JAD160593,
        ns52:jad100114,
        ns52:jad100663,
        ns60:JAD120946 ;
    ns0:fullName "Miia Kivipelto" ;
    ns0:hasAffiliation ns114:JAD190133,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:11.ID:JAD190133>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:11.ID:JAD190133>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:11.ID:JAD190133> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190133 ;
    ns0:inAuthorList ns150:JAD190133 .

ns40:JAD190160 ns0:inAuthorList ns150:JAD190160 .

ns40:JND160151 ns0:inAuthorList ns150:JND160151 .

ns40:XST180391 ns0:inAuthorList ns150:XST180391 .

ns40:XST190506 owl:sameAs ns33:XST190527 ;
    ns0:fullName "Zhanli Hu" ;
    ns0:hasAffiliation ns114:XST190506 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190506 ;
    ns0:inAuthorList ns150:XST190506 .

ns40:jad00656 ns0:inAuthorList ns150:jad00656 .

ns40:jad00836 ns0:inAuthorList ns150:jad00836 .

ns40:jad01074 ns0:inAuthorList ns150:jad01074 .

ns40:jad091549 ns0:inAuthorList ns150:jad091549 .

ns40:jad091651 ns0:inAuthorList ns150:jad091651 .

ns40:jad100201 ns0:inAuthorList ns150:jad100201 .

ns40:jad100630 ns0:inAuthorList ns150:jad100630 .

ns40:jad100702 ns0:inAuthorList ns150:jad100702 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:ADR170051> ns0:inAuthorList ns150:ADR170051 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:BLC180172> ns0:inAuthorList ns150:BLC180172 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD102124> ns0:inAuthorList ns150:JAD102124 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120223> ns0:inAuthorList ns150:JAD120223 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120946> ns0:inAuthorList ns150:JAD120946 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD121189> ns0:inAuthorList ns150:JAD121189 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD121474> ns0:inAuthorList ns150:JAD121474 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD121771> ns0:inAuthorList ns150:JAD121771 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD122383> ns0:inAuthorList ns150:JAD122383 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD130311> ns0:inAuthorList ns150:JAD130311 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD131916> ns0:inAuthorList ns150:JAD131916 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD132075> ns0:inAuthorList ns150:JAD132075 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD132147> ns0:inAuthorList ns150:JAD132147 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD141521> ns0:inAuthorList ns150:JAD141521 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD141623> ns0:inAuthorList ns150:JAD141623 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD150167> ns0:inAuthorList ns150:JAD150167 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD150746> ns0:inAuthorList ns150:JAD150746 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD150948> ns0:inAuthorList ns150:JAD150948 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160091> ns0:inAuthorList ns150:JAD160091 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160143> ns0:inAuthorList ns150:JAD160143 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160474> ns0:inAuthorList ns150:JAD160474 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160538> ns0:inAuthorList ns150:JAD160538 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160554> ns0:inAuthorList ns150:JAD160554 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD160642> ns0:inAuthorList ns150:JAD160642 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD161109> ns0:inAuthorList ns150:JAD161109 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD161173> ns0:inAuthorList ns150:JAD161173 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170073> ns0:inAuthorList ns150:JAD170073 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170123> ns0:inAuthorList ns150:JAD170123 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170231> ns0:inAuthorList ns150:JAD170231 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170368> ns0:inAuthorList ns150:JAD170368 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170410> ns0:inAuthorList ns150:JAD170410 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170483> ns0:inAuthorList ns150:JAD170483 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170534> ns0:inAuthorList ns150:JAD170534 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170556> ns0:inAuthorList ns150:JAD170556 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170560> ns0:inAuthorList ns150:JAD170560 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170971> ns0:inAuthorList ns150:JAD170971 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD171182> ns0:inAuthorList ns150:JAD171182 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD179932> ns0:inAuthorList ns150:JAD179932 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180025> ns0:inAuthorList ns150:JAD180025 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180291> ns0:inAuthorList ns150:JAD180291 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180394> ns0:inAuthorList ns150:JAD180394 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180486> ns0:inAuthorList ns150:JAD180486 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD180981> ns0:inAuthorList ns150:JAD180981 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181135> ns0:inAuthorList ns150:JAD181135 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190019> ns0:inAuthorList ns150:JAD190019 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190023> ns0:inAuthorList ns150:JAD190023 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190311> owl:sameAs ns2:JAD160304,
        ns26:JAD0044,
        ns26:jad100201,
        ns40:JAD111592,
        ns28:JAD170027,
        ns130:JAD170039,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD122182>,
        ns12:JAD190638,
        ns176:JAD180152,
        ns139:JAD180321,
        <http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD180512>,
        <http://ld.iospress.nl/rdf/contributor/Author:23.ID:JAD181016>,
        ns180:JAD161097,
        ns30:JAD161020,
        ns5:JAD131640,
        ns5:JAD140942,
        <http://ld.iospress.nl/rdf/contributor/Author:42.ID:JAD160668>,
        ns16:JAD131121,
        ns16:JAD170564,
        ns16:JAD190423,
        ns16:jad100459,
        ns52:JAD121408,
        ns52:JAD122110,
        ns52:JAD142214,
        ns52:JAD160348,
        ns52:JAD160766,
        ns52:JAD180223,
        ns57:JAD140669,
        ns57:JAD160645,
        <http://ld.iospress.nl/rdf/contributor/Author:76.ID:JAD110824>,
        ns60:JAD141260,
        ns60:JAD150440,
        ns60:JAD160518 ;
    ns0:fullName "Magda Tsolaki" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:12.ID:JAD190311>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:12.ID:JAD190311> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190311 ;
    ns0:inAuthorList ns150:JAD190311 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190369> owl:sameAs ns8:JAD181218 ;
    ns0:fullName "Yasuyuki Ohta" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190369> ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190369 ;
    ns0:inAuthorList ns150:JAD190369 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JND160151> ns0:inAuthorList ns150:JND160151 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JND190421> ns0:inAuthorList ns150:JND190421 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JPD160888> ns0:inAuthorList ns150:JPD160888 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JPD181568> owl:sameAs ns5:JPD191593 ;
    ns0:fullName "Werner Poewe" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JPD181568> ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD181568 ;
    ns0:inAuthorList ns150:JPD181568 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad00656> ns0:inAuthorList ns150:jad00656 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad00804> ns0:inAuthorList ns150:jad00804 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad01390> ns0:inAuthorList ns150:jad01390 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad091474> ns0:inAuthorList ns150:jad091474 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad100123> ns0:inAuthorList ns150:jad100123 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad100141> ns0:inAuthorList ns150:jad100141 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad100837> ns0:inAuthorList ns150:jad100837 .

ns28:JAD101221 ns0:inAuthorList ns150:JAD101221 .

ns28:JAD102145 ns0:inAuthorList ns150:JAD102145 .

ns28:JAD112003 ns0:inAuthorList ns150:JAD112003 .

ns28:JAD120637 ns0:inAuthorList ns150:JAD120637 .

ns28:JAD121474 ns0:inAuthorList ns150:JAD121474 .

ns28:JAD130053 ns0:inAuthorList ns150:JAD130053 .

ns28:JAD130104 ns0:inAuthorList ns150:JAD130104 .

ns28:JAD130128 ns0:inAuthorList ns150:JAD130128 .

ns28:JAD131265 ns0:inAuthorList ns150:JAD131265 .

ns28:JAD131334 ns0:inAuthorList ns150:JAD131334 .

ns28:JAD131574 ns0:inAuthorList ns150:JAD131574 .

ns28:JAD131820 ns0:inAuthorList ns150:JAD131820 .

ns28:JAD131916 ns0:inAuthorList ns150:JAD131916 .

ns28:JAD132345 ns0:inAuthorList ns150:JAD132345 .

ns28:JAD140057 ns0:inAuthorList ns150:JAD140057 .

ns28:JAD141512 ns0:inAuthorList ns150:JAD141512 .

ns28:JAD141623 ns0:inAuthorList ns150:JAD141623 .

ns28:JAD150914 ns0:inAuthorList ns150:JAD150914 .

ns28:JAD160025 ns0:inAuthorList ns150:JAD160025 .

ns28:JAD160126 ns0:inAuthorList ns150:JAD160126 .

ns28:JAD160143 ns0:inAuthorList ns150:JAD160143 .

ns28:JAD160188 ns0:inAuthorList ns150:JAD160188 .

ns28:JAD160285 ns0:inAuthorList ns150:JAD160285 .

ns28:JAD160341 ns0:inAuthorList ns150:JAD160341 .

ns28:JAD160407 ns0:inAuthorList ns150:JAD160407 .

ns28:JAD160524 ns0:inAuthorList ns150:JAD160524 .

ns28:JAD161023 ns0:inAuthorList ns150:JAD161023 .

ns28:JAD161139 ns0:inAuthorList ns150:JAD161139 .

ns28:JAD161158 ns0:inAuthorList ns150:JAD161158 .

ns28:JAD170402 ns0:inAuthorList ns150:JAD170402 .

ns28:JAD170507 ns0:inAuthorList ns150:JAD170507 .

ns28:JAD170537 ns0:inAuthorList ns150:JAD170537 .

ns28:JAD170556 ns0:inAuthorList ns150:JAD170556 .

ns28:JAD170583 ns0:inAuthorList ns150:JAD170583 .

ns28:JAD171182 ns0:inAuthorList ns150:JAD171182 .

ns28:JAD181212 owl:sameAs ns2:NRE182534,
        ns2:jad01168,
        ns8:JAD130281,
        ns8:JAD170414,
        ns8:JAD180746,
        ns8:jad01180,
        ns26:JAD150749,
        ns12:JAD101821,
        ns5:JAD120202,
        ns16:JAD161224,
        ns16:JAD181080,
        ns60:JAD180942,
        ns33:JAD160374 ;
    ns0:fullName "Eric B. Larson" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:13.ID:JAD181212> ;
    ns0:hasArticle ns1:jad-v70-i2-JAD181212 ;
    ns0:inAuthorList ns150:JAD181212 .

ns28:JAD190113 owl:sameAs ns2:JAD179924,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD131574>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181108>,
        ns12:JAD150978,
        ns118:JAD180341,
        ns5:jad100078,
        ns33:jad00971 ;
    ns0:fullName "Serge Gauthier" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:13.ID:JAD190113> ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190113 ;
    ns0:inAuthorList ns150:JAD190113 .

ns28:JAD190132 owl:sameAs ns26:JAD130380,
        ns40:JAD140942,
        ns40:JAD170583,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD122182>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD190334>,
        ns30:ADR170035,
        ns30:jad00920,
        <http://ld.iospress.nl/rdf/contributor/Author:39.ID:JAD160668>,
        ns5:JAD130359,
        ns16:JAD131088,
        ns16:JAD140924,
        ns52:JAD110365,
        ns57:jad100597,
        ns60:JAD150909,
        ns33:JAD111109,
        ns33:JAD121363,
        ns33:JAD170362 ;
    ns0:fullName "Hilkka Soininen" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190132>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:13.ID:JAD190132> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

ns28:JAD190533 owl:sameAs ns2:JAD170773,
        ns2:jad01177,
        ns8:JAD129035,
        ns40:JAD120787,
        ns40:JAD180025,
        ns28:JAD120508,
        ns130:JAD150167,
        ns12:JAD101959,
        ns12:JAD150525,
        ns30:JAD150883,
        ns30:JAD161275,
        ns5:JAD130035,
        ns5:JAD160110,
        ns5:JAD160573,
        ns5:JAD170368,
        ns5:jad091012,
        ns5:jad100207,
        ns16:JAD111361,
        ns16:JAD161114,
        ns16:JAD161257,
        ns16:JAD180099,
        ns16:JAD190187,
        ns16:jad00125,
        ns52:JAD142025,
        ns52:JAD170226,
        ns52:JAD170784,
        ns52:JAD170950,
        ns57:JAD120019,
        ns57:JAD140339,
        ns57:JAD160195,
        ns57:JAD160528,
        ns57:JAD161146,
        ns57:JAD170402,
        ns57:JAD190077,
        ns60:JAD120931,
        ns60:JAD150897,
        ns60:JAD161126,
        ns33:jad101023 ;
    ns0:fullName "Kaj Blennow" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:13.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:13.ID:JAD190533> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190533 ;
    ns0:inAuthorList ns150:JAD190533 .

ns28:JND190397 owl:sameAs ns8:JHD180287 ;
    ns0:fullName "Peggy C. Nopoulos" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JND190397> ;
    ns0:hasArticle ns1:jnd-v6-i3-JND190397 ;
    ns0:inAuthorList ns150:JND190397 .

ns28:JPD171081 ns0:inAuthorList ns150:JPD171081 .

ns28:JPD171135 ns0:inAuthorList ns150:JPD171135 .

ns28:jad00971 ns0:inAuthorList ns150:jad00971 .

ns28:jad01285 ns0:inAuthorList ns150:jad01285 .

ns28:jad100126 ns0:inAuthorList ns150:jad100126 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD0004> ns0:inAuthorList ns150:JAD0004 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD101221> ns0:inAuthorList ns150:JAD101221 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD111748> ns0:inAuthorList ns150:JAD111748 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD112123> ns0:inAuthorList ns150:JAD112123 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD120763> ns0:inAuthorList ns150:JAD120763 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD121927> ns0:inAuthorList ns150:JAD121927 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD130203> ns0:inAuthorList ns150:JAD130203 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD131820> ns0:inAuthorList ns150:JAD131820 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD141338> ns0:inAuthorList ns150:JAD141338 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD141773> ns0:inAuthorList ns150:JAD141773 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150250> ns0:inAuthorList ns150:JAD150250 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150261> ns0:inAuthorList ns150:JAD150261 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150446> ns0:inAuthorList ns150:JAD150446 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150556> ns0:inAuthorList ns150:JAD150556 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD150832> ns0:inAuthorList ns150:JAD150832 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160108> ns0:inAuthorList ns150:JAD160108 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160766> ns0:inAuthorList ns150:JAD160766 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD161019> ns0:inAuthorList ns150:JAD161019 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170507> ns0:inAuthorList ns150:JAD170507 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170509> ns0:inAuthorList ns150:JAD170509 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170537> ns0:inAuthorList ns150:JAD170537 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170583> ns0:inAuthorList ns150:JAD170583 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170893> ns0:inAuthorList ns150:JAD170893 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD171182> ns0:inAuthorList ns150:JAD171182 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD180291> ns0:inAuthorList ns150:JAD180291 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD180321> ns0:inAuthorList ns150:JAD180321 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD180507> ns0:inAuthorList ns150:JAD180507 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD180981> ns0:inAuthorList ns150:JAD180981 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD181088> ns0:inAuthorList ns150:JAD181088 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD181175> owl:sameAs ns60:jad01051 ;
    ns0:fullName "Ramon Diaz-Arrastia" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD181175> ;
    ns0:hasArticle ns1:jad-v71-i2-JAD181175 ;
    ns0:inAuthorList ns150:JAD181175 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JND170231> ns0:inAuthorList ns150:JND170231 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:NPM18117> ns0:inAuthorList ns150:NPM18117 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:jad00802> ns0:inAuthorList ns150:jad00802 .

ns43:JAD111832 ns0:inAuthorList ns150:JAD111832 .

ns43:JAD130461 ns0:inAuthorList ns150:JAD130461 .

ns43:JAD132072 ns0:inAuthorList ns150:JAD132072 .

ns43:JAD141011 ns0:inAuthorList ns150:JAD141011 .

ns43:JAD141521 ns0:inAuthorList ns150:JAD141521 .

ns43:JAD142409 ns0:inAuthorList ns150:JAD142409 .

ns43:JAD150446 ns0:inAuthorList ns150:JAD150446 .

ns43:JAD150832 ns0:inAuthorList ns150:JAD150832 .

ns43:JAD150948 ns0:inAuthorList ns150:JAD150948 .

ns43:JAD160108 ns0:inAuthorList ns150:JAD160108 .

ns43:JAD160126 ns0:inAuthorList ns150:JAD160126 .

ns43:JAD160195 ns0:inAuthorList ns150:JAD160195 .

ns43:JAD160209 ns0:inAuthorList ns150:JAD160209 .

ns43:JAD160536 ns0:inAuthorList ns150:JAD160536 .

ns43:JAD160573 ns0:inAuthorList ns150:JAD160573 .

ns43:JAD161019 ns0:inAuthorList ns150:JAD161019 .

ns43:JAD161158 ns0:inAuthorList ns150:JAD161158 .

ns43:JAD170123 ns0:inAuthorList ns150:JAD170123 .

ns43:JAD170128 ns0:inAuthorList ns150:JAD170128 .

ns43:JAD170260 ns0:inAuthorList ns150:JAD170260 .

ns43:JAD170347 ns0:inAuthorList ns150:JAD170347 .

ns43:JAD170555 ns0:inAuthorList ns150:JAD170555 .

ns43:JAD170657 ns0:inAuthorList ns150:JAD170657 .

ns43:JAD170712 ns0:inAuthorList ns150:JAD170712 .

ns43:JAD170834 ns0:inAuthorList ns150:JAD170834 .

ns43:JAD170971 ns0:inAuthorList ns150:JAD170971 .

ns43:JAD171140 ns0:inAuthorList ns150:JAD171140 .

ns43:JAD180048 ns0:inAuthorList ns150:JAD180048 .

ns43:JAD180071 ns0:inAuthorList ns150:JAD180071 .

ns43:JAD180572 ns0:inAuthorList ns150:JAD180572 .

ns43:JAD190132 ns0:inAuthorList ns150:JAD190132 .

ns43:JND170231 ns0:inAuthorList ns150:JND170231 .

ns43:jad00759 ns0:inAuthorList ns150:jad00759 .

ns130:JAD0002 ns0:inAuthorList ns150:JAD0002 .

ns130:JAD121474 ns0:inAuthorList ns150:JAD121474 .

ns130:JAD122182 ns0:inAuthorList ns150:JAD122182 .

ns130:JAD141773 ns0:inAuthorList ns150:JAD141773 .

ns130:JAD150446 ns0:inAuthorList ns150:JAD150446 .

ns130:JAD150948 ns0:inAuthorList ns150:JAD150948 .

ns130:JAD151155 ns0:inAuthorList ns150:JAD151155 .

ns130:JAD160126 ns0:inAuthorList ns150:JAD160126 .

ns130:JAD160407 ns0:inAuthorList ns150:JAD160407 .

ns130:JAD160949 ns0:inAuthorList ns150:JAD160949 .

ns130:JAD170971 ns0:inAuthorList ns150:JAD170971 .

ns130:JAD180048 ns0:inAuthorList ns150:JAD180048 .

ns130:JAD180158 ns0:inAuthorList ns150:JAD180158 .

ns130:JAD180275 ns0:inAuthorList ns150:JAD180275 .

ns130:JAD180788 ns0:inAuthorList ns150:JAD180788 .

ns130:JAD180981 ns0:inAuthorList ns150:JAD180981 .

ns130:JAD181175 ns0:inAuthorList ns150:JAD181175 .

ns130:JAD190772 owl:sameAs ns5:JAD170727 ;
    ns0:fullName "Charles R. Harrington" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:16.ID:JAD190772> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190772 ;
    ns0:inAuthorList ns150:JAD190772 .

ns130:KCA170010 ns0:inAuthorList ns150:KCA170010 .

ns130:KCA180045 ns0:inAuthorList ns150:KCA180045 .

ns130:jad00971 ns0:inAuthorList ns150:jad00971 .

ns130:jad090249 ns0:inAuthorList ns150:jad090249 .

ns130:jad100201 ns0:inAuthorList ns150:jad100201 .

ns130:jad100933 ns0:inAuthorList ns150:jad100933 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD111046> ns0:inAuthorList ns150:JAD111046 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD140057> ns0:inAuthorList ns150:JAD140057 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD140318> ns0:inAuthorList ns150:JAD140318 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD141521> ns0:inAuthorList ns150:JAD141521 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD150651> ns0:inAuthorList ns150:JAD150651 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD160209> ns0:inAuthorList ns150:JAD160209 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD160407> ns0:inAuthorList ns150:JAD160407 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD160645> ns0:inAuthorList ns150:JAD160645 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD170092> ns0:inAuthorList ns150:JAD170092 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD170123> ns0:inAuthorList ns150:JAD170123 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD170720> ns0:inAuthorList ns150:JAD170720 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD171140> ns0:inAuthorList ns150:JAD171140 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD180981> ns0:inAuthorList ns150:JAD180981 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD190119> owl:sameAs ns2:JAD131172,
        ns26:JAD150849,
        ns40:JAD111544,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120523>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160949>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170712>,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD122263>,
        ns132:JAD111046,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD102124>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:jad01328>,
        ns12:JAD110788,
        ns12:JAD121606,
        ns12:JAD122302,
        ns12:JAD130053,
        ns12:JAD132075,
        ns12:JAD180242,
        ns176:JAD110074,
        ns143:JAD150863,
        ns30:JAD170702,
        ns5:jad01129,
        ns5:jad01309,
        ns16:JAD180715,
        ns52:JAD150786,
        ns52:jad01285,
        <http://ld.iospress.nl/rdf/contributor/Author:61.ID:jad100933>,
        ns57:JAD112006,
        ns60:JAD101764,
        ns33:JAD140057,
        ns33:JAD170861 ;
    ns0:fullName "Daniela Galimberti" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:17.ID:JAD190119> ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD190132> owl:sameAs ns26:JAD180071,
        ns30:jad100114,
        ns16:jad100597 ;
    ns0:fullName "Sanna-Kaisa Herukka" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:17.ID:JAD190132>,
        ns149:JAD190132 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD190772> owl:sameAs ns2:jad00693 ;
    ns0:fullName "Claude M. Wischik" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:17.ID:JAD190772> ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190772 ;
    ns0:inAuthorList ns150:JAD190772 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:jad01170> ns0:inAuthorList ns150:jad01170 .

ns132:BLC180182 ns0:inAuthorList ns150:BLC180182 .

ns132:JAD101839 ns0:inAuthorList ns150:JAD101839 .

ns132:JAD102124 ns0:inAuthorList ns150:JAD102124 .

ns132:JAD120172 ns0:inAuthorList ns150:JAD120172 .

ns132:JAD160209 ns0:inAuthorList ns150:JAD160209 .

ns132:JAD160573 ns0:inAuthorList ns150:JAD160573 .

ns132:JAD170092 ns0:inAuthorList ns150:JAD170092 .

ns132:JAD170560 ns0:inAuthorList ns150:JAD170560 .

ns132:JAD170624 ns0:inAuthorList ns150:JAD170624 .

ns132:JAD170742 ns0:inAuthorList ns150:JAD170742 .

ns132:JAD171145 ns0:inAuthorList ns150:JAD171145 .

ns132:JAD180048 ns0:inAuthorList ns150:JAD180048 .

ns132:JAD180404 ns0:inAuthorList ns150:JAD180404 .

ns132:JAD190007 ns0:inAuthorList ns150:JAD190007 .

ns132:JND170280 ns0:inAuthorList ns150:JND170280 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD140777> ns0:inAuthorList ns150:JAD140777 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD141521> ns0:inAuthorList ns150:JAD141521 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD150555> ns0:inAuthorList ns150:JAD150555 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD150817> ns0:inAuthorList ns150:JAD150817 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD160108> ns0:inAuthorList ns150:JAD160108 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD160407> ns0:inAuthorList ns150:JAD160407 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD170742> ns0:inAuthorList ns150:JAD170742 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD170875> ns0:inAuthorList ns150:JAD170875 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD171145> ns0:inAuthorList ns150:JAD171145 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD180106> ns0:inAuthorList ns150:JAD180106 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD180981> ns0:inAuthorList ns150:JAD180981 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:jad00971> ns0:inAuthorList ns150:jad00971 .

ns12:1036922 ns0:inAuthorList ns150:1036922 .

ns12:AAC013 ns0:inAuthorList ns150:AAC013 .

ns12:AIC746 ns0:inAuthorList ns150:AIC746 .

ns12:AIC763 ns0:inAuthorList ns150:AIC763 .

ns12:AIS180507 ns0:inAuthorList ns150:AIS180507 .

ns12:ASY191521 ns0:inAuthorList ns150:ASY191521 .

ns12:BD180351 ns0:inAuthorList ns150:BD180351 .

ns12:BIR180175 ns0:inAuthorList ns150:BIR180175 .

ns12:BLC180175 ns0:inAuthorList ns150:BLC180175 .

ns12:BME1447 ns0:inAuthorList ns150:BME1447 .

ns12:BME1486 ns0:inAuthorList ns150:BME1486 .

ns12:BME1709 ns0:inAuthorList ns150:BME1709 .

ns12:BME1715 ns0:inAuthorList ns150:BME1715 .

ns12:BME1732 ns0:inAuthorList ns150:BME1732 .

ns12:BME1734 ns0:inAuthorList ns150:BME1734 .

ns12:BMR140162 ns0:inAuthorList ns150:BMR140162 .

ns12:BMR160543 ns0:inAuthorList ns150:BMR160543 .

ns12:BMR160585 ns0:inAuthorList ns150:BMR160585 .

ns12:BMR169775 ns0:inAuthorList ns150:BMR169775 .

ns12:BMR171041 owl:sameAs ns12:bmr00426 ;
    ns0:fullName "Amir Ahmadi" ;
    ns0:hasAffiliation ns14:BMR171041 ;
    ns0:hasArticle ns1:bmr-v32-i4-BMR171041 ;
    ns0:inAuthorList ns150:BMR171041 .

ns12:BPL180071 ns0:inAuthorList ns150:BPL180071 .

ns12:BRS106 ns0:inAuthorList ns150:BRS106 .

ns12:BRS113 ns0:inAuthorList ns150:BRS113 .

ns12:BSI183 ns0:inAuthorList ns150:BSI183 .

ns12:CBM181368 ns0:inAuthorList ns150:CBM181368 .

ns12:CBM567 ns0:inAuthorList ns150:CBM567 .

ns12:CH160241 ns0:inAuthorList ns150:CH160241 .

ns12:CH168033 ns0:inAuthorList ns150:CH168033 .

ns12:CH168051 ns0:inAuthorList ns150:CH168051 .

ns12:CH168052 ns0:inAuthorList ns150:CH168052 .

ns12:CH168110 ns0:inAuthorList ns150:CH168110 .

ns12:CH168115 ns0:inAuthorList ns150:CH168115 .

ns12:CH168123 ns0:inAuthorList ns150:CH168123 .

ns12:CH179103 ns0:inAuthorList ns150:CH179103 .

ns12:CH179203 ns0:inAuthorList ns150:CH179203 .

ns12:CH179218 ns0:inAuthorList ns150:CH179218 .

ns12:CH179227 ns0:inAuthorList ns150:CH179227 .

ns12:CH180417 ns0:inAuthorList ns150:CH180417 .

ns12:CH180457 ns0:inAuthorList ns150:CH180457 .

ns12:CH180515 ns0:inAuthorList ns150:CH180515 .

ns12:CH189120 ns0:inAuthorList ns150:CH189120 .

ns12:CH189126 ns0:inAuthorList ns150:CH189126 .

ns12:CH189301 ns0:inAuthorList ns150:CH189301 .

ns12:CH189307 ns0:inAuthorList ns150:CH189307 .

ns12:CH189309 ns0:inAuthorList ns150:CH189309 .

ns12:CH189312 ns0:inAuthorList ns150:CH189312 .

ns12:CH189319 ns0:inAuthorList ns150:CH189319 .

ns12:CH1953 ns0:inAuthorList ns150:CH1953 .

ns12:CH1985 ns0:inAuthorList ns150:CH1985 .

ns12:CH1990 ns0:inAuthorList ns150:CH1990 .

ns12:CH199008 ns0:inAuthorList ns150:CH199008 .

ns12:CH199221 owl:sameAs ns8:CH179112,
        ns8:CH179218,
        ns8:CH179225,
        ns30:CH179217 ;
    ns0:fullName "L.P. Beyer" ;
    ns0:hasAffiliation ns15:CH199221 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199221 ;
    ns0:inAuthorList ns150:CH199221 .

ns12:CH199222 ns0:inAuthorList ns150:CH199222 .

ns12:COM094 owl:sameAs ns2:COM035 ;
    ns0:fullName "Denis R. Hirschfeldt" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:COM094> ;
    ns0:hasArticle ns1:com-v8-i3-4-COM094 ;
    ns0:inAuthorList ns150:COM094 .

ns12:COM180219 ns0:inAuthorList ns150:COM180219 .

ns12:DS190015 owl:sameAs ns12:SW266 ;
    ns0:fullName "Enrico Motta" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:DS190015> ;
    ns0:hasArticle ns1:ds-v2-i1-2-DS190015 ;
    ns0:inAuthorList ns150:DS190015 .

ns12:DS190023 owl:sameAs ns12:SW224,
        ns30:SW222 ;
    ns0:fullName "Silvio Peroni" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:DS190023> ;
    ns0:hasArticle ns1:ds-v2-i1-2-DS190023 ;
    ns0:inAuthorList ns150:DS190023 .

ns12:FI1455 ns0:inAuthorList ns150:FI1455 .

ns12:FI1528 ns0:inAuthorList ns150:FI1528 .

ns12:FI1604 ns0:inAuthorList ns150:FI1604 .

ns12:FI1631 ns0:inAuthorList ns150:FI1631 .

ns12:FI1633 ns0:inAuthorList ns150:FI1633 .

ns12:FI1669 ns0:inAuthorList ns150:FI1669 .

ns12:FI1799 ns0:inAuthorList ns150:FI1799 .

ns12:HAB190363 owl:sameAs ns8:JRS740,
        ns12:HAB190368,
        ns12:HAB190369,
        ns12:HAB190383 ;
    ns0:fullName "Ali Akbari Sari" ;
    ns0:hasAffiliation ns83:HAB190363 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190363 ;
    ns0:inAuthorList ns150:HAB190363 .

ns12:HAB190364 ns0:inAuthorList ns150:HAB190364 .

ns12:HAB190371 ns0:inAuthorList ns150:HAB190371 .

ns12:HAB282 ns0:inAuthorList ns150:HAB282 .

ns12:HAB325 ns0:inAuthorList ns150:HAB325 .

ns12:HAB330 ns0:inAuthorList ns150:HAB330 .

ns12:HAB335 ns0:inAuthorList ns150:HAB335 .

ns12:HSM17133 ns0:inAuthorList ns150:HSM17133 .

ns12:HSM17251 ns0:inAuthorList ns150:HSM17251 .

ns12:HSM180405 ns0:inAuthorList ns150:HSM180405 .

ns12:HSM180465 owl:sameAs ns12:HSM1794 ;
    ns0:fullName "Umair Akram" ;
    ns0:hasAffiliation ns83:HSM180465 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180465 ;
    ns0:inAuthorList ns150:HSM180465 .

ns12:IA096 ns0:inAuthorList ns150:IA096 .

ns12:IA109 ns0:inAuthorList ns150:IA109 .

ns12:IA110 ns0:inAuthorList ns150:IA110 .

ns12:IA170030 ns0:inAuthorList ns150:IA170030 .

ns12:IA190020 ns0:inAuthorList ns150:IA190020 .

ns12:IDA814 ns0:inAuthorList ns150:IDA814 .

ns12:IDA857 ns0:inAuthorList ns150:IDA857 .

ns12:IDT269 ns0:inAuthorList ns150:IDT269 .

ns12:IES173142 ns0:inAuthorList ns150:IES173142 .

ns12:IES192167 ns0:inAuthorList ns150:IES192167 .

ns12:IFS152261 ns0:inAuthorList ns150:IFS152261 .

ns12:IFS16117 ns0:inAuthorList ns150:IFS16117 .

ns12:IFS161320 ns0:inAuthorList ns150:IFS161320 .

ns12:IFS161747 ns0:inAuthorList ns150:IFS161747 .

ns12:IFS161916 ns0:inAuthorList ns150:IFS161916 .

ns12:IFS162053 ns0:inAuthorList ns150:IFS162053 .

ns12:IFS162136 ns0:inAuthorList ns150:IFS162136 .

ns12:IFS162234 ns0:inAuthorList ns150:IFS162234 .

ns12:IFS162245 ns0:inAuthorList ns150:IFS162245 .

ns12:IFS16381 ns0:inAuthorList ns150:IFS16381 .

ns12:IFS1667 ns0:inAuthorList ns150:IFS1667 .

ns12:IFS16845 ns0:inAuthorList ns150:IFS16845 .

ns12:IFS169204 ns0:inAuthorList ns150:IFS169204 .

ns12:IFS169212 ns0:inAuthorList ns150:IFS169212 .

ns12:IFS169583 ns0:inAuthorList ns150:IFS169583 .

ns12:IFS169590 ns0:inAuthorList ns150:IFS169590 .

ns12:IFS169608 ns0:inAuthorList ns150:IFS169608 .

ns12:IFS169768 ns0:inAuthorList ns150:IFS169768 .

ns12:IFS169770 ns0:inAuthorList ns150:IFS169770 .

ns12:IFS169940 ns0:inAuthorList ns150:IFS169940 .

ns12:IFS169965 ns0:inAuthorList ns150:IFS169965 .

ns12:IFS17077 ns0:inAuthorList ns150:IFS17077 .

ns12:IFS171017 ns0:inAuthorList ns150:IFS171017 .

ns12:IFS17104 ns0:inAuthorList ns150:IFS17104 .

ns12:IFS171058 ns0:inAuthorList ns150:IFS171058 .

ns12:IFS171070 ns0:inAuthorList ns150:IFS171070 .

ns12:IFS171104 ns0:inAuthorList ns150:IFS171104 .

ns12:IFS171142 ns0:inAuthorList ns150:IFS171142 .

ns12:IFS171172 ns0:inAuthorList ns150:IFS171172 .

ns12:IFS171265 ns0:inAuthorList ns150:IFS171265 .

ns12:IFS171297 ns0:inAuthorList ns150:IFS171297 .

ns12:IFS171448 ns0:inAuthorList ns150:IFS171448 .

ns12:IFS17158 ns0:inAuthorList ns150:IFS17158 .

ns12:IFS17168 ns0:inAuthorList ns150:IFS17168 .

ns12:IFS171707 ns0:inAuthorList ns150:IFS171707 .

ns12:IFS171717 ns0:inAuthorList ns150:IFS171717 .

ns12:IFS172139 ns0:inAuthorList ns150:IFS172139 .

ns12:IFS172264 ns0:inAuthorList ns150:IFS172264 .

ns12:IFS17267 ns0:inAuthorList ns150:IFS17267 .

ns12:IFS17378 ns0:inAuthorList ns150:IFS17378 .

ns12:IFS17467 ns0:inAuthorList ns150:IFS17467 .

ns12:IFS17530 ns0:inAuthorList ns150:IFS17530 .

ns12:IFS17636 ns0:inAuthorList ns150:IFS17636 .

ns12:IFS17682 ns0:inAuthorList ns150:IFS17682 .

ns12:IFS17741 ns0:inAuthorList ns150:IFS17741 .

ns12:IFS179061 ns0:inAuthorList ns150:IFS179061 .

ns12:IFS179081 ns0:inAuthorList ns150:IFS179081 .

ns12:IFS179083 ns0:inAuthorList ns150:IFS179083 .

ns12:IFS17912 ns0:inAuthorList ns150:IFS17912 .

ns12:IFS179122 ns0:inAuthorList ns150:IFS179122 .

ns12:IFS179275 ns0:inAuthorList ns150:IFS179275 .

ns12:IFS179373 owl:sameAs ns2:IFS1688,
        ns8:IFS151517,
        ns8:IFS171838,
        ns12:IFS152553,
        ns12:IFS17597,
        ns12:IFS181697 ;
    ns0:fullName "Arsham Borumand Saeid" ;
    ns0:hasAffiliation ns83:IFS179373 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179373 ;
    ns0:inAuthorList ns150:IFS179373 .

ns12:IFS17940 ns0:inAuthorList ns150:IFS17940 .

ns12:IFS181040 ns0:inAuthorList ns150:IFS181040 .

ns12:IFS181051 ns0:inAuthorList ns150:IFS181051 .

ns12:IFS181055 ns0:inAuthorList ns150:IFS181055 .

ns12:IFS181131 ns0:inAuthorList ns150:IFS181131 .

ns12:IFS181189 ns0:inAuthorList ns150:IFS181189 .

ns12:IFS181291 ns0:inAuthorList ns150:IFS181291 .

ns12:IFS181322 owl:sameAs ns2:IFS141877,
        ns8:IFS17169,
        ns8:IFS181172,
        ns8:IFS181401,
        ns8:IFS182651,
        ns8:IFS182700,
        ns8:IFS18979,
        ns8:INF1223,
        ns12:IFS181255,
        ns16:IFS16727 ;
    ns0:fullName "Cengiz Kahraman" ;
    ns0:hasAffiliation ns15:IFS181322 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181322 ;
    ns0:inAuthorList ns150:IFS181322 .

ns12:IFS181330 ns0:inAuthorList ns150:IFS181330 .

ns12:IFS181385 ns0:inAuthorList ns150:IFS181385 .

ns12:IFS181467 ns0:inAuthorList ns150:IFS181467 .

ns12:IFS181482 ns0:inAuthorList ns150:IFS181482 .

ns12:IFS181527 ns0:inAuthorList ns150:IFS181527 .

ns12:IFS181617 ns0:inAuthorList ns150:IFS181617 .

ns12:IFS18169 ns0:inAuthorList ns150:IFS18169 .

ns12:IFS181941 owl:sameAs ns2:IFS181767,
        ns12:IFS151652,
        ns12:NHA190065,
        ns30:IFS182919 ;
    ns0:fullName "Muhammad Aslam" ;
    ns0:hasAffiliation ns14:IFS181941 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181941 ;
    ns0:inAuthorList ns150:IFS181941 .

ns12:IFS181972 ns0:inAuthorList ns150:IFS181972 .

ns12:IFS182569 owl:sameAs ns2:IFS16661 ;
    ns0:fullName "Zhen-Yu Xiu" ;
    ns0:hasAffiliation ns83:IFS182569 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182569 ;
    ns0:inAuthorList ns150:IFS182569 .

ns12:IFS182634 owl:sameAs ns8:IFS162131,
        ns12:IFS17649,
        ns30:IFS18667 ;
    ns0:fullName "Weihua Qu" ;
    ns0:hasAffiliation ns14:IFS182634,
        ns83:IFS182634 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182634 ;
    ns0:inAuthorList ns150:IFS182634 .

ns12:IFS182673 ns0:inAuthorList ns150:IFS182673 .

ns12:IFS1827 ns0:inAuthorList ns150:IFS1827 .

ns12:IFS182774 owl:sameAs ns8:IFS181153,
        ns12:IFS172009,
        ns12:IFS181123,
        ns12:IFS181253,
        ns12:IFS182579,
        ns12:INF1217,
        ns30:IFS181922 ;
    ns0:fullName "Tahir Mahmood" ;
    ns0:hasAffiliation ns14:IFS182774 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182774 ;
    ns0:inAuthorList ns150:IFS182774 .

ns12:IFS182876 owl:sameAs ns12:IFS181657,
        ns12:IFS181698,
        ns12:IFS182863 ;
    ns0:fullName "Ngo Van Hoa" ;
    ns0:hasAffiliation ns83:IFS182876,
        ns13:IFS182876 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182876 ;
    ns0:inAuthorList ns150:IFS182876 .

ns12:IFS182910 owl:sameAs ns8:IFS161759,
        ns8:IFS161988,
        ns8:IFS1650,
        ns8:IFS17267,
        ns8:IFS17482,
        ns8:IFS1788,
        ns8:IFS18659,
        ns12:IFS17465,
        ns12:IFS182568 ;
    ns0:fullName "Fu-Gui Shi" ;
    ns0:hasAffiliation ns15:IFS182910 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182910 ;
    ns0:inAuthorList ns150:IFS182910 .

ns12:IFS18347 ns0:inAuthorList ns150:IFS18347 .

ns12:IFS18518 ns0:inAuthorList ns150:IFS18518 .

ns12:IFS18702 ns0:inAuthorList ns150:IFS18702 .

ns12:IFS18824 owl:sameAs ns2:IFS181295,
        ns2:IFS181892,
        ns8:IFS161589,
        ns8:IFS16244,
        ns8:IFS16339,
        ns8:IFS17334,
        ns8:IFS18833,
        ns12:IFS161702,
        ns12:IFS161740,
        ns12:IFS1673,
        ns12:IFS17728,
        ns12:IFS18663,
        ns30:IFS172282,
        ns5:IFS181460 ;
    ns0:fullName "Bijan Davvaz" ;
    ns0:hasAffiliation ns14:IFS18824 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS18824 ;
    ns0:inAuthorList ns150:IFS18824 .

ns12:IFS18993 ns0:inAuthorList ns150:IFS18993 .

ns12:IFS190078 owl:sameAs ns2:JHS190601 ;
    ns0:fullName "Nikita Jain" ;
    ns0:hasAffiliation ns15:IFS190078 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS190078 ;
    ns0:inAuthorList ns150:IFS190078 .

ns12:IFS190116 owl:sameAs ns2:IFS171413,
        ns8:IFS169620,
        ns8:IFS17270,
        ns8:JCM819 ;
    ns0:fullName "Jun Ye" ;
    ns0:hasAffiliation ns14:IFS190116 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190116 ;
    ns0:inAuthorList ns150:IFS190116 .

ns12:IFS190205 owl:sameAs ns12:IFS152503 ;
    ns0:fullName "Samarjit Kar" ;
    ns0:hasAffiliation ns83:IFS190205 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190205 ;
    ns0:inAuthorList ns150:IFS190205 .

ns12:IFS190543 ns0:inAuthorList ns150:IFS190543 .

ns12:IFS190565 owl:sameAs ns2:IFS16550,
        ns2:IFS1665,
        ns2:IFS169170,
        ns8:IFS17366,
        ns8:IFS182860,
        ns8:IFS2161 ;
    ns0:fullName "X.L. Xin" ;
    ns0:hasAffiliation ns83:IFS190565 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190565 ;
    ns0:inAuthorList ns150:IFS190565 .

ns12:IFS1906 ns0:inAuthorList ns150:IFS1906 .

ns12:IFS1913 ns0:inAuthorList ns150:IFS1913 .

ns12:IFS2013 ns0:inAuthorList ns150:IFS2013 .

ns12:IFS2082 ns0:inAuthorList ns150:IFS2082 .

ns12:IFS2113 ns0:inAuthorList ns150:IFS2113 .

ns12:IFS2125 ns0:inAuthorList ns150:IFS2125 .

ns12:IFS2134 ns0:inAuthorList ns150:IFS2134 .

ns12:IFS2149 ns0:inAuthorList ns150:IFS2149 .

ns12:IFS2170 ns0:inAuthorList ns150:IFS2170 .

ns12:IFS2175 ns0:inAuthorList ns150:IFS2175 .

ns12:INF1100 ns0:inAuthorList ns150:INF1100 .

ns12:INF1160 ns0:inAuthorList ns150:INF1160 .

ns12:ISU830 ns0:inAuthorList ns150:ISU830 .

ns12:JAD00050 ns0:inAuthorList ns150:JAD00050 .

ns12:JAD100021 ns0:inAuthorList ns150:JAD100021 .

ns12:JAD101026 ns0:inAuthorList ns150:JAD101026 .

ns12:JAD101668 ns0:inAuthorList ns150:JAD101668 .

ns12:JAD101704 ns0:inAuthorList ns150:JAD101704 .

ns12:JAD101911 ns0:inAuthorList ns150:JAD101911 .

ns12:JAD101944 ns0:inAuthorList ns150:JAD101944 .

ns12:JAD101977 ns0:inAuthorList ns150:JAD101977 .

ns12:JAD102094 ns0:inAuthorList ns150:JAD102094 .

ns12:JAD110065 ns0:inAuthorList ns150:JAD110065 .

ns12:JAD110200 ns0:inAuthorList ns150:JAD110200 .

ns12:JAD110329 ns0:inAuthorList ns150:JAD110329 .

ns12:JAD110341 ns0:inAuthorList ns150:JAD110341 .

ns12:JAD110794 ns0:inAuthorList ns150:JAD110794 .

ns12:JAD111313 ns0:inAuthorList ns150:JAD111313 .

ns12:JAD111490 ns0:inAuthorList ns150:JAD111490 .

ns12:JAD111517 ns0:inAuthorList ns150:JAD111517 .

ns12:JAD111631 ns0:inAuthorList ns150:JAD111631 .

ns12:JAD111886 ns0:inAuthorList ns150:JAD111886 .

ns12:JAD111946 ns0:inAuthorList ns150:JAD111946 .

ns12:JAD111961 ns0:inAuthorList ns150:JAD111961 .

ns12:JAD112009 ns0:inAuthorList ns150:JAD112009 .

ns12:JAD112120 ns0:inAuthorList ns150:JAD112120 .

ns12:JAD120130 ns0:inAuthorList ns150:JAD120130 .

ns12:JAD120169 ns0:inAuthorList ns150:JAD120169 .

ns12:JAD120424 ns0:inAuthorList ns150:JAD120424 .

ns12:JAD120709 ns0:inAuthorList ns150:JAD120709 .

ns12:JAD120802 ns0:inAuthorList ns150:JAD120802 .

ns12:JAD120808 ns0:inAuthorList ns150:JAD120808 .

ns12:JAD120871 ns0:inAuthorList ns150:JAD120871 .

ns12:JAD121168 ns0:inAuthorList ns150:JAD121168 .

ns12:JAD121639 ns0:inAuthorList ns150:JAD121639 .

ns12:JAD121960 ns0:inAuthorList ns150:JAD121960 .

ns12:JAD121963 ns0:inAuthorList ns150:JAD121963 .

ns12:JAD122155 ns0:inAuthorList ns150:JAD122155 .

ns12:JAD122260 ns0:inAuthorList ns150:JAD122260 .

ns12:JAD122440 ns0:inAuthorList ns150:JAD122440 .

ns12:JAD122458 ns0:inAuthorList ns150:JAD122458 .

ns12:JAD129021 ns0:inAuthorList ns150:JAD129021 .

ns12:JAD129025 ns0:inAuthorList ns150:JAD129025 .

ns12:JAD130203 ns0:inAuthorList ns150:JAD130203 .

ns12:JAD130278 ns0:inAuthorList ns150:JAD130278 .

ns12:JAD130287 ns0:inAuthorList ns150:JAD130287 .

ns12:JAD130347 ns0:inAuthorList ns150:JAD130347 .

ns12:JAD130575 ns0:inAuthorList ns150:JAD130575 .

ns12:JAD130617 ns0:inAuthorList ns150:JAD130617 .

ns12:JAD130899 ns0:inAuthorList ns150:JAD130899 .

ns12:JAD131025 ns0:inAuthorList ns150:JAD131025 .

ns12:JAD131241 ns0:inAuthorList ns150:JAD131241 .

ns12:JAD131682 ns0:inAuthorList ns150:JAD131682 .

ns12:JAD132087 ns0:inAuthorList ns150:JAD132087 .

ns12:JAD132216 ns0:inAuthorList ns150:JAD132216 .

ns12:JAD132255 ns0:inAuthorList ns150:JAD132255 .

ns12:JAD132279 ns0:inAuthorList ns150:JAD132279 .

ns12:JAD132417 ns0:inAuthorList ns150:JAD132417 .

ns12:JAD132729 ns0:inAuthorList ns150:JAD132729 .

ns12:JAD132735 ns0:inAuthorList ns150:JAD132735 .

ns12:JAD132750 ns0:inAuthorList ns150:JAD132750 .

ns12:JAD140162 ns0:inAuthorList ns150:JAD140162 .

ns12:JAD140210 ns0:inAuthorList ns150:JAD140210 .

ns12:JAD140756 ns0:inAuthorList ns150:JAD140756 .

ns12:JAD140867 ns0:inAuthorList ns150:JAD140867 .

ns12:JAD141248 ns0:inAuthorList ns150:JAD141248 .

ns12:JAD141266 ns0:inAuthorList ns150:JAD141266 .

ns12:JAD141503 ns0:inAuthorList ns150:JAD141503 .

ns12:JAD141596 ns0:inAuthorList ns150:JAD141596 .

ns12:JAD141629 ns0:inAuthorList ns150:JAD141629 .

ns12:JAD141743 ns0:inAuthorList ns150:JAD141743 .

ns12:JAD141803 ns0:inAuthorList ns150:JAD141803 .

ns12:JAD141926 ns0:inAuthorList ns150:JAD141926 .

ns12:JAD142052 ns0:inAuthorList ns150:JAD142052 .

ns12:JAD142064 ns0:inAuthorList ns150:JAD142064 .

ns12:JAD142253 ns0:inAuthorList ns150:JAD142253 .

ns12:JAD142322 ns0:inAuthorList ns150:JAD142322 .

ns12:JAD142622 ns0:inAuthorList ns150:JAD142622 .

ns12:JAD143084 ns0:inAuthorList ns150:JAD143084 .

ns12:JAD143099 ns0:inAuthorList ns150:JAD143099 .

ns12:JAD150234 ns0:inAuthorList ns150:JAD150234 .

ns12:JAD150250 ns0:inAuthorList ns150:JAD150250 .

ns12:JAD150390 ns0:inAuthorList ns150:JAD150390 .

ns12:JAD150481 ns0:inAuthorList ns150:JAD150481 .

ns12:JAD150692 ns0:inAuthorList ns150:JAD150692 .

ns12:JAD150855 ns0:inAuthorList ns150:JAD150855 .

ns12:JAD150863 ns0:inAuthorList ns150:JAD150863 .

ns12:JAD150895 ns0:inAuthorList ns150:JAD150895 .

ns12:JAD150909 ns0:inAuthorList ns150:JAD150909 .

ns12:JAD151113 ns0:inAuthorList ns150:JAD151113 .

ns12:JAD151114 ns0:inAuthorList ns150:JAD151114 .

ns12:JAD151181 ns0:inAuthorList ns150:JAD151181 .

ns12:JAD160061 ns0:inAuthorList ns150:JAD160061 .

ns12:JAD160067 ns0:inAuthorList ns150:JAD160067 .

ns12:JAD160158 ns0:inAuthorList ns150:JAD160158 .

ns12:JAD160209 ns0:inAuthorList ns150:JAD160209 .

ns12:JAD160223 ns0:inAuthorList ns150:JAD160223 .

ns12:JAD160244 ns0:inAuthorList ns150:JAD160244 .

ns12:JAD160254 ns0:inAuthorList ns150:JAD160254 .

ns12:JAD160291 ns0:inAuthorList ns150:JAD160291 .

ns12:JAD160304 ns0:inAuthorList ns150:JAD160304 .

ns12:JAD160348 ns0:inAuthorList ns150:JAD160348 .

ns12:JAD160382 ns0:inAuthorList ns150:JAD160382 .

ns12:JAD160407 ns0:inAuthorList ns150:JAD160407 .

ns12:JAD160413 ns0:inAuthorList ns150:JAD160413 .

ns12:JAD160416 ns0:inAuthorList ns150:JAD160416 .

ns12:JAD160528 ns0:inAuthorList ns150:JAD160528 .

ns12:JAD160593 ns0:inAuthorList ns150:JAD160593 .

ns12:JAD160639 ns0:inAuthorList ns150:JAD160639 .

ns12:JAD160643 ns0:inAuthorList ns150:JAD160643 .

ns12:JAD160702 ns0:inAuthorList ns150:JAD160702 .

ns12:JAD160826 ns0:inAuthorList ns150:JAD160826 .

ns12:JAD160828 ns0:inAuthorList ns150:JAD160828 .

ns12:JAD160845 ns0:inAuthorList ns150:JAD160845 .

ns12:JAD160897 ns0:inAuthorList ns150:JAD160897 .

ns12:JAD160923 ns0:inAuthorList ns150:JAD160923 .

ns12:JAD160927 ns0:inAuthorList ns150:JAD160927 .

ns12:JAD160995 ns0:inAuthorList ns150:JAD160995 .

ns12:JAD161050 ns0:inAuthorList ns150:JAD161050 .

ns12:JAD161132 ns0:inAuthorList ns150:JAD161132 .

ns12:JAD161158 ns0:inAuthorList ns150:JAD161158 .

ns12:JAD161250 ns0:inAuthorList ns150:JAD161250 .

ns12:JAD170017 ns0:inAuthorList ns150:JAD170017 .

ns12:JAD170039 ns0:inAuthorList ns150:JAD170039 .

ns12:JAD170092 ns0:inAuthorList ns150:JAD170092 .

ns12:JAD170148 ns0:inAuthorList ns150:JAD170148 .

ns12:JAD170238 ns0:inAuthorList ns150:JAD170238 .

ns12:JAD170275 ns0:inAuthorList ns150:JAD170275 .

ns12:JAD170276 ns0:inAuthorList ns150:JAD170276 .

ns12:JAD170370 ns0:inAuthorList ns150:JAD170370 .

ns12:JAD170409 ns0:inAuthorList ns150:JAD170409 .

ns12:JAD170481 ns0:inAuthorList ns150:JAD170481 .

ns12:JAD170496 ns0:inAuthorList ns150:JAD170496 .

ns12:JAD170502 ns0:inAuthorList ns150:JAD170502 .

ns12:JAD170522 ns0:inAuthorList ns150:JAD170522 .

ns12:JAD170532 ns0:inAuthorList ns150:JAD170532 .

ns12:JAD170555 ns0:inAuthorList ns150:JAD170555 .

ns12:JAD170587 ns0:inAuthorList ns150:JAD170587 .

ns12:JAD170639 ns0:inAuthorList ns150:JAD170639 .

ns12:JAD170698 ns0:inAuthorList ns150:JAD170698 .

ns12:JAD170702 ns0:inAuthorList ns150:JAD170702 .

ns12:JAD170714 ns0:inAuthorList ns150:JAD170714 .

ns12:JAD170743 ns0:inAuthorList ns150:JAD170743 .

ns12:JAD170749 ns0:inAuthorList ns150:JAD170749 .

ns12:JAD170759 ns0:inAuthorList ns150:JAD170759 .

ns12:JAD170854 ns0:inAuthorList ns150:JAD170854 .

ns12:JAD170880 ns0:inAuthorList ns150:JAD170880 .

ns12:JAD170894 ns0:inAuthorList ns150:JAD170894 .

ns12:JAD170905 ns0:inAuthorList ns150:JAD170905 .

ns12:JAD170954 ns0:inAuthorList ns150:JAD170954 .

ns12:JAD171145 ns0:inAuthorList ns150:JAD171145 .

ns12:JAD171152 ns0:inAuthorList ns150:JAD171152 .

ns12:JAD179908 ns0:inAuthorList ns150:JAD179908 .

ns12:JAD179921 ns0:inAuthorList ns150:JAD179921 .

ns12:JAD180050 ns0:inAuthorList ns150:JAD180050 .

ns12:JAD180069 ns0:inAuthorList ns150:JAD180069 .

ns12:JAD180082 ns0:inAuthorList ns150:JAD180082 .

ns12:JAD180101 ns0:inAuthorList ns150:JAD180101 .

ns12:JAD180183 ns0:inAuthorList ns150:JAD180183 .

ns12:JAD180219 ns0:inAuthorList ns150:JAD180219 .

ns12:JAD180224 ns0:inAuthorList ns150:JAD180224 .

ns12:JAD180248 ns0:inAuthorList ns150:JAD180248 .

ns12:JAD180274 ns0:inAuthorList ns150:JAD180274 .

ns12:JAD180292 ns0:inAuthorList ns150:JAD180292 .

ns12:JAD180316 ns0:inAuthorList ns150:JAD180316 .

ns12:JAD180335 ns0:inAuthorList ns150:JAD180335 .

ns12:JAD180366 ns0:inAuthorList ns150:JAD180366 .

ns12:JAD180381 ns0:inAuthorList ns150:JAD180381 .

ns12:JAD180427 ns0:inAuthorList ns150:JAD180427 .

ns12:JAD180468 ns0:inAuthorList ns150:JAD180468 .

ns12:JAD180496 ns0:inAuthorList ns150:JAD180496 .

ns12:JAD180497 ns0:inAuthorList ns150:JAD180497 .

ns12:JAD180525 ns0:inAuthorList ns150:JAD180525 .

ns12:JAD180554 ns0:inAuthorList ns150:JAD180554 .

ns12:JAD180563 ns0:inAuthorList ns150:JAD180563 .

ns12:JAD180595 ns0:inAuthorList ns150:JAD180595 .

ns12:JAD180598 ns0:inAuthorList ns150:JAD180598 .

ns12:JAD180604 ns0:inAuthorList ns150:JAD180604 .

ns12:JAD180654 ns0:inAuthorList ns150:JAD180654 .

ns12:JAD180737 ns0:inAuthorList ns150:JAD180737 .

ns12:JAD180746 ns0:inAuthorList ns150:JAD180746 .

ns12:JAD180755 ns0:inAuthorList ns150:JAD180755 .

ns12:JAD180823 ns0:inAuthorList ns150:JAD180823 .

ns12:JAD180857 owl:sameAs ns8:JAD131892,
        ns8:JAD141305,
        ns40:JAD170564,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181095>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160474>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD151120>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD161208>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD170039>,
        ns12:JAD110797,
        ns12:JAD122155,
        ns12:JAD170859,
        ns12:JAD180676,
        ns139:JAD180531,
        ns30:JAD190541,
        ns5:JAD111400,
        ns5:JAD111628,
        ns5:JAD131232,
        ns5:JAD180513,
        ns16:JAD140138,
        ns52:JAD102043,
        ns52:JAD130296,
        ns52:JAD170324,
        ns57:JAD121003,
        ns57:JAD141767 ;
    ns0:fullName "Frans R.J. Verhey" ;
    ns0:hasAffiliation ns15:JAD180857 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD180857 ;
    ns0:inAuthorList ns150:JAD180857 .

ns12:JAD180882 ns0:inAuthorList ns150:JAD180882 .

ns12:JAD180897 ns0:inAuthorList ns150:JAD180897 .

ns12:JAD180904 ns0:inAuthorList ns150:JAD180904 .

ns12:JAD180981 ns0:inAuthorList ns150:JAD180981 .

ns12:JAD180986 ns0:inAuthorList ns150:JAD180986 .

ns12:JAD181087 ns0:inAuthorList ns150:JAD181087 .

ns12:JAD181108 ns0:inAuthorList ns150:JAD181108 .

ns12:JAD181170 ns0:inAuthorList ns150:JAD181170 .

ns12:JAD181189 owl:sameAs ns16:JAD181037 ;
    ns0:fullName "Annelie Nordin Adolfsson" ;
    ns0:hasAffiliation ns14:JAD181189 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181189 ;
    ns0:inAuthorList ns150:JAD181189 .

ns12:JAD181208 ns0:inAuthorList ns150:JAD181208 .

ns12:JAD181223 ns0:inAuthorList ns150:JAD181223 .

ns12:JAD181240 ns0:inAuthorList ns150:JAD181240 .

ns12:JAD190041 owl:sameAs ns8:JAD170564 ;
    ns0:fullName "Inez H.G.B. Ramakers" ;
    ns0:hasAffiliation ns14:JAD190041 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190041 ;
    ns0:inAuthorList ns150:JAD190041 .

ns12:JAD190119 owl:sameAs ns2:jad01170,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160668>,
        ns12:JAD101416,
        ns12:JAD111544,
        ns12:JAD122263,
        ns12:JAD131151,
        ns12:JAD131172,
        ns30:JAD101704,
        ns30:JAD120523,
        ns30:JAD180524,
        ns5:JAD122302,
        ns16:JAD130053,
        ns16:jad01309,
        ns52:JAD160599,
        ns60:JAD160074,
        ns33:JAD132075,
        ns33:JAD180723 ;
    ns0:fullName "Chiara Fenoglio" ;
    ns0:hasAffiliation ns14:JAD190119 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190119 ;
    ns0:inAuthorList ns150:JAD190119 .

ns12:JAD190146 owl:sameAs ns2:JAD121090,
        ns8:JAD141284,
        ns26:JAD122182,
        ns43:JAD150862,
        ns30:jad101368,
        <http://ld.iospress.nl/rdf/contributor/Author:38.ID:JAD110824>,
        ns16:JAD140684,
        ns52:JAD131694,
        ns57:JAD140321 ;
    ns0:fullName "Patrick G. Kehoe" ;
    ns0:hasAffiliation ns83:JAD190146 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190146 ;
    ns0:inAuthorList ns150:JAD190146 .

ns12:JAD190160 ns0:inAuthorList ns150:JAD190160 .

ns12:JAD190183 ns0:inAuthorList ns150:JAD190183 .

ns12:JAD190239 ns0:inAuthorList ns150:JAD190239 .

ns12:JAD190240 ns0:inAuthorList ns150:JAD190240 .

ns12:JAD190461 owl:sameAs ns8:JAD160235,
        ns26:JAD150786,
        ns57:JAD180416 ;
    ns0:fullName "Nicola Vanacore" ;
    ns0:hasAffiliation ns13:JAD190461 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190461 ;
    ns0:inAuthorList ns150:JAD190461 .

ns12:JAD190524 ns0:inAuthorList ns150:JAD190524 .

ns12:JAD190527 owl:sameAs ns5:JAD190540,
        ns16:JAD122026 ;
    ns0:fullName "Saima Hilal" ;
    ns0:hasAffiliation ns15:JAD190527,
        ns83:JAD190527,
        ns13:JAD190527 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190527 ;
    ns0:inAuthorList ns150:JAD190527 .

ns12:JAD190540 ns0:inAuthorList ns150:JAD190540 .

ns12:JAD190541 owl:sameAs ns8:JAD102043,
        ns8:JAD161208 ;
    ns0:fullName "Martin P.J. van Boxtel" ;
    ns0:hasAffiliation ns15:JAD190541 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190541 ;
    ns0:inAuthorList ns150:JAD190541 .

ns12:JAD190545 owl:sameAs ns16:JAD170604 ;
    ns0:fullName "Teresa Moreno-Ramos" ;
    ns0:hasAffiliation ns83:JAD190545 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190545 ;
    ns0:inAuthorList ns150:JAD190545 .

ns12:JAD190581 owl:sameAs ns2:JAD161234,
        ns2:JAD181194,
        ns12:JAD180569,
        ns30:JAD190508 ;
    ns0:fullName "Louis Jacob" ;
    ns0:hasAffiliation ns83:JAD190581 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190581 ;
    ns0:inAuthorList ns150:JAD190581 .

ns12:JAD190609 owl:sameAs ns2:JAD180524,
        ns12:JAD170938 ;
    ns0:fullName "Maria Elena Di Battista" ;
    ns0:hasAffiliation ns15:JAD190609 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190609 ;
    ns0:inAuthorList ns150:JAD190609 .

ns12:JAD190889 ns0:inAuthorList ns150:JAD190889 .

ns12:JAE170136 ns0:inAuthorList ns150:JAE170136 .

ns12:JAE170162 ns0:inAuthorList ns150:JAE170162 .

ns12:JAE171060 ns0:inAuthorList ns150:JAE171060 .

ns12:JAE190015 ns0:inAuthorList ns150:JAE190015 .

ns12:JAE191148 owl:sameAs ns12:JAE171008,
        ns12:JAE171252,
        ns12:JAE191149,
        ns12:JAE191283,
        ns12:JAE2122,
        ns12:JAE2271,
        ns30:JAE190821,
        ns30:JAE1979 ;
    ns0:fullName "Koji Fujiwara" ;
    ns0:hasAffiliation ns15:JAE191148 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191148 ;
    ns0:inAuthorList ns150:JAE191148 .

ns12:JAE191491 owl:sameAs ns12:JAE1988 ;
    ns0:fullName "Stéphane Clénet" ;
    ns0:hasAffiliation ns15:JAE191491 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191491 ;
    ns0:inAuthorList ns150:JAE191491 .

ns12:JBR152 ns0:inAuthorList ns150:JBR152 .

ns12:JCB15016 ns0:inAuthorList ns150:JCB15016 .

ns12:JCB15018 ns0:inAuthorList ns150:JCB15018 .

ns12:JCB179010 ns0:inAuthorList ns150:JCB179010 .

ns12:JCB189010 ns0:inAuthorList ns150:JCB189010 .

ns12:JCM181004 ns0:inAuthorList ns150:JCM181004 .

ns12:JCS108 ns0:inAuthorList ns150:JCS108 .

ns12:JCS15756 ns0:inAuthorList ns150:JCS15756 .

ns12:JCS16866 ns0:inAuthorList ns150:JCS16866 .

ns12:JCS171106 ns0:inAuthorList ns150:JCS171106 .

ns12:JCS17947 ns0:inAuthorList ns150:JCS17947 .

<http://ld.iospress.nl/rdf/contributor/Author:2.ID:JCS3(2-3)02> ns0:inAuthorList <http://ld.iospress.nl/rdf/contributor/List.Role:authors.ID:JCS3(2-3)02> .

ns12:JCS513 ns0:inAuthorList ns150:JCS513 .

ns12:JCS545 ns0:inAuthorList ns150:JCS545 .

ns12:JEM417 ns0:inAuthorList ns150:JEM417 .

ns12:JHD160210 ns0:inAuthorList ns150:JHD160210 .

ns12:JHD170236 ns0:inAuthorList ns150:JHD170236 .

ns12:JHD170270 ns0:inAuthorList ns150:JHD170270 .

ns12:JHD170284 ns0:inAuthorList ns150:JHD170284 .

ns12:JHD180285 ns0:inAuthorList ns150:JHD180285 .

ns12:JHD180287 ns0:inAuthorList ns150:JHD180287 .

ns12:JHD180297 ns0:inAuthorList ns150:JHD180297 .

ns12:JHD180328 ns0:inAuthorList ns150:JHD180328 .

ns12:JHD190001 ns0:inAuthorList ns150:JHD190001 .

ns12:JHD190365 owl:sameAs ns2:JHD180293 ;
    ns0:fullName "Karen E. Anderson" ;
    ns0:hasAffiliation ns13:JHD190365 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190365 ;
    ns0:inAuthorList ns150:JHD190365 .

ns12:JHS580 ns0:inAuthorList ns150:JHS580 .

ns12:JHS583 ns0:inAuthorList ns150:JHS583 .

ns12:JND180331 ns0:inAuthorList ns150:JND180331 .

ns12:JPD150622 ns0:inAuthorList ns150:JPD150622 .

ns12:JPD150632 ns0:inAuthorList ns150:JPD150632 .

ns12:JPD150672 ns0:inAuthorList ns150:JPD150672 .

ns12:JPD150680 ns0:inAuthorList ns150:JPD150680 .

ns12:JPD150685 ns0:inAuthorList ns150:JPD150685 .

ns12:JPD150733 ns0:inAuthorList ns150:JPD150733 .

ns12:JPD160816 ns0:inAuthorList ns150:JPD160816 .

ns12:JPD181365 ns0:inAuthorList ns150:JPD181365 .

ns12:JPD181434 ns0:inAuthorList ns150:JPD181434 .

ns12:JPD181486 ns0:inAuthorList ns150:JPD181486 .

ns12:JPD181516 ns0:inAuthorList ns150:JPD181516 .

ns12:JPD181523 ns0:inAuthorList ns150:JPD181523 .

ns12:JVR180999 ns0:inAuthorList ns150:JVR180999 .

ns12:JVR191014 ns0:inAuthorList ns150:JVR191014 .

ns12:JVR191040 ns0:inAuthorList ns150:JVR191040 .

ns12:JVR191042 ns0:inAuthorList ns150:JVR191042 .

ns12:JVR808 ns0:inAuthorList ns150:JVR808 .

ns12:JVR817 ns0:inAuthorList ns150:JVR817 .

ns12:JVR851 ns0:inAuthorList ns150:JVR851 .

ns12:JVR918 ns0:inAuthorList ns150:JVR918 .

ns12:KCA170007 ns0:inAuthorList ns150:KCA170007 .

ns12:KCA180034 ns0:inAuthorList ns150:KCA180034 .

ns12:KES190407 ns0:inAuthorList ns150:KES190407 .

ns12:MGS267 ns0:inAuthorList ns150:MGS267 .

ns12:MNM180224 ns0:inAuthorList ns150:MNM180224 .

ns12:MNM180242 ns0:inAuthorList ns150:MNM180242 .

ns12:MNM180263 ns0:inAuthorList ns150:MNM180263 .

ns12:NHA170023 ns0:inAuthorList ns150:NHA170023 .

ns12:NHA180055 ns0:inAuthorList ns150:NHA180055 .

ns12:NHA190065 owl:sameAs ns2:IFS181767,
        ns12:IFS151652,
        ns30:IFS182919 ;
    ns0:fullName "Muhammad Aslam" ;
    ns0:hasAffiliation ns15:NHA190065,
        ns14:NHA190065 ;
    ns0:hasArticle ns1:nha-v5-i2-NHA190065 ;
    ns0:inAuthorList ns150:NHA190065 .

ns12:NPM16101 ns0:inAuthorList ns150:NPM16101 .

ns12:NPM17125 ns0:inAuthorList ns150:NPM17125 .

ns12:NPM1786 ns0:inAuthorList ns150:NPM1786 .

ns12:NRE1420 ns0:inAuthorList ns150:NRE1420 .

ns12:NRE1435 ns0:inAuthorList ns150:NRE1435 .

ns12:NRE172156 ns0:inAuthorList ns150:NRE172156 .

ns12:NRE172238 ns0:inAuthorList ns150:NRE172238 .

ns12:NRE172274 ns0:inAuthorList ns150:NRE172274 .

ns12:NRE182424 ns0:inAuthorList ns150:NRE182424 .

ns12:NRE182471 ns0:inAuthorList ns150:NRE182471 .

ns12:NRE182525 ns0:inAuthorList ns150:NRE182525 .

ns12:NRE182665 ns0:inAuthorList ns150:NRE182665 .

ns12:NRE182683 ns0:inAuthorList ns150:NRE182683 .

ns12:NRE189009 ns0:inAuthorList ns150:NRE189009 .

ns12:NRE192700 ns0:inAuthorList ns150:NRE192700 .

ns12:NRE192752 ns0:inAuthorList ns150:NRE192752 .

ns12:RNN150581 ns0:inAuthorList ns150:RNN150581 .

ns12:RNN170725 ns0:inAuthorList ns150:RNN170725 .

ns12:RNN170785 ns0:inAuthorList ns150:RNN170785 .

ns12:SW151 ns0:inAuthorList ns150:SW151 .

ns12:SW180336 ns0:inAuthorList ns150:SW180336 .

ns12:THC1072 ns0:inAuthorList ns150:THC1072 .

ns12:THC1309 ns0:inAuthorList ns150:THC1309 .

ns12:THC174800 ns0:inAuthorList ns150:THC174800 .

ns12:THC181467 ns0:inAuthorList ns150:THC181467 .

ns12:THC199006 ns0:inAuthorList ns150:THC199006 .

ns12:THC199029 ns0:inAuthorList ns150:THC199029 .

ns12:THC199033 owl:sameAs ns12:JAD180823 ;
    ns0:fullName "Ping Gong" ;
    ns0:hasAffiliation ns15:THC199033 ;
    ns0:hasArticle ns1:thc-v27-iS1-THC199033 ;
    ns0:inAuthorList ns150:THC199033 .

ns12:THC946 ns0:inAuthorList ns150:THC946 .

ns12:VES634 ns0:inAuthorList ns150:VES634 .

ns12:WEB190403 ns0:inAuthorList ns150:WEB190403 .

ns12:WOR182813 ns0:inAuthorList ns150:WOR182813 .

ns12:WOR1840 ns0:inAuthorList ns150:WOR1840 .

ns12:WOR192876 ns0:inAuthorList ns150:WOR192876 .

ns12:WOR192889 ns0:inAuthorList ns150:WOR192889 .

ns12:WOR192957 ns0:inAuthorList ns150:WOR192957 .

ns12:WOR192961 ns0:inAuthorList ns150:WOR192961 .

ns12:WOR192962 ns0:inAuthorList ns150:WOR192962 .

ns12:WOR192986 owl:sameAs ns2:WOR2328 ;
    ns0:fullName "Reza Kazemi" ;
    ns0:hasAffiliation ns15:WOR192986 ;
    ns0:hasArticle ns1:wor-v64-i2-WOR192986 ;
    ns0:inAuthorList ns150:WOR192986 .

ns12:WOR2131 ns0:inAuthorList ns150:WOR2131 .

ns12:WOR2201 ns0:inAuthorList ns150:WOR2201 .

ns12:WOR2334 ns0:inAuthorList ns150:WOR2334 .

ns12:WOR2379 ns0:inAuthorList ns150:WOR2379 .

ns12:WOR2559 ns0:inAuthorList ns150:WOR2559 .

ns12:WOR2578 ns0:inAuthorList ns150:WOR2578 .

ns12:WOR2617 ns0:inAuthorList ns150:WOR2617 .

ns12:WOR2685 ns0:inAuthorList ns150:WOR2685 .

ns12:WOR2692 ns0:inAuthorList ns150:WOR2692 .

ns12:WOR2722 ns0:inAuthorList ns150:WOR2722 .

ns12:WOR2738 ns0:inAuthorList ns150:WOR2738 .

ns12:XST16245 ns0:inAuthorList ns150:XST16245 .

ns12:XST17285 ns0:inAuthorList ns150:XST17285 .

ns12:XST180393 ns0:inAuthorList ns150:XST180393 .

ns12:XST180395 ns0:inAuthorList ns150:XST180395 .

ns12:XST180413 owl:sameAs ns2:XST515,
        ns8:XST16208,
        ns8:XST16211,
        ns12:XST18383,
        ns12:XST547,
        ns12:XST574,
        ns12:XST602,
        ns30:XST16173,
        ns30:XST17324 ;
    ns0:fullName "Hengyong Yu" ;
    ns0:hasAffiliation ns15:XST180413 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180413 ;
    ns0:inAuthorList ns150:XST180413 .

ns12:XST180430 ns0:inAuthorList ns150:XST180430 .

ns12:XST190506 ns0:inAuthorList ns150:XST190506 .

ns12:XST190548 ns0:inAuthorList ns150:XST190548 .

ns12:XST502 ns0:inAuthorList ns150:XST502 .

ns12:bd000355 ns0:inAuthorList ns150:bd000355 .

ns12:bmr00321 ns0:inAuthorList ns150:bmr00321 .

ns12:bmr00380 ns0:inAuthorList ns150:bmr00380 .

ns12:bmr00447 ns0:inAuthorList ns150:bmr00447 .

ns12:cbm00432 ns0:inAuthorList ns150:cbm00432 .

ns12:ica00404 ns0:inAuthorList ns150:ica00404 .

ns12:ida00324 ns0:inAuthorList ns150:ida00324 .

ns12:ida00587 ns0:inAuthorList ns150:ida00587 .

ns12:ida00653 ns0:inAuthorList ns150:ida00653 .

ns12:idt00132 ns0:inAuthorList ns150:idt00132 .

ns12:jad00106 ns0:inAuthorList ns150:jad00106 .

ns12:jad00189 ns0:inAuthorList ns150:jad00189 .

ns12:jad00202 ns0:inAuthorList ns150:jad00202 .

ns12:jad00265 ns0:inAuthorList ns150:jad00265 .

ns12:jad00272 ns0:inAuthorList ns150:jad00272 .

ns12:jad00305 ns0:inAuthorList ns150:jad00305 .

ns12:jad00468 ns0:inAuthorList ns150:jad00468 .

ns12:jad00527 ns0:inAuthorList ns150:jad00527 .

ns12:jad00664 ns0:inAuthorList ns150:jad00664 .

ns12:jad00741 ns0:inAuthorList ns150:jad00741 .

ns12:jad00817 ns0:inAuthorList ns150:jad00817 .

ns12:jad00950 ns0:inAuthorList ns150:jad00950 .

ns12:jad01041 ns0:inAuthorList ns150:jad01041 .

ns12:jad01079 ns0:inAuthorList ns150:jad01079 .

ns12:jad01185 ns0:inAuthorList ns150:jad01185 .

ns12:jad01230 ns0:inAuthorList ns150:jad01230 .

ns12:jad01245 ns0:inAuthorList ns150:jad01245 .

ns12:jad091729 ns0:inAuthorList ns150:jad091729 .

ns12:jad100042 ns0:inAuthorList ns150:jad100042 .

ns12:jad100432 ns0:inAuthorList ns150:jad100432 .

ns12:jad100573 ns0:inAuthorList ns150:jad100573 .

ns12:jad100663 ns0:inAuthorList ns150:jad100663 .

ns12:jad100669 ns0:inAuthorList ns150:jad100669 .

ns12:jad100723 ns0:inAuthorList ns150:jad100723 .

ns12:jad100795 ns0:inAuthorList ns150:jad100795 .

ns12:jad100879 ns0:inAuthorList ns150:jad100879 .

ns12:jad101293 ns0:inAuthorList ns150:jad101293 .

ns12:jcs289 ns0:inAuthorList ns150:jcs289 .

ns12:jcs484 ns0:inAuthorList ns150:jcs484 .

ns12:jid150006 ns0:inAuthorList ns150:jid150006 .

ns12:mgs00071 ns0:inAuthorList ns150:mgs00071 .

ns176:JAD101221 ns0:inAuthorList ns150:JAD101221 .

ns176:JAD101416 ns0:inAuthorList ns150:JAD101416 .

ns176:JAD130461 ns0:inAuthorList ns150:JAD130461 .

ns176:JAD150257 ns0:inAuthorList ns150:JAD150257 .

ns176:JAD160380 ns0:inAuthorList ns150:JAD160380 .

ns176:JAD161223 ns0:inAuthorList ns150:JAD161223 .

ns176:JAD170128 ns0:inAuthorList ns150:JAD170128 .

ns176:JAD170231 ns0:inAuthorList ns150:JAD170231 .

ns176:JAD180275 ns0:inAuthorList ns150:JAD180275 .

ns176:jad01225 ns0:inAuthorList ns150:jad01225 .

ns176:jad091516 ns0:inAuthorList ns150:jad091516 .

ns139:JAD101914 ns0:inAuthorList ns150:JAD101914 .

ns139:JAD140225 ns0:inAuthorList ns150:JAD140225 .

ns139:JAD150749 ns0:inAuthorList ns150:JAD150749 .

ns139:JAD150883 ns0:inAuthorList ns150:JAD150883 .

ns139:JAD170327 ns0:inAuthorList ns150:JAD170327 .

ns139:JAD170560 ns0:inAuthorList ns150:JAD170560 .

ns139:jad00971 ns0:inAuthorList ns150:jad00971 .

ns139:jad100933 ns0:inAuthorList ns150:jad100933 .

<http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD110824> ns0:inAuthorList ns150:JAD110824 .

<http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD160108> ns0:inAuthorList ns150:JAD160108 .

<http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD160668> ns0:inAuthorList ns150:JAD160668 .

<http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD161097> ns0:inAuthorList ns150:JAD161097 .

<http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD180106> ns0:inAuthorList ns150:JAD180106 .

<http://ld.iospress.nl/rdf/contributor/Author:23.ID:JND180327> ns0:inAuthorList ns150:JND180327 .

<http://ld.iospress.nl/rdf/contributor/Author:23.ID:JPD191648> ns0:inAuthorList ns150:JPD191648 .

<http://ld.iospress.nl/rdf/contributor/Author:23.ID:jad090249> ns0:inAuthorList ns150:jad090249 .

ns180:JAD150863 ns0:inAuthorList ns150:JAD150863 .

ns180:JAD160108 ns0:inAuthorList ns150:JAD160108 .

ns180:JAD170920 ns0:inAuthorList ns150:JAD170920 .

ns180:JAD180321 ns0:inAuthorList ns150:JAD180321 .

ns180:JAD190193 ns0:inAuthorList ns150:JAD190193 .

ns141:JAD160310 ns0:inAuthorList ns150:JAD160310 .

ns141:JAD161097 ns0:inAuthorList ns150:JAD161097 .

ns141:JAD170347 ns0:inAuthorList ns150:JAD170347 .

ns141:JAD180158 ns0:inAuthorList ns150:JAD180158 .

<http://ld.iospress.nl/rdf/contributor/Author:26.ID:JAD150749> ns0:inAuthorList ns150:JAD150749 .

<http://ld.iospress.nl/rdf/contributor/Author:26.ID:JAD150863> ns0:inAuthorList ns150:JAD150863 .

<http://ld.iospress.nl/rdf/contributor/Author:26.ID:JAD160883> ns0:inAuthorList ns150:JAD160883 .

<http://ld.iospress.nl/rdf/contributor/Author:26.ID:JAD190644> owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181218>,
        ns60:JAD111070 ;
    ns0:fullName "Koji Abe" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:26.ID:JAD190644> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns143:JAD180512 ns0:inAuthorList ns150:JAD180512 .

ns143:JND180327 ns0:inAuthorList ns150:JND180327 .

ns183:JAD150749 ns0:inAuthorList ns150:JAD150749 .

ns183:jad090249 ns0:inAuthorList ns150:jad090249 .

<http://ld.iospress.nl/rdf/contributor/Author:29.ID:JAD160152> ns0:inAuthorList ns150:JAD160152 .

ns30:913075 ns0:inAuthorList ns150:913075 .

ns30:AAC181002 ns0:inAuthorList ns150:AAC181002 .

ns30:ADR180091 ns0:inAuthorList ns150:ADR180091 .

ns30:AIS370 ns0:inAuthorList ns150:AIS370 .

ns30:AO197 ns0:inAuthorList ns150:AO197 .

ns30:BD180351 ns0:inAuthorList ns150:BD180351 .

ns30:BD264 ns0:inAuthorList ns150:BD264 .

ns30:BD402 ns0:inAuthorList ns150:BD402 .

ns30:BIR180175 ns0:inAuthorList ns150:BIR180175 .

ns30:BLC150039 ns0:inAuthorList ns150:BLC150039 .

ns30:BLC170152 ns0:inAuthorList ns150:BLC170152 .

ns30:BME1299 ns0:inAuthorList ns150:BME1299 .

ns30:BME1348 ns0:inAuthorList ns150:BME1348 .

ns30:BME1468 ns0:inAuthorList ns150:BME1468 .

ns30:BME1486 ns0:inAuthorList ns150:BME1486 .

ns30:BME1542 ns0:inAuthorList ns150:BME1542 .

ns30:BMR579 ns0:inAuthorList ns150:BMR579 .

ns30:BSI155 ns0:inAuthorList ns150:BSI155 .

ns30:CBM181368 ns0:inAuthorList ns150:CBM181368 .

ns30:CBM190091 ns0:inAuthorList ns150:CBM190091 .

ns30:CH15081 ns0:inAuthorList ns150:CH15081 .

ns30:CH16142 ns0:inAuthorList ns150:CH16142 .

ns30:CH16195 ns0:inAuthorList ns150:CH16195 .

ns30:CH168039 ns0:inAuthorList ns150:CH168039 .

ns30:CH168047 ns0:inAuthorList ns150:CH168047 .

ns30:CH168105 ns0:inAuthorList ns150:CH168105 .

ns30:CH170252 ns0:inAuthorList ns150:CH170252 .

ns30:CH170266 ns0:inAuthorList ns150:CH170266 .

ns30:CH179235 ns0:inAuthorList ns150:CH179235 .

ns30:CH180449 ns0:inAuthorList ns150:CH180449 .

ns30:CH180457 ns0:inAuthorList ns150:CH180457 .

ns30:CH180531 ns0:inAuthorList ns150:CH180531 .

ns30:CH189123 ns0:inAuthorList ns150:CH189123 .

ns30:CH189403 ns0:inAuthorList ns150:CH189403 .

ns30:CH189404 ns0:inAuthorList ns150:CH189404 .

ns30:CH189409 ns0:inAuthorList ns150:CH189409 .

ns30:CH189411 ns0:inAuthorList ns150:CH189411 .

ns30:CH189905 ns0:inAuthorList ns150:CH189905 .

ns30:CH1964 ns0:inAuthorList ns150:CH1964 .

ns30:CH1982 ns0:inAuthorList ns150:CH1982 .

ns30:CH199005 ns0:inAuthorList ns150:CH199005 .

ns30:CH199201 ns0:inAuthorList ns150:CH199201 .

ns30:CH199204 owl:sameAs ns2:CH189405,
        ns12:CH189310 ;
    ns0:fullName "G. Negrão de Figueiredo" ;
    ns0:hasAffiliation ns252:CH199204 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199204 ;
    ns0:inAuthorList ns150:CH199204 .

ns30:CH199205 ns0:inAuthorList ns150:CH199205 .

ns30:CH2002 ns0:inAuthorList ns150:CH2002 .

ns30:FI1457 ns0:inAuthorList ns150:FI1457 .

ns30:FI1562 ns0:inAuthorList ns150:FI1562 .

ns30:FI1565 ns0:inAuthorList ns150:FI1565 .

ns30:FI1574 ns0:inAuthorList ns150:FI1574 .

ns30:FI1631 ns0:inAuthorList ns150:FI1631 .

ns30:FI1658 ns0:inAuthorList ns150:FI1658 .

ns30:FI1669 ns0:inAuthorList ns150:FI1669 .

ns30:HAB180344 ns0:inAuthorList ns150:HAB180344 .

ns30:HAB190362 owl:sameAs ns2:BD248,
        ns2:HAB303,
        ns12:HAB289,
        ns12:HAB317,
        ns16:NIB180141 ;
    ns0:fullName "Mohammad Taheri" ;
    ns0:hasAffiliation ns84:HAB190362 ;
    ns0:hasArticle ns1:hab-v27-i3-HAB190362 ;
    ns0:inAuthorList ns150:HAB190362 .

ns30:HAB190363 owl:sameAs ns2:HAB304,
        ns30:HAB190369 ;
    ns0:fullName "Tadesse Bekele Tafesse" ;
    ns0:hasAffiliation ns84:HAB190363 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190363 ;
    ns0:inAuthorList ns150:HAB190363 .

ns30:HAB190364 ns0:inAuthorList ns150:HAB190364 .

ns30:HAB190386 owl:sameAs ns12:HAB180360 ;
    ns0:fullName "Tosan Erhabor" ;
    ns0:hasAffiliation ns64:HAB190386 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190386 ;
    ns0:inAuthorList ns150:HAB190386 .

ns30:HAB302 ns0:inAuthorList ns150:HAB302 .

ns30:HAB316 ns0:inAuthorList ns150:HAB316 .

ns30:HSM17166 ns0:inAuthorList ns150:HSM17166 .

ns30:HSM180405 ns0:inAuthorList ns150:HSM180405 .

ns30:HSM180415 ns0:inAuthorList ns150:HSM180415 .

ns30:HSM180425 owl:sameAs ns5:HSM1773 ;
    ns0:fullName "Muhammad Hafeez" ;
    ns0:hasAffiliation ns252:HSM180425 ;
    ns0:hasArticle ns1:hsm-v38-i3-HSM180425 ;
    ns0:inAuthorList ns150:HSM180425 .

ns30:HSM18288 ns0:inAuthorList ns150:HSM18288 .

ns30:IA102 ns0:inAuthorList ns150:IA102 .

ns30:IA103 ns0:inAuthorList ns150:IA103 .

ns30:IA110 ns0:inAuthorList ns150:IA110 .

ns30:ICA00047 ns0:inAuthorList ns150:ICA00047 .

ns30:IDT180353 ns0:inAuthorList ns150:IDT180353 .

ns30:IES183223 ns0:inAuthorList ns150:IES183223 .

ns30:IFS141877 ns0:inAuthorList ns150:IFS141877 .

ns30:IFS152503 ns0:inAuthorList ns150:IFS152503 .

ns30:IFS152520 ns0:inAuthorList ns150:IFS152520 .

ns30:IFS15372 ns0:inAuthorList ns150:IFS15372 .

ns30:IFS161152 ns0:inAuthorList ns150:IFS161152 .

ns30:IFS161299 ns0:inAuthorList ns150:IFS161299 .

ns30:IFS161499 ns0:inAuthorList ns150:IFS161499 .

ns30:IFS16727 ns0:inAuthorList ns150:IFS16727 .

ns30:IFS16875 ns0:inAuthorList ns150:IFS16875 .

ns30:IFS169212 ns0:inAuthorList ns150:IFS169212 .

ns30:IFS169340 ns0:inAuthorList ns150:IFS169340 .

ns30:IFS169403 ns0:inAuthorList ns150:IFS169403 .

ns30:IFS169495 ns0:inAuthorList ns150:IFS169495 .

ns30:IFS169571 ns0:inAuthorList ns150:IFS169571 .

ns30:IFS171442 ns0:inAuthorList ns150:IFS171442 .

ns30:IFS171587 owl:sameAs ns2:IFS172270,
        ns2:IFS1869,
        ns2:IFS2190,
        ns8:IFS1734,
        ns8:IFS18518,
        ns8:IFS190565,
        ns12:IFS161601,
        ns12:IFS181755,
        ns12:IFS2074,
        ns30:IFS151031 ;
    ns0:fullName "Y.B. Jun" ;
    ns0:hasAffiliation ns31:IFS171587 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS171587 ;
    ns0:inAuthorList ns150:IFS171587 .

ns30:IFS171717 ns0:inAuthorList ns150:IFS171717 .

ns30:IFS172009 ns0:inAuthorList ns150:IFS172009 .

ns30:IFS172127 ns0:inAuthorList ns150:IFS172127 .

ns30:IFS172130 ns0:inAuthorList ns150:IFS172130 .

ns30:IFS17656 ns0:inAuthorList ns150:IFS17656 .

ns30:IFS17698 ns0:inAuthorList ns150:IFS17698 .

ns30:IFS17850 ns0:inAuthorList ns150:IFS17850 .

ns30:IFS179094 ns0:inAuthorList ns150:IFS179094 .

ns30:IFS181171 ns0:inAuthorList ns150:IFS181171 .

ns30:IFS181231 ns0:inAuthorList ns150:IFS181231 .

ns30:IFS181425 ns0:inAuthorList ns150:IFS181425 .

ns30:IFS18144 ns0:inAuthorList ns150:IFS18144 .

ns30:IFS181502 owl:sameAs ns30:IFS17497 ;
    ns0:fullName "Kostaq Hila" ;
    ns0:hasAffiliation ns63:IFS181502,
        ns84:IFS181502 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181502 ;
    ns0:inAuthorList ns150:IFS181502 .

ns30:IFS181519 owl:sameAs ns30:IFS172005 ;
    ns0:fullName "Farhad Hosseinzadeh Lotfi" ;
    ns0:hasAffiliation ns64:IFS181519 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS181519 ;
    ns0:inAuthorList ns150:IFS181519 .

ns30:IFS18169 ns0:inAuthorList ns150:IFS18169 .

ns30:IFS181739 owl:sameAs ns2:FI1290 ;
    ns0:fullName "Keyun Qin" ;
    ns0:hasAffiliation ns252:IFS181739 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS181739 ;
    ns0:inAuthorList ns150:IFS181739 .

ns30:IFS181742 owl:sameAs ns8:IFS190036,
        ns12:IFS181084,
        ns12:IFS182618,
        ns12:INF1131,
        ns30:INF1215 ;
    ns0:fullName "Florentin Smarandache" ;
    ns0:hasAffiliation ns63:IFS181742 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS181742 ;
    ns0:inAuthorList ns150:IFS181742 .

ns30:IFS181755 ns0:inAuthorList ns150:IFS181755 .

ns30:IFS182699 owl:sameAs ns2:JAE170038,
        ns2:JAE170163,
        ns12:JAE170092,
        ns5:JAE180001 ;
    ns0:fullName "Li Qiu" ;
    ns0:hasAffiliation ns252:IFS182699 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182699 ;
    ns0:inAuthorList ns150:IFS182699 .

ns30:IFS182961 ns0:inAuthorList ns150:IFS182961 .

ns30:IFS18647 ns0:inAuthorList ns150:IFS18647 .

ns30:IFS18760 ns0:inAuthorList ns150:IFS18760 .

ns30:IFS18904 ns0:inAuthorList ns150:IFS18904 .

ns30:IFS190098 owl:sameAs ns8:IFS171636 ;
    ns0:fullName "Guiwu Wei" ;
    ns0:hasAffiliation ns64:IFS190098 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190098 ;
    ns0:inAuthorList ns150:IFS190098 .

ns30:IFS190711 owl:sameAs ns2:FI1755,
        ns8:IFS18040,
        ns12:IFS190217 ;
    ns0:fullName "H. Garg" ;
    ns0:hasAffiliation ns63:IFS190711 ;
    ns0:hasArticle ns1:ifs-v37-i5-IFS190711 ;
    ns0:inAuthorList ns150:IFS190711 .

ns30:IFS191197 owl:sameAs ns8:IFS181832,
        ns8:IFS18757,
        ns12:IFS161681,
        ns5:IFS18993 ;
    ns0:fullName "Muhammad Irfan Ali" ;
    ns0:hasAffiliation ns63:IFS191197 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS191197 ;
    ns0:inAuthorList ns150:IFS191197 .

ns30:IFS2082 ns0:inAuthorList ns150:IFS2082 .

ns30:IFS2113 ns0:inAuthorList ns150:IFS2113 .

ns30:INF1183 ns0:inAuthorList ns150:INF1183 .

ns30:JAD00041 ns0:inAuthorList ns150:JAD00041 .

ns30:JAD0006 ns0:inAuthorList ns150:JAD0006 .

ns30:JAD0040 ns0:inAuthorList ns150:JAD0040 .

ns30:JAD101359 ns0:inAuthorList ns150:JAD101359 .

ns30:JAD101815 ns0:inAuthorList ns150:JAD101815 .

ns30:JAD101908 ns0:inAuthorList ns150:JAD101908 .

ns30:JAD101977 ns0:inAuthorList ns150:JAD101977 .

ns30:JAD102124 ns0:inAuthorList ns150:JAD102124 .

ns30:JAD110047 ns0:inAuthorList ns150:JAD110047 .

ns30:JAD110377 ns0:inAuthorList ns150:JAD110377 .

ns30:JAD110794 ns0:inAuthorList ns150:JAD110794 .

ns30:JAD111172 ns0:inAuthorList ns150:JAD111172 .

ns30:JAD111778 ns0:inAuthorList ns150:JAD111778 .

ns30:JAD111793 ns0:inAuthorList ns150:JAD111793 .

ns30:JAD120064 ns0:inAuthorList ns150:JAD120064 .

ns30:JAD120073 ns0:inAuthorList ns150:JAD120073 .

ns30:JAD120223 ns0:inAuthorList ns150:JAD120223 .

ns30:JAD120364 ns0:inAuthorList ns150:JAD120364 .

ns30:JAD120676 ns0:inAuthorList ns150:JAD120676 .

ns30:JAD120724 ns0:inAuthorList ns150:JAD120724 .

ns30:JAD120952 ns0:inAuthorList ns150:JAD120952 .

ns30:JAD121594 ns0:inAuthorList ns150:JAD121594 .

ns30:JAD122140 ns0:inAuthorList ns150:JAD122140 .

ns30:JAD122223 ns0:inAuthorList ns150:JAD122223 .

ns30:JAD122263 ns0:inAuthorList ns150:JAD122263 .

ns30:JAD122350 ns0:inAuthorList ns150:JAD122350 .

ns30:JAD122383 ns0:inAuthorList ns150:JAD122383 .

ns30:JAD129040 ns0:inAuthorList ns150:JAD129040 .

ns30:JAD129041 ns0:inAuthorList ns150:JAD129041 .

ns30:JAD130203 ns0:inAuthorList ns150:JAD130203 .

ns30:JAD130245 ns0:inAuthorList ns150:JAD130245 .

ns30:JAD130716 ns0:inAuthorList ns150:JAD130716 .

ns30:JAD130881 ns0:inAuthorList ns150:JAD130881 .

ns30:JAD131040 ns0:inAuthorList ns150:JAD131040 .

ns30:JAD131058 ns0:inAuthorList ns150:JAD131058 .

ns30:JAD131151 ns0:inAuthorList ns150:JAD131151 .

ns30:JAD131172 ns0:inAuthorList ns150:JAD131172 .

ns30:JAD131337 ns0:inAuthorList ns150:JAD131337 .

ns30:JAD131403 ns0:inAuthorList ns150:JAD131403 .

ns30:JAD131481 ns0:inAuthorList ns150:JAD131481 .

ns30:JAD131595 ns0:inAuthorList ns150:JAD131595 .

ns30:JAD131682 ns0:inAuthorList ns150:JAD131682 .

ns30:JAD131820 ns0:inAuthorList ns150:JAD131820 .

ns30:JAD132024 ns0:inAuthorList ns150:JAD132024 .

ns30:JAD132102 ns0:inAuthorList ns150:JAD132102 .

ns30:JAD132147 ns0:inAuthorList ns150:JAD132147 .

ns30:JAD132231 ns0:inAuthorList ns150:JAD132231 .

ns30:JAD132363 ns0:inAuthorList ns150:JAD132363 .

ns30:JAD132393 ns0:inAuthorList ns150:JAD132393 .

ns30:JAD132489 ns0:inAuthorList ns150:JAD132489 .

ns30:JAD140213 ns0:inAuthorList ns150:JAD140213 .

ns30:JAD140282 ns0:inAuthorList ns150:JAD140282 .

ns30:JAD141137 ns0:inAuthorList ns150:JAD141137 .

ns30:JAD141179 ns0:inAuthorList ns150:JAD141179 .

ns30:JAD141320 ns0:inAuthorList ns150:JAD141320 .

ns30:JAD141572 ns0:inAuthorList ns150:JAD141572 .

ns30:JAD141632 ns0:inAuthorList ns150:JAD141632 .

ns30:JAD141659 ns0:inAuthorList ns150:JAD141659 .

ns30:JAD150194 ns0:inAuthorList ns150:JAD150194 .

ns30:JAD150368 ns0:inAuthorList ns150:JAD150368 .

ns30:JAD150478 ns0:inAuthorList ns150:JAD150478 .

ns30:JAD150482 ns0:inAuthorList ns150:JAD150482 .

ns30:JAD150727 ns0:inAuthorList ns150:JAD150727 .

ns30:JAD150729 ns0:inAuthorList ns150:JAD150729 .

ns30:JAD150736 ns0:inAuthorList ns150:JAD150736 .

ns30:JAD150750 ns0:inAuthorList ns150:JAD150750 .

ns30:JAD150778 ns0:inAuthorList ns150:JAD150778 .

ns30:JAD150825 ns0:inAuthorList ns150:JAD150825 .

ns30:JAD150827 ns0:inAuthorList ns150:JAD150827 .

ns30:JAD150864 ns0:inAuthorList ns150:JAD150864 .

ns30:JAD150909 ns0:inAuthorList ns150:JAD150909 .

ns30:JAD151015 ns0:inAuthorList ns150:JAD151015 .

ns30:JAD151078 ns0:inAuthorList ns150:JAD151078 .

ns30:JAD151085 ns0:inAuthorList ns150:JAD151085 .

ns30:JAD151121 ns0:inAuthorList ns150:JAD151121 .

ns30:JAD151181 ns0:inAuthorList ns150:JAD151181 .

ns30:JAD160061 ns0:inAuthorList ns150:JAD160061 .

ns30:JAD160077 ns0:inAuthorList ns150:JAD160077 .

ns30:JAD160124 ns0:inAuthorList ns150:JAD160124 .

ns30:JAD160207 ns0:inAuthorList ns150:JAD160207 .

ns30:JAD160244 ns0:inAuthorList ns150:JAD160244 .

ns30:JAD160299 ns0:inAuthorList ns150:JAD160299 .

ns30:JAD160407 ns0:inAuthorList ns150:JAD160407 .

ns30:JAD160413 ns0:inAuthorList ns150:JAD160413 .

ns30:JAD160506 ns0:inAuthorList ns150:JAD160506 .

ns30:JAD160517 ns0:inAuthorList ns150:JAD160517 .

ns30:JAD160566 ns0:inAuthorList ns150:JAD160566 .

ns30:JAD160581 ns0:inAuthorList ns150:JAD160581 .

ns30:JAD160593 ns0:inAuthorList ns150:JAD160593 .

ns30:JAD160637 ns0:inAuthorList ns150:JAD160637 .

ns30:JAD160685 ns0:inAuthorList ns150:JAD160685 .

ns30:JAD160780 ns0:inAuthorList ns150:JAD160780 .

ns30:JAD160874 ns0:inAuthorList ns150:JAD160874 .

ns30:JAD160927 ns0:inAuthorList ns150:JAD160927 .

ns30:JAD160952 ns0:inAuthorList ns150:JAD160952 .

ns30:JAD160956 ns0:inAuthorList ns150:JAD160956 .

ns30:JAD160975 ns0:inAuthorList ns150:JAD160975 .

ns30:JAD161050 ns0:inAuthorList ns150:JAD161050 .

ns30:JAD161095 ns0:inAuthorList ns150:JAD161095 .

ns30:JAD161132 ns0:inAuthorList ns150:JAD161132 .

ns30:JAD161182 ns0:inAuthorList ns150:JAD161182 .

ns30:JAD161208 ns0:inAuthorList ns150:JAD161208 .

ns30:JAD161232 ns0:inAuthorList ns150:JAD161232 .

ns30:JAD161248 ns0:inAuthorList ns150:JAD161248 .

ns30:JAD161267 ns0:inAuthorList ns150:JAD161267 .

ns30:JAD161292 ns0:inAuthorList ns150:JAD161292 .

ns30:JAD170002 ns0:inAuthorList ns150:JAD170002 .

ns30:JAD170012 ns0:inAuthorList ns150:JAD170012 .

ns30:JAD170017 ns0:inAuthorList ns150:JAD170017 .

ns30:JAD170028 ns0:inAuthorList ns150:JAD170028 .

ns30:JAD170045 ns0:inAuthorList ns150:JAD170045 .

ns30:JAD170055 ns0:inAuthorList ns150:JAD170055 .

ns30:JAD170092 ns0:inAuthorList ns150:JAD170092 .

ns30:JAD170130 ns0:inAuthorList ns150:JAD170130 .

ns30:JAD170148 ns0:inAuthorList ns150:JAD170148 .

ns30:JAD170195 ns0:inAuthorList ns150:JAD170195 .

ns30:JAD170278 ns0:inAuthorList ns150:JAD170278 .

ns30:JAD170281 ns0:inAuthorList ns150:JAD170281 .

ns30:JAD170288 ns0:inAuthorList ns150:JAD170288 .

ns30:JAD170298 ns0:inAuthorList ns150:JAD170298 .

ns30:JAD170404 ns0:inAuthorList ns150:JAD170404 .

ns30:JAD170446 ns0:inAuthorList ns150:JAD170446 .

ns30:JAD170496 ns0:inAuthorList ns150:JAD170496 .

ns30:JAD170532 ns0:inAuthorList ns150:JAD170532 .

ns30:JAD170560 ns0:inAuthorList ns150:JAD170560 .

ns30:JAD170569 ns0:inAuthorList ns150:JAD170569 .

ns30:JAD170599 ns0:inAuthorList ns150:JAD170599 .

ns30:JAD170654 ns0:inAuthorList ns150:JAD170654 .

ns30:JAD170731 ns0:inAuthorList ns150:JAD170731 .

ns30:JAD170796 ns0:inAuthorList ns150:JAD170796 .

ns30:JAD170798 ns0:inAuthorList ns150:JAD170798 .

ns30:JAD170831 ns0:inAuthorList ns150:JAD170831 .

ns30:JAD170854 ns0:inAuthorList ns150:JAD170854 .

ns30:JAD170894 ns0:inAuthorList ns150:JAD170894 .

ns30:JAD170905 ns0:inAuthorList ns150:JAD170905 .

ns30:JAD170914 ns0:inAuthorList ns150:JAD170914 .

ns30:JAD170985 ns0:inAuthorList ns150:JAD170985 .

ns30:JAD170995 ns0:inAuthorList ns150:JAD170995 .

ns30:JAD171047 ns0:inAuthorList ns150:JAD171047 .

ns30:JAD171109 ns0:inAuthorList ns150:JAD171109 .

ns30:JAD171150 ns0:inAuthorList ns150:JAD171150 .

ns30:JAD179939 ns0:inAuthorList ns150:JAD179939 .

ns30:JAD180025 ns0:inAuthorList ns150:JAD180025 .

ns30:JAD180106 ns0:inAuthorList ns150:JAD180106 .

ns30:JAD180183 ns0:inAuthorList ns150:JAD180183 .

ns30:JAD180219 ns0:inAuthorList ns150:JAD180219 .

ns30:JAD180280 ns0:inAuthorList ns150:JAD180280 .

ns30:JAD180344 ns0:inAuthorList ns150:JAD180344 .

ns30:JAD180365 ns0:inAuthorList ns150:JAD180365 .

ns30:JAD180394 ns0:inAuthorList ns150:JAD180394 .

ns30:JAD180427 ns0:inAuthorList ns150:JAD180427 .

ns30:JAD180455 ns0:inAuthorList ns150:JAD180455 .

ns30:JAD180512 ns0:inAuthorList ns150:JAD180512 .

ns30:JAD180594 ns0:inAuthorList ns150:JAD180594 .

ns30:JAD180604 ns0:inAuthorList ns150:JAD180604 .

ns30:JAD180631 ns0:inAuthorList ns150:JAD180631 .

ns30:JAD180693 ns0:inAuthorList ns150:JAD180693 .

ns30:JAD180723 ns0:inAuthorList ns150:JAD180723 .

ns30:JAD180810 ns0:inAuthorList ns150:JAD180810 .

ns30:JAD180857 owl:sameAs ns12:JAD160766,
        ns139:JAD161208,
        ns16:JAD190541 ;
    ns0:fullName "Sebastian Köhler" ;
    ns0:hasAffiliation ns252:JAD180857 ;
    ns0:hasArticle ns1:jad-v70-i4-JAD180857 ;
    ns0:inAuthorList ns150:JAD180857 .

ns30:JAD180897 ns0:inAuthorList ns150:JAD180897 .

ns30:JAD180904 ns0:inAuthorList ns150:JAD180904 .

ns30:JAD180949 ns0:inAuthorList ns150:JAD180949 .

ns30:JAD180965 ns0:inAuthorList ns150:JAD180965 .

ns30:JAD180971 ns0:inAuthorList ns150:JAD180971 .

ns30:JAD181039 ns0:inAuthorList ns150:JAD181039 .

ns30:JAD181049 ns0:inAuthorList ns150:JAD181049 .

ns30:JAD181062 ns0:inAuthorList ns150:JAD181062 .

ns30:JAD181141 owl:sameAs ns8:JAD160291,
        <http://ld.iospress.nl/rdf/contributor/Author:2.ID:BMR11(1)02>,
        ns30:JAD111631,
        ns30:JAD150776,
        ns30:JAD180335,
        ns16:JAD160230,
        ns16:JAD170289,
        ns16:JAD190262,
        ns52:JAD180604 ;
    ns0:fullName "Richard B. Lipton" ;
    ns0:hasAffiliation ns252:JAD181141,
        ns31:JAD181141 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD181141 ;
    ns0:inAuthorList ns150:JAD181141 .

ns30:JAD181173 ns0:inAuthorList ns150:JAD181173 .

ns30:JAD181174 ns0:inAuthorList ns150:JAD181174 .

ns30:JAD181218 ns0:inAuthorList ns150:JAD181218 .

ns30:JAD181253 ns0:inAuthorList ns150:JAD181253 .

ns30:JAD181277 owl:sameAs ns26:JAD151097,
        ns26:JAD170327,
        ns30:JAD131085,
        ns5:JAD140309,
        ns5:JAD180563,
        ns16:JAD130596,
        ns52:JAD141986,
        ns52:JAD160320,
        ns60:JPD171228 ;
    ns0:fullName "Peter Paul De Deyn" ;
    ns0:hasAffiliation ns63:JAD181277,
        ns84:JAD181277 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181277 ;
    ns0:inAuthorList ns150:JAD181277 .

ns30:JAD181281 ns0:inAuthorList ns150:JAD181281 .

ns30:JAD190007 ns0:inAuthorList ns150:JAD190007 .

ns30:JAD190032 ns0:inAuthorList ns150:JAD190032 .

ns30:JAD190147 ns0:inAuthorList ns150:JAD190147 .

ns30:JAD190159 ns0:inAuthorList ns150:JAD190159 .

ns30:JAD190166 ns0:inAuthorList ns150:JAD190166 .

ns30:JAD190230 owl:sameAs ns2:JAD111697,
        ns2:JAD130086,
        ns2:JAD170587,
        ns26:JAD132147,
        ns30:JAD102103,
        ns30:JAD160163,
        ns52:JAD140276,
        ns57:JAD170555 ;
    ns0:fullName "Daniel A. Nation" ;
    ns0:hasAffiliation ns252:JAD190230 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190230 ;
    ns0:inAuthorList ns150:JAD190230 .

ns30:JAD190334 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD140777> ;
    ns0:fullName "Anne M. Koivisto" ;
    ns0:hasAffiliation ns252:JAD190334,
        ns63:JAD190334 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns30:JAD190341 owl:sameAs ns16:JAD120934 ;
    ns0:fullName "Gunhild Waldemar" ;
    ns0:hasAffiliation ns63:JAD190341 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190341 ;
    ns0:inAuthorList ns150:JAD190341 .

ns30:JAD190342 ns0:inAuthorList ns150:JAD190342 .

ns30:JAD190401 owl:sameAs ns2:JAD180441 ;
    ns0:fullName "He Jin" ;
    ns0:hasAffiliation ns252:JAD190401 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190401 ;
    ns0:inAuthorList ns150:JAD190401 .

ns30:JAD190402 owl:sameAs ns8:jad100186,
        ns40:JAD160322,
        ns30:JAD132306,
        ns16:JAD150548,
        ns33:JAD190041 ;
    ns0:fullName "Afina W. Lemstra" ;
    ns0:hasAffiliation ns64:JAD190402 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190402 ;
    ns0:inAuthorList ns150:JAD190402 .

ns30:JAD190545 ns0:inAuthorList ns150:JAD190545 .

ns30:JAD190590 owl:sameAs ns30:JAD122116 ;
    ns0:fullName "Marcus Richards" ;
    ns0:hasAffiliation ns64:JAD190590 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190590 ;
    ns0:inAuthorList ns150:JAD190590 .

ns30:JAD190644 owl:sameAs ns26:JAD181218 ;
    ns0:fullName "Nozomi Hishikawa" ;
    ns0:hasAffiliation ns252:JAD190644 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns30:JAD190823 ns0:inAuthorList ns150:JAD190823 .

ns30:JAD190889 ns0:inAuthorList ns150:JAD190889 .

ns30:JAE180085 ns0:inAuthorList ns150:JAE180085 .

ns30:JAE2259 ns0:inAuthorList ns150:JAE2259 .

ns30:JBR124 ns0:inAuthorList ns150:JBR124 .

ns30:JCB179010 ns0:inAuthorList ns150:JCB179010 .

ns30:JCM190015 ns0:inAuthorList ns150:JCM190015 .

<http://ld.iospress.nl/rdf/contributor/Author:3.ID:JCM2(3-4)10> ns0:inAuthorList <http://ld.iospress.nl/rdf/contributor/List.Role:authors.ID:JCM2(3-4)10> .

ns30:JCS548 ns0:inAuthorList ns150:JCS548 .

ns30:JHD160185 ns0:inAuthorList ns150:JHD160185 .

ns30:JHD160206 ns0:inAuthorList ns150:JHD160206 .

ns30:JHD170238 ns0:inAuthorList ns150:JHD170238 .

ns30:JHD170245 ns0:inAuthorList ns150:JHD170245 .

ns30:JHD180326 ns0:inAuthorList ns150:JHD180326 .

ns30:JHD190361 owl:sameAs ns2:JPD150668,
        ns12:JPD171173,
        ns5:JHD170256 ;
    ns0:fullName "Danny Bega" ;
    ns0:hasAffiliation ns252:JHD190361 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD190361 ;
    ns0:inAuthorList ns150:JHD190361 .

ns30:JHS550 ns0:inAuthorList ns150:JHS550 .

ns30:JND160182 ns0:inAuthorList ns150:JND160182 .

ns30:JND170277 ns0:inAuthorList ns150:JND170277 .

ns30:JND180320 ns0:inAuthorList ns150:JND180320 .

ns30:JPD140451 ns0:inAuthorList ns150:JPD140451 .

ns30:JPD150568 ns0:inAuthorList ns150:JPD150568 .

ns30:JPD150581 ns0:inAuthorList ns150:JPD150581 .

ns30:JPD150638 ns0:inAuthorList ns150:JPD150638 .

ns30:JPD150693 ns0:inAuthorList ns150:JPD150693 .

ns30:JPD160823 ns0:inAuthorList ns150:JPD160823 .

ns30:JPD160927 ns0:inAuthorList ns150:JPD160927 .

ns30:JPD171127 ns0:inAuthorList ns150:JPD171127 .

ns30:JPD179000 ns0:inAuthorList ns150:JPD179000 .

ns30:JPD181332 ns0:inAuthorList ns150:JPD181332 .

ns30:JPD181353 ns0:inAuthorList ns150:JPD181353 .

ns30:JPD181460 owl:sameAs ns8:JPD191635,
        ns57:JAD132156 ;
    ns0:fullName "Andrew J. Lees" ;
    ns0:hasAffiliation ns252:JPD181460 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD181460 ;
    ns0:inAuthorList ns150:JPD181460 .

ns30:JPD181516 ns0:inAuthorList ns150:JPD181516 .

ns30:JPD181519 ns0:inAuthorList ns150:JPD181519 .

ns30:JPD181523 ns0:inAuthorList ns150:JPD181523 .

ns30:JVR180999 ns0:inAuthorList ns150:JVR180999 .

ns30:JVR191023 ns0:inAuthorList ns150:JVR191023 .

ns30:JVR191024 owl:sameAs ns2:NRE1271,
        ns8:JVR894 ;
    ns0:fullName "Mykal Leslie" ;
    ns0:hasAffiliation ns252:JVR191024 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191024 ;
    ns0:inAuthorList ns150:JVR191024 .

ns30:JVR191026 owl:sameAs ns2:JVR191024,
        ns2:JVR810,
        ns2:JVR889,
        ns2:WOR2201,
        ns8:JVR180983,
        ns8:JVR808,
        ns8:JVR817,
        ns8:JVR888,
        ns8:JVR931,
        ns12:JVR811,
        ns12:JVR812,
        ns12:JVR836,
        ns12:JVR894,
        ns12:JVR899,
        ns12:JVR940,
        ns12:JVR941,
        ns30:JVR891,
        ns30:JVR896,
        ns30:NRE1271,
        ns30:WOR2206,
        ns52:WOR2596,
        ns60:NRE1274,
        ns116:WOR2199 ;
    ns0:fullName "Phillip D. Rumrill" ;
    ns0:hasAffiliation ns64:JVR191026 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191026 ;
    ns0:inAuthorList ns150:JVR191026 .

ns30:JVR191032 owl:sameAs ns2:JVR191036 ;
    ns0:fullName "Ellie Hartman" ;
    ns0:hasAffiliation ns252:JVR191032 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191032 ;
    ns0:inAuthorList ns150:JVR191032 .

ns30:JVR191037 ns0:inAuthorList ns150:JVR191037 .

ns30:JVR191042 owl:sameAs ns30:JVR191041 ;
    ns0:fullName "Taylor R. Morris" ;
    ns0:hasAffiliation ns252:JVR191042 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191042 ;
    ns0:inAuthorList ns150:JVR191042 .

ns30:JVR191055 owl:sameAs ns2:JVR816 ;
    ns0:fullName "Timothy N. Tansey" ;
    ns0:hasAffiliation ns64:JVR191055 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191055 ;
    ns0:inAuthorList ns150:JVR191055 .

ns30:JVR808 ns0:inAuthorList ns150:JVR808 .

ns30:JVR889 ns0:inAuthorList ns150:JVR889 .

ns30:JVR893 ns0:inAuthorList ns150:JVR893 .

ns30:JVR914 ns0:inAuthorList ns150:JVR914 .

ns30:JVR930 ns0:inAuthorList ns150:JVR930 .

ns30:KCA170007 ns0:inAuthorList ns150:KCA170007 .

ns30:KCA170018 ns0:inAuthorList ns150:KCA170018 .

ns30:KCA170019 ns0:inAuthorList ns150:KCA170019 .

ns30:MAS180455 ns0:inAuthorList ns150:MAS180455 .

ns30:MGC190793 ns0:inAuthorList ns150:MGC190793 .

ns30:MGC239 ns0:inAuthorList ns150:MGC239 .

ns30:MGS284 ns0:inAuthorList ns150:MGS284 .

ns30:NHA1611 ns0:inAuthorList ns150:NHA1611 .

ns30:NHA170023 ns0:inAuthorList ns150:NHA170023 .

ns30:NHA170028 ns0:inAuthorList ns150:NHA170028 .

ns30:NPM17145 ns0:inAuthorList ns150:NPM17145 .

ns30:NPM1786 ns0:inAuthorList ns150:NPM1786 .

ns30:NRE172212 ns0:inAuthorList ns150:NRE172212 .

ns30:NRE182424 ns0:inAuthorList ns150:NRE182424 .

ns30:NRE182446 ns0:inAuthorList ns150:NRE182446 .

ns30:NRE192754 ns0:inAuthorList ns150:NRE192754 .

ns30:NRE192771 ns0:inAuthorList ns150:NRE192771 .

ns30:RFT1512 ns0:inAuthorList ns150:RFT1512 .

ns30:RFT18109 ns0:inAuthorList ns150:RFT18109 .

ns30:RNN180812 ns0:inAuthorList ns150:RNN180812 .

ns30:SW294 ns0:inAuthorList ns150:SW294 .

ns30:THC1109 ns0:inAuthorList ns150:THC1109 .

ns30:THC1136 ns0:inAuthorList ns150:THC1136 .

ns30:THC191730 ns0:inAuthorList ns150:THC191730 .

ns30:THC891 ns0:inAuthorList ns150:THC891 .

ns30:VES534 ns0:inAuthorList ns150:VES534 .

ns30:VES586 ns0:inAuthorList ns150:VES586 .

ns30:WEB190403 ns0:inAuthorList ns150:WEB190403 .

ns30:WOR192938 owl:sameAs ns8:WOR2661 ;
    ns0:fullName "Venerina Johnston" ;
    ns0:hasAffiliation ns252:WOR192938 ;
    ns0:hasArticle ns1:wor-v63-i3-WOR192938 ;
    ns0:inAuthorList ns150:WOR192938 .

ns30:WOR192955 ns0:inAuthorList ns150:WOR192955 .

ns30:WOR192956 ns0:inAuthorList ns150:WOR192956 .

ns30:WOR192957 ns0:inAuthorList ns150:WOR192957 .

ns30:WOR193011 owl:sameAs ns30:WOR2318,
        ns30:WOR2737 ;
    ns0:fullName "Ulrika Bejerholm" ;
    ns0:hasAffiliation ns64:WOR193011 ;
    ns0:hasArticle ns1:wor-v64-i3-WOR193011 ;
    ns0:inAuthorList ns150:WOR193011 .

ns30:WOR2204 ns0:inAuthorList ns150:WOR2204 .

ns30:WOR2401 ns0:inAuthorList ns150:WOR2401 .

ns30:WOR2589 ns0:inAuthorList ns150:WOR2589 .

ns30:WOR2617 ns0:inAuthorList ns150:WOR2617 .

ns30:WOR2661 ns0:inAuthorList ns150:WOR2661 .

ns30:XST16245 ns0:inAuthorList ns150:XST16245 .

ns30:XST17366 ns0:inAuthorList ns150:XST17366 .

ns30:XST180418 ns0:inAuthorList ns150:XST180418 .

ns30:XST180427 ns0:inAuthorList ns150:XST180427 .

ns30:XST190548 owl:sameAs ns8:CBM542 ;
    ns0:fullName "Yulan Peng" ;
    ns0:hasAffiliation ns31:XST190548 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190548 ;
    ns0:inAuthorList ns150:XST190548 .

ns30:bmr00396 ns0:inAuthorList ns150:bmr00396 .

ns30:bmr00531 ns0:inAuthorList ns150:bmr00531 .

ns30:cbm00178 ns0:inAuthorList ns150:cbm00178 .

ns30:ica00404 ns0:inAuthorList ns150:ica00404 .

ns30:ica00441 ns0:inAuthorList ns150:ica00441 .

ns30:jad00408 ns0:inAuthorList ns150:jad00408 .

ns30:jad00543 ns0:inAuthorList ns150:jad00543 .

ns30:jad00634 ns0:inAuthorList ns150:jad00634 .

ns30:jad00741 ns0:inAuthorList ns150:jad00741 .

ns30:jad00795 ns0:inAuthorList ns150:jad00795 .

ns30:jad00942 ns0:inAuthorList ns150:jad00942 .

ns30:jad01003 ns0:inAuthorList ns150:jad01003 .

ns30:jad01019 ns0:inAuthorList ns150:jad01019 .

ns30:jad01074 ns0:inAuthorList ns150:jad01074 .

ns30:jad01163 ns0:inAuthorList ns150:jad01163 .

ns30:jad01225 ns0:inAuthorList ns150:jad01225 .

ns30:jad01275 ns0:inAuthorList ns150:jad01275 .

ns30:jad01364 ns0:inAuthorList ns150:jad01364 .

ns30:jad01410 ns0:inAuthorList ns150:jad01410 .

ns30:jad091630 ns0:inAuthorList ns150:jad091630 .

ns30:jad100198 ns0:inAuthorList ns150:jad100198 .

ns30:jad100288 ns0:inAuthorList ns150:jad100288 .

ns30:jad100318 ns0:inAuthorList ns150:jad100318 .

ns30:jad100405 ns0:inAuthorList ns150:jad100405 .

ns30:jad100723 ns0:inAuthorList ns150:jad100723 .

ns30:jad100843 ns0:inAuthorList ns150:jad100843 .

ns30:jad100888 ns0:inAuthorList ns150:jad100888 .

ns30:jad100933 ns0:inAuthorList ns150:jad100933 .

ns30:jad101011 ns0:inAuthorList ns150:jad101011 .

ns30:jad101350 ns0:inAuthorList ns150:jad101350 .

ns30:jcm00516 ns0:inAuthorList ns150:jcm00516 .

ns30:jcs151 ns0:inAuthorList ns150:jcs151 .

ns30:jcs265 ns0:inAuthorList ns150:jcs265 .

ns30:jcs410 ns0:inAuthorList ns150:jcs410 .

ns30:jcs494 ns0:inAuthorList ns150:jcs494 .

ns30:jcs510 ns0:inAuthorList ns150:jcs510 .

ns30:mas00306 ns0:inAuthorList ns150:mas00306 .

ns30:mgs00038 ns0:inAuthorList ns150:mgs00038 .

ns30:mgs00217 ns0:inAuthorList ns150:mgs00217 .

ns30:tad00403 ns0:inAuthorList ns150:tad00403 .

ns30:thc00473 ns0:inAuthorList ns150:thc00473 .

ns30:thc00680 ns0:inAuthorList ns150:thc00680 .

ns118:BLC160053 ns0:inAuthorList ns150:BLC160053 .

ns118:JAD180158 ns0:inAuthorList ns150:JAD180158 .

<http://ld.iospress.nl/rdf/contributor/Author:31.ID:JAD150883> ns0:inAuthorList ns150:JAD150883 .

<http://ld.iospress.nl/rdf/contributor/Author:31.ID:JAD160668> ns0:inAuthorList ns150:JAD160668 .

<http://ld.iospress.nl/rdf/contributor/Author:34.ID:JAD171145> ns0:inAuthorList ns150:JAD171145 .

<http://ld.iospress.nl/rdf/contributor/Author:36.ID:JAD121456> ns0:inAuthorList ns150:JAD121456 .

<http://ld.iospress.nl/rdf/contributor/Author:36.ID:JAD171145> ns0:inAuthorList ns150:JAD171145 .

<http://ld.iospress.nl/rdf/contributor/Author:37.ID:JAD150555> ns0:inAuthorList ns150:JAD150555 .

<http://ld.iospress.nl/rdf/contributor/Author:38.ID:JAD160668> ns0:inAuthorList ns150:JAD160668 .

<http://ld.iospress.nl/rdf/contributor/Author:39.ID:BLC189037> ns0:inAuthorList ns150:BLC189037 .

ns5:BME1571 ns0:inAuthorList ns150:BME1571 .

ns5:BME1651 ns0:inAuthorList ns150:BME1651 .

ns5:BMR160633 ns0:inAuthorList ns150:BMR160633 .

ns5:BMR170963 ns0:inAuthorList ns150:BMR170963 .

ns5:BMR171041 ns0:inAuthorList ns150:BMR171041 .

ns5:BPL160039 ns0:inAuthorList ns150:BPL160039 .

ns5:CBM170831 ns0:inAuthorList ns150:CBM170831 .

ns5:CBM171099 ns0:inAuthorList ns150:CBM171099 .

ns5:CBM181308 ns0:inAuthorList ns150:CBM181308 .

ns5:CBM477 ns0:inAuthorList ns150:CBM477 .

ns5:CBM533 ns0:inAuthorList ns150:CBM533 .

ns5:CBM609 ns0:inAuthorList ns150:CBM609 .

ns5:CH160241 ns0:inAuthorList ns150:CH160241 .

ns5:CH168002 ns0:inAuthorList ns150:CH168002 .

ns5:CH168029 ns0:inAuthorList ns150:CH168029 .

ns5:CH168110 ns0:inAuthorList ns150:CH168110 .

ns5:CH168115 ns0:inAuthorList ns150:CH168115 .

ns5:CH170259 ns0:inAuthorList ns150:CH170259 .

ns5:CH179202 ns0:inAuthorList ns150:CH179202 .

ns5:CH179211 ns0:inAuthorList ns150:CH179211 .

ns5:CH179217 ns0:inAuthorList ns150:CH179217 .

ns5:CH179224 ns0:inAuthorList ns150:CH179224 .

ns5:CH179235 ns0:inAuthorList ns150:CH179235 .

ns5:CH180545 ns0:inAuthorList ns150:CH180545 .

ns5:CH189114 ns0:inAuthorList ns150:CH189114 .

ns5:CH189115 ns0:inAuthorList ns150:CH189115 .

ns5:CH189116 ns0:inAuthorList ns150:CH189116 .

ns5:CH189125 ns0:inAuthorList ns150:CH189125 .

ns5:CH189130 ns0:inAuthorList ns150:CH189130 .

ns5:CH189402 ns0:inAuthorList ns150:CH189402 .

ns5:CH189406 ns0:inAuthorList ns150:CH189406 .

ns5:CH189407 ns0:inAuthorList ns150:CH189407 .

ns5:CH1983 ns0:inAuthorList ns150:CH1983 .

ns5:CH199204 owl:sameAs ns2:CH179104,
        ns2:CH2010,
        ns8:CH168039,
        ns8:CH2009,
        ns30:CH189406,
        ns5:CH189310,
        ns5:CH189405 ;
    ns0:fullName "J. Rübenthaler" ;
    ns0:hasAffiliation ns6:CH199204 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199204 ;
    ns0:inAuthorList ns150:CH199204 .

ns5:HAB190362 owl:sameAs ns30:BD248,
        ns30:HAB180358,
        ns5:BD180351,
        ns5:HAB180344,
        ns52:NIB180141,
        ns60:BD264 ;
    ns0:fullName "Soudeh Ghafouri-Fard" ;
    ns0:hasAffiliation ns120:HAB190362 ;
    ns0:hasArticle ns1:hab-v27-i3-HAB190362 ;
    ns0:inAuthorList ns150:HAB190362 .

ns5:HAB190363 ns0:inAuthorList ns150:HAB190363 .

ns5:HAB190364 ns0:inAuthorList ns150:HAB190364 .

ns5:HAB324 ns0:inAuthorList ns150:HAB324 .

ns5:HAB341 ns0:inAuthorList ns150:HAB341 .

ns5:HSM17100 ns0:inAuthorList ns150:HSM17100 .

ns5:HSM17111 ns0:inAuthorList ns150:HSM17111 .

ns5:HSM17118 ns0:inAuthorList ns150:HSM17118 .

ns5:HSM180472 ns0:inAuthorList ns150:HSM180472 .

ns5:HSM190490 ns0:inAuthorList ns150:HSM190490 .

ns5:IA102 ns0:inAuthorList ns150:IA102 .

ns5:IA110 ns0:inAuthorList ns150:IA110 .

ns5:IES192150 ns0:inAuthorList ns150:IES192150 .

ns5:IFS152168 ns0:inAuthorList ns150:IFS152168 .

ns5:IFS161152 ns0:inAuthorList ns150:IFS161152 .

ns5:IFS16252 ns0:inAuthorList ns150:IFS16252 .

ns5:IFS171049 ns0:inAuthorList ns150:IFS171049 .

ns5:IFS171118 ns0:inAuthorList ns150:IFS171118 .

ns5:IFS172203 ns0:inAuthorList ns150:IFS172203 .

ns5:IFS179084 ns0:inAuthorList ns150:IFS179084 .

ns5:IFS181127 ns0:inAuthorList ns150:IFS181127 .

ns5:IFS181153 ns0:inAuthorList ns150:IFS181153 .

ns5:IFS181329 ns0:inAuthorList ns150:IFS181329 .

ns5:IFS181477 ns0:inAuthorList ns150:IFS181477 .

ns5:IFS182515 ns0:inAuthorList ns150:IFS182515 .

ns5:IFS182671 ns0:inAuthorList ns150:IFS182671 .

ns5:IFS18607 ns0:inAuthorList ns150:IFS18607 .

ns5:IFS18667 ns0:inAuthorList ns150:IFS18667 .

ns5:IFS190067 ns0:inAuthorList ns150:IFS190067 .

ns5:IFS191197 ns0:inAuthorList ns150:IFS191197 .

ns5:JAD0006 ns0:inAuthorList ns150:JAD0006 .

ns5:JAD0058 ns0:inAuthorList ns150:JAD0058 .

ns5:JAD101005 ns0:inAuthorList ns150:JAD101005 .

ns5:JAD101359 ns0:inAuthorList ns150:JAD101359 .

ns5:JAD101515 ns0:inAuthorList ns150:JAD101515 .

ns5:JAD101611 ns0:inAuthorList ns150:JAD101611 .

ns5:JAD101632 ns0:inAuthorList ns150:JAD101632 .

ns5:JAD101722 ns0:inAuthorList ns150:JAD101722 .

ns5:JAD101908 ns0:inAuthorList ns150:JAD101908 .

ns5:JAD101911 ns0:inAuthorList ns150:JAD101911 .

ns5:JAD101974 ns0:inAuthorList ns150:JAD101974 .

ns5:JAD110251 ns0:inAuthorList ns150:JAD110251 .

ns5:JAD110329 ns0:inAuthorList ns150:JAD110329 .

ns5:JAD110405 ns0:inAuthorList ns150:JAD110405 .

ns5:JAD110473 ns0:inAuthorList ns150:JAD110473 .

ns5:JAD110482 ns0:inAuthorList ns150:JAD110482 .

ns5:JAD110584 ns0:inAuthorList ns150:JAD110584 .

ns5:JAD110719 ns0:inAuthorList ns150:JAD110719 .

ns5:JAD110794 ns0:inAuthorList ns150:JAD110794 .

ns5:JAD110857 ns0:inAuthorList ns150:JAD110857 .

ns5:JAD110911 ns0:inAuthorList ns150:JAD110911 .

ns5:JAD110989 ns0:inAuthorList ns150:JAD110989 .

ns5:JAD111370 ns0:inAuthorList ns150:JAD111370 .

ns5:JAD111628 ns0:inAuthorList ns150:JAD111628 .

ns5:JAD111736 ns0:inAuthorList ns150:JAD111736 .

ns5:JAD111796 ns0:inAuthorList ns150:JAD111796 .

ns5:JAD112111 ns0:inAuthorList ns150:JAD112111 .

ns5:JAD112141 ns0:inAuthorList ns150:JAD112141 .

ns5:JAD120148 ns0:inAuthorList ns150:JAD120148 .

ns5:JAD120169 ns0:inAuthorList ns150:JAD120169 .

ns5:JAD120424 ns0:inAuthorList ns150:JAD120424 .

ns5:JAD120532 ns0:inAuthorList ns150:JAD120532 .

ns5:JAD120709 ns0:inAuthorList ns150:JAD120709 .

ns5:JAD120769 ns0:inAuthorList ns150:JAD120769 .

ns5:JAD120877 ns0:inAuthorList ns150:JAD120877 .

ns5:JAD121228 ns0:inAuthorList ns150:JAD121228 .

ns5:JAD121420 ns0:inAuthorList ns150:JAD121420 .

ns5:JAD121945 ns0:inAuthorList ns150:JAD121945 .

ns5:JAD122026 ns0:inAuthorList ns150:JAD122026 .

ns5:JAD122098 ns0:inAuthorList ns150:JAD122098 .

ns5:JAD122293 ns0:inAuthorList ns150:JAD122293 .

ns5:JAD122353 ns0:inAuthorList ns150:JAD122353 .

ns5:JAD122425 ns0:inAuthorList ns150:JAD122425 .

ns5:JAD122458 ns0:inAuthorList ns150:JAD122458 .

ns5:JAD129041 ns0:inAuthorList ns150:JAD129041 .

ns5:JAD130320 ns0:inAuthorList ns150:JAD130320 .

ns5:JAD130506 ns0:inAuthorList ns150:JAD130506 .

ns5:JAD130551 ns0:inAuthorList ns150:JAD130551 .

ns5:JAD130656 ns0:inAuthorList ns150:JAD130656 .

ns5:JAD130779 ns0:inAuthorList ns150:JAD130779 .

ns5:JAD131085 ns0:inAuthorList ns150:JAD131085 .

ns5:JAD131166 ns0:inAuthorList ns150:JAD131166 .

ns5:JAD131343 ns0:inAuthorList ns150:JAD131343 .

ns5:JAD131403 ns0:inAuthorList ns150:JAD131403 .

ns5:JAD131430 ns0:inAuthorList ns150:JAD131430 .

ns5:JAD131610 ns0:inAuthorList ns150:JAD131610 .

ns5:JAD131724 ns0:inAuthorList ns150:JAD131724 .

ns5:JAD131820 ns0:inAuthorList ns150:JAD131820 .

ns5:JAD131850 ns0:inAuthorList ns150:JAD131850 .

ns5:JAD132186 ns0:inAuthorList ns150:JAD132186 .

ns5:JAD132219 ns0:inAuthorList ns150:JAD132219 .

ns5:JAD132561 ns0:inAuthorList ns150:JAD132561 .

ns5:JAD132672 ns0:inAuthorList ns150:JAD132672 .

ns5:JAD132768 ns0:inAuthorList ns150:JAD132768 .

ns5:JAD140162 ns0:inAuthorList ns150:JAD140162 .

ns5:JAD140177 ns0:inAuthorList ns150:JAD140177 .

ns5:JAD140282 ns0:inAuthorList ns150:JAD140282 .

ns5:JAD140309 ns0:inAuthorList ns150:JAD140309 .

ns5:JAD140336 ns0:inAuthorList ns150:JAD140336 .

ns5:JAD140393 ns0:inAuthorList ns150:JAD140393 .

ns5:JAD140636 ns0:inAuthorList ns150:JAD140636 .

ns5:JAD140639 ns0:inAuthorList ns150:JAD140639 .

ns5:JAD140669 ns0:inAuthorList ns150:JAD140669 .

ns5:JAD140756 ns0:inAuthorList ns150:JAD140756 .

ns5:JAD140924 ns0:inAuthorList ns150:JAD140924 .

ns5:JAD141230 ns0:inAuthorList ns150:JAD141230 .

ns5:JAD141266 ns0:inAuthorList ns150:JAD141266 .

ns5:JAD141287 ns0:inAuthorList ns150:JAD141287 .

ns5:JAD141314 ns0:inAuthorList ns150:JAD141314 .

ns5:JAD141380 ns0:inAuthorList ns150:JAD141380 .

ns5:JAD141521 ns0:inAuthorList ns150:JAD141521 .

ns5:JAD141572 ns0:inAuthorList ns150:JAD141572 .

ns5:JAD141959 ns0:inAuthorList ns150:JAD141959 .

ns5:JAD142052 ns0:inAuthorList ns150:JAD142052 .

ns5:JAD142442 ns0:inAuthorList ns150:JAD142442 .

ns5:JAD143084 ns0:inAuthorList ns150:JAD143084 .

ns5:JAD150244 ns0:inAuthorList ns150:JAD150244 .

ns5:JAD150257 ns0:inAuthorList ns150:JAD150257 .

ns5:JAD150481 ns0:inAuthorList ns150:JAD150481 .

ns5:JAD150537 ns0:inAuthorList ns150:JAD150537 .

ns5:JAD150587 ns0:inAuthorList ns150:JAD150587 .

ns5:JAD150630 ns0:inAuthorList ns150:JAD150630 .

ns5:JAD150752 ns0:inAuthorList ns150:JAD150752 .

ns5:JAD150862 ns0:inAuthorList ns150:JAD150862 .

ns5:JAD150863 ns0:inAuthorList ns150:JAD150863 .

ns5:JAD150898 ns0:inAuthorList ns150:JAD150898 .

ns5:JAD150992 ns0:inAuthorList ns150:JAD150992 .

ns5:JAD151116 ns0:inAuthorList ns150:JAD151116 .

ns5:JAD151120 ns0:inAuthorList ns150:JAD151120 .

ns5:JAD151121 ns0:inAuthorList ns150:JAD151121 .

ns5:JAD160008 ns0:inAuthorList ns150:JAD160008 .

ns5:JAD160053 ns0:inAuthorList ns150:JAD160053 .

ns5:JAD160124 ns0:inAuthorList ns150:JAD160124 .

ns5:JAD160209 ns0:inAuthorList ns150:JAD160209 .

ns5:JAD160238 ns0:inAuthorList ns150:JAD160238 .

ns5:JAD160268 ns0:inAuthorList ns150:JAD160268 .

ns5:JAD160320 ns0:inAuthorList ns150:JAD160320 .

ns5:JAD160377 ns0:inAuthorList ns150:JAD160377 .

ns5:JAD160485 ns0:inAuthorList ns150:JAD160485 .

ns5:JAD160544 ns0:inAuthorList ns150:JAD160544 .

ns5:JAD160545 ns0:inAuthorList ns150:JAD160545 .

ns5:JAD160574 ns0:inAuthorList ns150:JAD160574 .

ns5:JAD160645 ns0:inAuthorList ns150:JAD160645 .

ns5:JAD160647 ns0:inAuthorList ns150:JAD160647 .

ns5:JAD160685 ns0:inAuthorList ns150:JAD160685 .

ns5:JAD160716 ns0:inAuthorList ns150:JAD160716 .

ns5:JAD160722 ns0:inAuthorList ns150:JAD160722 .

ns5:JAD160742 ns0:inAuthorList ns150:JAD160742 .

ns5:JAD160762 ns0:inAuthorList ns150:JAD160762 .

ns5:JAD160800 ns0:inAuthorList ns150:JAD160800 .

ns5:JAD160820 ns0:inAuthorList ns150:JAD160820 .

ns5:JAD160828 ns0:inAuthorList ns150:JAD160828 .

ns5:JAD160850 ns0:inAuthorList ns150:JAD160850 .

ns5:JAD160881 ns0:inAuthorList ns150:JAD160881 .

ns5:JAD160923 ns0:inAuthorList ns150:JAD160923 .

ns5:JAD160970 ns0:inAuthorList ns150:JAD160970 .

ns5:JAD160977 ns0:inAuthorList ns150:JAD160977 .

ns5:JAD160983 ns0:inAuthorList ns150:JAD160983 .

ns5:JAD161050 ns0:inAuthorList ns150:JAD161050 .

ns5:JAD161053 ns0:inAuthorList ns150:JAD161053 .

ns5:JAD161160 ns0:inAuthorList ns150:JAD161160 .

ns5:JAD161208 ns0:inAuthorList ns150:JAD161208 .

ns5:JAD161292 ns0:inAuthorList ns150:JAD161292 .

ns5:JAD170012 ns0:inAuthorList ns150:JAD170012 .

ns5:JAD170061 ns0:inAuthorList ns150:JAD170061 .

ns5:JAD170086 ns0:inAuthorList ns150:JAD170086 .

ns5:JAD170123 ns0:inAuthorList ns150:JAD170123 .

ns5:JAD170190 ns0:inAuthorList ns150:JAD170190 .

ns5:JAD170231 ns0:inAuthorList ns150:JAD170231 .

ns5:JAD170238 ns0:inAuthorList ns150:JAD170238 .

ns5:JAD170554 ns0:inAuthorList ns150:JAD170554 .

ns5:JAD170555 ns0:inAuthorList ns150:JAD170555 .

ns5:JAD170581 ns0:inAuthorList ns150:JAD170581 .

ns5:JAD170595 ns0:inAuthorList ns150:JAD170595 .

ns5:JAD170692 ns0:inAuthorList ns150:JAD170692 .

ns5:JAD170712 ns0:inAuthorList ns150:JAD170712 .

ns5:JAD170762 ns0:inAuthorList ns150:JAD170762 .

ns5:JAD170807 ns0:inAuthorList ns150:JAD170807 .

ns5:JAD170854 ns0:inAuthorList ns150:JAD170854 .

ns5:JAD170858 ns0:inAuthorList ns150:JAD170858 .

ns5:JAD170859 ns0:inAuthorList ns150:JAD170859 .

ns5:JAD170903 ns0:inAuthorList ns150:JAD170903 .

ns5:JAD170917 ns0:inAuthorList ns150:JAD170917 .

ns5:JAD170985 ns0:inAuthorList ns150:JAD170985 .

ns5:JAD170995 ns0:inAuthorList ns150:JAD170995 .

ns5:JAD171038 ns0:inAuthorList ns150:JAD171038 .

ns5:JAD171125 ns0:inAuthorList ns150:JAD171125 .

ns5:JAD171145 ns0:inAuthorList ns150:JAD171145 .

ns5:JAD179924 ns0:inAuthorList ns150:JAD179924 .

ns5:JAD179939 ns0:inAuthorList ns150:JAD179939 .

ns5:JAD180025 ns0:inAuthorList ns150:JAD180025 .

ns5:JAD180028 ns0:inAuthorList ns150:JAD180028 .

ns5:JAD180036 ns0:inAuthorList ns150:JAD180036 .

ns5:JAD180050 ns0:inAuthorList ns150:JAD180050 .

ns5:JAD180125 ns0:inAuthorList ns150:JAD180125 .

ns5:JAD180176 ns0:inAuthorList ns150:JAD180176 .

ns5:JAD180205 ns0:inAuthorList ns150:JAD180205 .

ns5:JAD180280 ns0:inAuthorList ns150:JAD180280 .

ns5:JAD180336 ns0:inAuthorList ns150:JAD180336 .

ns5:JAD180432 ns0:inAuthorList ns150:JAD180432 .

ns5:JAD180496 owl:sameAs ns28:JAD180511,
        ns16:JAD160685 ;
    ns0:fullName "Wan Zurinah Wan Ngah" ;
    ns0:hasAffiliation ns6:JAD180496 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180496 ;
    ns0:inAuthorList ns150:JAD180496 .

ns5:JAD180501 ns0:inAuthorList ns150:JAD180501 .

ns5:JAD180554 ns0:inAuthorList ns150:JAD180554 .

ns5:JAD180663 ns0:inAuthorList ns150:JAD180663 .

ns5:JAD180715 ns0:inAuthorList ns150:JAD180715 .

ns5:JAD180737 ns0:inAuthorList ns150:JAD180737 .

ns5:JAD180788 ns0:inAuthorList ns150:JAD180788 .

ns5:JAD180855 ns0:inAuthorList ns150:JAD180855 .

ns5:JAD180865 ns0:inAuthorList ns150:JAD180865 .

ns5:JAD180882 ns0:inAuthorList ns150:JAD180882 .

ns5:JAD180904 ns0:inAuthorList ns150:JAD180904 .

ns5:JAD180911 ns0:inAuthorList ns150:JAD180911 .

ns5:JAD180912 ns0:inAuthorList ns150:JAD180912 .

ns5:JAD180943 ns0:inAuthorList ns150:JAD180943 .

ns5:JAD180981 ns0:inAuthorList ns150:JAD180981 .

ns5:JAD180982 ns0:inAuthorList ns150:JAD180982 .

ns5:JAD181038 ns0:inAuthorList ns150:JAD181038 .

ns5:JAD181080 ns0:inAuthorList ns150:JAD181080 .

ns5:JAD181099 ns0:inAuthorList ns150:JAD181099 .

ns5:JAD181152 ns0:inAuthorList ns150:JAD181152 .

ns5:JAD181170 ns0:inAuthorList ns150:JAD181170 .

ns5:JAD181186 ns0:inAuthorList ns150:JAD181186 .

ns5:JAD181261 owl:sameAs ns8:JAD161277,
        ns8:JAD179924,
        ns16:JAD150471,
        ns16:JAD170409,
        ns16:JAD180280 ;
    ns0:fullName "Adeline Su Lyn Ng" ;
    ns0:hasAffiliation ns6:JAD181261 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181261 ;
    ns0:inAuthorList ns150:JAD181261 .

ns5:JAD190030 ns0:inAuthorList ns150:JAD190030 .

ns5:JAD190033 ns0:inAuthorList ns150:JAD190033 .

ns5:JAD190056 ns0:inAuthorList ns150:JAD190056 .

ns5:JAD190074 ns0:inAuthorList ns150:JAD190074 .

ns5:JAD190087 owl:sameAs ns2:JAD190256 ;
    ns0:fullName "Shinji Matsunaga" ;
    ns0:hasAffiliation ns120:JAD190087 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190087 ;
    ns0:inAuthorList ns150:JAD190087 .

ns5:JAD190132 ns0:inAuthorList ns150:JAD190132 .

ns5:JAD190152 owl:sameAs ns8:jad00878,
        ns26:JAD180669,
        ns12:JAD122098,
        <http://ld.iospress.nl/rdf/contributor/Author:36.ID:JAD160668> ;
    ns0:fullName "Isabel Santana" ;
    ns0:hasAffiliation ns120:JAD190152 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190152 ;
    ns0:inAuthorList ns150:JAD190152 .

ns5:JAD190159 owl:sameAs ns2:JAD150736 ;
    ns0:fullName "Nagaendran Kandiah" ;
    ns0:hasAffiliation ns6:JAD190159 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190159 ;
    ns0:inAuthorList ns150:JAD190159 .

ns5:JAD190160 ns0:inAuthorList ns150:JAD190160 .

ns5:JAD190187 owl:sameAs ns40:JAD121930,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD171116>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad091651>,
        <http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD170875>,
        ns16:JAD142025,
        ns57:JAD150897,
        ns60:JAD190077,
        ns33:JAD121471 ;
    ns0:fullName "Henrik Zetterberg" ;
    ns0:hasAffiliation ns6:JAD190187,
        ns50:JAD190187,
        ns87:JAD190187,
        ns71:JAD190187 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190187 ;
    ns0:inAuthorList ns150:JAD190187 .

ns5:JAD190262 owl:sameAs ns8:JAD111631,
        ns8:JAD180604 ;
    ns0:fullName "Charles B. Hall" ;
    ns0:hasAffiliation ns87:JAD190262 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190262 ;
    ns0:inAuthorList ns150:JAD190262 .

ns5:JAD190281 owl:sameAs ns2:JAD00003,
        ns2:jad00545,
        ns8:JAD141626,
        ns8:JAD150134,
        ns8:JAD190790,
        ns8:jad00407,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad01239>,
        ns12:JAD00024,
        ns12:JAD110021,
        ns12:JAD122223,
        ns12:JAD132762,
        ns30:JAD190782,
        ns30:jad100666,
        ns5:JAD190197,
        ns5:jad00325,
        ns16:jad00838,
        ns52:JAD180023,
        ns52:JAD181039,
        ns52:jad00733,
        ns52:jad01155,
        ns57:JAD170999,
        ns57:jad00309,
        ns57:jad00418,
        ns57:jad01021 ;
    ns0:fullName "George Perry" ;
    ns0:hasAffiliation ns120:JAD190281 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190281 ;
    ns0:inAuthorList ns150:JAD190281 .

ns5:JAD190295 owl:sameAs ns8:JAD110428,
        ns5:JAD121648,
        ns57:JAD150574 ;
    ns0:fullName "Catherine Helmer" ;
    ns0:hasAffiliation ns120:JAD190295 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190295 ;
    ns0:inAuthorList ns150:JAD190295 .

ns5:JAD190368 ns0:inAuthorList ns150:JAD190368 .

ns5:JAD190405 ns0:inAuthorList ns150:JAD190405 .

ns5:JAD190656 owl:sameAs ns2:jad01153,
        ns8:JAD141890,
        ns60:JAD180619 ;
    ns0:fullName "Robert A. Rissman" ;
    ns0:hasAffiliation ns6:JAD190656 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190656 ;
    ns0:inAuthorList ns150:JAD190656 .

ns5:JAD190688 owl:sameAs ns12:JAD170595,
        ns30:JAD160970 ;
    ns0:fullName "Miloslav Kopecek" ;
    ns0:hasAffiliation ns87:JAD190688,
        ns153:JAD190688 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190688 ;
    ns0:inAuthorList ns150:JAD190688 .

ns5:JAD190898 owl:sameAs ns2:jad101311,
        ns8:JAD160122,
        ns8:jad00087,
        ns8:jad01113,
        ns40:JAD101518,
        ns40:JAD160046,
        ns40:JAD161109,
        ns12:jad01361,
        ns12:jad100327,
        ns30:JAD101068,
        ns30:jad100174,
        <http://ld.iospress.nl/rdf/contributor/Author:38.ID:JAD150883>,
        ns5:JAD101512,
        ns5:JAD121369,
        ns5:jad00147,
        ns5:jad00866,
        ns16:JAD122122,
        ns16:JAD130296,
        ns16:JAD131901,
        ns16:JAD180653,
        ns16:jad00079,
        ns16:jad091450,
        ns57:ADR170051,
        ns57:JAD160593,
        ns57:JAD170324,
        ns60:JAD170502,
        ns60:JAD190756,
        ns33:JAD160022,
        ns33:JAD170575 ;
    ns0:fullName "Bengt Winblad" ;
    ns0:hasAffiliation ns6:JAD190898,
        ns87:JAD190898 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190898 ;
    ns0:inAuthorList ns150:JAD190898 .

ns5:JAE160081 ns0:inAuthorList ns150:JAE160081 .

ns5:JAE180086 ns0:inAuthorList ns150:JAE180086 .

ns5:JAE180092 ns0:inAuthorList ns150:JAE180092 .

ns5:JAE1988 ns0:inAuthorList ns150:JAE1988 .

ns5:JAE198976 ns0:inAuthorList ns150:JAE198976 .

ns5:JBR180361 ns0:inAuthorList ns150:JBR180361 .

ns5:JCB15027 ns0:inAuthorList ns150:JCB15027 .

ns5:JCB179006 ns0:inAuthorList ns150:JCB179006 .

ns5:JCB189014 ns0:inAuthorList ns150:JCB189014 .

ns5:JCS17947 ns0:inAuthorList ns150:JCS17947 .

ns5:JHD180297 ns0:inAuthorList ns150:JHD180297 .

ns5:JHD180325 ns0:inAuthorList ns150:JHD180325 .

ns5:JPD150532 ns0:inAuthorList ns150:JPD150532 .

ns5:JPD160828 ns0:inAuthorList ns150:JPD160828 .

ns5:JPD160853 ns0:inAuthorList ns150:JPD160853 .

ns5:JPD171081 ns0:inAuthorList ns150:JPD171081 .

ns5:JPD181365 ns0:inAuthorList ns150:JPD181365 .

ns5:JPD181383 ns0:inAuthorList ns150:JPD181383 .

ns5:JPD181431 ns0:inAuthorList ns150:JPD181431 .

ns5:JPD181434 ns0:inAuthorList ns150:JPD181434 .

ns5:JPD181500 ns0:inAuthorList ns150:JPD181500 .

ns5:JPD191612 owl:sameAs ns2:jad01207,
        ns5:JPD171264 ;
    ns0:fullName "Shishuang Cui" ;
    ns0:hasAffiliation ns50:JPD191612 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191612 ;
    ns0:inAuthorList ns150:JPD191612 .

ns5:JVR180976 ns0:inAuthorList ns150:JVR180976 .

ns5:JVR191024 owl:sameAs ns2:JVR191021,
        ns2:JVR191055,
        ns12:JVR191047,
        ns5:JVR813 ;
    ns0:fullName "David R. Strauser" ;
    ns0:hasAffiliation ns123:JVR191024 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191024 ;
    ns0:inAuthorList ns150:JVR191024 .

ns5:JVR191038 owl:sameAs ns30:JVR180991 ;
    ns0:fullName "Jean Hall" ;
    ns0:hasAffiliation ns120:JVR191038 ;
    ns0:hasArticle ns1:jvr-v51-i2-JVR191038 ;
    ns0:inAuthorList ns150:JVR191038 .

ns5:JVR191039 ns0:inAuthorList ns150:JVR191039 .

ns5:JVR889 ns0:inAuthorList ns150:JVR889 .

ns5:JVR922 ns0:inAuthorList ns150:JVR922 .

ns5:JVR972 ns0:inAuthorList ns150:JVR972 .

ns5:KCA180047 ns0:inAuthorList ns150:KCA180047 .

ns5:KCA190063 owl:sameAs ns8:KCA170005,
        ns33:KCA180041 ;
    ns0:fullName "Primo N. Lara" ;
    ns0:hasAffiliation ns6:KCA190063 ;
    ns0:hasArticle ns1:kca-v3-i3-KCA190063 ;
    ns0:inAuthorList ns150:KCA190063 .

ns5:MGC180262 ns0:inAuthorList ns150:MGC180262 .

ns5:MGC180763 ns0:inAuthorList ns150:MGC180763 .

ns5:MGC247 ns0:inAuthorList ns150:MGC247 .

ns5:MGC249 ns0:inAuthorList ns150:MGC249 .

ns5:MNM16133 ns0:inAuthorList ns150:MNM16133 .

ns5:NHA1615 ns0:inAuthorList ns150:NHA1615 .

ns5:NHA170023 ns0:inAuthorList ns150:NHA170023 .

ns5:NHA170028 ns0:inAuthorList ns150:NHA170028 .

ns5:NHA170035 ns0:inAuthorList ns150:NHA170035 .

ns5:NHA170038 ns0:inAuthorList ns150:NHA170038 .

ns5:NPM1610 ns0:inAuthorList ns150:NPM1610 .

ns5:NPM1637 ns0:inAuthorList ns150:NPM1637 .

ns5:NPM1786 ns0:inAuthorList ns150:NPM1786 .

ns5:NRE1421 ns0:inAuthorList ns150:NRE1421 .

ns5:NRE172274 ns0:inAuthorList ns150:NRE172274 .

ns5:NRE172353 ns0:inAuthorList ns150:NRE172353 .

ns5:NRE182446 ns0:inAuthorList ns150:NRE182446 .

ns5:NRE182525 ns0:inAuthorList ns150:NRE182525 .

ns5:RNN150563 ns0:inAuthorList ns150:RNN150563 .

ns5:RNN150623 ns0:inAuthorList ns150:RNN150623 .

ns5:RNN170725 ns0:inAuthorList ns150:RNN170725 .

ns5:RNN170738 ns0:inAuthorList ns150:RNN170738 .

ns5:RNN170790 ns0:inAuthorList ns150:RNN170790 .

ns5:RNN180850 ns0:inAuthorList ns150:RNN180850 .

ns5:RNN180882 ns0:inAuthorList ns150:RNN180882 .

ns5:RNN190916 owl:sameAs ns8:RNN150623,
        ns5:RNN170773 ;
    ns0:fullName "M.R. Borich" ;
    ns0:hasAffiliation ns123:RNN190916 ;
    ns0:hasArticle ns1:rnn-v37-i3-RNN190916 ;
    ns0:inAuthorList ns150:RNN190916 .

ns5:SW156 ns0:inAuthorList ns150:SW156 .

ns5:THC1315 ns0:inAuthorList ns150:THC1315 .

ns5:THC170967 ns0:inAuthorList ns150:THC170967 .

ns5:THC199029 ns0:inAuthorList ns150:THC199029 .

ns5:VES622 ns0:inAuthorList ns150:VES622 .

ns5:WOR182840 ns0:inAuthorList ns150:WOR182840 .

ns5:WOR2201 ns0:inAuthorList ns150:WOR2201 .

ns5:XST17264 ns0:inAuthorList ns150:XST17264 .

ns5:XST17271 ns0:inAuthorList ns150:XST17271 .

ns5:XST180427 ns0:inAuthorList ns150:XST180427 .

ns5:XST180460 owl:sameAs ns60:XST18369 ;
    ns0:fullName "Youmin Guo" ;
    ns0:hasAffiliation ns6:XST180460 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180460 ;
    ns0:inAuthorList ns150:XST180460 .

ns5:XST180476 ns0:inAuthorList ns150:XST180476 .

ns5:XST190527 ns0:inAuthorList ns150:XST190527 .

ns5:XST598 ns0:inAuthorList ns150:XST598 .

ns5:cbm00245 ns0:inAuthorList ns150:cbm00245 .

ns5:cbm00364 ns0:inAuthorList ns150:cbm00364 .

ns5:ica00441 ns0:inAuthorList ns150:ica00441 .

ns5:idt00105 ns0:inAuthorList ns150:idt00105 .

ns5:jad00079 ns0:inAuthorList ns150:jad00079 .

ns5:jad00209 ns0:inAuthorList ns150:jad00209 .

ns5:jad00463 ns0:inAuthorList ns150:jad00463 .

ns5:jad00595 ns0:inAuthorList ns150:jad00595 .

ns5:jad00770 ns0:inAuthorList ns150:jad00770 .

ns5:jad00914 ns0:inAuthorList ns150:jad00914 .

ns5:jad00918 ns0:inAuthorList ns150:jad00918 .

ns5:jad00999 ns0:inAuthorList ns150:jad00999 .

ns5:jad01051 ns0:inAuthorList ns150:jad01051 .

ns5:jad01091 ns0:inAuthorList ns150:jad01091 .

ns5:jad01265 ns0:inAuthorList ns150:jad01265 .

ns5:jad01310 ns0:inAuthorList ns150:jad01310 .

ns5:jad01360 ns0:inAuthorList ns150:jad01360 .

ns5:jad01367 ns0:inAuthorList ns150:jad01367 .

ns5:jad091198 ns0:inAuthorList ns150:jad091198 .

ns5:jad091594 ns0:inAuthorList ns150:jad091594 .

ns5:jad100069 ns0:inAuthorList ns150:jad100069 .

ns5:jad100075 ns0:inAuthorList ns150:jad100075 .

ns5:jad100129 ns0:inAuthorList ns150:jad100129 .

ns5:jad100417 ns0:inAuthorList ns150:jad100417 .

ns5:jad100432 ns0:inAuthorList ns150:jad100432 .

ns5:jad100609 ns0:inAuthorList ns150:jad100609 .

ns5:jad100729 ns0:inAuthorList ns150:jad100729 .

ns5:jad100795 ns0:inAuthorList ns150:jad100795 .

ns5:jad101008 ns0:inAuthorList ns150:jad101008 .

ns5:jad101023 ns0:inAuthorList ns150:jad101023 .

ns5:thc00362 ns0:inAuthorList ns150:thc00362 .

ns5:thc00503 ns0:inAuthorList ns150:thc00503 .

<http://ld.iospress.nl/rdf/contributor/Author:40.ID:BLC189037> ns0:inAuthorList ns150:BLC189037 .

<http://ld.iospress.nl/rdf/contributor/Author:48.ID:JAD160668> ns0:inAuthorList ns150:JAD160668 .

ns16:ADR170035 ns0:inAuthorList ns150:ADR170035 .

ns16:AIS385 ns0:inAuthorList ns150:AIS385 .

ns16:AO179 ns0:inAuthorList ns150:AO179 .

ns16:BIR180175 ns0:inAuthorList ns150:BIR180175 .

ns16:BLC170152 ns0:inAuthorList ns150:BLC170152 .

ns16:BLC170159 ns0:inAuthorList ns150:BLC170159 .

ns16:BME1571 ns0:inAuthorList ns150:BME1571 .

ns16:BME1651 ns0:inAuthorList ns150:BME1651 .

ns16:BME1709 ns0:inAuthorList ns150:BME1709 .

ns16:BMR160756 ns0:inAuthorList ns150:BMR160756 .

ns16:BMR181215 ns0:inAuthorList ns150:BMR181215 .

ns16:BSI155 ns0:inAuthorList ns150:BSI155 .

ns16:CBM170230 ns0:inAuthorList ns150:CBM170230 .

ns16:CBM170278 ns0:inAuthorList ns150:CBM170278 .

ns16:CBM170472 ns0:inAuthorList ns150:CBM170472 .

ns16:CBM181526 ns0:inAuthorList ns150:CBM181526 .

ns16:CBM181836 ns0:inAuthorList ns150:CBM181836 .

ns16:CH160230 ns0:inAuthorList ns150:CH160230 .

ns16:CH16242 ns0:inAuthorList ns150:CH16242 .

ns16:CH168029 ns0:inAuthorList ns150:CH168029 .

ns16:CH168101 ns0:inAuthorList ns150:CH168101 .

ns16:CH170266 ns0:inAuthorList ns150:CH170266 .

ns16:CH170316 ns0:inAuthorList ns150:CH170316 .

ns16:CH170331 ns0:inAuthorList ns150:CH170331 .

ns16:CH170364 ns0:inAuthorList ns150:CH170364 .

ns16:CH179112 ns0:inAuthorList ns150:CH179112 .

ns16:CH179201 ns0:inAuthorList ns150:CH179201 .

ns16:CH179210 ns0:inAuthorList ns150:CH179210 .

ns16:CH179216 ns0:inAuthorList ns150:CH179216 .

ns16:CH179217 ns0:inAuthorList ns150:CH179217 .

ns16:CH179218 ns0:inAuthorList ns150:CH179218 .

ns16:CH179220 ns0:inAuthorList ns150:CH179220 .

ns16:CH179225 ns0:inAuthorList ns150:CH179225 .

ns16:CH180457 ns0:inAuthorList ns150:CH180457 .

ns16:CH180544 owl:sameAs ns12:CH170245 ;
    ns0:fullName "Raymund E. Horch" ;
    ns0:hasAffiliation ns21:CH180544 ;
    ns0:hasArticle ns1:ch-v72-i4-CH180544 ;
    ns0:inAuthorList ns150:CH180544 .

ns16:CH189107 ns0:inAuthorList ns150:CH189107 .

ns16:CH189131 ns0:inAuthorList ns150:CH189131 .

ns16:CH189313 ns0:inAuthorList ns150:CH189313 .

ns16:CH189410 ns0:inAuthorList ns150:CH189410 .

ns16:CH189415 ns0:inAuthorList ns150:CH189415 .

ns16:CH1958 ns0:inAuthorList ns150:CH1958 .

ns16:CH1982 ns0:inAuthorList ns150:CH1982 .

ns16:CH199201 owl:sameAs ns57:CH199206 ;
    ns0:fullName "Nan Ma" ;
    ns0:hasAffiliation ns21:CH199201,
        ns193:CH199201 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199201 ;
    ns0:inAuthorList ns150:CH199201 .

ns16:CH199202 owl:sameAs ns8:CH189123,
        ns5:CH168116,
        ns5:CH179102,
        ns5:CH189308,
        ns5:CH189404,
        ns5:CH189406,
        ns5:CH199222,
        ns16:CH179221,
        ns16:CH189114,
        ns16:CH189115,
        ns16:CH189116,
        ns16:CH189310,
        ns16:CH189405,
        ns16:CH189407,
        ns16:CH199204,
        ns16:CH2009,
        ns16:CH2010,
        ns52:CH168115,
        ns57:CH168034,
        ns57:CH179104,
        ns57:CH2046 ;
    ns0:fullName "D.A. Clevert" ;
    ns0:hasAffiliation ns21:CH199202 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199202 ;
    ns0:inAuthorList ns150:CH199202 .

ns16:CH199204 owl:sameAs ns5:CH179102,
        ns5:CH189404,
        ns16:CH179221,
        ns16:CH189114,
        ns16:CH189115,
        ns16:CH189116,
        ns16:CH189310,
        ns16:CH189405,
        ns16:CH2009,
        ns16:CH2010,
        ns52:CH168115,
        ns57:CH168034,
        ns57:CH179104,
        ns57:CH2046 ;
    ns0:fullName "D.-A. Clevert" ;
    ns0:hasAffiliation ns21:CH199204 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199204 ;
    ns0:inAuthorList ns150:CH199204 .

ns16:CH199210 owl:sameAs ns8:CH189321,
        ns12:JCB189013 ;
    ns0:fullName "J.-H. Küpper" ;
    ns0:hasAffiliation ns21:CH199210 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199210 ;
    ns0:inAuthorList ns150:CH199210 .

ns16:CH199212 owl:sameAs ns2:CH2005,
        ns8:CH16195,
        ns8:CH168124,
        ns8:CH179201,
        ns8:CH189129,
        ns8:CH189415,
        ns8:CH1963,
        ns8:CH1964,
        ns26:CH179226,
        ns28:CH1920,
        ns12:CH189411,
        ns30:CH170365,
        ns30:CH179202,
        ns30:CH179212,
        ns30:CH179216,
        ns30:CH199004,
        ns30:CH199213,
        ns30:CH199218,
        ns5:CH179106,
        ns16:CH16194,
        ns16:CH168100,
        ns16:CH179227,
        ns16:CH189319,
        ns16:CH199220,
        ns52:CH170265,
        ns57:CH168110,
        ns57:CH168120,
        ns57:CH170246,
        ns60:CH189107,
        ns60:CH189905,
        ns60:CH199009,
        ns33:CH189309,
        ns33:CH189315 ;
    ns0:fullName "Lukas Prantl" ;
    ns0:hasAffiliation ns193:CH199212 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199212 ;
    ns0:inAuthorList ns150:CH199212 .

ns16:FI1507 ns0:inAuthorList ns150:FI1507 .

ns16:HAB180352 ns0:inAuthorList ns150:HAB180352 .

ns16:HAB190364 ns0:inAuthorList ns150:HAB190364 .

ns16:HAB328 ns0:inAuthorList ns150:HAB328 .

ns16:HSM17166 ns0:inAuthorList ns150:HSM17166 .

ns16:IA110 ns0:inAuthorList ns150:IA110 .

ns16:IES182177 ns0:inAuthorList ns150:IES182177 .

ns16:IFS171567 ns0:inAuthorList ns150:IFS171567 .

ns16:IFS172130 ns0:inAuthorList ns150:IFS172130 .

ns16:IFS179116 ns0:inAuthorList ns150:IFS179116 .

ns16:IFS181329 ns0:inAuthorList ns150:IFS181329 .

ns16:IFS18347 ns0:inAuthorList ns150:IFS18347 .

ns16:JAD0010 ns0:inAuthorList ns150:JAD0010 .

ns16:JAD101878 ns0:inAuthorList ns150:JAD101878 .

ns16:JAD101995 ns0:inAuthorList ns150:JAD101995 .

ns16:JAD102100 ns0:inAuthorList ns150:JAD102100 .

ns16:JAD102124 ns0:inAuthorList ns150:JAD102124 .

ns16:JAD110029 ns0:inAuthorList ns150:JAD110029 .

ns16:JAD110200 ns0:inAuthorList ns150:JAD110200 .

ns16:JAD110365 ns0:inAuthorList ns150:JAD110365 .

ns16:JAD110566 ns0:inAuthorList ns150:JAD110566 .

ns16:JAD110629 ns0:inAuthorList ns150:JAD110629 .

ns16:JAD110662 ns0:inAuthorList ns150:JAD110662 .

ns16:JAD110788 ns0:inAuthorList ns150:JAD110788 .

ns16:JAD111268 ns0:inAuthorList ns150:JAD111268 .

ns16:JAD111472 ns0:inAuthorList ns150:JAD111472 .

ns16:JAD111490 ns0:inAuthorList ns150:JAD111490 .

ns16:JAD111766 ns0:inAuthorList ns150:JAD111766 .

ns16:JAD120358 ns0:inAuthorList ns150:JAD120358 .

ns16:JAD120481 ns0:inAuthorList ns150:JAD120481 .

ns16:JAD120994 ns0:inAuthorList ns150:JAD120994 .

ns16:JAD121045 ns0:inAuthorList ns150:JAD121045 .

ns16:JAD121144 ns0:inAuthorList ns150:JAD121144 .

ns16:JAD121246 ns0:inAuthorList ns150:JAD121246 .

ns16:JAD121408 ns0:inAuthorList ns150:JAD121408 .

ns16:JAD121606 ns0:inAuthorList ns150:JAD121606 .

ns16:JAD122302 ns0:inAuthorList ns150:JAD122302 .

ns16:JAD129007 ns0:inAuthorList ns150:JAD129007 .

ns16:JAD129041 ns0:inAuthorList ns150:JAD129041 .

ns16:JAD130080 ns0:inAuthorList ns150:JAD130080 .

ns16:JAD130107 ns0:inAuthorList ns150:JAD130107 .

ns16:JAD130143 ns0:inAuthorList ns150:JAD130143 .

ns16:JAD130527 ns0:inAuthorList ns150:JAD130527 .

ns16:JAD130575 ns0:inAuthorList ns150:JAD130575 .

ns16:JAD130596 ns0:inAuthorList ns150:JAD130596 .

ns16:JAD130698 ns0:inAuthorList ns150:JAD130698 .

ns16:JAD131604 ns0:inAuthorList ns150:JAD131604 .

ns16:JAD131766 ns0:inAuthorList ns150:JAD131766 .

ns16:JAD131844 ns0:inAuthorList ns150:JAD131844 .

ns16:JAD132195 ns0:inAuthorList ns150:JAD132195 .

ns16:JAD132219 ns0:inAuthorList ns150:JAD132219 .

ns16:JAD132333 ns0:inAuthorList ns150:JAD132333 .

ns16:JAD132429 ns0:inAuthorList ns150:JAD132429 .

ns16:JAD132528 ns0:inAuthorList ns150:JAD132528 .

ns16:JAD132558 ns0:inAuthorList ns150:JAD132558 .

ns16:JAD132786 ns0:inAuthorList ns150:JAD132786 .

ns16:JAD140588 ns0:inAuthorList ns150:JAD140588 .

ns16:JAD140759 ns0:inAuthorList ns150:JAD140759 .

ns16:JAD140846 ns0:inAuthorList ns150:JAD140846 .

ns16:JAD141053 ns0:inAuthorList ns150:JAD141053 .

ns16:JAD141137 ns0:inAuthorList ns150:JAD141137 .

ns16:JAD141287 ns0:inAuthorList ns150:JAD141287 .

ns16:JAD141518 ns0:inAuthorList ns150:JAD141518 .

ns16:JAD141722 ns0:inAuthorList ns150:JAD141722 .

ns16:JAD141743 ns0:inAuthorList ns150:JAD141743 .

ns16:JAD141824 ns0:inAuthorList ns150:JAD141824 .

ns16:JAD141869 ns0:inAuthorList ns150:JAD141869 .

ns16:JAD142085 ns0:inAuthorList ns150:JAD142085 .

ns16:JAD142088 ns0:inAuthorList ns150:JAD142088 .

ns16:JAD142103 ns0:inAuthorList ns150:JAD142103 .

ns16:JAD142214 ns0:inAuthorList ns150:JAD142214 .

ns16:JAD142595 ns0:inAuthorList ns150:JAD142595 .

ns16:JAD142895 ns0:inAuthorList ns150:JAD142895 .

ns16:JAD148009 ns0:inAuthorList ns150:JAD148009 .

ns16:JAD150436 ns0:inAuthorList ns150:JAD150436 .

ns16:JAD150440 ns0:inAuthorList ns150:JAD150440 .

ns16:JAD150622 ns0:inAuthorList ns150:JAD150622 .

ns16:JAD150630 ns0:inAuthorList ns150:JAD150630 .

ns16:JAD150686 ns0:inAuthorList ns150:JAD150686 .

ns16:JAD150727 ns0:inAuthorList ns150:JAD150727 .

ns16:JAD150785 ns0:inAuthorList ns150:JAD150785 .

ns16:JAD150863 ns0:inAuthorList ns150:JAD150863 .

ns16:JAD150883 ns0:inAuthorList ns150:JAD150883 .

ns16:JAD150985 ns0:inAuthorList ns150:JAD150985 .

ns16:JAD151000 ns0:inAuthorList ns150:JAD151000 .

ns16:JAD151015 ns0:inAuthorList ns150:JAD151015 .

ns16:JAD151016 ns0:inAuthorList ns150:JAD151016 .

ns16:JAD151068 ns0:inAuthorList ns150:JAD151068 .

ns16:JAD151120 ns0:inAuthorList ns150:JAD151120 .

ns16:JAD151130 ns0:inAuthorList ns150:JAD151130 .

ns16:JAD160067 ns0:inAuthorList ns150:JAD160067 .

ns16:JAD160073 ns0:inAuthorList ns150:JAD160073 .

ns16:JAD160116 ns0:inAuthorList ns150:JAD160116 .

ns16:JAD160195 ns0:inAuthorList ns150:JAD160195 .

ns16:JAD160244 ns0:inAuthorList ns150:JAD160244 .

ns16:JAD160273 ns0:inAuthorList ns150:JAD160273 .

ns16:JAD160560 ns0:inAuthorList ns150:JAD160560 .

ns16:JAD160562 ns0:inAuthorList ns150:JAD160562 .

ns16:JAD160593 ns0:inAuthorList ns150:JAD160593 .

ns16:JAD160637 ns0:inAuthorList ns150:JAD160637 .

ns16:JAD160641 ns0:inAuthorList ns150:JAD160641 .

ns16:JAD160671 ns0:inAuthorList ns150:JAD160671 .

ns16:JAD160730 ns0:inAuthorList ns150:JAD160730 .

ns16:JAD160758 ns0:inAuthorList ns150:JAD160758 .

ns16:JAD160803 ns0:inAuthorList ns150:JAD160803 .

ns16:JAD160833 ns0:inAuthorList ns150:JAD160833 .

ns16:JAD160923 ns0:inAuthorList ns150:JAD160923 .

ns16:JAD160970 ns0:inAuthorList ns150:JAD160970 .

ns16:JAD160983 ns0:inAuthorList ns150:JAD160983 .

ns16:JAD161012 ns0:inAuthorList ns150:JAD161012 .

ns16:JAD161080 ns0:inAuthorList ns150:JAD161080 .

ns16:JAD161153 ns0:inAuthorList ns150:JAD161153 .

ns16:JAD161162 ns0:inAuthorList ns150:JAD161162 .

ns16:JAD161188 ns0:inAuthorList ns150:JAD161188 .

ns16:JAD161197 ns0:inAuthorList ns150:JAD161197 .

ns16:JAD161200 ns0:inAuthorList ns150:JAD161200 .

ns16:JAD161227 ns0:inAuthorList ns150:JAD161227 .

ns16:JAD161248 ns0:inAuthorList ns150:JAD161248 .

ns16:JAD170017 ns0:inAuthorList ns150:JAD170017 .

ns16:JAD170039 ns0:inAuthorList ns150:JAD170039 .

ns16:JAD170041 ns0:inAuthorList ns150:JAD170041 .

ns16:JAD170086 ns0:inAuthorList ns150:JAD170086 .

ns16:JAD170092 ns0:inAuthorList ns150:JAD170092 .

ns16:JAD170101 ns0:inAuthorList ns150:JAD170101 .

ns16:JAD170226 ns0:inAuthorList ns150:JAD170226 .

ns16:JAD170239 ns0:inAuthorList ns150:JAD170239 .

ns16:JAD170278 ns0:inAuthorList ns150:JAD170278 .

ns16:JAD170317 ns0:inAuthorList ns150:JAD170317 .

ns16:JAD170347 ns0:inAuthorList ns150:JAD170347 .

ns16:JAD170367 ns0:inAuthorList ns150:JAD170367 .

ns16:JAD170448 ns0:inAuthorList ns150:JAD170448 .

ns16:JAD170494 ns0:inAuthorList ns150:JAD170494 .

ns16:JAD170496 ns0:inAuthorList ns150:JAD170496 .

ns16:JAD170498 ns0:inAuthorList ns150:JAD170498 .

ns16:JAD170522 ns0:inAuthorList ns150:JAD170522 .

ns16:JAD170531 ns0:inAuthorList ns150:JAD170531 .

ns16:JAD170561 ns0:inAuthorList ns150:JAD170561 .

ns16:JAD170583 ns0:inAuthorList ns150:JAD170583 .

ns16:JAD170601 ns0:inAuthorList ns150:JAD170601 .

ns16:JAD170697 ns0:inAuthorList ns150:JAD170697 .

ns16:JAD170712 ns0:inAuthorList ns150:JAD170712 .

ns16:JAD170721 ns0:inAuthorList ns150:JAD170721 .

ns16:JAD170753 ns0:inAuthorList ns150:JAD170753 .

ns16:JAD170796 ns0:inAuthorList ns150:JAD170796 .

ns16:JAD170815 ns0:inAuthorList ns150:JAD170815 .

ns16:JAD170854 ns0:inAuthorList ns150:JAD170854 .

ns16:JAD170861 ns0:inAuthorList ns150:JAD170861 .

ns16:JAD170865 ns0:inAuthorList ns150:JAD170865 .

ns16:JAD170948 ns0:inAuthorList ns150:JAD170948 .

ns16:JAD170964 ns0:inAuthorList ns150:JAD170964 .

ns16:JAD170966 ns0:inAuthorList ns150:JAD170966 .

ns16:JAD170972 ns0:inAuthorList ns150:JAD170972 .

ns16:JAD171034 ns0:inAuthorList ns150:JAD171034 .

ns16:JAD171083 ns0:inAuthorList ns150:JAD171083 .

ns16:JAD171088 ns0:inAuthorList ns150:JAD171088 .

ns16:JAD171094 ns0:inAuthorList ns150:JAD171094 .

ns16:JAD171140 ns0:inAuthorList ns150:JAD171140 .

ns16:JAD171162 ns0:inAuthorList ns150:JAD171162 .

ns16:JAD179939 ns0:inAuthorList ns150:JAD179939 .

ns16:JAD180030 ns0:inAuthorList ns150:JAD180030 .

ns16:JAD180070 ns0:inAuthorList ns150:JAD180070 .

ns16:JAD180106 ns0:inAuthorList ns150:JAD180106 .

ns16:JAD180125 ns0:inAuthorList ns150:JAD180125 .

ns16:JAD180223 ns0:inAuthorList ns150:JAD180223 .

ns16:JAD180280 ns0:inAuthorList ns150:JAD180280 .

ns16:JAD180351 ns0:inAuthorList ns150:JAD180351 .

ns16:JAD180446 ns0:inAuthorList ns150:JAD180446 .

ns16:JAD180455 ns0:inAuthorList ns150:JAD180455 .

ns16:JAD180503 ns0:inAuthorList ns150:JAD180503 .

ns16:JAD180554 ns0:inAuthorList ns150:JAD180554 .

ns16:JAD180586 ns0:inAuthorList ns150:JAD180586 .

ns16:JAD180592 ns0:inAuthorList ns150:JAD180592 .

ns16:JAD180604 ns0:inAuthorList ns150:JAD180604 .

ns16:JAD180609 ns0:inAuthorList ns150:JAD180609 .

ns16:JAD180644 ns0:inAuthorList ns150:JAD180644 .

ns16:JAD180645 ns0:inAuthorList ns150:JAD180645 .

ns16:JAD180690 ns0:inAuthorList ns150:JAD180690 .

ns16:JAD180723 ns0:inAuthorList ns150:JAD180723 .

ns16:JAD180737 ns0:inAuthorList ns150:JAD180737 .

ns16:JAD180897 ns0:inAuthorList ns150:JAD180897 .

ns16:JAD180971 ns0:inAuthorList ns150:JAD180971 .

ns16:JAD181004 ns0:inAuthorList ns150:JAD181004 .

ns16:JAD181037 owl:sameAs ns8:JAD181189 ;
    ns0:fullName "Rolf Adolfsson" ;
    ns0:hasAffiliation ns192:JAD181037 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD181037 ;
    ns0:inAuthorList ns150:JAD181037 .

ns16:JAD181038 ns0:inAuthorList ns150:JAD181038 .

ns16:JAD181108 ns0:inAuthorList ns150:JAD181108 .

ns16:JAD181169 ns0:inAuthorList ns150:JAD181169 .

ns16:JAD181176 ns0:inAuthorList ns150:JAD181176 .

ns16:JAD181282 owl:sameAs ns8:JAD181009 ;
    ns0:fullName "Michael W. Weiner" ;
    ns0:hasAffiliation ns75:JAD181282 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181282 ;
    ns0:inAuthorList ns150:JAD181282 .

ns16:JAD190011 owl:sameAs ns8:JAD101995,
        ns12:jad01227 ;
    ns0:fullName "Lisa L. Barnes" ;
    ns0:hasAffiliation ns75:JAD190011 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190011 ;
    ns0:inAuthorList ns150:JAD190011 .

ns16:JAD190183 owl:sameAs <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD161023>,
        ns33:JAD170990 ;
    ns0:fullName "Bernard Laurent" ;
    ns0:hasAffiliation ns21:JAD190183 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190183 ;
    ns0:inAuthorList ns150:JAD190183 .

ns16:JAD190322 owl:sameAs ns2:JAD180619 ;
    ns0:fullName "Sid E. O’Bryant" ;
    ns0:hasAffiliation ns192:JAD190322 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190322 ;
    ns0:inAuthorList ns150:JAD190322 .

ns16:JAD190334 owl:sameAs ns8:JAD111109,
        ns8:JAD140777,
        ns8:jad100597,
        ns12:JAD00041,
        ns12:JAD130104,
        ns30:JAD101911,
        ns30:JAD120946,
        ns5:JAD170534,
        ns52:JAD170854,
        ns57:JAD190132,
        ns60:JAD161142 ;
    ns0:fullName "Seppo Helisalmi" ;
    ns0:hasAffiliation ns21:JAD190334 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns16:JAD190459 ns0:inAuthorList ns150:JAD190459 .

ns16:JAD190562 owl:sameAs ns52:JAD180971 ;
    ns0:fullName "Jin-Tai Yu" ;
    ns0:hasAffiliation ns75:JAD190562 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190562 ;
    ns0:inAuthorList ns150:JAD190562 .

ns16:JAD190660 ns0:inAuthorList ns150:JAD190660 .

ns16:JAD190700 ns0:inAuthorList ns150:JAD190700 .

ns16:JAD190823 owl:sameAs ns2:JAD120505,
        ns5:JAD140930,
        ns16:JAD131934,
        ns16:JAD150791 ;
    ns0:fullName "Andrea Tales" ;
    ns0:hasAffiliation ns21:JAD190823,
        ns193:JAD190823 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190823 ;
    ns0:inAuthorList ns150:JAD190823 .

ns16:JAE180064 ns0:inAuthorList ns150:JAE180064 .

ns16:JAE189064 ns0:inAuthorList ns150:JAE189064 .

ns16:JCB15034 ns0:inAuthorList ns150:JCB15034 .

ns16:JCB189014 ns0:inAuthorList ns150:JCB189014 .

ns16:JHD150175 ns0:inAuthorList ns150:JHD150175 .

ns16:JHD170250 ns0:inAuthorList ns150:JHD170250 .

ns16:JHD180285 ns0:inAuthorList ns150:JHD180285 .

ns16:JHD180309 ns0:inAuthorList ns150:JHD180309 .

ns16:JND170292 ns0:inAuthorList ns150:JND170292 .

ns16:JND180331 ns0:inAuthorList ns150:JND180331 .

ns16:JPD140498 ns0:inAuthorList ns150:JPD140498 .

ns16:JPD150670 ns0:inAuthorList ns150:JPD150670 .

ns16:JPD160848 ns0:inAuthorList ns150:JPD160848 .

ns16:JPD160888 ns0:inAuthorList ns150:JPD160888 .

ns16:JPD171172 ns0:inAuthorList ns150:JPD171172 .

ns16:JPD181365 ns0:inAuthorList ns150:JPD181365 .

ns16:JPD181383 ns0:inAuthorList ns150:JPD181383 .

ns16:JVR191055 ns0:inAuthorList ns150:JVR191055 .

ns16:JVR812 ns0:inAuthorList ns150:JVR812 .

ns16:JVR889 ns0:inAuthorList ns150:JVR889 .

ns16:JVR922 ns0:inAuthorList ns150:JVR922 .

ns16:KCA180047 ns0:inAuthorList ns150:KCA180047 .

ns16:MGC256 ns0:inAuthorList ns150:MGC256 .

ns16:MNM180242 ns0:inAuthorList ns150:MNM180242 .

ns16:MNM180278 owl:sameAs ns30:MNM180242 ;
    ns0:fullName "Mostafa Qorbani" ;
    ns0:hasAffiliation ns75:MNM180278,
        ns194:MNM180278 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180278 ;
    ns0:inAuthorList ns150:MNM180278 .

ns16:NHA1615 ns0:inAuthorList ns150:NHA1615 .

ns16:NHA170023 ns0:inAuthorList ns150:NHA170023 .

ns16:NPM1741 ns0:inAuthorList ns150:NPM1741 .

ns16:NPM915112 ns0:inAuthorList ns150:NPM915112 .

ns16:NRE172274 ns0:inAuthorList ns150:NRE172274 .

ns16:NRE192700 ns0:inAuthorList ns150:NRE192700 .

ns16:PRM348 ns0:inAuthorList ns150:PRM348 .

ns16:RNN160703 ns0:inAuthorList ns150:RNN160703 .

ns16:RNN170725 ns0:inAuthorList ns150:RNN170725 .

ns16:RNN170745 ns0:inAuthorList ns150:RNN170745 .

ns16:THC1286 ns0:inAuthorList ns150:THC1286 .

ns16:THC171055 ns0:inAuthorList ns150:THC171055 .

ns16:WOR192971 ns0:inAuthorList ns150:WOR192971 .

ns16:WOR2733 ns0:inAuthorList ns150:WOR2733 .

ns16:XST16216 ns0:inAuthorList ns150:XST16216 .

ns16:XST180427 ns0:inAuthorList ns150:XST180427 .

ns16:XST180429 ns0:inAuthorList ns150:XST180429 .

ns16:XST18369 ns0:inAuthorList ns150:XST18369 .

ns16:XST190506 ns0:inAuthorList ns150:XST190506 .

ns16:XST190527 owl:sameAs ns60:XST190506 ;
    ns0:fullName "Yongfeng Yang" ;
    ns0:hasAffiliation ns21:XST190527 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190527 ;
    ns0:inAuthorList ns150:XST190527 .

ns16:XST190533 ns0:inAuthorList ns150:XST190533 .

ns16:jad00418 ns0:inAuthorList ns150:jad00418 .

ns16:jad00435 ns0:inAuthorList ns150:jad00435 .

ns16:jad00584 ns0:inAuthorList ns150:jad00584 .

ns16:jad00870 ns0:inAuthorList ns150:jad00870 .

ns16:jad00896 ns0:inAuthorList ns150:jad00896 .

ns16:jad01033 ns0:inAuthorList ns150:jad01033 .

ns16:jad01165 ns0:inAuthorList ns150:jad01165 .

ns16:jad01223 ns0:inAuthorList ns150:jad01223 .

ns16:jad01300 ns0:inAuthorList ns150:jad01300 .

ns16:jad01337 ns0:inAuthorList ns150:jad01337 .

ns16:jad01352 ns0:inAuthorList ns150:jad01352 .

ns16:jad100048 ns0:inAuthorList ns150:jad100048 .

ns16:jad100261 ns0:inAuthorList ns150:jad100261 .

ns16:jad100285 ns0:inAuthorList ns150:jad100285 .

ns16:jad100663 ns0:inAuthorList ns150:jad100663 .

ns16:jad100729 ns0:inAuthorList ns150:jad100729 .

ns16:jad100780 ns0:inAuthorList ns150:jad100780 .

ns16:jad100933 ns0:inAuthorList ns150:jad100933 .

ns16:mgs00024 ns0:inAuthorList ns150:mgs00024 .

<http://ld.iospress.nl/rdf/contributor/Author:52.ID:JAD110824> ns0:inAuthorList ns150:JAD110824 .

ns52:BIR180175 ns0:inAuthorList ns150:BIR180175 .

ns52:BME1403 ns0:inAuthorList ns150:BME1403 .

ns52:BMR171067 ns0:inAuthorList ns150:BMR171067 .

ns52:BSI155 ns0:inAuthorList ns150:BSI155 .

ns52:CBM170572 ns0:inAuthorList ns150:CBM170572 .

ns52:CBM181526 ns0:inAuthorList ns150:CBM181526 .

ns52:CBM660 ns0:inAuthorList ns150:CBM660 .

ns52:CH168040 ns0:inAuthorList ns150:CH168040 .

ns52:CH168121 ns0:inAuthorList ns150:CH168121 .

ns52:CH170252 ns0:inAuthorList ns150:CH170252 .

ns52:CH170266 ns0:inAuthorList ns150:CH170266 .

ns52:CH179208 ns0:inAuthorList ns150:CH179208 .

ns52:CH179216 ns0:inAuthorList ns150:CH179216 .

ns52:CH179220 ns0:inAuthorList ns150:CH179220 .

ns52:CH180428 owl:sameAs ns2:CH179235 ;
    ns0:fullName "Vladimir Cerny" ;
    ns0:hasAffiliation ns200:CH180428,
        ns55:CH180428,
        ns199:CH180428,
        ns102:CH180428 ;
    ns0:hasArticle ns1:ch-v72-i1-CH180428 ;
    ns0:inAuthorList ns150:CH180428 .

ns52:CH180449 ns0:inAuthorList ns150:CH180449 .

ns52:CH180545 ns0:inAuthorList ns150:CH180545 .

ns52:CH189108 ns0:inAuthorList ns150:CH189108 .

ns52:CH189126 ns0:inAuthorList ns150:CH189126 .

ns52:CH189129 ns0:inAuthorList ns150:CH189129 .

ns52:CH189131 ns0:inAuthorList ns150:CH189131 .

ns52:CH189318 ns0:inAuthorList ns150:CH189318 .

ns52:CH189906 ns0:inAuthorList ns150:CH189906 .

ns52:CH1915 ns0:inAuthorList ns150:CH1915 .

ns52:CH199201 owl:sameAs ns12:CH2028,
        ns30:CH168033,
        ns30:CH189125,
        ns30:CH189904,
        ns30:CH2004,
        ns16:CH168107,
        ns16:CH168114,
        ns16:CH189418,
        ns16:CH199006,
        ns16:CH199205,
        ns52:CH199005,
        ns57:CH189906,
        ns60:CH179210,
        ns33:CH2001 ;
    ns0:fullName "Andreas Lendlein" ;
    ns0:hasAffiliation ns200:CH199201,
        ns101:CH199201,
        ns55:CH199201 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199201 ;
    ns0:inAuthorList ns150:CH199201 .

ns52:CH199206 owl:sameAs ns8:CH2004,
        ns12:CH168114,
        ns30:CH168107 ;
    ns0:fullName "Karl Kratz" ;
    ns0:hasAffiliation ns200:CH199206 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199206 ;
    ns0:inAuthorList ns150:CH199206 .

ns52:IFS169328 ns0:inAuthorList ns150:IFS169328 .

ns52:JAD0058 ns0:inAuthorList ns150:JAD0058 .

ns52:JAD091153 ns0:inAuthorList ns150:JAD091153 .

ns52:JAD100525 ns0:inAuthorList ns150:JAD100525 .

ns52:JAD100987 ns0:inAuthorList ns150:JAD100987 .

ns52:JAD101263 ns0:inAuthorList ns150:JAD101263 .

ns52:JAD101551 ns0:inAuthorList ns150:JAD101551 .

ns52:JAD102145 ns0:inAuthorList ns150:JAD102145 .

ns52:JAD110116 ns0:inAuthorList ns150:JAD110116 .

ns52:JAD110329 ns0:inAuthorList ns150:JAD110329 .

ns52:JAD110341 ns0:inAuthorList ns150:JAD110341 .

ns52:JAD110428 ns0:inAuthorList ns150:JAD110428 .

ns52:JAD111070 ns0:inAuthorList ns150:JAD111070 .

ns52:JAD111076 ns0:inAuthorList ns150:JAD111076 .

ns52:JAD111109 ns0:inAuthorList ns150:JAD111109 .

ns52:JAD111208 ns0:inAuthorList ns150:JAD111208 .

ns52:JAD111223 ns0:inAuthorList ns150:JAD111223 .

ns52:JAD111628 ns0:inAuthorList ns150:JAD111628 .

ns52:JAD111697 ns0:inAuthorList ns150:JAD111697 .

ns52:JAD120064 ns0:inAuthorList ns150:JAD120064 .

ns52:JAD120508 ns0:inAuthorList ns150:JAD120508 .

ns52:JAD120973 ns0:inAuthorList ns150:JAD120973 .

ns52:JAD121270 ns0:inAuthorList ns150:JAD121270 .

ns52:JAD121420 ns0:inAuthorList ns150:JAD121420 .

ns52:JAD121822 ns0:inAuthorList ns150:JAD121822 .

ns52:JAD121861 ns0:inAuthorList ns150:JAD121861 .

ns52:JAD121864 ns0:inAuthorList ns150:JAD121864 .

ns52:JAD122302 ns0:inAuthorList ns150:JAD122302 .

ns52:JAD122431 ns0:inAuthorList ns150:JAD122431 .

ns52:JAD122458 ns0:inAuthorList ns150:JAD122458 .

ns52:JAD131334 ns0:inAuthorList ns150:JAD131334 .

ns52:JAD131496 ns0:inAuthorList ns150:JAD131496 .

ns52:JAD131766 ns0:inAuthorList ns150:JAD131766 .

ns52:JAD131796 ns0:inAuthorList ns150:JAD131796 .

ns52:JAD132087 ns0:inAuthorList ns150:JAD132087 .

ns52:JAD132363 ns0:inAuthorList ns150:JAD132363 .

ns52:JAD132489 ns0:inAuthorList ns150:JAD132489 .

ns52:JAD132642 ns0:inAuthorList ns150:JAD132642 .

ns52:JAD140183 ns0:inAuthorList ns150:JAD140183 .

ns52:JAD140312 ns0:inAuthorList ns150:JAD140312 .

ns52:JAD140336 ns0:inAuthorList ns150:JAD140336 .

ns52:JAD140651 ns0:inAuthorList ns150:JAD140651 .

ns52:JAD140669 ns0:inAuthorList ns150:JAD140669 .

ns52:JAD140756 ns0:inAuthorList ns150:JAD140756 .

ns52:JAD141554 ns0:inAuthorList ns150:JAD141554 .

ns52:JAD141986 ns0:inAuthorList ns150:JAD141986 .

ns52:JAD142109 ns0:inAuthorList ns150:JAD142109 .

ns52:JAD142844 ns0:inAuthorList ns150:JAD142844 .

ns52:JAD143084 ns0:inAuthorList ns150:JAD143084 .

ns52:JAD150181 ns0:inAuthorList ns150:JAD150181 .

ns52:JAD150280 ns0:inAuthorList ns150:JAD150280 .

ns52:JAD150378 ns0:inAuthorList ns150:JAD150378 .

ns52:JAD150394 ns0:inAuthorList ns150:JAD150394 .

ns52:JAD150428 ns0:inAuthorList ns150:JAD150428 .

ns52:JAD150438 ns0:inAuthorList ns150:JAD150438 .

ns52:JAD150471 ns0:inAuthorList ns150:JAD150471 .

ns52:JAD150478 ns0:inAuthorList ns150:JAD150478 .

ns52:JAD150497 ns0:inAuthorList ns150:JAD150497 .

ns52:JAD150523 ns0:inAuthorList ns150:JAD150523 .

ns52:JAD150537 ns0:inAuthorList ns150:JAD150537 .

ns52:JAD150543 ns0:inAuthorList ns150:JAD150543 .

ns52:JAD150548 ns0:inAuthorList ns150:JAD150548 .

ns52:JAD150612 ns0:inAuthorList ns150:JAD150612 .

ns52:JAD150619 ns0:inAuthorList ns150:JAD150619 .

ns52:JAD150652 ns0:inAuthorList ns150:JAD150652 .

ns52:JAD150735 ns0:inAuthorList ns150:JAD150735 .

ns52:JAD150804 ns0:inAuthorList ns150:JAD150804 .

ns52:JAD150897 ns0:inAuthorList ns150:JAD150897 .

ns52:JAD151084 ns0:inAuthorList ns150:JAD151084 .

ns52:JAD151101 ns0:inAuthorList ns150:JAD151101 .

ns52:JAD151114 ns0:inAuthorList ns150:JAD151114 .

ns52:JAD151116 ns0:inAuthorList ns150:JAD151116 .

ns52:JAD151158 ns0:inAuthorList ns150:JAD151158 .

ns52:JAD151198 ns0:inAuthorList ns150:JAD151198 .

ns52:JAD151200 ns0:inAuthorList ns150:JAD151200 .

ns52:JAD160073 ns0:inAuthorList ns150:JAD160073 .

ns52:JAD160110 ns0:inAuthorList ns150:JAD160110 .

ns52:JAD160191 ns0:inAuthorList ns150:JAD160191 .

ns52:JAD160254 ns0:inAuthorList ns150:JAD160254 .

ns52:JAD160271 ns0:inAuthorList ns150:JAD160271 .

ns52:JAD160300 ns0:inAuthorList ns150:JAD160300 .

ns52:JAD160320 ns0:inAuthorList ns150:JAD160320 .

ns52:JAD160326 ns0:inAuthorList ns150:JAD160326 .

ns52:JAD160357 ns0:inAuthorList ns150:JAD160357 .

ns52:JAD160625 ns0:inAuthorList ns150:JAD160625 .

ns52:JAD160667 ns0:inAuthorList ns150:JAD160667 .

ns52:JAD160773 ns0:inAuthorList ns150:JAD160773 .

ns52:JAD160778 ns0:inAuthorList ns150:JAD160778 .

ns52:JAD160892 ns0:inAuthorList ns150:JAD160892 .

ns52:JAD160904 ns0:inAuthorList ns150:JAD160904 .

ns52:JAD160977 ns0:inAuthorList ns150:JAD160977 .

ns52:JAD160979 ns0:inAuthorList ns150:JAD160979 .

ns52:JAD160983 ns0:inAuthorList ns150:JAD160983 .

ns52:JAD161006 ns0:inAuthorList ns150:JAD161006 .

ns52:JAD161078 ns0:inAuthorList ns150:JAD161078 .

ns52:JAD161109 ns0:inAuthorList ns150:JAD161109 .

ns52:JAD161142 ns0:inAuthorList ns150:JAD161142 .

ns52:JAD161152 ns0:inAuthorList ns150:JAD161152 .

ns52:JAD161166 ns0:inAuthorList ns150:JAD161166 .

ns52:JAD161193 ns0:inAuthorList ns150:JAD161193 .

ns52:JAD161248 ns0:inAuthorList ns150:JAD161248 .

ns52:JAD161295 ns0:inAuthorList ns150:JAD161295 .

ns52:JAD170092 ns0:inAuthorList ns150:JAD170092 .

ns52:JAD170102 ns0:inAuthorList ns150:JAD170102 .

ns52:JAD170229 ns0:inAuthorList ns150:JAD170229 .

ns52:JAD170250 ns0:inAuthorList ns150:JAD170250 .

ns52:JAD170267 ns0:inAuthorList ns150:JAD170267 .

ns52:JAD170287 ns0:inAuthorList ns150:JAD170287 .

ns52:JAD170402 ns0:inAuthorList ns150:JAD170402 .

ns52:JAD170444 ns0:inAuthorList ns150:JAD170444 .

ns52:JAD170530 ns0:inAuthorList ns150:JAD170530 .

ns52:JAD170555 ns0:inAuthorList ns150:JAD170555 .

ns52:JAD170556 ns0:inAuthorList ns150:JAD170556 .

ns52:JAD170638 ns0:inAuthorList ns150:JAD170638 .

ns52:JAD170861 ns0:inAuthorList ns150:JAD170861 .

ns52:JAD170894 ns0:inAuthorList ns150:JAD170894 .

ns52:JAD170985 ns0:inAuthorList ns150:JAD170985 .

ns52:JAD171111 ns0:inAuthorList ns150:JAD171111 .

ns52:JAD171166 ns0:inAuthorList ns150:JAD171166 .

ns52:JAD171182 ns0:inAuthorList ns150:JAD171182 .

ns52:JAD180082 ns0:inAuthorList ns150:JAD180082 .

ns52:JAD180125 ns0:inAuthorList ns150:JAD180125 .

ns52:JAD180280 ns0:inAuthorList ns150:JAD180280 .

ns52:JAD180291 ns0:inAuthorList ns150:JAD180291 .

ns52:JAD180316 ns0:inAuthorList ns150:JAD180316 .

ns52:JAD180425 ns0:inAuthorList ns150:JAD180425 .

ns52:JAD180432 ns0:inAuthorList ns150:JAD180432 .

ns52:JAD180531 ns0:inAuthorList ns150:JAD180531 .

ns52:JAD180594 ns0:inAuthorList ns150:JAD180594 .

ns52:JAD180645 ns0:inAuthorList ns150:JAD180645 .

ns52:JAD180693 ns0:inAuthorList ns150:JAD180693 .

ns52:JAD180701 ns0:inAuthorList ns150:JAD180701 .

ns52:JAD180711 ns0:inAuthorList ns150:JAD180711 .

ns52:JAD180723 ns0:inAuthorList ns150:JAD180723 .

ns52:JAD180746 ns0:inAuthorList ns150:JAD180746 .

ns52:JAD180755 ns0:inAuthorList ns150:JAD180755 .

ns52:JAD180882 ns0:inAuthorList ns150:JAD180882 .

ns52:JAD180912 ns0:inAuthorList ns150:JAD180912 .

ns52:JAD180919 ns0:inAuthorList ns150:JAD180919 .

ns52:JAD180985 ns0:inAuthorList ns150:JAD180985 .

ns52:JAD181099 ns0:inAuthorList ns150:JAD181099 .

ns52:JAD181115 ns0:inAuthorList ns150:JAD181115 .

ns52:JAD181145 ns0:inAuthorList ns150:JAD181145 .

ns52:JAD181170 owl:sameAs ns57:JAD161240 ;
    ns0:fullName "Jeffrey D. Holmes" ;
    ns0:hasAffiliation ns203:JAD181170 ;
    ns0:hasArticle ns1:jad-v71-is1-JAD181170 ;
    ns0:inAuthorList ns150:JAD181170 .

ns52:JAD181195 ns0:inAuthorList ns150:JAD181195 .

ns52:JAD181218 ns0:inAuthorList ns150:JAD181218 .

ns52:JAD181242 ns0:inAuthorList ns150:JAD181242 .

ns52:JAD181256 owl:sameAs ns26:JAD111109,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170362>,
        ns28:JAD160554,
        ns12:JAD180216,
        ns12:jad091681,
        ns5:JAD190334,
        ns52:JAD160633 ;
    ns0:fullName "Mikko Hiltunen" ;
    ns0:hasAffiliation ns203:JAD181256 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181256 ;
    ns0:inAuthorList ns150:JAD181256 .

ns52:JAD181291 ns0:inAuthorList ns150:JAD181291 .

ns52:JAD190007 ns0:inAuthorList ns150:JAD190007 .

ns52:JAD190306 owl:sameAs ns40:JAD141314,
        ns30:JAD190474,
        ns5:JAD130971,
        ns16:JAD101977,
        ns52:JAD111766,
        ns52:JAD140846,
        ns52:JAD150619,
        ns52:JAD171027,
        ns60:JAD150537,
        ns60:JAD190524,
        ns33:JAD141266 ;
    ns0:fullName "Perminder Sachdev" ;
    ns0:hasAffiliation ns101:JAD190306,
        ns102:JAD190306 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190306 ;
    ns0:inAuthorList ns150:JAD190306 .

ns52:JAD190459 owl:sameAs ns40:JAD161023,
        ns28:JAD110515,
        ns28:JAD120361,
        ns30:JAD171131,
        ns5:JAD130170,
        ns16:JAD180403,
        ns57:JAD112003,
        ns57:JAD170990,
        ns60:JAD190183 ;
    ns0:fullName "Pierre Krolak-Salmon" ;
    ns0:hasAffiliation ns101:JAD190459,
        ns102:JAD190459 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190459 ;
    ns0:inAuthorList ns150:JAD190459 .

ns52:JAD190545 ns0:inAuthorList ns150:JAD190545 .

ns52:JAD190644 ns0:inAuthorList ns150:JAD190644 .

ns52:JAE2212 ns0:inAuthorList ns150:JAE2212 .

ns52:JBR180316 ns0:inAuthorList ns150:JBR180316 .

ns52:JCB179013 ns0:inAuthorList ns150:JCB179013 .

ns52:JHD150172 ns0:inAuthorList ns150:JHD150172 .

ns52:JHD160206 ns0:inAuthorList ns150:JHD160206 .

ns52:JHD180294 ns0:inAuthorList ns150:JHD180294 .

ns52:JHD180325 ns0:inAuthorList ns150:JHD180325 .

ns52:JIN073 ns0:inAuthorList ns150:JIN073 .

ns52:JND180315 ns0:inAuthorList ns150:JND180315 .

ns52:JND180331 ns0:inAuthorList ns150:JND180331 .

ns52:JPD140515 ns0:inAuthorList ns150:JPD140515 .

ns52:JPD150680 ns0:inAuthorList ns150:JPD150680 .

ns52:JPD150755 ns0:inAuthorList ns150:JPD150755 .

ns52:JPD150764 ns0:inAuthorList ns150:JPD150764 .

ns52:JPD160847 ns0:inAuthorList ns150:JPD160847 .

ns52:JPD160996 ns0:inAuthorList ns150:JPD160996 .

ns52:JPD171199 ns0:inAuthorList ns150:JPD171199 .

ns52:JPD171277 ns0:inAuthorList ns150:JPD171277 .

ns52:JPD181365 ns0:inAuthorList ns150:JPD181365 .

ns52:JPD181374 ns0:inAuthorList ns150:JPD181374 .

ns52:JPD181386 ns0:inAuthorList ns150:JPD181386 .

ns52:JVR191026 ns0:inAuthorList ns150:JVR191026 .

ns52:JVR972 ns0:inAuthorList ns150:JVR972 .

ns52:MGC242 ns0:inAuthorList ns150:MGC242 .

ns52:NRE1428 ns0:inAuthorList ns150:NRE1428 .

ns52:NRE182505 ns0:inAuthorList ns150:NRE182505 .

ns52:NRE182565 ns0:inAuthorList ns150:NRE182565 .

ns52:RNN190926 owl:sameAs ns30:RNN150515 ;
    ns0:fullName "Ting Xiao" ;
    ns0:hasAffiliation ns199:RNN190926,
        ns102:RNN190926 ;
    ns0:hasArticle ns1:rnn-v37-i4-RNN190926 ;
    ns0:inAuthorList ns150:RNN190926 .

ns52:THC199031 ns0:inAuthorList ns150:THC199031 .

ns52:VES560 ns0:inAuthorList ns150:VES560 .

ns52:VES589 ns0:inAuthorList ns150:VES589 .

ns52:VES619 ns0:inAuthorList ns150:VES619 .

ns52:WOR2522 ns0:inAuthorList ns150:WOR2522 .

ns52:WOR2762 ns0:inAuthorList ns150:WOR2762 .

ns52:XST18369 ns0:inAuthorList ns150:XST18369 .

ns52:XST190506 ns0:inAuthorList ns150:XST190506 .

ns52:jad00315 ns0:inAuthorList ns150:jad00315 .

ns52:jad00639 ns0:inAuthorList ns150:jad00639 .

ns52:jad00764 ns0:inAuthorList ns150:jad00764 .

ns52:jad00804 ns0:inAuthorList ns150:jad00804 .

ns52:jad00907 ns0:inAuthorList ns150:jad00907 .

ns52:jad00987 ns0:inAuthorList ns150:jad00987 .

ns52:jad01004 ns0:inAuthorList ns150:jad01004 .

ns52:jad01191 ns0:inAuthorList ns150:jad01191 .

ns52:jad01212 ns0:inAuthorList ns150:jad01212 .

ns52:jad090940 ns0:inAuthorList ns150:jad090940 .

ns52:jad091474 ns0:inAuthorList ns150:jad091474 .

ns52:jad091489 ns0:inAuthorList ns150:jad091489 .

ns52:jad100561 ns0:inAuthorList ns150:jad100561 .

ns52:jad100870 ns0:inAuthorList ns150:jad100870 .

ns52:thc00307 ns0:inAuthorList ns150:thc00307 .

<http://ld.iospress.nl/rdf/contributor/Author:62.ID:JND170280> ns0:inAuthorList ns150:JND170280 .

<http://ld.iospress.nl/rdf/contributor/Author:63.ID:JND170280> ns0:inAuthorList ns150:JND170280 .

<http://ld.iospress.nl/rdf/contributor/Author:64.ID:JAD110824> ns0:inAuthorList ns150:JAD110824 .

<http://ld.iospress.nl/rdf/contributor/Author:69.ID:jad100933> ns0:inAuthorList ns150:jad100933 .

ns57:BMR160543 ns0:inAuthorList ns150:BMR160543 .

ns57:BMR640 ns0:inAuthorList ns150:BMR640 .

ns57:CBM170175 ns0:inAuthorList ns150:CBM170175 .

ns57:CBM181526 ns0:inAuthorList ns150:CBM181526 .

ns57:CBM515 ns0:inAuthorList ns150:CBM515 .

ns57:CBM655 ns0:inAuthorList ns150:CBM655 .

ns57:CH16197 ns0:inAuthorList ns150:CH16197 .

ns57:CH170253 ns0:inAuthorList ns150:CH170253 .

ns57:CH179209 ns0:inAuthorList ns150:CH179209 .

ns57:CH179210 ns0:inAuthorList ns150:CH179210 .

ns57:CH189107 ns0:inAuthorList ns150:CH189107 .

ns57:CH189126 ns0:inAuthorList ns150:CH189126 .

ns57:CH189301 ns0:inAuthorList ns150:CH189301 .

ns57:CH189309 ns0:inAuthorList ns150:CH189309 .

ns57:CH1961 ns0:inAuthorList ns150:CH1961 .

ns57:CH1981 ns0:inAuthorList ns150:CH1981 .

ns57:CH1990 ns0:inAuthorList ns150:CH1990 .

ns57:CH199223 owl:sameAs ns30:CH168052 ;
    ns0:fullName "C. Stief" ;
    ns0:hasAffiliation ns210:CH199223 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199223 ;
    ns0:inAuthorList ns150:CH199223 .

ns57:HAB341 ns0:inAuthorList ns150:HAB341 .

ns57:ISP180254 ns0:inAuthorList ns150:ISP180254 .

ns57:JAD00021 ns0:inAuthorList ns150:JAD00021 .

ns57:JAD100525 ns0:inAuthorList ns150:JAD100525 .

ns57:JAD100660 ns0:inAuthorList ns150:JAD100660 .

ns57:JAD100987 ns0:inAuthorList ns150:JAD100987 .

ns57:JAD101422 ns0:inAuthorList ns150:JAD101422 .

ns57:JAD101878 ns0:inAuthorList ns150:JAD101878 .

ns57:JAD102103 ns0:inAuthorList ns150:JAD102103 .

ns57:JAD110455 ns0:inAuthorList ns150:JAD110455 .

ns57:JAD110584 ns0:inAuthorList ns150:JAD110584 .

ns57:JAD110866 ns0:inAuthorList ns150:JAD110866 .

ns57:JAD110890 ns0:inAuthorList ns150:JAD110890 .

ns57:JAD111916 ns0:inAuthorList ns150:JAD111916 .

ns57:JAD111934 ns0:inAuthorList ns150:JAD111934 .

ns57:JAD112084 ns0:inAuthorList ns150:JAD112084 .

ns57:JAD120202 ns0:inAuthorList ns150:JAD120202 .

ns57:JAD120358 ns0:inAuthorList ns150:JAD120358 .

ns57:JAD120946 ns0:inAuthorList ns150:JAD120946 .

ns57:JAD121156 ns0:inAuthorList ns150:JAD121156 .

ns57:JAD121291 ns0:inAuthorList ns150:JAD121291 .

ns57:JAD121294 ns0:inAuthorList ns150:JAD121294 .

ns57:JAD121315 ns0:inAuthorList ns150:JAD121315 .

ns57:JAD121516 ns0:inAuthorList ns150:JAD121516 .

ns57:JAD122074 ns0:inAuthorList ns150:JAD122074 .

ns57:JAD122110 ns0:inAuthorList ns150:JAD122110 .

ns57:JAD129041 ns0:inAuthorList ns150:JAD129041 .

ns57:JAD130824 ns0:inAuthorList ns150:JAD130824 .

ns57:JAD131265 ns0:inAuthorList ns150:JAD131265 .

ns57:JAD131469 ns0:inAuthorList ns150:JAD131469 .

ns57:JAD132018 ns0:inAuthorList ns150:JAD132018 .

ns57:JAD132225 ns0:inAuthorList ns150:JAD132225 .

ns57:JAD132558 ns0:inAuthorList ns150:JAD132558 .

ns57:JAD132783 ns0:inAuthorList ns150:JAD132783 .

ns57:JAD140054 ns0:inAuthorList ns150:JAD140054 .

ns57:JAD140588 ns0:inAuthorList ns150:JAD140588 .

ns57:JAD140624 ns0:inAuthorList ns150:JAD140624 .

ns57:JAD140924 ns0:inAuthorList ns150:JAD140924 .

ns57:JAD140942 ns0:inAuthorList ns150:JAD140942 .

ns57:JAD141266 ns0:inAuthorList ns150:JAD141266 .

ns57:JAD141281 ns0:inAuthorList ns150:JAD141281 .

ns57:JAD141338 ns0:inAuthorList ns150:JAD141338 .

ns57:JAD141356 ns0:inAuthorList ns150:JAD141356 .

ns57:JAD141989 ns0:inAuthorList ns150:JAD141989 .

ns57:JAD142322 ns0:inAuthorList ns150:JAD142322 .

ns57:JAD142337 ns0:inAuthorList ns150:JAD142337 .

ns57:JAD142874 ns0:inAuthorList ns150:JAD142874 .

ns57:JAD142970 ns0:inAuthorList ns150:JAD142970 .

ns57:JAD148009 ns0:inAuthorList ns150:JAD148009 .

ns57:JAD150280 ns0:inAuthorList ns150:JAD150280 .

ns57:JAD150394 ns0:inAuthorList ns150:JAD150394 .

ns57:JAD150429 ns0:inAuthorList ns150:JAD150429 .

ns57:JAD150493 ns0:inAuthorList ns150:JAD150493 .

ns57:JAD150605 ns0:inAuthorList ns150:JAD150605 .

ns57:JAD150619 ns0:inAuthorList ns150:JAD150619 .

ns57:JAD150935 ns0:inAuthorList ns150:JAD150935 .

ns57:JAD151139 ns0:inAuthorList ns150:JAD151139 .

ns57:JAD160018 ns0:inAuthorList ns150:JAD160018 .

ns57:JAD160139 ns0:inAuthorList ns150:JAD160139 .

ns57:JAD160374 ns0:inAuthorList ns150:JAD160374 .

ns57:JAD160407 ns0:inAuthorList ns150:JAD160407 .

ns57:JAD160554 ns0:inAuthorList ns150:JAD160554 .

ns57:JAD160574 ns0:inAuthorList ns150:JAD160574 .

ns57:JAD160619 ns0:inAuthorList ns150:JAD160619 .

ns57:JAD160667 ns0:inAuthorList ns150:JAD160667 .

ns57:JAD160722 ns0:inAuthorList ns150:JAD160722 .

ns57:JAD160735 ns0:inAuthorList ns150:JAD160735 .

ns57:JAD160866 ns0:inAuthorList ns150:JAD160866 .

ns57:JAD160923 ns0:inAuthorList ns150:JAD160923 .

ns57:JAD160970 ns0:inAuthorList ns150:JAD160970 .

ns57:JAD160983 ns0:inAuthorList ns150:JAD160983 .

ns57:JAD161067 ns0:inAuthorList ns150:JAD161067 .

ns57:JAD161113 ns0:inAuthorList ns150:JAD161113 .

ns57:JAD161181 ns0:inAuthorList ns150:JAD161181 .

ns57:JAD161277 ns0:inAuthorList ns150:JAD161277 .

ns57:JAD170024 ns0:inAuthorList ns150:JAD170024 .

ns57:JAD170092 ns0:inAuthorList ns150:JAD170092 .

ns57:JAD170123 ns0:inAuthorList ns150:JAD170123 .

ns57:JAD170148 ns0:inAuthorList ns150:JAD170148 .

ns57:JAD170229 ns0:inAuthorList ns150:JAD170229 .

ns57:JAD170238 ns0:inAuthorList ns150:JAD170238 .

ns57:JAD170360 ns0:inAuthorList ns150:JAD170360 .

ns57:JAD170388 ns0:inAuthorList ns150:JAD170388 .

ns57:JAD170398 ns0:inAuthorList ns150:JAD170398 .

ns57:JAD170414 ns0:inAuthorList ns150:JAD170414 .

ns57:JAD170534 ns0:inAuthorList ns150:JAD170534 .

ns57:JAD170553 ns0:inAuthorList ns150:JAD170553 .

ns57:JAD170578 ns0:inAuthorList ns150:JAD170578 .

ns57:JAD170602 ns0:inAuthorList ns150:JAD170602 .

ns57:JAD170796 ns0:inAuthorList ns150:JAD170796 .

ns57:JAD170815 ns0:inAuthorList ns150:JAD170815 .

ns57:JAD170858 ns0:inAuthorList ns150:JAD170858 .

ns57:JAD170861 ns0:inAuthorList ns150:JAD170861 .

ns57:JAD170948 ns0:inAuthorList ns150:JAD170948 .

ns57:JAD170964 ns0:inAuthorList ns150:JAD170964 .

ns57:JAD171134 ns0:inAuthorList ns150:JAD171134 .

ns57:JAD171182 ns0:inAuthorList ns150:JAD171182 .

ns57:JAD180017 ns0:inAuthorList ns150:JAD180017 .

ns57:JAD180071 ns0:inAuthorList ns150:JAD180071 .

ns57:JAD180092 ns0:inAuthorList ns150:JAD180092 .

ns57:JAD180209 ns0:inAuthorList ns150:JAD180209 .

ns57:JAD180219 ns0:inAuthorList ns150:JAD180219 .

ns57:JAD180280 ns0:inAuthorList ns150:JAD180280 .

ns57:JAD180425 ns0:inAuthorList ns150:JAD180425 .

ns57:JAD180514 ns0:inAuthorList ns150:JAD180514 .

ns57:JAD180776 ns0:inAuthorList ns150:JAD180776 .

ns57:JAD180789 ns0:inAuthorList ns150:JAD180789 .

ns57:JAD180819 ns0:inAuthorList ns150:JAD180819 .

ns57:JAD180855 ns0:inAuthorList ns150:JAD180855 .

ns57:JAD180890 ns0:inAuthorList ns150:JAD180890 .

ns57:JAD180987 ns0:inAuthorList ns150:JAD180987 .

ns57:JAD180991 owl:sameAs ns2:JAD111370,
        ns12:JAD141959 ;
    ns0:fullName "Bruno Dubois" ;
    ns0:hasAffiliation ns208:JAD180991 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD180991 ;
    ns0:inAuthorList ns150:JAD180991 .

ns57:JAD181039 ns0:inAuthorList ns150:JAD181039 .

ns57:JAD181099 ns0:inAuthorList ns150:JAD181099 .

ns57:JAD181140 ns0:inAuthorList ns150:JAD181140 .

ns57:JAD181171 owl:sameAs ns16:JAD180496,
        ns57:JAD170880 ;
    ns0:fullName "Hanafi Ahmad Damanhuri" ;
    ns0:hasAffiliation ns208:JAD181171 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD181171 ;
    ns0:inAuthorList ns150:JAD181171 .

ns57:JAD181256 owl:sameAs ns26:JAD170583,
        ns40:JAD170362,
        ns28:JAD170534,
        ns43:JAD140777,
        ns130:JAD190132 ;
    ns0:fullName "Anne M. Remes" ;
    ns0:hasAffiliation ns210:JAD181256,
        ns208:JAD181256 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD181256 ;
    ns0:inAuthorList ns150:JAD181256 .

ns57:JAD181261 owl:sameAs ns8:JAD179924,
        ns16:JAD150471,
        ns16:JAD170409 ;
    ns0:fullName "Kok Pin Ng" ;
    ns0:hasAffiliation ns210:JAD181261 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD181261 ;
    ns0:inAuthorList ns150:JAD181261 .

ns57:JAD190107 owl:sameAs ns28:JAD170985,
        ns52:jad101348 ;
    ns0:fullName "Pascual Sánchez-Juan" ;
    ns0:hasAffiliation ns210:JAD190107 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190107 ;
    ns0:inAuthorList ns150:JAD190107 .

ns57:JAD190128 owl:sameAs ns52:JAD150895,
        ns60:JAD161006 ;
    ns0:fullName "Kyle B. Womack" ;
    ns0:hasAffiliation ns210:JAD190128,
        ns208:JAD190128,
        ns79:JAD190128 ;
    ns0:hasArticle ns1:jad-v70-i1-JAD190128 ;
    ns0:inAuthorList ns150:JAD190128 .

ns57:JAD190183 ns0:inAuthorList ns150:JAD190183 .

ns57:JAD190202 owl:sameAs ns8:JAD151113,
        ns26:JAD160979,
        ns52:JAD160641,
        ns57:JAD180030,
        ns57:JAD180485,
        ns33:JAD161292 ;
    ns0:fullName "Krista L. Lanctôt" ;
    ns0:hasAffiliation ns210:JAD190202,
        ns208:JAD190202,
        ns79:JAD190202 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190202 ;
    ns0:inAuthorList ns150:JAD190202 .

ns57:JAD190369 ns0:inAuthorList ns150:JAD190369 .

ns57:JAD190415 owl:sameAs ns28:JAD170555 ;
    ns0:fullName "Jennifer J. Manly" ;
    ns0:hasAffiliation ns210:JAD190415 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190415 ;
    ns0:inAuthorList ns150:JAD190415 .

ns57:JAD190524 owl:sameAs ns2:JAD131850,
        ns12:JAD160979,
        ns30:JAD180439,
        ns5:JAD131265,
        ns5:JAD170265,
        ns16:JAD150619,
        ns16:JAD171027,
        ns57:JAD190306,
        ns60:JAD160148,
        ns33:JAD150537 ;
    ns0:fullName "Henry Brodaty" ;
    ns0:hasAffiliation ns210:JAD190524 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190524 ;
    ns0:inAuthorList ns150:JAD190524 .

ns57:JAD190838 owl:sameAs ns2:JAD160866,
        ns60:JAD170604,
        ns33:JAD190545 ;
    ns0:fullName "Jorge Matías-Guiu" ;
    ns0:hasAffiliation ns210:JAD190838 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190838 ;
    ns0:inAuthorList ns150:JAD190838 .

ns57:JCB15014 ns0:inAuthorList ns150:JCB15014 .

ns57:JHD170269 ns0:inAuthorList ns150:JHD170269 .

ns57:JHD170283 ns0:inAuthorList ns150:JHD170283 .

ns57:JHD170284 ns0:inAuthorList ns150:JHD170284 .

ns57:JHD180309 ns0:inAuthorList ns150:JHD180309 .

ns57:JHD190354 owl:sameAs ns26:JHD180285,
        ns52:JHD180337,
        ns57:JHD160197,
        ns57:JHD180325,
        ns33:JHD170284 ;
    ns0:fullName "Ralf Reilmann" ;
    ns0:hasAffiliation ns210:JHD190354,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JHD190354>,
        ns106:JHD190354 ;
    ns0:hasArticle ns1:jhd-v8-i4-JHD190354 ;
    ns0:inAuthorList ns150:JHD190354 .

ns57:JIN073 ns0:inAuthorList ns150:JIN073 .

ns57:JND150125 ns0:inAuthorList ns150:JND150125 .

ns57:JND160201 ns0:inAuthorList ns150:JND160201 .

ns57:JND170209 ns0:inAuthorList ns150:JND170209 .

ns57:JND180315 ns0:inAuthorList ns150:JND180315 .

ns57:JPD150632 ns0:inAuthorList ns150:JPD150632 .

ns57:JPD150680 ns0:inAuthorList ns150:JPD150680 .

ns57:JPD171081 ns0:inAuthorList ns150:JPD171081 .

ns57:JPD171228 ns0:inAuthorList ns150:JPD171228 .

ns57:JPD181365 ns0:inAuthorList ns150:JPD181365 .

ns57:JPD181434 ns0:inAuthorList ns150:JPD181434 .

ns57:JPD181516 ns0:inAuthorList ns150:JPD181516 .

ns57:JPD191675 owl:sameAs ns2:jad00084,
        ns2:jad00519,
        ns8:JAD171071,
        ns26:JAD131589,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad00130>,
        ns12:JAD190074,
        ns52:JHD180309,
        ns57:JAD170894 ;
    ns0:fullName "Eliezer Masliah" ;
    ns0:hasAffiliation ns88:JPD191675 ;
    ns0:hasArticle ns1:jpd-v9-i4-JPD191675 ;
    ns0:inAuthorList ns150:JPD191675 .

ns57:MGC210 ns0:inAuthorList ns150:MGC210 .

ns57:MNM180261 owl:sameAs ns5:MNM180224 ;
    ns0:fullName "Roya Kelishadi" ;
    ns0:hasAffiliation ns210:MNM180261 ;
    ns0:hasArticle ns1:mnm-v12-i2-MNM180261 ;
    ns0:inAuthorList ns150:MNM180261 .

ns57:NHA170036 ns0:inAuthorList ns150:NHA170036 .

ns57:NRE182565 ns0:inAuthorList ns150:NRE182565 .

ns57:SW217 ns0:inAuthorList ns150:SW217 .

ns57:THC170967 ns0:inAuthorList ns150:THC170967 .

ns57:THC199031 ns0:inAuthorList ns150:THC199031 .

ns57:XST180418 ns0:inAuthorList ns150:XST180418 .

ns57:XST180464 owl:sameAs ns2:JAD100987,
        ns2:JAD130824,
        ns2:jad01317,
        ns5:XST16212,
        ns16:JAD170418,
        ns52:XST180461,
        ns60:XST18374,
        ns60:XST18388 ;
    ns0:fullName "Wei Qian" ;
    ns0:hasAffiliation ns210:XST180464,
        ns88:XST180464 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180464 ;
    ns0:inAuthorList ns150:XST180464 .

ns57:XST190506 owl:sameAs ns8:JCM607,
        ns5:XST180477,
        ns57:XST579 ;
    ns0:fullName "Dong Liang" ;
    ns0:hasAffiliation ns210:XST190506 ;
    ns0:hasArticle ns1:xst-v27-i4-XST190506 ;
    ns0:inAuthorList ns150:XST190506 .

ns57:XST190527 owl:sameAs ns33:XST190506 ;
    ns0:fullName "Xin Liu" ;
    ns0:hasAffiliation ns210:XST190527 ;
    ns0:hasArticle ns1:xst-v27-i5-XST190527 ;
    ns0:inAuthorList ns150:XST190527 .

ns57:XST502 ns0:inAuthorList ns150:XST502 .

ns57:XST598 ns0:inAuthorList ns150:XST598 .

ns57:ajw190019 ns0:inAuthorList ns150:ajw190019 .

ns57:bd000357 ns0:inAuthorList ns150:bd000357 .

ns57:jad00091 ns0:inAuthorList ns150:jad00091 .

ns57:jad00195 ns0:inAuthorList ns150:jad00195 .

ns57:jad00340 ns0:inAuthorList ns150:jad00340 .

ns57:jad00966 ns0:inAuthorList ns150:jad00966 .

ns57:jad00967 ns0:inAuthorList ns150:jad00967 .

ns57:jad01170 ns0:inAuthorList ns150:jad01170 .

ns57:jad01223 ns0:inAuthorList ns150:jad01223 .

ns57:jad01257 ns0:inAuthorList ns150:jad01257 .

ns57:jad01384 ns0:inAuthorList ns150:jad01384 .

ns57:jad091594 ns0:inAuthorList ns150:jad091594 .

ns57:jad100048 ns0:inAuthorList ns150:jad100048 .

ns57:jad100075 ns0:inAuthorList ns150:jad100075 .

ns57:jad100129 ns0:inAuthorList ns150:jad100129 .

ns57:jad100186 ns0:inAuthorList ns150:jad100186 .

ns57:jad100678 ns0:inAuthorList ns150:jad100678 .

ns57:jad101023 ns0:inAuthorList ns150:jad101023 .

ns57:jad101185 ns0:inAuthorList ns150:jad101185 .

ns60:BLC170111 ns0:inAuthorList ns150:BLC170111 .

ns60:BLC180172 ns0:inAuthorList ns150:BLC180172 .

ns60:CBM160058 ns0:inAuthorList ns150:CBM160058 .

ns60:CBM171099 ns0:inAuthorList ns150:CBM171099 .

ns60:CH179205 ns0:inAuthorList ns150:CH179205 .

ns60:CH179216 ns0:inAuthorList ns150:CH179216 .

ns60:CH189126 ns0:inAuthorList ns150:CH189126 .

ns60:CH189907 owl:sameAs ns2:CH168021,
        ns8:CH189408,
        ns28:CH179232,
        ns12:CH179000,
        ns12:CH180427,
        ns12:CH189901,
        ns30:CH179233,
        ns30:JCB179014,
        ns5:CH170244,
        ns52:CH160207,
        ns52:CH179235 ;
    ns0:fullName "Christian Lehmann" ;
    ns0:hasAffiliation ns217:CH189907,
        ns216:CH189907 ;
    ns0:hasArticle ns1:ch-v72-i1-CH189907 ;
    ns0:inAuthorList ns150:CH189907 .

ns60:CH199212 ns0:inAuthorList ns150:CH199212 .

ns60:CH199219 ns0:inAuthorList ns150:CH199219 .

ns60:CH2064 ns0:inAuthorList ns150:CH2064 .

ns60:JAD0025 ns0:inAuthorList ns150:JAD0025 .

ns60:JAD100714 ns0:inAuthorList ns150:JAD100714 .

ns60:JAD102133 ns0:inAuthorList ns150:JAD102133 .

ns60:JAD110761 ns0:inAuthorList ns150:JAD110761 .

ns60:JAD111046 ns0:inAuthorList ns150:JAD111046 .

ns60:JAD111109 ns0:inAuthorList ns150:JAD111109 .

ns60:JAD111370 ns0:inAuthorList ns150:JAD111370 .

ns60:JAD111592 ns0:inAuthorList ns150:JAD111592 .

ns60:JAD111778 ns0:inAuthorList ns150:JAD111778 .

ns60:JAD111949 ns0:inAuthorList ns150:JAD111949 .

ns60:JAD112006 ns0:inAuthorList ns150:JAD112006 .

ns60:JAD112060 ns0:inAuthorList ns150:JAD112060 .

ns60:JAD120379 ns0:inAuthorList ns150:JAD120379 .

ns60:JAD120976 ns0:inAuthorList ns150:JAD120976 .

ns60:JAD121156 ns0:inAuthorList ns150:JAD121156 .

ns60:JAD121180 ns0:inAuthorList ns150:JAD121180 .

ns60:JAD121408 ns0:inAuthorList ns150:JAD121408 .

ns60:JAD121663 ns0:inAuthorList ns150:JAD121663 .

ns60:JAD122170 ns0:inAuthorList ns150:JAD122170 .

ns60:JAD122263 ns0:inAuthorList ns150:JAD122263 .

ns60:JAD122329 ns0:inAuthorList ns150:JAD122329 .

ns60:JAD130104 ns0:inAuthorList ns150:JAD130104 .

ns60:JAD131172 ns0:inAuthorList ns150:JAD131172 .

ns60:JAD131373 ns0:inAuthorList ns150:JAD131373 .

ns60:JAD131496 ns0:inAuthorList ns150:JAD131496 .

ns60:JAD131766 ns0:inAuthorList ns150:JAD131766 .

ns60:JAD131802 ns0:inAuthorList ns150:JAD131802 .

ns60:JAD131820 ns0:inAuthorList ns150:JAD131820 .

ns60:JAD132147 ns0:inAuthorList ns150:JAD132147 .

ns60:JAD132783 ns0:inAuthorList ns150:JAD132783 .

ns60:JAD140138 ns0:inAuthorList ns150:JAD140138 .

ns60:JAD140240 ns0:inAuthorList ns150:JAD140240 .

ns60:JAD140678 ns0:inAuthorList ns150:JAD140678 .

ns60:JAD140846 ns0:inAuthorList ns150:JAD140846 .

ns60:JAD140864 ns0:inAuthorList ns150:JAD140864 .

ns60:JAD141314 ns0:inAuthorList ns150:JAD141314 .

ns60:JAD141497 ns0:inAuthorList ns150:JAD141497 .

ns60:JAD141521 ns0:inAuthorList ns150:JAD141521 .

ns60:JAD142214 ns0:inAuthorList ns150:JAD142214 .

ns60:JAD142229 ns0:inAuthorList ns150:JAD142229 .

ns60:JAD142595 ns0:inAuthorList ns150:JAD142595 .

ns60:JAD148009 ns0:inAuthorList ns150:JAD148009 .

ns60:JAD150234 ns0:inAuthorList ns150:JAD150234 .

ns60:JAD150464 ns0:inAuthorList ns150:JAD150464 .

ns60:JAD150586 ns0:inAuthorList ns150:JAD150586 .

ns60:JAD150606 ns0:inAuthorList ns150:JAD150606 .

ns60:JAD150695 ns0:inAuthorList ns150:JAD150695 .

ns60:JAD150895 ns0:inAuthorList ns150:JAD150895 .

ns60:JAD150914 ns0:inAuthorList ns150:JAD150914 .

ns60:JAD150946 ns0:inAuthorList ns150:JAD150946 .

ns60:JAD150961 ns0:inAuthorList ns150:JAD150961 .

ns60:JAD150985 ns0:inAuthorList ns150:JAD150985 .

ns60:JAD151139 ns0:inAuthorList ns150:JAD151139 .

ns60:JAD151198 ns0:inAuthorList ns150:JAD151198 .

ns60:JAD160056 ns0:inAuthorList ns150:JAD160056 .

ns60:JAD160149 ns0:inAuthorList ns150:JAD160149 .

ns60:JAD160152 ns0:inAuthorList ns150:JAD160152 .

ns60:JAD160252 ns0:inAuthorList ns150:JAD160252 .

ns60:JAD160271 ns0:inAuthorList ns150:JAD160271 .

ns60:JAD160273 ns0:inAuthorList ns150:JAD160273 .

ns60:JAD160324 ns0:inAuthorList ns150:JAD160324 .

ns60:JAD160398 ns0:inAuthorList ns150:JAD160398 .

ns60:JAD160449 ns0:inAuthorList ns150:JAD160449 .

ns60:JAD160560 ns0:inAuthorList ns150:JAD160560 .

ns60:JAD160619 ns0:inAuthorList ns150:JAD160619 .

ns60:JAD160651 ns0:inAuthorList ns150:JAD160651 .

ns60:JAD160766 ns0:inAuthorList ns150:JAD160766 .

ns60:JAD160821 ns0:inAuthorList ns150:JAD160821 .

ns60:JAD160939 ns0:inAuthorList ns150:JAD160939 .

ns60:JAD161019 ns0:inAuthorList ns150:JAD161019 .

ns60:JAD161047 ns0:inAuthorList ns150:JAD161047 .

ns60:JAD161078 ns0:inAuthorList ns150:JAD161078 .

ns60:JAD161114 ns0:inAuthorList ns150:JAD161114 .

ns60:JAD161139 ns0:inAuthorList ns150:JAD161139 .

ns60:JAD161173 ns0:inAuthorList ns150:JAD161173 .

ns60:JAD161179 ns0:inAuthorList ns150:JAD161179 .

ns60:JAD161228 ns0:inAuthorList ns150:JAD161228 .

ns60:JAD161252 ns0:inAuthorList ns150:JAD161252 .

ns60:JAD161259 ns0:inAuthorList ns150:JAD161259 .

ns60:JAD161267 ns0:inAuthorList ns150:JAD161267 .

ns60:JAD161277 ns0:inAuthorList ns150:JAD161277 .

ns60:JAD170001 ns0:inAuthorList ns150:JAD170001 .

ns60:JAD170072 ns0:inAuthorList ns150:JAD170072 .

ns60:JAD170124 ns0:inAuthorList ns150:JAD170124 .

ns60:JAD170190 ns0:inAuthorList ns150:JAD170190 .

ns60:JAD170414 ns0:inAuthorList ns150:JAD170414 .

ns60:JAD170415 ns0:inAuthorList ns150:JAD170415 .

ns60:JAD170419 ns0:inAuthorList ns150:JAD170419 .

ns60:JAD170458 ns0:inAuthorList ns150:JAD170458 .

ns60:JAD170520 ns0:inAuthorList ns150:JAD170520 .

ns60:JAD170521 ns0:inAuthorList ns150:JAD170521 .

ns60:JAD170537 ns0:inAuthorList ns150:JAD170537 .

ns60:JAD170557 ns0:inAuthorList ns150:JAD170557 .

ns60:JAD170560 ns0:inAuthorList ns150:JAD170560 .

ns60:JAD170574 ns0:inAuthorList ns150:JAD170574 .

ns60:JAD170583 ns0:inAuthorList ns150:JAD170583 .

ns60:JAD170602 ns0:inAuthorList ns150:JAD170602 .

ns60:JAD170771 ns0:inAuthorList ns150:JAD170771 .

ns60:JAD170861 ns0:inAuthorList ns150:JAD170861 .

ns60:JAD170893 ns0:inAuthorList ns150:JAD170893 .

ns60:JAD170998 ns0:inAuthorList ns150:JAD170998 .

ns60:JAD171013 ns0:inAuthorList ns150:JAD171013 .

ns60:JAD171027 ns0:inAuthorList ns150:JAD171027 .

ns60:JAD171088 ns0:inAuthorList ns150:JAD171088 .

ns60:JAD171140 ns0:inAuthorList ns150:JAD171140 .

ns60:JAD171169 ns0:inAuthorList ns150:JAD171169 .

ns60:JAD171182 ns0:inAuthorList ns150:JAD171182 .

ns60:JAD180013 ns0:inAuthorList ns150:JAD180013 .

ns60:JAD180025 ns0:inAuthorList ns150:JAD180025 .

ns60:JAD180082 ns0:inAuthorList ns150:JAD180082 .

ns60:JAD180087 ns0:inAuthorList ns150:JAD180087 .

ns60:JAD180250 ns0:inAuthorList ns150:JAD180250 .

ns60:JAD180316 ns0:inAuthorList ns150:JAD180316 .

ns60:JAD180486 ns0:inAuthorList ns150:JAD180486 .

ns60:JAD180564 ns0:inAuthorList ns150:JAD180564 .

ns60:JAD180572 owl:sameAs ns5:JAD180344,
        ns16:JAD131820,
        ns52:jad01018 ;
    ns0:fullName "Nicola T. Lautenschlager" ;
    ns0:hasAffiliation ns218:JAD180572,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff17.Author:8.ID:JAD180572> ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180572 ;
    ns0:inAuthorList ns150:JAD180572 .

ns60:JAD180645 ns0:inAuthorList ns150:JAD180645 .

ns60:JAD180663 ns0:inAuthorList ns150:JAD180663 .

ns60:JAD180723 ns0:inAuthorList ns150:JAD180723 .

ns60:JAD180820 ns0:inAuthorList ns150:JAD180820 .

ns60:JAD180897 ns0:inAuthorList ns150:JAD180897 .

ns60:JAD180904 ns0:inAuthorList ns150:JAD180904 .

ns60:JAD180976 ns0:inAuthorList ns150:JAD180976 .

ns60:JAD180985 ns0:inAuthorList ns150:JAD180985 .

ns60:JAD181022 ns0:inAuthorList ns150:JAD181022 .

ns60:JAD181152 ns0:inAuthorList ns150:JAD181152 .

ns60:JAD181171 owl:sameAs ns26:JAD170880 ;
    ns0:fullName "Ikuo Tooyama" ;
    ns0:hasAffiliation ns77:JAD181171 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD181171 ;
    ns0:inAuthorList ns150:JAD181171 .

ns60:JAD190007 ns0:inAuthorList ns150:JAD190007 .

ns60:JAD190369 ns0:inAuthorList ns150:JAD190369 .

ns60:JAD190562 owl:sameAs ns57:jad100816 ;
    ns0:fullName "Rudolph E. Tanzi" ;
    ns0:hasAffiliation ns77:JAD190562 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190562 ;
    ns0:inAuthorList ns150:JAD190562 .

ns60:JAD190644 owl:sameAs ns16:JAD143084,
        ns16:JAD181218 ;
    ns0:fullName "Yumiko Nakano" ;
    ns0:hasAffiliation ns77:JAD190644 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190644 ;
    ns0:inAuthorList ns150:JAD190644 .

ns60:JAD190645 owl:sameAs ns26:JAD160110,
        ns26:JAD170402,
        ns28:JAD120763,
        ns28:JAD160642,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160195>,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:jad00799>,
        ns5:JAD180592,
        ns52:jad01165,
        ns60:JAD110341,
        ns33:JAD180291 ;
    ns0:fullName "Sanjay Asthana" ;
    ns0:hasAffiliation ns77:JAD190645,
        ns215:JAD190645 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190645 ;
    ns0:inAuthorList ns150:JAD190645 .

ns60:JHD170238 ns0:inAuthorList ns150:JHD170238 .

ns60:JHD180285 ns0:inAuthorList ns150:JHD180285 .

ns60:JHD180293 ns0:inAuthorList ns150:JHD180293 .

ns60:JPD171113 ns0:inAuthorList ns150:JPD171113 .

ns60:JPD171135 ns0:inAuthorList ns150:JPD171135 .

ns60:JPD171195 ns0:inAuthorList ns150:JPD171195 .

ns60:JPD171228 ns0:inAuthorList ns150:JPD171228 .

ns60:JVR191023 owl:sameAs ns12:JVR838,
        ns12:JVR898,
        ns30:JVR809,
        ns30:JVR814,
        ns30:JVR816,
        ns5:JVR191022,
        ns5:JVR811,
        ns16:JVR813,
        ns52:JVR914,
        ns57:JVR930 ;
    ns0:fullName "Fong Chan" ;
    ns0:hasAffiliation ns215:JVR191023 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191023 ;
    ns0:inAuthorList ns150:JVR191023 .

ns60:NRE182525 ns0:inAuthorList ns150:NRE182525 .

ns60:RNN150515 ns0:inAuthorList ns150:RNN150515 .

ns60:RNN170767 ns0:inAuthorList ns150:RNN170767 .

ns60:RNN180812 ns0:inAuthorList ns150:RNN180812 .

ns60:THC170967 ns0:inAuthorList ns150:THC170967 .

ns60:XST180467 owl:sameAs ns12:XST17364,
        ns30:XST180422 ;
    ns0:fullName "Yu Lei" ;
    ns0:hasAffiliation ns215:XST180467 ;
    ns0:hasArticle ns1:xst-v27-i4-XST180467 ;
    ns0:inAuthorList ns150:XST180467 .

ns60:ajw190019 ns0:inAuthorList ns150:ajw190019 .

ns60:jad00471 ns0:inAuthorList ns150:jad00471 .

ns60:jad00809 ns0:inAuthorList ns150:jad00809 .

ns60:jad00896 ns0:inAuthorList ns150:jad00896 .

ns60:jad01031 ns0:inAuthorList ns150:jad01031 .

ns60:jad01074 ns0:inAuthorList ns150:jad01074 .

ns60:jad01116 ns0:inAuthorList ns150:jad01116 .

ns60:jad01129 ns0:inAuthorList ns150:jad01129 .

ns60:jad01187 ns0:inAuthorList ns150:jad01187 .

ns60:jad01212 ns0:inAuthorList ns150:jad01212 .

ns60:jad01300 ns0:inAuthorList ns150:jad01300 .

ns60:jad01309 ns0:inAuthorList ns150:jad01309 .

ns60:jad01392 ns0:inAuthorList ns150:jad01392 .

ns60:jad100333 ns0:inAuthorList ns150:jad100333 .

ns60:jad100432 ns0:inAuthorList ns150:jad100432 .

ns60:jad100597 ns0:inAuthorList ns150:jad100597 .

ns33:CH189108 ns0:inAuthorList ns150:CH189108 .

ns33:CH189129 ns0:inAuthorList ns150:CH189129 .

ns33:IES171187 ns0:inAuthorList ns150:IES171187 .

ns33:JAD0044 ns0:inAuthorList ns150:JAD0044 .

ns33:JAD101515 ns0:inAuthorList ns150:JAD101515 .

ns33:JAD101932 ns0:inAuthorList ns150:JAD101932 .

ns33:JAD101980 ns0:inAuthorList ns150:JAD101980 .

ns33:JAD110494 ns0:inAuthorList ns150:JAD110494 .

ns33:JAD110518 ns0:inAuthorList ns150:JAD110518 .

ns33:JAD110914 ns0:inAuthorList ns150:JAD110914 .

ns33:JAD111472 ns0:inAuthorList ns150:JAD111472 .

ns33:JAD111997 ns0:inAuthorList ns150:JAD111997 .

ns33:JAD120358 ns0:inAuthorList ns150:JAD120358 .

ns33:JAD120832 ns0:inAuthorList ns150:JAD120832 .

ns33:JAD121663 ns0:inAuthorList ns150:JAD121663 .

ns33:JAD122110 ns0:inAuthorList ns150:JAD122110 .

ns33:JAD130398 ns0:inAuthorList ns150:JAD130398 .

ns33:JAD130656 ns0:inAuthorList ns150:JAD130656 .

ns33:JAD130914 ns0:inAuthorList ns150:JAD130914 .

ns33:JAD131025 ns0:inAuthorList ns150:JAD131025 .

ns33:JAD131589 ns0:inAuthorList ns150:JAD131589 .

ns33:JAD131652 ns0:inAuthorList ns150:JAD131652 .

ns33:JAD132027 ns0:inAuthorList ns150:JAD132027 .

ns33:JAD132642 ns0:inAuthorList ns150:JAD132642 .

ns33:JAD140147 ns0:inAuthorList ns150:JAD140147 .

ns33:JAD140276 ns0:inAuthorList ns150:JAD140276 .

ns33:JAD140405 ns0:inAuthorList ns150:JAD140405 .

ns33:JAD140678 ns0:inAuthorList ns150:JAD140678 .

ns33:JAD140798 ns0:inAuthorList ns150:JAD140798 .

ns33:JAD141167 ns0:inAuthorList ns150:JAD141167 .

ns33:JAD141275 ns0:inAuthorList ns150:JAD141275 .

ns33:JAD141497 ns0:inAuthorList ns150:JAD141497 .

ns33:JAD141572 ns0:inAuthorList ns150:JAD141572 .

ns33:JAD141767 ns0:inAuthorList ns150:JAD141767 .

ns33:JAD141824 ns0:inAuthorList ns150:JAD141824 .

ns33:JAD141986 ns0:inAuthorList ns150:JAD141986 .

ns33:JAD150440 ns0:inAuthorList ns150:JAD150440 .

ns33:JAD150573 ns0:inAuthorList ns150:JAD150573 .

ns33:JAD150729 ns0:inAuthorList ns150:JAD150729 .

ns33:JAD150812 ns0:inAuthorList ns150:JAD150812 .

ns33:JAD150824 ns0:inAuthorList ns150:JAD150824 .

ns33:JAD150909 ns0:inAuthorList ns150:JAD150909 .

ns33:JAD150985 ns0:inAuthorList ns150:JAD150985 .

ns33:JAD160108 ns0:inAuthorList ns150:JAD160108 .

ns33:JAD160110 ns0:inAuthorList ns150:JAD160110 .

ns33:JAD160163 ns0:inAuthorList ns150:JAD160163 .

ns33:JAD160195 ns0:inAuthorList ns150:JAD160195 .

ns33:JAD160258 ns0:inAuthorList ns150:JAD160258 .

ns33:JAD160268 ns0:inAuthorList ns150:JAD160268 .

ns33:JAD160341 ns0:inAuthorList ns150:JAD160341 .

ns33:JAD160359 ns0:inAuthorList ns150:JAD160359 .

ns33:JAD160448 ns0:inAuthorList ns150:JAD160448 .

ns33:JAD160461 ns0:inAuthorList ns150:JAD160461 .

ns33:JAD160485 ns0:inAuthorList ns150:JAD160485 .

ns33:JAD160524 ns0:inAuthorList ns150:JAD160524 .

ns33:JAD160645 ns0:inAuthorList ns150:JAD160645 .

ns33:JAD160651 ns0:inAuthorList ns150:JAD160651 .

ns33:JAD160682 ns0:inAuthorList ns150:JAD160682 .

ns33:JAD160685 ns0:inAuthorList ns150:JAD160685 .

ns33:JAD160887 ns0:inAuthorList ns150:JAD160887 .

ns33:JAD160975 ns0:inAuthorList ns150:JAD160975 .

ns33:JAD161067 ns0:inAuthorList ns150:JAD161067 .

ns33:JAD161114 ns0:inAuthorList ns150:JAD161114 .

ns33:JAD161142 ns0:inAuthorList ns150:JAD161142 .

ns33:JAD170014 ns0:inAuthorList ns150:JAD170014 .

ns33:JAD170028 ns0:inAuthorList ns150:JAD170028 .

ns33:JAD170039 ns0:inAuthorList ns150:JAD170039 .

ns33:JAD170069 ns0:inAuthorList ns150:JAD170069 .

ns33:JAD170072 ns0:inAuthorList ns150:JAD170072 .

ns33:JAD170123 ns0:inAuthorList ns150:JAD170123 .

ns33:JAD170158 ns0:inAuthorList ns150:JAD170158 .

ns33:JAD170221 ns0:inAuthorList ns150:JAD170221 .

ns33:JAD170360 ns0:inAuthorList ns150:JAD170360 .

ns33:JAD170388 ns0:inAuthorList ns150:JAD170388 .

ns33:JAD170399 ns0:inAuthorList ns150:JAD170399 .

ns33:JAD170402 ns0:inAuthorList ns150:JAD170402 .

ns33:JAD170498 ns0:inAuthorList ns150:JAD170498 .

ns33:JAD170502 ns0:inAuthorList ns150:JAD170502 .

ns33:JAD170521 ns0:inAuthorList ns150:JAD170521 .

ns33:JAD170534 ns0:inAuthorList ns150:JAD170534 .

ns33:JAD170557 ns0:inAuthorList ns150:JAD170557 .

ns33:JAD170583 ns0:inAuthorList ns150:JAD170583 .

ns33:JAD170880 ns0:inAuthorList ns150:JAD170880 .

ns33:JAD170943 ns0:inAuthorList ns150:JAD170943 .

ns33:JAD170962 ns0:inAuthorList ns150:JAD170962 .

ns33:JAD171013 ns0:inAuthorList ns150:JAD171013 .

ns33:JAD171177 ns0:inAuthorList ns150:JAD171177 .

ns33:JAD180071 ns0:inAuthorList ns150:JAD180071 .

ns33:JAD180087 ns0:inAuthorList ns150:JAD180087 .

ns33:JAD180300 ns0:inAuthorList ns150:JAD180300 .

ns33:JAD180344 ns0:inAuthorList ns150:JAD180344 .

ns33:JAD180486 ns0:inAuthorList ns150:JAD180486 .

ns33:JAD180511 ns0:inAuthorList ns150:JAD180511 .

ns33:JAD180531 ns0:inAuthorList ns150:JAD180531 .

ns33:JAD180640 ns0:inAuthorList ns150:JAD180640 .

ns33:JAD180700 ns0:inAuthorList ns150:JAD180700 .

ns33:JAD180746 ns0:inAuthorList ns150:JAD180746 .

ns33:JAD180890 ns0:inAuthorList ns150:JAD180890 .

ns33:JAD180904 ns0:inAuthorList ns150:JAD180904 .

ns33:JAD180985 ns0:inAuthorList ns150:JAD180985 .

ns33:JAD181095 owl:sameAs ns8:JAD170850,
        ns26:JAD150695,
        ns26:JAD150796,
        ns26:JAD160285,
        ns40:JAD132306,
        ns40:JAD160091,
        ns40:JAD170608,
        ns40:JAD171088,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD141305>,
        ns12:JAD0058,
        ns5:JAD122227,
        ns5:JAD142136,
        ns5:JAD170784,
        ns5:jad01337,
        ns16:JAD141230,
        ns16:JAD170502,
        ns52:JAD122233,
        ns52:JAD151068,
        ns52:JAD151120,
        ns52:JPD181351,
        ns57:JAD111694,
        ns57:JAD132561,
        ns33:JAD170893 ;
    ns0:fullName "Philip Scheltens" ;
    ns0:hasAffiliation ns231:JAD181095 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181095 ;
    ns0:inAuthorList ns150:JAD181095 .

ns33:JAD181108 ns0:inAuthorList ns150:JAD181108 .

ns33:JAD181116 ns0:inAuthorList ns150:JAD181116 .

ns33:JAD181218 ns0:inAuthorList ns150:JAD181218 .

ns33:JAD190369 ns0:inAuthorList ns150:JAD190369 .

ns33:JAD190401 owl:sameAs ns5:JAD190501,
        ns60:JAD181049 ;
    ns0:fullName "Ying Han" ;
    ns0:hasAffiliation ns228:JAD190401,
        ns227:JAD190401,
        ns231:JAD190401,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:9.ID:JAD190401> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190401 ;
    ns0:inAuthorList ns150:JAD190401 .

ns33:JPD150656 ns0:inAuthorList ns150:JPD150656 .

ns33:JPD160888 ns0:inAuthorList ns150:JPD160888 .

ns33:JPD171264 ns0:inAuthorList ns150:JPD171264 .

ns33:JVR810 ns0:inAuthorList ns150:JVR810 .

ns33:KCA170018 ns0:inAuthorList ns150:KCA170018 .

ns33:KCA180045 ns0:inAuthorList ns150:KCA180045 .

ns33:WOR1973 ns0:inAuthorList ns150:WOR1973 .

ns33:ajw190019 ns0:inAuthorList ns150:ajw190019 .

ns33:cbm00414 ns0:inAuthorList ns150:cbm00414 .

ns33:jad00584 ns0:inAuthorList ns150:jad00584 .

ns33:jad00896 ns0:inAuthorList ns150:jad00896 .

ns33:jad01018 ns0:inAuthorList ns150:jad01018 .

ns33:jad01144 ns0:inAuthorList ns150:jad01144 .

ns33:jad01187 ns0:inAuthorList ns150:jad01187 .

ns33:jad01389 ns0:inAuthorList ns150:jad01389 .

ns33:jad01393 ns0:inAuthorList ns150:jad01393 .

ns33:jad090249 ns0:inAuthorList ns150:jad090249 .

ns33:jad091549 ns0:inAuthorList ns150:jad091549 .

ns33:jad100234 ns0:inAuthorList ns150:jad100234 .

ns242:BD160230 ns0:hasName "University Hospital of North Midlands and Keele University"@en,
        "Vardhman Mahavir Medical College and Safdarjung Hospital"@en .

ns242:BD180365 ns0:hasName "Aarhus University Hospital"@en,
        "Breast and Endocrinal Surgery Department"@en,
        "Department of Breast and Endocrinal Surgery"@en .

ns242:BLC190211 ns0:hasName "University of Iowa Department of Urology"@en,
        "University of Iowa Holden Comprehensive Cancer Center"@en,
        "University of Iowa Hospitals and Clinics"@en .

ns242:BLC190228 ns0:hasName "Cancer Biology and Genetics Division, Queen’s Cancer Research Institute"@en,
        "Department of Biomedical and Molecular Sciences"@en,
        "Department of Obstetrics and Gynecology"@en .

ns242:BME191064 ns0:hasName "Biomedical Engineering Department, Division of Biomechanics"@en,
        "Sahand University of Technology"@en .

ns242:BMR171004 ns0:hasName "Department of Physical Therapy, College of Nursing and Healthcare Sciences and Human Ecology"@en,
        "Department of Physical Therapy, College of Nursing, Healthcare Sciences and Human Ecology"@en .

ns242:BMR171041 ns0:hasName "Department of Orthotics and Prosthetics, School of Rehabilitation Sciences"@en .

ns242:BMR181131 ns0:hasName "Department of Sports Kinanthropology, Faculty of Physical Education and Sport"@en,
        "Faculty of Physical Education and Sports"@en .

ns242:BMR181171 ns0:hasName "Physical Therapy and Rehabilitation Department, Health Science Faculty, Balkan Campus"@en,
        "Physical Therapy and Rehabilitation Division, Health Science Faculty"@en .

ns242:BMR181185 ns0:hasName "Department of Orthopaedic Surgery-Spine Center"@en,
        "Department of Orthopedic Surgery"@en .

ns242:BMR181236 ns0:hasName "Department of Physiotherapy, Faculty of Paramedicine"@en,
        "Department of Physiotherapy, School of Rehabilitation"@en,
        "Department of physiotherapy, Faculty of rehabilitation"@en,
        "Physical Therapy Department, Rehabilitation Faculty"@en,
        "Tehran University of Medical Sciences"@en .

ns242:BRS190143 ns0:hasName "Department of Civil Construction and Environmental Engineering"@en,
        "University of Alabama at Birmingham"@en .

ns242:CBM182231 ns0:hasName "Biochemistry Department, Institute of Oncology"@en,
        "Department of Basic Oncology, Oncology Institute"@en .

ns242:CBM190273 ns0:hasName "Department of General Surgery"@en .

ns242:CBM192435 ns0:hasName "Department of General Surgery, Ruijin Hospital"@en,
        "Shanghai Institute of Digestive Surgery, Ruijin Hospital"@en,
        "Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital"@en .

ns242:CH180402 ns0:hasName "Pamukkale University"@en .

ns242:CH180452 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital"@en,
        "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Shanghai Research Center for Thyroid Diseases"@en,
        "Thyroid Institute"@en,
        "Ultrasound Research and Education Institute"@en .

ns242:CH180457 ns0:hasName "The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine"@en .

ns242:CH180470 ns0:hasName "Department of Occupational Therapy"@en .

ns242:CH180476 ns0:hasName "Department of Integrated Omics for Biomedical Sciences"@en .

ns242:CH189907 ns0:hasName "Department of Anaesthesiology and Intensive Care Medicine, Charles University in Prague, Faculty of Medicine Hradec Kralove"@en,
        "Department of Anaesthesiology and Intensive Care, University Hospital Hradec Kralove"@en .

ns242:CH199005 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns242:CH199009 ns0:hasName "Department of Plastic and Hand Surgery"@en .

ns242:CH199202 ns0:hasName "Department of Radiology"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich – Grosshadern Campus"@en,
        "Ludwig-Maximilians-University Munich - Grosshadern Campus"@en .

ns242:CH199205 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns242:CH199220 ns0:hasName "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery"@en,
        "University Medical Center Regensburg"@en .

ns242:CH199222 ns0:hasName "Department of Urology"@en,
        "Department of Urology, University Hospital Grosshadern"@en .

ns242:CH199223 ns0:hasName "Department of Urology"@en,
        "Department of Urology, University Hospital Grosshadern"@en .

ns242:CH199225 ns0:hasName "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Reconstructive and Hand Surgery at the University Medical Center Regensburg"@en .

ns242:CH199226 ns0:hasName "Fraunhofer Project Group PZ-Syn of the Fraunhofer Institute for Cell Therapy and Immunology, Branch Bioanalytics and Bioprocesses (IZI-BB), Potsdam"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en .

ns242:FI1814 ns0:hasName "Institute of Informatics"@en .

ns242:FI1816 ns0:hasName "Faculty of Mathematics, Informatics, and Mechanics"@en,
        "Institute of Informatics"@en,
        "University of Warsaw"@en .

ns242:FI1819 ns0:hasName "Concordia University"@en .

ns242:FI1830 ns0:hasName "College of Mechanical Engineering"@en,
        "School of Earth Sciences and Engineering"@en .

ns242:FI1837 ns0:hasName "Département d’Informatique"@en .

ns242:FI1838 ns0:hasName "Department of Computing and Software"@en .

ns242:FI1870 ns0:hasName "Artificial Intelligence Laboratory"@en,
        "CSAI research center, Department of Informatics, Systems and Communication"@en,
        "Complex Systems and Artificial Intelligence Research Centre"@en,
        "Complex Systems and Artificial Intelligence research center, Department of Informatics, Systems and Communication"@en,
        "Research Center for Advanced Science and Technology"@en,
        "University of Milan"@en .

ns242:FI1882 ns0:hasName "LIACS"@en,
        "Leiden University"@en .

ns242:FI1885 ns0:hasName "Key Laboratory of Image Information Processing and Intelligent Control, School of Automation"@en,
        "School of Artificial Intelligence and Automation"@en .

ns242:HAB180360 ns0:hasName "Department of Haematology"@en,
        "Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science"@en .

ns242:HAB190363 ns0:hasName "Department of Health Management and Economics, School of Public Health, International Campus"@en,
        "Department of Nursing, Faculty of Health Sciences"@en .

ns242:HAB190364 ns0:hasName "Department of Health in Emergencies and Disasters, School of Public Health"@en .

ns242:HAB190369 ns0:hasName "Department of Health Management and Economics, School of Public Health, Health Information Management Research Center"@en .

ns242:HAB190371 ns0:hasName "Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics"@en,
        "Department of Clinical Nutrition, School of Nutritional Sciences and Dietetics, Tehran"@en .

ns242:HAB190373 ns0:hasName "Biological Sciences Department, Faculty of Science"@en,
        "Main Medical Laboratory, Medical Services"@en .

ns242:HAB190374 ns0:hasName "Department of Medical Genetics"@en,
        "Department of Molecular Medicine"@en .

ns242:HAB190375 ns0:hasName "Department of Haematology"@en,
        "Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science"@en,
        "Department of Haematology, School of Medical Laboratory Science"@en .

ns242:HAB190383 ns0:hasName "Department of Health Management and Economics, International Campus"@en,
        "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Management and Economics, School of Public Health, International Campus"@en,
        "Department of Nursing, Faculty of Health Sciences"@en .

ns242:HAB190385 ns0:hasName "Dental College"@en,
        "Department of Gynecology and Obstetrics"@en .

ns242:HIS190271 ns0:hasName "Department of Mathematics and Computer Science, Faculty of Science"@en,
        "Department of Mathematics and Statistics, Faculty of Science"@en .

ns242:HSM180413 ns0:hasName "Doctor of Economics"@en,
        "University of Nice Sophia Antipolis"@en .

ns242:HSM180425 ns0:hasName "Beijing University of Posts and Telecommunications (BUPT)"@en,
        "Digital Enterprise Research Institute"@en,
        "School of Economics and Management"@en .

ns242:HSM190516 ns0:hasName "College of Business"@en .

ns242:IA180016 ns0:hasName "Dipartimento di Informatica"@en,
        "Università di Torino"@en .

ns242:IA190018 ns0:hasName "University of Roma"@en,
        "University of Roma Tor Vergata"@en .

ns242:IDA183930 ns0:hasName "Department of Information Management"@en,
        "Department of Information and Communication Engineering"@en .

ns242:IDA184238 ns0:hasName "Department of Data Science and Knowledge Engineering"@en,
        "Maastricht University"@en .

ns242:IDA184339 ns0:hasName "Department of Engineering"@en,
        "Dipartimento di Ingegneria"@en,
        "Dipartimento di Ingegneria – University of Ferrara Via Saragat 1"@en,
        "Università di Ferrara"@en .

ns242:IDA192765 ns0:hasName "College of Mathematics and System Science"@en,
        "College of Mathematics and Systems Science"@en .

ns242:IDA192786 ns0:hasName "Graduate School"@en .

ns242:IDT180064 ns0:hasName "College of Engineering and Technology"@en,
        "Electrical Power Engineering Department"@en .

ns242:IES183201 ns0:hasName "Research Institute of Sports and Industry Science"@en .

ns242:IES193141 ns0:hasName "Sport Science Faculty"@en .

ns242:IFS162405 ns0:hasName "Department of Computer Science, CCSIT"@en,
        "Imam Abdulrahman Bin Faisal University (IAU)"@en .

ns242:IFS171587 ns0:hasName "Abdul Wali Khan University"@en,
        "Department of Mathematics"@en .

ns242:IFS17193 ns0:hasName "Shenzhen Institutes of Advanced Technology"@en .

ns242:IFS171953 ns0:hasName "University of Semnan"@en .

ns242:IFS172129 ns0:hasName "Beijing Key Laboratory on MCAACI"@en,
        "School of Mathematics and Statistics"@en .

ns242:IFS179060 ns0:hasName "College of Earth Science and Engineering"@en,
        "College of Field Engineering"@en,
        "College of Mechanical and Electric Engineering"@en,
        "College of Safety Science and Engineering"@en .

ns242:IFS179090 ns0:hasName "College of Mechanical Engineering"@en,
        "College of Science"@en .

ns242:IFS179101 ns0:hasName "Chang Jiang Polytechnic"@en,
        "Postdoctoral Research Station of Zhongnan University of Economics and Law"@en .

ns242:IFS179120 ns0:hasName "School of Information Management"@en .

ns242:IFS179123 ns0:hasName "Glorious Sun School of Business and Management"@en .

ns242:IFS179161 ns0:hasName "School of Management"@en,
        "State Key Laboratory of Bioactive Substances and Functions of Natural Medicines"@en .

ns242:IFS179196 ns0:hasName "Department of Management Science and Engineering, Business School"@en .

ns242:IFS179200 ns0:hasName "Department of Industrial Design"@en,
        "Department of Industrial Design, School of Electromechanic Engineering"@en .

ns242:IFS179201 ns0:hasName "School of Mechatronics Engineering and Automation"@en,
        "School of Water Conservancy"@en .

ns242:IFS179210 ns0:hasName "College of Agriculture"@en,
        "School of Business"@en .

ns242:IFS179236 ns0:hasName "School of Business"@en .

ns242:IFS179246 ns0:hasName "Sichuan International Studies University"@en,
        "Yuncheng University"@en .

ns242:IFS179250 ns0:hasName "Department of Mathematics"@en .

ns242:IFS179251 ns0:hasName "Department of Accounting"@en .

ns242:IFS179252 ns0:hasName "Multimedia University"@en .

ns242:IFS179266 ns0:hasName "College of Information Science and Engineering"@en,
        "School of Cotton Textiles"@en,
        "School of Cotton textiles"@en .

ns242:IFS179280 ns0:hasName "School of Economics and Management"@en .

ns242:IFS179291 ns0:hasName "School of Computer Engineering"@en,
        "Shenzhen Polytechnic"@en .

ns242:IFS179316 ns0:hasName "University of Science and Technology Beijing"@en .

ns242:IFS181127 ns0:hasName "Department of Computer Science"@en .

ns242:IFS181220 ns0:hasName "Department of Mathematics, Research Institute for Natural Sciences"@en,
        "Research Institute for Natural Sciences, Department of Mathematics"@en,
        "Research Institute for Natural Sciences, Dept. of Mathematics"@en .

ns242:IFS181339 ns0:hasName "School of Artificial Intelligence"@en,
        "School of Computer Science and Engineering"@en .

ns242:IFS181362 ns0:hasName "School of Software Engineering"@en .

ns242:IFS181460 ns0:hasName "Department of Mathematics"@en .

ns242:IFS181501 ns0:hasName "College of Science"@en .

ns242:IFS181502 ns0:hasName "Department of Mathematics & Statistics"@en,
        "Department of Mathematics and Statistics"@en,
        "Department of Physics"@en .

ns242:IFS181516 ns0:hasName "Department of Mathematics"@en .

ns242:IFS181527 ns0:hasName "School of Mathematics"@en .

ns242:IFS181538 ns0:hasName "Department of Industrial Engineering"@en,
        "Istanbul Technical University"@en .

ns242:IFS181547 ns0:hasName "School of Mathematics"@en .

ns242:IFS181642 ns0:hasName "Hebei University"@en .

ns242:IFS181657 ns0:hasName "Faculty of Applied Sciences"@en,
        "Faculty of Basic Sciences"@en .

ns242:IFS181663 ns0:hasName "College of Applied Mathematics"@en,
        "College of Mathematics and Econometrics"@en .

ns242:IFS181697 ns0:hasName "Department of Mathematics"@en,
        "University of the Punjab"@en .

ns242:IFS181762 ns0:hasName "Hunan University"@en,
        "School of Mathematics and Statistics"@en .

ns242:IFS181769 ns0:hasName "College of Mathematics and Information Science"@en,
        "College of Mathematics and Information ScienceShaanxi Normal University"@en,
        "Department of Mathematics, Faculty of Science"@en .

ns242:IFS181790 ns0:hasName "Department of Computer Science & Engineering"@en,
        "Department of Computer Science and Engineering"@en .

ns242:IFS181799 ns0:hasName "ATS Lab, Aeronautics and Astronautics Engineering College"@en,
        "Air Force Engineering University"@en .

ns242:IFS181810 ns0:hasName "Decision Sciences Institute"@en .

ns242:IFS181813 ns0:hasName "Department of Civil and Environmental Engineering, College of Engineering"@en,
        "Department of Mathematical Sciences"@en .

ns242:IFS181829 ns0:hasName "Department of Mathematics"@en,
        "Department of Mathematics and Statistics"@en .

ns242:IFS181970 ns0:hasName "College of Management Science and Engineering"@en .

ns242:IFS181972 ns0:hasName "Department of Mathematics"@en .

ns242:IFS181990 ns0:hasName "Amirkabir University of Technology"@en,
        "Department of Electrical Engineering"@en .

ns242:IFS182512 ns0:hasName "College of Computer Science and Engineering, Shandong Province Key laboratory of Wisdom Mine Information Technology"@en,
        "Shenzhen Institutes of Advanced Technology"@en .

ns242:IFS182518 ns0:hasName "Huaqiao University"@en,
        "School of Electrical Engineering and Computing"@en .

ns242:IFS182540 ns0:hasName "Faculty of Information Teachnology–Vietnam National University of Agriculture"@en,
        "Faculty of Information Technology"@en .

ns242:IFS182554 ns0:hasName "Shandong University of Finance and Economics"@en .

ns242:IFS182558 ns0:hasName "College of Information Science and Technology"@en .

ns242:IFS182568 ns0:hasName "Beijing Key Laboratory on MCAACI"@en,
        "College of Science"@en,
        "Department of Neurology, Xuanwu Hospital"@en,
        "School of Mathematics and Statistics"@en .

ns242:IFS182572 ns0:hasName "Department of Mathematics"@en .

ns242:IFS182579 ns0:hasName "Department of Mathematics and Statistic"@en,
        "Department of Mathematics and Statistics"@en .

ns242:IFS182581 ns0:hasName "Beijing Jiaotong University"@en,
        "School of Economics and Management"@en,
        "School of Management and Economic"@en .

ns242:IFS182590 ns0:hasName "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns242:IFS182594 ns0:hasName "School of Information Science and Engineering"@en,
        "Shaoguan University"@en .

ns242:IFS182595 ns0:hasName "Department of Mathematics and Statistics"@en .

ns242:IFS182616 ns0:hasName "Department of Mathematics"@en,
        "University of the Punjab"@en .

ns242:IFS182618 ns0:hasName "Department of Math., Faculty of Mathematics"@en,
        "Department of Mathematics"@en,
        "Department of Mathematics, Faculty of Mathematics"@en .

ns242:IFS182651 ns0:hasName "Department of Industrial Engineering"@en,
        "Industrial Engineering Department"@en .

ns242:IFS18266 ns0:hasName "School of Business"@en,
        "Sichuan Normal University"@en .

ns242:IFS182751 ns0:hasName "Department of Mathematics"@en,
        "University of the Punjab"@en .

ns242:IFS182766 ns0:hasName "School of Mathematics and Statistics"@en .

ns242:IFS182774 ns0:hasName "School of Management Science and Engineering"@en .

ns242:IFS182778 ns0:hasName "Department of Electrical and Electronics"@en .

ns242:IFS182808 ns0:hasName "School of Mathematics and Information Sciences"@en .

ns242:IFS182809 ns0:hasName "Department of Mathematics"@en,
        "University of the Punjab"@en .

ns242:IFS182821 ns0:hasName "Henan Polytechnic University"@en .

ns242:IFS182828 ns0:hasName "Beijing Institute of Technology"@en .

ns242:IFS182863 ns0:hasName "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematical Economics"@en,
        "Faculty of Mathematics and Statistics"@en .

ns242:IFS182864 ns0:hasName "Department of Mathematical Sciences"@en,
        "School of Management and Engineering"@en .

ns242:IFS182876 ns0:hasName "Banking University of Ho Chi Minh City"@en,
        "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematical Economics"@en,
        "Faculty of Mathematics and Statistics"@en .

ns242:IFS182893 ns0:hasName "Department of Applied Chemistry"@en,
        "Northeast Forestry University"@en .

ns242:IFS182907 ns0:hasName "Faculty of IT"@en .

ns242:IFS182919 ns0:hasName "Department of Mathematics"@en,
        "University of the Punjab"@en .

ns242:IFS182924 ns0:hasName "Department of Mathematics"@en,
        "Department of Mathematics, Faculty of Science and Arts"@en .

ns242:IFS182928 ns0:hasName "Department of Mathematics"@en .

ns242:IFS182961 ns0:hasName "Department of Computer Science"@en,
        "Department of Mathematics"@en,
        "Mazandaran Adib Institute of Higher Education"@en,
        "Sama Technical and Vocational Training College"@en,
        "Young Researchers and Elite club, Central Tehran Branch"@en .

ns242:IFS18473 ns0:hasName "Department of Computer Science and Engineering"@en,
        "Discipline of Software Engineering, Department of Computer Science & Engineering"@en .

ns242:IFS18579 ns0:hasName "Department of Computer Science, CCSIT"@en,
        "Imam Abdulrahman Bin Faisal University (IAU)"@en .

ns242:IFS18586 ns0:hasName "School of Mathematics and Computer Science"@en .

ns242:IFS18659 ns0:hasName "Beijing Key Laboratory on MCAACI"@en,
        "College of Science"@en,
        "Department of Neurology, Xuanwu Hospital"@en,
        "School of Mathematics and Statistics"@en .

ns242:IFS18725 ns0:hasName "Department of Applied Mathematics"@en,
        "National Pingtung University"@en .

ns242:IFS18755 ns0:hasName "Hebei University"@en .

ns242:IFS18998 ns0:hasName "Department of Industrial Management"@en .

ns242:IFS190036 ns0:hasName "Department of Math., Faculty of Mathematics"@en,
        "Department of Mathematics"@en,
        "Department of Mathematics, Faculty of Mathematics"@en .

ns242:IFS190042 ns0:hasName "Fujian Chuanzheng Communications College"@en .

ns242:IFS190111 ns0:hasName "College of Science"@en .

ns242:IFS190149 ns0:hasName "Department of Mathematics, Firoozkooh Branch"@en .

ns242:IFS190215 ns0:hasName "University of Granada"@en .

ns242:IFS190344 ns0:hasName "School of Economics"@en .

ns242:IFS190349 ns0:hasName "Computer Science & Engineering"@en,
        "Department of Computer Science and Engineering, Sri Ramachandra Engineering and Technology"@en .

ns242:IFS190447 ns0:hasName "Department of Mathematics & Statistics"@en,
        "Department of Mathematics and Statistics"@en,
        "Department of Physics"@en .

ns242:IFS190450 ns0:hasName "School of Economics and ManagementShanxi University"@en,
        "Shanxi University"@en .

ns242:IFS190550 ns0:hasName "Department of Mathematics"@en,
        "University of the Punjab"@en .

ns242:IFS190554 ns0:hasName "Department of Industrial Management"@en .

ns242:IFS190580 ns0:hasName "Department of Mathematics"@en .

ns242:IFS190668 ns0:hasName "University of the Punjab"@en .

ns242:IFS190782 ns0:hasName "Northeast Forestry University"@en .

ns242:IFS190952 ns0:hasName "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematical Economics"@en,
        "Faculty of Mathematics and Statistics"@en .

ns242:IFS190988 ns0:hasName "Department of Mathematics"@en .

ns242:IFS191197 ns0:hasName "Department of Mathematics and Statistics"@en .

ns242:ISU180039 ns0:hasName "Division of Cancer Control and Population Sciences"@en,
        "National Cancer Institute"@en .

ns242:JAD180492 ns0:hasName "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en .

ns242:JAD180501 ns0:hasName "Centre for Research in Ageing and Cognitive Health"@en,
        "Centre for Research in Ageing and Cognitive Health (REACH), School of Psychology"@en .

ns242:JAD180521 ns0:hasName "Medical School"@en .

ns242:JAD180525 ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychology"@en,
        "University of Southern California"@en,
        "Veterans Affairs San Diego Healthcare System"@en .

ns242:JAD180562 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "The Australian National University"@en .

ns242:JAD180571 ns0:hasName "Department of Psychology"@en,
        "Neuroscience and Mental Health Institute"@en .

ns242:JAD180572 ns0:hasName "Centre for Healthy Brain Ageing"@en,
        "Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine"@en .

ns242:JAD180630 ns0:hasName "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "International Clinical Research Center"@en .

ns242:JAD180634 ns0:hasName "Department of Epidemiology"@en,
        "Department of Psychiatry, Neurology, and Epidemiology, Global Brain Health Institute"@en,
        "Departments of Epidemiology & Biostatistics, Neurology and Psychiatry"@en,
        "Departments of Psychiatry, Neurology, and Epidemiology"@en,
        "Departments of Psychiatry, Neurology, and Epidemiology & Biostatistics"@en,
        "San Francisco VA Medical Center"@en,
        "San Francisco Veterans Affairs Medical Center"@en,
        "University of California"@en,
        "University of California San Francisco"@en .

ns242:JAD180847 ns0:hasName "Department of Psychiatry"@en .

ns242:JAD180899 ns0:hasName "Department of Geriatric Behavioral Neurology"@en,
        "Geriatric Behavioral Neurology Project, New Industry Creation Hatchery Center (NICHe)"@en .

ns242:JAD180900 ns0:hasName "Brain and Mind Centre, Sydney Medical School"@en,
        "Neuroscience Research Australia"@en,
        "School of Medical Sciences"@en,
        "The University of Sydney"@en .

ns242:JAD180938 ns0:hasName "Department of Medicine, Division of Neurology"@en,
        "The University of British Columbia"@en .

ns242:JAD181030 ns0:hasName "MRC Centre for Synaptic Plasticity, School of Clinical Sciences"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine"@en .

ns242:JAD181033 ns0:hasName "Association Innovation Alzheimer"@en,
        "Centre Mémoire de Ressources et de Recherche (CMRR) –Teaching Hospital of Nice, Claude Pompidou Institute"@en,
        "CoBTeK (Cognition-Behaviour-Technology) Lab"@en,
        "EA 7276 CoBTeK –Cognition Behaviour Technology, University of Nice Sophia-Antipolis, Claude Pompidou Institute"@en,
        "School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en .

ns242:JAD181141 ns0:hasName "Albert Einstein College of Medicine"@en,
        "Saul R. Korey Department of Neurology"@en .

ns242:JAD181169 ns0:hasName "School of Physical Therapy"@en .

ns242:JAD181171 ns0:hasName "Department of Biochemistry, Faculty of Medicine, UKMMC"@en,
        "Molecular Neuroscience Research Center"@en .

ns242:JAD181178 ns0:hasName "Department of Preventive Gerontology"@en,
        "Department of Preventive Gerontology, Center for Gerontology and Social Science"@en,
        "Department of Preventive Gerontology, Section for Health Promotion"@en .

ns242:JAD181227 ns0:hasName "Department of Neurology"@en .

ns242:JAD181230 ns0:hasName "Department of Chemistry and Biochemistry"@en,
        "Department of Chemistry and Biochemistry University of Windsor"@en .

ns242:JAD181261 ns0:hasName "Department of Neurology"@en .

ns242:JAD181282 ns0:hasName "Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research"@en,
        "Department of Pathology and Laboratory Medicine, Perelman School of Medicine"@en,
        "Institute on Aging and Center for Neurodegenerative Disease Research, Perelman School of Medicine"@en .

ns242:JAD181296 ns0:hasName "Department of Neurology & Institute of Neurology"@en,
        "Department of Neurology & Institute of Neurology, Ruijin Hospital"@en,
        "Department of Neurology and Institute of Neurology"@en,
        "Department of Neurology and The Collaborative Innovation Center for Brain Science"@en .

ns242:JAD181298 ns0:hasName "Cognitive Impairment Center"@en .

ns242:JAD190011 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Department of Neurology"@en,
        "Emory Alzheimer's Disease Research Center, (ADRC)"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en .

ns242:JAD190019 ns0:hasName "Department of Behavioral Sciences and the Rush Alzheimer’s Disease Center"@en,
        "Department of Medicine"@en,
        "Department of Psychiatry"@en,
        "Rush Alzheimer’s Disease Center"@en,
        "University of Illinois at Chicago"@en .

ns242:JAD190074 ns0:hasName "Department of Neurobiology"@en,
        "Department of Neurobiology, Sagol School of Neuroscience, George S. Wise Faculty of Life Sciences"@en .

ns242:JAD190087 ns0:hasName "Faculty of Clinical Engineering, School of Health Sciences"@en .

ns242:JAD190091 ns0:hasName "Acute and Specialty Care"@en,
        "University of Pittsburgh School of Nursing"@en .

ns242:JAD190094 ns0:hasName "Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences"@en,
        "Department of Epidemiology and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences"@en .

ns242:JAD190107 ns0:hasName "Department of Neurology"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en .

ns242:JAD190113 ns0:hasName "Brainnetome Center, Institute of Automation"@en,
        "Department of Neurology, Xuanwu Hospital"@en,
        "Department of Nuclear Medicine, Xuanwu Hospital"@en,
        "National Laboratory of Pattern Recognition, Institute of Automation"@en .

ns242:JAD190124 ns0:hasName "Department of Medicine, David Geffen School of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, David Geffen School of Medicine"@en,
        "Department of Psychiatry and Biobehavioral Sciences"@en,
        "Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "Departments of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "Greater Los Angeles VA Healthcare System"@en,
        "Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "V.A. Greater Los Angeles Healthcare System"@en,
        "VA Greater Los Angeles Healthcare Center"@en .

ns242:JAD190142 ns0:hasName "School of Nursing"@en,
        "Vanderbilt Memory & Alzheimer's Center, Department of Neurology"@en .

ns242:JAD190158 ns0:hasName "State Key Laboratory of Brain and Cognitive Science, Institute of Biophysics"@en .

ns242:JAD190180 ns0:hasName "Department of Biochemistry and Biomedical Sciences"@en,
        "Seoul National University"@en .

ns242:JAD190181 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "Centre for Research on Ageing, Health and Wellbeing, Research School of Population Health"@en,
        "Dementia Collaborative Research Centre – Early Diagnosis and Prevention, Research School of Population Health"@en,
        "Neuroscience Research Australia"@en,
        "School of Psychology"@en,
        "University of New South Wales"@en .

ns242:JAD190183 ns0:hasName "Institute of Aging I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR) Neurology Unit"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR), Neurology Unit"@en,
        "Memory Research Centre of Lyon (CMRR); Geriatrics Unit, Charpennes Hospital"@en,
        "Neurology Unit"@en .

ns242:JAD190196 ns0:hasName "Department of Neurology"@en,
        "Okayama University of Science"@en .

ns242:JAD190197 ns0:hasName "Alzheimer Memorial Center, Department of Psychiatry and Psychotherapy"@en,
        "Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "Discipline of Psychiatry and Trinity College Institute of Neuroscience (TCIN)"@en,
        "Discipline of Psychiatry, School of Medicine, Trinity College Institute of Neuroscience, Trinity College Dublin"@en,
        "Sorbonne University"@en .

ns242:JAD190262 ns0:hasName "Department of Neurology"@en,
        "Einstein Aging Study"@en,
        "Saul B. Korey Department of Neurology"@en .

ns242:JAD190265 ns0:hasName "Department of Microbiology and Immunology"@en,
        "Medical University of South Carolina"@en .

ns242:JAD190266 ns0:hasName "Department of Family & Community Medicine"@en,
        "Department of Family and Community Medicine"@en,
        "Department of Medicine"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry"@en,
        "GRECC, the"@en,
        "South Texas Veterans' Health System Audie L. Murphy Division GRECC"@en,
        "South Texas Veterans’ Health System"@en .

ns242:JAD190278 ns0:hasName "Department of Psychiatry, Graduate School of Medical Science"@en .

ns242:JAD190293 ns0:hasName "Department of Clinical Psychology"@en,
        "Department of Psychology"@en,
        "Gerontology Center, Lifespan Institute"@en,
        "University of Kansas"@en,
        "University of Kansas Alzheimer’s Disease Center"@en .

ns242:JAD190316 ns0:hasName "Department of Radiology and Radiological Sciences"@en,
        "Institute of Imaging Science"@en,
        "Vanderbilt Brain Institute"@en,
        "Vanderbilt University Institute of Imaging Science"@en .

ns242:JAD190322 ns0:hasName "Alzheimer’s Therapeutic Research Institute"@en,
        "Alzheimer’s Therapeutic Research Institute (ATRI) at University of Southern California"@en,
        "Alzheimer’s Therapeutic Research Institute (ATRI), Keck School of Medicine"@en,
        "Department of Neurosciences"@en .

ns242:JAD190331 ns0:hasName "Hospital Central Militar"@en,
        "The Center for Structural and Functional Neurosciences"@en,
        "The University of Montana"@en,
        "University of Montana"@en .

ns242:JAD190340 ns0:hasName "Department of Neurology and Neurobiology of Aging"@en .

ns242:JAD190346 ns0:hasName "Department of Neurology, Hemorrhagic Stroke Research Program"@en,
        "Department of Neurology, Massachusetts General Hospital Stroke Research Center"@en .

ns242:JAD190368 ns0:hasName "Department of Biochemistry and Molecular Biology, School of Medicine"@en,
        "Department of Neurochemistry"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-Innovation Center of Neuroregeneration"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-innovation Center of Neuroregeneration"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co-innovation Center of Neuroregeneration"@en .

ns242:JAD190369 ns0:hasName "Okayama University"@en .

ns242:JAD190382 ns0:hasName "Department of Neurology, Huashan Hospital"@en,
        "Institute of Neurology"@en .

ns242:JAD190385 ns0:hasName "Department of Human Neuroscience"@en,
        "Department of Neurology and Psychiatry, Sapienza"@en .

ns242:JAD190394 ns0:hasName "Department of Medicine"@en,
        "Department of Neuroscience, Biomedicine, and Movement Sciences"@en .

ns242:JAD190399 ns0:hasName "Department of Neuropsychiatry"@en,
        "Department of Otorhinolaryngology-Head & Neck Surgery"@en .

ns242:JAD190405 ns0:hasName "Hospital Central Militar"@en,
        "Instituto Nacional de Pediatría"@en,
        "The Center for Structural and Functional Neurosciences"@en,
        "The University of Montana"@en,
        "Universidad del Valle de México"@en,
        "University of Montana"@en .

ns242:JAD190413 ns0:hasName "Danish Dementia Research Centre (DDRC), Department of Neurology, Rigshospitalet"@en,
        "Danish Dementia Research Centre, Department of Neurology, Rigshospitalet"@en,
        "Department of Neurology, Danish Dementia Research Centre (DDRC), Rigshospitalet"@en .

ns242:JAD190423 ns0:hasName "1st Department of Neurology, G.H. “AHEPA”, School of Medicine, Faculty of Health Sciences"@en,
        "3rd Department of Neurology"@en,
        "3rd Department of Neurology, Medical School"@en,
        "Information Technologies Institute"@en,
        "Medical School Aristotle University of Thessaloniki"@en .

ns242:JAD190440 ns0:hasName "Laboratoire de Psychologie des Pays de la Loire (EA 4638)"@en,
        "Unité de Gériatrie"@en,
        "University of Lille"@en,
        "Université Lille"@en .

ns242:JAD190446 ns0:hasName "Clinic for Psychosomatic and Psychotherapeutic Medicine"@en,
        "DZNE"@en,
        "DZNE, German Center for Neurodegenerative Diseases"@en,
        "Department of Psychiatry"@en,
        "Department of Psychosomatic Medicine"@en,
        "Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Centre for Neurodegenerative Diseases (DZNE)"@en .

ns242:JAD190459 ns0:hasName "Institute of Aging I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR) Neurology Unit"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR), Neurology Unit"@en,
        "Memory Research Centre of Lyon (CMRR); Geriatrics Unit, Charpennes Hospital"@en,
        "Neurology Unit"@en .

ns242:JAD190461 ns0:hasName "Brain Dynamics and Cognition"@en,
        "CMRR – Hospices Civils de Lyon, Inserm U1028, CNRS UMR5292"@en,
        "Centre Mémoire Ressources Recherche de Lyon"@en,
        "Claude Bernard University Lyon 1"@en,
        "Clinical Research Centre CRC - VCF (Vieillissement –Cerveau - Fragilité), Hospital of Charpennes"@en,
        "Clinical and Research Memory Center of Lyon"@en,
        "Clinical and Research Memory Centre of Lyon"@en,
        "French Federation of Memory Centers"@en,
        "Hospices civils de Lyon"@en,
        "Hôpital Gériatrique des Charpennes"@en,
        "INSERM U1028, CNRS UMR5292"@en,
        "INSERM, U1028; CNRS"@en,
        "Institute of Aging I-Vie"@en,
        "Lyon University Hospital"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Memory Research Centre of Lyon (CMRR); Geriatrics Unit, Charpennes Hospital"@en,
        "Médecine Gériatrique"@en,
        "Neurobiologie, CMRR, Gériatrie, Hospices Civils de Lyon"@en,
        "Research Clinic Centre (CRC) - VCF (Aging – Brain – Frailty), Charpennes Hospital"@en,
        "Research and Resources Memory Center of Lyon, Hôpital des Charpennes"@en,
        "University Lyon 1"@en,
        "University Lyon I"@en .

ns242:JAD190468 ns0:hasName "Department of Neurology"@en,
        "Emory Alzheimer's Disease Research Center"@en .

ns242:JAD190484 ns0:hasName "Departament de Biologia Cellular, Protein Folding and Stability Group, de Fisiologia i d’Immunologia, Unitat de Citologia i d’Histologia, Facultat de Biociències"@en,
        "Departament de Biologia Cel·lular, Fisiologia i Immunologia, Unitat de Citologia i Histologia, Facultat de Biociències"@en,
        "Departament de Bioquímica i Biologia Molecular, Protein Folding and Stability Group, Facultat de Biociències"@en,
        "Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Edifici C"@en,
        "Protein Folding and Stability Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències"@en .

ns242:JAD190494 ns0:hasName "Department of Experimental Medicine and Oncology"@en,
        "Department of Experimental Medicine and Oncology, General Pathology Section"@en,
        "Department of Internal Medicine and Medical Specialties (DIMI), Unit of Geriatric Medicine"@en,
        "Department of Neuroscience"@en,
        "Neuroscience Institute of Cavalieri Ottolenghi Foundation (NICO)"@en,
        "Neuroscience Institute of the Cavalieri Ottolenghi Foundation (NICO)"@en .

ns242:JAD190508 ns0:hasName "Epidemiology"@en .

ns242:JAD190541 ns0:hasName "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en .

ns242:JAD190546 ns0:hasName "Department of Geriatrics and Cognitive Disorders"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, School of Medicine"@en .

ns242:JAD190549 ns0:hasName "Institute for Neurodegenerative Diseases, Clinical Branch"@en,
        "Université de Bordeaux"@en .

ns242:JAD190555 ns0:hasName "Florida State University College of Medicine"@en .

ns242:JAD190562 ns0:hasName "Department of Neurology, Qingdao Municipal Hospital"@en,
        "Department of Neurology, Qingdao Municipal Hospital, School of Medicine"@en,
        "Genetics and Aging Research Unit, McCance Center for Brain Health"@en .

ns242:JAD190577 ns0:hasName "Institute of Pharmaceutical Sciences"@en,
        "Institute of Psychiatry, Psychology and Neuroscience"@en .

ns242:JAD190581 ns0:hasName "Epidemiology"@en .

ns242:JAD190590 ns0:hasName "Mental Health and Nursing Research Team"@en .

ns242:JAD190596 ns0:hasName "Department of Anesthesiology, Shanghai General Hospital"@en,
        "Department of Medical Examination, The Central Hospital of Wuhan, Tongji Medical College"@en .

ns242:JAD190609 ns0:hasName "Cognitive Impairment Center"@en,
        "Department of Rehabilitative Medicine"@en .

ns242:JAD190620 ns0:hasName "Department of Geriatric Medicine"@en .

ns242:JAD190622 ns0:hasName "Center for Comprehensive Care and Research on Memory Disorders"@en,
        "Department of Community Health Sciences"@en,
        "Medical Genome Center"@en .

ns242:JAD190644 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en .

ns242:JAD190656 ns0:hasName "Department of Neurosciences"@en,
        "University of California"@en .

ns242:JAD190660 ns0:hasName "Neurology Service and CIBERNED"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en .

ns242:JAD190670 ns0:hasName "Area of Neuroscience"@en,
        "Brain Connectivity Laboratory"@en,
        "Department of Imaging"@en,
        "Institute of Neurology"@en .

ns242:JAD190685 ns0:hasName "Department of Neurology"@en,
        "Seoul National University College of Medicine and Seoul National University Bundang Hospital"@en .

ns242:JAD190708 ns0:hasName "Department of Neurology"@en,
        "UCLA Medical Center"@en .

ns242:JAD190721 ns0:hasName "Dementia Research Group"@en,
        "Dementia Research Group, Clinical Neuroscience, Southmead Hospital"@en,
        "Dementia Research Group, Faculty of Medicine and Dentistry"@en,
        "Dementia Research Group, Institute of Clinical Neuroscience"@en,
        "Dementia Research Group, Institute of Clinical Neurosciences"@en,
        "Dementia Research Group, Institute of Clinical Neurosciences, School of Clinical Sciences"@en,
        "Dementia Research Group, John James Laboratories, Frenchay Hospital, Institute of Clinical Neurosciences, School of Clinical Sciences"@en,
        "Dementia Research Group, School of Clinical Sciences"@en,
        "Dementia Research Group, Translational Health Sciences, Bristol Medical School"@en,
        "Faculty of Medicine and Dentistry, School of Clinical Sciences, Dementia Research Group"@en,
        "Frenchay Hospital"@en,
        "School of Clinical Science, Institute of Clinical Neurosciences"@en,
        "University of Bristol"@en .

ns242:JAD190725 ns0:hasName "Acute and Specialty Care"@en,
        "University of Pittsburgh School of Nursing"@en .

ns242:JAD190782 ns0:hasName "Center for Neuropathology"@en,
        "Department of Pathology"@en,
        "Department of Pathology, Anatomy, and Laboratory Medicine, Rockefeller Neuroscience Institute"@en,
        "Department of Pathology, Division of Anatomic Pathology"@en,
        "Departments of Pathology and Neuroscience"@en,
        "University of Maryland"@en .

ns242:JAD190823 ns0:hasName "Centre for Innovative Ageing"@en,
        "Department of Psychology"@en .

ns242:JAD190838 ns0:hasName "Department of Neurology and Laboratory of Neurobiology, Hospital Clinico San Carlos"@en,
        "Department of Neurology and Laboratory of Neurobiology, Hospital Clínico San Carlos"@en,
        "Department of Neurology, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC)"@en,
        "Department of Neurology, Hospital Clínico Universitario San Carlos, San Carlos Institute for Health Research (IdISSC)"@en,
        "Department of Neurology, San Carlos Institute for Health Research (IdISSC)"@en .

ns242:JAD190870 ns0:hasName "Department of Cardiology"@en,
        "Department of Neurology"@en .

ns242:JAE180058 ns0:hasName "Hebei University of Science and Technology"@en .

ns242:JAE190021 ns0:hasName "Tsinghua University"@en .

ns242:JAE191149 ns0:hasName "Department of Electrical EngineeringDoshisha University"@en,
        "Doshisha University"@en .

ns242:JAE198972 ns0:hasName "Department of Electrical EngineeringUniversity Politehnica of Bucharest"@en .

ns242:JAE198976 ns0:hasName "Department of Electrical EngineeringUniversity Politehnica of Bucharest"@en,
        "Universitatea Politehnica"@en .

ns242:JBR180349 ns0:hasName "Vegetable Crops Department, Faculty of Agriculture"@en .

ns242:JBR190390 ns0:hasName "Norwegian Institute of Bioeconomy Research (NIBIO)"@en .

ns242:JHD180337 ns0:hasName "George-Huntington-Institute"@en,
        "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour"@en,
        "Institute of Animal Hygiene, Animal Welfare and Farm Animal Behavior"@en .

ns242:JHD190353 ns0:hasName "Department of Psychiatry"@en .

ns242:JHD190355 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Perelman School of Medicine"@en .

ns242:JHD190364 ns0:hasName "Department of Physical Medicine and Rehabilitation"@en .

ns242:JHD190365 ns0:hasName "Center for Health + Technology/Clinical Trials Coordination Center"@en,
        "Center for Human Experimental Therapeutics/Clinical Trials Coordination Center"@en .

ns242:JHD190380 ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry and Department of Neurology"@en,
        "Department of Psychiatry, Research Division"@en,
        "Department of Psychiatry, Research Division and Department of Neurology"@en,
        "Georgetown University"@en .

ns242:JHD199003 ns0:hasName "Clinical Pharmacology Unit"@en,
        "Huntington’s Disease Centre, Institute of Neurology"@en,
        "Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine"@en,
        "UCL Huntington’s Disease Centre, UCL Queen Square Institute of Neurology"@en .

ns242:JND190416 ns0:hasName "Friedrich-Baur-Institute, Department of Neurology"@en .

ns242:JPD181518 ns0:hasName "Department of Neurology"@en .

ns242:JPD191577 ns0:hasName "School of Allied Health"@en,
        "School of Public Health and Psychology"@en .

ns242:JPD191593 ns0:hasName "Reta Lila Weston Institute"@en,
        "Reta Lila Weston Institute of Neurological Studies"@en,
        "Reta Lila Weston Institute of Neurological Studies, UCL Queen Square Institute of Neurology"@en,
        "University College London"@en .

ns242:JPD191600 ns0:hasName "Department of Neurology"@en,
        "Department of Neuroscience"@en .

ns242:JPD191605 ns0:hasName "Department of Neurology"@en .

ns242:JPD191610 ns0:hasName "Department of Neurology"@en,
        "Mayo Clinic"@en .

ns242:JPD191627 ns0:hasName "Department of Neurology"@en,
        "Department of Radiology"@en,
        "Neurology Service and GRECC"@en,
        "Radiology"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en .

ns242:JPD191648 ns0:hasName "Critical Path Institute"@en .

ns242:JPD191802 ns0:hasName "Department of Neurology, Alzheimer Research Center"@en,
        "Department of Neurology, University Medical Center Groningen"@en .

ns242:JSA190242 ns0:hasName "Sanders-Brown Center on Aging"@en,
        "University of Kentucky"@en .

ns242:JVR191020 ns0:hasName "Kent State University"@en .

ns242:JVR191021 ns0:hasName "Department of Kinesiology and Community Health"@en,
        "The University of Illinois-Urbana"@en,
        "University of Illinois at Urbana-Champaign"@en .

ns242:JVR191022 ns0:hasName "Kent State University"@en .

ns242:JVR191024 ns0:hasName "Kent State University"@en,
        "School of Lifespan Development and Educational Sciences"@en .

ns242:JVR191026 ns0:hasName "Department of Early Childhood, Special Education, and Rehabilitation Counseling"@en,
        "University of Wisconsin-Madison"@en .

ns242:JVR191031 ns0:hasName "Cornell University"@en,
        "K. Lisa Yang and Hock E. Tan Institute on Employment and Disability, ILR School"@en .

ns242:JVR191032 ns0:hasName "University of Wisconsin-Stout Vocational Rehabilitation Institute"@en .

ns242:JVR191034 ns0:hasName "Department of Administration, Rehabilitation and Postsecondary Education"@en,
        "San Diego State University"@en .

ns242:JVR191038 ns0:hasName "University of Utah"@en .

ns242:JVR191039 ns0:hasName "University of Montana"@en .

ns242:JVR191045 ns0:hasName "University of Minnesota"@en .

ns242:JVR191046 ns0:hasName "A.J. Drexel Autism Institute"@en,
        "Drexel University"@en .

ns242:JVR191049 ns0:hasName "Department of Health Sciences/Mental Health, Activity and Participation, Medical Faculty"@en .

ns242:JVR191055 ns0:hasName "Department of Kinesiology and Community Health"@en,
        "University of Illinois at Urbana-Champaign"@en .

ns242:KCA190056 ns0:hasName "City of Hope Comprehensive Cancer Center"@en,
        "Department of Medical Oncology & Experimental Therapeutics"@en,
        "Istanbul Medeniyet University Hospital"@en .

ns242:KCA190063 ns0:hasName "Department of Internal Medicine, University of California Davis School of Medicine, Division of Hematology Oncology"@en,
        "University of California"@en,
        "University of California Davis School of Medicine"@en .

ns242:MAS190464 ns0:hasName "Departamento de Ciências Exatas"@en .

ns242:MGC180689 ns0:hasName "Department of Chemistry, Faculty of Sciences and Arts, Khulais"@en,
        "National Research Centre"@en .

ns242:MGC180717 ns0:hasName "Inner Mongolia University For The Nationlities"@en,
        "Inner Mongolia University for Nationalities"@en .

ns242:MGC180750 ns0:hasName "Xizang University for Nationalities"@en .

ns242:MGC180761 ns0:hasName "Department of Chemistry"@en,
        "University of Patras"@en .

ns242:MGC190783 ns0:hasName "Central South University"@en,
        "Institute of Electronic System Engineering of China"@en .

ns242:MGC190794 ns0:hasName "Department of Chemistry"@en,
        "University of Patras"@en .

ns242:MGC194 ns0:hasName "Department of Biological Science, Faculty of Science"@en,
        "Department of Biological Science, Faculty of Science, Jeddah"@en,
        "Department of Botany, Faculty of Science"@en .

ns242:MGC196 ns0:hasName "Material/Organometallics Laboratory, Department of Chemistry, Atma Ram Sanatan Dharma College"@en,
        "School of Material Chemistry"@en .

ns242:MGS190313 ns0:hasName "Computer Networks and Security Lab, School of Computer Science and Technology"@en,
        "School of Computer Science and Technology"@en .

ns242:MNM180275 ns0:hasName "Department of Home Economics and Ecology, Human Ecology Laboratory"@en,
        "Human Ecology Laboratory, Department of Home Economics and Ecology"@en .

ns242:MNM180278 ns0:hasName "Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease"@en,
        "Department of Pediatrics, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease"@en .

ns242:NHA170034 ns0:hasName "Department of Community Health Sciences, Clinical Nutrition Program, College of Applied Medical Sciences"@en,
        "Department of Human Nutrition and Dietetics"@en .

ns242:NHA180059 ns0:hasName "Aging and Alzheimer’s Institute"@en,
        "Charles Perkins Centre"@en .

ns242:NHA190068 ns0:hasName "Department of Medicine"@en,
        "Jesse Brown VA Medical Center"@en .

ns242:NPM180140 ns0:hasName "Department of Pediatrics"@en,
        "Department of Pediatrics, College of Medicine"@en,
        "The Ohio State University"@en .

ns242:NPM18119 ns0:hasName "Department of Pediatrics, Division of Neonatology"@en,
        "Seattle Children’s Hospital and University of Washington School of Medicine"@en,
        "University of Washington School of Medicine and Seattle Children’s Hospital"@en .

ns242:NPM1814 ns0:hasName "School of Food and Nutritional Sciences"@en .

ns242:NRE182635 ns0:hasName "Ambulatory Center for Dementia"@en,
        "Center for Cognitive Disorders and Dementia – Distretto Socio-Sanitario Catanzaro Lido – ASP Catanzaro"@en,
        "Neurorehabilitation Unit"@en .

ns242:NRE182636 ns0:hasName "Department of Basic Science for Physical Therapy, Faculty of Physical Therapy"@en .

ns242:NRE182641 ns0:hasName "Krannert School of Physical Therapy"@en,
        "University of Indianapolis"@en .

ns242:NRE182665 ns0:hasName "Department of Physical Education"@en,
        "Department of Physical Therapy"@en,
        "Department of Physiotherapy"@en .

ns242:NRE182671 ns0:hasName "Department of Occupational Health, Faculty of Medicine and Health Sciences"@en,
        "Sport Medicine Research Center, Najafabad Branch"@en,
        "Sports Medicine Research CenterNeuroscience InstituteTehran University of Medical Sciences"@en .

ns242:NRE192700 ns0:hasName "Federal University of Bahia (FUBA)"@en .

ns242:NRE192722 ns0:hasName "Department of Medicine ( Royal Melbourne Hospital)"@en,
        "Department of Rehabilitation Medicine"@en,
        "Department of Rehabilitation and Australian Rehabilitation Research Centre"@en .

ns242:NRE192748 ns0:hasName "Department of Rehabilitation Sciences"@en,
        "Department of Rehabilitation Sciences, Faculty of Applied Medical Sciences"@en .

ns242:NRE192752 ns0:hasName "Clinical Stroke Research Unit, Department of Neurology, Rigshospitalet, Faculty of Health Sciences"@en,
        "Faculty of Health Sciences"@en .

ns242:NRE192788 ns0:hasName "Department of Allied Health Sciences, Faculty of Medicine"@en,
        "Institute of Health and Biomedical Innovation"@en,
        "Movement Neuroscience Program, Institute of Health and Biomedical Innovation"@en,
        "Movement Neuroscience, Injury Prevention Program, Institute of Health and Biomedical Innovation"@en,
        "School of Exercise and Nutrition Sciences, Faculty of Health"@en .

ns242:NRE192801 ns0:hasName "Department of Physiotherapy"@en,
        "Department of Rehabilitation and Health Promotion Research, Faculty of Health Science"@en,
        "Department of Research in Rehabilitation and Health Promotion"@en .

ns242:PPR190132 ns0:hasName "Carnegie Mellon University"@en,
        "Clinical Health and Nutrition Centre (CHANCE), School of Science"@en .

ns242:RNN190910 ns0:hasName "Department of Anatomy & Neurobiology"@en,
        "Department of Neurology"@en .

ns242:THC191715 ns0:hasName "Department of Emergency Medicine"@en,
        "Department of Emergency Medicine, School of Medicine"@en .

ns242:THC191731 ns0:hasName "Division of Computer Science and Engineering"@en .

ns242:THC199002 ns0:hasName "Department of Biomedical Engineering, School of Medicine"@en .

ns242:THC199007 ns0:hasName "Department of Electric and Electronics Engineering, Faculty of Technology"@en,
        "Department of Electrical and Electronics Engineering, Faculty of Technology"@en .

ns242:THC199034 ns0:hasName "Beijing University of Chemical Technology"@en,
        "College of Information Science and Technology"@en,
        "Department of Computer"@en,
        "Information Center"@en .

ns242:THC199039 ns0:hasName "Department of Electronic Engineering"@en,
        "Institute of Biomedical Engineering Research"@en .

ns242:WOR192918 ns0:hasName "Army Research Laboratory"@en,
        "U.S. Army Research Laboratory"@en .

ns242:WOR192925 ns0:hasName "Patanjali Research Foundation"@en .

ns242:WOR192938 ns0:hasName "Department of Physical Therapy"@en,
        "School of Health and Rehabilitation Sciences"@en .

ns242:WOR192950 ns0:hasName "The University of Sydney"@en .

ns242:WOR192955 ns0:hasName "Department of Kinesiology"@en .

ns242:WOR192961 ns0:hasName "University of Portsmouth"@en .

ns242:WOR192968 ns0:hasName "School of Health and Rehabilitation Sciences"@en .

ns242:WOR192971 ns0:hasName "Faculty of Physical Therapy"@en .

ns242:WOR192976 ns0:hasName "Department of Neurobiology, Care Sciences and Society (NVS), Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Luleå University of Technology"@en,
        "School of Natural Sciences and Health"@en .

ns242:WOR192987 ns0:hasName "University of Zadar"@en .

ns242:WOR192997 ns0:hasName "University of the Western Cape"@en,
        "University of the Western Cape South Africa"@en .

ns242:WOR193009 ns0:hasName "University of the Western Cape"@en,
        "University of the Western Cape South Africa"@en,
        "University ofthe Western Cape"@en .

ns242:WOR193011 ns0:hasName "Department of Health Sciences/Mental Health and Mental Health Services Research, Medical Faculty"@en,
        "Department of Health Sciences/Mental Health, Activity and Participation, Medical Faculty"@en,
        "Lund University"@en .

ns242:WOR193013 ns0:hasName "Department of Psychology"@en,
        "Stockholm University"@en .

ns242:WOR193015 ns0:hasName "Department of Biomechanics, College of Physical Therapy"@en,
        "Department of Biomechanics, Faculty of Physical Therapy"@en .

ns242:XST180460 ns0:hasName "Department of Medical Imaging"@en,
        "Department of Radiology"@en .

ns242:XST180465 ns0:hasName "Department of Radiology"@en,
        "Department of Radiology, Affiliated Hospital of Jiangnan University"@en .

ns242:XST180466 ns0:hasName "The Sixth Affiliated Hospital of Sun Yat-sen University"@en,
        "the Sixth Affiliated Hospital of Sun Yat-sen University"@en .

ns242:XST190507 ns0:hasName "Department of Endoscope"@en,
        "Department of Urology"@en .

ns242:XST190523 ns0:hasName "Département de physique, de génie physique et d’optique"@en,
        "Laboratoire de recherche en imagerie et orthopédie"@en .

ns242:XST190541 ns0:hasName "Department of Radiology"@en .

ns242:ajw190043 ns0:hasName "Department of Nature Arrangement, Building and Hydraulics, Federal State Budgetary Educational Establishment of Higher Education"@en,
        "Federal State Budgetary Educational Establishment of Higher Education"@en .

ns242:ajw190048 ns0:hasName "Department of Environmental Sciences"@en,
        "Jahangirnagar University"@en .

ns242:ajw190054 ns0:hasName "School of Environment, College of Engineering"@en,
        "University of Tehran"@en .

ns242:red160101 ns0:hasName "Aditya Bioinnovation Private Limited"@en,
        "Indian Institute of Technology Hyderabad"@en .

ns242:wdl12104 ns0:hasName "Research Scholar"@en .

ns24:BD180341 ns0:hasName "Institute of Pathology, Forensic Medicine and Cytology"@en,
        "University Hospital Centre Split"@en .

ns24:BD190393 ns0:hasName "Department of Pathology"@en,
        "ESIC Medical College & Hospital"@en,
        "Hamdard Institute of Medical Sciences and Research"@en .

ns24:BLC190221 ns0:hasName "Department of Urology"@en,
        "University of Texas Southwestern Medical Center at Dallas"@en .

ns24:BME191064 ns0:hasName "Biomedical Engineering Department, Division of Biomechanics"@en,
        "Sahand University of Technology"@en .

ns24:BMR171041 ns0:hasName "Department of Orthotics and Prosthetics, School of Rehabilitation Sciences"@en .

ns24:BMR181228 ns0:hasName "Department of Physical Therapy"@en .

ns24:BRS190143 ns0:hasName "Department of Civil Construction and Environmental Engineering"@en,
        "University of Alabama at Birmingham"@en .

ns24:BRS190154 ns0:hasName "University of Florida"@en .

ns24:CBM182075 ns0:hasName "Department of Neurology"@en,
        "Department of Orthopedic Surgery"@en .

ns24:CBM182143 ns0:hasName "Department of Urology"@en .

ns24:CH180531 ns0:hasName "Department of Ultrasound, Zhongshan Hospital"@en,
        "Institute of Neurology"@en,
        "North China Electric Power University"@en .

ns24:CH180545 ns0:hasName "The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine"@en .

ns24:CH199005 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns24:CH199202 ns0:hasName "Department of Radiology"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich – Grosshadern Campus"@en,
        "Ludwig-Maximilians-University Munich"@en,
        "Ludwig-Maximilians-University Munich - Grosshadern Campus"@en .

ns24:CH199206 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry"@en .

ns24:CH199210 ns0:hasName "Faculty of Science"@en,
        "Institute of Biotechnology"@en,
        "Institute of Immunology"@en .

ns24:CH199214 ns0:hasName "University Medical Center Mainz"@en,
        "Zentrum für Kardiologie, Kardiologie I, Universitätsmedizin Mainz"@en .

ns24:CH199221 ns0:hasName "Department of Radiology"@en,
        "Institute of Radiology"@en,
        "University Hospital Regensburg"@en,
        "University Medical Center Regensburg"@en .

ns24:CH199222 ns0:hasName "Department of Urology"@en,
        "Department of Urology, University Hospital Grosshadern"@en .

ns24:CH199224 ns0:hasName "Departement of Radiology"@en,
        "Department of Radiology"@en,
        "Department of Radiology and Interdisciplinary Ultrasound"@en,
        "Institute of Radiology"@en,
        "University Hospital Regensburg"@en .

ns24:CH199225 ns0:hasName "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Reconstructive and Hand Surgery"@en,
        "Reconstructive and Hand Surgery at the University Medical Center Regensburg"@en .

ns24:FI1870 ns0:hasName "CSAI research center, Department of Informatics, Systems and Communication"@en,
        "Complex Systems and Artificial Intelligence Research Centre"@en .

ns24:FI1874 ns0:hasName "Dipartimento di Matematica e Informatica"@en,
        "Universitá di Palermo"@en .

ns24:FI1878 ns0:hasName "Dipartimento di Informatica, Sistemistica e Comunicazione"@en,
        "Università degli Studi di Milano-Bicocca"@en .

ns24:FI1881 ns0:hasName "Department of Mathematics"@en,
        "University of Turku"@en .

ns24:HAB190364 ns0:hasName "Department of Disasters and Emergency Health, School of Public Health"@en,
        "Department of Health in Emergencies and Disasters, School of Public Health"@en .

ns24:HAB190384 ns0:hasName "Department of Medical Genetics"@en,
        "GenIran Lab"@en,
        "Shahid Beheshti University of Medical Sciences"@en,
        "Urogenital Stem Cell Research Center"@en .

ns24:HAB190386 ns0:hasName "Department of Haematology"@en,
        "Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science"@en,
        "Department of Haematology, School of Medical Laboratory Science"@en .

ns24:HSM180397 ns0:hasName "Beijing University of Posts and Telecommunications"@en,
        "School of Economic and Management"@en,
        "School of Economics and Management"@en .

ns24:HSM180410 ns0:hasName "Beijing Institute of Technology"@en,
        "School of Management and Economics"@en .

ns24:HSM180472 ns0:hasName "School of Economics and Management"@en .

ns24:HSM190517 ns0:hasName "School of Economics and Management"@en .

ns24:HSM190548 ns0:hasName "Harbin Institute of Technology"@en .

ns24:IA180016 ns0:hasName "Department of Computer Science"@en,
        "Dipartimento di Informatica"@en,
        "Università di Torino"@en .

ns24:IDA184183 ns0:hasName "Anhui Provincial Key Laboratory of Network and Information Security"@en,
        "School of Computer and Information"@en,
        "School of Geography and Tourism"@en .

ns24:IDA184238 ns0:hasName "Department of Data Science and Knowledge Engineering"@en,
        "Department of Knowledge Engineering"@en,
        "Faculty of Arts and Social Sciences"@en,
        "Maastricht University"@en,
        "School of Computer Engineering"@en .

ns24:IDA192786 ns0:hasName "Graduate School"@en,
        "School of Management and Economics"@en .

ns24:IES192167 ns0:hasName "Graduate School of Biomedical and Health Sciences"@en .

ns24:IFS171927 ns0:hasName "Department of Computer"@en,
        "Department of Computer Engineering, Sari Branch"@en .

ns24:IFS172129 ns0:hasName "Beijing Key Laboratory on MCAACI"@en,
        "Beijing Key Laboratory on MCAACI, School of Mathematics and Statistics"@en,
        "School of Mathematics and Statistics"@en .

ns24:IFS172286 ns0:hasName "College of Mathematics and Econometrics"@en .

ns24:IFS179062 ns0:hasName "College of Foreign Languages and Literature"@en .

ns24:IFS179118 ns0:hasName "Shandong Key Laboratory of Civil Engineering Disaster Prevention and Mitigation"@en .

ns24:IFS179233 ns0:hasName "Central South University"@en,
        "Department of General Medicine"@en,
        "Hunan University"@en .

ns24:IFS179235 ns0:hasName "Sichuan Normal University"@en .

ns24:IFS179252 ns0:hasName "Multimedia University"@en .

ns24:IFS179262 ns0:hasName "School of Business"@en .

ns24:IFS179295 ns0:hasName "Computer Science and Software Engineering Institute"@en,
        "National Research Center of Trustworthy Embedded Software"@en .

ns24:IFS18071 ns0:hasName "Department of Computer Science"@en,
        "South Asian University"@en .

ns24:IFS18106 ns0:hasName "University of Semnan"@en .

ns24:IFS181133 ns0:hasName "School of Economics and Management"@en,
        "School of Management"@en .

ns24:IFS181322 ns0:hasName "Department of Industrial Engineering"@en,
        "Istanbul Technical University"@en .

ns24:IFS181339 ns0:hasName "School of Artificial Intelligence"@en .

ns24:IFS181408 ns0:hasName "Shanghai University"@en .

ns24:IFS181415 ns0:hasName "Department of Mathematics"@en,
        "Firat University"@en,
        "Fırat University"@en .

ns24:IFS181425 ns0:hasName "School of Economics and Management"@en .

ns24:IFS181478 ns0:hasName "COMSATS University Islamabad"@en,
        "Department of Mathematics"@en .

ns24:IFS181527 ns0:hasName "School of Mathematics"@en .

ns24:IFS181547 ns0:hasName "School of Mathematics"@en .

ns24:IFS181586 ns0:hasName "Department of Computer Science"@en,
        "Department of Computer ScienceCollege of Computer and Information Sciences King Saud University"@en .

ns24:IFS181663 ns0:hasName "College of Mathematics and Econometrics"@en .

ns24:IFS181799 ns0:hasName "ATS Lab, Aeronautics and Astronautics Engineering College"@en,
        "Air Force Engineering University"@en .

ns24:IFS181934 ns0:hasName "Universidad de las Américas Puebla"@en,
        "Université du Québec à Trois-Rivières"@en .

ns24:IFS181941 ns0:hasName "Deparment of Mathematics"@en,
        "Department of Mathematics"@en .

ns24:IFS181966 ns0:hasName "Departamento de Eletrônica Aplicada"@en,
        "Technological Institute of Aeronautics - ITA"@en .

ns24:IFS181970 ns0:hasName "College of Management Science and Engineering"@en .

ns24:IFS181990 ns0:hasName "Amirkabir University of Technology"@en,
        "Department of Electrical Engineering"@en .

ns24:IFS181997 ns0:hasName "Business School"@en,
        "University of Shanghai for Science and Technology"@en .

ns24:IFS182572 ns0:hasName "Department of Mathematics"@en .

ns24:IFS182595 ns0:hasName "Department of Mathematics"@en,
        "Department of Mathematics and Statistics"@en .

ns24:IFS182616 ns0:hasName "Department of Mathematics"@en .

ns24:IFS182651 ns0:hasName "Department of Industrial Engineering"@en,
        "Industrial Engineering Department"@en .

ns24:IFS182654 ns0:hasName "College of Mathematics"@en,
        "School of Mathematics"@en,
        "Southwest Jiaotong University"@en .

ns24:IFS18266 ns0:hasName "School of Business"@en,
        "Sichuan Normal University"@en .

ns24:IFS182681 ns0:hasName "College of Mathematics and Statistics"@en .

ns24:IFS182709 ns0:hasName "Bozok University"@en,
        "Department of Mathematics"@en,
        "Department of Mathematics, Faculty of Science and Arts"@en,
        "Yozgat Bozok University"@en .

ns24:IFS182725 ns0:hasName "School of Mathematics and Statistics"@en,
        "School of Mathematics and StatisticsBeijing Institute of Technology"@en .

ns24:IFS182775 ns0:hasName "Centre for Mathematics and Statistical Sciences"@en,
        "Lahore School of Economics"@en .

ns24:IFS182780 ns0:hasName "Department of Mathematics"@en,
        "University of Management and Technology"@en .

ns24:IFS182809 ns0:hasName "University of the Punjab"@en .

ns24:IFS182828 ns0:hasName "Beijing Institute of Technology"@en .

ns24:IFS182860 ns0:hasName "Department of Mathematics"@en,
        "Northwest University"@en .

ns24:IFS182873 ns0:hasName "Aligarh Muslim University"@en,
        "Department of Mathematics"@en .

ns24:IFS182877 ns0:hasName "College of Mathematical and System Sciences"@en,
        "School of Information Science and Engineering"@en,
        "Xinjiang University"@en .

ns24:IFS182926 ns0:hasName "University of Sfax"@en .

ns24:IFS182928 ns0:hasName "Department of Mathematics"@en .

ns24:IFS182934 ns0:hasName "School of Economics and Management"@en .

ns24:IFS182953 ns0:hasName "Alzahra University"@en,
        "Department of Mathematics, Central Tehran Branch"@en,
        "Islamic Azad University"@en .

ns24:IFS18755 ns0:hasName "Hebei University"@en .

ns24:IFS18760 ns0:hasName "Department of Computer Science"@en .

ns24:IFS18824 ns0:hasName "Department of Applied Mathematics with Oceanology and Computer Programming"@en,
        "Department of Applied Mathematics with Oceanology and ComputerProgramming"@en,
        "Vidyasagar University"@en .

ns24:IFS190054 ns0:hasName "Department of Mathematics"@en .

ns24:IFS190126 ns0:hasName "COMSATS University"@en,
        "Department of Mathematics"@en .

ns24:IFS190128 ns0:hasName "Advanced Manufacturing Institute"@en,
        "Industrial Engineering Department, College of Engineering"@en,
        "King Saud University"@en,
        "Princess Fatima Alnijiris's Research Chair for Advanced Manufacturing Technology"@en .

ns24:IFS190137 ns0:hasName "Department of Mathematics"@en,
        "Quaid-i-Azam University"@en .

ns24:IFS190213 ns0:hasName "Hubei University of Technology"@en,
        "School of Management"@en .

ns24:IFS190217 ns0:hasName "Department of Mathematics"@en,
        "National Institute of Technology Calicut"@en .

ns24:IFS190280 ns0:hasName "Beijing Institute of Technology"@en .

ns24:IFS190325 ns0:hasName "Department of Mathematics and Statistics"@en,
        "Riphah International University"@en .

ns24:IFS190408 ns0:hasName "Department of Mathematics, Science and Research Branch"@en .

ns24:IFS190595 ns0:hasName "Tongji University"@en .

ns24:IFS190668 ns0:hasName "Department of Mathematics"@en,
        "University of the Punjab"@en .

ns24:IFS190683 ns0:hasName "College of Electrical Engineering"@en,
        "College of Electrical Engineering and Information Technology"@en .

ns24:IFS190863 ns0:hasName "Business School"@en,
        "University of Shanghai for Science and Technology"@en .

ns24:JAD170300 ns0:hasName "Department of Epidemiology"@en,
        "Department of Epidemiology, Joseph P. Mailman School of Public Health"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, College of Physicians and Surgeons"@en,
        "Department of Psychology"@en,
        "Departments of Epidemiology and Psychiatry"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky Center, College of Physicians & Surgeons"@en,
        "Gertrude H. Sergievsky Center, College of Physicians and Surgeons"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en,
        "The Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en .

ns24:JAD180496 ns0:hasName "Department of Biochemistry"@en,
        "Department of Biochemistry, Faculty of Medicine"@en,
        "Department of Biochemistry, Faculty of Medicine, UKMMC"@en .

ns24:JAD180511 ns0:hasName "Department of Biochemistry"@en,
        "Department of Biochemistry, Faculty of Medicine"@en,
        "Department of Biochemistry, Faculty of Medicine, UKMMC"@en .

ns24:JAD180630 ns0:hasName "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "National Institute of Mental Health"@en .

ns24:JAD180730 ns0:hasName "Department of Psychology"@en .

ns24:JAD180780 ns0:hasName "School of Sport and Exercise Sciences"@en,
        "University of Birmingham"@en .

ns24:JAD180857 ns0:hasName "Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS)"@en,
        "Alzheimer Centre Limburg, School for Mental Health and Neuroscience (MHeNS)"@en,
        "Department of Psychiatry and Neuropsychology"@en,
        "Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en .

ns24:JAD180949 ns0:hasName "Institute of Social Medicine, Occupational Health and Public Health (ISAP)"@en,
        "Institute of Social Medicine, Occupational Health and Public Health, Medical Faculty"@en .

ns24:JAD180962 ns0:hasName "CERVO Brain Research Center"@en,
        "Centre de recherche de l’Institut universitaire en santé mentale de Québec"@en,
        "Department of Psychology"@en,
        "Faculty of Medicine"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute>"@en,
        "LC Campbell Cognitive Neurology Research Unit"@en,
        "Sunnybrook Health Sciences Centre"@en .

ns24:JAD181141 ns0:hasName "Albert Einstein College of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Albert Einstein College of Medicine"@en,
        "Einstein Aging Study"@en,
        "Saul B. Korey Department of Neurology"@en,
        "Saul R. Korey Department of Neurology"@en,
        "The Einstein Aging Study"@en .

ns24:JAD181178 ns0:hasName "Department of Preventive Gerontology"@en,
        "Department of Preventive Gerontology, Center for Gerontology and Social Science"@en,
        "Department of Preventive Gerontology, Section for Health Promotion"@en .

ns24:JAD181196 ns0:hasName "Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry"@en,
        "Gait and Brain Lab, Parkwood Institute"@en .

ns24:JAD181220 ns0:hasName "Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital"@en .

ns24:JAD181227 ns0:hasName "Department of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Medicine"@en .

ns24:JAD181259 ns0:hasName "IRCCS Fondazione Don Carlo Gnocchi"@en,
        "Laboratory of Molecular Medicine and Imaging in Rehabilitation"@en .

ns24:JAD181261 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, National Neuroscience Institute"@en .

ns24:JAD181265 ns0:hasName "Department of Public Health and Caring Sciences, Geriatrics"@en,
        "Department of Public Health and Caring Sciences/Geriatrics"@en,
        "Uppsala University"@en .

ns24:JAD181295 ns0:hasName "Department of Clinical Neuroscience"@en,
        "Department of Forensic Psychiatry, Niuvanniemi Hospital"@en,
        "Kuopio Research Centre of Geriatric Care"@en,
        "School of Pharmacy"@en,
        "School of Pharmacy, Faculty of Health Sciences"@en .

ns24:JAD181296 ns0:hasName "Department of Neurology & Institute of Neurology, Ruijin Hospital"@en,
        "Department of Neurology and Neuroscience Institute"@en .

ns24:JAD181298 ns0:hasName "Cognitive Impairment Center"@en .

ns24:JAD190025 ns0:hasName "Alzheimer's Disease Research and Clinical Centre, Department of Geriatric Medicine, Gérontopôle"@en,
        "Gerontopôle, INSERM U 1027"@en,
        "Inserm U 1027"@en .

ns24:JAD190074 ns0:hasName "Department of Neurobiology"@en,
        "Department of Neurobiology, Sagol School of Neuroscience, George S. Wise Faculty of Life Sciences"@en .

ns24:JAD190159 ns0:hasName "Department of Neurology"@en .

ns24:JAD190181 ns0:hasName "Neuroscience Research Australia"@en,
        "School of Psychology"@en .

ns24:JAD190187 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en .

ns24:JAD190230 ns0:hasName "Department of Psychology"@en,
        "University of Southern California"@en .

ns24:JAD190241 ns0:hasName "Cajal Institute (CSIC)"@en,
        "Cajal Institute and Ciberned"@en .

ns24:JAD190262 ns0:hasName "Department of Neurology"@en,
        "Einstein Aging Study"@en,
        "Saul B. Korey Department of Neurology"@en .

ns24:JAD190293 ns0:hasName "Department of Biological Sciences and the Eleanor Roosevelt Institute"@en,
        "Department of Neurology"@en,
        "University of Kansas Alzheimer's Disease Center"@en,
        "University of Kansas Alzheimer’s Disease Center"@en .

ns24:JAD190302 ns0:hasName "Cleveland Clinic Lou Ruvo Center for Brain Health"@en .

ns24:JAD190319 ns0:hasName "Aged Care Services"@en,
        "Department of Aged Care"@en,
        "Department of Medicine"@en,
        "Department of Medicine, Peninsula Clinical School, Central Clinical School"@en,
        "Department of Medicine, Peninsula Health, Peninsula Clinical School"@en,
        "Neurosciences"@en,
        "Stroke and Ageing Research Group, Vascular Brain Ageing Division, Department of Medicine, School of Clinical Sciences"@en .

ns24:JAD190322 ns0:hasName "Alzheimer’s Therapeutic Research Institute"@en,
        "Department of Family Preventive Medicine"@en,
        "Department of Neurosciences"@en .

ns24:JAD190334 ns0:hasName "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en .

ns24:JAD190368 ns0:hasName "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-Innovation Center of Neuroregeneration"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-innovation Center of Neuroregeneration"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co-innovation Center of Neuroregeneration"@en .

ns24:JAD190369 ns0:hasName "Okayama University"@en,
        "Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science"@en .

ns24:JAD190394 ns0:hasName "Department of Neuroscience, Biomedicine, and Movement Sciences"@en,
        "Department of Neurosciences, Biomedicine and Movement Sciences"@en,
        "Section of Clinical Neurology, Department of Neurological and Movement Sciences"@en .

ns24:JAD190399 ns0:hasName "Department of Neuropsychiatry"@en .

ns24:JAD190413 ns0:hasName "Danish Dementia Research Centre, Department of Neurology, Rigshospitalet"@en,
        "Laboratory of Neurobiology, Biomedicine Group, Department of Health Science and Technology"@en .

ns24:JAD190414 ns0:hasName "Dementia Clinics, Faculty of Medicine"@en,
        "Faculty of Medicine"@en .

ns24:JAD190423 ns0:hasName "Information Technologies Institute"@en .

ns24:JAD190427 ns0:hasName "Bordeaux CHU"@en,
        "INSERM"@en,
        "INSERM Center 897 & CIC-1401-EC"@en,
        "INSERM U708"@en,
        "Inserm"@en,
        "The UPMC University Paris 06"@en,
        "Univ Pierre et Marie Curie-Paris6"@en,
        "Université Pierre et Marie Curie-Paris6"@en,
        "Université de Bordeaux, Inserm"@en .

ns24:JAD190480 ns0:hasName "Department of Medicine, Section of Gerontologyand Geriatrics"@en,
        "Institute of Gerontology and Geriatrics, Department of Medicine"@en .

ns24:JAD190485 ns0:hasName "Department of Clinical Sciences Lund, Division of Oncology and Pathology"@en,
        "Lund UniversityLab Medicine"@en .

ns24:JAD190487 ns0:hasName "Center for Cognitive Disorders"@en .

ns24:JAD190517 ns0:hasName "Department of Neurology"@en .

ns24:JAD190527 ns0:hasName "Brain Center Rudolf Magnus, Department of Neurology"@en,
        "Department of Epidemiology"@en,
        "Department of Neurology"@en,
        "Department of Ophthalmology, Yong Loo Lin School of Medicine"@en,
        "Department of Radiology"@en,
        "Department of Radiology and Nuclear Medicine"@en,
        "Departments of Epidemiology, Radiology, Neurology"@en,
        "Departments of Neurology and Epidemiology"@en,
        "Duke-NUS Graduate Medical School"@en,
        "Memory Aging and Cognition Centre"@en,
        "Office of Clinical Sciences"@en,
        "Singapore Eye Research Institute"@en .

ns24:JAD190635 ns0:hasName "Department of Neurology, Laboratory for Dementia and Parkinsonism, National Parkinson’s Foundation Center for Excellence"@en,
        "Georgetown University Medical Center"@en .

ns24:JAD190638 ns0:hasName "Laboratory of Neurodegenerative Diseases, Center for Interdisciplinary Research and Innovation (CIRI – AUTH) Balkan Center, Buildings A & B"@en,
        "Laboratory of Psychology, School of Psychology"@en,
        "Laboratoty of Psychology, Department of Experimental and Cognitive Psychology, School of Psychology"@en .

ns24:JAD190660 ns0:hasName "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en,
        "Service of Neurology"@en .

ns24:JAD190691 ns0:hasName "Turku PET Centre"@en,
        "Turku PET Centre, University of Turku"@en .

ns24:JAD190771 ns0:hasName "Department of Drug Sciences, Pharmacology Section"@en,
        "Department of Drug Sciences, Pharmacology Unit, Center of Excellence in Applied Biology"@en,
        "Department of Experimental and Applied Pharmacology, Centre of Excellence in Applied Biology"@en .

ns24:JAD190775 ns0:hasName "Department of Human Health Sciences"@en,
        "Department of Neurology"@en .

ns24:JAE180067 ns0:hasName "Arts et Metiers ParisTechUniversité Lille"@en,
        "L2EP/Université Lille1"@en,
        "Université de Lille"@en .

ns24:JAE180089 ns0:hasName "College of Electronics and InformationHangzhou Dianzi University"@en,
        "Hangzhou Dianzi University"@en .

ns24:JAE180100 ns0:hasName "Nanjing University of Information Science and Technology"@en .

ns24:JAE180133 ns0:hasName "Hefei University of Technology"@en,
        "School of Electrical Engineering and Automation"@en .

ns24:JAE191148 ns0:hasName "Department of Electrical Engineering"@en,
        "Department of Electrical EngineeringDoshisha University"@en,
        "Doshisha University"@en .

ns24:JAE191149 ns0:hasName "Department of Electrical Engineering"@en,
        "Department of Electrical EngineeringDoshisha University"@en,
        "Doshisha University"@en .

ns24:JAE191283 ns0:hasName "Department of Electrical Engineering"@en,
        "Department of Electrical EngineeringDoshisha University"@en,
        "Doshisha University"@en .

ns24:JAE198976 ns0:hasName "Department of Electrical EngineeringUniversity Politehnica of Bucharest"@en .

ns24:JBR180345 ns0:hasName "Department of Agricultural, Food and Environmental Sciences"@en,
        "University College London"@en .

ns24:JBR180368 ns0:hasName "Departamento de Ingeniería en Alimentos"@en,
        "Department of Functional Biology"@en,
        "Instituto Universitario Fernández-Vega"@en .

ns24:JHD190364 ns0:hasName "Department of Physical Medicine and Rehabilitation"@en,
        "The University of Michigan"@en .

ns24:JHD190366 ns0:hasName "Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration"@en,
        "Department of Experimental Neurodegeneration, Center for Biostructural Imaging of Neurodegeneration, Center for Nanoscale Microscopy and Molecular Physiology of the Brain"@en .

ns24:JND190416 ns0:hasName "Department of Neurology, Friedrich-Baur-Institute"@en,
        "Friedrich-Baur-Institute, Department of Neurology"@en .

ns24:JPD181568 ns0:hasName "Department of Neurology"@en .

ns24:JPD191802 ns0:hasName "Department of Neurology, Parkinson Expertise Center, University Medical Center Groningen"@en,
        "Department of Neurology, University Medical Center Groningen"@en .

ns24:JVR191033 ns0:hasName "University of Maryland at College Park"@en .

ns24:JVR191035 ns0:hasName "University of Arkansas"@en .

ns24:JVR191036 ns0:hasName "University of Wisconsin-Stout"@en,
        "University of Wisconsin-Stout Vocational Rehabilitation Institute"@en .

ns24:JVR191037 ns0:hasName "Cornell University"@en,
        "University of Pennsylvania"@en .

ns24:JVR191038 ns0:hasName "Department of Family and Consumer Studies"@en,
        "University of Utah"@en .

ns24:JVR191041 ns0:hasName "University of Maryland at College Park"@en,
        "University of MarylandCollege Park"@en .

ns24:JVR191042 ns0:hasName "University of Maryland at College Park"@en,
        "University of MarylandCollege Park"@en .

ns24:JVR191044 ns0:hasName "Cornell University"@en .

ns24:JVR191049 ns0:hasName "Department of Health Sciences/Mental Health and Mental Health Services Research"@en,
        "Department of Health Sciences/Mental Health and Mental Health Services Research, Medical Faculty"@en,
        "Department of Health Sciences/Mental Health, Activity and Participation, Medical Faculty"@en,
        "Lund University"@en .

ns24:JVR191050 ns0:hasName "Institute on Disability"@en,
        "University of New Hampshire"@en .

ns24:KCA190056 ns0:hasName "City of Hope Comprehensive Cancer Center"@en .

ns24:MGC180760 ns0:hasName "Xizang University for Nationalities"@en .

ns24:MGC180761 ns0:hasName "Department of Chemistry"@en,
        "University of Patras"@en .

ns24:MGC190801 ns0:hasName "Department of Chemical Engineering, Faculty of Chemical and Metallurgical Engineering"@en,
        "Yildiz Technical University"@en .

ns24:MGC193 ns0:hasName "Department of Biological Science, Faculty of Science"@en,
        "Department of Botany, Faculty of Science"@en .

ns24:MGS190307 ns0:hasName "Computer Science Department"@en,
        "Department of Mathematics and Computer Science"@en,
        "Department of Mathematics and Computer Science, Rela(CS)2 Laboratory"@en,
        "RelaCS2 Laboratory"@en .

ns24:MGS190313 ns0:hasName "Computer Networks and Security Lab, School of Computer Science and Technology"@en,
        "School of Computer Science and Technology"@en .

ns24:MNM180250 ns0:hasName "Department of Nutrition and Dietetics, School of Health Science & Education"@en,
        "Department of Nutrition and Dietetics, School of Health Science and Education"@en .

ns24:MNM180265 ns0:hasName "Department of Nutrition, School of Public Health"@en,
        "Yazd Diabetic Research Center"@en .

ns24:NPM180140 ns0:hasName "Department of Pediatrics"@en,
        "The Ohio State University"@en .

ns24:NPM1814 ns0:hasName "School of Food and Nutritional Sciences"@en .

ns24:NRE182634 ns0:hasName "Department of Physiotherapy and Rehabilitation, Faculty of Health Sciences"@en,
        "Eastern Mediterranean University"@en .

ns24:NRE182637 ns0:hasName "Department of Neurosciences"@en,
        "Department of Systems Medicine"@en .

ns24:NRE182641 ns0:hasName "College of Health Science and School of Nursing"@en,
        "University of Indianapolis"@en .

ns24:NRE192701 ns0:hasName "Department of Rehabilitation Medicine, Division of Physical Therapy"@en,
        "Department of Rehabilitation Medicine, Division of Physical Therapy, School of Medicine"@en,
        "Division of Physical Therapy, Department of Rehabilitation Medicine"@en .

ns24:NRE192723 ns0:hasName "Institute of Sport Sciences and Physiotherapy"@en,
        "University of Tartu"@en .

ns24:RNN190927 ns0:hasName "Department of Rehabilitation Sciences"@en,
        "The Hong Kong Polytechnic University"@en .

ns24:TAD190225 ns0:hasName "Department of Human and Engineered Environment Studies, Graduate School of Frontier Sciences"@en,
        "Department of Mechanical Engineering"@en,
        "Department of Psychiatry"@en .

ns24:THC199029 ns0:hasName "Department of Cardiology"@en .

ns24:WOR192923 ns0:hasName "ALGORITMI Research Centre, School of Engineering"@en,
        "R&D Centro Algoritmi, Engineering School"@en .

ns24:WOR192947 ns0:hasName "Department of Kinesiology"@en,
        "Toronto Rehabilitation Institute"@en .

ns24:WOR192958 ns0:hasName "Military Performance Division"@en,
        "U.S. Army Research Institute of Environmental Medicine"@en .

ns24:WOR192962 ns0:hasName "University of Portsmouth"@en .

ns24:WOR192966 ns0:hasName "Finnish Institute of Occupational Health"@en,
        "University of Oulu"@en .

ns24:WOR192975 ns0:hasName "Department of Health Sciences and Health Policy"@en,
        "Swiss Paraplegic Research"@en .

ns24:WOR193005 ns0:hasName "Department of Industrial Engineering"@en,
        "Seoul National University"@en .

ns24:WOR193013 ns0:hasName "Department of Psychology"@en,
        "Stockholm University"@en .

ns24:WOR193018 ns0:hasName "The University of Sydney"@en .

ns24:XST180466 ns0:hasName "The Sixth Affiliated Hospital of Sun Yat-sen University"@en,
        "the Sixth Affiliated Hospital of Sun Yat-sen University"@en .

ns24:XST180487 ns0:hasName "Nanjing Medical University Affiliated Wuxi Second Hospital"@en,
        "Nanjing Medical University Affiliated Wuxi the Second Hospital"@en .

ns24:XST190503 ns0:hasName "Department of Mechanical Engineering"@en,
        "Department of Mechanical Engineering National Taipei University of Technology"@en .

ns24:XST190514 ns0:hasName "Imaging Science Research Center"@en,
        "Imaging Science-based Lung and Bone Disease Research Center"@en,
        "Medical Convergence Research CenterWonkwang University"@en .

ns24:XST190526 ns0:hasName "School of Life Science and Technology"@en,
        "School of Medical Instrument and Food Engineering"@en .

ns24:XST190533 ns0:hasName "Department of Biomedical Engineering, College of Materials Science and Engineering"@en .

ns24:jid190002 ns0:hasName "CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics"@en,
        "Graduate University"@en,
        "Harbin Institute of Technology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:CH199208> ns0:hasName "Helmholtz-Zentrum Dresden-Rossendorf"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:CH199219> ns0:hasName "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behavior"@en,
        "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD181217> ns0:hasName "Department of Neurology, Beijing Tiantan Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD181259> ns0:hasName "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation University of Milano"@en,
        "Department of Physiopathology and Transplantation"@en,
        "Don C. Gnocchi Foundation IRCCS"@en,
        "Don C. Gnocchi Foundation – ONLUS"@en,
        "IRCCS Fondazione Don Carlo Gnocchi"@en,
        "Laboratory of Molecular Medicine and Imaging in Rehabilitation"@en,
        "University of Milano and IRCCS SM Nascente"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190041> ns0:hasName "Alzheimer Centre and Department of Neurology"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190274> ns0:hasName "Departamento de Fisiología, Facultad de Medicina"@en,
        "Department of Physiology, Faculty of Medicine"@en,
        "Facultad de Medicina"@en,
        "University of Valencia"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190369> ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190414> ns0:hasName "Center for Neuroscience and Cell Biology of Coimbra and Faculty of Medicine"@en,
        "Department of Neurology and Laboratory of Neurosciences, Faculty of Medicine"@en,
        "Faculty of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190454> ns0:hasName "Department of Neurology, Peking Union Medical College Hospital"@en,
        "Department of Radiology, Carver College of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190469> ns0:hasName "Clinical Research Design and Evaluation, SAIHST"@en,
        "Department of Clinical Research Design & Evaluation, SAIHST"@en,
        "Department of Clinical Research Design and Evaluation, SAIHST"@en,
        "Department of Health Sciences and Technology, SAIHST"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Neuto Science Center"@en,
        "Samsung Medical Center, Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190480> ns0:hasName "Department of Geriatrics"@en,
        "Institute of Geriatrics and Gerontology"@en,
        "Institute of Gerontology and Geriatrics"@en,
        "Institute of Gerontology and Geriatrics, Department of Medicine"@en,
        "Policlinico Monteluce-Padiglione E"@en,
        "Sezione di Gerontologia e Geriatria, Dipartimento di Medicina Clinica e Sperimentale"@en,
        "University of Perugia"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JAD190644> ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JHD190346> ns0:hasName "Department of Psychology"@en,
        "San Diego State University-University of California"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JHD190355> ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Perelman School of Medicine"@en,
        "Raymond G. Perelman Center for Cellular & Molecular Therapeutics"@en,
        "Raymond G. Perelman Center for Cellular and Molecular Therapeutics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:JND190416> ns0:hasName "Department of Neurology, Friedrich-Baur-Institute"@en,
        "Friedrich-Baur-Institute, Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:10.ID:XST190506> ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns114:JAD190010 ns0:hasName "Center for Computational Biology and Bioinformatics"@en,
        "Center for Neuroimaging, Department of Radiology and Imaging Sciences"@en,
        "Department of Medical and Molecular Genetics"@en,
        "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Department of Radiology and Imaging Sciences and the Indiana Alzheimer’s Disease Center"@en,
        "Department of Radiology and Imaging Sciences, Center for Neuroimaging"@en,
        "Indiana Alzheimer Disease Center"@en,
        "Indiana University Network Science Institute"@en,
        "Medical and Molecular Genetics"@en,
        "Program in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute"@en .

ns114:JAD190133 ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC)"@en,
        "Aging Research Center (ARC), Department of NVS"@en,
        "Aging Research Center (ARC), Department of Neurobiology"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer Disease Research Center"@en,
        "Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Department of Geriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, KI- Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "National Institute for Health and Welfare"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health"@en,
        "Public Health Promotion Unit"@en,
        "Stockholms Sjukhem"@en .

ns114:JAD190274 ns0:hasName "Departamento de Fisiología, Facultad de Medicina"@en,
        "Department of Physiology, Faculty of Medicine"@en,
        "Facultad de Medicina"@en .

ns114:JAD190369 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en,
        "Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science"@en .

ns114:JAD190469 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en .

ns114:JAD190644 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en,
        "Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science"@en .

ns114:JND190414 ns0:hasName "National Institute of Neurological Disorders and Stroke/NIH"@en,
        "Neuromuscular and Neurogenetic Disorders of Childhood Section"@en .

ns114:JPD181568 ns0:hasName "Department of Neurology"@en .

ns114:JPD191672 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Division of Neurodegenerative Diseases"@en,
        "Division of Neurodegenerative Diseases, Department of Neurology"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Centre for Neurodegenerative Disease (DZNE)"@en .

ns114:XST190500 ns0:hasName "Collaborative Innovation Center for Brain Science"@en,
        "ICT NDT Engineering Research Center, Ministry of Education"@en,
        "The Key Lab of Optoelectronic Technology and Systems of the Education Ministry of China"@en .

ns114:XST190506 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190087> ns0:hasName "Faculty of Clinical Engineering, School of Health Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190133> ns0:hasName "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, NVS"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "Public Health Promotion Unit"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190346> ns0:hasName "Department of Neurology, Massachusetts General Hospital Stroke Research Center"@en,
        "J. Philip Kistler Stroke Research Center, Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190369> ns0:hasName "Okayama University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190660> ns0:hasName "Neurology Service and CIBERNED"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JAD190691> ns0:hasName "Clinical Neurology, Turku PET Centre"@en,
        "Clinical Neurosciences, Department of Neurosurgery"@en,
        "Department of Neurology"@en,
        "Division of Clinical Neurosciences"@en,
        "Turku PET Centre"@en,
        "Turku PET Centre and Division of Clinical Neurosciences"@en,
        "Turku PET Centre, University of Turku"@en,
        "Turku PET-Centre"@en,
        "Turku University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:12.ID:JPD181568> ns0:hasName "Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190019> ns0:hasName "Department of Medicine"@en,
        "Institute for Minority Health Research, College of Medicine at Chicago"@en,
        "University of Illinois at Chicago"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190132> ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine –Neurology, University of Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "NeuroCenter, Neurology"@en,
        "Neurology of NeuroCenter"@en,
        "Unit of Neurology"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190369> ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Graduate School of Medicine, Dentistry and Pharmacological Sciences"@en,
        "Okayama University"@en,
        "Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190568> ns0:hasName "Department of Medicine"@en,
        "Department of Medicine (Gerontology/Geriatrics), Neurology"@en,
        "Department of Medicine, Division of Geriatric Medicine"@en,
        "Department of Neurology"@en,
        "Department of Pathology and Laboratory Medicine"@en,
        "Department of Pharmacology"@en,
        "Genomics and Computational Biology Graduate Group, Perelman School of Medicine"@en,
        "Geriatric Research, Education, and Clinical Center"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC)"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC) VA Puget Sound Health Care System"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC)VA Puget Sound Health Care System"@en,
        "Geriatric Research, Education, and Clinical Centers"@en,
        "Medicine"@en,
        "Neurology"@en,
        "Pathology & Laboratory Medicine"@en,
        "Pharmacology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190660> ns0:hasName "Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED)"@en,
        "Neurology Service"@en,
        "Neurology Service and CIBERNED"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JAD190817> ns0:hasName "Department of Neurology, Graduate School of Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Sapporo Medical University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:13.ID:JND190397> ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Stead Family Children’s Hospital at the University of Iowa"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:14.ID:JAD190113> ns0:hasName "Department of Neurology, Xuanwu Hospital"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:14.ID:JAD190446> ns0:hasName "Department of Psychosomatic Medicine"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Center for Neurodegenerative Diseases (DZNE) –Rostock/Greifswald"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:14.ID:JAD190533> ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation Perth"@en,
        "Centre for Aging and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Clinical Research in Neuropsychiatry, Graylands Hospital"@en,
        "Centre for Neuromuscular and Neurological Disorders"@en,
        "Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care; The Sir James McCurker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre for Ageing and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence in Alzheimer’s Disease Research and Care, School of Medical Sciences"@en,
        "Department of Biomedical Sciences"@en,
        "KARVIAH Research Centre"@en,
        "KaRa Institute of Neurological Disease"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "McCusker Foundation for Alzheimer's Disease Research"@en,
        "McCusker Foundation for Alzheimer's Disease Research Inc"@en,
        "School of Biomedical Science"@en,
        "School of Biomedical Sciences"@en,
        "School of Exercise, Biomedical and Health Sciences"@en,
        "School of Medical Health and Sciences"@en,
        "School of Medical Sciences"@en,
        "School of Medical SciencesEdith Cowan University"@en,
        "School of Medical and Health Sciences"@en,
        "School of Psychiatry & Clinical Neurosciences"@en,
        "School of Psychiatry and Clinical Neuroscience"@en,
        "School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit, School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer’s Disease Research Unit"@en,
        "The CRC for Mental Health"@en,
        "The McCusker Alzheimer’s Research Foundation"@en,
        "The School of Exercise, Biomedical and Health Science"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit, School of Exercise, Biomedical and Health Sciences"@en,
        "The University of British ColumbiaUniversity of Western Australia"@en,
        "The University of Western AustraliaEdith Cowan University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:14.ID:JAD190660> ns0:hasName "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED"@en,
        "Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED)"@en,
        "Department of Neurology"@en,
        "Neurology Service"@en,
        "Neurology Service and CIBERNED"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en,
        "Service of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:15.ID:JAD180847> ns0:hasName "Center for Behavioral Genomics"@en,
        "Department of Psychiatry"@en,
        "University of California"@en,
        "VA Center of Excellence for Stress and Mental Health"@en,
        "Veterans' Administration San Diego Healthcare System"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:15.ID:JAD190098> ns0:hasName "Department of Demyelinating Disease and Aging"@en .

ns46:JAD190023 ns0:hasName "Department of Neurology"@en,
        "Gunma University School of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:17.ID:JAD190132> ns0:hasName "Institute of Clinical Medicine – Neurology, Universityof Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:17.ID:JAD190334> ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC), Department of Neurobiology"@en,
        "Department of Geriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, KI- Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, NVS"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine/Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "Memory Clinic, Department of Geriatrics, Karolinska University Hospital, Huddinge, Sweden; Aging Research Center and Alzheimer Disease Research Center, Karolinska Institute, Sweden; Department of Neurology"@en,
        "Public Health Promotion Unit"@en .

ns133:JAD190334 ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC)"@en,
        "Aging Research Center (ARC), Department of NVS"@en,
        "Aging Research Center (ARC), Department of Neurobiology"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer Disease Research Center"@en,
        "Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Department of Geriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, KI- Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine/Neurology"@en,
        "Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "National Institute for Health and Welfare"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health"@en,
        "Public Health Promotion Unit"@en,
        "Stockholms Sjukhem"@en .

ns134:JAD180949 ns0:hasName "Institute of Social Medicine, Occupational Health and Public Health"@en,
        "Institute of Social Medicine, Occupational Health and Public Health (ISAP)"@en,
        "USC Edward Roybal Institute on Aging"@en .

ns134:JAD190334 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en .

ns15:BLC190236 ns0:hasName "Baylor College of Medicine Medical Center"@en,
        "Department of Urologic Oncology"@en,
        "Professor and Beth and Dave Swalm Chair in Urologic Oncology, Director of Urologic Oncology, Scott Department of Urology"@en,
        "Scott Department of Urology"@en .

ns15:BLC190238 ns0:hasName "Division of Urology"@en .

ns15:BME191067 ns0:hasName "Department of Mechanical Engineering"@en,
        "Department of Mechanical Engineering, College of Engineering"@en,
        "King Khalid University"@en .

ns15:BMR181286 ns0:hasName "Department of Physiotherapy, School of Rehabilitation Sciences"@en .

ns15:BRS190154 ns0:hasName "Materials Science Engineering"@en,
        "University of Florida"@en .

ns15:CBM182111 ns0:hasName "Business school"@en,
        "Department of Pathology, Third Xiangya Hospital"@en,
        "Department of Urology, Huangshi Central Hospital"@en .

ns15:CBM192435 ns0:hasName "Department of General Surgery, Ruijin Hospital"@en .

ns15:CH180450 ns0:hasName "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Hand Surgery University Hospital of Erlangen"@en,
        "Department of Plastic and Hand Surgery and Laboratory for Tissue Engineering and Regenerative Medicine, University Hospital of Erlangen"@en .

ns15:CH180452 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Shanghai Research Center for Thyroid Diseases"@en,
        "Thyroid Institute"@en .

ns15:CH180545 ns0:hasName "The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine"@en .

ns15:CH199007 ns0:hasName "Department of Human Sciences, Society and Health"@en,
        "Human, Social and Health Department"@en .

ns15:CH199202 ns0:hasName "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich – Grosshadern Campus"@en,
        "Ludwig-Maximilians-University Munich - Grosshadern Campus"@en .

ns15:CH199205 ns0:hasName "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en .

ns15:CH199210 ns0:hasName "Brandenburg University of Technology Cottbus-Senftenberg"@en,
        "Institute of Biotechnology"@en .

ns15:CH199219 ns0:hasName "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour"@en,
        "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour and Virtual Center for Replacement – Complementary Methods to Animal Testing"@en .

ns15:CH199220 ns0:hasName "Center for Plastic-, Hand-, and Reconstructive Surgery"@en,
        "Department of Plastic and Hand Surgery"@en,
        "University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery"@en .

ns15:CH199221 ns0:hasName "Department of Radiology"@en,
        "University Hospital Regensburg"@en,
        "University Medical Center Regensburg"@en .

ns15:CH199224 ns0:hasName "Departement of Radiology"@en,
        "Department of Radiology"@en,
        "Institute for Radiology"@en,
        "University Hospital Regensburg"@en,
        "University Medical Center Regensburg"@en .

ns15:FI1833 ns0:hasName "Warsaw University of Technology"@en .

ns15:FI1848 ns0:hasName "Faculty of Mathematics and Computer Science"@en,
        "Institute of Mathematics and Cryptology"@en,
        "Military University of Technology"@en .

ns15:FI1870 ns0:hasName "CSAI research center, Department of Informatics, Systems and Communication"@en,
        "Complex Systems and Artificial Intelligence Research Centre"@en .

ns15:FI1874 ns0:hasName "Dipartimento di Matematica e Informatica"@en,
        "Universitá di Palermo"@en .

ns15:FI1878 ns0:hasName "Department of Informatics"@en,
        "Dipartimento di Informatica, Sistemistica e Comunicazione"@en,
        "Università degli Studi di Milano-Bicocca"@en .

ns15:HAB190373 ns0:hasName "Antibody Laboratory"@en,
        "Biological Sciences Department, Faculty of Science"@en,
        "Therapeutic and Protective Proteins Laboratory, Protein Research Department"@en .

ns15:HSM180472 ns0:hasName "Beijing University of Posts and Telecommunications"@en,
        "School of Economics and Management"@en .

ns15:IA190018 ns0:hasName "University of Roma"@en,
        "University of Roma Tor Vergata"@en .

ns15:ICA190603 ns0:hasName "Department of Systems Engineering, Intelligent Systems Lab"@en,
        "Intelligent Systems Lab Research Group"@en,
        "Systems Engineering and Automation Department, Intelligent Systems Laboratory"@en,
        "Universidad Carlos III de Madrid"@en .

ns15:IDA184238 ns0:hasName "Department of Data Science and Knowledge Engineering"@en,
        "Maastricht University"@en .

ns15:IDA184334 ns0:hasName "Anhui Provincial Key Laboratory of Network and Information Security"@en,
        "College of Geography and Tourism"@en,
        "School of Computer and Information"@en,
        "School of Geography and Tourism"@en .

ns15:IES182206 ns0:hasName "University Outpatient Clinic Potsdam"@en,
        "University Outpatient Clinic, Sports Medicine and Sports Orthopaedics"@en .

ns15:IES192150 ns0:hasName "Graduate School of Biomedical and Health Sciences"@en .

ns15:IFS16913 ns0:hasName "Department of Applied Mathematics"@en,
        "Department of Applied Mathematics with Oceanology and Computer Programming"@en,
        "Department of Mathematics"@en .

ns15:IFS171488 ns0:hasName "Department of Electrical Engineering, Science and Research Branch"@en,
        "Islamic Azad University"@en .

ns15:IFS171587 ns0:hasName "Department of Mathematics"@en .

ns15:IFS179235 ns0:hasName "School of Business"@en,
        "Sichuan Normal University"@en .

ns15:IFS179250 ns0:hasName "Department of Mathematics"@en .

ns15:IFS179302 ns0:hasName "Wuhan Textile University"@en,
        "Wuhan University"@en .

ns15:IFS179305 ns0:hasName "Management School"@en,
        "Shanghai Institute of Medical Imaging"@en .

ns15:IFS179315 ns0:hasName "School of Computer Science and Engineering"@en,
        "School of Computer Science and Technology"@en,
        "School of Mechanical EngineeringGuangxi University of Science and Technology"@en .

ns15:IFS179322 ns0:hasName "Central Software Institute"@en,
        "College of Agricultural Equipment Engineering"@en .

ns15:IFS181322 ns0:hasName "Department of Industrial Engineering"@en,
        "Industrial Engineering Department"@en,
        "Istanbul Technical University"@en .

ns15:IFS181408 ns0:hasName "Shanghai University"@en .

ns15:IFS181415 ns0:hasName "Firat University"@en,
        "Fırat University"@en .

ns15:IFS181452 ns0:hasName "Department of Applied Mathematics with Oceanology and Computer Programming"@en,
        "Department of Applied Mathematics with Oceanology and ComputerProgramming"@en,
        "Vidyasagar University"@en .

ns15:IFS181460 ns0:hasName "Department of Mathematics"@en .

ns15:IFS181524 ns0:hasName "Department of Electrical Engineering"@en,
        "Department of Electrical Engineering, Science and Research Branch"@en .

ns15:IFS181545 ns0:hasName "Sichuan Normal University"@en .

ns15:IFS181799 ns0:hasName "Air Force Engineering University"@en .

ns15:IFS181829 ns0:hasName "Department of Mathematics and Statistics"@en,
        "University of Insubria"@en .

ns15:IFS181832 ns0:hasName "Department of Mathematics and Statistic"@en,
        "Department of Mathematics and Statistics"@en,
        "Department of Mathematics and Statistics, Faculty of Basic and Applied Sciences"@en .

ns15:IFS181874 ns0:hasName "Shiraz University of Technology"@en .

ns15:IFS181966 ns0:hasName "Departamento de Eletrônica Aplicada"@en,
        "Technological Institute of Aeronautics - ITA"@en .

ns15:IFS182555 ns0:hasName "Department of Computer Science and Engineering"@en,
        "Department of Electrical Engineering and Automation"@en,
        "Department of Electrical and Information Engineering"@en,
        "Faculty of Mechanical Engineering"@en,
        "Faculty of Mechanical Engineering and Automation"@en,
        "Key Laboratory of Rock Mechanics and Geohazards of Zhejiang Province"@en,
        "Shaoxing University"@en,
        "Wuhan University of Technology"@en .

ns15:IFS182579 ns0:hasName "Department of Mathematics and Statistic"@en,
        "Department of Mathematics and Statistics"@en .

ns15:IFS182747 ns0:hasName "Shanxi University"@en .

ns15:IFS182798 ns0:hasName "Chongqing University of Posts and Telecommunications"@en,
        "College of Science"@en,
        "School of Science"@en .

ns15:IFS182815 ns0:hasName "Capital University of Economics and Business"@en .

ns15:IFS182893 ns0:hasName "Northeast Forestry University"@en .

ns15:IFS182910 ns0:hasName "Beijing Key Laboratory on MCAACI"@en,
        "Beijing Key Laboratory on MCAACI, School of Mathematics and Statistics"@en,
        "School of Mathematics and Statistics"@en .

ns15:IFS190078 ns0:hasName "Bharati Vidyapeeth’s College of Engineering, New Delhi"@en,
        "Computer Science and Engineering"@en .

ns15:IFS190148 ns0:hasName "Department of Mathematics"@en,
        "Department of Mathematics, Faculty of Mathematics"@en .

ns15:JAD170300 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en .

ns15:JAD180492 ns0:hasName "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en,
        "European Graduate School of Neuroscience EURON"@en,
        "School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en .

ns15:JAD180501 ns0:hasName "Centre for Research Excellence in Promoting Cognitive Health and Preventing Cognitive Decline"@en,
        "Centre for Research in Ageing and Cognitive Health (REACH)"@en,
        "Centre for Research in Ageing and Cognitive Health (REACH), School of Psychology"@en .

ns15:JAD180511 ns0:hasName "Department of Biochemistry"@en,
        "Department of Biochemistry, Faculty of Medicine, UKMMC"@en .

ns15:JAD180571 ns0:hasName "Department of Psychology"@en,
        "Neuroscience and Mental Health Institute"@en .

ns15:JAD180608 ns0:hasName "Centre for Research Excellence in Promoting Cognitive Health"@en,
        "Centre for Research in Ageing and Cognitive Health (REACH)"@en,
        "Centre for Research in Ageing and Cognitive Health (REACH), School of Psychology"@en,
        "Centre for Research in Ageing and Cognitive Health, School of Psychology, and PenCLAHRC"@en,
        "Centre for Research in Ageing and Cognitive Health, Washington Singer Laboratories"@en,
        "Department of Psychology"@en,
        "The Centre for Research in Ageing and Cognitive Health School of Psychology, College of Life and Environmental Sciences"@en,
        "University of Exeter Medical School"@en,
        "Wellcome Centre for Cultures and Environments of Health"@en .

ns15:JAD180857 ns0:hasName "Alzheimer Center Limburg"@en,
        "Alzheimer Centre Limburg"@en,
        "Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS)"@en,
        "Alzheimer Centre Limburg, School for Mental Health and Neuroscience (MHeNS)"@en,
        "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology"@en,
        "Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School for Mental Health and Neurosciences"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en,
        "Department of Psychiatry and Neuropsychology, School of Mental Health and Neurosciences (MHeNS)"@en,
        "Department of Psychiatry and Neuropsychology/Alzheimer Center Limburg"@en,
        "European Graduate School of Neuroscience EURON"@en,
        "Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en,
        "School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en,
        "School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en,
        "School for Mental Health and Neuroscience/Alzheimer Center Limburg"@en .

ns15:JAD181171 ns0:hasName "Molecular Neuroscience Research Center"@en,
        "Shiga University of Medical Science"@en .

ns15:JAD181178 ns0:hasName "Department of Preventive Gerontology"@en,
        "Department of Preventive Gerontology, Section for Health Promotion"@en .

ns15:JAD181261 ns0:hasName "Department of Neurology"@en .

ns15:JAD181285 ns0:hasName "Cleveland Clinic Lou Ruvo Center for Brain Health"@en,
        "Department of Neurology and Psychiatry"@en .

ns15:JAD190123 ns0:hasName "Centre for Neuroscience"@en,
        "Department of Health Sciences"@en .

ns15:JAD190132 ns0:hasName "Institute of Clinical Medicine - Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en .

ns15:JAD190159 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, National Neuroscience Institute"@en .

ns15:JAD190180 ns0:hasName "Department of Biochemistry and Biomedical Sciences"@en,
        "Seoul National University"@en .

ns15:JAD190216 ns0:hasName "Goethe-University"@en,
        "Institute of Occupational Medicine, Social Medicine and Environmental Medicine"@en .

ns15:JAD190222 ns0:hasName "Centre for Clinical Brain Sciences"@en,
        "Centre for Dementia Prevention"@en,
        "Department of Psychological Medicine"@en,
        "Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences"@en .

ns15:JAD190278 ns0:hasName "Department of Psychiatry, Graduate School of Medical Science"@en .

ns15:JAD190369 ns0:hasName "Okayama University"@en .

ns15:JAD190403 ns0:hasName "Centre for Vision Research"@en,
        "Neuroscience Graduate Diploma Program"@en,
        "School of Kinesiology and Health Science"@en .

ns15:JAD190414 ns0:hasName "Dementia Clinics, Faculty of Medicine"@en,
        "Faculty of Medicine"@en,
        "Laboratory of Language Studies"@en .

ns15:JAD190419 ns0:hasName "Department of Biochemistry and Molecular Biology, School of Basic Medicine and the Collaborative Innovation Center for Brain Science, Tongji Medical College"@en .

ns15:JAD190454 ns0:hasName "Department of Gynecologic Oncology"@en,
        "Department of Neurology, Peking Union Medical College Hospital"@en .

ns15:JAD190469 ns0:hasName "Department of Neurology, Samsung Medical Center"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en .

ns15:JAD190474 ns0:hasName "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "School of Medicine"@en .

ns15:JAD190484 ns0:hasName "Departament de Biologia Cellular, Protein Folding and Stability Group, de Fisiologia i d’Immunologia, Unitat de Citologia i d’Histologia, Facultat de Biociències"@en,
        "Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Edifici C"@en .

ns15:JAD190501 ns0:hasName "Department of Neurology"@en .

ns15:JAD190527 ns0:hasName "Department of Epidemiology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Department of Radiology and Nuclear medicine"@en,
        "Memory Aging & Cognition Centre"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en,
        "Saw Swee Hock School of Public Health"@en .

ns15:JAD190533 ns0:hasName "Department of Biomedical Sciences"@en,
        "KaRa Institute of Neurological Disease"@en,
        "School of Medical Health and Sciences"@en,
        "School of Psychiatry and Clinical Neurosciences"@en .

ns15:JAD190541 ns0:hasName "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en,
        "European Graduate School of Neuroscience EURON"@en,
        "School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en .

ns15:JAD190546 ns0:hasName "Department of Geriatrics and Cognitive Disorders"@en,
        "Department of Geriatrics and Cognitive Disorders, School of Medicine"@en .

ns15:JAD190564 ns0:hasName "Department of Neurobiology, George S. Wise Faculty of Life Sciences"@en,
        "Department of Neurobiology, Sagol School of Neuroscience, George S. Wise Faculty of Life Sciences"@en .

ns15:JAD190609 ns0:hasName "Cognitive Impairment Center"@en .

ns15:JAD190644 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Graduate School of Medicine, Dentistry and Pharmacological Sciences"@en,
        "Okayama University"@en,
        "Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science"@en .

ns15:JAD190656 ns0:hasName "University of California"@en .

ns15:JAD190661 ns0:hasName "Alzheimer's Disease and Memory Disorder Center, Department of Neurology"@en,
        "Department of Neurology"@en .

ns15:JAD190704 ns0:hasName "Department of Electrical and Electronic Engineering"@en,
        "iCV Research Group, Institute of Technology"@en,
        "iCV Research Lab, Institute of Technology"@en .

ns15:JAD190771 ns0:hasName "Department Experimental Applied Pharmacology"@en,
        "Department of Drug Sciences, Centre of Excellence in Applied Biology"@en,
        "Department of Drug Sciences, Pharmacology Section"@en,
        "Department of Experimental and Applied Pharmacology and Centre of Excellence in Applied Biology"@en,
        "Department of Experimental and Applied Pharmacology, Centre of Excellence in Applied Biology"@en .

ns15:JAD190798 ns0:hasName "Laboratory of Neurodegenerative Diseases"@en,
        "Laboratory of Neurodegenerative Diseases, Center for Interdisciplinary Research and Innovation (CIRI – AUTH) Balkan Center, Buildings A & B"@en,
        "Laboratory of Psychology, School of Psychology"@en,
        "Laboratory of Psychology, Section of Cognitive and Experimental Psychology, Faculty of Philosophy, School of Psychology"@en,
        "Laboratoty of Psychology, Department of Experimental and Cognitive Psychology, School of Psychology"@en .

ns15:JAD190817 ns0:hasName "Department of Neurology, School of Medicine"@en .

ns15:JAE180028 ns0:hasName "Department of Radiation Oncology"@en,
        "School of Materials Science and Engineering"@en,
        "Wuhan University of Technology"@en .

ns15:JAE190821 ns0:hasName "Department of Electrical EngineeringDoshisha University"@en,
        "Doshisha University"@en .

ns15:JAE190924 ns0:hasName "Department of Electrical Engineering"@en,
        "Department of Electrical EngineeringDoshisha University"@en,
        "Doshisha University"@en .

ns15:JAE191148 ns0:hasName "Department of Electrical Engineering"@en,
        "Department of Electrical EngineeringDoshisha University"@en,
        "Doshisha University"@en .

ns15:JAE191149 ns0:hasName "Department of Electrical Engineering"@en,
        "Department of Electrical EngineeringDoshisha University"@en,
        "Doshisha University"@en .

ns15:JAE191283 ns0:hasName "Department of Electrical Engineering"@en,
        "Department of Electrical EngineeringDoshisha University"@en,
        "Doshisha University"@en .

ns15:JAE191491 ns0:hasName "Arts et Metiers ParisTechUniversité Lille"@en,
        "L2EP/Université Lille1"@en .

ns15:JAE198972 ns0:hasName "Department of Electrical EngineeringUniversity Politehnica of Bucharest"@en .

ns15:JBR180345 ns0:hasName "Department of Agricultural, Food and Environmental Sciences"@en,
        "Dipartimento di Scienze Agrarie, Alimentari e Ambientali"@en .

ns15:JBR180350 ns0:hasName "School of Life Science and Biotechnology"@en,
        "School of Life Science and Biotechnology, Faculty of Chemical, Environmental and Biological Science and Technology"@en .

ns15:JCM190017 ns0:hasName "School of Electronic and Information Engineering"@en,
        "School of Information Science and Engineering"@en .

ns15:JHD180337 ns0:hasName "George Huntington Institute"@en,
        "George-Huntington-Institute"@en .

ns15:JHD199003 ns0:hasName "Huntington’s Disease Centre"@en,
        "Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine"@en,
        "UCL Huntington’s Disease Centre, UCL Queen Square Institute of Neurology"@en,
        "University College London (UCL) Institute of Neurology"@en .

ns15:JND190403 ns0:hasName "Center for Gene Therapy Research Institute"@en,
        "Department of Physical Therapy"@en .

ns15:JND190414 ns0:hasName "National Institute of Neurological Disorders and Stroke/NIH"@en,
        "Neuromuscular and Neurogenetic Disorders of Childhood Section"@en .

ns15:JPD191579 ns0:hasName "Department of Neurology"@en,
        "Neurology Service and GRECC"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en,
        "Veteran's Affairs Ann Arbor Healthcare System"@en .

ns15:JPD191610 ns0:hasName "Department of Neurology"@en,
        "Mayo Clinic"@en .

ns15:JPD191675 ns0:hasName "Tokyo Metropolitan Institute of Medical Science"@en,
        "Tokyo Metropolitan Institute of Medical Sciences"@en .

ns15:JPD191688 ns0:hasName "Department of Psychology"@en,
        "Institute on Aging & Lifelong Health"@en .

ns15:JPD191699 ns0:hasName "Department of Basic and Clinical Neuroscience, Institute of Psychiatry, Psychology and Neuroscience"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Clinical Neuroscience, Translational Neuropharmacology, Center for Molecular Medicine"@en,
        "Department of Neurology"@en .

ns15:JVR191021 ns0:hasName "University of Illinois at Urbana-Champaign"@en .

ns15:JVR191031 ns0:hasName "Cornell University"@en .

ns15:JVR191035 ns0:hasName "Department of Rehabilitation, Communication Disorders, and Human Resources"@en,
        "University of Arkansas"@en .

ns15:JVR191036 ns0:hasName "University of Wisconsin-Stout"@en,
        "University of Wisconsin-Stout Vocational Rehabilitation Institute"@en .

ns15:JVR191046 ns0:hasName "A.J. Drexel Autism Institute"@en,
        "Drexel University"@en .

ns15:JVR191049 ns0:hasName "Department of Health Sciences/Mental Health, Activity and Participation, Medical Faculty"@en,
        "Department of Health Sciences/Work and Mental Health"@en,
        "Lund University"@en .

ns15:KCA190056 ns0:hasName "City of Hope Comprehensive Cancer Center"@en .

ns15:KCA190059 ns0:hasName "Duke Cancer Institute and the Division of Medical Oncology at the Duke University School of Medicine in Durham"@en,
        "Duke University Departments of Medicine, Surgery, and Pharmacology and Cancer Biology, Division of Medical Oncology"@en .

ns15:MGC180751 ns0:hasName "Chemistry Department, Faculty of Science"@en,
        "Department of Chemistry, Faculty of Science"@en,
        "Faculty of Public Health and Health Informatics"@en .

ns15:NHA190065 ns0:hasName "College of Sciences"@en,
        "Department of Mathematics"@en,
        "Department of Psychiatry and Behavioral Neuroscience"@en,
        "Department of Statistics, Faculty of Science"@en .

ns15:NHA190068 ns0:hasName "Department of Medicine"@en .

ns15:NPM180140 ns0:hasName "Department of Obstetrics & Gynecology"@en,
        "The Ohio State University"@en .

ns15:NPM1813 ns0:hasName "Department of Pediatrics and Communicable Diseases"@en,
        "Department of Pediatrics, Division of Neonatal-Perinatal Medicine, C.S. Mott Children’s Hospital, Michigan Medicine"@en .

ns15:NRE182671 ns0:hasName "Department of Physiotherapy, School of Rehabilitation"@en,
        "Neuromusculoskeletal Research Center"@en,
        "Sports Medicine Research Center"@en,
        "Sports Medicine Research CenterNeuroscience InstituteTehran University of Medical Sciences"@en,
        "Tehran University of Medical Sciences"@en .

ns15:NRE192687 ns0:hasName "KU Leuven - University of Leuven"@en,
        "KU Leuven-University of Leuven"@en .

ns15:NRE192698 ns0:hasName "Center of Geriatrics and Gerontology, Medical Center – University of Freiburg, Faculty of Medicine"@en,
        "Centre for Geriatric Medicine and Gerontology, Faculty of Medicine"@en,
        "Department of Neurology, Faculty of Medicine"@en,
        "University Medical Center"@en .

ns15:RNN190910 ns0:hasName "Department of Anatomy & Neurobiology"@en .

ns15:RNN190919 ns0:hasName "Department of Neurology"@en .

ns15:RNN190924 ns0:hasName "Department of Physical Therapy, Cognitive-Motor Behavior and Balance Rehabilitation Laboratory"@en,
        "University of Illinois"@en .

ns15:THC199009 ns0:hasName "Faculty of Information Technology"@en,
        "Macau University of Science and Technology"@en .

ns15:THC199033 ns0:hasName "School of Life Science and Technology"@en,
        "School of Pharmacy"@en .

ns15:VES190651 ns0:hasName "Department of Otolaryngology-Head and Neck Surgery"@en,
        "Johns Hopkins School of Medicine"@en .

ns15:WOR192938 ns0:hasName "Department of Physiotherapy"@en,
        "School of Health and Rehabilitation Sciences"@en .

ns15:WOR192952 ns0:hasName "Faculty of Health, Kinesiology and Health Science"@en,
        "School of KinesiologyYork University"@en .

ns15:WOR192976 ns0:hasName "Luleå University of Technology"@en .

ns15:WOR192986 ns0:hasName "Department of Ergonomics, School of Health"@en,
        "Department of Occupational Health Engineering, School of Public Health"@en .

ns15:WOR192988 ns0:hasName "Department of Environmental Health, Research Centre on Environment and Health"@en,
        "Health and Environment Research Center"@en,
        "R&D Centro Algoritmi, Engineering School"@en .

ns15:WOR192998 ns0:hasName "Danish Ramazzini Center"@en,
        "Department of Occupational Medicine"@en .

ns15:XST180413 ns0:hasName "Department of Electrical and Computer Engineering"@en,
        "Departmentof Electrical and Computer Engineering"@en .

ns15:XST180477 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns15:XST180486 ns0:hasName "Department of Medical Image"@en .

ns15:XST180488 ns0:hasName "Department of Radiology"@en .

ns15:XST190533 ns0:hasName "Department of Biomedical Engineering, College of Materials Science and Engineering"@en .

ns15:ajw190048 ns0:hasName "Department of Environmental Sciences"@en,
        "Department of Pharmaceutical Sciences"@en .

ns15:ajw190055 ns0:hasName "Amity University"@en,
        "Amity University Uttar Pradesh"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:20.ID:JAD190399> ns0:hasName "Department of Brain and Cognitive Science"@en,
        "Department of Brain and Cognitive Sciences"@en,
        "Department of Neuropsychiatry"@en,
        "Department of Psychiatry"@en,
        "National Institute of Dementia"@en .

ns235:JAD180572 ns0:hasName "Brain and Ageing Research Program, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Neuropsychiatric Institute"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff1.Author:26.ID:JAD190644> ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Graduate School of Medicine, Dentistry and Pharmacological Sciences"@en,
        "Okayama University"@en .

ns252:ADR190132 ns0:hasName "Division of Molecular Psychiatry, Department of Psychiatry"@en,
        "Division of Molecular Psychiatry, Department of Psychiatry and Psychotherapy"@en,
        "Division of Molecular Psychiatry, Georg-August-University Goettingen"@en,
        "Georg-August-University"@en,
        "Georg-August-University Göttingen"@en .

ns252:ADR190135 ns0:hasName "Universiti Brunei Darussalam"@en .

ns252:AOP051 ns0:hasName "PROSTEP AG"@en .

ns252:BLC190218 ns0:hasName "Department of Surgery"@en,
        "Department of Surgery (Urology)"@en,
        "Department of Urology"@en,
        "University of Colorado Comprehensive Cancer Center"@en .

ns252:BMR171043 ns0:hasName "Department of Neurology, Jena University Hospital"@en,
        "Department of Orthopaedic, Jena University Hospital"@en,
        "Department of Orthopaedics, Jena University Hospital"@en,
        "Orthopaedic Department of the Waldkliniken Eisenberg"@en .

ns252:BMR181185 ns0:hasName "Department of Orthopaedic Surgery-Spine Center"@en,
        "Department of Orthopedic Surgery"@en .

ns252:BMR181289 ns0:hasName "Physiotherapy Department, Faculty of Rehabilitation"@en .

ns252:CBM190161 ns0:hasName "Department of Pathology"@en .

ns252:CH180450 ns0:hasName "Department of Plastic and Hand Surgery University Hospital of Erlangen"@en,
        "Department of Plastic and Hand Surgery and Laboratory for Tissue Engineering and Regenerative Medicine, University Hospital of Erlangen"@en .

ns252:CH180470 ns0:hasName "Department of Occupational Therapy"@en .

ns252:CH180545 ns0:hasName "The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine"@en .

ns252:CH199204 ns0:hasName "Department of Radiology"@en,
        "Ludwig-Maximilians-University Munich - Grosshadern Campus"@en .

ns252:CH199206 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en .

ns252:CH199209 ns0:hasName "Faculty Medical and Life Sciences"@en,
        "Furtwangen University"@en,
        "Hochschule Furtwangen"@en,
        "Institute of Transplantation Diagnostics and Cell Therapeutics"@en .

ns252:CH199218 ns0:hasName "Center for Plastic, Aesthetic, Hand & Reconstructive Surgery"@en,
        "Center for Plastic, Aesthetic, Hand &Reconstructive Surgery"@en,
        "Center of Plastic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Hand, and Reconstructive Surgery"@en .

ns252:CH199219 ns0:hasName "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour"@en,
        "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour and Virtual Center for Replacement – Complementary Methods to Animal Testing"@en .

ns252:CH199221 ns0:hasName "University Medical Center Regensburg"@en .

ns252:CH199222 ns0:hasName "Department of Urology"@en,
        "Department of Urology, University Hospital Grosshadern"@en .

ns252:CH199224 ns0:hasName "University Hospital Regensburg"@en .

ns252:CH199225 ns0:hasName "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Reconstructive and Hand Surgery at the University Medical Center Regensburg"@en .

ns252:DEV180249 ns0:hasName "University of Cyprus"@en .

ns252:FI1831 ns0:hasName "Gdansk University of Technology"@en,
        "Gdańsk University of Technology"@en,
        "Multimedia Systems Department, Faculty of Electronics, Telecommunications and Informatics"@en .

ns252:HAB190374 ns0:hasName "Department of Medical Genetics"@en,
        "Department of Medical Genetics, Faculty of Medicine"@en,
        "Department of Molecular Medicine"@en .

ns252:HAB190375 ns0:hasName "Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science"@en,
        "Department of Haematology, School of Medical Laboratory Science"@en .

ns252:HSM180397 ns0:hasName "Beijing University of Posts and Telecommunications"@en,
        "Beijing University of Posts and Telecommunications (BUPT)"@en,
        "School of Economics and Management"@en .

ns252:HSM180425 ns0:hasName "School of Economics and Management"@en .

ns252:ICA190603 ns0:hasName "Department of Systems Engineering, Intelligent Systems Lab"@en,
        "Intelligent Systems Lab Research Group"@en,
        "Systems Engineering and Automation Department, Intelligent Systems Laboratory"@en,
        "Universidad Carlos III de Madrid"@en .

ns252:IDA192847 ns0:hasName "Jiangsu High Technology Research Key Laboratory for Wireless Sensor Networks"@en,
        "School of Computer Science"@en .

ns252:IES183210 ns0:hasName "Department of Physical Education"@en,
        "Graduate Program of Physical Education"@en .

ns252:IFS179211 ns0:hasName "Key Laboratory of Process Optimization and Intelligent Decision-Making"@en,
        "School of Management"@en,
        "School of Management, HeFei University of Technology"@en .

ns252:IFS179252 ns0:hasName "Multimedia University"@en .

ns252:IFS181516 ns0:hasName "Department of Mathematics"@en .

ns252:IFS181538 ns0:hasName "Department of Industrial Engineering"@en,
        "Industrial Engineering Department"@en,
        "Istanbul Technical University"@en .

ns252:IFS181633 ns0:hasName "SASTRA Deemed University"@en,
        "School of Computing"@en .

ns252:IFS181739 ns0:hasName "College of Mathematics"@en,
        "School of Mathematics"@en .

ns252:IFS181799 ns0:hasName "Air Force Engineering University"@en .

ns252:IFS181982 ns0:hasName "Northwestern Polytechnical University"@en .

ns252:IFS182615 ns0:hasName "Department of Power and Control Engineering, School of Electrical and Computer Engineering"@en,
        "Power and Control department, Engineering faculty No. 1"@en,
        "Shiraz University"@en .

ns252:IFS182699 ns0:hasName "College of Electrical Engineering and New Energy"@en,
        "College of Mechatronics and Control Engineering"@en,
        "Hubei Key Laboratory of Cascaded Hydropower Stations Operation and Control"@en,
        "Laboratory of Space Collaborative Manipulation Technology"@en .

ns252:IFS182746 ns0:hasName "Department of Computer Science"@en,
        "Department of Computer Science and Engineering"@en,
        "Department of Mathematics"@en .

ns252:IFS182798 ns0:hasName "Chongqing University of Posts and Telecommunications"@en,
        "School of Science"@en,
        "School of science"@en .

ns252:IFS18877 ns0:hasName "Department of Applied Mathematics with Oceanology and Computer Programming"@en,
        "Department of Applied Mathematics with Oceanology and ComputerProgramming"@en,
        "Vidyasagar University"@en .

ns252:IFS190067 ns0:hasName "Department of Mathematics, Central Tehran Branch"@en,
        "Department of Mathematics, Science and Research Branch"@en .

ns252:JAD180492 ns0:hasName "Alzheimer Center Limburg"@en,
        "Alzheimer Centre Limburg"@en,
        "Alzheimer Centre Limburg, Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience (MHeNS)"@en,
        "Alzheimer Centre Limburg, School for Mental Health and Neuroscience (MHeNS)"@en,
        "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology"@en,
        "Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School for Mental Health and Neurosciences"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en,
        "Department of Psychiatry and Neuropsychology, School of Mental Health and Neurosciences (MHeNS)"@en,
        "European Graduate School of Neuroscience EURON"@en,
        "Faculty of Health, Medicine and Life Sciences, School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en,
        "School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en,
        "School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en,
        "School for Mental Health and Neuroscience/Alzheimer Center Limburg"@en .

ns252:JAD180857 ns0:hasName "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en .

ns252:JAD180932 ns0:hasName "Clinical and Health Psychology"@en,
        "Department of Clinical and Health Psychology"@en .

ns252:JAD181132 ns0:hasName "Australian Centre for Precision Health"@en,
        "Centre for Population Health Research"@en .

ns252:JAD181141 ns0:hasName "Albert Einstein College of Medicine"@en,
        "Department of Epidemiology and Population Health"@en,
        "Department of Epidemiology and Population Health, Albert Einstein College of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Albert Einstein College of Medicine"@en,
        "Departments of Neurology, Epidemiology, and Social Medicine, Montefiore Headache Unit"@en,
        "Einstein Aging Study"@en,
        "Innovative Medical Research"@en,
        "Institute for Aging Research, Albert Einstein College of Medicine"@en,
        "Saul B. Korey Department of Neurology"@en,
        "Saul R. Korey Department of Neurology"@en,
        "Saul R. Korey Department of Neurology, Albert Einstein College of Medicine"@en,
        "The Einstein Aging Study"@en .

ns252:JAD181168 ns0:hasName "Neurology Imaging Unit, Department of Medicine"@en,
        "Neurology Imaging UnitImperial College London"@en .

ns252:JAD181282 ns0:hasName "Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research"@en,
        "Institute of Neuroscience and Physiology"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "the Sahlgrenska Academy at University of Gothenburg"@en .

ns252:JAD190011 ns0:hasName "Department of Neurology"@en,
        "Emory Alzheimer's Disease Research Center"@en .

ns252:JAD190060 ns0:hasName "Department of Physiology"@en,
        "Department of Psychiatry"@en .

ns252:JAD190075 ns0:hasName "School of Molecular and Cell Biology"@en,
        "University of the Witwatersrand"@en .

ns252:JAD190077 ns0:hasName "Vanderbilt Memory & Alzheimer’s Center, Department of Neurology"@en .

ns252:JAD190087 ns0:hasName "Faculty of Clinical Engineering, School of Health Sciences"@en .

ns252:JAD190113 ns0:hasName "Beijing Key Laboratory on MCAACI"@en,
        "College of Science"@en,
        "Department of Neurology, Xuanwu Hospital"@en,
        "School of Mathematics and Statistics"@en .

ns252:JAD190132 ns0:hasName "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en .

ns252:JAD190142 ns0:hasName "School of Nursing"@en,
        "Vanderbilt University Department of Psychiatry and Behavioral Sciences"@en,
        "Vanderbilt University Medical Center"@en,
        "Vanderbilt University Medical Center Psychiatric Neuroimaging Program"@en,
        "Vanderbilt University School of Nursing"@en .

ns252:JAD190190 ns0:hasName "Department of Physiology and Biophysics"@en,
        "Veterans Affairs Western New York Healthcare System"@en .

ns252:JAD190222 ns0:hasName "Edinburgh Dementia Prevention, Centre for Clinical Brain Sciences"@en,
        "The University of Edinburgh"@en .

ns252:JAD190230 ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychology"@en,
        "University of Southern California"@en,
        "Veterans Affairs San Diego Healthcare System"@en .

ns252:JAD190237 ns0:hasName "Center of Excellence on Aging and Translational Medicine - CeSI-MeT"@en,
        "Department of Neuroscience Imaging and Clinical Sciences"@en .

ns252:JAD190244 ns0:hasName "ARC Centre of Excellence in Cognition and its Disorders"@en,
        "Faculty of Medicine"@en,
        "Neuroscience Research Australia"@en,
        "Norwich Medical School"@en,
        "School of Medical Sciences"@en .

ns252:JAD190293 ns0:hasName "University of Kansas Alzheimer’s Disease Center"@en,
        "University of Kansas School of Medicine"@en .

ns252:JAD190316 ns0:hasName "Department of Biomedical Engineering"@en,
        "Department of Radiology and Radiological Sciences"@en,
        "Institute of Imaging Science"@en,
        "Vanderbilt Brain Institute"@en,
        "Vanderbilt Ingram Cancer Center"@en,
        "Vanderbilt Institute of Chemical Biology"@en,
        "Vanderbilt Institute of Nanoscale Science and Engineering"@en,
        "Vanderbilt University Institute of Imaging Science"@en .

ns252:JAD190319 ns0:hasName "Department of Medicine"@en,
        "Department of Medicine, Peninsula Clinical School, Central Clinical School"@en,
        "Developmental Imaging"@en .

ns252:JAD190334 ns0:hasName "Institute of Clinical Medicine – Neurology"@en .

ns252:JAD190339 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology and Psychiatry"@en,
        "Functional Brain Center"@en,
        "Sackler Faculty of Medicine"@en .

ns252:JAD190365 ns0:hasName "Keenan Research Centre for Biomedical Research"@en,
        "Keenan Research Centre for Biomedical Research, Li Ka Shing Knowledge Institute"@en .

ns252:JAD190368 ns0:hasName "Department of Neurochemistry, Inge Grundke-Iqbal Research Floor"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-Innovation Center of Neuroregeneration"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education, Co-innovation Center of Neuroregeneration"@en .

ns252:JAD190385 ns0:hasName "Department of Human Neuroscience"@en,
        "Department of Neurology and Psychiatry, Sapienza"@en .

ns252:JAD190401 ns0:hasName "Beijing Geriatric Medical Research Center"@en,
        "Central Laboratory, Xuan Wu Hospital"@en,
        "Central Laboratory, Xuanwu Hospital"@en .

ns252:JAD190403 ns0:hasName "School of Kinesiology and Health Science"@en,
        "York University"@en .

ns252:JAD190413 ns0:hasName "Danish Dementia Research Centre (DDRC), Department of Neurology, Rigshospitalet"@en,
        "Danish Dementia Research Centre, Department of Neurology, Rigshospitalet"@en,
        "Danish Dementia Research Centre, Rigshospitalet"@en,
        "Department of Neurology, Danish Dementia Research Centre (DDRC), Rigshospitalet"@en,
        "Department of Neurology, Danish Dementia Research Centre, Neuroscience Center"@en,
        "Department of Neurology, Danish Dementia Research Centre, Rigshospitalet"@en,
        "Department of Neurology, Memory Disorders Research Group, Rigshospitalet"@en,
        "Department of Neurology, Section 2082, The Copenhagen Memory Clinic & The Memory Disorders Research Group, Rigshospitalet"@en .

ns252:JAD190474 ns0:hasName "Brain and Ageing Research Program, School of Psychiatry"@en,
        "Brain and Ageing Research Program, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Dementia Centre for Research Collaboration"@en,
        "Neuropsychiatric Institute"@en,
        "Neuropsychiatric Institute (NPI)"@en,
        "Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine"@en,
        "Prince of Wales Research Institute and Centre for Healthy Brain Aging"@en,
        "School of Medicine"@en,
        "School of Psychiatry"@en .

ns252:JAD190484 ns0:hasName "Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine"@en,
        "Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Edifici C"@en,
        "Protein Folding and Stability Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències"@en .

ns252:JAD190494 ns0:hasName "Department of Neuroscience"@en,
        "Neuroscience Institute of Cavalieri Ottolenghi Foundation (NICO)"@en .

ns252:JAD190533 ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical Sciences"@en,
        "Department of Biomedical Sciences"@en,
        "School of Medical Health and Sciences"@en .

ns252:JAD190540 ns0:hasName "Department of Pharmacology"@en,
        "Memory Aging & Cognition Centre"@en .

ns252:JAD190541 ns0:hasName "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en,
        "School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en .

ns252:JAD190620 ns0:hasName "Department of Geriatric Medicine"@en .

ns252:JAD190622 ns0:hasName "Center for Comprehensive Care and Research on Memory Disorders"@en .

ns252:JAD190644 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en .

ns252:JAD190645 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "Waisman Laboratory for Brain Imaging and Behavior"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns252:JAD190660 ns0:hasName "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en .

ns252:JAD190685 ns0:hasName "Department of Neurology"@en,
        "Seoul National University College of Medicine and Seoul National University Bundang Hospital"@en .

ns252:JAD190691 ns0:hasName "Radiopharmaceutical Chemistry Laboratory, Turku PET Centre"@en,
        "Turku PET Centre"@en .

ns252:JAD190700 ns0:hasName "Drug Research Division"@en,
        "Research Division"@en .

ns252:JAD190708 ns0:hasName "Department of Neurology"@en .

ns252:JAD190779 ns0:hasName "Department of Biological Sciences"@en .

ns252:JAD190838 ns0:hasName "Department of Neurology and Laboratory of Neurobiology, Hospital Clinico San Carlos"@en,
        "Department of Neurology and Laboratory of Neurobiology, Hospital Clínico San Carlos"@en .

ns252:JAE180057 ns0:hasName "School of Mechanical Engineering"@en,
        "School of Mechanical Engineering and Power EngineeringShanghai Jiao Tong University"@en .

ns252:JAE180100 ns0:hasName "Collaborative Innovation Center on Forecast and Evaluation of Meteorological Disasters, School of Atmospheric PhysicsNanjing University of Information Science and Technology"@en,
        "Nanjing University of Information Science and Technology"@en .

ns252:JHD190351 ns0:hasName "Department of Neurology, Huntington Centre NRW"@en .

ns252:JHD190353 ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry, Pediatrics and Neurology"@en,
        "Stead Family Children’s Hospital at the University of Iowa"@en .

ns252:JHD190361 ns0:hasName "Department of Neurology"@en,
        "Northwestern University"@en .

ns252:JHD190370 ns0:hasName "Department of Neurology"@en,
        "Institute of Health and Society"@en,
        "Institute of Health and SocietyUniversity of Oslo"@en,
        "Research Centre for Habilitation and Rehabilitation Models & Services, Institute of Health and Society, Faculty of Medicine"@en .

ns252:JPD181460 ns0:hasName "Reta Lila Weston Institute"@en,
        "Reta Lila Weston Institute of Neurological Studies"@en,
        "Reta Lila Weston Institute of Neurological Studies, UCL Queen Square Institute of Neurology"@en .

ns252:JPD191579 ns0:hasName "Department of Neurology"@en,
        "Department of Radiology"@en,
        "Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en,
        "Neurology"@en,
        "Neurology Service and GRECC"@en,
        "Radiology"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en .

ns252:JVR191024 ns0:hasName "Kent State University"@en .

ns252:JVR191032 ns0:hasName "University of Wisconsin-Stout"@en,
        "University of Wisconsin-Stout Vocational Rehabilitation Institute"@en .

ns252:JVR191033 ns0:hasName "University of Maryland at College Park"@en .

ns252:JVR191042 ns0:hasName "University of Maryland at College Park"@en,
        "University of MarylandCollege Park"@en .

ns252:KCA190056 ns0:hasName "City of Hope Comprehensive Cancer Center"@en,
        "Department of Medical Oncology & Experimental Therapeutics"@en .

ns252:MGC180771 ns0:hasName "College of Chemical and Molecular Engineering"@en,
        "Zhengzhou University"@en .

ns252:NHA190065 ns0:hasName "Department of Environmental Health (Division of Epidemiology & Biostatistics)"@en,
        "Department of Psychiatry and Behavioral Neuroscience"@en .

ns252:NPM180140 ns0:hasName "Department of Pediatrics"@en,
        "Department of Pediatrics, College of Medicine"@en,
        "The Ohio State University"@en .

ns252:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Paediatrics"@en,
        "Human Environments Analysis Laboratory"@en,
        "Lawson Health Research Institute"@en,
        "School of Food and Nutritional Sciences"@en .

ns252:NRE192687 ns0:hasName "KU Leuven - University of Leuven"@en,
        "KU Leuven-University of Leuven"@en .

ns252:NRE192700 ns0:hasName "Department of Physical Therapy"@en,
        "Federal University of Bahia (FUBA)"@en .

ns252:RNN190919 ns0:hasName "Department of Neurology"@en .

ns252:THC191715 ns0:hasName "Department of Emergency Medicine"@en,
        "Department of Emergency Medicine, School of Medicine"@en .

ns252:THC199009 ns0:hasName "Faculty of Information Technology"@en,
        "Macau University of Science and Technology"@en .

ns252:THC199010 ns0:hasName "Department of Cardiology"@en,
        "Graduate Institute of Radiological Science"@en .

ns252:THC199029 ns0:hasName "Department of Cardiology"@en .

ns252:THC199031 ns0:hasName "Department of Cardiology"@en .

ns252:THC199039 ns0:hasName "Institute of Biomedical Engineering Research"@en,
        "School of Electronics Engineering, College of IT Engineering"@en .

ns252:VES190666 ns0:hasName "Department of Neurology, College of Medicine"@en,
        "Department of Otolaryngology-Head and Neck Surgery, College of Medicine"@en,
        "Department of Rehabilitation Medicine, Seoul National University College of Medicine"@en .

ns252:WOR192938 ns0:hasName "School of Health and Rehabilitation Sciences"@en .

ns252:WOR192968 ns0:hasName "Department of Physiotherapy, School of Health and Rehabilitation Sciences"@en,
        "Division of Physiotherapy"@en,
        "RECOVER Injury Research Centre"@en,
        "School of Health and Rehabilitation Sciences"@en .

ns252:WOR192990 ns0:hasName "Community Rehabilitation and Disability Studies, Department of Community Health Sciences, Cumming School of Medicine"@en,
        "University of Calgary"@en .

ns252:WOR193013 ns0:hasName "Department of Psychology"@en,
        "Faculty of Economic and Management Sciences"@en,
        "Stockholm University"@en .

ns252:XST180477 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns252:XST180487 ns0:hasName "Nanjing Medical University Affiliated Wuxi Second Hospital"@en,
        "Nanjing Medical University Affiliated Wuxi the Second Hospital"@en .

ns252:XST190528 ns0:hasName "Northwestern Polytechnical University"@en .

ns252:ajw190027 ns0:hasName "Institute of Climate Change (IPI)"@en .

ns252:ajw190043 ns0:hasName "Department of Nature Arrangement, Building and Hydraulics, Federal State Budgetary Educational Establishment of Higher Education"@en,
        "Federal State Budgetary Educational Establishment of Higher Education"@en .

ns119:JAD180572 ns0:hasName "Academic Department for Old Age Psychiatry"@en,
        "Aged Care Psychiatry"@en,
        "Brain and Ageing Research Program, School of Psychiatry"@en,
        "Brain and Ageing Research Program, School of Psychiatry, Faculty of Medicine"@en,
        "Center for Healthy Brain Ageing"@en,
        "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing (CHeBA), School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Centre for Healthy Brain and Ageing"@en,
        "Dementia Centre for Research Collaboration"@en,
        "Dementia Centre for Research Collaboration, School of Psychiatry"@en,
        "Dementia Centre for Research Collaboration, School of Psychiatry, Faculty of Medicine"@en,
        "Dementia Collaborative Research Centre"@en,
        "Dementia Collaborative Research Centre – Assessment and Better Care"@en,
        "Dementia Collaborative Research Centre, School of Psychiatry"@en,
        "Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine"@en,
        "Dementia Collaborative Research Centre–Assessment and Better Care"@en,
        "Primary Dementia Collaborative Research Centre"@en,
        "Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine"@en,
        "School of Psychiatry"@en,
        "The University of New South Wales"@en .

ns6:ADR190118 ns0:hasName "Academy of Scientific and Innovative Research (AcSIR)"@en,
        "Neurobiology Group"@en,
        "Neurobiology Group, Division of Biochemical Sciences"@en .

ns6:ADR190132 ns0:hasName "Georg-August-University"@en,
        "Georg-August-University of Göttingen"@en .

ns6:CBM182020 ns0:hasName "Department of Neurology, The First Affiliated Hospital"@en,
        "The Department of Urology, The First Affiliated Hospital"@en .

ns6:CBM182143 ns0:hasName "Department of Pathology"@en,
        "Department of Urology"@en .

ns6:CH180454 ns0:hasName "Department of Neurology, Huashan Hospital"@en,
        "Ultrasound Department, Zhongshan Hospital"@en .

ns6:CH180457 ns0:hasName "The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine"@en .

ns6:CH199005 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry"@en .

ns6:CH199009 ns0:hasName "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Reconstructive Surgery"@en .

ns6:CH199201 ns0:hasName "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies (BCRT)"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en .

ns6:CH199202 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Radiology"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich - Grosshadern Campus"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich – Grosshadern Campus"@en,
        "Ludwig-Maximilians-University Munich"@en,
        "Ludwig-Maximilians-University Munich - Grosshadern Campus"@en,
        "Ludwig-Maximilians-University of Munich-Grosshadern Campus"@en .

ns6:CH199204 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Radiology"@en,
        "Ludwig-Maximilians-University Munich"@en,
        "Ludwig-Maximilians-University Munich - Grosshadern Campus"@en,
        "Ludwig-Maximilians-University of Munich-Grosshadern Campus"@en .

ns6:CH199205 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en,
        "Institute of Chemistry and Biochemistry, Department of Biology, Chemistry and Pharmacy"@en .

ns6:CH199219 ns0:hasName "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour"@en,
        "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour and Virtual Center for Replacement – Complementary Methods to Animal Testing"@en .

ns6:CH199224 ns0:hasName "Department of Radiology"@en,
        "Institute for Radiology"@en,
        "Institute of Radiology"@en,
        "University Hospital Regensburg"@en,
        "University Medical Center Regensburg"@en .

ns6:CH199225 ns0:hasName "Center for Plastic, Hand and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand- and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Department of Plastic-, Hand-, and Reconstructive Surgery"@en,
        "Reconstructive and Hand Surgery at the University Medical Center Regensburg"@en,
        "University Hospital Regensburg"@en .

ns6:FI1834 ns0:hasName "Warsaw University of Technology"@en .

ns6:HAB190374 ns0:hasName "Department of Molecular Medicine"@en,
        "Department of Molecular Medicine, School of Advanced Technologies in Medicine"@en .

ns6:HSM180397 ns0:hasName "Beijing University of Posts and Telecommunications"@en,
        "School of Economics and Management"@en .

ns6:ICA190605 ns0:hasName "School of Computer Science and Technology"@en,
        "University of Granada"@en .

ns6:IES192167 ns0:hasName "Faculty of Commercial Sciences"@en,
        "Graduate School of Biomedical and Health Sciences"@en .

ns6:IFS179302 ns0:hasName "School of Electrical Engineering"@en,
        "Wuhan Textile University"@en,
        "Wuhan University"@en .

ns6:IFS181425 ns0:hasName "Department of Information Management, School of Economics and Management"@en,
        "School of Economics and Management"@en .

ns6:IFS182512 ns0:hasName "College of Computer Science and Engineering, Shandong Province Key laboratory of Wisdom Mine Information Technology"@en .

ns6:JAD180496 ns0:hasName "Department of Biochemistry"@en,
        "Department of Biochemistry, Faculty of Medicine"@en,
        "Department of Biochemistry, Faculty of Medicine, UKMMC"@en .

ns6:JAD180900 ns0:hasName "Brain and Mind Centre"@en,
        "Faculty of Medicine"@en,
        "Neuroscience Research Australia"@en,
        "School of Medical Science"@en,
        "School of Medical Sciences"@en,
        "The University of Sydney"@en,
        "University of New South Wales"@en .

ns6:JAD181030 ns0:hasName "Aging Research Center"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine"@en .

ns6:JAD181141 ns0:hasName "Department of Epidemiology and Population Health"@en,
        "Department of Epidemiology and Population Health, Albert Einstein College of Medicine"@en,
        "Einstein Aging Study"@en,
        "Saul B. Korey Department of Neurology"@en,
        "Saul R. Korey Department of Neurology"@en .

ns6:JAD181174 ns0:hasName "Falls"@en,
        "Falls, Balance and Injury Research Centre, Neuroscience Research Australia"@en,
        "Prince of Wales Clinical School"@en .

ns6:JAD181196 ns0:hasName "Department of Medicine, Division of Geriatric Medicine, Parkwood Hospital"@en,
        "Gait and Brain Lab, Parkwood Institute"@en,
        "Lawson Health Research Institute"@en .

ns6:JAD181217 ns0:hasName "Department of Neurology, Beijing Tiantan Hospital"@en .

ns6:JAD181246 ns0:hasName "Institute of Cell Biophysics"@en .

ns6:JAD181261 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, National Neuroscience Institute"@en .

ns6:JAD181297 ns0:hasName "Department of Radiology"@en,
        "Department of Radiology and Nuclear Medicine"@en .

ns6:JAD190106 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, School of Medicine"@en,
        "Emory Alzheimer's Disease Research Center"@en,
        "Emory University"@en .

ns6:JAD190113 ns0:hasName "Department of Neurology, Xuanwu Hospital"@en .

ns6:JAD190124 ns0:hasName "Department of Medicine, David Geffen School of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, David Geffen School of Medicine"@en,
        "Greater Los Angeles VA Healthcare System"@en,
        "Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine"@en .

ns6:JAD190142 ns0:hasName "School of Nursing"@en,
        "Vanderbilt University Medical Center Psychiatric Neuroimaging Program"@en,
        "Vanderbilt University School of Nursing"@en .

ns6:JAD190159 ns0:hasName "Department of Neurology"@en,
        "Duke-NUS Graduate Medical School Singapore"@en .

ns6:JAD190180 ns0:hasName "Department of Biochemistry & Biomedical Sciences"@en,
        "Department of Biochemistry and Biomedical Science"@en,
        "Department of Biochemistry and Biomedical Sciences"@en,
        "Department of Biochemistry and Biomedical Sciences, College of Medicine"@en,
        "Department of Biochemistry and Molecular Biology"@en,
        "Department of Biomedical Sciences"@en,
        "Interdisciplinary Graduate Program of Genetic Engineering"@en,
        "Neuroscience Research Institute"@en,
        "Seoul National University"@en,
        "Seoul National University College of Medicine"@en,
        "University of California at San Diego"@en .

ns6:JAD190181 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing, Research School of Population Health"@en,
        "Dementia Collaborative Research Centre – Early Diagnosis and Prevention, Research School of Population Health"@en,
        "Neuroscience Research Australia"@en,
        "School of Psychology"@en,
        "University of New South Wales"@en .

ns6:JAD190187 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Department of Molecular Neuroscience"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute"@en,
        "UK Dementia Research Institute at UCL"@en .

ns6:JAD190202 ns0:hasName "Department of Psychiatry"@en,
        "Hurvitz Brain Sciences Program"@en,
        "University of Toronto"@en .

ns6:JAD190240 ns0:hasName "Department of Neurology"@en,
        "Gansu Provincial Hospital"@en .

ns6:JAD190241 ns0:hasName "Cajal Institute"@en,
        "Cajal Institute (CSIC)"@en,
        "Cajal Institute and Ciberned"@en .

ns6:JAD190302 ns0:hasName "Cleveland Clinic Lou Ruvo Center for Brain Health"@en .

ns6:JAD190333 ns0:hasName "Core research laboratory"@en,
        "Department of Genetics and BioEngineering, College of Engineering and Architecture"@en,
        "Department of Genetics, Faculty of Biology and Soil Sciences"@en,
        "Kazan Federal University"@en .

ns6:JAD190334 ns0:hasName "Department of Neurology"@en,
        "Institute of Biomedicine"@en,
        "Institute of Clinical Medicine – Neurology"@en .

ns6:JAD190369 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en,
        "Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science"@en .

ns6:JAD190382 ns0:hasName "Department of Neurology, Huashan Hospital"@en,
        "Department of Neurosurgery, Huashan Hospital"@en .

ns6:JAD190414 ns0:hasName "Cognitive Neuroscience Research Group, Department of Psychology and Educational Sciences and Centre for Biomedical Research (CBMR)"@en,
        "Faculty of Medicine"@en .

ns6:JAD190423 ns0:hasName "Information Technologies Institute"@en .

ns6:JAD190459 ns0:hasName "INSERM, U1028, CNRS, UMR5292, Neuropain team"@en,
        "INSERM, U1028; CNRS, UMR5292"@en,
        "INSERM, U1028; CNRS, UMR5292; Neuropain team"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR) Neurology Unit"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR), Neurology Unit"@en .

ns6:JAD190468 ns0:hasName "Department of Neurology"@en,
        "Emory University"@en .

ns6:JAD190469 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en .

ns6:JAD190501 ns0:hasName "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

ns6:JAD190524 ns0:hasName "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en .

ns6:JAD190533 ns0:hasName "Australian Alzheimer’s Research Foundation"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Cooperative Research Centre for Mental Health"@en,
        "Department of Biomedical Sciences"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "School of Psychiatry and Clinical Neurosciences"@en .

ns6:JAD190540 ns0:hasName "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Memory Aging & Cognition Centre"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en .

ns6:JAD190549 ns0:hasName "Institute for Neurodegenerative Diseases, Clinical Branch"@en,
        "Université de Bordeaux"@en .

ns6:JAD190645 ns0:hasName "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "University of Wisconsin"@en,
        "Wisconsin Alzheimer's Disease Research Center, Department of Medicine"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns6:JAD190656 ns0:hasName "Department of Neurosciences"@en,
        "University of California"@en .

ns6:JAD190685 ns0:hasName "Department of Neurology"@en .

ns6:JAD190708 ns0:hasName "Department of Neurology"@en,
        "Greater Los Angeles VA Healthcare System"@en .

ns6:JAD190771 ns0:hasName "Department of Drug Sciences, Centre of Excellence in Applied Biology"@en,
        "Department of Drug Sciences, Pharmacology Section"@en,
        "Department of Experimental and Applied Pharmacology, Centre of Excellence in Applied Biology"@en .

ns6:JAD190779 ns0:hasName "Department of Biological Sciences"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Alzheimer’s Disease Center"@en .

ns6:JAD190817 ns0:hasName "Department of Biological Sciences, Graduate School of Science"@en,
        "Department of Neurology, School of Medicine"@en .

ns6:JAD190898 ns0:hasName "Aging Research Center"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet"@en,
        "Alzheimer Disease Research Center, Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society"@en,
        "Department NVS, Karolinska Institute"@en,
        "Department of Geriatric Medicine"@en,
        "Department of Neurobiology, Care Science and Society, Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS), Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics"@en,
        "Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society"@en,
        "KI-Alzheimer Disease Research Center"@en,
        "KI-Alzheimer Disease Research Center (KI-ADRC)"@en,
        "KI-Alzheimer's Disease Research Center"@en,
        "Karolinska Institute"@en,
        "Karolinska Institutet"@en,
        "Karolinska Institutet – Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet, Dept NVS"@en,
        "Karolinska University Hospital"@en,
        "Section for Geriatric Medicine, NEUROTEC"@en,
        "Stockholm Gerontology Research Center"@en,
        "Theme Aging"@en .

ns6:JAE180100 ns0:hasName "Collaborative Innovation Center on Forecast and Evaluation of Meteorological Disasters, School of Atmospheric PhysicsNanjing University of Information Science and Technology"@en,
        "Collaborative Innovation Center on Forecast and Evaluation of Meteorological DisastersSchool of Atmospheric Physics"@en,
        "Nanjing University of Information Science and Technology"@en,
        "Zhejiang University of Science & Technology"@en .

ns6:JAE190021 ns0:hasName "Tsinghua University"@en .

ns6:JND190397 ns0:hasName "Department of Biostatistics, College of Public Health"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, Carver College of Medicine"@en .

ns6:JND190407 ns0:hasName "Department of Neurology"@en,
        "Leiden University Medical Center"@en .

ns6:JPD181460 ns0:hasName "Reta Lila Weston Institute"@en,
        "Reta Lila Weston Institute of Neurological Studies, UCL Queen Square Institute of Neurology"@en .

ns6:JVR191033 ns0:hasName "University of Maryland at College Park"@en,
        "University of MarylandCollege Park"@en .

ns6:KCA190054 ns0:hasName "Department of Medical Oncology"@en,
        "Hospital Universitario 12 de Octubre"@en .

ns6:KCA190056 ns0:hasName "City of Hope Comprehensive Cancer Center"@en,
        "Department of Medical Oncology and Experimental Therapeutics"@en .

ns6:KCA190063 ns0:hasName "Department of Internal Medicine, University of California Davis School of Medicine, Division of Hematology Oncology"@en,
        "University of California"@en,
        "University of California Davis Comprehensive Cancer Center"@en .

ns6:MGC180753 ns0:hasName "Department of Oncology Surgery"@en,
        "Shanghai Jiao Tong University"@en .

ns6:MNM180275 ns0:hasName "Department of Home Economics and Ecology, Human Ecology Laboratory"@en,
        "Human Ecology Laboratory, Department of Home Economics and Ecology"@en .

ns6:NHA190065 ns0:hasName "Department of Psychiatry and Behavioral Neuroscience"@en .

ns6:NHA190068 ns0:hasName "Department of Medicine"@en,
        "Jesse Brown VA Medical Center"@en .

ns6:NRE192722 ns0:hasName "Department of Medicine, Royal Melbourne Hospital"@en,
        "Department of Rehabilitation Medicine"@en .

ns6:NRE192745 ns0:hasName "Institute of NeuroscienceUniversity of Louvain"@en,
        "Neuro Musculo Skeletal Lab (Brussels), Faculté des Sciences de la Motricité"@en,
        "Université Catholique de Louvain"@en .

ns6:NRE192771 ns0:hasName "Federal University of Bahia (FUBA)"@en .

ns6:NRE192801 ns0:hasName "Department of Physiotherapy"@en,
        "Department of Public Health"@en,
        "Department of Research in Rehabilitation and Health Promotion"@en .

ns6:RNN180883 ns0:hasName "Department of Physical Medicine and Rehabilitation"@en,
        "Korea University"@en .

ns6:RNN190909 ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "Geriatric Research Education and Clinical Center, VA Pittsburgh Healthcare System"@en,
        "Geriatric Research Educational and Clinical Center"@en,
        "Psychiatry, and Alzheimer's Disease Research Center"@en .

ns6:THC181184 ns0:hasName "China-Japan Union Hospital of Jilin University"@en,
        "Department of Otolaryngology, Head and Neck Surgery"@en .

ns6:THC199004 ns0:hasName "Department of Neurology"@en,
        "Department of Reproductive Medicine"@en .

ns6:THC199010 ns0:hasName "Department of Cardiology"@en,
        "Graduate Institute of Radiological Science"@en .

ns6:WOR192952 ns0:hasName "Faculty of Health, Kinesiology and Health Science"@en,
        "School of KinesiologyYork University"@en .

ns6:WOR192953 ns0:hasName "Department of Kinesiology"@en .

ns6:WOR192989 ns0:hasName "School of Rehabilitation Science"@en,
        "School of Rehabilitation Science at McMaster University"@en .

ns6:WOR193010 ns0:hasName "Department of Kinesiology"@en,
        "School of Kinesiology and Recreation"@en .

ns6:XST180457 ns0:hasName "Key Laboratory of Opto-Electronics Technology & System"@en,
        "Key Laboratory of Optoelectronics Technology & System"@en .

ns6:XST180460 ns0:hasName "Department of Medical Imaging"@en,
        "Department of Radiology"@en .

ns6:XST180477 ns0:hasName "Beijing Center for Mathematics and Information Interdisciplinary Sciences"@en,
        "Guangdong Provincial Key Laboratory of Fire Science and Technology"@en,
        "Lauterbur Research Center for Biomedical Imaging"@en,
        "Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering"@en,
        "School of Engineering"@en .

ns6:XST180486 ns0:hasName "Department of Medical Image"@en,
        "Department of Medical Imaging"@en,
        "Department of PET-CT, The First Affiliated Hospital, Medical College"@en,
        "Department of Radiology"@en .

ns6:XST180487 ns0:hasName "Nanjing Medical University Affiliated Wuxi Second Hospital"@en,
        "Nanjing Medical University Affiliated Wuxi the Second Hospital"@en .

ns6:XST180490 ns0:hasName "College of Engineering"@en,
        "Department of Biochemistry and Molecular Biology, School of Medicine"@en,
        "Department of Biochemistry, Medical School"@en,
        "Department of Electrical and Computer Engineering"@en,
        "Jiangsu Key Laboratory of Neuroregeneration"@en,
        "Jiangsu Key Laboratory of NeuroregenerationNantong University"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education and Co-innovation Center of Neuroregeneration"@en,
        "Sino-Dutch Biomedical and Information Engineering School"@en .

ns6:XST190500 ns0:hasName "The Key Lab of Optoelectronic Technology and Systems of the Education Ministry of China"@en .

ns6:XST190502 ns0:hasName "Department of Radiology"@en,
        "Department of Radiology, the"@en .

ns6:XST190503 ns0:hasName "Department of Mechanical Engineering"@en,
        "Department of Mechanical Engineering National Taipei University of Technology"@en .

ns6:XST190506 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns6:XST190514 ns0:hasName "Imaging Science Research Center"@en,
        "Imaging Science-based Lung and Bone Disease Research Center"@en,
        "Medical Convergence Research CenterWonkwang University"@en .

ns21:CBM192435 ns0:hasName "Department of General Surgery, Ruijin Hospital"@en .

ns21:CH180515 ns0:hasName "Department of Neurology"@en,
        "Gansu Provincial Hospital"@en .

ns21:CH180540 ns0:hasName "Department of Biomedical Engineering"@en,
        "Department of Mechanical Engineering and Material Science and Engineering"@en,
        "Department of Mechanical and Materials Engineering"@en .

ns21:CH180544 ns0:hasName "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Hand Surgery and Laboratory for Tissue Engineering and Regenerative Medicine, University Hospital of Erlangen"@en .

ns21:CH180545 ns0:hasName "The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine"@en .

ns21:CH199005 ns0:hasName "Helmholtz Virtual Institute - Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns21:CH199009 ns0:hasName "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Reconstructive Surgery"@en .

ns21:CH199201 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns21:CH199202 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Clinical Radiology, Interdisciplinary Ultrasound Center"@en,
        "Department of Clinical Radiology, Interdisciplinary Ultrasound-Center"@en,
        "Department of Clinical Radiology, Interdisciplinary Ultrasound-Center, University Hospital Grosshadern"@en,
        "Department of Radiology"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich - Grosshadern Campus"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich – Grosshadern Campus"@en,
        "Ludwig-Maximilians-University Munich"@en,
        "Ludwig-Maximilians-University Munich - Grosshadern Campus"@en,
        "Ludwig-Maximilians-University of Munich-Grosshadern Campus"@en .

ns21:CH199204 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Radiology"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich - Grosshadern Campus"@en,
        "Ludwig-Maximilians-University Munich - Grosshadern Campus"@en,
        "Ludwig-Maximilians-University of Munich-Grosshadern Campus"@en .

ns21:CH199205 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns21:CH199206 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en .

ns21:CH199210 ns0:hasName "Brandenburg University of Technology Cottbus-Senftenberg"@en,
        "Institute of Biotechnology"@en .

ns21:CH199215 ns0:hasName "Department for General, Visceral, Vascular and Transplantation Surgery"@en,
        "Department of General, Thoracic, Vascular and Transplantation Surgery"@en .

ns21:CH199220 ns0:hasName "Center for Plastic, Aesthetic, Hand & Reconstructive Surgery"@en,
        "Center for Plastic, Aesthetic, Hand &Reconstructive Surgery"@en,
        "Center for Plastic, Hand and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand-, and Reconstructive Surgery"@en,
        "Center of Plastic and Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Reconstructive Surgery"@en,
        "Department of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Hand, and Reconstructive Surgery"@en,
        "Department of Plastic, Reconstructive and Hand Surgery"@en,
        "Department of Plastic-, Hand-, and Reconstructive Surgery"@en,
        "University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery"@en .

ns21:CH199225 ns0:hasName "Applied Stem Cell Research Center"@en,
        "Center for Plastic, Aesthetic, Hand & Reconstructive Surgery"@en,
        "Center for Plastic, Aesthetic, Hand &Reconstructive Surgery"@en,
        "Center for Plastic, Hand and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand- and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand-, and Reconstructive Surgery"@en,
        "Center of Plastic and Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic Surgery"@en,
        "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Reconstructive Surgery"@en,
        "Department of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Hand, and Reconstructive Surgery"@en,
        "Department of Plastic, Hand- and Reconstructive Surgery"@en,
        "Department of Plastic, Hand-and Reconstructive Surgery"@en,
        "Department of Plastic, Reconstructive and Hand Surgery"@en,
        "Department of Plastic-, Hand- and Reconstructive Surgery"@en,
        "Department of Plastic-, Hand-, and Reconstructive Surgery"@en,
        "Reconstructive and Hand Surgery at the University Medical Center Regensburg"@en,
        "University Center for Plastic, Hand and Reconstructive Surgery"@en,
        "University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery"@en,
        "University Hospital Regensburg"@en,
        "University Medical Center Regensburg"@en .

ns21:ICA190605 ns0:hasName "Department of Signal Theory, Networking and Communications"@en,
        "School of Computer Science and Technology"@en .

ns21:IES192167 ns0:hasName "Graduate School of Biomedical and Health Sciences"@en .

ns21:IFS172242 ns0:hasName "School of Computer Engineering and Science"@en .

ns21:JAD170300 ns0:hasName "Department of Epidemiology, Joseph P. Mailman School of Public Health"@en,
        "Department of Neurology"@en,
        "Department of Neurology, College of Physicians and Surgeons"@en,
        "Department of Neurology, College of Physiciansand Surgeons"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, College of Physicians and Surgeons"@en,
        "Gertrude H. Sergievsky"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky Center, College of Physicians and Surgeons"@en,
        "Sergievsky Center, College of Physiciansand Surgeons"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en,
        "The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en .

ns21:JAD180492 ns0:hasName "Alzheimer Centre Limburg, School for Mental Health and Neuroscience (MHeNS)"@en,
        "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en .

ns21:JAD180496 ns0:hasName "Department of Biochemistry, Faculty of Medicine"@en,
        "Department of Biochemistry, Faculty of Medicine, UKMMC"@en .

ns21:JAD180631 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "University of New South Wales"@en .

ns21:JAD180857 ns0:hasName "Department of Psychiatry and Neuropsychology, Alzheimer Centre Limburg, School for Mental Health and Neurosciences"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en .

ns21:JAD181047 ns0:hasName "Division of Psychiatry"@en,
        "Essex Partnership University Foundation Trust"@en,
        "Essex Partnership University NHS Foundation Trust"@en,
        "UCL Mental Health Sciences Unit"@en .

ns21:JAD181217 ns0:hasName "Department of Neurology, Beijing Tiantan Hospital"@en .

ns21:JAD181224 ns0:hasName "Institute of Mental Health, Division of Psychiatry and Applied Psychology, School of Medicine"@en,
        "Nottingham University"@en .

ns21:JAD181261 ns0:hasName "Department of Neurology"@en .

ns21:JAD181298 ns0:hasName "Cognitive Impairment Center"@en .

ns21:JAD190075 ns0:hasName "School of Molecular and Cell Biology"@en,
        "University of the Witwatersrand"@en .

ns21:JAD190077 ns0:hasName "Vanderbilt Memory & Alzheimer’s Center, Department of Neurology"@en .

ns21:JAD190090 ns0:hasName "Department of Neurological Sciences"@en,
        "Department of Translational Science and Molecular Medicine"@en .

ns21:JAD190106 ns0:hasName "Department of Neurology and Alzheimer's Disease Research Center"@en,
        "Emory University"@en .

ns21:JAD190128 ns0:hasName "Department of Neurology and Neurotherapeutics"@en,
        "Department of Radiology"@en,
        "University of Texas Southwestern Medical Center"@en .

ns21:JAD190133 ns0:hasName "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Hospital District of North Karelia"@en,
        "Institute of Public Health and Clinical Nutrition"@en,
        "Public Health Promotion Unit"@en .

ns21:JAD190146 ns0:hasName "Bristol Randomised Trials Collaboration (BRTC), Population Health Sciences, Bristol Medical School"@en,
        "Bristol Randomised Trials Collaboration, Bristol Trials Centre"@en .

ns21:JAD190153 ns0:hasName "Department of Neurology, Qingdao Municipal Hospital"@en,
        "Department of Neurology, Qingdao Municipal Hospital, School of Medicine"@en .

ns21:JAD190183 ns0:hasName "INSERM, U1028, CNRS, UMR5292, Neuropain team"@en,
        "INSERM, U1028; CNRS, UMR5292"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR) Neurology Unit"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR), Neurology Unit"@en .

ns21:JAD190187 ns0:hasName "Clinical Neurochemistry Lab"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Lab, The Sahlgrenska Academy at"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "The Sahlgrenska Academy at Göteborg University"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "The Sahlgrenska Academy at the University of Gothenburg"@en,
        "The Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences"@en,
        "University of Goteborg"@en,
        "the Sahlgrenska Academy at Göteborg University"@en .

ns21:JAD190202 ns0:hasName "Brain Sciences Research Program"@en,
        "Brain Sciences Research Program, Sunnybrook Research Institute"@en,
        "Department of Medicine (Neurology)"@en,
        "Department of Medicine, Division of Neurology"@en,
        "Department of Medicine, Neurology"@en,
        "Heart & Stroke Foundation Canadian Partnership for Stroke Recovery"@en,
        "Hurvitz Brain Sciences Program"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute>"@en,
        "Institute of Medical Science"@en,
        "Institute of Medical Science, Department of Medicine (Neurology)"@en,
        "LC Campbell Cognitive Neurology Research Unit"@en,
        "LC Campbell Cognitive Neurology Research Unit, Brain Sciences Research Program"@en,
        "LC Campbell Cognitive Neurology Research Unit, Heart and Stroke Foundation Centre for Stroke Recovery"@en,
        "LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre"@en,
        "LC Campbell Cognitive Research Unit, Division of Neurology, Deparatment of Medicine, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre"@en,
        "The Rotman Research Institute"@en,
        "University of Toronto"@en .

ns21:JAD190262 ns0:hasName "Department of Epidemiology and Population Health"@en,
        "Department of Epidemiology and Population Health, Albert Einstein College of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Albert Einstein College of Medicine"@en,
        "Einstein Aging Study"@en,
        "Institute for Aging Research, Albert Einstein College of Medicine"@en,
        "Saul B. Korey Department of Neurology"@en .

ns21:JAD190280 ns0:hasName "Department of Computer Science, School of Computer and Communication Engineering"@en,
        "Department of Neurochemistry"@en,
        "Department of Neurochemistry, Inge Grundke-Iqbal Research Floor"@en,
        "NYS Institute for Basic Research in Developmental Disabilities"@en,
        "New York Institute for Basic Research in Developmental Disabilities"@en,
        "New York State Institute for Basic Research In Developmental Disabilities"@en,
        "New York State Institute for Basic Research in Developmental Disabilities"@en .

ns21:JAD190323 ns0:hasName "Department of Neuroscience, Neurological Clinic"@en,
        "Unit of Neurology, Department of Clinical and Experimental Medicine"@en .

ns21:JAD190334 ns0:hasName "Department of Neurology"@en,
        "Division of Diagnostic Services, Chromosome and DNA Laboratory"@en,
        "Institute of Clinical Medicine - Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

ns21:JAD190365 ns0:hasName "Department of Laboratory Medicine"@en,
        "Department of Laboratory Medicine and Pathobiology"@en,
        "Division of Pathology"@en,
        "Keenan Biomedical Research Centre, the Li Ka Shing Knowledge Institute"@en,
        "Keenan Research Centre for Biomedical Research"@en,
        "Keenan Research Centre for Biomedical Research, Li Ka Shing Knowledge Institute"@en,
        "Keenan Research Centre for Biomedical Research, the Li Ka Shing Knowledge Institute"@en,
        "Laboratory Medicine, St. Michael’s Hospital"@en,
        "University of Toronto"@en .

ns21:JAD190369 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en .

ns21:JAD190423 ns0:hasName "1st Department of Neurology, Medical School"@en,
        "3rd Department of Neurology"@en,
        "3rd Neurologic Clinic, Medical School, G. Papanikolaou Hospital"@en,
        "Aristotle University of Thessaloniki"@en,
        "Greek Association of Alzheimer's Disease and Related Disorders"@en,
        "Information Technologies Institute"@en,
        "Laboratory of Neurodegenerative Diseases"@en,
        "Third Department of Neurology, Memory and Dementia Centre, Medical School"@en .

ns21:JAD190427 ns0:hasName "Bordeaux CHU"@en,
        "INSERM Center 897 & CIC-1401-EC"@en,
        "Université de Bordeaux, Inserm"@en .

ns21:JAD190458 ns0:hasName "Guangdong Provincial Key Laboratory of Bioengineering Medicine"@en,
        "Institute of Biomedicine & Department of Cell Biology"@en .

ns21:JAD190484 ns0:hasName "Protein Design and Immunotherapy Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències, Edifici C"@en,
        "Protein Folding and Stability Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències"@en .

ns21:JAD190519 ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry and Behavioral Sciences"@en,
        "Lou Ruvo Center for Brain Health"@en,
        "Mental Illness Research, Education, and Clinical Centers"@en,
        "Mental Illness and Parkinson's Disease Research, Education, and Clinical Centers"@en,
        "Northwest Network VISN-20 Mental Illness Research"@en,
        "Parkinson's Disease Research Education and Clinical Center (PADRECC) Northwest (Portland & Seattle)"@en,
        "Parkinson's Disease Research, Education, and Clinical Centers"@en,
        "University of Washington School of Medicine"@en .

ns21:JAD190524 ns0:hasName "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Centre for Healthy Brain and Ageing"@en,
        "Prince of Wales Research Institute and Centre for Healthy Brain Aging"@en .

ns21:JAD190541 ns0:hasName "Alzheimer Centrum Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en .

ns21:JAD190567 ns0:hasName "Department of Neurology"@en,
        "Institute for Ageing and Health, Campus for Ageing and Vitality"@en,
        "Institute of Neuroscience"@en,
        "Institute of Neuroscience, Campus for Ageing and Vitality"@en .

ns21:JAD190569 ns0:hasName "Department of Psychiatry and Behavioral Sciences"@en,
        "Joseph and Kathleen Bryan Alzheimer's Disease Research Center"@en .

ns21:JAD190572 ns0:hasName "Department of Public Health and Caring Sciences"@en,
        "Department of Public Health and Caring Sciences, Molecular Geriatrics, Rudbeck Laboratory"@en,
        "Department of Public Health/ Geriatrics"@en .

ns21:JAD190644 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en .

ns21:JAD190817 ns0:hasName "Department of Neurology, School of Medicine"@en .

ns21:JAD190823 ns0:hasName "Centre for Innovative Ageing"@en,
        "Department of Psychology"@en,
        "Department of Psychology, College of Human and Health Sciences"@en,
        "School of Experimental Psychology"@en .

ns21:JAD190838 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology and Laboratory of Neurobiology, Hospital Clinico San Carlos"@en,
        "Department of Neurology and Laboratory of Neurobiology, Hospital Clínico San Carlos"@en,
        "Department of Neurology, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC)"@en,
        "Department of Neurology, Hospital Clínico Universitario San Carlos, San Carlos Institute for Health Research (IdISSC)"@en,
        "Department of Neurology, San Carlos Institute for Health Research (IdISSC)"@en .

ns21:JAD190889 ns0:hasName "Centre for Innovative Ageing"@en,
        "College of Human and Health Sciences, Department of Psychology"@en,
        "Department of Experimental Psychology"@en,
        "Department of Psychology"@en,
        "Department of Psychology, College of Human and Health Sciences"@en,
        "School of Experimental Psychology"@en .

ns21:JPD191648 ns0:hasName "Critical Path Institute"@en .

ns21:MGC180763 ns0:hasName "College of Chemistry and Molecular Engineering"@en .

ns21:NRE182637 ns0:hasName "Department of Systems Medicine"@en,
        "Department of Systems Medicine, Neurology Unit"@en,
        "Department of Systems Medicine, Sleep Medicine Centre"@en,
        "IRCSS Fondazione Santa Lucia"@en,
        "Neuroscience PhD School"@en .

ns21:NRE192722 ns0:hasName "Department of Medicine ( Royal Melbourne Hospital)"@en,
        "Department of Rehabilitation Medicine"@en,
        "Department of Rehabilitation and Australian Rehabilitation Research Centre"@en .

ns21:NRE192745 ns0:hasName "Université Catholique de Louvain"@en,
        "Université catholique de Louvain"@en .

ns21:NRE192788 ns0:hasName "Movement Neuroscience Program, Institute of Health and Biomedical Innovation"@en,
        "Movement Neuroscience, Injury Prevention Program, Institute of Health and Biomedical Innovation"@en,
        "School of Exercise and Nutrition Sciences, Faculty of Health"@en .

ns21:RNN190919 ns0:hasName "Department of Neurobiology"@en,
        "Department of Neurology"@en .

ns21:THC191639 ns0:hasName "Institute of Fluid Science"@en .

ns21:THC199029 ns0:hasName "Department of Cardiology"@en,
        "Department of Dermatology"@en,
        "Dermatology"@en,
        "DermatologyThe First Hospital of China Medical University"@en,
        "First Affiliated Hospital of University of South China"@en,
        "Key Laboratory of Immunodermatology"@en .

ns21:THC199031 ns0:hasName "Department of Cardiology"@en .

ns21:WOR192958 ns0:hasName "Military Performance Division"@en,
        "U.S. Army Research Institute of Environmental Medicine"@en .

ns21:XST180460 ns0:hasName "Beijing University of Technology"@en,
        "Department of Medical Imaging"@en,
        "Department of Radiology"@en .

ns21:XST180477 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns21:XST180487 ns0:hasName "Nanjing Medical University Affiliated Wuxi Second Hospital"@en,
        "Nanjing Medical University Affiliated Wuxi the Second Hospital"@en .

ns21:XST190514 ns0:hasName "Department of Radiology"@en,
        "Imaging Science-based Lung and Bone Disease Research Center"@en,
        "Medical Convergence Research CenterWonkwang University"@en .

ns21:XST190526 ns0:hasName "School of Medical Instrument and Food Engineering"@en,
        "University of Shanghai for Science and Technology"@en .

ns21:XST190527 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns200:CH180404 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital"@en,
        "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Shanghai Center for Thyroid Diseases"@en,
        "Shanghai Research Center for Thyroid Diseases"@en,
        "Thyroid Institute"@en,
        "Ultrasound Research and Education Institute"@en .

ns200:CH180428 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesiology and Intensive Care"@en,
        "Department of Anaesthesiology and Intensive Care, University Hospital Hradec Kralove"@en,
        "Department of Anaesthesiology, Perioperative Medicine and Intensive Care"@en .

ns200:CH180457 ns0:hasName "The First Affiliated Hospital of Guangxi University of Traditional Chinese Medicine"@en .

ns200:CH180477 ns0:hasName "Second Affiliated Hospital of Harbin Medical University"@en .

ns200:CH199005 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns200:CH199201 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns200:CH199206 ns0:hasName "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en .

ns200:CH199220 ns0:hasName "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery"@en .

ns200:CH199223 ns0:hasName "Department of Urology, University Hospital Grosshadern"@en .

ns200:CH199224 ns0:hasName "University Hospital Regensburg"@en .

ns200:CH199225 ns0:hasName "Center for Plastic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic and Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Department of Plastic, Reconstructive and Hand Surgery"@en,
        "Reconstructive and Hand Surgery at the University Medical Center Regensburg"@en,
        "University Hospital Regensburg"@en .

ns200:IFS179239 ns0:hasName "Economics and Management School"@en,
        "North China Electric Power University"@en .

ns200:JAD181030 ns0:hasName "Ageing Epidemiology (AGE) Research Unit"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar"@en,
        "German Center for Neurodegenerative Diseases (DZNE) Munich"@en,
        "Munich Cluster for Systems Neurology (SyNergy)"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine"@en,
        "Technische Universität München"@en,
        "West London Cognitive Disorders Treatment and Research Unit"@en .

ns200:JAD181033 ns0:hasName "CMRR – EA CoBTeK- CHU –"@en,
        "Centre Mémoire de Ressource et de Recherche, EA CoBTeK"@en,
        "Centre Mémoire de Ressources et de Recherche"@en,
        "Centre Mémoire de Ressources et de Recherche (CMRR) –Teaching Hospital of Nice, Claude Pompidou Institute"@en,
        "Centre Mémoire de Ressources et de Recherche/EA COBTEK"@en,
        "Centre de recherche de ressource et de Recherche"@en,
        "CoBTeK (Cognition-Behaviour-Technology) Lab"@en,
        "CoBTeK Cognition Behaviour Technology EA 7276, Research Center Edmond and Lily Safra"@en,
        "EA 7276 CoBTeK –Cognition Behaviour Technology, University of Nice Sophia-Antipolis, Claude Pompidou Institute"@en,
        "EA CoBTeK"@en,
        "EA Cobtek"@en,
        "Laboratory of Human Motricity Sport and Health (LAHMESS, EA 6312)"@en,
        "Memory Center"@en,
        "Memory CenterCHU – CoBTeK Research"@en,
        "Research Memory Center EA COBTEK"@en,
        "Research Memory Centre"@en .

ns200:JAD181196 ns0:hasName "Department of Epidemiology & Biostatistics, Schulich Interfaculty Program in Public Health"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Medicine, Division of Geriatric Medicine, Parkwood Hospital"@en,
        "Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry"@en,
        "Departments of Medicine (Geriatric Medicine), and Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry"@en,
        "Gait and Brain Lab, Parkwood Institute"@en,
        "Lawson Health Research Institute"@en,
        "“Gait and Brain Lab”"@en .

ns200:JAD181217 ns0:hasName "Department of Neurology, Beijing Tiantan Hospital"@en .

ns200:JAD181261 ns0:hasName "Department of Neurology"@en .

ns200:JAD181265 ns0:hasName "Department of Public Health and Caring Sciences, Geriatrics"@en,
        "Department of Public Health and Caring Sciences/Geriatrics"@en,
        "Department of Public Health and Caring Sciences/Geriatrics, Faculty of Medicine"@en,
        "Department of Public Health/Geriatrics"@en,
        "Uppsala University"@en .

ns200:JAD181295 ns0:hasName "Kuopio Research Centre of Geriatric Care"@en,
        "School of Pharmacy"@en .

ns200:JAD181297 ns0:hasName "Department of Epidemiology"@en,
        "Department of Radiology"@en,
        "Department of Radiology and Nuclear Medicine"@en .

ns200:JAD190011 ns0:hasName "Department of Neurology"@en,
        "Department of Pathology and Alzheimer’s Disease Research Center"@en .

ns200:JAD190028 ns0:hasName "Department of Neurological Surgery"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Neurotherapeutics"@en,
        "Department of Neurology and Neurotherapeutics, Alzheimer's Disease Center"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, Alzheimer's Disease Center"@en,
        "Departments of Neurology and Neurotherapeutics"@en,
        "Departments of Psychiatry"@en .

ns200:JAD190077 ns0:hasName "Center for Human Genetics and Research, Department of Molecular Physiology & Biophysics"@en,
        "Vanderbilt Memory & Alzheimer's Center, Department of Neurology"@en,
        "Vanderbilt Memory & Alzheimer’s Center, Department of Neurology"@en,
        "Vanderbilt Memory and Alzheimer’s Center"@en .

ns200:JAD190099 ns0:hasName "Department of Neurology, Nanfang Hospital"@en .

ns200:JAD190107 ns0:hasName "Department of Neurology"@en,
        "Service of Neurology"@en .

ns200:JAD190113 ns0:hasName "Department of Neurology, Xuanwu Hospital"@en .

ns200:JAD190128 ns0:hasName "Center for BrainHealth"@en,
        "Department of Neurology and Neurotherapeutics"@en .

ns200:JAD190161 ns0:hasName "Commen Subjects Department"@en,
        "Department of Pharmacology and Experimental Therapeutics"@en .

ns200:JAD190187 ns0:hasName "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en .

ns200:JAD190202 ns0:hasName "Brain Sciences Research Program, Sunnybrook Research Institute"@en,
        "Department of Health Policy, Management and Evaluation"@en,
        "Department of Research Design and Biostatistics"@en,
        "Evaluative Clinical Sciences, Hurvitz Brain Sciences Program"@en,
        "Hurvitz Brain Sciences Program"@en .

ns200:JAD190237 ns0:hasName "Center of Excellence on Aging and Translational Medicine - CeSI-MeT"@en,
        "Department of Neurology"@en,
        "Department of Neurology, CESI-Center for Excellence on Aging"@en .

ns200:JAD190280 ns0:hasName "Department of Neurochemistry, Inge Grundke-Iqbal Research Floor"@en .

ns200:JAD190323 ns0:hasName "IRCCS Fondazione S. Lucia"@en,
        "Unit of Neurology, Department of Clinical and Experimental Medicine"@en,
        "Unit of Neurology, Department of Medical Specialties"@en .

ns200:JAD190334 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine – Neurology, Universityof Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "Neuro Center"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

ns200:JAD190339 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology and Psychiatry"@en,
        "Sackler Faculty of Medicine"@en .

ns200:JAD190340 ns0:hasName "Department of Neurology & Neurobiology of Aging"@en,
        "Department of Neurology and Neurobiology and Aging"@en,
        "Department of Neurology and Neurobiology of Aging"@en .

ns200:JAD190385 ns0:hasName "Department of Human Neuroscience"@en .

ns200:JAD190394 ns0:hasName "Department of Neuroscience, Biomedicine, and Movement Sciences"@en,
        "Neuromotor and Cognitive Rehabilitation Research CenterDepartment of NeurosciencesUniversity of Verona"@en .

ns200:JAD190415 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en .

ns200:JAD190458 ns0:hasName "Guangdong Provincial Key Laboratory of Bioengineering Medicine"@en,
        "Institute of Biomedicine & Department of Cell Biology"@en .

ns200:JAD190469 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en .

ns200:JAD190480 ns0:hasName "Institute of Gerontology and Geriatrics, Department of Medicine"@en,
        "Section of Gerontology and Geriatrics, Department of Medicine"@en,
        "Sezione di Gerontologia e Geriatria, Dipartimento di Medicina Clinica e Sperimentale"@en .

ns200:JAD190487 ns0:hasName "Center for Cognitive Disorders"@en .

ns200:JAD190517 ns0:hasName "Department of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Medicine"@en .

ns200:JAD190610 ns0:hasName "Department of Epidemiology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Department of Radiology and Nuclear Medicine"@en,
        "Department of Radiology and Nuclear medicine"@en,
        "Memory Ageing and Cognition Center (MACC)"@en,
        "Memory Aging & Cognition Centre"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en,
        "Saw Swee Hock School of Public Health"@en .

ns200:JAD190622 ns0:hasName "Center for Comprehensive Care and Research on Memory Disorders"@en .

ns200:JAD190696 ns0:hasName "Mental Health Unit"@en,
        "University College London"@en .

ns200:JAD190817 ns0:hasName "Department of Neurology, School of Medicine"@en .

ns200:JHD180337 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research"@en,
        "Department of Radiology"@en,
        "George-Huntington-Institute"@en .

ns200:JND190416 ns0:hasName "Department of Neurology, Friedrich-Baur-Institute"@en,
        "Friedrich-Baur-Institute, Department of Neurology"@en .

ns200:JPD191616 ns0:hasName "Department of Neurology"@en,
        "Radboud University Medical Centre, Donders Institute for Brain"@en .

ns200:JPD191675 ns0:hasName "Department of Neurology"@en,
        "Higashi Matsudo Municipal Hospital"@en,
        "Higashi-Matsudo City Hospital"@en,
        "Tokyo Metropolitan Institute of Medical Science"@en,
        "Tokyo Metropolitan Institute of Medical Sciences"@en .

ns200:JPD191713 ns0:hasName "Department of Neurology, Expert Center for Parkinson’s Disease, INSERM UMRS_1171"@en,
        "Inserm, U1171, Troubles cognitifs dégénératifs et vasculaires"@en,
        "Neurology and Movement Disorders Department"@en,
        "Service de Neurologie et Pathologie du Mouvement"@en,
        "U1171, INSERM"@en .

ns200:JVR191022 ns0:hasName "Center for Disability Studies"@en,
        "Kent State University"@en .

ns200:NHA180059 ns0:hasName "ANZAC Research Institute"@en,
        "Aging and Alzheimer’s Institute"@en,
        "Centre for Education and Research on Ageing and Ageing and Alzheimers Institute, Concord Hospital"@en,
        "Charles Perkins Centre"@en .

ns200:NPM17149 ns0:hasName "Department of Pediatrics, Division of Neonatal-Perinatal Medicine"@en,
        "Department of Pediatrics, Division of Neonatology"@en .

ns200:NRE182637 ns0:hasName "Department of Systems Medicine"@en,
        "IRCSS Fondazione Santa Lucia"@en,
        "Neuroscience PhD School"@en .

ns200:NRE192714 ns0:hasName "Alzheimer's Disease Assessment Unit/Laboratory of Neuropsychology, IRCCS “C. Mondino"@en,
        "Neuropsychology/Alzheimer’s Disease Assessment Unit"@en .

ns200:RNN190916 ns0:hasName "Centre for Brain Health"@en,
        "Department of Physical Therapy"@en,
        "Department of Physical Therapy, Faculty of Medicine"@en .

ns200:THC191715 ns0:hasName "Department of Emergency Medicine"@en,
        "Department of Emergency Medicine, School of Medicine"@en .

ns200:WOR192920 ns0:hasName "Department of Occupational Therapy"@en .

ns200:WOR192947 ns0:hasName "Department of Surgery"@en,
        "Institute of Biomaterials and Biomedical Engineering"@en,
        "Rehabilitation Sciences InstituteUniversity of Toronto"@en,
        "Toronto Rehabilitation Institute"@en,
        "iDAPT Technology R & D Team"@en .

ns200:WOR192960 ns0:hasName "University of Chichester"@en .

ns200:XST180465 ns0:hasName "Department of Radiology"@en .

ns200:XST180477 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns200:XST190527 ns0:hasName "Beijing Center for Mathematics and Information Interdisciplinary Sciences"@en,
        "Guangdong Provincial Key Laboratory of Fire Science and Technology"@en,
        "Lauterbur Research Center for Biomedical Imaging"@en,
        "Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering"@en,
        "School of Engineering"@en .

ns200:XST190548 ns0:hasName "Department of Biomedical Engineering, College of Materials Science and Engineering"@en .

ns210:CH199223 ns0:hasName "Department of Urology"@en,
        "Department of Urology, University Hospital Grosshadern"@en .

ns210:HAB190375 ns0:hasName "Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science"@en,
        "Department of Haematology, School of Medical Laboratory Science"@en .

ns210:JAD180630 ns0:hasName "Department of Neurology, Memory Clinic"@en,
        "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "Memory Clinic, Department of Neurology, Charles University"@en,
        "Memory Disorders Clinic, Department of Neurology"@en .

ns210:JAD180848 ns0:hasName "Centre for Hip Health and Mobility"@en,
        "Department of Physical Therapy"@en,
        "Department of Physical Therapy, Aging, Mobility, and Cognitive Neuroscience Lab"@en,
        "Djavad Mowafaghian Centre for Brain Health"@en .

ns210:JAD181030 ns0:hasName "Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine"@en,
        "Neuroepidemiology and Ageing Research, School of Public Health"@en .

ns210:JAD181168 ns0:hasName "Department of Nuclear Medicine"@en,
        "Institute of Neuroscience"@en,
        "Neurology Imaging Unit, Department of Medicine"@en .

ns210:JAD181217 ns0:hasName "Department of Neurology, Beijing Tiantan Hospital"@en .

ns210:JAD181220 ns0:hasName "Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital"@en,
        "Huazhong University of Science and Technology"@en .

ns210:JAD181256 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Medical Research Center"@en,
        "Medical Research Center, Oulu University Hospital, Oulu, Finland and Research Unit of Clinical Neuroscience, Neurology"@en,
        "NeuroCenter, Neurology"@en,
        "Research Unit of Clinical Neuroscience, Neurology"@en .

ns210:JAD181261 ns0:hasName "Department of Neurology"@en .

ns210:JAD190010 ns0:hasName "Department of Medical and Molecular Genetics"@en,
        "Indiana Alzheimer Disease Center"@en,
        "Medical and Molecular Genetics"@en .

ns210:JAD190025 ns0:hasName "Alzheimer Disease Research and Clinical Center, Gerontopole"@en,
        "CHU La Grave"@en,
        "CHU Toulouse"@en,
        "Department of Geriatrics, Gérontopôle, CHU Toulouse"@en,
        "Gerontopole"@en,
        "Gerontopole, Alzheimer’s Disease Research and Clinical Care, INSERM 1027"@en,
        "Gerontopôle, Department of Internal Medicine and Clinical Gerontology"@en,
        "Gerontopôle, INSERM U 1027"@en,
        "Gérontopôle"@en,
        "Gérontopôle de Toulouse, Département de Médecine Interne et Gérontologie Clinique"@en,
        "Gérontopôle, Department of Geriatrics, CHU Toulouse"@en,
        "INSERM U 558"@en,
        "INSERM U 558, Department of Geriatrics, CHU Toulouse"@en,
        "INSERM University of Toulouse"@en,
        "Inserm"@en,
        "Inserm U558"@en,
        "Toulouse Gerontopole University Hospital"@en,
        "Toulouse University Hospital"@en,
        "UMR INSERM"@en,
        "University of Toulouse III"@en .

ns210:JAD190107 ns0:hasName "Centro de Investigación en Red de Enfermedades Neurodegenerativas (CIBERNED)"@en,
        "Department of Neurology"@en,
        "Neurology Service"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en .

ns210:JAD190128 ns0:hasName "Center for BrainHealth, School of Behavioral and Brain Sciences"@en,
        "Department of Neurology and Neurotherapeutics"@en,
        "Department of Psychiatry"@en .

ns210:JAD190132 ns0:hasName "Division of Diagnostic Services, Chromosome and DNA Laboratory"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

ns210:JAD190161 ns0:hasName "Department of Pharmacology & Experimental Therapeutics"@en,
        "Department of Pharmacology and Experimental Therapeutics"@en,
        "Departments of Pharmacology & Experimental Therapeutics"@en,
        "Departments of Pharmacology & Experimental Therapeutics, Psychiatry"@en,
        "Departments of Pharmacology and Experimental Therapeutics"@en,
        "Pharmacology and Experimental Therapeutics"@en .

ns210:JAD190202 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Group"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology, Faculty of Medicine"@en,
        "Sunnybrook Research Institute"@en,
        "Toronto Rehabilitation Institute"@en,
        "University Health Network at Toronto Rehabilitation Institute"@en .

ns210:JAD190220 ns0:hasName "Center for Spirituality and the Mind"@en,
        "Department of Radiology"@en,
        "Division of Nuclear Medicine, Department of Radiology"@en,
        "Myrna Brind Center of Integrative Medicine"@en,
        "Thomas Jefferson University School of Medicine"@en .

ns210:JAD190264 ns0:hasName "Eli Lilly and Company"@en .

ns210:JAD190280 ns0:hasName "Department of Neurochemistry"@en,
        "Department of Neurochemistry, Inge Grundke-Iqbal Research Floor"@en,
        "New York State Institute for Basic Research in Developmental Disabilities"@en .

ns210:JAD190365 ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychiatry, Division of Geriatric Psychiatry, St. Michael’s Hospital"@en,
        "Faculty of Medicine, Department of Psychiatry"@en,
        "Keenan Research Centre"@en,
        "Keenan Research Centre for Biomedical Research"@en,
        "Keenan Research Centre for Biomedical Research, Li Ka Shing Knowledge Institute"@en,
        "Neuroscience Research Program, Keenan Research Centre for Biomedical Science"@en .

ns210:JAD190415 ns0:hasName "Department of Neurology, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons"@en .

ns210:JAD190494 ns0:hasName "Department of Experimental Medicine and Oncology"@en,
        "Department of Neuroscience"@en,
        "Neuroscience Institute of Cavalieri Ottolenghi Foundation (NICO)"@en .

ns210:JAD190524 ns0:hasName "Academic Department for Old Age Psychiatry"@en,
        "Aged Care Psychiatry"@en,
        "Center for Healthy Brain Ageing"@en,
        "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain and Ageing"@en,
        "Dementia Centre for Research Collaboration"@en,
        "Dementia Centre for Research Collaboration, School of Psychiatry"@en,
        "Dementia Collaborative Research Centre"@en,
        "Dementia Collaborative Research Centre, School of Psychiatry"@en,
        "Dementia Collaborative Research Centre, School of Psychiatry, UNSW Medicine"@en,
        "Primary Dementia Collaborative Research Centre"@en,
        "School of Psychiatry"@en,
        "The University of New South Wales"@en .

ns210:JAD190577 ns0:hasName "Institute of Pharmaceutical Science"@en,
        "Institute of Pharmaceutical Sciences"@en .

ns210:JAD190644 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en .

ns210:JAD190645 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Department of Medicine"@en,
        "Department of Medicine, Division of Geriatrics and Gerontology"@en,
        "Department of Medicine, Section of Geriatrics and Gerontology"@en,
        "Department of Veterans Affairs (VA) Geriatric Research"@en,
        "Division of Geriatrics and Gerontology, Department of Medicine"@en,
        "George Washington University"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "Geriatric Research, Education and Clinical Center (11G)"@en,
        "Geriatric Research, Education and Clinical Center (GRECC)"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "University of Wisconsin School of Medicine and Public Health"@en,
        "William S. Middleton Memorial Veterans Hospital Geriatric Research"@en,
        "Wisconsin Alzheimer's Disease Research Center"@en,
        "Wisconsin Alzheimer's Disease Research Center, (ADRC)"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns210:JAD190817 ns0:hasName "Department of Neurology, School of Medicine"@en .

ns210:JAD190838 ns0:hasName "Department of Neurology and Laboratory of Neurobiology, Hospital Clinico San Carlos"@en,
        "Department of Neurology and Laboratory of Neurobiology, Hospital Clínico San Carlos"@en,
        "Department of Neurology, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC)"@en,
        "Department of Neurology, San Carlos Institute for Health Research (IdISSC)"@en .

ns210:JAD190898 ns0:hasName "Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society"@en,
        "Department of Neurobiology, Division for Neurogeriatrics, Care Sciences and Society (NVS)"@en .

ns210:JHD180337 ns0:hasName "Department of Physical Therapy, School of Health Technology and Management"@en,
        "George-Huntington-Institute"@en .

ns210:JHD190354 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research"@en,
        "Department of Radiology"@en,
        "George-Huntington-Institute"@en .

ns210:JHD190355 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Perelman School of Medicine"@en,
        "Department of Psychology"@en .

ns210:MNM180261 ns0:hasName "Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-Communicable Disease"@en,
        "Department of Pediatrics, Child Growth and Development Research Center, Research Institute for Primordial Prevention of Non-communicable Disease"@en .

ns210:NRE182665 ns0:hasName "Department of Physical Therapy"@en .

ns210:NRE192752 ns0:hasName "Clinical Stroke Research Unit, Department of Neurology, Rigshospitalet, Faculty of Health Sciences"@en,
        "Faculty of Health Sciences"@en .

ns210:RNN190926 ns0:hasName "Department of Neurology"@en,
        "Neurology"@en,
        "NeurologyThe First Hospital of China Medical University"@en .

ns210:THC199029 ns0:hasName "Department of Cardiology"@en .

ns210:XST180464 ns0:hasName "College of Engineering"@en,
        "Department of Biochemistry and Molecular Biology, School of Medicine"@en,
        "Department of Biochemistry, Medical School"@en,
        "Department of Electrical and Computer Engineering"@en,
        "Jiangsu Key Laboratory of Neuroregeneration"@en,
        "Jiangsu Key Laboratory of NeuroregenerationNantong University"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education and Co-innovation Center of Neuroregeneration"@en,
        "Sino-Dutch Biomedical and Information Engineering School"@en .

ns210:XST190500 ns0:hasName "Department of Radiation Physics"@en,
        "Key Laboratory of Optoelectronics Technology & System"@en,
        "The Key Lab of Optoelectronic Technology and Systems of the Education Ministry of China"@en .

ns210:XST190506 ns0:hasName "Beijing Center for Mathematics and Information Interdisciplinary Sciences"@en,
        "Guangdong Provincial Key Laboratory of Fire Science and Technology"@en,
        "Lauterbur Research Center for Biomedical Imaging"@en,
        "Lauterbur Research Center for Biomedical Imaging, Institute of Biomedical and Health Engineering"@en,
        "School of Engineering"@en .

ns210:XST190527 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns77:CBM192435 ns0:hasName "Department of General Surgery"@en,
        "Department of General Surgery, Ruijin Hospital"@en,
        "Shanghai Institute of Digestive Surgery, Ruijin Hospital"@en,
        "Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital"@en .

ns77:CH199009 ns0:hasName "Center for Plastic, Aesthetic, Hand & Reconstructive Surgery"@en,
        "Center for Plastic, Aesthetic, Hand &Reconstructive Surgery"@en,
        "Center for Plastic, Hand and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand-, and Reconstructive Surgery"@en,
        "Center of Plastic and Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Reconstructive Surgery"@en,
        "Department of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Hand, and Reconstructive Surgery"@en,
        "Department of Plastic, Reconstructive and Hand Surgery"@en,
        "Department of Plastic-, Hand-, and Reconstructive Surgery"@en .

ns77:CH199206 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns77:JAD180630 ns0:hasName "Charles University in Prague and Motol University Hospital"@en,
        "Department of Neurology, 2nd Faculty of Medicine, Motol University Hospital"@en,
        "Department of Neurology, Memory Clinic"@en,
        "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "Department of Neurology, Memory Disorders Clinic"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "Memory Clinic, Department of Neurology, Charles University"@en,
        "Memory Disorders Clinic, Department of Neurology"@en,
        "Memory Disorders Clinic, Department of Neurology, 2nd Faculty of Medicine"@en .

ns77:JAD181113 ns0:hasName "Arizona Alzheimer's Consortium"@en,
        "Neurogenomics Division"@en,
        "Translational Genomics Research Institute"@en .

ns77:JAD181140 ns0:hasName "Department of Epidemiology, Graduate School of Public Health"@en,
        "University of Pittsburgh"@en .

ns77:JAD181168 ns0:hasName "Imperial College London"@en,
        "Neurology Imaging Unit, Department of Medicine"@en .

ns77:JAD181171 ns0:hasName "Molecular Neuroscience Research Center"@en .

ns77:JAD181203 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "HBSc Candidate"@en,
        "Hurvitz Brain Sciences Program"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Neuropsychopharmacology Research Group"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology, Faculty of Medicine"@en,
        "Sunnybrook Research Institute"@en,
        "Toronto Rehabilitation Institute"@en,
        "University Health Network at Toronto Rehabilitation Institute"@en .

ns77:JAD181256 ns0:hasName "Medical Research Center"@en,
        "Research Unit of Clinical Neuroscience, Neurology"@en,
        "Unit of Clinical Neuroscience, Neurology"@en .

ns77:JAD181265 ns0:hasName "Department of Public Health and Caring Sciences, Geriatrics"@en,
        "Department of Public Health and Caring Sciences, Molecular Geriatrics, Rudbeck Laboratory"@en,
        "Department of Public Health and Caring Sciences/Geriatrics"@en,
        "Department of Public Health and Caring Sciences/Molecular Geriatrics, Rudbeck Laboratory"@en,
        "Department of Public Health/ Geriatrics"@en,
        "Uppsala University"@en .

ns77:JAD181282 ns0:hasName "Alzheimer’s Disease Core Center, Perelman School of Medicine"@en,
        "Center for Neurodegenerative Disease Research (CNDR)"@en,
        "Department of Pathology & Laboratory Medicine and Center for Neurodegenerative Diseases Research"@en,
        "Department of Pathology & Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research"@en,
        "Department of Pathology and Laboratory Medicine"@en,
        "Department of Pathology and Laboratory Medicine, Institute on Aging, Center for Neurodegenerative Disease Research"@en,
        "Department of Pathology and Laboratory Medicine, Perelman School of Medicine"@en,
        "Department of Pathology, and Laboratory Medicine"@en,
        "Departments of Pathology and Laboratory Medicine"@en,
        "Institute on Aging and Center for Neurodegenerative Disease Research, Perelman School of Medicine"@en,
        "The University of Pennsylvania School of Medicine"@en,
        "Udall Parkinson’s Research Center, Perelman School of Medicine"@en .

ns77:JAD190094 ns0:hasName "Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences"@en,
        "Clinical Pharmacology and Geriatric Pharmacotherapy Unit, School of Pharmacy, Faculty of Health Sciences"@en,
        "Department of Epidemiology and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences"@en,
        "Kuopio Research Centre of Geriatric Care"@en,
        "NHMRC Cognitive Decline Partnership Centre"@en,
        "Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, Sansom Institute"@en,
        "Sansom Institute"@en .

ns77:JAD190132 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine - Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en .

ns77:JAD190152 ns0:hasName "CIBIT – Coimbra Institute for Biomedical Imaging and Life Sciences"@en,
        "CIBIT, Institute for Nuclear Sciences Applied to Health (ICNAS - P)"@en,
        "IBILI – Faculty of Medicine"@en,
        "Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine"@en .

ns77:JAD190161 ns0:hasName "Department of Neurology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology and Experimental Therapeutics"@en,
        "Departments of Neurology"@en,
        "Departments of Pharmacology and Experimental Therapeutics"@en,
        "Departments of Pharmacology and Neurology"@en,
        "Loyola University Medical Center"@en .

ns77:JAD190323 ns0:hasName "Department of Neuroscience, Neurological Clinic"@en,
        "Unit of Neurology, Department of Clinical and Experimental Medicine"@en .

ns77:JAD190346 ns0:hasName "Department of Neurology, Hemorrhagic Stroke Research Group"@en,
        "Department of Neurology, Hemorrhagic Stroke Research Program"@en,
        "Department of Neurology, Massachusetts General Hospital Stroke Research Center"@en .

ns77:JAD190480 ns0:hasName "Institute of Gerontology and Geriatrics, Department of Medicine"@en,
        "Section of Gerontology and Geriatrics, Department of Medicine"@en,
        "University of Perugia"@en .

ns77:JAD190524 ns0:hasName "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Neuropsychiatric Institute"@en,
        "Neuropsychiatric Institute (NPI)"@en .

ns77:JAD190562 ns0:hasName "Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases (MIND), Department of Neurology, Massachusetts General Hospital and"@en,
        "Genetics and Aging Research Unit, McCance Center for Brain Health"@en .

ns77:JAD190644 ns0:hasName "Department of Neurology, Graduate School of Medicine, Dentistry and Pharmaceutical Sciences"@en,
        "Okayama University"@en,
        "Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science"@en .

ns77:JAD190645 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Department of Medicine, Section of Geriatrics and Gerontology"@en,
        "Department of Veterans Affairs (VA) Geriatric Research"@en,
        "GRECC, William S. Middleton Memorial Veterans Hospital and Department of Medicine"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "Wisconsin Alzheimer's Institute"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns77:JAD190660 ns0:hasName "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas, CIBERNED"@en,
        "Neurology Service"@en,
        "Neurology Service and CIBERNED"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en,
        "Service of Neurology"@en .

ns77:JAD190817 ns0:hasName "Department of Neurology, School of Medicine"@en,
        "Department of Pharmacology, School of Medicine"@en .

ns77:JND190379 ns0:hasName "Department of Neurology and Neurosurgery"@en,
        "Department of Neurology, Brain Center Rudolf Magnus"@en .

ns77:JPD191616 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Donders Institute for Brain, Cognition and Behaviour"@en,
        "Department of Neurology, Donders Institute for Brain, Cognition, and Behavior"@en,
        "Donders Institute for Brain"@en,
        "Parkinson Center Nijmegen"@en,
        "Parkinson Center Nijmegen (ParC), Donders Institute for Brain, Cognition and Behaviour"@en,
        "Radboud University Medical Center"@en,
        "Radboud University Medical Center;"@en,
        "Radboud University Medical Centre"@en,
        "Radboud University Medical Centre, Donders Institute for Brain"@en,
        "Radboud University Nijmegen Medical Center"@en,
        "Radboud University Nijmegen Medical Centre"@en .

ns77:JVR191026 ns0:hasName "University of Wisconsin-Madison"@en .

ns77:XST180477 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns77:XST190527 ns0:hasName "Lauterbur Research Center for Biomedical Imaging"@en .

ns229:CBM182020 ns0:hasName "Department of Urology"@en,
        "The Department of Urology, The First Affiliated Hospital"@en .

ns229:CH189907 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesiology and Intensive Care"@en,
        "Department of Anaesthesiology and Intensive Care Medicine, Charles University in Prague, Faculty of Medicine Hradec Kralove"@en,
        "Department of Anaesthesiology and Intensive Care, University Hospital Hradec Kralove"@en,
        "Department of Anaesthesiology, Perioperative Medicine and Intensive Care"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en .

ns229:CH199223 ns0:hasName "Department of Urology"@en,
        "Department of Urology, University Hospital Grosshadern"@en .

ns229:JAD180572 ns0:hasName "Brain and Ageing Research Program, School of Psychiatry"@en,
        "Brain and Ageing Research Program, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging"@en,
        "Centre for Healthy Brain Aging (CHeBA), School of Psychiatry"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Department of Neuropsychiatry"@en,
        "Neuropsychiatric Institute"@en,
        "Neuropsychiatric Institute (NPI)"@en,
        "Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine"@en,
        "Prince of Wales Research Institute and Centre for Healthy Brain Aging"@en,
        "School of Medicine"@en,
        "School of Psychiatry"@en .

ns229:JAD180630 ns0:hasName "Department of Neurology, 2nd Faculty of Medicine, Motol University Hospital"@en,
        "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "Memory Disorders Clinic, Department of Neurology, 2nd Faculty of Medicine"@en .

ns229:JAD181217 ns0:hasName "Central Laboratory, Xuanwu Hospital"@en,
        "Department of Coloproctology"@en,
        "Department of Neurology, Beijing Tiantan Hospital"@en,
        "Institute of Aviation Medicine"@en .

ns229:JAD181246 ns0:hasName "Institute of Cell Biophysics"@en .

ns229:JAD181261 ns0:hasName "Department of Neurology"@en,
        "Duke-NUS Graduate Medical School Singapore"@en .

ns229:JAD190041 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology and Alzheimer Center"@en .

ns229:JAD190077 ns0:hasName "Alzheimer's Disease Center"@en,
        "Department of Neurology"@en,
        "Vanderbilt Memory & Alzheimer’s Center, Department of Neurology"@en,
        "Vanderbilt Memory and Alzheimer’s Center"@en .

ns229:JAD190132 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine – Neurology, Universityof Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine –Neurology, University of Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine, Neurology, School of Medicine"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "Neuro Center, Neurology"@en,
        "NeuroCentre, Neurology"@en,
        "Neurology of NeuroCenter"@en,
        "Unit of Neurology"@en .

ns229:JAD190161 ns0:hasName "Alzheimer’s Disease Center"@en,
        "Boston University School of Medicine"@en,
        "Department of Alzheimer's Disease Center"@en,
        "Department of Pharmacology & Experimental Therapeutics"@en,
        "Department of Pharmacology and Experimental Therapeutics"@en,
        "Department of Psychiatry"@en,
        "Departments of Pharmacology & Experimental Therapeutics"@en,
        "Departments of Pharmacology & Experimental Therapeutics, Psychiatry"@en,
        "Departments of Pharmacology and Experimental Therapeutics"@en,
        "Departments of Psychiatry"@en,
        "Pharmacology and Experimental Therapeutics"@en .

ns229:JAD190175 ns0:hasName "Department of Biochemistry and Biophysics"@en,
        "Department of Neuroscience"@en .

ns229:JAD190319 ns0:hasName "Department of Medicine"@en,
        "Department of Medicine, Peninsula Clinical School, Central Clinical School"@en,
        "Department of Medicine, Stroke and Ageing Research Group, School of Clinical Sciences at Monash Health"@en,
        "Menzies Institute for Medical Research"@en .

ns229:JAD190335 ns0:hasName "Dementia Research Centre, UCL Institute of Neurology"@en .

ns229:JAD190469 ns0:hasName "Department of Health Sciences and Technology, SAIHST"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Neuto Science Center"@en,
        "Samsung Medical Center, Department of Neurology"@en,
        "Stem Cell & Regenerative Medicine Institute"@en,
        "Stem Cell and Regenerative Medicine Institute"@en .

ns229:JAD190487 ns0:hasName "Alzheimer’s Disease Center, Beijing Institute for Brain Disorders; Center for Brain Disorders Research"@en,
        "Center for Cognitive Disorders"@en .

ns229:JAD190524 ns0:hasName "Bioanalytical Mass Spectrometry Facility"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "School of Medical Sciences"@en .

ns229:JAD190645 ns0:hasName "Geriatric Research Education and Clinical Center"@en,
        "University of Wisconsin"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en .

ns229:NRE182671 ns0:hasName "Department of Physiotherapy, Rehabilitation School"@en,
        "Department of Physiotherapy, School of Rehabilitation"@en,
        "Neuromusculoskeletal Research Center"@en,
        "Sports Medicine Research Center"@en,
        "Sports Medicine Research CenterNeuroscience InstituteTehran University of Medical Sciences"@en .

ns229:NRE192745 ns0:hasName "Université Catholique de Louvain"@en,
        "Université catholique de Louvain"@en .

ns229:THC199026 ns0:hasName "College of Biomedical Engineering"@en,
        "Department of Neurosurgery"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:11.ID:JAD190091> ns0:hasName "Department of Health and Community Systems"@en,
        "University of Pittsburgh School of Nursing"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:11.ID:JAD190691> ns0:hasName "Clinical Geriatrics"@en,
        "Clinical Geriatrics, Karolinska Institutet"@en,
        "Turku City Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:11.ID:KCA180049> ns0:hasName "Oregon Health & Science University"@en,
        "Oregon Health Sciences University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:12.ID:JAD190399> ns0:hasName "Department of Psychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:12.ID:JAD190772> ns0:hasName "Beijing Institute for Brain Disorders Alzheimer’s Disease Centre"@en,
        "Beijing Key Laboratory of Geriatric Cognitive Disorders"@en,
        "Beijing Municipal Key Laboratory of Geriatric Cognitive Disorders"@en,
        "Center of Alzheimer's Disease"@en,
        "Center of Alzheimer's disease"@en,
        "Center of Alzheimer’s Disease"@en,
        "Clinical Center for Neurodegenerative Disease and Memory Impairment"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Beijing Friendship Hospital"@en,
        "Department of Neurology, Innovation Center for Neurological Disorders, Xuan Wu Hospital"@en,
        "Department of Neurology, Innovation Center for Neurological Disorders, Xuanwu Hospital"@en,
        "Department of Neurology, Xuan Wu Hospital"@en,
        "Department of Neurology, XuanWu Hospital"@en,
        "Department of Neurology, Xuanwu Hospital"@en,
        "Department of nephropathy, Xuanwu Hospital"@en,
        "Innovation Center for Neurological Disorders, Department of Neurology, Xuanwu Hospital"@en,
        "Innovation Center for Neurological Disorders, Neurology Department, Xuanwu Hospital"@en,
        "Key Neurodegenerative Laboratory of Ministry of Education of the People’s Republic of China"@en,
        "National Clinical Research Center for Geriatric Disorders"@en,
        "National Clinical Research Center for Geriatric Disorders of the People’s Republic of China"@en,
        "Neurodegenerative Laboratory of Ministry of Education of the People's Republic of China"@en,
        "State Key Laboratory of Brain and Cognitive Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:13.ID:JAD190046> ns0:hasName "Catalan Institution for Research and Advanced Studies (ICREA)"@en,
        "Cognition and Brain Plasticity Group"@en,
        "Department of Cognition, Development and Education Psychology"@en,
        "Department of Cognition, Development and Education Psychology, Campus Bellvitge"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:13.ID:JPD181518> ns0:hasName "Department of Neurology"@en,
        "University of Rochester Medical Center"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:14.ID:JAD180949> ns0:hasName "Central Institute of Mental Health"@en,
        "Central Institute of Mental Health, Medical Faculty Mannheim/"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:14.ID:JAD190334> ns0:hasName "Department of Clinical Pathology and Cytology, Laboratory Medicine"@en,
        "Department of Immunology, Genetics and Pathology"@en,
        "Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University and Department of Pathology and Cytology"@en,
        "Department of Immunology, Genetics and Pathology, Rudbeck Laboratory, Uppsala University and Departmentof Pathology and Cytology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neuroscience and Neurology"@en,
        "Department of Pathology"@en,
        "Department of Pathology and Cytology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:3.ID:JAD190365> ns0:hasName "Department of Medical Imaging"@en,
        "Keenan Research Centre for Biomedical Research"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:5.ID:JAD190446> ns0:hasName "Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "Institute for Stroke and Dementia Research (ISD)"@en,
        "Institute for Stroke and Dementia Research, Klinikum Großhadern"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff10.Author:6.ID:JAD190446> ns0:hasName "Institute for Stroke and Dementia Research (ISD)"@en,
        "Institute for Stroke and Dementia Research, Klinikum der Universität München"@en .

ns218:JAD180521 ns0:hasName "Austin Health Centre for PET"@en,
        "Austin Health Continuing Care Clinical Service Unit"@en,
        "Department of Medicine"@en,
        "Department of Medicine, Austin Health"@en,
        "Department of Molecular Imaging & Therapy"@en,
        "Department of Molecular Imaging and Therapy"@en,
        "Department of Molecular Imaging and Therapy, Austin Health"@en,
        "Department of Nuclear Medicine"@en,
        "Department of Nuclear Medicine and Centre for PET"@en,
        "Department of Nuclear Medicine and Centre for PET, Austin Health"@en,
        "Department of Nuclear Medicine, Centre for PET"@en,
        "Department of Pathology"@en,
        "Florey Institute of Neuroscience and Mental Health"@en,
        "Melbourne Dementia Research Centre"@en,
        "The Department of Medicine, Austin Health"@en .

ns218:JAD180572 ns0:hasName "Academic Unit for Psychiatry of Old Age, St Vincent's Health, Department of Psychiatry"@en,
        "Department of Psychiatry, Academic Unit for Psychiatry of Old Age"@en,
        "School of Psychiatry and Clinical Neurosciences and West Australian Centre for Health & Ageing"@en,
        "The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "University of Melbourne"@en,
        "West Australian Centre for Health & Ageing"@en .

ns218:JAD180949 ns0:hasName "Central Institute of Mental Health"@en,
        "Central Institute of Mental Health, Medical Faculty Mannheim/"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:12.ID:JAD181212> ns0:hasName "Department of Neurological Sciences"@en,
        "Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer’s Disease Center"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:12.ID:JAD190691> ns0:hasName "Clinical Neurology, Turku PET Centre"@en,
        "Clinical Neurosciences, Department of Neurosurgery"@en,
        "Department of Neurology"@en,
        "Division of Clinical Neurosciences"@en,
        "Turku PET Centre"@en,
        "Turku PET Centre and Division of Clinical Neurosciences"@en,
        "Turku PET Centre, University of Turku"@en,
        "Turku PET-Centre"@en,
        "Turku University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:13.ID:JAD190399> ns0:hasName "Department of Neuropsychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:15.ID:JAD180949> ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychiatry, Klinikum rechts der Isar"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:15.ID:JAD190023> ns0:hasName "Centre for Research in Neurodegenerative Diseases, Departments of Medical Biophysics and Medicine (Neurology)"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Clinical Neurosciences, Cambridge Institute for Medical Research"@en,
        "Tanz Centre for Research in Neurodegenerative Diseases, and Departments of Medicine, Medical Biophysics and Laboratory Medicine and Pathobiology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff11.Author:16.ID:JAD190334> ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "MRC"@en,
        "Medical Research Center"@en,
        "Medical Research Center, Oulu University Hospital, Oulu, Finland and Research Unit of Clinical Neuroscience, Neurology"@en,
        "NeuroCenter, Neurology"@en,
        "Research Unit of Clinical Neuroscience, Neurology"@en .

ns181:JAD190644 ns0:hasName "Department of Gastrointestinal Immunology"@en,
        "Louis Pasteur Center for Medical Research"@en .

ns163:JAD190365 ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychiatry, Division of Geriatric Psychiatry, St. Michael’s Hospital"@en,
        "Faculty of Medicine, Department of Psychiatry"@en,
        "Keenan Research Centre"@en,
        "Keenan Research Centre for Biomedical Research"@en,
        "Neuroscience Research Program, Keenan Research Centre for Biomedical Science"@en .

ns219:JAD190133 ns0:hasName "Helsinki University Hospital and University of Helsinki;"@en,
        "University of Helsinki"@en .

ns174:JAD180521 ns0:hasName "Centre for Neuroscience"@en,
        "Cooperative Research Centre for Mental Health"@en,
        "Department of Pathology"@en,
        "Florey Institute for Neurosciences and Mental HealthUniversity of Melbourne"@en,
        "Mental Health Research Institute"@en,
        "Mental Health Research Institute of Victoria"@en,
        "National Dementia Diagnostics Laboratory"@en,
        "The Florey Institute"@en,
        "The Florey Institute for Neuroscience and Mental Health"@en,
        "The Florey Institute of Neuroscience and Mental Health"@en,
        "The Mental Health Research Institute"@en,
        "The Mental Health Research Institute of Victoria"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:10.ID:JAD181277> ns0:hasName "Cyclotron Research Center"@en,
        "Department of Neurology, Memory Clinic"@en,
        "GIGA Cyclotron Research Centre"@en,
        "Memory Center"@en,
        "Memory Centre, Neurology Department"@en,
        "Memory Clinic"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:13.ID:JAD180521> ns0:hasName "Academic Unit for Psychiatry of Old Age, St Vincent's Health, Department of Psychiatry"@en,
        "Academic Unit for Psychiatry of Old Age, St. Vincent's Health"@en,
        "Department of Psychiatry, Academic Unit for Psychiatry of Old Age"@en,
        "North Western Mental Health"@en,
        "School of Psychiatry and Clinical Neurosciences and West Australian Centre for Health & Ageing"@en,
        "School of Psychiatry and Clinical Neurosciences and Western Australian Centre for Health and Aging"@en,
        "The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "University of Melbourne"@en,
        "WA Centre for Health & Ageing"@en,
        "West Australian Centre for Health & Ageing"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:13.ID:JAD181212> ns0:hasName "Department of Medicine"@en,
        "Department of Medicine, Division of General Internal Medicine"@en,
        "Group Health Center for Health Studies"@en,
        "Group Health Cooperative Research Institute"@en,
        "Group Health Research Institute"@en,
        "Kaiser Permanente Washington Health Research Institute"@en,
        "Kaiser Permenente Washington Health Research Institute"@en,
        "Marianjoy Rehabilitation Hospital"@en,
        "University of Washington"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:14.ID:JAD190399> ns0:hasName "Department of Neuropsychiatry"@en,
        "Department of Psychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:16.ID:JAD190132> ns0:hasName "Institute of Clinical Medicine – Neurology"@en,
        "Medical Research Center"@en,
        "Medical Research Center, Oulu University Hospital, Oulu, Finland and Research Unit of Clinical Neuroscience, Neurology"@en,
        "NeuroCenter, Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:16.ID:JAD190334> ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "MRC"@en,
        "Medical Research Center"@en,
        "Medical Research Center, Oulu University Hospital, Oulu, Finland and Research Unit of Clinical Neuroscience, Neurology"@en,
        "NeuroCenter, Neurology"@en,
        "Research Unit of Clinical Neuroscience, Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:18.ID:JAD190446> ns0:hasName "Department of Psychiatry and Psychotherapy"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "Institute of Cognitive Neurology and Dementia Research (IKND)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:21.ID:JAD190334> ns0:hasName "Institute of Clinical Medicine – Neurosurgery, University of Eastern Finland and Neurosurgery of NeuroCenter"@en,
        "Medical Research Center"@en,
        "Neurosurgery of NeuroCenter"@en,
        "Unit of Neurosurgery"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:10.ID:JAD181277> ns0:hasName "Cyclotron Research Center"@en,
        "Department of Neurology, Memory Clinic"@en,
        "GIGA Cyclotron Research Centre"@en,
        "Memory Center"@en,
        "Memory Centre, Neurology Department"@en,
        "Memory Clinic"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:10.ID:JAD190446> ns0:hasName "Institute for Clinical Radiology"@en,
        "Institute for Clinical Radiology, Klinikum der Universität München"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:12.ID:JAD190533> ns0:hasName "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "UCL Institute of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:13.ID:JAD190533> ns0:hasName "Clinical Neurochemistry Lab"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Lab, The Sahlgrenska Academy at"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the"@en,
        "Clinical Neurochemistry Laboratory, Inst. of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Psychiatry and Neurochemistry"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory,Institute of Neuroscience and Physiology, Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital"@en,
        "Institute of Neurobiology and Physiology, Department of Neurochemistry and Psychiatry, Sahlgrenska University Hospital"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Neuropsychiatric Epidemiology Unit"@en,
        "The Sahlgrenska Academy at Göteborg University"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "The Sahlgrenska Academy at the University of Gothenburg"@en,
        "The Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences"@en,
        "University of Goteborg"@en,
        "the Sahlgrenska Academy at Göteborg University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:14.ID:JAD190399> ns0:hasName "Department of Neuropsychiatry"@en,
        "Department of Psychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:16.ID:JAD190132> ns0:hasName "Institute of Clinical Medicine – Neurology"@en,
        "Medical Research Center, Oulu University Hospital, Oulu, Finland and Research Unit of Clinical Neuroscience, Neurology"@en,
        "NeuroCenter, Neurology"@en,
        "Research Unit of Clinical Neuroscience, Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:17.ID:JAD190334> ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC), Department of Neurobiology"@en,
        "Department of Geriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, KI- Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, NVS"@en,
        "Division of Clinical Geriatrics, NVS"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine/Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "Memory Clinic, Department of Geriatrics, Karolinska University Hospital, Huddinge, Sweden; Aging Research Center and Alzheimer Disease Research Center, Karolinska Institute, Sweden; Department of Neurology"@en,
        "Public Health Promotion Unit"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:18.ID:JAD190334> ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC)"@en,
        "Aging Research Center (ARC), Department of NVS"@en,
        "Aging Research Center (ARC), Department of Neurobiology"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer Disease Research Center"@en,
        "Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Department of Geriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, KI- Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society"@en,
        "Division of Clinical Geriatrics, NVS"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine/Neurology"@en,
        "Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "National Institute for Health and Welfare"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health"@en,
        "Public Health Promotion Unit"@en,
        "Stockholms Sjukhem"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:20.ID:JAD190399> ns0:hasName "Department of Brain and Cognitive Science"@en,
        "Department of Brain and Cognitive Sciences"@en,
        "Department of Neuropsychiatry"@en,
        "Department of Psychiatry"@en,
        "National Institute of Dementia"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:10.ID:JAD190133> ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Department of Neuroscience and Neurology"@en,
        "Institute of Clinical Medicine - Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine –Neurology, University of Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine/Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "Neuro Center"@en,
        "NeuroCenter, Neurology"@en,
        "Neurocenter, Neurology"@en,
        "Neurology of NeuroCenter"@en,
        "Unit of Neurology"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:11.ID:JAD190133> ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC)"@en,
        "Aging Research Center (ARC), Department of NVS"@en,
        "Aging Research Center (ARC), Department of Neurobiology"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer Disease Research Center"@en,
        "Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Department of Geriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, KI- Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine/Neurology"@en,
        "Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "National Institute for Health and Welfare"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health"@en,
        "Stockholms Sjukhem"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:12.ID:JAD190446> ns0:hasName "Berlin Center for Advanced Neuroimaging, Bernstein Center for Computational Neuroscience"@en,
        "Bernstein Center for Computational Neuroscience"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:12.ID:JAD190533> ns0:hasName "Clinical Neurochemistry Laboratory"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "UCL Institute of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:13.ID:JAD190533> ns0:hasName "Clinical Neurochemistry Lab"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Lab, The Sahlgrenska Academy at"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the"@en,
        "Clinical Neurochemistry Laboratory, Inst. of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Psychiatry and Neurochemistry"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory,Institute of Neuroscience and Physiology, Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital"@en,
        "Institute of Neurobiology and Physiology, Department of Neurochemistry and Psychiatry, Sahlgrenska University Hospital"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Neuropsychiatric Epidemiology Unit"@en,
        "The Sahlgrenska Academy at Göteborg University"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "The Sahlgrenska Academy at the University of Gothenburg"@en,
        "The Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences"@en,
        "University of Goteborg"@en,
        "the Sahlgrenska Academy at Göteborg University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:14.ID:JAD190019> ns0:hasName "Department of Epidemiology and Biostatistics"@en,
        "Department of Neuroscience, Shiley-Marcos Alzheimer’s Disease Research Center"@en .

ns44:JAD190399 ns0:hasName "Department of Neuropsychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:18.ID:JAD190334> ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC)"@en,
        "Aging Research Center (ARC), Department of NVS"@en,
        "Aging Research Center (ARC), Department of Neurobiology"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer Disease Research Center"@en,
        "Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Department of Geriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, KI- Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine/Neurology"@en,
        "Institute of Public Health and Clinical Nutrition"@en,
        "Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "National Institute for Health and Welfare"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health"@en,
        "Public Health Promotion Unit"@en,
        "Stockholms Sjukhem"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:11.ID:JAD190133> ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC)"@en,
        "Aging Research Center (ARC), Department of NVS"@en,
        "Aging Research Center (ARC), Department of Neurobiology"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer Disease Research Center"@en,
        "Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Department of Geriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, KI- Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "National Institute for Health and Welfare"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health"@en,
        "Stockholms Sjukhem"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:12.ID:JAD181277> ns0:hasName "Biobank"@en,
        "Biobank, Institute Born-Bunge"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Ghent University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:12.ID:JAD190133> ns0:hasName "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, NVS"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "Public Health Promotion Unit"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:12.ID:JAD190533> ns0:hasName "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "UCL Institute of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:16.ID:JAD190399> ns0:hasName "Department of Psychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:17.ID:JAD190399> ns0:hasName "Department of Psychiatry"@en .

ns140:JAD190334 ns0:hasName "Institute of Clinical Medicine – Neurosurgery, University of Eastern Finland and Neurosurgery of NeuroCenter"@en,
        "Neurosurgery of NeuroCenter"@en,
        "Research Unit of Clinical Neuroscience, Neurosurgery"@en,
        "Unit of Neurosurgery"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff16.Author:12.ID:JAD190533> ns0:hasName "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute at UCL"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff16.Author:18.ID:JAD190399> ns0:hasName "Department of Neuropsychiatry"@en,
        "Department of Psychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff16.Author:18.ID:JAD190446> ns0:hasName "Department of Psychiatry and Psychotherapy"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "Institute of Cognitive Neurology and Dementia Research (IKND)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff17.Author:18.ID:JAD190446> ns0:hasName "Department of Psychiatry and Psychotherapy"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "Institute of Cognitive Neurology and Dementia Research (IKND)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff17.Author:20.ID:JAD190399> ns0:hasName "Department of Brain and Cognitive Science"@en,
        "Department of Brain and Cognitive Sciences"@en,
        "Department of Neuropsychiatry"@en,
        "Department of Psychiatry"@en,
        "National Institute of Dementia"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff17.Author:5.ID:JAD181277> ns0:hasName "Department of Neurology and Memory Clinic"@en,
        "Department of Neurology, Universitair Ziekenhuis Brussel (UZ Brussel)"@en,
        "Laboratory of Neurochemistry and Behavior"@en,
        "Memory Clinic and Division of Neurology"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), and Biobank, Institute Born-Bunge"@en,
        "University of Antwerp"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff17.Author:8.ID:JAD180572> ns0:hasName "Academic Unit for Psychiatry of Old Age, St Vincent's Health, Department of Psychiatry"@en,
        "Department of Psychiatry, Academic Unit for Psychiatry of Old Age"@en,
        "North Western Mental Health"@en,
        "School of Psychiatry and Clinical Neurosciences and West Australian Centre for Health & Ageing"@en,
        "The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "West Australian Centre for Health & Ageing"@en .

ns246:JAD190399 ns0:hasName "Department of Brain and Cognitive Science"@en,
        "Department of Brain and Cognitive Sciences"@en,
        "Department of Neuropsychiatry"@en,
        "Department of Psychiatry"@en,
        "National Institute of Dementia"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff19.Author:19.ID:JAD190446> ns0:hasName "Department of Neuropsychiatry, Charité - Universitätsmedizin, Berlin"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en .

ns182:JAD190446 ns0:hasName "Department of Psychiatry and Psychotherapy, Campus Charité Mitte"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en .

ns185:JAD180572 ns0:hasName "Healthy Brain Ageing Program, Ageing Brain Centre, Brain and Mind Centre"@en,
        "Parkinson’s Disease Research Clinic, Brain and Mind Centre"@en,
        "School of Psychology"@en .

ns243:BLC190228 ns0:hasName "Cancer Biology and Genetics Division, Queen’s Cancer Research Institute"@en,
        "Department of Biomedical and Molecular Sciences"@en,
        "Department of Obstetrics and Gynecology"@en,
        "Department of Obstetrics and Gynecology, Kingston Health Sciences Center"@en .

ns243:BMR181131 ns0:hasName "Faculty of Physical Education and Sports"@en,
        "Sports Technology Institute, Faculty of Electrical Engineering and Information Technology"@en .

ns243:CBM192435 ns0:hasName "Department of General Surgery, Ruijin Hospital"@en,
        "Shanghai Institute of Digestive Surgery, Ruijin Hospital"@en,
        "Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital"@en .

ns243:CH180452 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital"@en,
        "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Shanghai Research Center for Thyroid Diseases"@en,
        "Thyroid Institute"@en,
        "Ultrasound Research and Education Institute"@en .

ns243:CH199005 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns243:CH199205 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns243:HAB190363 ns0:hasName "Department of Health Management and Economics, School of Public Health, International Campus"@en,
        "Department of Nursing, Faculty of Health Sciences"@en .

ns243:HAB190367 ns0:hasName "Department of Health Management and Economics, International Campus"@en,
        "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Management and Economics, School of Public Health, International Campus"@en,
        "Department of Nursing, Faculty of Health Sciences"@en .

ns243:HAB190373 ns0:hasName "Biological Sciences Department, Faculty of Science"@en,
        "Main Medical Laboratory"@en,
        "Main Medical Laboratory, Medical Services"@en .

ns243:HAB190383 ns0:hasName "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Management and Economics, School of Public Health, International Campus"@en,
        "Department of Nursing, Faculty of Health Sciences"@en .

ns243:IDT180003 ns0:hasName "Bharati Vidyapeeth’s College of Engineering"@en,
        "Computer Science and Engineering"@en .

ns243:IDT180064 ns0:hasName "College of Engineering and Technology"@en,
        "Electrical Engineering Department"@en,
        "Electrical Power Engineering Department"@en .

ns243:IES183201 ns0:hasName "Department of Physical Activity Design"@en,
        "Research Institute of Sports and Industry Science"@en .

ns243:IFS172129 ns0:hasName "Beijing Key Laboratory on MCAACI"@en,
        "School of Mathematics and Statistics"@en .

ns243:IFS179161 ns0:hasName "Business School"@en,
        "State Key Laboratory of Bioactive Substances and Functions of Natural Medicines"@en .

ns243:IFS179201 ns0:hasName "Collaborative Innovation Center of Water Resources Efficient Utilization and Support Engineering"@en,
        "School of Mechatronics Engineering and Automation"@en .

ns243:IFS179266 ns0:hasName "College of Information Science & Engineering"@en,
        "College of Information Science and Engineering"@en,
        "School of Cotton Textiles"@en,
        "School of Cotton textiles"@en .

ns243:IFS181191 ns0:hasName "Key Laboratory of Electronic Information Application Technology for Scene Investigation, Ministry of Public Security"@en,
        "School of Communications and Information Engineering"@en .

ns243:IFS181663 ns0:hasName "College of Applied Mathematics"@en .

ns243:IFS181762 ns0:hasName "College of Mathematics and Econometrics"@en,
        "Hunan University"@en .

ns243:IFS181769 ns0:hasName "College of Mathematics and Information Science"@en,
        "Department of Mathematics, Faculty of Science"@en .

ns243:IFS181813 ns0:hasName "Department of Civil and Environmental Engineering, College of Engineering"@en,
        "School of Natural Sciences(SNS)"@en .

ns243:IFS182512 ns0:hasName "College of Computer Science and Engineering, Shandong Province Key laboratory of Wisdom Mine Information Technology"@en,
        "Shenzhen Institutes of Advanced Technology"@en .

ns243:IFS182590 ns0:hasName "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns243:IFS182594 ns0:hasName "College of Computer"@en,
        "Shaoguan University"@en .

ns243:IFS182651 ns0:hasName "Department of Industrial Engineering"@en,
        "Industrial Engineering Department"@en .

ns243:JAD180525 ns0:hasName "Department of Physiology and Neuroscience, Zilka Neurogenetic Institute, Keck School of Medicine"@en,
        "Department of Psychiatry"@en,
        "Department of Psychology"@en,
        "University of Southern California"@en,
        "Veterans Affairs San Diego Healthcare System"@en .

ns243:JAD180571 ns0:hasName "Department of Psychology"@en,
        "Neuroscience and Mental Health Institute"@en .

ns243:JAD180630 ns0:hasName "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "International Clinical Research Center"@en .

ns243:JAD180847 ns0:hasName "Department of Psychiatry"@en,
        "Desert Pacific Mental Illness Research Education and Clinical Center"@en .

ns243:JAD180899 ns0:hasName "Department of Geriatric Behavioral Neurology"@en,
        "The Osaki-Tajiri SKIP Center"@en .

ns243:JAD180900 ns0:hasName "Brain and Mind Centre, Sydney Medical School"@en,
        "Neuroscience Research Australia"@en,
        "School of Medical Sciences"@en .

ns243:JAD180938 ns0:hasName "BC Women’s and Children’s Hospital"@en,
        "The University of British Columbia"@en .

ns243:JAD180991 ns0:hasName "Brain and Spine Institute (ICM) – INSERM 1127"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Memory and Alzheimer’s Disease, National Reference Center for Rare Dementias"@en,
        "Département de Neurologie"@en,
        "Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer"@en,
        "INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, and Université Pierre et Marie Curie-Paris 6, UMR S 1127"@en .

ns243:JAD181030 ns0:hasName "MRC Centre for Synaptic Plasticity, School of Clinical Sciences"@en,
        "Translational Health Sciences, Bristol Medical School"@en .

ns243:JAD181141 ns0:hasName "Albert Einstein College of Medicine"@en,
        "Department of Epidemiology and Population Health"@en .

ns243:JAD190011 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Department of Neurology"@en,
        "Emory Alzheimer's Disease Research Center, (ADRC)"@en,
        "Emory University"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en .

ns243:JAD190019 ns0:hasName "Department of Behavioral Sciences and the Rush Alzheimer’s Disease Center"@en,
        "Department of Psychiatry"@en,
        "Institute for Minority Health Research"@en,
        "Rush Alzheimer’s Disease Center"@en,
        "University of Illinois at Chicago"@en .

ns243:JAD190094 ns0:hasName "Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences"@en,
        "Department of Epidemiology and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences"@en,
        "School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences"@en .

ns243:JAD190107 ns0:hasName "Instituto de Investigación Marqués de Valdecilla (IDIVAL)"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en .

ns243:JAD190119 ns0:hasName "Department of Neurological Sciences"@en,
        "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation, Neurodegenerative Disease Unit, “Dino Ferrari” Center"@en,
        "Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino Ferrari"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation"@en,
        "University of Milan"@en .

ns243:JAD190124 ns0:hasName "Department Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "Department of Medicine, David Geffen School of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, David Geffen School of Medicine"@en,
        "Department of Psychiatry and Biobehavioral Sciences"@en,
        "Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "Departments of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "Greater Los Angeles VA Healthcare System"@en,
        "Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "V.A. Greater Los Angeles Healthcare System"@en,
        "VA Greater Los Angeles Healthcare Center"@en .

ns243:JAD190181 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "Centre for Research on Ageing, Health and Wellbeing, Research School of Population Health"@en,
        "Dementia Collaborative Research Centre – Early Diagnosis and Prevention, Research School of Population Health"@en,
        "Neuroscience Research Australia"@en,
        "Neuroscience Research Australia (NeuRA)"@en,
        "School of Psychology"@en,
        "University of New South Wales"@en .

ns243:JAD190183 ns0:hasName "Institute of Aging I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR) Neurology Unit"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR), Neurology Unit"@en,
        "Memory Research Centre of Lyon (CMRR); Geriatrics Unit, Charpennes Hospital"@en,
        "Neurology Unit"@en .

ns243:JAD190196 ns0:hasName "Department of Legal Medicine, Graduate School of Medicine and Pharmaceutical Sciences"@en,
        "Okayama University of Science"@en .

ns243:JAD190262 ns0:hasName "Department of Neurology"@en,
        "Einstein Aging Study"@en,
        "Saul B. Korey Department of Neurology"@en .

ns243:JAD190266 ns0:hasName "Department of Family & Community Medicine"@en,
        "Department of Family and Community Medicine"@en,
        "Department of Medicine"@en,
        "Department of Psychiatry"@en,
        "Departments of Medicine"@en,
        "GRECC, the"@en,
        "South Texas Veterans' Health System Audie L. Murphy Division GRECC"@en,
        "South Texas Veterans’ Health System"@en .

ns243:JAD190293 ns0:hasName "Department of Clinical Psychology"@en,
        "Department of Psychology"@en,
        "Gerontology Center, Lifespan Institute"@en,
        "University of Kansas"@en .

ns243:JAD190340 ns0:hasName "Department of Neurology and Neurobiology of Aging"@en,
        "Department of Preemptive Medicine for Dementia"@en .

ns243:JAD190368 ns0:hasName "Department of Biochemistry and Molecular Biology, School of Medicine"@en,
        "Department of Neurochemistry"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-Innovation Center of Neuroregeneration"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-innovation Center of Neuroregeneration"@en .

ns243:JAD190385 ns0:hasName "Department of Human Neuroscience"@en,
        "Department of Neurology and Psychiatry, Sapienza"@en,
        "PhD Program in Behavioral Neuroscience"@en .

ns243:JAD190423 ns0:hasName "1st Department of Neurology, G.H. “AHEPA”, School of Medicine, Faculty of Health Sciences"@en,
        "1st Department of Neurology, U.H. “AHEPA”, Medical School, Faculty of Healthy Sciences"@en,
        "3rd Department of Neurology"@en,
        "3rd Department of Neurology, Medical School"@en,
        "Information Technologies Institute"@en,
        "Medical School Aristotle University of Thessaloniki"@en .

ns243:JAD190446 ns0:hasName "Clinic for Psychosomatic and Psychotherapeutic Medicine"@en,
        "DZNE"@en,
        "DZNE, German Center for Neurodegenerative Diseases"@en,
        "Department of Psychiatry"@en,
        "Department of Psychosomatic Medicine"@en,
        "Deutsches Zentrum für Neurodegenerative Erkrankungen (DZNE)"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Centre for Neurodegenerative Diseases (DZNE)"@en .

ns243:JAD190459 ns0:hasName "Institute of Aging I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR) Neurology Unit"@en,
        "Memory Research Centre of Lyon (CMRR); Geriatrics Unit, Charpennes Hospital"@en,
        "Neurology Unit"@en .

ns243:JAD190461 ns0:hasName "Brain Dynamics and Cognition"@en,
        "CMRR – Hospices Civils de Lyon, Inserm U1028, CNRS UMR5292"@en,
        "Centre Mémoire Ressources Recherche de Lyon"@en,
        "Claude Bernard University"@en,
        "Claude Bernard University Lyon 1"@en,
        "Clinical Research Centre CRC - VCF (Vieillissement –Cerveau - Fragilité), Hospital of Charpennes"@en,
        "Clinical and Research Memory Center of Lyon"@en,
        "French Federation of Memory Centers"@en,
        "Hospices civils de Lyon"@en,
        "Hôpital Gériatrique des Charpennes"@en,
        "INSERM U1028, CNRS UMR5292"@en,
        "INSERM, U1028; CNRS"@en,
        "Institute of Aging I-Vie"@en,
        "Lyon University Hospital"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Memory Research Centre of Lyon (CMRR); Geriatrics Unit, Charpennes Hospital"@en,
        "Médecine Gériatrique"@en,
        "Neurobiologie, CMRR, Gériatrie, Hospices Civils de Lyon"@en,
        "Research Clinic Centre (CRC) - VCF (Aging – Brain – Frailty), Charpennes Hospital"@en,
        "Research and Resources Memory Center of Lyon, Hôpital des Charpennes"@en,
        "University Lyon 1"@en,
        "University Lyon I"@en .

ns243:JAD190484 ns0:hasName "Departament de Biologia Cellular, Protein Folding and Stability Group, de Fisiologia i d’Immunologia, Unitat de Citologia i d’Histologia, Facultat de Biociències"@en,
        "Departament de Biologia Cellular, de Fisiologia i d’Immunologia, Unitat de Citologia i d’Histologia, Facultat de Biociències, Edifici C"@en,
        "Departament de Biologia Cel·lular, Fisiologia i Immunologia, Unitat de Citologia i Histologia, Facultat de Biociències"@en,
        "Departament de Bioquímica i Biologia Molecular, Protein Folding and Stability Group, Facultat de Biociències"@en,
        "Protein Folding and Stability Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències"@en .

ns243:JAD190494 ns0:hasName "Department of Experimental Medicine and Oncology"@en,
        "Department of Experimental Medicine and Oncology, General Pathology Section"@en,
        "Department of Internal Medicine and Medical Specialties (DIMI), Unit of Geriatric Medicine"@en,
        "Department of Neuroscience"@en,
        "Neuroscience Institute Cavalieri Ottolenghi Foundation (NICO)"@en,
        "Neuroscience Institute of Cavalieri Ottolenghi Foundation (NICO)"@en,
        "Neuroscience Institute of the Cavalieri Ottolenghi Foundation (NICO)"@en .

ns243:JAD190549 ns0:hasName "CHU de Bordeaux"@en,
        "Institute for Neurodegenerative Diseases, Clinical Branch"@en .

ns243:JAD190562 ns0:hasName "Department of Neurology, Qingdao Municipal Hospital"@en,
        "Department of Neurology, Qingdao Municipal Hospital, School of Medicine"@en .

ns243:JAD190609 ns0:hasName "Cognitive Impairment Center"@en,
        "Department of Rehabilitative Medicine"@en,
        "FORGEI"@en .

ns243:JAD190622 ns0:hasName "Center for Comprehensive Care and Research on Memory Disorders"@en,
        "Department of Community Health Sciences"@en,
        "Medical Genome Center"@en .

ns243:JAD190670 ns0:hasName "Brain Connectivity Laboratory"@en,
        "Department of Imaging"@en,
        "Institute of Neurology"@en .

ns243:JAD190707 ns0:hasName "Department of Medicine"@en,
        "Department of Medicine, Division of Gerontology and Geriatric Medicine"@en .

ns243:JAD190772 ns0:hasName "Institute for Complex Systems and Mathematical Biology"@en .

ns243:JAD190782 ns0:hasName "Center for Neuropathology"@en,
        "Department of Pathology"@en,
        "Department of Pathology, Division of Anatomic Pathology"@en,
        "Departments of Pathology and Neuroscience"@en,
        "University of Maryland"@en .

ns243:JHD180337 ns0:hasName "George-Huntington-Institute"@en,
        "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour"@en,
        "Institute of Animal Hygiene, Animal Welfare and Farm Animal Behavior"@en .

ns243:JHD190365 ns0:hasName "Center for Human Experimental Therapeutics/Clinical Trials Coordination Center"@en,
        "Department of Neurology"@en .

ns243:JHD199003 ns0:hasName "Clinical Pharmacology Unit"@en,
        "Huntington’s Disease Centre, Institute of Neurology"@en,
        "Laboratory of Clinical Pharmacology and Therapeutics"@en,
        "Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine"@en .

ns243:JPD191627 ns0:hasName "Department of Neurology"@en,
        "Department of Radiology"@en,
        "Neurology"@en,
        "Neurology Service and GRECC"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en .

ns243:MGC180689 ns0:hasName "Department of Chemistry of Natural Compounds"@en,
        "Department of Chemistry, Faculty of Sciences and Arts, Khulais"@en,
        "National Research Centre"@en .

ns243:MGC194 ns0:hasName "Department of Biological Science, Faculty of Science"@en,
        "Department of Botany, Faculty of Science"@en .

ns243:NHA170034 ns0:hasName "Department of Community Health Sciences, Clinical Nutrition Program, College of Applied Medical Sciences"@en,
        "Department of Human Nutrition & Dietetics"@en,
        "Department of Human Nutrition and Dietetics"@en .

ns243:NHA180059 ns0:hasName "Aging and Alzheimer’s Institute"@en,
        "Charles Perkins Centre"@en .

ns243:NHA190068 ns0:hasName "Department of Medicine"@en,
        "Jesse Brown VA Medical Center"@en .

ns243:NRE192722 ns0:hasName "Department of Medicine ( Royal Melbourne Hospital)"@en,
        "Department of Medicine (Royal Melbourne Hospital)"@en,
        "Department of Rehabilitation and Australian Rehabilitation Research Centre"@en .

ns243:NRE192788 ns0:hasName "Department of Allied Health Sciences, Faculty of Medicine"@en,
        "Institute of Health and Biomedical Innovation"@en,
        "Movement Neuroscience, Injury Prevention Program, Institute of Health and Biomedical Innovation"@en,
        "School of Exercise and Nutrition Science, Faculty of Health"@en,
        "School of Exercise and Nutrition Sciences, Faculty of Health"@en .

ns243:PPR190132 ns0:hasName "Carnegie Mellon University"@en,
        "Neuroplasticity Research Group, Clinical Health and Nutrition Centre (CHANCE), School of Science"@en .

ns243:WOR192937 ns0:hasName "School of Optometry and Vision Science"@en .

ns243:WOR193015 ns0:hasName "Department of Biomechanics, Faculty of Physical Therapy"@en,
        "Department of Physical Therapy, College of Applied Medical Sciences"@en .

ns243:XST190503 ns0:hasName "Department of Radiation Oncology"@en .

ns25:ADR190124 ns0:hasName "Department of Nursing"@en,
        "University of Massachusetts Lowell"@en .

ns25:BLC190236 ns0:hasName "Department of Urology"@en,
        "University of Kansas"@en .

ns25:BME191060 ns0:hasName "Department of Inorganic Biomaterials, Institute of Biomaterials and Bioengineering"@en,
        "Department of Inorganic Biomaterials, Institute of Biomaterials and BioengineeringTokyo Medical and Dental University"@en .

ns25:BMR181236 ns0:hasName "Department of Medical Genetics"@en,
        "Department of Physiotherapy, School of Rehabilitation Sciences"@en .

ns25:BMR181260 ns0:hasName "Faculty of Health Sciences"@en,
        "Physiotherapy Research Unit"@en .

ns25:BMR181326 ns0:hasName "Department of Physical and Rehabilitation Medicine"@en,
        "Department of Physical and Rehabilitation Medicine, Medical School"@en .

ns25:BMR181332 ns0:hasName "Department of Physiotherapy and Rehabilitation, Division of Physiotherapy and Rehabilitation, Faculty of Health Sciences"@en,
        "Istanbul University Faculty of Health Sciences"@en .

ns25:BMR181448 ns0:hasName "Department of Physical and Rehabilitation Medicine"@en .

ns25:CBM182212 ns0:hasName "Clinical Oncology Department"@en,
        "Clinical Oncology Department, Assiut University Hospital"@en .

ns25:CH180402 ns0:hasName "Pamukkale University"@en,
        "Pamukkale University, Faculty of MedicineDepartment of Physiology"@en .

ns25:CH180470 ns0:hasName "Department of Clinical Rehabilitation"@en .

ns25:CH180528 ns0:hasName "Department of Medicine"@en,
        "Division of Cardiology"@en,
        "Division of Cardiology, Dietrich Bonhoeffer Hospital"@en,
        "Division of Cardiology, Ulsan Medical Center"@en .

ns25:CH199005 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns25:CH199009 ns0:hasName "Department of Anaesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en .

ns25:CH199226 ns0:hasName "Brandenburg University of Technology"@en,
        "Institute of Biotechnology"@en .

ns25:DEV190266 ns0:hasName "University of Alabama at Birmingham"@en .

ns25:EFI190268 ns0:hasName "Institute for Information Science and Language Technology"@en,
        "Universität Hildesheim"@en,
        "Universität Hildesheim Germany"@en .

ns25:FI1814 ns0:hasName "Department of Computer Science"@en,
        "Infobright Inc."@en,
        "Institute of Informatics"@en,
        "Polish-Japanese Institute of Information Technology"@en,
        "University of Warsaw & Infobright"@en .

ns25:FI1820 ns0:hasName "School of Computing"@en,
        "School of Computing Science"@en .

ns25:FI1837 ns0:hasName "Department of Computing Science"@en,
        "LAAS-CNRS"@en .

ns25:FI1838 ns0:hasName "School of Computing"@en,
        "School of Computing Science"@en .

ns25:FI1882 ns0:hasName "Newcastle University"@en,
        "School of Computing"@en,
        "School of Computing Science"@en .

ns25:HAB190362 ns0:hasName "Department of Medical Genetics"@en,
        "Department of Medical Genetics, Faculty of Medicine"@en,
        "Phytochemistry Research Center"@en .

ns25:HAB190364 ns0:hasName "Department of Disaster and Emergency Health, School of Public Health, International Campus"@en,
        "Department of Disasters and Emergency Health, School of Public Health"@en .

ns25:HAB190369 ns0:hasName "Department of Health Management and Economics, School of Public Health, International Campus"@en,
        "Department of Nursing, Faculty of Health Sciences"@en .

ns25:HAB190371 ns0:hasName "Department of Disaster and Emergency Health, School of Public Health, International Campus"@en,
        "Department of Disasters and Emergency Health, School of Public Health"@en,
        "Department of Health in Emergencies and Disasters, School of Public Health"@en .

ns25:HAB190379 ns0:hasName "Department of Haematology"@en,
        "Department of Haematology and Blood Transfusion Science, Faculty of Medical Laboratory Science"@en,
        "Department of Haematology, School of Medical Laboratory Science"@en .

ns25:HAB190384 ns0:hasName "Department of Medical Genetics"@en,
        "Shahid Beheshti University of Medical Sciences"@en,
        "Urogenital Stem Cell Research Center"@en .

ns25:IA190023 ns0:hasName "Faculty of Computer Science"@en,
        "Free University of Bozen-Bolzano"@en .

ns25:IDA184183 ns0:hasName "Anhui Provincial Key Laboratory of Network and Information Security"@en,
        "School of Computer and Information"@en,
        "School of Geography and Tourism"@en .

ns25:IDA184195 ns0:hasName "CISUC, Department of Informatics Engineering"@en .

ns25:IDA184238 ns0:hasName "Department of Knowledge Engineering"@en,
        "Faculty of Arts and Social Sciences"@en,
        "Maastricht University"@en,
        "School of Computer Engineering"@en .

ns25:IDA184390 ns0:hasName "Social Computing and Human Computation Lab"@en,
        "University of Ontario Institute of Technology (UOIT)"@en .

ns25:IDT180136 ns0:hasName "Department of Computer & Informatics Engineering (DISK Lab)"@en,
        "Department of Electrical and Computer Engineering (DISK Lab)"@en .

ns25:IES183210 ns0:hasName "Department of Physical Education"@en,
        "Graduate Program in Physical Education"@en .

ns25:IFS172129 ns0:hasName "Beijing Key Laboratory on MCAACI"@en,
        "Beijing Key Laboratory on MCAACI, School of Mathematics and Statistics"@en,
        "School of Mathematics and Statistics"@en .

ns25:IFS17283 ns0:hasName "Department of Mechanical and Industrial Engineering"@en .

ns25:IFS179085 ns0:hasName "Anderson College of Business"@en,
        "Anderson College of BusinessRegis University"@en,
        "Faculty of Commerce"@en .

ns25:IFS179101 ns0:hasName "Wuhan New Opto Electronic Information Technology Co."@en,
        "Wuhan New Opto Electronic Information Technology Co., Ltd"@en .

ns25:IFS179118 ns0:hasName "College of Civil Engineering and Architecture"@en,
        "Shandong Key Laboratory of Civil Engineering Disaster Prevention and Mitigation"@en .

ns25:IFS179121 ns0:hasName "Faculty of Computer and Information Sciences"@en,
        "Faculty of Computers and Information"@en .

ns25:IFS179141 ns0:hasName "Department of Electronics and Communication Engineering"@en,
        "National Institute of Technology"@en .

ns25:IFS179145 ns0:hasName "Department of Electronics and Communication Engineering"@en,
        "National Institute of Technology"@en .

ns25:IFS179240 ns0:hasName "School of Business"@en,
        "Sichuan Normal University"@en .

ns25:IFS179241 ns0:hasName "School of Business"@en,
        "Sichuan Normal University"@en .

ns25:IFS179323 ns0:hasName "School of Industrial Engineering, College of Engineering"@en,
        "Universal Scientific Education and Research Network (USERN)"@en .

ns25:IFS179373 ns0:hasName "College of Mathematics"@en,
        "Department of Mathematics"@en,
        "Northwest University"@en,
        "School of Mathematics"@en,
        "School of MathematicsNorthwest University"@en .

ns25:IFS18034 ns0:hasName "Department of Civil Engineering"@en,
        "School of Civil Engineering"@en .

ns25:IFS181097 ns0:hasName "School of Mathematics and Statistics"@en .

ns25:IFS181220 ns0:hasName "Department of Mathematics"@en .

ns25:IFS181293 ns0:hasName "Department of Industrial Engineering"@en,
        "Department of Industrial Engineering, Faculty of Engineering"@en,
        "Shahed University"@en .

ns25:IFS181347 ns0:hasName "School of Economics and Commerce"@en .

ns25:IFS181362 ns0:hasName "Key Laboratory of Intelligent Information Processing in Universities of Shandong"@en .

ns25:IFS181452 ns0:hasName "Department of Mathematics"@en .

ns25:IFS181460 ns0:hasName "Department of Electronics Engineering"@en,
        "Karachi Institute of Economics and Technology"@en .

ns25:IFS181502 ns0:hasName "Department of Mathematics & Statistics"@en,
        "Department of Mathematics and Statistics"@en .

ns25:IFS181516 ns0:hasName "Department of Mathematics"@en .

ns25:IFS181602 ns0:hasName "Department of Mathematics and Descriptive Geometry, Faculty of Civil Engineering"@en,
        "Faculty of Civil Engineering"@en,
        "Palacky Univ. Olomouc"@en .

ns25:IFS181604 ns0:hasName "Graduate Program in Electrical Engineering"@en,
        "Operations and Management Center of the Amazonian Protection System"@en .

ns25:IFS181657 ns0:hasName "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematical Economics"@en,
        "Faculty of Mathematics and Statistics"@en .

ns25:IFS181832 ns0:hasName "Department of Mathematics"@en,
        "Islamabad Model College for Girls"@en .

ns25:IFS181922 ns0:hasName "Department of Mathematics"@en .

ns25:IFS181980 ns0:hasName "School of Economics and Management"@en .

ns25:IFS182540 ns0:hasName "Department of Math."@en,
        "Department of Mathematics"@en,
        "Mathematics Department"@en,
        "University of New Mexico"@en .

ns25:IFS182568 ns0:hasName "School of Civil Engineering and Architecture"@en,
        "School of Mathematics and Statistics"@en .

ns25:IFS182618 ns0:hasName "Department of Pure Mathematics, Faculty of Mathematics and Computer"@en,
        "Faculty of Mathematics and Computer"@en,
        "Mahani Mathematical Research Center"@en,
        "Mahani Mathematical Research center"@en .

ns25:IFS182643 ns0:hasName "School of Electronics and Communication Engineering, Guangxi Colleges and Universities Key Laboratory of Complex System Optimization and Big Data Processing"@en,
        "School of Information Science and Engineering"@en .

ns25:IFS182671 ns0:hasName "Faculty of Civil Engineering"@en,
        "Palacky Univ. Olomouc"@en .

ns25:IFS182673 ns0:hasName "National Institute of Technology"@en,
        "National Institute of Technology Calicut"@en .

ns25:IFS182709 ns0:hasName "Bozok University"@en,
        "Department of Mathematics, Faculty of Science and Arts"@en,
        "Yozgat Bozok University"@en .

ns25:IFS182746 ns0:hasName "Department of Computer Science"@en,
        "Department of Mathematics"@en,
        "Sama Technical and Vocational Training College"@en,
        "Young Researchers and Elite club, Central Tehran Branch"@en .

ns25:IFS182774 ns0:hasName "Department of Mathematics and Statistic"@en .

ns25:IFS182778 ns0:hasName "Glasgow Caledonian University"@en .

ns25:IFS182832 ns0:hasName "Department of Mathematics"@en .

ns25:IFS182836 ns0:hasName "School of Computer and Information Engineering"@en .

ns25:IFS182863 ns0:hasName "Faculty of Applied Sciences"@en,
        "Faculty of Basic Sciences"@en .

ns25:IFS182868 ns0:hasName "Department of Computer Science and Information Technology"@en,
        "Department of Computer Sciences and Information Technology"@en .

ns25:IFS182876 ns0:hasName "Faculty of Applied Sciences"@en,
        "Faculty of Basic Sciences"@en .

ns25:IFS182887 ns0:hasName "School of Mathematics and Information Sciences"@en .

ns25:IFS182907 ns0:hasName "College of Science and Engineering"@en .

ns25:IFS182919 ns0:hasName "Department of Mathematics"@en,
        "Department of Mathematics, Faculty of Arts and Sciences"@en,
        "Department of Mathematics, Faculty of art and Science"@en .

ns25:IFS182947 ns0:hasName "Department of Mathematics"@en .

ns25:IFS182951 ns0:hasName "Deparment of Mathematics"@en,
        "Department of Mathematics"@en .

ns25:IFS182961 ns0:hasName "Department of Applied Mathematics with Oceanology and Computer Programming"@en,
        "Department of Applied Mathematics with Oceanology and ComputerProgramming"@en,
        "Vidyasagar University"@en .

ns25:IFS182963 ns0:hasName "School of Mathematics and Statistics"@en,
        "Shenzhen Graduate School"@en .

ns25:IFS18659 ns0:hasName "School of Mathematics and Statistics"@en .

ns25:IFS18678 ns0:hasName "Business School"@en,
        "Key Laboratory of Intelligent Computing and Signal processing, Ministry of Education"@en,
        "School of Management"@en,
        "State Key Laboratory of Bioactive Substances and Functions of Natural Medicines"@en .

ns25:IFS190016 ns0:hasName "School of Mathematics, Statistic and Computer Sciences"@en,
        "School of Mathematics, Statistics and Computer Science"@en .

ns25:IFS190036 ns0:hasName "Department of Math."@en,
        "Department of Mathematics"@en .

ns25:IFS190205 ns0:hasName "Department of Computer Science and Engineering"@en,
        "Department of Electrical Engineering"@en .

ns25:IFS190408 ns0:hasName "Department of Mathematics, Science and Research Branch"@en,
        "Faculty of Engineering and Natural Science"@en .

ns25:IFS190447 ns0:hasName "Department of Mathematics & Statistics"@en,
        "Department of Mathematics and Statistics"@en .

ns25:IFS190565 ns0:hasName "Department of Mathematics Education"@en,
        "Department of Mathematics Education and RINS"@en .

ns25:IFS190711 ns0:hasName "Department of Mathematics, Qaemshahr Branch"@en .

ns25:IFS190952 ns0:hasName "Division of Computational Mathematics and Engineering"@en,
        "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns25:IFS191197 ns0:hasName "Department of Mathematics and Statistics"@en,
        "Department of Physics"@en .

ns25:JAD170300 ns0:hasName "Department of Epidemiology"@en,
        "Department of Epidemiology, Joseph P. Mailman School of Public Health"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, College of Physicians and Surgeons"@en,
        "Department of Psychology"@en,
        "Departments of Epidemiology and Psychiatry"@en,
        "G.H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky Center, College of Physicians & Surgeons"@en,
        "Gertrude H. Sergievsky Center, College of Physicians and Surgeons"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en,
        "The Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en .

ns25:JAD180381 ns0:hasName "Bordeaux University"@en,
        "CHU of Pointe-à-Pitre"@en,
        "Centre Hospitalier de Villeneuve/lot"@en,
        "Guadeloupe University Hospital"@en,
        "University Bordeaux"@en .

ns25:JAD180630 ns0:hasName "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "National Institute of Mental Health"@en .

ns25:JAD180949 ns0:hasName "Institute of Social Medicine, Occupational Health and Public Health, Medical Faculty"@en,
        "LIFE – Leipzig Research Center for Civilization Diseases"@en .

ns25:JAD180962 ns0:hasName "CERVO Brain Research Center"@en,
        "Centre de recherche de l’Institut universitaire en santé mentale de Québec"@en,
        "Faculty of Medicine"@en,
        "Hotchkiss Brain Institute"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute>"@en,
        "LC Campbell Cognitive Neurology Research Unit"@en,
        "Sunnybrook Health Sciences Centre"@en .

ns25:JAD181102 ns0:hasName "Department of Clinical Neurology"@en,
        "Department of Neurology"@en .

ns25:JAD181170 ns0:hasName "Faculty of Sport and Exercise Psychology"@en .

ns25:JAD181173 ns0:hasName "Cognitive Decline Partnership Centre, Faculty of Medicine and Health"@en,
        "Falls"@en,
        "Falls, Balance and Injury Research Centre, Neuroscience Research Australia"@en,
        "Prince of Wales Clinical School, Faculty of Medicine"@en .

ns25:JAD181203 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute and Department of Psychiatry"@en,
        "Neuropsychopharmacology Research Group"@en .

ns25:JAD181212 ns0:hasName "Department of Medicine"@en .

ns25:JAD181227 ns0:hasName "Department of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Medicine"@en .

ns25:JAD181277 ns0:hasName "Department of Neurology"@en .

ns25:JAD181295 ns0:hasName "Department of Clinical Neuroscience"@en,
        "Department of Forensic Psychiatry, Niuvanniemi Hospital"@en,
        "Kuopio Research Centre of Geriatric Care"@en,
        "School of Pharmacy"@en,
        "School of Pharmacy, Faculty of Health Sciences"@en .

ns25:JAD190153 ns0:hasName "Clinical Medicine, Queen Mary School"@en,
        "Department of Analytical Chemistry, College of Pharmacy"@en .

ns25:JAD190181 ns0:hasName "Neuroscience Research Australia"@en,
        "Neuroscience Research Australia (NeuRA)"@en .

ns25:JAD190183 ns0:hasName "Aging Psychiatry Unit"@en,
        "Brain Dynamics and Cognition"@en,
        "Department of Psychiatry"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Psychiatry Unit"@en .

ns25:JAD190187 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en .

ns25:JAD190202 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Sunnybrook Research Institute"@en .

ns25:JAD190256 ns0:hasName "Department of Psychiatry"@en,
        "PET/CT Dementia Research Center, Juntendo Tokyo Koto Geriatric Medical Center"@en .

ns25:JAD190278 ns0:hasName "Department of Clinical Neurosciences"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Hotchkiss Brain Institute and O’Brien Institute for Public Health"@en,
        "Hotchkiss Brain Institute"@en,
        "Mathison Centre for Mental Health Research and Education"@en .

ns25:JAD190319 ns0:hasName "Aged Care Services"@en,
        "Department of Aged Care"@en,
        "Department of Medicine, Peninsula Clinical School, Central Clinical School"@en,
        "Department of Medicine, Peninsula Health, Peninsula Clinical School"@en,
        "Neurosciences"@en,
        "Stroke and Ageing Research Centre, Medicine, School of Clinical Sciences, Monash Medical Centre"@en,
        "Stroke and Ageing Research Group, Vascular Brain Ageing Division, Department of Medicine, School of Clinical Sciences"@en .

ns25:JAD190342 ns0:hasName "Department of Psychology"@en,
        "Neuroscience and Mental Health Institute"@en .

ns25:JAD190344 ns0:hasName "Department of Clinical Chemistry, Neurochemistry Laboratory"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Departments of Clinical Chemistry"@en .

ns25:JAD190345 ns0:hasName "Department of Clinical Medicine"@en,
        "Department of Clinical Research"@en,
        "Department of Neuroscience and Pharmacology"@en,
        "Department of Nuclear Medicine"@en .

ns25:JAD190362 ns0:hasName "Faculty of Medicine"@en,
        "Faculty of medicine"@en .

ns25:JAD190430 ns0:hasName "Center for Alzheimer Research and Treatment, Brigham and Women's Hospital"@en,
        "Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Brigham and Women's Hospital"@en,
        "Department of Neurology, Brigham and Women’s Hospital"@en,
        "Department of Neurology, Center for Alzheimer Research and Treatment"@en,
        "Department of Neurology, Massachusetts General Hospital"@en,
        "Harvard Medical School"@en,
        "Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital"@en .

ns25:JAD190527 ns0:hasName "Brain Center Rudolf Magnus, Department of Neurology"@en,
        "Department of Epidemiology"@en,
        "Department of Neurology"@en,
        "Department of Ophthalmology, Yong Loo Lin School of Medicine"@en,
        "Department of Radiology"@en,
        "Department of Radiology and Nuclear Medicine"@en,
        "Departments of Epidemiology, Radiology, Neurology"@en,
        "Departments of Neurology and Epidemiology"@en,
        "Duke-NUS Graduate Medical School"@en,
        "Memory Aging and Cognition Centre"@en,
        "Office of Clinical Sciences"@en,
        "Singapore Eye Research Institute"@en .

ns25:JAD190540 ns0:hasName "Ageing Research Institute for Society and Education"@en,
        "Department of Pharmacology"@en,
        "Memory Aging & Cognition Centre"@en,
        "Memory Aging and Cognition Centre"@en .

ns25:JAD190546 ns0:hasName "Department of Psychiatry"@en,
        "PET/CT Dementia Research Center, Juntendo Tokyo Koto Geriatric Medical Center"@en .

ns25:JAD190555 ns0:hasName "Euromov"@en,
        "University of Montpellier"@en .

ns25:JAD190572 ns0:hasName "Department of Neuroscience"@en,
        "Departments of Neuroscience, Neurosurgery"@en .

ns25:JAD190661 ns0:hasName "Department of Biostatistics"@en,
        "Department of Biostatistics and Data Science, University of Texas Health Sciences Center at Houston"@en,
        "University of Texas"@en,
        "University of Texas Health Science Center"@en .

ns25:JAD190666 ns0:hasName "CAS Key Laboratory of Genome Sciences and Information"@en,
        "State Key Laboratory of Bioactive Substances and Functions of Natural Medicines"@en,
        "State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica"@en .

ns25:JAD190725 ns0:hasName "Department of Health and Community Systems"@en,
        "University of Pittsburgh School of Nursing"@en .

ns25:JAD190756 ns0:hasName "Aging Research Center (ARC), Department of NVS"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Department of Psychology"@en,
        "Division of Clinical Geriatrics, Department of NVS"@en,
        "Theme Aging"@en .

ns25:JAD190823 ns0:hasName "Department of Medicine"@en,
        "School of Medicine"@en,
        "Section of Geriatric Medicine, School of Medicine"@en .

ns25:JAD190889 ns0:hasName "Department of Medicine"@en,
        "School of Medicine"@en,
        "Section of Geriatric Medicine, School of Medicine"@en .

ns25:JAE170034 ns0:hasName "CONICET-Universidad Nacional de San Juan"@en,
        "Electrical Engineering DepartmentCONICET - Universidad Nacional de San Juan"@en .

ns25:JAE180107 ns0:hasName "CONICET - Universidad Nacional de San Juan"@en,
        "CONICET-Universidad Nacional de San Juan"@en,
        "Electrical Engineering DepartmentCONICET - Universidad Nacional de San Juan"@en .

ns25:JAE191291 ns0:hasName "Arts et Metiers ParisTechUniversity Lille"@en,
        "Arts et Metiers ParisTechUniversité Lille"@en,
        "L2EP/Université Lille1"@en .

ns25:JHD190353 ns0:hasName "George Huntington Institute"@en,
        "George-Huntington-Institute"@en .

ns25:JND190428 ns0:hasName "Department of Neuropediatrics, Children’s Hospital 1"@en,
        "Department of Pediatric Neurology, Developmental Neurology and Social Pediatrics"@en .

ns25:JPD181568 ns0:hasName "Department of Neurology"@en,
        "Neuroimaging Research Core Facility"@en .

ns25:JPD191593 ns0:hasName "Clinical Pharmacology Unit"@en,
        "Instituto de Medicina Molecular, Faculty of Medicine"@en,
        "Laboratory of Clinical Pharmacology and Therapeutics"@en,
        "Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine"@en .

ns25:JPD191604 ns0:hasName "Department of Neurology"@en,
        "Population Health Sciences, Bristol Medical School"@en .

ns25:JPD191630 ns0:hasName "Department of Neurology"@en,
        "Department of Neuroscience"@en .

ns25:JPD191635 ns0:hasName "Reta Lila Weston Institute"@en,
        "Reta Lila Weston Institute of Neurological Studies"@en .

ns25:JVR191020 ns0:hasName "Department of Early Childhood, Special Education, and Rehabilitation Counseling"@en,
        "University of Kentucky"@en,
        "University of Wisconsin – Madison"@en,
        "University of Wisconsin-Madison"@en .

ns25:JVR191022 ns0:hasName "Department of Kinesiology and Community Health"@en,
        "The University of Illinois-Urbana"@en,
        "University of Illinois"@en,
        "University of Illinois at Urbana-Champaign"@en .

ns25:JVR191023 ns0:hasName "Northern Illinois University"@en,
        "University of Wisconsin-Madison"@en,
        "Virginia Commonwealth University"@en .

ns25:JVR191024 ns0:hasName "Independent Rehabilitation Consultant"@en,
        "Rehabilitation Consultant"@en .

ns25:JVR191034 ns0:hasName "Interwork Institute"@en .

ns25:JVR191039 ns0:hasName "University of Kansas"@en .

ns25:JVR191049 ns0:hasName "Department of Health Sciences/Mental Health and Mental Health Services Research"@en,
        "Department of Health Sciences/Mental Health and Mental Health Services Research, Medical Faculty"@en,
        "Department of Health Sciences/Mental Health, Activity and Participation, Medical Faculty"@en,
        "Lund University"@en .

ns25:KCA180049 ns0:hasName "Fred Hutchinson Cancer Research Center"@en,
        "SWOG Statistical Center/Fred Hutchinson Cancer Research Center"@en .

ns25:KES190402 ns0:hasName "Department of Computer Science & Engineering"@en,
        "School of Computer Engineering, KIIT"@en .

ns25:KES190403 ns0:hasName "Department of Computer Science and Engineering"@en .

ns25:KES190406 ns0:hasName "Department of Computer Engineering"@en .

ns25:MGC193 ns0:hasName "Department of Botany, Faculty of Science"@en .

ns25:MGC196 ns0:hasName "Department of Chemistry, Maitreyi College"@en,
        "Maitreyi College"@en .

ns25:MGS190314 ns0:hasName "Department of Computing, School of Computing, Engineering and Built Environment"@en,
        "Glasgow Caledonian University"@en,
        "School of Computing and Mathematical Sciences"@en,
        "School of Engineering and Built Environment"@en,
        "School of Engineering and Built Environment Built Environment"@en .

ns25:MNM180275 ns0:hasName "Department of Nutrition and Dietetics, School of Health Science and Education"@en .

ns25:NHA180056 ns0:hasName "Department of Psychology, School of Psychology and Clinical Language Sciences"@en,
        "School of Psychology and Clinical Language Sciences"@en,
        "University of Reading"@en .

ns25:NRE192721 ns0:hasName "Bundang Jesaeng General Hospital"@en,
        "Department of Rehabilitation Medicine"@en .

ns25:NRE192725 ns0:hasName "Department of Occupational Therapy"@en .

ns25:PPR190136 ns0:hasName "Department of Physiotherapy"@en,
        "St Vincent’s University Hospital"@en .

ns25:RFT180106 ns0:hasName "Department of Engineering and Architecture"@en,
        "Department of Industrial Engineering"@en .

ns25:RNN180897 ns0:hasName "Department of Neurosciences, Biomedicine and Movement Sciences"@en,
        "Section of Clinical Neurology, Department of Neurological and Movement Sciences"@en .

ns25:RNN190916 ns0:hasName "Graduate Program in Rehabilitation Sciences, Faculty of Medicine"@en,
        "Graduate Studies in Rehabilitation Sciences"@en .

ns25:THC181480 ns0:hasName "Department of Biomedical Engineering"@en,
        "Department of Biomedical Engineering, Faculty of Engineering"@en .

ns25:VES190655 ns0:hasName "Department of Neurology"@en .

ns25:WOR192947 ns0:hasName "Department of Kinesiology"@en,
        "Toronto Rehabilitation Institute"@en .

ns25:WOR192975 ns0:hasName "Department of Health Sciences and Health Policy"@en,
        "University of Lucerne"@en .

ns25:WOR192984 ns0:hasName "Research Center for Health Sciences"@en,
        "Research Center for Health Sciences, Institute of Health"@en,
        "School of Health"@en .

ns25:XST180473 ns0:hasName "Department of Surgery"@en,
        "Department of Surgery, Division of Cardiovascular Surgery"@en,
        "Department of Surgery, National Cheng Kung University Hospital, College of Medicine"@en,
        "Division of Cardiovascular Surgery, College of Medicine"@en .

ns25:XST180486 ns0:hasName "Department of CT"@en,
        "Department of Radiology"@en .

ns25:XST180488 ns0:hasName "Department of Radiology"@en,
        "Department of Radiology, Affiliated Hospital of Jiangnan University"@en .

ns25:ajw190035 ns0:hasName "Department of Chemistry, Faculty of Sciences"@en,
        "Department of Pharmaceutical Biotechnology, Faculty of Pharmacy"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD181175> ns0:hasName "Center for BrainHealth, School of Behavioral and Brain Sciences"@en,
        "Department of Neurology and Neurotherapeutics"@en,
        "Department of Psychiatry"@en,
        "Departments of Neurology and Neurotherapeutics"@en,
        "School of Behavioral & Brain Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD190132> ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Neuro Center"@en,
        "Neuro Center, Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD190469> ns0:hasName "Clinical Research Design and Evaluation, SAIHST"@en,
        "Department of Clinical Research Design & Evaluation, SAIHST"@en,
        "Department of Clinical Research Design and Evaluation, SAIHST"@en,
        "Department of Health Sciences and Technology, SAIHST"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Neuto Science Center"@en,
        "Samsung Medical Center, Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD190533> ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Centre for Neuromuscular and Neurological Disorders"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "McCusker Foundation for Alzheimer's Disease Research"@en,
        "School of Medical Health and Sciences"@en,
        "School of Medical SciencesEdith Cowan University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JAD190775> ns0:hasName "Department of Human Health Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:10.ID:JHD190346> ns0:hasName "San Diego State University-University of California"@en,
        "San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JAD190119> ns0:hasName "Department of Pathophysiology and Transplantation"@en,
        "University of Milan"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JAD190469> ns0:hasName "Department of Neurology"@en,
        "Neuroscience Center"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JAD190666> ns0:hasName "CAS Key Laboratory of Genome Sciences and Information"@en,
        "CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics"@en,
        "Center of Alzheimer's disease"@en,
        "UC Davis Genome Center and Department of Biomedical Engineering"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JAD190691> ns0:hasName "Clinical Geriatrics"@en,
        "Turku City Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:JPD191672> ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Division of Neurodegenerative Diseases"@en,
        "Division of Neurodegenerative Diseases, Department of Neurology"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Centre for Neurodegenerative Disease (DZNE)"@en,
        "German Centre for Neurodegenerative Diseases (DZNE) Rostock"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:11.ID:XST190500> ns0:hasName "Collaborative Innovation Center for Brain Science"@en,
        "ICT NDT Engineering Research Center, Ministry of Education"@en,
        "The Key Lab of Optoelectronic Technology and Systems of the Education Ministry of China"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:12.ID:HAB190375> ns0:hasName "Medical Laboratory Science Council of Nigeria"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:12.ID:JAD180573> ns0:hasName "Neuroscience Research Australia"@en,
        "School of Medical Sciences"@en,
        "University of New South Wales"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:12.ID:JAD190119> ns0:hasName "Department of Pathophysiology and Transplantation"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation"@en,
        "University of Milan"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:12.ID:JAD190311> ns0:hasName "1st Department of Neurology"@en,
        "1st Department of Neurology, G.H. “AHEPA”, School of Medicine, Faculty of Health Sciences"@en,
        "1st Department of Neurology, Medical School"@en,
        "1st Department of Neurology, U.H. “AHEPA”, Medical School, Faculty of Healthy Sciences"@en,
        "3rd Department of Neurology"@en,
        "3rd Department of Neurology, Medical School"@en,
        "3rd Department of Neurology, “G. Papanicolaou” Hospital"@en,
        "3rd Department of Neurology, “G. Papanikolaou” General Hospital of Thessaloniki"@en,
        "3rd Neurologic Clinic, Medical School, G. Papanikolaou Hospital"@en,
        "Aristotle University of Thessaloniki"@en,
        "Department of Neurology"@en,
        "Greek Association of Alzheimer's Disease and Related Disorders"@en,
        "INSERM U 558"@en,
        "Information Technologies Institute"@en,
        "Laboratory of Neurodegenerative Diseases"@en,
        "Laboratory of Neurodegenerative Diseases, Center for Interdisciplinary Research and Innovation (CIRI – AUTH) Balkan Center, Buildings A & B"@en,
        "Medical School Aristotle University of Thessaloniki"@en,
        "Memory and Dementia Centre"@en,
        "Memory and Dementia Centre, 3rd Department of Neurology"@en,
        "Network Aging Research"@en,
        "Third Department of Neurology"@en,
        "Third Department of Neurology, Memory and Dementia Centre, Medical School"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:13.ID:JAD190019> ns0:hasName "Institute for Minority Health Research"@en,
        "Institute for Minority Health Research, College of Medicine at Chicago"@en,
        "University of Illinois at Chicago"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:13.ID:JAD190046> ns0:hasName "Catalan Institution for Research and Advanced Studies (ICREA)"@en,
        "Cognition and Brain Plasticity Group"@en,
        "Department of Cognition, Development and Education Psychology, Campus Bellvitge"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:13.ID:JAD190132> ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine –Neurology, University of Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Neuro Center"@en,
        "NeuroCenter, Neurology"@en,
        "Neurology of NeuroCenter"@en,
        "Unit of Neurology"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:13.ID:JAD190568> ns0:hasName "Department of Medicine"@en,
        "Department of Medicine (Gerontology/Geriatrics), Neurology"@en,
        "Department of Medicine, Division of Geriatric Medicine"@en,
        "Department of Neurology"@en,
        "Department of Pathology and Laboratory Medicine"@en,
        "Department of Pathology and Laboratory Medicine, Penn Neurodegeneration Genomics Center, Perelman School of Medicine"@en,
        "Department of Pharmacology"@en,
        "Geriatric Research, Education, and Clinical Center"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC)"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC) VA Puget Sound Health Care System"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC)VA Puget Sound Health Care System"@en,
        "Geriatric Research, Education, and Clinical Centers"@en,
        "Medicine"@en,
        "Neurology"@en,
        "Pathology & Laboratory Medicine"@en,
        "Pharmacology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD181175> ns0:hasName "Department of Neurology"@en,
        "Departments of Neurology and Neurotherapeutics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD181212> ns0:hasName "Department of Medicine"@en,
        "Department of Medicine, Division of General Internal Medicine"@en,
        "Group Health Research Institute"@en,
        "University of Washington"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD190119> ns0:hasName "Department of Neurological Sciences"@en,
        "Department of Neurological Sciences, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation, Neurodegenerative Disease Unit, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation, Neurology Unit"@en,
        "Department of Pathophysiology and Transplantation, “Dino Ferrari” Center"@en,
        "Fondazione Cá Granda"@en,
        "Neurology Unit"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation, ‘Dino Ferrari’ Center"@en,
        "Neurology Unit, “Dino Ferrari” Center"@en,
        "University of Milan"@en,
        "“Neurology Unit”, Department of Pathophysiology and Transplantation “Dino Ferrari” Center"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD190155> ns0:hasName "Banco Nacional de Cerebros, Laboratorio Nacional de Servicios Experimentales"@en,
        "Brain Bank, Laboratorio Nacional de Servicios Experimentales"@en,
        "Brain Bank-LaNSE"@en,
        "Department of Physiology, Biophysics and Neurociences"@en,
        "Department of Physiology, Biophysics and Neurosciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD190446> ns0:hasName "Department of Psychosomatic Medicine"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Center for Neurodegenerative Diseases (DZNE) –Rostock/Greifswald"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JAD190533> ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation Perth"@en,
        "Centre for Aging and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Clinical Research in Neuropsychiatry, Graylands Hospital"@en,
        "Centre for Neuromuscular and Neurological Disorders"@en,
        "Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care; The Sir James McCurker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre for Ageing and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence in Alzheimer’s Disease Research and Care, School of Medical Sciences"@en,
        "Department of Biomedical Sciences"@en,
        "KARVIAH Research Centre"@en,
        "KaRa Institute of Neurological Disease"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "McCusker Foundation for Alzheimer's Disease Research"@en,
        "McCusker Foundation for Alzheimer's Disease Research Inc"@en,
        "School of Biomedical Science"@en,
        "School of Biomedical Sciences"@en,
        "School of Exercise, Biomedical and Health Sciences"@en,
        "School of Medical Health and Sciences"@en,
        "School of Medical Sciences"@en,
        "School of Medical SciencesEdith Cowan University"@en,
        "School of Medical and Health Sciences"@en,
        "School of Psychiatry & Clinical Neurosciences"@en,
        "School of Psychiatry and Clinical Neuroscience"@en,
        "School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit, School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer’s Disease Research Unit"@en,
        "The CRC for Mental Health"@en,
        "The McCusker Alzheimer’s Research Foundation"@en,
        "The School of Exercise, Biomedical and Health Science"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit, School of Exercise, Biomedical and Health Sciences"@en,
        "The University of British ColumbiaUniversity of Western Australia"@en,
        "The University of Western AustraliaEdith Cowan University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:14.ID:JND190403> ns0:hasName "Department of Pediatrics"@en,
        "The Ohio State University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:15.ID:JAD190334> ns0:hasName "Institute of Clinical Medicine – Neurosurgery"@en,
        "Institute of Clinical Medicine –Neurosurgery, University of Eastern Finland and Department of Neurosurgery"@en .

ns265:JAD190023 ns0:hasName "Department of Neurology, Institute of Brain Science"@en,
        "Gunma University School of Medicine"@en .

ns265:JAD190119 ns0:hasName "Department of Neurological Sciences"@en,
        "Department of Neurological Sciences, Centro Dino Ferrari"@en,
        "Department of Neurological Sciences, Dino Ferrari Center"@en,
        "Department of Neurological Sciences, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation, Neurodegenerative Disease Unit, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation, “Dino Ferrari” Center"@en,
        "Dino Ferrari Centre, Department of Neurological Sciences, University of Milan"@en,
        "Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino Ferrari"@en,
        "Neurology Unit"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation, ‘Dino Ferrari’ Center"@en,
        "University of Milan"@en,
        "Università di Milano"@en .

ns149:JAD190132 ns0:hasName "Institute of Clinical Medicine – Neurology, Universityof Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Neuro Center"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

ns14:BME191064 ns0:hasName "Neurosciences Research Center"@en,
        "Tabriz University of Medical Science"@en .

ns14:BMR171041 ns0:hasName "Department of Physiotherapy, School of Rehabilitation Sciences"@en,
        "School of Rehabilitation Science"@en .

ns14:BMR181128 ns0:hasName "Department of Physiotherapy, School of Rehabilitation Sciences"@en,
        "School of Rehabilitation Science"@en .

ns14:BMR181131 ns0:hasName "Faculty of Physical Education and Sports"@en,
        "Sports Technology Institute, Faculty of Electrical Engineering and Information Technology"@en .

ns14:BMR181185 ns0:hasName "Department of Physical Medicine and Rehabilitation"@en,
        "Department of Physical Medicine and Rehabilitation, Pain Management, Medical School"@en .

ns14:BMR181296 ns0:hasName "Department of Sport Science, Sport Research Centre"@en,
        "Sports Research Centre"@en .

ns14:BMR181380 ns0:hasName "Faculty of Medicine"@en,
        "University of Novi Sad"@en .

ns14:BRS190144 ns0:hasName "School of Civil Engineering"@en,
        "University College Dublin"@en .

ns14:CH180402 ns0:hasName "Department of Physiology, Faculty of Medicine"@en,
        "Pamukkale University"@en,
        "Pamukkale University, Faculty of MedicineDepartment of Physiology"@en .

ns14:CH180404 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital"@en,
        "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en .

ns14:CH180452 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Shanghai Research Center for Thyroid Diseases"@en,
        "Thyroid Institute"@en .

ns14:CH180470 ns0:hasName "Department of Clinical Rehabilitation"@en,
        "Department of Clinical Rehabilitation, Faculty of Motor Rehabilitation"@en .

ns14:CH180476 ns0:hasName "Brain Korea 21 PLUS Project for Medical Science"@en .

ns14:CH199213 ns0:hasName "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Hand- and Reconstructive Surgery"@en,
        "Department of Plastic, Reconstructive and Hand Surgery"@en,
        "Reconstructive and Hand Surgery at the University Medical Center Regensburg"@en,
        "University Hospital Regensburg"@en .

ns14:CH199226 ns0:hasName "Brandenburg University of Technology Cottbus-Senftenberg"@en,
        "Institute of Biotechnology"@en .

ns14:FI1821 ns0:hasName "School of Automation"@en .

ns14:FI1831 ns0:hasName "Audio Acoustics Laboratory, Faculty of Electronics, Telecommunications and Informatics"@en,
        "Gdansk University of Technology"@en,
        "Gdansk University of Technology (GUT)"@en .

ns14:HAB190373 ns0:hasName "Antibody Laboratory"@en,
        "Biological Sciences Department, Faculty of Science"@en,
        "Main Medical Laboratory"@en,
        "Therapeutic and Protective Proteins Laboratory, Protein Research Department"@en .

ns14:HSM190517 ns0:hasName "Guanghua School of Management"@en,
        "School of Economics and Management"@en .

ns14:IA180015 ns0:hasName "DII"@en,
        "Department of Information Engineering and Mathematics (DIISM)"@en .

ns14:IA190023 ns0:hasName "Faculty of Computer Science"@en,
        "Free University of Bozen-Bolzano"@en .

ns14:IDA184334 ns0:hasName "Anhui Provincial Key Laboratory of Network and Information Security"@en,
        "College of Computer and Information"@en,
        "School of Computer and Information"@en,
        "School of Geography and Tourism"@en .

ns14:IES192105 ns0:hasName "Department of Physical Education and Sport, Ondokuz Mayıs University Performance Laboratory"@en,
        "Sport Science Faculty"@en .

ns14:IES193141 ns0:hasName "School of Kırkpınar Physical Education and Sport"@en,
        "School of Physical Education and Sports"@en .

ns14:IFS171049 ns0:hasName "Department of Mathematics"@en .

ns14:IFS179223 ns0:hasName "School of Business"@en,
        "Sichuan Normal University"@en .

ns14:IFS179262 ns0:hasName "School of Science"@en .

ns14:IFS179322 ns0:hasName "Central Software Institute"@en,
        "Collaborative Innovation Center of Machinery Equipment Advanced Manufacturing of Henan Province"@en .

ns14:IFS181541 ns0:hasName "Department of Supply Chain Management"@en,
        "Department of Supply Chain Management, Asper School of Business"@en .

ns14:IFS181547 ns0:hasName "Deparment of Mathematics"@en,
        "Department of Mathematics"@en .

ns14:IFS181697 ns0:hasName "Department of Pure Mathematics, Faculty of Mathematics and Computer"@en .

ns14:IFS181922 ns0:hasName "Department of Mathematics"@en .

ns14:IFS181941 ns0:hasName "College of Sciences"@en,
        "Department of Mathematics"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Behavioral Neuroscience"@en,
        "Department of Statistics, Faculty of Science"@en .

ns14:IFS181970 ns0:hasName "Institute of Management and Decision"@en,
        "Institute of Management and decision"@en,
        "Institute of management and decision"@en,
        "School of Economics and Management"@en,
        "Tai Yuan University"@en .

ns14:IFS182568 ns0:hasName "Beijing Key Laboratory on MCAACI"@en,
        "School of Mathematics and Statistics"@en .

ns14:IFS182572 ns0:hasName "Department of Mathematical Engineering"@en,
        "Department of Mathematics & Computer Science, Faculty of NaturalSciences"@en,
        "Department of Mathematics and Computer Science"@en,
        "Polytechnic University of Tirana"@en .

ns14:IFS182581 ns0:hasName "School of Mechanical, Electronic and Control Engineering"@en .

ns14:IFS182595 ns0:hasName "Department of Mathematics"@en,
        "Department of Mathematics Education"@en,
        "Department of Mathematics Education (and RINS)"@en,
        "Department of Mathematics Education and RINS"@en .

ns14:IFS182616 ns0:hasName "BORDA Research Unit and IME"@en .

ns14:IFS182634 ns0:hasName "Institute of Management and Decision"@en,
        "Institute of Management and decision"@en,
        "Tai Yuan University"@en .

ns14:IFS18266 ns0:hasName "School of Finance"@en .

ns14:IFS182745 ns0:hasName "School of Finance"@en .

ns14:IFS182774 ns0:hasName "Department of Mathematics and Statistic"@en,
        "Department of Mathematics and Statistics"@en .

ns14:IFS182951 ns0:hasName "Department of Mathematics"@en .

ns14:IFS18824 ns0:hasName "Department of Mathematics"@en,
        "Yazd University"@en .

ns14:IFS18950 ns0:hasName "Department of Civil Engineering"@en .

ns14:IFS190001 ns0:hasName "Chongqing Key Laboratory of Electronic Commerce & Supply Chain System"@en,
        "Chongqing Key Laboratory of Electronic Commerce and Supply Chain System"@en .

ns14:IFS190054 ns0:hasName "Department of Mathematics"@en,
        "Yazd University"@en .

ns14:IFS190116 ns0:hasName "Department of Electrical Engineering and Automation"@en,
        "Department of Electrical and Information Engineering"@en,
        "Faculty of Mechanical Engineering"@en,
        "Faculty of Mechanical Engineering and Automation"@en,
        "Shaoxing University"@en,
        "Wuhan University of Technology"@en .

ns14:IFS190217 ns0:hasName "School of Mathematics, Thapar Institute of Engineering & Technology"@en,
        "Thapar Institute of Engineering & Technology (Deemed University)"@en .

ns14:IFS190293 ns0:hasName "Department of Mathematics"@en .

ns14:JAD170300 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "G.H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en .

ns14:JAD180562 ns0:hasName "Department of Health Service and Population Research"@en,
        "King's College London"@en .

ns14:JAD180571 ns0:hasName "Department of Psychology"@en,
        "Neuroscience and Mental Health Institute"@en .

ns14:JAD180573 ns0:hasName "Falls, Balance and Injury Research Centre, Neuroscience Research Australia"@en,
        "School of Public Health and Community Medicine, Faculty of Medicine"@en,
        "University of New South Wales"@en .

ns14:JAD181132 ns0:hasName "Epidemiology and Public Health Group"@en,
        "University of Exeter Medical School"@en .

ns14:JAD181157 ns0:hasName "Department of Medicine, Peninsula Clinical School, Central Clinical School"@en,
        "Department of Medicine, Peninsula Health & Peninsula Clinical School"@en,
        "Department of Medicine, Peninsula Health, Peninsula Clinical School"@en,
        "Department of Medicine, Stroke and Ageing Research Group, School of Clinical Sciences at Monash Health"@en,
        "Menzies Institute for Medical Research"@en,
        "Neurosciences"@en,
        "Peninsula Clinical School, Central Clinical School"@en,
        "Stroke and Ageing Research Group, Vascular Brain Ageing Division, Department of Medicine, School of Clinical Sciences"@en .

ns14:JAD181173 ns0:hasName "Falls"@en,
        "Falls, Balance and Injury Research Centre, Neuroscience Research Australia"@en,
        "School of Public Health and Community Medicine, Faculty of Medicine"@en .

ns14:JAD181189 ns0:hasName "Department of Clinical Sciences"@en,
        "Department of Clinical Sciences, Psychiatry"@en .

ns14:JAD181203 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, Division of Geriatric Psychiatry"@en,
        "Division of Geriatric Psychiatry"@en,
        "Neuropsychopharmacology Research Group"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Sunnybrook Research Institute"@en .

ns14:JAD190041 ns0:hasName "Department of Psychiatry and Neuropsychology, Alzheimer Center Limburg, School for Mental Health and Neuroscience"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en .

ns14:JAD190074 ns0:hasName "Department of Neurosciences"@en,
        "Division of Neurosciences"@en,
        "Division of Neurosciences and Molecular Neuropathology Section, Laboratory of Neurogenetics"@en,
        "Molecular Neuropathology Section, Laboratory of Neurogenetics"@en .

ns14:JAD190092 ns0:hasName "Department of Radiology, Miller School of Medicine"@en,
        "Evelyn F. McKnight Brain Institute"@en .

ns14:JAD190119 ns0:hasName "Department of Neurological Sciences"@en,
        "Department of Neurological Sciences, Dino Ferrari Center"@en,
        "Department of Neurological Sciences, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation, Neurology Unit"@en,
        "Department of Pathophysiology and Transplantation, “Dino Ferrari” Center"@en,
        "Fondazione Cá Granda"@en,
        "Neurology Unit"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation, ‘Dino Ferrari’ Center"@en,
        "Neurology Unit, “Dino Ferrari” Center"@en,
        "University of Milan"@en,
        "“Neurology Unit”, Department of Pathophysiology and Transplantation “Dino Ferrari” Center"@en .

ns14:JAD190222 ns0:hasName "Centre for Clinical Brain Sciences"@en,
        "Centre for Dementia Prevention"@en,
        "Department of Psychological Medicine"@en,
        "Division of Psychiatry, Centre for Clinical Brain Sciences"@en .

ns14:JAD190269 ns0:hasName "Department of Endocrinology"@en,
        "Medical School of Southeast University"@en,
        "School of Medicine"@en .

ns14:JAD190281 ns0:hasName "Department of Pathology"@en .

ns14:JAD190413 ns0:hasName "CIRRAU-Centre for Integrated Register-based Research"@en,
        "Department of Depression and Anxiety/Psychosis Research Unit"@en,
        "Depression and Anxiety/Psychosis Research Unit"@en,
        "National Centre for Register Based Research"@en,
        "National Centre for Register-Based Research"@en,
        "National Centre for Register-based Research"@en,
        "The Lundbeck Foundation Initiative for Integrative Psychiatric Research"@en .

ns14:JAD190427 ns0:hasName "INSERM"@en,
        "INSERM, ISPED"@en,
        "InsermUniversité Victor Segalen Bordeaux2"@en,
        "University Bordeaux"@en,
        "University of Bordeaux"@en,
        "Université de Bordeaux, Inserm"@en .

ns14:JAD190469 ns0:hasName "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en .

ns14:JAD190474 ns0:hasName "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging"@en .

ns14:JAD190484 ns0:hasName "Departament de Biologia Cellular, Protein Folding and Stability Group, de Fisiologia i d’Immunologia, Unitat de Citologia i d’Histologia, Facultat de Biociències"@en,
        "Departament de Biologia Cellular, de Fisiologia i d’Immunologia, Unitat de Citologia i d’Histologia, Facultat de Biociències, Edifici C"@en .

ns14:JAD190533 ns0:hasName "Department of Biomedical Sciences"@en,
        "KaRa Institute of Neurological Disease"@en,
        "School of Medical Health and Sciences"@en,
        "School of Psychiatry and Clinical Neurosciences"@en .

ns14:JAD190564 ns0:hasName "Department of Neurobiology, George S. Wise Faculty of Life Sciences"@en,
        "Department of Neurobiology, Sagol School of Neuroscience, George S. Wise Faculty of Life Sciences"@en,
        "Sagol School of Neuroscience"@en .

ns14:JAD190567 ns0:hasName "Department of Neuroscience, Psychology and Behaviour"@en,
        "Institute for Ageing and Health, Campus for Ageing and Vitality"@en .

ns14:JAD190577 ns0:hasName "Institute of Psychiatry"@en,
        "Institute of Psychiatry, Psychology and Neuroscience, Department of Old Age Psychiatry, King’s College London"@en .

ns14:JAD190590 ns0:hasName "Mental Health Promotion Project"@en,
        "Research Project for Mental Health Promotion"@en .

ns14:JAD190638 ns0:hasName "1st Department of Neurology, Medical School"@en,
        "3rd Department of Neurology"@en,
        "Aristotle University of Thessaloniki"@en .

ns14:JAD190704 ns0:hasName "Department of Electrical and Electronic Engineering"@en,
        "iCV Research Group, Institute of Technology"@en .

ns14:JAD190721 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Department of Molecular Neuroscience"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute"@en,
        "UK Dementia Research Institute at UCL"@en .

ns14:JAD190782 ns0:hasName "Center for Neuropathology"@en,
        "Department of Pathology"@en .

ns14:JHD190353 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research"@en,
        "Department of Radiology"@en,
        "George Huntington Institute"@en,
        "George-Huntington-Institute"@en,
        "Institute for Clinical Radiology"@en .

ns14:JND190403 ns0:hasName "Department of Pediatrics"@en,
        "Department of Physical Therapy"@en .

ns14:JPD191579 ns0:hasName "Department of Neurology"@en,
        "Neurology Service and GRECC"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en,
        "Veteran's Affairs Ann Arbor Healthcare System"@en,
        "Veterans Affairs Ann Arbor Health System (VAAAHS) and GRECC"@en .

ns14:JPD191600 ns0:hasName "Department of Radiology"@en .

ns14:JPD191699 ns0:hasName "Department of Clinical Neuroscience"@en,
        "Department of Clinical Neuroscience, Translational Neuropharmacology, Center for Molecular Medicine"@en,
        "Department of Neurology"@en .

ns14:JRS180021 ns0:hasName "Department of Dental Surgery"@en,
        "Department of Pathology"@en .

ns14:JVR191025 ns0:hasName "Center for Disability Studies"@en,
        "Kent State University"@en,
        "School of Lifespan Development and Educational Sciences"@en .

ns14:JVR191034 ns0:hasName "Interwork Institute"@en .

ns14:JVR191038 ns0:hasName "University of Montana"@en .

ns14:JVR191043 ns0:hasName "University of Wisconsin-Stout"@en,
        "University of Wisconsin-Stout Vocational Rehabilitation Institute"@en .

ns14:KCA180049 ns0:hasName "SWOG Statistical Center"@en,
        "SWOG Statistical Center/Fred Hutchinson Cancer Research Center"@en .

ns14:KES190402 ns0:hasName "School of Computer Engineering"@en,
        "School of Computer Engineering, KIIT"@en .

ns14:KES190409 ns0:hasName "Aligarh Muslim University"@en,
        "Department of Computer Engineering"@en .

ns14:MGS190307 ns0:hasName "Department of Mathematics and Computer Science"@en,
        "Department of Mathematics and Computer Science, Software Engineering Research Laboratory"@en .

ns14:NHA180056 ns0:hasName "Department of Psychology, School of Psychology and Clinical Language Sciences"@en,
        "School of Psychology and Clinical Language Sciences"@en .

ns14:NHA190065 ns0:hasName "College of Sciences"@en,
        "Department of Mathematics"@en,
        "Department of Psychiatry"@en,
        "Department of Statistics, Faculty of Science"@en .

ns14:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Geography"@en,
        "Department of Paediatrics"@en,
        "Lawson Health Research Institute"@en,
        "School of Health Studies"@en .

ns14:NRE192748 ns0:hasName "Department of Neurosciences"@en .

ns14:NRE192771 ns0:hasName "University of São Paulo (USP)"@en .

ns14:RNN190908 ns0:hasName "Center for Interdisciplinary Research in Rehabilitation and Social Integration (CIRRIS)"@en,
        "Centre interdisciplinaire de recherche en réadaptation et intégration sociale, Département de Réadaptation, Faculté de médecine"@en,
        "Department of Rehabilitation, Faculty of Medicine"@en .

ns14:WOR192938 ns0:hasName "Department of Physiotherapy"@en,
        "School of Health and Rehabilitation Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff2.Author:21.ID:JAD190334> ns0:hasName "Institute of Clinical Medicine – Neurosurgery"@en,
        "Institute of Clinical Medicine – Neurosurgery, University of Eastern Finland and Neurosurgery of NeuroCenter"@en,
        "Neurosurgery of NeuroCenter"@en,
        "Unit of Neurosurgery"@en .

ns31:BD180365 ns0:hasName "Aarhus University Hospital"@en,
        "Breast and Endocrinal Surgery Department"@en .

ns31:CBM182383 ns0:hasName "Department of Pathology, Medical University of Athens"@en,
        "Laboratory of Biology, Medical School"@en .

ns31:CH180404 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital"@en,
        "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en .

ns31:CH199213 ns0:hasName "Applied Stem Cell Research Center"@en,
        "Center for Plastic, Aesthetic, Hand & Reconstructive Surgery"@en,
        "Center for Plastic, Aesthetic, Hand &Reconstructive Surgery"@en,
        "Center for Plastic, Hand and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand- and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand-, and Reconstructive Surgery"@en,
        "Center of Plastic and Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Reconstructive Surgery"@en,
        "Department of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Hand, and Reconstructive Surgery"@en,
        "Department of Plastic, Hand- and Reconstructive Surgery"@en,
        "Department of Plastic, Hand-and Reconstructive Surgery"@en,
        "Department of Plastic, Reconstructive and Hand Surgery"@en,
        "Department of Plastic-, Hand- and Reconstructive Surgery"@en,
        "Department of Plastic-, Hand-, and Reconstructive Surgery"@en,
        "University Center for Plastic, Hand and Reconstructive Surgery"@en,
        "University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery"@en,
        "University Medical Center Regensburg"@en .

ns31:FI1870 ns0:hasName "Department of Aeronautics and Astronautics, Graduate School of Engineering"@en,
        "RCAST"@en,
        "Research Center for Advanced Science and Technology"@en .

ns31:FI1878 ns0:hasName "Aix Marseille Université"@en,
        "Università degli Studi di Milano-Bicocca"@en .

ns31:HSM190490 ns0:hasName "School of Economics and Management"@en,
        "School of Management and Economics"@en .

ns31:IDA184239 ns0:hasName "FEP -- University of Porto"@en,
        "FEP, LIADD"@en,
        "Faculty of Economics of the University of Porto"@en,
        "INESC TEC"@en,
        "LIAAD – INESC Porto L.A."@en,
        "LIAAD-University of Porto"@en,
        "LIACC"@en,
        "LIACC-University of Porto"@en,
        "University of Porto"@en .

ns31:IES182206 ns0:hasName "Department of Computer Science/Therapy Science"@en,
        "Department of Computer/Therapy Science"@en,
        "Department of Cranio-Maxillofacial Surgery"@en,
        "University Outpatient Clinic, Sports Medicine and Sports Orthopaedics"@en .

ns31:IES192167 ns0:hasName "Sports Medical Center, Hiroshima University Hospital"@en .

ns31:IFS171587 ns0:hasName "Department of Mathematics"@en,
        "Department of Mathematics Education"@en,
        "Department of Mathematics Education (and RINS)"@en,
        "Department of Mathematics Education and RINS"@en .

ns31:IFS179300 ns0:hasName "College of Computer Science and Technology"@en .

ns31:IFS181246 ns0:hasName "College of Mechanical and Transportation Engineering"@en,
        "School of Mechanical and Transportation Engineering"@en .

ns31:IFS182581 ns0:hasName "School of Mechanical, Electronic and Control Engineering"@en .

ns31:JAD180501 ns0:hasName "Cambridge Institute of Public Health, Forvie Site"@en,
        "Department of Public Health and Primary Care"@en,
        "Department of Public Health and Primary Care, Cambridge Institute of Public Health"@en,
        "Department of Public Health and Primary Care, Institute of Public Health"@en,
        "Department of Public Health and Primary Care, Institute of Public Health, Forvie Site"@en,
        "Institute of Public Health"@en .

ns31:JAD180573 ns0:hasName "Academic Department for Old Age Psychiatry"@en,
        "Brain and Ageing Research Program, School of Psychiatry, Faculty of Medicine"@en,
        "Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine"@en,
        "University of New South Wales"@en .

ns31:JAD180900 ns0:hasName "Neuroscience Research Australia and the University of New South Wales"@en,
        "School of Medical Sciences"@en .

ns31:JAD181141 ns0:hasName "Albert Einstein College of Medicine"@en,
        "Department of Epidemiology and Population Health"@en,
        "Department of Epidemiology and Population Health, Albert Einstein College of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Albert Einstein College of Medicine"@en,
        "Departments of Neurology, Epidemiology, and Social Medicine, Montefiore Headache Unit"@en,
        "Einstein Aging Study"@en,
        "Innovative Medical Research"@en,
        "Institute for Aging Research, Albert Einstein College of Medicine"@en,
        "Saul B. Korey Department of Neurology"@en,
        "Saul R. Korey Department of Neurology, Albert Einstein College of Medicine"@en,
        "The Einstein Aging Study"@en .

ns31:JAD181171 ns0:hasName "Department of Biochemistry, Faculty of Medicine, UKMMC"@en,
        "Molecular Neuroscience Research Center"@en .

ns31:JAD181175 ns0:hasName "Departments of Neurology and Neurotherapeutics"@en,
        "Nuclear Medicine Center"@en .

ns31:JAD181268 ns0:hasName "Alzheimer's Disease Center"@en,
        "Department of Neurology"@en,
        "Department of Neurology, KU Alzheimer and Memory Program"@en,
        "The University of Kansas Alzheimer’s Disease Center"@en,
        "University of Kansas Alzheimer’s Disease Center"@en,
        "University of Kansas Medical Center"@en,
        "University of Kansas School of Medicine"@en .

ns31:JAD181282 ns0:hasName "Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Institute of Neuroscience and Physiology"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "the Sahlgrenska Academy at University of Gothenburg"@en .

ns31:JAD190142 ns0:hasName "Department of Biostatistics"@en,
        "Vanderbilt University Department of Psychiatry and Behavioral Sciences"@en,
        "Vanderbilt University Medical Center"@en,
        "Vanderbilt University Medical Center Psychiatric Neuroimaging Program"@en,
        "Vanderbilt University School of Nursing"@en .

ns31:JAD190175 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology and Clinical Neurophysiology"@en,
        "Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences"@en,
        "Department of Neuroscience, Faculty of Medicine"@en .

ns31:JAD190198 ns0:hasName "Center for Networked Biomedical Research in Neurodegenerative Diseases (CIBERNED)"@en,
        "Institute of Biomedical Research Hospital 12 Octubre (imas12)"@en,
        "Neuroscience Group"@en .

ns31:JAD190222 ns0:hasName "Division of Psychiatry, Centre for Clinical Brain Sciences"@en,
        "The University of Edinburgh"@en .

ns31:JAD190237 ns0:hasName "Department of Neuroscience Imaging and Clinical Sciences"@en,
        "Department of Neuroscience, Imaging, and Clinical Sciences"@en .

ns31:JAD190298 ns0:hasName "Department of Aging Science and Pharmacology, Faculty of Dental Sciences"@en,
        "Department of Medicine, Teaching and Science, Daping Hospital"@en,
        "Department of Neurology and Center for Clinical Neuroscience"@en,
        "Department of Neurology and Centre for Clinical Neuroscience, Daping Hospital"@en,
        "Department of Neurology, Daping Hospital"@en .

ns31:JAD190316 ns0:hasName "Department of Biomedical Engineering"@en,
        "Department of Radiology and Radiological Sciences"@en,
        "Institute of Imaging Science"@en,
        "Vanderbilt Brain Institute"@en,
        "Vanderbilt Ingram Cancer Center"@en,
        "Vanderbilt Institute of Chemical Biology"@en,
        "Vanderbilt Institute of Nanoscale Science and Engineering"@en,
        "Vanderbilt University Institute of Imaging Science"@en .

ns31:JAD190319 ns0:hasName "Department of Medicine, Peninsula Clinical School, Central Clinical School"@en,
        "Developmental Imaging"@en,
        "Stroke and Ageing Research Centre, Medicine, School of Clinical Sciences, Monash Medical Centre"@en .

ns31:JAD190329 ns0:hasName "Alzheimer’s Disease Center"@en,
        "Division of Gerontology, Geriatrics, and Palliative Care, Department of Medicine"@en .

ns31:JAD190346 ns0:hasName "Centre Hospitalier Sainte-Anne"@en,
        "Department of Neurology, Hemorrhagic Stroke Research Program"@en .

ns31:JAD190403 ns0:hasName "Centre for Vision Research"@en,
        "York University"@en .

ns31:JAD190459 ns0:hasName "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute I-Vie"@en .

ns31:JAD190474 ns0:hasName "Brain and Ageing Research Program, School of Psychiatry"@en,
        "Brain and Ageing Research Program, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Dementia Centre for Research Collaboration"@en,
        "Neuropsychiatric Institute"@en,
        "Neuropsychiatric Institute (NPI)"@en,
        "Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine"@en,
        "Prince of Wales Research Institute and Centre for Healthy Brain Aging"@en,
        "School of Psychiatry"@en .

ns31:JAD190491 ns0:hasName "Department of Family Medicine and Public Health"@en,
        "Division of Epidemiology, Department of Family Medicine and Public Health"@en .

ns31:JAD190494 ns0:hasName "Department of Neuroscience"@en,
        "Neuroscience Institute Cavalieri Ottolenghi Foundation (NICO)"@en,
        "Neuroscience Institute of Cavalieri Ottolenghi Foundation (NICO)"@en .

ns31:JAD190517 ns0:hasName "Department of Medicine"@en .

ns31:JAD190533 ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical Sciences"@en,
        "Department of Biomedical Sciences"@en,
        "School of Medical Health and Sciences"@en .

ns31:JAD190645 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "Waisman Laboratory for Brain Imaging and Behavior"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns31:JAD190721 ns0:hasName "Clinical Neurochemical Laboratory, Institute of Neuroscience & Physiology"@en,
        "Clinical Neurochemistry Lab"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, University of Gothenburg"@en,
        "Clinical Neurochemistry Lab, The Sahlgrenska Academy at"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the"@en,
        "Clinical Neurochemistry Laboratory, Inst. of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Neurochemistry"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Clinical Chemistry and Transfusion Medicine"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Psychiatry and Neurochemistry"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory,Institute of Neuroscience and Physiology, Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital"@en,
        "Institute of Neurobiology and Physiology, Department of Neurochemistry and Psychiatry, Sahlgrenska University Hospital"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Neurochemical Laboratory, Department of Neuroscience and Physiology, Section of Psychiatry and Neurochemistry"@en,
        "Neuropsychiatric Epidemiology Unit"@en,
        "The Sahlgrenska Academy at Göteborg University"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "The Sahlgrenska Academy at the University of Gothenburg"@en,
        "The Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences"@en,
        "University of Goteborg"@en,
        "the Sahlgrenska Academy at Göteborg University"@en .

ns31:JAE180058 ns0:hasName "Anhui University"@en .

ns31:JAE190086 ns0:hasName "Nanjing University of Aeronautics & Astronautics"@en,
        "Nanjing University of Aeronautics and Astronautics"@en,
        "State Key Laboratory of Mechanics and Control for Mechanical Structures"@en,
        "State Key Laboratory of Mechanics and Control of Mechanical Structures"@en,
        "State Key Laboratory of Mechanics and Control of Mechanical StructuresNanjing University of Aeronautics and Astronautics"@en .

ns31:JHD190364 ns0:hasName "Institute of Cognitive and Clinical Neurosciences, School of Psychological Sciences"@en,
        "School of Psychological Sciences, Monash Institute of Cognitive and Clinical Neurosciences, Faculty of Medicine, Nursing and Health Sciences"@en .

ns31:JPD191579 ns0:hasName "Department of Neurology"@en,
        "Department of Radiology"@en,
        "Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en,
        "Neurology"@en,
        "Neurology Service and GRECC"@en,
        "Radiology"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en,
        "Veterans Affairs Ann Arbor Health System (VAAAHS) and GRECC"@en .

ns31:JVR191036 ns0:hasName "Department of Rehabilitation Psychology & Special Education"@en,
        "Univeristy of Wisconsin-Madison"@en .

ns31:JVR191039 ns0:hasName "University of Kansas"@en .

ns31:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Paediatrics"@en,
        "Human Environments Analysis Laboratory"@en,
        "Lawson Health Research Institute"@en,
        "School of Food and Nutritional Sciences"@en .

ns31:NRE192700 ns0:hasName "Department of Physical Therapy"@en,
        "Federal University of Bahia (FUBA)"@en .

ns31:NRE192745 ns0:hasName "Université Catholique de Louvain"@en,
        "Université catholique de Louvain"@en .

ns31:RNN190926 ns0:hasName "Department of Neurology"@en,
        "NeurologyThe People’s Hospital of Liaoning Province"@en .

ns31:THC199009 ns0:hasName "Macau University of Science and Technology"@en,
        "State Key Laboratory of Quality Research in Chinese Medicines"@en .

ns31:WOR192958 ns0:hasName "Human Research Resources Organization"@en,
        "Human Resources Research Organization (HumRRO)"@en .

ns31:XST180465 ns0:hasName "Department of Pathology"@en .

ns31:XST190533 ns0:hasName "Department of Medical Oncology, West China Hospital"@en,
        "Department of Ultrasound"@en .

ns31:XST190548 ns0:hasName "Department of Medical Oncology, West China Hospital"@en,
        "Department of Ultrasound"@en .

ns50:BME191060 ns0:hasName "Department of Inorganic Biomaterials, Institute of Biomaterials and BioengineeringTokyo Medical and Dental University"@en,
        "Institute of Biomaterials and Bioengineering"@en .

ns50:CBM190013 ns0:hasName "Amrita School of Biotechnology"@en,
        "SIERS Research Laboratory"@en .

ns50:CH199205 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en,
        "Institute of Chemistry and Biochemistry, Department of Biology, Chemistry and Pharmacy"@en .

ns50:CH199222 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Clinical Radiology, Interdisciplinary Ultrasound Center"@en,
        "Department of Clinical Radiology, Interdisciplinary Ultrasound-Center"@en,
        "Department of Clinical Radiology, Interdisciplinary Ultrasound-Center, University Hospital Grosshadern"@en,
        "Department of Radiology"@en,
        "Institute for Clinical Radiology"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich - Grosshadern Campus"@en .

ns50:HAB190370 ns0:hasName "Department of Biomedical Technology"@en,
        "Genetic Engineering Division, Department of Microbial Biotechnology"@en .

ns50:IA190023 ns0:hasName "Faculty of Computer Science"@en,
        "Free University of Bozen-Bolzano"@en .

ns50:IFS179086 ns0:hasName "School of Computing"@en .

ns50:IFS179151 ns0:hasName "National Institute of Technology"@en .

ns50:IFS179319 ns0:hasName "Department of Clinical Pharmacy"@en,
        "Division of Respiratory Medicine, Department of Respiration, The Affiliated Drum Tower Hospital of Nanjing University Medical College"@en,
        "State Grid Dalian Power Supply Company"@en .

ns50:IFS181633 ns0:hasName "Department of Mathematics"@en,
        "National Institute of Technology"@en .

ns50:JAD180857 ns0:hasName "Department of Geriatrics & Radboud Alzheimer Center"@en,
        "Department of Medical Psychology"@en,
        "Donders Institute for Brain, Cognition and Behavior"@en,
        "Donders Institute for Brain, Cognition and Behaviour"@en,
        "Radboud University Medical Center"@en,
        "Vincent van Gogh Institute for Psychiatry"@en .

ns50:JAD180900 ns0:hasName "Brain and Mind Centre"@en,
        "Faculty of Medicine"@en,
        "Neuroscience Research Australia"@en,
        "School of Medical Science"@en,
        "School of Medical Sciences"@en,
        "The University of Sydney"@en,
        "University of New South Wales"@en .

ns50:JAD181141 ns0:hasName "Department of Epidemiology and Population Health"@en,
        "Department of Epidemiology and Population Health, Albert Einstein College of Medicine"@en,
        "Einstein Aging Study"@en,
        "Saul B. Korey Department of Neurology"@en .

ns50:JAD181288 ns0:hasName "Department of Medicine, Division of General Medicine and Primary Care"@en,
        "Department of Medicine, Division of Gerontology"@en,
        "Divisions of General Medicine and Primary Care and Gerontology, Department of Medicine"@en,
        "Harvard Medical School"@en .

ns50:JAD190023 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Institute of Brain Science"@en .

ns50:JAD190119 ns0:hasName "Department of Pathophysiology and Transplantation"@en,
        "University of Milan"@en .

ns50:JAD190165 ns0:hasName "Computer and Electrical Engineering and Computer Science Department"@en,
        "Department of Computer Science and Engineering"@en,
        "Department of Computer and Electrical Engineering and Computer Science"@en,
        "Florida Atlantic University"@en .

ns50:JAD190181 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing, Research School of Population Health"@en,
        "Dementia Collaborative Research Centre – Early Diagnosis and Prevention, Research School of Population Health"@en,
        "Neuroscience Research Australia"@en,
        "Neuroscience Research Australia (NeuRA)"@en,
        "University of New South Wales"@en .

ns50:JAD190187 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Department of Molecular Neuroscience"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute"@en,
        "UK Dementia Research Institute at UCL"@en .

ns50:JAD190339 ns0:hasName "Carmel Medical Center"@en,
        "Sackler Faculty of Medicine"@en .

ns50:JAD190468 ns0:hasName "Department of Medicine"@en,
        "Emory University"@en .

ns50:JAD190469 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en .

ns50:JAD190491 ns0:hasName "Department of Family Medicine and Public Health"@en,
        "Department of Radiology"@en,
        "Division of Epidemiology, Department of Family Medicine and Public Health"@en .

ns50:JAD190501 ns0:hasName "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

ns50:JAD190533 ns0:hasName "Australian Alzheimer’s Research Foundation"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Cooperative Research Centre for Mental Health"@en,
        "Department of Biomedical Sciences"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "School of Medical Health and Sciences"@en,
        "School of Psychiatry and Clinical Neurosciences"@en .

ns50:JAD190541 ns0:hasName "Department of Behavioural Science and Health"@en,
        "Department of Epidemiology and Public Health"@en .

ns50:JAD190549 ns0:hasName "CHU de Bordeaux"@en,
        "Institute for Neurodegenerative Diseases, Clinical Branch"@en .

ns50:JAD190622 ns0:hasName "Medical Genome Center"@en .

ns50:JAD190645 ns0:hasName "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "University of Wisconsin"@en,
        "Wisconsin Alzheimer's Disease Research Center, Department of Medicine"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns50:JAD190700 ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC), Department of Neurobiology, Care Sciences and Society"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet"@en,
        "Alzheimer Disease Research Center, Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer’s Disease Research Center, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society"@en,
        "Department NVS, Karolinska Institute"@en,
        "Department of Geriatric Medicine"@en,
        "Department of Neurobiology"@en,
        "Department of Neurobiology, Care Science and Society, Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS), Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurobiology, Division for Neurogeriatrics, Care Sciences and Society (NVS)"@en,
        "Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society"@en,
        "KI-Alzheimer Disease Research Center"@en,
        "KI-Alzheimer Disease Research Center (KI-ADRC)"@en,
        "KI-Alzheimer's Disease Research Center"@en,
        "Karolinska Institute"@en,
        "Karolinska Institutet"@en,
        "Karolinska Institutet – Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet, Dept NVS"@en,
        "Karolinska University Hospital"@en,
        "Section for Geriatric Medicine, NEUROTEC"@en,
        "Stockholm Gerontology Research Center"@en,
        "Theme Aging"@en .

ns50:JAE190009 ns0:hasName "China Three Gorges University"@en,
        "College of Electrical Engineering and New Energy"@en,
        "College of Mechatronics and Control Engineering"@en,
        "Hubei Key Laboratory of Cascaded Hydropower Stations Operation and Control"@en,
        "Laboratory of Space Collaborative Manipulation Technology"@en .

ns50:JBR180332 ns0:hasName "Department of Agronomy"@en,
        "Department of Mathematics"@en .

ns50:JHD190365 ns0:hasName "Department of Neurology"@en .

ns50:JPD181460 ns0:hasName "Reta Lila Weston Institute"@en,
        "The National Hospital for Neurology and Neurosurgery"@en .

ns50:JPD191612 ns0:hasName "Department of Neurology & Institute of Neurology"@en,
        "Department of Neurology and Institute of Neurology"@en,
        "Department of Neurology and The Collaborative Innovation Center for Brain Science"@en .

ns50:JVR191036 ns0:hasName "Univeristy of Wisconsin-Madison"@en,
        "University of Wisconsin"@en,
        "University of Wisconsin-Madison"@en .

ns50:NHA190068 ns0:hasName "Department of Medicine"@en,
        "Jesse Brown VA Medical Center"@en .

ns50:NRE192722 ns0:hasName "Department of Medicine (Royal Melbourne Hospital)"@en,
        "Department of Medicine, Royal Melbourne Hospital"@en .

ns50:NRE192801 ns0:hasName "Department of Physiotherapy"@en,
        "Department of Public Health"@en,
        "Department of Public Health – Section of Sport Science"@en .

ns50:RNN180883 ns0:hasName "Brain Convergence Research Center"@en,
        "Korea University"@en .

ns50:RNN190909 ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "Geriatric Research Educational and Clinical Center"@en,
        "Psychiatry, and Alzheimer's Disease Research Center"@en .

ns50:THC181510 ns0:hasName "Department of Pharmaceutical Sciences, School of Pharmacy"@en,
        "Institue of Materia Medica"@en,
        "Shanxi Medical University"@en .

ns50:THC191659 ns0:hasName "Department of Orthopaedics and Trauma Surgery, St. Josef Hospital"@en,
        "Department of Orthopedics and Trauma Surgery, St. Josef-Hospital Bochum, Katholisches Klinikum Bochum"@en .

ns50:XST190494 ns0:hasName "Department of Otolaryngology, Hearing and Balance Research Unit"@en,
        "Department of Otolaryngology-Head and Neck Surgery, Center for Otolaryngology-Head and Neck Surgery of Chinese PLA, Changhai Hospital"@en,
        "State Key Laboratory of Precision Measuring Technology and Instruments"@en .

ns22:CH180402 ns0:hasName "Pamukkale University"@en,
        "Pamukkale University, Faculty of MedicineDepartment of Physiology"@en .

ns22:CH199005 ns0:hasName "Helmholtz Virtual Institute - Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns22:CH199205 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns22:CH199219 ns0:hasName "Department of Veterinary Medicine, Institute for Veterinary Anatomy"@en,
        "Institute of Veterinary Anatomy, Department of Veterinary Medicine"@en,
        "Institute of Veterinary Anatomy, Faculty of Veterinary Medicine"@en .

ns22:HAB190371 ns0:hasName "Department of Health in Emergencies and Disasters, School of Public Health"@en .

ns22:JAD170300 ns0:hasName "Department of Epidemiology, Joseph P. Mailman School of Public Health"@en,
        "Department of Neurology"@en,
        "Department of Neurology, College of Physicians and Surgeons"@en,
        "Department of Neurology, College of Physiciansand Surgeons"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, College of Physicians and Surgeons"@en,
        "G.H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky Center, College of Physicians and Surgeons"@en,
        "Sergievsky Center, College of Physiciansand Surgeons"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en .

ns22:JAD180631 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "Neuroscience Research Australia"@en .

ns22:JAD181171 ns0:hasName "Department of Biochemistry"@en,
        "Department of Biochemistry, Faculty of Medicine"@en,
        "Department of Biochemistry, Faculty of Medicine, UKMMC"@en .

ns22:JAD181246 ns0:hasName "Institute of Theoretical and Experimental Biophysics"@en .

ns22:JAD181259 ns0:hasName "Biomarkers Research Program, Department of Biochemistry College of Science"@en,
        "Chair for Biomarkers of Chronic Diseases, Biochemistry Department, College of Science"@en,
        "Prince Mutaib Chair for Biomarkers of Osteoporosis"@en .

ns22:JAD181272 ns0:hasName "Department of Medical Biology, Faculty of Medicine"@en,
        "Faculté de Médecine"@en,
        "INRS- Institut Armand Frappier"@en,
        "INRS-Institut Armand Frappier"@en,
        "INRS-Institut Armand-Frappier"@en,
        "Institut sur la Nutrition et les Aliments Fonctionnels"@en,
        "Institute of Nutrition and Functional Foods"@en .

ns22:JAD181295 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Research Center for Comparative Effectiveness and Patient Safety (RECEPS) and School of Pharmacy"@en,
        "Research Centre for Comparative Effectiveness and Patient Safety"@en,
        "Research Centre for Comparative Effectiveness and Patient Safety (RECEPS)"@en,
        "School of Pharmacy"@en,
        "School of Pharmacy, Faculty of Health Sciences"@en .

ns22:JAD190090 ns0:hasName "Cell and Molecular Biology Program"@en,
        "Department of Neurological Sciences"@en .

ns22:JAD190119 ns0:hasName "Department of Neurosciences"@en,
        "Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA)"@en,
        "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation, Neurodegenerative Disease Unit, “Dino Ferrari” Center"@en,
        "Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino Ferrari"@en,
        "University of Milan"@en .

ns22:JAD190128 ns0:hasName "Department of Radiology"@en,
        "School of Behavioral & Brain Sciences"@en,
        "University of Texas Southwestern Medical Center"@en .

ns22:JAD190146 ns0:hasName "Bristol Randomised Trials Collaboration (BRTC), Population Health Sciences, Bristol Medical School"@en,
        "Population Health Sciences, Bristol Medical School"@en .

ns22:JAD190187 ns0:hasName "Clinical Neurochemistry Lab"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Lab, The Sahlgrenska Academy at"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "The Sahlgrenska Academy at Göteborg University"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "The Sahlgrenska Academy at the University of Gothenburg"@en,
        "The Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences"@en,
        "University of Goteborg"@en,
        "the Sahlgrenska Academy at Göteborg University"@en .

ns22:JAD190262 ns0:hasName "Department of Epidemiology and Population Health"@en,
        "Department of Epidemiology and Population Health, Albert Einstein College of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Albert Einstein College of Medicine"@en,
        "Einstein Aging Study"@en,
        "Institute for Aging Research, Albert Einstein College of Medicine"@en,
        "Saul B. Korey Department of Neurology"@en .

ns22:JAD190339 ns0:hasName "Department of Neurology"@en,
        "Sackler Faculty of Medicine"@en .

ns22:JAD190423 ns0:hasName "1st Department of Neurology, Medical School"@en,
        "1st Department of Neurology, U.H. “AHEPA”, Medical School, Faculty of Healthy Sciences"@en,
        "3rd Department of Neurology"@en,
        "3rd Neurologic Clinic, Medical School, G. Papanikolaou Hospital"@en,
        "Aristotle University of Thessaloniki"@en,
        "Greek Association of Alzheimer's Disease and Related Disorders"@en,
        "Laboratory of Neurodegenerative Diseases"@en,
        "Third Department of Neurology, Memory and Dementia Centre, Medical School"@en .

ns22:JAD190458 ns0:hasName "Cell Biology Department and National Engineering Research Center of Genetic Medicine"@en,
        "Institute of Biomedicine & Department of Cell Biology"@en .

ns22:JAD190495 ns0:hasName "Clinical and Behavioural Neurology"@en,
        "Department of Behavioural and Clinical Neurology"@en,
        "Department of Clinical Behavioural Neurology"@en,
        "Department of Clinical and"@en,
        "Department of Clinical and Behavioral Neurology"@en,
        "Department of Clinical and Behavioural Neurology"@en,
        "Department of Clinical and Behavioural Neurology, Santa Lucia Foundation"@en,
        "Department of NeuroScience"@en,
        "Department of Neurology"@en,
        "Department of Neuroscience"@en,
        "Department of System Medicine"@en,
        "Department of Systemic Medicine"@en,
        "Department of Systems Medicine"@en,
        "Dipartimento di Neuroscienze"@en,
        "Dipartimento di Neuroscienze, Policlinico Tor Vergata"@en,
        "Fondazione IRCCS “Santa Lucia”"@en,
        "Fondazione Santa Lucia"@en,
        "Fondazione Santa Lucia IRCCS"@en,
        "IRCCS Fondazione Santa Lucia"@en,
        "IRCCS Santa Lucia Foundation"@en,
        "IRCCS Santa Lucia Foundation, Department of Clinical and Behavioural Neurology"@en,
        "Laboratory of Clinical and Behavioral Neurology"@en,
        "Laboratory of Clinical and Behavioural Neurology"@en,
        "Neuroscience Department"@en,
        "University “Tor Vergata”"@en,
        "University “Tor Vergata” Rome"@en,
        "Università degli Studi di Roma “Tor Vergata”"@en,
        "Università di Roma Tor Vergata"@en .

ns22:JAD190519 ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry and Behavioral Sciences"@en,
        "Mental Illness Research, Education, and Clinical Centers"@en,
        "Mental Illness and Parkinson's Disease Research, Education, and Clinical Centers"@en,
        "Northwest Network VISN-20 Mental Illness Research"@en,
        "Parkinson's Disease Research Education and Clinical Center (PADRECC) Northwest (Portland & Seattle)"@en,
        "Parkinson's Disease Research, Education, and Clinical Centers"@en,
        "University of Washington School of Medicine"@en .

ns22:JAD190538 ns0:hasName "Department of Internal Medicine"@en,
        "Rush Institute for Healthy Aging"@en .

ns22:JAD190571 ns0:hasName "MRC Unit for Lifelong Health and Ageing"@en,
        "MRC Unit for Lifelong Health and Ageing at UCL"@en .

ns22:JHD180337 ns0:hasName "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour"@en,
        "Institute of Animal Hygiene, Animal Welfare and Farm Animal Behavior"@en .

ns22:NPM1854 ns0:hasName "Department of Radiology"@en,
        "Fetal Medicine Institute"@en .

ns22:NRE182565 ns0:hasName "Danish Center for Sleep Medicine, Department of Neurophysiology Rigshospitalet, Faculty of Health Sciences"@en,
        "Faculty of Health Sciences"@en .

ns22:NRE182637 ns0:hasName "Department of Systems Medicine"@en,
        "Department of Systems Medicine, Neurology Unit"@en,
        "Department of Systems Medicine, Sleep Medicine Centre"@en,
        "IRCSS Fondazione Santa Lucia"@en,
        "Neuroscience PhD School"@en .

ns22:NRE192722 ns0:hasName "Department of Medicine ( Royal Melbourne Hospital)"@en,
        "Department of Medicine (Royal Melbourne Hospital)"@en,
        "Department of Rehabilitation and Australian Rehabilitation Research Centre"@en .

ns22:NRE192788 ns0:hasName "Movement Neuroscience, Injury Prevention Program, Institute of Health and Biomedical Innovation"@en,
        "School of Exercise and Nutrition Science, Faculty of Health"@en,
        "School of Exercise and Nutrition Sciences, Faculty of Health"@en .

ns22:XST190514 ns0:hasName "Department of Radiology"@en,
        "Department of RadiologyWonkwang University School of Medicine"@en,
        "Imaging Science-based Lung and Bone Disease Research Center"@en .

ns101:CBM182257 ns0:hasName "Department of Neurosurgery"@en,
        "Institute of Infectious Diseases, Southwest Hospital"@en .

ns101:CBM192435 ns0:hasName "Shanghai Institute of Digestive Surgery, Ruijin Hospital"@en,
        "Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital"@en .

ns101:CBM192437 ns0:hasName "Department of Medical Oncology"@en,
        "Department of Radiology"@en .

ns101:CH180404 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital"@en,
        "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Shanghai Center for Thyroid Diseases"@en,
        "Shanghai Research Center for Thyroid Diseases"@en,
        "Thyroid Institute"@en,
        "Ultrasound Research and Education Institute"@en .

ns101:CH199005 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns101:CH199201 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns101:HAB190384 ns0:hasName "Department of Medical Genetics"@en,
        "Shahid Beheshti University of Medical Sciences"@en .

ns101:JAD180991 ns0:hasName "AP-HP"@en,
        "CNR-MAJ"@en,
        "CRCICM, IM2A, UMR-S975 AP-HP"@en,
        "CRicm-UMRS975"@en,
        "Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer"@en .

ns101:JAD181171 ns0:hasName "Department of Biochemistry"@en,
        "Department of Biochemistry, Faculty of Medicine"@en,
        "Department of Biochemistry, Faculty of Medicine, UKMMC"@en .

ns101:JAD181196 ns0:hasName "Department of Epidemiology & Biostatistics, Schulich Interfaculty Program in Public Health"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Medicine, Division of Geriatric Medicine, Parkwood Hospital"@en,
        "Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry"@en,
        "Departments of Medicine (Geriatric Medicine), and Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry"@en,
        "Gait and Brain Lab, Parkwood Institute"@en,
        "Lawson Health Research Institute"@en,
        "School of Kinesiology, Faculty of Health Sciences"@en,
        "“Gait and Brain Lab”"@en .

ns101:JAD181268 ns0:hasName "Alzheimer's Disease Center"@en,
        "Department Molecular and Integrative Physiology"@en,
        "Department of Neurology"@en,
        "Department of Neurology, KU Alzheimer and Memory Program"@en,
        "Departments of Neurology"@en,
        "Molecular and Integrative Physiology"@en,
        "The University of Kansas Alzheimer’s Disease Center"@en,
        "University of Kansas Alzheimer's Disease Center"@en,
        "University of Kansas Alzheimer’s Disease Center"@en,
        "University of Kansas Medical Center"@en,
        "University of Kansas School of Medicine"@en,
        "University of Kansas School of Medicine Alzheimer’s Disease Center"@en .

ns101:JAD181295 ns0:hasName "Kuopio Research Centre of Geriatric Care"@en,
        "School of Pharmacy"@en .

ns101:JAD181297 ns0:hasName "Department of Epidemiology"@en,
        "Department of Radiology"@en,
        "Department of Radiology and Nuclear Medicine"@en .

ns101:JAD190023 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Institute of Brain Science"@en .

ns101:JAD190028 ns0:hasName "Department of Neurological Surgery"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Neurotherapeutics"@en,
        "Department of Neurology and Neurotherapeutics, Alzheimer's Disease Center"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, Alzheimer's Disease Center"@en,
        "Departments of Neurology and Neurotherapeutics"@en,
        "Departments of Psychiatry"@en .

ns101:JAD190128 ns0:hasName "Center for BrainHealth"@en,
        "School of Behavioral & Brain Sciences"@en .

ns101:JAD190175 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology and Clinical Neurophysiology"@en,
        "Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences"@en .

ns101:JAD190187 ns0:hasName "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en .

ns101:JAD190220 ns0:hasName "Department of Radiology"@en .

ns101:JAD190237 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, CESI-Center for Excellence on Aging"@en,
        "Department of Neuroscience, Imaging, and Clinical Sciences"@en .

ns101:JAD190306 ns0:hasName "Brain and Ageing Research Program, School of Psychiatry"@en,
        "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Centre for Healthy Brain and Ageing"@en,
        "Dementia Centre for Research Collaboration"@en,
        "Department of Neuropsychiatry"@en,
        "Neuropsychiatric Institute"@en,
        "Neuropsychiatric Institute (NPI)"@en,
        "Primary Dementia Collaborative Research Centre"@en,
        "Prince of Wales Research Institute and Centre for Healthy Brain Aging"@en,
        "School of Medicine"@en,
        "School of Psychiatry"@en .

ns101:JAD190335 ns0:hasName "Nuffield Department of Clinical Neurosciences"@en,
        "Nuffield Department of Clinical Neurosciences, University of Oxford"@en .

ns101:JAD190339 ns0:hasName "Department of Neurology and Psychiatry"@en,
        "Sackler Faculty of Medicine"@en .

ns101:JAD190458 ns0:hasName "Cell Biology Department and National Engineering Research Center of Genetic Medicine"@en,
        "Institute of Biomedicine & Department of Cell Biology"@en .

ns101:JAD190459 ns0:hasName "Brain Dynamics and Cognition"@en,
        "CMRR – Hospices Civils de Lyon, Inserm U1028, CNRS UMR5292"@en,
        "Centre Mémoire Ressources Recherche de Lyon"@en,
        "Claude Bernard University Lyon 1"@en,
        "Clinical Research Centre CRC - VCF (Vieillissement –Cerveau - Fragilité), Hospital of Charpennes"@en,
        "Clinical and Research Memory Center of Lyon"@en,
        "French Federation of Memory Centers"@en,
        "Hôpital Gériatrique des Charpennes"@en,
        "INSERM, U1028; CNRS"@en,
        "Institute of Aging I-Vie"@en,
        "Lyon University Hospital"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Médecine Gériatrique"@en,
        "Neurobiologie, CMRR, Gériatrie, Hospices Civils de Lyon"@en .

ns101:JAD190469 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en .

ns101:JAD190495 ns0:hasName "Department of Neuroscience"@en,
        "Department of Systems Medicine"@en,
        "Fondazione IRCCS “Santa Lucia”"@en .

ns101:JAD190517 ns0:hasName "Department of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Medicine"@en .

ns101:JAD190533 ns0:hasName "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Cooperative Research Centre for Mental Health"@en,
        "School of Medical Health and Sciences"@en .

ns101:JAD190567 ns0:hasName "Department of Neuroscience, Psychology and Behaviour"@en,
        "Institute for Ageing and Health"@en .

ns101:JAD190660 ns0:hasName "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Hospital Sierrallana"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en,
        "Service of Neurology"@en .

ns101:NHA180059 ns0:hasName "ANZAC Research Institute"@en,
        "Aging and Alzheimer’s Institute"@en,
        "Centre for Education and Research on Ageing and Ageing and Alzheimers Institute, Concord Hospital"@en,
        "Charles Perkins Centre"@en .

ns101:NRE182637 ns0:hasName "Department of Systems Medicine"@en,
        "IRCSS Fondazione Santa Lucia"@en,
        "Neuroscience PhD School"@en .

ns101:THC199029 ns0:hasName "Department of Pharmacy"@en .

ns101:XST190503 ns0:hasName "Cancer Center"@en,
        "Department of Radiation Oncology"@en,
        "Department of Radiology, School of Medicine, College of Medicine"@en .

ns208:JAD180630 ns0:hasName "Department of Neurology, Memory Clinic"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "Memory Clinic, Department of Neurology, Charles University"@en,
        "Memory Disorders Clinic, Department of Neurology"@en .

ns208:JAD180848 ns0:hasName "Centre for Hip Health and Mobility"@en,
        "Department of Physical Therapy"@en,
        "Department of Physical Therapy, Aging, Mobility, and Cognitive Neuroscience Lab"@en,
        "Djavad Mowafaghian Centre for Brain Health"@en .

ns208:JAD180932 ns0:hasName "Department of Biomedical Engineering"@en,
        "J Crayton Pruitt Family Department of Biomedical Engineering"@en .

ns208:JAD180991 ns0:hasName "Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer"@en,
        "Institut de la Mémoire, INSERM U1127, ICM"@en,
        "Institute for Memory and Alzheimer's Disease, ICM, UMR-S975, AP-HP, Pitié-Salpêtrière Hospital Group"@en .

ns208:JAD181171 ns0:hasName "Department of Biochemistry, Faculty of Medicine"@en,
        "Department of Biochemistry, Faculty of Medicine, UKMMC"@en .

ns208:JAD181256 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "MRC"@en,
        "Medical Research Center"@en,
        "Medical Research Center, Oulu University Hospital, Oulu, Finland and Research Unit of Clinical Neuroscience, Neurology"@en,
        "NeuroCenter, Neurology"@en,
        "Research Unit of Clinical Neuroscience, Neurology"@en .

ns208:JAD181297 ns0:hasName "Department of Epidemiology"@en,
        "Department of Neurology"@en,
        "Department of Radiology"@en,
        "Department of Radiology and Nuclear Medicine"@en,
        "Erasmus Medical Center"@en .

ns208:JAD190010 ns0:hasName "Department of Medical and Molecular Genetics"@en,
        "Indiana Alzheimer Disease Center"@en,
        "National Centralized Repository for Alzheimer’s Disease and Related Dementias (NCRAD)"@en .

ns208:JAD190128 ns0:hasName "Center for BrainHealth, School of Behavioral and Brain Sciences"@en,
        "Department of Neurology and Neurotherapeutics"@en,
        "Department of Psychiatry"@en,
        "School of Behavioral & Brain Sciences"@en .

ns208:JAD190154 ns0:hasName "Charles F. and Joanne Knight Alzheimer’s Disease Research Center"@en,
        "Department of Hope Center for Neurological Disorders"@en,
        "Department of Neurological Surgery"@en,
        "Department of Neurology"@en,
        "Department of Neurosurgery"@en,
        "Department of Radiology"@en,
        "Departments of Radiology and Neurological Surgery"@en,
        "Knight Alzheimer Disease Research Center"@en,
        "Knight Alzheimer’s Disease Research Center"@en .

ns208:JAD190175 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology and Clinical Neurophysiology"@en,
        "Department of Neuromedicine and Movement Science (INB)"@en,
        "Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences"@en,
        "University Hospital of Trondheim"@en .

ns208:JAD190202 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Group"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology, Faculty of Medicine"@en,
        "Sunnybrook Research Institute"@en,
        "Toronto Rehabilitation Institute"@en,
        "University Health Network at Toronto Rehabilitation Institute"@en .

ns208:JAD190264 ns0:hasName "Department of Psychological and Brain Sciences"@en,
        "Eli Lilly and Company"@en .

ns208:JAD190306 ns0:hasName "Aged Care Psychiatry"@en,
        "Center for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain and Ageing"@en,
        "Dementia Collaborative Research Centre"@en,
        "Dementia Collaborative Research Centre, School of Psychiatry"@en,
        "Primary Dementia Collaborative Research Centre"@en,
        "School of Psychiatry"@en,
        "The University of New South Wales"@en .

ns208:JAD190494 ns0:hasName "Department of Experimental Medicine and Oncology"@en,
        "Department of Neuroscience"@en,
        "Neuroscience Institute Cavalieri Ottolenghi Foundation (NICO)"@en,
        "Neuroscience Institute of Cavalieri Ottolenghi Foundation (NICO)"@en .

ns208:JAD190645 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Department of Medicine"@en,
        "Department of Medicine, Division of Geriatrics and Gerontology"@en,
        "Department of Medicine, Section of Geriatrics and Gerontology"@en,
        "Department of Veterans Affairs (VA) Geriatric Research"@en,
        "Division of Geriatrics and Gerontology, Department of Medicine"@en,
        "George Washington University"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "Geriatric Research, Education and Clinical Center (11G)"@en,
        "Geriatric Research, Education and Clinical Center (GRECC)"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "University of Wisconsin School of Medicine and Public Health"@en,
        "William S. Middleton Memorial Veterans Hospital Geriatric Research"@en,
        "Wisconsin Alzheimer's Disease Research Center"@en,
        "Wisconsin Alzheimer's Disease Research Center, (ADRC)"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns208:JHD190365 ns0:hasName "CHET"@en,
        "Department of Neurology"@en .

ns208:JND190416 ns0:hasName "Department of Neuropediatrics and Muscle Disorders, Medical Center – University of Freiburg, Faculty of Medicine"@en,
        "Department of Neuropediatrics and Muscle Disorders, Medical Center-University of Freiburg, Faculty of Medicine"@en .

ns168:CBM192435 ns0:hasName "Department of General Surgery"@en,
        "Shanghai Institute of Digestive Surgery, Ruijin Hospital"@en,
        "Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital"@en .

ns168:CH199206 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns168:CH199223 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Clinical Radiology, Interdisciplinary Ultrasound Center"@en,
        "Department of Clinical Radiology, Interdisciplinary Ultrasound-Center"@en,
        "Department of Clinical Radiology, Interdisciplinary Ultrasound-Center, University Hospital Grosshadern"@en,
        "Department of Radiology"@en,
        "Institute for Clinical Radiology"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich - Grosshadern Campus"@en,
        "Interdisciplinary Ultrasound-Center Ludwig-Maximilians-University of Munich – Grosshadern Campus"@en .

ns168:JAD180630 ns0:hasName "Charles University in Prague and Motol University Hospital"@en,
        "Department of Neurology, 2nd Faculty of Medicine, Motol University Hospital"@en,
        "Department of Neurology, Memory Clinic"@en,
        "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "Department of Neurology, Memory Disorders Clinic"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "Memory Clinic, Department of Neurology, Charles University"@en,
        "Memory Disorders Clinic, Department of Neurology"@en,
        "Memory Disorders Clinic, Department of Neurology, 2nd Faculty of Medicine"@en .

ns168:JAD180932 ns0:hasName "Anesthesiology"@en,
        "Center for Movement Disorders and Neurorestoration"@en,
        "Clinical and Health Psychology"@en,
        "Department of Clinical and Health Psychology"@en,
        "J Crayton Pruitt Family Department of Biomedical Engineering"@en .

ns168:JAD181203 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Hurvitz Brain Sciences Program"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Neuropsychopharmacology Research Group"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology, Faculty of Medicine"@en,
        "Sunnybrook Research Institute"@en,
        "Toronto Rehabilitation Institute"@en,
        "University Health Network at Toronto Rehabilitation Institute"@en .

ns168:JAD181256 ns0:hasName "MRC"@en,
        "Medical Research Center"@en,
        "Unit of Clinical Neuroscience, Neurology"@en .

ns168:JAD190094 ns0:hasName "Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences"@en,
        "Clinical Pharmacology and Geriatric Pharmacotherapy Unit, School of Pharmacy, Faculty of Health Sciences"@en,
        "Department of Epidemiology and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences"@en,
        "Kuopio Research Centre of Geriatric Care"@en,
        "NHMRC Cognitive Decline Partnership Centre"@en,
        "Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, Sansom Institute"@en,
        "Sansom Institute"@en,
        "School of Public Health and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences"@en .

ns168:JAD190119 ns0:hasName "Department of Pathophysiology and Transplantation"@en,
        "Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino Ferrari"@en .

ns168:JAD190152 ns0:hasName "CIBIT, Institute for Nuclear Sciences Applied to Health (ICNAS - P)"@en,
        "IBILI – Faculty of Medicine"@en,
        "Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine"@en,
        "Institute for Nuclear Sciences Applied to Health (ICNAS)"@en .

ns168:JAD190154 ns0:hasName "Department of Psychology"@en,
        "Department of Radiology"@en .

ns168:JAD190161 ns0:hasName "Department of Neurology"@en,
        "Department of Pharmacology"@en,
        "Departments of Neurology"@en,
        "Departments of Pharmacology and Experimental Therapeutics"@en,
        "Departments of Pharmacology and Neurology"@en,
        "Loyola University Medical Center"@en .

ns168:JAD190175 ns0:hasName "Department of Neurology"@en,
        "Department of Neuromedicine and Movement Science (INB)"@en,
        "Department of Neuroscience, Faculty of Medicine"@en,
        "University Hospital of Trondheim"@en .

ns228:JAD180630 ns0:hasName "Department of Neurology, 2nd Faculty of Medicine, Motol University Hospital"@en,
        "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "Memory Disorders Clinic, Department of Neurology, 2nd Faculty of Medicine"@en .

ns228:JAD190119 ns0:hasName "Department of Neurological Sciences"@en,
        "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation, Neurodegenerative Disease Unit, “Dino Ferrari” Center"@en,
        "University of Milan"@en,
        "“Neurology Unit”, Department of Pathophysiology and Transplantation “Dino Ferrari” Center"@en .

ns228:JAD190132 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine – Neurology, Universityof Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine –Neurology, University of Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine, Neurology, School of Medicine"@en,
        "Neuro Center"@en,
        "Neuro Center, Neurology"@en,
        "NeuroCentre, Neurology"@en,
        "Neurology of NeuroCenter"@en,
        "Unit of Neurology"@en .

ns228:JAD190283 ns0:hasName "Department of Neurobiology and Behavior"@en,
        "Johns Hopkins University"@en .

ns228:JAD190319 ns0:hasName "Department of Medicine, Peninsula Clinical School, Central Clinical School"@en,
        "Department of Medicine, Stroke and Ageing Research Group, School of Clinical Sciences at Monash Health"@en,
        "Menzies Institute for Medical Research"@en,
        "Stroke and Ageing Research Centre, Medicine, School of Clinical Sciences, Monash Medical Centre"@en .

ns228:JAD190401 ns0:hasName "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

ns228:JAD190469 ns0:hasName "Department of Health Sciences and Technology, SAIHST"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Neuto Science Center"@en,
        "Samsung Medical Center, Department of Neurology"@en,
        "Stem Cell & Regenerative Medicine Institute"@en,
        "Stem Cell and Regenerative Medicine Institute"@en .

ns228:JAD190487 ns0:hasName "Alzheimer’s Disease Center, Beijing Institute for Brain Disorders; Center for Brain Disorders Research"@en,
        "Center for Brain Disorders Research"@en,
        "Center for Cognitive Disorders"@en .

ns228:JAD190524 ns0:hasName "Bioanalytical Mass Spectrometry Facility"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "School of Medical Sciences"@en .

ns228:JAD190707 ns0:hasName "Department of Internal Medicine, Division of Geriatric Medicine"@en,
        "Department of Internal Medicine, Division of Gerontology and Geriatric Medicine"@en,
        "Department of Medicine"@en,
        "Department of Pharmacological and Physiological Science"@en,
        "Division of Geriatric Medicine"@en,
        "GRECC"@en,
        "Geriatric Research Education and Clinical Center (GRECC)"@en,
        "Geriatric Research Educational and Clinical Center (GRECC)"@en .

ns228:JHD190346 ns0:hasName "Department of Psychiatry"@en,
        "San Diego State University/University of California San Diego Joint Doctoral Program in Clinical Psychology"@en,
        "VA San Diego Healthcare System"@en .

ns228:JPD191612 ns0:hasName "Department of Neurology and Institute of Neurology"@en,
        "Department of Neurology and The Collaborative Innovation Center for Brain Science"@en .

ns179:JAD190446 ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "Institute of Human Genetic"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff21.Author:30.ID:JAD190446> ns0:hasName "Department of Psychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff24.Author:10.ID:JAD190446> ns0:hasName "Division of Neuroradiology, Department of Medical Imaging"@en,
        "Institute for Clinical Radiology, Klinikum der Universität München"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:BLC190228> ns0:hasName "Cancer Biology and Genetics Division, Queen’s Cancer Research Institute"@en,
        "Cancer Biology and Genetics, Queen’s Cancer Research Institute"@en,
        "Department of Biomedical and Molecular Sciences"@en,
        "Department of Obstetrics and Gynecology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:BMR181131> ns0:hasName "Faculty of Physical Education and Sports"@en,
        "Institute of Physiotherapy, Balneology and Medical Rehabilitation"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:CBM192435> ns0:hasName "Department of General Surgery, Ruijin Hospital"@en,
        "Shanghai Institute of Digestive Surgery, Ruijin Hospital"@en,
        "Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:CH180452> ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital"@en,
        "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Shanghai Center for Thyroid Diseases"@en,
        "Shanghai Research Center for Thyroid Diseases"@en,
        "Thyroid Institute"@en,
        "Ultrasound Research and Education Institute"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:HAB190363> ns0:hasName "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Management and Economics, School of Public Health, International Campus"@en,
        "Department of Nursing, Faculty of Health Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:HAB190367> ns0:hasName "Department of Health Management and Economics, International Campus"@en,
        "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Management and Economics, School of Public Health, International Campus"@en,
        "Department of Nursing, Faculty of Health Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD181178> ns0:hasName "Department of Preventive Gerontology"@en,
        "Department of Preventive Gerontology, Center for Gerontology and Social Science"@en,
        "Department of Social and Behavioral Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD181282> ns0:hasName "Department of Neurology"@en,
        "Department of Pathology and Laboratory Medicine, Perelman School of Medicine"@en,
        "Institute on Aging and Center for Neurodegenerative Disease Research, Perelman School of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190019> ns0:hasName "Department of Behavioral Sciences and the Rush Alzheimer’s Disease Center"@en,
        "Department of Psychiatry"@en,
        "Rush Alzheimer’s Disease Center"@en,
        "University of Illinois at Chicago"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190107> ns0:hasName "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED)"@en,
        "Neurology Service and Centro de Investigación Biomédica en Red sobre Enfermedades Neurodegenerativas (CIBERNED), ‘Marqués de Valdecilla’ University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190266> ns0:hasName "Department of Family & Community Medicine"@en,
        "Department of Family and Community Medicine"@en,
        "Department of Medicine"@en,
        "Department of Psychiatry"@en,
        "Departments of Family and Community Medicine"@en,
        "GRECC, the"@en,
        "South Texas Veterans' Health System Audie L. Murphy Division GRECC"@en,
        "South Texas Veterans’ Health System"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190368> ns0:hasName "Department of Biochemistry and Molecular Biology, School of Medicine"@en,
        "Department of Neurochemistry"@en,
        "Department of Neurochemistry, Inge Grundke-Iqbal Research Floor"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-Innovation Center of Neuroregeneration"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-innovation Center of Neuroregeneration"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190397> ns0:hasName "David Geffen School of Medicine"@en,
        "Department Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "Department of Medicine, David Geffen School of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, David Geffen School of Medicine"@en,
        "Department of Psychiatry and Biobehavioral Sciences"@en,
        "Department of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "Departments of Psychiatry and Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "Greater Los Angeles VA Healthcare System"@en,
        "Psychiatry & Biobehavioral Sciences, David Geffen School of Medicine"@en,
        "V.A. Greater Los Angeles Healthcare System"@en,
        "VA Greater Los Angeles Healthcare Center"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190440> ns0:hasName "Institut Universitaire de France"@en,
        "Unité de Gériatrie"@en,
        "University of Lille"@en,
        "Université Lille"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190461> ns0:hasName "Brain Dynamics and Cognition"@en,
        "CMRR – Hospices Civils de Lyon, Inserm U1028, CNRS UMR5292"@en,
        "Centre Mémoire Ressources Recherche de Lyon"@en,
        "Claude Bernard University Lyon 1"@en,
        "Clinical Research Centre CRC - VCF (Vieillissement –Cerveau - Fragilité), Hospital of Charpennes"@en,
        "Clinical and Research Memory Center of Lyon"@en,
        "French Federation of Clinical and Research Memory Centre of Lyon, Lyon"@en,
        "French Federation of Memory Centers"@en,
        "Hospices civils de Lyon"@en,
        "Hôpital Gériatrique des Charpennes"@en,
        "INSERM U1028, CNRS UMR5292"@en,
        "INSERM, U1028; CNRS"@en,
        "Institute of Aging I-Vie"@en,
        "Lyon University Hospital"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Memory Research Centre of Lyon (CMRR); Geriatrics Unit, Charpennes Hospital"@en,
        "Médecine Gériatrique"@en,
        "Neurobiologie, CMRR, Gériatrie, Hospices Civils de Lyon"@en,
        "Research Clinic Centre (CRC) - VCF (Aging – Brain – Frailty), Charpennes Hospital"@en,
        "Research and Resources Memory Center of Lyon, Hôpital des Charpennes"@en,
        "University Lyon 1"@en,
        "University Lyon I"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190622> ns0:hasName "Center for Comprehensive Care and Research on Memory Disorders"@en,
        "Department of Community Health Sciences"@en,
        "Department of Public Health"@en,
        "Medical Genome Center"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JAD190823> ns0:hasName "Centre for Innovative Ageing"@en,
        "Department of Psychology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:JPD191627> ns0:hasName "Department of Neurology"@en,
        "Department of Radiology"@en,
        "Neurology Service and GRECC"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:MGC196> ns0:hasName "Department of Chemistry, Atma Ram Sanatan Dharma College"@en,
        "Material/Organometallics Laboratory, Department of Chemistry, Atma Ram Sanatan Dharma College"@en,
        "School of Material Chemistry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:NHA170034> ns0:hasName "Department of Community Health Sciences, Clinical Nutrition Program, College of Applied Medical Sciences"@en,
        "Department of Human Nutrition and Dietetics"@en,
        "Tübingen Ageing and Tumour Immunology Group, Zentrum für Medizinische Forschung"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:NRE192722> ns0:hasName "Australian Rehabilitation Research Centre"@en,
        "Department of Medicine ( Royal Melbourne Hospital)"@en,
        "Department of Rehabilitation and Australian Rehabilitation Research Centre"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:NRE192788> ns0:hasName "Department of Allied Health Sciences, Faculty of Medicine"@en,
        "Institute of Health and Biomedical Innovation"@en,
        "Movement Neuroscience, Injury Prevention Program, Institute of Health and Biomedical Innovation"@en,
        "School of Exercise and Nutrition Sciences, Faculty of Health"@en .

ns90:CH199218 ns0:hasName "Department of Radiotherapy"@en .

ns90:EFI190289 ns0:hasName "Escola de Comunicações e Artes"@en,
        "Universidade de São Paulo"@en .

ns90:HAB190362 ns0:hasName "Department of Medical Genetics"@en,
        "Department of Medical Genetics, Faculty of Medicine"@en,
        "Phytochemistry Research Center"@en .

ns90:HAB190369 ns0:hasName "Department of Health Management and Economics, School of Public Health, International Campus"@en,
        "Department of Nursing, Faculty of Health Sciences"@en .

ns90:HAB190371 ns0:hasName "Department of Disaster and Emergency Health, School of Public Health, International Campus"@en,
        "Department of Disasters and Emergency Health, School of Public Health"@en,
        "Department of Health in Emergencies and Disasters, School of Public Health"@en .

ns90:HAB190383 ns0:hasName "Department of Health Management and Economics, School of Public Health, Health Information Management Research Center"@en .

ns90:IDA184183 ns0:hasName "Anhui Provincial Key Laboratory of Network and Information Security"@en,
        "School of Computer and Information"@en,
        "School of Geography and Tourism"@en .

ns90:IDT180003 ns0:hasName "Department of Computer Science"@en,
        "Department of Computer Science and Engineering"@en .

ns90:IES192152 ns0:hasName "Department of Physical Therapy, College of Nursing and Healthcare Sciences and Human Ecology"@en,
        "Department of Physical Therapy, College of Nursing, Healthcare Sciences and Human Ecology"@en .

ns90:IFS17707 ns0:hasName "Department of Mathematics"@en .

ns90:IFS179085 ns0:hasName "Anderson College of Business"@en,
        "Faculty of Commerce"@en .

ns90:IFS181602 ns0:hasName "Centre of Excellence IT4Innovations"@en,
        "Faculty of Civil Engineering"@en,
        "Palacky Univ. Olomouc"@en .

ns90:IFS181813 ns0:hasName "Department of Mathematics"@en .

ns90:IFS182568 ns0:hasName "School of Civil Engineering and Architecture"@en,
        "School of Mathematics and Statistics"@en .

ns90:IFS182590 ns0:hasName "Department of Mathematics"@en .

ns90:IFS182746 ns0:hasName "Department of Computer Science"@en,
        "Department of Mathematics"@en,
        "Mazandaran Adib Institute of Higher Education"@en,
        "Sama Technical and Vocational Training College"@en,
        "Young Researchers and Elite club, Central Tehran Branch"@en .

ns90:IFS182868 ns0:hasName "Department of Computer Sciences and Information Technology"@en,
        "Research Center for Basic Sciences & Modern Technologies (RBST)"@en .

ns90:IFS182963 ns0:hasName "School of Mathematics and Statistics"@en,
        "School of Science"@en,
        "Shenzhen Graduate School"@en .

ns90:IFS190264 ns0:hasName "Key Laboratory of Information Security and Intelligent Control in Universities of Shandong"@en,
        "School of Information Engineering"@en,
        "Shandong Youth University of Political Science"@en .

ns90:IFS190952 ns0:hasName "Division of Computational Mathematics and Engineering"@en,
        "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns90:JAD170300 ns0:hasName "Department of Epidemiology"@en,
        "Department of Epidemiology, Joseph P. Mailman School of Public Health"@en,
        "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, College of Physicians and Surgeons"@en,
        "Department of Psychology"@en,
        "Departments of Epidemiology and Psychiatry"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky Center, College of Physicians & Surgeons"@en,
        "Gertrude H. Sergievsky Center, College of Physicians and Surgeons"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en,
        "The Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en .

ns90:JAD180630 ns0:hasName "Department of Neurology and Centre of Clinical Neuroscience, Neuropsychology Laboratory"@en,
        "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "National Institute of Mental Health"@en .

ns90:JAD180962 ns0:hasName "CERVO Brain Research Center"@en,
        "Centre de recherche de l’Institut universitaire en santé mentale de Québec"@en,
        "Faculty of Medicine"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute>"@en,
        "LC Campbell Cognitive Neurology Research Unit"@en,
        "Mathison Centre for Mental Health Research & Education"@en,
        "Sunnybrook Health Sciences Centre"@en .

ns90:JAD181173 ns0:hasName "Cognitive Decline Partnership Centre, Faculty of Medicine and Health"@en,
        "Falls, Balance and Injury Research Centre, Neuroscience Research Australia"@en,
        "Prince of Wales Clinical School"@en,
        "Prince of Wales Clinical School, Faculty of Medicine"@en .

ns90:JAD181196 ns0:hasName "Department of Medicine (Geriatrics)"@en,
        "Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry"@en .

ns90:JAD181256 ns0:hasName "Department of Neurology"@en,
        "Division of Diagnostic Services, Chromosome and DNA Laboratory"@en,
        "Institute of Clinical Medicine - Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

ns90:JAD181295 ns0:hasName "Department of Clinical Neuroscience"@en,
        "Department of Forensic Psychiatry, Niuvanniemi Hospital"@en,
        "Kuopio Research Centre of Geriatric Care"@en,
        "School of Pharmacy"@en,
        "School of Pharmacy, Faculty of Health Sciences"@en .

ns90:JAD190038 ns0:hasName "Centre de Recherche de l’Institut Universitaire de Gériatrie de Montréal"@en,
        "Département de Psychologie"@en .

ns90:JAD190155 ns0:hasName "School of Medicine and Dentistry"@en,
        "School of Medicine, Medical Sciences and Nutrition"@en .

ns90:JAD190162 ns0:hasName "Department of Epidemiology and Preventive Medicine, School of Public Health and Preventive Medicine"@en,
        "Research Department of Practice and Policy"@en .

ns90:JAD190183 ns0:hasName "Aging Psychiatry Unit"@en,
        "Brain Dynamics and Cognition"@en,
        "Department of Psychiatry"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Psychiatry Unit"@en .

ns90:JAD190202 ns0:hasName "Department of Psychiatry"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Sunnybrook Research Institute"@en .

ns90:JAD190266 ns0:hasName "Department of Epidemiology and Biostatistics"@en,
        "Department of Family & Community Medicine"@en,
        "Department of Family and Community Medicine"@en,
        "Department of Psychiatry"@en,
        "Departments of Family and Community Medicine"@en .

ns90:JAD190283 ns0:hasName "Department of Statistics"@en,
        "Institute for Memory Impairments and Neurological Disorders and Alzheimer’s Disease Research Center"@en .

ns90:JAD190342 ns0:hasName "Department of Psychology"@en,
        "Neuroscience and Mental Health Institute"@en .

ns90:JAD190345 ns0:hasName "Department of Clinical Research"@en,
        "Department of Neuroscience and Pharmacology"@en,
        "Department of Nuclear Medicine"@en .

ns90:JAD190371 ns0:hasName "Department of Geriatrics"@en,
        "Institut Universitaire de France"@en,
        "Laboratoire SCALab UMR CNRS 9193 – University of Lille"@en,
        "Laboratoire de Psychologie des Pays de la Loire (EA 4638)"@en,
        "Unité de Gériatrie"@en,
        "University Lille"@en,
        "University of Lille"@en,
        "Université Lille"@en,
        "Université de Lille"@en .

ns90:JAD190430 ns0:hasName "Center for Alzheimer Research and Treatment, Brigham and Women's Hospital"@en,
        "Center for Alzheimer Research and Treatment, Brigham and Women’s Hospital"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Brigham and Women's Hospital"@en,
        "Department of Neurology, Brigham and Women’s Hospital"@en,
        "Department of Neurology, Center for Alzheimer Research and Treatment"@en,
        "Department of Neurology, Massachusetts General Hospital"@en,
        "Harvard Medical School"@en,
        "Massachusetts Alzheimer's Disease Research Center, Massachusetts General Hospital"@en .

ns90:JAD190459 ns0:hasName "Aging Psychiatry Unit"@en,
        "Cellule régionale d'observation de la démence"@en,
        "INSERM U1028, CNRS UMR5292"@en .

ns90:JAD190507 ns0:hasName "Department of Neurology"@en,
        "Departments of Pathology and Laboratory Medicine (Division of Neuropathology) and Neurology"@en,
        "Indiana Alzheimer Disease Center"@en .

ns90:JAD190622 ns0:hasName "Department of Community Health Sciences"@en,
        "Department of Public Health"@en .

ns90:JAD190670 ns0:hasName "Division of Neuroscience"@en,
        "NeTS Center - Istituto Universitario di Studi Superiori (IUSS)"@en,
        "Neurorehabilitation Unit, Department of Clinical Neurosciences"@en,
        "University School for Advanced Studies IUSS Pavia"@en .

ns90:JAD190775 ns0:hasName "Department of Human Health Sciences"@en,
        "Department of Neurology"@en .

ns90:JND190403 ns0:hasName "Department of Biological Chemistry and Pharmacology"@en,
        "Department of Neurology"@en .

ns90:JPD191707 ns0:hasName "CHU Nantes"@en,
        "Department of Neurology"@en,
        "Inserm"@en,
        "Nantes University"@en,
        "University Nantes"@en,
        "Université de Nantes"@en .

ns90:NRE182637 ns0:hasName "Department of Neurosciences"@en,
        "Department of Systems Medicine"@en .

ns90:WOR193015 ns0:hasName "Department of Developmental Disorders in Pediatrics and its Surgery, College of Physical Therapy"@en,
        "Department of Physical Therapy for Obstetrics and Gynecology, Faculty of Physical Therapy"@en .

ns90:XST190538 ns0:hasName "Department of Medical Imaging and Radiological Sciences, College of Health Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JAD180634> ns0:hasName "Department of Medicine"@en,
        "Department of Medicine, Division of General Internal Medicine"@en,
        "Group Health Center for Health Studies"@en,
        "Group Health Cooperative Research Institute"@en,
        "Group Health Research Institute"@en,
        "Kaiser Permanente Washington Health Research Institute"@en,
        "Kaiser Permenente Washington Health Research Institute"@en,
        "Marianjoy Rehabilitation Hospital"@en,
        "University of Washington"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JAD190133> ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Department of Neuroscience and Neurology"@en,
        "Institute of Clinical Medicine - Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine –Neurology, University of Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Institute of Clinical Medicine/Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "Neuro Center"@en,
        "NeuroCenter, Neurology"@en,
        "Neurocenter, Neurology"@en,
        "Neurocenter/ Neurology"@en,
        "Neurology of NeuroCenter"@en,
        "Unit of Neurology"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JAD190334> ns0:hasName "Institute of Clinical Medicine – Neurosurgery"@en,
        "Neuro Center"@en,
        "Neuro CenterKuopio University Hospital"@en,
        "Neurosurgery of NeuroCenter"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JAD190469> ns0:hasName "Clinical Research Design and Evaluation, SAIHST"@en,
        "Department of Clinical Research Design & Evaluation, SAIHST"@en,
        "Department of Clinical Research Design and Evaluation, SAIHST"@en,
        "Department of Health Sciences and Technology, SAIHST"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Neuto Science Center"@en,
        "Samsung Alzheimer Research Center"@en,
        "Samsung Medical Center, Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:JPD191610> ns0:hasName "Banner Sun Health Research Institute"@en,
        "Civin Laboratory for Neuropathology"@en,
        "Civin Laboratory of Neuropathology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:10.ID:KCA190064> ns0:hasName "Department of Medical Oncology, Hospital Clínico San Carlos"@en,
        "Medical Oncology Department"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:11.ID:JAD190010> ns0:hasName "Center for Computational Biology and Bioinformatics"@en,
        "Center for Neuroimaging, Department of Radiology and Imaging Sciences"@en,
        "Department of Medical and Molecular Genetics"@en,
        "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Department of Radiology and Imaging Sciences and the Indiana Alzheimer’s Disease Center"@en,
        "Department of Radiology and Imaging Sciences, Center for Neuroimaging"@en,
        "Indiana Alzheimer Disease Center"@en,
        "Indiana University Network Science Institute"@en,
        "Program in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:11.ID:JAD190660> ns0:hasName "Department of Nuclear Medicine, University Hospital Marqués de Valdecilla"@en,
        "Nuclear Medicine Department, University Hospital Marqués de Valdecilla"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:11.ID:XST190500> ns0:hasName "Collaborative Innovation Center for Brain Science"@en,
        "ICT NDT Engineering Research Center, Ministry of Education"@en,
        "The Key Lab of Optoelectronic Technology and Systems of the Education Ministry of China"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:12.ID:JAD190046> ns0:hasName "Department of Psychology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:13.ID:BLC180206> ns0:hasName "Genetic and Molecular Epidemiology Group"@en,
        "Spanish National Cancer Research Centre (CNIO)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:13.ID:JAD180521> ns0:hasName "Academic Unit for Psychiatry of Old Age, Department of Psychiatry"@en,
        "Academic Unit for Psychiatry of Old Age, St Vincent's Health, Department of Psychiatry"@en,
        "Academic Unit for Psychiatry of Old Age, St. Vincent's Health"@en,
        "Department of Psychiatry, Academic Unit for Psychiatry of Old Age"@en,
        "North Western Mental Health"@en,
        "School of Psychiatry and Clinical Neurosciences and West Australian Centre for Health & Ageing"@en,
        "School of Psychiatry and Clinical Neurosciences and Western Australian Centre for Health and Aging"@en,
        "The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "University of Melbourne"@en,
        "West Australian Centre for Health & Ageing"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:13.ID:JAD190568> ns0:hasName "Department of Medicine"@en,
        "Department of Medicine (Gerontology/Geriatrics), Neurology"@en,
        "Department of Medicine, Division of Geriatric Medicine"@en,
        "Department of Neurology"@en,
        "Department of Pathology and Laboratory Medicine"@en,
        "Department of Pathology and Laboratory Medicine, Perelman School of Medicine"@en,
        "Department of Pharmacology"@en,
        "Geriatric Research, Education, and Clinical Center"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC)"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC) VA Puget Sound Health Care System"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC)VA Puget Sound Health Care System"@en,
        "Geriatric Research, Education, and Clinical Centers"@en,
        "Medicine"@en,
        "Neurology"@en,
        "Pathology & Laboratory Medicine"@en,
        "Pharmacology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:13.ID:JND190403> ns0:hasName "Department of Neurology"@en,
        "Department of Physical Medicine and Rehabilitation"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:14.ID:JAD190533> ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation Perth"@en,
        "Centre for Aging and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Clinical Research in Neuropsychiatry, Graylands Hospital"@en,
        "Centre for Neuromuscular and Neurological Disorders"@en,
        "Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care; The Sir James McCurker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre for Ageing and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence in Alzheimer’s Disease Research and Care, School of Medical Sciences"@en,
        "Department of Biomedical Sciences"@en,
        "KARVIAH Research Centre"@en,
        "KaRa Institute of Neurological Disease"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "McCusker Foundation for Alzheimer's Disease Research"@en,
        "McCusker Foundation for Alzheimer's Disease Research Inc"@en,
        "School of Biomedical Science"@en,
        "School of Biomedical Sciences"@en,
        "School of Exercise, Biomedical and Health Sciences"@en,
        "School of Medical Health and Sciences"@en,
        "School of Medical Sciences"@en,
        "School of Medical SciencesEdith Cowan University"@en,
        "School of Medical and Health Sciences"@en,
        "School of Psychiatry & Clinical Neurosciences"@en,
        "School of Psychiatry and Clinical Neuroscience"@en,
        "School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit, School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer’s Disease Research Unit"@en,
        "The CRC for Mental Health"@en,
        "The McCusker Alzheimer’s Research Foundation"@en,
        "The School of Exercise, Biomedical and Health Science"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit, School of Exercise, Biomedical and Health Sciences"@en,
        "The University of British ColumbiaUniversity of Western Australia"@en,
        "The University of Western AustraliaEdith Cowan University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:15.ID:JAD190334> ns0:hasName "Institute of Clinical Medicine –Neurosurgery, University of Eastern Finland and Department of Neurosurgery"@en,
        "Neurosurgery of NeuroCenter"@en .

ns83:ADR190135 ns0:hasName "Institute of Reproductive Medicine"@en .

ns83:BLC190218 ns0:hasName "Department of Pathology"@en,
        "Department of Urology"@en .

ns83:BME191058 ns0:hasName "Physiatry Service"@en,
        "School of Medicine, Faculty of Medicine"@en,
        "University of Montreal"@en .

ns83:BME191060 ns0:hasName "Department of Biofunction Research, Institute of Biomaterials and Bioengineering"@en,
        "Department of Fixed Prosthodontics, Graduate School of Medical and Dental SciencesTokyo Medical and Dental University"@en,
        "Institute of Biomaterials and Bioengineering"@en .

ns83:BMR181181 ns0:hasName "Department of Allied Health Studies"@en,
        "Epidemiology, Biostatistics, and Population Medicine, School of Public Health"@en .

ns83:BMR181228 ns0:hasName "Department of Physical Therapy"@en .

ns83:CBM182212 ns0:hasName "Pediatric Oncology Department, South Egypt Cancer Institute"@en,
        "Radiation Oncology Department, South Egypt Cancer Institute"@en .

ns83:CH180404 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Ultrasound Research and Education Institute"@en .

ns83:CH180452 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Shanghai Center for Thyroid Diseases"@en,
        "Shanghai Research Center for Thyroid Diseases"@en,
        "Thyroid Institute"@en .

ns83:CH199009 ns0:hasName "Central Institute for Biomedical Engineering, Department of Biomaterials"@en,
        "Department of Biomaterials"@en .

ns83:CH199212 ns0:hasName "Center for Plastic-, Hand- and Reconstructive Surgery"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en .

ns83:FI1843 ns0:hasName "Institut de Recherche en Informatique de Toulouse (IRIT)"@en .

ns83:FI1882 ns0:hasName "Faculty of Mathematics and Computer Science"@en .

ns83:HAB190363 ns0:hasName "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Sciences"@en,
        "School of Public Health"@en .

ns83:HAB190367 ns0:hasName "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Sciences"@en,
        "School of Public Health"@en .

ns83:HSM180465 ns0:hasName "Guanghua School of Management"@en,
        "School of Economics and Management"@en .

ns83:IDA184334 ns0:hasName "Anhui Provincial Key Laboratory of Network and Information Security"@en,
        "School of Computer and Information"@en,
        "School of Geography and Tourism"@en .

ns83:IDT180136 ns0:hasName "Department of Mechanical Engineering and Aeronautics"@en,
        "University of Patras"@en .

ns83:IES183210 ns0:hasName "Clinical and Toxicological Analysis Department"@en,
        "Department of Clinical Analysis and Toxicology, Center for Health Sciences"@en .

ns83:IFS17707 ns0:hasName "Department of Mathematics"@en .

ns83:IFS179373 ns0:hasName "Department of Pure Mathematics, Faculty of Mathematics and Computer"@en,
        "Faculty of Mathematics and Computer"@en,
        "Mahani Mathematical Research Center"@en .

ns83:IFS181502 ns0:hasName "Department of Mathematics"@en,
        "Islamabad Model College for Girls"@en,
        "Islamabad Model College for Girls F-6/2"@en,
        "Islamabad Model College for Girls F-6/2 Islamabad"@en .

ns83:IFS181516 ns0:hasName "Department of Electronics"@en,
        "Department of Electronics Engineering"@en,
        "Karachi Institute of Economics and Technology"@en .

ns83:IFS181657 ns0:hasName "Division of Computational Mathematics and Engineering"@en,
        "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns83:IFS181777 ns0:hasName "College of Mathematics and Information Science"@en,
        "Data Recovery Key Lab of Sichuan Province"@en,
        "School of Mathematics and Information Science"@en .

ns83:IFS181917 ns0:hasName "School of Computer Engineering"@en .

ns83:IFS181970 ns0:hasName "Institute of Management and Decision"@en,
        "Institute of Management and decision"@en,
        "School of Economics and Management"@en,
        "Tai Yuan University"@en .

ns83:IFS182569 ns0:hasName "College of Applied Mathematics"@en .

ns83:IFS182634 ns0:hasName "Institute of Management and decision"@en,
        "School of Economics and Management"@en,
        "Tai Yuan University"@en .

ns83:IFS182643 ns0:hasName "School of Electronics and Information Engineering"@en,
        "School of Information Science and Engineering"@en .

ns83:IFS182671 ns0:hasName "Machine Intelligence Institute"@en .

ns83:IFS182823 ns0:hasName "Center for General Education"@en,
        "Research Center for Nonlinear Analysis and Optimization"@en .

ns83:IFS182832 ns0:hasName "Department of Mathematics"@en .

ns83:IFS182863 ns0:hasName "Division of Computational Mathematics and Engineering"@en,
        "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns83:IFS182876 ns0:hasName "Division of Computational Mathematics and Engineering"@en,
        "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns83:IFS18877 ns0:hasName "Institute of Mathematics"@en,
        "Institute of MathematicsYunnan University"@en .

ns83:IFS190001 ns0:hasName "Chongqing Key Laboratory of Electronic Commerce & Supply Chain System"@en,
        "School of Management and Economics"@en .

ns83:IFS190205 ns0:hasName "Department of Mathematics"@en .

ns83:IFS190344 ns0:hasName "China Institute of Manufacturing Development"@en,
        "School of Mathematical Sciences"@en .

ns83:IFS190444 ns0:hasName "Department of System Engineering and Engineering Management"@en,
        "Department of Systems Engineering and Engineering Management"@en .

ns83:IFS190459 ns0:hasName "Baoqing Meteorological Bureau"@en,
        "Department of Orthodontics, Affiliated Hospital of Stomatology"@en .

ns83:IFS190565 ns0:hasName "College of Mathematics"@en,
        "Department of Mathematics"@en,
        "Northwest University"@en,
        "School of Mathematics"@en .

ns83:IFS190706 ns0:hasName "Department of Information Technology, Faculty of Computer and Information Sciences"@en,
        "Faculty of Computer and Information Sciences"@en .

ns83:IFS190711 ns0:hasName "Department of Computer"@en,
        "Department of Computer Engineering, Sari Branch"@en .

ns83:IFS190810 ns0:hasName "Department of Mathematics, Maharishi Markandeshwar"@en .

ns83:IFS190905 ns0:hasName "College of Computer"@en,
        "School of Information Science and Engineering"@en,
        "Shaoguan University"@en .

ns83:IFS191092 ns0:hasName "Department of Electrical & Computer Engineering"@en,
        "Department of Electrical and Computer Engineering"@en .

ns83:JAD170300 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Taub Institute for Research on Alzheimer’s Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en .

ns83:JAD180464 ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychiatry, Faculty of Medicine"@en .

ns83:JAD180521 ns0:hasName "Academic Unit for Psychiatry of Old Age"@en,
        "Academic Unit for Psychiatry of Old Age, Department of Psychiatry"@en,
        "Academic Unit for Psychiatry of Old Age, St. Vincent's Health Department of Psychiatry"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, St George's Hospital"@en,
        "Mental Health Research Institute"@en,
        "National Ageing Research Institute"@en,
        "The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry"@en,
        "The Florey Institute for Neuroscience and Mental Health"@en,
        "The Florey Institute of Neuroscience and Mental Health"@en,
        "The Mental Health Research Institute"@en,
        "The University of Melbourne"@en .

ns83:JAD180608 ns0:hasName "Centre for Research Excellence in Promoting Cognitive Health"@en,
        "Centre for Research Excellence in Promoting Cognitive Health and Preventing Cognitive Decline"@en,
        "Centre for Research in Ageing and Cognitive Health (REACH), School of Psychology"@en,
        "Centre for Research in Ageing and Cognitive Health, School of Psychology, and PenCLAHRC"@en,
        "Centre for Research in Ageing and Cognitive Health, Washington Singer Laboratories"@en,
        "Department of Psychology"@en,
        "The Centre for Research in Ageing and Cognitive Health School of Psychology, College of Life and Environmental Sciences"@en,
        "University of Exeter Medical School"@en,
        "Wellcome Centre for Cultures and Environments of Health"@en .

ns83:JAD180949 ns0:hasName "Department of Economic and Social Sciences & Institute of Social Medicine, Rehabilitation Sciences and Healthcare Research (ISRV)"@en,
        "Institute of Social Medicine, Occupational Health and Public Health (ISAP)"@en,
        "LIFE – Leipzig Research Center for Civilization Diseases"@en .

ns83:JAD181102 ns0:hasName "Clinical Division of Neurogeriatrics and Division of General Neurology, Department of Neurology"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Section of Neurogeriatrics"@en,
        "Division of Neurogeriatrics, Department of Neurology"@en,
        "Medical University of Graz"@en .

ns83:JAD181132 ns0:hasName "Epidemiology and Public Health Group"@en,
        "The Alan Turing Institute"@en .

ns83:JAD181157 ns0:hasName "Department of Medicine, Peninsula Clinical School, Central Clinical School"@en,
        "Department of Medicine, Peninsula Health & Peninsula Clinical School"@en,
        "Department of Medicine, Peninsula Health, Peninsula Clinical School"@en,
        "Department of Medicine, Stroke and Ageing Research Group, School of Clinical Sciences at Monash Health"@en,
        "Departments of Medicine & Geriatric Medicine"@en,
        "Menzies Institute for Medical Research"@en,
        "Neurosciences"@en,
        "Stroke and Ageing Research Group, Vascular Brain Ageing Division, Department of Medicine, School of Clinical Sciences"@en .

ns83:JAD181169 ns0:hasName "Faculty of Health Sciences"@en .

ns83:JAD181203 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, Division of Geriatric Psychiatry"@en,
        "Division of Geriatric Psychiatry"@en,
        "Neuropsychopharmacology Research Group"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Sunnybrook Research Institute"@en,
        "University of Toronto"@en .

ns83:JAD181285 ns0:hasName "Cleveland Clinic Lou Ruvo Center for Brain Health"@en,
        "Department of Neurology and Psychiatry"@en,
        "School of Allied Health Science"@en .

ns83:JAD190074 ns0:hasName "Department Neurosciences, School of Medicine"@en,
        "Department of Neurosciences"@en,
        "Division of Neurosciences"@en,
        "Division of Neurosciences and Molecular Neuropathology Section, Laboratory of Neurogenetics"@en .

ns83:JAD190091 ns0:hasName "University Center for Social & Urban Research"@en,
        "University of Pittsburgh"@en .

ns83:JAD190146 ns0:hasName "Dementia Research Group"@en,
        "Dementia Research Group, Institute of Clinical Neuroscience"@en,
        "Dementia Research Group, Institute of Clinical Neurosciences, School of Clinical Sciences"@en,
        "Dementia Research Group, School of Clinical Sciences"@en,
        "Dementia Research Group, Translational Health Sciences, Bristol Medical School"@en,
        "Faculty of Medicine and Dentistry, School of Clinical Sciences, Dementia Research Group"@en,
        "Frenchay Hospital"@en .

ns83:JAD190155 ns0:hasName "School of Medicine and Dentistry"@en,
        "School of Medicine, Medical Sciences and Nutrition"@en,
        "University of Aberdeen"@en .

ns83:JAD190159 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, National Neuroscience Institute"@en,
        "School of Psychiatry"@en .

ns83:JAD190187 ns0:hasName "Clinical Memory Research Unit, Department of Clinical Sciences, Malmö"@en,
        "Department of Clinical Sciences, Clinical Memory Research Unit"@en .

ns83:JAD190217 ns0:hasName "Department of Epidemiology, Rollins School of Public Health"@en,
        "Division of Epidemiology and Community Health, School of Public Health"@en .

ns83:JAD190262 ns0:hasName "Department of Public Health Sciences"@en,
        "Division of Biostatistics, School of Medicine"@en .

ns83:JAD190405 ns0:hasName "Auditory Research Center"@en,
        "Department of Anatomy"@en .

ns83:JAD190413 ns0:hasName "CIRRAU-Centre for Integrated Register-based Research"@en,
        "Department of Depression and Anxiety/Psychosis Research Unit"@en,
        "National Centre for Register Based Research"@en,
        "National Centre for Register-Based Research"@en,
        "National Centre for Register-based Research"@en,
        "The Lundbeck Foundation Initiative for Integrative Psychiatric Research"@en .

ns83:JAD190460 ns0:hasName "Department of Neurology"@en .

ns83:JAD190518 ns0:hasName "Department of Neurosciences"@en .

ns83:JAD190519 ns0:hasName "Department of Genomic Medicine Institute"@en,
        "Department of Medicine"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC) VA Puget Sound Health Care System"@en .

ns83:JAD190527 ns0:hasName "Department of Epidemiology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Department of Radiology and Nuclear Medicine"@en,
        "Department of Radiology and Nuclear medicine"@en,
        "Memory Aging & Cognition Centre"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en,
        "Saw Swee Hock School of Public Health"@en .

ns83:JAD190533 ns0:hasName "Department of Biomedical Sciences"@en,
        "KaRa Institute of Neurological Disease"@en,
        "School of Medical Health and Sciences"@en,
        "School of Psychiatry and Clinical Neurosciences"@en .

ns83:JAD190538 ns0:hasName "Department of Behavioral Sciences"@en,
        "Department of Neurological Sciences"@en,
        "Rush Alzheimer’s Disease Center"@en .

ns83:JAD190545 ns0:hasName "Department of Neurology and Laboratory of Neurobiology, Hospital Clinico San Carlos"@en,
        "Department of Neurology, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC)"@en .

ns83:JAD190563 ns0:hasName "Department of Psychiatry and Behavioral Sciences"@en,
        "Mental Illness Research, Education, and Clinical Center"@en,
        "VA Northwest Network Mental Illness Research, Education, and Clinical Center"@en .

ns83:JAD190581 ns0:hasName "Faculty of Medicine"@en .

ns83:JAD190610 ns0:hasName "Raffles Neuroscience Centre"@en .

ns83:JAD190685 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, College of Medicine"@en .

ns83:JAD190708 ns0:hasName "Department of Psychiatry and Biobehavioral Sciences"@en,
        "UCLA Longevity Center at the Semel Institute for Neuroscience and Human Behavior"@en .

ns83:JAD190721 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Department of Molecular Neuroscience"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute"@en,
        "UK Dementia Research Institute at UCL"@en .

ns83:JAD190756 ns0:hasName "Department of Psychology"@en .

ns83:JAD190823 ns0:hasName "Department of Psychology"@en .

ns83:JHD190349 ns0:hasName "Department of Neurology"@en,
        "Northwestern University"@en .

ns83:JHD190353 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research"@en,
        "Department of Radiology"@en,
        "George-Huntington-Institute"@en,
        "Institute for Clinical Radiology"@en .

ns83:JND190428 ns0:hasName "Department of Neuropediatrics"@en,
        "Department of Pediatric Neurology"@en .

ns83:JPD181565 ns0:hasName "University of Toledo College of Medicine"@en .

ns83:JPD191579 ns0:hasName "Department of Neurology"@en,
        "Neurology Service and GRECC"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en,
        "Veteran's Affairs Ann Arbor Healthcare System"@en .

ns83:JPD191616 ns0:hasName "Department for Learning, Health Informatics Centre, Informatics, Management, and Ethics"@en,
        "Karolinska Institutet"@en .

ns83:JPD191688 ns0:hasName "Department of Psychology"@en,
        "Institute on Aging & Lifelong Health"@en,
        "Research Affiliate, Institute of Aging and Lifelong Health"@en .

ns83:JVR191022 ns0:hasName "Kent State University"@en,
        "School of Foundations, Leadership, and Administration"@en .

ns83:JVR191024 ns0:hasName "School of Allied Health Professions"@en,
        "Virginia Commonwealth University"@en .

ns83:JVR191039 ns0:hasName "Department of Family and Consumer Studies"@en,
        "University of Utah"@en .

ns83:JVR191047 ns0:hasName "Department of Kinesiology and Community Health"@en,
        "The University of Illinois-Urbana"@en,
        "University of Illinois at Urbana-Champaign"@en .

ns83:JVR191055 ns0:hasName "University of Wisconsin"@en,
        "University of Wisconsin-Madison"@en,
        "University of Wisconsin–Madison"@en .

ns83:KES190403 ns0:hasName "Department of Computer Science and Engineering"@en .

ns83:MAS190464 ns0:hasName "Departamento de Estatística"@en .

ns83:MGC180751 ns0:hasName "Chemistry Department, Faculty of Science"@en,
        "Faculty of Public Health and Health Informatics"@en .

ns83:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Geography"@en,
        "Department of Paediatrics"@en,
        "Lawson Health Research Institute"@en,
        "School of Health Studies"@en .

ns83:NRE182671 ns0:hasName "Department of Physiotherapy, School of Rehabilitation"@en,
        "Neuromusculoskeletal Research Center"@en,
        "Sports Medicine Research Center"@en,
        "Tehran University of Medical Sciences"@en .

ns83:NRE192725 ns0:hasName "School of Nursing"@en .

ns83:NRE192762 ns0:hasName "Department of Neuroscience"@en,
        "Division of Neurology and Neurorehabilitation"@en,
        "Istituto Auxologico Italiano"@en .

ns83:PRM190611 ns0:hasName "School of Nursing"@en .

ns83:TAD180217 ns0:hasName "Centre for Studies in Aging"@en,
        "Department of Occupational Science and Occupational Therapy, Institute of Biomaterials and Biomedical Engineering"@en,
        "Institute of Biomaterials and Biomedical Engineering"@en .

ns83:WOR192975 ns0:hasName "Swiss Paraplegic Center"@en .

ns83:WOR192984 ns0:hasName "Department of Physiotherapy, School of Rehabilitation Sciences"@en,
        "Department of Rehabilitation, School of Rehabilitation Sciences"@en,
        "Physiotherapy Department, School of Rehabilitation Sciences"@en .

ns83:WOR192988 ns0:hasName "Algoritmi Centre"@en,
        "Department of Environmental Health, Research Centre on Environment and Health"@en,
        "R&D Centro Algoritmi, Engineering School"@en .

ns83:WOR193008 ns0:hasName "Dalhousie University"@en,
        "Department of Psychiatry, Island Medical Program and Maurice Young Centre for Applied Ethics"@en,
        "Mental Health and Substance Use Services"@en .

ns83:WOR193022 ns0:hasName "Department of Industrial Design"@en,
        "Department of Industrial Design, College of Management"@en .

ns83:XST190491 ns0:hasName "Department of Medical Imaging, Faculty of Health Sciences"@en,
        "Faculty of Health Sciences"@en .

ns83:XST190527 ns0:hasName "Department of Electronic Information Engineering"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:21.ID:JAD190334> ns0:hasName "Institute of Clinical Medicine – Neurosurgery, University of Eastern Finland and Neurosurgery of NeuroCenter"@en,
        "Neurosurgery of NeuroCenter"@en,
        "Unit of Neurosurgery"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:27.ID:JAD190446> ns0:hasName "Department of Medical Sciences, Neuroscience and Signalling Laboratory, Institute for Biomedicine – iBiMED"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "Department of Psychiatry and Psychotherapy, University Medical Center (UMG)"@en,
        "Department ofPsychiatry and Psychotherapy"@en,
        "Georg-August-University Göttingen"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "LVR-Hospital Essen, Department of Psychiatry and Psychotherapy"@en,
        "LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine"@en,
        "iBiMED, Medical Sciences Department"@en .

ns64:BLC190218 ns0:hasName "Department of Surgery (Urology)"@en,
        "Department of Urology"@en,
        "University of Colorado Comprehensive Cancer Center"@en .

ns64:BMR181128 ns0:hasName "Department of Orthopaedic Surgery, Shafa Yahyaiian Hospital"@en,
        "Department of Orthopaedic Surgery, Shafa Yahyaiian hospital"@en .

ns64:CH180402 ns0:hasName "Gedik University"@en .

ns64:CH180404 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Ultrasound Research and Education Institute"@en .

ns64:CH199212 ns0:hasName "Applied Stem Cell Research Center"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Hand-and Reconstructive Surgery"@en,
        "University Center for Plastic, Hand and Reconstructive Surgery"@en .

ns64:HAB190386 ns0:hasName "Medical Laboratory Science Council of Nigeria"@en .

ns64:IFS171049 ns0:hasName "College of Sciences"@en,
        "Department of Mathematics"@en .

ns64:IFS181293 ns0:hasName "Department of Industrial Engineering, Faculty of Industrial and Mechanical Engineering, Qazvin Branch"@en,
        "Faculty of Industrial and Mechanical Engineering, Qazvin Branch"@en .

ns64:IFS181460 ns0:hasName "Department of Mathematics"@en .

ns64:IFS181519 ns0:hasName "Department of Mathematics, Science and Research Branch"@en .

ns64:IFS181604 ns0:hasName "Center of Natural Sciences and Technology"@en .

ns64:IFS181922 ns0:hasName "Department of Mathematics and Statistic"@en,
        "Department of Mathematics and Statistics"@en .

ns64:IFS182673 ns0:hasName "School of Mathematics"@en,
        "School of Mathematics, Thapar Institute of Engineering & Technology"@en,
        "Thapar Institute of Engineering & Technology (Deemed University)"@en .

ns64:IFS190098 ns0:hasName "School of Business"@en .

ns64:JAD180496 ns0:hasName "Molecular Neuroscience Research Center"@en,
        "Molecular Neuroscience Research Centre"@en,
        "Shiga University of Medical Science"@en .

ns64:JAD180521 ns0:hasName "Academic Unit for Psychiatry of Old Age"@en,
        "Academic Unit for Psychiatry of Old Age, Department of Psychiatry"@en,
        "Academic Unit for Psychiatry of Old Age, St. Vincent’s Health"@en,
        "Department of Psychiatry, Academic Unit for Psychiatry of Old Age"@en,
        "National Ageing Research Institute"@en,
        "National Aging Research Institute"@en,
        "The Academic Unit for Psychiatry of Old Age, St. Vincent's Health, Department of Psychiatry"@en,
        "University of Melbourne Academic Unit for Psychiatry of Old Age"@en .

ns64:JAD180572 ns0:hasName "School of Psychiatry"@en,
        "Sydney Medical School"@en .

ns64:JAD180573 ns0:hasName "Academic Department for Old Age Psychiatry"@en,
        "Brain and Ageing Research Program, School of Psychiatry, Faculty of Medicine"@en,
        "Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine"@en,
        "Prince of Wales Hospital"@en .

ns64:JAD180634 ns0:hasName "Department of Epidemiology"@en,
        "Kaiser Permanente Washington Health Research Institute"@en .

ns64:JAD181295 ns0:hasName "Department of Clinical Neuroscience"@en,
        "Karolinska Institutet"@en,
        "National Institute for Health and Welfare"@en,
        "University of Eastern Finland"@en .

ns64:JAD181298 ns0:hasName "Department of Neurological Sciences"@en,
        "Department of Neurological Sciences, Dino Ferrari Center"@en,
        "Department of Neurological Sciences, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation, Neurology Unit"@en,
        "Department of Pathophysiology and Transplantation, “Dino Ferrari” Center"@en,
        "Fondazione Cá Granda"@en,
        "Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino Ferrari"@en,
        "Neurology Unit"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation, ‘Dino Ferrari’ Center"@en,
        "Neurology Unit, “Dino Ferrari” Center"@en,
        "University of Milan"@en,
        "“Neurology Unit”, Department of Pathophysiology and Transplantation “Dino Ferrari” Center"@en .

ns64:JAD190049 ns0:hasName "Centre for Integrated Genomic Medical Research"@en,
        "Division of Informatics, Imaging & Data Sciences, School of Health Sciences"@en .

ns64:JAD190142 ns0:hasName "Department of Psychiatry and Behavioral Science"@en,
        "Vanderbilt University Department of Psychiatry and Behavioral Sciences"@en,
        "Vanderbilt University Medical Center"@en,
        "Vanderbilt University Medical Center Psychiatric Neuroimaging Program"@en,
        "Vanderbilt University School of Nursing"@en .

ns64:JAD190152 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Dementia Clinic"@en .

ns64:JAD190175 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology and Clinical Neurophysiology"@en,
        "Department of Neuromedicine and Movement Science"@en,
        "Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences"@en,
        "Department of Neuroscience, Faculty of Medicine"@en .

ns64:JAD190181 ns0:hasName "Institute for Ageing and Health"@en,
        "Newcastle Institute for Ageing"@en .

ns64:JAD190316 ns0:hasName "Department of Biomedical Engineering"@en,
        "Department of Radiology and Radiological Sciences"@en,
        "Institute of Imaging Science"@en,
        "Vanderbilt Brain Institute"@en,
        "Vanderbilt Ingram Cancer Center"@en,
        "Vanderbilt Institute of Chemical Biology"@en,
        "Vanderbilt Institute of Nanoscale Science and Engineering"@en,
        "Vanderbilt University Institute of Imaging Science"@en .

ns64:JAD190329 ns0:hasName "Department of Biostatistics"@en,
        "Division of Gerontology, Geriatrics, and Palliative Care, Department of Medicine"@en .

ns64:JAD190344 ns0:hasName "Department of Pathology"@en,
        "Departments of Pathology"@en .

ns64:JAD190368 ns0:hasName "Department of Neurochemistry, Inge Grundke-Iqbal Research Floor"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education of China, Co-Innovation Center of Neuroregeneration"@en .

ns64:JAD190402 ns0:hasName "Alzheimer Center, Department of Neurology"@en,
        "Department of Neurology"@en,
        "Department of Neurology & Alzheimer Centre"@en,
        "Department of Neurology and Alzheimer Center"@en .

ns64:JAD190415 ns0:hasName "Dr. John T. Macdonald Foundation Department of Human Genetics"@en,
        "John P. Hussman Institute for Human Genomics"@en,
        "John P. Hussman Institute for Human Genomics, Miller School of Medicine"@en,
        "The John P. Hussman Institute for Human Genomics"@en,
        "University of Miami"@en .

ns64:JAD190427 ns0:hasName "CMRR, Department of Neurology"@en,
        "INSERM E361, Pathologies of the Nervous System"@en,
        "INSERM U1061"@en,
        "INSERM U888"@en,
        "INSERM U888; Université Montpellier 1"@en,
        "Inserm U1061 ‘Neuropsychiatry: epidemiological and clinical research’"@en,
        "Inserm, U1061"@en,
        "Memory Research and Resources Center, CMRR of Montpellier, Department of Neurology"@en,
        "Montpellier University"@en,
        "University of Montpellier"@en,
        "Université Montpellier"@en,
        "Université de Montpellier, Inserm, U1061"@en .

ns64:JAD190474 ns0:hasName "Brain and Ageing Research Program, School of Psychiatry"@en,
        "Brain and Ageing Research Program, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Dementia Centre for Research Collaboration"@en,
        "Department of Neuropsychiatry"@en,
        "Neuropsychiatric Institute"@en,
        "Neuropsychiatric Institute (NPI)"@en,
        "Primary Dementia Collaborative Research Centre, School of Psychiatry, Faculty of Medicine"@en,
        "Prince of Wales Research Institute and Centre for Healthy Brain Aging"@en,
        "School of Psychiatry"@en .

ns64:JAD190484 ns0:hasName "Current address: Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine"@en,
        "Department of Clinical Chemistry and Transfusion Medicine, Institute of Biomedicine"@en,
        "Protein Folding and Stability Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biociències"@en .

ns64:JAD190508 ns0:hasName "Faculty of Medicine"@en .

ns64:JAD190540 ns0:hasName "Department of Pharmacology"@en,
        "Memory Aging & Cognition Centre"@en .

ns64:JAD190590 ns0:hasName "MRC Unit for Lifelong Health and Ageing"@en,
        "MRC Unit for Lifelong Health and Ageing at UCL"@en .

ns64:JAD190609 ns0:hasName "Division of Geriatric Medicine"@en,
        "Gérontopôle"@en .

ns64:JAD190645 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "Waisman Laboratory for Brain Imaging and Behavior"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns64:JAD190721 ns0:hasName "Clinical Neurochemical Laboratory, Institute of Neuroscience & Physiology"@en,
        "Clinical Neurochemistry Lab"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology, University of Gothenburg"@en,
        "Clinical Neurochemistry Lab, The Sahlgrenska Academy at"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the"@en,
        "Clinical Neurochemistry Laboratory, Inst. of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Neurochemistry"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Clinical Chemistry and Transfusion Medicine"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Psychiatry and Neurochemistry"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory,Institute of Neuroscience and Physiology, Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Institute of Biomedicine, Department of Clinical Chemistry and Transfusion Medicine, Sahlgrenska University Hospital"@en,
        "Institute of Neurobiology and Physiology, Department of Neurochemistry and Psychiatry, Sahlgrenska University Hospital"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Neurochemical Laboratory, Department of Neuroscience and Physiology, Section of Psychiatry and Neurochemistry"@en,
        "Neuropsychiatric Epidemiology Unit"@en,
        "The Sahlgrenska Academy at Göteborg University"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "The Sahlgrenska Academy at the University of Gothenburg"@en,
        "The Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences"@en,
        "University of Goteborg"@en,
        "the Sahlgrenska Academy at Göteborg University"@en .

ns64:JAD190782 ns0:hasName "Case Western Reserve University"@en,
        "College of Sciences"@en,
        "College of Sciences, One UTSA Circle"@en,
        "Dean and Professor of Biology"@en,
        "Department of Biology and UTSA Neuroscience Institute"@en,
        "Department of Biology, College of Sciences"@en,
        "Department of Pathology"@en,
        "Department of Pathology, School of Medicine"@en,
        "Institute of Pathology"@en,
        "The University of Texas at San Antonio"@en,
        "UTSA Neurosciences Institute and Department of Biology"@en,
        "UTSA Neurosciences Institute and Department of Biology, College of Sciences"@en,
        "University of Texas at San Antonio"@en .

ns64:JBR180349 ns0:hasName "School of Biosciences"@en .

ns64:JBR190387 ns0:hasName "NIBIO"@en,
        "NIBIO-Norwegian Institute of Bioeconomy Research"@en .

ns64:JPD181518 ns0:hasName "Department of Biostatistics"@en,
        "Department of Biostatistics, College of Public Health"@en .

ns64:JPD191579 ns0:hasName "Department of Neurology"@en,
        "Department of Radiology"@en,
        "Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en,
        "Neurology"@en,
        "Neurology Service and GRECC"@en,
        "Radiology"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en .

ns64:JPD191610 ns0:hasName "Banner Sun Health Research Institute"@en,
        "Civin Laboratory for Neuropathology"@en .

ns64:JVR191025 ns0:hasName "Independent Rehabilitation Consultant"@en,
        "Rehabilitation Consultant"@en .

ns64:JVR191026 ns0:hasName "Center for Disability Studies"@en,
        "Department of Early Childhood, Special Education, and Rehabilitation Counseling, 208B Taylor Education Building"@en,
        "Kent State University"@en,
        "School of Lifespan Development and Educational Sciences"@en .

ns64:JVR191038 ns0:hasName "University of Kansas"@en .

ns64:JVR191040 ns0:hasName "Department of Administration, Rehabilitation, and Postsecondary Education"@en,
        "San Diego State University"@en .

ns64:JVR191055 ns0:hasName "University of Wisconsin-Madison"@en .

ns64:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Paediatrics"@en,
        "Human Environments Analysis Laboratory"@en,
        "Lawson Health Research Institute"@en,
        "School of Food and Nutritional Sciences"@en .

ns64:VES190668 ns0:hasName "Epidemiology"@en .

ns64:WOR193011 ns0:hasName "Department of Health Sciences/Mental Health, Activity and Participation, Medical Faculty"@en,
        "Department of Health Sciences/Work and Mental Health"@en,
        "Lund University"@en .

ns64:WOR193013 ns0:hasName "Department of Psychology"@en,
        "Faculty of Economic and Management Sciences"@en,
        "North-West University"@en .

ns64:XST190506 ns0:hasName "Department of Biomedical Engineering"@en .

ns120:ADR190118 ns0:hasName "Academy of Scientific and Innovative Research (AcSIR)"@en,
        "Neurobiology Group"@en .

ns120:BLC190209 ns0:hasName "Institute of Cancer and Genomic Sciences"@en,
        "NUTRIM School for Nutrition and Translational Research in Metabolism"@en,
        "NUTRIM School for Nutrition and Translational Research in Metabolism and CAPHRI Care and Public Health Research Institute"@en,
        "School for Nutrition and Translational Research in Metabolism"@en .

ns120:CH180470 ns0:hasName "Department of Clinical Rehabilitation"@en,
        "Department of Physiotherapy"@en .

ns120:CH199005 ns0:hasName "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry"@en .

ns120:FI1870 ns0:hasName "CSAI research center, Department of Informatics, Systems and Communication"@en,
        "Complex Systems and Artificial Intelligence Research Centre"@en,
        "Complex Systems and Artificial Intelligence research center, Department of Informatics, Systems and Communication"@en,
        "University of Milan"@en .

ns120:HAB190362 ns0:hasName "Department of Medical Genetics"@en,
        "Shahid Beheshti University of Medical Sciences"@en,
        "Urogenital Stem Cell Research Center"@en .

ns120:HSM180425 ns0:hasName "University of Peshawar"@en .

ns120:JAD180857 ns0:hasName "Department of Geriatrics & Radboud Alzheimer Center"@en,
        "Department of Medical Psychology"@en,
        "Department of Medical Psychology & Radboudumc Alzheimer Center"@en,
        "Donders Institute for Brain, Cognition and Behavior"@en,
        "Donders Institute for Brain, Cognition and Behaviour"@en,
        "Radboud University Medical Center"@en,
        "Vincent van Gogh Institute for Psychiatry"@en .

ns120:JAD181140 ns0:hasName "Department of Epidemiology"@en,
        "Department of Psychiatry, Neurology and Epidemiology"@en,
        "Department of Psychiatry, Neurology, and Epidemiology, Global Brain Health Institute"@en,
        "Departments of Epidemiology & Biostatistics, Neurology and Psychiatry"@en,
        "Departments of Psychiatry, Neurology, and Epidemiology"@en,
        "Departments of Psychiatry, Neurology, and Epidemiology & Biostatistics"@en,
        "San Francisco VA Medical Center"@en,
        "San Francisco Veterans Affairs Medical Center"@en,
        "University of California"@en,
        "University of California San Francisco"@en .

ns120:JAD181174 ns0:hasName "Falls"@en,
        "Prince of Wales Clinical School"@en,
        "Prince of Wales Clinical School, Faculty of Medicine"@en .

ns120:JAD181196 ns0:hasName "Department of Medicine (Geriatrics)"@en,
        "Department of Medicine, Division of Geriatric Medicine, Parkwood Hospital"@en,
        "Lawson Health Research Institute"@en .

ns120:JAD181212 ns0:hasName "Department of Psychosocial and Community Health"@en .

ns120:JAD181256 ns0:hasName "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "Neuro Center"@en .

ns120:JAD181272 ns0:hasName "Department of Medicine"@en,
        "Department of Medicine, Geriatric Division, Research Center on Aging"@en,
        "Department of Medicine, Research Center on Aging, Graduate Program in Immunology, Faculty of Medicine and Health Sciences"@en,
        "Research Center on Aging"@en,
        "Research Center on Aging, Graduate Program in Immunology, Faculty of Medicine and Health Sciences"@en .

ns120:JAD181295 ns0:hasName "Center for Psychiatry Research"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Forensic Psychiatry"@en,
        "Department of Forensic Psychiatry, Niuvanniemi Hospital"@en,
        "Karolinska Institutet"@en,
        "University of Eastern Finland"@en .

ns120:JAD181298 ns0:hasName "Department of Biomedical, Surgical and Dental Sciences"@en,
        "Department of Neurological Sciences"@en,
        "Department of Neurological Sciences, Centro Dino Ferrari"@en,
        "Department of Neurological Sciences, Dino Ferrari Center"@en,
        "Department of Neurological Sciences, ‘Dino Ferrari’ Center"@en,
        "Department of Neurological Sciences, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation, Dino Ferrari Center"@en,
        "Department of Pathophysiology and Transplantation, Neurodegenerative Disease Unit, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation, Neurology Unit"@en,
        "Department of Pathophysiology and Transplantation, “Dino Ferrari” Center"@en,
        "Dino Ferrari Center, Department of Pathophysiology and Transplantation"@en,
        "Dino Ferrari Centre, Department of Neurological Sciences, University of Milan"@en,
        "Fondazione Cá Granda"@en,
        "Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino Ferrari"@en,
        "Neurology Unit"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation, ‘Dino Ferrari’ Center"@en,
        "Neurology Unit, “Dino Ferrari” Center"@en,
        "University of Milan"@en,
        "“Neurology Unit”, Department of Pathophysiology and Transplantation “Dino Ferrari” Center"@en .

ns120:JAD190041 ns0:hasName "Department of Geriatric Medicine"@en,
        "Department of Geriatrics"@en,
        "Departments of Neurology and Geriatrics Brain Centre Rudolf Magnus"@en .

ns120:JAD190087 ns0:hasName "Department of Geriatrics and Cognitive Disorders"@en,
        "Department of Psychiatry, School of Medicine"@en .

ns120:JAD190152 ns0:hasName "Center for Neuroscience and Cell Biology (CNC)"@en,
        "Center for Neuroscience and Cell Biology (CNC.IBILI), Faculty of Medicine"@en,
        "Center for Neuroscience and Cell Biology, Faculty of Medicine"@en,
        "Department of Neurology"@en,
        "Faculty of Medicine"@en,
        "Neurology Department"@en .

ns120:JAD190281 ns0:hasName "Case Western Reserve University"@en,
        "College of Sciences"@en,
        "College of Sciences, One UTSA Circle"@en,
        "Dean and Professor of Biology"@en,
        "Department of Biology and UTSA Neuroscience Institute"@en,
        "Department of Biology, College of Sciences"@en,
        "Department of Pathology"@en,
        "Department of Pathology, School of Medicine"@en,
        "Institute of Pathology"@en,
        "The University of Texas at San Antonio"@en,
        "UTSA Neurosciences Institute and Department of Biology"@en,
        "UTSA Neurosciences Institute and Department of Biology, College of Sciences"@en,
        "University of Texas at San Antonio"@en .

ns120:JAD190295 ns0:hasName "INSERM"@en,
        "INSERM, ISPED"@en,
        "InsermUniversité Victor Segalen Bordeaux2"@en,
        "University of Bordeaux"@en .

ns120:JAD190302 ns0:hasName "Cleveland Clinic Lou Ruvo Center for Brain Health"@en,
        "University of California"@en .

ns120:JAD190339 ns0:hasName "Carmel Medical Center"@en,
        "Rabin Medical Center"@en .

ns120:JAD190402 ns0:hasName "Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer Center and Department of Neurology, Department of Epidemiology and Biostatistics"@en,
        "Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer Center, Department of Neurology"@en,
        "Alzheimer Centre and Department of Neurology"@en,
        "Department of Epidemiology & Biostatistics"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Neurology"@en,
        "Epidemiology and Biostatistics"@en,
        "Neurology and Alzheimer Center, Neuroscience Campus Amsterdam"@en,
        "Neuroscience Campus Amsterdam"@en .

ns120:JAD190426 ns0:hasName "University of Exeter"@en,
        "University of Exeter Medical School"@en .

ns120:JAD190469 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Samsung Alzheimer Research Center"@en .

ns120:JAD190491 ns0:hasName "Department of Family Medicine and Public Health"@en,
        "Department of Radiology"@en,
        "Division of Epidemiology, Department of Family Medicine and Public Health"@en .

ns120:JAD190501 ns0:hasName "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

ns120:JAD190538 ns0:hasName "Department of Behavioral Sciences"@en,
        "Department of Neurological Sciences"@en,
        "Departments of Neurological Sciences and Behavioral Sciences, and Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer’s Disease Center"@en .

ns120:JAD190540 ns0:hasName "Department of Pharmacology"@en,
        "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en .

ns120:JAD190541 ns0:hasName "Department of Epidemiology and Public Health"@en .

ns120:JAD190545 ns0:hasName "Department of Neurology and Laboratory of Neurobiology, Hospital Clinico San Carlos"@en,
        "Department of Neurology and Laboratory of Neurobiology, Hospital Clínico San Carlos"@en,
        "Department of Neurology, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC)"@en,
        "Department of Neurology, Hospital Clínico Universitario San Carlos, San Carlos Institute for Health Research (IdISSC)"@en,
        "Department of Neurology, San Carlos Institute for Health Research (IdISSC)"@en .

ns120:JAD190700 ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC), Department of Neurobiology, Care Sciences and Society"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet"@en,
        "Alzheimer Disease Research Center, Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer’s Disease Research Center, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences, and Society"@en,
        "Department NVS, Karolinska Institute"@en,
        "Department of Geriatric Medicine"@en,
        "Department of Neurobiology"@en,
        "Department of Neurobiology, Care Science and Society, Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS), Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society"@en,
        "KI-Alzheimer Disease Research Center"@en,
        "KI-Alzheimer Disease Research Center (KI-ADRC)"@en,
        "KI-Alzheimer's Disease Research Center"@en,
        "Karolinska Institute"@en,
        "Karolinska Institutet"@en,
        "Karolinska Institutet – Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet, Dept NVS"@en,
        "Karolinska University Hospital"@en,
        "Section for Geriatric Medicine, NEUROTEC"@en,
        "Stockholm Gerontology Research Center"@en,
        "Theme Aging"@en .

ns120:JAD190708 ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry and Biobehavioral Sciences"@en,
        "Greater Los Angeles VA Healthcare System"@en .

ns120:JAD190823 ns0:hasName "Department of Psychology"@en .

ns120:JAE170051 ns0:hasName "Kunming University of Science and Technology"@en,
        "Nanjing University of Information Science and Technology"@en .

ns120:JBR180332 ns0:hasName "Department of Crop Sciences, College of Agricultural and Marine Sciences"@en,
        "Department of Mathematics"@en .

ns120:JPD191610 ns0:hasName "Banner Sun Health Research Institute"@en,
        "Brain Bank"@en,
        "Civin Laboratory for Neuropathology"@en .

ns120:JPD191675 ns0:hasName "Department of Physiology"@en .

ns120:JVR191038 ns0:hasName "University of Kansas"@en .

ns120:NRE192722 ns0:hasName "Australian Rehabilitation Research Centre"@en,
        "Department of Medicine, Royal Melbourne Hospital"@en .

ns120:RNN190909 ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "Geriatric Research Educational and Clinical Center"@en,
        "Psychiatry, and Alzheimer's Disease Research Center"@en .

ns193:CH180476 ns0:hasName "Institute for Bio-Medical Convergence, College of Medicine"@en .

ns193:CH180528 ns0:hasName "2nd Medical Department"@en,
        "Department of Medical II."@en .

ns193:CH199201 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns193:CH199205 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns193:CH199212 ns0:hasName "Applied Stem Cell Research Center"@en,
        "Center for Plastic, Aesthetic, Hand & Reconstructive Surgery"@en,
        "Center for Plastic, Aesthetic, Hand &Reconstructive Surgery"@en,
        "Center for Plastic, Hand and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand- and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand-, and Reconstructive Surgery"@en,
        "Center of Plastic and Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic Surgery"@en,
        "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Reconstructive Surgery"@en,
        "Department of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Hand, and Reconstructive Surgery"@en,
        "Department of Plastic, Hand- and Reconstructive Surgery"@en,
        "Department of Plastic, Hand-and Reconstructive Surgery"@en,
        "Department of Plastic, Reconstructive and Hand Surgery"@en,
        "Department of Plastic-, Hand- and Reconstructive Surgery"@en,
        "Department of Plastic-, Hand-, and Reconstructive Surgery"@en,
        "University Center for Plastic, Hand and Reconstructive Surgery"@en,
        "University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery"@en,
        "University Medical Center Regensburg"@en .

ns193:IFS181717 ns0:hasName "School of Mathematical Sciences"@en .

ns193:JAD170300 ns0:hasName "Department of Epidemiology, Joseph P. Mailman School of Public Health"@en,
        "Department of Neurology"@en,
        "Department of Neurology, College of Physicians and Surgeons"@en,
        "Department of Neurology, College of Physiciansand Surgeons"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, College of Physicians and Surgeons"@en,
        "Gertrude H. Sergievsky"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky Center, College of Physicians and Surgeons"@en,
        "Sergievsky Center, College of Physiciansand Surgeons"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "The Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en .

ns193:JAD180932 ns0:hasName "Anesthesiology"@en,
        "Department of Anesthesiology"@en,
        "Division of Multispecialty Adult Anesthesiology"@en .

ns193:JAD181033 ns0:hasName "German Research Center for Artificial Intelligence (DFKI)"@en,
        "German Research Institute for Artificial Intelligence"@en .

ns193:JAD181113 ns0:hasName "Interdepartmental Program “Autism 0–90”, “G. Martino” Hospital"@en,
        "Unit of Child and Adolescent Neuropsychiatry, “Gaetano Martino” University Hospital"@en .

ns193:JAD181288 ns0:hasName "Geriatric Anesthesia Research Unit, Department of Anesthesia, Critical Care and Pain Medicine"@en .

ns193:JAD190038 ns0:hasName "Centre de Recherche"@en,
        "Centre de Recherche de l’Institut Universitaire de Gériatrie de Montréal"@en,
        "Department of Medicine"@en,
        "PERFORM Centre and Department of Psychology"@en,
        "Research Centre"@en .

ns193:JAD190090 ns0:hasName "Department of Neurological Sciences"@en,
        "Neuroscience Program"@en .

ns193:JAD190175 ns0:hasName "Department of Neuromedicine and Movement Science"@en,
        "Department of Neuroscience, Faculty of Medicine"@en .

ns193:JAD190237 ns0:hasName "Department of Basic and Applied Biology"@en,
        "Department of Life, Health and Environmental Sciences"@en .

ns193:JAD190517 ns0:hasName "DGI Clinical Inc."@en,
        "Dalhousie University"@en,
        "Divisions of Geriatric Medicine & Neurology, Department of Medicine"@en .

ns193:JAD190524 ns0:hasName "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Centre for Healthy Brain and Ageing"@en,
        "Neuroscience Research Australia"@en,
        "Prince of Wales Research Institute and Centre for Healthy Brain Aging"@en .

ns193:JAD190756 ns0:hasName "Department of Psychology"@en .

ns193:JAD190823 ns0:hasName "Department of Psychology"@en,
        "Department of Psychology, College of Human and Health Sciences"@en,
        "School of Experimental Psychology"@en .

ns193:JAE191291 ns0:hasName "Valeo"@en,
        "Valeo/2 rue André Charles Boulle"@en .

ns193:JND180345 ns0:hasName "Clinical Neurological Sciences"@en,
        "Department of Paediatrics, Clinical Neurological Sciences & Epidemiology"@en,
        "Department of Pediatrics, Clinical Neurological Sciences and Epidemiology"@en,
        "Division of Pediatric Neurology"@en,
        "Epidemiology"@en .

ns193:NRE182565 ns0:hasName "Danish Center for Sleep Medicine, Department of Neurophysiology Rigshospitalet, Faculty of Health Sciences"@en,
        "Department of Neurophysiology, Danish Center for Sleep Medicine"@en .

ns193:NRE192722 ns0:hasName "Australian Rehabilitation Research Centre"@en,
        "Department of Medicine ( Royal Melbourne Hospital)"@en,
        "Department of Rehabilitation and Australian Rehabilitation Research Centre"@en .

ns193:NRE192745 ns0:hasName "Cliniques Universitaires Saint-Luc"@en,
        "Université catholique de Louvain"@en .

ns193:PPR190133 ns0:hasName "Allied Health Research Unit"@en,
        "Department of Health Sciences, Institute of Therapeutic Sciences"@en .

ns193:RNN190919 ns0:hasName "Department of Neurobiology"@en,
        "Department of Neurology"@en,
        "Department of UAB Epilepsy Center"@en .

ns193:WOR192942 ns0:hasName "Faculty of Health Sciences"@en .

ns193:XST180453 ns0:hasName "Department of Radiology"@en,
        "Department of Radiology, Fudan University Shanghai Cancer Center; Department of Oncology, Shanghai Medical College"@en,
        "Fudan University Shanghai Cancer Center"@en .

ns193:XST190494 ns0:hasName "Department of Electrical and Computer Engineering"@en,
        "Departmentof Electrical and Computer Engineering"@en .

ns55:CBM192435 ns0:hasName "Shanghai Institute of Digestive Surgery, Ruijin Hospital"@en,
        "Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital"@en .

ns55:CH180404 ns0:hasName "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital"@en,
        "Department of Medical Ultrasound, Shanghai Tenth People’s Hospital, Ultrasound Research and Education Institute"@en,
        "Shanghai Center for Thyroid Diseases"@en,
        "Shanghai Research Center for Thyroid Diseases"@en,
        "Thyroid Institute"@en,
        "Ultrasound Research and Education Institute"@en .

ns55:CH180428 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesiology and Intensive Care"@en,
        "Department of Anaesthesiology, Perioperative Medicine and Intensive Care"@en .

ns55:CH180476 ns0:hasName "Institute for Bio-Medical Convergence, College of Medicine"@en .

ns55:CH189907 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Clinical Biochemistry and Diagnostics"@en .

ns55:CH199005 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns55:CH199201 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns55:JAD181196 ns0:hasName "Department of Epidemiology & Biostatistics, Schulich Interfaculty Program in Public Health"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Medicine (Geriatrics)"@en,
        "Department of Medicine, Division of Geriatric Medicine, Parkwood Hospital"@en,
        "Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry"@en,
        "Departments of Medicine (Geriatric Medicine), and Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry"@en,
        "Gait and Brain Lab, Parkwood Institute"@en,
        "Lawson Health Research Institute"@en,
        "“Gait and Brain Lab”"@en .

ns55:JAD190010 ns0:hasName "Center for Neuroimaging, Department of Radiology and Imaging Sciences"@en,
        "Department of Radiology and Imaging Sciences, Center for Neuroimaging"@en,
        "Indiana Alzheimer Disease Center"@en .

ns55:JAD190077 ns0:hasName "Center for Human Genetics and Research, Department of Molecular Physiology & Biophysics"@en,
        "Vanderbilt Genetics Institute"@en,
        "Vanderbilt Memory & Alzheimer's Center, Department of Neurology"@en,
        "Vanderbilt Memory & Alzheimer’s Center, Department of Neurology"@en,
        "Vanderbilt Memory and Alzheimer’s Center"@en .

ns55:JAD190128 ns0:hasName "Center for BrainHealth"@en,
        "Department of Psychiatry"@en .

ns55:JAD190469 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Samsung Alzheimer Research Center"@en .

ns55:JAD190634 ns0:hasName "Department of Pharmacology & Neuroscience; Institute for Healthy Aging"@en,
        "Institute of Translational Medicine, Graduate School of Biomedical Sciences"@en,
        "University of North Texas Health Sciences Center"@en .

ns55:JBR180345 ns0:hasName "Department of Clinical Sciences, Faculty of Medicine"@en,
        "Department of Odontostomatologic and Specialized Clinical Sciences"@en,
        "Dipartimento di Scienze Cliniche Specialistiche ed Odontostomatologiche (DISCO)-Sez. Biochimica, Facolta di Medicina"@en .

ns55:JHD190346 ns0:hasName "Department of Psychiatry"@en,
        "Research Service"@en .

ns55:JPD181518 ns0:hasName "Department of Biostatistics"@en,
        "Department of Biostatistics, College of Public Health"@en,
        "Department of Biostatistics, NeuroNEXT Data Coordinating Center"@en .

ns55:NRE182665 ns0:hasName "Department of Physical Therapy"@en .

ns55:NRE192752 ns0:hasName "Department of Ophthalmology"@en,
        "Department of Ophthalmology, Rigshospitalet"@en,
        "Faculty of Health Sciences"@en .

ns55:NRE192754 ns0:hasName "Department of Physical Therapy"@en,
        "Faculty of Healthy Sciences of Trairi"@en .

ns79:ADR190139 ns0:hasName "Neurobank, Group of Neuroscience, SIU"@en,
        "Neuroscience Group of Antioquia (GNA)"@en,
        "Neuroscience Group of Antioquia, Medical School"@en,
        "Neuroscience Group, Faculty of Medicine"@en .

ns79:CH180434 ns0:hasName "Department of Engineering"@en,
        "Department of Neurology, College of Medicine"@en,
        "ICT unit, Guro Hospital"@en,
        "School of Mechanical Engineering"@en .

ns79:CH180476 ns0:hasName "Catholic Kwandong University International St. Mary’s Hospital"@en,
        "Institute for Bio-Medical Convergence, College of Medicine"@en .

ns79:CH189907 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Clinical Biochemistry and Diagnostics"@en .

ns79:CH199219 ns0:hasName "Charité – Universitätsmedizin Berlin"@en,
        "Department of Radiology, Charité – Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin"@en .

ns79:JAD190010 ns0:hasName "Department of Medical and Molecular Genetics"@en,
        "Indiana Alzheimer Disease Center"@en .

ns79:JAD190046 ns0:hasName "Department of Psychology"@en .

ns79:JAD190128 ns0:hasName "Center for BrainHealth, School of Behavioral and Brain Sciences"@en,
        "Department of Neurology and Neurotherapeutics"@en,
        "Department of Psychiatry"@en .

ns79:JAD190175 ns0:hasName "Department of Neurology and Clinical Neurophysiology"@en,
        "Department of Neuromedicine and Movement Science"@en,
        "Department of Neuromedicine and Movement Science (INB)"@en,
        "Department of Neuromedicine and Movement Science, Faculty of Medicine and Health Sciences"@en,
        "University Hospital of Trondheim"@en .

ns79:JAD190202 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Group"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology, Faculty of Medicine"@en,
        "Sunnybrook Research Institute"@en,
        "Toronto Rehabilitation Institute"@en,
        "University Health Network at Toronto Rehabilitation Institute"@en .

ns79:JAD190220 ns0:hasName "Center for Spirituality and the Mind"@en,
        "Division of Nuclear Medicine, Department of Radiology"@en,
        "Marcus Institute of Integrative Health"@en,
        "Myrna Brind Center of Integrative Medicine"@en,
        "Thomas Jefferson University School of Medicine"@en .

ns79:JAD190264 ns0:hasName "Department of Radiology and Imaging Sciences"@en,
        "Eli Lilly and Company"@en .

ns79:JAD190338 ns0:hasName "Department of Clinical Sciences and Community Health"@en,
        "Department of Medical Sciences and Community Health"@en,
        "Fondazione Cà Granda"@en,
        "Geriatric Unit"@en,
        "Geriatric Unit, Department of Clinical Sciences and Community"@en,
        "Geriatric Unit, Department of Clinical Sciences and Community Health"@en,
        "Geriatric Unit, Department of Medical Sciences and Community Health"@en .

ns79:JAD190365 ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychiatry, Division of Geriatric Psychiatry, St. Michael’s Hospital"@en,
        "Faculty of Medicine, Department of Psychiatry"@en,
        "Institute of Medical Sciences"@en,
        "Keenan Research Centre"@en,
        "Keenan Research Centre for Biomedical Research"@en,
        "Neuroscience Research Program, Keenan Research Centre for Biomedical Science"@en .

ns79:JAD190545 ns0:hasName "Department of Neurology and Laboratory of Neurobiology, Hospital Clinico San Carlos"@en,
        "Department of Neurology and Laboratory of Neurobiology, Hospital Clínico San Carlos"@en .

ns79:JAD190569 ns0:hasName "Department of Neurology"@en,
        "Division of Neurology, Department of Medicine"@en,
        "Joseph and Kathleen Bryan Alzheimer's Disease Research Center"@en .

ns79:JAD190620 ns0:hasName "Positron Medical Center"@en,
        "Research Team for Neuroimaging"@en,
        "Tokyo Metropolitan Institute of Gerontology"@en .

ns79:JAD190645 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Department of Medicine"@en,
        "Department of Medicine, Division of Geriatrics and Gerontology"@en,
        "Department of Medicine, Section of Geriatrics and Gerontology"@en,
        "Department of Veterans Affairs (VA) Geriatric Research"@en,
        "Division of Geriatrics and Gerontology, Department of Medicine"@en,
        "George Washington University"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "Geriatric Research, Education and Clinical Center (11G)"@en,
        "Geriatric Research, Education and Clinical Center (GRECC)"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "University of Wisconsin School of Medicine and Public Health"@en,
        "William S. Middleton Memorial Veterans Hospital Geriatric Research"@en,
        "Wisconsin Alzheimer's Disease Research Center"@en,
        "Wisconsin Alzheimer's Disease Research Center, (ADRC)"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns79:JPD191610 ns0:hasName "Civin Laboratory for Neuropathology"@en,
        "Sun Health Research Institute"@en .

ns215:CBM192435 ns0:hasName "Department of General Surgery"@en,
        "Shanghai Institute of Digestive Surgery, Ruijin Hospital"@en,
        "Shanghai Key Laboratory of Gastric Neoplasms, Ruijin Hospital"@en .

ns215:CH199206 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials for Medicine”"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biochemistry and Biology"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns215:JAD190175 ns0:hasName "Department of Neurology"@en,
        "Department of Neuromedicine and Movement Science"@en,
        "Department of Neuromedicine and Movement Science (INB)"@en,
        "Department of Neuroscience, Faculty of Medicine"@en,
        "University Hospital of Trondheim"@en .

ns215:JAD190283 ns0:hasName "Department of Statistics"@en,
        "Institute for Memory Impairments and Neurological Disorders"@en .

ns215:JAD190338 ns0:hasName "Department of Clinical Sciences and Community Health"@en,
        "Department of Internal Medicine"@en,
        "Fondazione Cà Granda"@en,
        "Geriatric Unit, Department of Medical Sciences and Community Health"@en .

ns215:JAD190645 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Department of Medicine, Section of Geriatrics and Gerontology"@en,
        "Department of Veterans Affairs (VA) Geriatric Research"@en,
        "GRECC, William S. Middleton Memorial Veterans Hospital and Department of Medicine"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "Wisconsin Alzheimer's Institute"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns215:JHD190346 ns0:hasName "Department of Psychiatry"@en,
        "Psychology Service"@en,
        "Research Service"@en .

ns215:JND190416 ns0:hasName "Department of Neuropediatrics and Muscle Disorders, Medical Center-University of Freiburg, Faculty of Medicine"@en,
        "John Walton Muscular Dystrophy Research Centre"@en .

ns215:JVR191023 ns0:hasName "University of Wisconsin-Madison"@en .

ns215:XST180467 ns0:hasName "Department of Radiation Oncology"@en .

ns227:CH180528 ns0:hasName "2nd Medical Department"@en,
        "Department of Medical II."@en .

ns227:JAD181259 ns0:hasName "Department of Neurosciences and Biomedical Technologies."@en,
        "Laboratory of Neurobiology"@en,
        "Neurology Unit"@en,
        "Ospedale San Gerardo"@en,
        "School of Medicine and Surgery and Milan Center for Neuroscience (NeuroMI)"@en,
        "Scientific Institute E. Medea"@en .

ns227:JAD181261 ns0:hasName "Department of Neurology"@en,
        "Duke-NUS Graduate Medical School Singapore"@en,
        "Duke-NUS Medical School"@en .

ns227:JAD190161 ns0:hasName "Alzheimer’s Disease Center"@en,
        "Boston University School of Medicine"@en,
        "Department of Alzheimer's Disease Center"@en,
        "Department of Pharmacology & Experimental Therapeutics"@en,
        "Department of Psychiatry"@en,
        "Departments of Pharmacology & Experimental Therapeutics"@en,
        "Departments of Pharmacology & Experimental Therapeutics, Psychiatry"@en,
        "Departments of Pharmacology and Experimental Therapeutics"@en,
        "Departments of Psychiatry"@en,
        "Pharmacology and Experimental Therapeutics"@en .

ns227:JAD190401 ns0:hasName "Beijing Geriatric Medical Research Center"@en,
        "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

ns227:JAD190469 ns0:hasName "Department of Health Sciences and Technology, SAIHST"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Neuto Science Center"@en,
        "Samsung Alzheimer Research Center"@en,
        "Samsung Medical Center, Department of Neurology"@en,
        "Stem Cell & Regenerative Medicine Institute"@en,
        "Stem Cell and Regenerative Medicine Institute"@en .

ns227:JAD190545 ns0:hasName "Department of Neurology and Laboratory of Neurobiology, Hospital Clinico San Carlos"@en,
        "Department of Neurology, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC)"@en,
        "Department of Neurology, San Carlos Institute for Health Research (IdISSC)"@en .

ns227:JAD190549 ns0:hasName "Centre Mémoire Ressources Recherche de Lyon"@en,
        "Department of Neurocognition"@en,
        "Département de Neurologie cognitive et de Neuro-ophtalmologie"@en,
        "INSERM U1028, CNRS UMR5292"@en,
        "Research Memory Center (CMRR)"@en,
        "Research and Resources Memory Center of Lyon, Hôpital Pierre Wertheimer"@en,
        "Service de Neurologie; Unité 402, Groupement Hospitalier Est"@en,
        "University Lyon I"@en .

ns227:JAD190645 ns0:hasName "Geriatric Research Education and Clinical Center"@en,
        "University of Wisconsin"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en .

ns227:JHD190346 ns0:hasName "Department of Psychiatry"@en,
        "VA San Diego Healthcare System"@en .

ns227:JPD191610 ns0:hasName "Civin Laboratory for Neuropathology"@en,
        "The Cleo Roberts Center for Clinical Research"@en .

ns227:NRE182671 ns0:hasName "Department of Physiotherapy, Rehabilitation School"@en,
        "Department of Physiotherapy, School of Rehabilitation"@en,
        "Neuromusculoskeletal Research Center"@en,
        "Sports Medicine Research Center"@en .

ns227:NRE192745 ns0:hasName "Cliniques Universitaires Saint-Luc"@en,
        "Université catholique de Louvain"@en .

ns227:THC199026 ns0:hasName "College of Biomedical Engineering"@en,
        "Department of Neurosurgery"@en .

ns244:BLC190228 ns0:hasName "Cancer Biology and Genetics Division, Queen’s Cancer Research Institute"@en,
        "Department of Biomedical and Molecular Sciences"@en,
        "Department of Obstetrics and Gynecology"@en,
        "Department of Urology, Kingston Health Sciences Center"@en .

ns244:JAD190019 ns0:hasName "Department of Behavioral Sciences and the Rush Alzheimer’s Disease Center"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Behavioral Sciences"@en,
        "Rush Alzheimer’s Disease Center"@en,
        "University of Illinois at Chicago"@en .

ns244:JPD191627 ns0:hasName "Department of Neurology"@en,
        "Department of Radiology"@en,
        "Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en,
        "Neurology Service and GRECC"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en .

ns244:WOR192938 ns0:hasName "Department of Physical Therapy"@en,
        "School of Health and Rehabilitation Sciences"@en .

ns258:HAB190363 ns0:hasName "Department of Health Management and Economics, School of Public Health, Health Information Management Research Center"@en .

ns258:HAB190367 ns0:hasName "Department of Health Management and Economics, School of Public Health, Health Information Management Research Center"@en .

ns258:IFS179323 ns0:hasName "School of Industrial Engineering, College of Engineering"@en,
        "Universal Scientific Education and Research Network (USERN)"@en .

ns258:JAD170300 ns0:hasName "Department of Epidemiology"@en,
        "Department of Epidemiology, Joseph P. Mailman School of Public Health"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, College of Physicians and Surgeons"@en,
        "Department of Psychology"@en,
        "Departments of Epidemiology and Psychiatry"@en,
        "Gertrude H. Sergievsky Center"@en,
        "Gertrude H. Sergievsky Center, College of Physicians & Surgeons"@en,
        "Gertrude H. Sergievsky Center, College of Physicians and Surgeons"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain, College of Physicians and Surgeons"@en,
        "Taub Institute for Research on Alzheimer’s Disease and the Aging Brain"@en,
        "The Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en .

ns258:JAD180630 ns0:hasName "Department of Neurology, Memory Clinic, 2nd Faculty of Medicine"@en,
        "International Clinical Research Center"@en,
        "Memory Clinic, Department of Neurology"@en,
        "National Institute of Mental Health"@en .

ns258:JAD181173 ns0:hasName "Cognitive Decline Partnership Centre, Faculty of Medicine and Health"@en,
        "Falls, Balance and Injury Research Centre, Neuroscience Research Australia"@en,
        "Prince of Wales Clinical School, Faculty of Medicine"@en .

ns258:JAD181196 ns0:hasName "Department of Geriatric Medicine, Division of Geriatric Medicine"@en,
        "Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry"@en .

ns258:JAD181259 ns0:hasName "Laboratory of Molecular Medicine and Imaging in Rehabilitation"@en,
        "Milan Center for Neuroscience"@en .

ns258:JAD181295 ns0:hasName "Department of Clinical Neuroscience"@en,
        "Department of Forensic Psychiatry"@en,
        "Department of Forensic Psychiatry, Niuvanniemi Hospital"@en,
        "Kuopio Research Centre of Geriatric Care"@en,
        "School of Pharmacy"@en,
        "School of Pharmacy, Faculty of Health Sciences"@en .

ns258:JAD190183 ns0:hasName "Aging Psychiatry Unit"@en,
        "Brain Dynamics and Cognition"@en,
        "Department of Psychiatry"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Psychiatry Unit"@en .

ns258:JAD190589 ns0:hasName "Departments of Psychiatry and BioEngineering"@en,
        "Departments of Psychiatry and Bioengineering"@en .

ns258:JAD190638 ns0:hasName "Laboratory of Neurodegenerative Diseases"@en,
        "Laboratory of Neurodegenerative Diseases, Center for Interdisciplinary Research and Innovation (CIRI – AUTH) Balkan Center, Buildings A & B"@en,
        "Laboratory of Psychology, School of Psychology"@en .

ns258:JAD190666 ns0:hasName "Cunji Medical School"@en,
        "State Key Laboratory of Bioactive Substances and Functions of Natural Medicines"@en,
        "State Key Laboratory of Bioactive Substances and Functions of Natural Medicines, Institute of Materia Medica"@en .

ns258:JAD190688 ns0:hasName "Department of Public Health and Primary Care"@en,
        "Department of Public Health and Primary Care, Cambridge Institute of Public Health"@en,
        "Institute of Public Health"@en .

ns258:JND180314 ns0:hasName "Department of Translational Medicine, IGBMC, U964, UMR7104"@en,
        "Institut de Génétique et de Biologie Moléculaire et Cellulaire, Centre National de la Recherche Scientifique, Institut National de la Santé et de la Recherche Médicale"@en,
        "Strasbourg University"@en .

ns258:JND190403 ns0:hasName "Department of Biological Chemistry and Pharmacology"@en,
        "Department of Neurology"@en .

ns258:NHA190068 ns0:hasName "Division of Epidemiology and Biostatistics"@en,
        "Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL and Faculty of Health Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:10.ID:JAD181175> ns0:hasName "Center for BrainHealth, School of Behavioral and Brain Sciences"@en,
        "Department of Neurology and Neurotherapeutics"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry"@en,
        "School of Behavioral & Brain Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:10.ID:JAD190817> ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, School of Medicine"@en,
        "Sapporo Medical University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:10.ID:JND190379> ns0:hasName "Department of Rehabilitation"@en,
        "Donders Centre for Neuroscience, Department of Rehabilitation"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:11.ID:JAD190666> ns0:hasName "CAS Key Laboratory of Genome Sciences and Information"@en,
        "CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics"@en,
        "Center of Alzheimer's disease"@en,
        "Cunji Medical School"@en,
        "UC Davis Genome Center and Department of Biomedical Engineering"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:12.ID:JAD190113> ns0:hasName "Alzheimer’s Disease Research Unit"@en,
        "McConnell Brain Imaging Centre"@en,
        "McGill Center for Studies in Aging"@en,
        "McGill Centre for Studies in Aging (MCSA)"@en,
        "Translational Neuroimaging Laboratory, Douglas Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:13.ID:JAD181175> ns0:hasName "Department of Clinical Sciences"@en,
        "Department of Clinical Sciences (Biostatistics)"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry"@en,
        "University of Texas Southwestern Medical Center at Dallas"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:13.ID:JAD190113> ns0:hasName "Alzheimer's Disease Research Unit"@en,
        "Alzheimer’s Disease Research Unit"@en,
        "Departments of Neurology & Neurosurgery, Psychiatry, and Medicine"@en,
        "McGill Center for Studies in Aging"@en,
        "McGill Centre for Studies in Aging (MCSA)"@en,
        "McGill University Research Center for Studies in Aging"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:13.ID:JAD190568> ns0:hasName "Department of Genetics, Perelman School of Medicine"@en,
        "Department of Medicine"@en,
        "Department of Medicine (Gerontology/Geriatrics), Neurology"@en,
        "Department of Medicine, Division of Geriatric Medicine"@en,
        "Department of Neurology"@en,
        "Department of Pathology and Laboratory Medicine"@en,
        "Department of Pharmacology"@en,
        "Geriatric Research, Education, and Clinical Center"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC)"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC) VA Puget Sound Health Care System"@en,
        "Geriatric Research, Education, and Clinical Center (GRECC)VA Puget Sound Health Care System"@en,
        "Geriatric Research, Education, and Clinical Centers"@en,
        "Medicine"@en,
        "Neurology"@en,
        "Pathology & Laboratory Medicine"@en,
        "Pharmacology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:15.ID:JAD180957> ns0:hasName "Department of Neurology, Memory and Aging Center"@en,
        "Memory and Aging Center, Department of Neurology"@en,
        "University of California San Francisco"@en,
        "University of California at San Francisco Memory and Aging Center"@en .

ns264:JAD180949 ns0:hasName "Department for Neurodegenerative Diseases and Geriatric Psychiatry"@en,
        "Department of Neurodegenerative Diseases and Geriatric Psychiatry"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Center for Neurodegenerative Disorders (DZNE, Bonn)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:19.ID:JAD190334> ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Neurology of NeuroCenter"@en .

ns13:BMR181181 ns0:hasName "Department of Allied Health Studies"@en,
        "School of Allied Health Professions"@en .

ns13:BMR181341 ns0:hasName "Department of Physical Therapy for Musculoskeletal Disorders and its Surgery, Faculty of Physical Therapy"@en,
        "Department of Physiotherapy, College of Health Sciences"@en,
        "Physiotherapy Department, College of Health Sciences"@en .

ns13:CH199002 ns0:hasName "Centre Hospitalier Régional Universitaire CHRU de Montpellier"@en,
        "Service de Gynécologie Obstétrique"@en .

ns13:HAB190368 ns0:hasName "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Sciences"@en,
        "School of Public Health"@en .

ns13:HAB190369 ns0:hasName "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Sciences"@en,
        "School of Public Health"@en .

ns13:HAB190373 ns0:hasName "Antibody Laboratory"@en,
        "Biological Sciences Department, Faculty of Science"@en,
        "Therapeutic and Protective Proteins Laboratory, Protein Research Department"@en .

ns13:HAB190383 ns0:hasName "Department of Health Management and Economics, School of Public Health"@en,
        "Department of Health Sciences"@en,
        "School of Public Health"@en .

ns13:IDT180003 ns0:hasName "Department of Computer Science and Engineering"@en,
        "MIR Labs"@en,
        "Machine Intelligence Research Labs"@en,
        "Machines Intelligence Research Labs (MIR Labs)"@en,
        "Norwegian Center of Excellence for Quantifiable Quality of Service"@en .

ns13:IFS181657 ns0:hasName "Division of Computational Mathematics and Engineering"@en,
        "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns13:IFS181813 ns0:hasName "Department of Mathematics"@en .

ns13:IFS182746 ns0:hasName "Department of Physics, Sari Branch"@en .

ns13:IFS182863 ns0:hasName "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns13:IFS182876 ns0:hasName "Division of Computational Mathematics and Engineering"@en,
        "Division of Computational Mathematics and Engineering, Institute for Computational Science"@en,
        "Faculty of Mathematics and Statistics"@en .

ns13:IFS190344 ns0:hasName "China Institute of Manufacturing Development"@en,
        "School of Mathematical Sciences"@en .

ns13:IFS190706 ns0:hasName "Faculty of Computer and Information Sciences"@en,
        "Northern Borders University"@en .

ns13:IFS190952 ns0:hasName "Faculty of Applied Sciences"@en,
        "Faculty of Basic Sciences"@en .

ns13:JAD181030 ns0:hasName "Department of Infectious Disease Epidemiology"@en,
        "Department of Infectious Disease Epidemiology, School of Public Health, Faculty of Medicine"@en .

ns13:JAD190011 ns0:hasName "Department of Environmental Health, Rollins School of Public Health"@en,
        "Rollins School of Public Health"@en .

ns13:JAD190074 ns0:hasName "Department of Neurosciences"@en,
        "Department of Pathology, School of Medicine"@en,
        "Division of Neurosciences"@en,
        "Division of Neurosciences and Molecular Neuropathology Section, Laboratory of Neurogenetics"@en .

ns13:JAD190092 ns0:hasName "Department of Radiology, Miller School of Medicine"@en .

ns13:JAD190261 ns0:hasName "Department of Alzheimer's Disease Center"@en,
        "Department of Anatomy & Neurobiology and Neurology, Framingham Heart Study"@en,
        "Department of Anatomy & Neurobiology, Neurology and Epidemiology"@en,
        "Department of Anatomy & Neurobiology, Neurology, & Epidemiology"@en,
        "Department of Anatomy and Neurobiology"@en,
        "Department of Biostatistics"@en,
        "Department of Epidemiology"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Boston"@en,
        "Departments of Anatomy and Neurobiology"@en,
        "Departments of Anatomy and Neurobiology, Neurology and Epidemiology, Schools of Medicine and Public Health"@en,
        "Framingham Heart Study"@en,
        "Neurology"@en,
        "The National Heart, Lung, and"@en .

ns13:JAD190331 ns0:hasName "Auditory Research Center"@en,
        "Department of Anatomy"@en,
        "Lake Erie College of Osteopathic Medicine"@en .

ns13:JAD190342 ns0:hasName "School for Health and Related Research"@en,
        "School of Health and Related Research"@en .

ns13:JAD190440 ns0:hasName "University of Lille"@en,
        "Université de Lille"@en .

ns13:JAD190460 ns0:hasName "Department of Applied Linguistics, Faculty of Informatics and Management"@en,
        "Department of Neurology"@en .

ns13:JAD190461 ns0:hasName "National Center for Disease Prevention and Health Promotion"@en,
        "National Centre for Disease Prevention and Health Promotion"@en,
        "National Centre of Epidemiology"@en,
        "National Institute of Health"@en .

ns13:JAD190501 ns0:hasName "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

ns13:JAD190527 ns0:hasName "Department of Epidemiology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Department of Radiology and Nuclear medicine"@en,
        "Memory Aging & Cognition Centre"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en,
        "Saw Swee Hock School of Public Health"@en .

ns13:JAD190538 ns0:hasName "Department of Behavioral Sciences"@en,
        "Department of Neurological Sciences"@en,
        "Rush Alzheimer’s Disease Center"@en .

ns13:JAD190563 ns0:hasName "Department of Psychiatry and Behavioral Sciences"@en,
        "Mental Illness Research, Education, and Clinical Center"@en .

ns13:JAD190638 ns0:hasName "3rd Department of Neurology"@en,
        "Aristotle University of Thessaloniki"@en,
        "Laboratory of Neurodegenerative Diseases"@en .

ns13:JAD190708 ns0:hasName "Department of Psychiatry and Biobehavioral Sciences"@en,
        "The John Wayne Cancer Institute and Pacific Neuroscience Institute"@en,
        "UCLA Longevity Center at the Semel Institute for Neuroscience and Human Behavior"@en .

ns13:JAD190721 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Department of Molecular Neuroscience"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute"@en,
        "UK Dementia Research Institute at UCL"@en .

ns13:JHD190353 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research"@en,
        "Department of Radiology"@en,
        "George-Huntington-Institute"@en,
        "Institute for Clinical Radiology"@en .

ns13:JHD190365 ns0:hasName "Department of Psychiatry and Department of Neurology"@en,
        "Department of Psychiatry, Research Division and Department of Neurology"@en .

ns13:JND180314 ns0:hasName "Department of Translational Medicine, IGBMC, U964, UMR7104"@en,
        "Strasbourg University"@en .

ns13:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Geography"@en,
        "Department of Paediatrics"@en,
        "Lawson Health Research Institute"@en,
        "School of Health Studies"@en .

ns13:NRE192762 ns0:hasName "Department of Neuroscience"@en,
        "Department of Neurosciences"@en,
        "Division of Neurology and Neurorehabilitation"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:27.ID:JAD190446> ns0:hasName "Department of Medical Sciences, Neuroscience and Signalling Laboratory, Institute for Biomedicine – iBiMED"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "Department of Psychiatry and Psychotherapy, University Medical Center (UMG)"@en,
        "Department of Psychiatry and Psychotherapy, University Medical Center Goettingen"@en,
        "Department ofPsychiatry and Psychotherapy"@en,
        "Georg-August-University Göttingen"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "LVR-Hospital Essen, Department of Psychiatry and Psychotherapy"@en,
        "LVR-Hospital Essen, Department of Psychiatry and Psychotherapy, Faculty of Medicine"@en,
        "iBiMED, Medical Sciences Department"@en .

ns63:BME191060 ns0:hasName "Department of Biofunction Research, Institute of Biomaterials and Bioengineering"@en,
        "Institute of Biomaterials and Bioengineering"@en,
        "School of DentistryAichi Gakuin University"@en .

ns63:CBM182009 ns0:hasName "College of Bioinformatics Science and Technology"@en .

ns63:CBM182333 ns0:hasName "Department of Epidemiology, College of Preventive Medicine"@en .

ns63:CBM192435 ns0:hasName "Department of Pathology, Ruijin Hospital"@en .

ns63:CH199004 ns0:hasName "Center for Plastic, Aesthetic, Hand & Reconstructive Surgery"@en,
        "Center for Plastic, Aesthetic, Hand &Reconstructive Surgery"@en,
        "Center for Plastic, Hand and Reconstructive Surgery"@en,
        "Center for Plastic-, Hand-, and Reconstructive Surgery"@en,
        "Center of Plastic and Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and Reconstructive Surgery"@en,
        "Center of Plastic, Hand and reconstructive Surgery"@en,
        "Centre of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic and Hand Surgery"@en,
        "Department of Plastic and Reconstructive Surgery"@en,
        "Department of Plastic, Hand and Reconstructive Surgery"@en,
        "Department of Plastic, Hand, and Reconstructive Surgery"@en,
        "Department of Plastic, Reconstructive and Hand Surgery"@en,
        "Department of Plastic-, Hand-, and Reconstructive Surgery"@en,
        "University Center of Plastic-, Aesthetic, Hand- and Reconstructive Surgery"@en .

ns63:CH199009 ns0:hasName "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour"@en,
        "Institute for Animal Hygiene, Animal Welfare and Farm Animal Behaviour and Virtual Center for Replacement - Complementary Methods to Animal Testing"@en .

ns63:HAB190371 ns0:hasName "Department of Geography and Environmental Studies"@en .

ns63:IFS179078 ns0:hasName "Department of EEE"@en .

ns63:IFS179155 ns0:hasName "Department of Computer Science and Engineering"@en,
        "Faculty of Computer and Information Sciences"@en,
        "Faculty of Computers and Information"@en,
        "Faculty of Computers and Information Sciences"@en .

ns63:IFS181502 ns0:hasName "Department of Mathematics and Computer Science"@en,
        "Polytechnic University of Tirana"@en .

ns63:IFS181742 ns0:hasName "Department of Math."@en,
        "Department of Mathematics"@en .

ns63:IFS181769 ns0:hasName "College of Information Science and Technology"@en .

ns63:IFS182919 ns0:hasName "College of Sciences"@en,
        "Department of Statistics, Faculty of Science"@en .

ns63:IFS190447 ns0:hasName "Research Institute for Natural Sciences"@en,
        "Research Institute of Natural Sciences"@en .

ns63:IFS190711 ns0:hasName "School of Mathematics"@en,
        "School of Mathematics, Thapar Institute of Engineering & Technology"@en,
        "Thapar Institute of Engineering & Technology (Deemed University)"@en .

ns63:IFS191197 ns0:hasName "Department of Mathematics"@en,
        "Islamabad Model College for Girls"@en,
        "Islamabad Model College for Girls F-6/2 Islamabad"@en .

ns63:JAD181037 ns0:hasName "Department of Clinical Sciences"@en,
        "Department of Clinical Sciences, Psychiatry"@en .

ns63:JAD181132 ns0:hasName "Centre for Population Health Research"@en,
        "South Australian Health and Medical Research Institute"@en .

ns63:JAD181277 ns0:hasName "Biobank"@en,
        "Biobank, Institute Born-Bunge"@en,
        "Department of Biomedical Sciences, Laboratory of Neurochemistry and Behavior"@en,
        "Department of Biomedical Sciences, Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Department of Health Care Sciences"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Alzheimer Research Center"@en,
        "Department of Neurology and Memory Clinic"@en,
        "Department of Neurology, Alzheimer Research Center"@en,
        "Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), and Biobank, Institute Born-Bunge"@en,
        "University of Groningen"@en .

ns63:JAD181295 ns0:hasName "Department of Forensic Psychiatry"@en,
        "Karolinska Institutet"@en,
        "National Institute for Health and Welfare"@en,
        "University of Eastern Finland"@en .

ns63:JAD190133 ns0:hasName "Center for Life Course Health Research, Faculty of Medicine"@en,
        "Medical Research Center Oulu"@en,
        "Oulu City Hospital"@en,
        "University of Oulu"@en .

ns63:JAD190197 ns0:hasName "Department of Biology"@en,
        "Department of Pharmacobiology"@en,
        "Department of Physiology and Pharmacology"@en,
        "IRCCS Santa Lucia Foundation"@en,
        "IRCSS Santa Lucia Foundation"@en,
        "Laboratory of Neuropharmacology"@en .

ns63:JAD190202 ns0:hasName "Department of Psychiatry"@en .

ns63:JAD190293 ns0:hasName "Department of Neurology"@en,
        "University of Kansas School of Medicine"@en .

ns63:JAD190334 ns0:hasName "Institute of Clinical Medicine – Neurology"@en,
        "Neurology of NeuroCenter"@en .

ns63:JAD190341 ns0:hasName "Department of Neurology, Danish Dementia Research Centre, Rigshospitalet"@en,
        "Department of Neurology, Memory Disorders Research Group, Rigshospitalet"@en .

ns63:JAD190518 ns0:hasName "Department Neurosciences, School of Medicine"@en,
        "Department of Neuroscience"@en,
        "Department of Neurosciences"@en,
        "Department of Pathology"@en,
        "Department of Pathology, School of Medicine"@en,
        "Departments of Neurosciences and Pathology University of California San Diego"@en,
        "Division of Neuroscience and Laboratory of Neurogenetics"@en,
        "Division of Neurosciences"@en,
        "Division of Neurosciences and Molecular Neuropathology Section, Laboratory of Neurogenetics"@en,
        "Division of Neurosciences, National Institute on Aging"@en,
        "Molecular Neuropathology Section, Laboratory of Neurogenetics"@en .

ns63:JAD190609 ns0:hasName "Division of Geriatric Medicine"@en,
        "Gérontopôle"@en,
        "Éducation, éthique, santé (EA 7505)"@en .

ns63:JAD190708 ns0:hasName "Department of Neurology"@en,
        "The John Wayne Cancer Institute and Pacific Neuroscience Institute"@en .

ns63:JPD191579 ns0:hasName "Department of Neurology"@en,
        "Department of Radiology"@en,
        "Department of Radiology, Division of Nuclear Medicine"@en,
        "Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en,
        "Neurology"@en,
        "Neurology Service and GRECC"@en,
        "Radiology"@en,
        "University of Michigan Morris K. Udall Center of Excellence for Parkinson’s Disease Research"@en .

ns63:JPD191616 ns0:hasName "Center for Interdisciplinary Research Egas Moniz(CiiEM)"@en,
        "Centro de Investigação Interdisciplinar Egas Moniz (CiiEM)"@en,
        "Clinical Pharmacology Unit"@en,
        "Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine"@en .

ns63:JVR191022 ns0:hasName "Independent Rehabilitation Consultant"@en,
        "Rehabilitation Consultant"@en .

ns63:NPM18117 ns0:hasName "Department of Pediatrics, Division of Neonatology"@en,
        "Division of Neonatology, Department of Pediatrics"@en .

ns63:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Paediatrics"@en,
        "Human Environments Analysis Laboratory"@en,
        "Lawson Health Research Institute"@en,
        "School of Food and Nutritional Sciences"@en .

ns63:NPM1818 ns0:hasName "Department of Biostatistics & Inpatient’s Safety Research Center"@en,
        "Department of Biostatistics and Epidemiology, Inpatient’s Safety Research Center"@en .

ns63:NRE182671 ns0:hasName "Department of Physical Therapy"@en,
        "Franklin Pierce University"@en .

ns63:THC199007 ns0:hasName "Department of Computer Technologies, Vocational School of Technical Sciences"@en .

ns63:WOR192984 ns0:hasName "Department of Ergonomics, School of Health"@en,
        "Department of Occupational Health Engineering, School of Public Health"@en .

ns63:XST190527 ns0:hasName "Department of Biomedical Engineering"@en .

ns123:CBM192435 ns0:hasName "Department of Pathology, Ruijin Hospital"@en .

ns123:IES193178 ns0:hasName "Faculty of Medicine"@en,
        "Middle East Technical University"@en .

ns123:IFS179095 ns0:hasName "Faculty of Computer and Information Sciences"@en,
        "Faculty of Computers and Information"@en .

ns123:IFS181460 ns0:hasName "Department of Mathematics"@en,
        "Yazd University"@en .

ns123:JAD180521 ns0:hasName "Department of Medicine and Radiology, Royal Melbourne Hospital"@en,
        "Department of Radiology"@en,
        "Department of Radiology, Royal Melbourne Hospital"@en .

ns123:JAD180636 ns0:hasName "CEDOC, Nova Medical School/Faculdade de Ciências Médicas"@en,
        "Universidade Nova de Lisboa"@en .

ns123:JAD181295 ns0:hasName "Center for Psychiatry Research"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Forensic Psychiatry"@en,
        "Department of Forensic Psychiatry, Niuvanniemi Hospital"@en,
        "Karolinska Institutet"@en,
        "University of Eastern Finland"@en .

ns123:JAD190153 ns0:hasName "Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College"@en .

ns123:JAD190272 ns0:hasName "Department of Neuropsychiatry"@en,
        "Department of Psychiatry and Neuropathobiology, Faculty of Life Sciences"@en .

ns123:JAD190327 ns0:hasName "Department of Geriatric Medicine"@en,
        "Norwegian Advisory Unit for Ageing and Health"@en,
        "Norwegian National Advisory Unit on Ageing and Health"@en,
        "Norwegian National Advisory Unit on Ageing and Health (Ageing and Health)"@en .

ns123:JAD190329 ns0:hasName "Einstein Aging Study and the Department of Neurology"@en,
        "Helen Wills Neuroscience Institute"@en .

ns123:JAD190334 ns0:hasName "Department of Neurology"@en,
        "Institute of Biomedicine"@en,
        "Neurology of NeuroCenter"@en .

ns123:JAD190344 ns0:hasName "Alzheimer Center"@en,
        "Alzheimer Center & Department of Neurology"@en,
        "Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience"@en,
        "Alzheimer Center and Department of Neurology"@en,
        "Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer Center, Department of Neurology"@en,
        "Alzheimer Centre & Department of Neurology"@en,
        "Alzheimer Centre and Department of Neurology"@en,
        "Alzheimer Centre and Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer center & Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer center, Neuroscience Campus Amsterdam"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Alzheimer Center"@en,
        "Department of Neurology and Alzheimer Center, Neuroscience Campus Amsterdam"@en,
        "Department of Neurology and Alzheimer Centre"@en,
        "Department of Neurology and Alzheimer’s Center"@en,
        "Department of Neurology, Alzheimer Center"@en,
        "Department of Neurology, Alzheimer Center Amsterdam, Amsterdam Neuroscience"@en,
        "Department of Neurology, Alzheimer Centre"@en,
        "Department of Neurology, Alzheimer’s Center"@en,
        "Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Department of Neurology, VUmc Alzheimer Center"@en,
        "Department of Neurology/Alzheimer Center"@en,
        "Department of Psychiatry and Neuropsychology"@en,
        "Departments of Neurology"@en,
        "Neurology Department"@en,
        "Neurology, Alzheimer Center"@en .

ns123:JAD190414 ns0:hasName "Cognitive Neuroscience Research Group, Department of Psychology and Educational Sciences and Centre for Biomedical Research (CBMR)"@en,
        "Department of Psychology and Educational Sciences and Centre for Biomedical Research (CBMR), Cognitive Neuroscience Research Group"@en .

ns123:JAD190427 ns0:hasName "CHU Bordeaux Centre Mémoire Ressource et Recherche/ Institut des Maladies Neurodégénératives clinique (IMNc) Hopital Pellegrin"@en,
        "CM2R (Centre Mémoire de Ressources et Recherche)"@en,
        "CMRR Hôpital Pellegrin"@en,
        "CMRR d'Aquitaine"@en,
        "CMRR de Bordeaux, Clinique Neurologique"@en,
        "Department of Neurology"@en,
        "Insem"@en,
        "Inserm, U897"@en,
        "Univ Bordeaux"@en .

ns123:JAD190459 ns0:hasName "INSERM, U1028, CNRS, UMR5292, Neuropain team"@en,
        "INSERM, U1028; CNRS, UMR5292"@en,
        "INSERM, U1028; CNRS, UMR5292; Neuropain team"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR) Neurology Unit"@en,
        "Memory Clinical and Research Center of Saint Etienne (CMRR), Neurology Unit"@en,
        "Neuropain Team"@en .

ns123:JAD190501 ns0:hasName "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

ns123:JAD190538 ns0:hasName "Department of Behavioral Sciences"@en,
        "Department of Neurological Sciences"@en,
        "Departments of Neurological Sciences and Behavioral Sciences, and Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer’s Disease Center"@en .

ns123:JAD190798 ns0:hasName "1st Department of Neurology"@en,
        "1st Department of Neurology, G.H. “AHEPA”, School of Medicine, Faculty of Health Sciences"@en,
        "1st Department of Neurology, Medical School"@en,
        "1st Department of Neurology, School of Medicine"@en,
        "1st Department of Neurology, U.H. “AHEPA”, Medical School, Faculty of Healthy Sciences"@en,
        "1st University Department of Neurology, AHEPA Hospital, Medical School"@en,
        "3rd Department of Neurology"@en,
        "3rd Department of Neurology, Medical School"@en,
        "3rd Department of Neurology, “G. Papanicolaou” Hospital"@en,
        "3rd Department of Neurology, “G. Papanikolaou” General Hospital of Thessaloniki"@en,
        "3rd Neurologic Clinic, Medical School, G. Papanikolaou Hospital"@en,
        "Aristotle University of Thessaloniki"@en,
        "Department of Neurology"@en,
        "Greek Association of Alzheimer's Disease and Related Disorders"@en,
        "INSERM U 558"@en,
        "Information Technologies Institute"@en,
        "Laboratory of Neurodegenerative Diseases"@en,
        "Laboratory of Neurodegenerative Diseases, Center for Interdisciplinary Research and Innovation (CIRI – AUTH) Balkan Center, Buildings A & B"@en,
        "Medical School Aristotle University of Thessaloniki"@en,
        "Memory and Dementia Centre"@en,
        "Memory and Dementia Centre, 3rd Department of Neurology"@en,
        "Network Aging Research"@en,
        "Third Department of Neurology"@en,
        "Third Department of Neurology, Memory and Dementia Centre, Medical School"@en .

ns123:JAD190889 ns0:hasName "Department of Psychology"@en .

ns123:JND190397 ns0:hasName "Department of Biostatistics"@en,
        "Department of Biostatistics, College of Public Health"@en,
        "Department of Psychiatry, Carver College of Medicine"@en .

ns123:JND190415 ns0:hasName "AP-HP, Pitié-Salpêtrière Hospital"@en,
        "APHP, Cochin Hospital, Cardiology Department, FILNEMUS, Centre de Référence de Pathologie Neuromusculaire Nord/Est/Ile de France, Paris-Descartes"@en,
        "Department of Cardiology, AP-HP, Cochin Hospital"@en .

ns123:JVR191023 ns0:hasName "Department of Rehabilitation Sciences"@en,
        "University of Texas at El Paso"@en,
        "University of Wisconsin-Madison"@en .

ns123:JVR191024 ns0:hasName "Department of Kinesiology and Community Health"@en,
        "The University of Illinois-Urbana"@en,
        "University of Illinois"@en,
        "University of Illinois at Urbana-Champaign"@en .

ns123:KCA180049 ns0:hasName "University of Michigan"@en,
        "University of Michigan Medical School"@en .

ns123:MNM180261 ns0:hasName "Department of Pediatrics"@en,
        "Pediatrics Department"@en .

ns123:RNN190916 ns0:hasName "Department of Rehabilitation Medicine, Division of Physical Therapy"@en,
        "Department of Rehabilitation Medicine, Division of Physical Therapy, School of Medicine"@en,
        "Division of Physical Therapy, Department of Rehabilitation Medicine"@en .

ns123:XST180490 ns0:hasName "College of Engineering"@en,
        "Department of Biochemistry and Molecular Biology, School of Medicine"@en,
        "Department of Biochemistry, Medical School"@en,
        "Department of Electrical and Computer Engineering"@en,
        "Jiangsu Key Laboratory of Neuroregeneration"@en,
        "Jiangsu Key Laboratory of NeuroregenerationNantong University"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education and Co-innovation Center of Neuroregeneration"@en,
        "Sino-Dutch Biomedical and Information Engineering School"@en .

ns123:XST190491 ns0:hasName "Department of Physics, Faculty of Science"@en .

ns192:BLC190218 ns0:hasName "Cedars-Sinai Samuel Oschin Comprehensive Cancer Institute"@en,
        "University of Colorado Cancer Center"@en .

ns192:CH199005 ns0:hasName "Helmholtz Virtual Institute - Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute - Multifunctional Materials in Medicine"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Helmholtz Virtual Institute “Multifunctional Biomaterials in Medicine”"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns192:IFS181516 ns0:hasName "Department of Information Technology"@en,
        "Department of Mathematics"@en .

ns192:JAD181037 ns0:hasName "Department of Clinical Sciences"@en,
        "Department of Clinical Sciences, Psychiatry"@en .

ns192:JAD181113 ns0:hasName "Interdepartmental Program “Autism 0–90”, “G. Martino” Hospital"@en,
        "Mafalda Luce Center for Pervasive Developmental Disorders"@en .

ns192:JAD181140 ns0:hasName "Intramural Research Program"@en,
        "National Institute on Aging"@en .

ns192:JAD181277 ns0:hasName "Department of Neurology and Memory Clinic"@en,
        "Laboratory of Neurochemistry and Behavior"@en,
        "Memory Clinic and Division of Neurology"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), and Biobank, Institute Born-Bunge"@en,
        "University of Antwerp"@en .

ns192:JAD190041 ns0:hasName "Alzheimer Centre Nijmegen"@en,
        "Department of Geriatric Medicine"@en,
        "Department of Geriatrics"@en,
        "Department of Geriatrics & Radboud Alzheimer Center"@en,
        "Department of Geriatrics & Radboud UMC Alzheimer Center, Radboud Institute for Health Sciences"@en,
        "Department of Geriatrics, Radboud Alzheimer Center, Donders Institute for Brain, Cognition and Behaviour"@en,
        "Radboud Alzheimer Center, Department of Geriatric Medicine"@en,
        "Radboud Alzheimer Centre, Department of Geriatric Medicine"@en,
        "Radboud University Nijmegen Medical Centre"@en,
        "Radboudumc Alzheimer Center, Donders Institute for Brain, Cognition and Behaviour"@en,
        "Radboudumc Alzheimer Centre, Department of Geriatrics, Donders Centre for Brain, Cognition and Behavior"@en .

ns192:JAD190052 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Department of Medicine, Section of Geriatrics and Gerontology"@en,
        "Department of Veterans Affairs (VA) Geriatric Research"@en,
        "Division of Geriatrics and Gerontology, Department of Medicine"@en,
        "GRECC, William S. Middleton Memorial Veterans Hospital and Department of Medicine"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "Wisconsin Alzheimer's Institute"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns192:JAD190154 ns0:hasName "Alzheimer Disease Research Center"@en,
        "Alzheimer's Disease Research Center"@en,
        "Charles F. and Joanne Knight Alzheimer Disease Research Center"@en,
        "Charles F. and Joanne Knight Alzheimer’s Disease Research Center"@en,
        "Department of Immunology"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Alzheimer's Disease Research Center"@en,
        "Department of Neurology, Department of Pathology and Immunology"@en,
        "Department of Occupational Therapy"@en,
        "Department of Pathology"@en,
        "Department of Pathology and Immunology"@en,
        "Department of Physical Therapy"@en,
        "Department of Radiology"@en,
        "Departments of Neurology and of Pathology and Immunology"@en,
        "Departments of Neurology, Pathology and the Alzheimer's Disease Research Center"@en,
        "Hope Center for Neurological Disorders"@en,
        "Knight Alzheimer Disease Research Center"@en,
        "Knight Alzheimer's Disease Research Center"@en,
        "Knight Alzheimer’s Disease Research Center"@en,
        "Pathology and Immunology"@en,
        "The Alzheimer’s Disease and Memory Disorders Center"@en,
        "The Knight Alzheimer’s Disease Research Center, Department of Neurology"@en,
        "The Rehabilitation Institute of St. Louis"@en,
        "Washington University School of Medicine"@en .

ns192:JAD190322 ns0:hasName "Department of Pharmacology & Neuroscience; Institute for Healthy Aging"@en,
        "University of North Texas Health Sciences Center"@en .

ns192:JAD190339 ns0:hasName "Brain Center"@en,
        "Department of Neurology"@en,
        "Sackler Faculty of Medicine"@en .

ns192:JAD190344 ns0:hasName "Alzheimer Center & Department of Neurology"@en,
        "Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer Center and Department of Neurology"@en,
        "Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer Center, Department of Neurology"@en,
        "Alzheimer Centre & Department of Neurology"@en,
        "Alzheimer Centre and Department of Neurology"@en,
        "Alzheimer Centre and Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer center & Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer center and Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Amsterdam UMC"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Alzheimer Centre"@en,
        "Department of Old Age Psychiatry"@en,
        "Departments of Neurology"@en,
        "Neurology and Alzheimer Center, Neuroscience Campus Amsterdam"@en .

ns192:JAD190604 ns0:hasName "Department of Anatomy and Neurobiology; Molecular & Structural Biology Program, Greenebaum Cancer Center"@en,
        "Department of Pharmaceutical Sciences"@en .

ns192:JAD190775 ns0:hasName "Normal Pressure Hydrocephalus Center"@en .

ns192:JPD181518 ns0:hasName "Department of Neurology"@en .

ns192:JPD191610 ns0:hasName "Barrow Neurological Institute"@en,
        "Lonnie and Muhammad Ali Movement Disorder Center, Department of Neurology"@en .

ns192:JPD191675 ns0:hasName "Institute of Agrobiological Sciences"@en .

ns199:BLC190209 ns0:hasName "Institute of Cancer and Genomic Sciences"@en,
        "Institute of Cancer and Genomic Sciences, College of Medical and Dental Sciences"@en,
        "The Institute of Cancer and Genomic Sciences"@en,
        "University Hospital Birmingham"@en .

ns199:CH180402 ns0:hasName "Suleyman Demirel University"@en .

ns199:CH180428 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesiology and Intensive Care"@en,
        "Department of Anaesthesiology, Perioperative Medicine and Intensive Care"@en .

ns199:CH199005 ns0:hasName "Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Helmholtz Virtual Institute – Multifunctional Biomaterials for Medicine"@en,
        "Institute of Biomaterial Science"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Chemistry"@en,
        "Institute of Chemistry and Biochemistry"@en .

ns199:JAD180630 ns0:hasName "Charles University Prague"@en,
        "National Institute of Mental Health"@en .

ns199:JAD180932 ns0:hasName "Department of Orthopedic Surgery"@en .

ns199:JAD180966 ns0:hasName "AP-HP"@en,
        "Alzheimer Institute, Research and Resource Memory Centre, AP-HP"@en,
        "CNR-MAJ (Reference Center for Early-Onset Alzheimer’s Disease and Related Disorders)"@en,
        "CNRS, UMR 7225"@en,
        "CRICM"@en,
        "CRICM UPMC Inserm UMR 975 Pitié-Salpêtrière Hospital"@en,
        "Centre de Référence Démence Rares"@en,
        "Centre de Référence des Démences Rares"@en,
        "Centre des Maladies Cognitives et Comportementales (IM2A), Institut du Cerveau et de la Moelle épinière (ICM), UMR-S975"@en,
        "Centre of excellence of neurodegenerative disease (CoEN), ICM, CIC Neurosciences, APHP Department of Neurology, Hopital Pitié-Salpêtrière"@en,
        "Département de Neurologie"@en,
        "Département de Neurologie, AP-HP"@en,
        "Département de Neurologie, Institut de la Mémoire et de la Maladie d’Alzheimer"@en,
        "Département des maladies du système nerveux"@en,
        "INSERM U 1127, CNRS UMR 7225, Sorbonne Universités, and Université Pierre et Marie Curie-Paris 6, UMR S 1127"@en,
        "INSERM U610"@en,
        "Institut de la Mémoire et de la Maladie d’Alzheimer"@en,
        "Institut de la Mémoire, INSERM U1127, ICM"@en,
        "Institut du Cerveau et de la Moelle Epinière"@en,
        "Institut du Cerveau et de la MoelleÉpinière (ICM)"@en,
        "Institute for Memory and Alzheimer's Disease, ICM, UMR-S975, AP-HP, Pitié-Salpêtrière Hospital Group"@en,
        "Institute for Memory and Alzheimer’s disease (IM2A) and ICM, Salpêtrière University Hospital"@en,
        "Institute of Memory and Alzheimer’s Disease (IM2A), UMR S1127, AP-HP, Pitié-Salpêtrière University Hospital"@en,
        "Pierre et Marie Curie University"@en,
        "Research and Resource Memory Centre"@en,
        "Société Française de Neurologie"@en,
        "Sorbonne Universities"@en,
        "Sorbonne Université, Inserm, CNRS"@en,
        "Sorbonne Universités"@en,
        "UPMC Univ Paris06"@en,
        "Université Pierre et Marie Curie"@en .

ns199:JAD181196 ns0:hasName "Department of Epidemiology & Biostatistics, Schulich Interfaculty Program in Public Health"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Geriatric Medicine, Division of Geriatric Medicine"@en,
        "Department of Medicine, Division of Geriatric Medicine, Parkwood Hospital"@en,
        "Department of Medicine, Division of Geriatric Medicine, Schulich School of Medicine and Dentistry"@en,
        "Departments of Medicine (Geriatric Medicine), and Epidemiology and Biostatistics, Schulich School of Medicine & Dentistry"@en,
        "Gait and Brain Lab, Parkwood Institute"@en,
        "Lawson Health Research Institute"@en,
        "“Gait and Brain Lab”"@en .

ns199:JAD190028 ns0:hasName "Department of Neurological Surgery"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Neurotherapeutics"@en,
        "Department of Neurology and Neurotherapeutics, Alzheimer's Disease Center"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry, Alzheimer's Disease Center"@en,
        "Departments of Neurology and Neurotherapeutics"@en,
        "Departments of Psychiatry"@en .

ns199:JAD190152 ns0:hasName "CNC.IBILI"@en,
        "CNC.IBILI Consortium"@en,
        "Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine"@en .

ns199:JAD190154 ns0:hasName "Department of Psychiatry"@en,
        "Knight Alzheimer Disease Research Center"@en .

ns199:JAD190334 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine – Neurology, Universityof Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "Neuro Center"@en,
        "Neurology of NeuroCenter"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

ns199:JAD190399 ns0:hasName "Department of Neuropsychiatry"@en .

ns199:JAD190524 ns0:hasName "Centre for Clinical Epidemiology and Biostatistics"@en,
        "Department of Medicine"@en,
        "School of Medicine and Public Health"@en,
        "University of Newcastle and Hunter Medical Research Institute"@en .

ns199:JAD190549 ns0:hasName "APHM"@en,
        "Aix Marseille Univ"@en,
        "Department of Neurology and Neuropsychology University Hospital la Timone"@en,
        "Département de Neurologie et de Neuropsychologie"@en,
        "Neurology and Neuropsychology Department and CMMR PACA Ouest"@en .

ns199:JAD190610 ns0:hasName "Department of Epidemiology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Department of Radiology and Nuclear Medicine"@en,
        "Department of Radiology and Nuclear medicine"@en,
        "Memory Ageing and Cognition Center (MACC)"@en,
        "Memory Aging & Cognition Centre"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en,
        "Saw Swee Hock School of Public Health"@en .

ns199:JAD190622 ns0:hasName "Center for Comprehensive Care and Research on Memory Disorders"@en,
        "Department of Cognition and Behavior Science"@en .

ns199:JAD190628 ns0:hasName "Beijing Geriatric Medical Research Center"@en,
        "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en,
        "PKU Care Rehabilitation Hospital"@en .

ns199:JAD190634 ns0:hasName "Department of Pharmacology & Neuroscience; Institute for Healthy Aging"@en,
        "Department of Pharmacology and Neuroscience, Graduate School of Biomedical Sciences"@en,
        "University of North Texas Health Sciences Center"@en .

ns199:JAD190707 ns0:hasName "Department of Internal Medicine"@en,
        "Department of Internal Medicine, Division of Geriatric Medicine"@en,
        "Division of Geriatric Medicine"@en,
        "Geriatric Research Education and Clinical Center (GRECC)"@en .

ns199:JHD190346 ns0:hasName "Department of Psychiatry"@en,
        "Research Service"@en .

ns199:RNN190926 ns0:hasName "Department of Dermatology"@en,
        "DermatologyThe First Hospital of China Medical University"@en,
        "Key Laboratory of Immunodermatology"@en .

ns199:WOR192947 ns0:hasName "Department of Surgery"@en,
        "Institute of Biomaterials and Biomedical Engineering"@en,
        "Rehabilitation Sciences InstituteUniversity of Toronto"@en,
        "Toronto Rehabilitation Institute"@en,
        "iDAPT Technology R & D Team"@en .

ns199:XST190503 ns0:hasName "Cancer Center"@en,
        "Department of Radiation Oncology"@en,
        "Department of Radiology, School of Medicine, College of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:BLC190209> ns0:hasName "Institute of Cancer and Genomic Sciences"@en,
        "The Institute of Cancer and Genomic Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD181265> ns0:hasName "Department of Community Medicine and Rehabilitation, Geriatric Medicine"@en,
        "Department of Community Medicine and Rehabilitation, Physiotherapy"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD181282> ns0:hasName "Center for Biomedical Image Computing and Analytics"@en,
        "Department of Radiology, Center for Biomedical Image Computing and Analytics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD190077> ns0:hasName "Clinical Neurochemistry Lab"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Lab, The Sahlgrenska Academy at"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the"@en,
        "Clinical Neurochemistry Laboratory, Inst. of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Psychiatry and Neurochemistry"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Neuropsychiatric Epidemiology Unit"@en,
        "The Sahlgrenska Academy at Göteborg University"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "The Sahlgrenska Academy at the University of Gothenburg"@en,
        "The Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences"@en,
        "University of Goteborg"@en,
        "the Sahlgrenska Academy at Göteborg University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD190154> ns0:hasName "Charles F. and Joanne Knight Alzheimer’s Disease Research Center"@en,
        "Department of Hope Center for Neurological Disorders"@en,
        "Department of Neurological Surgery"@en,
        "Department of Neurology"@en,
        "Department of Neurosurgery"@en,
        "Department of Radiology"@en,
        "Departments of Radiology and Neurological Surgery"@en,
        "Knight Alzheimer Disease Research Center"@en,
        "Knight Alzheimer’s Disease Research Center"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD190716> ns0:hasName "Center for Neuropsychological Research"@en,
        "Center for Neuropsychological Research, Institute of Neurology of the Policlinico Gemelli"@en,
        "Department of Gerontology, Neurosciences & Orthopedics"@en,
        "Institute of Neurology"@en,
        "Research Center for Neuropsychology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JHD190354> ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research"@en,
        "Department of Radiology"@en,
        "George-Huntington-Institute"@en,
        "Institute for Clinical Radiology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:NRE192778> ns0:hasName "Department of Geriatrics, Neuroscience and Orthopedics"@en,
        "Department of Geriatrics, Neurosciences and Orthopedics"@en,
        "Don Carlo Gnocchi Onlus Foundation"@en .

ns217:CH189907 ns0:hasName "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine’s, Faculty of Medicine"@en,
        "Department of Anesthesia"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Computer Science"@en,
        "Department of Immunology, Faculty of Medicine"@en,
        "Department of Microbiology and Immunology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Faculty of Medicine"@en,
        "Department of Physiology and Biophysics"@en,
        "Departments of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesiology, Pain Management and Perioperative Medicine"@en,
        "Departments of Microbiology and Immunology"@en,
        "Pain Management and Perioperative Management Dalhousie University"@en .

ns217:JAD181095 ns0:hasName "Alzheimer Center, Department of Neurology"@en,
        "Department of Neurology"@en,
        "Department of Neurology & Alzheimer Centre"@en,
        "Department of Neurology and Alzheimer Center"@en,
        "Department of Neurology and Alzheimer Centre"@en,
        "Department of Neurology, Alzheimer Center"@en .

ns217:JAD181175 ns0:hasName "Department of Neurology"@en,
        "Departments of Psychiatry"@en .

ns217:JAD190077 ns0:hasName "Clinical Neurochemistry Laboratory"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute at UCL"@en .

ns217:JAD190094 ns0:hasName "Centre for Medicine Use and Safety, Faculty of Pharmacy and Pharmaceutical Sciences"@en,
        "Clinical Pharmacology and Geriatric Pharmacotherapy Unit, School of Pharmacy, Faculty of Health Sciences"@en,
        "Department of Epidemiology and Preventive Medicine, Faculty of Medicine, Nursing and Health Sciences"@en,
        "Kuopio Research Centre of Geriatric Care"@en,
        "NHMRC Cognitive Decline Partnership Centre"@en,
        "Quality Use of Medicines and Pharmacy Research Centre, School of Pharmacy and Medical Sciences, Sansom Institute"@en,
        "Sansom Institute"@en .

ns217:JAD190133 ns0:hasName "Helsinki University Hospital and University of Helsinki;"@en,
        "University of Oulu"@en .

ns217:JAD190154 ns0:hasName "Department of Psychology"@en,
        "Knight Alzheimer Disease Research Center"@en .

ns217:JAD190620 ns0:hasName "Department of Functional Brain Imaging Research, Clinical Research Cluster, National Institute of Radiological Sciences"@en .

ns217:JAD190634 ns0:hasName "Department of Pharmacology"@en,
        "Department of Pharmacology and Neuroscience"@en,
        "Department of Pharmacology and Neuroscience, Graduate School of Biomedical Sciences"@en,
        "Institute for Aging & Alzheimer's Disease Research"@en,
        "Institute of Aging and Alzheimer's Disease Research"@en .

ns217:JAD190707 ns0:hasName "Department of Internal Medicine"@en,
        "Department of Internal Medicine, Division of Geriatric Medicine"@en,
        "Department of Internal Medicine, Division of Geriatrics"@en,
        "Division of Geriatric Medicine"@en,
        "GRECC"@en,
        "GRECC - Geriatric Research, Education and Clinical Center"@en,
        "Geriatric Research Education and Clinical Center (GRECC)"@en,
        "Geriatric Research Educational and Clinical Center (GRECC)"@en,
        "Research & Development Service"@en,
        "Research and Development Service"@en,
        "Saint Louis University School of Medicine"@en,
        "Veterans Affairs Medical Center-St. Louis"@en .

ns217:JHD190346 ns0:hasName "Department of Psychiatry"@en,
        "Psychology Service"@en,
        "Research Service"@en .

ns231:CH189907 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesiology and Intensive Care"@en,
        "Department of Anaesthesiology and Intensive Care, University Hospital Hradec Kralove"@en,
        "Department of Anaesthesiology, Perioperative Medicine and Intensive Care"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anaesthesia, Pain Management and Perioperative Medicine"@en .

ns231:JAD181095 ns0:hasName "Alzheimer Center"@en,
        "Alzheimer Center & Department of Neurology"@en,
        "Alzheimer Center & Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer Center Amsterdam, Department of Neurology, Amsterdam Neuroscience"@en,
        "Alzheimer Center and Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer Center, Department of Neurology"@en,
        "Alzheimer Centre and Department of Neurology"@en,
        "Alzheimer Centre and Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Alzheimer center & Department of Neurology, Neuroscience Campus Amsterdam"@en,
        "Department of Neurology and Alzheimer Center"@en,
        "Department of Neurology and Alzheimer Centre"@en,
        "Department of Neurology, Alzheimer Center"@en,
        "Department of Neurology, Alzheimer’s Center"@en,
        "Department of Neurology/Alzheimer Center"@en,
        "Department of Psychiatry and Neuropsychology"@en,
        "Neurology, Alzheimer Center"@en .

ns231:JAD181259 ns0:hasName "Department of Neurosciences and Biomedical Technologies."@en,
        "Milan Center for Neuroscience"@en,
        "Neurology Unit"@en,
        "Ospedale San Gerardo"@en,
        "School of Medicine and Surgery and Milan Center for Neuroscience (NeuroMI)"@en,
        "Scientific Institute E. Medea"@en .

ns231:JAD190161 ns0:hasName "Alzheimer’s Disease Center"@en,
        "Boston University School of Medicine"@en,
        "Department of Alzheimer's Disease Center"@en,
        "Department of Pharmacology & Experimental Therapeutics"@en,
        "Department of Psychiatry"@en,
        "Departments of Pharmacology & Experimental Therapeutics"@en,
        "Departments of Pharmacology & Experimental Therapeutics, Psychiatry"@en,
        "Departments of Pharmacology and Experimental Therapeutics"@en,
        "Departments of Psychiatry"@en,
        "Pharmacology and Experimental Therapeutics"@en .

ns231:JAD190319 ns0:hasName "Department of Medicine, Peninsula Clinical School, Central Clinical School"@en,
        "Department of Medicine, Stroke and Ageing Research Group, School of Clinical Sciences at Monash Health"@en,
        "Menzies Institute for Medical Research"@en .

ns231:JAD190401 ns0:hasName "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

ns231:JAD190620 ns0:hasName "Department of Functional Brain Imaging Research, Clinical Research Cluster, National Institute of Radiological Sciences"@en,
        "Molecular Imaging Center"@en,
        "National Institutes for Quantum and Radiological Science and Technology"@en .

ns259:IFS190565 ns0:hasName "Department of Mathematics"@en,
        "Department of Mathematics Education"@en,
        "Department of Mathematics Education and RINS"@en .

ns259:NHA190068 ns0:hasName "Division of Epidemiology and Biostatistics, University of Illinois at Chicago, Chicago, IL and Faculty of Health Sciences"@en,
        "Faculty of Health Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:10.ID:JAD180511> ns0:hasName "Faculty of Medicine"@en,
        "Faculty of Medicine, Universiti Teknologi Mara"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:10.ID:JAD180763> ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "Centre for Research on Ageing, Health and Wellbeing, Research School of Population Health"@en,
        "Centre for Research on Ageing, Health andWellbeing, Research School of Population Health"@en,
        "Dementia Collaborative Research Centre – Early Diagnosis and Prevention, Research School of Population Health"@en,
        "Neuroscience Research Australia"@en,
        "Neuroscience Research Australia (NeuRA)"@en,
        "School of Psychology"@en,
        "The Australian National University"@en,
        "UNSW Ageing Futures Institute"@en,
        "University of New South Wales"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:12.ID:JAD190272> ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychiatry and Neuropathobiology, Faculty of Life Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:13.ID:JAD190446> ns0:hasName "Clinical Neuroscience Unit, Department of Neurology"@en,
        "Department for Neurodegenerative Diseases and Geriatric Psychiatry"@en,
        "Department of Neurology"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Center for Neurodegenerative Diseases, DZNE"@en,
        "Neurology Department"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:14.ID:JAD190113> ns0:hasName "Department of Neurology, Xuanwu Hospital"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:14.ID:JAD190533> ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation Perth"@en,
        "Centre for Aging and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Clinical Research in Neuropsychiatry, Graylands Hospital"@en,
        "Centre for Neuromuscular and Neurological Disorders"@en,
        "Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care; The Sir James McCurker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre for Ageing and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence in Alzheimer’s Disease Research and Care, School of Medical Sciences"@en,
        "Department of Biomedical Sciences"@en,
        "KARVIAH Research Centre"@en,
        "KaRa Institute of Neurological Disease"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "McCusker Foundation for Alzheimer's Disease Research"@en,
        "McCusker Foundation for Alzheimer's Disease Research Inc"@en,
        "School of Biomedical Science"@en,
        "School of Biomedical Sciences"@en,
        "School of Exercise, Biomedical and Health Sciences"@en,
        "School of Medical Health and Sciences"@en,
        "School of Medical Sciences"@en,
        "School of Medical SciencesEdith Cowan University"@en,
        "School of Medical and Health Sciences"@en,
        "School of Psychiatry & Clinical Neurosciences"@en,
        "School of Psychiatry and Clinical Neuroscience"@en,
        "School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit, School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer’s Disease Research Unit"@en,
        "The CRC for Mental Health"@en,
        "The McCusker Alzheimer’s Research Foundation"@en,
        "The School of Exercise, Biomedical and Health Science"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit, School of Exercise, Biomedical and Health Sciences"@en,
        "The University of British ColumbiaUniversity of Western Australia"@en,
        "The University of Western AustraliaEdith Cowan University"@en .

ns131:JAD180949 ns0:hasName "DZNE"@en,
        "Department for Neurodegenerative Diseases and Geriatric Psychiatry"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Center for Neurodegenerative Disorders (DZNE, Bonn)"@en .

ns131:JAD190087 ns0:hasName "Department of Nephrology, School of Medicine"@en .

ns138:JAD181173 ns0:hasName "Falls, Balance and Injury Research Centre, Neuroscience Research Australia"@en,
        "School of Public Health and Community Medicine"@en,
        "School of Public Health and Community Medicine, Faculty of Medicine"@en .

ns138:JAD190010 ns0:hasName "Biostatistics"@en,
        "Department of Biostatistics"@en,
        "Division of Biostatistics, Department of Medicine"@en,
        "Indiana Alzheimer Disease Center"@en .

ns138:JAD190261 ns0:hasName "Department of Alzheimer's Disease Center"@en,
        "Department of Anatomy & Neurobiology, Neurology and Epidemiology"@en,
        "Department of Anatomy & Neurobiology, Neurology, & Epidemiology"@en,
        "Department of Anatomy and Neurobiology"@en,
        "Department of Biostatistics"@en,
        "Department of Epidemiology"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Boston"@en,
        "Departments of Anatomy and Neurobiology"@en,
        "Departments of Anatomy and Neurobiology, Neurology and Epidemiology, Schools of Medicine and Public Health"@en,
        "Framingham Heart Study"@en,
        "Neurology"@en,
        "The National Heart, Lung, and"@en .

ns138:JAD190533 ns0:hasName "Department of Biomedical Sciences"@en,
        "KaRa Institute of Neurological Disease"@en,
        "School of Medical Health and Sciences"@en,
        "School of Psychiatry and Clinical Neurosciences"@en .

ns138:JAD190538 ns0:hasName "Department of Behavioral Sciences"@en,
        "Department of Neurological Sciences"@en,
        "Rush Alzheimer’s Disease Center"@en .

ns138:JAD190645 ns0:hasName "Alzheimer’s Disease Research Center"@en,
        "Medical Scientist Training Program"@en,
        "Medical Scientist and Neuroscience Training Programs"@en,
        "Neuroscience Training Program"@en .

ns138:JAD190721 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Department of Molecular Neuroscience"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute"@en,
        "UK Dementia Research Institute at UCL"@en .

ns138:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Geography"@en,
        "Department of Paediatrics"@en,
        "Human Environments Analysis Laboratory"@en,
        "Lawson Health Research Institute"@en,
        "School of Health Studies"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:26.ID:JAD190446> ns0:hasName "DZNE"@en,
        "Department for Neurodegenerative Diseases and Geriatric Psychiatry"@en,
        "Department of Neurodegenerative Diseases and Geriatric Psychiatry"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en .

ns184:JAD180572 ns0:hasName "Brain and Mind Centre"@en,
        "Healthy Brain Ageing Program, Ageing Brain Centre, Brain and Mind Centre"@en,
        "Parkinson’s Disease Research Clinic, Brain and Mind Centre"@en .

ns184:JAD190446 ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "German Center for Neurodegenerative Diseases"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Center for Neurodegenerative Diseases, DZNE"@en,
        "German Center for Neurodegenerative Disorders (DZNE, Bonn)"@en .

ns84:HAB190362 ns0:hasName "Department of Medical Genetics"@en,
        "Departments of Medical Genetics"@en,
        "Urogenital Stem Cell Research Center"@en .

ns84:HAB190363 ns0:hasName "School of Pharmacy, College of Health and Medical Sciences"@en .

ns84:HAB190367 ns0:hasName "School of Pharmacy, College of Health and Medical Sciences"@en .

ns84:ICA190605 ns0:hasName "Department of Radiology"@en .

ns84:IFS181502 ns0:hasName "Department of Mathematics and Computer Science"@en .

ns84:JAD180572 ns0:hasName "Brain and Mind Centre"@en,
        "School of Psychiatry"@en .

ns84:JAD181132 ns0:hasName "Centre for Population Health Research"@en,
        "Population, Policy and Practice, Great Ormond Street Institute of Child Health"@en .

ns84:JAD181277 ns0:hasName "Biobank"@en,
        "Biobank, Institute Born-Bunge"@en,
        "Department of Biomedical Sciences, Laboratory of Neurochemistry and Behavior"@en,
        "Department of Biomedical Sciences, Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Department of Health Care Sciences"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Alzheimer Research Center"@en,
        "Department of Neurology and Memory Clinic"@en,
        "Department of Neurology, Alzheimer Research Center"@en,
        "Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), and Biobank, Institute Born-Bunge"@en,
        "University of Groningen"@en .

ns84:JAD181295 ns0:hasName "Karolinska Institutet"@en,
        "National Institute for Health and Welfare"@en,
        "Public Health Solutions"@en,
        "University of Eastern Finland"@en .

ns84:JAD190133 ns0:hasName "Center for Life Course Health Research, Faculty of Medicine"@en,
        "Medical Research Center Oulu"@en,
        "Oulu City Hospital"@en .

ns84:JAD190183 ns0:hasName "EA 4607 SNA- EPIS PRES Lyon"@en,
        "Public Health and Medical Information Unit"@en .

ns84:JAD190197 ns0:hasName "Department of Biology"@en,
        "Department of Pharmacobiology"@en,
        "Department of Physiology and Pharmacology"@en,
        "IRCCS Santa Lucia Foundation"@en,
        "IRCSS Santa Lucia Foundation"@en .

ns84:JAD190264 ns0:hasName "Avid Radiopharmaceuticals"@en,
        "University of Texas Southwestern Medical Center"@en .

ns84:JAD190293 ns0:hasName "Department of Molecular and Integrative Physiology"@en,
        "University of Kansas School of Medicine"@en .

ns84:JAD190440 ns0:hasName "Marcs Institute for Brain and Behaviour"@en,
        "School of Social Sciences and Psychology"@en,
        "School of Social Sciences and Psychology & Marcs Institute for Brain and Behaviour"@en .

ns84:JAD190518 ns0:hasName "Department Neurosciences, School of Medicine"@en,
        "Department of Neuroscience"@en,
        "Department of Neurosciences"@en,
        "Department of Pathology"@en,
        "Department of Pathology, School of Medicine"@en,
        "Departments of Neurosciences and Pathology University of California San Diego"@en,
        "Division of Neurosciences"@en,
        "Division of Neurosciences and Molecular Neuropathology Section, Laboratory of Neurogenetics"@en,
        "Division of Neurosciences, National Institute on Aging"@en,
        "Laboratory of Neurogenetics"@en,
        "Molecular Neuropathology Section, Laboratory of Neurogenetics"@en .

ns84:JHD190365 ns0:hasName "Columbia University Medical Center"@en,
        "Department of Neurology"@en,
        "Taub Institute for Research on Alzheimer's Disease and the Aging Brain"@en .

ns84:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Paediatrics"@en,
        "Human Environments Analysis Laboratory"@en,
        "Lawson Health Research Institute"@en,
        "School of Food and Nutritional Sciences"@en .

ns84:NRE192745 ns0:hasName "Université Catholique de Louvain"@en,
        "Université catholique de Louvain"@en .

ns84:WOR192968 ns0:hasName "Department of Physiotherapy, School of Health and Rehabilitation Sciences"@en,
        "Division of Physiotherapy"@en,
        "RECOVER Injury Research Centre"@en,
        "RECOVER Injury Research Centre, Faculty of Health and Behavioural Sciences"@en,
        "School of Health and Rehabilitation Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:30.ID:JAD190446> ns0:hasName "Department of Psychiatry"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en .

ns87:CH180428 ns0:hasName "Dalhousie University"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine’s, Faculty of Medicine"@en,
        "Department of Anesthesia"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Computer Science"@en,
        "Department of Immunology, Faculty of Medicine"@en,
        "Department of Microbiology and Immunology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Faculty of Medicine"@en,
        "Department of Pharmacology, Microbiology and Immunology"@en,
        "Department of Physiology and Biophysics"@en,
        "Departments of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesiology, Pain Management and Perioperative Medicine"@en,
        "Departments of Microbiology and Immunology"@en,
        "Pain Management and Perioperative Management Dalhousie University"@en .

ns87:CH199218 ns0:hasName "Center for Plastic, Aesthetic, Hand &Reconstructive Surgery"@en,
        "Center of Plastic, Aesthetic, Hand and Reconstructive Surgery"@en,
        "Department of Otorhinolaryngology"@en,
        "Department of Surgery, Hagey Laboratory for Pediatric Regenerative Medicine"@en .

ns87:HAB190371 ns0:hasName "The National Center for Addiction Studies (INCAS); Tehran University of Medical Sciences (TUMS); Family and Sexual Health Division, Brian and Spinal Injury Research Center (BASIR), Neuroscience Institution"@en .

ns87:IFS181742 ns0:hasName "Department of Mathematics"@en .

ns87:IFS190565 ns0:hasName "Department of Mathematics"@en .

ns87:JAD181030 ns0:hasName "Aging Research Center"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS), Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health"@en .

ns87:JAD181110 ns0:hasName "Department of Pathology"@en,
        "Department of Pathology, Division of Neuropathology"@en,
        "Departments of Pathology"@en,
        "Sanders-Brown Center on Aging"@en,
        "University of Kentucky"@en,
        "University of Kentucky Alzheimer's Disease Center"@en .

ns87:JAD181169 ns0:hasName "School of Physiotherapy and Exercise Science"@en .

ns87:JAD181203 ns0:hasName "Department of Health Sciences Research"@en,
        "Department of Health Sciences Research, Division of Epidemiology"@en,
        "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Behavioral Sciences, School of Medicine"@en,
        "Department of Psychiatry, Division of Geriatric Psychiatry and Neuropsychiatry"@en,
        "Departments of Neurology and Health Sciences Research"@en,
        "Division of Epidemiology, Department of Health Sciences Research"@en,
        "Division of Epidemiology, Department of Health Sciences Research, and the Department of Neurology"@en .

ns87:JAD181256 ns0:hasName "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine–Neurology"@en,
        "Neuro Center"@en,
        "Neuro Center, Neurology"@en .

ns87:JAD190011 ns0:hasName "Department of Neurological Sciences"@en,
        "Department of Pathology"@en,
        "Department of Pathology (Neuropathology)"@en,
        "Departments of Pathology and Neurological Sciences, and Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer’s Disease Center"@en,
        "Rush University Medical Center"@en .

ns87:JAD190091 ns0:hasName "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "University of Pittsburgh School of Medicine"@en .

ns87:JAD190187 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Department of Molecular Neuroscience"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute"@en,
        "UK Dementia Research Institute at UCL"@en .

ns87:JAD190262 ns0:hasName "Department of Epidemiology and Population Health"@en,
        "Department of Epidemiology and Population Health, Albert Einstein College of Medicine"@en,
        "Einstein Aging Study"@en,
        "Saul B. Korey Department of Neurology"@en .

ns87:JAD190327 ns0:hasName "Department of Geriatric Medicine"@en,
        "Norwegian Advisory Unit for Ageing and Health"@en,
        "Norwegian National Advisory Unit on Ageing and Health (Ageing and Health)"@en .

ns87:JAD190334 ns0:hasName "Department of Neurology"@en,
        "Institute of Biomedicine"@en .

ns87:JAD190342 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "Centre for Research on Ageing, Health and Wellbeing, Research School of Population Health"@en,
        "Centre for Research on Ageing, Health andWellbeing, Research School of Population Health"@en,
        "Dementia Collaborative Research Centre – Early Diagnosis and Prevention, Research School of Population Health"@en,
        "Neuroscience Research Australia"@en,
        "Neuroscience Research Australia (NeuRA)"@en,
        "School of Psychology"@en,
        "The Australian National University"@en,
        "UNSW Ageing Futures Institute"@en,
        "University of New South Wales"@en .

ns87:JAD190533 ns0:hasName "Australian Alzheimer’s Research Foundation"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Cooperative Research Centre for Mental Health"@en,
        "Department of Biomedical Sciences"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "School of Psychiatry and Clinical Neurosciences"@en .

ns87:JAD190538 ns0:hasName "Department of Behavioral Sciences"@en,
        "Department of Neurological Sciences"@en,
        "Departments of Neurological Sciences and Behavioral Sciences, and Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer’s Disease Center"@en .

ns87:JAD190540 ns0:hasName "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Department of Radiology and Nuclear medicine"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en .

ns87:JAD190609 ns0:hasName "Bracco Medical Department"@en,
        "Villa Santa Maria"@en,
        "Villa Santa Maria Institute"@en .

ns87:JAD190610 ns0:hasName "Brain Center Rudolf Magnus, Department of Neurology"@en,
        "Department of Epidemiology"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Epidemiology"@en,
        "Department of Radiology"@en,
        "Departments of Epidemiology and Neurology"@en,
        "Departments of Epidemiology, Radiology, Neurology"@en,
        "Departments of Neurology and Epidemiology"@en,
        "Erasmus Medical Center"@en .

ns87:JAD190688 ns0:hasName "National Institute of Mental Health"@en .

ns87:JAD190708 ns0:hasName "Department of Neurology"@en,
        "Greater Los Angeles VA Healthcare System"@en,
        "V.A. Greater Los Angeles Healthcare System"@en .

ns87:JAD190898 ns0:hasName "Aging Research Center"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet"@en,
        "Alzheimer Disease Research Center, Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Department NVS, Karolinska Institute"@en,
        "Department of Geriatric Medicine"@en,
        "Department of Neurobiology, Care Science and Society, Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS), Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Center for Alzheimer Research, Division for Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics"@en,
        "Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society"@en,
        "KI-Alzheimer Disease Research Center"@en,
        "KI-Alzheimer Disease Research Center (KI-ADRC)"@en,
        "KI-Alzheimer's Disease Research Center"@en,
        "Karolinska Institute"@en,
        "Karolinska Institutet"@en,
        "Karolinska Institutet – Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet, Dept NVS"@en,
        "Karolinska University Hospital"@en,
        "Section for Geriatric Medicine, NEUROTEC"@en,
        "Stockholm Gerontology Research Center"@en,
        "Theme Aging"@en .

ns87:JVR191022 ns0:hasName "University of Wisconsin-Madison"@en .

ns87:NRE192745 ns0:hasName "Institute of NeuroscienceUniversity of Louvain"@en,
        "Neuro Musculo Skeletal Lab (Brussels), Faculté des Sciences de la Motricité"@en,
        "Université Catholique de Louvain"@en .

ns87:PPR190137 ns0:hasName "Orthopaedic Clinical Research Unit, Maisonneuve-Rosemont Hospital Research Center"@en,
        "School of Rehabilitation, Faculty of Medicine"@en .

ns87:THC199015 ns0:hasName "Department of Life Science"@en .

ns87:XST190491 ns0:hasName "Center for Diagnostic Nuclear Imaging, Faculty of Medicine"@en,
        "Department of Physics, Faculty of Science"@en .

ns195:JAD190052 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Department of Medicine, Section of Geriatrics and Gerontology"@en,
        "Department of Veterans Affairs (VA) Geriatric Research"@en,
        "GRECC, William S. Middleton Memorial Veterans Hospital and Department of Medicine"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "Wisconsin Alzheimer's Institute"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns195:JAD190090 ns0:hasName "Department of Family Medicine"@en,
        "Department of Neurological Sciences"@en .

ns195:JAD190154 ns0:hasName "Alzheimer Disease Research Center"@en,
        "Alzheimer's Disease Research Center"@en,
        "Charles F. and Joanne Knight Alzheimer Disease Research Center"@en,
        "Charles F. and Joanne Knight Alzheimer’s Disease Research Center"@en,
        "Department of Immunology"@en,
        "Department of Neurology"@en,
        "Department of Neurology and Alzheimer's Disease Research Center"@en,
        "Department of Neurology, Department of Pathology and Immunology"@en,
        "Department of Occupational Therapy"@en,
        "Department of Pathology"@en,
        "Department of Pathology and Immunology"@en,
        "Department of Physical Therapy"@en,
        "Department of Radiology"@en,
        "Departments of Neurology and of Pathology and Immunology"@en,
        "Departments of Neurology, Pathology and the Alzheimer's Disease Research Center"@en,
        "Hope Center for Neurological Disorders"@en,
        "Knight Alzheimer Disease Research Center"@en,
        "Knight Alzheimer's Disease Research Center"@en,
        "Knight Alzheimer’s Disease Research Center"@en,
        "Pathology and Immunology"@en,
        "The Alzheimer’s Disease and Memory Disorders Center"@en,
        "The Knight Alzheimer’s Disease Research Center, Department of Neurology"@en,
        "The Rehabilitation Institute of St. Louis"@en,
        "Washington University School of Medicine"@en .

ns195:JAD190165 ns0:hasName "Departments of Psychiatry and Neurology, Sanders-Brown Center on Aging"@en,
        "Stanford University and VA Palo Alto Health Care System"@en,
        "Stanford/VA Alzheimer Center"@en,
        "War-Related Illness and Injury Study Center, VA Palo Alto Health Care System and Department of Psychiatry & Behavioral Sciences"@en .

ns195:JAD190202 ns0:hasName "Brain Sciences Research Program"@en,
        "Brain Sciences Research Program, Sunnybrook Research Institute"@en,
        "Department of Medicine (Neurology)"@en,
        "Department of Medicine, Division of Neurology"@en,
        "Department of Medicine, Neurology"@en,
        "Heart & Stroke Foundation Canadian Partnership for Stroke Recovery"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute>"@en,
        "Institute of Medical Science"@en,
        "Institute of Medical Science, Department of Medicine (Neurology)"@en,
        "LC Campbell Cognitive Neurology Research Unit"@en,
        "LC Campbell Cognitive Neurology Research Unit, Brain Sciences Research Program"@en,
        "LC Campbell Cognitive Neurology Research Unit, Heart and Stroke Foundation Centre for Stroke Recovery"@en,
        "LC Campbell Cognitive Neurology Research Unit, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre"@en,
        "LC Campbell Cognitive Research Unit, Division of Neurology, Deparatment of Medicine, Sunnybrook Research Institute, Sunnybrook Health Sciences Centre"@en,
        "The Rotman Research Institute"@en,
        "University of Toronto"@en .

ns195:JAD190237 ns0:hasName "Department of Basic and Applied Biology"@en,
        "Sbarro Institute for Cancer Research and Molecular Medicine and Center for Biotechnology"@en .

ns195:JAD190262 ns0:hasName "Department of Epidemiology and Population Health"@en,
        "Department of Epidemiology and Population Health, Albert Einstein College of Medicine"@en,
        "Department of Neurology, Albert Einstein College of Medicine"@en,
        "Einstein Aging Study"@en,
        "Institute for Aging Research, Albert Einstein College of Medicine"@en,
        "Saul B. Korey Department of Neurology"@en .

ns195:JAD190331 ns0:hasName "Department of Mathematics"@en,
        "Indian Statistical Institute"@en,
        "Mathematics Department"@en .

ns195:JAD190414 ns0:hasName "Chronic Diseases Research Center, NOVA Medical School"@en,
        "Chronic Diseases Research Centre, NOVA Medical School"@en .

ns195:JAD190688 ns0:hasName "Alzheimer’s Disease Research Center, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "International Clinical Research Center and St.Anne‘s University Hospital"@en,
        "National Institute of Mental Health"@en .

ns195:JAD190888 ns0:hasName "Department of Neuropsychology"@en .

ns195:JHD190364 ns0:hasName "Department of Psychiatry, Neurology and Psychological and Brain Sciences, Carver College of Medicine"@en,
        "Departments of Psychiatry, Neurology, and Psychology, Carver College of Medicine"@en .

ns195:JVR191022 ns0:hasName "University of Wisconsin – Madison"@en,
        "University of Wisconsin-Madison"@en .

ns195:JVR191023 ns0:hasName "College of Rehabilitation Medicine"@en,
        "Department of Psychiatry"@en,
        "Fujian Key Laboratory of Rehabilitation Technology"@en,
        "Fujian University of Traditional Chinese Medicine"@en .

ns195:MGS190313 ns0:hasName "School of Engineering"@en .

ns195:NRE192745 ns0:hasName "Université Catholique de Louvain"@en,
        "Université catholique de Louvain"@en .

ns102:BMR170948 ns0:hasName "Department of Spine Disorders and Pediatric Orthopedics"@en,
        "University of Medical Sciences"@en .

ns102:CH180428 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesiology and Intensive Care"@en,
        "Department of Anaesthesiology, Perioperative Medicine and Intensive Care"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en .

ns102:HAB190372 ns0:hasName "Department of Microbial Biotechnology"@en,
        "Microbial Biotechnology"@en,
        "Microbial Biotechnology Department"@en .

ns102:JAD190023 ns0:hasName "Department of Neurology"@en .

ns102:JAD190152 ns0:hasName "CNC.IBILI Consortium"@en,
        "Coimbra Institute for Clinical and Biomedical Research (iCBR), Faculty of Medicine"@en,
        "Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine"@en .

ns102:JAD190161 ns0:hasName "Commen Subjects Department"@en,
        "Department of Histology and Embriology"@en .

ns102:JAD190306 ns0:hasName "Brain and Ageing Research Program, School of Psychiatry"@en,
        "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry, Faculty of Medicine"@en,
        "Centre for Healthy Brain Aging"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Centre for Healthy Brain and Ageing"@en,
        "Dementia Centre for Research Collaboration"@en,
        "Department of Neuropsychiatry"@en,
        "Neuropsychiatric Institute"@en,
        "Neuropsychiatric Institute (NPI)"@en,
        "Primary Dementia Collaborative Research Centre"@en,
        "Prince of Wales Research Institute and Centre for Healthy Brain Aging"@en,
        "School of Medicine"@en,
        "School of Psychiatry"@en .

ns102:JAD190322 ns0:hasName "Alzheimer’s Disease Cooperative Study"@en,
        "Department of Neuroscience, School of Medicine at UCSD"@en,
        "Department of Neurosciences"@en,
        "Shiley-Marcos Alzheimer’s Disease Research Center"@en,
        "University of California"@en .

ns102:JAD190459 ns0:hasName "Brain Dynamics and Cognition"@en,
        "CMRR – Hospices Civils de Lyon, Inserm U1028, CNRS UMR5292"@en,
        "Centre Mémoire Ressources Recherche de Lyon"@en,
        "Claude Bernard University Lyon 1"@en,
        "Clinical Research Centre CRC - VCF (Vieillissement –Cerveau - Fragilité), Hospital of Charpennes"@en,
        "Clinical and Research Memory Center of Lyon"@en,
        "French Federation of Memory Centers"@en,
        "Hôpital Gériatrique des Charpennes"@en,
        "INSERM, U1028; CNRS"@en,
        "Institute of Aging I-Vie"@en,
        "Lyon University Hospital"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Aging Institute I-Vie"@en,
        "Memory Clinical and Research Center of Lyon (CMRR), Hospital of Charpennes"@en,
        "Médecine Gériatrique"@en,
        "Neurobiologie, CMRR, Gériatrie, Hospices Civils de Lyon"@en .

ns102:JAD190567 ns0:hasName "Institute for Ageing and Health"@en,
        "The Evington Centre, Leicestershire Partnership NHS Trust"@en .

ns102:JAD190628 ns0:hasName "Beijing Geriatric Medical Research Center"@en,
        "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en,
        "PKU Care Rehabilitation Hospital"@en .

ns102:JAD190772 ns0:hasName "Aberdeen Biomedical Imaging Center"@en,
        "Aberdeen Biomedical Imaging Centre, School of Medicine, Medical Sciences and Nutrition"@en .

ns102:JAD190838 ns0:hasName "Department of Nuclear Medicine, Hospital Clínico San Carlos"@en,
        "Department of Nuclear Medicine, Hospital Clínico San Carlos, San Carlos Health Research Institute (IdISSC)"@en,
        "Department of Nuclear Medicine. Hospital Clinico San Carlos"@en .

ns102:JHD180337 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research"@en,
        "Department of Radiology"@en,
        "George-Huntington-Institute"@en .

ns102:RNN190926 ns0:hasName "Department of Dermatology"@en,
        "Key Laboratory of Immunodermatology"@en .

ns102:WOR192947 ns0:hasName "Department of Surgery"@en,
        "Institute of Biomaterials and Biomedical Engineering"@en,
        "Rehabilitation Sciences InstituteUniversity of Toronto"@en,
        "Toronto Rehabilitation Institute"@en,
        "iDAPT Technology R & D Team"@en .

ns102:XST190503 ns0:hasName "Cancer Center"@en,
        "Department of Radiation Oncology"@en,
        "Department of Radiology, School of Medicine, College of Medicine"@en,
        "Taipei Cancer Center"@en .

ns88:HAB190384 ns0:hasName "Department of Biology, Arsanjan Branch"@en,
        "Department of Biology, Tonekabon Branch"@en,
        "Department of Medical Genetics"@en,
        "Department of Medical Genetics, Faculty of Medicine"@en,
        "Department of Medical Genetics, School of Medicine"@en,
        "Department of Medical Genetics, School of Medicine Sciences"@en,
        "Departments of Medical Genetics"@en,
        "Genetic Research Center"@en,
        "Genetics of Non Communicable Disease Research Center"@en,
        "Shahid Beheshti University of Medical Sciences"@en,
        "Student Research Committee"@en,
        "Urogenital Stem Cell Research"@en,
        "Urogenital Stem Cell Research Center"@en,
        "Urogenital Stem Cell Research Center, Shahid Labbafi Nejad Educational Hospital"@en .

ns88:JAD181113 ns0:hasName "Arizona Alzheimer's Consortium"@en,
        "Banner Sun Health Research Institute"@en,
        "Civin Laboratory for Neuropathology"@en,
        "Civin Laboratory of Neuropathology"@en,
        "Civin Laboratory of Neuropathology at Banner Sun Health Research Institute"@en .

ns88:JAD181168 ns0:hasName "Department of Nuclear Medicine"@en,
        "Institute of Neuroscience"@en .

ns88:JAD181212 ns0:hasName "Department of Psychiatry and Behavioral Science"@en,
        "Geriatric Research, Education, and Clinical Center"@en,
        "VA Puget Sound Health Care System"@en .

ns88:JAD190077 ns0:hasName "Clinical Neurochemistry Lab"@en,
        "Clinical Neurochemistry Lab, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Lab, The Sahlgrenska Academy at"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, Sahlgrenska Academy at the"@en,
        "Clinical Neurochemistry Laboratory, Inst. of Neuroscience and Physiology"@en,
        "Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Psychiatry and Neurochemistry"@en,
        "Department of Psychiatry and Neurochemistry, Clinical Neurochemistry Laboratory, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Neuropsychiatric Epidemiology Unit"@en,
        "The Sahlgrenska Academy at Göteborg University"@en,
        "The Sahlgrenska Academy at University of Gothenburg"@en,
        "The Sahlgrenska Academy at the University of Gothenburg"@en,
        "The Torsten Söderberg Professorship in Medicine at the Royal Swedish Academy of Sciences"@en,
        "University of Goteborg"@en,
        "the Sahlgrenska Academy at Göteborg University"@en .

ns88:JAD190306 ns0:hasName "Aged Care Psychiatry"@en,
        "Center for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing"@en,
        "Centre for Healthy Brain Ageing and Dementia Collaborative Research Centre"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain and Ageing"@en,
        "Dementia Collaborative Research Centre"@en,
        "Dementia Collaborative Research Centre, School of Psychiatry"@en,
        "Primary Dementia Collaborative Research Centre"@en,
        "The University of New South Wales"@en .

ns88:JAD190426 ns0:hasName "Alzheimer Disease and Other Cognitive Unit"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona"@en,
        "Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Department"@en,
        "Alzheimer's disease and other cognitive disorders unit, Neurology Service"@en,
        "Alzheimer's disease and other cognitive disorders unit. IDIBAPS"@en,
        "Alzheimer’s Disease Unit and Other Cognitive Disorders Unit"@en,
        "Alzheimer’s Disease Unit and Other Cognitive Disorders Unit, Hospital Clínic de Barcelona, and"@en,
        "Alzheimer’s Disease and Other Cognitive Disorders Unit"@en,
        "Alzheimer’s Disease and Other Cognitive Disorders Unit, Hospital Clínic"@en,
        "Alzheimer’s Disease and Other Cognitive Disorders Unit, Neurology Service"@en,
        "Alzheimer’s disease and other cognitive disorders unit"@en,
        "Alzheimer’s disease and other cognitive disorders unit, Neurology Service"@en,
        "Barcelona Beta Brain Research Center"@en,
        "BarcelonaBeta Brain Research Center"@en,
        "Barcelonaβeta Brain Research Center"@en,
        "CIBER Fragilidad y Envejecimiento Saludable ("@en,
        "CIBER Fragilidad y Envejecimiento Saludable (CIBERFES)"@en,
        "Clinical Research Program"@en,
        "Clinical Research Program, Barcelonaβeta Brain Research Center"@en,
        "Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS)"@en,
        "Institut d'Investigació Biomédica August Pi i Sunyer (IDIBAPS)"@en,
        "Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)"@en .

ns88:JND190397 ns0:hasName "Department of Neurology, Institute of Neurological Sciences"@en .

ns88:JPD181518 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Department of Neurology"@en,
        "Department of Neurosciences"@en,
        "Department of Neurosciences, Shiley-Marcos Alzheimer’s Disease Research Center"@en,
        "Neurology Service"@en,
        "Shiley-Marcos Alzheimer’s Disease Research Center"@en,
        "University of California"@en,
        "Veterans Affairs San Diego Healthcare System"@en .

ns88:JPD191675 ns0:hasName "Department Neurosciences, School of Medicine"@en,
        "Department of Neurosciences"@en,
        "Department of Pathology"@en,
        "Department of Pathology, School of Medicine"@en,
        "Departments of Neurosciences and Pathology University of California San Diego"@en,
        "Division of Neurosciences"@en,
        "Division of Neurosciences and Molecular Neuropathology Section, Laboratory of Neurogenetics"@en,
        "Division of Neurosciences, National Institute on Aging"@en,
        "Molecular Neuropathology Section, Laboratory of Neurogenetics"@en .

ns88:XST180464 ns0:hasName "College of Engineering"@en,
        "Department of Biochemistry and Molecular Biology, School of Medicine"@en,
        "Department of Biochemistry, Medical School"@en,
        "Department of Electrical and Computer Engineering"@en,
        "Jiangsu Key Laboratory of Neuroregeneration"@en,
        "Jiangsu Key Laboratory of NeuroregenerationNantong University"@en,
        "Key Laboratory of Neuroregeneration of Jiangsu and Ministry of Education and Co-innovation Center of Neuroregeneration"@en,
        "Sino-Dutch Biomedical and Information Engineering School"@en .

ns216:BD180350 ns0:hasName "Department of Clinical Laboratory Medicine"@en,
        "Shiga University of Medical Science"@en .

ns216:CH189907 ns0:hasName "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine’s, Faculty of Medicine"@en,
        "Department of Anesthesia"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Computer Science"@en,
        "Department of Immunology, Faculty of Medicine"@en,
        "Department of Microbiology and Immunology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Faculty of Medicine"@en,
        "Department of Pharmacology, Microbiology and Immunology"@en,
        "Department of Physiology and Biophysics"@en,
        "Departments of Anesthesiology, Pain Management and Perioperative Medicine"@en,
        "Departments of Microbiology and Immunology"@en,
        "Pain Management and Perioperative Management Dalhousie University"@en .

ns216:FI1872 ns0:hasName "Department of Radiology"@en .

ns216:JAD180932 ns0:hasName "Anesthesiology"@en,
        "Center for Movement Disorders and Neurorestoration"@en,
        "Clinical and Health Psychology"@en,
        "Department of Anesthesiology"@en,
        "Department of Clinical and Health Psychology"@en .

ns216:JAD181203 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Departments of Neurology and Health Sciences Research"@en,
        "Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Hurvitz Brain Sciences Program"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Neuropsychopharmacology Research Group"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology, Faculty of Medicine"@en,
        "Sunnybrook Research Institute"@en,
        "Toronto Rehabilitation Institute"@en,
        "University Health Network at Toronto Rehabilitation Institute"@en .

ns216:JAD190010 ns0:hasName "Biostatistics"@en,
        "Department of Biostatistics, School of Medicine"@en,
        "Division of Biostatistics, Department of Medicine"@en .

ns216:JAD190077 ns0:hasName "Clinical Neurochemistry Laboratory"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute at UCL"@en .

ns216:JAD190524 ns0:hasName "Centre for Health Brain Ageing, School of Psychiatry, UNSW Medicine"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "Neuropsychiatric Institute"@en,
        "Neuropsychiatric Institute (NPI)"@en .

ns216:JAD190577 ns0:hasName "Clinical and Translational Neuroscience Unit, Laboratory of Behavioral Neuroscience"@en,
        "Clinical and Translational Neuroscience Unit, Laboratory of Behavioral Neuroscience, National Institute on Aging (NIA)"@en,
        "Clinical and Translational Neuroscience Unit, Laboratory of Behavioural Neuroscience"@en,
        "National Institute on Aging"@en,
        "Unit of Clinical and Translational Neuroscience, Laboratory of Behavioral Neuroscience"@en .

ns216:JAD190716 ns0:hasName "Brighton & Sussex Medical School, CISC"@en,
        "Neuroimaging Laboratory"@en,
        "Neuroimaging Laboratory, Santa Lucia Foundation"@en .

ns216:KCA180049 ns0:hasName "Department of Internal Medicine, University of California Davis School of Medicine, Division of Hematology Oncology"@en,
        "UC Davis Comprehensive Cancer Center"@en,
        "University of California"@en,
        "University of California Davis Comprehensive Cancer Center"@en,
        "University of California Davis School of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:9.ID:JAD181259> ns0:hasName "Department of Neuroscience"@en,
        "Department of Neurosciences and Biomedical Technologies."@en,
        "Neurology Unit"@en,
        "Ospedale San Gerardo"@en,
        "School of Medicine and Surgery and Milan Center for Neuroscience (NeuroMI)"@en,
        "Scientific Institute E. Medea"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:9.ID:JAD190046> ns0:hasName "Alzheimer Laboratory, Neurology Department, Hospital de la Santa Creu i Sant Pau"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service"@en,
        "Barcelona Down Medical Center"@en,
        "CIBERNED"@en,
        "CIBERNED, Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas"@en,
        "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas"@en,
        "Centro de Investigación Biomédica en Red en Enfermedades Neurodegenerativas, CIBERNED"@en,
        "Centro de Investigación Biomédica en Red en enfermedades Neurodegenerativas"@en,
        "Department of Neurology, Hospital de la Santa Creu i Sant Pau"@en,
        "Department of Neurology, Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau"@en,
        "Department of Neurology, Inst. Investigacions Biomèdiques-Hospital Sant Pau"@en,
        "Down Medical Center"@en,
        "Memory Unit, Department of Neurology"@en,
        "Memory Unit, Department of Neurology, Hospital de la Santa Creu i Sant Pau"@en,
        "Memory Unit, Department of Neurology, Institut d’Investigacions Biomèdiques Sant Pau - Hospital de Sant Pau"@en,
        "Memory Unit, Neurology Department"@en,
        "Universitat Autònoma de BarcelonaCentro de Investigación Biomédica en Red en enfermedades Neurodegenerativas, CIBERNED"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:9.ID:JAD190401> ns0:hasName "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff5.Author:9.ID:NRE192745> ns0:hasName "Université Catholique de Louvain"@en,
        "Université catholique de Louvain"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:0.ID:WOR192968> ns0:hasName "Department of Physical Therapy"@en,
        "School of Health and Rehabilitation Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:0.ID:XST190503> ns0:hasName "Department of Radiation Oncology"@en,
        "Department of Radiation Oncology, Wanfang Hospital"@en .

ns39:JAD181259 ns0:hasName "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation University of Milano"@en,
        "Department of Physiopathology and Transplantation"@en,
        "Department of Physiopathology and Transplants"@en,
        "Don C. Gnocchi Foundation IRCCS"@en,
        "Don C. Gnocchi Foundation – ONLUS"@en,
        "Laboratory of Molecular Medicine and Imaging in Rehabilitation"@en,
        "University of Milano and IRCCS SM Nascente"@en .

ns39:JAD190533 ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation"@en,
        "Centre for Neuromuscular and Neurological Disorders"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "McCusker Foundation for Alzheimer's Disease Research"@en,
        "School of Medical Health and Sciences"@en,
        "School of Medical SciencesEdith Cowan University"@en .

ns39:NRE192778 ns0:hasName "Department of Neurorehabilitation"@en,
        "IRCSS S. Raffaele Pisana Roma"@en,
        "San Raffaele University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:11.ID:JAD190010> ns0:hasName "Center for Computational Biology and Bioinformatics"@en,
        "Center for Neuroimaging, Department of Radiology and Imaging Sciences"@en,
        "Department of Medical and Molecular Genetics"@en,
        "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Department of Radiology and Imaging Sciences and the Indiana Alzheimer’s Disease Center"@en,
        "Department of Radiology and Imaging Sciences, Center for Neuroimaging"@en,
        "Indiana Alzheimer Disease Center"@en,
        "Indiana University Network Science Institute"@en,
        "Program in Medical Neuroscience, Paul and Carole Stark Neurosciences Research Institute"@en,
        "Radiology and Imaging Sciences"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:11.ID:JAD190132> ns0:hasName "Department of Clinical Medicine, Unit of Neurology"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Institute of Biomedicine"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine – Neurology, University of Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology, Universityof Eastern Finland and Department of Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "NeuroCenter, Neurology"@en,
        "Neurology of NeuroCenter"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:11.ID:JAD190133> ns0:hasName "Aging Research Center"@en,
        "Aging Research Center (ARC)"@en,
        "Aging Research Center (ARC), Department of NVS"@en,
        "Aging Research Center (ARC), Department of Neurobiology"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer Disease Research Center"@en,
        "Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Department of Geriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, KI- Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Department of Neurobiology, Care Sciences and Society, Karolinska Institutet-Alzheimer's Disease Research Center"@en,
        "Department of Neurobiology, Division of Clinical Geriatrics, Care Sciences and Society"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Institute of Clinical Medicine"@en,
        "Department of Neurology, School of Medicine"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research"@en,
        "Division of Clinical Geriatrics, Center for Alzheimer Research, Department of Neurobiology, Care Sciences and Society"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine, Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Karolinska Institutet Alzheimer Disease Research Center (KI-ADRC)"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center"@en,
        "Karolinska Institutet Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Karolinska Institutet Center for Alzheimer Research"@en,
        "National Institute for Health and Welfare"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health"@en,
        "Stockholms Sjukhem"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:11.ID:JAD190666> ns0:hasName "CAS Key Laboratory of Genome Sciences and Information"@en,
        "CAS Key Laboratory of Genome Sciences and Information, Beijing Institute of Genomics"@en,
        "Center of Alzheimer's disease"@en,
        "Center of Alzheimer’s Disease"@en,
        "UC Davis Genome Center and Department of Biomedical Engineering"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:12.ID:JAD181095> ns0:hasName "Department of Psychiatry and Neuropsychology"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Center Limburg"@en,
        "Department of Psychiatry and Neuropsychology, School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en,
        "Department of Psychiatry and Neuropsychology, School of Mental Health and Neurosciences (MHeNS)"@en,
        "School for Mental Health and Neuroscience, Alzheimer Centre Limburg"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:13.ID:JAD190446> ns0:hasName "Clinical Neuroscience Unit, Department of Neurology"@en,
        "Department for Neurodegenerative Diseases and Geriatric Psychiatry"@en,
        "Department of Neurology"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "German Center for Neurodegenerative Diseases, DZNE"@en,
        "Neurology Department"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:14.ID:JAD190533> ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation Perth"@en,
        "Centre for Aging and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Clinical Research in Neuropsychiatry, Graylands Hospital"@en,
        "Centre for Neuromuscular and Neurological Disorders"@en,
        "Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care; The Sir James McCurker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre for Ageing and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence in Alzheimer’s Disease Research and Care, School of Medical Sciences"@en,
        "Department of Biomedical Sciences"@en,
        "KARVIAH Research Centre"@en,
        "KaRa Institute of Neurological Disease"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "McCusker Foundation for Alzheimer's Disease Research"@en,
        "McCusker Foundation for Alzheimer's Disease Research Inc"@en,
        "School of Biomedical Science"@en,
        "School of Biomedical Sciences"@en,
        "School of Exercise, Biomedical and Health Sciences"@en,
        "School of Medical Health and Sciences"@en,
        "School of Medical Sciences"@en,
        "School of Medical SciencesEdith Cowan University"@en,
        "School of Medical and Health Sciences"@en,
        "School of Psychiatry & Clinical Neurosciences"@en,
        "School of Psychiatry and Clinical Neuroscience"@en,
        "School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit, School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer’s Disease Research Unit"@en,
        "The CRC for Mental Health"@en,
        "The McCusker Alzheimer’s Research Foundation"@en,
        "The School of Exercise, Biomedical and Health Science"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit, School of Exercise, Biomedical and Health Sciences"@en,
        "The University of British ColumbiaUniversity of Western Australia"@en,
        "The University of Western AustraliaEdith Cowan University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:2.ID:NPM1814> ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Geography"@en,
        "Department of GeographyWestern University"@en,
        "Department of Paediatrics"@en,
        "Lawson Health Research Institute"@en,
        "School of Health Studies"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:2.ID:NRE192788> ns0:hasName "School of Creative Practice, Faculty of Creative Industries"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:2.ID:WOR192989> ns0:hasName "School of Physical Therapy"@en,
        "School of Rehabilitation Science"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:26.ID:JAD190446> ns0:hasName "DZNE"@en,
        "Department for Neurodegenerative Diseases and Geriatric Psychiatry"@en,
        "Department of Neurodegenerative Diseases and Geriatric Psychiatry"@en,
        "Department of Psychiatry"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en .

ns186:JAD190293 ns0:hasName "Department of Biochemistry and Molecular Biology"@en,
        "University of Kansas School of Medicine"@en .

ns186:JAD190316 ns0:hasName "Department of Biomedical Engineering"@en,
        "Department of Radiology and Radiological Sciences"@en,
        "Institute of Imaging Science"@en,
        "Vanderbilt Brain Institute"@en,
        "Vanderbilt Ingram Cancer Center"@en,
        "Vanderbilt Institute of Chemical Biology"@en,
        "Vanderbilt Institute of Nanoscale Science and Engineering"@en,
        "Vanderbilt University Institute of Imaging Science"@en .

ns186:JAD190501 ns0:hasName "Department of Psychiatry and Psychotherapy"@en,
        "Department of Psychiatry and Psychotherapy, Medical Faculty"@en .

ns186:JAD190533 ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical Sciences"@en,
        "Department of Biomedical Sciences"@en,
        "School of Medical Health and Sciences"@en .

ns186:JAD190670 ns0:hasName "CERMAC"@en,
        "Clinical Neurosciences Department, San Raffaele Turro Hospital"@en,
        "Department of Nuclear Medicine"@en,
        "Department of Nuclear Medicine, Division of Neuroscience"@en,
        "Division of Neuroscience"@en,
        "IBFM-CNR"@en,
        "In Vivo Human Molecular and Structural Neuroimaging Unit, Division of Neuroscience"@en,
        "Istituto di Bioimmagini e Fisiologia Molecolare C.N.R."@en,
        "Nuclear Medicine Department"@en,
        "Nuclear Medicine Unit"@en,
        "Nuclear Medicine Unit and Division of Neuroscience, IRCCS San Raffaele Scientific Institute"@en,
        "Universitá Vita-Salute San Raffaele"@en,
        "Vita Salute San Raffaele University"@en,
        "Vita-Salute San Raffaele University"@en .

ns186:NHA190068 ns0:hasName "Department of Kinesiology and Nutrition"@en .

ns186:RNN190909 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology and McKnight Brain Institute"@en .

ns71:CH180428 ns0:hasName "Dalhousie University"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine’s, Faculty of Medicine"@en,
        "Department of Anesthesia"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Computer Science"@en,
        "Department of Immunology, Faculty of Medicine"@en,
        "Department of Microbiology and Immunology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Faculty of Medicine"@en,
        "Department of Pharmacology, Microbiology and Immunology"@en,
        "Department of Physiology and Biophysics"@en,
        "Departments of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesiology, Pain Management and Perioperative Medicine"@en,
        "Departments of Microbiology and Immunology"@en,
        "Pain Management and Perioperative Management Dalhousie University"@en .

ns71:HAB190367 ns0:hasName "Departement of Midwifery, College Medicine of Health Sciences"@en .

ns71:ICA190605 ns0:hasName "Department of Signal Theory, Networking and Communications"@en,
        "University of Granada"@en .

ns71:JAD180572 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "Neuroscience Research Australia"@en,
        "School of Psychology"@en,
        "University of New South Wales"@en .

ns71:JAD180949 ns0:hasName "Institute of General Practice (ifam), Medical Faculty"@en,
        "Institute of General Practice, Medical Faculty"@en .

ns71:JAD181295 ns0:hasName "Center for Psychiatric Research"@en,
        "Center for Psychiatry Research"@en,
        "Department of Clinical Neuroscience"@en,
        "Department of Forensic Psychiatry"@en,
        "Department of Forensic Psychiatry, Niuvanniemi Hospital"@en,
        "Karolinska Institutet"@en,
        "University of Eastern Finland"@en .

ns71:JAD190011 ns0:hasName "Department of Neurological Sciences"@en,
        "Department of Pathology"@en,
        "Department of Pathology (Neuropathology)"@en,
        "Departments of Pathology and Neurological Sciences, and Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer’s Disease Center"@en,
        "Rush University Medical Center"@en .

ns71:JAD190128 ns0:hasName "Department of Neurology"@en,
        "Departments of Neurology and Neurotherapeutics"@en .

ns71:JAD190183 ns0:hasName "Department of Psychiatry"@en,
        "Psychiatry Unit, Hôpital Pasteur"@en .

ns71:JAD190187 ns0:hasName "Clinical Neurochemical Laboratory"@en,
        "Clinical Neurochemistry Laboratory"@en,
        "Department of Molecular Neuroscience"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, the Sahlgrenska Academy at the"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry, The Sahlgrenska Academy"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute"@en,
        "UK Dementia Research Institute at UCL"@en .

ns71:JAD190197 ns0:hasName "College of Sciences"@en,
        "College of Sciences, One UTSA Circle"@en,
        "Department of Pathology"@en,
        "Department of Pathology, School of Medicine"@en,
        "The University of Texas at San Antonio"@en,
        "UTSA Neurosciences Institute and Department of Biology"@en .

ns71:JAD190342 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "Centre for Research on Ageing, Health and Wellbeing, Research School of Population Health"@en,
        "Centre for Research on Ageing, Health andWellbeing, Research School of Population Health"@en,
        "Dementia Collaborative Research Centre – Early Diagnosis and Prevention, Research School of Population Health"@en,
        "Neuroscience Research Australia"@en,
        "Neuroscience Research Australia (NeuRA)"@en,
        "School of Psychology"@en,
        "The Australian National University"@en,
        "University of New South Wales"@en .

ns71:JAD190469 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Chonnam National University Hospital"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en .

ns71:JAD190533 ns0:hasName "Australian Alzheimer’s Research Foundation"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Cooperative Research Centre for Mental Health"@en,
        "Department of Biomedical Sciences"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "School of Psychiatry and Clinical Neurosciences"@en .

ns71:JAD190540 ns0:hasName "Department of Epidemiology"@en,
        "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en .

ns75:JAD181170 ns0:hasName "School of Health Studies"@en .

ns75:JAD181203 ns0:hasName "Cardiac Rehabilitation Program"@en,
        "Division of Clinical Pharmacology"@en,
        "Sunnybrook Research Institute"@en,
        "Toronto Rehabilitation Institute"@en,
        "University Health Network at Toronto Rehabilitation Institute"@en .

ns75:JAD181256 ns0:hasName "A.I. Virtanen Institute for Molecular Sciences"@en,
        "Institute of Clinical Medicine –Neurology, University of Eastern Finland and Department of Neurology"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

ns75:JAD181282 ns0:hasName "Department of Medicine"@en,
        "Department of Psychiatry"@en,
        "Department of Radiology"@en,
        "Department of Radiology, Center for Imaging of Neurodegenerative Diseases"@en .

ns75:JAD190011 ns0:hasName "Department of Behavioral Sciences"@en,
        "Department of Neurological Sciences"@en,
        "Departments of Neurological Sciences and Behavioral Sciences, and Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer's Disease Center"@en,
        "Rush Alzheimer’s Disease Center"@en .

ns75:JAD190052 ns0:hasName "Alzheimer's Disease Research Center"@en,
        "Alzheimer’s Disease Research Center"@en,
        "Alzheimer’s Diseases Research Center"@en,
        "Department of Medicine, Section of Geriatrics and Gerontology"@en,
        "Department of Veterans Affairs (VA) Geriatric Research"@en,
        "GRECC, William S. Middleton Memorial Veterans Hospital and Department of Medicine"@en,
        "Geriatric Research Education and Clinical Center"@en,
        "Geriatric Research, Education and Clinical Center"@en,
        "School of Medicine and Public Health"@en,
        "University of Wisconsin"@en,
        "Wisconsin Alzheimer's Institute"@en,
        "Wisconsin Alzheimer’s Disease Research Center"@en,
        "Wisconsin Alzheimer’s Institute"@en .

ns75:JAD190090 ns0:hasName "Department of Neurological Sciences"@en,
        "Hauenstein Neurosciences Center"@en .

ns75:JAD190092 ns0:hasName "National Institute of Neurological Disorders and Stroke"@en .

ns75:JAD190119 ns0:hasName "Department of Neurosciences"@en,
        "Department of Neurosciences, Psychology, Drug Research and Child Health (NEUROFARBA)"@en,
        "Department of Pathophysiology and Transplantation, Neurodegenerative Disease Unit, “Dino Ferrari” Center"@en,
        "Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino Ferrari"@en,
        "University of Milan"@en .

ns75:JAD190237 ns0:hasName "Department of Basic and Applied Biology"@en,
        "National Institute for Nuclear Physics (INFN)"@en .

ns75:JAD190340 ns0:hasName "Department of Environmental and Preventive Medicine"@en,
        "Department of Oral and Maxillofacial Surgery"@en .

ns75:JAD190507 ns0:hasName "Genetics and Aging Research Unit"@en,
        "Genetics and Aging Research Unit, MassGeneral Institute for Neurodegenerative Diseases (MIND), Department of Neurology, Massachusetts General Hospital and"@en,
        "Genetics and Aging Research Unit, McCance Center for Brain Health"@en,
        "Massachusetts General Hospital"@en .

ns75:JAD190562 ns0:hasName "Department of Neurology and Institute of Neurology, Huashan Hospital, Shanghai Medical College"@en .

ns75:JAD190610 ns0:hasName "Academic Medicine Research Institute"@en,
        "Singapore Eye Research Institute"@en .

ns75:MNM180278 ns0:hasName "Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute"@en,
        "Non-Communicable Diseases Research Center"@en,
        "Non-communicable Diseases Research Center"@en .

ns201:JAD181030 ns0:hasName "Ageing Epidemiology (AGE) Research Unit"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar"@en,
        "German Center for Neurodegenerative Diseases (DZNE) Munich"@en,
        "Munich Cluster for Systems Neurology (SyNergy)"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine"@en,
        "Technische Universität München"@en,
        "West London Cognitive Disorders Treatment and Research Unit"@en .

ns201:JAD190010 ns0:hasName "Center for Neuroimaging, Department of Radiology and Imaging Sciences"@en,
        "Department of Radiology and Imaging Sciences, Center for Neuroimaging"@en,
        "Indiana Alzheimer Disease Center"@en,
        "Radiology and Imaging Sciences"@en .

ns201:JAD190091 ns0:hasName "Department of Medicine, Division of Geriatric Medicine"@en,
        "Department of Medicine, Division of Geriatric Medicine and Gerontology"@en .

ns201:JAD190152 ns0:hasName "CNC.IBILI Consortium"@en,
        "Faculty of Medicine"@en,
        "Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine"@en .

ns201:JAD190154 ns0:hasName "Department of Psychiatry"@en .

ns201:JAD190202 ns0:hasName "Brain Sciences Research Program, Sunnybrook Research Institute"@en,
        "Department of Health Policy, Management and Evaluation"@en,
        "Department of Research Design and Biostatistics"@en,
        "Evaluative Clinical Sciences, Hurvitz Brain Sciences Program"@en .

ns201:JAD190414 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Academic Medical Center"@en,
        "Department of Psychology"@en,
        "Faculty of Social and Behavioral Sciences"@en .

ns201:JAD190574 ns0:hasName "Central Institute of Mental Health"@en,
        "Department of Geriatric Psychiatry"@en,
        "Department of Geriatric Psychiatry, Central Institute of Mental Health, Medical Faculty Mannheim"@en,
        "Department of Gerontopsychiatry"@en .

ns201:JAD190628 ns0:hasName "Beijing Geriatric Medical Research Center"@en,
        "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en,
        "PKU Care Rehabilitation Hospital"@en .

ns201:JAD190631 ns0:hasName "Faculty of Sciences and Technology – NOVA University"@en,
        "Serviço de Neurologia"@en .

ns201:JHD180337 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research"@en,
        "Department of Radiology"@en,
        "George-Huntington-Institute"@en .

ns201:JVR191023 ns0:hasName "University of Alabama"@en,
        "University of Wisconsin-Madison"@en .

ns201:MNM180261 ns0:hasName "Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute"@en,
        "Department of Public Health"@en,
        "Non-Communicable Diseases Research Center"@en,
        "Non-communicable Diseases Research Center"@en .

ns201:RNN190916 ns0:hasName "Centre for Brain Health"@en,
        "Department of Physical Therapy"@en,
        "Department of Physical Therapy, Faculty of Medicine"@en,
        "The Djavad Mowafaghian Centre for Brain Health"@en .

ns201:WOR192947 ns0:hasName "Department of Surgery"@en,
        "Institute of Biomaterials and Biomedical Engineering"@en,
        "Rehabilitation Sciences InstituteUniversity of Toronto"@en,
        "Toronto Rehabilitation Institute"@en,
        "iDAPT Technology R & D Team"@en .

ns106:CH199009 ns0:hasName "Institute of Biomaterial Science and Berlin-Brandenburg Center for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies (BCRT)"@en,
        "Institute of Biomaterial Science and Berlin-Brandenburg Centre for Regenerative Therapies Helmholtz-Zentrum Geesthacht"@en .

ns106:JAD181168 ns0:hasName "Department of Nuclear Medicine"@en,
        "Institute of Neuroscience"@en .

ns106:JAD181212 ns0:hasName "Department of Psychiatry and Behavioral Science"@en,
        "Department of Psychiatry and Behavioral Sciences"@en,
        "Geriatric Research, Education, and Clinical Center"@en .

ns106:JAD190041 ns0:hasName "Department of Neurology and Alzheimer Center"@en,
        "Department of Neurology, Erasmus MC"@en .

ns106:JHD190354 ns0:hasName "Department of Clinical Radiology"@en,
        "Department of Neurodegenerative Diseases and Hertie-Institute for Clinical Brain Research"@en,
        "Department of Radiology"@en,
        "George-Huntington-Institute"@en .

ns106:JHD190364 ns0:hasName "Department of Medical Social Sciences"@en,
        "Department of Preventive Medicine"@en,
        "Departments of Medical Social Sciences and Preventative Medicine"@en,
        "Northwestern University"@en .

ns106:JVR191022 ns0:hasName "Florida Atlantic University"@en,
        "Florida Atlantic University-Boca Raton"@en .

ns106:JVR191026 ns0:hasName "University of Kentucky"@en,
        "Virginia Commonwealth University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:CH180528> ns0:hasName "Institute for Clinical Hemostasiology and Transfusion Medicine"@en,
        "Institute of Clinical Haemostasiology and Transfusion Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190041> ns0:hasName "Department of Neurology and Alzheimer Center"@en,
        "Erasmus MC – University Medical Center"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190077> ns0:hasName "Clinical Neurochemistry Laboratory"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute at UCL"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190152> ns0:hasName "CIBIT, Institute for Nuclear Sciences Applied to Health (ICNAS - P)"@en,
        "Faculty of Medicine"@en,
        "IBILI – Faculty of Medicine"@en,
        "Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190334> ns0:hasName "Department of Radiology"@en,
        "Institute of Clinical Medicine – Pathology, University of Eastern Finland and Department of Pathology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190399> ns0:hasName "Department of Psychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JPD181518> ns0:hasName "Department of Neurology"@en,
        "Department of Neuropathology"@en,
        "Department of Neurosurgery"@en,
        "Paracelsus-Elena-Klinik"@en .

ns230:CH189907 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesiology and Intensive Care"@en,
        "Department of Anaesthesiology and Intensive Care, University Hospital Hradec Kralove"@en,
        "Department of Anaesthesiology, Perioperative Medicine and Intensive Care"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anesthesiology, Perioperative Medicine and Intensive Care"@en .

ns230:JAD181203 ns0:hasName "Cardiac Rehabilitation Program"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute>"@en,
        "LC Campbell Cognitive Neurology Research Unit"@en,
        "Pharmacology and Toxicology"@en .

ns230:JAD190524 ns0:hasName "Bioanalytical Mass Spectrometry Facility"@en,
        "Centre for Healthy Brain Ageing, School of Psychiatry"@en,
        "Centre for Healthy Brain Aging, School of Psychiatry"@en,
        "School of Medical Sciences"@en,
        "School of Medical Sciences, Faculty of Medicine"@en .

ns230:JAD190756 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Brigham and Women’s Hospital"@en,
        "Department of Neurology, Center for Brain/Mind Medicine"@en,
        "Department of Psychiatry"@en,
        "Harvard Medical School"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:1.ID:JAD190756> ns0:hasName "Aging Research Center (ARC), Department of NVS"@en,
        "Center for Alzheimer Research, Division of Neurogeriatrics, Department of NVS"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Department of Psychology"@en,
        "Division of Clinical Geriatrics, Department of NVS"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:10.ID:JAD190046> ns0:hasName "Alzheimer Disease and Other Cognitive Unit"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Department of Neurology"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Department"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona"@en,
        "Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Department"@en,
        "Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Service"@en,
        "Alzheimer's disease and other cognitive disorders unit, Neurology Service"@en,
        "Alzheimer’s Disease and Other Cognitive Disorders Unit"@en,
        "Alzheimer’s Disease and Other Cognitive Disorders Unit, Hospital Clínic"@en,
        "Alzheimer’s Disease and Other Cognitive Disorders Unit, Neurology Service"@en,
        "Alzheimer’s disease and Other Cognitive Disorders Unit, Neurology Service"@en,
        "Alzheimer’s disease and other cognitive disorders unit"@en,
        "Alzheimer’s disease and other cognitive disorders unit, Neurology Service"@en,
        "Barcelona Beta Brain Research Center"@en,
        "Barcelona Beta Brain Research Centre"@en,
        "BarcelonaBeta Brain Research Center"@en,
        "BarcelonaBeta Brain Research Centre"@en,
        "Barcelonaβeta Brain Research Center"@en,
        "CIBER Fragilidad y Envejecimiento Saludable ("@en,
        "CIBER Fragilidad y Envejecimiento Saludable (CIBERFES)"@en,
        "Clinical Research Program"@en,
        "Clinical Research Program, Barcelonaβeta Brain Research Center"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Alzheimer's Disease and other Cognitive Disorders Unit"@en,
        "Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)"@en,
        "Institut d'Investigacions Biomédiques August Pi i Sunyer (IDIBAPS)"@en,
        "Institut d'Investigació Biomèdica August Pi i Sunyer (IDIBAPS)"@en,
        "Institut d'Investigació Biomédica August Pi i Sunyer (IDIBAPS)"@en,
        "Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:10.ID:JAD190098> ns0:hasName "Department of Dementia and Higher Brain Function"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:10.ID:JAD190155> ns0:hasName "Brain Health Consortium, Department Biology and Chemistry"@en,
        "Case Western Reserve University"@en,
        "College of Sciences"@en,
        "College of Sciences, One UTSA Circle"@en,
        "Dean and Professor of Biology"@en,
        "Department of Biology and UTSA Neuroscience Institute"@en,
        "Department of Biology, College of Sciences"@en,
        "Department of Pathology"@en,
        "Department of Pathology, School of Medicine"@en,
        "Institute of Pathology"@en,
        "The University of Texas at San Antonio"@en,
        "UTSA Neurosciences Institute and Department of Biology"@en,
        "UTSA Neurosciences Institute and Department of Biology, College of Sciences"@en,
        "University of Texas at San Antonio"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:10.ID:JND190397> ns0:hasName "Department of Radiology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:11.ID:JAD180847> ns0:hasName "Boston University"@en,
        "Department of Psychology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:11.ID:JAD190023> ns0:hasName "Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:11.ID:JAD190087> ns0:hasName "Department of Geriatrics and Cognitive Disorders"@en,
        "Department of Geriatrics and Cognitive Disorders, School of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:12.ID:JAD190311> ns0:hasName "1st Department of Neurology"@en,
        "1st Department of Neurology, G.H. “AHEPA”, School of Medicine, Faculty of Health Sciences"@en,
        "1st Department of Neurology, Medical School"@en,
        "1st Department of Neurology, U.H. “AHEPA”, Medical School, Faculty of Healthy Sciences"@en,
        "3rd Department of Neurology"@en,
        "3rd Department of Neurology, Medical School"@en,
        "3rd Department of Neurology, “G. Papanicolaou” Hospital"@en,
        "3rd Department of Neurology, “G. Papanikolaou” General Hospital of Thessaloniki"@en,
        "3rd Neurologic Clinic, Medical School, G. Papanikolaou Hospital"@en,
        "Aristotle University of Thessaloniki"@en,
        "Department of Neurology"@en,
        "Greek Association of Alzheimer's Disease and Related Disorders"@en,
        "INSERM U 558"@en,
        "Information Technologies Institute"@en,
        "Laboratory of Neurodegenerative Diseases"@en,
        "Medical School Aristotle University of Thessaloniki"@en,
        "Memory and Dementia Centre"@en,
        "Memory and Dementia Centre, 3rd Department of Neurology"@en,
        "Network Aging Research"@en,
        "Third Department of Neurology"@en,
        "Third Department of Neurology, Memory and Dementia Centre, Medical School"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:13.ID:JAD181095> ns0:hasName "Biobank, Institute Born-Bunge"@en,
        "Department of Biomedical Sciences, Laboratory of Neurochemistry & Behaviour>, Institute Born-Bunge"@en,
        "Department of Neurology and Alzheimer Center"@en,
        "Department of Neurology and Alzheimer Research Center"@en,
        "Department of Neurology and Memory Clinic"@en,
        "Department of Neurology/Memory Clinic, ZNA"@en,
        "Laboratory of Neurochemistry and Behavior"@en,
        "Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, Institute Born-Bunge"@en,
        "Reference Center for Biological Markers of Dementia (BIODEM), Laboratory of Neurochemistry and Behavior, and Biobank, Institute Born-Bunge"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:14.ID:JAD190533> ns0:hasName "Australian Alzheimer Research Foundation"@en,
        "Australian Alzheimer’s Research Foundation Perth"@en,
        "Centre for Aging and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre for Clinical Research in Neuropsychiatry, Graylands Hospital"@en,
        "Centre for Neuromuscular and Neurological Disorders"@en,
        "Centre of Excellence for Alzheimer's Disease Research & Care, School of Exercise Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care, School of Medical Sciences"@en,
        "Centre of Excellence for Alzheimer's Disease Research and Care; The Sir James McCurker Alzheimer's Disease Research Unit, Hollywood Private Hospital; Centre for Ageing and Alzheimer's Disease, School of Exercise, Biomedical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care"@en,
        "Centre of Excellence for Alzheimer’s Disease Research and Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence for Alzheimer’s disease Research & Care, School of Medical and Health Sciences"@en,
        "Centre of Excellence in Alzheimer’s Disease Research and Care, School of Medical Sciences"@en,
        "Department of Biomedical Sciences"@en,
        "KARVIAH Research Centre"@en,
        "KaRa Institute of Neurological Disease"@en,
        "KaRa Institute of Neurological Diseases"@en,
        "McCusker Foundation for Alzheimer's Disease Research"@en,
        "McCusker Foundation for Alzheimer's Disease Research Inc"@en,
        "School of Biomedical Science"@en,
        "School of Biomedical Sciences"@en,
        "School of Exercise, Biomedical and Health Sciences"@en,
        "School of Medical Health and Sciences"@en,
        "School of Medical Sciences"@en,
        "School of Medical SciencesEdith Cowan University"@en,
        "School of Medical and Health Sciences"@en,
        "School of Psychiatry & Clinical Neurosciences"@en,
        "School of Psychiatry and Clinical Neuroscience"@en,
        "School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit (Hollywood Private Hospital)"@en,
        "Sir James McCusker Alzheimer's Disease Research Unit, School of Psychiatry and Clinical Neurosciences"@en,
        "Sir James McCusker Alzheimer’s Disease Research Unit"@en,
        "The CRC for Mental Health"@en,
        "The Cooperative Research Centre for Mental Health"@en,
        "The McCusker Alzheimer’s Research Foundation"@en,
        "The School of Exercise, Biomedical and Health Science"@en,
        "The School of Psychiatry and Clinical Neuroscience"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit"@en,
        "The Sir James McCusker Alzheimer's Disease Research Unit, School of Exercise, Biomedical and Health Sciences"@en,
        "The University of British ColumbiaUniversity of Western Australia"@en,
        "The University of Western AustraliaEdith Cowan University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:15.ID:JAD190446> ns0:hasName "DZNE, German Center for Neurodegenerative Diseases"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "Section for Dementia Research, Hertie-Institute of Clinical Brain Research and Department of Psychiatry and Psychotherapy"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:17.ID:JAD190119> ns0:hasName "Department of Biomedical, Surgical and Dental Sciences"@en,
        "Department of Neurological Sciences"@en,
        "Department of Neurological Sciences, Centro Dino Ferrari"@en,
        "Department of Neurological Sciences, Dino Ferrari Center"@en,
        "Department of Neurological Sciences, ‘Dino Ferrari’ Center"@en,
        "Department of Neurological Sciences, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation"@en,
        "Department of Pathophysiology and Transplantation “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation, Dino Ferrari Center"@en,
        "Department of Pathophysiology and Transplantation, Neurodegenerative Disease Unit, “Dino Ferrari” Center"@en,
        "Department of Pathophysiology and Transplantation, Neurology Unit"@en,
        "Department of Pathophysiology and Transplantation, “Dino Ferrari” Center"@en,
        "Dino Ferrari Center, Department of Pathophysiology and Transplantation"@en,
        "Dino Ferrari Centre, Department of Neurological Sciences, University of Milan"@en,
        "Neurodegenerative Disease Unit, Department of Pathophysiology and Transplantation, Centro Dino Ferrari"@en,
        "Neurology Unit"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation"@en,
        "Neurology Unit, Department of Pathophysiology and Transplantation, ‘Dino Ferrari’ Center"@en,
        "Neurology Unit, “Dino Ferrari” Center"@en,
        "University of Milan"@en,
        "“Neurology Unit”, Department of Pathophysiology and Transplantation “Dino Ferrari” Center"@en .

ns112:JAD190365 ns0:hasName "Department of Clinical Neurosciences"@en,
        "Department of Psychiatry"@en,
        "Departments of Psychiatry and Neurology, Mathison Centre for Mental Health Research & Education, Hotchkiss Brain Institute"@en,
        "Departments of Psychiatry, Clinical Neurosciences, and Community Health Sciences, Hotchkiss Brain Institute and O’Brien Institute for Public Health"@en,
        "Hotchkiss Brain Institute"@en,
        "Mathison Centre for Mental Health Research and Education"@en .

ns112:JAD190533 ns0:hasName "Department of Biomedical Sciences"@en,
        "KaRa Institute of Neurological Disease"@en,
        "School of Medical Health and Sciences"@en,
        "School of Psychiatry and Clinical Neurosciences"@en,
        "The Cooperative Research Centre for Mental Health"@en .

ns112:NPM1814 ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Geography"@en,
        "Department of Paediatrics"@en,
        "Lawson Health Research Institute"@en,
        "School of Health Studies"@en .

ns177:JAD190644 ns0:hasName "Department of Neurology"@en,
        "Okayama University Graduate School of Medicine, Dentistry and Pharmaceutical Science"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:3.ID:JAD190316> ns0:hasName "Department of Biomedical Engineering"@en,
        "Department of Radiology and Radiological Sciences"@en,
        "Institute of Imaging Science"@en,
        "Vanderbilt Brain Institute"@en,
        "Vanderbilt Ingram Cancer Center"@en,
        "Vanderbilt Institute of Chemical Biology"@en,
        "Vanderbilt Institute of Nanoscale Science and Engineering"@en,
        "Vanderbilt University Institute of Imaging Science"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:3.ID:NRE192788> ns0:hasName "School of Health and Rehabilitation Sciences"@en,
        "School of Health and Rehabilitation Sciences, Faculty of Health and Behavioural Sciences"@en .

ns124:CH180428 ns0:hasName "Dalhousie University"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine’s, Faculty of Medicine"@en,
        "Department of Anesthesia"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Computer Science"@en,
        "Department of Immunology, Faculty of Medicine"@en,
        "Department of Microbiology and Immunology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Faculty of Medicine"@en,
        "Department of Pharmacology, Microbiology and Immunology"@en,
        "Department of Physiology and Biophysics"@en,
        "Departments of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesiology, Pain Management and Perioperative Medicine"@en,
        "Departments of Microbiology and Immunology"@en,
        "Pain Management and Perioperative Management Dalhousie University"@en .

ns124:IFS182843 ns0:hasName "School of Economics and Management"@en,
        "Tongji University"@en .

ns124:JAD190342 ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "Centre for Research on Ageing, Health and Wellbeing, Research School of Population Health"@en,
        "Centre for Research on Ageing, Health andWellbeing, Research School of Population Health"@en,
        "Dementia Collaborative Research Centre – Early Diagnosis and Prevention, Research School of Population Health"@en,
        "Neuroscience Research Australia"@en,
        "Neuroscience Research Australia (NeuRA)"@en,
        "School of Psychology"@en,
        "The Australian National University"@en,
        "University of New South Wales"@en .

ns124:JAD190540 ns0:hasName "Department of Pharmacology, Yong Loo Lin School of Medicine"@en,
        "Memory Aging and Cognition Centre, Department of Pharmacology"@en,
        "Saw Swee Hock School of Public Health"@en .

ns194:ICA190605 ns0:hasName "Department of Psychiatry, Robinson Way"@en,
        "Department of Signal Theory, Networking and Communications"@en .

ns194:JAD180949 ns0:hasName "Institute for Biometrics"@en,
        "Institute of Biometrics"@en,
        "Institute of General Practice"@en,
        "WG Medical Statistics and IT-Infrastructure"@en,
        "Work Group Medical Statistics and IT-Infrastructure"@en,
        "Working Group Medical Statistics and IT Infrastructure"@en .

ns194:JAD181295 ns0:hasName "Department of Neurology"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine-Neurology"@en,
        "Research Center for Comparative Effectiveness and Patient Safety (RECEPS) and School of Pharmacy"@en,
        "Research Centre for Comparative Effectiveness and Patient Safety"@en,
        "Research Centre for Comparative Effectiveness and Patient Safety (RECEPS)"@en,
        "School of Pharmacy"@en,
        "School of Pharmacy, Faculty of Health Sciences"@en .

ns194:JAD190019 ns0:hasName "Albert Einstein College of Medicine"@en,
        "Department of Epidemiology and Population Health"@en,
        "Department of Epidemiology and Population Health, Albert Einstein College of Medicine"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Albert Einstein College of Medicine"@en,
        "Departments of Neurology, Epidemiology, and Social Medicine, Montefiore Headache Unit"@en,
        "Einstein Aging Study"@en,
        "Innovative Medical Research"@en,
        "Institute for Aging Research, Albert Einstein College of Medicine"@en,
        "Saul B. Korey Department of Neurology"@en,
        "Saul R. Korey Department of Neurology"@en,
        "Saul R. Korey Department of Neurology, Albert Einstein College of Medicine"@en,
        "The Einstein Aging Study"@en .

ns194:JAD190090 ns0:hasName "Department of Neurological Sciences"@en,
        "Michigan Alzheimer’s Disease Core Center"@en .

ns194:JAD190133 ns0:hasName "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Hospital District of North Karelia"@en,
        "Institute of Public Health and Clinical Nutrition"@en .

ns194:JAD190610 ns0:hasName "Academic Medicine Research Institute"@en,
        "Singapore Eye Research Institute"@en .

ns194:MNM180278 ns0:hasName "Chronic Diseases Research Center, Endocrinology and Metabolism Population Sciences Institute"@en,
        "Non-communicable Diseases Research Center"@en .

ns203:JAD181030 ns0:hasName "Ageing Epidemiology (AGE) Research Unit"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "Department of Psychiatry and Psychotherapy, Klinikum rechts der Isar"@en,
        "German Center for Neurodegenerative Diseases (DZNE) Munich"@en,
        "German Center for Neurodegenerative Disorders (DZNE)"@en,
        "Munich Cluster for Systems Neurology (SyNergy)"@en,
        "Neuroepidemiology and Ageing Research Unit, School of Public Health, Faculty of Medicine"@en,
        "Technische Universität München"@en,
        "West London Cognitive Disorders Treatment and Research Unit"@en .

ns203:JAD181169 ns0:hasName "School of Occupational Therapy"@en,
        "School of Occupational Therapy, Faculty of Health Sciences"@en .

ns203:JAD181170 ns0:hasName "School of Occupational Therapy"@en,
        "School of Occupational Therapy, Faculty of Health Sciences"@en .

ns203:JAD181256 ns0:hasName "Department of Clinical Medicine, Unit of Neurology"@en,
        "Department of Neurology"@en,
        "Institute of Biomedicine"@en,
        "Institute of Clinical Medicine – Neurology"@en,
        "Institute of Clinical Medicine – Neurology, University of Eastern Finland and Department of Neurology"@en,
        "NeuroCenter, Neurology"@en,
        "Neurology of NeuroCenter"@en,
        "University of Eastern FinlandKuopio University Hospital"@en .

ns203:JAD190094 ns0:hasName "Department of Medicine at The Royal Melbourne Hospital"@en,
        "Neurocenter"@en .

ns203:JAD190237 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, CESI-Center for Excellence on Aging"@en,
        "Departments of Neurology and Pharmacology, Institute for Mind Impairments and Neurological Disorders – iMIND"@en .

ns203:JAD190628 ns0:hasName "Beijing Geriatric Medical Research Center"@en,
        "Beijing Institute of Geriatrics"@en,
        "Center of Alzheimer’s Disease"@en,
        "Department of Neurology"@en,
        "National Clinical Research Center for Geriatric Disorders"@en,
        "PKU Care Rehabilitation Hospital"@en .

ns203:VES190655 ns0:hasName "Department of Neurology and German Center for Vertigo and Balance Disorders"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JAD180521> ns0:hasName "CSIRO"@en,
        "CSIRO Molecular and Health Technologies"@en,
        "Centre for Medical Research (Royal Melbourne Hospital), Faculty of Medicine, Dentistry and Health Sciences"@en,
        "Department of Medicine (Royal Melbourne Hospital)"@en,
        "Healthy Brain Initiative, Faculty of Health Science"@en,
        "Mental Health Research Institute"@en,
        "National Ageing Research Institute"@en,
        "National Aging Research Institute"@en,
        "Preventative Health Flagship"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JAD180848> ns0:hasName "Centre for Hip Health and Mobility"@en,
        "Department of Physical Therapy"@en,
        "Department of Physical Therapy, Aging, Mobility, and Cognitive Neuroscience Lab"@en,
        "Djavad Mowafaghian Centre for Brain Health"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JAD190691> ns0:hasName "Department of Psychology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JHD180337> ns0:hasName "Department of Physical Therapy, School of Health Technology and Management"@en,
        "George-Huntington-Institute"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JPD191616> ns0:hasName "CNS — Campus Neurológico Sénior"@en,
        "Clinical Pharmacology Unit"@en,
        "Clinical Pharmacology Unit, Instituto de Medicina Molecular, Faculty of Medicine"@en,
        "Instituto de Medicina Molecular, Faculdade de Medicina"@en,
        "Instituto de Medicina Molecular, Faculty of Medicine"@en,
        "Laboratory of Clinical Pharmacology and Therapeutics"@en,
        "Laboratory of Clinical Pharmacology and Therapeutics, Faculty of Medicine"@en,
        "Laboratory of Clinical Pharmacology and TherapeuticsUniversity of Lisbon"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:JVR191023> ns0:hasName "Global Recruiters of Madison (Wisconsin)"@en,
        "Program in Rehabilitation Psychology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff7.Author:7.ID:KCA190064> ns0:hasName "Department of Medical Oncology"@en,
        "Medical Oncology Department"@en .

ns81:JAD181203 ns0:hasName "Department of Pharmacology and Toxicology"@en,
        "Department of Psychiatry"@en,
        "Departments of Neurology and Psychiatry"@en,
        "Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Hurvitz Brain Sciences Program"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology"@en,
        "Neuropsychopharmacology Research Group"@en,
        "Neuropsychopharmacology Research Group, Hurvitz Brain Sciences Program"@en,
        "Neuropsychopharmacology Research Program, Sunnybrook Research Institute and Departments of Psychiatry and Pharmacology/Toxicology, Faculty of Medicine"@en,
        "Sunnybrook Research Institute"@en,
        "Toronto Rehabilitation Institute"@en,
        "University Health Network at Toronto Rehabilitation Institute"@en .

ns81:JAD190077 ns0:hasName "Clinical Neurochemistry Laboratory"@en,
        "Department of Neurodegenerative Disease"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology"@en,
        "Department of Psychiatry and Neurochemistry, Institute of Neuroscience and Physiology, The Sahlgrenska Academy"@en,
        "Institute of Neuroscience and Physiology, Department of Psychiatry and Neurochemistry"@en,
        "UCL Institute of Neurology"@en,
        "UK Dementia Research Institute at UCL"@en .

ns81:JAD190756 ns0:hasName "Aging Research Center"@en,
        "Aging Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Alzheimer Disease Research Center, Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Alzheimer's Disease Research Center, Department of Neurobiology, Care Sciences and Society"@en,
        "Department NVS, Karolinska Institute"@en,
        "Department of Neurobiology, Care Sciences and Society"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Department of Neurobiology, Care Sciences and Society (NVS), Center for Alzheimer Research, Division of Neurogeriatrics"@en,
        "Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics"@en,
        "KI-Alzheimer Disease Research Center"@en,
        "KI-Alzheimer Disease Research Center (KI-ADRC)"@en,
        "KI-Alzheimer's Disease Research Center"@en,
        "Karolinska Institute"@en,
        "Karolinska Institutet"@en,
        "Karolinska Institutet, Dept NVS"@en,
        "Section for Geriatric Medicine, NEUROTEC"@en .

ns81:JHD190364 ns0:hasName "Department of Psychological and Brain Sciences"@en .

ns270:CH189907 ns0:hasName "Centrum for Research and Development"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesiology and Intensive Care"@en,
        "Department of Anaesthesiology and Intensive Care, University Hospital Hradec Kralove"@en,
        "Department of Anaesthesiology, Perioperative Medicine and Intensive Care"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Research and Development"@en .

ns270:JAD190399 ns0:hasName "Department of Neurology"@en,
        "Department of Neuropsychiatry"@en,
        "Department of Psychiatry, School of Medicine"@en .

ns270:JAD190414 ns0:hasName "Center for Neuroscience and Cell Biology (CNC)"@en,
        "Center for Neuroscience and Cell Biology (CNC.IBILI), Faculty of Medicine"@en,
        "Center for Neuroscience and Cell Biology, Faculty of Medicine"@en,
        "Department of Neurology"@en,
        "Faculty of Medicine"@en,
        "Neurology Department"@en .

ns270:JAD190426 ns0:hasName "Banner Sun Health Research Institute"@en,
        "Brigham and Women’s Hospital and Harvard Medical School"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:10.ID:CH199208> ns0:hasName "Helmholtz-Zentrum Dresden-Rossendorf"@en,
        "Technische Universität Dresden"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:10.ID:JAD190191> ns0:hasName "Berenson-Allen Center for Non-invasive Brain Stimulation, Beth Israel Deaconess Medical Center"@en,
        "Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:10.ID:JAD190399> ns0:hasName "Department of Psychiatry"@en,
        "Department of Psychiatry, School of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:10.ID:JAD190772> ns0:hasName "School of Medical Sciences, College of Life Sciences and Medicine"@en,
        "School of Medicine, Medical Sciences and Nutrition"@en,
        "University of Aberdeen"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:11.ID:JAD190046> ns0:hasName "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic"@en,
        "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service, Hospital Clínic de Barcelona"@en,
        "Alzheimer’s Disease and Other Cognitive Disorders Unit"@en,
        "August Pi i Sunyer Biomedical Research Institute (IDIBAPS)"@en,
        "Institut d'Investigació Biomédica August Pi i Sunyer (IDIBAPS)"@en,
        "Institut d’Investigació Biomèdica August Pi i Sunyer (IDIBAPS)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:11.ID:JAD190155> ns0:hasName "Biology Department"@en,
        "Biology Department and Center for Developmental Neuroscience, College of Staten Island"@en,
        "College of Staten IslandThe City University of New York"@en,
        "Department of Biology and Center for Developmental Neuroscience"@en,
        "New York State Institute for Basic Research In Developmental Disabilities"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:13.ID:JAD190334> ns0:hasName "Department of Pathology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:14.ID:JAD190046> ns0:hasName "Alzheimer's Disease and Other Cognitive Disorders Unit, Neurology Service"@en,
        "Alzheimer's Disease and other Cognitive Disorders Unit"@en,
        "Alzheimer's Disease and other Cognitive Disorders Unit, Neurology Department"@en,
        "Alzheimer’s Disease and Other Cognitive Disorders Unit, Hospital Clínic"@en,
        "August Pi i Sunyer Biomedical Research Institute (IDIBAPS)"@en,
        "Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:14.ID:JPD181518> ns0:hasName "Institute for Neurodegenerative Disorders"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:15.ID:JAD180847> ns0:hasName "Center for Behavioral Genomics"@en,
        "Center of Excellence for Stress and Mental Health"@en,
        "Department of Psychiatry"@en,
        "University of California"@en,
        "VA Center of Excellence for Stress and Mental Health"@en,
        "Veterans' Administration San Diego Healthcare System"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:15.ID:JAD190446> ns0:hasName "DZNE, German Center for Neurodegenerative Diseases"@en,
        "Department of Psychiatry and Psychotherapy"@en,
        "Section for Dementia Research, Hertie Institute for Clinical Brain Research and Department of Psychiatry and Psychotherapy"@en,
        "Section for Dementia Research, Hertie-Institute of Clinical Brain Research and Department of Psychiatry and Psychotherapy"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:16.ID:JAD190772> ns0:hasName "School of Medicine, Medical Sciences and Nutrition"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:17.ID:JAD180949> ns0:hasName "Department of Primary Medical Care"@en,
        "Department of Primary Medical Care, Center for Psychosocial Medicine"@en,
        "Institute of Primary Medical Care"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:17.ID:JAD190772> ns0:hasName "School of Medicine, Medical Sciences and Nutrition"@en,
        "University of Aberdeen"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:2.ID:NPM1814> ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology & Biostatistics"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Geography"@en,
        "Department of Paediatrics"@en,
        "Lawson Health Research Institute"@en,
        "School of Health Studies"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:20.ID:JAD190334> ns0:hasName "Department of Clinical Pathology"@en,
        "Department of Pathology"@en,
        "Institute of Clinical Medicine – Radiology, University of Eastern Finland and Department of Radiology"@en,
        "Institute of Clinical Medicine, Pathology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:3.ID:JAD190316> ns0:hasName "Department of Biomedical Engineering"@en,
        "Department of Radiology and Radiological Sciences"@en,
        "Institute of Imaging Science"@en,
        "Vanderbilt Brain Institute"@en,
        "Vanderbilt Ingram Cancer Center"@en,
        "Vanderbilt Institute of Chemical Biology"@en,
        "Vanderbilt Institute of Nanoscale Science and Engineering"@en,
        "Vanderbilt University Institute of Imaging Science"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:3.ID:NPM1814> ns0:hasName "Children’s Health Research Institute"@en,
        "Department of Epidemiology & Biostatistics"@en,
        "Department of Epidemiology and Biostatistics"@en,
        "Department of Paediatrics"@en,
        "Human Environments Analysis Laboratory"@en,
        "Lawson Health Research Institute"@en,
        "School of Food and Nutritional Sciences"@en .

ns153:CH180428 ns0:hasName "Dalhousie University"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine’s, Faculty of Medicine"@en,
        "Department of Anesthesia"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Computer Science"@en,
        "Department of Immunology, Faculty of Medicine"@en,
        "Department of Microbiology and Immunology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Faculty of Medicine"@en,
        "Department of Pharmacology, Microbiology and Immunology"@en,
        "Department of Physiology and Biophysics"@en,
        "Departments of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesiology, Pain Management and Perioperative Medicine"@en,
        "Departments of Microbiology and Immunology"@en,
        "Pain Management and Perioperative Management Dalhousie University"@en .

ns153:JAD190688 ns0:hasName "Charles University Prague"@en,
        "National Institute of Mental Health"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190038> ns0:hasName "Centre de Recherche"@en,
        "Centre de Recherche de l’Institut Universitaire de Gériatrie de Montréal"@en,
        "Centre de recherche"@en,
        "Department of Medicine"@en,
        "PERFORM Centre and Department of Psychology"@en,
        "Research Centre"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190133> ns0:hasName "Chronic Disease Prevention Unit"@en,
        "Department of Chronic Disease Prevention"@en,
        "Hospital District of North Karelia"@en,
        "Institute of Public Health and Clinical Nutrition"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190197> ns0:hasName "Centro de Biologia Molecular “Severo Ochoa” (CSIC-UAM)"@en,
        "Centro de Biologia Molecular “Severo Ochoa” CSIC/Universidad Autonoma de Madrid"@en,
        "Centro de Biología Molecular Severo Ochoa (CSIC-UAM)"@en,
        "Centro de Investigacion en Red de Enfermedades Neurodegenerativas (CIBERNED)"@en,
        "Department of Neuroscience, Centro de Biologia Molecular ‘Severo Ochoa’ CSIC/UAM"@en,
        "Networking Research Center on Neurodegenerative, Diseases (CIBERNED)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190365> ns0:hasName "Department of Laboratory Medicine"@en,
        "Department of Laboratory Medicine and Pathobiology"@en,
        "Division of Pathology"@en,
        "Keenan Biomedical Research Centre, the Li Ka Shing Knowledge Institute"@en,
        "Keenan Research Centre for Biomedical Research"@en,
        "Keenan Research Centre for Biomedical Research, the Li Ka Shing Knowledge Institute"@en,
        "Laboratory Medicine, St. Michael’s Hospital"@en,
        "University of Toronto"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190610> ns0:hasName "Academic Medicine Research Institute"@en,
        "Singapore Eye Research Institute"@en,
        "Singapore National Eye Centre"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff8.Author:5.ID:JAD190688> ns0:hasName "Alzheimer’s Disease Research Center, Division of Neurogeriatrics, Department of Neurobiology, Care Sciences and Society (NVS)"@en,
        "Charles University Prague"@en,
        "International Clinical Research Center and St.Anne‘s University Hospital"@en .

ns251:JAD181277 ns0:hasName "Department of Neurology"@en,
        "Department of Neurology, Cliniques Universitaires Saint-Luc"@en,
        "Department of Radiology"@en,
        "Harvard Medical School"@en,
        "Institute of Neuroscience"@en,
        "Institute of Neuroscience (IoNS)"@en,
        "Neurology Department, Saint Luc University Hospital"@en .

ns251:JAD190094 ns0:hasName "Department of Medicine at The Royal Melbourne Hospital"@en,
        "Department of Medicine at the Royal Melbourne Hospital"@en,
        "Neurocenter"@en .

ns251:JAD190197 ns0:hasName "Centro de Biología Molecular Severo Ochoa (CSIC-UAM)"@en,
        "Centro de Biología Molecular “Severo Ochoa”"@en,
        "Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (CIBERNED)"@en,
        "Networking Research Center on Neurodegenerative, Diseases (CIBERNED)"@en .

ns209:JAD180521 ns0:hasName "CSIRO"@en,
        "CSIRO Molecular and Health Technologies"@en,
        "Centre for Medical Research (Royal Melbourne Hospital), Faculty of Medicine, Dentistry and Health Sciences"@en,
        "Healthy Brain Initiative, Faculty of Health Science"@en,
        "Mental Health Research Institute"@en,
        "National Ageing Research Institute"@en,
        "National Aging Research Institute"@en,
        "Preventative Health Flagship"@en,
        "School of Psychology"@en .

ns169:BLC180206 ns0:hasName "IUOPA"@en,
        "Preventive Medicine and Public Health"@en .

ns169:JAD190091 ns0:hasName "Department of Health Behavior & Health Education"@en,
        "University of Michigan School of Public Health"@en .

ns169:KCA190064 ns0:hasName "Department of Medical Oncology"@en,
        "Medical Oncology Department"@en .

ns37:JAD181203 ns0:hasName "Department of Pharmacology & Toxicology"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute>"@en,
        "LC Campbell Cognitive Neurology Research Unit"@en,
        "Pharmacology and Toxicology"@en .

ns37:JAD190414 ns0:hasName "Center for Neuroscience and Cell Biology (CNC)"@en,
        "Center for Neuroscience and Cell Biology (CNC.IBILI), Faculty of Medicine"@en,
        "Center for Neuroscience and Cell Biology, Faculty of Medicine"@en,
        "Department of Neurology"@en,
        "Faculty of Medicine"@en,
        "Neurology Department"@en,
        "Neuropsychology Unit"@en .

ns37:JAD190426 ns0:hasName "Banner Sun Health Research Institute"@en,
        "Brigham and Women’s Hospital and Harvard Medical School"@en,
        "Department of Neurology, Center for Brain/Mind Medicine"@en .

ns37:JAD190469 ns0:hasName "Department of Health Sciences and Technology, SAIHST"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Department of Neurology, Sungkyunkwan University School of Medicine"@en,
        "Departments of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Neuto Science Center"@en,
        "Samsung Medical Center, Department of Neurology"@en,
        "Stem Cell & Regenerative Medicine Institute"@en,
        "Stem Cell and Regenerative Medicine Institute"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:JAD181212> ns0:hasName "Center for Computational Biology and Bioinformatics"@en,
        "Center for Neuroimaging, Department of Radiology and Imaging Sciences"@en,
        "Department of Medical and Molecular Genetics"@en,
        "Department of Neurology"@en,
        "Department of Psychiatry"@en,
        "Department of Radiology and Imaging Sciences and the Indiana Alzheimer’s Disease Center"@en,
        "Department of Radiology and Imaging Sciences, Center for Neuroimaging"@en,
        "Indiana Alzheimer Disease Center"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:JAD190010> ns0:hasName "Center for Imaging of Neurodegenerative Diseases"@en,
        "Center for Imaging of Neurodegenerative Diseases (CIND)"@en,
        "Center for Imaging of Neurodegenerative Diseases, Department of Radiology"@en,
        "Department of Medicine"@en,
        "Department of Psychiatry"@en,
        "Department of Radiology"@en,
        "Department of Radiology and Biomedical Imaging"@en,
        "Department of Radiology, Center for Imaging of Neurodegenerative Diseases"@en,
        "Department of Radiology, Medicine, and Psychiatry"@en,
        "Department of Veterans Affairs Medical Center"@en,
        "Departments of Radiology and Biomedical Imaging, Psychiatry, Medicine, and Neurology"@en,
        "University of California"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:JAD190469> ns0:hasName "Clinical Research Design and Evaluation, SAIHST"@en,
        "Department of Clinical Research Design & Evaluation, SAIHST"@en,
        "Department of Clinical Research Design and Evaluation, SAIHST"@en,
        "Department of Health Sciences and Technology, SAIHST"@en,
        "Department of Neurology"@en,
        "Department of Neurology, Samsung Medical Center"@en,
        "Neuroscience Center"@en,
        "Neuto Science Center"@en,
        "Samsung Medical Center, Department of Neurology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:JAD190691> ns0:hasName "Department of Radiology"@en,
        "Turku University Hospital"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:10.ID:KCA180049> ns0:hasName "CHRISTUS Santa Rosa Medical Center Hospital"@en,
        "The University of Texas Health Science Center at San Antonio"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:11.ID:JAD190399> ns0:hasName "Department of Neuropsychiatry"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:11.ID:JAD190772> ns0:hasName "Alzheimer's Disease Research Unit"@en,
        "Alzheimer’s Disease Research Unit"@en,
        "Departments of Neurology & Neurosurgery, Psychiatry, and Medicine"@en,
        "McGill Center for Studies in Aging"@en,
        "McGill Centre for Studies in Aging"@en,
        "McGill Centre for Studies in Aging (MCSA)"@en,
        "McGill Centre for Studies in Aging, Alzheimer’s Disease Research Unit, and"@en,
        "McGill University Research Center for Studies in Aging"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:13.ID:JAD180949> ns0:hasName "Department of Health Economics and Health Services Research, Hamburg Center for Health Economics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:13.ID:JAD181175> ns0:hasName "Department of Clinical Sciences"@en,
        "Department of Clinical Sciences (Biostatistics)"@en,
        "Department of Psychiatry"@en,
        "Departments of Population and Data Sciences"@en,
        "University of Texas Southwestern Medical Center at Dallas"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:13.ID:JAD190046> ns0:hasName "Catalan Institution for Research and Advanced Studies (ICREA)"@en,
        "Cognition and Brain Plasticity Group"@en,
        "Department of Cognition, Development and Education Psychology, Campus Bellvitge"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:13.ID:JAD190334> ns0:hasName "Department of Pathology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:17.ID:JAD190087> ns0:hasName "Department of Molecular Pathobiology of Brain Diseases"@en,
        "Department of Molecular Pathobiology of Brain Diseases (Department of Neurology)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:20.ID:JAD190334> ns0:hasName "Department of Clinical Pathology"@en,
        "Department of Pathology"@en,
        "Institute of Clinical Medicine – Radiology, University of Eastern Finland and Department of Radiology"@en,
        "Institute of Clinical Medicine, Pathology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:3.ID:JAD190316> ns0:hasName "Department of Biomedical Engineering"@en,
        "Department of Radiology and Radiological Sciences"@en,
        "Institute of Imaging Science"@en,
        "Vanderbilt Brain Institute"@en,
        "Vanderbilt Ingram Cancer Center"@en,
        "Vanderbilt Institute of Chemical Biology"@en,
        "Vanderbilt Institute of Nanoscale Science and Engineering"@en,
        "Vanderbilt University Institute of Imaging Science"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:4.ID:CH180428> ns0:hasName "Dalhousie University"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Anaesthesia, Pain Management and Perioperative Medicine’s, Faculty of Medicine"@en,
        "Department of Anesthesia"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Department of Anesthesia, Pain Management and Perioperative Medicine, Faculty of Medicine"@en,
        "Department of Computer Science"@en,
        "Department of Immunology, Faculty of Medicine"@en,
        "Department of Microbiology and Immunology"@en,
        "Department of Pharmacology"@en,
        "Department of Pharmacology, Faculty of Medicine"@en,
        "Department of Pharmacology, Microbiology and Immunology"@en,
        "Department of Physiology and Biophysics"@en,
        "Departments of Anaesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesia, Pain Management and Perioperative Medicine"@en,
        "Departments of Anesthesiology, Pain Management and Perioperative Medicine"@en,
        "Departments of Microbiology and Immunology"@en,
        "Pain Management and Perioperative Management Dalhousie University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:5.ID:JAD180498> ns0:hasName "Centre for Research on Ageing, Health and Wellbeing"@en,
        "Centre for Research on Ageing, Health and Wellbeing, Research School of Population Health"@en,
        "Centre for Research on Ageing, Health andWellbeing, Research School of Population Health"@en,
        "Dementia Collaborative Research Centre – Early Diagnosis and Prevention, Research School of Population Health"@en,
        "Neuroscience Research Australia"@en,
        "Neuroscience Research Australia (NeuRA)"@en,
        "School of Psychology"@en,
        "The Australian National University"@en,
        "UNSW Ageing Futures Institute"@en,
        "University of New South Wales"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:5.ID:JAD190365> ns0:hasName "Department of Laboratory Medicine"@en,
        "Department of Laboratory Medicine and Pathobiology"@en,
        "Division of Pathology"@en,
        "Keenan Biomedical Research Centre, the Li Ka Shing Knowledge Institute"@en,
        "Keenan Research Centre for Biomedical Research"@en,
        "Keenan Research Centre for Biomedical Research, the Li Ka Shing Knowledge Institute"@en,
        "Laboratory Medicine, St. Michael’s Hospital"@en,
        "University of Toronto"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:5.ID:JAD190446> ns0:hasName "Dementia Research Section and Memory Clinic, Alzheimer Memorial Center and Geriatric Psychiatry Branch, Department of Psychiatry"@en,
        "German Center for Neurodegenerative Diseases (DZNE)"@en,
        "Institute for Stroke and Dementia Research (ISD)"@en,
        "Institute for Stroke and Dementia Research, Klinikum Großhadern"@en .

ns204:JAD190133 ns0:hasName "Cognition and Work Team"@en,
        "Department of Neurology"@en,
        "Finnish Institute of Occupational Health"@en,
        "Institute of Occupational Health"@en,
        "Research and Service Centre for Occupational Health"@en .

ns204:JAD190670 ns0:hasName "National Center for Disease Prevention and Health Promotion"@en,
        "National Center for Epidemiology Surveillance and Health Promotion"@en,
        "National Centre for Disease Prevention and Health Promotion"@en,
        "National Centre for Epidemiology, Surveillance and Health Promotion"@en,
        "National Centre of Epidemiology"@en,
        "National Institute of Health"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:7.ID:JAD180949> ns0:hasName "Department of Health Economics and Health Services Research, Hamburg Center for Health Economics"@en,
        "Department of Medical Sociology and Health Economics, Hamburg Center for Health Economics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:7.ID:JAD190019> ns0:hasName "Department of Psychology"@en,
        "San Diego State University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:7.ID:JAD190533> ns0:hasName "Australian eHealth Research Centre"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:8.ID:BLC180206> ns0:hasName "Biomedical Research Networking Center for Epidemiology and Public Health (CIBERESP)"@en,
        "IUOPA"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:9.ID:JAD181203> ns0:hasName "Hurvitz Brain Sciences Program"@en,
        "Hurvitz Brain Sciences Program, Sunnybrook Research Institute>"@en,
        "LC Campbell Cognitive Neurology Research Unit"@en,
        "Pharmacology and Toxicology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:9.ID:JAD181232> ns0:hasName "Department of Neurology, CMRR"@en,
        "Department of Neurology, Hôpitaux Civils de Colmar and INSERM U-1118, School of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:9.ID:JAD190091> ns0:hasName "Departments of Psychiatry, Epidemiology, Sociology, Psychology, Community Health, Nursing, Health and Rehabilitation Sciences; University Center for Social and Urban Research; Center for Caregiving Research, Policy and Training; Geriatric Education Center of Pennsylvania; Aging Institute of UPMC Senior Services"@en,
        "University Center for Social and Urban Research"@en,
        "University of Pittsburgh School of Medicine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:aff9.Author:9.ID:KCA190064> ns0:hasName "Department of Medical Oncology"@en,
        "University Hospital Gregorio Marañón"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AAC192101> ns0:hasName "LIPADE"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AIC190617> ns0:hasName "Università della Svizzera italiana"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AIC190622> ns0:hasName "Umeå University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AIS190539> ns0:hasName "Campus Minden"@en,
        "Faculty of Computer Science"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:AO190214> ns0:hasName "NEMO, Computer Science Department"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY181516> ns0:hasName "Department of Mathematics, Graduate School of Education"@en,
        "Hiroshima University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY191518> ns0:hasName "Institute of Mathematics of the Academy of Sciences of the Czech Republic"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY191520> ns0:hasName "Department of Mathematics"@en,
        "ETH Zürich"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY191521> ns0:hasName "Department of Mathematics"@en,
        "ETH Zürich"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ASY191524> ns0:hasName "Dipartimento di Matematica “F. Casorati”"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:BSI190185> ns0:hasName "School of Psychological Science"@en,
        "University of Bristol, Bristol"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:COM099> ns0:hasName "School of Mathematics and Statistics"@en,
        "University of Waterloo"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:COM180231> ns0:hasName "Google LLC"@en,
        "University of Chicago"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:ISP180248> ns0:hasName "Department of Engineering and Architecture"@en,
        "Faculty of Engineering"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:JCS191289> ns0:hasName "Department of Computer Science"@en,
        "New York Institute of Technology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:JHS190616> ns0:hasName "Faculty of Electrical and Computer Engineering"@en,
        "University of Prishtina"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:JHS190622> ns0:hasName "Suwon University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:JHS190623> ns0:hasName "Korea Advanced Institute of Science and Technology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:SW190359> ns0:hasName "Ming Hseih Department of Electrical Engineering"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:SW190362> ns0:hasName "Center for Applied Autonomous Sensor Systems"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:SW190364> ns0:hasName "Centre for Translation Studies"@en,
        "Technical University Dresden"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:0.ID:SW318> ns0:hasName "Department of Computational Linguistics"@en,
        "Monash University"@en .

ns91:AIS190536 ns0:hasName "Department of Computer Science"@en .

ns91:ASY191521 ns0:hasName "ETH Zürich"@en .

ns91:BSI190185 ns0:hasName "School of Psychological Science"@en,
        "University of Bristol, Bristol"@en .

ns91:ISP180249 ns0:hasName "Petroleum University of Technology"@en,
        "University of Science & Technology"@en .

ns91:JCS191315 ns0:hasName "MSIS"@en,
        "MSIS Department"@en,
        "Management Science and Information Systems Department"@en .

ns91:JHS190624 ns0:hasName "Computer Engineering and Information Technology Department"@en,
        "Razi University"@en .

ns91:SW190355 ns0:hasName "L3S Research Center"@en,
        "Leibniz Universität Hannover"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:14.ID:BSI190185> ns0:hasName "Clinical Research and Imaging Centre"@en,
        "School of Experimental Psychology"@en,
        "School of Psychological Science"@en,
        "University of Bristol, Bristol"@en .

ns73:AAC190457 ns0:hasName "Institute of Information Systems"@en,
        "Institute of Logic and Computation"@en .

ns73:AIC190616 ns0:hasName "Department of Computing Science"@en .

ns73:AIC190618 ns0:hasName "Universidad Complutense de Madrid"@en .

ns73:AO190214 ns0:hasName "NEMO, Computer Science Department"@en,
        "Ontology & Conceptual Modeling Research Group (NEMO), Department of Computer Science"@en,
        "Ontology and Conceptual Modeling Research Group (NEMO)"@en .

ns73:ASY191520 ns0:hasName "ETH Zürich"@en .

ns73:BSI190185 ns0:hasName "School of Experimental Psychology"@en,
        "School of Psychological Science"@en .

ns73:JCS191315 ns0:hasName "MSIS Department"@en,
        "Management Science and Information Systems Department"@en .

ns73:SW190359 ns0:hasName "Ming Hseih Department of Electrical Engineering"@en .

ns73:SW190369 ns0:hasName "Iran University of Science and Technology"@en .

ns117:AIC190615 ns0:hasName "Department of Informatics"@en,
        "King’s College London"@en .

ns117:JCS191274 ns0:hasName "School of Information Systems"@en,
        "Singapore Management University"@en .

ns117:JCS191289 ns0:hasName "Department of Computer Science"@en,
        "New York Institute of Technology"@en .

ns117:SW190358 ns0:hasName "Ghent University – imec"@en,
        "Univesiteit Gent"@en .

ns117:SW190362 ns0:hasName "Center for Applied Autonomous Sensor Systems"@en,
        "Örebro University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affa.Author:4.ID:JCS191286> ns0:hasName "Athens University of Economics and Business"@en,
        "Department of Informatics"@en,
        "Information Security and Critical Infrastructure Protection Research Group, Department of Informatics"@en .

ns125:ISP180253 ns0:hasName "University of Trieste"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:0.ID:AIS190539> ns0:hasName "Campus Minden"@en,
        "Faculty of Computer Science"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:0.ID:ASY191518> ns0:hasName "Institute of Mathematics of the Academy of Sciences of the Czech Republic"@en,
        "Technical University Berlin"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:0.ID:ASY191524> ns0:hasName "Dipartimento di Matematica “F. Casorati”"@en,
        "at the"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:0.ID:ISP180248> ns0:hasName "Department of Engineering and Architecture"@en,
        "Faculty of Engineering"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:AAC192101> ns0:hasName "DIBRIS"@en,
        "Department of Informatics, Bioengineering, Robotics and Systems Engineering"@en,
        "University of Genoa"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:AIS190536> ns0:hasName "Department of Computer Science"@en,
        "WN Laboratory"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:COM093> ns0:hasName "School of Mathematics and Computer Sciences"@en,
        "School of Mathematics and Statistics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:COM180231> ns0:hasName "Department of Mathematics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:DS190015> ns0:hasName "Knowledge Media Institute"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:DS190016A> ns0:hasName "Department of Computer Science and Engineering"@en,
        "Digital Humanities Advanced Research Centre (DHARC), Department of Classical Philology and Italian Studies"@en,
        "Digital Humanities Advanced Research Centre, Department of Classical Philology and Italian Studies"@en,
        "STLab-ISTC, Consiglio Nazionale delle Ricerche"@en,
        "Semantic Technology Laboratory, Institute of Cognitive Sciences and Technologies"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:DS190023> ns0:hasName "Knowledge Media Institute"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:JCS181244> ns0:hasName "Department of Computer Science"@en,
        "Department of Informatics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:SW190359> ns0:hasName "Department of Computer Science"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:1.ID:SW190365> ns0:hasName "Department of Computer Science"@en,
        "Italian National Research Council"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:2.ID:AO190214> ns0:hasName "Faculty of Computer Science"@en,
        "Ontology & Conceptual Modeling Research Group (NEMO), Department of Computer Science"@en,
        "Ontology and Conceptual Modeling Research Group (NEMO)"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:2.ID:ASY191519> ns0:hasName "Department of Mathematics, Faculty of Sciences of Bizerte"@en,
        "Institute for Scientific Computing and Applied Mathematics"@en,
        "The Institute for Scientific Computing and Applied Mathematics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:2.ID:JCS191287> ns0:hasName "Horst Görtz Institute for IT Security"@en,
        "Ruhr-University Bochum"@en,
        "University of Mannheim"@en,
        "Vienna University of Technology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:2.ID:JCS191289> ns0:hasName "Department of Mathematics and HIT Center"@en,
        "University of Padua"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:3.ID:JCS191315> ns0:hasName "Department of Computer Science & Engineering"@en,
        "Dept. of Computer Science and Engineering"@en,
        "Indian Institute of Technology"@en,
        "School of Information Technology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affb.Author:3.ID:JHS190615> ns0:hasName "Department of Information and Communication Technology, Manipal Institute of Technology (MIT)"@en,
        "Department of Mechanical and Manufacturing Engineering, Manipal Institute of Technology"@en .

ns122:BSI190186 ns0:hasName "Department of Radiology"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:11.ID:JCS191289> ns0:hasName "Department of Information and Computer Science"@en,
        "University of California, Irvine"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:AIS190536> ns0:hasName "Jheronimus Academy of Data Science"@en,
        "Statistics and Research Methods"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:COM094> ns0:hasName "Department of Mathematics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:COM101> ns0:hasName "Department of Mathematics"@en,
        "School of Mathematics and Statistics"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:COM180207> ns0:hasName "Department of Computer Science"@en,
        "University of Cambridge"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:DS190015> ns0:hasName "Knowledge Media Institute"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:DS190023> ns0:hasName "Department of Computer Science and Engineering"@en,
        "Digital Humanities Advanced Research Centre (DHARC), Department of Classical Philology and Italian Studies"@en,
        "STLab-ISTC, Consiglio Nazionale delle Ricerche"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:JCS171070> ns0:hasName "France Télécom R&D"@en,
        "LSV"@en,
        "Laboratoire Spécification et Vérification"@en,
        "School of Computer Science"@en,
        "Univ Rennes, CNRS, IRISA"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:2.ID:JCS191306> ns0:hasName "Center for Secure Information Systems"@en,
        "Center for Secure Information Systems and Department of Information and Software Systems Engineering"@en,
        "George Mason University"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affc.Author:5.ID:BSI190185> ns0:hasName "Department of Neurobiology, A.I. Virtanen Institute"@en,
        "Department of Neurobiology, A.I.Virtanen Institute"@en .

<http://ld.iospress.nl/rdf/organization/Affiliation:affd.Author:3.ID:DS190019> ns0:hasName "Knowledge Media Institute"@en .

ns121:AO190211 ns0:hasName "Department of Computer Science"@en .

ns1:aac-v10-i2-AAC192101 ns0:hasKeywords "Computational argumentation"@en,
        "benchmarks"@en,
        "community resources"@en ;
    ns0:hasPubAbstract "In this paper, we provide an overview of the benchmarks that have been recently employed in Abstract Argumentation. We first describe the benchmark suite from previous editions of the International Competition of Computational Models of Argumentation (ICCMA), and then briefly describe the benchmarks for non-Dung frameworks. This article is a contribution to the new Argument & Computation Community Resources (ACCR) corner."@en ;
    ns0:hasPubTitle "Assessment of benchmarks for abstract argumentation"@en .

ns1:adr-v3-i1-ADR190132 ns0:hasKeywords "Alzheimer’s disease"@en,
        "N-terminally truncated Aβ"@en,
        "cognitive deficits"@en,
        "fear conditioning"@en,
        "hippocampus"@en,
        "neuron loss"@en,
        "prepulse inhibition"@en,
        "sensorimotor gating"@en ;
    ns0:hasPubAbstract "Sensorimotor deficits have been described in several neuropsychiatric disorders including Alzheimer’s disease. The aim of the present study was to evaluate possible sensorimotor gating deficits in the Tg4-42 mouse model of Alzheimer’s disease using the prepulse inhibition task (PPI). Previous studies indicated that the hippocampus is essentially involved in the regulation of PPI. We analyzed 7-month-old homozygous Tg4-42 mice as mice at this age display severe neuron loss especially in the CA1 region of the hippocampus. Our results revealed a reduced startle response and PPI in Tg4-42 mice. The observed deficits in startle response and PPI are likely due to altered sensory processing abilities rather than hearing deficits as Tg4-42 displayed intact hearing in the fear conditioning task. The present study demonstrates for the first time that sensorimotor gating is impaired in Tg4-42 mice. Analyzing startle response as well as the PPI may offer valuable measurements to assess the efficacy of therapeutic strategies in the future in this Alzheimer’s disease model."@en ;
    ns0:hasPubTitle "Reduced Acoustic Startle Response and Prepulse Inhibition in the Tg4-42 Model of Alzheimer’s Disease"@en .

ns1:adr-v3-i1-ADR190135 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "curcumin"@en,
        "cyclin dependent kinase 5"@en,
        "donepezil"@en,
        "glycogen synthase kinase 3β"@en,
        "tau hyperphosphorylation"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is the most common form of dementia. Extracellular amyloid-β (Aβ) aggregation and tau hyperphosphorylation are the key drivers of AD. Glycogen synthase kinase 3 (GSK3) and cyclin dependent kinase 5 (Cdk5) have been known as leading applicants arbitrating abnormal tau hyperphosphorylation. Thus, we evaluated the efficacy and underlying mechanism of action of curcumin in scopolamine-induced AD rats in our study. We found that curcumin-treated AD rats markedly reduced the levels of Aβ40 and Aβ42 in the brain and in the plasma in comparison to untreated AD rats. Moreover, the levels of phosphorylated tau at Ser396 (PHF13), Ser202/Thr205 (AT8), and Aβ40/42 (MOAB2) were decreased significantly in AD rats treated with curcumin. Phospho-GSK3β (Tyr216), the active form of GSK3β, and total GSK3β were significantly decreased in AD rats treated with curcumin. Furthermore, Cdk5 and its activators p35 and p25 were significantly decreased in curcumin-treated AD rats. The reduced levels of Cdk5, p35, p25, and GSK3β in curcumin-treated AD rats may result decreased Aβ aggregation and tau hyperphosphorylation, thus ameliorating AD. Impaired spatial memory and locomotor activity in AD rats were partially reversed by curcumin. Therefore, curcumin, as a natural compound present in turmeric, may be a more effective therapeutic agent in the treatment of AD in humans."@en ;
    ns0:hasPubTitle "Curcumin Downregulates GSK3 and Cdk5 in Scopolamine-Induced Alzheimer’s Disease Rats Abrogating Aβ40/42 and Tau Hyperphosphorylation"@en .

ns1:ais-v11-i5-AIS190536 ns0:hasKeywords "Ambient assisted living"@en,
        "anomaly detection"@en,
        "elderly behavior analysis"@en,
        "health interventions"@en,
        "remote monitoring"@en ;
    ns0:hasPubAbstract "Rapid population aging and the availability of sensors and intelligent objects motivate the development of healthcare systems; these systems, in turn, meet the needs of older adults by supporting them to accomplish their day-to-day activities. Collecting information regarding older adults daily activity potentially helps to detect abnormal behavior. Anomaly detection can subsequently be combined with real-time, continuous and personalized interventions to help older adults actively enjoy a healthy lifestyle. This paper introduces a system that uses a novel approach to generate personalized health feedback. The proposed system models user’s daily behavior in order to detect anomalous behaviors and strategically generates interventions to encourage behaviors conducive to a healthier lifestyle. The system uses a Mamdani-type fuzzy rule-based component to predict the level of intervention needed for each detected anomaly and a sequential decision-making algorithm, Contextual Multi-armed Bandit, to generate suggestions to minimize anomalous behavior. We describe the system’s architecture in detail and we provide example implementations for the anomaly detection and corresponding health feedback."@en ;
    ns0:hasPubTitle "Personalized real-time anomaly detection and health feedback for older adults"@en .

ns1:ajw-v16-i4-ajw190043 ns0:hasKeywords "Runoff"@en,
        "disrupted homogeneity of runoff series"@en,
        "economic activity"@en,
        "spring flooding"@en,
        "summer low-water period"@en,
        "winter low-water period"@en ;
    ns0:hasPubAbstract "A runoff is a multi-factor phenomenon being of great importance in the life of humans, animals and plants. Rivers are known to meet the needs of biota and economic activity in fresh water. A channel runoff represents constantly replenished resources of self-purification capacity. This makes it almost the only source that provides the needs of industry, agriculture as well as housing and public utility sector in water of the required quality. The ecological situation of the territory and the extent to which natural complexes are changed due to the increased technogenic processes resulting in the depletion of the channel runoff and transformation of its regime, depend on the state of water bodies. This paper presents the study of the runoff formation factors and the role of economic activities in changing the water volume of rivers. Statistical methods and data on human activities within river basins were used in establishing the starting point of changes in the hydrological characteristics and determining the degree of the runoff change. Rivers with disrupted runoff regime were identified; changes in annual and seasonal runoff were assessed. The role of hydraulic engineering construction and irrigation reclamation facilities in the dynamics of hydrologic processes as the main factors of changes in the water volume of river systems was grounded. The study results can be used in water management calculations to restore runoff values, in construction of economic facilities in catchments and riverbeds, as well as in adjustment of water management circuits for industrial enterprises and settlements."@en ;
    ns0:hasPubTitle "Impact of Anthropogenic Factors on Runoff Formation in the Southern Urals"@en .

ns1:ajw-v16-i4-ajw190048 ns0:hasKeywords "Benthic communities"@en,
        "monsoon seasons"@en,
        "physico-chemical parameters"@en,
        "south-eastern coast of Bangladesh"@en ;
    ns0:hasPubAbstract "Benthic communities are important to any aquatic ecosystem and form important food source for most organisms especially fish. The study about macro benthos was carried out in a canal of south-eastern coast of Bangladesh with some physico-chemical parameters of water and soil during post and pre-monsoon seasons. The canal originates from hilly areas and opens into the Bay of Bengal. Polychaetes were the most abundant group followed by Oligocheates Bivalves crabs during post-monsoon. Oligocheates were the most abundant group followed by Polychaetes, Bivalves during pre-monsoon. Salinity showed positive significant relationship with the Polycheates and as well as Phosphate-Phosphorus. A negative significant relationship was found between Chemical Oxygen Demand (COD) and Oligocheates abundance in the investigated canal and a positive relationship was found between Total Suspended Solids and Oligocheates abundance. There was no relationship among the parameters of water as well as soil and crab abundance. The abundance of macro benthos is useful indicators of the condition of the canal and of the canal habitat as a whole. The effect of anthropogenic induced stressors had resulted in an unstable physically controlled environment characterized by a low density of macrobenthos."@en ;
    ns0:hasPubTitle "Abundance of Macrobenthos with Special Reference to Some Physico-Chemical Parameters of South-Eastern Coastal Area, Bangladesh"@en .

ns1:ao-v14-i3-AO190214 ns0:hasKeywords "Description Logics"@en,
        "OWL"@en,
        "Ontology of Events"@en,
        "SAT"@en,
        "SROIQ"@en ;
    ns0:hasPubAbstract "In recent years, there has been a growing interest in the application of foundational ontologies, i.e., formal ontological theories in the philosophical sense, to provide a theoretically sound foundation for improving the theory and practice of conceptual modeling and knowledge representation. This paper addresses one particular foundational theory of events termed UFO-B, which has been successfully employed as a reference model for addressing problems from complex media management, enterprise architecture, software engineering, and modeling of events in petroleum exploration. Despite its success, there is still no formalization of UFO-B in a decidable knowledge representation language that could support reasoning about complex events and event relations. We address this gap by proposing a number of alternative translations from UFO-B’s original axiomatization (in first-order logic and in the Alloy formal language) to the description logic  SROIQ, which is the formal underpinning of OWL 2 DL. Additionally, to support practical applications, we translated these  SROIQ theories to OWL 2 DL TBoxes, which were validated by showing that all the intended models of UFO-B (the logical models of the UFO-B specification in Alloy) that we generated are consistent with these UFO-B TBoxes. In a sense, the specification in Alloy implements the specification in first-order logic, while the OWL 2 TBoxes implement the  SROIQ specifications. Incidentally, the methodology that we designed for the translation from UFO-B’s original axiomatization in FOL and Alloy to  SROIQ came to be a key contribution of this work by providing us evidence of the inadequacy of DLs for the specification of comprehensive foundational ontologies."@en ;
    ns0:hasPubTitle "Representing a reference foundational ontology of events in  SROIQ"@en .

ns1:asy-v114-i3-4-ASY191520 ns0:hasKeywords "Helmholtz resonator"@en,
        "Subwavelength resonance"@en,
        "hybridization"@en,
        "metasurface"@en ;
    ns0:hasPubAbstract "In this paper, a mathematical modeling of the physical mechanism underlying the concept of tunable metasurfaces is provided. The scattering properties of two metasurfaces are analyzed. The considered metasurfaces are designed by placing either a Helmholtz resonator or a pair of Helmholtz resonators in a periodic lattice. The subwavelength resonant properties and the concept of hybridization of Helmholtz resonators are exploited in order to shape the scattered waves in unusual way by such metasurfaces."@en ;
    ns0:hasPubTitle "A mathematical framework for tunable metasurfaces. Part I"@en .

ns1:asy-v114-i3-4-ASY191521 ns0:hasKeywords "Tunable metasurface"@en,
        "cavity"@en,
        "field enhancement"@en ;
    ns0:hasPubAbstract "This paper is concerned with wave propagation inside a cavity with a tunable boundary condition. It is a follow-up of [Asympt. Anal. (2019), to appear]. Cavities, because they trap waves for long times due to their reflecting walls, are used in a vast number of scientific domains. Indeed, in these closed media and due to interferences, the free space continuum of solutions becomes a discrete set of stationary eigenmodes. These enhanced stationary fields are commonly used in fundamental physics to increase wave-matter interactions. The eigenmodes and associated eigenfrequencies of a cavity are imposed by its geometrical properties through the boundary conditions. In this paper, we show the effect of a small change of boundary condition on the Green’s function of the cavity. This is achieved through the use of a tunable reflecting metasurface. The boundary condition can be switched from Dirichlet to Neumann at some specific resonant frequencies."@en ;
    ns0:hasPubTitle "A mathematical framework for tunable metasurfaces. Part II"@en .

ns1:bd-v38-i2-BD180365 ns0:hasKeywords "Inflammatory Breast Cancer (IBC)"@en,
        "inflammation"@en,
        "metastases"@en ;
    ns0:hasPubAbstract "INTRODUCTION: Inflammatory Breast Cancer (IBC) is a distinct and rare type of breast cancer accounting for up to 6% of all breast cancer cases in Europe. The aim of this study was to investigate diagnostic methods, treatments, and outcome after IBC in patients treated at a single institution in Denmark.   METHOD: All patients treated for IBC at Aarhus University Hospital between 2000 and 2014 were identified and included in the cohort. Survival was assessed using Kaplan-Meier curves and log-rank statistics.   RESULTS: A total of 89 patients were identified with a median follow up of 3.6 years. The overall survival at 5 and 10 years were 41% and 18%, respectively. The disease free survival at 5 and 10 years were 47% and 27%, respectively. Thirty-four percent had distant metastasis at time of diagnosis. Patients with ER positive tumors had a significantly better overall survival than patients with ER negative tumors (p = 0.01).   CONCLUSION: Despite a more aggressive systemic and loco-regional treatment today, IBC is still a very serious disease with a high mortality."@en ;
    ns0:hasPubTitle "Inflammatory breast cancer: A review from our experience"@en .

ns1:blc-v5-i2-BLC180206 ns0:hasKeywords "CD8"@en,
        "Urothelial carcinoma"@en,
        "methodology"@en,
        "prognosis"@en ;
    ns0:hasPubAbstract "Background: Major interest lies in the evaluation of immune infiltrate in bladder cancer. CD8+ cytotoxic lymphocytes are key effectors of adaptive immune response.   Objectives: The aims of the study were to set up a standardized methodology for CD8+ lymphocytes estimation in NMIBC and investigate how intra-tumoral heterogeneity influences CD8+ immune infiltrate.   Methods: We considered 995 NMIBC included in the Spanish Bladder Cancer (SBC)/EPICURO Study. Duplicate 0.6 mm TMA spots and paired full sections (FS) for 50 selected cases were double stained with anti-pan cytokeratin antibody and anti-CD8 antibody. Slides were digitalized and CD8+ cells were automatically counted after tissue recognition (tumor vs stroma). Spatial heterogeneity was assessed and a resampling strategy was applied to estimate the proper number of 0.6 mm TMA spots providing an adequate CD8+ cell estimate. Association between CD8+ count and expression of urothelial differentiation markers was estimated. Cox regression models were performed to assess association between CD8+ cell count and risk of recurrence and progression.   Results: Microscopic examination of full sections showed spatial heterogeneity for CD8+ infiltrates. Simulation analyses demonstrated that 5 TMA regions provided a correct sampling of tumor and stromal compartments in Ta while 2 and 6 TMA regions were necessary in T1, respectively. CD8+ cells infiltration was associated with stage, regardless of the histological compartment analyzed (median CD8 + /mm2 were 25/mm2 and 129/mm2 in tumor and stroma respectively in Ta and 111/mm2 and 344/mm2 in T1; p-value = 0.006). CD8+ infiltration in tumor compartment was significantly associated with low FGFR3 expression. CD8 + /mm2 count in the tumor compartment was not associated with prognosis.   Conclusion: Differences identified between Ta and T1 tumours supported the hypothesis that rigorous efforts should be placed in proper study design. These results provide a new framework to investigate microenvironment complexity in bladder cancer."@en ;
    ns0:hasPubTitle "CD8+ Cytotoxic Immune Infiltrate in Non-Muscle Invasive Bladder Cancer: A Standardized Methodology to Study Association with Clinico-Pathological Features and Prognosis"@en .

ns1:blc-v5-i3-BLC190236 ns0:hasKeywords "BCG"@en,
        "Carcinoma in situ"@en,
        "NMIBC"@en,
        "bladder cancer"@en,
        "transitional cell carcinoma"@en ;
    ns0:hasPubAbstract "Purpose of the review: To review the most recent literature with regards to the pathogenesis, diagnostics, clinical implications and treatment strategies for Carcinoma in Situ (CIS) of the Bladder.   Recent findings: There have been advancements in understanding the genetic composition and biochemical behavior of CIS. Technological advancements including Photodynamic Diagnosis (PDD) with Hexaminolevulinate (HVA) better detect CIS compared to traditional white light (WL) cystoscopy. Recently published single and multi-center studies have enabled better understanding of the impact of CIS on clinical and cancer related outcomes, including disease recurrence and patient survival. Alternative intravesical chemotherapeutic and immunotherapies for CIS have been investigated, especially in the setting of Bacillus Calmette-Guerin (BCG) unresponsive disease. While these demonstrate a great deal of promise, they have not garnered much success.   Summary: The genetics of CIS is linked to aggressive, and at times resistant disease, with increased cancer progression and associated clinically worse cancer specific outcomes. New technologies have enabled a more effective diagnosis of CIS. The development of a standardized definition for clinical trials and greater disease understanding will enable us to develop better treatment options."@en ;
    ns0:hasPubTitle "CIS of the Bladder: Significance and Implications for Therapy"@en .

ns1:bmr-v32-i4-BMR181128 ns0:hasKeywords "Blount and Moe exercise"@en,
        "Spinal deformity"@en,
        "brace"@en,
        "static balance"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Exercises are usually prescribed in association with orthotic intervention for management of idiopathic scoliosis, however the role of these exercises on the efficacy of brace and/or balance is not clear yet.   OBJECTIVES:  To investigate the role of exercise (the Blount and Moe protocol) on static balance and Cobb angle changes in adolescents with spinal deformities during weaning from brace.   METHODS:  Seventeen brace users were allocated into 3 groups (good, moderate, and weak), according to their exercise quality and quantity static balance was evaluated on 4 conditions (standing on a platform/foam; with/without brace) using a force platform. Center of pressure displacement parameters were compared among the 3 groups. The mean Cobb angles of scoliosis and kyphosis at the beginning of brace use and at the start of the weaning phase were compared in general and among the 3 analogous groups.   RESULTS:  No significant difference was found in the static balance parameters and also in Cobb angles among the 3 groups. However, scoliosis and kyphosis Cobb angles were improved significantly as a result of using the brace (p< 0.01).   CONCLUSIONS:  The exercise quantity and quality in association with bracing, up to the weaning phase, has no effect on static balance and changes in scoliosis and kyphosis, but the curvature of scoliosis and kyphosis is reduced after wearing a brace."@en ;
    ns0:hasPubTitle "Effect of exercise on static balance and Cobb angle during the weaning phase of brace management in idiopathic scoliosis and hyperkyphosis: A preliminary study"@en .

ns1:bmr-v32-i4-BMR181131 ns0:hasKeywords "Golfers"@en,
        "ice-hockey players"@en,
        "muscle power"@en,
        "tennis players"@en,
        "trunk rotations"@en ;
    ns0:hasPubAbstract "BACKGROUND:  The asymmetric loading of trunk muscles in sports like golf or tennis may cause side-to-side imbalances in rotational muscle strength and endurance. Such imbalances may be compounded by the presence of low back pain (LBP) and related injuries. However, trunk rotational power is a better predictor of athlete performance, and therefore its ability to reveal these asymmetries/dysbalances should be investigated.   OBJECTIVE:  This study compares peak and mean values of power during trunk rotations on the dominant and non-dominant side in golfers, ice-hockey players, tennis players, and an age-matched control group of fit individuals.   METHODS:  Groups of 17 golfers, 17 ice-hockey players, 21 tennis players, and 39 fit individuals performed standing trunk rotations to each side with a bar weight of 5.5, 10.5, 15.5, and 20 kg placed on the shoulders. Peak power and mean power in the acceleration phase of trunk rotations were measured using the FiTRO Torso Premium system.   RESULTS:  Peak power and mean power in the acceleration phase of trunk rotations were significantly higher on the dominant (D) than non-dominant (ND) side at weights of 5.5 kg (14 and 14%), 10.5 kg (17 and 14%), 15.5 kg (16 and 15%), and 20 kg (16 and 16%) in ice-hockey players, at 5.5 kg (14 and 13%), 10.5 kg (17 and 14%), and 15.5 kg (15% – only peak power) in tennis players, and at 5.5 kg (17 and 18%) and 10.5 kg (19 and 17%) in golfers. However, their values did not differ significantly at these weights (< 10%) in the age-matched control group. The D/ND ratio was the highest in ice-hockey players (1.18, 1.19), followed by golfers (1.16, 1.17) and finally tennis players (1.12, 1.16).   CONCLUSION:  Taking into account significantly higher trunk rotational power on the dominant than the non-dominant side in golfers, tennis players and ice-hockey players at lower and/or higher weights and no significant side-to-side differences in a control group of fit individuals, this parameter may be considered specific to their asymmetric loading during trunk rotations. However, whether these asymmetries/dysbalances expressed by the D/ND ratio could also identify the likelihood of LBP, needs to be proven."@en ;
    ns0:hasPubTitle "Between-side differences in trunk rotational power in athletes trained in asymmetric sports"@en .

ns1:bmr-v32-i4-BMR181228 ns0:hasKeywords "Forward head posture"@en,
        "exercise"@en,
        "mobilization"@en,
        "neck pain"@en,
        "respiration"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Although commonly utilized treatments, no study has directly compared the effectiveness of joint mobilization and stabilization exercise in individuals with forward head posture (FHP).   OBJECTIVE: This study aimed to investigate the effects of upper cervical and upper thoracic spine mobilization versus deep cervical flexors exercise (DCFE) in individuals with FHP.   METHODS:  Thirty-one participants with FHP were randomized into the mobilization (n= 15) or exercise (n= 16) group. The treatment period was 4 weeks with follow-up assessment at 4 weeks and 6 weeks after the initial examination. Outcomes assessed included the craniovertebral angle (CVA), numeric pain rating scale (NPRS), respiratory function, and the global rating of change (GRC).   RESULTS: Participants in the mobilization group demonstrated significant improvements (p< 0.05) in CVA, NPRS, and respiratory function, as compared to those in the exercise group. In addition, 9 of 15 (60%) participants in the mobilization group, as compared to 4 of 16 participants (25%) in the exercise group, had a GRC score of +4 or higher.   CONCLUSIONS: The combination of upper cervical and upper thoracic spine mobilization indicated better overall short-term outcomes in CVA, NPRS, respiratory function, and GRC compared with DCFE in individuals with FHP."@en ;
    ns0:hasPubTitle "Upper cervical and upper thoracic spine mobilization versus deep cervical flexors exercise in individuals with forward head posture: A randomized clinical trial investigating their effectiveness"@en .

ns1:bmr-v32-i6-BMR181236 ns0:hasKeywords "Chronic low back pain"@en,
        "posture"@en,
        "surface electromyography"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Changes in the motor control of the spine were found in patients with chronic low back pain (CLBP). Sudden loading of the spine is supposed to be the cause of about 12% of lower back injuries. However, some aspects of this problem, such as alterations in the sensory-motor control of the spine, remain questionable.   OBJECTIVE:  To investigate the effects of familiarization with loading, weight and size of loading on neuromuscular responses during sudden upper limb loading in CLBP patients.   METHODS:  In this quasi-experimental study surface electromyography of the erector spinae (ES) and transverses abdominis/internal oblique (TrA/IO) and external oblique (EOA) muscles were recorded in 7 men and 13 women with CLBP and 20 asymptomatic subjects (10 men and 10 women) aged 18–45 years from the general community familiarization. Moreover, investigating control of the posture measurements of the center of pressure (COP) and vertical ground reaction force (GRF) or Fz were recorded using a force plate. Data were analyzed using paired t-test and independent t-test with the significance level of 0.05.   RESULTS:  Data analyses were performed using SPSS version 18. Some electromyography and force plate variables were significantly different for different conditions in each group and between the asymptomatic and low back pain groups (p⩽ 0.05).   CONCLUSION:  Several motor control changes were observed in the CLBP patients. These patients showed decreased trunk muscle activity as well as too early and too delayed responses compared to asymptomatic subjects."@en ;
    ns0:hasPubTitle "The effects of familiarization with loading, weight and size of loading on neuromuscular responses during sudden upper limb loading in chronic low back pain patients"@en .

ns1:brs-v14-i4-BRS190143 ns0:hasKeywords "Acceleration"@en,
        "B-WIM"@en,
        "Kalman filter"@en,
        "MFI"@en,
        "decomposition"@en,
        "measurements"@en,
        "orthogonal"@en,
        "proper"@en,
        "strain"@en ;
    ns0:hasPubAbstract "Bridge Weigh-in-Motion (B-WIM) is the theory of utilizing field measurements to infer the weights of the overhead traffic that passes at full highway speed. There exist a consensus that conventional instrumentation faces substantial practical problems that halts the feasibility of this theory, namely installation time and complexity, especially for high elevation bridges. This article will escort through a new concept by moving from B-WIM system based on strain data to a new B-WIM system based on acceleration records. Kalman-filter-based estimation algorithm is developed to estimate the state vector (displacement and velocities) using limited measured acceleration response. The measured response is transformed to the modal response using the pseudoinverse of the mode shape matrix, which allows utilizing limited measurements number during the estimation process. The estimated state vector is used to feed a moving force identification (MFI) algorithm that shows a good estimating for a quarter-car load."@en ;
    ns0:hasPubTitle "Acceleration-based bridge weigh-in-motion"@en .

ns1:brs-v15-i1-2-BRS190154 ns0:hasKeywords "Dynamic analysis"@en,
        "Winkler model"@en,
        "seismic analysis"@en,
        "soil-structure interaction"@en,
        "spatial variability"@en ;
    ns0:hasPubAbstract "In the US, bridges classified as critical and irregular (in select seismic zones) are required to be designed for seismic loadings using time-history analysis. To promote use of time-history analysis in designs across wider ranges of bridge configurations and seismic site classifications, design-oriented tools are being developed. In this study, a multiple-support excitation algorithm was used in conjunction with the beam on nonlinear Winkler foundation model to compare piled substructure responses from an in-service integral abutment bridge, which was subjected to a parametric set of ground motions. The effects of spatially varying (versus non-spatially varying) ground motions on design-relevant response quantities were assessed, and the merits of conducting analyses with and without considerations for spatial variability in ground motions were emphasized. Based on the results presented, conditions were identified under which simplifying assumptions may be warranted in conducting nonlinear dynamic analysis for bridge seismic design."@en ;
    ns0:hasPubTitle "Comparative study of spatially and non-spatially varying ground motions in design-oriented seismic analysis of bridges"@en .

ns1:cbm-v25-i2-CBM182020 ns0:hasKeywords "AIB1"@en,
        "immunohistochemistry"@en,
        "prognosis"@en,
        "upper tract urothelial carcinoma"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Amplified in breast cancer 1 (AIB1) is a candidate oncogene in human breast cancer, which has been identified to be amplified and overexpressed in several types of other human cancers. Abnormalities of AIB1 and its clinical/prognostic significance, however, in upper tract urothelial carcinoma (UTUC) remain unclear.   OBJECTIVE:  To explore what role AIB1 plays in upper tract urothelial carcinoma.   METHODS:  The expression of AIB1 was analyzed using immunohistochemical staining in 133 UTUC patients. Overall, cancer specific and recurrence-free survival rates (OS, CSS, and RFS) were estimated using the Kaplan-Meier method. Multivariable COX regression models containing relevant clinicopathological variables addressed the prediction of postoperative outcome.   RESULTS:  High AIB1 expression was observed to be associated with increased hazard ratios for 5-year CSS (80.6% vs. 55.8%, p= 0.008) and OS (78.1% vs. 54.8%, p= 0.006). Multivariable analysis revealed that elevated AIB1 expression was an independent prognostic predictor of OS, CSS and RFS. Additionally, pT, pN and hydronephrosis were independently associated with oncologic outcome of UTUC. Three proposed nomograms were proposed to provide an individualized risk estimate of postoperative outcome in patients with UTUC.   CONCLUSIONS:  AIB1 can be used as an independent molecular marker for the prognosis of clinical outcomes of UTUC."@en ;
    ns0:hasPubTitle "Impact of AIB1 expression on the prognosis of upper tract urothelial carcinoma after radical nephroureterectomy"@en .

ns1:cbm-v25-i4-CBM182212 ns0:hasKeywords "Monocytes"@en,
        "overall survival"@en,
        "pediatric solid tumors"@en,
        "progression free survival"@en ;
    ns0:hasPubAbstract "BACKGROUND AND AIM:  We aimed to quantify monocyte subsets in newly diagnosed pediatric patients with solid tumors at South Egypt Cancer Institute (SECI) and Assiut University Hospital (AUH), and investigate their roles in the treatment outcomes.   PATIENTS AND METHODS:  This is a prospective case-controlled study included 100 patients with de novo solid tumors and forty age and sex matched healthy children to provide blood samples as control subjects to determine normal count of monocyte subsets, blood samples were collected from cancer patients before the first cycle of chemotherapy, these blood samples were subjected to routine laboratory tests and assessment of monocyte subsets using flow cytometry.   RESULTS:  Significant accumulations of intermediate monocytes and non classical monocytes (P< 0.000) in pediatric cases compared to controls were detected, there was a significant impact of non classical and intermediate monocytes on the type of response (P< 0.008, P< 0.4 respectively), The median OS for 100 patients with pediatric solid tumors involved in our study was 27 ± 0.589 months with 95% CI = 25.846–28.154, while the median PFS was 26 ± 0.610 months with 95% CI = 24.805–27.195, significant positive correlation between non-classical monocytes and OS (r=+0.659, P< 0.041).   CONCLUSION:  Solid conclusion regarding the impact of monocyte classes in pediatric tumors is premature, although, in this study, non-classical and intermediate monocytes were associated with better response to treatment in pediatric solid tumors and non-classical monocytes were correlated with higher overall survival; further studies are needed for better understanding and specification of monocyte functions in different pediatric tumors."@en ;
    ns0:hasPubTitle "Prognostic impact of circulating monocyte subsets in pediatric solid tumors"@en .

ns1:cbm-v26-i3-CBM182143 ns0:hasKeywords "Bladder cancer"@en,
        "TATI"@en,
        "combined expression"@en,
        "p53"@en,
        "prognostic value"@en,
        "progression"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Urothelial carcinoma of the bladder is a heterogeneous disease for which reliable prognostic molecular biomarkers have not been established.   OBJECTIVE:  To investigate the prognostic value of tumor-associated trypsin inhibitor (TATI) expression combined with p53 expression in bladder cancer patients who have undergone radical cystectomy.   METHODS:  Tissue microarrays from 110 patients were analyzed immunohistochemically for TATI and p53 protein expression. Complete clinical-pathological information and follow-up data were collected. Univariable Kaplan-Meier analysis and log-rank test were performed to assess the association between TATI and p53 expression patterns with clinical outcomes. Cox’s proportional hazard analysis was performed to identify potential independent risk factors for predicting disease progression and evaluate the prognostic value of combining the expression of TATI and p53 on progression-free survival (PFS) and overall survival (OS).   RESULTS:  TATI expression was positively correlated with favorable differentiation of bladder cancer, and lower tumor stage. p53 expression was positively related to tumor stage, tumor grade, and lymph-node invasion. Univariate Kaplan-Meier analysis revealed significant differences between TATI-positive vs. TATI-negative and p53-positive vs. p53-negative patients, regarding PFS. Multivariate analysis showed that both TATI and p53 expression were independent factors for predicting disease progression.   CONCLUSION:  TATI expression patterns could enhance the prognostic value of p53 overexpression on progression."@en ;
    ns0:hasPubTitle "Prognostic value of the combined expression of tumor-associated trypsin inhibitor (TATI) and p53 in patients with bladder cancer undergoing radical cystectomy"@en .

ns1:ch-v72-i1-CH180428 ns0:hasKeywords "Endothelial glycocalyx"@en,
        "joint surgery"@en,
        "neuraxial anesthesia"@en ;
    ns0:hasPubAbstract "BACKGROUND: Damage of the endothelial glycocalyx (EG) has been described during surgery, but the effect of different anesthesia techniques remains unknown. Perfused boundary region (PBR) evaluated by side-stream dark field (SDF) imaging of the sublingual microcirculation enables in vivo EG assessment. PBR values are inversely related to the EG thickness.   OBJECTIVE: The aim of the observational study was to evaluate the changes of PBR in patients undergoing elective joint surgery under general (GA) vs. neuraxial anesthesia (NA). Our hypothesis was that PBR will be lower in patients in NA.   METHODS: Sixty consecutive patients (ASA 1–3) undergoing elective total knee or hip replacement under GA or NA were included in this prospective observational cohort study. PBR in the sublingual microcirculation was recorded in each patient using SDF at two time points - before surgery and 2 hours after surgery.   RESULTS: Before surgery, there was no significant difference in baseline PBR between groups (NA: 1.95 μm (±0.24); GA: 2.02 μm (±0.26); p = 0.098). Postoperatively (2 hours after surgery) PBR was significantly increased in both groups with respect to baseline values (NA: 2.09 μm (±0.19), GA: 2.20 μm (±0.25); p < 0.001). In the GA group, postoperative PBR values were significantly higher than in the NA group (p = 0.006).   CONCLUSION: Joint surgery led to significant increases of PBR. Patients in the GA group had significantly higher PBR values 2 hours after surgery compared to NA group. This might implicate that NA is associated with less EG damage then GA in elective hip/knee surgery."@en ;
    ns0:hasPubTitle "Neuraxial anesthesia is less harmful to the endothelial glycocalyx during elective joint surgery compared to general anesthesia"@en .

ns1:ch-v72-i1-CH180452 ns0:hasKeywords "Thyroid"@en,
        "elastography"@en,
        "guideline"@en,
        "shear wave elastography"@en,
        "ultrasound"@en ;
    ns0:hasPubAbstract "Ultrasound elastography has been introduced into clinical practice for a decade and arisen continuous increasing attention worldwide. Shear wave elastography (SWE) is a further extension of ultrasound elastography on the basis of strain elastography, providing a two-dimensional distribution map of tissue stiffness and quantitative measurement of the tissue stiffness in Young’s modulus (kPa) and/or shear wave speed (m/s). The Society of Ultrasound in Medicine, Chinese Medical Association (CMA) has recently released a series of guidelines for the use of SWE, including the technique and principle of SWE, and use of SWE in liver fibrosis, breast, thyroid, and musculoskeletal system. Herein, a part of SWE in thyroid nodules is presented. In this guideline, the background, classification and technology of SWE, examination methods, diagnostic performance, prognosis evaluation, reproducibility, and limitations are discussed and recommendations are given. The recommendations are based on the published literatures with regard to SWE with different levels of evidence, particularly a mid-term result of the prospective multi-center clinical trial of SWE in thyroid, as well as the Society of Ultrasound in Medicine, CMA expert’s consensus. The document provides an overall analysis of SWE in thyroid from clinical perspective, which aimed to provide recommendations to the clinicians with regard to the management of thyroid nodules by the assistance of SWE."@en ;
    ns0:hasPubTitle "Guidelines and recommendations on the clinical use of shear wave elastography for evaluating thyroid nodule1"@en .

ns1:ch-v72-i2-CH180450 ns0:hasKeywords "ICG angiography"@en,
        "NPWT"@en,
        "O2C"@en,
        "SPY"@en,
        "Skin perfusion patterns"@en,
        "abdominoplasty"@en,
        "body contouring surgery"@en,
        "ciNPT"@en,
        "ciNPWT"@en,
        "closed incisional negative pressure wound therapy"@en,
        "combined laser Doppler spectrophotometry"@en,
        "high-risk patients"@en,
        "maintenance of weight loss"@en,
        "obesity"@en,
        "oxygen saturation"@en,
        "postbariatric surgery"@en,
        "postoperative complications"@en,
        "postoperative wound care"@en,
        "relative hemoglobin content"@en,
        "weight loss"@en,
        "wound healing"@en ;
    ns0:hasPubAbstract "BACKGROUND: Negative pressure wound therapy applied over closed incisions (ciNPT) has been shown to influence wound healing. Therefore, the aim of this study was to examine the short-term effects of ciNPT on skin perfusion patterns in postbariatric wounds.   METHODS: 17 patients were included. Patients from the study group received a ciNPT dressing with a continuous negative pressure of – 125 mmHg for five days. Two intra- and two postoperative measurements were performed using both a combined laser Doppler spectrophotometry and an ICG angiography system to determine oxygen saturation (sO2), hemoglobin content (rHb) and perfusion patterns.   RESULTS: Three days postoperatively the sO2 was significantly higher in the study group compared to the control group and also compared to the end of the operation. Concerning the rHb, there was no statistical significant alteration in or between the groups, but a trend towards a correlated alteration of sO2 and rHb. ICG angiography showed an earlier and stronger enhancement of perfusion parameters in the study group.   CONCLUSION: CiNPT has a positive effect on oxygen saturation and tissue perfusion, which are both associated with the wound healing process. The use of ciNPT could therefore possibly reduce the risk of wound healing complications in this high-risk patient group."@en ;
    ns0:hasPubTitle "Changes of perfusion patterns of surgical wounds under application of closed incision negative pressure wound therapy in postbariatric patients1"@en .

ns1:ch-v73-i1-CH199213 ns0:hasKeywords "Lymphedema surgery"@en,
        "lymphovenous anastomosis"@en,
        "microsurgery"@en,
        "postoperative care"@en,
        "results"@en ;
    ns0:hasPubAbstract "BACKGROUND: The optimal surgical treatment for lymphedema is still subject of intensive research. Therefore, it is vital to investigate what significance lymphovenous anastomosis (LVA) has in this context.   OBJECTIVE: This study aims to determine the short- and long-term results as well as the most important factors that can improve outcomes after LVA.   METHODS: This study includes a complete data set of 26 patients who received LVA for a therapy-resistant lymphedema. Patients were followed up for an average of 23 months.   RESULTS: 50% of the patients reported a subjective improvement. Without conservative treatment after the operation the patients showed significant better results (100% vs. 40.9%, p = 0.030). The localization of lymphedema as well as the region of LVA had a significant influence. In patients with lymphedema affecting the entire leg, symptom improvement was significantly lower (35.3% vs. 77.8%, p = 0.039). Patients who received LVA in an upper limb show a significantly higher improvement in symptoms than patients who received LVA in a lower limb (100% vs. 30%, p = 0.021).   CONCLUSIONS: We identified factors with a significant influence on the outcome of patients after receiving LVA. Patients with early-stage upper extremity lymphedema seem to benefit most from this procedure."@en ;
    ns0:hasPubTitle "Factors affecting outcomes after supermicrosurgical lymphovenous anastomosis in a defined patient population"@en .

ns1:com-v8-i2-COM180231 ns0:hasKeywords "Asymptotic density"@en,
        "coarse computability"@en,
        "dense computability"@en,
        "generic computability"@en,
        "quasiminimality"@en,
        "reducibilities"@en ;
    ns0:hasPubAbstract "This paper concerns algorithms that give correct answers with (asymptotic) density 1. A dense description of a function  g : ω → ω is a partial function f on ω such that  { n : f ( n ) = g ( n ) } has density 1. We define g to be densely computable if it has a partial computable dense description f. Several previous authors have studied the stronger notions of generic computability and coarse computability, which correspond respectively to requiring in addition that g and f agree on the domain of f, and to requiring that f be total. Strengthening these two notions, call a function g effectively densely computable if it has a partial computable dense description f such that the domain of f is a computable set and f and g agree on the domain of f. We compare these notions as well as asymptotic approximations to them that require for each  ε > 0 the existence of an appropriate description that is correct on a set of lower density of at least  1 − ε. We show that certain implications hold among these various notions of approximate computability, and that no other implications between these notions hold, in the strong sense that any Boolean combination of these notions is satisfied by a c.e. set unless it is ruled out by the implications we describe. We define reducibilities corresponding to dense and effectively dense reducibility and show that their uniform and nonuniform versions are different. We show that there are natural embeddings of the Turing degrees into the corresponding degree structures, and that these embeddings are not surjective and indeed that sufficiently random sets have quasiminimal degree. We show that nontrivial upper cones in the generic, dense, and effective dense degrees are of measure 0 and use this fact to show that there are minimal pairs in the dense degrees."@en ;
    ns0:hasPubTitle "Dense computability, upper cones, and minimal pairs"@en .

ns1:ds-v2-i1-2-DS190015 ns0:hasKeywords "SciGraph"@en,
        "Spatial scientometrics"@en,
        "affiliations"@en,
        "conference papers"@en,
        "grid.ac"@en,
        "scholarly communication"@en,
        "scholarly knowledge"@en ;
    ns0:hasPubAbstract "In the last decade, the research literature has reached an enormous volume with an unprecedented current annual increase of 1.5 million new publications. As research gets ever more global and new countries and institutions, either from academia or corporate environments, start to contribute, it is important to monitor this complex phenomenon and understand its dynamics and equilibria. We present a study on a conference proceedings dataset extracted from Springer Nature SciGraph that illustrates insightful geographical trends and highlights the unbalanced growth of competitive research institutions worldwide in the 1996–2016 period. The main contribution of this work is fourfold. In the first instance, we found that the distributions of institutions and publications among countries follow a power law, consistently with previous literature, i.e., very few countries keep producing most of the papers accepted by high-tier conferences. Secondly, we show how the turnover rate of country rankings is extremely low and steadily declines over time, suggesting an alarmingly static landscape in which new entries struggle to emerge. We also performed an analysis of the venue locations and their effect on the distribution of countries involved in the publications, underlining the central role of Europe and China as knowledge hubs. Finally, we evidence the presence of an increasing gap between the number of institutions initiating and overseeing research endeavours (i.e. first and last authors’ affiliations) and the total number of institutions participating in research. The paper also discusses our experience in working with authors’ affiliations: an utterly simple matter at first glance, that is instead revealed to be a complex research and technical challenge."@en ;
    ns0:hasPubTitle "Geographical trends in academic conferences: An analysis of authors’ affiliations"@en .

ns1:ds-v2-i1-2-DS190023 ns0:hasKeywords "Semantic publishing"@en,
        "data mining"@en,
        "ontologies"@en,
        "scholarly data"@en,
        "visual analytics"@en ;
    ns0:hasPubAbstract "The increasing interest in analysing, describing, and improving the research process requires the development of new forms of scholarly data publication and analysis that integrates lessons and approaches from the field of Semantic Technologies, Science of Science, Digital Libraries, and Artificial Intelligence. This editorial summarises the content of the Special Issue on Scholarly Data Analysis (Semantics, Analytics, Visualisation), which aims to showcase some of the most interesting research efforts in the field. This issue includes an extended version of the best papers of the last two editions of the “Semantics, Analytics, Visualisation: Enhancing Scholarly Dissemination” (SAVE-SD 2017 and 2018) workshop at The Web Conference."@en ;
    ns0:hasPubTitle "Editorial: Special Issue on Scholarly Data Analysis (Semantics, Analytics, Visualisation)"@en .

ns1:fi-v167-i3-FI1814 ns0:hasKeywords "bicluster"@en,
        "boolean reasoning"@en,
        "continuous data biclustering"@en,
        "discernibility function"@en,
        "dissimilarity biclusters"@en,
        "prime implicants"@en,
        "similarity biclusters"@en ;
    ns0:hasPubAbstract "Biclustering is considered as the method of finding two–dimensional subgroups in a matrix of scalars. The paper introduces a new approach to biclustering continuous matrices on the basis of boolean function analysis. We draw the strong relation between inclusion–maximal (maximal with respect to inclusion) biclusters of the assumed maximal difference between the data in a bicluster and prime implicants of a boolean function describing the data. These biclusters are called similarity biclusters. In the opposition to them, a new notion of dissimilarity biclusters was also introduced in the paper."@en ;
    ns0:hasPubTitle "On Boolean Representation of Continuous Data Biclustering"@en .

ns1:fi-v168-i2-4-FI1831 ns0:hasKeywords "EEG"@en,
        "brain activity"@en,
        "brain-computer interfaces"@en,
        "data clustering"@en,
        "deep learning"@en,
        "machine learning"@en ;
    ns0:hasPubAbstract "A method for assessing separability of EEG signals associated with three classes of brain activity is proposed. The EEG signals are acquired from 23 subjects, gathered from a headset consisting of 14 electrodes. Data are processed by applying Discrete Wavelet Transform (DWT) for the signal analysis and an autoencoder neural network for the brain activity separation. Processing involves 74 wavelets from 3 DWT families: Coiflets, Daubechies and Symlets. Euclidean distance between clusters normalized with respect to the standard deviation of the whole set of data are used to separate each task performed by participants. The results of this stage allow for an assessment of separability between subsets of data associated with each activity performed by experiment participants. The speed of convergence of the training process employing deep learning-based clustering is also measured."@en ;
    ns0:hasPubTitle "Method for Clustering of Brain Activity Data Derived from EEG Signals"@en .

ns1:fi-v169-i1-2-FI1837 ns0:hasKeywords "Weighted Petri net"@en,
        "analysis"@en,
        "approximation"@en,
        "event graph"@en,
        "marked graph"@en,
        "persistence"@en,
        "synthesis"@en,
        "theory of regions"@en ;
    ns0:hasPubAbstract "Numerous real-world systems can be modeled with Petri nets, which allow a combination of concurrency with synchronizations and conflicts. To alleviate the difficulty of checking their behaviour, a common approach consists in studying specific subclasses. In the converse problem of Petri net synthesis, a Petri net of some subclass has to be constructed efficiently from a given specification, typically from a labelled transition system (lts) describing the behaviour of the desired net. In this paper, we focus on a notorious subclass of persistent Petri nets, the weighted marked graphs (WMGs), also called generalised (or weighted) event (or marked) graphs or weighted T-nets. In such nets, edges have multiplicities (weights) and each place has at most one ingoing and one outgoing transition. Although extensively studied in previous works and benefiting from strong results, both their analysis and synthesis can be further investigated. We provide new behavioural properties of WMGs expressed on their reachability graph, notably backward persistence and strong similarities between any two sequences sharing the same starting state and the same destination state. Besides, we design a general synthesis procedure aiming at the WMG class. Finally, when no solution to the synthesis problem exists, i.e., when the given lts is not WMG-solvable, we show how to construct a WMG whose reachability graph is a minimal over-approximation of the given lts."@en ;
    ns0:hasPubTitle "Analysis and Synthesis of Weighted Marked Graph Petri Nets: Exact and Approximate Methods"@en .

ns1:fi-v169-i1-2-FI1838 ns0:hasKeywords "Petri net"@en,
        "interval order"@en,
        "interval sequence"@en,
        "operational semantics"@en,
        "sequence of maximal antichains"@en ;
    ns0:hasPubAbstract "A representation of interval orders by sequences of antichains is discussed, and its relationship to the Fishburn’s representation by sequences of the beginnings and endings of domain elements is analysed in detail. Moreover, an operational semantics based on sequences of maximal antichains is proposed and investigated for a general class of safe Petri nets with context arcs."@en ;
    ns0:hasPubTitle "Operational Semantics, Interval Orders and Sequences of Antichains"@en .

ns1:fi-v171-i1-4-FI1874 ns0:hasKeywords "Minimal absent words"@en,
        "sequence comparison"@en,
        "similarity measures"@en ;
    ns0:hasPubAbstract "In this paper we investigate similarity measures based on minimal absent words, introduced by Chairungsee and Crochemore in [1]. They make use of a length-weighted index on a sample set corresponding to the symmetric difference M(x)ΔM(y) of the minimal absent words M(x) and M(y) of two sequences x and y, respectively. We first propose a variant of this measure by choosing as a sample set a proper subset 𝒟(x, y) of M(x)ΔM(y), which appears to be more appropriate for distinguishing x and y. From the algebraic point of view, we prove that 𝒟(x, y) is the base of the ideal generated by M(x)ΔM(y). We then remark that such measures are able to recognize whether the sequences x and y share a common structure, but they are not able to detect the difference on the number of occurrences of such a structure in the two sequences. In order to take into account such a multiplicity, we introduce the notion of multifactor, and define a new measure that uses both absent words and multifactors. Surprisingly, we prove that this similarity measure coincides with a distance on sequences introduced by Ehrenfeucht and Haussler in [2], in the context of block-moves strategies. In this way, our result creates a non trivial bridge between similarity measures based on absent words and those based on the block-moves approach."@en ;
    ns0:hasPubTitle "Some Investigations on Similarity Measures Based on Absent Words"@en .

ns1:hab-v27-i3-HAB190373 ns0:hasKeywords "Haemophilus influenzae type b"@en,
        "anti-CPS"@en,
        "antibody isotypes"@en,
        "herd immunity"@en,
        "innate immunity"@en,
        "seroepidemiology"@en,
        "vaccines"@en ;
    ns0:hasPubAbstract "Haemophilus influenzae type b (Hib) are one of most dangerous microbes that occupies the paediatric nasopharyngeal as a commensal opportunistic bacterium, which may lead to meningitis in uncontrolled infection. Colonisation of pharyngeal tissues is the starting point for most H. influenzae infections, which may develop into invasive diseases, such meningitis. The vaccination against Hib in specific, as well as against most of vaccines preventable diseases; in general, play a major role in reducing children (< 5 years old) Hib meningitis from 57/100,000 to the lowest known Hib meningitis incidents in the history. First invented Hib vaccine was licensed in 1985 and contained Hib capsular polysaccharide (CPS); afterward, conjugate vaccines have been innovated and licensed on the road to improve Hib vaccine efficacy. Polyribosylribitol phosphate (PRP) is the main vaccine unite structure. Since anti-CPS antibodies in the serum reflect the extent of the acquired immunity against Hib infections, the concentration of ⩾ 0.15 g/ml of anti-CPS is believed to be an indicator for short-term protection from invasive Hib diseases, whereas one-month post-completion of primary Hib immunization concentration of ⩾ 1.0 g/ml is trusted to be immunological protective. As considered that serum anti-CPS antibodies are effectively linked to protection, the evaluation of antibodies concentration and reconsideration of published worldwide populations antibodies concentration are consider vital strides on the way to accurate valuation of Hib immunity that induced by vaccination; either direct or herd. As documented, some populations; worldwide, still susceptible to invasive Hib infections. Several populations worldwide remain vulnerable to Hib-related infections. We believe that up-to-date review article regarding circulated Hib immunology, represented in anti-Hib antibodies and worldwide Hib incidences will provide a precious information for microbiologists, public health officials, epidemiologists, immunologists, and strategic preventive healthcare executives."@en ;
    ns0:hasPubTitle "Circulating innate and adaptive immunity against anti-Haemophilus influenzae type b"@en .

ns1:hab-v27-i4-HAB190386 ns0:hasKeywords "Menstrual cycle"@en,
        "Nigeria"@en,
        "Sokoto"@en,
        "Usmanu Danfodiyo University"@en,
        "acute phase reactants"@en,
        "students"@en ;
    ns0:hasPubAbstract "BACKGROUND:  The menstrual cycle is the cycle of natural variations that occurs in the uterus and ovary as an essential part of making sexual reproduction possible. It is characterized by hormonal changes but the changes that occur in some active phase reactants (APR) parameters have not been fully elucidated.   OBJECTIVE:  The aim of this study was to compare the serum albumin, ESR, and C-reactive protein levels in follicular and luteal phases of menstruation.   METHODS:  A total of 90 healthy regularly menstruating women where used for this study. Forty-five of the study participants were in their follicular phase while the other 45 where in their luteal phase. Four milliliters of blood were withdrawn from each patient under aseptic condition and two milliliters was dispensed into EDTA container while the other two milliliters were dispensed into a plane container. The EDTA anticoagulated blood was used for ESR and full blood count while the serum from the plain tubes was used for analysis of C-reactive protein and Serum Albumin. Sysmex K-3 auto-analyser (Sysmex, Kobe Japan) was used for te determination of full blood count, the Westergren method was used for ESR estimation, Bromo Cresyl Green method was used for serum albumin and ELISA method was used for CRP determination. Data analysis was carried out using SPSS version 23.   RESULTS:  This study showed a statistically significant difference in the ESR (p= 0.03) among menstruating women in the follicular and luteal phases of menstruation. Sociodemographic factors had no statistically significant effect on the APR parameters of menstruating women in the follicular and luteal phases of menstruation (p> 0.05). There were no statistically significant differences between acute phase proteins of menstruating women in the follicular phase and luteal phases (p> 0.05). Also, age and marital status did not affect the acute phase proteins among menstruating women in the follicular phase and luteal phases (p> 0.05).   CONCLUSIONS:  There is need to generate data on menstrual disorders and their impact on women’s health status, quality of life and social integration. It is vital that evaluation and treatment of menstrual complaints should be given a higher priority in primary care programs. There is need to invest in public enlightenment program to increase awareness in secondary schools to increase the level of awareness among adolescents as well as young females."@en ;
    ns0:hasPubTitle "Menstrual cycle-associated effects on some acute phase reactants parameters of Students in Usmanu Danfodiyo University Sokoto, North Western Nigeria"@en .

ns1:hab-v27-iS1-HAB190364 ns0:hasKeywords "Community"@en,
        "Ethiopia"@en,
        "drought"@en,
        "health"@en,
        "resilience"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Drought is a serious issue which might be caused by climate change that could create famine and health problems. Drought reduces air quality, increases fungal infestation, reduces people hand washing, affects mental health, leads to malnutrition by decreasing agricultural production, and increases diseases transmitted by insects. This study aimed to determine and describe community health status through building drought resilience in Ethiopia.   METHODS:  This review was conducted based on the available peer-reviewed articles that were published from January 2004 to December 2018 Online databases from PubMed, MEDLINE, Scopus, EMBASE and Google Scholar were searched for studies related to the building drought and community health resilience at different regions of Ethiopia that were published in English language. The search was made by using “Emergency disaster”, “prevention”, “preparedness”, “response”, “recovery”, “drought”, “food insecurity”, “coping strategies” and “drought health policy” as keywords.   RESULTS:  Most of the reviewed articles deal with the impact of climate change on the human health in relation to food security. The associated factors of the impact of drought on food security is basically due to lack of irrigation and farmland, the scarcity of water due to the direct effect of drought, flood, severe soil erosion, livestock dispossession, family size of the household and literacy of the households. Various coping strategies were employed by the households to alleviate the high and continued food insecurity problem such as reducing the number and amount of meal, scrounging cash and grain, searching for off-farm and non-farm jobs, getting food aid, vending of livestock, and partake in food for work programs.   CONCLUSION:  The findings explored components of the coping strategies to the building resilience create fruitful health conditions for the food insecure household. The effect of agricultural support services as reliance’s on drought and community health situation was regarded as a positive outcome. Moreover, the means to get adequate food security strategies in all regions of Ethiopia should be designed. Furthermore, future researches are recommended for finding the best building strategies for each region of Ethiopia."@en ;
    ns0:hasPubTitle "Impact of climate change on community health and resilience in Ethiopia: A review article"@en .

ns1:hsm-v38-i3-HSM180472 ns0:hasKeywords "Brain-gain migration"@en,
        "China"@en,
        "logit model"@en,
        "random utility theory"@en ;
    ns0:hasPubAbstract "The People’s Republic of China (PRC) has become an international student destination, a phenomenon that requires researching its consequences and implications. This study investigates influences on international students’ decision to leave or to stay in China after completing their studies. Through a snowball sampling technique, empirical data were gleaned from 283 foreign students in different universities in China. Using a binary logit model, the results show that the majority of respondents wish to stay and to work in China. While most foreign students value high wages, many prefer the working conditions and lifestyle in China. Yet some students are cynical about the limited job opportunities for foreigners in China, which compel them to leave after completing their studies. Despite its limitations, this empirical study not only provides pertinent future-research paths but also policymaking recommendations."@en ;
    ns0:hasPubTitle "Should I stay or should I go? Foreign-student intent in China"@en .

ns1:hsm-v38-i4-HSM190517 ns0:hasKeywords "P2P lending market"@en,
        "Successful borrowing times"@en,
        "behavior of investors"@en,
        "identify credit risk"@en,
        "online P2P lending"@en ;
    ns0:hasPubAbstract "The development of online peer-to-peer lending is in full bloom due to the support of network technology and information technology. More and more people are keen to participate in them. Online P2P lending platforms provide services where investors lend money to borrowers without the involvement of traditional financial institutions. Due to its convenience, the platforms have attracted many investors and borrowers. However, these investors may suffer a significant loss if they cannot make better borrowing decisions based on prediction credit risk. The purpose of this article is to study the relationship between successful borrowing times (SBT) and successful loans and default loans. This article further explores SBT plays an importance of the role in online P2P lending. Data was collected from PaiPaiDai, an online P2P lending platform in China. Logistic modeling was employed to test the proposed hypotheses. The results show that the probability of default loan by borrowers with more SBT is low, and the probability of successful loan is higher. It shows that investors are more willing to choose borrowers with more SBT. The investors can effectively recognize the value of SBT in the transaction process, and can identify credit risk through SBT in the online P2P lending market. SBT can predict credit risk, which suggests the proposed method has favorable potential being implemented in real-world P2P lending platforms."@en ;
    ns0:hasPubTitle "The effect of successful borrowing times on behavior of investors: An empirical investigation of the P2P online lending market"@en .

ns1:ia-v13-i1-IA180016 ns0:hasKeywords "Description logics"@en,
        "computational creativity"@en,
        "concept generation"@en,
        "nonmonotonic reasoning"@en,
        "typicality"@en ;
    ns0:hasPubAbstract "In this work we exploit a nonmonotonic Description Logic of typicality as a tool for the generation and the exploration of novel creative concepts. Our logic, called TCL, is able to deal with the phenomenon of prototypical concept combination, which has been shown to be problematic to be modelled in formalisms like fuzzy logic. The logic TCL is the result of combining three main ingredients: (i) the logic of typicality   ALC +    T   R   , that allows one to describe typical properties of a class by means of a typicality operator, (ii) the distributed semantics of probabilistic Description Logics, that allows one to provide a probability distribution over worlds/scenarios, and (iii) established heuristics used by humans for concept composition coming from the field of cognitive semantics. Our approach could be useful in many applicative scenarios, ranging from video games to the creation of new movie characters."@en ;
    ns0:hasPubTitle "Applying a description logic of typicality as a generative tool for concept combination in computational creativity"@en .

ns1:ia-v13-i1-IA190018 ns0:hasKeywords "Question answering in Italian"@en,
        "deep learning"@en,
        "recurrent neural network with attention"@en ;
    ns0:hasPubAbstract "The recent breakthroughs in the field of deep learning led to state-of-the-art results in several NLP tasks, such as Question Answering (QA). Unfortunately, the requirements of such neural QA systems are very strict due to the size of the involved training datasets. In cross-linguistic settings these requirements are not satisfied as training datasets for QA over non-English texts are often not available. This represents the major barrier for a wide-spread adoption of neural QA methods in NLP applications. In this paper, the acquisition of a large scale dataset for an open-domain factoid question answering system in Italian is discussed. It is obtained by automatic translation and linguistic elicitation of an existing English dataset, i.e. the SQuAD question-answer pair corpus. Even though the quality of the resulting corpus for Italian might not be completely satisfying, our work allowed to generate more than 60 thousand question-answer pairs. In the paper the impact of this resource on the QA process over the Italian Wikipedia is studied, according to different training conditions and architectural constraints. A comparative evaluation against the English version, in line with standards in the SQuAD literature, is carried out. The outcomes show that the results achievable for Italian are below the state-of-the-art for English, but the ability of learning not to respond (i.e. the adoption of techniques for detecting question whose answers are simply not available, i.e. EMPTY set of answers) allows the system to pursue reasonable levels of precision. This make it already usable within realistic application scenarios. Finally, an error analysis is presented that suggests possible future research directions on still critical but highly beneficial enhancements, in view of concrete QA applications in Italian."@en ;
    ns0:hasPubTitle "Enabling deep learning for large scale question answering in Italian"@en .

ns1:ica-v26-i4-ICA190603 ns0:hasKeywords "Transfer learning"@en,
        "deep learning"@en,
        "multi-object tracking"@en,
        "pair-wise binary classification"@en,
        "person re-identification"@en ;
    ns0:hasPubAbstract "Learning to discriminate, whether two person-images correspond to the same person or not, is a daunting challenge when only two images per person are available. This task is called single-shot person re-identification (re-id) and it assumes that each one of the two available images was captured from a different camera view entailing variations in pose, resolution, scale, illumination and background. Addressing this task through supervised training of a deep convolutional neural network is susceptible to model overfitting due to the critical lack of enough labelled data. This paper proposes to exploit the transference of learning previously acquired from a multi-object-tracking (MOT) domain. In this context, a unique deep triplet architecture has been trained on both domains. Six different levels of transfer learning have been implemented and evaluated, proving that the transference of leaning from a different domain remarkably increases the re-id performance. Experimental results validate accuracy and robustness of the proposed method as comparable to other state-of-the-art techniques. These results also confirm that, despite the data problem, deep learning is also applicable to the single-shot re-id task."@en ;
    ns0:hasPubTitle "Transferring learning from multi-person tracking to person re-identification"@en .

ns1:ida-v23-iS1-IDA192786 ns0:hasKeywords "FN-CFSFDP algorithm"@en,
        "Fuzzy clustering on fuzzy sets"@en,
        "Kappa coefficient"@en,
        "fuzzy number"@en,
        "improved Euclidean distance"@en ;
    ns0:hasPubAbstract "This paper made improvements on clustering by fast search and find of density peaks (CFSFDP) algorithm and extended this algorithm to fuzzy numbers (FN-CFSFDP algorithm). Using FN-CFSFDP algorithm, classical information included in the samples are extended to fuzzy sets, and fuzzy samples can be clustered by searching the density peak. Firstly, by means of error analysis, improved Euclidean distance between fuzzy numbers was defined, and some key parameters or operating quantities mainly including cut-off distance and Gaussian Kernel function of fuzzy samples were introduced in detail. Next, 76 random simulations in total were performed on four sets of samples under different conditions with different t-values, different sample sizes, index numbers, cluster numbers and fetching rules. Moreover, Kappa coefficients in above simulations were calculated. Finally, both advantages and disadvantages of the proposed FN-CFSFDP were concluded and some recommendations for improvement were put forward, which can provide insightful guidance for further investigations of fuzzy clustering algorithms on fuzzy sets."@en ;
    ns0:hasPubTitle "A clustering algorithm for fuzzy numbers based on fast search and find of density peaks"@en .

ns1:idt-v13-i3-IDT180136 ns0:hasKeywords "Data mining"@en,
        "educational data"@en,
        "machine learning"@en,
        "prediction model"@en,
        "self-labeled algorithms"@en,
        "semi-supervised learning"@en,
        "student academic performance"@en,
        "two-level classification algorithm"@en ;
    ns0:hasPubAbstract "During the last decades, educational data mining has become a significant tool for the prediction of students’ progress and performance. In this work, we present a new semi-supervised self-trained two-level classification algorithm for predicting students’ graduation time. The proposed algorithm has three major features: Firstly, it identifies with high accuracy the students at-risk of not completing their studies; secondly, it classifies the students based on their expected graduation time; thirdly, it meaningfully relates the explicit classification information of labeled data with the information hidden in the unlabeled data. Our preliminary numerical experiments indicate that the proposed algorithm exhibits reliable predictions based on the students’ performance during the first two years of their studies."@en ;
    ns0:hasPubTitle "A semi-supervised self-trained two-level algorithm for forecasting students’ graduation time"@en .

ns1:ies-v27-i3-IES182206 ns0:hasKeywords "Tibialis anterior"@en,
        "instability"@en,
        "peroneus longus"@en,
        "soleus"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Compensating unstable situations is an important functional capability to maintain joint stability, to compensate perturbations and to prevent (re-)injury. Therefore, reduced maximum strength and altered neuromuscular activity are expected by inducing instability to load test situations. Possible effects are not clear for induced instability during maximum legpress tests in healthy individuals.   OBJECTIVE:  To compare isokinetic legpress (LP) strength and lower-leg muscle activity using stable (S) and unstable (UN) footplates.   METHODS:  16 males (28 ± 4 yrs, 179 ± 7 cm, 75 ± 8 kg) performed five maximum LP in concentric (CON) and eccentric (ECC) mode. The maximum force (Fmax) and muscle activity were measured under conditions of S and UN footplates. The tested muscles comprised of the tibialis anterior (TA), peroneus longus (PL) and soleus (SOL) and their activity were quantified against the MVIC of each muscle respectively.   RESULTS:  The main finding revealed a significant reduction in Fmax under UN condition: 11.9 ± 11.3% in CON and 23.5 ± 47.8% in ECC (P< 0.05). Significant findings were also noted regarding the RMS derived values of the EMG of PL and TA.   CONCLUSION:  Unstable LP reduced force generation and increased the activity of PL and TA muscles which confirmed greater neuromuscular effort to compensate instability. This may have some implications for resistance testing and training coupled with an unstable base in the prevention and rehabilitation of injury to the neuromusculoskeletal system."@en ;
    ns0:hasPubTitle "Muscle activity and strength in maximum isokinetic legpress testing with unstable footplates in active individuals"@en .

ns1:ies-v27-i4-IES193141 ns0:hasKeywords "Swimming"@en,
        "breast stroke"@en,
        "front crawl"@en,
        "stretching"@en,
        "warm up"@en,
        "women"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Warm up exercises are common practice before training and competition in almost every sport. Although, swimming is a popular sport throughout the world, studies on the effects of warm-up are scarce.   OBJECTIVE: The purpose of this study is to compare the effects of different stretching warm-up and exercise protocols on swim performance.   METHODS:  Fourteen sub-elite college women swimmers volunteered to participate in the study. The four stretching and warm-up protocols they followed were; (I) without stretching (WS); (II) static stretch (SS); (III) in-water (IW); and (IV) dry land (DL).   RESULTS: There was a significant main effect for 50-meter front crawl (F = 70,453; p= 0.00) and breaststroke swimming performances (F = 145.504; p= 0.000). The best 50-meter front crawl and breaststroke performance detected immediately after IW was 28.1 and next, 39.9 seconds. Pairwise comparison indicated that the best 50-meter front crawl performance monitored after IW protocol was 28.0 ± 2.9 (p= 0.000) compared with that after WS – 29.8 ± 2.3 (p= 0.000) and after SS – 30.7 ± 2.2 (p= 0.000).   CONCLUSIONS:  Pre-event low-intensity IW warm-ups may be optimal for 50-meter front crawl and breaststroke swimming performance."@en ;
    ns0:hasPubTitle "The effects of different stretching and warm-up exercise protocols on 50-meter swimming performance in sub-elite women swimmers"@en .

ns1:ifs-v36-i6-IFS172129 ns0:hasKeywords "(L, M)-fuzzy topology; (L, M)-fuzzy internal relation; (L, M)-fuzzy enclosed relation; (L, M)-fuzzy IRDP mapping; (L, M)-fuzzy ERDP mapping"@en ;
    ns0:hasPubAbstract "In this paper, the concepts of (L, M)-fuzzy internal relations and (L, M)-fuzzy enclosed relations between two L-fuzzy sets are introduced. They are defined respectively to be M-fuzzy subsets of LX × LX satisfying a set of axioms. A categorical approach is provided to present these relations. It is proved that the category of (L, M)-fuzzy internal relation spaces, the category of (L, M)-fuzzy enclosed relation spaces and the category of (L, M)-fuzzy topological spaces are isomorphic. In addition, some (L, M)-fuzzy internal relations and (L, M)-fuzzy enclosed relations are naturally constructed from (L, M)-fuzzy quasi-uniformities and (L, M)-fuzzy S-quasi-proximities."@en ;
    ns0:hasPubTitle "(L, M)-fuzzy internal relations and (L, M)-fuzzy enclosed relations"@en .

ns1:ifs-v36-i6-IFS17707 ns0:hasKeywords "Big-Data"@en,
        "Sum distance metric"@en,
        "strongest strong cycle (SSC)"@en,
        "θ-fuzzy graph"@en ;
    ns0:hasPubAbstract "— In this paper, new concepts are introduced to enhance the process of block identification in fuzzy graphs using sum distance metric and special type of cycles, which is called a strongest strong cycle, locamin cycle. An Algorithm is developed for retrieving information from Big-Data using block identification."@en ;
    ns0:hasPubTitle "Identification of fuzzy blocks using sum distance metric"@en .

ns1:ifs-v36-i6-IFS181220 ns0:hasKeywords "almost φ-fuzzy subalgebra (semi-ideal), BCK/BCI-algebra, (weakly) vanishing, (pre-) level subset, (weak) fuzzy subalgebra property, (μ, φ)-(extreme, special), e-ideal, Bin (X)"@en ;
    ns0:hasPubAbstract "In this paper, we introduce the notions of an almost φ-fuzzy subalgebra and an almost φ-fuzzy semi-ideal in groupoids by using the concept of a function. This concepts are generalizations of a fuzzy subalgebra and a fuzzy ideal in groupoids respectively. We discuss some relations between almost φ-fuzzy subalgebras and vanishing, level subsets. By introducing the notions of (μ, φ)-extremes, e-ideals, we obtain several properties of almost φ-fuzzy subalgebras. The relations between almost φ-fuzzy semi-ideals and (μ, φ)-special elements are discussed. Finally we discuss fuzzy algebraic structures of almost φ-fuzzy semi-ideals by diagrams."@en ;
    ns0:hasPubTitle "Almost φ-fuzzy semi-ideals in groupoids"@en .

ns1:ifs-v36-i6-IFS181322 ns0:hasKeywords "CODAS"@en,
        "Livability index"@en,
        "decision making"@en,
        "fuzzy inference system"@en,
        "neutrosophic sets"@en ;
    ns0:hasPubAbstract "Neutrosphic sets define the uncertainty with three parameters, namely truthiness, indeterminacy and falsity. COmbinative Distance-based ASsessment (CODAS) method computes the Euclidean as the primary measure and Hamming distances as the secondary measure to assess alternatives based on predetermined criteria. In this paper, CODAS method is extended to its interval-valued neutrosophic CODAS version for handling the vagueness and impreciseness in human thoughts. A fuzzy inference system can be used as a decision making process of mapping from a given input to an output using fuzzy logic. The inputs of the used ordinary fuzzy Mamdani type inference system are crisp while the rules are fuzzy. The applicability of the proposed methodology is illustrated through the assessment of livability index of urban districts. Sensitivity analysis demonstrates the robustness of the decision-making methodology."@en ;
    ns0:hasPubTitle "An integrated methodology using neutrosophic CODAS & fuzzy inference system: Assessment of livability index of urban districts"@en .

ns1:ifs-v36-i6-IFS181362 ns0:hasKeywords "Visual tracking"@en,
        "convolutional network"@en,
        "object detection"@en,
        "online learning"@en ;
    ns0:hasPubAbstract "Visual tracking is a popular research topic in computer vision. In this paper, we propose a novel tracking framework which leverages stable and adaptive memories of target appearance for robust tracking where the target undergoes significant appearance change as well as background clutter. First, we define a stable-adaptive memory network which exploits the embedding of the target patch in the first video frame, named as \"reliable memory\", as well as the embeddings of patches collected online that are referred as \"adaptive memories\". Through the fusion of these two types of memories, a good balance between stability and plasticity can be made. During tracking, the network searches the candidate which has the highest similarity with the memorized patterns as the tracking result. Second, we train an online detector to re-detect the target in case of tracking failure and update the memory network. By virtue of the proposed mechanism, our tracker can handle the drift problem well and is able to track the object in challenging situations robustly. Experimental results on challenging benchmark video sequences show that the proposed tracking framework achieves state-of-the-art tracking performance with high accuracy and robustness."@en ;
    ns0:hasPubTitle "Robust online visual tracking via stable and adaptive memories"@en .

ns1:ifs-v36-i6-IFS181415 ns0:hasKeywords "Statistical convergence"@en,
        "dual numbers"@en,
        "lacunary sequence"@en ;
    ns0:hasPubAbstract "Dual number algebra is a powerful mathematical tool for the kinematic and dynamic analysis of spatial mechanisms. The algebra of dual numbers has been originally conceived by Clifford [1], but its first applications to mechanics are due to Kotelnikov [2] and Study [3]. In this paper, we focus on summability of sequences of dual numbers. We introduce the concepts of strongly    N θ p  (   D   )  -summability and lacunary statistical convergence for sequences of dual numbers. We give some certain properties of these concepts and some inclusion relations."@en ;
    ns0:hasPubTitle "Lacunary statistical convergence and strongly lacunary summable for sequences of dual numbers"@en .

ns1:ifs-v36-i6-IFS181425 ns0:hasKeywords "Muirhead mean"@en,
        "multi-attribute group decision making"@en,
        "q-rung orthopair fuzzy set"@en,
        "q-rung orthopair uncertain linguistic Muirhead mean"@en,
        "q-rung orthopair uncertain linguistic set"@en ;
    ns0:hasPubAbstract "The recently proposed q-rung orthopair fuzzy set (q-ROFS) is an effective tool for handling fuzziness and uncertainty in the process of multi-attribute group decision making (MAGDM). Considering that in most MAGDM problems, not only decision makers’ quantitative evaluation information but also their qualitative assessment opinions should be taken into account, this paper proposes a concept of q-rung orthopair uncertain linguistic sets (q-ROULSs) by combining q-ROFSs with uncertain linguistic variables (ULVs). The proposed q-ROULSs parallel to intuitionistic uncertain linguistic sets (IULSs) and Pythagorean uncertain linguistic sets (PULSs), but provide more freedom for decision makers to express their evaluation information. Afterwards, we propose operational laws and a comparison law for q-ROULSs. To effectively aggregate q-rung orthopair uncertain linguistic information, we extend the Muirhead mean (MM) operator to q-ROULSs and propose a family of q-rung orthopair uncertain linguistic Muirhead mean operators. The prominent advantage of the proposed operators is that the interrelationship among any numbers of input arguments can be captured. In addition, some desirable properties and special cases of the proposed operators are studied. Moreover, we propose a new method to MAGDM problems based on the proposed operators within q-rung orthopair uncertain linguistic context. Finally, we conduct a numerical experiment to demonstrate the validity and superiorities of the proposed method."@en ;
    ns0:hasPubTitle "A novel approach to multi-attribute group decision making based on q-rung orthopair uncertain linguistic information"@en .

ns1:ifs-v36-i6-IFS181527 ns0:hasKeywords "FFLPPs"@en,
        "ranking function"@en,
        "simplex method"@en ;
    ns0:hasPubAbstract "Bhardwaj and Kumar (J. Optim. Theory Appl. 163(2), 685-696 (2014)) pointed out that Khan et al. (J. Optim. Theory Appl. 159(2), 536-546 (2013)) have assumed some mathematical incorrect assumptions in their proposed method for solving fully fuzzy linear programming problems (FFLPPs). However, Khan et al. (J. Optim. Theory Appl. 173(1), 353-356 (2017)) replied that their proposed method is valid and no mathematical incorrect assumptions have been considered. The aim of this commentary is to make the researchers aware that Khan et al. (J. Optim. Theory Appl. 173(1), 353-356 (2017)) are misleading the others. In actual case, Khan et al. (J. Optim. Theory Appl. 159(2), 536-546 (2013)) have considered mathematical incorrect assumptions in their proposed method due to which some of the elements of the optimal simplex table, obtained by Khan et al. (J. Optim. Theory Appl. 159(2), 536-546 (2013)), are not triangular fuzzy numbers."@en ;
    ns0:hasPubTitle "Commentary on “A reply to a Note on the paper “A simplified novel technique for solving fully fuzzy linear programming problems””"@en .

ns1:ifs-v36-i6-IFS181604 ns0:hasKeywords "Amazon region"@en,
        "GMDH"@en,
        "artificial neural network"@en,
        "hydropower generation"@en ;
    ns0:hasPubAbstract "This study both presents a novel methodology and compares the performance of computational intelligence techniques for the predictive modeling of the monthly potential for hydropower generation. Two different approaches are employed to forecasting energy generation: polynomial neural network and conventional artificial neural network (ANN). The first one technique is a deep learning type named group method of data handling (GMDH). And the second one is the multilayer perceptron (MLP) feed forward with back-propagation algorithm. The ANN dealt with two different optimization algorithms for training the model: Levenberg-Marquardt and Bayesian regulation. Rainfall data are used as inputs to feed the models. The performance of each model is scrutinized based on three statistical performance criteria. The results found that the computational intelligence techniques can model the dynamic, seasonal and non-linear behavior of the studied issue. The predictions from the GMDH method resulted in slightly better accuracy than the values obtained by the conventional ANN. The analyzes also showed that the values that determine the steady energy of the hydropower plant are well captured by the models. This feature makes the model an important tool for energy planning and decision making."@en ;
    ns0:hasPubTitle "Artificial neural networks approaches for predicting the potential for hydropower generation: a case study for Amazon region"@en .

ns1:ifs-v36-i6-IFS181633 ns0:hasKeywords "Decision making"@en,
        "probabilistic linguistic term set"@en,
        "statistical variance and WASPAS method"@en ;
    ns0:hasPubAbstract "This paper focuses on proposing a new decision framework under probabilistic linguistic term set (PLTS) for rational decision making. The PLTS concept is a generalization of hesitant fuzzy linguistic term set (HFLTS) which overcomes the limitation of HFLTS by associating occurring probability to each linguistic term. Initially, a new aggregation operator is presented for fusing decision makers’ (DMs) preferences. Following this, a new extension is put forward for statistical variance (SV) method under PLTS for criteria weight calculation and a new extension is presented for WASPAS (weighted arithmetic sum product assessment) method under PLTS context for ranking objects. The applicability of the proposed decision framework is demonstrated by using a numerical example and the strength and weakness of the proposal are investigated by comparison with other state-of-the-art methods."@en ;
    ns0:hasPubTitle "A decision-making framework under probabilistic linguistic term set for multi-criteria group decision-making problem"@en .

ns1:ifs-v36-i6-IFS181697 ns0:hasKeywords "Strong Pythagorean fuzzy graph"@en,
        "complete Pythagorean fuzzy graph"@en,
        "connected Pythagorean fuzzy graph"@en,
        "multi-criteria decision making"@en,
        "regular Pythagorean fuzzy graph"@en ;
    ns0:hasPubAbstract "Graph operations produce new classes of graphs from initial ones which in turn may be useful for the modeling and recognition of computer network designs. A Pythagorean fuzzy set-based model offers more flexibility to cope with human evaluation information as compared to intuitionistic fuzzy model. The main objective of this research study is to expand the area of discussion on Pythagorean fuzzy graphs by establishing fruitful results and notions related to an operation on Pythagorean fuzzy graphs called strong product. Certain concepts, including connectedness, completeness, regularity and partially regularity of strong product Pythagorean fuzzy graphs are discussed. It is shown that the strong product of two regular Pythagorean fuzzy graphs may not be regular. Moreover, some necessary and sufficient conditions for the strong product of two regular Pythagorean fuzzy graphs to be regular are established. Finally, an algorithm for Pythagorean fuzzy multi-criteria decision making is presented and problem concerning to evaluation of domestic airlines in Japan is solved to demonstrate the applicability of PFGs in realistic scenarios."@en ;
    ns0:hasPubTitle "Certain Notions of Pythagorean Fuzzy Graphs"@en .

ns1:ifs-v36-i6-IFS181829 ns0:hasKeywords "LA-hyperrings, fuzzy hyperideals, complex fuzzy hyperideals, (α, β)-complex fuzzy hyperideals"@en ;
    ns0:hasPubAbstract "In this paper, we introduce the concept of complex fuzzy left and complex fuzzy right hyperideals and discuss some basic properties of LA-hyperrings. We also introduce the concept of (α, β)-complex fuzzy hyperideals and discuss the important features of non-associative LA-hyperrings."@en ;
    ns0:hasPubTitle "A study of (α, β)-complex fuzzy hyperideals in non-associative hyperrings"@en .

ns1:ifs-v36-i6-IFS181941 ns0:hasKeywords "Spherical fuzzy sets"@en,
        "spherical fuzzy t’-conorm"@en,
        "spherical fuzzy t’-norm"@en ;
    ns0:hasPubAbstract "In this paper, we introduce spherical fuzzy sets (SFSs) which is an advanced tool of the fuzzy sets, intuitionistic fuzzy sets and picture fuzzy sets. We investigate the basic properties of SFSs and compare the idea SFSs with picture fuzzy sets. The spaces of spherical membership grades and picture membership grades are examined by graphically. Some useful operation such as spherical fuzzy t’-norms and spherical fuzzy t’-conorms are introduced. Also introduced spherical fuzzy negator and some classifications of spherical fuzzy t’-norms and spherical fuzzy t′-conorms which are useful for development the aggregation operator to aggregate the spherical fuzzy information. Finally, a food circulation center evaluation problem is given as a practical application to demonstrate the usage and applicability of the proposed ranking approach."@en ;
    ns0:hasPubTitle "Spherical fuzzy sets and its representation of spherical fuzzy t-norms and t-conorms"@en .

ns1:ifs-v36-i6-IFS181966 ns0:hasKeywords "Analog circuits"@en,
        "fuzzifier"@en,
        "interval type-2 fuzzy logic"@en,
        "low-power"@en ;
    ns0:hasPubAbstract "An analog type-2 fuzzy membership function generator is analyzed, while its low power features are demonstrated. Developed and designed to work as part of an energy-efficient type-2 fuzzy system (i.e. controller, neural network), it operates in current-mode, allowing multiple settings, such as: variable shape, position, slope and size of the Footprint of Uncertainty. All these parameters can be updated/adjusted during actual operation, being suitable for real-time applications, even with online learning. The achieved robustness and flexibility of the architecture allow operation with different values of supply voltage and maximum degree of membership current. Simulations based on CADENCE software were performed to assess the functionalities. The circuit was prototyped in TSMC CMOS 0.18μm technology and experimental results show a power consumption of 72.56μW, 7.86μW, and 478.1nW when operating with power supplies of 1.2V, 1V, and even with 0.6V, respectively, much less than the nominal supply voltage of the TSMC CMOS 0.18μm technology (1.8V). These results attest the circuit is robust, low-power, functional and suitable for systems that require energy efficiency, presenting a high potential for practical implementations including those that require real-time dedicated hardware."@en ;
    ns0:hasPubTitle "Low power membership function generator for interval type-2 fuzzy system"@en .

ns1:ifs-v36-i6-IFS181990 ns0:hasKeywords "Electricity price"@en,
        "emission reduction"@en,
        "locational marginal price"@en,
        "loss reduction"@en,
        "multi-objective optimization"@en ;
    ns0:hasPubAbstract "This paper presents a new electricity pricing methodology in distribution networks by imploying Distributed Generations (DGs). As long as the Locational Marginal Price (LMP) is used in the pricing of short-term operations as an efficient method, it can be performed in distribution network consequently. The proposed pricing method is modeled as an optimization problem with the specific control variables and objectives. The variables are LMPs and DGs power factors, and objectives are total losses and emission. Also, profit earned from reduction of loss and emission was allocated between DGs. Reduction of loss and emission was compensated by DGs production. As a result, more production resulted to high price of DG buses rather than market price. This price should be provided by Distribution Company (DISCO), and DISCO earns this money form the profit. Because of the multi-objective nature of the problem, a Multi-Objective Genetic Algorithm Optimization (MOGA) is implemented to solve. In order to validate the proposed method, a comparison between MOGA and Multi-Objective Particle Swarm Optimization (MOPSO) is performed consequently. The proposed method allows the decision-makers to apply their preferences among losses/emission reduction and DISCO’s benefit. furthermore, the feasibility of the proposed method is investigated using the IEEE-32 bus test system."@en ;
    ns0:hasPubTitle "A multi-objective LMP pricing strategy in distribution networks based on MOGA algorithm"@en .

ns1:ifs-v36-i6-IFS182512 ns0:hasKeywords "Influential user detection"@en,
        "clustering"@en,
        "social media data mining"@en,
        "user behavior analysis"@en ;
    ns0:hasPubAbstract "High influential users are playing an important role in promoting information propagation in social media. Thus, it has been a very interesting problem to identify influential users in social media, and attracted numerous researchers. A great deal of research work has been devoted to solving this problem. However, the existing methods mainly focus on the network topology, ignoring users’ behaviors. In this paper, we propose an High Influential Users Detection (HIUD) algorithm by analyzing users’ behaviors. To evaluate the performance of our algorithm, we carry out extensive experiments on Sina and Tencent microblogging data sets, and compare it with other methods. The experimental results have shown that the HIUD achieves the best performance. Furthermore, we also make a spatial analysis on those high influential users with thermodynamic map."@en ;
    ns0:hasPubTitle "Identifying High Influential Users in Social Media by Analyzing Users’ Behaviors"@en .

ns1:ifs-v36-i6-IFS182590 ns0:hasKeywords "Goursat problems, fuzzy delay partial differential equations, Ulam stability, Caputo gH-differentiability"@en ;
    ns0:hasPubAbstract "In this paper, we consider Goursat boundary value problems for fuzzy delay fractional partial differential equations under Caputo gH-derivatives. Firstly, the unique solvability of the problems in finite domain is considered. Secondly, by restricting the force function and boundary conditions by exponential growth and using fixed point approach, the existence and the Ulam-Hyers stability of fuzzy mild solutions of the problem in infinite domain are investigated in two types with different geometric behaviors. It is necessary to implement that in many engineering applications, e.g. numerical solutions of a fuzzy dynamical system, the object of optimization problems or the trajectory of a economical dynamics etc., where finding the exact solution is more difficult than solving its approximate solutions, Ulam-Hyers stability is quite useful. Finally, as usual some examples are given to illustrate the obtained theoretical results."@en ;
    ns0:hasPubTitle "On Goursat problem for fuzzy delay fractional hyperbolic partial differential equations"@en .

ns1:ifs-v36-i6-IFS182673 ns0:hasKeywords "Hesitant Fuzzy Topological Spaces, continuous hesitant fuzzy mappings, connected hesitant fuzzy set, compact hesitant fuzzy topological spaces"@en ;
    ns0:hasPubAbstract "This paper addresses an extension of the concept of topological spaces to that of hesitant fuzzy spaces. The topology is established using a conjunction and disjunction operator on hesitant fuzzy sets whose properties are discussed in the beginning. Some examples are discussed before introducing the concepts of interior and closure of a hesitant fuzzy set. The properties of these operators are verified to justify the definitions. The concepts of a hesitant fuzzy subspace topology and continuous mappings on hesitant fuzzy sets are studied. The concepts of connectedness and compactness of hesitant fuzzy topological spaces are studied and various results regarding them are proved."@en ;
    ns0:hasPubTitle "A topological structure involving hesitant fuzzy sets"@en .

ns1:ifs-v36-i6-IFS18659 ns0:hasKeywords "Convex structure, convexity-preserving mapping, convex-to-convex mapping, (L, M)-fuzzy convex space, (L, M)-fuzzy convexity degree"@en ;
    ns0:hasPubAbstract "In this paper, we introduce the degree to which a mapping   C :  L X  ⟶ M   is an (L, M)-fuzzy convexity. When   ( X ,  C X  )   and   ( Y ,  C Y  )   are (L, M)-fuzzy convex spaces to some extent, the degrees to which a mapping f : X ⟶ Y is convexity-preserving or convex-to-convex are defined. Finally, the degree to which a surjective mapping f : X ⟶ Y is a quotient mapping is also defined. We not only give their characterizations but also discuss the relationships among them."@en ;
    ns0:hasPubTitle "Degrees of (L, M)-fuzzy convexities"@en .

ns1:ifs-v36-i6-IFS18755 ns0:hasKeywords "Intuitionistic fuzzy graphs"@en,
        "fuzzy threshold graph"@en,
        "intuitionistic fuzzy alternating 4-cycle"@en,
        "intuitionistic fuzzy threshold graphs"@en ;
    ns0:hasPubAbstract "In this study, we provide a generalization of fuzzy threshold graphs, and introduce three notions, which are intuitionistic fuzzy threshold graphs, intuitionistic fuzzy alternating 4-cycle, and threshold dimension of intuitionistic fuzzy graphs. Then we discuss some properties about intuitionistic fuzzy graphs, and obtain two main results. The first one is that under some conditions, an intuitionistic fuzzy graph is equivalent to an intuitionistic fuzzy threshold graph. The second one is that the underlying graph of an intuitionistic fuzzy threshold graph is a split graph, and conversely, a given split graph can be used to construct an intuitionistic fuzzy threshold graph. Finally, we give two applications of intuitionistic fuzzy threshold graphs, which are used to control water resource and power resources, respectively. Through the two applications, we know that intuitionistic fuzzy threshold graphs are more appropriate than fuzzy threshold graphs in controlling water resource and power resource, because intuitionistic fuzzy sets are more suitable and powerful to deal with uncertainty and vagueness compared to fuzzy sets."@en ;
    ns0:hasPubTitle "Intuitionistic fuzzy threshold graphs"@en .

ns1:ifs-v37-i1-IFS171049 ns0:hasKeywords "A MAGDM approach based on an extended VIKOR method using trapezoidal cubic fuzzy numbers"@en,
        "The definition and arithmetical operations of trapezoidal cubic fuzzy numbers"@en,
        "The extended VIKOR method using trapezoidal cubic fuzzy numbers"@en,
        "plant location selection"@en,
        "shannon entropy"@en ;
    ns0:hasPubAbstract "This paper presents a new concept of trapezoidal cubic fuzzy numbers and solves the plant location selection (PLS) problem based on a new decision method with cubic fuzzy information captured through trapezoidal cubic fuzzy numbers. In the decision process, the unknown weights of the criteria are unearthed by using the Shannon entropy theory and the weights of the decision makers by integrating the Evidence theory with Bayes approximation. Based on trapezoidal cubic fuzzy numbers, we extend the classical VIKOR method to solve the MAGDM problems under cubic fuzzy environment based on the TrCFNs on proposed method."@en ;
    ns0:hasPubTitle "Cubic Fuzzy multi-attribute group decision-making with an application to plant location selected based on a new extended Vikor method"@en .

ns1:ifs-v37-i1-IFS179101 ns0:hasKeywords "Grey relevance"@en,
        "complex set"@en,
        "economic indicators"@en,
        "empirical test"@en ;
    ns0:hasPubAbstract "Macroeconomics is a very complex and huge system. With the improvement of China’s market economy, it is of great theoretical significance and practical value to apply quantitative economics methods and models to study the macroeconomic state and forecast the economic development trend. The development of regional economy is restricted by natural conditions and social and humanistic conditions, and it is a complex system with many factors and levels. By using grey system theory, data processing can reduce its randomness and strengthen the inherent trend of data, so it is possible to use as few data as possible to establish a model describing economic system. Through empirical test, the author analyses the main factors of unbalanced regional economic development and puts forward the comparative advantages of regional development. According to the simulation results, the predicted results are stable and reliable. The conclusion of the study has a certain reference value for the formulation of macroeconomic policies. By strengthening the guidance of government classification, the regional economic disparity will be narrowed continuously."@en ;
    ns0:hasPubTitle "Quantitative analysis of regional economic indicators prediction based on grey relevance degree and fuzzy mathematical model"@en .

ns1:ifs-v37-i1-IFS181293 ns0:hasKeywords "RCPSP-MR"@en,
        "Taguchi method"@en,
        "distribution rules"@en,
        "four-part non-distinct (FPND) approach"@en,
        "fuzzy sets theory"@en,
        "multi-route work package"@en ;
    ns0:hasPubAbstract "Multiple routes of networks in fuzzy environments are essential issues in the project scheduling problems (PSPs) with resource constraints, fuzzy RCPSP-MR. Route assignment to flexible work package defined in a project activity network indicates more complexities in front of canonical PSP. Also, in the last few decades, considering uncertainties’ concepts in project schedules have been essential and attracted the attention of researchers and project managers. Therefore, in this article, a new weighted mathematical model is presented under uncertainty conditions, and a new hybrid fuzzy approach is provided via two fuzzy primary methods. Then, a new four-part non-distinct (FPND) approach is proposed based on PSO, binary particle swarm optimization (BPSO) and genetic algorithm (GA) to minimize project end cost. In this approach as the first part and to generate high-quality primary routes for flexible work package, six different rules are investigated, and the appropriate route is chosen. In the second part, initial solutions are generated via PSO. Then, in the third part, initial solutions are improved based on GA. Finally, in the last part, assigned routes are improved with binary PSO. To appraise the effectiveness of the presented approach, influential parameters are tuned by Taguchi method. Finally, to evaluate the performance of FPND, 70 numerical examples are designed in different dimensions, and results are compared with other well-known algorithms."@en ;
    ns0:hasPubTitle "A new weighted mixed integer nonlinear model and FPND solution algorithm for RCPSP with multi-route work packages under fuzzy uncertainty"@en .

ns1:ifs-v37-i1-IFS181538 ns0:hasKeywords "Pythagorean fuzzy sets"@en,
        "Water treatment"@en,
        "analytic hierarchy process (AHP)"@en,
        "hesitant fuzzy sets"@en,
        "intuitionistic fuzzy sets"@en ;
    ns0:hasPubAbstract "Water treatment technology (WTT) selection is an excessively important problem since dramatic increases in health problems originated from drinking waters occur day by day. WTTs have high initial investments and operating and maintenance costs with different lives and capacities. Besides, their selection depends on the output quality of the water, capacity, land structure, and environmental issues. Therefore, WTT selection problem is a multi-criteria problem, which requires linguistic evaluations rather than exact numerical evaluations. In this paper, we propose a multi-expert and multi-criteria hesitant Pythagorean fuzzy decision analysis to select best fit WTT for clarification process in water treatment. Aggregation operators and pairwise comparisons for hesitant Pythagorean fuzzy sets (HPFSs) are applied in the analysis. Comparative analyses are additionally realized to show the validity of the proposed approach and the robustness of the givendecisions."@en ;
    ns0:hasPubTitle "Water treatment technology selection using hesitant Pythagorean fuzzy hierachical decision making"@en .

ns1:ifs-v37-i1-IFS181769 ns0:hasKeywords "decision-making"@en,
        "m-polar fuzzy set"@en,
        "m-polar fuzzy soft set"@en,
        "possibility m-polar fuzzy soft set"@en ;
    ns0:hasPubAbstract "The major concern of this paper is to highlight the notion of possibility m-polar fuzzy soft set (because it is useful in decision-making and other similar problems). For convenience of practical applications, several operations (such as subset, equal, complement, union, intersection, inf product, and sup product) over the possibility m-polar fuzzy soft sets are introduced. We present two algorithms by using inf product or sup product operations of possibility m-polar fuzzy soft sets for fuzzy decision-making problem. Finally, we construct an algorithm using a possibility m-polar fuzzy soft set to solve the decision-making problems and illustrate its applicability through a numerical example. From the study, we conclude that the proposed approach is viable in order to handle the uncertainties during the decision-making problems."@en ;
    ns0:hasPubTitle "Possibility m-polar fuzzy soft sets and its application in decision-making problems"@en .

ns1:ifs-v37-i1-IFS181832 ns0:hasKeywords "Fuzzy sets"@en,
        "covering based q-rung orthopair fuzzy rough set"@en,
        "q-rung orthopair fuzzy TOPSIS methodology"@en,
        "q-rung orthopair fuzzy sets"@en,
        "q-rung orthopair fuzzy β-covering"@en,
        "q-rung orthopair fuzzy β-covering neighborhoods"@en ;
    ns0:hasPubAbstract "In this manuscript we develop a comprehensive model to tackle decision making problems where strong points of view are in the favor and against some projects, entities or plans. Therefore a new approach is adopted to hybrid q-rung orthopair fuzzy sets with notions of covering rough set and TOPSIS. This model has stronger capability than intuitionistic fuzzy set and Pythagorean fuzzy set to manage the uncertainty. Furthermore an example is given to demonstrate how the proposed method helps us in decision making problems."@en ;
    ns0:hasPubTitle "Covering based q-rung orthopair fuzzy rough set model hybrid with TOPSIS for multi-attribute decision making"@en .

ns1:ifs-v37-i1-IFS182540 ns0:hasKeywords "COPRAS method"@en,
        "Pythagorean fuzzy sets"@en,
        "entropy measures"@en ;
    ns0:hasPubAbstract "Pythagorean fuzzy sets are an extension of the intuitionistic fuzzy sets, and it also overcomes the limitations of the intuitionistic fuzzy sets. The entropy of a Pythagorean fuzzy set (PFS) is a measure of uncertainty related to the PFS. In this article, we exploit the concept of probability for defining the fuzzy entropy of Pythagorean fuzzy sets as an extension of the fuzzy entropy of Intuitionistic fuzzy sets (IFSs). Compared to some previous measures, the new measure is simpler, closer to the statistical significance and it reflects better fuzzy properties. After that, we give some numerical examples to compare our proposed entropy measure to some existing entropy of Pythagorean fuzzy sets. The results on numerical examples show that the proposed entropy measures seem to be more reliable for presenting the degree of fuzziness of a PFS and/or IFS. We also proposed a COPRAS multi-criteria decision-making method with weights calculated based on the proposed new entropy measure. The illustrated numerical example shows that the calculated results according to the proposed new method are similar to the calculation results according to some other existing methods."@en ;
    ns0:hasPubTitle "A new fuzzy entropy on Pythagorean fuzzy sets"@en .

ns1:ifs-v37-i1-IFS182618 ns0:hasKeywords "n–valued refined neutrosophic EQ–(pre)filters"@en,
        "n–valued refined neutrosophic EQ–subalgebras"@en ;
    ns0:hasPubAbstract "This study introduces the notion of n-valued refined neutrosophic (EQ-subalgebras)EQ–(pre)filters and investigates some of their properties. We show how to construct n-valued refined neutrosophic EQ-(pre)filters and determine the relationship between n-valued refined neutrosophic EQ-(pre)filters and EQ–(pre)filters with respect to (α, β, γ)-level set. Finally, the extension of n–valued refined neutrosophic EQ–(pre)filters are considered via homomorphisms and some applications of n–valued refined neutrosophic EQ–(pre)filters are presented."@en ;
    ns0:hasPubTitle "On Neutrosophic Refined EQ–Filters"@en .

ns1:ifs-v37-i1-IFS182651 ns0:hasKeywords "Spherical fuzzy sets"@en,
        "VIKOR"@en,
        "multicriteria decision making"@en,
        "warehouse location selection"@en ;
    ns0:hasPubAbstract "The extensions of ordinary fuzzy sets such as intuitionistic fuzzy sets (IFS), Pythagorean fuzzy sets (PFS), and neutrosophic sets (NS), whose membership functions are based on three dimensions, aim at collecting experts’ judgments more informatively and explicitly. In the literature, generalized three-dimensional spherical fuzzy sets have been developed by Kutlu Gündoğdu and Kahraman (2019), including their arithmetic operations, aggregation operators, and defuzzification operations. Spherical Fuzzy Sets (SFS) are a new extension of Intuitionistic, Pythagorean and Neutrosophic Fuzzy sets, a SFS is characterized by a membership degree, a nonmembership degree, and a hesitancy degree satisfying the condition that their squared sum is equal to or less than one. These sets provide a larger preference domain in 3D space for decision makers (DMs). In this paper, our aim is to extend classical VlseKriterijumska Optimizacija I Kompromisno Resenje (VIKOR) method to spherical fuzzy VIKOR (SF-VIKOR) method and to show its applicability and validity through an illustrative example and to present a comparative analysis between spherical fuzzy TOPSIS (SF-TOPSIS) and SF-VIKOR. We handle a warehouse location selection problem with four alternatives and four criteria in order to demonstrate the performance of the proposed SF-VIKOR method."@en ;
    ns0:hasPubTitle "A novel VIKOR method using spherical fuzzy sets and its application to warehouse site selection"@en .

ns1:ifs-v37-i1-IFS182671 ns0:hasKeywords "Aggregation operators"@en,
        "decision making"@en,
        "induced aggregation"@en,
        "ordered weighted averaging operators"@en,
        "orness/andness"@en,
        "preference model"@en ;
    ns0:hasPubAbstract "In this work, we propose some two-layer preference models that can be appropriately applied in management problems such as the group decision making about predicting the future market share of certain product. By introducing the convex IOWA operator paradigm and some related properties and definitions, we list some detailed preference and inducing preference models to demonstrate and exemplify the proposed conceptual frame of two-layer preference model. The convex IOWA operator paradigm facilitates the modeling process and, from mathematical view, makes it stricter. When relevant inducing information and aggregation selection change, the proposed models can be easily adapted to accommodate more different applications in decision making and evaluation."@en ;
    ns0:hasPubTitle "Two-layer preference models with methodologies using induced aggregation in management administration and decision making"@en .

ns1:ifs-v37-i1-IFS182893 ns0:hasKeywords "3D-PCNN"@en,
        "color image segmentation"@en,
        "improved product cross entropy"@en,
        "whale optimization algorithm"@en ;
    ns0:hasPubAbstract "Considering that the 3D pulse-coupled neural network (3D-PCNN) model has the deficiency of high parameter complexity and low accuracy in color image segmentation, swarm intelligence optimization algorithm is adopted to optimize the image segmentation process. In this paper, whale optimization algorithm (WOA) is adopted to optimize the 3D-PCNN model parameters E and β. The improved product cross entropy (IPCE) is chosen as the fitness function of optimization algorithm. WOA algorithm is used to find the minimum fitness function, and the corresponding optimal parameters are obtained. Through the study of image segmentation in the image segmentation library of University of Berkeley and the actual plant canopy image, the maximum entropy value and the Tsallis entropy value are compared and analyzed. Experimental results illustrate that the proposed algorithm can obtain more accurate image segmentation effect and higher segmentation rate."@en ;
    ns0:hasPubTitle "3DPCNN based on whale optimization algorithm for color image segmentation"@en .

ns1:ifs-v37-i2-IFS179235 ns0:hasKeywords "Interval neutrosophic numbers (INNs)"@en,
        "Multiple attribute decision making (MADM)"@en,
        "dual generalized weighted BM (DGWBM) operator"@en,
        "dual generalized weighted geometric Bonferroni mean (DGWGBM) operator"@en,
        "strategic supplier selection"@en ;
    ns0:hasPubAbstract "In this article, we expand the dual generalized weighted BM (DGWBM) and the dual generalized weighted geometric BM (DGWGBM) operator with interval neutrosophic numbers (INNs) to propose the dual generalized interval neutrosophic number BM (DGINNBM) operator, dual generalized interval neutrosophic number WBM (DGINNWBM) operator, dual generalized interval neutrosophic numbers GBM (DGINNGBM) operator and dual generalized interval neutrosophic numbers WGBM (DGINNWGBM) operator, then the MADM methods are proposed with these operators. In the end, we utilize an applicable example for strategic supplier selection to prove the proposed methods."@en ;
    ns0:hasPubTitle "Approaches to strategic supplier selection under interval neutrosophic environment"@en .

ns1:ifs-v37-i2-IFS179250 ns0:hasKeywords "Soft set"@en,
        "bipolar soft set"@en,
        "fuzzy soft set"@en,
        "multi-fuzzy bipolar soft set"@en,
        "multi-fuzzy set"@en ;
    ns0:hasPubAbstract "Soft set theory, proposed by Molodtsov, has been regarded as an effective mathematical tool to deal with vagueness and uncertainties. It is worth noting that the decision making theory has been proven a more effective tool in the real-world problems under imprecise environments. In this paper, we introduce a new fuzzy soft model, called the multi-fuzzy bipolar soft set model. Some operations of this notion are first investigated and some of the related properties are studied. Finally, an algorithm based on multi-fuzzy bipolar soft set is presented and an illustrative example is given to analyze the application of the proposed algorithm."@en ;
    ns0:hasPubTitle "A decision making approach based on multi-fuzzy bipolar soft sets"@en .

ns1:ifs-v37-i2-IFS179262 ns0:hasKeywords "IVIFN VIKOR method"@en,
        "Multiple attribute decision making (MADM)"@en,
        "Prospect theory"@en,
        "VIKOR method"@en,
        "financing risk assessment"@en,
        "interval-valued intuitionistic fuzzy numbers (IVIFNs)"@en,
        "rural tourism projects"@en ;
    ns0:hasPubAbstract "Recently, the VIKOR has been used to solve multiple attribute decision making (MADM) problems. The interval-valued intuitionistic fuzzy sets (IVIFSs) are useful tools to depict uncertainty of the MADM problems. In this paper, we will extend VIKOR method to the MADM with the interval-valued intuitionistic fuzzy numbers (IVIFNs). Firstly, the definition, comparison and distance of IVIFNs are briefly introduced. Then, the extended classical VIKOR method is proposed to deal with MADM problems with the IVIFNs, and its significant characteristic is that it can fully consider the decision makers’ bounded rationality which is a real action in decision making. Finally, a numerical example for financing risk assessment of rural tourism projects is proposed and a comparative analysis is also given."@en ;
    ns0:hasPubTitle "VIKOR method for financing risk assessment of rural tourism projects under interval-valued intuitionistic fuzzy environment"@en .

ns1:ifs-v37-i2-IFS179373 ns0:hasKeywords "(fuzzy) co-annihilator"@en,
        "(fuzzy) prefilter"@en,
        "EQ-algebra"@en,
        "EQΔ-algebra"@en,
        "fuzzy congruence relation"@en ;
    ns0:hasPubAbstract "In this paper, we introduce the co-annihilator ⊥A of a set A and the co-annihilator of (F : a) of a relative to a prefilter (filter) F in an EQ-algebra ɛ. We investigate related properties of them, and obtain that the lattice of all prefilters   PF ( ɛ )   forms a pseudo-complemented lattice and the collection of all co-annihilators   COA ( ɛ )   forms a Boolean algebra in a separated EQ-algebra ɛ. Moreover, we introduce the notion of Δ-co-annihilators in an EQΔ-algebra ɛΔ and conclude that the collection of all Δ-prefilters    PF Δ  (  ɛ Δ  )   in an ℓEQΔ-algebra ɛΔ constitutes a relative pseudo-complemented lattice. Finally, we introduce and investigate two types of fuzzy co-annihilators AnnR (μ) and Ann (μ, ν) in ɛ. We come to a conclusion that the set of all fuzzy filters   FF ( ɛ )   in a residuated ℓEQ-algebra ɛ forms a relative pseudo-complemented lattice whence → is the Gödel residuated implication in Str (μ, ν)."@en ;
    ns0:hasPubTitle "Co-annihilators and fuzzy co-annihilators in EQ-algebras"@en .

ns1:ifs-v37-i2-IFS181452 ns0:hasKeywords "RSM index"@en,
        "Social Network"@en,
        "fuzzy networks"@en,
        "link prediction"@en ;
    ns0:hasPubAbstract "Prediction of links/ connections in social networks is useful for increasing business in the area of telecom and social media. All types of social networking organization are trying to increase their nodes, i.e. the number of members. So the calculation of link prediction is the most important task because this calculation will help how to increase the number of user on a social network. A new technique of link prediction, namely RSM index, is introduced in this paper. Few essential properties have been established. Also, a comparative study with the existing methods is depicted with suitable tables and graphs."@en ;
    ns0:hasPubTitle "RSM index: A new way of link prediction in social networks"@en .

ns1:ifs-v37-i2-IFS182579 ns0:hasKeywords "Cubic fuzzy graphs"@en,
        "bipolar fuzzy graphs"@en,
        "cubic bipolar fuzzy graph"@en,
        "strong cubic bipolar fuzzy graphs"@en ;
    ns0:hasPubAbstract "Recently, Jun et al. have introduced the concept of cubic set as a generalization of the concept of fuzzy set and that of the interval valued fuzzy set. This concept has been widely applied in many circumstances like pattern recognition, decision making etc. So far, no attention has been paid towards graph of cubic set therefore leads us in this manuscript to study the concepts of interval valued bipolar fuzzy graph (IVBFG) and cubic bipolar fuzzy graph (CBFG). Some graph theoretic terms for CBFGs are defined along with the several operations. Illustrative examples are provided to explain the defined terms and several results are discussed. As application, a cubic bipolar fuzzy influence graph in a social group is elaborated."@en ;
    ns0:hasPubTitle "Cubic bipolar fuzzy graphs with applications"@en .

ns1:ifs-v37-i2-IFS182778 ns0:hasKeywords "Light-weight, secure, visual image encryption, chaos, Deoxyribonucleic acid, permutation, diffusion"@en ;
    ns0:hasPubAbstract "With the exponential growth of Internet technologies, digital information exchanged over the Internet is also significantly increased. In order to ensure the security of multimedia contents over the open natured Internet, data should be encrypted. In this paper, the quantum chaotic map is utilized for random vectors generation. Initial conditions for the chaos map are computed from a DNA (Deoxyribonucleic acid) sequence along with plaintext image through Secure Hash Algorithm-512 (SHA-512). The first two random vectors break the correlation among pixels of the original plaintext image via row and column permutation, respectively. For the diffusion characteristics, the permuted image is bitwise XORed with a random matrix generated through the third random vectors. The diffused image is divided into Least Significant Bit (LSB) and Most Significant Bits (MSBs) and Discrete Wavelet Transform (DWT) is applied to the carrier image. The HL and HH blocks of the carrier image are replaced with LSBs and MSBs of the diffused image for the generation of a visually encrypted image. The detailed theoretical analysis and experimental simulation of the designed scheme show that the proposed encryption algorithm is highly secured. Efficiency and robustness of the proposed visually image encryption scheme is also verified via a number of attack analyses, i.e., sensitivity attack analysis (> 99%), differential attack analysis (NPCR > 99, UACI > 33), brute force attack (almost 7.9892), statistical attack (correlation coefficient values are almost 0 or less than zero), noise tolerance, and cropping attack. Further security analyses such as encryption quality (ID ≅ 1564, DH = 3.000), homogeneity (0.3798), contrast (10.4820) and energy (0.0144) of the scheme are also evaluated."@en ;
    ns0:hasPubTitle "DNA key based visual chaotic image encryption"@en .

ns1:ifs-v37-i2-IFS182907 ns0:hasKeywords "Fuzzy"@en,
        "Partial Selection"@en,
        "Requirements"@en,
        "Security"@en ;
    ns0:hasPubAbstract "Resource limitations in software projects rarely allow for the security requirements to be fully realized. As such, Prioritization and Selection (PAS) techniques are used to find an optimal subset of the requirements. Consequently, some of the security requirements will be ignored. But ignoring security requirements may (a) leave some of the security threats unattended and (b) negatively impact the effectiveness of the selected requirements. To mitigate this, we have proposed a fuzzy framework, referred to as Prioritization And Partial Selection (PAPS), that reduces the number of ignored security requirements by allowing for partial satisfaction of those requirements. We achieve this by relaxing the satisfaction conditions of security requirements, when tolerated, based on their priorities specified by a fuzzy inference system. Taking into account the partiality of security in PAPS mitigates the adverse impact of ignoring security requirements and enhances the accuracy of prioritization and selection. Our proposed framework is scalable to a large number of requirements."@en ;
    ns0:hasPubTitle "A fuzzy framework for prioritization and partial selection of security requirements in software projects"@en .

ns1:ifs-v37-i2-IFS182928 ns0:hasKeywords "03E72"@en,
        "18B30"@en,
        "54A40"@en,
        "Soft set"@en,
        "bipolar soft set"@en,
        "fuzzy soft set"@en,
        "generalised multi-fuzzy bipolar soft set"@en,
        "multi-fuzzy set"@en ;
    ns0:hasPubAbstract "Soft set theory, proposed by Molodtsov, has been regarded as an effective mathematical tool to deal with uncertainty. In this work, new soft model, called the generalised multi-fuzzy bipolar soft model is proposed, and an algorithm based on this notion is presented. Some basic properties of this concept are studied and the related results are investigated. Finally, an application based on generalised multi-fuzzy soft sets in decision making is analyzed."@en ;
    ns0:hasPubTitle "Generalised multi-fuzzy bipolar soft sets and its application in decision making"@en .

ns1:ifs-v37-i2-IFS18877 ns0:hasKeywords "(∈ , ∈ ∨ q)-bipolar fuzzy soft subalgebra/ideal"@en,
        "Bipolar BCK/BCI-algebra"@en,
        "q-bipolar fuzzy soft set"@en,
        "soft set"@en,
        "∈-bipolar fuzzy soft set"@en ;
    ns0:hasPubAbstract "In this paper, the concept of quasi-coincidence of a bipolar fuzzy point within a bipolar fuzzy set is introduced. The notion of ∈-bipolar fuzzy soft set and q-bipolar fuzzy soft set is introduced based on a bipolar fuzzy set and characterizations for an ∈-bipolar fuzzy soft set and a q-bipolar fuzzy soft set to be bipolar fuzzy soft BCK/BCI-algebras are given. Also, the notion of (∈ , ∈ ∨ q)-bipolar fuzzy subalgebras and ideals are introduced and characterizes for an ∈-bipolar fuzzy soft set and q-bipolar fuzzy soft set to be a bipolar fuzzy soft BCK/BCI-algebras are established. Some characterization theorems of these (∈ , ∈ ∨ q)-bipolar fuzzy soft subalgebras and ideals are derived. The relationship among these (∈ , ∈ ∨ q)-bipolar fuzzy soft subalgebras and ideals are also considered."@en ;
    ns0:hasPubTitle "Bipolar fuzzy soft subalgebras and ideals of BCK/BCI-algebras based on bipolar fuzzy points"@en .

ns1:ifs-v37-i2-IFS190036 ns0:hasKeywords "SN"@en,
        "Single–valued neutrosophic directed (graphs)hypergraphs"@en,
        "WSN"@en,
        "positive equivalence relation"@en,
        "α-(semiself-self)derivable single–valued neutrosophic digraph"@en ;
    ns0:hasPubAbstract "This paper considers networks as wireless sensor (hyper)networks and social (hyper)networks by single–valued neutrosophic (directed)(hyper)graphs.The notion of single–valued neutrosophic hypergraphs are extended to single–valuedneutrosophic directed hypergraphs and conversely. We derived single–valued neutrosophic digraphs from single–valued neutrosophic directed hypergraphs via a positive equivalence relation. It tries to use single–valued neutrosophic directed hypergraphs and positive equivalence relation to create the sensor clusters and to access to cluster heads in wireless sensor (hyper)networks. Finally, the concept of α-derivable single–valued neutrosophic digraph is considered as the energy-efficient protocol of wireless sensor networks and is applied this concept as a tool in wireless sensor (hyper)networks."@en ;
    ns0:hasPubTitle "Single-valued neutrosophic directed (Hyper)graphs and applications in networks"@en .

ns1:ifs-v37-i3-IFS181339 ns0:hasKeywords "Lung sound"@en,
        "Mel cepstrum coefficient"@en,
        "Welch power spectrum"@en,
        "linear prediction cepstral coefficient"@en,
        "random forest"@en ;
    ns0:hasPubAbstract "A two stage recognition method combined multiple kind of features was proposed to overcome the limitation of single kind of feature in the lung sound recognition. The method combines the improved Welch power spectrum, Mel cepstrum coefficients and the linear prediction cepstral coefficients based on the wavelet decomposition. In the first stage, pneumonia samples and asthma samples are firstly taken as the abnormal category. Then a two-class classifier based on random forests is trained to identify the normal samples and the abnormal samples. In the second stage, a classifier based on random forests is trained to recognize pneumonia and asthma from the samples classified as the abnormal samples in the first stage. To further improve the accuracy, a multi granularity cycle segmentation method of lung sounds was presented, which is based on the short time zero crossing rate. It can better segment lung sounds. Experimental results showed that the proposed method greatly improved the recognition accuracy, especially for improving the accuracy of pneumonia and asthma."@en ;
    ns0:hasPubTitle "A two stage recognition method of lung sounds based on multiple features"@en .

ns1:ifs-v37-i3-IFS182809 ns0:hasKeywords "Cubic m-polar fuzzy ordered weighted averaging (CMPFOWA) operator and Cubic m-polar fuzzy hybrid averaging (CMPFHA) operator"@en,
        "Cubic m-polar fuzzy set (CMPFS)"@en,
        "Cubic m-polar fuzzy weighted averaging (CMPFWA) operator"@en,
        "MAGDM for agricultural purpose"@en,
        "membership degrees"@en ;
    ns0:hasPubAbstract "In multi-attribute group decision-making (MAGDM) problems, there exist some multi-polarity for the attributes and criteria. Sometimes in real life situations, we deal with the both membership and non-membership grades for the attributes in the presence of multi-polarity. For this purpose, we change verbally stated information into mathematical language with the help of uncertain linguistic variables to deal with the ambiguities and uncertainties. In that case, we construct some extensions from the existing hybrid structures of fuzzy set to handle these types of problems. That’s why from the prevailing concepts of cubic set and m-polar fuzzy set, we innovate the concept of cubic m-polar fuzzy set (CMPFS). We investigate its numerous operations with the help of examples. With the enthusiasm of CMPFS, we establish certain aggregation operators based on cubic m-polar fuzzy numbers (CMPFNs) namely Cubic m-polar fuzzy weighted averaging (CMPFWA), Cubic m-polar fuzzy ordered weighted averaging (CMPFOWA) and Cubic m-polar fuzzy hybrid averaging (CMPFHA) operators corresponding to R-order and P-order, simultaneously. Using the score function and accuracy function a relation is proposed, through which we can compare the CMPFNs. This manuscript presents a novel approach for treating ambiguities based on the application of land selection using linguistic variables in CMPF decision theory. An algorithm based on MAGDM is intended for a given agricultural project, which will produce results according to the proposed operators one by one. Furthermore, a comparative analysis is listed to demonstrate the difference, advantages, validity, simplicity, flexibility and superiority to the proposed operators."@en ;
    ns0:hasPubTitle "MAGDM for agribusiness in the environment of various cubic m-polar fuzzy averaging aggregation operators"@en .

ns1:ifs-v37-i3-IFS182951 ns0:hasKeywords "GIVPFEHA operator"@en,
        "GIVPFEOWA operator"@en,
        "GIVPFEWA operator"@en,
        "Group decision-making"@en ;
    ns0:hasPubAbstract "The concept of interval-valued Pythagorean fuzzy (IVPF) sets is capable of handling imprecise and ambiguous information and managing complex uncertainty in real-world applications. The focus of our this paper is to introduce some generalized operators, such as the generalized interval-valued Pythagorean fuzzy Einstein weighted averaging (abbreviated as GIVPFEWA) operator, the generalized interval-valued Pythagorean fuzzy Einstein ordered weighted averaging (abbreviated as GIVPFEOWA) operator, and the generalized interval-valued Pythagorean fuzzy Einstein hybrid averaging (abbreviated as GIVPFEHA) operator along with their some general properties, such as idempotency, commutativity, monotonicity and boundedness. Furthermore, the method for multiple attribute group decision making problems based on these operators was developed, and the operational processes were illustrated in detail. The main advantage of using the proposed methods and operators is that these operators and methods give a more complete view of the problem to the decision makers. These methods provide more general, more accurate and precise results as compared to the existing methods. Therefore these methods play a vital role in real world problems. Finally the proposed operators have been applied to decision-making problems to show the validity, practicality and effectiveness of the new approach. A systematic comparison between the existing work and the proposed work also has been given."@en ;
    ns0:hasPubTitle "Some new generalized interval-valued Pythagorean fuzzy aggregation operators using einstein t-norm and t-conorm"@en .

ns1:ifs-v37-i3-IFS182961 ns0:hasKeywords "Intuitionistic fuzzy digraph"@en,
        "gain"@en,
        "intuitionistic fuzzy bridge"@en,
        "intuitionistic fuzzy cutvertices"@en,
        "loss"@en ;
    ns0:hasPubAbstract "Theoretical concepts of graphs are highly utilized by computer science applications. Especially in research areas of computer science such as data mining, image segmentation, clustering, image capturing and networking. The intuitionistic fuzzy graphs are more flexible and compatible than fuzzy graphs due to the fact that they have many applications in networks. The main purpose of this paper is to introduce some connectivity concepts in the intuitionistic fuzzy graphs. Analogous to fuzzy cutvertices and fuzzy bridges in fuzzy graphs, intuitionistic fuzzy cutvertices and intuitionistic fuzzy bridges are introduced and characterized. We also proposed the concept of gain and loss for paths and pairs of vertices. Finally, we give an application of intuitionistic fuzzy digraphs."@en ;
    ns0:hasPubTitle "Novel concepts in intuitionistic fuzzy graphs with application"@en .

ns1:ifs-v37-i3-IFS190054 ns0:hasKeywords "algorithms"@en,
        "coloring of q-rung orthopair fuzzy directed hypergraphs"@en,
        "dual directed hypergraphs"@en,
        "q-Rung orthopair fuzzy directed hypergraphs"@en ;
    ns0:hasPubAbstract "A q-rung orthopair fuzzy model is a powerful framework for illustrating uncertainty and vagueness. This model is more practical, flexible and appropriate as compared to fuzzy, intuitionistic fuzzy and Pythagorean fuzzy models. Directed hypergraphs are utilized to execute higher-order relationships in communications and social webbing. In this research study, we design a new framework for manipulating q-rung orthopair fuzzy data by means of combinative theory of q-rung orthopair fuzzy sets and directed hypergraphs. We introduce certain new concepts, including q-rung orthopair fuzzy directed hypergraphs, dual directed hypergraphs, line graphs and coloring of q-rung orthopair fuzzy directed hypergraphs. Further, we implement some interesting concepts of q-rung orthopair fuzzy directed hypergraphs to real life problems."@en ;
    ns0:hasPubTitle "q-Rung orthopair fuzzy directed hypergraphs: A new model with applications"@en .

ns1:ifs-v37-i3-IFS190217 ns0:hasKeywords "Pythagorean fuzzy soft sets"@en,
        "decision making problem"@en,
        "distance measure"@en,
        "entropy"@en,
        "fuzzy soft sets"@en,
        "pattern recognition problem"@en ;
    ns0:hasPubAbstract "A Pythagorean fuzzy soft set is a parameterized family of Pythagorean fuzzy sets and a generalization of intuitionistic fuzzy soft sets. In this paper, the notions of entropy and distance measures are defined for the Pythagorean fuzzy soft sets (PFSSs). Since, the already existing techniques for finding entropy and distance measures are not working for PFSSs, it is necessary to introduce these techniques in the contest of PFSSs. This work proposes a characterization of the Pythagorean fuzzy soft entropy. Also, the expressions for the standard distance measures like Hamming distance and Euclidean distance are obtained. Further, the applications of PFSSs in decision making problem and pattern recognition problem are discussed. Finally, comparative studies with other existing equations are also carried out."@en ;
    ns0:hasPubTitle "Entropy and distance measures of Pythagorean fuzzy soft sets and their applications"@en .

ns1:ifs-v37-i3-IFS190344 ns0:hasKeywords "Multi-attribute decision making"@en,
        "hybrid Z-information"@en,
        "order relation"@en,
        "rank aggregation"@en,
        "supplier selection"@en ;
    ns0:hasPubAbstract "Z-numbers contain both of the cognitive information and the reliability of information. Since there are many types of cognitive information, by considering the reliability of these information, decision making with hybrid Z-information would be a practical issue, which has merely been considered. The aim of this paper is to introduce a multi-attribute decision making (MADM) with hybrid Z-information based on ranking aggregation method. By using the Technique for Order Preference by Similarity to an Ideal Solution (TOPSIS) method, single rankings of alternatives under attributes are firstly produced. Then, final ranking(s) of alternatives with the lowest disagreement among single rankings could be derived according to ranking aggregation. As a result, a MADM with hybrid Z-information is transformed to be a ranking aggregation problem. The advantage of the developed method is that no algebra structures of hybrid Z-information is needed, so complex calculating process is avoided. In this paper, the mathematical structure of the case that MADM with hybrid Z-numbers is clear. Besides, the combination of ranking aggregation method and studies on Z-numbers could simplify the processing of hybrid Z-numbers. Finally, an example of supplier selection in green supply chain environment is introduced to illustrate the feasibility and validity of the developed model."@en ;
    ns0:hasPubTitle "Rank aggregation based multi-attribute decision making with hybrid Z-information and its application"@en .

ns1:ifs-v37-i4-IFS179302 ns0:hasKeywords "Capsule network"@en,
        "bionic manipulator"@en,
        "image processing"@en,
        "pseudo color image"@en ;
    ns0:hasPubAbstract "People can rely on complex tactile systems to perceive the basic physical properties of an object, and take the corresponding action and pressure to grab the object. However, this task is not easy for mechanical manipulator. The feedback of most manipulators is limited to pressure, it is difficult for manipulators to identify the other properties of the object by touch. A new manipulator method is designed in this paper. The tactile images are reflected by flexible tactile sensor in this manipulator system. A large number of tactile images are used to build training set by which the capsule network is trained to evaluate images. When an object is captured by a manipulator, and parameters such as shape, rigidity, weight and density of target objects are analyzed. Pseudo color transformation of tactile images is performed, in this way, the changes of each parameter of tactile signals can be observed visibly. It is innovative to process the tactile image by using capsule network and realize the evolutionary bionic tactile function."@en ;
    ns0:hasPubTitle "Evolutionary bionic manipulator method based on capsule network"@en .

ns1:ifs-v37-i4-IFS181408 ns0:hasKeywords "Fuzzy interval"@en,
        "bounds of variance"@en,
        "inequalities"@en,
        "semi-variance"@en ;
    ns0:hasPubAbstract "Variance in fuzzy set theory, generally applied in investment decision, risk evaluation, and so on, can be described as a measurement that gauges the deviation of a fuzzy number. In this paper, in order to extend the application range and enrich the research area of variance, the concepts of variance bounds and semi-variances are defined and discussed from a theoretical point of view. With respect to some frequently-used fuzzy intervals, four relatively simple calculation formulas for upper and lower bounds of variance, and upside and downside semi-variances are put forward respectively, with the aid of which several correlation inequalities are subsequently presented and proved. Besides, in order to depict the concepts and inequalities more distinctly, plenty of examples are introduced to make some numerical illustration."@en ;
    ns0:hasPubTitle "Calculation formulas and correlation inequalities for variance bounds and semi-variances of fuzzy intervals"@en .

ns1:ifs-v37-i4-IFS181663 ns0:hasKeywords "(L, M)-fuzzy concave spaces"@en,
        "(L, M)-fuzzy hull relations"@en,
        "(L, M)-fuzzy interior operators"@en,
        "(L, M)-fuzzy interior relations"@en ;
    ns0:hasPubAbstract "In this paper, the notions of (L, M)-fuzzy concave spaces, (L, M)-fuzzy interior spaces, (L, M)-fuzzy interior relations and (L, M)-fuzzy hull relations are introduced. It is proved that the category of (L, M)-fuzzy concave spaces, the category of (L, M)-fuzzy interior spaces, the category of (L, M)-fuzzy interior relation spaces and the category of (L, M)-fuzzy hull relation spaces are isomorphic. Moreover, it is proved that these categories are all isomorphic to the category of (L, M)-fuzzy convex spaces when L is a completely distributive lattice with an order-reversing involution."@en ;
    ns0:hasPubTitle "Some characterizations of (L, M)-fuzzy convex spaces"@en .

ns1:ifs-v37-i4-IFS181742 ns0:hasKeywords "Abel-Grassmann’s groupoid (AG-groupoid)"@en,
        "Clifford semigroup"@en,
        "Semigroup"@en,
        "completely regular semigroup"@en,
        "neutrosophic extended triplet group (NETG)"@en ;
    ns0:hasPubAbstract "From the perspective of semigroup theory, the characterizations of a neutrosophic extended triplet group (NETG) and AG-NET-loop (which is both an Abel-Grassmann groupoid and a neutrosophic extended triplet loop) are systematically analyzed and some important results are obtained. In particular, the following conclusions are strictly proved: (1) an algebraic system is neutrosophic extended triplet group if and only if it is a completely regular semigroup; (2) an algebraic system is weak commutative neutrosophic extended triplet group if and only if it is a Clifford semigroup; (3) for any element in an AG-NET-loop, its neutral element is unique and idempotent; (4) every AG-NET-loop is a completely regular and fully regular Abel-Grassmann groupoid (AG-groupoid), but the inverse is not true. Moreover, the constructing methods of NETGs (completely regular semigroups) are investigated, and the lists of some finite NETGs and AG-NET-loops are given."@en ;
    ns0:hasPubTitle "On neutrosophic extended triplet groups (loops) and Abel-Grassmann’s groupoids (AG-groupoids)"@en .

ns1:ifs-v37-i4-IFS182643 ns0:hasKeywords "Complex fuzzy sets"@en,
        "approximate orthogonality"@en,
        "approximately orthogonality preserving"@en,
        "operators"@en ;
    ns0:hasPubAbstract "This paper presents the notion of approximate orthogonality of complex fuzzy sets, which is a generalization of the existing concept. Based on the new concept, we present some basic properties of the approximate orthogonality of complex fuzzy sets. Furthermore, we discuss approximately orthogonality preserving with respect to complement, union and intersection operations of complex fuzzy sets."@en ;
    ns0:hasPubTitle "Approximate orthogonality of complex fuzzy sets and approximately orthogonality preserving operators"@en .

ns1:ifs-v37-i4-IFS182798 ns0:hasKeywords "Fuzzy set"@en,
        "G - V intuitionistic fuzzy matroid"@en,
        "fuzzy matroid"@en,
        "intuitionistic fuzzy set"@en,
        "matroid"@en,
        "rank function"@en ;
    ns0:hasPubAbstract "The purpose of this paper is to study matroids on intuitionistic fuzzy sets, so as to generalize G - V fuzzy matroids.The ranking, union and intersection between two intuitionistic fuzzy sets are firstly defined by using the similarity function h and the accuracy function H of the intuitionistic fuzzy value. Then a G - V intuitionistic fuzzy matroid which can be regarded as an extension of G - V fuzzy matroids is proposed. Particularly, the induced matroid sequence and the rank function of a G - V intuitionistic fuzzy matroid and their properties are studied."@en ;
    ns0:hasPubTitle "A generalization of G-V fuzzy matroids based on intuitionistic fuzzy sets"@en .

ns1:ifs-v37-i4-IFS182828 ns0:hasKeywords "L-fuzzy set"@en,
        "L-fuzzy soft set"@en,
        "complete lattice isomorphism"@en,
        "fuzzy set of type 2"@en,
        "soft set"@en ;
    ns0:hasPubAbstract "In this paper, it is shown that an L-fuzzy soft set on X with a set E of parameters can be regarded as an LX-fuzzy set on E, and it can also be regarded as an LE-fuzzy set on X. Moreover an LE-fuzzy set on X can also be regarded as an L-fuzzy sets on E × X. In particular, a soft set on X with a set E of parameters actually can be regarded as a 2E-fuzzy set or a crisp subset of E × X. This shows that the concept of (fuzzy) soft set is redundant. Further it is shown that the notions of soft groups, soft rings and fuzzy soft semigroups are respectively special cases of the corresponding L-fuzzy groups, L-fuzzy rings and L-fuzzy semigroups. Therefore, theoretical workers should stop working in these restrictive and complicated programs, while applied workers should transfer the need or appropriateness of (fuzzy) soft set notions to lattice-valued fuzzy sets or fuzzy sets of type 2."@en ;
    ns0:hasPubTitle "Fuzzy soft sets as L-fuzzy sets"@en .

ns1:ifs-v37-i4-IFS182832 ns0:hasKeywords "40F05"@en,
        "40G05"@en,
        "40J05"@en,
        "Orlicz function"@en,
        "Triple sequences"@en,
        "difference sequence"@en,
        "duals"@en,
        "fuzzy numbers"@en,
        "integral sequence"@en,
        "rough convergence"@en ;
    ns0:hasPubAbstract "There are several notions of convergence of fuzzy number sequences in the literature. The aim of this paper is to introduce and study a new concept of the rough fuzzy ideal convergent triple sequences defined by Orlicz function. Also, some topological properties of the resulting sequence spaces of rough fuzzy numbers were examined."@en ;
    ns0:hasPubTitle "Rough convergence of Bernstein fuzzy I-convergent of χf(Δ,p)3I(F) space defined by Orlicz function"@en .

ns1:ifs-v37-i4-IFS18824 ns0:hasKeywords "Hyper BE-algebra"@en,
        "doubt intuitionistic fuzzy hyper filter"@en,
        "doubt intuitionistic fuzzy implicative hyper filter"@en ;
    ns0:hasPubAbstract "The purpose of this study is to apply the intuitionistic fuzzy hyper filters to hyper BE-algebras and to derive the conditions for an intuitionistic fuzzy set to be a doubt intuitionistic fuzzy hyper filter in hyper BE-algebras. The findings of the study establish the notion that an intuitionistic fuzzy set of a hyper BE-algebra is an intuitionistic fuzzy hyper filter if and only if the complement of this intuitionistic fuzzy set is a doubt intuitionistic fuzzy hyper filter. The content of this manuscript also includes the introduction of the notion of doubt intuitionistic fuzzy implicative hyper filter in hyper BE-algebras and some related properties."@en ;
    ns0:hasPubTitle "Doubt intuitionistic fuzzy hyper filters in hyper BE-algebras"@en .

ns1:ifs-v37-i4-IFS190205 ns0:hasKeywords "Probabilistic interval-valued intuitionistic hesitant fuzzy set"@en,
        "TOPSIS"@en,
        "linear programming"@en,
        "multi-attribute group decision making"@en,
        "similarity measure"@en ;
    ns0:hasPubAbstract "Interval-valued intuitionistic hesitant fuzzy set (IVIHFS) has a key role in multiple attribute decision making (MADM) problems due to its ability to represent the decision maker’s hesitant opinions using preferred and non-preferred intervals. In this paper, we develop an interactive decision-making approach to solve multi-attribute group decision making (MAGDM) problems with incomplete weight information using probabilistic interval-valued intuitionistic hesitant fuzzy set (P-IVIHFS), which is an extension of IVIHFS. The assessments provided by the decision makers for individual alternatives regarding different attributes are expressed using probabilistic interval-valued intuitionistic hesitant fuzzy elements (P-IVIHFEs). Linear programming (LP) is used to obtain the optimal weights of attributes from the partially known weight information. Moreover, we extend the technique for order preference by similarity to ideal solution (TOPSIS) method in the framework of P-IVIHFS for the ranking purpose. Finally, we have solved a numerical example for the supplier selection problem using the proposed method to illustrate the applicability of the proposed approach. The comparative study demonstrates the suitability of the proposed approach over the existing methods."@en ;
    ns0:hasPubTitle "Multiple attribute decision making based on probabilistic interval-valued intuitionistic hesitant fuzzy set and extended TOPSIS method"@en .

ns1:ifs-v37-i4-IFS190668 ns0:hasKeywords "BNS-topology, BNS-topological properties, BNS-TOPSIS, MCGDM, medical diagnosis"@en ;
    ns0:hasPubAbstract "In this paper, we bring out the idea of bipolar neutrosophic soft topology based on bipolar neutrosophic soft set (BNS-set). We study the properties of classical topology under bipolar neutrosophic soft (BNS) vagueness. The BNS-topology is the generalization of the fuzzy topology. We discuss certain properties of BNS-topology including, BNS-closure, BNS-interior, BNS-exterior and BNS-frontier by utilizing BNS-points. We also study the concept of BNS-subspace, BNS-neighborhoods and BNS-base for BNS-topology with the help of detailed examples and theorems. Furthermore, we propose: Technique for Order Preferences by Similarity to an Ideal Solution (TOPSIS) method under BNS-topological environment to deal with similarities in medical diagnosis. We see the importance of BNS-topology in multi criteria group decision making (MCGDM) as well. We present a numerical example with real background to demonstrate the validity of our model. Finally, we make a method-based and set-based comparison analysis of proposed method with some existing methods. Compared with existing MCGDM models, this study provides a flexible framework to form an approximate decision model to real-world MCGDM problems."@en ;
    ns0:hasPubTitle "A novel extension of TOPSIS to MCGDM with bipolar neutrosophic soft topology"@en .

ns1:jad-v69-i3-JAD181272 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Mini-Mental State Examination (MMSE)"@en,
        "Montreal Cognitive Assessment (MoCA)"@en,
        "carboxymethyl lysine (CML)"@en,
        "extracellular vesicles"@en,
        "pentosidine"@en ;
    ns0:hasPubAbstract "Background: Both advanced glycation end products (AGEs) N-(1-carboxymethyl)-L-lysine (CML) and pentosidine were found in the brain from Alzheimer’s disease (AD) patients and were associated with the neuropathological hallmarks of AD. In AD patients, the circulating level of both AGEs remains unknown. Moreover, their levels in peripheral extracellular vesicles (EVs) and their association with AD remain to be determined. Finally, it is not known if neuronal cells can release AGEs via EVs and propagate AGEs.   Objective: To determine the levels of circulating CML and pentosidine during the progression of AD. Moreover, their levels in circulating EVs were determined and their association with the clinical cognitive scores were analyzed. Finally, we have studied the possibility that neuronal cells eliminate and transfer these AGEs through EVs.   Methods: CML and pentosidine levels were measured in serum and in circulating EVs. Released-EVs from SK-N-SH neuronal cells were isolated and CML levels were also determined.   Results: The levels of CML in albumin-free serum proteins were higher in the early stage of AD while the levels of pentosidine remained unchanged. In contrast, the levels of CML in the EVs were lower in the moderate stage of AD. Interestingly, the levels of CML in serum were negatively correlated with the clinical cognitive scores MMSE and MoCA. For the first time, we were able to demonstrate that CML was present in EVs released from neuronal cells in culture.   Conclusion: Peripheral and circulating EVs levels of CML can differentiate early to moderate AD. In the brain, neuronal CML can propagate from cells-to-cells via EVs."@en ;
    ns0:hasPubTitle "Circulating and Extracellular Vesicles Levels of N-(1-Carboxymethyl)-L-Lysine (CML) Differentiate Early to Moderate Alzheimer’s Disease"@en .

ns1:jad-v69-i3-JAD181288 ns0:hasKeywords "Confusion assessment method"@en,
        "postoperative delirium severity"@en,
        "reliability"@en,
        "validity"@en ;
    ns0:hasPubAbstract "Previous studies showed that the Confusion Assessment Method based delirium severity evaluation tool (CAM-S) had good reliability and validity. However, there is no Chinese version of the CAM-S. Therefore, we set out to perform a prospective investigation in older Chinese patients who had total joint replacement surgery under general anesthesia in Tenth People’s Hospital in Shanghai, P.R. China. A total of 576 participants, aged 60 years or older, were screened, 179 participants were enrolled, and 125 of them were included for the final analysis. Pre-operative evaluations were conducted one day before the surgery. Postoperative evaluations were conducted twice daily from postoperative day 1 to day 3. The incidence of postoperative delirium was 24.8%. The Chinese version of CAM-S [including a Short Form (CAM-S Short Form) and a Long Form (CAM-S Long Form)] had an optimal reliability reflected by internal consistency (Cronbach’s α= 0.748 and 0.839 for CAM-S Short Form and CAM-S Long Form respectively), split-halves reliability (Pearson correlation coefficient = 0.372 and 0.384 for CAM-S Short Form and CAM-S Long Form respectively), and inter-rater reliability (intra-class correlation coefficients = 0.629 and 0.945 for CAM-S Short Form and CAM-S Long Form respectively). Additionally, the Chinese version of CAM-S also showed a good discriminate validity. The domain scores of CAM-S were inversely correlated with corresponding domain scores of the MMSE. Finally, a receiver operating characteristic (ROC) analysis obtained an optimal cutoff point of 2.5 for CAM-S Short Form and 3.5 for CAM-S Long Form in recognizing delirium diagnosed by CAM. The areas under the ROC were 0.989 (95% CI 0.972 – 1.000, p < 0.001) and 0.964 (95% CI 0.946 – 0.982, p < 0.001), respectively. These data suggest that the Chinese version of CAM-S has good reliability and validity in evaluating postoperative delirium in geriatric Chinese patients and may be a useful tool to assess the severity of delirium."@en ;
    ns0:hasPubTitle "The Reliability and Validity of the Chinese Version of Confusion Assessment Method Based Scoring System for Delirium Severity (CAM-S)"@en .

ns1:jad-v69-i3-JAD190075 ns0:hasKeywords "37 kDa/67 kDa laminin receptor (LRP/LR)"@en,
        "Alzheimer’s disease"@en,
        "TERT"@en,
        "amyloid-β"@en,
        "telomerase"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) represents the most common form of neurodegenerative disorders with only palliative treatments currently available. Amyloid plaque formation caused by amyloid-β (Aβ) aggregation and neurofibrillary tangle formation caused by hyperphosphorylated tau are hallmarks for the development of AD. The 37 kDa/67 kDa laminin receptor (LRP/LR) has been implicated in AD and tools blocking or downregulating LRP/LR impede amyloid plaque formation in vitro and in vivo. We have recently shown that LRP::FLAG enhances telomerase activity with a concomitant reduction of senescent markers. Here, we overexpressed LRP::FLAG in HEK293 and SH-SY5Y cells, which resulted in an increase in hTERT levels as well as increased telomerase activity and increased cell viability in the presence of cytotoxic levels of exogenous Aβ. LRP::FLAG overexpression decreased Aβ shedding and intracellular Aβ levels in HEK293 cells. This suggests that LRP::FLAG rescues cells from Aβ-induced cytotoxicity through increased telomerase activity. This study recommends LRP::FLAG as a novel alternative therapeutic for AD treatment through activation of telomerase activity."@en ;
    ns0:hasPubTitle "LRP::FLAG Rescues Cells from Amyloid-β-Mediated Cytotoxicity Through Increased TERT Levels and Telomerase Activity"@en .

ns1:jad-v69-i3-JAD190124 ns0:hasKeywords "Alzheimer’s disease"@en,
        "logopenic variant primary progressive aphasia"@en,
        "posterior cortical atrophy"@en,
        "working memory"@en ;
    ns0:hasPubAbstract "Background: The neuropsychological recognition of early-onset Alzheimer’s disease (AD) can be difficult because of non-amnestic variants such as logopenic variant primary progressive aphasia (lvPPA) and posterior cortical atrophy (PCA).   Objective: This study evaluated the similarities and differences between typical amnestic AD (tAD) and lvPPA and PCA on a screening neuropsychological battery.   Methods: We enrolled 51 patients meeting NIA-AA criteria for biomarker-supported AD (amnestic or non-amnestic) and having an age of onset of <65 years of age. Based on additional recommended clinical criteria for lvPPA and PCA, the early-onset AD patients were divided into three groups (28 tAD, 9 lvPPA, 14 PCA) of comparable age and dementia severity. We then analyzed their profiles on a focused, screening neuropsychological battery for early-onset AD.   Results: In addition to greater variance on the Mini-Mental State Examination, the lvPPA and PCA variants had episodic memory impairment that did not significantly differ from the memory impairment in the tAD patients. Despite differences on language and visuospatial tasks, they did not significantly distinguish the lvPPA and PCA from tAD. The lvPPA group, however, was distinguishable by worse performance on measures reflecting working memory (digit span forward, memory registration).   Conclusions: On neuropsychological screening, all clinical early-onset AD subtypes may have memory impairments. Screening batteries for early-onset AD should also include measures of working memory, which is disproportionately decreased in lvPPA."@en ;
    ns0:hasPubTitle "Neuropsychological Similarities and Differences Between Amnestic Alzheimer’s Disease and its Non-Amnestic Variants"@en .

ns1:jad-v69-i4-JAD181296 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amnestic mild cognitive impairment"@en,
        "default mode network"@en,
        "repetitive transcranial magnetic stimulation"@en,
        "resting-state functional MRI"@en ;
    ns0:hasPubAbstract "Background: Repetitive transcranial magnetic stimulation (rTMS) is thought to be effective in alleviating cognitive symptoms in patients with amnestic mild cognitive impairment (aMCI), but the mechanisms related to network modification are poorly understood.   Objective: Here we tested rTMS efficacy and explored the effect of rTMS-induced changes in the default mode network (DMN) and their predictive value for treatment response.   Methods: Twenty-one subjects clinically diagnosed with aMCI were recruited to complete a 10-session randomized and sham-controlled rTMS treatment targeting the right dorsolateral prefrontal cortex. Resting-state functional magnetic resonance imaging in tandem with neuropsychological assessments were administered before and after the intervention. Changes in functional connectivity of the DMN and relevant brain regions, as well as the correlations between baseline functional connectivity and clinical rating scales were calculated in order to elucidate the mechanism of treatment response to rTMS therapy.   Results: Compared to the sham group, the rTMS group achieved improvement of neuropsychological performance and significant functional connectivity changes within the DMN. Group×Time interactions were found between posterior cingulate gyrus and right fusiform gyrus (F (1,19)  = 17.154, p = 0.001), and also left anterior cingulate gyrus (F (1,19)  = 3.908, p = 0.063), showing an rTMS-induced deactivation of functional connectivity within the DMN. Baseline functional connectivity analysis of seeds within the DMN in the rTMS group revealed negative correlation with AVLT-Recognition score changes.   Conclusion: rTMS-induced hypoconnectivity within DMN is associated with clinical cognitive improvements in patients with aMCI. Further, pre-rTMS baseline activity of the DMN at rest may be a predictor for favorable rTMS treatment response."@en ;
    ns0:hasPubTitle "Repetitive Transcranial Magnetic Stimulation Induced Hypoconnectivity Within the Default Mode Network Yields Cognitive Improvements in Amnestic Mild Cognitive Impairment: A Randomized Controlled Study"@en .

ns1:jad-v69-i4-JAD190146 ns0:hasKeywords "Dementia"@en,
        "humans"@en,
        "patient care"@en,
        "qualitative research"@en,
        "randomized controlled trial"@en,
        "research design"@en ;
    ns0:hasPubAbstract "Background: Low participation in clinical trials is a major challenge to advancing clinical Alzheimer’s disease (AD) research and care. Factors influencing recruitment to AD trials are not fully understood.   Objective: To identify barriers to, and facilitators of, recruitment in a UK multi-center, secondary care AD trial (Reducing pathology in Alzheimer’s Disease through Angiotensin TaRgeting (RADAR) trial) and implications for improving recruitment to AD trials.   Methods: Semi-structured qualitative telephone interviews with a purposive sample of 17 trial site staff explored the RADAR trial recruitment pathway and views and experiences of recruitment. Interviews were analyzed thematically.   Results: Diagnostic and care pathways hindered identifying patients with mild-moderate AD, with a lack of up-to-date patient records and data access problems affecting screening. Research is not routinely embedded in AD care but facilitated recruitment when it was. Clinicians’ and patients’ favorable view of the trial purpose facilitated recruitment, although the complexity of participant information sheets and requirement for study companion created challenges.   Conclusion: These findings have important implications for the design of future AD trials and for planning how to best interface with clinical commitments to ensure sufficient and timely recruitment. Challenges to AD trial recruitment can occur at care pathway, clinician, and patient and companion levels. Recruitment can be facilitated by: improving diagnostic processes and systems for recording and sharing patient information, embedding research into routine patient care, collaborating with a range of services to identify and approach eligible patients, training and engaging trial staff, and providing patients with clear and concise study information."@en ;
    ns0:hasPubTitle "Challenges to and Facilitators of Recruitment to an Alzheimer’s Disease Clinical Trial: A Qualitative Interview Study"@en .

ns1:jad-v69-i4-JAD190241 ns0:hasKeywords "Alzheimer’s disease"@en,
        "animal models of disease"@en,
        "co-morbidities"@en,
        "insulin-like growth factor 1"@en ;
    ns0:hasPubAbstract "Increasing evidence supports the notion that Alzheimer’s disease (AD), a condition that presents heterogeneous pathological disturbances, is also associated to perturbed metabolic function affecting insulin and insulin-like growth factor I (IGF-I). While impaired insulin activity leading to insulin resistance has been associated to AD, whether altered IGF-I function affects the disease is not entirely clear. Despite the limitations of mouse models to mimic AD pathology, we took advantage that serum IGF-I deficient mice (LID mice) present many functional perturbations present in AD, most prominently cognitive loss, which is reversed by treatment with systemic IGF-I. We analyzed whether these mice display other pathological traits that are usual co-morbidities of AD. We found that LID mice not only display cognitive disturbances, but also show altered mood and sociability, increased susceptibility to epileptiform activity, and a disturbed sleep/wake cycle. Collectively, these data suggest that reduced IGF-I activity contributes to heterogeneous deficits commonly associated to AD. We suggest that impaired IGF-I activity needs to be taken into consideration when modeling this condition."@en ;
    ns0:hasPubTitle "Serum Insulin-Like Growth Factor I Deficiency Associates to Alzheimer’s Disease Co-Morbidities"@en .

ns1:jad-v69-i4-JAD190281 ns0:hasKeywords "Calpain"@en,
        "calpastatin"@en,
        "cognitive deficits"@en,
        "dementia"@en,
        "motor dysfunction"@en,
        "neurodegeneration"@en,
        "neuroinflammation"@en,
        "neuromuscular junction"@en,
        "tau phosphorylation"@en,
        "tauopathy"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) and other tauopathies are characterized by intracellular accumulation of microtubule-associated tau protein leading to neurodegeneration. Calpastatin is the endogenous inhibitor of calpain, a calcium-dependent cysteine protease that has been increasingly implicated in tauopathies. In this study, we generated a neuron specific calpastatin overexpressing knock-in transgenic mouse model and crossed it with the PS19 tauopathy mouse model expressing human P301S mutant tau protein. The forced expression of calpastatin in neurons significantly alleviated tau hyperphosphorylation measured by immunocytochemistry and immunoblot. The genetic inhibition of calpain by calpastatin also greatly suppressed characteristic hippocampal neuron loss and widespread astrogliosis and microgliosis in PS19 mice. Consistently, PS19 mice with neuronal calpastatin overexpression exhibited remarkably alleviated cognitive deficits, muscle weakness, skeletal muscle atrophy, and neuromuscular denervation, together implying the neuroprotective effects of neuronal calpastatin in PS19 mice of tauopathy. In sum, this study provides additional evidence supporting the pathological role of calpain in neurodegenerative diseases associated with tau pathology, and suggests that targeting calpain is likely a promising therapeutic approach for these devastating diseases."@en ;
    ns0:hasPubTitle "Inhibition of Calpain Protects Against Tauopathy in Transgenic P301S Tau Mice"@en .

ns1:jad-v70-i1-JAD190025 ns0:hasKeywords "Alzheimer’s disease"@en,
        "dementia"@en,
        "mild cognitive impairment"@en,
        "neuropsychiatric symptoms"@en ;
    ns0:hasPubAbstract "Background: Neuropsychiatric symptoms (NPS) are prevalent in mild cognitive impairment (MCI), but we do not know much about their role in progression to dementia.   Objective: To investigate NPS and the risk of progression to probable Alzheimer’s disease dementia (AD) among subjects with MCI.   Methods: 96 MCI participants were followed for 4 years. Progression to probable AD was defined by the change of CDR total score from 0.5 to ≥1, reviewed by an expert consensus panel. NPS were determined using the Neuropsychiatric Inventory (NPI) 12-items. This study analyzed prognostic value of each NPI item and 5 sub-syndromes of NPS (apathy, psychosis, affective, hyperactivity, and vegetative) for prediction of progression to probable AD. A Cox proportional hazard model was used; hazard ratios (HRs) and 95% confidence intervals (CIs) were estimated with time dependent variable to compare the incidence of progression considering presence/absence of any NPS or sub-syndromes throughout the study.   Results: The presence of symptoms “agitation/aggression”, “delusions”, and “aberrant motor behavior” significantly increased the risk of probable AD (HR = 3.9; 95% CI = 1.9–8.2; HR = 13.9; 95% CI = 4.1–48.9; HR = 4.3; 95% CI = 1.7–10.3, respectively). The presence of sub-syndromes “psychosis” and “hyperactivity” were also predictors of progression (HR = 14.0; 95% CI = 4.4–44.5; HR = 2.0; 95% CI = 1.1–3.7, respectively). These results did not change after adjusting by potential confounders.   Conclusion: Presence of delusions, agitation/aggression, and aberrant motor behavior is predictor of progression to probable AD."@en ;
    ns0:hasPubTitle "Neuropsychiatric Symptoms and Risk of Progression to Alzheimer’s Disease Among Mild Cognitive Impairment Subjects"@en .

ns1:jad-v70-i1-JAD190165 ns0:hasKeywords "Aging"@en,
        "Alzheimer’s disease"@en,
        "dementia"@en,
        "mass screening"@en ;
    ns0:hasPubAbstract "Background: Memory dysfunction is characteristic of aging and often attributed to Alzheimer’s disease (AD). An easily administered tool for preliminary assessment of memory function and early AD detection would be integral in improving patient management.   Objective: Our primary aim was to utilize machine learning in determining initial viable models to serve as complementary instruments in demonstrating efficacy of the MemTrax online Continuous Recognition Tasks (M-CRT) test for episodic-memory screening and assessing cognitive impairment.   Methods: We used an existing dataset subset (n = 18,395) of demographic information, general health screening questions (addressing memory, sleep quality, medications, and medical conditions affecting thinking), and test results from a convenience sample of adults who took the M-CRT test. M-CRT performance and participant features were used as independent attributes: true positive/negative, percent responses/correct, response time, age, sex, and recent alcohol consumption. For predictive modeling, we used demographic information and test scores to predict binary classification of the health-related questions (yes/no) and general health status (healthy/unhealthy), based on the screening questions.   Results: ANOVA revealed significant differences among HealthQScore groups for response time true positive (p = 0.000) and true positive (p = 0.020), but none for true negative (p = 0.0551). Both % responses and % correct had significant differences (p = 0.026 and p = 0.037, respectively). Logistic regression was generally the top-performing learner with moderately robust prediction performance (AUC) for HealthQScore (0.648–0.680) and selected general health questions (0.713–0.769).   Conclusion: Our novel application of supervised machine learning and predictive modeling helps to demonstrate and validate cross-sectional utility of MemTrax in assessing early-stage cognitive impairment and general screening for AD."@en ;
    ns0:hasPubTitle "Episodic-Memory Performance in Machine Learning Modeling for Predicting Cognitive Health Status Classification"@en .

ns1:jad-v70-i1-JAD190230 ns0:hasKeywords "Alzheimer’s disease"@en,
        "atypical AD"@en,
        "cluster analysis"@en,
        "heterogeneity"@en,
        "neuroimaging"@en ;
    ns0:hasPubAbstract "Background: Clinical-pathological Alzheimer’s disease (AD) subtypes may help distill heterogeneity in patient presentation. To date, no studies have utilized neuropsychological and biological markers to identify preclinical subtypes with longitudinal stability.   Objective: The objective of this study was to empirically derive AD endophenotypes using a combination of cognitive and biological markers.   Methods: Hierarchical cluster analysis grouped dementia-free older adults using memory, executive and language abilities, and cerebrospinal fluid amyloid-β and phosphorylated tau. Brain volume differences, neuropsychological trajectory, and progression to dementia were compared, controlling for age, gender, education, and apolipoprotein E4 (ApoE4).   Results: Subgroups included asymptomatic-normal (n = 653) with unimpaired cognition and subthreshold biomarkers, typical AD (TAD; n = 191) showing marked memory decline, high ApoE4 rates and abnormal biomarkers, and atypical AD (AAD; n = 132) with widespread cognitive decline, intermediate biomarker levels, older age, less education and more white matter lesions. Cognitive profiles showed longitudinal stability with corresponding patterns of cortical atrophy, despite nearly identical rates of progression to AD dementia.   Conclusion: Two clinical-pathological AD subtypes are identified with potential implications for preventative efforts."@en ;
    ns0:hasPubTitle "Disentangling Heterogeneity in Alzheimer’s Disease: Two Empirically-Derived Subtypes"@en .

ns1:jad-v70-i1-JAD190266 ns0:hasKeywords "Aging"@en,
        "cognition"@en,
        "dementia"@en,
        "functional status"@en,
        "g"@en,
        "intelligence"@en,
        "mild cognitive impairment"@en,
        "δ"@en ;
    ns0:hasPubAbstract "Background: The latent variable “δ” (for “dementia) is a transdiagnostic measure of dementia severity. δ can be reified and applied to individuals as a composite “d-score”. Like Spearman’s general intelligence factor “g”, δ can be constructed from almost any cognitive battery. So many are available that we must further distinguish each composite as a δ “homolog”. Fourteen have been validated. All are strongly associated with dementia severity and potentially with mild cognitive impairment (MCI) conversion.   Objectives: To assess δ’s impact on MCI conversion risk.   Methods: A new δ homolog (dDx) was constructed in 1,230 Mexican-American (MA) and 2,215 non-Hispanic White (NHW) participants in the Texas Alzheimer’s Research and Care Consortium (TARCC). 1,445 normal controls (NC) and 723 MCI were followed annually for up to 6 years.   Results: Each SD decrease in the dDx score increased the risk of conversion sixteen-fold [OR = 16.39 (CI: 5.0–52.6)]. Cases below the optimal diagnostic threshold for Alzheimer’s disease (AD) versus NC were labeled as having a functionally salient cognitive impairment (FSCI). Such cases were at a 73-fold increase risk of a diagnosis of AD [OR = 73.19 (95% CI: 58.3–92.0)]. However, 25.6% of MCI cases were also FSCI(+). They accounted disproportionately for prospective conversions. Age <80 years, the absence of an ɛ4 allele, <12 years of education, and MA ethnicity independently increased the risk of diagnosing FSCI as MCI.   Conclusion: A sizable minority of MCI cases may be misdiagnosed and they account disproportionately for AD conversions."@en ;
    ns0:hasPubTitle "δ Scores Identify Subsets of “Mild Cognitive Impairment” with Variable Conversion Risks"@en .

ns1:jad-v70-i1-JAD190316 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid"@en,
        "high throughput screening"@en ;
    ns0:hasPubAbstract "A robust fluorescent readout assay using topologically-sensitive dyes improves the screening of novel amyloid-binding molecules. One of the key components that make this assay more realistic is the use of endogenous amyloid obtained from 5XFAD mouse brains. The assay conditions were optimized for high throughput screening operation with Z-prime values >0.6. Using a combination of library of 3,500 compounds including known drugs, natural-derived molecules and random organic molecules, 8 unique molecules were identified as potential amyloid-binding agents."@en ;
    ns0:hasPubTitle "A Robust and Scalable High-Throughput Compatible Assay for Screening Amyloid-β-Binding Compounds"@en .

ns1:jad-v70-i2-JAD181220 ns0:hasKeywords "16S ribosomal RNA sequencing"@en,
        "gut microbiota"@en,
        "tau"@en,
        "tauopathy"@en ;
    ns0:hasPubAbstract "Emerging evidence suggests that gut microbiota dysbiosis plays a role in neurodegenerative disorders. However, whether the composition and diversity of the gut microbiota are altered in tauopathies remains largely unknown. This study was aimed to examine the diversity and composition of the gut microbiota in tauopathies, as well as the correlation with pathological changes in the brain. We collected fecal samples from 32 P301L tau transgenic mice and 32 age- and gender-matched littermate mice at different ages. The 16S ribosomal RNA sequencing technique was used to analyze the microbiota composition in feces. Brain tau pathology levels were measured by immunohistochemistry. The diversity and composition of the gut microbiota significantly changed with aging. At the phylum level, the relative abundance of Bacteroidetes was increased, while Firmicutes were decreased in P301L mice compared with that in Wt mice after 3 months of age. In addition, Actinobacteria was decreased in P301L mice at 3 and 6 months of age, meanwhile Tenericutes was decreased in P301L mice at 10 months of age. Moreover, several specific macrobiota were highly associated with the levels of AT8-tau or pT231-tau protein in the brain. Our findings suggest that gut microbiota changed with aging, as well as in the tauopathy mice model. Modulation of the gut microbiota may be a potential strategy for treatment of tauopathy."@en ;
    ns0:hasPubTitle "Gut Microbiota Alteration and Its Time Course in a Tauopathy Mouse Model"@en .

ns1:jad-v70-i2-JAD181268 ns0:hasKeywords "Amyloid-β protein"@en,
        "pulsatile flow"@en,
        "transcranial doppler sonography"@en,
        "vascular endothelium"@en ;
    ns0:hasPubAbstract "Background: Vascular health is closely related to Alzheimer’s disease (AD). Vascular function measured by flow mediated dilation (FMD) or pulsatility index (PI) can be used as marker of peripheral and central vascular health but is poorly characterized in those at risk for AD.   Objective: To assess the relationship of peripheral and central vascular function with amyloid-β (Aβ) and white matter lesion burden among cognitively normal older adults.   Methods: We enrolled participants 65 years of age and older. Using Doppler ultrasound, we assessed brachial artery FMD, and middle cerebral artery (PI). Global Aβ burden, quantified using [18F] Florbetapir PET imaging, and white matter lesion volume (WML) were used as measures of AD pathology and vascular brain injury.   Results: After adjusting for age and cardiovascular risk factors, the data (n = 83) showed a negative association between FMD and Aβ burden (β= –0.03, p < 0.001). FMD at a cut-off of 4.45% had 88% specificity and 75% sensitivity to elevated Aβ (AUC = 0.86, 95% CI: 0.77–0.95). FMD was not related to WML volume (p = 0.8), and PI was unrelated to Aβ burden or WML volume (0 > 0.4).   Conclusions: Among cognitively normal older adults, blunted peripheral vascular function, as measured by brachial artery FMD, is associated with Aβ burden. These findings provide support for further exploration into the pathophysiological relationship of vascular health and AD risk as measured by Aβ."@en ;
    ns0:hasPubTitle "Vascular Health is Associated with Amyloid-β in Cognitively Normal Older Adults"@en .

ns1:jad-v70-i3-JAD190098 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "neuron"@en,
        "oligomer"@en,
        "oxidative stress"@en,
        "synapse"@en ;
    ns0:hasPubAbstract "Soluble amyloid-β (Aβ) oligomers (AβOs), which elicit neurotoxicity and synaptotoxicity, are thought to play an initiating role in the pathology of Alzheimer’s disease (AD). Since AβOs are a key therapeutic target, we attempted to identify natural agents that reduce AβO neurotoxicity. Using an assay system in which primary cultured neurons are treated with AβOs, we found that Rhodiola rosea extracts and one of its main constituents, tyrosol, significantly inhibited AβO-induced caspase-3 activation. We then assessed the in vivo efficacy of tyrosol by oral administration of the compound into AD model (5XFAD) transgenic and non-transgenic mice from either 2 or 4 to 7 months of age. In both paradigms, tyrosol treatment did not affect body weights of mice. Immunohistochemical analysis revealed that the immunoreactivity of spinophilin, a dendritic synaptic protein, was significantly reduced in three hippocampal subregions of vehicle-treated AD mice compared with non-transgenic mice, which was reversed in tyrosol-treated AD mice. Tyrosol treatment also prevented the enhancement of 4-hydroxy-2-nonenal immunoreactivity in the hippocampal CA3 region of AD mice. By contrast, tyrosol administration did not affect Aβ accumulation, as evaluated by immunohistochemical and biochemical analyses. Moreover, the Barnes maze test showed that tyrosol administration modestly mitigated spatial memory impairment in AD mice. These findings collectively indicate that the natural agent tyrosol protects neurons against AβO neurotoxicity in vitro and ameliorates synaptic disturbance, oxidative stress responses, and cognitive impairment in vivo. We thus suggest that tyrosol is potentially an effective, safe, and unique drug candidate for AD."@en ;
    ns0:hasPubTitle "Tyrosol Reduces Amyloid-β Oligomer Neurotoxicity and Alleviates Synaptic, Oxidative, and Cognitive Disturbances in Alzheimer’s Disease Model Mice"@en .

ns1:jad-v70-i3-JAD190508 ns0:hasKeywords "Anti-dementia drugs"@en,
        "Poland"@en,
        "older adults"@en,
        "one-year persistence"@en,
        "predictors"@en ;
    ns0:hasPubAbstract "Background: Previous studies have suggested that there are substantial differences between countries in terms of persistence with antidementia drugs and that the management of dementia is likely to be population-specific.   Objective: The aim of this study was to analyze the one-year persistence with donepezil, memantine, and rivastigmine in more than 66,000 elderly patients followed in Poland.   Methods: This study included patients who were prescribed donepezil, memantine, or rivastigmine for the first time in general and neuropsychiatric practices in Poland between September 2016 and December 2017 (index date; N = 66,030). The primary outcome of the study was the one-year persistence with donepezil, memantine, and rivastigmine. Non-persistence was defined as a gap of at least 90 days without anti-dementia therapy. The secondary outcome was the identification of variables significantly associated with treatment non-persistence.   Results: After 12 months of follow-up, 42.2% of donepezil users, 46.0% of rivastigmine users, and 65.9% of memantine users were persistent (log-rank p-value <0.001). Memantine (hazard ratio [HR] = 0.58) and rivastigmine users (HR = 0.92) were less likely to discontinue treatment one year after initiation than donepezil users. Furthermore, a younger age (60–64 years: HR = 1.32; 65–74 years: HR = 1.13) and therapy initiated by a neuropsychiatrist (HR = 1.11) were positively associated with therapy discontinuation, while we observed a negative association between the prescription of anti-psychotic drugs and non-persistence (HR = 0.81).   Conclusion: One-year persistence with donepezil, memantine, and rivastigmine was low in elderly patients followed in Poland, and was influenced by age, physician specialty, and co-therapy."@en ;
    ns0:hasPubTitle "One-Year Persistence with Donepezil, Memantine, and Rivastigmine in More than 66,000 Elderly Patients Followed in Poland"@en .

ns1:jad-v70-i3-JAD190518 ns0:hasKeywords "Aging"@en,
        "Alzheimer’s disease"@en,
        "cognitive impairment"@en,
        "neurodegeneration"@en ;
    ns0:hasPubAbstract "Dr. Robert Terry (January 14, 1924-May 20, 2017) studied normal aging and Alzheimer’s disease for more than five decades. He was at a visionary neuropathologist who trained generations of researchers in the field of neurodegenerative disorders and was always at the cutting edge of incorporating ever advancing technology into the fields of neuroscience and neuropathology. He was among the first to study plaques and tangles using electron microscopy, described the effects of aluminum on neurons, and collaborated to develop new approaches to study synaptic pathology in the context of cognitive impairment in Alzheimer’s disease. Dr. Terry made indelible contributions to our understanding of Alzheimer’s disease and dementia. In memory of Bob: veteran, physician-scientist, collaborator, friend, husband, and father."@en ;
    ns0:hasPubTitle "Remembering Robert D. Terry at a Time of Change in the World of Alzheimer’s Disease"@en .

ns1:jad-v70-i4-JAD190092 ns0:hasKeywords "Adiposity"@en,
        "brain aging"@en,
        "epidemiology"@en,
        "neuroimaging"@en,
        "structural MRI"@en ;
    ns0:hasPubAbstract "Background: Adiposity may increase risk for dementia and Alzheimer’s disease (AD), but mechanisms are unclear.   Objective: To examine associations between measures of adiposity with AD-signature region cortical thickness and hippocampal volume.   Methods: We used data from the Northern Manhattan Study, a clinically stroke-free cohort of mostly Hispanic participants. Exposures of interest included body mass index (BMI), waist-hip-ratio (WHR), waist circumference (WC), and adiponectin concentration, measured at study entry. AD-signature region cortical thickness and hippocampal volume were obtained using Freesurfer. We estimated associations using multivariable linear regression, adjusting for sociodemographics and health behaviors. We re-examined estimates after adjustment for APOE ɛ4 allele status or carotid intima-media thickness (cIMT), among those cognitively unimpaired, and after weighting for the inverse probability of selection into the MRI sub-study. We also repeated analyses for cortical thickness in non-AD signature regions.   Results: The sample (N = 947, 63% women, 66% Hispanic/Latino, 26% obese) had a mean (SD) age = 63 (8) years. Greater BMI and WC (both z-scored) were associated with thinner AD-signature region cortex (also z-scored) (BMI: β [95% CI] = –0.09 [–0.18, –0.01], WC: β [95% CI] = –0.11 [–0.20, –0.02]). We did not find evidence that adiposity was related to hippocampal volume. Results were consistent after adjustment for APOE ɛ4 allele status or cIMT, after weighting for selection, among those cognitively unimpaired, and for non-AD signature region cortical thickness.   Conclusion: Greater BMI and WC were related to cortical thinning within and outside the AD-signature region, suggesting a global effect not specific to AD."@en ;
    ns0:hasPubTitle "Measures of Adiposity and Alzheimer’s Disease-Related MRI Markers: The Northern Manhattan Study"@en .

ns1:jad-v70-i4-JAD190220 ns0:hasKeywords "18F-FDG"@en,
        "Alzheimer’s disease"@en,
        "Mini-Mental State Examination"@en,
        "amyloid-β protein"@en,
        "florbetapir"@en,
        "mild cognitive impairment"@en,
        "positron emission tomography"@en ;
    ns0:hasPubAbstract "Background: 18F-Fluorodeoxyglucose (18F-FDG) positron emission tomography (PET) and 18F-florbetapir PET are approved neuroimaging biomarkers for the Alzheimer’s disease (AD) and mild cognitive impairment (MCI).   Objectives: This study aims to compare the efficacy of 18F-FDG and 18F-florbetapir PET at evaluating the cognitive performance of patients with AD, MCI, and normal controls (NC).   Methods: 63 subjects (36 male/27 female, mean age = 68.3) including 19 AD, 23 MCI, and 21 NC underwent 18F-FDG and 18F-florbetapir PET imaging. A global quantification approach was applied on supra-tentorial, frontal, parieto-occipital, temporal, and cerebellar brain regions by calculating the global SUVmean ratios (GSUVr) as the weighted average of all regional SUVmean. 18F-FDG and 18F-florbetapir GSUVr of each region were subsequently correlated with the Mini-Mental State Examination (MMSE).   Results: Subjects were studied in five categories as NC, MCI patients, AD patients, MCI and AD patients grouped together (MCI/AD), and a group including all the subjects (NC/MCI/AD). Both 18F-FDG and 18F-florbetapir could successfully detect subjects with dementia (p < 0.001). Studied in all regions and groups, the correlation analysis of 18F-FDG GSUVr with MMSE scores was significant in more regions and groups compared to that of 18F-florbetapir. We also demonstrated that the correlation of 18F-FDG GSUVr with MMSE is stronger than that of 18F-florbetapir in the supra-tentorial and temporal regions.   Conclusions: This study reveals how 18F-FDG-PET global quantification is a superior indicator of cognitive performance in AD and MCI patients compared to 18F-florbetapir PET. Accordingly, we still recommend 18F-FDG-PET over amyloid imaging in the evaluation for AD and MCI."@en ;
    ns0:hasPubTitle "18F-FDG Is a Superior Indicator of Cognitive Performance Compared to 18F-Florbetapir in Alzheimer’s Disease and Mild Cognitive Impairment Evaluation: A Global Quantitative Analysis"@en .

ns1:jad-v70-i4-JAD190302 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cognitive decline"@en,
        "dementia"@en,
        "neuropathology"@en,
        "neuropsychological tests"@en ;
    ns0:hasPubAbstract "Background: Variable rate of cognitive decline among individuals with Alzheimer’s disease (AD) is an important consideration for disease management, but risk factors for rapid cognitive decline (RCD) are without consensus.   Objective: To investigate demographic, clinical, and pathological differences between RCD and normal rates of cognitive decline (NCD) in AD.   Methods: Neuropsychology test and autopsy data was pulled from the National Alzheimer’s Coordinating Center database from individuals with a clinical diagnosis of AD. Individuals with average decline of 3 or more points on the Mini-Mental Status Examination (MMSE) per year over 3 years were labeled RCD; all others were NCD.   Results: Sixty individuals identified as RCD; 230 as NCD. These neuropsychology tests differed at baseline (RCD versus NCD): WMS-LM Immediate Recall (4.35[3.39] versus 6.31[3.97], p < 0.001), Animal Naming (12.1[4.83] versus 13.9[4.83], p = 0.007), TMT Part B (187[86.1] versus 159[79.0], p = 0.02), WAIS-Digit Symbol (29.5[11.3] versus 29.5[11.3], p = 0.04), and the BNT (21.5[7.05] versus 23.6[5.09], p = 0.04). RCD had more thyroid disease (30% versus 16%, p = 0.01) and greater usage of AD medication at baseline (80% versus 62%, p = 0.01). RCD had more severe cerebral amyloid angiopathy (1.62[1.0] versus 1.13[1.0], p = 0.002), more neocortical Lewy bodies (20% versus 10%, p = 0.04), and more atrophy (1.54[0.92] versus 1.17[0.83], p = 0.04). A model combining select variables was significant above chance (χ2 = 25.8, p = 0.002), but not to clinical utility (AUC < 0.70; 95% CI).   Conclusion: Individuals with RCD have more severe pathology, more comorbidities, and lower baseline neuropsychology test scores of language and executive function."@en ;
    ns0:hasPubTitle "The Pathology of Rapid Cognitive Decline in Clinically Diagnosed Alzheimer’s Disease"@en .

ns1:jad-v70-i4-JAD190329 ns0:hasKeywords "[18F]AV-1451"@en,
        "[18F]AV-45"@en,
        "amyloid-β"@en,
        "brain segmentation"@en,
        "neuroimaging"@en,
        "positron emission tomography"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Background: Tools for efficient evaluation of amyloid- and tau-PET images are needed in both clinical and research settings.   Objective: This study was designed to validate a semi-automated image analysis methodology, called Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER). We tested BLAzER using two different segmentation platforms, FreeSurfer (FS) and Neuroreader (NR), for regional brain PET quantification in participants in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) dataset.   Methods: 127 amyloid-PET and 55 tau-PET studies with volumetric MRIs were obtained from ADNI. The BLAzER methodology utilizes segmentation of MR images by FS or NR, then visualizes and quantifies regional brain PET data using FDA-cleared software (MIM), enabling quality control to ensure optimal registration and to detect segmentation errors.   Results: BLAzER analysis required ∼5 min plus segmentation time. BLAzER using FS segmentation showed strong agreement with ADNI for global amyloid-PET standardized uptake value ratios (SUVRs) (r = 0.9922, p < 0.001) and regional tau-PET SUVRs across all Braak staging regions (r > 0.97, p < 0.001) with high inter-operator reproducibility (ICC > 0.97) and nearly identical dichotomization as amyloid-positive or -negative (2 discrepant cases out of 127). Comparing FS versus NR segmentation with BLAzER, global SUVRs were strongly correlated for amyloid-PET (r = 0.9841, p < 0.001), but were systematically higher (4% on average) with NR, likely due to more inclusion of white matter with NR-defined regions.   Conclusions: BLAzER provides an efficient methodology for regional brain PET quantification. FDA-cleared components and visualization of registration reduce barriers between research and clinical applications."@en ;
    ns0:hasPubTitle "Biomarker Localization, Analysis, Visualization, Extraction, and Registration (BLAzER) Methodology for Research and Clinical Brain PET Applications"@en .

ns1:jad-v70-i4-JAD190405 ns0:hasKeywords "Air pollution"@en,
        "Alzheimer’s disease continuum"@en,
        "alpha synuclein"@en,
        "auditory gain"@en,
        "auditory nuclei"@en,
        "auditory plasticity"@en,
        "brainstem auditory evoked potentials"@en,
        "children"@en,
        "combustion and friction-derived nanoparticles"@en,
        "hyperphosphorylated tau"@en ;
    ns0:hasPubAbstract "A major impediment in early diagnosis of Alzheimer’s disease (AD) is the lack of robust non-invasive biomarkers of early brain dysfunction. Metropolitan Mexico City (MMC) children and young adults show hyperphosphorylated tau, amyloid-β, and α-synuclein within auditory and vestibular nuclei and marked dysmorphology in the ventral cochlear nucleus and superior olivary complex. Based on early involvement of auditory brainstem centers, we believe brainstem auditory evoked potentials can provide early AD biomarkers in MMC young residents. We measured brainstem auditory evoked potentials in MMC clinically healthy children (8.52±3.3 years) and adults (21.08±3.0 years, 42.48±8.5 years, and 71.2±6.4 years) compared to clean air controls (6.5±0.7 years) and used multivariate analysis adjusting for age, gender, and residency. MMC children had decreased latency to wave I, delays in waves III and V, and longer latencies for interwave intervals, consistent with delayed central conduction time of brainstem neural transmission. In sharp contrast, young adults have significantly shortened interwave intervals I–III and I–V. By the 5th decade, wave V and interval I–V were significantly shorter, while the elderly cohort had significant delay in mean latencies and interwave intervals. Compensatory plasticity, increased auditory gain, cochlear synaptopathy, neuroinflammation, and AD continuum likely play a role in the evolving distinct auditory pathology in megacity urbanites. Understanding auditory central and peripheral dysfunction in the AD continuum evolving and progressing in pediatric and young adult populations may shed light on the complex mechanisms of AD development and help identify strong noninvasive biomarkers. AD evolving from childhood in air pollution environments ought to be preventable."@en ;
    ns0:hasPubTitle "Increased Gain in the Auditory Pathway, Alzheimer’s Disease Continuum, and Air Pollution: Peripheral and Central Auditory System Dysfunction Evolves Across Pediatric and Adult Urbanites"@en .

ns1:jad-v70-i4-JAD190519 ns0:hasKeywords "Alzheimer’s disease"@en,
        "atypical variant"@en,
        "biomarkers"@en,
        "cerebrospinal fluid"@en,
        "cortical atrophy"@en,
        "hippocampal atrophy"@en,
        "mild cognitive impairment"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Background: Cerebrospinal fluid (CSF) levels of total tau (t-tau) protein are thought to reflect the intensity of the neuronal damage in neurodegeneration, including Alzheimer’s disease (AD). The recent link of CSF t-tau to rapidly progressive AD raises the question among other AD clinical variants regarding CSF t-tau. We investigated the clinical phenotypes of AD patients with varying CSF t-tau levels.   Objective: We tested the hypothesis that highly elevated CSF t-tau level would have a higher likelihood of presenting with atypical non-amnestic variants of AD.   Methods: Retrospective comparative case study of 97 patients evaluated in a memory clinic with clinical presentation and CSF biomarkers consistent with AD. We compared the age, sex, education, APOE ɛ4 status, Montreal Cognitive Assessment (MoCA) score, clinical phenotype, and MRI volumetric measures by CSF t-tau quartile at baseline. Multivariable logistic regression models were used to evaluate if CSF t-tau levels predict non-amnestic presentations controlling for covariates.   Results: Non-amnestic AD had a higher median CSF t-tau level compared to amnestic-AD (p = 0.014). Each 50 pg/ml increase in CSF t-tau was associated with an increase in the odds of having a non-amnestic presentation (7.4%) and aphasia (10.6 %) as the initial presenting symptom even after taking into account; age, sex, education, APOE ɛ4, MoCA, and CSF Aβ42. Logopenic AD had higher t-tau and p-tau levels compared to other variants.   Conclusions: Highly elevated CSF t-tau levels could indicate more cortical involvement presenting with early non-amnestic symptoms in atypical AD subtypes, particularly in the logopenic variant."@en ;
    ns0:hasPubTitle "Highly Elevated Cerebrospinal Fluid Total Tau Level Reflects Higher Likelihood of Non-Amnestic Subtype of Alzheimer’s Disease"@en .

ns1:jad-v70-is1-JAD180562 ns0:hasKeywords "Chronic obstructive pulmonary disease"@en,
        "lower to middle income countries"@en,
        "mild cognitive impairment"@en,
        "premature death"@en,
        "prevalence"@en ;
    ns0:hasPubAbstract "Background: Chronic obstructive pulmonary disease (COPD) is a major disease burden which accounts for 5% of all deaths globally, with most of those (>90%) occurring in lower to middle income countries (LMIC). It is also emerging as an important modifiable dementia risk factor.   Objective: To address the knowledge gap surrounding the nature of the associations between COPD, dementia, and mortality, and the geographical variation of those associations in LMIC.   Methods: Data from the 10/66 study surveying 15,394 participants (mean age 74 years, 62% female) across 8 countries was used to estimate the prevalence of self-reported COPD and its association with incident dementia and premature death. Proportional sub-hazards models using a cumulative incidence function were applied to identify the probability of incident dementia onset given the risk of premature death, with estimates pooled across countries via random effect meta-analysis.   Results: Over the 3-year follow-up, almost 10% of participants developed dementia and 14% were deceased. COPD was not significantly associated with dementia incidence except in Cuba. However, fully adjusted models indicated that individuals with COPD were at a 28% increased risk of premature death, a trend present across most countries when analyzed individually.   Conclusion: The link between COPD and dementia is currently somewhat different and weaker in LMIC than in developed countries. This may be because premature death in the populations studied mask the development of clinical dementia. Given the global trend toward increased life expectancy, it is critical that the disease burden associated with COPD be addressed without delay if a further rise in dementia prevalence associated with COPD is to be avoided in LMIC."@en ;
    ns0:hasPubTitle "Chronic Obstructive Pulmonary Disease and Risk of Dementia and Mortality in Lower to Middle Income Countries"@en .

ns1:jad-v70-is1-JAD180571 ns0:hasKeywords "Biomarkers"@en,
        "Victoria Longitudinal Study"@en,
        "dementia prevention"@en,
        "memory trajectories"@en,
        "protective factors"@en,
        "risk factors"@en ;
    ns0:hasPubAbstract "Background: Non-demented cognitive aging trajectories are characterized by vast level and slope differences and a spectrum of outcomes, including dementia.   Objective: The goal of AD risk management (and its corollary, promoting healthy brain aging) is aided by two converging objectives: 1) classifying dynamic distributions of non-demented cognitive trajectories, and 2) identifying modifiable risk-elevating and risk-reducing factors that discriminate stable or normal trajectory patterns from declining or pre-impairment patterns.   Method: Using latent class growth analysis we classified three episodic memory aging trajectories for n = 882 older adults (baseline Mage=71.6, SD=8.9, range = 53-95, female=66%): Stable (SMA; above average level, sustained slope), Normal (NMA; average level, moderately declining slope), and Declining (DMA; below average level, substantially declining slope). Using random forest analyses, we simultaneously assessed 17 risk/protective factors from non-modifiable demographic, functional, psychological, and lifestyle domains. Within two age strata (Young-Old, Old-Old), three pairwise prediction analyses identified important discriminating factors.   Results: Prediction analyses revealed that different modifiable risk predictors, both shared and unique across age strata, discriminated SMA (i.e., education, depressive symptoms, living status, body mass index, heart rate, social activity) and DMA (i.e., lifestyle activities [cognitive, self-maintenance, social], grip strength, heart rate, gait) groups.   Conclusion: Memory trajectory analyses produced empirical classes varying in level and slope. Prediction analyses revealed different predictors of SMA and DMA that also varied by age strata. Precision approaches for promoting healthier memory aging—and delaying memory impairment—may identify modifiable factors that constitute specific targets for intervention in the differential context of age and non-demented trajectory patterns."@en ;
    ns0:hasPubTitle "Modifiable Risk Factors Discriminate Memory Trajectories in Non-Demented Aging: Precision Factors and Targets for Promoting Healthier Brain Aging and Preventing Dementia"@en .

ns1:jad-v71-i1-JAD190272 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid angiopathy"@en,
        "cerebral blood flow"@en,
        "cerebral microbleeds"@en ;
    ns0:hasPubAbstract "Background: Although cerebral microbleeds (CMBs) are commonly observed in patients with Alzheimer’s disease (AD), their clinical relevance for AD remains unclear.   Objective: We investigated the significance of CMBs in AD by examining the relationship between CMBs and cerebral blood flow (CBF) in patients with AD.   Methods: Thirty-four patients (aged 77.9±7.6 years; 17 men) with probable AD and multiple (≥8) CMBs were selected from 394 consecutive patients. For each lobe of the brain, the correlation between the number of CMBs observed on susceptibility-weighted images and the decrease in CBF observed on single-photon emission computed tomography was assessed.   Results: The number of microbleeds was significantly correlated with the severity of decrease in the occipital lobe (Spearman’s r = 0.531, p < 0.001) and temporal lobe (r = 0.437, p < 0.001) but not in the frontal lobe (r = 0.201, p = 0.101) and parietal lobe (r = 0.178, p = 0.146). These results were unchanged in the partial correlational analysis after controlling the effect of other small vessel disease such as lacunars and white matter hyperintensities.   Conclusion: Multiple CMBs are associated with cerebral hypoperfusion in AD. The effects of CMBs on CBF differed according to brain location, possibly reflecting different distributions of the underlying cerebral amyloid angiopathy and AD-related histopathology, such as neurofibrillary tangles."@en ;
    ns0:hasPubTitle "Cerebral Microbleeds Are Associated with Cerebral Hypoperfusion in Patients with Alzheimer’s Disease"@en .

ns1:jad-v71-i1-JAD190402 ns0:hasKeywords "Blood pressure"@en,
        "clinical progression"@en,
        "dementia"@en,
        "orthostatic hypotension"@en ;
    ns0:hasPubAbstract "Background: Orthostatic hypotension (OH) has been cross-sectionally and longitudinally related to dementia in the general population. Whether OH contributes to clinical progression to mild cognitive impairment (MCI) or dementia is less certain. Also, differences in risk of progression between patients with early OH (EOH) versus delayed and/or prolonged OH (DPOH) are unclear.   Objective: Assess the prevalence of EOH and DPOH, investigate the longitudinal association between EOH and DPOH and either incident MCI or dementia.   Methods: 1,882 patients from the Amsterdam Dementia Cohort [64±8 years; 43% female; n = 500 with subjective cognitive decline (SCD), n = 341 MCI, n = 758 Alzheimer’s disease (AD), n = 49 vascular dementia (VaD), n = 146 frontotemporal dementia (FTD), n = 88 Lewy body dementia (DLB)]. Definition OH: systolic blood pressure (BP) drop≥20 mmHg and/or a diastolic BP drop≥10 mmHg at 1 and/or 3 minutes after standing. EOH: OH only at 1 minute, DPOH: OH at (1 and) 3 minutes.   Results: Prevalence OH: 19% SCD, 28% MCI, 41% dementia. Compared to SCD, odds of having OH were highest in patients with VaD and DLB; ORs (95% CI) were 2.6 (1.4–4.7) and 5.1 (3.1–8.4), respectively. After a mean (SD) follow-up of 2.2 (1.4) years, 105 (22%) of SCD or MCI patients showed clinical progression. Compared to patients without OH, those with DPOH had an increased risk of progression; hazard ratio (95% CI) was 1.7 (1.1–2.7), and those with EOH did not; 0.8 (0.3–1.9).   Conclusion: Compared to SCD, prevalence of OH was higher in MCI and highest in dementia, particularly in VaD and DLB. DPOH, more likely associated with autonomic dysfunction, is a risk factor for incident MCI or dementia."@en ;
    ns0:hasPubTitle "Orthostatic Hypotension: An Important Risk Factor for Clinical Progression to Mild Cognitive Impairment or Dementia. The Amsterdam Dementia Cohort"@en .

ns1:jad-v71-i1-JAD190474 ns0:hasKeywords "Alzheimer’s disease"@en,
        "dementia"@en,
        "hypertension"@en,
        "meta-analysis"@en,
        "midlife"@en ;
    ns0:hasPubAbstract "Background: Hypertension is an established risk factor for stroke and vascular dementia but recent meta-analyses examining the association between Alzheimer’s disease (AD) and hypertension have found no significant association. These meta-analyses included short term studies starting in late life which may have obscured the real effect of midlife hypertension.   Objective: To examine the association of AD with midlife hypertension, by including only studies with a sufficiently long follow up duration.   Methods: Relevant studies were found by searches of MEDLINE, EMBASE, and PubMed. Study outcomes were grouped by measures of blood pressure and definition of hypertension (e.g., systolic hypertension > 140 mmHg or > 160 mmHg). We assessed pooled effect estimates using random effects models and heterogeneity of pooled estimates through the I2 statistic.   Results: Literature search found 3,426 publications of which 7 were eligible studies. There was a significant association between systolic hypertension (>160 mm Hg) and AD (HR 1.25, 95CI 1.06 – 1.47, p = 0.0065). Similarly, for systolic hypertension > 140 mm Hg, there was a smaller but still significant association (HR 1.18, 95CI 1.02 – 1.35, p = 0.021). For diastolic hypertension, all four studies found no significant associations between diastolic hypertension and AD, and these data could not be pooled due to heterogeneity in reporting.   Conclusions: Our study found that midlife stage 1 and stage 2 systolic hypertension is associated with increased risk of AD by 18 and 25%, respectively, although no association was found for diastolic hypertension. It is likely that assertive control of systolic hypertension starting in midlife is important to preventing AD."@en ;
    ns0:hasPubTitle "Midlife Hypertension and Alzheimer’s Disease: A Systematic Review and Meta-Analysis"@en .

ns1:jad-v71-i1-JAD190491 ns0:hasKeywords "Aging"@en,
        "cognitive decline"@en,
        "cognitive reserve"@en,
        "exercise"@en,
        "longitudinal study"@en,
        "physical activity"@en ;
    ns0:hasPubAbstract "Background: Although physical activity has been associated with better cognitive function and reduced dementia risk, its association with cognitive decline in normal aging remains uncertain.   Objective: To determine whether physical activity in youth and older age are associated with age-related cognitive change.   Methods: Over a period of 27 years, 2,027 community-dwelling adults (mean age 73.5; 60% women) of the Rancho Bernardo Study of Healthy Aging completed up to seven cognitive assessments, including tests of global cognitive function, executive function, verbal fluency, and episodic memory. At each visit, participants reported concurrent physical activity. At baseline (1988– 1992), participants additionally reported physical activity as a teenager and at age 30. For each age period, participants were classified as regularly active (3+ times/week) or inactive.   Results: Associations between concurrent physical activity and better cognitive function were stronger with advancing age on all tests, even after accounting for education, health, and lifestyle factors, as well as survival differences (ps < 0.05). Baseline physical activity did not predict rates of cognitive decline (ps > 0.40). Individuals who were physically active at age 30 and older age maintained the highest global cognitive function with advancing age (p = 0.002).   Conclusion: Regular physical activity is associated with better cognitive function with advancing age. Physical activity in young adulthood may contribute to cognitive reserve, which together with physical activity in later years, may act to preserve cognitive function with age."@en ;
    ns0:hasPubTitle "Physical Activity and Trajectories of Cognitive Change in Community-Dwelling Older Adults: The Rancho Bernardo Study"@en .

ns1:jad-v71-i1-JAD190581 ns0:hasKeywords "Dementia"@en,
        "United Kingdom"@en,
        "migraine"@en,
        "retrospective cohort study"@en,
        "sex differences"@en ;
    ns0:hasPubAbstract "Background: Most previous studies focusing on the migraine headache-dementia relationship have failed to simultaneously adjust for several common comorbidities.   Objective: The goal of this retrospective cohort study was to investigate the association between migraine headaches and dementia in general practices in the UK.   Methods: The current study sample included patients who received a migraine diagnosis in one of 67 general practices in the UK between January 1997 and December 2016 (index date). Patients without migraine diagnoses were matched 1 : 1 to patients with migraine diagnoses based on propensity scores using a greedy algorithm and derived from the logistic regression using age, sex, index year, and co-diagnoses. The main outcome of the study was the association between migraine headaches and the incidence of dementia within 10 years of the index date.   Results: This study included 7,454 individuals with or without migraine diagnoses. Mean age was 67.7 years (SD = 5.8 years), and 72.9% of patients were women. Within 10 years of the index date, 5.2% of participants with and 3.7% of those without migraine headaches were diagnosed with dementia (log-rank p < 0.001). The respective figures were 5.8% and 3.6% in women (log-rank p < 0.001) and 4.5% and 3.4% in men (log-rank p = 0.722). We observed a positive association between migraine diagnoses and all-cause dementia (hazard ratio [HR] = 1.43) as well as Alzheimer’s disease (HR = 1.87). Sensitivity analyses further revealed that these associations were only significant in women (all-cause dementia: HR = 1.65; Alzheimer’s disease: HR = 2.27).   Conclusion: Migraine diagnoses were positively associated with all-cause dementia and Alzheimer’s disease in women."@en ;
    ns0:hasPubTitle "Association Between Migraine Headaches and Dementia in More than 7,400 Patients Followed in General Practices in the United Kingdom"@en .

ns1:jad-v71-i2-JAD181102 ns0:hasKeywords "Alzheimer’s disease"@en,
        "behavioral"@en,
        "caregiver"@en,
        "psychotropic drugs"@en ;
    ns0:hasPubAbstract "Behavioral and psychological symptoms of dementia are common in Alzheimer’s disease (AD) and associated with a more rapid decline in cognitive function. Psychotropic substances are frequently used in AD, but we lack conclusive evidence of their efficacy in this setting. SSRI and trazodone were reported to have positive effects on cognition. Based on the prospective registry of dementia in Austria (PRODEM), we investigated the effects of psychotropic substances on cognition, behavioral symptoms, and caregiver burden (CB) in patients with AD, followed up prospectively over a 12-month period. We used the Mini-Mental State Examination (MMSE), the Neuropsychiatric Inventory (NPI), and the Zarit caregiver burden interview. The study cohort consisted of 309 patients. Patients taking no psychotropic drugs (NO) or those undergoing consistent monotherapy with a psychotropic drug for 12 months were analyzed further (NO 101 patients, SSRI 22, trazodone 8, atypical neuroleptics or benzodiazepines (ANL/BZD) 18). Additionally, the subgroup of patients who started taking any of the substances during the study period were analyzed further to determine the effects before versus six months after the start of medication. MMSE, NPI, and CB at baseline and during follow-up did not differ between the groups. MMSE and CB declined over 12 months in the overall group (MMSE: 21.2±4 versus 19.7±5, p = 0.001 and CB 20.3±12 versus 24.7±14.2, p = 0.007), but no statistically significant changes were registered within groups over 12 months. When trazodone was started, only NPI improved significantly after 6 months (33.4±18 versus 18.9±22.7, p < 0.01). ANL/BZD or SSRI, when started, did not alter MMSE, NPI, or CB. SSRI had no beneficial effect on cognition. We conclude that trazodone might be helpful in the treatment of behavioral symptoms."@en ;
    ns0:hasPubTitle "Effects of Psychotropic Medication on Cognition, Caregiver Burden, and Neuropsychiatric Symptoms in Alzheimer’s Disease over 12 Months: Results from a Prospective Registry of Dementia in Austria (PRODEM)"@en .

ns1:jad-v71-i2-JAD190222 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid"@en,
        "dementia"@en,
        "multimorbidity"@en ;
    ns0:hasPubAbstract "Background: Multimorbidity (the co-occurrence of multiple chronic conditions) is increasingly common, especially among people with dementia. Few neuroimaging studies have explored amyloid biomarkers in people with multimorbidity.   Objective: We aimed to conduct the first study of the association between multimorbidity and cerebrospinal fluid amyloid-β42 (CSF Aβ).   Method: The European Prevention of Alzheimer’s Dementia (EPAD) Longitudinal Cohort Study V500.0 dataset includes volunteers aged ≥50 years from 12 sites. Participants undergo detailed phenotyping, including CSF measures and a self-reported medical history. Using logistic and linear regression analyses, we explored the association between multimorbidity and continuous chronic condition count with CSF Aβ positivity (Aβ42 <1000pg/ml) and continuous CSF Aβ concentration. All models were adjusted for age, sex, APOE status, education, and family history of dementia.   Results: Among 447 eligible participants without dementia, the mean (SD) age was 66.6 (6.6) years, 234 (52.3%) were women, and 157 (35.1%) were amyloid positive. With chronic conditions regarded as pseudo-continuous, each additional condition carried a decreased likelihood of amyloid positivity (OR = 0.82, 95% CI: 0.68–0.97; p = 0.026). With CSF Aβ as a continuous variable, each additional condition was associated with an increase of 54.2 pg/ml (95% CI: 9.9–98.5, p = 0.017). Having ≥2 conditions was inversely associated with amyloid positivity (OR 0.59, 95% CI: 0.37–0.95, p = 0.030) compared to one or none.   Conclusion: Our findings suggest that the established association between multimorbidity and dementia may be due to a pathway other than amyloid. However, this cross-sectional study does not allow us to make causal inferences. Longitudinal work is required to confirm the inverse association found."@en ;
    ns0:hasPubTitle "Associations Between Multimorbidity and Cerebrospinal Fluid Amyloid: A Cross-Sectional Analysis of the European Prevention of Alzheimer’s Dementia (EPAD) V500.0 Cohort"@en .

ns1:jad-v71-i2-JAD190306 ns0:hasKeywords "cognitive training"@en,
        "memory"@en,
        "mild cognitive impairment"@en,
        "randomized controlled trial"@en,
        "transcranial direct current stimulation"@en,
        "treatment"@en ;
    ns0:hasPubAbstract "Background: There is currently no effective intervention for improving memory in people at increased risk for dementia. Cognitive training (CT) has been promising, though effects are modest, particularly at follow-up.   Objective: To investigate whether adjunctive non-invasive brain stimulation (transcranial direct current stimulation, tDCS) could enhance the memory benefits of CT in amnestic mild cognitive impairment (aMCI).   Methods: Participants with aMCI were randomized to receive CT with either Active tDCS (2 mA for 30 min and 0.016 mA for 30 min) or Sham tDCS (0.016 mA for 60 min) for 15 sessions over a period of 5 weeks in a double-blind, sham-controlled, parallel group clinical trial. The primary outcome measure was the California Verbal Learning Task 2nd Edition.   Results: 68 participants commenced the intervention. Intention-to-treat (ITT) analysis showed that the CT+Active tDCS group significantly improved at post treatment (p = 0.033), and the CT+Sham tDCS group did not (p = 0.050), but there was no difference between groups. At the 3-month follow-up, both groups showed large-sized memory improvements compared to pre-treatment (CT+Active tDCS: p < 0.01, d = 0.99; CT+Sham tDCS: p < 0.01, d = 0.74), although there was no significant difference between groups.   Conclusion: This study found that CT+Active tDCS did not produce greater memory improvement compared to CT+Sham tDCS. Large-sized memory improvements occurred in both conditions at follow-up. One possible interpretation, based on recent novel findings, is that low intensity tDCS (used as ‘sham’) may have contributed biological effects. Further work should use a completely inert tDCS sham condition."@en ;
    ns0:hasPubTitle "A Pilot Double-Blind Randomized Controlled Trial of Cognitive Training Combined with Transcranial Direct Current Stimulation for Amnestic Mild Cognitive Impairment"@en .

ns1:jad-v71-i2-JAD190338 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cognitive manifestations"@en,
        "left right asymmetry"@en,
        "right Alzheimer’s disease"@en,
        "right hemisphere"@en,
        "syndromic diversity"@en,
        "variant of Alzheimer’s disease"@en,
        "visuospatial ORCID: 0000-0002-0368-3834"@en ;
    ns0:hasPubAbstract "Background: Alzheimer’s disease (AD) is a clinically heterogeneous disease. Multiple atypical syndromes, distinct from the usual amnesic phenotype, have been described. In this context, the existence of a right variant of AD (RAD), characterized by enduring visuospatial impairment associated with right-sided asymmetric brain damage, has been proposed. However, to date, this phenotype remains controversial. In particular, its peculiar characteristics and the independence from more prevalent cases (especially the posterior cortical atrophy syndrome) have to be demonstrated.   Objective: To explore the existence of focal RAD on the basis of existing literature.   Methods: We performed a literature search for the description of atypical AD presentations, potentially evoking cases of focal RAD. To be considered as affected by RAD, the described cases had to present: 1) well documented right-sided asymmetry at neuroimaging; 2) predominant cognitive deficits localizable on the right hemisphere; 3) no specific diagnosis of a known variant of AD.   Results: Twenty-one cases were found in the literature, but some of them were subsequently excluded because some features of a different clinical syndrome were overlapped with the clinical features of RAD. Thirteen positive cases, three of them with pathologically confirmed AD, remained. A common right clinical-radiological syndrome, characterized by memory and visuospatial impairment with temporal and parietal involvement, consistently emerged. However, the heterogeneity among the reports prevented a definitive and univocal description of the syndrome.   Conclusion: Even if sporadic observations strongly support the existence of a focal RAD, no definitive conclusions can still be drawn about it as an independent condition."@en ;
    ns0:hasPubTitle "Does the Right Focal Variant of Alzheimer’s Disease Really Exist? A Literature Analysis"@en .

ns1:jad-v71-i2-JAD190403 ns0:hasKeywords "Aging"@en,
        "alzheimer’s disease"@en,
        "apolipoprotein E4"@en,
        "dementia risk"@en,
        "geriatric assessment"@en,
        "motor skills"@en,
        "movement"@en,
        "visuomotor integration"@en ;
    ns0:hasPubAbstract "Background: Cognitive-motor integration (CMI) involves concurrent thought and action which requires the interaction of large brain networks. Given that early-stage dementia involves neural network dysfunction, deficits in CMI may prove useful for early dementia detection.   Objective: Our research objective was to investigate sex-related differences in the ability to integrate rules into action.   Methods: Based on family medical history, we recruited male and female participants both with and without dementia risk factors. Participants did not demonstrate cognitive impairment at the time of testing. Participants were tested on four increasingly dissociated visuomotor tasks (eye and hand movements were made in different spatial planes and/or visual feedback was reversed).   Results: We observed significantly greater hand movement endpoint error scores and corrective path lengths in at-risk females compared to at-risk males in the most complex CMI condition (plane-change + feedback reversal). Multiple regression analyses revealed both sex and family history as significant predictors of worse performance in a CMI condition requiring visual feedback reversal. Further, the regression analyses provided preliminary evidence that having an APOE ɛ4 allele was a significant predictor of poorer CMI performance in the two plane-change CMI conditions.   Conclusion: These data suggest that underlying brain networks controlling simultaneous thought and action may differ between the sexes in ways that may be clinically relevant in dementia progression. Preliminary data also suggest an important connection between APOE variant and CMI performance in individuals at risk of developing dementia."@en ;
    ns0:hasPubTitle "Cognitive-Motor Integration Performance Is Affected by Sex, APOE Status, and Family History of Dementia"@en .

ns1:jad-v71-i2-JAD190454 ns0:hasKeywords "brain volumes"@en,
        "cerebral microbleeds"@en,
        "cerebral small vessel disease"@en,
        "hippocampus"@en,
        "white matter"@en ;
    ns0:hasPubAbstract "Background: Few studies have investigated the correlation between cerebral microbleeds (CMBs), a hemorrhagic imaging marker of cerebral small vessel disease (CSVD), and brain volume.   Objective: We investigated the association between the burden and locations of CMBs and brain volume in community-dwelling populations.   Methods: Data were obtained from 1,029 participants who underwent brain magnetic resonance imaging (MRI) and APOE genotyping. Volumes of the whole brain, subcortical white matter (WM), cortical gray matter (GM), and hippocampus were extracted. Linear regression models were used to investigate the relationship between the CMB burden and their location with structural changes.   Results: Regarding burden, participants with≥3 CMBs had significantly lower whole brain (β= –1.124, p = 0.0133), subcortical WM (β= –1.020, p = 0.0043), and hippocampus (β= –0.015, p = 0.0088) volumes than those without CMBs. Regarding location and burden, the presence of≥3 strictly lobar CMBs was negatively associated with whole brain volume (β= –2.838, p = 0.0088). Additionally, higher CMB burdens in strictly lobar locations or deep/mixed locations were associated with lower subcortical WM volume (β= –1.689, p = 0.0482; β= –0.872, p = 0.0464, respectively). Finally, the presence of≥3 deep/mixed CMBs was associated with lower hippocampus volume (β= –0.018, p = 0.0088), and these associations were independent of other ischemic markers of CSVD. However, the CMB burden and distributional pattern did not correlate with cortical GM volumes.   Conclusion: A higher CMB burden, in specific locations, is associated with decreased brain volumes in community-dwelling populations."@en ;
    ns0:hasPubTitle "Cerebral Microbleeds Correlated with White Matter and Hippocampal Volumes in Community-Dwelling Populations"@en .

ns1:jad-v71-i2-JAD190661 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cognitive decline"@en,
        "cohort effects"@en,
        "disease progression"@en ;
    ns0:hasPubAbstract "Background: Accurate prediction of Alzheimer’s disease (AD) cognitive and functional outcomes in clinical research requires consistent underlying rates of change over time.   Objective: To examine cohort effects in AD progression rate over five years of follow-up using a clinical database of probable AD patients.   Methods: Baseline characteristics of three cohorts enrolled from 1995–1999, 2000–2004, and 2005–2009 were compared using ANOVA and chi-square tests. Differences in 5-year decline on the Mini-Mental State Examination (MMSE), Alzheimer’s Disease Assessment Scale-Cognitive Subscale (ADAS-Cog) and Clinical Dementia Rating Scale Sum of Boxes (CDR-SB), the Lawton and Brody Physical Self-maintenance Scale (PSMS), and Activities of Daily Living Scale (ADL) were assessed using longitudinal mixed effects regression, adjusting for age, sex, education, and other relevant clinical characteristics.   Results: Cohorts 1 (n = 287), 2 (n = 257), and 3 (n = 374) did not differ on age, race, APOE genotype, or cognitive and functional measures. Educational attainment increased over time (13.4, 14.1, and 14.5 years, respectively, p < 0.001). Anti-dementia drug use at baseline was less common in Cohort 1 (32.2% versus 65.0%, and 66.8%, p < 0.001). The rate of decline in MMSE and CDR-SB did not differ across cohorts. ADAS-Cog scores for Cohort 2 declined more slowly than Cohort 3 (Btime ×cohort2 = -0.91 ± 0.35, p = 0.009), whereas Cohort 1 did not differ from cohort 3 (reference). Cohorts 1 and 2 differed from Cohort 3 in progression rate on the PSMS, but not the IADL.   Conclusions: There were no consistent temporal trends in progression rates over time. Longitudinal data over 15–20 years may be confidently pooled for outcomes analysis, but unexplained variability in rate of decline on some measures may occur."@en ;
    ns0:hasPubTitle "Cohort Effects in Progression Rate on Cognitive and Functional Measures in an Alzheimer’s Disease Clinical Cohort"@en .

ns1:jad-v71-i3-JAD181037 ns0:hasKeywords "Air pollution"@en,
        "Alzheimer’s disease"@en,
        "apolipoprotein E"@en,
        "dementia"@en ;
    ns0:hasPubAbstract "It is widely known that the apolipoprotein E (APOE) ɛ4 allele imposes a higher risk for Alzheimer’s disease (AD). Recent evidence suggests that exposure to air pollution is also a risk factor for AD, and results from a few studies indicate that the effect of air pollution on cognitive function and dementia is stronger in APOE ɛ4 carriers than in non-carriers. Air pollution and interaction with APOE ɛ4 on AD risk thus merits further attention. We studied dementia incidence over a 15-year period from the longitudinal Betula study in Northern Sweden. As a marker for long-term exposure to traffic-related air pollution, we used modelled annual mean nitrogen oxide levels at the residential address of the participants at start of follow-up. Nitrogen oxide correlate well with fine particulate air pollution levels in the study area. We had full data on air pollution, incidence of AD and vascular dementia (VaD), APOE ɛ4 carrier status, and relevant confounding factors for 1,567 participants. As expected, air pollution was rather clearly associated with dementia incidence. However, there was no evidence for a modifying effect by APOE ɛ4 on the association (p-value for interaction > 0.30 for both total dementia (AD+VaD) and AD). The results from this study do not imply that adverse effects of air pollution on dementia incidence is limited to, or stronger in, APOE ɛ4 carriers than in the total population."@en ;
    ns0:hasPubTitle "Traffic-Related Air Pollution as a Risk Factor for Dementia: No Clear Modifying Effects of APOE ɛ4 in the Betula Cohort"@en .

ns1:jad-v71-i3-JAD181132 ns0:hasKeywords "APOE"@en,
        "Accelerometry"@en,
        "Apolipoprotein E"@en,
        "UK Biobank"@en,
        "cognitive decline"@en,
        "dementia"@en,
        "gene-environment interaction"@en,
        "physical activity"@en,
        "sedentary"@en ;
    ns0:hasPubAbstract "Background: Apolipoprotein E (APOE) genotype affects the risk of Alzheimer’s disease (AD) with inconclusive evidence on the opportunity to mitigate related adverse effects by lifestyle changes.   Objective: To examine the individual and interactive associations of APOE and objectively-measured physical activity (PA) and sedentary activity with cognitive decline.   Methods: We used data from middle-aged and older UK Biobank participants with repeat tests on visuospatial memory (n = 52,767) and fluid intelligence (n = 19,713), and who also took part in the accelerometer sub-study. PA and sedentary activity were assessed by a wrist-worn accelerometer over a seven-day period. Cognitive decline was defined as >1 standard deviation (SD) reduction in memory or fluid intelligence score, and the mean follow up from baseline was 5.8 years.   Results: There was an age dependent association between APOE ɛ4 genotype and memory decline (page-interaction = 0.01), with the association only seen in participants who were >65 years (OR 1.33, 95% CI 1.11 to 1.24; for <65 years OR 1.06, 95% CI 0.99 to 1.14). The OR for the APOE ɛ4 association with fluid intelligence decline was 1.11 (95% CI 0.99 to 1.24), and there was no evidence for age interaction (page-interaction = 0.99). High PA and low sedentary activity were associated with reduced mean memory decline (p < 0.02 for both). There was no interaction between PA or sedentary activity with APOE ɛ4 regarding either of the cognitive decline measures (p > 0.63 for all).   Conclusion: This large-scale study using objectively measured PA did not find differential effects of PA on cognitive decline based on APOE genotype."@en ;
    ns0:hasPubTitle "Physical Activity, APOE Genotype, and Cognitive Decline: Exploring Gene-Environment Interactions in the UK Biobank"@en .

ns1:jad-v71-i3-JAD190264 ns0:hasKeywords "Hippocampal sparing"@en,
        "limbic predominant"@en,
        "subtype"@en,
        "tau"@en ;
    ns0:hasPubAbstract "At autopsy, individuals with Alzheimer’s disease (AD) exhibit heterogeneity in the distribution of neurofibrillary tangles in neocortical and hippocampal regions. Subtypes of AD, defined using an algorithm based on the relative number of tangle counts in these regions, have been proposed—hippocampal sparing (relative sparing of the hippocampus but high cortical load), limbic predominant (high hippocampal load but lower load in association cortices), and typical (balanced neurofibrillary tangles counts in the hippocampus and association cortices) AD—and shown to be associated with distinct antemortem clinical phenotypes. The ability to distinguish these AD subtypes from the more typical tau signature in vivo could have important implications for clinical research. Flortaucipir positron emission tomography (PET) images acquired from 45 amyloid-positive participants, defined clinically as mild cognitive impairment or AD, aged 50–92 years, 56% female, and estimated to be Braak V-VI based on their PET pattern of tau pathology, were studied. By translating the neuropathologic algorithm to flortaucipir PET scans, patterns of tau pathology consistent with autopsy findings, and with a similar prevalence, were identified in vivo. 6/45 (13%) participants were identified as hippocampal sparing and 6/45 (13%) as limbic predominant AD subtypes. Hippocampal sparing participants were significantly younger than those assigned to the other two subtypes. Worse performance on delayed recall was associated with increased hippocampal tau signal, and worse performance on the trail making test B-A was associated with lower values of the hippocampus to cortex ratio. Prospective studies can further validate the flortaucipir SUVR cut-points and the phenotype of the corresponding AD subtypes."@en ;
    ns0:hasPubTitle "Tau Subtypes of Alzheimer’s Disease Determined in vivo Using Flortaucipir PET Imaging"@en .

ns1:jad-v71-i3-JAD190507 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "biomarkers"@en,
        "clinical trial design"@en,
        "combined modality therapy"@en,
        "inflammation"@en,
        "selection of subjects"@en,
        "tau protein"@en,
        "treatment outcomes"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) clinical trials, focused on disease modifying drugs and conducted in patients with mild to moderate AD, as well as prodromal (early) AD, have failed to reach efficacy endpoints in improving cognitive function in most cases to date or have been terminated due to adverse events. Drugs that have reached clinical stage were reviewed using web resources (such as clinicaltrials.gov, alzforum.org, company press releases, and peer reviewed literature) to identify late stage (Phase II and Phase III) efficacy clinical trials and summarize reasons for their failure. For each drug, only the latest clinical trials and ongoing trials that aimed at improving cognitive function were included in the analysis. Here we highlight the potential reasons that have hindered clinical success, including clinical trial design and choice of outcome measures, heterogeneity of patient populations, difficulties in diagnosing and staging the disease, drug design, mechanism of action, and toxicity related to the long-term use. We review and suggest approaches for AD clinical trial design aimed at improving our ability to identify novel therapies for this devastating disease."@en ;
    ns0:hasPubTitle "Developing Effective Alzheimer’s Disease Therapies: Clinical Experience and Future Directions"@en .

ns1:jad-v71-i3-JAD190569 ns0:hasKeywords "Cognitive function"@en,
        "executive function"@en,
        "inflammation"@en,
        "insulin sensitivity"@en,
        "leptin"@en,
        "metabolic function"@en,
        "obesity"@en ;
    ns0:hasPubAbstract "Background: Greater body weight has been associated impairments in neurocognition and greater dementia risk, although the mechanisms linking weight and neurocognition have yet to be adequately delineated.   Objective: To examine metabolic mechanisms underlying the association between obesity and neurocognition.   Methods: We conducted a secondary analysis of weight, neurocognition, and the potentially mediating role of metabolic and inflammatory biomarkers among 160 participants from the ENLIGHTEN trial of vascular cognitive impairment, no dementia (CIND). Neurocognition was assessed using a 45-minute assessment battery assessing Executive Function, Verbal and Visual Memory. We considered three metabolic biomarkers: insulin resistance (homeostatic model assessment [HOMA-IR]), plasma leptin, and insulin-like growth factor (IGF-1). Inflammation was assessed using C-reactive protein. Multiple regression analyses were used.   Results: Participants included 160 sedentary older adults with CIND. Participants tended to be overweight or obese (mean BMI = 32.5 [SD = 4.8]). Women exhibited higher BMI (p = 0.043), CRP (p < 0.001), and leptin (p < 0.001) compared with men. Higher BMI levels were associated with worse performance on measures of Executive Function (β= –0.16, p = 0.024) and Verbal Memory (β= –0.16, p = 0.030), but not Visual Memory (β= 0.05, p = 0.500). Worse metabolic biomarker profiles also were associated with lower Executive Function (β= –0.12, p = 0.050). Mediation analyses suggested leptin was a plausible candidate as a mediator between BMI and Executive Function.   Conclusions: In overweight and obese adults with vascular CIND, the association between greater weight and poorer executive function may be mediated by higher leptin resistance."@en ;
    ns0:hasPubTitle "Association Between Insulin Resistance, Plasma Leptin, and Neurocognition in Vascular Cognitive Impairment"@en .

ns1:jad-v71-i4-JAD190335 ns0:hasKeywords "Assistive technology"@en,
        "dyslexia"@en,
        "posterior cortical atrophy"@en,
        "reading"@en ;
    ns0:hasPubAbstract "Background: Progressive reading impairment is an early and debilitating symptom of posterior cortical atrophy (PCA) arising from the progressive deterioration of visual processing skills.   Objective: The goal of this study was to test the effectiveness of a purpose-built reading app (ReadClear) co-produced with people living with PCA and designed to reduce the reading difficulties experienced by this population (e.g., getting lost in the page and missing words when reading).   Methods: Twenty subjects with PCA were included in a cross-over design home-based study aimed at determining whether ReadClear could 1) enhance the subjective reading experience (reading pleasantness) and 2) improve reading accuracy (reducing the number of reading errors) compared with a sham condition (a standard e-reader).   Results: Reading using ReadClear provided a better subjective reading experience than sham (p = 0.018, d = 0.5) and significantly reduced the percentage of reading errors (p < 0.0001, r = 0.82), particularly errors due to omissions (p = 0.01, r = 0.50), repeated words (p = 0.002, r = 0.69), and regressions in the text (p = 0.003, r = 0.69). We found that different kinds of reading errors were related to specific neuropsychological profiles.   Conclusion: ReadClear can assist reading in people living with PCA by reducing the number of reading errors and improving the subjective reading experience of users."@en ;
    ns0:hasPubTitle "ReadClear: An Assistive Reading Tool for People Living with Posterior Cortical Atrophy"@en .

ns1:jad-v71-i4-JAD190382 ns0:hasKeywords "Cognitive dysfunction"@en,
        "cohort studies"@en,
        "predictors"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "Background: Post-stroke cognitive impairment (PSCI) significantly affects stroke survivors’ quality of life and rehabilitation. A risk model identifying cognitive decline at admission would help to improve early detection and management of post-stroke patients.   Objective: To develop a new clinical risk score for ischemic stroke survivors in predicting 6–12 months PSCI.   Methods: We prospectively enrolled 179 patients diagnosed with acute ischemic stroke within a 7-day onset. Data were analyzed based on baseline demographics, clinical risk factors, and radiological parameters. Logistic regression and area under the receiver operating curve (AUROC) were used to evaluate model efficiency.   Results: One hundred forty-five subjects completed a 6–12-month follow-up visit, and 77 patients (53.1%) were diagnosed with PSCI. Age (β= 0.065, OR = 1.067, 95% CI = 1.016–1.120), years of education (β= –0.346, OR = 0.707, 95% CI = 0.607–0.824), periventricular hyperintensity grading (β= 1.253, OR = 3.501, 95% CI = 1.652–7.417), diabetes mellitus (β= 1.762, OR = 5.825, 95% CI = 2.068–16.412), and the number of acute nonlacunar infarcts (β= 0.569, OR = 1.766, 95% CI = 1.243–2.510) were independently associated with 6–12 month PSCI, constituting a model with optimal predictive efficiency (AUC = 0.884, 95% CI = 0.832–0.935).   Conclusions: The optimized risk model was effective in screening stroke survivors at high risk of developing 6–12 months PSCI in a simple and pragmatic way. It could be a potential tool to identify patients with a high risk of PSCI at an early stage in clinical practice after further independent external cohort validation."@en ;
    ns0:hasPubTitle "Predictors of Cognitive Impairment After Stroke: A Prospective Stroke Cohort Study"@en .

ns1:jad-v71-i4-JAD190401 ns0:hasKeywords "Alzheimer-associated neuronal thread protein"@en,
        "Alzheimer’s disease"@en,
        "biomarker"@en,
        "depressive state"@en,
        "subjective cognitive decline"@en ;
    ns0:hasPubAbstract "Subjective cognitive decline (SCD) is a risk factor for Alzheimer’s disease (AD). Urinary Alzheimer-associated neuronal thread protein (AD7c-NTP) has been identified as a biomarker for AD. It was hypothesized that if urinary AD7c-NTP were also elevated in SCD, as it is in prodromal AD (mild cognitive impairment stage), it could be a convenient and efficient clinical biomarker for the early diagnosis of SCD. SCD is often accompanied by a depressive state (DS), and the impact of DS on urinary AD7c-NTP levels remains unknown. A total of 297 right-handed Chinese Han subjects were recruited, including 98 subjects with SCD, 92 patients with DS, and 107 well-matched cognitively normal controls (NC). The levels of AD7c-NTP in urine samples were measured using an enzyme-linked immunosorbent assay AD7c-NTP kit. Our results demonstrated that urinary AD7c-NTP levels in the SCD group (0.7561±0.5657 ng/mL) were not significantly higher than in either the DS (0.7527±0.5607 ng/mL) or NC (0.7214±0.5077 ng/mL) groups. Furthermore, urinary AD7c-NTP levels were not correlated with Hamilton Depression Rating Scale and Hamilton Anxiety Scale scores, but they were negatively associated with Mini-Mental State Examination scores (r = –0.222, p = 0.033) and Montreal Cognitive Assessment-Basic scores (r = –0.207, p = 0.048). Urinary AD7c-NTP level is not elevated in SCD and is unaffected by DS. Urinary AD7c-NTP may therefore not be a good potential biomarker for SCD and DS, although it may become elevated with more severe cognitive decline."@en ;
    ns0:hasPubTitle "Urinary Alzheimer-Associated Neuronal Thread Protein is not Elevated in Patients with Subjective Cognitive Decline and Patients with Depressive State"@en .

ns1:jad-v71-i4-JAD190666 ns0:hasKeywords "Alzheimer’s disease"@en,
        "immune dysregulation"@en,
        "peripheral blood"@en,
        "precision medicine"@en,
        "vascular dementia"@en ;
    ns0:hasPubAbstract "Immune dysregulation has been observed in the brain and blood of patients with Alzheimer’s disease (AD). However, a convenient assay to evaluate peripheral immune dysregulation in AD has not been developed, partly due to the inconsistent observations from different studies. We hypothesized that peripheral immune dysregulation may only exist in a subpopulation of AD patients; therefore it may be valuable to identify this subpopulation with a convenient assay. Along this line, we selected 14 candidate genes based on our analysis of microarray data on peripheral blood of AD and other diseases. We used RT-qPCR to examine the expression of these 14 genes in a cohort of 288 subjects, including 74 patients with AD, 64 patients with mild cognitive impairment (MCI), 51 patients with vascular dementia (VaD), and 99 elderly controls with no cognitive dysfunction/impairment. Seven of these 14 genes displayed significant difference in group comparison. Switching from group comparison to individualized evaluation revealed more in-depth information. First, there existed a wide dynamic range for the expression of these immune genes in peripheral blood even within the control group. Second, for the vast majority of the patients (AD, VaD, and MCI patients), the expression of these genes fell within the dynamic range of the control group. Third, a small portion of outliers were observed in the patient groups, more so in the VaD group than that in the AD or MCI groups. This is our first attempt to conduct personalized evaluation of peripheral immune dysregulation in AD and VaD. These findings may be applicable to the identification of peripheral immune dysregulation in AD and VaD patients which may lead to tailored treatment toward those patients."@en ;
    ns0:hasPubTitle "Evaluation of Peripheral Immune Dysregulation in Alzheimer’s Disease and Vascular Dementia"@en .

ns1:jad-v71-i4-JAD190700 ns0:hasKeywords "APOE"@en,
        "Alzheimer’s disease"@en,
        "cerebrospinal fluid"@en,
        "diagnosis"@en,
        "mouse"@en,
        "neurodegenerative disease"@en,
        "plasma"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is a progressive neurodegenerative disease without a cure. The pathological process starts decades before clinical onset, and thus clinical trials of drugs aimed at treating AD should start at a presymptomatic stage. Therefore, it is critical to diagnose AD at an early stage. Tau, phosphorylated tau, and amyloid-β peptide (Aβ) in cerebrospinal fluid (CSF), and positron emission tomography (PET) imaging of Aβ or tau accumulation are supportive biomarkers for AD diagnosis, but there is no reliable presymptomatic diagnostic marker. Since CSF sampling is invasive, and PET imaging is expensive and available only at specialized centers, a reliable blood biomarker has long been sought for. Here we describe a novel extramembrane fragment from solute carrier family 38 member 10 (SLC38A10, S38AA) that we found to be decreased in pyramidal neurons in AD cases by proteomics and immunohistochemical analysis. We detected a S38AA fragment in CSF and found the levels to correlate with severity of AD and APOE genotype. Importantly, the plasma levels of the fragment also showed a significant correlation with Mini-Mental State Examination scores in AD. Moreover, plasma from other neurodegenerative disease was analyzed and the fragment was found to be increased specifically in AD. Interestingly, the fragment is detected in mouse, rat, and monkey, and increases in amyloid precursor protein transgenic mice as the AD-like pathology progresses. We propose that the S38AA fragment in plasma could be a novel quantitative diagnostic marker for AD and potentially a marker of disease progression in AD."@en ;
    ns0:hasPubTitle "A Fragment of S38AA is a Novel Plasma Biomarker of Alzheimer’s Disease"@en .

ns1:jad-v71-i4-JAD190725 ns0:hasKeywords "Data disclosure"@en,
        "data management"@en,
        "data sharing"@en,
        "ecological momentary assessment"@en,
        "ethics"@en,
        "research subjects"@en ;
    ns0:hasPubAbstract "New advances in digital technologies and data-collection methods support expansion of the traditional research model in the current Digital Age. As researchers continue to explore ways to collect, manage, and share individual-level research study data, investigators must also acknowledge new ethical considerations that arise. To ensure protection of research participants, participants must remain a priority across the research continuum by researchers, institutional review boards, funding agencies, and consumers. Big data and data sharing also require additional investments and oversight to ensure proper management and, and even more important, protection of human subjects."@en ;
    ns0:hasPubTitle "Research Data Disclosure in the Digital Age"@en .

ns1:jad-v71-is1-JAD181173 ns0:hasKeywords "Aged"@en,
        "cognition"@en,
        "dementia"@en,
        "executive function"@en,
        "gait"@en,
        "walking speed"@en ;
    ns0:hasPubAbstract "Background: While gait has been linked with cognition, few studies have contrasted the strength of the relationships between gait speed and cognitive domains in people with cognitive impairment (CI).   Objectives: Investigate the association between gait speed and global cognitive function and cognitive domains in older people with CI.   Method: Three-hundred-and-nine community-dwelling people with CI (mean age 82 years, 47% female, and mean gait speed 0.62±0.23 m/s) were included using baseline data from the Intervention-Falls in Older Cognitively Impaired Study (iFOCIS). Usual gait speed (m/s) was measured over 2.4 m. Global cognitive function and individual cognitive domains (attention; memory; verbal fluency; language; visuospatial ability) were assessed using the Addenbrooke’s Cognitive Examination-III (ACE-III). Additionally, executive function was assessed using the Frontal Assessment Battery (FAB).   Results: Participants mean±standard deviation ACE-III and FAB scores were 62.8±19.3 and 11.4±4.6, respectively. In separate multiple linear regression analyses adjusting for confounders, global cognitive function, and each cognitive domain, was significantly associated with gait speed. Executive function demonstrated the strongest association (FAB: standardized β= 0.278, p < 0.001, adjusted R2 = 0.431), and remained significantly associated with gait speed when adjusted for attention, memory, language, and visuospatial ability.   Conclusion: In this large study of older people with CI, global cognition and each cognitive domain were associated with gait speed. Executive function had the strongest association, possibly reflecting the higher-level cognitive processes and complex motor task responses required for gait control. Future longitudinal studies are needed to explore the temporal relationships between declines in executive function and gait, and whether the facilitation of executive function lessens gait decline."@en ;
    ns0:hasPubTitle "Associations Between Gait Speed and Cognitive Domains in Older People with Cognitive Impairment"@en .

ns1:jad-v71-is1-JAD181227 ns0:hasKeywords "Cognition"@en,
        "gait"@en,
        "motoric cognitive risk syndrome"@en ;
    ns0:hasPubAbstract "Background: Motoric cognitive risk (MCR) syndrome is a cognitive-motor syndrome associated with increased risk of transition to dementia. The clinical phenotype of MCR is not yet established.   Objective: To systematically assess clinical gait abnormalities in older adults with MCR.   Methods: Of the 522 community-dwelling non-demented adults aged 65 and older enrolled in the Central Control of Mobility in Aging study, 43 were diagnosed with MCR (47% women) based on presence of cognitive complaints and slow gait velocity (MCRv). Four additional subtypes of MCR were defined by substituting slow gait with short stride length (MCRsl, n = 41), slow swing time (MCRsw, n = 21), high stride length variability (MCRslv, n = 24), and high swing time variability (MCRswv, n = 25). The prevalence of clinical gait abnormalities (neurological or non-neurological) in MCR overall (n = 81) and subtypes was studied. We also examined if gait abnormalities predicted further cognitive and functional decline in MCR cases.   Results: Most clinical gait abnormalities were mild (walked without assistance) in the five MCR subtypes (44 to 61%). Neurological (range 24 to 46%) and non-neurological gait abnormalities (33 to 61%) were common in all MCR subtypes. Neurological gaits were most frequent in MCRsl (46%) and non-neurological gaits in MCRv (61%). Over a median 3.02 years of follow-up, presence of gait abnormality in MCR cases at baseline predicted worsening disability scores (estimate 0.17, p-value = 0.033) but not decline on cognitive scores (p-value = 0.056).   Conclusion: Clinical gait abnormalities are common in MCR syndrome and its subtypes, and are associated with accelerated functional decline."@en ;
    ns0:hasPubTitle "Gait Dysfunction in Motoric Cognitive Risk Syndrome"@en .

ns1:jad-v71-is1-JAD190038 ns0:hasKeywords "Alzheimer’s disease"@en,
        "anatomical structural covariance"@en,
        "gait"@en,
        "mild cognitive impairment"@en,
        "neuroimaging"@en ;
    ns0:hasPubAbstract "Background: Gait impairment is observed in early stages of dementia, such as mild cognitive impairment (MCI), and is associated with morphological brain volume changes like atrophy.   Objective: This study aims to characterize the brain’s grey matter (GM) volume covariance associated with gait speed in patients with amnestic mild cognitive impairment (aMCI) and non-amnestic MCI (naMCI).   Methods: Gait speed was measured in 171 patients with MCI (age 72.0±5.1; 36.8% female; 41 with aMCI and 130 naMCI) at normal and rapid gait speeds. Brain GM covariance networks were computed using voxel-based morphometry, using the main neural correlates of gait speed in each group and for each walking condition as seed regions.   Results: Normal gait speed correlated with GM volume in the left frontal cortex in patients with aMCI, and in bilateral caudate and left putamen in those with naMCI. Rapid gait speed correlated with GM volume in the bilateral caudate and right cerebellum in naMCI, but without any GM region in aMCI. For normal gait speed, the left caudate nucleus volume in naMCI covaried with subcortico-frontal regions, while the left frontal cortex covaried with cortical regions involving the frontal cortex in aMCI. For rapid gait speed, subcortico-frontal regions were similar as for normal speed in naMCI.   Conclusion: Brain GM volume covariance associated with gait speed varies according to the type of MCI; it involved subcortico-frontal regions for patients with naMCI and the frontal cortex in those with aMCI."@en ;
    ns0:hasPubTitle "Structural Brain Volume Covariance Associated with Gait Speed in Patients with Amnestic and Non-Amnestic Mild Cognitive Impairment: A Double Dissociation"@en .

ns1:jad-v71-is1-JAD190106 ns0:hasKeywords "Cognition"@en,
        "dementia"@en,
        "gait"@en,
        "implementation"@en ;
    ns0:hasPubAbstract "There is increasing interest in gait evaluations in clinical settings given the associations between gait and health outcomes. However, efforts examining implementation of gait evaluation in neurological clinics are lacking. Herein, gait implementation within a cognitive neurology clinic is presented. Over a 21-month period, a gait evaluation was collected on 81% of eligible patients (n = 2,622; mean age 73.2±9.5; age range 49–94 years; 47% female). Patients and staff reported being satisfied with the gait assessment. These finding have implications for gait evaluations in clinical settings and for clinical research aimed at understanding the impact of cognitive symptomatology on gait."@en ;
    ns0:hasPubTitle "The Feasibility of Measuring Gait in an Outpatient Cognitive Neurology Clinical Setting"@en .

ns1:jad-v72-i1-JAD190458 ns0:hasKeywords "Acidic fibroblast growth factor14-154"@en,
        "CRMP2"@en,
        "collapsin response mediator protein 2"@en,
        "glycogen synthase kinase 3β"@en,
        "neurons"@en ;
    ns0:hasPubAbstract "Glycogen synthase kinase 3β (GSK3β) is a key component of pathogenesis in Alzheimer’s disease, and its inhibitors can restore cognitive function as therapeutic interventions in neurodegenerative diseases. The previous studies showed that acidic fibroblast growth factor (aFGF) could increase the phosphorylation of GSK3β through the PI3K/Akt signaling pathway. We found that aFGF14–154 markedly increased the average length of neurites in neurons damaged by amyloid-β (Aβ), and this promoting effect was blocked by GSK3β inhibitor. It is still unknown which downstream substrates of GSK3β are related to the neurite growth facilitated by aFGF14-154. The downstream substrates interacting with GSK3β were screened by co-immunoprecipitation and LTQ-Orbitrap proteomics technology in our study. Collapsin response mediator protein 2 (CRMP2) has been identified as a protein interacting with GSK3β, which is involved in the axon formation and neuron regeneration by regulating microtubule reorganization. aFGF14-154 increased the phosphorylation of GSK3β (Ser9) to inhibit its activity, then was followed by a low phosphorylation level of CRMP2 (Thr514), which led to the neurite growth. The knockdown of CRMP2 blocked the rescue of aFGF14–154 with broken neurites and shrunken cell bodies in neurons with Aβ injury. These results highlight the important role of CRMP2 and its phosphorylation through GSK3β in the effect that aFGF14-154 promoted the growth of neurite damaged by Aβ."@en ;
    ns0:hasPubTitle "aFGF Promotes Neurite Growth by Regulating GSK3β-CRMP2 Signaling Pathway in Cortical Neurons Damaged by Amyloid-β"@en .

ns1:jad-v72-i1-JAD190527 ns0:hasKeywords "Cerebral small vessel disease"@en,
        "dementia"@en,
        "enlarged perivascular spaces"@en,
        "magnetic resonance imaging"@en ;
    ns0:hasPubAbstract "Perivascular compartments surrounding the penetrating arteries in the brain are part of a physiologic system, which facilitates fluids exchange and clearance of solutes from the brain. The perivascular compartments become visible on MRI when enlarged and are commonly referred to as perivascular spaces (ePVS). Previous studies on the association between ePVS and dementia have been inconsistent due to varying methods of measuring ePVS. As a frame of reference for future MRI studies on ePVS, we systematically review the literature on ePVS as a marker of vascular brain injury related to dementia from population-based as well as hospital-based settings. We identified three longitudinal and ten cross-sectional studies involving 7,581 persons. Potential outcomes were all-cause dementia, Alzheimer’s disease, and vascular dementia. There was considerable heterogeneity in ePVS assessment: with studies using either visual inspection or segmentation, examining different brain locations and implementing different grading scales. Moreover, out of the total of 13 studies, all five studies on vascular dementia reported an association with presence of basal ganglia ePVS after adjustment for age, gender, and white matter hyperintensities. For seven studies on Alzheimer’s disease and all-cause dementia, the results were ambiguous. This review did not identify an independent association of ePVS with prevalent or incident dementia. Harmonized methods for ePVS assessment, tested across different populations, may benefit future MRI studies on ePVS and dementia."@en ;
    ns0:hasPubTitle "Enlarged Perivascular Spaces and Dementia: A Systematic Review"@en .

ns1:jad-v72-i1-JAD190555 ns0:hasKeywords "Cognitive decline"@en,
        "dementia"@en,
        "five factor model"@en,
        "informant-rated cognition"@en ;
    ns0:hasPubAbstract "Personality traits, such as higher Neuroticism and lower Conscientiousness, are associated with risk of Alzheimer’s disease and other dementias. A diagnosis of dementia relies, in part, on informant ratings of the individual’s cognitive status. Here we examine whether self-reported personality traits are associated with four measures of informant-rated cognition up to a decade later. Participants from the Health and Retirement Study (N = 2,536) completed a five-factor model measure of personality in 2006 or 2008. Informants completed the 2016 Harmonized Cognitive Assessment Protocol (HCAP), which included ratings of the participant’s current cognitive functioning and change in cognitive function over the last decade assessed with the IQCODE, Blessed, 1066, and CSID. Controlling for characteristics of the participant, informant, and their relationship, higher Neuroticism and lower Conscientiousness were associated consistently with worse informant-rated cognition. The association between Openness and better informant-rated cognition was due primarily to higher baseline cognitive function. Extraversion and Agreeableness were associated with better informant-rated cognition only among participants who were cognitively intact at follow-up. The present research suggests that knowledgeable informants are able to detect cognitive deficits associated with personality."@en ;
    ns0:hasPubTitle "Self-Reported Personality Traits and Informant-Rated Cognition: A 10-Year Prospective Study"@en .

ns1:jad-v72-i1-JAD190572 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Morris water maze"@en,
        "PET"@en,
        "amyloid-β"@en,
        "inflammation"@en,
        "neurodegeneration astrocytes"@en,
        "traumatic brain injury"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is the leading cause of dementia worldwide, affecting over 10% of the elderly population. Epidemiological evidence indicates that traumatic brain injury (TBI) is an important risk factor for developing AD later in life. However, which injury-induced processes that contribute to the disease onset remains unclear. The aim with the present study was to identify cellular processes that could link TBI to AD development, by investigating the chronic impact of two different injury models, controlled cortical impact (CCI) and midline fluid percussion injury (mFPI). The trauma was induced in 3-month-old tg-ArcSwe mice, carrying the Arctic mutation along with the Swedish mutation, and the influence of TBI on AD progression was analyzed at 12- and 24-weeks post-injury. The long-term effect of the TBI on memory deficiency, amyloid-β (Aβ) pathology, neurodegeneration and inflammation was investigated by Morris water maze, PET imaging, immunohistochemistry, and biochemical analyses. Morris water maze analysis demonstrated that mice subjected to CCI or mFPI performed significantly worse than uninjured tg-ArcSwe mice, especially at the later time point. Moreover, the injured mice showed a late upregulation of reactive gliosis, which concurred with a more pronounced Aβ pathology, compared to uninjured AD mice. Our results suggest that the delayed glial activation following TBI may be an important link between the two diseases. However, further studies in both experimental models and human TBI patients will be required to fully elucidate the reasons why TBI increases the risk of neurodegeneration."@en ;
    ns0:hasPubTitle "Long-Term Effects of Traumatic Brain Injury in a Mouse Model of Alzheimer’s Disease"@en .

ns1:jad-v72-i1-JAD190638 ns0:hasKeywords "Cardiovascular risk factors"@en,
        "cognitive impairment"@en,
        "inhibitory control"@en,
        "vascular hypothesis of cognitive aging"@en,
        "visuospatial ability"@en,
        "working memory"@en ;
    ns0:hasPubAbstract "Cardiovascular health declines with age, due to vascular risk factors, and this leads to an increasing risk of cognitive decline. Mild cognitive impairment (MCI) is defined as the negative cognitive changes beyond what is expected in normal aging. The purpose of the study was to compare older adults with vascular risk factors (VRF), MCI patients, and healthy controls (HC) in main dimensions of cognitive control. The sample comprised a total of 109 adults, aged 50 to 85 (M = 66.09, S.D. = 9.02). They were divided into three groups: 1) older adults with VRF, 2) MCI patients, and 3) healthy controls (HC). VRF and MCI did not differ significantly in age, educational level, or gender as was the case with HC. The tests used mainly examine inhibition, cognitive flexibility, and working memory processing. Results showed that the VRF group had more Set Loss Errors in drawing designs indicating deficits in establishing cognitive set and in cognitive shifting. MCI patients displayed lower performance in processing. Hence, different types of specific impairments emerge in vascular aging and MCI, and this may imply that discrete underlying pathologies may play a role in the development of somewhat different profiles of cognitive decline."@en ;
    ns0:hasPubTitle "Cognition in Vascular Aging and Mild Cognitive Impairment"@en .

ns1:jad-v72-i1-JAD190716 ns0:hasKeywords "Alzheimer’s disease"@en,
        "dynamic and static cognitive reserve"@en,
        "hippocampus"@en,
        "mild cognitive impairment"@en,
        "parahippocampal gyrus"@en ;
    ns0:hasPubAbstract "Background: Cognitive reserve (CR) explains the individual resilience to neurodegeneration. Years of formal education express the static measure of reserve (sCR). A dynamic aspect of CR (dCR) has been recently proposed.   Objective: The aim of the study was to compare sCR and dCR indexes, respectively, to detect brain abnormalities in Alzheimer’s disease (AD) patients.   Methods: 117 individuals [39 AD, 40 amnestic mild cognitive impairment (aMCI), 38 healthy subjects (HS)] underwent neuropsychological evaluation and a 3T-MRI. T1-weighted volumes were used for manual segmentation of the hippocampus and of the parahippocampal cortices. Years of formal education were used as an index of sCR. Partial Least Square analysis was used to decompose the variance of individual MMSE scores, considered as a dCR index. In aMCI and AD patients, the brain abnormalities have been assessed comparing individuals with high and low levels of sCR and dCR in turn. Moreover, we investigated the effect of the different CR indexes in mediating the relationship between changes in brain volumes and memory performances.   Results: sCR and dCR indexes classified differently individuals having high or low levels of CR. Smaller hippocampal and parahippocampal volumes in high dCR patients were found. The sCR and dCR indexes mediated significantly the relationship between brain abnormalities and memory in patients.   Conclusions: CR mediated the relationship between brain and memory dysfunctions. We hypothesized that sCR and dCR indexes are a representation of different warehouses of reserve not operating in parallel but forming a complex system, in which crystalized cognitive abilities and actual cognitive efficiency interact with brain atrophy impacting on memory."@en ;
    ns0:hasPubTitle "Testing for the Myth of Cognitive Reserve: Are the Static and Dynamic Cognitive Reserve Indexes a Representation of Different Reserve Warehouses?"@en .

ns1:jad-v72-i2-JAD190461 ns0:hasKeywords "Alzheimer’s disease"@en,
        "detection"@en,
        "diagnosis"@en,
        "general practitioner"@en,
        "memory"@en,
        "neurocognitive disorder"@en ;
    ns0:hasPubAbstract "Neurocognitive disorders causing progressive cognitive, functional, and behavioral impairment remain underdiagnosed. The needs for a timely diagnosis are now widely acknowledged since person-centered care helps to preserve life quality and prevent crises. One powerful barrier to detection in primary care is the lack of an easy-to-follow stepwise approach, grounded in evidence and consistent with high-quality specialty practice. To help fill this gap, the current European Joint Action proposes a graduated diagnosis strategy tailored to the patients’ needs and wills, clarifying appropriate components for primary and specialty care. This strategy considers a first evaluation in primary care that may detect a neurocognitive disorder, that would lead to a second evaluation step allowing etiological diagnosis hypotheses performed mostly by the specialist. A third evaluation stage considering some biological, electrophysiological, or neuroimaging complementary techniques would be proposed to atypical cases or patients willing to consider access to research."@en ;
    ns0:hasPubTitle "Toward a Sequential Strategy for Diagnosing Neurocognitive Disorders: A Consensus from the “Act On Dementia” European Joint Action"@en .

ns1:jad-v72-i2-JAD190468 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "amyloidosis"@en,
        "biomarkers"@en,
        "mild cognitive impairment"@en,
        "prodromal Alzheimer’s disease"@en,
        "recognition memory"@en,
        "signal detection"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Background: The utility of recognition memory for identifying persons with biomarker evidence of Alzheimer’s disease (AD) is unclear since prior studies of mild cognitive impairment (MCI) relied only on clinical diagnosis and did not include simultaneous measures of central amyloidosis and tauopathy.   Objective: We evaluated whether recognition memory and associated indices, including discriminability and response bias from signal detection theory, differentiate persons with amnestic MCI (aMCI) due to prodromal AD from non-prodromal AD.   Method: Sixty older adults with aMCI were classified as prodromal AD (n = 28) or non-prodromal AD (n = 32) based upon cerebrospinal fluid levels of amyloid-β and tau. Memory was assessed using the Hopkins Verbal Learning Test-Revised which includes free recall and recognition.   Results: ANCOVAs adjusting for age indicated comparable (all p > 0.05) performances between prodromal and non-prodromal MCI groups respectively on traditional HVLT-R recognition measures of hits (mean±SD: 9.5±3.0 versus 10.9±1.7), false alarms (1.8±1.8 versus 1.5±1.5), and hits minus false alarms (7.7±3.0 versus 9.2±2.6). In contrast, discriminability (d’), which reflects how easily targets and distractors are distinguished, was significantly (p = 0.009) poorer in the prodromal versus non-prodromal groups (3.1±1.9 versus 4.8±2.0, effect size = 0.87). In addition, only d’ significantly predicted group membership (OR = 0.66, CI = 0.48–0.92, p = 0.04). Response bias, the tendency to report that a target did or did not appear, was comparable between groups (0.08±1.1 versus –0.04±1.3).   Conclusion: Recognition discriminability is significantly poorer in aMCI with biomarker evidence of prodromal AD. In contrast to traditional recognition indices, discriminability from signal detection theory may be superior in identifying aMCI due to AD versus non-AD etiologies."@en ;
    ns0:hasPubTitle "Recognition Memory Performance as a Cognitive Marker of Prodromal Alzheimer’s Disease"@en .

ns1:jad-v72-i2-JAD190779 ns0:hasKeywords "Alzheimer’s disease"@en,
        "MK0677"@en,
        "amyloid-β"@en,
        "growth hormone secretagogue receptor 1α"@en,
        "hippocampus"@en ;
    ns0:hasPubAbstract "Hippocampal lesions including synaptic injury, neuroinflammation, and impaired neurogenesis are featured pathology closely associated with neuronal stress and cognitive impairment in Alzheimer’s disease (AD). Previous studies suggest that ghrelin and its receptor, growth hormone secretagogue receptor 1α (GHSR1α), promote hippocampal synaptic function and neurogenesis. GHSR1α activation thus holds the potential to be a therapeutic avenue for the treatment of hippocampal pathology in AD; however, a comprehensive study on the preventive effect of MK0677 on hippocampal lesions in AD-related conditions is still lacking. In this study, we treated a transgenic mouse model of AD-like amyloidosis (5xFAD mice) at the asymptomatic stage with MK0677, a potent ghrelin mimetic. We found that MK0677 fostered hippocampal neurogenesis in 5xFAD mice but observed little preventive function with regards to the development of hippocampal amyloid-β (Aβ) deposition, synaptic loss, microglial activation, or cognitive impairment. Furthermore, MK0677 at a dose of 3 mg/kg significantly increased 5xFAD mouse mortality. Despite enhanced hippocampal neurogenesis, MK0677 treatment has little beneficial effect to prevent hippocampal lesions or cognitive deficits against Aβ toxicity. This study, together with a failed large-scale clinical trial, suggests the ineffectiveness of MK0677 alone for AD prevention and treatment."@en ;
    ns0:hasPubTitle "MK0677, a Ghrelin Mimetic, Improves Neurogenesis but Fails to Prevent Hippocampal Lesions in a Mouse Model of Alzheimer’s Disease Pathology"@en .

ns1:jad-v72-i2-JAD190898 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amber codon"@en,
        "amyloid-β precursor protein"@en,
        "cell biology"@en,
        "click chemistry"@en,
        "confocal microscopy"@en,
        "γ-secretase"@en ;
    ns0:hasPubAbstract "The amyloid-β protein precursor (AβPP) is critical in the pathophysiology of Alzheimer’s disease (AD), since two-step proteolytic processing of AβPP generates the neurotoxic amyloid-β peptide (Aβ). We developed a dual fluorescence labeling system to study the exact subcellular location of γ-secretase cleavage of AβPP. The C-terminal tail of AβPP was fluorescently labeled using a SNAP-tag, while the Aβ region of AβPP was fluorescently tagged with a dye at a genetically-encoded noncanonical amino acid (ncAA). The ncAA was introduced at specific positions in AβPP using a genetic code expansion strategy and afterwards, the reactive side-chain of the ncAA was coupled to the dye using a bioorthogonal labeling chemistry. In proof-of-concept experiments, HEK293T cells were transfected with plasmids containing engineered AβPP harboring an amber mutation and an amber codon suppression system with an evolved tRNA synthetase/tRNA pair and grown in the presence of a lysine-derived ncAA. Processing of the AβPP variants was validated with ELISA and immunoblotting, and seven AβPP mutants that showed similar cleavage pattern as wild-type AβPP were identified. The AβPP mutant was fluorescently labeled with 6-methyl-tetrazine-BDP-FL and TMR-Star at the ncAA and SNAP-tag, respectively. Using this approach, AβPP was fluorescently labeled at two sites in living cells with minimal background to allow monitoring of Aβ and C-terminal cleavage products simultaneously. The method described provides a powerful tool to label Aβ with minimal perturbations of its processing, thus enabling studies of the trafficking of the cleavage products of AβPP."@en ;
    ns0:hasPubTitle "Dual Bioorthogonal Labeling of the Amyloid-β Protein Precursor Facilitates Simultaneous Visualization of the Protein and Its Cleavage Products"@en .

ns1:jad-v72-i3-JAD190274 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "glutamate excitotoxicity"@en,
        "long-term potentiation"@en,
        "memory"@en,
        "p-tau"@en ;
    ns0:hasPubAbstract "Glutamate excitotoxicity has long been related to Alzheimer’s disease (AD) pathophysiology, and it has been shown to affect the major AD-related hallmarks, amyloid-β peptide (Aβ) accumulation and tau phosphorylation (p-tau). We investigated whether oral administration of monosodium glutamate (MSG) has effects in a murine model of AD, the double transgenic mice APP/PS1. We found that AD pathogenic factors appear earlier in APP/PS1 when supplemented with MSG, while wildtype mice were essentially not affected. Aβ and p-tau levels were increased in the hippocampus in young APP/PS1 animals upon MSG administration. This was correlated with increased Cdk5-p25 levels. Furthermore, in these mice, we observed a decrease in the AMPA receptor subunit GluA1 and they had impaired long-term potentiation. The Hebb-Williams Maze revealed that they had memory deficits. We show here for the first time that oral MSG supplementation can accelerate AD-like pathophysiology in a mouse model of AD."@en ;
    ns0:hasPubTitle "Oral Monosodium Glutamate Administration Causes Early Onset of Alzheimer’s Disease-Like Pathophysiology in APP/PS1 Mice"@en .

ns1:jad-v72-i3-JAD190495 ns0:hasKeywords "Alzheimer’s disease"@en,
        "LIBRA Index"@en,
        "apathy"@en,
        "depression"@en,
        "mild cognitive impairment"@en,
        "modifiable risk factors"@en,
        "neuropsychological tests"@en,
        "subjective cognitive decline"@en ;
    ns0:hasPubAbstract "Background: Alzheimer’s disease is the principal cause of dementia and is determined, in at least one third cases, by modifiable risk factors (MRF). The “Lifestyle for Brain Health (LIBRA)” index was recently developed to quantify the individual risk of progression to dementia ascribable to MRF.   Objective: The aim of this study was to investigate the association between LIBRA scores and markers of cognitive performance, functional independence, and psycho-behavioral symptoms in a community-based sample of Italian elders.   Methods: 308 senior participants with mild cognitive impairment (MCI) or subjective cognitive decline (SCD) were evaluated with a complete neuropsychological battery and semi-structured interviews for the assessment of depression, apathy, and functional autonomy. All the 12 LIBRA MRF were available for the calculation of LIBRA scores. A modified version of the index (LIBRA-2) was calculated by removing depression weight from the LIBRA index. Partial correlation analyses, controlling for age and education, assessed the association between LIBRA indices and cognitive, functional, and behavioral outcomes. Separate analyses were repeated in the MCI and SCD subgroups.   Results: In participants with SCD (SCDp), significant correlations existed between LIBRA and markers of impairment in global cognition, visuo-spatial attention, and semantic fluency. LIBRA-2 associated with psycho-behavioral symptoms in the whole sample and in SCDp. LIBRA-2 only associated with apathy in the MCI subgroup.   Conclusions: The LIBRA index might be useful to determine the lifestyle-attributable risk of cognitive and psycho-behavioral decline in Italian seniors at risk, while in those with overt cognitive impairment, these outcomes are presumably mainly associated with non-modifiable factors."@en ;
    ns0:hasPubTitle "The LIBRA Index in Relation to Cognitive Function, Functional Independence, and Psycho-Behavioral Symptoms in a Sample of Non-Institutionalized Seniors at Risk of Dementia"@en .

ns1:jad-v72-i3-JAD190634 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Mexican Americans"@en,
        "SEPT8 protein"@en,
        "cognitive dysfunction"@en,
        "epigenetics"@en ;
    ns0:hasPubAbstract "The Mexican American population is among the fastest growing aging population and has a younger onset of cognitive decline. This group is also heavily burdened with metabolic conditions such as hypertension, diabetes, and obesity. Unfortunately, limited research has been conducted in this group. Understanding methylation alterations, which are influenced by both genetic and lifestyle factors, is key to identifying and addressing the root cause for mild cognitive impairment, a clinical precursor for dementia. We conducted an epigenome-wide association study on a community-based Mexican American population using the Illumina EPIC array. Following rigorous quality control measures, we identified 10 CpG sites to be differentially methylated between normal controls and individuals with mild cognitive impairment annotated to PKIB, KLHL29, SEPT9, OR2C3, CPLX3, BCL2L2-PABPN1, and CCNY. We found four regions to be differentially methylated in TMEM232, SLC17A8, ALOX12, and SEPT8. Functional gene-set analysis identified four gene-sets, RIN3, SPEG, CTSG, and UBE2L3, as significant. The gene ontology and pathway analyses point to neuronal cell death, metabolic dysfunction, and inflammatory processes. We found 1,450 processes to be enriched using empirical Bayes gene-set enrichment. In conclusion, the functional overlap of differentially methylated genes associated with cognitive impairment in Mexican Americans implies cross-talk between metabolically-instigated systemic inflammation and disruption of synaptic vesicular transport."@en ;
    ns0:hasPubTitle "Genome-Wide Methylation of Mild Cognitive Impairment in Mexican Americans Highlights Genes Involved in Synaptic Transport, Alzheimer’s Disease-Precursor Phenotypes, and Metabolic Morbidities"@en .

ns1:jad-v72-i3-JAD190798 ns0:hasKeywords "Attentional control"@en,
        "cognitive control"@en,
        "dementia"@en,
        "healthy aging"@en,
        "mild cognitive impairment"@en,
        "psychometric assessment"@en,
        "subjective cognitive decline"@en ;
    ns0:hasPubAbstract "Background: Subjective cognitive decline (SCD) and mild cognitive impairment (MCI) are acknowledged stages of the clinical spectrum of Alzheimer’s disease (AD), and cognitive control seems to be among the first neuropsychological predictors of cognitive decline. Existing tests are usually affected by educational level, linguistic abilities, cultural differences, and social status, constituting them error-prone when differentiating between the aforementioned stages. Creating robust neuropsychological tests is therefore prominent.   Objective: The design of a novel psychometric battery for the cognitive control and attention assessment, free of demographic effects, capable to discriminate cognitively healthy aging, SCD, MCI, and mild Dementia (mD).   Methods: The battery initial hypothesis was tuned using iterations of administration on random sampling healthy older adults and people with SCD, MCI, and mD, from the area of Thessaloniki, Greece. This resulted in the first release of the REflexes MEasurement DEviceS for Alzheimer battery (REMEDES for Alzheimer-R4Alz).   Results: The first release lasts for almost an hour. The battery was design to assess working memory (WM) including WM storage, processing, and updating, enriched by episodic buffer recruitment. It was also designed to assess attention control abilities comprising selective, sustained, and divided attention subtasks. Finally, it comprises an inhibitory control, a task/rule switching or set-shifting, and a cognitive flexibility subtask as a combination of inhibition and task/rule switching abilities.   Conclusion: The R4Alz battery is an easy to use psychometric battery with increasing difficulty levels and assumingly ecological validity, being entertaining for older adults, potentially free of demographic effects, and promising as a more accurate and early diagnosis tool of neurodegeneration."@en ;
    ns0:hasPubTitle "REMEDES for Alzheimer-R4Alz Battery: Design and Development of a New Tool of Cognitive Control Assessment for the Diagnosis of Minor and Major Neurocognitive Disorders"@en .

ns1:jae-v58-i2-JAE180058 ns0:hasKeywords "3-DOF motor"@en,
        "Halbach array"@en,
        "magnetic field calculation"@en,
        "permanent magnet"@en,
        "structure optimization"@en,
        "taguchi method"@en,
        "torque"@en ;
    ns0:hasPubAbstract "In this paper, a new type of permanent magnet type 3-DOF hybrid driven motor is proposed in view of the poor precision of existing deflection movement control and low speed of multi-degree-of-freedom motor rotation. The motor contains two part named lateral rotation module and internal deflection modules. The output torque of the motor, the rotation speed and control precision are improved by the coordinated control of rotation movement and deflection movement. The magnetic field shielding and optimization of two modules inside and outside the motor are realized by using Halbach permanent magnet array, and the magnetic field characteristics of the motor are improved. First, using analytical method and finite element method, the magnetic field characteristics and distribution of the permanent magnet of the motor are analyzed, and the electromagnetic characteristics of load and no load condition and output torque of the motor is analyzed by finite element method. Then, the loss of this motor is analyzed and calculated, the motor response surface equation is built by using taguchi method and central composite design method. Finally, the optimal structure parameters of motor is proposed by the numerical model based on maximizing the motor output torque of the target, and it is compared with finite element and experiment to verify the accuracy of the structural parameters. It provides a new theoretical basis for the follow-up optimization of the motor."@en ;
    ns0:hasPubTitle "Calculation and optimization of a permanent magnetic hybrid driven 3-DOF motor"@en .

ns1:jae-v61-i3-JAE190021 ns0:hasKeywords "EMAT"@en,
        "focal position selection"@en,
        "line focusing"@en,
        "numerical simulation"@en ;
    ns0:hasPubAbstract "As the focal position of a line-focusing electromagnetic acoustic transducer (LF-EMAT) affects the intensity of the focal signal, we measure the displacement signal and the selection method of the focal line position is then studied in this work to improve the signal intensity and detection precision for a shear-vertical (SV) wave LF-EMAT. We calculate the magnetostatics field and bulk wave propagation utilizing the finite element method (FEM). We simulate the characteristics of the SV wave, and we find that the radiant distance and propagation direction has a great influence on the amplitude of the displacement of the specimen. The superposition area of SV waves from different sources possesses better focusing ability, and the triangular area (normalized amplitude of the SV waves lower than 10%) near the surface of a specimen should be avoided to be chosen when designing the meander line coils. As for the line-focusing EMAT described in this manuscript, the selection of focal positions for different thickness specimens or detection depth is completely different. Moreover, we perform an experiment to validate the simulation results and lead to a conclusion that the position of the focal point is required to be appropriately close to the excitation coils to enhance the intensity of the signal, while the best focal position should be calculated."@en ;
    ns0:hasPubTitle "Numerical evaluation of focal position selection by line-focusing electromagnetic acoustic transducer with experimental validation"@en .

ns1:jae-v61-iS1-JAE191148 ns0:hasKeywords "Fe-based amorphous sheet"@en,
        "Magnetostriction"@en,
        "electrical steel sheet"@en,
        "laser Doppler vibrometer"@en,
        "single sheet tester"@en ;
    ns0:hasPubAbstract "One of the main cause of acoustic noise from iron core in electrical machines is magnetostriction. However, good reproducibility of magnetostriction measurement cannot be expected due to its ppm-order value. To measure the magnetostriction accurately, it is required to clarify principal factors affecting the measurement accuracy. In this paper, a high-resolution method of measuring magnetostriction by means of an open-type single sheet tester equipped with double laser Doppler vibrometers is investigated. It is revealed that the odd components of a magnetostriction waveform should be removed as noises because the reproducibility of odd harmonic components is low. To improve the reproducibility, the friction between a test specimen and a support plate installed under the specimen should be reduced. Furthermore, it is demonstrated that the developed measuring system can be also applied to magnetostriction measurement of Fe-based amorphous sheets."@en ;
    ns0:hasPubTitle "High-resolution measurement method for magnetostriction of electrical steel sheets using an open-type single sheet tester"@en .

ns1:jae-v61-iS1-JAE191283 ns0:hasKeywords "Soft magnetic composite"@en,
        "acid etching"@en,
        "magnetic properties"@en ;
    ns0:hasPubAbstract "Soft magnetic composites (SMCs) are magnetic materials obtained by compression molding of iron powders with an insulating coating and are suitable for a core of a motor having a complicated structure. It is known that its magnetic property is deteriorated by machining process due to the short circuit of the insulated layer on the material surface. In general, the acid etching treatment is performed to improve the degradation of the magnetic properties. In this paper, first the resistivity of the ring specimen of the SMC applying the acid etching treatment for a different immersion time is measured. Next, the magnetic properties of the specimen are measured, and the effect of the machining process and the acid etching treatment on the magnetic and electric properties of the SMC is investigated."@en ;
    ns0:hasPubTitle "Influences of machining and acid etching on magnetic properties of soft magnetic composites"@en .

ns1:jae-v61-iS1-JAE191291 ns0:hasKeywords "Punching"@en,
        "magnetic characterization"@en,
        "stator"@en ;
    ns0:hasPubAbstract "An experimental approach is proposed to study the influence of the punching on the magnetic behavior of a stator core strips. Specimens of a non-oriented M330-A35 punched lamination sheet are picked up from a real manufacturing process. The proposed approach is based on the use of two types of specimens; one is a closed magnetic circuit while the second one is split into two parts. Magnetic measurements are performed on both types and compared with those made on specimens cut by WEDM which has a lower impact on the magnetic behavior. The specific purpose of this paper is to investigate the impact of punching in presence of an air gap that exists in electrical machines between rotor and stator. Therefore a dedicated device, optimized by FEM simulations, is developed in order to account accurately the air gap."@en ;
    ns0:hasPubTitle "Punching effect directly on electrical machine stator strips"@en .

ns1:jae-v61-iS1-JAE198972 ns0:hasKeywords "B-H relationship"@en,
        "green function method"@en,
        "inverse magnetic field problem"@en,
        "polarization method"@en,
        "soft magnetic composites"@en ;
    ns0:hasPubAbstract "The static B-H relationship is a very important parameter, used in the characterization of magnetic materials. In the paper is presented a novel laboratory equipment that has an “8” figure shaped magnetic circuit, which is made from a negligible hysteresis soft alloy. The experimental set-up consists of two DC coils, in which the currents i1 and i2 are set, to obtain a null value of the magnetic flux in the median yoke that has an “O” shaped figure, with two AC coils. A stationary magnetic field inverse problem is solved, starting with a couple of DC currents (i1, i2) and a piecewise linear normal magnetization curve is computed. The nonlinearity of B-H relationship is treated by polarization fixed-point iterative method, while for each iteration the Green function is engaged. The static magnetization curve is compared, with the B-H relationship measured, using a high precision metrological device, on a toroidal sample made from the same material."@en ;
    ns0:hasPubTitle "Assessment of static B-H relationship for soft magnetic alloys using a novel equipment"@en .

ns1:jae-v61-iS1-JAE198976 ns0:hasKeywords "Grain-oriented alloys"@en,
        "electro-erosion"@en,
        "energy losses"@en,
        "laser cutting"@en,
        "magnetocrystalline anisotropy"@en,
        "normal magnetization curve"@en,
        "orientation distribution functions"@en,
        "punching"@en ;
    ns0:hasPubAbstract "Grain-oriented silicon iron alloys present an important magnetocrystalline anisotropy, which has a strong influence on the normal magnetization curve and the energy losses. The theory of Orientation Distribution Functions (ODF), applied in the case of materials presenting crystalline symmetry of body centered cubic structure and orthorhombic strip symmetry, is taken into consideration. The magnetocrystalline anisotropy is analyzed on JFE Steel Corp. commercial grade M-0H grain-oriented electrical steel, cut at different angles with respect to the rolling direction, ranging from 0° to 90° in equal steps of 15°. The accuracy of the ODF method is analyzed by taking into account firstly three sets of experimental data, obtained for 0°, 45°, and 90°, then four sets, in the case of 0°, 30°, 60°, and 90° cut samples, and in the last case for all seven directions. The magnetic properties are predicted for any arbitrary direction and a relative error is analyzed, in each case, between the experimental and the numerical data. Finally, a proper number of experimental measurements was chosen, by considering a compromise between the magnitude of the error and the amount of experimental data. The samples were cut through mechanical punching, laser and travelling wire electro-erosion technologies. The normal magnetization curves and the energy losses were measured utilizing an industrial single strip tester (SST), at the frequency of 50 Hz. The model presented in the paper is a useful tool in the electric transformer cores’ design since every magnetic property could be predicted with an increased accuracy in the case of each angle."@en ;
    ns0:hasPubTitle "Application of orientation distribution functions’ theory in the case of grain-oriented steels cut through classical and non-conventional technologies"@en .

ns1:jbr-v9-i2-JBR180349 ns0:hasKeywords "Fragaria × ananassa"@en,
        "bioactive compounds"@en,
        "postharvest storage"@en,
        "quality"@en ;
    ns0:hasPubAbstract "BACKGROUND: Strawberry is one of the most highly consumed fruits worldwide. However, it is highly a perishable fruit postharvest.   OBJECTIVE: To assess the effect of dipping strawberry fruits after harvest in plant growth regulators to maintain postharvest quality.   METHODS: Treatments tested were: 2 and 4 mM salicylic acid (SA), 0.25 and 0.50 mM abscisic acid (ABA) and methyl jasmonate at 0.25 and 0.50 mM (MeJA). Bioactive compounds and fungal growth were assessed over 12 days of storage at 4°C.   RESULTS: Both concentrations of SA and MeJA significantly suppressed weight loss, decay and respiration rate and 0.50 mM ABA also reduced decay. Both concentrations of SA retarded color development, and total soluble solids content was enhanced by 0.50 mM ABA and MeJA treatments. The most effective treatments for preserving firmness were 0.25 mM MeJA and 4 mM SA. Reduction in loss of ascorbic acid and bioactive compounds during storage was achieved using the highest concentrations of SA, ABA, and MeJA. Fungal growth was suppressed by all treatments but the best treatment was MeJA at both concentrations.   CONCLUSIONS: All three plant growth regulators reduce postharvest changes in strawberry but effects differ amongst the treatments."@en ;
    ns0:hasPubTitle "Impact of salicylic acid, abscisic acid, and methyl jasmonate on postharvest quality and bioactive compounds of cultivated strawberry fruit"@en .

ns1:jhd-v8-i3-JHD199003 ns0:hasKeywords "Huntington disease"@en,
        "clinical trials"@en ;
    ns0:hasPubAbstract "In this edition of the Huntington’s Disease Clinical Trials Corner we expand on the HD-DBS and on the TRIHEP3 trials, and we list all currently registered and ongoing clinical trials in Huntington’s disease."@en ;
    ns0:hasPubTitle "Huntington’s Disease Clinical Trials Corner: June 2019"@en .

ns1:jnd-v6-i3-JND180314 ns0:hasKeywords "ECC"@en,
        "SOCE"@en,
        "Triad"@en,
        "calcium"@en,
        "cardiomyopathy"@en,
        "dyad"@en,
        "excitation-contraction coupling"@en,
        "membrane remodeling"@en,
        "myopathy"@en,
        "store-operated Ca2+ entry"@en ;
    ns0:hasPubAbstract "Muscle contraction requires specialized membrane structures with precise geometry and relies on the concerted interplay of electrical stimulation and Ca2+ release, known as excitation-contraction coupling (ECC). The membrane structure hosting ECC is called triad in skeletal muscle and dyad in cardiac muscle, and structural or functional defects of triads and dyads have been observed in a variety of myopathies and cardiomyopathies. Based on their function, the proteins localized at the triad/dyad can be classified into three molecular pathways: the Ca2+ release complex (CRC), store-operated Ca2+ entry (SOCE), and membrane remodeling. All three are mechanistically linked, and consequently, aberrations in any of these pathways cause similar disease entities. This review provides an overview of the clinical and genetic spectrum of triad and dyad defects with a main focus of attention on the underlying pathomechanisms."@en ;
    ns0:hasPubTitle "Abnormal Excitation-Contraction Coupling and Calcium Homeostasis in Myopathies and Cardiomyopathies"@en .

ns1:jnd-v6-i3-JND190379 ns0:hasKeywords "Feeding and swallowing problems"@en,
        "bulbar function"@en,
        "dysphagia"@en,
        "spinal muscular atrophy."@en ;
    ns0:hasPubAbstract "Background: Spinal muscular atrophy (SMA) is hereditary motor neuron disorder, characterised by the degeneration of motor neurons and progressive muscle weakness. It is caused by the homozygous loss of function of the survival motor neuron (SMN) 1 gene. SMA shows a wide variability of disease severity.   Objective: To investigate self-reported bulbar problems in patients with SMA, and their relationship to age, functional motor scores and active maximum mouth opening.   Methods: We used the Diagnostic List of Dysphagia and Dysarthria in (pediatric) patients and relevant recent clinical data from the national SMA database.   Results: The 118 included patients with SMA frequently reported jaw problems (34%), fatigue associated with mastication (44%), choking (56%) and intelligibility problems (27%). Jaw, mastication and swallowing problems frequently occurred in combination with each other. There was an increase of reported bulbar problems in patients with SMA type 3a, older than 30 years of age, compared to younger patients of this SMA type. The Hammersmith Functional Motor Scale Expanded scores showed a negligible correlation with jaw and mastication problems, a low negative correlation with swallowing problems and a moderate negative correlation with intelligibility problems. Reduced mouth opening showed a significant, but low correlation with bulbar complaints in patients with SMA type 2.   Conclusions: Fatigue associated with mastication and swallowing problems were frequently reported complaints. Patients 30 years and older with milder forms of SMA showed an increase of self-reported bulbar problems."@en ;
    ns0:hasPubTitle "Bulbar Problems Self-Reported by Children and Adults with Spinal Muscular Atrophy"@en .

ns1:jnd-v6-i4-JND190414 ns0:hasKeywords "Calpainopathy"@en,
        "LGMD2A"@en,
        "deep intronic mutation"@en,
        "phosphorodiamidate morpholino oligomer (PMO)"@en ;
    ns0:hasPubAbstract "Calpainopathy, also known as limb girdle muscular dystrophy (LGMD) type 2A (LGMD2A) or LGMD R1 Calpain3-related, is one of the most common genetically characterized forms of limb-girdle muscular dystrophy with a wide range of phenotypic severity. We evaluated a consanguineous family with a clinical phenotype consistent with calpainopathy in whom conventional sequencing did not detect any mutations in the CAPN3 gene. Using whole exome sequencing paired with haplotype analysis, we identified a homozygous deep intronic single base pair deletion in CAPN3 (c.946-29delT). Familial segregation studies were consistent with recessive inheritance. Immunoblotting of muscle tissue from the patient showed complete absence of calpain 3. In silico analysis predicted the deletion to disrupt the branch point and subsequently alter splicing of exon 7. Studies of patient fibroblasts and muscle tissue confirmed altered splicing, resulting in an inclusion of a 389-bp intronic sequence upstream of exon 7, originating from a cryptic splice acceptor site in intron 6. This out-of-frame insertion results in a premature stop codon, leading to an apparent absence of protein likely due to degradation of the transcript via nonsense-mediated decay. We then designed phosphorodiamidate morpholino oligomers (PMOs) as splice modulators to block the new splice acceptor site. This approach successfully prevented the aberrant splicing – reverting the majority of the splice to the wildtype transcript. These results confirm the pathogenicity of this novel deep intronic mutation and provide a mutation-specific therapeutic strategy. Thus, deep intronic mutations in CAPN3 may be pathogenic and should be considered in the appropriate clinical setting. The identification of mutations which may be missed by traditional Sanger sequencing is essential as they may be excellent targets for individualized therapeutic strategies using RNA-directed splice modulation."@en ;
    ns0:hasPubTitle "Identification of a Novel Deep Intronic Mutation in CAPN3 Presenting a Promising Target for Therapeutic Splice Modulation"@en .

ns1:jnd-v6-i4-JND190428 ns0:hasKeywords "Nusinersen"@en,
        "SMA treatment"@en,
        "Spinal muscular atrophy"@en,
        "newborn screening"@en,
        "prognosis"@en ;
    ns0:hasPubAbstract "Objective: Spinal muscular atrophy (SMA) is the most common neurodegenerative disease in childhood. The study was conducted to assess the impact of early detection of SMA by newborn screening (NBS) on the clinical course of the disease.   Methods: Screening was performed in two federal states of Germany, Bavaria and North Rhine Westphalia, between January 2018 and February 2019. The incidence in the screening population was calculated as number of detected patients with a homozygous deletion in the SMN1-gene per number of screened patients. To get an idea about the incidence of newly diagnosed SMA in the year prior to screening a survey covering all neuropediatric centers in the state of Bavaria was conducted, identifying all SMA-cases in 2017 and 2018. Following positive NBS and confirmatory diagnostic test, treatment was advised according to the recommendations of the “American SMA NBS Multidisciplinary Working Group”. Immediate treatment with Nusinersen was recommended in children with 2 and 3 SMN2 copies and a conservative strict follow-up strategy in children with ≥4 copies. All children underwent regular standardized neuropediatric examination, CHOP INTEND and HINE-2 testing as well as electrophysiological exams every 2-3 months.   Results: 165,525 children were screened. 22 cases of SMA were identified, meaning an incidence rate of 1:7524. SMN2 copy number analysis showed 2 SMN2 copies in 45% of patients, 3 SMN2 copies in 19 % and 4 SMN2 copies in 36%. These findings are confirmed in the most recent statistical data-cut from 31st August 2019 (incidence 1:7089, 2 SMN2 copies in 44%, 3 in 15% and 4 in 38%). Comparison with up-to-date German data on SMA incidence and the Bavarian survey give evidence that NBS did not lead to a relevant increase in incidence. 10 patients with 2 or 3 SMN2 copies were treated with Nusinersen, starting between 15– 39 days after birth, in 7/10 patients before onset of symptoms. Presymptomatically treated patients (age at last examination: 1– 12 months, median 8 months) showed no muscle weakness by the age of one month to one year. One child with 4 SMN2 copies became symptomatic at the age of 8 months.   Conclusions: Newborn screening, resulting in presymptomatic treatment, improves outcome in children with genetically proven SMA. Newborn screening for SMA should be introduced in all countries where therapy is available. An immediate therapy in cases with 4 SMN2 copies should be considered."@en ;
    ns0:hasPubTitle "One Year of Newborn Screening for SMA – Results of a German Pilot Project"@en .

ns1:jpd-v9-i3-JPD181460 ns0:hasKeywords "Parkinson’s disease"@en,
        "eye movements"@en,
        "impulse control disorders"@en,
        "impulsive compulsive behaviours"@en,
        "saccades"@en ;
    ns0:hasPubAbstract "Fifteen individuals with Parkinson’s disease (PD) and impulsive compulsive behaviours (PD+ICB) were compared to 15 PD patients without ICBs (PD-ICB) and 15 healthy controls (HC) on a pro-saccades and an anti-saccades task to assess if ICBs are associated with distinct saccadic abnormalities. PD+ICB made shorter saccades than HC and more direction errors in the anti-saccades task than PD-ICB and HC, suggesting that patients with ICBs have greater difficulty in suppressing automatic saccades towards a given target. Saccadic assessment has the potential to evolve into a marker to guide therapeutic decisions in patients at risk of developing ICBs."@en ;
    ns0:hasPubTitle "Saccadic Direction Errors are Associated with Impulsive Compulsive Behaviours in Parkinson’s Disease Patients"@en .

ns1:jpd-v9-i3-JPD191579 ns0:hasKeywords "Autonomic symptoms"@en,
        "Parkinson’s disease"@en,
        "blood pressure"@en,
        "fatigue"@en,
        "hypotension"@en ;
    ns0:hasPubAbstract "Background/Objective: Fatigue is a common debilitating symptom in Parkinson’s disease (PD) of unclear etiology. Hypotension and blood pressure variability are common in PD though their relationship to other non-motor symptoms is less well understood.   Methods: We conducted a cross-sectional study to explore differences in 24-hour ambulatory blood pressure measurements in PD subjects (n = 35) with and without fatigue. Subjects underwent hourly systolic (SBP) and diastolic (DBP) blood pressure testing in their home environment. The presence of fatigue was assessed using the Movement Disorders Society Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) part 1. We compared blood pressure measurements in fatigued vs. non-fatigued PD subjects, assessed over 4 epochs: overnight, morning, midday, and evening.   Results: PD subjects with symptoms of fatigue demonstrated lower mean DBP, compared to those without fatigue (67.8±4.8 mmHg vs. 75.6±9.4 t = 2.57, p = 0.014). These intergroup differences were most notable in the morning. The two groups did not differ in scoring on the Survey of Autonomic Symptoms or on an office-based blood assessment of SBP or DBP performed on the day of 24-hour monitor initiation.   Conclusions: Fatigue in PD may be a clinical manifestation of low-grade systemic hypotension."@en ;
    ns0:hasPubTitle "Fatigue in Parkinson’s Disease Associates with Lower Ambulatory Diastolic Blood Pressure"@en .

ns1:jpd-v9-i3-JPD191648 ns0:hasKeywords "Dopamine transporter"@en,
        "EMA"@en,
        "PPMI"@en,
        "PRECEPT"@en,
        "SWEDD"@en,
        "enrichment biomarker"@en ;
    ns0:hasPubAbstract "As therapeutic trials target early stages of Parkinson’s disease (PD), appropriate patient selection based purely on clinical criteria poses significant challenges. Members of the Critical Path for Parkinson’s Consortium formally submitted documentation to the European Medicines Agency (EMA) supporting the use of Dopamine Transporter (DAT) neuroimaging in early PD. Regulatory documents included a comprehensive literature review, a proposed analysis plan of both observational and clinical trial data, and an assessment of biomarker reproducibility and reliability. The research plan included longitudinal analysis of the Parkinson Research Examination of CEP-1347 Trial (PRECEPT) and the Parkinson’s Progression Markers Initiative (PPMI) study to estimate the degree of enrichment achieved and impact on future trials in subjects with early motor PD. The presence of reduced striatal DAT binding based on visual reads of single photon emission tomography (SPECT) scans in early motor PD subjects was an independent predictor of faster decline in UPDRS Parts II and III as compared to subjects with scans without evidence of dopaminergic deficit (SWEDD) over 24 months. The EMA issued in 2018 a full Qualification Opinion for the use of DAT as an enrichment biomarker in PD trials targeting subjects with early motor symptoms. Exclusion of SWEDD subjects in future clinical trials targeting early motor PD subjects aims to enrich clinical trial populations with idiopathic PD patients, improve statistical power, and exclude subjects who are unlikely to progress clinically from being exposed to novel test therapeutics."@en ;
    ns0:hasPubTitle "The Qualification of an Enrichment Biomarker for Clinical Trials Targeting Early Stages of Parkinson’s Disease"@en .

ns1:jpd-v9-i4-JPD191593 ns0:hasKeywords "Clinical trials"@en,
        "Parkinson’s disease"@en,
        "motor fluctuations"@en,
        "opicapone"@en,
        "safety"@en ;
    ns0:hasPubAbstract "Background: Opicapone is a catechol O-methyltransferase (COMT) inhibitor indicated for use as adjunct to levodopa therapy in patients with Parkinson’s disease (PD) and motor fluctuations.   Objective: To characterize the safety and tolerability of adjunct opicapone (25 and 50 mg) in a pooled population of levodopa-treated PD patients who participated in the opicapone Phase-3 clinical program.   Methods: Patient-level data (placebo, opicapone 25 mg and 50 mg) from the BIPARK-1 and BIPARK-2 double-blind and open-label studies were combined.   Results: Pooled analyses included 766 patients from the double-blind studies and 848 patients from the open-label studies. In the double-blind studies, 63.3% of opicapone-treated patients reported treatment-emergent adverse events (TEAEs) versus 57.2% in the placebo group. The most common TEAEs reported in the opicapone group compared to placebo were dyskinesia, constipation and insomnia. The incidence of serious TEAEs was similar across opicapone and placebo groups (3.5% versus 4.3%, respectively). Overall, 71.3% patients treated with open-label opicapone reported at least one TEAE; most occurred within the first 2 months of the open-label studies, and then decreased thereafter. Throughout the Phase-3 clinical program, there were no serious AEs suggestive of hepatic toxicity, and the incidence of gastrointestinal disorders such as nausea and diarrhea remained low (<2%). There were no relevant changes in laboratory parameters including liver enzymes, vital signs, physical or neurological examinations, or ECG readings.   Conclusions: Long-term use of opicapone once-daily over 1-year at doses of 25 mg or 50 mg was generally safe and well tolerated, supporting its clinical usefulness in the management of PD motor fluctuations."@en ;
    ns0:hasPubTitle "Safety Profile of Opicapone in the Management of Parkinson’s Disease"@en .

ns1:jpd-v9-i4-JPD191600 ns0:hasKeywords "Lewy body dementia"@en,
        "Parkinson’s disease"@en,
        "hippocampus"@en,
        "magnetic resonance imaging"@en,
        "shape"@en,
        "structure"@en ;
    ns0:hasPubAbstract "Background: Dementia with Lewy bodies (DLB) and Parkinson’s disease (PD) are considered subtypes of the α-synucleinopathy continuum that show similar and dissimilar clinical and morphological features.   Objective: To further our understanding of brain abnormalities that might differentiate both disorders more clearly, we performed quantitative magnetic resonance (MR) imaging of the subcortical and cortical grey matter.   Methods: Three-dimensional T1 weighted 3 tesla MR images of 14 DLB and 62 age- and gender-matched PD patients were examined to study cortical and subcortical grey matter structure. We used volumetric measurements to study total grey matter, and volumes of the pallidum, amygdala, putamen, caudate nucleus, thalamus and hippocampus. Whole-brain and structural network-based methods were used to identify local differences in grey matter and vertex-based shape analysis was used to assess focal hippocampal changes.   Results: Volumetric, whole-brain and network-based analyses showed reduced hippocampal (p = 0.008) and right parahippocampal region volumes (p = 0.030) in DLB compared to PD patients. Shape analysis showed atrophy in the head and body of the right (p = 0.040) and in the head of the left (p = 0.030) hippocampus of DLB patients.   Conclusion: DLB patients showed atrophy of the hippocampus and parahippocampal gyrus compared to PD patients with a differential involvement of the head and body of the hippocampus. Further studies should examine if these group-based findings can be used to differentiate both disorders on an individual level."@en ;
    ns0:hasPubTitle "Regional Structural Hippocampal Differences Between Dementia with Lewy Bodies and Parkinson’s Disease"@en .

ns1:jpd-v9-i4-JPD191612 ns0:hasKeywords "16s rRNA gene"@en,
        "Multiple system atrophy"@en,
        "blood"@en,
        "feces"@en,
        "microbiota"@en ;
    ns0:hasPubAbstract "Background and Objective: To explore the alterations of microbial 16s ribosomal (rRNA) gene in the feces and blood of Chinese patients with multiple system atrophy (MSA) and its relationships with clinical features.   Methods: 40 MSA patients (MSA-P/MSA-C: 23/17) and their healthy spouses were recruited. Fecal and blood microbiota were investigated by high-throughput IllUmina Miseq sequencing targeted on the V3-V4 functional region of 16s rRNA gene. The relationships between microbiota and clinical characteristics were analyzed.   Results: The abundances of Lactobacillus, Gordonibacter, Phascolarctobacterium, and Haemophilus in feces and abundances of Leucobacter, and Bacteroides in blood were different between MSA patients and healthy controls (HC). Combining the taxa from feces and blood, six genera were identified to be predictive of MSA, achieving an area under the curve (AUC) of 0.853. The abundances of Phascolarctobacterium and Ruminococcus in feces were lower in MSA-P than those in MSA-C. The abundances of Blastococcus, Bacillus, and Acinetobacter in blood were different between MSA subtypes. These five genera differentiated MSA subtypes with an AUC of 0.898. Functional predictions indicated that gene functions involving biosynthetic metabolism and bacterial secretion systems were significantly different between the MSA and HC. The differential genera were associated with disease duration, anxiety, and autonomic dysfunctions.   Conclusions: We confirmed the alterations of microbial 16s rRNA gene in the feces and blood occurs in Chinese patients with MSA. Microbiota dysbiosis was related to MSA clinical manifestations. Elucidating these differences in microbiomes will be helpful to improve our knowledge of the microbiota in the pathogenesis of MSA."@en ;
    ns0:hasPubTitle "Fecal and Blood Microbial 16s rRNA Gene Alterations in Chinese Patients with Multiple System Atrophy and Its Subtypes"@en .

ns1:jpd-v9-is2-JPD191802 ns0:hasKeywords "Parkinson’s disease"@en,
        "faecal microbiome transplantation"@en,
        "prebiotics"@en,
        "probiotics"@en ;
    ns0:hasPubAbstract "Abstract Faecal microbiome transplantation (FMT) is an attractive technique, because the administration is relatively simple and in general has a mild adverse effect pattern. Moreover, FMT consists of a broad mixture, which could be beneficial, because at this moment it is not known what type of changes in the microbiome are needed. However, except from a few cases no clinical data in Parkinson’s disease (PD) is available yet. There is some indication that FMT might be beneficial in severe constipated PD patients, but the clinical data to support this are very scarce. So, actually there are no good data in the public domain to support FMT at this moment in PD patients. FMT at this moment is a black box with too many unanswered questions, also with respect to safety concerns. Only the administration of species of Lactobacillus and Bifidobacterium over a time period of four to twelve weeks has repeatedly proven to be effective in treating constipation in PD. Also, no solid clinical data are available about the possible effects of probiotic treatment on motor symptoms or progression of PD. Therefore, also probiotic treatments in PD should wait until better clinical data become available, in order to select the right target populations and to have good estimates of the clinical effects to be expected."@en ;
    ns0:hasPubTitle "Faecal Transplantation, Pro- and Prebiotics in Parkinson’s Disease; Hope or Hype?"@en .

ns1:jvr-v51-i1-JVR191020 ns0:hasKeywords "Multiple sclerosis"@en,
        "employment"@en,
        "medical and psychosocial aspects"@en ;
    ns0:hasPubAbstract "BACKGROUND: Multiple sclerosis (MS) is one of the most common neurological disorders in the world, and it is increasing in incidence and prevalence in the United States.   OBJECTIVE: This article describes the medical, psychosocial, and vocational aspects of MS. Current information regarding the diagnosis and treatment of MS is presented. The authors review recent research on the impact of MS on health, function, employment, and community participation.   CONCLUSION: Important considerations for providing responsive vocational rehabilitation services to people with MS are thoroughly discussed."@en ;
    ns0:hasPubTitle "Multiple sclerosis: A high-incidence immune-mediated disease of the central nervous system"@en .

ns1:jvr-v51-i1-JVR191021 ns0:hasKeywords "Multiple sclerosis"@en,
        "career development"@en,
        "vocational rehabilitation"@en ;
    ns0:hasPubAbstract "OBJECTIVE: The purpose of this article is to introduce the Illinois Work and Well-Being Model as a framework that can be applied to facilitate the career development of people with multiple sclerosis (MS). The model emphasizes the interaction of contextual and career development domains to improve participation in the areas of work, society, community, and home.   CONCLUSION: A brief discussion of potential implications regarding vocational rehabilitation research, service, and policy is offered, with the overall goal of reinforcing career development as the foundation of vocational rehabilitation services for adults with MS and other chronic health conditions."@en ;
    ns0:hasPubTitle "Applying the Illinois Work and Well-Being Model to increase labor force participation among people with multiple sclerosis"@en .

ns1:jvr-v51-i1-JVR191025 ns0:hasKeywords "Measurement"@en,
        "dichotomous data"@en,
        "employment"@en,
        "factor analysis"@en,
        "multiple sclerosis"@en ;
    ns0:hasPubAbstract "OBJECTIVE: The purpose of this study was to examine the factor structure of satisfaction ratings on a collection of 38 employment concerns items among people with Multiple sclerosis (MS).   RESULTS: Analyses included a cross validation to establish and confirm a factor structure. The original 38 items were reduced to 17, which were found to form three distinct factors during the calibration portion of the cross validation. These three factors were Environmental/Personal Resources, Fair Treatment, and Legal Rights, which were confirmed during the validation portion of the cross validation.   CONCLUSION: It appears that the three-factor structure of these 17 items is suitable for use with individuals with MS in the evaluation of their employment-related concerns and in the subsequent delivery of rehabilitation interventions."@en ;
    ns0:hasPubTitle "The factor structure of satisfaction ratings for selected employment concerns among people with multiple sclerosis"@en .

ns1:jvr-v51-i2-JVR191031 ns0:hasKeywords "Communities of practice"@en,
        "PROMISE"@en,
        "Supplemental Security Income"@en,
        "knowledge management"@en,
        "organizational learning"@en,
        "situated learning"@en,
        "systems learning"@en,
        "transition planning"@en,
        "youth with disabilities"@en ;
    ns0:hasPubAbstract "BACKGROUND: Communities of practice continue to gain in popularity across industry sectors as a method for improving organizational performance and a multi-faceted typology has emerged over time. However, the extant literature has little to say regarding how multiple communities, constellations and networks of practice can form around a central problem in an attempt to address a broad systemic issue.   OBJECTIVE: This article explores the contemporary challenges and limitations of the community of practice model and describes the approach one state took in employing a multi-faceted ‘Center of Practice’ to address the poor post-school outcomes of youth with disabilities who receive Supplemental Security Income (SSI).   CONCLUSION: The NYS PROMISE Center of Practice is described, as are perspectives on essential core elements, and propositions for consideration when implementing large systems level Centers of Practice to address challenges and limitations described in the literature with communities of practice. Lessons learned and implications for future research end this article."@en ;
    ns0:hasPubTitle "Centering communities, constellations and networks of practice to improve youth post-school outcomes through PROMISE"@en .

ns1:jvr-v51-i2-JVR191032 ns0:hasKeywords "SSI"@en,
        "Work incentives benefits counseling"@en,
        "disability"@en,
        "employment"@en,
        "transition-aged youth"@en ;
    ns0:hasPubAbstract "BACKGROUND: Work incentive benefits counseling has been shown to be a promising practice in vocational rehabilitation and has had a demonstrated impact on positive employment outcomes for adults with disabilities (Wilhelm & McCormick 2013).   OBJECTIVE: In this study, the Wisconsin Promoting the Readiness of Minors in Supplemental Security Income (PROMISE) demonstration project implemented a new model of work incentive benefits counseling targeting transition-age youth receiving Supplemental Security Income (SSI) benefits including their families.   METHODS: PROMISE youth and families received work incentive benefits counseling through a consultative approach and impact on employment outcomes were assessed.   RESULTS: Preliminary results indicate that youth who received work incentives benefits counseling (N = 535) had significantly higher work activity and explored a greater number of job opportunities, than youth who did not receive benefits counseling (N = 476). Additionally, 81% of PROMISE treatment youth with earnings above the Substantial Gainful Activity (SGA) level had met with a benefits specialist at least once.   CONCLUSION: This study contributes to the growing evidence demonstrating that work incentives benefits counseling positively influences employment and earnings outcomes for low-income transition-age youth with disabilities. Youth and families preferred the consultation approach, providing information as needed and meeting families where they were at."@en ;
    ns0:hasPubTitle "The impact of work incentives benefits counseling on employment outcomes of transition-age youth receiving Supplemental Security Income (SSI) benefits"@en .

ns1:jvr-v51-i2-JVR191035 ns0:hasKeywords "PROMISE"@en,
        "SSI"@en,
        "Youth with disabilities"@en,
        "transition from school to work"@en,
        "work experience"@en ;
    ns0:hasPubAbstract "BACKGROUND: One of the goals of PROMISE is to improve employment outcomes resulting in life-span reductions in youth reliance on SSI. Initial and prior employment is associated with long-term career trajectories for youth with disabilities. More research is needed to develop evidence-based practices that improve early employment outcomes for youth with disabilities receiving SSI benefits.   OBJECTIVE: We seek to provide information about the demographic and intervention factors associated with the successful completion of 200-hour, interest-based summer work experiences.   METHODS: Outcome data for 126 youth who participated in interest-based summer work experiences were collected. Regression analyses were conducted to explore associations between the number of hours worked and various discrete intervention variables.   RESULTS: Interest-based job placement, case management, and job readiness training were significant predictors of success in the summer work experience.   CONCLUSION: Particular aspects of service delivery, such as job readiness training, interest-based job placement, and personalized introductions to local workforce centers by case managers can significantly improve employment outcomes for youth with disabilities. State and federal agencies tasked with improving employment outcome for youth SSI recipients are provided substantiated justification to allocate resources that align with this evidence."@en ;
    ns0:hasPubTitle "Employment supports in early work experiences for transition-age youth with disabilities who receive Supplemental Security Income (SSI)"@en .

ns1:jvr-v51-i2-JVR191042 ns0:hasKeywords "enrollment"@en,
        "randomized clinical trials"@en,
        "recruitment"@en,
        "supplemental security income"@en,
        "transition-age youth with disabilities"@en ;
    ns0:hasPubAbstract "BACKGROUND: Recruiting and enrolling participants into randomized controlled trials is difficult. Reviews of the extent to which trials achieve targets on time and within budget commonly report failure or delay. PROMISE—Promoting Readiness of Minors in Supplemental Security Income (SSI)—a six program cooperative study of randomized trials testing effectiveness of service programs for transition-aged youth with disabilities receiving SSI benefits on employment and educational outcomes, provides an unusual opportunity to describe successful recruitment and enrollment into large-scale trials.   OBJECTIVE: The purpose is to profile recruitment strategies used within and across the six PROMISE programs for meeting enrollment targets of SSI youth and families.   METHODS: From descriptive data extracted from process analysis reports of each of the six PROMISE programs, we constructed cross-program profiles of recruitment strategies.   RESULTS: All six programs met their enrollment targets on time. Although they contacted most potential participants through initial mailings and telephone calls, the programs reported that multiple contacts using multiple strategies, especially resource-intensive in person meetings and assignment of staff full-time to recruitment activities, were needed to meet enrollment targets.   CONCLUSIONS: Because all PROMISE programs met their required enrollment targets, researchers designing large-scale, field-based randomized controlled trials may benefit from using a mix of recruitment strategies deployed by full-time recruiters."@en ;
    ns0:hasPubTitle "Strategies for recruiting participants into randomized controlled trials: A cross-program profile of the PROMISE demonstration program"@en .

ns1:jvr-v51-i3-JVR191046 ns0:hasKeywords "Autism spectrum disorder (ASD)"@en,
        "Vocational Rehabilitation (VR)"@en,
        "Workforce Innovation and Opportunity Act (WIOA)"@en,
        "law/legal issues"@en,
        "policy"@en,
        "transition"@en ;
    ns0:hasPubAbstract "BACKGROUND: The problem of persistently low rates of employment and earnings for people with autism is well established. In the U.S., the 2014 Workforce Innovation and Opportunity Act (WIOA) updated the legal framework for the federal Vocational Rehabilitation (VR) program which assists people with disabilities to find and maintain employment.   OBJECTIVE: This study examined whether and how the needs of transition-age youth and adults with autism are addressed in state WIOA plans.   METHODS: We analyzed WIOA documents for all states plus the District of Columbia using content analysis.   RESULTS: Of the 51 state plans, 44 contained references to autism, and 19 explicitly identified autism as a disability group that is underserved by the state VR agency. Even among states that clearly defined autism as underserved, only 10 provided comprehensive plans which defined goals and strategies to address the vocational needs of this group. We discuss major themes related to VR service delivery for people with autism identified within the state plans.   CONCLUSIONS: This study identifies state policy aimed at facilitating employment for people with autism and contributes to efforts to discover why individuals with autism in some states have better employment outcomes than in others."@en ;
    ns0:hasPubTitle "Employment policy and autism: Analysis of state Workforce Innovation and Opportunity Act (WIOA) implementation plans"@en .

ns1:kca-v3-i3-KCA190063 ns0:hasKeywords "Chromophobe"@en,
        "collecting duct"@en,
        "epidemiology"@en,
        "kidney cancer"@en,
        "papillary"@en ;
    ns0:hasPubAbstract "Background: While most renal cell carcinomas (RCC) are of the clear cell subtype, other histologic subtypes are well described and have distinct clinical behavior. This study seeks to evaluate survival of clear and non-clear cell RCC retrospectively from a large, population-based cancer registry.   Objectives: The key objectives of this study were to determine cancer-specific survival (CSS) and overall survival (OS) of RCC by histologic subtype and to examine survival by histologic subtype since the advent of anti-angiogenesis therapy in 2006.   Methods: Within the California Cancer Registry (CCR), we used multivariable Cox proportional hazards models to assess the association of histologic subtype with CSS and OS, adjusted for sociodemographic and clinical factors.   Results: In the CCR, 33,539 RCC patients were diagnosed between 2004 and 2014. The most common subtype, clear cell RCC, comprised 82.6% (n = 27,717) of cases. The next most common subtypes were papillary (8.8%, 2,948) and chromophobe (5.2%, 1,759). RCC was more common in men (62.9%, 21,097) compared to women (37.1%, 12,442). Across histologic subtypes, patients with low neighborhood socioeconomic status had lower CSS (HR = 1.07, 95% CI 1.02–1.13, p = 0.011) and OS (HR = 1.14, 95% CI: 1.10–1.19, p < 0.001). On multivariate analysis, we observed an interaction between histologic subtype and CSS, finding that patients in the anti-angiogenesis treatment era with clear cell had a significant improvement in CSS (HR: 0.87, 95% CI: 0.82–0.92, p < 0.001) as did patients with collecting duct subtype (HR: 0.25, 95% CI: 0.12–0.51, p < 0.001), while there were no differences in outcomes over time among patients with chromophobe or papillary subtypes. After 2006, compared to clear cell subtype, patients with chromophobe subtype had a better CSS (HR = 0.40, 95% CI: 0.30–0.53, p < 0.001), while those with collecting duct carcinomas had a poorer CSS (HR = 1.83, 95% CI: 1.29–2.59, p = 0.001).   Conclusions: In the era following anti-angiogenesis therapy development, patients with chromophobe subtype RCC continue to have a better prognosis compared with clear cell RCC, and patients with collecting duct subtype continue to have a significantly worse prognosis, with more advanced disease at diagnosis. There have been improvements in CSS in patients with clear cell and collecting duct subtypes since the advent of anti-angiogenesis therapy."@en ;
    ns0:hasPubTitle "Evolving Epidemiologic Trends of Renal Cell Cancer by Histologic Subtype: An Updated Analysis of the California Cancer Registry"@en .

ns1:kes-v23-i2-KES190402 ns0:hasKeywords "K-means clustering"@en,
        "Recommender system"@en,
        "data mining"@en,
        "item based collaborative filtering"@en ;
    ns0:hasPubAbstract "The heightening in the available information in the form of digital data and the number of users on the Internet have engendered a challenge of overburden of data which obstructs access to interested item on the Internet timely. There are many information retrieval systems which try to solve the problem of information overloading but in their cases prioritization and personalization of information were absent. The main aim is to develop a recommender system using item based collaborative filtering technique and K-means. The most popular algorithm in the recommender system’s field is the collaborative filtering technique. Recommender systems are the filtering systems for information that concerned with the problem of information overburden by filtering essential information fragment out of enormous dynamically promoted information according to person’s attentiveness, taste and distinguished behavior about them. We are considering m users, n items (in numbers) and presenting a model to fabricate a recommendation for the mobile user by a new approach."@en ;
    ns0:hasPubTitle "Recommender system using item based collaborative filtering (CF) and K-means"@en .

ns1:kes-v23-i2-KES190403 ns0:hasKeywords "Diabetes mellitus"@en,
        "adaboost"@en,
        "data mining"@en,
        "voting expert"@en ;
    ns0:hasPubAbstract "In this work, an efficient scheme has been proposed for the computer-aided detection of the wide-spread disease diabetes. This scheme involves certain data mining techniques for the purpose of detecting the chances of diabetes by looking into a patient’s medical record. This work attempts to classify the nature of diabetes (Type-I and Type-II) as well. It also tries to determine the level of risk associated presently with the affected patient. Four different algorithms namely decision tree, Naive Bayes, support vector machine (SVM), and Adaboost-M1 have been used for the purpose of labeling the records as either diabetic or non-diabetic. A comparison strategy is then followed to adopt the best scheme among these through the voting expert. The proposed work gives satisfactory diagnosis result when compared to the ground-truth data. Overall accuracy rate of 95% is achieved through k-fold cross-validation (k=10) method. Comparison of the proposed work with other state-of-the-art schemes has also been performed that favors the said work."@en ;
    ns0:hasPubTitle "A data mining scheme for detection and classification of diabetes mellitus using voting expert strategy"@en .

ns1:mas-v14-i3-MAS190464 ns0:hasKeywords "Frailty"@en,
        "gamma distribution"@en,
        "informative censoring mechanism"@en,
        "log-odd log-logistic Weibull"@en,
        "regression model"@en,
        "residual analysis"@en ;
    ns0:hasPubAbstract "One of the main characteristics of data from survival analysis is that the random variable of interest is not always observed, so that some observations are censored. The usual methods consider that these observations do not carry information about the distribution of the response variable (non-informative censoring). In other words, it is considered that an observation is censored simply by the fact that the event of interest (failure or death) did not occur during the period of study. However, in many situations, the survival time is clearly perturbed by the censoring mechanism, so the effect produced must be included in the analysis. The question is that once informative censoring is assumed to be non-informative, the results of the analysis can mask biases and thus weakening the model’s predictive power. Therefore, we consider the informative censoring mechanism in the odd-logistic Weibull regression model, based on the method described in Huang and Wolfe (2002), to analyze the variations which occur for estimating the model parameters. We obtain maximum likelihood estimates of the parameters by considering censored data and evaluate local influence on the estimates for different perturbation schemes. In addition, we define martingale and deviance residuals to detect outliers and evaluate the model assumptions. We show that the proposed regression model is useful to the analysis of real data and may give more realistic fits than other special regression models."@en ;
    ns0:hasPubTitle "The log-odd logistic-Weibull regression model under informative censoring"@en .

ns1:mgc-v15-i2-MGC196 ns0:hasKeywords "Hexacoordinate tin"@en,
        "antifertility"@en,
        "fungitoxicity"@en,
        "phenethylamine"@en,
        "synthesis"@en ;
    ns0:hasPubAbstract "A group of organotin(IV) complexes with thiohydrazones derived from phenethylamine were synthesised in 1:1 complexes. The following organotin(IV) complexes have been synthesized: (C6H5CH2)2Sn(L1)Cl2, (p-ClC6H4CH2)2 Sn(L2)Cl2, (C6H5CH2)2Sn(L2)Cl2, (C6H5CH2)2Sn(L3)Cl2, (p-ClC6H4CH2)2Sn(L3)Cl2, (C6H5CH2)2Sn(L4)Cl2, (C6H5CH2)3 Sn(L5)Cl, where L1 = benzaldehyde phenylethylamine N-thiohydrazone, L2 = salicylaldehyde phenylethylamine N-thiohydrazone, L3 = p-methylacetophenone phenylethylamine N-thiohydrazone, L4 = cinnamaldehyde phenylethylamine N-thiohydrazone and L5 = benzaldehyde 2-phenylethyl N-(2-phenylethyl-N-thio)-1,2-ethanediamine. The complexes were pure and characterized by elemental analysis and molecular weight determination studies. Infrared and multinuclear (1H, 13C, 119Sn NMR) spectra of the compounds are compatible with the presence of a neutral ligand attached to the metal through the S-C-N-N chelating system and formation of hexacoordinated tin complexes. Biological screenings for anti-tuberculosis, anti-fertility, anti-fungal (ED50) and anti-bacterial activity were performed. Using thermogravimetric (TGA) and differential thermal analysis (DTA) various thermodynamic and kinetic parameters were calculated including reaction order (n), apparent activation energy (Ea), apparent activation entropy (S#) and heat of reaction (ΔH) and correlated with the structural aspects for solid-state decomposition of complexes."@en ;
    ns0:hasPubTitle "Organotin(IV) complexes of thiohydrazones of phenethylamine: Synthesis, characterization, biological and thermal study"@en .

ns1:mgc-v18-i4-MGC180761 ns0:hasKeywords "Propargyl chloride"@en,
        "the Meyer reaction"@en,
        "the Strecker reaction"@en ;
    ns0:hasPubAbstract "Propargyl chloride, CH≡C–CH2Cl, was virtually inert towards NaH2AsO3, reacted to a very small extent with Na2HAsO3, but with Na3AsO3 gave a mixture of salts in which sodium 1-propynylarsonate, CH3–C≡C–AsO3Na2 6, predominated, the allenylarsonate, CH2 = C = CH–AsO3Na2 4, being present in (very) small amounts, while the isomeric 2-propynylarsonate CH≡C–CH2–AsO3Na2 5 was not detected. These results can be understood by attack of AsO33– on propargyl chloride to form 5 followed by base catalyzed prototropic rearrangements to 4 and to 6. Separation of 6 from 4 was tried as acids or salts without success. The purity of the product as acid 6 and lead salt of 6 was >80%. The reaction of propargyl chloride with Na2SO3 required dilute aqueous solutions (∼0.3 M) in order to give the salt CH≡C–CH2–SO3Na·4H2O, 11·4H2O, in ∼80% yields. More concentrated solutions (1 or 2 M) produced 11 and by-products from which CH2 = C = CH-SO3Na 10, but not CH3–C≡C–SO3Na 12, has been identified spectroscopically, while potassium 2-chloro-2-propenylsulfonate tetrahydrate CH2 = CCl–CH2–SO3K·4H2O, 13·4H2O, was isolated."@en ;
    ns0:hasPubTitle "The reaction of propargyl chloride with As(III) and S(IV) nucleophiles"@en .

ns1:mgs-v15-i2-MGS190307 ns0:hasKeywords "AGR (agent"@en,
        "AGR-based open MAS"@en,
        "AOP (Aspect Oriented Programming)"@en,
        "MaDKit"@en,
        "Open MAS"@en,
        "Run-Time Monitoring"@en,
        "group"@en,
        "role)"@en ;
    ns0:hasPubAbstract "In Open Multi-Agent Systems (Open MAS), no central authority can control all the agents. The agents share some features like: heterogeneity, different aims and objectives, autonomy, self-interested that conflicts individual goals and limited trust. Also, agents, in Open MAS, can enter and leave a system at any time. In order to ensure that the system carries out its goals, it must be observed and controlled. For that, it is necessary to define monitoring mechanisms for: (1) understanding and analyzing the system behavior, and (2) helping developers to review and examine, at run-time, agents’ communications and other different events (agents’ lifecycle, agent requested roles, performed actions by a given agent, etc.) generated during the system execution. In this paper, an AOP-based approach for monitoring Open MAS is proposed. The proposed approach is supported by RT-MTOMAS (Real-Time Monitoring Tool for Open Multi-Agent Systems), a new tool we developed for dealing with Open MAS monitoring issues. RT-MTOMAS provides, also, a behavioral model in order to illustrate agents’ interactions. The developed tool is illustrated through a concrete case study. We outlined its integration with MaDKit agent platform."@en ;
    ns0:hasPubTitle "Monitoring open multi-agent systems: An aspect-oriented programming based approach"@en .

ns1:mnm-v12-i2-MNM180278 ns0:hasKeywords "Anthropometry"@en,
        "children"@en,
        "diet"@en,
        "nutrient intake"@en ;
    ns0:hasPubAbstract "BACKGROUND: Nutrient patterns play a role as an interface between food patterns and the food metabolome integrating measurements. The nutrients can improve our knowledge about the reason of some chronic diseases.   OBJECTIVE The aim of the present study was to identify the major nutrient patterns in adolescents and to assess their relationship with obesity.   METHODS This is a nationwide cross-sectional study. Usual dietary intakes were collected using a validated 168-item semi-quantitative food frequency questionnaire (FFQ).   RESULTS Dietary data were analysed in 4288 subjects aged 11.43±3.23 years. Subjects in the fourth quartile of the first nutrient pattern tended to have higher weight, body mass index (BMI), waist circumference (WC) and hip circumference than those in the first quartile. Individuals in the fourth quartile of the second nutrient pattern had significantly lower means of weight, WC and hip circumference than those in the first quartile. The third nutrient pattern was not correlated with any alteration in BMI and wrist circumference in boys as well as in BMI, waist circumference and wrist circumference among girls.   CONCLUSIONS Findings indicated that second nutrient pattern which mostly characterized by high consumption in mono-unsaturated fatty acid, poly-unsaturated fatty acid, potassium, calcium, vitamin E, biotin and vitamin K was associated with lower risk of obesity, while first nutrient pattern with high amounts of carbohydrate, thiamin, iron and manganese was correlated with higher risk of obesity."@en ;
    ns0:hasPubTitle "Association of nutrient patterns with anthropometric indices in children and adolescents: The weight disorders survey of the CASPIAN-IV study"@en .

ns1:nha-v5-i2-NHA180056 ns0:hasKeywords "Blueberry plants"@en,
        "anthocyanins"@en,
        "cerebrovascular circulation"@en,
        "cognition"@en,
        "cognitive function"@en,
        "flavonoids"@en,
        "healthy aging"@en,
        "vascular endothelium"@en ;
    ns0:hasPubAbstract "BACKGROUND: Consumption of flavonoids, natural compounds found in foods such as berries and cocoa, have been shown to be beneficial for cognitive function. However, less is known about potential mechanisms and acute benefits for the older population.   OBJECTIVE: To determine whether acute intake of flavonoid-rich blueberry could have beneficial effects on cognitive function in a sample of healthy older adults and identify possible mechanisms.   METHODS: A cross-over randomised controlled trial (RCT) was conducted (N = 18) with volunteers receiving a flavonoid-rich blueberry beverage (579mg of antho- and pro-cyanidins) on one visit and a sugar-matched control on another. Cognitive function was measured at baseline, 2 and 5 hours post consumption of the intervention and blood pressure (BP), arterial stiffness and plasma brain-derived neurotrophic factor (BDNF) concentration at baseline and an hour post-intervention.   RESULTS: Whilst there was no significant effect of the intervention on global cognitive function, performance was significantly different at 2 compared to 5 hours following the control beverage (p < 0.05), with a decline in performance relative to baseline at 2 hours, whereas cognitive function improved following the blueberry beverage at both post intervention time points. There was also a trend towards the blueberry beverage attenuating the increase in systolic BP evident following the control drink (p = 0.08). Finally, there was a decrease in plasma concentration of BDNF post consumption of the control drink which was attenuated following the blueberry beverage, although not significantly (p > 0.05).   CONCLUSIONS: A single dose of flavonoid-rich blueberry could have a potentially protective effect on cognitive function in healthy older adults, possibly due to improved cerebrovascular function and positive interactions with cell signalling pathways involved in cognitive processes."@en ;
    ns0:hasPubTitle "Acute effects of flavonoid-rich blueberry on cognitive and vascular function in healthy older adults"@en .

ns1:nha-v5-i2-NHA180059 ns0:hasKeywords "Fear conditioning"@en,
        "SIRT1"@en,
        "aging"@en,
        "classically conditioned memory"@en,
        "hippocampus"@en ;
    ns0:hasPubAbstract "BACKGROUND: Sirtuin 1 (SIRT1) is a NAD+-dependent enzyme that has important roles in many biological processes involved in aging, including cell growth and repair, inflammation, and energy regulation. SIRT1 activity is modulated in response to certain nutritional interventions that increase healthspan and longevity in rodents, including calorie restriction (CR) and intermittent fasting (IF). In addition to positively influencing cardiometabolic health, SIRT1 is important for brain health and may be critical in the preservation of memory processes that deteriorate during aging.   OBJECTIVE: To investigate the role of brain-associated SIRT1 expression in the acquisition of fear memory in mice at 45 and 65 weeks of age.   METHODS: Mice with brain-specific knock-out or overexpression of Sirt1 were assessed on a fear conditioning paradigm to determine the role of SIRT1 in fear memory acquisition.   RESULTS: In the current study, mice lacking the expression of brain SIRT1 could not learn the fear conditioning paradigm during training, context, or cue phases.   CONCLUSIONS: The results of the study indicate that SIRT1 expression in the brain is critical for the formation of fear memory in male mice at two distinct ages, highlighting the essential role of SIRT1 in fear memory acquisition during aging."@en ;
    ns0:hasPubTitle "Central nervous system SIRT1 expression is required for cued and contextual fear conditioning memory responses in aging mice"@en .

ns1:nre-v44-i3-NRE182641 ns0:hasKeywords "Parkinson disease"@en,
        "boxing"@en,
        "exercise"@en,
        "intensity"@en,
        "participation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Exercise may modify disease progression in persons with Parkinson disease (PD).   OBJECTIVE: The purpose of this longitudinal cohort study was to determine factors that predict motor, activity, and participation-based outcomes over two years in exercisers with PD.   METHODS: A convenience sample with idiopathic PD was included in the analysis [n = 74; mean age 66.7(8.4) years; male 54%; median months post diagnosis 69.0(76.0), median Hoehn and Yahr score 1.0(2.0)]. Exercise behaviors (minutes of exercise/week, peak rate of perceived exertion (RPE) and mode of exercise) and outcomes of impairment [grip strength], activity [10-meter walk test, functional reach test, activity specific balance confidence scale] and participation [Parkinson Disease Questionnaire-39] were assessed at baseline, 6, 12, 18 and 24 months.   RESULTS: Using generalized estimating equations at least one exercise behavior was a significant predictor across most of the models (p≤0.026), with higher RPE predicting better outcomes in all activity and participation domains. Younger age, male gender and lower disease severity also significantly predicted better outcomes over time (p≤0.041).   CONCLUSIONS: Exercise behaviors contributed to activity and participation-based outcomes over two years in exercisers with PD. Participation in high-intensity exercise programs may enhance maintenance of health and function over time in individuals with PD."@en ;
    ns0:hasPubTitle "Predictors of outcomes in exercisers with Parkinson disease: A two-year longitudinal cohort study"@en .

ns1:nre-v44-i4-NRE192687 ns0:hasKeywords "Meta-analysis"@en,
        "Somatosensation"@en,
        "Somatosensory Rehabilitation"@en,
        "Stroke"@en,
        "Systematic Review"@en,
        "Upper Limb"@en ;
    ns0:hasPubAbstract "BACKGROUND: Research mainly focuses on motor recovery of the upper limb after stroke. Less attention has been paid to somatosensory recovery.   OBJECTIVE: To review and summarize the effect of upper limb somatosensory interventions on somatosensory impairment, motor impairment, functional activity and participation after stroke.   METHODS: Biomedical databases Ovid Medline, EMBASE, Web of Science, PEDro, and OTseeker were searched with an update in May 2018. Randomized controlled trials investigating the effect of somatosensory-specific interventions focusing on exteroceptive, proprioceptive or higher cortical somatosensory dysfunction, or any combination were eligible for inclusion. Quality of included studies were assessed using Physiotherapy Evidence Database (PEDro) scale. Standardized Mean Differences and Mean Differences and 95% confidence intervals were calculated and combined in meta-analyses.   RESULTS: Active somatosensory interventions did not show a significant effect on somatosensation and activity, but demonstrated a significant improvement in motor impairment (SMD = 0.73, 95% CI = 0.14 to 1.32). No study evaluating active somatosensory intervention included participation. Passive somatosensory interventions significantly improved light touch sensation (SMD = 1.13, 95% CI = 0.20 to 2.05). Passive somatosensory interventions did not show significant effects on proprioception and higher cortical somatosensation, motor impairment, activity and participation.   CONCLUSIONS: To date, there is low quality evidence suggesting active somatosensory interventions having a beneficial effect on upper limb impairment and very low quality evidence suggesting passive somatosensory interventions improving upper limb light touch sensation. There is a need for further well-designed trials of somatosensory rehabilitation post stroke."@en ;
    ns0:hasPubTitle "Effectiveness of somatosensory interventions on somatosensory, motor and functional outcomes in the upper limb post-stroke: A systematic review and meta-analysis"@en .

ns1:nre-v44-i4-NRE192700 ns0:hasKeywords "Nintendo Wii"@en,
        "Parkinson disease"@en,
        "rehabilitation"@en,
        "virtual reality"@en ;
    ns0:hasPubAbstract "BACKGROUND: Randomized clinical trials (RCTs) used the Nintendo Wii (NW) in the treatment of Parkinson Disease, however, no meta-analysis was developed to determine the effects in these patients.   OBJECTIVE: To analyze RCTs that investigated the effects of NW versus traditional physiotherapy on balance rehabilitation and quality of life of patients with PD.   METHODS: Electronic research was conducted between December 2018 and January 2019 in the MEDLINE, PEDro, CENTRAL, LILACS and SciELO databases. The methodological quality was evaluated by the PEDro scale and the completeness of the description of the interventions by the TIDieR checklist. Weighted mean differences (WMD) and 95% confidence interval (CI) were calculated.   RESULTS: Five studies were included and presented an average of 5.4 (1.5) on the PEDro scale and 6.7 (1.4) on the TIDieR. Compared to traditional physiotherapy, combined NW and traditional physiotherapy resulted in improvement in balance WMD 1.24 (95% CI: CI: 0.2 to 2.3 N = 72) and quality of life WMD– 8.9 (95% CI: –15.2 to –2.6 N = 56).   CONCLUSION: combined NW and traditional physiotherapy was more effective on balance rehabilitation and quality of life of patients with PD, but the values demonstrated a poor methodological quality and a low level of completeness of the intervention descriptions."@en ;
    ns0:hasPubTitle "Effects of the Nintendo Wii training on balance rehabilitation and quality of life of patients with Parkinson’s disease: A systematic review and meta-analysis"@en .

ns1:nre-v45-i1-NRE192725 ns0:hasKeywords "Cognitive assessment"@en,
        "electronic assessment"@en,
        "mobile technology"@en,
        "traumatic brain injury"@en ;
    ns0:hasPubAbstract "BACKGROUND: Electronic cognitive assessment tools present potential benefits for clinical practice; however, they warrant examination before use with clinical populations such as people with traumatic brain injury (TBI).   OBJECTIVE: The primary study purpose was to compare results from a tablet-based, electronic cognitive assessment to two paper cognitive assessments when administered to adults with TBI. We also explored the effect of iPad comfort on performance.   METHODS: We employed a quasi-experimental, correlational study design. Forty adults between 18 to 615 months post TBI completed the Standardized Touchscreen Assessment of Cognition (STAC), the Montreal Cognitive Assessment (MoCA), and the Cognitive Linguistic Quick Test (CLQT) in a systematically, counterbalanced order. We compared participants’ performance on these tools and examined the effect of iPad comfort.   RESULTS: Three STAC subtests had a good relationship with CLQT subtests: orientation, generative naming category, and generative naming first letter. A good relationship was also identified between two STAC and two MoCA subtests: orientation and generative naming first letter. People who were very comfortable using the iPad performed statistically better on the STAC first letter fluency item than participants who were not comfortable.   CONCLUSIONS: Moderate correlations suggest validity for some STAC items; however, modifications and further testing are needed."@en ;
    ns0:hasPubTitle "Touchscreen tablet-based cognitive assessment versus paper-based assessments for traumatic brain injury"@en .

ns1:nre-v45-i1-NRE192748 ns0:hasKeywords "Multiple sclerosis"@en,
        "motor training"@en,
        "rehabilitation"@en,
        "sleep"@en ;
    ns0:hasPubAbstract "BACKGROUND: Sleep disturbances are highly prevalent in people with multiple sclerosis(MS), and are associated with pain, fatigue, depression, and reduced quality of life (QoL). Importantly, sleep has been considered a critical brain state for motor learning and memory consolidation. Therefore, interventions that target sleep managementin people with MS are needed.   OBJECTIVES: To explore the effects of a six weeks moderate-intensity aerobic exercise intervention on sleep characteristics and sleep-related biomarkers specifically serotonin, melatoninand cortisol in people with MS using a pilot randomized controlled trial.   METHODS: Participants were randomly allocated to either a moderate-intensity aerobic exercise program (MAE, n = 20) or a home exercise program (HEP, n = 20). Participants were assessed at baseline and follow-up. Subjective and objective measures were used to assess sleep quality. The Pittsburgh Sleep Quality Index (PSQI) and Insomnia Severity Index (ISI) were used to subjectively assess sleep. While Actigraphy was used to objectivelyassess sleep. Blood samples were collected for measurement of cortisol, melatonin and serotonin from MS participants in both groups at 8:00 am±1 hour.   RESULTS: Seventeen participants in the MAE and 13 in the HEP group completed the study. Compared to the HEP group, people with MS who participated in a moderate-intensity aerobic exercise experienced significant improvements (P < 0.05) on the PSQI, ISI, and several objective sleep parameters measured using actigraphy. Only the serotonin levels increased significantly over the six-week period in the MAE group compared to the HEP group. The change score in serotonin (from baseline to follow up assessment) was significantly correlatedwith the change score in PSQI (r = –0.97, p < 001) and the change score in ISI (r = –0. 56, p = 0.015) only in the MAE group but not the HEP group.   CONCLUSIONS: Exercise may be a non-pharmacological, inexpensive, safe method to improve sleep quality in people with MS. The improvement in the serotonin level due to aerobic exercisemight explain one of the physiologic mechanisms driving these improvements."@en ;
    ns0:hasPubTitle "The effects of aerobic exercise on sleep quality measures and sleep-related biomarkers in individuals with Multiple Sclerosis: A pilot randomised controlled trial"@en .

ns1:nre-v45-i2-NRE192771 ns0:hasKeywords "Parkinson’s disease"@en,
        "conventional exercises"@en,
        "rehabilitation"@en,
        "virtual reality"@en ;
    ns0:hasPubAbstract "BACKGROUND: Studies have demonstrated that the combination of Nintendo Wii (NW) with Conventional Exercises (CE) was effective in the rehabilitation of patients with Parkinson’s Disease (PD), but there are no studies comparing the effects of this combination on both techniques isolated.   OBJECTIVE: To investigate if the effects of the combination of NW to CE are superior to isolated techniques in the rehabilitation of balance, gait, functional mobility and improvement of the quality of life of individuals with PD.   METHODS: 45 patients with PD were divided into three groups, NW alone, CE alone and NW plus EC. The sessions occurred for 50 minutes, twice a week and evaluations administered before and after the 2-month intervention.   RESULTS: Significant differences were found in the pre and post intervention analyzes of all the outcomes in the three groups, but there was no difference between the groups. The effect size was evaluated, in which the NW plus CE group had a greater magnitude of the therapeutic effect.   CONCLUSION: The NW plus CE was statistically as effective as each intervention alone in the rehabilitation of patients with PD, however, the use of this combination provided a magnitude of the therapeutic effect superior to the other groups."@en ;
    ns0:hasPubTitle "Efficacy of the Nintendo Wii combination with Conventional Exercises in the rehabilitation of individuals with Parkinson’s disease: A randomized clinical trial"@en .

ns1:nre-v45-i2-NRE192778 ns0:hasKeywords "Robot-Assisted Gait Training"@en,
        "Stroke"@en,
        "end-effector device"@en,
        "neurologic gait disorders"@en,
        "rehabilitation"@en ;
    ns0:hasPubAbstract "BACKGROUND: End-effector robots allow intensive gait training in stroke subjects and promote a successful rehabilitation. A comparison between conventional and end-effector Robot-Assisted Gait Training (RAGT) in subacute stroke patients is needed.   OBJECTIVE: To investigate the efficacy of end-effector RAGT in subacute stroke patients.   METHODS: Twenty-six subacute stroke patients were divided into two group: 14 patients performed RAGT (RG); 12 patients performed conventional gait training (CG). Clinical assessment and gait analysis were performed at the beginning (T0) and at the end (T1) of the rehabilitation.   RESULTS: The RG revealed a significant improvement in body function, activities, participation scales, and in the distance measured with the 6 MWT. The affected lower limb’s spasticity significantly decreased at T1. In gait analysis, RG showed significantly increases in many parameters. The CG significantly improved clinical assessments but showed no significant changes in gait parameters. Statistically significant differences between RG and CG were found in MRC-HE, TCT, 10 MWT, 6 MWT, and TUG. No significant difference between groups was registered in gait kinematics.   CONCLUSIONS: Both rehabilitation treatments produce promising effects in subacute stroke patients. RAGT device offers a more intensive, controlled, and physiological gait training and significantly improved deambulation."@en ;
    ns0:hasPubTitle "Efficacy of end-effector Robot-Assisted Gait Training in subacute stroke patients: Clinical and gait outcomes from a pilot bi-centre study"@en .

ns1:nre-v45-i2-NRE192801 ns0:hasKeywords "Parkinson’s disease"@en,
        "Walking agility"@en,
        "clinical test"@en,
        "discriminative properties"@en,
        "risk of falling"@en ;
    ns0:hasPubAbstract "BACKGROUND: Clinical tests that can discriminate between people at risk of falling and those not at risk are warranted. The discriminative properties of the Six-Spot Step Test was investigated in people with Parkinson’s disease at risk of falling.   METHODS: Eighty-one participants with a median age of 69 years (Q1–Q3:63–74) and a median Hoehn and Yahr score of 2.5 (Q1–Q3:2–3) completed the Six-Spot Step Test and the Timed “Up and Go” test. A mini-BESTest score of 19 or below was used as a cut-off for defining risk of falling, and a receiver operating characteristics curve was generated to determine clinical relevant cut-off scores.   RESULTS: A cut-off score of 7.0 and 6.8 seconds identified people not at risk of falling, while 11.1 and 9.4 seconds identified people at risk of falling for the Six-Spot Step Test and the Timed “Up and Go” test, respectively. When maximizing the sensitivity and specificity a cut-off score of 9.2 (accuracy of 84%) and 8.1 seconds (accuracy of 70%) was found for the Six-Spot Step Test and the Timed “Up and Go” test, respectively.   CONCLUSION: The Six-Spot Step Test discriminates accurately between people with Parkinson’s disease at risk of falling and people not at risk."@en ;
    ns0:hasPubTitle "A study of the discriminative properties of the Six-Spot Step Test in people with Parkinson’s disease at risk of falling"@en .

ns1:rnn-v37-i3-RNN190909 ns0:hasKeywords "Excitotoxicity"@en,
        "NMDA"@en,
        "glutamate"@en,
        "hippocampus"@en,
        "traumatic brain injury"@en ;
    ns0:hasPubAbstract "Background: Altered glutamatergic neurotransmission after traumatic brain injury (TBI) contributes to excitotoxic cell damage and death. Prevention or suppression of such changes is a desirable goal for treatment of TBI. Memantine (3,5-dimethyl-1-adamantanamine), an uncompetitive NMDA receptor antagonist with voltage-dependent open channel blocking kinetics, was reported to be neuroprotective in preclinical models of excitotoxicity, brain ischemia, and in TBI when administered prophylactically, immediately, or within minutes after injury.  Methods: The current study examined effects of memantine administered by single intraperitoneal injection to adult male rats at a more clinically relevant delay of one hour after moderate-severe controlled cortical impact (CCI) injury or sham surgery. Histopathology was assessed on days 1, 7, 21, and 90, vestibulomotor function (beam balance and beam walk) was assessed on days 1–5 and 71–75, and spatial memory (Morris water maze test, MWM) was assessed on days 14–21 and 83–90 after CCI injury or sham surgery.  Results: When administered at 10 mg/kg, but not 2.5 or 5 mg/kg, memantine preserved cortical tissue and reduced neuronal degeneration 1 day after injury, and attenuated loss of synaptophysin immunoreactivity in the hippocampus 7 days after injury. No effects of 10 mg/kg memantine were observed on histopathology at 21 and 90 days after CCI injury or sham surgery, or on vestibulomotor function and spatial memory acquisition assessed during any of the testing periods. However, 10 mg/kg memantine resulted in trends for improved search strategy in the MWM memory retention probe trial.  Conclusions: Administration of memantine at a clinically-relevant delay after moderate-severe CCI injury has beneficial effects on acute outcomes, while more significant improvement on subacute and chronic outcomes may require repeated drug administration or its combination with another therapy."@en ;
    ns0:hasPubTitle "Acute and chronic effects of single dose memantine after controlled cortical impact injury in adult rats"@en .

ns1:rnn-v37-i4-RNN190910 ns0:hasKeywords "Exosomes"@en,
        "cortical injury"@en,
        "recovery"@en,
        "rhesus monkey"@en ;
    ns0:hasPubAbstract "Background: Exosomes from mesenchymal stromal cells (MSCs) are endosome-derived vesicles that have been shown to enhance functional recovery in rodent models of stroke.   Objective: Building on these findings, we tested exosomes as a treatment in monkeys with cortical injury.   Methods: After being trained on a task of fine motor function of the hand, monkeys received a cortical injury to the hand representation in primary motor cortex. Twenty-four hours later and again 14 days after injury, monkeys received exosomes or vehicle control. Recovery of motor function was followed for 12 weeks.   Results: Compared to monkeys that received vehicle, exosome treated monkeys returned to pre-operative grasp patterns and latency to retrieve a food reward in the first three-five weeks of recovery.   Conclusions: These results provide evidence that in monkeys exosomes delivered after cortical injury enhance recovery of motor function."@en ;
    ns0:hasPubTitle "Mesenchymal derived exosomes enhance recovery of motor function in a monkey model of cortical injury"@en .

ns1:sw-v10-i5-SW190362 ns0:hasKeywords "Deep neural network"@en,
        "geo data"@en,
        "ontocity"@en,
        "ontological and spatial reasoning"@en,
        "semantic referee"@en,
        "semantic segmentation"@en ;
    ns0:hasPubAbstract "Understanding why machine learning algorithms may fail is usually the task of the human expert that uses domain knowledge and contextual information to discover systematic shortcomings in either the data or the algorithm. In this paper, we propose a semantic referee, which is able to extract qualitative features of the errors emerging from deep machine learning frameworks and suggest corrections. The semantic referee relies on ontological reasoning about spatial knowledge in order to characterize errors in terms of their spatial relations with the environment. Using semantics, the reasoner interacts with the learning algorithm as a supervisor. In this paper, the proposed method of the interaction between a neural network classifier and a semantic referee shows how to improve the performance of semantic segmentation for satellite imagery data."@en ;
    ns0:hasPubTitle "Semantic referee: A neural-symbolic framework for enhancing geospatial semantic segmentation"@en .

ns1:thc-v27-iS1-THC199007 ns0:hasKeywords "Fuzzy logic"@en,
        "automatic report generation"@en,
        "decision support system"@en,
        "individualized medical advices"@en ;
    ns0:hasPubAbstract "In 2005, global cardiovascular diseases caused 30% of deaths in Europe, which is 46% of total deaths for all death groups. Today, according to the International Adult Diabetes Federation, 20% to 25% of the adult population in the world has Metabolic Syndrome. Turkish Statistical Institute claims that in Turkey 408782 people died of circulatory system diseases in 2016 and it is expected that numbers will dramatically increase. In 2003, total worldwide healthcare budget of Diabetes Mellitus was up to 64.9 billion International Dollars with the continuing rise in prevalence, it is expected that total costs will increase to 396 billion International Dollars by 2025.  The main purpose of this study was to present a clinical decision support system that calculates Metabolic Syndrome existence and evaluate HeartScore risk level for Turkish population. The second objective was to create a detailed personal report about individual’s risk level of Metabolic Syndrome and HeartScore and give advice to him/her to reduce it. The fuzzy logic risk assessment system (FLRAS) was formed in LabVIEW graphical development platform according to International Diabetes Federation and European Heart Journal’s criteria. Mamdani type fuzzy logic sets were identified for each input variable and membership functions were assigned depending on the magnitude of the input limits. System’s performance was tested on 96 (72 females, 24 males) patient data. Results show that the proposed system was able to evaluate the Metabolic Syndrome risk with 0.9285 specificity, 0.92708 accuracy and 0.925 sensitivity."@en ;
    ns0:hasPubTitle "Fuzzy logic based risk assessment system giving individualized advice for metabolic syndrome and fatal cardiovascular diseases"@en .

ns1:thc-v27-iS1-THC199009 ns0:hasKeywords "Bayesian information criterion"@en,
        "Biomarker selection"@en,
        "Log-sum regularization"@en,
        "path seeking scheme"@en ;
    ns0:hasPubAbstract "Biomarker selection or feature selection from survival data is a topic of considerable interest. Recently various survival analysis approaches for biomarker selection have been developed; however, there are growing challenges to currently methods for handling high-dimensional and low-sample problem. We propose a novel Log-sum regularization estimator within accelerated failure time (AFT) for predicting cancer patient survival time with a few biomarkers. This approach is implemented in path seeking algorithm to speed up solving the Log-sum penalty. Additionally, the control parameter of Log-sum penalty is modified by Bayesian information criterion (BIC). The results indicate that our proposed approach is able to achieve good performance in both simulated and real datasets with other ℓ1 type regularization methods for biomarker selection."@en ;
    ns0:hasPubTitle "A novel Log penalty in a path seeking scheme for biomarker selection"@en .

ns1:thc-v27-iS1-THC199010 ns0:hasKeywords "Effective dose"@en,
        "TLD"@en,
        "cardiac interventional examination"@en,
        "phantom"@en,
        "semi-empirical formula"@en ;
    ns0:hasPubAbstract "BACKGROUND: Effective and skin doses gain much attention since the cardiac catheterization laboratory (CCL) is a place where both patients and medical staff are exposed to X-ray or fluoroscopy environment and gain a cumulative dose during the cardiac interventional procedure.   OBJECTIVE:  These doses for pediatric and adult patients undergone cardiac interventional examination using five PMMA phantoms and thermoluminescence dosimeter (TLD)/ionization chamber technique were estimated in this work with the further clinical verification.   METHODS:  Five PMMA phantoms (10, 30, 50, 70, and 90 kg) were customized to represent baby, child, adult female, adult male, and overweight adult (by Asian complexion standards), respectively, in accordance with the ICRU-48 report. Each phantom could be disassembled into 31 plates to insert TLD chips for measuring X-ray exposed dose or assisted with an auxiliary plate to insert high-sensitivity ionization chamber for surveying low-energy fluoroscopy dose.   RESULTS:  The data acquired from five phantoms were integrated into four semi-empirical formulas, in order to fit the binary quadratic form “Dose = A⋅BMI2+B⋅DAP2+C⋅BMI+ D⋅DAP+E”. The latter linked the X-ray and fluoroscopy effective/skin doses, respectively, with a high coefficient of determination R2(from 0.888 to 0.986).   CONCLUSIONS: The model refinement with DAP share adjustment is envisaged."@en ;
    ns0:hasPubTitle "Estimation and clinical verification of the effective and skin doses for pediatric and adult patients undergoing the cardiac interventional examination using five PMMA phantoms and TLD/ionization chamber technique"@en .

ns1:thc-v27-iS1-THC199031 ns0:hasKeywords "Apoptosis"@en,
        "coated balloons"@en,
        "gefitinib"@en,
        "paclitaxel"@en,
        "proliferation"@en,
        "restenosis"@en ;
    ns0:hasPubAbstract "OBJECTIVE:  To explore the effect of gefitinib-coated balloon suppressive action on the excessive hyperplasia of intima after balloon injury of common carotid artery in rats and on the PI3K/AKT signal pathway.   METHODS:  MTT method and the expression of Bcl-2 and Caspase-3 proteins were detected in vitro; Adult SD rats were randomly split into 5 groups, namely sham group, model group, low-dosage gefitinib-coated balloon group, high-dosage gefitinib-coated balloon group, and paclitaxel-coated balloon group. The intimal proliferation of arteries, PCNA, P-AKT and PI3K protein expression, the cell apoptosis, expression of MMP9, TGFβ and IL6 mRNA were measured by hematoxylin and eosin (H&E) staining, immunohistochemistry, TUNEL staining, and RT-qPCR.   RESULTS:  At the same time and concentration, Gefitinib suppressed the proliferation of smooth muscle cell more significantly than paclitaxel. Bcl-2 and Caspase-3 in vascular smooth muscle and endothelial cells (VSMC, EC) were significantly down-regulated and up-regulated after the cells were treated with gefitinib and paclitaxel. In gefitinib- and paclitaxel-coated balloon groups, significant up-regulations were found in the area of lumen. Furthermore, the expression of PCNA suggested that all coated balloons could suppress the excessive proliferation of smooth muscle cells in the hyperplastic intima compared with the control group. In gefitinib- and paclitaxel-coated balloon group, the expression of PI3K/AKT was significantly down-regulated. The use of drug-coated balloons mitigated the cell apoptosis in TUNEL. The expressions of MMP9, TGFβ and IL6 mRNA in the model group were obviously up-regulated; and they were obviously down-regulated in the high-dose gefitinib-coated balloon group compared with the model group.   CONCLUSIONS:  Gefitinib-coated balloons were able to suppress the excessive proliferation in the common carotid arterial intima of rats more effectively than the paclitaxel-coated ones. The underlying mechanism may cover the PI3K/AKT signal pathway."@en ;
    ns0:hasPubTitle "Gefitinib-coated balloon inhibits the excessive hyperplasia of intima after vascular injuries through PI3K/AKT pathway"@en .

ns1:thc-v27-iS1-THC199039 ns0:hasKeywords "Actuator"@en,
        "electromagnetic"@en,
        "finite element method"@en,
        "implantable bone conduction hearing device"@en ;
    ns0:hasPubAbstract "BACKGROUND:  This paper describes the design and implementation of a dual-coil type electromagnetic actuator for implantable bone conduction hearing devices.   OBJECTIVE:  The structure of the proposed actuator was designed to generate maximum Lorentz force via the dual-coil method with a closed magnetic circuit. To satisfy the indications required by implantable bone conduction hearing devices, high output was generated within a specific frequency range using a vibrational membrane with a cantilever.   METHODS:  The structure of the membrane consists of a fixed ring, a circular plate, and two cantilevers connected symmetrically. Variable elements of the vibrational membrane affecting the actuator frequency characteristics were analyzed through mathematical modeling and finite element analysis, based on the analysis used to derive the optimum structure of the vibrational membrane. The components of the actuator were fabricated through chemical etching and computer numerical control process, and the bone conduction actuator was fabricated through the precision assembly process.   RESULTS:  The output characteristics of the implemented actuator were measured using a laser Doppler vibrometer. As a result of measurement, the proposed actuator generated mechanical resonance at 1.2 kHz.   CONCLUSIONS:  By comparing the measured results with the finite element analysis results, we confirmed the validity of the proposed actuator design."@en ;
    ns0:hasPubTitle "Design of a dual-coil type electromagnetic actuator for implantable bone conduction hearing devices"@en .

ns1:ves-v29-i2-3-VES190655 ns0:hasKeywords "Bárány Society"@en,
        "Orthostatic vertigo"@en,
        "autonomic dysfunction"@en,
        "classification"@en,
        "hemodynamic"@en,
        "orthostatic dizziness"@en,
        "orthostatic hypotension"@en,
        "postural tachycardia syndrome"@en ;
    ns0:hasPubAbstract "This paper presents the diagnostic criteria for hemodynamic orthostatic dizziness/vertigo to be included in the International Classification of Vestibular Disorders (ICVD). The aim of defining diagnostic criteria of hemodynamic orthostatic dizziness/vertigo is to help clinicians to understand the terminology related to orthostatic dizziness/vertigo and to distinguish orthostatic dizziness/vertigo due to global brain hypoperfusion from that caused by other etiologies. Diagnosis of hemodynamic orthostatic dizziness/vertigo requires: A) five or more episodes of dizziness, unsteadiness or vertigo triggered by arising or present during upright position, which subsides by sitting or lying down; B) orthostatic hypotension, postural tachycardia syndrome or syncope documented on standing or during head-up tilt test; and C) not better accounted for by another disease or disorder. Probable hemodynamic orthostatic dizziness/vertigo is defined as follows: A) five or more episodes of dizziness, unsteadiness or vertigo triggered by arising or present during upright position, which subsides by sitting or lying down; B) at least one of the following accompanying symptoms: generalized weakness/tiredness, difficulty in thinking/concentrating, blurred vision, and tachycardia/palpitations; and C) not better accounted for by another disease or disorder. These diagnostic criteria have been derived by expert consensus from an extensive review of 90 years of research on hemodynamic orthostatic dizziness/vertigo, postural hypotension or tachycardia, and autonomic dizziness. Measurements of orthostatic blood pressure and heart rate are important for the screening and documentation of orthostatic hypotension or postural tachycardia syndrome to establish the diagnosis of hemodynamic orthostatic dizziness/vertigo."@en ;
    ns0:hasPubTitle "Hemodynamic orthostatic dizziness/vertigo: Diagnostic criteria"@en .

ns1:wor-v63-i4-WOR192952 ns0:hasKeywords "Risk stratification"@en,
        "adverse events"@en,
        "blood pressure screening"@en,
        "physically demanding occupations"@en ;
    ns0:hasPubAbstract "OBJECTIVE: The purpose of this study was to examine the impact of applying six commonly-used and two proposed resting blood pressure (BP) cut-points to clear individuals for maximal exercise in non-clinical health, wellness, commercial fitness agencies and physically demanding occupation test sites.   METHODS: Participants (n = 1670) completed the Physical Activity Readiness Questionnaire for Everyone (PAR-Q+) and had their resting BP measured. Individuals with a BP >160/90 mmHg were further screened for contraindications to exercise using the ePARMed-X+ (www.eparmedx.com), all 1670 were cleared. There were no adverse events during or post exercise.   RESULTS: The percentages of participants cleared for each BP cut-point were: <130/80 mmHg (85.3%), <140/90 mmHg (93.4%), <144/90 mmHg (94.6%), <144/94 mmHg (96.3%), <150/100 mmHg (98.6%), <160/90 mmHg (95.6%), <160/94 mmHg (97.8%) and <160/100 mmHg (99.5%). Individuals who would not have been cleared without further screening were significantly older, had a higher BMI, or had a lower maximal oxygen consumption.   CONCLUSIONS: Conservative or lower resting BP cut-points currently applied to clear individuals for maximal exercise provide an unnecessary barrier. For individuals categorized as low-to- moderate risk by evidence-based screening tools such as the PAR-Q+ and ePARmed-X+, we recommend a resting BP cut-point of <160/94 mmHg to clear for maximal exercise until sufficient evidence is amassed to support the increase to <160/100 mmHg."@en ;
    ns0:hasPubTitle "Impact of applying different resting blood pressure cut-points to clear for maximal exercise"@en .

ns1:wor-v64-i1-WOR192947 ns0:hasKeywords "Slips"@en,
        "falls"@en,
        "footwear"@en,
        "homecare workers"@en,
        "icy surfaces"@en,
        "outdoor workers"@en ;
    ns0:hasPubAbstract "BACKGROUND: Falls are among the leading causes of occupational injuries for workers exposed to outdoor winter conditions such as Personal Support Workers (PSWs). Slip resistant footwear is known to reduce the risk of falls, however, it is difficult to predict how well a particular boot will perform prior to purchasing them. Our recently developed Maximum Achievable Angle (MAA) test can be used to rate footwear objectively to address this gap.   OBJECTIVE: To rate the slip resistance of a selection of winter footwear that meets the needs and preferences of PSWs.   METHODS: We selected 40 representative types of footwear based on survey results from 677 PSWs and applied our MAA test to rate slip resistance.   RESULTS: Comfort and slip resistance were rated the most important features for selecting winter footwear. Of the 40 types of footwear tested, six were found to have a good slip resistance on ice.   CONCLUSION: The vast majority of winter footwear that meet the needs and preferences of PSWs, perform poorly on ice. Therefore, PSWs should consult our website (ratemytreads.com) for selecting appropriate footwear that will keep them safe in the winter."@en ;
    ns0:hasPubTitle "Selecting slip resistant winter footwear for personal support workers"@en .

ns1:wor-v64-i1-WOR192968 ns0:hasKeywords "Interaction effect"@en,
        "coping strategy"@en,
        "social support"@en,
        "work stress"@en ;
    ns0:hasPubAbstract "BACKGROUND: Work-related psychosocial factors such as job strain are thought to contribute to elevated psychological stress in office workers. One factor that may impact the relationship between job strain and psychological distress is the individual’s coping resources.   OBJECTIVE: The purpose of this study is to examine the interaction effect of coping resources on the relationship between job strain and psychological distress in office workers.   METHODS: 220 office workers in Australia and Korea completed the Job Content Questionnaire (to evaluate job strain and social support at work), the Depression, Anxiety, and Stress Scale, (DASS-21, a measure of psychological distress), and the Coping with Job Stress Scale to assess control and escape coping. Hierarchical regression analyses were executed to examine the interaction and moderating effect of coping resources.   RESULTS: Job strain had a direct positive relationship with all three domains of psychological distress. The relationship between job strain and depression was positively moderated by escape coping, but negatively moderated by social support. Use of higher levels of escape coping predicted higher levels of depression and anxiety symptoms when higher levels of job strain were perceived.   CONCLUSIONS: Findings suggest there may be a direct relationship between job strain and psychological distress in office workers. This relationship, however, may be moderated by the office workers coping resources (coping strategies and social support). It is suggested that the evaluation of coping might be a key consideration in the elements of the assessment of psychological distress in office workers."@en ;
    ns0:hasPubTitle "Job strain and psychological distress in office workers: The role of coping"@en .

ns1:wor-v64-i1-WOR192975 ns0:hasKeywords "Return to work"@en,
        "non-participant observation"@en,
        "person-environment fit"@en,
        "person-job fit"@en,
        "vocational counseling"@en,
        "work participation"@en,
        "work rehabilitation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Matching an individual’s capabilities, interests and needs with corresponding job demands and characteristics is an established procedure in vocational rehabilitation (VR). Yet, a systematic exposition of specific factors affecting the determination and attainment of a person-job match in VR practice is currently missing.   OBJECTIVE: To examine factors, assessments and interventions related to job matching (JM) in VR of persons with spinal cord injury (SCI) by using a literature-based conceptual JM framework.   METHODS: Applying a qualitative descriptive design, data were collected by overt non-participant observations across the VR process of two individuals with SCI, representing major return-to-work scenarios (returning to the pre-injury job and preparing for vocational retraining).   RESULTS: Person-related, job-related and environmental factors were identified that either played a direct or indirect role in determining and attaining a person-job match. The factors were evaluated by different work-related and medical assessments and were targeted by a number of JM-related interventions.   CONCLUSIONS: While our conceptual framework may serve as a generic blueprint to facilitate JM approaches in VR practice, the specific factors identified in our study are particularly valuable for developing JM applications aimed at promoting sustainable return to work for persons with SCI."@en ;
    ns0:hasPubTitle "Factors, assessments and interventions related to job matching in the vocational rehabilitation of persons with spinal cord injury"@en .

ns1:wor-v64-i1-WOR192976 ns0:hasKeywords "Accidents"@en,
        "risk management"@en,
        "safety design"@en,
        "safety interventions and prevention"@en,
        "technical solutions"@en ;
    ns0:hasPubAbstract "BACKGROUND: The paper is a research review focusing on occupational safety in the construction industry.   OBJECTIVE: The purpose is to present research that highlights the areas of occupational safety and risks and to identify areas where research is lacking.   METHODS: 146 articles from scientific journals, mainly covering the construction industry in Europe, Canada, USA, Australia and Japan have been studied. The findings are presented under 11 categories: accident statistics; individual factors; legislation and regulations; ethical considerations; risk management; leadership, management, organization; competence; safety design; cost-benefit calculations; programs and models; and technical solutions.   RESULTS: The research is dominated by initiatives from researchers and government authorities, while the construction industry only appears as the object for the research. There is a scarcity of research on integrated systems encompassing subcontractors, as well as a lack of research with sociological perspectives on accidents. Furthermore, only a few studies have applied a gender perspective on safety in construction, i.e. there is a need of further research in this particular area.   CONCLUSIONS: A range of initiatives have been taken to increase safety in the construction industry and the initiatives are mainly reported to be successful. There are some cultural differences, but basically researchers present similar results regardless of country."@en ;
    ns0:hasPubTitle "Occupational safety in the construction industry"@en .

ns1:wor-v64-i2-WOR192989 ns0:hasKeywords "Welfare"@en,
        "disability pensions"@en,
        "employment"@en,
        "social assistance"@en ;
    ns0:hasPubAbstract "BACKGROUND: Active labour market policies (ALMP) are used in advanced welfare states to support transitions to work for people who are unemployed or underemployed, including people with disabilities (PWD) in receipt of means-tested disability income support.   OBJECTIVE: This study explores the nature, strength, and limitations of ALMP across advanced welfare states (ALMP) for people with disabilities (PWD) in receipt of income benefits from social assistance programs.   METHODS: Following the eight steps of a scoping study, we identified 21 documents through a scan of eight databases and consultation with key informants. The majority of these documents are scholarly publications including seven literature reviews, two program evaluations, four social policy analyses, and two longitudinal studies.   RESULTS: We extracted key findings related to delivery of labour (re)entry interventions for people with disabilities. Six themes are identified that discuss these ALMP features: 1) welfare ideology and the role of citizenship; 2) conditionality of benefits; 3) work capacity and the need for an appropriate definition of disability; 4) the politics of employment outcomes for PWD; 5) the missing elements of a successful ALMP; and 6) moving beyond ALMP. The findings indicate that while various approaches are used in reintegrating PWD into mainstream employment, there are significant limitations that curtail the impact of these policies.   CONCLUSIONS: Regardless of welfare regime, no welfare state provides a policy mix that results in long-term employment success for PWD in receipt of means-tested income benefits."@en ;
    ns0:hasPubTitle "Active labour market policies for people with disabilities in receipt of public income benefits: A scoping review"@en .

ns1:wor-v64-i3-WOR193011 ns0:hasKeywords "Vocational rehabilitation"@en,
        "mental illness"@en,
        "occupational health"@en,
        "occupational therapy"@en ;
    ns0:hasPubAbstract "BACKGROUND: Research is needed on how to optimize the return-to-work process for persons with mental health problems.   OBJECTIVE: To develop a model that explains how employer and rehabilitation professional mental health literacy may influence strategies used in the return-to-work of persons with mental health problems.   METHODS: A grounded theory study design was used to collect and analyse interview data from 23 employers and 22 rehabilitation professionals.   RESULTS: The analysis resulted in four categories, illustrated in a conceptual process model: 1) seeing mental health problems through past experiences; 2) separating understandable and incomprehensible mental health problems; 3) balancing safeguarding one’s personal interest with providing adequate support; and 4) facing conflicts and uncertainty in employee/service user return-to-work. A positional map of employer/rehabilitation types was created based on level of negative attitudes and uncertainty in supporting employees/service users and the employer in relation to the level of comprehensive understanding of mental health problems.   CONCLUSIONS: Professional mental health literacy needs to be increased. Interventions need to be developed that provide employers with targeted support and knowledge in mental health literacy. Education on how to prevent and detect common mental health problems in the workplace is needed."@en ;
    ns0:hasPubTitle "Exploring the service and knowledge gap between rehabilitation professionals and employers in the return-to-work process of people with mental health problems in Sweden"@en .

ns1:wor-v64-i3-WOR193015 ns0:hasKeywords "Elementary school screening"@en,
        "spinal mouse device"@en,
        "spine deformities"@en ;
    ns0:hasPubAbstract "BACKGROUND: Sagittal spine curvature deformities are common among elementary school students due to long malposition and lack of physical activity.   OBJECTIVES: This study aims to compare sagittal spine deformities among first graders (young and elder school students) in elementary schools.   METHODS: The sagittal spinal curvatures of 45 young school students aged 5–7 years and 50 elder school students aged 9–11 years were examined by using spinal mouse device.   RESULTS: Independent sample t-test shows statistically significant differences in sagittal spinal deformities with increased thoracic kyphosis and spinal flexion in young children than elder children (P = .000, t = 10.72). However, young children show lesser lordosis than elder children (P = .001, t = –4.47). In addition, the young children established a higher significant coefficient of compensation (CC) than elder children (P = .000 t = 12.58).   CONCLUSION: The results suggest that the forward flexion of the trunk is more common among young children than elder children. This may be attributed to differences in postural awareness and way of sitting among students of elementary school. So, it is recommended to encourage the proper postures among students of first graders especially young children."@en ;
    ns0:hasPubTitle "A comparison of sagittal spine deformities among elementary school students using spinal mouse device"@en .

ns1:xst-v27-i3-XST180466 ns0:hasKeywords "Malignant ureteral obstruction"@en,
        "fluoroscopic"@en,
        "percutaneous antegrade"@en,
        "ureteral stent"@en ;
    ns0:hasPubAbstract "OBJECTIVE: To investigate the clinical efficacy and safety of fluoroscopic guided percutaneous antegrade ureteral stents placement used for treatment of malignant ureteral obstruction.   METHODS: Between April 2016 and March 2018, fluoroscopic guided percutaneous ureteral stents was performed in 25 patients, including 7 patients (28%) with bilateral obstruction. The most common cancer diagnoses were cervical cancer (28%), rectal cancer (24%) and colon cancer (16%) among these patients. Clinical data were retrospectively analyzed with respect to the efficacy, safety and outcome of this treatment method.   RESULTS: Percutaneous antegrade placement of ureteral stents was performed in all cases, including 12 ureters that failed in the initial retrograde ureteral stents placement. The median stent patency time for the antegrade ureteral stents were 10.4 (95% CI: 8.3–12.6) months. The primary complications included mild flank pain and discomfort (44%), hematuria (44%), urinary tract infection (8%), bladder irritation symptoms (4%), and arterial bleeding (4%).   CONCLUSION: Fluoroscopic guided percutaneous ureteral stents placement is a safe, efficient procedure and has a high success rate in patients with malignant ureteral obstruction."@en ;
    ns0:hasPubTitle "Clinical application of fluoroscopic guided percutaneous antegrade ureteral stents placement for the treatment of malignant ureteral obstruction"@en .

ns1:xst-v27-i3-XST180488 ns0:hasKeywords "Triple negative breast cancer"@en,
        "X-ray mammography"@en,
        "evaluation of tumor characteristics"@en,
        "quantitative imaging markers"@en ;
    ns0:hasPubAbstract "PURPOSE: To explore the radiomics features of triple negative breast cancer (TNBC) and non-triple negative breast cancer (non-TNBC) based on X-ray mammography, and to differentiate the two groups of cases.   MATERIALS AND METHODS: Preoperative mammograms of 120 patients with breast ductal carcinoma confirmed by surgical pathology were retrospectively analyzed, which include 30 TNBC and 90 non-TNBC patients. The manual segmentation of breast lesions was performed by ITK-SNAP software and 12 radiomics features were extracted by Omni-Kinetics software. The differences of these radiomics features between TNBC and non-TNBC groups were compared, and the receiver operating characteristic (ROC) curve was used to determine the optimal cutoff value of each radiomics parameter for differentiating TNBC from non-TNBC, and the corresponding area under the curve (AUC), sensitivity and specificity were obtained.   RESULTS: There were statistically significant differences for 4 radiomics features between TNBC and non-TNBC datasets (P < 0.05). They were the roundness, concavity, gray average and skewness of breast lesions. Compared with non-TNBC, TNBC cases have following characteristics of (1) more round with the roundness of 0.621 vs. 0.413 (P < 0.001), (2) more regular with the concavity of 0.087 vs. 0.141 (P < 0.01), (3) higher density or gray average (67.261 vs. 56.842, P < 0.05), and (4) lower skewness (– 0.837 vs.– 0.671, P = 0.034). AUCs of ROC curves computed using features of the roundness and concavity were both larger than 0.70.   CONCLUSION: Radiomics features based on X-ray mammography may be helpful to distinguish between TNBC and non-TNBC, which were associated with breast tumor histology."@en ;
    ns0:hasPubTitle "A pilot study of radiomics technology based on X-ray mammography in patients with triple-negative breast cancer"@en .

ns1:xst-v27-i4-XST190491 ns0:hasKeywords "CT dose index"@en,
        "CT head"@en,
        "Mis-centering position"@en,
        "radiation dose"@en ;
    ns0:hasPubAbstract "There are several factors that may contribute to the increase in radiation dose of CT including the use of unoptimized protocols and improper scanning technique. In this study, we aim to determine significant impact on radiation dose as a result of mis-centering during CT head examination. The scanning was performed by using Toshiba Aquilion 64 slices multi-detector CT (MDCT) scanner and dose were measured by using calibrated ionization chamber. Two scanning protocols of routine CT head; 120 kVp/ 180 mAs and 100 kVp/ 142 mAs were used represent standard and low dose, respectively. As reference measurement, the dose was first measured on standard cylindrical polymethyl methacrylate (PMMA) phantom that positioned at 104 cm from the floor (reference isocenter). The positions then were varied to simulate mis-centering by 5 cm from isocenter, superiorly and inferiorly at 109 cm, 114 cm, 119 cm, 124 cm and 99 cm, 94 cm, 89 cm, 84 cm, respectively. Scanning parameter and dose information from the console were recorded for the radiation effective dose (E) measurement. The highest mean CTDIvol value for MCS and MCI were 105.06 mGy (at +10 cm) and 105.51 mGy (at – 10 cm), respectively which differed significantly (p < 0.05) as compared to the isocenter. There were large significant different (p < 0.05) of mean Dose Length Product (DLP) recorded between isocenter to the MCS (85.8 mGy.cm) and MCI (93.1 mGy.cm). As the low dose protocol implemented, the volume CTDI (CTDIvol) were significantly increase (p < 0.05) for MCS (at +10 cm) and MCI (at – 10 cm) when compared to the isocenter. The phantom study revealed a noticeable different in radiation dose between isocenter and experimental groups due to degradation of the bowtie filter performance. It is anticipated that these noteworthy findings may emphasize the importance of accurate patient centering at the isocenter of CT gantry, so that CT optimization practice can be achieved."@en ;
    ns0:hasPubTitle "The effects of mis-centering on radiation dose during CT head examination: A phantom study"@en .

ns1:xst-v27-i4-XST190494 ns0:hasKeywords "CT imaging"@en,
        "FBP algorithm"@en,
        "reconstruction algorithm"@en,
        "scanning mode"@en,
        "triple-source CT"@en ;
    ns0:hasPubAbstract "Multi-source computed tomography (CT) imaging has unique technical advantages not only for dynamic objects, but also for large-size objects by designing its imaging scan mode. Using the triple-source fan-beam imaging scan mode under three circular trajectories with two different radii, we in this study developed and analyzed theoretically several exact reconstruction algorithms in terms of full-scan and short-scan for three sets of truncated projection data. This triple-source scan configuration in different radii cases is easier to be simulated by a single-source scan configuration in an industrial CT system. The proposed algorithms are based on the idea of filtering-back-projection (FBP) algorithm, and can reconstruct the large-size objects under the same CT devices. The developed algorithms avoid data rebinning and can provide exact and fast image reconstruction. The results of the numerical simulation based data analysis verified that new algorithms were accurate and effective."@en ;
    ns0:hasPubTitle "FBP-type CT reconstruction algorithms for triple-source circular trajectory with different scanning radii"@en .

ns1:xst-v27-i5-XST190526 ns0:hasKeywords "Radiogenomics"@en,
        "computed tomography"@en,
        "non-small cell lung cancer"@en,
        "radiomics features"@en ;
    ns0:hasPubAbstract "OBJECTIVE: Radiogenomics investigates radiographic imaging phenotypes associated with gene expression patterns. This study aims to explore relationships between CT imaging radiomics features and gene expression data in non-small cell lung cancer (NSCLC).   METHODS: Eighty-nine NSCLC patients are included in the study. Radiomics features are extracted and selected to quantify the phenotype of tumors on CT-scans. Co-expressed genes are also clustered and the first principal component of the cluster is represented, which is defined as a metagene. Then, statistical analysis was performed to assess association of CT radiomics features with metagenes. In addition, predictive models are built and metagene enrichment are conducted to further evaluate performance of NSCLC radiogenomics statistically and biologically.   RESULTS: There are 187 significant pairwise correlations between a CT radiomics feature and a metagene of NSCLC, where eighteen metagenes are annotated with Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) terms. Metagenes are predicted in terms of radiomics features with an accuracy of 41.89% –89.93%.   CONCLUSIONS: This study reveals the associations between CT imaging radiomics features and NSCLC co-expressed gene sets. The findings suggest that CT radiomics features can reflect important biological information of NSCLC patients, which may have a significant clinical impact as CT is routinely used in clinical practice, assisting in improving medical decision-support at low cost."@en ;
    ns0:hasPubTitle "Correlation between CT based radiomics features and gene expression data in non-small cell lung cancer"@en .

ns1:xst-v27-i5-XST190548 ns0:hasKeywords "Anchor Box"@en,
        "Automatic location"@en,
        "breast tumor"@en,
        "deep learning"@en,
        "fully connected convolutional networks"@en,
        "segmentation"@en,
        "ultrasound image"@en ;
    ns0:hasPubAbstract "BACKGROUND: Breast cancer has the highest cancer prevalence rate among the women worldwide. Early detection of breast cancer is crucial for successful treatment and reducing cancer mortality rate. However, tumor detection of breast ultrasound (US) image is still a challenging work in computer-aided diagnosis (CAD).   OBJECTIVE: This study aims to develop a novel automated algorithm for breast tumor detection based on deep learning.   METHODS: We proposed a new deep learning network named One-step model which have one input and two outputs, the first one was the segmentation result and the other one was used for false-positive reduction. The proposed One-step model includes three key components: Base-net, Seg-net, and Cls-net based on Anchor Box. The model chose DenseNet to construct Base-net, the decoder part of RefineNet as Seg-net, and connected several middle layers of Base-net and Seg-net to Cls-net. From the first output acquired by Base-net and Seg-net, the model detected a series of suspicious lesion regions. Then the second output from the Cls-net was used to recognize and reduce the false-positive regions.   RESULTS: Experimental results showed that the new model achieved competitive detection result with 90.78% F1 score, which was 8.55% higher than Single Shot MultiBox Detector (SSD) method. In addition, running new model is also computational efficient and has comparative cost effect as SSD.   CONCLUSIONS: We established a novel One-step model which improves location accuracy by generating more precise bounding box via Seg-net and removing false targets by another object detection network (Cls-net). On the other hand, a real-time detection of tumor is achieved by sharing the common Base-net. The experimental results showed that the new model performed well on various irregular and blurred ultrasound images. As a result, this study demonstrated feasibility of applying deep learning scheme to detect breast lesions depicting on US image."@en ;
    ns0:hasPubTitle "New one-step model of breast tumor locating based on deep learning"@en .

ns2:ASY1387 ns0:inAuthorList ns150:ASY1387 .

ns2:BD248 ns0:inAuthorList ns150:BD248 .

ns2:BME1464 ns0:inAuthorList ns150:BME1464 .

ns2:CH168021 ns0:inAuthorList ns150:CH168021 .

ns2:CH179104 ns0:inAuthorList ns150:CH179104 .

ns2:CH179201 ns0:inAuthorList ns150:CH179201 .

ns2:CH179210 ns0:inAuthorList ns150:CH179210 .

ns2:CH179235 ns0:inAuthorList ns150:CH179235 .

ns2:CH189405 ns0:inAuthorList ns150:CH189405 .

ns2:CH199201 ns0:inAuthorList ns150:CH199201 .

ns2:CH2010 ns0:inAuthorList ns150:CH2010 .

ns2:CH2049 ns0:inAuthorList ns150:CH2049 .

ns2:COM035 ns0:inAuthorList ns150:COM035 .

ns2:DS190019 ns0:inAuthorList ns150:DS190019 .

ns2:FI1290 ns0:inAuthorList ns150:FI1290 .

ns2:FI1755 ns0:inAuthorList ns150:FI1755 .

ns2:HAB190363 owl:sameAs ns8:HAB190368,
        ns8:HAB190369 ;
    ns0:fullName "Addis Adera Gebru" ;
    ns0:hasAffiliation ns242:HAB190363,
        ns243:HAB190363,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff3.Author:0.ID:HAB190363> ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190363 ;
    ns0:inAuthorList ns150:HAB190363 .

ns2:HAB303 ns0:inAuthorList ns150:HAB303 .

ns2:HAB304 ns0:inAuthorList ns150:HAB304 .

ns2:HSM1768 ns0:inAuthorList ns150:HSM1768 .

ns2:IFS141877 ns0:inAuthorList ns150:IFS141877 .

ns2:IFS151517 ns0:inAuthorList ns150:IFS151517 .

ns2:IFS162347 ns0:inAuthorList ns150:IFS162347 .

ns2:IFS16236 ns0:inAuthorList ns150:IFS16236 .

ns2:IFS16550 ns0:inAuthorList ns150:IFS16550 .

ns2:IFS1665 ns0:inAuthorList ns150:IFS1665 .

ns2:IFS16661 ns0:inAuthorList ns150:IFS16661 .

ns2:IFS169170 ns0:inAuthorList ns150:IFS169170 .

ns2:IFS169324 ns0:inAuthorList ns150:IFS169324 .

ns2:IFS169572 ns0:inAuthorList ns150:IFS169572 .

ns2:IFS171070 ns0:inAuthorList ns150:IFS171070 .

ns2:IFS17124 ns0:inAuthorList ns150:IFS17124 .

ns2:IFS171413 ns0:inAuthorList ns150:IFS171413 .

ns2:IFS172262 ns0:inAuthorList ns150:IFS172262 .

ns2:IFS17530 ns0:inAuthorList ns150:IFS17530 .

ns2:IFS181296 ns0:inAuthorList ns150:IFS181296 .

ns2:IFS181657 owl:sameAs ns2:IFS152405,
        ns8:IFS18604,
        ns12:IFS190952 ;
    ns0:fullName "Truong Vinh An" ;
    ns0:hasAffiliation ns242:IFS181657 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181657 ;
    ns0:inAuthorList ns150:IFS181657 .

ns2:IFS181698 ns0:inAuthorList ns150:IFS181698 .

ns2:IFS181892 ns0:inAuthorList ns150:IFS181892 .

ns2:IFS182569 ns0:inAuthorList ns150:IFS182569 .

ns2:IFS182572 owl:sameAs ns2:IFS161821,
        ns2:IFS171587,
        ns2:IFS17728,
        ns8:IFS181188,
        ns12:IFS181460 ;
    ns0:fullName "Asghar Khan" ;
    ns0:hasAffiliation ns242:IFS182572 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182572 ;
    ns0:inAuthorList ns150:IFS182572 .

ns2:IFS18266 owl:sameAs ns2:FI1669,
        ns8:IFS179235 ;
    ns0:fullName "Hui Gao" ;
    ns0:hasAffiliation ns242:IFS18266 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS18266 ;
    ns0:inAuthorList ns150:IFS18266 .

ns2:IFS182768 ns0:inAuthorList ns150:IFS182768 .

ns2:IFS182919 owl:sameAs ns2:IFS181648,
        ns2:IFS182751,
        ns2:IFS182809,
        ns8:IFS190905 ;
    ns0:fullName "Muhammad Riaz" ;
    ns0:hasAffiliation ns242:IFS182919 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182919 ;
    ns0:inAuthorList ns150:IFS182919 .

ns2:IFS18961 ns0:inAuthorList ns150:IFS18961 .

ns2:IFS191197 owl:sameAs ns12:IFS18757 ;
    ns0:fullName "Noor Rehman" ;
    ns0:hasAffiliation ns242:IFS191197 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS191197 ;
    ns0:inAuthorList ns150:IFS191197 .

ns2:IFS2074 ns0:inAuthorList ns150:IFS2074 .

ns2:IFS2082 ns0:inAuthorList ns150:IFS2082 .

ns2:IFS2110 ns0:inAuthorList ns150:IFS2110 .

ns2:IFS2121 ns0:inAuthorList ns150:IFS2121 .

ns2:IFS2128 ns0:inAuthorList ns150:IFS2128 .

ns2:IFS2190 ns0:inAuthorList ns150:IFS2190 .

ns2:JAD00003 ns0:inAuthorList ns150:JAD00003 .

ns2:JAD100987 ns0:inAuthorList ns150:JAD100987 .

ns2:JAD111340 ns0:inAuthorList ns150:JAD111340 .

ns2:JAD111370 ns0:inAuthorList ns150:JAD111370 .

ns2:JAD111697 ns0:inAuthorList ns150:JAD111697 .

ns2:JAD120505 ns0:inAuthorList ns150:JAD120505 .

ns2:JAD121090 ns0:inAuthorList ns150:JAD121090 .

ns2:JAD130086 ns0:inAuthorList ns150:JAD130086 .

ns2:JAD130824 ns0:inAuthorList ns150:JAD130824 .

ns2:JAD131172 ns0:inAuthorList ns150:JAD131172 .

ns2:JAD142685 ns0:inAuthorList ns150:JAD142685 .

ns2:JAD150736 ns0:inAuthorList ns150:JAD150736 .

ns2:JAD150747 ns0:inAuthorList ns150:JAD150747 .

ns2:JAD150985 ns0:inAuthorList ns150:JAD150985 .

ns2:JAD160304 ns0:inAuthorList ns150:JAD160304 .

ns2:JAD161023 ns0:inAuthorList ns150:JAD161023 .

ns2:JAD161234 ns0:inAuthorList ns150:JAD161234 .

ns2:JAD170587 ns0:inAuthorList ns150:JAD170587 .

ns2:JAD170807 ns0:inAuthorList ns150:JAD170807 .

ns2:JAD170990 ns0:inAuthorList ns150:JAD170990 .

ns2:JAD179924 ns0:inAuthorList ns150:JAD179924 .

ns2:JAD180024 ns0:inAuthorList ns150:JAD180024 .

ns2:JAD180524 ns0:inAuthorList ns150:JAD180524 .

ns2:JAD180619 ns0:inAuthorList ns150:JAD180619 .

ns2:JAD190256 ns0:inAuthorList ns150:JAD190256 .

ns2:JAE170038 ns0:inAuthorList ns150:JAE170038 .

ns2:JAE170163 ns0:inAuthorList ns150:JAE170163 .

ns2:JHD180293 ns0:inAuthorList ns150:JHD180293 .

ns2:JIN030 ns0:inAuthorList ns150:JIN030 .

ns2:JPD150668 ns0:inAuthorList ns150:JPD150668 .

ns2:JVR180991 ns0:inAuthorList ns150:JVR180991 .

ns2:JVR191021 owl:sameAs ns2:JVR191055,
        ns12:JVR191047,
        ns5:JVR813 ;
    ns0:fullName "David R. Strauser" ;
    ns0:hasAffiliation ns242:JVR191021 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191021 ;
    ns0:inAuthorList ns150:JVR191021 .

ns2:JVR191024 owl:sameAs ns12:JVR812,
        ns12:JVR899,
        ns30:JVR891,
        ns30:WOR2206 ;
    ns0:fullName "Phillip D. Rumrill" ;
    ns0:hasAffiliation ns242:JVR191024 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191024 ;
    ns0:inAuthorList ns150:JVR191024 .

ns2:JVR191026 owl:sameAs ns2:WOR2200 ;
    ns0:fullName "Malachy Bishop" ;
    ns0:hasAffiliation ns242:JVR191026 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191026 ;
    ns0:inAuthorList ns150:JVR191026 .

ns2:JVR191033 ns0:inAuthorList ns150:JVR191033 .

ns2:JVR191036 ns0:inAuthorList ns150:JVR191036 .

ns2:JVR191048 ns0:inAuthorList ns150:JVR191048 .

ns2:JVR810 ns0:inAuthorList ns150:JVR810 .

ns2:JVR816 ns0:inAuthorList ns150:JVR816 .

ns2:JVR889 ns0:inAuthorList ns150:JVR889 .

ns2:MGC246 ns0:inAuthorList ns150:MGC246 .

ns2:MGC255 ns0:inAuthorList ns150:MGC255 .

ns2:NRE1271 ns0:inAuthorList ns150:NRE1271 .

ns2:NRE182534 ns0:inAuthorList ns150:NRE182534 .

ns2:WOR192857 ns0:inAuthorList ns150:WOR192857 .

ns2:WOR2200 ns0:inAuthorList ns150:WOR2200 .

ns2:WOR2201 ns0:inAuthorList ns150:WOR2201 .

ns2:WOR2328 ns0:inAuthorList ns150:WOR2328 .

ns2:WOR2661 ns0:inAuthorList ns150:WOR2661 .

ns2:XST17282 ns0:inAuthorList ns150:XST17282 .

ns2:XST515 ns0:inAuthorList ns150:XST515 .

ns2:jad00084 ns0:inAuthorList ns150:jad00084 .

ns2:jad00519 ns0:inAuthorList ns150:jad00519 .

ns2:jad00693 ns0:inAuthorList ns150:jad00693 .

ns2:jad01153 ns0:inAuthorList ns150:jad01153 .

ns2:jad01168 ns0:inAuthorList ns150:jad01168 .

ns2:jad01170 ns0:inAuthorList ns150:jad01170 .

ns2:jad01207 ns0:inAuthorList ns150:jad01207 .

ns2:jad01317 ns0:inAuthorList ns150:jad01317 .

ns2:thc00776 ns0:inAuthorList ns150:thc00776 .

ns8:CBM542 ns0:inAuthorList ns150:CBM542 .

ns8:CH160241 ns0:inAuthorList ns150:CH160241 .

ns8:CH16212 ns0:inAuthorList ns150:CH16212 .

ns8:CH168039 ns0:inAuthorList ns150:CH168039 .

ns8:CH168124 ns0:inAuthorList ns150:CH168124 .

ns8:CH170252 ns0:inAuthorList ns150:CH170252 .

ns8:CH179112 ns0:inAuthorList ns150:CH179112 .

ns8:CH179218 ns0:inAuthorList ns150:CH179218 .

ns8:CH179225 ns0:inAuthorList ns150:CH179225 .

ns8:CH189123 ns0:inAuthorList ns150:CH189123 .

ns8:CH189308 ns0:inAuthorList ns150:CH189308 .

ns8:CH189321 ns0:inAuthorList ns150:CH189321 .

ns8:CH189408 ns0:inAuthorList ns150:CH189408 .

ns8:CH2004 ns0:inAuthorList ns150:CH2004 .

ns8:CH2009 ns0:inAuthorList ns150:CH2009 .

ns8:FI1820 owl:sameAs ns8:FI1567 ;
    ns0:fullName "Maciej Koutny" ;
    ns0:hasAffiliation ns25:FI1820 ;
    ns0:hasArticle ns1:fi-v167-i4-FI1820 ;
    ns0:inAuthorList ns150:FI1820 .

ns8:HAB190383 owl:sameAs ns2:HAB190368,
        ns8:HAB190367 ;
    ns0:fullName "Ali Mohammad Mosadeghrad" ;
    ns0:hasAffiliation ns90:HAB190383 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190383 ;
    ns0:inAuthorList ns150:HAB190383 .

ns8:HAB190386 owl:sameAs ns2:HAB180360,
        ns52:HAB282 ;
    ns0:fullName "Osaro Erhabor" ;
    ns0:hasAffiliation ns24:HAB190386 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190386 ;
    ns0:inAuthorList ns150:HAB190386 .

ns8:HAB304 ns0:inAuthorList ns150:HAB304 .

ns8:IDA173589 ns0:inAuthorList ns150:IDA173589 .

ns8:IDA183918 ns0:inAuthorList ns150:IDA183918 .

ns8:IFS161586 ns0:inAuthorList ns150:IFS161586 .

ns8:IFS161589 ns0:inAuthorList ns150:IFS161589 .

ns8:IFS161759 ns0:inAuthorList ns150:IFS161759 .

ns8:IFS162131 ns0:inAuthorList ns150:IFS162131 .

ns8:IFS162299 ns0:inAuthorList ns150:IFS162299 .

ns8:IFS16244 ns0:inAuthorList ns150:IFS16244 .

ns8:IFS16339 ns0:inAuthorList ns150:IFS16339 .

ns8:IFS1657 ns0:inAuthorList ns150:IFS1657 .

ns8:IFS169620 ns0:inAuthorList ns150:IFS169620 .

ns8:IFS17088 ns0:inAuthorList ns150:IFS17088 .

ns8:IFS171636 ns0:inAuthorList ns150:IFS171636 .

ns8:IFS17169 ns0:inAuthorList ns150:IFS17169 .

ns8:IFS171838 ns0:inAuthorList ns150:IFS171838 .

ns8:IFS172009 ns0:inAuthorList ns150:IFS172009 .

ns8:IFS17270 ns0:inAuthorList ns150:IFS17270 .

ns8:IFS17334 ns0:inAuthorList ns150:IFS17334 .

ns8:IFS17366 ns0:inAuthorList ns150:IFS17366 .

ns8:IFS17595 ns0:inAuthorList ns150:IFS17595 .

ns8:IFS17728 ns0:inAuthorList ns150:IFS17728 .

ns8:IFS17811 ns0:inAuthorList ns150:IFS17811 .

ns8:IFS17850 ns0:inAuthorList ns150:IFS17850 .

ns8:IFS180001 ns0:inAuthorList ns150:IFS180001 .

ns8:IFS181040 ns0:inAuthorList ns150:IFS181040 .

ns8:IFS181172 ns0:inAuthorList ns150:IFS181172 .

ns8:IFS181330 ns0:inAuthorList ns150:IFS181330 .

ns8:IFS181401 ns0:inAuthorList ns150:IFS181401 .

ns8:IFS181488 ns0:inAuthorList ns150:IFS181488 .

ns8:IFS181541 ns0:inAuthorList ns150:IFS181541 .

ns8:IFS181657 owl:sameAs ns2:IFS161919,
        ns2:IFS182863 ;
    ns0:fullName "Ho Vu" ;
    ns0:hasAffiliation ns25:IFS181657 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181657 ;
    ns0:inAuthorList ns150:IFS181657 .

ns8:IFS181698 ns0:inAuthorList ns150:IFS181698 .

ns8:IFS181832 owl:sameAs ns8:IFS18757,
        ns12:IFS161681,
        ns5:IFS18993 ;
    ns0:fullName "Muhammad Irfan Ali" ;
    ns0:hasAffiliation ns25:IFS181832 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS181832 ;
    ns0:inAuthorList ns150:IFS181832 .

ns8:IFS182651 owl:sameAs ns8:IFS182700 ;
    ns0:fullName "Cengiz Kahraman" ;
    ns0:hasAffiliation ns24:IFS182651 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182651 ;
    ns0:inAuthorList ns150:IFS182651 .

ns8:IFS18266 owl:sameAs ns2:IFS16554,
        ns2:IFS16946,
        ns12:IFS179235 ;
    ns0:fullName "Mao Lu" ;
    ns0:hasAffiliation ns24:IFS18266 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS18266 ;
    ns0:inAuthorList ns150:IFS18266 .

ns8:IFS182860 owl:sameAs ns8:IFS2161 ;
    ns0:fullName "Xiao Long Xin" ;
    ns0:hasAffiliation ns24:IFS182860 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS182860 ;
    ns0:inAuthorList ns150:IFS182860 .

ns8:IFS18659 owl:sameAs ns8:IFS161988,
        ns8:IFS1650,
        ns8:IFS1788,
        ns12:IFS17465,
        ns12:IFS182568 ;
    ns0:fullName "Fu-Gui Shi" ;
    ns0:hasAffiliation ns25:IFS18659 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS18659 ;
    ns0:inAuthorList ns150:IFS18659 .

ns8:IFS18979 ns0:inAuthorList ns150:IFS18979 .

ns8:IFS190036 owl:sameAs ns12:IFS182618,
        ns12:INF1131,
        ns30:INF1215 ;
    ns0:fullName "Florentin Smarandache" ;
    ns0:hasAffiliation ns25:IFS190036 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS190036 ;
    ns0:inAuthorList ns150:IFS190036 .

ns8:IFS190054 owl:sameAs ns2:IFS171443,
        ns2:IFS181972,
        ns2:IFS2107 ;
    ns0:fullName "Muhammad Akram" ;
    ns0:hasAffiliation ns24:IFS190054 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190054 ;
    ns0:inAuthorList ns150:IFS190054 .

ns8:IFS190565 owl:sameAs ns2:IFS172270,
        ns2:IFS1869,
        ns8:IFS1734,
        ns8:IFS18518,
        ns12:IFS161601,
        ns12:IFS2074,
        ns30:IFS151031 ;
    ns0:fullName "Y.B. Jun" ;
    ns0:hasAffiliation ns25:IFS190565,
        ns259:IFS190565 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190565 ;
    ns0:inAuthorList ns150:IFS190565 .

ns8:IFS191197 owl:sameAs ns2:IFS171172,
        ns2:JAE150030 ;
    ns0:fullName "Abbas Ali" ;
    ns0:hasAffiliation ns25:IFS191197 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS191197 ;
    ns0:inAuthorList ns150:IFS191197 .

ns8:IFS2041 ns0:inAuthorList ns150:IFS2041 .

ns8:IFS2075 ns0:inAuthorList ns150:IFS2075 .

ns8:IFS2077 ns0:inAuthorList ns150:IFS2077 .

ns8:IFS2082 ns0:inAuthorList ns150:IFS2082 .

ns8:IFS2110 ns0:inAuthorList ns150:IFS2110 .

ns8:IFS2114 ns0:inAuthorList ns150:IFS2114 .

ns8:IFS2121 ns0:inAuthorList ns150:IFS2121 .

ns8:IFS2125 ns0:inAuthorList ns150:IFS2125 .

ns8:INF1165 ns0:inAuthorList ns150:INF1165 .

ns8:INF1223 ns0:inAuthorList ns150:INF1223 .

ns8:JAD101560 ns0:inAuthorList ns150:JAD101560 .

ns8:JAD101818 ns0:inAuthorList ns150:JAD101818 .

ns8:JAD101995 ns0:inAuthorList ns150:JAD101995 .

ns8:JAD102043 ns0:inAuthorList ns150:JAD102043 .

ns8:JAD110065 ns0:inAuthorList ns150:JAD110065 .

ns8:JAD110428 ns0:inAuthorList ns150:JAD110428 .

ns8:JAD111631 ns0:inAuthorList ns150:JAD111631 .

ns8:JAD129021 ns0:inAuthorList ns150:JAD129021 .

ns8:JAD130281 ns0:inAuthorList ns150:JAD130281 .

ns8:JAD131892 ns0:inAuthorList ns150:JAD131892 .

ns8:JAD132363 ns0:inAuthorList ns150:JAD132363 .

ns8:JAD140777 ns0:inAuthorList ns150:JAD140777 .

ns8:JAD141284 ns0:inAuthorList ns150:JAD141284 .

ns8:JAD141305 ns0:inAuthorList ns150:JAD141305 .

ns8:JAD141413 ns0:inAuthorList ns150:JAD141413 .

ns8:JAD141563 ns0:inAuthorList ns150:JAD141563 .

ns8:JAD141794 ns0:inAuthorList ns150:JAD141794 .

ns8:JAD141890 ns0:inAuthorList ns150:JAD141890 .

ns8:JAD151113 ns0:inAuthorList ns150:JAD151113 .

ns8:JAD160230 ns0:inAuthorList ns150:JAD160230 .

ns8:JAD160235 ns0:inAuthorList ns150:JAD160235 .

ns8:JAD160291 ns0:inAuthorList ns150:JAD160291 .

ns8:JAD160641 ns0:inAuthorList ns150:JAD160641 .

ns8:JAD161208 ns0:inAuthorList ns150:JAD161208 .

ns8:JAD170130 ns0:inAuthorList ns150:JAD170130 .

ns8:JAD170414 ns0:inAuthorList ns150:JAD170414 .

ns8:JAD170564 ns0:inAuthorList ns150:JAD170564 .

ns8:JAD170850 ns0:inAuthorList ns150:JAD170850 .

ns8:JAD180131 ns0:inAuthorList ns150:JAD180131 .

ns8:JAD180604 ns0:inAuthorList ns150:JAD180604 .

ns8:JAD180746 ns0:inAuthorList ns150:JAD180746 .

ns8:JAD181009 ns0:inAuthorList ns150:JAD181009 .

ns8:JAD181152 ns0:inAuthorList ns150:JAD181152 .

ns8:JAD181189 ns0:inAuthorList ns150:JAD181189 .

ns8:JAD181218 ns0:inAuthorList ns150:JAD181218 .

ns8:JAD190104 ns0:inAuthorList ns150:JAD190104 .

ns8:JAE150132 ns0:inAuthorList ns150:JAE150132 .

ns8:JAE191149 owl:sameAs ns8:JAE171008,
        ns8:JAE171252,
        ns8:JAE190924,
        ns8:JAE2122,
        ns8:JAE2271,
        ns12:JAE190821,
        ns12:JAE1979 ;
    ns0:fullName "Yasuhito Takahashi" ;
    ns0:hasAffiliation ns24:JAE191149 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191149 ;
    ns0:inAuthorList ns150:JAE191149 .

ns8:JAE198972 ns0:inAuthorList ns150:JAE198972 .

ns8:JCM819 ns0:inAuthorList ns150:JCM819 .

ns8:JHD180287 ns0:inAuthorList ns150:JHD180287 .

ns8:JHD199003 ns0:inAuthorList ns150:JHD199003 .

ns8:JIN092 ns0:inAuthorList ns150:JIN092 .

ns8:JPD160985 ns0:inAuthorList ns150:JPD160985 .

ns8:JPD191635 owl:sameAs ns57:JAD132156 ;
    ns0:fullName "Andrew J. Lees" ;
    ns0:hasAffiliation ns25:JPD191635 ;
    ns0:hasArticle ns1:jpd-v9-i3-JPD191635 ;
    ns0:inAuthorList ns150:JPD191635 .

ns8:JVR180983 ns0:inAuthorList ns150:JVR180983 .

ns8:JVR180991 ns0:inAuthorList ns150:JVR180991 .

ns8:JVR180997 ns0:inAuthorList ns150:JVR180997 .

ns8:JVR191021 ns0:inAuthorList ns150:JVR191021 .

ns8:JVR191043 ns0:inAuthorList ns150:JVR191043 .

ns8:JVR808 ns0:inAuthorList ns150:JVR808 .

ns8:JVR817 ns0:inAuthorList ns150:JVR817 .

ns8:JVR888 ns0:inAuthorList ns150:JVR888 .

ns8:JVR894 ns0:inAuthorList ns150:JVR894 .

ns8:JVR931 ns0:inAuthorList ns150:JVR931 .

ns8:KCA170005 ns0:inAuthorList ns150:KCA170005 .

ns8:MNM180249 ns0:inAuthorList ns150:MNM180249 .

ns8:RNN150623 ns0:inAuthorList ns150:RNN150623 .

ns8:THC1227 ns0:inAuthorList ns150:THC1227 .

ns8:WOR2201 ns0:inAuthorList ns150:WOR2201 .

ns8:WOR2661 ns0:inAuthorList ns150:WOR2661 .

ns8:XST16208 ns0:inAuthorList ns150:XST16208 .

ns8:XST16211 ns0:inAuthorList ns150:XST16211 .

ns8:XST18377 ns0:inAuthorList ns150:XST18377 .

ns8:hab00178 ns0:inAuthorList ns150:hab00178 .

ns8:jad00407 ns0:inAuthorList ns150:jad00407 .

ns8:jad00878 ns0:inAuthorList ns150:jad00878 .

ns8:jad01137 ns0:inAuthorList ns150:jad01137 .

ns8:jad01180 ns0:inAuthorList ns150:jad01180 .

ns8:jad01404 ns0:inAuthorList ns150:jad01404 .

ns8:jad091450 ns0:inAuthorList ns150:jad091450 .

ns26:CH170275 ns0:inAuthorList ns150:CH170275 .

ns26:CH180388 ns0:inAuthorList ns150:CH180388 .

ns26:JAD0044 ns0:inAuthorList ns150:JAD0044 .

ns26:JAD111109 ns0:inAuthorList ns150:JAD111109 .

ns26:JAD122182 ns0:inAuthorList ns150:JAD122182 .

ns26:JAD130380 ns0:inAuthorList ns150:JAD130380 .

ns26:JAD131589 ns0:inAuthorList ns150:JAD131589 .

ns26:JAD132147 ns0:inAuthorList ns150:JAD132147 .

ns26:JAD150695 ns0:inAuthorList ns150:JAD150695 .

ns26:JAD150749 ns0:inAuthorList ns150:JAD150749 .

ns26:JAD150786 ns0:inAuthorList ns150:JAD150786 .

ns26:JAD150796 ns0:inAuthorList ns150:JAD150796 .

ns26:JAD150849 ns0:inAuthorList ns150:JAD150849 .

ns26:JAD160110 ns0:inAuthorList ns150:JAD160110 .

ns26:JAD160285 ns0:inAuthorList ns150:JAD160285 .

ns26:JAD160979 ns0:inAuthorList ns150:JAD160979 .

ns26:JAD170327 ns0:inAuthorList ns150:JAD170327 .

ns26:JAD170402 ns0:inAuthorList ns150:JAD170402 .

ns26:JAD170880 ns0:inAuthorList ns150:JAD170880 .

ns26:JAD180071 ns0:inAuthorList ns150:JAD180071 .

ns26:JAD180669 ns0:inAuthorList ns150:JAD180669 .

ns26:JAD181218 ns0:inAuthorList ns150:JAD181218 .

ns26:jad100201 ns0:inAuthorList ns150:jad100201 .

ns40:JAD111544 ns0:inAuthorList ns150:JAD111544 .

ns40:JAD111592 ns0:inAuthorList ns150:JAD111592 .

ns40:JAD132306 ns0:inAuthorList ns150:JAD132306 .

ns40:JAD160046 ns0:inAuthorList ns150:JAD160046 .

ns40:JAD160091 ns0:inAuthorList ns150:JAD160091 .

ns40:JAD160322 ns0:inAuthorList ns150:JAD160322 .

ns40:JAD161023 ns0:inAuthorList ns150:JAD161023 .

ns40:JAD170583 ns0:inAuthorList ns150:JAD170583 .

ns40:JAD170608 ns0:inAuthorList ns150:JAD170608 .

ns40:JAD170858 ns0:inAuthorList ns150:JAD170858 .

ns40:JAD171088 ns0:inAuthorList ns150:JAD171088 .

ns40:JAD181218 ns0:inAuthorList ns150:JAD181218 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120466> ns0:inAuthorList ns150:JAD120466 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD120523> ns0:inAuthorList ns150:JAD120523 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD131574> ns0:inAuthorList ns150:JAD131574 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD140777> ns0:inAuthorList ns150:JAD140777 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD141305> ns0:inAuthorList ns150:JAD141305 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD161023> ns0:inAuthorList ns150:JAD161023 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD170362> ns0:inAuthorList ns150:JAD170362 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD171116> ns0:inAuthorList ns150:JAD171116 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181095> owl:sameAs ns40:JAD170564,
        <http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160474>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD161208>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD170039>,
        ns12:JAD170859,
        ns139:JAD180531 ;
    ns0:fullName "Frans Verhey" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:12.ID:JAD181095> ;
    ns0:hasArticle ns1:jad-v69-i4-JAD181095 ;
    ns0:inAuthorList ns150:JAD181095 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181108> ns0:inAuthorList ns150:JAD181108 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD181218> ns0:inAuthorList ns150:JAD181218 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad00130> ns0:inAuthorList ns150:jad00130 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad091651> ns0:inAuthorList ns150:jad091651 .

ns28:CH179232 ns0:inAuthorList ns150:CH179232 .

ns28:CH1920 ns0:inAuthorList ns150:CH1920 .

ns28:JAD110515 ns0:inAuthorList ns150:JAD110515 .

ns28:JAD120361 ns0:inAuthorList ns150:JAD120361 .

ns28:JAD120763 ns0:inAuthorList ns150:JAD120763 .

ns28:JAD148009 ns0:inAuthorList ns150:JAD148009 .

ns28:JAD160554 ns0:inAuthorList ns150:JAD160554 .

ns28:JAD160642 ns0:inAuthorList ns150:JAD160642 .

ns28:JAD170027 ns0:inAuthorList ns150:JAD170027 .

ns28:JAD170410 ns0:inAuthorList ns150:JAD170410 .

ns28:JAD170534 ns0:inAuthorList ns150:JAD170534 .

ns28:JAD170555 ns0:inAuthorList ns150:JAD170555 .

ns28:JAD170985 ns0:inAuthorList ns150:JAD170985 .

ns28:JAD180511 ns0:inAuthorList ns150:JAD180511 .

ns28:JAD190311 ns0:inAuthorList ns150:JAD190311 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160195> ns0:inAuthorList ns150:JAD160195 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160668> ns0:inAuthorList ns150:JAD160668 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160949> ns0:inAuthorList ns150:JAD160949 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD170712> ns0:inAuthorList ns150:JAD170712 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:jad00799> ns0:inAuthorList ns150:jad00799 .

ns43:JAD150862 ns0:inAuthorList ns150:JAD150862 .

ns130:JAD170039 ns0:inAuthorList ns150:JAD170039 .

ns130:JAD170123 ns0:inAuthorList ns150:JAD170123 .

ns130:JAD190132 owl:sameAs ns26:JAD170583,
        ns40:JAD170362,
        ns43:JAD140777 ;
    ns0:fullName "Anne M. Remes" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff12.Author:16.ID:JAD190132>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:16.ID:JAD190132> ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD122263> ns0:inAuthorList ns150:JAD122263 .

ns132:JAD111046 ns0:inAuthorList ns150:JAD111046 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD102124> ns0:inAuthorList ns150:JAD102124 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD122182> ns0:inAuthorList ns150:JAD122182 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD151120> ns0:inAuthorList ns150:JAD151120 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD190334> owl:sameAs ns40:JAD140942,
        <http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD122182> ;
    ns0:fullName "Hilkka Soininen" ;
    ns0:hasAffiliation ns134:JAD190334,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:19.ID:JAD190334> ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:jad01328> ns0:inAuthorList ns150:jad01328 .

ns12:BD248 ns0:inAuthorList ns150:BD248 .

<http://ld.iospress.nl/rdf/contributor/Author:2.ID:BMR11(1)02> ns0:inAuthorList <http://ld.iospress.nl/rdf/contributor/List.Role:authors.ID:BMR11(1)02> .

ns12:CH168114 ns0:inAuthorList ns150:CH168114 .

ns12:CH170245 ns0:inAuthorList ns150:CH170245 .

ns12:CH170265 ns0:inAuthorList ns150:CH170265 .

ns12:CH179000 ns0:inAuthorList ns150:CH179000 .

ns12:CH179224 ns0:inAuthorList ns150:CH179224 .

ns12:CH180427 ns0:inAuthorList ns150:CH180427 .

ns12:CH189310 ns0:inAuthorList ns150:CH189310 .

ns12:CH189901 ns0:inAuthorList ns150:CH189901 .

ns12:FI1574 ns0:inAuthorList ns150:FI1574 .

ns12:HAB180360 ns0:inAuthorList ns150:HAB180360 .

ns12:HAB190369 owl:sameAs ns8:JRS740,
        ns12:HAB190368,
        ns12:HAB190383 ;
    ns0:fullName "Ali Akbari Sari" ;
    ns0:hasAffiliation ns13:HAB190369 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190369 ;
    ns0:inAuthorList ns150:HAB190369 .

ns12:HAB289 ns0:inAuthorList ns150:HAB289 .

ns12:HAB317 ns0:inAuthorList ns150:HAB317 .

ns12:IFS151652 ns0:inAuthorList ns150:IFS151652 .

ns12:IFS152503 ns0:inAuthorList ns150:IFS152503 .

ns12:IFS1673 ns0:inAuthorList ns150:IFS1673 .

ns12:IFS171049 owl:sameAs ns8:IFS151652,
        ns8:IFS162007,
        ns8:IFS16797,
        ns8:IFS181329,
        ns8:IFS181516,
        ns12:IFS171567,
        ns12:IFS181922 ;
    ns0:fullName "S. Abdullah" ;
    ns0:hasAffiliation ns14:IFS171049 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS171049 ;
    ns0:inAuthorList ns150:IFS171049 .

ns12:IFS171060 ns0:inAuthorList ns150:IFS171060 .

ns12:IFS171443 ns0:inAuthorList ns150:IFS171443 .

ns12:IFS17597 ns0:inAuthorList ns150:IFS17597 .

ns12:IFS17649 ns0:inAuthorList ns150:IFS17649 .

ns12:IFS179235 owl:sameAs ns2:IFS16554,
        ns2:IFS16946 ;
    ns0:fullName "Mao Lu" ;
    ns0:hasAffiliation ns15:IFS179235 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179235 ;
    ns0:inAuthorList ns150:IFS179235 .

ns12:IFS181084 ns0:inAuthorList ns150:IFS181084 .

ns12:IFS181123 ns0:inAuthorList ns150:IFS181123 .

ns12:IFS181255 ns0:inAuthorList ns150:IFS181255 .

ns12:IFS181657 owl:sameAs ns12:IFS181698,
        ns12:IFS182863 ;
    ns0:fullName "Ngo Van Hoa" ;
    ns0:hasAffiliation ns83:IFS181657,
        ns13:IFS181657 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181657 ;
    ns0:inAuthorList ns150:IFS181657 .

ns12:IFS181697 owl:sameAs ns2:IFS1688,
        ns8:IFS151517,
        ns12:IFS152553 ;
    ns0:fullName "Arsham Borumand Saeid" ;
    ns0:hasAffiliation ns14:IFS181697 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181697 ;
    ns0:inAuthorList ns150:IFS181697 .

ns12:IFS181755 ns0:inAuthorList ns150:IFS181755 .

ns12:IFS182579 owl:sameAs ns8:IFS181153,
        ns12:IFS172009,
        ns12:IFS181253,
        ns12:INF1217,
        ns30:IFS181922 ;
    ns0:fullName "Tahir Mahmood" ;
    ns0:hasAffiliation ns15:IFS182579 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182579 ;
    ns0:inAuthorList ns150:IFS182579 .

ns12:IFS18663 ns0:inAuthorList ns150:IFS18663 .

ns12:IFS190148 owl:sameAs ns2:IFS1667 ;
    ns0:fullName "M. Hamidi" ;
    ns0:hasAffiliation ns15:IFS190148 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190148 ;
    ns0:inAuthorList ns150:IFS190148 .

ns12:IFS190217 owl:sameAs ns8:IFS18040 ;
    ns0:fullName "Harish Garg" ;
    ns0:hasAffiliation ns14:IFS190217 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS190217 ;
    ns0:inAuthorList ns150:IFS190217 .

ns12:JAD0058 ns0:inAuthorList ns150:JAD0058 .

ns12:JAD101416 ns0:inAuthorList ns150:JAD101416 .

ns12:JAD101821 ns0:inAuthorList ns150:JAD101821 .

ns12:JAD110788 ns0:inAuthorList ns150:JAD110788 .

ns12:JAD110797 ns0:inAuthorList ns150:JAD110797 .

ns12:JAD111544 ns0:inAuthorList ns150:JAD111544 .

ns12:JAD121606 ns0:inAuthorList ns150:JAD121606 .

ns12:JAD122098 ns0:inAuthorList ns150:JAD122098 .

ns12:JAD122263 ns0:inAuthorList ns150:JAD122263 .

ns12:JAD122302 ns0:inAuthorList ns150:JAD122302 .

ns12:JAD130053 ns0:inAuthorList ns150:JAD130053 .

ns12:JAD130104 ns0:inAuthorList ns150:JAD130104 .

ns12:JAD131151 ns0:inAuthorList ns150:JAD131151 .

ns12:JAD131172 ns0:inAuthorList ns150:JAD131172 .

ns12:JAD131343 ns0:inAuthorList ns150:JAD131343 .

ns12:JAD132075 ns0:inAuthorList ns150:JAD132075 .

ns12:JAD141959 ns0:inAuthorList ns150:JAD141959 .

ns12:JAD150978 ns0:inAuthorList ns150:JAD150978 .

ns12:JAD151026 ns0:inAuthorList ns150:JAD151026 .

ns12:JAD170319 ns0:inAuthorList ns150:JAD170319 .

ns12:JAD170595 ns0:inAuthorList ns150:JAD170595 .

ns12:JAD170938 ns0:inAuthorList ns150:JAD170938 .

ns12:JAD180030 ns0:inAuthorList ns150:JAD180030 .

ns12:JAD180216 ns0:inAuthorList ns150:JAD180216 .

ns12:JAD180242 ns0:inAuthorList ns150:JAD180242 .

ns12:JAD180511 owl:sameAs ns60:JAD170880 ;
    ns0:fullName "Suzana Makpol" ;
    ns0:hasAffiliation ns15:JAD180511 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180511 ;
    ns0:inAuthorList ns150:JAD180511 .

ns12:JAD180676 ns0:inAuthorList ns150:JAD180676 .

ns12:JAD181194 ns0:inAuthorList ns150:JAD181194 .

ns12:JAD190074 owl:sameAs ns8:JAD171071,
        ns57:JAD170894 ;
    ns0:fullName "Eliezer Masliah" ;
    ns0:hasAffiliation ns14:JAD190074,
        ns83:JAD190074,
        ns13:JAD190074 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190074 ;
    ns0:inAuthorList ns150:JAD190074 .

ns12:JAD190256 ns0:inAuthorList ns150:JAD190256 .

ns12:JAE170092 ns0:inAuthorList ns150:JAE170092 .

ns12:JAE171008 ns0:inAuthorList ns150:JAE171008 .

ns12:JAE171252 ns0:inAuthorList ns150:JAE171252 .

ns12:JAE191283 owl:sameAs ns12:JAE191149,
        ns12:JAE2122,
        ns30:JAE190821 ;
    ns0:fullName "Koji Fujiwara" ;
    ns0:hasAffiliation ns15:JAE191283 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191283 ;
    ns0:inAuthorList ns150:JAE191283 .

ns12:JAE1988 ns0:inAuthorList ns150:JAE1988 .

ns12:JAE2271 ns0:inAuthorList ns150:JAE2271 .

ns12:JCB189013 ns0:inAuthorList ns150:JCB189013 .

ns12:JHD180325 ns0:inAuthorList ns150:JHD180325 .

ns12:JPD171173 ns0:inAuthorList ns150:JPD171173 .

ns12:JPD191619 ns0:inAuthorList ns150:JPD191619 .

ns12:JVR180991 ns0:inAuthorList ns150:JVR180991 .

ns12:JVR811 ns0:inAuthorList ns150:JVR811 .

ns12:JVR836 ns0:inAuthorList ns150:JVR836 .

ns12:JVR894 ns0:inAuthorList ns150:JVR894 .

ns12:JVR898 ns0:inAuthorList ns150:JVR898 .

ns12:JVR940 ns0:inAuthorList ns150:JVR940 .

ns12:JVR941 ns0:inAuthorList ns150:JVR941 .

ns12:KCA170019 ns0:inAuthorList ns150:KCA170019 .

ns12:SW224 ns0:inAuthorList ns150:SW224 .

ns12:SW266 ns0:inAuthorList ns150:SW266 .

ns12:XST17364 ns0:inAuthorList ns150:XST17364 .

ns12:XST18383 ns0:inAuthorList ns150:XST18383 .

ns12:XST547 ns0:inAuthorList ns150:XST547 .

ns12:XST574 ns0:inAuthorList ns150:XST574 .

ns12:XST602 ns0:inAuthorList ns150:XST602 .

ns12:bmr00426 ns0:inAuthorList ns150:bmr00426 .

ns12:his00158 ns0:inAuthorList ns150:his00158 .

ns12:ica00416 ns0:inAuthorList ns150:ica00416 .

ns12:jad01227 ns0:inAuthorList ns150:jad01227 .

ns12:jad01361 ns0:inAuthorList ns150:jad01361 .

ns12:jad091681 ns0:inAuthorList ns150:jad091681 .

ns176:JAD110074 ns0:inAuthorList ns150:JAD110074 .

ns139:JAD161208 ns0:inAuthorList ns150:JAD161208 .

ns139:JAD180321 ns0:inAuthorList ns150:JAD180321 .

<http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD170875> ns0:inAuthorList ns150:JAD170875 .

<http://ld.iospress.nl/rdf/contributor/Author:22.ID:JAD180512> ns0:inAuthorList ns150:JAD180512 .

<http://ld.iospress.nl/rdf/contributor/Author:23.ID:JAD181016> ns0:inAuthorList ns150:JAD181016 .

ns180:JAD161097 ns0:inAuthorList ns150:JAD161097 .

ns143:JAD150749 ns0:inAuthorList ns150:JAD150749 .

ns143:JAD150863 ns0:inAuthorList ns150:JAD150863 .

ns30:ADR170035 ns0:inAuthorList ns150:ADR170035 .

ns30:BD248 ns0:inAuthorList ns150:BD248 .

ns30:BME1377 ns0:inAuthorList ns150:BME1377 .

ns30:BME1464 ns0:inAuthorList ns150:BME1464 .

ns30:CH168052 ns0:inAuthorList ns150:CH168052 .

ns30:CH168107 ns0:inAuthorList ns150:CH168107 .

ns30:CH179217 ns0:inAuthorList ns150:CH179217 .

ns30:CH179233 ns0:inAuthorList ns150:CH179233 .

ns30:CH189406 ns0:inAuthorList ns150:CH189406 .

ns30:CH189407 ns0:inAuthorList ns150:CH189407 .

ns30:CH1962 ns0:inAuthorList ns150:CH1962 .

ns30:CH199213 owl:sameAs ns2:CH2005,
        ns8:CH16195,
        ns8:CH179201,
        ns8:CH189129,
        ns8:CH189415,
        ns8:CH1963,
        ns8:CH1964,
        ns26:CH179226,
        ns12:CH189411,
        ns30:CH170365,
        ns30:CH179202,
        ns30:CH179212,
        ns30:CH179216,
        ns30:CH199004,
        ns30:CH199218,
        ns5:CH179106,
        ns16:CH168100,
        ns16:CH179227,
        ns16:CH189319,
        ns16:CH199220,
        ns52:CH170265,
        ns57:CH168110,
        ns57:CH168120,
        ns57:CH170246,
        ns60:CH189107,
        ns60:CH189905,
        ns60:CH199009,
        ns33:CH189309,
        ns33:CH189315 ;
    ns0:fullName "Lukas Prantl" ;
    ns0:hasAffiliation ns31:CH199213 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199213 ;
    ns0:inAuthorList ns150:CH199213 .

ns30:HAB180358 ns0:inAuthorList ns150:HAB180358 .

ns30:HAB190369 ns0:inAuthorList ns150:HAB190369 .

ns30:HAB304 ns0:inAuthorList ns150:HAB304 .

ns30:HIS241 ns0:inAuthorList ns150:HIS241 .

ns30:IFS172005 ns0:inAuthorList ns150:IFS172005 .

ns30:IFS172282 ns0:inAuthorList ns150:IFS172282 .

ns30:IFS17497 ns0:inAuthorList ns150:IFS17497 .

ns30:IFS17848 ns0:inAuthorList ns150:IFS17848 .

ns30:IFS181291 ns0:inAuthorList ns150:IFS181291 .

ns30:IFS181460 owl:sameAs ns8:IFS162058 ;
    ns0:fullName "Muhammad Izhar" ;
    ns0:hasAffiliation ns64:IFS181460 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181460 ;
    ns0:inAuthorList ns150:IFS181460 .

ns30:IFS18667 ns0:inAuthorList ns150:IFS18667 .

ns30:IFS18877 owl:sameAs ns8:IFS171176,
        ns8:IFS171187,
        ns8:IFS2113,
        ns12:IFS172195,
        ns12:IFS181452,
        ns30:IFS2114,
        ns30:IFS2121,
        ns5:IFS171685,
        ns5:IFS18347 ;
    ns0:fullName "Madhumangal Pal" ;
    ns0:hasAffiliation ns252:IFS18877 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS18877 ;
    ns0:inAuthorList ns150:IFS18877 .

ns30:JAD101068 ns0:inAuthorList ns150:JAD101068 .

ns30:JAD101704 ns0:inAuthorList ns150:JAD101704 .

ns30:JAD101911 ns0:inAuthorList ns150:JAD101911 .

ns30:JAD102103 ns0:inAuthorList ns150:JAD102103 .

ns30:JAD120523 ns0:inAuthorList ns150:JAD120523 .

ns30:JAD120802 ns0:inAuthorList ns150:JAD120802 .

ns30:JAD120946 ns0:inAuthorList ns150:JAD120946 .

ns30:JAD121525 ns0:inAuthorList ns150:JAD121525 .

ns30:JAD122116 ns0:inAuthorList ns150:JAD122116 .

ns30:JAD131085 ns0:inAuthorList ns150:JAD131085 .

ns30:JAD132225 ns0:inAuthorList ns150:JAD132225 .

ns30:JAD132306 ns0:inAuthorList ns150:JAD132306 .

ns30:JAD132414 ns0:inAuthorList ns150:JAD132414 .

ns30:JAD141294 ns0:inAuthorList ns150:JAD141294 .

ns30:JAD142052 ns0:inAuthorList ns150:JAD142052 .

ns30:JAD143084 ns0:inAuthorList ns150:JAD143084 .

ns30:JAD150776 ns0:inAuthorList ns150:JAD150776 .

ns30:JAD150883 ns0:inAuthorList ns150:JAD150883 .

ns30:JAD160163 ns0:inAuthorList ns150:JAD160163 .

ns30:JAD160970 ns0:inAuthorList ns150:JAD160970 .

ns30:JAD161020 ns0:inAuthorList ns150:JAD161020 .

ns30:JAD170702 ns0:inAuthorList ns150:JAD170702 .

ns30:JAD171131 ns0:inAuthorList ns150:JAD171131 .

ns30:JAD180055 ns0:inAuthorList ns150:JAD180055 .

ns30:JAD180335 ns0:inAuthorList ns150:JAD180335 .

ns30:JAD180425 ns0:inAuthorList ns150:JAD180425 .

ns30:JAD180439 ns0:inAuthorList ns150:JAD180439 .

ns30:JAD180524 ns0:inAuthorList ns150:JAD180524 .

ns30:JAD181186 ns0:inAuthorList ns150:JAD181186 .

ns30:JAD190014 ns0:inAuthorList ns150:JAD190014 .

ns30:JAD190113 owl:sameAs ns2:IFS161927,
        ns8:IFS17465,
        ns8:IFS17912 ;
    ns0:fullName "Yu Zhong" ;
    ns0:hasAffiliation ns252:JAD190113 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190113 ;
    ns0:inAuthorList ns150:JAD190113 .

ns30:JAD190474 owl:sameAs ns40:JAD141314,
        ns5:JAD130971,
        ns16:JAD101977,
        ns52:JAD111766,
        ns52:JAD140846,
        ns52:JAD171027,
        ns57:JAD120169,
        ns60:JAD150537,
        ns60:JAD190524,
        ns33:JAD141266 ;
    ns0:fullName "Perminder S. Sachdev" ;
    ns0:hasAffiliation ns252:JAD190474,
        ns31:JAD190474,
        ns64:JAD190474 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190474 ;
    ns0:inAuthorList ns150:JAD190474 .

ns30:JAD190508 owl:sameAs ns2:JAD181194,
        ns12:JAD180569 ;
    ns0:fullName "Louis Jacob" ;
    ns0:hasAffiliation ns64:JAD190508 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190508 ;
    ns0:inAuthorList ns150:JAD190508 .

ns30:JAD190541 owl:sameAs ns40:JAD170564,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD161208>,
        <http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD170039>,
        ns12:JAD170859 ;
    ns0:fullName "Frans R.J. Verhey" ;
    ns0:hasAffiliation ns252:JAD190541 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190541 ;
    ns0:inAuthorList ns150:JAD190541 .

ns30:JAD190782 owl:sameAs ns2:jad00545,
        ns8:JAD141626,
        ns8:JAD150134,
        ns8:JAD190790,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad01239>,
        ns12:JAD00024,
        ns12:JAD110021,
        ns12:JAD122223,
        ns12:JAD132762,
        ns30:jad100666,
        ns5:JAD190197,
        ns5:jad00325,
        ns16:jad00838,
        ns52:JAD180023,
        ns52:JAD181039,
        ns52:jad00733,
        ns52:jad01155,
        ns57:JAD170999,
        ns57:jad00309,
        ns57:jad00418,
        ns57:jad01021 ;
    ns0:fullName "George Perry" ;
    ns0:hasAffiliation ns64:JAD190782 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190782 ;
    ns0:inAuthorList ns150:JAD190782 .

ns30:JAE1979 ns0:inAuthorList ns150:JAE1979 .

ns30:JCB179014 ns0:inAuthorList ns150:JCB179014 .

ns30:JVR180991 ns0:inAuthorList ns150:JVR180991 .

ns30:JVR191022 owl:sameAs ns2:WOR2601 ;
    ns0:fullName "Richard T. Roessler" ;
    ns0:hasAffiliation ns63:JVR191022 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191022 ;
    ns0:inAuthorList ns150:JVR191022 .

ns30:JVR191041 ns0:inAuthorList ns150:JVR191041 .

ns30:JVR814 ns0:inAuthorList ns150:JVR814 .

ns30:JVR896 ns0:inAuthorList ns150:JVR896 .

ns30:MNM180242 ns0:inAuthorList ns150:MNM180242 .

ns30:NRE1271 ns0:inAuthorList ns150:NRE1271 .

ns30:NRE172306 ns0:inAuthorList ns150:NRE172306 .

ns30:RNN150515 ns0:inAuthorList ns150:RNN150515 .

ns30:SW222 ns0:inAuthorList ns150:SW222 .

ns30:THC199011 ns0:inAuthorList ns150:THC199011 .

ns30:VES190668 owl:sameAs ns8:JAD181180,
        ns12:JAD180808 ;
    ns0:fullName "Karel Kostev" ;
    ns0:hasAffiliation ns64:VES190668 ;
    ns0:hasArticle ns1:ves-v29-i4-VES190668 ;
    ns0:inAuthorList ns150:VES190668 .

ns30:WOR2318 ns0:inAuthorList ns150:WOR2318 .

ns30:WOR2737 ns0:inAuthorList ns150:WOR2737 .

ns30:XST16173 ns0:inAuthorList ns150:XST16173 .

ns30:XST17324 ns0:inAuthorList ns150:XST17324 .

ns30:XST180422 ns0:inAuthorList ns150:XST180422 .

ns30:jad00920 ns0:inAuthorList ns150:jad00920 .

ns30:jad01337 ns0:inAuthorList ns150:jad01337 .

ns30:jad100114 ns0:inAuthorList ns150:jad100114 .

ns30:jad101368 ns0:inAuthorList ns150:jad101368 .

ns118:JAD180341 ns0:inAuthorList ns150:JAD180341 .

<http://ld.iospress.nl/rdf/contributor/Author:36.ID:JAD160668> ns0:inAuthorList ns150:JAD160668 .

<http://ld.iospress.nl/rdf/contributor/Author:38.ID:JAD110824> ns0:inAuthorList ns150:JAD110824 .

<http://ld.iospress.nl/rdf/contributor/Author:39.ID:JAD160668> ns0:inAuthorList ns150:JAD160668 .

ns5:ADR170035 ns0:inAuthorList ns150:ADR170035 .

ns5:BD180351 ns0:inAuthorList ns150:BD180351 .

ns5:CH170244 ns0:inAuthorList ns150:CH170244 .

ns5:CH189308 ns0:inAuthorList ns150:CH189308 .

ns5:CH189309 ns0:inAuthorList ns150:CH189309 .

ns5:CH189310 ns0:inAuthorList ns150:CH189310 .

ns5:CH189323 ns0:inAuthorList ns150:CH189323 .

ns5:CH189405 ns0:inAuthorList ns150:CH189405 .

ns5:CH189415 ns0:inAuthorList ns150:CH189415 .

ns5:CH189905 ns0:inAuthorList ns150:CH189905 .

ns5:CH199206 ns0:inAuthorList ns150:CH199206 .

ns5:CH199222 owl:sameAs ns5:CH168116,
        ns5:CH179102,
        ns5:CH189404,
        ns16:CH179221,
        ns16:CH189114,
        ns16:CH189115,
        ns16:CH189116,
        ns16:CH189405,
        ns16:CH189407,
        ns16:CH2009,
        ns16:CH2010,
        ns52:CH168115,
        ns57:CH168034,
        ns57:CH1986,
        ns57:CH2046 ;
    ns0:fullName "D.-A. Clevert" ;
    ns0:hasAffiliation ns50:CH199222 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199222 ;
    ns0:inAuthorList ns150:CH199222 .

ns5:HAB180344 ns0:inAuthorList ns150:HAB180344 .

ns5:HAB299 ns0:inAuthorList ns150:HAB299 .

ns5:HSM1773 ns0:inAuthorList ns150:HSM1773 .

ns5:IFS169572 ns0:inAuthorList ns150:IFS169572 .

ns5:IFS171164 ns0:inAuthorList ns150:IFS171164 .

ns5:IFS179095 owl:sameAs ns8:IFS179057 ;
    ns0:fullName "M. Elhoseny" ;
    ns0:hasAffiliation ns123:IFS179095 ;
    ns0:hasArticle ns1:ifs-v37-i1-IFS179095 ;
    ns0:inAuthorList ns150:IFS179095 .

ns5:IFS181460 owl:sameAs ns2:IFS181295,
        ns8:IFS18833,
        ns12:IFS161702,
        ns12:IFS161740,
        ns12:IFS17728 ;
    ns0:fullName "Bijan Davvaz" ;
    ns0:hasAffiliation ns123:IFS181460 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181460 ;
    ns0:inAuthorList ns150:IFS181460 .

ns5:IFS190565 owl:sameAs ns2:IFS1856,
        ns2:IFS2075,
        ns2:IFS2114,
        ns8:IFS152553,
        ns8:IFS190148,
        ns12:IFS181488 ;
    ns0:fullName "R.A. Borzooei" ;
    ns0:hasAffiliation ns87:IFS190565 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190565 ;
    ns0:inAuthorList ns150:IFS190565 .

ns5:JAD111400 ns0:inAuthorList ns150:JAD111400 .

ns5:JAD120202 ns0:inAuthorList ns150:JAD120202 .

ns5:JAD121648 ns0:inAuthorList ns150:JAD121648 .

ns5:JAD122071 ns0:inAuthorList ns150:JAD122071 .

ns5:JAD122227 ns0:inAuthorList ns150:JAD122227 .

ns5:JAD122302 ns0:inAuthorList ns150:JAD122302 .

ns5:JAD130170 ns0:inAuthorList ns150:JAD130170 .

ns5:JAD130359 ns0:inAuthorList ns150:JAD130359 .

ns5:JAD131232 ns0:inAuthorList ns150:JAD131232 .

ns5:JAD131640 ns0:inAuthorList ns150:JAD131640 .

ns5:JAD132225 ns0:inAuthorList ns150:JAD132225 .

ns5:JAD140930 ns0:inAuthorList ns150:JAD140930 .

ns5:JAD140942 ns0:inAuthorList ns150:JAD140942 .

ns5:JAD142136 ns0:inAuthorList ns150:JAD142136 .

ns5:JAD160110 ns0:inAuthorList ns150:JAD160110 .

ns5:JAD170195 ns0:inAuthorList ns150:JAD170195 .

ns5:JAD170727 ns0:inAuthorList ns150:JAD170727 .

ns5:JAD170731 ns0:inAuthorList ns150:JAD170731 .

ns5:JAD170784 ns0:inAuthorList ns150:JAD170784 .

ns5:JAD180199 ns0:inAuthorList ns150:JAD180199 .

ns5:JAD180344 ns0:inAuthorList ns150:JAD180344 .

ns5:JAD180513 ns0:inAuthorList ns150:JAD180513 .

ns5:JAD180563 ns0:inAuthorList ns150:JAD180563 .

ns5:JAD180592 ns0:inAuthorList ns150:JAD180592 .

ns5:JAD180595 ns0:inAuthorList ns150:JAD180595 .

ns5:JAD181145 ns0:inAuthorList ns150:JAD181145 .

ns5:JAD190334 owl:sameAs ns52:JAD160633 ;
    ns0:fullName "Mikko Hiltunen" ;
    ns0:hasAffiliation ns6:JAD190334,
        ns123:JAD190334,
        ns87:JAD190334 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190334 ;
    ns0:inAuthorList ns150:JAD190334 .

ns5:JAD190342 owl:sameAs ns2:JAD141248,
        ns2:JAD160826,
        ns2:JAD161209,
        ns2:JAD190181,
        ns2:JAD190506,
        ns8:JAD112126,
        ns12:JAD140630,
        ns12:JAD160774,
        ns12:JAD170055,
        ns5:JAD170050,
        ns5:JAD180572,
        ns16:JAD180631 ;
    ns0:fullName "Kaarin J. Anstey" ;
    ns0:hasAffiliation ns87:JAD190342,
        ns71:JAD190342,
        ns124:JAD190342 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190342 ;
    ns0:inAuthorList ns150:JAD190342 .

ns5:JAD190501 owl:sameAs ns60:JAD181049 ;
    ns0:fullName "Ying Han" ;
    ns0:hasAffiliation ns6:JAD190501,
        ns50:JAD190501,
        ns120:JAD190501,
        ns123:JAD190501 ;
    ns0:hasArticle ns1:jad-v72-i2-JAD190501 ;
    ns0:inAuthorList ns150:JAD190501 .

ns5:JAD190540 owl:sameAs ns16:JAD122026 ;
    ns0:fullName "Saima Hilal" ;
    ns0:hasAffiliation ns6:JAD190540,
        ns120:JAD190540,
        ns87:JAD190540,
        ns71:JAD190540,
        ns124:JAD190540 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190540 ;
    ns0:inAuthorList ns150:JAD190540 .

ns5:JAD190708 owl:sameAs ns57:JAD131481 ;
    ns0:fullName "Mario F. Mendez" ;
    ns0:hasAffiliation ns6:JAD190708,
        ns120:JAD190708,
        ns87:JAD190708 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190708 ;
    ns0:inAuthorList ns150:JAD190708 .

ns5:JAE180001 ns0:inAuthorList ns150:JAE180001 .

ns5:JHD170256 ns0:inAuthorList ns150:JHD170256 .

ns5:JPD171264 ns0:inAuthorList ns150:JPD171264 .

ns5:JPD191593 ns0:inAuthorList ns150:JPD191593 .

ns5:JVR191022 owl:sameAs ns12:JVR838,
        ns30:JVR809,
        ns30:JVR816,
        ns5:JVR811,
        ns52:JVR914,
        ns57:JVR930 ;
    ns0:fullName "Fong Chan" ;
    ns0:hasAffiliation ns87:JVR191022 ;
    ns0:hasArticle ns1:jvr-v51-i1-JVR191022 ;
    ns0:inAuthorList ns150:JVR191022 .

ns5:MNM180224 ns0:inAuthorList ns150:MNM180224 .

ns5:NRE182452 ns0:inAuthorList ns150:NRE182452 .

ns5:RNN170773 ns0:inAuthorList ns150:RNN170773 .

ns5:THC199011 ns0:inAuthorList ns150:THC199011 .

ns5:XST16212 ns0:inAuthorList ns150:XST16212 .

ns5:XST180477 owl:sameAs ns8:JCM607,
        ns57:XST579 ;
    ns0:fullName "Dong Liang" ;
    ns0:hasAffiliation ns6:XST180477 ;
    ns0:hasArticle ns1:xst-v27-i3-XST180477 ;
    ns0:inAuthorList ns150:XST180477 .

ns5:jad00920 ns0:inAuthorList ns150:jad00920 .

ns5:jad01129 ns0:inAuthorList ns150:jad01129 .

ns5:jad01309 ns0:inAuthorList ns150:jad01309 .

ns5:jad01337 ns0:inAuthorList ns150:jad01337 .

ns5:jad100078 ns0:inAuthorList ns150:jad100078 .

<http://ld.iospress.nl/rdf/contributor/Author:42.ID:JAD160668> ns0:inAuthorList ns150:JAD160668 .

ns16:CH16194 ns0:inAuthorList ns150:CH16194 .

ns16:CH16196 ns0:inAuthorList ns150:CH16196 .

ns16:CH168044 ns0:inAuthorList ns150:CH168044 .

ns16:CH189310 ns0:inAuthorList ns150:CH189310 .

ns16:CH189324 ns0:inAuthorList ns150:CH189324 .

ns16:CH199006 ns0:inAuthorList ns150:CH199006 .

ns16:CH199205 owl:sameAs ns12:CH2028,
        ns30:CH168033,
        ns30:CH189125,
        ns30:CH189904,
        ns30:CH2004,
        ns16:CH168107,
        ns16:CH168114,
        ns16:CH189418,
        ns52:CH199005,
        ns57:CH189906,
        ns60:CH179210,
        ns33:CH2001 ;
    ns0:fullName "Andreas Lendlein" ;
    ns0:hasAffiliation ns21:CH199205,
        ns22:CH199205,
        ns193:CH199205 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199205 ;
    ns0:inAuthorList ns150:CH199205 .

ns16:IFS16727 ns0:inAuthorList ns150:IFS16727 .

ns16:JAD111736 ns0:inAuthorList ns150:JAD111736 .

ns16:JAD120022 ns0:inAuthorList ns150:JAD120022 .

ns16:JAD120934 ns0:inAuthorList ns150:JAD120934 .

ns16:JAD130053 ns0:inAuthorList ns150:JAD130053 .

ns16:JAD131088 ns0:inAuthorList ns150:JAD131088 .

ns16:JAD131121 ns0:inAuthorList ns150:JAD131121 .

ns16:JAD131820 ns0:inAuthorList ns150:JAD131820 .

ns16:JAD131934 ns0:inAuthorList ns150:JAD131934 .

ns16:JAD140138 ns0:inAuthorList ns150:JAD140138 .

ns16:JAD140684 ns0:inAuthorList ns150:JAD140684 .

ns16:JAD140924 ns0:inAuthorList ns150:JAD140924 .

ns16:JAD141230 ns0:inAuthorList ns150:JAD141230 .

ns16:JAD141542 ns0:inAuthorList ns150:JAD141542 .

ns16:JAD142025 ns0:inAuthorList ns150:JAD142025 .

ns16:JAD143084 ns0:inAuthorList ns150:JAD143084 .

ns16:JAD150548 ns0:inAuthorList ns150:JAD150548 .

ns16:JAD150791 ns0:inAuthorList ns150:JAD150791 .

ns16:JAD160230 ns0:inAuthorList ns150:JAD160230 .

ns16:JAD160685 ns0:inAuthorList ns150:JAD160685 .

ns16:JAD161224 ns0:inAuthorList ns150:JAD161224 .

ns16:JAD161257 ns0:inAuthorList ns150:JAD161257 .

ns16:JAD170289 ns0:inAuthorList ns150:JAD170289 .

ns16:JAD170324 ns0:inAuthorList ns150:JAD170324 .

ns16:JAD170418 ns0:inAuthorList ns150:JAD170418 .

ns16:JAD170502 ns0:inAuthorList ns150:JAD170502 .

ns16:JAD170564 ns0:inAuthorList ns150:JAD170564 .

ns16:JAD170604 ns0:inAuthorList ns150:JAD170604 .

ns16:JAD171027 ns0:inAuthorList ns150:JAD171027 .

ns16:JAD180055 ns0:inAuthorList ns150:JAD180055 .

ns16:JAD180299 ns0:inAuthorList ns150:JAD180299 .

ns16:JAD180403 ns0:inAuthorList ns150:JAD180403 .

ns16:JAD180496 owl:sameAs ns57:JAD170880 ;
    ns0:fullName "Hanafi Ahmad Damanhuri" ;
    ns0:hasAffiliation ns21:JAD180496 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180496 ;
    ns0:inAuthorList ns150:JAD180496 .

ns16:JAD180524 ns0:inAuthorList ns150:JAD180524 .

ns16:JAD180653 ns0:inAuthorList ns150:JAD180653 .

ns16:JAD180715 ns0:inAuthorList ns150:JAD180715 .

ns16:JAD181080 ns0:inAuthorList ns150:JAD181080 .

ns16:JAD181218 ns0:inAuthorList ns150:JAD181218 .

ns16:JAD190262 owl:sameAs ns30:JAD111631,
        ns52:JAD180604 ;
    ns0:fullName "Richard B. Lipton" ;
    ns0:hasAffiliation ns21:JAD190262,
        ns22:JAD190262,
        ns195:JAD190262 ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190262 ;
    ns0:inAuthorList ns150:JAD190262 .

ns16:JAD190423 owl:sameAs ns12:JAD190638,
        ns176:JAD180152,
        ns52:JAD160766,
        ns57:JAD140669,
        ns57:JAD160645,
        ns60:JAD141260 ;
    ns0:fullName "Magda Tsolaki" ;
    ns0:hasAffiliation ns21:JAD190423,
        ns22:JAD190423 ;
    ns0:hasArticle ns1:jad-v70-i3-JAD190423 ;
    ns0:inAuthorList ns150:JAD190423 .

ns16:JAD190541 owl:sameAs ns12:JAD160766 ;
    ns0:fullName "Sebastian Köhler" ;
    ns0:hasAffiliation ns21:JAD190541 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190541 ;
    ns0:inAuthorList ns150:JAD190541 .

ns16:JHD190354 ns0:inAuthorList ns150:JHD190354 .

ns16:JVR813 ns0:inAuthorList ns150:JVR813 .

ns16:NIB180141 ns0:inAuthorList ns150:NIB180141 .

ns16:bmr00519 ns0:inAuthorList ns150:bmr00519 .

ns16:jad01309 ns0:inAuthorList ns150:jad01309 .

ns16:jad100459 ns0:inAuthorList ns150:jad100459 .

ns16:jad100597 ns0:inAuthorList ns150:jad100597 .

ns16:jad100795 ns0:inAuthorList ns150:jad100795 .

ns52:CH160207 ns0:inAuthorList ns150:CH160207 .

ns52:CH179235 ns0:inAuthorList ns150:CH179235 .

ns52:JAD101809 ns0:inAuthorList ns150:JAD101809 .

ns52:JAD102043 ns0:inAuthorList ns150:JAD102043 .

ns52:JAD110365 ns0:inAuthorList ns150:JAD110365 .

ns52:JAD111766 ns0:inAuthorList ns150:JAD111766 .

ns52:JAD121408 ns0:inAuthorList ns150:JAD121408 .

ns52:JAD122110 ns0:inAuthorList ns150:JAD122110 .

ns52:JAD122233 ns0:inAuthorList ns150:JAD122233 .

ns52:JAD130296 ns0:inAuthorList ns150:JAD130296 .

ns52:JAD130698 ns0:inAuthorList ns150:JAD130698 .

ns52:JAD131694 ns0:inAuthorList ns150:JAD131694 .

ns52:JAD140276 ns0:inAuthorList ns150:JAD140276 .

ns52:JAD140924 ns0:inAuthorList ns150:JAD140924 .

ns52:JAD142214 ns0:inAuthorList ns150:JAD142214 .

ns52:JAD142337 ns0:inAuthorList ns150:JAD142337 .

ns52:JAD150786 ns0:inAuthorList ns150:JAD150786 .

ns52:JAD150864 ns0:inAuthorList ns150:JAD150864 .

ns52:JAD150895 ns0:inAuthorList ns150:JAD150895 .

ns52:JAD150985 ns0:inAuthorList ns150:JAD150985 .

ns52:JAD151068 ns0:inAuthorList ns150:JAD151068 .

ns52:JAD151120 ns0:inAuthorList ns150:JAD151120 .

ns52:JAD160348 ns0:inAuthorList ns150:JAD160348 .

ns52:JAD160593 ns0:inAuthorList ns150:JAD160593 .

ns52:JAD160599 ns0:inAuthorList ns150:JAD160599 .

ns52:JAD160641 ns0:inAuthorList ns150:JAD160641 .

ns52:JAD160750 ns0:inAuthorList ns150:JAD160750 .

ns52:JAD160874 ns0:inAuthorList ns150:JAD160874 .

ns52:JAD160952 ns0:inAuthorList ns150:JAD160952 .

ns52:JAD170039 ns0:inAuthorList ns150:JAD170039 .

ns52:JAD170324 ns0:inAuthorList ns150:JAD170324 .

ns52:JAD170625 ns0:inAuthorList ns150:JAD170625 .

ns52:JAD170627 ns0:inAuthorList ns150:JAD170627 .

ns52:JAD171027 ns0:inAuthorList ns150:JAD171027 .

ns52:JAD180223 ns0:inAuthorList ns150:JAD180223 .

ns52:JAD180485 ns0:inAuthorList ns150:JAD180485 .

ns52:JAD180971 ns0:inAuthorList ns150:JAD180971 .

ns52:JHD180309 ns0:inAuthorList ns150:JHD180309 .

ns52:JHD180337 owl:sameAs ns26:JHD180285,
        ns57:JHD160197,
        ns57:JHD180325,
        ns33:JHD170284 ;
    ns0:fullName "Ralf Reilmann" ;
    ns0:hasAffiliation ns200:JHD180337,
        ns102:JHD180337,
        ns201:JHD180337 ;
    ns0:hasArticle ns1:jhd-v8-i3-JHD180337 ;
    ns0:inAuthorList ns150:JHD180337 .

ns52:JPD181351 ns0:inAuthorList ns150:JPD181351 .

ns52:NIB180141 ns0:inAuthorList ns150:NIB180141 .

ns52:WOR2596 ns0:inAuthorList ns150:WOR2596 .

ns52:XST180461 ns0:inAuthorList ns150:XST180461 .

ns52:jad01018 ns0:inAuthorList ns150:jad01018 .

ns52:jad01165 ns0:inAuthorList ns150:jad01165 .

ns52:jad01285 ns0:inAuthorList ns150:jad01285 .

ns52:jad100114 ns0:inAuthorList ns150:jad100114 .

ns52:jad100663 ns0:inAuthorList ns150:jad100663 .

ns52:jad100678 ns0:inAuthorList ns150:jad100678 .

ns52:jad101348 ns0:inAuthorList ns150:jad101348 .

<http://ld.iospress.nl/rdf/contributor/Author:61.ID:jad100933> ns0:inAuthorList ns150:jad100933 .

ns57:CH16142 ns0:inAuthorList ns150:CH16142 .

ns57:CH179104 ns0:inAuthorList ns150:CH179104 .

ns57:CH1986 ns0:inAuthorList ns150:CH1986 .

ns57:CH199206 ns0:inAuthorList ns150:CH199206 .

ns57:JAD111694 ns0:inAuthorList ns150:JAD111694 .

ns57:JAD112003 ns0:inAuthorList ns150:JAD112003 .

ns57:JAD112006 ns0:inAuthorList ns150:JAD112006 .

ns57:JAD120169 ns0:inAuthorList ns150:JAD120169 .

ns57:JAD121003 ns0:inAuthorList ns150:JAD121003 .

ns57:JAD130032 ns0:inAuthorList ns150:JAD130032 .

ns57:JAD132195 ns0:inAuthorList ns150:JAD132195 .

ns57:JAD132561 ns0:inAuthorList ns150:JAD132561 .

ns57:JAD140321 ns0:inAuthorList ns150:JAD140321 .

ns57:JAD141767 ns0:inAuthorList ns150:JAD141767 .

ns57:JAD150574 ns0:inAuthorList ns150:JAD150574 .

ns57:JAD160230 ns0:inAuthorList ns150:JAD160230 .

ns57:JAD160593 ns0:inAuthorList ns150:JAD160593 .

ns57:JAD161228 ns0:inAuthorList ns150:JAD161228 .

ns57:JAD161240 ns0:inAuthorList ns150:JAD161240 .

ns57:JAD170324 ns0:inAuthorList ns150:JAD170324 .

ns57:JAD170458 ns0:inAuthorList ns150:JAD170458 .

ns57:JAD170555 ns0:inAuthorList ns150:JAD170555 .

ns57:JAD170990 ns0:inAuthorList ns150:JAD170990 .

ns57:JAD180030 ns0:inAuthorList ns150:JAD180030 .

ns57:JAD180416 ns0:inAuthorList ns150:JAD180416 .

ns57:JAD180485 ns0:inAuthorList ns150:JAD180485 .

ns57:JAD180943 ns0:inAuthorList ns150:JAD180943 .

ns57:JAD181297 owl:sameAs ns143:JAD150749,
        ns5:JAD179938,
        ns16:JAD170407,
        ns52:JAD140186,
        ns52:JAD180375,
        ns57:JAD170458,
        ns33:JAD160116 ;
    ns0:fullName "M. Arfan Ikram" ;
    ns0:hasAffiliation ns208:JAD181297 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD181297 ;
    ns0:inAuthorList ns150:JAD181297 .

ns57:JAD190077 owl:sameAs ns2:JAD170773,
        ns2:jad01177,
        ns8:JAD129035,
        ns40:JAD120787,
        ns40:JAD180025,
        ns28:JAD120508,
        ns130:JAD150167,
        ns12:JAD101959,
        ns12:JAD150525,
        ns30:JAD161275,
        ns5:JAD130035,
        ns5:JAD160573,
        ns5:JAD170368,
        ns5:jad091012,
        ns5:jad100207,
        ns16:JAD111361,
        ns16:JAD161114,
        ns16:JAD180099,
        ns16:JAD190187,
        ns16:jad00125,
        ns52:JAD142025,
        ns52:JAD170226,
        ns52:JAD170784,
        ns52:JAD170950,
        ns57:JAD120019,
        ns57:JAD140339,
        ns57:JAD160195,
        ns57:JAD160528,
        ns57:JAD161146,
        ns57:JAD170402,
        ns60:JAD150897,
        ns60:JAD161126 ;
    ns0:fullName "Kaj Blennow" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff4.Author:7.ID:JAD190077>,
        ns88:JAD190077 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190077 ;
    ns0:inAuthorList ns150:JAD190077 .

ns57:JAD190132 owl:sameAs ns8:JAD111109,
        ns8:jad100597,
        ns12:JAD00041,
        ns5:JAD170534,
        ns52:JAD170854 ;
    ns0:fullName "Seppo Helisalmi" ;
    ns0:hasAffiliation ns210:JAD190132 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190132 ;
    ns0:inAuthorList ns150:JAD190132 .

ns57:JAD190306 owl:sameAs ns2:JAD131850,
        ns12:JAD160979,
        ns5:JAD131265,
        ns5:JAD170265,
        ns16:JAD150619,
        ns60:JAD160148 ;
    ns0:fullName "Henry Brodaty" ;
    ns0:hasAffiliation ns208:JAD190306,
        ns88:JAD190306 ;
    ns0:hasArticle ns1:jad-v71-i2-JAD190306 ;
    ns0:inAuthorList ns150:JAD190306 .

ns57:XST180477 ns0:inAuthorList ns150:XST180477 .

ns57:jad100597 ns0:inAuthorList ns150:jad100597 .

ns57:jad100816 ns0:inAuthorList ns150:jad100816 .

<http://ld.iospress.nl/rdf/contributor/Author:76.ID:JAD110824> ns0:inAuthorList ns150:JAD110824 .

ns60:BD264 ns0:inAuthorList ns150:BD264 .

ns60:JAD101764 ns0:inAuthorList ns150:JAD101764 .

ns60:JAD110341 ns0:inAuthorList ns150:JAD110341 .

ns60:JAD111070 ns0:inAuthorList ns150:JAD111070 .

ns60:JAD120931 ns0:inAuthorList ns150:JAD120931 .

ns60:JAD120946 ns0:inAuthorList ns150:JAD120946 .

ns60:JAD130080 ns0:inAuthorList ns150:JAD130080 .

ns60:JAD132351 ns0:inAuthorList ns150:JAD132351 .

ns60:JAD132558 ns0:inAuthorList ns150:JAD132558 .

ns60:JAD140624 ns0:inAuthorList ns150:JAD140624 .

ns60:JAD150440 ns0:inAuthorList ns150:JAD150440 .

ns60:JAD150729 ns0:inAuthorList ns150:JAD150729 .

ns60:JAD150776 ns0:inAuthorList ns150:JAD150776 .

ns60:JAD150909 ns0:inAuthorList ns150:JAD150909 .

ns60:JAD151175 ns0:inAuthorList ns150:JAD151175 .

ns60:JAD160074 ns0:inAuthorList ns150:JAD160074 .

ns60:JAD160230 ns0:inAuthorList ns150:JAD160230 .

ns60:JAD160518 ns0:inAuthorList ns150:JAD160518 .

ns60:JAD161006 ns0:inAuthorList ns150:JAD161006 .

ns60:JAD161142 ns0:inAuthorList ns150:JAD161142 .

ns60:JAD180619 ns0:inAuthorList ns150:JAD180619 .

ns60:JAD180942 ns0:inAuthorList ns150:JAD180942 .

ns60:JAD190077 owl:sameAs ns40:JAD121930,
        <http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190533>,
        ns57:JAD150897,
        ns33:JAD121471 ;
    ns0:fullName "Henrik Zetterberg" ;
    ns0:hasAffiliation ns217:JAD190077,
        ns216:JAD190077,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff6.Author:8.ID:JAD190077>,
        ns81:JAD190077 ;
    ns0:hasArticle ns1:jad-v71-i1-JAD190077 ;
    ns0:inAuthorList ns150:JAD190077 .

ns60:JAD190183 ns0:inAuthorList ns150:JAD190183 .

ns60:JAD190756 owl:sameAs ns2:jad101311,
        ns8:JAD160122,
        ns8:jad00087,
        ns8:jad01113,
        ns40:JAD101518,
        ns40:JAD161109,
        ns12:jad100327,
        ns30:jad100174,
        <http://ld.iospress.nl/rdf/contributor/Author:38.ID:JAD150883>,
        ns5:JAD101512,
        ns5:JAD121369,
        ns5:jad00147,
        ns5:jad00866,
        ns16:JAD122122,
        ns16:JAD130296,
        ns16:JAD131901,
        ns16:jad00079,
        ns16:jad091450,
        ns57:ADR170051,
        ns60:JAD170502 ;
    ns0:fullName "Bengt Winblad" ;
    ns0:hasAffiliation ns81:JAD190756 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190756 ;
    ns0:inAuthorList ns150:JAD190756 .

ns60:NRE1274 ns0:inAuthorList ns150:NRE1274 .

ns60:XST18369 ns0:inAuthorList ns150:XST18369 .

ns60:XST18374 ns0:inAuthorList ns150:XST18374 .

ns60:XST18388 ns0:inAuthorList ns150:XST18388 .

ns60:XST190506 ns0:inAuthorList ns150:XST190506 .

ns60:jad01051 ns0:inAuthorList ns150:jad01051 .

ns33:CH170253 ns0:inAuthorList ns150:CH170253 .

ns33:JAD110608 ns0:inAuthorList ns150:JAD110608 .

ns33:JAD111109 ns0:inAuthorList ns150:JAD111109 .

ns33:JAD112120 ns0:inAuthorList ns150:JAD112120 .

ns33:JAD121363 ns0:inAuthorList ns150:JAD121363 .

ns33:JAD130062 ns0:inAuthorList ns150:JAD130062 .

ns33:JAD132075 ns0:inAuthorList ns150:JAD132075 .

ns33:JAD140057 ns0:inAuthorList ns150:JAD140057 .

ns33:JAD150537 ns0:inAuthorList ns150:JAD150537 .

ns33:JAD150899 ns0:inAuthorList ns150:JAD150899 .

ns33:JAD160022 ns0:inAuthorList ns150:JAD160022 .

ns33:JAD160374 ns0:inAuthorList ns150:JAD160374 .

ns33:JAD160866 ns0:inAuthorList ns150:JAD160866 .

ns33:JAD161292 ns0:inAuthorList ns150:JAD161292 .

ns33:JAD170362 ns0:inAuthorList ns150:JAD170362 .

ns33:JAD170575 ns0:inAuthorList ns150:JAD170575 .

ns33:JAD170861 ns0:inAuthorList ns150:JAD170861 .

ns33:JAD170893 ns0:inAuthorList ns150:JAD170893 .

ns33:JAD170990 ns0:inAuthorList ns150:JAD170990 .

ns33:JAD180291 ns0:inAuthorList ns150:JAD180291 .

ns33:JAD180378 ns0:inAuthorList ns150:JAD180378 .

ns33:JAD180723 ns0:inAuthorList ns150:JAD180723 .

ns33:JAD181195 ns0:inAuthorList ns150:JAD181195 .

ns33:JAD190041 owl:sameAs ns8:jad100186 ;
    ns0:fullName "Afina W. Lemstra" ;
    ns0:hasAffiliation ns229:JAD190041 ;
    ns0:hasArticle ns1:jad-v70-i2-JAD190041 ;
    ns0:inAuthorList ns150:JAD190041 .

ns33:JAD190545 owl:sameAs ns2:JAD160866,
        ns60:JAD170604 ;
    ns0:fullName "Jordi A. Matías-Guiu" ;
    ns0:hasAffiliation ns227:JAD190545 ;
    ns0:hasArticle ns1:jad-v71-i4-JAD190545 ;
    ns0:inAuthorList ns150:JAD190545 .

ns33:KCA180041 ns0:inAuthorList ns150:KCA180041 .

ns33:XST190506 ns0:inAuthorList ns150:XST190506 .

ns33:XST190527 ns0:inAuthorList ns150:XST190527 .

ns33:jad00971 ns0:inAuthorList ns150:jad00971 .

ns33:jad101023 ns0:inAuthorList ns150:jad101023 .

ns1:blc-v5-i2-BLC190209 ns0:hasKeywords "Bladder cancer"@en,
        "MRE11"@en,
        "MRE11 isoform 1"@en,
        "MRE11 isoform 2"@en,
        "rs1805363"@en ;
    ns0:hasPubAbstract "Background: DNA double strand breaks are the cytotoxic lesions produced by ionising radiation. Critical for the repair of these lesions is the DNA damage response protein MRE11 which, in a complex with RAD50 and NBS1, mediates DNA damage signalling and double-strand break repair. We previously found the presence of an MRE11 germline single nucleotide polymorphism (SNP), rs1805363 (G > A), to be associated with poor outcome following radiotherapy (RT) and increased expression of MRE11 isoform 2 in a limited panel of bladder cancer cell lines and tumours.   Objectives: To look for further evidence in support of the SNP/isoform association in a larger panel of germline and tumour samples donated by patients diagnosed with invasive bladder cancer, and to test the hypothesis that bladder cancer cells expressing MRE11 isoform 2 would be more radio resistant than cells expressing MRE11 isoform 1.   Methods: Germline DNA from 189 patients with invasive bladder cancer (141 T2, 48 T1) was genotyped for the rs1805363 G > A SNP. Loss of heterozygosity was determined by genotyping tumour DNA in 17GA germline patients. The Cancer Genome Atlas was mined to correlate presence of the GA germline genotype with MRE11 isoform expression. We used colony formation assays and γH2AX foci kinetics after ionising radiation in RT112 MRE11 knockdown cells expressing ectopic MRE11 isoform 1 or 2.   Results: Of the 189 germline DNA samples, 22 contained both the A minor allele and G major allele with the remaining wild type containing only the G major allele. LOH was identified in seven of 17 available tumour samples. Tumour MRE11 isoform 2 expression was found to be significantly higher (p = 0.007) in patients’s samples containing the A minor allele compared to those with only the G major allele (n = 23). In the TCGA database we found 16% (66 out of 406) of bladder tumours heterozygous for the SNP and only two homozygous, and a significant relative increase of isoform 2 usage (p = 0.017). We identified no significant difference in radio sensitivity between bladder cancer cells expressing either MRE11 isoform.   Conclusions: In this study the MRE11 isoform 2 was not found to be associated with increased cellular sensitivity to radiation. We conclude that the previously reported association between the germline rs1805363 SNP and poor survival in MIBC patients following RT is unlikely to be related to the DNA damage response function of MRE11 isoform 2."@en ;
    ns0:hasPubTitle "MRE11A Isoform Expression Associated with Outcome Following Radiotherapy in Muscle-Invasive Bladder Cancer does not Alter Cell Survival and DNA Double-Strand Break Repair Following Ionising Radiation"@en .

ns1:blc-v5-i2-BLC190218 ns0:hasKeywords "Bladder cancer"@en,
        "PD-1"@en,
        "PD-L1"@en,
        "atezolizumab"@en,
        "avelumab"@en,
        "biomarkers"@en,
        "durvalumab"@en,
        "immunotherapy"@en,
        "nivolumab"@en,
        "pembrolizumab"@en ;
    ns0:hasPubAbstract "Background: The activity of PD-1/PD-L1 inhibitors in the treatment of advanced bladder cancer (BC) is promising for many patients. However, a subset of patients do not benefit from treatment, thus leading to an effort to better identify predictive molecular biomarkers of response.   Objective: To conduct a systematic review of the literature on predictive molecular biomarkers associated with response to PD-1 and PD-L1 inhibitors in advanced bladder cancer, defined as locally-advanced, unresectable, or metastatic (mBC) disease.   Methods: A search of the literature was performed using Embase (1947 – January 2019), Medline (1946 – January 2019), and EBM Reviews for Cochrane Central Register of Controlled Trials (as of December 2018). Studies examining the association of molecular biomarkers with clinical outcome in BC treated with PD-1 or PD-L1 monotherapy were included. Outcomes of interest were overall survival (OS), cancer-specific survival (CSS), progression-free survival (PFS), duration of response, and objective response rate (ORR).   Results: Using the study search criteria, 899 unique abstract citations were found, of which 834 did not meet the eligibility criteria. Full text of the remaining 65 citations were screened, and 50 studies excluded, including 18 review articles. Eight additional studies from the bibliography of the review papers were included, making a total of 23 studies. Five PD-1 / PD-L1 antibodies have been tested in BC immunohistochemistry (IHC). These studies used different expression scoring criteria and generally had poor ability to discriminate likelihood for response. Overall, the data suggests CD8+ T cell infiltration is necessary to mediate an antitumor immune response, but other immune cell populations, such as neutrophils may suppress T cell-mediated immunity and efficacy of PD-1/PD-L1 blockade. An IFNγ signature is a promising predictor, but there needs to be consensus on the optimal gene panel composition, and prospective validation. Tumor mutation burden (TMB) is a promising predictor in six studies reporting on 1200 patients, but there is not a consensus on the optimal definition of “high TMB”. Detection of T cell receptor (TCR) clonal expansion has only been conducted in small studies and so its predictive value remains inconclusive. Epithelial-mesenchymal transformation (EMT) and transforming growth factor β (TGFβ) are associated with poor prognosis and possibly intrinsic resistance to PD-1/PD-L1 checkpoint blockade, but more work needs to be done to build upon and confirm the initial findings.   Conclusions: Currently no molecular biomarker is sufficiently mature for routine clinical use, while some candidates, or a combination show great promise and need further study."@en ;
    ns0:hasPubTitle "Molecular Biomarkers of Response to PD-1/ PD-L1 Immune Checkpoint Blockade in Advanced Bladder Cancer"@en .

ns1:bme-v30-i4-BME191064 ns0:hasKeywords "Aneurysm"@en,
        "Transcranial Doppler"@en,
        "blood velocity"@en,
        "cerebral arteries"@en,
        "computational fluid dynamics"@en ;
    ns0:hasPubAbstract "BACKGROUND: The development of any disturbance in the Circle of Willis (COW) can change the hemodynamics of blood flow and result in damage to the vascular system. Clinical methods such as TCD for diagnosing an aneurysm or growth factors and rupture can measure blood velocity. Several factors influence the accuracy of TCD that can lead to wrong evaluations and affect the treatment planning.   OBJECTIVE: In this study, the conformity between CFD and TCD was accomplished for investigating the accuracy of the clinical method (TCD) in different vessels of the Circle of Willis.   METHODS: The realistic three-dimensional models have been produced from angiography images. Considering fluid-structure interaction, a domain of the blood flow and vessel wall has been simulated by the ANSYS.CFX software. The velocity in the cerebral arteries has been calculated and compared with the velocity acquired from TCD.   RESULTS: According to the findings, there were significant differences between the results obtained from computational fluid dynamics and Doppler test in different vessels of the Circle of Willis. In some areas, differences close to 80 cm/s were also reported.   CONCLUSION: According to the results, there are possibilities of errors in carrying out a Doppler test in some arteries and can lead to wrong estimates and ultimately incorrect decisions."@en ;
    ns0:hasPubTitle "Comparison of blood velocity between Transcranial Doppler and numerical method in the patient-specific Circle of Willis with aneurysm"@en .

ns1:bmr-v32-i4-BMR171041 ns0:hasKeywords "Pressure measurement"@en,
        "Scheuermann’s kyphosis"@en,
        "brace"@en,
        "reliability"@en,
        "sphygmomanometer"@en ;
    ns0:hasPubAbstract "BACKGROUND:  There is a lack of evidence in reliability of the modified sphygmomanometer to measure the brace-interface pad pressure in adolescents with Scheuermann’s kyphosis (SK).   OBJECTIVES:  To evaluate the intra- and inter-observer reliability of modified sphygmomanometer for measuring interface pad pressure in the Milwaukee brace.   METHODS:  Two observers measured the pressure of the shoulder and kyphosis pads in Milwaukee brace on 33 adolescents with SK with an average age of 14.67 ± 1.72 years and Cobb angle 64.48∘± 7.53∘. All measurements were obtained in one day. The measurements were done in the inhalation and exhalation of tidal breathing during standing and sitting positions. The intraclass correlation coefficient (ICC), 95% confidence interval (CI), and linear mixed model ANOVA effects were calculated.   RESULTS: The intra-observer reliability varied from a good ICC of 0.81 (0.66–0.90) to an excellent of 0.97 (0.95–0.98). The inter-observer reliability also varied from a good ICC of 0.82 (0.67–0.91) to an excellent of 0.96 (0.93–0.98). The linear mixed model ANOVA analysis showed that the rater, position, and breathing had a significant effect on the pad pressure measurements.   CONCLUSIONS: The modified sphygmomanometer is a reliable tool to measure the pad pressure of the Milwaukee brace for adolescents with SK."@en ;
    ns0:hasPubTitle "The intra- and inter-observer reliability of interface pressure measurements of the Milwaukee brace in adolescents with hyperkyphosis"@en .

ns1:bmr-v32-i5-BMR181185 ns0:hasKeywords "Spondylolisthesis"@en,
        "back pain"@en,
        "epidural"@en,
        "non-surgical treatment"@en,
        "steroids"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Non-surgical treatment is the primary approach to degenerative conditions of the lumbar spine and may involve multiple modalities. There is little literature to guide an evidence-based approach to care.   OBJECTIVE:  To determine the effectiveness of CNT (comprehensive non-surgical treatment) in patients with degenerative spondylolisthesis (DS) and spondylolytic spondylolisthesis (SS), and to identify predictor variables for success of CNT in avoiding surgery.   METHODS:  All patients who underwent CNT for spondylolisthesis (n: 203) were included. CNT consisted of patient education, pain control with transforaminal epidural steroid injections (TFEs) and/or medications, and exercise programs.   RESULTS:  Surgical and non-surgical patients were similar in age, smoking status, comorbidity scores, facet joint widening, and translation of spondylolisthesis. After CNT, only 21.6% of patients with DS and 31.3% of patients with SS chose to have surgery in 3-years follow-up. The non-surgical group reported significantly better pain relief (73.6% vs 55%) after TFEs for a longer period (152.8 vs 45.6 days) and lower opioid use than the surgical group (28.2% vs 55.3%).   CONCLUSIONS:  CNT is effective in spondylolisthesis and more successful in DS than SS. CNT may decrease the need for surgery, particularly in patients who report pain relief greater than 70% for average five months after TFEs."@en ;
    ns0:hasPubTitle "Comprehensive non-surgical treatment decreased the need for spine surgery in patients with spondylolisthesis: Three-year results"@en .

ns1:ch-v72-i1-CH180457 ns0:hasKeywords "Combination"@en,
        "TI-RADS"@en,
        "Thyroid nodules"@en,
        "contrast-enhanced ultrasound"@en,
        "fine-needle aspiration"@en ;
    ns0:hasPubAbstract "BACKGROUND: The thyroid imaging reporting and data system (TI-RADS), classified and determined the risk of thyroid nodule malignancy with ultrasound scanning. Contrast-enhanced ultrasound (CEUS) is newly developed methods which could measure perfusion features.   OBJECTIVE: The aim of the study was to investigate the value of diagnosing thyroid nodules using TI-RADS combined with CEUS and determine whether improvements were made to the diagnostic accuracy.   METHODS: The features of conventional ultrasonography (US) and CEUS ion 117 case of thyroid nodules samples, which were confirmed by fine-needle aspiration and/or surgery, were retrospectively analyzed. The independent US and CEUS predictors for malignancy were determined and quantified using logistic regression analysis. The receiver operating characteristic (ROC) curve analysis was used to compare the diagnostic efficiency of each method in predicting malignant solid thyroid nodules.   RESULTS: The TI-RADS + CEUS combination had the highest accuracy (94.02%), sensitivity (94.74%), specificity (93.33%), PPV (93.10%) and NPV (94.92%), significantly greater than that of TI-RADS alone and CEUS alone (χ2 = 8.746, P < 0.001; χ2 = 9.825, P < 0.001). The area under the ROC curve (AUC) of TI-RADS alone, CEUS alone, and combined use of TI-RADS and CEUS were 0.871, 0.884, and 0.942, respectively. The following conventional US and CEUS features based on logistic regression analysis showed significant predictive value for thyroid malignant nodules: Obscure margin, calcification, hypoechoic, low enhancement, rim-like enhancement.   CONCLUSIONS: TI-RADS in combination with CEUS has superior diagnostic efficiency in the discrimination of benign and malignant thyroid lesions, compared with TI-RADS and CEUS alone."@en ;
    ns0:hasPubTitle "Diagnostic performance of thyroid imaging reporting and data system (TI-RADS) alone and in combination with contrast-enhanced ultrasonography for the characterization of thyroid nodules"@en .

ns1:ch-v72-i2-CH180404 ns0:hasKeywords "Stiffness distribution"@en,
        "Young’s modulus"@en,
        "radiofrequency ablation"@en,
        "tissue elastometer"@en ;
    ns0:hasPubAbstract "OBJECTIVE:  To investigate the stiffness distribution in the ablated zone after radiofrequency ablation (RFA), we used a device called tissue elastometer based on gross liver samples.  MATERIALS:  AND METHODS: Twelve freshly excised porcine livers were subject to RFA under a same setup to form elliptic ablated samples. Each sample was cut open for gross examination, and then the surface of the section plane was sliced into one piece for Young’s modulus test using the tissue elastometer. Five test points along the long- and short-axis on each piece were selected to evaluate stiffness distribution respectively. Among them, four points distributed equidistantly from center to boundary in the ablated zone and one was in the unablated zone.  RESULTS:  In the ablated zone, we found the Young’s moduli were significantly different among the four test points both in long- (F = 99.04, p <0.001) and short-axis (F = 79.47, p <0.001) directions. The Young’s modulus showed a downtrend in each direction, and was linearly related to the distance from the center to the test point (for long axis, R2 = 0.968; for short axis, R2 = 0.984, both p <0.001). A more significant downtrend was observed in short-axis direction. The Young’s moduli gained from the inner edge of ablated zone were comparable and significantly higher than those from the outer edge for both directions. The maximum value of 24.71kPa for Young’s modulus was the appropriate threshold to ensure the tissues were necrotic completely.  CONCLUSION:  The stiffness inside the ablated zone represented a radial distribution with downtrend, following a linear law. The stiffness at the inner edge of ablated zone is stable and significantly higher than that at the outer edge. The maximum value of 24.71 kPa close to the inner edge of Wz may be used as the standard of complete ablation."@en ;
    ns0:hasPubTitle "Stiffness distribution in the ablated zone after radiofrequency ablation for liver: An ex-vivo study with a tissue elastometer"@en .

ns1:ch-v73-i1-CH199201 ns0:hasKeywords "AFM"@en,
        "Biomaterials"@en,
        "elastic modulus"@en,
        "electrospinning"@en,
        "force mapping"@en ;
    ns0:hasPubAbstract "The mechanical properties of electrospun fiber meshes typically are measured by tensile testing at the macro-scale without precisely addressing the spatial scale of living cells and their submicron architecture. Atomic force microscopy (AFM) enables the examination of the nano- and micro-mechanical properties of the fibers with potential to correlate the structural mechanical properties across length scales with composition and functional behavior. In this study, a polyesteretherurethane (PEEU) polymer containing poly(p-dioxanone) (PPDO) and poly(ɛ-caprolactone) (PCL) segments was electrospun into fiber meshes or suspended single fibers. We employed AFM three point bending testing and AFM force mapping to measure the elastic modulus and stiffness of individual micro/nanofibers and the fiber mesh. The local stiffness of the fiber mesh including the randomized, intersecting structure was also examined for each individual fiber. Force mapping results with a set point of 50 nN demonstrated the dependence of the elasticity of a single fiber on the fiber mesh architecture. The non-homogeneous stiffness along the same fiber was attributed to the intersecting structure of the supporting mesh morphology. The same fiber measured at a point with and without axial fiber support showed a remarkable difference in stiffness, ranging from 0.2 to 10 nN/nm respectively. For the region, where supporting fibers densely intersected, the stiffness was found to be considerably higher. In the region where the degrees of freedom of the fibers was not restricted, allowing greater displacement, the stiffness were observed to be lower. This study elucidates the relationship between architecture and the mechanical properties of a micro/nanofiber mesh. By providing a greater understanding of the role of spatial arrangement and organization on the surface mechanical properties of such materials, we hope to provide insight into the design of microenvironments capable of regulating cell functionality."@en ;
    ns0:hasPubTitle "Mechanical characterization of electrospun polyesteretherurethane (PEEU) meshes by atomic force microscopy"@en .

ns1:ch-v73-i1-CH199204 ns0:hasKeywords "CEUS"@en,
        "Spleen"@en,
        "contrast-enhanced ultrasound"@en,
        "focal splenic lesion"@en,
        "tumor"@en ;
    ns0:hasPubAbstract "BACKGROUND: Frequently focal splenic lesions (FSL) - cysts, hemangioma, hamartoma, metastases or infarction amongst others – are incidentally found within the scope of the sonographic examination of the abdomen. By using native B-mode and Color Doppler the underlying entity often is not elucidated. Thus, more elaborate imaging modalities like CT and MRI scans with their associated risks are used to clarify the entity of FSL.   PURPOSE: The aim of the present retrospective single-center study is to evaluate the diagnostic performance of CEUS examination for assessing splenic focal lesions by comparison with findings from CT and MRI scans.   MATERIALS AND METHODS: Between 2010–2018 46 patients were included in the study. All patients underwent native B-mode, Color Doppler and CEUS after given informed consent. The applied contrast agent was a second-generation blood pool agent (SonoVue®, Bracco, Milan, Italy). CEUS examinations were performed and interpreted by a single experienced radiologist (EFSUMB Level 3).   RESULTS: All patients were examined without occurrence of any side effects. In total, 53 FSL were investigated (9% traumatic vs. 91% non-traumatic). Compared to CT, CEUS showed a sensitivity, specificity, PPV, NPV of 100% for assessing infarction, hematoma, hamartoma, cystic and malignant lesions. In comparison with MRI, CEUS presented a sensitivity, specificity, PPV, NPV of 100% for evaluating pseudolesions, hemangioma, hamartoma, cystic and malignant lesions.   CONCLUSION: With an excellent safety profile CEUS shows an equipollent diagnostic performance for differentiating FSL compared to CT and MRI scans."@en ;
    ns0:hasPubTitle "Single-center study: The diagnostic performance of contrast-enhanced ultrasound (CEUS) for assessing focal splenic lesions compared to CT and MRI"@en .

ns1:ch-v73-i1-CH199210 ns0:hasKeywords "Colon cancer"@en,
        "cyclophosphamide"@en,
        "dehydration"@en,
        "hyperosmotic"@en,
        "osmolality"@en ;
    ns0:hasPubAbstract "BACKGROUND: In most clinical studies older people are underrepresented compared to the demographic reality. However, risk for some severe diseases like cancer typically increase with age. Most insight into cancer treatment comes from mixed-age patient cohorts, leading to a lack of detailed understanding of cancer drug effects in the elderly population. There is growing evidence that cancer drug effects can be influenced by dehydration conditions often found in older people. Colon cancer remains the second leading cause of death by cancer in Europe. Inter- and intra-heterogeneity of tumors contribute to why some individuals do not respond to specific cancer therapies or may often suffer a relapse.   OBJECTIVE: Our study applies an in vitro drug test system for simulating treatment with cytostatics of colorectal cancer in elderly patients with dehydration condition.   METHODS: Two well-known colon cancer cell lines, Caco-2 and RKO, harboring defined cancer-related mutations, were step-wisely adapted from routine culture medium to a severe hyperosmotic condition (397 mOmol/kg) by adding sodium chloride to the medium. We investigated the effects of these cell culture conditions, which should mimic cellular dehydration in elderly people, on the growth characteristics of the cells. Therefore, cell proliferation was investigated by measuring population doubling times. Furthermore, we investigated how the metabolic activity of the cells was influenced by treatment with different concentrations of cyclophosphamide (CPA) under normal and hyperosmotic conditions.   RESULTS: We found that Caco-2 and RKO cell lines have an identical cell doubling time of 23 hours in normosmotic medium. However, hyperosmotic medium lifted the doubling time of Caco-2 cells to 31 hours while that of RKO cells did not change. Despite reduced cell proliferation rates, hyperosmotic medium sensitized Caco-2 cells to treatment with 10 mM CPA for 48 hours as measured by metabolic activity assays on ATP levels.   CONCLUSIONS: The two investigated colon cancer cells lines reacted differently to hyperosmotic conditions. Only the growth of Caco-2 cells was reduced by increased osmolality. Despite this reduced growth their sensitivity to an alkylating cytostatic agent was even slightly increased. We are now in line to examine these effects in more detail and with more tumor cell lines."@en ;
    ns0:hasPubTitle "Colon cancer cells cultured under hyperosmotic conditions as in vitro model to investigate dehydration effects on cancer drug susceptibility"@en .

ns1:ch-v73-i1-CH199212 ns0:hasKeywords "Correlative light and electron microscopy (CLEM)"@en,
        "Epon"@en,
        "chemotherapy"@en,
        "chorioallantoic membrane (CAM)"@en,
        "doxorubicin"@en,
        "sarcoma"@en,
        "tumor"@en ;
    ns0:hasPubAbstract "BACKGROUND: Doxorubicin is a cytostatic drug from the group of anthracycline antibiotics that is widely used as a chemotherapeutic agent. Side effects of the active substance include cardiotoxicity and nephrotoxicity. Doxorubicin-treated renal epithelial cells and (sarcoma) tumors are examined by correlative light and electron microscopy (CLEM) to investigate the subcellular localization of doxorubicin.   METHODS: The kidney epithelial cell line MDCK II (Madin-Darby Canine Kidney) grown on culture dishes were treated with doxorubicin. Subsequently, the cells are analyzed by means of fluorescence and transmission electron microscopy (TEM). In vivo, alveolar rhabdomyosarcoma (RH 30) tumor cells are transferred to the chorioallantoic membrane (CAM) of the chicken embryo. Doxorubicin is injected into a vein of the chicken embryo. After 24 hours, the tumor is removed and examined using CLEM.   RESULTS: The kidney epithelial cells and the doxorubicin-injected tumors show a clear staining of the cell nucleus, which correlates with electron-dense regions (heterochromatin). High-resolution TEM shows that doxorubicin treatment leads to an enormous stress situation with an increased formation of membrane blebbings.   CONCLUSIONS: CLEM is a promising new method to visualize the pattern of fluorescing drugs (e.g. doxorubicin) in renal epithelial cells and tumors, and to localize the drug in its subcellular context combined with high resolution."@en ;
    ns0:hasPubTitle "Subcellular localization of the chemotherapeutic agent doxorubicin in renal epithelial cells and in tumor cells using correlative light and electron microscopy"@en .

ns1:ch-v73-i1-CH199218 ns0:hasKeywords "Wound healing"@en,
        "irradiation"@en,
        "platelet-rich plasma"@en,
        "proliferation"@en,
        "scratch assay"@en,
        "viability"@en ;
    ns0:hasPubAbstract "BACKGROUND: To overcome the compromised wound healing in radiation induced chronic wounds platelet-rich plasma (PRP), as therapeutic agent, is current subject of studies. PRP is associated with pro-angiogenic effects. Nevertheless, effects of platelet-rich plasma in cutaneous wound healing processes are poorly understood so far.   Methods: In this study, the migration of endothelial cells, fibroblasts and keratinocytes in conjunction with platelet-rich plasma treatment is investigated in the context of radiation effects. Additionally, cell proliferation and viability after external radiation was analyzed regarding treatment by platelet-rich plasma.   RESULTS: All cell cultures showed a trend towards decreasing proliferation and viability after irradiation irrespective of PRP. Upon PRP treatment, irradiated fibroblasts as well as endothelial cells showed an enhanced proliferation whereas proliferation and viability of keratinocytes was reduced after PRP treatment. Scratch assays support the positive effect of PRP on fibroblast and endothelial cell migration, whereas a negative effect on keratinocytes was observed after PRP treatment.   CONCLUSIONS: The present study documents both deleterious effects of external radiation as well as the protective effect of PRP. In summary, increased viability, proliferation and migration are indeed a consequence of the pro-proliferative effect exerted by PRP. Therefore, treatment with PRP products might be useful in the management of chronic radiogenic wounds."@en ;
    ns0:hasPubTitle "Impact of platelet-rich plasma on cell migration processes after external radiation"@en .

ns1:ch-v73-i1-CH199221 ns0:hasKeywords "CEUS"@en,
        "Contrast enhanced ultrasound"@en,
        "TIC-analysis"@en,
        "hepatocellular carcinoma"@en,
        "quantitative analysis"@en ;
    ns0:hasPubAbstract "OBJECTIVE: The use of a standardized dynamic contrast enhanced ultrasound (CEUS) protocol to determine perfusion of hepatocellular carcinomas (HCC) using quantitative analysis.   METHODS: Retrospective analysis of 27 patients with hepatocellular carcinoma examined by a standardized protocol (bolus injection of 2.4 ml sulphur hexafluoride microbubbles, arterial phase to portal venous phase using continuous CINE-loops over 1 minute, short CINE-loops after 2, 3, 4, 5 and 6 minutes and additional single images for B-mode, CCDS). The examination was performed by an experienced sonographer with a high resolution, multi-frequency transducer (1–6 MHz). The reading of the reference imaging (contrast enhanced CT and MRI) and histopathology, if necessary, was performed independently. Retrospective analysis of the CEUS DICOM loops was done using time intensity curve analysis (TIC) with evaluation of the time to peak (TTP) and the area under the curve (AUC).   RESULTS: All tumor lesions were characterized by CEUS, based on typical contrast patterns for HCC lesions with arterial enhancement and wash out in the late phase, corresponding to MRI with liver specific contrast agent or contrast enhanced CT. Mean TTP (SD) in the tumor centre (C) was 19.93 (11.31), in the periphery (P) 22.94 (9.44) and in the normal liver tissue (LT) 28.19 (11.34) with significant differences between all zones C/P (p = 0.013), C/LT (p = 0.005) and P/LT (p = 0.022). AUC mean (SD) in the tumor centre (C) was 660.03 (292.64), in the periphery (P) 586.04 (237.01) and in the normal liver tissue (LT) 484.20 (236.99), also with significant differences between all zones C/P (p = 0.001), C/LT (p < 0.001) and P/LT (p < 0.001).   CONCLUSION: TIC-analysis is an easy-to-use tool for the dynamic evaluation of microvascularization in hepatocellular carcinoma and allows a fast and cost-efficient quantitative analysis."@en ;
    ns0:hasPubTitle "Quantitative perfusion analysis of hepatocellular carcinoma using dynamic contrast enhanced ultrasound (CEUS) to determine tumor microvascularization"@en .

ns1:ch-v73-i1-CH199226 ns0:hasKeywords "Biotransformation"@en,
        "CYP"@en,
        "HepG2"@en,
        "HepaFH3"@en,
        "NADPH-cytochrome P450 reductase"@en,
        "POR"@en,
        "Upcyte® hepatocytes"@en,
        "cytochrome P450 monooxygenase"@en,
        "hepatocytes"@en,
        "xenobiotics"@en ;
    ns0:hasPubAbstract "BACKGROUND: Human hepatocyte in vitro cell culture systems are important models for drug development and toxicology studies in the context of liver xenobiotic metabolism. Often, such culture systems are used to elucidate the biotransformation of xenobiotics or drugs and further investigate drug and drug metabolite effects on biological systems in terms of potential therapeutic benefit or toxicity. Human hepatocytes currently used for such in vitro studies are mostly primary cells or cell lines derived from liver cancers. Both approaches have limitations such as low proliferation capacity and progressive dedifferentiation found in primary cells or lack of liver functions in cell lines, which makes it difficult to reliably predict biotransformation of xenobiotics in patients. In order to overcome these limitations, HepaFH3 cells and Upcyte® hepatocytes representing primary-like hepatocytes of the first and second generation are increasingly used. Based on primary human hepatocyte cells transduced for stable expression of Upcyte® proliferation genes, they are mitotically active and exhibit liver functions over an extended period, making them comparable to primary human hepatocytes. These hepatocyte models show active liver metabolism such as urea and glycogen formation as well as biotransformation of xenobiotics. The latter is based on the expression, activity and inducibility of cytochrome P450 enzymes (CYP) as essential phase I reaction components. However, for further characterisation in terms of performance and existing limitations, additional studies are needed to elucidate the mechanisms involved in phase I reactions. One prerequisite is sufficient activity of microsomal NADPH-cytochrome P450 reductase (POR) functionally connected as electron donor to those CYP enzymes.   OBJECTIVE: For Upcyte® hepatocytes and HepaFH3 cells, it is so far unknown to what extent POR is expressed, active, and may exert CYP-modulating effects. Here we studied POR expression and corresponding enzyme activity in human hepatoblastoma cell line HepG2 and compared this with HepaFH3 and Upcyte® hepatocytes representing proliferating primary-like hepatocytes.   METHODS: POR expression of those hepatocyte models was determined at mRNA and protein level using qRT-PCR, Western Blot and immunofluorescence staining. Kinetic studies on POR activity in isolated microsomes were performed by a colorimetric method.   RESULTS: The investigated hepatocyte models showed remarkable differences at the level of POR expression. Compared to primary-like hepatocytes, POR expression of HepG2 cells was 4-fold higher at mRNA and 2-fold higher at protein level. However, this higher expression did not correlate with corresponding enzyme activity levels in isolated microsomes, which were comparable between all cell systems tested. A tendency of higher POR activity in HepG2 cells compared to HepaFH3 (p = 0.0829) might be present. Compared to primary human hepatocyte microsomes, POR activity was considerably lower in all hepatocyte models.   CONCLUSION: In summary, our study revealed that POR expression and activity were clearly detectable in all in vitro hepatocyte models with the highest POR expression in cancer cell line HepG2. However, POR activity was lower in tested hepatocyte models when compared to human primary hepatocyte microsomes. Whether this was caused by e.g. polymorphisms or metabolic differences of investigated hepatocyte models will be target for future studies."@en ;
    ns0:hasPubTitle "NADPH-cytochrome P450 reductase expression and enzymatic activity in primary-like human hepatocytes and HepG2 cells for in vitro biotransformation studies"@en .

ns1:fi-v171-i1-4-FI1878 ns0:hasKeywords "Reaction Systems"@en,
        "Simulation of Biochemical Systems"@en ;
    ns0:hasPubAbstract "Reaction systems are a computational model inspired by the bio-chemical reactions that happen inside biological cells. They have been and currently are studied for their many nice theoretical properties. They are also a useful modeling tool for biochemical systems, but in order to be able to employ them effectively in the field the presence of efficient and widely available simulators is essential. Here we explore three different algorithms and implementations of the simulation, comparing them to the current state of the art. We also show that we can obtain performances comparable to GPU-based simulations on real-world systems by using a carefully tuned CPU-based simulator."@en ;
    ns0:hasPubTitle "The Many Roads to the Simulation of Reaction Systems"@en .

ns1:fi-v171-i1-4-FI1882 ns0:hasKeywords "Reaction system"@en,
        "context-independent process"@en,
        "enabling equivalence"@en,
        "functional equivalence"@en,
        "interactive process"@en,
        "living cell"@en,
        "model of computation"@en,
        "transition system"@en ;
    ns0:hasPubAbstract "Reaction systems were introduced in order to provide an abstract model for the study of the biochemical processes that take place in the living cell. Processes of this kind are the result of the interactions between reactions and may be influenced by the environment. Thus, reaction systems can be considered as a model of (interactive) computation. In previous works, various equivalences defined directly on reaction systems and processes had been proposed and compared. These equivalences were all based on functional equivalence that compares a system’s behaviour at every stage of its execution. In this paper, in contrast, we investigate enabling equivalence which focuses on the system behaviour only in specific stages of its evolution, namely those where all of its reactions are active. We discuss the effect of such an approach and, in particular, its relationship to a transition system representation of the system’s behaviour."@en ;
    ns0:hasPubTitle "Reaction Systems and Enabling Equivalence"@en .

ns1:hab-v27-i3-HAB190362 ns0:hasKeywords "NT5E"@en,
        "multiple sclerosis"@en ;
    ns0:hasPubAbstract "CD73, also entitled as ecto-5′-nucleotidase (NT5E), is an ecto-nucleotidase that contributes in the breakage of extracellular ATP to adenosine and the preservation of immune balance. In spite of acknowledged role for immune response imbalance in the pathogenesis of multiple sclerosis (MS), data regarding NT5E expression in MS patients are scarce. In the current study, we assessed expression of NT5E in peripheral blood of MS patients and healthy subjects to unravel its role in the pathogenesis of MS. Results of Multilevel Bayesian model showed no significant difference in NT5E expression between total MS patients and healthy subjects. However, its expression was significantly lower in male MS patients compared with male controls (P= 0.031, 95% credible intervals: [-6.93, -0.56]). No significant correlation was found between expression of NT5E and age in any study subgroups. Remarkably, NT5E transcript levels had 92.31% sensitivity and 80% specificity in diagnosis of MS disease. The diagnostic power of NT5E transcripts was 86.2% based on AUC values. Consequently, the current study indicates the role of NT5E in the pathogenesis of MS disease in male subjects. Moreover, expression level of this gene might be used as a putative marker especially in male MS patients."@en ;
    ns0:hasPubTitle "Dys-regulation of peripheral transcript levels of ecto-5’-nucleotidase in multiple sclerosis patients"@en .

ns1:hab-v27-i4-HAB190369 ns0:hasKeywords "Ethiopia"@en,
        "Food insecurity"@en,
        "malnutrition"@en,
        "non communicable diseases"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Currently, Ethiopia is undergoing an epidemiological transition. Consequently, NCDs are becoming an increasingly important public health problem in the country. Furthermore, the country has faced a high level of food insecurity.   METHODS:  We conducted a comprehensive review based on published articles from 2010 to 2018 and WHO reports on food insecurity, malnutrition and their impacts on the burden of NCDs death in order to obtain a deeper understanding of the seriousness of the NCDs cause of deaths in relation to food insecurity and malnutrition. In addition, policy for protecting vulnerability and the implementation of SDGs on food insecurity, malnutrition, and NCDs were also discussed. The results of this review highlight the progress that was made in the overall condition of food insecurity, nutrition, and diseases in the country.   RESULTS:  The finding shows that there has been large burden of recurrent food insecurity, which could be due to malnutrition that might be associated to inconsistent rainfall distribution and also the experience of violent conflict in recent periods. However, the prevalence of undernourishment was declined from 75% in 1990s to 32% in 2015 though the numbers indicate a marginal reduction. But unexpectedly still the child mortality rate of under-five that results from malnutrition accounts about 57% of all children deaths. As the result of malnutrition, obesity is recognized as the determinants for a number of NCDs such as diabetes, cancer, and cardiovascular diseases. Communicable diseases seems the only identified health problem in the country, however; the burden of NCDs is facing major aspects. Hence, NCDs like cardiovascular diseases and diabetes, currently, are among the leading causes of death among adults, which is responsible for 39% of deaths in the country in 2015 while the risk of premature NCDs mortality was reached about 15.2%. Of these deaths, 4% was due to cancer and 9% was related to other NCDs such as obesity and nutrition-related cases. Therefore, food insecurity has a high-flying impact in early death from chronic health conditions and the cause of undernutrition that leads to an augmented susceptibility and decreased flexibility to NCDs as a result of compromised nutrition.   CONCLUSION:  In order to sustain the economic growth, reduce poverty and achieving food security, the Ethiopian government has started discourse at high level of agenda hoping to avoid recurrent violent conflict, food insecurity and famine by targeting urban low-income households and empowering youth and women."@en ;
    ns0:hasPubTitle "Impact of food insecurity and malnutrition on the burden of Non-communicable diseases and death in Ethiopia: A situational analysis"@en .

ns1:hab-v27-i4-HAB190374 ns0:hasKeywords "Long non-coding RNA"@en,
        "cancer"@en,
        "lncRNA"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Long non-coding RNAs (lncRNAs) are a group of transcripts larger than 200 nucleotides that are not translated to proteins. These transcripts regulate expression of numerous genes at different levels by acting as decoys, scaffolds, and enhancers. Thus they regulate cell development, differentiation and fate.   OBJECTIVE:  To find the role of lncRNAs in various diseases.   METHODS:  We searched PubMed and google scholar and summarized the data regarding the role of lncRNAs in cancer and neurologic disorders.   RESULTS:  Several recent studies have shown that their expressions are up-/down-regulated in malignant tissues. Consequently, they have suggested that lncRNAs can differentiate cancer samples from normal samples. Their application as biomarker is not limited to cancers. In several neurologic or psychiatric disorders researchers have found aberrant expression of lncRNAs.   CONCLUSIONS:  Taken together, lncRNAs constitute a novel vast area of research to find answer to fundamental biologic questions."@en ;
    ns0:hasPubTitle "Long non-coding RNAs: Diverse roles in various disorders"@en .

ns1:hab-v27-i4-HAB190384 ns0:hasKeywords "SGO1"@en,
        "SGO1-AS1"@en,
        "Shugoshin-like protein 1"@en,
        "breast cancer"@en,
        "lncRNA"@en ;
    ns0:hasPubAbstract "Shugoshin-like protein 1 (SGO1) participated in the proper progression of mitosis. This fundamental role has indicated the importance of this gene in the pathogenesis of cancer as a disorder of mitotic cell division. A previous high throughput study of long non-coding RNAs (lncRNAs) expression in lung cancer has identified aberrant expression of SGO1-antisense 1 (SGO1-AS1) in these specimens. In the current study, we quantified expression of SGO1 and SGO1-AS1 in 39 breast cancer tissues and their paired adjacent non-cancerous tissues (ANCTs). Expression of SGO1-AS1 was considerably decreased in tumoral tissues compared with ANCTs (expression ratio = 0.49, P value = 0.03). However, we could not identify significant difference in expression of SGO1 between these two sets of specimens (expression ratio = 2.9, P value = 0.2). Transcript quantities of SGO1-AS1 were associated with age at disease onset (P= 0.01). Expression of either gene was associated with hormone receptors status or clinical features such as grade and stage. There was an inverse correlation between expressions of genes in both sets of samples. Finally, transcript amounts of SGO1-AS1 could distinguish these two sets of samples with accuracy of 63% (P value = 0.03). Our results imply significance of SGO1-AS1 in breast cancer and necessitate conduction of mechanistic studies to find the molecular pathways in this regard."@en ;
    ns0:hasPubTitle "Assessment of SGO1 and SGO1-AS1 contribution in breast cancer"@en .

ns1:hab-v27-iS1-HAB190383 ns0:hasKeywords "Emergency medical services"@en,
        "assurance"@en,
        "ethiopia"@en,
        "leadership"@en,
        "motivation"@en,
        "structure"@en ;
    ns0:hasPubAbstract "BACKGROUND:  The research was assessed the Ethiopian Emergency Medical Services Case teams’ and officers views on Emergency Medical services in Ethiopia. The aim of study was to present the point of views, prospect and priorities of Emergency medical services case teams and its coordinator along some main dimensions of emergency medical services, such as Leadership, Motivation, Structure, and Assurance for implementation.   METHODS:  Six focus group discussion were facilitated with EMS case teams, focal persons and FMoH emergency medical services case teams from December to August, 2017 in all regions chosen of the study. The focus group techniques were used in the study as qualitative research method for examination of viewpoints of case team members towards to the emergency medical care system and overall pre-hospital and at hospital emergency care services. The discussion was addressing the topics of: general aspects of emergency Medical Services (EMS) and which occupations included in EMS; possibilities to importance review EMS issues based on Leadership, Motivation, Structure, and Assurance for implementation of EMS in the country. Finally, thematic analysis was used to evaluate data sets which collected during the focus group discussion.   RESULTS:  There were 6 focus groups in total: an Emergency medical services case teams, officers, Directorates, and integrated disease prevention and control program coordinators groups in each of the regional, city Administration Health Bureau and Federal Ministry of Health in Ethiopia. Findings of the thematic analysis were summarized along the following dimensions: Leadership, Motivation, Structure, and Assurance for implementation. The result shown that lack of resources, shortage of training, lack of professionals and community awareness on EMS, immaturity of EMS strategic plan and lack of revision, workload as a result of limited skilled manpower, lack of partnerships and collaboration on EMS and lack of research and community services evidence are among factors affecting the quality EMS and continuity of the program at various health care facilities at the regional and national levels.   CONCLUSION:  The study shows views of the Ethiopian Emergency Medical Services Case teams’ and officers in Emergency Medical services in Ethiopia. The participants were considered determining factors of the EMS were rather similar among the participated regional, city Administration Health Bureau and Federal Ministry of health. Nonetheless, there was some degree of difference among those participated institutes. Especially, as a national level, Ethiopian Ministry of Health is exists only one emergency medical service directorate that leading the whole national activities. Therefore, EMS program need to respond to the challenges by respondents to articulate emergency medical services policies appropriate to Ethiopia, including the pre-hospital, at hospital care system and Ambulance services with more reformed professional skills and case team work at country level including all regions, Zone, Woreda (Districts) and other related sectors."@en ;
    ns0:hasPubTitle "Perceptions of leadership, motivation, structure, and assurance for implementation of emergency medical services in Ethiopia: Perspectives of emergency medical services case teams based on focus group discussions"@en .

ns1:hsm-v38-i3-HSM180397 ns0:hasKeywords "NK model"@en,
        "Service innovation"@en,
        "implementation path"@en,
        "service ecosystem"@en,
        "service-oriented logic"@en ;
    ns0:hasPubAbstract "Service innovation is an important driver of enterprise self-development and growth in the current service-attuned economy. And across economic sectors, the prevalence of self-organized and self-governed ecosystems renders service innovation increasingly crucial to such service ecosystems. Scholars study service innovation from the perspective of service ecosystem, yet little attention is paid to systematically researching service-innovation components within service ecosystems, especially the implementation path of such components. Based on service-oriented logic, this study presents a framework for service innovation in service ecosystems, built upon five elements: actor-to-actor (A2A) networks, value proposition, resource integration, institutionalization processes, and information technology (IT). This might be the first study to use a combination of the Decision-Making Trial and Evaluation Laboratory (DEMATEL) based Analytic Network Process (ANP) method (called DEMATEL based ANP, or DANP) and the NK model to obtain the optimal path of service innovation in China. Despite the study’s limitations, the results show that enterprises must first develop IT capabilities and innovative value propositions, and then enhance their resource-integration capability and enlarge their A2A networks, as they accelerate their institutionalization processes. Future research must investigate service-innovation components and enhances the idea of service ecosystems, and provides guidelines how to implement service innovation in practice."@en ;
    ns0:hasPubTitle "Toward a service-innovation ecosystem of enterprises in China"@en .

ns1:hsm-v38-i3-HSM180425 ns0:hasKeywords "Corruption"@en,
        "South Asia"@en,
        "economic growth"@en,
        "fixed-random effect model"@en,
        "income inequality"@en ;
    ns0:hasPubAbstract "By using panel data over the 2001–2016 time-period, this study investigates the dynamic relations between corruption, income inequality and the decline in South Asia. Namely, the panel data are subjected to the Chow probability test, the fixed-effect model, random-effect GLS regression and the Hausman test. The empirical results show that economic growth is adversely affected by income inequality, i.e., they show the significant effect of the Gini coefficient on economic decline. It is evident that income maldistribution leads to decline, yet corruption seems to have a positive effect on economic growth. Despite its limitations, the study yields both future-research directions and policymaking recommendations toward curbing the decline in South Asia."@en ;
    ns0:hasPubTitle "Corruption, income inequality and decline in South Asia"@en .

ns1:ia-v13-i1-IA190023 ns0:hasKeywords "JSON"@en,
        "MongoDB"@en,
        "NoSQL"@en,
        "Ontology-based data access"@en,
        "query optimization"@en ;
    ns0:hasPubAbstract "The database (DB) landscape has been significantly diversified during the last decade, resulting in the emergence of a variety of non-relational (also called NoSQL) DBs, e.g., xml and json-document DBs, key-value stores, and graph DBs. To enable access to such data, we generalize the well-known ontology-based data access (OBDA) framework so as to allow for querying arbitrary data sources using sparql. We propose an architecture for a generalized OBDA system implementing the virtual approach. Then, to investigate feasibility of OBDA over non-relational DBs, we compare an implementation of an OBDA system over MongoDB, a popular json-document DB, with a triple store. This article is an extended and revised version of an article that appeared in the proceedings of the 17th International Conference of the Italian Association for Artificial Intelligence (AI*IA) [4]."@en ;
    ns0:hasPubTitle "Ontology-based data access – Beyond relational sources"@en .

ns1:ica-v26-i4-ICA190605 ns0:hasKeywords "Unilateral sensorineural hearing loss"@en,
        "alexNet"@en,
        "double-density dual-tree complex wavelet transform"@en,
        "dual-tree complex wavelet transform"@en,
        "kernel principal component analysis"@en,
        "magnetic resonance imaging"@en,
        "multinomial logistic regression"@en ;
    ns0:hasPubAbstract "AIM:  Unilateral sensorineural hearing loss is a brain disease, which causes slight morphology changes within brain structure. Traditional manual method may ignore this change.   METHOD:  In this work, we developed a novel method, based on the double-density dual-tree complex (DDDTCWT), and radial basis function kernel principal component analysis (RKPCA) and multinomial logistic regression (MLR) for the magnetic resonance imaging scanning. We first used DDDTCWT to extract features. Afterwards, we used RKPCA to reduce feature dimensionalities. Finally, MLR was employed to be the classifier.   RESULT:  The 10 times of 10-fold stratified cross validation showed our method achieved an overall accuracy of 96.44 ± 0.88%. The sensitivities of detecting left-sided sensorineural hearing loss, right-sided sensorineural hearing loss, and healthy controls were 96.67 ± 2.72%, 96.67 ± 3.51%, and 96.00 ± 4.10%, respectively.   CONCLUSION:  Our method performed better than both raw and improved AlexNet, and eight state-of-the-art methods via a stringent statistical 10 × 10-fold stratified cross validation. The MLR gives better classification performance than decision tree, support vector machine, and back-propagation neural network."@en ;
    ns0:hasPubTitle "Unilateral sensorineural hearing loss identification based on double-density dual-tree complex wavelet transform and multinomial logistic regression"@en .

ns1:ida-v23-i5-IDA184238 ns0:hasKeywords "Relation extraction"@en,
        "distant supervision"@en,
        "identity resolution"@en ;
    ns0:hasPubAbstract "To extract structured knowledge from unstructured text sources we need to understand the semantic relationships between entities. State-of-the-art relation extraction techniques take advantage of the abundance of data on the web. However, in domains with sparse data such as social networks which have limited occurrences of entities and relationship patterns, bootstrapping techniques and pattern detection methods are inefficient and inaccurate. In this paper, we introduce REDS, a Relation Extraction approach based on Distant Supervision. REDS extracts the named entities from text documents and assigns a fingerprint to each potential relationship among the named entities. Then, it queries a knowledge repository for similar matches to each fingerprint. An assessor uses the query results and the data statistics to measure the validity of the relationships corresponding to the queried fingerprints, and labels each potential relationship with the predicted type. In addition to handling the relation extraction in presence of data sparsity, REDS uses an information retrieval framework that makes it scalable and capable of dealing with noisy data. We implement and test REDS on a non-English historical archive consisting of unstructured notarial acts and structured civil registers; By means of manual evaluations REDS achieves precision of 0.90."@en ;
    ns0:hasPubTitle "Distant supervision of relation extraction in sparse data"@en .

ns1:idt-v13-i3-IDT180003 ns0:hasKeywords "Aquatic behavior"@en,
        "alert"@en,
        "confidence score"@en,
        "earthworm"@en,
        "fuzzification"@en,
        "opinion"@en,
        "rules"@en,
        "sea turtle"@en ;
    ns0:hasPubAbstract "Tsunami occurrence has created havoc for humans. This unfortunate event however does provide some pre-alert signals which if carefully analyzed can help in pre-sensing this havoc. The signals can be in form of certain indicators in environment and in nature which can be sensed dynamically. Various studies have reported cases of animal behavioral signals prior to tsunami. These changes are a result of environmental changes before any such event occurrence. This paper proposes a confident fuzzified system derived over marine behavior to predict tsunamis (3CCCOVFTP). The system uses an overlap function based linguistic rule derived algorithm creating three class of classifications. Using this system, aquatic behavior is studied, analyzed and classified to produce alerts in real time. Initially, the behavioral attributes are identified for both turtle and earthworm dataset which do produce anomalous signals. The attributed data is further analyzed to retrieve fuzzy rules using which alert, pre-alert or no alert overlapped opinions are extracted. The dataset for analysis includes the following derived parameters: adaptive electromagnetic field, Underwater count of particular specie Deviation in angle of motion (calculated for both sea turtles and earthworms defining their navigation activity per month and per day). The proposed system generates criteria three class categorization on the basis of the derived inputs. From the result obtained, confidence level for each extracted rule is formulated to derive optimized rule set that can serve mathematical formulation to in time alert generation. For prediction of any similar activity in the coming years, 2004 has been utilized as the baseline opinion year with resulting constraint as default rule. The tertiary classification formulated using the proposed algorithm classifies the behavior into three alert categories: Alert, Pre-Alert and No-Alert. Based on the quantified confident opinions, alerts primarily based on aquatic animal behavior can be generated for future years."@en ;
    ns0:hasPubTitle "Proficient 3-class classification model for confident overlap value based fuzzified aquatic information extracted tsunami prediction"@en .

ns1:ies-v27-i3-IES183210 ns0:hasKeywords "Physiological monitoring"@en,
        "glucocorticoids"@en,
        "soccer"@en,
        "sports"@en,
        "youth sports"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Sports competitions are significant sources of psychophysiological stress, especially for young athletes submitted to competitions in a congested match schedule.   OBJECTIVE:  In order to verify the effect of short recovery periods (24-hours) in the subsequent match, the response of salivary cortisol (sC) and match intensity were investigated in two successive soccer matches during an official tournament.   METHODS:  Twenty (20) young soccer players (16.8 ± 0.5 years; 172.9 ± 7.7 cm; 65.0 ± 7.9 kg) accepted to participate and 14 completed the 2 matches within a two day-period. Subjects provided saliva samples before and after each match and the session rate of perceived exertion, (session-RPE) method was utilized to define the match intensity.   RESULTS:  The sC concentration significantly increased in both matches (ρ< 0.05), representing an increase of 74% and 112% in matches 1 and 2, respectively. Moreover, the variation was not different between the matches (ρ> 0.05). There was no variation in match internal load for match 1 to match 2 (ρ> 0.05). A significant difference was noted between high and low salivary cortisol groups divided a posteriori into both matches (match 1: p< 0.001; ES: 2.7 and match 2: p< 0.001; ES: 2.3).   CONCLUSIONS:  The findings of this study indicate that the short recovery-time did not influence the sC and match internal load responses in the subsequent match. In addition, athletes with high responsiveness to the stressful demands of the matches tend to maintain this condition regardless of the time on field and the RPE reported."@en ;
    ns0:hasPubTitle "Acute effect of successive matches in salivary cortisol concentrations and match internal load in young soccer players"@en .

ns1:ifs-v36-i6-IFS181657 ns0:hasKeywords "Caputo-Hadamard-type fuzzy derivative"@en,
        "Fractional fuzzy differential equations"@en,
        "Fuzzy fractional calculus"@en ;
    ns0:hasPubAbstract "In this paper, the existence and uniqueness results of solution for an initial value problem of fractional differential equations with the Caputo-Hadamard concept of fractional derivative in the case of the order α ∈ (1, 2) have been investigated. Banach’s contraction mapping principle and Schauder fixed point theorem are used to obtain the existence and uniqueness results. In addition, the dependence of the solution on the initial conditions and the right-hand side of the given problem is analyzed."@en ;
    ns0:hasPubTitle "The existence of solutions for an initial value problem of Caputo-Hadamard-type fuzzy fractional differential equations of order α ∈ (1, 2)"@en .

ns1:ifs-v36-i6-IFS181922 ns0:hasKeywords "Spherical fuzzy sets"@en,
        "decision making problems"@en,
        "similarity measures"@en ;
    ns0:hasPubAbstract "The novel concept of spherical fuzzy set consists of positive, neutral and negative membership grades which satisfy the conditions that the square sum of its membership grades is less than or equal to 1. In this paper, we investigate the family of novel similarity measures between spherical fuzzy sets based on cosine function by considering the positive, neutral, negative and refusal grades in SFSs. To implement the proposed similarity measures, we provide some numerical applications of decision-making problems. A comparative study of the proposed and existing similarity measures is established. The proposed method is more advance as compare to the previous all reflexive."@en ;
    ns0:hasPubTitle "The cosine similarity measures of spherical fuzzy sets and their applications in decision making"@en .

ns1:ifs-v36-i6-IFS182572 ns0:hasKeywords "DFS AG-groupoid"@en,
        "DFS int-uni product"@en,
        "DFS quasi-ideals"@en,
        "DFS-set"@en,
        "Decision making"@en,
        "Left regular AG-groupoids"@en ;
    ns0:hasPubAbstract "In this paper, we apply the concept of double-framed soft set (briefly DFS-set) to non-associative and non-commutative structure called Abel Grassmann’s groupoid (briefly AG-groupoid). We define double-framed soft quasi-ideals (briefly DFS quasi-ideal) of AG-groupoids and discuss their properties in left regular AG-groupoids. We also characterize left regular AG-groupoids in terms of DFS quasi-ideals. Application of DFS sets in decision making situation is provided."@en ;
    ns0:hasPubTitle "On algebraic properties of DFS sets and its application in decision making problems"@en .

ns1:ifs-v36-i6-IFS182616 ns0:hasKeywords "(m, N)-soft sets"@en,
        "2010 Mathematics Subject Classification"@en,
        "N-soft sets"@en,
        "decision-making"@en,
        "rough set"@en,
        "soft set"@en ;
    ns0:hasPubAbstract "The theory of soft sets is a powerful mathematical tool to handle the vagueness in data, while the m-polar fuzzy (mF, for short) sets have ability to deal with uncertainty as well as multi-polarity of the data in many situations. In this research article we present two novel hybrid models for soft computing, namely, m-polar fuzzy N-soft sets ((m, N)-soft sets, for short) and m-polar fuzzy N-soft rough sets ((m, N)-soft rough sets, for short). We define related concepts and investigate some of their fundamental properties. We also present applications of these hybrid models to multi-attribute decision-making."@en ;
    ns0:hasPubTitle "Hybrid multi-attribute decision-making model based on (m, N)-soft rough sets"@en .

ns1:ifs-v36-i6-IFS182863 ns0:hasKeywords "Random fractional differential equations"@en,
        "Riemann-Liouville generalized Hukuhara differentiability"@en ;
    ns0:hasPubAbstract "In this paper an initial value problem for random fuzzy fractional differential equations (RFFDEs) with Riemann-Liouville generalized Hukuhara differentiability are introduced. The equivalence between a random fuzzy fractional differential equation and a random fuzzy fractional integral equation under suitable conditions is shown. In addition, the existence and uniqueness results for RFFDEs using the idea of successive approximations are presented."@en ;
    ns0:hasPubTitle "Random fractional differential equations with Riemann-Liouville-type fuzzy differentiability concept"@en .

ns1:ifs-v36-i6-IFS182876 ns0:hasKeywords "Fuzziness and randomness in the fish proportional harvesting model"@en,
        "Random fractional differential equations"@en,
        "Riemann-Liouville generalized Hukuhara differentiability"@en ;
    ns0:hasPubAbstract "In this paper, the existence and uniqueness results of an initial value problem for random fuzzy differential equations with Riemann-Liouville fractional derivative (RFFDEs) are introduced. A method to find analytical solution of RFFDEs is also proposed. Finally, some initial value problems of linear random fractional fuzzy differential equation and the fish proportional harvesting model in fuzzy environment are given to show the efficiency of the method."@en ;
    ns0:hasPubTitle "On the initial value problem for random fuzzy differential equations with Riemann-Liouville fractional derivative: Existence theory and analytical solution"@en .

ns1:ifs-v36-i6-IFS182919 ns0:hasKeywords "N-soft basis"@en,
        "N-soft closure"@en,
        "N-soft exterior"@en,
        "N-soft interior"@en,
        "N-soft topology"@en,
        "multi-criteria group decision-making"@en ;
    ns0:hasPubAbstract "N-soft set introduced by Fatimah et al. [10] is the extension of soft set introduced by Molodtsov [30]. Soft set and N-soft set are important mathematical models for binary and non-binary evaluations respectively. In this article, we introduce some fundamental operations on N-soft set and the notion of N-soft topology. We introduce certain properties of N-soft topology including N-soft interior, N-soft exterior, N-soft closure, N-soft basis, N-soft frontier and their related results. We also present some illustrations to explain these concepts. Furthermore, we present multi-criteria group decision-making methods by using N-soft set and N-soft topology to deal with uncertainties in the real world problems."@en ;
    ns0:hasPubTitle "N-soft topology and its applications to multi-criteria group decision making"@en .

ns1:ifs-v36-i6-IFS191197 ns0:hasKeywords "Rough set"@en,
        "inclusion degree"@en,
        "preference relation"@en,
        "soft preference relation"@en,
        "soft set"@en ;
    ns0:hasPubAbstract "The extension of rough set model is a crucial and vast research direction in rough set theory. Meanwhile decision making can be considered as a mental process in which human beings make a choice among several alternatives. However, with the increasing complexity of real decision making problems, the decision makers frequently face the challenge of characterizing their preferences in an uncertain context. In the present paper, we initiate a multi attribute group decision making problem in the presence of multi attribute and multi decision in decision making with preferences. We further present the concept of soft preference relation and soft dominance relation corresponding to decision attribute in the multi criteria and multi decision information system. Further we present the idea of variable precision multi decision soft dominance based rough set model and their applications in solving a multi agent conflict analysis decision problem. The proposed method addresses the limitations of the Pawlak’s model and Sun’s conflict analysis model and thus improve these models. Finally, the results on labor management negotiation problems show that the proposed algorithms are more effective and efficient for feasible consensus strategy when compared with other techniques."@en ;
    ns0:hasPubTitle "Variable precision multi decision λ-soft dominance based rough sets and their applications in conflict problems"@en .

ns1:ifs-v37-i1-IFS181547 ns0:hasKeywords "IVTIFNs"@en,
        "Interval-valued intuitionistic fuzzy numbers"@en,
        "transportation problem"@en ;
    ns0:hasPubAbstract "Bharti and Singh (International Journal of Fuzzy Systems 20 (2018), 1511-1522) proposed a method for solving a special type of interval-valued intuitionistic fuzzy transportation problems (IVIF-TPs) (transportation problems (TPs) in which the quantity of the product to be supplied is represented as a real number, whereas, all the other parameters are represented as interval-valued triangular intuitionistic fuzzy numbers (IVTIFNs)). In this note, an interval-valued intuitionistic fuzzy transportation problem (IVIF-TP) is solved by Bharti and Singh’s method and shown that more than one IVTIFNs, representing the optimal interval-valued intuitionistic fuzzy (IVIF) transportation cost is obtained, which is mathematically incorrect as the obtained distinct IVTIFNs has different physical meanings. Also, it is pointed out that to resolve this flaw of Bharti and Singh’s method may be considered as a challenging open research problem."@en ;
    ns0:hasPubTitle "A note on “Transportation problem under interval-valued intuitionistic fuzzy environment”"@en .

ns1:ifs-v37-i1-IFS182581 ns0:hasKeywords "multi-attribute decision making"@en,
        "q-rung orthopair fuzzy uncertain linguistic set"@en,
        "q-rung orthopair uncertain linguistic choquet integral operators"@en ;
    ns0:hasPubAbstract "Multiple attribute decision making (MADM) problems widely exist in real decision making, and MADM methods with linguistic information have achieved great success. However, as the complexity of decision making problems is increasing in the real world, it is of great necessity to further develop new expression of evaluation information and aggregation technologies that can reflect the correlation among multi-attributes under uncertain decision-making environment. In response, this paper originally presents q-rung orthopair fuzzy uncertain linguistic set (q-ROULS) by combining q-rung orthopair fuzzy set (q-ROFS) and uncertain linguistic set (ULS). Then operational laws, expected functions and accuracy functions of q-rung orthopair uncertain linguistic variables (q-ROULVs) are also defined. Considering the correlation between q-ROULVs, we propose a family of q-rung orthopair fuzzy uncertain linguistic Choquet integral operators to aggregate q-rung orthopair uncertain linguistic information. Further, a novel MADM technique is presented based on the proposed q-rung orthopair fuzzy uncertain linguistic Choquet integral operators. The developed MADM method with q-rung orthopair fuzzy uncertain linguistic information enriches fuzzy decision-making theory and provides a new way for decision makers (DMs) under q-rung orthopair fuzzy uncertain linguistic environment."@en ;
    ns0:hasPubTitle "q-Rung orthopair fuzzy uncertain linguistic choquet integral operators and their application to multi-attribute decision making"@en .

ns1:ifs-v37-i2-IFS179252 ns0:hasKeywords "Bayesian belief networks"@en,
        "Fuzzy cognitive maps"@en,
        "causal knowledge systems"@en,
        "evaluation"@en,
        "knowledge engineering"@en ;
    ns0:hasPubAbstract "Fuzzy cognitive maps (FCM) and Bayesian belief networks (BBN) are two of the most frequently used causal knowledge frameworks for modelling, representing and reasoning about causal knowledge. In this paper, an evaluation of their different roles in the engineering process of developing causal knowledge systems is conducted, based on their inherent features. The evaluation criteria adopted in this research are understandability, usability, modularity, scalability, expressiveness, inferential capability, rigour, formality and preciseness. All of these are commonly used to evaluate the strengths and weaknesses of traditional knowledge representation frameworks. These criteria are used to reveal the fundamental characteristics of FCM and BBN. The findings of this study show that FCM is more appropriate for use in modelling causal knowledge, whereas BBN is more superior in model representation and inference. This study deepens the understanding of the role of FCM and BBN in the development of causal knowledge systems."@en ;
    ns0:hasPubTitle "An evaluation of the role of fuzzy cognitive maps and Bayesian belief networks in the development of causal knowledge systems"@en .

ns1:ifs-v37-i2-IFS182568 ns0:hasKeywords "L-fuzzy convex subgroup"@en,
        "L-fuzzy convex subgroup degree"@en,
        "L-fuzzy convexity"@en ;
    ns0:hasPubAbstract "In this paper, the notions of L-fuzzy convex subgroup and L-fuzzy convex subgroup degree are introduced and their characterizations are given. A new method for describing L-fuzzy convexity is obtained. Also, L-fuzzy convexity preserving mappings and L-fuzzy convex-to-convex mappings are analyzed. Besides, we provide a counter example to illustrate one of the conclusions."@en ;
    ns0:hasPubTitle "A new approach of describing L-fuzzy convexity"@en .

ns1:ifs-v37-i2-IFS182746 ns0:hasKeywords "Cartesian product"@en,
        "Signed product cordial labeling"@en,
        "Total signed product cordial labeling"@en,
        "complete bipartite graph"@en ;
    ns0:hasPubAbstract "Apart from other labeling signed product and total signed product labeling already have been applied on different kind of graphs. Signed product cordial labeling for the graph G = (V, E), where each vertex is labelled by 1 or -1 and edge label is induced by multiplication of two of it end vertices with the following restriction that the absolute difference between total number of vertices labelled by 1 and -1 is at most 1, similarly for the edges also. Total signed product cordial labeling follows property that absolute difference between total number of vertices and edges labelled by -1 and total number of vertices and edges labelled by 1 is at most 1. In this paper, we have considered Cartesian product between two balanced bipartite graphs and apply above labeling on it. We have designed some suitable algorithms which will driven by any kind of computer programming language. Illustration with example and complexity of the algorithms are analysed successfully."@en ;
    ns0:hasPubTitle "Algorithmic implementation of signed product and total signed product cordial labeling on complex graph"@en .

ns1:ifs-v37-i2-IFS182774 ns0:hasKeywords "MAGDM"@en,
        "Power average"@en,
        "muirhead mean operator"@en,
        "single valued neutrosophic sets"@en ;
    ns0:hasPubAbstract "The power average (PA) has the property that it can eliminate the influence of inconvenient data and the Muirhead mean (MM) operator takes the correlations among the input arguments, and the single valued neutrosophic (SVN) set is a better tool to deal with incomplete, inconsistent and indeterminate information than fuzzy set (FS) and intuitionistic FS (IFS). Thus the main goal of this article is to develop a few new operators for aggregating SVN information and apply them to multiple-attribute group decision making (MAGDM). To fully utilize the advantages of MM operator and PA operator, we develop the single-valued neutrosophic power MM (SVNPMM) operator, weighted single-valued neutrosophic power MM (WSVNPMM) operator, single-valued neutrosophic power dual MM (SVNPDMM) operator and weighted single-valued neutrosophic power dual MM (WSVNPDMM) operator, and discuss their essential properties, particular cases about the parameter vector. The obvious advantages of the proposed operators are that it can eliminate the influence of inconvenient data and can take the correlation among input data at the same time. Moreover, based on the developed aggregation operators, a novel technique to MAGDM problem is proposed. Lastly, a numerical example is provided to show the efficiency and realism of the proposed technique."@en ;
    ns0:hasPubTitle "Some single-valued neutrosophic power muirhead mean operators and their application to group decision making"@en .

ns1:ifs-v37-i3-IFS181813 ns0:hasKeywords "Molecular descriptor"@en,
        "atom bond connectivity index"@en,
        "cellular neural network"@en,
        "general Randić index"@en,
        "geometric arithmetic index"@en ;
    ns0:hasPubAbstract "Graph theory is a fundamental and energetic tool for designing and modeling a graph/network. There are certain topological indices based on degree, distance and eccentricity, etc. The topological indices essentially relate certain physio-concoction properties and bio-activity to the corresponding synthetic and atomic structure. In this paper, our aim is to figure out degree-based topological indices mainly atom-bond connectivity (ABC), geometric-arithmetic (GA), ABC4 and GA5 indices for cellular neural network (CNN) and give closed results of these indices for cellular neural network. Moreover, we also compute general Randi   c ´    index Rα of CNN for   α = { 1 , - 1 ,  1 2  , -  1 2  }   only and give analytical closed form results. A 3D graph analysis for comparison of indices is also given."@en ;
    ns0:hasPubTitle "Topological properties of cellular neural networks"@en .

ns1:ifs-v37-i3-IFS190447 ns0:hasKeywords "Fuzzy preference relation, fuzzy rough set, β-covering rough sets"@en ;
    ns0:hasPubAbstract "The notions of fuzzy upward β-covering, the fuzzy upward β-neighborhood, upward β-neighborhood and fuzzy complement β-neighborhood are introduced and several related properties are studied. Furthermore, multigranulation optimistic/pessimistic fuzzy rough sets based on fuzzy upward β-covering are initiated and their fundamental properties are investigated. We also find the upward β-neighborhood in the fuzzy upward covering approximation space and present the optimistic/pessimistic multigranulation rough sets to further enrich the presented notions. The medicine selection via fuzzy upward β-covering rough sets in medical diagnosis is another main contribution of the present work. It is also explored that which medicine can be prescribed for which particular symtom(s) and which disease."@en ;
    ns0:hasPubTitle "Medicines selection via fuzzy upward β-covering rough sets"@en .

ns1:ifs-v37-i4-IFS171587 ns0:hasKeywords "Hybrid structure"@en,
        "h-Hemiregular hemirings."@en,
        "hybrid h-bi (h-quasi)-ideals"@en,
        "hybrid h-ideals"@en,
        "hybrid h-product"@en,
        "hybrid h-sum"@en,
        "hybrid structures operations"@en ;
    ns0:hasPubAbstract "Using the notions of a soft set and a fuzzy set, Jun’s introduced a new type of notion called a hybrid structure, which is a generalization of soft set and fuzzy set. In this paper, we apply hybrid structure in hemirings and introduce the concept of hybrid h-ideals of hemirings and the related properties are investigated. Some operational properties of hybrid structures are first investigated. The concepts of a hybrid h-sum and a hybrid h-product are discussed and the related properties are investigated. The notions of hybrid h-ideals, hybrid h-bi-ideals and hybrid h-quasi-ideals are introduced and several properties are provided. The notion of a hybrid level set is introduced and the basic properties of hybrid h-ideals, hybrid h-bi-ideals and hybrid h-quasi-ideals are studied in detail. The characterizations of h-hemiregular hemirings are discussed and several important results of a h-hemiregular hemirings are provided."@en ;
    ns0:hasPubTitle "Hybrid structures applied to hemirings"@en .

ns1:ifs-v37-i4-IFS182595 ns0:hasKeywords "N-cubic sets"@en,
        "N-fuzzy sets"@en,
        "aggregation operators"@en,
        "applications"@en,
        "cubic sets"@en ;
    ns0:hasPubAbstract "The generalization of different types of fuzzy sets is on the way since the discovery of fuzzy sets by Zadeh 1965 based on mathematical logic. Some of them are, the interval-valued fuzzy sets,   N  -fuzzy sets and interval-valued   N  -fuzzy sets, where   N  -fuzzy sets are used to the co-domain [−1, 0] for the membership function. Cubic sets are the combination of interval-valued fuzzy sets and fuzzy sets presented in 2012 by Jun et al. Since the cubic sets considered only the positive aspects of a certain thing in many physical problems and ignore the negative aspects totally. So to cover the negative part the need was felt to extend the concept of cubic sets along the co-domain [−1, 0]. Thus in this paper, we initiate a new theory by mixing the cubic sets with N-fuzzy sets and define the new notion of   N  -cubic sets. We are inspired by the hybrid nature of the cubic sets which can handle positive characteristics of a certain thing in a much better way as compared to the fuzzy sets. Whereas, our case will be more helpful in order to characterize the negative characteristics of a certain thing in a more affective way as compared to   N  -fuzzy sets. Motivating from the idea of cubic sets, we initiate to combine the interval-valued   N  -fuzzy sets and   N  -fuzzy sets to produce a new class of cubic sets known as   N  -cubic sets based on mathematical logics. We define   N  -cubic sets and define many different operations like P-union (resp., P-intersection) R-union (resp., R-intersection) and complement. The notions of external and internal   N  -cubic sets and related operations and properties are investigated. We discuss some algebraic properties of   N  -cubic sets and define some aggregation operators which will be helpful in order to find more algebraic and practical applications in the future. At the end we present a   N  -cubic-decision making Problem by using the developed procedure."@en ;
    ns0:hasPubTitle "N-Cubic sets and aggregation operators"@en .

ns1:ifs-v37-i4-IFS18266 ns0:hasKeywords "Multiple attribute decision making (MADM)"@en,
        "bipolar fuzzy set"@en,
        "dual hesitant bipolar fuzzy Hamacher hybrid geometric (DHBFHHG) operator"@en,
        "dual hesitant bipolar fuzzy Hamacherhybrid average (DHBFHHA) operator"@en,
        "dual hesitant bipolar fuzzy set"@en ;
    ns0:hasPubAbstract "In this paper, we investigate the multiple attribute decision making problems based on the Hamacher aggregation operators with dual hesitant bipolar fuzzy information. Then, motivated by the idea of Hamacher operations, we have developed some Hamacher aggregation operators for aggregating dual hesitant bipolar fuzzy information: dual hesitant bipolar fuzzy Hamacher weighted average (DHBFHWA) operator, dual hesitant bipolar fuzzy Hamacher weighted geometric (DHBFHWG) operator, dual hesitant bipolar fuzzy Hamacher ordered weighted average (DHBFHOWA) operator, dual hesitant bipolar fuzzy Hamacher ordered weighted geometric (DHBFHOWG) operator, dual hesitant bipolar fuzzy Hamacher hybrid average (DHBFHHA) operator and dual hesitant bipolar fuzzy Hamacher hybrid geometric (DHBFHHG) operator. Then, we have utilized these operators to develop some approaches to solve the dual hesitant bipolar fuzzy multiple attribute decision making problems. Finally, a real-world example is then analyzed to illustrate the relevance and effectiveness of the proposed methodology."@en ;
    ns0:hasPubTitle "Dual hesitant bipolar fuzzy hamacher aggregation operators and their applications to multiple attribute decision making"@en .

ns1:ifs-v37-i4-IFS190565 ns0:hasKeywords "Boolean algebra"@en,
        "Heyting algebra"@en,
        "Hoop"@en,
        "co-annihilator"@en,
        "filter"@en,
        "pseudo-complement"@en ;
    ns0:hasPubAbstract "In this paper, we introduce the notion of co-annihilator in hoops and investigate some related properties of them. Then we prove that the set of filters   F ( A )   form two pseudo-complemented lattices (with ∗ and ⊤) that if A has (DNP), then the two pseudo-complemented lattices are the same. Moreover, by defining the operation → on the lattice   F ( A )  , we prove that   F ( A )   is a Heyting algebra and by defining of the product operation, we show that   F ( A )   is a bounded hoop. Finally, we define the C - Ann (A) to be the set of all co-annihilators of A, then we have that it had made a Boolean algebra. Also, we give an extension of a filter, which leads to a useful characterization of α-filters on hoops. For instance, we obtain a series of characterizations of α-filters. In addition, we show that there are no non-trivial α-filters on hoop-chains. That implies the structure of all α-filters contains only trivial α-filters on hoops. On hoops, we prove that the set of all α-filters is a pseudo-complemented lattice. Moreover, the structure of all α-filters can form a Boolean algebra under certain conditions."@en ;
    ns0:hasPubTitle "On co-annihilators in hoops"@en .

ns1:ifs-v37-i4-IFS190952 ns0:hasKeywords "Ulam-hyers stability"@en,
        "fuzzy fractional integro-differential equations"@en,
        "ulam-hyers-rassias stability"@en ;
    ns0:hasPubAbstract "The results of this paper is motivated from some recent papers treating the problem of the existence and stability of a solution for Volterra integro-differential equations in fuzzy setting with fractional order derivative (FFVIDEs). By constructing successive approximation method in the space of fuzzy functions, we establish the Ulam-Hyers stability and Ulam-Hyers-Rassias stability for the given problems with two concepts of fuzzy-type fractional derivative."@en ;
    ns0:hasPubTitle "Stability for initial value problems of fuzzy Volterra integro-differential equation with fractional order derivative"@en .

ns1:ifs-v37-i5-IFS181970 ns0:hasKeywords "Dual hesitant fuzzy set"@en,
        "attribute weight"@en,
        "bidirectional projection measure"@en ;
    ns0:hasPubAbstract "The aim of this paper is to investigate dual hesitant fuzzy multiple attribute decision making problems where the attribute values provided by experts are expressed in dual hesitant fuzzy element, and the attribute weight is unknown. We present a new method to derive the weights of attributes and rank the preference order of alternatives based on bidirectional projection models. We introduce some notions, such as some dual hesitant fuzzy operational laws, dual hesitant fuzzy ideal point, the modules of dual hesitant fuzzy elements, and distance between two intuitionistic trapezoidal fuzzy numbers. We also introduce the cosine of the included angle between the attribute value vectors of each alternative and the dual hesitant fuzzy ideal point. Then we establish the bidirectional projection models to measure the similarity degrees between each alternative and the dual hesitant fuzzy ideal point, and the Jaynes maximum information entropy method is used to determine the attribute weight. Furthermore, we establish a nonlinear optimization model to obtain the weight vector of attributes. Finally, we illustrate the developed projection models with a numerical example."@en ;
    ns0:hasPubTitle "Multiple attribute decision making based on bidirectional projection measures of dual hesitant fuzzy set"@en .

ns1:ifs-v37-i5-IFS190711 ns0:hasKeywords "Shortest path problem"@en,
        "dynamic programming"@en,
        "interval-valued fuzzy numbers"@en,
        "wireless sensor network"@en ;
    ns0:hasPubAbstract "Researchers have studied several different types of directed shortest path (SP) problems under fuzzy environment. However, few researchers have focused on solving this problem in an interval-valued fuzzy network. Thus, in order to light these, we investigate a generalized kind of the SP problem under interval-valued fuzzy environment namely all pairs shortest path (APSP) problem. The main contributions of the present study are fivefold: (1) In the interval-valued fuzzy network under consideration, each arc weight is represented in terms of interval-valued fuzzy number. (2) We seek the shortest weights between every pair of nodes in a given interval-valued fuzzy network based on a dynamic approach. (3) In contrast to most existing approaches, which provide the shortest path between two predetermined nodes, the proposed approach provides the interval-valued fuzzy shortest path between every pair of nodes. (4) Similarly to the competing methods in the literature, the proposed approach not only gives the interval-valued fuzzy weights of all pairs shortest path but also provides the corresponding interval-valued fuzzy APSP. (5) The efficiency of the proposed approach is illustrated through two applications of APSP problems in wireless sensor networks and robot path planning problems."@en ;
    ns0:hasPubTitle "A novel approach for solving all-pairs shortest path problem in an interval-valued fuzzy network"@en .

ns1:jad-v60-i3-JAD170300 ns0:hasKeywords "Cohorts"@en,
        "dementia"@en,
        "incidence"@en,
        "race/ethnicity"@en,
        "secular trends"@en ;
    ns0:hasPubAbstract "Background: Determination of secular trends in cognitive aging is important for prioritization of resources, services, and research in aging populations. Prior studies have identified declining dementia incidence associated with changes in cardiovascular risk factors and increased educational attainment. However, few studies have examined these factors in multi-ethnic cohorts.   Objective: To identify secular trends in the incidence rate of dementia in an elderly population.   Methods: Participants in this study were drawn from the Washington Heights-Inwood Columbia Aging Project, a multi-ethnic cohort study of northern Manhattan residents aged 65 years and older. Cox proportional hazards models were used to examine differences in the incidence of dementia in cohorts recruited in 1992 and 1999, with age at dementia or age at last follow-up visit as the “time-to-event” variable.   Results: Overall, there was a 41% reduction in the hazard ratio for dementia among participants in the 1999 cohort compared with those in the 1992 cohort, adjusting for age, sex, race, and baseline memory complaints (HR = 0.59). The reduction in incidence was greatest among non-Hispanic Whites and African-Americans and lowest among Hispanic participants (HRs = 0.60, 0.52 and 0.64, respectively), and was associated with increases in level of educational attainment, especially among African-Americans. Reduction in incidence of dementia was also greater among persons 75 years or older than among younger participants (HR = 0.52 versus HR = 0.69).   Conclusions: Our results support previous findings that secular trends in dementia incidence are changing, including in aging minority populations."@en ;
    ns0:hasPubTitle "Secular Trends in the Incidence of Dementia in a Multi-Ethnic Community"@en .

ns1:jad-v69-i3-JAD180991 ns0:hasKeywords "Alzheimer’s disease"@en,
        "frontotemporal dementia"@en,
        "moral emotions"@en ;
    ns0:hasPubAbstract "Background: Emotions, with or without moral valence, appear to be altered in the behavioral variant of frontotemporal dementia (bvFTD) but the relative degree of moral emotion breakdown, which could be a marker of bvFTD diagnosis, remains unexplored.   Objective: To assess moral emotions in bvFTD, to differentiate bvFTD from typical Alzheimer’s disease (AD) based on moral emotion processing, and to provide a sensitive and specific assessment tool contributing to bvFTD diagnosis.   Methods: We investigated moral emotions in 22 bvFTD patients, 15 patients with typical AD having positive CSF AD biomarkers, and 45 healthy controls. The ‘Moral Emotions Assessment’ task consisted in 42 scenarios exploring positive and negative moral emotions. To control for moral-specificity, we contrasted the 42 moral scenarios with 18 extra-moral scenarios eliciting the emotions without involving any inter-human moral context.   Results: bvFTD patients were more impaired in emotion processing than AD patients and healthy controls and had significantly poorer performance in the processing of moral emotions than of emotions without moral valence. ROC analyses of data on moral scenarios showed a high area under the curve (83%), and indicated a cut-off score (< 37/42) for differentiating bvFTD from AD with a sensitivity of 82% and specificity of 73%.   Conclusion: Our findings demonstrate that bvFTD patients have disorders in emotion processing which is mainly related to failure regarding moral emotions. They also show that this deficit is reliably detected by the ‘Moral Emotions Assessment’ which represents a sensitive and specific diagnostic tool detecting bvFTD and differentiating it from AD."@en ;
    ns0:hasPubTitle "Moral Emotions in Frontotemporal Dementia"@en .

ns1:jad-v69-i4-JAD180900 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Lewy body pathology"@en,
        "Von Economo neurons"@en,
        "behavioral variant frontotemporal dementia"@en ;
    ns0:hasPubAbstract "The selective loss of von Economo neurons has been linked to the behavioral deficits in behavioral variant frontotemporal dementia (bvFTD) but whether these neurons are affected in bvFTD patients with underlying Alzheimer’s disease (AD) has yet to be established. The present study assesses the von Economo neurons in pathological AD cases clinically diagnosed with either AD or bvFTD. Our results demonstrate no significant loss of von Economo neurons in all pathological AD cases, irrespective of clinical diagnosis or co-existing Lewy body pathology. These results suggest that the behavioral deficits in patients with clinical bvFTD and underlying pathological AD are not driven by the loss of von Economo neurons."@en ;
    ns0:hasPubTitle "Von Economo Neurons in Behavioral Variant Frontotemporal Dementia with Underlying Alzheimer’s Disease"@en .

ns1:jad-v69-i4-JAD181033 ns0:hasKeywords "Apathy"@en,
        "assessment"@en,
        "machine learning"@en,
        "neuropsychiatric symptoms"@en,
        "speech analysis"@en,
        "voice analysis"@en ;
    ns0:hasPubAbstract "Background: Apathy is present in several psychiatric and neurological conditions and has been found to have a severe negative effect on disease progression. In older people, it can be a predictor of increased dementia risk. Current assessment methods lack objectivity and sensitivity, thus new diagnostic tools and broad-scale screening technologies are needed.   Objective: This study is the first of its kind aiming to investigate whether automatic speech analysis could be used for characterization and detection of apathy.   Methods: A group of apathetic and non-apathetic patients (n = 60) with mild to moderate neurocognitive disorder were recorded while performing two short narrative speech tasks. Paralinguistic markers relating to prosodic, formant, source, and temporal qualities of speech were automatically extracted, examined between the groups and compared to baseline assessments. Machine learning experiments were carried out to validate the diagnostic power of extracted markers.   Results: Correlations between apathy sub-scales and features revealed a relation between temporal aspects of speech and the subdomains of reduction in interest and initiative, as well as between prosody features and the affective domain. Group differences were found to vary for males and females, depending on the task. Differences in temporal aspects of speech were found to be the most consistent difference between apathetic and non-apathetic patients. Machine learning models trained on speech features achieved top performances of AUC = 0.88 for males and AUC = 0.77 for females.   Conclusions: These findings reinforce the usability of speech as a reliable biomarker in the detection and assessment of apathy."@en ;
    ns0:hasPubTitle "Detecting Apathy in Older Adults with Cognitive Disorders Using Automatic Speech Analysis"@en .

ns1:jad-v69-i4-JAD190342 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cognition"@en,
        "genetic predisposition to disease"@en,
        "single nucleotide polymorphism"@en ;
    ns0:hasPubAbstract "The association of Apolipoprotein E (APOE) with late-onset Alzheimer’s disease (LOAD) and cognitive endophenotypes of aging has been widely investigated. There is increasing interest in evaluating the association of other LOAD risk loci with cognitive performance and decline. The results of these studies have been inconsistent and inconclusive. We conducted a systematic review of studies investigating the association of non-APOE LOAD risk loci with cognitive performance in older adults. Studies published from January 2009 to April 2018 were identified through a PubMed database search using keywords and by scanning reference lists. Studies were included if they were either cross-sectional or longitudinal in design, included at least one genome-wide significant LOAD risk loci or a genetic risk score, and had one objective measure of cognition. Quality assessment of the studies was conducted using the quality of genetic studies (Q-Genie) tool. Of 2,466 studies reviewed, 49 met inclusion criteria. Fifteen percent of the associations between non-APOE LOAD risk loci and cognition were significant. However, these associations were not replicated across studies, and the majority were rendered non-significant when adjusting for multiple testing. One-third of the studies included genetic risk scores, and these were typically significant only when APOE was included. The findings of this systematic review do not support a consistent association between individual non-APOE LOAD risk and cognitive performance or decline. However, evidence suggests that aggregate LOAD genetic risk exerts deleterious effects on decline in episodic memory and global cognition."@en ;
    ns0:hasPubTitle "Association of Alzheimer’s Disease Genetic Risk Loci with Cognitive Performance and Decline: A Systematic Review"@en .

ns1:jad-v70-i1-JAD180847 ns0:hasKeywords "Alzheimer’s disease"@en,
        "default mode network"@en,
        "functional connectivity"@en,
        "mild cognitive impairment"@en,
        "posterior cingulate cortex"@en,
        "resting state functional magnetic resonance imaging"@en ;
    ns0:hasPubAbstract "Background: Large-scale brain networks such as the default mode network (DMN) are often disrupted in Alzheimer’s disease (AD). Numerous studies have examined DMN functional connectivity in those with mild cognitive impairment (MCI), a presumed AD precursor, to discover a biomarker of AD risk. Prior reviews were qualitative or limited in scope or approach.   Objective: We aimed to systematically and quantitatively review DMN resting state fMRI studies comparing MCI and healthy comparison (HC) groups.   Methods: PubMed was searched for relevant articles. Study characteristics were abstracted and the number of studies showing no group difference or hyper- versus hypo-connnectivity in MCI was tallied. A voxel-wise (ES-SDM) meta-analysis was conducted to identify regional group differences.   Results: Qualitatively, our review of 57 MCI versus HC comparisons suggests substantial inconsistency; 9 showed no group difference, 8 showed MCI > HC and 22 showed HC > MCI across the brain, and 18 showed regionally-mixed directions of effect. The meta-analysis of 31 studies revealed areas of significant hypo- and hyper-connectivity in MCI, including hypoconnectivity in the posterior cingulate cortex/precuneus (z = –3.1, p < 0.0001). Very few individual studies, however, showed patterns resembling the meta-analytic results. Methodological differences did not appear to explain inconsistencies.   Conclusions: The pattern of altered resting DMN function or connectivity in MCI is complex and variable across studies. To date, no index of DMN connectivity qualifies as a useful biomarker of MCI or risk for AD. Refinements to MCI diagnosis, including other biological markers, or longitudinal studies of progression to AD, might identify DMN alterations predictive of AD risk."@en ;
    ns0:hasPubTitle "Resting State Abnormalities of the Default Mode Network in Mild Cognitive Impairment: A Systematic Review and Meta-Analysis"@en .

ns1:jad-v70-i1-JAD181246 ns0:hasKeywords "Dopamine transporter"@en,
        "electroencephalogram"@en,
        "frequency spectrum"@en,
        "hippocampus"@en,
        "secondary motor cortex"@en,
        "substantia nigra"@en,
        "ventral tegmental area"@en ;
    ns0:hasPubAbstract "Cognitive malfunction, synaptic dysfunction, and disconnections in neural networks are core deficits in Alzheimer’s disease (AD). 5xFAD mice, a transgenic model of AD, are characterized by an enhanced level of amyloid-β and abnormal neurotransmission. The dopaminergic (DA) system has been shown to be involved in amyloid-β transformations and neuronal plasticity; however, its role in functional network changes in familial AD still remains unclear. In 5xFAD and non-transgenic freely moving mice, electroencephalograms (EEGs) were simultaneously recorded from the secondary motor cortex (MC), superficial layers of the hippocampal CA1 area (HPC), substantia nigra (SN), and ventral tegmental area (VTA). EEGs and their frequency spectra were analyzed before and after systemic injection of a DA receptor agonist, apomorphine (APO). In the baseline EEG from MC and HPC of 5xFAD mice, delta and alpha oscillations were enhanced and beta activity was attenuated, compared to control mice. In VTA and SN of 5xFAD mice, delta-theta activity was decreased and beta oscillations dominated. In control mice, APO suppressed delta activity in VTA to a higher extent than in MC, whereas in 5xFAD mice, this difference was eliminated due to attenuation of the delta suppression in VTA. APO increased beta activity in MC of mice from both groups while significant beta suppression was observed in VTA of 5xFAD mice. These mice were characterized by significant decrease of tyrosine hydroxylase immunopositive cells in both VTA and SN and of DA transporter in MC and hippocampal dentate gyrus. We suggest that the EEG modifications observed in 5xFAD mice are associated with alterations in dopaminergic transmission, resulting in adaptive changes in the cerebral networks in the course of familial AD development."@en ;
    ns0:hasPubTitle "Loss of Midbrain Dopamine Neurons and Altered Apomorphine EEG Effects in the 5xFAD Mouse Model of Alzheimer’s Disease"@en .

ns1:jad-v70-i1-JAD190153 ns0:hasKeywords "ABI3"@en,
        "biomarkers"@en,
        "mild cognitive impairment"@en,
        "total tau"@en,
        "variant"@en ;
    ns0:hasPubAbstract "A potential role for ABI3 gene has been suggested in the risk of Alzheimer’s disease (AD), but the detailed mechanism before typical AD onset was unclear. In this study, we investigated the associations of ABI3 common variants with cerebrospinal fluid biomarkers and cognitive function scores among non-demented elderly from the ADNI database. We found that, in the progressive mild cognitive impairment group, rs5978930 was associated with total tau levels and rs16947151 was associated with cognitive function scores at baseline and over time, suggesting that ABI3 variants may be associated with cognitive decline and may influence AD onset through tau pathology."@en ;
    ns0:hasPubTitle "Common Variants in ABI3 Influence Cerebrospinal Fluid Total Tau Levels and Cognitive Decline in Progressive Mild Cognitive Impairment Patients"@en .

ns1:jad-v70-i2-JAD181168 ns0:hasKeywords "Alzheimer’s disease"@en,
        "PET"@en,
        "amyloid"@en,
        "mild cognitive impairment"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Background: Amyloid plaque and tau-containing neurofibrillary tangles are important features of Alzheimer’s disease (AD). However, the relationship between these processes is still debated.   Objective: We aimed to investigate local and distant relationships between tau and amyloid deposition in the cortex in mild cognitive impairment (MCI) and AD using PET imaging.   Methods: Seventy-nine subjects (51 controls, 13 amyloid-positive MCI subjects, and 15 amyloid positive AD subjects) underwent MRI and 18F-flutemetamol PET. All MCI/AD subjects and 8 healthy controls as well as 33 healthy control subjects from the ADNI dataset also had 18F-AV1451 PET. Regional and distant correlations were examined after sampling target-to-cerebellar ratio images. Biological parametric mapping was used to evaluate voxel level correlations locally.   Results: We found multiple clusters of voxels with highly significant positive correlations throughout the association cortex in both MCI and AD subjects.   Conclusion: The multiple clusters of positive correlations indicate that tau and amyloid may interact locally and be involved in disease progression. Our findings suggest that targeting both pathologies may be required."@en ;
    ns0:hasPubTitle "Tau Aggregation Correlates with Amyloid Deposition in Both Mild Cognitive Impairment and Alzheimer’s Disease Subjects"@en .

ns1:jad-v70-i2-JAD181178 ns0:hasKeywords "Alzheimer’s disease"@en,
        "older adults"@en,
        "social frailty"@en ;
    ns0:hasPubAbstract "We investigated the association between social frailty and Alzheimer’s disease (AD) incidence among community-dwelling older adults in Japan. A 53-month follow-up cohort study was conducted in Obu City, Japan. Participants comprised 3,720 community-dwelling older adults (mean age, 71.7 years; 48.4% men). The operational definition of social frailty comprised five items: going out infrequently, rarely visiting friends, feeling unhelpful to friends or family, living alone, and not always talking with someone each day. During follow-up, the cumulative AD incidence risk between socially robust, pre-frail, and frail groups was 4.1%, 5.5%, and 10.7%, respectively. In both crude (HR 2.72, 95% CI 1.90–3.89, p < 0.001) and adjusted Cox proportional hazards models (HR 1.53, 95% CI 1.03–2.28, p = 0.035), social frailty was associated with a significantly higher AD incidence risk. The present study revealed that social frailty is strongly associated with AD incidence among Japanese older adults. Further research should elucidate whether social frailty prevention is effective for decreasing AD risk."@en ;
    ns0:hasPubTitle "Impact of Social Frailty on Alzheimer’s Disease Onset: A 53-Month Longitudinal Cohort Study"@en .

ns1:jad-v70-i2-JAD190278 ns0:hasKeywords "Dementia"@en,
        "depression"@en,
        "mild behavioral impairment"@en,
        "mild cognitive impairment"@en,
        "neuropsychiatric symptoms"@en,
        "sleep disorder"@en,
        "subjective cognitive decline"@en ;
    ns0:hasPubAbstract "Background: Mild behavioral impairment (MBI) has been proposed as risk factor for dementia, and for some, an early manifestation of dementia.   Objective: We examined the prevalence of MBI in the psychiatric outpatient clinic, and compared the incidence of dementia in MBI with that in other psychiatric diseases.   Methods: Retrospective chart review was conducted in 2,853 consecutive outpatients over the age of 50. MBI was diagnosed according to the International Society to Advance Alzheimer’s Research and Treatment research diagnostic criteria. The incidence rate of dementia was examined in the patients who were followed up for at least 1 month. Kaplan-Meier survival analyses and Cox proportional hazards regression models were performed to compare the time to onset of dementia between MBI and other psychiatric diseases.   Results: The prevalence of MBI was 3.5% and the incidence of dementia was 30.7 cases per 1000 person-years. The hazard ratio (HR) for dementia was higher for MBI than other psychiatric diseases (HR: 8.07, 95% confidence interval: 4.34–15.03, p < 0.001). In MCI patients, the cumulative survival in MCI with affective dysregulation tended to be lower than that in MCI without (p = 0.090).   Conclusions: Psychiatric outpatients often meet MBI criteria. MBI, especially the affective dysregulation domain, increases the risk of dementia in this psychiatric outpatient population. Since late-onset psychiatric and behavioral symptoms may be prodromal symptoms of dementia in some, careful observation is needed, and psychiatric clinicians should keep prodromal dementia on their differential diagnosis when assessing those with new onset psychiatric symptomatology in older adults."@en ;
    ns0:hasPubTitle "Prevalence of Mild Behavioral Impairment and Risk of Dementia in a Psychiatric Outpatient Clinic"@en .

ns1:jad-v70-i2-JAD190323 ns0:hasKeywords "Amyloid"@en,
        "PET imaging"@en,
        "Parkinson’s disease"@en,
        "dementia"@en,
        "dementia with Lewy bodies"@en,
        "synucleinopathies"@en ;
    ns0:hasPubAbstract "Background: Dementia in Parkinson’s disease (PDD) is common presumably due to combined neuropathological substrates. Amyloid-β (Aβ) plaques are well described in PDD but their contribution in synucleinopathies is still controversial.   Objective: To investigate regional [18F]Florbetapir binding and its relative contribution to cognitive dysfunction in a cohort of PDD patients and to test whether PDD patients with comorbid amyloidopathy have different clinical and neuropsychological characteristics.   Methods: 21 PDD patients, 20 with Alzheimer’s disease (AD), and 9 control subjects underwent amyloid positron emission tomography (PET) imaging, neurological, and neuropsychological assessment. Radioligand binding was compared across the groups. PDD scans were interpreted qualitatively and semiquantitatively and categorized as positive or negative. Annual longitudinal Mini-Mental State Examination (MMSE) of PDD subjects was retrospectively collected in order to relate Aβ burden to the course of cognitive impairment.   Results: [18F]Florbetapir PET imaging was positive in 11 PDD patients (52.38%) using the semi-quantitative method. There were no group differences between PDD subjects with increased cortical [18F]Florbetapir (+) and those without (–), according to demographic and clinical parameters. PDD+ performed worse on Digit Span Foward and on Rey Auditory Verbal Learning Test delayed recall than the PDD– with a significant negative correlation between global cortical retention and specific memory tests. Aβ load did not correlate with MMSE ratings although PDD+ demonstrated a faster clinical progression of dementia.   Conclusions: Significant Aβ deposition is common in PDD patients contributing to memory impairment and driving a faster rate of cognitive decline."@en ;
    ns0:hasPubTitle "Clinical Correlates of Cerebral Amyloid Deposition in Parkinson’s Disease Dementia: Evidence from a PET Study"@en .

ns1:jad-v70-i2-JAD190331 ns0:hasKeywords "Air pollution"@en,
        "Alzheimer’s disease continuum"@en,
        "ApoE ɛ4"@en,
        "Mexico City"@en,
        "PM2.5"@en,
        "Paris"@en,
        "Santiago de Chile"@en,
        "combustion and friction derived nanoparticles"@en,
        "suicide"@en,
        "tauopathies"@en ;
    ns0:hasPubAbstract "Exposures to fine particulate matter (PM2.5) and ozone (O3) ≥US EPA standards are associated with Alzheimer’s disease (AD) risk. The projection of 13.8 million AD cases in the US by the year 2050 obligate us to explore early environmental exposures as contributors to AD risk and pathogenesis. Metropolitan Mexico City children and young adults have lifetime exposures to PM2.5 and O3, and AD starting in the brainstem and olfactory bulb is relentlessly progressing in the first two decades of life. Magnetite combustion and friction-derived nanoparticles reach the brain and are associated with early and progressive damage to the neurovascular unit and to brain cells. In this review: 1) we highlight the interplay environment/genetics in the AD development in young populations; 2) comment upon ApoE ɛ4 and the rapid progression of neurofibrillary tangle stages and higher suicide risk in youth; and 3) discuss the role of combustion-derived nanoparticles and brain damage. A key aspect of this review is to show the reader that air pollution is complex and that profiles change from city to city with common denominators across countries. We explore and compare particulate matter profiles in Mexico City, Paris, and Santiago in Chile and make the point of why we should invest in decreasing PM2.5 to at least our current US EPA standard. Multidisciplinary intervention strategies are critical for prevention or amelioration of cognitive deficits and AD progression and risk of suicide in young individuals. AD pathology evolving from childhood is threating the wellbeing of future generations."@en ;
    ns0:hasPubTitle "Air Pollution, Combustion and Friction Derived Nanoparticles, and Alzheimer’s Disease in Urban Children and Young Adults"@en .

ns1:jad-v70-i2-JAD190385 ns0:hasKeywords "Alzheimer’s disease"@en,
        "mild cognitive impairment"@en,
        "somatosensory temporal discrimination threshold"@en,
        "subjective cognitive decline"@en,
        "temporal processing"@en ;
    ns0:hasPubAbstract "Background: The temporal processing of sensory information can be evaluated by testing the somatosensory temporal discrimination threshold (STDT), which is defined as the shortest interstimulus interval needed to recognize two sequential sensory stimuli as separate in time. The STDT requires the functional integrity of the basal ganglia and of the somatosensory cortex (S1). Although there is evidence that time processing is impaired in patients with Alzheimer’s disease (AD), no study has yet investigated STDT in patients with various degree of cognitive impairment.   Objective: The aim of our study was to understand how cognition and attention deficits affect STDT values in patients with cognitive abnormalities.   Methods: We enrolled 63 patients: 28 had mild-moderate AD, 16 had mild cognitive impairment (MCI), and the remaining 19 had subjective cognitive deficit (SCD). A group of 45 age-matched healthy subjects acted as controls. Paired tactile stimuli for STDT testing consisted of square-wave electrical pulses delivered with a constant current stimulator through surface electrodes over the distal phalanx of the index finger.   Results: STDT values were higher in AD and MCI patients than in SCD subjects or healthy controls. Changes in the STDT in AD and MCI were similar in both conditions and did not correlate with disease severity.   Conclusions: STDT alterations in AD and MCI may reflect a dysfunction of the dopaminergic system, which signals salient events and includes the striatum and the mesocortical and mesolimbic circuits."@en ;
    ns0:hasPubTitle "Somatosensory Temporal Discrimination Threshold in Patients with Cognitive Disorders"@en .

ns1:jad-v70-i2-JAD190426 ns0:hasKeywords "Alzheimer’s disease"@en,
        "caregivers"@en,
        "cost of illness"@en,
        "dementia"@en,
        "disease progression"@en,
        "health care costs"@en,
        "health policy"@en,
        "long-term care"@en,
        "resource allocation"@en ;
    ns0:hasPubAbstract "While it is generally understood that Alzheimer’s disease (AD) and related dementias (ADRD) is one of the costliest diseases to society, there is widespread concern that researchers and policymakers are not comprehensively capturing and describing the full scope and magnitude of the socioeconomic burden of ADRD. This review aimed to 1) catalogue the different types of AD-related socioeconomic costs described in the literature; 2) assess the challenges and gaps of existing approaches to measuring these costs; and 3) analyze and discuss the implications for stakeholders including policymakers, healthcare systems, associations, advocacy groups, clinicians, and researchers looking to improve the ability to generate reliable data that can guide evidence-based decision making. A centrally emergent theme from this review is that it is challenging to gauge the true value of policies, programs, or interventions in the ADRD arena given the long-term, progressive nature of the disease, its insidious socioeconomic impact beyond the patient and the formal healthcare system, and the complexities and current deficiencies (in measures and real-world data) in accurately calculating the full costs to society. There is therefore an urgent need for all stakeholders to establish a common understanding of the challenges in evaluating the full cost of ADRD and define approaches that allow us to measure these costs more accurately, with a view to prioritizing evidence-based solutions to mitigate this looming public health crisis."@en ;
    ns0:hasPubTitle "Tip of the Iceberg: Assessing the Global Socioeconomic Costs of Alzheimer’s Disease and Related Dementias and Strategic Implications for Stakeholders"@en .

ns1:jad-v70-i3-JAD181113 ns0:hasKeywords "Alzheimer’s disease"@en,
        "RNA profiling"@en,
        "microarray"@en,
        "middle temporal gyrus"@en,
        "postmortem brains"@en ;
    ns0:hasPubAbstract "We used Illumina Human HT-12 v4 arrays to compare RNA expression of middle temporal gyrus (MTG; BA21) in Alzheimer’s disease (AD = 97) and non-demented controls (ND = 98). A total of 938 transcripts were highly differentially expressed (adj p < 0.01; log2 FC ≥ |0.500|, with 411 overexpressed and 527 underexpressed in AD. Our results correlated with expression profiling in neurons from AD and ND obtained by laser capture microscopy in MTG from an independent dataset (log2 FC correlation: r = 0.504; p = 2.2e-16). Additionally, selected effects were validated by qPCR. ANOVA analysis yielded no difference between genders in response to AD, but some gender specific genes were detected (e.g., IL8 and AGRN in males, and HSPH1 and GRM1 in females). Several transcripts were associated with Braak staging (e.g., AEBP1 and DNALI1), antemortem MMSE (e.g., AEBP1 and GFAP), and tangle density (e.g., RNU1G2, and DNALI1). At the pathway level, we detected enrichment of synaptic vesicle processes and GABAergic transmission genes. Finally, applying the Weighted Correlation Network Analysis, we identified four expression modules enriched for neuronal and synaptic genes, mitochondria-associated membrane, chemical stimulus and olfactory receptor and non-coding RNA metabolism genes. Our results represent an extensive description of MTG mRNA profiling in a large sample of AD and ND. These data provide a list of genes associated with AD, and correlated to neurofibrillary tangles density. In addition, these data emphasize the importance of mitochondrial membranes and transcripts related to olfactory receptors in AD."@en ;
    ns0:hasPubTitle "Transcriptome Changes in the Alzheimer’s Disease Middle Temporal Gyrus: Importance of RNA Metabolism and Mitochondria-Associated Membrane Genes"@en .

ns1:jad-v70-i3-JAD190074 ns0:hasKeywords "Alzheimer’s disease"@en,
        "apolipoprotein E4"@en,
        "autophagy"@en,
        "mitochondrial dynamics"@en,
        "mitophagy"@en ;
    ns0:hasPubAbstract "This study examined the effects of apolipoprotein E4 (APOE4), the most prevalent genetic risk factor for Alzheimer’s disease (AD), on proteins involved in mitochondrial dynamics and autophagy, in the hippocampus of targeted replacement mice. Immunohistochemical measurements revealed that the levels of the mitochondrial fusion-mediating protein, MFN1, were higher, whereas those of corresponding fission-regulating protein, DRP-1, were lower in the hippocampus of ApoE4 mice than in the corresponding ApoE3 mice, indicating that APOE4 is associated with increased mitochondrial fusion and decreased fission. A similar ApoE4-driven decrease in DRP-1 was also observed in AD brains. The levels of the mitochondrial proteins COX1 and Tom40, were higher in the ApoE4 mice, which is consistent with the increased fusion. Measurements of the levels of cleaved PINK1 and parkin, which mark and target mitochondria for mitophagic degradation, revealed lower levels of cleaved PINK1, suggesting reduced mitochondrial membrane potential, and higher levels of parkin in the hippocampus of ApoE4 compared with the ApoE3 mice, indicating altered mitophagy. The levels of the ubiquitin-binding scaffold protein, p62/SQSTM1, which directs selected cargo to the autophagosomes, were also higher in the ApoE4 mice. These findings suggest that APOE4 is associated with enhanced mitochondrial fusion and decreased fission. Additionally, the results indicate that mitophagy/autophagy is reduced in ApoE4 mice, resulting in higher levels of proteins such as parkin and p62, which are normally degraded during this process. Taken together, these results suggest a novel mechanism that may underlie the pathological effects of APOE4 and indicate that use of APOE4 genotyping could pave the way for identification of novel APOE4-related therapeutic targets."@en ;
    ns0:hasPubTitle "The Effects of APOE4 on Mitochondrial Dynamics and Proteins in vivo"@en .

ns1:jad-v70-i3-JAD190094 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Australia"@en,
        "anticoagulants"@en,
        "atrial fibrillation"@en,
        "dementia"@en,
        "direct oral anticoagulants"@en,
        "incidence"@en,
        "prevalence"@en,
        "trends"@en,
        "warfarin"@en ;
    ns0:hasPubAbstract "Background: People with Alzheimer’s disease (AD) are less likely to use oral anticoagulants than people without AD.   Objective: We investigated incidence and prevalence of warfarin and direct oral anticoagulant (DOAC) use, and determined predictors of DOAC and warfarin initiation in older people with AD and the general population.   Methods: Australian Pharmaceutical Benefits Scheme data for 356,000 people aged ≥65 years dispensed warfarin or DOACs during July 2013-June 2017 were analyzed. Changes in annual incidence and prevalence were estimated using Poisson regression. Predictors of DOAC versus warfarin initiation were estimated using multivariable logistic regression separately for people with AD and the general population.   Results: Oral anticoagulant prevalence increased from 8% in people with AD and 9% in the general population to 12% in both groups from 2013/2014 to 2016/2017. DOAC prevalence increased (from 2.4% to 7.8% in people with AD, 3.2% to 7.7% in the general population) while warfarin prevalence declined (6.6% to 4.5%, 7.0% to 4.3%, correspondingly). The incidence of warfarin use decreased by 45–55%. In people with AD, women were less likely to initiate DOACs than men, whereas presence of arrhythmias or pain/inflammation increased likelihood of initiating DOACs. Age ≥85 years, cardiovascular diseases, gastric acid disorder, diabetes, and end-stage renal disease were associated with lower odds of DOAC initiation in the general population.   Conclusion: DOAC introduction has coincided with increased anticoagulation rates in people with AD. Rates are now similar in older people with AD and the general population. Compared to previous years, DOACs are now more likely to be initiated, particularly for those aged ≥85 years."@en ;
    ns0:hasPubTitle "Trends and Predictors of Oral Anticoagulant Use in People with Alzheimer’s Disease and the General Population in Australia"@en .

ns1:jad-v70-i3-JAD190107 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid PET"@en,
        "corticobasal syndrome"@en,
        "presenilin-1"@en ;
    ns0:hasPubAbstract "Dementia is not just a disease of old age. Early-onset dementia affects people younger than 65 and its differential diagnosis is broader than in older people. Nevertheless, although young people are considerably more liable to develop a rare form of dementia, Alzheimer’s disease (AD) remains the most common diagnosis. The aim of this article is to report on an early-onset AD patient associated with the rare pathogenic variant PSEN1 (Leu85Pro) presenting as a possible corticobasal syndrome with asymmetric limb apraxia, parkinsonian signs, and myoclonus."@en ;
    ns0:hasPubTitle "A Rare PSEN1 (Leu85Pro) Mutation Causing Alzheimer’s Disease in a 29-Year-Old Woman Presenting as Corticobasal Syndrome"@en .

ns1:jad-v70-i3-JAD190142 ns0:hasKeywords "Cognition"@en,
        "dementia"@en,
        "pain"@en,
        "sex differences"@en ;
    ns0:hasPubAbstract "Background: Sex differences in pain have been shown to exist in older adults with normal cognition and people with Alzheimer’s disease. It is unknown if sex differences in pain in older adults exist in a range of communicative older adults with varying cognitive ability from no impairment to moderately severe cognitive impairment.   Objective: This study proposes to compare the association between psychophysical responses to experimental thermal pain between males and females to determine if sex differences in pain exist across the cognitive spectrum.   Methods: We conducted a secondary analysis of data from an age- and sex-matched between-groups cross-sectional study examining the psychophysical response to contact heat in people with and without dementia.   Results: Median age of males (n = 38) and females (n = 38) was 73 (range: 68–87) with similar distributions of Mini-Mental State Examination (MMSE) scores (range: 11–30). Findings revealed inverse statistically significant associations with the threshold temperature of warmth (females: r = –0.41, p = 0.010; males: r = –0.33, p = 0.044). There was an apparent divergent pattern of MMSE associations with unpleasantness ratings between the groups. At the moderate pain threshold, that difference became statistically significant (p = 0.033). Females demonstrated a positive association of MMSE with unpleasantness (r = 0.30, p = 0.072), while males demonstrated an inverse association at that respective threshold (r = –0.20, p = 0.221).   Conclusions: Between-group findings suggest that patterns of responses to thermal stimulus intensity may differ between males and females with worsening cognition with females reporting significantly less unpleasantness with the percept of moderate pain and males reporting significantly higher unpleasantness with moderate pain perception."@en ;
    ns0:hasPubTitle "Sex Differences in Associations of Cognitive Function with Perceptions of Pain in Older Adults"@en .

ns1:jad-v70-i3-JAD190159 ns0:hasKeywords "Alzheimer’s disease"@en,
        "apolipoprotein E4"@en,
        "cerebral small vessel diseases"@en,
        "cognitive aging"@en,
        "leukoaraiosis"@en,
        "magnetic resonance imaging"@en,
        "mild cognitive impairment"@en ;
    ns0:hasPubAbstract "Background: Asymmetrical patterns of cerebral damage have been widely observed in a range of neurodegenerative diseases, including Alzheimer’s disease (AD).   Objective: To elucidate the clinical associations of asymmetrical white matter hyperintensities (WMH) in mild cognitive impairment (MCI) and AD.   Methods: Regional WMH asymmetry of 340 participants (90 healthy controls, 132 MCI, 118 AD) was calculated as the difference in normalized hemispheric WMH volume (WMH/ICV) adjusted for structural brain asymmetry of respective lobar regions and total WMH. WMH asymmetry was analyzed in relation to disease classification, cognition, and APOE4 status using ANCOVA and multiple regression analysis, controlling for gender, age, ethnicity, and correcting for multiple comparisons using Bonferroni correction. Moderation analysis examined interaction effects of APOE4 on associations between cognition and WMH asymmetry.   Results: Greater left-dominant occipital WMH asymmetry was observed in AD, compared to healthy controls and MCI, and was associated with poorer global cognition, memory, language, and executive functions among cognitively impaired participants (MCI and AD). Cognitively impaired APOE4 carriers displayed greater left-dominant WMH asymmetry in the whole brain and frontal lobe, compared to non-carriers. Importantly, effects were independent of structural brain asymmetry, global cerebral atrophy, and overall WMH burden. Moderation analysis demonstrated associations between left-dominant WMH asymmetry and cognition in cognitively impaired APOE4 non-carriers, but not APOE4 carriers.   Conclusion: Leftward asymmetry of WMH may be more pathological in nature, compared to symmetrical WMH. Furthermore, the detrimental effects of WMH asymmetry was more relevant in APOE4-negative cognitive impairment, compared to APOE4-positive which may be driven primarily by AD pathology."@en ;
    ns0:hasPubTitle "Association of Asymmetrical White Matter Hyperintensities and Apolipoprotein E4 on Cognitive Impairment"@en .

ns1:jad-v70-i3-JAD190180 ns0:hasKeywords "Alzheimer’s disease"@en,
        "SH-SY5Y cells"@en,
        "autophagy-mediated secretion"@en,
        "beclin1"@en,
        "tau protein"@en ;
    ns0:hasPubAbstract "Increased levels of total tau (t-tau) and hyperphosphorylated tau (p-tau) proteins in the cerebrospinal fluid of Alzheimer’s disease (AD) patients are well documented and strongly correlate with AD pathology. Recent studies have further shown that human tau can be released into the extracellular space and transferred to nascent neurons. However, because the tau protein has no signal peptide identity, the mechanisms underlying its secretion remain poorly understood. In the present study, we confirmed that tau protein secretion was promoted by autophagy inducers and downregulated by beclin1 knockdown or autophagy inhibitors derived from human wild type tau (wt-tau)-overexpressing SH-SY5Y cells. Moreover, both t-tau and p-tau secretion were increased by autophagy activation. Furthermore, we identified that six isoforms of tau protein are secreted in an autophagy-dependent manner. These results indicate that both normal and pathological tau are secreted via an autophagy-mediated secretory pathway in neurons. Understanding this new pathway for tau secretion may provide critical future insights into tau pathologies, such as AD."@en ;
    ns0:hasPubTitle "Autophagy-Mediated Secretory Pathway is Responsible for Both Normal and Pathological Tau in Neurons"@en .

ns1:jad-v70-i3-JAD190237 ns0:hasKeywords "Aging"@en,
        "BDNF"@en,
        "T2DM"@en,
        "dementia"@en,
        "diabetes"@en,
        "exendin-4"@en,
        "insulin"@en,
        "insulin resistance"@en,
        "neurotrophic factors"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is a multifactorial condition in which, along with amyloid-β (Aβ) and tau-related pathology, the synergistic activity of co-morbidity factors promote the onset and progression of the disease. Epidemiological evidence indicates that glucose intolerance, deficits in insulin secretion, or type-2 diabetes mellitus (T2DM) participate in increasing cognitive impairment or dementia risk. Insulin plays a pivotal role in the process as the hormone critically regulates brain functioning. GLP-1, the glucagon-like peptide 1, facilitates insulin signaling, regulates glucose homeostasis, and modulates synaptic plasticity. Exenatide is a synthetic GLP-1 analog employed in T2DM. However, exenatide has also been shown to affect the signaling of the brain-derived neurotrophic factor (BDNF), synaptic plasticity, and cognitive performances in animal models. In this study, we tested whether exenatide exerts neuroprotection in a preclinical AD model set to mimic the clinical complexity of the human disease. We investigated the effects of exenatide treatment in 3xTg-AD mice challenged with a high-fat diet (HFD). Endpoints of the study were variations in systemic metabolism, insulin and neurotrophic signaling, neuroinflammation, Aβ and tau pathology, and cognitive performances. Results of the study indicate that exenatide reverts the adverse changes of BDNF signaling and the neuroinflammation status of 3xTg-AD mice undergoing HFD without affecting systemic metabolism or promoting changes in cognitive performances."@en ;
    ns0:hasPubTitle "Exenatide Reverts the High-Fat-Diet-Induced Impairment of BDNF Signaling and Inflammatory Response in an Animal Model of Alzheimer’s Disease"@en .

ns1:jad-v70-i3-JAD190280 ns0:hasKeywords "Anesthesia"@en,
        "cognitive impairment"@en,
        "eEF2"@en,
        "insulin"@en,
        "intranasal delivery"@en,
        "mTOR"@en,
        "synaptic proteins"@en ;
    ns0:hasPubAbstract "General anesthesia increases the risk for cognitive impairment and Alzheimer’s disease (AD) in vulnerable individuals such as the elderly. We previously reported that prior administration of insulin through intranasal delivery can prevent the anesthesia-induced cognitive impairment and biochemical changes in the brain. However, little is known about the underlying molecular mechanisms. Here, we report that general anesthesia resulted in downregulation of mammalian/mechanistic target of rapamycin (mTOR) and eukaryotic elongation factor 2 (eEF2) in the brain along with reduction of presynaptic proteins and brain-derived neurotrophic factor and cognitive impairment in aged mice. Prior administration of intranasal insulin prevented these anesthesia-induced changes. These results suggest the involvement of the mTOR-eEF2 signaling pathway in the anesthesia-induced brain changes and cognitive impairment and in the prevention of these changes with insulin. Correlation analyses and the use of eEF2 kinase inhibitor further support our conclusions. These studies shed light on the molecular mechanism by which anesthesia and insulin could act on synaptic proteins and cognitive function."@en ;
    ns0:hasPubTitle "Intranasal Insulin Increases Synaptic Protein Expression and Prevents Anesthesia-Induced Cognitive Deficits Through mTOR-eEF2 Pathway"@en .

ns1:jad-v70-i4-JAD190293 ns0:hasKeywords "APOE"@en,
        "TOMM40"@en,
        "cognition"@en,
        "factor analysis"@en,
        "longitudinal"@en ;
    ns0:hasPubAbstract "TOMM40 ‘523 is associated with Alzheimer’s disease (AD), but APOE linkage disequilibrium confounds this association. In 170 APOE ɛ3 homozygotes, we evaluated relationships between short and very long TOMM40 alleles and longitudinal declines in three cognitive domains (attention, verbal memory, and executive function). We used factor analysis to create composite scores from 10 individual cognitive tests, and latent growth curve modeling adjusting for clinical status (normal, amnestic mild cognitive impairment, or AD) to summarize initial performance and change over three years. Relative to individuals with two very long TOMM40 alleles, APOE ɛ3 homozygotes with one or two short alleles showed lower baseline cognitive performance regardless of clinical status. The number of short or very long TOMM40 alleles was not associated with longitudinal cognitive changes. In APOE ɛ3 homozygotes from the University of Kansas Alzheimer’s Disease Center cohort, an association between TOMM40 ‘523 and cognition is consistent with the possibility that TOMM40 influences cognition independent of APOE."@en ;
    ns0:hasPubTitle "TOMM40 ‘523 Associations with Baseline and Longitudinal Cognition in APOE ɛ3 Homozygotes"@en .

ns1:jad-v70-i4-JAD190368 ns0:hasKeywords "PKA"@en,
        "TDP-43"@en,
        "mRNA processing"@en,
        "phosphorylation"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Trans-active response DNA-binding protein of 43 kDa (TDP-43) is a highly conserved and ubiquitously expressed nuclear protein. As a member of heterogeneous ribonucleoproteins, TDP-43 plays pivotal roles in mRNA processing. We recently found that TDP-43 promoted tau mRNA instability via acting on the 3’-untranslated region of its mRNA and enhanced tau exon 10 inclusion. TDP-43 is a phospho-protein. The function and the pathological aggregation of TDP-43 are regulated by the phosphorylation. In the present study, we determined phosphorylation of TDP-43 by cyclic AMP-dependent protein kinase (PKA). We found that TDP-43 was co-immunoprecipitated by and co-localized with PKA in the nucleus. PKA phosphorylated TDP-43 at Ser379, Ser403/404, and Ser409/410 in vitro and in cultured cells. Phosphorylation of TDP-43 at these sites enhanced mutually their phosphorylation by PKA in vitro and in cultured cells. Overexpression of PKA suppressed TDP-43’s activity in promoting tau mRNA instability and tau exon 10 inclusion. These findings shed light on the role of PKA in phosphorylation and function of TDP-43. Downregulation of PKA signaling in AD brain may attenuate the impact of TDP-43 pathology in tau pathogenesis."@en ;
    ns0:hasPubTitle "Cyclic AMP-Dependent Protein Kinase Phosphorylates TDP-43 and Modulates Its Function in Tau mRNA Processing"@en .

ns1:jad-v70-i4-JAD190440 ns0:hasKeywords "Alzheimer’s disease"@en,
        "autobiographical memory"@en,
        "self"@en,
        "self-continuity"@en ;
    ns0:hasPubAbstract "We investigated, for the first time, how people with mild Alzheimer’s disease (AD) reflect on continuity of their self (i.e., whether they are the same person they were before). We invited people with mild AD and control participants to conduct The Thinking about Life Experiences (TALE) Scale. More specifically, we invited participants to indicate whether they think about their life story: when they want to feel that they are the same person that they were before (Item 1), when they are concerned about whether they are still the same type of person that they were earlier (Item 2), when they are concerned about whether their values have changed over time (Item 3), when they are concerned about whether their beliefs have changed over time (Item 4), and when they want to understand how they have changed from who they were before (Item 5). The scores of people with AD and control participants on the items of the TALE scale were similar, except for the first item on which people with AD provided higher scores than did control participants. As demonstrated by scores on Item 1, people with mild AD can retrieve autobiographical memories to reflect on situations in which they want to feel that they are the same person that they were before. In other words, people with mild AD can draw on their personal and meaningful events to maintain a continuous sense of self or even to reflect on situations in which they are concerned about their self-continuity."@en ;
    ns0:hasPubTitle "Memories Supporting Myself: Autobiographical Memory Supports Self-Continuity in Alzheimer’s Disease"@en .

ns1:jad-v70-is1-JAD180501 ns0:hasKeywords "Aging"@en,
        "cognition"@en,
        "cognitive reserve"@en,
        "social isolation"@en ;
    ns0:hasPubAbstract "Background: There is some evidence to suggest that social isolation may be associated with poor cognitive function in later life. However, findings are inconsistent and there is wide variation in the measures used to assess social isolation.   Objective: We conducted a systematic review and meta-analysis to investigate the association between social isolation and cognitive function in later life.   Methods: A search for longitudinal studies assessing the relationship between aspects of social isolation (including social activity and social networks) and cognitive function (including global measures of cognition, memory, and executive function) was conducted in PsycInfo, CINAHL, PubMed, and AgeLine. A random effects meta-analysis was conducted to assess the overall association between measures of social isolation and cognitive function. Sub-analyses investigated the association between different aspects of social isolation and each of the measures of cognitive function.   Results: Sixty-five articles were identified by the systematic review and 51 articles were included in the meta-analysis. Low levels of social isolation characterized by high engagement in social activity and large social networks were associated with better late-life cognitive function (r = 0.054, 95% CI: 0.043, 0.065). Sub-analyses suggested that the association between social isolation and measures of global cognitive function, memory, and executive function were similar and there was no difference according to gender or number of years follow-up.   Conclusions: Aspects of social isolation are associated with cognitive function in later life. There is wide variation in approaches to measuring social activity and social networks across studies which may contribute to inconsistencies in reported findings."@en ;
    ns0:hasPubTitle "Social Isolation and Cognitive Function in Later Life: A Systematic Review and Meta-Analysis"@en .

ns1:jad-v70-is1-JAD180511 ns0:hasKeywords "Aging"@en,
        "Malay population"@en,
        "cognitive function"@en,
        "protein profiling"@en ;
    ns0:hasPubAbstract "Background: Many studies on biochemical and psychological variables have aimed to elucidate the association between aging and cognitive function. Demographic differences and protein expression have been reported to play a role in determining the cognitive capability of a population.   Objective: This study aimed to determine the effect of age on the protein profile of Malay individuals and its association with cognitive competency.   Methods: A total of 160 individuals were recruited and grouped accordingly. Cognitive competency of each subject was assessed with several neuropsychological tests. Plasma samples were collected and analyzed with Q Exactive HF Orbitrap. Proteins were identified and quantitated with MaxQuant and further analyzed with Perseus to determine differentially expressed proteins. PANTHER, Reactome, and STRING were applied for bioinformatics output.   Results: Our data showed that the Malay individuals are vulnerable to the deterioration of cognitive function with aging, and most of the proteins were differentially expressed in concordance. Several physiological components and pathways were shown to be involved, giving a hint of a promising interpretation on the induction of aging toward the state of the Malays’ cognitive function. Nevertheless, some proteins have shown a considerable interaction with the generated protein network, which provides a direction of focus for further investigation.   Conclusion: This study demonstrated notable changes in the expression of several proteins as age increased. These changes provide a promising platform for understanding the biochemical factors affecting cognitive function in the Malay population. The exhibited network of protein-protein interaction suggests the possibility of implementing regulatory intervention in ameliorating Malay cognitive function."@en ;
    ns0:hasPubTitle "Effect of Age on the Protein Profile of Healthy Malay Adults and its Association with Cognitive Function Competency"@en .

ns1:jad-v70-is1-JAD180573 ns0:hasKeywords "Aged"@en,
        "Alzheimer’s disease"@en,
        "indigenous population"@en,
        "neurocognitive disorders"@en,
        "social determinants of health"@en ;
    ns0:hasPubAbstract "Dementia prevalence in Aboriginal and Torres Strait Islander Australians is three to five times higher than the general Australian population. A better understanding of the underlying biomedical and social risk factors is needed to guide dementia prevention in Aboriginal Australians. The current study is the first to examine potential risk factors for dementia in the majority urban and regional population, with a representative sample of 336 Aboriginal Australians aged 60 years and older. Participants included 45 people with a dementia diagnosis (n = 27 probable/possible Alzheimer’s disease); and 286 people without dementia. Univariate logistic regression analyses (controlling for age) identified childhood trauma, mid-life factors (history of unskilled work, past high-risk alcohol use), and medical factors (history of stroke, head injury with loss of consciousness, epilepsy) as risk factors for dementia. Multivariable analysis revealed age, childhood trauma, unskilled work, stroke, and head injury as independent predictors of all-cause dementia. A range of comorbid factors related to dementia was also identified (i.e., functional impairment, incontinence, recent hospital admission, low body mass index, living in residential care, depression, current high-risk alcohol use, social isolation, low physical activity levels). These findings extend previous outcomes in a remote Aboriginal population by highlighting that life-course social determinants of health, in addition to neurological disorders, likely play an important role in elevating dementia risk. Certain psychosocial and medical exposures are highly prevalent in Aboriginal Australians, similar to other indigenous populations, and should be considered when designing targeted and culturally appropriate prevention initiatives to reduce the burden of dementia."@en ;
    ns0:hasPubTitle "Factors Associated with the High Prevalence of Dementia in Older Aboriginal Australians"@en .

ns1:jad-v70-is1-JAD180634 ns0:hasKeywords "Alzheimer’s disease"@en,
        "dementia"@en,
        "health promotion"@en,
        "integrated delivery of health care"@en,
        "risk reduction behavior"@en ;
    ns0:hasPubAbstract "This article describes the protocol for the Systematic Multi-domain Alzheimer’s Risk Reduction Trial (SMARRT), a single-blind randomized pilot trial to test a personalized, pragmatic, multi-domain Alzheimer’s disease (AD) risk reduction intervention in a US integrated healthcare delivery system. Study participants will be 200 higher-risk older adults (age 70–89 years with subjective cognitive complaints, low normal performance on cognitive screen, and ≥ two modifiable risk factors targeted by our intervention) who will be recruited from selected primary care clinics of Kaiser Permanente Washington, oversampling people with non-white race or Hispanic ethnicity. Study participants will be randomly assigned to a two-year Alzheimer’s risk reduction intervention (SMARRT) or a Health Education (HE) control. Randomization will be stratified by clinic, race/ethnicity (non-Hispanic white versus non-white or Hispanic), and age (70–79, 80–89). Participants randomized to the SMARRT group will work with a behavioral coach and nurse to develop a personalized plan related to their risk factors (poorly controlled hypertension, diabetes with evidence of hyper or hypoglycemia, depressive symptoms, poor sleep quality, contraindicated medications, physical inactivity, low cognitive stimulation, social isolation, poor diet, smoking). Participants in the HE control group will be mailed general health education information about these risk factors for AD. The primary outcome is two-year cognitive change on a cognitive test composite score. Secondary outcomes include: 1) improvement in targeted risk factors, 2) individual cognitive domain composite scores, 3) physical performance, 4) functional ability, 5) quality of life, and 6) incidence of mild cognitive impairment, AD, and dementia. Primary and secondary outcomes will be assessed in both groups at baseline and 6, 12, 18, and 24 months."@en ;
    ns0:hasPubTitle "Systematic Multi-Domain Alzheimer’s Risk Reduction Trial (SMARRT): Study Protocol"@en .

ns1:jad-v71-i1-JAD181297 ns0:hasKeywords "Aging"@en,
        "brain"@en,
        "cognition"@en,
        "epidemiology"@en,
        "gray matter"@en,
        "magnetic resonance imaging"@en ;
    ns0:hasPubAbstract "Background: It is increasingly recognized that the complex functions of human cognition are not accurately represented by arbitrarily-defined anatomical brain regions. Given the considerable functional specialization within such regions, more fine-grained studies of brain structure could capture such localized associations. However, such analyses/studies in a large community-dwelling population are lacking.   Objective: To perform a fine-mapping of cognitive ability to cortical and subcortical grey matter on magnetic resonance imaging (MRI).   Methods: In 3,813 stroke-free and non-demented persons from the Rotterdam Study (mean age 69.1 (±8.8) years; 55.8% women) with cognitive assessments and brain MRI, we performed voxel-based morphometry and subcortical shape analysis on global cognition and separate tests that tapped into memory, information processing speed, fine motor speed, and executive function domains.   Results: We found that the different cognitive tests significantly associated with grey matter density in differential but also overlapping brain regions, primarily in the left hemisphere. Clusters of significantly associated voxels with global cognition were located within multiple anatomic regions: left amygdala, hippocampus, parietal lobule, superior temporal gyrus, insula and posterior temporal lobe. Subcortical shape analysis revealed associations primarily within the head and tail of the caudate nucleus, putamen, ventral part of the thalamus, and nucleus accumbens, more equally distributed among the left and right hemisphere. Within the caudate nucleus both positive (head) as well as negative (tail) associations were observed with global cognition.   Conclusions: In a large population-based sample, we mapped cognitive performance to cortical and subcortical grey matter density using a hypothesis-free approach with high-dimensional neuroimaging. Leveraging the power of our large sample size, we confirmed well-known associations as well as identified novel brain regions related to cognition."@en ;
    ns0:hasPubTitle "High-Dimensional Mapping of Cognition to the Brain Using Voxel-Based Morphometry and Subcortical Shape Analysis"@en .

ns1:jad-v71-i1-JAD190283 ns0:hasKeywords "Advanced normalization tools"@en,
        "FreeSurfer"@en,
        "linear mixed effects models"@en,
        "longitudinal processing"@en ;
    ns0:hasPubAbstract "Longitudinal studies of development and disease in the human brain have motivated the acquisition of large neuroimaging data sets and the concomitant development of robust methodological and statistical tools for quantifying neurostructural changes. Longitudinal-specific strategies for acquisition and processing have potentially significant benefits including more consistent estimates of intra-subject measurements while retaining predictive power. Using the first phase of the Alzheimer’s Disease Neuroimaging Initiative (ADNI-1) data, comprising over 600 subjects with multiple time points from baseline to 36 months, we evaluate the utility of longitudinal FreeSurfer and Advanced Normalization Tools (ANTs) surrogate thickness values in the context of a linear mixed-effects (LME) modeling strategy. Specifically, we estimate the residual variability and between-subject variability associated with each processing stream as it is known from the statistical literature that minimizing the former while simultaneously maximizing the latter leads to greater scientific interpretability in terms of tighter confidence intervals in calculated mean trends, smaller prediction intervals, and narrower confidence intervals for determining cross-sectional effects. This strategy is evaluated over the entire cortex, as defined by the Desikan-Killiany-Tourville labeling protocol, where comparisons are made with the cross-sectional and longitudinal FreeSurfer processing streams. Subsequent linear mixed effects modeling for identifying diagnostic groupings within the ADNI cohort is provided as supporting evidence for the utility of the proposed ANTs longitudinal framework which provides unbiased structural neuroimage processing and competitive to superior power for longitudinal structural change detection."@en ;
    ns0:hasPubTitle "Longitudinal Mapping of Cortical Thickness Measurements: An Alzheimer’s Disease Neuroimaging Initiative-Based Evaluation Study"@en .

ns1:jad-v71-i2-JAD190546 ns0:hasKeywords "Cholinesterase inhibitors"@en,
        "donepezil"@en,
        "galantamine"@en,
        "meta-analysis"@en,
        "mild cognitive impairment"@en,
        "rivastigmine"@en ;
    ns0:hasPubAbstract "Background: The clinical benefit of cholinesterase inhibitors (ChEIs) for mild cognitive impairment (MCI) remains inconclusive.   Objective: We performed a systematic review and meta-analysis of the efficacy/safety of ChEIs on subjects with MCI.   Methods: We included randomized controlled trials (RCTs) of ChEIs in subjects with MCI, using cognitive function scores as a primary outcome measure.   Results: Fourteen RCTs (six using donepezil, four using galantamine, and four using rivastigmine) with 5,278 subjects were included. We found no significant difference in cognitive function scores between the ChEIs and placebo groups [standardized mean difference (SMD) = –0.06, p = 0.38, I2 = 76% ]. However, in the secondary outcomes, ChEIs were associated with a lower incidence of progression to dementia compared with placebo (risk ratio = 0.76, the number needed to treat = 20). For safety outcomes, ChEIs were associated with a lower prevalence of fall than placebo. On the other hand, compared with placebo, ChEIs were associated with a higher incidence of discontinuation due to all causes, discontinuation due to adverse events, at least one adverse event, abnormal dreams, diarrhea, dizziness, headache, insomnia, loose stools, muscle cramps, nausea, vomiting, and weight loss.   Conclusions: Although ChEIs have a slight efficacy in the treatment of MCI, there are many safety issues. Therefore, ChEIs are difficult to recommend for MCI. However, the efficacy and safety of ChEIs on MCI with a biomarker-based diagnosis is unclear. Further RCTs are needed to confirm the efficacy and safety of ChEIs when used for individual neuropathological classifications of MCI."@en ;
    ns0:hasPubTitle "Efficacy and Safety of Cholinesterase Inhibitors for Mild Cognitive Impairment:A Systematic Review and Meta-Analysis"@en .

ns1:jad-v71-i2-JAD190567 ns0:hasKeywords "Alzheimer’s disease"@en,
        "alpha-synuclein"@en,
        "biomarker"@en,
        "blood"@en,
        "dementia"@en,
        "dementia with Lewy bodies"@en,
        "erythrocytes"@en,
        "vascular dementia"@en ;
    ns0:hasPubAbstract "Background: Discovering biomarkers for dementia is a pivotal step toward successful early diagnosis and treatment. Although plasma biomarkers have been explored, no consensus has been reached. Alpha-synuclein (AS), a 14 kDa synaptic protein associated with several neurodegenerative diseases, exists natively within erythrocytes (ERC). This protein is characteristic of Lewy body diseases, in which it aggregates into toxic Lewy bodies. As ERC are implicated in dementia, they are a potential target for future biomarkers.   Objective: The aims of this study were to assess AS levels within ERC and whether AS can be used as a peripheral biomarker to differentiate between dementia and aged matched healthy control subjects.   Methods: A total of 114 samples (60 aging controls, 36 Alzheimer’s disease, 12 vascular dementia (VaD) and 6 dementia with Lewy bodies (DLB) subjects) were analyzed. We used Bradford assay to measure protein concentration, indirect ELISA to detect levels of AS, and immunoblotting to identify AS composition. Data were analyzed with nonparametric tests.   Results: AS oligomers were present in dementia blood samples, whereas in controls, AS was largely monomeric. There was a significant increase in AS levels in DLB whole blood (p = 0.005; Kruskal-Wallis test), with a sensitivity and specificity of 100.0% and 93.9%. Protein concentrations in ERC isolated at pH 5.7 were significantly increased in dementia patients compared to controls (17.58 versus 40.33μg/ml; p≤0.005; Mann-Whitney test). In the VaD group, the protein concentration in the pH5.7 ERC fraction had sensitivity and specificity of 91.7% and 62.1%.   Conclusions: ERC protein concentration and AS levels have a potential for development of a novel diagnostic dementia blood test."@en ;
    ns0:hasPubTitle "Erythrocytes as Biomarkers for Dementia: Analysis of Protein Content and Alpha-Synuclein"@en .

ns1:jad-v71-i3-JAD190319 ns0:hasKeywords "Blood pressure"@en,
        "cerebrovascular circulation"@en,
        "cognitive dysfunction"@en,
        "dementia"@en,
        "hemodynamics"@en,
        "type 2 diabetes mellitus"@en,
        "vascular stiffness"@en ;
    ns0:hasPubAbstract "Background: Type 2 diabetes (T2D) is associated with an increased risk of cognitive impairment and dementia with poorly understood underlying mechanisms.   Objective: We examined the role of blood pressure (BP), aortic stiffness, and hemodynamics in this association.   Methods: Cross-sectional sample of late middle-aged twins discordant for T2D from the Australian Twin Registry. Measurements included neuropsychological battery and brain MRI including arterial spin labelling (ASL) to measure cerebral perfusion. Mobil-o-Graph devices were used to non-invasively obtain 24-hour BP, aortic stiffness, and hemodynamic measures. Using mixed modelling, we studied associations of T2D with cognition, MRI measures, BP, aortic stiffness, and hemodynamics.   Results: There were 23 twin pairs with mean age 63.7 (SD = 6.1) years. T2D (β=–0.45, p < 0.001) and age (β=–0.05, p = 0.022) were independently associated with poorer attention but not with memory or perceptual speed. T2D was associated with reduced nocturnal central systolic BP dipping (β=–3.79, p = 0.027), but not with BP, aortic stiffness, cerebral perfusion, or other hemodynamic measures. There was a statistically significant interaction between T2D and central systolic BP dipping in predicting attention scores (both p < 0.05 for the interaction term) whereby there was a positive association between BP dipping and attention scores in those with T2D, but not in those without T2D.   Conclusion: We found an association between T2D and reduced nocturnal central systolic dipping, but not with any other measures of BP, stiffness or hemodynamic measures. Further study of the role of nocturnal central BP dipping in the association between T2D and cognitive impairment may help identify potential mechanisms."@en ;
    ns0:hasPubTitle "Blood Pressure, Aortic Stiffness, Hemodynamics, and Cognition in Twin Pairs Discordant for Type 2 Diabetes"@en .

ns1:jad-v71-i3-JAD190340 ns0:hasKeywords "Cigarette smoking"@en,
        "dementia"@en,
        "diabetes mellitus"@en,
        "insurance"@en,
        "long-term care"@en ;
    ns0:hasPubAbstract "Background: Both cigarette smoking and diabetes mellitus are well-established risk factors for development of dementia. However, the interaction between smoking and diabetes is yet unknown.   Objective: In this study, we clarify association between smoking, diabetes, and dementia risk in older adults.   Methods: Participants in this study included community residents aged 65 years and older who had participated in a health checkup in 2006, followed for 10 years (n = 9,403) and had long-term care insurance information data. Furthermore, the risk estimates of smoking status and diabetes diagnosis on dementia adjusted for the competing risk of death prior to dementia were analyzed.   Results: During follow-up, 2,647 participants developed dementia. The smoking status–diabetes interaction on development of dementia was statistically significant (p≤0.001). Among those patients exposed to both factors, 17% of risk of development of dementia was attributable to the interaction of these factors. Current smokers with diabetes had significantly greater risks of development of dementia than never smokers without diabetes (reference): multivariable-adjusted risk of dementia in current smokers without diabetes (subdistribution hazard ratio [sHR], 1.25; 95% confidence interval [CI], 1.05–1.48); never smokers with diabetes (1.31, 1.16–1.47); and current smokers with diabetes (1.86, 1.39–2.48). However, no such association was noted for former smokers with and without diabetes.   Conclusions: Current smoking, but not former smoking, was associated with increased risk of development of dementia in older adults with and without diabetes. Moreover, the synergistic effect of current smoking and diabetes on dementia was noted."@en ;
    ns0:hasPubTitle "Presence of a Synergistic Interaction Between Current Cigarette Smoking and Diabetes Mellitus on Development of Dementia in Older Adults"@en .

ns1:jad-v71-i3-JAD190394 ns0:hasKeywords "0000-0002-1561-2187"@en,
        "Alzheimer’s disease"@en,
        "behavioral symptoms"@en,
        "cortisol"@en,
        "gardens"@en,
        "non-pharmacological treatment"@en ;
    ns0:hasPubAbstract "Background: Behavioral and psychological symptoms of dementia (BPSD) affect 60–90% of patients with Alzheimer’s disease (AD).   Objective: To determine if environmental therapy is an effective strategy to reduce BPSD, we tested 163 patients with AD with Neuropsychiatric Inventory (NPI) before and after 6 months of an indoor therapeutic garden (TG) or standard environment.   Methods: A single-blind randomized controlled trial on AD patients with BPSD. Participants were randomized to an indoor TG (N = 82), or standard environment (control, N = 81) for 6 months. Primary outcome: change in the NPI score from baseline (T0) to end of treatment (T1). Secondary outcomes: change in use of quetiapine, cognition, activities of daily living, salivary cortisol, blood pressure from T0 to T1.   Results: NPI score significantly ameliorated (TG versus control: –31.8 points), quetiapine dosage (–150 mg), blood pressure (–2.6 mm Hg), and salivary cortisol (–6.4 to –2.1 Nmol/l) were significantly reduced, the Mini-Mental State Examination significantly improved (1.8 points) in the TG versus control arm at T1 (p < 0.001). No adverse events were reported.   Conclusion: The indoor TG seems safe and may reduce BPSD, medication intake, and cortisol levels in AD."@en ;
    ns0:hasPubTitle "An Indoor Therapeutic Garden for Behavioral Symptoms in Alzheimer’s Disease: A Randomized Controlled Trial"@en .

ns1:jad-v71-i3-JAD190494 ns0:hasKeywords "Alzheimer’s disease"@en,
        "NF-kB pathway"@en,
        "TREM2"@en,
        "Uch-L1"@en,
        "neuroinflammation"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "Neuroinflammation is involved in the pathogenesis of Alzheimer’s disease, and the transcription factor NF-κB is a player in this event. We found here that the ischemic damage alone or in association with Aβ1-42 activates the NF-κB pathway, induces an increase of BACE1 and a parallel inhibition of Uch-L1 and TREM2, both in vitro and in vivo, in Tg 5XFAD and in human brains of sporadic AD. This mechanism creates a synergistic loop that fosters inflammation. We also demonstrated a significant protection exerted by the restoration of Uch-L1 activity. The rescue of the enzyme is able to abolish the decrease of TREM2 and the parameters of neuroinflammation."@en ;
    ns0:hasPubTitle "Stroke and Amyloid-β Downregulate TREM-2 and Uch-L1 Expression that Synergistically Promote the Inflammatory Response"@en .

ns1:jad-v71-i4-JAD190540 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cerebral microbleeds"@en,
        "cerebrovascular disease"@en,
        "cognition"@en,
        "mixed-pathology"@en ;
    ns0:hasPubAbstract "Background: Cerebral microbleeds (CMBs) in the lobar and deep locations have been associated with two distinct pathologies namely cerebral amyloid angiopathy (CAA) and hypertensive arteriopathy. However, the role of mixed-location CMBs in cerebrovascular disease and cognitive impairment remain unexplored.   Objective: The present study aims to investigate the association of strictly lobar, strictly deep and mixed-location CMBs with cognitive impairment and dementia as well as functional decline.   Methods: A prospective case-control study, where 520 patients underwent 3T brain MRI to assess region and lobe-specific CMBs, and other cerebrovascular diseases (CeVD) markers such as cortical infarcts, lacunes, and white matter hyperintensities. Patients were classified as no cognitive Impairment, cognitive impairment no dementia (CIND), and dementia [Alzheimer’s disease (AD) and vascular dementia (VaD)]. Severity of cognitive impairment was assessed using Clinical Dementia Rating scale.   Results: Mixed-location CMBs were associated with dementia [Odds ratio (OR):1.23; 95% confidence interval (CI):1.04, 1.47]. When stratified by the presence of CeVD, mixed-location CMBs were associated with CIND [OR:1.20;95% CI:1.02, 1.42], AD [OR:1.22;95% CI:1.02, 1.46], and VaD [OR:1.33;95% CI:1.08, 1.62]. Furthermore, CMBs in frontal, parietal, and temporal regions were associated with CIND whereas those in parietal, temporal, and occipital regions were associated with AD. Mixed-location CMBs were also associated with increased severity of cognitive impairment [OR:1.02; 95% CI:1.00, 1.05].   Conclusion: Mixed-location CMBs are associated with cognitive impairment and dementia in the presence of CeVD. Furthermore mixed-location CMBs were linked with increased severity of cognitive impairment, suggesting severe parenchymal damage as well as microangiopathy to be common underlying mechanisms in the elderly."@en ;
    ns0:hasPubTitle "Mixed-Location Cerebral Microbleeds: An Imaging Biomarker for Cerebrovascular Pathology in Cognitive Impairment and Dementia in a Memory Clinic Population"@en .

ns1:jad-v71-is1-JAD181140 ns0:hasKeywords "Cognitive disorders"@en,
        "epidemiology"@en,
        "geriatrics"@en,
        "walking speed"@en ;
    ns0:hasPubAbstract "Background: Performance on complex walking tasks may provide a screen for future cognitive decline.   Objective: To identify walking tasks that are most strongly associated with subsequent cognitive decline.   Methods: Community-dwelling older adults with Modified Mini-Mental State (3MS) >85 at baseline (n = 223; mean age = 78.7, 52.5% women, 25.6% black) completed usual-pace walking and three complex walking tasks (fast-pace, narrow-path, visuospatial dual-task). Slope of 3MS scores for up to 9 subsequent years (average = 5.2) were used to calculate a cognitive maintainer (slope ≥0) or decliner (slope <0) outcome variable. Logistic regression models assessed associations between gait speeds and being a cognitive decliner. A sensitivity analysis in a subsample of individuals (n = 66) confirmed results with adjudicated mild cognitive impairment (MCI) or dementia at 8-9 years post-walking assessment.   Results: Cognitive decliners were 52.5% of the sample and on average were slower for all walking tasks compared to maintainers. In models adjusted for demographic and health variables, faster fast-pace (OR = 0.87 per 0.1 m/s, 95% CI: 0.78, 0.97) and dual-task (OR = 0.84 per 0.1 m/s, 95% CI: 0.73, 0.96) gait speeds were associated with lower likelihood of being a cognitive decliner. Usual-pace gait speed was not associated (OR = 0.96 per 0.1 m/s, 95% CI: 0.85, 1.08). Results were nearly identical in analyses with adjudicated MCI or dementia as the outcome.   Conclusion: Fast-pace and dual-task walking may provide simple and effective tools for assessing risk for cognitive decline in older individuals with high cognitive function. Such screening tools are important for strategies to prevent or delay onset of clinically meaningful change."@en ;
    ns0:hasPubTitle "Complex Walking Tasks and Risk for Cognitive Decline in High Functioning Older Adults"@en .

ns1:jad-v71-is1-JAD181170 ns0:hasKeywords "Aged"@en,
        "assistive devices"@en,
        "cane"@en,
        "dementia"@en,
        "gait"@en ;
    ns0:hasPubAbstract "Background: Cognitive deficits and gait problems are common and progressive in Alzheimer’s disease (AD). Prescription of a 4-wheeled walker is a common intervention to improve stability and independence, yet can be associated with an increased falls risk.   Objectives: 1) To examine changes in spatial-temporal gait parameters while using a 4-wheeled walker under different walking conditions, and 2) to determine the cognitive and gait task costs of walking with the aid in adults with AD and healthy older adults.   Methods: Twenty participants with AD (age 79.1±7.1 years) and 22 controls (age 68.5±10.7 years) walked using a 4-wheeled walker in a straight (6 m) and Figure of 8 path under three task conditions: single-task (no aid), dual-task (walking with aid), and multi-task (walking with aid while counting backwards by ones).   Results: Gait velocity was statistically slower in adults with AD than the controls across all conditions (all p values <0.025). Stride time variability was significantly different between groups for straight path single task (p = 0.045), straight path multi-task (p = 0.031), and Figure of 8 multi-task (0.036). Gait and cognitive task costs increased while multi-tasking, with performance decrement greater for people with AD. None of the people with AD self-prioritized gait over the cognitive task while walking in a straight path, yet 75% were able to shift prioritization to gait in the complex walking path.   Conclusion: Learning to use a 4-wheeled walker is cognitively demanding and any additional tasks increases the demands, further adversely affecting gait. The increased cognitive demands result in a decrease in gait velocity that is greatest in adults with AD. Future research needs to investigate the effects of mobility aid training on gait performance."@en ;
    ns0:hasPubTitle "Effect of Learning to Use a Mobility Aid on Gait and Cognitive Demands in People with Mild to Moderate Alzheimer’s Disease: Part II – 4-Wheeled Walker"@en .

ns1:jad-v71-is1-JAD181196 ns0:hasKeywords "Aging"@en,
        "cognition"@en,
        "dual-task gait"@en,
        "gait"@en ;
    ns0:hasPubAbstract "Background: Poor dual-task gait (walking while performing a cognitively demanding task) has been linked to progression to dementia in older adults with mild cognitive impairment (MCI). However, many of these findings come from research environments; gait performance across the cognitive spectrum has not previously been studied in a clinical setting.   Objective: To examine whether patients from a memory clinic show differences in usual and dual-task gait speed and dual-task cost (DTC) based on cognitive diagnosis.   Methods: Patients in the Aging Brain and Memory Clinic (London, ON) performed a usual gait walk and three dual-task gait walks: counting backwards by ones, naming animals, and counting backwards by seven (serial sevens) out loud. Patients were timed with a stopwatch over a six-meter path marked on the floor. One-way ANOVA was performed to evaluate associations between gait speed and DTC (%) across groups.   Results: One hundred ninety-four patients with subjective cognitive impairment (SCI; n = 46), MCI (n = 77), or dementia (n = 71) were assessed. Performance in usual (p < 0.001) and dual-task gait speed (counting gait p < 0.001; naming animals p < 0.001; serial sevens p = 0.004) decreased across the spectrum of cognitive impairment. Patients with dementia had significantly higher DTC in both counting gait (p = 0.02) and naming animals (p = 0.04) conditions compared with patients with SCI and MCI, who had statistically similar DTC in all conditions.   Conclusion: Dual-task gait performance significantly declines across the cognitive spectrum in a clinical setting. Dual-task gait testing may be used in conjunction with traditional assessments for diagnosing cognitive impairments."@en ;
    ns0:hasPubTitle "Are Cognitive Subtypes Associated with Dual-Task Gait Performance in a Clinical Setting?"@en .

ns1:jad-v72-i1-JAD190538 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Apolipoproteins E"@en,
        "cognitive aging"@en,
        "race relations"@en ;
    ns0:hasPubAbstract "Background: The association of the APOE ɛ4 allele with incident Alzheimer’s dementia is higher among European Americans (EAs) than African Americans (AAs), but similar for the rate of cognitive decline.   Objective: To examine the racial differences in the association of the APOE ɛ4 allele with incident Alzheimer’s dementia and cognitive decline.   Methods: Using a population-based sample of 5,117 older adults (66% AAs and 63% females), we identified cognitive trajectory groups from a latent class mixed model and examined the association of the APOE ɛ4 allele with these groups.   Results: The frequency of the APOE ɛ4 allele was higher among AAs than EAs (37% versus 26%). Four cognitive trajectories were identified: slow, mild, moderate, and rapid. Overall, AAs had a lower baseline global cognition than EAs, and a higher proportion had rapid (7% versus 5%) and moderate (20% versus 15%) decline, but similar mild (44% versus 46%), and lesser slow (29% versus 34%) decline compared to EAs. Additionally, 25% of AAs (13% of EAs) with mild and 5% (<1% of EAs) with slow decline were diagnosed with incident Alzheimer’s dementia. The APOE ɛ4 allele was associated with higher odds of rapid and moderate decline compared to slow decline among AAs and EAs, but not with mild decline.   Conclusions: AAs had lower cognitive levels and were more likely to meet the cognitive threshold for Alzheimer’s dementia among mild and slow decliners, explaining the attenuated association of the ɛ4 allele with incident Alzheimer’s dementia among AAs."@en ;
    ns0:hasPubTitle "Race, APOE ɛ4, and Long-Term Cognitive Trajectories in a Biracial Population Sample"@en .

ns1:jad-v72-i1-JAD190771 ns0:hasKeywords "Amyloid-β"@en,
        "SNARE complex"@en,
        "intracellular signaling"@en,
        "neurotransmitter release"@en,
        "presynaptic function"@en,
        "synaptic vesicle cycle"@en ;
    ns0:hasPubAbstract "It is now more than two decades since amyloid-β (Aβ), the proteolytic product of the amyloid-β protein precursor (AβPP), was first demonstrated to be a normal and soluble product of neuronal metabolism. To date, despite a growing body of evidence suggests its regulatory role on synaptic function, the exact cellular and molecular pathways involved in Aβ-driven synaptic effects remain elusive. This review provides an overview of the mounting evidence showing Aβ-mediated effects on presynaptic functions and neurotransmitter release from axon terminals, focusing on its interaction with synaptic vesicle cycle. Indeed, Aβ peptides have been found to interact with key presynaptic scaffold proteins and kinases affecting the consequential steps of the synaptic vesicle dynamics (e.g., synaptic vesicles exocytosis, endocytosis, and trafficking). Defects in the fine-tuning of synaptic vesicle cycle by Aβ and deregulation of key molecules and kinases, which orchestrate synaptic vesicle availability, may alter synaptic homeostasis, possibly contributing to synaptic loss and cognitive decline. Elucidating the presynaptic mechanisms by which Aβ regulate synaptic transmission is fundamental for a deeper comprehension of the biology of presynaptic terminals as well as of Aβ-driven early synaptic defects occurring in prodromal stage of AD. Moreover, a better understating of Aβ involvement in cellular signal pathways may allow to set up more effective therapeutic interventions by detecting relevant molecular mechanisms, whose imbalance might ultimately lead to synaptic impairment in AD."@en ;
    ns0:hasPubTitle "Amyloid-β and Synaptic Vesicle Dynamics: A Cacophonic Orchestra"@en .

ns1:jad-v72-i1-JAD190775 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "cerebrospinal fluid biomarker"@en,
        "idiopathic normal pressure hydrocephalus"@en,
        "leucine rich α-2-glycoprotein"@en,
        "tap test"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Background: Extensive research into cerebrospinal fluid (CSF) biomarkers was performed in patients with idiopathic normal pressure hydrocephalus (iNPH). Most prior research into CSF biomarkers has been one-point observation.   Objective: To investigate dynamic changes in CSF biomarkers during routine tap test in iNPH patients.   Methods: We analyzed CSF concentrations of tau, amyloid-β (Aβ) 42 and 40, and leucine rich α-2-glycoprotein (LRG) in 88 consecutive potential iNPH patients who received a tap test. We collected two-point lumbar CSF separately at the first 1 ml (First Drip (FD)) and at the last 1 ml (Last Drip (LD)) during the tap test and 9 patients who went on to receive ventriculo-peritoneal shunt surgery each provided 1 ml of ventricular CSF (VCSF).   Results: Tau concentrations were significantly elevated in LD and VCSF compared to FD (LD/FD = 1.22, p = 0.003, VCSF/FD = 2.76, p = 0.02). Conversely, Aβ42 (LD/FD = 0.80, p < 0.001, VCSF/FD = 0.38, p = 0.03) and LRG (LD/FD = 0.74, p < 0.001, VCSF/FD = 0.09, p = 0.002) concentrations were significantly reduced in LD and VCSF compared to FD. Gait responses to the tap test and changes in cognitive function in response to shunt were closely associated with LD concentrations of tau (p = 0.02) and LRG (p = 0.04), respectively.   Conclusions: Dynamic changes were different among the measured CSF biomarkers, suggesting that LD of CSF as sampled during the tap test reflects an aspect of VCSF contributing to the pathophysiology of iNPH and could be used to predict shunt effectiveness."@en ;
    ns0:hasPubTitle "Two-Point Dynamic Observation of Alzheimer’s Disease Cerebrospinal Fluid Biomarkers in Idiopathic Normal Pressure Hydrocephalus"@en .

ns1:jad-v72-i2-JAD190415 ns0:hasKeywords "APOE"@en,
        "African American"@en,
        "Alzheimer’s disease"@en,
        "cognitive reserve"@en,
        "educational attainment"@en,
        "episodic memory"@en,
        "genetic risk"@en,
        "neuropsychological evaluation"@en ;
    ns0:hasPubAbstract "Background: The APOE ɛ4 allele is a well-known risk factor for Alzheimer’s disease (AD). Previous research argues that higher education helps to preserve cognition in older adults with AD pathology because of its key role in cognitive reserve and resilience.   Objective: To test if higher educational level buffers the effect of APOE ɛ4 on cognition among older non-Hispanic Blacks.   Methods: Participants were 849 non-demented older non-Hispanic Blacks (38.3% APOE ɛ4+), who underwent a comprehensive neuropsychological evaluation. Multiple linear regression models tested the relationship between APOE ɛ4 status and twelve cognitive measures with education (up to high school and beyond high school) as a moderator.   Results: Education buffered the effects of the APOE ɛ4 allele, such that there was no impact of APOE ɛ4 status on word-list memory retention and working memory among participants with more than a high school degree. This pattern was not observed for ten other cognitive measures of verbal and visual episodic memory, semantic memory, executive function, and processing speed—although a similar trend was observed for switching ability in executive functioning. The buffering effect of education was stronger among women than men.   Conclusion: Our findings suggest that genetic effects on late-life cognition may be modified by environmental factors such as educational attainment. These results are consistent with the framework of cognitive reserve such that engaging in cognitively enriching activities and acquiring skills and knowledge with more years of education may increase the capacity to maintain cognitive function despite high genetic risk for impairment."@en ;
    ns0:hasPubTitle "Education Moderates the Relation Between APOE ɛ4 and Memory in Nondemented Non-Hispanic Black Older Adults"@en .

ns1:jad-v72-i2-JAD190501 ns0:hasKeywords "Alzheimer’s disease"@en,
        "clinical characteristic"@en,
        "neuropsychiatric symptoms"@en,
        "prevention trials"@en,
        "sleep disorders"@en,
        "subjective cognitive decline"@en,
        "subjective cognitive decline questionnaire"@en ;
    ns0:hasPubAbstract "Background: Subjective cognitive decline (SCD) refers to the self-perception of cognitive decline among cognitively normal elderly individuals. SCD related worry confers a higher risk of developing cognitive decline. However, the clinical characteristics of SCD patients with worry are not clear.   Objective: To explore the clinical characteristics of SCD patients with worry.   Methods: A cross-sectional study was carried out, with 270 consecutive participants of the Sino Longitudinal Study on Cognitive Decline (SILCODE) study. Participants were classified as normal controls (n = 36), SCD patients without worry (n = 91), or SCD patients with worry (n = 143) and were comprehensively compared on 1) their self-perception of cognitive decline, 2) multiple cognitive domains, 3) neuropsychiatric symptoms, and 4) sleep status.   Results: SCD patients with worry had significantly more self-perception of cognitive decline (p < 0.001); increased depression (p < 0.001) and anxiety (p < 0.001); decreased sleep quality (p < 0.001), sleep latency (p < 0.05), sleep time (p < 0.01), and sleep efficiency (p < 0.05); more sleep disorders (p < 0.05) and daytime dysfunction (p < 0.05); and a higher global score on the Pittsburgh Sleep Quality Index (p < 0.001) than normal controls. Although there was a significant increase only in self-perception of cognitive decline (p < 0.001), anxiety (p < 0.001), and Pittsburgh Sleep Quality Index scores (p < 0.05), the severity of the increase in those without worry was between that in SCD patients with worry and normal controls.   Conclusion: Our findings show that participants who had SCD with worry showed distinct clinical characteristics compared with normal controls and SCD patients without worry, which could be useful for understanding the higher risk in SCD patients with worry of subsequently developing Alzheimer’s disease."@en ;
    ns0:hasPubTitle "Clinical Characteristics in Subjective Cognitive Decline with and without Worry: Baseline Investigation of the SILCODE Study"@en .

ns1:jad-v72-i2-JAD190656 ns0:hasKeywords "Alzheimer’s disease"@en,
        "C57BL/6"@en,
        "extracellular vesicles"@en,
        "induced pluripotent stem cells"@en,
        "tau"@en,
        "tauopathy"@en ;
    ns0:hasPubAbstract "Extracellular vesicles (EVs) are a heterogeneous group of secreted particles consisting of microvesicles, which are released by budding of the cellular membrane, and exosomes, which are secreted through exocytosis from multivesicular bodies. EV cargo consists of a wide range of proteins and nucleic acids that can be transferred between cells. Importantly, EVs may be pathogenically involved in neurodegenerative diseases such as Alzheimer’s disease (AD). While EVs derived from AD neurons have been found to be neurotoxic in vitro, little is known about the pathological consequences of AD EVs in vivo. Furthermore, although all known familial AD (fAD) mutations involve either amyloid-β protein precursor (AβPP) or the machinery that processes AβPP, hyperphosphorylation of the microtubule associated protein tau appears to play a critical role in fAD-associated neurodegeneration, and previous reports suggest EVs may propagate tau pathology in the AD brain. Therefore, we hypothesized that fAD EVs may have a mechanistic involvement in the development of fAD-associated tau pathology. To test this, we isolated EVs from iPSC-derived neuronal cultures generated from an fAD patient harboring a A246E mutation to presenilin-1 and stereotactically injected these EVs into the hippocampi of wild-type C57BL/6 mice. Five weeks after injection, mice were euthanized and pathology evaluated. Mice injected with fAD EVs displayed increased tau phosphorylation at multiple sites relative to PBS and non-disease control EV injected groups. Moreover, fAD EV injected hippocampi contained significantly more tau inclusions in the CA1 hippocampal neuronal field than controls. In total, these findings identify EVs as a potential mediator of fAD-associated tau dysregulation and warrant future studies to investigate the therapeutic potential of EV-targeted treatments for fAD."@en ;
    ns0:hasPubTitle "Extracellular Vesicles Isolated from Familial Alzheimer’s Disease Neuronal Cultures Induce Aberrant Tau Phosphorylation in the Wild-Type Mouse Brain"@en .

ns1:jad-v72-i2-JAD190721 ns0:hasKeywords "Alzheimer’s disease"@en,
        "angiotensin-(1-7)"@en,
        "angiotensin-II"@en,
        "angiotensin-II converting enyme-1 (ACE1)"@en,
        "angiotensin-II converting enyme-2 (ACE2)"@en,
        "cerebrospinal fluid"@en,
        "renin-angiotensin system"@en ;
    ns0:hasPubAbstract "Observations in autopsied brain tissue indicate that overactivation of the classical renin-angiotensin system (cRAS) and underactivity within regulatory RAS pathways (rRAS) are associated with pathology in Alzheimer’s disease (AD). The primary aim of this study was to investigate whether cerebrospinal fluid (CSF) markers of RAS are altered in AD in relation to established CSF markers of disease pathology (lower Aβ42 and elevated tau) and CSF markers of capillary dysfunction. We studied 40 controls and 40 AD cases grouped according to a biomarker profile (i.e., AD cases t-tau>400 pg/mL, pTau >60 pg/mL, and Aβ42 <550 pg/mL). Angiotensin-II converting enyme-1 (ACE1) and ACE2 enzyme activity was measured using fluorogenic peptide substrates; sPDGFRβ and albumin level by sandwich ELISA; and angiotensin-I (Ang-I), Ang-II, and Ang-(1-7) by direct ELISA. CSF Aβ42, total, and phosphorylated tau levels were previously measured by INNOTEST sandwich ELISA. CSF ACE1 activity was significantly elevated in AD (p = 0.008) and positively correlated with ACE2 in AD (r = 0.420, p = 0.007). CSF ACE1 weakly correlated with t-tau (r = 0.294, p = 0.066) and p-tau (r = 0.329, p = 0.038) but not with Aβ42 in the controls but not in AD. ACE1 correlated positively with sPDGFRβ (r = 0.426, p = 0.007), a marker of pericyte injury, and ACE2 correlated positively with albumin (r = 0.422, p = 0.008), a marker of blood-brain barrier integrity. CSF Ang-I, Ang-II, and Ang-(1-7) levels were unchanged in AD. This cross-sectional CSF study indicates RAS dysfunction in relation to capillary damage in AD."@en ;
    ns0:hasPubTitle "Cerebrospinal Fluid Changes in the Renin-Angiotensin System in Alzheimer’s Disease"@en .

ns1:jad-v72-i3-JAD190487 ns0:hasKeywords "Behavioral and psychological symptoms"@en,
        "Tai Chi"@en,
        "cognitive function"@en,
        "dementia"@en,
        "depressive mood"@en ;
    ns0:hasPubAbstract "Background: Tai Chi exercise is a non-pharmacological therapy that has received increased attention in recent years. A Tai Chi program has been specifically modified for older people with cognitive impairments by the research team.   Objective: We aim to assess the effects of this Tai Chi program on mild dementia.   Methods: Eighty older people with mild dementia were recruited and randomly assigned to a Tai Chi group or a control group. The Tai Chi group practiced the Tai Chi program three times a week for 10 months, while the control group continued receiving routine treatments. All participants were assessed for cognitive function, behavior/mood, and activities of daily living at baseline, 5 months, and 10 months.   Results: The Tai Chi group performed better than the control group. Repeated measures ANOVA revealed a significant group×time interaction in the Montreal Cognitive Assessment (MoCA). Further analysis of sub-items of the MoCA showed a significant time effect in naming and abstraction. It was statistically significant in both main effect of time and group×time interaction in the Neuropsychiatric Inventory (NPI) and Geriatric Depression Scale (GDS). Paired sample t test showed the Tai Chi group scored lower at 5 and 10 months in the NPI and at 10 months in the GDS compared with baseline. The Tai Chi group scored lower than the control group at 10 months in the NPI and GDS.   Conclusion: The results suggest this Tai Chi program may help improve cognitive function and mental well-being for older adults with mild dementia."@en ;
    ns0:hasPubTitle "Effects of a Modified Tai Chi Program on Older People with Mild Dementia: A Randomized Controlled Trial"@en .

ns1:jad-v72-i3-JAD190562 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "amyloid-β protein precursor"@en,
        "autophagy"@en,
        "curcumin"@en,
        "curcumin analog"@en,
        "oligomerization"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is a devastating neurodegenerative disease with no cure currently available. A pathological hallmark of AD is accumulation and deposition of amyloid-β protein (Aβ), a ∼4 kDa peptide generated through serial cleavage of the amyloid-β protein precursor (AβPP) by β- and γ-secretases. Curcumin is a natural compound primarily found in the widely used culinary spice, turmeric, which displays therapeutic potential for AD. Recently, we reported the development of curcumin analogs and identified a lead compound, curcumin-like compound-R17 (CLC-R17), that significantly attenuates Aβ deposition in an AD transgenic mouse model. Here, we elucidated the mechanisms of this analog on Aβ levels and AβPP processing using cell models of AD. Using biochemical methods and our recently developed nanoplasmonic fiber tip probe technology, we showed that the lead compound potently lowers Aβ levels in conditioned media and reduces oligomeric amyloid levels in the cells. Furthermore, like curcumin, the lead compound attenuates the maturation of AβPP in the secretory pathway. Interestingly, it upregulated α-secretase processing of AβPP and inhibited β-secretase processing of AβPP by decreasing BACE1 protein levels. Collectively, our data reveal mechanisms of a promising curcumin analog in reducing Aβ levels, which strongly support its development as a potential therapeutic for AD."@en ;
    ns0:hasPubTitle "A Curcumin Analog Reduces Levels of the Alzheimer’s Disease-Associated Amyloid-β Protein by Modulating AβPP Processing and Autophagy"@en .

ns1:jad-v72-i3-JAD190590 ns0:hasKeywords "Cohort studies"@en,
        "dementia"@en,
        "psychological well-being"@en,
        "risk factors"@en,
        "women"@en ;
    ns0:hasPubAbstract "Background: There is growing interest in public health strategies to modify dementia risk in midlife to reduce the burden of cognitive impairment in subsequent decades. Risk reduction messages should include key recommendations for women in response to the high prevalence of dementia observed in this population. Midlife is a critical period for dementia-related brain changes and psychosocial crises. Psychological well-being can improve resilience to crises, yet it is not well understood with respect to dementia risk reduction.   Objective: This study aimed to examine the association between midlife psychological well-being and cognitive function in later life in women.   Methods: The study included 703 women from the British 1946 birth cohort in the Medical Research Council’s National Survey of Health and Development. Psychological well-being at 52 years was assessed using the Ryff Scales of Psychological Well-being over six dimensions: autonomy, environmental mastery, personal growth, positive relations with others, purpose in life, and self-acceptance. Cognitive function at 69 years was measured using the Addenbrooke’s Cognitive Examination, Third Edition.   Results: After controlling for cognitive ability at eight years, educational attainment by 26 years, occupational attainment and marital status by 53 years, depression, smoking, and physical exercise at 60–64 years, there was a significant association between greater personal growth and lower self-acceptance at 52 years, and better cognition at 69 years. However, there was no association between cognition and the other four Ryff scales.   Conclusion: Most aspects of midlife psychological well-being, except for personal growth and self-acceptance, were not prospectively associated with cognition."@en ;
    ns0:hasPubTitle "Midlife Psychological Well-Being and its Impact on Cognitive Functioning Later in Life: An Observational Study Using a Female British Birth Cohort"@en .

ns1:jad-v72-i3-JAD190688 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Czech Republic"@en,
        "cognitive impairment"@en,
        "epidemiology"@en,
        "prevalence"@en,
        "trends"@en ;
    ns0:hasPubAbstract "Background: Studies from North America and Western Europe suggest stable or declining trends in impaired cognition across birth cohorts.   Objective: We aimed to examine changes in the age-specific prevalence of cognitive impairment in the Czech Republic.   Methods: The study used two samples from the population-based Czech Survey on Health, Ageing and Retirement in Europe. Age-specific prevalence of cognitive impairment (defined based on scores in verbal fluency, immediate recall, delayed recall, and temporal orientation) was compared between participants in wave 2 (2006/2007; n = 1,107) and wave 6 (2015; n = 3,104). Logistic regression was used to estimate the association between the wave and cognitive impairment, step-wise adjusting for sociodemographic and clinical characteristics. Multiple sensitivity analyses, focusing on alternative operationalizations of relative cognitive impairment, impact of missing cognitive data, and survival bias, were carried out.   Results: The most conservative estimate suggested that the age-specific prevalence of cognitive impairment declined by one fifth, from 11% in 2006/2007 to 9% in 2015. Decline was observed in all sensitivity analyses. The change was associated with differences in physical inactivity, management of high blood cholesterol, and increases in length education.   Conclusion: Older adults in the Czech Republic, a country situated in the Central and Eastern European region, have achieved positive developments in cognitive aging. Longer education, better management of cardiovascular factors, and reduced physical inactivity seem to be of key importance."@en ;
    ns0:hasPubTitle "Changes in Cognitive Impairment in the Czech Republic"@en .

ns1:jad-v72-i3-JAD190782 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Amyloid-β"@en,
        "contusion"@en,
        "epilepsy"@en,
        "neurodegenerative disease"@en,
        "phosphorylated tau"@en,
        "traumatic brain injury"@en ;
    ns0:hasPubAbstract "Traumatic brain injury (TBI) is widely assumed to be causal in neurodegenerative disease, based on epidemiological surveys demonstrating an increased risk of Alzheimer disease (AD) following TBI, and on recent theories surrounding repetitive head movement. We tested this assumption by evaluating 30 consecutive forensic examinations in which neuropathology consultation was sought, and in which a history of remote TBI was uncovered during the course of the investigation. In this series, there was a high frequency of psychiatric co-morbidities (100%), remote contusion (90%), and seizures (63%). Extent of proteinopathy showed no differences with age-matched controls. A subset of the cases showed focal geographic tauopathy that correlated with older age at autopsy, but had no correlation with clinical signs, and was minimal in comparison with the encephalomalacia secondary to trauma. The results suggest that cerebral contusion and post-traumatic epilepsy may be over-represented in civilian TBI, while structural brain damage from trauma is the predominant cause of morbidity following TBI. We found no evidence that TBI initiates a progressive proteinopathy."@en ;
    ns0:hasPubTitle "Neuropathology in Consecutive Forensic Consultation Cases with a History of Remote Traumatic Brain Injury"@en .

ns1:jad-v72-i3-JAD190889 ns0:hasKeywords "Intra-individual variability"@en,
        "methodology"@en,
        "reaction time"@en,
        "subcortical ischemic vascular cognitive impairment"@en ;
    ns0:hasPubAbstract "In this study, reaction time (RT), intraindividual variability (IIV), and errors, and the effects of practice and processing load upon such function, were compared in patients with subcortical ischemic vascular cognitive impairment (SIVCI) [n = 27] and cognitively healthy older adults (CH) [n = 26]. Compared to CH aging, SIVCI was characterized by a profile of significantly slowed RT, raised IIV, and higher error levels, particularly in the presence of distracting stimuli, indicating that the integrity and/or accessibility of the additional functions required to support high processing load, serial search strategies, are reduced in SIVCI. Furthermore, although practice speeded RT in SIVCI, unlike CH, practice did not lead to an improvement in IIV. This indicates that improvement in RT in SIVCI can in fact mask an abnormally high degree of IIV. Because IIV appears more related to disease, function, and health than RT, its status and potential for change may represent a particularly meaningful, and relevant, disease characteristic of SIVCI. Finally, a high level of within-group variation in the above measures was another characteristic of SIVCI, with such processing heterogeneity in patients with ostensibly the same diagnosis, possibly related to individual variation in pathological load. Detailed measurement of RT, IIV, errors, and practice effects therefore reveal a degree of functional impairment in brain processing not apparent by measuring RT in isolation."@en ;
    ns0:hasPubTitle "Subcortical Ischemic Vascular Cognitive Impairment: Insights from Reaction Time Measures"@en .

ns1:jae-v61-i2-JAE180100 ns0:hasKeywords "Field effect transistor"@en,
        "JFET"@en,
        "MOSFET"@en,
        "invalidation"@en ;
    ns0:hasPubAbstract "Based on the invalidation and damage of the field effect transistors under lightning radiation, we establish the breakdown experiment with open-circuit voltage wave and the protection experiment with TVS as the protection device. The junction field effect transistor and the metal oxide semiconductor field effect transistor are used as material. We draw some conclusions. In the breakdown experiment, the breakdown voltage of the MOSFETs is higher than that of the JFETs as a whole. The MOSFET can be adopted in the amplifier circuit which is expected to get higher input resistance and breakdown voltage. The drain-source resistance can recover to the original resistance value after being placed a period of time, but the gate-source resistance is irreversible. The invalidation of the device under test is due to the breakdown of gate-source. The TVS can protect the FTEs well. The change of pin resistance of the MOSFET is inconspicuous. MOSFETs are more stable for debugging and development of the amplifier circuit. The results provide some significance for the development and improvement of the lightning electric fields change measuring instruments in the future."@en ;
    ns0:hasPubTitle "Damaged mechanism analysis of FET under lightning"@en .

ns1:jae-v61-iS1-JAE191149 ns0:hasKeywords "Permendur"@en,
        "laminated specimen"@en,
        "mechanical stress"@en ;
    ns0:hasPubAbstract "This paper investigates the influence of laminating process of permendur for improvement of power density motors. A permendur has a high stress sensitivity, however the influence of manufacturing process on the magnetic properties of a permendur has not been sufficently discussed. Therefore, we discussed the influence of manufacturing process by measuring the laminated and single sheet specimen and carrying out 3D analysis of a surface permanent magnet synchronous motor (SPMSM) using the measured magnetic properties of the laminated and the single sheet specimens. As a consequence, deterioration of magnetization property by laminating process does not affect significantly motor property in motors having a wide gap."@en ;
    ns0:hasPubTitle "Deterioration of magnetic property of permendur due to laminating process for improvement of power density in permanent magnet motors"@en .

ns1:jbr-v9-i2-JBR180345 ns0:hasKeywords "Scion"@en,
        "nutritional quality"@en,
        "plant yield"@en,
        "sensorial quality"@en,
        "sweetheart"@en ;
    ns0:hasPubAbstract "BACKGROUND: New sweet cherries rootstocks and cultivars can be valorized on the market if they express improved plant yield efficiency and fruit quality, and also including highest content of antioxidant compounds (mainly anthocyanins but also significant amounts of phenolic acids and flavonols).   OBJECTIVE: The goal of this study was to compare the effect of 10 new rootstock genotypes, now available for cherry, on plant growth and fruit quality of the cultivar “Sweetheart”, a very late auto-fertile sweet cherry cultivar.   METHODS: Plants vegetative and productive parameters, as well as fruit sensorial quality, were measured during a 5-year cycle (2011–2015), while fruit nutritional quality was investigated for the last 3 years (2013–2015).   RESULTS: For the agronomical traits, the vigorous rootstock Adara/Major and intermediate Gisela 6 stands out for the plant yield. From the qualitative point of view, the intermediate MaxMa 14 and Gisela 6, and the dwarf Gisela 5, differed for reduced fruit size but with optimal sugar/acid ratio. The higher fruit nutritional value were detected for “Sweetheart” trees grafted on Adara/Major (vigorous), the best MaxMa 14 (weaker) and Gisela 5 (dwarfing) rootstocks.   CONCLUSIONS: There is not a univocal combination between the scion and rootstock equally valid for all the considered parameters. The rootstock capable of ensuring good yields, sensorial and nutritional quality is Adara/Major. From the productive and qualitative point of view, Gisela 6 is well adapted to these conditions, while MaxMa 14 rootstock stands out for nutritional quality, although induces a high reduction of vigor, poor vegetative renewal and low average fruit weight."@en ;
    ns0:hasPubTitle "The rootstock effects on vigor, production and fruit quality in sweet cherry (Prunus avium L.)"@en .

ns1:jcs-v27-i4-JCS191315 ns0:hasKeywords "ABAC"@en,
        "RBAC"@en,
        "TRBAC"@en,
        "deploying"@en,
        "enabling"@en,
        "temporal"@en,
        "time attributes"@en ;
    ns0:hasPubAbstract "The flexibility, portability and identity-less access control features of Attribute Based Access Control (ABAC) make it an attractive choice to be employed in many application domains. However, commercially viable methods for implementation of ABAC do not exist while a vast majority of organizations use Role Based Access Control (RBAC) or their temporal extensions, such as Temporal Role Based Access Control (TRBAC). In this paper, we present a solution for organizations having a RBAC/TRBAC that can deploy an ABAC policy. Essentially, we propose a method for the translation of an ABAC policy (including time constraints) into a form that can be adopted by an RBAC/TRBAC system. We experimentally demonstrate that time taken to evaluate an access request in RBAC and TRBAC systems is significantly less than that of the corresponding ABAC system. Since the cost of security management is more expensive under RBAC when compared to ABAC, we present an analysis of the different management costs and present mitigation approaches by considering various administrative operations."@en ;
    ns0:hasPubTitle "Deploying ABAC policies using RBAC systems"@en .

ns1:jhd-v8-i4-JHD190355 ns0:hasKeywords "Huntington’s disease"@en,
        "Multidisciplinary"@en,
        "health services"@en,
        "outcomes"@en ;
    ns0:hasPubAbstract "Background: Clinical care for Huntington’s disease (HD) is often provided in experienced centers that provide multidisciplinary care. However, the value of these centers and their uptake by HD families remain unknown.   Objective: To describe the services provided by a new HD center, including estimates of capture of the population served.   Methods: Retrospective review of a HD Center launched in 2015, including quantitative and qualitative data on clinic visits, demographic and clinical data.   Results: We observed a rapid and ongoing growth on the annual number of clinic encounters, with high demand for in-clinic multidisciplinary care. Using census data and estimates of HD prevalence, we determined that we served about 20% of local patients with HD. Most HD patients received pharmacological treatment for psychiatric symptoms, and over half were treated for chorea. About 25% of new HD diagnoses were on patients without family history of HD. Finally, the demand for predictive testing in at risk individuals significantly increased following the press release reporting the successful completion of the Ionis-HTTRx (RG 6042) trial.   Conclusions: This report indicates a high demand for multidisciplinary care by HD families, supporting its value, providing a snapshot of the organization and function of a single center. Furthermore, it demonstrates how dissemination of news related to research advances influence clinical behavior. Reporting similar information from other HD centers to would provide us with a more global view of the status of HD care across multiple geographical areas."@en ;
    ns0:hasPubTitle "Addressing the Value of Multidisciplinary Clinical Care in Huntington’s Disease: A Snapshot of a New Huntington’s Disease Center"@en .

ns1:jpd-v9-i4-JPD181568 ns0:hasKeywords "Multimodal MRI"@en,
        "R2*"@en,
        "diffusion tensor imaging"@en,
        "multiple system atrophy"@en,
        "principal component analysis"@en,
        "progressive supranuclear palsy"@en ;
    ns0:hasPubAbstract "Background: The diagnostic potential of multimodal MRI approaches to discriminate among progressive supranuclear palsy (PSP), Parkinson variant of multiple system atrophy (MSA-P) and Parkinson’s disease (PD) has not been well investigated.   Objective: To identify disease-specific neurodegenerative patterns and evaluate the diagnostic accuracy of dedicated MRI, iron concentration (R2*), microstructural integrity (mean diffusivity; MD and fractional anisotropy; FA) as well as volumes were analyzed in patients with PSP, MSA-P and PD.   Methods: 3T MRI of 18 PSP and 16 MSA-P patients were compared with 16 PD patients matched for age and disease duration as well as 21 healthy controls. Statistical parametric mapping (SPM) was applied to objectively identify focal MRI changes throughout the whole-brain. Following dimensionality reduction of significant and multiple comparison-corrected SPM clusters through principal component analysis (PCA), stepwise receiver-operating characteristic curve analysis (ROC) was applied to determine the diagnostic potential of multimodal MRI parameters.   Results: PCA revealed two components involving multiple regions identified from SPM analysis. The first component was primarily composed of the mean MD value of the thalamus and the mean MD and FA values of the dentatorubrothalamic tract and the corpus callosum. The second component mainly consisted of mean MD and FA values of the middle cerebellar peduncle. ROC analysis showed 92% of PSP patients were differentiated correctly from MSA-P and PD and 80% of MSA-P patients could be distinguished from PD.   Conclusion: Multimodal MRI improved the detection of disease-specific neurodegenerative patterns in PSP and MSA-P and highlights its potential to improve the diagnostic accuracy of atypical parkinsonian disorders."@en ;
    ns0:hasPubTitle "Diagnostic Potential of Multimodal MRI Markers in Atypical Parkinsonian Disorders"@en .

ns1:jvr-v51-i2-JVR191033 ns0:hasKeywords "Randomized clinical trials"@en,
        "Supplemental Security Income"@en,
        "engagement"@en,
        "retention"@en,
        "transition"@en,
        "youth"@en ;
    ns0:hasPubAbstract "BACKGROUND: Unbiased estimates of treatment effectiveness in longitudinal randomized clinical trials require meeting many design criteria, especially ensuring full exposure to intervention services. However, engaging participants into interventions, and retaining them at high rates, can be thwarted by everyday challenges faced by disadvantaged populations. We are unaware of studies evaluating effective strategies for engaging and retaining transition-age youth with disabilities in clinical trials of community-based transition programs.   OBJECTIVE: The purpose of this paper is to describe and qualitatively assess the effectiveness of strategies used by Maryland PROMISE staff for reengaging youth, who have disengaged from services, and are at high risk of study dropout.   METHODS: Data collected from the project’s management information system, and from interviews with staff assigned solely to reengaging participants, was analyzed to describe effective strategies for reengaging youth in program services.   RESULTS: Staff successful at reengaging hard-to-serve youth into program services are persistent, flexible, and trustworthy. They increased the overall engagement rate from about 50 to 80 percent by study endpoint.   CONCLUSION: An intensive and proactive focus on engagement improves retention rates of youth participating in field-based randomized controlled trials of intervention programs. We suggest investigators conducting similar trials for hard-to-serve populations develop plans and allocating resources for engaging youth in program services."@en ;
    ns0:hasPubTitle "Engaging and retaining youth SSI recipients in a research demonstration program: Maryland PROMISE"@en .

ns1:jvr-v51-i2-JVR191034 ns0:hasKeywords "Interventions"@en,
        "SSI"@en,
        "transition"@en,
        "youth"@en ;
    ns0:hasPubAbstract "BACKGROUND: The Workforce Innovation and Opportunity Act prioritized provision of vocational rehabilitation (VR) services to young adults with disabilities, reinforcing the importance of assisting young persons with disabilities to prepare for and engage in employment.   OBJECTIVE: The purpose of this investigation was to examine patterns of provision of career and work-based learning interventions to young SSI recipients.   METHODS: This investigation was accomplished through analysis of case service data of 1,646 individuals who participated in a multiyear program designed to improve educational and employment outcomes. Discrepancies in career and work-based learning interventions were examined based upon age, gender, disability type, parent employment status, parent education level, and youth and parent expectations about work and education.   RESULTS: No differences in interventions were observed by gender, age at enrollment, or type of disability. Affirmative expectations about going to work or attending college after completing high school were associated with higher mean intervention scores for some types of career and work-based learning interventions.   CONCLUSIONS: Findings suggest that gender, age, and disability did not contribute to differences in provision of services to young SSI recipients. Additional findings underscore the importance of fostering youth and parent expectations about youth engaging in work after completing high school."@en ;
    ns0:hasPubTitle "Career and work-based learning interventions for young recipients of Supplemental Security Income"@en .

ns1:jvr-v51-i3-JVR191049 ns0:hasKeywords "Employment support"@en,
        "mental health literacy"@en,
        "return-to-work"@en,
        "sick leave"@en,
        "workplace"@en ;
    ns0:hasPubAbstract "BACKGROUND: Mental health problems are the main cause of sick leave in today’s working age population. Employers are responsible for their employees’ work environment and preventing work-related illnesses, but their knowledge regarding mental health problems is lacking. Employer beliefs and support strategies need further exploration.   OBJECTIVE: To explore employers’ beliefs, knowledge and strategies use in providing support to employees with mental health problems.   METHODS: This grounded theory study comprised 24 interviews with employers in a variety of workplaces, and included women and men in large and small organizations in a Swedish context.   RESULTS: Two categories related to the aims emerged: comprehending mental health problems is complex, and lacking established conditions to support work. The results show that employers seek to support employees with mental health problems but have low expectations and lack knowledge and strategies. Employers acknowledged experiences of inadequate support and collaboration from other actors in the return-to-work (RTW) process.   CONCLUSIONS: To close the service gap and improve the RTW process, employers need to increase their mental health literacy. Other actors need to improve their understanding of employer situations and provide them with necessary support."@en ;
    ns0:hasPubTitle "Employers’ beliefs, knowledge and strategies used in providing support to employees with mental health problems"@en .

ns1:jvr-v51-i3-JVR191055 ns0:hasKeywords "Young adult"@en,
        "career development"@en,
        "central nervous system cancer"@en,
        "employment"@en,
        "functioning"@en ;
    ns0:hasPubAbstract "PURPOSE: This paper examines individual’s perceptions of emotional and physical functioning and self-management on career development.   DESIGN: A cross-sectional mediation design.   SAMPLE: 81 young adult survivors of childhood cancer (M = 18.90, SD = 0.97) diagnosed with a brain tumor prior to the age of 18.   METHODS: Multiple regression and correlation were used examine if physical and emotional functioning mediates symptom management on job awareness, job acquisition, and job maintenance.   FINDINGS: Symptom management was associated with approximately 0.16 points higher job awareness scores as mediated by emotional functioning, 0.11 points higher job acquisition scores as mediated by emotional functioning, and 0.16 points higher job maintenance scores as mediated by physical functioning.   CONCLUSIONS: Physical and emotional functioning have a differential impact on specific career development factors suggesting the need to develop specific targeted career and vocational interventions."@en ;
    ns0:hasPubTitle "Impact of self-management and functioning on the career development of young adult CNS Survivors"@en .

ns1:mgs-v15-i3-MGS190313 ns0:hasKeywords "Quality of experience (QoE)"@en,
        "cloud gaming"@en,
        "network parameters"@en,
        "quality of service (QoS)"@en ;
    ns0:hasPubAbstract "Cloud gaming is a new way of online gaming, which renders the game data on the cloud side instead of the end user’s system and is forwarded via a high-speed network. In cloud gaming; game software and emulators run on the high-speed server of cloud and services available for users on the commercial and free basis. Users can use rendered data of game from the cloud using thin heterogeneous devices via the Internet to play the game anytime and anywhere. The popularity of cloud gaming has increased since the late 2000s which attract the industry and academia. Quality of experience (QoE) domain has been added in cloud gaming models to assess user satisfaction, enjoyment, and needs during online gaming. In this research paper; we survey and analyze the previous cloud gaming models and models and offer aspects of future development; which will help to give the quality of service (QoS) according to service level agreement (SLA) and increase user satisfaction level for cloud gaming, hence, improving the overall QoE."@en ;
    ns0:hasPubTitle "Quality of experience (QoE) in cloud gaming models: A review"@en .

ns1:mnm-v12-i2-MNM180261 ns0:hasKeywords "Weight disorders"@en,
        "anthropometric indices"@en,
        "double burden of nutrition disorders"@en,
        "early life factors"@en ;
    ns0:hasPubAbstract "BACKGROUND: Childhood weight disorder is a major public health problem worldwide. Although high income countries are facing to obesity, middle and low-income countries are struggling with a double burden of nutritional disorders.   OBJECTIVES: To determine the association between early life factors with weight disorders and central obesity among children and adolescents.   METHODS: This cross-sectional multi-centric study was conducted on 14400 students, aged 7-18 years in 2015 as a national surveillance program. Students were selected by random cluster sampling from 30 provinces of Iran. Early life factors were obtained via validated questionnaire from parents. Physical examination and anthropometric indices were documented. Weight disorders were includes underweight, excess weight based on World Health Organization growth charts and abdominal obesity.   RESULTS: Students with low birth weight had higher odds for underweight than students with normal weight (OR = 1.29, 95% CI: 1.03-1.65). The odds of excess weight in students with high birth weight were 36% higher than students with normal birth weight (OR = 1.36, 95% CI: 1.04-1.79,). In multivariate model, consuming cow’s milk in the two first years of life, prolonged breast feeding, high birth weight, and low pre-conception mother’s weight was associated with abdominal obesity.   CONCLUSION: This study underscores the importance of early life factors on weight disorders in particular obesity and abdominal obesity of children and adolescents in later life."@en ;
    ns0:hasPubTitle "Association of early life factors with weight disorders and abdominal obesity in children and adolescents: The CASPIAN-V study"@en .

ns1:mnm-v12-i2-MNM180275 ns0:hasKeywords "Comprehensive parental feeding questionnaire"@en,
        "Greece"@en,
        "parental feeding practices"@en,
        "validation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Parental feeding practices can affect children’s eating behavior and diet quality. Greek children seem to have poor diet quality and high rates of obesity. Measuring parental feeding practices could facilitate in the formation of target interventions aiming at improving children’s eating behaviours.   OBJECTIVE: The aim of the current study was to develop and validate the Comprehensive Parental Feeding Questionnaire (CPFQ) in the Greek language.   METHODS: The sample consisted of 399 parents (71.2% mothers) of children 2–12 years old. A translation to the Greek language of the CPFQ tool, was conducted followed by a repeatability test, explanatory and confirmatory factor analysis, measures of internal consistency test and factor correlations.   RESULTS: Factor analysis resulted in a final questionnaire of 42 items distributed over 6 factors. Cronbach alpha values were adequate (0.64–0.89) and the correlations between factors were low (rho = –0.212 – 0.405). In addition, mothers use more the “child control” feeding practice (p = 0.002), parents with girls use more the “monitoring” feeding practice (p = 0.010) and normal weight parents use less the “restriction” feeding practice (p = 0.047), in comparison to overweight parents.   CONCLUSIONS: Results support the reliability and validity of the CPFQ for the Greek population."@en ;
    ns0:hasPubTitle "Development and validation of the Greek version of the comprehensive parental feeding questionnaire"@en .

ns1:nha-v5-i2-NHA190065 ns0:hasKeywords "25-(OH)D"@en,
        "BMI"@en,
        "Vitamin D"@en,
        "age"@en,
        "dementia"@en,
        "sex"@en ;
    ns0:hasPubAbstract "BACKGROUND: Vitamin D deficiency is common in Western societies and has been implicated in a number of health conditions including late-life dementia.   OBJECTIVE: To assess whether vitamin D level is associated with all-cause dementia in late life.   METHODS: This was a retrospective case control study using the electronic medical record of an urban medical center to obtain information on age, sex, body mass index, 25-hydroxy vitamin D (25-(OH)D) values, and presence of dementia diagnosis in patients 65 to 90 years old. We classified patients to quartiles according to vitamin D values and performed logistic regression analysis to determine associations between vitamin D quartiles and incidence of dementia diagnosis.   RESULTS: Rates of all-cause dementia decreased with increasing levels of 25-(OH)D independent of age, sex, and BMI, factors that also predicted dementia. Vitamin D levels above 38 ng/mL were associated with the lowest rate of all-cause dementia.   CONCLUSIONS: We observed dose-dependent, inverse associations of 25-hydroxy vitamin D levels with all-cause, late life dementia independent of age, sex, and BMI. There may be greater protection for supra-sufficient levels, a notion that warrants evaluation in controlled trials."@en ;
    ns0:hasPubTitle "Vitamin D level predicts all-cause dementia"@en .

ns1:nre-v44-i3-NRE182637 ns0:hasKeywords "Parkinson’s disease"@en,
        "aging"@en,
        "back function"@en,
        "physiotherapy"@en,
        "postural deformity"@en,
        "rehabilitation"@en,
        "trunk alignment"@en ;
    ns0:hasPubAbstract "BACKGROUND: Postural deformities, such as Pisa syndrome (PS), and camptocormia and antecollis (C&A) are common in patient with Parkinson’s disease (PwPD). These deformities can lead to back disability and pain with different mechanisms, including abnormal loading or stress on soft tissues as muscles, lumbar discs and ligaments.   OBJECTIVES: To evaluate the effect of different postural deformities including PS and C&A on back function and pain in PwPD.   METHODS: The function, disability and pain were assessed by Oswestry disability index (ODI) and brief pain inventory (BPI). All participants completed clinical assessments by the Unified Parkinson’s Disease Rating Scale (UPDRS), Modified Hoenh & Yahr (mH&Y) staging and the Levodopa Equivalent Daily Dose (LEDD).   RESULTS: PS and C&A groups significantly showed worse disability ODI and pain BPI, and higher LEDD and mH&Y stage compared with PD groups. However, no differences were found in PD duration and UPDRS in the same groups. Moreover, no differences were observed between PS and C&A groups in the mentioned scales.   CONCLUSION: These results demonstrated that PS and C&A are associated with severe impairment of back functions and pain. Rehabilitation programs for PwPD and PS, and C&A should include spine alignment and postural training."@en ;
    ns0:hasPubTitle "The effect of postural deformities on back function and pain in patients with Parkinson’s disease"@en .

ns1:nre-v44-i3-NRE182665 ns0:hasKeywords "Stroke"@en,
        "activity levels"@en,
        "neurorehabilitation"@en,
        "sleep-wake cycle"@en ;
    ns0:hasPubAbstract "BACKGROUND: Activity levels and disturbances of the sleep-wake pattern affect health and quality of life and need to be further explored in patients with stroke.   OBJECTIVE: To evaluate activity levels and their association with sleep-wake patterns in patients with stroke.   METHODS: Ten adults with (51±6 years) and 10 without stroke (52±7 years) participated in the study; they were matched on age, sex and educational level. Neurological status, motor function, sleep quality, and activity levels were measured. The groups were compared using Student t-tests and the association between the measures was assessed using Pearson’s correlation.   RESULTS: Compared to people without stroke, those with stroke had worse sleep quality (p = 0.044), twice lower 24h-activity levels (p < 0.0001), higher interdaily stability and intradaily variability, lower activity during the most active 10 h and during the least active 5 h. Sleep quality was associated with activity level (r= –0.72) and with within-day activity variability (r= 0.53).   CONCLUSIONS: Activity level and fragmentation are associated with sleep-wake patterns and sleep quality in patients with stroke."@en ;
    ns0:hasPubTitle "Circadian activity rhythm and fragmentation are associated with sleep-wake patterns and sleep quality in patients with stroke"@en .

ns1:nre-v45-i1-NRE192722 ns0:hasKeywords "Spasticity"@en,
        "balance"@en,
        "disability"@en,
        "gait"@en,
        "impairment"@en,
        "participation"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "BACKGROUND: There are limited evidence of instrumented measures of gait and balance to determine the functional effects of botulinum toxin injections (BoNT-A) in spasticity after stroke.   OBJECTIVE: To evaluate the functional changes in gait and balance following upper limb and lower limb BoNT-A in persons with stroke.   METHODS: A pre-post prospective study of 35 stroke patients with upper and/or lower limb spasticity after focal treatment with BoNT-A. Assessments were at baseline (T0), 6-weeks (T1) and 12-weeks (T2), using validated subjective and objective physical activity measures.   RESULTS: After BoNT-A injections, significant improvements in most measures of impairments, activity and participation domains were found at T1 (p < 0.05, effect sizes (r) = 0.5–0.9). There was a significant increase in low intensity physical activity (at T1) and sedentary time reductions at both follow-up periods. Instrumented gait/balance measures showed a significant increase in cadence and turn velocity, but no changes in sway measures were found using posturography. Improvements in most outcome measures were maintained at 12-weeks.   CONCLUSION: BONT-A improved scores in most clinical measures but only in some of the objective gait/balance and physical activity measures. Further robust studies should utilize a larger sample size to better determine the benefits of BoNT-A for stroke-related spasticity."@en ;
    ns0:hasPubTitle "Multidimensional evaluation of changes in limb function following botulinum toxin injection in persons with stroke"@en .

ns1:nre-v45-i2-NRE192752 ns0:hasKeywords "Sleep"@en,
        "circadian rhythm"@en,
        "clinical trials"@en,
        "fatigue"@en,
        "light"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "BACKGROUND: Daylight entrains the central circadian pacemaker to the 24-hour day and is crucial for optimal alertness and sleep-quality. Rehabilitation patients tend to lack exposure to sufficient natural light.   OBJECTIVE: Installed diurnal naturalistic light may reduce the known disrupted sleep quality and fatigue seen in post stroke patients.   METHODS: Stroke patients were randomized to either an intervention rehabilitation unit (IU) equipped with naturalistic lighting (artificial sunlight spectrum) or to a control rehabilitation unit (CU) with standard indoor lighting. At inclusion and discharge, fatigue and subjective sleep quality were measured.   RESULTS: Ninety stroke patients were included between May 2014, and June 2015. At discharge, patients from the IU experienced less fatigue than the CU patients, based on the Multidimensional Fatigue Inventory questionnaire general (IU, n = 28; CU, n = 30; diff – 20.6%, 95% confidence interval (CI) [– 35.0%; – 3.0%]; P = 0.025) and the Rested Statement (IU, n = 28; CU, n = 30; diff + 41.6%, 95% CI [+4.6%; +91.8%]; P = 0.025). No differences were detected between groups in sleepiness or subjective sleep quality by the Pittsburgh Sleep Quality Index.   CONCLUSIONS: Fatigue was significantly reduced in rehabilitation patients exposed to naturalistic lighting during admission."@en ;
    ns0:hasPubTitle "An exploratory investigation of the effect of naturalistic light on fatigue and subjective sleep quality in stroke patients admitted for rehabilitation: A randomized controlled trial"@en .

ns1:rnn-v37-i3-RNN190916 ns0:hasKeywords "Stroke"@en,
        "continuous theta burst stimulation"@en,
        "motor function"@en,
        "skilled motor practice"@en,
        "transcallosal inhibition"@en,
        "transcranial magnetic stimulation"@en ;
    ns0:hasPubAbstract "Background: In individuals with chronic stroke, impairment of the paretic arm may be exacerbated by increased contralesional transcallosal inhibition (TCI). Continuous theta burst stimulation (cTBS) can decrease primary motor cortex (M1) excitability and TCI. However, contralesional cTBS shows inconsistent effects after stroke. Variable effects of cTBS could stem from failure to pair stimulation with skilled motor practice or a focus of applying cTBS over M1.   Objective: Here, we investigated the effects of pairing cTBS with skilled practice on motor learning and arm function. We considered the differential effects of stimulation over two different brain regions: contralesional M1 (M1c) or contralesional primary somatosensory cortex (S1c).   Methods: 37 individuals with chronic stroke participated in five sessions of cTBS and paretic arm skilled practice of a serial targeting task (STT); participants received either cTBS over M1c or S1c or sham before STT practice. Changes in STT performance and Wolf Motor Function Test (WMFT) were assessed as primary outcomes. Assessment of bilateral corticospinal, intracortical excitability and TCI were secondary outcomes.   Results: cTBS over sensorimotor cortex did not improve STT performance and paretic WMFT-rate beyond sham cTBS. TCI was reduced bi-directionally following the intervention, regardless of stimulation group. In addition, we observed an association between STT performance change and paretic WMFT-rate change in the M1c stimulation group only.   Conclusions: Multiple sessions of STT practice can improve paretic arm function and decrease TCI bilaterally, with no additional benefit of prior cTBS. Our results suggest that improvement in STT practice following M1c cTBS scaled with change in paretic arm function in some individuals. Our results highlight the need for a better understanding of the mechanisms of cTBS to effectively identify who may benefit from this form of brain stimulation."@en ;
    ns0:hasPubTitle "The effects of five sessions of continuous theta burst stimulation over contralesional sensorimotor cortex paired with paretic skilled motor practice in people with chronic stroke"@en .

ns1:rnn-v37-i4-RNN190926 ns0:hasKeywords "Bumetanide"@en,
        "functional recovery"@en,
        "neural damage"@en,
        "neuroplasticity"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "Stroke often leads to neuronal injury and neurological functional deficits. Whilst spontaneous neurogenesis and axon regeneration are induced by ischemic stroke, effective pharmacological treatments are also essential for the improvement of neuroplasticity and functional recovery after stroke. However, no pharmacological therapy has been demonstrated to be able to effectively improve the functional recovery after stroke. Bumetanide is a specific Na+-K+-Cl– co-transporter inhibitor which can maintain chloride homeostasis in neurons. Therefore, many studies have focused on this drug’s effect in stroke recovery in recent years. Here, we first review the function of Na+-K+-Cl– co-transporter in neurons, then how bumetanide’s role in reducing brain damage, promoting neuroplasticity, leading to functional recovery after stroke, is elucidated. Finally, we discuss current limitations of bumetanide’s efficiency and their potential solutions. These results may provide new avenues for further exploring mechanisms of post-stroke functional recovery as well as promising therapeutic targets for functional disability rehabilitation after ischemic stroke."@en ;
    ns0:hasPubTitle "Bumetanide: A review of its neuroplasticity and behavioral effects after stroke"@en .

ns1:rnn-v37-i5-RNN190919 ns0:hasKeywords "Memory"@en,
        "epilepsy"@en,
        "fMRI"@en,
        "intervention"@en,
        "memory impairment"@en,
        "paired associate learning task"@en,
        "rehabilitation"@en ;
    ns0:hasPubAbstract "Background: Memory deficits are very common in epilepsy, but no standard of care exists to effectively manage them.   Objective:  We assessed effectiveness of cognitive rehabilitation (CR) on memory and neural plasticity in people with epilepsy (PWE) reporting memory impairments.   Methods:  Nine PWE completed 6 weekly sessions adapted from 2 generic CR programs enriched with information regarding epilepsy. Participants completed neuropsychological, mood, and quality of life (QOLIE-31) measures prior and after completion of CR; 5/9 participants also completed pre- and post-CR fMRI while performing a verbal paired associates learning task. FMRI data were analyzed using group spatial independent components analysis methods; paired t-tests compared spatial activations for pre-/post-CR.   Results:  Improvements were seen in immediate recall in Rey Auditory Verbal Learning Task, QOLIE-31, and read word recognition in paired associates task (all p’s≤0.05). FMRI changes comparing pre-to-post CR were noted through increased activation in the left inferior frontal gyrus (IFG) and anterior cingulate and decreased activation in the left superior temporal gyrus; also noted were decreased activations in the default mode network (DMN), right cingulate, right middle temporal gyrus, right supramarginal gyrus, and increased DMN activation in the left cuneus.   Conclusions:  This study demonstrates feasibility of conducting CR program in PWE with fMRI as a mechanistic biomarker. Improvements in cognition and cortical plasticity await confirmation in larger samples."@en ;
    ns0:hasPubTitle "Memory response and neuroimaging correlates of a novel cognitive rehabilitation program for memory problems in epilepsy: A pilot study"@en .

ns1:sw-v10-i6-SW190359 ns0:hasKeywords "DBpedia"@en,
        "Linked Open Data"@en,
        "RDF"@en,
        "Relevance metrics"@en,
        "SPARQL"@en,
        "Semantic Web"@en,
        "data mining"@en,
        "graph embedding"@en,
        "recommender systems"@en ;
    ns0:hasPubAbstract "Knowledge Graphs (KGs) have become useful sources of structured data for information retrieval and data analytics tasks. Enabling complex analytics, however, requires entities in KGs to be represented in a way that is suitable for Machine Learning tasks. Several approaches have been recently proposed for obtaining vector representations of KGs based on identifying and extracting relevant graph substructures using both uniform and biased random walks. However, such approaches lead to representations comprising mostly popular, instead of relevant, entities in the KG. In KGs, in which different types of entities often exist (such as in Linked Open Data), a given target entity may have its own distinct set of most relevant nodes and edges. We propose specificity as an accurate measure of identifying most relevant, entity-specific, nodes and edges. We develop a scalable method based on bidirectional random walks to compute specificity. Our experimental evaluation results show that specificity-based biased random walks extract more meaningful (in terms of size and relevance) substructures compared to the state-of-the-art and the graph embedding learned from the extracted substructures perform well against existing methods in common data mining tasks."@en ;
    ns0:hasPubTitle "Extracting entity-specific substructures for RDF graph embeddings"@en .

ns1:thc-v27-i6-THC191715 ns0:hasKeywords "Membrane"@en,
        "blood"@en,
        "centrifugation"@en,
        "nucleic acid amplification"@en ;
    ns0:hasPubAbstract "BACKGROUND:  To detect most of bloodborne pathogens, serum must be separated from whole blood for efficient nucleic acid amplification. Centrifugation is the most commonly used preparation step for whole blood, but it is not easy to use a centrifuge in rural areas where electricity is not accessible.   OBJECTIVE:  This study aimed to develop a simple method for obtaining serum suitable for nucleic acid amplification without the use of any instruments.   METHODS:  Whole blood spiked with Escherichia coli (E. coli) was separated into serum and cellular fraction using 2 closely attached membranes with different characteristics. After brief heating, bacterial DNA in the serum was used for polymerase chain reaction (PCR).   RESULTS:  Serum was successfully separated from cellular fraction after filtration of one membrane sheet. Membrane sheet containing serum was heated and bacterial DNA in the serum was used for PCR. The quality and concentration of DNA in the heated serum was sufficient for PCR and amplified E. coli gene products were observed.   CONCLUSIONS:  Separation of bacteria-containing serum was feasible using two membrane sheets and the DNA isolated from serum can be used for PCR after brief heating."@en ;
    ns0:hasPubTitle "A simple blood preparation method for nucleic acid amplification tests using membranes"@en .

ns1:wor-v63-i3-WOR192938 ns0:hasKeywords "Coping strategy"@en,
        "cultural adaptation"@en,
        "psychometric properties"@en,
        "translation"@en,
        "work stress"@en ;
    ns0:hasPubAbstract "BACKGROUND: Currently, there are no assessment tools for measuring coping strategies for stress at work in the Korean language.   OBJECTIVE: The purpose of this study was to translate the Latack Coping Scale to workplace stress into Korean and examine its psychometric properties in a Korean working population.   METHODS: Translation of the the Latack Coping Scale was performed according to the scientific guidelines for cross-cultural adaptation. Two hundred and forty one general workers in Korea completed the new Korean version of the Latack Coping Scale as well as the Type D Personality Scale-14 (negative affectivity). Psychometric properties (reliability and validity) were evaluated.   RESULTS: Factor analysis yielded a model that was consistent with the originally proposed subscales of the questionnaire. Good to excellent internal consistency and measurement consistency over a one week interval were obtained for five subscales (Cronbach’s alpha; 0.61 to 0.86 and ICC (2.2); 0.80 to 0.87). Escape coping scales were positively associated with Type D personality while control coping scales were negatively associated with Type D personality.   CONCLUSIONS: This Korean version of the Latack Coping Scale has shown excellent validity and reliability in the Korean working population. Organizations investigating work stress and coping methods in Korean workers can use this instrument with confidence."@en ;
    ns0:hasPubTitle "Cross-cultural adaptation and validation of the Latack Coping Scale in the general working population in Korea"@en .

ns1:wor-v63-i4-WOR192958 ns0:hasKeywords "Physical employment standards"@en,
        "cut-scores"@en,
        "sensitivity"@en,
        "specificity"@en ;
    ns0:hasPubAbstract "BACKGROUND: Beginning in 2017, successfully passing the four-part pre-enlistment Occupational Physical Assessment Test (OPAT) became a requirement for all U.S. Army recruits. To ensure the test accurately identifies individuals who are qualified for their job, it was necessary to examine classification errors.   OBJECTIVE: The objectives were to 1) determine the accuracy of OPAT cut-scores for combat arms Soldiers, and 2) determine which events contribute to the individuals that are misclassified as passing or failing the OPAT   METHODS: A total of 741 trainees were tested on the OPAT within two weeks of entering their initial entry training. At the end of their training, trainees were tested on simulations of the most physically demanding tasks of their job.   RESULTS: There was a high classification concordance (76.5%) between success on the OPAT and job task simulations. False positives (6.7%) were misclassified because they did not perform as well on the strength-dominant task simulations. While the interval aerobic run was the greatest contributor to false negatives (16.8%), previous studies indicated high performance on this event as a potential key indicator of injury and attrition risk.   CONCLUSIONS: The findings provide insight on how the accuracy of the OPAT, and similar pre-employment tests, could be improved."@en ;
    ns0:hasPubTitle "U.S. Army physical demands study: Accuracy of occupational physical assessment test classifications for combat arms soldiers"@en .

ns1:wor-v64-i2-WOR192984 ns0:hasKeywords "Music effect"@en,
        "operating theatre"@en,
        "surgical personnel"@en,
        "surgical technicians"@en ;
    ns0:hasPubAbstract "BACKGROUND: Music is an economical, advantageous and reliable means of reducing stress or stress-related problems.   OBJECTIVE: The present study aims to evaluate the effects of playing music during surgery on the performance of the surgical team through a systematic review of published studies.   METHODS: The relevant databases of Medline/PubMed, Scopus and Science Direct were searched up to July 2018 to find related articles. The comprehensive literature search was reduced to 19 articles that met inclusion criteria.   RESULTS: The articles comprised 13 studies and reported on the positive effects of music on the performance of the surgical team. The effects included a more relaxing and pleasant environment, more accurate and precise performance of tasks, a decrease in the mental workload and task completion time, increased situation awareness, a reduction in stress and anxiety and improved memory consolidation. Five studies reported on the negative effects of music during surgery as being a negative impact on task completion, poor auditory performance and increased likelihood of having to repeat requests. The remaining article reported no significant differences between groups compared.   CONCLUSIONS: Most studies reported positive effects of music on the surgical team during surgery. These results indicate that it may be possible to improve the performance of the surgical team during surgery while playing controlled music."@en ;
    ns0:hasPubTitle "The effects of playing music during surgery on the performance of the surgical team: A systematic review"@en .

ns1:wor-v64-i3-WOR193013 ns0:hasKeywords "Occupational health psychology"@en,
        "limit-setting"@en,
        "signaling"@en,
        "work climate"@en ;
    ns0:hasPubAbstract "BACKGROUND: Overall, health-related correlates of job demands and job resources are well-known. However, in today’s working life, personal resources are considered to be of increasing importance. Beyond general mental ability, knowledge regarding personal resources remains limited. This is particularly so among women working in the welfare sector, a sector mainly employing women and with the work typically involving clients.   OBJECTIVE: This study investigated the importance of job demands, job resources, and personal resources for health-related outcomes, as well as the mitigating effects of resources, among women working within the Swedish welfare sector.   METHODS: Self-reports from 372 women employed within the welfare sector were analyzed using hierarchical multiple regression.   RESULTS: Overall, increasing job demands were associated with poorer health outcomes while increasing job resources and personal resources were associated with better health. Additionally, lower control aggravated the effects of quantitative job demands on health outcomes while lower feedback mitigated the effect of qualitative demands. However, personal resources had no moderating effect.   CONCLUSIONS: Job resources seem more pertinent to health than personal resources, at least among women working within the welfare sector in Sweden."@en ;
    ns0:hasPubTitle "Do personal resources matter beyond job demands and job resources? Main and interaction effects on health-related outcomes among women working within the welfare sector"@en .

ns1:xst-v27-i3-XST180465 ns0:hasKeywords "Triple-negative breast cancer"@en,
        "X-ray"@en,
        "clinicopathologic features"@en,
        "computed tomography"@en,
        "perfusion"@en,
        "prognosis"@en ;
    ns0:hasPubAbstract "PURPOSE: To investigate associations between the clinicopathologic features and CT perfusion parameters of triple-negative breast cancer (TNBC) and non-TNBC using low-dose computed tomography perfusion imaging (LDCTPI), and to find potential clinical applications in the prognosis assessment of TNBC.   MATERIALS AND METHODS: A total of 60 patients with breast cancer confirmed by pathological examination were studied prospectively using LDCTPI on a 64-slice spiral CT scanner. The acquired volume data were used for calculations, mapping, and analysis by using a tumor perfusion protocol in the CT perfusion software package to measure 2 parameters namely, blood flow (BF), and permeability surface (PS) area product. Patients were grouped into TNBC (n = 27) and non-TNBC (n = 33) subtypes. Associations between these two subtypes and clinicopathologic characteristics were evaluated by both univariate and multivariate logistic regression. CT perfusion parameters values were compared for clinicopathologic characteristics using independent 2-sample t test.   RESULTS: TNBC displayed higher CT perfusion parameters values (BF: 57.56±10.94 vs 52.70±7.79 mL/100 g/min, p = 0.006; PS: 38.98±9.46 vs 33.39±8.07 mL/100 g/min, p = 0.001) than non-TNBC. In addition, breast cancer with poorly histologic grade or positive Ki-67 expression showed higher BF and PS values than those with well and moderately histologic grade or negative Ki-67 expression (p < 0.05). TNBC had poorer histologic grade (P = 0.032) and higher Ki-67 expression (P = 0.013) than non-TNBC.   CONCLUSION: LDCTPI is a functional imaging technology from the perspective of hemodynamics with potential of clinical applications. The BF and PS values were higher in TNBC patient group than non-TNBC group. TNBC patients also have poorer clinicopathologic outcome."@en ;
    ns0:hasPubTitle "A pilot study of low-dose CT perfusion imaging (LDCTPI) technology in patients with triple-negative breast cancer"@en .

ns1:xst-v27-i3-XST190500 ns0:hasKeywords "Spectral CT"@en,
        "deep learning"@en,
        "material decomposition"@en,
        "photon-counting detector"@en ;
    ns0:hasPubAbstract "BACKGROUND:Spectral computed tomography (CT) has the capability to resolve the energy levels of incident photons, which has the potential to distinguish different material compositions. Although material decomposition methods based on x-ray attenuation characteristics have good performance in dual-energy CT imaging, there are some limitations in terms of image contrast and noise levels.   OBJECTIVE:This study focused on multi-material decomposition of spectral CT images based on a deep learning approach.   METHODS:To classify and quantify different materials, we proposed a multi-material decomposition method via the improved Fully Convolutional DenseNets (FC-DenseNets). A mouse specimen was first scanned by spectral CT system based on a photon-counting detector with different energy ranges. We then constructed a training set from the reconstructed CT images for deep learning to decompose different materials.   RESULTS:Experimental results demonstrated that the proposed multi-material decomposition method could more effectively identify bone, lung and soft tissue than the basis material decomposition based on post-reconstruction space in high noise levels.   CONCLUSIONS:The new proposed approach yielded good performance on spectral CT material decomposition, which could establish guidelines for multi-material decomposition approaches based on the deep learning algorithm."@en ;
    ns0:hasPubTitle "Multi-material decomposition of spectral CT images via Fully Convolutional DenseNets"@en .

ns1:xst-v27-i4-XST180460 ns0:hasKeywords "Interstitial lung diseases"@en,
        "computer-aided CT quantification"@en,
        "mean lung density"@en ;
    ns0:hasPubAbstract "OBJECTIVE: Identification of interstitial lung disease (ILD) may be difficult in certain cases using pulmonary function tests (PFTs) or subjective radiological analysis. We evaluated the efficacy of quantitative computed tomography (CT) with 3-dimensional (3D) reconstruction for distinguishing ILD patients from healthy controls.   MATERIALS AND METHODS: We retrospectively collected chest CT images of 102 ILD patients and 102 healthy matched controls, and measured the following parameters: lung parenchymal volume, emphysema indices low attenuation area LAA910 volume, LAA950 volume, LAA910%, and LAA950%, and mean lung density (MLD) for whole lung, left lung, right lung, and each lobe, respectively. The Mann-Whitney U test was used to compare quantitative CT parameters between groups. Receiver operating characteristic (ROC) curves, Bayesian stepwise discriminant analysis, and deep neural network analysis were used to test the discriminative performance of quantitative CT parameters. Binary logistic regression was performed to identify ILD markers.   RESULTS: Total lung volume was lower in ILD patients than controls, while emphysema and MLD values were higher (P < 0.001) except LAA910 volume in right middle lobe. LAA910 volume, LAA950 volume, LAA910%, LAA950%, and MLD accurately distinguished ILD patients from healthy controls (AUC >0.5, P < 0.05), and high MLD was a significant marker for ILD (OR = 1.047, P < 0.05).   CONCLUSIONS: This quantitative CT analysis can effectively identify ILD patients, providing an alternative to subjective image analysis and PFTs."@en ;
    ns0:hasPubTitle "Computer-aided identification of interstitial lung disease based on computed tomography"@en .

ns1:xst-v27-i4-XST180486 ns0:hasKeywords "Bronchial morphological changes in pulmonary contusion"@en,
        "CT quantification for pulmonary contusion"@en,
        "acute respiratory distress syndrome (ARDS)"@en,
        "pulmonary contusion combined with ARDS"@en ;
    ns0:hasPubAbstract "BACKGROUND Quantitative measurement of bronchial morphological changes in pulmonary contusion with acute respiratory distress syndrome (ARDS) has important clinical implications.   OBJECTIVE To investigate the morphological changes in bronchus before and after treatment in patients with pulmonary contusion combined with ARDS using an automated bronchial three-dimensional computed tomography (3D-CT) measurement method.   METHODS The study involves a dataset of CT images of 62 patients diagnosed with pulmonary contusion combined with ARDS. The volume of pulmonary contusion lesions was calculated as a percentage of the total lung volume using the automated 3D-CT method. The bronchial luminal cross-sectional area, wall cross-sectional area, the maximum and average wall thickness, the maximum and average luminal densities, intraluminal and extraluminal diameters, and circumferences of generations 2–4 bronchi before and after treatment were measured. Furthermore, the corresponding differences were analyzed statistically.   RESULTS The luminal cross-sectional area, wall cross-sectional area, intraluminal and extraluminal diameters, and circumferences of generations 2–4 bronchi were all significantly lower before treatment than after treatment (P < 0.05). However, the maximum and average wall thicknesses were both significantly higher before treatment than after treatment (P < 0.05). No significant difference was found in the maximum and average luminal densities before and after treatment (P > 0.05). The percentage of the pulmonary contusion lesion volume to the total lung volume correlated positively with the thoracic trauma severity score (r = 0.74, P < 0.01).   CONCLUSIONS Quantitative bronchial CT image analysis enables to detect and assess bronchial morphological changes in patients diagnosed with pulmonary contusion combined with ARDS."@en ;
    ns0:hasPubTitle "Application of automated bronchial 3D-CT measurement in pulmonary contusion complicated with acute respiratory distress syndrome"@en .

ns1:xst-v27-i4-XST190533 ns0:hasKeywords "Ultrasound image"@en,
        "absorbing Markov chain"@en,
        "adaptive selective replacement"@en,
        "automatic detection"@en,
        "breast tumor"@en,
        "saliency model"@en ;
    ns0:hasPubAbstract "BACKGROUND: Automatic detection of tumor in breast ultrasound (BUS) images is important for the subsequent image processing and has been researched for decades. However, there still lacks a robust method due to poor quality of BUS images.   OBJECTIVE: To propose and test a salient object detection method for BUS images.   METHODS: BUS image is preprocessed by an adaptively selective replacement and speckle reducing anisotropic diffusion (SRAD) algorithm. Then, the preprocessed image is segmented into super pixels by a simple linear iterative clustering (SLIC) algorithm to form a graph model, and the saliency of the nodes in the graph is calculated by using the absorbed time of absorbing Markov chain (AMC). Finally, the initial saliency map is optimized by the recurrent time of ergodic Markov chain (EMC) and a distance weighting formula.   RESULTS: Results of the proposed method were compared both qualitatively and quantitatively with two saliency detection models. It was observed that the proposed method outperformed the comparison models and yielded the highest Accuracy value (97.49% vs. 86.63% and 90.33%) using a dataset of 1000 BUS images.   CONCLUSIONS: After the adaptively selective replacement, AMC can effectively distinguish tumors from background by random walks."@en ;
    ns0:hasPubTitle "Salient object detection method for breast tumor in ultrasound images based on absorbing Markov chain"@en .

ns1:xst-v27-i5-XST190514 ns0:hasKeywords "Intraoperative computed tomography (iCT) system"@en,
        "body"@en,
        "brain"@en,
        "mobile CT"@en,
        "operating room"@en ;
    ns0:hasPubAbstract "BACKGROUND: Intraoperative computed tomography (iCT) system has been developed focusing on combining the advanced imaging techniques for the best imaging modality. However, the use of iCT system in the operating rooms is limited due to the lack of flexible mobility.   OBJECTIVE: This study aims to develop a mobile iCT imaging system and assess its imaging performance in a phantom study.   METHODS: The mobile iCT system with mecanum omni-directional wheels has three major components namely, a rotating gantry, a slip-ring and a stationary gantry. Performance of mecanum iCT system was evaluated using the indices of signal-to-noise (SNR), contrast-to noise (CNR), and spatial resolution (MTF). Anatomical landmarks on phantom images were assessed using a 5-point scale (5 = definitely seen; 4 = probably seen; 3 = equivocal; 2 = probably not seen; and 1 = definitely not seen).   RESULTS: The mecanum iCT system can be conveniently used for a whole-body scan under intraoperative conditions even in narrow operating rooms due to a smaller turning radius. The image quality of the mecanum iCT system was found to be acceptable for clinical applications (with SNR = 162.72, CNR = 134.29 and MTF = 694 μm). The diagnostic scores on the phantom images were ‘definitely seen’ value.   CONCLUSIONS: The proposed mecanum iCT system achieved the improved flexible mobility and has potential to better serve as a useful imaging tool in the clinical intraoperative setting."@en ;
    ns0:hasPubTitle "Development of mobile intraoperative computed tomography imaging system and assessment of its performance in a brain and body phantom study"@en .

ns2:FI1669 ns0:inAuthorList ns150:FI1669 .

ns2:HAB180360 owl:sameAs ns52:HAB282 ;
    ns0:fullName "Osaro Erhabor" ;
    ns0:hasAffiliation ns242:HAB180360 ;
    ns0:hasArticle ns1:hab-v27-i3-HAB180360 ;
    ns0:inAuthorList ns150:HAB180360 .

ns2:IFS161821 ns0:inAuthorList ns150:IFS161821 .

ns2:IFS161927 ns0:inAuthorList ns150:IFS161927 .

ns2:IFS1667 ns0:inAuthorList ns150:IFS1667 .

ns2:IFS1688 ns0:inAuthorList ns150:IFS1688 .

ns2:IFS171172 ns0:inAuthorList ns150:IFS171172 .

ns2:IFS172270 ns0:inAuthorList ns150:IFS172270 .

ns2:IFS181295 ns0:inAuthorList ns150:IFS181295 .

ns2:IFS181767 ns0:inAuthorList ns150:IFS181767 .

ns2:IFS181972 owl:sameAs ns2:IFS171443,
        ns2:IFS2107 ;
    ns0:fullName "Muhammad Akram" ;
    ns0:hasAffiliation ns242:IFS181972 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181972 ;
    ns0:inAuthorList ns150:IFS181972 .

ns2:IFS182809 owl:sameAs ns2:IFS181648,
        ns2:IFS182751,
        ns8:IFS190905 ;
    ns0:fullName "Muhammad Riaz" ;
    ns0:hasAffiliation ns242:IFS182809 ;
    ns0:hasArticle ns1:ifs-v37-i3-IFS182809 ;
    ns0:inAuthorList ns150:IFS182809 .

ns2:IFS182863 owl:sameAs ns2:IFS161919 ;
    ns0:fullName "Ho Vu" ;
    ns0:hasAffiliation ns242:IFS182863 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182863 ;
    ns0:inAuthorList ns150:IFS182863 .

ns2:IFS1856 ns0:inAuthorList ns150:IFS1856 .

ns2:IFS1869 ns0:inAuthorList ns150:IFS1869 .

ns2:IFS2075 ns0:inAuthorList ns150:IFS2075 .

ns2:IFS2114 ns0:inAuthorList ns150:IFS2114 .

ns2:JAD131850 ns0:inAuthorList ns150:JAD131850 .

ns2:JAD141248 ns0:inAuthorList ns150:JAD141248 .

ns2:JAD160866 ns0:inAuthorList ns150:JAD160866 .

ns2:JAD181194 ns0:inAuthorList ns150:JAD181194 .

ns2:JAD190181 owl:sameAs ns2:JAD160826,
        ns2:JAD161209,
        ns8:JAD112126,
        ns12:JAD140630,
        ns12:JAD160774,
        ns5:JAD180572,
        ns16:JAD180631 ;
    ns0:fullName "Kaarin J. Anstey" ;
    ns0:hasAffiliation ns242:JAD190181,
        ns243:JAD190181 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD190181 ;
    ns0:inAuthorList ns150:JAD190181 .

ns2:JAD190506 ns0:inAuthorList ns150:JAD190506 .

ns2:JAE150030 ns0:inAuthorList ns150:JAE150030 .

ns2:WOR2601 ns0:inAuthorList ns150:WOR2601 .

ns2:jad00545 ns0:inAuthorList ns150:jad00545 .

ns2:jad101311 ns0:inAuthorList ns150:jad101311 .

ns8:CH16195 ns0:inAuthorList ns150:CH16195 .

ns8:FI1567 ns0:inAuthorList ns150:FI1567 .

ns8:HAB190367 owl:sameAs ns2:HAB190368 ;
    ns0:fullName "Ali Mohammad Mosadeghrad" ;
    ns0:hasAffiliation ns258:HAB190367 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190367 ;
    ns0:inAuthorList ns150:HAB190367 .

ns8:HAB190369 owl:sameAs ns8:HAB190368 ;
    ns0:fullName "Addis Adera Gebru" ;
    ns0:hasAffiliation ns25:HAB190369,
        ns90:HAB190369 ;
    ns0:hasArticle ns1:hab-v27-i4-HAB190369 ;
    ns0:inAuthorList ns150:HAB190369 .

ns8:IFS151517 ns0:inAuthorList ns150:IFS151517 .

ns8:IFS151652 ns0:inAuthorList ns150:IFS151652 .

ns8:IFS152553 ns0:inAuthorList ns150:IFS152553 .

ns8:IFS162007 ns0:inAuthorList ns150:IFS162007 .

ns8:IFS162058 ns0:inAuthorList ns150:IFS162058 .

ns8:IFS16797 ns0:inAuthorList ns150:IFS16797 .

ns8:IFS171187 ns0:inAuthorList ns150:IFS171187 .

ns8:IFS17267 ns0:inAuthorList ns150:IFS17267 .

ns8:IFS1734 ns0:inAuthorList ns150:IFS1734 .

ns8:IFS17465 ns0:inAuthorList ns150:IFS17465 .

ns8:IFS17482 ns0:inAuthorList ns150:IFS17482 .

ns8:IFS179057 ns0:inAuthorList ns150:IFS179057 .

ns8:IFS17912 ns0:inAuthorList ns150:IFS17912 .

ns8:IFS179235 owl:sameAs ns8:INF1165 ;
    ns0:fullName "Hui Gao" ;
    ns0:hasAffiliation ns24:IFS179235 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS179235 ;
    ns0:inAuthorList ns150:IFS179235 .

ns8:IFS18040 ns0:inAuthorList ns150:IFS18040 .

ns8:IFS181329 ns0:inAuthorList ns150:IFS181329 .

ns8:IFS182700 ns0:inAuthorList ns150:IFS182700 .

ns8:IFS18518 ns0:inAuthorList ns150:IFS18518 .

ns8:IFS18757 ns0:inAuthorList ns150:IFS18757 .

ns8:IFS18833 ns0:inAuthorList ns150:IFS18833 .

ns8:IFS190148 ns0:inAuthorList ns150:IFS190148 .

ns8:IFS2161 ns0:inAuthorList ns150:IFS2161 .

ns8:JAD111109 ns0:inAuthorList ns150:JAD111109 .

ns8:JAD150134 ns0:inAuthorList ns150:JAD150134 .

ns8:JAD160122 ns0:inAuthorList ns150:JAD160122 .

ns8:JAD171071 ns0:inAuthorList ns150:JAD171071 .

ns8:JAD179924 ns0:inAuthorList ns150:JAD179924 .

ns8:JAD181180 ns0:inAuthorList ns150:JAD181180 .

ns8:JAD190790 ns0:inAuthorList ns150:JAD190790 .

ns8:JAE171008 ns0:inAuthorList ns150:JAE171008 .

ns8:JAE171252 ns0:inAuthorList ns150:JAE171252 .

ns8:JAE2122 ns0:inAuthorList ns150:JAE2122 .

ns8:JCM607 ns0:inAuthorList ns150:JCM607 .

ns8:jad00087 ns0:inAuthorList ns150:jad00087 .

ns8:jad01113 ns0:inAuthorList ns150:jad01113 .

ns8:jad100186 ns0:inAuthorList ns150:jad100186 .

ns8:jad100597 ns0:inAuthorList ns150:jad100597 .

ns26:JAD170583 ns0:inAuthorList ns150:JAD170583 .

ns26:JHD180285 ns0:inAuthorList ns150:JHD180285 .

ns40:JAD101518 ns0:inAuthorList ns150:JAD101518 .

ns40:JAD140942 ns0:inAuthorList ns150:JAD140942 .

ns40:JAD160587 ns0:inAuthorList ns150:JAD160587 .

ns40:JAD161109 ns0:inAuthorList ns150:JAD161109 .

ns40:JAD170362 ns0:inAuthorList ns150:JAD170362 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:JAD190533> owl:sameAs ns40:JAD121930,
        ns57:JAD150897,
        ns33:JAD121471 ;
    ns0:fullName "Henrik Zetterberg" ;
    ns0:hasAffiliation <http://ld.iospress.nl/rdf/organization/Affiliation:aff13.Author:12.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff14.Author:12.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff15.Author:12.ID:JAD190533>,
        <http://ld.iospress.nl/rdf/organization/Affiliation:aff16.Author:12.ID:JAD190533> ;
    ns0:hasArticle ns1:jad-v71-i3-JAD190533 ;
    ns0:inAuthorList ns150:JAD190533 .

<http://ld.iospress.nl/rdf/contributor/Author:12.ID:jad01239> ns0:inAuthorList ns150:jad01239 .

<http://ld.iospress.nl/rdf/contributor/Author:14.ID:JAD160474> ns0:inAuthorList ns150:JAD160474 .

ns43:JAD140777 ns0:inAuthorList ns150:JAD140777 .

<http://ld.iospress.nl/rdf/contributor/Author:17.ID:JAD122182> ns0:inAuthorList ns150:JAD122182 .

ns12:HAB190383 owl:sameAs ns8:JRS740,
        ns12:HAB190368 ;
    ns0:fullName "Ali Akbari Sari" ;
    ns0:hasAffiliation ns13:HAB190383 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190383 ;
    ns0:inAuthorList ns150:HAB190383 .

ns12:HSM1794 ns0:inAuthorList ns150:HSM1794 .

ns12:IFS152553 ns0:inAuthorList ns150:IFS152553 .

ns12:IFS161601 ns0:inAuthorList ns150:IFS161601 .

ns12:IFS161681 ns0:inAuthorList ns150:IFS161681 .

ns12:IFS161702 ns0:inAuthorList ns150:IFS161702 .

ns12:IFS161740 ns0:inAuthorList ns150:IFS161740 .

ns12:IFS17465 ns0:inAuthorList ns150:IFS17465 .

ns12:IFS17728 ns0:inAuthorList ns150:IFS17728 .

ns12:IFS181253 ns0:inAuthorList ns150:IFS181253 .

ns12:IFS181452 owl:sameAs ns8:IFS171176,
        ns8:IFS2113,
        ns12:IFS172195,
        ns30:IFS2114,
        ns30:IFS2121,
        ns5:IFS171685,
        ns5:IFS18347 ;
    ns0:fullName "Madhumangal Pal" ;
    ns0:hasAffiliation ns15:IFS181452 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS181452 ;
    ns0:inAuthorList ns150:IFS181452 .

ns12:IFS181460 owl:sameAs ns2:IFS171587,
        ns2:IFS17728,
        ns8:IFS181188 ;
    ns0:fullName "Asghar Khan" ;
    ns0:hasAffiliation ns15:IFS181460 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181460 ;
    ns0:inAuthorList ns150:IFS181460 .

ns12:IFS181488 ns0:inAuthorList ns150:IFS181488 .

ns12:IFS181922 owl:sameAs ns8:IFS181516,
        ns12:IFS171567 ;
    ns0:fullName "Saleem Abdullah" ;
    ns0:hasAffiliation ns14:IFS181922 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181922 ;
    ns0:inAuthorList ns150:IFS181922 .

ns12:IFS182568 owl:sameAs ns8:IFS161988,
        ns8:IFS1650,
        ns8:IFS17267,
        ns8:IFS17482,
        ns8:IFS1788 ;
    ns0:fullName "Fu-Gui Shi" ;
    ns0:hasAffiliation ns14:IFS182568 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182568 ;
    ns0:inAuthorList ns150:IFS182568 .

ns12:IFS182618 ns0:inAuthorList ns150:IFS182618 .

ns12:IFS182863 owl:sameAs ns12:IFS181698 ;
    ns0:fullName "Ngo Van Hoa" ;
    ns0:hasAffiliation ns83:IFS182863,
        ns13:IFS182863 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182863 ;
    ns0:inAuthorList ns150:IFS182863 .

ns12:IFS18757 ns0:inAuthorList ns150:IFS18757 .

ns12:IFS190952 owl:sameAs ns2:IFS152405,
        ns8:IFS18604 ;
    ns0:fullName "Truong Vinh An" ;
    ns0:hasAffiliation ns13:IFS190952 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS190952 ;
    ns0:inAuthorList ns150:IFS190952 .

ns12:IFS2074 ns0:inAuthorList ns150:IFS2074 .

ns12:INF1131 ns0:inAuthorList ns150:INF1131 .

ns12:JAD00024 ns0:inAuthorList ns150:JAD00024 .

ns12:JAD00041 ns0:inAuthorList ns150:JAD00041 .

ns12:JAD110021 ns0:inAuthorList ns150:JAD110021 .

ns12:JAD122223 ns0:inAuthorList ns150:JAD122223 .

ns12:JAD160766 ns0:inAuthorList ns150:JAD160766 .

ns12:JAD160979 ns0:inAuthorList ns150:JAD160979 .

ns12:JAD170055 ns0:inAuthorList ns150:JAD170055 .

ns12:JAD180569 ns0:inAuthorList ns150:JAD180569 .

ns12:JAD180808 ns0:inAuthorList ns150:JAD180808 .

ns12:JAD190638 owl:sameAs ns52:JAD160766,
        ns57:JAD140669 ;
    ns0:fullName "Magda Tsolaki" ;
    ns0:hasAffiliation ns14:JAD190638,
        ns13:JAD190638 ;
    ns0:hasArticle ns1:jad-v72-i1-JAD190638 ;
    ns0:inAuthorList ns150:JAD190638 .

ns12:JAE190821 owl:sameAs ns8:JAE190924,
        ns8:JAE2271,
        ns12:JAE1979 ;
    ns0:fullName "Yasuhito Takahashi" ;
    ns0:hasAffiliation ns15:JAE190821 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE190821 ;
    ns0:inAuthorList ns150:JAE190821 .

ns12:JAE191149 owl:sameAs ns12:JAE2122,
        ns30:JAE190821 ;
    ns0:fullName "Koji Fujiwara" ;
    ns0:hasAffiliation ns15:JAE191149 ;
    ns0:hasArticle ns1:jae-v61-iS1-JAE191149 ;
    ns0:inAuthorList ns150:JAE191149 .

ns12:JVR191047 owl:sameAs ns2:JVR191055,
        ns5:JVR813 ;
    ns0:fullName "David R. Strauser" ;
    ns0:hasAffiliation ns83:JVR191047 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191047 ;
    ns0:inAuthorList ns150:JVR191047 .

ns12:JVR812 ns0:inAuthorList ns150:JVR812 .

ns12:JVR838 ns0:inAuthorList ns150:JVR838 .

ns12:JVR899 ns0:inAuthorList ns150:JVR899 .

ns12:jad100327 ns0:inAuthorList ns150:jad100327 .

ns176:JAD180152 ns0:inAuthorList ns150:JAD180152 .

ns139:JAD180531 ns0:inAuthorList ns150:JAD180531 .

ns30:CH170365 ns0:inAuthorList ns150:CH170365 .

ns30:CH179202 ns0:inAuthorList ns150:CH179202 .

ns30:CH189125 ns0:inAuthorList ns150:CH189125 .

ns30:CH189904 ns0:inAuthorList ns150:CH189904 .

ns30:CH199004 owl:sameAs ns2:CH2005,
        ns8:CH179201,
        ns8:CH189129,
        ns8:CH189415,
        ns8:CH1963,
        ns8:CH1964,
        ns26:CH179226,
        ns12:CH189411,
        ns30:CH179212,
        ns30:CH179216,
        ns30:CH199218,
        ns16:CH199220,
        ns52:CH170265,
        ns57:CH168110,
        ns57:CH168120,
        ns57:CH170246,
        ns60:CH189107,
        ns60:CH189905,
        ns60:CH199009,
        ns33:CH189309 ;
    ns0:fullName "L. Prantl" ;
    ns0:hasAffiliation ns63:CH199004 ;
    ns0:hasArticle ns1:ch-v71-i4-CH199004 ;
    ns0:inAuthorList ns150:CH199004 .

ns30:CH2004 ns0:inAuthorList ns150:CH2004 .

ns30:IFS151031 ns0:inAuthorList ns150:IFS151031 .

ns30:IFS181922 owl:sameAs ns8:IFS181153,
        ns12:IFS172009,
        ns12:INF1217 ;
    ns0:fullName "Tahir Mahmood" ;
    ns0:hasAffiliation ns64:IFS181922 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181922 ;
    ns0:inAuthorList ns150:IFS181922 .

ns30:IFS182919 owl:sameAs ns2:IFS181767 ;
    ns0:fullName "Muhammad Aslam" ;
    ns0:hasAffiliation ns63:IFS182919 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS182919 ;
    ns0:inAuthorList ns150:IFS182919 .

ns30:INF1215 ns0:inAuthorList ns150:INF1215 .

ns30:JAD111631 ns0:inAuthorList ns150:JAD111631 .

ns30:JAD161275 ns0:inAuthorList ns150:JAD161275 .

ns30:JVR809 ns0:inAuthorList ns150:JVR809 .

ns30:JVR816 ns0:inAuthorList ns150:JVR816 .

ns30:JVR891 ns0:inAuthorList ns150:JVR891 .

ns30:WOR2206 ns0:inAuthorList ns150:WOR2206 .

ns30:jad100174 ns0:inAuthorList ns150:jad100174 .

ns30:jad100666 ns0:inAuthorList ns150:jad100666 .

<http://ld.iospress.nl/rdf/contributor/Author:38.ID:JAD150883> ns0:inAuthorList ns150:JAD150883 .

ns5:CH168116 ns0:inAuthorList ns150:CH168116 .

ns5:CH179106 ns0:inAuthorList ns150:CH179106 .

ns5:IFS18993 ns0:inAuthorList ns150:IFS18993 .

ns5:JAD101512 ns0:inAuthorList ns150:JAD101512 .

ns5:JAD121369 ns0:inAuthorList ns150:JAD121369 .

ns5:JAD130971 ns0:inAuthorList ns150:JAD130971 .

ns5:JAD131265 ns0:inAuthorList ns150:JAD131265 .

ns5:JAD170050 ns0:inAuthorList ns150:JAD170050 .

ns5:JAD170265 ns0:inAuthorList ns150:JAD170265 .

ns5:JAD170534 ns0:inAuthorList ns150:JAD170534 .

ns5:JAD179938 ns0:inAuthorList ns150:JAD179938 .

ns5:JAD190197 owl:sameAs ns8:JAD141626,
        ns12:JAD132762,
        ns52:JAD181039,
        ns52:jad00733 ;
    ns0:fullName "George Perry" ;
    ns0:hasAffiliation ns71:JAD190197 ;
    ns0:hasArticle ns1:jad-v69-i3-JAD190197 ;
    ns0:inAuthorList ns150:JAD190197 .

ns5:JVR811 ns0:inAuthorList ns150:JVR811 .

ns5:jad00147 ns0:inAuthorList ns150:jad00147 .

ns5:jad00325 ns0:inAuthorList ns150:jad00325 .

ns5:jad00866 ns0:inAuthorList ns150:jad00866 .

ns16:CH168100 ns0:inAuthorList ns150:CH168100 .

ns16:CH168107 ns0:inAuthorList ns150:CH168107 .

ns16:CH168114 ns0:inAuthorList ns150:CH168114 .

ns16:CH179227 ns0:inAuthorList ns150:CH179227 .

ns16:CH189319 ns0:inAuthorList ns150:CH189319 .

ns16:CH189407 ns0:inAuthorList ns150:CH189407 .

ns16:CH189418 ns0:inAuthorList ns150:CH189418 .

ns16:JAD101977 ns0:inAuthorList ns150:JAD101977 .

ns16:JAD122026 ns0:inAuthorList ns150:JAD122026 .

ns16:JAD122122 ns0:inAuthorList ns150:JAD122122 .

ns16:JAD130296 ns0:inAuthorList ns150:JAD130296 .

ns16:JAD131901 ns0:inAuthorList ns150:JAD131901 .

ns16:JAD150471 ns0:inAuthorList ns150:JAD150471 .

ns16:JAD150619 ns0:inAuthorList ns150:JAD150619 .

ns16:JAD170407 ns0:inAuthorList ns150:JAD170407 .

ns16:JAD170409 ns0:inAuthorList ns150:JAD170409 .

ns16:JAD180099 ns0:inAuthorList ns150:JAD180099 .

ns16:JAD190187 owl:sameAs ns2:JAD170773,
        ns2:jad01177,
        ns8:JAD129035,
        ns40:JAD120787,
        ns40:JAD180025,
        ns28:JAD120508,
        ns130:JAD150167,
        ns12:JAD101959,
        ns12:JAD150525,
        ns5:JAD130035,
        ns5:JAD160573,
        ns5:JAD170368,
        ns5:jad091012,
        ns5:jad100207,
        ns16:JAD111361,
        ns16:JAD161114,
        ns16:jad00125,
        ns52:JAD142025,
        ns52:JAD170226,
        ns52:JAD170950,
        ns57:JAD120019,
        ns57:JAD140339,
        ns57:JAD160195,
        ns57:JAD160528,
        ns57:JAD161146,
        ns57:JAD170402,
        ns60:JAD150897,
        ns60:JAD161126 ;
    ns0:fullName "Kaj Blennow" ;
    ns0:hasAffiliation ns21:JAD190187,
        ns22:JAD190187 ;
    ns0:hasArticle ns1:jad-v69-i4-JAD190187 ;
    ns0:inAuthorList ns150:JAD190187 .

ns16:jad00079 ns0:inAuthorList ns150:jad00079 .

ns16:jad00838 ns0:inAuthorList ns150:jad00838 .

ns16:jad091450 ns0:inAuthorList ns150:jad091450 .

ns52:CH199005 owl:sameAs ns12:CH2028,
        ns30:CH168033 ;
    ns0:fullName "Andreas Lendlein" ;
    ns0:hasAffiliation ns200:CH199005,
        ns101:CH199005,
        ns55:CH199005,
        ns199:CH199005 ;
    ns0:hasArticle ns1:ch-v71-i4-CH199005 ;
    ns0:inAuthorList ns150:CH199005 .

ns52:JAD140186 ns0:inAuthorList ns150:JAD140186 .

ns52:JAD140846 ns0:inAuthorList ns150:JAD140846 .

ns52:JAD160633 ns0:inAuthorList ns150:JAD160633 .

ns52:JAD170784 ns0:inAuthorList ns150:JAD170784 .

ns52:JAD170854 ns0:inAuthorList ns150:JAD170854 .

ns52:JAD180023 ns0:inAuthorList ns150:JAD180023 .

ns52:JAD180375 ns0:inAuthorList ns150:JAD180375 .

ns52:JAD180604 ns0:inAuthorList ns150:JAD180604 .

ns52:JVR914 ns0:inAuthorList ns150:JVR914 .

ns52:jad01155 ns0:inAuthorList ns150:jad01155 .

ns57:ADR170051 ns0:inAuthorList ns150:ADR170051 .

ns57:CH189906 ns0:inAuthorList ns150:CH189906 .

ns57:JAD131481 ns0:inAuthorList ns150:JAD131481 .

ns57:JAD132156 ns0:inAuthorList ns150:JAD132156 .

ns57:JAD160645 ns0:inAuthorList ns150:JAD160645 .

ns57:JAD170880 ns0:inAuthorList ns150:JAD170880 .

ns57:JAD170894 ns0:inAuthorList ns150:JAD170894 .

ns57:JAD170999 ns0:inAuthorList ns150:JAD170999 .

ns57:JHD160197 ns0:inAuthorList ns150:JHD160197 .

ns57:JHD180325 ns0:inAuthorList ns150:JHD180325 .

ns57:JVR930 ns0:inAuthorList ns150:JVR930 .

ns57:XST579 ns0:inAuthorList ns150:XST579 .

ns57:jad00309 ns0:inAuthorList ns150:jad00309 .

ns57:jad00418 ns0:inAuthorList ns150:jad00418 .

ns57:jad01021 ns0:inAuthorList ns150:jad01021 .

ns60:CH179210 ns0:inAuthorList ns150:CH179210 .

ns60:JAD141260 ns0:inAuthorList ns150:JAD141260 .

ns60:JAD160148 ns0:inAuthorList ns150:JAD160148 .

ns60:JAD170502 ns0:inAuthorList ns150:JAD170502 .

ns60:JAD170880 ns0:inAuthorList ns150:JAD170880 .

ns60:JAD181049 ns0:inAuthorList ns150:JAD181049 .

ns60:JAD190524 owl:sameAs ns40:JAD141314,
        ns60:JAD150537 ;
    ns0:fullName "Perminder Sachdev" ;
    ns0:hasAffiliation ns77:JAD190524,
        ns216:JAD190524 ;
    ns0:hasArticle ns1:jad-v72-i3-JAD190524 ;
    ns0:inAuthorList ns150:JAD190524 .

ns33:CH189315 ns0:inAuthorList ns150:CH189315 .

ns33:CH2001 ns0:inAuthorList ns150:CH2001 .

ns33:JAD141266 ns0:inAuthorList ns150:JAD141266 .

ns33:JAD160116 ns0:inAuthorList ns150:JAD160116 .

ns33:JHD170284 ns0:inAuthorList ns150:JHD170284 .

ns1:bme-v30-i4-BME191060 ns0:hasKeywords "Hydroxyapatite"@en,
        "cell differentiation"@en,
        "cell proliferation"@en,
        "chondrogenic cell"@en,
        "surface topography"@en ;
    ns0:hasPubAbstract "BACKGROUND: The scaffold for head and neck reconstruction needs mechanical strength to maintain specific forms. Hydroxyapatite (HA) enhances the mechanical strength of hydrogel and is routinely used for cartilage regeneration. However, there is a demand for hydroxyapatite that controls chondrogenic cell behavior.   OBJECTIVE: Our aim was to regulate HA morphology through a hydrothermal process using organic acid and enhance chondrocyte proliferation and differentiation using shaped-regulated HA.   METHODS: HA was synthesized from dodecanedioic acid (DD:HA) and oleic acid (OA:HA) by a hydrothermal method and then coated onto glass plates. Surface properties of the samples were compared by various techniques. Surface roughness and contact angles were calculated. Proliferation and differentiation of chondrogenic cells were measured by MTT assays and Alcian Blue staining, respectively, after various incubation periods.   RESULTS: The morphological structures of DD:HA and OA:HA were different; however, the crystallinity and chemical structures were similar. Surface roughness and hydrophilic behavior were higher on DD:HA. DD:HA enhanced chondrogenic cell proliferation over time. The differentiation of ATDC5 cells was also increased on the DD:HA surface compared with those in other groups.   CONCLUSIONS: DD:HA enhanced cell viability to a greater extent than OA:HA did, indicating its excellent potential as an inorganic material compatible with chondrocyte regeneration."@en ;
    ns0:hasPubTitle "Plate-like hydroxyapatite synthesized from dodecanedioic acid enhances chondrogenic cell proliferation"@en .

ns1:ch-v72-i3-CH180545 ns0:hasKeywords "Biopsy"@en,
        "TIRADS"@en,
        "Thyroid ultrasound"@en,
        "contrast-enhanced ultrasound"@en,
        "nodule size"@en,
        "thyroid malignancy"@en ;
    ns0:hasPubAbstract "OBJECTIVE: This study aimed to evaluate the impact of thyroid nodule sizes on the diagnostic performance of Korean thyroid imaging reporting and data system (TIRADS) and contrast-enhanced ultrasound (CEUS).   METHODS: In total, 308 consecutive patients with 382 thyroid nodules underwent US-guided FNA or surgery were included in this retrospective study. The nodule size was classified into 3 categories: ≤10 mm (group A), 10–20 mm (group B), and ≥20 mm (group C). We compared the risk of malignancy in each subgroup, categorized according to the TIRADS and CEUS patterns.   RESULTS: In group A, the differences in diagnostic value between TIRADS and CEUS were significant (AUC: 0.804 vs 0.733, P = 0.028, sensitivity: 81.8% vs 72.7%, P = 0.013, specificity: 88.9% vs 79.4%, P = 0.011). In group B, the AUC (0.897), sensitivity (88.1%) and specificity (91.9%) of CEUS were highest. In group C, the specificity of CEUS was significantly higher compared with TIRADS classification (90.8% vs 82.9%, P = 0.023), while the sensitivity and AUC showed no significant difference between the two models (84.2% vs 81.5%, P > 0.406, 0.848 vs 0.820, P = 0.545).   CONCLUSIONS: Nodule size influences the diagnostic accuracy of the two methods. TIRADS have best value in nodules ≤10 mm, while CEUS perform best for differentiating lesions >10 mm, especially in lesions ≥20 mm."@en ;
    ns0:hasPubTitle "Impact of thyroid nodule sizes on the diagnostic performance of Korean thyroid imaging reporting and data system and contrast-enhanced ultrasound"@en .

ns1:ch-v72-i4-CH180528 ns0:hasKeywords "Left atrium"@en,
        "dysfunction"@en,
        "magnetocardiography"@en,
        "paroxysmal atrial fibrillation"@en ;
    ns0:hasPubAbstract "BACKGROUND: Magnetocardiography (MCG) is a non-invasive technique and to characterize the magnetic field, a pseudo-current conversion was used. The role of MCG in detecting left atrial (LA) dysfunction in patients with paroxysmal atrial fibrillation (PAF) is unknown.   OBJECTIVE: The aim of this study was to evaluate LA function using MCG in patients with PAF and healthy subjects, to identify possible indices to diagnose PAF.   METHODS: We enrolled a total of 70 subjects including 26 healthy volunteers (group 1) and 22 marathon runners (group 2) who did not exhibit any cardiac abnormalities, and 22 patients with PAF (group 3) which was documented by electrocardiography (ECG). Spatiotemporal activation graph (STAG) in base-apex and left-right direction was reconstructed. The maximum value of LA pseudo-current under rest and peak exercise were measured between the end of the P wave and beginning of the Q wave.   RESULTS: LA pseudo-current increase at peak exercise in PAF patients was significantly lower than in healthy volunteers and marathon runners (0.4±0.3 pT in group 3 vs. 0.8±0.3 pT in group 1 vs. 1.1±0.5 pT in group 2, p < 0.001). PAF patients had less pseudo-current increase in STAG at peak exercise than healthy volunteers and marathon runners (46% of 26 PAF patients, 81% of 22 healthy subjects vs. 81% of 22 marathon runners, p = 0.002). Sensitivity, specificity, and the area under the receiver-operator characteristics curve of LA pseudo-current increase at peak exercise for differentiating PAF patients from healthy subjects were 77%, 92%, and 0.896.   CONCLUSIONS: MCG can provide important non-invasive information for detecting LA dysfunction in PAF patients. Therefore, MCG may help in differentiating PAF patients from healthy subjects."@en ;
    ns0:hasPubTitle "Magnetocardiography detects left atrial dysfunction in paroxysmal atrial fibrillation"@en .

ns1:ch-v73-i1-CH199205 ns0:hasKeywords "Mesenchymal stem cells"@en,
        "cell density"@en,
        "laminin-5"@en,
        "osteogenesis"@en,
        "roughness"@en ;
    ns0:hasPubAbstract "Laminin-5 (Ln-5), an important extracellular matrix (ECM) protein, plays a critical role in regulating the growth and differentiation of mesodermal tissues, including bone. Ln-5 can be secreted by the mesenchymal stem cells (MSCs), and Ln-5 promotes MSCs osteogenic differentiation. It has been demonstrated that a substrate’s surface topography could regulate MSC secretion and differentiation. A better understanding of the mechanism of how Ln-5 and surface roughness regulate MSC osteogenic differentiation would guide the design of surface topography and coatings of orthopedic implants and cell culture substrates. However, few studies have investigated the relationship between surface roughness and the secretion of Ln-5 in MSC osteogenic differentiation. Whether substrate surface topography regulates MSC differentiation via regulating Ln-5 secretion and how surface topography contributes to the secretion of Ln-5 are still not known. In this study, the influence of microscale roughness at different levels (R0, R1 and R2) on the secretion of Ln-5 of human bone marrow MSCs (hBMSCs) and subsequent osteogenic differentiation were examined. hBMSCs spreading, distribution and morphology were greatly affected by different roughness levels. A significantly higher level of Ln-5 secretion was detected on R2, which correlated to the local cell density regulated by the rough surface. Ln-5 binding integrins (α2 and α3) were strongly activated on R2. In addition, the results from hBMSCs on R0 inserts with different cell densities further confirmed that local cell density regulated Ln-5 secretion and cell surface integrin activation. In addition, the mineralization level of MSCs on R2 was remarkably higher than that on R0 and R1. These results suggest that hBMSC osteogenic differentiation level on R2 roughness was enhanced via increased Ln-5 secretion that was attributed to rough surface regulated local cell density. Thus, the microroughness could serve as effective topographical stimulus in cell culture devices and bone implant materials."@en ;
    ns0:hasPubTitle "Microscale roughness regulates laminin-5 secretion of bone marrow mesenchymal stem cells"@en .

ns1:ch-v73-i1-CH199220 ns0:hasKeywords "LVA"@en,
        "Lymphedema"@en,
        "augmented reality"@en,
        "indocyanine green (ICG)"@en,
        "lymph node transplantation"@en,
        "lymph vessel transplantation"@en ;
    ns0:hasPubAbstract "BACKGROUND: A physiological and minimal invasive form of surgery with minimal risk to treat lymphedemas is the so-called supermicrosurgical lymphovenous anastomosis (LVA) where a lymph vessel is connected with a venule.   METHODS: 30 patients (between 2018 and 2019) with secondary upper extremity lymphedema refractory to conservative therapy (manual lymph drainage and compression therapy were operated using the “simplified lymphovenous anastomosis” method). For the assessment of lymphatic supermicrosurgery, an operating microscope in which a near-infrared illumination system is integrated (Leica M530 OHX with glow technology ULT530, Leica Microsystems) and the IC-FlowTM Imaging System(Diagnostic Green)/Visionsense System (Medtronic) together with a ZEISS S8 microscope was used. Augmented reality intraoperative indocyanin green (ICG) lymphography-navigated modified “simplified lymphovenous anastomosis” were performed on the Leica microscope. All patients were informed about Off-label-use of ICG lymphography.   RESULTS: 57 LVAs were performed with modified “simplified lymphovenous anastomosis” lymphography-guidance on 30 upper extremities. All patients showed good patency after lymphovenous anastomosis.   CONCLUSIONS: Supermicrosurgery in the case of LVA is minimally invasive, highly effective, and shows a very low complication rate. The surgeon/equipment-related factors restrict the pratice of LVA, and its effectiveness limited by technical constraints."@en ;
    ns0:hasPubTitle "Augmented reality of indocyanine green fluorescence in simplified lymphovenous anastomosis in lymphatic surgery"@en .

ns1:ch-v73-i1-CH199222 ns0:hasKeywords "Prostate cancer"@en,
        "contrast enhanced ultrasound"@en,
        "follow up"@en,
        "high intensity focused ultrasound therapy"@en,
        "image fusion"@en ;
    ns0:hasPubAbstract "INTRODUCTION: Focal therapy (FT) of the prostate for low risk prostate cancer (PCa) is an alternative to traditional definite treatment options like external beam radiotherapy or radical prostatectomy. However, follow up after FT is still challenging and is subject to current studies. Significance of imaging after FT such as multiparametric MRI (mpMRI) is currently not well established. In this study, we aimed to evaluate the efficacy of alternative imaging during the follow up of low risk PCa treated with focal HIFU therapy using CEUS and image fusion.   MATERIALS AND METHODS: Retrospective single arm study in patients with uni- or bilateral, low or intermediate risk prostate cancer treated with HIFU at our institution between October 2016 and January 2018. CEUS in combination with image fusion using an axial T2-weighted MRI sequence was performed during follow up 3, 6, 9 and 12 months after the therapy.   RESULTS: 4 consecutive patients with Gleason score (GS) 6 and 4 patients with GS 7a prostate cancer were included in the study. Hemiablation was performed in 7 patients with unilateral tumor. One patient underwent whole gland treatment due to histological proven bilateral PCa. Mean patient age at time of therapy was 70.3 (54–83) years and mean Prostate-specific antigen (PSA) level prior treatment was 7.8 ng/ml (2.1–14.4), after 3 months mean PSA level was 3.9 ng/ml (0.1–7.2), after 6 months 3.5 ng/ml (0.2–6.0), after 9 months 3.1 ng/ml (0.2–6.8) and 3.3 ng/ml (0.2–6.1) after 12 months. CEUS showed no signs of microvascularisation after 3, 6, 9 and 12 months in the ablated zone. 3 months posttreatment the necrotic tissue was still visible in the B-mode scan, although with no signs of vascularization performing CEUS. After 6 months the ablated side of the prostate was almost completely atrophic. And after 9 months the necrotic tissue was completely resolved. Between 9 and 12 months no changes in microvascularisation and perfusion could be shown.   CONCLUSIONS: MpMRI/CEUS image fusion is a cost-effective and feasible technique to monitor the perfusion of the ablation zone after focal therapy of the prostate."@en ;
    ns0:hasPubTitle "Follow-up after focal therapy of the prostate with high intensity focused ultrasound (HIFU) using contrast enhanced ultrasound (CEUS) in combination with MRI image fusion"@en .

ns1:hab-v27-i4-HAB190375 ns0:hasKeywords "Haematological parameters"@en,
        "Nigeria"@en,
        "Sokoto"@en,
        "diabetic patients"@en,
        "manganese"@en,
        "specialist hospital"@en,
        "zinc levels"@en ;
    ns0:hasPubAbstract "BACKGROUND:  World Health Organization statistics identifies that there are about 150 million people with diabetes mellitus worldwide and suggest that this figure may double by 2025.   OBJECTIVE:  This research was conducted to determine the status of full blood count, zinc and manganese levels among Diabetic patients attending Specialist Hospital, Sokoto.   METHODS:  The participants were divided into two groups; 58 diabetic subjects and 29 non-diabetic controls. Five milliliters of blood were collected into EDTA and plain containers for full blood count, serum zinc and manganese analysis. The FBC investigation was carried out using automated Mythic Haematology analyzer (Orphee, Switzerland) while Zn and Mn investigations were carried out using Atomic Absorption Spectrometry (AAS). The FBC, Zn and Mn status of both control and subjects were compared statistically.   RESULTS:  The results obtained in this study showed a significant increase in RBC, PCV, Hb, Basophils, Eosinophil, Lymphocyte count and Manganese levels of diabetic subjects (p⩽ 0.05) when compared with controls. There was no statistically significant difference in the other FBC parameters and Zinc levels between diabetic subjects and non-diabetic controls (p> 0.05). There was a statistically significant difference in the Hb, PCV and lymphocyte of diabetic patients based on gender (p< 0.05). FBC, Manganese and Zinc have no effect based on age group, while other socio-demographic factors also have no effect on the FBC, Manganese and Zinc parameters of diabetic patients. The study also showed no statistical difference in the FBC, Manganese and Zinc of smokers and non-smokers (p> 0.05, respectively). In conclusion, this research shows that some haematological parameters (RBC count, Basophils, Eosinophil, Lymphocyte, Hb and Manganese) of the diabetic patients are significantly higher compared to non-diabetic controls. Marital status had a significant effect on the Hb, PCV and Lymphocyte of the diabetic patients (p< 0.05). The age group had no significant effect on the Hb, PCV and Lymphocyte of diabetic subjects (p> 0.05).   CONCLUSIONS  There is need to routinely monitor the full blood count, zinc and manganese levels among diabetic subjects in the area to optimize the care offered to these patients."@en ;
    ns0:hasPubTitle "Some haematological parameters, manganese and zinc levels among diabetic patients of African descent attending Specialist Hospital Sokoto, Nigeria"@en .

ns1:hab-v27-iS1-HAB190363 ns0:hasKeywords "Ethiopia"@en,
        "Prevalence"@en,
        "emergency department"@en,
        "health institutes"@en,
        "magnitude"@en,
        "pattern"@en,
        "trauma"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Trauma is one of the important public health problems that causes significant economic and social crisis with more than 10% of all disease cases are associated with it. We aimed to identify and describe the prevalence, patterns, magnitude and associated factors of trauma in the Emergency Department at Health Institute in Ethiopia.   METHODS:  In this systematic review, we searched for peer-reviewed and grey literature publications reporting the prevalence, pattern, magnitude and associated factors of trauma between 2000 and 2019. The documents which recruited are directly related to trauma and emergency department. In this regard, we searched databases of PubMed, Elsevier, Science directed, MEDLINE, and Google scholar by using Google as searching engine. Furthermore, publication with secondary data and not in English was excluded.   FINDINGS:  A total of 9,768 injured participants were included in the studies, of which 71.2% (6950) were males. Among the injured participants, 53.4% of cases were living in Addis Ababa followed by Gondar and Jimma with 20.3% and 11.3% cases, respectively. Severe road traffic accident, occupational injury, and surgical patients were among the major risk factors of trauma. The mortality rate of the trauma case fatality was reached about 4%. The majority of the studies (37.5%) analyzed the pattern and magnitude of trauma among patients seen at emergency outpatient department of health institutes in Ethiopia. The largest percentage of studies (62.5%) relied on systematic random sampling. Thirty eight percent of the reviewed studies were utilized retrospective approaches to address the research questions. An completed the registry forms and/or Kampla Trauma Score (KTS), which accounted for 37.5% of articles on prevalence, pattern, magnitude and associated factors of trauma in the emergency was the most commonly used strategy. The majority (75%) of the reviewed studies were used both descriptive statistics and bivarate and multivariate logistic regression for data analysis. The majority 6950 (71%) of the participants who have been included in those reviewed articles were male and 2818 (29%) were female by gender. Meanwhile, the majority 5 (62.5%) of reviewed studies had included < 1000 injured persons.   CONCLUSION:  The degree and types of injuries in different hospitals in Ethiopia was considerably high and its casualty is also under predictable. Therefore, a variety of actions including policy decision should be implemented in order to minimize the incidence of trauma at department of emergency care center in the country."@en ;
    ns0:hasPubTitle "Prevalence, pattern, magnitude and associated factors of trauma in the Emergency Department at Health Institutes in Ethiopia: A systematic review"@en .

ns1:ies-v27-i4-IES192167 ns0:hasKeywords "Different whole-body-vibration frequencies"@en,
        "flexibility"@en,
        "physical performance"@en ;
    ns0:hasPubAbstract "BACKGROUND:  Effects of whole-body-vibration (WBV) training have been claimed to depend on individual characteristics and vibration frequency; however, there have not been any studies focusing on effects of different WBV frequencies on flexibility, jump performance, and dynamic balance ability in the same group.   METHODS:  Twenty healthy men participants were randomly assigned to three conditions [0 Hz, 25 Hz, 40 Hz] prior to the study. They stood barefoot on the non-dominant leg and performed WBV of 5 sets × 30 seconds. In pre- and post-WBV in each condition, the participants measured ankle dorsiflexion angle; single leg squat jump (SLSJ) height; and dynamic postural stability index (DPSI), anterior-posterior stability index (APSI), medial-lateral stability index (MLSI), and vertical stability index (VSI).   RESULTS:  Ankle dorsiflexion angle at 25 and 40 Hz and SLSJ height at 25 Hz significantly increased after WBV (p< 0.01). DPSI and APSI at 25 Hz and 40 Hz significantly decreased, except VSI, which was significant only at 25 Hz (p< 0.05).   CONCLUSIONS:  The acute effects of exposure to WBV on flexibility, jump performance, and dynamic balance ability differ by the selected vibration frequencies."@en ;
    ns0:hasPubTitle "The effects of two different whole-body-vibration frequencies on ankle dorsiflexion angle, vertical jump height, and postural stability after landing"@en .

ns1:ifs-v36-i6-IFS181502 ns0:hasKeywords "Rough set"@en,
        "incomplete information"@en,
        "preference relation"@en,
        "soft set"@en ;
    ns0:hasPubAbstract "The present paper aims to initiate the study of multi attribute group decision making in the presence of incomplete multi attribute and incomplete multi decision while making a decision with preferences in an incomplete information system. The concept of soft preference relation and soft dominance relation corresponding to decision attribute in incomplete multi criteria and incomplete multi decision information system is also presented. The discernibility matrix and discernibility function approach is proposed for decision attribute reduction to find all the reducts in an incomplete information system. A new technique of ranking the feasible alternative is proposed. Using the idea of soft dominance based rough sets, several uncertainty measures, such as approximate precision, rough degree, approximate quality and their mutual relationships are discussed in an incomplete information system. Finally the validity of these concepts are proved by applying these in solving multi-agent conflict analysis problems."@en ;
    ns0:hasPubTitle "Soft ordered approximations and incomplete information system"@en .

ns1:ifs-v36-i6-IFS181799 ns0:hasKeywords "Optimal diagnostic policy"@en,
        "Q-learning"@en,
        "imperfect tests"@en,
        "reinforcement learning"@en ;
    ns0:hasPubAbstract "As an efficient way for fault diagnosis, diagnostic policy is to build a test sequence to achieve specified fault diagnosis and accurate failure location with minimal test cost. Traditional diagnostic policy building methods are not suitable for unreliable and imperfect tests due to the uncertainty caused by various outside or inside interference in the real-world systems extensively. Therefore, in this paper, a novel method for diagnostic policy based on Q-learning is proposed to get the optimal policy of long run in the realistic systems. We construct the diagnostic policy model based on the framework of RL. Then the probability of false alarm or misdetection can be learnt from the environment not partial statistic data through Q-learning algorithm. And the optimal diagnostic policy with imperfect tests is obtained with high efficiency, also considering the test cost and information gain. The proposed method is illustrated by a real-world application. The effectiveness and feasibility of this method are also verified by comparison results."@en ;
    ns0:hasPubTitle "A Q-learning based method of optimal fault diagnostic policy with imperfect tests"@en .

ns1:jad-v69-i3-JAD190154 ns0:hasKeywords "Alzheimer disease"@en,
        "amyloid-β"@en,
        "apolipoproteins E"@en,
        "body mass index"@en,
        "obesity"@en,
        "positron emission tomography"@en ;
    ns0:hasPubAbstract "Background: Both low and high body mass index (BMI) have been associated with an increased risk of dementia, including that caused by Alzheimer’s disease (AD). Specifically, high middle-age BMI or a low late-age BMI has been considered a predictor for the development of AD dementia. Less studied is the relationship between BMI and AD pathology.   Objective: We explored the association between BMI and cortical amyloid-β (Aβ) burden in cognitively normal participants that were either in mid-life (45–60 years) or late-life (>60).   Methods: We analyzed cross-sectional baseline data from the Knight Alzheimer Disease Research Center (ADRC) at Washington University. Aβ pathology was measured in 373 individuals with Aβ PET imaging and was quantified using Centiloid units. We split the cohort into mid- and late-life groups for analyses (n = 96 and n = 277, respectively). We ran general linear regression models to predict Aβ levels from BMI while controlling for age, sex, years of education, and APOE4 status. Analyses were also conducted to test the interaction between BMI and APOE4 genotype and between BMI and sex.   Results: Higher BMI was associated with lower cortical Aβ burden in late-life (β= –0.81, p = 0.0066), but no relationship was found in mid-life (β= 0.04, p > 0.5). The BMI×APOE4+ and BMI×male interaction terms were not significant in the mid-life (β= 0.28, p = 0.41; β= 0.64, p = 0.13) or the late-life (β= 0.17, p > 0.5; β= 0.50, p = 0.43) groups.   Conclusion: Higher late-life BMI is associated with lower cortical Aβ burden in cognitively normal individuals."@en ;
    ns0:hasPubTitle "Higher Body Mass Index Is Associated with Lower Cortical Amyloid-β Burden in Cognitively Normal Individuals in Late-Life"@en .

ns1:jad-v69-i4-JAD181095 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Parkinson’s disease"@en,
        "automobile driving"@en,
        "cognitive decline"@en,
        "dementia with Lewy bodies"@en,
        "frontotemporal dementia"@en,
        "neurodegenerative diseases"@en,
        "vascular dementia"@en ;
    ns0:hasPubAbstract "Background/Objective: Neurodegenerative disorders impact fitness to drive of older drivers, but on-road driving studies investigating patients with different neurodegenerative disorders are scarce. A variety of driving errors have been reported in patients with Alzheimer’s disease (AD), but it is unclear which types of driving errors occur most frequently. Moreover, patients with other neurodegenerative disorders than AD typically present with different symptoms and impairments, therefore different driving errors may be expected.   Methods: Patients with AD (n = 80), patients with other neurodegenerative disorders with cognitive decline (i.e., vascular dementia, frontotemporal dementia, dementia with Lewy bodies/Parkinson’s disease, n = 59), and healthy older drivers (n = 45) participated in a fitness-to-drive assessment study including on-road driving.   Results: Patients with AD performed significantly worse than healthy older drivers on operational, tactical, visual, and global aspects of on-road driving. In patients with AD, on-road measures were significantly associated with ‘off-road’ measures. Patients with neurodegenerative disorders other than AD showed large overlap in the types of driving errors. Several driving errors were identified that appear to be characteristic for patients with particular neurodegenerative disorders.   Conclusion: Patients from each group of neurodegenerative disorders commonly display tactical driving errors regarding lane positioning, slow driving, observation of the blind spot, and scanning behavior. Several other tactical and operational driving errors, including not communicating with cyclists and unsteady steering, were more frequently observed in patients with non-AD neurodegenerative disorders. These findings have implications for on-road and ‘off-road’ fitness-to-drive assessments for patients with neurodegenerative disorders with cognitive decline."@en ;
    ns0:hasPubTitle "Driving Difficulties Among Patients with Alzheimer’s Disease and Other Neurodegenerative Disorders"@en .

ns1:jad-v70-i1-JAD190128 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cognitive impairment"@en,
        "fractional amplitude of low frequency fluctuations"@en,
        "functional magnetic resonance imaging"@en,
        "sildenafil."@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is the most common cause of neurodegenerative cognitive impairment, defined by abnormal accumulations of amyloid-β and tau. Approaches directly targeting these proteins have not resulted in a disease modifying therapy. Neurovascular unit dysfunction is a feature of AD offering an alternative target for intervention. Sildenafil, a phosphodiesterase 5 (PDE5) inhibitor, improves cognitive functioning in mouse models of AD. Recent work in AD patients has demonstrated increased cerebral blood flow, as well as brain oxygen utilization after a single dose of sildenafil. Its effect on nitric oxide-cGMP signaling may have downstream effects on neuroplasticity, amyloid-β processing, and improved neurovascular unit function. Fractional amplitude of low frequency fluctuations (fALFF) assesses spontaneous neural activity via resting state fMRI BOLD signal (0.01–0.08 or 0.10 Hz). In AD, other assessments have revealed increased fALFF in hippocampi and parahippocampal gyri. Here, we examined the effects of a single dose of sildenafil on fALFF in a cohort of 10 AD patients. We found a decrease (p < 0.03, α= 0.05) in fALFF an hour after sildenafil administration in the right hippocampus. Additionally, cerebral vascular reactivity in response to carbon dioxide inhalation, a measure of neural vascular reserve previously collected on most of these participants, was not significantly correlated with this decrease, implying that change in fALFF may not have been solely due to altered vascular reactivity to CO2. We demonstrate that in patients with AD, hippocampal fALFF decreases in response to sildenafil, suggesting a normalization. These findings support further investigation into the effects of sildenafil in AD."@en ;
    ns0:hasPubTitle "A Pilot Study of Changes in Medial Temporal Lobe Fractional Amplitude of Low Frequency Fluctuations after Sildenafil Administration in Patients with Alzheimer’s Disease"@en .

ns1:jad-v70-i1-JAD190322 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Down syndrome"@en,
        "amyloid"@en,
        "biomarkers"@en,
        "blood"@en,
        "neurofilament light"@en,
        "plasma"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Background: Adults with Down syndrome (DS) are at very high risk for Alzheimer’s disease (AD). Neurofilament light (NF-L) has emerged as a potential blood-based biomarker of neurodegeneration due to AD.   Objective: To understand the relationship between plasma NF-L with age, brain amyloid, and tau pathology, neurodegeneration as well as cognitive and functional performance.   Methods: We analyzed imaging data as well as cognitive measures in relation to plasma NF-L in adults with DS, ages 30 to 60 who were enrolled in the Down Syndrome Biomarker Initiative.   Results: We found significant correlations between NF-L plasma concentrations and amyloid pathology (r = 0.73, p = 0.007, pa = 0.041) and significant inverse correlations with regional glucose metabolism in 5 of 6 regions examined, which were Anterior cingulate (r = –0.55, p = 0.067, pa = 0.067), Posterior cingulate r = –0.90, p < 0.001, pa < 0.001), Lateral Temporal (r = –0.78, p = 0.004, pa = 0.012), Frontal cortex (r = –0.90, p < 0.001, p pa < 0.001), Parietal cortex (r = –0.82, p = 0.002, pa = 0.008), Precuneus (r = –0.73, pa = 0.010, pa = 0.020), and with hippocampal volume (r = –0.52, p = 0.084, pa = 0.084); and an inverse correlation with direct measures of cognition: CAMCOG (r = –0.66 p = 0.022, pa = 0.066) and positive correlation with CANTAB Paired Associates Learning (PAL) error rate (r = 0.68, p = 0.015, pa = 0.060). Finally, we found inverse relationships with informant-based functional measures (r = –0.57, p = 0.059, pa = 0.084) and OMQ-PF (r = –0.74, p = 0.008, pa = 0.041).   Conclusion: Plasma NF-L is associated with progressive neurodegeneration as well as with declines in cognitive and functional measures in adults with DS."@en ;
    ns0:hasPubTitle "Plasma Neurofilament Light and Alzheimer’s Disease Biomarkers in Down Syndrome: Results from the Down Syndrome Biomarker Initiative (DSBI)"@en .

ns1:jad-v70-i3-JAD190152 ns0:hasKeywords "Alzheimer’s disease"@en,
        "diffusion tensor imaging"@en,
        "optical coherence tomography"@en,
        "retrograde degeneration"@en,
        "white matter"@en ;
    ns0:hasPubAbstract "This study aims to investigate the relationship between structural changes in the retina and white matter in the brain, in early Alzheimer’s disease (AD). Twenty-three healthy controls (mean age = 63.4±7.5 years) and seventeen AD patients (mean age = 66.5±6.6 years) were recruited for this study. By combining two imaging techniques—optical coherence tomography and diffusion tensor imaging (DTI)—the association between changes in the thickness of individual retinal layers and white matter dysfunction in early AD was assessed. Retinal layers were segmented, and thickness measurements were obtained for each layer. DTI images were analyzed with a quantitative data-driven approach to evaluating whole-brain diffusion metrics, using tract-based spatial statistics. Diffusion metrics, such as fractional anisotropy, are markers for white matter integrity. Multivariate and partial correlation analyses evaluating the association between individual retinal layers thickness and diffusion metrics were performed. We found that axial diffusivity, indexing axonal integrity, was significantly reduced in AD (p = 0.016, Cohen’s d = 1.004) while in the retina, only a marginal trend for significance was found for the outer plexiform layer (p = 0.084, Cohen’s d = 0.688). Furthermore, a positive association was found in the AD group between fractional anisotropy and the inner nuclear layer thickness (p < 0.05, r = 0.419, corrected for multiple comparisons by controlling family-wise error rate). Our findings suggest that axonal damage in the brain dominates early on in this condition and shows an association with retinal structural integrity already at initial stages of AD. These findings are consistent with an early axonal degeneration mechanism in AD."@en ;
    ns0:hasPubTitle "Interplay Between Macular Retinal Changes and White Matter Integrity in Early Alzheimer’s Disease"@en .

ns1:jad-v70-i3-JAD190339 ns0:hasKeywords "Cognitive impairment"@en,
        "neuroimaging"@en,
        "predictors"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "Background: Stroke is a major cause of cognitive impairment and dementia. However, the underlying mechanisms beyond post-stroke cognitive impairment (PSCI) are not fully explained to date.   Objective: We studied the contribution of vascular pathology measures to PSCI, separate from and in conjunction with pathologic markers associated with Alzheimer’s disease (AD).   Methods: Data from 397 cognitively intact ischemic stroke patients were available. All patients underwent 3T MRI and evaluated for white matter hyperintensity volume (WMHV) and integrity, ischemic lesions, small vessel disease (SVD) markers and grey matter (GM), hippocampal and cerebrospinal fluid (CSF) volumes. Comprehensive cognitive tests were performed on admission and after two years. We used multiple regression to evaluate the contributions of vascular pathology measures (Framingham risk score, WMHV, and existence of SVD) and AD-associated markers (apolipoprotein E4 status and hippocampal volume).   Results: During two years follow-up, 80 participants (20.2%) developed PSCI. Low GM and cortex volume and high WMHV and CSF volume, but not the new lesion volume, predicted the development of PSCI in a dose-dependent relationship (p = 0.001). Vascular related imaging markers and risk factors predicted PSCI better than AD related markers (p < 0.001).   Conclusions: Brain structural measures, including total GM volume, WMHV, and CSF volume were independently associated with PSCI and may serve as early biomarkers for risk prediction. In our sample, vascular pathology measures contributed significantly better to PSCI prediction than markers associated with AD. The newly detected ischemic lesion has not emerged as biomarker for PSCI risk, thus maybe a part of the ongoing vascular pathology."@en ;
    ns0:hasPubTitle "Vascular and Neurodegenerative Markers for the Prediction of Post-Stroke Cognitive Impairment: Results from the TABASCO Study"@en .

ns1:jad-v70-i3-JAD190423 ns0:hasKeywords "Alzheimer’s disease"@en,
        "assistive technology"@en,
        "mild cognitive impairment"@en,
        "non-pharmacological interventions"@en,
        "patient engagement"@en,
        "remote monitoring"@en,
        "smart homes"@en ;
    ns0:hasPubAbstract "Background: Interactive smart home systems are particularly useful for people with cognitive impairment.   Objective: To investigate the long-term effects of Assistive Technology (AT) combined with tailored non-pharmacological interventions for people with cognitive impairment.   Methods: 18 participants (12 with mild cognitive impairment and 6 with Alzheimer’s disease) took part in the study that we evenly allocated in one of three groups: 1) experimental group (EG), 2) control group 1 (CG1), and 3) control group 2 (CG2). EG received the system installed at home for 4 to 12 months, during which they received tailored non-pharmacological interventions according to system observations. CG1 received tailored interventions for the same period, but only according to state-of-the-art self-reporting methods. Finally, CG2 neither had a system installation nor received interventions. All groups underwent neuropsychological assessment before and after the observational period.   Results: After several months of continuously monitoring at home and deployment of tailored interventions, the EG showed statistically significant improvement in cognitive function, compared to the CG1 and CG2. Moreover, EG participants, who received the sensor-based system, have shown improvement in domains such as sleep quality and daily activity, as measured by the multi-sensor system. In addition, the feedback collected from the participants concludes that the long-term use of the multi-sensor system by people with cognitive impairment can be both feasible and beneficial.   Conclusion: Deploying a sensor-based system at real home settings of people with cognitive limitations living alone and maintaining its use long-term is not only possible, but also beneficial for clinical decision making in order to tackle cognitive, functional, and behavioral related problems."@en ;
    ns0:hasPubTitle "Long-Term Impact of Intelligent Monitoring Technology on People with Cognitive Impairment: An Observational Study"@en .

ns1:jad-v70-i4-JAD190161 ns0:hasKeywords "Alzheimer’s disease"@en,
        "U-shape"@en,
        "amylin"@en,
        "amyloid-β peptide"@en,
        "pramlintide"@en,
        "synapse"@en,
        "tauopathy"@en ;
    ns0:hasPubAbstract "Recent studies demonstrate that peripheral amylin treatment reduces pathology in mouse models of Alzheimer’s disease (AD). However, soluble and aggregated amylin are distinct species; while amylin is a physiological neuropeptide, amylin aggregation is a pathological factor for diabetes. We thus hypothesized that because of their similarity in secondary structures, amylin antagonizes amyloid-β peptide (Aβ)-induced AD pathology in neurons with a dose-dependent pattern. To test the hypothesis, we conducted both in vitro and in vivo experiments with different doses of amylin and with its analog, pramlintide. Here we report that a high concentration of either Aβ or amylin alone induced tau phosphorylation (pTau) in primary neurons. Interestingly, with a low concentration, amylin had direct effects to reverse the Aβ-induced pTau, as well as damaged neuronal synapses and neurite disorganization. However, when the concentration was high (10.24 μM), amylin lost the effects against the Aβ-induced cellular AD pathology and, together with Aβ, worsened tauopathy in neurons. In the 5XFAD AD mouse model, daily peripheral amylin treatment with a low dose (200 μg/kg) more effectively reduced amyloid burden, and increased synapse, but with a high dose (800 μg/kg), it more effectively reduced tauopathy. Correspondingly, amylin treatment improved learning and memory in these mice. It demonstrates that amylin has a dose-dependent U-shape effect against AD pathogenesis. Within a physiological range, amylin is a neuroprotective hormone against AD in neurons; but when both Aβ and amylin concentrations are elevated, imbalance of Aβ and amylin may contribute to brain AD pathogenesis."@en ;
    ns0:hasPubTitle "Effects of Amylin Against Amyloid-β-Induced Tauopathy and Synapse Loss in Primary Neurons"@en .

ns1:jad-v70-i4-JAD190413 ns0:hasKeywords "Analgesics"@en,
        "dementia"@en,
        "elderly"@en,
        "opioid"@en,
        "pain"@en ;
    ns0:hasPubAbstract "Background: We recently reported frequent use of opioids among elderly with dementia. Discrepancies in clinical practice may in part explain the higher use of opioids in elderly with dementia, which geographical variation may be able to clarify.   Objective: To investigate geographical variation in opioid use in elderly with dementia compared to elderly without dementia.   Methods: Register-based cross-sectional study in the entire elderly (≥65 years) population of Denmark in 2015. Data included place of residence, prescriptions, and discharge diagnoses from hospital contacts. Prevalence of opioid use among elderly with (n = 36,014) and without dementia (n = 1,011,787) was compared nationwide across the five Danish regions using logistic regression analysis and for the 98 municipalities using age and sex standardization.   Results: 32.5% of elderly with dementia and 16.9% without were treated with an opioid in 2015. For home-living elderly with dementia, there was a 4-fold difference in opioid use (9.4 to 36.8%) between municipalities compared to a 1.6-fold (12.7 to 20.2%) difference for elderly without. In nursing home residents there was a 2-fold difference (dementia: 26.5 to 55.2%; no dementia: 31.8 to 60.4%). Differences between the five regions were minor.   Conclusion: Opioid use in elderly with dementia was frequent and almost twice as high compared to elderly without dementia, which may challenge patient safety. The pronounced geographical variations at municipality level, particularly among elderly with dementia, indicate differences in the approach to treatment of chronic pain in primary care. Our study suggests that more guidance on treatment of pain in elderly with dementia is needed."@en ;
    ns0:hasPubTitle "Geographical Variation in Opioid Use in Elderly Patients with Dementia: A Nationwide Study"@en .

ns1:jad-v70-i4-JAD190484 ns0:hasKeywords "3xTg-AD"@en,
        "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "immunotherapy"@en,
        "scFv"@en ;
    ns0:hasPubAbstract "The intracellular deposition of amyloid-β (Aβ) peptides has been described in the brains of both Alzheimer’s disease (AD) patients and animal models. A correlation between the intracellular amyloid burden and neurodegeneration has recently been reported in a triple-transgenic AD (3xTg-AD) murine model. In the present study, we assessed the effect of scFv-h3D6, an anti-Aβ single-chain variable fragment (scFv) derived from the antibody bapineuzumab, on amyloid pathology in 5-month-old 3xTg-AD female mice, focusing on intracellular Aβ clearance, neuronal survival, and functional abilities. We also examined neuroinflammation and the histology of peripheral organ samples to detect any adverse effects. A single intraperitoneal injection of scFv-h3D6 dramatically reduced intracellular Aβ burden in the deep layers of the cerebral cortex, pyramidal cells layer of the hippocampus, and basolateral amygdalar nucleus. The treatment prevented neuronal loss in the hippocampus and amygdala, while neither astrogliosis nor microgliosis was induced. Instead, an increase in the size of the white pulp after the treatment indicated that the spleen could be involved in the clearance mechanism. Although the treatment did not ameliorate behavioral and psychological symptoms of dementia-like symptoms, the results of cognitive testing pointed to a noticeable improvement in spatial memory. These findings indicated that the mechanism underlying the therapeutic effect of scFv-h3D6 was the clearance of intracellular Aβ, with subsequent prevention of neuronal loss and amelioration of cognitive disabilities. The treatment was safe in terms of neuroinflammation and kidney and liver function, whereas some effects on the spleen were observed."@en ;
    ns0:hasPubTitle "Treatment with scFv-h3D6 Prevented Neuronal Loss and Improved Spatial Memory in Young 3xTg-AD Mice by Reducing the Intracellular Amyloid-β Burden"@en .

ns1:jad-v70-is1-JAD180492 ns0:hasKeywords "Aging"@en,
        "cognition"@en,
        "dementia"@en,
        "education"@en,
        "gender"@en,
        "lifestyle"@en,
        "modifiable risk factors"@en,
        "prevention"@en ;
    ns0:hasPubAbstract "Background: Several modifiable risk factors for cognitive decline have been identified, but whether differences by gender and educational level exist is unclear.   Objective: The present study aims to clarify this by prospectively investigating the relationship between health and lifestyle factors and cognitive functioning in different subgroups defined by gender and educational level.   Methods: 2,347 cognitive healthy individuals (mean age = 54.8, SD = 6.8, range: 41–71; 51.8% female; 26.2% low education) from the Doetinchem Cohort Study were examined for cognitive function at baseline, and at 5- and 10-year follow-up. Health- and lifestyle factors were captured by a poly-environmental risk score labelled ‘LIfestyle for BRAin Health’ (LIBRA). This score consists of 12 modifiable risk and protective factors for cognitive decline and dementia, with higher scores indicating greater risk (range: –2.7 to +12.7). Heterogeneity in associations between LIBRA and decline in verbal memory, cognitive flexibility, and mental speed between males and females and individuals with different levels of education were assessed in linear mixed models.   Results: Overall, higher LIBRA scores predicted faster decline in verbal memory, cognitive flexibility, and mental speed over 10 years. Higher LIBRA scores were further associated with increased risk for incident cognitive impairment (one-point increase in LIBRA: HR = 1.09, 1.04–1.14, p = 0.001). In general, these effects were similar across gender and educational level.   Conclusion: A composite risk score comprising unhealthy lifestyle and relatively poor health in midlife is significantly associated with a worse course of cognition 10 years later. These associations were for the most part unrelated to gender or educational differences."@en ;
    ns0:hasPubTitle "Gender and Educational Differences in the Association between Lifestyle and Cognitive Decline over 10 Years: The Doetinchem Cohort Study"@en .

ns1:jad-v70-is1-JAD180496 ns0:hasKeywords "Alzheimer’s disease"@en,
        "hippocampus"@en,
        "microarray analysis"@en,
        "tocotrienol-rich fraction"@en,
        "transgenic mouse"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) is a progressive neurodegenerative disorder characterized by loss of memory and other cognitive abilities. AD is associated with aggregation of amyloid-β (Aβ) deposited in the hippocampal brain region. Our previous work has shown that tocotrienol rich fraction (TRF) supplementation was able to attenuate the blood oxidative status, improve behavior, and reduce fibrillary-type Aβ deposition in the hippocampus of an AD mouse model. In the present study, we investigate the effect of 6 months of TRF supplementation on transcriptome profile in the hippocampus of APPswe/PS1dE9 double transgenic mice. TRF supplementation can alleviate AD conditions by modulating several important genes in AD. Moreover, TRF supplementation attenuated the affected biological process and pathways that were upregulated in the AD mouse model. Our findings indicate that TRF supplementation can modulate hippocampal gene expression as well as biological processes that can potentially delay the progression of AD."@en ;
    ns0:hasPubTitle "Tocotrienol Rich Fraction Supplementation Modulate Brain Hippocampal Gene Expression in APPswe/PS1dE9 Alzheimer’s Disease Mouse Model"@en .

ns1:jad-v70-is1-JAD181141 ns0:hasKeywords "Cohort analysis"@en,
        "epidemiologic methods"@en,
        "incidence study"@en,
        "mild cognitive impairment"@en ;
    ns0:hasPubAbstract "Background: The transition from normal cognition to Alzheimer’s disease is considered a continuum, with amnestic mild cognitive impairment (aMCI) an intermediate clinical cognitive state. Although prior work suggests that dementia incidence rates may be declining, there is little information regarding temporal trends in aMCI incidence.   Objective: To determine whether age specific rates of aMCI have changed over sequential birth cohorts among individuals included in the population-based Einstein Aging Study (EAS) cohort. A secondary objective was to examine trends in aMCI rates among Blacks and Whites and by sex.   Methods: Age specific incidence of aMCI was examined by birth year among 1,233 individuals age 70 years and above enrolled in the population-based EAS cohort between November 1, 1993 and February 22, 2016 and who had at least one annual follow-up assessment (5,321 person years of follow-up). Poisson regression was used to determine whether there has been a change in age specific aMCI rates over sequential years of birth.   Results: No significant change in aMCI rates was identified in the overall cohort, among Blacks or Whites, or among males or females born between 1899 and 1946.   Conclusions: Despite a trend for decreased dementia incidence in the EAS cohort, rates of incident aMCI have not changed. These apparently conflicting results may indicate a delay or decrease in the rates of transition from aMCI to dementia within the cohort. However, further studies are needed to confirm whether rates of aMCI have changed in other populations, and how aMCI rates are related to secular trends in dementia risk factors."@en ;
    ns0:hasPubTitle "A Birth Cohort Analysis of Amnestic Mild Cognitive Impairment Incidence in the Einstein Aging Study (EAS) Cohort"@en .

ns1:jad-v70-is1-JAD190181 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cohort studies"@en,
        "meta-analysis"@en,
        "prevention"@en,
        "risk factor"@en,
        "vascular dementia"@en ;
    ns0:hasPubAbstract "Background: The translation of evidence on dementia risk factors into clinical advice requires careful evaluation of the methodology and scope of data from which risk estimates are obtained.   Objective: To evaluate the quantity, quality, and representativeness of evidence, we conducted a review of reviews of risk factors for Alzheimer’s disease (AD), Vascular dementia (VaD), and Any Dementia.   Methods: PubMed, Cochrane library, and the Global Index Medicus were searched to identify meta-analyses of observational studies of risk factors for AD, VaD, and Any Dementia. PROSPERO CRD42017053920.   Results: Meta-analysis data were available for 34 risk factors for AD, 26 risk factors for Any Dementia and eight for VaD. Quality of evidence varied greatly in terms of the number of contributing studies, whether data on midlife exposure was available, and consistency of measures. The most evidence was available for cardiovascular risk factors. The most geographically representative evidence (five of six global regions) was available for alcohol, physical activity, diabetes, high midlife BMI, antihypertensives, and motor function. Evidence from Australia/Oceana or Africa was limited. With the exception of diabetes, meta-analysis data were unavailable from Latin America/Caribbean. Midlife specific data were only available for cholesterol and arthritis.   Conclusion: There is a lack of midlife specific data, limited data on VaD, and a lack of geographical representation for many risk factors for dementia. The quality, quantity, and representativeness of evidence needs to be considered before recommendations are made about the relevance of risk factors in mid- or late-life or for dementia subtypes."@en ;
    ns0:hasPubTitle "A Systematic Review of Meta-Analyses that Evaluate Risk Factors for Dementia to Evaluate the Quantity, Quality, and Global Representativeness of Evidence"@en .

ns1:jad-v71-i1-JAD190344 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid"@en,
        "frontotemporal dementia"@en,
        "frontotemporal lobar degeneration"@en ;
    ns0:hasPubAbstract "To investigate amyloid-β (Aβ) in frontotemporal dementia (FTD), cerebrospinal fluid (CSF) Aβ38, Aβ40, and Aβ42 in frontotemporal lobar degeneration (FTLD; N = 18 genetically and/or pathologically confirmed and N = 8 FTD with concomitant amyotrophic lateral sclerosis) were compared with Alzheimer’s disease (AD; pathological or Pittsburgh-compound-B Positron-emission-tomography (PIB-PET) positive; N = 25) and controls (N = 24). For all the Aβ subtypes, group difference was seen and post-hoc analysis revealed lower levels in FTLD compared to controls (p≤0.05). Aβ42/40 ratio showed no difference between FTLD and controls; however, a difference was seen between AD versus FTLD (p < 0.01). This is an intriguing finding, suggesting a possible role of Aβ in FTLD pathogenesis."@en ;
    ns0:hasPubTitle "Cerebrospinal Fluid Amyloid-β Subtypes in Confirmed Frontotemporal Lobar Degeneration Cases: A Pilot Study"@en .

ns1:jad-v71-i1-JAD190610 ns0:hasKeywords "Cognitive impairment"@en,
        "Indian"@en,
        "dementia"@en,
        "epidemiology"@en,
        "population-based"@en,
        "prevalence"@en,
        "risk factors"@en ;
    ns0:hasPubAbstract "Background: Dementia is the leading cause of dependency and disability among older persons worldwide. There remains, however, limited studies on dementia rates within the Asia-Pacific region, with little data on differences across major Asian ethnic groups.   Objective: To study the prevalence of cognitive impairment (CI) and dementia in community-dwelling Indians from Singapore and to examine interethnic differences among Chinese, Malays, and Indians.   Methods: Participants (>60 years) drawn from the Indian component of the multiethnic Epidemiology of Dementia in Singapore (EDIS) study were screened using the locally validated Abbreviated Mental Test and Progressive Forgetfulness Questionnaire. Screen-positive participants underwent further detailed neuropsychological assessments. CI was classified into Cognitive impairment no dementia (CIND)-mild, CIND-moderate, and dementia.   Results: Of 961 Indian adults, 120 (12.5%) had CIND-mild, 101 (10.5%) CIND-moderate, and 12 (1.2%) dementia. The overall age-standardized prevalence of any CI was 24.6%. The prevalence of any CI increased with age (15.7% in ages 60–64 years to 30.1% in ages≥80 years), and was higher in women than men. Multivariate analysis showed that age, lower education, and hypertension were independently associated with CI. Even after demographic and cardiovascular risk factor adjustment, Indians were more likely to be cognitively impaired compared to Chinese (odds ratio [OR], 95% CI:1.37 [1.01–1.86]) but not Malays (0.89 [0.72–1.10]).   Conclusions: Among elderly Indians, the overall prevalence of any CI was 24.6%. Despite similar assessment protocols and risk factor adjustments, the prevalence of CI was higher in Indians compared to Chinese but similar to Malays. Further research is needed to unravel other factors that may underlie these ethnic differences."@en ;
    ns0:hasPubTitle "Prevalence and Risk Factors for Cognitive Impairment and Dementia in Indians: A Multiethnic Perspective from a Singaporean Study"@en .

ns1:jad-v71-i2-JAD190346 ns0:hasKeywords "Cerebral amyloid angiopathy"@en,
        "cerebral hemorrhage"@en,
        "cerebral small vessel disease"@en,
        "dementia"@en ;
    ns0:hasPubAbstract "Background and Objective: Cerebral amyloid angiopathy (CAA) accounts for the majority of lobar intracerebral hemorrhage (ICH); however, the risk factors for dementia conversion after ICH occurrence in CAA patients are unknown, especially in the long-term period after ICH. Therefore, we aimed to unravel the predictors for late post-ICH dementia (6 months after ICH event) in probable CAA patients.   Methods: From a large consecutive MRI prospective cohort of spontaneous ICH (2006–2017), we identified probable CAA patients (modified Boston criteria) without dementia 6 months post-ICH. Cognitive outcome during follow-up was determined based on the information from standardized clinical visit notes. We used Cox regression analysis to investigate the association between baseline demographic characteristics, past medical history, MRI biomarkers, and late post-ICH dementia conversion (dementia occurred after 6 months).   Results: Among 97 non-demented lobar ICH patients with probable CAA, 25 patients (25.8%) developed dementia during a median follow-up time of 2.5 years (IQR 1.5–3.8 years). Pre-existing mild cognitive impairment, increased white matter hyperintensities (WMH) burden, the presence of disseminated cortical superficial siderosis (cSS), and higher total small vessel disease score for CAA were all independent predictors for late dementia conversion.   Conclusion: In probable CAA patients presenting with lobar ICH, high WMH burden and presence of disseminated cSS are useful neuroimaging biomarkers for dementia risk stratification. These findings have implications for clinical practice and future trial design."@en ;
    ns0:hasPubTitle "Predictors for Late Post-Intracerebral Hemorrhage Dementia in Patients with Probable Cerebral Amyloid Angiopathy"@en .

ns1:jad-v71-i2-JAD190365 ns0:hasKeywords "Alzheimer’s disease"@en,
        "behavioral symptoms"@en,
        "biomarkers"@en,
        "cerebrospinal fluid"@en,
        "neuropsychiatry"@en,
        "systematic review"@en ;
    ns0:hasPubAbstract "Background: Neuropsychiatric symptoms (NPS) are common, accelerate the conversion to dementia, and are associated with increased caregiver burden in Alzheimer’s disease (AD) and mild cognitive impairment (MCI).   Objective: The aim of this study is to identify potential associations between the core cerebrospinal fluid (CSF) biomarkers (amyloid/tau) and NPS in AD/MCI.   Methods: For this systematic review, four databases, PubMed (1946–2018), Cochrane (2005–2018), EMBASE (1947–2018), and PsycINFO (1806–2018) were searched for relevant observational studies using an extensive list of keywords. English studies were selected for critical appraisal based on our inclusion/exclusion criteria. Inclusion criteria were defined as 1) at least one AD CSF biomarker has been measured; 2) at least one NPS has been assessed; and 3) analysis has been done to examine the association between core AD CSF biomarker and NPS (main outcome). Animal, postmortem, and review studies were excluded.   Results: In total, 21 studies qualified for the systematic review. The overall picture regarding the association between NPS and AD CSF biomarkers is conflicting. However, agitation/aggression was significantly and consistently related to core AD CSF biomarkers. Moreover, depression was the only NPS to occasionally be associated with lower core AD CSF pathology.   Conclusion: Our study has revealed agitation/aggression as the most consistent NPS related to core AD CSF biomarkers. Future studies are required to focus on other neglected NPS domains such as disinhibition. Moreover, why depression was the only NPS inversely associated with core AD CSF pathology remains to be elucidated. Our study also revealed a great degree of heterogeneity, hence calling for a more standardized “objective” approach for the evaluation of NPS."@en ;
    ns0:hasPubTitle "Cerebrospinal Fluid Correlates of Neuropsychiatric Symptoms in Patients with Alzheimer’s Disease/Mild Cognitive Impairment: A Systematic Review"@en .

ns1:jad-v71-i2-JAD190549 ns0:hasKeywords "Alzheimer’s disease"@en,
        "eye-tracking"@en,
        "mild cognitive impairment"@en,
        "spatial decision"@en ;
    ns0:hasPubAbstract "Background/Objective: Performances on spatial decision eye-tracking tasks are known to be impaired in patients with moderate Alzheimer’s disease (AD), but the clinical relevance of this deficit during earlier stages of AD remains unclear.   Methods: This study recruited patients with amnestic mild cognitive impairment (aMCI, prodromal AD), patients with mild AD, and age-matched controls from three French memory clinics. Participants’ ability to make spatial judgments and decisions was assessed with an eye-tracking system, and cognitive performance on conventional neuropsychological tests was evaluated.   Results: We enrolled 26 controls, 25 aMCI patients (median Mini-Mental State Exam [MMSE] 26), and 23 mild-AD patients (median MMSE 23). Patients with mild AD had higher error rates on the spatial decision task than aMCI patients and controls (32.4% versus 23.5%; p < 0.01 and 32.4% versus 22.2%; p < 0.05, respectively), but there were no differences among the groups in anticipation rate or the percentage of express saccades. Additionally, error rates on the spatial decision task were inversely correlated with performance on visual memory tests (immediate and delayed recall on the DMS- 48: r =–0.44, p = 0.0019 and r =–0.43, p = 0.0020, respectively), semantic fluency (r =–0.44, p = 0.0016), and global cognition (MMSE: r =–0.44, p = 0.0019). Performance on the spatial decision task was not correlated with anti-saccades, processing speed, or attentional performance.   Conclusions: Patients with mild AD made more errors on a spatial decision task than aMCI patients and controls. We hypothesize that impaired visuospatial judgment may explain these results and distinguish aMCI patients from mild AD patients."@en ;
    ns0:hasPubTitle "A Spatial Decision Eye-Tracking Task in Patients with Prodromal and Mild Alzheimer’s Disease"@en .

ns1:jad-v71-i3-JAD190685 ns0:hasKeywords "Cognitive improvement"@en,
        "dementia with Lewy bodies"@en,
        "depressive symptoms"@en ;
    ns0:hasPubAbstract "Background: Although dementia with Lewy bodies (DLB) is a degenerative disease involving irreversible pathological changes and subsequent progressive cognitive decline, some patients have presented with improved cognitive function at follow-ups. Their clinical and neuropsychological characteristics and the factors influencing this improvement remain unclear.   Objective: To investigate differences in clinical and neuropsychological characteristics between DLB patients with and without cognitive improvement at a one-year follow-up, and to identify predictive factors of cognitive improvement.   Methods: This retrospective study included 60 DLB patients, 28 patients in the improved group, and 32 patients in the non-improved group. A multiple linear regression model was used to compare changes in cognitive function test scores between groups over the course of one year. Binary logistic regression analysis was performed to determine the odds ratios (ORs) of depressive symptoms as a predictor for cognitive improvement.   Results: The improved group showed significant increases in immediate and delayed verbal memory function in one year over the non-improved group. We also found that baseline depressive symptoms were associated with an increased probability of cognitive improvement (OR 1.234, CI 1.043– 1.460).   Conclusion: Depressive symptoms at baseline were related to a higher probability of a cognitive improvement at one-year follow-up. In addition, immediate and delayed verbal memory function showed significant improvement during one year in improved patients compared to non-improved patients."@en ;
    ns0:hasPubTitle "Depressive Symptoms and Cognitive Improvement in Patients with Dementia with Lewy Bodies"@en .

ns1:jad-v71-i4-JAD190545 ns0:hasKeywords "Alzheimer’s disease"@en,
        "PET"@en,
        "biomarkers"@en,
        "exosomes"@en,
        "frontotemporal dementia"@en ;
    ns0:hasPubAbstract "We aimed to study the expression of circulating heat-shock protein HSP70 and exosomes in plasma of a cohort of patients with Alzheimer’s disease (AD) and frontotemporal dementia (FTD) at different stages. We performed correlations with clinical scales and FDG-PET. HSP70 levels were higher within exosomes than free in plasma. Moderate correlations were found between exosomal HSP70 and CDR, FTLD-CDR, and extension of hypometabolism. Our results suggest modifications in the level of exosomal HSP70 during the course of neurodegeneration, regardless of AD or FTD, and therefore HSP70 could have a potential role in the follow-up of these disorders."@en ;
    ns0:hasPubTitle "Exosomal HSP70 for Monitoring of Frontotemporal Dementia and Alzheimer’s Disease: Clinical and FDG-PET Correlation"@en .

ns1:jad-v71-i4-JAD190609 ns0:hasKeywords "Aging"@en,
        "TRELONG"@en,
        "hand grip"@en,
        "mediterranean-style dietary pattern score"@en,
        "mini-mental state examination"@en,
        "physical performance"@en,
        "short physical performance battery"@en ;
    ns0:hasPubAbstract "Background: Nutrition plays an important role in the aging process. Adherence to the Mediterranean diet (MedDiet) has been shown to be associated with lower rates of diseases. Cognitive status seems to be strongly interrelated with physical well-being, so that one influences the other. Physical performance measures are not only associated with clinical and subclinical age-related modifications, but are also able to predict disability, institutionalization, and mortality.   Objective: To evaluate prospectively the associations between Mediterranean-Style Dietary Pattern Score (MSDPS), clinical characteristics, and cognition of the population sample of The TREVISO LONGEVA (TRELONG) Study, in Treviso, Italy.   Methods: Global cognition, physical performance measures, MSDPS, and other clinical features were detected in 2010 in 82 men and 108 women. These characteristics were evaluated in relation to the physical performance measures identified 3.8 years later in 2013 in the same subjects, using a semantic connectivity map, through Auto-CM system, to grasp further and non-linear associations between variables which might remain, otherwise, undetected.   Results: The Auto-CM system’s map showed a close association between better levels of global cognition and MSDPS in 2010 and higher physical performance in 2013. On the other hand, worse levels of global cognition and MSDPS in 2010 were associated with lower physical performance in 2013.   Conclusion: The prevention models for successful aging may benefit from integrated programs that include cognitive, physical, and dietary interventions, since these aspects are mutually interrelated."@en ;
    ns0:hasPubTitle "Artificial Neural Networks Help to Better Understand the Interplay Between Cognition, Mediterranean Diet, and Physical Performance: Clues from TRELONG Study"@en .

ns1:jad-v71-i4-JAD190707 ns0:hasKeywords "Alzheimer’s disease"@en,
        "RNA sequence analysis"@en,
        "cognition"@en,
        "hippocampus"@en,
        "insulin"@en,
        "intranasal"@en ;
    ns0:hasPubAbstract "Research on intranasal delivery of drugs, peptides, and proteins has grown over the past decade as an alternate way to deliver substrates to the brain. Recent work has shown intranasal (INL) delivery of insulin improves memory and cognition in healthy subjects as well as patients with Alzheimer’s disease (AD) and in AD mouse models. However, the molecular mechanism(s) for the beneficial effect of insulin on memory are still unclear. Using the SAMP8 mouse model of AD, we investigated the impact of INL insulin on protein and gene expression in brain regions including the olfactory bulb, hypothalamus, and hippocampus. We found genes and proteins in the insulin receptor signaling pathway were not activated by the doses tested. However, we did find the expression of genes present in the hippocampus involved in other pathways, especially those related to inflammation, were altered due to age and with a dose of INL insulin previously shown to improve cognition. These alternate pathways could be targets of insulin when delivered via the INL route to aid in memory improvement."@en ;
    ns0:hasPubTitle "Molecular Mechanisms of Intranasal Insulin in SAMP8 Mice"@en .

ns1:jad-v71-is1-JAD181169 ns0:hasKeywords "Aged"@en,
        "assistive devices"@en,
        "cane"@en,
        "dementia"@en,
        "gait"@en ;
    ns0:hasPubAbstract "Background: People with Alzheimer’s disease (AD) exhibit balance and walking impairments that increase falls risk. Prescription of a mobility aid is done to improve stability, yet also requires increased cognitive resources. Single-point canes require unique motor sequencing for safe use. The effect of learning to use a single-point cane has not been evaluated in people with AD.   Objectives: In people with AD and healthy adult controls: 1) examine changes in gait while using a cane under various walking conditions; and 2) determine the cognitive and gait costs associated with concurrent cane walking while multi-tasking.   Methods: Seventeen participants with AD (age 82.1±5.6 years) and 25 healthy controls (age 70.8±14.1 years) walked using a single-point cane in a straight (6 meter) and a complex (Figure of 8) path under three conditions: single-task (no aid), dual-task (walking with aid), and multi-task (walking with aid while counting backwards by ones). Velocity and stride time variability were recorded with accelerometers.   Results: Gait velocity significantly slowed for both groups in all conditions and stride time variability was greater in the AD group. Overall, multi-tasking produced a decrease in gait and cognitive demands for both groups, with more people with AD self-prioritizing the cognitive task over the gait task.   Conclusion: Learning to use a cane demands cognitive resources that lead to detrimental changes in velocity and stride time variability. This was most pronounced in people with mild to moderate AD. Future research needs to investigate the effects of mobility aid training on gait performance."@en ;
    ns0:hasPubTitle "Effect of Learning to Use a Mobility Aid on Gait and Cognitive Demands in People with Mild to Moderate Alzheimer’s Disease: Part I – Cane"@en .

ns1:jad-v71-is1-JAD181265 ns0:hasKeywords "Alzheimer’s disease"@en,
        "attention"@en,
        "biomarkers"@en,
        "cerebrospinal fluid"@en,
        "dementia"@en,
        "executive function"@en,
        "gait"@en,
        "mild cognitive impairment"@en,
        "subjective cognitive impairment"@en ;
    ns0:hasPubAbstract "Background: Tools to identify individuals at preclinical stages of dementia disorders are needed to enable early interventions. Alterations in dual-task performance have been detected early in progressive neurodegenerative disorders. Hence, dual-task testing may have the potential to screen for cognitive impairment caused by neurodegeneration. Exploring correlations between dual-task performance and biomarkers of neurodegeneration is therefore of interest.   Objective: To investigate correlations between Timed Up-and-Go dual-task (TUGdt) outcomes and Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarkers amyloid-β 42 (Aβ42), total tau (t-tau), and phosphorylated tau (p-tau).   Methods: This cross-sectional cohort study included 90 participants (age range 49–84 years) undergoing memory assessment, who were subsequently diagnosed with AD, other dementia disorders, mild cognitive impairment, or subjective cognitive impairment. TUG combined with “Naming Animals” (TUGdt NA) and “Months Backwards” (TUGdt MB), respectively, were used to assess dual-task performance. The number of correct words and time taken to complete the tests were measured. The CSF biomarkers were analysed by ELISA. Spearman’s rank correlation was used for analyses between TUGdt outcomes (TUGdt NA and TUGdt MB), and CSF biomarkers, adjusted for age, gender, and educational level.   Results: The number of correct words, as well as the number of correct words/10 s during TUGdt NA correlated negatively to CSF t-tau and p-tau. No correlations were found between any time scores and CSF biomarkers.   Conclusion: The correlations between TUGdt NA and t-tau and p-tau may indicate that neurodegeneration affects dual-task performance. Longitudinal studies are needed to further explore dual-task testing in screening for cognitive impairment due to neurodegeneration."@en ;
    ns0:hasPubTitle "Dual-Task Performance and Neurodegeneration: Correlations Between Timed Up-and-Go Dual-Task Test Outcomes and Alzheimer’s Disease Cerebrospinal Fluid Biomarkers"@en .

ns1:jad-v71-is1-JAD190517 ns0:hasKeywords "Cognition"@en,
        "cumulative frailty score"@en,
        "dementia"@en,
        "slow gait"@en ;
    ns0:hasPubAbstract "Background: Frailty is highly prevalent among older adults, and associated with cognitive decline. Relationship between frailty and motoric cognitive risk syndrome (MCR), a pre-dementia syndrome characterized by the presence of subjective cognitive complaints and slow gait, is yet to be elucidated.   Objective: To examine whether frailty increases the risk of developing incident MCR.   Methods: We analyzed 641 adults, aged 65 and above, participating in the LonGenity study. Frailty was defined using a 41-point cumulative deficit frailty index (FI). MCR was diagnosed at baseline and annual follow-up visits using established criteria. Cox proportional hazard models were used to study the association of baseline frailty with incident MCR, and reported as hazard ratio (HR) with 95% confidence intervals (CI) adjusted for age, sex, and education.   Results: At baseline, 70 participants (10·9%) had prevalent MCR. Of the remaining 571 non-MCR participants (mean age 75.0, 57.3% women), 70 developed incident MCR (median follow-up 2.6 years). Higher frailty scores at baseline were associated with an increased risk of incident MCR (HR for each 0.01 increase in the FI: 1.07; 95% CI 1.03–1.11; p = 0.0002). The result was unchanged even after excluding mobility related or chronic illnesses items from the FI as well as accounting for reverse causation, competing risk of death, baseline cognitive status, social vulnerability, and excluding participants with mild cognitive impairment syndrome.   Conclusions: Higher levels of frailty increase risk for developing MCR and suggest shared mechanisms. This association merits further study to identify strategies to prevent cognitive decline."@en ;
    ns0:hasPubTitle "Frailty and Risk of Incident Motoric Cognitive Risk Syndrome"@en .

ns1:jad-v72-i1-JAD190577 ns0:hasKeywords "Asymptomatic Alzheimer’s disease"@en,
        "brain"@en,
        "metabolomics"@en,
        "neurotransmitters"@en ;
    ns0:hasPubAbstract "Background: Cholinesterase inhibitors represent three of the four treatments for Alzheimer’s disease (AD), and target the pathological reduction of acetylcholine levels. Here we aimed to study the role of other neurotransmitter pathways in AD pathology.   Objective: This study aimed to determine associations between AD pathology at both symptomatic and asymptomatic stages of disease progression, and the metabolism of a range of non-cholinergic neurotransmitters.   Methods: Tissue samples were obtained from three groups, controls, AD, and ‘asymptomatic AD’ (ASYMAD), i.e., cognitively normal individuals that had significant AD neuropathology. Three brain areas were studied, the middle frontal gyrus (MFG), the inferior temporal gyrus (ITG), and the cerebellum.   Results: 12 of 15 metabolites involved in neurotransmitter metabolism were shown to be associated with AD pathology. Decreases in dopamine were most pronounced in the MFG with lower levels seen in the ASYMAD group compared to control (FC = 0.78, p = 2.9×10–2). In the ITG significant changes were seen in GABAergic and serotonin metabolism between control and AD patients; however, these changes were not seen between control and ASYMAD individuals.   Conclusion: These results indicate that dopamine could be depleted in brains with AD pathology but intact cognition, while an imbalance of several neurotransmitters is evident in the brains of AD patients."@en ;
    ns0:hasPubTitle "Neurotransmitter Imbalance in the Brain and Alzheimer’s Disease Pathology"@en .

ns1:jad-v72-i1-JAD190708 ns0:hasKeywords "Magnetic resonance imaging"@en,
        "traumatic brain injury"@en,
        "volumetric quantification"@en ;
    ns0:hasPubAbstract "Background: While traumatic brain injury (TBI) is recognized as a risk factor for dementia, there is lack of clinical tools to identify brain changes that may confer such vulnerability. Brain MRI volumetric quantification can sensitively identify brain atrophy.   Objective: To characterize regional brain volume loss in persons with TBI presenting with cognitive impairment.   Methods: IRB approved review of medical records in patients with cognitive decline focused on those who had documented TBI histories and brain MRI scans after TBI (n = 40, 67.7±14.5 years) with volumetric quantification by applying an FDA cleared software program. TBI documentation included head trauma mechanism. Brain volumes were compared to a normative database to determine the extent of atrophy. Correlations between these regions and global tests of cognition (MMSE in n = 17, MoCA in n = 27, n = 14 in both) were performed.   Results: Multiple regions demonstrated volume loss in TBI, particularly ventral diencephalon, putamen, and pallidum with smaller magnitude of atrophy in temporal lobes and brainstem. Lobar structures showed strongest correlations between atrophy and lower scores on MMSE and MoCA. The hippocampus, while correlated to tests of cognitive function, was the least atrophic region as a function of TBI history.   Conclusion: Persons with TBI history exhibit show regional brain atrophy. Several of these areas, such as thalamus and temporal lobes, also correlate with cognitive function. Alzheimer’s disease atrophy was less likely given relative sparing of the hippocampi. Volumetric quantification of brain MRI in TBI warrants further investigation to further determine its clinical potential in TBI and differentiating causes of cognitive impairment."@en ;
    ns0:hasPubTitle "MRI Volumetric Quantification in Persons with a History of Traumatic Brain Injury and Cognitive Impairment"@en .

ns1:jad-v72-i2-JAD181259 ns0:hasKeywords "Alzheimer’s disease"@en,
        "D4T"@en,
        "NLRP3-inflammasome"@en,
        "amyloid-β phagocytosis"@en,
        "autophagy"@en,
        "cytokines"@en ;
    ns0:hasPubAbstract "Background: Alzheimer’s disease (AD) is associated with the accumulation of amyloid-β (Aβ) within senile plaques in the brain and neuroinflammation, possibly driven by the activation of the NLRP3 inflammasome. Nucleoside reverse transcriptase inhibitors (NRTI) hamper the NLRP3 inflammasome assembly.   Objective: We utilized an in vitro model reproducing the Aβ-driven inflammation seen in AD to analyze whether stavudine (D4T), a prototypical NRTI, modulates Aβ-mediated inflammasome activation and the ability of macrophages to eliminate Aβ via phagocytosis and autophagy.   Methods: THP-1-derived macrophages were stimulated in vitro with Aβ42 or with Aβ42 after LPS-priming in the presence/absence of D4T. NLRP3 and TREM2 expression was analyzed by RT-PCR; phagocytosis, as well as ASC-Speck formation, was analyzed by Amnis FlowSight Imaging; NLRP3-produced cytokines were quantified by ELISA and, finally, autophagy was analyzed by measuring p-ERK1/2, p-AKT, beclin, p70-S6Kinase, and Lamp by ELISA and western blot.   Results: IL-1β, IL-18, and caspase-1 were increased whereas Aβ phagocytosis and TREM2 were reduced in LPS+Aβ42-stimulated cells. D4T reduced NLRP3 assembly as well as IL-18 and caspase-1 production, but did not affect IL-1β production and TREM2 expression. Notably, whereas D4T reduced Aβ phagocytosis, Aβ autophagy by macrophages was stimulated by D4T, as witnessed by the down-modulation of ERK1/2 and AKT phosphorylation and the upregulation of beclin, LAMP, and p70-S6K, their downstream targets.   Conclusion: In this in vitro model of AD, D4T reduces NLRP3 inflammasome-associated inflammation and stimulates Aβ autophagy by macrophages. It will be interesting to verify the possibly beneficial effects of D4T in the clinical scenario."@en ;
    ns0:hasPubTitle "Stavudine Reduces NLRP3 Inflammasome Activation and Modulates Amyloid-β Autophagy"@en .

ns1:jad-v72-i2-JAD190670 ns0:hasKeywords "Alzheimer’s disease"@en,
        "biomarkers"@en,
        "early diagnosis"@en,
        "healthcare organizational models"@en,
        "mild cognitive impairment"@en,
        "prodromal Alzheimer’s disease"@en,
        "public health"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease is the most common age-related neurodegenerative disorder and its burden on patients, families, and society grows significantly with lifespan. Early modifications of risk-enhancing lifestyles and treatment initiation expand personal autonomy and reduce management costs. Many clinical trials with potentially disease-modifying drugs are devoted to mild cognitive impairment (MCI) prodromal-to-Alzheimer’s disease. The identification of biomarkers for early diagnosis may thus be crucial for early intervention and identification of high-risk subjects, the most appropriate target of new drugs as soon as they will be discovered. INTERCEPTOR is a strategic project by the Italian Ministry of Health and the Italian Medicines Agency (AIFA), aiming to validate the best combination (highly accurate, non-invasive, available on the whole national territory and financially sustainable) of biomarkers and organizational model for early diagnosis. 500 MCI subjects will be enrolled at baseline and followed-up for 3 years for at least 400 of them in order to define a “hub & spoke” nationwide model with recruiting (spokes) centers for MCI identification and expert (hubs) centers for risk diagnosis."@en ;
    ns0:hasPubTitle "The Italian INTERCEPTOR Project: From the Early Identification of Patients Eligible for Prescription of Antidementia Drugs to a Nationwide Organizational Model for Early Alzheimer’s Disease Diagnosis"@en .

ns1:jad-v72-i3-JAD190480 ns0:hasKeywords "Cytokines"@en,
        "dementia"@en,
        "inflammation"@en,
        "markers"@en,
        "sex"@en ;
    ns0:hasPubAbstract "Background: Elevated peripheral levels of different cytokines and chemokines in subjects with Alzheimer’s disease (AD), as compared with healthy controls (HC), have emphasized the role of inflammation in such a disease. Considering the cross-talking between the central nervous system and the periphery, the inflammatory analytes may provide utility as biomarkers to identify AD at earlier stages.   Objective: Using an advanced statistical approach, we can discriminate the interactive network of cytokines/chemokines and propose a useful tool to follow the progression and evolution of AD, also in light of sex differences.   Methods: A cohort of 289 old-age subjects was screened for cytokine and chemokine profiling, measured in plasma, after a thorough clinical and neuropsychological evaluation. A custom algorithm based on Fisher linear discriminant analysis was applied to ascertain a classification signature able to discriminate HC from mild cognitive impairment (MCI) and AD.   Results: We observed that a joint expression of three proteins (a “signature” composed by IFN-α2, IL-1α, TNFα) can discriminate HC from AD with an accuracy of 65.24%. Using this signature on MCI samples, 84.93% of them were classified as “non-HC”. Stratifying MCI samples by sex, we observed that 87.23% of women were classified as “non-HC”, and only 57.69% of males. Indeed, in a scatter plot of IFN-α2 and IL-1α, the HC group was better separated from MCI and AD in women as compared with men.   Conclusion: These findings suggest that AD is accompanied by a peripheral inflammatory response that can already be present in MCI subjects, thus providing a mean for detecting this at-risk status and allow an anticipated intervention."@en ;
    ns0:hasPubTitle "Cognitive Decline and Alzheimer’s Disease in Old Age: A Sex-Specific Cytokinome Signature"@en .

ns1:jcs-v27-i4-JCS191289 ns0:hasKeywords "Authentication"@en,
        "PIN inference"@en,
        "information leakage"@en,
        "password inference"@en,
        "shoulder-surfing attacks"@en ;
    ns0:hasPubAbstract "This paper studies leakage of user passwords and PINs based on observations of typing feedback on screens or from projectors in the form of masked characters (∗ or ∙) that indicate keystrokes. To this end, we developed an attack called Password and Pin Information Leakage from Obfuscated Typing Videos (PILOT). Our attack extracts inter-keystroke timing information from videos of password masking characters displayed when users type their password on a computer, or their PIN at an ATM. We conducted several experiments in various attack scenarios. Results indicate that, while in some cases leakage is minor, it is quite substantial in others. By leveraging inter-keystroke timings, PILOT recovers 8-character alphanumeric passwords in as little as 19 attempts. When guessing PINs, PILOT significantly improved on both random guessing and the attack strategy adopted in our prior work (In European Symposium on Research in Computer Security (2018) 263–280 Springer). In particular, we were able to guess about 3% of the PINs within 10 attempts. This corresponds to a 26-fold improvement compared to random guessing. Our results strongly indicate that secure password masking GUIs must consider the information leakage identified in this paper."@en ;
    ns0:hasPubTitle "PILOT: Password and PIN information leakage from obfuscated typing videos1"@en .

ns1:jhd-v8-i3-JHD190353 ns0:hasKeywords "Huntington’s disease"@en,
        "Q-Motor"@en,
        "adolescents"@en,
        "children"@en,
        "development"@en,
        "endpoint"@en,
        "motor"@en ;
    ns0:hasPubAbstract "Q-Motor is utilized across various clinical trials in adults with Huntington’s disease (HD) to provide quantitative, reliable assessments of motor abilities. With gene-knockdown therapies entering the clinic, development of preventative therapies for pediatric carriers of the HD mutation seems imminent. It is currently unclear if Q-Motor is useful for tracking changes in motor abilities in pediatric HD patients or at-risk youth, as most assessments have never been administered in children. We demonstrate the feasibility of administering Q-Motor tasks in a sample of children recruited from the community, and we show that Q-Motor is sensitive to age-related changes in motor abilities."@en ;
    ns0:hasPubTitle "A Feasibility Study of Quantitative Motor Assessments in Children Using the Q-Motor Suite"@en .

ns1:jhd-v8-i4-JHD190346 ns0:hasKeywords "California Verbal Learning Test"@en,
        "Huntington’s disease"@en,
        "Parkinson’s disease"@en,
        "discriminability"@en,
        "recall"@en,
        "recognition"@en,
        "verbal memory"@en ;
    ns0:hasPubAbstract "Background: Parkinson’s disease (PD) and Huntington’s disease (HD) are two neurodegenerative diseases affecting frontal-striatal function and memory ability. Studies using the original California Verbal Learning Test (CVLT) to examine recall and recognition abilities between these groups have produced mixed findings. Some found that individuals with HD demonstrate worse recall and recognition than those with PD, whereas others reported comparable performance.   Objective: We utilized multiple indices of recall and recognition discriminability, provided by the second and third editions of the CVLT (CVLT-II and CVLT-3, respectively), that allow for a more thorough assessment of more nuanced aspects of verbal memory function.   Methods: We examined differences between individuals with PD (n = 72) and those with HD (n = 77) on CVLT-II indices of recall discriminability (immediate, short delay free and cued, long delay free and cued) and recognition discriminability (total, source, semantic, and novel) using standardized scores while controlling for education and Dementia Rating Scale-2 scores.   Results: The HD group performed significantly worse than the PD group on all measures of recall and recognition discriminability (ps < 0.05), and group differences were associated with large Cohen’s d effect sizes.   Conclusions: Our findings suggest that individuals with HD are more impaired than individuals with PD in more nuanced aspects of recall and recognition memory function. These CVLT indices yield more thorough assessments of recall and recognition memory function and have the potential to improve efforts to characterize and distinguish profiles of memory loss in different neurodegenerative populations, including PD and HD."@en ;
    ns0:hasPubTitle "Recall and Recognition Discriminability in Parkinson’s Disease and Huntington’s Disease"@en .

ns1:jnd-v6-i3-JND190397 ns0:hasKeywords "Myotonic dystrophy"@en,
        "magnetic resonance imaging"@en,
        "neuroanatomy"@en ;
    ns0:hasPubAbstract "Background: Few adequately-powered studies have systematically evaluated brain morphology in adult-onset myotonic dystrophy type 1 (DM1).   Objective: The goal of the present study was to determine structural brain differences between individuals with and without adult-onset DM1 in a multi-site, case-controlled cohort. We also explored correlations between brain structure and CTG repeat length.   Methods: Neuroimaging data was acquired in 58 unaffected individuals (29 women) and 79 individuals with DM1 (50 women). CTG repeat length, expressed as estimated progenitor allele length (ePAL), was determined by small pool PCR. Statistical models were adjusted for age, sex, site, and intracranial volume (ICV).   Results: ICV was reduced in DM1 subjects compared with controls. Accounting for the difference in ICV, the DM1 group exhibited smaller volume in frontal grey and white matter, parietal grey matter as well as smaller volume of the corpus callosum, thalamus, putamen, and accumbens. In contrast, volumes of the hippocampus and amygdala were significantly larger in DM1. Greater ePAL was associated with lower volumes of the putamen, occipital grey matter, and thalamus. A positive ePAL association was observed for amygdala volume and cerebellar white matter.   Conclusions: Smaller ICV may be a marker of aberrant neurodevelopment in adult-onset DM1. Volumetric analysis revealed morphological differences, some associated with CTG repeat length, in structures with plausible links to key DM1 symptoms including cognitive deficits and excessive daytime somnolence. These data offer further insights into the basis of CNS disease in DM1, and highlight avenues for further work to identify therapeutic targets and imaging biomarkers."@en ;
    ns0:hasPubTitle "Brain Structural Features of Myotonic Dystrophy Type 1 and their Relationship with CTG Repeats"@en .

ns1:jnd-v6-i3-JND190403 ns0:hasKeywords "ClinicalTrials.gov NCT02122952 (https://clinicaltrials.gov/ct2/show/NCT02122952) and NCT01736553(https://clinicaltrials.gov/ct2/show/NCT01736553)"@en,
        "Gene therapy"@en,
        "natural history"@en,
        "neuromuscular diseases"@en,
        "spinal muscular atrophy"@en ;
    ns0:hasPubAbstract "Background: Spinal muscular atrophy type 1 (SMA1) is the leading genetic cause of infant mortality for which therapies, including AVXS-101 (onasemnogene abeparvovec, Zolgensma®) gene replacement therapy, are emerging.   Objective: This study evaluated the effectiveness of AVXS-101 in infants with spinal muscular atrophy type 1 (SMA1) compared with a prospective natural history cohort and a cohort of healthy infants.   Methods: Twelve SMA1 infants received the proposed therapeutic dose of AVXS-101 (NCT02122952). Where possible, the following outcomes were compared with a natural history cohort of SMA1 infants (n = 16) and healthy infants (n = 27) enrolled in the NeuroNEXT (NN101) study (NCT01736553): event-free survival, CHOP-INTEND scores, motor milestone achievements, compound muscle action potential (CMAP), and adverse events.   Results: Baseline characteristics of SMA1 infants in the AVXS-101 and NN101 studies were similar in age and genetic profile. The proportion of AVXS-101–treated infants who survived by 24 months of follow-up was higher compared with the NN101 study (100% vs 38%, respectively). The average baseline CHOP-INTEND score for NN101 SMA1 infants was 20.3, worsening to 5.3 by age 24 months; the average baseline score in AVXS-101–treated infants was 28.2, improving to 56.5 by age 24 months. Infants receiving AVXS-101 achieved motor milestones, such as sitting unassisted and walking. Improvements in CMAP peak area were observed in AVXS-101–treated infants at 6 and 24 months (means of 1.1 and 3.2 mV/s, respectively).   Conclusions: In this study, AVXS-101 increased the probability of survival, rapidly improved motor function, and enabled motor milestone achievement in SMA1 infants."@en ;
    ns0:hasPubTitle "AVXS-101 (Onasemnogene Abeparvovec) for SMA1: Comparative Study with a Prospective Natural History Cohort"@en .

ns1:jvr-v51-i1-JVR191026 ns0:hasKeywords "Multiple sclerosis"@en,
        "chronic illness"@en,
        "quality of life"@en ;
    ns0:hasPubAbstract "BACKGROUND: Multiple sclerosis (MS) is among the most prevalent chronic neurological conditions worldwide and is associated with a wide range of symptoms and psychosocial impacts. Quality of life (QOL) is recognized as a comprehensive and person-centered framework for exploring and understanding these impacts. Although there is a strong history of including people with MS in the development of health-related and patient-reported outcomes QOL instruments in MS, there have been relatively few large-scale qualitative investigations of what is important to the QOL of people with MS. As part of an ongoing evaluation by the National Multiple Sclerosis Society (NMSS), in which the NMSS is seeking to evaluate the impact of its work on the lives of people living with MS, we surveyed a sample of 748 Americans with MS about the areas of their life that are most important to their QOL.   RESULTS: The results suggest that social relationships, health, independence, and participation in meaningful activities, including employment, were among their top priorities. The diversity of life areas identified underscores the importance of understanding the individual’s unique priorities and experiences of QOL, and recognizing the diversity of the population.   CONCLUSION: The results are discussed in terms of the implications for understanding of priorities and experiences of Americans living with MS."@en ;
    ns0:hasPubTitle "Life domains that are important to quality of life for people with multiple sclerosis: A population-based qualitative analysis"@en .

ns1:jvr-v51-i2-JVR191036 ns0:hasKeywords "Employment"@en,
        "SSI"@en,
        "disability"@en,
        "transition-aged youth"@en ;
    ns0:hasPubAbstract "BACKGROUND: Promoting the Readiness of Minors in Supplemental Security Income (PROMISE) is a U.S. Department of Education federal demonstration grant in collaboration with Health and Human Services, Labor, and the Social Security Administration. Wisconsin PROMISE is one of six model demonstration sites.   OBJECTIVE: Through state inter-agency collaboration, the Wisconsin Division of Vocational Rehabilitation implemented Wisconsin PROMISE coordinated services and supports to youth with disabilities receiving supplemental security income (SSI) benefits and their families to improve education and career and financial self-sufficiency outcomes.   METHODS: Wisconsin PROMISE enrolled 2,024 youth with disabilities receiving SSI benefits and their families who were randomly assigned to usual services or PROMISE services.   RESULTS: Early data indicates positive results regarding engagement, employment, and earnings outcomes. Wisconsin PROMISE youth employment rates went from 1% in 2013 to 67% in 2018, 10-percentage points higher than observed with the control group.   CONCLUSION: An overview of early findings from the Wisconsin PROMISE project site related to VR engagement, employment, and earnings outcomes of youth and family participants provides lessons learned that can be applied to VR practice."@en ;
    ns0:hasPubTitle "Early findings from the Wisconsin PROMISE project: Implications for policy and practice"@en .

ns1:jvr-v51-i2-JVR191039 ns0:hasKeywords "SSI"@en,
        "Transition"@en,
        "disability"@en,
        "employment"@en,
        "engagement"@en ;
    ns0:hasPubAbstract "BACKGROUND: Youth with disabilities receiving SSI experience economic disparities across the lifespan. PROMISE demonstrations strived to overcome these disparities by offering an array of services to improve long-term economic outcomes. Unfortunately, people living at or near poverty often focus energies on meeting basic needs rather than engaging in future-oriented activities.   OBJECTIVE: This paper explores engagement with PROMISE services at one demonstration site (called ASPIRE) as a predictor of intermediary employment outcomes.   METHODS: Study 1 uses youth survey data at enrollment and 36-months to compare intermediary outcomes between ASPIRE control and intervention youth (n = 1241). Study 2 uses participation data from case management records to construct a logistic regression to explore predictors of employment for ASPIRE intervention youth. Study 3 uses case management records about training participation to explore impacts of various ASPIRE engagement strategies.   RESULTS: Study 1. There were few differences between intervention and control group participants in terms of self-determination, expectations, employment, and education 36-months after enrollment. Study 2. Intervention youth receiving higher rates of face-to-face case-management services (OR = 1.181) and career exploration activities in year 2 (OR = 1.516) and year 1 (OR = 1.426) become employed at higher rates in year 3, relative to those receiving fewer services. Study 3. Engagement with ASPIRE services was low across the project. A large incentive in the final 7-months of the project resulted in an exponential increase in financial literacy training participation.   CONCLUSIONS: Future demonstrations focused on SSI youth with disabilities should utilize incentives early in the project to promote engagement with case-management services and future-oriented training and activities."@en ;
    ns0:hasPubTitle "Engaging SSI youth and families with ASPIRE services"@en .

ns1:kca-v3-i3-KCA190064 ns0:hasKeywords "Bellini tumor"@en,
        "Collecting duct carcinoma"@en,
        "chemotherapy"@en,
        "kidney cancer"@en ;
    ns0:hasPubAbstract "Introduction: Collecting duct carcinomas (CDC), also known as Bellini’s tumors, are a rare and aggressive subtype of renal cell carcinoma. Therefore, there are very few data about their management, and there is no standard therapy for this malignancy. We report the outcome of CDC patients treated on institutions belonging to the ‘Grupo Centro’ of Genitourinary Tumors, a novel networking cooperative group in Spain.   Material and Methods: Patients with CDC diagnosed between 1995 and 2015 were included. They had to have an appropriate follow-up, as well as available tissue for further correlative studies. Demographic baseline features and therapy outcomes were collected in a retrospective fashion. Approval for this data collection was obtained from a central ethical committee.   Results: A total of 43 patients were analysed, with a median overall survival (OS) of 14 months (95% CI: 9.2–18.8 months). 29 of them (67.4%) were diagnosed as localized disease, and 14 (32.6%) as metastatic disease. For the subgroup of patients diagnosed without metastases, median relapse-free survival (RFS) is 22 months (95% CI: 12.4–35.6 months), and median OS, 53 months (95% CI: 35.5–84.3 months). For the subgroup of patients with metastatic disease, median OS is 6 months (95% CI: 4.1–7.8 months). 16 patients (55.2%) with stage IV disease received systemic therapy, mainly platinum-based chemotherapy, with a response rate of 12.5% and a median progression-free survival (PFS) of 2 months.   Conclusions: CDC of the kidney is a malignancy with poor prognosis and few responses to therapy. Median OS of our group in the metastatic setting is similar to what has been observed in previous series. There is a clear need to improve the armamentarium we have for the systemic approach of patients with advanced CDC."@en ;
    ns0:hasPubTitle "Collecting Duct Carcinoma of the Kidney: Analysis of Our Experience at the SPANISH ‘Grupo Centro’ of Genitourinary Tumors"@en .

ns1:npm-v12-i2-NPM1814 ns0:hasKeywords "Alcohol"@en,
        "cannabis"@en,
        "pregnancy"@en,
        "risk factors"@en,
        "tobacco"@en ;
    ns0:hasPubAbstract "BACKGROUND:  With limited Canadian research on predictors of drug use during pregnancy, the primary objective was to assess the relative effects of socioeconomic, demographic, and mental health risk factors associated with drug use during pregnancy. Predictors of an Apgar score < 7 and fetal macrosomia were examined as secondary outcomes.  METHODS:  This retrospective cohort study consisted of 25,734 pregnant women from Southwestern Ontario. Data were prospectively obtained from perinatal and neonatal databases at a tertiary hospital in London, Ontario. Using a Geographic Information System, neighborhood-level socioeconomic variables were obtained by mapping maternal postal codes. Separate logistic regressions were computed for all outcome variables.  RESULTS:  The rates of alcohol, tobacco, and cannabis use during pregnancy were 1.9%, 16.2%, and 2.3%, respectively. The mean maternal age was 29.4±5.4 years. Maternal age was inversely associated with alcohol, tobacco and cannabis use, whereas lone-parent household, depression, and anxiety increased the odds of substance use. Depression was the top risk factor of all three substances. Compared to women who were not depressed during pregnancy, women who were depressed were 2.15 times more likely to use alcohol (95% CI: 1.60, 2.90), 1.70 times more likely to smoke tobacco (95% CI: 1.48, 1.95), and 2.56 times more likely to use cannabis (95% CI: 1.95, 3.35). Adverse birth outcomes were also associated with overweight and obesity, gestational diabetes and insulin-dependent diabetes.  CONCLUSIONS:  Maternal depression is the primary risk factor of drug use during pregnancy. Policy interventions that target at-risk women are important considerations to improve maternal mental health."@en ;
    ns0:hasPubTitle "Predictors of drug use during pregnancy: The relative effects of socioeconomic, demographic, and mental health risk factors"@en .

ns1:npm-v12-i3-NPM180140 ns0:hasKeywords "Pregestational diabetes mellitus"@en,
        "breastfeeding outcome"@en,
        "early feeding"@en,
        "in-hospital formula supplementation"@en ;
    ns0:hasPubAbstract "OBJECTIVE: To ascertain the rate of in-hospital supplementation as it relates to early breastfeeding (BF) and early formula feeding (FF) and its effects on BF (exclusive and partial) at the time of discharge for infants born to women with pregestational diabetes mellitus (PGDM).   METHODS: Retrospective cohort investigation of 282 women with PGDM who intended to BF and their asymptomatic infants admitted to the newborn nursery for blood glucose monitoring and routine care. Early feeding was defined by the initial feeding if given within four hours of birth.   RESULTS: Of the 282 mother-infant dyads, for 134 (48%) early feeding was BF and for 148 (52%) early feeding was FF. Times from birth to BF and FF (median 1 hr, 0.3–6) were similar, while the time to first BF for those who FF and supplemented was longer (median 6 hr., 1–24). Ninety-seven infants (72%) who first BF also supplemented. Of these, 22 (23%) BF exclusively, 67 (69%) BF partially and 8 (8%) FF at discharge. One hundred seventeen (79%) who first FF also supplemented. Of these, 21 (18%) BF exclusively, 76 (65%) BF partially and 20 (17%) FF at discharge.   CONCLUSION: Regardless of the type of first feeding, the majority of infants born to women with PGDM require supplementation. Even when medically indicated, in-hospital supplementation is an obstacle, albeit not absolute, to exclusive BF at discharge. Parents should be reminded that occasional supplementation should not deter resumption and continuation of BF."@en ;
    ns0:hasPubTitle "In-hospital formula supplementation and breastfeeding initiation in infants born to women with pregestational diabetes mellitus"@en .

ns1:nre-v44-i3-NRE182671 ns0:hasKeywords "Meta-analysis"@en,
        "cycling"@en,
        "disability"@en,
        "functional electrical stimulation"@en,
        "lower limb"@en,
        "stroke"@en ;
    ns0:hasPubAbstract "BACKGROUND: One of the leading causes of disability in the world with enormous economic burden is stroke.   OBJECTIVE: To quantify the effectiveness of different protocols of cycling with/without functional electrical stimulation on functional mobility after stroke.   METHODS: Multiple databases were searched till 2018. Data extraction was performed using a pre-determined data collection form. The quality of the evidence was evaluated using the Grading of Recommendations Assessment, Development and Evaluation.   RESULTS: A total of 14 trials satisfied eligibility criteria and were included. Cycling had a positive effect on the 6-meter walking test performance (SMD, 0.41; 95% CI, 0.11 –0.71; I2 = 0% ) compared with no or placebo intervention (control). Compared with control, cycling had a positive effect on 10-meter walking speed (SMD, 0.30; 95% CI, 0.05 –0.55; I2 = 0% ), and on balance based on the Berg score (SMD, 0.32; 95% CI, 0.06 –0.57; I2 = 49% ). Cycling with functional electrical stimulation had a positive effect on balance (SMD, 1.48; 95% CI, 0.99 –1.97; I2 = 91% ) compared with cycling alone.   CONCLUSIONS: It appears that cycling has a positive effect on walking speed, walking ability and balance. Functional electrical stimulation combined with cycling has positive effects on balance beyond cycling alone."@en ;
    ns0:hasPubTitle "The effects of cycling with and without functional electrical stimulation on lower limb dysfunction in patients post-stroke: A systematic review with meta-analysis"@en .

ns1:nre-v45-i2-NRE192745 ns0:hasKeywords "Cerebral palsy"@en,
        "motor assessment"@en,
        "robotic"@en,
        "serious game"@en,
        "upper limb"@en ;
    ns0:hasPubAbstract "BACKGROUND: The ROBiGAME project aims to implement serious games on robots to rehabilitate upper limb (UL) motor function in children with cerebral palsy (CP). Serious game characteristics (target position, level of assistance/resistance, level of force) are typically adapted based on the child’s assessment before and continuously during the game (measuring UL working area, kinematics and muscle strength).   OBJECTIVE: This study developed an UL robotic motor assessment protocol to configure the serious game.   METHODS: Forty-nine healthy children and 20 CP children participated in the study. The clinical assessment consisted of the child’s UL length and isometric force. The robot assessment consisted of the child’s UL working area (WA), the UL isometric and isokinetic force in three directions and the UL kinematics during a pointing task toward targets placed at different distances.   RESULTS: Results showed that WA and UL isometric force were moderately to highly correlated with clinical measures. Ratios between the UL isokinetic force generated on three directions were established. The velocity and straightness indexes of all children increased when they had to reach to targets placed more distant.   CONCLUSIONS: This protocol can be integrated into different serious games in order to continuously configure the game characteristics to a child’s performance.   Trial registration: The study was registered at ClinicalTrials.gov (NCT02543424), 12 August 2015."@en ;
    ns0:hasPubTitle "Validation of a robot serious game assessment protocol for upper limb motor impairment in children with cerebral palsy"@en .

ns1:nre-v45-i2-NRE192788 ns0:hasKeywords "Parkinson’s disease"@en,
        "cognition"@en,
        "dance"@en,
        "psychological symptoms"@en,
        "quality of life"@en ;
    ns0:hasPubAbstract "BACKGROUND: While dance may improve motor features in Parkinson’s disease (PD), it is not yet clear if the benefits extend to non-motor features.   OBJECTIVE: To determine whether dance classes based on Dance for PD®, improve cognition, psychological symptoms and Quality of Life (QoL) in PD.   METHODS: Participants were allocated to a Dance Group (DG; n = 17) or Control Group (CG: n = 16). Participants had early-stage PD (Hoehn & Yahr: DG = 1.6±0.7, CG = 1.5±0.8) with no cognitive impairment (Addenbrooke’s score: DG = 93.2±3.6, CG = 92.6±4.3). The DG undertook a one-hour class, twice weekly for 12 weeks, while the CG had treatment as usual. Both groups were assessed for disease severity (MDS-UPDRS), cognition (NIH Toolbox® cognition battery, Trail Making Test), psychological symptoms (Hospital Anxiety and Depression Scale, MDS-UPDRS-I) and QoL (PDQ-39, MDS-UPDRS-II).   RESULTS: Group comparison of pre-post change scores showed that selected cognitive skills (executive function and episodic memory), psychological symptoms (anxiety and depression) as well as QoL (PDQ-39 summary index) were significantly improved by the intervention (DG > CG, p’s < 0.05, Cohen’s d > 0.8).   DISCUSSIONS and CONCLUSION: Dance classes had a clear benefit on psychological symptoms, QoL and a limited cognitive benefit. Follow-up assessment is required to confirm the durability of these effects."@en ;
    ns0:hasPubTitle "Impacts of dance on cognition, psychological symptoms and quality of life in Parkinson’s disease"@en .

ns1:xst-v27-i4-XST180487 ns0:hasKeywords "320-detector computed tomography (CT)"@en,
        "iterative reconstruction"@en,
        "low dose"@en,
        "paranasal sinus"@en,
        "pediatric"@en,
        "wide-detector"@en ;
    ns0:hasPubAbstract "BACKGROUND: Computed tomography (CT) is considered a standard modality for imaging the paranasal sinus (PS), but increasingly radiation dose is of concern, especially in children.   Objective: This study aims to investigate the feasibility of using a 320-detector CT scanner with a 16 cm wide-detector combined with iterative reconstruction (IR) algorithm to further reduce radiation dose when scanning the PS.   METHODS: A total of 90 children who underwent CT of the PS were randomly allocated into three groups namely, (1) the experimental group using low-dose wide-detector scan (n = 30, 9±4 years); (2) low-dose helical group (n = 30, 9±4 years); and (3) pediatric conventional group (n = 30, 8±4 years). Statistical software SPSS 19.0 was used for one-way ANOVA analysis of the general data (age, BMI), image quality, and radiation dose. Multiple comparisons of data without homogeneity of variance were analyzed by Bonferroni test and Tamhane’s test.   RESULTS: All patients underwent successful CT examinations. No significant differences in the general data and image quality evaluation were detected between three groups (all P values > 0.05). CTDIvol and DLP were 2.87 mGy and 32.58 mGy·cm in the experimental group, 4.92 mGy and 70.84 mGy·cm in the low-dose helical group, and 9.95 mGy and 131.83 mGy·cm in the conventional group, respectively, which were significantly different among these three groups as indicated by multiple comparisons (all P values < 0.05). In the experimental group, the effective radiation dose was 0.07 mSv, which was reduced by 76% and 56% comparing to the conventional group and the low-dose helical group, respectively.   CONCLUSIONS: The 320-detector CT scanner equipped with the wide-detector combined with IR can further reduce radiation dose, while maintaining good image quality comparing to the low-dose helical or pediatric modes."@en ;
    ns0:hasPubTitle "Wide-detector CT combined iterative reconstruction in pediatric low-dose scan of the paranasal sinus"@en .

ns1:xst-v27-i4-XST190503 ns0:hasKeywords "Real-time adaptive control parameters"@en,
        "organ motion correction"@en,
        "respiratory motion compensation"@en,
        "ultrasound image tracking"@en ;
    ns0:hasPubAbstract "PURPOSE: This study evaluates the feasibility of our previously developed Respiratory Motion Compensation System (RMCS) combined with the Phase Lead Compensator (PLC) to eliminate system delays during the compensation of respiration-induced tumor motion. The study objective is to improve the compensation effect of RMCS and the efficay of radiation therapy to reduce its side effects to the patients.   MATERIAL AND METHODS: In this study, LabVIEW was used to develop the proposed software for calculating real-time adaptive control parameters, combined with PLC and RMCS for the compensation of total system delay time. Experiments of respiratory motion compensation were performed using 6 pre-recorded human respiration patterns and 7 sets of different sine waves. During the experiments, a respiratory simulation device, Respiratory Motion Simulation System (RMSS), was placed on the RMCS, and the detected target motion signals by the Ultrasound Image Tracking Algorithm (UITA) were transmitted to the RMCS, and the compensation of respiration induced motion was started. Finally, the tracking error of the system is obtained by comparing the encoder signals bwtween RMSS and RMCS. The compensation efficacy is verified by the root mean squared error (RMSE) and the system compensation rate (CR).   RESULTS: The experimental results show that the calcuated CR with the simulated respiration patterns is between 42.85% ∼3.53% and 33.76% ∼2.62% in the Right-Left (RL) and Superior-Inferior (SI), respectively, after the RMCS compensation of using the adaptive control parameters in PLC. For the compensation results of human respiration patterns, the CR is between 58.95% ∼8.56% and 62.87% ∼9.05% in RL and SI, respectively.   CONCLUSIONS: During the respiratory motion compensation, the influence of the delay time of the entire system (RMCS+RMSS+UITA) on the compensation effect was improved by adding an adaptive control PLC, which reduces compensation error and helps improve efficacy of radiation therapy."@en ;
    ns0:hasPubTitle "Adaptive control of phase leading compensator parameters applied to respiratory motion compensation system"@en .

ns2:HAB190368 ns0:inAuthorList ns150:HAB190368 .

ns2:IFS152405 ns0:inAuthorList ns150:IFS152405 .

ns2:IFS161919 ns0:inAuthorList ns150:IFS161919 .

ns2:IFS16554 ns0:inAuthorList ns150:IFS16554 .

ns2:IFS16946 ns0:inAuthorList ns150:IFS16946 .

ns2:IFS171443 ns0:inAuthorList ns150:IFS171443 .

ns2:IFS171587 owl:sameAs ns2:IFS17728,
        ns8:IFS181188,
        ns8:IFS1884 ;
    ns0:fullName "Asghar Khan" ;
    ns0:hasAffiliation ns242:IFS171587 ;
    ns0:hasArticle ns1:ifs-v37-i4-IFS171587 ;
    ns0:inAuthorList ns150:IFS171587 .

ns2:IFS182751 owl:sameAs ns2:IFS181648,
        ns8:IFS190905 ;
    ns0:fullName "Muhammad Riaz" ;
    ns0:hasAffiliation ns242:IFS182751 ;
    ns0:hasArticle ns1:ifs-v37-i2-IFS182751 ;
    ns0:inAuthorList ns150:IFS182751 .

ns2:IFS2107 ns0:inAuthorList ns150:IFS2107 .

ns2:JAD160826 ns0:inAuthorList ns150:JAD160826 .

ns2:JAD170773 ns0:inAuthorList ns150:JAD170773 .

ns2:JVR191055 owl:sameAs ns5:JVR813 ;
    ns0:fullName "David R. Strauser" ;
    ns0:hasAffiliation ns242:JVR191055 ;
    ns0:hasArticle ns1:jvr-v51-i3-JVR191055 ;
    ns0:inAuthorList ns150:JVR191055 .

ns2:jad01177 ns0:inAuthorList ns150:jad01177 .

ns8:CH179201 ns0:inAuthorList ns150:CH179201 .

ns8:HAB190368 ns0:inAuthorList ns150:HAB190368 .

ns8:IFS161988 ns0:inAuthorList ns150:IFS161988 .

ns8:IFS1650 ns0:inAuthorList ns150:IFS1650 .

ns8:IFS171176 ns0:inAuthorList ns150:IFS171176 .

ns8:IFS1788 ns0:inAuthorList ns150:IFS1788 .

ns8:IFS181153 ns0:inAuthorList ns150:IFS181153 .

ns8:IFS181516 owl:sameAs ns12:IFS171567 ;
    ns0:fullName "Saleem Abdullah" ;
    ns0:hasAffiliation ns25:IFS181516 ;
    ns0:hasArticle ns1:ifs-v36-i6-IFS181516 ;
    ns0:inAuthorList ns150:IFS181516 .

ns8:IFS18604 ns0:inAuthorList ns150:IFS18604 .

ns8:IFS2113 ns0:inAuthorList ns150:IFS2113 .

ns8:JAD112126 ns0:inAuthorList ns150:JAD112126 .

ns8:JAD129035 ns0:inAuthorList ns150:JAD129035 .

ns8:JAD141626 ns0:inAuthorList ns150:JAD141626 .

ns8:JAE190924 ns0:inAuthorList ns150:JAE190924 .

ns8:JAE2271 ns0:inAuthorList ns150:JAE2271 .

ns40:JAD120787 ns0:inAuthorList ns150:JAD120787 .

ns40:JAD121930 ns0:inAuthorList ns150:JAD121930 .

ns40:JAD141314 ns0:inAuthorList ns150:JAD141314 .

ns40:JAD170564 ns0:inAuthorList ns150:JAD170564 .

ns40:JAD180025 ns0:inAuthorList ns150:JAD180025 .

ns28:JAD120508 ns0:inAuthorList ns150:JAD120508 .

ns130:JAD150167 ns0:inAuthorList ns150:JAD150167 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD161208> ns0:inAuthorList ns150:JAD161208 .

<http://ld.iospress.nl/rdf/contributor/Author:19.ID:JAD170039> ns0:inAuthorList ns150:JAD170039 .

ns12:CH2028 ns0:inAuthorList ns150:CH2028 .

ns12:HAB190368 owl:sameAs ns8:JRS740 ;
    ns0:fullName "Ali Akbari Sari" ;
    ns0:hasAffiliation ns13:HAB190368 ;
    ns0:hasArticle ns1:hab-v27-iS1-HAB190368 ;
    ns0:inAuthorList ns150:HAB190368 .

ns12:IFS172009 ns0:inAuthorList ns150:IFS172009 .

ns12:IFS172195 ns0:inAuthorList ns150:IFS172195 .

ns12:IFS181698 ns0:inAuthorList ns150:IFS181698 .

ns12:INF1217 ns0:inAuthorList ns150:INF1217 .

ns12:JAD101959 ns0:inAuthorList ns150:JAD101959 .

ns12:JAD132762 ns0:inAuthorList ns150:JAD132762 .

ns12:JAD150525 ns0:inAuthorList ns150:JAD150525 .

ns12:JAD170859 ns0:inAuthorList ns150:JAD170859 .

ns12:JAE1979 ns0:inAuthorList ns150:JAE1979 .

ns12:JAE2122 ns0:inAuthorList ns150:JAE2122 .

ns30:CH168033 ns0:inAuthorList ns150:CH168033 .

ns30:IFS2114 ns0:inAuthorList ns150:IFS2114 .

ns30:IFS2121 ns0:inAuthorList ns150:IFS2121 .

ns30:JAE190821 ns0:inAuthorList ns150:JAE190821 .

ns5:CH179102 ns0:inAuthorList ns150:CH179102 .

ns5:CH189404 ns0:inAuthorList ns150:CH189404 .

ns5:IFS171685 ns0:inAuthorList ns150:IFS171685 .

ns5:IFS18347 ns0:inAuthorList ns150:IFS18347 .

ns5:JAD130035 ns0:inAuthorList ns150:JAD130035 .

ns5:JAD160573 ns0:inAuthorList ns150:JAD160573 .

ns5:JAD170368 ns0:inAuthorList ns150:JAD170368 .

ns5:JAD180572 owl:sameAs ns2:JAD161209,
        ns12:JAD140630,
        ns12:JAD160774,
        ns16:JAD180631 ;
    ns0:fullName "Kaarin J. Anstey" ;
    ns0:hasAffiliation ns71:JAD180572 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180572 ;
    ns0:inAuthorList ns150:JAD180572 .

ns5:jad091012 ns0:inAuthorList ns150:jad091012 .

ns5:jad100207 ns0:inAuthorList ns150:jad100207 .

ns16:CH179221 ns0:inAuthorList ns150:CH179221 .

ns16:CH189114 ns0:inAuthorList ns150:CH189114 .

ns16:CH189115 ns0:inAuthorList ns150:CH189115 .

ns16:CH189116 ns0:inAuthorList ns150:CH189116 .

ns16:CH189405 ns0:inAuthorList ns150:CH189405 .

ns16:CH199220 owl:sameAs ns2:CH2005,
        ns8:CH189129,
        ns8:CH189415,
        ns8:CH1963,
        ns8:CH1964,
        ns26:CH179226,
        ns12:CH189411,
        ns30:CH179212,
        ns30:CH179216,
        ns30:CH199218,
        ns52:CH170265,
        ns57:CH168120,
        ns57:CH170246,
        ns60:CH189107,
        ns60:CH189905,
        ns60:CH199009,
        ns33:CH189309 ;
    ns0:fullName "L. Prantl" ;
    ns0:hasAffiliation ns21:CH199220 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199220 ;
    ns0:inAuthorList ns150:CH199220 .

ns16:CH2009 ns0:inAuthorList ns150:CH2009 .

ns16:CH2010 ns0:inAuthorList ns150:CH2010 .

ns16:JAD111361 ns0:inAuthorList ns150:JAD111361 .

ns16:JAD161114 ns0:inAuthorList ns150:JAD161114 .

ns16:jad00125 ns0:inAuthorList ns150:jad00125 .

ns52:CH168115 ns0:inAuthorList ns150:CH168115 .

ns52:HAB282 ns0:inAuthorList ns150:HAB282 .

ns52:JAD142025 ns0:inAuthorList ns150:JAD142025 .

ns52:JAD160766 ns0:inAuthorList ns150:JAD160766 .

ns52:JAD170226 ns0:inAuthorList ns150:JAD170226 .

ns52:JAD170950 ns0:inAuthorList ns150:JAD170950 .

ns52:JAD181039 ns0:inAuthorList ns150:JAD181039 .

ns52:jad00733 ns0:inAuthorList ns150:jad00733 .

ns57:CH168034 ns0:inAuthorList ns150:CH168034 .

ns57:CH168110 ns0:inAuthorList ns150:CH168110 .

ns57:CH2046 ns0:inAuthorList ns150:CH2046 .

ns57:JAD120019 ns0:inAuthorList ns150:JAD120019 .

ns57:JAD140339 ns0:inAuthorList ns150:JAD140339 .

ns57:JAD140669 ns0:inAuthorList ns150:JAD140669 .

ns57:JAD150897 ns0:inAuthorList ns150:JAD150897 .

ns57:JAD160195 ns0:inAuthorList ns150:JAD160195 .

ns57:JAD160528 ns0:inAuthorList ns150:JAD160528 .

ns57:JAD161146 ns0:inAuthorList ns150:JAD161146 .

ns57:JAD170402 ns0:inAuthorList ns150:JAD170402 .

ns60:JAD150537 ns0:inAuthorList ns150:JAD150537 .

ns60:JAD150897 ns0:inAuthorList ns150:JAD150897 .

ns60:JAD161126 ns0:inAuthorList ns150:JAD161126 .

ns60:JAD170604 ns0:inAuthorList ns150:JAD170604 .

ns33:JAD121471 ns0:inAuthorList ns150:JAD121471 .

ns1:bsi-v8-i1-2-BSI190185 ns0:hasKeywords "T2 relaxation time"@en,
        "acute ischaemic stroke"@en,
        "diffusion MRI"@en,
        "stroke onset time"@en ;
    ns0:hasPubAbstract "Background and objective: In hyperacute ischaemic stroke, T2 of cerebral water increases with time. Quantifying this change may be informative of the extent of tissue damage and onset time. Our objective was to develop a user-unbiased method to measure the effect of cerebral ischaemia on T2 to study stroke onset time-dependency in human acute stroke lesions.   Methods: Six rats were subjected to permanent middle cerebral occlusion to induce focal ischaemia, and a consecutive cohort of acute stroke patients ( n = 38) were recruited within 9 hours from symptom onset. T1-weighted structural, T2 relaxometry, and diffusion MRI for apparent diffusion coefficient (ADC) were acquired. Ischaemic lesions were defined as regions of lowered ADC. The median T2 difference (ΔT2) between lesion and contralateral non-ischaemic control region was determined by the newly-developed spherical reference method, and data compared to that obtained by the mirror reference method. Linear regressions and receiver operating characteristics (ROC) were compared between the two methods.   Results: ΔT2 increases linearly in rat brain ischaemia by 1.9 ± 0.8 ms/h during the first 6 hours, as determined by the spherical reference method. In patients, ΔT2 linearly increases by 1.6 ± 1.4 and 1.9 ± 0.9 ms/h in the lesion, as determined by the mirror reference and spherical reference method, respectively. ROC analyses produced areas under the curve of 0.83 and 0.71 for the spherical and mirror reference methods, respectively.   Conclusions: Data from the spherical reference method showed that the median T2 increase in the ischaemic lesion is correlated with stroke onset time in a rat as well as in a human patient cohort, opening the possibility of using the approach as a timing tool in clinics."@en ;
    ns0:hasPubTitle "Determining T2 relaxation time and stroke onset relationship in ischaemic stroke within apparent diffusion coefficient-defined lesions. A user-independent method for quantifying the impact of stroke in the human brain"@en .

ns1:ch-v71-i4-CH199005 ns0:hasKeywords "Adipocyte"@en,
        "cold"@en,
        "dedifferentiation"@en,
        "lipid"@en ;
    ns0:hasPubAbstract "Lipid-containing adipocytes can dedifferentiate into fibroblast-like cells under appropriate culture conditions, which are known as dedifferentiated fat (DFAT) cells. However, the relative low dedifferentiation efficiency with the established protocols limit their widespread applications. In this study, we found that adipocyte dedifferentiation could be promoted via periodic exposure to cold (10°C) in vitro. The lipid droplets in mature adipocytes were reduced by culturing the cells in periodic cooling/heating cycles (10–37°C) for one week. The periodic temperature change led to the down-regulation of the adipogenic genes (FABP4, Leptin) and up-regulation of the mitochondrial uncoupling related genes (UCP1, PGC-1α, and PRDM16). In addition, the enhanced expression of the cell proliferation marker Ki67 was observed in the dedifferentiated fibroblast-like cells after periodic exposure to cold, as compared to the cells cultured in 37°C. Our in vitro model provides a simple and effective approach to promote lipolysis and can be used to improve the dedifferentiation efficiency of adipocytes towards multipotent DFAT cells."@en ;
    ns0:hasPubTitle "Dedifferentiation of mature adipocytes with periodic exposure to cold"@en .

ns1:ch-v72-i1-CH189907 ns0:hasKeywords "Hypernatremia"@en,
        "endothelial glycocalyx"@en,
        "sublingual microcirculation"@en,
        "syndecan"@en ;
    ns0:hasPubAbstract "BACKGROUND AND OBJECTIVE: The endothelial glycocalyx (EG) is fragile and sensitive to damage such as exposure to hypernatremia. Our aim was to describe the influence of hypernatremia on the EG in sublingual and brain microcirculation in rabbits.   METHODS: Hypernatremia was induced by intravenous administration of 10% NaCl solution. The sublingual and brain microcirculation were evaluated by the Side-stream Dark Field imaging before (T1) and 20 minutes after infusion of 10% saline (T2). Damage to the EG was quantified by automated analysis of Perfused Boundary Region (PBR) indicating the amount of penetration of red blood cells into the EG. Syndecan-1 levels were also measured.   RESULTS: Hypernatremia was reached in all 20 animals, the PBR values of the sublingual area raised from 1,98 (0,3) to 2,17 (0,18) μm (p = 0,05). The levels of syndecan-1 (1,23 (0,36); 1,31 (0,33) ng/l, p = 0,3) did not mirror PBR changes.   CONCLUSIONS: Hypernatremia increased the PBR within the sublingual microcirculation in our animal model, probably due to compression of the EG related to temporary intravascular hypervolemia and changes of the EG charge in RBC instead of direct damaging effect on EG, which has been excluded by rather unchanged levels of syndecan-1."@en ;
    ns0:hasPubTitle "Effect of acute hypernatremia induced by hypertonic saline administration on endothelial glycocalyx in rabbits"@en .

ns1:ch-v72-i2-CH180470 ns0:hasKeywords "Dance movement therapy"@en,
        "elderly women"@en,
        "erythrocyte deformability"@en,
        "haemorheology"@en,
        "plasma viscosity"@en ;
    ns0:hasPubAbstract "OBJECTIVE:  The aim of this study was to analyse the effects of dance movement therapy exercises (DMT) on the rheological properties of blood in elderly women.  METHODS:  The study encompassed group of women (mean aged: 67 years), who were subjected to three-month dance movement therapy programme (n = 20). Blood samples from all the women were examined for their haematological, rheological, and biochemical parameters both prior to the study and three months thereafter.  RESULTS:  DMT did not cause statistically significant differences in the number of erythrocytes, thrombocytes, leukocytes and the haematocrit value. DMT affected the rheological parameters of the blood in elderly women, improving the erythrocyte deformability at the lowest shear stress value and reducing the half-time of the total aggregation. Plasma viscosity and concentration of fibrinogen did not change after dance therapy.  CONCLUSIONS:  DMT modulate rheological properties of blood of older women. The results of this study suggest that physical exercise program for older women can prevent unfavorable age-related changes. Some indicators such as the haematological parameters, plasma viscosity and fibrinogen level were not affected by DMT in older women, suggesting the maintenance of homeostasis."@en ;
    ns0:hasPubTitle "Effects of dance movement therapy on the rheological properties of blood in elderly women"@en .

ns1:ch-v72-i2-CH180476 ns0:hasKeywords "Cardiac hypertrophy"@en,
        "MEK inhibitor"@en,
        "TAK733"@en,
        "norepinephrine"@en ;
    ns0:hasPubAbstract "BACKGROUND: Cardiac hypertrophy is an important risk factor for heart failure. The MEK-ERK axis has been reported as a major regulator in controlling cardiac hypertrophy. TAK733 is a potent and selective MEK inhibitor that suppresses cell growth in a broad range of cell lines.   OBJECTIVE: Therefore, we aimed to investigate the anti-hypertrophic effect of TAK733 in cardiomyocytes.   METHODS: Cardiomyocyte hypertrophy was induced with norepinephrine (NE) or phenylepinephrine (PE) using H9c2 cells. To confirm the cardiomyocyte hypertrophy, cell size and protein synthesis were measured and hypertrophy-related gene expression was estimated by reverse transcription polymerase chain reaction. To identify the signaling pathway involved, immunoblot analysis were performed.   RESULTS: We observed that NE activated MEK-ERK signaling and increased ANP and BNP expression, resulting in cardiomyocyte hypertrophy. TAK733 significantly reduced cardiomyocyte hypertrophy by regulating NE-induced ERK1/2 and ERKThr188 activation, hypertrophy marker expression, and cardiomyocyte hypertrophy through depression of MEK activity. In addition, we examined that PE-induced cardiomyocyte hypertrophy was also attenuated by TAK733.   CONCLUSIONS: Here, we report that TAK733 suppressed NE- or PE-induced cardiomyocyte hypertrophy by repressing a crucial component of cardiac hypertrophy-related pathways. These results suggest that TAK733 may be a useful therapeutics for cardiac hypertrophy and warrants further in vivo studies."@en ;
    ns0:hasPubTitle "TAK733 attenuates adrenergic receptor-mediated cardiomyocyte hypertrophy via inhibiting ErkThr188 phosphorylation"@en .

ns1:ch-v73-i1-CH199202 ns0:hasKeywords "CEUS"@en,
        "MRI"@en,
        "adenocarcinoma"@en,
        "gallbladder alterations"@en,
        "histopathological findings"@en ;
    ns0:hasPubAbstract "BACKGROUND: Conventional ultrasound and MRI are very important techniques for the detection of gallbladder alterations. In the past years, studies showed that the additional use of contrast media to the conventional ultrasound allows the early depiction of pathological microvessels and their flow elucidating suspect findings stipulating the prompt therapy approach.   OBJECTIVE: The study aims to evaluate the performance of CEUS in gallbladder diseases and compare it to MR imaging using histopathological findings as a gold standard.   MATERIAL AND METHODS: The retrospective mono-center study analysed 18 patients with gallbladder alterations between 2009 and 2017. All patients underwent CEUS and MRI examinations and all results were confirmed in the pathology. CEUS images were performed and interpreted by a single experienced physician.   RESULTS: CEUS imaging results compared to MR imaging of the gallbladder demonstrated a sensitivity of 100%, specificity of 93%, a positive predictive value of 67% and a negative predictive value of 100%.   CONCLUSION: CEUS enables the depiction and characterization of important vascularization’s patterns facilitating the early differentiation between malignant and benign findings. In this study, CEUS displayed a better diagnostic accuracy than MRI proving to be a valuable additional tool to the established imaging modalities."@en ;
    ns0:hasPubTitle "Performance of contrast-enhanced ultrasound (CEUS) compared to MRI in the diagnostic of gallbladder diseases"@en .

ns1:ch-v73-i1-CH199206 ns0:hasKeywords "E-modulus"@en,
        "Electrospun fibers"@en,
        "mesenchymal stem cells"@en,
        "osteogenic differentiation"@en,
        "polyetheresterurethane"@en ;
    ns0:hasPubAbstract "Electrospinning has attracted significant attention as a method to produce cell culture substrates whose fibrous structure mimics the native extracellular matrix (ECM). In this study, the influence of E-modulus of fibrous substrates on the lineage commitment of human adipose-derived stem cells (hADSCs) was studied using fiber meshes prepared via the electrospinning of a polyetheresterurethane (PEEU) consisting of poly(ρ-dioxanone) (PPDO) and poly(ɛ-caprolactone) (PCL) segments. The PPDO: PCL weight ratio was varied from 40:60 to 70:30 to adjust the physiochemical properties of the PEEU fibers. The cells attached on stiffer PEEU70 (PPDO:PCL,= 70:30) fiber meshes displayed an elongated morphology compared to those cultured on softer fibers. The nuclear aspect ratio (width vs. length of a nucleus) of hADSCs cultured on softer PEEU40 (PPDO:PCL = 40:60) fibers was lower than on stiffer fibers. The osteogenic differentiation of hADSCs was enhanced by culturing on stiffer fibers. Compared to PEEU40, a 73% increase of osteocalcin expression and a 34% enhancement of alkaline phosphatase (ALP) activity was observed in cells on PEEU70. These results demonstrated that the differentiation commitment of stem cells could be regulated via tailoring the mechanical properties of electrospun fibers."@en ;
    ns0:hasPubTitle "The effect of stiffness variation of electrospun fiber meshes of multiblock copolymers on the osteogenic differentiation of human mesenchymal stem cells"@en .

ns1:ch-v73-i1-CH199223 ns0:hasKeywords "Low-risk prostate cancer"@en,
        "PI-RADS classification"@en,
        "active surveillance"@en,
        "fusion biopsy"@en,
        "multiparametric MRI"@en ;
    ns0:hasPubAbstract "INTRODUCTION: Multiparametric-Magnetic Resonance Imaging (mpMRI)-Ultrasound fusion guided biopsy (Fbx) has emerged as the new standard of risk stratification for prostate cancer (PCa) with superior detection rates of clinically significant PCa than randomized biopsy. In the present study, we evaluated patients with suspicion of clinically significant PCa on mpMRI, but histopathologically proven Gleason 6 PCa in Fbx.   MATERIAL AND METHODS: Between 2015 and 2019, 849 patients underwent Fbx and concurrent systematic 12-core biopsy at our department. 234 patients were diagnosed with Gleason 6 PCa in either mpMRI-targeted and/or concurrent systematic biopsy. Patients were analyzed regarding PSA, mpMRI findings according to PI-RADS classification, histopathological results of Fbx and systematic 12-core biopsy. 99/234 patients were also analyzed in regards of histopathology of the whole-mount specimen of subsequent radical prostatectomy (RP).   RESULTS: In 131/234 patients (56%), Gleason 6 PCa was detected in the mpMRI target. In 103/234 patients (44%), Gleason 6 PCa was detected in the concurrent systematic 12-core biopsy with negative mpMRI-targeted biopsy. Men with evidence of Gleason 6 in the mpMRI target had significantly higher amounts of overall positive biopsies (median 4 vs. 2, p < 0.001) and higher maximum tumor infiltration per biopsy core (30% vs. 20%, p < 0.001) compared to men with negative mpMRI-targeted biopsy. Detection of Gleason 6 in mpMRI Target lesions correlated significantly with the PI-RADS score (p < 0.001). Patients with positive mpMRI-target had significantly higher tumor infiltration in whole-mount specimen after prostatectomy (20% vs. 15%, p = 0.0026) compared to men without detection of Gleason 6 in mpMRI-targeted biopsy but in additional systematic biopsy.   CONCLUSION: Detection of Gleason 6 PCa in mpMRI-targeted biopsy indicates higher tumor burden compared to detection of Gleason 6 PCa in concurrent systematic biopsy and negative mpMRI-targeted biopsy."@en ;
    ns0:hasPubTitle "Detection of Gleason 6 prostate cancer in patients with clinically significant prostate cancer on multiparametric magnetic resonance imaging"@en .

ns1:ch-v73-i1-CH199224 ns0:hasKeywords "Microwave ablation (MWA)"@en,
        "contrast enhanced ultrasound (CEUS)"@en,
        "perfusion analysis"@en,
        "primary and secondary liver malignancies"@en,
        "radiofrequency ablation (RFA)"@en ;
    ns0:hasPubAbstract "AIM: Evaluation of the post-interventional success following ablative techniques (radiofrequency and microwave) using a new color coded perfusion quantification software with CEUS in patients with primary and secondary liver malignancies.   MATERIAL AND METHODS: 75 patients (60 males, 15 females, age 24–84 years, mean 62.7 years) with 128 malignant liver lesions were included in this study. Between 01/2013 and 06/2018, the therapeutic interventional procedure in 88 lesions was MWA, in 40 lesions RFA. All patients underwent CEUS using a convex multifrequency probe (1–6 MHz) following application of 1–2.4 ml sulphur hexaflouride microbubbles, before and within 24 hours following RFA and MWA to detect residual tumor tissue. Postprocessing of the stored DICOM loops from 15 sec up to 1 min using a perfusion quantification software regarding peak enhancement (pE), time to peak (TTP), mean transit time (MTT), rise time (Ri) and Wash-in area under the curve (WiAUC) in the center of the lesion, the border area and periphery was performed.   RESULTS: In patients treated with RFA, pE differences between center of the lesion vs. surrounding liver were found to be statistically extremely significant (p < 0.001), differences between center of the lesion and margin were also statistically significant (p < 0.01). mTT, TTP, WiAuC and Ri showed no significant difference between center, margin or surrounding liver. In patients treated with MWA, statistically significant differences (p < 0.05) were found for pE, Ri and mTT regarding the differences between center of lesion and surrounding tissue. WiAuC and TTP showed no significant differences between center, margin or surrounding liver.   CONCLUSION: CEUS with perfusion imaging is a valuable supporting tool for post-interventional success control following RFA and MWA of primary and secondary liver maligancies. Focus should be placed upon pE following MWA and pE, Ri and mTT following RFA."@en ;
    ns0:hasPubTitle "Color coded perfusion analysis and microcirculation imaging with contrast enhanced ultrasound (CEUS) for post-interventional success control following thermal ablative techniques of primary and secondary liver malignancies"@en .

ns1:fi-v171-i1-4-FI1870 ns0:hasKeywords "Cellular Automata"@en,
        "Crowding"@en,
        "Modeling and Simulations"@en,
        "Pedestrian Crowds"@en ;
    ns0:hasPubAbstract "Models for the automated analysis and simulation of the complex phenomena observable in built environment crowded by pedestrians have been studied for over thirty years. Nonetheless, one of the commonly agreed upon rules guiding regulation of distance among pedestrian, i.e. proxemics, was defined and discussed in static settings, whereas scenarios of interest generally deal with individual and collective movements in crowds. The present paper presents a systemic perspective on the research aimed at defining a dynamic form of proxemics. The paper firstly reports the results of an experiment focused on proxemics and pedestrians personal space, as the hidden dimension of human spatial behavior in crowded environments. We propose a representation of personal space through discrete potentials and an innovative crowding estimation method (i.e. Cumulative Mean Crowding), going beyond simple perceived density evaluation. The experimental setting is introduced and applied to appraise the potential impact of this novel pedestrian perception mechanism on innovative simulation models."@en ;
    ns0:hasPubTitle "Unveiling the Hidden Dimension of Pedestrian Crowds: Introducing Personal Space and Crowding into Simulations"@en .

ns1:hab-v27-iS1-HAB190367 ns0:hasKeywords "Client satisfaction"@en,
        "Ethiopia"@en,
        "emergency department services"@en,
        "emergency medical care"@en,
        "quality care"@en ;
    ns0:hasPubAbstract "BACKGROUND:  The utilization of the emergency department to provide an emergency medical services is crucial for the communities who need an urgent medical care that is associated with various cases. This aim of this review was to describe the client satisfaction on the services of Emergency department and the quality of emergency medical care in Ethiopia.   METHOD:  We searched peer-reviewed published articles related to clients’ satisfaction on emergency department services and the quality of emergency medical care between January 2000 and December 2017. The articles were retrieved from databases of PubMed, Scopus, Ovid, Google Scholar, MEDLINE, EMBASE and ScienceDirect. Furthermore, studies published in other language than English was excluded.   RESULTS:  A total of 2094 participants: 906 (43%) males and 1188 (57%) females were recruited in those reviewed papers to express their satisfaction on the service and the quality of emergency medical care of the Emergency department. Based on the study findings, majority 1177 (56%) of the participants were satisfied by emergency outpatient department (OPD) services. The majority 1018 (83%) of the participants were satisfied with the manner that was showed by the staffs working at the Emergency OPD. In similar manner, the satisfaction level of the participants in the Emergency OPD towards the accessibility of the emergency care services, courtesy of the staffs, quality of the services, physical environments, and existence of good communication with services provider were 72%, 97%, 81.5%, 55%, and 66%, respectively while 97.2% of them were dissatisfied with their privacy. On the other hand, 76% of the participants were satisfied with the service provided in the radiology section and other laboratory work.   CONCLUSION:  This study finding shown that there was the variety of client perception on the emergency department and its quality care. Therefore, Emergency outpatient department should be raised progressively further by health care managers, governmental executives, EMS directorate, and others to address the efficient attribute of deprived value of health care and continuity of care delivery system being tied with new policy in Ethiopia."@en ;
    ns0:hasPubTitle "Client satisfaction on Emergency department services and quality of emergency medical care in Ethiopia: A systematic review"@en .

ns1:hab-v27-iS1-HAB190371 ns0:hasKeywords "Anthropometric"@en,
        "Ethiopia"@en,
        "children"@en,
        "malnutrition"@en,
        "morbidity"@en,
        "mortality"@en ;
    ns0:hasPubAbstract "PURPOSE:  Famines and food shortages are one of the most common long time histories of Ethiopia. Hence, malnutrition has been persisted at alarming raters in the country. Moreover, it is a major cause of morbidity and mortality in Afar National Regional State of Ethiopia. Specifically, in Amibara and Awash Fentale districts. The anthropometric data were presented on height, weight, MUAC, weight/height/Age and Body Mass Index (BMI) of under-five children.   METHODS:  A cross-sectional descriptive survey was conducted from March 01, 2017 to June 15, 2018. The data was collected by using anthropometric measurement. A multi stage random sampling procedure was applied in order to recruit the required sample size. The data collections were conducted at two selected districts in Afar region by trained interviewers and health care providers. The data were analyzed by using SPSS Version 23. Bivariate analysis between dependent and independent variables was employed. Multivariate analysis was also done to control for possible confounding variable by selecting variable which show statistically significant association (P< 0.05).   RESULTS:  Out of 410 under five children’s anthropometric finding, the majorities (62.7%) of those registered under five children were male and (33.3%) were female. The majority (46.8%) of under five children were less than or equal to 50 cm by their height. Most (54.1%) of under five children were less than or equal to 12.5 cm by their MUAC. It indicated that they were diagnosed with severe malnutrition based on anthropometric measurements. Meanwhile, majority (64%) of under five children were less than 60% their weight/age. Regression analysis result indicated that all of the variables were not significant predictors of BMI for under five children (P> 0.05). Based on ANOVA result, there was significant difference between sex and other predictors (P= 0.031). This finding implies that improvement in food aid and poverty alleviation programs are very important. Based on the finding, it is important to provide high quality and quantity of food. Moreover, less access to assets and health services commonly contributed for malnutrition. Highlighting under five children’s malnutrition will help to develop and design future policies and programs in Ethiopia."@en ;
    ns0:hasPubTitle "Assessment of malnutrition and anthropometric measurement among 0–59 months aged children in Amibara and Awash Fentale districts, afar national regional state of Ethiopia"@en .

ns1:ifs-v36-i6-IFS181460 ns0:hasKeywords "Rough set"@en,
        "fuzzy hyperideal"@en,
        "fuzzy set"@en,
        "hyperquantale"@en,
        "rough fuzzy hyperideal."@en ;
    ns0:hasPubAbstract "Fuzzy set theory and Rough set theory are two useful mathematical tools for dealing with uncertainty and provides a general mathematical framework for dealing with uncertainty. In this paper, we introduce the notions of hyperideals of hyperquantales. The notions of (upper, lower) rough hyperideals of hyperquantales are given. Furthermore the notions of fuzzy hyperideals of hyperquantales are introduce and investigate their properties. Then, we introduce the concept of prime fuzzy hyperideals and establish relationships between these hyperideals and prime fuzzy hyperideals of hyperquantales. Finally we define rough upper (lower) fuzzy hyperideals of hyperquantales and investigate several related properties."@en ;
    ns0:hasPubTitle "Fuzzy hyperideals of hyperquantales"@en .

ns1:ifs-v36-i6-IFS181516 ns0:hasKeywords "Paythagorean cubic fuzzy sets"@en,
        "aggregation operators"@en,
        "confidence levels"@en,
        "decision making"@en ;
    ns0:hasPubAbstract "Pythagorean cubic fuzzy set, is an extension of the interval valued Pythagorean fuzzy set which relax the condition of the square sum of its membership and non-membership degree is less than or equal to one to supremum square sum of its membership and non-membership functions is less than one. Based on this information and by combining the idea of the confidence levels of each Pythagorean cubic fuzzy number, the proposed study investigated a new averaging and geometric operators, namely confidence Pythagorean cubic fuzzy weighted and geometric operators along with their order are presented. Some of their desired properties related to the new defined operators have been investigated. Under the given information, a multi criteria decision making process has been proposed with a numerical example for showing the effectiveness and validity of it."@en ;
    ns0:hasPubTitle "Pythagorean cubic fuzzy aggregation information based on confidence levels and its application to multi-criteria decision making process"@en .

ns1:jad-v69-i3-JAD181282 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β"@en,
        "cerebrospinal fluid"@en,
        "diagnosis"@en,
        "mild cognitive impairment"@en,
        "positron emission tomography"@en ;
    ns0:hasPubAbstract "There are conflicting results regarding how APOE genotype, the strongest genetic risk factor for Alzheimer’s disease (AD), influences spatial and longitudinal amyloid-β (Aβ) deposition and its impact on the selection of biomarker cut-points. In our study, we sought to determine the impact of APOE genotype on cross-sectional and longitudinal florbetapir positron emission tomography (PET) amyloid measures and its impact in classification of patients and interpretation of clinical cohort results. We included 1,019 and 1,072 Alzheimer’s Disease Neuroimaging Initiative participants with cerebrospinal fluid Aβ1 - 42 and florbetapir PET values, respectively. 623 of these subjects had a second florbetapir PET scans two years after the baseline visit. We evaluated the effect of APOE genotype on Aβ distribution pattern, pathological biomarker cut-points, cross-sectional clinical associations with Aβ load, and longitudinal Aβ deposition rate measured using florbetapir PET scans. 1) APOE ɛ4 genotype influences brain amyloid deposition pattern; 2) APOE ɛ4 genotype does not modify Aβ biomarker cut-points estimated using unsupervised mixture modeling methods if white matter and brainstem references are used (but not when cerebellum is used as a reference); 3) findings of large differences in Aβ biomarker value differences based on APOE genotype are due to increased probability of having AD neuropathology and are most significant in mild cognitive impairment subjects; and 4) APOE genotype and age (but not gender) were associated with increased Aβ deposition rate. APOE ɛ4 carrier status affects rate and location of brain Aβ deposition but does not affect choice of biomarker cut-points if adequate references are selected for florbetapir PET processing."@en ;
    ns0:hasPubTitle "APOE Effect on Amyloid-β PET Spatial Distribution, Deposition Rate, and Cut-Points"@en .

ns1:jad-v69-i3-JAD181295 ns0:hasKeywords "Aged"@en,
        "Alzheimer’s disease"@en,
        "dementia"@en,
        "opioids"@en,
        "pharmacoepidemiology"@en,
        "pneumonia"@en ;
    ns0:hasPubAbstract "Background: Pneumonia is a common cause for hospitalization and excess mortality among persons with Alzheimer’s disease (AD), but little research exists evaluating drug use as its risk factor.   Objective: We investigated the association between opioid use and hospital-treated pneumonia among community dwellers with AD.   Methods: This study was part of the Medication use and Alzheimer’s Disease (MEDALZ) cohort. We included all community dwellers newly diagnosed with AD during 2010–2011 in Finland with incident prescription opioid use (n = 5,623) and age-, sex-, and time since AD diagnosis-matched nonusers (n = 5,623). Opioid use data, modelled from pharmacy dispensing data, and hospital-treated pneumonia were retrieved from nationwide registers. Patients with active cancer treatment were excluded. Hazard models compared opioid users to nonusers, adjusting for comorbidities, socioeconomic position. and other drug use.   Results: Incident opioid use was associated with an increased risk of hospital-treated pneumonia compared to nonuse (adjusted HR, aHR 1.34, 95% CI 1.14–1.57). Highest risk was observed during the first two months of use (aHR 2.58, 95% CI 1.87–3.55). Compared to weak opioids, buprenorphine was not associated with a higher risk of pneumonia (aHR 1.20, 95% CI 0.83–1.76), but strong opioids were (aHR 1.84, 95% CI 1.15–2.97). The risk was higher for those using ≥50 morphine milligram equivalents (MME)/day (aHR 2.03, 95% CI 1.24–3.31), compared to using <50 MME/day.   Conclusions: Opioid use was associated with a risk of hospital-treated pneumonia in a dose-dependent manner among persons with AD. Risk-minimization strategies should be considered if opioid therapy is needed."@en ;
    ns0:hasPubTitle "Hospital-Treated Pneumonia Associated with Opioid Use Among Community Dwellers with Alzheimer’s Disease"@en .

ns1:jad-v69-i3-JAD181298 ns0:hasKeywords "C9ORF72"@en,
        "Progranulin"@en,
        "TREDEM"@en,
        "dementia with Lewy bodies"@en,
        "diagnosis"@en,
        "frontotemporal dementia"@en,
        "neuroimaging"@en,
        "overlap"@en ;
    ns0:hasPubAbstract "In the present work, we report the case of a patient presenting signs of Lewy body dementia (DLB) and frontotemporal dementia (FTD) throughout different phases of the disease. In January 2017, a 79-year-old right-handed living man was admitted to our Memory Clinic for the presence of behavioral disturbances and progressive cognitive decline. For the previous six years, he was monitored by other Neurological Clinics for the onset of extrapyramidal features. Indeed, through the first phase of the disease (2011–2014), the patient predominantly showed: extrapyramidal features, initial cognitive decline, sleep disturbances, and visual hallucinations, together with a reduced dopamine transporter uptake in basal ganglia at the DATscan, suggesting a diagnosis of DLB. In a second phase (2015–2017), while his extrapyramidal features remained substantially stable, his cognitive profile deteriorated, with an additional development of severe behavioral and neuropsychiatric disturbances. Again, a subsequent DATscan study was positive and slightly worse than the preceding one; however, the 18F-FDG PET showed reduced metabolic activity in the frontal and temporal lobes, with the occipital regions left spared. Genetic analysis revealed a hexanucleotide expansion in C9ORF72 (6//38 repeats; ITALSGEN NV <30). In conclusion, we report the case of a patient presenting, firstly, with probable DLB and, in a second phase, with predominant bvFTD features with stable parkinsonism. Even though some clinical and neuropsychological aspects can co-exist in different neurodegenerative diseases, we find such a significant intersection of clinical features to be fairly atypical. Moreover, what is challenging to define is whether the two clinical phenotypes are somehow lying on a continuum, or if they are two individual entities."@en ;
    ns0:hasPubTitle "Overlap Between Frontotemporal Dementia and Dementia with Lewy Bodies: A Treviso Dementia (TREDEM) Registry Case Report"@en .

ns1:jad-v69-i3-JAD190197 ns0:hasKeywords "Alzheimer’s disease"@en,
        "GSK3"@en,
        "lithium"@en,
        "neurotoxicity"@en,
        "post-translational modification"@en,
        "precision medicine"@en,
        "systems pharmacology"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Systems pharmacology is a novel framework for drug research that models traditional and innovative pharmacological parameters and provides the overall efficacy and safety profile of a drug across body systems and complex, non-linear, molecular interactions. Lithium chloride, a pharmacological compound approved for the therapy of psychiatric disorders, represents a poorly explored compound for the treatment of Alzheimer’s disease (AD). Lithium has been shown to reduce downstream effects associated with the aberrant overactivation of certain molecular pathways, such as glycogen synthase kinase 3 subunit β (GSK3-β)-related pathways, involved in AD-related pathophysiology. It seems that overactivation and overexpression of GSK3-β lead to an impairment of long-term potentiation and amyloid-β induced neurotoxicity that can be normalized using lithium. Moreover, a growing body of evidence has demonstrated that lithium’s GSK3-β inhibitory effect prevents tau phosphorylation in mouse models of tauopathies. Clinical data have been inconclusive, partly due to methodological limitations. The lack of studies exploring the dynamics of protein misfolding in AD and investigating the specific tau-isoforms appearing prior to the accumulation of neurofibrillary tangles calls for new and optimized clinical trials. Advanced computer modeling based on a formal implementation of quantitative parameters and basic enzymatic insights into a mechanism-based model would present a good start to tackle these non-linear interactions. This innovative approach will pave the way for developing “molecularly” biomarker-guided targeted therapies, i.e., treatments specifically adapted (“tailored”) to the individual, consistently with the primary objectives and key conceptual points of precision medicine and precision pharmacology."@en ;
    ns0:hasPubTitle "Lithium as a Treatment for Alzheimer’s Disease: The Systems Pharmacology Perspective"@en .

ns1:jad-v69-i4-JAD180932 ns0:hasKeywords "Anesthesia"@en,
        "cognitive dysfunction"@en,
        "dementia"@en,
        "functional magnetic resonance imaging"@en,
        "mild cognitive impairment"@en,
        "orthopedics"@en,
        "surgery"@en ;
    ns0:hasPubAbstract "Background: Research shows that older adults can have a decline in three key resting state networks (default mode network, central executive network, and salience network) after total knee arthroplasty and that patients’ pre-surgery brain and cognitive integrity predicts decline.   Objectives: First, to assess resting state network connectivity decline from the perspective of nodal connectivity changes in a larger older adult surgery sample. Second, to compare pre-post functional connectivity changes in mild cognitive impairment (MCI) versus non-MCI.   Methods: Surgery (n = 69) and non-surgery (n = 65) peers completed a comprehensive preoperative neuropsychological evaluation and pre- and acute (within 48 hours) post-surgery/pseudo-surgery functional brain magnetic resonance imaging scan. MCI was classified within both (MCI surgery, n = 13; MCI non-surgery, n = 10). Using standard coordinates, we defined default mode network, salience network, central executive network, and the visual network (serving as a control network). The functional connectivity of these networks and brain areas (nodes) that make up these networks were examined for pre-post-surgery changes through paired samples t-test and ANOVA.   Results: There was a decline in RSN connectivity after surgery (p < 0.05) only in the three cognitive networks (not the visual network). The default mode and salience network showed nodal connectivity changes (p < 0.01). MCI surgery had greater functional connectivity decline in DMN and SN. Non-surgery participants showed no significant functional connectivity change.   Conclusion: Surgery with general anesthesia selectively alters functional connectivity in major cognitive resting state networks particularly in DMN and SN. Participants with MCI appear more vulnerable to these functional changes."@en ;
    ns0:hasPubTitle "Mild Cognitive Impairment and Decline in Resting State Functional Connectivity after Total Knee Arthroplasty with General Anesthesia"@en .

ns1:jad-v69-i4-JAD190183 ns0:hasKeywords "Alzheimer’s disease"@en,
        "behavior"@en,
        "dementia"@en,
        "neuropsychiatry"@en ;
    ns0:hasPubAbstract "Background: Premorbid personality could play a role in the onset of behavioral and psychological symptoms (BPS) in Alzheimer’s disease (AD) but prospective studies are lacking.   Objective: The present study aimed at prospectively assessing the influence of premorbid personality traits on BPS evolution in a population of patients with prodromal or mild AD.   Methods: We used a multicenter prospective cohort study of 237 patients followed-up for 18 months. The influence of personality traits on BPS evolution, measured with Neuropsychiatric Inventory (NPI), was assessed using linear mixed-effect models.   Results: A principal components analysis of the 12 NPI behavioral domains yielded five factors labelled as psychotic symptoms, affective symptoms, behavioral dyscontrol, apathy/appetite symptoms, and sleep disorders. During the follow-up, higher neuroticism was significantly associated with a higher progression of affective symptoms (p < 0.0001), apathy/appetite symptoms (p = 0.002), sleep disorders (p = 0.001) as well as global NPI scores (p < 0.0001). Greater conscientiousness was related to a lower evolution of psychotic (p = 0.002), affective (p = 0.02) and apathy/appetite symptoms (p = 0.02), and global NPI score (p < 0.0001). Higher openness was associated with lower affective symptoms evolution (p = 0.01). A significant relationship was found between higher extraversion, lower affective symptoms (p = 0.02), and higher behavioral dyscontrol (p = 0.04).   Conclusion: The present analysis suggests that premorbid personality may influence the evolution of BPS in prodromal or mild AD. Given these results, it seems important to give more importance to personality assessment in early AD, in order to better identify and manage patients at risk of adverse behavioral changes."@en ;
    ns0:hasPubTitle "Does Personality Predict Behavioral and Psychological Symptoms of Dementia? Results from PACO Prospective Study"@en .

ns1:jad-v69-i4-JAD190187 ns0:hasKeywords "Alzheimer’s disease"@en,
        "brevican"@en,
        "neurocan"@en,
        "tenascin-C"@en,
        "tenascin-R"@en ;
    ns0:hasPubAbstract "Background: Brevican, neurocan, tenascin-C, and tenascin-R are extracellular matrix (ECM) proteins that are mainly expressed in the brain. They play important roles in proliferation and migration of neurons and other cell types in the brain. These ECM proteins may also be involved in various pathologies, including reactive gliosis.   Objective: The aim of the study was to investigate if ECM protein concentrations in cerebrospinal fluid (CSF) are linked to the neurodegenerative process in Alzheimer’s disease (AD).   Methods: Lumbar CSF samples from a non-AD control group (n = 50) and a clinically diagnosed AD group (n = 42), matched for age and gender, were analyzed using commercially available ELISAs detecting ECM proteins. Mann-Whitney U test was used to examine group differences, while Spearman’s rho test was used for correlations.   Results: Brevican, neurocan, tenascin-R, and tenascin-C concentrations in AD patients did not differ compared to healthy controls or when the groups were dichotomized based on the Aβ42/40 cut-off. CSF tenascin-C and tenascin-R concentrations were significantly higher in women than in men in the AD group (p = 0.02).   Conclusion: ECM proteins do not reflect AD-pathology in CSF. CSF tenascin-C and tenascin-R upregulation in women possibly reveal sexual dimorphism in the central nervous system immunity during AD."@en ;
    ns0:hasPubTitle "Cerebrospinal Fluid Concentrations of Extracellular Matrix Proteins in Alzheimer’s Disease"@en .

ns1:jad-v70-i2-JAD181030 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid"@en,
        "cognitive reserve"@en,
        "cortisol"@en ;
    ns0:hasPubAbstract "Elevated cortisol as a measure of hypothalamic-pituitary-adrenal-axis hyperactivity has emerged as a predictor of clinical progression of Alzheimer’s disease (AD), in conjunction with amyloid-β (Aβ) abnormalities. Yet factors exist which have the propensity to delay AD symptomatic expression in the face of an AD-type biomarker-based pathological profile. This study sought to determine whether abnormal cerebrospinal fluid (CSF) Aβ and elevated cortisol levels are associated with clinical transition to mild cognitive impairment (MCI) and AD in cognitively normal (CN) individuals, and if this association is modified by reserve proxies. Data from 91 CN individuals participating in the Alzheimer’s Disease Neuroimaging Initiative (ADNI) with available morning CSF cortisol and Aβ42 were evaluated. Reserve was modelled as a latent composite score of standardized intracranial volume and lifetime experience proxies. Cox regressions were used to test associations between baseline CSF cortisol/Aβ42, reserve score and AD progression; adjusting for age, sex, apolipoprotein E genotype, and depressive symptoms. Individuals with elevated cortisol + abnormal Aβ42 levels at baseline showed highest risk of clinical progression. After a median of 84 months follow-up, significant cortisol/Aβ/ reserve interaction for clinical progression was noted (adjusted HR = 0.15, p < 0.001), suggesting a moderating effect of reserve on the association between cortisol/Aβ+ and clinical progression. Our findings indicate that cortisol hypersecretion accelerates clinical progression in CN individuals presenting with pathological Aβ42. High reserve reduces the associated AD progression risk in these high-risk individuals."@en ;
    ns0:hasPubTitle "Cortisol, Amyloid-β, and Reserve Predicts Alzheimer’s Disease Progression for Cognitively Normal Older Adults"@en .

ns1:jad-v70-i2-JAD190023 ns0:hasKeywords "Alzheimer vaccines"@en,
        "Alzheimer’s disease"@en,
        "amyloid-β oligomers"@en,
        "plant"@en,
        "prevention"@en,
        "soybean"@en,
        "spatial memory"@en ;
    ns0:hasPubAbstract "Amyloid-β (Aβ) plays a central role in the pathogenesis of Alzheimer’s disease (AD). Because AD pathologies begin two decades before the onset of dementia, prevention of Aβ amyloidosis has been proposed as a mean to block the pathological cascade. Here, we generate a transgenic plant-based vaccine, a soybean storage protein containing Aβ4–10, named Aβ+, for oral Aβ immunization. One mg of Aβ+ or control protein (Aβ–) was administered to TgCRND8 mice once a week from 9 weeks up to 58 weeks. Aβ+ immunization raised both anti-Aβ antibodies and cellular immune responses. Spatial learning decline was prevented in the Aβ+ immunized group in an extended reference memory version of Morris water maze test from 21 to 57 weeks. In Tris-buffered saline (TBS), sodium dodecyl sulfate (SDS), and formic acid (FA) serial extractions, all sets of Aβ species from Aβ monomer, low to high molecular weight Aβ oligomers, and Aβ smears had different solubility in TgCRND8 brains. Aβ oligomers decreased in TBS fractions, corresponding to an increase in high molecular weight Aβ oligomers in SDS extracts and Aβ smears in FA fraction of the Aβ+ treated group. There was significant inhibition of histological Aβ burden, especially in diffuse plaques, and suppression of microglial inflammation. Processing of amyloid-β protein precursor was not different between Aβ+ and Aβ– groups. No evidence of amyloid-related inflammatory angiopathy was observed. Thus, Aβ+ oral immunization could be a promising, cheap, and long-term safe disease-modifying therapy to prevent the pathological process in AD."@en ;
    ns0:hasPubTitle "Oral Immunization with Soybean Storage Protein Containing Amyloid-β 4–10 Prevents Spatial Learning Decline"@en .

ns1:jad-v70-i4-JAD180857 ns0:hasKeywords "Cognition"@en,
        "dementia"@en,
        "depressive symptoms"@en,
        "mild cognitive impairment"@en,
        "proxy-report"@en,
        "subjective cognitive decline"@en ;
    ns0:hasPubAbstract "Background: It is uncertain whether self- and proxy-reported cognitive decline in older adults reflect an actual objective cognitive dysfunction in the clinical sense, and if these are predictive for developing dementia.   Objective: The aim of the present study is to investigate the cross-sectional and longitudinal relation between subjective cognitive decline and objective cognitive performance, depressive symptoms, and to determine the predictive value for development of dementia.   Methods: We included 405 patients without dementia at first visit from the Maastricht memory clinic participating in a longitudinal cohort study. Subjective cognitive decline was measured using a self- and proxy-report questionnaire. All patients underwent a standardized neuropsychological assessment. Follow-up assessments were performed yearly for three consecutive years, and once after five years.   Results: Subjective cognitive decline was associated with lower cognitive performance and more depressive symptoms. When comparing self- (n = 342, 84%) and proxy-reported decline (n = 110, 27%), it was shown that proxy reports were associated with a more widespread pattern of lower cognitive performance. In participants without cognitive impairment proxy-reported decline was not associated with depressive symptoms. In contrast, self-reported decline was associated with a stable course of depressive symptoms at follow-up. Proxy-reported cognitive decline (HR = 1.76, 95% CI = 1.12– 2.78), and mutual complaints (HR = 1.73, CI:1.09– 2.76) predicted incident dementia while self-reported decline did not reach statistical significance (HR = 1.26, 95% CI = 0.65– 2.43).   Conclusion: Proxy-reported cognitive decline was consistently associated with lower cognitive performance and conversion to dementia over 5 years. Self-reported cognitive decline in patients without cognitive impairment might indicate underlying depressive symptoms and thus deserve clinical attention as well."@en ;
    ns0:hasPubTitle "Association Between Proxy- or Self-Reported Cognitive Decline and Cognitive Performance in Memory Clinic Visitors"@en .

ns1:jad-v71-i1-JAD190620 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid"@en,
        "diabetes mellitus"@en,
        "diabetes-related dementia"@en,
        "positron emission tomography"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Background/Objective: Although type 2 diabetes mellitus (DM) is a risk factor for the development of dementia, the underlying brain pathologies and mechanisms vary among patients. In this study, we classified patients with clinically diagnosed Alzheimer’s disease (AD) associated with DM into subgroups based on their amyloid and tau accumulation patterns on positron emission tomography (PET), and analyzed the differences in clinical features and brain imaging findings between the subgroups.   Methods: Sixty-four patients with probable or possible AD associated with DM were classified using PiB (detects amyloid, A) and PBB3 (detects tau, T) PET studies. Patients were classified into the A+/T+ group (n = 35, AD pathology), the A– /T+ group (n = 19, tauopathy), and the A– /T– group (n = 10, non-amyloid/non-tau neuronal damage).   Results: Compared with the A+/T+ group, the A– /T+ group showed less-well controlled glycemia, longer duration of diabetes, more glucose variability, higher frequency of insulin therapy and biochemical hypoglycemia, and greater impairment of frontal lobe function, slower progression of cognitive decline, fewer APOE4 carriers, less severe medial temporal lobe atrophy, and lower frequency of posterior cerebral hypoperfusion. This subgroup showed different clinical and radiological features from AD.   Conclusion: Among patients with clinically diagnosed AD with DM, there are subgroups with neuronal damage independent of AD pathology. A subgroup of dementia patients suspected of having tauopathy is strongly associated with DM-related metabolic abnormalities. This study highlights the identification of a novel dementia subgroup (diabetes-related dementia), which is important for considering appropriate therapies and care in clinical practice."@en ;
    ns0:hasPubTitle "Classification of Clinically Diagnosed Alzheimer’s Disease Associated with Diabetes Based on Amyloid and Tau PET Results"@en .

ns1:jad-v71-i2-JAD181175 ns0:hasKeywords "Aerobic exercise"@en,
        "amyloid deposition"@en,
        "brain volume"@en,
        "cardiovascular fitness"@en,
        "mild cognitive impairment"@en ;
    ns0:hasPubAbstract "Background: The current evidence is inconclusive to support the benefits of aerobic exercise training (AET) for preventing neurocognitive decline in patients with amnestic mild cognitive impairment (aMCI).   Objective: To examine the effect of a progressive, moderate-to-high intensity AET program on memory and executive function, brain volume, and cortical amyloid-β (Aβ) plaque deposition in aMCI patients.   Methods: This is a proof-of-concept trial that randomized 70 aMCI patients to 12 months of AET or stretching and toning (SAT, active control) interventions. Primary neuropsychological outcomes were assessed by using the California Verbal Learning Test-second edition (CVLT-II) and the Delis–Kaplan Executive Function System (D-KEFS). Secondary outcomes were the global and hippocampal brain volumes and the mean cortical and precuneus Aβ deposition.   Results: Baseline cognitive scores were similar between the groups. Memory and executive function performance improved over time but did not differ between the AET and SAT groups. Brain volume decreased and precuneus Aβ plaque deposition increased over time but did not differ between the groups. Cardiorespiratory fitness was significantly improved in the AET compared with SAT group. In amyloid positive patients, AET was associated with reduced hippocampal atrophy when compared with the SAT group.   Conclusion: The AET and SAT groups both showed evidence of slightly improved neuropsychological scores in previously sedentary aMCI patients. However, these interventions did not prevent brain atrophy or increases in cortical Aβ deposition over 12 months. In amyloid positive patients, AET reduced hippocampal atrophy when compared with the SAT group."@en ;
    ns0:hasPubTitle "Exercise Training in Amnestic Mild Cognitive Impairment: A One-Year Randomized Controlled Trial"@en .

ns1:jad-v71-i2-JAD190155 ns0:hasKeywords "Alzheimer’s disease"@en,
        "SC35"@en,
        "SH-SY5Y"@en,
        "cell cycle"@en,
        "phospho-tau protein"@en,
        "staurosporine"@en ;
    ns0:hasPubAbstract "It has been reported that the main function of tau protein is to stabilize microtubules and promote the movement of organelles through the axon in neurons. In Alzheimer’s disease, tau protein is the major constituent of the paired helical filament, and it undergoes post-translational modifications including hyperphosphorylation and truncation. Whether other functions of tau protein are involved in Alzheimer’s disease is less clear. We used SH-SY5Y human neuroblastoma cells as an in vitro model to further study the functions of tau protein. We detected phosphorylated tau protein as small dense dots in the cell nucleus, which strongly colocalize with intranuclear speckle structures that were also labelled with an antibody to SC35, a protein involved in nuclear RNA splicing. We have shown further that tau protein, phosphorylated at the sites recognized by pT231, TG-3, and AD2 antibodies, is closely associated with cell division. Different functions may be characteristic of phosphorylation at specific sites. Our findings suggest that the presence of tau protein is involved in separation of sister chromatids in anaphase, and that tau protein also participates in maintaining the integrity of the DNA (pT231, prophase) and chromosomes during cell division (TG-3)."@en ;
    ns0:hasPubTitle "Phospho-Tau Protein Expression in the Cell Cycle of SH-SY5Y Neuroblastoma Cells: A Morphological Study"@en .

ns1:jad-v71-i2-JAD190541 ns0:hasKeywords "Aging"@en,
        "cohort study"@en,
        "dementia"@en,
        "epidemiology"@en,
        "health inequalities"@en,
        "lifestyle"@en,
        "mediation"@en,
        "prevention"@en,
        "public health"@en,
        "risk factors"@en,
        "socioeconomic status"@en ;
    ns0:hasPubAbstract "Background: Differences in dementia risk across the gradient of socioeconomic status (SES) exist, but their determinants are not well understood.   Objective: This study investigates whether health conditions and lifestyle-related risk factors explain the SES inequalities in dementia risk.   Methods: 6,346 participants from the English Longitudinal Study of Ageing were followed up from 2008/2009 until 2014/2015. We used Cox regression adjusted for age, gender, wealth/education, and clustering at the household level to examine the association between SES markers (wealth, education) and time to dementia in a structural equation model including potential mediation or effect modification by a weighted compound score of twelve modifiable risk and protective factors for dementia (‘LIfestyle for BRAin health’ (LIBRA) score).   Results: During a median follow-up of 6 years, 192 individuals (3.0%) developed dementia. LIBRA scores decreased with increasing wealth and higher educational level. A one-point increase in the LIBRA score was associated with a 13% increase in dementia risk (hazard ratio (HR) = 1.13, 95% confidence interval 1.07–1.19). Higher wealth was associated with a decreased dementia risk (HR = 0.58, 0.39–0.85). Mediation analysis showed that 52% of the risk difference between the highest and lowest wealth tertile was mediated by differences in LIBRA (indirect effect: HR = 0.75, 0.66–0.85). Education was not directly associated with dementia (HR = 1.05, 0.69–1.59), but was a distal risk factor for dementia by explaining differences in wealth and LIBRA scores (indirect effect high education: HR = 0.92, 0.88–0.95).   Conclusion: Socioeconomic differences in dementia risk can be partly explained by differences in modifiable health conditions and lifestyle factors."@en ;
    ns0:hasPubTitle "Modifiable Risk Factors Explain Socioeconomic Inequalities in Dementia Risk: Evidence from a Population-Based Prospective Cohort Study"@en .

ns1:jad-v71-i3-JAD190262 ns0:hasKeywords "Alzheimer’s disease"@en,
        "classification"@en,
        "early diagnosis"@en,
        "machine learning"@en,
        "magnetic resonance imaging"@en,
        "mild cognitive impairment"@en,
        "predictive analytics"@en ;
    ns0:hasPubAbstract "Background: Predicting clinical course of cognitive decline can boost clinical trials’ power and improve our clinical decision-making. Machine learning (ML) algorithms are specifically designed for the purpose of prediction; however. identifying optimal features or algorithms is still a challenge.   Objective: To investigate the accuracy of different ML methods and different features to classify cognitively normal (CN) individuals from Alzheimer’s disease (AD) and to predict longitudinal outcome in participants with mild cognitive impairment (MCI).   Methods: A total of 1,329 participants from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) were included: 424 CN, 656 MCI, and 249 AD individuals. Four feature-sets at baseline (hippocampal volume and volume of 47 cortical and subcortical regions with and without demographics and APOE4) and six machine learning methods (decision trees, support vector machines, K-nearest neighbor, ensemble linear discriminant, boosted trees, and random forests) were used to classify participants with normal cognition from participants with AD. Subsequently the model with best classification performance was used for predicting clinical outcome of MCI participants.   Results: Ensemble linear discriminant models using demographics and all volumetric magnetic resonance imaging measures as feature-set showed the best performance in classification of CN versus AD participants (accuracy = 92.8%, sensitivity = 95.8%, and specificity = 88.3%). Prediction accuracy of future conversion from MCI to AD for this ensemble linear discriminant at 6, 12, 24, 36, and 48 months was 63.8% (sensitivity = 74.4, specificity = 63.1), 68.9% (sensitivity = 75.9, specificity = 67.8), 74.9% (sensitivity = 71.5, specificity = 76.3), 75.3%, (sensitivity = 65.2, specificity = 79.7), and 77.0% (sensitivity = 59.6, specificity = 86.1), respectively.   Conclusions: Machine learning models trained for classification of CN versus AD can improve our prediction ability of MCI conversion to AD."@en ;
    ns0:hasPubTitle "Optimizing Machine Learning Methods to Improve Predictive Models of Alzheimer’s Disease"@en .

ns1:jad-v71-i4-JAD190019 ns0:hasKeywords "Bilingualism"@en,
        "Hispanics/Latinos"@en,
        "cognition"@en,
        "memory"@en,
        "serial learning"@en,
        "sex differences"@en ;
    ns0:hasPubAbstract "Sixty percent of Hispanics/Latinos are bilingual which research suggests may confer certain cognitive advantages. Female sex confers cognitive advantages in verbal learning and memory compared to male sex, regardless of race or ethnicity. Understanding the independent and interactive associations of bilingualism and sex with cognition may aid in predicting cognitive aging in Hispanics/Latinos. We examined baseline (2008–2011) data from the Hispanic Community Health Study/Study of Latinos, a multicenter, prospective community-based study. Our analyses included 6,110 males and females ≥45 years old who self-reported birth and parents’ origin outside of the continental US, Spanish as their first language, and were evaluated in Spanish. Bilingualism was assessed along a Likert scale (1 = only Spanish to 4 = English>Spanish) for language proficiency (reading/spoken) and patterns of use (thinking/socializing). Cognitive testing included verbal learning, memory, fluency, and Digit Symbol Substitution (DSS). Linear regression models adjusted for relevant confounders, the complex survey design, and sampling weights. Participants’ self-reported language proficiency was Spanish better than English, while patterns of use suggested more Spanish than English. Higher language proficiency was associated with higher performance on all cognitive indices while higher patterns of use associated with higher fluency and DSS scores (p-values < 0.01). Female sex was associated with higher performance on all cognitive indices (p-values < 0.05). There were no significant interactions with bilingualism (regardless of metric) by sex on cognition. For Hispanics/Latinos residing in the continental US and reporting birth and parents’ origin elsewhere, bilingualism and female sex have independent cognitive benefits that are important to consider when evaluating cognitive performance."@en ;
    ns0:hasPubTitle "The Independent and Interactive Associations of Bilingualism and Sex on Cognitive Performance in Hispanics/Latinos of the Hispanic Community Health Study/Study of Latinos"@en .

ns1:jad-v71-i4-JAD190427 ns0:hasKeywords "Cohort studies"@en,
        "death"@en,
        "dementia"@en,
        "type 2 diabetes mellitus"@en ;
    ns0:hasPubAbstract "Diabetes is associated with a higher dementia and mortality risk. However, few studies have accounted for death when estimating the association between diabetes and dementia. We estimated absolute and relative risks of all-cause dementia according to diabetes exposure status in older adults while accounting for competing risk of death using illness-death models. Effect modification by specific characteristics (age, gender, education, cardiovascular risk factors, body mass index, cardiovascular history, depressive symptomatology, impaired renal function, and APOE ɛ4 genotype) was also investigated. We analyzed the Three-City study data, a French population-based cohort of adults aged 65 years and above who were followed up for 12 years from 1999–2001. Among 8,328 participants selected in the analytical sample (median age, 73.3 years; 60.3% women), 809 (9.3%) presented with diabetes at baseline. Over a median follow-up period of 8.3 years, 836 participants developed incident dementia. Baseline diabetes was associated with a higher risk of dementia: hazard ratio, 1.79 [95% confidence interval, 1.46–2.19]. No effect modification was shown. Diabetes was associated with a higher 12-year absolute risk of dementia and a lower dementia-free life expectancy (e.g., 14.5% [11.2–18.1] versus 8.7% [7.6–10.2], and 13.4 [12.7–14.1] years versus 16.5 [16.0–17.1] years, respectively, for a 70-year-old woman with the highest level of education). These findings support the potential impact of preventing diabetes on reducing dementia risk in older adults, with a 2-3-year higher dementia-free life expectancy for individuals without diabetes, and inform the design of future interventional trials."@en ;
    ns0:hasPubTitle "Diabetes-Associated Dementia Risk and Competing Risk of Death in the Three-City Study"@en .

ns1:jad-v71-i4-JAD190459 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cognitive function"@en,
        "neuroticism"@en,
        "openness"@en,
        "personality"@en ;
    ns0:hasPubAbstract "Background: A link between personality traits and cognitive performance has been shown in normal adults and elderly individuals. Very few studies have evaluated this link in Alzheimer’s disease (AD).   Objective: To better understand cognitive performance as regards to personality traits, our study was aimed to evaluate the role of premorbid personality on cognitive functioning in a population of patients presenting prodromal or mild AD.   Methods: 181 elderly with prodromal or mild AD participated in a cross-sectional, prospective cohort study. The participants completed a personality inventory and a neuropsychological battery exploring memory, attention, executive function, language, and praxis. Cognitive performance were compared according to the level of each personality trait, using multivariate MANOVA models.   Results: A higher level of neuroticism was associated with lower performance at similarities test (D = 9.49, p = 0.003), delayed Free and Cued Selective Reminding test (D = 5.22, p = 0.02), and digit span score (D = 7.99, p = 0.006). A higher level of openness was related to better performance at similarities (D = 4.33, p = 0.04), letter fluency (D = 11.45, p = 0.001), and category fluency test (D = 5.85, p = 0.02). Neuroticism interfered negatively with cognitive functioning at the prodromal stage; the association between openness and cognitive function was observed at both prodromal and mild AD stage.   Conclusion: These results suggest that personality traits, in particular neuroticism and openness, modulate cognitive abilities in patients with early AD. These results encourage the development of stress management programs to prevent its negative effects on cognitive aging."@en ;
    ns0:hasPubTitle "Personality Traits are Related to Selective Cognitive Impairment in Early Alzheimer’s Disease"@en .

ns1:jad-v71-i4-JAD190756 ns0:hasKeywords "Aging"@en,
        "brain-derived neurotrophic factor"@en,
        "cognitive training"@en,
        "mindfulness"@en,
        "physical exercise"@en ;
    ns0:hasPubAbstract "Previous studies have indicated that an active lifestyle is associated with better brain health and a longer life, compared to a more sedentary lifestyle. These studies, both on human and animal subjects, have typically focused on a single activity, usually physical exercise, but other activities have received an increasing interest. One proposed mechanism is that physical exercise increases levels of brain-derived neurotrophic factor (BDNF) in the brain. For the first time, the long-term effects on serum BDNF levels were compared in persons who engaged in either physical exercise training, cognitive training, or mindfulness practice during 5 weeks, and compared with an active control group. Two cohorts of healthy older individuals, one from the Boston area in the US and one from the Växjö area in Sweden, participated. A total of 146 participants were randomly assigned to one of the four groups. All interventions were structurally similar, using interactive, computer-based software that directed participants to carry out specified activities for 35 minutes/day, 5 days per week for 5 weeks. Blood samples were obtained at baseline and soon after the completion of the 5-week long intervention program, and serum BDNF levels were measured using a commercially available ELISA. Only the group that underwent cognitive training increased their serum BDNF levels after 5 weeks of training (F1,74 = 4.22, p = 0.044, partial η2 = 0.054), corresponding to an average 10% increase. These results strongly suggest that cognitive training can exert beneficial effects on brain health in an older adult population."@en ;
    ns0:hasPubTitle "Differential Effects of Physical Exercise, Cognitive Training, and Mindfulness Practice on Serum BDNF Levels in Healthy Older Adults: A Randomized Controlled Intervention Study"@en .

ns1:jad-v72-i2-JAD190622 ns0:hasKeywords "Cognitive frailty"@en,
        "frailty syndrome"@en,
        "mild cognitive impairment"@en,
        "physical frailty"@en,
        "white matter hyperintensity"@en ;
    ns0:hasPubAbstract "Background: Cognitive frailty (CF) is defined as simultaneous presence of physical frailty (PF) and cognitive impairment among older adults without dementia. Although white matter hyperintensities (WMH) as expressions of cerebral small vessel disease are associated with physical and cognitive decline and could manifest as CF, this association remains yet to be clarified.   Objects: To clarify the association between CF and WMH among memory clinic patients.   Methods: The subjects of this cross-sectional study were 121 cognitively normal (CN) and 212 mildly cognitively impaired (MCI) patients who presented to the Memory Clinic at the National Center for Geriatrics and Gerontology of Japan. PF status was defined based on the definition proposed by Fried and colleagues. CF was defined as simultaneous presence of pre-PF or PF and MCI. WMH volumes were measured using an automatic segmentation application. Multiple liner regression analyses with adjustment for cardiovascular risk factors were performed.   Results: Of all subjects, 77 (63.6%) and 22 (18.2%) CN patients and 132 (62.3%) and 65 (30.7%) MCI patients were categorized into pre-PF and PF, respectively. Multiple liner regression analysis showed that those with CF had higher WMH volumes than those without (β= 0.23). When categorized into six groups according to PF and cognitive status, the PF/CN (β= 0.15), pre-PF/MCI (β= 0.41), and PF/MCI (β= 0.34) groups had higher WMH volumes than the non-PF/CN group.   Conclusions: This study showed increased WMH volumes in CF and PF, indicating that WMH could be one of the key underlying brain pathologies of CF."@en ;
    ns0:hasPubTitle "Cross-Sectional Association Between Cognitive Frailty and White Matter Hyperintensity Among Memory Clinic Patients"@en .

ns1:jad-v72-i3-JAD190823 ns0:hasKeywords "Methodology"@en,
        "Trail Making Test"@en,
        "reaction time"@en,
        "subcortical ischemic vascular cognitive impairment"@en ;
    ns0:hasPubAbstract "Slowed behavioral reaction time is associated with pathological brain changes, including white matter lesions, the common clinical characteristic of subcortical ischemic vascular cognitive impairment (SIVCI). In the present study, reaction time (RT) employing Trails B of the Trail Making Test, with responses capped at 300 s, was investigated in SIVCI (n = 27) compared to cognitively healthy aging (CH) (n = 26). RT was significantly slowed in SIVCI compared to CH (Cohen’s d effect size = 1.26). Furthermore, failure to complete Trails B within 300 s was also a characteristic of SIVCI although some ostensibly cognitively healthy older adults also failed to complete within this time limit. Within the SIVCI group, RT did not differ significantly with respect to whether the patients were classified as having moderate/severe or mild, periventricular white matter changes visible on their diagnostic CT/MRI scans. This, together with the high degree of overlap in RT between the two SIVCI subgroups, raises the possibility that using visible ratings scales in isolation may lead to the underestimation of disease level."@en ;
    ns0:hasPubTitle "Reaction Time and Visible White Matter Lesions in Subcortical Ischemic Vascular Cognitive Impairment"@en .

ns1:jad-v72-i3-JAD190838 ns0:hasKeywords "Alzheimer’s disease"@en,
        "biomarkers"@en,
        "frontotemporal dementia"@en,
        "neurofilament"@en,
        "positron emission tomography"@en,
        "primary progressive aphasia"@en ;
    ns0:hasPubAbstract "Background: Primary progressive aphasia (PPA) is a heterogeneous syndrome that is difficult to diagnose at early stages. Plasma neurofilament light chain (NFL) has been proposed as a potential biomarker for PPA.   Objective: To examine the diagnostic properties of plasma NFL in PPA and to evaluate its association with clinical stages of the disease and brain metabolism.   Methods: Our study included 80 participants (13 with non-fluent, 12 with semantic, and 16 with logopenic variant PPA; 13 with amnestic Alzheimer’s disease [AD]; 13 with behavioral variant frontotemporal dementia; and 13 healthy controls). Plasma NFL concentration was measured using a high-sensitivity enzyme-linked immunosorbent assay (ELISA) kit. PET imaging was performed in a subgroup of patients.   Results: NFL discriminated patients from controls with an area under the curve of 0.914 (95% CI, 0.843–0.984; p < 0.001) (cut-off: 76.46 pg/mL; 94% sensitivity, 76.9% specificity). There were no significant differences between clinical syndromes (PPA subtypes), the main clinical forms of dementia (frontotemporal dementia and AD), or the expected pathological groups (frontotemporal lobar degeneration-tau [FTLD-tau], FTLD-TDP43, and AD). NFL levels showed weak to moderate correlations with age and functional scale score. We found no significant correlation with the extent of hypometabolism observed on FDG-PET images.   Conclusion: Plasma NFL is a non-specific marker of neurodegeneration, and may be helpful in the diagnosis of PPA. However, NFL does not permit differential diagnosis between PPA subtypes and is not correlated with the extent of neurodegeneration."@en ;
    ns0:hasPubTitle "Plasma Neurofilament Light Chain in Primary Progressive Aphasia and Related Disorders: Clinical Significance and Metabolic Correlates"@en .

ns1:jhd-v8-i3-JHD180337 ns0:hasKeywords "Point-light display"@en,
        "biomarker"@en,
        "neurodegenerative disease"@en,
        "visual perception"@en ;
    ns0:hasPubAbstract "Background: The ability of healthy individuals to detect biological motion by using a small number of moving points is well established in animals and humans. Perception of human movements may depend on internal models that drive self-generated movements and influence motion discrimination (Reed CL et al. 1995 and 2007). As a person’s motor repertoire deteriorates, the accuracy of these models may also decrease.  Objective: Determine if people with symptomatic Huntington’s disease (HD) have difficulty perceiving movements.  Methods: In this study point-light displays were created with a Vicon Motion Capture System by recording one individual with (impaired) and one individual without (healthy) Parkinson’s disease using a 13 joint marker set. Participants were asked to distinguish between three movements and determine if the movement was impaired or healthy. The ability of participants with and without HD to distinguish movement patterns and the time to perception were recorded.  Results: Analyses found participants with HD had a decreased ability to correctly detect movements and point-light image type. The stair climbing motion showed the largest effect as participants with HD had more difficulty correctly identifying both the movement and whether it was impaired or healthy. In addition, the participants without HD showed an improvement as trials progressed which could not be observed in the HD cohort.  Conclusions: As people with symptomatic HD have difficulty perceiving movements further investigations using point-light displays should be done to determine if these impairments might serve as an easily administered, non-invasive marker of disease state."@en ;
    ns0:hasPubTitle "Biological Motion Perception in Huntington’s Disease"@en .

ns1:jhd-v8-i4-JHD190365 ns0:hasKeywords "Huntington’s disease"@en,
        "at risk"@en,
        "genetic privacy"@en,
        "observational trial"@en,
        "psychological stressors"@en ;
    ns0:hasPubAbstract "Background: There is limited understanding of the feasibility of conducting long-term research among undiagnosed (pre-symptomatic) adults at risk to develop Huntington disease (HD), while protecting their emotional well-being and safety.   Objective: To assess pre-specified events pertaining to emotional well-being, safety, and feasibility among healthy consenting adults at risk for developing HD who have chosen not to undergo genetic testing.   Methods: PHAROS research participants prospectively reported the occurrence of events pertaining to psychological distress (psychiatric evaluations, depression, suicidality) and feasibility (maintaining confidentiality, study attrition). PHAROS enrolled 1001 participants.   Results: Events pertaining to psychological distress were reported by 35% of participants. The most common events included heightened suicide risk (26%), new onset depression (12%), and new mental health evaluation (9%); all occurred significantly more frequently among participants with expanded trinucleotide CAG repeats (≥37). Five deaths occurred, none related to suicide. Forty-one percent of participants reported self-disclosure of their HD at-risk status, and 15% reported that someone else (usually a family member) had done so. Confidentiality of CAG test results was maintained by investigators. The withdrawal rate was largely uniform over the study period and did not differ significantly by gender or CAG status.   Conclusions: The potentially vulnerable research participants in PHAROS showed good emotional tolerability and safety. Individual CAG data were not disclosed, and confidentiality about disclosure of at-risk HD status was well maintained by others (family, friends, etc.). Long-term research participation of adults at risk for HD who choose not to undergo pre-symptomatic DNA testing is well tolerated, safe and feasible."@en ;
    ns0:hasPubTitle "The Prospective Huntington At-Risk Observational Study (PHAROS): The Emotional Well-Being, Safety and Feasibility of Long-Term Research Participation"@en .

ns1:jpd-v9-i3-JPD191616 ns0:hasKeywords "Boxing training"@en,
        "Parkinson’s disease"@en,
        "community exercise"@en,
        "physiotherapy"@en ;
    ns0:hasPubAbstract "Background: Persons with Parkinson’s disease (PD) benefit from continuous exercise through participation in community-based exercise programs. However, community programs often lack PD-specific knowledge needed to provide safe and adequately dosed exercise.   Objective: To evaluate the acceptability and safety of a PD-specific boxing program in the community.   Methods: We developed specific educational resources to facilitate the boxing instructors. We also organized an educational and practical workshop for patients (n = 26) and instructors (n = 10), and assessed: (a) participants’ satisfaction; (b) instructors’ appreciation of the educational resources; and (c) numbers of patients interested in participating in the boxing program. After 18 months, patients and instructors completed a questionnaire evaluating: (a) participants’ satisfaction; (b) adverse events; (c) facilitators and barriers; and (d) proportion of participants at follow-up.   Results: Twenty-six persons with PD (62% men) and 10 boxing instructors participated in the workshop. 81% of patients and 80% of instructors were very satisfied. Instructors found the educational materials “very helpful” (60%) or “helpful” (40%). Patients expressed a clear interest (54%) or possible interest (46%) in the program. We initiated classes with 10 participants. At 18-months follow-up, the program consisted of four boxing sessions/week, led by three instructors, with 40 participants. Seventeen patients responded to the questionnaire at follow-up. Participants were “very satisfied” (53%), “satisfied” (35%) and neither satisfied nor unsatisfied (12%) with the program. Adverse effects were mild (e.g., muscle aches). Transportation and physical disability were the main barriers for participation.   Conclusions: The boxing program was well-received, with increasing numbers of participants at 18 months. The educational resources can support boxing instructors participating in current and future boxing classes being delivered in the community."@en ;
    ns0:hasPubTitle "Implementation of a Community-Based Exercise Program for Parkinson Patients: Using Boxing as an Example"@en .

ns1:jpd-v9-i4-JPD191675 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Parkinson’s disease"@en,
        "amyloid cascade hypothesis"@en,
        "amyloidogenic proteins"@en,
        "antimicrobial protection model"@en,
        "cross-seeding"@en,
        "evolvability hypothesis"@en ;
    ns0:hasPubAbstract "Aging-related neurodegenerative disorders are frequently associated with the aggregation of multiple amyloidogenic proteins (APs), although the reason why such detrimental phenomena have emerged in the post-reproductive human brain across evolution is unclear. Speculatively, APs might provide physiological benefits for the human brain during developmental/reproductive stages. Of relevance, it is noteworthy that cross-seeding (CS) of APs has recently been characterized in cellular and animal models of neurodegenerative disease, and that normal physiological CS of multiple APs has also been observed in lower organisms, including yeast and bacteria. In this context, our main objective is to discuss a possible involvement of the CS of APs in promoting evolvability, a hypothetical view regarding the function of APs as an inheritance of acquired characteristics against human brain stressors, which are transgenerationally transmitted to offspring via germ cells. Mechanistically, the protofibrils formed by the CS of multiple APs might confer hormesis more potently than individual APs. By virtue of greater encoded stress information in parental brains being available, the brains of offspring can cope more efficiently with forth-coming stressors. On the other hand, subsequent neurodegeneration caused by APs in parental brain through the antagonistic pleiotropy mechanism in aging, may suggest that synergistically, multiple APs might be more detrimental compared to singular AP in neurodegeneration. Taken together, we suggest that the CS of multiple APs might be involved in both evolvability and neurodegenerative disease in human brain, which may be mechanistically and therapeutically important."@en ;
    ns0:hasPubTitle "Possible Role of Amyloid Cross-Seeding in Evolvability and Neurodegenerative Disease"@en .

ns1:jvr-v51-i1-JVR191024 ns0:hasKeywords "Multiple sclerosis"@en,
        "workplace discrimination"@en ;
    ns0:hasPubAbstract "BACKGROUND: The purpose of this study was to investigate the patterns in allegations of workplace discrimination by individuals with multiple sclerosis (MS).   OBJECTIVE: To describe the discrimination, both actual and perceived, that has occurred against individuals with MS in comparison to a group of individuals with other disabilities (GENDIS) through analysis of the United States Equal Employment Opportunity Commission (EEOC) Integrated Mission System (IMS) database.   METHODS: An ex post facto, causal-comparative quantitative design was used to examine Americans with Disabilities Act Amendments Act (ADAAA) Title I complaints received by the EEOC from people with MS from 2009 through 2016 (n = 4,000) in comparison to the GENDIS group over the same time period (n = 139,728).   RESULTS: The MS group was less likely to allege discrimination regarding discharge but more likely to allege discrimination regarding reasonable accommodation, constructive discharge, discipline, insurance benefits, and demotion. Charging parties with MS were more likely to be female, younger, and Caucasian and less likely to identify as African American, Hispanic/Mexican, or Asian. The EEOC was more likely to evaluate allegations by adults with MS as having merit than those filed by the GENDIS group. Implications for vocational rehabilitation practice include the need for consultation regarding recognition of on-the-job discrimination and procedures for filing allegations consistent with EEOC guidelines; greater use of physical and occupational therapy; and development of cognitive support technology strategies to aid in job performance."@en ;
    ns0:hasPubTitle "Workplace discrimination allegations and outcomes involving charging parties with multiple sclerosis and other disabilities under Title I of the Americans with Disabilities Act Amendments Act: A causal comparative analysis"@en .

ns1:jvr-v51-i2-JVR191038 ns0:hasKeywords "SSI"@en,
        "Transition"@en,
        "disability"@en,
        "employment"@en,
        "self-determination"@en ;
    ns0:hasPubAbstract "BACKGROUND: As one of the PROMISE projects, ASPIRE sought to enhance education and career outcomes to reduce long-term reliance on SSI. Self-determination training was offered to transition-age youth with disabilities receiving SSI as an evidence-based intervention to improve employment and post-secondary outcomes.   OBJECTIVE: To investigate the implementation of self-determination training for transition-age youth with disabilities, and provide lessons learned to inform future programs.   METHODS: Researchers used grounded theory and qualitative methods to obtain data on challenges encountered and successful strategies for delivering self-determination training to youth with disabilities. Informants were case managers and trainers in a six-state demonstration.   RESULTS: Challenges encountered included low attendance and adapting training for groups with a range of disabilities. Successful strategies included scheduling other events in conjunction with the self-determination workshops and adapting the curriculum to be more interactive and relevant to the interests of teens. Youth outcomes were enhanced by increasing self-awareness and skills for disability disclosure.   CONCLUSION: Considering the wide variety of training content and delivery formats, self-determination training can prepare youth with disabilities for post-secondary education and employment."@en ;
    ns0:hasPubTitle "Teaching self-determination to youth with disabilities: The ASPIRE model"@en .

ns1:kca-v3-i3-KCA190056 ns0:hasKeywords "Targeted therapy"@en,
        "checkpoint inhibitor"@en,
        "immunotherapy"@en,
        "renal cell carcinoma"@en ;
    ns0:hasPubAbstract "Background: Both late and early phase immune checkpoint inhibitor (CPI) combination trials indicate an impending role of combinations in the first-line treatment of metastatic renal cell carcinoma (mRCC). Sequencing the options following failure of CPI combinations is an emerging conundrum.   Objective: To present our single-center clinical experience with targeted therapies (TT) following first-line CPI combinations.   Methods: mRCC patients who received TT following failure of a combination regimen with CPI were identified from an institutional database. Clinical information including tumor characteristics, survival outcomes, and adverse events was retrieved from medical records. Descriptive statistics and Kaplan-Meier survival functions were performed.   Results: Of 11 patients identified, median age was 63 (31–79) and 8 (73%) patients were male. First-line treatment was a CPI and TT combination in 7 (64%) patients while the rest received combination of two CPIs. The majority of patients (82%) were intermediate risk category at the initiation of targeted therapies. TTs utilized included cabozantinib (46%), lenvatinib and everolimus (27%), sunitinib (18%), and temsirolimus (9%). Best response was stable disease for 10 (91%) and partial response for 1 (9%) patient. In a median follow up of 9.1 months (range, 4.9–34.1), median progression free survival was 7.7 (95% CI 4.6–10.8) months. Progression has occurred in 7 patients, and 3 patients remain on treatment. One patient discontinued treatment due to toxicity.   Conclusions: In our report, TTs demonstrate effective disease control and safety. Further exploration in prospective setting is warranted."@en ;
    ns0:hasPubTitle "Targeted Therapies Following First-Line Immune Checkpoint Inhibitor Combination in Metastatic Renal Cell Carcinoma: A Single Center Experience"@en .

ns1:nha-v5-i2-NHA190068 ns0:hasKeywords "Carrageenan"@en,
        "inflammation"@en,
        "log-rank test"@en,
        "ulcerative colitis"@en ;
    ns0:hasPubAbstract "This article is an invited response to a critique by industry of our published study about the impact of carrageenan supplement on the interval to relapse in ulcerative colitis patients on a no-carrageenan diet."@en ;
    ns0:hasPubTitle "Reply to critique of “A randomized trial of the effects of the no-carrageenan diet on ulcerative colitis disease activity”"@en .

ns1:thc-v27-iS1-THC199029 ns0:hasKeywords "DM rats"@en,
        "ERK1/ 2mitogen-activated protein kinase"@en,
        "Exogenous hydrogen sulfide"@en,
        "MMPs/TIMPs expression dysregulation"@en,
        "inflammatory reaction"@en,
        "myocardial fibrosis"@en,
        "protein kinase C"@en ;
    ns0:hasPubAbstract "OBJECTIVE To investigate the roles and underlying mechanism of exogenous H2S (hydrogen sulfide) in attenuating the myocardial fibrosis in diabetic rats.   METHODS:  A total of 40 SD rats were randomly divided into 4 groups: control group, STZ group, STZ + H2S group and H2S group. To build the DM rat model , the rats in the STZ group and STZ + H2S group were injected streptozotocin (STZ) intraperitoneally, While the rats in the STZ + H2S group and the H2S group received sodium hydrosulfide (NaHS), which provides exogenous H2S. Eight weeks later, the myocardial tissues of rats were used to detecting the collagen deposition through Masson staining, as well as some protein expressions related to myocardial fibrosis and signaling pathway by western blotting.   RESULTS:  Comparing to control group, the collagen deposition of myocardial matrix remarkably increased in the STZ group, and almost all the proteins that are relative to myocardial fibrosis, inflammatory and signaling pathway show an overexpression, except for PPARG and NF-κBp65. When Compared with the STZ group, the collagen deposition was obviously attenuated in STZ + H2S group, as well as the protein expressions above-mentioned, While PPARG was up-regulated.   CONCLUSION:  The myocardial fibrosis in DM rats can be attenuated effectively by exogenous H2S, and the underlying mechanism is likely to regulating PKC-ERK1/2MAPK signaling pathway, improving the MMPs/TIMPs expression dysregulation and inhibiting inflammatory reaction."@en ;
    ns0:hasPubTitle "H2S attenuates the myocardial fibrosis in diabetic rats through modulating PKC-ERK1/2MAPK signaling pathway"@en .

ns1:xst-v27-i4-XST190506 ns0:hasKeywords "CT image reconstruction"@en,
        "Dictionary learning"@en,
        "few-view"@en,
        "regularization"@en,
        "total generalized variation"@en ;
    ns0:hasPubAbstract "X-ray radiation is harmful to human health. Thus, obtaining a better reconstructed image with few projection view constraints is a major challenge in the computed tomography (CT) field to reduce radiation dose. In this study, we proposed and tested a new algorithm that combines penalized weighted least-squares using total generalized variation (PWLS-TGV) and dictionary learning (DL), named PWLS-TGV-DL to address this challenge. We first presented and tested this new algorithm and evaluated it through both data simulation and physical experiments. We then analyzed experimental data in terms of image qualitative and quantitative measures, such as the structural similarity index (SSIM) and the root mean square error (RMSE). The experiments and data analysis indicated that applying the new algorithm to CT data recovered images more efficiently and yielded better results than the traditional CT image reconstruction approaches."@en ;
    ns0:hasPubTitle "Few-view CT image reconstruction using improved total variation regularization"@en .

ns2:IFS17728 ns0:inAuthorList ns150:IFS17728 .

ns2:IFS181648 ns0:inAuthorList ns150:IFS181648 .

ns8:IFS181188 ns0:inAuthorList ns150:IFS181188 .

ns8:IFS190905 ns0:inAuthorList ns150:IFS190905 .

ns8:JRS740 ns0:inAuthorList ns150:JRS740 .

ns12:IFS171567 ns0:inAuthorList ns150:IFS171567 .

ns5:JVR813 ns0:inAuthorList ns150:JVR813 .

ns16:JAD180631 owl:sameAs ns2:JAD161209,
        ns12:JAD140630,
        ns12:JAD160774 ;
    ns0:fullName "Kaarin J. Anstey" ;
    ns0:hasAffiliation ns21:JAD180631,
        ns22:JAD180631 ;
    ns0:hasArticle ns1:jad-v70-is1-JAD180631 ;
    ns0:inAuthorList ns150:JAD180631 .

ns60:CH199009 owl:sameAs ns2:CH2005,
        ns8:CH189129,
        ns8:CH189415,
        ns8:CH1963,
        ns8:CH1964,
        ns26:CH179226,
        ns12:CH189411,
        ns30:CH179212,
        ns30:CH179216,
        ns30:CH199218,
        ns52:CH170265,
        ns57:CH168120,
        ns57:CH170246,
        ns60:CH189107,
        ns60:CH189905,
        ns33:CH189309 ;
    ns0:fullName "L. Prantl" ;
    ns0:hasAffiliation ns77:CH199009 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199009 ;
    ns0:inAuthorList ns150:CH199009 .

ns1:ch-v71-i4-CH180402 ns0:hasKeywords "Nordic hamstring exercise"@en,
        "RBC deformability"@en,
        "erythrocyte aggregation"@en,
        "oxidative stress"@en ;
    ns0:hasPubAbstract "BACKGROUND: The Nordic hamstring exercise (NHE) has been proven to be an effective preventive technique for hamstring injuries. Hemorheological parameters (erythrocyte deformability and aggregation) play a critical role in exercise influencing oxygenation. Although previous studies presented hemorheological alterations induced by different types of exercise, changes in red blood cell (RBC) deformability and aggregation following NHE remain unknown. Present study was designed to explore possible alterations in hemorheological and oxidative parameters after an acute bout of NHE.   METHODS: 10 healthy, male, active students (mean age 19.9±0.23, BMI: 21.56±0.54) participated to the study. They performed a single session of seven-repetitions of NHE followed by a familiarisation period. Blood samples were obtained before and immediately after the exercise from the antecubital vein. Hemorheological parameters were measured by an ektacytometer.   RESULTS: NHE did not change deformability, hematocrit and oxidative stress but, increased RBC aggregation index (AI, p = 0.011) and decreased RBC aggregation half time (t½, p = 0.009).   CONCLUSIONS: Our results suggest that, increased RBC aggregation following an acute bout of NHE may result in increased plasma skimming and thus ease the flow of blood."@en ;
    ns0:hasPubTitle "Hemorheological alterations following an acute bout of nordic hamstring exercise in active male participants1"@en .

ns1:ch-v73-i1-CH199219 ns0:hasKeywords "Maturation"@en,
        "micromorphology"@en,
        "muscular artery type"@en,
        "porcine femoral artery"@en,
        "tunica media"@en ;
    ns0:hasPubAbstract "BACKGROUND: In cardiovascular research small pigs breeds like Göttingen® minipigs (GM) are established animal models, but systematic data about the micromorphology of the GM vasculature at different ages are scarce.   OBJECTIVE: The study was aimed at gaining knowledge about the micromorphology of the femoral artery (FA) from German Landrace pigs (DL) and GM during the period of growth over a body weight range of 10–40 kg.   METHODS: FA samples from DL aged two or three months were compared to GM ones, aged 18 or 40 months using transmitted light microscopy.   RESULTS: All FA samples showed typical characteristics of muscular arteries. Growth was associated with increased vessel wall thickness. In the GM this resulted in a slight decrease of the luminal diameter (LD), while in the DL pigs, an increase of the LD and smooth muscle cell content (10%) with decreased elastic fiber content (10%) has been detected. In contrast, within the 22 months lasting growth period of the GM, the tunica media content of smooth muscle cells and elastic fibers remained stable.   CONCLUSIONS: FA maturation strongly depends on the pig breed and age. It can be different from what is described in humans."@en ;
    ns0:hasPubTitle "Growth-related micromorphological characteristics of the porcine femoral artery"@en .

ns1:ch-v73-i1-CH199225 ns0:hasKeywords "Postoperative free flap monitoring"@en,
        "flap monitoring"@en,
        "flux imaging"@en,
        "microcirculatory function"@en,
        "tissue oxygenation"@en,
        "tissue perfusion"@en,
        "transcutaneous oxygen measurement"@en ;
    ns0:hasPubAbstract "BACKGROUND: Reconstruction of soft tissue defects with free flaps is a common procedure in plastic and reconstructive surgery. Most postoperative complications occur within the first 48–72 hours after surgery. After postoperative complications, short perfusion restoration times may improve flap survival rates by up to 30–50%. Ratiometric fluorescence imaging is an additional or alternative method of postoperative flap monitoring.   OBJECTIVE: To test the efficacy and utility of transepidermal oxygen flux imaging to evaluate postoperative skin oxygenation of free and local flaps in the first 48 hours after surgery.   METHODS: The study included 32 patients (aged between 18 and 80 years; mean age 52.9) with a tissue defect covered with a free flap transplant at the Department of Plastic and Reconstructive Surgery of the University Medical Center Regensburg. Postoperative oxygen flux was measured with the ‘VisiSens system’ placed on the vascular pedicle as well as on the peripheral and central part of the flap.   RESULTS: Values of oxygen flux were higher in case of flap congestion (0.069±0.012) or flap necrosis (0.155±0.083) than in cases without any complications (0.061±0.006). Flux values of different areas of the same flap showed only minimal differences (central part: 0.065±0.008, peripheral part: 0.070±0.009, vascular pedicle: 0.056±0.004); the level of significance was p = 0.904.   CONCLUSION: Imaging transepidermal oxygen flux by ratiometric luminescence seems to be a reliable alternative, indirect method of postoperative flap monitoring with regard to microcirculatory function and flap viability."@en ;
    ns0:hasPubTitle "Transcutaneous oxygen measurement using ratiometric fluorescence imaging as a valid method for monitoring free flap transplants"@en .

ns1:jad-v69-i3-JAD181203 ns0:hasKeywords "Cognition"@en,
        "coronary artery disease"@en,
        "exercise"@en,
        "memory"@en,
        "sphingolipids"@en,
        "type 2 diabetes"@en ;
    ns0:hasPubAbstract "Background: Exercise prevents recurrent cardiovascular events and it may combat cognitive decline in coronary artery disease (CAD); however, evidence in type 2 diabetes (T2DM) has been mixed. T2DM and memory decline have been associated with differences in the plasma sphingolipidome.   Objective: Here, we will investigate whether T2DM-related sphingolipids predict less memory improvement over an exercise intervention for CAD.   Methods: Among participants with CAD entering a 6-month exercise intervention, we matched 20 with T2DM to 40 without T2DM for age, sex, and body mass index. We assessed 45 sphingolipid species using high-performance liquid chromatography coupled electrospray ionization tandem mass spectrometry with multiple reaction monitoring. We assessed memory using the California Verbal Learning Test, 2nd Ed, and the revised Brief Visuospatial Learning Test.   Results: Partial least squares discriminant analysis identified 8 species that distinguished T2DM from non-T2DM groups with 83% (95% confidence interval [70%, 95%]) accuracy in a receiver operator characteristic curve (validated by internal resampling, 1000 permutations, p = 0.01). At baseline, T2DM-associated sphingolipids (ceramide C22 : 0, monohexylceramide C16 : 1, and lactosylceramide C24 : 0) were associated with poorer memory, attention, and psychomotor processing speed performance. Among 50 completers, an indirect effect of T2DM on less improvement in verbal memory was mediated by monohexylceramide C16 : 1 (0.86 fewer words recalled, 95% bootstrap confidence interval [–2.32, –0.24]), and an indirect effect of T2DM on less visuospatial memory improvement was mediated by ceramide C22 : 0 concentrations (0.42 fewer points, 95% bootstrap confidence interval [–1.17, –0.05]).   Conclusions: Ceramide species associated with T2DM predicted poorer cognitive responses to exercise in patients with CAD."@en ;
    ns0:hasPubTitle "Plasma Sphingolipids Mediate a Relationship Between Type 2 Diabetes and Memory Outcomes in Patients with Coronary Artery Disease Undertaking Exercise"@en .

ns1:jad-v69-i3-JAD181256 ns0:hasKeywords "Alzheimer’s disease"@en,
        "early onset"@en,
        "frontotemporal dementia"@en,
        "frontotemporal lobar degeneration"@en,
        "genetics"@en,
        "human"@en,
        "microtubule-associated protein tau"@en,
        "missense"@en,
        "mutation"@en,
        "presenilin-1"@en ;
    ns0:hasPubAbstract "A lot of effort has been done to unravel the genetics underlying early-onset Alzheimer’s disease (AD) and frontotemporal lobar degeneration (FTLD). However, many familial early-onset dementia (EOD) cases still show an unclear genetic background. The aim of this study was to evaluate the role of the known causative mutations and possible pathogenic variants associated with AD and FTLD in a Finnish EOD cohort. The cohort consisted of 39 patients (mean age at onset 54.8 years, range 39–65) with a positive family history of dementia or an atypical or rapidly progressive course of the disease. None of the patients carried the C9orf72 hexanucleotide repeat expansion. Mutations and variants in APP, PSEN1, PSEN2, MAPT, GRN, VCP, CHMP2B, FUS, TARDBP, TREM2, TMEM106B, UBQLN2, SOD1, PRNP, UBQLN1, and BIN1 were screened by using a targeted next generation sequencing panel. Two previously reported pathogenic mutations (PSEN1 p.His163Arg and MAPT p.Arg406Trp) were identified in the cohort. Both patients had familial dementia with an atypical early onset phenotype. In addition, a heterozygous p.Arg71Trp mutation in PSEN2 with an uncertain pathogenic nature was identified in a patient with neuropathologically confirmed AD. In conclusion, targeted investigation of the known dementia-linked genes is worthwhile in patients with onset age under 55 and a positive family history, as well as in patients with atypical features."@en ;
    ns0:hasPubTitle "Mutation Analysis of the Genes Linked to Early Onset Alzheimer’s Disease and Frontotemporal Lobar Degeneration"@en .

ns1:jad-v69-i4-JAD181277 ns0:hasKeywords "Advance directive"@en,
        "Alzheimer’s disease"@en,
        "dementia"@en,
        "end of life"@en,
        "euthanasia"@en,
        "expert opinion"@en ;
    ns0:hasPubAbstract "Background: Palliative care and Advance Care Planning (ACP) are increasingly recommended for an optimal management of late-stage dementia. In Belgium, euthanasia has been decriminalized in 2002 for patients who are “mentally competent” (interpreted as non-demented). It has been suggested that advance directives for euthanasia (ADE) should be made possible for dementia patients.   Objective: This study presents the results of an internet survey among Belgian dementia specialists.   Methods: In 2013, the Belgian Dementia Council (BeDeCo) organized a debate on end of life decisions in dementia. Participants were medical doctors who are specialists in the dementia field. After the debate, an anonymous internet survey was organized. The participation rate was 55%. The sample was representative of the BeDeCo members.   Results: The results showed consensus in favor of palliative care and ACP, although ACP is not systematically addressed in practice. Few patients with dementia have requested euthanasia, but for those who did the participants had agreed to implement it for some patients. A majority of participants (94%) believe that most patients and their families are poorly informed about euthanasia. Although most participants (77%) said they approved the Law on euthanasia, 65% said they were against an extension of the Law to allow ADE for dementia.   Conclusion: Palliative care and ACP are clearly accepted by professionals, although a gap between recommendation and practice remain. Euthanasia is a much more debated issue, even if a majority of professionals are, in principle, in favor of the current Law and seem to disapprove with a Law change allowing ADE for dementia. A better education for both health professionals and the lay public will be a key element in the future."@en ;
    ns0:hasPubTitle "Dementia, End of Life, and Euthanasia: A Survey Among Dementia Specialists Organized by the Belgian Dementia Council"@en .

ns1:jad-v70-i1-JAD180630 ns0:hasKeywords "Mild cognitive impairment"@en,
        "prodromal Alzheimer’s disease"@en,
        "questionnaire of cognitive complaints"@en,
        "subjective cognitive complaints"@en,
        "subjective cognitive decline"@en ;
    ns0:hasPubAbstract "Background: Subjective cognitive complaints (SCCs) may represent an early cognitive marker of Alzheimer’s disease (AD). There is a need to identify specific SCCs associated with an increased likelihood of underlying AD.   Objective: Using the Questionnaire of Cognitive Complaints (QPC), we evaluated the pattern of SCCs in a clinical sample of non-demented older adults in comparison to cognitively healthy community-dwelling volunteers (HV).   Methods: In total, 142 non-demented older adults from the Czech Brain Aging Study referred to two memory clinics for their SCCs were classified as having subjective cognitive decline (SCD, n = 85) or amnestic mild cognitive impairment (aMCI, n = 57) based on a neuropsychological evaluation. Furthermore, 82 age-, education-, and gender-matched HV were recruited. All subjects completed the QPC assessing the presence of specific SCCs in the last six months.   Results: Both SCD and aMCI groups reported almost two times more SCCs than HV, but they did not differ from each other in the total QPC score. Impression of memory change and Impression of worse memory in comparison to peers were significantly more prevalent in both SCD and aMCI groups in comparison to HV; however, only the latter one was associated with lower cognitive performance.   Conclusion: The pattern of QPC-SCCs reported by SCD individuals was more similar to aMCI individuals than to HV. A complaint about memory change seems unspecific to pathological aging whereas a complaint about worse memory in comparison to peers might be one of the promising items from QPC questionnaire potentially reflecting subtle cognitive changes."@en ;
    ns0:hasPubTitle "Differences in Subjective Cognitive Complaints Between Non-Demented Older Adults from a Memory Clinic and the Community"@en .

ns1:jad-v70-i1-JAD190011 ns0:hasKeywords "Alzheimer’s disease"@en,
        "blood pressure"@en,
        "hypertension"@en,
        "mild cognitive impairment"@en,
        "neuropathology"@en,
        "prevention"@en,
        "renin angiotensin system"@en,
        "tau"@en ;
    ns0:hasPubAbstract "Background: Individuals taking renin angiotensin system (RAS) acting antihypertensives exhibit slower cognitive decline and are less likely to progress from mild cognitive impairment (MCI) to Alzheimer’s disease (AD), but the mechanism remains unclear.   Objective: We tested the hypothesis that individuals taking RAS acting antihypertensives exhibit less AD-related neuropathology and slower disease progression than individuals taking non-RAS acting antihypertensives.   Method: Participants included 83 individuals with MCI who were taking an antihypertensive at baseline, had at least two follow-up visits, and had postmortem neuropathological data. Participants were old (M = 83.1 years), 32% male, well educated (M = 15.7 years), and 9.2% Black.   Results: RAS medication users (N = 38) were less likely to progress to AD than non-RAS users (N = 45). RAS users exhibited fewer neurofibrillary tangles than non-RAS users in the hippocampal CA1 region (p < 0.01), entorhinal cortex (p = 0.03), and the angular gyrus, inferior temporal, mid-frontal cortex, and superior frontal (p = 0.01).   Conclusion: Prevention or clearance of neurofibrillary tangles represents a mechanism by which RAS medications may slow disease progression."@en ;
    ns0:hasPubTitle "Neurofibrillary Tangles and Conversion to Mild Cognitive Impairment with Certain Antihypertensives"@en .

ns1:jad-v70-i2-JAD181217 ns0:hasKeywords "Alzheimer’s disease"@en,
        "clinical features"@en,
        "neuropathological mechanism"@en,
        "olfactory dysfunctions"@en,
        "structural MRI"@en ;
    ns0:hasPubAbstract "We explored changes in clinical features and neuropathological mechanisms underlying olfactory dysfunction (OD) in 60 patients with Alzheimer’s disease (AD). Olfactory function was evaluated using the Sniffin’ Sticks test and a threshold discrimination identification (TDI) score. Based on the TDI score, we divided patients according to the presence or absence of OD (AD-OD and AD-NOD, respectively). Cognitive and neuropsychiatric symptoms were evaluated by a series of rating scales. The volumes and cortical thickness of the thalamus, hippocampus, and amygdala were measured using structural magnetic resonance imaging. Neuropathological protein levels in cerebrospinal fluid were measured. The frequency of OD was 50%. TDI scores were lower in the AD-OD group than in the AD-NOD group (p < 0.001). Compared with the AD-NOD group, the AD-OD group showed greater cognitive function impairments (p < 0.001), and daily living activities were more severely compromised (p = 0.019). The AD-OD group had lower hippocampal and amygdala volumes (p = 0.025, p = 0.030, respectively) and a more pronounced reduction in cortical thickness (p = 0.010). The total tau level was lower in the AD-OD group than the AD-NOD group (p = 0.040). Lower Mini-Mental State Examination scores and thinner AD-signature cortices were associated with lower TDI scores (OR = 0.826, p < 0.001; OR = 1.433, p = 0.008). Overall, in AD patients, the impairments in olfactory discrimination and identification seem to be more correlated with cognitive levels. OD in AD may be an indicator of pathological cognitive decline and structural changes."@en ;
    ns0:hasPubTitle "Clinical, Structural, and Neuropathological Features of Olfactory Dysfunction in Patients with Alzheimer’s Disease"@en .

ns1:jad-v71-i1-JAD190010 ns0:hasKeywords "Alzheimer’s disease"@en,
        "longitudinal"@en,
        "progression"@en,
        "shortening"@en,
        "telomere"@en ;
    ns0:hasPubAbstract "Background: Although shorter telomeres have been associated with Alzheimer’s disease (AD), it is unclear whether longitudinal change in telomere length is associated with AD progression.   Objective: To investigate the association of telomere length change with AD diagnosis and progression.   Methods: In 653 individuals from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) cohort, T/S ratio (telomere versus single copy gene), a proxy of telomere length, was measured for up to five visits per participant (N = 1918 samples post-QC) using quantitative PCR (qPCR). T/S ratio was adjusted for batch effects and DNA storage time. A mixed effects model was used to evaluate association of telomere length with AD diagnostic group and interaction of age and diagnosis. Another mixed effects model was used to compare T/S ratio changes pre- to post-conversion to MCI or AD to telomere change in participants with stable diagnoses.   Results: Shorter telomeres were associated with older age (Effect Size (ES) = –0.23) and male sex (ES = –0.26). Neither baseline T/S ratio (ES = –0.036) nor T/S ratio change (ES = 0.046) differed significantly between AD diagnostic groups. MCI/AD converters showed greater, but non-significant, telomere shortening compared to non-converters (ES = –0.186).   Conclusions: Although AD compared to controls showed small, non-significant effects for baseline T/S ratio and T/S ratio shortening, we did observe a larger, though still non-significant effect for greater telomere shortening in converters compared to non-converters. Although our results do not support telomere shortening as a robust biomarker of AD progression, further investigation in larger samples and for subgroups of participants may be informative."@en ;
    ns0:hasPubTitle "Telomere Shortening in the Alzheimer’s Disease Neuroimaging Initiative Cohort"@en .

ns1:jad-v71-i1-JAD190077 ns0:hasKeywords "Alzheimer’s disease"@en,
        "cerebrovascular"@en,
        "neurodegeneration"@en,
        "neurofilament light"@en,
        "vascular risk"@en ;
    ns0:hasPubAbstract "Background: Vascular risk factors promote cerebral small vessel disease and neuropathological changes, particularly in white matter where large-caliber axons are located. How Alzheimer’s disease pathology influences the brain’s vulnerability in this regard is not well understood.   Objective: Systemic vascular risk was assessed in relation to cerebrospinal fluid concentrations of neurofilament light, a biomarker of large-caliber axonal injury, evaluating for interactions by clinical and protein markers of Alzheimer’s disease.   Methods: Among Alzheimer’s Disease Neuroimaging Initiative participants with normal cognition (n = 117), mild cognitive impairment (n = 190), and Alzheimer’s disease (n = 95), linear regression related vascular risk (as measured by the modified Framingham Stroke Risk Profile) to neurofilament light, adjusting for age, sex, education, and cognitive diagnosis. Interactions were assessed by cognitive diagnosis, and by cerebrospinal fluid markers of Aβ42, hyperphosphorylated tau, and total tau.   Results: Vascular risk and neurofilament light were not related in the main effect model (p = 0.08). However, interactions emerged for total tau (p = 0.01) and hyperphosphorylated tau (p = 0.002) reflecting vascular risk becoming more associated with cerebrospinal fluid neurofilament light in the context of greater concentrations of tau biomarkers. An interaction also emerged for the Alzheimer’s disease biomarker profiles (p = 0.046) where in comparison to the referent ‘normal’ biomarker group, individuals with abnormal levels of both Aβ42 and total tau showed stronger associations between vascular risk and neurofilament light.   Conclusion: Older adults may be more vulnerable to axonal injury in response to higher vascular risk burdens in the context of concomitant Alzheimer’s disease pathology."@en ;
    ns0:hasPubTitle "Adverse Vascular Risk Relates to Cerebrospinal Fluid Biomarker Evidence of Axonal Injury in the Presence of Alzheimer’s Disease Pathology"@en .

ns1:jad-v71-i1-JAD190202 ns0:hasKeywords "Alzheimer’s disease"@en,
        "behavioral symptoms"@en,
        "biomarkers"@en,
        "geriatric psychiatry"@en ;
    ns0:hasPubAbstract "Background: Agitation is a prevalent and difficult-to-treat symptom of Alzheimer’s disease (AD). The endocannabinoid system (ECS) has been a target of interest for the treatment of agitation. However, ECS signaling may interact with AD-related changes in brain cholesterol metabolism. Elevated brain cholesterol, reflected by reduced serum 24-S-hydroxycholesterol (24S-OHC), is associated with reduced membrane fluidity, preventing ligand binding to cannabinoid receptor 1.   Objective: To assess whether 24S-OHC was associated with agitation severity and response to nabilone.   Methods: 24S-OHC was collected from AD patients enrolled in a clinical trial on nabilone at the start and end of each phase. This allowed for the cross-sectional and longitudinal investigation between 24S-OHC and agitation (Cohen Mansfield Agitation Inventory, CMAI). Post-hoc analyses included adjustments for baseline standardized Mini-Mental Status Exam (sMMSE), and analyses with CMAI subtotals consistent with the International Psychogeriatric Association (IPA) definition for agitation (physical aggression and nonaggression, and verbal aggression).   Results: 24S-OHC was not associated with CMAI scores cross-sectionally or longitudinally, before and after adjusting for baseline sMMSE. However, 24S-OHC was associated with greater CMAI IPA scores at baseline (F(1,36) = 4.95, p = 0.03). In the placebo phase only, lower 24S-OHC at baseline was associated with increases in CMAI IPA scores (b = –35.2, 95% CI –65.6 to –5.0, p = 0.02), and decreases in 24S-OHC were associated with increases in CMAI IPA scores (b = –20.94, 95% CI –57.9 to –4.01, p = 0.03).   Conclusion: 24S-OHC was associated with agitation severity cross-sectionally, and longitudinally in patients with AD. However, 24S-OHC did not predict treatment response, and does not change over time with nabilone."@en ;
    ns0:hasPubTitle "24S-Hydroxycholesterol Is Associated with Agitation Severity in Patients with Moderate-to-Severe Alzheimer’s Disease: Analyses from a Clinical Trial with Nabilone"@en .

ns1:jad-v71-i1-JAD190469 ns0:hasKeywords "Alzheimer’s disease"@en,
        "FP-CIT PET"@en,
        "L-dopa"@en,
        "parkinsonism"@en,
        "presenilin 1"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease patients with presenilin 1 (PSEN1) mutations commonly show parkinsonism in addition to dementia. Yet, whether these patients show dopaminergic deficit and response to L-dopa is largely unknown. We report a 43-year-old woman with a PSEN1 mutation (A434T) who showed right side dominant parkinsonism. As disease progressed, she developed bilateral parkinsonism which was markedly relieved by L-dopa. Amyloid (Florbetaben) positron-emission tomography (PET) showed cortical florbetaben uptake, relatively sparing the striatum. Initial dopamine transporter (FP-CIT) PET showed asymmetrically decreased FP-CIT uptake in the left striatum. We suggest that in Alzheimer’s disease patients with PSEN1 mutation, parkinsonism may be relieved by L-dopa when it is associated with presynaptic dopaminergic deficit."@en ;
    ns0:hasPubTitle "Dopa Responsive Parkinsonism in an Early Onset Alzheimer’s Disease Patient with a Presenilin 1 Mutation (A434T)"@en .

ns1:jad-v71-i4-JAD190175 ns0:hasKeywords "Alzheimer’s disease"@en,
        "apolipoprotein A-II"@en,
        "apolipoprotein E"@en,
        "biomarkers"@en,
        "dementia"@en,
        "dimers"@en ;
    ns0:hasPubAbstract "The APOE ɛ4 gene variant is the strongest genetic risk factor for Alzheimer’s disease (AD), whereas APOE ɛ3 conventionally is considered as ‘risk neutral’ although APOE ɛ3-carriers also develop AD. Previous studies have shown that the apolipoprotein E3 (apoE3) isoform occurs as monomers, homodimers and heterodimers with apolipoprotein A-II in human body fluids and brain tissue, but the relevance of a plasma apoE3 monomer/dimer profile to AD is unknown. Here we assessed the distribution of monomers, homodimers and heterodimers in plasma from control subjects and patients with mild cognitive impairment (MCI) and AD with either a homozygous APOE ɛ3 (n = 31 control subjects, and n = 14 MCI versus n = 5 AD patients) or APOE ɛ4 genotype (n = 1 control subject, n = 21 MCI and n = 7 AD patients). Total plasma apoE levels were lower in APOE ɛ4-carriers and overall correlated significantly to CSF Aβ42, p(Thr181)-tau and t-tau levels. Apolipoprotein E dimers were only observed in the APOE ɛ3-carriers and associated with total plasma apoE levels, negatively correlated to apoE monomers, but were unrelated to plasma homocysteine levels. Importantly, the APOE ɛ3-carrying AD patients versus controls exhibited a significant decrease in apoE homodimers (17.8±9.6% versus 26.7±6.3%, p = 0.025) paralleled by an increase in apoE monomers (67.8±18.3% versus 48.5±11.2%, p = 0.008). In the controls, apoE monomers and heterodimers were significantly associated with plasma triglycerides; the apoE heterodimers were also associated with levels of high-density lipoprotein cholesterol. The physiological relevance of apoE dimer formation needs to be further investigated, though the distribution of apoE in monomers and dimers appears to be of relevance to AD in APOE ɛ3 subjects."@en ;
    ns0:hasPubTitle "Plasma Apolipoprotein E Monomer and Dimer Profile and Relevance to Alzheimer’s Disease"@en .

ns1:jad-v72-i1-JAD190691 ns0:hasKeywords "11C-PIB"@en,
        "APOE"@en,
        "Alzheimer’s disease"@en,
        "PET scan"@en,
        "amyloid"@en,
        "cerebrovascular lesions"@en,
        "cognition"@en,
        "follow-up study"@en,
        "insulin resistance"@en,
        "magnetic resonance imaging"@en ;
    ns0:hasPubAbstract "Background: Type 2 diabetes (T2DM) increases the risk for Alzheimer’s disease (AD) but not for AD neuropathology. The association between T2DM and AD is assumed to be mediated through vascular mechanisms. However, insulin resistance (IR), the hallmark of T2DM, has been shown to associate with AD neuropathology and cognitive decline.   Objective: To evaluate if midlife IR predicts late-life cognitive performance and cerebrovascular lesions (white matter hyperintensities and total vascular burden), and whether cerebrovascular lesions and brain amyloid load are associated with cognitive functioning.   Methods: This exposure-to-control follow-up study examined 60 volunteers without dementia (mean age 70.9 years) with neurocognitive testing, brain 3T-MRI and amyloid-PET imaging. The volunteers were recruited from the Finnish Health 2000 survey (n = 6062) to attend follow-up examinations in 2014–2016 according to their insulin sensitivity in 2000 and their APOE genotype. The exposure group (n = 30) had IR in 2000 and the 30 controls had normal insulin sensitivity. There were 15 APOE ɛ4 carriers per group. Statistical analyses were performed with multivariable linear models.   Results: At follow-up the IR+group performed worse on executive functions (p = 0.02) and processing speed (p = 0.007) than the IR- group. The groups did not differ in cerebrovascular lesions. No associations were found between cerebrovascular lesions and neurocognitive test scores. Brain amyloid deposition associated with slower processing speed.   Conclusion: Midlife IR predicted poorer executive functions and slower processing speed, but not cerebrovascular lesions. Brain amyloid deposition was associated with slower processing speed. The association between midlife IR and late-life cognition might not be mediated through cerebrovascular lesions measured here."@en ;
    ns0:hasPubTitle "Midlife Insulin Resistance as a Predictor for Late-Life Cognitive Function and Cerebrovascular Lesions"@en .

ns1:jad-v72-i3-JAD190524 ns0:hasKeywords "Alzheimer’s disease"@en,
        "apolipoproteins"@en,
        "lipidomics"@en,
        "lipids"@en,
        "liquid chromatography-mass spectrometry"@en,
        "plasma"@en ;
    ns0:hasPubAbstract "Apolipoprotein E (APOE) genotype is an established genetic risk factor for sporadic Alzheimer’s disease (AD) but the extent to which APOE genotype influences the plasma lipidome is unknown, even though lipids are potential diagnostic or prognostic biomarkers for AD. We quantified plasma lipids using untargeted liquid chromatography coupled mass spectrometry in a total of 152 non-demented participants aged 65–100 years carrying at least one ɛ2 or ɛ4 allele (ɛ2/ɛ2 or ɛ2/ɛ3, n = 38: ɛ4/ɛ3 or ɛ4/ɛ4, n = 38), who were roughly matched to an ɛ3/ɛ3 control by age, sex, and lipid-lowering medication (n = 76). Low density lipoprotein cholesterol levels were genotype dependent (ɛ4/ɛ4> ɛ4/ɛ3> ɛ3/ɛ3> ɛ2/ɛ3> ɛ2/ɛ2). The greatest variation in lipids was related to the ɛ2 isoform, where various lysophosphatidylcholines and all phosphatidylethanolamine (PE) subclasses were elevated relative to ɛ3/ɛ3 and ɛ4 carriers. APOE ɛ4 carriers had reduced phosphatidylinositol relative to ɛ3/ɛ3 and ɛ2 carriers. Logistic regression revealed that ɛ2 carriers were at least 4 times higher odds of being in the highest tertile of PE lipid level relative to ɛ3/ɛ3. The elevation in PE and other phospholipids in ɛ2 carriers may indicate the protective effect of ɛ2 is linked to these phospholipids. Additionally, high baseline PE in cognitively normal participants predicted protection against cognitive decline six years later. Our data suggest substantial modulation of plasma lipids by APOE genotype and therefore indicates possible lipid targets and pathomechanisms involved in AD risk."@en ;
    ns0:hasPubTitle "APOE Genotype Differentially Modulates Plasma Lipids in Healthy Older Individuals, with Relevance to Brain Health"@en .

ns1:jad-v72-i3-JAD190645 ns0:hasKeywords "African Americans"@en,
        "Alzheimer’s disease"@en,
        "Apolipoprotein E4"@en,
        "aging"@en,
        "cerebrovascular circulation"@en,
        "glucose"@en,
        "metabolic syndrome"@en,
        "neuroimaging"@en,
        "risk factors"@en ;
    ns0:hasPubAbstract "Background: Alzheimer’s disease (AD) has a higher prevalence among African Americans. Targeting cardiovascular and metabolic risk factors may be potential mechanisms to modify AD risk and address racial/ethnic disparities in AD dementia.   Objective: This study investigated relationships among cardiovascular and metabolic risk factors, APOE genotype, AD biomarkers, and intracranial arterial blood flow in Whites and African Americans enriched for AD risk.   Methods: 399 cognitively unimpaired adults from the Wisconsin Alzheimer’s Disease Research Center completed physical and neuroimaging examinations. A 4D Flow MRI sequence (phase-contrast vastly under sampled isotropic projection imaging) measured intracranial arterial flow in the Circle of Willis. Linear mixed-effects regression models estimated relationships between risk factors and intracranial arterial flow and tested interactions with racial group, APOE genotype, and AD biomarkers, with separate models per risk factor.   Results: Higher fasting glucose was associated with lower intracranial arterial flow; no additional relationships between flow and risk factors were observed. Main effects of racial group were observed, without an interaction, indicating lower flow in African Americans compared to Whites. In race-stratified analyses, higher glucose and triglycerides were associated with lower flow for African Americans, but not for Whites. No main effects or interactions among risk factors, APOE, or AD biomarkers, and flow were observed.   Conclusion: Elevated fasting glucose and triglycerides were associated with lower intracranial arterial flow; these relationships were more prominent in African Americans. Targeting metabolic risk factors may impact intracranial arterial health. Additional research is needed to determine if this will impact disparities in dementia prevalence."@en ;
    ns0:hasPubTitle "Association of Cardiovascular and Alzheimer’s Disease Risk Factors with Intracranial Arterial Blood Flow in Whites and African Americans"@en .

ns1:jhd-v8-i4-JHD190364 ns0:hasKeywords "Huntington disease"@en,
        "Neuro-QoL"@en,
        "PROMIS"@en,
        "emotion"@en,
        "mental health"@en,
        "reliability"@en,
        "validity"@en ;
    ns0:hasPubAbstract "Background: Patient-reported outcomes (PROs) for mental health are important for persons with Huntington disease (HD) who commonly experience symptoms of depression, anxiety, irritability, anger, aggression, and apathy. Given this, there is a need for reliable and valid patient-reported outcomes measures of mental health for use as patient-centered outcomes in clinical trials.   Objective: Thus, the purpose of this study was to establish the psychometric properties (i.e., reliability and validity) of six Neuro-QoL and PROMIS mental health measures to support their clinical utility in persons with HD.   Methods: 294 individuals with premanifest (n = 102) or manifest HD (n = 131 early HD; n = 61 late HD) completed Neuro-QoL/PROMIS measures of Emotional and Behavioral Dyscontrol, Positive Affect and Well-Being, Stigma, Anger, Anxiety, and Depression, legacy measures of self-reported mental health, and clinician-rated assessments of functioning.   Results: Convergent validity and discriminant validity for the Neuro-QoL and PROMIS measures of Emotional and Behavioral Dyscontrol, Positive Affect and Well-Being, Stigma, Anger, Anxiety, and Depression, were supported in persons with HD. Neuro-QoL measures of Anxiety and Depression also demonstrated moderate sensitivity and specificity (i.e., they were able to distinguish between individuals with and without clinically significant anxiety and depression).   Conclusions: Findings provide psychometric support for the clinical utility of the Neuro-QoL/PROMIS measures of mental health measures in persons with HD. As such, these measures should be considered for the standardized assessment of health-related quality of life in persons with HD."@en ;
    ns0:hasPubTitle "Validation of Neuro-QoL and PROMIS Mental Health Patient Reported Outcome Measures in Persons with Huntington Disease"@en .

ns1:jnd-v6-i4-JND190416 ns0:hasKeywords "Nusinersen"@en,
        "prospective observational study"@en,
        "safety"@en,
        "spinal muscular atrophy"@en,
        "treatment"@en ;
    ns0:hasPubAbstract "Objective: Spinal muscular atrophy (SMA) is a progressive autosomal recessive motor neuron disease caused by loss of the SMN1 gene. Based on randomized clinical trials in children with SMA type 1 and 2, Nusinersen has been approved as the first treatment for all types of SMA, including adults with SMA type 3.   Methods: We evaluated the safety and treatment effects of Nusinersen in longstanding adult 5q-SMA type 3. Patients were treated with intrathecal loading doses at day 1, 14, 28 and 63, followed by maintenance dose every four months up to 300 days. We monitored the patients within SMArtCARE, a prospective open-label outcome study for disease progression, side effects and treatment efficacy, encompassing clinical examination including MRC sum score, vital capacity in sitting position (VC, VC % pred.), ALS Functional Rating Scale (ALS-FRS), 6-Minute-Walk-Test (6MWT), Revised Upper Limb Module (RULM), and Hammersmith Functional Rating Scale (HFMSE). We also measured biomarkers in the spinal fluid (phosphorylated neurofilament heavy chain pNFH, neuron-specific enolase NSE, proteins, ß-Amyloid 1–40, ß-Amyloid 1–42, tau and phospho-tau) and creatine kinase (CK). Assessments were performed at baseline, day 63 (V4), day 180 (V5) and day 300 (V6). For statistical analysis, we compared baseline to V4, V5 and V6, using the paired sample t-test. When there were significant differences, we added cohen's d and effect size r for evaluation of clinical meaningfulness.   Results: 19 patients were included, 17 of them have completed the observation period of 10 months (day 300, V6). Patients were aged 18 to 59 years with disease duration ranging from 6 to 53 years. Except for the 6MWT, the RULM and the peak cough flow, there were no relevant significant changes in all functional outcome assessments at V4, V5 or V6, compared to baseline. For the 6MWT, there was a statistically significant improvement at visit 5 and at visit 6. RULM-score increased significantly at V6, and peak cough flow at visit 5. In biomarker studies, there was a significant decline in NSE and pTAU as well as a slight increase in proteins. In safety analysis, overall, Nusinersen applications were well tolerated. Eleven patients reported adverse events that were related to the study procedures, comprising back pain in seven patients and post-lumbar-puncture headache following intrathecal administration in four patients. Post-lumbar-puncture headache was reported in three females and one male, in total eleven times of 108 punctures (10%). No serious adverse events occurred.   Conclusions: This prospective observational study indicates a mild treatment effect in adults with long-standing SMA3 after 10 months of treatment with Nusinersen, which had never occurred in the natural history of the disease. In our cohort, the most significant outcome measures were the 6MWT with statistically significant changes after day 180 and day 300, RULM after day 300 and peak cough flow after day 180."@en ;
    ns0:hasPubTitle "Safety and Treatment Effects of Nusinersen in Longstanding Adult 5q-SMA Type 3 – A Prospective Observational Study"@en .

ns1:jvr-v51-i1-JVR191023 ns0:hasKeywords "Multiple sclerosis"@en,
        "community participation"@en,
        "functional disability"@en,
        "health-related quality of life"@en ;
    ns0:hasPubAbstract "BACKGROUND: The International Classification of Functioning, Disability and Health (ICF) has received considerable attention as a model of disability in recent years. Within the ICF framework, community integration and participation are considered one of the most important outcomes of health and rehabilitation interventions. Participation is a very complex and subjective concept and therefore very difficult to measure. Most participation measures are relatively long and not ideal for public health and rehabilitation surveillance or for testing complex models using structural equation modeling.   OBJECTIVE: The main purpose of this study was to report the psychometric validation results for the brief Multiple Sclerosis Community Participation Scale (MSCPS) with 256 individuals with multiple sclerosis (MS).   RESULTS: Participants indicated that living independently; getting around; participating in recreational and social activities; and engaging in health promoting behaviors are highly important and meaningful life roles, followed by participating in meaningful life roles as children, spouses, parents, and full-time workers. Being a student, church member, and a part-time worker were the least important life roles for people with MS in the present study.   IMPLICATIONS: Because of its brevity, the MSCPS has an advantage over other long form participation measures, making it suitable for public health surveillance, community follow-up of patients recently discharged from hospitals, and for researchers who are searching for abbreviated measures to test complex ICF models.   CONCLUSION: The MSCPS appears to be a promising rehabilitation/health assessment and public health surveillance tool for individuals with MS, one that can be used by rehabilitation counselors to assess levels of community participation in their interview, assessment, and rehabilitation planning protocols."@en ;
    ns0:hasPubTitle "Psychometric validation of the brief Multiple Sclerosis Community Participation Scale"@en .

ns1:kca-v3-i2-KCA180049 ns0:hasKeywords "Renal cell carcinoma"@en,
        "adjuvant chemotherapy"@en,
        "everolimus"@en,
        "pharmacokinetics"@en,
        "therapeutic drug monitoring"@en ;
    ns0:hasPubAbstract "Background: S0931 is assessing recurrence-free survival in renal cell carcinoma (RCC) patients randomized to receive everolimus (EVE) versus placebo for one year following nephrectomy. Due to a higher than expected dropout rate, we assessed EVE trough levels in the adjuvant setting to evaluate the relationship between EVE exposure and probability of toxicity.   Methods: Patients received 10 mg daily EVE for nine 6-week cycles. Pre-dose whole blood samples were collected pre-cycle 2 and pre-cycle 3 and analyzed for EVE. Patients with pre-cycle 2 and/or pre-cycle 3 EVE results were used in the analysis. Patients were segregated into quartiles (Q) based on EVE levels and logistic regression was used to model the most common adverse event outcomes using EVE trough as a predictor. Hazard and odds ratios were adjusted for age, BMI and performance status.   Results: A total of 467 patients were included in this analysis. Quartiles normalized to an EVE dose of 10 mg/day were < 9.0, 9.0–12.9, 12.9–22.8, and > 22.8 ng/mL, respectively. EVE trough levels increased with increasing age (p < 0.001). Furthermore, EVE trough levels were higher in men than women (19.4 versus 15.4 ng/mL, p = 0.01). Risk of grade 2 + triglycerides was increased in Q2 and Q3 vs Q1 (OR = 2.08; p = 0.02 and OR = 2.63; p = 0.002). Risk of grade 2 + rash was increased in Q2 and Q4 vs Q1 (OR = 2.99; p = 0.01 and OR = 2.90; p = 0.02). There was also an increased risk of any grade 3 + tox in Q2 vs Q1 (OR = 1.71; p = 0.05).   Conclusions: We identified significant gender and age-related differences in EVE trough levels in patients receiving adjuvant treatment for RCC. Furthermore, our analysis identified significant associations between EVE exposure and probability of toxicity."@en ;
    ns0:hasPubTitle "Everolimus Exposure as a Predictor of Toxicity in Renal Cell Cancer Patients in the Adjuvant Setting: Results of a Pharmacokinetic Analysis for SWOG S0931 (EVEREST), a Phase III Study (NCT01120249)"@en .

ns1:xst-v27-i3-XST180477 ns0:hasKeywords "Low dose computed tomography"@en,
        "dictionary learning"@en,
        "penalized weighted least squares"@en,
        "total variation"@en ;
    ns0:hasPubAbstract "Recently, low-dose computed tomography (CT) has become highly desirable due to the increasing attention paid to the potential risks of excessive radiation of the regular dose CT. However, ensuring image quality while reducing the radiation dose in the low-dose CT imaging is a major challenge. Compared to classical filtered back-projection (FBP) algorithms, statistical iterative reconstruction (SIR) methods for modeling measurement statistics and imaging geometry can significantly reduce the radiation dose, while maintaining the image quality in a variety of CT applications. To facilitate low-dose CT imaging, we in this study proposed an improved statistical iterative reconstruction scheme based on the penalized weighted least squares (PWLS) standard combined with total variation (TV) minimization and sparse dictionary learning (DL), which is named as a method of PWLS-TV-DL. To evaluate this PWLS-TV-DL method, we performed experiments on digital phantoms and physical phantoms, and analyzed the results in terms of image quality and calculation. The results show that the proposed method is better than the comparison methods, which indicates the potential of applying this PWLS-TV-DL method to reconstruct low-dose CT images."@en ;
    ns0:hasPubTitle "Iterative image reconstruction for sparse-view CT via total variation regularization and dictionary learning"@en .

ns1:xst-v27-i5-XST190527 ns0:hasKeywords "Positron emission tomography (PET)"@en,
        "feature extraction"@en,
        "low-sampled data"@en,
        "maximum likelihood-expectation maximization (MLEM)"@en,
        "total variation (TV)"@en ;
    ns0:hasPubAbstract "PURPOSE: To reduce the cost of positron emission tomography (PET) scanning systems, image reconstruction algorithms for low-sampled data have been extensively studied. However, the current method based on total variation (TV) minimization regularization nested in the maximum likelihood-expectation maximization (MLEM) algorithm cannot distinguish true structures from noise resulting losing some fine features in the images. Thus, this work aims to recover fine features lost in the MLEM-TV algorithm from low-sampled data.   METHOD: A feature refinement (FR) approach previously developed for statistical interior computed tomography (CT) reconstruction is applied to PET imaging to recover fine features in this study. The proposed method starts with a constant initial image and the FR step is performed after each MLEM-TV iteration to extract the desired structural information lost during TV minimization. A feature descriptor is specifically designed to distinguish structure from noise and artifacts. A modified steepest descent method is adopted to minimize the objective function. After evaluating the impacts of different patch sizes on the outcome of the presented method, an optimal patch size of 7×7 is selected in this study to balance structure-detection ability and computational efficiency.   RESULTS: Applying MLEM-TV-FR algorithm to the simulated brain PET imaging using an emission activity phantom, a standard Shepp-Logan phantom, and mouse results in the increased peak signal-to-noise ratio (PSNR) and structural similarity (SSIM) as comparing to using the conventional MLEM-TV algorithm, as well as the substantial reduction of the used sampling numbers, which improves the computational efficiency.   CONCLUSIONS: The presented algorithm can achieve image quality superior to that of the MLEM and MLEM-TV approaches in terms of the preservation of fine structure and the suppression of undesired artifacts and noise, indicating its useful potential for low-sampled data in PET imaging."@en ;
    ns0:hasPubTitle "Positron emission tomography image reconstruction using feature extraction"@en .

ns2:CH2005 ns0:inAuthorList ns150:CH2005 .

ns2:JAD161209 ns0:inAuthorList ns150:JAD161209 .

ns8:CH189129 ns0:inAuthorList ns150:CH189129 .

ns8:CH1964 ns0:inAuthorList ns150:CH1964 .

ns12:CH189411 ns0:inAuthorList ns150:CH189411 .

ns12:JAD140630 ns0:inAuthorList ns150:JAD140630 .

ns12:JAD160774 ns0:inAuthorList ns150:JAD160774 .

ns30:CH179212 ns0:inAuthorList ns150:CH179212 .

ns30:CH199218 owl:sameAs ns8:CH189415,
        ns8:CH1963,
        ns26:CH179226,
        ns30:CH179216,
        ns52:CH170265,
        ns57:CH170246 ;
    ns0:fullName "Lukas Prantl" ;
    ns0:hasAffiliation ns252:CH199218 ;
    ns0:hasArticle ns1:ch-v73-i1-CH199218 ;
    ns0:inAuthorList ns150:CH199218 .

ns57:CH168120 ns0:inAuthorList ns150:CH168120 .

ns60:CH189107 ns0:inAuthorList ns150:CH189107 .

ns60:CH189905 ns0:inAuthorList ns150:CH189905 .

ns33:CH189309 ns0:inAuthorList ns150:CH189309 .

ns1:cbm-v26-i2-CBM192435 ns0:hasKeywords "CrkL"@en,
        "Gastric cancer"@en,
        "immunohistochemistry"@en,
        "prognosis"@en,
        "tumorigenesis"@en ;
    ns0:hasPubAbstract "BACKGROUND:  The signaling adapter protein CrkL plays vital roles in multiple cancers. However, the expression pattern of CrkL protein and its clinical significance have not been well characterized in human gastric cancer (GC) so far.   OBJECTIVE:  To investigate the association of tissue-based CrkL protein expression level with the clinicopathological characteristics and prognosis of GC patients.   METHODS:  The expression level of CrkL protein in 380 GC patients was analyzed by immunohistochemistry. The associations of CrkL protein expression level with clinicopathologicalal characteristics and clinical outcome were evaluated.   RESULTS:  Compared with the matched adjacent non-tumor tissues, CrkL protein expression level was significantly up-regulated in tumor tissues. In addition, there was a positive correlation between CrkL and Ki67 expression levels in GC patients. An elevated CrkL level statistically correlated with aggressive clinicopathologicalal characteristics, such as larger tumor size, deeper local invasion, more lymph node metastasis, advanced TNM stage, and poorer prognosis. Notably, multivariate analysis identified tissue-based CrkL level as an independent predictor for the unfavorable prognosis of GC.   CONCLUSIONS:  These results indicate that CrkL protein may serve as a novel prognostic biomarker in GC."@en ;
    ns0:hasPubTitle "Overexpression of CrkL as a novel biomarker for poor prognosis in gastric cancer"@en .

ns1:jad-v69-i3-JAD190087 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amyloid-β peptide"@en,
        "blood component removal"@en,
        "hemodialysis"@en,
        "tau protein"@en ;
    ns0:hasPubAbstract "The accumulation of amyloid-β protein (Aβ) and tau in the brain is a major pathological change related to Alzheimer’s disease. We have continued to develop Extracorporeal Blood Aβ Removal Systems (E-BARS) as a method for enhancing Aβ clearance from the brain. Our previous report revealed that dialyzers effectively remove blood Aβ and evoke large Aβ influxes into the blood, resulting in a decrease in brain Aβ accumulation after initiating hemodialysis, and that patients who underwent hemodialysis had lower brain Aβ accumulation than those who did not. Here, plasma total tau concentrations from 30 patients undergoing hemodialysis were measured using an ultrasensitive immunoassay and compared to those from 11 age-matched controls. Plasma total tau concentrations were higher in patients with renal failure regardless of whether they underwent hemodialysis, suggesting the involvement of the kidneys in tau degradation and excretion. Hemodialyzers effectively removed blood Aβ but not extracorporeal blood tau. The influx of tau into the blood was observed at around the 1 h period during hemodialysis sessions. However, the influx amount of tau was far smaller than that of Aβ. Furthermore, histopathological analysis revealed similar, not significantly less, cerebral cortex phosphorylated tau accumulation between the 17 patients who underwent hemodialysis and the 16 age-matched subjects who did not, although both groups showed sparse accumulation. These findings suggest that hemodialysis may induce both tau and Aβ migration into the blood. However, as a therapeutic strategy for Alzheimer’s disease, it may only be effective for removing Aβ from the brain."@en ;
    ns0:hasPubTitle "Influx of Tau and Amyloid-β Proteins into the Blood During Hemodialysis as a Therapeutic Extracorporeal Blood Amyloid-β Removal System for Alzheimer’s Disease"@en .

ns1:jad-v70-i1-JAD190046 ns0:hasKeywords "Aging"@en,
        "biomarkers"@en,
        "cognition"@en,
        "early detection"@en,
        "memory decline"@en,
        "tau"@en,
        "voxel-based morphometry"@en ;
    ns0:hasPubAbstract "Background: We investigated a sample of cognitively healthy subjects with normal Alzheimer’s disease (AD) cerebrospinal fluid (CSF) biomarker levels to identify the earliest variables related to longitudinal memory changes.   Objective: Employing a new highly demanding learning and memory test (the Ancient Farming Equipment Test; AFE-T), we aimed to investigate whether a biomarker related to neurodegeneration (i.e., CSF tau) was associated with longitudinal memory decline.   Methods: Thirty-two cognitively and biologically normal (CBN) subjects underwent MRI, neuropsychological assessment, and the AFE-T at baseline and 18 months later. To explore the relationship between cognitive performance and relevant factors, a linear model was set up. For a secondary analysis that further explore the effect of tau, the subjects were divided into CBN-Tau↓ (tau < 228.64 pg/ml; n = 16) and CBN-Tau↑ (tau > 228.64 pg/ml; n = 16). We also performed voxel-based morphometry (VBM) to identify regions of grey matter volume that would predict both baseline and longitudinal cognitive performance.   Results: Our main finding was an association between CSF tau and longitudinal memory decline measured with AFE-T (B = –0.17, p < 0.05; r = –0.414; p < 0.01), and further analyses showed different evolvement between subgroups, with an accelerated decline in individuals with higher tau (F(1,31) = 8.37; p < 0.01). VBM results suggested that AFE-T performance is related to grey matter volume in a medial temporal, middle frontal, and posterior cerebellar network at baseline, and that there are strategic brain areas driving the longitudinal cognitive changes.   Conclusions: The present findings provide evidence for structural and biological markers linked to cognitive aging by highlighting the role of tau, a marker of neurodegeneration, which can be related with the earliest memory changes in healthy subjects."@en ;
    ns0:hasPubTitle "Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer’s Disease Cerebrospinal Fluid Biomarker Levels"@en .

ns1:jad-v70-i2-JAD181212 ns0:hasKeywords "Cognition"@en,
        "cognitively-defined Alzheimer’s disease subgroups"@en,
        "depression"@en,
        "psychometrics"@en,
        "restless sleep"@en,
        "traumatic brain injury"@en ;
    ns0:hasPubAbstract "Background: There is considerable heterogeneity in clinical presentation among people with late-onset Alzheimer’s disease (LOAD). We have categorized people with LOAD into subgroups based on relative impairments across cognitive domains. These 6 groups are people with no relatively impaired domains (AD-No Domains), 4 groups with one relatively impaired domain (AD-Memory, AD-Executive, AD-Language, and AD-Visuospatial), and a group with multiple relatively impaired domains (AD-Multiple Domains). Our previous analysis demonstrated that genetic factors vary across cognitively-defined LOAD groups.   Objective: To determine whether risks associated with depression and traumatic brain injury with loss of consciousness (TBI) for cognitively defined LOAD subgroups are similar.   Methods: We used cognitive data at LOAD diagnosis from three prospective cohort studies to determine cognitively-defined subgroups. We compared subgroups in endorsement of items from the Centers for Epidemiological Studies Depression (CES-D) scale and history of TBI.   Results: Among 1,505 people with LOAD from the three studies, there were substantial differences across subgroups in total CES-D score, with lower scores (less depression) for people with AD with relative impairments in memory (AD-Memory) compared to those in other groups. Differences were noteworthy for the sleep-related item of the CES-D, as people with AD-Memory were less likely to report restless sleep than people in other groups. There were no differences in TBI history across groups.   Conclusions: Differences in risk factor associations across subgroups such as differences in endorsement of depression symptoms and restless sleep provide support for the hypothesis that there are biologically coherent subgroups of AD."@en ;
    ns0:hasPubTitle "Associations Between Depression, Traumatic Brain Injury, and Cognitively-Defined Late-Onset Alzheimer’s Disease Subgroups"@en .

ns1:jad-v70-i2-JAD190041 ns0:hasKeywords "Alzheimer’s disease"@en,
        "dementia"@en,
        "dementia with Lewy Bodies"@en,
        "quality of Life"@en ;
    ns0:hasPubAbstract "Background: Quality of Life (QoL) is an important outcome measure in dementia, particularly in the context of interventions. Research investigating longitudinal QoL in dementia with Lewy bodies (DLB) is currently lacking.   Objective: To investigate determinants and trajectories of QoL in DLB compared to Alzheimer’s disease (AD) and controls.   Methods: QoL was assessed annually in 138 individuals, using the EQ5D-utility-score (0–100) and the health-related Visual Analogue Scale (VAS, 0–100). Twenty-nine DLB patients (age 69±6), 68 AD patients (age 70±6), and 41 controls (age 70±5) were selected from the Dutch Parelsnoer Institute-Neurodegenerative diseases and Amsterdam Dementia Cohort. We examined clinical work-up over time as determinants of QoL, including cognitive tests, neuropsychiatric inventory, Geriatric Depression Scale (GDS), and disability assessment of dementia (DAD).   Results: Mixed models showed lower baseline VAS-scores in DLB compared to AD and controls (AD: β±SE = -7.6±2.8, controls: β±SE = -7.9±3.0, p < 0.05). An interaction between diagnosis and time since diagnosis indicated steeper decline on VAS-scores for AD patients compared to DLB patients (β±SE = 2.9±1.5, p < 0.1). EQ5D-utility-scores over time did not differ between groups. Higher GDS and lower DAD-scores were independently associated with lower QoL in dementia patients (GDS: VAS β±SE = -1.8±0.3, EQ5D-utility β±SE = -3.7±0.4; DAD: VAS = 0.1±0.0, EQ5D-utility β±SE = 0.1±0.1, p < 0.05). No associations between cognitive tests and QoL remained in the multivariate model.   Conclusion: QoL is lower in DLB, while in AD QoL shows steeper decline as the disease advances. Our results indicate that non-cognitive symptoms, more than cognitive symptoms, are highly relevant as they impact QoL."@en ;
    ns0:hasPubTitle "Trajectories and Determinants of Quality of Life in Dementia with Lewy Bodies and Alzheimer’s Disease"@en .

ns1:jad-v70-i3-JAD190113 ns0:hasKeywords "Alzheimer’s disease"@en,
        "mild behavioral impairment checklist"@en,
        "neuropsychiatric inventory questionnaire"@en,
        "reliability"@en,
        "validity"@en ;
    ns0:hasPubAbstract "Background: The Mild Behavioral Impairment Checklist (MBI-C), a screening scale for neuropsychiatric symptom evaluation, facilitates Alzheimer’s disease (AD) screening. However, its validity and reliability for use as an AD screening tool have not been determined.   Objective: To develop an AD screening scale suitable for the Chinese population.   Methods: The MBI-C was translated into Chinese and back-translated with the original author’s consent. Forty-six AD patients, attending the Xuanwu hospital memory clinic, and 50 sex- and education-matched controls from the community underwent a full neuropsychological evaluation, including MBI-C assessment. Among them, 15 AD patients were evaluated repeatedly, and eight were evaluated simultaneously by two different clinicians, to assess MBI-C reliability.   Results: The MBI-C demonstrated good internal consistency reliability, test–retest reliability, and inter-rater reliability. Its optimal cutoff point was 6/7 for identifying AD dementia, with a sensitivity of 86.96% and specificity of 86.00%, and its detection rate for moderate–severe AD dementia was higher than that of the Neuropsychiatric Inventory Questionnaire (NPI-Q). Pearson’s correlation coefficients ranged from 0.702 to 0.831, indicating content validity. Seven factors were extracted during principal component analysis, with a cumulative contribution of 70.55%. Moreover, the Pearson’s correlation coefficient was 0.758, indicating its criterion validity. The MBI-C could also distinguish AD dementia severity. MBI-C scores were significantly negatively correlated with MMSE and MoCA scores, and positively correlated with ADL scores.   Conclusion: This study showed that the Chinese version of MBI-C has high reliability and validity, and could replace the NPI-Q for AD dementia screening in the Chinese population."@en ;
    ns0:hasPubTitle "Reliability and Validity of the Chinese Version of the Mild Behavioral Impairment Checklist for Screening for Alzheimer’s Disease"@en .

ns1:jad-v70-i4-JAD190414 ns0:hasKeywords "Alzheimer’s disease"@en,
        "amnestic"@en,
        "amyloid-β"@en,
        "anosognosia"@en,
        "depressive symptoms"@en,
        "mild cognitive impairment"@en,
        "subjective memory complaints"@en ;
    ns0:hasPubAbstract "Background: The use of biomarkers, in particular amyloid-β (Aβ) changes, has allowed the possibility to identify patients with subjective memory complaints (SMCs) and amnestic mild cognitive impairment (aMCI) who suffer from Alzheimer’s disease (AD). Since it is unfeasible that all patients with aMCI could presently undergo biomarkers assessment, it would be important that SMCs might contribute to identify the aMCI patients who have AD amyloid pathology.   Objectives: To know whether aMCI patients with amyloid biomarkers (Aβ+) present greater SMCs as compared to those without amyloid biomarkers (Aβ-).   Methods: Participants were selected from a cohort of nondemented patients with cognitive complaints and a comprehensive neuropsychological evaluation, on the basis of 1) diagnosis of aMCI; 2) detailed assessment of memory difficulties with the SMC Scale; and 3) known amyloid status. The amyloid status was determined on the basis of either CSF Aβ1–42 concentration or amyloid PET imaging.   Results: Of the 176 patients with aMCI studied, 90 were Aβ+ and 86 were Aβ-. The two groups did not differ in terms of age, gender, and education. The SMC total score was not significantly different in the Aβ+ aMCI patients (9.48±4.18) when compared to the Aβ- aMCI patients (10.52±4.57). The Aβ+ aMCI patients had lower scores on the MMSE and memory/learning tests, but not on the Geriatric Depression Scale, when comparing to the Aβ- aMCI patients.   Conclusions: Evaluating SMCs does not seem helpful to identify, among patients with aMCI, those who have AD."@en ;
    ns0:hasPubTitle "Can Subjective Memory Complaints Identify Aβ Positive and Aβ Negative Amnestic Mild Cognitive Impairment Patients?"@en .

ns1:jad-v71-i3-JAD190133 ns0:hasKeywords "Aging"@en,
        "cognition"@en,
        "dementia"@en,
        "memory"@en ;
    ns0:hasPubAbstract "Background: Subjective memory complaints (SMCs) may be the first sign of cognitive decline in aging.   Objective: To examine whether SMCs reported by oneself and informant predict cognitive change over 2 years among at-risk elderly people, and to determine the relationship of different types of SMCs (prospective and retrospective memory complaints) and change in cognitive function.   Methods: This investigation is part of the FINGER project, which is a multicenter randomized controlled trial aiming at preventing cognitive decline in cognitively healthy older adults with increased risk of dementia. A subsample of 303 control-group participants (aged 60–80 years) and their informants (n = 261) rated the frequency of SMCs, using the Prospective and Retrospective Memory Questionnaire (PRMQ). Cognitive performance was measured at baseline and at 1- and 2-year follow-up visits using a neuropsychological test battery.   Results: Participants who reported more SMCs improved less in global cognition, executive function, and memory during the subsequent 2 years in the fully-adjusted analyses. Self-reported retrospective memory problems predicted less improvement in all cognitive domains, whereas prospective memory problems did not. Informant-reported memory problems were not linked to subsequent change in cognition.   Conclusion: Our results indicate that self-reported SMCs, measured with PRMQ, predict future cognitive change in several cognitive domains. By contrast, reports by informants were not linked to changes in cognition. Among cognitively healthy at-risk elderly individuals, the persons themselves observe more easily problems relevant for their future cognitive trajectories than their informants."@en ;
    ns0:hasPubTitle "Self and Informant Memory Reports in FINGER: Associations with Two-Year Cognitive Change"@en .

ns1:jad-v71-i4-JAD190091 ns0:hasKeywords "Amyloid"@en,
        "cognitive dysfunction"@en,
        "ecological momentary assessment"@en,
        "ethics"@en,
        "research subjects"@en ;
    ns0:hasPubAbstract "As calls for transparency in human subjects research grow, investigators conducting Alzheimer’s disease (AD) biomarker research are increasingly required to consider their ethical obligations regarding the return of AD biomarker test results to research participants. When disclosing these test results to potentially vulnerable participants, investigators may face unique challenges to identify adverse events, particularly psychological events. The purpose of this paper is to describe our research team’s experience with developing and implementing a process for enhanced adverse event monitoring following the return of amyloid-β (Aβ) imaging results to research participants with mild cognitive impairment (MCI). Ethical and logistical considerations are presented along with preliminary findings from an ongoing randomized controlled trial of Aβ imaging results disclosure in MCI. Following receipt of amyloid imaging results, participants underwent 14 days of adverse event monitoring using ecological momentary assessment (EMA), a strategy to capture health, behaviors, and mood as they occur in participants’ natural settings in real time. EMA telephone calls were placed at random during waking hours to screen for mood changes. Investigators were alerted for positive depression, anxiety, suicidal ideation screenings, or for two days of failed call attempts. Preliminary feasibility of twenty-four participants with MCI who participated in EMA mood assessments was successfully completed 83% (SD = 0.4) of the time over 14 days with no alerts for anxiety or depression screening items. EMA, when used with standard adverse event monitoring, is a promising and novel approach to maximize early detection of negative psychological reactions following AD biomarker results disclosed in research settings."@en ;
    ns0:hasPubTitle "Research Use of Ecological Momentary Assessment for Adverse Event Monitoring Following Amyloid-β Results Disclosure"@en .

ns1:jad-v72-i1-JAD181171 ns0:hasKeywords "Alzheimer’s disease"@en,
        "LC-MS"@en,
        "palm oil"@en,
        "proteomics"@en,
        "tocotrienol"@en ;
    ns0:hasPubAbstract "Tocotrienol-rich fraction (TRF) is a mixture of vitamin E analogs derived from palm oil. We previously demonstrated that supplementation with TRF improved cognitive function and modulated amyloid pathology in AβPP/PS1 mice brains. The current study was designed to examine proteomic profiles underlying the therapeutic effect of TRF in the brain. Proteomic analyses were performed on samples of hippocampus, medial prefrontal cortex (mPFC), and striatum using liquid chromatography coupled to Q Exactive HF Orbitrap mass spectrometry. From these analyses, we profiled a total of 5,847 proteins of which 155 proteins were differentially expressed between AβPP/PS1 and wild-type mice. TRF supplementation of these mice altered the expression of 255 proteins in the hippocampus, mPFC, and striatum. TRF also negatively modulated the expression of amyloid beta A4 protein and receptor-type tyrosine-protein phosphatase alpha protein in the hippocampus. The expression of proteins in metabolic pathways, oxidative phosphorylation, and those involved in Alzheimer’s disease were altered in the brains of AβPP/PS1 mice that received TRF supplementation."@en ;
    ns0:hasPubTitle "Modulation of Proteome Profile in AβPP/PS1 Mice Hippocampus, Medial Prefrontal Cortex, and Striatum by Palm Oil Derived Tocotrienol-Rich Fraction"@en .

ns1:jad-v72-i3-JAD190772 ns0:hasKeywords "Acetylcholinesterase inhibitor"@en,
        "Alzheimer’s disease"@en,
        "clinical trials"@en,
        "drug interaction"@en,
        "hydromethylthionine"@en,
        "leucomethylthioninium"@en,
        "population pharmacokinetics"@en ;
    ns0:hasPubAbstract "Background: Although hydromethylthionine is a potent tau aggregation inhibitor, no difference was found in either of two Phase III trials in mild to moderate Alzheimer’s disease (AD) comparing doses in the range 150–250 mg/day with 8 mg/day intended as a control.   Objective: To determine how drug exposure is related to treatment response.   Methods: A sensitive plasma assay for the drug was used in a population pharmacokinetic analysis of samples from 1,162 of the 1,686 patients who participated in either of the Phase III trials with available samples and efficacy outcome data.   Results: There are steep concentration-response relationships for steady state plasma levels in the range 0.3–0.8 ng/ml at the 8 mg/day dose. Using a threshold based on the lower limit of quantitation of the assay on Day 1, there are highly significant differences in cognitive decline and brain atrophy in patients with above threshold plasma levels, both for monotherapy and add-on therapy, but with effect sizes reduced by half as add-on. Plasma concentrations in the range 4–21 ng/ml produced by the high doses are not associated with any additional benefit.   Conclusions: Hydromethylthionine has pharmacological activity on brain structure and function at the 8 mg/day dose as monotherapy or as add-on to symptomatic treatments. This combined with a plateau at higher doses is consistent with the lack of dose-response seen in the Phase III trials. Treatment benefit is predicted to be maximal at 16 mg/day as monotherapy. A placebo-controlled trial in mild/moderate AD is now ongoing to confirm efficacy at this dose."@en ;
    ns0:hasPubTitle "Concentration-Dependent Activity of Hydromethylthionine on Cognitive Decline and Brain Atrophy in Mild to Moderate Alzheimer’s Disease"@en .

ns8:CH189415 ns0:inAuthorList ns150:CH189415 .

ns8:CH1963 ns0:inAuthorList ns150:CH1963 .

ns26:CH179226 ns0:inAuthorList ns150:CH179226 .

ns30:CH179216 ns0:inAuthorList ns150:CH179216 .

ns52:CH170265 ns0:inAuthorList ns150:CH170265 .

ns57:CH170246 ns0:inAuthorList ns150:CH170246 .

ns1:ch-v73-i1-CH199009 ns0:hasKeywords "CI-AKI"@en,
        "Contrast agent"@en,
        "Iodixanol"@en,
        "Iopromide"@en,
        "contrast-induced acute kidney injury"@en,
        "tissue oxygen partial pressure"@en ;
    ns0:hasPubAbstract "Repeated injections of iodinated contrast media (CM) can lead to a deterioration of the renal blood flow, can redistribute blood from the renal cortex to other parts of the kidney and can cause small decreases of the blood flow in cortical capillaries, a significant reduction in blood flow in peritubular capillaries and a significant reduction in blood flow in the vasa recta. Therefore, a study in pigs was designed, to show whether the repeated injection of CM boli, alone, can cause a reduction of oxygenation in the cortico-medullar renal tissue – the region with the highest oxygen demand in the kidney - of pigs. While the mean pO2-value had only decreased by 0.3 mmHg from 29.9±4.3 mmHg to 29.6±4.3 mmHg (p = 0.8799) after the tenth Iodixanol bolus, it decreased by 5.9 mmHg from 34.0±4.3 mmHg to 28.1±4.3 mmHg after the tenth Iopromide bolus (p = 0.044). This revealed a remarkable difference in the influence of these CM on the oxygen partial pressure in the kidney. Repeated applications of CM had a significant influence on the renal oxygen partial pressure. In line with earlier studies showing a redistribution of blood from the cortex to other renal areas, this study revealed that Iodixanol – in contrast to Iopromide - induced no changes in the pO2 in the cortico-medullar region which confirms that Iodixanol did not hinder the flow of blood through the renal micro-vessels. These results are in favor of a hypothesis from Brezis that a microcirculatory disorder might be the basis for the development of CI-AKI."@en ;
    ns0:hasPubTitle "Effect of iodinated contrast media on the oxygen tension in the renal cortico-medullary region of pigs"@en .

ns1:jad-v70-i1-JAD181261 ns0:hasKeywords "Cerebrovascular disease"@en,
        "medial temporal lobe"@en,
        "neurodegeneration"@en,
        "suspected non-Alzheimer’s pathophysiology"@en,
        "white matter hyperintensity"@en,
        "young onset dementia."@en ;
    ns0:hasPubAbstract "Background: Non-amyloid mechanisms behind neurodegeneration and cognition impairment are unclear. Cerebrovascular disease (CVD) may play an important role in suspected non-Alzheimer’s pathophysiology (SNAP), especially in Asia.   Objective: To examine the association between CVD and medial temporal lobe atrophy (MTA) in amyloid-β negative patients with mild amnestic type dementia.   Methods: Thirty-six mild dementia patients with complete neuropsychological, cerebrospinal fluid (CSF) biomarker, and neuroimaging information were included. Only patients with clinically significant MTA were recruited. Patients were categorized based on their CSF Aβ levels. Neuroimaging and neuropsychological variables were analyzed.   Results: Despite comparable MTA between Aβ positive and negative patients, Aβ-negative patients had significantly greater white matter hyperintensities (WMH; Total Fazekas Rating) than their Aβ-positive counterparts (6.42 versus 4.19, p = 0.03). A larger proportion of Aβ-negative patients also had severe and confluent WMH. Regression analyses controlling for baseline characteristics yielded consistent results.   Conclusion: Our findings demonstrate that MTA is associated with greater CVD burden among Aβ-negative patients with amnestic type dementia. CVD may be an important mechanism behind hippocampal atrophy. This has implications on clinical management strategies, where measures to reduce CVD may slow neurodegeneration and disease progression."@en ;
    ns0:hasPubTitle "Medial Temporal Atrophy in Amyloid-Negative Amnestic Type Dementia Is Associated with High Cerebral White Matter Hyperintensity"@en .

ns1:jad-v70-is1-JAD180521 ns0:hasKeywords "Adherence"@en,
        "cerebrovascular disease"@en,
        "mild cognitive impairment"@en,
        "physical activity"@en,
        "subjective memory complaints"@en ;
    ns0:hasPubAbstract "Background: Previous studies have demonstrated that physical activity (PA) interventions can improve physical and cognitive outcomes in older adults, but most have been relatively short in duration (<1 year) with a few having specifically targeting individuals at risk of developing Alzheimer’s disease.   Objective: To examine adherence and physical health outcomes in a 24-month home-based PA intervention in older adults at risk of Alzheimer’s disease.   Methods: Participants 60 years and older with mild cognitive impairment (MCI) or subjective memory complaints (SMC) with at least 1 cerebrovascular risk factor recruited from The Australian Imaging Biomarkers and Lifestyle Flagship Study of Aging (AIBL) were randomized to a PA or control group (n = 106). The control group continued with their usual lifestyle. The PA group received a 24-month home-based program with a target of 150 minutes/week of moderate PA and a behavioral intervention. Retention (participants remaining) and PA adherence (PA group only, percent PA completed to the PA prescribed) were determined at 6, 12, 18, and 24 months. Assessments at baseline, 6, 12, and 24 months included, PA; fitness; body composition and fat distribution. Key outcome measures were PA adherence and PA.   Results: The 24-month retention rate (97.2%) and the median PA adherence 91.67% (Q1–Q3, 81.96, 100.00) were excellent. In the long-term the intervention group achieved significantly better improvements in PA levels, leg strength, fat mass and fat distribution compared to the control.   Conclusion: This study demonstrates that in this target group, long-term PA adherence is achievable and has physical health benefits."@en ;
    ns0:hasPubTitle "A Randomized Controlled Trial of Adherence to a 24-Month Home-Based Physical Activity Program and the Health Benefits for Older Adults at Risk of Alzheimer’s Disease: The AIBL Active-Study"@en .

ns1:jad-v70-is1-JAD180572 ns0:hasKeywords "Alzheimer’s disease"@en,
        "clinical trial"@en,
        "cognitive decline"@en,
        "cognitive training"@en,
        "dementia"@en,
        "depression"@en,
        "non-pharmacological"@en,
        "nutrition"@en,
        "physical activity"@en,
        "randomized controlled trial"@en ;
    ns0:hasPubAbstract "Background: Maintain Your Brain (MYB) is a randomized controlled trial of an online multi-modal lifestyle intervention targeting modifiable dementia risk factors with its primary aim being to reduce cognitive decline in an older age cohort.   Methods: MYB aims to recruit 8,500 non-demented community dwelling 55 to 77 year olds from the Sax Institute’s 45 and Up Study in New South Wales, Australia. Participants will be screened for risk factors related to four modules that comprise the MYB intervention: physical activity, nutrition, mental health, and cognitive training. Targeting risk factors will enable interventions to be personalized so that participants receive the most appropriate modules. MYB will run for three years and up to four modules will be delivered sequentially each quarter during year one. Upon completing a module, participants will continue to receive less frequent booster activities for their eligible modules (except for the mental health module) until the end of the trial.   Discussion: MYB will be the largest internet-based trial to attempt to prevent cognitive decline and potentially dementia. If successful, MYB will provide a model for not just effective intervention among older adults, but an intervention that is scalable for broad use."@en ;
    ns0:hasPubTitle "Maintain Your Brain: Protocol of a 3-Year Randomized Controlled Trial of a Personalized Multi-Modal Digital Health Intervention to Prevent Cognitive Decline Among Community Dwelling 55 to 77 Year Olds"@en .

ns1:jad-v72-i3-JAD190817 ns0:hasKeywords "Alzheimer’s disease"@en,
        "CD14"@en,
        "electron paramagnetic resonance imaging"@en,
        "mesenchymal stem cells"@en,
        "microglia"@en,
        "oxidative stress"@en ;
    ns0:hasPubAbstract "Mesenchymal stem cells (MSC) are increasingly being studied as a source of cell therapy for neurodegenerative diseases, and several groups have reported their beneficial effects on Alzheimer’s disease (AD). In this study using AD model mice (APdE9), we found that transplantation of MSC via the tail vein improved spatial memory in the Morris water maze test. Using electron paramagnetic resonance imaging to evaluate the in vivo redox state of the brain, we found that MSC transplantation suppressed oxidative stress in AD model mice. To elucidate how MSC treatment ameliorates oxidative stress, we focused on amyloid-β (Aβ) pathology and microglial function. MSC transplantation reduced Aβ deposition in the cortex and hippocampus. Transplantation of MSC also decreased Iba1-positive area in the cortex and reduced activated ameboid shaped microglia. On the other hand, MSC transplantation accelerated accumulation of microglia around Aβ deposits and prompted microglial Aβ uptake and clearance as shown by higher frequency of Aβ-containing microglia. MSC transplantation also increased CD14-positive microglia in vivo, which play a critical role in Aβ uptake. To confirm the effects of MSC on microglia, we co-cultured the mouse microglial cell line MG6 with MSC. Co-culture with MSC enhanced Aβ uptake by MG6 cells accompanied by upregulation of CD14 expression. Additionally, co-culture of MG6 cells with MSC induced microglial phenotype switching from M1 to M2 and suppressed production of proinflammatory cytokines. These data indicate that MSC treatment has the potential to ameliorate oxidative stress through modification of microglial functions, thereby improving Aβ pathology in AD model mice."@en ;
    ns0:hasPubTitle "Transplantation of Mesenchymal Stem Cells Improves Amyloid-β Pathology by Modifying Microglial Function and Suppressing Oxidative Stress"@en .

ns1:jpd-v9-i3-JPD191610 ns0:hasKeywords "Parkinson’s disease"@en,
        "atherosclerotic cardiovascular disease"@en,
        "sympathetic nervous system"@en,
        "α-synuclein"@en ;
    ns0:hasPubAbstract "Background: Some epidemiology studies suggest that atherosclerotic cardiovascular disease (ASCVD) risk factors increase the risk of developing Parkinson’s disease (PD). However, conflicting data suggest lower rates of ASCVD in PD.   Objective: The objective of this study is to determine, with data from a longitudinal clinicopathological study, whether ASCVD risk factors are associated with a PD diagnosis and/or increased brain or peripheral load of Lewy-type synucleinopathy (LTS).   Methods: All subjects were followed to autopsy and neuropathological examination in the Arizona Study of Aging and Neurodegenerative Disorders (AZSAND). Multivariable regression models, including age, gender, and smoking history, were used to investigate the association of a PD diagnosis or brain or submandibular gland LTS load with ASCVD risk factors.   Results: 150 subjects were included (PD n = 60, controls n = 90). Univariable comparisons and regression models showed a general trend to inverse associations. The multivariable odds ratio (OR) of brain LTS load for carotid artery disease was 0.93 (95% CI: 0.86 to 0.98; p = 0.02), for anticoagulant use 0.95 (95% CI: 0.90 to 0.99; p = 0.04) and for abnormal heart weight 0.96 (95% CI: 0.92 to 0.99; p = 0.01). Composite clinical and overall (clinical + pathology composite risk scores) composite risk scores were also significantly lower in the PD subjects (p = 0.0164 and 0.0187, respectively). Submandibular gland LTS load was not significantly related to ASCVD conditions.   Conclusions: This study shows associations of higher brain LTS with lower prevalence of both clinical and pathological indices of ASCVD in PD subjects versus age-similar controls. We suggest that this is due to α-synuclein pathology-induced sympathetic denervation in PD."@en ;
    ns0:hasPubTitle "Brain Lewy-Type Synucleinopathy Density Is Associated with a Lower Prevalence of Atherosclerotic Cardiovascular Disease Risk Factors in Patients with Parkinson’s Disease1"@en .

ns1:jpd-v9-i4-JPD181518 ns0:hasKeywords "Parkinson’s disease"@en,
        "biomarkers"@en,
        "disease progression"@en,
        "surrogate endpoint"@en ;
    ns0:hasPubAbstract "Background: Improved prediction of Parkinson’s disease (PD) progression is needed to support clinical decision-making and to accelerate research trials.   Objectives: To examine whether baseline measures and their 1-year change predict longer-term progression in early PD.   Methods: Parkinson’s Progression Markers Initiative study data were used. Participants had disease duration ≤2 years, abnormal dopamine transporter (DAT) imaging, and were untreated with PD medications. Baseline and 1-year change in clinical, cerebrospinal fluid (CSF), and imaging measures were evaluated as candidate predictors of longer-term (up to 5 years) change in Movement Disorders Society-Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) score and DAT specific binding ratios (SBR) using linear mixed-effects models.   Results: Among 413 PD participants, median follow-up was 5 years. Change in MDS-UPDRS from year-2 to last follow-up was associated with disease duration (β= 0.351; 95% CI = 0.146, 0.555), male gender (β= 3.090; 95% CI = 0.310, 5.869), and baseline (β= –0.199; 95% CI = –0.315, –0.082) and 1-year change (β= 0.540; 95% CI = 0.423, 0.658) in MDS-UPDRS; predictors in the model accounted for 17.6% of the variance in outcome. Predictors of percent change in mean SBR from year-2 to last follow-up included baseline rapid eye movement sleep behavior disorder score (β= –0.6229; 95% CI = –1.2910, 0.0452), baseline (β= 7.232; 95% CI = 2.268, 12.195) and 1-year change (β= 45.918; 95% CI = 35.994,55.843) in mean striatum SBR, and 1-year change in autonomic symptom score (β= –0.325;95% CI = –0.695, 0.045); predictors in the model accounted for 44.1% of the variance.   Conclusions: Baseline clinical, CSF, and imaging measures in early PD predicted change in MDS-UPDRS and dopamine-transporter binding, but the predictive value of the models was low. Adding the short-term change of possible predictors improved the predictive value, especially for modeling change in dopamine-transporter binding."@en ;
    ns0:hasPubTitle "Predicting Progression in Parkinson’s Disease Using Baseline and 1-Year Change Measures"@en .

ns1:jvr-v51-i1-JVR191022 ns0:hasKeywords "Multiple sclerosis"@en,
        "employment"@en,
        "rural"@en ;
    ns0:hasPubAbstract "BACKGROUND: This article presents descriptive findings from a sub-sample of 414 people with multiple sclerosis (MS) residing in rural areas that was derived from a national survey of the employment concerns of Americans with MS.   OBJECTIVE: Respondents were asked to evaluate 38 employment concerns items on two dimensions, importance and satisfaction, for the purpose of identifying strengths and weaknesses in the employment policies and practices affecting the labor force participation of Americans with MS.   RESULTS: Results revealed a total of 13 employment strengths and 25 employment weaknesses that must be addressed in direct service and advocacy efforts if more rural residents with MS are to continue their careers while coping with this intrusive and unpredictable disease.   CONCLUSION: Implications of these findings for future rehabilitation programming and research are examined."@en ;
    ns0:hasPubTitle "Priority employment concerns identified by Americans with MS residing in rural areas: Results of a national survey"@en .

ns1:jad-v71-i1-JAD190369 ns0:hasKeywords "Alzheimer’s disease"@en,
        "chronic cerebral hypoperfusion"@en,
        "edaravone"@en,
        "neural oxidative stress"@en,
        "neuroinflammation"@en,
        "neuronal loss"@en ;
    ns0:hasPubAbstract "Alzheimer’s disease (AD) and chronic cerebral hypoperfusion (CCH) often coexist in dementia patients in aging societies. The hallmarks of AD including amyloid-β (Aβ)/phosphorylated tau (pTau) and pathology-related events such as neural oxidative stress and neuroinflammation play critical roles in pathogenesis of AD with CCH. A large number of lessons from failures of drugs targeting a single target or pathway on this so complicated disease indicate that disease-modifying therapies targeting multiple key pathways hold potent potential in therapy of the disease. In the present study, we used a novel mouse model of AD with CCH to investigate a potential therapeutic effect of a free radical scavenger, Edaravone (EDA) on AD with CCH via examining motor and cognitive capacity, AD hallmarks, neural oxidative stress, and neuroinflammation. Compared with AD with CCH mice at 12 months of age, EDA significantly improved motor and cognitive deficits, attenuated neuronal loss, reduced Aβ/pTau accumulation, and alleviated neural oxidative stress and neuroinflammation. These findings suggest that EDA possesses clinical and pathological benefits for AD with CCH in the present mouse model and has a potential as a therapeutic agent for AD with CCH via targeting multiple key pathways of the disease pathogenesis."@en ;
    ns0:hasPubTitle "Clinical and Pathological Benefits of Edaravone for Alzheimer’s Disease with Chronic Cerebral Hypoperfusion in a Novel Mouse Model"@en .

ns1:jad-v71-i3-JAD190533 ns0:hasKeywords "Alzheimer’s disease"@en,
        "blood biomarkers"@en,
        "plasma amyloid-β"@en,
        "plasma amyloid-β ratios"@en,
        "preclinical Alzheimer’s disease"@en,
        "single molecule array"@en ;
    ns0:hasPubAbstract "Background: Aberrant amyloid-β (Aβ) deposition in the brain occurs two decades prior to the manifestation of Alzheimer’s disease (AD) clinical symptoms and therefore brain Aβ load measured using PET serves as a gold standard biomarker for the early diagnosis of AD. However, the uneconomical nature of PET makes blood markers, that reflect brain Aβ deposition, attractive candidates for investigation as surrogate markers.   Objective: Investigation of plasma Aβ as a surrogate marker for brain Aβ deposition in cognitively normal elderly individuals.   Methods: Plasma Aβ40 and Aβ42 concentrations were measured using the ultrasensitive Single Molecule Array (Simoa) assay in 95 cognitively normal elderly individuals, who have all undergone PET to assess brain Aβ deposition. Based on the standard uptake value ratios (SUVR) obtained from PET imaging, using the tracer 18F-Florbetaben, plasma Aβ was compared between 32 participants assessed to have low brain Aβ load (Aβ–, SUVR <1.35) and 63 assessed to have high brain Aβ load (Aβ+, SUVR ≥1.35).   Results: Plasma Aβ42/Aβ40 ratios were lower in the Aβ+ group compared to the Aβ–group. Plasma Aβ40 and Aβ42 levels were not significantly different between Aβ–and Aβ+ groups, although a trend of higher plasma Aβ40 was observed in the Aβ+ group. Additionally, plasma Aβ42/Aβ40 ratios along with the known AD risk factors, age and APOE ɛ4 status, resulted in Aβ+ participants being distinguished from Aβ–participants based on an area under the receiver operating characteristic curve shown to be 78%.   Conclusion: Plasma Aβ ratios in this study are a potential biomarker for brain Aβ deposition and therefore, for preclinical AD. However, this method to measure plasma Aβ needs further development to increase the accuracy of this promising AD blood biomarker."@en ;
    ns0:hasPubTitle "Ultrasensitive Detection of Plasma Amyloid-β as a Biomarker for Cognitively Normal Elderly Individuals at Risk of Alzheimer’s Disease"@en .

ns1:jad-v72-i1-JAD190660 ns0:hasKeywords "Dementia"@en,
        "differential diagnosis"@en,
        "drawings"@en,
        "semantic dementia"@en,
        "semantic knowledge"@en ;
    ns0:hasPubAbstract "Background: Semantic dementia (SD) is a subtype of frontotemporal lobe degeneration characterized by semantic loss, with other cognitive functions initially preserved. SD requires differential diagnosis with Alzheimer’s disease (AD) and behavioral variant frontotemporal dementia (bvFTD). Semantic knowledge can be evaluated through different tests; however, most of them depend on language.   Objective: We describe the development of a brief drawing task that may be helpful for the differential diagnosis of SD.   Methods: Seventy-two patients, including 32 AD, 19 bvFTD, and 21 SD were asked to draw 12 items with different age of acquisition and familiarity, belonging to four different semantic categories. We employed the drawings of healthy volunteers to build a scoring scheme.   Results: Turtle, strawberry, train, and envelope were the items of each category that best discriminated between groups and were selected for the Brief drawing task. The discriminatory power of the Brief drawing task between SD versus AD and bvFTD patients, estimated through the area under the curve was 0.84 (95% CI = 0.72–0.96, p = 0.000007). In a logistic model, the Brief drawing task (p = 0.003) and VOSP “number location” subtest (p = 0.016) were significant predictors of the diagnosis of SD versus AD and bvFTD after adjustment by the main covariates. The Brief drawing task provided clinically useful qualitative information. SD drawings were characterized by loss of the distinctive features, intrusions, tendency to prototype, and answers like “I don’t know what this is”.   Conclusion: The Brief drawing task appears to reveal deficits in semantic knowledge among patients with SD that may assist in the differential diagnosis with other neurodegenerative diseases."@en ;
    ns0:hasPubTitle "A Brief Drawing Task for the Differential Diagnosis of Semantic Dementia"@en .

ns1:jad-v72-i1-JAD190132 ns0:hasKeywords "C9orf72 protein"@en,
        "cholesterol"@en,
        "frontotemporal dementia"@en,
        "frontotemporal lobar degeneration"@en,
        "inflammation"@en,
        "lipoproteins"@en ;
    ns0:hasPubAbstract "Decreased levels of serum high-density lipoprotein (HDL) cholesterol have previously been linked to systemic inflammation and neurodegenerative diseases, such as Alzheimer’s disease. Here, we aimed to analyze the lipoprotein profile and inflammatory indicators, the high-sensitivity C-reactive peptide (hs-CRP) and glycoprotein acetyls (GlycA), in sporadic and C9orf72 repeat expansion-associated frontotemporal lobar degeneration (FTLD) patients. The C9orf72 hexanucleotide repeat expansion is the most frequent genetic etiology underlying FTLD. The concentrations of different lipid measures in the sera of 67 FTLD patients (15 C9orf72 repeat expansion carriers), including GlycA, were analyzed by nuclear magnetic resonance spectroscopy. To verify the state of systemic inflammation, hs-CRP was also quantified from patient sera. We found that the total serum HDL concentration was decreased in C9orf72 repeat expansion carriers when compared to non-carriers. Moreover, decreased concentrations of HDL particles of different sizes and subclass were consistently observed. No differences were detected in the very low- and low-density lipoprotein subclasses between the C9orf72 repeat expansion carriers and non-carriers. Furthermore, hs-CRP and GlycA levels did not differ between the C9orf72 repeat expansion carriers and non-carriers. In conclusion, the HDL-related changes were linked with C9orf72 repeat expansion associated FTLD but were not seen to associate with systemic inflammation. The underlying reason for the HDL changes remains unclear."@en ;
    ns0:hasPubTitle "Low Serum High-Density Lipoprotein Cholesterol Levels Associate with the C9orf72 Repeat Expansion in Frontotemporal Lobar Degeneration Patients"@en .

ns1:jad-v69-i3-JAD190119 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Aquaporin 4"@en,
        "glymphatic system"@en,
        "normal pressure hydrocephalus"@en ;
    ns0:hasPubAbstract "Aquaporin4 (AQP4) is a water channel protein located at astrocyte foot processes that plays a role in glymphatic system, a highly organized fluid transport pathway which seems to be involved in Alzheimer’s disease (AD) and normal pressure hydrocephalus (NPH) pathophysiology. Cerebrospinal fluid (CSF) AQP4 levels were determined in 11 patients with AD, 10 patients with NPH, and 9 controls. We found significantly reduced AQP4 in AD patients, a trend in reduction in NPH patients, and a correlation between AQP4 and amyloid-β CSF levels. This study indicates the potential role of AQP4 and glymphatic system in neurodegenerative diseases pathophysiology."@en ;
    ns0:hasPubTitle "Cerebrospinal Fluid Level of Aquaporin4: A New Window on Glymphatic System Involvement in Neurodegenerative Disease?"@en .

ns1:jad-v71-i3-JAD190644 ns0:hasKeywords "Dementia"@en,
        "dietary supplement"@en,
        "mild cognitive impairment"@en,
        "oxidative stress"@en,
        "randomized controlled trial"@en ;
    ns0:hasPubAbstract "Oxidative stress is part of the entire pathological process that underlies the development of Alzheimer’s disease (AD), including the mild cognitive impairment (MCI) stage. Twendee X (TwX) is a supplement containing a strong antioxidative mix of eight antioxidants, which has been shown to have a clinical and therapeutic benefit in AD model mice. Here, we conducted a multicenter, randomized, double-blind, and placebo-controlled prospective interventional study to evaluate the efficacy of TwX in mitigating MCI. The primary outcomes were differences in Mini-Mental State Examination (MMSE) and Hasegawa Dementia Scale-revised (HDS-R) scores between baseline and six months for placebo and TwX groups. Seventy-eight subjects with MCI were randomized into placebo (n = 37) and TwX (n = 41) groups. MMSE scores at six months differed significantly between the TwX and placebo groups (p = 0.018), and HDS-R scores for the TwX group exhibited a significant improvement at six months relative to baseline (p = 0.025). The TwX group did not show any change in affective or activities of daily living scores at six months. The present study indicates that strong antioxidative supplement TwX is clinical beneficial for cognitive function in subjects with MCI."@en ;
    ns0:hasPubTitle "Clinical Benefits of Antioxidative Supplement Twendee X for Mild Cognitive Impairment: A Multicenter, Randomized, Double-Blind, and Placebo-Controlled Prospective Interventional Study"@en .

ns1:jad-v69-i3-JAD180949 ns0:hasKeywords "Cognition"@en,
        "cohort study"@en,
        "longitudinal"@en,
        "oldest-old"@en,
        "sex differences"@en,
        "verbal episodic memory"@en ;
    ns0:hasPubAbstract "Background: Sex differences in verbal episodic memory function have been widely reported. However, sex-specific effects on rates of episodic memory decline remain controversial, and evidence is particularly scarce in the oldest-old population.   Objective: We aimed to investigate sex differences in trajectories of episodic memory performance in oldest-old individuals.   Methods: Based on 13-year longitudinal data with 9 follow-up assessments of a large sample of cognitively unimpaired old (75+) primary care patients (n = 3,254) participating in the German AgeCoDe/AgeQualiDe study, we used linear mixed effects analyses to model sex-specific trajectories of change in verbal episodic memory while accounting for covarying factors.   Results: We found that even in the highest age group women outperformed men in immediate (b = –1.71, p < 0.001) and delayed (b = –0.85, p < 0.001) free recall conditions. Associated late-life trajectories, however, did not differ significantly between the sexes. We further demonstrated that younger age, higher education, and an absence of depressive symptoms predicted better performance in both sexes. In contrast, past occurrences of stroke and APOE ɛ4 carrier status showed a negative relation to test scores.   Conclusion: Our findings confirm previous research suggesting that women perform better in verbal episodic memory tests. We add that this advantage is still present in the oldest-old age groups. Our results indicate that sociodemographic and health related factors are as important as genetically based APOE ɛ4 carrier status in the prediction of normal cognitive development in advanced old age."@en ;
    ns0:hasPubTitle "Women Outperform Men in Verbal Episodic Memory Even in Oldest-Old Age: 13-Year Longitudinal Results of the AgeCoDe/AgeQualiDe Study"@en .

ns1:jad-v70-i4-JAD190399 ns0:hasKeywords "Dementia"@en,
        "mild cognitive impairment"@en,
        "sequential hypothesis"@en,
        "sleep"@en ;
    ns0:hasPubAbstract "Prospective studies concerning sleep architecture and cognitive function have focused on individual sleep measures per se, without considering the complementary role of non-REM (NREM) and REM sleep. We explored the association between NREM/REM cycle-related sleep architecture and cognitive decline. Community-dwelling elderly people in Korea from the Korean Longitudinal Study on Cognitive Aging and Dementia were enrolled. They were cognitively normal and underwent overnight polysomnography at baseline. A NREM/REM cycle is a sequence of NREM and REM sleep, uninterrupted by a waking period of >2 min. After 4 years, the development of mild cognitive impairment (MCI) or dementia was related to the measures of sleep architecture, including NREM/REM cycle parameters by logistic regression analyses. Of 235 participants (mean [SD] age 68 [5] years; 60% female) at baseline, 14 (5.9%) developed MCI/dementia at follow-up. A short average cycle length (OR, 0.97 [95% CI, 0.94–0.99]; p = 0.02) was significantly associated with cognitive decline. When its substructure and NREM and REM sleep outside of cycles were considered simultaneously, the average REM sleep duration per cycle (OR, 0.87 [95% CI, 0.76–0.98]; p = 0.03) was significantly related to the outcome. In conclusion, short average duration of NREM/REM cycles, especially average REM sleep duration in each cycle, in cognitively normal elderly might be used as an early marker of cognitive decline."@en ;
    ns0:hasPubTitle "Short Average Duration of NREM/REM Cycle Is Related to Cognitive Decline in an Elderly Cohort: An Exploratory Investigation"@en .

ns1:jad-v71-i4-JAD190334 ns0:hasKeywords "Alzheimer’s disease"@en,
        "Data and results has been partly presented as an abstract at Hydrocephalus 2017"@en,
        "Japan"@en,
        "Kobe"@en,
        "computer-assisted diagnosis"@en,
        "normal pressure hydrocephalus"@en ;
    ns0:hasPubAbstract "Background: Idiopathic normal pressure hydrocephalus (iNPH) patients often develop Alzheimer’s disease (AD) related brain pathology. Disease State Index (DSI) is a method to combine data from various sources for differential diagnosis and progression of neurodegenerative disorders.   Objective: To apply DSI to predict clinical AD in shunted iNPH-patients in a defined population.   Methods: 335 shunted iNPH-patients (median 74 years) were followed until death (n = 185) or 6/2015 (n = 150). DSI model (including symptom profile, onset age of NPH symptoms, atrophy of medial temporal lobe in CT/MRI, cortical brain biopsy finding, and APOE genotype) was applied. Performance of DSI model was evaluated with receiver operating characteristic (ROC) curve analysis.   Results: A total of 70 (21%) patients developed clinical AD during median follow-up of 5.3 years. DSI-model predicted clinical AD with moderate effectiveness (AUC = 0.75). Significant factors were cortical biopsy (0.69), clinical symptoms (0.66), and medial temporal lobe atrophy (0.66).   Conclusion: We found increased occurrence of clinical AD in previously shunted iNPH patients as compared with general population. DSI supported the prediction of AD. Cortical biopsy during shunt insertion seems indicated for earlier diagnosis of comorbid AD."@en ;
    ns0:hasPubTitle "Predicting Development of Alzheimer’s Disease in Patients with Shunted Idiopathic Normal Pressure Hydrocephalus"@en .

ns1:jad-v72-i2-JAD190446 ns0:hasKeywords "amyloid, anisotropy, cerebral white matter, cognition, diagnosis, diffusion tensor imaging, mild cognitive impairment, subjective cognitive decline"@en ;
    ns0:hasPubAbstract "Diffusion changes as determined by diffusion tensor imaging are potential indicators of microstructural lesions in people with mild cognitive impairment (MCI), prodromal Alzheimer’s disease (AD), and AD dementia. Here we extended the scope of analysis toward subjective cognitive complaints as a pre-MCI at risk stage of AD. In a cohort of 271 participants of the prospective DELCODE study, including 93 healthy controls and 98 subjective cognitive decline (SCD), 45 MCI, and 35 AD dementia cases, we found reductions of fiber tract integrity in limbic and association fiber tracts in MCI and AD dementia compared with controls in a tract-based analysis (p < 0.05, family wise error corrected). In contrast, people with SCD showed spatially restricted white matter alterations only for the mode of anisotropy and only at an uncorrected level of significance. DTI parameters yielded a high cross-validated diagnostic accuracy of almost 80% for the clinical diagnosis of MCI and the discrimination of Aβ positive MCI cases from Aβ negative controls. In contrast, DTI parameters reached only random level accuracy for the discrimination between Aβ positive SCD and control cases from Aβ negative controls. These findings suggest that in prodromal stages of AD, such as in Aβ positive MCI, multicenter DTI with prospectively harmonized acquisition parameters yields diagnostic accuracy meeting the criteria for a useful biomarker. In contrast, automated tract-based analysis of DTI parameters is not useful for the identification of preclinical AD, including Aβ positive SCD and control cases."@en ;
    ns0:hasPubTitle "Multicenter Tract-Based Analysis of Microstructural Lesions within the Alzheimer’s Disease Spectrum: Association with Amyloid Pathology and Diagnostic Usefulness"@en .

